<SEC-DOCUMENT>0001144204-15-015672.txt : 20150312
<SEC-HEADER>0001144204-15-015672.hdr.sgml : 20150312
<ACCEPTANCE-DATETIME>20150312164559
ACCESSION NUMBER:		0001144204-15-015672
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150312
DATE AS OF CHANGE:		20150312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		15696458

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v403470_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR ANNUAL AND TRANSITION REPORTS PURSUANT
TO SECTIONS 13 OR 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>ANNUAL REPORT
                                         PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the fiscal year ended December&nbsp;31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number)</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 10%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><B>Florida</B></td>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>65-0643773</B></td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization</B></P></td>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></td>
    <TD>&nbsp;</TD></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2
                                         Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></td>
    <TD STYLE="vertical-align: bottom; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>20100</U></B></P></td></tr>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: center"><B>Title of each class</B></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><B>Name of each exchange on which registered</B></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><B>Common stock, par value $0.001 per share</B></td>
    <td style="font-size: 10pt; text-align: center"><B>NYSE MKT</B></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(g)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). &nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if disclosure of
delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best
of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="width: 25%; text-indent: 0in">Large accelerated filer</td>
    <TD NOWRAP STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></td>
    <TD NOWRAP STYLE="width: 40%; text-indent: 0in">&nbsp;</td>
    <TD NOWRAP STYLE="width: 25%; text-indent: 0in">Accelerated filer</td>
    <TD NOWRAP STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="text-indent: 0in">Non-accelerated filer</td>
    <TD NOWRAP STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></td>
    <TD NOWRAP STYLE="text-indent: 0in">(Do not check if a smaller reporting company)</td>
    <TD NOWRAP STYLE="text-indent: 0in">Smaller reporting company</td>
    <TD NOWRAP STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">The aggregate market value of the voting
common equity held by non-affiliates of the Registrant, as of June 30, 2014 was approximately $179 million (based upon a per share
price equal to $3.65, the closing price for shares of the Registrant&rsquo;s common stock reported by the NYSE MKT for such date).
Shares of common stock held by each officer, director and holder of 5% or more of the outstanding common stock have been excluded
in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination
for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">On March 1, 2015, approximately 93,603,819
shares of the Registrant&rsquo;s common stock, par value $0.001 per share, were outstanding.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 12%; text-align: right">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 78%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Page</B></td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><B><A HREF="#a_001">PART I</A></B></td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <td colspan="2" style="vertical-align: top"><A HREF="#a_002">Cautionary Statement Regarding Forward-Looking Statements</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">1</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 1.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_003">Business</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">3</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 1A.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_004">Risk Factors</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">30</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 1B.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_005">Unresolved Staff Comments</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">51</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 2.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_006">Properties</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">51</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 3.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_007">Legal Proceedings</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">51</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 4.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_008">Mine Safety Disclosures</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">51</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="#a_009"><B>PART II</B></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 5.</td>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#a_010">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></P></td>
    <TD STYLE="vertical-align: bottom; text-align: right">52</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 6.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_011">Selected Financial Data</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">54</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 7.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_012">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">55</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 7A.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_013">Quantitative and Qualitative Disclosures About Market Risk</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">64</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 8.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_014">Financial Statements and Supplementary Data</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">64</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 9.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">64</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 9A.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_016">Controls and Procedures</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">65</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 9B.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_017">Other Information</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">66</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="#a_018"><B>PART III</B></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 10.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_019">Directors, Executive Officers and Corporate Governance</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">67</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 11.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_020">Executive Compensation</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">70</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 12.</td>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></P></td>
    <TD STYLE="vertical-align: bottom; text-align: right">81</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 13.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_022">Certain Relationships and Related Transactions, and Director Independence</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">83</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item 14.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_023">Principal Accountant Fees and Services</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">84</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="#a_024"><B>PART IV</B></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 15.</td>
    <TD STYLE="vertical-align: top"><A HREF="#a_025">Exhibits and Financial Statement Schedules</A></td>
    <TD STYLE="vertical-align: bottom; text-align: right">86</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_032">Signatures</A></td>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right">90</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms,
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics,
Inc. and its consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix
Ltd., our wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Risk Factors,&rdquo;
and other statements included elsewhere in this Annual Report on Form 10-K, which are not historical, constitute &ldquo;forward-looking
statements&rdquo; within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section
21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs,
intentions or strategies for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo;
&ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases of similar import, as they relate to our company or our subsidiaries
or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject
to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only
predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we
undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to
reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events,
except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could
cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian
                                         Ministry of Health, or the Brazilian MOH, with its purchase obligations under our supply
                                         and technology transfer agreement which may result in the termination of such agreement
                                         which may have a material adverse effect on our company;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil,
                                         Canada, Australia and other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the supply of drug product pursuant to our supply arrangement with Fiocruz;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk of significant
                                         delays in the commercial introduction of taliglucerase alfa in the United States, Brazil,
                                         Israel, Canada, Australia and other markets as planned;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the acceptance and use of taliglucerase alfa or any of our product candidates, if approved,
                                         by physicians, patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we
                                         will not be able to develop a successful sales and marketing organization for taliglucerase
                                         alfa in Israel, or for any other product candidate, in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay
                                         in the commencement or completion of our preclinical studies and clinical trials which
                                         may be caused by several factors, including: unforeseen safety issues; determination
                                         of dosing issues; lack of effectiveness during clinical trials; slower than expected
                                         rates of patient recruitment; inability to monitor patients adequately during or after
                                         treatment; inability or unwillingness of medical investigators and institutional review
                                         boards to follow our clinical protocols; or lack of sufficient funding to finance our
                                         clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the
                                         results of our clinical trials will not support the applicable claims of safety or efficacy,
                                         that our product candidates will not have the desired effects or include undesirable
                                         side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on
                                         performance by third party providers of services and supplies, including without limitation,
                                         clinical trial services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the approval
                                         or the potential rejection of any application filed with or submitted to the regulatory
                                         authorities reviewing taliglucerase alfa outside of the United States, Israel, Brazil,
                                         Canada, Australia and other countries in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish
                                         and maintain strategic license, collaboration and distribution arrangements, and to manage
                                         our relationships with Pfizer Inc., Fiocruz and any other collaborator, distributor or
                                         partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         our ability to make scheduled payments of the principal of, to pay interest on or to
                                         refinance our 2018 convertible notes, or any other indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         our ability to finance our research programs, the expansion of our manufacturing capabilities
                                         and the ongoing costs in the case of delays in regulatory approvals for taliglucerase
                                         alfa outside of the United States, Israel, Brazil, Canada, Australia and other countries
                                         in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation
                                         and filing of applications for regulatory approval of our other product candidates in
                                         the United States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations
                                         with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products
                                         that are competitive to our product candidates may be granted orphan drug status in certain
                                         territories and, therefore, will be subject to potential marketing and commercialization
                                         restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development
                                         of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress
                                         of our research and development activities and our clinical activities with respect to
                                         any product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks
                                         and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product
                                         liability risks, and risks of securing adequate levels of product liability and clinical
                                         trial insurance coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of
                                         infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of
                                         obtaining patents covering our products and processes and in successfully enforcing our
                                         intellectual property rights against third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         changes in healthcare laws, rule s and regulations in the United States or elsewhere;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption
                                         of our operations due to terrorist activities and armed conflict, including as a result
                                         of the disruption of the operations of regulatory authorities, our subsidiaries, our
                                         manufacturing facilities and our customers, suppliers, distributors, collaborative partners,
                                         licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration or foreign regulatory authorities may not accept or approve a marketing application filed
by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed
under the heading <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Risk Factors&rdquo; in this Annual Report and are described
from time to time in the reports we file with the U.S. Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_003"></A><B>Item&nbsp;1. &nbsp;Business </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, clinically superior versions of
recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon
known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins
for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. With our experience, and having successfully
developed Elelyso<SUP>TM</SUP>, our first drug product, we believe ProCellEx will enable us to develop additional proprietary
recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.
We are now also applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our current product candidates
and our current projections regarding their respective stages of clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="tpg6.jpg">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the U.S. Food and Drug Administration, or the
FDA, approved for sale our first commercial product, taliglucerase alfa for injection, which is being marketed in the United States
and Israel under the brand name Elelyso, as an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients
with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved by the Brazilian National
Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria, or ANVISA) in March 2013, and by the Israeli Ministry of
Health, or the Israeli MOH, in September 2012. It has also been approved by other regulatory agencies for other countries. Taliglucerase
alfa is being marketed under the name Uplyso<SUP>TM</SUP><FONT STYLE="font-size: 10pt"> </FONT>in Brazil and certain other Latin
American countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2014, the FDA approved Elelyso for injection for
pediatric patients and the Israeli MOH approved the pediatric indication in January 2015. Prior to the U.S. pediatric approval,
Elelyso was approved for pediatric indications in Australia and Canada but in no other jurisdiction. In September 2014, CONITEC,
the National Commission for Incorporation of Technologies in Brazil&rsquo;s Unified Healthcare System, announced that it had decided
to give a positive funding recommendation for Uplyso in the treatment of adult patients with types 1 and 3 Gaucher disease, and
established that Uplyso will be the first choice for treatment for new adult Gaucher patients in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed
in the United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and
supply agreement by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer
Agreement. We granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer
Agreement, but we retained those rights in Israel, and later in Brazil. We have agreed to a specific allocation between
Protalix Ltd. and Pfizer of the responsibilities for the continued development efforts for taliglucerase alfa outside of
Israel and Brazil. Protalix Ltd. has been marketing taliglucerase alfa in Israel since 2013 and in Brazil since January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2013, we entered into a Supply and
Technology Transfer Agreement, or the Brazil Agreement, with Fiocruz, for taliglucerase alfa. The agreement became effective
in January 2014. The technology transfer is designed to be completed in four stages and is intended to transfer to Fiocruz
the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole
expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the
technology transfer is seven years. Under the agreement, Fiocruz committed to purchase at least approximately $40 million
worth of taliglucerase alfa during the first two years of the term. Since the agreement went into effect, we have recorded
revenues of approximately $3.5 million for sales of taliglucerase alfa to Fiocruz in 2014 and, during the first quarter of
2015,  we  received a purchase order for approximately $5.7 million of taliglucerase
alfa out of which we have delivered approximately $1.7 million of the product. In subsequent years, Fiocruz is required to
purchase at least approximately $40 million worth of taliglucerase alfa per year. We are not required to complete the final
stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, Brazil, Israel and Chile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
PRX-102, or </FONT>alpha-GAL-A<FONT STYLE="font-family: Times New Roman, Times, Serif">, a therapeutic protein candidate for the
treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase I/II clinical trial. We
expect to report interim efficacy and safety results for the 1 mg/kg dose group of the trial during the third quarter of 2015
and to report final efficacy and safety results for the 0.2mg, 1 mg and 2mg/kg dose groups of the trial during the fourth quarter
of 2015. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
PRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein. We
expect to initiate a <FONT STYLE="font-family: Times New Roman, Times, Serif">proof of concept efficacy study</FONT> during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation. We expect to initiate a
proof of concept efficacy study during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells. PRX-102 has been the subject of successful proof of concept clinical trials, as described below, and we intend to focus
our efforts on a new formulation of the treatment during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold
the worldwide commercialization rights to all of our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
We have built an internal marketing team designed to serve the Israeli and Brazilian market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union
and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition,
we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2015, we announced our newly implemented
strategy for accelerated growth. The strategy centers around prioritizing existing and new pipeline candidates to focus on
clinically superior products  that offer a clear competitive advantage over
existing treatments. The strategy was the culmination of two month of intensive review by our management of the
company&rsquo;s internal resources and of the markets in which we think we can operate. The following highlights the details
of the strategic plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>PRX-102 for the Treatment of Fabry
disease</B>. PRX-102 is designed to be an improved enzyme replacement therapy product for the treatment of Fabry disease given
its potential for clinically superior outcomes and enhanced safety when compared to currently marketed enzyme replacement therapies.
The product candidate remains a key focus for our company, and we intend to aggressively push PRX-102 through clinical development.
Interim efficacy and safety data from our ongoing phase I/II trial are described in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Oral Anti-TNF (PRX-106) Anti Inflammatory</B>.
Oral anti-TNF represents a novel mode of administering a recombinant anti-TNF protein. We plan to initiate clinical efficacy trials
of Oral Anti-TNF during 2015. Upon reviewing the proof of concept (POC) data, expected in early 2016, we intend to collaborate
with a well-suited partner for further development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>AIR DNase (PRX-110) for Cystic
Fibrosis</B>. AIR DNase has an actin inhibition resistance that is designed to improve lung function and lower the incidence
of recurrent infections by enhancing the enzyme&rsquo;s efficacy in patients sputa. The product candidate has demonstrated
improved disease parameters in animal models and human sputum testing when compared to the currently marketed product. We
plan to initiate clinical efficacy trials of AIR DNase for the treatment of Cystic Fibrosis (CF) during 2015. Upon reviewing
the results of the trial, expected in early 2016, we intend to collaborate with a well-suited partner for further
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Oral GCD (PRX-112) for Gaucher Disease</B>.
Oral GCD represents a novel mode of administrating taliglucerase alfa. The initial clinical data generated for this compound in
pre-clinical and clinical trials is promising. In 2015, we intend to focus on improving the product candidate&rsquo;s formulation
and delivery in order to transform it into a commercially viable product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Potential Pipeline Candidates</B>.
We aim to expand our pipeline by leveraging the advantages of our proprietary ProCellEx<SUP>&reg;</SUP> protein expression technology.
The focus is expected to be on biologics with improved clinical profiles than the currently marketed proteins for these indications.
Biosimilars will not be a market on which we focus, and will only be considered in the case of proteins that are highly difficult
to express or that represent opportunities for early market entry arising from the intellectual property advantages arising from
ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Elelyso&trade; for Gaucher Disease</B>.
We anticipate continuing to increase market share in Israel. Additionally, our management intends to continue to work closely
with Pfizer, our collaboration partner, and with the Brazilian government, to increase sales globally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recombinant proteins have revolutionized the treatment of a
variety of diseases and disorders. Recombinant proteins are forms of human proteins that are produced, or expressed, using a mammalian,
plant, bacterial or yeast cell as a production engine. In the early 1970s, a number of key scientific breakthroughs, including,
among others, the demonstration of genetic engineering and genetic sequencing techniques, as well as the synthesis of genes, led
to the advancement of recombinant protein technology. As a result, the market for pharmaceutical therapeutics has undergone a
transformation as recombinant proteins and other biologic products have become an increasingly significant portion of the global
drug market and the focus of research worldwide. The IMS Institute for Healthcare Informatics reports that global biologic spending
was $169 billion in 2012 and anticipated to reach $221 billion in 2017 (<FONT STYLE="font-family: Times New Roman, Times, Serif">Report
by the IMS Institute for Healthcare Informatics</FONT>, Nov. 2013).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mammalian cell-based systems are the current industry standard
for expression of recombinant therapeutic glycoproteins (complex proteins that contain sugar residues), including catalytic enzymes
and monoclonal antibodies. Mammalian cell-based systems were first introduced in the late 1980s and are currently used to produce
many of the biotechnology industry&rsquo;s largest and most successful therapeutic proteins, including Epogen<SUP>&reg;</SUP>,
Neupogen<SUP>&reg;</SUP>, Cerezyme<SUP>&reg;</SUP>, Rituxan<SUP>&reg;</SUP>, Humira<SUP>&reg;</SUP>, Enbrel<SUP>&reg;</SUP>, Neulasta<SUP>&reg;</SUP>,
Remicade<SUP>&reg;</SUP> and Herceptin<SUP>&reg;</SUP>. Mammalian cell-based expression technology is based on the introduction
of a human gene encoding for a specific therapeutic protein into the genome of a mammalian cell. The cells most often used in
connection with mammalian cell-based protein expression are Chinese hamster ovary (CHO) cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mammalian cell-based expression systems have become the dominant
system for the expression of recombinant proteins due to their capacity for sophisticated, proper protein folding (which is necessary
for proteins to carry out their intended biological activity), assembly and post-expression modification, such as glycosilation
(the addition of sugar residues to a protein which is necessary to enable specific biological activity by the protein). While
bacterial and yeast cell-based expression systems were the first protein expression systems developed by the biotechnology industry
and remain cost-effective compared to mammalian cell-based production methodologies, proteins expressed in bacterial and yeast
cell-based systems lack the capacity for sophisticated protein folding, assembly and post-expression modifications, which are
key factors of mammalian cell-based systems. Accordingly, such systems cannot be used to produce glycoproteins or other complex
proteins and, therefore, bacterial and yeast cell-based systems are limited to the expression of the most basic, simple proteins,
such as insulin and growth hormones. Due to their significant advantages, mammalian cell-based expression systems can produce
proteins with superior quality and efficacy compared to proteins expressed in bacteria and yeast cell-based systems. As a result,
the majority of currently approved therapeutic proteins, as well as those under development, are produced in mammalian cell-based
systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Despite the utility and widespread use of mammalian cell-based
systems, they are subject to a number of disadvantages. CHO cells and other mammalian cells are highly sensitive and can only
be grown under near perfect conditions, requiring highly complex, expensive, stainless steel bioreactors which tightly regulate
the required temperature, pH and oxygen levels. As a result, such bioreactor systems are very costly and complicated to operate.
CHO cells and other mammalian cells are also susceptible to viral infections, including human viruses, and several cases of viral
contamination have occurred recently. The FDA and other regulatory authorities require viral inactivation and other rigorous and
detailed procedures for mammalian cell-based manufacturing processes in order to address these potential hazards, thereby increasing
the cost and time demands of such expression systems. Furthermore, the current FDA and other procedures only ensure screening
for scientifically identified, known viruses. Accordingly, compliance with current FDA and other procedures does not fully guarantee
that patients are protected against transmission of unknown or new potentially fatal viruses that may infect mammalian cells.
In addition, mammalian cell-based expression systems require large quantities of sophisticated and expensive growth medium to
accelerate the expression process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several companies and research institutions have explored alternatives
to mammalian cell-based production technologies that overcome some of these disadvantages, focusing primarily on the expression
of human proteins in genetically-modified organisms, or GMOs, such as transgenic field-grown, whole plants and transgenic animals.
However, these alternate techniques may be restricted by regulatory and environmental risks regarding contamination of agricultural
crops and by the difficulty in applying cGMP standards of the pharmaceutical industry to these expression technologies and none
of these technologies have been approved by the regulatory agencies with jurisdiction over any substantial market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ProCellEx: Our Proprietary Protein Expression System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx is our proprietary production system. We have developed
ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins.
ProCellEx consists of a comprehensive set of capabilities and proprietary technologies, including advanced genetic engineering
and plant cell culture technology, which enables us to produce complex, proprietary and biologically equivalent proteins for a
variety of human diseases. This protein expression system facilitates the creation and selection of high expressing, genetically
stable cell lines capable of expressing recombinant proteins. The entire protein expression process, from initial nucleotide cloning
to large-scale production of the protein product, occurs under cGMP-compliant, controlled processes. Our plant cell culture technology
uses plant cells, such as carrot and tobacco cells, which undergo advanced genetic engineering and are grown on an industrial
scale in a flexible bioreactor system. Cell growth, from scale up through large-scale production, takes place in flexible, sterile,
polyethylene bioreactors which are confined to a clean-room environment. Our bioreactors are well-suited for plant cell growth
using a simple, inexpensive, chemically-defined growth medium as a catalyst for growth. The reactors are custom-designed and optimized
for plant cell cultures, easy to use, entail low initial capital investment, are rapidly scalable at a low cost and require less
hands-on maintenance between cycles. Our protein expression system does not involve mammalian or animal components or transgenic
field-grown, whole plants at any point in the production process. As a result, through our ProCellEx protein expression system,
we believe that we can develop recombinant therapeutic proteins yielding substantial cost advantages, accelerated development
and other competitive benefits when compared to mammalian cell-based protein expression systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx system is capable of producing proteins with
an amino acid sequence and three dimensional structure practically equivalent to that of the desired human protein, and with a
very similar, although not identical, glycan, or sugar, structure, as demonstrated in our internal research and external laboratory
studies. In collaboration with the Weizmann Institute of Science, we have demonstrated that the three-dimensional structure of
a protein expressed in our proprietary plant cell-based expression system retains the same three-dimensional structure as exhibited
by the mammalian cell-based expressed version of the same protein. In addition, proteins produced by our ProCellEx system maintain
the biological activity that characterize that of the naturally-produced proteins. Based on these results, we believe that proteins
developed using our ProCellEx protein expression system have the intended composition and correct biological activity of their
human equivalent proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the ProCellEx system will enable us, in certain
cases, to develop and commercialize recombinant proteins without infringing upon the method-based patents or other intellectual
property rights of third parties. The major elements of our ProCellEx system are patent protected in most major countries. Moreover,
we expect to enjoy method-based patent protection for the proteins we develop using our proprietary ProCellEx protein expression
technology, although there can be no assurance that any such patents will be granted. In some cases, we may be able to obtain
patent protection for the compositions of the proteins themselves. We have filed for United States and international composition
of matter patents for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have successfully demonstrated the feasibility of our ProCellEx
system through: the FDA&rsquo;s approval of taliglucerase alfa; the clinical and preclinical studies we have performed to date,
including the positive efficacy and safety data in our clinical trials for both Elelyso and PRX102 for the treatment of Fabry
disease; preclinical results in well-known models in our enzyme for each of Fabry disease, DNase and antiTNF; and by expressing,
on an exploratory, research scale, many additional complex therapeutic proteins belonging to different drug classes, such as enzymes,
hormones, monoclonal antibodies, cytokines and vaccines. The therapeutic proteins we have expressed to date in research models
have produced the intended composition and similar biological activity compared to their respective human-equivalent proteins.
Moreover, several of such proteins demonstrated advantageous biological activity when compared to the biotherapeutics currently
available in the market to treat the applicable disease or disorder. We believe that the FDA&rsquo;s approval of taliglucerase
alfa represents a strong proof-of-concept of our ProCellEx system and plant cell-based protein expression technology. We also
believe that the significant benefits of our ProCellEx system, if further substantiated in clinical trials and in the successful
commercialization of taliglucerase alfa and our other product candidates, have the potential to transform the industry standard
for the development of complex therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also using our ProCellEx system to produce active recombinant
proteins through oral administration of plant cells expressing biotherapeutic proteins. In such method, an enzyme is naturally
encapsulated within carrot cells genetically engineered to express the targeted enzyme. Plant cells have the unique attribute
of a cellulose cell wall which makes them resistant to enzyme degradation when passing through the digestive tract. The plant
cell itself serves as a delivery vehicle, once released and absorbed, to transport the enzyme in active form to the bloodstream.
With initial proof of concept now demonstrated, this would be the first time an enzyme will be administered orally rather than
through intravenous therapy. To date we have completed successful preclinical animal studies for oral GCD and oral antiTNF, and
in early clinical trials of oral GCD in Gaucher patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our manufacturing facility, in which we
utilize our ProCellEx system, was determined to be acceptable by each of the FDA, the European Medicines Agency, or the EMA,
ANVISA, the Israeli MOH, the Australian Therapeutic Goods Administration, or the TGA, and Health Canada, after GMP
inspections were performed as part of their respective reviews for marketing approval of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Advantages of Our ProCellEx Protein Expression
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to continue to leverage the multiple unique advantages
of our proprietary ProCellEx protein expression system, including our advanced genetic engineering technology and plant cell-based
protein expression methods, to develop our pipeline. Significant advantages of ProCellEx over mammalian, bacterial, yeast and
transgenic cell-based expression technologies, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Biologic Optimization.</I> </B>Our
ProCellEx protein expression system has internal capabilities developed to improve the biologic dynamics of the expressed protein.
For example, the proteins produced through our system have uniform glycosilation patterns and therefore do not require the lengthy
and expensive post-expression modifications that are required for certain proteins produced by mammalian cell-based systems. Such
post-expression modifications in mammalian cell-produced proteins are made in order to expose the terminal mannose sugar residues,
which are structures on a protein that are key elements in allowing the expressed protein to bind to a target cell and subsequently
be taken into the target cell for therapeutic benefit. In addition, these steps do not guarantee the exposure of all of the
required terminal mannose sugar residues, resulting in potentially lower effective yields and inconsistency in potency from batch
to batch. We believe this quality increases the potency and consistency of the expressed proteins, and thus, the effectiveness
of the protein which presents an additional cost advantage of ProCellEx over competing protein expression methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Ability to Penetrate Certain Patent-Protected
Markets.</I> </B>ProCellEx has the potential to provide workaround manufacturing that does not infringe the method-based patents
or other intellectual property rights of third parties. Certain biotherapeutic proteins available for commercial sale are not
protected by patents that cover the compound and are available for use in the public domain. Rather, the process of expressing
the protein product in mammalian or bacterial cell systems is protected by method-based patents. Using our plant cell-based protein
expression technology, we are able to express an equivalent protein without infringing upon these method-based patents. Moreover,
we expect to enjoy method-based patent protection for the proteins we develop using our proprietary ProCellEx protein expression
technology, although there can be no assurance that any such patents will be granted. In some cases, we may be able to obtain
patent protection for the compositions of the proteins themselves. We have filed for U.S. and international composition of matter
patents for taliglucerase alfa, PRX-102 and certain of our other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Broad Range of Expression Capabilities.
</I></B>Our ProCellEx protein expression system is able to produce a broad array of complex glycosilated proteins, which are difficult
to produce in other systems, such as bacterial and yeast cell-based systems, as well as CHO (Chinese Hamster Ovary) systems. We
have successfully demonstrated the feasibility of our ProCellEx system by producing, on an exploratory, research scale, a variety
of therapeutic proteins belonging to different classes of recombinant drugs, such as enzymes, hormones, monoclonal antibodies,
cytokines and vaccines. We have demonstrated that the recombinant proteins we have expressed<B> </B>to date have the intended
composition and correct biological activity of their human-equivalent protein, with several of such proteins demonstrating advantageous
biological activity compared to the currently available biotherapeutics. In specific cases, we have been successful in expressing
proteins that have not been successfully expressed in other production systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Significantly Lower Capital and Production
Costs.</I></B> Our ProCellEx system entails a lower cost of scale-up and of production. Plant cells grow rapidly under a variety
of conditions and are not as sensitive as mammalian cells are to temperature, pH and oxygen levels. Our system, therefore, does
not require the highly complex, expensive, stainless steel bioreactors typically used in mammalian cell-based production systems
to maintain very specific temperature, pH and oxygen levels. Instead, we use simple polyethylene bioreactors that can be maintained
at the room temperature of the clean-room in which they are placed. This system also reduces ongoing production and monitoring
costs typically associated with mammalian cell-based expression technologies. Furthermore, while mammalian cell-based systems
require very costly growth media at various stages of the production process to achieve target yields of proteins, plant cells
require only simple and much less expensive solutions based on sugar, water and microelements at infrequent intervals to achieve
target yields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Elimination of the Risk of Viral
Transmission or Infection by Mammalian Components.</I> </B>By nature, plant cells do not carry the risk of infection by human
or other animal viruses. As a result, the risk of contamination of our products under development and the potential risk of viral
transmission from our products and product candidates to future patients, whether from known or unknown mammalian viruses, is
eliminated. Because our products and product candidates do not bear the risk of mammalian viral transmission, we are not required
by the FDA or other regulatory authorities to perform the constant monitoring procedures for mammalian viruses during the protein
expression process that are required in mammalian cell-based production. In addition, the production process of our ProCellEx
system is void of any mammalian components which are susceptible to the transmission of prions, such as those related to bovine
spongiform encephalopathy (commonly known as &ldquo;mad-cow disease&rdquo;). These factors further reduce the risks and operating
costs of our ProCellEx system compared to mammalian cell-based expression systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I>Potential ability to administer
active therapeutic enzymes</I></B><I> <B>orally. </B></I>We are using our ProCellEx system to produce active recombinant proteins
through oral administration of plant cells expressing biotherapeutic proteins. Plant cells have the unique attribute of a cellulose
cell wall which makes them resistant to enzyme degradation when passing through the digestive tract. The plant cell itself serves
as a delivery vehicle, once released and absorbed, to transport the enzyme in active form to the bloodstream. If proven effective,
this would be the first time an enzyme will be administered orally rather than through intravenous therapy. To date we have completed
successful preclinical animal studies for oral GCD and oral anti TNF, and early clinical trials of oral GCD in Gaucher patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Elelyso, Our First Commercial Product</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elelyso (taliglucerase alfa), our first commercial product,
is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. On May 1, 2012, the
FDA approved Elelyso for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a
confirmed diagnosis of type 1 Gaucher disease. It was subsequently approved by the Israeli MOH, ANVISA and the regulatory authorities
of other countries<FONT STYLE="font-family: Times New Roman, Times, Serif">. In August 2014, the FDA approved Elelyso for injection
for pediatric patients and the Israeli MOH approved the pediatric indication in January 2015. Prior to the U.S. pediatric approval,
Elelyso was approved for pediatric indications in Australia and Canada but in no other jurisdiction. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that taliglucerase alfa has the potential to offer
patients and healthcare payors an effective and cost efficient treatment of Gaucher disease compared to the currently available
ERTs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Gaucher Disease Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gaucher disease, a hereditary, genetic disorder with severe
and debilitating symptoms, is the most prevalent lysosomal storage disorder in humans. Lysosomal storage disorders are metabolic
disorders in which a lysosomal enzyme, a protein that degrades cellular substrates in the lysosomes of cells, is mutated or deficient.
Lysosomes are small membrane-bound cellular structures within cells that contain enzymes necessary for intracellular digestion.
Gaucher disease is caused by mutations or deficiencies in the gene encoding GCD, a lysosomal enzyme that catalyzes the degradation
of the fatty substrate, glucosylceramide (GlcCer). The normal degradation products of GlcCer are glucose and ceramide, which are
easily excreted by the cells through normal biological processes. Patients with Gaucher disease lack or otherwise have dysfunctional
GCD and, accordingly, are not able to break down GlcCer. The absence of an active GCD enzyme leads to the accumulation of GlcCer
in lysosomes of certain white blood cells called macrophages. Macrophages affected by the disease become highly enlarged due to
the accumulation of GlcCer and are referred to as &ldquo;Gaucher cells.&rdquo; Gaucher cells accumulate in the spleen, liver,
lungs, bone marrow and brain. Signs and symptoms of Gaucher disease may include enlarged liver and spleen, abnormally low levels
of red blood cells and platelets and skeletal complications. In some cases, the patient may suffer an impairment of the central
nervous system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Current Treatments for Gaucher Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The standard of care for Gaucher disease is enzyme replacement
therapy using recombinant GCD to replace the mutated or deficient natural GCD enzyme. It is estimated that there are approximately
12,000 people suffering from Gaucher disease worldwide, but only approximately 6,000 patients are undergoing treatment. Enzyme
replacement therapy is a medical treatment in which recombinant enzymes are injected into patients in whom the enzyme is lacking
or dysfunctional. Cerezyme and VPRIV<SUP>&reg;</SUP>, enzyme replacement therapies commercialized by Genzyme Corporation (acquired
by Sanofi), or Genzyme, and Shire plc, or Shire, respectively, are the only recombinant GCDs currently available on the market
for the treatment of Gaucher disease. As enzyme replacement therapy does not cure the genetic disorder, but rather provides an
external source for transfusion of the missing or mutated enzyme, Gaucher patients generally receive the treatment over their
entire lifetime. According to public reports by Sanofi, consolidated sales of Cerezyme during the year ended December 31, 2014
were &euro;715 million (or approximately $865 million), a growth of approximately 8% compared to the same period in 2013. Shire
reported annual worldwide sales of VPRIV of approximately $367 million in 2014, a growth of 7% compared to VPRIV&rsquo;s sales
in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Cerdelga<SUP>&reg;</SUP> (eliglustat) is a substrate
reduction therapy for Gaucher disease marketed by Sanofi. Cerdelga was approved for marketing by the FDA in August 2014 and by
the European Commission in January 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cerezyme is produced through a mammalian cell-based protein
expression process in CHO cells and VPRIV is produced using a human cancer cell line. There are no known severe side effects to
the use of Cerezyme or VPRIV, and Cerezyme&rsquo;s approved use over the past decade suggests that it is an effective treatment
of Gaucher disease. However, Cerezyme and VPRIV are both subject to the limitations of most mammalian cell-based therapeutic proteins,
including lengthy and costly production processes and contamination risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zavesca (miglustat), which is marketed by Actelion Ltd., or
Actelion, is a small molecule drug for the treatment of Gaucher disease. Zavesca has been approved by the FDA for use in the United
States as an oral treatment. However, it has many side effects and the FDA has approved it only for administration to those patients
who cannot be treated through ERT, and, accordingly, have no other treatment alternative. As a result, Zavesca&rsquo;s use has
been limited with respect to treating Gaucher disease. However, Zavesca is also used to treat other rare disorders. Actelion has
reported total sales of Zavesca of approximately CHF 103 million (approximately $104 million) in 2014, an increase of approximately
8% compared to sales in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Pipeline Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 for the Treatment of Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing PRX-102, our proprietary plant cell expressed
chemically modified version of the recombinant alpha-GAL-A protein, a therapeutic enzyme, for the treatment of Fabry disease,
a rare genetic lysosomal storage disorder. We believe that PRX-102 has the potential to be an improved version of the currently
marketed Fabry disease enzymes, Fabrazyme<SUP>&reg;</SUP> and Replagal<SUP>&reg;</SUP>, with improved activity in the Fabry disease
target organs and significantly longer half-life due to higher stability, which together can potentially lead to improved substrate
clearance. We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Fabry Disease Background</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fabry disease is characterized by subnormal or absent enzymatic
activity of alpha-GAL-A, a lysosomal enzyme which primarily catalyses the hydrolysis of terminal alpha-galactosyl groups of glycolipids,
mainly the glycosphingolipid globotriaosylceramide (Gb3). The accumulation of Gb3 in body tissues results in Fabry disease. The
ultimate consequence of glycosphingolipid deposition in the vasculature and other tissues is end-organ failure, particularly of
the kidney, but also of the heart and cerebrovascular system. In addition, involvement of the central, peripheral and autonomic
nervous systems results in episodes of pain and impaired peripheral sensation. Fabry disease affects approximately 8,000 people
globally. In PRX-102, the prh-alpha-GALA, naturally occurring as a homodimer, is PEGylated and cross-linked to support and reinforce
the homodimeric structure, which is crucial for the enzymatic activity of this enzyme. PRX-102 has been shown to be taken up by
Fabry patients&rsquo; cells where it localizes to the lysosome, in which Gb3 accumulates. PRX-102 is characterized by higher stability
under physiologically relevant conditions, and extended circulation residence time as compared to current ERTs for Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Current Treatments for Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently there are two drugs available on the market to treat
Fabry disease. Fabrazyme, marketed by Genzyme, is approved for the treatment of Fabry disease in the United States and the European
Union. Sanofi reported &euro;460&nbsp;million (approximately $557 million) in worldwide sales of Fabrazyme in 2014, a growth of
23% compared to 2013. The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed
by Shire. Shire reported $500 million in sales of Replagal in 2014, an increase of 7% compared to 2013. According to public reports
by Shire, during 2012 Shire withdrew its Biologics License Application (BLA) for Replagal with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2015, we announced the completion of enrollment
in our phase I/II clinical trial in adult Fabry patients.&nbsp;The phase I/II clinical trial is a worldwide, multi-center, open
label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy parameters of PRX-102
in adult Fabry patients. There were 18 adult Fabry patients (11 male and 7 female) enrolled in the trial, each in one of three
dosing groups, 0.2 mg/kg, 1mg/kg and 2mg/kg. Each patient receives intravenous infusions of PRX-102 every two weeks for 12 weeks,
with a six-month efficacy follow up period. All patients that completed the trial have opted to continue to receive PRX-102 in
an open-label extension trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January and February 2015, we announced positive interim
efficacy and safety data from the study. PRX-102 demonstrated meaningful clinical benefits across the following key disease parameters
already in the low dose of 0.2 mg/kg:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">&bull;</TD><TD>Major reduction in Gb3 in Renal Peritubular Capillaries;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">&bull;</TD><TD>Significant improvement in all pain parameters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">&bull;</TD><TD>Stabilization of cardiac and kidney function with favorable
                                         trends; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">&bull;</TD><TD>Low level of antibody formation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interim efficacy analysis includes six patients enrolled
in the 0.2mg/kg dose group at six months of treatment (for Gb3 in renal peritubular capillaries n=5). The interim safety analysis
includes 12 patients; six patients enrolled in the 0.2mg/kg dose group and six patients enrolled in the 1mg/kg dose group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an analysis of kidney biopsies with randomized blinded
scoring, PRX-102 demonstrated a major reduction from baseline in renal peritubular capillary Gb3 using both the quantitative Barisoni
Lipid Inclusion Scoring System (BLISS) and the semi quantitative method. Using the BLISS method, a reduction in the rate of 82.2%
for males, 65.4% for females and 75.5% for males and females combined were observed. Absolute change from baseline was -4.5, -1.2
and -3.2, respectively. Applying the semi quantitative scoring method, commonly used by approved enzyme replacement therapies,
PRX-102 demonstrated a reduction of 69.6% in abnormal capillary score.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Using the well-accepted Brief Pain Inventory scale, a 100%
reduction in pain at its worst, a 60.0% reduction in mean severity, and 78.8% reduction on mean interference (which includes walking,
working, sleeping, enjoyment of life and others) were observed. In addition to a 100% reduction in worst pain, all patients also
reported a 100% reduction in mean interference, with the exception of one patient who experienced a 33.3% reduction. See Figure
1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 1. Improvement in Brief Pain Inventory (BPI)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><img src="tpg14.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reductions of plasma Lyso-Gb3 and plasma Gb3 concentrations
were also observed. Females (n=2) demonstrated a -2.4 ng/mL mean change in Lyso-Gb3 and a -0.4 &micro;g/mL mean change in plasma
Gb3. Males (n=4) demonstrated a -96.2 ng/mL and a -1.3 &micro;g/mL change, respectively. All patients demonstrated a reduction
in absolute Lyso-Gb3 concentration and all patients demonstrated a reduction in Gb3 except for one patient. See Figure 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 2. Semi Quantitative Method</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="tpg15a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A meaningful reduction in the total score of Mainz Severity
Score Index (MSSI), which looks at general, neurological, cardiovascular and renal parameters, was also demonstrated, with a reduction
in all parameters included in MSSI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The leading causes for death of Fabry patients include cardiovascular
disease and renal failures. All patients that participated in the trial exhibited stable cardiac and kidney function, with favorable
trends after only six months, as measured by left ventricular mass (LVM), left ventricular mass index (LVMI), ejection fraction
(EF), estimated glomerular filtration rate (eGFR) and urine protein. See Figures 3 and 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 3. Stability of Cardiac Parameters by MRI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="tpg15b.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 4. Stable Kidney Functions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="tpg16.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The safety analysis for adverse events represents a total of
6.7 patient years. PRX-102 was well tolerated, with the majority of events being mild and moderate. Only one of the 12 patients
evaluated for safety experienced hypersensitivity and discontinued per protocol.&nbsp; For this patient, anti PRX-102 IgG was
negative and anti PRX-102 IgE was positive at baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Six patients receiving the 0.2mg/kg dose and two patients receiving
the 1m/kg dose were evaluated for antibody formation. Of these eight patients, only two patients, or 33% of the 0.2 mg/kg dose
cohort, developed antibodies. All adverse events experienced by these patients were deemed by the investigators to be unrelated
to PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRX-102 has a significantly longer circulatory half-life (T&frac12;)
of approximately 60 hours, and a substantially higher area under the curve (AUC) of approximately 70,000 ng/mL*hour for the 0.2mg/kg
dose, when compared to currently marketed enzyme replacement therapies. These enhanced pharmacokinetic benefits are believed to
be the result of the chemical modifications made to PRX-102, including cross-linking and covalent bonding to make the enzyme a
more stable homo-dimer. See Figures 5 and 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure
                                         5. Improved Pharmacokinetics</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><img src="tpg16a.jpg"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P></td>
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure
                                         6. Area under the Curve (AUC)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><img src="tpg16b.jpg">&nbsp;</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to report interim results from the 1mg/kg cohort
in the third quarter of 2015, and full top-line results from all dosing cohorts in the fourth quarter of 2015. We intend to request
an end of phase II meeting with the FDA in the fourth quarter of 2015, and anticipate initiating a phase III pivotal trial in
early 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B>PRX-106; Oral antiTNF as an Anti Inflammatory
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our oral antiTNF product candidate is a recombinant antiTNF
(Tumor, Necrosis Factor) protein that we are expressing through ProCellEx. AntiTNF drugs represent the biggest category of biological
drugs in the world today with combined sales of over $20 billion a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oral antiTNF is a plant cell-expressed form of the fused protein
that is naturally encapsulated within carrot cells genetically engineered to express the enzyme. Plant cells have the unique attribute
of a cellulose cell wall which makes them resistant to enzyme degradation when passing through the digestive tract. The plant
cell itself serves as a delivery vehicle, once released and absorbed, to transport the enzyme in active form to the bloodstream.
If proven effective, our experimental oral antiTNF would be the first protein to be administered orally rather than through injectable
therapy. We believe that our oral delivery mechanism could be applied to additional proteins and has the potential to change the
method of protein administration in certain indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently developing oral antiTNF an orally-administered
anti inflammatory using plant cells as a natural capsule for the expressed protein. In preclinical studies, oral PRX-106 alleviated
immune-mediated hepatitis and reduced interferon gamma levels in a concanavalin A (ConA) inflammatory mouse model. Additionally,
oral administration of PRX-106 alleviated immune mediated colitis in a well-established mouse model, promoting serum levels of
anti-inflammatory IL-10 and regulatory T-cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">pr-antiTNF is a plant cell-expressed recombinant fusion protein
made from the binding domain of the human TNF receptor (TNFR), fused to the Fc component of a human antibody domain. It has an
identical amino acid sequence to Enbrel and our in vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits
similar or better activity to Enbrel. See Figure 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 7. IBD Animal Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="tpg17.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are now conducting additional preclinical studies on oral antiTNF for several attractive indications, and we </FONT>plan to initiate
clinical efficacy trials of oral anti TNF during 2015. Upon reviewing the proof of concept (POC) data, expected in early 2016,
we intend to collaborate with a well-suited partner for further development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B><I>PRX-110; AIR DNase for the Treatment of Cystic
Fibrosis </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRX-110, or AIR DNase, is our plant cell recombinant form of
human deoxyribonuclease I (DNase I) that we are developing for the treatment of Cystic Fibrosis, to be administered by inhalation.
DNase I cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of Cystic Fibrosis patients. Currently,
Pulmozyme<SUP>&reg;</SUP> is the only DNase I commercially available, with annual sales of approximately $626 million in sales
for 2014, according to public reports by F. Hoffman-La Roche Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In vitro studies with PRX-110 demonstrated improved enzyme
kinetics, less sensitivity to inhibition by actin and improved ex vivo efficacy when compared to Pulmozyme. Preclinical studies
of PRX-110 administered by inhalation showed substantial enzymatic activity in lungs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AIR DNase has an actin inhibition resistance that is designed
to improve lung function and lower the incidence of recurrent infections by enhancing the enzyme&rsquo;s efficacy in patients&rsquo;
sputa. The product candidate has demonstrated improved disease parameters in animal and human models sputum testing when compared
to the currently marketed product. See Figure 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 8. Rheology Data Analysis in in human sputum samples
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><img src="tpg18.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We plan to initiate clinical efficacy trials of AIR DNase for
the treatment of Cystic Fibrosis during 2015. Upon reviewing the results of the trial, expected in early 2016, we intend to collaborate
with a well-suited partner for further development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-112; Orally Administered GCD for the Treatment
of Gaucher Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing PRX-112, an orally-delivered glucocerebrosidase
(GCD) enzyme for the enzyme replacement therapy treatment of Gaucher disease. In 2015, our focus with respect to oral GCD, will
be on improving oral GCD&rsquo;s formulation and delivery in order to transform the product candidate into a commercially viable
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Oral GCD Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2015, the last Gaucher patient was treated in our
phase IIa clinical trial of oral GCD. The phase IIa clinical trial was a 28-day open-label, sequential dose escalation study to
evaluate the safety of PRX-112, and study the dose dependent pharmacokinetics of PRX-112 in na&iuml;ve adult Gaucher patients.
The primary objective of the trial was to measure the safety of oral GCD in Gaucher patients. Additional objectives included an
evaluation of oral GCD&rsquo;s pharmacokinetic profile and exploratory endpoints. The trial covered 17 na&iuml;ve adult Gaucher
patients. Subjects receive once daily oral administrations of PRX-112 for five consecutive days at each dose, with a two-day washout
period between doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An initial analysis of the results demonstrates that oral
GCD was well tolerated. No patient discontinued the study prematurely, there were no drug-related serious adverse events
(SAE) reported and no treatment-induced antibodies were detected in any of the patients participating in the trial. Four
patients experienced adverse reactions, all of which were transient in nature, mild and moderate and the patients that
experienced the adverse reactions recovered without further events. Active GCD enzyme was detected in the blood circulation
of 10 out of the 17 participants in the trial. In addition, elevated platelet levels were observed in 10 out of the 17
participants in the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to focus our efforts on a new formulation of the
treatment during 2015 in order to prepare a viable solution for further clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Phase I Trial Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We completed a phase I clinical trial of oral GCD, which was
an exploratory, open label study to evaluate the safety and pharmacokinetics of oral GCD in Gaucher patients. Patients received
re-suspended lyophilized carrot cells in a single oral administration during the first segment of the trial and three consecutive
daily administrations during the second segment of the trial. The primary objective of the trial was to measure the safety of
oral GCD in Gaucher patients. Additional objectives included an evaluation of oral GCD&rsquo;s pharmacokinetic profile and exploratory
endpoints. The results demonstrate that oral GCD was well tolerated across all three doses tested. No patient discontinued the
study prematurely, there were no drug related serious adverse events (SAE) reported and no treatment-induced antibodies were detected
in any of the patients participating in the trial. All adverse reactions were transient in nature, mild and moderate and the patients
that experienced the adverse reactions recovered without further events. One patient experienced nausea related to treatment and
two patients experienced mild dizziness and dizziness, which was possibly related to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmacokinetic (PK) studies revealed that active GCD enzyme
was detected in the patients&rsquo; blood circulation, measured in the well-established assay in leucocytes of Gaucher patients,
following oral administration of oral GCD. C max analysis showed an average increase of over 100% in enzymatic activity from base
line, with an increase ranging from approximately 50% to 350% among the different, individual patients in the study. In general,
the PK profile of oral GCD has a pattern of continuous enzyme presence over approximately 30 hours from administration. Platelet
levels in 3 out of 8 thrombocytopenic Gaucher patients tested showed meaningful, rapid and unexpected improvement in platelet
count after short-term treatment with oral GCD. The data demonstrates platelet count increases ranging from 27% to 78% from base
line. Thus, with a daily oral administration of oral GCD, we expect to achieve a steady state level of active GCD enzyme in the
blood circulation of patients similar to the physiological state in healthy individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Platelet levels in 3 out of 8 thrombocytopenic Gaucher patients
tested showed meaningful, rapid and unexpected improvement in platelet count after short-term treatment with Oral GCD. The data
demonstrates platelet count increases ranging from 27% to 78% from base line.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Commercialization Agreement for <FONT STYLE="font-family: Times New Roman, Times, Serif">taliglucerase
alfa</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive,
worldwide license to develop and commercialize taliglucerase alfa. Under the terms and conditions of the Pfizer Agreement, Protalix
Ltd. retained the right to commercialize taliglucerase alfa in Israel and Brazil. In connection with the execution of the Pfizer
Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement
and subsequently paid Protalix Ltd. an additional $30.0 million milestone payment. In addition to the milestone payments, Protalix
Ltd. is eligible to payments equal to 40% of the net profits earned by Pfizer on sales of taliglucerase alfa (or share 40% of
the net loss). In calculating the net profits, there are certain agreed upon limits on the amounts that may be deducted from gross
sales for certain expenses and costs of goods sold. Protalix Ltd. retained the manufacturing rights to taliglucerase alfa, and
Pfizer and Protalix Ltd. agreed to a specific allocation of the responsibilities for the continued development efforts for taliglucerase
alfa prior to its approval. Protalix Ltd. will manufacture all of the taliglucerase alfa needed for all purposes under the agreement
and Pfizer will purchase the taliglucerase alfa from Protalix Ltd., subject to certain terms and conditions. </FONT>The Pfizer
Agreement also provides for reimbursement by Pfizer of certain costs to be incurred by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will be subject to a withholding tax on the U.S. revenue
source portion of the payments made to us for our share of Pfizer&rsquo;s in net profits under the Pfizer Agreement. Currently,
the withholding tax rate is 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology Transfer Agreement with Fiocruz</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We entered into the Brazil Agreement with Fiocruz in June 2013,
which became effective in January 2014. The technology transfer is designed to be completed in four stages and is intended to
transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility,
at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial
term of the technology transfer is seven years. Under the agreement, Fiocruz committed to purchase at least approximately $40
million worth of taliglucerase alfa during the first two years of the term. Since the agreement went into effect, we have recorded
revenues of approximately $3.5 million for sales of taliglucerase alfa to Fiocruz in 2014 and, during the first quarter of 2015, we
received a purchase order for  approximately $5.7 million of taliglucerase alfa out of which
we have delivered approximately $1.7 million of the product. In subsequent years, Fiocruz is required to purchase at least approximately
$40 million worth of taliglucerase alfa per year. We are not required to complete the final stage of the technology
transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. If Fiocruz fails to comply with
certain of its purchase commitments under the agreement, we may terminate the agreement, and all of our rights to the technology
will be returned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a proactive intellectual property strategy which
includes patent filings in multiple jurisdictions, including the United States and other commercially significant markets. As
of December 31, 2014, we hold, or have license rights to 64 patents and 95 pending patent applications with respect to various
compositions, methods of production and methods of use relating to our ProCellEx protein expression system and our proprietary
product pipeline. As of December 31, 2014, we hold, with a third party, one joint patent and one joint patent application, and
licensed rights to two patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our competitive position and future success depend in part
on our ability, and that of our licensees, to obtain and leverage the intellectual property covering our product candidates, know-how,
methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property
and to operate without infringing the intellectual property of third parties. We seek to protect our competitive position by filing
United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology
and improvements to existing technology. Our patent strategy includes obtaining patents, where possible, on methods of production,
compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership
opportunities to develop and maintain our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2014, our patent portfolio consists of several
patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and
system and product candidates, as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect                                          to our ProCellEx protein expression system, we have been issued 19
                                                                                                                 patents in the United                                          States, Australia, the European Union, Israel, Canada, the
                                                                                                                 Czech Republic, Hungary, Japan,                                          Poland, Mexico, Hong Kong, India and Korea, and hold
                                                                                                                 three pending patent applications.                                          Among other things, the patents cover the methods
                                                                                                                 that we use for culturing and harvesting                                          plant cells and/or tissues in consecutive
                                                                                                                 cycles. Of the issued patents in this family, 13 are expected to expire in 2017 and six are expected to expire in 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                         to our ProCellEx protein expression system, we hold four issued patents and 13 patent applications
                                         relating to the large scale production of proteins in cultured plant cells. The issued
                                         patents and any patents to issue in the future based on pending patent applications in
                                         this patent family are expected to expire in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing 23 issued patents in India, South Africa, Russian Federation,
                                         Australia, China, the United States, Ukraine, Singapore, Japan, Europe, Hong Kong, Mexico, Korea Canada, Brazil and Israel and 13 patent applications relating to the production
                                         of recombinant glycosylated lysosomal proteins in our plant culture platform, including
                                         taliglucerase alfa, and uses of these proteins and cells containing these proteins for
                                         the treatment of lysosomal disorders. The issued patents and any patents to issue in
                                         the future based on pending patent applications in this patent family are expected to
                                         expire in 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing four granted patents relating to a system and method for production
                                         of antibodies in a plant cell culture, and antibodies produced in such a system. The
                                         issued patents in this patent family are expected to expire in 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing four issued patents in South Africa, Australia and Singapore,
                                         and seven pending patent applications relating to a new method for delivering active recombinant
                                         proteins systemically through oral administration of transgenic plant cells. The issued
                                         patents and any patents to issue in the future based on patent applications in this patent
                                         family are expected to expire in 2026.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing three granted patents in the United States, South Africa and
                                         Australia, and five pending patent applications relating to saccharide containing protein
                                         conjugates. The issued patents and any patents to issue in the future based on the patent
                                         applications in this patent family are expected to expire in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing 11 pending patent application relating to Nucleic Acid construct
                                         for expression of alpha-galactosidase enzyme in plants and plant cells. The patents to
                                         issue in the future based on the patent applications in this patent family, if at all, are expected to  expire
                                         in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing three granted patents in Europe, New Zealand and South Africa
                                         and 16 pending patent applications relating to multimeric protein structures of &alpha;-galactosidase
                                         and to uses thereof in treating Fabry disease. The issued patents and any patents to
                                         issue in the future based on the patent applications in this patent family are expected
                                         to expire in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing two pending patent applications relating to therapeutic proteins
                                         with stabilized quaternary structure. The patents to issue in the future based on the
                                         patent applications in this patent family, if at all, are expected to  expire in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                         patent family containing one granted patent in Europe and two pending patent applications
                                         relating to multimeric protein structures of glucocerebrosidase and to uses thereof in
                                         treating Gaucher disease. The issued patent and any patent applications to issue in the
                                         future based on the patent applications in this patent family, if at all, are expected to  expire in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold three
                                         patent families containing eight pending applications relating to plant recombinant human
                                         DNase I and uses in therapy. The patents to issue in the future based on these patent
                                         applications, if at all, are expected to expire in 2033.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold two
                                         PCTs and patent applications relating to plant recombinant TNF alpha inhibitor polypeptides.
                                         The patents to issue in the future based on these patent applications, if at all, are expected to
                                         expire in 2034.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our patent
                                         portfolio includes a patent that we co-own that covers human glycoprotein hormone and
                                         chain splice variants, including isolated nucleic acids encoding these variants.&nbsp;
                                         More specifically, this patent covers a new splice variant of human FSH. This patent
                                         was issued in the United States and is expected to expire in 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                         to taliglucerase alfa, we have licensed the rights to two patents from Virginia Tech
                                         Intellectual Properties, Inc., or Virginia Tech, that are expected to expire in 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.25pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We co-own
                                         a PCT that covers use of plant cells expressing a TNF alpha polypeptide inhibitor in
                                         therapy.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.25pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold two
                                         patent families relating to oral delivery of plant cells comprising recombinant glucocerebrosidase
                                         for the treatment of Gaucher disease. The patents to issue in the future based on patent
                                         application in this patent family, if at all, are expected to expire in 2033 and 2035.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are aware of U.S. patents, and corresponding international
counterparts of such patents, owned by third parties that contain claims covering methods of producing GCD. We do not believe
that, if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to
infringe any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that,
if we choose or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable
terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2005, Protalix Ltd. entered into a license agreement
with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize
Icon&rsquo;s technology to express certain proteins in our ProCellEx protein expression system. Under the terms of the agreement,
we are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&rsquo;s
technology in our technology. As consideration for the license, we are obligated to make royalty payments equal to varying low,
single-digit percentages of net sales of products by us, our affiliates, or any sublicensees under the agreement. In addition,
we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license,
upon the achievement of certain milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Our license agreement with
Icon remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under
the agreement expire, 20 years after the first commercial sale of any product under the agreement. Icon may terminate the agreement
upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such
material breach within 30 days after we receive such notice. Further, Icon may terminate the agreement in connection with certain
events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to
conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to
reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation
to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2005, Protalix Ltd. entered into a license agreement
with Virginia Tech University, pursuant to which we received a non-exclusive worldwide license to make, have made, use, sell,
offer for sale and import certain of Virginia Tech&rsquo;s patents. As consideration for the license, we made a one-time license
fee payment to Virginia Tech, and we are obligated to make royalty payments equal to varying low, single-digit percentages of
net sales of licensed products by Protalix Ltd., its subsidiaries and/or their affiliates. Upon commercialization of a licensed
product, the royalty payment is subject to a low, annual minimum amount. In addition, we were obligated to make milestone payments
equal to $150,000, in the aggregate, upon the achievement of certain milestones, which milestone payments have been satisfied.
We have the right to grant sublicenses under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our license agreement with Virginia Tech remains in effect
until the earlier of the expiration of the last patent under the agreement or 10 years after the first commercial sale of any
licensed product. Virginia Tech may terminate the agreement upon written notice to us that we are in material breach of our obligations
under the agreement if we are unable to remedy such material breach within a fixed number of days after we receive such notice,
which number may be doubled if we are making good faith efforts to achieve a cure and the extension will not increase the damages
suffered by Virginia Tech. We have the right to terminate the agreement at any time upon prior written notice delivered an agreed-upon
number of days prior to the date of termination.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Manufacturing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are obligated to manufacture all of the
taliglucerase alfa drug product needed under the Pfizer Agreement, subject to certain terms and conditions. Our drug product candidates,
including taliglucerase alfa, must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other
relevant foreign regulatory authorities. We use our current facility, which has approximately 20,000 sq/ft of clean rooms built
according to industry standards, to develop, process and manufacture taliglucerase alfa and other recombinant proteins. We intend
to use our current manufacturing space to produce all of the taliglucerase alfa we need in the near future, included the taliglucerase
alfa to be purchased by Pfizer. In addition, we intend to use our manufacturing space to produce all of the drug substance needed
in connection with the clinical trials for our product candidates. Current capacity of our facility can serve all of our current
and expected commercial and clinical needs, and may be sufficient to serve our production needs for the commercialization of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">O</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">ur
manufacturing facilities in Carmiel, Israel, have undergone successful audits by the Israeli MOH, the FDA, ANVISA, and the </FONT>European
Union<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>under the European Union&rsquo;s centralized marketing authorization
procedure,<FONT STYLE="font-family: Times New Roman, Times, Serif"> the Australian TGA and Health Canada</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged a contract manufacturer in Europe to act as
an additional source of fill and finish activities for taliglucerase alfa. According to our agreement with Pfizer, Pfizer will
be responsible for the fill and finish activities for taliglucerase alfa. We have engaged other contract manufacturers to perform
fill/finish activities for PRX-102 and for our oral treatment of Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our current facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and we have elected to participate in the alternative benefits program. Our facility is located in a
Zone A location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period commencing
with the year in which we first generate taxable income from the relevant Approved Enterprise and after we use our NOLs. We expect
to be entitled to similar tax benefits for a number of years thereafter. To remain eligible for these tax benefits, we must continue
to meet certain conditions, and if we increase our activities outside of Israel, for example, by future acquisitions, such increased
activities generally may not be eligible for inclusion in Israeli tax benefit programs. In addition, our technology is subject
to certain restrictions with respect to the transfer of technology and manufacturing rights. &ldquo;See Risk Factors&mdash;The
manufacture of our products is an exacting and complex process, and if we or one of our materials suppliers encounter problems
manufacturing our products, it will have a material adverse effect on our business and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raw Materials and Suppliers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the raw materials that we require throughout
the manufacturing process of Elelyso and our current and potential drug product candidates are widely available from numerous
suppliers and are generally considered to be generic industrial biological supplies. We rely on a single approved supplier for
certain materials relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified
additional suppliers for most of the materials required for the production of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Development and regulatory approval of our pharmaceutical products
are dependent upon our ability to procure active ingredients and certain packaging materials from sources approved by the FDA
and other regulatory authorities. Since the FDA and other regulatory approval processes require manufacturers to specify their
proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of a supplemental
application to use a new supplier in connection with any drug candidate or approved product, if any, would be required if active
ingredients or such packaging materials were no longer available from the specified supplier, which could result in manufacturing
delays. From time to time, we intend to continue to identify alternative FDA-approved suppliers to ensure the continued supply
of necessary raw materials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The biotechnology and pharmaceutical industries are characterized
by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the
fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and
development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many
specialized biotechnology companies have formed collaborations with large, established companies to support research, development
and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions
of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&rsquo; financial,
marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations
are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies
on their own or through collaborations with pharmaceutical and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We specifically face competition from companies with approved
treatments of Gaucher disease. In addition to Elelyso, there are two other ERTs for the treatment of Gaucher disease; Cerezyme
which is marketed by Genzyme (acquired by Sanofi) and VPRIV, which is marketed by Shire. To a much lesser extent, we also compete
with Actelion. In addition, Sanofi has commercialized Cerdelga, a substrate reduction therapy for Gaucher disease. Cerdelga was
approved for marketing by the FDA in August 2014 and by the European Commission in January 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are two approved ERTs for the treatment of Fabry disease;
Fabrazyme which is marketed by Genzyme and Replagal, which is marketed by Shire. Fabrazyme is available in the United States and
the European Union. Replagal is available in the European Union. In 2012, Shire withdrew its BLA for Replagal in the United States.
In addition, we are aware of other clinical stage, early clinical stage and experimental drugs which are being developed for the
treatment of Fabry disease by Amicus Therapeutics and other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also face competition from companies that are developing
other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include, among others, iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH, none of which are cell-based.
Rather, such companies base their product development on transgenic plants or whole plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several biogeneric companies are pursuing the
opportunity to develop and commercialize follow-on versions of other currently marketed biologic products, including growth
factors, hormones, enzymes, cytokines and monoclonal antibodies, which are areas that interest us. These companies include,
among others, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva
Pharmaceutical Industries Ltd. or Teva. See &ldquo;Risk Factors&mdash;Developments by competitors may render our products or
technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations
and financial condition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scientific Advisory Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have reorganized our scientific advisory board by establishing
a core team of advisors. The scientific advisory board may invite additional experts to attend meetings on a case-by-case basis.
Members of our scientific advisory board consult with our management within their professional areas of expertise; exchange strategic
and business development ideas with our management; attend scientific, medical and business meetings with our management, such
as meetings with the FDA and comparable foreign regulatory authorities, meetings with strategic or potential strategic partners
and other meetings relevant to their areas of expertise; and attend meetings of our scientific advisory board. We expect our scientific
advisory board to convene at least twice annually, and we frequently consult with the individual members of our scientific advisory
board. Our scientific advisory board currently includes the following people:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 48%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Name</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"></P></td>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Affiliation</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">Roger D. Kornberg, Ph.D. (Chairman)</td>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laureate of the Nobel Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member, U.S. National Academy of Sciences</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Winzer Professor of Medicine, Department of Structural
        Biology at Stanford University</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2001 Welch Prize (highest award granted in the field
        of chemistry in the United States)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2002 Leopold Mayer Prize (the highest award granted
        in the field of biomedical sciences from the French Academy of Sciences)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">Professor Aaron Ciechanover, M.D., D.Sc.</td>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laureate of the Nobel Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distinguished research Professor at the Cancer and
        Vascular Biology Research Center of the Rappaport Research Institute and Faculty of Medicine at the Technion, Israel&rsquo;s
        Institute of Technology</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">American Academy of Arts and Sciences, Member</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">Alexander Levitzki, Ph.D.</td>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wolfson Family Professor of Biochemistry in the Department
        of Biological Chemistry of The Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">American Association for Cancer Research, 2013 Award
        for Outstanding Achievement in Chemistry in Cancer Research</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1990 Israel Prize in Biochemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1990 Rothschild Prize in Biology</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2002 Hamilton-Fairley Award, European Society of Medical
        Oncology</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2005 Wolf Prize for Medicine</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2012 Nauta Award in Pharmacochemistry, The European
        Federation of Medicinal Chemistry (EFMC) (the highest award from the European Federation for Medicinal Chemistry)</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; width: 48%">Richard Lerner, M.D.</td>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Institute Professor and the Lita
                           Annenberg Hazen Professor of Immunochemistry at the Skaggs Institute for Chemical Biology of The Scripps
                           Research Institute</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1978 Parke-Davis Award</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1990 The San Marino Prize</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1995 Wolf Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1996 California Scientist of the Year Award</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2002 University of California Presidential Medal</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member, Royal Swedish Academy of Sciences</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member, United States National Academy of Sciences</P></td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The testing, manufacture, distribution, advertising and marketing
of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States,
including the FDA, and by similar authorities in other countries. Any product that we develop must receive all relevant regulatory
approvals or clearances, as the case may be, before it may be marketed in a particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory process, which includes overseeing preclinical
studies and clinical trials of each pharmaceutical compound to establish its safety and efficacy and confirmation by the FDA that
good laboratory, clinical and manufacturing practices were maintained during testing and manufacturing, can take many years, requires
the expenditure of substantial resources and gives larger companies with greater financial resources a competitive advantage over
us. Delays or terminations of clinical trials that we undertake would likely impair our development of product candidates. Delays
or terminations could result from a number of factors, including stringent enrollment criteria, slow rate of enrollment, size
of patient population, having to compete with other clinical trials for eligible patients, geographical considerations and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA review process can be lengthy and unpredictable, and
we may encounter delays or rejections of our applications when submitted. Generally, in order to gain FDA approval, we must first
conduct preclinical studies in a laboratory and in animal models to obtain preliminary information on a compound and to identify
any potential safety problems. The results of these studies are submitted as part of an IND application that the FDA must review
before human clinical trials of an investigational drug can commence. Clinical trials may be terminated by the clinical trial
site, sponsor or the FDA if toxicities appear that are either worse than expected or unexpected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trials are normally performed in three sequential
phases and generally take two to five years, or longer, to complete. Phase I consists of testing the drug product in a small number
of humans, normally healthy volunteers, to determine preliminary safety and tolerable dose range. Phase II usually involves studies
in a limited patient population to evaluate the effectiveness of the drug product in humans having the disease or medical condition
for which the product is indicated, determine dosage tolerance and optimal dosage and identify possible common adverse effects
and safety risks. Phase III consists of additional controlled testing at multiple clinical sites to establish clinical safety
and effectiveness in an expanded patient population of geographically dispersed test sites to evaluate the overall benefit-risk
relationship for administering the product and to provide an adequate basis for product labeling. Phase IV clinical trials may
be conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completion of clinical trials of a new drug product,
FDA and foreign regulatory authority marketing approval must be obtained. Assuming that the clinical data support the product&rsquo;s
safety and effectiveness for its intended use, a new drug application, or NDA, is submitted to the FDA for review. Generally,
it takes one to three years to obtain approval. If questions arise during the FDA review process, approval may take a significantly
longer period of time. The testing and approval processes require substantial time and effort and approval on a timely basis,
if at all, or the approval that we receive may be for a narrower indication than we had originally sought, potentially undermining
the commercial viability of the product. Even if regulatory approvals are obtained, approved products are subject to continual
review and holders of an approved product are required, for example, to report certain adverse reactions and production problems,
if any, to the FDA, and to comply with certain requirements concerning advertising and promotional labeling for the product. Also,
quality control and manufacturing procedures relating to a product must continue to conform to cGMP after approval, and the FDA
periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend
time, money and effort in the area of production and quality control to comply with cGMP and other aspects of regulatory compliance.
The later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements with respect
to any product may result in restrictions on the marketing of the product or withdrawal of the product from the market as well
as possible civil or criminal sanctions. See also &ldquo;&mdash;International Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Orphan Drug Act of 1983, the FDA may grant
orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a
disease or condition that affects fewer than 200,000 individuals in the United States. The FDA grants orphan drug designation
to drugs that may provide a significant therapeutic advantage over existing treatments and target conditions affecting
200,000 or fewer U.S. patients per year. Orphan drug designation does not convey any advantage in or shorten the duration of
the regulatory review and approval process. Among the other benefits of orphan drug designation are possible funding and tax
savings to support clinical trials and for other financial incentives and a waiver of the marketing application user fee and
most likely priority review. If a significant therapeutic advantage over existing treatments is shown in the marketing
application, the FDA may grant orphan drug approval and provide a seven-year period of marketing exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA has a fast track program that is intended to expedite
or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs
and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to the combination
of the product and the specific indication for which it is being studied. For a fast track product, the FDA may consider for review
on a rolling basis sections of the NDA before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA as they become available and determines that
the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We used
the rolling submission option for our taliglucerase alfa NDA, which we completed in April 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The United States federal government regulates healthcare through
various agencies, including but not limited to the following: (i) the FDA, which administers the Federal Food, Drug, and Cosmetic
Act (FDCA), as well as other relevant laws; (ii) the Center for Medicare &amp; Medicaid Services (CMS), which administers the
Medicare and Medicaid programs; (iii) the Office of Inspector General (OIG) which enforces various laws aimed at curtailing fraudulent
or abusive practices, including by way of example, the Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to
as Stark, the Anti-Inducement Law, the Civil Money Penalty Law and the laws that authorize the OIG to exclude healthcare providers
and others from participating in federal healthcare programs; and (iv) the Office of Civil Rights, which administers the privacy
aspects of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). All of the aforementioned are agencies within
the Department of Health and Human Services (HHS). Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs, especially through the Veterans Health Care Act of
1992, the Public Health Service within HHS under Public Health Service Act &sect; 340B (42 U.S.C. &sect; 256b), the Department
of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid and other
state sponsored or funded programs and their internal laws regulating all healthcare activities. Many states also have anti-kickback
and anti-physician referral laws that are similar to the federal laws, but may be applicable in situations where federal laws
do not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Medicare is the federal healthcare program for those who are
(i) over 65 years of age, (ii) disabled, (iii) suffering from end-stage renal disease or (iv) suffering from Lou Gehrig&rsquo;s
disease. Medicare consists of part A, which covers inpatient costs, part B, which covers services by physicians and laboratories,
durable medical equipment and certain drugs, primarily those administered by physicians, and part D, which provides drug coverage
for most prescription drugs other than those covered under part B. Medicare also offers a managed care option under part C. Medicare
is administered by CMS. In contrast, Medicaid is a state-federal healthcare program for the poor and is administered by the states
pursuant to an agreement with the Secretary of Health and Human Services. Most state Medicaid programs cover most outpatient prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2010, the Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, PPACA, became law in the United
States. PPACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly
affects the pharmaceutical industry. Key provisions of PPACA specific to the pharmaceutical industry, among others, include the
following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An annual,
                                         nondeductible fee on any entity that manufactures or imports certain branded prescription
                                         drugs and biologic agents into the United States, apportioned among these entities according
                                         to their market share in certain federal government healthcare programs (excluding sales
                                         of any drug or biologic product marketed for an orphan indication), beginning in 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An increase
                                         in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive
                                         to January 1, 2010, to 23.1% and 13% of the average manufacturer price for branded and
                                         generic drugs, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Medicare
                                         Part D coverage gap discount program, in which manufacturers must agree to offer 50%
                                         point-of sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
                                         during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient
                                         drugs to be covered under Medicare Part D, beginning in 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Extension
                                         of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals
                                         who are enrolled in Medicaid managed care organizations, effective March 23, 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion
                                         of eligibility criteria for Medicaid programs by, among other things, allowing states
                                         to offer Medicaid coverage to additional individuals beginning in April 2010 and by adding
                                         new mandatory eligibility categories for certain individuals with income at or below
                                         133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing both
                                         the volume of sales and manufacturers&rsquo; Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion
                                         of the entities eligible for discounts under the Public Health Service pharmaceutical
                                         pricing program, effective January 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>New requirements
                                         to report certain financial arrangements with physicians and others, including reporting
                                         any &ldquo;transfer of value&rdquo; made or distributed to prescribers and other healthcare
                                         providers and reporting any investment interests held by physicians and their immediate
                                         family members during each calendar year beginning in 2012, with reporting starting in
                                         2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new requirement
                                         to annually report drug samples that manufacturers and distributors provide to physicians,
                                         effective April 1, 2012;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A licensure
                                         framework for follow-on biologic products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Patient-Centered
                                         Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
                                         clinical effectiveness research, along with funding for such research.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to regulations and product registration requirements
in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements,
labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to
obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements
for licensing a product in a foreign country may differ significantly from FDA requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmaceutical products may not be imported into, or manufactured
or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals
in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli MOH requires pharmaceutical companies
to conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific
advances as well as social and ethical values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relevant legislation of the European Union requires that
medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations,
of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union.
Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order
to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized
procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical,
biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials.
All of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate
the quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal
products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect
not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that
treat conditions for which no current therapy exists or are expected to bring a significant benefit to patients over existing
therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli Government Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the current principal Israeli
tax laws applicable to us and Protalix Ltd., and of the Israeli Government programs from which Protalix Ltd. benefits. Some parts
of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore,
the views expressed in the discussion may not be accepted by the tax authorities in question. The discussion should not be construed
as legal or professional tax advice and does not cover all possible tax considerations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Corporate Tax Structure in Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income of Protalix Ltd., other than income from &ldquo;Approved
Enterprises,&rdquo; is taxed in Israel at the regular rates which were 25% in 2012 and 2013 and 26.5% for 2014 and thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capital gains on the sale of assets are subject to capital
gain tax according to the corporate tax rate in effect for the year of selling the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the corporate taxes in Israel, we are subject
to a withholding tax on the U.S. revenue source portion of the payments made to us for our share of Pfizer&rsquo;s net profits
under the Pfizer Agreement. The withholding tax rate is 15%. See &ldquo;Business&mdash;Commercialization Agreement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Law for the Encouragement of Capital Investments, 1959.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Law for the Encouragement of Capital Investments, 1959,
or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets).
Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an
&ldquo;Approved Enterprise,&rdquo; is entitled to benefits. These benefits may include cash grants from the Israeli government
and tax benefits, based upon, among other things, the location of the facility in which the investment is made and specific elections
made by the grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd. will continue to enjoy the tax benefits under
the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix Ltd. in the future, Protalix Ltd.
will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion
is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law prior to its amendment, a company
that wished to receive benefits had to receive approval from the &ldquo;Investment Center&rdquo; of the Israeli Ministry of Industry,
Trade and Labor, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment
program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics
of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An Approved Enterprise may elect to forego any entitlement
to the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under
which the undistributed income from the Approved Enterprise is fully exempt from corporate tax for a defined period of time. Under
the alternative package of benefits, a company&rsquo;s undistributed income derived from an Approved Enterprise will be exempt
from corporate tax for a period of between two and 10 years from the first year of taxable income, depending upon the geographic
location within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible
for the reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits
period (up to an aggregate benefits period of either seven or 10 years, depending on the location of the company or its definition
as a foreign investors&rsquo; company). If a company has more than one Approved Enterprise program or if only a portion of its
capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The
tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise.
Income from activity that is derived from different Approved Enterprises does not enjoy these tax benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has an Approved Enterprise program is eligible
for further tax benefits if it qualifies as a foreign investors&rsquo; company. A foreign investors&rsquo; company eligible for
benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and
appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents.
A company that qualifies as a foreign investors&rsquo; company and has an Approved Enterprise program is eligible for tax benefits
for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 25%, depending on the amount of the company&rsquo;s
shares held by non-Israeli shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a company that has an Approved Enterprise program is a wholly
owned subsidiary of another company, the percentage of foreign investments is determined based on the percentage of foreign investment
in the parent company. The tax rates and related levels of foreign investments are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Percent of Foreign
    Ownership</B></FONT></TD>
    <TD NOWRAP STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Rate of</B> <B>Reduced Tax</B>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0-49%</FONT></TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25%</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49-74%</FONT></TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20%</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">74-90%</FONT></TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15%</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 49%; text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">90-100%</FONT></TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our original facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved
Enterprise program, the facility is located in a top priority location, or &ldquo;Zone A,&rdquo; and, therefore, the income from
that Approved Enterprise will be tax exempt in Israel for a period of 10 years, commencing with the year in which taxable income
is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix
Ltd. may not continue to qualify for its benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has elected to participate in the alternative
benefits program and that subsequently pays a dividend out of the income derived from the Approved Enterprise during the tax exemption
period will be subject to corporate tax in respect of the amount distributed at the rate that would have been applicable had the
company not elected the alternative benefits program (generally 10% to 25%, depending on the extent to which non-Israeli shareholders
hold such company&rsquo;s shares). If the dividend is distributed within 12 years after the commencement of the benefits period
(or, in the case of a foreign investor&rsquo;s company, without time limitation), the dividend recipient is taxed at the reduced
withholding tax rate of 15% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty.
After this period, the withholding tax rate is 25%, or at the lower rate under an applicable tax treaty. In the case of a company
with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding
tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted
into foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Investment Law also provides that an Approved Enterprise
is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This
benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The benefits available to an Approved Enterprise are conditioned
upon terms stipulated in the Investment Law and regulations and the criteria set forth in the applicable certificate of approval.
If Protalix Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix Ltd. may be
required to refund the received benefits, linked to the Israeli consumer price index with the addition of interest or alternatively
with an additional penalty payment. We believe that Protalix Ltd. currently operates in compliance with all applicable conditions
and criteria, but there can be no assurance that Protalix Ltd. will continue to do so. Furthermore, there can be no assurance
that any Approved Enterprise status granted to Protalix Ltd.&rsquo;s facilities will entitle Protalix Ltd. to the same benefits
to which it is currently entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law, the approval of the Investment Center
is required only for Approved Enterprises that receive cash grants. Approved Enterprises that do not receive benefits in the form
of governmental cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Approved Enterprises
are required to make certain investments as specified in the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amended Investment Law specifies certain conditions for
an Approved Enterprise to be entitled to benefits. These conditions include:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the Approved
                                         Enterprise&rsquo;s revenues from any single country or a separate customs territory may
                                         not exceed 75% of the Approved Enterprise&rsquo;s total revenues; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at least
                                         25% of the Approved Enterprise&rsquo;s revenues during the benefits period must be derived
                                         from sales into a single country or a separate customs territory with a population of
                                         at least 14 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that Protalix Ltd. will comply with
the above conditions in the future or that Protalix Ltd. will be entitled to any additional benefits under the Investment Law.
In addition, it is possible that Protalix Ltd. may not be able to operate in a manner that maximizes utilization of the potential
benefits available under the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, the Israeli Government has considered reducing
the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits
available under the Investment Law could materially impact the cost of our future investments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Encouragement of Industrial Research and Development Law,
1984</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, Protalix Ltd. has received grants from the <FONT STYLE="font-family: Times New Roman, Times, Serif">OCS
</FONT>for the financing of a portion of its research and development expenditures in Israel. As of December 31, 2014, the OCS
approved grants in respect of Protalix Ltd.&rsquo;s continuing operations totaling approximately $36.8 million, measured from
inception. Protalix Ltd. is required to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied
to the grants received on or after January 1, 1999) to the OCS through payments of royalties at a rate of 3% to 6% of the revenues
generated from an OCS-funded project, depending on the period in which revenues were generated. As of December 31, 2014, Protalix
Ltd. either paid or accrued royalties payable of $5.6 million and Protalix Ltd.&rsquo;s contingent liability to the OCS with respect
to grants received was approximately $30.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Israeli Law for the Encouragement of Industrial Research
and Development, 1984, and related regulations, or the Research Law, recipients of grants from the OCS are prohibited from manufacturing
products developed using these grants outside of the State of Israel without special approvals, although the Research Law does
enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased
royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel,
it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending
on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, Protalix Ltd. is prohibited
from transferring the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except
under limited circumstances and only with the approval of the OCS&rsquo; Research Committee. Protalix Ltd. may not receive the
required approvals for any proposed transfer and, if received, Protalix Ltd. may be required to pay the OCS a portion of the consideration
that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that
Protalix Ltd. has already paid to the OCS, the amount of time that has elapsed between the date on which the know-how was transferred
and the date on which the OCS grants were received and the sale price and the form of transaction will be taken into account in
order to calculate the amount of the payment to the OCS. Approval of the transfer of technology to residents of the State of Israel
is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including
the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any
such transfer, if requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law, the Research Committee to allow the
transfer outside of Israel of know-how derived from an approved program and the related manufacturing rights. In general, the
Research Committee may approve transfer of know-how in limited circumstances as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                         of a sale of know-how itself to a non-affiliated third party, provided that upon such
                                         sale the owner of the know-how pays to the OCS an amount, in cash, as set forth in the
                                         Research Law. In addition, the amendment provides that if the purchaser of the know-how
                                         gives the selling Israeli company the right to exploit the know-how by way of an exclusive,
                                         irrevocable and unlimited license, the research committee may approve such transfer in
                                         special cases without requiring a cash payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                         of a sale of a company which is the owner of know-how, pursuant to which the company
                                         ceases to be an Israeli company, provided that upon such sale, the owner of the know-how
                                         makes a cash payment to the OCS as set forth in the Research Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                         of an exchange of know-how such that in exchange for the transfer of know-how outside
                                         of Israel, the recipient of the know-how transfers other know-how to the company in Israel
                                         in a manner in which the OCS is convinced that the Israeli economy realizes a greater,
                                         overall benefit from the exchange of know-how.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Research Committee may, in special cases, approve the transfer
of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results
therefrom, outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The State of Israel does not own intellectual property rights
in technology developed with OCS funding and there is no restriction on the export of products manufactured using technology developed
with OCS funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described
above. For a description of such restrictions, please see &ldquo;Risk Factors&mdash;Risks Relating to Our Operations in Israel.&rdquo;
OCS approval is not required for the export of any products resulting from the research or development or for the licensing of
any technology in the ordinary course of business.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Law for the Encouragement of Industry (Taxes), 1969</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that Protalix Ltd. currently qualifies as an &ldquo;Industrial
Company&rdquo; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.
The Industry Encouragement Law defines &ldquo;Industrial Company&rdquo; as a company resident in Israel and incorporated in Israel,
that derives 90% or more of its income in any tax year (other than specified kinds of passive income such as capital gains, interest
and dividends) from an &ldquo;Industrial Enterprise&rdquo; operating in Israel (including Judea &amp; Samara territories and the
Gaza strip), that it owns. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise whose major activity in a given
tax year is industrial production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following corporate tax benefits, among others, are available
to Industrial Companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amortization
                                         of the cost of purchased know-how and patents over an eight-year period for tax purposes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>accelerated
                                         depreciation rates on equipment and buildings;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>under specified
                                         conditions, an election to file consolidated tax returns with other related Israeli Industrial
                                         Companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expenses
                                         related to a public offering are deductible in equal amounts over three years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eligibility for the benefits under the Industry Encouragement
Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix Ltd. may fail to
qualify or may not continue to qualify as an &ldquo;Industrial Company&rdquo; or that the benefits described above will not be
available in the future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax Benefits for Research and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under specified conditions, Israeli tax laws allow a tax deduction
by a company for research and development expenditures, including capital expenditures, for the year in which such expenditures
are incurred. These expenditures must relate to scientific research and development projects and must be approved by the OCS.
Furthermore, the research and development projects must be for the promotion of the company and carried out by or on behalf of
the company seeking such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds
received through government grants for the finance of such scientific research and development projects. Expenditures not so approved
are deductible over a three-year period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2014, we had 234 employees, of whom 32 have
a Ph.D. or an M.D.in their respective scientific fields. We believe that our relations with these employees are good. We believe
that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of
Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply
to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries,
length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented
by a labor union or represented under a collective bargaining agreement. See &ldquo;Risk Factors&mdash;We depend upon key employees
and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could
adversely affect our ability to develop and market our products.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal business address is set forth below. Our executive
offices and our main research manufacturing facility are located at that address. Our telephone number is +972-4-988-9488. We
were originally incorporated in the State of Florida in April 1992, and Protalix Ltd., our wholly-owned subsidiary and sole operating
unit, is an Israeli company and was originally incorporated in Israel on December 27, 1993. During 1999, Protalix Ltd. changed
its focus from plant secondary metabolites to the expression of recombinant therapeutic proteins in plant cells, and in April
2004 changed its name to Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx<SUP>&reg;</SUP> is our registered trademark. Each
of the other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K belongs to its respective holder.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Available Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate website is www.protalix.com. We make available
on our website, free of charge, our Commission filings, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file
these documents with, or furnish them to, the Commission. Additionally, from time to time, we provide notifications of material
news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences
may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is
not intended to be incorporated by reference into this report or in any other report or document we file and any references to
these websites are intended to be inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also listed on the Tel Aviv Stock Exchange, or the TASE,
and, accordingly, we submit copies of all our filings with the Commission to the Israeli Securities Authority and the TASE. Such
copies can be retrieved electronically through the TASE&rsquo;s internet messaging system (www.maya.tase.co.il) and through the
MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our website also includes printable versions of our Code of
Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors.
Each of these documents is also available in print, free of charge, to any shareholder who requests a copy by addressing a request
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2 Snunit Street, Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">P.O. Box 455</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carmiel 20100, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Mr. Yossi Maimon, Chief Financial
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt"><A NAME="a_004"></A>Item&nbsp;1A. &nbsp;&nbsp;Risk
Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>You should carefully consider the risks described below
together with the other information included in this Annual Report on Form 10-K. Our business, financial condition or results
of operations could be adversely affected by any of these risks. If any of these risks occur, the value of our common stock could
decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Financial Condition and Capital Requirements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently have no significant product revenues and may
need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which
will have a dilutive effect on our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not generated significant revenues from product
sales and only minimal revenues from research and development services and other fees, other than the milestone payments we have
received in connection with our license and supply agreement with Pfizer. For the years ended December 31, 2014, 2013 and 2012,
we had net losses of $29.9 million, $27.8 million and $11.6 million, respectively, primarily as a result of expenses incurred
through a combination of research and development activities and expenses supporting those activities, which includes share-based
compensation expense. Drug development and commercialization is very capital intensive. Our lead product was first approved for
marketing by the FDA in May 2012, by the Israeli MOH in September 2012 and, subsequently, in certain other countries. We fund
all of our operations and capital expenditures from the revenues we generate from sales of taliglucerase alfa supplemented with
our cash on hand, other licensing fees and grants and the net proceeds of any equity or debt offerings. Based on our current plans
and capital resources, we believe that our cash and cash equivalents will be sufficient to enable us to meet our planned operating
needs for at least 12 months. However, changes may occur that could consume our existing capital at a faster rate than projected,
including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development
efforts and the costs of protecting our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may seek additional financing to implement and fund product
development, preclinical studies and clinical trials for the drugs in our pipeline, as well as additional drug candidates and
other research and development projects. If we are unable to secure additional financing in the future on acceptable terms, or
at all, we may be unable to commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates
from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product
licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities
in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business
and results of operations. Any additional source of financing will likely involve the issuance of our equity securities, which
will have a dilutive effect on our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Commercialization of taliglucerase
alfa </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We cannot predict the share in net income we will receive
from Pfizer&rsquo;s sales of taliglucerase alfa. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Taliglucerase alfa has been approved for marketing in the United
States, Israel, Brazil and other territories. Otherwise, we have no other products approved for marketing. As we have invested
a significant portion of our efforts and financial resources in the development of taliglucerase alfa, our ability to generate
product revenue depends heavily on the successful commercialization of taliglucerase alfa. Under the Pfizer Agreement, Pfizer
holds an exclusive worldwide license to develop and commercialize taliglucerase alfa, except in Israel and Brazil. Sales of taliglucerase
alfa worldwide (except Israel and Brazil) are dependent upon Pfizer&rsquo;s sales and marketing efforts, which we do not control
and may not be able to effectively influence, and on the actions and decisions of foreign regulatory authorities. Upon the approval
of taliglucerase alfa in additional markets, if at all, Pfizer may experience delays in, or be unable to achieve, the commercial
introduction of taliglucerase alfa in those markets, which would have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future revenues under our collaboration with Pfizer from
Pfizer&rsquo;s sales of taliglucerase alfa will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number
                                         of Gaucher patients who will be treated with taliglucerase alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the willingness
                                         of Gaucher patients to switch from other ERTs to taliglucerase alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competition
                                         from Cerezyme, VPRIV and Cerdelga, and other current or future approved treatments of
                                         Gaucher disease;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer&rsquo;s
                                         efforts under the Pfizer Agreement and the effectiveness of Pfizer&rsquo;s commercial
                                         strategy and its execution of that strategy, including its pricing strategy and the effectiveness
                                         of its efforts to obtain adequate third-party reimbursements;</TD></TR></TABLE>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                         marketing approvals and reimbursement from additional regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued
                                         acceptable safety and efficacy profile of our product candidates following approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful
                                         audit of our facilities by additional regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining
                                         the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements
                                         with third parties; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the capacity
                                         of physicians and health care providers to provide treatment to Gaucher patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot accurately predict the amount of revenues we will generate under our collaboration with Pfizer in future periods, if any.
</FONT>Any failure to commercialize taliglucerase alfa or the experience of significant delays in doing so will have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
market share and/or other indicators of market acceptance of taliglucerase alfa may not meet the expectations of investors or
public market analysts, which would have a </FONT>material adverse effect on our business, results of operations and financial
condition<FONT STYLE="font-family: Times New Roman, Times, Serif"> and the market price of our common stock would likely decline.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fiocruz may not comply with the terms and conditions of
the Supply and Technology Transfer Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Uplyso was first approved for marketing in Brazil in
March 2013. Under our <FONT STYLE="font-family: Times New Roman, Times, Serif">Supply and Technology Transfer Agreement with
Fiocruz, we are not required to complete the final stage of the technology transfer for the production of Uplyso until
Fiocruz purchases at least approximately $280 million worth of Uplyso. </FONT>However, we do not control and may not be able
to effectively influence Fiocruz&rsquo;s ability to distribute Uplyso in Brazil. With respect to the first required purchase
amount, we have recorded revenues of approximately $3.5 million for sales of Uplyso to Fiocruz in 2014 and,  during the first
quarter of 2015, we  received a purchase order for approximately $5.7 million of Uplyso out of which we have delivered
approximately $1.7 million of the product. If Fiocruz fails to comply with the purchase requirements of the Supply and Technology
Transfer Agreement, we may terminate the agreement and market Uplyso in Brazil on our own or through Pfizer. Any failure by
Fiocruz to comply with the purchase requirements of the Supply and Technology Transfer Agreement, or any other material
breach by Fiocruz of the agreement, may have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot accurately predict the amount of revenues we will generate under our Supply and Technology Transfer with Fiocruz in future
periods, if any. </FONT>Any failure by Fiocruz to distribute Uplyso in Brazil, or the experience of significant delays in doing
so, may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If safety issues regarding taliglucerase alfa that were
not known at the time of approval are discovered, or if we or Pfizer fail to comply with continuing U.S. and applicable foreign
regulations, commercialization efforts for taliglucerase alfa could be adversely affected and taliglucerase alfa could lose its
approval or its sales could be suspended. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Drug products remain subject to continuing regulatory oversight
after they are approved for marketing, including the review of additional safety information. Drugs are more widely used by patients
once approved for sale and, therefore, side-effects and other problems may be observed after approval that were not seen or anticipated,
or were not as prevalent or severe, during clinical trials or nonclinical studies. The subsequent discovery of previously unknown
problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead
to the withdrawal of the product from the market. The reporting of adverse safety events involving taliglucerase alfa or public
speculation about such events could cause our stock price to decline or experience periods of volatility and may have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we or Pfizer fail to comply with applicable continuing regulatory
requirements, we or Pfizer may be subject to fines and/or criminal prosecutions, and taliglucerase may become subject to suspension
or withdrawal of regulatory approval, product recalls and seizures and operating restrictions. In addition, the manufacturers
we and Pfizer engage to produce taliglucerase alfa and the manufacturing facilities in which taliglucerase alfa is made are subject
to periodic review and inspection by the FDA and foreign regulatory authorities. If problems are identified during the review
or inspection of these manufacturers or manufacturing facilities, it could result in our inability to use the facility to make
our product or a determination that inventories are not safe for commercial sale, which may have a material adverse effect on
our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If physicians, patients, third party payors and others in
the medical community do not accept and use taliglucerase alfa, or any of our other product candidates, if approved, our ability
to generate revenue from product sales will be materially impaired. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Physicians and patients, and other healthcare providers, may
not accept and use taliglucerase alfa or any of our other product candidates, if approved for marketing. Future acceptance and
use of taliglucerase alfa or any of our other product candidates, if approved, will depend upon a number of factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>perceptions
                                         by physicians, patients, third party payors and others in the medical community about
                                         the safety and effectiveness of taliglucerase alfa or our other drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the willingness
                                         of the target patient population to try new therapies and of physicians to prescribe
                                         these therapies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence
                                         and severity of any side effects, including any limitations or warnings contained in
                                         our products&rsquo; approved labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pharmacological
                                         benefits of taliglucerase alfa or our other drug candidates relative to competing products
                                         and products under development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the efficacy
                                         and potential advantages relative to competing products and products under development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>relative
                                         convenience and ease of administration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>effectiveness
                                         of education, marketing and distribution efforts by us and our licensees and distributors,
                                         if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publicity
                                         concerning taliglucerase alfa or our other drug candidates or competing products and
                                         treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>coverage
                                         and reimbursement of our products by third party payors; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price
                                         for our products and competing products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because we expect sales of taliglucerase alfa to generate substantially
all of our product revenues for the foreseeable future, any lack of market acceptance of taliglucerase alfa would have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If the market opportunities for taliglucerase alfa or our
other product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our development efforts have focused mainly on relatively
rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates
of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which
are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed,
the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry
disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in
the broader world population. If the market opportunities for our current product candidates are smaller than we believe they
are, our revenues may be adversely affected and our business may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Coverage
and reimbursement may not be available for</B></FONT><B> taliglucerase alfa or any of our other product candidates, if approved<FONT STYLE="font-family: Times New Roman, Times, Serif">,
in all territories which could diminish our sales or affect our ability to sell taliglucerase alfa or any other products profitably.
</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Market acceptance and sales of taliglucerase alfa or any of
our other product candidates, if approved, will depend on worldwide coverage and reimbursement policies. Government authorities
and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay
for and establish reimbursement levels. Although, to date taliglucerase alfa is covered and reimbursed in all the approved territories,
coverage might not be available for taliglucerase alfa or any of our other product candidates, if approved, in all territories.
Obtaining reimbursement approval for an approved product from governments and other third party payors is a time consuming and
costly process that requires our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness
data for the use of our products, if and when approved, to every payor. We may not be able to provide data sufficient to gain
acceptance with respect to coverage and reimbursement or we might need to conduct post-marketing studies in order to demonstrate
the cost-effectiveness of approved products, if any, to such payors&rsquo; satisfaction. Such studies might require our collaborators
or us to commit a significant amount of management time and financial and other resources. Even if a payor determines that taliglucerase
alfa, or any other approved product, if any, is eligible for reimbursement, the payor may impose coverage limitations that preclude
payment for some uses that are approved by the FDA or other regulatory authorities. In addition, full reimbursement may not be
available for high priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed
in all cases or at a rate that allows us to make a profit or even cover our costs. Also, limited reimbursement amounts may reduce
the demand for, or the price of, our product candidates. Except with respect to taliglucerase alfa, we have not commenced efforts
to have our product candidates covered and reimbursed by government or third-party payors. If coverage and reimbursement are not
available or are available only to limited levels, the sales of our products, if approved may be diminished or we may not be able
to sell such products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We and our collaborating partners may be subject, directly
or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating
partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All marketing activities associated with taliglucerase alfa
in the United States, as well as marketing activities in the United States related to any other products for which we obtain regulatory
approval, if any, will be<FONT STYLE="font-family: Times New Roman, Times, Serif">, directly or indirectly through our customers,
</FONT>subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United
States<FONT STYLE="font-family: Times New Roman, Times, Serif">, including, without limitation, the federal Anti-Kickback Statute,
the federal False Claims Act and HIPAA. </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">These laws may adversely
impact, among other things, our proposed sales, marketing and education programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration,
directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good
or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The
term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value, including for example, gifts, discounts,
the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership
interests and providing anything at less than its fair market value. The reach of the Anti-Kickback Statute was also broadened
by the </FONT>Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, or the PPACA<FONT STYLE="font-family: Times New Roman, Times, Serif">, which, among other things, amends the intent requirement
of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &sect; 1320a-7b,
effective March 23, 2010. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of
this statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute,
which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal
health program that the person knows or should know is for an item or service that was not provided as claimed or is false or
fraudulent. The federal Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements
and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback
Statute include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid
and other state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute,
some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare
and Medicaid programs, and do not contain identical safe harbors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal False Claims Act imposes liability on any person
who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare
program. The &ldquo;qui tam&rdquo; provisions of the False Claims Act allow a private individual to bring civil actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these
state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. When an entity
is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained
by the government, plus civil penalties of $5,500 to $11,000 for each separate false claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Health Insurance Portability and Accountability Act of
1996, or HIPAA, created several new federal crimes, including health care fraud, and false statements relating to health care
matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit
program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for health care benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are unable to predict whether we could be subject to actions
under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that taliglucerase alfa,
or any of our products, if approved for marketing, will be sold in a foreign country, we and our collaborators, including Pfizer,
may be subject to similar foreign laws and regulations. If we or any of our collaborators are found to be in violation of any
of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including
civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment
or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have a limited operating history which may limit the
ability of investors to make an informed investment decision. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Taliglucerase alfa is our only product with commercial approvals.
The successful commercialization of our drug candidates will require us to perform a variety of functions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continuing
                                         to perform preclinical development and clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>participating
                                         in regulatory approval processes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating
                                         and manufacturing products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>conducting
                                         sales and marketing activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our operations have been limited to organizing and staffing
our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical
trials and clinical trials of our principal drug candidates. To date, we have commenced a phase III clinical trial in connection
with only one drug candidate, taliglucerase alfa, which trial was completed in August 2009. These operations provide a limited
basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our strategy, in certain cases, is to enter into collaboration
agreements with third parties to leverage our ProCellEx system to develop product candidates. If we fail to enter into these agreements
or if we or the third parties do not perform under such agreements or terminate or elect to discontinue the collaboration, it
could have a material adverse effect on our revenues. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our strategy, in certain cases, is to enter into arrangements
with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Under these arrangements,
we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements.
Our partners may control key decisions relating to the development of the products and we may depend on our partners&rsquo; expertise
and dedication of sufficient resources to develop and commercialize our product candidates. The rights of our partners limit our
flexibility in considering alternatives for the commercialization of our product candidates. If we or any of our current or future
partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct their obligations
under such arrangements in a timely manner, there is a dispute about their obligations or if either party terminates the applicable
agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive a sufficient amount
of royalty or milestone payments from them, if any, which may have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have limited experience in selling, marketing or distributing
products and limited internal capability to do so. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently have very limited sales, marketing or distribution
capabilities and no experience in building a sales force and distribution capabilities. Pfizer holds an exclusive, worldwide right
to develop and commercialize taliglucerase alfa worldwide, except in Israel and Brazil. If we decide to market any of our other
products directly, if any, we must commit significant financial and managerial resources to develop a marketing and sales force
with technical expertise and with supporting distribution capabilities. Factors that may inhibit our efforts to commercialize
our products directly and without strategic partners include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability
                                         to recruit and retain adequate numbers of effective sales and marketing personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability
                                         of sales personnel to obtain access to an adequate numbers of physicians or to pursuance
                                         them to prescribe our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the lack
                                         of complementary products to be offered by sales personnel, which may put us at a competitive
                                         disadvantage relative to companies with more extensive product lines;&nbsp;and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen
                                         costs and expenses associated with creating and sustaining an independent sales and marketing
                                         organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be successful in recruiting or retaining the sales
and marketing personnel necessary to sell any of our products upon approval, if at all, which would have a material adverse effect
on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may enter into distribution arrangements and marketing
alliances for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if
at all, may impair our ability to commercialize our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While we do sell directly taliglucerase alfa in Israel and
Brazil and we intend to build a sales force to market other product candidates at least in certain regions if approved, we do
not anticipate having the resources in the foreseeable future to develop global sales and marketing capabilities for all of the
products we develop. We may pursue arrangements regarding the sales and marketing and distribution of one or more of our product
candidates, such as our current license and supply agreement with Pfizer for taliglucerase alfa, and our future revenues may depend,
in part, on our ability to enter into and maintain arrangements with other companies having sales, marketing and distribution
capabilities and the ability of such companies to successfully market and sell any such products. Any failure to enter into such
arrangements and marketing alliances on favorable terms, if at all, could delay or impair our ability to commercialize our product
candidates and could increase our costs of commercialization. Any use of distribution arrangements and marketing alliances to
commercialize our product candidates will subject us to a number of risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be
                                         required to relinquish important rights to our products or product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may not
                                         be able to control the amount and timing of resources that our distributors or collaborators
                                         may devote to the commercialization of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors
                                         or collaborators may experience financial difficulties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors
                                         or collaborators may not devote sufficient time to the marketing and sales of our products;
                                         and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>business
                                         combinations or significant changes in a collaborator&rsquo;s business strategy may adversely
                                         affect a collaborator&rsquo;s willingness or ability to complete its obligations under
                                         any arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to enter into additional co-promotion arrangements
with third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market.
We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter
into may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ProCellEx protein expression system is based on our
proprietary plant cell-based expression technology which has a limited history and any material problems with the system, which
may be unforeseen, may have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology. The success of our business is dependent upon the successful development and approval
of our product and product candidates produced through this technology. Although taliglucerase alfa is produced through ProCellEx,
the technology remains novel. Accordingly, the technology remains subject to certain risks. Mammalian cell-based protein expression
systems have been used in connection with recombinant therapeutic protein expression for more than 20 years and are the subject
of a wealth of data; in contrast, there is not a significant amount of data generated regarding plant cell-based protein expression
and, accordingly, plant cell-based protein expression systems may be subject to unknown risks. In addition, the protein glycosilation
pattern created by our protein expression system is not identical to the natural human glycosilation pattern and, although to
date clinical data for up to five years of follow-up on taliglucerase alfa has not demonstrated any sign of any effect, the longer
term effect of the protein glycosilation pattern created by our protein expression system on human patients, if any, is still
unknown. Lastly, as our protein expression system is a new technology, we cannot always rely on existing equipment; rather, there
is a need to design custom-made equipment and to generate specific growth media for the plant cells which may not be available
at favorable prices, if at all. Any material problems with the technology underlying our plant cell-based protein expression system
may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently depend heavily on the success of taliglucerase
alfa, our first commercial product. Any failure to successfully commercialize taliglucerase alfa, or the experience of significant
delays in doing so, will have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have invested a significant portion of our efforts and financial
resources in the development of taliglucerase alfa. Our ability to generate product revenue, depends heavily on the successful
development and commercialization of taliglucerase alfa. Pfizer holds an exclusive worldwide license to develop and commercialize
taliglucerase alfa, except in Israel and Brazil. The successful commercialization of taliglucerase alfa will depend on several
factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                         marketing approvals and reimbursement from additional regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful
                                         audit of our facilities by additional regulatory authorities;</TD></TR></TABLE>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining
                                         the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements
                                         with third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer&rsquo;s
                                         efforts under the Pfizer Agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Fiocruz&rsquo;s
                                         activities in Brazil;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Fiocruz&rsquo;s
                                         purchasing the minimum quantities under the Technology Transfer Agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our marketing
                                         efforts in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued
                                         acceptable safety and efficacy profile of taliglucerase alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the availability
                                         of reimbursement to patients from healthcare payors for taliglucerase alfa; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other risks
                                         described in these Risk Factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to successfully commercialize taliglucerase alfa
or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to develop and commercialize our other
product candidates, our business will be adversely affected. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A key element of our strategy is to develop and commercialize
a portfolio of new products in addition to taliglucerase alfa. We seek to do so through our internal research programs and strategic
collaborations for the development of new products. Research programs to identify new product candidates require substantial technical,
financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially
show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many
reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product
                                         candidate is not capable of being produced in commercial quantities at an acceptable
                                         cost, or at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product
                                         candidate may not be accepted by patients, the medical community or third-party payors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competitors
                                         may develop alternatives that render our product candidates obsolete;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the research
                                         methodology used may not be successful in identifying potential product candidates; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product
                                         candidate may on further study be shown to have harmful side effects or other characteristics
                                         that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory
                                         approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to develop or commercialize any of our other product
candidates may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Clinical trials are very expensive,
time-consuming and difficult to design and implement and may result in unforeseen costs which may have a material adverse effect
on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Human clinical trials are very expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time-consuming. Other than taliglucerase alfa, all of our other drug candidates are in the clinical, preclinical
or research stages and will take at least several years to complete. Preliminary and initial results from a clinical trial do
not necessarily predict final results, and failure can occur at any stage of the trials. We may encounter problems that cause
us to abandon or repeat preclinical studies or clinical trials. Companies in the pharmaceutical and biotechnology industries have
suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. Data obtained
from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. Failure or delay
in the commencement or completion of our clinical trials may be caused by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen
                                         safety issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>determination
                                         of dosing issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of effectiveness
                                         during clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>slower than
                                         expected rates of patient recruitment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability
                                         to monitor patients adequately during or after treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability
                                         or unwillingness of medical investigators and institutional review boards to follow our
                                         clinical protocols; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of sufficient
                                         funding to finance the clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure or delay in commencement or completion of any clinical
trials may have a material adverse effect on our business, results of operations and financial condition. In addition, we or the
FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants
in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies
in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>If the results of our clinical
trials do not support our claims relating to any drug candidate or if serious side effects are identified, the completion of development
of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly
impair our ability to generate product revenues.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results of our clinical trials with respect to any drug
candidate might not support our claims of safety or efficacy, the effects of our drug candidates may not be the desired effects
or may include undesirable side effects or the drug candidates may have other unexpected characteristics.&nbsp;&nbsp;Further,
success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing.&nbsp;&nbsp;The
clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses.&nbsp;&nbsp;In
addition, our clinical trials may involve a specific and small patient population.&nbsp;&nbsp;Results of early clinical trials
conducted on a small patient population may not be indicative of future results.&nbsp;&nbsp;Adverse or inconclusive results may
cause us to abandon a drug candidate and may delay development of other drug candidates.&nbsp;&nbsp;Any delay in, or termination
of, our clinical trials will delay the filing of NDAs with the FDA, or other filings with other foreign regulatory authorities,
and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would
have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>We may find it difficult to enroll
patients in our clinical trials, which could cause significant delays in the completion of such trials or may cause us to abandon
one or more clinical trials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Some of the diseases or disorders
that our drug candidates are intended to treat are relatively rare and we expect only a subset of the patients with these diseases
to be eligible for our clinical trials. Our clinical trials generally mandate that a patient cannot be involved in another clinical
trial for the same indication. Therefore, subjects that participate in ongoing clinical trials for products that are competitive
with our drug candidates are not available for our clinical trials. An inability to enroll a sufficient number of patients for
any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical
trials altogether, which will have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Patients may discontinue their
participation in our clinical trials, which may negatively impact the results of these studies and extend the timeline for completion
of our development programs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patients enrolled in our clinical trials may discontinue their
participation at any time during the study as a result of a number of factors, including withdrawing their consent or experiencing
adverse clinical events, which may or may not be judged related to our drug candidates under evaluation. The discontinuation of
patients in any one of our studies may cause the results from that study not to be positive or to not support a filing for regulatory
approval of the applicable drug candidate, which would have a material adverse effect on our business, results of operations and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because our clinical trials depend upon third-party researchers,
the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain
extent, beyond our control, which could impair our clinical development programs and our competitive position. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend upon independent investigators and collaborators,
such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our
employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The
investigators may not assign as great a priority to our clinical development programs or pursue them as diligently as we would
if we were undertaking such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical
development programs, or if their performance is substandard, the approval of our NDA and other marketing applications, and our
introduction of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material
adverse effect on our business and results of operations. The collaborators may also have relationships with other commercial
entities, some of whom may compete with us. If our collaborators also assist our competitors, our competitive position could be
harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The manufacture of our products is an exacting and complex
process, and if we or one of our materials suppliers encounter problems manufacturing our products, it will have a material adverse
effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and foreign regulators require manufacturers to register
manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar
requirements that the FDA or foreign regulators establish. We or our materials suppliers may face manufacturing or quality control
problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance
with the FDA&rsquo;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing our drug candidates.
Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely affect our clinical
research activities and our ability to market and develop our products. To date, our current facility has passed audits by the
FDA, the Israeli MOH, ANVISA and the IMB on behalf of the EMA but remains subject to audit by other foreign regulatory authorities.
There can be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements for our current
facility or any facility we may establish in the future, which would have a material adverse effect on our business, results of
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on third parties for final processing of taliglucerase
alfa and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and
commercialization of taliglucerase alfa and our other product candidates or result in higher product costs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no experience in the final filling and freeze drying
steps of the drug manufacturing process. We have engaged a European contract manufacturer to act as an additional source of fill
and finish activities for taliglucerase alfa and have engaged other parties for our other product candidates. We currently rely
primarily on other third-party contractors to perform the final manufacturing steps for taliglucerase alfa on a commercial scale.
We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all because the number of
potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve any manufacturer
and/or replacement manufacturer, including us, and we or any such third party manufacturer might be unable to formulate and manufacture
our drug products in the volume and of the quality required to meet our clinical and commercial needs. If we engage any contract
manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time
required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the rules and regulations
of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are
not in compliance with applicable regulations. Each of these risks could delay our clinical trials, the approval, if any, of taliglucerase
alfa and our other potential drug candidates by the FDA and other regulatory authorities, or the commercialization of taliglucerase
alfa and our other drug candidates or could result in higher product costs or otherwise deprive us of potential product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Developments by competitors may render our products or technologies
obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compete against fully integrated pharmaceutical companies
and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies
and other public and private research organizations. Our drug candidates will have to compete with existing therapies and therapies
under development by our competitors. In addition, our commercial opportunities may be reduced or eliminated if our competitors
develop and market products that are less expensive, more effective or safer than our drug products. Other companies have drug
candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop
drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be
commercialized earlier. Even if we are successful in developing effective drugs, our products may not compete successfully with
products produced by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We specifically face competition from companies with approved
treatments of Gaucher disease. In addition to Elelyso, there are two other ERTs for the treatment of Gaucher disease; Cerezyme
and VPRIV. To a much lesser extent, we also compete with Actelion. In addition, Cerdelga, Genzyme&rsquo;s orally-delivered small
molecule drug for the treatment of Gaucher disease, was approved in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are two approved ERTs for the treatment of Fabry disease;
Fabrazyme and Replagal. Fabrazyme is available in the United States and the European Union. Replagal is available in the European
Union. In 2012, Shire elected to withdraw its BLA for Replagal in the United States. In addition, we are aware of other clinical
stage, early clinical stage and experimental drugs which are being developed for the treatment of Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also face competition from companies that are developing
other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include iBio, Medicago and Greenovation Biotech GmbH, none of which are cell-based. Rather, such companies
base their product development on transgenic plants or whole plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most of our competitors, either alone or together with their
collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater
financial resources than we do, as well as significantly greater experience in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developing
                                         drugs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>undertaking
                                         preclinical testing and human clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                         marketing approvals from the FDA and other regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating
                                         and manufacturing drugs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>launching,
                                         marketing and selling drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These organizations also compete with us to attract qualified
personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated
costs on our business which would have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we in-license drug candidates, we may delay or otherwise
adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to our own internally developed drug candidates,
we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential
to take advantage of our development know-how and technology. If we in-license any additional drug candidate, our capital requirements
may increase significantly. In addition, in-licensing additional drug candidates may place a strain on the time of our existing
personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize
our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may delay the
development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to successfully manage our growth, there
could be a material adverse impact on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have grown rapidly and expect to continue to grow. To manage
our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand
our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not be able
to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any inability on the
part of our management to manage growth could delay the execution of our business plans or disrupt our operations. If we are unable
to manage our growth effectively, we may not use our resources in an efficient manner, which may delay the development of our
drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we acquire companies, products or technologies, we may
face integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are presented with appropriate opportunities, we may
acquire or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of
any acquisition or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated
with the integration process, including difficulties in the integration of the operations of an acquired company, integration
of acquired technology with our products, diversion of our management&rsquo;s attention from other business concerns, the potential
loss of key employees or customers of the acquired business and impairment charges if future acquisitions are not as successful
as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization
expenses or charges relating to acquired intangible assets.<B> </B>Any failure to successfully integrate other companies, products
or technologies that we may acquire may have a material adverse effect on our business and results of operations. Furthermore,
we may have to incur debt or issue equity securities to pay for any additional future acquisitions or investments, the issuance
of which could be dilutive to our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We depend upon key employees and consultants in a competitive
market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop
and market our products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are highly dependent upon the principal members of our management
team, especially our President and Chief Executive Officer, Moshe Manor, as well as the Chairman of our Board of Directors, Shlomo
Yanai, our other directors, our scientific advisory board members, consultants and collaborating scientists. Many of these people
have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue
to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical
development and regulatory programs. We have employment agreements with Moshe Manor and our other executive officers that may
be terminated by us or the applicable officer at any time with varying notice periods of 60 to 90 days. Although these employment
agreements generally include non-competition covenants, the applicable noncompetition provisions can be difficult and costly to
monitor and enforce. The loss of any of these persons&rsquo; services may adversely affect our ability to develop and market our
products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also depend in part on the continued service of our key
scientific personnel and our ability to identify, hire and retain additional personnel, including marketing and sales staff. We
experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees
and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While
we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely
to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our collaborations with outside scientists and consultants
may be subject to restriction and change. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We work with medical experts, chemists,
biologists and other scientists at academic and other institutions, and consultants who assist us in our research, development,
regulatory and commercial efforts, including the members of our scientific advisory board. These scientists and consultants have
provided, and we expect that they will continue to provide, valuable advice regarding our programs. These scientists and consultants
are not our employees, may have other commitments that would limit their future availability to us and typically will not enter
into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity,
we may lose their services. In addition, we will be unable to prevent them from establishing competing businesses or developing
competing products. For example, if a key scientist acting as a principal investigator in any of our clinical trials identifies
a potential product or compound that is more scientifically interesting to his or her professional interests, his or her availability
to remain involved in our clinical trials could be restricted or eliminated, which may have a material adverse effect on our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Under current U.S. and Israeli law, we may not be able to
enforce employees&rsquo; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from
the expertise of some of our former employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into non-competition agreements with substantially
all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or
working for our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements
against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former
employees gained while working for us. <B> </B>If we cannot enforce our employees&rsquo; non-compete agreements, we may be unable
to prevent our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If product liability claims are brought against us, it may
result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clinical testing, marketing and use of our products and
product candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury
or disease, or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval,
could result in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0
million per occurrence and $10.0 million in the aggregate, an amount we consider reasonable and customary. However, this insurance
coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential
claims. We may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We
expect to obtain product liability insurance coverage before commercialization of our product candidates; however, such insurance
is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate
insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage
or one that is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and
development, which may have a material adverse effect on our business, results of operations and financial condition. Product
liability claims, even if without merit, may result in reduced demand for our products, if approved, which would have a material
adverse effect on our business, financial condition and results of operations. In addition, the existence of a product liability
claim could affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reforms in the healthcare industry and the uncertainty associated
with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our
products, if approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Increasing healthcare expenditures have been the subject of
considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain
healthcare costs. Numerous proposals that would result in changes in the U.S. healthcare system have been introduced or proposed
in the U.S. Congress and in some state legislatures within the United States, including reductions in the pricing of prescription
products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical
products. Legislation passed in recent years has imposed certain changes to the way in which drugs, including our product candidates,
are covered and reimbursed in the United States. For example, federal legislation and regulations have implemented new reimbursement
methodologies for certain drugs, created a voluntary prescription drug benefit, Medicare Part D, and have imposed significant
revisions to the Medicaid Drug Rebate Program. The PPACA imposes yet additional changes to these programs. We believe that legislation
that reduces reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers
will prescribe or administer our products, if approved. This could materially and adversely impact our business by reducing our
ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition,
we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and
usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governments outside the United States tend to impose strict
price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In some countries, particularly European Union member states,
the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with
governmental authorities can take considerable time (six to 12&nbsp;months or longer) after the receipt of marketing approval
for a product. To obtain reimbursement or pricing approval in some countries with respect to any product candidate that achieves
regulatory approval, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate
to other available therapies. If reimbursement of our products upon approval, if at all, is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, our prospects for generating revenue, if any, could be adversely affected
which would have a material adverse effect on our business, results of operations and financial condition. Further, if we achieve
regulatory approval of any product, we must successfully negotiate product pricing for such product in individual countries. As
a result, the pricing of our products, if approved, in different countries may vary widely, thus creating the potential for third-party
trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products could
undermine our sales in markets with higher prices <FONT STYLE="font-family: Times New Roman, Times, Serif">which could have a
material adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ability to utilize net operating loss carryforwards
may be limited.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our net operating loss carryforwards, or
&ldquo;NOLs&rdquo;, as of December 31, 2014, are equal to approximately $138.8&nbsp;million, of which approximately $17
million may be restricted under Section 382 of the Internal Revenue Code of 1986, as amended, or the &ldquo;Code.&rdquo;
Section 382 of the Code imposes limitations on a corporation&rsquo;s ability to utilize NOLs to offset taxable income if the
corporation experiences an &ldquo;ownership change.&rdquo; In general terms, an &ldquo;ownership change&rdquo; may result
from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a
three-year period. In the event that an ownership change has occurred, or were to occur, utilization of our NOLs would be
subject to an annual limitation under Section 382, which is generally the fair market value of the pre-change entity
multiplied by the long-term tax exempt rate, which is published monthly by the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are a holding company with no operations of our own.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a holding company with no operations of our own. Accordingly,
our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent
upon the earnings from the business conducted by Protalix Ltd. The distribution of those earnings or advances or other distributions
of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of our subsidiary and
are subject to various business considerations and U.S. and Israeli law. If Protalix Ltd. is unable to make sufficient distributions
or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash
resources necessary to conduct our corporate operations which would have a material adverse effect on our business, results of
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>We are subject to extensive governmental
regulation including the requirement of FDA or comparable approval before our drug candidates may be marketed.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Both before and after approval of
our drug candidates, we, our drug candidates, our suppliers, our contract manufacturers and our contract testing laboratories
are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. Failure to comply with applicable
requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of the following
actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warning letters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines and
                                         other monetary penalties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unanticipated
                                         expenditures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in
                                         the FDA&rsquo;s or other foreign regulatory authorities&rsquo; approving, or the refusal
                                         of any regulatory authority to approve, any drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product recall
                                         or seizure;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interruption
                                         of manufacturing or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>operating
                                         restrictions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions;
                                         and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>criminal
                                         prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to the approval requirements,
other numerous and pervasive regulatory requirements apply, both before and after approval, to us, our drug candidates, and our
suppliers, contract manufacturers, and contract laboratories. These include requirements related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>testing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>quality control;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>advertising;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>promotion;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>export;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reporting
                                         to the FDA certain adverse experiences associated with use of the drug candidate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                         additional approvals for certain modifications to the drug candidate or its labeling
                                         or claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We also are subject to inspection
by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory requirements, as are our
suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that the FDA or any other
comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or distribution, or require
substantial resources to correct. We may be required to make modifications to our manufacturing operations in response to these
inspections which may require significant resources and may have a material adverse effect upon our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The approval process for any drug
candidate may also be delayed by changes in government regulation, future legislation or administrative action or changes in policy
of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory reviews of such drug candidate.
Delays in obtaining regulatory approvals with respect to any drug candidate may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay commercialization
                                         of, and our ability to derive product revenues from, such drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay any
                                         regulatory-related milestone payments payable under outstanding collaboration agreements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require us
                                         to perform costly procedures with respect to such drug candidate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>otherwise
                                         diminish any competitive advantages that we may have with respect to such drug candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Delays in the approval process for
any drug candidate may have a material adverse effect upon our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>We may not obtain the necessary
U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would
have a material adverse effect on our business, financial condition and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We need FDA approval to commercialize
our drug candidates in the United States, EMA approval to commercialize our drug candidates in the European Union and approvals
from foreign regulators to commercialize our drug candidates elsewhere. In order to obtain FDA approval of any of our drug candidates,
we must submit to the FDA an NDA or a Biologic License Application (BLA) demonstrating that the drug candidate is safe for humans
and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as
preclinical studies, as well as human tests, which are referred to as clinical trials. In the European Union, we must submit an
MAA to the EMA. Satisfaction of the FDA&rsquo;s, the EMA&rsquo;s and foreign regulatory authorities&rsquo; regulatory requirements
typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources
for research, development and testing. Taliglucerase alfa has been approved for marketing in the United States, Israel, Brazil,
Mexico, Chile and Uruguay, and marketing applications are outstanding in other countries. Even if we comply with all the requests
of regulatory authorities, the authorities may ultimately reject the marketing applications filed for taliglucerase alfa or that
we file for our other product candidates in the future, if any, or we might not obtain regulatory clearance in a timely manner
for taliglucerase alfa in certain countries or for any of our other drug candidates. Companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier
trial results or in preliminary findings or other comparable authorities for such clinical trials.&nbsp;&nbsp;Further, even if
favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept
or approve the marketing application filed by a pharmaceutical or biotechnology company for the drug candidate. Failure to obtain
approval of the FDA, EMA or comparable foreign authorities of any of our drug candidates in a timely manner, if at all, will severely
undermine our business, financial condition and results of operation by reducing our potential marketable products and our ability
to generate corresponding product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our research and clinical efforts
may not result in drugs that the FDA, EMA or foreign regulatory authorities consider safe for humans and effective for indicated
uses, which would have a material adverse effect on our business, financial condition and results of operations.&nbsp;&nbsp;After
clinical trials are completed for any drug candidate, if at all, the FDA, EMA and foreign regulatory authorities have substantial
discretion in the drug approval process of the drug candidate in their respective jurisdictions and may require us to conduct
additional clinical testing or perform post-marketing studies which would cause us to incur additional costs. Incurring such costs
may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>We have only limited experience
in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors may affect our ability
or the time we require to obtain necessary regulatory approvals.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have only limited experience in filing and prosecuting the
applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover, some of the drug candidates
that are likely to result from our development programs may be based on new technologies that have not been extensively tested
in humans. The regulatory requirements governing these types of drug candidates may be less well defined or more rigorous than
for conventional products. As a result, we may experience a longer regulatory process in connection with obtaining regulatory
approvals of any products that we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>If any of our other competitors
are able to obtain orphan drug exclusivity for any products that are competitive with our products, we may be precluded from selling
or obtaining approval of our competing products by the applicable regulatory authorities for a significant period of time.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the United States, the European
Union and other countries, a drug may be designated as having orphan drug status, subject to certain conditions. There can be
no assurance that a drug candidate that receives orphan drug designation will receive orphan drug marketing exclusivity and more
than one drug can have orphan designation for the same indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Foreign regulations regarding orphan
drugs are similar to those in the United States but there are several conceptual differences. For example, the exclusivity period
in the European Union is generally 10 years.<FONT STYLE="font-family: Times New Roman, Times, Serif"> The EMA/European Commission
has granted orphan drug designation and exclusivity to VPRIV in the European Union. For this reason,</FONT> CHMP has recommended
that the EC not issue a Marketing Authorization for taliglucerase alfa in the European Union. Therefore, <FONT STYLE="font-family: Times New Roman, Times, Serif">VPRIV
</FONT>has orphan market exclusivity in the European Union for a 10-year period commencing on its authorization in August 2010
which may <FONT STYLE="font-family: Times New Roman, Times, Serif">have a </FONT>material adverse effect on our business, results
of operations and financial condition<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we may apply to the FDA or any comparable
foreign regulatory authority for orphan drug designation for any one or more of our drug candidates. None of our currently developed
drug candidates have been designated as an orphan drug and there is no guarantee that the FDA or any other regulatory authority
will grant such designation in the future. In addition, neither orphan drug designation nor orphan drug exclusivity prevents competitors
from developing or marketing different drugs for that indication. Even if we obtain orphan drug exclusivity for one or more indications
for one of our drug candidates, we may not be able to maintain the exclusivity. For example, if a competitive product that is
the same drug or biologic as one of our drug candidates is shown to be clinically superior to the drug candidate, any orphan drug
exclusivity granted to the drug candidate will not block the approval of the competitive product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Intellectual Property Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we fail to adequately protect or enforce our intellectual
property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our
business, competitive position and results of operations would suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2014, we had 94 pending patent applications
and one joint pending patent application with a third party. However, the filing of a patent application does not mean that we
will be issued a patent, or that any patent eventually issued will be as broad as requested in the patent application or sufficient
to protect our technology. Any modification required to a current patent application may delay the approval of such patent application
which would have a material adverse effect on our business, results of operations and financial condition. In addition, there
are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent
applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality
of the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our licensors
and collaborators to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve
our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary
rights of third parties. We have filed U.S. and international patent applications for process patents, as well as<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>
</B></FONT>composition of matter patents, for taliglucerase alfa and other product candidates. However, we cannot predict:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the degree
                                         and range of protection any patents will afford us against competitors and those who
                                         infringe upon our patents, including whether third parties will find ways to invalidate
                                         or otherwise circumvent our licensed patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if and when
                                         patents will issue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or
                                         not others will obtain patents claiming aspects similar to those covered by our licensed
                                         patents and patent applications; or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether we
                                         will need to initiate litigation or administrative proceedings, which may be costly,
                                         and whether we win or lose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2014, we hold, or have license rights to,
64 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient
proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the
U.S. Patent and Trademark Office or foreign patent offices issue patents to us or our licensors, others may challenge the patents
or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license
from or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furthermore, the life of our patents is limited. The patents
we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our
ProCellEx protein expression system are expected to expire between 2017 and 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on confidentiality agreements that could be breached
and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to enter agreements relating to the non-disclosure
of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as
well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries
and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to
enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently
develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual
property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can
be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by
confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures
we employ, we still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements
                                         may be breached;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements
                                         may not provide adequate remedies for the applicable type of breach; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our trade
                                         secrets or proprietary know-how will otherwise become known.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any breach of our confidentiality agreements or our failure
to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we infringe the rights of third parties we could be prevented
from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs
and may have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not received to date any claims of infringement by
any third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public
profile and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence
of a judgment adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive
position. If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may
incur substantial costs and we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain licenses,
                                         which may not be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>redesign
                                         our products or processes to avoid infringement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stop using
                                         the subject matter claimed in the patents held by others, which could cause us to lose
                                         the use of one or more of our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>defend litigation
                                         or administrative proceedings that may be costly whether we win or lose, and which could
                                         result in a substantial diversion of management resources; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any costs incurred in connection with such events or the inability
to sell our products may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we cannot meet requirements under our license agreements,
we could lose the rights to our products, which could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend on licensing agreements with third parties to maintain
the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and
satisfy performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout
the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of
years after the first commercial sale of the relevant product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we are responsible for the cost of filing and
prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations
under our license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Operations in Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential political, economic and military instability in
the State of Israel, where the majority of our senior management and our research and development facilities are located, may
adversely affect our results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive office and operations are located in the State
of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business. Since the State of
Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. Any hostilities
involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant
downturn in the economic or financial condition of Israel, could affect adversely our operations and product development. Although
Israel has entered into various agreements with Egypt, Jordan and the Palestinian Authority, there have been times since October
2000 when Israel has experienced an increase in unrest and terrorist activity. The establishment in 2006 of a government in the
Palestinian Authority by representatives of the Hamas militant group has created additional unrest and uncertainty in the region.
Starting in December 2008, for approximately three weeks, Israel engaged in an armed conflict with Hamas in the Gaza Strip. Armed
conflicts have taken place between Israel and Hamas in the Gaza Strip in 2008, 2012 and 2014. Our facilities in northern Israel
are in range of rockets that were fired from Lebanon into Israel during a 2006 war with the Hizbollah in Lebanon, and suffered
minimal damages during one of the rocket attacks. Our insurance policies do not cover us for the damages incurred in connection
with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage
for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may
cease providing such coverage or the coverage might not be enough to cover potential damages. If our facilities are damaged as
a result of hostile action, our operations may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, since the end of 2010, numerous
acts of protest and civil unrest have taken place in several countries in the Middle East and North Africa, many of which involved
significant violence. Civil unrest in Egypt, which borders Israel, has resulted in significant changes to the country&rsquo;s
government. There is currently a civil war in Syria, also bordering Israel, and Israel has been hit by rockets and mortars originating
from Syria. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel&rsquo;s
position within the region is not clear at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our operations may be disrupted by the obligations of our
personnel to perform military service which could have a material adverse effect on our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many of our male employees in Israel, including members of
senior management, are obligated to perform up to one month (in some cases more) of annual military reserve duty until they reach
the age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the
absence of a significant number of our employees related to military service or the absence for extended periods of military service
of one or more of our key employees. A disruption could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because a certain portion of our expenses is incurred in
New Israeli Shekels, or NIS, our results of operations may be seriously harmed by currency fluctuations and inflation. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We report our financial statements in U.S. dollars, our functional
currency. Although most of our expenses are incurred in U.S. dollars, we pay a portion of our expenses in New Israeli Shekels,
or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation
of the NIS in relation to the U.S. dollar or if the timing of these devaluations lags behind inflation in Israel. In that event,
the U.S. dollar cost of our operations in Israel will increase and our U.S. dollar-measured results of operations will be adversely
affected. To the extent that the value of the NIS increases against the dollar, our expenses on a dollar cost basis increase.
Our operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date,
we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk
of financial exposure from fluctuations in the exchange rate of the U.S. dollar against the NIS. These measures, however, may
not adequately protect us from material adverse effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The tax benefits available to us require that we meet several
conditions and may be terminated or reduced in the future, which would increase our taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are able to take advantage of tax exemptions and reductions
resulting from the &ldquo;Approved Enterprise&rdquo; status of our facilities in Israel. To remain eligible for these tax benefits,
we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at
least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be
canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment
policy by the Investment Center and may not be continued in the future at their current levels or at any level. In recent years
the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these
benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &ldquo;Approved
Enterprise&rdquo; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely
affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by
future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Israeli government grants we have received for certain
research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel
and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously
received together with interest and penalties which could have a material adverse effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development efforts have been financed, in
part, through grants that we have received from the OCS. We, therefore, must comply with the requirements of the Research Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law we are prohibited from manufacturing
products developed using these grants outside of the State of Israel without special approvals, although the Research Law does
enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased
royalties. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do receive
approval to manufacture products developed with government grants outside of Israel, we may be required to pay an increased total
amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed
outside of Israel, as well as at a possibly increased royalty rate. This restriction may impair our ability to outsource manufacturing
or engage in similar arrangements for those products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, we are prohibited from
transferring the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except under
limited circumstances and only with the approval of the OCS&rsquo; Research Committee. We may not receive the required approvals
for any proposed transfer and, if received, we may be required to pay the OCS a portion of the consideration that we receive upon
any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that we have already paid
to the OCS, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which the
OCS grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount
of the payment to the OCS. Approval of the transfer of technology to residents of the State of Israel is required, and may be
granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions
on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer,
if requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These restrictions may impair our ability to sell our technology
assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even
after we have repaid the full amount of royalties payable for the grants. For the years ended December 31, 2013 and 2014, we recorded
grants totaling $3.4 million and $5.1 million from the OCS, respectively. The grants represent 10.4% and 17.2%, respectively,
of our gross research and development expenditures for the years ended December 31, 2013 and 2014. If we fail to satisfy the conditions
of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and
may become subject to criminal charges, any of which could have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors may have difficulties enforcing a U.S. judgment,
including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers
and most of our directors or asserting U.S. securities laws claims in Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most of our directors and none of our officers are residents
of the United States, and most of their assets and our assets are located outside the United States. Service of process upon our
non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us, some of our directors
and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel
that investors may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain
a judgment based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors.
Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors
because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli courts might not enforce judgments rendered outside
Israel which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli
court may declare a foreign civil judgment enforceable only if it finds that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         was rendered by a court which was, according to the laws of the state of the court, competent
                                         to render the judgment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         may no longer be appealed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the obligation
                                         imposed by the judgment is enforceable according to the rules relating to the enforceability
                                         of judgments in Israel and the substance of the judgment is not contrary to public policy;
                                         and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         is executory in the state in which it was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if these conditions are satisfied, an Israeli court will
not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of
Israel. An Israeli court also will not declare a foreign judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         was obtained by fraud;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is
                                         a finding of lack of due process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         was rendered by a court not competent to render it according to the laws of private international
                                         law in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment
                                         is at variance with another judgment that was given in the same matter between the same
                                         parties and that is still valid; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at the time
                                         the action was brought in the foreign court, a suit in the same matter and between the
                                         same parties was pending before a court or tribunal in Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Investing in our Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The market price of our common stock may fluctuate significantly.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock may fluctuate significantly
in response to numerous factors, some of which are beyond our control, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Purchases
                                         of Uplyso by Fiocruz;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer&rsquo;s
                                         and our commercialization efforts for Elelyso;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the results
                                         of our ongoing studies regarding our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>announcements
                                         regarding partnerships or collaborations by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments
                                         concerning intellectual property rights and regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the announcement
                                         of new products or product enhancements by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations
                                         in our and our competitors&rsquo; results of operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in
                                         earnings estimates or recommendations by securities analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments
                                         in the biotechnology industry; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general market
                                         conditions and other factors, including factors unrelated to our operating performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, stock markets in general, and the market for biotechnology
companies in particular, have recently experienced price and volume fluctuations. Continued market fluctuations could result in
extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility
of our common stock may be worse if the trading volume of our common stock is low. We have not paid, and do not expect to pay,
any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations.
As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold
at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future sales of our common stock could
reduce our stock price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock could drop significantly
if our existing shareholders sell a large number of shares of our common stock or are perceived by the market as intending to
sell them. All of our outstanding shares of our common stock are freely tradable without restriction or further registration under
the federal securities laws, unless owned by our affiliates. At December&nbsp;31, 2014, there were options to purchase common
stock issued and outstanding and unvested restricted shares covering 7,465,025 shares of our common stock with a weighted average
exercise price of $3.96 per share. Also at December&nbsp;31, 2014, there were 1,923,444 shares of common stock remaining available
for future for issuance in connection with future grants of incentives under our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Servicing our debt requires a significant amount of cash,
and we may not have sufficient cash flow from our business to pay our debt. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to pay interest on, or to make any scheduled payment
of the principal of, the Notes, depends on our future performance, which is subject to economic, financial, competitive and other
factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt
and make necessary expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives,
such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive.
Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. If we raise
additional debt, it would increase our interest expense, leverage and operating and financial costs. In addition, the terms of
the indenture governing the Notes and the agreements governing future indebtedness may restrict us from adopting any of these
alternatives. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which
could result in a default on our debt obligations. The failure to generate sufficient cash flow or to effect any of these alternatives
could significantly adversely affect the value of the Notes and our ability to pay amounts due under the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our significant level of indebtedness could adversely affect
our business, financial condition and results of operations and prevent us from fulfilling our obligations under the Notes and
our other indebtedness.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The outstanding Notes represent a significant amount of indebtedness
and substantial debt service requirements. We may also incur additional indebtedness to meet future financing needs. Our substantial
indebtedness could have material adverse effects on our business, financial condition and results of operations. For example,
it could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make it more
                                         difficult for us to satisfy our financial obligations, including with respect to the
                                         Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>result in
                                         an event of default if we fail to comply with the financial and other restrictive covenants
                                         contained in agreements governing any future indebtedness, which event of default could
                                         result in all of our debt becoming immediately due and payable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase
                                         our vulnerability to general adverse economic, industry and competitive conditions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the
                                         availability of our cash flow to fund working capital, capital expenditures, acquisitions
                                         and other general corporate purposes because we will be required to dedicate a substantial
                                         portion of our cash flow from operations to the payment of principal and interest on
                                         our indebtedness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit our
                                         flexibility in planning for, or reacting to, and increasing our vulnerability to changes
                                         in our business, the industry in which we operate and the general economy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prevent us
                                         from raising funds necessary to purchase Notes surrendered to us by holders upon a fundamental
                                         change (as described in the indenture governing the Notes), which failure would result
                                         in an event of default with respect to the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>place us
                                         at a competitive disadvantage compared to our competitors that have less indebtedness
                                         or are less highly leveraged and that, therefore, may be able to take advantage of opportunities
                                         that our debt levels or leverage prevent us from exploiting; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit our
                                         ability to obtain additional financing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of these factors may have a material and adverse effect
on our business, financial condition and results of operations and our ability to meet our payment obligations under the Notes
and our other indebtedness. Our ability to make payments with respect to the Notes and to satisfy any other debt obligations will
depend on our future operating performance and our ability to generate significant cash flow in the future, which will be affected
by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as well as other factors
affecting our company and industry, many of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Any conversion of the Notes will dilute the ownership interest
of our existing stockholders, including holders who had previously converted their notes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The conversion of some or all of the Notes will dilute the
ownership interests of our existing stockholders. Any sales in the public market of our common stock issuable upon such conversion
could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short
selling by market participants because the conversion of the Notes could depress the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our common stock is listed for trade on more than one stock
exchange, and this may result in price variations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed for trade on both the NYSE MKT and
the TASE. Dual-listing may result in price variations between the exchanges due to a number of factors. First, our common stock
is traded in U.S. dollars on the NYSE MKT and in NIS on the TASE. In addition, the exchanges are open for trade at different times
of the day and on different days. For example, the TASE opens generally during Israeli business hours, Sunday through Thursday
while the NYSE MKT opens generally during U.S. business hours, Monday through Friday. The two exchanges also have differing vacation
schedules. Differences in the trading schedules, as well as volatility in the exchange rate of the two currencies, among other
factors, may result different trading prices for our common stock on the two exchanges. Other external influences may have different
effects on the trading price of our common stock on the two exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors, executive officers, principal shareholders and
affiliated entities own a significant percentage of our capital stock, and they may make decisions that an investor may not consider
to be in the best interests of our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our directors, executive officers, principal shareholders and
affiliated entities beneficially own, in the aggregate, approximately 33% of our outstanding common stock. As a result, if some
or all of them acted together, they would have the ability to exert substantial influence over the election of our Board of Directors
and the outcome of issues requiring approval by our shareholders. This concentration of ownership may have the effect of delaying
or preventing a change in control of our company that may be favored by other shareholders. This could prevent the consummation
of transactions favorable to other shareholders, such as a transaction in which shareholders might otherwise receive a premium
for their shares over current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Failure to maintain effective internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and operating results. In addition,
current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect
on the price of our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective internal controls are necessary for us to provide
reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our
results of operation could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 404 of the Sarbanes-Oxley Act of 2002 requires annual
management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent
registered public accounting firm addressing these assessments. We continuously monitor our existing internal controls over financial
reporting systems to confirm that they are compliant with Section 404, and we may identify deficiencies that we may not be able
to remediate in time to meet the deadlines imposed by the Sarbanes-Oxley Act. This process may divert internal resources and will
take a significant amount of time and effort to complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If, at any time, it is determined that we are not in compliance
with Section 404, we may be required to implement new internal control procedures and reevaluate our financial reporting. We may
experience higher than anticipated operating expenses as well as increased independent auditor fees during the implementation
of these changes and thereafter. Further, we may need to hire additional qualified personnel. If we fail to maintain the adequacy
of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to conclude
on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act, which could result in our being unable to obtain an unqualified report on internal controls from our independent auditors.
Failure to maintain an effective internal control environment could also cause investors to lose confidence in our reported financial
information, which could have a material adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with changing regulation of corporate governance
and public disclosure may result in additional expenses, divert management&rsquo;s attention from operating our business which
could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been other changing laws, regulations and standards
relating to corporate governance and public disclosure in addition to the Sarbanes-Oxley Act, as well as new regulations promulgated
by the Commission and rules promulgated by the national securities exchanges, including the NYSE MKT and the NASDAQ. These new
or changed laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity,
and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies,
which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards are likely
to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating
activities to compliance activities. Our board members, Chief Executive Officer and Chief Financial Officer could face an increased
risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting
and retaining qualified board members and executive officers, which could have a material adverse effect on our business. If our
efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing
bodies, we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which would
have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The issuance of preferred stock or additional shares of
common stock could adversely affect the rights of the holders of shares of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors is authorized to issue up to 100,000,000
shares of preferred stock without any further action on the part of our shareholders. Our Board of Directors has the authority
to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we
have no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may, at any time, authorize the issuance
of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive
dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares,
together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of
the holders of our common stock. In addition, our Board of Directors, without further shareholder approval, may, at any time,
issue large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without
any further action on the part of our shareholders may impede a takeover of our company and may prevent a transaction that is
favorable to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the rules of the TASE, other than incentives under our
amended 2006 stock incentive plan, we were prohibited from issuing any securities of any class or series different than the common
stock that is listed on the TASE for the 12-month period immediately succeeding our initial listing, which occurred on September&nbsp;6,
2010. As of the date hereof, the rules of the TASE allow us to issue securities with preferential rights with respect to dividends
but such other securities may not include voting rights. The foregoing does not limit our liability to issue and grant options
and warrants for the purchase of shares of our common stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_005"></A>Item&nbsp;1B. &nbsp;&nbsp;Unresolved
Staff Comments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt"><A NAME="a_006"></A>Item&nbsp;2.&nbsp;&nbsp;Properties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our manufacturing facility and executive offices are located
in Carmiel, Israel. The facilities currently contain approximately 20,000 sq/ft of manufacturing space and additional 48,000 sq/ft
of laboratory, warehouse and office space and are leased at a rate of approximately $85,000 per month. In addition, we are entitled
to use an additional 13,000 sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion
of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business,
and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. We have leased the facility
through 2016, subject to three options exercisable by us to extend the term for a five-year period, for an aggregate of 15 additional
years. Upon the exercise of each option to extend the term of the lease, if any, the then current base rent shall be increased
by 10%. We also lease an office in Ramat Gan, Israel, for approximately $2,500 per month.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><A NAME="a_007"></A>Item&nbsp;3.&nbsp;&nbsp;Legal
Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><A NAME="a_008"></A>Item&nbsp;4.&nbsp;&nbsp;Mine
Safety Disclosures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 28.05pt"><B><A NAME="a_009"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><A NAME="a_010"></A>Item 5.</TD><TD STYLE="text-align: justify">Market for
                                         Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of
                                         Equity Securities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our common stock began trading on the NYSE
MKT (formerly, the American Stock Exchange) on March 12, 2007 under the symbol &ldquo;PLX.&rdquo; Our common stock is also listed
on the TASE under the symbol &ldquo;PLX.&rdquo; The following table sets forth the quarterly high and low closing prices for our
common stock on the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price Range</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0">Fourth Quarter 2014&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.65</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Third Quarter 2014&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Second Quarter 2014&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">First Quarter 2014&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Fourth Quarter 2013&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Third Quarter 2013&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Second Quarter 2013&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">First Quarter 2013&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">These quotations reflect prices between dealers
and do not include retained mark-ups, mark-downs and commissions and may not necessarily represent actual transactions. There
were approximately 85 holders of record of our common stock at March 1, 2015. A substantially greater number of holders of our
common stock are &ldquo;street name&rdquo; or beneficial holders, whose shares are held of record by banks, brokers and other
financial institutions. To date, we have not declared or paid any cash dividends on our common stock. We do not anticipate paying
any dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>STOCK PERFORMANCE
GRAPH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following graph compares the cumulative
total shareholder return data for our common stock from December 31, 2009 through December 31, 2014 to the cumulative return over
such time period of (i) The NYSE MKT Composite Index and (ii) The Nasdaq Biotechnology Index. The graph assumes an investment
of $100 on December 31, 2009 in each of our common stock, the stocks comprising the NYSE MKT Composite Index and the stocks comprising
the Nasdaq Biotechnology Index, including dividend reinvestment, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>The stock price performance shown on
the graph below represents historical price performance and is not necessarily indicative of any future stock price performance.
Notwithstanding anything to the contrary set forth in any of our previous filings under the Securities Act or the Exchange Act,
which might incorporate future filings made by us under those statutes, this Stock Performance Graph will not be incorporated
by reference into any of those prior filings, nor will such report or graph be incorporated by reference into any future filings
made by us under those Acts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="tpg56.jpg"></P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: -37.4pt"><A NAME="a_011"></A>Item&nbsp;6.&nbsp;&nbsp;Selected
Financial Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The selected consolidated financial data
below should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and our consolidated financial statements and the related notes included elsewhere in this Annual Report
on Form 10-K. The selected consolidated statements of operations data for the years ended December&nbsp;31, 2014, 2013 and 2012
and the selected consolidated balance sheet data as of December&nbsp;31, 2014 and 2013, are derived from the audited consolidated
financial statements included elsewhere in this Annual Report. The statement of operations data for the years ended December 31,
2011 and 2010 and the balance sheet data as of December 31, 2012, 2011 and 2010 are derived from audited financial statements
not included in this Annual Report. The historical results presented below are not necessarily indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" NOWRAP STYLE="font-weight: bold; text-align: center">Year Ended December&nbsp;31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-style: italic; text-align: center">(in thousands, except share and per share amounts)</TD><TD STYLE="font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 9pt; text-indent: -9pt">Consolidated Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 45%; text-align: justify; padding-left: 9pt; text-indent: -9pt">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">6,642</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">8,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">34,870</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10,479</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">13,651</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Our share in the Collaboration Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,418</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(446</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,525</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,053</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,107</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Research and development expenses, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,689</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Selling, General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,763</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Financial income (expenses), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,998</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,529</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,790</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,943</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Net loss per share of common stock,
    basic and <BR>diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><P STYLE="text-align: right">&#9;0.32</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; text-indent: -9pt">Weighted average number of shares of common stock used
    in computing net loss per share of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,960,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,645,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,845,901</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,368,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,891,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">86,398</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">All other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,805</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,470</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,693</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,755</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,071</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; text-indent: -9pt">Capital deficiency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,601</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B><A NAME="a_012"></A>Item 7.</B></TD><TD STYLE="text-align: justify"><B>Management&rsquo;s
                                         Discussion and Analysis of Financial Condition and Results of Operations</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our consolidated financial statements and the
related notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and
analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. You should read &ldquo;Risk Factors&rdquo; in Item 1A of this Annual Report on
Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described
in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP>
protein expression system. Using our ProCellEx system, we are developing a pipeline of proprietary, clinically superior
versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that rely
upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including
proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. With our experience, and having
successfully developed Elelyso, our first drug product, we believe ProCellEx will enable us to develop additional proprietary
recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same
indications. Because we are primarily targeting biologically superior versions of highly active, well-tolerated and
commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk
compared to other biopharmaceutical development processes for completely novel therapeutic proteins. We are now also applying
the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the U.S. Food and Drug Administration, or the
FDA, approved for sale our first commercial product, taliglucerase alfa for injection, which is being marketed in the United States
and Israel under the brand name Elelyso, as an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients
with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved by ANVISA in March 2013, by
the Israeli MOH in September 2012 and by other regulatory agencies in other countries. Taliglucerase alfa is being marketed under
the name Uplyso<FONT STYLE="font-size: 10pt"> </FONT>in Brazil and certain other Latin American countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2014, the FDA approved Elelyso for injection for
pediatric patients and the Israeli MOH approved the pediatric indication in January 2015. Prior to the U.S. pediatric approval,
Elelyso was approved for pediatric indications in Australia and Canada but in no other jurisdiction. In September 2014, CONITEC
announced that it had decided to give a positive funding recommendation for Uplyso in the treatment of adult patients with types
1 and 3 Gaucher disease, and established that Uplyso will be the first choice for treatment for new adult Gaucher patients in
Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taliglucerase
alfa is our proprietary, recombinant form of GCD that is produced or expressed through ProCellEx. Taliglucerase alfa is the first
plant cell-based recombinant therapeutic protein to be approved by the FDA or by the regulatory authorities with jurisdiction
over any substantial market. Gaucher disease is a rare and serious lysosomal</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">storage
disorder with severe and debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that
is naturally found in human cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement
by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer
an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those
rights in Israel, and later in Brazil. We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities
for the continued development efforts for taliglucerase alfa outside of Israel. Protalix Ltd. has been marketing taliglucerase
alfa in Israel since 2013 and in Brazil since January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2013, we entered into a Supply and
Technology Transfer Agreement, or the Brazil Agreement, with Fiocruz, for taliglucerase alfa. The agreement became effective
in January 2014. The technology transfer is designed to be completed in four stages and is intended to transfer to Fiocruz
the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole
expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the
technology transfer is seven years. Under the agreement, Fiocruz committed to purchase at least approximately $40 million
worth of taliglucerase alfa during the first two years of the term. Since the agreement went into effect, we have recorded
revenues of approximately $3.5 million for sales of taliglucerase alfa to Fiocruz in 2014 and, during the first quarter of
2015,  we  received a purchase order  for approximately $5.7 million of taliglucerase
alfa out of which we have delivered approximately $1.7 million of the product. In subsequent years, Fiocruz is required to
purchase at least approximately $40 million worth of taliglucerase alfa per year. We are not required to complete the final
stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, Brazil, Israel and Chile. In addition taliglucerase alfa is currently being provided
to Gaucher patients under special access agreements or named patient provisions in certain countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
PRX-102, or </FONT>alpha-GAL-A<FONT STYLE="font-family: Times New Roman, Times, Serif">, a therapeutic protein candidate
for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase I/II
clinical trial. We expect to report interim
efficacy and safety results for the 1 mg/kg dose group of the trial during the third quarter of 2015 and to report final
efficacy and safety results for the 0.2mg, 1 mg and 2mg/kg dose groups of the trial during the fourth quarter of 2015. We
expect to enter into a pivotal phase III by early 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
PRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti inflammatory treatment for various inflammatory diseases using plant cells as a natural capsule
for the expressed protein. We expect to initiate a <FONT STYLE="font-family: Times New Roman, Times, Serif">proof of concept efficacy
study</FONT> during 2015 and announce results by early 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
PRX-110, a proprietary plant cell recombinant human DNase under development for the treatment of cystic fibrosis, to be administered
by inhalation. We expect to initiate a proof of concept efficacy study during 2015</FONT> and announce results by early 2016<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells. PRX-102 has been the subject of successful proof of concept clinical trials, as described in Item 1, and we intend to focus
our efforts on a new formulation of the treatment during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold
the worldwide commercialization rights to all of our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
We have built an internal marketing team designed to serve the Israeli and Brazilian market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for some of our other product candidates in certain regions, subject
to required marketing approvals, as the need arises. In addition, we continuously evaluate potential strategic marketing partnerships
as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K. We believe that
the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and
results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting
principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements,
as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and
judgments, including those described in greater detail below. We base our estimates on historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Functional Currency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The currency of the primary economic environment in which our
operations are conducted is the U.S. dollar. Most of our revenues are derived in dollars. In addition, most of our expenses and
capital expenditures are incurred in dollars, and the major source of our financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currently, our source of revenues comes from
sales of taliglucerase alfa pursuant to our license agreement with Pfizer, our sales of taliglucerase alfa in Israel and Brazil
and from milestone payments under the Pfizer Agreement. We recognize revenue when the earnings process is complete, which is when
revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or
services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recognize revenue from milestone payments
received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. Pursuant to this guidance, we determine whether our arrangement with Pfizer involves
multiple revenue-generating deliverables that should be accounted for as a combined unit of accounting or separate units of accounting
for revenue recognition purposes. If we determine that there are multiple units of accounting, the consideration from the arrangement
is allocated among the separate units based on a relative fair value allocation. If the arrangement represents a single unit of
accounting, the revenue is recognized over the performance obligation period. As the arrangement with Pfizer requires our continued
involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payments
we received from Pfizer are deferred and recognized over the related performance period. We estimated the performance period of
14 years based on the date that the last relevant patent relating to taliglucerase alfa expires. The $25.0 million milestone payment
received in connection with the FDA&rsquo;s approval of taliglucerase alfa in the United States was considered to be a substantive
milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone
was achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under the terms and conditions of
the Pfizer Agreement, we are entitled to 40% of the net profits or loss from sales of taliglucerase alfa by Pfizer
and reimbursement of our certain related expenses we incur in connection with Pfizer&rsquo;s sales (other than those related
to sales in Israel and Brazil). We hold all rights to taliglucerase alfa in Israel and Brazil. We recognize our share of net profit
or loss under the Pfizer Agreement based on reports we receive from Pfizer summarizing the results of the
collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its
subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November
30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recognize revenues received from the sale
of a product when the sales price is fixed or determinable and collectability is reasonably assured. The revenues represent our
cost with respect to the product sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recognize net product revenue from our
sales of Elelyso in Israel when persuasive evidence of an arrangement exists, the product has been delivered to the customer,
title and risk of loss have passed to the customer, the price to the buyer is fixed or determinable and collection from the customer
is reasonably assured. Product sale transactions are evidenced by customer purchase orders, customer contracts, invoices and/or
the related shipping documents. Amounts collected from customers and remitted to governmental authorities, which represents value-added
taxes related to Elelyso sales in Israel, are presented on a net basis in our Consolidated Statements of Operations, in that taxes
billed to customers are not included as a component of net product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expense to remain our
primary expense in the near future as we continue to develop our product candidates. Research and development expense consists
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>internal
                                         costs associated with research and development activities;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>payments
                                         made to third party contract research organizations, investigative/clinical sites and
                                         consultants;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing
                                         development costs;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>personnel-related
                                         expenses, including salaries, benefits, travel, and related costs for the personnel involved
                                         in research and development;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>activities
                                         relating to the advancement of product candidates through preclinical studies and clinical
                                         trials; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>facilities
                                         and other allocated expenses, which include direct and allocated expenses for rent and
                                         maintenance of facilities, as well as laboratory and other supplies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table identifies our current major research and
development projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid"><B>Project</B></P></TD>
    <TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Status</B></P></TD>
    <TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Expected
        Near Term Milestones</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRX 102 &ndash;
    alpha-GAL-A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    I/II clinical trial, ongoing</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report interim efficacy and safety
        results for the 1 mg/kg dose group during the third quarter of 2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report final efficacy and safety
        results for the 0.2mg, 1 mg and 2mg/kg dose groups during the fourth quarter of 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRX 106 &ndash; Oral antiTNF</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preclinical</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Initiate
    proof of concept efficacy study</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRX-110 &ndash;
    AIR DNase</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preclinical</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Initiate proof of concept efficacy
        study</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRX 112 &ndash;
    Oral Glucocerebrosidase</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    IIa clinical trial</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Develop
    new formulation</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We anticipate incurring increasing costs in connection with
the continued development of all four of the product candidates in our pipeline. Our internal resources, employees and infrastructure
are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record
and maintain research and development costs per project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The costs and expenses of our projects are partially funded
by grants we have received from the OCS. Each grant is deducted from the related research and development expenses as the costs
are incurred. For additional information regarding the grant process, see &ldquo;Business&mdash;Israeli Government Programs&mdash;Encouragement
of Industrial Research and Development Law, 1984&rdquo; in Item 1 of this Annual Report. There can be no assurance that we will
continue to receive grants from the OCS in amounts sufficient for our operations, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At this time, due to the inherently unpredictable nature of
preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are
unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline
for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially
from expectations. While we are currently focused on advancing each of our product development programs, our future research and
development expenses will depend on the clinical success of each product candidate, as well as ongoing assessments of each product
candidate&rsquo;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates
may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements
would affect our development plans and capital requirements. See &ldquo;Risk Factors&mdash;If we are unable to develop and commercialize
our product candidates, our business will be adversely affected&rdquo; and &ldquo;&mdash;We may not obtain the necessary U.S.,
EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have
a material adverse effect on our business, financial condition and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expenses to continue
to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development
programs for our product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for our
product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining
regulatory approvals, could cause a delay in generating product revenue and cause our research and development expense to increase
and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate
with any certainty when we would recognize any net cash inflows from our projects. See &ldquo;Risk Factors&mdash;Clinical trials
are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs which may have a material
adverse effect on our business, results of operations and financial condition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-Based Compensation</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The discussion below regarding share-based
compensation relates to our share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In accordance with the guidance, we record
the benefit of any grant to a non-employee and remeasure the benefit in any future vesting period for the unvested portion of
the grants, as applicable. In addition, we use the straight-line accounting method for recording the benefit of the entire grant,
unlike the graded method we use to record grants made to employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We measure share-based compensation cost
for all share-based awards at the fair value on the grant date and recognition of share-based compensation over the service period
for awards that we expect will vest. The fair value of stock options is determined based on the number of shares granted and the
price of our ordinary shares, and calculated based on the Black-Scholes valuation model. We recognize such value as expense over
the service period, net of estimated forfeitures, using the accelerated method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of determining the fair value of the restricted
shares of common stock granted to employees during the fiscal year ended December 31, 2013, our management used the fair value
of our common stock which was the closing sale price of our common stock on the NYSE MKT on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The guidance requires companies to estimate
the expected term of the option rather than simply using the contractual term of an option. Because of lack of data on past option
exercises by employees, the expected term of the options could not be based on historic exercise patterns. Accordingly, we adopted
the simplified method, according to which companies may calculate the expected term as the average between the vesting date and
the expiration date, assuming the option was granted as a &ldquo;plain vanilla&rdquo; option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In performing the valuation, we assumed an
expected 0% dividend yield in the previous years and in the next years. We do not have a dividend policy and given the lack of
profitability, dividends are not expected in the foreseeable future, if at all. The guidance stipulates a number of factors that
should be considered when estimating the expected volatility, including the implied volatility of traded options, historical volatility
and the period that the shares of the company are being publicly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
risk-free interest rate described above has been based on the implied yield of U.S. federal reserve zero&ndash;coupon government
bonds. The remaining</FONT> term of the bonds used for each valuation was equal to the expected term of the grant. This methodology
has been applied to all grants valued by us. The guidance requires the use of a risk&ndash;free interest rate based on the implied
yield currently available on zero&ndash;coupon government issues of the country in whose currency the exercise price is expressed,
with a remaining term equal to the expected life of the option being valued. This requirement has been applied for all grants
valued as part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2014 Compared to the Year
Ended December&nbsp;31, 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenue of $13.7 million for
the year ended December&nbsp;31, 2014, an increase of approximately $3.2 million, or 30%, compared to revenue of $10.5 million
for the year ended December 31, 2013. Revenues for the year ended December&nbsp;31, 2014 include $5.2 million of products sold
in Israel and $3.5 million in Brazil. Revenues also represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone
payments of $1.1&nbsp;million in each quarterly period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.5 million as our share of net income
in the collaboration under the Pfizer Agreement during the year ended December&nbsp;31, 2014, an increase of approximately $475,000,
or 46%, compared to revenue of $1.0 million recorded for the year ended December 31, 2013. Our share in the collaboration recorded
for the year ended December 31, 2014 represents our 40% share of the net income generated during the period, which was primarily
the result of revenues generated by Pfizer in the United States which exceeded the expenses during such period. Under the terms
and conditions of the Pfizer Agreement, we record income or loss equal to 40% of the profit or loss realized from sales of taliglucerase
alfa and related expenses incurred based on reports we receive from Pfizer summarizing the results of the collaborative activities
under the Pfizer Agreement for the applicable period. Under the terms and conditions of the Pfizer Agreement, financial information
of Pfizer&rsquo;s subsidiaries that operate outside the United States is included based on the fiscal year ending November 30,
while financial information for the U.S. entity is included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $9.1 million for the year ended December
31, 2014, an increase of $3.6 million, or 67%, compared to the cost of revenues of $5.4 million for the year ended December 31,
2013. Cost of revenues for the year ended December 31, 2014 consists primarily of the costs of the $1.1 million of products we
delivered at cost to Pfizer under the Pfizer Agreement, write-down of inventory of $1.7 million, and certain fixed costs relating
to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, amounting to approximately $4.2
million, and to a much lesser extent, the direct cost of products we sold in Israel and Brazil for which revenues were recognized
during the period. Cost of revenues for the years ended December 31, 2013 and 2014 include an aggregate of $472,000 and $1.1 million,
respectively, in royalties payable to the OCS and to a certain academic institution in connection with gross sales of taliglucerase
alfa during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $29.8&nbsp;million for
the year ended December&nbsp;31, 2014, a decrease of $3.6 million, or 11% from $33.3&nbsp;million for the year ended December&nbsp;31,
2013. The decrease resulted primarily from a decrease of $1.4 million in payroll and related expenses primarily due to a decrease
in share-based compensation and a decrease of $1.0 million in cost of materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses were $9.7&nbsp;million
for the year ended December&nbsp;31, 2014, an increase of $1.3 million, or 15%, from $8.4&nbsp;million for the year ended December&nbsp;31,
2013. The increase resulted primarily from sales and marketing expenses of approximately $1.8 million, primarily in connection
with sales in Brazil, which was partially offset by a decrease of $383,000 in salaries expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expenses were $4.7&nbsp;million for the year ended
December 31, 2014, compared to $674,000 for the year ended December 31, 2013. Financial expenses resulted primarily from interest
expense of $3.1 million for the 4.5% convertible note and from the devaluation of the New Israeli Shekel against the U.S. dollar
in the amount of $1.3 million, which was partially offset by financial income which resulted primarily from interest earned on
short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2013 Compared to the Year
Ended December&nbsp;31, 2012</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenue of $10.5 million for
the year ended December&nbsp;31, 2013, an increase of approximately $609,000, or 6%, compared to revenue of $9.9 million for the
year ended December 31, 2012, excluding the one-time $25.0 million payment we received from Pfizer under the Pfizer Agreement
in connection with the FDA&rsquo;s approval of taliglucerase alfa on May 1, 2012. The revenues represent our sales of taliglucerase
alfa in Israel, the cost of products we deliver to Pfizer under the Pfizer Agreement and a pro rata amortization equal to $1.1
million in each quarterly period resulting from the $65.0&nbsp;million upfront and milestone payments we received from Pfizer
in 2009. The revenues for the year ended December 31, 2013 include $5.0 million from products we sold in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.0 million as our share of net income
in the collaboration under the Pfizer Agreement during the year ended December&nbsp;31, 2013, compared to the $446,000 of loss
recorded for the year ended December 31, 2012. Our share in the collaboration recorded for the year ended December 31, 2013 represents
our 40% share of the net income generated during the period, which was primarily the result of revenues generated by Pfizer in
the United States which exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement, we record
income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based
on reports we receive from Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable
period. Under the terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate
outside the United States is included based on the fiscal year ending November 30, while financial information for the U.S. entity
is included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $5.4 million for the year ended December
31, 2013, a decrease of $2.7 million, or 33%, compared to the cost of revenues of $8.1 million for the year ended December 31,
2012. Cost of revenues for the year ended December 31, 2013 consists primarily of certain fixed costs relating to our manufacturing
facility, including rent, depreciation, salary and maintenance expenses amounting to approximately $4.9 million, and to a much
lesser extent, the direct cost of products we sold in Israel and products we delivered to Pfizer for which revenues were recognized
during the period. Cost of revenues for the years ended December 31, 2012 and 2013 include an aggregate of $2.2 million and $472,000,
respectively, in royalties payable to the OCS and to a certain academic institution in connection with gross sales of taliglucerase
alfa during the period. Prior to the FDA&rsquo;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase
alfa were classified as research and development expenses. Effective as of the FDA approval of taliglucerase alfa, we capitalize
all manufacturing costs associated with taliglucerase alfa and expense such costs as cost of revenues, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $33.3&nbsp;million for
the year ended December&nbsp;31, 2013, a decrease of $3.4 million, or 9.1% from $36.7&nbsp;million for the year ended December&nbsp;31,
2012. The decrease resulted primarily from a decrease of $2.1 million in payroll and related expenses primarily due to a decrease
in share-based compensation and a decrease of $1.2 million resulting from the winding down of certain clinical trials for taliglucerase
alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses were $8.4&nbsp;million
for the year ended December&nbsp;31, 2013, a decrease of $1.4 million, or 14%, from $9.8&nbsp;million for the year ended December&nbsp;31,
2012. The decrease resulted primarily from a decrease of $1.5 million in payroll and related expenses primarily due to a decrease
in share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expense was $674,000 for the year ended December
31, 2013, compared to financial income of $554,000 for the year ended December 31, 2012. Financial expense resulted primarily
from interest expense of $1.0 million for the 4.5% convertible note which was partially offset by financial income which resulted
primarily from interest earned on short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures and the lack of significant product sales revenue due to the recent launch of taliglucerase alfa in the
United States and Israel, we have not been profitable and have generated operating losses since our inception. To date, we have
funded our operations primarily with proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and
ordinary shares of Protalix Ltd., and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection
with the sale of such shares, through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million
in connection with an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we
generated gross proceeds of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of
our common stock. We believe that the funds currently available to us as are sufficient to satisfy our capital needs for at least
12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our public
funding sources since 2007:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; padding-left: 0">Security</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left; padding-left: 0">Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center; padding-left: 5.4pt">2007</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">10,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">50,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,168,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September 18, 2013, we completed
a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including
$9.0 million aggregate principal amount of Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option,
which was exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement
and subsequently paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.&rsquo;s meeting a certain
milestone. Protalix Ltd. also received a milestone payment of $25.0 in connection with the FDA&rsquo;s approval of
taliglucerase alfa in May 2012. Protalix Ltd. is also entitled to payments equal to 40% of the net profits earned by Pfizer
on its global sales of taliglucerase alfa (except in Israel and Brazil). In calculat</FONT>ing net profits there are certain agreed
upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold. Pfizer has
also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones under a clinical
development agreement between Pfizer and Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $29.2
million for the year ended December 31, 2014. The net loss for the year ended December 31, 2014 of $29.9 million was further
increased by a decrease of $7.2 million in deferred revenues, but was partially offset by $3.1 million in depreciation, $1.4
million in financial expenses mainly due to exchange rate differences and share based compensation of $1.2 million. Net
cash used in investing activities for the year ended December 31, 2014 was $1.0 million and consisted primarily of purchases
of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $30.7 million
for the year ended December 31, 2013. The net loss for the year ended December 31, 2013 of $27.8 million was further increased
by a decrease of $7.2 million in deferred revenues and an increase of $3.9 million in inventories, but was partially offset by
share based compensation of $4.1 million and $3.5 million in depreciation. Net cash used in investing activities for the year
ended December 31, 2013 was $2.1 million and consisted primarily of purchases of property and equipment. Net cash provided by
financing activities was $66.9 million, consisting primarily of net proceeds from our offering of 2018 4.5% convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in
the near future. We expect to continue to incur significant research and development expenses, including expenses related primarily
to the clinical trials of PRX-102 and the advancement of our other product candidates into clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient <B> </B>for at least 12 months. We have based this estimate on assumptions that are subject to
change and may prove to be wrong, and we may be required to use our available capital resources sooner than we currently expect.
Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates,
we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and
anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer&rsquo;s commercialization efforts for taliglucerase alfa in the United States
and other countries and, if anticipated
marketing approvals of taliglucerase alfa are granted in other jurisdictions, the progress of Pfizer&rsquo;s global commercialization
efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review
of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims
and other intellectual property rights, the number and development requirements of other product candidates that we pursue and
the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. We
currently do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or
more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently
anticipate. We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable.
Any sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional
equity or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms,
if at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and
development programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or
others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize
independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the years ended December&nbsp;31, 2012, 2013 or 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us by
increased or decreased costs mainly for goods and services acquired outside of Israel. We do not believe currency fluctuations
have had a material effect on our results of operations during the years ended December&nbsp;31, 2012, 2013 or 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of December&nbsp;31, 2013 and 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain recently issued accounting pronouncements are discussed
in Note 1(p) of the financial statements included in Item 8 of this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our significant
contractual obligations at December 31, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Less than 1 year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">3-5 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">More than 5 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt; width: 35%">Convertible notes&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">81,420</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">72,105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Operating lease obligations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,425</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Purchase obligations (1)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Certain clinical contract</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">981</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Liability for employee rights
    upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 0in; padding-left: 5.4pt">Total&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,609</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,880</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,105</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,253</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1) Represents open purchase orders issued
to certain suppliers and other vendors mainly in connection with our research and development activities that were outstanding
as of December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The foregoing table does not include (i)
annual license fees, which are immaterial, (ii) payments we may be required to make to certain of our licensors in the time periods
set forth above upon the achievement of agreed-upon milestones and (iii) royalty payments payable by us to certain of our licensors
in connection with the commercial sale of our product candidates, if any. If all of the contingencies with respect to milestone
payments under our research and license agreements are met, the aggregate milestone payments payable would be approximately $0.3
million and would be payable, if at all, as our projects progress over the course of a number of years. The royalty payments payable
in connection with sales of each of our product candidates, if any, shall not exceed low, single-digit percentages of net sales
of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Quarterly Financial Data (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="30" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Three
    Months Ended</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="30" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(U.S.
    dollars in thousands)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">March 31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">June 30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Sept. 30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Dec. 31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">March 31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">June 30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Sept. 30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Dec. 31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%"><FONT STYLE="font-size: 8pt">Revenues</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">3,568</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,264</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,284</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,363</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">6,696</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,425</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,396</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">2,134</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Net profit (loss) for the period</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(4,321</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(6,837</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(5,747</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(10,885</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(7,345</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(6,119</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(8,010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,469</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 8pt">Earnings (loss) per
    share of common stock, basic and diluted</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.05</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.08</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD NOWRAP STYLE="width: 0.6in; text-align: left"><B><A NAME="a_013"></A>Item 7A.</B></TD><TD STYLE="text-align: justify"><B>Quantitative
                                         and Qualitative Disclosures about Market Risk</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. Most of our revenues and approximately 50% of our expenses and capital
expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar
is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange
in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items
are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains
or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 0">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3.856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3.611</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3.578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Rate at year-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.733</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.889</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects
due to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve
principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances
primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes
in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains
may decline in the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -38.25pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify; font-weight: bold">
<TD STYLE="width: 0in; font-weight: bold"></TD><TD STYLE="width: 0.6in; text-align: left; font-weight: bold"><A NAME="a_014"></A>Item 8.</TD><TD STYLE="text-align: justify; font-weight: bold">Financial
                                         Statements and Supplementary Data</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">See the Index to Consolidated Financial Statements
on Page F-1 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.05pt; text-indent: -40.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify; font-weight: bold">
<TD STYLE="width: 0in; font-weight: bold"></TD><TD STYLE="width: 0.6in; text-align: left; font-weight: bold"><B><A NAME="a_015"></A>Item 9.</B></TD><TD STYLE="text-align: justify; font-weight: bold"><B>Changes
                                         in and Disagreements with Accountants on Accounting and Financial Disclosure</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify; font-weight: bold">
<TD STYLE="width: 0in; font-weight: bold"></TD><TD NOWRAP STYLE="width: 0.6in; text-align: left; font-weight: bold"><B><A NAME="a_016"></A>Item 9A.</B></TD><TD STYLE="text-align: justify; font-weight: bold"><B>Controls
                                         and Procedures</B></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluation of Disclosure Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the
effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this
Form 10-K. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Form 10-K,
is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms. Disclosure
controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management,
including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The evaluation of our disclosure controls
and procedures included a review of the controls&rsquo; objectives and design, our implementation of the controls and their effect
on the information generated for use in this Form 10-K. In the course of the controls evaluation, we reviewed identified data
errors, control problems or acts of fraud, and sought to confirm that appropriate corrective actions, including process improvements,
were being undertaken. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including
the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures
can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these various evaluation activities are
to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls
and procedures as dynamic systems that change as conditions warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-K, our disclosure controls
and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports
is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information
related to our company and our consolidated subsidiaries are made known to management, including the Chief Executive Officer and
Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management Report on Internal Control over Financial Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management is responsible for
establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the
reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S.
generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that:
(i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions
of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company
are being made only in accordance with authorizations of management and our directors; and (iii) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material
effect on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Management assessed our internal
control over financial reporting as of December 31, 2014, the end of our fiscal year. Management based its assessment on
criteria established in Internal Control&mdash;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of
the Treadway Commission (COSO). Management&rsquo;s assessment included evaluation of elements such as the design and
operating effectiveness of key financial reporting controls, process documentation, accounting policies and our overall
control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on our assessment, management
has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting
purposes in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&rsquo;s assessment
with the Audit Committee of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The effectiveness of our internal
control over financial reporting as of December 31, 2014 has been audited by Kesselman &amp; Kesselman, an independent registered
public accounting firm, as stated in their report included herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to
their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within
a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty
and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of
some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls
is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness
to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration
in the degree of compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in our internal control over
financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the year
ended December 31, 2014 that have materially affected, or that are reasonably likely to materially affect, our internal
control over financial reporting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B><A NAME="a_017"></A>Item&nbsp;9B.
&nbsp;&nbsp;Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A>PART III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.65pt; text-indent: -43.65pt"><B><A NAME="a_019"></A>Item&nbsp;10.&#9;Directors,
Executive Officers and Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our directors and executive officers, their
ages and positions as of March 1, 2015 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 60%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Directors</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shlomo Yanai</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the Board</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Moshe Manor</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director, President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amos Bar Shalev (1)(2)(3)&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Zeev Bronfeld (1)(2)(3)&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yodfat Harel Buchris (1)(2)(3)&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">42</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Roger D. Kornberg, Ph.D.&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">67</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aharon Schwartz, Ph.D. </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Executive Officers</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Einat Brill Almon, Ph.D.&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Senior Vice President, Product Development</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yossi Maimon, CPA&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">44</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vice President, Chief Financial Officer, Treasurer and Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tzvi Palash&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Operating Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yoseph Shaaltiel, Ph.D.&#9;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive VP, Research and Development</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 25.9pt">(1) Member of Nominating Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 25.9pt">(2) Member of Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 25.9pt">(3) Member of Compensation
Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shlomo Yanai.</B> Mr. Yanai has served as the
Chairman of our Board of Directors since July 2014. Mr. Yanai is currently the Chairman of the Board of Cambrex Corporation
(NYSE:CBM) and a director of Lumenis Ltd. (NASDAQ:LMNS). Mr. Yanai served as President and Chief Executive Officer of Teva
(NASDAQ:TEVA, TASE:TEVA) from March 2007 until May 2012 and, prior to joining Teva, Mr. Yanai was President and Chief
Executive Officer of Makhteshim-Agan Industries Ltd., from 2003 until 2006. Before that, he was a Major General in the Israel
Defense Forces, where he served for 32 years, in various positions, the last two positions being Commanding Officer of the
Southern Command and Head of the Division of Strategic Planning. Mr. Yanai was the head of the Israeli security delegation to
the peace talks at Camp David, Shepherdstown and Wye River. He currently serves as a member of the Board of Governors of the
Technion &mdash; Israel Institute of Technology of Haifa, Israel, and of the International Advisory Board, MBA Program of
Ben-Gurion University of the Negev, Israel, as well as an honorary member of the Board of the Institute for Policy and
Strategy of the Interdisciplinary Center (IDC), Herzliya, Israel. Mr. Yanai holds a bachelor&rsquo;s degree in political
science and economics from Tel Aviv University, a master&rsquo;s degree in national resources management from George
Washington University, and is a graduate of the Advanced Management Program of Harvard Business School and U.S. National War
College (NDU). Mr. Yanai was the recipient of the Max Perlman Award for Excellence in Global Business Management from
Tel Aviv University, Israel, in 2005 and was awarded an honorary doctorate by Bar-Ilan University, Israel, in 2012. We
believe Mr. Yanai&rsquo;s qualifications to serve as Chairman of our Board of Directors include his vast global operating
experience in the life-science and pharmaceutical and agro-chemicals industry. He also brings a global perspective to the
Board, incorporating his industry and Board leadership experience and his distinguished military service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Moshe Manor. </B>Mr. Manor<B> </B>has served as
our President and Chief Executive Officer and as a director of our company since November 2014. Mr. Manor has served in a number
of senior executive positions at Teva (NASDAQ:TEVA, TASE:TEVA) from 1984 through 2012. Most recently, he served as President,
Teva Asia &amp; Pacific where he led the strategy and development of a high growth region for Teva. Prior to that, he was
Group Vice President, Global Branded Products, leading the Innovative Commercial and Research &amp; Development franchises.
From 2006 through 2008, Mr. Manor was Senior Vice President, Global Innovative Resources, and was responsible for generating
over $3 billion in sales with Copaxone<SUP>&reg;</SUP> and Azilect<SUP>&reg;</SUP>. Previously, he served as director of
Teva Israel. Most recently, Mr. Manor serves on the Board of Directors of Kamedis Ltd. and Coronis Partners, and as Chairman
of the Board of Directors of a startup company named MEway Pharma. He holds a BA in Economics from the Hebrew University
in Jerusalem, and an MBA from the Tel-Aviv University. We believe Mr. Manor&rsquo;s qualifications to serve on our Board
of Directors include his extensive experience in the life-science and pharmaceutical industry on a global scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left: white 0.25pt solid"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amos Bar Shalev.</B> Mr. Bar Shalev has served as our director
since July 2008. Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 31, 2008, and as our director
from December 31, 2006 through January 31, 2008. Mr. Bar Shalev was not nominated for reelection at our annual meeting of shareholders
on January 31, 2008. On July 14, 2008, our Board of Directors appointed Mr. Bar Shalev to serve on the board, at which time he
was reappointed to the board of directors of Protalix Ltd. as well. Mr. Bar Shalev brings to us extensive experience in managing
technology companies. Currently, Mr. Bar Shalev serves on the boards of directors of Ocure Ltd. and Velox Ltd., privately-held
Israeli companies. From 2004 through 2013, Mr. Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its
portfolio. In addition, he has served on the board of directors of Aposense Ltd. (TASE: APOS), an Israeli publicly-traded company
listed on the TASE, since 2011, and served on the board of directors of Highcon Systems Ltd., a privately-held Israeli company,
from 2010 through 2012. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the
TGF (Templeton Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the board of directors
of many other companies, including, among others, NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation
Ltd.), Objet Geometrix (merged with Stratasys, Inc. (NASDAQ: SSYS)), Verisity, Scitex Vision (acquired by Hewlett Packard), Golden
Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun
Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University
in 1981. He holds the highest award from the Israeli Air Force for technological achievements. We believe Mr. Bar Shalev&rsquo;s
qualifications to serve on our Board of Directors include his years of experience in the management of Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Zeev Bronfeld.</B> Mr. Bronfeld has served as a director
of Protalix Ltd. since 1996 and as our director since December 31, 2006. From 2010 through July 2014, he served as the interim
Chairman of our Board of Directors. Mr. Bronfeld brings to us vast experience in management and value building of biotechnology
companies. Mr. Bronfeld is an experienced businessman who is involved in a number of biotechnology companies. He is a co-founder
of Biocell Ltd. (TASE:BCEL), an Israeli publicly traded holding company specializing in biotechnology companies, and has served
as its Chief Executive Officer since 1986. Mr. Bronfeld currently serves as a director of Biocell Ltd. and Macrocure Ltd. (NASDAQ:
MCUR) and the as chairman of the board of directors of D.N.A. Biomedical Solutions Ltd. (TASE:DNA), all of which are public companies.
Mr. Bronfeld is also a director of a number of privately-held companies, most of which are involved in the life sciences, such
as The Trendlines Group, Contipi Medical Ltd. and TransBiodiesel Ltd. From 2004 through 2012, Mr. Bronfeld served as a director
of D. Medical Industries Ltd., a company that was dually-listed on the Nasdaq and the TASE.
Mr. Bronfeld received a B.A. in Economics from the Hebrew University in 1975. We believe Mr. Bronfeld&rsquo;s qualifications to
serve on our Board of Directors include his years of experience in the management of private and public Israeli companies, including
life science companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yodfat Harel Buchris.</B>&nbsp;&nbsp; Mrs. Harel Buchris
has served as our director since June 2007. Commencing in February 2014, Mrs. Harel Buchris serves as the employer representative
in Israel&rsquo;s National Labor Court and she currently serves on the board of directors of YP and 6 Partners Ltd., a Business
Consulting and Investment Company. From 2006 to 2013, Mrs. Harel Buchris served as a Managing Director of Tamares Capital Ltd.,
a private investment group with interests in real estate, technology, manufacturing, leisure and media. At Tamares Capital, Mrs.
Harel Buchris served as the Business Development Director and the head of the Israel office. Prior to joining Tamares Capital,
from 2004 to 2006, she was the Head of the Medical Desk of Orbotech, Ltd. (NASDAQ:ORBK), a company providing high-tech inspection
and imaging solutions for bare printed circuit board (PCB), flat panel display (FPD) and PCB assembly manufacturing worldwide.
Prior to that, from 1994 to 2003, she was a Managing Director of Harel-Hertz Investment House Ltd., a business investment company
with offices in Tel Aviv, Israel and Tokyo, Japan. In 2002, Harel-Hertz Investment House became the Israeli representative office
for ITX Corporation, a publicly-traded company in Japan. Mrs. Harel Buchris has served on the board of directors of Tamares Capital,
Tamares Hotels, El Al, British Israel, Storewiz, N-trig, Secure Pharma, Siklu and Tamares Telecom. Mrs. Harel Buchris holds a
B.A. in Communications and Political Science from Bar Ilan University and an executive M.B.A. from Bradford University, Great
Britain. She has also completed programs in Mediation at Gome, Israel Mediation Center, Directors&rsquo; Studies and Advanced
Advertising and Marketing at the Israel Management Center. We believe Mrs. Harel Buchris&rsquo; qualifications to serve on our
Board of Directors include her experience in the management of Israeli and other businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Roger D. Kornberg, Ph.D.</B> Professor Kornberg has served
as our director since February 2008. He has served as a director of OphthaliX Inc. (OTCBB:OPLI), since 2012 and of Biozone Pharmaceuticals,
Inc. (otcqb:BZNE) since 2014. He served as a director of Teva  (NASDAQ:TEVA, TASE:TEVA) from 2007 through 2013.
He also serves as the Chief Scientist and a director of Biozone Pharmaceuticals. Professor Kornberg is a member of the U.S. National
Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University, Stanford,
California. He has been a member of the faculty of Stanford University since 1972. Prior to that, he was a professor at Harvard
Medical School. Professor Kornberg is a renowned biochemist and in 2006 he was awarded the Nobel Prize in Chemistry in recognition
for his studies of the molecular basis of eukaryotic transcription, the process by which DNA is copied to RNA. Professor Kornberg
is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in
the United States, and the 2002 Leopold Mayer Prize, the highest award granted in the field of biomedical sciences from the French
Academy of Sciences. He received his B.S. in Chemistry from Harvard University in 1967 and his Ph.D. in Chemistry from Stanford
University in 1972. He holds honorary degrees from universities in Europe and Israel, including the Hebrew University in Jerusalem,
where he currently is a visiting professor. We believe Professor Kornberg&rsquo;s qualifications to serve on our Board of Directors
include his expertise in chemistry and medicine and his experience in the academic arena.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Aharon Schwartz, Ph.D.</B> Dr.
Schwartz has retired from Teva  (NASDAQ:TEVA, TASE:TEVA) in 2011 where he served in a number of positions from 1975 through
2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of
the board of directors of a number of life science companies, including BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX), Yissum-the
TTO of the Hebrew University of Jerusalem, DPharm Ltd. (TASE:DPRM), BioCancell Ltd. (TASE:BICL), CureTech Ltd. and Biomas
Ltd., and a member of the board of directors of Alcobra Ltd. (NASDAQ:ADHD). Dr. Schwartz received his Ph.D. in organic
chemistry in 1978 from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and
physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of
Jerusalem in the history and philosophy of science. We believe Dr. Schwartz&rsquo;s qualifications to serve on our Board of
Directors include his extensive experience in the life-science and pharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Almon joined Protalix Ltd.
in December 2004, originally as a Senior Director and later as a Vice President and then Senior Vice President, Product Development,
and became our Senior Vice President, Product Development on December 31, 2006. Dr. Almon has many years of experience in the
management of life science projects and companies, including biotechnology and agrobiotech, with direct experience in clinical,
device and scientific software development, as well as a strong background and work experience in Intellectual Property. Prior
to joining Protalix Ltd., from 2001 to 2004, she served as Director of R&amp;D and IP of Biogenics Ltd., a company that developed
an autologous platform for tissue-based protein drug delivery. Biogenics, based in Israel, is a wholly-owned subsidiary of Medgenics
Inc. Dr. Almon has trained as a biotechnology patent agent at leading IP firms in Israel. Dr. Almon holds a Ph.D. and an M.Sc.
in molecular biology of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried
out Post-Doctoral research at the Hebrew University in the area of plant molecular biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yossi Maimon, CPA.</B>&nbsp;&nbsp;Mr. Maimon joined Protalix
Ltd. on October 15, 2006 as its Chief Financial Officer and became our Vice President and Chief Financial Officer on December
31, 2006. Prior to joining Protalix, from 2002 to 2006, he served as the Chief Financial Officer of Colbar LifeScience Ltd., a
biomaterial company focusing on aesthetics, where he led all of the corporate finance activities, fund raisings and legal aspects
of Colbar including the sale of Colbar to Johnson and Johnson. Mr. Maimon has a B.A. in accounting from the City University of
New York and an MBA from Tel Aviv University, and he is a Certified Public Accountant in the United States (New York State) and
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Tzvi Palash.</B> Mr. Palash has served
as Protalix Ltd.&rsquo;s Chief Operating Officer since September 6, 2010. Prior to joining Protalix Ltd., from 2006 through 2010,
Mr. Palash served as a General Manager of ColBar LifeScience Ltd. In that position, Mr. Palash served as a member of the Global
Aesthetic Management Team at the Consumer Group of Johnson &amp; Johnson. Prior to that, from 2001 through 2006, Mr. Palash served
as the Vice President, Operations of ColBar LifeScience, and he has served in different positions at Teva. Mr. Palash has an M.Sc.
in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yoseph Shaaltiel, Ph.D.</B>&nbsp;&nbsp;Dr. Shaaltiel founded
Protalix Ltd. in 1993 and has served as a member of our Board of Directors and as our Vice President, Research and Development
since December 31, 2006. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate at the
MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the
Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University of
California at Berkeley and at Rutgers University in New Jersey. He has co-authored over 40 articles and abstracts on plant biochemistry
and holds seven patents. Dr. Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc.
in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 16(a) of the Exchange Act requires
our directors, executive officers and holders of more than 10% of our common stock to file with the Commission reports regarding
their ownership and changes in ownership of our equity securities. We believe that all Section&nbsp;16 filings requirements were
met by our officers and directors during 2014. In making this statement, we have relied solely upon examination of the copies
of Forms 3, 4 and 5, Schedule 13s and written representations of our former and current directors, officers and 10% shareholders.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We require that all Audit Committee members possess
the required level of financial literacy and at least one member of the Audit Committee meet the current standard of requisite
financial management expertise as required by the NYSE MKT and applicable rules and regulations of the Commission. Messrs. Bar
Shalev and Bronfeld, and Mrs. Harel Buchris have been appointed by the Board of Directors to serve on the Audit Committee until
their respective successors have been duly elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee operates under a formal charter
that governs its duties and conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">All members of the Audit Committee are independent
from our executive officers and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our independent registered public accounting
firm reports directly to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee meets with management and
representatives of our registered public accounting firm prior to the filing of officers&rsquo; certifications with the Commission
to receive information concerning, among other things, effectiveness of the design or operation of our internal controls over
financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee has adopted a Policy for
Reporting Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation against Reporting employees to enable
confidential and anonymous reporting of improper activities to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Messrs. Bar Shalev and Bronfeld qualify as &ldquo;audit
committee financial experts&rdquo; under the applicable rules of the Commission. In making the determination as to these individuals&rsquo;
status as audit committee financial experts, our Board of Directors determined they have accounting and related financial management
expertise within the meaning of the aforementioned rules, as well as the listing standards of the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We have adopted a Code of Business Conduct and
Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors
are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to
the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The Code of Business Conduct and Ethics includes
provisions applicable to all of our employees, including senior financial officers and members of our Board of Directors and is
posted on our website (www.protalix.com). We intend to post amendments to or waivers from any such Code of Business Conduct and
Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.3pt; text-indent: -42.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.3pt; text-indent: -42.3pt"><B><A NAME="a_020"></A>Item</B>&nbsp;<B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Executive
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The primary goals of the Compensation
Committee of our Board of Directors with respect to executive compensation are to attract and retain the most talented and dedicated
executives possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives,
and to align executives&rsquo; incentives with shareholder value creation. To achieve these goals, the Compensation Committee
implements and maintains compensation plans that tie a portion of executives&rsquo; overall compensation to key strategic goals
such as developments in our clinical path, the establishment of key strategic collaborations, the build-up of our pipeline and
the strengthening of our financial position. The Compensation Committee evaluates individual executive performance with a goal
of setting compensation at levels the committee believes are comparable with executives in other companies of similar size and
stage of development operating in the biotechnology industry while taking into account our relative performance and our own strategic
goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Elements of Compensation</B><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45pt; background-color: white">Executive compensation
consists of following elements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Base Salary.</I></B> Base salaries for
our executives are established based on the scope of their responsibilities taking into account competitive market compensation
paid by other companies for similar positions. Generally, we believe that executive base salaries should be targeted near the
median of the range of salaries for executives in similar positions with similar responsibilities at comparable companies. Except
for the compensation offered to our new President and Chief Executive Officer, we did not make any changes to the compensation
of our executive officers. The Compensation Committee plans to convene later in 2015 to evaluate the current incentive plans and
plan going forward, including updating its peer companies, as substantially all of the 2012 compensation milestones described
below have expired and are no longer in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The companies reviewed by the Compensation
Committee in making compensation recommendations to our Board of Directors in 2012 include, among others, the following companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>InterMune, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Vivus, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Biomarin Pharmaceutical
                                         Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Rigel Pharmaceuticals,
                                         Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Momenta Pharmaceuticals,
                                         Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Nektar Therapeutics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Theravance,
                                         Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Dendreon Corp.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Compensation Committee intends to
continue reviewing and revising the peer group periodically to ensure that it continues to reflect companies similar to our company
in size and development stage. The Compensation Committee also reviews an executive compensation report and analysis of publicly-traded
biotechnology companies prepared by third party experts from a well-known consulting firm for additional data and other information
regarding executive compensation for comparative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Base salaries are usually reviewed annually,
and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance
and experience. The base salaries of each of our President and Chief Executive Officer, our Executive Vice President, Research
and Development, our Senior Vice President, Product Development, our Vice President and Chief Financial Officer and our Chief
Operating Officer, who we refer to collectively as the &ldquo;Named Executive Officers,&rdquo; are discussed herein. The above
discussion does not include compensation granted to Dr. David Aviezer, our former President and Chief Executive Officer, as he
retired from the Company in November 2014 and is no longer to the same compensation. On July 15, 2012, our Board of Directors
adopted certain recommendations of the Compensation Committee regarding the compensation of our Named Executive Officers with
no change in the base salary component.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Annual Bonus</I>.</B> The Compensation Committee has the
authority to award discretionary annual bonuses to our executive officers. The discretionary annual bonus awards were intended
to compensate officers for achieving financial, clinical, regulatory and operational goals and for achieving individual annual
performance objectives. For any given year, the compensation objectives vary, but relate generally to strategic factors such as
developments in our clinical path, the execution of a license agreement for the commercialization of product candidates, the establishment
of key strategic collaborations, the build-up of our pipeline and financial factors such as capital raising. Bonuses are awarded
generally based on corporate performance, with adjustments made within a range for individual performance, at the discretion of
the Compensation Committee. The Compensation Committee determines, on a discretionary basis, the size of the entire bonus pool
and the amount of the actual award to each Named Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Compensation Committee selects, in its discretion, the executive
officers of our company or our subsidiary who are eligible to receive bonuses for any given year. Any bonus granted by the Compensation
Committee will generally be paid in the first quarter of the year, unless such bonus was, by its terms, made payable upon the
achievement of a specific milestone. The Compensation Committee has not fixed a minimum or maximum award for any executive officer&rsquo;s
annual discretionary bonus, unless specified in the officer&rsquo;s employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each of our executive officers is eligible for a discretionary
annual bonus under his or her employment agreement. The Compensation Committee has not fixed a minimum or a maximum amount for
any officer&rsquo;s annual discretionary bonus, nor is any executive officer entitled to a minimum or maximum bonus amount under
his or her employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 15, 2012, our Board of Directors adopted certain recommendations
of the Compensation Committee regarding the compensation of our Named Executive Officers at that time, including the grant of
certain incentive bonuses to be paid to them upon the achievement of a number of designated milestones, as set forth below. In
addition, our Board of Directors approved the grant of restricted stock to our Named Executive Officers at that time, as described
below, and to other members of our management team. The bonus amounts were determined by the Compensation Committee, in its discretion
after review materials regarding peer companies, review with our legal counsel and review of materials provided by accounting
firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The bonuses adopted by the Board of Directors in 2012 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Clinical<BR> Development<BR> Milestones<BR> per Clinical<BR>
    Product<BR> Candidate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Other<BR> Clinical<BR> Development<BR> Milestone for<BR>
    Clinical<BR> Product<BR> Candidate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Undisclosed<BR> Substantial<BR> Commercial<BR> Agreement</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Entry into a<BR> Substantial<BR> Transaction</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Entry into a<BR> Change in<BR> Control<BR> Transaction</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Yoseph Shaaltiel, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">170,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">120,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">180,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">TBD out of $900,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">170,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yossi Maimon, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tzvi Palash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Substantially all of the milestones described above had a 24-month
time limit for achievement and, as such, are currently expired. The Compensation Committee plans to convene later in 2015 to evaluate
the current incentive plans and adopt new compensation goals going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to the bonuses granted to our Named Executive Officers,
additional members of our management team are entitled to certain incentive bonuses payable upon the achievement of designated
milestones. If we achieve agreed-upon advancements in the clinical development of each of certain designated product candidates
during an agreed-upon amount of time immediately following the Board of Director&rsquo;s approval of the bonuses, our Named Executive
Officers will be entitled to the amounts listed in the first two columns of the table set forth above. The amounts are payable
upon achievement of the applicable milestone if, at such time, we have available an agreed-upon minimum cash balance. If we do
not have the minimum cash balance, the bonuses will be considered earned, and will be payable when we next achieve the minimum
cash balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The grants of restricted stock to the Named Executive Officers
in 2012 at that time are as shown in the table immediately following this paragraph. The grants were made in accordance with the
terms and conditions of our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Named Executive Officer</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of Restricted Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 69%; text-align: left">Yoseph Shaaltiel, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 28%; text-align: right">210,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yossi Maimon, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tzvi Palash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The restricted shares detailed above vest in 16 equal, quarterly
increments over a four-year period, commencing upon the date of grant. In addition, each vested share is subject to a 24-month
lock-up period, commencing upon the applicable vesting date. Immediately and automatically in the event of a Corporate Transaction
or a Change in Control, all of the restricted shares listed above shall vest and the lock-up periods shall terminate, subject
to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Options and Share-Based Compensation.
</I></B>Our amended 2006 stock incentive plan authorizes us to grant options to purchase shares of common stock, restricted stock
and other securities to our employees, directors and consultants. Our Compensation Committee is the administrator of the stock
incentive plan. Stock option or other grants are generally made at the commencement of employment and following a significant
change in job responsibilities or to meet other special retention or performance objectives. The Compensation Committee reviews
and approves stock option and other awards to executive officers based upon a review of competitive compensation data, its assessment
of individual performance, a review of each executive&rsquo;s existing long-term incentives, and retention considerations. The
exercise price of stock options granted under our amended 2006 stock incentive plan must be equal to at least 100% of the fair
market value of our common stock on the date of grant; however, in certain circumstances, grants may be made at a lower price
to Israeli grantees who are residents of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Severance and Change in Control
Benefits.</I></B> Pursuant to the employment agreements entered into with each of our executive officers, the executive officer
is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance. The intention of such Manager&rsquo;s
Policies is to provide the Israel-based officers with severance protection of one month&rsquo;s salary for each year of employment.
In addition, stock option and other agreements with each of our Named Executive Officers, as amended, provide that all of the
outstanding options and other securities granted by us to each Named Executive Officer are subject to accelerated vesting immediately
upon a change in control of our company. As set forth above, our Board of Directors adopted certain recommendations of the Compensation
Committee on July 15, 2012, regarding the compensation of our Named Executive Officers, including cash bonuses for Named Executive
Officers if we complete a Corporate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Other Compensation.</I></B> Consistent
with our compensation philosophy, we intend to continue to maintain our current benefits for our executive officers; however,
the Compensation Committee in its discretion may revise, amend, or add to the officer&rsquo;s executive benefits if it deems it
advisable. As an additional benefit to all of our Israel-based Named Executive Officers and for most of our employees, we generally
contribute to certain funds amounts equaling a total of approximately 15% of their gross salaries for certain pension and other
savings plans for the benefit of the Named Executive Officers. In addition, in accordance with customary practice in Israel, our
Israel-based executives&rsquo; agreements require us to contribute towards their vocational studies, and to provide annual recreational
allowances, a company car and a company phone. We believe these benefits are currently equivalent with median competitive levels
for comparable companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Executive Compensation.</I></B>
We refer to the &ldquo;Summary Compensation Table&rdquo; set forth in Section 11 of the Annual Report on Form 10-K for information
regarding the compensation earned during the fiscal year ended December&nbsp;31, 2014 by: our current President and Chief Executive
Officer, our former President and Chief Executive Officer, our Executive Vice President, Research and Development, our Senior
Vice President, Product Development, our Vice President and Chief Financial Officer and our Chief Operating Officer, who we refer
to collectively as the &ldquo;Named Executive Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Committee Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>The above report of the Compensation Committee
does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by us
under the Securities Act of 1933 or the Securities Exchange Act of 1934.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The Compensation Committee has reviewed and discussed
the Compensation Discussion and Analysis set forth below with our management. Based on this review and discussion, the Compensation
Committee has recommended to our Board of Directors that the Compensation Discussion and Analysis be included in our Annual Report
on Form 10&ndash;K and our annual proxy statement on Schedule 14A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Respectfully submitted on March 10, 2015,
by the members of the Compensation Committee of the Board of Directors<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Amos Bar Shalev</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Zeev Bronfeld</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Yodfat Harel Buchris</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth a summary for
the fiscal years ended December 31, 2014, 2013 and 2012, respectively, of the cash and non-cash compensation awarded, paid or
accrued by us or Protalix Ltd. to each of our current President and Chief Executive Officer, our former President and Chief Executive
Officer, our Executive Vice President, Research and Development, our Senior Vice President, Product Development, our Vice President
and Chief Financial Officer and our Chief Operating Officer, who we refer to collectively as the &ldquo;Named Executive Officers.&rdquo;
There were no restricted stock awards, long-term incentive plan payouts or other compensation paid during fiscal years 2014, 2013
and 2012 by us or Protalix Ltd. to the Named Executive Officers, except as set forth below. All of the Named Executive Officers
are employees of our subsidiary, Protalix Ltd. All currency amounts are expressed in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name and Principal Position</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Salary($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Bonus
    ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock<BR>
    Award(s) ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Award(s)<BR> ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">All
    Other<BR> Compensation<BR> ($)(1)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Total
                           ($)</B></FONT></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; text-align: left"><FONT STYLE="font-size: 8pt">Moshe Manor (2)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">93,667</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">200,962</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">18,399</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">313,028</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Current President and</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Executive Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">David Aviezer, Ph.D., MBA (3)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">443,840</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(386,196</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(138,728</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">100,109</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">419,025</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Former President and</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">527,672</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">870,147</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">213,581</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">112,662</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,774,062</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Executive Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">493,960</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">675,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">860,963</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,101,142</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">99,080</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,230,145</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yoseph Shaaltiel, Ph.D.</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">305,548</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">90,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">232,979</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">62,651</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">84,719</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">775,897</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Executive Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">302,901</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">120,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">429,927</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">140,770</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">81,672</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,075,270</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Research and Development</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">283,655</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">225,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">409,838</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">608,826</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">67,257</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,594,576</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Einat Brill Almon, Ph.D.</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">263,917</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">85,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">205,244</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">56,170</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">68,489</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">678,820</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Senior Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">261,505</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">100,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">378,745</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">126,208</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">66,600</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">933,058</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Product Development</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">244,716</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">215,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">361,048</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">547,846</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">67,763</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,436,373</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yossi Maimon, CPA</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">299,090</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">225,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">205,244</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">56,170</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">74,493</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">859,997</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">292,096</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">110,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">378,745</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">126,208</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">67,739</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">974,788</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Financial Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">268,618</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">157,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">361,048</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">544,199</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">58,231</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,389,596</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Tzvi Palash</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">233,669</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">113,161</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11,413</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">74,520</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">482,763</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Operating Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">231,668</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">208,822</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">72,055</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">72,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">604,650</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">216,451</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">199,064</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">152,240</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">66,274</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">669,029</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes
employer contributions to pension and/or insurance plans and other miscellaneous payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Manor commenced his tenure as our President and Chief Executive Officer as of November 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Aviezer&rsquo;s tenure as our President and Chief Executive Officer ended as of November 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.4pt; text-indent: -37.4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth information with
respect to the Named Executive Officers concerning equity awards as of December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Awards</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number
    <BR>of Securities <BR>Underlying <BR>Unexercised <BR>Options <BR>Exercisable (#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number
    <BR>of Securities <BR>Underlying <BR>Unexercised <BR>Options <BR>Unexercisable (#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    <BR>Exercise <BR>Price ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    <BR>Expiration <BR>Date</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number
    of Shares or <BR>Units of Stock That <BR>Have Not Vested (#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Market
    Value of <BR>Shares or Units of <BR>Stock That Have <BR>Not Vested ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left"><FONT STYLE="font-size: 8pt">Moshe Manor</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">56,250</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">843,750</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">2.37</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">/29/2024</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">David Aviezer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">853,563</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/10/2016</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">600,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/7/2018</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">100,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2019</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">208,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">41,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2020</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">104,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">192,280</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yoseph Shaaltiel</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">122,162</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.001</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/30/2016</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">263,728</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/7/2018</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2019</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">120,833</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,167</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2020</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">91,875</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">169,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Einat Brill Almon</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">311,272</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/7/2018</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">108,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">21,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2020</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">80,938</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">148,926</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yossi Maimon</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">175,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/7/2018</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">108,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">21,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/25/2020</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">80,938</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">148,926</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Tzvi Palash</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">160,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7.55</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">/29/2020</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">44,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">82,110</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Potential Payments upon Termination or Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each of our Named Executive Officers (while they remain employed
by our company) is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance upon termination.
The intention of such Manager&rsquo;s Policies is to provide our officers with severance protection of one month&rsquo;s salary
for each year of employment. We do not provide any change in control benefits to our Named Executive Officers except for certain
cash bonuses and the acceleration of the vesting periods for outstanding options and restricted stock, subject to certain conditions.
Had we experienced a change of control on December 31, 2014, the value of the acceleration of the vesting period of Mr. Manor&rsquo;s
options would be $0; as of the same date all options held by each of our other Named Executive Officers were fully vested and,
accordingly, the value of the acceleration of the stock options held by each of them as of such date would be zero. In addition,
had we experienced a change of control on December 31, 2014, the value of the acceleration of the shares of restricted stock held
by each of Dr. Shaaltiel, Dr. Brill Almon, Mr. Maimon and Mr. Palash would be $169,050, $148,926, $148,926, and $82,110, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Employment Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Moshe Manor.</B> Mr. Manor joined Protalix Ltd. as its President
and Chief Executive Officer pursuant to an employment agreement dated September 28, 2014. Pursuant to the employment agreement,
his current monthly base salary is NIS 100,000 (approximately $25,714) and Mr. Manor is entitled to an annual discretionary bonus
subject to the sole discretion of our Board of Directors. The Board of Directors shall determine the bonus on the basis of agreed-upon
annual objectives which shall include both measurable and strategic parameters. The monthly salary is subject to cost of living
adjustments from time to time as may be required by law. The Board of Directors also granted to Mr. Manor options to purchase
900,000 shares of our common stock at an exercise price equal to $2.37 per share, the closing sales price of the common stock
on the NYSE MKT for the last trading day immediately preceding the effective date of the grant. The options vest over four years
on a quarterly basis in 16 equal increments, subject to certain conditions. Vesting of the options will be accelerated in full
upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company&rsquo;s 2006 Stock Incentive Plan,
as amended. Mr. Manor&rsquo;s employment agreement is terminable by our company on 90 days written notice for any reason during
the first year of the agreement&rsquo;s term and on 180 days written notice thereafter. Mr. Manor may terminate the agreement
on 90 days written notice for any reason during its term. We may terminate the Agreement for cause without notice. Mr. Manor is
entitled to be insured by the Company under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational
studies, annual recreational allowances, a company car and a company phone. Mr. Manor is entitled to 24 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>David Aviezer, Ph.D., MBA.</B> Dr. Aviezer originally
served as Protalix Ltd.&rsquo;s Chief Executive Officer on a consultancy basis pursuant to a Consulting Services Agreement
between Protalix Ltd. and Agenda Biotechnology Ltd., a company wholly-owned by Dr. Aviezer. On September 11, 2006, Protalix
Ltd. entered into an employment agreement with Dr. Aviezer pursuant to which he agreed to be employed as Protalix
Ltd.&rsquo;s President and Chief Executive Officer, which agreement supersedes the Consultancy Services Agreement. Dr.
Aviezer served as our President and Chief Executive Officer until November 2014. At the end of Dr. Aviezer&rsquo;s tenure as
our President and Chief Executive Officer, his monthly base salary was NIS 148,000 (approximately $38,056) and he was
entitled to an annual bonus at the Board&rsquo;s discretion. The monthly salary was subject to cost of living adjustments
from time to time. Dr. Aviezer was eligible under the employment agreement to receive a substantial bonus in the event of
certain public offerings or acquisition transactions, which bonus shall be at the discretion of the Board, and certain
specified bonuses in the event Protalix achieves certain specified milestones. In connection with the employment agreement,
in addition to other options already held by Dr. Aviezer granted to Dr. Aviezer options to purchase 16,000 ordinary shares of
Protalix Ltd. at an exercise price equal to $59.40 per share, which we assumed as options to purchase 977,297 shares of our
common stock at $0.97 per share. Such options vest quarterly retroactively from June 1, 2006, over a four-year period. In
addition, in 2008 we granted to Dr. Aviezer an option to purchase 600,000 shares of our common stock at an exercise price
equal to $5.00 per share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we
granted Dr. Aviezer an option to purchase 100,000 shares of our common stock at an exercise price equal to $2.65 per share.
As of December 31, 2009, all of those options had fully vested. In 2010, we granted Dr. Aviezer an option to purchase 250,000
shares of our common stock at an exercise price equal to $6.90 per share, which option vests quarterly over a
three-year period commencing upon FDA approval of taliglucerase alfa, if at all, and on July 16, 2012, we granted Dr. Aviezer
418,000 restricted shares of common stock that vest quarterly in 16 equal increments over a four-year period. Dr.
Aviezer&rsquo;s employment agreement was terminable by either party on 90 days&rsquo; written notice for any reason and
terminable by us  for cause without notice. Dr. Aviezer was entitled to be insured by Protalix Ltd. under a
Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual recreational
allowances, a company car and a company phone. Dr. Aviezer was entitled to 29 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yoseph Shaaltiel, Ph.D.</B> Dr. Shaaltiel founded Protalix Ltd.
in 1993 and currently serves as our Executive Vice President, Research and Development. Dr. Shaaltiel entered into an employment
agreement with Protalix Ltd. on September 1, 2001. Pursuant to the employment agreement, his current monthly base salary is NIS
85,000 (approximately $21,856) per month. The employment agreement is terminable by Protalix Ltd. on 90 days&rsquo; written notice
for any reason and we may terminate the agreement for cause without notice. In 2008 we granted to Dr. Shaaltiel an option to purchase
263,728 shares of our common stock at an exercise price equal to $5.00 per share. The option vests variably over a five-year period
that commenced on January 1, 2008. In 2009, we granted Dr. Shaaltiel an option to purchase 50,000 shares of our common stock at
an exercise price equal to $2.65 per share. As of December 31, 2009, all of those options had fully vested. In 2010, we granted
Dr. Shaaltiel an option to purchase 145,000 shares of our common stock at an exercise price equal to $6.90 per share, which option
vests quarterly over a three-year period commencing upon FDA approval of taliglucerase alfa, if at all, and on July 16, 2012,
we granted Dr. Shaaltiel 210,000 restricted shares of common stock that vest quarterly in 16 equal increments over a four-year
period. Dr. Shaaltiel is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company
contributions towards vocational studies, annual recreational allowances, a company car and a company phone. Dr. Shaaltiel is
entitled to 29 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Brill Almon joined Protalix
Ltd. on December 19, 2004 as its Vice President, Product Development, pursuant to an employment agreement effective on December
19, 2004 by and between Protalix Ltd. and Dr. Brill Almon, and currently serves as our Senior Vice President, Product Development.
Pursuant to the employment agreement, her current monthly base salary is NIS 73,500 per month (approximately $18,899). She is
also entitled to certain specified bonuses in the event that Protalix achieves certain specified clinical development milestones
within specified timelines. In connection with the employment agreement, Protalix agreed to grant to Dr. Brill Almon options to
purchase 7,919 ordinary shares of Protalix Ltd. at exercise prices equal to $24.36 and $59.40 per share, which we assumed as options
to purchase 483,701 shares of our common stock at $0.40 and $0.97 per share. The options vest over four years. In addition, in
2008 we granted to Dr. Brill Almon an option to purchase 311,272 shares of our common stock at an exercise price equal to $5.00
per share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Dr. Brill
Almon an option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31,
2009, all of those options had fully vested. In 2010, we granted Dr. Brill Almon an option to purchase 130,000 shares of our common
stock at an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA
approval of taliglucerase alfa, if at all, and on July 16, 2012, we granted Dr. Brill Almon 185,000 restricted shares of common
stock that vest quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party
on 60 days&rsquo; written notice for any reason and we may terminate the agreement for cause without notice. Dr. Brill Almon is
entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational
studies, annual recreational allowances, a company car and a company phone at up to NIS 1,000 per month. Dr. Brill Almon is entitled
to 29 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yossi Maimon, CPA.</B> Mr. Maimon joined Protalix Ltd. as its
Chief Financial Officer pursuant to an employment agreement effective as of October 15, 2006 by and between Protalix Ltd. and
Mr. Maimon and currently serves as our Chief Financial Officer. Pursuant to the employment agreement, his current monthly base
salary is NIS 73,500 (approximately $18,899) and Mr. Maimon is entitled to an annual discretionary bonus and additional discretionary
bonuses in the event Protalix achieves significant financial milestones, subject to the Board&rsquo;s sole discretion. The monthly
salary is subject to cost of living adjustments from time to time. In connection with the employment agreement, Protalix agreed
to grant to Mr. Maimon options to purchase 10,150 ordinary shares of Protalix Ltd. at an exercise price equal to $59.40 per share,
which we assumed as options to purchase 619,972 shares of our common stock at $0.97 per share. The first 25% of such options shall
vest on the first anniversary of the grant date and the remainder shall vest quarterly in 12 equal increments. In addition, in
2008 we granted to Mr. Maimon an option to purchase 175,000 shares of our common stock at an exercise price equal to $5.00 per
share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Mr. Maimon
an option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009,
all of those options had fully vested. In 2010, we granted Mr. Maimon an option to purchase 130,000 shares of our common stock
at an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA approval
of taliglucerase alfa, if at all, and on July 16, 2012, we granted Mr. Maimon 185,000 restricted shares of common stock that vest
quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party on 60 days&rsquo;
written notice for any reason and we may terminate the agreement for cause without notice. Mr. Maimon is entitled to be insured
by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual
recreational allowances, a company car and a company phone. Mr. Maimon is entitled to 29 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tzvi Palash. </B>Mr. Palash joined Protalix Ltd. as its Chief
Operating Officer pursuant to an employment agreement effective September 6, 2010 and currently serves as our Chief Operating
Officer. Pursuant to the employment agreement, Mr. Palash&rsquo;s current monthly base salary is NIS 69,000 (approximately $17,742)
and Mr. Palash is entitled to an annual discretionary bonus for performance subject to the sole discretion of our compensation
committee. The monthly salary is subject to cost of living adjustments from time to time as may be required by law. In connection
with the employment agreement, we granted to Mr. Palash options to purchase 160,000 shares of our common stock with an exercise
price equal to $7.55 per share. The first 25% of such options vested on the first anniversary of the grant date and the remainder
vest quarterly in 12 equal increments. In addition, on July 16, 2012, we granted Mr. Palash 102,000 restricted shares of common
stock that vest quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party
on 60 days&rsquo; written notice for any reason and we may terminate the agreement for cause without notice. Mr. Palash is entitled
to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies,
annual recreational allowances, a company car, a company phone, a company laptop and lodging accommodations in the Carmiel area.
Mr. Palash is entitled to 27 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Amended 2006 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Board of Directors and a majority of our
shareholders approved our 2006 Stock Incentive Plan on December 14, 2006. Our shareholders approved an amendment to the plan on
June 17, 2012 and subsequently on November 10, 2014. There are 13,841,655 shares of our common stock reserved for issuance, in
the aggregate, under the amended 2006 Stock Incentive Plan, subject to adjustment for a stock split or any future stock dividend
or other similar change in our common stock or our capital structure. As of December 31, 2014, options to acquire 1,923,444 shares
of common stock remain available for grant under the amended 2006 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our amended 2006 Stock Incentive Plan provides
for the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights,
collectively referred to as &ldquo;awards.&rdquo; Stock options granted under the amended 2006 Stock Incentive Plan may be either
incentive stock options under the provisions of Section 422 of the Internal Revenue Code, or non-qualified stock options. Incentive
stock options may be granted only to employees. Awards other than incentive stock options may be granted to employees, directors
and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The amended 2006 Stock Incentive Plan is also
designed to comply with the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to
Amendment 132 thereto) (the &ldquo;tax ordinance&rdquo;) and is intended to enable us to grant awards to grantees who are Israeli
residents as follows: (i) awards to employees pursuant to Section 102 of the tax ordinance; and (ii) awards to non-employees pursuant
to Section 3(I) of the tax ordinance. For this purpose, &ldquo;employee&rdquo; refers only to employees, office holders and directors
of our company or a related entity excluding those who are considered &ldquo;Controlling Shareholders&rdquo; pursuant to, or otherwise
excluded by, the tax ordinance. In accordance with the terms and conditions imposed by the Tax Ordinance, grantees who receive
awards under the amended 2006 stock incentive plan may be afforded certain tax benefits in Israel as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Board of Directors or the Compensation Committee,
referred to as the &ldquo;plan administrator,&rdquo; will administer our amended 2006 stock incentive plan, including selecting
the grantees, determining the number of shares to be subject to each award, determining the exercise or purchase price of each
award, and determining the vesting and exercise periods of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The exercise price of stock options granted under
the 2006 stock incentive plan must be equal to at least 100% of the fair market value of our common stock on the date of grant;
however, in certain circumstances, grants may be made at a lower price to Israeli grantees who are residents of the State of Israel.
If, however, incentive stock options are granted to an employee who owns stock possessing more than 10% of the voting power of
all classes of our stock or the stock of any parent or subsidiary of our company, the exercise price of any incentive stock option
granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive stock options
must not exceed five years. The maximum term of all other awards must not exceed 10 years (or five years in the case of an incentive
stock option granted to any participant who owns stock representing more than 10% of the voting power of all classes of our stock
or the stock of any parent or subsidiary of our company). The plan administrator will determine the exercise or purchase price
(if any) of all other awards granted under the amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the amended 2006 stock incentive plan,
incentive stock options and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed
of in any manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of the
participant only by the participant. Other awards shall be transferable by will or by the laws of descent or distribution and
to the extent and in the manner authorized by the plan administrator by gift or pursuant to a domestic relations order to members
of the participant&rsquo;s immediate family. The amended 2006 stock incentive plan permits the designation of beneficiaries by
holders of awards, including incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">If the service of a participant in the amended
2006 stock incentive plan is terminated for any reason other than cause, the participant may exercise awards that were vested
as of the termination date for a period ending upon the earlier of 12 months from the date of termination (or such shorter or
longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator.
If the service of a participant in the amended 2006 stock incentive plan is terminated for cause, the participant may exercise
awards that were vested as of the termination date for a period ending upon the earlier of 14 days from the date of termination
(or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined
by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In the event of a corporate transaction, all
awards will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&rsquo;s award agreement,
in the event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion
will automatically become fully vested and exercisable immediately upon termination of a participant&rsquo;s service if the participant
is terminated by the successor company or us without cause within 12 months after the corporate transaction. With respect to the
portion of each award that is not assumed or replaced, such portion will automatically become fully vested and exercisable immediately
prior to the effective date of the corporate transaction so long as the participant&rsquo;s service has not been terminated prior
to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In the event of a change in control, except as
otherwise provided in a participant&rsquo;s award agreement, following a change in control (other than a change in control that
also is a corporate transaction) and upon the termination of a participant&rsquo;s service without cause within 12 months after
a change in control, each award of such participant that is outstanding at such time will automatically become fully vested and
exercisable immediately upon the participant&rsquo;s termination. In addition, the stock options and shares of restricted stock
issued to each of our Named Executive Officers are subject to accelerated vesting immediately upon a corporate transaction or
a change in control of our company, as defined in our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under our amended 2006 stock incentive plan,
a corporate transaction is generally defined as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>a
merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing our company&rsquo;s
state of incorporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>the
sale, transfer or other disposition of all or substantially all of our assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>the
complete liquidation or dissolution of our company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>any
reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger
are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise,
or in which securities possessing more than forty percent (40%) of the total combined voting power of our outstanding securities
are transferred to a person or persons different from those who held such securities immediately prior to such merger; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>acquisition
in a single or series of related transactions by any person or related group of persons of beneficial ownership of securities
possessing more than fifty percent (50%) of the total combined voting power of our outstanding securities but excluding any such
transaction or series of related transactions that the plan administrator determines not to be a corporate transaction (provided
however that the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all
or substantially all of our shares unless the principal purpose of such transaction is changing our company&rsquo;s state of incorporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">Under our amended 2006 stock incentive plan,
a change of control is defined as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>the
direct or indirect acquisition by any person or related group of persons of beneficial ownership of securities possessing more
than fifty percent (50%) of the total combined voting power of our outstanding securities pursuant to a tender or exchange offer
made directly to our shareholders and which a majority of the members of our board (who have generally been on our board for at
least 12 months) who are not affiliates or associates of the offeror do not recommend shareholders accept the offer; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;&nbsp;</FONT>a
change in the composition of our board over a period of 12 months or less, such that a majority of our board members ceases, by
reason of one or more contested elections for board membership, to be comprised of individuals who were previously directors of
our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Unless terminated sooner, the amended 2006 stock
incentive plan will automatically terminate on December 31, 2020. Our Board of Directors has the authority to amend, suspend or
terminate our amended 2006 stock incentive plan. No amendment, suspension or termination of the amended 2006 stock incentive plan
shall adversely affect any rights under awards already granted to a participant. To the extent necessary to comply with applicable
provisions of federal securities laws, state corporate and securities laws, the Internal Revenue Code, the rules of any applicable
stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to awards granted to residents
therein (including the Tax Ordinance), we shall obtain shareholder approval of any such amendment to the 2006 stock incentive
plan in such a manner and to such a degree as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>Impact of Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The awards granted to employees pursuant to Section
102 of the Tax Ordinance under the amended 2006 stock incentive plan may be designated by us as approved options under the capital
gains alternative, or as approved options under the ordinary income tax alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">To qualify for these benefits, certain requirements
must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired
upon the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust
with the trustee and ending 24 months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the terms of the capital gains alternative,
we may not deduct expenses pertaining to the options for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the amended 2006 stock incentive plan,
we may also grant to employees options pursuant to Section 102(c) of the Tax Ordinance that are not required to be held in trust
by a trustee. This alternative, while facilitating immediate exercise of vested options and sale of the underlying shares, will
subject the optionee to the marginal income tax rate of up to 50% as well as payments to the National Insurance Institute and
health tax on the date of the sale of the shares or options. Under the 2006 stock incentive plan, we may also grant to non-employees
options pursuant to Section 3(I) of the Tax Ordinance. Under that section, the income tax on the benefit arising to the optionee
upon the exercise of options and the issuance of common stock is generally due at the time of exercise of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">These options shall be further subject to the
terms of the tax ruling that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with the merger.
Under the tax ruling, the options issued by us in connection with the assumption of Section 102 options previously issued by Protalix
Ltd. under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative
and the issuance date of the original options shall be deemed the issuance date for the assumed options for the calculation of
the respective holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth information with respect to compensation
of our non-employee directors during fiscal year 2014. The fees to our current directors were paid by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Fees Earned or<BR> Paid in Cash ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Option Awards</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 41%; text-align: left">Shlomo Yanai (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">87,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">69,521</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">157,021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Zeev Bronfeld</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amos Bar Shalev</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yodfat Harel Buchris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Roger D. Kornberg</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Aharon Schwartz (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Eyal Sheratzky (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">(1)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Yanai&rsquo;s tenure on our Board of Directors commenced on July 24, 2014. On that same date, the Board of Directors granted to
Mr. Yanai a 10-year option to purchase 150,000 shares of our common stock with an exercise price of $3.37 per share. The options
vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares
vest in eight equal quarterly increments over the subsequent two year period, subject to certain terms and conditions. The vesting
of the options is accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in our amended
2006 Stock Incentive Plan. We estimated the fair value of the option on the date of grant using the Black-Scholes option-pricing
model to be approximately $193,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">(2)&nbsp;&nbsp;&nbsp;&nbsp;Dr.
Schwartz was elected to serve on our Board of Directors on November 10, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">(3)&nbsp;&nbsp;&nbsp;&nbsp;Mr.
Sheratzky&rsquo;s tenure on our Board of Directors ended on November 10, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Directors&rsquo; fees paid to each of Zeev Bronfeld
and Eyal Sheratzky are paid to the applicable director&rsquo;s employer in accordance with arrangements between the director and
the employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Compensation Committee currently consists
of Messrs. Bar Shalev and Bronfeld and Mrs. Harel Buchris. No member of our Compensation Committee or any executive officer of
our company or of Protalix Ltd. has a relationship that would constitute an interlocking relationship with executive officers
or directors of another entity. No Compensation Committee member is or was an officer or employee of ours or of Protalix Ltd.
Further, none of our executive officers serves on the board of directors or compensation committee of any entity that has one
or more executive officers serving as a member of our Board of Directors or Compensation Committee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt"><A NAME="a_021"></A>Item&nbsp;12.&nbsp;&nbsp;Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Security Ownership of Certain Beneficial Owners
and Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth information, as
of March 1, 2015, regarding beneficial ownership of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person who
                                         is known by us to own beneficially more than 5% of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each director;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our Chief
                                         Executive Officer, our Executive Vice President, Research and Development, our Senior
                                         Vice President, Product Development, our Chief Financial Officer and our Chief Operating
                                         Officer; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all of our directors
                                         and executive officers collectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Unless otherwise noted, we believe that all persons
named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by
each of them. For purposes of these tables, a person is deemed to be the beneficial owner of securities that can be acquired by
such person within 60 days from March 1, 2015 upon exercise of options, warrants and convertible securities. Each beneficial owner&rsquo;s
percentage ownership is determined by assuming that options, warrants and convertible securities that are held by such person
(but not those held by any other person) and that are exercisable within such 60 days from such date have been exercised. The
information set forth below is based upon information obtained from the beneficial owners, upon information in our possession
regarding their respective holdings and upon information filed by the holders with the Commission. The percentages of beneficial
ownership are based on 93,603,819 shares of our common stock outstanding as of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The address for all directors and officers is
c/o Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park, P.O. Box 455, Carmiel, Israel, 20100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount and Nature of<BR>
    Beneficial Ownership</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<BR> Class
    (%)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Board of Directors and Executive Officers</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shlomo Yanai (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Moshe Manor (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">112,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">*</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amos Bar Shalev</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Zeev Bronfeld (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,162,481</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yodfat Harel Buchris (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137,424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Roger D. Kornberg, Ph.D. (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Aharon Schwartz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D. (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">557,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yossi Maimon (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">421,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tzvi Palash (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yoseph Shaaltiel, Ph.D. (9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,176,936</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All executive officers and directors as a <BR> group (11 persons) (10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,850,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">5% Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Al-Rov (Israel) Ltd. (11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,915,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Federated Investors Inc. (12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,270,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Baillie Gifford &amp; Co. (13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,510,158</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Consonance Capital Management LP (14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,077,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">* less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Does
not include 150,000 shares of our common stock underlying options that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 112,500 shares of our common stock issuable upon exercise of outstanding options within 60 days of March 1, 2015. Does not
include 787,500 shares of our common stock underlying options that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of shares of our common stock held directly by Mr. Bronfeld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
shares held by YP &amp; 6 Partners Ltd. Mrs. Harel Buchris is a director and shareholder of YP &amp; 6 Partners Ltd. Mrs. Harel
Buchris disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 50,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 430,439 shares of our common stock issuable upon exercise of outstanding options within 60 days of March 1, 2015 and 127,188
restricted shares of our common stock that have vested or will vest within 60 days of March 1, 2015. Does not include 10,833 shares
of our common stock underlying options that will not vest within 60 days of March 1, 2015 and 57,813 restricted shares of our
common stock that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 294,167 shares of our common stock issuable upon exercise of outstanding options within 60 days of March 1, 2015 and 127,188
restricted shares of our common stock that have vested or will vest within 60 days of March 1, 2015. Does not include 10,833 shares
of our common stock underlying options that will not vest within 60 days of March 1, 2015 and 57,813 restricted shares of our
common stock that will not vest within 60 days of March, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 160,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of March 1, 2015 and 70,125
restricted shares of our common stock that have vested or will vest within 60 days of March 1, 2015. Does not include 31,875 restricted
shares of our common stock that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 463,754 shares of our common stock held by Dr. Shaaltiel, 568,807 shares of our common stock issuable upon exercise of outstanding
options within 60 days of March 1, 2015 and 144,375 restricted shares of our common stock that have vested or will vest within
60 days of March, 2015. Does not include 12,083 shares of our common stock underlying options that will not vest within 60 days
of March 1, 2015 and 65,625 restricted shares of our common stock that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 2,765,339 shares of our common stock, 1,615,912 shares of our common stock issuable upon exercise of outstanding options within
60 days of March 1, 2015 and 468,875 restricted shares of our common stock that have vested or will vest within 60 days of March
1, 2015. Does not include 971,250 shares of common stock issuable upon exercise of outstanding options and 213,125 restricted
shares of our common stock that will not vest within 60 days of March 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(11)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address is Alrov Tower, 46 Rothschild Blvd., Tel Aviv 66883, Israel. Consists of 4,229,337 shares of our common stock held by
Al-Rov (Israel) Ltd., or Al-Rov Israel, and 686,046 shares of our common stock held by Techno-Rov Holdings (1993) Ltd., or Techno-Rov
Holdings. Al-Rov Israel owns 100% of the outstanding shares of Al-Rov Technologies Holdings LTD, the holder of 80% of Techno-Rov
Holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(12)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a Schedule 13G/A filed on February 11, 2015 by Federated Investors, Inc. for December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(13)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a Schedule 13G/A filed by Baillie Gifford &amp; Co. on January 29, 2015 for December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(14)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a Schedule 13G filed on February 17, 2015 by Consonance Capital Management LP for December 31, 2014.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Equity Compensation Plan Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table provides information as of
December&nbsp;31, 2014 with respect to the shares of our common stock that may be issued under our existing equity compensation
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>A</B></P> </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>B</B></P> </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>C</B></P> </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Plan Category</B></P> <!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number&nbsp;of&nbsp;Securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to
                                         be Issued</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Upon
                                         Exercise of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding
                                         Options</B></P> <!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted&nbsp;Average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise
                                         Price of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding&nbsp;Options</B></P> <!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number&nbsp;of&nbsp;Securities&nbsp;Remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Available
                                         for Future Issuance</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Under&nbsp;Equity&nbsp;Compensation&nbsp;Plans</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Excluding
                                         Securities Reflected in</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Column
                                         A)</B></P> <!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12pt; padding-left: 12pt">Equity Compensation Plans Approved by Shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,833,159</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.38</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,923,444</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; padding-bottom: 1pt">Equity Compensation Plans Not Approved by Shareholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">631,866</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10.24</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,465,025</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.96</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,923,444</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45.35pt; text-indent: -45.35pt"><A NAME="a_022"></A>Item&nbsp;13.&nbsp;&nbsp;&nbsp;Certain
Relationships and Related Transactions, and Director Independence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Corporate Governance and Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In compliance with the listing requirements of the NYSE MKT, we
have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting high standards of professional
and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly monitor developments
in the area of corporate governance to ensure we are in compliance with the standards and regulations required by the NYSE MKT.
A summary of our corporate governance measures follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe a majority of the members of our Board of Directors
are independent from management. When making determinations from time to time regarding independence, the Board of Directors will
reference the listing standards adopted by the NYSE MKT as well as the independence standards set forth in the Sarbanes-Oxley
Act of 2002 and the rules and regulations promulgated by the Commission under that Act. We anticipate our Board of Directors will
analyze whether a director is independent by evaluating, among other factors, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
the member of the Board of Directors has any material relationship with us, either directly, or as a partner, shareholder or officer
of an organization that has a relationship with us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
the member of the Board of Directors is a current employee of our company or any of our subsidiaries, or was an employee of our
company or any of our subsidiaries within three years preceding the date of determination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
the member of the Board of Directors is, or in the three years preceding the date of determination has been, affiliated with or
employed by (i) a present internal or external auditor of our company or any affiliate of such auditor or (ii) any former internal
or external auditor of our company or any affiliate of such auditor, which performed services for us within three years preceding
the date of determination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
the member of the Board of Directors is, or in the three years preceding the date of determination has been, part of an interlocking
directorate, in which any of our executive officers serve on the Compensation Committee of another company that concurrently employs
the member as an executive officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
the member of the Board of Directors receives any compensation from us, other than fees or compensation for service as a member
of the Board of Directors and any committee of the Board of Directors and reimbursement for reasonable expenses incurred in connection
with such service and for reasonable educational expenses associated with Board of Directors or committee membership matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
an immediate family member of the member of the Board of Directors is a current executive officer of our company or was an executive
officer of our company within three years preceding the date of determination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
an immediate family member of the member of the Board of Directors is, or in the three years preceding the date of determination
has been, affiliated with or employed in a professional capacity by (i) a present internal or external auditor of ours or any
of our affiliates or (ii) any former internal or external auditor of our company or any affiliate of ours which performed services
for us within three years preceding the date of determination; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>Whether
an immediate family member of the member of the Board of Directors is, or in the three years preceding the date of determination
has been, part of an interlocking directorate, in which any of our executive officers serve on the Compensation Committee of another
company that concurrently employs the immediate family member of the member of the Board of Directors as an executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The above list is not exhaustive and we anticipate that the Audit
Committee will consider all other factors which could assist it in its determination that a director will have no material relationship
with us that could compromise that director&rsquo;s independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under these standards, our Board of Directors has determined that
Messrs. Bar Shalev and Bronfeld and Mrs. Harel Buchris are considered &ldquo;independent&rdquo; pursuant to the rules of the NYSE
MKT and Section 10A(m)(3) of the Exchange Act. In addition, our Board of Directors has determined that at least two of these directors
are able to read and understand fundamental financial statements and have substantial business experience that results in their
financial sophistication, qualifying them for membership on our audit committee. Our Board of Directors has also determined that
Mr. Bar Shalev, Mr. Bronfeld, Mrs. Harel Buchris, Dr. Kornberg, Dr. Schwartz and Mr. Yanai are &ldquo;independent&rdquo; pursuant
to the rules of the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The position of chairman of the board is not held by our chief
executive officer at this time. The Board of Directors does not have a policy mandating the separation of these functions. We
believe it is in our best interest that Mr. Yanai serve as the chairman of our board. This decision was based on Mr. Yanai&rsquo;s
vast global operating experience in the life-science and pharmaceutical and agro-chemicals industry as well as the global perspective
he brings to our Board of Directors, incorporating his industry and board leadership experience and his distinguished military
service. Our non-management directors hold formal meetings, separate from management, at least twice per year. We have no formal
policy regarding attendance by our directors at annual shareholders meetings, although we encourage such attendance and anticipate
most of our directors will attend these meetings. Messrs. Bronfeld, Bar Shalev, Manor and Yanai, and Mrs. Harel Buchris attended
our 2014 annual meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The Board&rsquo;s Role in Risk Oversight </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors oversees an enterprise-wide approach to
risk management, designed to support the achievement of business objectives, including organizational and strategic objectives,
to improve long-term organizational performance and enhance shareholder value. The involvement of our Board of Directors in setting
our business strategy is a key part of its assessment of management&rsquo;s plans for risk management and its determination of
what constitutes an appropriate level of risk for the company. The participation of our Board of Directors in our risk oversight
process includes receiving regular reports from members of senior management on areas of material risk to our company, including
operational, financial, legal and regulatory, and strategic and reputational risks. While the full board has the ultimate oversight
responsibility for the risk management process, various committees of the board also have responsibility for risk management.
For example, financial risks, including internal controls, are overseen by the audit committee and risks that may be implicated
by our executive compensation programs are overseen by the compensation committee. Upon identification of a risk, the assigned
board committee or our full Board of Directors discuss or review risk management and risk mitigation strategies. Additional review
or reporting on enterprise risks is conducted as needed or as requested by our Board of Directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.55pt; text-indent: -40.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.55pt; text-indent: -40.55pt"><A NAME="a_023"></A><B>Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal
Accountant Fees and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth fees billed to us by our independent
registered public accounting firm during the fiscal years ended December 31, 2014 and 2013 for: (i) services rendered for the
audit of our annual financial statements and the review of our quarterly financial statements; (ii) services by our independent
registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements
and that are not reported as Audit Fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning;
and (iv) all other fees for services rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">2014</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">2013</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">246,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">246,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">57,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All Other Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,560</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Policy on Audit Committee Pre-Approval of Audit and Permissible
Non-Audit Services of Independent Auditors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to entering into the engagement letter with our independent
registered accountants, our Audit Committee approved the 2014 audit fees. For fiscal year 2015, our Audit Committee has approved
fees for certain permissible non-audit services to be rendered by our independent registered accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_024"></A><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.75pt; text-indent: -42.75pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.75pt; text-indent: -42.75pt"><A NAME="a_025"></A><B>Item&nbsp;15.&nbsp;&nbsp;&nbsp;Exhibits
and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">The following documents are filed as part
of this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 48pt">1.</TD><TD><I>Financial Statements</I>. The following Consolidated Financial
                                         Statements of Protalix BioTherapeutics, Inc. are included in Item&nbsp;8 of this Annual
                                         Report on Form 10-K:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 91%; padding-left: 0.1in">&nbsp;</td>
    <td style="width: 9%; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Page</B></P>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 12pt; text-indent: -12pt">Report of Independent Registered Public Accounting
    Firm</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-2</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">Consolidated Balance Sheets as of December 31,
    2013 and 2014</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-3</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">Consolidated Statements of Operations for the
    years ended December 31, 2012, 2013 and 2014</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-4</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">Consolidated Statements of Changes in Capital
    Deficiency for the years ended December 31, 2012, 2013 and 2014</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-5</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 12pt; text-indent: -12pt">Consolidated Statements of Cash Flows for the years
    ended December 31, 2012, 2013 and 2014</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-6</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-left: 12pt; text-indent: -12pt">Notes to Consolidated Financial Statements</td>
    <td nowrap style="vertical-align: bottom; padding-left: 0.1in; text-align: center">F-8</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.<I>&nbsp;&nbsp;Financial Statement Schedule.
</I>Financial statement schedules have been omitted since they are either not required, are not applicable or the required information
is shown in the consolidated financial statements or related notes. <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in">3.<I>&nbsp;&nbsp;Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="8" NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Incorporated
        by Reference</B></P></td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B><br>
        <B>Number</B></P></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><br>
        <B>Exhibit Description</B></P></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><br>
        <B>Form</B></P></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>File</B><br>
        <B>Number</B></P></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></td>
    <TD NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Filed</B><br>
        <B>Herewith</B></P></td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.1</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Amended and Restated Articles of Incorporation of the Company</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">S-4</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">333-48677</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.4</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">March 26, 1998</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.2</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Article of Amendment to Articles of Incorporation dated June 9, 2006</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8-A</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">001-33357</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.2</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">March 9, 2007</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.3</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Article of Amendment to Articles of Incorporation dated December 13, 2006</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8-A</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">001-33357</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.3</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">March 9, 2007</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.4</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Article of Amendment to Articles of Incorporation dated December 26, 2006</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8-A</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">001-33357</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.4</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">March 9, 2007</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.5</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Article of Amendment to Articles of Incorporation dated February 26, 2007</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8-A</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">001-33357</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.5</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">March 9, 2007</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.6</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Article of Amendment to Articles of Incorporation dated December 17, 2014</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">X</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">3.7</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Amended and Restated Bylaws of the Company</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">X</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">4.1</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Form of Restricted Stock Agreement/Notice</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8-K</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">001-33357</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3.1</td>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 24.6pt; text-align: center">July 18, 2012</td>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indenture, dated as of September 18, 2013, between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 18, 2013</FONT></TD>
    <TD STYLE="width: 11%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of 4.50% Convertible Note due 2018</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 18, 2013</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2006 Stock Incentive Plan, as amended</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Def 14A</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annex A</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 9, 2014</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement between Protalix Ltd. and Yoseph Shaaltiel, dated as of September 1, 2004</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 8, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement between Protalix Ltd. and Einat Almon, dated as of December 19, 2004 &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 8, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement between Protalix Ltd. and Yossi Maimon, dated as of October 15, 2006 &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 8, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5&dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License Agreement entered into as of April 12, 2005, by and between Icon Genetics AG and Protalix Ltd. &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K/A</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 20, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease Agreement between Protalix Ltd. and Angel Science Park (99) Ltd., dated as of October 28, 2003 as amended on April 18, 2005 &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 8, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock Option Award Agreement grant by and between the Company and Steven Rubin, dated as of December 31, 2006 &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 30, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">First Amendment to the December 31, 2006 Stock Option Award Agreement by and between the Company and Steven Rubin, effective as of February 28, 2007 &nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 30, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Scientific Advisory Board Agreement dated August 5, 2007 by and between the Company and Aaron Ciechanover, M.D.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August 6, 2007</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unprotected Lease Agreement</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10-K</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-33357</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 17, 2008</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%">10.11&dagger;</td>
    <td style="width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exclusive License and Supply Agreement dated as of November
        30, 2009 between Protalix Ltd. and Pfizer Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <td style="width: 7%; text-align: center">10-K</td>
    <TD NOWRAP STYLE="width: 12%; text-align: center">001-33357</td>
    <td style="width: 8%; text-align: center">10.16</td>
    <td style="width: 16%; padding-left: 6.95pt; text-align: center">February 26, 2010</td>
    <td style="width: 11%; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.12</td>
    <td>Employment Agreement by and between Protalix Ltd., and Tzvi Palash dated as of August&nbsp;29, 2010</td>
    <td style="text-align: center">8-K</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.1</td>
    <td style="padding-left: 6.95pt; text-align: center">September 7, 2010</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.13&dagger;</td>
    <td>License Agreement between Protalix BioTherapeutics Ltd. and Virginia Tech Intellectual Properties, Inc.</td>
    <td style="text-align: center">10-Q</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.2</td>
    <td style="padding-left: 6.95pt; text-align: center">November 8, 2010</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.14&dagger;</td>
    <td>Amended and Restated Agreement between Protalix Ltd. and Comercio e Servi&ccedil;os Ltda. dated June 17, 2013</td>
    <td style="text-align: center">10-Q</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.1</td>
    <td style="padding-left: 6.95pt; text-align: center">May 8, 2014</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.15&dagger;</td>
    <td>Amendment dated June 18, 2013 to the Exclusive License and Supply Agreement between Pfizer Inc. and Protalix Ltd., dated
    as of November 30, 2009</td>
    <td style="text-align: center">10-Q</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.2</td>
    <td style="padding-left: 6.95pt; text-align: center">May 8, 2014</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.16&dagger;</td>
    <td>Technology Transfer and Supply Agreement made as of June 18, 2013 by and between Protalix Ltd. and Funda&ccedil;&atilde;o
    Oswaldo Cruz</td>
    <td style="text-align: center">10-Q</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.3</td>
    <td style="padding-left: 6.95pt; text-align: center">May 8, 2014</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.17</td>
    <td>Employment Agreement with Moshe Manor dated September 28, 2014</td>
    <td style="text-align: center">8-K</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">10.1</td>
    <td style="padding-left: 6.95pt; text-align: center">September 29, 2014</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>21.1</td>
    <td><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subsidiaries</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <td style="text-align: center">10-K</td>
    <TD NOWRAP STYLE="text-align: center">001-33357</td>
    <td style="text-align: center">21.1</td>
    <td><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6.95pt; text-align: center">February 26, 2010</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6.95pt; text-align: center">&nbsp;</P></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 6.95pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>23.1</td>
    <td><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consent of Kesselman &amp; Kesselman, Certified Public
        Accountants (Isr.), A member of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm for the Registrant</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>31.1</td>
    <td>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>31.2</td>
    <td>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%">32.1</td>
    <td style="width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">18 U.S.C. Section 1350, as adopted pursuant to Section
        906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></td>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 12%; text-align: center">&nbsp;</td>
    <td style="width: 8%; text-align: center">&nbsp;</td>
    <td style="width: 16%; padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="width: 11%; text-align: center">X</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%">32.2</td>
    <td style="width: 35%">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification
    of Chief Financial Officer</td>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 12%; text-align: center">&nbsp;</td>
    <td style="width: 8%; text-align: center">&nbsp;</td>
    <td style="width: 16%; padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="width: 11%; text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.INS</td>
    <td>XBRL INSTANCE FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.SCH</td>
    <td>XBRL SHEMA FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.CAL</td>
    <td>XBRL CALCULATION FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.DEF</td>
    <td>XBRL DEFINITION FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.LAB</td>
    <td>XBRL LABEL FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.PRE</td>
    <td>XBRL PRESENTATION FILE</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 9pt; text-align: center">&nbsp;</td>
    <td style="text-align: center">X</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">_____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&dagger; Portions of this exhibit were omitted
and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&rsquo;s
application requesting confidential treatment under Rule 24b-2 of the Exchange Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_032"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, as of March 12, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">PROTALIX BIOTHERAPEUTICS, INC.</td></tr>
<tr>
    <td style="vertical-align: top; width: 50%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 45%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>By:</td>
    <td style="border-bottom: Black 1pt solid">/s/ Moshe Manor</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; padding-left: 0.1in">&nbsp;</td>
    <td style="vertical-align: bottom">Moshe Manor</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints Moshe Manor and Yossi Maimon, and each of them, as his true and
lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead,
in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do
or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 31%; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Signature</B></P></td>
    <td style="width: 44%; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.55pt; border-bottom: Black 0.5pt solid"><B>Title</B></P></td>
    <td style="width: 25%; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-indent: 27.55pt">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Moshe Manor</td>
    <td rowspan="2" style="padding-left: 12.5pt; text-align: center">President, Chief Executive Officer &nbsp;(Principal Executive
    Officer) and Director</td>
    <td rowspan="2" style="text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td>Moshe Manor</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr>
    <td style="border-bottom: Black 1pt solid">/s/ Yossi Maimon</td>
    <td rowspan="2" style="vertical-align: top; padding-left: 12.5pt; text-align: center">Chief Financial Officer, Treasurer and
    Secretary (Principal Financial <br>
    and Accounting Officer)</td>
    <td rowspan="2" style="vertical-align: top; text-align: right">March 12, 2015 </td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Yossi Maimon</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Shlomo Yanai</td>
    <td rowspan="2" style="vertical-align: top; padding-left: 12.5pt; text-align: center">Chairman of the Board</td>
    <td rowspan="2" style="vertical-align: top; text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Shlomo Yanai</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Amos Bar Shalev</td>
    <td rowspan="2" style="padding-left: 12.5pt; text-align: center">Director</td>
    <td rowspan="2" style="text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Amos Bar Shalev</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr>
    <td style="border-bottom: Black 1pt solid">/s/ Zeev Bronfeld</td>
    <td rowspan="2" style="vertical-align: top; padding-left: 12.5pt; text-align: center">Director</td>
    <td rowspan="2" style="vertical-align: top; text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Zeev Bronfeld</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Yodfat Harel Buchris</td>
    <td style="padding-left: 12.5pt; text-align: center">Director</td>
    <td style="text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Yodfat Harel Buchris</td>
    <td style="padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Aharon Schwartz</td>
    <td style="padding-left: 12.5pt; text-align: center">Director</td>
    <td style="text-align: right">March 12, 2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Aharon Schwartz, Ph.D.</td>
    <td style="padding-left: 12.5pt; text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 91%"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></td>
    <td style="width: 9%"><B>Page</B></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_026"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></A></td>
    <td>F-2</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-left: 16.8pt; text-indent: -16.8pt"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_027">Consolidated Balance Sheets as of December 31, 2013 and 2014</A></td>
    <td><FONT STYLE="text-transform: uppercase">F-3</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_028">Consolidated Statements of Operations for the years ended December 31, 2012, 2013 and 2014</A></td>
    <td style="vertical-align: bottom"><FONT STYLE="text-transform: uppercase">F-4</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_029">Consolidated Statements of Changes in Capital Deficiency for the years ended December 31, 2012, 2013 and 2014</A></td>
    <td style="vertical-align: bottom"><FONT STYLE="text-transform: uppercase">F-5</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_030">Consolidated Statements of Cash Flows for the years ended December 31, 2012, 2013 and 2014</A></td>
    <td style="vertical-align: bottom"><FONT STYLE="text-transform: uppercase">F-6</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#a_031">Notes to Consolidated Financial Statements</A></td>
    <td><FONT STYLE="text-transform: uppercase">F-8</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tpg95.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_026"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the shareholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In our opinion, the accompanying consolidated balance
sheets and the related consolidated statements of operations, changes in capital deficiency and cash flows present fairly, in
all material respects, the financial position of Protalix BioTherapeutics, Inc. and its subsidiaries at December 31, 2014
and 2013, and the results of their operations and their cash flows for each of the three years in the period ended December
31, 2014, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion,
the Company maintained, in all material respects, effective internal control over financial reporting as of December 31,
2014, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The Company&rsquo;s management is responsible for these financial
statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness
of internal control over financial reporting, included in the accompanying &ldquo;Management&rsquo;s Report on Internal
Control over Financial Reporting&rdquo; appearing under Item 9A. Our responsibility is to express opinions on these financial
statements and on the Company&rsquo;s internal control over financial reporting based on our integrated audits. We conducted
our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of
material misstatement and whether effective internal control over financial reporting was maintained in all material
respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. Our audit of internal control over financial
reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the
assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We
believe that our audits provide a reasonable basis for our opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A company&rsquo;s internal control over financial reporting is
a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s internal control
over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the company&rsquo;s assets that could have a material effect on the financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 54%">Tel-Aviv, Israel</td>
    <td style="width: 46%; text-align: center">/s/ Kesselman &amp; Kesselman</td></tr>
<tr style="vertical-align: top">
    <td>March 12, 2015</td>
    <td style="text-align: center">Kesselman &amp; Kesselman</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">Certified Public Accountants (Isr.)</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 11.55pt">&nbsp;</td>
    <td style="text-align: center">A member firm of PricewaterhouseCoopers</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 11.55pt">&nbsp;</td>
    <td style="text-align: center">International Limited</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Kesselman &amp; Kesselman, Trade Tower,
25 Hamered Street, Tel-Aviv 6812508, Israel, P.O Box 5005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_027"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands, except share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">86,398</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">54,767</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable- Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,202</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">FUNDS IN RESPECT OF EMPLOYEE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,555</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,282</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">DEFERRED CHARGES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,470</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -14.2pt; padding-left: 14.2pt">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,696</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,464</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,232</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Liability in connection with collaboration operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,371</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">912</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">107,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">140,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">134,071</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMMITMENTS <FONT STYLE="font-weight: normal; font-style: normal">(Note 6)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CAPITAL DEFICIENCY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Common Stock, $0.001 par value:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Authorized - as of December 31, 2013 and 2014,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">150,000,000 shares; issued and outstanding - as of December 31, 2013 and 2014, 93,551,098
    shares and 93,603,819 shares, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,633</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(211,385</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(241,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total capital deficiency</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,946</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(55,601</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,470</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>The accompanying notes
are an integral part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_028"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands, except shares and
per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold; text-align: left">REVENUES (see Note 11(c))</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">34,870</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,479</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">13,651</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(446</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,053</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,280</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,107</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,665</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,313</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,761</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt">Less &ndash; grants and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,111</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,689</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,816</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,650</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>SELLING, GENERAL AND
    ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">EXPENSES</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,385</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,116</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,204</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">FINANCIAL EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,935</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">196</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME (EXPENSES) &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(27,790</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,943</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock &ndash; basic and
    diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Weighted average number of shares of common stock used
    in computing loss per share of common stock, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,845,901</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,368,138</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,891,846</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_029"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL
DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands, except share data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2012</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">86</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">145,814</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">(171,977</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">(26,077</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2012:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Common stock&nbsp;issued for cash (net of issuance costs
    of $1,780)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to restricted stock
    award, net of forfeitures of 3,208 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,496,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees
    and non-employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,187,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2012</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,489,809</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">180,145</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(183,595</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(3,357</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2013:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to restricted stock
    award, net of forfeitures of 17,834 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,834</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,076</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,551,098</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">184,346</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(211,385</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(26,946</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2014:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Share-based compensation related to restricted stock
    award, net of forfeitures of 185,709 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,209</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">775</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees
    (includes net exercise)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,930</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2014</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,603,819</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">185,633</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(241,328</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(55,601</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Represents an amount less than $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_030"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: 9pt; padding-left: 5.4pt">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(11,618</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(27,790</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(29,943</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Adjustments required to reconcile net loss to net cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25in; padding-left: 5.4pt">provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt; padding-left: 5.4pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,751</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,089</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 9pt; padding-left: 5.4pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,140</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt; padding-left: 5.4pt">Financial expenses (income), net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(264</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Changes in accrued liability for employee rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25in; padding-left: 5.4pt">upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Gain on amounts funded in respect of employee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25in; padding-left: 5.4pt">rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Gain on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Amortization of debt issuance costs and debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10.35pt; padding-left: 28.35pt">Increase (decrease) in deferred revenues (including
    non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,160</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,170</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Decrease (increase) in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(799</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Decrease (increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,760</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,918</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,290</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding-left: 0.25in">Increase (decrease) in accounts payable and accruals
(including long term )</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,977</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">954</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 5.4pt">Net cash provided by (used in) operating
    activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">635</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,653</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,068</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,890</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(785</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Proceeds from sale of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Investment in restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(90</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Amounts funded in respect of employee rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.25in; padding-left: 5.4pt">upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 5.4pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,102</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt; padding-left: 5.4pt">Net proceeds from issuance of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">66,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 9pt; padding-left: 5.4pt">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 9pt; padding-left: 5.4pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 5.4pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,558</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,892</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">226</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">NET INCREASE (DECREASE) IN CASH AND
    CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,631</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">BALANCE OF CASH AND CASH <FONT STYLE="font-size: 10pt"><B>EQUIVALENTS
    AT BEGINNING OF YEAR</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">86,398</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">BALANCE OF CASH AND CASH
    EQUIVALENTS AT END OF YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,035</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">86,398</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,767</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(CONTINUED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt; text-indent: -9pt">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT
    INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,136</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">186</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">120</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9.2pt; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTARY DISCLOSURE ON CASH<BR> &nbsp;&nbsp;&nbsp;&nbsp;FLOWS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Interest paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0"  style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: left; padding-right: 9pt; padding-left: 9pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral
        part of the consolidated financial statements.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
</table>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_031"></A>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries,
the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development
and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein
expression system (&ldquo;ProCellEx&rdquo;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the
laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application process
in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On May 1, 2012, the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement therapy (ERT)
for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary,
recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved
by the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012, by the Brazilian Ministry of Health (the
&ldquo;Brazilian MOH&rdquo;) in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase
alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In August 2014, the FDA approved taliglucerase alfa for
injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia
and Canada but in no other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Taliglucerase alfa is being marketed in the United States
under the brand name Elelyso&trade; by Pfizer Inc. (&ldquo;Pfizer&rdquo;), the Company&rsquo;s commercialization partner, as provided
in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &ldquo;Pfizer Agreement&rdquo;). The
Company, through Protalix Ltd., markets Elelyso in Israel, and in Brazil under the brand name Uplyso&trade;. See Note 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Protalix Ltd. granted Pfizer an exclusive, worldwide license
to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014,
in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities
for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million
in connection with the execution of the Pfizer Agreement and additional $30.0 million milestone payment mainly in connection with
the FDA&rsquo;s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer
the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively,
except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retains
exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits
on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On June 18, 2013, Protalix Ltd. entered into a Supply
and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo Cruz
(&ldquo;Fiocruz&rdquo;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil
is Uplyso. The first term of the technology transfer is seven years and the agreement may be extended for an additional
five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four
stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its
own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of
taliglucerase alfa. Under the agreement, Fiocruz  committed to purchase at least approximately $40 million worth of
taliglucerase alfa during the first two years of the agreement. With respect to the first required purchase amount, the
Company has recorded revenues of approximately $3.5 million for sales of taliglucerase alfa to Fiocruz in 2014. In subsequent years, Fiocruz is required to purchase at
least approximately $40 million worth of taliglucerase alfa per year. Protalix Ltd. is not required to complete
the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase
alfa. The Brazil Agreement became effective during January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">If Fiocruz fails to comply with certain of
its purchase commitments under the agreement, the Company has the right to terminate the agreement and all rights to the
technology that were transferred to Fiocruz will be returned to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In September 2014, CONITEC, the National Commission for
Incorporation of Technologies in Brazil&rsquo;s Unified Healthcare System, announced that it had decided to give a positive funding
recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that
taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">To facilitate the arrangement with Fiocruz, Pfizer amended
its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization
and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as
defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil
on Protalix Ltd.&rsquo;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Protalix Ltd. is required to pay a fee equal to 5% of the
net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant
to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil
Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States, Brazil, Chile and Israel. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In addition to the approval of taliglucerase alfa for marketing
in the United States, Israel, Brazil and other countries, successful completion of the Company&rsquo;s development programs and
its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products
internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its
operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process
for each of its product candidates during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Obtaining marketing approval with respect to any product
candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required
to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis
of presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company&rsquo;s financial statements have been prepared
in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of estimates in the preparation of financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results may differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Functional
currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The dollar is the currency of the primary economic environment
in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&rsquo;s revenues are derived in
dollars. Most of the Company&rsquo;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&rsquo;s
financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Transactions and balances originally denominated in
dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical
and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated
below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &ndash; exchange
rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such
as depreciation and amortization, etc.) &ndash; historical exchange rates. Currency transaction gains and losses are carried to
financial income or expenses, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company considers all short-term, highly liquid
investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase,
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Inventories are valued at the lower of cost or market.
Cost of raw and packaging materials and purchased products is determined using the &ldquo;moving average&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Cost of finished products is determined as follows:
the value of the raw and packaging materials component is determined primarily on a using the &ldquo;moving average&rdquo; basis;
the value of the labor and overhead component is determined on an average basis over the production period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">If actual market prices for finished products prove
less favorable than those projected by management, inventory write-downs may be required. Inventory is written down for estimated
obsolescence based upon management assumptions about future demand and market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property
and equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 48pt; text-align: left">1.</TD><TD STYLE="text-align: justify">Property and equipment
                                         are stated at cost, net of accumulated depreciation and amortization.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 48pt">2.</TD><TD>The Company&rsquo;s assets are depreciated by the straight-line
                                         method on the basis of their estimated useful lives as follows:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 48pt"></TD><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Furniture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">10-15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Leasehold improvements are amortized by the straight-line
method over the expected lease term, which is shorter than the estimated useful life of the improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment
in value of long-lived assets: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company tests long-lived assets for impairment if an indication
of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges)
is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their
estimated fair values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income
taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
income taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Deferred taxes are determined utilizing the assets and
liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases
of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be
in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the
weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The
Company has provided a full valuation allowance with respect to its deferred tax assets. See Note 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uncertainty
in income taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Tax benefits recognized in the financial statements are
those that the Company&rsquo;s management deems at least more likely than not to be sustained, based on technical merits. The
amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&rsquo;s management deems more
likely than not to be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company recognizes revenue when the earnings process
is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists,
delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues
from the license and supply agreement with Pfizer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The Company recognizes revenue from milestone payments
received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&rsquo;s continued involvement with
respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received
from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14
years (commencing upon the date of the Company&rsquo;s receipt of the up-front license payment payable by Pfizer under the Pfizer
Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate,
based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue
recognition is recorded as revenue during the period during which the milestone is achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues
from selling products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The Company recognizes revenues from<FONT STYLE="font-size: 10pt">
</FONT>selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company&rsquo;s
share in the collaboration agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the terms and conditions of the Pfizer Agreement,
the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except
with respect to sales in Israel and Brazil (since 2014), where the Company retained exclusive marketing rights. Since Pfizer bears
most of the risks and rewards relating to the agreement, the Company&rsquo;s share in the profits and loss in the agreement is
recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it
receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under
the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included
based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year
ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>k.&nbsp;&nbsp;&nbsp;&nbsp;Research
and development costs </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Research and development costs are expensed as incurred
and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment
and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist
of Israel&rsquo;s Ministry of Industry, Trade and Labor (the &ldquo;OCS&rdquo;) are recognized when the grant becomes receivable,
provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant
and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses
as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Reimbursements received from Pfizer are recognized when
the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions
attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted
from the research and development expenses as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In connection with purchases of assets, amounts assigned
to intangible assets to be used in a particular research and development project that have no alternative future use are charged
to research and development costs at the purchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the
goods are consumed or the related services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentration
of credit risks and trade receivable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Financial instruments that potentially subject the Company
to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated
financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one
financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed
to any significant credit risk on these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company&rsquo;s trade receivables represent amounts
to be received from Pfizer and the Company&rsquo;s customers in Israel. The Company does not require Pfizer or any of its Israeli
customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer&rsquo;s financial
condition and believes there is no significant risk with respect to Pfizer&rsquo;s payment of the receivables. As all Israeli
customers are government entities, the Company believes there is no significant risk with respect to its receivables from such
entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>m.&nbsp;&nbsp;&nbsp;&nbsp;Share-based
compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company accounts for employee&rsquo;s share-based
payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions
is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures
based on historical experience and anticipated future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company elected to recognize compensation cost for
an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option
award approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">When stock options are granted as consideration for
services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options
issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related
service period using the straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
loss per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Diluted LPS does not include 7,280,469, 10,675,304 and
18,850,724 shares of Common Stock underlying outstanding options, restricted shares of Common Stock and shares issuable upon
conversion of the convertible notes (issued in September 2013) for the fiscal years ended December 31, 2012, 2013 and 2014, respectively,
because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt"><B>o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible
notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in">The convertible notes are accounted
for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine
whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible
notes as a liability, on an aggregated basis, in their entirely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt"><B>p.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recently
issued accounting pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in">In August 2014, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued amended guidance related to the disclosure of uncertainties about an entity's ability to continue
as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity&rsquo;s
ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective
date of December 31, 2016. The Company believes that the adoption of this new standard will not have a material impact on its consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in">In May 2014, the FASB issued guidance on revenue from
contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The
underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount
that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of
transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract
costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be
recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding
the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance
is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The
guidance permits the use of either a retrospective or cumulative effect transition method. The Company is currently evaluating
the potential effect of the amended guidance on its consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 2 - LICENSE AND SUPPLY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">On November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered
into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase
alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize
taliglucerase alfa in Israel. As mentioned in Note 1, in June 2013, Pfizer returned the commercialization rights in Brazil to
Protalix Ltd. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with
the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $5.0 million upon the Company&rsquo;s filing
of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $25.0 million milestone
payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to 40% of the
results (profits or losses) earned on Pfizer&rsquo;s sales of taliglucerase alfa. Such result (profit or loss) will be calculated
while, in addition to other adjustments, taking into account Protalix Ltd.&rsquo;s cost of goods sold and Pfizer&rsquo;s commercial
expenses, with certain expenses capped or borne solely by one party (&ldquo;Collaboration Operation&rdquo;). As of December 31,
2014 and 2013, the Company accrued a liability in respect of its share in the <FONT STYLE="font: 10pt Times New Roman, Times, Serif">accumulated
losses of the collaboration operation equal to</FONT> approximately $7.1 million and $8.0 million, respectively. After deducting
the losses, the Company is entitled to receive in cash its share in the profits of the collaboration operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company has determined that the initial, non-refundable
upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line
basis as revenue over the estimated relationship period (approximately $4.6 million per year). The Company has estimated that
the relationship period for its arrangement with Pfizer will be approximately 14 years (commencing upon the Company&rsquo;s receipt
of the up-front license payment) based on the Company&rsquo;s last material patent relating to taliglucerase alfa to expire. The
$25.0 million milestone payment received during 2012 in connection with the FDA&rsquo;s approval of taliglucerase alfa in the
United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded
as revenue during the period in which the milestone was achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 - LICENSE AND SUPPLY AGREEMENT </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company&rsquo;s deliverables under this collaboration
include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain
research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase
alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">According to the terms and conditions of the Pfizer Agreement,
the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company
for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments
received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 3 - PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD>Composition of property and equipment grouped by major
                                         classifications is as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">14,858</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">15,138</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,154</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equipment under construction</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 7.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">32,030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">32,736</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less &ndash; accumulated depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,711</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.3pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify">Depreciation
                                         and amortization in respect of property and equipment totaled approximately $3.7 million,
                                         $3.5 million and $3.1 million for the years ended December 31, 2012, 2013 and 2014, respectively.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 4 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD>Inventories at December&nbsp;31, 2013 and 2014 consisted
                                         of the following:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"></TD><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,342</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,616</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,919</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify">During
                                         the years ended December 31, 2013 and 2014, the Company recorded approximately $1.6 million
                                         and $1.7 million, respectively, for write-down of inventory under cost of revenues.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON
RETIREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Israeli Subsidiary is required to make a severance
payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability
to the employees (based upon length of service and the latest monthly salary - one month&rsquo;s salary for each year employed)
is recorded on the Company&rsquo;s balance sheets under &ldquo;Liability for employee rights upon retirement.&rdquo; The liability
is recorded as if it were payable at each balance sheet date on an undiscounted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The liability is funded in part from the purchase of
insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these
liabilities are included in the Company&rsquo;s balance sheets under &ldquo;Funds in respect of employee rights upon retirement.&rdquo;
These policies are the Company&rsquo;s assets. However, under labor agreements and subject to certain limitations, any policy
may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended
December 31, 2012, 2013 and 2014, the Company deposited approximately<B> </B>$177,000, $194,000 and $195,000, respectively, with
insurance companies in connection with its severance payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">In accordance with the current employment agreements
with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable
employee in order to secure the employee&rsquo;s rights upon retirement. The Company is fully relieved from any severance pay
liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect
of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&rsquo;s balance
sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have
been irrevocably transferred to the applicable insurance companies (the &ldquo;Contribution Plans&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The amounts of severance pay expenses were approximately
$1.0 million for each of the years ended December 31, 2012, 2013 and 2014, of which approximately<B> </B>$670,000, $801,000 and
$779,000 in the years ended December 31, 2012, 2013 and 2014, respectively, were in respect of a Contribution Plan. Gain on amounts
funded in respect of employee rights upon retirement totaled approximately<B> </B>$36,000, $58,000 and $22,000 for the years ended
December 31, 2012, 2013 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company expects to contribute approximately $863,000
in the year ending December 31, 2015 to insurance companies in connection with its severance liabilities for its operations for
that year, approximately<B> </B>$685,000 of which will be contributed to one or more Contribution Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">During the five-year period following December 31, 2014,
the Company expects to pay future benefits to three<B> </B>employees upon each such employee&rsquo;s normal retirement age. The
Company anticipates that the benefits payable will be immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 6 - COMMITMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty
Commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development
activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of
the related projects was not assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In the case of failure of a project that was partly financed
as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the terms of the funding arrangements with the OCS,
royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall not
exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&nbsp;1, 2001,
interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government
grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of
the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly,
an increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Royalty expenses to the OCS are included in the statement
of operations as a component of the cost of revenues and were approximately $1.5 million, $392,000 and $951,000 during the years
ended December&nbsp;31, 2012, 2013 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">At December 31, 2014, the maximum royalty amount payable
by the Company under these funding arrangements is approximately $30 million (without interest, assuming 100% of the funds are
payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 6 &ndash; COMMITMENTS</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties
at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range
of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations
as a component of the cost of revenues and were approximately $674,000, $80,000 and $104,000 during the years ended December&nbsp;31,
2012, 2013 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under each agreement, the Company is also obligated to
pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for
varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the
research and license agreements are met, the aggregate milestone payments payable would be approximately $0.3 million and would
be payable, if at all, as the Company&rsquo;s projects progress over the course of a number of years. No milestone payments were
made during 2012, 2013 and 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">None of the agreements has a fixed termination date. Subject
to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial
sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales
of any product under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subcontracting
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company has entered into sub-contracting agreements
with several clinical providers and consultants<B> </B>in Israel, the United States and certain other countries in connection
with its primary product development process. As of December 31, 2014, total commitments under said agreements were approximately
$1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company is a party to a number of lease agreements
for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three
occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental
payments are approximately $85,000. As of December 31, 2014, the Company provided bank guarantees of approximately $315,000 ,
in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required
in each of the next three years under the operating leases for such premises are approximately as follows: 2015 - $1,014,000,
2016 &ndash; $1,009,000, 2017 $1,009,000. Lease expenses totaled approximately $971,000, $1,133,000 and $1,044,000 for the years
ended December 31, 2012, 2013 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vehicle
Lease and Maintenance Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company entered into several three-year lease and
maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate
approximately $51,000. The expected lease payments for the years ending December 31, 2015, 2016 and 2017 are approximately $504,000,
$289,000 and $118,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 7 - SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights
of the Company&rsquo;s common stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company&rsquo;s common stock is listed on the NYSE
MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders
of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by
the Board of Directors. Since its inception, the Company has not declared any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 7 SHARE CAPITAL</B> (continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
based compensation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">On December 14, 2006, the Board of
Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &ldquo;Plan&rdquo;). The Plan has since
been amended to, among other things, increase the number of shares of common stock available under the plan to
13,841,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by
Sections&nbsp;102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the
Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the
Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including
amounts recorded as salary benefits in the Company&rsquo;s accounts, in respect of options granted to employees under the
Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli
non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">As of December 31, 2014, 1,923,444 shares of Common
Stock remain available for grant under the Plan.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">For purposes of determining the fair value of the options
and restricted stock granted to employees and non-employees, the Company&rsquo;s management uses the fair value of the Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">From January 1, 2012 through December 31, 2014, the
Company granted options and shares of restricted stock to certain employees and non-employees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Options
and restricted stock granted to employees:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>Below is a table summarizing all of the options and restricted
                                         stock grants to employees for each year of the three-year period ended December 31, 2014:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 81%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year of<BR> grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No. of options<BR> or
    restricted<BR> stock granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> price range</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value<BR> at grant<BR>
    (U.S.<BR> dollars in<BR> thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration<BR> period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2012</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">400,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">n/a</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,288</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">n/a</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2014</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">900,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2.37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">4 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">10 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Set forth below are grants made by the Company to employees
(including related parties) during the three-year period ended December 31, 2014 (such grants appear in the table above):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in">On July 16, 2012, the Company&rsquo;s
Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees.
Of such restricted stock, 1,100,000 of the shares were issued to the Company&rsquo;s named executive officers and vest in 16 equal,
quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period,
commencing upon the applicable vesting dates. Immediately and automatically in the event of a Corporate Transaction or a Change
in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named
executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares
of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year
period, commencing upon the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in">On September 28, 2014, the Company&rsquo;s
Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase 900,000 shares
of Common Stock to its then newly appointed President and Chief Executive Officer with an exercise price of $2.37 per share. The
options vest over a four-year period in 16 equal quarterly increments. Vesting of the options will be accelerated in full upon
a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, as amended. The Company estimated the
fair value of the options on the date of grant, using the Black-Scholes option-pricing model, to be approximately $1 million based
on the following weighted average assumptions: dividend yield of 0% for all years; expected volatility of 62%; risk-free interest
rate of 1.86%; and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>The fair value of restricted stock granted during the year ended
                                         December 31, 2012 was $8.6 million based on the Company&rsquo;s share price on the NYSE
                                         MKT on the grant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The total unrecognized compensation cost of employee
stock options and restricted stock at December 31, 2014 is approximately $1.4 million (net of forfeiture rate). The unrecognized
compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.0 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The total cash received from employees as a result of
employee stock option exercises for the years ended December 31, 2012, 2013 and 2014 was approximately $1.2 million, $112,000
and $46,000, respectively. The Company did not realize any tax benefit in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">During 2014, the Company issued 133,930 shares of Common
Stock in connection with the exercise of 139,388 options by certain employees of the Company. The Company received cash proceeds
equal to approximately $46,000 in connection with such exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Options
granted to consultants, directors, and other service providers:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in">On July 24, 2014, the Company&rsquo;s Board of Directors approved,
subject to certain terms and conditions, the grant of a 10-year option to purchase 150,000 shares of Common Stock to its then newly
elected chairman of the Board of Directors with an exercise price equal to $3.37 per share. The options vest over a three-year
period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly
increments over the subsequent two-year period. Vesting of the options are subject to acceleration in full upon a Corporate Transaction
or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date
of grant using the Black-Scholes option-pricing model to be approximately $193,000 based on the following weighted average assumptions:
dividend yield of 0% for all years; expected volatility of 62%; risk-free interest rates of 1.9%; and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">No cash was received from consultants as a result of consultant
stock option exercises for the years ended December 31, 2013 and 2014. Approximately $39,000 was received during the year ended
December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">During 2013 and 2014, no shares of Common Stock were issued
in connection with the exercise of options by consultants of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of share option plans, and related information, under all of the Company&rsquo;s equity incentive plans for the years
ended December&nbsp;31, 2012, 2013 and 2014 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Options granted to employees:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"></TD><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; text-indent: -9pt; padding-left: 9pt">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,141,030</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,253,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.923</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,153,898</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.951</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 15.95pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.370</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 15.95pt">Forfeited and Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,858</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.372</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,201</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.833</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">861,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.418</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">139,388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.446</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,253,579</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.923</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,153,898</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.951</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,870,309</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.770</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,258,441</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.201</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,614,148</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.591</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,905,559</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.933</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(*)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The total intrinsic value
of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately </FONT>$4.8 million, $306,000
and $447,000<FONT STYLE="font-size: 10pt">, respectively.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-indent: -14.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Restricted stock granted to employees:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Restricted
    Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: center">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,394,708</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">970,208</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 15.95pt">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">185,709</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,394,708</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">970,208</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">386,124</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Options and restricted stocks granted to consultants, directors,
                                         and other service providers:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; text-indent: -9pt; padding-left: 9pt">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,238,692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5.385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">912,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7.259</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">912,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7.259</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">296,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.678</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">326,267</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">912,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">912,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,208,592</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.136</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">912,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">912,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">912,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">(*) &#9;The total intrinsic value
of options exercised during the year ended December 31, 2012 was approximately </FONT>$2.3 million<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B><BR></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>The following tables summarize information concerning outstanding
                                         and exercisable options and restricted stock as of December 31, 2014:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options and restricted stock
    <BR>outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise <BR>prices</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR>options and<BR>
    restricted stock <BR>outstanding <BR>at end of <BR>year</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR>average <BR>remaining
    <BR>contractual <BR>life</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> options<BR> exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR>average <BR>remaining
    <BR>contractual <BR>life</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: center">n/a (Restricted Stock)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">490,624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">n/a</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">n/a</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;n/a</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 27%">0.001</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 15%">719,207</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 15%">0.54</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 15%">719,207</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 15%">0.54</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">0.120</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,801</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,801</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">0.972</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995,853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995,853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2.350</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2.370</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2.650</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">3.020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">3.370</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">5.000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">6.810</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">6.900</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">991,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">829,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">7.550</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">9.660</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">$</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt">16.700</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,465,025</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,817,984</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate intrinsic value of the total outstanding options
and restricted stock and of total vested and exercisable options as of December 31, 2014 is approximately $3.6 million and $2.7
million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">e.</TD><TD>The following table illustrates the effect of share-based compensation
                                         on the statement of operations:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: -12.6pt; padding-left: 12.6pt">Cost of revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,756</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">936</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12.6pt; padding-left: 12.6pt">Marketing, General and administrative
    expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,434</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">306</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,751</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,089</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,242</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Public
and 144A Offerings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February 22,&nbsp;2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price
to the public of $5.25 per share. The net proceeds to the Company were approximately $25.4 million (net of underwriting commissions
and issuance costs of $1.8 million).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September 18, 2013, the Company completed a private offering of 4.50% convertible notes due 2018. The net proceeds from the offering,
including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million
in aggregate principal amount of the Notes, were $66.8 million (net of the initial purchaser&rsquo;s discount and commission and
offering expenses payable by the Company). See also Note 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 8 - CONVERTIBLE NOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">On September 18, 2013, the Company
completed a private placement of $69.0 million in aggregate principal amount of Notes, including $9.0 million aggregate principal
amount of Notes related to the initial purchaser&rsquo;s over-allotment option, which was exercised in full. In connection with
the completion of the offering, the Company entered into an indenture (the &ldquo;Indenture&rdquo;) with The Bank of New York
Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of 4.50% per year, payable semiannually
in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">The net proceeds from the offering,
including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million
in aggregate principal amount of the Notes, were $66.8 million, after deducting the initial purchaser&rsquo;s discount and commission
and offering expenses payable by the Company. The debt discount and debt issuance costs are deferred and amortized over the convertible
notes period (5 years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">Holders may convert their Notes at
any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate
for the Notes is 173.6593 shares of the Common Stock for each $1,000 principal amount of Notes (equivalent to an initial conversion
price of approximately $5.76 per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common
Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some
events but will not be adjusted for any accrued and unpaid interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in">Prior to September 19, 2016, the
Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may
redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with
a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion
price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending
on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price
will equal the sum of (i) 100% of the principal amount of the Notes being redeemed, plus (ii) accrued and unpaid interest, including
additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining
scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from
the redemption date to the maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">The following table sets forth total interest expense
recognized for the years ended December 31, 2013 and 2014 related to the Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">(U.S. Dollars in thousands)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -10pt; padding-left: 10pt">Contractual interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">888</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Amortization of debt issuance costs
    and debt discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,015</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,549</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 9 - FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">The accounting standard establishes a fair value hierarchy
that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 9 - FAIR VALUE MEASUREMENT </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to
Level 1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">Level 3: Unobservable inputs are used when little or
no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">In determining fair value, the Company utilizes valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt">The fair value of the convertible notes as of December
31, 2014 is approximately $52.4 million based on level 2 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 10 - TAXES ON INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><B>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Protalix BioTherapeutics, Inc. is taxed according to
U.S. tax laws. The Company&rsquo;s income is taxed in the United States at the rate of up to 39%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Israeli Subsidiary is taxed according to Israeli
tax laws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Measurement
of results for tax purposes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Since 2008, the Company has measured the results of the
Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation),
1985, the Subsidiary&rsquo;s results for tax purposes have been measured through 2007 on a real basis, based on changes in the
Israel consumer price index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax
rates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The income of the Israeli Subsidiary, other than income
from &ldquo;Approved Enterprises,&rdquo; is taxed in Israel at the regular rates which were 25% in 2012 and 2013 and 26.5% for 2014 and thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 10 &ndash; TAXES ON INCOME </B>(continued)<B>:</B><BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Capital gain is subject to capital gain tax
according to corporate tax rate in the year of selling the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>The
Law for the Encouragement of Capital Investments, 1959 (the &ldquo;Encouragement of Capital Investments Law&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the Encouragement of Capital Investments Law, including
Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &ldquo;Approved
Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; status the Israeli Subsidiary is entitled to various tax benefits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Reduced
tax rates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Income derived from the Approved Enterprise during a
10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the
maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary has an &ldquo;Approved Enterprise&rdquo;
plan since 2004 and &ldquo;Benefited Enterprise&rdquo; plan since 2009. The period of benefits in respect of the main enterprise
of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">If the Israeli Subsidiary subsequently pays a dividend
out of income derived from the &ldquo;Approved Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; during the tax exemption
period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would
have been applicable had such income not been exempted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">In addition to the corporate taxes in Israel, the Company
might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of
Pfizer&rsquo;s net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Accelerated
depreciation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery
and equipment used by the Approved Enterprise and the Benefited Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Conditions
for entitlement to the benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary&rsquo;s entitlement to the benefits
described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli
Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount
of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect
to its &ldquo;Approved Enterprise&rdquo; from the Investment Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment
of the Law for the Encouragement of Capital Investments, 1959</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Encouragement of Capital Investments Law was amended
as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the
&ldquo;Capital Investments Law Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Capital Investments Law Amendment sets alternative
benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 10 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The benefits granted to the Benefited Enterprises will
be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period.
The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria
are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Under the transitional provisions of the Encouragement
of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of
Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital
Investments Law. The Company will be allowed to set the &ldquo;year of election&rdquo; no later than tax year 2012, provided that
the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company
will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above
available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not
to have the Capital Investments Amendment apply to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><B>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Tax
losses carried forward to future years</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">As of December 31, 2014, the Company had aggregate net
operating loss (NOL) carry-forwards equal to approximately $138.8 million that are available to reduce future taxable income as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;<B>The
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The NOL carry-forward of the Company equal to approximately
$16.9 million may be restricted under Section 382 of the Internal Revenue Code (&ldquo;IRC&rdquo;). IRC Section 382 applies whenever
a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change
year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value
of the pre-change entity multiplied by the IRC long-term tax exempt rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Protalix
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">At December 31, 2014, the Israeli Subsidiary had approximately
$121.9 million of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 10 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"><B>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The components of the Company&rsquo;s net deferred tax
assets at December 31, 2013 and 2014 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>In respect of:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(491</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(372</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Provision for vacation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Severance pay obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,658</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Net operating loss carry forwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40,111</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Deferred taxes are computed using the tax rates expected
to be in effect when those differences reverse. The Company used tax rates of 39%, 26.5% and 0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reconciliation
of the theoretical tax expense to actual tax expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The main reconciling item between the statutory tax
rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry
forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><B>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
assessments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In accordance with the Income Tax Ordinance, as of December
31, 2014, all of Protalix Ltd.&rsquo;s tax assessments through tax year 2010<FONT STYLE="font-size: 10pt"> </FONT>are considered
final.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">A summary of open tax years by major jurisdiction is
presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; font-weight: bold; text-decoration: none; text-align: left; border-bottom: Black 1pt solid; padding-left: 0">Jurisdiction:</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 15%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><B>Years:</B></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Israel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2011-2014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">United States (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2010-2014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">(*) Includes federal, state and local (or similar provincial
jurisdictions) tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt">&nbsp;<B>PROTALIX BIOTHERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 11 - </B> <B>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>Balance sheets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -26.45pt; padding-left: 26.45pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
    assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 0.5in">Institutions</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">356</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">124</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">State of Israel (see Note&nbsp;6a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.5in">Sundry</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,457</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,202</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">(U.S. dollars in thousands)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accruals
    &ndash; other:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0.5in">Payroll and related expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,557</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,243</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">914</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Provision for vacation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Royalties payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">495</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Liability in connection with collaboration operation - current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Property and equipment suppliers</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,073</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,496</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Statements of operations:</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic">(U.S. dollars in thousands)</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues:</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 0.5in">Deferred revenues from the license and supply agreement with
    Pfizer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Milestone payment (see Note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Revenues from selling products</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,916</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,088</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -28.85pt; padding-left: 28.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,870</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,479</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,651</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>NOTE 12 - RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 0; padding-left: 9pt; text-indent: -9pt">Compensation (including
    share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2014 and the
    Chairman of the Board for part of 2014)</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">375</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">509</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">560</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>v403470_ex3-6.htm
<DESCRIPTION>EXHIBIT 3.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">PROTALIX BIOTHERAPEUTICS, INC., a Florida
corporation (the &ldquo;Corporation&rdquo;), hereby adopts the following Articles of Amendment to its Articles of Incorporation
(the &ldquo;Amendment&rdquo;), pursuant to the provisions of Section 607.1003 of the Florida Business Corporation Act (the &ldquo;Act&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. The Articles of Incorporation of the
Corporation are hereby amended to adopt a new Article XII, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&ldquo;Article XII-Quorum
for Shareholder Meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">One third (1/3) of the shares
entitled to be cast on any matter by a voting group shall constitute a quorum of that voting group for action on that matter.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The Amendment was approved and adopted
by the Board of Directors of the Corporation at a meeting held on September 4, 2014 and by the holders of the common stock of the
Corporation at a meeting of shareholders held on November 10, 2014. The holders of the common stock of the Corporation are the
only voting group entitled to vote on the Amendment, and the vote of the holders of the shares of common stock was sufficient to
approve the Amendment under the Act and the Articles of Incorporation and Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp; The Amendment
shall become effective as of the close of business on the date of the filing of the Amendment with the Secretary of State of the
State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned has
executed these Articles of Amendment as of this 17th day of December, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">PROTALIX BIOTHERAPEUTICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">/s/ Moshe Manor</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: &nbsp;&nbsp;Moshe Manor</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-indent: 0.125in">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>3
<FILENAME>v403470_ex3-7.htm
<DESCRIPTION>EXHIBIT 3.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Adopted November 10, 2014)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.1 Registered Office.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registered office of the corporation
in the State of Florida shall be 1201 Hays Street, Tallahassee, Florida 32301.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.2 Other Offices.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The corporation shall also have and maintain
an office or principal place of business at 2 Snunit Street, Science Park, PO Box 455, Carmiel Israel 20100, and may also have
offices at such other places, both within and without the State of Florida, as the Board of Directors may from time to time determine
or the business of the corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.3 Registered Agent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors shall designate a
registered agent for service of process on the corporation for the State of Florida and for each state in which the corporation
qualifies to do business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHAREHOLDERS&rsquo; MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.1 Place of Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings
of shareholders may be held at such place, either within or without this State, as may be designated by or in the manner provided
in these Bylaws or, if not so designated, as determined by the Board of Directors. The Board of Directors may, in its sole discretion,
determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as authorized
by paragraph (b) of this Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors
may adopt, shareholders and proxyholders not physically present at a meeting of shareholders may, by means of remote communication:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participate
in a meeting of shareholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be
deemed present in person and vote at a meeting of shareholders whether such meeting is to be held at a designated place or solely
by means of remote communication, provided that (A) the corporation shall implement reasonable measures to verify that each person
deemed present and permitted to vote at the meeting by means of remote communication is a shareholder or proxyholder, (B) the corporation
shall implement reasonable measures to provide such shareholders and proxyholders a reasonable opportunity to participate in the
meeting and to vote on matters submitted to the shareholders, including an opportunity to read or hear the proceedings of the meeting
substantially concurrently with such proceedings, and (C) if any shareholder or proxyholder votes or takes other action at the
meeting by means of remote communication, a record of such vote or other action shall be maintained by the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section 2.1, &ldquo;remote communication&rdquo;
shall include (1) telephone or other voice communications and (2) electronic mail or other form of written or visual electronic
communications satisfying the requirements of Section 2.11(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.2 Annual Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">The annual meetings of the shareholders
of the corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall
be held on such date and at such time as may be designated from time to time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.3 Special Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Special Meetings of the shareholders of
the corporation may be called, for any purpose or purposes, by the Chairman of the Board or the President or the Board of Directors
at any time. Upon written request of any shareholder or shareholders holding in the aggregate not less than 10% of all of the votes
entitled to be cast on any issue proposed to be considered at the Special Meeting signed, dated and delivered in person or sent
by registered mail to the Chairman of the Board, President or Secretary of the corporation, the Secretary shall call a special
meeting of shareholders to be held at the principal office of the corporation or at such place and at such time as the Secretary
may fix, such meeting to be held not less than 10 nor more than 60 days after the receipt of such request, and if the Secretary
shall neglect or refuse to call such meeting within seven days after the receipt of such request, the shareholder making such request
may do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.4 Notice of Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law or the corporation&rsquo;s Articles of Incorporation, as amended, written notice of each meeting of
shareholders, specifying the place, if any, date and hour and purpose or purposes of the meeting, and the means of remote communication,
if any, by which shareholders and proxyholders may be deemed to be present in person and vote at such meeting shall be given not
less than 10 nor more than 60 days before the date of the meeting to each shareholder entitled to vote thereat, directed to his,
her or its address as it appears upon the books of the corporation; except that where the matter to be acted on is a merger or
consolidation of the corporation or a sale, lease or exchange of all or substantially all of its assets, such notice shall be given
not less than 20 nor more than 60 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any meeting action is proposed to be taken which, if taken, would entitle shareholders fulfilling the requirements of Section
607.1302 of the Florida Business Corporation Act to an appraisal of the fair value of their shares, the notice of such meeting
shall contain a statement of that purpose and to that effect and shall be accompanied by a copy of Sections 607.1301 through 607.1333
of the Florida Business Corporation Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time, place, if any,
thereof, and the means of remote communication, if any, by which shareholders and proxyholders may be deemed to be present in person
and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken unless the adjournment is for
more than 30 days, or unless after the adjournment a new record date is fixed for the adjourned meeting, in which event a notice
of the adjourned meeting shall be given to each shareholder of record entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of the time, place and purpose of any meeting of shareholders may be waived in writing, either before or after such meeting, and,
to the extent permitted by law, will be waived by any shareholder by his attendance thereat, in person or by proxy. Any shareholder
so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof
had been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the manner by which notice otherwise may be given effectively to shareholders, any notice to shareholders given by the
corporation under any provision of the Florida Business Corporation Act, the corporation&rsquo;s Articles of Incorporation, as
amended, or these Amended and Restated Bylaws shall be effective if given by a form of electronic transmission consented to by
the shareholder to whom the notice is given. Any such consent shall be revocable by the shareholder by written notice to the corporation.
Any such consent shall be deemed revoked if (i) the corporation is unable to deliver by electronic transmission two consecutive
notices given by the corporation in accordance with such consent and (ii) such inability becomes known to the secretary or an assistant
secretary of the corporation or to the transfer agent or other person responsible for the giving of notice; <U>provided</U>, <U>however</U>,
the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given
pursuant to this subparagraph (e) shall be deemed given: (1) if by facsimile telecommunication, when directed to a number at which
the shareholder has consented to receive notice; (2) if by electronic mail, when directed to an electronic mail address at which
the shareholder has consented to receive notice; (3) if by a posting on an electronic network together with separate notice to
the shareholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and (4)
if by any other form of electronic transmission, when directed to the shareholder. An affidavit of the Secretary or an assistant
secretary or of the transfer agent or other agent of the corporation that the notice has been given by a form of electronic transmission
shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of these Amended and Restated
Bylaws, &ldquo;electronic transmission&rdquo; means any form of communication, not directly involving the physical transmission
of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced
in paper form by such a recipient through an automated process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.5 Quorum and Voting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
all meetings of shareholders except where otherwise provided by law, the corporation&rsquo;s Articles of Incorporation or these
Amended and Restated Bylaws, the presence, in person or by proxy duly authorized, of the holders of at least one-third (33 1/3%)
of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. Shares, the voting
of which at said meeting have been enjoined, or which for any reason cannot be lawfully voted at such meeting, shall not be counted
to determine a quorum at said meeting. In the absence of a quorum, any meeting of shareholders may be adjourned, from time to time,
by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting.
At such adjourned meeting at which a quorum is present or represented, any business may be transacted which might have been transacted
at the original meeting. The shareholders present at a duly called or convened meeting at which a quorum is present may continue
to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum. </FONT>
<FONT STYLE="font-size: 10pt">Abstentions and &quot;broker non-votes&quot; are counted as present and entitled to vote for purposes
of determining a quorum. A &quot;broker non-vote&quot; occurs when a broker holding shares for a beneficial owner does not vote
on a particular proposal because the broker does not have discretionary voting power for that particular item and has not received
instructions from the beneficial owner. Abstentions and, if applicable, broker non-votes, are not counted as votes &quot;for&quot;
or &quot;against&quot; any proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law, the corporation&rsquo;s Articles of Incorporation or these Amended and Restated Bylaws, action on
a matter (other than the election of directors) by a voting group is approved if the votes cast within the voting group favoring
the action exceed the votes cast opposing the action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
a separate vote by a class or classes is required, at least one-third (33 1/3%) of the outstanding shares of such class or classes
present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter,
and the affirmative vote of the majority of shares of such class or classes present in person or represented by proxy at the meeting
shall be the act of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.6 Voting Rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law, only persons in whose names shares entitled to vote stand on the stock records of the corporation
on the record date for determining the shareholders entitled to vote at said meeting shall be entitled to vote at such meeting.
Shares standing in the names of two or more persons shall be voted or represented in accordance with the determination of the majority
of such persons, or, if only one of such persons is present in person or represented by proxy, such person shall have the right
to vote such shares and such shares shall be deemed to be represented for the purpose of determining a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
person entitled to vote or to execute consents shall have the right to do so either in person or by an agent or agents authorized
by a written proxy executed by such person or his duly authorized agent, which proxy shall be filed with the Secretary of the corporation
at or before the meeting at which it is to be used. Said proxy so appointed need not be a shareholder. No proxy shall be voted
on after eleven (11) months from its date unless the proxy provides for a longer period. Unless and until voted, every proxy shall
be revocable at the pleasure of the person who executed it or of his legal representatives or assigns, except in those cases where
an irrevocable proxy permitted by statute has been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the manner in which a shareholder may authorize another person or persons to act for him as proxy pursuant to subsection
(b) of this section, the following shall constitute a valid means by which a shareholder may grant such authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
shareholder may execute a writing authorizing another person or persons to act for him as proxy. Execution may be accomplished
by the shareholder or his authorized officer, director, employee or agent signing such writing or causing his or her signature
to be affixed to such writing by any reasonable means including, but not limited to, by facsimile signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
shareholder may authorize another person or persons to act for him as proxy by transmitting or authorizing the transmission of
a telephone, telegram, cablegram or other means of electronic transmission to the person who will be the holder of the proxy or
to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder
of the proxy to receive such transmission, provided that any such telephone, telegram, cablegram or other means of electronic transmission
must either set forth or be submitted with information from which it can be determined that the telephone, telegram, cablegram
or other electronic transmission was authorized by the shareholder. Such authorization can be established by the signature of the
shareholder on the proxy, either in writing or by a signature stamp or facsimile signature, or by a number or symbol from which
the identity of the shareholder can be determined, or by any other procedure deemed appropriate by the inspectors or other persons
making the determination as to due authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to subsection
(c) of this section may be substituted or used in lieu of the original writing or transmission for any and all purposes for which
the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction
shall be a complete reproduction of the entire original writing or transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.7 Voting Procedures and Inspectors of Elections.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
corporation shall, in advance of any meeting of shareholders, appoint one or more inspectors to act at the meeting and make a written
report thereof. The corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to
act. If no inspector or alternate is able to act at a meeting of shareholders, the person presiding at the meeting shall appoint
one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his duties, shall take and
sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his, her or its
ability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
inspectors shall (i) ascertain the number of shares outstanding and the voting power of each, (ii) determine the shares represented
at a meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable
period a record of the disposition of any challenges made to any determination by the inspectors and (v) certify their determination
of the number of shares represented at the meeting and their count of all votes and ballots. The inspectors may appoint or retain
other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
date and time of the opening and the closing of the polls for each matter upon which the shareholders will vote at a meeting shall
be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by
the inspectors after the closing of the polls unless a court of competent jurisdiction, upon application by shareholders entitled
to vote at said meeting shall determine otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies,
any envelopes submitted with those proxies, any information provided in accordance with the Florida Business Corporation Act, ballots
and the regular books and records of the corporation, except that the inspectors may consider other reliable information for the
limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons
which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the shareholder
holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors
at the time they make their certification pursuant to subsection (b)(v) of this section shall specify the precise information considered
by them including the person or persons from whom they obtained the information, when the information was obtained, the means by
which the information was obtained and the basis for the inspectors&rsquo; belief that such information is accurate and reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.8 List of Shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The officer who has charge of the stock ledger of the corporation
shall prepare and make, or shall cause to be prepared at least 10 days before every meeting of shareholders, a complete list of
the shareholders entitled to vote at said meeting showing the address of and the number of shares registered in the name of each
shareholder. The corporation need not include electronic mail addresses or other electronic contact information on such list. Such
list shall be open to the examination of any shareholder for any purpose germane to the meeting for a period of at least 10 days
prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access
to such list is provided with the notice of the meeting, or (ii) during ordinary business hours at the principal place of business
of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation
may take reasonable steps to ensure that such information is available only to shareholders of the corporation. If the meeting
is to be held at a place other than the principal office of the corporation, the list shall be produced and kept at the time and
place of the meeting during the whole time thereof, and may be inspected by any shareholder who is present. If the meeting is to
be held solely by means of remote communication, then the list shall also be open to the examination of any shareholder during
the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall
be provided with the notice of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.9 Shareholder Proposals at Annual Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At an annual meeting of the shareholders, only such business
shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business
must be specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors,
otherwise properly brought before the meeting by or at the direction of the Board of Directors, or otherwise properly brought before
the meeting by a shareholder. In addition to any other applicable requirements for business to be properly brought before an annual
meeting by a shareholder, whether or not the shareholder is seeking to have a proposal included in the corporation&rsquo;s proxy
statement or information statement under any applicable rule of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
including, but not limited to, Regulation 14A or Regulation 14C under the Securities and Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;), the shareholder must have given timely notice thereof in writing to the Secretary of the corporation.
To be timely, a shareholder&rsquo;s notice must be delivered to or mailed and received at the principal executive offices of the
corporation not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy materials
(or, in the absence of proxy materials, its notice of the meeting) for the previous year&rsquo;s annual meeting of shareholders
(or the date on which the corporation mails such materials for the current year if during the prior year the corporation did not
hold an annual meeting or if the date of the annual meeting was changed more than 30 days from the prior year). A shareholder&rsquo;s
notice to the Secretary shall set forth as to each matter the shareholder proposes to bring before the annual meeting (i) a brief
description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the
annual meeting, (ii) the name and record address of the shareholder proposing such business, (iii) the class and number of shares
of the corporation which are beneficially owned by the shareholder, (iv) any material interest of the shareholder in such business,
(v) as to the shareholder giving the notice and any Shareholder Associated Person (as defined below), whether and the extent to
which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement,
arrangement or understanding (including, but not limited to, any short position or any borrowing or lending of shares of stock)
has been made, the effect or intent of which is to mitigate loss or increase profit to or manage the risk or benefit of stock price
changes for, or to increase or decrease the voting power of, such shareholder or any such Shareholder Associated Person with respect
to any share of stock of the corporation (each, a &ldquo;Relevant Hedge Transaction&rdquo;), and (vi) as to the shareholder giving
the notice and any Shareholder Associated Person, to the extent not set forth pursuant to the immediately preceding clause, (a)
whether and the extent to which such shareholder or Shareholder Associated Person has direct or indirect beneficial ownership of
any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege
or a settlement payment or mechanism at a price related to any class or series of shares of the corporation, whether or not such
instrument or right shall be subject to settlement in the underlying class or series of capital stock of the corporation or otherwise,
or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value
of shares of the corporation (a &ldquo;Derivative Instrument&rdquo;), (b) any rights to dividends on the shares of the corporation
owned beneficially by such shareholder that are separated or separable from the underlying shares of the corporation, (c) any proportionate
interest in shares of the corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership
in which such shareholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner and
(d) any performance-related fees (other than an asset-based fee) that such shareholder is entitled to based on any increase or
decrease in the value of shares of the corporation or Derivative Instruments, if any, as of the date of such notice, including
without limitation any such interests held by members of such shareholder&rsquo;s immediate family sharing the same household (which
information shall be supplemented by such shareholder and beneficial owner, if any, not later than 10 days after the record date
for the meeting to disclose such ownership as of the record date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section 2.9 and Section 2.10, &ldquo;Shareholder
Associated Person&rdquo; of any shareholder shall mean (i) any person controlling or controlled by, directly or indirectly, or
acting in concert with, such shareholder, (ii) any beneficial owner of shares of stock of the corporation owned of record or beneficially
by such shareholder and (iii) any person controlling, controlled by or under common control with such Shareholder Associated Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding anything in these Amended and Restated Bylaws
to the contrary, no business shall be conducted at the annual meeting except in accordance with the procedures set forth in Section
2.1 and this Section 2.9; <U>provided</U>, <U>however</U>, that nothing in this Section 2.9 shall be deemed to preclude discussion
by any shareholder of any business properly brought before the annual meeting in accordance with said procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Chairman of an annual meeting shall, if the facts warrant,
determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions
of Section 2.1 and this Section 2.9, and if he should so determine he shall so declare to the meeting, and any such business not
properly brought before the meeting shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nothing in this Section 2.9 shall affect the right of a shareholder
to request inclusion of a proposal in the corporation&rsquo;s proxy statement or information statement to the extent that such
right is provided by an applicable rule of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.10 Nominations of Persons for Election to the Board
of Directors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to any other applicable requirements, only persons
who are nominated in accordance with the following procedures shall be eligible for election as directors. Nominations of persons
for election to the Board of Directors of the corporation may be made at a meeting of shareholders by or at the direction of the
Board of Directors, by any nominating committee or person appointed by the Board of Directors or by any shareholder of the corporation
entitled to vote for the election of directors at the meeting who complies with the notice procedures set forth in this Section
2.10. Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely
notice in writing to the Secretary of the corporation, which shall be the exclusive means for a shareholder to make nominations
whether or not the shareholder is seeking to have a proposal included in the corporation&rsquo;s proxy statement or information
statement under an applicable rule of the SEC, including, but not limited to, Regulation 14A or Regulation 14C under the Exchange
Act. To be timely, a shareholder&rsquo;s notice must be delivered to or mailed and received at the principal executive offices
of the corporation, not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy
materials (or, in the absence of proxy materials, its notice of the meeting) for the previous year&rsquo;s annual meeting of shareholders
(or the date on which the corporation mails such materials for the current year if during the prior year the corporation did not
hold an annual meeting or if the date of the annual meeting was changed more than 30 days from the prior year). Such shareholder&rsquo;s
notice shall set forth (a) as to each person whom the shareholder proposes to nominate for election or re-election as a director,
(i) the name, age, business address and residence address of the person, (ii) the principal occupation or employment of the person,
(iii) the class and number of shares of the corporation which are beneficially owned by the person, and (iv) any other information
relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant to Regulation
14A under the Exchange Act; (b) as to the shareholder giving the notice, (i) the name and record address of the shareholder, and
(ii) the class and number of shares of the corporation which are beneficially owned by the shareholder; (c) as to the shareholder
giving the notice and any Shareholder Associated Person (as defined in Section 2.9), to the extent not set forth pursuant to the
immediately preceding clause, whether and the extent to which any Relevant Hedge Transaction (as defined in Section 2.9) has been
entered into, and (d) as to the shareholder giving the notice and any Shareholder Associated Person, (1) whether and the extent
to which any Derivative Instrument (as defined in Section 2.9) is directly or indirectly beneficially owned, (2) any rights to
dividends on the shares of the corporation owned beneficially by such shareholder that are separated or separable from the underlying
shares of the corporation, (3) any proportionate interest in shares of the corporation or Derivative Instruments held, directly
or indirectly, by a general or limited partnership in which such shareholder is a general partner or, directly or indirectly, beneficially
owns an interest in a general partner and (4) any performance-related fees (other than an asset-based fee) that such shareholder
is entitled to based on any increase or decrease in the value of shares of the corporation or Derivative Instruments, if any, as
of the date of such notice, including without limitation any such interests held by members of such shareholder&rsquo;s immediate
family sharing the same household (which information shall be supplemented by such shareholder and beneficial owner, if any, not
later than 10 days after the record date for the meeting to disclose such ownership as of the record date). The corporation may
require any proposed nominee to furnish such other information as may reasonably be required by the corporation to determine the
eligibility of such proposed nominee to serve as a director of the corporation. No person shall be eligible for election as a director
of the corporation unless nominated in accordance with the procedures set forth herein. These provisions shall not apply to nomination
of any persons entitled to be separately elected by holders of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Chairman of the meeting shall, if the facts warrant, determine
and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and if he should so determine,
he shall so declare to the meeting and the defective nomination shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.11 Fixing Record Dates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the corporation may determine the shareholders entitled to notice of or to vote at any meeting of shareholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the
resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less
than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining
shareholders entitled to notice of or to vote at a meeting of shareholders shall be at the close of business on the day preceding
the day on which notice is given, or, if notice is waived, at the close of business on the day preceding the date on which the
meeting is held. A determination of shareholders of record entitled notice of or to vote at a meeting of shareholders shall apply
to any adjournment of the meeting; <U>provided</U>, <U>however</U>, that the Board of Directors may fix a new record date for the
adjourned meeting, subject to the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the corporation may determine the shareholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the shareholders entitled to exercise any rights in respect of any change, conversion or exchange of
stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not
precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days
prior to such action. If no record date is fixed, the record date for determining shareholders for any such purpose shall be at
the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.1 Number and Term of Office.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of directors which shall constitute the whole of
the Board of Directors shall be fixed from time to time by resolution of the Board of Directors. With the exception of the first
Board of Directors, which was elected by the incorporators, and except as provided in Section 3.3 of this Article III, the directors
shall be elected by a plurality vote of the shares represented in person or by proxy at the shareholders annual meeting in each
year and entitled to vote on the election of directors. Elected directors shall hold office until the next annual meeting and until
their successors shall be duly elected and qualified. Directors need not be shareholders. If, for any cause, the Board of Directors
shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of
the shareholders called for that purpose in the manner provided in these Amended and Restated Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.2 Powers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The powers of the corporation shall be exercised, its business
conducted and its property controlled by or under the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.3 Vacancies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vacancies and newly created directorships resulting from any
increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than
a quorum, or by a sole remaining director, and each director so elected shall hold office for the unexpired portion of the term
of the director whose place shall be vacant and until his successor shall have been duly elected and qualified. A vacancy in the
Board of Directors shall be deemed to exist under this section in the case of the death, removal or resignation of any director,
or if the shareholders fail at any meeting of shareholders at which directors are to be elected (including any meeting referred
to in Section 3.4 below) to elect the number of directors then constituting the whole Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.4 Resignations and Removals.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
director may resign at any time by delivering his resignation to the Board of Directors, the Chairman of the Board, or the Secretary
in writing or by electronic transmission, such resignation to specify whether it will be effective at a particular time, upon receipt
or at the pleasure of the Board of Directors. If no such specification is made it shall be deemed effective at the pleasure of
the Board of Directors. When one or more directors shall resign from the Board effective at a future date, a majority of the directors
then in office, including those who have so resigned (prior to the resignation being in effect), shall have power to fill such
vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director
so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor
shall have been duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
a special meeting of shareholders called for the purpose in the manner hereinabove provided, any director may be removed from office,
with or without cause, if the number of votes cast to remove the director exceeds the number of votes cast not to remove him or
her, and a new director may be elected by of the shareholders in the manner provided by these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.5 Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
annual meeting of the Board of Directors shall be held immediately after the annual shareholders&rsquo; meeting and at the place
where such meeting is held or at the place announced by the Chairman at such meeting. No notice of an annual meeting of the Board
of Directors shall be necessary, and such meeting shall be held for the purpose of electing officers and transacting such other
business as may lawfully come before it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as hereinafter otherwise provided, regular meetings of the Board of Directors shall be held in the principal office of the corporation.
Regular meetings of the Board of Directors may also be held at any place, within or without the United States, as determined by
the Chairman of the Board or by the written consent of all directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special
meetings of the Board of Directors may be held at any time and place within or without the State of Florida whenever called by
the Chairman of the Board or, if there is no Chairman of the Board, by the Chief Executive Officer, or by any of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
notice of the time and place of all regular and special meetings of the Board of Directors shall be delivered personally to each
director or sent by telegram or facsimile transmission or other form of electronic transmission at least 48 hours before the start
of the meeting, or sent by first class mail at least 120 hours before the start of the meeting. Notice of any meeting may be waived
in writing at any time before or after the meeting and will be waived by any director by attendance thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.6 Quorum and Voting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time in accordance
with Section 3.1 of Article III of these Bylaws, but not less than one; <U>provided</U>, <U>however</U>, at any meeting whether
a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the
next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
each meeting of the Board at which a quorum is present, all questions and business shall be determined by a vote of a majority
of the directors present, unless a different vote be required by law, the corporation&rsquo;s Articles of Incorporation or these
Amended and Restated Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or
other communication equipment by means of which all persons participating in the meeting can hear each other, and participation
in a meeting by such means shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transactions of any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall
be as valid as though had at a meeting duly held after regular call and notice if a quorum be present and if, either before or
after the meeting, each of the directors not present shall sign a written waiver of notice, or a consent to holding such meeting,
or an approval of the minutes thereof. All such waivers, consents or approvals shall be filed with the corporate records or made
a part of the minutes of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.7 Action Without Meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise restricted by the corporation&rsquo;s Articles
of Incorporation or these Amended and Restated Bylaws, any action required or permitted to be taken at any meeting of the Board
of Directors or of any committee thereof may be taken without a meeting, if all members of the Board or of such committee, as the
case may be, consent thereto in writing or by electronic transmission, and such writing or writings or electronic transmission
or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the
minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.8 Fees and Compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors and members of committees may receive such compensation,
if any, for their services, and such reimbursement for expenses, as may be fixed or determined by resolution of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.9 Committees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Committees:</B> The Board of Directors may, from time to time, appoint such committees as may be permitted by law. Such other committees
appointed by the Board of Directors shall have such powers and perform such duties as may be prescribed by the resolution or resolutions
creating such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Term:</B>
The terms of members of all committees of the Board of Directors shall expire on the date of the next annual meeting of the Board
of Directors following their appointment; <U>provided</U>, that they shall continue in office until their successors are appointed.
The Board of Directors, subject to the provisions of subsection (a) of this Section 3.9, may at anytime increase or decrease the
number of members of a committee or terminate the existence of a committee; <U>provided</U>, that no committee shall consist of
less than two members. The membership of a committee member shall terminate on the date of his death or voluntary resignation,
but the Board may at any time for any reason remove any individual committee member and the Board may fill any committee vacancy
created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of
the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings:</B>
Unless the Board of Directors shall otherwise provide, regular meetings of the committees appointed pursuant to this Section 3.9
shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof
has been given to each member of such committee, no further notice of such regular meetings need be given thereafter; special meetings
of any such committee may be held at the principal office of the corporation required to be maintained pursuant to Section 1.2
of Article I hereof; or at any place which has been designated from time to time by resolution of such committee or by written
consent of all members thereof, and may be called by any director who is a member of such committee upon written notice to the
members of such committee of the time and place of such special meeting given in the manner provided for the giving of written
notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any
special meeting of any committee may be waived in writing at any time after the meeting and will be waived by any director by attendance
thereat. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of
business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 4.1 Officers Designated.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The officers of the corporation shall be a President, a Secretary
and a Treasurer. The Board of Directors may also appoint a Chairman of the Board, a chief executive officer, chief financial officer,
one or more Vice-Presidents, assistant secretaries, assistant treasurers, and such other officers and agents with such powers and
duties as the Board of Directors or the President shall deem appropriate or necessary. The order of the seniority of the Vice-
Presidents shall be in the order of their nomination unless otherwise determined by the Board of Directors. The Board of Directors
may assign such additional titles to one or more of the officers as they shall deem appropriate. Any one person may hold any number
of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation
of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors, or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 4.2 Tenure and Duties of Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>General:</B>
All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected
and qualified, unless sooner removed. Any officer may be removed at any time by the Board of Directors. If the office of any officer
becomes vacant for any reason, the vacancy may be filled by the Board of Directors. Nothing in these Amended and Restated Bylaws
shall be construed as creating any kind of contractual right to employment with the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of the Chairman of the Board of Directors:</B> The Chairman of the Board of Directors (if there be such an officer appointed) when
present shall preside at all meetings of the shareholders and the Board of Directors. The Chairman of the Board of Directors shall
perform such other duties and have such other powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of President:</B> The President shall be the chief executive officer of the corporation and, in the absence of the Chairman of
the Board, and shall preside at all meetings of the shareholders and at all meetings of the Board of Directors, unless the Chairman
of the Board of Directors has been appointed and is present. The President shall perform such other duties and have such other
powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Vice-Presidents:</B> The Vice-Presidents, in the order of their seniority, may assume and perform the duties of the President
in the absence or disability of the President or whenever the office of the President is vacant. The Vice-President shall perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Secretary:</B> The Secretary shall attend all meetings of the shareholders and, if invited, of the Board of Directors and each
committee thereof, and shall record all acts and proceedings thereof in the minute book of the corporation, which may be maintained
in either paper or electronic form. The Secretary shall give notice, in conformity with these Amended and Restated Bylaws, of all
meetings of the shareholders and of all meetings of the Board of Directors and any Committee thereof requiring notice. The Secretary
shall perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The President
may direct any assistant secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary,
and each assistant secretary shall perform such other duties and have such other powers as the Board of Directors or the President
shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Treasurer:</B> The Treasurer shall keep or cause to be kept the books of account of the corporation in a thorough and proper
manner, and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board
of Directors or the President. The Treasurer, subject to the order of the Board of Directors, shall have the custody of all funds
and securities of the corporation. The Treasurer shall perform all other duties commonly incident to his office and shall perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. The
President may direct any assistant treasurer to assume and perform the duties of the Treasurer in the absence or disability of
the Treasurer, and each assistant treasurer shall perform such other duties and have such other powers as the Board of Directors
or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTION OF CORPORATE INSTRUMENTS, AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>VOTING OF SECURITIES OWNED BY THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 5.1 Execution of Corporate Instruments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors may in its discretion determine the method and designate the signatory officer or officers, or other person
or persons, to execute any corporate instrument or document, or to sign the corporate name without limitation, except where otherwise
provided by law, and such execution or signature shall be binding upon the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise specifically determined by the Board of Directors or otherwise required by law, formal contracts of the corporation,
promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the corporation, and other corporate instruments
or documents requiring the corporate seal, and certificates of shares of stock owned by the corporation, shall be executed, signed
or endorsed by the Chairman of the Board (if there be such an officer appointed) or by the President; such documents may also be
executed by any Vice-President and by the Secretary or Treasurer or any assistant secretary or assistant treasurer. All other instruments
and documents requiring the corporate signature but not requiring the corporate seal may be executed as aforesaid or in such other
manner as may be directed by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the
corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution
of any corporate instrument may be effected in such form, either manual, facsimile or electronic signature, as may be authorized
by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 5.2 Voting of Securities Owned by Corporation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All stock and other securities of other corporations owned or
held by the corporation for itself or for other parties in any capacity shall be voted, and all proxies with respect thereto shall
be executed, by the person authorized so to do by resolution of the Board of Directors or, in the absence of such authorization,
by the Chairman of the Board (if there be such an officer appointed), or by the President, or by any Vice-President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHARES OF STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.1 Form and Execution of Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of stock of the corporation shall be represented by certificates,
or shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock, or a
combination of both. To the extent that shares are represented by certificates, such certificates shall be in a form approved by
the Board of Directors. Each certificate shall be signed in the name of the corporation by (A) the Chairman or Vice Chairman of
the Board or the President or a Vice President and (B) the Secretary or an Assistant Secretary or the Treasurer or an Assistant
Treasurer, and sealed with the seal of the corporation (which seal may be a facsimile, engraved or printed); <U>provided</U>, <U>however</U>,
that where any such certificate is countersigned by a transfer agent other than the corporation or one of its employees, or is
registered by a registrar other than the corporation or one of its employees, the signature of the officers of the corporation
upon such certificates may be facsimiles, engraved or printed. In case any officer who shall have signed or whose facsimile signature
has been placed upon such certificates shall have ceased to be such officer before such certificates shall be issued, they may
nevertheless be issued by the corporation with the same effect as if such officer were still in office at the date of their issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.2 Lost Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors may direct a new certificate or certificates
(or uncertificated shares in lieu of a new certificate) to be issued in place of any certificate or certificates theretofore issued
by the corporation alleged to have been lost or destroyed, upon the making of an affidavit of that fact by the person claiming
the certificate of stock to be lost or destroyed. When authorizing such issue of a new certificate or certificates (or uncertificated
shares in lieu of a new certificate), the Board of Directors may, in its discretion and as a condition precedent to the issuance
thereof, require the owner of such lost or destroyed certificate or certificates, or his legal representative, to indemnify the
corporation in such manner as it shall require and/or to give the corporation a surety bond in such form and amount as it may direct
as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost
or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.3 Transfers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to any restrictions on transfer and unless otherwise
provided by the Board of Directors, shares of stock may be transferred only on the books of the corporation by the surrender to
the corporation or its transfer agent of shares in certificated form, properly endorsed or accompanied by a written assignment
or power of attorney properly executed, with transfer stamps (if necessary) affixed, or upon proper instructions from the holder
of uncertificated shares, in each case with such proof of the authenticity of signature as the corporation or its transfer agent
may reasonably require. Except as otherwise provided by applicable law, the corporation shall be entitled to recognize the exclusive
right of a person in whose name any share or shares stand on the record of shareholders as the owner of such share or shares for
all purposes, including, without limitation, the rights to receive dividends or other distributions and to vote as such owner,
and the corporation may hold any such shareholder of record liable for calls and assessments and the corporation shall not be bound
to recognize any equitable or legal claim to or interest in any such share or shares on the part of any other person whether or
not it shall have express or other notice thereof. Whenever any transfers of shares shall be made for collateral security and not
absolutely, and both the transferor and transferee request the corporation to do so, such fact shall be stated in the entry of
the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.4 Registered Shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation shall be entitled to recognize the exclusive
right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner, and shall not
be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether
or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER SECURITIES OF THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All bonds, debentures and other corporate securities of the
corporation, other than stock certificates, may be signed by the Chairman of the Board (if there be such an officer appointed),
or the President or any Vice-President or such other person as may be authorized by the Board of Directors and the corporate seal
impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an assistant
secretary, or the Treasurer or an assistant treasurer; <U>provided</U>, <U>however</U>, that where any such bond, debenture or
other corporate security shall be authenticated by the manual signature of a trustee under an indenture pursuant to which such
bond, debenture or other corporate security shall be issued, the signature of the persons signing and attesting the corporate seal
on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest
coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be
signed by the Treasurer or an assistant treasurer of the corporation, or such other person as may be authorized by the Board of
Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested
any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon has ceased to be an officer
of the corporation before the bond, debenture or other corporate security so signed or attested shall have been delivered, such
bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the
person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION OF OFFICERS, DIRECTORS,
EMPLOYEES AND AGENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.1 Right to Indemnification.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each person who was or is a party or is threatened to be made
a party to or is involved (as a party, witness, or otherwise), in any threatened, pending, or completed action, suit, or proceeding,
whether civil, criminal, administrative, or investigative (hereinafter a &ldquo;Proceeding&rdquo;), by reason of the fact that
he, or a person of whom he is the legal representative, is or was a director, officer, employee, or agent of the corporation or
is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation or of a partnership,
joint venture, trust, or other enterprise, including service with respect to employee benefit plans, whether the basis of the Proceeding
is alleged action in an official capacity as a director, officer, employee, or agent or in any other capacity while serving as
a director, officer, employee, or agent (hereafter an &ldquo;Agent&rdquo;), shall be indemnified and held harmless by the corporation
to the fullest extent authorized by the Florida Business Corporation Act, as the same exists or may hereafter be amended or interpreted
(but, in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits the
corporation to provide broader indemnification rights than were permitted prior thereto) against all expenses, liability, and loss
(including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid or to be paid in settlement,
and any interest, assessments, or other charges imposed thereon, and any federal, state, local, or foreign taxes imposed on any
Agent as a result of the actual or deemed receipt of any payments under this Article) reasonably incurred or suffered by such person
in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing for any
of the foregoing in, any Proceeding (hereinafter &ldquo;Expenses&rdquo;); <U>provided</U>,<U> however</U>, that except as to actions
to enforce indemnification rights pursuant to Section 8.3 of this Article, the corporation shall indemnify any Agent seeking indemnification
in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part thereof) was authorized
by the Board of Directors of the corporation. The right to indemnification conferred in this Article shall be a contract right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.2 Authority to Advance Expenses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenses incurred by an officer or director (acting in his capacity
as such) in defending a Proceeding shall be paid by the corporation in advance of the final disposition of such Proceeding; <U>provided</U>,
<U>however</U>, that if required by the Florida Business Corporation Act, such Expenses shall be advanced only upon delivery to
the corporation of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
that he is not entitled to be indemnified by the corporation as authorized in this Article or otherwise. Expenses incurred by other
Agents of the corporation (or by the directors or officers not acting in their capacity as such, including service with respect
to employee benefit plans) may be advanced upon such terms and conditions as the Board of Directors deems appropriate. Any obligation
to reimburse the corporation for Expense advances shall be unsecured and no interest shall be charged thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.3 Right of Claimant to Bring Suit.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a claim under Section 8.1 or 8.2 of this Article is not paid
in full by the corporation within 30 days after a written claim has been received by the corporation, the claimant may at any time
thereafter bring suit against the corporation to recover the unpaid amount of the claim and, if successful in whole or in part,
the claimant shall be entitled to be paid also the expense (including attorneys&rsquo; fees) of prosecuting such claim. The burden
of proving such a defense shall be on the corporation. Neither the failure of the corporation (including its Board of Directors,
independent legal counsel, or its shareholders) to have made a determination prior to the commencement of such action that indemnification
of the claimant is proper under the circumstances because he has met the applicable standard of conduct set forth in the Florida
Business Corporation Act, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel,
or its shareholders) that the claimant had not met such applicable standard of conduct, shall be a defense to the action or create
a presumption that claimant has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.4 Provisions Nonexclusive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights conferred on any person by this Article shall not
be exclusive of any other rights that such person may have or hereafter acquire under any statute, provision of the corporations&rsquo;
Articles of Incorporation or any agreement, vote of shareholders or disinterested directors or otherwise, both as to action in
an official capacity and as to action in another capacity while holding such office. To the extent that any provision of the corporation&rsquo;s
Articles of Incorporation or any agreement, or vote of the shareholders or disinterested directors is inconsistent with these Amended
and Restated Bylaws, the provision, agreement or vote shall take precedence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.5 Authority to Insure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation may purchase and maintain insurance to protect
itself and any Agent against any Expense, whether or not the corporation would have the power to indemnify the Agent against such
Expense under applicable law or the provisions of this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.6 Survival of Rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights provided by this Article shall continue as to a person
who has ceased to be an Agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.7 Effect of Amendment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any amendment, repeal, or modification of this Article shall
not adversely affect any right or protection of any Agent existing at the time of such amendment, repeal, or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.8 Subrogation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of payment under this Article, the corporation
shall be subrogated to the extent of such payment to all of the rights of recovery of the Agent, who shall execute all papers required
and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable
the corporation effectively to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.9 No Duplication of Payments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation shall not be liable under this Article to make
any payment in connection with any claim made against the Agent to the extent the Agent has otherwise actually received payment
(under any insurance policy, agreement, vote, or otherwise) of the amounts otherwise indemnifiable hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.10 Indemnification and Insurance under Israeli
Securities Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Florida Business Corporation Act, the corporation
may indemnify and insure any office holder of the corporation from and against any payment which the office holder is obligated
to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 5278-1968, as amended (&ldquo;Israeli
Securities Law&rdquo;) and from and against reasonable litigation expenses, including attorneys&rsquo; fees, that an office holder
may incur in connection with a proceeding under Chapters H&rsquo;3, H&rsquo;4 or I&rsquo;1 of the Israeli Securities Law. Subject
to the Florida Business Corporation Act, the corporation is permitted to provide an office holder advanced payments to cover expenses
covered under this Section 8.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FISCAL YEAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fiscal year of the corporation shall begin on the first
day in January of each calendar year and end on the last day of each December following.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE X</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whenever, under any provisions of these Amended and Restated
Bylaws, notice is required to be given to any shareholder, the same shall be given either (1) in writing, timely and duly deposited
in the mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the corporation
or its transfer agent, or (2) by a means of electronic transmission that satisfies the requirements of Section 2.4(e) of these
Amended and Restated Bylaws, and has been consented to by the shareholder to whom the notice is given. Any notice required to be
given to any director may be given by either of the methods hereinabove stated, except that such notice other than one which is
delivered personally, shall be sent to such address or (in the case of electronic communication) such e-mail address, facsimile
telephone number or other form of electronic address as such director shall have filed in writing or by electronic communication
with the Secretary of the corporation, or, in the absence of such filing, to the last known post office address of such director.
If no address of a shareholder or director be known, such notice may be sent to the principal office of the corporation. An affidavit
of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect
to the class of stock affected, specifying the name and address or the names and addresses of the shareholder or shareholders,
director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall
be conclusive evidence of the statements therein contained. All notices given by mail, as above provided, shall be deemed to have
been given as at the time of mailing and all notices given by means of electronic transmission shall be deemed to have been given
as at the sending time recorded by the electronic transmission equipment operator transmitting the same. It shall not be necessary
that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect
of any one or more, and any other permissible method or methods may be employed in respect of any other or others. The period or
limitation of time within which any shareholder may exercise any option or right, or enjoy any privilege or benefit, or be required
to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him in
the manner above provided, shall not be affected or extended in any manner by the failure of such a shareholder or such director
to receive such notice. Whenever any notice is required to be given under the provisions of the statutes or of the corporation&rsquo;s
Articles of Incorporation, or of these Amended and Restated Bylaws, a waiver thereof in writing signed by the person or persons
entitled to said notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time
stated therein, shall be deemed equivalent thereto. In the event that the action taken by the corporation is such as to require
the filing of a certificate under any provision of the Florida Business Corporation Act, the certificate shall state, if such is
the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom
communication is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE XI<BR>
AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors shall have the authority to repeal, alter
or amend these Amended and Restated Bylaws or adopt new Bylaws (including, without limitation, the amendment of any Amended and
Restated Bylaws setting forth the number of directors who shall constitute the whole Board of Directors) by unanimous written consent
or at any annual, regular, or special meeting by the affirmative vote of a majority of the whole number of directors, subject to
the power of the shareholders to change or repeal such Bylaws and provided that the Board of Directors shall not make or alter
any Bylaws fixing the qualifications, classifications or term of office of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>v403470_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the
Registration Statements on Form S-8 (No. 333-148983 and No. 333-182677) of Protalix BioTherapeutics, Inc. of our report dated
March 12, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which
appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants (lsr.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">A member firm of PricewaterhouseCoopers International
Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 12,
2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>v403470_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated: March 12, 2015</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>v403470_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 17.95pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.95pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.95pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated: March 12, 2015</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>v403470_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2014 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated: March 12, 2015</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>v403470_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<body>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2014 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated: March 12, 2015</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tpg14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg14.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`(F`RD#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBO*?
MBK^T5J_PV_:,^&_@I?!D]YH7CV[GL)/$<FJ0PQ6=PEC>W:Q16ZAY9F"V3;R_
MDHHGB*-*?,6,W=@Z-]M3U:BOG/X(?MQZ]\5?C-HNEZCX!L=#\"^-Y-9@\(Z_
M%XA-Y?ZA+ID_ER"[L?LR+:K,BS30E+B<[(L2"%V"5]&4+6*EW_K5;KT>O78.
MK7;3_AGU]5H%%%%`!1110`4444`%%%%`!7B/BW_@HU\%_`O@;XL>)-6\:Q6.
MC_`W4%TOQO*^FWA?0[AEB=5,0A,DP99HRK0K(K;B`20<>W5^3_\`P4"_8L\8
M?%7_`(*J3?#FW\"^)M8^"/[34GAC7/'>LV>DR2Z3IKZ!]N>6"ZN%39$URD5@
MBAW!8YZY"G&I*ISQITUK+1=D]'=_W5%2OLV^75:FD5!0E4GM'5VW:V:7]YMJ
MWE?1GZ,67[7/P]U+X@?#_P`+6WB#[3KGQ2T6X\1>&+>&QN9%U'3X(X9);@R"
M,I"@6XAQYS(6,@506XKTBOQ7_84_95_:6UWX%_'.WF\.^,/!?Q(^"GP>N/@A
M\,M2U&UFTN;7I([N^F-_83R;5VR11:;'',KE5=0P90H)AUS]ERXU[X7^)O\`
MAG_X&_$'X<Z(O[-.M^'OB%IUSX!U#P[-XK\036T0TZU%O/!"^J:C'(EZ6NH8
MYN)MIF)F53K6J02G*G=I*4EYK][*'I>,()]I5$K)Z$T:<G)0J.SYHQ;Z)WI1
MEUZ2G.W>,&[]3]KJX?P9^T?X+^(7QN\:?#G1]9^V>,_AW!87/B#3OLD\?]GQ
MWR226I\UD$4F]8G.(W8KM^;:2,_E?^V+^Q)#\+_V5/V?=6\*_"C5M;\:>&?`
MUUJ4_@F_^%>H^+-#\8:_>6=BERVI26;+<Z9K7F(&34[EE*D2`R95P/=OV./V
M:K'X4?\`!:7XR>,O%'P9D\.ZK\1/"OAO5?#&OP>%I-2L]/O%L[M-:A.LQ0-#
M!<O(5$ADE1[GY&^?<N=Y4DJLJ=]$Y*_=QO:W=/E;?5*S=N:-^>-;FH^UM9M1
M:OVE*"=_-*7DFT[-\LCZ0^'_`/P5,^!GQ.^,W_"`Z3XPOQXB;7[WPK"U]X:U
M73]-O-7L\_:=/@U"XMH[.>Y3!/E13,[`94$<UZQ\</BF/@C\(?$?BYO#OBKQ
M;_PCMA+??V+X:TXZCK&J%!D0VMN"/-F;HJY`)/)`YK\V?V(/^"=/Q"^(OB+Q
MMXC\='4-(\+_``Y_:`\6?$7PIX.D\.SZ/JOB/4=SI973:G-.5:Q=96*"*U3<
MV&,S*"M?*$_P*^,'Q"TSXM:MI7P/UWP:WC_]G;Q+I7B#0?#GPJU[0?/\0BXA
MD@L[VYO))GU[4MLLA74%`-QOEVESYF.&527L$_MNGS^G[KVBT\Y*4>MO=YK.
M2B^R-->WE'[*GRK_`,&\CU\HN,NE_>Y=(N2_?30-6_M[0K*^^RW=E]M@2?[/
M=1^7/!N4-LD7G:ZYP1G@@BK=?C!^TI^PMXG\;^`/VTO%#?"?Q5K'CK3]'\"7
MGPUO&\/7-Q>P:A;:-9+<3:0-A(N8Y(1'*]N/,'E!'.%VC]E]*:1M+MC-N\TQ
M*7W#!W8&<UWXBFH3:7E]S5U]VS_X.G'1FY4J<W]I?<THWO\`^!:=[/1%BBBB
ML#8****`"BBB@`HHHH`****`"BBB@`HHHH`X']JO6;SP[^R]\2-0T^ZN;&_L
M?"VIW%M<V\K136\J6DK(Z.I!5E8`@@@@@&OR[TKXY?".7_@FQX9\2?#+]IKQ
MIXB_:IE\'Z7?Z+H6F?'+6/%FK:KXF:&!_LDF@3ZC<P3K)<%HYH9+4I'&TK'R
M@F]/U6^/7@2\^*7P,\:>&=/DMH;_`,1:%?:7;27#,L*2SV[Q(7*@D*&8$D`G
M&>#TK'_9%^$NI?`/]E3X:^!=8FL;G5O!OA?3=$O9K-V>WEFMK6.%VC9E5BA9
M"06521C(!XJ:,6IU9/3^%9K?1U>:SUMO&^C6UT[6'4E_"LKVY[I[?\N[776]
MI==K]SPG]L'_`(*.^-/V/_A[XL\8ZE\,-$;P5\,K&RF\5:QX@\6MX=;4;F:*
M.62WT.-[.:+4I$$@C&^>V5YR(49F#E;GQ=_;NTOX5?$CXK:U9>&=8UA_`OP1
MM_B7&TOB6Y@M-3M_-U-TLQ9%7M[>8_93NNE5I&$BHP98E%>/_M@?\$I/'WQY
M^)/Q\NM*T/X(ZM>?&33WL=$^(GBEKBX\4?#ZUDTE;";3;.U%FZM;OMG8/'>P
M;#?S.T4VS9+VOC;_`()[_$KXD>&_B0]_=^!]/UCQY^SU:_"I(;?4;J>VM=9C
M&I[Y3(ULK&SS>Q8DV>8=KYB&!NSJ2J.G*:5I6;7DW2JZ?]NS4$N][-RB^:6]
M"G2C.%.3O'W4[]4JE+73O!S?=6O:+22[OX`?MZ>,?'GQU\$^#?'WPKMO`4?Q
M2\+77BSPG=6GB;^V)F@MC;&:VU&+[+"EK<K'>0,%AENHS\X\P;06X7]O/]JC
M7OV7?VY?#^O6]QJVI>'/"_P1\=>+[SPU'JDEI8ZS<:=+I4L/F*`R"0*9465H
MW*"5\`Y(/K$G[*?B)_VE/@'XR^V:+_9?PK\':UX>U:+SI?M%Q<7L>EK$T`\O
M:T8-E+N+LA&Y,`Y.WA?^"@G[`WC#]J[XIWFN>'=2\-6=I<?!WQE\/534;B>.
M07^L"R%M*1'"X\A?L[^8V=XRNU'R<;XSW9WH=%6MU^S65/?O>%O.SW,<#:4(
M_6/M>RNMK>_3Y]M=E)O6^ZV/+OVI_P#@J!\8O"O[//BR'_A5>C_#_P`3^+OA
M/KOC[P)J/_"9&^DLXK"WBDN!?(-.V6]]##=0S1PQM<PRNIC:>,?O*].\"_ML
M_%+41X'^&OAOX;^$O%_Q8C\$6GBSQ4M]X\N;/0]&LYF>&SSJ']F2W$]W=-#*
MXB-HBJ(Y2TN`AD@_:]_X)W>+?VCM'\'V&GZQX=T^/1/A)XN^'][+<23%OMFK
MV%A;031JL?S0HUK(7+%6`*85B2!P'CO_`()<^(O''Q"\'_$SQ/\`!K]F?XK^
M,!X(LO!?B7POXTOIKS2;,V,LSVM_IFHRZ1<2(SK-(LT+62!@8\29B)EN?(JE
M2,?A;6ODGB.7O_T[OIU3=E=J(WEAZ4I?':3:[-^QNNG15&KO1Z+HGW=K_P`%
M5-<^)FJ_"30?AQ\*5U[Q;\3H_$EM?:?KOB=-(M_!^H:#<6]O?VU[/#;W19!+
M+*BRP1R%F6$A"DQDCI^$_P#@K+KGQ1OOA_X0\-?#;0+3XK^,M1\2Z5<Z+XI\
M9G1]&L[K0+E;;4(+?4([&XFO)2[K)%&EFK/`LLKB'RRIWO@-^P5XD^&7Q:^!
M/B9]%^#/@ZR^'NA>*+36]"\`Z/+HVDV]UJTFGR1)90;2)5C^RR+).YA:5MKB
M%-YC3FY/V$/B'X=^&6N^&;[X?_LZ_&OPSXB^(OB;QA=^&/'<ES#;(NH:C-=6
M-Q'=-87B+/#'*\<D)LFR9<I<*$*RY_:2EM:3?^+G245\6EFVMVTE>25Y&GN^
MRNM[V_[=M-W>VJM&_P`.[]V]D=GJG[47C:7XT?"WP_K7PKN/#?Q,\3>'/%EU
M;:;<_$"0:'#-IS6"KO-I%)'=6]R9XVBN)[9;BW0-_HZ/))'7GW_!/O\`;N^(
M,/[&7[,6M?%C1=/U*X^,VHC0[CQ+:^()+MX)I[2>YL[BYB:SA"-<3PO;^5&Q
M2)G@"NX?:FE^R1_P36\8?L]^-O@CJ%[K'ALZ1\.=.\96]QI%G>74\.A1ZU=V
M4]EIFG/,FZ:TLH[=X!)+Y+%4C*Q(#L3S_P"+'P%\4?LS?\$5K'X0^--<\!Z+
M\3/"<EEI_P`-+O2]4>\/B/6K"ZBO='$4-S!"XNY9[=0UM&)L*KD2,N[:DW".
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M1<9!/[JRO+BXP.3]G`[U52,8U(0DTXJ4%)]'%2BIR?9-7;V23=K(RIR<H3G%
M--QFXKJI.,G!>J=EYVUN>4?M9>(%\!_M5>)#\<)?VAM/^".D>&;2Y\%ZK\.[
MSQ.--M'A5O[4?5Y_#S"_%Q_J61[XM;"&-V1A(9L]=X'_`&K+7]FK]E+P7%X5
M^(UO^U-J'C[Q6_A7X;WD.KV^_4U;S7CM[_5(FG6864%O<&XOC&TK+!EHI)B?
M,['Q+X'^.WP[_:"\0>-OA;JG@?XG>`?B#:6UU+X:\8^*]0TA?#EW#%'&EQIE
MY!:7\;6MQ$"TEO\`9XP)5$JR-YCJ/$?B'_P1YU/XJ_"_4M>\3V?PJ\4_$S5?
MB?\`\+7NO#&K6$MSX'N+AM.33)-)D$D;R21M:KDWK6^\W($_V8*/(I4^9*T[
MKOWNZD>9-:W?*Y-22NE'E2O/E')1:7)YV[?!+EL]++FLG%NS<N;11YCO->_X
M*D:Y\)/'H\'_`!&^&=AX=\4:3XET#3?$/]E>*&U32[#1];EFM+'6;>X:S@DG
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MO5-+R:BVF[V^*;C!+1<L6V[^^^]^)_\`P5/U[X!^!/B1;^./A;;VWQ.^&\_A
MZ63PUHGB@:A8Z]I^M:E'I]M>65]+:P.VV4SH\<UM$RR0!<[)$E/)?M;?MA?%
M'X?>#/CU:VOA#1?#'Q?\&_!!O&(N;'XB7^HZ%IZ&ZU:-&MXI=/CB:ZACM3/Y
MAM$:9V2W=UCC64-G_P""8?B3Q#\#_'&BZ1\)_P!EGX'ZAX@UWPS=V-AX`T^4
M&6UTS5[/4+A[[4UL;0SLXAE6*!;%5C8`M,_F$Q^G?M/?L*>)OCS\5_CCJUGJ
MVA6.F?%+X*CX:V!F>5I[2_\`.U5S-*@3;Y`6^BY5RY*N-HP">?%1DZ+BEK[^
MW;V+Y;6?VIVOK>[:]U:+LP<J:GS3V4H?=[2GS75K-)<[6FRO>32;P_`/_!1[
M4_A%\,/$]M\6O"UCH>M_#_X5V'Q#CFTWQ%+K$/B:U=;B*5(Y9;2WD$Z2P0JX
M*-\U[%@G(+=)X2^-OB#P#^W]X5\,:\-2MM-^.G@27Q'%I-QJ+WMOX<UK2_LD
M=W;VS2!2(Y;>\B)541=]FTFQ7FD)\/\`VA/V>=4^.OQJ_92\#>(-8\'Z3\2O
M"\#Q?$'P[X<U8ZJL_A:)K>[,C/+!!.MK/J&D:=%NDA129Y8@7PS'VO7O#\GQ
MW_X*U>&=5L3YFB?`+P9J-MJ=PH!C_M?7'M#%:!@?]9'9V9FD0CY5O+5O^6@Q
MZ56498IS6SE4].5*HXM>3;@M?^7D+)*^OET8RCAU"5U:,+][MTU;U34F_P#I
MW.[;M<^I:***Y3H"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"O#_VCOV>?B-\7?CK\-/$WAGQYX)\-Z#\/=2.K-I>I^#;K5;S49Y+
M:ZLY@+J/4[9(D-O=,%'D.4D4.6=<QU[A10M&GV_KYANG'NK?UV^1\Y_`C]AS
M7OA1\6])U+5O'UCKW@OP3/K5QX/T.#P\;&\TUM3G,DGVR]-S(+OR8WDABV06
M_P`DA,GG.%<>\>,/`VB?$+218:_H^EZY8K()1;:A:1W,(<9`;:X(R,GG&>36
MI10M(J*Z?UJ]WZO4.K??7^ET]%H<'^RRQ?\`9C^'+,26/A?3"2>_^B15WE<'
M^RO_`,FP_#C_`+%?3/\`TDBKO*`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHIEO<1WEO'-#(DL4JAT=&W*ZGD$$=0?6@!]%4]
M?\06'A/0KW5-4OK/3=,TV![J[O+J988+6%%+/)([$*J*H)+$@``DUR?A?]IS
MX:^-_!V@>(M%^(7@?6/#_BNXEL]$U.RUVUN+/6)XEE:6*VE1RDSHL$Y94)*B
M&0D#8V"^[[?KM]]AV?\`7EJSN**X'P7^U=\+?B1\.E\8>'?B5X!U[PB^H1Z2
MNMZ=XAM+K3FO9)(XH[87$<AC\YI)8D6/=N+2(`"6`+K']JCX8:I<>-(;7XC^
M`[B7X;@MXM2+Q!:.WA8`.2;\"3_1<"*0_OMO^K?^Z<%FM_ZV_P`U]Z[BCKJO
M3Y[6^]'>45';74=[;1S0R1S0S*'1T8,KJ1D$$<$$=ZDHVT8)W5T%%%%`!111
M0`55UW7;'POHEYJ>IWEKIVFZ?`]S=7=U*L,%M$BEGD=V(555026)``!)JU7/
M_%CX<6/QB^%WB3PCJ<MU!IOBC2[G2;J2U95GCBGB:)V0LK*&"L2"5(SC(/2@
MJ-KZ[$?PP^,O@_XW:'-JG@OQ5X;\7:;;SFVEN]%U.'4((I0JL8V>)F4.%93M
M)SA@>XKI*\2_81_8+\'_`/!/7X5ZGX0\%ZEXDU33=5U5]7EEUJXAFG65HHHB
MJF**)=NV%3@J3DGGH![;71BHT8U6L.W*/1M6>VNGJ<V&E5E33KI*6MTM5OI^
M`5\:R?\`!1;XO:E\/OBEX_T;X+^`]2^'?PJ\0:_I-_*_Q)N;?7[ZWT:ZFAN9
MX+(Z.;;S&6!WCB>]52<*TBYW#[*KXF_9F_X)6Z#K.E?$N;XL:7XZDD\5?$GQ
M-K8T(?$765\/:MIEUJL\]MY^E6M^-/DBFA9#)#-`=X8K*A)85R1YG4:6BY)/
M7;FYH)=KZ.6EU=7=]#K]Q4TWOSQ6F_+RS;]-5'6SL[+J>J_$'_@J/\%?A7(W
M]O>(/$%G;VMI8WNJ7UOX1UB_TWPZEZB26XU*^MK62UT]VCEC<K=2QE4D1V`1
ME8W/'O\`P4/^'/P:\0^)K3QIKVGZ3#H_BFS\(6(L;?4=2N]1U&YTJ/4H;7R(
M[3_CXEC9A%'`UP)3Y2AO.D$"_)/_``4L_90^/G[3^E?'+P9;^%?BAXHT[6-+
MGL/AI%HOCW3O"_@?2[1]-MMZW\-O<0:A>7C7,5PBPWD-U9'S(5#6\;S2)WVM
M?L?_`!-UW]J/3_%G_"*M!I)^-VA>,Y7;4K0M!ID'@C^S)YB!+D[+W]SL`+MC
M>JE/GK>GRS:>R;COT4JD%KYQBY-[I6O>Q*CR1:EJU";TZRC%-6\I/1+?=+N?
M6_P`_:0\'_M/>#KO7/!NH7EY::=J$VDW\%_I5WI-_IMY"0)+>YL[N**XMY`&
M5MDL:DJZL`592>$U7_@I)\'=%^*\/@^Z\1:S'J%QX@7PG'J7_"+:LWA]]7+%
M!I_]L"U_L[[3Y@,1B^T;A*#$0)`4J']C;X+^)OA3\8/VB]4U_3?L%CX\^(PU
M[0I?M$4OVZR_L/2;7S<(S&/]]:SIMD"M\F<;2I/R!\>_V6OVB/CIX\LKKQ%X
M0^*OBKQ)X9^*FE>(;:_G^(6F:7X&@\.V/B1+J&#3M*M+F-KNZ%D8V=M6M/-4
MPRE+EFCMXI9IQ4JM&+TC)4W+^[S<G-KM>/-+1]GU5G,]*=5K>+FH^=N?ET[.
MRU6EVNCNOL7]B;]M_3_VT+'XB7%CX?\`$'A\>`_%M]X:VZGI&H6/VQ+=]BSA
MKJVAR[[6+Q(&:'*J_)!/FOPT_P""P'@KQ=\5K'0]9M6T7P^_PQA^)-YXJCL]
M6DT&WA<LS*+NXT^W00+$A83R^67=O*\M95*'N?V%?A?XL^$5W\:='\2^&[[2
M8=6^(FL>(]'U)KJTFM-:L[^3S8VB$4S31M'C:ZSQQ'<?EWK\U?,7P6_8C^)/
MP[\$>%=%\4?!V/QUIU]^SG%\/=9T>?Q%8V=BNIV\DTSZ?=3K*TJ).L@B2XMH
MIU1^6*`!ZQIRDXTW+^2#=_YG0J2E>W:HH)I6LVHVUL]N6#]KY5+1M_+[91TO
MH_W=]7I;WK]3[:^`7[6G@?\`:7NM8M?"]YKL>J>'Q!)J&EZ]X;U+P[J=K%.'
M,$YL]0MX)_(D\N4),$,;M%(JL2C@><^,/V]KWPMX#^,UTG@?[1XK^%_BRV\)
M:7H3:P(O^$FGO8[%M.E\[R3Y"3M?QJ<)+L\N3&\J5KG?^"=_PT^*G@#XB^,_
M[;A^+GAWX42VMO\`\(_X:^)WB73/$VNZ=J#2S/<FWOK2XNYC8",PHBWEY/+O
M#[1$BC>[XI?LP>-M:_X*3^&?$VEZ?N^%NL06.M^*;E;N"-5U328M1BLXGA)$
MTGG-?VLN]0RJ=*0-MRH;2I&\HQB[*2MT;CJFY=5S*,9**;<6Y)/6UN>$FH2E
M*S<=5O[VEE'O9RDN9Z.*BWLG?IO#'_!0K1O%I^"\]OIEK;Z7\5/".H>-M4O[
MW55MH?"6FV5M;/.\Q9,.5GO((6#&(+^\<GY-IV/A]_P4:^$/Q,TGQ!?:?XBU
M>SA\-Z`_BJY76?#&JZ-+=:0BLS:A:1WEM$][:@+_`*ZU65,L@SET#?/=O_P3
MH\>>./#O[3'A74HM/T>QU_0-4\(?#>_N9XY87LM2NKW5)6D$1:2*%9[N"U*%
M%;98@A7&UB_X\?!KXO\`[;E[)K6H?"75/AC-X)^&'BGP]:V6K:YI5Y<>)M7U
MBSAMU@M'L[F5$LHS;[C+=-`[L\/[E`KE<<16DJ3JTX^]RRERZZ.TY15^KLH)
MQ^)2NKZHWI4X^VC2E+W>;E<M-4G%.5DE:[<K/:R4K6NCVR?_`(*D_!J/0['4
M(M2\=7T6K+//I\-C\.O$=Y=:E:0K$TFH6]O%8M-/IX$\(^W1HUJ3*@$I+`%/
M`7_!1/PO\4/VU;'X2^'['5-8TW5?`UOXUT_Q19Z=?3Z5J$5Q(?*$=RMO]E\D
MP@.)_/*N[^4/WBE3YI^US^S?KFJ^"_A.VE_"_P"*NJ>)/"OAA]+M_$_PN\=Z
M?X=\2>%)Q]A?[,8;VYMK&]L9FMOG29[B,-;QC[-('WII?LS_``;^-'@K]K?P
M'XN^)NG'Q5J&J?".W\,^)O$NF3V$=K8:Q!?2W;B:'?"["19%17M;=D+JQ*0H
M1CLE&*Q'(G>*E)-]&E"KROOK*,>RNTKR4CD4Y/#\[5I-1=NJ;G3YE\HN6]W9
M-VCRGU_1116)L%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110!Y3\/?VU_AS\4OC->>`=%U;5Y?$5J;U4-SX=U*ST_4&LI
ME@NUL[^:W2TO&@E<)(MO-(4.<@;3CU:OA;]C;]F/XE?#G]N'4O%.M>$?&FDV
M=Y-X@?6;K5?$&FWWA!%N;Q9;8^&[**XDN[%YBJR7'G0VXD)E,GFR>4R_:OC#
MP]>>)=)%O9:[JOAZ82!_M6GQVSS$#/R8N(I4P<_W<\#!'.2&M*$GNU=KL[O3
M[K`_XDXK9.R\T<O^RO\`\FP_#C_L5],_])(J[RN#_97_`.38?AQ_V*^F?^DD
M5=Y0`4444`%%%%`'(_%'X]>#_@LMK_PE&O6>DM>']S')N>20>H1`6V_[6,9[
MUT7A[Q%8>+=%M]2TN\M]0L+M-\-Q!()(Y!TX(XZ@CV(Q7PW_`,%%/V;_`!SX
MC^.4GB32](UCQ'I.IV\,4"V%N]TUB40*T91`64$@OG&TF0\YS7K_`/P3%D&D
M_`[4M$N[XG6M/UB=KO3)@T=QI((11&Z,`1ED=N.,L1U!`^*P/$N+JYW4RS$4
M>2"ORR=TW;KKH[K5):I=]3[3'<-X2EDE/,J%;GF[<T59I7Z::JST;>C?;0^D
M:***^U/BPHHHH`****`"BBB@`HHHH`****`"O.OVA?V>6_:#T[3+;_A.OB+X
M'739'E,GA/6!ILEV6`&)6\MBRK@X`P,L>O&/1:\W_:,_:07]G73=+N/^$$^)
M'CIM4EDC$/A#0SJDEJ$`.Z8;U"*=P`R<D@X'!JHXAT'[5.UBZ>#EBI>PBKN7
M3;S\CQOQQ_P3`NM?\&ZI8V/Q\_:":ZO+62"-=3\7&ZLG+*1MFB$:EXSG#*&&
M0365\$O^"5>I>!_A9HNEZQ\=/C98ZE9P;9[;PUXI>QTFV8DDI!$T3,$&<9.-
MQR=JYVCB_P!L#_@L1XE^$_PSL=0\*_!WXC^&-2N-3CMFN_B%X5EL=+>,Q2L4
MC>.X#-.2BE5SC:LA[4?L?_\`!8CQ+\6/AG?:AXJ^#OQ'\3ZE;ZG);+=_#WPK
M+?:6D8BB8)(\EP66<%V++G&UHSWK3_6RK_`]IY_"O\CU/^(=XKV'U[V2MM\6
MOYV_$];\2?\`!/S4=)^%7BW3M)^)GQ)\;:EK%E$MII_COQ&;[29)H+F&ZC23
M;`7C21H1"[JKD1RN?+<@+7$?$']D7XQ^*8=#UZ'PG\&Y_&.H^,[[Q-K7G^*[
MZ*+P[:S:?%IXL["Y&DO)="18HYY2\=JIEB5=K`AT[/Q'^VUJ'Q:^"/Q)71_#
M?Q"^!^L:+X9N]0LO%/Q'TB+P_HNG2JNU97NYEN88PC,')DAD4*K,4<*5/B:_
M\%`M1\`_L]_!'6O$'QT\)V-QX@\3:MI%S>W^MZ+J4?CQ(X;KR9K#4([+3[>X
MLXY3;IOM[")VD:!&?AQ<<>(Q4<1SUJCN[)/IHY+1;;RC&_71=.8Y(Y?5P<XX
M=KE?O.U[[0=^_P!ERMYO7I;U;QI^PWXD\`_L+^"_AWX!TGP_XR\5>'=0TC47
MG\=^.=7N(;">U$1GEL[VXM]0N(]PB:%(D2*-([B3&T9C?DS^PU\6=1^#'B+P
M_J7AKX/WUQI'@^]\(^%K67Q'>26NLO=WT5T=3OY&TLFTG@:".6-(HKDM,7;S
M8\AAF?\`#1WQ,_9Q_P"":/@GQY\8/C)X9\)^)=;\0:)=3:SK.J:5=+J=A=/;
MN]E%+_9NEV\#M%YSLOV:>2.&.;;,S;9HN.MO^"@>[X?^-O$&N?M*:E:Z?#HY
MU#7SH3>%XV^&NLG5(K:QT*&:ZLWMX6NQ)+$QU1Y6`MO.\V!-[CIQJ;Q,E5UG
M>6W3W=4NUXMQ2>J>BL^0X<#)1HTYTM%[MK];3NFV_-)MW2:U_F/T!^$%GKFF
M_"SP]:^)K/2=/U^UT^&&_MM,OY+^SAE5`K"*>2&!Y$XX9HHR?[HKHZY#]G[Q
M5-XY^!7@W6+C7]#\576I:+:7$^LZ+<QW.G:I*T*EY[>6,!'B=LLK*`I!!``X
M'7U>(YO:RYM[N_WF>'452BH;65O2P4445B;!1110`445ROQU^&?_``NKX)^,
M/!WV[^S?^$LT6\T?[9Y/G?9?M$#Q>9LW+NV[\[=PSC&1UH*C9NS.JHKYM_X)
MA?\`!/?_`(=O_`_6?!O_``EW_"9?VOK<FL_;/[*_L[RM\$$7E[/.ESCR<[MP
M^]C'&3])5T8JG2IU7"A/GCT=FKZ=GKH]#FPU2I.FI58\LM=+WMKW7=:A7B_[
M.'[=O@O]IB^^*5OI=OKFAR?"+Q!>^']:_MF&*`3?99)8GO8#'*^ZU:2WN$5W
MV,6MY`47'/M%?F3IW[/?Q'\/:OJ=GI/@OQ,MK\<_'7B_P-XHN/[/DC_LK2)/
M%-[J-OJ<VX#%L^GS:JD4I!5I+VVVG$F3S14I3]FM+IV;V4KI1OMHV[;V5[NR
M5UUR451]H]U*-UWCRS<ON2OUO;E6K/KSX/\`_!27X4?$W]E72_C)KGB"T^%O
M@K5M2N](BG\>7UGH;1W-M=SVK1NSS&)69[>1E7?N*CD`@J.\^(O[5OPM^#_P
MXTCQEXM^)7@'POX1\0>4-+US5_$-I8Z;J7FQF6+R+B618Y-\8+KL8[E!(R.:
M_.>R^`GQ!^&/Q`^'/CG5+KXZ>`_".BZY\2],DNO`G@Z#7]7T:YU'Q1-=V=U)
MIEQIM_*UI=6D3*MS;6S,NZ+++%,Q/40Z+XB^`/A'X7V_AFT^.'AGPEK4GB;6
M;CQYJ?P?@\4_$#1Y;K4;2?[#8V.F63P:+#J"^?.3=::ZJJ+'+#!.%"U=2UCI
M=OSM9NR?G)+F6S=THQDVKS*+C5E![)R6G57=FNMD[1>C6\G**1]S>)OVR/A#
MX*\`Z7XLUCXJ?#?2?"VN63:EINL7OB:RM]/U"U5XHVN(9WD$<D0>X@4NK%0T
MT8SEUSVG@WQMHWQ%\):?X@\/ZMI>NZ#J]NEY8:EIUTEU:7L#C<DL4J$HZ,""
M&4D$<@U^9O\`P3@_9G\6^&/BG^S*WBKX=^,].D\`W?Q9>YN?$>@0Q3:1/>ZW
M!)9S226R"SBDN+:678]L5BD4S"',=?67_!+'P'KGPO\`V.[G1]4T&^T._MO&
MGC"6ST[4;:2Q*VTGB/4I;4A67*PO"\3(P4J8W5E!4C+G%*GS^3:ZZ)M+S=U9
M]/34E]+?S.+_`/)M?)>[W>^^EV[PW_P4T\.:_?>%]2F\`_$C2_AMXWU>#1/#
MWQ"O(--_L#5KBYE,-F5BCO7U&**YFVQQ2SV<<;&2,E@LB,WK4G[3WPUB^-B_
M#1OB%X'7XC21><OA4Z]:C6VC\OS=XL]_G[?+!?.S&T9Z<U\&^$M-U?P5XC\&
MGX+>#?VC/A#\5O\`A(H(?$_PWNX-8U/X9I:SZG#-JVV]OH'T:&WC@6[EMY=)
MEMI7,JH(BS&!>9^&7[-GB#2]2U+X8_$#Q#^UE)XBF^*]UXFCTSPUX)T:X\,W
M_F:RVI6FL1^()](988TA,32K-J:72&&2".,_N8W*4>9PB^K:OW2Y+--:27O-
M\RLGRN/+'E<Q5O=4YQZ=.WQMWZKX4K.]N9/F;:@?I1:?&WP7?^&M)UJ#Q=X7
MFT?Q!?KI>EW\>JP-;:E=M(T2V\,@;;),9$=`BDL61AC((K.\%_M/?#7XD?%#
M6O`_AWXA^!M>\:>&@YU?0-.UZUNM4TH(X1S<6T;F6+:[*IWJ,%@#R:^)O"O[
M(OQ$/[?6M?#Z/2M0TOX2^!-3\0?%?PAKI@<:?_;&N6OV:&S5_NF6TO+K7KDH
MN=BW%HW!(KE/V`?V?]3TI?V?_!?B[5OVLF\9_!YBUYHM_P""-&T_PKX>NX+2
M:VN9?[<&D6_VZSN#(ZJ+6_N;B<7"/*I*RO'G2;E%2?5)VZZW4N[O3E%\VEFG
M%II.[=;W+\NMKK[M8_\`@<7%K6Z?,FFU8^V;[]O_`.#PUF&QTOXD?#_Q!-'=
M1V^I_P!G^+M)8Z%&]E<7J7%TLETCB-H+:1@(U>0KEPGEI)(C/V-?V^OAC^W5
M\-=)\1>`_%&BWTFK6T]X-(&J6D^IVD,4_DLTT,,LFS#%,\D#S$&>1GYK^`_P
M#\1>#?V4_P!B;2(_!VN:;=>&?'+:GKUF=+FCDT@2Z/KWFSW2%<PAI[A`6D`&
M^91G+`'QJ6Q\<?LP_P#!/3X(_$SPQX4\267Q7^%MSJGPQO-%U72[C2YKS^W;
MG[+`JBX1//A34SI$ZS1;XV2.;8S$G!S-:)<SORI+=MI)6OI9SE%.^D4VV^AI
M4IKF23LN7FN_\4[KUY8MZ;Z)+J_T^\*?%[PGX\U".TT/Q1X=UJZEMY+M(;'4
MH;B1X8YVMWE"HQ)19D>(MT#HRD[@17F?B3]O'PKX9^&OQ6\22Z)XMG;X1:^?
M#.HZ7#:0MJ&J7S1VCVZ6:&8(XN/MML(C(\>3)\VP<UU?[._@#1_V=OAGX/\`
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M:@.Q-TT4C"``1R',A7A&/8X^(;/]CKXA>./!/[1W@ZP\-ZAIMSX)\%Z[\/?A
MO+<(UC;ZK;ZK=W.H[+65L1B,6YTJT,JL0'MG!*E2HD^/FEWG[5U[_:WPQ^%O
MQ$\)Z;X$^"?BOPSK$.K^"[[P[-<27ME`FGZ#:P3PQM?&*6WD?-L);>,JH20F
M8`Y8BNHTG6A'[,I*/5*TY1N_.*@GLU*=G:249;4:-ZT:,GIS<KET=G%-KU<I
M6Z-0NKIMQ^OM9_X*$_`+PYX<GUC4/CA\'[#2+759-"FOKCQEIT5M%J$:[Y+-
MI&F"BX5?F:(G>!R1BFV7[=OPWU+]LS_A1-OXBTJ7QY_PCB>)5MEU&U)EA=R%
MA2,2^<TWE*9RNS`B9'R0W'S7^U-\,(?A;X1^".KZ"WQC^'7C#POX"F\.:9K'
MA/X:/XZT6"U;^S'FT;5=*AMY[H)-]E3:\0ML"&53=1L51['[*W_"6_#/]J/P
M#XD^('PWN/`<=Y\!K73)[+PMX7NY-!T*ZL[V:YDL%%LLT=F4MRGEV[R$D_NH
MFF9>>FI&%.NX2?NQ<TWTM&%5IWZ7<(O6WQ6U5I2YHRE.@JB7O24&EU]Z=--6
MZV4I+2^U]'>,?K3]I+]H+1OV7/@[J7C;Q!:ZI>:3I<]I;RQ:?&DEPS7-U%;)
MM5W1<!YE)RPPH.,G`/7:_P"(+#PGH5[JFJ7UGINF:;`]U=WEU,L,%K"BEGDD
M=B%5%4$EB0``2:^;?^"H,EQ\8/\`@F]XBO\`PEIFN>*%U3^P]6LK;2-*N;Z^
MN[8:G97!>.UBC:=R(59RBH7`!XR,5YS_`,%`?B>_[=?[*>K>'?AGI/QM@U'P
MWK6B>)M6M9?AMJ_A^^U+3++4[:>ZAL?[<T^.SN[H1H72U<2"8QA&1E8BL9<R
MDX/1J23_`+J=DVUII'5O;1/5&T+-<_2SMYNVB3[O1+S:/J;P/^U;\+?B=\*]
M5\=>&_B5X!\0^"-"\XZEXATSQ#:7>E:?Y*"27SKF.0Q1[$(9MS#:I!.`:H^#
M/VT?@[\1_AIKOC3P[\6/AGKW@[POD:SKVG>)[&ZTS2,*&/VBXCE,4.%(;YV'
M!!Z5\1ZQHVKP>%OB=\2/"-E\>?C!K6H#PQH^H7GQ;^$EM%IOV>#55F:\@\/V
MFGZ3J>I7.G1R23JPBY)C6&21XV1.!\)_![4_&OQ6^.GB7QU:?M5>,=`UK2?A
M]JNE>-U^'-GH_B*74-)U>^=[RSTL:?"6CLYC#(;6ZLIKMX$8B*YC:!I-%&][
MZ;;].K>MK^[JK\L79I3?+)J?LN6^UO.[2MULTV[VYI:7Y%=(^Y/BW_P5$^!W
MPD\'_#OQ%+\1O!>L^'?BAXC3PUHFKZ;XBT^;3Y9<N)IC/YP1H8639(R%RKO&
MI`W9'T%7YCZ-#\3-7\">$_$GB3POKGBC2/#/QST76G\66'PHO_#/B;Q=8IIK
MVT^JZEHB1M=&6*5HK<W`MXA)'`KB&.%%8_H]X-^(.E>/I=8CTN:XEDT'49-)
MOEFM)K=H;F-49E`D5=Z[9$8.N48,"K$4J>L&WOS;?W>2E+\)3:OWLM'H3*5I
MI+;E7W\]1??RQ3MZLY']K+]J#P_^QU\"M6\?>)+/6M4L=-EMK2#3=&MENM2U
M:[N;B.VMK6VB9D5YI9I41064<Y)`!(T/AA^TCX*^+G@CP'KVD>(--^R_$S34
MU7PW!<W"076JPF!;AO*B8[G9(F#.J@E`#G&*\$_;-^'/Q6_:/_;#^&'AWP'>
MZ7X3\._#&WG\=:EKGB3PK>:SHVIZHX>RT^Q6.*\LA,\<<E[<MMG/E.EJ67YU
MS\\6/P!^+O[.OP`\4>'Y-`O?&GBS]E[XAV_Q+\!7/A[P[>V=GXHT.^\Z2_T?
M3TEEN"9D@NM6M$MA<2L@^Q[B`RFHA-*#G4TUNGVBI*,G;=N[<K:7A"ZO<TJ1
M?,HT]7;5=Y-.45=V26D8WN[2GK;E9]]^/?VK_A;\*O">H:]XH^)7@#PWH>DZ
MH=#OM1U3Q#:6=I9:@%W&SEEDD5$N`O/E,0^.<4>//VK_`(6_"OP/I?B;Q1\2
MO`'AOPWK=JM]IVK:IXAM+.QO[=C$%FAFDD5)(R9X0&4D$S1\_,N?ST7]D[XA
M?L]7/[._CCQ#KGQD\-(?#?B*Z\9ZI\.?"UMXFU;1O%.NW=OJ=S)-I\VG:C*T
M#D7-MYUO;M)%Y<2,R12,:]3_`&7OV9_^$8^-?[.^K:?H?Q:OM`TU_'6NB^\>
M:+9V.H:7/J$EJ4D>"Q@A@L%N-]S)%;O%#,JRNKQ1N'1=%&2TGNFT_)IM-:7^
M*W-%MKW6M'N1*2YO=U3VZ735T_EI&2L_>OJM$_JW_ALWX/CXR0_#K_A:WPU_
MX6#<LB0^&/\`A)[+^V96>(3(%M/-\XEHB)``O*$,..:DUO\`;"^$GAGXJW'@
M74OBE\.=/\<6KVT<WAZY\2V4.JPM<O%';JUJT@E4RO/`J`K\[31A<EUS^;_[
M0MC\3OBSXGT^SF\*?$O2[CPQ\<-*\03>`O"'P@_L_P`-6VGVWBI9)-=O-9N+
M>4ZI>3V[QSO)IEW&?WK&6VV1W4BW?CMI$7@/X/?#WX5:]\-?%DOQ%T/]I'1_
M$MUX@D\+7*Z-*MWXL6Z75XM7>,6DLDUK=1P&&.9KE6D=&B"1.5K"Q55TD_MS
M4;>3=)<RZ-+GEM>_+T][E=?]W[2VJA&3OTO'GT?KRQ[6YUJ_=YOTAD_:>^&L
M7QL7X:-\0O`Z_$:2+SE\*G7K4:VT?E^;O%GO\_;Y8+YV8VC/3FNVDD\J-F/1
M1DU^6/PR_9L\0:7J6I?#'X@>(?VLI/$4WQ7NO$T>F>&O!.C7'AF_\S66U*TU
MB/Q!/I#+#&D)B:59M32Z0PR01QG]S&_Z9>%_B!I?Q`BUR/2YKB:30;^72;Y)
M;2:W:*YC5690)%4NNV1&#IE&#`JQ%<M24OJWM8_%RMV]%'7Y.2B_/>S?*G+W
M:K@]KV3[ZR2^]1YEY;72YGXC\)O^"GWPY^-/[)WAOXPZ):>*3X?\2>(-,\,C
M3[FQCAU33KR_O[>R@6XB:7:J[KJ"8LKL&AD61-X90WJ<G[3WPUA^-B_#5_B'
MX&7XC/%YZ^%3KUJ-;:/R_-WBSW^=M\L%\[,;1GIS7YW:=^S-\1OAI^Q!^S#_
M`&'X)\23MXAO?A[8>/-!BTN1;_1+K3M7TZXCU6>`J'18K>">WN&8;E5;0L`D
M+%>D\3?#WQ!>?`W6O@5;_#GQROQ@U#XR2>+;7Q(/#%V-$6)O$?\`:D>O'6Q'
M]C5H]-"Q>49_M.Z/[.(MI&>V<(\[C'_GY*/G9>S5^UO>E/=^ZK-JTI1==*%W
M'U]$^=J_7[*@]%>3NMXQE]\6GQ^\":@-)^S^-O",W]O6%QJNF>7K%NW]HV=O
MM^T7,.'_`'D,6]-\BY5-ZY(R*Z#PUXFTWQIX=L-8T?4+'5M)U2WCN[*]LYUG
MM[R&10R2QR*2KHRD$,I((((-?D_\>OV5?BEI_C/Q=IOAOP7XR^P^#?$NH^"?
M#=Y;:=+*MUIWBN/6IKF\@VY4VEG+JVEK)*3MC.GS;]NS-?J]X4\,V?@OPMIN
MCZ?"MOI^DVL5E;1+TCBC0(BCZ*`*PI^]251];?C=Z_\`;KIOR;DGMK-7W*OL
MUJM=>CV2:]9*?R47]HT****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@#@_V5_^38?AQ_V*^F?^DD5=Y7!_
MLK_\FP_#C_L5],_])(J[R@`HHHH`****`/BG_@IS_P`%0M0_9,\4:?X-\&Z:
ML_BAA#?WUYJ-L_V2*W+9$48./,:3!#.IP@R`=^=G7?#_`%>/]M'X7Z)\;OAC
M%/X3\?6Z-;W-O=1%;?4VC`$EI,Q`6:,\!)A[`[67$?JG[57[&_@?]L7PE:Z5
MXPL;@R:?,)K._LG6&]M.1O5)"K#8X&&4@@\'A@K#Q+X9_%WQ%_P3GU/2?AW\
M4W74OAC(RV/A?QS!;B..Q'\%IJ*KQ&P'`EZ$#))&\IZV,R[+\SRR.%IP?MHN
M][VD[=8/NMTE9K6U];\.#S#'9=F#Q,IKV4E:UKQUZ279[.^C\M#W_P"`/[05
MC\;M(NH9+:;1?$^C,(-8T:Y&VXL)>G0_>C/\+#K['BO0J\C^.GP%D^(-W9>.
M/`^H0Z/XZTV$/8W\39M]5AX(MY\</&PZ-SC(ZBM;X`?M"6_QBM;S3=0LWT'Q
MEH3>3K&C3G]Y;M_ST3^_$W4,/4>H)^.P>-JT:JP6.^/[,ME-+\II;QZ[QTNE
M]1C,%2JTGC<#\'VH[N#?YP?273:6MF_1J***]L\4****`"BBB@`HHHH`****
M`"BBN-^,/[/_`(1^/EG8V_BS26U:'37:2W3[7/;A&8`$_NG7/`'7..<=36=:
M510;I).71-V7WI.WW,3O;0U/B+\,O"_Q6T%=/\7>'M!\2:7;RBZ6VU>PBO+>
M.1591($E5E#!68;L9`8^IJ#X4>`_!_@'PC'#X'T7PWHF@ZBWVY$T.SAM;2Y9
MU4><!"`C%E5!NYR%7G`%>*?%?_@F=\/==\!WUIX2T2UT+7IM@M[ZXOKVX2`!
MU+?(92"2H8#((YJC\$O^"8G@SPSX1DM_'&GV/B;5OM+/'=VUU>6JB$JN$*K*
M`2&W<@#@CK7BO%9E]84/J\-K\W.[>E_9WO\`*WF'UG$<OL?L[VN[?=;]#Z0\
M2^)=/\&^'+_6-6O+;3=+TNWDN[R[N)!'#;0QJ6>1V/"JJ@DD\`"O,KW]N#X=
M6'ACP7KDEYXH;0OB!;I=:1JD?A#6)+%$<H$^USK:F.Q9VD152[:%F8[0"V15
MOP3^RAX7^"-IK5Y\.=/LO#7B34=/DM+>]O7N]3M8I#S&TMNUPAD19`K%5DC9
M@"H=,YKQF']@OXL'X2?"WP?=?%KX?7FE^`?._M&"3X>WRVVN'*BUF6-=:!BF
MMXS*4\UKB'SG2;R0\,.SU*<\0X7G%*79-M=>K47?;I9>=[K6DHNWM--]OE;I
M_7RL_6-%_;L^&>L_!_1?';ZIK^D^&_$>JVVBZ5)K7A;5=(N]2N;@H(1#:75M
M'<21L'#^:L9B"+(Y<)&[+3B_X*!_#*]'B3[#<>-M8;PLX6Y32O`>O:@]^OV@
MVS2V"P6;G484F&R26R$T<1(WLH8$\KK7_!/S_A`OV,=#^$?P<O/AS\,!I]UI
MMY?WH\#?:++4I;5H97F-G:WEGMGFFMX6>5I7.T,I#$AUY27_`()L>+=3\!7F
M@ZYXP^$?C+3[#2?^$<\/:9XG^%\NJ:+;:8][#=RIJ%HVJC[?<;K:U$<JR0)&
M8=QB=FR.RMRJJXTM8ZZOKIHU\^Z3L]M-<:/,Z2=323MHNFNOSMV=K]==/JCP
M!XZTOXG^!M'\2:)<276CZ]91:A9326\EN\D,J!T+1R*LB$J1E7564\$`@BM>
MN5^!WPVF^#OPA\.^%[C5KK79]#LH[62_GW!KA@.2%9G94!X1&=RJ!5+,1N/5
M43LI/EV"FY.*<M^H4445)04444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!7)^.?@AX<^)/CCPSX@UJWU"\OO!\[W6F0_VK=QV"3L`!-+9I(+>XD3&
M8WFC=HF):,H237644=4^JV#HUWT"BBB@`HHHH`*AU#3[?5K">UNH(;JUNHVB
MFAE0/'*C##*RG@J02"#P0:FHHWT8)M.Z([:VCLK:.&&..&&%0B(BA510,``#
M@`#M4E%%%[ZL$K*R"BBB@`JMIFC6>BI,MG:6UHMQ,]Q*(8EC$LKG+R-@<LQY
M)/)/6K-%`!1110`4444`%>+^%/\`@GS\)_!7Q4_X3#3?#^J0ZA'JLVO0:=)X
MCU.;0;+49B[2WL&DO<-I\%RS22.9HK=9-\LC;MSL3[110M)<RW_I_HON!ZQY
M7M_7^;^\*K:9HUGHJ3+9VEM:+<3/<2B&)8Q+*YR\C8'+,>23R3UJS10`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110!^;?_``3T\5*G_!036CJ,GP8\7?$;Q)JGBY?%+VGA22W^
M(?@JTMM3V6":EJ+WDS-8R0+;100FWMD:,V[1;U0EOT0\87FMV6DA]`T_2]2O
MO,`,.H:A)8PA.<GS$AF.1QQLP<GD8YU**(Z4XP_E5O+3MY>K?J#UG*;ZN_\`
MP_2_HDO)'!_LK_\`)L/PX_[%?3/_`$DBKO*X/]E?_DV'X<?]BOIG_I)%7>4`
M%%%%`!1110`5F>,O!FD_$/PM?:'KFGVFK:1J41@NK2ZC$D4Z'L0?S!Z@@$<B
ML;6OBYI_@_Q;<:;X@\O0[5H&NK'4KF95L[V..,O,N\X$<L85V*-UC&]2P601
MZ/@+Q;-XXT-M2;3+O2[6XE;[$MT-D]Q!@;9GC(!BWG)"-\P7:6"L2BZ<LXVF
MM/,)1NK/8^5IK'QC_P`$O+]IK)=6\=?L_2.6EM<FXU;P,"<EDSS-:#J0>5'/
M!!,GK7C_`.'6B_M-^&M#^(WPW\06-OXEM8OM&BZ]9MNAO$YS;S@<M&>5*L-R
M'<"/O*?:)8EGB:.15='!5E89#`]017R?\0/V<O%W[%GC#4/'WP.LVU7PQ?2&
MZ\2?#O>5@N/[]QIW_/*8#GRP,-C`!PJ#JQF&PV;TG0Q5E4>TME)K9M_9FGJI
M*VN]GJ<^#Q.(RNJJV&U@MUO9/=6^U%K>+Z;76A[)^S[^T.OQ4-YH.N69\/\`
MCO0ALU72)>.G'GPG^.)N"""<9&2059O3J^=X+SPA^WU\/-.\=_#O7)-&\9:"
M2MI>[?*O=*G&=UG>1<G:3D%3D8)*[E)#=M\`/VA9?B#?WGA;Q18CP]\0-#4"
M_P!.8_)=+VN+<Y^>)NO!.W/4C!/S%'$8C!8C^S\Q^+:,FK<UNC[375;26L>J
M7T-?#T,70^OY?\.\HK7E\UW@^CWB])=&_4J***]D\8****`"BBB@`HHHH`*\
MW_:+^)WQ"^&NFZ7)\/\`X8M\3+J[E=;R'_A(K71EL$4#:Q:<'>6)(PHXVDDC
MC/I%%73DHRNU?R=_T:?XC6C/D#XC?MC?M(>';;29!^S8NDR7&J06Z(?'^FWA
MU'>2&MQ&B;\E=S[T/[OR][9C5U)\.?VQOVD/$5MJTA_9L75I+?5)[=T'C_3;
M,Z=L("VYC=-^0NU][G]YYF]<1LBCZRUKQ%9>'%M6OKA+5+RX2UB=\A3*^=BE
MNB[B-HSC+%5'+`&EX"^(>B_%#PY%J_A_4(=4TNXQY5S"#Y<N55OE)`S@,`<=
M&#*<,I`[?K$.2_L(^OO?_)?J/ZS2YO9V7-VOK]U[GSCX^^-'QT^(7P.\=VVM
M?!O7_AFUOI:S0ZCHGBFWUS4IXA/$+N*UBM$\\77V4SM$8U9S(JA!O*`_/_Q@
M\8_&SP]\`["V^%_@']I3Q%X'A\9QZGH=X-2EB\4?8$O=.3[+?KK=]!JYMY&?
M56Q,CD(MMYC16ZMG]&O$NO1>%O#E_J<\-]<0Z=;R7,D5G:R75S*J*6*QPQAG
MD<XP$0%F.``2:\)\5_\`!0.#PW\)?`?CBW^%?Q-UCPSXZBM7:ZLY=#C;07N9
M4BCBNXI]2CD=]SY/V5;@`(QSQSYF(E!R<_A3LK*]M[IZMNZ:T=U:[6O-8VC)
MMQY8[._X6:UZ-/5:WT['B'_""^/OV6_^":/@E?%'B[XO>)/&4WB#1-8NF\*Z
M3XJUG6)PSV\MQ9WB2W.JZ@L*)',TNR6"!F18O+196AEQ_AKXL^+%O8^)[WPI
MX9_:$\4^)-5TE[7QO;ZG+>:<+;4YM211-H":]/:V""&R-\R_8&6#/V0R"1@%
M/NWP?_X*B^"?C7^R]I'Q8T?P_P"*+C0-:\06OAV&VL;O2-:N+>6>2)!-<2Z;
M?7-K;QIYP+K-.DJD;/+,CQ1OF?$'_@K3X+^%_@;7_$NM>#?'&FZ#IR17.C:A
M?W>AZ=:>++1K^.P:[M)KK48HX($FG@+-J#6A*3(R!P3C7&7E6?/[K=THKLXI
M6:W>C3TL_=3W@VN/#Q_<*,'=:7?FI;KM[VE]5JULT>I?L*ZIXFU?]C/X73>,
MM+\4:+XL_P"$8L(]6M/$DJR:LMRD"I(URPDD)D=E+G>Y?Y_G"ON4>K5@_"SX
M@6_Q7^&GA_Q19P/:VGB+3K?4H(7NK6Z:-)HUD53+:RS6\F`P^>&62-NJNRD,
M=ZM,3)RK2E)6=WIVU"E;D7+M9!1116)H%%>9?MG_`+1G_#(?[)OQ%^*']C_\
M)#_P@.@7>N?V9]K^R?;_`"(FD\KS=C^7NQC=L;'H:I:O^W=\&_!MUING^*/B
MM\,O"NO:E+#:+I.J>*K&UNUNY(89A;".217,NRX@;9MW%9HSC#KDCJ[+?3\;
MV_():)-];_\`DMK_`'77])GK5%><:)^V+\(_$MYXPM]-^*GPXU"X^'B22^*H
MK;Q+92OX92,NLC7P60FU"&-PQEV@%&SC!JW\+_VI_AC\;_&.M>'?!?Q'\!^+
M_$'ALD:OIFB>(+34+S2R'*'SX8I&>+#@K\X'((ZT1UM;JK_+OZ!+3?O;Y]O7
M4[RBN!\-?M6_"[QG\8=1^'>C_$GP#JWQ`T<2&_\`#-GXAM)]8LA'MWF6T60S
M)MW+G<HQN&>HJ+Q?^UU\)_A]\6K'P#KWQ.^'FA^.M4$9L_#FH>([.VU:[$F1
M'Y=J\@E??@[=JG.#C.*7,K)]]O/T[AM>_3?R]3T.BO$?V*?V^_A[^WGI'C*\
M\!Z]H.K1^#?$5YH-S'8ZQ;7\K)!,\,=XRPNVR&X\J1X6)Q)&`P/)`]*^+'QC
M\(_`;P1<^)O'/BKPWX+\-V;HEQJNNZG#IUC`SL$0/-,RHI9B%`)Y)`')IO1*
M3V:37I))K[TUIOTW#[3CUBVGZQ;3^YI_GL=)17"WO[4?PST[X9:3XVN/B+X%
MM_!NO*S:9KTFOVJZ9J(6*69C#<F3RI`(H)I#M8X2&1NBL1J?"7XT>#OC[X*A
M\2>!/%GAGQKX=N9'BAU70=4@U*RE=&VNJS0LR$JP((!R",&G9W:[;^7J'1/O
MMY^ATU%?*_Q/_P""I7A3P+^WVGP-@U7X5P2:+X=_X27Q7JGB'Q_!H]QI$'[Z
M1H;>S\B4W%Q%;0/=2I+);K%`R2%BK9'T!XI^.'@OP-;V\VM^,/"^CQ7FF7.M
M0/?:K!;K/86R))<W:EV&Z"%)(VDD'R(KJ6(!&9C).FJJV=]?1M/Y7B]=G9M:
M(J46JGLFO>TT]4FOP:]+ZG445POPN_:@^&GQP\5:WH/@OXB>!?&&N>&6"ZQI
MVB:]:ZA=:42Q4"XBAD9XCN5A\X'*D=J\W^+?_!4OX"_"WX4_$CQ/#\6/AOXF
MF^%NE7.I:WI&D>*].N-0@:$F,6[1B;,<TD^R!%?;F61$^\0*52HJ<>:6UF_D
MMWY_(*<'.2A'>Z7S>R^9]!45Y3^SU^U=H'[2DNF7?AC7?A_K6BZMX9M/$$#Z
M/XJCU+4`TTTT,@:WCCVBV1X6C6X$IWRQS1F-#$2VU\,_VI_AC\:?&>N^&_!O
MQ&\!^+/$7A=F36=+T;7[2_O=(97,;"XABD9X2)%*$.!A@1U&*TJ0<).$MU?_
M`,E;3^YIF<:D91YX[:?BDU]Z:_X<[RBO-_A_^V3\(?BUX[7PKX3^*GPW\3^*
M)+%=331]*\365Y?M:,B.MP((Y&D\HI(C!]NTAU.<$5FVO[9WP]\)_!WP[XL\
M??$/X2^$;?7]-;4X[I/&EM/H\\2/%')+:WLRVXN(%>>!3*(T&Z:,$`LH,WZO
M^M_\G]QHHMOE2U/6J*X'Q-^U;\+O!7P>L/B)K/Q)\`Z3\/\`51$;+Q->^(;2
MWT>\$N?+,=V\@A??@[=K'=CC-:GPI^.G@GX\:1<:AX'\8^%?&5A:/''/<Z%J
MT&HPPM)"D\89X78*6AEBD4$\I(C#(8$NSNUVW\O7L3=63[[>?H=517+_`!M^
M,.A?L^?!WQ1XZ\3W36?AWP?I5SK&I3*NYD@@C:1]J_Q-M4@*.22!WKQ7X1?\
M%"(_$?QEUWP?\0/#^D_#.3P[X-\-^*;V\U#Q$CPP7&M7-W;1:>QDAB42));Q
MQAMQ\R2<(J\`NHZNR_JZ;_*+^[S02]V/,]O^#%?G**^9])45\T_'S_@K7\"/
M@K^SOJ'Q(L/B;\.?&6BV.MV7APMH_BW3YHOMUU/'&(FE64JICCD:XD7EEAAE
M?:0IKTKQK^VC\'?AL_A=?$7Q8^&>@-XW@CNO#@U+Q/8VIU^*3:$DM/,E'VA&
MWIAH]P.]<=11'7;O;YM72^:=UY!+W?B\_P`'9_<]'YGIE%><_&G]L+X2_LW7
M8M_B'\4/AWX$N6CBE6'Q#XDL]+D99?-$1"SR(2'-O.%/\7DR8SL;'B_[%W_!
M5KP7^TO^RC=?&KQ=KWPE^&_@%[];.TO)/B';WWV(MC9!JCR06\-C>E7B;[,)
M9B!*OSG(R1:=[=+7^;LOQ&XM;_UI?\E<^KJ*X+5/VJOA?H?PKTSQU>_$CP%9
M^"=:5GT[Q#/X@M(]*OU6*69C%<F3RI`(H9I"58X2*1NBDC.\6_MM?!GP#'X5
M?7?BY\,=%3QU;QW?AIK_`,4V-L/$,,FWRY;/?*/M"-O3:T6X'>N#R*?*[\O6
M]OGV]='IY"OIS=+7^7?T\STZBN-^+W[1OP]_9\LX[CQ]X\\&^![>:"2ZCEU_
M6K;34>*-XHY)`9G4%$>>!68<!IHP<%US5\1?M2_#'PA\&[/XC:M\1O`>E_#W
M4$BDM?$]WK]I!HURLIQ$R7;2"%@YX4ASN/3-3S*U^FP^5_UY;_<=Y17GVK?M
M:?"O0?@K:_$J^^)GP^L_AU?%1;>*9_$5G'HMP6<QKLO&D$+9<%1A^6!'6JGQ
M(_:2L=+_`&8]1^*/@*/2_B=HMC8?VQ;_`-B:M')#JUE&P:X>TGC$D<TBPK*T
M:`A9)$5"\88NI*2BFY:*.]^GKV[Z]-0@G-I1U<MO/T[GIE%9?@GQII?Q'\&:
M3XAT.^@U+1==LX=0L+N!MT=U!*@>.13W5E8$?6M2KE&49.,E9HB,E**E'5,*
M***DH****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`***"<"@`HKXM_9-_P""E7AW]J+]O+6/#^B_
M%WP%K'AW4M(U"+0O"&GZOI]QJ$,EA=Q1-=S(O^E)/.#=2"%F*K;Q0/L1S+7U
M]XP\8VG@?21>WL.JS0F01[=/TRYU";)R?]7;QN^./O;<#C)Y%$?>IPJK:2;7
MHI./XVOZ6O9W2).U2=+K%V?K9/\`6U]NUU9OE_V5_P#DV'X<?]BOIG_I)%7>
M5P?[*_\`R;#\./\`L5],_P#22*N\H`****`"BBB@#Q#]KC]ESQ%^U=X8O-&7
MQE=>#;+3YH+S17TQ!*\EY'AUGN@P!*H_W(XV&TJ)"Y;8L?`>#?VW/%G[,NHV
M/A7]H[15T=I'%K8^/=+C,V@ZN>BF?:,VLK=2&4*?F.$4"OJZJ7B/PWI_C#0K
MK2]6L;/5--OHS%<6MW"LT,Z'JK(P(8>Q%=E/%+E]E5C>/W->:?\`G=&D:FG+
M):$FCZS9^(=*M[[3[JVOK&\C$L%Q;RB6*9",AE920P(Y!!P:LU\HZQ^Q?XX_
M93U:XU[]G?7(X=*FD,][\/==G:71[LDY8VDK'=:R'GC.TDC+!0%KNOV>?V]O
M#'QE\4-X/\06.H?#OXE6P`N?"^O#R;B0_P!ZVD("W"'!(*?,0,[0.:)X6\?:
M47S1_%>J_577F#IZ7CJC&_:)_8\UBQ\?S?%3X,WUOX7^)4:YU"RD^72_%T8.
M3#=(,`2'M+P<]2#ATQ/"WQ`\._M[Z5):[+SX;?'#P$^9;*X&S4-'F7KCIY]H
MY/4<8<9`W#=]45XO^U5^QOIO[0<MCXBT;4KCP;\2O#HWZ)XFL1B>`C/[F8?\
MMH&R04;IN.."P8K+#9AA_J>8JZV4NL>U[:M+=->]'>/8Y*$\1@:_UO`NSW<>
MC[^5WU3TDM'W+_P"_:%NO%FMW7@OQI:Q:%\0='7,]L.(-4B'2YMB?O*1R5'(
MY[`X]9KXXTKXDM\??$5K\,?BY;CX<?'3P[_I'A_6K-MMKK!'W;FREXW*Y'SP
M$YX.,,K!/:?@-\?]1U+Q))X#\?6T>C^/M-CW*5XMM=A&<7%N>AR!EDZCG@89
M5^=OB<MQ"P.8NZE_#J=)KHFUIS=GM+I:5T>]*&'S"@\=EZLX_'3ZQ?5I;\O=
M;QZW5F>O4445ZQY`4444`%%%%`!7"?'+]FGP3^TE8:?:^--&;6;?2Y'EM4^V
MW%L(V<`,?W,B;N`/O9QSC&37=UQOQ?/Q`^QV/_"`KX-^T;V^V'Q`;G8%P-OE
MB$9SG.=Q[#KGB*F*GAH^VAS77\N_;0/J5/%_[/6Y>66_-;E[ZWNO^">0Z_\`
M\$I/@KJ45NECX5.F[+A))Y%U.^EDEB7DQKNG*KN.`6*M\NX`!B&6C\.O^"2W
MPB\,^%K>SU_1/^$FU"$`/J#7E[9O/\J[BR1W&P?-N(V@84J#N(+M>^*_BO\`
M:4\&>";J^M]-^&^J,F%,>@V][<7T8/\`&D<I"OCC@!CS]TC)#?A)XN_:4\:^
M"+:^N-,^'6ELQ*!/$%M>VU],!_RT>.([4SR`"%/&=N""?/\`]>L3[7ZKRU[V
MO\+V];_\`W_XAOEOL_K=L/:_+O'_`-)M;\+G;_#G]B3P#\$8=<F\`V6H>"M8
MUO3I-..JV-])=W%H&Y66..\,\!D1@K+YD3KD8*LI93G?#+]B#2?A_P###P7X
M5U#QAXT\8VG@-+U-,N=9.GI.3<026X>06MI!&SPPS31QL$!`F<OO;!&A87GQ
M1T_PCXIF^(%WX;T_2H='N)(;SP-9WU]K%K($)+PV\D,WG2!=Q1$BD9G"J(WS
MMKXN\;:OX\\:_L]_L^ZQH6J?'K_A+=!TV:SG\,ZCX5\?6=UX@NXYK92]_?07
M%I%;2((VVRZQ'<P3*[D(XW$]$L<\7"52M&3NK-2NY62?35ZV25M7?HD.GEM+
M`N-'#N$8IW7)91N[=4DNNM]%\S[/^,'[(D'Q2_9RT'X:Z?XZ\;>"=-\/_P!G
M+'J6B+IDFH7*6.PPI(;VSN(<>9%%(Q2)6+1@9"EE;E_!O_!/L_#RRU#^Q/C%
M\6-/U#['_9>A:@(]!EF\)6#7*W$MG91R:8T#1RLD:LUU'<2A8D"2)C->)?\`
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MS[6_#IZ!3=X)^7K^/4****S-#YE_X+/_`/*)K]HK_L0-6_\`29Z^+?&?@;1;
MO]G3_@IYJ\VE:?-JEUX=M+.6Z>!6EDAA\&6<L498C.U))'<#LS$]:_6RBL:M
M'GA5A?\`B0</2[O?S[6T]3HHUN2I2G:_)+FMW^'3_P`E\_P/R)_X*B^&].\!
M?#WX?:;HMG;Z3I\/[*GCW3E@M(Q$@M8M/T<QPX'\"$`JIX!YZUZ9\/OBU\,_
MC1\8OV0--_9V.CZMJ'PKTR_F\466B01QW7A/03HLL#:5J*H,V4T]^;/;:S!'
M:6V=]O[EF'WO^T7\#=)_:;^`?C+X=:]<:C9Z)XXT:ZT._GL)$CNHH+B)HG:)
MG1U#A6)!96`.,@]*Z/PCX:@\%^$]+T>U::2UTFTBLX6E(,C)&@12Q``S@#.`
M!GL*ZJE1U)U)/3F=UUU<JTWOI9.HDTU[RYEI?3EC34:-.EORJ2?HXTH^MVH-
MIW]UV>MC\8/AA^T5I?BGQ=^Q)>/\1/AW8Z9X<\?1)<_#_P`):/*I^&<E[8:C
M"UKXAU*ZNKJY_M![J:.V7S39_:)3=,89V`:'ZA_99^-?P7^"$'QG^&WQTO/"
M\/Q(\2?%W5M6N/"VO6:ZEK'B^.XU))-%N[+3_+>XOXEMULUB:".41&U(RAA8
M)^AU%33ERMONY7]&Z3LF[NZ=-6;<M]=D56O/U7+;UC[3HK*S]IJDEJK]6?)/
M_!)CQQHVHZ'\<O#,&J:?+XD\-_&+Q=+JNE+.OVW3H[K5[F:V>:+.]$FB.^-F
M`#KDJ3@U5_;\\3:3\(OVU_V=_B)\1K_2](^#_A<:[;WFKZL%72]`UZYAMH]-
MN[F9AY=MF,7L"7$C*JO<!-P:50WV!16<4XQI)?\`+M07KRQ4;^3TNM^65GK;
M6I2YIU)/[<IR].:3E;S2O9[75UI<_)5/#&A?%S]H/1O$6EZ7:ZE\'_'/[66G
MZYX4E>$/I>N2P^$[K[7J5F"H22"34H))%G3*2R1M(K/G>WV%^PSIEOHO[;_[
M8EO:Q+;P2>.-%NFC3A3++X:TQI'Q_>9N2>YKZHHJJ/[N/(MK6^7+1C_[A3^?
M2VI4ESSYY=OQYZD[^O[QKONV]6?GW^W-X1U3X@?M0?M5Z#H>GW>K:UK7[+<=
MC865K&9)[R>6[\0)'%&HY9V9@H`Y)(%?//[9O[7'P[_:A\#^#5^'_BK2_%BZ
M+^S+\1CJ<FFS"YBTR:31]*'V2=TRL=TFPE[=B)8P4+*H=2?V*HKG="]&5&^Z
MDOO]OK\O;;=>7=7TZ:>*Y<3#$6^%IV](THM?/V2MVYGH['Y?_MI?!G4+6'X)
M^'?A3I/]E^*+S]G#QYH6@6^D`6LI8:?HOV:WB*X"D2-\G3#-G(/-=!\4/VA/
MV=/C7_P3)\0>"OAO-X1\0?$'PS\$/$-AI.A:3I@OM;\$Q#13%=6ETD41DTIV
M=(X6CN/(,LD8C"LZ[1^D%-,R+,L99?,8%E7/S$#&2![9'YBNC&7KQK1V]IS?
M*\JLE_Z==^]NEV<V#E]7]@UJZ7X_`G?Y4TEV\[(_,BS\1WW[1WC+XI7'P7\0
MZ?KFN>(OV3]'M/#.IZ1?)+')??:]<A01S(2HD68%#W1U(."#B[X4^)_PP^/7
MC']BSPW\#9='OO$WPJU&5_$6FZ)"(+OP!HR:'=6M_9ZI`%#Z>9+LVL7V>X$;
MR31#"L8B4_2RBG7?M'-[<SO\^>K-?+]ZXR7VDK:7TR4;04>T>7Y.G3IM^MJ=
MXOHWUL?E-^S+X!T7PG^P!_P3@NM+TNQT^X_X3RWN#);Q"-FDN]$UR2Y8D=3*
M_+D_>/6K?_!/OPIIOB75/^"<4VH6%I?3:/\`"SQ;?6+SQ!S:3A-'C$J9^ZX2
M61<CG#GUK]3J*J,VJDZG\TW+T]QPM\KWO\K=3>I4YI<W]WE?G[TY-_/GL_3S
M/R/_`&9_$'A?]G']K/PGXU^(EWI?AGX0>&?'OQ;T72M8U61;?1/"^O7&OQM;
MM-/(PAM6ELX]0ABD?:"7>,-NE"GZ&_X(MZSX-\5_$C]K;7/A[;P1>"]<^+KW
M^FSVUH]O:W_FZ+IDLMS"&`WQ32R/,DB_)(DR2(2CJ3]0?'W]GG4/C1J>AZCH
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MK/M`!;:"<9.222J7NS4G]F2DO/2S7DE96WNW+;J.3Y>6/6U_*THR5N][-/:V
MF_3\S/\`@J]:Z7X"_:8^,VI+';Z7IMK\/_AEJFJ3(OEPPP6GCJ8O/)CA4B@C
M)+'A40]`*I_$SXHV?@']K/\`::U'QO\`'#]G'P#X0^+UEIEYH-U\1/"$WB"#
MQKX5_L>&-8],NDUBR@NH$G:\#6D,<S^9/YAW"XCS^L%%9QI_NO92U7OWOUYY
M<S^:LE?MS+[2Y='5]]SCIK!Z=.2,8K_TEOUY7]G7\^?^"??PJC^'7[<FCZ=>
M:YJGC34_"_[-GA?2;?Q#K&AW&BZE>P?VKJ@+2VESFXMW<0P[HY29`4&[YLU\
MZ_"Z]\0_#C]G_P#8!^(%QXV\`?#OP#X:\"ZK:OXE\<:!/K'A[0M;N8[5;62X
M$=]8K;22VZWL45S+.$4N\8&^=,_LA16SG)RYV[N[>OG*K)WM;7]Z[=%**E;[
M)C&R4E;XE%:=.6$(>>CY-5V;C?J?D]X.\$Z!XB\1_"G7M/\`B1X1^+7AWQI^
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MU<6'AWX.^#?BM\7--35]2F6WT/PQK%QK`%A+<22?NK??"M_#%*[*H>8H&#2A
M7_6ZBM?:2]M[:]W::U_OSYF^FJ5TO.TNG*\XV6'5"VUO_)8SC;KI>5VK[)KK
M=?F)^U?\3?"=Y^TQ\"?C!\+_`!I\)?`?P8T^]\6I<>-_$'@ZXO?!Z^*+HVBC
M47DBNM/A=[F-;Z*/4S</`\AEC#M)**]R_P"":%CX?T[X4?&[Q=9_%#PK\4/"
M?B_Q5?:Y<W?A7P==>'?"UK,+2*&__LXS75TEY%++"\LL]O<21-<//SO\ROLF
MN/\`C_\`!33?VC?@[KW@;6[S5+/0_$]O]AU06$B1S7=HS#S[8LR-MCGBWPN5
M`<)*^QD?:Z\]2G>A*C'[4913?12:D[]TFEHK>ZHK6WO:1E>K&<^C3=O)25UV
M=GN[ZN3^UIXC_P`$6M*U'1?^"47P#M]4CFBN/^$.LI(XY5*M';NN^!2#R,0M
M&,>U?3U0Z=IUOH^GV]I:PQ6UK:QK###$H5(D4855`X`````J:NO$U%4K2J1V
M;;U\V<]*,HP2E:]EMM\O(****Q-`HHHH`****`"BBB@`HHHH`****`"BBFR3
M)$R*S*K2-M0$XW'!.!ZG`)^@-`#J***`"BBB@`HHHH`****`"BBFB9&F:,,O
MF*`S+GY@#G!(]\'\C0`ZBBB@`HHHH`****`"BBB@`HHHH`QY?`>DS>/8?%#6
MN=<M]/DTN.Y\U_EMI)$E=-F=G+QH<D;AMP#@D'8HHHV2BME^K;?WMM^K;#JW
MU?Z))?@DO1)'!_LK_P#)L/PX_P"Q7TS_`-)(J[RN#_97_P"38?AQ_P!BOIG_
M`*215WE`!1110`4444`%%%%`!7GO[0W[+7@?]J/PNNE^,M#@U#[.=UG>QDPW
MVGOU#PS+AT(.#@':<#((XKT*BJIU)0ES0=F-2:=T?)`UKXV?L$C;JD>I_'7X
M4VO2^@4?\)7H4(_YZITO$4?Q#Y^I)10!7T#\"/VC?!?[2_@U==\$Z_9:Y8\+
M,L9*SVCG^":)L/&WLP&>HR.:[:OG_P"/'[`.B^/?&3>./`6KWOPM^)D>677=
M%0"*_.0=EY;<1W"$CG(!/&2P&*[/:4JVE7W9=UL_5?JON9?-&7Q:/N=]^TE^
MS'X5_:F\!?V'XGM'+6[^?I^H6S>5>Z5./NS02=58$#CHV`""*^6O%VO:M\/]
M2TSX9?M`WS0R+/CP)\5[93$K3#!CCNVS^YGX&[<=K@9)R!*>_P##'[=7B3]G
MK7[7PO\`M%>'X?"\UQ(+>P\:Z4K3>'-6;H/,;&ZUD.,[7&.I.Q<5]">-?!'A
M?X_?#:XTG6;/3?$OAG7K<%D+":"YC;#*Z.I^C*ZG(.""#@U5:E"5!X+,(>TH
MR_#SB^CZV^^SLUA[.OAZ\<9A)<E2.S6S\GW7Y>ET_/?@;\?=4M_%A^'OQ$6W
MT_QK:INL[N/Y;3Q'`.DT)X&_`.Y..<X`P57V:O@GXQ?#'6/V.M$A\.^-)M:\
M7?`Z&X5]"\4VX,NN_#B;(\OS"HW2VP.!D=``!@A%/OG[-O[3<]]J&G^$/&5]
M8W>K7T`GT'Q!:.K:?XKMOX9(G'R^;C[R>OH>*^<E"MEE2-#%3]I1F[4ZO?\`
MN3[371OXO6W-['[G,J<J^%CR58J]2EV_OP[P[I?#Z;>]4445Z9Y04444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!7*_'7Q5KG@;X)^,-:\,Z;_;'B
M31]%O+W2K#[/)<?;;J.!WAB\N,AWWN%7:A#'.`02*ZJB@J+L[L^;?^"87[1_
MQ?\`VG/@?K.N?&CP'_PKWQ)9ZW)96EA_8E[I/GV@@@=9O+NW=VS(\B[@=OR8
MQD&OI*BBNC%5H5:KJ0@HI]%LM/Z9S8:E*E34)R<GKJ]]_P"D%?EK^R]\4;[]
MDS4_VBCI,GEWGQA\7>+;OPU"PR)?$T/BNYT?CG!,B7NC@KQA;9FY^8K^I5>5
M-^Q'\+9-1\-WDGA&UFNO"'BR_P#'.CR2W5Q(UCK-\UPUU=+ND.=[74Y\MLQJ
M64JJE$V\T8IS]_X6G%KNFU?[K77FDGHV=<JG[GDC\2E&2?\`AC/\VTGH_=<N
MMD_SK_9E^*?C[X)?#_X=_L^_"C2_B;_9::I\1=8N]1\#_P#"-2>(?L^G>+9[
M*")#XAE6Q\HFYWS/LEFSY(4*&=Q[IXK_`&BOC,/AA\/?"WC#4/C%X&^*FHW6
MJF'PYX(\*>'=8\7>,-/MKB""VO[BYE>\T'28Q'<QO<F9XT>4@0RP@>0_T;XM
M_P""?7PG\9>%=*TF?P]J6GKH.MZEXATR_P!'\1:GI&K:9>ZC--/?20:A:W$=
MW$L\EQ*7C241L&"[=JJHS]5_X)I?!O4?#/AO2[;P_KV@KX3AO+>POO#_`(NU
MC0]5=+R1)KP7%_9W45U=_:)HTEF-Q+(995$C[G^:JYG+6IJVW=]]6TU_+96C
M;5-7;7,TXS+E]K*<-KR:7DV]'K[U[\U[IIZ)V5W\D_LS_M4?'C]J5?V=?"6H
M_$S7/`FH>+HOB'9^+-2M/#^BR:W=MH&L6]E:/AHKFPM[K;D3&*.6W;S)@B#,
M4L7U%^P%\:?%'QX_8?DU;QEJ4>M>)-)U+Q'X;N]36VCM6U3^S-5O=.2Z>*(+
M&DDJ6RNZQJJ!V;:JK@#K/@[^P1\(OV?M6\-WG@OP79^''\'OK#:)#9W5PMKI
M@U::*>_2*#S#$J220QD(%VQ[<1A`2#V?PJ^!GA7X)>`KCPQX8TO^S-#N[[4-
M2EMOM,TVZXOKJ:[NGWR.SCS)YY7P#A=^%"J`!GBH^TP\J4=Y*7I=MV[NR3M\
MMAPERRC+M*__`&[>3MYO6._:U[;_`)S?L>>+_BQ\0_AI\-?A]X3^+FM?#/PS
MX7_9D\)^+X!H^@Z5?7DNJ2B^@!:6^MKA?LY2WC\R()O8QQE)8?W@EYD?M>>-
M_#WBVX_:DDUC4-0U\_LH:7XW;PHL-E'H<UW-)(WDLQ@%RMLL[&<_Z0'!W`OY
M8"#]'OAI^QK\-_@_/;2>'?#?]G26?A"R\!1'^T+J;9HMF96MK3]Y(V=AGE_>
M']ZV[YG.!C,\,_L#_"?P?/X5;3_"K0P^#?"/_"!Z?:MJM[)9S:&(_+%A=V[3
M&*^B5<[?M2RLI9F!#,2=Z\U4JRJ]6YM=_>6(6_32I27ERNVRYE)Q=DEI[FG1
M\KH-Z==:=1_]O+N[?+FF?&S]ISX4>`?'VL:SHWQAD\/VOP\UK69=?\?0^!H_
M^$?UFVM#-:&PBT.ZD:2WD/FAHKN&9E,<)\XCS`W!_M,_`7Q%XY^,?[).K?%'
MXF>+?B=;WAUCQK>^'K_P]X;DTA;RTT47JPVL!TLL(]V^)'E>6XC20E)EEQ*/
MLCP!_P`$S_@S\-],U2SL?#>M7MOJGA^?PH$UGQ7J^L_V9I,ZA)K&P-Y=2G3[
M=U"!H[3RE(BBX_=IM]&OOV??"&I>*/`VM3:1YFI?#:*>'PY-]JF']G)/;BVE
M&T/MDW0C;^\#8ZC!YK&HI-3Y':5H\KM?E:=1MVV>\+?X;=$WG&/P*>JN^;6W
M,FJ:MIM\,_\`P*_5I?%/["W[2W[3'QNN/A-\0=0\)?%74O"OQ+MH=2\1V^KG
MP3#X2T*PN[9IXKC2'LKPZPWE.8%`O!.TL3R%DBDV[.3TK]JOX]:=^S1\!]6_
MX3+XA>//&'[1FK-8S6_AW2_"UK/X8M+2SOKQSI*7\5O;-=S1VT8D-_//&`)V
MBB&$CK[&^&W_``3I^#_PC^(UEXGT'PS?VMYI-W=7^DZ?-XAU.[T/0;FY+^?/
MI^ES7#V-C*WFRC?;01L%FE4$"1PVQXA_8D^&/BCX`:+\,;OPVW_"'>&I;>XT
M:"#4[RWO-'G@?S(;BUO8Y5NX)T8G;-'*L@#,-V"0:J6?P*RNM+[*][7Z^K2;
MU3:5K5"ZOS.^F]K:V:3MTW3LG;1:7U?R3XE^.7[36B:#\-_".M7GC3X:W'B[
MXN6OA6Q\3^)].\+WWB+5]"GT74+J8S0:;+<:='=17%N5BF1(T(C@9[>0"6.6
M/P[^U%\7-3^)O_"B)/B;K"ZHWQGOO`W_``L)M)TE==&DV_AF/Q`JK#]D_LXW
MC/*+?>;3888Y&\L28<?5W@W]@?X4^!+/0X['PY>3W/A_Q,/&5OJ.HZYJ&I:G
M<ZN+:6T6\NKRXGDN+QUMY7A47,DBJ@10`(T"R>,_V$OA;X]LO$D5]X>O89O%
MGB6+QC?7VGZYJ&G:A%J\=K#9I>VUW;SI/9R"V@2$FV>(%#(I!$DFZJ;2<N?6
M^W2W\'\N2K_BYE>RD^4GJDHZ63\]7[;7_P`GI[[<NGPJ_P`]_M2_''XV?#OX
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MZMMZ^LKIV7PVC:-E=/5O5JTR3;BUI:VGRLU?[5W[UW9K;9:_*?[:FLS_`+/?
M[3'Q(_LF:>QU#]H;X>66A:5-$CL4URWU)-)AD!&`K;-=M6/S9VVK-P%)/DFN
MVNE_`K0]&^!K:[IGA7PS^SGXP\0>.6O;[3)K^VTW0['3?[1TEVLX722YBM[O
M6K%51&4R-IQC4[^GZ%_%/]G/P7\:_&/@KQ!XGT./5-8^'>J-K/A^Y-Q-"VGW
M1C,9?$;J)%*G[D@9-RHVW<BL,GQO^QO\,_B3XQ\9:]KWA.QU35/B!X<7PEX@
M>XEE:/4],4R$0-%O\M?]8V9%42$!`6(1`N,(N,;===?1\].6FJE";<;](.Z]
MXV;C*7O;:=%U2A46JVE!*3OO/LE<_./XO_M*?%:Y\,_&GP'XDUSXT>(/`?BK
M]GKQIXAL;SXF>&/#^A7EY=6`@MA<V-OIL4%W;V\L=X2T&IV\<ZXB(`RXKH?A
M)\8?'&B_\%&OB3\/M#U"Z^'GA?QYXN\.0ZEX]6&RNI%N8O!^F30:+:0SB5$N
M;I8I29[B`Q+'$T<>Z>6,Q_8-C_P2N^!]O?ZE?77AGQ!KNK:OX?U'PI>:KKWC
M+6]9U.XTF^CCCN;!KN[NY9_LY$8*1[]L+O*\0C>61FZOQ+^PK\*_%VC^+['4
M/"HF@\=7^FZKK#+J5W'++>:=%;Q6-Q%(LH>WEA2TM]KP-&P:,-DL23T4Y1C)
M/RL_/]XY:VWM%I=FXI-<ETXE)RA;K:7HG*--:=;7A)OJD[I\VJ^/OAG\6OB=
M\1_V@/!/PX\,_$!OAKH?B[QA\6)-:N_#WAG1_MTR:5X@@2T:$SVLD"3_`+YQ
M)-+#,9A)*7#2LDT>M^S+^T?\8/VP%^'OP[F^*&I>"=4M;3QC<Z]XOT;1-+?5
MO$3:)X@.B6RI%=6T]E")`?M%P$ML[O+6,PJ6!^NO"'['OPY\!^/M)\4:3X=^
MRZ[H=UKEY971U"ZD\F76;E+K4FVM(5;SIHT?#`A,80("0?$_VE?V!;Q=%\'Z
M7\*_!/@V^T/0=4UG69K6]^(/B/P5K5G?:E.]S<7%IKFF?:+E8999KCSK-HO*
MDWQ$.@@5#E&2C"G&2O9-/S=I):K71N+[-I)V5VM*TN=SE#1N;:T7PN4I-6V;
M::5]TKN+;23ZO_@E1\9?&WQW_8XL]>^(GB&S\5>+(?$WB32+O5+2QBL;>Z2R
MUR^LX3'#'\JH(H(P,EF(`+,[$L?)OVU-9G_9[_:8^)']DS3V.H?M#?#RRT+2
MIHD=BFN6^I)I,,@(P%;9KMJQ^;.VU9N`I)]C_8T_8=;]E#X-?#7PO:ZVEE#X
M+FU>_O=/T59K32[R;4IYKAX%A\S:UO!).PB\U'D_=H0R$N&]-^*?[.?@OXU^
M,?!7B#Q/H<>J:Q\.]4;6?#]R;B:%M/NC&8R^(W42*5/W)`R;E1MNY%877C&=
M5*>L+VDM-8M.,M%I=)N45MS)7T,J<VE*4=&VW'NK2YHK79:*+TORMZ=#X8^'
M?@:U\$^.O`?[.5K"LVA_`?XA:SXQ6P5"IET2SL%U'2H50?>2*[UJQC1C\N[3
MR!DJ:ZWX0_M#_%GPSX3_`&:_BIXA^),_C#3?VB=3L[#5?!SZ1IUMI?AY=2T^
MXO[=M+EA@6\)M?(6-_M<]P)8S*^(V"X^O]+^`'A#1?CGJWQ*M=&CA\;:[I,&
MAWVI">4FXLX9'DCC,9;R@0SG+A`[`(&8A%`XKX7?\$_?A-\&OB5;^*_#WAN\
MM=2T]KM]*MKC7=1O-*\/M=,6N&TW3YIWL]/,F6#&TAB)5W7[K,#/--J\W=MQ
M;?=K23\W5@H<TMX23<;DRA&S4%;1I=+)W<=ME3G*3C'52BTI-)67P'\5OBG\
M8IOV4/V6?C+JFK^)OC=X\\1?$:VU+2O!<$.C:/8K/'HFOK#%;R+!#(ID41M,
M\\\P!5S#&N5B/Z#?L,>*-6^(/[,?AGQ5K7CY/B-?>+[<:T^I0:=#I]E:^<`Q
ML[6!(TDC@@;=&JW)DN`582R,P(&EIW[(7P[TGP=\/?#]OX>\O2?A7J2:OX6@
M^WW)_LNZ2&>!9-QDW2XCN9UVREU^?.,A2(?!'[*/AWX3^+[&^\&R:AX7TM=9
MU3Q!J.CVE_=&QU.\OU_?,86F,,:&7=-Y:Q[1*S.NQGD,A1]R%2+^U*Z\ERPC
M;U?*VWNK):\SMIB'SSA./2-GY^].7W+F22T3NV_AC?Y-_:0F'PS_`."T^E_$
MY91;6_AGP5X7\/ZS*QPATO5]5UZT8,>RK?#392QS@0'.`21Y5X"^-WB3PE\>
M_CA\2/"UU#I7BCX[6/P\CTW5;ZV^TQZ/::MXBUC2K"\\EB%9HM-^RR+&QV-+
MC<,,P/Z&_%O]D'X<_'9O&?\`PEGAJ'6A\0O#47A#Q`LMW<(NH:7%)<21V^$D
M`C*O=SL)(]LF7'S?*NV'Q)^Q=\+_`!?8^([74_!^GWEKXL\/V'A;4[>264PS
M:=8-.]G"B;]L30O<RLDD8616*G=E$*NE[L$I:M/TO%RYI0NMKV5I+5.4NB5Z
MQ$E-U''[2@O24%!*7GM+39VA=7;:^5?C7^TW\6?V4?BAXJ^$$?Q$NO'6H:Y9
M^%;GP]XQ\1Z1IRZEX9;6M=_L6<7$-C!:VEPL6//M\PH6DWI(9%`JK\??VJOB
MO^R-\5M>^#:_$/4/'-]XIB\*-H'C37M+TV/5/"AUK6FT><SQ6=M;V<_E[/.M
MMUNNZ4LDOFH!7T]X<_X)_?";P]\._&'A>3PW>:_I_C]8T\0W/B37=1\0:GJJ
MQ*%@62_OIYKO$.-T($H$+$M'L8EJ/#G_``3^^$WA[X=^,/"\GAN\U_3_`!^L
M:>(;GQ)KNH^(-3U58E"P+)?WT\UWB'&Z$"4"%B6CV,2U*&G+S^]:3;Z<T>D-
M/@M_/&\I=49RUYN72Z5NO*U:\M?BOK[C]U7T/&OV,OAQXA^&'_!4;X_Z?XB\
M?:G\1;AO`?@N2VU35;*RM=26$W7B#]W<BRA@MG8/YA5XX(OW9C5E9E:1]7_@
MN)I'_"0?\$W_`!18?V7I>N?;O$7A:W_LW4WV6.H;_$>F+Y$[>7)B)\[7/EOA
M6/R-]T]YX7_X)U^`?A7I_C:X\"R>*?#?BOX@VUA::WXHN/%.KZMK5ZEE+(]N
MSW=U=O.\D:S2QJ[2'Y"D;;XHUC'I'Q__`&?_``K^U!\*=0\$^-M/NM2\.ZI+
M;3SPVNI76FSB2WN([F"1+BVDCFC=)H8W#1NIR@YQD45O>Y+='%]%M)-]^W7?
M=ETY<M=U'M>/X1C'RZI]3X_UGX*ZI^Q)^S-\=/B3X=_9S_9C^`OBKPU\.=:O
M=&\1?#B[CU+46N(;5YTCE230K!?)#Q)(0SR*S1H#&1R.)^//QP^+'P>\$>,=
M#\3_`!&;XE6OC[]G'Q1X_>VUKPQI"6.AZI8Q6BF*U@CM@);&0:@0;>^:[;$"
M!I'#/N^MM-_X)V?#:ST3Q#I=U=?%;Q!I/BK1KO0-4T_Q#\5?%.N6=U9W49BG
M3R;S498U=D)`E11(F3M92:P?VX?V)5^-'P,UVQ\!:#X;_P"$^O?`NI?#;2=1
MUS6KVSM-'TC4EA2Z.V*.<3.GV>"15>,,YA"^;&'9B7=W?5-62\W&JNKLO?G3
M=]+<K;VUUP\H1E!RTM+F;\E*D^BN_=A45M;\R2O?3QGQO\<OBUXJ^'7QX^(G
MAWXG-X'T_P#9YMHXM+\+1:)ILND^(&M-#L]7N'U22:![E8Y_M7DJ+.:U\J-`
M_P`['@N_VX_B5)XJUWX<G5&TWQM\2_$/A;4?AU/+96QGTWP_J]L)[Y=GE;)I
M+`:=K)W2(Q(%OOSN&?H3QM_P3G^$_P`4?$5OK/B7P_>ZAJ3VMC:ZM';:YJ.G
MZ9XE6SQ]G_M/3[>X2TU`)C"K=Q3`+A/N@"H[O]EJ\^('[?&C_%SQ-I/AFUM?
MAOX>O=`\'RV5[)=7]Y_:!MWNKBZ1K>-;8QBW,44<<DX99Y69D)"#7F7M[OX=
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MX9?"35?!M]X>\+QZ??>`K74K31KC[=<RRQC49(I;^29GD8W4]Q)!'))/<&25
MG#,7W.Y:IH_["GPO\.W7A&XTWP_?:;<>!==U/Q'HLUGKFH6\EM>:E<27-\79
M)P9H9YI79[>4O"?E'E[54#2Z]SNF[NV^KUM_A>VD;Z))6ME+6GRK>_X>\[7W
MW<==9)+=]>5_:8\7>-/'7[5?P_\`A'X5\<:I\-;'6_#NL>*]5UW1["PN]6N%
MLI["VBL[?[?!<6T:L]_YDKM!(V(D5=F\L/CC7=/UK]N?]J#]F71/B9XDDUV/
MP#\1_&?AZ_A31-)GTGQ/<Z#')Y&I26UU:3K'<2H!')Y3*(G,Q@\A]KK^AGQZ
M_9<\%_M*Q:,WBJQU7[=X=GDN-*U71M<O]!U;36D0QRB&^L)H+F-)$.UT60+(
M`H8-@8K>#OV/?AM\/A\/O[%\+VVF_P#"K5NU\,B&YG'V`W<1BNG?Y_W\DJLQ
M>2?S'9W9RQ=BQBG[MF]U?YOGYHR\N6/N<NJ?QOWDA5O>7+'K:_I9IQ\^9^]?
M=6Y5HV?+?_!77Q#<>$?B/;:K:QV,UUIOP(^*%U"E[90WUL[I!HK*)8)E>*9"
M0-T<B,C#(92"17SU\4M;\0?L_?MB_'#XLZ')JGC+XAO#\/O`OAA)M'\/O-X=
MBUYA%)]AEF@MS&T0:00PR7<=O)),/M'F_*R_IK\9_P!EWP+^T)<M-XPT/^UY
M&\/ZKX6)^VW%OG3=36%+Z#]U(O\`K5MX1O\`OIL^1ER<YGB/]BOX7^,-/\=6
M>K>$;+4[7XE6%EIGB2&ZGFFCU&"SC:.U&UG(B:)6)62+8X8*^[<JL%%6A%=4
M^]KISJ2DKZV<HR4>:UUJUMKO4FI1IQ[<]].K4>5VZ\KBW9M)Z+J[>;_L+>*/
MC>_C_P`4:+\1O#OQ0'@V.RMKS1=>^(+^$TUMKPNZ7%F4\.W#V[P!!%)&[01.
M"TJLT@V%>=_X*_\`A_2_%/@OX*Z?K7P[_P"%L:7=?%"P6X\)?9M/N?[;7^S]
M1/E>7J$L-HV"`^)I%7Y.N<`^G>'_`-@SP;\./!_BFS\'7GBS1?$'BZ.V@O?%
M&H>*=7US7A#;ONBA6_O+N2Z6),R%(1*(5::0F-O,D#^F>/?A1H'Q/O?#MQKF
MG_;IO">K)KFE-Y\D?V6\2*6)9<(P#X2:0;7ROS9QD`AU8J4J?]V4)/3=1FI/
M3:]E9;7TOK=O*G>,:G]Z,DM=G*#BO.UW=]M;=$OS/\)_';0_V7O$7[2WQ.^#
M_P``['X"P?!'X>26?B#P#?VNE://XDUII#<V%_+9:7/+!]BAA695OA*/M`N)
MT5L6Q8=#\:?&/[1$7[)WQOL?&WAWXQ:CX%UCX0^)IM4U;Q\O@FV.CZBFG2-"
M+!=`NWE:WF#3*T=S'*Z%(2)_OAONWQK^RA\/_B+\8[?Q]K7AR&^\40Z#<^%Y
M;@W,Z0ZCI=P2TEE>6ZN(+R'<694N(Y!&SLR;2S$\+X/_`."8/P4\%>']:TNW
M\,ZUJ%AKGARX\(/%K/BS6-8_L[1[A/+GL+`W=U*=/MW4(&2S,((BB_YYIM5F
MX<K_`)6NZNW-WU[N2?\`=^%74%S;4:D:>(C5Z*<9=FTE3T^7+)6^UNVG)V^0
M?V]?VT/B9\)?A[\0O$7PG\=?%K5KSX1>'+6\N](\.^!]#3P=X=:WL;6ZDBUG
M4=643WTDZSY9-(N!-!$4!@61?,E9\0(]>\`_'S]JKQ)_PE6H:VEYX]^&$`TG
M6-(TF\TZ`75]I'S(C6>_?#&[1Q.SLR#;)DS*LP^N_BG_`,$LO@;\:;_Q%)XE
M\(ZGJ%CXNB$>N:.OBC5[?1-7=;5+5+BXTV*Z6SENDBCA"7+0F=&@A=75XHV7
MI-9_8,^%FO\`BC5]8NO#^H27>O)HZZB@U_44M;UM)G@N-/F>W6<0M/#);P_O
MBGF,B;'9D)4]"G'VL*KZ23?6ZYE*2_!))W:NW?ORTXN$*</Y59]+VY;?<E*^
MU]$UNSYE\2?M-_%G1_@IJ_[1"_$2Z.CZ3\1Y?#*_#;^R-.&C3:5%XA.@E#<>
M0=0_M%L&X$@NA%YI6/R"F<\[8_M-_&S3-&N_BA=_%?4+W2M-_:'D^&<7@X>'
M]+BTFYT27Q,=(7SYA;F\:ZB2<.DT=Q$A$$2O%(WF22?6TW_!/[X33_&7_A.V
M\-WG]L'6!XB:R&NZB-"?50@4:BVD^?\`V>;P8#?:3;F7>`^_>`U:LG[&'PUF
M\%3>'6\-YT>X\8CQ_);_`-H77S:V-174A=[O-W?\?BB7RP?*XV[-GRUCA?<J
M4Y5-8IJZWTYJ3:N][QC46O62[MK6M[U.I&.\F[/:R<:B2\K2E!W6_+Y)/YJ^
M%'[0OQ8^'G[:UCH'QF\3?$7PFOBCQ%J6GZ+IUQX/TS4/A_XBM&EN_P"S8=-U
M6Q7[;8ZA]G@@ED759L2,;A(X3NB>+[FKQGP3_P`$_?A3\/?BU'XTTK0=6CU:
MVU*\UFSLY_$FJ76BZ7?W9D-S=VFERW#6%K<2&:<M+!`C_OYN?WC[O9J(Z4HQ
MENM_T]7O=Z7TT0JFM64X[/9?-[+HMK+6VUWH%%%%`!1110`4444`>)^$OVE_
M&1_:RC^''BSX?Z;X?TS7M)U36O#FK6/B-M3N;F"PN;2"3[=;?98TLVD%Y$\8
M2XN`P#!BCC:?;*\!^`O[-'Q2^&G[27C+QMXJ^)7@GQGI?BR>0);KX(NK#5].
MLD=VLK".\_M26W$%N)'SMLU:9W=V;<V:]J\8>!M$^(6DBPU_1]+URQ602BVU
M"TCN80XR`VUP1D9/.,\FB/\`"A?XK:][W;5^ETK)VTNKH)?'*VU]/N6W6S=[
M7U[VV.7_`&5_^38?AQ_V*^F?^DD5=Y7!_LK_`/)L/PX_[%?3/_22*N\H`***
M*`"BBB@#S+XZ_'/4/@9:F\O-+^U:7>7UA;6=U;Q23;#+<PPS12H@+!]CN\;*
M-KD;"`P7S.W\&:EJFL:0;K5K&/39;B0O!:!M\MO#QM65@2ID/)8+\J[MH+;=
M[>?_`+1?[*FG_M.Z3-I_B35+S[!'<6TUA!;[HDLO+D1IF(5QYDLBB2,.W$:N
M-JYW%^+L_P!D#XD?#DRMX*^.7B=+=),V]CXCLX]8B$>!B(R.0RX.?F4#`P,<
M9/HQIX>=)+G49];IVZ6U5_GI^&_A5*V/I8J4O9.=*RM9QO>[O=-KRMKMNK[?
M15%?/?\`PL;]HCX:?\AKP#X-^(%I'UG\.:LVGW&WU,5P"&;_`&4_"GV__!1?
MPCX=G6W\=>'O'7PYN,A"VN:)+]F9C_<EB#AE_P!H@"H_L^L_X=I?X6F_N6OX
M&O\`;F%CI7;I_P".+BO_``)KE^YGT#17)_#WX\>"_BQ&K>&O%7A_6V89\JTO
MHY)5[_,@.Y3[$"NLKCE"4'RR5F>I2K0J1YZ;37=.Z*/B?POIOC;0+K2=8T^R
MU72[Z,Q7-I=PK-!.A_A9&!##V(KY=U7]C;QY^R7J=QKG[/.MH^BR.T]Y\/-?
MN&ETNX).6-G,QW6TA[`G:2>6V@+7UA16U'$3IZ+5/=/5/Y?KOV-HS:/"/@-^
MW%X._:$U:Z\$>)--NO!'CY8S#J'A#Q)$(YY@1AO)+`)<Q,,X*\LO)4#FO#/V
MD?V+M5_9IT_4-5\`Z7?>*?A;=7#:AJG@ZWD/V_PY/U-_I#G)5EZM#T8#&",&
M/ZE_:)_93\"_M3>&DT_QAHL5Y):_-9:A"WD7^FOU#P3K\R$'!QRI(&01Q7AP
M\3_&S]@OY->AU+XY?"NVZ:K:H#XIT.'UGCSB[11_&#NX)8J`%KLA&A6IRH<J
ME":M*G+X9+R??MLUT;!TWSQKX>3A4B[QDMT_)]5W3T9K_L8?MPV/Q#L-+T'7
MM:M=4>_7R]#\0+^[CUG;@&"96YBO$RH9&Y;((SN5G^GZ^"?BU^SAX3_:N\-:
MA\5OV<]:TB_U"_(FU[PXDGD6VLR#+`M&<-9WPRQ5R%W$G/#N7[3]A#_@H/'X
MWN_^$%\=27>G^)-/G^P13:DGDW*RCC[+=*<;9N"%?I)C'WP<_.UJ,\LER3;E
M0;2C*7Q0;VA5_*%3:6TK3^+TO=QZ;C%0KQ5Y06BFEO.FOQG#>.\;Q^'["HHH
MKN/+"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****``]*_/KQ9
M_P`%=?&GPY;1UUS0?"ZMIND>+XO%(AMYP8M7TIM7^P);CSR5AN4T.^8HWF.0
MT>UP`2WZ"U\T_$/_`()5?#3XE>,/%^MWUYXMBN_&WBW2?%]^L%_&$BET^(Q"
MTAW1,8[2=9+DS1@Y8WEP59"_$<O-*S;2LU=;W?NW_P"W4W-?WHQ5FF:1DHQ;
MM>5TUV=KNW_;S2CY1<GND?,?Q?\`CG\;O%7Q6\/:3:>*?#W@W6M-^-GA/0M>
M2.UU:^L]0DN/"MG?2Q"`ZHJ16JSO-FWCPDA$4C$RK))-I_!3]K;XW_"/3?$/
MB[4]<\)^)/AO-^T3J?P_;2=3M[^\\0"TO?$CZ=!+!?M=+!;1VTD\2I:?995\
MF`XF0N$C^H_B;_P3S\+?$CQ-KVN)XE\9>']>UOQMIGCY-0TV6S:33=1L-/AT
M^(0I<6TL1A>WAPZRI(29'*LIV[73_P#!/#P5/\,+KPFVJ>*/[-N_B2OQ2>07
M,'G#4QK*ZP(0?)V_9OM"!=NW?Y>1YF[YZWP\DJJG45E=72VL_JRDE\H54NUU
M:S:,ZVM'V<7=J*5_[RC7U_\``ITWYVUT1TG[9GQZU;]G?X)-J_AW3=/U7Q/K
M6L:9X:T2#4)7CLEOM1O8;*&6X*`OY,;3B1U3#,L952"P(^-?^"A7[3/QU\"_
M"'XF?"_4_%W@G3_'6CV/ASQ5IOB[PWX?U#3;;4-*N]:CL)[-K,ZF\UO/',@W
M2"ZDCF@F9-D;%B/NW]H'X$:%^TG\*=1\(^(CJ$-C?/!<0W>GW)M;W3;JWF2>
MVN[>4<I-#/''*C8(W(,AAE3X]KG_``3%\,^._`?C[3_&'CKXC>-/%'Q$M;&Q
MOO&.J2Z;'K-C;6,_VFR@M8[:RAL88X;@O-M^RD2/(QE\S@#G2>[[W?G&RY4N
MS4TY-Z)Q]V_0J6UH^5O)\WO-]TX:):M2U\U\W?$3]J;X_?L\?$/]L#QQ8^)O
M`^O>$_@G<Z)JFH:/K.G:C<-JB+X=TZXOK;3%6]6/24;][*A87@:6X^=1L+R]
M1\:/^"J_CR#XR?$JQ\`^&]4OM+^%&H1Z4^B1_"/Q9XHN?&MTMI!=SQ0:OI:-
M9:8<7"P)Y\5RV]3(ZI&R@^^^+/\`@G1X2\=_#?XW>&]8\1>,K]?C]9P6GBC4
M&FLX[L&+2X-,\VWV6RQ1N\5NKMF-D\QF*JJ80-\;_P#!/33=>^(WB+7_``U\
M2_BQ\-K?QP;9_%>D^%-3L[6S\1RP1+`+AI);66YL[A[>..%Y]/GM962*,[PZ
M*XT5_=C?:*5_[UHIOSCI+2S6J?*$G%QBXKU7DDK)>=[MNZ?2^QYSXI_;!^.W
MB3Q?\;K_`,!^%_"]_H?PATBUO[#PK>Z'>/XD\675UHL=]'8B5;M$LY8IG"G-
MO.TH?RPD;)O?K?\`@G?^V'J7[3MWXRTW6/'WPR\::CX7E@CGMM#\.ZKX/U_1
M)F,B2VVIZ#J<L]U:X:,&*=I0)P[@1((@\OI+_LEZ"C_%.2VUKQAIMS\6HX$U
M*[L-7>TO--:&QCL8Y+.XC"S12".-7WL[MYF3G'RUQ_AW]BG6OAPWBKQ-IOQ0
M\;>+OBIX@TVTT6U\6>*DTKSM+L()VF6VB@L]/AM?++23.Q:`RR%P#*NV-HW3
MDE)IKW;?.^_G?71[::J3MRO.2?LXZ^]U[/X?3IS6>NNZU4HZ'[?_`(9^(7BK
MX/Z/;^`;/Q'J\,?B&RE\4:1X:UV/0M?UG1OG%Q;V%])-`MO/O:&0M]HMV:**
M5$FC=U-?(]S\99O!_P`'?B+IGA7QE\<?"5_I?C+P*LW@3XA3:C+XF\(^?XGM
M[&ZEBUBXN[EM1TZ_CB8+Y%S<6ZA)@LA$S1I]R?M(?LRZ+^TMH6BQW^I:]X<U
MWPKJ::UX=\1:'<1P:IH%ZL;Q>="9$DA<-%++$\4T4L4D<K*\;`UYRW_!-7PU
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M#/B#=7WAWXF?%KPQX-O_`!"_BFZ\"Z3JUK:Z'+?R2^?,RRK;?VC##+<9GDMH
M;Q+>1WD#1E)9$<T'_@GKIO@SX@W5]X=^)GQ:\,>#;_Q"_BFZ\"Z3JUK:Z'+?
MR2^?,RRK;?VC##+<9GDMH;Q+>1WD#1E)9$>:&GL^?IO_`.2W^^T[;O56Y=.2
M:VO/R==O3W[+U7N7VV=Y2UY_%F_;U^.'A_P3XL^*VL6?PO;X7^"OBA?>!KK0
M;73;[^W=1TV+7FTA=22^:Z\F&:(NCM;&UE$PMW*S0F94A^ZZ^'_V6_\`@F)J
MDNH>-[KXF>)/'T/AW5/BYKOCBW\`G4]/G\.ZIG5Y;O3;V39"]VJX%M/]E%TD
M)DB5I("YDW?<%%/^!3ONXQ;[J\(W3\^;F;72]M/AC5:WUBIR[<TDNUE.5K>7
M+;7KY[LHHHH)"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HKROX<?MJ?#?XL_&;4/`.@ZY?7?B33Q>G$NB7]M87WV*=+>\%I
M?2PK:WC6\TB1S+;2R&)SM<*00/5*/LJ71ZKS6V@/1N+W6C\GV9P?[*__`";#
M\./^Q7TS_P!)(J[RN#_97_Y-A^''_8KZ9_Z215WE`!1110`4444`%%>)_%/_
M`(*'_"/X.?$_4/!>N>)IX_%6DK$]WI\&E7D[0)(D<@8R+$8\".17(#DX.`"V
M%/9?L_?M*>"?VI?!=QXA\!ZU_;NCVMX^GS3_`&2>U,<ZHCLA29$?A9$.<8^;
MKUK".*HRJ.E&:<ENKJZ^1U3P.(A#VDZ<E&R=VG:TOA=^TK.W>VAW5,N+>.[@
M:.6-)(Y!M9'7<K#T(I]%;G*>4?$/]ASX3?$^1I=4\"Z''=,=WVFPB.GS[NS%
MX"A8CU;-<E_PQ'XB\!C=\/OC)X^\.JG^KL]5>/6[&/\`V5BF`VC\37T)179#
M'XB*Y>:Z[/5?<[H\NKDN"G+G]FHR[QO%_?&S_$^>_P"W/VDOAG_Q]:'\/_B9
M9QG@V%X^CZA(/]KS080?]VE_X>"Z?X,^7XA>`?B%X`V?ZR[NM*:\TY?7$\.[
M=COA?2OH.BJ^M4I?Q*:]5>+_`%7X&?\`9V(I_P"[XB7I)*:_27_DQP/PX_:E
M^'/Q;\M?#OC3P]J4TGW;=;Q8[@_]LGQ)^:UWU><_$?\`9%^&/Q:\QM?\#^'K
MR:7[]PEJ+>Y;_MK'MD_\>K@?^&!5\%'?\/?B7\0_`^W_`%=F-0_M'3D]/W$V
M<X]VZ4>SPL_AFX^JNOO6O_DH>VS*E\=.-1=XRY7_`.`RT_\`)Q?CI_P3_P!'
M\9>,I/'/P\UB\^%?Q+7+?VSHZ`6^I'.2M[;?ZN=6/4D!B<$EL`5\I?M6Z9<>
M)-<M+7XW:+9?"OXH0K]DT?XC:6CS>%?%``^6WO2!OAW8&-XW1XW#:H"GZL%G
M^TG\,O\`5WGP]^)UC'U\^*31M2E^FW,"Y]^]9_BS]KL'P[>:+\7?@GXTTG2;
MR/RK[%C%K^D,O<22Q_*1W'RGI[5W4X3E'V4^6K!IIJZ;:>ZL]6G_`"M->AHL
M^HQ:>)C.FXNZ;37*ULU.-XIKI[QP_P"Q1^W1J6B:_#\,?BP/[+\06J(NGZE/
M.)(;V)O]4?.!VRQN/]7.I(;H<-U^S*_+/XR?LR_#WQYI(NO@'\2]!N+>WD>X
MM_!'B#4#:/;2.07&G2W.V2$MC#1/NC<\L?E0#TS]BS_@IO<?#F*?P'\8K/6M
M&U+04V+-<V<DEW:Q@?+YD:@R2Q$`;'C#GY@/F4AA\OC,-+*6N=MX=Z)ROS4W
MTC.^O+TC-WM\,FW:4OK,/['.:;K8*49U5JU&UIK^:*6BE_-%:/XH]8Q_0"BO
M$?AM_P`%!OAK\6/B/HOA/1K[59==UZZN;>T@ETZ6%62&*:8S%V`38R0,54$R
M#<NY%YQ[=6U#$4JT%5HR4HO9IIK[T>;7P]:A/V=>#C+M)-/[G9A1116QB%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110!\=?LP_!+XD:-\6_A_H/B#P)?>'?#WP>O/$UP/$T^
MJ6%Q9^*%OIY5L_L<,,SW*9@F:27[3%#Y;QA$\X-YB_6/C#P]>>)=)%O9:[JO
MAZ82!_M6GQVSS$#/R8N(I4P<_P!W/`P1SG4HHCI%+MU[^;Z>6B2#2[:Z].WD
MO^#=^9XM\!/@KXGT_P"!?@NWN/B#X\T6XAT&QCETX66DJ+!Q;H##B2Q:0;#\
MN'9F^7DDY-=;_P`*@\0?]%4\>?\`@)HO_P`KZ[RB@#@_^%0>(/\`HJGCS_P$
MT7_Y7T?\*@\0?]%4\>?^`FB__*^N\HH`X/\`X5!X@_Z*IX\_\!-%_P#E?1_P
MJ#Q!_P!%4\>?^`FB_P#ROKO**`/RE_;"_9T\8:5^V=\0-6C\._$GQI_:36`B
MUF+PM<72W,::?;*1YEI:K`=K!D.P#[@#?,"3]'?\$M_@%XB\,?`WQ(LFH>._
MAW]L\3SW2Z;)HT-FT^ZUM`9RE_:/)\S*RY0B/$8`&X,3Z=XW_P""@FE^!/CW
M>>"KCX?_`!$NM,TO7M,\,W_BVV72WT:RU#48H)+6%HS>B_;=]I@4O':,BF3)
M8*K,OJ7P'^,6F?M#?!+PCX\T6"^M='\9Z/:ZW90WJ(ES%#<1+*BR*C,H<*P!
M"LP!S@GK7SN%X;I+%U,RC.3YG9J]DF]4M+/;5>6O4[L1BN>ZDY<SC!/WE9QB
MK1T45MRM+5VLUO<J?\*HU[_HIGC?_P`!='_^0:/^%4:]_P!%,\;_`/@+H_\`
M\@UV]%>Q]3I]Y?\`@4O\SS^5?TSB/^%4:]_T4SQO_P"`NC__`"#1_P`*HU[_
M`**9XW_\!='_`/D&NWHH^IT^\O\`P*7^8<J_IG$?\*HU[_HIGC?_`,!='_\`
MD&L+4/`GC*W^)ND:;#\0/&TFBW>EWUS=W?V#23Y-Q%+9K!'O^P[1O26X.""3
MY600%;/JE%'U.GWE_P"!2_S#E7],XC_A5&O?]%,\;_\`@+H__P`@T?\`"J->
M_P"BF>-__`71_P#Y!KMZ*/J=/O+_`,"E_F'*OZ9Q'_"J->_Z*9XW_P#`71__
M`)!H_P"%4:]_T4SQO_X"Z/\`_(-=O11]3I]Y?^!2_P`PY5_3/%?B+^P]H/Q;
M#GQ)KVK:Q+)UGN-(T0SCZ2BPWC\#7S!^V#_P3@T;X$>!-#UGP+9_$+Q;J;:L
MMB;)(3JBV-O)#,[S+%;P;T&^.-2W"C?@]17Z$UY=\0?VGE\)_&S3O`.A^!_&
MGCS6I+:"_P!8DT,Z=%:^&+.>9X8;F[DO;NWW*[17!$=L)YMMO(?+&4WSB\&\
M3A9X!U)J-1.-N>36J[-VT6NNG?0O+J>'PF/IYG&E%SI-23LKZ>=KZ[=VW9:V
M/A[]D?X$>-M._:E\'B]\.^/O"L>Z[?\`MI=`=%T[_0IQDR7%N\"E\^7\ZDGS
M,#G!'WM_PJ#Q!_T53QY_X":+_P#*^O/O`W_!1GP-X]^'?Q@\1VNF^*K>'X*Z
MUJ6A:O93V<7VS4YK.1XM]DBRL)8YYHY(H2Q1GD1E*J17I_[/_P`9]-_:-^!?
M@[X@:+:ZE8Z1XVT6TURRM]0C2.[@AN85F1)51W02!7`8*[`$'!(YKS>&^'Z6
M4X1X:C)R5U)M_P!]:>EU';R=]3W^),^JYMB_K%:/*XIPLM;<K=U][Z_+3:C_
M`,*@\0?]%4\>?^`FB_\`ROH_X5!X@_Z*IX\_\!-%_P#E?7>45[Q\^<'_`,*@
M\0?]%4\>?^`FB_\`ROH_X5!X@_Z*IX\_\!-%_P#E?7>44`>3?$_X>>-/"_PT
M\1:EH?Q&\=ZEK6G:9<W6GV;:?H\HNKA(F:.,HE@&;<X484@G.`0:]9HHH`**
M**`"LOQ1XPL?!UM;R7S7/^ES?9X$M[26ZEEDV,^U4B5F/RH['`X"FM2N7^('
M_(V>!_\`L-R?^FV^K:C!2E:6UF_N39G6DXQO'NOQ=@_X7!I/_/IXH_\`":U+
M_P",4?\`"X-)_P"?3Q1_X36I?_&*ZBBJYJ/\K^]?_(D\M7NON?\`F<O_`,+@
MTG_GT\4?^$UJ7_QBC_A<&D_\^GBC_P`)K4O_`(Q7444<U'^5_>O_`)$.6KW7
MW/\`S.7_`.%P:3_SZ>*/_":U+_XQ1_PN#2?^?3Q1_P"$UJ7_`,8KJ**.:C_*
M_O7_`,B'+5[K[G_F<O\`\+@TG_GT\4?^$UJ7_P`8H_X7!I/_`#Z>*/\`PFM2
M_P#C%=111S4?Y7]Z_P#D0Y:O=?<_\SE_^%P:3_SZ>*/_``FM2_\`C%'_``N#
M2?\`GT\4?^$UJ7_QBNHHHYJ/\K^]?_(ARU>Z^Y_YG+_\+@TG_GT\4?\`A-:E
M_P#&*/\`A<&D_P#/IXH_\)K4O_C%=111S4?Y7]Z_^1#EJ]U]S_S.7_X7!I/_
M`#Z>*/\`PFM2_P#C%'_"X-)_Y]/%'_A-:E_\8KJ**.:C_*_O7_R(<M7NON?^
M9R__``N#2?\`GT\4?^$UJ7_QBC_A<&D_\^GBC_PFM2_^,5U%%'-1_E?WK_Y$
M.6KW7W/_`#.7_P"%P:3_`,^GBC_PFM2_^,4?\+@TG_GT\4?^$UJ7_P`8KJ**
M.:C_`"O[U_\`(ARU>Z^Y_P"9R_\`PN#2?^?3Q1_X36I?_&*/^%P:3_SZ>*/_
M``FM2_\`C%=111S4?Y7]Z_\`D0Y:O=?<_P#,Y?\`X7!I/_/IXH_\)K4O_C%'
M_"X-)_Y]/%'_`(36I?\`QBNHHHYJ/\K^]?\`R(<M7NON?^9R_P#PN#2?^?3Q
M1_X36I?_`!BC_A<&D_\`/IXH_P#":U+_`.,5U%%'-1_E?WK_`.1#EJ]U]S_S
M.7_X7!I/_/IXH_\`":U+_P",4?\`"X-)_P"?3Q1_X36I?_&*ZBBCFH_RO[U_
M\B'+5[K[G_F<O_PN#2?^?3Q1_P"$UJ7_`,8H_P"%P:3_`,^GBC_PFM2_^,5U
M%%'-1_E?WK_Y$.6KW7W/_,Y?_A<&D_\`/IXH_P#":U+_`.,4?\+@TG_GT\4?
M^$UJ7_QBNHHHYJ/\K^]?_(ARU>Z^Y_YG+_\`"X-)_P"?3Q1_X36I?_&*/^%P
M:3_SZ>*/_":U+_XQ7444<U'^5_>O_D0Y:O=?<_\`,Y?_`(7!I/\`SZ>*/_":
MU+_XQ1_PN#2?^?3Q1_X36I?_`!BNHHHYJ/\`*_O7_P`B'+5[K[G_`)G+_P#"
MX-)_Y]/%'_A-:E_\8H_X7!I/_/IXH_\`":U+_P",5U%%'-1_E?WK_P"1#EJ]
MU]S_`,SE_P#A<&D_\^GBC_PFM2_^,4?\+@TG_GT\4?\`A-:E_P#&*ZBBCFH_
MRO[U_P#(ARU>Z^Y_YG+_`/"X-)_Y]/%'_A-:E_\`&*/^%P:3_P`^GBC_`,)K
M4O\`XQ7444<U'^5_>O\`Y$.6KW7W/_,Y?_A<&D_\^GBC_P`)K4O_`(Q1_P`+
M@TG_`)]/%'_A-:E_\8KJ**.:C_*_O7_R(<M7NON?^9R__"X-)_Y]/%'_`(36
MI?\`QBC_`(7!I/\`SZ>*/_":U+_XQ7444<U'^5_>O_D0Y:O=?<_\SE_^%P:3
M_P`^GBC_`,)K4O\`XQ1_PN#2?^?3Q1_X36I?_&*ZBBCFH_RO[U_\B'+5[K[G
M_F<O_P`+@TG_`)]/%'_A-:E_\8H_X7!I/_/IXH_\)K4O_C%=111S4?Y7]Z_^
M1#EJ]U]S_P`SE_\`A<&D_P#/IXH_\)K4O_C%'_"X-)_Y]/%'_A-:E_\`&*ZB
MBCFH_P`K^]?_`"(<M7NON?\`F<O_`,+@TG_GT\4?^$UJ7_QBC_A<&D_\^GBC
M_P`)K4O_`(Q7444<U'^5_>O_`)$.6KW7W/\`S.7_`.%P:3_SZ>*/_":U+_XQ
M1_PN#2?^?3Q1_P"$UJ7_`,8KJ**.:C_*_O7_`,B'+5[K[G_F<O\`\+@TG_GT
M\4?^$UJ7_P`8H_X7!I/_`#Z>*/\`PFM2_P#C%=111S4?Y7]Z_P#D0Y:O=?<_
M\SE_^%P:3_SZ>*/_``FM2_\`C%;7AOQ)9^+-(COK&222WD>2,&2%X75D=HW5
MD<!E965@00""*O5R_P`(/^13N_\`L-ZM_P"G*YIRC3=-S@FFFEJ[[W\EV%&4
MU-1DUL^EMK>;[G44445S&X4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`'PY\=/\`@G)XL^)'[8/BKQMIO@CX+K+XC\0Z%J^G_$BZU*XC\:^%+:QB
MLDN+6TB33CN686TR8&H1H4NWWHZ[XY/:O^">/PW^*7P,_9T\+_#WXD:#X!TV
M/P%H&FZ%INH^&_%-WK#:P+>#R9)9H9].M/LV=B,%5Y\[V!8;06]YHHI?NX.G
M'9V?S6B?W77GUN[,J4G+\/P_K_*P4444$A1110`4444`%%%%`!1110`5\5_M
ME?\`!-/4OV@_VJYO'&G>%/A'JS:Y::!:IXKUX21>)_A\^F7\UR]SI)2TE,LD
MR3``?:+3RWB#%I5;:OVI10M)*79W_KK]UF$M8N/?0^+/#?\`P33\8:3\8_#6
ML_\`"2>'[+PY/XN\0:]XTTZW\^23Q!;MX@O-;T!$;:@62VN+HF8,"I#.BEAA
MJ^B?V-O@[JG[/'[)7PS\!ZU/8W6L>#/"^G:)>S63N]M+-;VT<3M&SJK%"RD@
MLJDC&0.E>E454).$'3CLVG\U?_-_TBJDG.I*K+>3N_O;_5_T@HHHJ20HHHH`
M****`"BBB@`KE_B!_P`C9X'_`.PW)_Z;;ZNHKE_B!_R-G@?_`+#<G_IMOJZ,
M-\;])?\`I+,:_P`/S7YHZBBBBN<V"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N7^$'_(
MIW?_`&&]6_\`3E<UU%<O\(/^13N_^PWJW_IRN:Z(_P`"7K'\I&,OXJ]'^:.H
MHHHKG-@HHHH`****`"BBB@`HHKF_C'\5=+^!GPF\2>,]<^T_V/X5TRXU6\%O
M'YDS10QM(P1<@%B%P`2!DC)`YI2E97948N3LCI**\Q_9M_::C_:)_P"$HM;C
MP;XP\`Z]X/U"+3M4T;Q']@>YA:6VBNHG66QNKJV='BF0_+,64Y#*O&?3JIJQ
M$9)JZ"BBBD,****`"BBB@`HHHH`***^!OVXO^"JGC[]DC_@IUX$^&\6A^#[O
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M9/)NWMFBD1%VS13R(/-4L542,GK7[+W[9&D_M6^`_&&J:1X;\4>']:\!Z[>^
M&==\.:VMJNI:?J-LB.T#-:SSV[[TEB97CF=2)!SG($\RY7-;)<VFNEHNZMOI
M.#TO\4>Z'RM247HV[=M;R5GVUA):_P`K['L%%?GS_P`$[_\`@L1)^T1\)?&G
MQ$^)7CKX.Z+I?@?2=6U7Q?X(L-.U#3O%WPU-C.`8;R&XGE>_7RBRO/';VJB:
M,(B2F0B+O+S_`(+;?#OPGH[7'C#P'\5O`=Y#-X>EN-/UNRTW[3::7K=Q]FLM
M8D-O>RQ+9B;]W*-_VB)N&@&1G10;DHK=VM_V\VHZK1WLVK-II.2=DV9N247)
M[*]_^W;7NMU:Z332:;2M=J_V517RQXW_`."N'P^\*?$;QAX1T_PUX]\5>)/"
M_C/3_A]9V.D6MD3XGURZL_MKVEC)-=11_P"C6X9[B2Y:"./:0&8X!RM/_P""
MRW@'Q-K?PYT+P]X&^*7B7QA\2KC6]/L_#EC86"7^E7^CS1Q:C9WKS7D=O#)#
MYC/O\YH66)MLC%HA)-/W[<FM]O.\5+[N646WLDU?=%2]V_-I;_-K\XR7K&7\
MKM]>45^8_@#_`(*X_$S0/C7\&?!NFZ%XF^,FF_$CXA^.?#VJZG/H.CZ'J$2:
M3+<B*QL(QJJ0@6WE`M/<\SP*"/W[&,?27@O_`(*Z?#?QYHOP_DL=$\<?VU\0
M_B'?_#2WT"2SM1JFDZG8-<?;)+M!<%$MX4M_-9T=VV31$(2Q`*?OQA*/VDFE
MUUY4OQE%7VNU9M-,*GN.2ETO^'/?\*<G;=):I/0^IJ***`"BBB@`HHHH`***
M*`"BBB@`KE_B!_R-G@?_`+#<G_IMOJZBN7^('_(V>!_^PW)_Z;;ZNC#?&_27
M_I+,:_P_-?FCJ****YS8****`/B7]J3_`(*@7GP>_;Y3X7?VUX?\!^"O"^E:
M+J7B;Q-K?@;6O$5O<7&JW[VUK9?:;*6&TTE2L+?Z7?2-&7G0",B.0G9_X*'_
M`+<7Q*^!?Q,NO"'PML?!C:IX=^&NN?%#5I_$EC<7L5[;:=)#%'IT"0W-OY,M
MP\DG^D,TBQ"+F%]P([']H_\`X)@^!?VF_C5>>,M8USQEI<?B"PTO3/%&AZ5/
M:1:9XOMM-O6O;.*\,EN]PH29F!-M-`SH=C%EXKG?BO\`\$A/"'QAU"^OM6^)
M/QB;5-6BU[2M2U!M9M+JZO\`0]8GCFN]!+W%K+Y>GJ8E6%8?+FA7(289).7[
MQTHQ6DOWFN^K35._DI.,GTY8M<K;:EK>G[5N2O'W-/)6=3JM6E)+SDGS)+W?
MH;X2_%RQ^*GP-\,^/-G]DZ;XDT*UU_9=2J/L4,]ND^)'X7Y%;ENG!-:W@[Q[
MH?Q%TIK[P_K6DZ[8QRF%KC3[N.ZB60`$H60D;@&4XSG!'K5CPSX<L?!WAS3]
M(TVW6TTW2[:.SM(%)*PQ1J$1`3DX"@#DYXKD?A!_R4'XJ?\`8T0?^F72ZZJ\
MH.I)TE:-W9=ET_`Y:$:BIQ55WE97?=]?Q.\HHHK(U"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Y?X0?\`(IW?_8;U
M;_TY7-=17+_"#_D4[O\`[#>K?^G*YKHC_`EZQ_*1C+^*O1_FCJ****YS8***
M*`"BBB@`HHHH`*X7]IKP!X@^*O[/GC+PWX5U.ST?Q#KFDSV=C=7:L;=7="-L
MA4%E1P2A=`60,64%E`KNJ*BI34X.$MFK?U?0J,G&2DNG]=-3YL_X)K_LAZM^
MQUX#\3:%)X9\%_#WPOJ&I1W6A^#/"NOWNOZ;H8$")/*MY=VUM*7N)!O:(0JB
M%2P+/)(Q]#^/WA.+2$T[Q-9ZAXCM=4_X2+0K8K#KM['9M%+JEI!(AM1*("&B
M=U.8^=Q/7FO4*X/]H[_DGVG_`/8T>'?_`$]6-:RDY.[\E]RMU_I=-#.$%!6C
MY_B[G>4445)04444`%%%%`!1110`5\C?MI?\$HM/_;.^*?Q+\1:EXRFT>'XA
M?"<?#2*UBTSS)-)GCU&34(-467SEWF.9H_W.U<^7GS!G`^N:*F4%+?S7_@47
M%_\`DLFO*]UK9E1J..B\G_X#)27W2BGYVL]+H_/71/\`@WV\*P>`O"_A;4_'
MVIWVAZ3\(-6^%^K&'3/)O=9NM2O$O;G6!,TS^7(UP))/*9903)S(0"#);?\`
M!#7S?V5M?^&[:O\``CPO?:K'H\?]N^!_@TGAN36TL+A)Y(-;B34Y!J=K<^6!
M)`K6ZDLYS@@#]!J*IZW??_Y*4_\`TJ<G\[;))0HI))=/_D8Q_*$5\K[MM_`'
MP2_X(8P?!RSTN.W\<^&K&.P^-5A\9#I_AWP.NBZ3`]OIYM'TNUM5O)!;PLQ9
MT?<Y1<*5D.9#])_LM_L>R?LT:S\:KR+Q3-J,GQ?\<7GC-'BT]+>30S<6EK;"
M!2[RK,R?9MXD95!+X,>!S[913YFDXKJN7Y6IK\J5/7?W?-W;U?,^]_G>;_.I
M/[^R5OAOXN_\$:[C]L#XAZUXF^.WQ#T?Q9JEQ\/[_P"'>EW/A3PA_P`(U<06
MEZVZ6YNY)+N[-U<*0#&JB&",O,1#^\^6KX,_X(I:99?L??$KX3ZLWP+TF;QY
MX6A\/1>)OA_\(T\(ZK'-$-T5Y>LNH3B\99TAFV+Y"[T;LPV_=U%1RKE<5LU;
MMI>3^6LY.ZUU]"N9\RGU3NO5**_*$5;;3S=_SYNO^""NDZK^QU\._`.M>-](
M\:^//`OCB[^(-]XF\7>$(]9TKQAJ=Y+,;O\`M+27N5$T4D,PC`%RKH88G#_*
M5/IGPK_X)9P_#SX\?`WQY#J'PU\-/\';;Q'!-H7@/X?CPQHNL/JT<4?FQVXO
M9_LSQK$I8EI3*V3^[X%?75%:1FU)SCHVV_OBH:+9+E222T22LD9.G%I1?3_Y
M)R^;YFVV]7?4^&]`_P"".NJ?#W4?AOKWA?XH:?:>+_AG\2?%/CRQO-2\*/>V
M%U;Z^]S]IL)+9+V)]R)<!4G68<QY,>&VCC?V9?V"9]*_X+[_`!R^*4F@^*-/
M\":#I%K?>'UO[!X-&G\1:O:VT>J7VGLP"22&WL84FDCR=\[JQ!`%?HM14T?W
M<HRC]F+BO1Q4+>EDG;^9*6][W4]]24OM6?S4W._JW*2_PR:VT"BBB@`HHHH`
M****`"BBB@`HHHH`*Y?X@?\`(V>!_P#L-R?^FV^KJ*Y?X@?\C9X'_P"PW)_Z
M;;ZNC#?&_27_`*2S&O\`#\U^:.HHHHKG-@HHHH`****`"N#^$'_)0?BI_P!C
M1!_Z9=+KO*X/X0?\E!^*G_8T0?\`IETN@#O****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HKY5_X+@?$OQ%\'O\`@DY\<_$OA/7-6\,^(M)\.-)8
MZII=T]K>63F6-=\4J$/&V&(#*01G@BOAS_@W?_;L\<?#.W^)_P`.?V@/B1XD
M\6G3O`>B?&?0M?\`%6KRW]R-%O=-AFOAY\[,_DV\C1@`M@$RGCFHIU(RE4C+
M3DBI7[WYG9>:C"4O1,J<9*,))7YI6]/A2?SE.,?5H_8VBOP%_P""1?[8GQ[^
M-7_!:_X8^(O''Q-^(=QX'^/OAGQ)XXT_P9>ZY<OHVEZ>+G48+*..S+^2@5;-
M'5E0'!!SR<_8'C'_`(.(O$U[H?C;XF?#G]F'QA\1/V:?AOK#Z7K_`,2D\5V.
MFRND$J1W=S9:7*AENX4#AD82(&'#F'#;;?NQ@ZGNN46VG]FTG!\SV5I*S;:5
M]"5[TYQAJHR44U]J\5*/+U=XNZM=M*^Q^G5%?)/[0_\`P46^)-IIO@:X_9W_
M`&<O%7[0]OXV\.V_BQ-57Q%9>%]"MM/G'[I1?7099+MLHWV95#"-M^>"*\!U
M[_@Y)T32?^"8&E_M'1_"'Q!)>1>.X_`/B'P?+JZQ7>D7N&:8PS^01<;5"[5,
M<1=FVDQD&AZ-QEHTTFGO=R4-NW.U%O9/=A%J24HZIJ]UM\+G]_*G)+=I:(_3
M2BOA']EC_@LGXL^*G[>>D_`GXL?L\^*O@;JGCC0)_$W@B\U3Q!:ZG)KMG&7;
M;<0P(!9W'DHS-`9)'C92C8^5FK_\''?Q[^,/[.7_``3@OO$7PANO$.CM_;=K
M:^+M;\/VZS:MH.@R)*+JZMLD>7(&\I?-#*T8<L&3'F)-:7LX1J2VD[+_`,"Y
M'?M:2?-?56>A5%*I-PB]E?\`\EYE;O=6Y;:.ZU/O:BOS;_X)#_%7X1:'X%\?
M?%+X?_MG_%CX[?#'1_#KWWB70OB9K']K:QX6G@W2F]W31PW-M#Y,<R>7Y1BE
M92ZR/L&.N_89_P""Q7Q*_;=\:>%=>L_V5_&WAS]G[QY>WEIH7Q'N/$ME=3;8
M$G9)[S2XT\VT@<VTB&8R/&KM&H=]ZYVE"TN3K:[OHDG=*[V]ZS<==5MK=+&-
M2\.=K2]EUO9)NRWTO[VFCWTLW][45^6_BS_@XY\5:EX.\;?%7X;_`++'C+XA
M?LT_#W5SI>L?$8>*[+3;B6.*6..YNK32I(VFN(D\P,K"105YD,&'V=Q^TW_P
M7S'PV^.WP:\"?"CX,:_\;-0^/O@F+Q;X,_L_7(M)DNY)68QP7"7$16WB$,<D
MDD[.?*V$&,@%AE&5TFD_>LDK.^L7-:;ZQBVM-;:7-I1<7+F^S>[Z*S47KMHY
M)2UTOK8_1"BO@7XN?\%C_B3IGQLT?X-_"_\`9CUOXJ?'33_"MEXH\?\`AB+Q
MMI^E:;X#^TQHPLWU25&AN;A6=>$55=&5D9OF5?>O^":__!030?\`@I%^S>OC
MC2=%U+PKK&DZG<>'O$WAW4)4EN?#^K6VT7%J9%P)%4NI23"ET9241LHMQBY7
M<=;7Z[I/E;7\T5+3F5U?2]V1*7+;FZV_%<R3[-QUL[.VMCZ`HHHJ1A1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%<O\(/\`D4[O_L-ZM_Z<KFNH
MKE_A!_R*=W_V&]6_].5S71'^!+UC^4C&7\5>C_-'44445SFP4444`%%%%`!1
M110`444%MHR>`.IH;MJP"N#_`&CO^2?:?_V-'AW_`-/5C5OX,?M$?#_]H[0[
MS5/AYXZ\'>/--T^Y-E=7?AW6K;5(+:<*&,3O`[JL@5E.TD'#`XYJI^T=_P`D
M^T__`+&CP[_Z>K&AIK</([RBBB@`HHHH`****`"BJ\NJVL&I0V<ES;I>7"/+
M%`T@$DJ(5#LJ]2%+J"1P-PSU%6*`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBN-^.GP>;XX^!_[#'BOQEX-_TA+@W_`(8U$:??$+G]WYI1L(<Y(`!.T<XR
M#=.,7)*3LN^Y,VU%N*NSLJAL-0M]5LX[BUFAN;>8;HY8G#HX]01P:^8]=_X)
MD2:IHEY:Q?'[]HSS+B!XD^U>,?M$&64@>9'Y2[TYY7<N1D9&<UR_P#_X).ZC
M\.?AA8Z5JGQO^,>F7L+.[VOA3Q*VGZ7#N8MB.)HV.3G);C))X%>FL'@N1R]O
MK=:<K.'ZSBN=+V.G?F1]E$X%>?\`A']K#X6?$#P?=>(M!^)7P_UOP_8ZK'H5
MSJ=AXAM+FSM]1D>.-+-Y4D*+<,\T2B(D.6E0`989XCPA^PVW@KPOXPTY?BO\
M7O$P\6:%<Z)M\3Z\-4AL#,A47$2>6A61<\$-@@D>A'C?BS]CSXS>*?A5J%U-
MX+^"#^-VN_#5KI>E?\)7?+I.D6FC&5_ML5X=(:5;J<320>4MJJQPOCSGP5;S
M:D81J249<T4HV=K7NW?[K+_P*^T7?MIN<HQ<E9N]]5I977K?7TM;>2/ISP[^
MU?\`"WQ?I7B^_P!)^)7@#5+'X?/)%XIN+3Q#:3Q>&GCW^8MZRR$6Q7RY-PE*
MXV-G&#B[I?[1/P_UOXH7G@>R\=>#;SQIINGKJUWH$&M6TFJ6MFP0K<R6P?S5
MA(DC(D*A3YB\_,,^`V7["FN>#?V'/B%X/T_3]%\4>//'KWUW+8>)?&FK7GAR
MSNKB]FGBDMC<0W(LQ`)EE5;6SC5I84X4XD7#^%G[('Q:L)X+;Q9X5^#]WHVD
MS:OXB6UC\3WE]_PDFHZAITEHVF7@DTI%CL4\^13<;9W>.&'_`$9<%1G&]Y1E
MIRQ];RMJEY7NUW2MN]+?PQE'[4FFMK1TLW?KK9KH]=HL^NO!_C+2/B'X6T_7
M/#^JZ;KFB:M`EU8ZAI]REU:WL+C*R12H2KHP.0RD@BM*O*OV)OA[XP^$G[,7
MA3POXZT_PSIWB+P_:_898]`U:?5+%T0D(ZS36ML^67!*F(!3P&;K7JM5+<2=
MT%<O\0/^1L\#_P#8;D_]-M]745R_Q`_Y&SP/_P!AN3_TVWU;8;XWZ2_])9E7
M^'YK\T=11117.;!1110`4444`%<'\(/^2@_%3_L:(/\`TRZ77>5P?P@_Y*#\
M5/\`L:(/_3+I=`'>4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'S
M7_P6&^`'B[]J;_@F9\8OA[X#TG^W?&'BK0S9Z78?:H;7[5+YT;;?,F=(UX4G
M+L!QUK\RO^"C?_!#G]H3XS_LW?LDR?"S1_[)^(F@_#2T^%/Q-B35["'[%ICV
MD$<WF.\P2XCC9KI66!I&8,I3/!K]R:*B-.*DY-7NXMI[/E4U9^4HU)1DNJ>E
MB_:2Y5%:64E_X%RN_K%PC*/9K6Y^;=W_`,$P?%WP\_X+9_L^^-/!_@\1_`?X
M7?!R7P'+J@U*U7[%*J7\<4!@:47#DK+$2ZQE<N<MD''P+X1_X-V?&G[.NN>*
MO`NL_L3^#/VDFNM8G?PY\4F^,UWX6L[:SGQY'V[2X[A)I#`3NE6%%9@&1&D(
M61OZ'J*N5Y2YY:NTD_/FG*H[O=/FD[.-G;2^]YC[L7&.B?+;RY(*FK=_=2NG
M=-Z]%;\8?^"D_P#P2)^+WB[XJ_`N&U^`^C_M'?`WP#\-K?PP/A=I7Q,G\(Z;
MX7UR$!7OX[BYF6>>)D*HC,\DSK&1*5(5G\OT[_@B'^TGX:_X(DZA\$X_AOIW
M_">0_'5?%<&E:?XBL6M'T=(5C%S#//<#]WE?E25A/MQN0'-?O=16E.HXS=3J
MY*3\VJD:NO?WHI7>O*[7VM$HIPC#I%<OR]G*G\O=DW967-JUO?X5_:/_`&-_
MB1X]_P""Y'[-OQBTGPY]J^'/@'P?K.EZ]J_]H6L?V"YN(;A84\AI!-)N+J,Q
MQLHSR1S7OG[<_P`2/CI\)OA_HFN_`KX;^&?BUJEIJJC7/"^IZZNAWFH6#1NN
M;*[E_<13),8G8S!E,22*H+E:]NHK&S5.-)/2+;_\"FYM/I:\FO3SU'&*4W-]
M4E_X#%13];*_K]Q^//[/O_!'+XI_M0?M8?'GXP>//A3X-_9,TCXH?#?4_AW!
MX+\/:S::S<7UU>QH9=7NI;)5M6#2$L0`)'>/+("/-D]0_P""4OA']LS]G3X3
M_#O]FOX@?`/P7I/P]\$B\T?5OB8OCJUNX=6TI3<>4+/381]I2=]\062;:-JL
M7C1FPOZ;44<L.7V=O<LDXZV:3E)>>\Y;-*SM:UD.4I-\]_>NVGU5U&+MTVA'
M6U[J][ZGXB^"_P!@?]MK]E_]@WXC_L2>#?@SX)\7>`_&&IWVGZ/\6Y_'%K9V
M6FZ/J+HTIN--8?;'FC5I@S(ORLWR),J*TGT-\'_^"57C_P#9N_X*=?LDZQHN
MEMKOPO\`@G\'[GP5K'B8WMM#_IYBN%7_`$9I?/(D:0,-B,JAP"W!K]-**TA-
MQ<9/62MJ]VE3E35^FD9R>B5V[NY-2$9IQV3ULMDW.-1M>LH1OT2T21^+O_!4
MW_@B'XH\=?\`!3OQ5\<K7]G#0OVLO`WQ(TJUAN/##?$:7P/J7A?4;:&&#[0+
MCSHXYH9(XA\OSMN9AMC"!I/NC_@C#^Q=)^Q1^ROJ>E77PC\(_!&\\4^(+C73
MX3T+Q-?>)#ID3Q0QQ1W=]=2R>;=*L6US;D0'`**"6S]=45.'_<T_90VM;Y7Y
MK:6OJE9N[25D[%5_WLU4ENK?>H\M];VT[63>K5PHHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`KE_A!_P`BG=_]AO5O_3E<UU%<O\(/^13N
M_P#L-ZM_Z<KFNB/\"7K'\I&,OXJ]'^:.HHHHKG-@HHHH`****`"BBB@`KQ__
M`(*"^"/$'Q+_`&&_BUX>\*PZA=>(=:\*:C96,%CY?VJXDDMW7RXO,^0R,"54
M-\I)`/%>P45-2/-%Q?4JG+EDI=CYM_X)S^(_%VMZ3XT@U36OB5XD\#Z;?VEM
MX3U+Q[X.B\)ZV\8LX_M,/V*.PL/]&CEPL<CVB%B90&D15-=U^TC8>)39Z7<+
MJVACPY_PD_A[=8G293?$_P!KV0XN?M.P?/@X\@_*"O7YAZQ7!_M'?\D^T_\`
M[&CP[_Z>K&M)RYG=F5.')'E_K^OZT.\HHHJ2PHHHH`****`/R1_:9^$G[2US
M_P`%'=/N(9KR^\77$S7/AC4[#,.F0V,9Y"[B5CB0.%EC<DDR'=O\P,_VEX0_
MX**K\.KNQT#XZ^$]7^%?B&0+#_:<L1N?#^HRXP6ANH]P3)!;8Y^0$`N3S3?%
M_P#P5&\(^%_B9+HT.D:CJ6DVLQ@GU6&5,;@2"T<?\:@CKN&>PZ9^B;FST7XF
M>#U2XM]/US0]8MUD\JXA6>WNX7`9<HP(92"#@BNNCQIEN<+ZO!1E[)<K<;IK
MS6EFODU>]FKF6(X1S'*OW]7FC[5W7-9I^3UNG\T[;IEGP_XCT_Q;HUOJ6E7U
MGJ>GWB>9!=6DRS0S+_>5U)5A[@U<KYH\0?\`!.:W^'VLW&N_!/QAK?PEUB9C
M++86Q^VZ#?-_TULY"5!.,`H0%!.%JDO[9GQ'_9MQ;_'+X=S?V1#\K>,O!ROJ
M&E[1_P`M)[<_OK=>.6(.2>%%=']GQJZX2?-_=>DONV?_`&ZV_)'-]<E3TQ$>
M7S6L?OW7S27F?4E%<K\)?C?X1^._AI=7\'^(M*\1:><!I+.<.T)/19$^]&W^
MRX!]JZJO.G"4).,U9KHSLC*,ES1=T%%%%24%%%%`!1110`4444`%<7\>OVB/
M!O[,7@3_`(2;QUK2Z%HGVE+07!MIK@M*X)50D2.Y)"L>%X`.:[2BIE>WN[_U
MZ&E&5-33JIN/5)V=O)M.WW/T/COXP?\`!;_X'^#/ASJ6I>$=>/C;Q%;^7]CT
M46-_IOVTM(BM^_EM2B;49GY'.S`Y(KF/V=?^"\WPU^(ZZQ_PL.Q_X5B]GY/V
M`>==:T-2#^9YG,%H/+V;4^\/F\SCH:^Q/C)\&_#?[0'PWU+PCXNTW^UO#NK>
M5]KM/M$MOYOERI*GSQ,KKB2-#PPZ8Z9%<Q^SC^QO\-_V21K/_"O?#G_"/_\`
M"0>1]O\`^)A=7?VCR?,\O_7R/MV^;)]W&=W.<#'#*GC/:IJ<>7KI^E[_`/DR
M]._U%+&<.K!3A/#U/:WT?M%MI]KE2771TY>NONY/P)_;\^%/[4.K:KIGP]\3
M_P#"3:OI%BVH36:Z=>6CF($+D&:%`WS,J_+DC<.*\Q^%O_!1OQ9XU_9UE\9:
MK\*X])U^S\4:;H6I>'CJ>IV4^AVMV]NOVNZ&JZ5I]R&'G%52"VFCE8)MFV&2
M2'ZNNK9;RUDA<R*LJE&*.T;`$8X92"I]P01VKQ/5O^"=GPPUWX4W7@V\3XA7
M.DWVJ0ZQ=W4GQ&\1MJ]Y<0@"'SM2^W?;9(H\`I"\QB1E5E0,`1V4>>-_:6>U
MNFM]>KW6F_I;<^;Q4J$IKZO%QCK\34GMW48K?796\]CA?AM_P4.\6?$+X$_&
M3QLGPID4_#2[OH-*L%O]2M1KT=K-<1/.]U?Z9:VZQ@0&1FL9+\*NX`O($C?3
MT+]M_P`:>-?&PL]#^'?AE]#UNXO]"\-:AJ/B^:UGU'6K.U>XEANH(]/E%K9G
MR+E!<K)-(3$I^S`."/4];_96\%Z]^S[>_"Z6UURW\&ZA%+#<6]EXBU&SO)4E
MF,TH-[#.MW^\=FWXE^=796RK%3PUA_P3(^#MA8:Q:G1_%UY;ZYH\^AW,=]XZ
MUZ\5+>>!;>=X1->-Y%S+"@22ZAV7$@+;I&+MFM4Y?X;+_%;=]DWK;6S[K0PT
M<8='S-RZ^ZVK);:K772_J[Q]!_9E^,-W\?/@?H?BV]TW3M+GU=96\K3M1?4K
M"94F>-)[6Z>&!KBVF5!+%*88_,CD1@H!%=Y7-_"7X4Z7\%/`MGX=T6X\176G
M6)<Q2:WK]_KMZ=S%B&NKZ::X<`G`#2$*,*,``#I*UJ<KDW#8B-[>]O\`UZ!7
M+_$#_D;/`_\`V&Y/_3;?5U%<O\0/^1L\#_\`8;D_]-M]6N&^-^DO_269U_A^
M:_-'44445SFP4444`?$O[;/Q\^)?[-G[9&D^)O$FM?%CP_\`LZ^5X=TQ+WPG
M:>%;G34UBZU2:VG355OXWU1;9UEL4WV2@J&D(96&X4/^"GO[4OQ+\%?&?4_!
M?P^\>?\`"NO^$1^#OB/XJ37L5A874FK75A+!%:V<WVR"=5L\O*TQB6.;F/;*
MG(/TE\7?V)_A[\>OB/IGB?QA9^)->N-(N+6\M]+N/%FK?\(^9[:3S;>:32%N
M1I\LD<@5P\ENS;D1LY52.,\4_P#!)[X!^,;22&]\#W*I<:GJVJW1M/$6J6;W
MTFJS)-J,-PT-RK3VES)&C26DI:V;8!Y6!BLN6;IJ%[-.H[[_`!1M"_?EDW*V
MUHQCK=M:\T?:<[6C4--E[K]ZW;FBE&^]Y2EI9)^K?`[XHW'Q,_9X\'^-=4L7
MT^Z\0>'++6[NRMXI)FMGFMDF>)$`+L5+%0H!8X`QGBL?]GGQ);^+?$OQ-U"U
MCOX;>X\41;4O;&>QG&W1],4[H9D21>0<;E&1@C(()]&L+"#2K"&UM88;:UMH
MUBAAB0)'$BC"JJC@````#@`5Q/P@_P"2@_%3_L:(/_3+I==5>495)2@K)MV7
M9=$<M",XTXQF[M)7?=]6=Y11161J>7_!ZP\07?Q(\9KJ7C;Q%JUCX:UE=.MK
M*XMM.CAEC?3K.YS(T5JDA99+E\%748500>2?4*X+X/\`_)0OBI_V-,'_`*9=
M+KO:[LPE>JM$O=CLDMXIO9+JSEP<;0>KWENV^K74****X3J"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N7^$'_(IW?\`V&]6_P#3
ME<UU%<O\(/\`D4[O_L-ZM_Z<KFNB/\"7K'\I&,OXJ]'^:.HHHHKG-@HHHH`*
M***`"BBB@`HHHH`*X/\`:._Y)]I__8T>'?\`T]6-=Y7!_M'?\D^T_P#[&CP[
M_P"GJQH`[RBBB@`HHHH`****`/A_QE_P2>UB]^)$[:+XBT>U\+7$YD4W`E-Y
M:QL2=@0+L?:.`2ZYZX'2O7O`?Q7UC]E'^R_!?Q(CA/AJW2/3]#\5VL6VT>-%
M"QPW2\^3(%`&[[IQU.&>OH*J?B#P]8^+-$N=-U.SM[_3[Q#'/;SQB2.53V(/
M!KY/#\)8;`SEB,K;IU'W;<6OY7'MYJS71VT?U>(XLQ..A'#YHE4IKLDI)_S)
M]_)W3ZJ^JM6]Q'=P)+$ZR1R*'1T.Y7!Y!![@TXC(KY]G\&^+/V.9WO/"L=]X
MP^&X8R7.@LYDU#1%ZE[5CS)&.OEGD?BS5[%\,?BGH/QA\)P:UX=U"'4+"?@L
MAP\+=T=3RK#N#S^&#7L8+,E5G]7KQY*JWB^J[Q?VH^:U6TDGH>1C,M=*'UBA
M+GI/:2Z/M)?9EY/1[Q;6IY+\6?\`@G7X!\>>)6\2^&_[3^&OC12637?"D_\`
M9\S,3D^;$O[N56/WLJ&89!;FN5_X61^T)^ROE?%OAVU^-WA*WZZSX:A%GK\*
M#^*6Q/R3-QPL1]RU?4E%?20S*IR\E=*I'M+=>DMUZ7MY'S\L#"_/2;@_+9^J
MV?W7\SRWX!?MG?#G]I0M;^%_$5N^L0Y%QHUZIM-2MF7[P:"3#G;T)7<H]:]2
MKRWX^_L9?#G]I0K<>*/#MN^L0X-OK-DQM-2MF7[I6>/#G;U`;<H]*\M_X5O^
MT)^ROAO"7B*U^-WA*WZ:-XEF%GK\*#^&*^'R3-QRTH]@M7]7PU;^!/E?\L_T
MEM_X$H^I/MJ]+^-'F7>/ZQW^YL^I**\%^$W_``44\`^//$J^&O$G]I_#7QHI
M"OH7BN#^SYF8G`\J5OW<JL?NX8,PP0O->]`Y%<>(PM6A+EJQ:_7T[KS1T4<1
M3JKFIN_]=>P4445@;!1110`5S?Q5\,^(O%GA;[)X7\3KX1U+SE<WYTV/4/W8
MSE!'(0O/'S<XQ[Y'25C>.OB+X?\`A=H#:MXFUW1O#NEJZQ&\U.]CL[<.WW5W
MR,%R>PSDU,Z7M8NF[ZZ:-I_)JS7R"U]#Q+Q_\*OCMX6\'7^H:3\7I_$&I6T8
M:WT^'PAI\+73$@8WL^%`SDGG@'`)P#S?[/OPP_:$U[PC+!KWQ'U+P=+I\@BM
MX;S0;'57N8R,[_.9]Y(.1AN@`P3T'IGB?]OGX+^%]"N-0;XH^`+Z.VVL\5EX
MBLKB<J6`9EC67<^T$L54%B%(56;"E-,_;\^"^JZUJ%FGQ1\`Q#3O+5KB?Q#9
MQ0SLZ[ML1:4&3:-NYE&T%MH8LKJOFRX7;JJLI5;)-6YZEG\[\W;9V\B/JKO?
M7[V;OPD^'7CWP;K%U-XK^(W_``FEE-!LBM1X?M]-:"3<#O#Q,2>,C:1W!R,<
M_&.L_L^^(M;_`&0;CP;>?LI>+-4)^(VH:C86^KW'A36-8\/V-U-/<G6+.2YU
M=HOM^US")WN1/'-.TY6<(4E^U-$_:D^&OBG2-9OM'\>^#]=M_#UC)J6I'2M6
M@OGL[:,%GE=869@H`/./;K7E\_\`P4F\-Z!\&/%WC#Q)X'^(?A.?PC;6]^?#
MVHP:?)K&JV=Q%)-!<VT=O=RQ%'C@N6*RRQR1+:S-*D:KD^AAL+]7DXPO=6^)
MMO62:UDVVVXV2OMS66[6O*U!4WU;:WO=1DG\DIW?2_+?1V?CWA7_`()Z3_!W
M]@OXY:?'X+U[Q7XP^,$^IWUYX6TZ/P[I=U--->W)MT>\MQ9BZCV3H\OV^\N&
M:,21Y<,T3\EH7[)7BCQ?KFLZKXB_9W\26>NZGI^K?\)#X@E;PEJ&K>)]*N].
M^SVOAZ,7%Y/#,UM(T#>3>@:>&T_<&EW@-]!?#;_@J9X'^*GPL^+7BW2?#_BF
M\L_@_>3V.IV-C=:1JNI7DL4LT1"6UE?3R6N6A8_Z>+7:A\QML:NZ]1X6_;R\
M-^)OB:^BR>'_`!5H_AYC=06_C#4?L,.A7=Y:V_VFZLU(N3=+)#$LS-));I!_
MHTP$K%0#48KW[=8)/RCRZ/RTLKO?1.][.>;W*?E-M><KJZ\]5>R7=K9-)_P3
MK^#VH?`;]EC1_"]]X9;P?;Z?>7KZ?I$]OIUO>6EK)<22I]JBTQFTZ.=B[.R6
M6VW&X!$C'R+[C7$_L]?';3?VD/A=;^+-)TW7-)L[B]O;'[)J]LMM>126EW-:
MR;XPS;,O"Q`)#`$;E5LJ.VK:I*3E[V_]?CW(IQ25EW?YZA7+_$#_`)&SP/\`
M]AN3_P!-M]745R_Q`_Y&SP/_`-AN3_TVWU:8;XWZ2_\`2617^'YK\T=11117
M.;!1110`4444`%<'\(/^2@_%3_L:(/\`TRZ77>5P?P@_Y*#\5/\`L:(/_3+I
M=`'>4444`<%\'_\`DH7Q4_[&F#_TRZ77>UP7P?\`^2A?%3_L:8/_`$RZ77>U
MV8[^(O\`##_TB)SX7X'ZR_\`2F%%%%<9T!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!Y
M_KOQUO-$^(</AM?`/C*\N[J*XN;6>";2Q!<P020QR3*7O%8*&N(>'57._A>#
MCT"N"\1?\G/^#_\`L5M=_P#2O1Z[VNS$J')3<8I75WOKJUU;['-0<N::D[V=
MEMV3Z)=PHHHKC.D****`"BBB@`HHHH`*Y?X0?\BG=_\`8;U;_P!.5S745R_P
M@_Y%.[_[#>K?^G*YKHC_``)>L?RD8R_BKT?YHZBBBBN<V"BBB@`HHHH`****
M`"N'_:3^+5Y\"O@3XH\6:?X?UOQ5J6BV+36>DZ1IUQJ%W?3DA8T6"W229EWL
MI;RT9E0,P4XQ7<45,XMQ:14))239\L_\$K/BQ+\0_`7Q"T^\USXD>)-0T#Q;
M*D^H^+_#FLZ+-*TUK;RN(8=3BC>*+SFG9;9,K;H\:X52F?3OVD?%FH+9Z7I0
M\,:XUBWB?P\3K(EL_L*_\3>R;!7S_M'4;.(3\Q'\.6KTS2O#^GZ#+>/8V-G9
MOJ-P;N[:"%8S=3%54RN5`W.511N.3A0,\"N/_:._Y)]I_P#V-'AW_P!/5C6C
MDG&*72,5\XQ2;^;5S.,6G*[O>4G\G)M?<G8[RBBBI*"BBB@`HHHH`****`"O
M&_B=^S;?:/XLG\;?#*]@\.>+)/GO;)Q_Q+->`Y*SQCA7/.)%P<DG@G</9**X
M\;@:.*AR55MJFM'%]XO=/_AGH=F"QU;"SYZ3WT:>JDNS6S7_``ZU/-?@G^TE
M8_%'4;C0-5LI_"_C;31_IVAWK`2#'_+2%NDL1ZAE[8)&""?2JX7XV_L^Z'\<
M-/MVOOM&GZUII\S3-8LF\J]TZ0<@HXY*YZJ>#['!'"^$OC_KWP2\0VOA7XM"
M"-;E_)TOQ9`FS3]2]%G[03>N<*>>@&YO-CCJV"DJ68.\=E4V7DIK:+\_A?\`
M==D>C+`T<9%U<O5I;NGN_-P>\EY?$O[R39[I12(ZR(&4AE89!!X(I:]X\(Y7
MXM?!'PC\=_#3:1XP\.Z5XBT\Y*QWD`=H2>K1O]Z-O]I"#[UX*W[&?Q'_`&;<
MW'P-^(DW]D0_,O@WQBSZAI>T?\LX+@?OK=>.%!.2>6%?4E%=F'QU:E'DB[Q_
ME>J^Y_FM?,YJV$I5'SM6EW6C^]?EL?-'A_\`X*,V_P`/M9M]"^-G@_6_A+K$
MS"**_N1]MT&^;_IE>1@J"<9(<`*",M7T7X?\1Z?XMT:WU+2KZSU/3[Q/,@NK
M299H9E_O*ZDJP]P:/$'AW3_%NC7&FZK8V>IZ?>)Y<]K=P+-#,O\`=9&!5A[$
M5\Z>(/\`@G-;_#[6;C7?@GXPUOX2ZQ,QEEL+8_;=!OF_Z:V<A*@G&`4("@G"
MUO\`['7_`.G4OG*/_P`DO_)C+_::7_3Q?)2_^1?_`)*?2]%?+:_MF?$?]FW%
MO\<OAW-_9$/RMXR\'*^H:7M'_+2>W/[ZW7CEB#DGA17O7PF^.'A'X[>&5UCP
M?XBTGQ#I_&^2SG#M"3SMD3[T;?[+@'VK#$8&M1CSR5X_S+5?>NOD]?(UHXRE
M4?*G:79Z/[G^>QU58GC[X:>&_BMH:Z7XH\/Z)XDTU95G6TU6QBO(!(H(#[)%
M9=P#$`XR,GUJ#X;?%KPS\8=(NM0\+:YINO65G=R6,\UE.)4CFC.&0D?@0>A!
M##(()K_&/Q=XG\%>#_MGA+P@WC;5O/2,:<-4ATW$9SND,LN5XP!@`DY'N:QC
M3FJG)M+STM\W:QI*O&%-U=TM=$V_DE=OY(XKQ7^P+\&?%7A^XT__`(5CX!TU
M;H!'GL?#EC#<*N0657\DE-R@KN7#J&)5E8!@S1/^"?OP7T'5]1NH_AEX%N(]
M1,;_`&:Y\/V4\-LRKM+1;HBR;@%W+NV97<%#,Y;AOB'^U!\=]!\&WMY_PH=-
M':W"LET_C73[H*V]=J>4$W2;SA-B$.V_"D,0:P?@?^U[\=O&VA1W'_"F8_$;
M-I]A,'7Q19:9O62W5Q<^5(A?$Y+,,?(H78!NCD)]2.%QCIN2J*W^./EUYK?B
M>1+B?#QJJC:I=Z_PZGY<M^G1'O6C?LJ?#/PQIVL6NC_#_P`&Z''KVGRZ5J#:
M5H]O8R75K*,20L\**Q1N.,]0#U`KQKQ3_P`$F/`WQ/\`AGJWA_QQXV^+GC+4
M=4@%HOB*3Q.VAZK:6RVDUI%;K_9,=G;R0QQ7%QA)X90YGD,OFYQ7JWP4^*?Q
M&\<Z[>6_C/X6'P%8PVQE@O3XDM=46>3<!Y92(!EX);<>/E(X.,_+OA3]I37O
MVF?V3]4E\#_M(-JWCRQ^(%]X6L-7\"1^'KFWU">6[D2TAGBGM+U(K2*`_:/E
M/GFW@+&:5LLWDU(2]K*G.SDU&^JE?WDHZIM73EIUU:75'L4,2JU)8A723:]Z
M,HM>[*3=I)-*T'?H[)O177T@/V-M)TK]D"\^#.A^+/&WA_1;JRN-/_MJ*[M]
M0UN."XF>28&>^@N$D9UDDC,DL;R%7+;O,Q)7#>'_`/@EWX7CMIM/\3>/OBAX
MV\/2V]RJ:/?ZA9:9!;W=U`(+J_CFTNUL[I+F9#+G$WEH;B4QQQ[ACROPK\:/
MC!\.OV"_CE\2/B'\7-(\.K;SZF_A/Q'J]YI5Q#I4%O>W-O&@MQI=A%;S2%(H
MHUN)]0!E="2_,,G&6O[?.O?%*Z\17WA/]HSP>NK7FE:QOT::_P!$BT/P3I<.
MFF:P\2SW0M)YX8YIA;MY]PTUHRWQ"V[;!6*DG*I+=\MY=;IJ]O\`@='J[;FB
MC^[I+9<S4?)KE5_);6:W6G6S^W?V9/V9O#_[)WPWN/"WAF^\5ZAIMQJU]K+2
M^(=?N];O!-=W#SR+Y]U(\A0,YP"Q)Y9B\CN[>AUX?_P3M^*VJ_&+]EG1]7UK
MQ%_PF.H+=WEJ_B"'5K'6+/6U2X<+/:WME8:?;W-OMPBR1V</W""&92[>X5M4
MC)2M+7;[K:?@9TY1:O'N_ON[_B%<O\0/^1L\#_\`8;D_]-M]745R_P`0/^1L
M\#_]AN3_`--M]6F&^-^DO_2637^'YK\T=11117.;!1110`4444`%<'\(/^2@
M_%3_`+&B#_TRZ77>5P?P@_Y*#\5/^QH@_P#3+I=`'>4444`<%\'_`/DH7Q4_
M[&F#_P!,NEUWM<%\'_\`DH7Q4_[&F#_TRZ77>UV8[^(O\,/_`$B)SX7X'ZR_
M]*84445QG0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`'!>(O^3G_``?_`-BMKO\`Z5Z/
M7>UP7B+_`).?\'_]BMKO_I7H]=[77B/X=+_"_P#TJ1ST?CJ>O_ML0HHHKD.@
M****`"BBB@`HHHH`*Y?X0?\`(IW?_8;U;_TY7-=17+_"#_D4[O\`[#>K?^G*
MYKHC_`EZQ_*1C+^*O1_FCJ****YS8****`"BBB@`HHHH`****`"N#_:._P"2
M?:?_`-C1X=_]/5C7>5P?[1W_`"3[3_\`L:/#O_IZL:`.\HHHH`****`"BBB@
M`HHHH`****`"L[Q9X2TSQUX>NM)UBQM]2TV\3RYK>=-R./\`$=01R#R.:T:*
MF<(SBXR5T]TRH3E"2E%V:V:/GM])\7?L8.9-,74?&WPN0Y>QSYNJ>'$[F(G_
M`%T"_P!T\J/0`L?:OA]\1-%^*GA6VUKP_J%OJ>FW0RDT1Z'NK#JK#NI`(]*V
MJ\5^('[.6K>!O%-SXR^%-S;Z-KD[>9J6B3<:7KV.2&7I%*><.N!D\XRS5X/U
M?$9=KADYT>L/M1_P-[K^X]OLO:)[OUBAF.F):A6Z3VC+_';9_P!];_:6\CVJ
MBO._@A^T=I7QA>YTR>VN/#WBW2_EU'0K_P"6ZMB.K+T\R,]G7L1D#(KT2O8P
MN+HXFFJU"7-%_P!6?5-=4]4]SR,5A:V&J.E7CRR7]771I]&M&M@HHHKH.<",
MBOEW]KW_`()E>%_C-X=U;5O`,</P]^(%Q#(JZCI4CV4&IJZD26]TD1"LDH.&
M<*6[G<,J?J*BNK"8RMAJGM*,K/\`!^375'/B,+2KPY*JNOR].Q^>O_!'O]A[
MXH?`;Q]KWBCQ5<:AX3TD^9IDF@N%;^V9(RRB9P<@1HV3'(O+Y.#L8[_T*HKF
M_BG\.C\4?"_]E_V]XD\-_OEF-WH=X+2Z.W/R;]K?*<\@#G`YIYQF=?%U)8EQ
M3E;1+3;97_5AE>7T<-".'YFHWU;U^=OT1T4TRV\+22,L<<8+,S'"J!U)-5="
M\1:?XHL/M6F7UGJ-J6*":UF6:,D=1N4D9%>(^)/V$(?$F@WEA<?%+XO745U$
MT9BO=?%Q;OZ;XS&`ZYP2N1GU'6L3X5?\$X8/AMH\\$?Q+^(-G/<2;Y&T&]&D
MPR`#Y=T?[PLPR>2W?H*^2EF&;*M&,<(N2SN_:1NGTT_K_/ZJ.7Y4Z+E+%OGN
MK+V<K6ZZ_P!?Y?2M>=^._P!KWX3?"WP4OB3Q-\4/AWX=\.R:G-HBZKJGB2SL
M[)K^)I$EM!-)($\]&BE5HL[U,;@@%3A_PE^`)^$VL75Y_P`)KX_\4"Z@\C[-
MX@U<7L$?S`[U&P%6XQG/0GCICY@;]BWXL:E^SI)X6D\!_#;0-8L?&6H:UX?_
M`.$5^,'B#P[!X=M;I9]DD<]AI4$DC0B;R_L;(()$&6=>$'L86M5G&]:GROM=
M._O)63T5VFVKZ*WO-+4\?$4J,)6I3YE?>S6G+)WMJ]&DM$V[Z)L^H/#/[6?P
MK\::-XNU+1_B9\/]6T_P`TB>*+JR\16=Q#X;:,.7%ZZR%;8J(Y"1*5QL;/0U
M:MOVE/AS>?$;4O!\/C[P3+XNT?3/[:O]$37+5M2L;#"-]KEMP_F)!B2,^8RA
M,.ISR*^?]`_8#U_X:_L%^.O`EG_9GQ`^('C,7DL__"5^*]3;0#=S7DTL=U!'
M-'=II_E"43B*TME3SHE'&!*OGNO_`/!/3XR?%7X6:MX.U^W^&?ANPD35]9AO
M]*\4:E>7>IZEJ.GM:M83D6%J\-HGG2)]JBE:9HXH2L43#Y>I[SBOLQT>MG*V
MJ6SM?5:7:7+\3TY8WY(2:UDVFM+I:6?:^MGK:_O7Y8L^TOA+\:/!WQ]\%0^)
M/`GBSPSXU\.W,CQ0ZKH.J0:E92NC;759H69"58$$`Y!&#735Y)^Q;\)O%WP;
M^#LFE^,KIFU&;4KB[M[`^+M2\7+H]NVT);#5=22.\O!E6EWS(I0S&-1Y<:&O
M6ZNHDGIV7WVU6FFCTT;79M:DQ;=[]W^>C^:U"N7^('_(V>!_^PW)_P"FV^KJ
M*Y?X@?\`(V>!_P#L-R?^FV^K7#?&_27_`*2S.O\`#\U^:.HKE_C=X+7XC_!S
MQ5H$FM^)/#4>LZ5<V;:MX>O/L>K::'B93/:S8/ESIG<CX.U@#BNHJ#5+./4=
M,N+>5F6.>)HW*]0""#BN'$INC)1WL]]MCJHRY9J3[H_)3]F__@DC_P`$[?VK
M_!GPF\0:QX$\=^*/&GQVTF_\0Z9?^-?%>NR>(O$QM"AOKR^EM+O[(MP6F1WP
M4#F3Y`<$#Z2_X)!?L9_!/X3Z1J'Q(^`-U\7?!OP_UB75/#H^'VL^)IKWP]:7
MMEJ4EI<ZC%:S2SLMS))9D"7SSF(@;$)('YI^//V-OA[X(^"WP"USX#_$#]OS
MQOX\^(5WJ^D_"KP7%\6]*\-S66FP,W]HW<-RMI-#863I#&X"X\T-"'5>=OZP
M?\$2K+P39?\`!-#X=M\/[KQY=>'[IM2N93XUNX;O7X;^34;I[^*[EBCC221+
MMKA-P0%@H)Y)KNA)-3J4_=LVK;;WTMIHHV3TLI=FDEA7C;EA/5MIW>NBYM;]
M&Y*ZUNTF]5<\)_X*H_\`!6&Z_9^_;"\`_#?PI\5/"'@%?#?B+PO-XUAU&?3O
MMFM6NJ:K%`UG&EUEXX(;%;FXN)XE#1^;:D2H-X;N/^"G?[4_Q*\&?&74O!OP
M]\?#X=KX1^#OB/XJ2WL5A87<FKW5A+!%:VDWVR"=5LSOE:8Q+',<Q[94Y!^O
M/C%\"_"OQ^T32=.\7:7_`&M9Z'K=AXBL8_M,UOY%_93K<6LV8G4MLE16VL2C
M8PRL,BO(_%/_``2>^`?C&TDAO?`]RJ7&IZMJMT;3Q%JEF]])JLR3:C#<-#<J
MT]I<R1HTEI*6MFV`>5@8KCY9^Q5.^JE4=_\`%!*"](2O*VWNI:\\FM^:/M.>
MVEH*W^&3<W?O)>[?=<SLTH13]6^!WQ1N/B9^SQX/\:ZI8OI]UX@\.66MW=E;
MQ23-;/-;),\2(`78J6*A0"QP!C/%8_[//B2W\6^)?B;J%K'?PV]QXHBVI>V,
M]C.-NCZ8IW0S(DB\@XW*,C!&003Z-86$&E6$-K:PPVUK;1K%##$@2.)%&%55
M'`````'``KB?A!_R4'XJ?]C1!_Z9=+KIKRC*I*4%9-NR[+HCFH1G&G&,W=I*
M[[OJSO*XGX\?&&]^"WA"/4M.\#>,OB%>33>4NE^&ULEN54([O*\E[<VUM'&J
MH>7F4L2JJ&8@5VU>._ML?"#5/C?\+K/0['X:?"'XM6,E^LNH>'OB)=26FFNB
MQOLGBE6ROML\<A3`-N<JS8="!NYJW-R>YO\`\'^NWJMUTT[<WO;?U_7Z/8YK
MX,?M'_\`"5_#+QI\2?!?@GQCX^M/%&L:9JNGZ-I9L++5)+>ZT'2)%9AJ%U:P
M(45P65I@>"`&/%>A_LO_`+1,7[3WPSF\2P^%?%'@W[/JM]H\NG:\UBUTD]G<
M/;3$-97-S`R"6.10R2MG8?;/BO[,WPV^+WPK^"WQ5\$:;K'AS7?&6BVMI8Z1
MXJUK5+R8WFM_V!IZ%[J%XI9/LT;"%A(9YI9075U4KO?Z%^"'PGT[X$?![PSX
M-TGS&T_PSIL&G0O*Q>2;RT"F1V/+.Y!9F))+,2>37J9CRK$2Y?AM"W_@*[=K
M==^:ZV.#"7]C&^]Y7^][W[WTMMRM-)G4T445YYUA1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110!P7B+_DY_P`'_P#8K:[_`.E>CUWM<%XB_P"3G_!__8K:[_Z5Z/7>UUXC
M^'2_PO\`]*D<]'XZGK_[;$****Y#H"BBB@`HHHH`****`"N7^$'_`"*=W_V&
M]6_].5S745R_P@_Y%.[_`.PWJW_IRN:Z(_P)>L?RD8R_BKT?YHZBBBBN<V"B
MBB@`HHHH`****`"LWQCJFH:+X3U*\TG2_P"V]4MK:22ST_[2MM]MF"DI$96^
M6,,V`6(.T'.#C!TJP/BIH7B#Q/\`#37M-\*:_;^%?$U_836^EZU/IHU*/2KE
MD*QW!MF=%F\MB&\MG4-C!.,U-2ZB[7OY6O\`*^E_73N5"SDD_P`;V_#7[M3A
M/V5?V@_$7QN;QSI/B_PGIGA'Q5\/=?&@ZE;Z3K4FM:7<,]E:WL<MO=R6MJ\@
M\J[165H$*.CCD88[W[1W_)/M/_[&CP[_`.GJQKG/V+_@+XR_9Q^%LGAOQ=XJ
M\(^+Y4N7N8K_`$7PU=Z--<RRLTEQ/=FYU&^:XN)9G:1I`T8RQ`7&,3_M(_#'
MPU)9Z7XF;P[H;>(X_$_AY5U4V$7VY1_:]E'@3;=_W"5Z_=)'2M)65DNRO:]F
M[*[U[N[,XMO5]WO;:^FWD>L4445)04444`%%%%`'F&O_`+5_AGP)H=U_PDTT
M6@^(K.9;4Z%-<QB[NYGR(OLVXJ)HI,$K+\J!0YD,9CD">AZ!J+ZOHEI=2+;Q
MS3Q*\B03^?&CD?,JR8&X`Y&[`SCH.E>*?%_]B32?VD]*;4O'UOI.K^*X'\S3
M/-A:YTW1T&<6J1MM,D;@XED.R20G<IBV1+'R]M_P29^$MM:PW6CZ=XB^'^K3
M1JURWA?Q1?1(DNT;@A=L%0>`=BY`!VCD5W<F%<=9-/KI=?FM/O\`\];0MN?3
M]%?,?_#"GQ(\'#_BC?VEOB=8[?N_\));6OB+\_-5,]OU]:/^$8_:W\"_\>?B
MCX,^/(%^]_:NFW>EW+_[OD$Q@].O')]JGZK!_!4C\[K\U;\1>S71H^G**^8Q
M^U+^T#X)&/$O[.DFJP+]Z\\->*[6YS["W<"3\<XYH'_!4GPOX<.WQG\/?C%X
M!V_?EUCPG-Y'U5X2^Y<Y&<=0>*/J%9_"E+T:?Y-A[*70^G**\-\#_P#!2WX#
M?$/9_9_Q1\+0F3A1J,[::3^%RL=>N^%O'>A^.;3[1HFL:5K$&,^98W<=PGYH
M2.XK"I0JT_CBUZIHF49+='*?&_\`9UT?XT1VM[YUQH?B?2_FTS7+`^7=V;#D
M#(QO3DY1N.3C!.:Y'P-^T3K'PS\36WA#XL0V^FZE<-Y6F>(H1MTS6_0$](9O
M53@$],`J#[=63XY\!Z/\2_#-SHVO:?;:IIMXNV2"9<@^A!ZJPZA@00>017A8
MK+9*H\5@FH5'O_+/RDN_:2]Y>:T/6PN91=-87&KGI]/YH><7V[Q?NOR>IK`Y
MHKY[6;Q=^Q<^V8ZEXW^%J'B7_6ZKX;3W_P">T"COU4#L!AO</!GC72?B'X;M
M=8T._M]2TV\7?#<0-N5AW'J".A!P0>"`:VP.91KR=&HN2K'>+W]4]I1[->CL
M]#''9;*A%5J;YZ<MI+;T:WC+NGZJZU-2BBLGQGXFE\(:0+]=/N=0MX9!]K6V
M&Z:"'G=*J`9DV\$HOS%=Q4,P"MZ<8MNR/+E)17-+8UJ*\_\`A5^T%8?&6^DC
MT&U:]M;.]O+:\O(YU>VMUAFDBC(<<.\VQ9%1?NQL&8C*;_0*NI3E3ERS5F9T
M,13K0]I2=UW_`*_KH%%%%9FP4444`%%%%`!1110`5R_Q`_Y&SP/_`-AN3_TV
MWU=17+_$#_D;/`__`&&Y/_3;?5T8;XWZ2_\`268U_A^:_-'44$9%%<[\7?B'
M_P`*D^%OB+Q1_8?B+Q-_PCVG3ZC_`&1H%E]MU34_*0OY%K!E?-F?&U$R-S$#
M(KEE)1BW+8Z(Q<FHK=GY9_LV0_L:?L2?\%6=8TWPY\:],NKS4/"&JKI&I:]\
M6--O])^'%U/JRBXT32[25,6\\LDCRE99I'_=NOED-(3]D_\`!&:/PW8?\$_/
M#.F^$])UC2=%T'6O$&CJ-6U5=4O[Z:UUJ^MY[R>X6&%6EN)HY)V"Q*%,I49"
M@G\\-3_;?_X)??\`#:,/Q/\`&=KX)\!ZY9Z!<:/KWPZ\2?`J[34=,UQ[Y+F2
M\O6CLI(A?PLDD+%1(V68B7'!^OO^")?[8'PQ^)'@G4/AG\)+CXC?$?PGH]YK
M?B3_`(63-X(NM"\+7=Q?:O->R:7%+<MYC7<`O5#+L`94+@C.T:86+^K0I[R2
MDG;5)*<G'5:6LV[];J]YW,\5*U6<]DYQ:OHW>G:6G?FLNZ]ZUH'WM1114E!7
MFG@GQ):>#=;^,VL:A(T5CI.OK>7+JI8I''H6F.Y`')PH/`YKTNO#O&?_`"3?
M]I+_`*ZW7_J-Z?515VD*6BN>"6W_``<5_LVWD"RQ7_C.2.095ET%R"/^^JD_
MXB(OV<?^?SQK_P"""3_XJOP7_9^^)MSX$T/R_LUK?6LW)BN(PVQO53V]^QKT
MC_AHK_J7])_[]#_"OU:EP7ETH*3<M?-?Y'Y]4XHQL9.-H_<_\S]@/!O_``7=
M^`?@GQ'XLU*^NO%PM?&&JQZOIY31'9C`EC:61WC=\K>=:3<>@4]ZZ#_B(B_9
MQ_Y_/&O_`(()/_BJ_'/Q!\>?L.DZ')_8>F/]LLFFP8QB/%S.F!QT^3/U)K+_
M`.&BO^I?TG_OT/\`"NBMP7E\Y7E*6R6ZZ)+L<]'B?&QC9*.[Z/J[]S]F=3_X
M.-/V:M&T^:ZNM2\906]NI>21]!<*H'_`J^X?"_B*W\7^&=.U:S\S[)JEK%=P
M;UVMLD0.N1V.".*_D5_;%^+%YX\\,R6OV>UL+&!"PAMXPOF-C[S'OCL.@K^L
MSX"?\D+\%_\`8!L?_2>.OA>)<JP^!JQIX>^JUN_^`CZ[(\PK8NG*=:WR.LHH
MHKYD]P****`"BBB@`HHHH`****`"BBB@`HHHH`**XV/X\>'YOB!-X75?$3:S
M;O&LL8\.:B88ED9T21IO(\H1,T<@$A?8?+;#?*<=E6E2C4IV]I%J^JNK77<S
MIU83^!IV[!11169H%%%%`!1110`4444`%%%%`!1110`4444`%%%<9^T5=Z%8
M_`3QE+XHOK'3/#BZ-=?VG>7L<LEI:6WE,)))UB>.0PJN2^UT^0-\RC+"*DG&
M#DNB]/Q*A'FDH]RKXB_Y.?\`!_\`V*VN_P#I7H]=[7YS_P#!,SQ9\/OA?\8;
M_1M&U[X7R^&-6O-?BT#5O`*II?A'Q-<O:>'YIH-!L(Y9EB:);>7S8;:YNBT\
M5U+O5F>&'JO^"3EOX"TS]H/XK?\`"L]4^%?BSPOJVD:1>RZY\,[$Z;H,5P)K
MX"UO+?S[H/K/EN)+BY>Y,TJ-;B2"#8K3>CB(W5**_P"?:E][D[/LK7LWO:V[
M2?'1NO:S?\]OE[L;KOKT6WHFU]W4445PG4%%%%`!1110`4444`%<O\(/^13N
M_P#L-ZM_Z<KFNHKE_A!_R*=W_P!AO5O_`$Y7-=$?X$O6/Y2,9?Q5Z/\`-'44
M445SFP4444`%%%%`!1110`4444`%<'^T=_R3[3_^QH\._P#IZL:[RN#_`&CO
M^2?:?_V-'AW_`-/5C0!WE%%%`!1110`4444`%%?G_P#M)?M[:_\``[]J:#PU
MIVO:CJGA?PZL^G7DEO`MQ>$S>66!WL(Y9[<@)&[X(.=X?+&3K;O_`(*UKI#6
M^EZ9\,_$$DD,:Q(VO:U%I[L!A=SNZN2>N2222/KBG[-4U5G4C&+O9RE&-[.W
MVFNO];'@QXBPGM9T97YH.SM&4M?+E3/M.BOD?0/VR_BA\3-O]B3?`3P^T@!6
M/6/%3W4@Z?P0[3Z]NK#T-=CIG@;X_>/[?S3\7O`>BQ-_'H7AU=05>O0SO[#K
MZGT&=J5.C4UC6A\I<W_I-S99QS_PJ-27_;JC_P"EN)]#T5X"?V./&7B`_P#%
M0?'CXE7`;[W]D?9])]>GEHV.O^>P?^";W@'5\_\`"1:IX]\7;OO_`-L>);F7
MS.N<[&3KD_\`?1K7V&'7Q5;^D6_SY2OKF.E\&'M_BFE_Z2IG;?%SP_\`"'6_
M-_X3RR^'%UVD_MV*R<\$GGSAV.?QS7S)\3/@W^Q"MXUU<3>$-+OHN4N/#FK7
M4;Q'N5%HY3N1]T\&OH/PW^P%\&?"A7[+\//#TNS&/MD37GIU\YGST'7W]37?
M>&_A#X3\&A?['\+^'=*\O[OV/388-O3IM4>@_(5O3Q5*E\$Y_)J/_P`D5&IF
MSV<(?^!2_P#D#X''_"!Z1M;X5_&;]J"7IY%MIT-SJUB/I#<Q+G@_WOX1Z#.A
MX=^*O[6^F7B_\(XWB[Q=9C_5IXQ\`6>CN!CHS172D]#R2">/6OT*HK1YI#_G
MVI?XK/\`%),?L<PG_$Q"_P"W817_`*4YGR5!\;OVN+'0M]Y\&_!E]=A/F6UU
M6&+)[X1KQOKC>>..M?-Q^,_Q\^"GCC6M8A^&'BSX?C5LFYM]$\,RWVB[^1YK
M@2SHC],%%`/L"<_J-17EXY87%PY:M&*:UC*-U*+[Q;;^::::T::T._+/;X.H
MYNM.:>DHR:Y9+LU&,5Z-6:>L6G9GY]^&?VGK/QCI]H?'G[4/B3PG?77RRV"^
M&8='%NW.4%PB/&<?-@E@W`)`(`KJ/%'PP^%WB_PS:75M\?O%7C:&\O(H+^]D
M\<I>Q:3`X):8PP8VJ"-GS?+%YI=\I&PKZ*_:+_90\/\`[05HEU,L>E^)+-?]
M$U6.%9&&.D<R-\LT1[HW8G&,G/R_\0O@K\,X,^$_B9\'/A[H/C*\8Q6GB&"W
M&F:'?1X)>[:2!HGWJ!DP@AW=E7,8<LG/@^(JF$G&CF;Y=;*I%14'V4E9<DO5
M\LGL]>5=E3A#*\=!U,'&4G]J$IRG)=W'F;YH^:]Z/5?:?OW[.WPX_P"&9]>L
M_`NDZA_:EC?3W^HSV'FR7!TBU>>9[:Y,K#Y2Z[(6C;_6.&>/_5S%O=*^;_V&
M[#P7\+K1?"'PQU>U\3^$@GF7$CN(]3TR=4`+RB0(\]O)@!2`6B<A1NC(\GZ0
MKHJ8REBG[>C-3B_M)IW^ZYS++?J"^J\KCRVT:::7H]4%%%%9C"BBB@`HHHH`
M****`"N7^('_`"-G@?\`[#<G_IMOJZBN7^('_(V>!_\`L-R?^FV^KHPWQOTE
M_P"DLQK_``_-?FCJ****YS8^0?VY?^"JEQ^R)^U7\-_A=HWPSU#QQ)XLO]&B
M\1:P=:BTRT\*6NK:I_9EE-M:.1[J1YTF_=(%PL62X#9'LG[$'[4@_;(_9PTG
MQXVA_P#"-W=Y>ZCIE[I@O/MBV=U8WUQ8SJLWEQ^8GF6[E6V+D$<"OB3_`(+"
M^&?V5?V@?VW_``/\.?C1\4?'WP$\?:9X57Q7IGCC1O&6G^%]/NK2'4?W%C-<
M7+ONN([J/[3"/(!4Q,R2@AEK[6_8)\!_"GX7?LC>"?#?P3US1O$GPST.S:RT
MC5-+U>+5H+\I(XGE-U$S)+*T_FF0J<>87&%Q@/#:X9RGK+FE9K9QNTEY.+BT
M[ZMWZ*[,1[M91CHK1WWORW?_`(%=-6T45JKO3U^BBBD`5X=XS_Y)O^TE_P!=
M;K_U&]/KW&O#O&?_`"3?]I+_`*ZW7_J-Z?54_B1,MF?R]?#W_D!QUT5<[\/?
M^0''715_0&'_`(<?0_':WQLWO%W_`"+_`(6_[!;_`/I;=5@UO>+O^1?\+?\`
M8+?_`-+;JL&NFIO\E^1C';[SS#]H3_D`W7_7,_RK^O?X"?\`)"_!?_8!L?\`
MTGCK^0C]H3_D`W7_`%S/\J_KW^`G_)"_!?\`V`;'_P!)XZ_*N-O]YCZ/]#]"
MX6_@2^1UE%%%?$GU`4444`%%%%`!1110`4444`%%%%`!1110!P7AW_DY_P`8
M?]BMH7_I7K%=[7!>'?\`DY_QA_V*VA?^E>L5WM=F._B+_##_`-(B<^%^!^LO
M_2F%%%%<9T!1110`4444`%%%%`!1110`4444`%%%%`!17YM_LW>.4\=Z_P"(
MK+Q5KFK1^1JUXEO>"=W.!.X"/SG'H>W0^WLW_"%>$/\`H<-0_P"_K?XU]9'A
M=N*DZCU5_@D_Q1\O4XFC"3C[-Z>:/H'Q%_R<_P"#_P#L5M=_]*]'KO:^&]5\
M(^%E^,.A1KXJOFMVT;46>7S6RC">P"KU[@L?^`BNF_X0KPA_T.&H?]_6_P`:
MZ*W#-X4U[1Z+^27\TG^IST^)HJ4G[-ZONNR1]?45\#_M#>*?#'P9^&M_JNGZ
M[JFL:JL;?9+43.(V?^](V>%'7`Y/08Y([C_@A]\2M<^+?[#W]N^(M1N-4U2Z
M\4ZPKS3.6*HMTRHB^BJH"@#@`"O%S/)_J=-3Y[W=OA:_,]C+<V^MR:4+6\[G
MV!1117BGL!1110`4444`%<O\(/\`D4[O_L-ZM_Z<KFNHKE_A!_R*=W_V&]6_
M].5S71'^!+UC^4C&7\5>C_-'44445SFP4444`%%%%`!1110`5D^/?'FC_"[P
M1J_B3Q%J5KH^@Z#9RZAJ-]<OLAM+>)"\DCGLJJ"3]*UJ\M_;7^&&M?&7]E/Q
MUX;\-P6]WX@U#3&;3;:>801W=Q&RRQPM(<B,2,@3>00N[)!`Q4S;46U_G^'4
MJFKR2?YV_%Z+U>QJ?`#]IGP?^TWH>JWWA*ZUA_[#OAIVI6>L:#?Z%J.GSF&*
M=4FL[Z&&XCW0S12*S1A75P5)'-._:._Y)]I__8T>'?\`T]6-<1^R9H7B[7_B
M?\3/B'XL\%ZK\.SXRGTVUT_0=6OK&\U**"RM2C3SM8SSVZ^9++(%1)I#LC5F
M*LYC3;_:2^&&O>+M)MY]-\4^*H8VUS17_LRRM;"2"!4U*U+S@O:O+F-5:;YI
M"@,?S*4RITDK;=EUOT_K3=;/5&=-MQN_RL>L45P?_"H/$'_15/'G_@)HO_RO
MH_X5!X@_Z*IX\_\``31?_E?4E'>45P?_``J#Q!_T53QY_P"`FB__`"OH_P"%
M0>(/^BJ>//\`P$T7_P"5]`'>45P?_"H/$'_15/'G_@)HO_ROH_X5!X@_Z*IX
M\_\``31?_E?0!\8ZA\=?V"[^^FFNM6DN;B5G:65X/$<C2LYR[%MIW%CR3DYZ
MU]S?#D^'/%GPH\.S:$(]1\+7FEVTVE-,'E$UHT*F%CYV7.8RO+_-SSSFOP!3
M]BKXRH@4_"/XGY48/_%*WW_QJOVH_94^!_BK2/V7OAO:7GC[Q]H-Y:^%M,AG
MTQK'2HSITBVD0:`K+8M(OED%<.Q8;?F).37AY57E4E)3IJ/HK7N[N_S;?JS[
MKBWA+*,HHTZF6SYG)V>L7HEI\,5^)Z/KW[.G@#Q.6.H>"?"MT[=9'TN'S/\`
MOK;G]:X[4OV`_A/?S^=%X5&GW"_=EL;^YMV7IT"R`=O2NH_X5!X@_P"BJ>//
M_`31?_E?1_PJ#Q!_T53QY_X":+_\KZ[JN6X.IK4I1?K%/]#X-TXO=''_`/#$
MEGI8_P")+\0OBGH>T<1V_B!GA_%'4Y[]^IH_X9^^*6B#_B4?&K4F5?\`EEJF
M@6MYOZ\%\AAUZCVKL/\`A4'B#_HJGCS_`,!-%_\`E?1_PJ#Q!_T53QY_X":+
M_P#*^L?['PJ^!./^&4H_DT3[*/0X_P#LG]H+P_\`ZC5_AAX@C7D_;+2[LY6'
M/3RR5!Z=>*/^%K_&S0/^/[X4Z+K:K]Z32_$L</'<A9ER>G3.3D>]=A_PJ#Q!
M_P!%4\>?^`FB_P#ROK!\(_#OQKJWB#Q1;ZA\2/'EK::9JB6VF2?V?HZ?:[<V
M5K*TF38$-B>6=,K@?N\8RI)/[-DOX=::^:E_Z4I![/LV9H_:YUS1CC7/@_\`
M$RTQPS:?91ZDB].24<<#GD#H!ZT)^W_\.[$A=9D\1^&VS@C5-#N8]IXX)5&`
MZUV'_"H/$'_15/'G_@)HO_ROI#\'_$##!^*GCS_P$T7_`.5]'U7&Q^"NG_B@
MG_Z2XARRZ/\`#_ABGH/[8?PM\1X^S^._#:;N@N;M;7_T;MKM="\<Z+XIQ_9F
ML:7J6[I]ENXYL]?[I/H?R->9Z[^Q_9^*<_VGXKUK4=W7[5H7AZ;/3^]II]!^
M0KB]>_X)<^!O$>[[1KGB:/=U^RVVDVO_`**LE]*+YC'I"7SE'])A^\\OZ^\^
ME*^8/^"MGB/1O"W[+=K=:SK$.DH==MH[820R2?;93'-^Y!16VG:'?<V%Q$03
MR`=GP_\`\$Y]$\*$'3?B+\6K`KT-MKL4..O]V`>I_.O(_P#@I/\`L=>(-<^!
MOANPTG4_B)\2E7Q+#)<Z?J+?VE]EB%I=YN%$$22!@Q5-S,5`E.03C'F9U*O6
MR^M1Q%'W7%I\LD_NND_P/8R''1PF84L563Y8/F=K7LM=+]]ORU/'_P#@FUXX
MT=_VSO#6FC7H+6^O+.[DM[11(QU)?LTC;`54J,*#+\Y`(BXR<`_J%7Y9_LG?
MLA^.H_VROA]KTVA^-_!L>EF^CN-7&C&(VT;6%RJ_-<P/%R[!/F4_ZPXPV"/T
M0_X5!X@_Z*IX\_\``31?_E?7G\`8-8;*_9I-/F;=^]E^%K'I<49]#.*]+&Q7
M*W!*2[-2EI>ROI9_,[RBN#_X5!X@_P"BJ>//_`31?_E?1_PJ#Q!_T53QY_X"
M:+_\KZ^W/F3O**X/_A4'B#_HJGCS_P`!-%_^5]'_``J#Q!_T53QY_P"`FB__
M`"OH`[RBO)OB?\//&GA?X:>(M2T/XC>.]2UK3M,N;K3[-M/T>475PD3-'&42
MP#-N<*,*03G`(->LT`%%%%`!7+_$#_D;/`__`&&Y/_3;?5U%<O\`$#_D;/`_
M_8;D_P#3;?5T8;XWZ2_])9C7^'YK\T=11117.;'YP?\`!4OP_P"(?VDOV\/#
MOPE^&OP)_9'\>?$"Q\"'Q9?^)/CAH1U./^S?M[VR6-BL$;7!9)BTCDDQJ)ER
M%9P6^D?^"2WQ<\._'#]@+P+XA\,^`?"OPOL9?MUG<^&/#4,$6D:7?6U]<6]X
M+80*L1B>YBFD5E'S!\Y8DL?F/_@K3H_[-7Q__;M\(?#+]J;2_A7HW@G3?`%Y
MXHT/Q+XKU6[T.ZN]2-ZMNUE;W\-Y;*8XX\2R6SEFD,D;(!Y;&OH;_@BQ\2K7
MXL_\$Q/A/K6G^$_#O@O3&L+BTL=,T"RFL]+-O!=SP17%O%,\DJQSI&L_[UWD
M)E)9F8DDP?\`NTGW;=_2=2/ERM6M:SYK<][MH,5_'2[)?^D1>G>][\U_=^"V
MJ.1_X*<?'SXJ_LX?%/X:>(?#_B+Q)X9^'LGB?0]/U_46TG2+GPO#:W-\(;B'
M4"WG:NUQ*&BBMVLXH8(WF4S3;<LF1_P4]_:E^)?@KXSZGX+^'WCS_A77_"(_
M!WQ'\5)KV*PL+J35KJPE@BM;.;[9!.JV>7E:8Q+'-S'ME3D'Z/\`C!^PS\,/
MCW\3-*\6>+?#]YJ^IZ/<VM]';'6[^'2KJXM7+VT]UI\<ZV=W+"QS')<0R,FU
M=I&U<<?XI_X)/?`/QC:20WO@>Y5+C4]6U6Z-IXBU2S>^DU69)M1AN&AN5:>T
MN9(T:2TE+6S;`/*P,5CRS]GR7L[U'??XH*,%Z1E>=MM%'7F;6G-#VG/:ZM!6
MVVDW+T<HVC??5O3E2?JWP.^*-Q\3/V>/!_C75+%]/NO$'ARRUN[LK>*29K9Y
MK9)GB1`"[%2Q4*`6.`,9XKS.\\26_BWX-_M%ZA:QW\-O<2WFU+VQGL9QM\.V
M"G=#,B2+R#C<HR,$9!!/O5A80:580VMK##;6MM&L4,,2!(XD48554<`````<
M`"O%/&?_`"3?]I+_`*ZW7_J-Z?7=4E&59R@K)O1=E?1'+2C.-%1F[M+5]W;5
MG\O7P]_Y`<==%7._#W_D!QUT5?O6'_AQ]#\AK?&S>\7?\B_X6_[!;_\`I;=5
M@UO>+O\`D7_"W_8+?_TMNJP:Z:F_R7Y&,=OO/,/VA/\`D`W7_7,_RK^O?X"?
M\D+\%_\`8!L?_2>.OY"/VA/^0#=?]<S_`"K^O?X"?\D+\%_]@&Q_])XZ_*N-
MO]YCZ/\`0_0N%OX$OD=91117Q)]0%%%%`!1110`4444`%%%%`!1110`445SO
MQ5^*FB_!?P->>(M?DU!--LS&C)8:;<ZE>3O(ZQI'#:VT<D\\C,R@)%&S$G@&
MDY)*[!)O1&)X=_Y.?\8?]BMH7_I7K%=[7S_\/?VJ_`OBG5_B!\5;/6+IO`^D
M^"K"^OKN32[N&ZLDLKW75NTELWB%TDT+PRH\+1"4.A79NXKU+X+_`!MT7X]^
M$GUK0K/Q9964=PUL4\0^%=4\.7190K$BWU"W@F9,,,2!"A.0"2"!VXZ+]K;J
MHPOY>['<YL*_W=^\I)>JD[_=U.NHHHKC.D****`"BBB@`HHHH`****`"BBB@
M`HHHH`_)_P"!W_(;\4?]AF\_]*'KTRO,_@=_R&_%'_89O/\`TH>O3*_<,!_N
M\/1'Y/B_XTO4Q;__`)*+I7_8-O/_`$;:5M5BW_\`R472O^P;>?\`HVTK:KT)
M;1]/U9RQW?\`71'F?[4?_).[K_KDU?0G_!OO_P`H[[;_`+&G6O\`TK:OGO\`
M:C_Y)W=?]<FKZ$_X-]_^4=]M_P!C3K7_`*5M7Y_QI\,/7]#[+AC>7H?;E%%%
M?GY]@%%%%`!1110`5R_P@_Y%.[_[#>K?^G*YKJ*Y?X0?\BG=_P#8;U;_`-.5
MS71'^!+UC^4C&7\5>C_-'44445SFP4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`'RSXT_P""KOAGX=W_`(HEUOX<?%&Q\-^'9/$-K!XB\K29K#6[
MG1+>YN+VWMHX[]KI6,=G<%&N8(8V,>"ZEEW?45I<K>VD4R[@LR!P#U`(S7YN
M_&?_`()%^/OB3??$V'1/!WP)\(ZMXPU+Q9J"_$2RU:Z'BC7[75;74(K?2K^-
M-,C*VH>[MS(6N[E5%HI2%G$;1_>'P%U'X@7_`(*8?$;PWX/\+ZU;S>3!;>'/
M$MSKUK+`$3$C33V%DR2%MX,8B8`*IWDL54HVE1BW\5E?[E?\6U:R:M>UK-UB
M$HU+0U7-/Y)-<GWJ[OL[VNFK+MJ***"0HHHH`****`"BBB@`HHHH`*\N^(/[
M3R^$_C9IW@'0_`_C3QYK4EM!?ZQ)H9TZ*U\,6<\SPPW-W)>W=ON5VBN"([83
MS;;>0^6,IO\`4:^*_P!LK_@FGJ7[0?[5<WCC3O"GPCU9M<M-`M4\5Z\)(O$_
MP^?3+^:Y>YTDI:2F629)@`/M%IY;Q!BTJMM4C_$BGM?7[G^MNJ[73"6D)-;V
MT^]?I?\`.SV?J_@;_@HSX&\>_#OXP>([73?%5O#\%=:U+0M7LI[.+[9J<UG(
M\6^R196$L<\T<D4)8HSR(RE5(KT_]G_XSZ;^T;\"_!WQ`T6UU*QTCQMHMIKE
ME;ZA&D=W!#<PK,B2JCN@D"N`P5V`(."1S7RUX;_X)I^,-)^,?AK6?^$D\/V7
MAR?Q=X@U[QIIUOY\DGB"W;Q!>:WH"(VU`LEM<71,P8%2&=%+##5]$_L;?!W5
M/V>/V2OAGX#UJ>QNM8\&>%].T2]FLG=[:6:WMHXG:-G56*%E)!95)&,@=*JG
M9TY.7Q>ZDO\`P*[^?NNW3YZ55256<8?"G*S[J[M]R2UZWOZ>E4445)(4444`
M%%%%`!1110`5R_Q`_P"1L\#_`/8;D_\`3;?5U%<O\0/^1L\#_P#8;D_]-M]7
M1AOC?I+_`-)9C7^'YK\T=12.VU"<;L#IZTM%<TKM61L?C+\2_P!L?6_^"V'A
M+X'_``0\/S?`V3XK>);O7/$WC74;[P)9>+H/A1INGW$MO%$^G:BUQ&M[.S0P
ML[LNX,S(%61&K]!O^"0?[0^K?M1?\$[/AOXLURQT#3]46WNM&G30K86VES?V
M?=SV"S6L0^5()%M@Z*N%"N`H`P!N?$G7/V8_V*?&&K:[XPO/@/\`"37_`(H"
M7^U-0UB72=!O/%H0YE\Z64QO=[3+\VXOCS.?O<^A?LZ:_P##GQ%\%]!F^$E[
MX)OOAW#";717\(S6LNBQQ1.T9CMC;$PA4=60JG"E2.""*=#2BUU;3D]US*ZL
MNR4;*V[=V]0KZU%+:UU'_"]7?HVY:WZ**2T;.VHHHH`*\.\9_P#)-_VDO^NM
MU_ZC>GU[C7AWC/\`Y)O^TE_UUNO_`%&]/JJ?Q(F6S/Y>OA[_`,@..NBKG?A[
M_P`@..NBK^@,/_#CZ'X[6^-F]XN_Y%_PM_V"W_\`2VZK!K>\7?\`(O\`A;_L
M%O\`^EMU6#734W^2_(QCM]YYA^T)_P`@&Z_ZYG^5?U[_``$_Y(7X+_[`-C_Z
M3QU_(1^T)_R`;K_KF?Y5_7O\!/\`DA?@O_L`V/\`Z3QU^5<;?[S'T?Z'Z%PM
M_`E\CK****^)/J`HHHH`****`"BBB@`HHHH`****`"O/_P!J'Q[XX^&GP0UK
M5OAOX%N/B-XTA$<>FZ'%?VMEYS/(J-*TEU-#$5B1FD*&5#)LV!E+;ASM[_P4
M"^#-A?7%O)\0M!$UK*\$H5W8*Z,589"D'!!''I4?_#PWX*_]%#T/_P`B?_$U
MURRO%SC94IV?:+_.W7RU[',LPPT9:U(_-K_,\'^!/A"XTKPI\0/!&N?`_P"+
M%]%XG\"K+XET^XU+P_::IK=W=W^LO>%I+75S##-?27=Q)%Y5P$B".&D@(B#^
MN?\`!/WP%XT\"^&_&?\`PD6D^//#'AK4-;6?PKX?\;>+?^$HU_2+06D$<PN+
MW[5>962Y2:6./[7<;%<?,@(ACR]$_;K^$=M\?O$VK2>.M&73;WP_I%I!.?,V
MR2PW.IO(@^7JJSQ$_P"^*[#_`(>&_!7_`**'H?\`Y$_^)KT,9E^,=;G5*6L(
M+X7;11?1=+6MLELD]3DPV.PWL^651:2F]9+JW??OO?=]6SV:BO&?^'AOP5_Z
M*'H?_D3_`.)KT[X??$'1?BMX+T[Q%X=U*UUC0]6B$]G>V[;HKF,D@,I[@X/-
M>96PM>BKU8.-^Z:_,[J6(I5-*<D_1IFQ1117.;!1110`4444`%%%%`!1110`
M4444`?D_\#O^0WXH_P"PS>?^E#UZ97F?P._Y#?BC_L,WG_I0]>F5^X8#_=X>
MB/R?%_QI>IBW_P#R472O^P;>?^C;2MJL6_\`^2BZ5_V#;S_T;:5M5Z$MH^GZ
MLY8[O^NB/,_VH_\`DG=U_P!<FKZ$_P"#??\`Y1WVW_8TZU_Z5M7SW^U'_P`D
M[NO^N35]"?\`!OO_`,H[[;_L:=:_]*VK\_XT^&'K^A]EPQO+T/MRBBBOS\^P
M"BBB@`HHHH`*Y?X0?\BG=_\`8;U;_P!.5S745R_P@_Y%.[_[#>K?^G*YKHC_
M``)>L?RD8R_BKT?YHZBBBBN<V"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`*Y?X@?\`(V>!_P#L-R?^FV^KJ*Y?X@?\C9X'_P"PW)_Z;;ZN
MC#?&_27_`*2S&O\`#\U^:.HHHHKG-C\S/^"IO[,7Q,\4?\%)?#'Q*\._L;^#
M?VL/!EO\.F\.7=IXH\3Z+8VMA>G47N$>"'40X25(P0T@B;S%N%4,GEL&^T?V
M"=*U+1/V5?#-MJWP2\/_`+.NH1FZ\WP!HE]8WUCH>;F4@QRV4<=NWG`B8[$&
M&F(.6!)_.W_@X1_88A_:@_::\)ZMXHM_"OB6QA\+V5IX!\+Z_P#$"V\+Q>(=
M=BU^VEU#2K<27,4C7.H:=(($E1'6,Q+DHYB8?8'_``0U^#C?`K_@E]\--!^R
M>'M-B;^TM2@L=#UZ/7K'3H;O4KJYBMDOXWDCNC$DJQM*CLK,C$&JP?\`N;OT
ME*RZZSF]=EJVVM)-*UVDXN3QG^\)K6ZC=]-()=;[62?PIRO:_+)+ZTHHHJ1!
M7AWC/_DF_P"TE_UUNO\`U&]/KW&O#O&?_)-_VDO^NMU_ZC>GU5/XD3+9G\O7
MP]_Y`<==%7._#W_D!QUT5?T!A_X<?0_':WQLZ[QUX1U;3O"GARXN-+U"""WT
MYDEDDMG5(F-Y<$!B1@$AE(!ZAAZBN1HHKHE)-W1C%-+4\P_:$_Y`-U_US/\`
M*OZ]_@)_R0OP7_V`;'_TGCK^0C]H3_D`W7_7,_RK^O?X"?\`)"_!?_8!L?\`
MTGCK\KXV_P!YCZ/]#]"X6_@2^1UE%%%?$GU`4444`%%%%`!1110`4444`%%%
M%`'X&_"CQI:^&/BEXS34M-M]6T^37K_,4G#1G[3)\RG^8Z']:]2_X6OX*_Z%
M*/\`/_Z]>%Z-_P`E'\9?]AZ__P#2F2N@K^E,K_W2GZ+\C\-QT5]8GZL]*B^)
MGA%-7GG;PO&UO)#'&D6?N.K2%FZ]PR#_`(#5K_A:_@K_`*%*/\__`*]>6G_5
MCZG^E-KT6<?*BC^V=\9M/?X67EAX<T.WT=[F-A/=`YF*8^XO]W/<]>W'.?UL
M_P""-_\`RBW^!?\`V*=K_(U^)_[4/_(F7'_7(U^V'_!&_P#Y1;_`O_L4[7^1
MK\D\1)-U*:?F?HO!<4H3L?2U%%%?FI]R%%%%`!1110`4444`%%%%`!1110!^
M3_P._P"0WXH_[#-Y_P"E#UZ97F?P._Y#?BC_`+#-Y_Z4/7IE?N&`_P!WAZ(_
M)\7_`!I>IBW_`/R472O^P;>?^C;2MJL6_P#^2BZ5_P!@V\_]&VE;5>A+:/I^
MK.6.[_KHCS/]J/\`Y)W=?]<FKZ$_X-]_^4=]M_V-.M?^E;5\]_M1_P#).[K_
M`*Y-7T)_P;[_`/*.^V_[&G6O_2MJ_/\`C3X8>OZ'V7#&\O0^W****_/S[`**
M**`"BBB@`KE_A!_R*=W_`-AO5O\`TY7-=17+_"#_`)%.[_[#>K?^G*YKHC_`
MEZQ_*1C+^*O1_FCJ****YS8****`"BBB@`HHHH`**H^*/$5OX1\-:AJUU'?3
M6NF6TEU-'964U]<NB*68100J\LSD`[8XT9V.`JDD"O#8O^"@^D:M\'_"_B71
M_`'Q&UW7/&6MZAH&E^$+2#3H]<DN;"6ZCNRYFO([.*./[)*Q>2Y4$&-1F1UC
M*<DE=_U<=GOZ_@KO\#Z`HKE?@?\`&#2?C_\`"/P]XTT-+Z'3/$5DEY%!>P^1
M=VA/#P3QY.R:-PT;ID[71ADXKJJN47%N+)B[JX4445(PHHHH`****`/FOP]_
MP5-^'>O_`/!1G7/V9&TOQAI_CC1;43KJEU9P+HFHRFS@O?LL$RSM*9Q;S^9M
M>%%Q#+AC@;JO[-?_``5L^%7[3?Q4^,?AG3EU[PW:_!$&77?$/B);2QT2YMQ/
M=0-=6\_VACY"O9SYDE6(;5!Y'-?(?[?'_!.G]H3Q1\:?VB_BQ\(?#=K_`,+%
M@\:>#_%'PRN9=3LXO[76VT5M+U./+SH(0L=Q+D3F/?Y8V[LJ:X/XC_\`!$[X
MR>%/`?Q8\)>!]-\S2H_!GPTL='N8]1T^*3Q?<:!.UQJ5NBSEXXII)`'5KN(0
M/(RA\H7(FC)N$7/3X8OSYH<SG;^X_=:ZNZT9=9)+W>UUZJ2BX^LD^9/IKT3/
MU-3]LOX/R?!-OB4OQ6^&S?#F.;[,WBH>)K+^Q%E\P1>6;SS/)W>80FW?G<<=
M>*7Q%^V-\(O"'@G1_$VK?%3X;Z7X;\0V,FJ:5JMWXELH;'4[2/RQ)<03-($E
MB3S8MSH2H\U,D;AGX1N/V4OC=\.=&D\8_#GPW\>%\3>,OB1%KWCF;Q2WPZG\
M9PVZ:0]G]MT)82=#MVD'E0S-,%G=/,P/F).)_P`$]O\`@F?\7O@WXP_9#G\=
M>#5%O\(]5^)-WKD]UJ6FW3:5_:L^[3I56%]K-,I8_P"CI^[W'<L><5I"//)Q
MVMU??D4G;NN9\J>FJ::N1*7+RO>[?W7G9OM\*NM?B3OLG^C/B7]HCPIHO[.^
MK?%+3M4M?%7@W2]"N/$4=]H-S#?1ZE:0PM,6MI%?RI-RH=I#A2<?,!S7!^%O
M^"DWP3U3X'^#_'GB#XC>#OAYIGC3PYIWBFSM/%^OV&DWMM97Z%[9ID>;:I8J
MZ`AF4O$X5FVFO%_V1OV1?B+\,/\`@C/XP^$VN>'S8^/-0T_QG:V&D_;[:4-]
MNOM2DL4$J2&%0\4\)`+@(&PVT@@>/_`'_@F[\4/"^I:%<>(/`MJLNF_L@V/P
ML\R6_L)F@\0JTOGV"D2DX*LN91^Y8?\`+0XKGG4DE4DELHN*ZOW*TFO-MPIQ
M\G):7:3VC3C[J;UYI1;_`.XE*"EZ<LIS\U%ZV39]<:S_`,%/_@[X?_;CT7]G
MZ[\5:7#XX\0>'T\06,KZG8K8S^9-''!8JQG$K7DRR+-'"L1WQ`N"1P>\T;]L
M;X0^([OQC;Z?\5/AO?S_``[CDE\51V_B6RE?PRD9=9&O@LA-J$,;AC+M`*-G
M&#7P[^S[^Q-\:O@G\;OV;_$EUX1U2X^P?LYQ_"7Q)>6&JZ=)/X+U@26<HNK@
M2W2?:(%,<@+6AG?,?"D%2?%?@W_P27^+&F?L:ZIX,\2>%_C9<?$WP3\(O%/@
M'PX\^L>"H_!.I/?*4\JU>T,6JR+<2)%.C:B!Y;;S(P;);;$?NXSY/><?:?\`
M;W+*JH6]5&'^)3NG>/O9X>U2<%/W5+V=_P"[=0YKW[-S_P`/+KHU;[3^/W_!
M93X8?#_]HKX5?"_P-XN^$?CKQ-\1]:N=,O'G^(=II]GX=CMU&_SGBCN6:ZEE
M988+8HAFEW+O3::]YT;]L;X0^([OQC;Z?\5/AO?S_#N.27Q5';^);*5_#*1E
MUD:^"R$VH0QN&,NT`HV<8-?*:?L,_$2R^('[%+:/H,'A^P^$?PXU_P`/>([N
MWN;54\-W]WHEC:VX6-9`9?\`2(I.8`ZC9DD`@GY?^#?_``27^+&F?L:ZIX,\
M2>%_C9<?$WP3\(O%/@'PX\^L>"H_!.I/?*4\JU>T,6JR+<2)%.C:B!Y;;S(P
M;)8Q/[I34/>Y5-I_S6<U%*W?DB[:MJI=/1)SA/WRIRG[O-RIK^6[C=N]NDGK
MLN35:W/T_P!=_;L^"'A;P+-XHU/XR?"K3O#-OJKZ#+J]UXLL(;&/444N]FT[
M2A!<*H+&(G>`,D8J[\4/VQOA%\$$5O&GQ4^&_A!9+2"_4ZWXELM/#6\[.L$P
M\V1?W<C1R!'^ZQC8`DJ<?"7QX_X)^_%S1Y/V2=:\,Z/XV72?A9\-KOP5XCT'
MP%-X676M'N;NPLXY)84UP-ILL+&V>"4HPE`=2A92]6?AA_P3`\2?#7XGW7]A
M>"_$DW@VQ_9>D^&N@S>+M3TBZUNWU.2^NI?[.G:VE,0<12QJTD7^C8`42$+1
MBOW?.X>]RN=O/EC4:V_G<(<K5_XEK-I<QA7[2,7/W;J+?ES2II]O@4I.2T^!
MO1/3[U\<?M,_#?X8ZWX6TSQ)\0/!'A[4O',JP>&[34]=M;2?Q!(Q152S21PU
MPQ:6,`1!B3(@_B&5TO\`:7^'&M_&>^^&]E\0/!-Y\1--A^TWGA>#7+636K2+
M:C^9)9A_.1=LB-N9`,.IZ$5\$?LD?L>_&']F/XH_#O5_%7PCN/B7I^O?`?PK
M\-=5MO[:TAX_!VI:?(S7<=Z+F=?,LI#/YC268NW+6S?NGS'G,_9#_P"";'Q$
M^'O[4MO'\2[+XV:E9^%_B[KWQ%T#7M"U#P<O@^X:_P#/9;BZWA?$&]X;AK>6
M'YTW(NTF(*5WE3BJ_LT_=O/7_#44(_?"]1?S+165Y&/M)>R<VM;0T\Y4W-_=
M+W'V>KUM%_J!1116!L%%%%`!1110`4444`%%%%`!7+_$#_D;/`__`&&Y/_3;
M?5U%<O\`$#_D;/`__8;D_P#3;?5T8;XWZ2_])9C7^'YK\T=1114.I6*ZIIUQ
M:R%ECN(VB8K]X!@0<?G7+-M1;BKLWC:^I^9?_!:W]A7XT?$_]K/X8_&+X2_"
M70?C1=>%Y-#']G7?B&ST;4/#LFEZR=4:6UEN\1JEY&3;2LC>8-D1VNH93]<?
M\$MOV=_%G[+G[#G@WPGX[&FQ>,C)J&LZQ:Z?)YEGIMSJ%_<7SVD+9.8X3<>4
M""1^[X)&"?PQ_;J_X)(?`?\`X(FIJ6L?$2Q^!O[2&@S%]4@\+:[XVUOP3\26
MAN;H06R6D5C=S6MW;0[7:2<VD18I+C:%"C]P/^"2-CX`L?\`@GS\/?\`A5_P
MQ\:?!WP//!<W.F^$_%27"ZIIHDNII)&<SRRR-'+(SRQNSG='*C`*"%&N#LL'
M*,'=*5]OAE.[DKZ;M+926FC2W6,O]8BY;M)+^\HJT96UZ-JUUN[IM*WG/_!1
M.WUSQO\`M7?!_P`(?#'QQX^L_BY+KFFZ_<Z=IGB&XM=!T'PO:W>[4KO4[*%E
MAN8[D#[-$MR)'>8J(BBI.:\K_P""H/[2?_"R_C/XCT'PS\6M:T#PSX#^#'C/
MQC;WO@[Q-<62CQ-I=Q;0!+B:RE0S-9;VWV4K,A:<>9$2JX^VOBG^P_\`!7XY
M^/HO%7C;X0?"_P`8^*($CCBUC7/"MCJ&H1K&28U$\T32`(22H#<$\8J;Q)^Q
MG\'_`!E:6=OK'PI^&NJP:?K$WB&UCO/#%E.EMJ<SAYKY`T1"W,C@,TPP[$9+
M$US>SE[-03MK4>G1RCR1:[<FE1+?VBNI+F]W15(JISM7T@M>JC+FDGO\7P7_
M`)'9IV][0_9_\::[XO\`V:?!/B+Q!:/-XFU3PS8ZCJ5M;HD327<EK')+&@9@
MBDR%@`6"CC)`YKSF\UBXU[X-_M%W=UI5_HEQ-+>;K*]>%YX<>';`#<89)(^0
M`PVN>&&<'('T!7AWC/\`Y)O^TE_UUNO_`%&]/KNJ5%.NYQ5DW>W:[V^1RTJ;
MA14).[2M?O9;_,_EZ^'O_(#CKHJYWX>_\@..NBK]ZP_\./H?D-;XV%%%%;&9
MYA^T)_R`;K_KF?Y5_7O\!/\`DA?@O_L`V/\`Z3QU_(1^T)_R`;K_`*YG^5?U
M[_`3_DA?@O\`[`-C_P"D\=?EO&W^\Q]'^A^@<+?P)?(ZRBBBOB3Z@****`"B
MBB@`HHHH`****`"BBB@#^>O1O^2C^,O^P]?_`/I3)705S^C?\E'\9?\`8>O_
M`/TIDKH*_I3*O]TI^B_(_#<=_O$_5CC_`*L?4_TIM./^K'U/]*;7HLY3RW]J
M'_D3+C_KD:_;#_@C?_RBW^!?_8IVO\C7XG_M0_\`(F7'_7(U^V'_``1O_P"4
M6_P+_P"Q3M?Y&OR+Q"_BP^9^B<%_PYGTM1117YN?<!1110`4444`%%%%`!11
M10`4444`?D_\#O\`D-^*/^PS>?\`I0]>F5YG\#O^0WXH_P"PS>?^E#UZ97[A
M@/\`=X>B/R?%_P`:7J8M_P#\E%TK_L&WG_HVTK:K#O/!DUYKJZA_;6K0RQJ\
M<:(EOLC1RC,HS$202B\DD\=>M;E>A.UE8Y8WN[GF?[4?_).[K_KDU?0G_!OO
M_P`H[[;_`+&G6O\`TK:OGO\`:C_Y)W=?]<FKZ$_X-]_^4=]M_P!C3K7_`*5M
M7Y_QI\,/7]#[+AC>7H?;E%%%?GY]@%%%%`!1110`5R_P@_Y%.[_[#>K?^G*Y
MKJ*Y?X0?\BG=_P#8;U;_`-.5S71'^!+UC^4C&7\5>C_-'44445SFP4444`%%
M%%`!1110!1\47&IVGAK4)=%L['4-8CMI&L;6]NWL[:YG"DQI+,D<K1(S8#.L
M4A4$D(Q&T_'/PS_9A_:`\!^"?!^K-X=^#K>-O`WC3Q#KEOI0\;:E)I6K:?K,
ME[-*CWO]D++;7$$EU&%Q;3)(L+9\LR#R_M2BI:O?^NM_QV_*SU'NK/\`K1K\
M+W7F>=_LH?!R^^`'[//A?PGJM]::EJ^FV[R:C<VD;1VTMW-*\\_DJQ+"(2R.
M$#$MM"Y).346C1:[X-^/6D:/=>+=<\0Z9K.AZG?/!J-O8H+>6WN-/2,QM;V\
M38VW,@(8MGY>XR?2:X/Q#_R<]X/_`.Q7US_TKT>M)2N[DQ5E8[RBBBI&%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`5R_Q`_P"1L\#_`/8;D_\`3;?5U%<O\0/^1L\#_P#8;D_]-M]7
M1AOC?I+_`-)9C7^'YK\T=14.I6SWNG7$,<K0231LBRK]Z,D$!ATZ=>M345RS
MBI1<9;,WC)IW1^0?[+G_``;1_&3]BSQ+<ZY\-/VO?#&@^(KF\N;TZ]=?`+0]
M6UQ7N!MF`U&\N9;H(XR"@E"'<QVY9L_IW^RW\.O'GPH^!VBZ#\3/B-_PMGQI
M8F?^T/%/]@6^@_VENF=X_P#0[=FBB\N-DC^4_-Y>X\L:]!HK13:AR=%9+R2V
M2[+R6A,HJ4G-[MMOI=O=NVX4445(PKP[QG_R3?\`:2_ZZW7_`*C>GU[C7AWC
M/_DF_P"TE_UUNO\`U&]/JJ?Q(F6S/Y>OA[_R`XZZ*N=^'O\`R`XZZ*OZ`P_\
M./H?CM;XV%%%%;&9YA^T)_R`;K_KF?Y5_7O\!/\`DA?@O_L`V/\`Z3QU_(1^
MT)_R`;K_`*YG^5?U[_`3_DA?@O\`[`-C_P"D\=?EO&W^\Q]'^A^@<+?P)?(Z
MRBBBOB3Z@****`"BBB@`HHHH`****`"BBB@#^>O1O^2C^,O^P]?_`/I3)705
MS^C?\E'\9?\`8>O_`/TIDKH*_I3*O]TI^B_(_#<=_O$_5CC_`*L?4_TIM..-
MGWAZTVO1D<J/+?VH?^1,N/\`KD:_;#_@C?\`\HM_@7_V*=K_`"-?B?\`M0_\
MB9<?]<C7[8?\$;_^46_P+_[%.U_D:_(O$+^+#YGZ)P7_``YGTM1117YN?<!1
M7#7'QIN+3XJ6?A23P7XJ6;4$GG@OO-T\VDEO!)#'+/\`\?7FA%:XA^4QAR'X
M0X..YK:I1G32<NJNM4]/D9TZL9WY>FCT:_,****Q-`HHHH`****`"BBB@#\G
M_@=_R&_%'_89O/\`TH>O3*\S^!W_`"&_%'_89O/_`$H>O3*_<,!_N\/1'Y/B
M_P"-+U"BBBNPYSS/]J/_`))W=?\`7)J^A/\`@WW_`.4=]M_V-.M?^E;5\]_M
M1_\`).[K_KDU?0G_``;[_P#*.^V_[&G6O_2MJ^#XT^&'K^A]APQO+T/MRBBB
MOS\^P"BBB@`HHHH`*Y?X0?\`(IW?_8;U;_TY7-=17+_"#_D4[O\`[#>K?^G*
MYKHC_`EZQ_*1C+^*O1_FCJ****YS8****`"BBB@`HHHH`***^+/^"UTVCW/P
MH^'.GZW=?"73;2X\5&9;KXM6ZS_#Y62PNAY>JHSHKLRNS6R%TS<1HV[Y=K9U
MJG)'F\TOO:14(\SMY-_<KGVG7!^(?^3GO!__`&*^N?\`I7H]<?\`\$WY;*3]
M@_X3KIL.H0:?!X;M8+=;N8S,T<:;%>.0JF^W8+NA;8FZ%HSM7.T:FGZAXEOO
MVH_#?_"0:3H>EI'X8UK[*=/U:6^,P^UZ3NWA[:'R\?+@`OG)Z8&>BK#DFX=F
MT8TY\\%/NKGK%%%%9F@4444`%5=:U>'P_HUW?W/G?9[&%[B7RHFFDV(I8[40
M%F.`<*H))X`)JU10O,/0_.?X:_\`!<.3Q9^UO_9=]X?EA^&VK3)INGK#;M+J
MEK)N(6Y=4R9-Y(#1("57;MW,I\S]&*^9?C?_`,$L/AW\3_&.N>,=$_M#P?X[
MU#RKJPU339C'%IM_$YD6[6%<`N[;1)SA@,C:Y+G9_9+_`&K-7\4>*[[X6_%"
MUM]"^+/AN,-(J';:^);8#Y;ZT/`8$#+(.5.>!AE3Z#,J>#Q--5LOAR\J]Y=>
MGO>:Z-^C:6YXN!EB:$W2QLK\S]U]/3R?5+[F?0-%%%?/GM!1110`4444`%%%
M%`!1110`4444`%<7XW_:1^'?PRUYM*\2>/O!?A_5$19&L]2UNVM+A5;E6*2.
M&P>QQS7:5Q/C3]FCX<?$CQ#-JWB+X?\`@G7M6N`JRWNHZ%:W5Q(%`50TDB%C
MA0`,G@`"MJ'LN;]]>WE:_P")G6]IR_NK7\_^`<?X^_X*'?!/X=:)'?W7Q,\'
MW\<EQ';B+2M3AU&<%SC>8X&=@BC+,Q&`!W)`.T/VTO@Z1_R5CX:?^%/9?_':
MYWXG?\$X_@G\4]`AT^Z^'7A?2$ANHKH3Z+IT.F7#;&R8VDA56:-QE64]CD88
M*PZ)/V*_@Y&BJ/A/\-<*,#/AFR)_/RZ[Y?V;R*W/?6_P^5OU.-?7N9WY+:6W
M^9S7QB_:_N+?3?#\/PAT_P`&_%/6/$!OIHO,\6#3M)AM[*-'N6>\M[>\/F@R
MPHL:PG<9,LR*I->8_&S_`(*CZQ\/?"UQJ_A_X6W6MV=YHWAG6-!-UJ-UYVLI
MK%P8O^/;3;'4+I5AX'R02RR.L@$2HJ2R>S^/_P!AWX6_$3P39^'9?"R^'])L
M;R2_BB\*:A=^%Y/,DB\F4-+ILMO(\<D>%DC9C'(%3>K;5Q7N/V#_`(9W7QGM
M?'K:9XA77K&&QM[6!/%>K)I%I'9%6M4BTP7(L8UB9`RA8`-S.3DNY;R[+VNC
M]SF7KR_:717>EM=-==5;OU]E_?Y7Z<UU9]=$D_OV=KG*_&7]N76O@W+X62X^
M'<UXOBCPJ^L0S'56M$.J&6TAATU8Y[=+A5,EV@DFN(8&B5D_<NWF)$[PK^V=
MXLGUWPKH?B#X=:=I^N7OC.?P;XDDTSQ-]NTO0YEL/MT#P326L$]V9H7A.TVT
M*H1.&?*1B;KOCM^Q#\/?VE/'-CXB\7VWBN\U'3=.FTJW2R\8ZSI=G'!-GS/]
M%M;J*!I"2K>:8S(&BA8,#%&5S9/^"?'PQDT?PG9"W\<11^"]7EU_3YHO'VOQ
M75QJ$A&^YO9UO1+J$A`V!KQIL1ED&$9E+BU[3FDO=OMY<R>^GV;KUL[Z-LDO
MW?*OBL]=M>1I::Z<]I??T]T]LHHHJ1A7+_$#_D;/`_\`V&Y/_3;?5U%<O\0/
M^1L\#_\`8;D_]-M]71AOC?I+_P!)9C7^'YK\T=11117.;!1110`4444`%>'>
M,_\`DF_[27_76Z_]1O3Z]QKP[QG_`,DW_:2_ZZW7_J-Z?54_B1,MF?R]?#W_
M`)`<==%7._#W_D!QUT5?T!A_X<?0_':WQL****V,SS#]H3_D`W7_`%S/\J_K
MW^`G_)"_!?\`V`;'_P!)XZ_D(_:$_P"0#=?]<S_*OZ]_@)_R0OP7_P!@&Q_]
M)XZ_+>-O]YCZ/]#]`X6_@2^1UE%%%?$GU`4444`%%%%`!1110`4444`%%%%`
M'\]>C?\`)1_&7_8>O_\`TIDKH*Y_1O\`DH_C+_L/7_\`Z4R5T%?TIE7^Z4_1
M?D?AN._WB?JPHHHKT#E/+?VH?^1,N/\`KD:_;#_@C?\`\HM_@7_V*=K_`"-?
MB?\`M0_\B9<?]<C7[8?\$;_^46_P+_[%.U_D:_(_$+^+#YGZ)P7_``YGTM11
M17YN?<'AM]\<]/U;_@HCH'@--)\20WVF^"=;O6U&YT]K?3;G_2]#+1P2N0T[
M(LL19XU:(%RGF&2.5$]RKYC\<Z#\3[G_`(*H>`=<@\-^`V\"V'@O7M+6^D\5
M7:ZM)#-<Z)+-,;,:<8@\<T21K']J(D21I"\901/].5M)R="DY[VE_P"ESM^%
MORW3,XJ*JS4>Z_\`2(W_`!"BBBL30****`"BBB@`HHHH`_)_X'?\AOQ1_P!A
MF\_]*'KTRO,_@=_R&_%'_89O/_2AZ],K]PP'^[P]$?D^+_C2]0HHHKL.<\S_
M`&H_^2=W7_7)J^A/^#??_E'?;?\`8TZU_P"E;5\]_M1_\D[NO^N35]"?\&^_
M_*.^V_[&G6O_`$K:O@^-/AAZ_H?8<,;R]#[<HHHK\_/L#R_QU8>(+_\`:#T/
M2K/QMXBT?2=6T;4-1EM+2VTYTCDM9M/C4*TUK(^UA=2%@6)R%VE0"#ZA7!>(
MO^3G_!__`&*VN_\`I7H]=[7;BI7ITM%\/1)7]Z2ULM=$MSEP\;3J:O?NWT3T
MOMOT"BBBN(Z@KE_A!_R*=W_V&]6_].5S745R_P`(/^13N_\`L-ZM_P"G*YKH
MC_`EZQ_*1C+^*O1_FCJ****YS8****`"BBB@`HHHH`****`"N#\0_P#)SW@_
M_L5]<_\`2O1Z[RN#\0_\G/>#_P#L5]<_]*]'H`[RBBB@`HHHH`***;+*L,;.
M[*B("S,QP%`[F@!U>1_M:_LG:;^TYX4M)(;R;P[XU\.R?;/#GB*U^6ZTJY'(
MY'+1,0`R=QR,$`U0\/?\%`?AKXF^)*^&;?5+M9I9A;PWTEOMLIY"0`JOG/).
M`64+[XP:]KKGRO.*%:7ML#54G%V;BT[/L_7[FCHS+*:]!*EC:;CS*Z335UW7
M]71X+^R3^UAJ7Q`U_4/AQ\1]/B\-_%KPO$&O;1>+;6[<<+?6AZ-&W4J/ND_@
M/>J\>_:W_9*L_P!I'1-/U+3=0D\+_$'PNYNO#GB.V&)["8<^6^/OPOT9#D8)
M..H.5^R)^UK=?%6_U#P'X]L$\+_%OPJ@75M+;Y8M0C&`+VU/1X7X/&=NX=00
M3[E>A"M3>)PZM;XH_P`OFO[K_P#)7H^C?CT:TZ4U0KN]_AEW\G_>_/==4>[4
M445Y9Z`4444`%%%%`!1110`4444`%>'_`!Q;]I,_$*X_X5JOP/7PH(H_(/B9
MM4.H-)M'F%OLX\L+NR%`R<#).3@>X45G4AS*UVO0Z<+B?83Y^6,O*2NC\QO^
M"C#?MG!?!ZOMVDWI_P"+/C7,Y_T?_C^[^OE=O]=[5[I\%F_;1?X.>$V;_A0V
MYM&LR?\`A(QK@UG_`%"?\?N./M7_`#UQ_'NKZO\`&OCS1_ASHG]I:YJ%OIMB
M9XK?SIB=OF2.$0<>K$<]`,DX`)&M7%#!Q56351WTTOMV^^S/?K<4>TPM/"_5
MJ?N-N_+O=OIT^\^)_P!MK0OC!K_[,'A__A-?$4GA_P`:V?B1YX;?X7Z'XVU6
MSUR'[)*L5K<-HEW9WUJ&D8DS33?9E9(RZL2`.1_:XC^(WQ>^/VN>!?#.K?&S
MPWJGBJP\)I-.ND>)O^$8\.2)>[[Z*#4-->PB=1!(IFDAOTED+.C2E81%']G?
M'SX\:;^SUX1T_6-4TOQ!JT&H:O9:.D>DV?VAH'N9EB6:5F94BA3=N9W89P%4
M/(\<;^1_M6?\%,M!_8UU#6T\;^`_&NGZ?IR02Z=JLFJ>';33]>22YM;5WAFN
M=4B%ND4MY"KM??95/.POCGMI1C"4%)W]Y.SZM):>?-I?O9*-K3YOGL14E54Y
M)*-XM:?9N[W2Z)6_%W;7*EY?^VYKOC+X5>/O`_A_0]6^.&J7:^`[G2]4;PMX
M=U^^TE%$MKYMTMS%%<@:C);PWGE?:;N:XC9(MA$DY>?!\,ZY-I'B?X9VUK9_
MM.6NCW/CFXG\+:MJ<?CJ^:QT*-K(RPZQ;D2/+)<W9N(H3K:JL%JTLP=%BBCE
M^D/'W[??A7X<IX?:]T/Q==)XD\*MXJLIK"VM[NUE7=`D5E'<1SF">ZF>XC5!
M;R2Q#AGE1)(FDYJX_P""F^@Z3XN\#^'=6\`^-]#\2>--?F\-2:-?:KX<34=%
MO(C;EA);KJIDNU$%U!<,VFK>>7"^Z3805'13YEB?>UG?;;[=[^34M+[6FTU:
MHCFERN@E'X;:=?L/\.7WK;OE3^RSZ7HHHK,H*Y?X@?\`(V>!_P#L-R?^FV^K
MJ*Y?X@?\C9X'_P"PW)_Z;;ZNC#?&_27_`*2S&O\`#\U^:.HHHHKG-@HHHH`^
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M[/0_9_\`&FN^+_V:?!/B+Q!:/-XFU3PS8ZCJ5M;HD327<EK')+&@9@BDR%@`
M6"CC)`YKSF\UBXU[X-_M%W=UI5_HEQ-+>;K*]>%YX<>';`#<89)(^0`PVN>&
M&<'('T!7AWC/_DF_[27_`%UNO_4;T^NRI44Z[G%63=[=KO;Y''2IN%%0D[M*
MU^]EO\S^7KX>_P#(#CKHJYWX>_\`(#CKHJ_>L/\`PX^A^0UOC84445L9GF'[
M0G_(!NO^N9_E7]>_P$_Y(7X+_P"P#8_^D\=?R$?M"?\`(!NO^N9_E7]>_P`!
M/^2%^"_^P#8_^D\=?EO&W^\Q]'^A^@<+?P)?(ZRBBBOB3Z@****`"BBB@`HH
MHH`****`"BBB@#^>O1O^2C^,O^P]?_\`I3)705S^C?\`)1_&7_8>O_\`TIDK
MH*_I3*O]TI^B_(_#<=_O$_5A1117H'*>6_M0_P#(F7'_`%R-?MA_P1O_`.46
M_P`"_P#L4[7^1K\3_P!J'_D3+C_KD:_;#_@C?_RBW^!?_8IVO\C7Y'XA?Q8?
M,_1."_X<QTO_``5;^$HO;N&&;Q%=?8[B6UD>'3"R[XW*,!E@>H/4"C_AZS\*
M_P"[XH_\%9_^*K\R?@MX_N/`GQ+\92)#!>6TNMWHEMYUW(W^D2<CT8>M>M?\
M-%P_]"[IO_?`KZ3">'N6U:$*OOZI/XE_\B>#BN-,PI5I4THV3[/_`#/K'5_^
M"EWPUO/C?X=UQ!XD^PZ=H>J6,N=-._S)[C3GCP-W(Q;29/;Y?6NK_P"'K/PK
M_N^*/_!6?_BJ^%+CX\PR^)[.\_L'3P(+6>'R]HVMO>$Y/N-F/^!&K_\`PT7#
M_P!"[IO_`'P*[)^'>7248OG]U6^)=V_Y?,Y8\;9A%MI1UUV?9+OY'VS/_P`%
M7_A1;0O)(WB:..-2S,VF850.22=W2O;?@E\9-#_:$^$^@^-?#,\EUX?\26HO
M+":2/RVEB)(#8[9QGZ5^)7[<_P`=KSQ1\)KS2[.SM-*M9HR;@P)B2<?W2W]W
MV'7O7ZE_\$>/^47WP/\`^Q5M?Y&OS_C+A_"96Z<<-S7=[W:?W62/M.%\YQ68
M*<L1;3:R:_5GTI1117PY]8%%%%`!1110!^3_`,#O^0WXH_[#-Y_Z4/7IE>9_
M`[_D-^*/^PS>?^E#UZ97[A@/]WAZ(_)\7_&EZA11178<YYG^U'_R3NZ_ZY-7
MT)_P;[_\H[[;_L:=:_\`2MJ^>_VH_P#DG=U_UR:OH3_@WW_Y1WVW_8TZU_Z5
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M9K;;J]=[I=#BP^TXO?F7Y)O7KLE:UK2>S5CL:***X3K"N7^$'_(IW?\`V&]6
M_P#3E<UU%<O\(/\`D4[O_L-ZM_Z<KFNB/\"7K'\I&,OXJ]'^:.HHHHKG-@HH
MHH`****`"BBB@`KYQ_X**_&OQU\.-*^'?AGX>V/C*YUSXA>(WTV>X\)1Z+)K
MEE:6]C<WLK6@UF6/3Q(QMT0M<;P(WD*HS["/HZN'^._[.GA/]I'P[I^F^*K7
M5)%TF]&HZ?>:5K5[HNI:;<"-XC);WEE-#<PLT<LL;>7(NY)'1LJQ!F<6UIW3
M[;._]+KL5&5ON?2_3^M>F]GL5?V4/B7;_&#]G'P?XBMK_P`3:FNH:<GFW'B.
MVM+?5VF0F.9;N.T1+99UD1U?[.HBW*=F5P3DZ?\`$_PU\1?VH_#<?A_Q#H>N
MOI_AC6ENET^_BNC;%KO2=H<(QVYVMC.,[3Z&N\^&OPWT/X/_``_T?PMX:T^'
M2=!T"TCL;"TB+,L$2#"C<Q+,>Y9B68DDDDDUS_B'_DY[P?\`]BOKG_I7H]:5
M))R;7^7X:V^\SIIJ*3.\HHHJ2@HHHH`*R_''A>/QQX*UC19)I+>/6+*:R>6/
M[T0EC9"P]QNS6I14U(1G%PEL]&53G*$E..ZU/SET;_@F/\2KOQ\-,NH=/T_1
MTEPVM+=1RQ;!_$D082EL=`RKSU('-?57]K_'KX=_\?&D^#/B'9Q][*X;2[YQ
M[B3,7X+7N%%?)97P7A,N4OJ52I!R>ZDNFRLXN+2N[7BWKN?69EQEB\P<?KM.
MG-16B<7\W=-23=E>S2TV/$8_VX=)\,.L?CCPKXR\"R9VM/?Z:\UEG_9FBW;A
M[[17/_'WX<^#/VTM,TO7O`'CC2=*^)OA1C<^'=<L;E#<6S]3!/']]H'Y#*RG
M&XG!!96^C)$65&5E5E88((R"*\Z\>?LC?#?XD.TFI^$=)6X;G[1:1FSFW=F+
MQ%22/?->UAY9Q@YJI0J0J6_F3B_1N/-%I]5R6/'K+*,5!PK4YT[_`,K4E\HR
MY6K?XSEOV0_VM9/C4^I^#_&.GQ^%_BMX1/DZ[HK'"S`8`N[8G_6029!!!.W<
M!D@JS>X5\K_$W_@FQN\2:?XL\%^-?$5CXN\-H7T:35+C[4L)&2(!+@.L+$D%
M&$BX=LHP)!Q/V?/VXOBSXU\0>(/#>K>!='U3Q1X/F\G5M%CO5TW5H4P,7`1R
MT<T39&&BX(*]-RD].(S*;O6EA9PBOBY;5(KTY6Y\OFX*VUWN84<LAI2IXF$V
M]N:].3]>9*%_2;OOH?8=%>)VO[=7A?1KE+;QAH_BSP'=,=G_`!.-*D6!F_V9
M8]P(]S@5Z;X)^*OAGXD6_F^']?T?6%QDBTNTE9?]Y0<K]"!6>%S;!XF7)1J)
MR[7M+YQ>J^:'BLIQF'CSUJ;4>]KQ^4EH_DS?HHHKT#SPHHHH`****`"O,?B=
M^QQ\./C)XNFUWQ)X=;4M5G1(WF.HW4650;5`5)548'H!Z]:].KQ#XW_'?XS>
M!?B#<:;X+^`K>/-!BBC:/6#XUL-*$[LH+J()59P%)VY.,D'`Q@F)X&EBU[*K
M&,EO:7+;_P`FTO\`B'LU/1V^?_!.7^)7_!+/X=^+?L?]@_;?"?V??YWV>:6[
M^U9V[<^<[;=N#]W&=QST%;OA[_@FM\(]+T*SMKWPY)JEY!"J37<FI7<37+@8
M+E4E"J2><*`!7E7Q2_;8_:4\)ZGIGE?LXKI\UQ;WSBR_X3.QU1KL1P&3S1'`
M@E41,$)P=K^9Y?\`K)(B-_P9^UI^T=J?@_2;F/\`9G36H[BSAE74$^)6DJM^
M&0$3`+'M`?.["\<\<5A_J;@8R]K[&EKYPM\DW9;=/\P^IQWLOO1Z)\3/V&=`
M\7?`G_A7WA;Q-XP^&.CMJ\&L2W'AV6SNKJ:2%UD6,G4[>\01^9'$Y"HI)B`W
M;6=6HR_L%VVH_'S4/'NI?$KXBZM)J-WI5[)H]U%HOV&.33FC>V5)4T];Q8@Z
MS2>2+GR@]W<NJ*TA(\N_:<\>>.OB'\-?"EY\2?`?Q@^'NBF]U*#4-(^'&LZG
MJNL3W0ME.FR-<:`!=);,YN`V2D0D2+SCM*Y\,_:2TS]JCXT?%_P%X1N/#OQB
M\'1:II%CHNI^)]*U/_BEXI$N-%FN+ZX31]9M=061I?[1A8AK=O**!/W0N9*W
MPU%4JL:%&*BXRBE:W*NJL_A]UI72VO&2OK9UHJ--QE\/+*Z79;JRW35TGU::
MT/LS]IW]AZW_`&H_B#H^N7_Q'^(7AJWT33I["WTG14T@69DE=)/M1:YL)[CS
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ME=<UU>[/T0HHHJ2@KE_B!_R-G@?_`+#<G_IMOJZBN7^('_(V>!_^PW)_Z;;Z
MNC#?&_27_I+,:_P_-?FCJ****YS8****`"BBB@`KP[QG_P`DW_:2_P"NMU_Z
MC>GU[C7AWC/_`))O^TE_UUNO_4;T^JI_$B9;,_EZ^'O_`"`XZZ*N=^'O_(#C
MKHJ_H##_`,./H?CM;XV%%%%;&9YA^T)_R`;K_KF?Y5_7O\!/^2%^"_\`L`V/
M_I/'7\A'[0G_`"`;K_KF?Y5_7O\``3_DA?@O_L`V/_I/'7Y;QM_O,?1_H?H'
M"W\"7R.LHHHKXD^H"BBB@`HHHH`****`"BBB@`HHHH`_GKT;_DH_C+_L/7__
M`*4R5T%<_HW_`"4?QE_V'K__`-*9*Z"OZ4RK_=*?HOR/PW'?[Q/U84445Z!R
MGEO[4/\`R)EQ_P!<C7[8?\$;_P#E%O\``O\`[%.U_D:_$_\`:A_Y$RX_ZY&O
MVP_X(W_\HM_@7_V*=K_(U^1^(7\6'S/T3@O^',_*OPG_`,CWXP_[#E[_`.E$
ME=57*^$_^1[\8?\`8<O?_2B2NJK]DRG_`'.GZ+\C\US+_>9^K(G_`./V/_<;
M^:U+4+%C>*WEOM4%<Y'<CW]JFKT#A/)?VL?^1&NO^N1_K7[#?\$>/^47WP/_
M`.Q5M?Y&OQY_:Q_Y$:Z_ZY'^M?L-_P`$>/\`E%]\#_\`L5;7^1K\8\3OXM+Y
MGZAP)_#G\CZ4HHHK\J/T`****`"BBB@#\G_@=_R&_%'_`&&;S_TH>O3*\S^!
MW_(;\4?]AF\_]*'KTROW#`?[O#T1^3XO^-+U"BBBNPYSS/\`:C_Y)W=?]<FK
MZ$_X-]_^4=]M_P!C3K7_`*5M7SW^U'_R3NZ_ZY-7T)_P;[_\H[[;_L:=:_\`
M2MJ^#XT^&'K^A]APQO+T/0KK]N#Q%K'QI\8>$-#\/Z5<7'A6_:S*S22>9.BA
M3Y@P0/XN0.GZUK?\-&_$[_H3])_[ZE_QKY0U_4[C1OVW?BE=6LTEO<0Z](R2
M(VUE.Q*],'QR\3X_Y"<U=6#R'#U</3J*G%MI7NY;_)G#C<XQ=.O.$9NR;Z+_
M`".WUGX]_$27XZ>'+QO"NEK>0:#JL,40,NUXWN--+L><Y!2,#_>/M76?\-&_
M$[_H3])_[ZE_QKY]U+XR>(I/BIHMTVH2^=#I5_$C>BM-9%A^)1?RKH/^%Y>)
M_P#H)S5W5.':+C!>RAHN\N[?<X89UC$Y-5'J^R[+R/6-=_:I^(7AG1[G4-0\
M,:'9V-G&99YY9)52)!R23FND_8(_:V_X;5^!,OC5=.CTV$:S?:7%&C$^8MM*
M8O,YSC<03CL"*^+_`-KKXJ:_XF^%%Y9WFI7$EK(C,\0;"N0.,^M>P?\`!O[_
M`,H]+?\`[&G6?_2MJ^5XBRVEA:4>2"BV^EWT\V?29#CJ^(G+VTKJWE^A]M5R
M_P`(/^13N_\`L-ZM_P"G*YKJ*Y?X0?\`(IW?_8;U;_TY7-?,Q_@2]8_E(^BE
M_%7H_P`T=11117.;!1110`4444`%%%%`!117&?M`?'/2/V<OA1JGBW6H;Z]M
M]/V1P6%@L;7NJ7,CB.&UMUD=$::61E10SJN6RS*H+"9U(PCS2V*C%R?+'<[.
MN#\0_P#)SW@__L5]<_\`2O1ZZ3X>>-K7XE>`-#\1V,=Q#8^(-/M]2MTG4+*D
M<T:R*'"D@,`PR`2,]SUKF_$/_)SW@_\`[%?7/_2O1ZTJ0E"3A)6:T9G"<9Q4
MXZIZH[RBBBI*"BBB@`HHHH`****`"BBB@`KPO]KS]DF?XPW&G^-O!.H+X6^+
M/A-2^BZPGRI=J,DV=T,?O('R1R#MW'J"RM[I16^'Q%2A452F]?P:ZIKJGU1E
M6HPJPY)[?UJNS1XQ^RE^U78_M,:'JF@Z_I/_``C?Q`\,D6OB7PU>#+6S]/-C
M!SYEN_56&>H!)RK-K^-OV,?AIXZN3<7'A6QL+[.Y;K3"UC,C?WLQ%03[D&N7
M_:Y_9-OOB9J^G_$+X?:@GAGXM>%8S_9NH=(-5A&2;&['1XGY`)^Z3Z9%;7[)
M'[6=A^TMX;O+2\LI/#?CSPRXM/$GAVZ^6XTVX'!90>6A8@E'&01P>:>993@\
M;2]NJ:E#K%I/E?S^R^CZ;/6S;R_-,7@ZGLE4<9=))M<R^77NNNZTT6;_`,,Q
M>-O`@W>"?BSXCAA3E;'Q##'JT+#^X'8!D7Z`F@?$GXV?#SC7?`?A_P`96J<-
M=>'-2-O*!_>,,XRS>RXY]J]PHKYS^PX4]<+5G3\E*Z_\!GS17R2/>_MN=33%
M4X5/6-G_`.!0Y9/YMGB^F_MV^";>]CL_$T'B/P-?N=H@U[2Y;<%N^'4,N/<D
M<5ZEX2\?:'X^LOM.AZQI>L6^,^99723J/KM)Q^-7M3TJUUJR>VO+:WN[>3AX
MIHQ(C?4'@UY?XM_8B^&OBF]^V1>'DT'4%.4N]%F?3Y(CZ@1D)GZJ:.7-:.SA
M57G>#^]<Z;^40YLJK;J=)^5IK[GR-??(]8HKP_\`X9X^)'@'YO!_Q8U.\MT^
M[8^*+1-05_0&<8D4?05R/QN_:G^+7[.?@62Z\4>#?"UPUQ(+.TUC3-1=K1)V
M#,-UNX\T@JKGJ!D8)Y`K+$<0+"TW5QU&=-15V[*2^^#=O^WE$VH9`\545/`U
MH5')V2NXO[II7_[=;/IZBOC?]B#]N[Q9\5/B];^$O%C6VI+K"3-:W45NL,EN
M\<;2%6"84H51NV<D<XKVWXM_L+?"OX[>-IO$7BOPNVK:Q<1I$\YU2\ARJ+M4
M!(Y548`[`9Y/4FNWA[.L%FU#ZS2<E&[3]U735M&N9+9WT;//XDR;,,HK?5I1
MC*=D_B:BT[ZIJ,GNK6:7^?=^//BGX=^%\5I)XAU:TT>&^E6""6Z8I')(SH@7
M=]T,2Z\$]`S=%8C8TK4X=:TNVO+=F:WNXEFB9D9"RL`02K`$<'H0"*^8?B1_
MP2*^$_BRULXM"T^;PKY,RR7$T%U=74MP@="8QYTS(H*"09VDAF1LX4J^]I7_
M``2O^"-OI=M'>>#([J\CB59YH]5U&))7`&Y@GVEMH)R0NXXSC)ZU]+*E@>1-
M5)7Z^ZO_`)+]6?(QQ&<NK*,J%/ETL_:2^>OLV_\`R5>K/7/B_P#''PK\!M#T
M[4?%FK1Z3:ZOJEMHUE^YDGDNKNX<)%$D<:L[$G+,0,(B.[%41F'G/Q4_X**_
M#'X+>/;[PSXB_P"%D6NL6154CM_AIXDO(=1)E@A"V<T%@\5ZWF7,"D6SR$;^
M<`,13^+7[$TL?[.#?#WX/ZQX?^',,VMVNL3SZUH]YXE@;R)HY]B1?;[9T9I(
M(<MYI4*)`$W/O5WQV_8/T?\`:=U6ZF^($VA>*K&\GT4/I6HZ"EUIIL["X%U-
M;&":1U87-Q\SLV<+'`I#^2&/FRM[1*/P\R3;T?*[7=DWMK=;OHG;7W*;E[&]
M16GRMV3NN97TNU%ZZ6=O6U[KK/&O[9GPW^'&I6UCKWB&32=0NO#DOBP6=SIE
MVEU!IT90&2:+RM\,C,X1()`LTCK(J(S1N%R-"_;[^&_B:^\,6=@WCVZO_%EW
M/96MDGP^\0?:["2&6**7^T(?L7F::BM/"=]ZL"%)%<,4.ZN2_:F_8?\`%7QO
M\6>$1X1\9^"?`O@_P;HTFGV.C/X*FOI89_,@E@>.6+4+>*.")[.SQ`(#E$E7
M>/,4Q<WXF_X)IZQ\1=9\/:OXJ\1?"K7O$D/B63Q1K.OR?#9O[6M;DFS5/[!N
M'U%VT?$-C`C,_P!K9RNXD?=JJ?*ZOO:0_'?YK;7U6VOND[JE=:R_#;SM]K\/
M2[^N****DH*Y?X@?\C9X'_[#<G_IMOJZBN7^('_(V>!_^PW)_P"FV^KHPWQO
MTE_Z2S&O\/S7YHZBBBBN<V"BBB@`HHHH`*\.\9_\DW_:2_ZZW7_J-Z?7N->'
M>,_^2;_M)?\`76Z_]1O3ZJG\2)ELS^7KX>_\@..NBKG?A[_R`XZZ*OZ`P_\`
M#CZ'X[6^-A1116QF>8?M"?\`(!NO^N9_E7]>_P`!/^2%^"_^P#8_^D\=?R$?
MM"?\@&Z_ZYG^5?U[_`3_`)(7X+_[`-C_`.D\=?EO&W^\Q]'^A^@<+?P)?(ZR
MBBBOB3Z@\/\`A)^W=H/Q>^,T7A.U\)^.-)T_53J:>'_$^HVUHFB^*)-.G6"[
M2T,=P]RK*Q9D^T00B9(I)(C(B[J]PKY7_9U_9)^)'@+XM^$X/$S^!X_`?PMN
MO$%SX<O=+U&ZN-7UW^TIW,(N[>2WCBM/(@ED5_+FN/.DV./)4&-OJBB/P1?E
M\]WNNC\@?QR7G\OD^J\_^&11110`4444`%%%%`!1110!_/7HW_)1_&7_`&'K
M_P#]*9*Z"N?T;_DH_C+_`+#U_P#^E,E=!7]*95_NE/T7Y'X;CO\`>)^K"BBB
MO0.4\M_:A_Y$RX_ZY&OVP_X(W_\`*+?X%_\`8IVO\C7XG_M0_P#(F7'_`%R-
M?MA_P1O_`.46_P`"_P#L4[7^1K\C\0OXL/F?HG!?\.9^5?A/_D>_&'_8<O?_
M`$HDKJJY7PG_`,CWXP_[#E[_`.E$E=57[)E/^YT_1'YKF7^\S]6%%%%>@<)Y
M+^UC_P`B-=?]<C_6OV&_X(\?\HOO@?\`]BK:_P`C7X\_M8?\B-=?]<C_`%K]
MAO\`@CQ_RB^^!_\`V*MK_(U^,>)W\6E\S]0X$_AS^1]*4445^5'Z`%%%%`!1
M110!^3_P._Y#?BC_`+#-Y_Z4/7IE>9_`[_D-^*/^PS>?^E#UZ9NK]PP'^[P]
M$?D^+_C2]0HHW4;J[#G/,_VH_P#DG=U_UR:OH3_@WW_Y1WVW_8TZU_Z5M7SW
M^U$<_#NZ_P"N35]"?\&^_P#RCOMO^QIUK_TK:O@^-/AAZ_H?8<,;R]#R'QE_
MR>?\6/\`L.2?^@)73#I7,^,O^3S_`(L?]AR3_P!`2ND#C'45]3D_^YTO\*_(
M^=S+_>9^K,>__P"2BZ5_V#;S_P!&VE;58=^X_P"%BZ7R/^0;>?\`HVUK;WCU
M%>M)Z1]/U9Y\=W_71'G'[3?_`"3NZ_ZYM_*OH+_@W]_Y1Z6__8TZS_Z5M7S[
M^TV<_#NZ_P"N;?RKZ"_X-_?^4>EO_P!C3K/_`*5M7P'&GP0]?T/L.%_BEZ'V
MU7+_``@_Y%.[_P"PWJW_`*<KFNHKE_A!_P`BG=_]AO5O_3E<U\/'^!+UC^4C
MZR7\5>C_`#1U%%%%<YL%%%%`!1110`4444`%>-_M??LF7G[4.GZ#)IOQ$\;?
M#_5/"S7EQ82:$FF20W,]Q:O;9G2_LKM"%CDE5615=1-)@Y(Q[)16=:E&I!PE
MLS2G4E3DIQW1PG[,'PLU3X'_`+.W@GP?KFO7?B;5O#>C6VGW6I7"P*]S)'&%
M./)AA38N-JD1*2JJ6RVYCA:?X3U#PQ^U'X;:^\3ZYXB6Z\,:T8UU"*SC%IB[
MTG(3[/!$3G(SO+?=&,<Y]8K@_$/_`"<]X/\`^Q7US_TKT>NBM5E5J2J2W;;?
MS.>C3C3@J<=DDE\CO****S-`HHHH`***AU*PM]5TZXM;J..:UN(VBFC<95T8
M$,#[$$B@'MH345\9>(OVA=!^'O[1UUIOC#Q'X@'PYOM%L8[+4WLI98=1C2YO
M/+CGN$9F:%F:11)L!N$A7<S)N>;ZV\%>/]#^).B1ZEX?UC3=:T^3[MQ8W*3Q
MY]"5)P?8\BNS$X*=%*3O9];.WIZ]T>7E^;4<5*4(M*46U:Z;T>]NSZ/K^>O1
M117&>H%%%%`!7@/[6O[*.J>-?$FG_$SX9WEOX?\`BUX9C*VT[@+;>(+;^*QN
MQQN5@,*Q^Z<<CAE]^HKHPV(G0G[2G_P&NJ:ZI]3&O0A5AR3_`."GW7FCR?\`
M9+_:OTO]J#P?=,UI-X?\7^'Y?L7B+P]='%UI%R,@@@X+1L02KXP0".""!ZQ7
MSW^UE^RKK&M>+K/XK?"N:WT;XL>'X]I5SLM/%%J/O65T,@'(`".2,$*"1A63
MLOV4_P!JC1_VI/!%Q>6UK<:)XCT6;[#K^@W@VWFC78R&C=2`2I(.U\`,`>`P
M91U8K#0E#ZSAOAZKK%]O-/H_D]=^?#UYQE["O\71])+_`#[KYK0]2HHHKS3N
M"L#XG?#+1OB_X+O-`UZU^V:;>@;E#%71@<JZL.58'D'\#D$@[]%9U:4*L'3J
M).+5FGJFGT9I2JSIS52FVI)W36Z:ZH\A_9__`&)O!?[.?B"?5M'&J:AJDT9A
M2ZU*9)7MT.-P0(B*,XY."V,C."0=+XF_%+XC>%_%LUGX;^%;>*=+C1"FH'Q)
M:V/FL1E@(G!8;3QD]<>E>F45Y\,II4<.L-@6Z*3O[BC_`.W1DM?2^FYZ$\VJ
MUL0\3C4JS:M[[E_[;*+T];:['R_\;OVU/B=\&O#UK>ZM\(8=#BNKA84N9]>C
MU"(GJ4*P*"K,/NEB!GLV,5UVG?M`_&#5-/M[J'X$R>5<1K*GF>,+.)]K#(RC
M(&4\\A@".A`->Y45Q1R?'*K*4L=4Y7:RY:5UWN_9M/Y17FV=DLWP+I1C'!4^
M97N^:K9]K+VB:MYR?DD?+O[9/[6.O?`W]ES3_&7BSQ!X:^`=Y'XMTNQF_MK5
M-/O%U.U>ZB\VWAGE984:2+S68E'=8H9BH0[9H_G7]J_]JKXQ#]K'Q)X-^&/Q
MJ\.ZQ<>)-2TFQT'1?#_C#099O"4,TFG;WU&WD\.7EQ8><KS^7<RSWJ.+A`MN
MI*-'^EE%>WAZ4J?+[23E9J][)M73=[)*[M;1)*[TU=_%Q%55.;V<5&Z=K7:6
M]K7;>E^K;??:WPW^VY^VAKW[+'C[P/X7U#XR>#?#GB#5O`=S)?:->3Z=-?Q7
M22VJ3:T7DCA:=(8A>RQB.VMX6^RW+/&R@1P>3^-O^"@7CSP]KW@?3=!^,5GX
MJ\"2:]?_`-E>+Y=;T/3-6^*T,,^GHMCII31;G3]1G$ES=P""T2QDF\F(K<`K
M,]?IY1713E:M[66JUTZ;W\]ORT>B27/4C>E[..CTUZ[6\M_^#OJ%%%%24%<O
M\0/^1L\#_P#8;D_]-M]745R_Q`_Y&SP/_P!AN3_TVWU=&&^-^DO_`$EF-?X?
MFOS1U%%%%<YL%%%%`'Y%?\%5!;ZK^VY\5+35?W?Q:CLOAXWP(,GEMJ2S_P!M
M2'4I='5MT@<,/],,`S]GC3S`4`)7_@K-^T)\*/VD_BYK$GB#4K?6_`6B_##Q
MSX=\+&_M6@@'Q#L[NU@$%BERJ[]7C'RVKPJ7;?+Y3,"U?KI16/LFX*FWUF]-
M-9QY;KSBFW?K/EEI:ST52U1U$M7R;ZZ0L[>C:2M_*Y+6]UPO[/\`)XDTS]FG
MP2_BF.^U#Q=;^&;$ZNC;5N;F^%K'YX.\HHD:4-]XJ,GG';R>X\3^)?&FA?'#
M1;#X<^+I+[Q%>R6B!KO256SEDT*PA592;W_=?,>\;77G<&5?I*N#^$'_`"4'
MXJ?]C1!_Z9=+KLK5N>K*K:UVW;HKNYRT:7LZ4:5[V25^KLK'X,Z+_P`&\W[5
MVA62PQ>&/"+!1U;Q#!_C5S_AP#^UG_T*_@W_`,*&#_&OZ%J*]O\`UHS#^?\`
M`\W^P<'_`"G\]/\`PX!_:S_Z%?P;_P"%#!_C1_PX!_:S_P"A7\&_^%#!_C7]
M"U%'^M&8?S_@']@X/^4_G)^(?_!N)^U=X[T.:W;PSX/AF9"J./$4&/QK]SOA
M5\8=:\+>'M*\&S?#7QO-KGAK0M/^VQQ7.D&,(RR0HZLU\`0SVTV!]X!<D#(S
M[17!^'O^3GO&'_8KZ'_Z5ZQ7F8[,J^+DI5W=H[L+@J6'35)6N'_"W_$'_1*_
M'G_@7HO_`,L*/^%O^(/^B5^//_`O1?\`Y85WE%<)U'!_\+?\0?\`1*_'G_@7
MHO\`\L*/^%O^(/\`HE?CS_P+T7_Y85WE%`'!_P#"W_$'_1*_'G_@7HO_`,L*
MS[?]H;4[OQ1>:+'\,O'C:E86L%[/#]HT<>7#.\R1-N^W[3N:WF&`21LY`R,^
MF5P?A[_DY[QA_P!BOH?_`*5ZQ0`?\+?\0?\`1*_'G_@7HO\`\L*/^%O^(/\`
MHE?CS_P+T7_Y85WE%`'!_P#"W_$'_1*_'G_@7HO_`,L*/^%O^(/^B5^//_`O
M1?\`Y85WE%`'!_\`"W_$'_1*_'G_`(%Z+_\`+"L^W_:&U.[\47FBQ_#+QXVI
M6%K!>SP_:-''EPSO,D3;OM^T[FMYA@$D;.0,C/IE<'X>_P"3GO&'_8KZ'_Z5
MZQ0!^2^N?\$G?VF(_%^N7ND^"]%6UU34KF]3[1KMH)`LDSNH(60@$!AG!/-0
M_P##JO\`:L_Z$[PW_P"#ZV_^+K]JJ*^DCQ7F44HJ>BTV/#EP[@6W)QU?F?BK
M_P`.J_VK/^A.\-_^#ZV_^+H_X=5_M6?]"=X;_P#!];?_`!=?M511_K9F7\_X
M"_U;P'\OXGX=^.O^".O[47CW0)K&Z\'>'%$BD*ZZ]:Y4_P#?=?HU_P`$_;CQ
M9^S%^RSX#^$.N_#OQ5?>+?A_X:L8M4.G7FE26I#M.B21R27B%E9H)1RH8;.0
M,C/U57!^'O\`DY[QA_V*^A_^E>L5YN89MB<;;ZP[V._!Y;0PM_8JUS\J]:_X
M)>?M+V_BG6KK1_!>CQVNIZC<7B_:-<L_,VR2LZ@@2$`@,,X)Y[U7_P"'9?[5
MO_0G^'?_``>6O_QROV8HKV(\99I&*BIZ+38\V7#.7MN3AJ_,_&?_`(=E_M6_
M]"?X=_\`!Y:__'*/^'9?[5O_`$)_AW_P>6O_`,<K]F**/]=,U_G_``#_`%7R
M_P#D_$_$_P`=?\$E/VH?'WA^;3[SP?X?"RJ0'77;7<I_[^5^A'["=UXK_90_
M9>^%OPC\2?#OQ5=>+/#_`(:,4IT^\TJ2UN!;-$DSQR/>(=H:XA'S*K'?P.#C
MZHK@_$/_`"<]X/\`^Q7US_TKT>O+S+.L5C^7ZR[\NVAZ&!RO#X._L%:X?\+?
M\0?]$K\>?^!>B_\`RPH_X6_X@_Z)7X\_\"]%_P#EA7>45Y)Z!P?_``M_Q!_T
M2OQY_P"!>B__`"PH_P"%O^(/^B5^//\`P+T7_P"6%=Y10!P?_"W_`!!_T2OQ
MY_X%Z+_\L*S[C]H;4[3Q19Z+)\,O'BZE?VL][!#]HT<^9#`\*2MN^W[1M:XA
M&"03OX!P<>F5P?B'_DY[P?\`]BOKG_I7H]`'Y[M^Q;^T7X?U+5#H?@.R6WU"
M_N+O=<ZW9"3;)*SJ,+,0,`C/)YIO_#)?[4W_`$(^C_\`@[L__CM?J-17N1XB
MQR2BI:+R/)_L7"MW<3\N?^&2_P!J;_H1]'_\'=G_`/':/^&2_P!J;_H1]'_\
M'=G_`/':_4:BG_K'COYOP#^Q<)_*?E3XH_8D_:;\7Z+-8WG@72&AG4J2-<L]
MR_3][7T#_P`$Q/!GC;]AK]G[3OA;XN^'_B*^\47FH:QKT']E7VF36\EJ;J,L
M=\EW'AE^TP@J0.7^7<`2/M6N#\0_\G/>#_\`L5]<_P#2O1ZXL9FF(Q45&L[V
M.K"X"CAVW21\)_&K]DSX_>)/CEXR\3>%/`<=M8^)M2>\C_M#5[!;A(RJ@*52
M=E!X.<,:YK_AC[]JC_H3])_\'%E_\>K]3:*ZJ>?XR$%",M$K+0YY9/AI2<FM
M7J?E<W[%_P"U#)=I=-X-TO[3"C11G^V++;L<J6S^^ZY1/UJ3_AC[]JC_`*$_
M2?\`P<67_P`>K]3:*TEQ)CFDN;;R)6281:\I^4OB']AW]I[Q1I$UE>>"])DA
MG4JW_$XL@1]/WU?3W_!)7X4^*?V1?@G9_"?QUH%UI7B*XN]8\0VUQ'<VUS9W
M%N;N'*AHY6<2+]IBR&0#DX8XKZ\K@_$/_)SW@_\`[%?7/_2O1ZX<9FF(Q45&
ML[V.K#8"C0;E31WE<O\`"#_D4[O_`+#>K?\`IRN:ZBN7^$'_`"*=W_V&]6_]
M.5S7/'^!+UC^4C:7\5>C_-'44445SFP4444`%%%%`!1110`445\R_P#!53XG
M_!'X8?L\64GQQTSP-XATS5-46P\/:)XON+>'1]4U9X9?)$[71^S1HB^8YFGR
ML04LN9`@.=:HX0YDKOHN[>B2\WLEU=D73CS.S_JW7T75]%J?35<'XA_Y.>\'
M_P#8KZY_Z5Z/67^Q-H^E^&_V0OAII>B^-K#XD:7H_ANQTZW\3V5XEY;ZX((5
MB-PDR,RNK%#@AF]R3DU7T_4/$M]^U'X;_P"$@TG0]+2/PQK7V4Z?JTM\9A]K
MTG=O#VT/EX^7`!?.3TP,]%:"A4E!.Z3:OM?Y&5.7-%2[GK%%%%9E!1110`5#
M?V$&JV,UK=0PW-K<QM%-#*@>.5&&&5E/!!!((/!!J:B@-]&9NH>#](U>&ZCN
MM+TVZCOK9;.Y66V1UN(%+%8G!'S("[D*>!O;CDUX_P"-O^"?G@;5M<DUKPJV
MK_#?Q$W(U#PQ=&R#'KAX1^Z9?4!1G)R:]RHK>CBJM)WIR:_KJNIQXG+\-B%:
MM!/MIJO1[I^:/G87W[0?P%&+FV\/_&;08?\`EK;[='UM5]2AS"^!V7+,1UYK
M=^'O[??P]\7ZTNBZU=:AX#\2#`?2?%%J=.F4GCAW_=MD\##9/I7ME8/Q"^%O
MAOXLZ*=.\3:'I>NV9SB*]MEF"$]U)&5;W7!K?ZS1J?QH:]XZ?AM]R1Q_4<50
M_P!UK-K^6?O+Y2TDO5N7H;D,RW$2R1LLD<@#*RG(8'H0:=7SO-^POJ'PLE:Z
M^$'Q`\0^!<$N-&O'_M717]A#*2T>>A8,Q`Z#BFC]IGXJ?!']W\3?AI-K&FP\
M/X@\%L;V'`_B>U?$J`=2Q..>!VH^IJ?^[S4O)Z/[GH_DV']JSHZ8VDX?WE[T
M?O2NO648H^BJ*X'X/?M1>`?CW"/^$5\4:;J5SC+69<PWD>.NZ&0+(,8/.W''
M6N^KDJ4YTY<LTT^ST/2H8BE6@JE&2E%]4[K[T%?.G[5W[+>NIXUB^+WPCDAT
MOXI:/$$N[-CML_%]HN-UI<C(!?:`$D.""%!(PC)]%T5KA<5.A/GAZ-/9KJFN
MJ88C#QK0Y9?)]4^Z\SS/]EK]J70?VJ/`3ZII<=QINL:;*;/6]$O!LO=%NER&
MAE4@'J#M;`#`'H0RCTROG#]J7]F7Q%H/Q`7XQ_!]H;+XB:="$U726^6S\8VB
M];>8#`\X`823KD*,C"LOI/[,/[3GAW]JCX<)KNAM+:WEJYM=6TFY&V\T:Z7A
MX)D."""#@X`8#/J!TXK#0</K.&^#JNL7V?EV?7U,,/B)*7L*_P`71])+NO/N
MNGH>C4445YQVA1110`4444`%%%%`!1110`4444`%<O\`$#_D;/`__8;D_P#3
M;?5U%<O\0/\`D;/`_P#V&Y/_`$VWU=&&^-^DO_268U_A^:_-'44445SFP444
M4`%%%%`!7!_"#_DH/Q4_[&B#_P!,NEUWE<'\(?\`DH/Q4_[&B#_TRZ70!WE?
M)O\`P6R\6>)O!W[`6JW'A'5=6T?7;SQ1X:TZ&?3=>NM"GE2XURQ@DA^VVO[^
MW25)&C:2(%@KL0&Z'ZRKGOBG\)/"GQR\$7GAGQMX8\/>,/#>H%#=:3KFG0ZA
M8W)1PZ;X9E9&VNJL,@X*@CD5,HWY?)Q?JDTVNNZ5MF73ERN[[/\`%6/RV^!7
MQD^)GPW^//A3X8>(/&7BV/5/#O[2RZ3J&G)XTU#Q+96VD7GA2XO[?2AJUV5N
M]1A1L2LMW&C)(0NS"(Q_6JO)[S]@GX%ZC\*+3P'<?!?X3S^!M/OFU.U\.R>$
M-/;2;:[8%6N$M3%Y2RD,P+A0Q#$9Y->D>$O".D^`/"VFZ'H.EZ?HNB:/;1V5
MAI]A;);6MC!&H2.**)`%2-5`554`````"M(NU/D>ZY=>]J<(.^[W@WN[\SOK
MOE+6?.NST]9SEI\II>7*M^FA7!^'O^3GO&'_`&*^A_\`I7K%=Y7-:7X,N+'X
MP:[XB:2$V>J:-IVG11@GS%>VGOY')&,;2+I`,$G*MD#C,E'2U^=?_!8WX[^/
M/!_[2W@7P_I,.I7O@7P[\/?%7Q&UW2;'XBZGX`E\0/IHM5$2ZGIT$D[-#%/+
M(MMOABD9U:60"-0?T4KB_C%^SA\._P!H>+2X_B!X#\%^.H]#N/M>FKXAT2VU
M,:?-Q^]A$Z-Y;\#YEP>!S42C+FC*+VONKK6+2=NO*VI):7<59IZK2G)1O=7V
MZVZIM7Z72<6];)MV>S_'OQ%_P4N^)'P-_:.^,GQ"T?Q!\0M4\,_%:['P_P#`
MWAS6;VYO[7PQXBN_#NAW^A;;<O(D#/)=7XFV##LJDDD9/WU_P1+NO$T?['^N
MZ3XL\9>*/'FJ^%?B%XH\/#6O$.IS:C?W4-GJD]O'OFF9G("H,#.`.!@5]'7_
M`.SWX!U34Y[VZ\#^#[B\NM:@\233RZ-;O++JD$:Q0W[,4R;J.-$1)C^\544!
M@`!6UX-\`Z#\.M/NK3P_HNDZ%:WMY/J-Q#IUG':QSW4\ADGG=4`#2R2,SNY^
M9F8DDDYK>$HQT2TY%#OLX23;>[YO:7?6,HI_"<\HMI)O7G<F]KW4XVLM$K<E
MELFI/J:U<'X>_P"3GO&'_8KZ'_Z5ZQ7>5S6E^#+BQ^,&N^(FDA-GJFC:=IT4
M8)\Q7MI[^1R1C&TBZ0#!)RK9`XSF:'2T444`%%%%`!7!^'O^3GO&'_8KZ'_Z
M5ZQ7>5P?A[_DYWQ?_P!BOH?_`*5ZQ0!WE>$?\%1/%^K?#_\`X)O_`!VUS0=4
MU'1-;T?P)K%Y8:A87+VUU93I9RLDL4J$,CJP!#*000"#7N]9WB[PAI/Q`\+:
MCH>O:7IVMZ)K%N]G?Z??VR7-K>P.I5XI8G!5T92058$$$@BL<53E4HSIQ=FT
MU?M=&V%J*G6A4DKI-.W>S/QKG^,/Q:_9[T/XC>$]:\9^,M%U34D^%?BC1[*T
M^).L>,(]-L[W7H[*];^U-0\J\BDO"K"2S\L0B,?*\@=P/VEKR?0OV"?@7X7^
M&>M>"M-^"_PGT[P;XDFBN-6T&U\(:?#IFJ2Q$&-Y[98A%*R%5*EU)4@8QBNX
M^%OPE\*_`WP-9^%_!/AGP_X/\-:;O-II.B:=#I]C:[W:1_+AA547<[,QP!EF
M)/)-=E2HI<WG)OY-))>7*DDK:/=*.QRTZ;BDO)+[EO\`-ZOKKJY.[?05P?A[
M_DY[QA_V*^A_^E>L5WE<UI?@RXL?C!KOB)I(39ZIHVG:=%&"?,5[:>_D<D8Q
MM(ND`P2<JV0.,XFATM?&/_!7[QY\0;?4_@%X!\"W$]K#\3/'C:=K)B\5WWA(
MW]O;:;>7JV)U:Q@GNK,326Z9:!!(XC,89%=V'V=7+_&#X'>"OVA?!S>'?'W@
M_P`+^./#[S)<-IGB#2H-3LVE3.QS#,K)N7)P<9&>*SJ1;2Y>C3^YI^:Z=5;O
MH5&5K^:DO1M-)_)N^C3[.Y^,]M_P5.UOX:_'[PK^T/'JGQ0TGX*^#?A[X8C\
M2^![[Q3?>(+6W@U&37[%[MGED<W<ZZA9Z?MO'4RRQ-N;&\@?8G_!"OQ+\3-4
M?XZ6'Q4\8>)O%?B6T\0Z/J$\>K:C/=1Z+/J&@V&H7%G:I*Q$%O%/<R(D2!54
M*.!7V%J?[+_PSUO2[ZQO/AWX%O+'4]-L]&O+>;0;62*[L;-B]I:2*8\/!`S,
MT<;`I&6)4`FNC\/?#_0?".MZSJ6DZ'I&EZEXBG2ZU:ZM+..&?4YDB6%))W4!
MI76)$0,Y)"HJC@`5T1DE*I)Z\W-;R3FI6ZWZW;;?G8SDKN+6FD;KNU%1OTMU
MVLFNES7K@_$/_)SW@_\`[%?7/_2O1Z[RN:U3P9<7WQ@T+Q$LD(L]+T;4=.EC
M)/F,]S/82(0,8V@6K@Y(.67`/.,RCI:***`"BBB@`K@_$/\`R<]X/_[%?7/_
M`$KT>N\K@_$/_)SOA#_L5]<_]*]'H`[RJ'BF9[?PQJ4D;-')':RLK*<,I"'!
M!J_39H5N(6CD59(Y`596&58'J"*QQ%-U*4H1=FTU]Z+IR49J3Z,_!OX,_'KX
MS_"?]E`>(_$'C[QY:S?%+]F;Q1K^C3Q_$[6?%-U>ZM8"";^V)EOBC:+.D<P2
M-++S8F+',BLB@_M_\$]0N-5^#/A&ZNIIKFZN=%LY9II7+R2NT"%F9CR22223
MR2:X[P#^P9\#?A3IWB"S\+_!CX3^&[/Q99-INN0:5X1T^SCUFU;.ZWN5CB43
M1')RDFY3D\5U'P5_9Y\`?LV>&+C1/ASX&\'^`=%N[EKV>P\.:-;:5:S3E50R
MM'`B*TA5$4L1DA%&<`5U<ZM)=[6\K3JRMZ6J):6^%))*ULYJ\E)=&[^=XTU]
M]X-ZW^)N][W["N#\0_\`)SW@_P#[%?7/_2O1Z[RN:U3P9<7WQ@T+Q$LD(L]+
MT;4=.EC)/F,]S/82(0,8V@6K@Y(.67`/.,QG2U\H_P#!9SXK>-?A5^Q)*/`.
MH3Z-KGBOQ5X?\*OJ<.H2:;)I]MJ&J6]K.ZWD<4SVA:.1HQ<)$[PF7>BEU45]
M75C_`!!^'?A_XM>#-0\-^*M"T?Q-X=U:+R+[2]6LH[VRO8\@[)89%9'7(!PP
M(R!4R3=GV:=NC2:;B]]))6>CT>SV*C*U_1J_9M636VJ>JU6VY^,?QF_;4\=>
M$?BK\/-9\+WGQ,\%V/[/3>,+SQMX67XCZOXOT_Q+'HNOZ-!J+/>7CK/J,(T^
M[O'B^TQ*\,B[`B^6,_1?_!(3]H7QU^T3^WE\4/%WB#Q?XKU3PG\2O!.G^./#
M/A^^OK@Z=H6G7&LZK:V'V>U<A(6DL+2TDD*HI=Y'))SFONS1/V5OA?X:T+3]
M+TWX;^`M/TS2-*NM"L;2V\/VD4%EIUTRM=6<2+&%2WF95,D2@(Y4%@<"MGPC
M\&_"'@#58[_0?"OAO1+Z'2[?0X[BPTR&VECT^W+&WLPR*"+>(NY2('8FYL`9
M-:T9<G)?7EY[ONYJ:;UO;7V;BKOEM))NYG57.IVTYG%KR47%I:6OI[12=O>O
M%M:'25P?B'_DY[P?_P!BOKG_`*5Z/7>5P?B'_DYWPA_V*^N?^E>CU!1WE<O\
M(/\`D4[O_L-ZM_Z<KFNHKE_A!_R*=W_V&]6_].5S71'^!+UC^4C&7\5>C_-'
M44445SFP4444`%%%%`!1110`4444`%<'XA_Y.>\'_P#8KZY_Z5Z/7>5P?B'_
M`).>\'_]BOKG_I7H]`'>4444`%%%%`!5?5-2AT;3+B\N/,$%K$TTA2-I&VJ"
M3A5!9C@=%!)Z`$U8JCXF\16GA#PYJ&K7\C16.EVTEW<NL;2,D<:EV(5068A0
M>`"3V!H]0,^^^)_A[3O#8U>36-/;3F@AN8YHIA+YT<S;860+DOYC?*@4$NW"
MY/%;U?CW??M:>-/"'[5VH?$[PQX?\/W&GWD\QL]!U$N8].1V8+(J1G"S$.SN
MT?\`%)-M!WN7^VT_:H_:6\+:?(VM?LSV^JF-L&?2/&]GAAP!B$J\AYR<YX!&
M1P36.7XBCC8.>&G&5FT_>CIVO=K7\'TNM6X6FKQ:^]'U317RKIG_``4D\3Z?
M(R^(_P!FWX[:?@$[M*T4:HN<X&2#'QC))YQQP<YJ*V_X+(_"6SNEB\0:=\0_
M!^2`QUCPW-&(\]R(C(>!\W`/'KTKN^J5G\,;^FOY7+]G+L?5]%?.^@?\%8/V
M>?$LJI;_`!,TJ-FZ?:K.[M!^)EB4#IWKT'1/VQ/A+XD2-K#XH?#VZ,BA@L?B
M&T+@8SROF9!QV(R*F>'JP^*+7JF2X26Z(OC'^Q_\._CK,;K7O#=F=4SN34[/
M-I?1MU#>='AF(/(#9'M7!#X&?&CX%_-X#^(4/CC1X>5T3QHADN%7T2]CPY;'
M`#@*,5[_`*/KMCXBL_M&GWEK?6^=OFV\JRIGTRI(JU6M/'58QY&^:/9ZKY7V
M^5CRJ^48:I-U8IPG_-%\K^=M_22:/GNP_;[MO`E['I_Q8\&>)?AG>NPC%[<0
MF_TB9NF$NH00?Q7`!&37M_@[QSHOQ#T2/4M!U;3=:T^;[EQ97"3QGVW*2,^W
M45?O]/M]5LI;:Z@AN;>=2DD4J!TD4]00>"/8UXCXQ_X)^>";W6I-:\'3ZS\,
M_$3\_;O#-VUG&YYP'@_U3)R<J%7(.,U=\+4W3@_+5?=NOO9ERYC0^%JM'S]V
M?WKW7]T?4]TKYI_:=_9K\2>`OB3_`,+H^#D,,?C>UCV>(-`)\NU\96B\E&`X
M%RH'R/U)`'.`#<_MG]H+X"_\?VGZ#\9=!A_Y>+$KI.M*HSRT1S"^!CY4RQ.>
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M7V?Z/JO.Z/0P^(ES>QK?&ONDNZ_5=/2S.[HHHKSSL"BBB@`HHHH`****`"BB
MB@`KE_B!_P`C9X'_`.PW)_Z;;ZNHKE_B!_R-G@?_`+#<G_IMOJZ,-\;])?\`
MI+,:_P`/S7YHZBBBBN<V"BBB@`HHHH`*X/X0?\E!^*G_`&-$'_IETNN\K@_A
M!_R4'XJ?]C1!_P"F72Z`.\HHHH`****`"BOSX_X+-_M*^,/V)?BQX'\?:-KN
MO1Z)XP\&^*?`L6DIJLMO8-XADM$O-&F6+/E?:GEMYX$D.'_>A5/)%?*/PS_;
M.^/7@7X'^,?#:>./$GB/XE_L8_#SQU_PEE[<:C-=C7]5^VK!H]W?0N\GVG98
MQW%R@F9OF3(!P36:J+E;>Z4I6\H<SEKMHE!Z_P#/R/F:>S?-!=).,;]G)I1N
MM[.7,D_[DC]M:*_(O]LKQ7XH_9)\(VMO\+OB]\3O$$/CS]GCQ;XL\23:MXWU
M'69[>:RL;633]=LWGFD:PDDN+J1,6AAA8$83,:8Q_P!GN7XU>/?!/Q6^'MA\
M1]6\%_$&YTGP%J6D^%=?^*^MZHOBBTG$EW=7&G^(;P_;;&?4HX[JU:*VA`MI
M+3*DA_-7:46I2@]XV77?GG!]+M)TY.R3E;7DTERY1DI4X55M*[6RTM!ZW=E?
MVB6K4?[VL;_L917Y)_$KQM_PNS]E?]GW7M/U3]H3X<ZX?C?8_"_Q3HUQ\7]:
MGN+6/^T+J/4=.-]97JKJ$:2AHX[YRUP8XU'F#;@>Z?\`!8N_U[X=1?LM^$?"
MLWQ;U+3M;^(`T.^TCPCXXNM'U[Q%:IHNH.D#ZC)?6SN?,BCD9Y[H%C'EF9C@
MYR=J?.M;S4%;6_,H--6NFFJD=KW=[.UFW]MP>EH.3Z6Y7--:VUO3EO:VE[.Z
M7WQ17XP_M9?M)_'GX"_#'X4^"?$'C3XI7'Q3_9\^'=M\0_&;^$-/U?6;;Q!J
M/]H1?9=)UFYL(9(_*?3K34EDDNV6&20B4N0NX]A^WE^T=XJ^,G[17Q(T_P`%
M_%#Q]X=\'^+O!7PKN=&N/#_B&ZL&T^/5_%,D$]U:F-P(II;9U5G4`NJJK9`Q
M6G+>I&G3][FFX*WES6?;WG"5E?9<VS0;*\]+14GOU<+].BG%OUMNF?K=17PS
M_P`$Y/VBO&GQ;_;7^('A?QIK&H2:YX!^'GAW2/$.D_:W-E;:Y#J.LP75Y%`6
M*Q_:XXK>X5L!WAEMR>,8^YJ<HI)2B[IW:?=7:37D[77DQ:J<J<MXVOY-Q4FO
M57L_-!1114#"N#\/?\G/>,/^Q7T/_P!*]8KO*X/P]_R<]XP_[%?0_P#TKUB@
M#O****`"BBORG_X*%?ML^*_V'_\`@JUK_P`4=0\5>-;CX0_#/PKX;B\4>%K:
M_N9=*-MJS:[;_;19JQC^T+>V^FCS0A;87&<&HE446E+KI\[.WWO3YW*C3E*,
MI1ULD[?-+];^>Q^K%%?BAX=^*/QRT/\`8%_:(M_$WQ%\>:G\0C\2?`09I/%V
MHZ8VE2:PNAW5YIEK=0L9["TWWLT&+=1LC)PA/!]Q_P""C?B;QI\+/@7\*_@+
MH.N_%?X>^.O&":YXFU2]\"^(_%GQ)U?2(+&VE^RC[?\`9VU22UEU&YTY7+PK
M&J"2+A2":J-TX\T^C2LM7K",W;ORQDWI=OEVU04XJI;D>CN[NZ5KM*_:[26M
MDK[Z,_3ZBOR5^&_[?/C3XR?M!^&?CQ8^*O$UKX#TKX3^&+KQIX6.IS1Z7IW]
MI76LV6HWIM2XB2XLKZVMF>8@,EO;W`]`/<O"MQ\3_C__`,$/?@R/"_C]K/XE
M^+-"\.3O>:SXIN=(OO%A!AN+S3TU1-US!=7=O'.BSQAI%+$Y7EUTJ4W!3;^S
M)1>[U<I1NK)MKW;W2;=[13::)I^\TN\5+[XQE9WLD];.[26C;2=S[XHK\@_#
MGQ8\:_M8?%?]G;P=X5T_XIZ4MO:>.]/\4^#O$GQUUW19+34=,O\`3H9HVU[2
M//N-32UDEFC@>;<9$8[G4C%=A^T5\:?B%\(_VM?'?[+-CXV\:1ZS\;_&7A;7
M?`&IOKUU-J.CZ%.2VOQ6]PTAF2*WCTF[(",-OVY<%2P-*G'G<$O^7FD=M?>L
MMNEKSNKQY8O44KQC*3^QK+?1+?I?1V5FE*[6A^IE%?DEX-U+XG+^Q7^V=\5K
MK7/&$<_AU_B-8>'/$@^,/B.YN[)[2\NH[>*+0W`T^S6!(P(KB&5I5V+A5W$C
MRJQ^.GQ4^%_PF\;:;J7CKX@>$?$=OJOPDN(-$;XBZUXH-W8ZCJD/VC5K?5+Y
MUN%CO?,FMI[)(TBC-KC,@D!,X?\`>N"6G,J3_P#!K=E\DKOKU2<4Y)XB]&,Y
M/7E=1/\`[A6O][DDNG1OF:B_W"HK\T_!/[*VI?%_]M/]L3X>Z+\5/CIH,GA7
M0]!7P7<'XK>);B+PY>ZAIUS+).(Y;UTD'GK&VV5750I50H.*]:_X(A_$CXD?
MM.?LW:Q\;_BAJ]Q)KGQ.U0QV>@PZC+<:9X=M--7^SMD$3'RTDGN+>YN9&C5=
MWGH#G8,%+WT^EHJ7KS.UEW:W>V@5/=?=-V_!2NUT35^^JMV/M*BBB@`K@_$/
M_)SW@_\`[%?7/_2O1Z[RN#\0_P#)SW@__L5]<_\`2O1Z`.\HHHH`***^>/\`
M@K9XUUGX<_\`!,;X\Z]X=U;5-!UW2/!&J7=AJ6FW4EK>6,R6[E)8I8R'C=3R
M&4@@]#45)<L'+LC2C3]I4C375I?>?0]%?AE\1?VROB]JWAOP[\'X/B'\2-,U
MS]F?Q=II\9:XNK7D%]XKMM2\2:;:Z#'=72MNN$ETJ\NGF5W8220H6!QQ]G_L
M^Q>+O&W_``52_:+U[7+[6[[P#\,_$EC%#<7'Q9\0:=;>'XSX=LYVBC\/PJ=-
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M7!^(?^3GO!__`&*^N?\`I7H]=Y7!^(?^3GO!_P#V*^N?^E>CT`=Y7+_"#_D4
M[O\`[#>K?^G*YKJ*Y?X0?\BG=_\`8;U;_P!.5S71'^!+UC^4C&7\5>C_`#1U
M%%%%<YL%%%%`!1110`4444`%>'_M;^(?%FK?$#X8>`/"GC'5/A^WCC4KXZAK
MVE65E=ZE;V]I923B*W6]@GME:27R@SR0R81750K.)$]PKA/CY^S;X1_:7T#3
M-/\`%EKJSKHM\-3TV\TC7+[0]1TZY\J2$R07EC-#<1%HII8VV2`,DC*P()%1
M43:LOSM^14?T?2_3^M=UNM48W[$GQ,USXN_LL^#]<\374.H>(I+:2SU*]B@6
MW2_N+::2VDN!$ORQ^:T)DV+PA?:,@"L/Q'^T;\/5_:/\+W1\>>#/LMGX=UFV
MGF_MNV\N&5[K2BD;-OPK,(Y"%/)$;8^Z<>K_``[^'NB_"7P'H_A?PWIMMH_A
M_P`/V<6GZ=96ZXCM8(E"(B]^%`&223U))J+4/!(O_B;I'B3[25;2=+OM-%OY
M>?-^TRV<F_=GC;]DQC!SYG48YVJ23DVN_9+\%HO1:(SBFHI,P?\`AJCX8?\`
M11_`?_A06G_QRC_AJCX8?]%'\!_^%!:?_'*[RBH*.#_X:H^&'_11_`?_`(4%
MI_\`'*/^&J/AA_T4?P'_`.%!:?\`QRN\HH`X/_AJCX8?]%'\!_\`A06G_P`<
MKEOCC^VMX%^'_P`%?&&O:%XX\`ZIKFB:)>W^GV1UNWE^V7$4#R11;$D#MN=5
M7:I!.<#FO9:YCXV_#?\`X7)\&/%WA`WG]G#Q5HMYHYN_*\[[+]H@>'S-F5W;
M=^=NX9QC(ZU-2_*^7<WPKIJM!U?ANK^E]?P/RA'_``<$?&:,[F\,_#%E7D@:
M=?`D?7[8?Y5^I/\`PU1\,/\`HH_@/_PH+3_XY7P&?^#<MF&&^,@VGKCPE_\`
M=M?IQ7FY;'%1YOK/E;5/O?;Y'V/&>(R*I['^Q;:<W-927\O+\27GL<'_`,-4
M?##_`**/X#_\*"T_^.4?\-4?##_HH_@/_P`*"T_^.5WE%>H?#GCOBWX@_L_^
M/I6DUW7/@[K3R9W-?WFFW);(`.2Y/8#\A7`^+/@[^Q_XU3;?6/P+CSU:SO+"
MR8\YY:%T)/'7.>W>OJ"BKC4G'X6T4I-;'Q+K'[#G[%FI`M;:CX+TFXSGS['Q
MW)&X&<X`-T5Q_P`!JGI?[(OP/\)QL/#7[4'CSPOQ@+IOQ-M8X^YY4@Y&3DC/
M/M7W-6#X1\$CPIX@\47PN3/_`,)-JB:D4\O;]GVV5K:[,Y.[/V;=GC[^,<9.
MWURO>[FWZN_YE>TGW/C.S^&.H>%;KS/#_P"W7Y*J0476;G3=8Q@<9\V<`\DY
MXYX]`:+OQY\:O#5T3I?[67P#\3Q*3M&LV]E8;QC`R+<MCN>#P0.HK[JHI?6I
MVLTO_`8_G:X>T?E]R/AC4OVTOCYX4*[M>_9,\4J`,_V9XMDM7/..?M$RC/<X
MXYX]*Y_XE?\`!0/5_&GA9;/XA?`KX9^*K,,5WVGQ-T6[*9SS''EI$(`^\&'.
M.1FOT'HJXXI1ES*"O_V\OR:,ZD85(N%2*:?1[?<?DGI/[=FB_!^5Y?`$?Q@^
M'<BD%-$4VOBC06SDE0LDR/&"",NNYO8$9/,6_P#P4/\`$7A+XR?\+"\&Z/I_
MA?Q7KV(/$5BUO<+HGB1BK%)7MGVLERIY)CE^?+'*_.9/V3KQG]N/]DF3]LCX
M6Z3X=BU^W\.2:5K,>KK<S::;]9-L$\)C\L31$9$Y.=W;&#GCKEG,U3DO9J3:
ML^[]>_E=[]5N>3_8>'4D\.W3MJDG>%[:>ZU*R[\B3MWV?R+^RY_P5@\>>/\`
M]I'P7X>\;:AX/TKP?K%WJ$E_J;0+9>3MM+F:*!I'E9%C#^2$R!(=H!=\G/W)
M_P`-4?##_HH_@/\`\*"T_P#CE?.O[,/_``2GOOV>?C_X=\<77Q`T[7%T%[I_
ML4/AEK)IS-;S0_ZPWD@7;YQ(^0G`(XSFOL:O#HSG)RE./*KNRT;2Z7:W]?P6
MR]6E"4,/2IU6I5%&TI*]I.[ULTK:65DNE[MMLX/_`(:H^&'_`$4?P'_X4%I_
M\<H_X:H^&'_11_`?_A06G_QRN\HK89P?_#5'PP_Z*/X#_P#"@M/_`(Y1_P`-
M4?##_HH_@/\`\*"T_P#CE=Y10!P?_#5'PP_Z*/X#_P#"@M/_`(Y7:Z9J=MK6
MFV]Y9W$%W9W<2S03PR"2.:-@"KJPX92"""."#4]8/PN\$CX:?#+P[X;6Y-XO
MA_2[;31<&/R_/\F)8]^W)VYVYQDXSU-`&]1110`5R_Q`_P"1L\#_`/8;D_\`
M3;?5U%<O\0/^1L\#_P#8;D_]-M]71AOC?I+_`-)9C7^'YK\T=11117.;!111
M0`4444`%<'\(/^2@_%3_`+&B#_TRZ77>5Q7PLTJZT_QS\2IKBVN((;[Q'#/;
M/)&56XC&D:;&70G[RAXW7(R-R,.H-`':T444`%%%%`'-_$OX-^$/C18:;:^,
M?"OAOQ9:Z/J$6K6$.LZ9#?QV-[%GRKF)9581S)N;;(N&7<<$9IOAOX*^#?!W
MC/Q)XDT?PEX9TKQ%XR,)\0:I9Z7!!>ZZ8D*1?:IE4//L1BJ^86V@D#`-=-11
MT:[_`*VO^2^Y=@NW_7;;[KO[SR_X??L0?!;X2^&O$NB^%?A#\+_#.C^,[<6G
MB"QTGPK8V5MKL(#J(KN..)5G3$D@VR!AB1QCYCG0\:_LG?"OXE6=Q;^(_AG\
M/_$%O=Z1!H$\6I>';2Z2;38)A/#9,)(R&MXYE61(C\BN`P`(S7H%%#UW_JUT
MOP;7S87=[_UT?YI?<NQQUE^SQ\/],\%>'/#5OX%\'6_ASP?=0WV@Z5'HMLME
MHEQ"2T,UK"$V021EF*M&%*EC@C-;'BCX<^'O'&JZ+?:UH.C:Q?>&KS^T-(N+
MVRCN)=*N?+>+S[=G4F*3RY'3>A#;789P2*V:*=W>_G?YZ:^NBU\D%E:WE;Y=
MO35Z>9@6_P`*?"]IK_B#5HO#>@1ZIXLBBM]<O$T^);C68XD:.)+E]NZ941F5
M1(6"JQ`P"17/:?\`LF_"O288([7X9_#^UCM;2PL(5B\.VB+%;6$WGV,*@1\1
MVTW[R%!\L3_,@4\UZ!12CH[KR_"]ONN[>K#?1_UM_DON1SN@_"+PGX5^(&N^
M+-+\+^'=-\5>*$@CUG6;7388=0U=8%V0+<3JHDF$:_*@=CM'`P*Z*BBCI8.M
MPHHHH`*X/P]_R<]XP_[%?0__`$KUBN\KBM"TJZA_:*\57S6UPME<>'-&@BN#
M&1%+)'<ZJSHK="RB2,D#D"1<]1D`[6BBB@`KD/&7[/O@+XBW&M3>(/!'A#79
MO$EI;V&KOJ.C6]TVJVUO(TMO#<%T/FQQ2.[HCY5&=B`"2:Z^B@#A_&/[,?PU
M^(FA>)-+\0?#WP/KNF>,KB&[\06FH:%:W4&NS0K&L,MTCH5G>-8H@K2!BHC0
M`C:,0_";]E+X6_`2[M[CP+\-?`/@N>SLY-/@DT'P]:::\%M)+Y\D"F&-2L;3
M?O&0?*7^8@GFN^HHC[NJ_K2WY:>@/569P>A_LM?#'PQINO6>F_#GP'I]GXJM
M);#6H+;0+2&/5[:62>66&Y58P)HWDN;EV1\JS7$I()=B;6M_L[?#_P`3?!M/
MASJ7@7P;J'P]CMH;-/#%SHMM+HRP0LK11"T9#"$1D0JNS"E%(`P*[*BCI;II
M^&WW7=O4?,[\W7?\O\E]R/)_&?[!/P+^(W@_P[X>\0_!?X3Z]H'@^%[?0=,U
M'PAI]U9Z)$Y!=+6)XBD"L54D1A0=HST%=E/\%/!MUXWT'Q-)X1\,R>)/"]I)
M8:+JS:7`U]I%M(H62&WFV[X8V4`,B$*0`"#73447=[_/YN]W^+^]DV5K?+]?
MS2^X\GM/V#?@;8>+/$.O0?!CX3PZYXN@NK77=1C\(Z>MWK45T<W,=S*(M\R3
M$YD60L'_`(LUO>(OV7/AGXOU&UO-6^'7@75+NRL[33K>>[T"TGD@M;2<7%K`
MC-&2L4,ZK+&@^6.10R@,,UW5%$?=M;IMY6O:WI=_>^XY:WOUW\[VO^2^Y=C&
MT?X<^'_#WB[6O$&GZ#HUCKWB-8%U;4K>RCBO-4$"E(1/*JAY1&K%4WD[02!@
M&E\`_#OP_P#"GPK;Z#X7T+1_#>AV;2-!IVE64=G:P&1VD<K%&JHI9V9C@<LQ
M)Y)K8HH`****`"N#\0_\G/>#_P#L5]<_]*]'KO*XK7=*NIOVBO"M\MM<-96_
MAS68);@1DQ1227.E,B,W0,PCD(!Y(C;'0X`.UHHK\7_A9^Q7\5KOXE^#/$VG
M^!?%VE^*OAKXI^*GC/0);[2KBSAFN6\3V%Q:VKR.@54U*Q%W!&S9#QSO(F[9
MD*G)2KJE+2-I2;[*-K^NC;^5BN5\G-'>Z27FU)K7HKI)OI>_2S_:"LSQIX*T
M;XD>$M1T#Q%I.F:]H6L6[VE_IVHVJ75I>PN,/%+%("CHP."K`@CK7Y+>,/V&
M+7]H7]FCX/Z[K_P'N-:UZ\_:4N[^^37_``(SZM:>&+OQ%J5TXNHYX/.BL'CE
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MK/C#]F3Q3I^FGPIX!N='O+[5)782:;XB'[V2\U(J+9K-V\DLK7*B(M@GZ`^)
M?_!//Q+XH_92_9;\$VG[/_P6\!3M\1;#4M?TW3_"TOBSP\T*^';N-M1UVQ%K
MIA\UI2L;I(^$?ROW[DA:VE35[+5WBOG*I*F_N4%)]TU]E<POA6^EI/Y0IPJ+
M3SYN5=FGU]T_2?Q9^S-\-_'OA+1?#^N?#[P1K6@^&[=K32=-O]"M;BTTN%K=
MK9HX(G0I$AMW:$J@`,;%/NDBM*/X,^#X?B3;>,E\)^&E\86>F?V);ZX-,@&I
M06&_S/LB7&WS%@W_`#>4&V;N<9K\A_\`@IU_P3E\8>(?VB/%]QX9^$7A/Q!X
M9\%_!'0=-1=$^&C[RT6KW1OHO";B1XM,U2.W=Y84`NF7,2XY#GZ+_9H_8BU3
M7_\`@H]^T%\5-8\%^#FTR+5]/;0-5\5_#>6X\67J_P#"-6</G:;K$L\?V=%E
MWI(BVTA,BS*61B0N<JON2K=E.7G[LG!>=YJ]O*ZU5V'):2I^44OG&,FNUHMJ
M_FN^A^B5%?C;^R5^S'\7OV</A=^RSX'TWP#XR^QVVH0>/[+S=%N!'X5U";PM
MJMKJ-C?%D"VO_$Q:"=1<,FY]2D11B(XT_%O_``3]TW7O^",G@232?A+K\GQ^
M\?+X=?QQ=ZYX+U"[UC7+T^(=-N-7EUR(K')>QI.)9`+EP3;K*8G6(R/6TZ?+
M)I:VE&/JY.S:[J,DTW?L^NA))24;[IR]$F]'YN-FEKNU]F[_`%_K@_$/_)SW
M@_\`[%?7/_2O1Z@_99^`]K^S;\$]*\)VNE?#S1S9-++/#X(\*#POHC222,Y>
M&P$\_DD@C=F9RS`MD9P+VNZ5=3?M%>%;Y;:X:RM_#FLP2W`C)BBDDN=*9$9N
M@9A'(0#R1&V.AQ,DD[)W,XMM79VM<O\`"#_D4[O_`+#>K?\`IRN:ZBN7^$'_
M`"*=W_V&]6_].5S6T?X$O6/Y2,Y?Q5Z/\T=11117.;!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`5YC^VMKU]X6_8W^+&IZ7>7>FZGIW@[5[FTN[69H)
M[69+*9DDCD4AD=6`(92""`1S7IU4]?T"P\6:%>Z7JEC9ZEIFI0/:W=G=0K-!
M=0NI5XY$8%61E)!4@@@D&L<13<Z4H+=IK[T;8>HJ=6-22NDT_N9^:?[/'B3X
MC?!+]LGX6^`/$NL>)-)'BC6M(UO^QH_BAK/CJSELY?#WB@2--?:HL5VK37%G
M!(;1HS;(;2.2-WD\SR_TXKQF#_@G)^SS:^`+CPG'\!_@S'X6O+Z/5)]&7P3I
MJZ?/=QHT:7#0>3Y;2JCNH<KN"NP!P2*]6\)>$=)\`>%M-T/0=+T_1=$T>VCL
MK#3["V2VM;&"-0D<442`*D:J`JJH`````%=E6HIZVUO^'Z65EV>_N_"N6,;<
MJ72*7S3;;\[WOKJMKO<T****Q-`HHHH`****`"BBB@`HHHH`*^"_VT_C)XNT
M3]MC5KRYT^ZUCX<_"72/#&HW%AIWQ2U;PA?1S:IJ=U`]RMC8P>5K&?LT2+;W
MES'"3&Z*I,SFOO2N.\<?L\?#_P")WC_P]XL\2>!?!WB'Q3X1?S-"UG4]%MKO
M4-%;<&W6T\B&2$[@#F-EY`-$=*D9]G?\&OZU7>]T$K\DHK=JWXK\]NO9IIM'
MP!\,_P!H_P`9^&[_`.)'PQU3QIXJO->^/WC_`,2V'P_OI=4DEO=$CMO$-[IN
MJ16;NQ,*6&GPP7D2)PI9]H&*^QO^";WB/4O&'_!/KX(ZMK6IZEK6KZEX&T:Y
MO=0U"Y>ZN[V9[*)GEEE<EY)&8EF9B22222:]*T_X2^%=)U"SN[7PSX?M;K3;
MF\O+2:+3H4DM9[QVDNY8V"Y5YW9FE88,C,2Q))K2\+^%M,\#^&]/T;1=-L='
MT?2K=+2RL;*W2WMK.%%"I%'&@"HBJ``J@````55.2C3E!ZM\NOE'F25O)->M
MM>A562E5G-:)N32[<S;?WZ:=+::%ZBBBI)"BBB@`HHHH`****`"J'B'PMI?B
MZQ6UU;3;#5+9'$BQ7=NDT:L`0&"L",X)&?<T4549.+O'<4HIJS,;_A1_@K_H
M3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:**V^M5_YW][,OJ]+^5?<@_X4
M?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBCZU7_`)W][#ZO2_E7
MW(/^%'^"O^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_^)HHH^M5_P"=_>P^
MKTOY5]R#_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:**/K5?\`
MG?WL/J]+^5?<@_X4?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBC
MZU7_`)W][#ZO2_E7W(/^%'^"O^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_
M^)HHH^M5_P"=_>P^KTOY5]R#_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__
M`(*H/_B:**/K5?\`G?WL/J]+^5?<@_X4?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z
M$_PO_P""J#_XFBBCZU7_`)W][#ZO2_E7W(/^%'^"O^A/\+_^"J#_`.)H_P"%
M'^"O^A/\+_\`@J@_^)HHH^M5_P"=_>P^KTOY5]R#_A1_@K_H3_"__@J@_P#B
M:/\`A1_@K_H3_"__`(*H/_B:**/K5?\`G?WL/J]+^5?<@_X4?X*_Z$_PO_X*
MH/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBCZU7_`)W][#ZO2_E7W(/^%'^"O^A/
M\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_^)HHH^M5_P"=_>P^KTOY5]R#_A1_
M@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:**/K5?\`G?WL/J]+^5?<
M@_X4?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBCZU7_`)W][#ZO
M2_E7W(/^%'^"O^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_^)HHH^M5_P"=
M_>P^KTOY5]R#_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:**/K
M5?\`G?WL/J]+^5?<@_X4?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_X
MFBBCZU7_`)W][#ZO2_E7W(/^%'^"O^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`
M@J@_^)HHH^M5_P"=_>P^KTOY5]R#_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3
M_"__`(*H/_B:**/K5?\`G?WL/J]+^5?<@_X4?X*_Z$_PO_X*H/\`XFC_`(4?
MX*_Z$_PO_P""J#_XFBBCZU7_`)W][#ZO2_E7W(/^%'^"O^A/\+_^"J#_`.)H
M_P"%'^"O^A/\+_\`@J@_^)HHH^M5_P"=_>P^KTOY5]R#_A1_@K_H3_"__@J@
M_P#B:/\`A1_@K_H3_"__`(*H/_B:**/K5?\`G?WL/J]+^5?<@_X4?X*_Z$_P
MO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBCZU7_`)W][#ZO2_E7W(/^%'^"
MO^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_^)HHH^M5_P"=_>P^KTOY5]R#
M_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:**/K5?\`G?WL/J]+
M^5?<@_X4?X*_Z$_PO_X*H/\`XFC_`(4?X*_Z$_PO_P""J#_XFBBCZU7_`)W]
M[#ZO2_E7W(/^%'^"O^A/\+_^"J#_`.)H_P"%'^"O^A/\+_\`@J@_^)HHH^M5
M_P"=_>P^KTOY5]R#_A1_@K_H3_"__@J@_P#B:/\`A1_@K_H3_"__`(*H/_B:
M**/K5?\`G?WL/J]+^5?<@_X4?X*_Z$_PO_X*H/\`XFM[1M$L_#FFQV>GV=K8
M6<.?+@MXEBCCR23A5``R23QW)HHK.=:I-6G)OU94:4(N\4E\BU11169H%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
C%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tpg15a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg15a.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.CE#-49!1D1"0S(P-S$Q131!0S$V0SE#.4$W,30P-S9%
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.CE#-49!1D1#0S(P-S$Q131!
M0S$V0SE#.4$W,30P-S9%(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.CE#
M-49!1D0Y0S(P-S$Q131!0S$V0SE#.4$W,30P-S9%(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.CE#-49!1D1!0S(P-S$Q131!0S$V0SE#.4$W,30P-S9%
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`$&`54#`1$``A$!`Q$!_\0`Z0`!
M``$$`@,!``````````````<&"`D*!`4"`PL!`0$``04!`0$`````````````
M!P$$!08(`PD"$```!@(!`0,$!@\6!0$%"0`!`@,$!08`!P@1$A,)(105"C$6
M5I87=U$BLG/3U#65M39VUE>W.4%QD=$R<B,S4Y.S)#1TE-6V-Y<8.!IA4M+B
M6%7PH4(G1X%49$4F9B@9*1$``@$"`P('"`T+`P0"`P````$"`P01$@4A!C%!
M<7(3-0=1L2(RTA0T%_!A@:%"4K(S<U05-@B1T9(C4X.3=)15&-,D%L&"A"7A
MHO&C9/_:``P#`0`"$0,1`#\`W^,`8`P!@#`&`,`8`P!@#`-<_P`4ODERKXM\
MG8O=UHVMM.N^''0Z#0X^ZK<3)S1#K;FH]R6&]LFXVG?FK]L0DM:=F:LL\.Y9
MLF3.N*I.D074/W1SF*;`(#I_BB<GN.6[O$?V+;JQ\/O%.A>);HO1*+ZU[?DH
M>^:FJF]ZAIBNP4'J+6[NI246I!P$Y=4I9\U=R<;WAGBI$BBHFH;`(0Y"<P><
M>U)J/U!J/<%VBZY>O'7V#P]L4S([E#5EW0H50I"%EK^I:+<]6ZL;SM'U?+$3
M77=O!4?SZ*R*:'?+HKJ"F!EE\,#E9S-WGR=\1+3W(8FF5M=\7^0`:GH1*E;Y
MF7O5;2;4:E3,9!.!D:;".[Q!O8^54>.9^260D!D5#(`@=,O>@!%>^?&RM^J[
M!S'N57X]T>?X\<"]]TWCYO%_;-WM:=O^ZV>Q+5)*6F=+ZD-4Y*/G8F,]NC7T
M:E(RK)S/]RL+4H`'D`YOAY;.Y9[X\4WQ.I?<]Q=JZCX]6K6>I]6ZU@=P7'VC
MT:-M^K:I?8D?@B-4XFLSUEL<;(B^E9N0<!(QLB8[%L55L'>X!+-+\52WWZV\
MO+A%ZOTM5.+?#[9V\M*W6\[/Y"(TG;<K>-%5):>L%D+K<U'E6,'KN1E4P:ME
MW+\TBHR$SXC91,HIB!9I6_6$IH]%YGS=FXZP+VR<7N(M-YCU3VJ6G94/4MDT
M*W69.NIP!G6U]1Z\M3!^F5=-RUE6L6]B)!`_:25\@X!2?+;QD]X1FG^5&MIJ
MCL=(;:I/&SCCRNUKLKC-O&I;62;ZTW-N^M:[-5K'8[5K!W7JOL1H1X;MD]%R
M+"09*G4:+!T(I@$+1O,?DRSYR1%3DN1>T!H#;QW;WI:3@'UQ<I0`Z-A.&2U]
M+K)^V#NV:5%:V-$9,S/L@W3<]50*'0`P"\72WCWJ[/VY-:\7TS396O6+BYR2
MY-Z;ONO;ELB1J]CB^.[*0D'L!)SU]U!K^'LK"R(,Q(C-U=68C4UB'*(F#LB(
M'!-XG7(B]N?"<WQL*FO]!ZOY;26Y-H(ZPU#LJ%V0\N6I*?Q>?[>:Q^V4Y[5;
M1PK+^?L3*1\=7G[4Y3*$\X=&,4Z(`>SB_P"/)M+DA%N;5!\%+O)U:]<<=J<@
M=%+5VPS\0E,R.NEP&(U!?KKM"A:_UJTN%Y8.4#LW\!+3<2BY[;8Z@J"GV@,D
M'AY<])7F?JC:EMM=3I%+V/I^REK-^U?6+-<%+#19Q:J,K06H;$B=HT+6DU3;
M:R*Z%%05$%XQRF4'+=T=$W4`,<*7CWV*J:GY#7#<O&RNZ[V[JYUJIA4.-KS:
M4NRV,V6W;ML=0ZZGMJ6&<UY&Z]8:ND)-TV?JV^L2=BA2M>\3*850)V@+EK]X
ME7)6D;5X]\3S:)XXO.5>^(C=%X2DC<EY!#C37=>:9;U]=^L;8AM:>V^4V!.'
MLJ)"0*4,"C1%([I5;N!*.`1%JCQI=K<CI[A/K_0W%NGN]B<M&_*EE-^W[=:D
M10M=37$2[LJ?L67A;57*+8G&R:18`!RO".V+1!5SVD0.0A>],0#A:9\<VT;L
MY51VI*IQ&NS_`$J]Y9V[A[)[%C@O;JTTZX5!=S#N=E6PB^NFFJVE`>V=F=L#
M%&SJV!LV.FY5:=D1(`&PW@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`Z)O:*R[L,E4FEB@G5KAV#&5EZPWEX]:PQ47)G63C9*2A4W!I)BPD%&RA4%E
M4BIJF3,!!$2CT`[W`&`6W;`X=<4]K;.A-T[+X[Z=OFV*X,.,+L"V4&NSEH8F
MKRYW,`<DI(,%UU5(-PH)V9E!.9L;RIB7H&`=C+\4N-,^SOT?-Z)U7*L=J;#K
MVV]DM']*@G3>\[/J2D,M6+]:$E69B3-L@%:\Q,T?+@==`6B0E,'8+T`IJUZ/
MX;ZS8A?[UKO0E`BX;<RN_P`;C;HNFU:+C-\S;3T(KM8\[->8LFFQ91DIYJ,F
M*I7BI#=CMCUZ8!7E6T'H.O[4M'(BF:LUS$[?V9!L(RX;:KM<AFEMO$"@E'GC
M49RRQZ!'4\T*A'MA2.JHIU(D3H;H`8!'E\XB<,;+MJ*WYLGC_H*7W,D^AS1>
MSK=1::O<5Y6"(<L`N6;E&7G4A+0R9Q!FJ<RB[8`#NQ+V0Z`2[7]>ZAUI;;M;
MJW5:-2;MNRP1<Q?IZ.81,)8-FV:%B&U?AW\^\3*@\LLO&PB"31`R@JJIMRE(
M7H4`#`(IEN)'#E]N"7VW.:`T.ZW=>X>5AYRYR=%IZEWN$/)0ZL%-MY-RY8B^
MG4GT"<[-R=0JIE&@F2.84Q$N`6][<\)SA3L'CUO?CYK[3=%X[,N0.K7>G[?L
M#25'I]8OK6ENYAI.^BV,FM"NT%V;:29E42;.4UFR8_J2!Y.@$O4'P]>%6N-:
M6?4]=XR:1;TV_LZFALV+)K2HMVVRW5*,S<5Z1NS5K%(MIMQ&R+$CM`JA12;N
M>ITBD'`)(+Q.XRDLQ+F70NJ0MB>T'6["6+VDP/I@NWGU;&GO-D@^%GW_`+<W
M55,,<I(=?.#LQ[H3"3R8!#L!P^\.W4EJ])5W0G%K7ERN25^I*+AC4]?5R>L#
M>Y0RZNR*='E!%J[=M9R`!524C6X"F=KVSJ)]CM#@$PU+2?&"P5W14S1M=:?G
M:GHY@Z)QTEZO#UF6KVMHQY"'J#P-72$61Q'0;)Q7TS1RGF!RD,V**0_*@(8!
M2%?X*<+*6KL%]6^+NAZZ.SX.<@-C&CM;55BUM-=L+@[^Q0\R@2.*T/#R[H16
M=(`4B*IP`QP$0`0`D?2V@./^C*4]IVAM5:UUQ1+"[=2\I#4"MPD3"6%[((E;
M.Y*4+&MRI33ATU("1E5S*F%(H$Z]D`#`(\JO!/AA2*SL>F5/BSH>"J>WX\L1
MM&NL-8U,D1?(A,ZRB$19V1HPZ$K$M%7!SH-5`%!!0PF3(4WEP"%+CQP\+",B
M(KBQ?=3\/8N*UXT-N&)T[:837$=[36=QF`IYM@H0\H5!S!HVN;4",%\(IA(+
M`5OVE!*!0`NHC=`<=:1)ZNL\1J7551D]+5Z8H^GYB.JE<@5=;5FW$:M)VL4=
MPV:-25V,L96J1'+9KW9'0D+V@,.`=$TX?<5V&XEN0;'CUJ!GNUP_4EE]H-:'
M7F]Q6F%6OF*LVK,(L2.#SBK3]C,]'JZ,7R"I@%Q^`,`Z*:M%9K:L,C8K%!0"
MUCEV]?KR4U+Q\4K.SSM-55K"0R;YP@>4EW*3=0R;9`#K'*0P@40`<`[W`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`-3V/WCMC1[_P`?'D!5*YLF;Y,0W.K4
M6JVSO4]/@]@;*JO'EO2-<1FL9="(LL78VL30XJN3\J_6?%BI8K`IUW:;!THE
MW8@4EJ#Q!_%29<>-F\BK+"[2V+4.'G.O7C.ZTX-,D?[(Y(\&]B5&(1N3VJKH
MZGU4XMMDUQ/SA92-DX:NQ1W+=NH@X2$"=K`(&Y,^)]XGFLZEQVKMEV=:M8[+
MY$<>>1W+=5E7M44)O)Z.8S&UDX+C95MT(VNDVYS":?HNN5TG5G[F.1L"CPZ@
M^<B*?=`!L_:_Y+574G#+CMN+:>UIOD<WNM;T]!.]S:>H<KL=MLNV[)3CF+>Y
M0\%JRKB#6DOYE\8_GQ8]LT9,0*HY[KH<<`MU\6+D!R8T5&<6D=-2=QUMI?8N
M\CU/E?R,USJ1?=]_T-K$M8?OZ_,UZ@I0-M1*E;+>DA&.I9:(DDHI(_>"B(F`
M0`P;[G@N:_/.E\#6&ZK%NN<U57_&"=TG5^Q)?C95Z[+;HXSQ-"F9+7_)?<VG
M;71'T)7U8&?(_BF2LE%L(6105!VLQ*N*)B@;"7B`QVRV-,U-&<?V'+QYO1B_
MD6.KU^+SVA5ZF,W;6,CD%UN0OPH$#2B.L#%32#N9%FLZ[8&+&ID4[0E`PQ>*
M[5-WW/@Q6:3S-B.-4ESKF]);7CF]CJ'%7E5O2$D3/7;@U-JO'FUZW.O7=5\@
MW:S5N1Y*O6BK=%VX27:ID9%$N`6.\BJ-L.PQ6YT>6?&?E$;;-^\)OB90/#7J
MDC7M@[FNNM>2<%"34?L.O0%]I,*I!T7?*&R30,E,3+\T0Z,S*!U%`334)@'$
MW3I[D.YD^6U&WEK/?%S\4VU;C\/][P8VQ`4W8EA&'U]4Z=J-.\2FO=P0[)6C
MZ^I]8L49;37)->29"Z755%P1?O4QP#8F\4/?W)/2,KP^@*9<M@Z8T'L2[6^(
MY5\G=2:34WO=-6-X.D!(Z]B8ZI>UF[HP$7L6Z]IHYF%H61*U32`@%(*G:P#$
M?S<\23Q%-6;8AX?CBMR6NR-%K7%:;B36[C-'U:F\@JQ?GT*79MP1HD9I>VW)
M]W<4Z6&6[=FIAZX[^428JE(/4#E<@_$>Y\LN3/.?7&BMQ;&LNU-"<TM,:MXL
M\6ZIQ5;WC7VWZ==8C6\EL6L[2W1'U)_[6V==A9B2>`X6EH9Q%D*"YSN2J$(F
M!%SS7FX[%S6J<S):/L\6P@/&PYV2Q9:$U=8F#!Q2I'A1+QL+=)>8)'*-IB*E
MIUZ=BUFS&*U>K=$DS"?Y7`((A^6WB"\//#BX.:=XXT_DAKN\4_@I/;*@8%#1
M[%U3[=M1AM"Z]UKR5:R^F-HW.RVMO%-TUG=;[=-*FQ6!<LBH94I4P,P[;;7/
MCD7NGDQ!VNW777>AJ-X<&C=X,M21FB892%VGNG;FD;PML;6:]SM%>?6)6'C9
MU%,'<)'K!*IN#I)F71`!35`Q6)<P?%:T;HOA%J?4=3><=*$AX>^G[KKR55TW
M/IU>Z\FY*5?!<=;;"@4-';GL#./KB!&R`U=J%8D52/!<!("(@4H&3Y'FWS;J
M_B5ZVU]M:S7*1TM882@J7'7.I=(2<%1]$MD=,&M^W;9OFV[5U@R4FM<M[,91
M:/M=>NJ)V!2)LG$.JJ1;`,?W(/7^S.6OAF>(3XC[.C6VQ;#YZ<A..P\>:Y7J
M6^V'<J]P\X^[YJ$#I(\14XILK)29+&5G)W!RR3*F1P#U,QQ`/E@`JC=.]^9&
M]:3O6E'^$WEUQGUYS7\-4VF-U;7XHR6MKG)V.S;28*<D*FTU\QIM,6F:EJ1K
MW"Y)P8LJ<4=8Z2CEP"8J8!.;GG%XESCD')P;6;VTWY$Q_B!-]0QG!%+BFX6T
M$_X1%NC:-6W7(<B5JJ0Y5%]:KJ3_`+84[41%-Z0K0(T0ZA@$:ZV\1_G]L/?J
M\!K3<>PMM;!K7BN;%XU'XS,>*K4FGG_#"M7F0C[AL:V<@8ZJHM(RQZ]K_P`N
MF\&=:*(*MTVZS)P=451`DO7_`"B\4K;UXYWZBU_MG8%CVM2=?;)VEH?8<=QU
M:U'C7!2M`V6V<4;1-DA=HZGI&QZELJYU..<0KQ+TI;V4@FJ>1;O&O83`P%M'
M(+F9N[GWX4'+KGA<&LAKNJ-^2_$R-\/'5TE`P\7<:+N?3NP-9P%QM<;-MDUI
MZ8G;EN>5G(IL45C%*PCSD(3LJ'#`-S.$5D%H:(6EDRHRJL8P5DT2AV2I2"C5
M(SU,I?)T*FY$P`'_``P#L\`8`P!@#`&`,`8`P!@#`&`0=R1;QKK2M\0F=M3N
MD(I2)#TALBLV"&JD_"MBN$3G;1=FG&4@U@74UV09@Z33!VD"XBW.FMV#E`P^
MZ/Y2::@_"0XC;$Y$WS8FV;;(56K46/KD-M:YQNS-I;P?LY%K$TRX7*.LD)+,
M);N3`[D7\^_;,XUNF9Z[.!4R]H")JC/6JOJ,];\P>3]QL=6JO`(;/J#9-%VU
M<HVJV_?<AL'8Y;^SK.RJ3*1SW;VSM.PJ=7A(HKPSI^[;AYYYFHJZ6,`&;OAS
M([>E^*''"5W\1\3=DCI36SW:995HDPEAO#FJ1:MA-,,44T4F<P>0,<SM(I"`
MFX$Y>R7IT`"K[W<-BU,Y7;"LU&2AGEBKE>CU7=EE&,@92R3$?!MG+MNG`.D$
MDVSM^!SE(H<13*/3R^3`.P](;E]S&O??9/?>O@$60&HGE5VK?MX5O3FGH7;.
MTX6K5[8MYCK)86TU<XBD)NT:DUGSIUL&[\T`W?K)-E3I]\1(_8[?8```"4_2
M&Y?<QKWWVSWWK8!:-R!X.:DY3VB)NV_N+VB=C7"%KKJGL[0_METB)]:GO7A7
M[NH2LM7(F'?3U37>@*IHQ\=PQ%0QC=UU,;J!<Q4H*^4*L0%)I&M=15"GU6)8
MP-9J];F9&%@("$C&Y&D=$P\3'U%NQCX]DV3*1))(A2$*```8!4/I#<ON8U[[
M[9[[UL`>D-R^YC7OOMGOO6P!Z0W+[F->^^V>^];`'I#<ON8U[[[9[[UL`>D-
MR^YC7OOMGOO6P!Z0W+[F->^^V>^];`'I#<ON8U[[[9[[UL`>D-R^YC7OOMGO
MO6P"+*!J)[JRS[2N>O-.Z?J5IW;;6]\VQ-Q%EL*+V]W!I#LZ^VL,\<]<4*O(
MI0L>@V`Q0('=I@'3`)3](;E]S&O??;/?>M@#TAN7W,:]]]L]]ZV`/2&Y?<QK
MWWVSWWK8`](;E]S&O??;/?>M@'2V.-V-<*_.5.U:_P!56.L6:)D8&PU^:L$M
M)0\Y"2[15A*1,K'NJFJU?1TBR7.BLBH4R:B9Q*8!`1#`/"L1&P:57(.GT[7.
MI*K5*Q%,(*N5JNS4E#0,#"Q;9-G&Q,/$Q]1;L8V-8-$BIHHHD(FF0H%*``&`
M4GM+>4CI&N(V_;TMIG757<RK.";SEHO<XPCUYF1!8S",25&J'$[QV5N?L$`.
MINR.6]U=VUE2=>[G&G13VREL6TRVBZ#K.\=\M,T&VJW>H2BVJ=-9IM+A:7'@
M1]K;F51MPV9Q3-7;-X\7FV-()Y9W5>@=DS*\JA7(]PW:OIQ5LI4TC%C&;ETF
M118?E"F.`".>%GJFG:A)QL:U.JXK;E>.'*9/>#<G>[=2G3K;RZ==6-.JVH.M
M#)F:VO*F\7AQ\1''%78.G6<1=F?%FDZIK]+N=NNF[K!9H4NR*]KG8EIMTV5&
M\;+KMWG:,VJ]O+-3C<HN'C!THBJ/9.3J00-E^:L766"2O4Q$SM=L,)JA:*DH
MD\9/,'-_F6O;B;$BO&]RY.G7T'#5*524422.!B&./7L#V@P"V&$X[Z(1UKH;
M2<!I3BN?5NE[E&77C[KN/N[MS6JS>*(]DGT=/5.(3AU49::K,G).G`G.#DZ+
MI0RI_P!E#M`!*>RN2TWJB_:QUM;H>DM[)M-IL":BCH6B2+#UJGZLK9;/?+[>
M)=]",FE;IM?:.&K=1VH)^T[?()E*/:,8H%:.-QS+77[C;"\WHDNKFL,>Q+[%
M3VBX<THL`0@*#,DLC6`6BEXXQ!#LJIJF*<1`"]1$`$"!&_/&KRNE=<<C:HXI
M5TT=L_9$%J^#V/7I.U$AHR<L-Z=ZS92MD;S=5AY2(K2%]:!&.'1D#"DLLF<2
M"D(G`"[?TAN7W,:]]]L]]ZV`/2&Y?<QKWWVSWWK8`](;E]S&O??;/?>M@$CL
M#/CLFIY-)LA(&03%ZBS64<-$G(E`52-UUD6ZJR)3]0*8Q""(?F!@'+P!@#`&
M`,`8!ZET$'*1D7**3A$_3M)+ID52-V1`P=I-0#%-T,'4.H>S@'&&+C!2%`8Y
MB*)CF4,B+1OW1E#%[)CBGW?8$YBAT$>G40P#]"-CP301!@R!)LH"S9(&J`)M
MU0$1!5`G8[*2@"/ZHH`.`<W`(JW!]KE?^,O5?XP:[@$JX`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P#&IXJ7$/9G-7C9$ZBU3)UJ(LS':M+NYWUI>.V4>G
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M^`FHUQ6/?DD&,(*:+]*23`K$AFW:/M)!IS]H<%N3?(!YR-F[]`Z=J+;<E<X%
M5>%IC6_66U$3B^-&XG-]VF2URY:A#-CDL,4[53BB-$1!8@E3<BF;M&P#M=@>
M&E;7<GR6G]9P^HZA8=C<S.,._=1S#`7<*]I%$U6.H%-E1[!:.@C#3YNS+U&;
M.+>,`K>2,^ZNE/V93L@3UR-I6QX[G1HG:%4KRMCAKQQ9Y-\=&+R2@7=BH]%V
M?+N:1LZB25[:-"?Q*LW5&F/HMPLJHBBH=%)N8Y3+$Z@4AP]XD["X]I;?LMHU
MA&3UUO\`!L7LG7(W8%*J.CK)9F,BV=%:U?1E'UY$:^UNNLHEWZLPLC+2CDY`
M!9<XFZ@!;#9>-G(RC^%O,<,[=KQFKMC:F_V]8I\CK>Q2%_A637;G*E]NAY=I
M]^2J0*U1A]951TLH]=.""EYPRZIG#O$RB!G\(7L$(03"<2%*43F\IC=D`#M&
M_P")NG4<`\L`8`P!@#`&`,`8`P!@#`&`,`BK<'VN5_XR]5_C!KN`2K@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`,;?BF\^7WAQ\:&7(&/UNTVDLZV93M?
MFK;VQ*UE%%*U!)=J5&11C)8YA9"P#]B[KY<#?J@Z9LNZ>@TMX]7CIE:JZ,)1
M;S*.;##VL5WS![PZM4T7397U*FJLXM+*WEQQ]O!F/SPP/'7F/$2Y17CC6KQZ
MAZ$\IFF93:YK!#;&4LR3YRRG8>&:5LB+JNQ""2KOTKVS+]Z)4A*`"'E'IF=]
M]S['=.I3H6UV[JM+QL(*,8KES/%]XQ>ZN\MWO%&=6O;*WIQ6SPLTG[F"P1=3
MK#Q,GS.D[>NO)>#A=6W746N;)LJ[\4T*C=X'D#38>O6(D2HM$/[R\C*7NNL@
MU<(][8*Z9&*!PJF!3]E0O303<"Y7;_/[4VFGVUHV>J6S)R0U)7..MCF&-7@H
MF0=3B7)J^N]=:^C:TDZGF'GTFUGV@^D"*B@1!$P&(=0>H`!1KGQ(Z'"3-TB;
MGIO<M,;:KWGKOC[MN?E6E'=P5&O&W3U4NLW2;J'ND@XMU=L*=VBSN'42DZ-&
M%=AYTF02F``*XW-R%M%8Y=:.T97Y9C"4]MIG=_);>[L\$K8)R0USKH:W3JU7
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M>EKY`\>(>U["/'+;+J%VVGIO9CN'9ECXB4O>E]C6;6L_.Q;%,YTV3*PK5LK\
MJ!!["'G(IE\A`P"\'`&`,`8`P!@#`&`,`8`P!@$5;@^URO\`QEZK_&#7<`E7
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`6N\N.'>C>;VK6VG.04%*V*B-
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M:)(%?)@/G`*',<Y@*\M_"K05Y)M-.Q0$TY)N7<&KMZ7L$;/,-?/]B:="E%HL
MBR[EP7T:Q8!K^,[YJCV47/=&[P![PW4!MCCA)WCD9HWD'5;>%2EM=TS;VI[X
MV3;K>D+9K#:T9#O"MX.40,(PMFJ-[J<7)L5U$UD>R#@AB]3E$`(SE?#:XV6B
M0N<W?6]TV#9+S!1<)+VVS3T>A<$%:_:8B[5FQ1]LK$'7+"C:JM;8%H_C7ZCE
M59HNEU)T*8Y3`2[4.)NNZ4I,RL39MK*W2UWJD7V];)>['G3[`O[K7;?S&IU>
MWV%L=J,GK^.C!,U&"(DC'*(J*=I(3JJG.!QTN)U$1V%![:E9[8&RKSK]S;)G
M43?;-ZFK=4]8V2V1SZ*?RU8A3`@#9T>)?JQQ'*XNW;6.541;J)@<W:`['B+Q
M]-QDT15M6/[`E<+624N%VV'<46:L<A;=E;*M\W?K]8&L>LX=*,&#VSV)SYJ@
M)S"DU*F41$0$<`N6P!@#`&`,`8`P!@$=;8VE5-,4&P;'NGIP\!76Z2B[2L5N
M=M]CDG3MPDRCHJ#K5;824S+RDF_<)HHI(HB';.`G$A`,<H%M4-SWTM:-0<;]
MMU"'V1:3\LV_G&C-9Q=402VA:"MX)]99LS^"D99C$UMM58..5<2CA\_1;,R@
M4HJ&443(<"B(WQ,-#V8LVPH52W+L.YT6!O%CW!K:IT=HM?-)Q^N;)(5&U-ME
M1,K/Q3-A.IS\0[28QS%S(/)9-L==DFNAV53`7NZYV%3MM4"E;1UY.-K+1-AU
M>#N=/L#,JQ&TS6[)&MY:'D4DW":+A$KIBZ(<2*$(H01$IBE,`@`%/[>`35VO
M@`"(_"7JOV`$?_J%70_,P"5,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!1.QF=UD:58(_7BE72MKYB=G%JW,
M)<U<3\Z$$'2C\L$8DH/8:'.*8)"`BH!>H@'7`,76HO#\WGJ?47!V*8[1U:[W
M!P2]N=>IDF-:M8:XV;0]ATU2FVJ-N$6I*'LE=GS)&2=LW3%RX207:E*9-0BI
MP*!U&N_#7V_H_8&[-Q:FW-KY?9O+6LW2.Y)C=:+.KU%M;K5<K-:HJZZGC(BQ
M(2+%.HL+<YBR1<HY71D4FZ"ZBZ*@J%,!DUT!INN\>-'ZET3473Y_6M0Z]J>O
M(60DQ3&2D6%4A6D.E(/^Y*5$'C_S45E`(`$*<X@4.@!@%*;JUW2'\?&3#VM1
MKJ3D-D:Q(]>*E6[UP5>]5YJL"@D5*`]XW,)!\GL#@%??`]K'W&0_[VM]&P!\
M#VL?<9#_`+VM]&P!\#VL?<9#_O:WT;`,`_CT/GFD:-Q;DM4OY:A+V#:]KC+"
M-3G)F`-.Q:-32<),)%:,?-U5T$EQ[9.HCV#^4,TS?:K6IZ=!T*DZ<\SVQ;B^
M#VCH[\--AIM_O?<4]3M;:[H*WCX%:G&I';+;LDG@_;6#,6E2GX6R0C.2?<C=
MSUV0513%[$/KU;5#M%S%`3E1<DF`3=-Q']0<.@]/9`!R&'J^LIX>=W'#\>7Y
MSZ+P[/>SRI!36@Z7M7["EY)4W2N?^4^VO?U;OZYRGVOK7UJX_3E^<_7JZ[/?
M[%I7\"EY(Z5S_P`I]M>_JW?USC[7UKZU<?IR_./5UV>_V+2OX%+R1TKG_E/M
MKW]6[^N<?:^M?6KC].7YQZNNSW^Q:5_`I>2.E<_\I]M>_JW?USC[7UKZU<?I
MR_./5UV>_P!BTK^!2\D=*Y_Y3[:]_5N_KG'VOK7UJX_3E^<>KKL]_L6E?P*7
MDE+W*SU:GUZ1GE.2VZ9A1F@H=M$QEVMIWLBY`@BDV2,>9!)`IS!\LH<>R0OE
M\OL9^Z>J:W4EE5W77_?+\YX7.XG9S:4'7JZ#I;BN)4*6+_\`J55X/LWN_G=N
M+DQ1X3?=]TN?4-9H$@>6?N%MR$LK2TRUB3;,RP]VD&[&N+Q@1G4[AJ)E70J=
MDX@4I0SKG</>_<FWW>H6U_NU1N]2ITHQJW$[RNI5IKAJ..#4&_BQV(^2'X@-
MTM[8[]W-:PU[S31:M>I.WM*-C;4X6M*36%%2AEE54?CU,9,VU-2\<H>D:_@*
MQL.7;[=N$8BY),;"E*^UK;ZPJK/'"Z"R\-%/%F#,6K94B(`F80,"8&'RB.6>
MM7MAJ&I5+O3+2-C8S:RT8SE-0P23PE+!O%XO;W2/M+M;RSL86U_<2NKN*>:K
M**@Y;6UX,=BP6S9W"RJ4\/'D0\D))TPYYV>+9NWSYRQCD]%4)PG&-'#E55HP
M375F@47(Q0.5,IS`!C@3J/E'-\I;Y;A0IPA4W5MISC%)R\[KK,TEB\,NS%[<
M/;-.J;L;XSJ2E#>*XC!R;2\VI/!-[%CCQ<!?)'\>ZVUURWJCQ=G(71*H!!+;
M(4A44'[FR>B19>W$T&F[&/([&1'SSS8#]SVP['7LY']6ZLYZH[R%M&-@Z^=4
M,S<5#-CT6?QL,O@YN'CX3=*=O=1T]6LZ[E>*EEZ;*DW/+ATF7@QQ\+#@XBQ-
MOX=G(Y)9LHMS[M+E-)9!1=$VAZ`0'*2:A#+(&.6;$Q`<$*)1$/*':ZADARWS
MW`<6H[J6J;3P?G=?9W'XO$:5'=??)-.6\=PTFMGFU+;[Y?)L;CO`VO7EAJU*
M?M=;7*4B2,H;8L?!-IQ_79`JB!C2[>$D7:4>]5.1,Y>[4.!`[P1Z^0,C[2[N
MQL]4I7E_:QN["$\94)3E!3CM\%SCX2XMJV[#<]0MKNZL*EM9W$K>\E'"-514
MG%[/"47L?(^Z6=T[P_\`>T#;:U-V7FU8KG78B;CI"<J+O2E(BVMGBFK@BKV#
M<23.9.[8(R*)13,JD`G(!NH!US>+[>[<>YLJMO:[L6]"YG3E&%175:3IR:V3
M47'!N+VX/8S4[3=O>VA=4ZUSK]>M0A-.4';THJ:3VQ;3Q6*V8HNEW?QD1V)1
M5JYJNWDT9;#RD:\3OD-5H^V/46#0ZAGL4$1-/6[$R4D4Q2F4$W:(!?('ES3]
MW]1TK2]15UK%C#4;/))=#*I*FLSX)9H)O&/<XS9M9LM0U"R=OIEW.RNLR?2Q
MA&;27"LLL%M[O$:D7-]YN3CQSJL&EK9R%V?L2&9Z^UU+/YJ&D'NNCBI.MI%P
M9Q'UFMS'H1LZ:(`1,X@/\:[`&,(&\N1/VNZY:WNO*ZW<MI:39JA"/0TJU2<7
M)8XS;E@\98K9Q8'>?X0]T]/J;DSM][Z=IK=S*\JM5;BVI*<8^"HP32>R.#>U
M[<?:.X:KUEVW1<DY2;?3*LF50$U[K<$5T^T'44UDC3/5-0@^00^3D0_:^L_6
MKC].7YSLGU=]GG]BTK^!2\D]_2N?^4^VO?U;OZYQ]KZU]:N/TY?G'JZ[/?[%
MI7\"EY(Z5S_RGVU[^K=_7./M?6OK5Q^G+\X]779[_8M*_@4O)'2N?^4^VO?U
M;OZYQ]KZU]:N/TY?G'JZ[/?[%I7\"EY(Z5S_`,I]M>_JW?USC[7UKZU<?IR_
M./5UV>_V+2OX%+R1TKG_`)3[:]_5N_KG'VOK7UJX_3E^<>KKL]_L6E?P*7DD
M`<A-PH:CICV2J&]MQW6V*H*>C&`WVWMHAB/0?X]+.?3/;.FF/E*@G\NH(>42
MEZCEW97VLW-90E=W"IX[?#EC[FTP&\6ZG9]HNG5+FCH&E3N5%N*="EE3XG+"
M.U+N+A-@'P#0-O;PU]8[*W"L[V+?)R_[B)*6FU/W\M+ND&&PYIA'-#/';I58
M&<<Q;IHH)]KLIID``_-Z]`:4LNGTEBWX"VMMM\K>UL^4>_-3IM[+VKEIPS5G
MX,(QA!=Q1A%*,4N))&9OX'M8^XR'_>UOHV9`U,C]ZVXO1KMU'R,QJ=@_9+JM
M7K)[;H-J[:.43"19NZ;+S":S==(X"!B'*!BB'00RVE>V<).,ZU)27"G**:]\
MS5+=S>&O2C6H6%[.C-)QE&A5<6GP--1P:?$T5TAJ353M!%RVJ4$Y;.44UT'"
M';60706("B2R*J;@R:J2J9@,4Q1$#`/4,N$TUBMJ9AYPG3FZ=1.-2+:::P::
MV--/@:XT2,Q8M(UFVCV"";5DS03;-6Z0"":""10(FD0!$1`I"AT#*GY.5@#`
M&`,`8`P!@#`&`,`BK<'VN5_XR]5_C!KN`2K@#`&`:V7K'G]V_$7XY+A_8U'-
M)WXZNASGWCIC\,'WQN?Y>/RF8$8P`%FVZ@`_Q=+YDN0=\)\K[Y].*'S,>1'8
M=`^0'Z`94]1T#Y`?H!@#H'R`_0#`'0/D!^@&`.@?(#]`,`H;8(`%><]`#]0I
M_!CGO;_.&)UKT&7LXC(AZK3_`*HO$!^X'1_V:NV3KNGZ`^4^6_;W]Z(\UFZI
MFU$$#`&`,`8`P!@&DCXQOY4Z\_%)IW[$2&0_V@>G?]D>\?0G\*7W5_\`)J=]
M%H!`#LAY`_0_XY'$>`[,/+H'R`_0#*@BC:NV(_5#:NNY"JVBPM[!8X"NJ.X)
MHT",@36&=CJ\S?SDF^<-T$$_/Y1/L-TP5<+%`PE+V2F,%_86$K^4XPG3@X0E
M+"3>,LL7)J*7M+AV)&J[T;UT-UJ=O5KVMU<0N+FE2<J48Y*72U84HRJ3DTEX
M4UA%8SDL6E@FSU[6V;(:JCUIAQ1G%DBO2D'`QHQ=FB6<S.V"PR2$5'0D/!O6
MAEG3Y9XN'0!5*44RF.(E*41Q864+Z2IJJH5,LI/&+:C&*Q<G)/@P]KVBF].\
MUQNM0E=U+&5S:]+3I0R5J<:E6K5FH0ITZ4HXN3D_C)8)O8D2V!1Z%[:8)G[)
M1.GU*<4SB4!.F)R_*G%,W4.H>0>G4,L.3@-KVX>$L)8;5W/:]P=`^0'Z`8!;
M7R)#I6WG3_[J;Y@<RNE_.KG&A[]=65.9^<VW/5M/R3^F_C`W9^,VP9T%IGH%
M+F(^1V^?WGO/I69X\OS5S0+Y>MVZO*3D<JJW0444W-L4QSF13$QS#9I#J8PB
M7J(CG-^NQC]LW>Q>D3^4S[&]EU2HNSG04I2P^RK;C?[*)NO5+9]$TQQ#J>WM
MI66/IVN=:<?ZW=KQ:I4RA8^OU>M4-C*3$HY!!-9=1-FP:G,":1#JJ"`%(4QA
M`HSRKZVTW1:=[=-JA"A3X$VVY*,8QC%;93G)J,(K;*345M9\FMX+2XO]\M1M
M;99J\]1NL-N"25:HW)M[%&,4Y2DVE&*;;21:)JOQ?N,.PM<[NVS=*/R7XW:]
MT7JF.WM-6GDKHBSZSAKKIB:254@=B:TE$EI^.MD?.B")&L=WK>=.=V@`L"]Z
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M][R7'U]0N2>W;72D=>O=WV'C_HZQ[;I7'*-VM)$CM?2&ZI6`7+)PI+*3O':3
M>*8S#U-BB==5!,@D$]EIDXZK=RMZ'@48W4;;IIXQHNYE3Z7S=5-JZ10<'-M*
MG3Z2'23CB\+R_3T^WC6JX2KRMIW"HQVUN@IRRNKDV>`Y*48;<TW"66+26-=0
M/B0\;[!RBF^*3=:ZLK?#3]TI9;[*U]DPU1+;#UOK*L[DV#KV,LJDV,P%EIVM
M;:SE7IW,8VC>Z[Q-)VHLD=,/S1JTZME<7\Y*E:VU"XKR<_!4J%I=0LKFM%[5
MT=*ZJ1I-R<7)J4H*4(RDJ77^UN+2U>,Z]Y.A"$8)MQJ7-&M<6]*:V-5*U"A.
MK&,5+".53<)2C%]Y_GVT_P#Y._\`/-[5]K_`1YOZ>\Z]J#'VU_!U[<_:G\+7
MM=]L';^#CT9_^H_.^]\Z]K7\<\VZ_L.7_F%YYOTG1S\Z^S?/.@P?3Y?-_.N@
MR<'G/1[.BS8=)^KS9BU\]MO._-LT>B^T_,NFQ70Y_./-NESX^C]+LZ3#'+X6
M7`O;Z@'3J(!U'H'_`!'H(]`^2/0,M"Z/PIBG*!R&*<I@ZE,40,4P?)`0Z@(8
M!Y8`P!@#`(JW!]KE?^,O5?XP:[@$JX`P!@&MEZQY_=OQ%^.2X?V-1S2=^.KH
M<Y]XZ8_#!]\;G^7C\IF!&+_D;;^;I?,AD'?"?*^^?3BA\S'D1V.5/48`P!@#
M`*&V%]KSG]8I_!CGO;_.&)UKT&7LXC(?ZK3_`*HO$!^X'1_V:NV3KNGZ`^4^
M6_;W]Z(\UFZIFU$$#`&`,`8`P!@&DCXQOY4Z\_%)IW[$2&0_V@>G?]D>\?0G
M\*7W5_\`)J=]%H!/U`?^WYN1Q'@.S#SRH(HV]K60VI7X^MH6P*LP:6.M6==0
ME>0G'+J0J<\PL,0F0[B4CTVS4SM@!%R]DYE$S"`&((=<O]/O(6-5UG3Z2;A*
M/C94E*+B^)XO![#5M[=W+C>BPIZ="[5K0A<4:S?1*HY3H58U::Q<XI1S1PDL
M&VGL:9V4WK\MGN>O[A8II9^77I)>1C:\BP1:PKRYRS0(XEQ<D,NX6*\AXU5P
MDQ0ZG(W,Y.IVA.`#GXI7?06U6WHQPZ;!.6.,E!;<G(W@Y/CPP+B]T!:GK-AJ
M^HUG46GJI.%)14:<KBI'(KAK%O-3@Y1IQQ:BYN6..!(N69L(P"VKD3]K;S^:
MF^8',KI?SJYQH>_75E3F?G-MSU;3\D_IOXP-V?C-L&=!:9Z!2YB/D=OG]Y[S
MZ5F8[=5RN^O];V2X:]HZ.Q[-`M?/VM+4F@@%YUNB/:=M(Z2.S>HDD^X`3()J
M$`BIP[':*)@'/6]JW-"VE5M*?2UXK%0QRYNZD\'M[G=+/=NQT;4M9H6&O7CL
M-,JRRRN%3Z14F^"4X)Q>3'QFGC%;<'@:%VZK>ZV%MS:-Y?PCFKO;?>[38GM<
M>F.9W7W4M+.GCB(=F5204%Q'*J"D<3$(/4OE`,YQU&O*ZOJUQ.+A.=24G%\,
M6WP/D/L-NAIE+1-UM-TBWK1N:%M94:<:L<,M6,()*I'!M836U8-['PFQ#N^O
M\B_$-\%3D]IFF:;-1KG;.-Q*-IB$D+*"LWLYY4HR)>)+`W78QR%?;V\T#YK'
ME<*CWQW`&.)$NAC2VZ^IZCNY0O%;5(>;5[6K&$7FJ5:="K3G-QCL>;+%RIQV
MRE))+:T?,OM`T/=K=3M$N]/T_58WUQ7\]5>:ADHV]6ZIUHPI.IFEG<)5$JLD
ME&"QQQ::6'#CMQ#:;JU5S4U[J7C]SBU1PVNOA8ZNI')#7D]KG84?M6X>(_2;
M,QL+RV:>UYO:QUMGLW8E>AH(XS3V-=MX6;[;5HBZ.<R92R%O'4IU-)UC4K2?
M_J5O%87FBY89ZE&G!SJ7<W1>%6%"3E;=.IKI:DU7J052<4W!^A9[?4=%L:D/
M_<4M)OK;5,TLM.I&I3Z"A3519J<J_P`]YK)-PI4W&$\BG@IW\.JZ<GZ=R@Y7
M>*OR0JF[=TZEU-P(TQQLBPUGPUV?H38VS;1"7>O2[JJZVX[[8G0V)=9ZCL41
M6GYE19*)7D9%9.,,+-``+DJU["TLM9N[M9KO7=X[*I#H_#3PA4MJEQ&"6>C:
M1J5X*/3?KG&%>I)98Q3L:5E.[N=&T>TEEM-&TN\QE5624(I*I3MYU-L*MQ5A
M3E*2I2=*,XT(+PZCD6Q<].)M_9<T/$;V5&<?N5\_RFYA.N&NY_"=W+JFM[74
MKVM]DPC.J5_836Z6NF/$J7INVU$C%-.;5M2J+<T`15-!0W;[M3#Z%;W6G3IZ
M'ITH4]Y['>VI6K59O_;5-*N*\*ES*%27ZN=&=O"YIUJ22J5:D+59)QC%QR>K
MW5IJ7F^M:A&I+=FYW8='H5%><0OZ49JUA*$<:D:JJU:=2A/&,*3J7&::S2QS
M2<Y.'>I'>S-1Z_I$+8(WF9SXG)N`V/:JU9[,>LZYUXWUG48'FOR%K51\]/4Z
MC?KUIVJL:&G-)H(.'3B>:$`_;[8F\[B%G+5KJPTZE*>[=&G=7MQ2X7*QC=4[
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MU$9_LU!G=2S[60A%IF51<MFS=*0F%0:$,U%)54#)-@#`&`,`BK<'VN5_XR]5
M_C!KN`2K@#`&`:V7K'G]V_$7XY+A_8U'-)WXZNASGWCIC\,'WQN?Y>/RF8$8
MO^1MOYNE\R&0=\)\K[Y].*'S,>1'8Y4]1@#`&`,`H;87VO.?UBG\&.>]O\X8
MG6O09>SB,A_JM/\`JB\0'[@='_9J[9.NZ?H#Y3Y;]O?WHCS6;JF;400,`8`P
M!@#`.*]>LXQD[D9%VV81[!LN]?/GBZ;9HS9M4C+N73IRL8B+=NW1(8YSG$"E
M*`B(@`9^Z=.I5J1I4HN563222Q;;V))+:VWL2/S.<*<'4J-1IQ3;;V));6V^
M)+C-#OQ0MT5K='/:][FU.SD[=25J+0:U%20IMX=.8=U<DO%/G\>$HX;J+PSE
M9N)VS@"]%DQ`>@#U`-.[4-P]Y-)UV&G7]"?32MZ=1]&G5R*2\6>12RU%\*#V
MKAX&F=D?A=[3-V*6X534+>M"3A?5J:C4G"CF<6O#CTDHYJ;QV2CBGM7"F67A
MLRWAY`UZ_`/D>FH+Z>R.ENA?I8>;W/\`!J^0=(OMEMF\>EM%_P"1;_ZA^_";
M</P?/_KU!?3V5_XC?_5[G^#5\@IZY+;]K:_U%O\`Z@^$VX?@^?\`UZ@OI['_
M`!&_^KW/\&KY`]<EM^UM?ZBW_P!0?";</P?/_KU!?3V/^(W_`-7N?X-7R!ZY
M+;]K:_U%O_J#X3;A^#Y_]>H+Z>Q_Q&_^KW/\&KY`]<EM^UM?ZBW_`-0?";</
MP?/_`*]07T]C_B-_]7N?X-7R!ZY+;]K:_P!1;_ZA'FQG]JOD&ZC24=^R>*)&
M(BN>8@SHF$0$`(J4'X"`=1]D/8SWH;LZE;S4XV]SL?[&KY!B]6[3M-U>TG:U
MZMJG*."?G%#9_P#L-Q+U="#EJWX6FJ8*=8K1DO&[%W6@^8N.P*K=0VR9U8@&
M,D=1,Q3I*%,42F$#%,`ADO:="<+*G"I&49J.U---<J:37NH^<V^JPWHO%C%K
MI7MBU)/VU*+::]M-F<M1,BI#)J%*<AP$IBF`!*8!#H("`_)#+TU8QL[7\,3C
M_M;D'6]ZR\-W"S%8SVSUAJ5%*OW.30[L\7(6!F4G5=PP4)U/V>A70`4%NT!?
M+KMYNOI-]J<-4KP_71VRBO%FUP.2XVO?XR7=WNV[?W=C<NXW(TRYPL*JPI57
MBZUM!X])"A+X,9K@QQ=/:X8-[,C49&,8=BVCHULDT9M$B(H((IE33333*!"%
M*0@`4I2E````\@!Y,V+@V+@(C;;;E)MR;Q;>UMOA;?&WQG/P4&`,`]8I)"J5
M<4DQ6(0Z9%A(452)J"4QTRJ=.V4AS$*(@`]!$`^1C@X.,>UQ'%]&1O:$WH]C
MVA>!(";S1#M"_`!*#X1[OJ+P"F$`5_5]!]G'P<OP>YQ=WO[1\+-\+##'CPPP
MP_)LY#`;XE,/(\@;E7:'5M/<RJCOJ>H&W*4X7T2[XEV":LG'BN;-HSAY)6&E
M[NV;'0DA3K/<V$5(Q#MFHA+,#`)'9$@5[D0,A'AXT>PU#45TE;Y1=_5':.PM
MK6.\[0F^2;G41MC[&M\A$5V,/<TXG1UCLFN:O5?1$2UC8N+9*)>9-8\"&(8W
M550"_C`,/?B;;4VM6=G<8]>:FLJ*+^S1NZ[38]?W+:D]QJU/?8NKUB(;Q2E@
MY*UOMS56ME7L$J@XBZ\W1<DFTE7*K@J*3,%B`60Z8Y%6S9U9K4;R-Y,[NH56
MKWAW([(UW=)VPN=&6'8V^6FQ-FU39MJ-+0#\C;94QK@:S"-H-`KB1;2<:^2D
MCMW0OP4P#.CPYLVUKIQ0XX6[>C5=EN.S:4UM.;,;NHXL.\+=).IQ;N>.^B2$
M2)%OEGZISKM@(0$%3&(!2@7L@!RMTREY)'Q;=E3X5U%I;(U@+*17N1V3AV<M
MZKQT2K1_M9<E:`JX_8Q'OU.R4>UT']3@%>^GMI?@ZK?^(ROWDX`]/;2_!S6_
M\1E?O)P!Z>VE^#FM_P"(ROWDX!KJ>L.2%M>Z[XFELE9BX%$FX+<9LK'V<\\=
M=4:>D!DU$C0,/W!2D\O:[1^H^3I^;FD[\=70YS[QTQ^&#[Y7/\O'Y;,',7_(
MVW\W2^9#(.^$^5]\^G%#YF/(CL<J>HP!@#`&`4-L+[7G/ZQ3^#'/>W^<,3K7
MH,O9Q%]_JQ+VR,N3G/HU<@8Z=5-0M)><IR%@/`E1*$W<P3[HY(:8\X$X"81Z
M@0"]GV1ZY.NZ?H#Y3Y;]O?WICS6;E7I[:7X.:W_B,K]Y.;400/3VTOP<UO\`
MQ&5^\G`'I[:7X.:W_B,K]Y.`/3VTOP<UO_$97[R<`>GMI?@YK?\`B,K]Y.`/
M3VTOP<UO_$97[R<`M5Y7::Y`<EZM5]:LG,'KS63VR(NMRQ<1=':EDV!3FQ2+
M$J,3.I59`L"V?.T^CLQDE062,`?_``B4^Y;F;RV&ZEW7U:K:*YU>-'"UE)KH
MZ-5O#I)Q?C81VQP>QKV\5J^]&A7F\5M2TZG<=!ILJN-PDGGJ4U\",O@XOQL>
M%<F#T@_'$B6&O?%!DZLRHM>K%:K6B-%PK"B13\TA`MX1C!R"39NB\381:I%C
MI@(BIW?>`IU,8QQ$>L\=D6IWU]8UKV\JSJW5>XG*I*3Q<I-\+_Z=Q;%L(F[1
M=.LK:[IVEM3C3H4J,(P26&5)<"]FWA+0&LOQP6;HJKZ_G6RYTRBL@#\%BI*=
M/ER$6*0`4(!O8'H`B'YF3ATU/N,BAT<'@>_TGQJ]PT]_2O\`LQT]/XK]GN%.
MB'I/C5[AI[^E?]F.GI_%?L]P=$/2?&KW#3W]*_[,=/3^*_9[@Z(>D^-7N&GO
MZ5_V8Z>G\5^SW!T0])\:O<-/?TK_`+,=/3^*_9[@Z(@O>UUUA$59PUUI2%XZ
M:<IF!6?F'7?A'("`@)8]B!0*=Z</844'LIAY0`1]C#:UJ,[:TGYMX-7*_"[G
M)[?MF3TJQI7%U'IEC3QX.[R^T;L_JTTU?T_".T:,34XF?;*7G=2GI*2NJT6]
M<*&V7/&4.LU&LR?8'O1,4/V8PB!>ODZ@&<,[Q3G4UJXJ5&Y3=1MMO%M]ULZQ
MT.$*>E48024%#8EL2Y#/7Z>VE^#FM_XC*_>3F$,J/3VTOP<UO_$97[R<`>GM
MI?@YK?\`B,K]Y.`2`Q4=K,VRK]JDR>J(IG=-$'0O46RYB@*B*;L4&HN2)F\@
M'[LG:#R]D/8P#E8`P!@#`-=[QKH9&;V1II>/T'K6^72D:2W9L>L[!V9=>3E7
M<NXRKRE,5O6IM5LN.%THSN5OCBH+.;(Z2D'9C+Q<.=-ND<>V*8%V/@W2L5(\
M=MGLH%YK2:@:]R#N\%"6S3%IW7>]47**;U^GNV5DIEUWQ=;W<IU)RB]!)^5)
M[Y@PDT7#1(IC('44`RX8!TT[7*]:&18VRP,-8HXJY')6$[%L9=D5RD4Y4W!6
ML@@X0!=,JA@*?L]H`,/0?*.`>N2JU9F21B4O7(*53A%DG,,G)1$>^)$.$"E(
MBO&$=-U2L%D2$*!3I=@Q0```?)@'>X!%6X/M<K_QEZK_`!@UW`)5P!@#`-;+
MUCS^[?B+\<EP_L:CFD[\=70YS[QTQ^&#[XW/\O'Y3,",7_(VW\W2^9#(.^$^
M5]\^G%#YF/(CL<J>IQ'S]A%M%G\H_91C!N`&</I%V@Q9-RF,!"BNZ=*)()`8
MY@`.T8.HB`!Y1S]1A.<LD$Y2?$EB_P`B/*O7H6U)U[JI"E0CPRG)1BN64FDO
M=9Q&T_`/(Y>89SL*ZB&O>>=2S>58K1C;N0`5?.'Y%Q:(]T!@[7:.'3J'R<_3
MI58S5.49*H^!8/%\BX3RI7]A6MY7=&O1G:1QS5%.+@L.'&2>58<>+.3'R<9+
MM2/HB182K%0QR$>QKQN^:'.F/94(1PU451,=,WD,`#U`?9S\SA.G++43C+N-
M8/WSTM[FVNZ2KVE2G5HMX9H24HXKA6,6ULXSFY^3V*&V%]KSG]8I_!CGO;_.
M&)UKT&7LXC(?ZK3_`*HO$!^X'1_V:NV3KNGZ`^4^6_;W]Z(\UFZIFU$$#`&`
M,`8!C8Y:;*W!MC93'A3QU]/5*PV*$96'=^[`8OV3#5^L)-04A;UB3,1%-_<+
M,D0Z"`MU!%#J)>T4_;,E*FYFE:'HVE2W]WGZ.M;4JCA:6N*;N*\>.I';A2AL
M;S+;R8*4>;T:CJVJ:C'<_0,]*O4@I7%Q@TJ-%\4'QU)\"PX.7'#(-4J^2IU>
MO5@DI,3A*]"QL,69L#Y23G)4(YHDT"0EY!7HH\D7?==M900#M',(]`R-+VY=
M[=U;MPA3=6I*66"RPCF>.6,>**X$NX;Y:T%:VU.V4IS5."CFD\92P6&,GQM\
M;/GK^L/_`)6Z\?$KI+["R>=)]C'4[^EEWT0CVF=9_NX]XQ.)?M9?SLG0B.7C
M'GE"@P!@#`&`0YMKZE+?.A^9S7M?]&GS#-:+Z1'E/H#>K#_D?=#_`';[K_&=
M8<XIU_K>OSSJ31NK:7--@;,.908`P!@#`&`,`8!JI\M*!OF%VC>=@_"UR,CJ
M=;MI[+3KD;6JQXMLJA62UV?]&'*[9ZSW3%4>N1DB5[TB7$:U91<JU!0[`@H`
M(`!E]\*F.LT9QKD6MGD]A2KCX1K`M'N-CU7DU4)4L6O%P*K<D9&<JK):-@*P
MASG.HBNT<!$*'.?N2`H"QC`9+\`8`P!@$5;@^URO_&7JO\8-=P"5<`8`P#6R
M]8\_NWXB_')</[&HYI._'5T.<^\=,?A@^^-S_+Q^4S`C%_R-M_-TOF0R#OA/
ME??/IQ0^9CR(['*GJ1QMFKPMRHLG7K`PM$C%.GT$[60IK9L]L*;B)F6<JQ=L
MV;LBJ#M)H^9IG63$BG;2`0[!NO3+RPKU+>ZC6I.$:B4EX>R.U---K@Q3V/NF
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MB-0\UZ6/FKQ?1QSX-RBI_"4'+:X\'NXX/`D'='[<\PK_`&W%Q7GE7S?/3ITJ
MTK;9T<J].DE"-5O-BDD\N5R2EB2ME@;24-L+[7G/ZQ3^#'/>W^<,3K7H,O9Q
M&0_U6G_5%X@/W`Z/^S5VR==T_0'RGRW[>_O1'FLW5,VH@@8`P!@%INU>5L'1
M-X:LX\4^JRFT=I7Y^F^LD#7'C5N76NO"$4\^OEM>."G;,FR:G8[AJH9-5R3M
M"40ZI@IN>C[FW&H[OWF\]]6A9Z/;1PA.:;Z>MQ4::6UOAQDL5%X8\>&KZGO/
M1LM9MM!M*4KG4J\L9Q@TNAI<=2;>Q+@P3P;_`"8W7@F0#F5`A`5,0J9E`*';
M,0@G,0AC].T)"&4,(![`"8?DCFFXO##B-GP6./&>>4*GSMO6'_RMUX^)727V
M%D\Z<[&.IW]++OH@KM,ZS_=Q[QB<2_:R_G9.A$<O&//*%!@#`&`,`AS;7U*6
M^=#\SFO:_P"C3YAFM%](CRGT!O5A_P`C[H?[M]U_C.L.<4Z_UO7YYU)HW5M+
MFFP-F',H,`8`P!@#`&`,`U[?&8G=?T;=/&>^;:LO$JS:^84;:,.ZT'RR9[^N
M==FY:2F*<1CL^N:_TG1;_'-I"N*BG&*34_'N&Y`DB-6P).%04P"0_!QF=W2M
M2O*U:D^+D[Q0<;CVJI%L-2+<FZ_):ELB:$"F&H=?T7>]`K:D73:S($.=Z3OD
M4$)!TY*U;H)@#=(#.?@#`&`,`BK<'VN5_P",O5?XP:[@$JX`P!@&MEZQY_=O
MQ%^.2X?V-1S2=^.KH<Y]XZ8_#!]\;G^7C\IF!&+_`)&V_FZ7S(9!WPGROOGT
MXH?,QY$=CE3U&`,`8`P"AMA?:\Y_6*?P8Y[V_P`X8G6O09>SB,A_JM/^J+Q`
M?N!T?]FKMDZ[I^@/E/EOV]_>B/-9NJ9M1!`P!@'`]*Q?I/T)Z28>F?,?2GHC
MSQOZ3]&=^+7TCYAWGG?F/G0"GWW8[OO`[/7KY,].AK=#YQDET&;+FP>7-ACE
MQX,<-N&..&T_'2T^DZ'-'ILN;+BL<,<,<.'#'9CP8EO6B.+M"T/8-GW:+D)^
MX["VW:Y"QV^_W5VA*6IRR6<F6B:L@^2;MR-J]`(B":"*9"@;L@8_42E[.S[Q
M;WZEO%:VFGUHTZ&F65%0IT:2<:::6$JC6+QG-[6V^3A>.!T3=NQT2XN;RG*=
M:_NJKG.K4:<VL?!@G@L(QX$E[O$7*9JAL(P#YVWK#_Y6Z\?$KI+["R>=.=C'
M4[^EEWT05VF=9_NX]XQ.)?M9?SLG0B.7C'GE"@P!@#`&`0YMKZE+?.A^9S7M
M?]&GS#-:+Z1'E/H#>K#_`)'W0_W;[K_&=8<XIU_K>OSSJ31NK:7--@;,.908
M`P!@#`&`,`8!AZF:;3O$AV!R"MK"@;%J5-TI"[GX=0U_8;-A*LCR6=&7`-EU
M)S6TJ_8YFEU+6NVJW%N8*R&40D3R[)98C8[0HD7`DWPLG<4XT_M]O*/-V+[T
MAN0MUK_*%IONQT:UW2+WA"5ZGL'[6.GM8059UU+TU>DI0KF)=Q4>T(\:K@NX
M2([47*`&3C`+;=]<H]=Z`E]?U*?2D;#L':CB?3HE&A'=<CI&585)BWD;789&
M;N$[6*G7*U76SUN#EX_?H$%=TBBD"BJA28!'EVYL5JG304UIJ;:MZV+$Z:#?
MU^HE")09V1UUJ]1[(1["5G)E6\L*O,2U@=1#P(J.B'LB[D"M%CIE[!`,8"YK
M5^RJ;N37%$VSKN83GZ'LFI0%WI\TFBNW+)URS1C:7B7@MG*:3EJHLR=$$Z2A
M2J)GZE,`&`0P#HMOJ)^UZ`+WA.T&R]6=2]LH"'_S!KOLAUZATP"4^_0_=DOW
MPGZ>`._0_=DOWPGZ>`._0_=DOWPGZ>`:VOK'1R'UOQ&[!R'Z;DM_7LF*;IUI
MJ73KT$?D9I._'5T.<^\=,?A@^^-S_+Q^4S`G%_R-M_-TOF0R#OA/E??/IQ0^
M9CR(['*GJ,`8`P!@%#;"^UYS^L4_@QSWM_G#$ZUZ#+V<1D-]5L.0G*'Q`1.8
MI0]H.C_*8P%__.KM\D0R==T_0'RGRW[>_O1'FLW4>_0_=DOWPGZ>;400._0_
M=DOWPGZ>`43LFV2]-H-PM57JDAL&QU^OR<K"4F$<LT96SR31L=5I$,E7BR*!
M%72H`'41$W9Z]DIC=DHY#2K2WO\`4J%G=UX6UK5JQC.K/%QIQ;VR>&+V+_Y:
M6TL]0N*]I8U;FVHRKW%.FY1IQPS3:6R*Q[O_`.,7L+->'O'FYPL[9.4G)%^A
M,<F-N1Z*+N/(X%2'U!0SG*[BM8UE`53I(>9E[!GZI>HJ+E[/4>ASJ;SOOO1I
M]Q;TMT-UEDW4LI-J7PKFMP2KU'QX[<BXEM[B6H[I[OWM&O4WEWA>?>*ZCM7P
M:%+AC1@N+#X3XW[K>0#OT/W9+]\)^GD;&]#OT/W9+]\)^G@#OT/W9+]\)^G@
M'SNO6'3%-XMMW,4P&`=*Z3Z"40$/)#2?YH=0SISL8ZG?TLN^B"NTSK/]W'O&
M)U+]K+^=DZ$1R\8\\H4&`,`8`P"'-M?4I;YT/S.:]K_HT^89K1?2(\I]`/U8
ME5,G@^Z&`RA"C[=]U>0QR@/]YUA_,$>N<4Z_UO7YYU)HW5M+FFP)WZ'[LE^^
M$_3S#F4'?H?NR7[X3]/`'?H?NR7[X3]/`/8`@(`("`@/E`0'J`A\D!#V<`_<
M`8`P!@&O?8=E^':^W]N6)U;XG^Q.!>R9[8.QI'>VE(S9NKM<5Z;V+3)Z,I-U
MOWM)W_1+8SI5CM+I-!3SZ&4C1L2'9D2I+]!<"!E0X357BS3]0/XWB=L>!V]3
M7]ZM%BO.SXW:37<U@O>UK"JVD[E9M@;#;RLNI.7:4,N@=SWBA`10[E-)))`J
M1"@7@8!8SRBX>CO';FC=]UI]K[X0=(0NSZ@RKFW*(78>MK14=L,8%&>;R4,G
M(1C^-G8F0K#-RR>MU1^4!9!0AB*]HH%M6LO#-O?'MLBIHG?C!&8M/'QUQ]V@
MYV115[)%*1Q[]?=@0ELUO$15DB`JBM,=;-EHZ,A5U7D82*(S1,("V$R@&231
M.GZQQ]TOJO1M+4>K534E`JNO:^XDE"*R+N,JD,TAVSR043(FD=\\(T[U42%*
M3O#CV0`.@8!2.Z=?49]&Q<N]J4`[DY#9&L"/7SB-;J.G1%[W7FRQ5UA)VU`5
M;"*9NH^4@],`K_X(=7>X&J_69G]#P!\$.KO<#5?K,S^AX`^"'5WN!JOUF9_0
M\`UTO6'J94ZMKOB8M7*[#PBSK<%N2<*QK%!HHLD6GI'*FJ9(A1.0#^7H/YN:
M3OQU=#G/O'3'X8/OC<_R\?ELP;Q?\C;?S=+YD,@[X3Y7WSZ<4/F8\B.QRIZC
M`&`,`8!0VPOM><_K%/X,<][?YPQ.M>@R]G$7X^K#U:MVCD[SZ1L<'&3:3:A:
M2%N229HNRH"I-W,5!2!4I@(*@IEZ]/9[(9.NZ?H#Y3Y;]O?WHCS6;EGP0ZN]
MP-5^LS/Z'FU$$$7;F5XX:$UQ9=I[*K=/A*K669G#A4T.R.\D'BG4C"&B&G8!
M1_,2KD2HMT">4YS=1Z%`Q@R^A:'J6\>J4M'TJFZEY6E@NY%<<I/BC%;9-\"]
MLQNKZM8Z'I]34]1FH6U-8ONM\48KCE)[$B,.)L+8-LZV<[)W7HW7>NPN,^^F
M]:4UI"=FR0NM71$1K9;P9P!D36-XB`N#=T5/HDJ4#$*;Y4,OOGIF[^BZJM*T
M"O4NN@IJ%>J\,DJZQS]%AMR+@VX[4\&S&[KW^LZII[U#6*,*'33<J--8YXT7
MXG28_#?#LPV/:BZ#X(=7>X&J_6=G]#S439!\$.KO<#5?K,S^AX`^"'5WN!JO
MUF9_0\`?!#J[W`U7ZS,_H>`?/H]8&A(>O>+!=8R"C643'IZ9TLJ1FP;IMFY5
M5H>2,JH"20%(!U!`.H_F],Z<[&.IW]++OH@OM,ZS_=Q[QBP2_:R_G9.A$4O&
M//*%!@#`&`,`AS;7U*6^=#\SFO:_Z-/F&:T7TB/*;ZWJS^O:-8?")T5(SE3@
M95^K=MT@J\?1K9PY4[&RYY,G;54(8YNRFF4H>7R``9Q3K_6]?GG4NC=6TN:9
M\/@AU=[@:K]9F?T/,.9,?!#J[W`U7ZS,_H>`/@AU=[@:K]9F?T/`*\9,FD<T
M;,&#9%FR9HD;M6K<A4D&Z"10*FDDF4`*1,A0Z``>0`P#E8`P!@#`,(GB4TEM
M&;ZT]=YVH7_76F9VA7N(VCR2XQ<8ZMO[D*-W;RU7<4/6EA,\U=M^>J.LYABF
M[?*23:O/3N)!D@T4<-4C=5`+J_#1=[,=Z(LWM]@[.SK+;:UM:Z5MFQ-1U_1>
MU]FZ<29P@U:^;1UA6X:M,H&U/WAGC4JZL5$/)-@T;O'#%JJN9/`,B&`,`8`P
M"*MP?:Y7_C+U7^,&NX!*N`,`8!K9>L>?W;\1?CDN']C4<TG?CJZ'.?>.F/PP
M??&Y_EX_*9@1B_Y&V_FZ7S(9!WPGROOGTXH?,QY$=CE3U&`,`8`P"AMA?:\Y
M_6*?P8Y[V_SAB=:]!E[.(R'^JT_ZHO$!^X'1_P!FKMDZ[I^@/E/EOV]_>B/-
M9N96ZVUJA5B>N=QFF%=JU8BW<S.S<FN1LQC8UBD99PY75./L%*7H4H=3G.(%
M*`F$`'=+*RN]1NZ=A8TY5;RM-1A"*Q<I/8DO9@EM>P@"ZNK>QMIWEW.-.VIQ
M<I2;P22X6_9MX"))6FZ)Y7TS5EZEXB)V53&4M![4UR^=@_)'&D46Z@Q4LI'J
M&:E=IE37,!F[M(Z?:#Y8G4,S5&^WBW-OKS3Z,YVE_*$[>NEAFRM^%'-MPX/&
MBT^XS%U;31-Z+.VO:L(W%FI1K4F\<,</!EALQX>"2P[J)]]C-;,X,`8`P!@'
MSMO6'_RMUX^)727V%D\Z<[&.IW]++OH@KM,ZS_=Q[QB<2_:R_G9.A$<O&//*
M%!@#`&`,`AS;7U*6^=#\SFO:_P"C3YAFM%](CRGT!O5A_P`C[H?[M]U_C.L.
M<4Z_UO7YYU)HW5M+FFP-F',H,`8`P!@#`&`,`Q1<U.>VP](TRX5BJ:WGM:[<
M;7"`A*U9MA5B/N]"GJ%*S!64G?\`7RT'=:Y6;;:F,<8%6=4G9RKR#M81(43B
M4"J`7(\%MB\C=G:2&R<EJP6"M?MKF652F5Z676,S?*`B@P5@[K8-6DNNQB:^
MDI)VNZ1(Q";?`LU;I.NJ8..Z*!>9@#`&`,`BK<'VN5_XR]5_C!KN`2K@#`&`
M:V7K'G]V_$7XY+A_8U'-)WXZNASGWCIC\,'WQN?Y>/RF8$8P0!FVZCT_BZ7S
M(9!R\9\K[Y].*#2HQQ[B.PZA\D/T<_6#/3-'NH=0^2'Z.,&,T>ZAU#Y(?HXP
M8S1[J'4/DA^CC!C-'NH=0^2'Z.,&,T>ZBAM@B`UYST_Y%/X,<]K?YPQ6LM.R
ME@^+_H9$/5:?]47B`_<#H_[-7;)UW3]`?*?+?M[^]$>:S9DY*\:]D<G]M:^J
M5UGXF-XB59HA;[E4(EX]3M.TKZPD1&+K%G*"22#>EL42D<"":AA6-VRF`#"0
MR<W[J[U:5NEHMS>V%*<]]:TG3I59)=';T7'PJE/C=5O%;5LV-;,4^4MXMWM0
MWDU2A:WE2,=U:252I3BWGK54_!A/BZ-<.Q[=O'AA?*P8,8IBSC(QFVCXZ.:M
MV+!@R03;,V3-JD5!LU:MT2D20;MT2%(0A0`I2@``'3(]J5*E:I*K5DY59-MM
MO%MO:VV]K;?"S<X0A2@J=-*-.*222P22X$EQ)'+S\'[&`,`8`P#YVWK#_P"5
MNO'Q*Z2^PLGG3G8QU._I9=]$%=IG6?[N/>,3B7[67\[)T(CEXQYY0H,`8`P!
M@$.;:^I2WSH?F<U[7_1I\PS6B^D1Y3Z`WJP_Y'W0_P!V^Z_QG6'.*=?ZWK\\
MZDT;JVES38&S#F4&`,`8`P!@#`&`83+%X>VH-0\K'O*;=G)C5%<I%GV59KL#
M;8]-HM0VI>'MEC9!LZT_?.0=JNA1V'I.-9R!RMJLI"D*FT:M4A4[+?MF`R<<
M=8CCM"4=\RXQ2=`?ZV/991V=MK&WLK;2HBP.DF:LI&PQ(J9F(6M)%(*2@QK+
MS9L@*G;*B05!$P$]X`P!@#`(JW!]KE?^,O5?XP:[@$JX`P!@&LUZRM/PD!J[
MB.M-2Q(COMNW<(]92/=R*:[Y.EMQ3:B@S$%`,H!NH=1`!`HAUZ],\*VY&O;]
M8:9H$*<[F#S24ZD:>Q[-CEL;QXB4.R[M2W6[*-3N-=WIJU*5O4HJ%-QI3JXS
M3QVQAM22VXFJ\&WY0@`0M\.0I0`I2AKF>`"E`.@%#Y?KT`,K'\-':1!9584,
M/YFF3#4_&WV8U9N<M:N<7_\`PU\%[27$C]^&&5]WRG^'4[_UY^O\:^TGZA;_
M`-33/Q_FOV7_`-ZN?Z&N/AAE?=\I_AU._P#7C_&OM)^H6_\`4TQ_FOV7_P!Z
MN?Z&N/AAE?=\I_AU._\`7C_&OM)^H6_]33'^:_9?_>KG^AKCX897W?*?X=3O
M_7C_`!K[2?J%O_4TQ_FOV7_WJY_H:X^&&5]WRG^'4[_UX_QK[2?J%O\`U-,?
MYK]E_P#>KG^AKGH<[6>O4%6KJ\F707(*:J1M<SH@8I@Z"`?+]0-\@0\H8_QK
M[2N*PH8_S-,H_P`:W9=)8/6;EK^1KF7KP(=$[U-R,VR\U!M=&EU:^L-2W;:D
MRWADFML942C3<XO&5ME'3`NQ[-]F'RC<_:3['F:*ACB/3L&DW0^S^V[+]UZ]
M]V@4:5;>*[C.E9VD:F>,$U@[FI*&'BX^`D]CPXWLY1[4^U&AVO;ZT(=GM>M'
M=ZU4*EU=RI.DY3QQ\WIPGB\'AX3?#B]F"V[R61L5&`,`8`P!@#`/G;>L/_E;
MKQ\2NDOL+)YTYV,=3OZ67?1!7:9UG^[CWC$XE^UE_.R="(Y>,>>4*'42M@@H
M/NO3,O'QG?E4.B#QP1(RB:(`*RI2>4_<H@8.V?IV"]?*(9:W5_966'G=6G3S
M8X9FEBEPOD7&^!<9<4+2ZNL?-J<ZF'#E6/#P+E?$N%GI<VBMLUVK9U/13==Z
M1LHT(J\2*#A-Z;LLSI*]KN1([,/1(1,`*#^IZY^*FI:?1G&G5KTHSFDXXR6U
M2\7!\'A<6W;Q'ZA8WM2$JE.E4<(MIX)[,OC8KAV<?<XSO<OBT&4*D.;:^I2W
MSH?F<U[7_1I\PS6B^D1Y3Z`WJP_Y'W0_W;[K_&=8<XIU_K>OSSJ31NK:7--@
M;,.908`P!@#`&`,`8!KX^+U8J%IWDYQ7Y`WJ?X82;2OZJW/0`U=R]AMRWMO(
MH6N?H#KV\T:G:IU=M1"O/85]'H1[N=D&1"*IR)&)#@=4N`7]>&5N"J;KT#/V
MNG5CCM5HIAM&U5ARRXQTW8M(UX:9@VD,C+D>Q.S]9ZHL@VY@[4%M(&]%BD04
M2)@J8Y#E(!D4P#%QXH%\WNQU:ZUEJ.N[S@*O:]?[0M&U=^:/C3O;=K^`I=6=
M2$/3*<\C9%O.UZZ;#G3(H^F$43%BHEN[43,#H[?H!896]XR-\8:]1Y,[1W=J
M2@D\*[4FQM/NYJX7O4<U=>03MI/1^T[BI+PDLPE;UM*"]'P*T;&/%7B@H2GG
M`,E3.3"`&:GAU,;<L/%#CA.[\2>([JF-*:VDMI)R3%.+D_;P\JD6O83RL8DD
M@E'RJD@<YG2!2$*DN)R@4H!T`#E[IFK<E'Q;5K1A?1Z&R-8"TD_;1$,_/3$O
M==.F7S1=,RS?OE_V/J;KV>O:'R!@%?>V?87X,#>_."^A8`]L^POP8&]^<%]"
MP![9]A?@P-[\X+Z%@&JMZU!*V21TGP]+.50:ZFGNRZ&06].Q\J*Z@TA$!3!-
MD0ITA*7Y;M#Y/S/9R6>R'KZK]&OE$>=HW5-/GOO&M#3=[W6!@F42<D/+HLT$
MTVKF4BVCA\1`I>A4%70I=XY*F`?*F/U,`>3J.==TZTXP6.W8<XUJ<,[:V;2J
MO\QUO_\`1ZO]9VGT'/WYQ+N(\>CC[8_S'6__`-'J_P!9VGT''G$NXAT<?;'^
M8ZW_`/H]7^L[3Z#CSB7<0Z./MC_,=;__`$>K_6=I]!QYQ+N(=''VQ_F.M_\`
MZ/5_K.T^@X\XEW$.CC[91=_Y$7QU6)%BQ3@X91Z@JW4D8Z(9)R"*)R""@,US
M(B+54Y1Z=X7Y<H?J1`?+EI?756-O+)X+:X>,N;6C3E66;:L3,GZIC8[>;?O/
M91K&O[FJWU[HUDF5]8T6AHYFE.7A1%L@I*F6$6YCK*&`I.A2FZ]0ZFSCSM,J
MU*NLQZ24I98X+%MX+'@6/$=+;BTZ=/399(J.+3>"PQ>'"_;-W[VS["_!@;WY
MP7T+(V-X'MGV%^#`WOS@OH6`/;/L+\&!O?G!?0L`>V?87X,#>_."^A8`]L^P
MOP8&]^<%]"P![9]A?@P-[\X+Z%@#VS["_!@;WYP7T+`/GU>L"NY-[XL%U<2\
M1Z#>FTSI<IH\9!M)]E,L/)`FKYTT*5$>]#_X?9#IY?9SISL8ZG?TLN^B"^TS
MK/\`=Q[QBP2_:R_G9.A$4O&//*%"$=E4ZPV*P(O8TDTT9DILS!DDZC(1C*=7
M>R;DIE(B;+,KI,UZLLBF4P@D`K=[VOEBATZZ=O%I-_J%\JUOTT**LZE//0E"
M-5RF]M.ITC471:2>SPL<=J-FT74;.SM'2K]%*IYS">6K&4J:C%;)PR)M54\5
MMV88;&<6PU6V2E$BJ>2$,W?-(2M-U&<,\AD-?.9"+5:KBSE$W9PL7H5BHV`!
M(B;M*%`.P(]<\M0TS5+G1*6DJBXUXT:*<:<J:M7*#B\LU+];T<7'@B\6N!GI
M9W^GT-4J:BZN:E*K5>,U-W"C)-8QP_5YY)\+X'PD[E$XE(*G8[SL$[SN^O=]
MYV0[SN^U\L"?;Z]GKY>GLYNWA8>%AFPVX<&/'A[7<-5>&.S@/W`(<VU]2EOG
M0_,YKVO^C3YAFM%](CRF^IZM!-VYCX16BD(BCFFV9;MNGL/PLL3'`KUV7/B;
M^*NDS+)]DXB7R^SV>OL"&<4Z_P!;U^>=2:-U;2YIEEY2\T:MPXU#/[IWK74*
MQ5(8H-V#,ETKKBP6R>7*;T=5ZG$#W2\S.R)RCV4B"!4TRG54,1,AC!70=`U+
M>34H:9I=-SKR>U_!A'CG-\45[[V+:RNKZO8Z)8RO[^>6E'@7'*7%&*XV_P#Y
M>PU/]/\`K'G(&+Y>V39NX(-.6XNW99O!ETK!E9^D-6UYBJN6&L]7FE4DEIBU
M)E7%29*X."$D41*D5#ND.ST-J?8WI4]W866F2PUZDG+II8X59/AA)<$8O#"&
M&V/"\<60Q8]IFH1UN5U?+'2*C2Z-<-.*X)1?'+XW%+BPP1M07SQ"-':RXWM.
M75WLU)A>.LDPA7T1LLE^C)=A.+6)9-I!P4!$P4?*6&?MTG(*>:I0[)HO)F=E
M.B"'>$,4.8]3I5M&OEIFI0G2U&5948TLK=251XO+",4Y2>5.>,4TH1<WX*;)
MYT^4-5MG>V$H3LHTG5=3-&,(TUAC*4I-1BL6H^$UX34?&:1TL+XJW`B6XN2?
M,17D54HS1E?MGP=6:=D(RX-;'`[0!RBS^"YYK=W66NSS;&6<N$P;PA87THZ2
M4(JD@=(Q3C^;M.Q5I*O@U?-*WR?K.FEBTXT^CS9I0RRZ2*VT\LG445%X+9J[
MG<4Z6R=I'-6S_J^BCLPG-U,JC&6*4)/9-M*#DVD7#\9>5O'WF-K4-N<;=E16
MS:(2>F*I(2#./G8"7K]JKRX-INKVRI6R*@;=4;)&*'(*S&38M'14U"'['8.0
MQO>M:UZ%*E7FEYO7IJ=.<6I1G%MK&,HMQ>#3C)8XQDG&2331XTKFC5JU:$6U
M7HSRSBTXRB\,5C&23P:VQ>&$EMBVB%8[Q-^"4MR;_P`GD=R+J3KD$:Q2E+1J
M*<7;@@'E]@X\96:UQ'[-/72ZLD=E1$>45'5=0FE)IN!3%.V*8IBA:Z=..K4:
MEQI[52C3A5FWCAFA0>%:I34L'5ITFGTDZ>>,,LG)I1DU[WW_`*V487WZN4IT
MX[?@RK?,QGACT<JNSHXSRN>:.5/-''N*=XB_"^^U?=5UJ^]:^]JG'RLR5WVE
M..86W1+&*HL7(6:'<7NO'EZ\Q/?Z0O-4R58M9>OEDX]Z]8*H-U5%0`@^;KPC
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MZ5<Q@,DF`>)BE.4Q#E*<ARB4Q3`!BF*8.ABF*/4#%,`]!`?9P#@N8F*>E:%>
M1D>[+'K)N&!7+-LN5BNB'1)9H"J9P;+)`'0IB=D2_F#@'88!%6X/M<K_`,9>
MJ_Q@UW`)5P!@#`-37UK_`/N/X:_'A=O[#(Y+/9#U]5^B7RB/.T;JFGSWWC40
MCOY,E\Z+G6T?$7(<Z5?&?*=A@\Q@#`&`,`I:W_4A;]:?YG+.^]'9=6?SR-A[
MU07_`%`^(+]PNC?LS=\Y"[2>N%R,Z3W(ZM?N&]ID<FZC`&`,`8`P!@'SMO6'
M_P`K=>/B5TE]A9/.G.QCJ=_2R[Z(*[3.L_W<>\8G$OVLOYV3H1'+QCSRA08`
MP!@#`(<VU]2EOG0_,YKVO^C3YAFM%](CRGT!O5A_R/NA_NWW7^,ZPYQ3K_6]
M?GG4FC=6TN:9:^6NJM>[,TALE:]U"NVM2KZWV++0!I^%C9@8B1"HRA@>QPR#
M9P+)UU1+^R)]D_RH>7R9^=%N[NUU&BK6K4IJ=>FI99..*SK8\&L5[3/35+:W
MN+*KT].$\M*;69)X/*]JQX&?,UXEQ<?.<I>.$++-&\A%R^\]81LDQ>(IN6CQ
MB]N44W=-7+=8ITET%T3B4Q#`)3%'H(=,[9WCG.GN_?5*;<9QM*K36QIJ#P:?
M$SEC0XQGK%I":3@[FFFGM36=;&C<_P#'KIM.U%PBX^0]&K<=J&J5WGGQFN!M
M^0U5._H?#I>'N+J<7Y(7B@0#`L?;*K`':BQ=LWOFT>JK)D4<KI@4##P,[RZG
MOQH-_7NG0N*-S6FKJK^LC%JUJPC;M3:CC=*;I1E.<53VR4E)([!IVE!;I:[:
MT;?IJ533U'S6FU3E44KBBW4BTF_]O@J\XPC*<XP:2:Q:P$2UH6>\2-Z;#4O+
M:Y1LEX^FF]L__P!O$-09EMHELNTA&4@MRM)I)@$I4W6O-:.F!J>[9(R*E:</
MI`JRL@!R"8;S3G4M);H2GFTBI;W>N33K85,[GTJC)J>11CJT:BC1Z1PZ*-"4
MJ;QELL[Y1OI[T0?_`+15=%TJGDI-4W&--TET*<<V:6G.$JU7(IU:B>6<<$9C
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MHPM=2TS1M.C!5=`_XG?4-1S+;97%O&K"WMT\5*VE*MT=-TH./G/32E/.GLO=
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MO"M<6NY=@EVS[0?2YJ"6J(BW,/H3S@)L09]/*!\S3LJ"T=:WGJ=`TUERK/TB
MUE:+P9O$Z=].GXW18PR](L#55JDW>O3NCI[(J>.?P>A>DRU?#@^=Z"+HN'`J
MC4\>C>):SXI/&KE-<YZU37(G?O%79'$@]G7G-6Z\N.G=#UW<&LH]QYF1_#Q$
M_N&PP,=L-V)"@7LL9R'=2())I*(JG$G3$F>,DOA+)U=MQ%B(ZD3,]+4Z,N%A
M:5XD_P`8XKBLXCV9T(MZJ@VI,&YD8FWM7CIV=W[9T'L@695<'.+E8Q!-@&37
M`&`,`8!%6X/M<K_QEZK_`!@UW`)5P!@#`-37UK_^X_AK\>%V_L,CDL]D/7U7
MZ)?*(\[1NJ:?/?>-1"._DR7SHN=;1\1<ASI5\9\IV&#S&`,`8`P"EK?]2%OU
MI_F<L[[T=EU9_/(V'O5!?]0/B"_<+HW[,W?.0NTGKA<C.D]R.K7[AO:9')NH
MP!@#`&`,`8!\[;UA_P#*W7CXE=)?863SISL8ZG?TLN^B"NTSK/\`=Q[QB<2_
M:R_G9.A$<O&//*%!@#`&`,`AS;7U*6^=#\SFO:_Z-/F&:T7TB/*?0&]6'_(^
MZ'^[?=?XSK#G%.O];U^>=2:-U;2YIG(VM`/[7J_9%6B@1&4LM#M]?C?.#F3;
M^?S5?D(UF+A0A%3IH`X<E[9@*82EZB`#[&6%G6A;WE*O4QR0JPD\.'",DWA[
M>"+VYIRK6U2C##-*$DL>ZTT:1O'3P%.>&MN06D]@60=,^U^A;8HMOG3,+O8G
M#PT17+,PEI`&""M(;IN'9FK4W=$,=,IC]`$Q0\N=(ZSVP;IW^D75C0A>]/6M
MYPCC3@EFE%I8OI'@L7MV$(Z9V;;PV>HT+NK*UZ*E6A-X5)-X1DF\%DX<#>H<
MM6KYLLT>MD';1RD9)PU=HIN&ZZ1PZ'2705*=)5,P#T$I@$!SF1I26#6*)V4I
M1>,6TSB%A88D9Z$)$QA(84CH#$%8-2Q@HJ'%0Z/F`)`U[HYS"82]CH(CURLO
M#\?;P<.W@X/R8+#N8%(MP\39P\&SAX?RXO'NGX2#A$VS!FG#Q9&<6L1Q&-21
M[0K:.<)B<R:[!`J()-%DS*&$IDP*8!,/0?+E6VY*;;SI8)\:6&&&/<PV<FPI
M@LKAAX#X5Q/;CP<NWEVGM)%QB<@K+DCF!)9=`K5:3(S;ED%FI!*8K95Z"8.5
M$"F(`@03"4!`/)Y,HMF*6Q-XOVWP8ON["K2DTY;7'@]K'N=PI5?6&M7,E=YE
MSKVD.9?9D-'5S8\JXJD$M(W^O1#)_'1,#=7JK`SFTPL9'RKI!NU?&7011<JD
M(4"J'`WXE3ISMY6DXIVLYN<H-)PE-QC%RE'@<G&$8N36.6,5C@D>D:U6->E<
MQE)7-".6G--YJ<<V?+"7#%9VYX1:6;PN':4;_EKX[?!=\!_P#:;^!?SKS[X)
M/@RI?P:>>^D?2_GOM&]"^UGSSTM_&N]\V[SSC]DZ]ORY>>>7?[6I\WT?C/Q,
M<<G#XN.W#@QV\)9^:6N./14\>DZ3Q5X^&&?@\;#9FX<-G`6+6_P@>-=OWQ?N
M29]E\JX#;6Q9M>=F9ZO\A;8BC$K*E222CZ:QE$I9&DPC)!!--!G%^:H)$3*`
M%ZE`<MBX+[M&Z79Z+I[BG,MD;CV@@XF74R%@W=L:7V;;&PNF[-MZ*:3\R4CE
MO"-BLP,BU*'83444,'E..`3-@#`&`,`BK<'VN5_XR]5_C!KN`2K@#`&`:FOK
M7_\`<?PU^/"[?V&1R6>R'KZK]$OE$>=HW5-/GOO&HA'?R9+YT7.MH^(N0YTJ
M^,^4[#!YC`&`,`8!2UO^I"WZT_S.6=]Z.RZL_GD;#WJ@O^H'Q!?N%T;]F;OG
M(7:3UPN1G2>Y'5K]PWM,CDW48`P!@#`&`,`^=MZP_P#E;KQ\2NDOL+)YTYV,
M=3OZ67?1!7:9UG^[CWC$XE^UE_.R="(Y>,>>4*#`&`,`8!#FVOJ4M\Z'YG->
MU_T:?,,UHOI$>4^@-ZL/^1]T/]V^Z_QG6'.*=?ZWK\\ZDT;JVES38&S#F4/S
MH'R`_0P#]P!@#`&`,`8`P!@#`(=W'N$FG8,L\KKC:.Q&R;25DI%OK*LM;"ZB
M8N%:"^?OGY7TM#(%'N`$$$$U%'+DX"5-,P@/0"WF2\0K0BD/3IK7S/8VYV]Q
MT5&<F4VNJ:4[GY&!T7,@IZ'OMC92+F%5CTIE1LX391Q>\E7AVC@$FQNY.(`7
M;Z\O]/VM0Z;LW7TXSLU%V!6(2XU"PL!4\SFJW8XYO+0\FW!8B2Q$WC!T0_9.
M4IR=>AB@8!``*<V\435VO@4!$?A+U7Y``1_^H5<#\S_B.`2I@#`&`:FOK7_]
MQ_#8?S/APNW]AD?TLEGLAZ^J_1KY1'G:-U33Y[[QJ(1W\F2^=%SK:/B+D.=*
MOC/E.PP>93%PGW%:@74FSCG,K(&4;LHYFW;.G1!?/5`00</P9I++H1;,3=ZX
M4`H]E,@@'E$,QVK7U33K&5S1IRJU\5&,4I/PI/!.65-J$>&3PV)=UE]IUI"]
MNXT*LU3HX.4FVEX,5BU'%I.3X(KNLABL7^?]J$PT/+R-FLOP@3=2;6-:NR!6
M<0S(H!QFG[-G&%[IE%M@4%!$2"<ZG=I''J(CFH:;KM]]E5:3JU+G4?/ZE"-5
MTI9:<<?G)1C#9&$<<L<,6\L7PFQWVDVGVC3J*G"A9>:0JNFJD<9OXD6Y;92>
M&:6."6,D2%I^?>677\+)2,HZFI$%95F]E'C46CAXHREGK9)95(&S5$3F;)$Z
MBF0"`/D]D!#,[NG?U=1T&C<5ZLJUQC.,IRCE<G&<DFUA%<"7`L.(Q&\5I3LM
M7JT:-.-*CA!QBGBEFA%M+:WPM\+Q),S8S"E+6_ZD+?K3_,Y9WWH[+JS^>1L/
M>J"A_P#R!\04?S/:+HP.OY\Q=^GZ/3.0NTGKA<C.D]R.K7[AO:9')NHP!@#`
M&`,`8!\[?UA_\K==_B5TE]AI/.G.QCJ=_2R[Z(*[3.L_W<>\8FTOVLOYV3H1
M'+QCSRA08`P!@#`(<VU]2EOG0_,YKVO^C3YAFM%](CRGT!_5AP__`,?-#?\`
M&[[K$/\`C_\`,ZQ!Y/\`[0SBG7^MZ_/.I-&ZMI<TV!<PYE!@#`&`,`8`P!@#
M`&`,`LMYIZ3Y`<@:?6]9ZEV'3*+KF<DWR6^XN:+;8VT[)H1V?=!KFMW6IK@_
MHL195SF2FWC=%1^O'"9LV5;"J=4`(7EN&FYJ_?Y#9^EK/I6A2FP.*E3XLWV@
M/ZQ:'^O*5%:^D;0XHEKU.$8\BI,Q8"-N;YF>(D")-G*:3<Q5D1(<#@7M<?-,
MP'';1FHM#U5Z]DZ[J#751UW$2<D"99"39U2$9PY)-\1']A3=R`M164(3Y0AC
MB!?(`8!3&ZM>TQ]'1<N\@&KF1?[)U@5VY.L]*=8JUZKS94#`FZ(0O;;F$H]`
M#R#\GRX!7_P1:X]RS/\`I,A].8`^"'7'N69_TF0^G,`?!#KCW+,_Z3(?3F`:
MJWK4%,K%6TIP]6@(A"-5=;LNB2YTE7)Q43+2$3@00775```WE\@=<EGLAZ^J
M_1KY1'G:-U33Y[[QJ;QW\F2^=%SK:/B+D.=*OC/E.PP>9^@(@/4!$!^2`]!_
M]V5X.`H>I!%%MWGFR23?OEE'"W<)D1[YPL(&675[L"]XNJ8.ICCU,8?9'/S"
M,:>/1I1Q;;P6&+?"WAPM\;X6?J4I3PSMRP6"QVX)<"7M+B1^(((-4BH-D$6R
M!!.)$&Z1$42"H<RAQ(DF4I"B=0XF'H'E,(B/E'*0A"G')3BHP7$E@MNU[%W7
MMY1*<YRS3;E/NMXO\K/;GZ*%+6_ZD+?K3_,Y9WWH[+JS^>1G^]4DJU?M&_>?
MR4]&(R2;:C:0%`JJCA/N^\F;H*G3N%DNO;%,OL]?8SD+M)ZX7(SI/<CJU^X;
MQGP0ZX]RS/\`I,A].9')NH^"'7'N69_TF0^G,`?!#KCW+,_Z3(?3F`/@AUQ[
MEF?])D/IS`'P0ZX]RS/^DR'TY@#X(=<>Y9G_`$F0^G,`?!#KCW+,_P"DR'TY
M@'SZO6!82*KWBP76,AF:;!B33.EEBMTC*G*"JL-)"H?M+**'ZFZ!^;T\F=.=
MC'4[^EGWT07VF=9_NX]XQ8)?M9?SLG0B*7C'GE"@P!@#`&`0YMKZE+?.A^9S
M7M?]&GS#-:+Z1'E-]3U:#7M-L/A%:*D9B!;/GJMVW2"CA19X0Y^QLN>3+U*D
MY3('1-,H>0`\@?)SBG7^MZ_/.I-&ZMI<TSX?!#KCW+,_Z3(?3F8<R@^"'7'N
M69_TF0^G,`#J'6X^0:LSZ#_^)D/IS`*^9,FL<S;,&2)6[1FBFW;(%$QBI(I%
M`B:91.8QQ`I0Z>41'`.5@#`&`,`8`P!@#`&`,`BK<'VN5_XR]5_C!KN`2K@#
M`&`:FOK7_P#<?PU^/"[?V&1R6>R'KZK]$OE$>=HW5-/GOO&HA'?R9+YT7.MH
M^(N0YTJ^,^4[#!YC`&`,`8!2UO\`J0M^M/\`,Y9WWH[+JS^>1L/>J"_Z@?$%
M^X71OV9N^<A=I/7"Y&=)[D=6OW#>TR.3=1@#`&`,`8`P#YVWK#_Y6Z\?$KI+
M["R>=.=C'4[^EEWT05VF=9_NX]XQ.)?M9?SLG0B.7C'GE"@P!@#`&`0YMKZE
M+?.A^9S7M?\`1I\PS6B^D1Y3Z`WJP_Y'W0_W;[K_`!G6'.*=?ZWK\\ZDT;JV
MES38&S#F4&`,`8`P!@#`&`,`8`P!@#`&`15N#[7*_P#&7JO\8-=P"5<`8`P#
M4U]:_P#[C^&OQX7;^PR.2SV0]?5?HE\HCSM&ZII\]]XU$([^3)?.BYUM'Q%R
M'.E7QGRG88/,8`P!@#`*6M_U(6_6G^9RSOO1V75G\\C8>]4%_P!0/B"_<+HW
M[,W?.0NTGKA<C.D]R.K7[AO:9')NHP!@#`&`,`8!\[;UA_\`*W7CXE=)?863
MSISL8ZG?TLN^B"NTSK/]W'O&)Q+]K+^=DZ$1R\8\\H4&`,`8`P"'-M?4I;YT
M/S.:]K_HT^89K1?2(\I]`;U8?\C[H?[M]U_C.L.<4Z_UO7YYU)HW5M+FFP-F
M',H,`8`P!@#`&`,`8`P!@#`&`,`BK<'VN5_XR]5_C!KN`2K@#`&`:FOK7_\`
M<?PU^/"[?V&1R6>R'KZK]$OE$>=HW5-/GOO&HA'?R9+YT7.MH^(N0YTJ^,^4
M[#!YC`&`,`8!2UO^I"WZT_S.6=]Z.RZL_GD;#WJ@O^H'Q!?N%T;]F;OG(7:3
MUPN1G2>Y'5K]PWM,CDW48`P!@#`&`,`^=MZP_P#E;KQ\2NDOL+)YTYV,=3OZ
M67?1!7:9UG^[CWC$XE^UE_.R=&1'+QCSRA08`P!@#`(<VU]2EOG0_,YKVO\`
MHT^89K1?2(\I]`;U8?\`(^Z'^[?=?XSK#G%.O];U^>=2:-U;2YIL#9AS*#`&
M`,`8`P!@#`&`,`8`P##CRJVC(K\LMQ:RVAO:Z<?M64#A.TVWIIW5KNKJ].X[
M2?6N]1MQLA+"4R/MVFM>-(.$2;P?:<-T@D^\5:+"N00`O\X<VS:=\XH<<+KO
M!FJPW!;-*:VL&RFKB-"&<DN4M5(M[.G=0Y2)EB7:[Y8ZBK8"D!!0PD`I>ST`
M#F;JEKHE'1:#2G1CR-2V3J_S.04MZ;)9V<+Y73(E48G@E_->]<=$Q'O3]D![
M7EZ=G`*_]/[+_!U#>_\`3^]?`'I_9?X.8;W_`*?WKX`]/[+_``<PWO\`T_O7
MP#"!XW/`+E5XC.N-!5'4%6I$'(ZPV)9;;,K3]]:&069RE:3B&R*(+1L4(J><
MEZCV3'Z%]D`]G-VW&WCM=VM0JWERG+-32BMO#CCMP3-6WJT6OKEI"VH/#";;
MX.##BQ:,`:7JZ_B?()D23)I("$`"E`;?'"/0/DB+H1$<DN?:["<LSD_<4L%_
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MTU;6T7720%[9D59/*E)6)Q(IO`29RQS`HE+$$ANR0O0HAU$?8BW>W6K;7+V-
MU;\&&U;=C]U(WS=W2Z^E6LJ%;N[.#@]QLV2_3^R_P<PWO_3^]?-3-B'I_9?X
M.8;W_I_>O@#T_LO\',-[_P!/[U\`IQEL:]O[1/5-'6\:$E78V"E'JA[ZW!L=
MO8#2A&16Y@KAE3*IC$J]YVB%`.I>@FZ^0"H_3^R_P<PWO_3^]?`'I_9?X.8;
MW_I_>O@#T_LO\',-[_T_O7P#5)\5[P:><W-GF]:.2.JH76</6)77VNJHS9SU
M[8J.O/:I'.VS]8Q3I1JO='4<`!0%(/8'RCDL;E;^6N[&DNT:_P!TYR>.UI)^
MTHO;[I'N\VZ5QKNI*YQ_VZ@E@L,6URM;#'__`+=SQ00\G8TCY/\`]W1WTWFS
MOM;@]KG+'DEY)@_5V_B>_'RA_MW?%!_Y=(^^^.^F\IZVJ?QY?DEY(]7;^+[\
M?*'^W=\4'_ETC[[X[Z;QZVJ?QY?DEY(]7;^+[\?*'^W=\4'_`)=(^^^.^F\>
MMJG\>7Y)>2/5V_B^_'RA_MW?%!_Y=(^^^.^F\>MJG\>7Y)>2/5V_B^_'RA_M
MW?%!_P"72/OOCOIO'K:I_'E^27DCU=OXOOQ\HZ*P^K=^)A98]2/D4]*`0Y3`
M19&XQZ:R1A#IVBF!WY0^2`^0<_%3M5MZT'3JMR@UW)>2?J'9_4I24Z:PFO;C
MY1M)>#OQ/Y&\`>!^MN,>T*A49RXTVS;%DWTE"7QN2.<M;3<).?CSHE2AI(I1
M!J^*4P=Z(@8H]0#KTR%=6N:=WJ%6XH[:<I8KA_ZI/WB3].H3MK*G0J>/%8/V
M+$R@^G]E_@YAO?\`I_>OF.+T>G]E_@YAO?\`I_>O@#T_LO\`!U"A^??T^G_N
MJXC@'=T:U)W:IPEI38J1I9AJ=<S!9=)RHT52<+-5T!<(@5)<"+(&Z'``[0=!
MZ![&`59@#`&`,`8`P!@#`.@G*I5[.://9*W`6$\0Z\]BC3D/'2QHQ[\I_&X\
MS]LX%DZ_8R_LB?9/\J'E\F`=_@'H<-6SLA$W3=!RFFL@Y(1PBFL0CAJL1PV7
M(50IBE6;KIE.F</EB'*`@("`#@'OP!@#`&`,`8!Z'3IJQ:N7KYRW9LF:"SIV
M[=+)MVK5LW3,JNY<N%C$20002()CG,(%*4!$1``P"C(7:.L[+$2D_7-BT6?@
M80R9)J;A;=7Y6(B#JE`Z19228R"[./,J0P"4%3D$P#U#`*Y*8#`!BB!BF`#%
M,40$#`(=0$!#R"`A@'[@#`&`,`8`P#CD:-$W*[U-JW3>.4T47+LB*97+A)L*
M@MTEURE!55-`5C]@IA$"]L>G3J.`<C`&`,`8`P!@%)RM]HT#.Q56G+G4X:S3
MW8"#KLK8H>.G9D5%113"*B'CQ&0D>\6*)"]RF?J8.@>7`.RAK)7;%Z2]K\]"
MSOH64<PDQZ&E&,GZ)FF78\\B)+S)=?S"4:=X7O6ZO853[0=HH=0P#]@K'7K0
MR/)5F>AK%')/'D<H_@I1C+LDY".7.UD&!W4>NX0(\8.DS)K)";MI*%$I@`0Z
M8!W.`,`8`P!@#`/0U:M62";5FV0:-D@$$F[5%-!!(#&$Y@312*1,@"<PB/0`
M\H]<`]^`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@%LW-3LAPZY7"<.I?\MV[^T`
MB(`)?@TLW:`1`!$`$,`UA9UL$1IWDT@PF(&ZL)KP@.-<E;Y&OP%+IK"CO878
M$8UHE:]&:WL%BJ5LF;FRDIAT[?3#AM-QZ<8V3(3S1ST(!MV4^0<R$!&J.825
M@Q39,DDD)92$47<)%9H"5RGZ"F9MN1(_7H`'4*<!#REZ=!$"I\`8`P!@#`&`
M,`8`P!@#`&`,`UWJ2PWY%\F>6<A0K!&V3D`EXAM,%&O;0BM+-:FZXPS3379F
MJ;.5V&I#[X:H5'7#B4"$4K';8JS+8H,DWI%79R@6:\1?A@CG/,='@T#FPOMI
M[^Y2:MYOO&:BD>'%^UJ;ZOC_`%WR?C&T@BV^$R]-M!JR+![5ZH:7LRKU*OJJ
MLRICVA`RS^"4CI]OQ/V4VX_.VLAI)MRWY&MM82#4CU()&I-[8V1CY%VE)HMI
G9&7?F(=5\1ZDD\(].J"Y"*@8H`9A,`8`P!@#`&`,`8`P!@#`/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tpg15b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg15b.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`(N`S,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`**\9_X*,^*=3\#_`/!/KXYZUHNHWVCZQI/@#7;V
MQO[*X>WN;*>/3YWCEBD0AD=6`964@@@$$&OD7X\_&_QQ\%_^"<?['_[0R^+_
M`!5)9>`V\+WOQ#1M5N&BU_1M3LX;*^GO4W8N7BDN([A7E#%61F!!)-%/WY./
M:5./_@QR2?HG&[\M>@YQ<8I[W51I?]>U%V]9<R2\S](**_%_]J?X@_%3]JWX
M>ZIXK\'?%SXE^#;#XU?M,P?#_P`'W6@^*;ZQMK31]/TZ_P!.66U$4JA(KB^M
MY9Y`H"R-&A8-M!KC_BK_`,%0OB)^VQ_PH'7O"_C;Q=X17X8:WX)T+XB6^A:O
M/I\.L>)-6U<VU[8W2PE5EBAATV9O+<E2+\?*!C)A_P!\X):<TJ<=>GM(QE?_
M`+=YXQEVDXKJ+$6I<SWY8SD_^W92A9=[N$FO[J;Z'[H4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!17BOP:^`G@7QWX;UC5
M-<\%^$]9U2Y\4:^)KR^TBWN+B4)K%XB[G="QVJJJ,G@*!T%=;_PRM\+_`/HF
M_@+_`,)^T_\`C=>A6P^'IS=.4Y73:^%=/^WCCIUJTX*:BK-7^)]?^W3O:*X+
M_AE;X7_]$W\!?^$_:?\`QNC_`(96^%__`$3?P%_X3]I_\;K/DPO\\O\`P%?_
M`"9IS5_Y5_X$_P#Y$[VBN"_X96^%_P#T3?P%_P"$_:?_`!NC_AE;X7_]$W\!
M?^$_:?\`QNCDPO\`/+_P%?\`R8<U?^5?^!/_`.1.]HK@O^&5OA?_`-$W\!?^
M$_:?_&Z/^&5OA?\`]$W\!?\`A/VG_P`;HY,+_/+_`,!7_P`F'-7_`)5_X$__
M`)$[VBN"_P"&5OA?_P!$W\!?^$_:?_&Z/^&5OA?_`-$W\!?^$_:?_&Z.3"_S
MR_\``5_\F'-7_E7_`($__D3O:*X+_AE;X7_]$W\!?^$_:?\`QNC_`(96^%__
M`$3?P%_X3]I_\;HY,+_/+_P%?_)AS5_Y5_X$_P#Y$[VBN"_X96^%_P#T3?P%
M_P"$_:?_`!NC_AE;X7_]$W\!?^$_:?\`QNCDPO\`/+_P%?\`R8<U?^5?^!/_
M`.1.]HK@O^&5OA?_`-$W\!?^$_:?_&Z/^&5OA?\`]$W\!?\`A/VG_P`;HY,+
M_/+_`,!7_P`F'-7_`)5_X$__`)$[VBN"_P"&5OA?_P!$W\!?^$_:?_&Z/^&5
MOA?_`-$W\!?^$_:?_&Z.3"_SR_\``5_\F'-7_E7_`($__D3O:*X+_AE;X7_]
M$W\!?^$_:?\`QNC_`(96^%__`$3?P%_X3]I_\;HY,+_/+_P%?_)AS5_Y5_X$
M_P#Y$[VBN"_X96^%_P#T3?P%_P"$_:?_`!NC_AE;X7_]$W\!?^$_:?\`QNCD
MPO\`/+_P%?\`R8<U?^5?^!/_`.1.]HK@O^&5OA?_`-$W\!?^$_:?_&Z/^&5O
MA?\`]$W\!?\`A/VG_P`;HY,+_/+_`,!7_P`F'-7_`)5_X$__`)$[VBN"_P"&
M5OA?_P!$W\!?^$_:?_&Z/^&5OA?_`-$W\!?^$_:?_&Z.3"_SR_\``5_\F'-7
M_E7_`($__D3O:*X+_AE;X7_]$W\!?^$_:?\`QNC_`(96^%__`$3?P%_X3]I_
M\;HY,+_/+_P%?_)AS5_Y5_X$_P#Y$[VBN"_X96^%_P#T3?P%_P"$_:?_`!NC
M_AE;X7_]$W\!?^$_:?\`QNCDPO\`/+_P%?\`R8<U?^5?^!/_`.1.]HK@O^&5
MOA?_`-$W\!?^$_:?_&Z/^&5OA?\`]$W\!?\`A/VG_P`;HY,+_/+_`,!7_P`F
M'-7_`)5_X$__`)$[VBN"_P"&5OA?_P!$W\!?^$_:?_&Z/^&5OA?_`-$W\!?^
M$_:?_&Z.3"_SR_\``5_\F'-7_E7_`($__D3O:*X+_AE;X7_]$W\!?^$_:?\`
MQNC_`(96^%__`$3?P%_X3]I_\;HY,+_/+_P%?_)AS5_Y5_X$_P#Y$[VBN"_X
M96^%_P#T3?P%_P"$_:?_`!NC_AE;X7_]$W\!?^$_:?\`QNCDPO\`/+_P%?\`
MR8<U?^5?^!/_`.1.]HK@O^&5OA?_`-$W\!?^$_:?_&Z/^&5OA?\`]$W\!?\`
MA/VG_P`;HY,+_/+_`,!7_P`F'-7_`)5_X$__`)$[VBN"_P"&5OA?_P!$W\!?
M^$_:?_&Z/^&5OA?_`-$W\!?^$_:?_&Z.3"_SR_\``5_\F'-7_E7_`($__D3O
M:*X+_AE;X7_]$W\!?^$_:?\`QNC_`(96^%__`$3?P%_X3]I_\;HY,+_/+_P%
M?_)AS5_Y5_X$_P#Y$[VBN"_X96^%_P#T3?P%_P"$_:?_`!NC_AE;X7_]$W\!
M?^$_:?\`QNCDPO\`/+_P%?\`R8<U?^5?^!/_`.1.]HK@O^&5OA?_`-$W\!?^
M$_:?_&Z/^&5OA?\`]$W\!?\`A/VG_P`;HY,+_/+_`,!7_P`F'-7_`)5_X$__
M`)$[VBN"_P"&5OA?_P!$W\!?^$_:?_&Z/^&5OA?_`-$W\!?^$_:?_&Z.3"_S
MR_\``5_\F'-7_E7_`($__D3O:*X+_AE;X7_]$W\!?^$_:?\`QNC_`(96^%__
M`$3?P%_X3]I_\;HY,+_/+_P%?_)AS5_Y5_X$_P#Y$[VBN"_X96^%_P#T3?P%
M_P"$_:?_`!NC_AE;X7_]$W\!?^$_:?\`QNCDPO\`/+_P%?\`R8<U?^5?^!/_
M`.1.]HK@O^&5OA?_`-$W\!?^$_:?_&Z/^&5OA?\`]$W\!?\`A/VG_P`;HY,+
M_/+_`,!7_P`F'-7_`)5_X$__`)$[VBN"_P"&5OA?_P!$W\!?^$_:?_&Z/^&5
MOA?_`-$W\!?^$_:?_&Z.3"_SR_\``5_\F'-7_E7_`($__D3O:*\5^,OP$\"^
M!/#>CZIH?@OPGHVJ6WBC0!#>6.D6]O<1!]8LT;:Z(&&Y693@\AB.AKVJIK48
M1IQJ4Y-IMK56VMYON%.K-S<)I)I)Z.^]_)=@H)P.F?;UHH/3CKVKDEMH=!X+
M\._VW)M7^&OQ0\0^+_!.H>#KCX;Z[_8HT=;^+5-0U%Y+.RN;6("`&,7<K7T4
M`@BDF7S<!99`0:X/5O\`@HKX\O/AIH=[X;^$6CZUXO;P[J_BCQ%HMSXT-E:Z
M5:Z;=FTDAMKO[$YN[F656\I7B@B(1C)+%\N^]X,_X)V:YXON/'4/QD\<:/XS
MTWQ=XHM?&5K'X,T[6O`M[I&IP6D%HCK>6VLS3,@BMXB$#)B0NQ+`JJ8%E_P2
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MW:^]NAST>?V<?:?%97]>IZ711169H%%%%`!1110`4444`%%%%`!1110!A?%#
MX::)\9_AIXA\'^);+^TO#OBK3;C2-4M/.DA^U6MQ$T4L>^-E==R.PW(P89R"
M#S7E7A'_`()R?";P=^S[XD^%4>E^*]6^'GBO2ET.^T/7O&VN:Y;16*QF);>V
M^V7<K6B!&P!;&/&U#U12/<J*EQ34HM:25GYK71]UJ]^[*YG=._PNZ\GIJNST
M7W+L>.:!^P!\(?"WPC^&/@33O!\-GX3^#6K6VN^#["/4+L+I%[;B413;_-WS
M$>?*2)FD#ER6#'!K"T__`();?`72='UO3[7X?6MK:>(O'L7Q.U%(=2O8_M/B
M&.598[W(FRH5U#"!2(.O[O!.?H"BM.:7-SWUO>_6]XN_K>,7?>\8OHK9\J4>
M1;6M;I:TE;TM*2MM:4N["BBBI*"BBB@`HHHH`****`"BBB@`HHHH`**S[#Q9
MI>J:_J&DVNI6-QJFE+&U[:13J\]F)`3&9$!W)N`)&X#(&16A3::W!-/8**\A
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M<<3?:;?]^\2P@31DN`PI_:Y>NFGJ[+[WHN[T0N96OZ_@KO[EJ^RU/<J***!A
M1110!P7[.'_)/=1_[&GQ%_Z>KZN]K@OV</\`DGNH_P#8T^(O_3U?5WM=>8?[
MU4_Q/\V<^#_@0]%^04445R'0%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<%^T?_R3W3O^
MQI\._P#IZL:[VN"_:/\`^2>Z=_V-/AW_`-/5C7>UV3_W6'^*7Y0.>/\`'EZ1
M_.04445QG0%%<;J7[17P^T?P?XF\17GCKP;:^'_!=W)8>(=3FUJVCL]"N(]O
MF0W<I?9!(F]-R2%2N]<@9%9'B']LKX0>$?`'ASQ9JWQ6^&VE^%O&$HAT#6;O
MQ-90Z?K<ASA+6=I!'.QP<"-F/!H6NWE^.WW]._0'IOY_AO\`=U[=3TFN#^$'
M_)0?BI_V-$'_`*9=+KO*X/X0?\E!^*G_`&-$'_IETN@#O****`"BBB@`HHHH
M`SO%WBJQ\#^%M0UG4IO(T_2[=[JXDQG:B*6.!W/'`[GBO@[]G/\`;U\9W/QO
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M"_Q`2+U@$,SY_P!T,*/^&P]6A^:;X._%=8E^\8]*21P/90_/TKMM4_:9^'6C
M,5N/'7A&-U(4H-6@9QQGE0Q(KF]3_;P^$FD+NE\:Z>V!G]S!//WQ_`A_*O/J
MXRE2_B8^*]?9_P#`/0I9+F-3^'2F_2#?Y(S3^VRJC+?"7XV*HZL?"_`'J?WM
M'_#=.B_]"/\`%+_PFW_^*J4_M[>`[P_\2V/Q5K63A?L.@W+;_3&Y5Z]OZ4G_
M``V4]^/^);\+?BU?#&1(V@^3$P[X9GY(],5S_P!L4OL8V,O2'-_Z2S?_`%=S
M1?%3<?\`$E'\VB+_`(;Y\&KPVC^.8V'WE;0)LJ?0TO\`P\&^',?RS3>(K:4?
M>BET.Z#I]<(14G_#1GQ$U+_D&_!/Q!*QR!]MUFULAD<\ELX&._KQS2CXD_'#
M5O\`CW^&?AG2=Q'%[XC6?:#Z^4O;OC\,T?VM7?P5)2_[EZMOONE^(?V#BU\<
MZ:]:E/\`)3O^!%_P\5^$4/RW7B:ZL9?^><^CWH;'KQ$>*L6?_!0CX.WX;R_&
MENNWKYEA=Q_ENB&?PJ/_`(R$U5?^:2:3&P_Z?KB92#^"X(^O^$-[\(/C+XG*
M_P!H?$3PG8XW`&V\+QW10'T\YNW_`.O-']I9H_X=-R_[A<O_`*56B']CV^/$
MTE_X$_\`TE2-:T_;L^$EZY5/&^EJ5&?WD<T8_-D%6[;]M+X57<PC7QUH*LW=
MYBB_FP`KDKS]CSQ5XC15UKXJ7UY@AL6WAVQM5R!C@!3CCM^/-5'_`."<7AO4
MTQJGC#Q]J"XP8_M\,,+=QE5BZCUS3^N9^_AH1_[>LO\`TFI,/[/PL?BQ47_A
MA-_^E*)Z)%^UK\,9I51?'WA0,QP-VI1*/Q).!^-71^TQ\-R?^2@>"?\`P>VO
M_P`77G=A_P`$V_A9;X^TZ=K&H\@G[3JL_P`WKG8R]:WM,_80^$FD)MB\%:>V
M!C]]//.?S=S733JY^_BITE_V]/\`^1_4:P^61^*M-^E-?FZGZ&'^TK^WCX7^
M#G@V.?P[J.A^+-;O7,<%M:7Z31P`#)DE,9)"C(`'!8G@C!(J_L6_MMM^TSJ&
MH:+JVF6^FZ]I]O\`;%^RLQ@N(=X1B`V2I4N@P2<[L\8K%_:D_P""?MCX^\*:
M98_#O0O!_AV\ANS/=W=P\L#M'LP(UV1ON!)R=V,;!CJ:/V&?V-/%/[,_CK6M
M2\03>%[Z+4K`6T,UA<3R7$+"16*X>)%V-C).2<HF.,UX<:G$?]N051+ZOUY5
M>.W=KFO?KM^)[TJW#BR>=."E]8OHVG??>Z]WEMNKW_`^G****_0#XLI^(M(;
MQ!X?OM/6\O-/:^MY+<75HXCN+8NI7S(V((5USD$@@$#@U\Z?\.U_^J_?M+_^
M%Q_]HKZ2O[^#2[&:ZNIHK>VMT:6665PD<2*,LS,>```22>`*\T_X;=^"_P#T
M5[X7_P#A56/_`,=K>CF%3#:0ERW]/U#^S98K54W*W9/3[CY7^%G_``1X\3>%
MOVC/%FOZA\7_`!Y8Z+?J?L>J:+K#VOB#4O,8.RW<Y4@[6`R<'S#AL)T'O'P_
M_8&;P!XVTK6U^-G[0&L_V7<I<_8-5\7"ZL;P*<F.:(PC?&W0C(.#P0>:\]^#
MO_!;WX+_`!@^)-AX<V^)?"JZAYNW5O$*65CID.R-Y/WDWVEMF[9M7*\LRC@F
MOH#PW^UO\*?&6O6NE:/\3OA[JVJ7\@AMK.S\16<]Q<.>BHBR%F8^@!-;U.)J
MV*U]HGI;9=O0TK<'5\`^6KAY1?Q:W?7_`(!XKXE_9@^+2_$W4+#2[?X=WG@%
M/''_``L6QO[S6KR'69KI8Q*NF26_V.6**)KL9-XD[,D!V"U8C)Y_X>_L(?$#
MXB_!_P`%^&?BC#H?AH>&OB5K7C&Y;P+\0M:@N)[._CU>1$BOK>VT^YBE2?4D
MC9%8(\<3,6^?RJ]FT_\`;'75_CKXV\'V?PW^)%]I/P\G%IKGBNUATZXTNWN#
MIL&HB&.V2\.ISR&&YA4"&R?=(^T9P36*W_!0&PU3X,>$?%WA_P"&WQ*\37GC
M3Q+?>%;#PW:)I5IJZ7=F;_SS+]LOH+:-%&G7!YGW\H-NXD#@II0I*"5XVBTN
MVD8Q??X812ONH\V[<G-1-S<GHW>[[W4I/R^W*3MLY6V22X#QU^R;\7OB%\4?
MC`#I_P`/M%\+^*O"NE:'X8U)_%^I:KJ8N=)NKJXLY+ZW>QBS'.UR!-MNY'41
M'YIC(2N1\5_V:OVA_B#%J7B*/PQ\%U\4^)?%7AS6+W2F\<:C%8:7::'<PW,*
M1W@T9I+J:Y=9@Q>WA$"F,#SMIS[)8_M[^&!)\18]6\->/?#<WPQTBRU?5H=2
MT@+-<BZ-S&D-JD;NUQ()K66+=&#%(VTPR31L'/*ZG_P4VM/#FE:U-K'P:^-&
MCWG@^42>*[&:TTB:7PM8M%%*FH3R0ZC)#/`R2$K'9R7%R?)F'D90BJC?VD7>
M\ERM/NU+F4K[/75VTY==%=F;Y==+;IKLN6UK;JRVZWTU>A],6S2/;1F98XYB
MH+JCEU5L<@$@$C/?`SZ"I*%;<H/KSR,44F..P4444#."_9P_Y)[J/_8T^(O_
M`$]7U=[7!?LX?\D]U'_L:?$7_IZOJ[VNO,/]ZJ?XG^;.?!_P(>B_(****Y#H
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`."_:/_Y)[IW_`&-/AW_T]6-=[7!?M'_\D]T[
M_L:?#O\`Z>K&N]KLG_NL/\4OR@<\?X\O2/YR"D?&P[AD8Y&,YI:*XI*ZL=!\
M%?`W]H+PM\"?A_\`M`:KH/P5^*]]HND>,+#5?"_AFU^$6O:9]KA&G:596SV=
MO-IZ?)#<VTA;R8V>&.$R!"#'OX2TT6P^'_@R/5I/`'Q1\<6/CSP)XQT::*W^
M&.N*R>(M6U--0O+/[#=VD<]E97,DY6*:Y2.V9+4>;,I4%OTPHI2AS149-Z1Y
M?E[-TW\W%[_S*+M9<KU5:49<T?YN;7NI<R[;/3I>+DNMUR?PC\,ZUX2^!?AC
M1K^YA_X2+3-!M;*YN)=UU']JCMT1G;YE:0>8"3\REAW&<US_`.SS;ZI:>)?B
M;'K5Y87^I+XHB\Z>RLWM()/^)/IFW;$\LK+A<`YD;)!/&<#TRN#^$'_)0?BI
M_P!C1!_Z9=+K:M5=2I*I+=MO[SFHTU3IQIQV22^X[RBBBLS0****`"BBB@#S
MO]K/P</'W[.WBG22;Q?M-LK!K6%II$*2(X8HN691MRP0,Y4-M5FPI^'?@U^Q
M9X@;XJ^%1X@86NCZM.MS97&CZC#<W&HP+AC/`87)2%0R,TS[0H=0-TC(C?H1
M\3?&3_#_`,#:AJ\=JMY):*NV.2<01`LZH'ED.1'$N[<[X.U%8A6(P?C_`,;_
M`+#TNA?%S_A)_!WQ;\7>&_%6LZLNF^(X=%N4AMDO;G%TC0V;_+)`BS&1H2Y(
MC9I-Y9'63QL=P9EN;XFGB\;=2AHK;22=[2T;LF^EF[V]/I,GXNQ668:I@Z,X
MQ4]==TVK76O9=4]M.I[I_P`._P#X:WB;=2L=;UKC!^VZW=MGG(^[(O2M;3/V
M(_A1I!'D^"-';:<_O@\__H;&O+QIG[67P6_U&I?#?XT:9#VNH&\/ZO-CI@H3
M;+GON)YH/_!3:/X:_)\6OA1\2OAGY?\`KM0;3_[6TB/U_P!*M\[L=>$Z5WPX
M1R].]&A3D_*,6_N:YOP.6>=9I-6^L3:[*<ORO^A[GI7[/'@'0P/LG@GPG;D`
M#<FDP!CCID[<G\:Z/2_#6FZ'_P`>6GV-GC./(@6/&>O0"N&^$'[7WPO^/?EK
MX1\=>&M:N)ONVD=XL=Y^,#[91^*UZ/6L<#3P[Y8TU%^EOT/-K8FO-_O9-^K;
M_,****U.<****`"BBB@`HHHH`****`"BBB@`HHHH`KZKI5KKVEW-C?6UO>65
MY$T%Q;SQB2*>-@59'5LAE()!!&"#BO-_^&(_@O\`]$A^%_\`X2MC_P#&J]'U
MG6+;P]H]UJ%Y,MO9V,+W$\K`XCC12S,<<\`$UXU_P\:^#/\`T.7_`)2;[_XS
M7#B\9@Z+2Q,XQ;VYFE]US6GC*E#2$W&_9V/F_P#9J_X(/Z+\$/C7HGB?Q%XS
MTOQ]HNE>?YV@ZCX3C%M?>9!)$N\R7$J_(SK(,QGYD'0\CZZT#]D+X3>%=;L]
M3TOX7_#O3=2T^9;BUN[7PW9PSVTJD%71UC#*P(!!!!!%>:Z%_P`%.OAO?>/-
M:L;[4GL=#LTA.FZG]CN9/[08@F4&-8R\>TX`W#GD\<9[+PC^W=\*?'?BBPT7
M2_%:W.I:I.MM;0G3KN/S9&.%7<\049/')%>=@\PRA+EHU8;[<RO?;2[OTTMH
M]UN>CF'%&.Q\_:8FNV[6TM'37I&R>^]CS[X@_P#!/R]\9_MDP_%ZSN_A#X?U
M;2Y#=Z=J5A\.'A\5W,PT][..'4=8745:\L07W-;+##O6*%/,79N.7X-_X)EM
MXJ^$GAGP;\:-6^'/Q8T7P[X\U/QLUA)X!^SZ;J'VV/42UO+;7=[>*3'<ZB\J
M2YX6*-=A;,I[WQS\9_B7I_[7?_"`:78^!8=%UCP3JFM:#<74EU-=27]K/I\2
MM=;0BQP;KUP8HQ([")6\U"Q1?%?B!^W#\6O!'P0T*ZDU;P7<:MJ?Q(NO!\/B
MK1/AAK_B:PUJPATV[NC=VNA6-ZU[D7%L]L62ZFCQ!)-G8P">[3:]FE':UTGV
M4^1VOU4DO-JUKV:7ERNY-O?9V_Z]M].G+=>3[:,[GQ-^P'XO\:?$3XH7-]X^
M\&Z?X1\<^&['P]HVDZ/X'DM;SPS_`&=///IDPGDU"6"8PO<,73[+&DGEQ!1$
M%8-@>-?V`_C;XU\5_P#"077QM^'-UJ6K7UO>>(=-O/AC>2Z#JPLU0:?$ELFM
MI/&D$GFS,KW,JS2R@LH1%CK4N_VS?B5X$G^+D'B#2?!NH7'@_P`,:!JWAQ+*
MVU"Q^W3ZE/>VJO>K,&EMU:2WBD:`1L]NKO&TDY3S#Y[\>OVT_CY^S[!XOTO4
M?$'POU7Q#X%,5VT]C\+M>FTG7H+BV$T4=S<Q:I+#X>6-H;A)+V_EEM@C1RD1
MJCJ::M42EOI9OUTWUO?NN;INK*(^^[16KZ:?RKY6MHK/EW>UV?=ULLB6T8F:
M.28*`[(A16;')`))`SVR<>IJ2H;"[74+&&X1HV2:-9%:-PZ,",@AAP1[CK4U
M5*]]10:<4X[!1114E'!?LX?\D]U'_L:?$7_IZOJ[VN"_9P_Y)[J/_8T^(O\`
MT]7U=[77F'^]5/\`$_S9SX/^!#T7Y!1117(=`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%!.!0`45PWPN_:?^&OQPT?6]1\%?$/P-XPT_PS(T.KW.
MB:]:ZA#I3JI9DN'A=A$P4$D.00`35OX,_'[P)^T=X4DU[X>>-O"/CS0X;AK1
M]1\.ZQ;ZI:),H5FB,L#N@<!E)7.0&!QR*%KMV3^3V?H^@/3?O;YK=>J.NHHH
MH`***P?#OQ5\+^,/&&O^'=)\2:#JGB#PHT*:WIEIJ$4]YH[3)YD(N8E8O"9$
M^90X&Y>1D4`;U%<7H_[2/P[\0_"G4/'FG^/O!=]X'T@7#7_B*WUNVETFR%N2
MLYENE<Q)Y15@^YAL(.<8JGX4_:T^%?COXBVO@_0_B9\/]9\77VGQZO;:)8^(
MK.XU&XLI(UECNDMTD,C0M&ZN)`I4JP8'!!H6NB_JZO\`DF_1`]-_ZLTOS:7J
MT>@45Q?A?]H_X>>./BMK7@/1?'G@O6/''AR/SM6\.V6MVUQJVEIE!NGM4<RQ
M+ETY=0/G7U%:WQ*^*?ACX,^$+CQ#XP\1Z#X3T"T>..?4]9U"*QLX6D=8XU:6
M5E12SLJJ">68`<D4;I-==O/IH'5KJMS>HKG?%7Q=\)^!/$_A[1-<\4>'=&UK
MQ=-);:%87VI0V]UK4L:;WCMHW8-,RK\Q6,,0.3Q6+\0/VJ/AA\)M;U;3?%7Q
M'\!^&=2T'3$UO4[75?$%I9SZ=8/*(4NYDDD5HX&E(C$K`(7(4'/%+F5K^OX*
M[^Y:OR#?;R_%V7WO1>9WE%<#KG[5GPN\,?!BU^(^I?$GP#I_P\OQ&UMXHN?$
M%I#HMP)&VH4O&D$+;FX&'.3P.:TO#GQ\\"^,?%FG:#I'C3PGJFNZQHJ>);#3
MK/5[>>[O=*=@B7\42N7>U9B%$R@QDD`-DU7*[M=M/G:]ON3?IJ%U:_S^5[7^
M]I>IUE%%%(`HH+;1D\`=37*Z#\=?!'BKX42>/-+\9>%=2\#0VT][)XBM=6MY
MM)2"#>)I3=*YB$<?EOO8MA=C9(P:+I)M]!J+;LCJJ*\<^&O_``42_9^^,WC:
MQ\,^#_CI\'/%GB35&9;+2M&\::;?7UV54NPCABF9W(568[0<!2>@JE8?\%./
MV;=5\40Z':_M"?`^YUJYNEL8=/B\=Z6]U+<,^Q85C$^XR%R%"@9).,9IV;:7
M5["O9-]CW"BBBD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'!?
MM'_\D]T[_L:?#O\`Z>K&N]K@OVC_`/DGNG?]C3X=_P#3U8UWM=D_]UA_BE^4
M#GC_`!Y>D?SD%%%!Z<=>U<;.@**^+3\:_BUI_@[Q]X5U#XB+-XIE^+NE>![3
MQ+9:!:6W]AV=Y8Z9<SFSM9%ECRGVBY6'[4;DIO0R-.$*MQ?_``N?XU>.-5\:
M?#NR^,FM:'JOPET[Q-J3>*8?#VCS7_BF2UN(?[/CO89+4VR1)%,4F%K%`\S(
MK));C<K1[2%N:^G*Y?)0C4D_^W8SC?NW97LRI0:ER^:C\W*4(_\`@4HM+MO*
MQ^@U<'\(/^2@_%3_`+&B#_TRZ76G\+/B,WCSX*>'/%UU;-;MK.B6VKS6]NCW
M#1&6!961%4%W(W$``%CQ@9.*YS]GGQ);^+?$OQ-U"UCOX;>X\41;4O;&>QG&
MW1],4[H9D21>0<;E&1@C(()WJTY4YNG/=-I_(QI5(U(*I'9I-?,],HHHK,T"
MBBB@`HHHH`S_`!3JZZ%X?NKIK&\U+RUVBUM8?-EN&8A0@7IR2`2Q"J,EBJ@D
M?'_A_P#9Y^,7@/XV^(M:\-ZU8Z#8ZAJ26<-M-HK:G;:>LEI:L@A=B'%NORV[
M21@`&UCRJHI\K[0HKLPN,E04E%)\VCNK_@SR\PRN&,E"4Y-<CNK-IWUZJS/G
M\ZE^TUX6_P!=IOPB\50KT^RW%Y8W#?[WF90=>,=E]31_PT]\6_#?_(P?`/6C
M&O6;1?$%KJ.\=R(P%8=^#Z>]?0%%5]<@_CI1?WK\FE^!']EU8_PL1->O+)?^
M31;_`!/B+XO:S^S[\6O,;XD_`+QEX;NI/];?W7A&2QF)[M]HM6WNH.[!)['B
MN0\.'X>^%GS\(?VL/%W@?RR=FE>)PVIZ;"1GY%AO$C\L<8)W,>_/%?H963XC
M\!:'XQ7;J^BZ3JB],7EG'/\`^A`UU0S&FERM2MVYDU]THO\`,N,,TAI&M&2[
M2@_S4DO_`"4^2_"_[5?QZ\&LJMI_P<^.6FK]VX\'^)X]/U!E_O-%,61FZ_+&
M.>F<UUVF_P#!5;P#X?OX[#XBZ#X\^$^I2-Y83Q-H4T=O(W_3.:(.K+Q]X[17
MH/B;]@WX.^+0WVKX=^&8=W!^Q6WV+_T24Q^%<IJ7_!,KX<FPFM=&OO''A>VF
M0HT6E>(;A8]OIME,@(X'!S]T57M,OJ?&FO16_5K_`,E']8S&/QT82\XS:?W.
M#7XGL'PU^-7@_P",FG?:_"?BC0/$ENJ[F;3;^*Y\L?[00DJ?8X-=-7POXM_X
M(9^$[[48[S0?&VM:)>6[F2&Y.GPM.C<_,9(#`Q;WSD\^M=#X2_9$_:7^"ICC
M\+_&^R\2649_X]?$T<LZNHZ#?(D\JCKPL@[<^F<\'A9?P:Z]))K\;-">958_
M'AYKTY)+\)7_`/)3['HKY8O/VD_VCOA1;SR>*O@KI?BZUA.!=>%=2(+#N1`3
M-,W_`'PM<M!_P6R\">']5_L[QAX/\:>%=27`DMKB&+?&>.JRO$^.O\.>.GIG
M'*<3+6DE+_#)/\$[_@3_`&SAU\:G'UA-+[^6WXGVA17SWX>_X*C?!K6K>&2Z
M\0:AHOVCF+^T-)N45^_#JC)_X]W%=_X8_:[^%OC$JNG_`!"\(32/]V)]4ABE
M;Z([!OTKGJ8'$P^.G)?)FM+.,#4=J=:+?;F5_NO<]%HJMI6LV>NV@N+&ZMKR
M!NDD$JR(>_4$BK-<NVYZ"::N@HJ)[Z&*\CMVFB6XF1I(XBX#NJE0Q`ZD`LN2
M.FX>HJ*TURRU`V_V>\M9OMD)N(/+E5O/B&W+K@_,OSKR./F'J*=F+F6Q:HHH
MI%!2.OF(5.<,,<'!_.J?B2_N]*\/7]U86+:I?6]M)+;62RK"UW(JDK$';Y5+
M,`NYN!G)XKYO_P"&I_VD?^C5?_,F:7_\;K:EAY5/AM\Y)?FT5&+>WYH]+\!_
ML6?#7X9>,[7Q%H?AV6QUFQ=GAN?[4O)&4LI5LAY2K9#$'(.<UZE7P5\._P!K
MW]HZXU_POO\`@C?ZOH]T]_\`V'$_CNQMVU0ID`373)MN?+B\PQ\+YR*9OWOE
M^8/<?A[^T=\>O$7CG2;'Q!^S>WAS1;RZ2&]U1?'^FWIT^)CAI?)50T@4<E5.
M2!QD\4X9+'"1<:,816]HN"\MDU=Z?H5]7Y-%;[T;?QB_X)_?#3X]?$R\\7>)
MHO'5SK6H:/<Z!-]C^(&OZ;9BQN8EBG@2TMKV.W19%1"VR,%GC1R=ZJPUOA'^
MQIX#^"6@Z!INBP^*[JS\*ZE_:NCC7?&&L:\^F3_8Y+(")[ZZF=(A;S2((0?*
M&\L$#8:OC3]H#]H#7?"7[0?B*Y\&^(_&'C#]I#1_'GV#1_A5:^+WM[74?#AM
M`4=M)FN(++[(8G-PVHR)N6<>6+D%5C&+I.J_%[XJ?"[2?!UWI/Q5_P"$DD^-
M%Q874/BSXH3>#[C5XSX;O+V:'^T?#ES?RVL"7"^<MK"/(7]U&H"*=G-A9<].
M]/1<J=NZ;@[:=G5][M/F7]YQ6TG:>MFU]T9WWVNJ;MWBXOR7VE>_L!?##5OB
M!XX\3:CIWBC6-0^)&ER:+XA@U/QCK-_IM]9N7/D+8S736L*H9)?+\J)/*\V3
MR]F]LXLG_!,;X23Z0UC)#\1Y+>XE>74=_P`3?$S2:]O2.,IJ3G4-^HQB.-8U
MCNS*B1[HU4(S*?FG6/VE;?P#\2/VE/!OAOXV76O^*/#?@30[Q])A\8IX@U'P
MB8KC4(=5^QQ;#*TMG;?9]TDD!N'98'G+R2;CYK\6OCUXRTOPI\2+/X!ZA\8?
MBM\`=%-KK,'CGP[\0;37'AU)((S)ID6K:GJR7DMH)1%/-Y$DVUPUO@)),@J-
ME)*.UE9KHKO>VB2UM9M.6B=VFXE)ZN6]W?S=D]+V;>R::32U=K:?JY;6T=E;
M1PPQQPPPJ$1$4*J*!@``<``=JDJOI-[)J.E6MQ-:7&GS7$22/:SE&EMF(!,;
MF-F0LIX.QF7(X)&#5BJE>^H1M;0****DHX+]G#_DGNH_]C3XB_\`3U?5WM<%
M^SA_R3W4?^QI\1?^GJ^KO:Z\P_WJI_B?YLY\'_`AZ+\C#\*>-8_%6O>)K%+=
MX6\-:DFFN[-D3LUG;76X>@Q<A<>JD]ZW*X/X0?\`)0?BI_V-$'_IETNN\KD.
M@****`"BBB@`HHHH`****`"BBB@`HHHH`****`"FS?ZIOH:=01D5-2/-%Q[@
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M`?M$+\8_B1\45^%NFS:%IOA[7_"?QM\*?$/X@:)<:C<O#<1MK=NR06\;OL*2
MW:1&&,R".3<JE?)/V<_VZ?C"_P#P3G_;[T^W^*GQ.D;X<VOA>^\+ZGJ'Q8M_
M'6L:)+>3%+CR?$&G[(I$<0J=D&%CRZ'+^8S?O-X:_8]^$?@OX0ZI\/='^%OP
MYTGP#KCM+J7AJS\-64&CZ@[;0S36BQB&0G8F2RG.Q?057M?V)O@S9>&+[1(?
MA'\,8=%U338-&O;!/"UBMK=V,$AE@M)(Q%M>".1F=(V!568D`$YK64DY3OM*
M,8]4U;E=_6\;)W6DKZ-/FBC+DY6^DE+_`,F5UZ2COYWU:EI\6?L%>#/B)^R?
M_P`%@/$7PIUWXX?%7XO>'?&/P@M?'UW'XUU8:@-.U8ZL]M)]A541+6W(+XAB
M15`*@[O+3;E?LL?M<?"G]F+_`(+'_MR1_$KXG?#WX>R:QJ/A%K!?$WB.STEK
MX1Z.0YB%Q(F\+N7.W.-PSU%?HQ'\+O#,/Q$'B]?#N@KXL&FC1AK8L(AJ(L1)
MYHM/M&WS/($A+^7NV[CG&>:\]^)W_!//X`_&WQO?>)O&?P-^#_B[Q)J10WFK
M:UX,T[4+Z[*($7S)I86=]J*JC<3@*!T`H]I*Z>GPSB_1U.>-O\,4H^B,84TH
M2B^K@_G&$8R_\"DG+YGY-_'+PBWAO]H?XJ_L)^'))I_#_P"U=\1-%^)/AZ^L
MWD-K%X7OLWFO-'*F45$?3'C100)!<@]"V)OVF)='_9A_X+<_%3XT*MKHF@_`
MG5?ANNI2(HC@T_0M1L+S1[H8'"QQK=P28"G`@&`.H_9:'X'>"K?QIHOB2/P?
MX7C\1>&]/;2-(U5=*@%[I=DV`UK!-LWQ0G`S&A"G`XJAXH_9G^&_CBZ\53ZU
M\/\`P1K$WCJU@L?$DE[H5K<-X@MX/]3#>%T)N(X\G8LNX+V`K**=-0]D]8/K
MU44HPB_)0BD][N4WUL;2DJGM%4VFK.W1RDI5)*^SD[VTTM#L?D!_P1D^R^"?
M^"J7B#XM>+KK3]!D^+7P/U#XL:[?WT\=O!9VVH^)Y[J"2:5MJHD5@+8%F("K
M'U`''UI_P<5>-]%\9_\`!%/QEXBT?5]+U;P_J=WX<U"SU.SNDGL[NV?5[%TG
MCF4E'C9"&#J2I!R#BOKKQG^R3\/?%_A_6K2/PCX7T>^UKPI)X).JV6@V#7MM
MI#(RK9(9H)(VMTW;EMY$>#(&8V&09X?V4_AS)^SMH_PFU+P;X=\0_#K1--M-
M)MM`UNPBU*Q:WM518%>*961]GEH06!(90>M:R<8PIPI*RI.+BG_*JLYV?I'D
MBN^OD$9/VTJ]3>I=RMWY(1;7K)2?DK'P]_P5A^,_PP_:W_8]A^(WP8^)GP[^
M(_C[]EO6]-^*]O9^%_$MGJEPEM82@W<<@MI6:..2U,_489D45\L_M,FR_:I_
MX)2?MU?M;1PR-8_&ZZL-(\'RW$;I,GAS2+NULX'"N`T7GW"W$K(,9PA//3]>
M/A1^Q!\%O@.NL+X'^$'PO\&+XBM#I^JC0O"MCIW]IVQSF"?R8E\V,Y/R/E>3
MQ6[/^SE\/;GX,+\.)/`?@R3X>+;K:+X7;1+8Z*(58.L7V/9Y.P,`P79@$`XS
M64H+EFE]K5>3?*I/YQA"*\G/N5AZG).E)_8:OYQCK&/;24I2]>7LK?@U^UC:
MQ^)?V:O&G[(K>7)9?`FZ\=?%*[LFP3#HG]B?;]&)!!ROVW7U5?FSFR)^7"X^
ML_\`@G-_REB_9W_[,LT?_P!.EO7Z6ZI^S)\-M<U[7=4O?A[X'O-4\4:0/#^L
MWD^A6LEQJ^F@!197#E"TUN``/*<E,#I5SPY\`_`O@[Q9IVO:1X+\)Z7KNCZ*
MGAJPU&STBW@N[+2D8.EA%*J!TM58!A"I$8(!"Y%=%&JH3YWN[7\VJ=:GS>KC
M.#?G%]SG<;TU3[)I>CJ4JC7HI1G;RE%=&?A;_P`'`'_!1?5/AG^UIXUU#X2_
M%;]H+0?''PLU'2].U/2F^*NC>'?"=C(!:SQ?9?#F#J&MI*LTHG=@%0D9:2%0
MB^U?MW>%OBI^T)^U+^V]>:7^T1\</AKH?P+^'&A>,-"T;PAXFETZSEU(Z/>7
M&)``66W8POYD4+1>8SHS%C&F/U.\<_L=_"/XH>-=2\2^)OA7\.?$7B/6=.;2
M-0U74_#5E=WM]9,NTVLLTD9>2$J`#&Q*D<8K6'[/7@$/XD;_`(0?P?N\9:?%
MI/B`_P!C6V=<LHHFABMKKY/W\*1.\:QR;E5'90`"17(H26&5)/WUS-2_O225
M[>37,M[-]X\TNQ58^VYVO=T37=*<)??RJ4?G?2[2_(GXS?M::U\?OVDO@QHO
MQB_:G\8?LT^#8OV?M(^)%CJVA:[:^'8_%?B.>1!/]H:5#%=QJJY^P[3O^;:H
M!?/IW_!/J;[1_P`&F6M2>=]H\SX7^-&\W9L\W+:I\V.V>N.U?HMXW_9*^%/Q
M,T3POIOB3X9?#WQ!IO@?9_PCEIJ7AVSNX-`V!%3[(DD96WVK'&!Y87`10.@K
M8T'X%>"/"OPHD\!Z7X-\*Z;X&FMI[*3P[:Z3;PZ2\$^\S1&U5!$8Y/,?>I7#
M;VR#DUKBU&K0Q%&"M[1NWDG*HU?T4U'32T%Z+'`R="K0J2=_9\E_/EC%.WJT
MY:W=Y/;5R_&__@AO/IMO\2_@FVI/_P`$LXPV@1+;'P05'Q8,YTXA`V[_`)?2
M>+G'/^NQ5/\`X(A?L*?%/XE>`OA]XZ/P;_87\0?"[_A,=5N;GQ#XC\)W=U\2
M?)AUJZ621+GRC!]HCD0B!BV%1(LX(K]8/AW_`,$YOV>_A#XTT_Q)X3^`_P`&
M?"_B+29#+8ZII'@K3;*]LW*E2T<T4*NA*L1E2#@D=Z]*^'7PR\-_"#PG!H/A
M+P_H?A?0K6266'3M(L(K&TB>61I9&6*)50%Y'=V(&69F)R2371*LG6]OUZ+I
MO?\`X'H<\:+5!T+Z/EU](RCI_P"!)_>;E%%%<YL%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110!P7[1__`"3W3O\`L:?#O_IZL:[VN"_:/_Y)[IW_
M`&-/AW_T]6-=[79/_=8?XI?E`YX_QY>D?SD8&@?%?POXK\=:]X7TOQ)H&I>)
MO"HMVUO2+74(9K[1Q<(7@-S`K%X?-0%DW@;U!(R*WR-PQ7X<_P#!2GX+?%SQ
MS_P4R_:$\2?!OP;^T]>QZ!;Z*?%NK?#S]H[1_`U@P32(I85:PFT^2?<D1D.#
M+(269@%$@6OT6_X(S?M@R?M>_L5Z/+?:+XFT77_`HM?#>J)KOB>W\47E\186
MEW;7KZI`J1WCW%G=VLSR"-#YDLBE?ER>/#Q]O1<UNE%M>4M+][7T6G4Z<1^Z
MJ1CTEL_/E3:TZK7TV>IVFB_\$S?A'HGAOQ=I/V/QYJ%GXZN[74=7.J?$3Q%J
M4[WEL\3V]Y#-<7SR6MU&T$&V>W:.4""(;L(H#O$G_!,SX+^+/!6A^'[WPSK#
M:?H*:A%&\/BG5[>[U&/4)5FOXK^YCNEGU"*ZE17GCO'F29E!<,:]ZHH6FBZ6
M_#;[N@^9MW^?S>_WD=M;1V5M'##''##"H1$10JHH&``!P`!VKA_A!_R4'XJ?
M]C1!_P"F72Z[RN#^$'_)0?BI_P!C1!_Z9=+HO?5DI65D=Y1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%8_C3X>Z!\2=(;3_`!%H>CZ_8MG-MJ-G
M'=0G/7Y)`1^E;%%-2:=T!\T^+O\`@D]\(]3U&;4/"]OXC^&VKS#YKWPGK$U@
MQQR!Y9+1``]@@KS?Q3_P3G^*'@]6;0_$7PK^*%HGW++QWX1AAN@H`&T7MJOF
MNQ`X+;1G&>*^WJ*[J>9XF'VK^NOX[KY,FK"%5<M:*DO-)_F?G)J?PYTSX9W;
M3?$3]ECQMX;DC&#KWPZUR;58`.OF>3'*IB4'!^8$C:..U=5\+/&7P9^(%RMK
MX+_:;^)'A+4@WEC2==UTVXA?^X(;R-=S#@85FZ5]XUQOQ4_9X\!_'"U:'Q?X
M/\.^(\KM62_L(YIHQ_L2$;T/NI!KK_M9STJ7^3NONE?\T>>\CRQNZHJ+[Q]W
M\K?F?.?Q<^'7Q4\,W/AC3K'XWVGB76M:N6E\,VU[X8@CF:6,!I)%NXFP%6-V
M9]V0T89=L@)0]I_P3^URRTSX;Z!H.L.W_">3>'K;49=ZEO.TL86U,38VI&@8
M(8SM;S!*V&W%V\[^,/\`P2P\+^'UL[#X4ZI\1O`FI:K="9(]*UJ=M%L#&ZN;
MFX67?\R-M:-$=7:3;MVJKR1^\?LS>#-<^$-A=^%_$\USXBUZ1WU*?Q;]E,:>
M(MS`;I@"PAFB4I$(BQ4QHAC)`=(JQ.)ISPW+%I]?A47^&EO*][Z^F='(J5#$
MK%4IR>C7+)REO;7WI.STMITTMN>K4445X9ZP455UVUNK[1+R&QNEL+Z:!TM[
MEH1,+>0J0LA0D!MIP=I(SC&17A'_``SM\=_^CC/_`"P=/_\`BZZ*-&$_BFH^
MO-^B9QXK%5:32IT95+_RN"MZ\TH_A<^@:*^&/AM^SI\<#\:XE;XF>)-'L8--
MC&D:O/X.AFM]OF7NV&2V9]ENZH9F4G<4CN(XV,99(J]Z\$_`WXS:#XOTV\UC
MX[+KVE6MPDEWIS>"K*V^VQ`_-'YJ/N3(R-PZ=<'I75B,#2INRK1>E]I?_(M?
MB>;@LXQ%=7>%FM;;T[>NLT_N3TVN>VT5\:_&GPWX%U__`(*;V]KXA\`>./%F
MEZ]\/=8T/Q)-?^!M<USPW<^9+IEQ;V?GO;2Z>(VAMKEC%&P0R[@P\Z4!_+)_
M^";5GXG_`&:_A=I?AWX2_"KP>?B%\2Y_'6M>&=>^&BZQX<\-P2Z'J4=I!>Z1
M%-:HLL,"V4#MYL:B[+/@E@I\RG>=-3\OQYW&WSC%S3^75-_0224G%OS^7)S7
M_P#`K1^:?=+]':*_.G6/!2^&OB1^TIX5\!^#/B5#=ZEX$T.U>:Q\':_I>GZU
M+87&H#4;/2[RY58%'V6>**UA@NBBHZ)`2L1V^*_&3]F'P?/\5Y/&_P`.?@S;
M6/@?2XKN+P7\/?%?[-FO:UHFL:G+;Z>;JXBL8X[8:!(TEG;0+>7<2QN6N)0'
M56<OFCSI;Q:O=*^FNJ2U:;5E;5OIN2E*]GH]=]-5%.U]D];.]DM[V/V`HJKH
MD]Q<Z-9R7EJEC=20HTULDOFK;N5&Y`X`#!3D9P,XS@5:JI1L[,F,N9)A1114
ME'!?LX?\D]U'_L:?$7_IZOJ[VN"_9P_Y)[J/_8T^(O\`T]7U=[77F'^]5/\`
M$_S9SX/^!#T7Y'!_"#_DH/Q4_P"QH@_],NEUWE<'\(/^2@_%3_L:(/\`TRZ7
M7>5R'0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`<%^T?_`,D]T[_L:?#O_IZL:[VN"_:/
M_P"2>Z=_V-/AW_T]6-=[79/_`'6'^*7Y0.>/\>7I'\Y'RY^U[_P19_9A_;Q^
M+<'COXJ_"C3/$WBV"WCM3J,>IW^FR7,<9^03"UGB6<J/E!E#$*`N=H`'LO[.
MO[+7P]_9)\'ZCX?^&_A/2O!^BZMJMSK=U9:>A6%[NX8-+(%).T<*JHN$155$
M554*.^HKCA[D>6&BUV\VF_O:3?FDSHG[[YI:O3?R5E]R;2\M#B?V@OCC8_L\
M?#2;Q)>:3K.O,;VSTRRTO21!]MU*[N[F.UMX(C<2Q0JSRRH-TLL:*"2S`#->
M)ZI_P5-T*S\$QZC:?"WXN:QK5K'K-SKOANPLM,EU3PS;:3<_9KV>Y/VX6TJK
M*0J):3W$LWS>4CE)`G??MZ?`/6OVFOV;-4\&Z-;>']635+JU.IZ)KEY-8:=X
MCL$F1KC3YKJ"*6:V66,$>;'%(P(`VE6:OFWP-^P#\:O@K\/K&U\%V7PCLVOO
M#NN^#SX<O/$6IRZ7X'TR\NHYK(6-W]B,^H+;8FS#-%:AQ*D:2P)$-V2E.\K+
MO:^FJC>"])3]V3Z*[;I\JE4TM#W4^ZNUVO[W3>,=5IJ[)*=VH?=7A_7K/Q5H
M-CJFG7$=YI^I6\=U:SQG*3Q.H9'4^A4@CZUQ_P`(/^2@_%3_`+&B#_TRZ76W
MX#^'5MX$^%.B^$H[BZGL]&TF#2%G$C0SR1Q0K$'W(04<A<Y4@@\@BN4_9Y\.
M6_A'Q+\3=/M9+^:WM_%$6U[V^GOISNT?3&.Z:9WD;DG&YC@8`P``.FLH*I)4
MW>-W;TZ'/1<W3BZBM*ROZ]3TRBBBLS0****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**K:QI-OK^D75C=(TEK>PO!,J
MNR%D92K`,I!'!/((([5XY_P[J^#?_0G_`/E6OO\`X]7#C*F,BU]5IQDNO--Q
M^ZT)W_`[L'3P<D_K5247TY8*7WWG"WXGH/ACXY>$?&GCG4O#6EZ]87VN:3G[
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ML\_$[XU?M'7%W'X'^&/B3X97'@'7?!=W;:IX\U+2-1U9=36T=U=+?2Y1`F^T
M\DO'<,X28R`!D$;<GX&_X)T>-/%W@_PYI/C[7=:TO1=+\=GQ*FC:5\6O$VKW
MVB60T2ZL/)M?$$HM=3E:2ZF69HV:.-$:1%+#A_IZ=Y03>]O3[;7XPLU:^MV[
M+0^;GRIZ>?\`Z0FK?]OW3O;2R6NI[UX=_;B^%?BFV\:36OBZWCA^'6GPZIXE
MDN[2XLUT:&43$"8S1J%E4V\Z20_ZV*2)HY%1QMKEA_P4_P#@ZUA`R:GXVEU:
MXO9+!?#D?P^\0R>)E>.&*=Y&T=;$Z@D"Q30L9VMQ#B:/Y\NH/`^.OV3?B]\0
MOBC\8`=/^'VB^%_%7A72M#\,:D_B_4M5U,7.DW5U<6<E];O8Q9CG:Y`FVW<C
MJ(C\TQD)7S#XU_\`!-_XX?'#X^ZE\8KUO"NB^,]>T63PQ_8/AOXM>)O#ECH,
M`$!@U`:EIUG!/J4PDCD9K2>VBB*M&OFYCW,<WOKE3<6K]GU[V5VTE9M<M^:3
M45<A::3_`*T5_DKMWL^:UHKF:/T*MKA;NVCE42*LBAP'0HP!&>58`@^Q`(J2
MJ'A;3+O1?#&FV=_J$FK7UI:Q0W%])$L37DBH`TI1?E4NP+8'`S@5?JYI*347
M=?UZ?D33<G%.2L^H4445)1P7[.'_`"3W4?\`L:?$7_IZOJ[VN"_9P_Y)[J/_
M`&-/B+_T]7U=[77F'^]5/\3_`#9SX/\`@0]%^1P?P@_Y*#\5/^QH@_\`3+I=
M=Y7!_"#_`)*#\5/^QH@_],NEUWE<AT!7XI?M;?M<_M,?L5_M+7GA74O#.N:+
MJ'Q4TWQ?86GB[7OC,USHNK2)#-?6EY8:1%%=/I(M(8?)B,<%N)6F`G92/-7]
MK:^0_P!I[]E;X7^!?VE/V?9M#^&_@+1YOB%\5M1/BF2Q\/VENWB4OX(\7[_M
MQ2,&YW>=+GS=V?-?^\<YU(-NZ[-?>K6VV[[^CW6D));]T_NZ^=NB_%%C_@E5
M=>*M*TWXE>'?&]IXI\,^)M(UJTN)/".M^.KKQTWAR">P@,?E:Q=2//<).R2R
MF-]GDN754V%9)/K2N1^#/P!\"?LX^%)-!^'G@GPCX#T.:X:[?3O#NCV^EVCS
M,%5I3%`B(7(506QDA0,\"NNK>I+F=_)+[DEW?]=%LN>G!QC9^?Y^B_K=MZA1
M114&@445^?WQR\8?$[X`_MQ:7X@U+1/C%JBZ[XYD33;K2O%D-WX7U+PW'H<T
MTFFQ:"+WSGOU>"6;S$TYI#*B_P"D^6VP3[1*:C+1=^FZ7ZW_`,*D]6DG7*^1
MR6MKZ>B;_2R\VKV5VOT!HKX9_P"";G[9G_"T?VGOB'X;\17GQ:E\8>(K#2O$
M<VC:YX(\2Z;IWA8SK??Z+']NM$@LX5CMTA1R8ENY;:61`\C.!8_9/_:RU'XO
M_P#!1#5(]7C^,6BMXCT#4DL?#>N>"_$6DZ/I%O97L,=M)NNK=+-IY4\^9[A&
MY-S'!O?RX]U0]ZK&BMVI/NERQ<FM-]FK[$3?+2=5K1.*_P#`I**?XW[GV]11
M10,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`X+]H_
M_DGNG?\`8T^'?_3U8UWM<%^T?_R3W3O^QI\._P#IZL:[VNR?^ZP_Q2_*!SQ_
MCR](_G(****XSH"BBB@`K@_A!_R4'XJ?]C1!_P"F72Z[RN#^$'_)0?BI_P!C
M1!_Z9=+H`[RBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MH[FZCLH&EFDCABC&6=V"JH]R:X?Q5^U-\,_`X;^V/B%X)TQEZI<ZW;1N?8*7
MR3P>`,UI3I3F[03?HKD3J0AK)I>IWE%?/OB+_@JA\!/#<WDM\0K&_N"=J1:=
M975\TK<\*8HF'..N<=.>:S?^'FWA_6^/#/PT^-7C#=PDFF>$I?)/7!+RLFU>
MG..-PXZX[(Y3C&KNE)+S5E][L<SS'"IV]HF_)W_(^E**^&/VROVTOCK?_`'7
M;CP?\&O&'@BQ2$F^\0:A<PF\L+;H[16Z$NK8(S)SY8WG`(WK+_P1,^*_Q0\?
M_"'4+'Q5:S7W@O2CY>A:U>2M]I=P</;*""98EY(<D;"-@W#`CZIY'6A@Y8R4
MH^ZTK73?X-J_EO;7UYXYM3EB5AHQ>JO>S2_%?CL?<5%%%>*>H%%%%`!1110`
M4444`%%%%`!1110`4444`<%^SA_R3W4?^QI\1?\`IZOJ[VN"_9P_Y)[J/_8T
M^(O_`$]7U=[77F'^]5/\3_-G/@_X$/1?D<'\(/\`DH/Q4_[&B#_TRZ77Y?\`
M_!Q]^W7\6/V3_P!HWX6:/\/_`(@:_P"#=)US0[F>_33F4"61;@*LA!!R0O'T
MK]0/A!_R4'XJ?]C1!_Z9=+K\7_\`@[6_Y.E^#?\`V+=W_P"E0KKR2,98R"DK
MK7?7H<^:2<<-)Q=CQ2W_`."@G[2UU;1S1_M*:])'(-RD7*\C_OBN,^*G[;G[
M0VM^._AG<ZA\?];OKK2?$LUUILS3J3IUP='U.%IA\G4PRS1?28U\N+]VL3Q9
M_P`A[PQ_V$W_`/2.YK]"KX+#**M3CNNB[KR/C:.(KM_&]GU?9GWI_P`-^_M-
M$_+^TEKF/^OE?_B*Y/XO_P#!5+]I+X4>&FO&_:'\3:C=R<0VT$REF/\`>;Y.
M%'Z]O;Y3!Q7,?$PYTIO]VJK8/#1IMJG'[E_D%'$5G-)SE][/ZO\`_@E%\5_$
M/QT_X)O?!GQAXLU2XUKQ)XB\+VM[J-]/CS+J9E^9VP`,GZ5]"5\M?\$2/^42
MG[/W_8FV7_H)KZEK\GG\3/T"/PH*XW1/V=OA_P"&OC#JGQ#TWP+X-T_Q_KEN
M+/4?$UMHMM%K&H0#RP(IKM4$TB?NHOE9B/W:<?*,?SKZW_P55_:.U_X\^-M#
MC^/'BG0H=-UV^MK-))4$/EI<2*L8.S@A0``>N/6M8_M^?M-+_P`W):[_`.!*
M_P#Q%?34>%<3.*J1G'5>?7?H>'4X@HQ;@XO\.GS/VMT'X>Z!XY_X*=_&:SUK
M0]'UBS?X:_#S4&@OK..XC:Y@UKQ?)!.5<$>9&\43(_WE:-"""HQ]%MX?T]]?
MCU9K&S;5([=K1+PPK]H2%F5VB#XW!"RJQ7."5!QD"OYDM"_;;_:&M?VC_%FJ
MQ?M`:U%K%YX:T6UNM0\]=US;Q76K-#"3MZ1O-<,/^NYKM1^W[^TT?^;D=>_\
M"4_^(HI<)XEJ\916K[[[-[=?R"IQ%1O:49;+MY-=>A_2)17\S>B?\%;_`-HW
MPS^TU\.?#1^.WB?7XM6\4:59Z@JR(T'DRWD2/$<I\Q96(/8`^O3^F2O'S#+Y
MX.I[.;3?D>E@\9'$PYXII>84445YYV!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`<%^T?\`\D]T[_L:?#O_`*>K&N]K@OVC_P#DGNG?]C3X
M=_\`3U8UWM=D_P#=8?XI?E`YX_QY>D?SD%%%%<9T'S3_`,%;+N_@_8LU*&WU
MG2/#NDZAKNB67B#5-8LI;S2K'2)=3MDOGOHHY[=FLC`76X!FB7R6EWNJ;B/A
M75-?^"_B3X76>G_%72?@;:_#.Q\+>,=/^&]SX8T$:)X0\2:Q'?0JE_H=D)9@
MFI2(X6`V\TL[NMP]LY#R`?L!16:IVYM7K?;=7BHJS_NZRCT4I.33:5M/:?#Y
M6_!M_P#DVD9=XI)6UOR?PC?Q%'\"_##:U&9O%BZ#:F_CNY/++WOV=/,$C*K;
M<R9!*JV.2`>E<_\`L\W&J7?B7XFR:U9V%AJ3>*(O.@LKQ[N"/_B3Z9MVRO%$
MS97!.8UP21SC)],K@_A!_P`E!^*G_8T0?^F72ZZ*U3VE24[6NV[+97.>C3]G
M3C3O>R2OWL=Y11169H%%%%`!1110!YC^V-^T<O[)7[.'B3X@MHYU_P#X1_[-
MBP%U]E^T&:ZAMQ^\V/MP9=WW3]W'?-?&_P`'_P#@OW#\3?BUX7\-WGPOBT6U
M\1:M:Z9+J#^*1(EBL\R1&9E-H@*INW$%EX!Y%?67_!0#]G[6OVI/V1O%W@7P
M[/IMMK.MBT:VDOY'CMP8;R"X8,RJQ&5B8#Y3R1G`R1^2/[,O_!+WXL_&+XV:
MAH;Z'INA_P#"%W\2ZQ+KZR&R1U97\G:BGSBZ88*IVLC`[@&!/G8JECYU;X;X
M$E=Z65W;6^O;8^\X;CPW_9\WFS7MG*7+K).RBFK)-)ZWW^>A^U7_``N_P7_T
M-_A?_P`&L'_Q5::>.]#E1676=*96&01=QD$?G7P=:?\`!"Q-9F\S6O'?AVWC
M;K;:/X&LX`G7I+([L>W4<?K72>&_^"!'P9TUQ)JFJ>-M8E_B4WEO;0GZ+'""
M/^^J]6IAYQ6E2#].?]8(^3C4RV7_`#^CZPIO\JI]CZC\2_#FD6QFN_$&B6L*
M]9)KZ)%'&>I;'0'\JXSQ/^VK\(/!R,=1^)W@.!H\YC&N6\DO&<_(KENQ'3KQ
MUKRO1_\`@C+^SEI5NJOX!DO9%_Y:W&MWY8_@LP7]*U8O^"27[.T*;5^&>F_\
M"O[QC^9FKGC*HG[T4_237_MK-94<L:]VK47_`'#B_P#W*A=3_P""KWP)M+UK
M2Q\93:]??PVVDZ/>WCOSC@K%LZX'WNX]:KK_`,%(X=?P/#/P:^.7B,/]RXC\
M+FVM&Z8_>RN,9R#TZ<T:C_P2"_9RU5%63X:VBA3D>3JM_"?Q*3C/XU4_X<S_
M`+-G_1-__+@U3_Y)KJCBH16E"[\ZC_2FOS.=X/!2WQ4UZ4(_FZ[_`"+8_:D^
M//BC_D!?LXW5I"V,7.N>+[.TV=.L*JS^O?C'X4"__:T\5[?+L/@;X3MV^\+F
M?4-0NDZ=-F(_7.?7VS53_AS/^S9_T3?_`,N#5/\`Y)H_X<S_`+-G_1-__+@U
M3_Y)JO[2JKX,-37_`&]-_G=?@+^S<K?QXNL_^X5-?E51:'[.O[1?B@9U;]H/
M3M$C;[UOHG@NU;=])9F+CH#P.=Q'3%+_`,.\-2\0C_BIOCQ\<=6_O0V>NIIM
MO)_O1QQ\X^4]>HSWQ5,?\$??@;&-L>C^)(8UX2-/$U^%0=@/WO0=*7_AT!\$
M?^@7XH_\*>__`/CM']L8]?!"$?117XJ%P_L;)'\5>H_6%_SK6+]M_P`$GO@I
M<7"S:UH>N>*;E3D2ZQX@OKA@>>PE53P<<@]!WKN/"O["7P9\&%38?"_P0KI]
MV2?28;F1?HTBLP_.O./^'0'P1_Z!?BC_`,*>_P#_`([2'_@D1\'[4[M/_P"$
MXTF7HTEIXIO59U_NG<YXZ'\*SJ9MF<U:<FU_C?Y6+AD^11^&I)/_`*\Q_P#E
MESZ.\/>#])\(P>7I.EZ;I<9&"EI;)"I_!0*TJ^7_`/ATO\-?^@]\4/\`PK;K
M_&C_`(=+_#7_`*#WQ0_\*VZ_QKC=7$-W<5_X%_P#J6#RM*RQ$O\`P7_]N=5^
MVO\`\%`?!7["\/AQ?&&E^)=4_P"$K^U"U32+:";:(/)\SS/-FC`!\],8SGGI
M7,?L.?\`!2;X8?M8^,9O`?@'PWXE\-MH6D-J$4%YIUI:6<=O'+%$4C$$SA2&
MF3"[0,9YXQ7S%_P47_X)!^)-0;P:WP=TOQ1XN\O[:-7&L>)HI?LN?L_D>7]J
ME3&[$V=F?NKG'%:W_!'C]@;XM?LM?M-ZYXB\>>$_[!T>[\,7&G0SG5+*ZWSO
M=VDBIMAF=A\L3G)`''7)%>=]:QGUKV;C:%UT;6W<^L_L7A_^PWBHUE*ND[)R
M497YK+W+M[??N?I)1117LGYT%%%%`!1110`4444`%%%%`!1110`4444`<%^S
MA_R3W4?^QI\1?^GJ^KO:X+]G#_DGNH_]C3XB_P#3U?5WM=>8?[U4_P`3_-G/
M@_X$/1?D<'\(/^2@_%3_`+&B#_TRZ77XO_\`!VM_R=+\&_\`L6[O_P!*A7[0
M?"#_`)*#\5/^QH@_],NEU^+_`/P=K?\`)TOP;_[%N[_]*A7;D/\`OL/G^1RY
MM_NLC\OD^[69J?@?1=;O&N+S1]+O+A@`TLUI'([8X&21FM-/NTM?ITH1DK25
MSX:,I1UB[#8(([6!(HD6..-0J(HVJH'``'8"N9^)G_(+;_=-=17+_$S_`)!;
M?[IK+$?PGZ&E'XT?U/?\$1_^42?[/O\`V)ME_P"@FOJ:OEG_`((C_P#*)/\`
M9]_[$VR_]!-?4U?D$_B9^BP^%'\>_P`7/^3AOB%_V,VH_P#I5+676I\7/^3A
MOB'_`-C-J/\`Z52UEU^N8/\`@1]$?G>(_BR]3F]$GOY_'E[=3:-J%I:W5G!;
MK++);D*T3SL<A)6;!\Q0,`\YSBND#8HHK:E3Y%:]]6]?/7I8BI/F=[?TBK\(
M#G]KCX5_]CIHW_I?!7]DU?QL_"#_`).X^%?_`&.FC?\`I?!7]DU?GO$O^]?(
M^PR/_=_F%%%%?.GLA1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`<%^T?_P`D]T[_`+&GP[_Z>K&N]K@OVC_^2>Z=_P!C3X=_]/5C7>UV3_W6
M'^*7Y0.>/\>7I'\Y!1117&=`45QGQ]^+T?P3^&=YK*6;:KJTTD=AHVEI(L<F
MKZA.XBMK52Q`&^1E!8\(NYVPJL1\N7?[9/QR\6_#?1K7PW)\*;'QMI?A+7?%
M7B*[U/1=0GTO4FTZ_:RBL[2".\26V$[([-/)+/Y(50(9BQV1*I%:R>FOX1<Y
M?^`Q3D^MK63;2*C!MV6[M^+45]\FDNE][)-GVM7!_"#_`)*#\5/^QH@_],NE
MUM^`_B/8^-_A3HOBYL:;INL:3!K!^TR*HM8I(5E^=ONC:K<G..#7EWPL_:3^
M'6G>.?B5-<>/O!4$-]XCAGMGDURV5;B,:1IL9="7^90\;KD9&Y&'4&MJE.5.
M;A/=.S]494ZD9P4X;-77HSW*BN#_`.&J/AA_T4?P'_X4%I_\<H_X:H^&'_11
M_`?_`(4%I_\`'*@L[RBN#_X:H^&'_11_`?\`X4%I_P#'*/\`AJCX8?\`11_`
M?_A06G_QR@#O**X/_AJCX8?]%'\!_P#A06G_`,<H_P"&J/AA_P!%'\!_^%!:
M?_'*`.\HK@_^&J/AA_T4?P'_`.%!:?\`QRC_`(:H^&'_`$4?P'_X4%I_\<H`
M[RBN#_X:H^&'_11_`?\`X4%I_P#'*/\`AJCX8?\`11_`?_A06G_QR@#O**X/
M_AJCX8?]%'\!_P#A06G_`,<H_P"&J/AA_P!%'\!_^%!:?_'*`.\HK@_^&J/A
MA_T4?P'_`.%!:?\`QRC_`(:H^&'_`$4?P'_X4%I_\<H`[RBN#_X:H^&'_11_
M`?\`X4%I_P#'*/\`AJCX8?\`11_`?_A06G_QR@#O**X/_AJCX8?]%'\!_P#A
M06G_`,<H_P"&J/AA_P!%'\!_^%!:?_'*`.\HK@_^&J/AA_T4?P'_`.%!:?\`
MQRC_`(:H^&'_`$4?P'_X4%I_\<H`[RBN#_X:H^&'_11_`?\`X4%I_P#'*/\`
MAJCX8?\`11_`?_A06G_QR@#O**X/_AJCX8?]%'\!_P#A06G_`,<H_P"&J/AA
M_P!%'\!_^%!:?_'*`.\HK@_^&J/AA_T4?P'_`.%!:?\`QRC_`(:H^&'_`$4?
MP'_X4%I_\<H`[RBN#_X:H^&'_11_`?\`X4%I_P#'*/\`AJCX8?\`11_`?_A0
M6G_QR@#O**X/_AJCX8?]%'\!_P#A06G_`,<H_P"&J/AA_P!%'\!_^%!:?_'*
M`.\HK@_^&J/AA_T4?P'_`.%!:?\`QRNUTS4[;6M-M[RSN(+NSNXEF@GAD$D<
MT;`%75APRD$$$<$&@">BBB@`HHHH`****`."_9P_Y)[J/_8T^(O_`$]7U=[7
M!?LX?\D]U'_L:?$7_IZOJ[VNO,/]ZJ?XG^;.?!_P(>B_(X/X0?\`)0?BI_V-
M$'_IETNOQ?\`^#M;_DZ7X-_]BW=_^E0K]H/A!_R4'XJ?]C1!_P"F72Z_%_\`
MX.UO^3I?@W_V+=W_`.E0KMR'_?8?/\CES;_=9'Y?)]VEI$^[2U^H'PH5R_Q-
M_P"06W^[745R_P`3?^06W^[6.(_A,VH?Q$?U/?\`!$?_`)1)_L^_]B;9?^@F
MOJ:OEG_@B/\`\HD_V??^Q-LO_037U-7X_/XF?HD/A1_'O\6SG]H;XA_]C-J/
M_I5+676G\6_^3AOB'_V,VH_^E4M9E?KF#_@1]$?G>(_BR]0HHHKJ,2K\(#_Q
MES\*_P#L=-&_]+X*_LFK^-GX0?\`)W/PI_['31O_`$O@K^R:OSGB7_>OD?9Y
M'_N_S"BBBOG3V0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M."_:/_Y)[IW_`&-/AW_T]6-=[7!?M'_\D]T[_L:?#O\`Z>K&N]KLG_NL/\4O
MR@<\?X\O2/YR"BBBN,Z#E/C'\!_`_P"T5X17P_\`$'P9X4\=:"LZW0TWQ#I%
MOJEF)E!"R>5.C)O4,P#8R-Q]:\#7_@D7\-O"G@K3=`^'^K>*?A'I]M;:KIVH
M+X*CTS3?[=L=2G2:YM;D&S=0`8T6.:!8KF)%PDRY)/U/14\JW_IZ6=^Z:T:>
MC6CTT*YGH^VWEUT[-/5-:IZK4I^']!L_"N@V.EZ=;QV>GZ;;QVMK!&,)!$BA
M411Z!0`/I6;X1\$CPIX@\47PN3/_`,)-JB:D4\O;]GVV5K:[,Y.[/V;=GC[^
M,<9.]16DI.3YI;F<8J*Y8[!1114E!1110`4444`%%>'_`/!1GXD^*/A-^R)X
MBUKP7>ZUI_B1;[2;*TFT>&PEU'_2=3M+:1;=;]6M/.:.5U0W`\L,P+$`9'A/
M[$/[3WQ2US]KJS^&/CO7/%TDFG67B:ZN]+\6:=HL7B".*+_A&I-/>\FTE/L#
MN%U"]*FR;RS')&LN9HW"E']Y4=):-)O79V5VEYVZ%2BU%2[NWIHW=^6EK]VD
M?<U%%%!(4444`%%%%`!6#\.O!(^'_A^XL5N3=?:-4U#4MYCV;?M=[/=;,9/W
M/.VY[[<X&<#>HH`****`"BBB@`HHHH`**^*Q^UQXSU']OC6K+6&^+.@_#;0?
M%\'@/2Y-&LO#4WA74;Z32XKH'4GF:36A,\UQY:M;)%`H2`,3NE8^!V'_``4F
M^,DW_!**X6;QLD7[0K>'6\50>(/[%LF)TDZ.^NK??91%]FV>7')I^XQX\Y02
M"3R4OWD/:+;W?_)[6]'RM2:WY7S6L:QI.57V*:O>WS]Y/ULX..GVM%=GZH45
M7TB=KK2;620[I)(D9CCJ2`35BG)6=CFIU%."FMFK_>%%%%(T"BBB@`K!^%W@
MD?#3X9>'?#:W)O%\/Z7;::+@Q^7Y_DQ+'OVY.W.W.,G&>IK>HH`****`"BBB
M@`HHHH`X+]G#_DGNH_\`8T^(O_3U?5WM<%^SA_R3W4?^QI\1?^GJ^KO:Z\P_
MWJI_B?YLY\'_``(>B_(X/X0?\E!^*G_8T0?^F72Z_%__`(.UO^3I?@W_`-BW
M=_\`I4*_:#X0?\E!^*G_`&-$'_IETNOQ?_X.UO\`DZ7X-_\`8MW?_I4*[<A_
MWV'S_(Y<V_W61^7L?W!3J;']P4ZOU`^%"N7^)O\`R"F^E=17+_$W_D$M]*QQ
M'\)FU#^(C^I__@B1Q_P24_9^_P"Q-LO_`$$U]2U\M_\`!$GC_@DM^S__`-B;
M9?\`H)KZDK\?J?$S]$A\*/X]OBW_`,G#?$/_`+&;4?\`TJEK,K2^+?\`R</\
M0O\`L9M2_P#2J2LVOUS!_P`"/HC\[Q'\67J%%%%=1B5_@_S^UU\*?^QST;_T
MO@K^R2OXV_@]_P`G=?"G_L<]&_\`2^"O[)*_.>)?]Z^1]GD?\#YA1117SI[(
M4444`%%%%`!1110`445YG^TO^USX*_9&T/2=2\;MXLAL=:O8M-M9M&\(:OX@
M7[3--%;P0R?V?;3^4\TT\,40DVF620(FYN*`/3**P_AO\0K#XJ^"-/\`$&EV
M^N6MAJ2,\,6L:+>:-?(`Q4^9:7D45Q$<J<"2-21@C(()W*`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`."_:/_P"2>Z=_V-/AW_T]6-=[7!?M'_\`)/=._P"QI\._^GJQKO:[
M)_[K#_%+\H'/'^/+TC^<@HHHKC.@****`"BBB@`HHHH`****`"BBB@#E?C5\
M%_#O[0GPUU#PCXJM;VZT/4VA>9+/4KG3;A7AF2>)X[BVDCGB=)8T</&ZL"HY
MKR-_^"6OP=^TV5Y%:_$6SUJRFNIO[=M/B;XFMM<O#<I:I,MSJ,>H+=W2%+&S
M4)/*ZHMO&%"@8KZ&HHC[LN>.C[CYGM_6NC^]#8T\J-5&["C`R23^9Y-.HHH$
MM-$%%%%`!117P_\`$C_@H!\8)OB!^VMX7\#Z#X)O]9_9VT;1=4\'P7EC=2G5
MY+G2VO[B&["7">83L9(_*\K;N7=O[Q.I&"E*6T8N3]$TG^:-*=.522C'=M+Y
MMI+\6?<%%?G]\:_^"OWB'5=#\.ZU\)+'PGJ.DS?`/7/C;K1UBVGN'MHX[5/[
M+MT,4\6W?=^>LP8,2D#!3&WS5YYX3_X+@_$K5?\`@G9J6O7WA[P%#^T?;^)8
M/#MIHL=I>?V'=)<6"ZU%?>1YYN!`-',LK?O^9(&`8;@HNK^[4W+[&_\`X,E2
M]/CBU^.UVLZ?[Q4W'[>WR@JFO;W))_.VY^HE%?"O["G_``4Z\>_M._M"?!'P
MGKVD>$+/3OB5\!(OBEJ<FGVMQ'-!J;7MO;F&$O.ZK;;)F.UE9\@?O,9!^ZJU
MJ494W:7>2^<9R@__`":+^6I$*BEMVB__``**DOPD@HHHK(L****`/*[W]BKX
M;ZA\>E^)4NAWQ\5?:EU!@NMWZZ7+>K;?9%O7TX3"R>\6WQ$+EH#,$55#@*N,
MI/\`@G?\&4TH6?\`P@MCL7P"?A<)3=W)N5\-G.=.$WF>8$.<[]WF9YWYKVFB
MB/N_#I_PS7Y-KT;6S92G).Z>NGX--?<TFNS28VW@6U@2.-=L<:A5&>@'`IU%
M%!$8I*RV"BBB@84444`%%%%`!1110`4444`%%%%`'!?LX?\`)/=1_P"QI\1?
M^GJ^KO:X+]G#_DGNH_\`8T^(O_3U?5WM=>8?[U4_Q/\`-G/@_P"!#T7Y'!_"
M#_DH/Q4_[&B#_P!,NEU^+_\`P=K?\G2_!O\`[%N[_P#2H5^T'P@_Y*#\5/\`
ML:(/_3+I=?B__P`':W_)TOP;_P"Q;N__`$J%=N0_[[#Y_D<N;?[K(_+V/[@I
MU-C^X*=7Z@?"A7+_`!-/_$J;Z5U%<O\`$SG2V_W:QQ'\)FU#^(C^J#_@B5_R
MB6_9_P#^Q-LO_037U)7RW_P1*_Y1+?L__P#8FV7_`*":^I*_'ZGQ,_1(?"C^
M/7XN?\G#?$/_`+&74O\`TJEK-K2^+?\`R</\0O\`L9M2_P#2J2LVOUS!_P`"
M/HC\[Q'\67J%%%%=1B5_@[S^US\*O^QST?\`]+X:_LDK^-OX._\`)W'PK_['
M31O_`$OAK^R2OSGB7_>OD?99'_`"BBBOG3V@HHHH`****`"BBB@`KY__`."E
MG_)NOAS_`+*K\./_`%-]"KJ_VU?BCXN^#?[.FK>(/`]K]K\16MYIT$?_`!2^
MH>*/LT$U_;PW-Q_9MA)'=77DV\DLOEPNK'R\]`:^%O\`@I3^VWXK;]E'X,ZM
M'XR\*W7A6^\;:-?>+?&'_"J/$$&GZ3>Z5XST'RH;FU:]\S1C"PN6FBOY2\QL
MG@C,,LJE737.^5=[?A?[NW=Z*[T*Y7:_K^"O_7;=V6I^GU%>-?MS?&KQG\#?
MV4/%'CKX?6_A'4M1\.Z;-J\LNMR3O:+;0P23%HXH,-.[E$C"F:)5$IDWMY8B
MD]AM93-;1N>K*&./<46?4B^S[ZDE%%%(84444`>+W/[?7P[L_P!H:S^%DT/Q
M(B\::E+/':6[_#;Q&MG=)!+##/<1WQL?LC6L<ES;J]R)C`OGQ9D`=2?:*^?_
M`(C?\I3?@W_V2KQY_P"G?P97T!0`4444`%%%%`!1110`4444`%%%%`!17%_M
M'^,O$'PZ_9[\=>(/">F_VQXIT/P_?W^CV'V&:^^VWD5N[PQ?9X2LLVZ157RX
MR'?.%()!KY5U?]N7XE/^SQI6K:#XJT?Q!XDC\:?V%XFO;7]GWQ@T_A6T.F37
M:"X\-+?'55D>06H$[2+$8[M&"$$,9YEKY)/Y-V_-[NRZ*[T*Y79/O?\`!7?_
M``.ORU/MZBO,[?XFZ[XW_96T[Q9X#U7P7XNUK5M%MK^PU:1+BQT6]$B(SW:P
MJTTPC"%Y$MS)N8JL331Y,RW?V4OBEJ7QQ_9@^'7C36(K&#5O%OAK3M8O8[.-
MH[>.:XMHY7$:LS,J!G.`S,0,9)/-:NFU*<?Y&D_GS6T>OV7_`%<S4M(O^:_X
M6_S1W]%%%04%%%?)O_!4#PCXJT_3M%^)%FEWJ7@/X9Z'K.I^*-*M/BSK?P_N
M)@OV2>.XCDTY-EY)'%;72+#=R0Q;K@9D4%B)<DFN;1=7V5F[_A;MKJTM2Z=-
MS?+'?IYOHOZ^2>Q]945\9O-KWPN_;ST'QQXD@UC4_!OQ?URVTSP?-#\5=<C?
M1R^@A_L\_A=E33'C\RSNY&F22656G5S&-K.G"_\`!0/QUXNMOVT(K[1=4\91
M^#_`D'AJ;Q'J^D^-[O1K?P%YVJ2,TDFCQRI!KHO8=L;K,K"!(B8Q*[>2=.5J
M4(RTYG9_W7:[3Z*UU>]EKHW=7RE-*#FG]E27FGIIWUOM=Z/2]TOT&HHHJ2@H
MHHH`X+]H_P#Y)[IW_8T^'?\`T]6-=[7!?M'_`/)/=._[&GP[_P"GJQKO:[)_
M[K#_`!2_*!SQ_CR](_G(****XSH"O@#XP_ME?$OP%^WMK5G;^(/&/_"#Z%JK
MVX0Z+IK>`[F!-$>8Z;)J`MSJ*:XUXI(7SA;!#&AS*PB;[_KR.[_86^&-]\;6
M^($VBZK)KTFH#6'M3XBU+^Q)+\0?9Q>MI7VC^SVNO+`'GFW,F0&W;@#6-2$Y
M/W7;1_?=:VZZ7^=MU<N,DHM-7_X9]=UK;Y7ZV9YC^Q)\0?B-'\4](TCQO\0M
M0^(-OX\^'5AXXC%YI-AIZZ!>/-LN+:U^R0QEK1A/%L6X:::/R#NFEWG;[Q\7
M/B]+\(M(O-3F\*^(]9TC3;*2_O;[3GLO+M(HPS/N6:XCD8A5+81&R.!D\5S_
M`.SG^QC\.?V4)+^3P/HNH:?)J%M;V#/?:Y?ZLUK9VYD-O96QO)I3;6D1ED,=
MM!LA0NVU!FM;]JC_`)-A^(__`&*^I_\`I)+754E&7PJV_P",FTO^W8M1ON[7
M>K,(1DF^9WV\MHI-VZ7DG*VRO9;'>4445F:!1110`4444`%%%%`!1110`444
M4`%?+O@[]A/QY\+?V\_BK\7?#/Q'\&KX;^,EQHC>(/#>K^";B]NXH=.LQ:>7
M;7T>IPI&TJ[VW26LH4LORL%.[ZBHH22ES>5O*S:;36S6BW"[Y7'O_G?Y?(^!
M?V7/^"%.F_LQ_!/]HCP;;_$B\UM?C5HE[X4T&ZN=&V_\(+HDHOVM[")/M!^T
M)#+J$\A.Z+?A1A,`TRW_`."#6@Q_M.:7\2I/'UY)<:7\)4^'0TTZ2?L[ZHFF
MOI:Z[C[1@.+*1XA!M)`8GSN2#]^T5$Z<9Q<):IJS\URSCKYVG*[W;?,VY6:I
M3:ES];M_-N$G\KPA9;)+E24;I_(G[(?_``2L_P"&5?C3\)_&'_">?V]_PJ_X
M.Q_";[)_8GV7^T]MW!<?VAO\]_*SY.WR=K_>SYG&#]=T45O4JRGK+O)_.4G-
M_?*3?E>RTLC.,%';LE\HQ45]R27RN]0HHHK,H****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`X+]G#_DGNH_]C3XB_\`3U?5WM<%^SA_R3W4
M?^QI\1?^GJ^KO:Z\P_WJI_B?YLY\'_`AZ+\C@_A!_P`E!^*G_8T0?^F72Z_%
M_P#X.UO^3I?@W_V+=W_Z5"OV@^$'_)0?BI_V-$'_`*9=+K\7_P#@[6_Y.E^#
M?_8MW?\`Z5"NW(?]]A\_R.7-O]UD?E[']P4ZFQ_<%.K]0/A0KE_B7_R"V_W?
M\:ZBN7^)?_(+;_=K'$?PF;4/XB/ZH/\`@B5_RB6_9_\`^Q-LO_037U)7RW_P
M1*_Y1+?L_P#_`&)ME_Z":^I*_'ZGQ,_1(?"C^/7XM_\`)P_Q"_[&;4O_`$JD
MK-K2^+?_`"</\0O^QFU'_P!*I:S:_7,'_`CZ(_.\1_%EZA111748E?X._P#)
MW'PK_P"QTT;_`-+X:_LDK^-OX._\G<?"K_L=-'_]+X:_LDK\YXE_WKY'V61_
MP`HHHKYT]H****`"BBB@`HHKYU_X*$?MLZA^QCI?@V:PTG3]3;Q5J$UB[7DC
MJEOLCWAOE]>A]*Z<'A*N*K1P]%7E)V73\688G$0H4G6J_"MSV3XM^`]4^)'@
MN;2]'\:>)OA_?22(ZZQH,&GS7L04Y**M_:W5OM8<'="3CH5/-?%?_!1;]@BQ
MTG]C#P_X17XD?$R;PWK'Q+\(Q>*;22XT[S/&-QJGC72!<WEW<"S%Q!.K3,\8
ML9;6*,HBB/RU"5N0_P#!1OXM3Q+(OP]\/O'(`RLLTY#`]"#GFO'OVZOV\OBA
MXJ^"6AVU[X#T6UAB^(?@>[5TDFRTL'BS2)HDY/1I(T4^S&OHY\#9M3BZDJ:L
ME=^]%Z=5OJM$VMFTG:Z1X5/C#+)R4(U'>ZMI):]'MOJTGNDVKV;/MCX^_L<-
M\>O@EXB^'K?$KX@>%?#7B(+:O%HD.C>99:?]D%L^G0M<Z?/B!^9"[[YPY.V9
M4Q&/4/`7AJZ\&^#-,TJ^UW5O$]WI]NL$NK:G';1WE^P&/-E6VAA@#GN(XD7T
M45\=M_P44^+BG_DG.A_A)/\`XU2\1?\`!3?XF^$="NM4U3P'X=L=/L8S+//-
M/,J1J.Y.?_U]*V?`N=.[<%KWG'_/[^[U>IFN+\IT2GMHDHOKY6_K;8^Z**\%
M_P""<'[9DO[>/[-4?C^72(=%\S5[_3$@BD+JZVTQB$G/(W8SCG'K7O5?(UJ<
MJ<W3ENG9_(^EIU%."G'9ZA7P+^WD?A]X(_X*"^#_`!LVK_L]>-?B;''X=T33
M_AYXB\-PZMXZ6,:I<-]NT>X6[\^R*QWDD[/]CE3%CN:2-0TB??5%9QTJ0G_*
MT_Z[>MGZ%O6$H=)*WXI_FNC7J?F1\)OVB_V<E_X+=WVJ>`]0^&/AA?"OP_\`
M&]OXZ\2QZK96U_K6IPZMH$MRNHEV^T&&V5)VCFN"%817(B_=0%C[WXN_9H^$
M?Q:_X*:>%-4T/X=_#N/Q7X%L?^$_\2^*[/P_:)J]Y<W22V.E0O>K'YDBNJ7T
M[`OD&TMCRK"N\^(W_*4WX-_]DJ\>?^G?P97T!44*<:2A;>/RU=WIU24FFE?2
MR3;0ZCYN?^]\]-%KW?+=-Z)WNDNI1115B"BBB@`HHHH`****`"BBO"_^"AW[
M6U]^Q5^SLWC:PTJSUB==4M=/,%R[+&%F8J6^7GC'2IJ5%"+G+9'1A<+4Q%:-
M"DKRDTETU9Z]X[\.7GB[P?J.F:?KVK>%[V^@:*'5M+CMI+S3V/22);J&:`L.
MPEB=?537QS^VI\%O&_[%?[%WQ-^)'@/XE?$?7O%FCQWGC7QCK-]K>AZ7JFOV
M-CIK[H49O#][9Q&*&WC6*&WL[8,V6>8,79^)TK_@KK\6-;TV&\L_AOX9NK6X
M0/'+'<SLKJ>X.:\I_P""@O\`P4U^*GC[]@GXWZ%J'PYT.QT_6O`&O6-S<I-/
MNMXI=.G1W&3C*JQ(SZ5Y*SK!2?+S;Z;/O?\`/?OL]#[:IX:\0TJ;J2HJT;OX
MX=O773;\-3[@^`W[,7C?1_V:6\$ZGKVH?";[+IEOH6F6G@_Q%:>*DTR"!MS7
MJ7FJ:+%))=W(9HYA<0S1A55H]DC,U>E?LP?`5?V8?@9X=\!0>*?$WC"Q\+VB
M:?8W^O+9"]6VC4)#"QL[>WB81HJJ&\O>0,LS-DGXU;_@K!\7Q_S2_P`/_P#@
M1/\`XU%<?\%:OBW9V\DTWPS\.10PJ7D=[F9510,DDDX``[U7^L&#O)\WQ;Z/
M6U[=.EW;M=]V5_Q"[B*R7L5IM[\>R7?R7SUW/T-HKY5_X)9_\%&;K_@HAX:\
M?7USH=CHX\%ZW'I"/:3/(EYNMTE+X;D`%L#U`SQ7U57ITZBG%3CLSX?&86IA
MJTL/5^*+L[.^J\UHPK@_BG^RU\,?CIXKT/7O&WPY\!^,=<\,N)-'U'7-`M-0
MN])8.L@:WEFC9XCO56RA'S*#U`KXD_X+'_M8>//@)^TA\.]%\,^+=8\-Z/K6
MC3S7BV+[<R+.%$A&.<`XQZ5Y/:_'/XN7=K'-#\<M4DCD4,I^U]0?^`UY.*SJ
MEAZW)*+NM;JWX:GWV0^&N/S;!1QE"K!1E?1\U]';6T6NA],_MY_L(_`_QW^U
M;^SKK&N?!KX4ZSJ_C7XG7EMXAOK[PE87%SKT2^#?$LZQW<CQ%KA1+;6\@60L
M`\$3=44CZ*N/V+?@Y=ZYX1U2;X3?#.74OA_!#:^%[M_"]BT_AN&%MT,=D_E;
MK9(VY58BH4\C%?D?\?\`XN_%2\^+'P-DNOC%J5U-;>-[F2TE-SDV4O\`PC>N
M*91QP3&TD?TE->H_\+M^,#=/CAJG_@4/\*P_UBH046HONMM+77<]2'A!FE64
MX^VIZ.S^+6ZC+^7;5?-'ZUT5^*_[0_[<7Q8^`G@2;4V^,FN:IJ#*1;6<-QDN
M?[S''RJ/7J>@]OTP_P""87Q5U_XX_P#!/OX2^+O%.H2ZMXB\0^';>]O[R0`-
M<2MG+$``5WX#,H8N[@FK=SY/BG@_$Y%R+$U(R<KZ1OI;O=(]XHHHKT3Y$X+]
MH_\`Y)[IW_8T^'?_`$]6-=[7!?M'_P#)/=._[&GP[_Z>K&N]KLG_`+K#_%+\
MH'/'^/+TC^<@HHHKC.@***^8_P!H+XU?&#X(_M'>&K6W\3_#76O!>N'4M7N?
M#R^"[V+7+'1=/LS+=7']HG5C`[BX>TA!^QJ,WB?+A23G4J1@N:>BW;[6_';7
M;9,N-.4](:OMU?H?3E<'^U1_R;#\1_\`L5]3_P#226O)_P!CG]HSXG>/?B'9
MZ+\2F\!W2^+O!-EXZT0^&=.N[,Z3'-*4FL+EKBXF^U-&)+;9<HL`D_>Y@BPN
M>\_;&^)_AKPK\!/'.CZIXAT/3=6U3PQJ*V=C=7\4-S=EK>5%$<;,&?<WRC:#
MD\=:WG3E#27FOFFXM?*2:[::-JS,8U(R^'R^YI23^<6GWUUL[H]8HHHJ"PHH
MHH`****`"BBO._VD_P!I31/V9_!<>J:K'->75Y(8;*RA8+)<N!D\G[JCC+<X
MR."2!7/B\71PU&5?$2481U;?0Z,+A:V)K1H4(N4I:)+J>B45XS^S'^VKX=_:
M2@OH4MY-!U;3D$LUI<SJZM&6VAT?C<`2`<@8+#KFO4+OQ]H5A+LGUK287QG;
M)>1J<?0FL<'FF$Q5!8C#U%*#V>WYV:^9MC,LQ6%K/#UZ;4UNM_RT?R-:BN3N
M_CSX&L(FDG\9^$X8U."TFKVZ@?B7K-N_VJ?AI92!7\>^$6)&?W>JPR#\U8BJ
MEF6$C\56*_[>7^9,<MQ<OAI2?_;K_P`COJ*\KN_VV_A391LS^.-'8(<'RR\A
M].`JDG\*S;S_`(*#_!^Q=5?QE"VX9_=Z?=R#\UB-<LL_RR/Q8FFO^WX_YG5'
M(<SE\.&J/_MR7^1[-17B?_#P+X;SC_1;K7KYFYC6WT2Z8RCU7*#MS]*!^W9X
M:N/^/3PQ\1+\+]XV_AZ5MGUR16?^L>5]*\7Z-/\`*YI_J[F?6A)>J:_.Q[91
M7B?_``VBUUQ:?"GXQW&[_5.?#GEQ2#L=QDX!]2*/^&K_`!-='_1/@W\0WV_>
M^T116^/3&6.>_P!*/]8<!TFWZ1D_RBP_U?QW6"7K**_.2/;**\3'[1?Q*NQ_
MHOP1UQ_,_P!5]HUVUM\^F[(.W\>E'_"Y?C3>G]W\&+*QV]3<>+K63?\`38O&
M/>C^WL*_AC4?I2J__(6#^P<5]J5->M6E_P#)W/;**\3_`.$[^/%Y_J_`?@NS
M\SA1<:VTGE>[;!SCKQ0=0_:'O>(M/^$=EMY+7$]_(&^FSI^-']N0?PT:C_[A
MR7YI!_8LU\56FO\`N)%_DV>V45XF-&_:$O!NDUKX5V;2<,MO9WD@B]U+G)]>
M>]<S\9/AU\?+SX6Z\L?C/0;YOL;YL]+TDQ75XO\`'&CDDJQ7=C:,DX`ZYK.M
MGE2%.52.%JNR;VBMO65_POY&E')*<ZD:<L335VEO)[^D;?C;S/?]%\:Z/XDO
M[JUT[5M,U"ZL3MN(;:Z262`YQAU4DKR".:TZ_+G]BCPWXHN_VG_#G]AP7L<V
MG7Z-JC!"JV]J&Q.LIZ+E-ZX/5B`.<5^HU<G"?$4\XPLJ\Z7)RRMO=/T=EMLS
MJXJX>AE&)C0A5Y^:-^S7JKO?=!1117U)\N%%<;\=#\0AX'_XMFO@UO$IN$Y\
M3M<BQ6'G>?\`1QO+YV@#@<DD\8/A^O7G[96GZ)>7$%K^SG>S0PN\=O:G5_/G
M8`D*GF,L>X]!O8+G&2!S79A\'[6-^>,?5V.6MBO9NW+)^BN?45%?`'[$?C_]
MLKQ[\/=6D\CP+]GM]4G5;GX@6]]!>R2%V\V*);?!\J.3<HWJ`I.Q20FU/=M&
MU#]J32K75[GQ);_!&ZL[?2;V2VB\.G5/M[WBV[FV""=3&5,P0,"/NDXR1@Z9
MEE[P<:DIU(RY$W9.[=E>R7?R[D8'&?6G!1A)<S2NU9*[MJ^WF?1-%?DC\2OV
ME/"/AG]F/X@:YX/_`&G/&L>E?\*WAU+7M5O/B#)<&#QAB9H=-%Q=R,^FWDQ,
MKR:;9_963[+$!%&A9'^E/'^H7_QR_;4C\5>'_%BS?"_0_AWHFOMXHT_XOZGH
M>G:)'/<:R6U.#3K>&;2=6!2"-B;\B';`F=Z$K7#*/*N9[7:=O)M7OHK/E;BV
MXWC:3M<ZX2YEIV37SY;*V]USI223M)-*]C[:HK\T?AC^U7X`^(G[,GP\C\4?
MM`W4GPIA\>^*]'\2^,K3XE36,WF0W=]+I%K>:U:SI+;1RP>7(F+B$2!+9!NC
ME$;])^Q5^T]9#]KWX2>&/$GQPU#6O$7B3X<ZJB^%-?\`$-O#>'RKO3VTR9]/
M&R5KNXL!/<^;.LD[J\S!A&-JD8MU?8]7?\(.?D[NVBZWOY!*5HN7;_Y-1^Y7
MU?R\S]"J***DHX+]G#_DGNH_]C3XB_\`3U?5WM<%^SA_R3W4?^QI\1?^GJ^K
MO:Z\P_WJI_B?YLY\'_`AZ+\C@_A!_P`E!^*G_8T0?^F72Z_%_P#X.UO^3I?@
MW_V+=W_Z5"OV@^$'_)0?BI_V-$'_`*9=+K\7_P#@[6_Y.E^#?_8MW?\`Z5"N
MW(?]]A\_R.7-O]UD?E[']P4ZD3[M+7Z@?"A7+_$L_P#$K;_=KJ*Y?XF?\@UO
M]VL<1_"9M0_B(_J@_P"")/\`RB6_9_\`^Q-LO_037U)7RU_P1(_Y1*_L_P#_
M`&)ME_Z":^I:_'Y_$S]$A\*/X]?BT?\`C(?XA_\`8S:C_P"E4M9M:GQ;X_:&
M^(?_`&,VH_\`I5+677ZY@_X$?1'YWB/XLO4****ZC$K?!T_\9<_"K_L=-&_]
M+X:_LEK^-GX._P#)W/PK_P"QTT;_`-+X:_LFK\YXE_WKY'V61_P`HHHKYT]H
M****`"BBB@`K\^_^"^?_`")GPG_[#UU_Z35^@E?GW_P7T/\`Q1GPG_[#UU_Z
M3U[W"_\`R-:'^+]#R<^_Y%]7T/EGP]\2-=T;1X;6UU2ZBMXUPB!LA1Z#/;VK
MS_\`:Q^)^OWGPMTI)-4N'5?&?A60`X^\OB'3F4].S`'\*Z6R_P"/5/H*\\_:
MH_Y)EI?_`&.'A?\`]/\`I]?TACXQ^JU-/LO\F?A^#_WB'^)?F>U#XM^),_\`
M(7NOS'^%>>_M*^/]9\2?#R:VO=0N+BWPSF,M\I('!([XKH*X?X]?\B7-_N-_
M*M<5%>REIT,\/_$1^A7_``;F?\HTM/\`^QHUO_TL>ONZOA#_`(-R#N_X)GZ:
M?^IGUK_TL>ON^OY8S#_>:G^)_F?T%@_X$/1?D?D#\;/B;=W7[>WQ6T76=>UZ
MVT>WUZ1('M[J3_1!Y<9P%#?<R3P.F?PK>.F>'%_YJ%K9_P"WR3_XNO+?VF_^
M4@/Q@_[&"7_T7'5&OZ*X>PM.>6T)-+X5TCV\TS\2SRK...JJ,G\3ZON7?%UA
MX?\`^&V?AZ!XYUAH?^$'\3EYS=/NC;[?X>P@.[HPW$C_`&!Z5ZE_9OAU^GQ`
MUK_P+?\`^*KY8\3_`/)W?@?_`+$_Q%_Z6Z'7I%=V&P5-U*O^)=(_RQ\CBK8B
MIR4_>>W=_P`TCF?^"@OQWE^"WPJU"'P7XL\076L36TA>]-W(JV0VG&SYN9/?
MHON>G[?_``3NI+[X,^$9II))IIM%LWDD=BS.Q@0DDGDDGG)K^=;]OD_\6]U3
M_KW?_P!!-?T3?`G_`)(AX-_[`=E_Z3I7Y%XCQY<53@MDGT2[=DC]*X'N\/.3
MU=T=51117YP?<!1110`4444`%?%?_!?#_DP&X_[&/3/_`$8U?:E?%?\`P7R_
MY1_W'_8QZ;_Z,:N;&?P)^C/:X<_Y&F'_`,<?S1^97@3Q]K7AOP[#;V.I75M!
M@-L5OE![X':L[XS7&N_&OX;:MX5O/%>O:7INO6TMC?M8?9_-N;:6-HY829HI
M`%97()4!AQAA4.@?\@F#_<%7*_-HR<9<RW/[,E2C5H^RGLU9]-/D7O!_CSQA
MX:THV][XV\0^(IC(7^U:@MK'*`0/DQ;PQ)@8_NYY.2>,4?BQ\3->UGP3=VMS
MJEW);S#$B;\!QZ''4>U%8/Q&_P"18FHCK*Y-2/)1<5?1=6V_O>K/N/\`X-:O
M^2.?&[_L<;?_`-(8J_4^ORO_`.#6<Y^#?QN_['*#_P!(8J_5"OTK"?P8^B/X
MSX@_Y&5?_$S\F_\`@X%/_&5/PL_[%^Z_]*5KY.C;]VM?6/\`P<"_\G4_"O\`
M[`%U_P"E(KY-C^X*^)SS_>Y'])>&7_(BI?/\V>?_`!.^&OC#QIXST/4M+\3>
M&]+L_#M\=1LK>Z\/3WDAE:TGM6$DBWD09=MQ(P"HI!"\D`Y[W3A<16,*W4T4
MUTL:B:2&,Q1N^/F*J68J"<D`LQ`XR>M2T5YDJCDDGT\D?=4<+3I3E4A>\G=W
M;:OMLVTM$EHD>8_M+MGPI-G_`)YFOW)_X(T_\HLO@5_V*=K_`"-?AI^TT<>$
M;C_KD:_<O_@C3_RBR^!7_8IVO\C7U?#OPR/P;QB_C4?F?3-%%%?3'XH<%^T?
M_P`D]T[_`+&GP[_Z>K&N]K@OVC_^2>Z=_P!C3X=_]/5C7>UV3_W6'^*7Y0.>
M/\>7I'\Y!1117&=`5PTO[/VAWWQD\0>-;^;4-4OO$/A^W\,R6-U(CV-I91RS
MRNL,84%6G:?]ZS,V\0PC@(,]S14RBGHUW_%-/[TVGY-H:DUMY?@TU]S2?JCQ
M?]E[]BC2_P!F#5)+Y?&7CSQU>PZ/:^&]+G\475I,^AZ5;LS164'V>W@W+N;+
M33^;<2[(_,E?8N.L_:H_Y-A^(_\`V*^I_P#I)+7>5P?[5'_)L/Q'_P"Q7U/_
M`-)):TE)O=W_`*N_FVVV]VVV]6R;).Z_K2R^Y))+HDDM$=Y1114C"BBB@`HH
MHH`*^>O^"BOP7T_XK?"[3[IKX6OB#2;ATT>#;N;4Y)5!:V49X+>6K;S\J+&S
M-M0,R_0M>#_\%`-2UNU^#YL_"_AG5-=\0ZTLFFK=:?IDEW-I]I(%-Q\R(Q02
M!40CC<.>J<>5GE/#5,!5ABXN4+:I;OJDK=;VL=6!S&M@*\<7AW:4=5^7X[,^
M(_@'86?@;7]6OO'7P;\:^/O#\,4)AN_#LL=_]EC?<?M#6\,BR-$P&!)G:-DJ
MXWHP7Z,^#OQ!_8^^*=Q]@TU_"NFZIOVOIVO&;3KN.3_GGBY*[F]D+#]:Y?\`
M8K\)?&JR>;0[.WD\(Q:7;2265SXB\,2X6.21#+!%.RJ5#.$<QY()4MCY:].^
M+'[,?Q.^-%GY/BS0?V?_`!D&7:)-7TJ[\Z`>L<B#>I//((Q7@9#A\C6"IK^S
MFG;5\L9._7XKR>NVVENAZ6*XOS+&3=:K5FF^D9-)>D4['L&G?LK_``PB6.:#
MP+X1E5E!1FTV*56!'!Y!!^M:EG\`/`>G(5M_!/A&!6.2(]'MU!/X)7Q#;_\`
M!.GXQ_"R_P#M7PSU1_AZ<EEL-"\5W,VE[NN7MKQ9`_/0;N.:[_P5\1?VT/A6
ML:>(?A_X,^*%C&#ODM=4MM(U"3'<G?Y//HL9-?387`Y;4?+0IJ+[2IN'XVY?
M_)CA>98FIO6D_5R_SM^)]:VGP[\/Z?(K6^A:/"T8PICLHU*C&.,+Z5I6>GV^
MGJRV\$,"L<D1H%S^5?%_B'_@L-/\*[Q+;XB?!?QWX#FD(19+\DVLC=/DF,:H
MR_[0XKT#X;?\%,M`^*MFUQH/@CQUXAAC'SMH5O!JGEGN&$4N5'N<5>(J4L)_
M$@XKOR2M\I)6?R9R5JM3_EXW\[GTM17B'_#=_AVV_P"/[PC\2M+['[5X=D7#
M=U^4GD<_E2C_`(*'_"RV_P"/_5]4TKL?M>C7:[6_N';&?FZ^W!YKF_MO`=:T
M5ZM+\[&'MH=SVZBO(M/_`&\OA'J>WR_&VGKN7</-@GAX_P"!H.?;K6WIW[6?
MPQU3;Y?C[PFNY=P\[4HH>/\`@9&#[=:VAFF"G\-:+])+_,?M(/9H]"HKF-/^
M-O@S5]OV3Q=X8NMPW+Y6J0/D>HPU;>G>(M/UC;]DOK.ZWC<ODS*^X>HP:ZH5
MJ<_@DGZ,KF3V+E%%%:#"BBB@`HK-T;QAI?B'5M4L+&^M[J\T698+Z&-LM;.R
M!U##W5@?S'4$#2J8R4E>+N`44450!6;XP\9Z/\/?#EUK&OZMINAZ19!3<7VH
M726UM`&8*-\CD*N68`9/)('>N=^/7P9;X[^!/[!'BWQKX+_TE+@ZAX6U(:??
MD*#^[\TH^$.<D``G:.<9!^1_VQ_^"6'B37?V</$5KX1^*7QW^('B*0VIM-`\
M1>-(IM-O\74+/YJ2I&AV1AY%RXP\:GDX!YL15JP3<(7T[_H>SE>!P6(J0AB:
M_L^:23T>B;6M]E\]%U/KSX>?M#>`/B[JTVG^$_''@_Q1?6\)N);;2=9MKV:*
M,$*798G8A=S*,D8RP'>NP+;1D\`=37Y/_P#!/[_@DC\6O#OQGU*X\>2^//A3
MH[:++'#JWA/Q596][<SF>W*V[M"\S&)E#N05`W1)SD`'[J^#?[$#?!/QW#XA
M7XO?'7QA]EAEC.D^(O%*ZA87.]&7YHFB7+#.Y3N&&`YQD'FHXK$3I<[IV>OE
M^&YZ.=9/EF$K.GAL6IZ75E=-]N:+M_EU.E\%_MP_!7XD>$_$&O\`AWXO_"[7
MM"\)^7_;FHZ=XJL+JTT;S"5C^TRQRE(=Q!"^85R00*U_&/[4/PS^'?Q3T7P+
MX@^(G@70O&WB58WTCP_J&O6MKJNJK([(AM[9Y!+*&='4%%.2K`<@U\%WO[,_
MQ>L_V(?'WPUC^%OQ=\=^%M/\,6WAWX>Z!X[E\"-X@T&_%M=VWVN"YL+J&U6S
MBMW@CWS2O>%GDV@J6S]'7_P*\8?$S]H'5_B)JD'CSP_X5OOA]I&GW_@'9X:O
M(_%<\4NKR7&E7PG2X`94NH4S!>0PN9R#*Z@E?4E9>]':_P`[6OYVU[*5M%J]
MOEY15Y17G;_P))>3T;>KC>SV2N>R>)/VI_ACX.^$_P#PGVL?$?P'I7@7SS:_
M\)'>>(+2#2?.$K0F/[4T@BWB56CV[L[U*]014WAC]I?X<>-OB'%X1T7X@>"=
M7\63Z7'KD>BV6N6MQJ,FGR*C1W@MT<R&W=70K*%V$.I!.17R'\#OA_\`$[X;
M_#SX>>(;C]G_`,9"X^'OC;Q5>?\`"'C5?#2Z@;/5IKR:UOK-AJ+68:&.X6W>
M-[J!PLMQM$BA1)-^Q_\`!_XA>!/BY\//#/BWX#ZUX;\,_#^2[U33=>T:_P!`
MN-).I7UM*LDLY-\M^J6MO,UC&L=JYD(#DB-(\*/\3DZ=]NE_3?L]/A:ZK.4F
ME?U_]*M^2VZ[KHG]V4444BC@OV</^2>ZC_V-/B+_`-/5]7>UP7[.'_)/=1_[
M&GQ%_P"GJ^KO:Z\P_P!ZJ?XG^;.?!_P(>B_(X/X0?\E!^*G_`&-$'_IETNOQ
M?_X.U/\`DZ7X-_\`8MWG_I4*_:#X0?\`)0?BI_V-$'_IETNOQ?\`^#M7_DZ3
MX-_]BW=_^E0KMR'_`'V'S_(Y<V_W61^7R?=I:1/NTM?J!\*%<O\`$S_D&M_N
MUU%<O\3/^06W^Z:QQ'\)FM'XT?U/_P#!$@Y_X)*?L_?]B;9?^@FOJ6OEG_@B
M/_RB3_9]_P"Q-LO_`$$U]35^/S^)GZ+#X4?Q[_%S_DX;XA_]C-J/_I5+676I
M\7/^3AOB'_V,VH_^E4M9=?KF#_@1]$?G>(_BR]0HHHKJ,2K\(/\`D[CX5_\`
M8Z:-_P"E\%?V35_&S\'_`/D[CX5_]CIHW_I?!7]DU?G/$O\`O7R/L\C_`-W^
M84445\Z>R%%%%`!1110`5^??_!?4X\%_"?\`[#UU_P"D]?H)7Y]_\%]O^1+^
M$_\`V'KK_P!)Z][A?_D:T/\`%^AY.??\B^KZ'Q[9?\>R?[HKSW]JC_DF6E_]
MCAX7_P#3_I]>AV7_`![)]!6%\0/A%X3^+$-K'XJ\+^'?$T=BS-;KJNFPWBVY
M;&XH)%;:3@9QUP*_I7%TY5*$J<-Y)K7ST[,_#,/4C"M&<MD[_<=%7#_'O_D2
MIO9'_E74>%O"FE^!]`M]*T73=/T?2[,%;>SL;=+>W@!)8A40!5R23P.I-<O\
M?#_Q0]Q_US?^5&(O[!\V]AT+>U5NY^A/_!N/Q_P3.TW_`+&?6O\`TL>ON^OA
M#_@W)X_X)GZ;_P!C/K7_`*6/7W?7\L9A_O-3_$_S/Z`P?\"'HOR/Q+_::/\`
MQL$^,/\`V'Y/_1<=4P<U<_::_P"4@OQA_P"P_)_Z+CJF.E?TEPS_`,BNC_A7
MY'X?GW^_5/5_F>;^)_\`D[OP/_V)_B+_`-+=#KTBO/+KX"75[\8K'QE)X\\8
MM<::EQ;VVG>5I@LH[:XD@DFMO^//SBC-;0?,9#(`G#C+9]#KTL+&:G4E*-KR
MNMMN6*Z-]C@Q$H\L%%WLM=^[?5+N?-O[?IV_#S5/^N##_P`=-?T4?`G_`)(A
MX-_[`=E_Z3I7\Z_[?_\`R3O4O^N+?^@FOZ*/@3_R1#P;_P!@.R_])TK\7\2?
M]\AZ/]#]1X'_`-UEZHZJBBBOS<^V"BBB@`HHHH`*^*_^"^7_`"C_`+C_`+&/
M3?\`T8U?:E?%?_!?+_DP"X_[&/3?_1C5S8S^!/T9[7#O_(TP_P#CC^:/RR\/
MG_B56_\`N"KM4?#O_('M_P#KF/Y5>K\T/[0I_"@K!^(O/AB:MZL+XB?\BS-]
M/Z54/B1GB/X<O0^W_P#@UD.?@S\;?^QQ@_\`2&*OU2K\K?\`@UD_Y(Q\;/\`
ML<8/_2&*OU2K]*PG\&/HC^,>(/\`D95O\3/R;_X.!S_QE3\*_P#L`7/_`*4K
M7R;%]ROK#_@X(_Y.I^%?_8`N?_2D5\GQ_<%?$YY_O<C^DO#+_D14OG^;'444
M5Y)^A'E_[3G_`")]Q_UR-?N7_P`$:?\`E%E\"O\`L4[7^1K\-/VG/^1/G_ZY
MU^Y?_!&G_E%E\"O^Q3M?Y&OKN'?AD?S[XQ?QJ/S/IFBBBOIC\5."_:/_`.2>
MZ=_V-/AW_P!/5C7>UP7[1_\`R3W3O^QI\._^GJQKO:[)_P"ZP_Q2_*!SQ_CR
M](_G(****XSH"O)KO]K2U;XVZQX1TWP;XPUC2?"N(_$WBZW;3H="\-3FV^U>
M1.9[N.ZDD$#PN3;6\R*+B,,RG>$]9KX7^(W_``2IOO'7[8NO>+E\,_">SL/$
MGBC_`(2:;X@PAX_'5E;MHZZ?+HT:BTVO;2,A8R->!?+F=#;L0';*<IW]Q=';
MM>Z2OMI9RD]4_=LFVTG<>7EO+_@VL]O.Z2V:5[O1-KZ`_9C_`&V-+_::\1W6
MEQ^#/'G@FY;1[7Q)I/\`PDUK:0#Q#I5R\B17ML(+B9E7*#?#<"&XC\V+?$F\
M5UG[5'_)L/Q'_P"Q7U/_`-)):\G_`&,_V=/B=X$\::;KGQ.7P'9W'A/P39>!
M=)B\+ZC=WR:G'#)OFOYS<6\!MVD\N`+;)YPCQ)F>7<NSO/VQOA[I_B3X">.=
M4N+C7([K3_#&HM$EKK5Y:VS[;>5AYD$4JQ2\]1(K9'!R.*Z:B@OX;NM?NYFH
MM[:N/*VK*S;5E:RP@YW?-Y??RIR7HI<R3ZI)W>[]8HHHK,T"BBB@`HHHH`**
M*P?''CN/P!':WE_;LNBLS+>WX8;--Z;9)1VBZAI,X3@L-FYTJ,7)V1-2I&$>
M:6W]?UY&]17FOP0_:=T/X[65C<Z4ULD-Q80W$[/>1DQ7$@4_9D4<R,F2'8`*
MK849;>$]*JJE*=.7+-69GA\32KP52D[I]0HHHK,V(KZQAU.SDM[F&*XMYE*2
M12H'1P>H(/!'UKPCXG?\$RO@O\3=3_M+_A#[?PSK2MOBU/PW,^D7$+]W'DE4
M+>[*:]\HK6E7J4W>G)KT949..Q\M#]DSX[?!@EOAO\=+CQ%8Q_ZO1_B#8C45
M;'0->Q`3@=L*H_E0/VR/C-\&UV_$[X#:SJ%G#_K-9\!W::O"X[M]D8B9%'4E
MFZ?2OJ6BM_KG-_%@I?*S^]6_&Y7M+_$KGSU\.OV]?V?_`(YWGV'_`(2/P[8Z
MMYG[W3?$=H--NDE_NE;A5#/S_`6Z_6O5KGX&>`?$-NLLW@[PA?138E5WTFWE
M63/(8$H<YSU]Z/BI^S_X'^.-A]G\8>$O#_B2/;M5K^QCFDB'^PY&Y#[J0:\,
MN?\`@EMH/@2:2Z^$_CSXA?"6Y+%UM=+U9[O2V8\DR6LY;?SSC>!64L+@:NZY
M?5*2^]6?X,7+3?E^)ZUJ/['_`,+M4W>9X#\,KN;<?)LDAY]MF,#V'%8NH_L`
M?!_5-WF>"[-=QW'R;NYA_+9(,?0<5YV9_P!K+X&K\T/P[^.&EP]T8^'=9F`]
M<YMES[9.:FM/^"IOAGP3=Q6?Q4\%_$'X2WCL(_/UG1Y+C39&/&([F$,'&>-V
MT#WKEGPWAJFL:,)^BBW]S5_P)^K)[),[+_AWM\-;4?\`$OM=>TG;]S[)K=TO
MECT&YSQ1_P`,+Z/:?\@_QW\5-)V_<^Q^)'7RQW`W*>M>A?"_X[>"_C9I_P!J
M\(^*O#_B2$+N;^S[Z.=HA_MJI+*?9@#765P2R+!1=O8J+\E;\K&7L8KH>(_\
M,@:W8?\`(/\`C)\48]OW/MFH)=X'?=N0;N_7IQZ5A_$?X/\`Q2^&7@35-8T?
MXN>*M6N=-@:2UL!X<M]0GNY#P(\`%FRQQG:=HYP0M?15%9SR7#N+5/FB^C4Y
MJWW20>RCT_-GP'^P_>?%#X<?M(2WWB+PCXV;3_&DK1:Q<W&BW$<:S.Q9+ASL
M"KM<G).`JNYK[\HHHR;*WE]!T/:.:NWKTOO^.OJPIT^16N%%%%>L:&;XI\8:
M3X&THW^M:IINCV*L$-Q?7*6\08]!N<@9/IFN:_X:9^&__10/!'_@]M?_`(NN
MD\6>"M&\>Z6MCKFDZ9K5DL@E%O?VJ7$0<`@-M<$9`)YZ\FO/_B5^Q_X'\:^!
M-4TG2_"_A#P]?:A"88]1@\/VKRVN2,L@VJ=VW(!!!!.1R*\_%RQJN\.HM6V=
M[M]NQ$N?[)8\(_MA_#/QAI37<7C3PY8JL\L'E:AJ,-K,=CE=X1V!V-C<I[@C
MH<@=)X8^-G@WQMJRZ?HOB[PSJ]\ZEUMK+5(+B9@!DD(C$D`>U>.?L\_\$ZO#
M?P7U+4I-9ET?QM;ZA&BI#J>@P-]F=2?F1G+D9!((&,\9Z"O8O#?P/\%^#-8C
MU'1_!_A?2=0@#"*ZL]*@@FCW`J<.JAAD$@X/()%<N!J9I.$98F,(OJM6_E9M
M?B3#VC^*QY7:_M\V?B3P1XIUCPS\+_BUXINO"?B%_#USH]MI5II^HRE;**]-
MULO[JW2&#R)HR!</#,6.P1%B`9(_V\]/USQAHMCX;^'?Q,\7Z+JGA;3?&-WK
MVE6=C]ET?3K_`.T_9VFM9KN/4)92MK*QAM;2>3[JA2[!:\RU_P#8+^/&M:-\
M1+*/XX_#*TM_B5XHBU_5H8_A=?B*XMA8Q64NG/C7A)Y,L=M;%GCDC?Y9AG;*
M%3T>U_82TC5/BY:_$OQ)IOPQ\0?$S1?"6FZ!H&KR^!T^S^&KRT>^D-W91R7$
MD\$,C7B`P1W"L%@`\XE@5]F%^1-[VAIY\GO]DUS6M[T7>^O+8WG;F:7]ZS_[
M?7+YIJ-[Z-;:-W'6?_!0#2?$/PA\-^)M`\`?$CQ%K'BW5]1T73/"=I:V$&M2
M3:?/<0W;2&XNXK2"./[-(VZ:Y3.Y%`,CK&8?AC_P4+TOXF^-O`FGK\.?B5HN
M@_$DO;Z!XEU"/2_[.NKR.SFNYK.2*&]DO8)HEM[F-C-;)%YENRB0AHV?C_A[
M^P;\5?A[X!T`VWQ:\`MX^\*^)M:US3-8_P"%=W(TM[;5Y)I[RRN+)M7:9_W\
MV^.2*[A*B&)660!]\7P1_P""9FI?"/X[^%?%LOBKP+.GAD,9M4TOP,^E^,?$
MF^*7S+;4M86_=+FQ:YG>X^R_9%0-%;8.Z$.UQM[2S^'_`('2UMGWZZZJR><K
M\K[V=O6[M>_E^'9ZKZWHHHJ2C@OV</\`DGNH_P#8T^(O_3U?5WM<%^SA_P`D
M]U'_`+&GQ%_Z>KZN]KKS#_>JG^)_FSGP?\"'HOR.#^$'_)0?BI_V-$'_`*9=
M+K\7_P#@[5_Y.C^#?_8N7?\`Z5"OV@^$'_)0?BI_V-$'_IETNOQ?_P"#M7_D
MZ3X-_P#8N7?_`*5"NW(?]]A\_P`CES;_`'61^7R?=I:1/NTM?J!\*%<O\3/^
M06W^Z:ZBN7^)G_(+;_=-88G^%+T-J'\1']3W_!$?_E$G^S[_`-B;9?\`H)KZ
MFKY9_P""(_\`RB3_`&??^Q-LO_037U-7Y!/XF?HD/A1_'O\`%S_DX;XA_P#8
MS:C_`.E4M9=:GQ<_Y.&^(?\`V,VH_P#I5+677ZY@_P"!'T1^=XC^++U"BBBN
MHQ*OP@_Y.Z^%7_8Z:+_Z7PU_9-7\;/P@_P"3NOA5_P!CIHO_`*7PU_9-7YSQ
M+_O7R/L\C_W?YA1117SI[(4444`%%%%`!7Y]_P#!?49\%_"?_L/77_I/7Z"5
M^?G_``7RY\&_"?\`[#UU_P"D]>_PO_R-:'^(\C/O^1?5]#X]LO\`CU3Z"I:B
MLO\`CU3Z"I:_IT_!@KA_CZ,^![C_`*YO_*NXKA_CT?\`BBYO]Q_Y5SXK^#+T
M-L/_`!$?H5_P;E?\HT-._P"QHUK_`-+'K[NKX1_X-R_^4:.G_P#8T:U_Z6/7
MW=7\KYA_O53_`!/\S^@L'_`AZ+\C\2_VFO\`E()\8O\`L/R?^BXZIC@5=_::
M'_&P+XQ?]A^3_P!%QU2K^D^&?^171_PK\D?A^??[]4]7^84445[IXY\V_M_#
M/P[U/_K@_P#Z":_HH^!/_)$/!O\`V`[+_P!)TK^=G]OKGX=ZK_U[O_Z#7]$W
MP)_Y(AX-_P"P'9?^DZ5^%^)/^^0]'^A^L<#_`.ZR]4=51117YN?<!1110`44
M44`%?%?_``7R_P"3`+C_`+&/3?\`T8U?:E?%?_!?'_DP&?\`[&/3/_1C5S8S
M^!/T9[7#G_(TP_\`CC^:/RQ\/<:/;_\`7,?RJ]5/0/\`D$P?[@JY7YH?VA3^
M%!6%\1/^19F^G]*W:POB*?\`BF9O\]JJ.YGB/X<O0^X/^#64;?@Q\;/^QQ@_
M](8J_5&ORP_X-:O^2.?&W_L<;?\`](8J_4^OTK"?P8^B/XQX@_Y&5?\`Q,_)
MK_@X&&?VJOA9_P!@"Y_]*17R=']P5]9?\'`G_)U7PM_[%^Y_]*17R;']P5\3
MGG^]R/Z3\,O^1%2^?YL=1117DGZ">7_M-+N\(S?]<Z_<O_@C3_RBR^!7_8IV
MO\C7X;?M+'_BE9O^N=?N3_P1I_Y19?`O_L4[7^1KZ[AWX9'\_>,7\:C\_P!#
MZ9HHHKZ8_%#@OVC_`/DGNG?]C3X=_P#3U8UWM<%^T?\`\D]T[_L:?#O_`*>K
M&N]KLG_NL/\`%+\H'/'^/+TC^<CR']M?]L[PY^PQ\'8?%WB#1/&'BN?4=3M]
M%T?P[X3TO^U-<U^]G+%+>TM]R"201I+(067"1.>3@'@?A%_P5E^%OQNNO@_:
MZ%;^+#J'Q@U?5/#L.GW>G):7WA35--LY+J]L-6@DD$EM<1+&R%%63+%2"8V6
M0]%_P4F^#OA3XH_LJ:UK'BM?&B1_#!O^$]TZY\(7QLM>MKK38Y)P+.7^&26(
M2P$'[R3N`5)##XS_`&>O"?Q:_;%_X*-_!_XY>./V+=6^#D.GK<ZE-XRTKXU:
M1JVGWZ3:1/;6\U[I4,(:ZD,4J0I,GES*IC#NT40C''AO?E.$MTT^UHM:7;T;
MDU45KWT5K[/JK^[3YU_+*W5N2OT6ME>#OK=N2:U37ZC445P:_M3?#%OC>WPR
M'Q&\!GXD*GF'PF-?M/[<"^5YV?L?F>?CRB),[/N'=TYH6KLMR>ESO*X/]JC_
M`)-A^(__`&*^I_\`I)+5OX4_M$?#_P".]YKEOX'\=>#O&5QX9NOL.L1:%K5M
MJ+Z3<98>3<"%V,,F4<;7P?E;C@U4_:H_Y-A^(_\`V*^I_P#I)+1Y@=Y1110`
M4444`%%%%`!7-_$KPC>>/]*715F@MM$U)9(=7;DW$T!&#!&,842`L&<G*J"%
M&Y@Z=)151DXOF1%2FIQ<);,^8_A?_P`$R/`>@^';#3?$_ACP[KJKI\7VBY1Y
MH;F*\"A90CIL,D+DLX+X=#Q\RE1'O?\`#M;X9Z9_R`_^$N\,\?+_`&7XCNX_
M+P,#&]VZ9)^I/;BO?J*[99IBY.[J/[W;[MCR:?#V6PBHJC'3KRJ_WVO^)X"?
MV&M2T<?\23XU?&2QVC"QW>M)?0QC&``KQ]`,\9].F*&_9U^-6BAO[*^/D\\8
M)VPZGX2L[C/0<R!@W`]L$^F:]^HI?VA6^U9^L8O\T7_8>$7P<T?\,YQ_*2/`
MO^$>_:8T)_\`1?$7PAUY?^HCI][:'K_TQ)[#WZGT!I%^)7[16@[?MGPR\"Z_
M@C<-,\2-:;NIX\]#CCCZG/2O?J*7UQ/XJ<7\FOR:#^R6OX=>I'_MY2_]*4CP
M'_AJWXF:)_R'/@!XNM]HRW]EZQ::GCC)QL*Y[?4Y'44'_@H#INEC_B>?#/XR
M>']H^:2[\+NT.0.<.CMN`)`SCN.E>_44_K%!_%27R;_5L/J.,C\&);_Q1B__
M`$E1/!;;_@IA\&_.\F^\3W>CW.2/)U#1KV!ACKR8MO!XQG.0:ZS0_P!M3X2>
M(CBV^(W@]6/07&IQ6Y/('`D*^OXUZ5=6D5]`T4T4<T3?>1U#*>_(-<KKG[/_
M`(#\3G.I>"?".H$]?M.CV\W<G^)#W)_.CFPC^S)?]O)_^VH/9YG'_EY3E_VY
M*/\`[?+\C3T'XF>&_%)7^R_$&B:EO.%^RWT4V[G'&UCWX^M:]Y90ZC:26]Q#
M'<03*4DCD4,C@]00>"*\AUS_`()]_!CQ""+CX>Z#'G_GV5[7MC_EDR^M8?\`
MP[6^&>F?\@/_`(2[PSQ\O]E^([N/R\#`QO=NF2?J3VXHY,(]IR7_`&ZO_DOT
M#VV9QWI0?I.2_!P_4F^)_P#P31^"_P`4=0&H2>"[/P]K,;%XM2\.R/I%S"Y_
MC!@*JS>[*U<FW[(?QN^#C^9\-?CQJ.M6,7W-&\?V2ZI')Z`WB`3*!TPJ_P`J
MZ8_L-:EHX_XDGQJ^,ECM&%CN]:2^AC&,`!7CZ`9XSZ=,4-^SK\:M%#?V5\?)
MYXP3MAU/PE9W&>@YD#!N![8)],UU1J:<OMTUVDF_TE8M9IC8Z3PTGZ2@_P#T
MJ43F!^U[\;O@TVSXE_`C4=:L8OOZSX`O5U2-_4BS<B90.N6;I]*W?"O_``5/
M^"?BNQN=OBIM-U2R*BYTC5+22PU"(E@&`CE"^8R@EBD1=B`0H9L*;?\`PCW[
M3&A/_HOB+X0Z\O\`U$=/O;0]?^F)/8>_4^@-<)\=?#OQ.\>^#[P?$3X(_"?Q
MK8V\#>=<Q:XEK):1X)=TFN5S%M7.6##')Y&16D</0J/WN7_MV5OPE_FA2SJ$
M4W4H5(_]NMK_`,EYCZ4N?BOH8/A];.[75W\4%7TU=/9;C[3#A2UR"#M$"*RL
MTA.WYE499T5NDK\\_P#@FC\(]8^$'BR6QU30YM+M[C58=^B2^7"WFFWCNHYU
MFW?O/)6<2_8W(PK&5`TD)2OT,KAS#"QP]3V<7S>9ME^.CBZ7MJ::5VM=]';5
M=/1ZA1117"=QQ?QY^,X^!'@3^W#X5\:>,?\`24MAIWA?2CJ5^2V3O\L,N$7;
MRQ(`R!U(%>#>*?\`@IOJ<6@W#Z/^SW^T:^I1@-"E]X'=+>3#`LK,LQ9-RY`<
M*VTD':V-I^K:S_%?A6P\;^'[C2M4@^U:?>`+/!YC(LZ@@E&VD%D;&&4_*RDJ
MP*D@]5&I1C_$A?YO\BXRBMT?)_A/_@K6GCO69+C1_@?\>M5\.PVZJT]AX2^U
M3-=-M<*=L^Q$$3(PY9G\U3A`H+]MX7_X*(0^)6U(7'P<^.WAJ+3=+O-3:\U_
MPFUE8D6\#S&,RB1]K.$*K\O+$#J0#[M;>"]+LO%#:U!9I!J4EHMC)+$S()85
M;<BNH.UMASM+`E`[A2`[`Z%U:Q7UK)!/''-#,I22-U#*ZD8((/!!'&#4XNI2
MG2E&A#EDT[.][.VCMULS6G4I*:<HW6E]?O/@'XO_`/!5+QE^R/:Z;I?Q6\3_
M``+TWQ%\4/#$6O\`@>XFDET'2]%E))N;>_>[O6-XEO$\;K+$;5KEE,2Q1-(K
M+U?A+_@H)XX^,GQE^'NF^"]8\&WVB^)_`6B>*BEKX!UW7[+6+R]>_26W.NV$
M[V>CP*UFJ"6[AG(+2'$A0I7T#\$/V)?AM^SM9ZK!X5T74H8]8L4TJ4ZCK^HZ
ML]M8QAQ'8VS7<\K6MHF]]EO;F.)"V50&NBT7]GWPIX;M;R/3;"\TXWWAZT\+
M236NIW4,Z:?:"<6\4<JR!XWC^TS$2HRRY<'>2JD8W24K+6Z:\E>?NZW6B<%=
MJ7,XMR5]^6*E9*3Z6?K^[UZ/6TW9-<O,E%I;>`>"/VJ?BY\6OACX#TG2I/AU
MH/Q%\7>(O$NEWFK76BWVHZ'IUMH]]=6[-'9K=0RS22^5"H#740&^23!V"(^>
M?LT_\%G-+^/O[2'P]^'LOB;X0Z;JEQ/>>'/%FF)K\4FK3Z]!#,S+86YG$D=J
MKP`!I4D,K70C4JT#M)[UI/\`P3/^$>A_#&#PC:V?CR/3+/6YO$=G='XB>(FU
M;3K^=9%GFMM1-\;RW\T33>8D4RI(9I2ZL78GTSPU\`O!_@W3/!UEI6AV^GV?
M@!&CT"&!W2/3U:!H&P`V')C=@2^XDL6^]S2C93;Z=OE;=WM;736[M)V:LU)2
MMIOKKVUOMUTMKTU2[G84444BS@OV</\`DGNH_P#8T^(O_3U?5WM<%^SA_P`D
M]U'_`+&GQ%_Z>KZN]KKS#_>JG^)_FSGP?\"'HOR.#^$'_)0?BI_V-$'_`*9=
M+K\7O^#M?_DZ3X-?]BY=_P#I4*_:'X0?\E!^*G_8T0?^F72Z_%[_`(.U_P#D
MZ3X-?]BY=_\`I4*[<A_WV'S_`".7-O\`=9'Y?I]VEI$^[2U^H'PH5R_Q-.-+
M;_=-=17+?$[_`)!3?[IK'$_PI&M'XT?U/_\`!$?_`)1)_L^_]B;9?^@FOJ:O
MEK_@B1Q_P24_9^_[$VR_]!-?4M?C\_B9^BP^%'\>_P`7/^3AOB'_`-C-J/\`
MZ52UEUI_%P_\9#_$/_L9=1_]*I:S*_7,'_`CZ(_.\1_%EZA111748E3X0_\`
M)W7PI_['71O_`$OAK^R>OXV/A#_R=U\*?^QUT;_TOAK^R>OSGB7_`'KY'V>1
M_P"[_,****^=/9"BBB@`HHHH`*_/W_@OC_R)OPG_`.P]=?\`I/7Z!5^?G_!?
M+_D3/A1_V';K_P!)Z^@X6_Y&U#_%^C/'S_\`Y%]7T_4^/;+_`(]4^@J6HK+_
M`(]4^@J6OZ</PA[A7#_'K_D2YO\`<?\`E7<5P_QZ_P"1*F_W&_E7/BOX4O0V
MP_\`$1^A?_!N;_RC2T__`+&?6O\`TK:ONVOA+_@W-_Y1I:?_`-C/K7_I6U?=
MM?ROF'^]5/\`$_S/Z`P?^[P]%^1^)O[37_*0'XQ?]C!)_P"BXZHU>_:;_P"4
M@7Q@_P"P_)_Z+CJC7])\,_\`(LH_X5^2/Q#/O]^J>K_,****]T\<^;_V^/\`
MDGFK?]>[_P#H)K^B;X$_\D0\&_\`8#LO_2=*_G9_;X_Y)[JG_7N__H)K^B;X
M$_\`)$/!O_8#LO\`TG2OPOQ*_P!\AZ/]#]8X'_W67JCJJ***_-S[@****`"B
MBB@`KXK_`."^/_)@,_\`V,>F?^C&K[4KXK_X+X_\F`S_`/8QZ9_Z,:N;&?P)
M^C/:X<_Y&N'_`,<?S1^6>@?\@F#_`'!5RJ6@?\@J'_<%7:_-#^T*?PH*P?B+
M_P`BS-_GL:WJPOB)SX9F^G]*J.YGB/X<O0^X_P#@UK_Y(Y\;/^QPM_\`TABK
M]3J_+'_@UL_Y(W\;/^QPM_\`TABK]3J_2L'_``(^B/XQX@_Y&5?_`!,_)O\`
MX.!/^3JOA;_V+]S_`.E(KY-C^X*^LO\`@X$_Y.J^%O\`V+]S_P"E(KY-B^X*
M^)SS_>Y'])^&?_(AI?/\V.HHHKR3]!/,?VE?^15F_P"N=?N5_P`$:O\`E%G\
M"_\`L4[7^1K\-?VEO^14F_ZYU^Y7_!&S_E%I\"_^Q4M?Y&OKN'?AD?S]XQ?Q
MJ/S/IBBBBOIC\4."_:/_`.2>Z=_V-/AW_P!/5C7>UP7[1_\`R3W3O^QI\._^
MGJQKO:[)_P"ZP_Q2_*!SQ_CR](_G(\+_`."D_P`3(_AE^Q'\2)/+\6-?ZUX=
MU+2M-D\/VUT;FWNY;*?RI'NH(95T^-6&3>W`2W@.&D=1U_*?_@A3^SW\/=3_
M`&N?!/B;P/\`L6_#_P`-WW@N&2'6OB3X7_:=L_'":!/+87$7F2:7;7<P_P!)
M.^-4.=GF%@3Y>:_8;]L#Q5KW@7]DWXG:WX5OK/2_%&C^%-4O=(O;JZM+6"TO
M([25X99)KO\`T:-%D"DO/^Z4`E_E!K\TOV!?^"OUU^TA^T?\$_#_`,:/A3^S
M;)XRTBV.BP_%#_A>_@?7M<@OI;0Q.]EI]E^_1[Z=4B,%JP`\\##*N*Y,#IB9
M\OQ-17;2T[6>EWNFKJ]XZ2LT=6,UPL;_``^_Y](7NO2UGRRVEW/USKXE^+,?
MBJ#]K_Q%I'PGUSXS7-]X\U&?_A,=%U;P0]CX+TZ(:%]D6_M=:FTZ%FG$EOIX
M58+^Y#,TO[D#<\7VU16-2DJB<9;--.W5.VGIIKIYIIJY5.HX.\=_ZU]>WXIJ
MZ/C3_@G;9S>)/B7X;U/3_`7C#P+IG@OX3Z1X+U=->\+W/A_?J,,Q86D*S1I]
MJCM56;]]#OMQ]J'E2OODV^Y_MC6'B6X^`GCF72]6T.STF/PQJ/VRVNM)EN;F
M<?9Y2WES+<QK'E>`6C?!YY'RUZQ7!_M4?\FP_$?_`+%?4_\`TDEKIJ5I5'>6
M]Y/YRE*;^5Y.RZ*RN[7.>%-1V\E\HQ45\[15^[N]-EWE%%%9F@4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%0:CIEMK%KY%Y;P74
M.])/+FC$B[D8.IP>,JRA@>Q`/45/10#5U9E&7PQIL\LSR:?8N]Q<1WDK-`I,
MD\801RL<<NHC0*QY&Q<'@5>HHIW;W$HI;!1112&<K\8SXX'@_P#XM\OA4^(#
M.G/B%K@68BYW_P"H&\O]W`X')],'PWXBWG[3VG^#+Z:^U+X%Z3;QJK?:K0ZO
M]HC?>NP1C:V]V?:HCVMO+!=K;MI^G*&;:N3P!R2>U=5#%>STY$_5:GFXS+GB
M&VJDHZ6LG9?=_P`$^+_@-\0/VF_'FI7TBW/PQM;R";4(DT[7SJ"DA-0F29XO
M))5UCE'D+EF,:1QC"^9ND]S^$[?'D>-K?_A.A\(_^$;V2?:#H+:@+Y6VG84\
MX;"-V,@XXSCD8/IOAWQ;I7C"UDGTG4]/U2&)_+>2TN$G5&Z[25)`/(XK0K2M
MF,*Z<J<(I/:R_)F&$R.IA>6-2M4DX[W>_JOZT/S7T;XU>`/BY\+OC[I-G\:O
M%'Q:\0>&/B%!8>$X]!^+5]IM]>7^HZ=IUM9P22:+<V_EV;ZA)<`HJ"WB,5PP
MC!B?'?ZM\&?%GA']JW2]#F\8>*+KPC\*_AEH$FK>+-6^,.MZ+<:3*)M82;5I
M-/$4VGZM,XMD>0ZD1&!"H8.F5KZE\?\`[7_PE^%'AN_UGQ3\4?AWX:T?2M7/
MA^]OM5\26=G;6>I"/S#92222*J7(C^?RF(?;SC'-,OOVQ?A'IGC+PMX<N?BG
M\.+?Q#XXM8+[PWI<OB6R2\\06\Y(@FLX3)ON(Y"I"-&&#$'!.*X:?\.,8;V@
MKKJXPM%Z:IM7E>+3::U]V[]NI)7ES;/F?HG-.5[Z-)JVJLFW=:V/ACX8_M5^
M`/B)^S)\/(_%'[0-U)\*8?'OBO1_$OC*T^)4UC-YD-W?2Z1:WFM6LZ2VT<L'
MER)BXA$@2V0;HY1&^+^P!\:]7T[]KWPY;^*O'+?$S6O%UW'!I&FI\9M7/B7P
MSI2Z,J07.J>#]JV7E2K;_:7O)7,A?4(GVEV%?H9XD_:G^&/@[X3_`/"?:Q\1
M_`>E>!?/-K_PD=YX@M(-)\X2M"8_M32"+>)5:/;NSO4KU!%-'[5WPM/Q$\/>
M$/\`A97@'_A+/%UBFIZ%HO\`PD-I_:.M6CHSI<6UOYGF31,J.P>-64A&(.`:
MJF_WKG'KI9>B[=7;2UFHW6US.2M%I]GOT7-?KT3LGYZ]DN^HHHJ2C@OV</\`
MDGNH_P#8T^(O_3U?5WM<%^SA_P`D]U'_`+&GQ%_Z>KZN]KKS#_>JG^)_FSGP
M?\"'HOR.#^$'_)0?BI_V-$'_`*9=+K\7O^#M?_DZ3X-?]BY=_P#I4*_:'X0?
M\E!^*G_8T0?^F72Z_%__`(.UO^3I?@W_`-BW=_\`I4*[<A_WV'S_`".7-O\`
M=9'Y?(<I2TV/[@IU?J!\*%<O\3O^02W^[745R_Q-_P"02_\`NUAB?X4O0VH?
MQ$?U/_\`!$C_`)1*_L__`/8FV7_H)KZEKY:_X(D?\HE?V?\`_L3;+_T$U]2U
M^03^)GZ)#X4?Q[?%S_DXCXA_]C+J/_I5+696G\7/^3A_B'_V,NH_^E4M9E?K
MF#_@1]$?G>(_BR]0HHHKJ,2I\(#G]KCX4_\`8ZZ-_P"E\%?V3U_&S\(!_P`9
M<?"G_L==&_\`2^"O[)J_.>)?]Z^1]GD?^[_,****^=/9"BBB@`HHHH`*_/W_
M`(+Y?\B7\*?^P[=?^DXK]`J_/S_@OD<>#/A1_P!AVZ_])Z^@X6_Y&U#_`!?H
MSQ\^_P"1?5]/U/CVQ.;6/Z"I:AL?^/2/_=%35_3A^#A7#_'HX\%3?[C?RKN*
MX?X^?\B3-_NM7/BOX,O0VP_\1'Z%_P#!N;_RC2T__L9]:_\`2MJ^[:^$?^#<
MPY_X)I:?_P!C1K7_`*6/7W=7\KYA_O53_$_S/Z!P?\"'HOR/Q,_:=_Y2`_&#
M_L/R_P#HN.J57OVG?^4@7Q?_`.P_+_Z+CJC7])\,_P#(LH_X5^2/Q#/O]^J>
MK_,****]T\<^;_V]S_Q0&I?]>[_^@FOZ)O@3_P`D0\&_]@.R_P#2=*_G8_;Y
M/_%`:E_U[R?^@U_1/\"?^2(>#?\`L!V7_I.E?A?B5_OD/1_H?K'`_P#NLO5'
M54445^;GW`4444`%%%%`!7Q7_P`%\/\`DP*?_L8]-_\`1C5]J5\5_P#!?$X_
M8!G_`.QCTS_T8U<V,_@3]&>UPY_R-</_`(X_FC\L_#YSI,/^X*N52\/_`/()
MA_W!5VOS0_M"G\*"L/XB?\BQ/]*W*P?B+_R+$WT/\JJ.YGB/X<O0^Y/^#6O_
M`)(Y\;/^QPM__2&*OU.K\L/^#6H_\6<^-O\`V.-O_P"D,5?J?7Z5A/X,?1'\
M8\0?\C*M_B9^3?\`P<"G'[5'PM_[%^Y_]*17R;']P5]9?\'`Q_XRI^%O_8OW
M/_I2*^38_N"OB<\_WN1_2?AE_P`B*E\_S8ZBBBO)/T$\Q_:6_P"13F_ZYFOW
M*_X(U?\`*+/X%_\`8IVO\C7X:_M+?\BI-_US-?N3_P`$:3G_`()9?`O_`+%.
MU_D:^NX=^&1_/OC%_&H_/]#Z9HHHKZ8_%3@OVC_^2>Z=_P!C3X=_]/5C7>UP
M7[1__)/=._[&GP[_`.GJQKO:[)_[K#_%+\H'/'^/+TC^<CC?VB?A+_POW]G_
M`,<>!3?)I8\::!?:$;Q[1+M;3[3;R0^887^20+OSL;AL8/!K\A?$?_!O1\>?
MB_X6L?#^O>$_V"/A_9^';!M/L=9\"^!;R/6M9$J):/<7DTT0\NXB@:6[BDB)
M87<40)",[#]K**XZ7[NK[6.^G_DMVONN_OUZ'5*3E!0?1MKYVO\`?9?=I;4C
MM+?[):11;F?RT";CU;`QFI**^!/CA^V;K]G^WI9Q16WQBT>/0YM6\-Z'HH\#
M^(TT/7'32IYVU":X2W^PW2O=B%(SO8016K2;D$\FW.M64$Y2Z)RTWLNRZN[2
MMYWV3%2HZ*,=KI>2OW?1)7=_+N??=<'^U1_R;#\1_P#L5]3_`/226OF__@GG
M>3:#\6M!M;'Q[XQ\<V'CKX3Z/XTUEM=\47.O)'J,T[A;NW\Z1ULX[H//^YMQ
M';G[(OE1)Y;Y]T_;&\6:AH_P$\<V-OX8US5;6[\,:B)=0M9;-;:RS;RJ3()9
MTE.T?,?+C?CID\5TU:+INTN\E\XRE!_*\79]59V5[&5.HI;>3^4HJ2^=I*_9
MW6N[]8HHHK(T"BBB@`HHHH`***\Q_:._;&^&_P"R4FCM\0O$G_"/_P!OF86`
M^P75V;CR?+\SB"-RNWS8_O8^]QGFIG.,%S3=EYFV'P]6O45*A%RD]DDVWUT2
MUV/3J*\>_9[_`&^/A+^U3XPNM`\!^+/[=U>QLVU":W.F7EJ5@5TC9\SQ(IPT
MB#`)/S=*]AI4ZD9KF@TUY%8K"U\-/V6(@X2[233^YA1115G.%%%%`!1110`4
M444`%%%%`!1110`445F^,/&>C_#WPY=:QK^K:;H>D604W%]J%TEM;0!F"C?(
MY"KEF`&3R2!WH;MJRHQ<FHQ5VS2HKS/PK^V?\(O''B5='TCXG>`]0U22Y2SA
MM8-=MFDNYG"E$A&_]\3N`_=[OFROW@0/3*F,D]F75H5*3M4BX^J:"BBBJ,CF
M_BG\.C\4?"_]E_V]XD\-_OEF-WH=X+2Z.W/R;]K?*<\@#G`YKQOXF?L-:EK'
M@#5K71_BE\4[S4;BV9(;?5O$)FL;C/6.5`@)5ERO7C.2".#]$45Y>/R7"8R[
MKQNVK7NUI\F>I@<ZQ>#LJ$K).]K)Z_-'Q/\`LE_L!^.-$O=6F\4:]XH\!6LB
M+''!X?UI(;B\<'(=VC+IL4%@`?FRV>`.?HKX;?LSGX;>+8-6_P"%@?$[7Q"C
MH;'6=<%W9R[E*_,AC&2,Y!!&"!]*].HKS\KX5R_`4XTZ2;<7=-MWO>_2R_"Q
MW9IQ5C\?4E.JTE)6:25K6MUN_P`3\Z5^`_C80^+I-)^!?Q^^&0T?XFP^,/!7
M_""7GP^CN8(CX>&D/B"^OY[)8@HN=T;1A\7$#)R)!'ZWX$_9K^*_B+XACQE\
M2-9UZZ8_#/1-)\2>&=$MM`FTWQ]?0R:L]W8W*7D#LORW,2YAGM8':=ANV#"?
M7=%?2?\`+M4WT45KKI&/*M-M5NFK-ZV/`E-RDY/S_&7/OOH[VUNKNSU/@WX'
M?#_XG?#?X>?#SQ#<?L_^,A<?#WQMXJO/^$/&J^&EU`V>K37DUK?6;#46LPT,
M=PMN\;W4#A9;C:)%"B3C_P!@#]C?]H#]DOXX+:M%XFTO0?%?B9?$.MPV;>&)
MO!MII;:>D0TYW,8UY[ZV:-88C$WV0!(VW;-\9_2*BJC*U7VW7;RM[K:\[N*;
M\[VLG8RE%.#AM>^V^M]NUE)I=-GNDPHHHJ2C@OV</^2>ZC_V-/B+_P!/5]7>
MUP7[.'_)/=1_[&GQ%_Z>KZN]KKS#_>JG^)_FSGP?\"'HOR.#^$'_`"4'XJ?]
MC1!_Z9=+K\7_`/@[5_Y.E^#?_8MW?_I4*_:#X0?\E!^*G_8T0?\`IETNOQ?_
M`.#M;_DZ7X-_]BW=_P#I4*[<A_WV'S_(Y<V_W61^7L?W!3J;']P4ZOU`^%"N
M7^)G.E2?[M=17+_$S_D%-_NUCB?X4C:A_$1_4_\`\$2/^42O[/\`_P!B;9?^
M@FOJ6OEK_@B1_P`HE?V?_P#L3;+_`-!-?4M?C\_B9^B0^%'\>_Q<_P"3AOB'
M_P!C-J/_`*52UEUJ?%S_`).&^(?_`&,VH_\`I5+677ZY@_X$?1'YWB/XLO4*
M***ZC$J_"`9_:Y^%7_8ZZ-_Z7P5_9-7\;7P?_P"3N/A7_P!CIHW_`*7P5_9+
M7YSQ+_O7R/LLC_@!1117SI[04444`%%%%`!7Y]_\%]#_`,4;\)O^P]=?^DU?
MH)7Y]_\`!?3_`)$WX3?]AZZ_])J]_A;_`)&U#_$>1GW_`"+ZOH?'MC_QZ1_[
MHJ:H[/BV3Z"I*_IT_!@KA_CW_P`B5-_N-7<5P_QX_P"1,F_ZYM_*N?%?P9>A
MMA_XB]3]"O\`@W).?^":&G_]C3K?_I8]?=U?"/\`P;D\?\$T-/\`^QIUO_TL
M>ONZOY7S#_>:G^)_F?T%@_X$/1?D?B9^TV<_\%`OC![:_)_Z+CJE5S]IK_E(
M'\8O^Q@D_P#1<=4Z_I/AG_D64?\`"OR1^'9]_OU7_$_S"BBBO=/(/F[]OH?\
M6\U0_P#3O)_Z":_HG^!/_)$/!O\`V`[+_P!)TK^=?]OWCX<:M_U[2?\`H!K^
MBCX$_P#)$/!O_8#LO_2=*_#/$K_?*?H_T/UC@?\`W67JCJJ***_-C[@****`
M"BBB@`KXK_X+YG'[`$W_`&,FF?\`HQJ^U*^*O^"^?_)@$W_8R:9_Z-:N;&?P
M)^C/:X<_Y&F'_P`<?S1^6?A__D$P_P"X*NU3T#C28/\`<%7*_-#^T*?PH*P?
MB-_R+,WT/\JWJPOB)SX:F^AJH[F>(_AR]#[A_P"#6@Y^#OQN_P"QQM__`$@A
MK]4*_*__`(-:/^2/?&__`+'*W_\`2"&OU0K]*PG\&/HC^,>(/^1E6_Q,_)G_
M`(.!C_QE7\+?^Q>NO_2E:^3X_N"OK'_@X$Y_:M^%?_8O77_I2M?)T?W!7Q.>
M?[W(_I/PR_Y$5+Y_FQU%%%>2?H)YA^TM_P`BK-_N5^Y/_!&8Y_X)7_`G_L4K
M3^1K\-_VE?\`D5)_^N=?N1_P1EX_X)7_``)_[%*T_D:^NX=^&1_/WC%_&H_/
M]#Z:HHHKZ8_%#@OVC_\`DGNG?]C3X=_]/5C7>UP7[1__`"3W3O\`L:?#O_IZ
ML:[VNR?^ZP_Q2_*!SQ_CR](_G(****XSH"J=_P"']/U34K&]NK&SN+S2W>2S
MGEA5Y+1G0HS1L1E"R,RDKC()'0U<HH`X_P"$G[/'P_\`@`NK+X#\"^#_``2N
MOW1OM4&@Z+;:;_:5P<YFF\E%\R3D_,V3R>:I_M4?\FP_$?\`[%?4_P#TDEKO
M*X/]JC_DV'XC_P#8KZG_`.DDM'2P>9WE%%%`!1110`4444`%?G=_P7N^"?C/
MXP/\)V\(^$?%'BH::-8%W_8^E3WWV7S/L.SS/*5MN[8^,XSM/H:_1&J^K:M:
MZ#I=S?7US;V=E9Q-/<7$\@CB@C4$L[,>%4`$DG@`5SXK#K$4W1?6WYW/6R/-
MI99C88Z$5)POH]M4U^I^.W_!+W]A+XFZY^T#JT>M1_%[X.V:>'IV76K33I]*
MDN7^TVN+4R31;6##<^T<DP@]`:^\O^'=?B7_`*..^.__`(.8O_C=?0OP\^(N
MA_%CP=8^(/#>J6>LZ+J2>9;W=L^Z.0`D'W!!!!!P0000"*L>(/&.D>$XO,U7
M5--TR,C(:[N4A!_%B*QP^4PHKV33;OYI_<>KFW&F+QU?ZS'EBFEHE%KUNTWJ
M?.(_8,^)"C"_M,?%':.!FWM2<>YQS1_PP=\2O^CF/BA_X#6O^%>F>*/VY?@W
MX.W"_P#BAX%21?O1PZS!<2+TZI&S,.H[5PM]_P`%8O@:MPUOIGBG4/$5XO\`
MR[Z3H=]<N>N,$1!><8^]7I4\AKS5X4IO_P`"/$GQ=4@[2J4U_P!NT_\`Y$S1
M^Q?\;(QMC_:B\5B->%W^%[!FQVR<\GW[TO\`PQE\;O\`HZ+Q1_X2EA_C5L?\
M%'EUYMOAOX+?'3Q!N.$G'AC[+:-SC_6RR#&<J>G0Y[&C_AJCX[^)5_XD7[-U
M];Q-TN-;\7V5GLZ'F(*SG/(Z\<?2M/\`5^JOB]WUJ6_.2,_];ZC^'E?I1@_R
MILIC]E+]I"$;8OVK)!&O""3X;:7(X';+&3+'W[TO_#*W[2?_`$=9_P"8RTO_
M`..5;_MG]K3Q2/\`1]%^!WA6)N#]NO-0OYTZC*^4`A/`//&#]:/^%$_M*^*6
MSJ7QV\-^&XV^_%HG@R&YXSRJO</D<$C=@D;1[T?V)27QUDO^WYO_`-)N'^M6
M+?PT(O\`[@45_P"E113'[/?[4%O^[7]H?P[<*GRK++X#M5>0?WF"O@$]2!Q2
M_P#"@?VHO^C@O"__`(0MO_\`%U;'[!/BSQ#SXD_:(^,EV3RW]C7L&C@GCIY<
M;8&1T!Z<>M`_X)2_"O5QCQ)<>//&0(PPUKQ3>2[NHY\MT]O^^1[Y/[,P,?BK
MR?\`AYG_`.E2B'^LF8/X</2^<*2_*#.-\47WQ^^'NZ/6/VBO@A8K#D&74]*B
MM)&`SRRF0!3P>!QP?2O.O$_[9'C[PBS"Z_:F^`DVWK]BT.2^]N/)+Y_"OIWP
MO_P3>^!7A`K]E^%_A6;801]MMS?>_/G%\_C7HWA?X(>"_!`0:+X/\+Z.(\!/
ML6E06^W&!QL48Z#\A1]5RZ/VJDO^WE']9!_;F8/_`)=4%_W#B_TB?GF/^"E/
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M"BBBO0/DPHHHH`****`"BBB@`HHHH`****`."_9P_P"2>ZC_`-C3XB_]/5]7
M>UP7[.'_`"3W4?\`L:?$7_IZOJ[VNO,/]ZJ?XG^;.?!_P(>B_(X/X0?\E!^*
MG_8T0?\`IETNOQ?_`.#M;_DZ7X-_]BW=_P#I4*_8CP7XWL_!?Q,^)D-[:ZY(
MUUXB@N(VL]&O+V,I_8^FIR\,3J#N1OE)!Q@XP03^7_\`P<2?L<_%?]N7X\?#
M77/A5\._%WBS3?#VB7%I?RC3I+'R)7N`ZKBY$9;*\Y4$>^:Z<FJPIXN,YNRU
MW]##,J<IX>48J[/QV3[M+7TDO_!'_P#:H5?^2"^+OQDM_P#XY0/^"07[5`_Y
MH)XP_P"_EM_\=K[[^VL'_.OO1\A_9N)_D?W'S;7+_$S_`)!3?[M?7/\`PZ"_
M:H_Z('XO_P"_MM_\=K*\7?\`!%[]JGQ)I30Q_`GQA#-CY6\RVP?K^]K.MG&$
ME!Q4U]YI2R_$1FFX/[C]^_\`@B1_RB5_9_\`^Q-LO_037U+7RO\`\$MA??LY
M?\$[_@_X%\9:!XLT?Q5X6\-6NGZI8_\`"/7UQ]EG089/,BB>-L>J,1[U[M8?
M'CP_JMA#=6L/B>YM;F-989HO#.I/'*C#*LK"#!!!!!'!!K\SE\3/N(_"C^2G
MXN?\G#?$/_L9M1_]*I:RZ^I?B7_P2`_:>U3XS>,M6L?@EXOOM/U;7+V\M9`8
M(_,BDN'=&PT@894@X(!&>:S#_P`$@/VJ,?\`)!?%W_?RW_\`CE?I6'S?"0I1
MBYJ]NZ/AZN7XB4W)0>_8^;:*^DO^'07[5'_1`_&'_?VV_P#CM(/^"07[5'_1
M`_%__?VV_P#CE;?VU@_YU]Z,_P"S<3_(_N/F;X/_`/)W'PJ_['31O_2^"O[)
M*_EY^&__``1K_:@TK]H7X?>(+OX)>+K'3=#\3:9J%_(3!)Y4$-W%)(X59"QV
MHK'`!)QP">*_I4O?CQX?TV%9+B'Q/;QM(D0:3PSJ2J7=@B+DP=69E4#J20!R
M:^)S[$4ZV(4Z;NK'U&449TZ/+-69V5%<G_PNG1_^?/Q9_P"$MJ?_`,CT?\+I
MT?\`Y\_%G_A+:G_\CUX9ZQUE%<G_`,+IT?\`Y\_%G_A+:G_\CT?\+IT?_GS\
M6?\`A+:G_P#(]`'645R?_"Z='_Y\_%G_`(2VI_\`R/1_PNG1_P#GS\6?^$MJ
M?_R/0!UE?GW_`,%]/^1-^$__`&'KK_TFK[23X\>'Y+^2U6'Q.UU#&DLD(\,Z
MEYB(Y8*Q7R,@,4<`G@E&]#7Q[_P6"\#^)OVF?"'@&/P#X1\7^([G0-5N+N\A
M71+JU9$:#:N#.D:G+<<$X[U[7#E:G2S.C4JM1BGJWHD>7G5.=3`U(05VULCX
MOM/^/=?I4E(?V<_VB,?+\#_&:@<`;8__`(J@?LZ_M$_]$1\:?]\Q_P#Q5?O?
M^N&4_P#/Z/WH_(?]6LQ_Y]O[F+7$?'C_`)$N;_<?^5=L?V=/VBL_\D1\9_B$
M_P#BJS?%W[)7[07B[0IK.;X*^,E\Q2%;8AVG_OJLJW%V53@XJM'7S1I2X=S"
M,U)TG]S/N7_@W*_Y1HZ?_P!C1K?_`*6/7W=7Q#_P19\'Z]^R5^P[9^#_`(@^
M&?%GA_Q%#KVJ7K6G]A7EUB&:Y9XVWP1NGS*0<;LCN`:^K++X\>']2A:2WA\3
MW$:R/$6C\,ZDRAT8HZY$'565E(Z@@@\BOYYQTE+$3E'57?YG[-A8M48)[V7Y
M'X^_M-''_!0+XQ?]C!)_Z+CJG7:_M2_LT?&'7/VM?B-XJ\+_``K\8Z]I'B+6
M7NK&Y%D;=9(BB`,5EVN"2#P5!X^F>*/[.7[1&?\`DB?C+_OE/_BJ_=LDXFRS
M#X"C2J5H\RBKJZTT/R7-<AQU;%U*D*;LV^C[A10/V=?VB/\`HB/C3_OF/_XN
MFG]G7]HK/_)$?&GY1_\`Q5>K_KAE/_/Z/WH\_P#U9S#_`)]O[F?.'[?O_).=
M6_Z]G_\`0#7]$_P)_P"2(>#?^P'9?^DZ5^$O[17[`_[1'QE\!W]C!\%?&4-Y
M+`ZIE(\2$J0!][CZU^V7PV^+ND^!/@[H%OK%KXGT^31M&MX[UI?#>HB.V,4"
MB3<_D;<+M.6SC`SG%?DW'F88;&8F%3#34E9[._8_1.$<'6PU"4*\7%W6Z/4J
M*Y/_`(73H_\`SY^+/_"6U/\`^1Z/^%TZ/_SY^+/_``EM3_\`D>O@SZXZRBN3
M_P"%TZ/_`,^?BS_PEM3_`/D>C_A=.C_\^?BS_P`);4__`)'H`ZRBN3_X73H_
M_/GXL_\`"6U/_P"1Z/\`A=.C_P#/GXL_\);4_P#Y'H`ZROBK_@OG_P`F`3?]
MC)IG_HUJ^HW^/'A^._CM6A\3K=31O+'"?#.I>8Z(5#,%\C)"ET!(X!=?45\R
M_P#!7C0-:_:?_8_F\+^!?#7BW7=>;6[&\%K_`&#>6N8HW)=M\T2)P.V[)[5S
MXJ+=&26]F>MD-2%/,J%2HTHJ<6V]$E?JS\J]`_Y!,'^X*N5T$/[&7[1MK"L<
M?P/\:;8QM!(BY_\`'Z?_`,,=?M(?]$/\9_E%_P#%U\+_`&5BOY']Q_4BX[R1
M+E^L1^]?YG.5A?$3_D69OI7H!_8Y_:0/_-#_`!E^/E?_`!=0:I^Q'^T7K.GR
M6\WP0\8A9!C($?'O]ZB.5XI._(_N(J<=9)*#BJ\?O7^9]4?\&M/'P=^-W_8X
MV_\`Z015^J%?FO\`\$#O@EXV_8L^&GQ1T_XF>#?%OAF\\2>)(=0TZ/\`L>XO
M//@6TCC+9MTD"X=2,,0>,XQS7WM;?'CP_>37$<,/B>62UD$4ZIX9U)FA<JKA
M6`@^4[75L'G#`]"*^[PL6J44^Q_+F=U(5,?6G3=TY.S6J9^9G_!P+_R=;\*_
M^Q>NO_2E:^3H_N"OM;_@LS\#?B!^TS\<O`OB#X=^`?&'BFQT+19[6Z*Z5-9E
M)6G#*N+A8R?EYR`1^/%?)I_8Y_:0_P"B&^,ORB_^+KY3-<#7JXF4H1=O0_=N
M!.*<KP&34J.)K1C+72ZNM7N<[171#]CG]I#_`*(=XR_*+_XNC_ACC]I`_P#-
M#_&'X^5_\57G_P!DXK^1_<?8?Z^Y)_S_`(_>CP_]I;_D5)O^N=?N1_P1GX_X
M)8?`G_L4[3^1K\B?B/\`\$^_VB_'OAV:T_X4KXQAF885]L9_/YJ_7'_@F=/=
M_L^_L"_"?P3XOT'Q9I'B;PSX>M['4K+_`(1Z^N/LTR@[E\R*%HVQZJQ'O7T>
M1X:I14E431^.^)V<X/,)TIX2HI6O>S3L?3]%5="UNU\3:'9ZE8R^?9:A`ES;
MRA2OF1NH96P0",@@X(!JU7OGY.<%^T?_`,D]T[_L:?#O_IZL:[VN"_:/_P"2
M>Z=_V-/AW_T]6-=[79/_`'6'^*7Y0.>/\>7I'\Y!1117&=`5\I_&O]L[QK\$
M_P!LC3_#E[)X;F\"WD5U))8S^%=5T^[\J'2Y[P2VVNW$J:;>W330^7_9MO$\
MZQ,\Q?;#+M^K*\9\7_L86/Q'^,D?B;Q-XX\>>(O#MK>G5++P3>S6+:!87AM&
MM3,A6U6]<>7),1#+=/`'F9A$"L>S*HIO2&CL]>SV_P`VKIJ^FEU*.E-P5^?7
M^O\`.U_*^_PRY']CG]HSXG>/?B'9Z+\2F\!W2^+O!-EXZT0^&=.N[,Z3'-*4
MFL+EKBXF^U-&)+;9<HL`D_>Y@BPN>\_;&^)_AKPK\!/'.CZIXAT/3=6U3PQJ
M*V=C=7\4-S=EK>5%$<;,&?<WRC:#D\=:S_V7OV*-+_9@U22^7QEX\\=7L.CV
MOAO2Y_%%U:3/H>E6[,T5E!]GMX-R[FRTT_FW$NR/S)7V+CK/VJ/^38?B/_V*
M^I_^DDM=-24'\"MO]W,W%/?51Y4W=W:;N[W?/!33?,^WW\J4GZ.7,TNB:5EL
MN\HHHK,T"BBB@`HHHH`*^=?^"FO[-/C/]J']G.XT7P7KLUC>6DOVN?2=RQPZ
M^J\B!Y.JD$;E!.PMC<.%9/HJBNC"XJ>'K1KT[7B[J^J,<10C6I2I3V:MH?G)
M_P`$\O\`@E'JU]\,I=2^*NH^+M'L=5;S;3PK::G/IXCR`&FN40@B1E&W9P0O
MWN<`?3/A[_@EA\`_#DOFK\/+"^G8[GEU"]NKUI&XR3YLK#G'ICD\<FOH*BO0
MQF?8VO4E4]HXWZ1;2_#]3CPV486C34.12MU:39Y_X9_90^%_@Q5_LGX<^!]/
M9?XX-#ME<]N6V9/4]37=V5C#IMNL-O#%;PKG"1H%49Y/`XJ6BO+J5JE1WFV_
M5W.^%.$/@27H%%%%9EA1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`'!?LX?\D]U'_L:?$7_`*>KZN]K@OV</^2>ZC_V
M-/B+_P!/5]7>UUYA_O53_$_S9SX/^!#T7Y')_#G_`)'#Q]_V'HO_`$V6%=97
M)_#G_D</'W_8>B_]-EA765R'0%%%?G_^PK_P5,\5_M&?'WP/X8U#QQ\#/'$G
MC.VUV;5O#7A"SGM->^'HL),127[-J-V)$D.V(J\-JV^9&7<`RB>=<W*^S?W*
M[\_T[V"6D>;S2^_^O\C]`**\K_8C^.&K?M)_LH>!?'6N6^GVNK^)M,6\NH;"
M-X[:-RS#"*[.P''=B?>O5*K8`KD_@)_R0OP7_P!@&Q_])XZZRN3^`G_)"_!?
M_8!L?_2>.@#K***^-OVW_P#@H_??!']HBZ^'>@ZYIG@U?"_AB#Q;XD\2:G\-
M?$/CFRLK6>:YBB22+27@2RC5;2>62ZN[E$50@5''F/"?:4>_^3;^Y)OOII=Z
M%<KY7+HM_FTE^+2_%V5V?9-%?)WPX_;U\3:S_P`%*/$WPJUBU\+R?#F:V@M?
M"VLV$<HO+C4QIEKJ4L,\C2M$Z36T\TD/EHI`LY=Q;(-7OV%/VW?%?[5_[0OQ
M=TO4M*T'3_`_A^/3M1\%3VL,ZW^HZ=<7&I6OVFY9W*,)FT[SX?+1`(;B/.XY
M-$?>5_)O[G:S[-[I=5KL9N22OZ?BK_=T;V3T['U'7)_&G_D3[/\`[#VC?^G.
MUKK*Y/XT_P#(GV?_`&'M&_\`3G:T%'64444`%%%%`!1110!R>C?\ET\1_P#8
M!TK_`-*-2KK*Y/1O^2Z>(_\`L`Z5_P"E&I5UE`!117P#I'_!4OQ7)^V:W@4^
M./@;J[2?%2;P"OPXM+.>'QK!IRHS?VNT_P#:,H*1*IE<-81HR(P$JL5)4'S5
MHT%\4MO_``*,?SE%=EJW9)M%3W*3K/9;_P#@,I?E%^NRNVD??U%>5_LF_'+5
MOCOX>\:7>L6^G6\GASQOK?AJV%G&Z*]M97CP1.^YVS(54%B,*3T51Q7JE$7S
M0C-;2C&2]))27X,):2E#K%N+]8MI_B@KD_@M_P`B?>?]A[6?_3G=5UE<G\%O
M^1/O/^P]K/\`Z<[JF!UE%%?+_P"W[^W-J7[.7Q&\!_#_`,,-]C\4>.+34=6.
MI-X$USQPFF65B;99#_96C[;J9Y)+J)0[2PQ1J)&9V81Q23*232[_`*)M_<DW
MZ(J,6[OM_7_`]3Z@HKXFMO\`@I9XBMOVJ_@WH-O?^!?&'PF\>>$M)O-4\4Z7
MIMU8S/J6IRW<%E<01R7,@@LY+BVCA,$OF3))=Q@R$JU=K\+/VW?%?Q0_X*4^
M(OAC;Z7H,?PPTO0=1-CJ?DS_`-IZCJNG7&FQ7C*Y<1?94?4#;X$9?SK.;Y\8
M%:4XN<E&/5U%_P""[\]^UK===8]S.I)03<^G(_\`P9;EMWO?\)=CZDKD_CW_
M`,D+\:?]@&^_])Y*ZRN3^/?_`"0OQI_V`;[_`-)Y*DHZRBBB@`HHHH`****`
M.3UG_DNGAS_L`ZK_`.E&FUUE<GK/_)=/#G_8!U7_`-*--KK*`"BBO@']L3_@
MJ7XK_9Y_:B\=^%K#QQ\#;+_A#KCP]%H_@#6[.<>+/'IU$QB6.QN%U%/+<%RJ
M,+"=00-_&2%?WXP_F=EZ_G]UPEI%R[*_]?\`!/OZBO*_@K\<M6^(_P"T)\9/
M"=];Z=%IWP]U/3++3I((W6:9+G3(+MS,2Y5F$DK`;54!0`03DGU2B+NDT`5R
M?PY_Y'#Q]_V'HO\`TV6%=97)_#G_`)'#Q]_V'HO_`$V6%,#K***^?_\`@H3^
MV1-^R)X&\(Q:5#YGB;XB>(D\-:1(?#^I>(DL7^S7%U+<MIVFJUY>".&VDQ##
ML+NR!I(4WRI,I6^;2^;=EY:OOH5&+=_)-OT2N_N2Z:]CZ`HKX'^)7_!4CQ=\
M,O#_`,%=:T[5_`OQ`\.ZU?:T?B+J<7A'5/#-UIMEIU[:VMSY&G7EW)/8W%I]
MJ+SQW9=BMK(0L990/5/BA^V_XJT;_@H_\._A/X<TO0;GP/J,DFG^*=5NH9WO
M(]1ETN^U&VMK1U=8E,<-DDDV]9,K?6^W:<FM(QN[+NU]RO?7H]D^KT,Y22BY
M/HK_`(VMZK=KHM7U/J2BBBI*.3^`G_)"_!?_`&`;'_TGCKK*Y/X"?\D+\%_]
M@&Q_])XZZR@#@OVC_P#DGNG?]C3X=_\`3U8UWM<%^T?_`,D]T[_L:?#O_IZL
M:[VNR?\`NL/\4OR@<\?X\O2/YR"BBBN,Z`HHKQGQ]^VEI?PL^.NE^#_$?@_Q
MMHNCZY=RZ;8>,KN&RCT"ZO8[":_>V7_2?MF1;V\Y\TVP@+1,@E+<5+DEO_7]
M?G9;M%*+>W]?UN^R3>R9[-7!_M4?\FP_$?\`[%?4_P#TDEKD_P!F/]MC2_VF
MO$=UI<?@SQYX)N6T>U\2:3_PDUK:0#Q#I5R\B17ML(+B9E7*#?#<"&XC\V+?
M$F\5UG[5'_)L/Q'_`.Q7U/\`])):TE&4=U_6S^::::W333U3(4D]%_6EU]Z:
M:?5--:-'>4445(PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#@OV</^2>Z
MC_V-/B+_`-/5]7>UP7[.'_)/=1_[&GQ%_P"GJ^KO:Z\P_P!ZJ?XG^;.?!_P(
M>B_(Y/X<_P#(X>/O^P]%_P"FRPKK*Y/X='/C#Q]_V'8O_3985UE<AT!7R+\#
M_P#@F[XQ\#WGPSTSQA\2O"?B3P;\']:NO$'AFTTGP/+I.K_:IDNXE%U?2ZC=
M))$L=[,&2&W@:1A'EPH:-_KJBIY5S*3W7_`?WII6>ZZ!]EQZ/1^C5FO1IZ]S
MP7]AW]F?XD_LI>!=+\%^(/B#X'\8>"?#NGFQTB#3O!5UH^J1D2;E>XN7U2YB
MEPI92$MXLD@Y`!4^]44571+^O^#\PZM]_P"OD%<G\!/^2%^"_P#L`V/_`*3Q
MUUE5="T2U\-:)9Z;8P^19:?`EM;Q!BWEQHH55R22<``9)S0!:KYM_:=_87\2
M?&7XK>(O$7@_XB6G@BW^(GA%/`_C.WN?#[:K->Z?'+<-%+82BZA6SO$6]O%$
MLL=S'^\0F$["&^DJ*F4(R^)7WTZ.Z:::V::;T>A<:DH_"^WX--?<TG\CY#^,
MG_!*&W^(/PY\?Z'X=^(&I>"[[Q+J6@ZEX=U>TTY;B\\)OI=A!IXV%Y,3M+;Q
M2H6.S"W###8R?8/@=^R1I7P!^,?B'Q%H-U';Z)JGA?0/"NGZ)':[5TJWTG[:
ML9$N\[PRW87&U=OE=6W<>N45I&37-;[3N_-VM=]]-/O[LR]G&T5;X59>2NG9
M>5U<*Y/XT_\`(GV?_8>T;_TYVM=9576=$M?$%HEO>0^=#'/#<JI8KB2*198V
MX/9T4XZ''.1Q4E%JBBB@`HHHH`****`.3T;_`)+IXC_[`.E?^E&I5UE<GHY_
MXOGXB_[`6E?^E&I5UE`!7R+K?_!-_P`8^*_$'B;1=4^)/A.;X5^*/B"GQ"GT
MB'P1*OB&WN8[N"]BABU-]1>!%$]M%EQ8^9Y9=59&(D7ZZHHBN6HJJ^):?C&6
MVV\8OY!+WH>S>V_X./Y2:^9X'^SM^S-\2?V?_BCXF>/XA>!]4^'/B7Q/JWB9
M]&;P5=0ZW!)?2O-Y0U'^U&A*I(PY^Q9901\I.X>^4441]V$::VBE%>B5DO.R
M5M0EK*4WO)MOU;NW\V[A7)_!;_D3[S_L/:S_`.G.ZKK*JZ-HEKX?M'M[.'R8
M9)YKEE#%LR2R-+(W)[N[''09XP.*`+5>)_M+_LQ>*?B9\5_!GQ"^'OC31_!'
MCCP?8ZCHPGUKP]+KVFWVGWWV=YHGMHKRT<2+-:6TB2";"[&!1PW'ME%)QOK_
M`%JK/[TVGW3:V*C)K8^1/^'2>BZ?\,]8\+:?XTU:&UOOAQ;>![*^N;-)[^QO
MK>^N;^+6#(&5'F6ZG641!$4-$,,`0!W/[._[!=O^SYXT^'.LP>)IM5F\#^"M
M1\,7[36`CFU^^U"]L[Z[U21Q(1&\MQ;2R-&%89N3A@%`/T%13I^XTXZ6YK>7
M-S\UNU_:2O;NOY8VSG%334NMK^?+R6OWMR1MZ/\`FE<KD_CW_P`D+\:?]@&^
M_P#2>2NLJKKNB6OB71+S3;Z'S[+4('MKB(L5\R-U*LN001D$C(.:"BU1110`
M4444`%%%%`')ZS_R73PY_P!@'5?_`$HTVNLKD]8/_%\_#O\`V`M5_P#2C3:Z
MR@`KY2_:#_X)]^-OC'X^^+@TSXC^#=(\`_&_3;32/$^D:CX%EU35(K>*T:TD
M-G>'48X(Y'B9BK36<ZH^TE7`VGZMHJ90C+XE?\NVJZ^CT*C.47>.Y\[^!/V2
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MGBG_`(2BZE7Q5-XJ1]+\BW\07/B#[/\`:3#'YS_9;>-8/+CA9IF\LJ&D9@SO
M4_9J_P""8A_9_P##GPCCO/B!?>+/$'PZ\3:CXGUC6[[3%CNO%<USIESID0D"
MRD0F&VEMHPPW[EM%!`+%A]6T44_<OR:72CIVCJEZ+HMMNR)J14U:>NK?SE\3
M]7?4****!G)_`3_DA?@O_L`V/_I/'765R?P$.?@9X+_[`5C_`.DZ5UE`'!?M
M'_\`)/=._P"QI\._^GJQKO:X+]H__DGNG?\`8T^'?_3U8UWM=D_]UA_BE^4#
MGC_'EZ1_.04445QG0%?+WQ,^"'QE^+G[65]=^(-!^&NI?">WLIM*\.SQ^+KV
MVU;0TNK3R;S4'L#I<D-Q?'?)%&?MD:1P.ZCYI9"WU#16<Z<9Z3U5FFNC35G^
M%_SWLRHU)1UCH]->JM_7Z;71\U_L9_LZ?$[P)XTTW7/B<O@.SN/"?@FR\"Z3
M%X7U&[ODU..&3?-?SFXMX#;M)Y<`6V3SA'B3,\NY=GJ?[0O[/VA_''P#KMK<
M:%X<O/$5UI%S8:9J.H6,<LEA*\;B-ED*,Z!9&#97D'D<UZ#16\ZDI_%YOYMN
M3?SDV^VNB2LC.-.,?A7;[DE%+Y127RUN[LX/_AE?X8?]$X\!_P#A/VG_`,;H
M_P"&5_AA_P!$X\!_^$_:?_&Z[RBH*.#_`.&5_AA_T3CP'_X3]I_\;H_X97^&
M'_1./`?_`(3]I_\`&Z[RB@#@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'
M_P"$_:?_`!NN\HH`X/\`X97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG
M_P`;KO*^9?\`@H9_P4,_X89U7P;9^1\+8_\`A++;4[K[=X]^('_"':=%]B6W
M/D1S_8KOSKB7S_DCVID1L<UG4J1IKFGL:4Z<IRY8[GKW_#*_PP_Z)QX#_P#"
M?M/_`(W1_P`,K_##_HG'@/\`\)^T_P#C=<W^R#^U>W[5ND^)KIO#%]X5;P[=
M:;;&VO+@27#?;-$TW5<2*%`C>/\`M#R2H+9,);(W;5]@KHJTITY<DUKI^*NO
MP,:<U.*G'9I->CU.#_X97^&'_1./`?\`X3]I_P#&Z/\`AE?X8?\`1./`?_A/
MVG_QNN\HK,HX/_AE?X8?]$X\!_\`A/VG_P`;H_X97^&'_1./`?\`X3]I_P#&
MZ[RB@#@_^&5_AA_T3CP'_P"$_:?_`!NC_AE?X8?]$X\!_P#A/VG_`,;KO**`
M/)?AU^QSX#\-^'[BWU;P+X#U"ZDU34+I)3HEO)M@FO9YH(\M'G]W"\<>WHNS
M`X`K>_X97^&'_1./`?\`X3]I_P#&Z[RB@#@_^&5_AA_T3CP'_P"$_:?_`!NC
M_AE?X8?]$X\!_P#A/VG_`,;KO**`.#_X97^&'_1./`?_`(3]I_\`&Z/^&5_A
MA_T3CP'_`.$_:?\`QNN\HH`X/_AE?X8?]$X\!_\`A/VG_P`;H_X97^&'_1./
M`?\`X3]I_P#&Z[ROFKX^?\%%=(^$W[8/AOX-V-]\*;?Q%J=O8WM\OC+X@1^&
M;F2*\N7M[>'2[;[-<2ZC=,89B8L0J#Y*^:3+\A'6<8+>3LO7?]`>D7)[)79Z
MS_PRO\,/^B<>`_\`PG[3_P"-T?\`#*_PP_Z)QX#_`/"?M/\`XW7B?PX_X*9+
MX[\`?'#4IO!,ECKGPE\1WV@Z5HZZNLC^+0E]/IUC*DAB40&[OK::`(5?RV3[
MSU[5^RO\;7_:5_9G^'_Q#DTD:%)XX\.V&O-IHNOM0L#<VZ3&'S=B>9LW[=^Q
M=V,[1G%.,6TVNG+?_MY-KYZ.ZW6SL[#E%Q;B]TVGZQ=G^.W1]+CO^&5_AA_T
M3CP'_P"$_:?_`!NC_AE?X8?]$X\!_P#A/VG_`,;KO**0C@_^&5_AA_T3CP'_
M`.$_:?\`QNC_`(97^&'_`$3CP'_X3]I_\;KO**`.#_X97^&'_1./`?\`X3]I
M_P#&Z/\`AE?X8?\`1./`?_A/VG_QNN\HH`XSX/\`PDM?A'=^+(=-L]*TW1]8
MUA=0L++3X!!#:Q_8;2!EV*H56,L$K_+D'>#G)('9T44`%%%%`!1110!P7[.'
M_)/=1_[&GQ%_Z>KZN]K@OV</^2>ZC_V-/B+_`-/5]7>UUYA_O53_`!/\V<^#
M_@0]%^1R?PY_Y'#Q]_V'HO\`TV6%=97)_#G_`)'#Q]_V'HO_`$V6%=97(=`4
M444`%%%%`!7.Z[\5]`\,_$?P_P"$;Z_\GQ#XJM[NZTNT\B1OM4=J(C<-O"E%
MV>=%P[`G=QG!QT5?+W[9/C3_`(5!^V7\#?&NH^'_`!WJWAO2=+\2V5]=>&?!
M^J^)7LI;A-/\D2Q:=;SRH'\J3#,@7Y#S4RE9K^NC_4J,;['MMC^T+X-U#PYX
MUU9-<ACT_P"'5U=67B26:&6'^R9;:%+B8.'4$@0R)(&4%61U92P(-<_\)_VU
MOAG\;_C#JOP_\->(Y+SQAHNBV7B&]TR?3+RSDAL;N..6"7,T2*Q*2Q%D4EXS
M(H=4)`KY3_:G^"WB[QY^T[=Z/X/\-^(KKX9_M;:1HL?BR^DTFYMH_#W]FRJ;
M]KU)(UDM9+_1W6S19E5A+;*C`'BL_P#:-\!?$#X'_M+?%KX\>"?AWXH\6>(O
M`_BC2ETS2-/TYVE\5Z1>Z%96-[!;<`2K%<);3L4.%:Q(/0BDI.*C*:W]UK9\
MR]UNSVBYM-7VBI:N]T64I.,&MN:_2SLXJ_5I*47M[UG9+1_9_P`+?VJ/`/QJ
M^+'CSP/X7\01ZMXG^&<]O:^)+2.UG1=.EG5VC3S6012G]W(&\IWV,C*VU@16
MA\,_C?H_Q:\7>-M)T>*_=O`.KKH6H7<D2K;379M8+EXX6W$OY:7$2N2H`<LH
MR5;'SE_P3U_9FU[]FS]H_P"(5GK%G>W#WO@OPO)J&NFWE%GKFM276N76J2Q2
MN,.QN;MI&4$E!.@(`*U\Q?'KQ+<1?""ST/5O!.C_`!-C_P"&C?&!\0^"]<@O
M]0M/$%NJ:I<V:RVFG6.HW5Q'''-I]PJK8S(ACB>01[1(MSM"HZ;:=HW;75J=
M.+:T?NOF;2WORJ^[)B^:#J+3WK)/>SISFD_.\4GT5WH?JW7)_"7XQ:;\8K7Q
M`VGV]_97'AG7;SP_J%K>HB30W%N^-V$9AY<L;13QG.3%/&2%)*CX'_9=_8^^
M'?Q#\._LFZ#IWA'0?&GPV\(Z1XK_`+:@@\,W%MH=AK`GLR;>[L[F)&26*[28
M(E[$LWFVHD9!*F5^G/V/8&D_:F_:BN[6.2/2IO'&FPJ2I"37<?AW2A<.OKP8
M5)'\4;=P2:C'WY0?12?W2@DWKMJ_FXZ[D\UX*2[K\I>[ZZ)]])*W4^B****D
MH****`"BBB@#D]&_Y+IXC_[`.E?^E&I5UE<GHW_)=/$?_8!TK_THU*NLH`**
M**`"@G:,T4V49B;Z&IJ2:BV@1Y[IW[5O@'5OA=X1\:0:]N\+^.KZTTW1;]K*
MX1+NXNI/*MT96C#1>9)A`TH1=S*,@LH.=^T'^VS\,OV6;;7)O'7B231U\-Z+
M'XAU(1:7>7S6MC)=+:1RE;>*0DO.X14`+MM<A2J.5^4_V>/",?[4O_!*J3]G
MN31?B-X/^(FE^$'2*?Q#X#UO1;/2M5MY_-LYXKR[M([:=HKM;>4"&5R0A8`@
M$C*?P+\1?VD/V._B1\5_%/P_\3:'X_\`B=KWA*TM_"\^ES#5-)TO2=2L0T3P
M;=X7[4VJW6X#!AF1^G-+WFI<O35-[-2]V-N[4KN5OLZ:/WBI<L6K][6ZIIIN
M_9..D=-)*[;343[&^-?[:'PQ_9W_`&?[/XI>,/%=KI?@/44M'M-42VGNQ=K=
M;3`8XH4>5]RL&^5#M0,S856([+P_\3-#\4^,]<\/6%]Y^L>&TMI-1M_)D7[.
MMRC/"=S*%;<J,?E)QCG'%?F7\<OV8/B5XF^#GQC^$K>!_$UQX'_9^\.ZX/AW
M+%82RCQ7/JT#C3TLECSY[:=8S7EDRA209TQSG'W1\%O"NJZ5^U=\9-2N--O[
M6QU2R\/I974MNT<-VT5K<+((W(VN48J&P3M)&<9JZDHJE[:">NJ751MHFOYM
M'?;=*R:=\O>514WTNF^C:ZK?W6FN^J>IW/P.^-^C_M!^#+GQ!H$5^-)AU:_T
MF&>YB6,7K6=U+:RS1`,286EAD",<%E`;&"">QK\IO&_B69_^"77[(.FZEX)T
M?XFP2:N8/%'@O7(+_4+;7I[33=32XCGM-.L=2N;@0WZ+-A+*>-'@1G\L*LB=
M;_P3;_94^&.C_$/P7XCA\+^'=6\%_#?X9V[V6JCPU<6&DZ#X@@UK5'OQ'!=Q
M1O!?VK-(A:>-+R-2Q?897#%XQGR2:LFTY+56C!S<GMORZ=+M:J]C6I%I-PU;
M2:7=N?*HK>]DT[[M7TT9]^>'/C=H_BSXU^*/`MC%?S:IX/L+&^U.Y\I?L<)O
M#/Y5N'W;C,$@,C+MPJ2Q'/S@5V%?G[XQ^$.J?M"_\$T-5\7+X?UV\\0?'SQ_
MX;\<7]IIPN?[0BTN37]*%HN82)8C;Z-;6V]TV^68I7RO)'(:U_P3_P!)^$?Q
M)^(NK>!?A&VBS>%/C9X)N/`KZ7H,B0Z#I,PT'^V9-)14V6UK+OO_`+6UL$1]
MLOG$^7\NE&FY35.I[KNHN^Z;=-/_`,!=1KS4&]+Z)J\'.FT_BMV:2=FGJ_>M
M?;2_E8^V]!_;9^'/B7XY?\*YM=6UA?$TDUU:VK7'AW4K72]3N+4$W-O::E+`
MMC=3P[7WQ03NZ&*4,H,4FWJO@;\8M,^/WPHT7Q=I$%]9V>L1,QM+Y$2[L)D=
MHYK:949U6:*5)(W"LP#HP!(YKYCTCX]0_M)_\%"-,L_$GA#XK>&=%^$NKWMG
MX22]^&_B!+/Q#JKVLEM-J\FIBS^P0V26\MS#`&G_`'IF>1BN(5;T#_@FA`R_
M!;QI<0QR0Z3??$WQC<:8K*5'D'7KT%E']UIA,X]0P(P#@9T_>BGWC>_31I67
M9M2YK:M):V=T*I[K?^)1MU5U-W\TN6U[*[>FEF_HBBBB@`HHHH`Y/6?^2Z>'
M/^P#JO\`Z4:;765R>L_\ET\.?]@'5?\`THTVNLH`****`"O(]9_;A\`:-\=[
MKX;@>.]3\5:==6EE?+I'@+7M4T_3I;I$DA%Q?VUG)9P`QR(Y:69513N<J`2/
M7*^&=$U+4/AA_P`%0OBI>ZKXA_:`\.:3XDUO0GT[2_#WPTN-9\+>)5&E6UNS
MW6I)HUT8`DH*.4O;<((\MM`9BHN]6,.C_K^M'Z`_@E+LOZ_JZ]3Z(^&?[<?P
M_P#C%\5=0\'^&_\`A.M2U+2]2OM'NK[_`(0+7H=#BN[*22*YB_M62S6P)22)
MTR)R&9=JDD@'3\5_M9^#O`_C;QUH^K7-Y9Q?#?P[;>)O$6I&W+V=A;W!N?*C
MRI,CSE;65_+1&.TIW=0?&/\`@G9^SOXU\#:KXZ\1:UXX^)6EZ5>_$CQC=V_@
MB^TS2K?1Y()]:O6@ND=M/&H,LBLLZ-]K*-O!`*$+5;PQ\.+#XT_&7]LSP/XJ
MFUJTL]<O-'=)].P]];Z?+X?M$BGM5"R?O4NK>[9`8V)DC^ZXP"I.T(RZ\G,[
M[7LM/76]K[)W>Z-)1_?5*<=E-Q7FE*U_.Z7;S2>A[GX._:W\`^//"_A;5M-U
M:^:'QEJTVA:7:W&C7UKJ#WL)F\^":SEA6XMVB\B8R>?'&(PA+E1@G<^$OQBT
MWXQ6OB!M/M[^RN/#.NWGA_4+6]1$FAN+=\;L(S#RY8VBGC.<F*>,D*25'YT6
M'P?^-/P'\=>!_&6CZA\5+C5?&EUJ%WIZR>%+75+UC=:S83_8M<>.P,.EB]MW
MNKB[FACLEB-M:VXDS9IYWUW^Q[`TG[4W[45W:QR1Z5-XXTV%25(2:[C\.Z4+
MAU]>#"I(_BC;N"3I!7W_`)6VNS4H+7;35[I-WB[)6<L>;=+NK/NFI6MJU=V3
MT;7NR5WKR_1%%%%24%%%%`')_`3_`)(7X+_[`-C_`.D\==97)_`3_DA?@O\`
M[`-C_P"D\==90!P7[1__`"3W3O\`L:?#O_IZL:[VN"_:/_Y)[IW_`&-/AW_T
M]6-=[79/_=8?XI?E`YX_QY>D?SD%%%%<9T!1110`4444`%%%%`!1110`4444
M`%>,?M*_L^>.OB/\4O!/C/X>^-O"7A#7/"-EJ>G.OB+PG<>(+2]AO?LI;$<.
MH631NAM5PQ=P0Q!7H:]GHJ914E9_UT*C)K5'RU^Q/^P-XT_8=\2W.FZ#\1O"
MNK_#?5'LKG4-)OO!DR:T\]OHUGIN8;Z+45MX8V:RCE$?V%@JLT8.-KK]2T45
MI*;E:_16^2V^[;T)>KN_ZM_7SZA1114@%%%%`!1110`4444`%%%%`!1110`5
M\W_M'_L)ZU\</BOK6J:;XZT[0O"GCJST;3_&.CW7APZA=W\.F7DMS";&Z^TQ
M+9R2"=XY&DAN1@(R+&X+-](44=4_Z^:Z^CT!ZIQ?7^M'NOEZ;,^5]*_X)?6%
MG\7O!7BJ?QE?21^%_$OB/Q%?Z;#IZ1V_B+^TM6N-5L8;@L[,!I]S.9(V7!=P
M6P@8K7MW[+WP5_X9M_9N\!?#W^TO[:_X0?P_8Z%]O^S_`&?[;]F@2'S?+W/L
MW;,[=S8SC)ZUW5%.#<(.G'1-WMYZZ^NKOWZ[(J<G.<JLOBEN^^K?ZNW;9:!1
M112)"BBB@`HHHH`****`"BBB@`HHHH`X+]G#_DGNH_\`8T^(O_3U?5WM<%^S
MA_R3W4?^QI\1?^GJ^KO:Z\P_WJI_B?YLY\'_``(>B_(Q/"GAJ;0==\374KQ-
M'K6I)>PA"<H@L[:`AN.NZ%CQG@COD#;HHKD.@****`"BBB@`HHHH`****`"O
M'?BC^P1\+?B]XANM9U31-8T_7+S5QKKZMH'B75/#^I)>?8EL6E2YL+B&:/?:
MI'%(J.JRK%'O#%%(]BHI.*>_]=?S2?R&I-;'-_"/X1>'O@5\/['POX6T]M.T
M?3S(Z1O<2W4TTDDC2RS33S,\L\TLCO))-*[22.[.[,S$F;X?_#/1/A;IM_::
M'9&SAU34[O6+O=-),\]W=3///(6D9F^:1SA<[44*BA455&]15.3;YGO_`$_S
M2^X72W2]_GKKZZO[WW"BBBD`4444`%%%%`&)8>&IK7XCZMK#/$;>_P!-LK)$
M!.]7AENW8GC&")TQSV;IQG;HHH`****`"BBB@`HHHH`****`/'?&_P"P1\+?
M'N@V.GW&B:QI*Z7KM_XDL+K0/$NJ:#?Z??7QE:\>"[L;B&XB2=II6DB218G+
MY*$@$=EX!^`G@_X:?"-?`FE:':_\(HT,\%Q87K/J`U`7#.]PUR]PSR7,DSR2
M/+),SO*TCL[,S$GL**-ERK;3\%9?<M%Y:#YG?FZWO\V[M^K;;]61VUM'96T<
M,,<<,,*A$1%"JB@8``'``':I***+WU8DK*R`C<,5A?#'X:Z+\'/A]H_A7PW9
M?V?H6@VJ6=E;F:29HXT&!NDD9I)&/4N[,S$DL2236[10`4444`%%%%`&)?\`
MAJ:Z^(^DZPKQ"WL--O;)T).]GFEM'4CC&`('SSW7KSC;HHH`****`"BBB@`K
MG[/X6:#I_P`4-0\:6^G)#XFU73;?1[R]21U-U:P232PQNF=C>6]Q,58KN'FL
M,X.*Z"BCK?\`KM^3L'2W1_H[K\4GZJX5@_#_`.&>B?"W3;^TT.R-G#JFIW>L
M7>Z:29Y[NZF>>>0M(S-\TCG"YVHH5%"HJJ-ZBCK?Y?U]R^X-U;SO\]5?ULVO
MF^X4444`%%%%`&)\-/#4W@OX<>']'N7BDN-)TVVLI7B)*.\<2H2N0#@D'&0*
MVZ**`."_:/\`^2>Z=_V-/AW_`-/5C7>UP7[1_P#R3W3O^QI\._\`IZL:[VNR
M?^ZP_P`4OR@<\?X\O2/YR"BBBN,Z#/\`%VH_V1X3U2Z\G4+G[+:2R^38)ONI
M=J$[8E[R'&%'=B*_%?\`9B;X?:-\/]<&JWWP9U+P#?'P:_CR\\",%TF'1AJL
MJO%XQ`^5M6=I4-W+*522(7`EBBB20R_MQ14QC:JJO9Q=N]FW9]T]+K316O9L
M<WS4W3VO?UUMJNS5G9]&[VND?./_``3!M_#UM\!_$2^!8]/C^&)\9ZR_@D::
MH&EG2FN,@V.WY?L9N#<F(Q_NBA7ROW7EU[)K7Q2/A_XBZ3X?NO#^N1PZY<-9
MV>K!K5K*69;:6Y*8$WGJ?+@D&3$%RN,\@GJJX/XO_P#)0?A7_P!C1/\`^F75
M*TE*Z2[)*[U;LDKM]6[7;ZMLB,;-ONV_2[;LO)7LO([RBBBI*"BBB@`HHHH`
M****`"BBB@`HHHH`****`/S8^&FL>(/BQ_P6[_:*\/ZS8?'[Q=X;\&:CX0;1
MV\.?$BXT;PWX.\[2DFF>[T\:O:"XBED4.R1VMUNVON3YR'7_`()`>(O$?Q9_
M:%^,6N>)]+^/WB:?0?BWXNT?3_%-Y\1IIO!^F6<,Y2&P.D/JXR45BJ$::R*7
M0AQMROUQJ7_!/+X7WW[1FM?%B&U\:Z/XY\2W%C<ZQ=Z+X\U[2;75WLHUBMOM
M-G:WD=K.J1H%V21,K`L&#;FSVWP+_9P\%_LU:7XBL_!.C?V+;>*_$%[XHU5/
MM<]S]JU&\</<3YF=RN]@#L3"+_"HJL.^11OTIN/_`&\W3UZ=(RULGJD[IL,3
M^\TC_-!_*,))KKO)IVVMJK-([BBBBI`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`."_9P_Y)[J/_`&-/B+_T]7U=[7!?LX?\D]U'
M_L:?$7_IZOJ[VNO,/]ZJ?XG^;.?!_P`"'HOR"BBBN0Z`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@#@OVC_P#DGNG?]C3X=_\`3U8UWM<%^T?_`,D]T[_L:?#O_IZL:[VN
MR?\`NL/\4OR@<\?X\O2/YR"BBBN,Z`HJ'4;]-+T^>ZD69H[>-I7$,+S2$*,G
M:B`LS<<*H))X`)KP?3O^"FOPCO(/$#75YX^T.;PS:6E[>6FN_#GQ'HUY*EW<
M_9;5;:WN[&*6[EFN`8HXK=9)'<;54GBE=7Y>O]?Y,=G:_P#7;\VOO/?JX/XO
M_P#)0?A7_P!C1/\`^F75*T/@E\</#/[1'P]M_%'A.]NKW2;BXN+0_:M/N-/N
MK:XMYG@G@GMKF..>"6.6-T:.6-74J<@5G_%__DH/PK_[&B?_`-,NJ54HM.S$
MFGL=Y1112`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BL/X@?$_PU\)M#34_%7B+0_#.FR3"W6[U6_BLH&D()"!Y&5=Q"L0,Y(4
M^E8/@K]J+X9_$KQ'!H_ASXB>!?$&KW08PV.FZ]:W5S*%4LVV..0L<*"3@<`$
MU+J13Y6]3>.%K2A[2,&XKK9V^\[JBBBJ,`HJGXBOKK2_#]]=6-BVJ7UO;R2V
M]FLJPM=R*I*Q!V^52Q`7<W`SD\5\Z?\`#4'[1G_1K?\`YDG3/_C==6'PDZR;
M@XZ=Y1C_`.E-7^1SUL1"EI)/Y1D_R3/I>BOSY^`G[;'[46O_`+1OQ"TNZ^$4
MGBB+3'03>'VU*WTE/#K<",)>2`I,'3YL?-YGWT(4'/T-\/\`]HCXZ^(/&VE6
M.O?LZ-X=T6[N4BO=37Q[IUX;"(G#2^2JAI`HY*J<D#C)XKLQ62UZ#M*4'HG\
M<.JOLVF_DM>ESEP^:4JJO%2WM\,N]MTFOQTZGT!17YZ_$[X3Z7??M4:S>:I\
M-OB#+\5K7QX^J/X[TKPSJBR1^#_L.)(+76K9&Q']G:2W&GV\ZW#71,B6^XB0
M\SX/_9U;]I_]CSX5^`=#\`V]EIV@_&'Q#=S:=\5?A)JU]I%G82)X@N+6>?3;
MXV,DT;1W-J$F\T*DTJ*Q,BF.O'I-U*2J):Z:=4FHMM^CDXO^_&<=T>I)*-1P
M>RYM>]N>UO7E3_PSA+J?IA17YTZQX*7PU\2/VE/"O@/P9\2H;O4O`FAVKS6/
M@[7]+T_6I;"XU`:C9Z7>7*K`H^RSQ16L,%T45'1("5B.WC?'7@;P'X&M6USP
M+\'OBQX7^'\?Q'\*:SX5\/Z)\,O$EI:VTMG=63ZSJ']AV]F#:CR(U59+FW1I
M7BN#"7,C%[C9U(Q3TDXZ^4I*+?HM6GUM;3=9OF5TUJKZ>:CS6]>C73?78_4B
MBH[:X6[MHY5$BK(H<!T*,`1GE6`(/L0"*DI;:,I.ZN@HHHH`\D^'GB#Q-\,=
M*U329OASXNU3_B?:O>Q7=E=Z3Y$\-SJ5S<Q,OFWJ./W<JY#(I!R,5O?\+@\0
M_P#1*_'O_@7HO_RPKO:*[JF,C.3G*E&[=W\7_P`D<L,+*$5&-1V7^'_Y$X+_
M`(7!XA_Z)7X]_P#`O1?_`)84?\+@\0_]$K\>_P#@7HO_`,L*[VBI^LT_^?4?
MOG_\D5[&?_/Q_P#DO_R)P7_"X/$/_1*_'O\`X%Z+_P#+"C_A<'B'_HE?CW_P
M+T7_`.6%=[11]9I_\^H_?/\`^2#V,_\`GX__`"7_`.1."_X7!XA_Z)7X]_\`
M`O1?_EA1_P`+@\0_]$K\>_\`@7HO_P`L*[VBCZS3_P"?4?OG_P#)![&?_/Q_
M^2__`")P7_"X/$/_`$2OQ[_X%Z+_`/+"C_A<'B'_`*)7X]_\"]%_^6%=[11]
M9I_\^H_?/_Y(/8S_`.?C_P#)?_D3@O\`A<'B'_HE?CW_`,"]%_\`EA1_PN#Q
M#_T2OQ[_`.!>B_\`RPKO:*/K-/\`Y]1^^?\`\D'L9_\`/Q_^2_\`R)P7_"X/
M$/\`T2OQ[_X%Z+_\L*/^%P>(?^B5^/?_``+T7_Y85WM%'UFG_P`^H_?/_P"2
M#V,_^?C_`/)?_D3@O^%P>(?^B5^/?_`O1?\`Y84?\+@\0_\`1*_'O_@7HO\`
M\L*[VBCZS3_Y]1^^?_R0>QG_`,_'_P"2_P#R)P7_``N#Q#_T2OQ[_P"!>B__
M`"PH_P"%P>(?^B5^/?\`P+T7_P"6%=[11]9I_P#/J/WS_P#D@]C/_GX__)?_
M`)$X+_A<'B'_`*)7X]_\"]%_^6%'_"X/$/\`T2OQ[_X%Z+_\L*[VBCZS3_Y]
M1^^?_P`D'L9_\_'_`.2__(G!?\+@\0_]$K\>_P#@7HO_`,L*/^%P>(?^B5^/
M?_`O1?\`Y85WM%'UFG_SZC]\_P#Y(/8S_P"?C_\`)?\`Y$X+_A<'B'_HE?CW
M_P`"]%_^6%'_``N#Q#_T2OQ[_P"!>B__`"PKO:*/K-/_`)]1^^?_`,D'L9_\
M_'_Y+_\`(G!?\+@\0_\`1*_'O_@7HO\`\L*/^%P>(?\`HE?CW_P+T7_Y85WM
M%'UFG_SZC]\__D@]C/\`Y^/_`,E_^1."_P"%P>(?^B5^/?\`P+T7_P"6%'_"
MX/$/_1*_'O\`X%Z+_P#+"N]HH^LT_P#GU'[Y_P#R0>QG_P`_'_Y+_P#(G!?\
M+@\0_P#1*_'O_@7HO_RPH_X7!XA_Z)7X]_\``O1?_EA7>T4?6:?_`#ZC]\__
M`)(/8S_Y^/\`\E_^1."_X7!XA_Z)7X]_\"]%_P#EA1_PN#Q#_P!$K\>_^!>B
M_P#RPKO:*/K-/_GU'[Y__)![&?\`S\?_`)+_`/(G!?\`"X/$/_1*_'O_`(%Z
M+_\`+"C_`(7!XA_Z)7X]_P#`O1?_`)85WM%'UFG_`,^H_?/_`.2#V,_^?C_\
ME_\`D3@O^%P>(?\`HE?CW_P+T7_Y84?\+@\0_P#1*_'O_@7HO_RPKO:*/K-/
M_GU'[Y__`"0>QG_S\?\`Y+_\B<%_PN#Q#_T2OQ[_`.!>B_\`RPH_X7!XA_Z)
M7X]_\"]%_P#EA7>T4?6:?_/J/WS_`/D@]C/_`)^/_P`E_P#D3@O^%P>(?^B5
M^/?_``+T7_Y84?\`"X/$/_1*_'O_`(%Z+_\`+"N]HH^LT_\`GU'[Y_\`R0>Q
MG_S\?_DO_P`B<%_PN#Q#_P!$K\>_^!>B_P#RPH_X7!XA_P"B5^/?_`O1?_EA
M7>T4?6:?_/J/WS_^2#V,_P#GX_\`R7_Y$X+_`(7!XA_Z)7X]_P#`O1?_`)84
M?\+@\0_]$K\>_P#@7HO_`,L*[VBCZS3_`.?4?OG_`/)![&?_`#\?_DO_`,B<
M%_PN#Q#_`-$K\>_^!>B__+"C_A<'B'_HE?CW_P`"]%_^6%=[11]9I_\`/J/W
MS_\`D@]C/_GX_P#R7_Y$X+_A<'B'_HE?CW_P+T7_`.6%'_"X/$/_`$2OQ[_X
M%Z+_`/+"N]HH^LT_^?4?OG_\D'L9_P#/Q_\`DO\`\B<%_P`+@\0_]$K\>_\`
M@7HO_P`L*/\`A<'B'_HE?CW_`,"]%_\`EA7>T4?6:?\`SZC]\_\`Y(/8S_Y^
M/_R7_P"1."_X7!XA_P"B5^/?_`O1?_EA1_PN#Q#_`-$K\>_^!>B__+"N]HH^
MLT_^?4?OG_\`)![&?_/Q_P#DO_R)P7_"X/$/_1*_'O\`X%Z+_P#+"C_A<'B'
M_HE?CW_P+T7_`.6%=[11]9I_\^H_?/\`^2#V,_\`GX__`"7_`.1."_X7!XA_
MZ)7X]_\``O1?_EA1_P`+@\0_]$K\>_\`@7HO_P`L*[VBCZS3_P"?4?OG_P#)
M![&?_/Q_^2__`")P7_"X/$/_`$2OQ[_X%Z+_`/+"C_A<'B'_`*)7X]_\"]%_
M^6%=[11]9I_\^H_?/_Y(/8S_`.?C_P#)?_D3R3XA^(/$WQ.TK2])A^'/B[2_
M^)]I%[+=WMWI/D00VVI6US*S>5>NY_=Q-@*C$G`Q7K=%%9UL1SQ4%%12;>E^
MMN[?9%4Z/))R<FV[;VZ7[)=PHHHKG-@KX_\`'_P$^(FM>'O$OQ+F\'7&K>/F
M^).FZ[:^&8=3LUNI_#^DW7V:UM8+B21;=9)+<W%^(Y95437DD;/'DLOV!12M
M[RFMTTUY-2C)/U3BOE=;-CWBX/9W3\TTTUZ-/UND^AX[^Q;X(\2>&?!'BK6?
M%6A3>%=6\<^*]1\1C1+BZ@NKK28)62.&*>2W>2!IC'"CN(I)$1I"BO(%WMH_
M%;P_=P?&_P"&>I-KFJ36<WB*:)-*>.V^QP-_8NI?O%98A/NX/#2LOSGY>F/4
M:X/XO_\`)0?A7_V-$_\`Z9=4I]%%;122\E%))?))$]7+JVV_63;?XL[RBBB@
M84444`%%%%`!117YCM_P<:98[/@YN3^$MXLP2/<?8C_.N;$8RC0M[5VOY/\`
M0]G*.'\?F?/]1I\W+:^L5:][?$UV>Q^G%%>4>`?VS_A[XE^$7A?Q5K7B[P?X
M5;Q%H]IJKV6H:];1O9&>%)#$S.RY*%PI.!R.@Z5@^)?^"FOP#\*,5NOBGX5E
MV_\`/G.U[W(_Y8J_I_+U%6\122NY+[SFCE..E)PA1DVG;2+?Y(]UHKYC'_!7
M+X/ZPO\`Q3<GC7QCN'R#1O"M]+YAYP!YD:=2"/K^=#?\%&M7UU?^*=_9\^/6
MI;AE);[0$TV"08!!5Y)"2I&><#L.]9_7*/25_37\CJ_U>S%?'2<?\5H_^E-'
MTY17S)_PU'^T/XB?&D?LTFQA/W;G6?'%C#CGH8D5GZ$'.<=1Z91=<_:^\3C_
M`$?0O@-X7C;AOM][J-],@Y&5\H!"1UY..1UYH^M1?PJ3_P"W7^J0O[#JK^)4
MIQ_[B0?X1<F?3E%?,9^"7[4WBD?Z=\</!'A7<.?[%\&)?;#@=/M+C.",<]B3
MZ"G']A?XE>(GW>(OVEOB=<[OO?V-:6>C]\\>6K8[_IV&*?MYO:F_P_S#^S,-
M'X\5#Y*HW_Z0E^)]-51UWQ1IOA>#S=2U&QTZ+!.^ZG2%<#&>6(]1^=?.(_X)
M7>$-57;XB^(/QK\8`_?&L^,[B3S!R,'RPG4''T_&KVA_\$E/V>]#F\[_`(5W
M:ZA<-R\VH:E>7C2G&,GS)F&?H`,T<]=[17S?^2#ZOE<?BKS?^&FOS<U^1Z%X
ME_;0^$/@]V74OBA\/[253@Q-K]J9>I'W`^[J".G:O/\`7?\`@K3^SWH,HC;X
MC6=]._$<5AIUY>-(V,A1Y4+#)Z<D#/I7>^&?V*/@]X.VMIOPM\`6TB])?[!M
MFE[?QLA;L.]=_H/A32_"T/EZ7INGZ;'C&RUMTA7&<]%`[DG\:+8A]8KY-_J@
MY\IC]BI+_MZ,?_;9GSF?^"J?@W5@/^$<\!_&?QANR4_L;P;<2^8,9&/,*=1D
M_0'VRH_;N^(OB%O^*=_9I^*=RI^Z=8FM-()Y[^8[8X(/Y^F:^F995@B:21E1
M$!9F8X"@=237G_C;]K7X6_#?S!KWQ$\%:7)'D&&?6;=9LC@@1[]Q(]`*N.'Q
M$W92?R7_``XUC,"OX>%O_BG)_P#I/(?GK_P6'^*_Q@^(?[,V@KX^^$NG_#G0
M8_$]O+#,OBF#5[E[@6EXJQE85"A2I=MV>,*.IX^=_P#@CDP?_@I#\-]IW8.I
MDX[?\2N\K](OC!_P55^#-UHLT/AGQ]JEYKNEO]LA;1M$O+V$%`V5G&Q8Y(&7
M=N&\''S*RLJ,/2/V9/C;J'[4#0^)+RUU7P=#I<*[?"]Y');WKO(A'VNX#JK/
M`V)!`%&Q@K.V9`(X,:_#M=5%BZLFDFMUKI]V_IH?587C58?*:F6QPJBIJ2NI
M227,K7M+F;W_`)M?(]JHHHKL/SL*KZQK%IX>TFZU#4+JWL;&QA>XN;FXD$4-
MO&@+,[LQ`554$DD@``FHO$EG>ZCX=U"WTV^73=1N+:2.UO&@$ZVLI4A)#&2`
MX5L':2,XQD9KY&^-O[''[27BOX,>+M+_`.&C_P#A*O[2T6\M?[%_X0#2['^U
M]\#K]E^T>8/)\W.SS,C9NW=JQK5907NQ<O2WZM?@>EE^"HXB5JU>--72]Y3U
M3[<L9+3S:/HOP3^U!\,OB1XDAT?PW\1/`FO:Q=AFBL=-UZTNKF;:I9BL<<A9
ML*I)P.`">@KNZ_'G]CO_`()5_M(_#G]H_P`-ZT+4_##[";D_\)*9-+UK^S=]
MK-'_`,>GVAO,\S=Y73Y?,W?PU^@'P\_9R^/OAKQSI.H:]^TBOB71;.Z26^TI
MOA[I]F-0A!^>+SHY-\989`9<D'G!Z5R87&5JD;U*36ODOS:?X'NY[D.782KR
MX3&PFN6_VF[W>B<(RCT6\D^]E9G83_MK_#RU^,?B+P-+?>(H=6\'@MKM^_A7
M55T#1L627Q%SJYMO[.A(MI8Y"'N`0'48R0*H:C^WW\+['X.^'_'D&I^)-9\.
M^*M7GT+23HOA#6-7O[Z\@-R)HTLK6UDNL)]CN27,03$1.[!4GSCQ5^RC\0K/
M]MN^^(W@O2M'\,Z?<7G]JZG=K\5->:/QG)'I0LX[6[T!K-M,M=S1VRF\C::9
M$M4959F*KS_P]_80^('Q%^#_`(+\,_%&'0_#0\-?$K6O&-RW@7XA:U!<3V=_
M'J\B)%?6]MI]S%*D^I)&R*P1XXF8M\_E5Z$;R@GULKW]=6O+LG:2LVU9IGR4
M^52\OUY6[?\`@27=--)/F4DO=/#O[<7PK\4VWC2:U\76\</PZT^'5/$LEW:7
M%FNC0RB8@3&:-0LJFWG22'_6Q21-'(J.-M<J?^"HGP7ATK[7=:YXKTU8+LVE
M_!J'@;7K*[T/"0N;C4;>6S673[39<0M]KNTBM]K@^9@''!>.OV3?B]\0OBC\
M8`=/^'VB^%_%7A72M#\,:D_B_4M5U,7.DW5U<6<E];O8Q9CG:Y`FVW<CJ(C\
MTQD)7`^(_P"SK^TQX\\5ZUK$_A;X'3:;\0)[5/%GAI/'VJ6BM96,86VMH]17
M1'>9)Y'G:X#6T1\ORX58@NY=TYJVSMY/5V=^VFMMUYZ7S?,KKJK_`))Z?/2^
MS\C[>5@Z@CD'D$=Z*CMFD>VC,RQQS%075'+JK8Y`)`)&>^!GT%24/30<=5<*
M***!A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`455UO5X=`T
M6\O[C=Y%C`]Q)M&3M12QP/H*^#?@M_P5"\<?&OX<QWFGZIX5LO&7CRYT(>&/
M#FM?#3Q%H(\,6NJ7+(MU<7-]/$-=BBB!!DL([:-Y45=\:S(ZJ/O3]G'5Z*WG
M)VBOFT]=E9W:02M&'M):+5_)6N_E=7ZZJR;/ORN#^+__`"4'X5_]C1/_`.F7
M5*Q?V0OBUXH^*7@/7K;QM_8,WBSP;XDU#PYJ5WHEK+::=J)@D#17$,$TLTD(
M>"2$M&TLFR3>`[J`QVOB_P#\E!^%?_8T3_\`IEU2JZ)K5-)I]TTFG\TTQ7U:
M>Z;3\FFTU\FFM-.QWE%%%(84444`%%%%`!7X\C_@WW^-"#:/$OPP('`/]I7W
M/_DG7[#5\B^/_P#@K9X5^$OQE_X5OK=C#<>*K>9["YU"UO8H]%BNBR"$O,S%
MHHSN)FW!F@967$N-QEY*\P?+&+DXW>G;K^1[F3<58O)N=X:27M+7NK[7M^;O
M^)V7P!_X)H_"?X:?"KPOI^O?#?P%K7B;3])M;?5KV;34O8[R[2!$FE7SEY#2
M!F&57KG`->Q>&?@MX-\%LIT?PGX9TDKT-EI<%OCD'^%1W`_(5QOB#]MOX4?#
MK3(5\2?%#P!#J4<2BYCMM5B9C)C#%85=Y`I8'`.2!W.*\_N?^"M?P=O[AH?#
M-UXL\<7"':8O#_AN\N3N],M&BGMT..16U'*YI?NZ;MWM^MCEQ&.QN)DYU9RE
M?75NQ],45\OWO[?7Q`UZV:;PK^S?\3+B)>C^)[FT\-H.WS&9GV\D#GUK%U#]
MH?\`:.\1R+''I_[/_P`.EE&=NO\`B>74;A%Z946Y52<Y(SQV-=4<OJO>R^:_
M)-O\#SY1Y?B:7S1]=45\3ZAJOCW7XGD\5_ME_#7PO:;MLUKH%AID07)Q@7$\
MV]3Z<=3["L/4/AI\`]4GV^-OVK_%GC5I!NDMY_B)"MB<GD+';X"YP,C=G@=*
MVCE<NK;](R?YI+\3.5;#Q^*HOO/MCQC\4/#/P\A\SQ!XBT/0XP-Q;4+^*U4#
MUR["O(_&G_!3OX!^`W9;SXG>';IE.-NF-)J>XYQ@?9EDS^%>`^'M._8(^'(^
MTI)X'U&;?EY-0DO-7DE<YRS++YF<Y)/&,_A7H7AG_@HI^R5\)9%A\/ZYX7T-
MHU^4:1X4NH5`QC`,-KCIQC-=$<IG]FC5E_V[;])&,LPP,=ZJ_P#`DOU9L+_P
M5%\.^)>/!WPT^-'C@,<+-I7A25;;ZM)*R;1C'..XH_X:D_:#\:#;X=_9S;28
M6^[>>(_%MK;[?8V\:F3T.<]B*E_X>R?".Y^6Q/C35)NIBM?#%XSJO]X[D`QG
M`Z]Q2?\`#T7PK=#=8?#SXU:K&>(Y+3P?,RRGT7<PYSQSCFJ_L^NML,_^WK__
M`&I/]J8/I)/YW_(C;PY^UQXY_P"/KQ)\%_`MNWW?[,T^\U2ZC'3YO/(C)ZGC
MC@>]'_##_P`4O&7_`"./[2WQ"NED^^OAK3[3P_@'LK1AR..,]<\U+_P\:O[_
M`.6P_9]_:'DD7EA=^%5M5`]BTIR?:D_X;I^(5^-VG_LW_%"19.(?M<MM:%CT
M&\,QV#/<YXYH^KXU?#",?_`%^+=_Q#^UJ/V7]T6_T8V'_@DS\*-7D63Q9-X[
M^($RD-YGB/Q1>7!9LYR1&\8/0<$8.!Q7H'@C]@_X,?#HHVD_##P3#+'C9--I
M45S,F/224,P_/FN"_P"&L_CS?\:?^S!JDC+]_P"U^.-.M`/3!93N_I2?\+Y_
M::U(?N?@'X9TWSON?;/&]O-Y'^_Y:_-C_9J)8?&R5IU8V_Z^0_)2!YI%_P`[
M_P"W)_Y'ONH?#?0M3TJQL)=+M5T_3[F.[@M(U\JW$L?^K+1KA7"G#!6!`948
M#<JD*NBZ'XKUZRUR'[-=ZAH[3VD-W;S_`#1Y)2:%BAPRAE&Z-\@/&IP&12/E
MGXT:U^V!X]^%^M:?HWA7X=^%;J:V9#<V.M23:BRD<BV+`1I(0"H9\8W9!4@,
M/&_^"(?PZ^+WA;Q;XENM0^U:3\//.FM]0L=5B<2W&HH2A,"L08Y$8;9&.0<;
M2"P!2XY/_LE3$RK1O'HG>]_3OT[ZWL<<LU?UB%"-.5I7U::M]_X_J?I)1117
M@GK$=U=1V-M)--)'##"I>21V"JB@9))/``'.37&?\-,_#?\`Z*!X(_\`![:_
M_%UV-_80:K8S6MU##<VUS&T4T,J!XY488964\$$$@@\$5Q<_[,OP[:!Q'X!\
M#)(5(1FT"U95/8D;!GZ9%<F)^M:?5^7SO?\`"Q,N;[)1TS]KSX9ZIKFI:>OC
MCPS%)I9C#RS:E#'!/O7<#%(S;9,=&VD[3P<<5M:-\?O`?B/5;>QT_P`;>$;^
M^NG$<-O;ZQ;RRS,>BJJN2Q]@*\%^#G_!,:S^&WQ.AU[5O$&B^*K#]Z+G2KOP
MO$+><.IQM#2NL95BK`JO\..A->\Z5^SYX!T+4[>]L?`_A"SO+219H)X-&MXY
M874Y5E8("K`\@CD5YF`K9M4CS8FG&&NU[NWR;7EZK8S@ZC^))'$^,_VG/$GA
M_P#:6N/AW8?#NZO_`#?".H>(M(U&;6K>W76KFUDLHS:QQ@.8XRUZBF:9D8-&
M^(G7:[>0?%'_`(*>:]\'/@[;ZQXH\+_"?PGX@C\?S>`M0F\1_$\Z7X0MI8]/
MFOC<1ZRVFF1QB(6^R2SB87'F1]$#-Z9\:?V'[WXQ?'&3QU#\9_BWX/NQX?OO
M#=II^@#0XK73K:\2+SGADFTV6Y68RP03*YG8I)$-N$+(UOX)?L26GP>\*^"]
M)O/'WCCQI'X`UJ36]&FUF#2+>2%GL;FS:%Q86%JDB%;N>4NZF9I6W-(PRI]R
MDGR>^];/[_:-IZ?].[1ML[WT:][HE92TV_\`M+6_\#]Z_E;5/3EK;_@H+?Z7
M#\2WU[P"MB/`7A[1];T\Z?XCMM0C\4-J,EU!"MM(%2-(9)[8"*61E9XYD=XH
M&S&//_C#_P`%0?B!\`VU#3/%GPY^$FE^,-&NXH7T!_BM,EUXH6>%);6'0%DT
MA'U.]E(GB^RNEN1+&BAW60.OJWB'_@G]9^-/B=\2?$6N_$SXF:M:_$W14T*\
MT5VTFULM+@ADFDM'M);>PCNXY;9[B9HW>XD)+Y?S"J;</7?^":+>*?#_`(@T
M_4_CA\9-07QQ$]GXQFG@\-M)XNLS"+=;2X']D;((4@\R,?8EMF/GR.S-(0XJ
M]YII:::/UU3:UO;=JZ5[I/8F*L[2=UY;[+5)VTO=I73Z-]3Z:AD\V)6VLFX`
M[6ZK[&G5#IFG0Z/IMO9VZ>7;VL:PQ)DMM50`!D\G`'>IJ<K7TV)AS<JYMPHH
MHI%!7R_\:_\`@JQX#^!OQ3UGPGJFFZU-J&B3""9X4!C8E5;C\&%?4%?BI_P4
M=_Y/=^(?_817_P!$QU]5PGE.'S#$SI8F]E&^CMK=(^>XCS*M@J$:E"UV[:J_
M1GW%_P`/K_AK_P!`GQ#_`-^UH_X?7_#7_H$^(?\`OVM?'7P\_8^\/^./`_@W
M5EU'6&FU3P_JFK:S`CQK]E:%;_[(\1*']VS6160,"02N&&]<<SI7[$GB77);
M&VM-9\+S:I-<:7!?Z>+B<7&BC4=OV5[@F$(5.]`WDM*R%U#`&OKO]6\BYY4W
MS)QT=V_YG'\U^*[H^:>?9M[-5-+-7V6UE+\FOQ['W7_P^O\`AK_T"?$/_?M:
M/^'U_P`-?^@3XA_[]K7PW9_L37M_X;EU>'QYX!DT^/[6PE#:CB2.T\G[5(O^
MA\K%YRY'WGP?+#\9@NOV)_$UAI_C2ZDOM+G3P'=FWU);>&]9)5#1#S(KC[/]
MFY656"/*DI4$[.@-QX9R)NUW][[I=N[L^W4)9[G$5=I;VV6]KVWWL?=?_#Z_
MX:_]`GQ#_P!^UH_X?7_#7_H$^(?^_:U^<G[17PZL?A%\=/%7AC39;J>PT/4I
M;."2Y96F=%.`6*JH)^@`]JXNNFAP;E-6G&K!2M))K7H]3GK<49E2J2IR:O%M
M/3L?J?\`\/K_`(:_]`GQ#_W[6C_A]?\`#7_H$^(?^_:U^6%%:_ZCY7VE_P"!
M&?\`K9F'=?<?J?\`\/K_`(:_]`GQ#_W[6MGQ/_P5Y^'WA71/#E]<:7KK1>)M
M.?4K8+&,I&MW<6I#>^^V<_0BOR7KT/XT_P#)-OA%_P!BE/\`^GW5ZPJ\%Y9&
M4$D]7;?R;_0TI\58]QDVUHNWFE^I^AG_``^O^&O_`$"?$/\`W[6C_A]?\-?^
M@3XA_P"_:U^6%%;_`.H^5]I?^!&?^MF8=U]Q^I__``^O^&O_`$"?$/\`W[6C
M_A]?\-?^@3XA_P"_:U\Q>,_V"?"_AOPQXFU:+4/$/V/2O!]KJ]H\EQ"0VHO$
MTLL;XBR8E38=H`8>8/F/?C3^PGJGANQUH:Q<27=TWAH:UH8LH;FS^T3&_@M!
M'+%>6\,H!\TD?*H.4(<C(KRH9#D,M%S?>_7\M?0]"6<9PDF^6WHO)?FTO4^S
M_P#A]?\`#7_H$^(?^_:T?\/K_AK_`-`GQ#_W[6OSW_:)_9<\3?LR:EIMOXB6
MW9=524P2PQ7$2EXGV2)B>*)SM)4AU4QN&4H[#FO.*[\/P?D]:"JTKN+ZJ7R.
M.MQ-F=*;IU;)KHU\S]3_`/A]?\-?^@3XA_[]K6SXV_X*\_#WP+>V,%UI>NNU
M_IUKJ2%(QQ'/$LJ`^X5AFOR7KT/]I#_D9/#/_8I:+_Z0PTI<%Y8JL86E9I]>
MU@CQ5CW3E*ZTMT]3]#/^'U_PU_Z!/B'_`+]K1_P^O^&O_0)\0_\`?M:_+"O:
MOAU\#O#6J?LYQ^,-2M+S4-0FU.^LO+'C+3-!CA2""WD5DBNH7DN7)F;*Q'/R
MJ,9848C@_*:,>:2EO;XO\[+\2L/Q-F5:?)%J^O3MKTNS[E_X?7_#7_H$^(?^
M_:T?\/K_`(:_]`GQ#_W[6OBJ;_@G;XXTS2M/U#5+S1=&T^\L9;ZXNKV.]2*P
M6.U%V5<BV/FL8MQS;^<H9&4L&&*S];_8>\0:)XATO3?^$@\-ZA+J6HS:63I\
M.HWC6TZ6Z7*JT45HTS>9#(C*8HWQDA]A5@.=<-Y"WRJ3;]7_`)?=WTMNC;^W
M,XY>:RMZ+M?OT6_;6^S/N7_A]?\`#7_H$^(?^_:T?\/K_AK_`-`GQ#_W[6OC
M=?V`-;O;"'2;61I/%MOX@U73-0*B::RBMK.VMYO-2..!KEF;SB-JHSG*#RP<
MUXS\5OACJOP:^(>J^&-:C2/4M(E\J79NVL"H96&X!@&5E8!E5@#@@'(%8?A?
M(Z\N2FVW:]N;IW]":V?YM2ASS22O;;KKIZZ'Z7?\/K_AK_T"?$/_`'[6OH']
MES]IO1?VK_AU<>)=!M[RVLK>_DT]DN5PY=$C<GZ8D%?A?7ZL?\$3/^31]5_[
M&>Z_])[6O+XHX9P.!P/M\.GS72U=]ST,@S[%XO%^QK-6LWHC[`HHHK\W/N`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HK&^(VM:QX<^'VN:AX=T5?$NOV.GSW&FZ0UZMBNJ7
M*1LT5N9W!6'S'"IYC`A=V2"!7P+^VA_P6=\5?"&]\*Z!I?@77/@_XJU'5;FR
MU*'XG^';(6\D<=O')&;"^EUS3=$O-[2A3Y.L/.A0C[*V6:*>;7E6^FGJ[:=_
M.VQ7+IS/;7\%?7M?I?=Z+9GZ&ZA80ZK83VMQ&LUO<QM%*C='5A@@_4&OF+1/
M^"5/AG1_"C:;)\1OBI?7FEV>EZ=X3U6XO-.^W>!K73KD7-I#8%;)8Y`KJBN]
MZEU),B!)7D7(/N/[.^N>-/$WP+\)ZA\1=)TW0?'5YID$NN:?82![>TNBH,B)
MMDE4<]56:95.5$LH`D;LJN4.2;:>J>Z[J]FGNFKNS6J3=K7=XC+F@K[=GYVT
M:[:*ZV;2?1'#_L_?`FP_9Z\!2:+::MKGB&\OK^YU;5-9UF2*34-8O;B0R2W$
MQACBB!)(54BCCC1$1$154*,;XK>!M$L_C?\`#/Q!#H^EPZ]=^(IK:?4DM(UO
M)HAHNI8C:4#>R_(ORDX^4>@KU&N#^+__`"4'X5_]C1/_`.F75*&[_P!=%HDO
M)+1+HA_\/ZMZMONV]6^K.\HHHI`%%%%`!1110`5^?/Q(_P""#.@^/OC;#K2^
M*I;#P[J2SW.LVMI;+#+%=,Q95LU(=(X#N/RN79`@&7W97]!JJVVNV-X+8PWE
MK,+R$W%N4E5O/C&W+I@_,HWKR./F'J*[<'C\1A6W0=KZ/2_Y]NAC4IQDTV[-
M;-.S^]='U6S/CGP/_P`$+_A%X1L[-I-6\<7.H11*MS/#J26J7+XPQ"I'N52<
MD+N.`<9/4]O%_P`$E_A(Z!;P^-M2V#$?VKQ/>'RAZ+M=>O\`2OI6SO8=1LX;
MBWECN+>X0212QL&212,AE(X((Y!'6I*WEG6.;NZLOOM^1C+`X>>LHI^NOYGS
M99_\$B/V>K2X69OA_P#:KA>6DN-;U&4RL>K,#/M)/7IUK:T__@F%\`],C98_
MAGH+!CD^:\TQ_`NY(_"O>:*SEFV.EO6G_P"!/_,(Y?A5M2C_`.`K_(\ET[]@
MKX*:7(C1_"OP&QC&T>=HL$P/&.0ZD'ZFMK3_`-D_X6:3"8[7X:?#^UC9MQ6+
MP]:(I/3.!'UX'Y5Z!16$L9B);SE][-8X6BMH+[D<_I_PE\*Z3,)+7PSX?M9`
M-H:+3H48#TR%K:L-.M]+@\JUMX;>/.=D2!%SZX%345A*<I;LUC%+9!1114E!
M1110`4444`%%%%`!1110!2\2:T/#?AZ_U%K6]O5T^VDN3;V<)FN)PBEMD:#E
MW;&%4<DD"OFC5/\`@IE=/IEPMC^S_P#M+1WAB80//X"+Q+)@[2RBX!*@XR`0
M2.XZU]257U33H]8TRXLYC,L-U$T+F&9X9`K`@[70AD;!X92"#R"#S6]&I3C_
M`!(W^=BHR2W1\?>&_P#@KA-XMUBQM;'X%_'&XDL8V/B""S\,&\FLIOFC6*,"
M5?E\Y)09)`I_<,OEY8F/T7X>_P#!05?B!XYTG0V^"?[0FA?VM=):_P!H:MX-
M-O8V9<X#S2"5MD8SRV"`.3Q7L]C\,M!TJ[T6:STNWLI/#L#6FGFVS"+>!E"M
M#A2`T9PIV-E=R(V-RJ1NUO4K89_!3M\V7*4.B/A']H']L+Q]\%]>\0_$Z'Q7
MXDU_2_#/Q&_X01?A5HOA^UU`ZM!]E!4H(+:74FU!]ZW:E)A$+<*#;G#.W&Z7
M^V;\7/BO\'=-LM)UWXS7GBVX^+$V@7Y\,^!M.\,ZPUDVA76H?8[*'Q5:06WD
MPSQ@;IP;CR8UW.SN-WW@/V>/A^OQE/Q&'@7P>/B$UK]A/BC^Q;;^V3;XV^3]
MKV>=Y>WC;OQCC%;"_#W0$U&.\70]'6[BOVU5)Q91^8EXT)@:Y#8R)C"S1F3[
MQ1BN<'%>?AX\L.6IJ^5*_FO9W?\`V]R2;[<[BM%=YU)7ES0TU;MY-5++RY>>
M*\^12>NB^1_%W[0GQ4^"<OQUBUCQDFHMX5\%^'-7T5]5T6QMO^$::]N-1MIK
MB[\AQ'/)$EO'-.PE6!GBD,20QL$'D?[3/[=?Q0_9-\0?$+X9P>-_B5XXD\)B
MRUX^/U^&[ZY<Z?#);QR'1YVTC2QIT<TL@5Q)-#&4M9G^8RF&0?<ND_L=?"/0
M/B'K_BZQ^%?PXLO%GBN">VUO6H/#5E'J.L13X,\=S<+&))EDP-ZNQ#8&<UI^
M`/V</AW\)_AI+X+\*^`O!?AKP=.[O)H6E:);6>F2,Y!<FWC18B6(!)*\XYJK
MMR4]M%INKIO3TV=]Y;-6O>''HK_KLE?YZZ=+W3N=9I.IQZUI5K>0K<)#=Q),
MBSP/;RJK`$!XY`KHV#RK@,#P0""*L444W:^A2O;4****0!7XJ?\`!1W_`)/=
M^(?_`&$5_P#1,=?M77XJ?\%'?^3W?B'_`-A%?_1,=?>>'_\`OU3_``?JCX_C
M/_=8?XOT9PWA?]H?QEX+%J-+UJ2S6ST:X\/Q!;>(C[#/)))+"P*G<&>1VRV6
M!(P1M7&E;_M9>/[.RTN"'7(X?['GL[B&6/3K5;B9[,8M?/E$?F7"Q#A%F9U7
M`P.!7=?#?]K>Q\.VOPYTN^U3QM8:'X-TF[CG@TNXDA1]1DGNGCGV0W-N\B".
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M\<0FFVJS(N50J2%&!N4=6`,>D_LH>.M8T73]272]/M=.U336UBWNK[6;&R@^
MRK+'"9'>:9%C_>2QJ`Y5CO&`1S7I'P"_:*T;X._"KPWJ,DK27^AOX@L'LH"A
MN#+>VUM]FN"C,N8MT3*S#)78.#E0>B\?_MZ>%+C3+B#PUX?NDCMM'N-(TVTU
M?2K.[LQ&=0LYH5EB=G1E\BV8-\I(=@5_OC2IBL="LJ.'I+DVV>EN9:V:T?NM
M66BNNQE2P^%G2]M7J/G;[[W<;O5=/?3N]79[)I^*_P##)_CYM8:Q3189IOM%
MC;(T6I6DD,[WJ-):^5*LICD654;#HS+D8)!(%>=.C1.RLI5E."",$&OJ5/VH
MO"OQ*\?/!:?;_#</B#7_``UJ*)>^3#IWAV*P259X(G5QB!-X,0"*2N05!QN^
M<?B)KUOXJ^(.NZI:QM%:ZEJ%Q=0H1@HCR,RC'L"*[,#B<3.;CB(VT7Y1OU=]
M7):?R]=SFQ5##QAS497_`.'EY+9*+?\`BZ&/7H?QI_Y)M\(O^Q2G_P#3[J]>
M>5Z'\:?^2;?"+_L4I_\`T^ZO75B/CI_XO_;9'/1^"?I_[=$\\HHHKJ.<].?]
MLGXE/8-;?\)/,L+1F/:MG;K@&&"$X(CR#Y=K`,CD;,@Y9B:_B3]K/Q]XJ%R+
MG6+6%;NVDM)19:39V(,<EQ'<O@0Q)AFFC20N,-NR<_,V?.:*Y5@<,FI*G&ZV
MT6GX'1];K\O+SNW:[]?S.B^)/Q1U?XM:]_:FM_V7)?-N,DUGI5K8&=F8LSR"
MWC02.6))=\L?6N=HHKHITXPBH05DNBT1C.I*<N:;N_,*]#_:0_Y&3PS_`-BE
MHO\`Z0PUYY7H?[2'_(R>&?\`L4M%_P#2&&L*G\>'I+]#:'\&7JOU//*U+OQG
MJ5[X.LM`EN=VDZ==37MO!Y:CRYIEC61MV-QRL,8P20-O`&3G+HK=Q3W,(R:V
M.\NOVE?&%X(V>^T\7"Z9)H[W::/9)=W-K)`+=HYIUB$LW[I0H:1F9<9!!YJS
M9_M7^/+.^N+C^V;>8WDKRW$5SI=I<07)>W2V82121,CJ8HT7:RE<J&QNYKSJ
MBL'@\.]X1VMLMM[>E]398JLK6F]'=:O?:_K;2YZ/-^UIX^N=5^V2ZU;S2-<W
M-W)'+I=F]O.]Q`EO/YD)B,<B/%&BE&4I\N<;LFN#UW6IO$6L7-]<):1S74AE
M=;6UBM85)_N11*L:#_950!V%5**NGAZ5-WIQ2TMHDM.WH34KU9JTY-ZWU;W[
M^H5^K'_!$S_DT?5?^QGNO_2>UK\IZ_5C_@B9_P`FCZK_`-C/=?\`I/:U\KQS
M_P`BM_XD?0\)?[_\F?8%%%%?BY^I!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&+\2?`=G\4_A
MWKWAG49;Z#3_`!%IUQIES)97+6US'%-&T;M%*N&C<*Q*LO*G!'2OGO\`8X_X
M).?#+]C&P\:6>EM-XFTWQ[ID&C:OIVI>']`TW3;JTB$P\N2STK3K*VN&=9Y%
M>2XCED9<+N"Y4_3U%)))MKJK/TU_S?R;0Y-M)/H[KUT_R7W(Q_`'P]T#X4>#
M=/\`#GA;0]'\->'M(B$%CI>E64=G9V48)(2*&,*B+DGA0!S6Q5?5[ZWTS2KJ
MXN[B&TM;>)Y)IYG"1PH`2SLQP`H`))/``K\B_A1%\*OA7\#]:\!Z5J7[.OCS
MX+:)J7@U_'OQ!^''AF+1]'U6S-_)!/9>()HKJ[@NW`2">XD,X7R;N3SX8X6+
M2"GS5.1[MQU_Q.S;?1):MO?9:CY%&FYK9=%N[+9+J[V22[WT2;/U\K@_B_\`
M\E!^%?\`V-$__IEU2O+?^"8-OX>MO@/XB7P+'I\?PQ/C/67\$C35`TLZ4UQD
M&QV_+]C-P;DQ&/\`=%"OE?NO+KO?BMXANY_C?\,]-;0]4ALX?$4TJ:J\EM]C
MG;^Q=2_=JJRF?=R>6B5?D/S=,W*-DGW2>NC5TG9KHU>S71IF<97;79M>MFU=
M>3M=>1ZC1114E!1110`4444`%?%_[12^*)OC3I&J?#[08]:\'R:9JD\VG3W+
MPV^J+Y]F;V2)44N;=V-NQ5#B<QS$(RR$S?:%?F3X]_;J^)EY\6+O5X=<U#1T
MM;EEATI3_HT"*Q`C>,C#D="6!)/IQCQ<XXRPW#_)5Q$'/GNDEV2U>ZU5U;7_
M`#7I8'@?$\2QG1P]14_9V;;WO?1;/1V=]+;7[/ZPTO\`:>^+6GZ5;W%Y\![B
M\T^6)9(+K0O%-G>QS1D94I'@';@KCJ",D58;]OJWT7CQ!\*_C%H(7[TTOAPS
M6XZ])(W;/3TJQX:_;;DG\.Z?=:Q\,_B=9/=6T<SSVVAFXLR64'*.&SM))QE0
M<8]:O1?M_P#PS@95U+5-5T.1R%"ZAH]U%R>G(C('KR>E=L>+,EFKS<8W[RE#
M_P!+9P2X.SZG[M.<YV_N0G_Z0E^91TW_`(*4_!N[NOLUUXKDT>\[P:EI=W:L
MO..2T>WKD=>QKMO#7[5_PQ\7[1IWQ`\'7$CXQ%_:\"RG./X&8-W`Z=3CK6?;
M_M5_"7QQ:^1+XR\)W$,G/EW\Z1*>#U$V!TR.?7'>JMW\(?@?\4=Q/A_X9ZQ)
M)G,D%M9O*?7YT&[OGKWKNHYEE-?^%/[IQE^B.&MEF?8?^+&/SA.'_MTOR/4=
M+UFSURU$UE=6UY"W22"59%/?J"15FO"M3_X)K_!F^NOM%OX1;2;H?=GT[4[N
MU9?H$E"]O2JP_8"L]&Y\/_%#XQ>']OW8;?Q(TMOVZI(C9[XYX)_"NSV6%>U1
MKUC_`)2?Y'']8S&/QT(O_#/])0C^9[]17@(_9J^,7A\?\27X^ZE)&O\`RQU?
MPS:7N_ZR95AR2>/8=J#I'[3/AL?Z/K'PA\31KU^V6E[93,.>GEDH#TZ\4?5(
M/X:L7]Z_-)?B/^U*L?XF'J+TY9?^DR;_``/?J*\!/QI^/OAO_D(?!G0]>C7.
MZ71_%<,.!SR$F7+=.F<G(]Z!^VUKV@G;XA^"'Q:L<'#/INGQ:I&GJ2T;CY1@
M\@'@#UH_L^J_AL_247^%[A_;>&7Q\T?\4)K\7&WXGOU%>`I_P4K^%^GD+KL_
MB?PJ^<%=7\/W<.T\<$JC`<G'7'%=3X<_;C^$/BG;]E^(OA6,MT%U?+:$_A+M
MJ98#$Q5W3E]S+IYUE\WRQK0OVYE?[KW/5:*R/#OQ`T'Q?C^R=;TC5-W3[)>1
MSYZ_W2?0_D:UZYI1:=F>C&<9*\7=!15+6O$5CX<6U:^N$M4O+A+6)WR$,KYV
M*6Z+N(VC.,L54<L`:6G?$71=6OK>UM=0AGN+JXNK6.)`2S26SM'/QCA8W4J6
M.%W%1G+*"<DFKI$NK!/E;5S:HHHJ30JZZ;Y=$O/[,6U;4O(?[(+IF6`R[3L\
MPJ"P3=C)`)QG%?/GB&3]J"+P_?->77[/]C9K;R&>X$VL0FWCVG<_F9&S:,G=
MD8QFOHVBNBAB/9_93]4<.,P7M_MRC_A=OO/B'X0_$C]IGQ=\0;ZR;4?A['/8
MWOEPKK<>H6]KJ4O]GVK?NUC4,/W#+<>5((SON)F\O,>(O<?!)_:.'B_3?^$D
M7X)-H/VA/[0&FMJBWGDY^?RO,!3?CH&X)ZXZUZYH_B_2?$-_=VNGZIIU]=:>
MVRZAM[E)9+9LD8=5)*G((P<=#6C6]3,H5E>G3C:UM$<.%R&IAM*M>HW>^KMY
MJZ=_^"CXU^-/AOP+K_\`P4WM[7Q#X`\<>+-+U[X>ZQH?B2:_\#:YKGANY\R7
M3+BWL_/>VET\1M#;7+&*-@AEW!AYTH#^63_\$VK/Q/\`LU_"[2_#OPE^%7@\
M_$+XES^.M:\,Z]\-%UCPYX;@ET/4H[2"]TB*:U1988%LH';S8U%V6?!+!3]E
M_$/]M3X8?"SQAXHT#6_%=O;ZQX+\-W?B[7+:"UN+IM,TVU6-YY9##&X$BI-"
MXASYS)*C*A5@3D:C^W[\/-(^&6F>++JU^)UOINM:P="T^TD^&/B5=8O;L6\E
MR1'IIL/MKQ^3%(_G+"8L1M\^017G4>54DEM:UUV=24O_`$O1><;;MGT$G+FO
MWOZW5-1;7I!W:[-/9(^4M8\%+X:^)'[2GA7P'X,^)4-WJ7@30[5YK'P=K^EZ
M?K4MA<:@-1L]+O+E5@4?99XHK6&"Z**CHD!*Q';XK\9/V8?!\_Q7D\;_``Y^
M#-M8^!]+BNXO!?P]\5_LV:]K6B:QJ<MOIYNKB*QCCMAH$C26=M`MY=Q+&Y:X
ME`=59S^E'AW]N+X5^*;;QI-:^+K>.'X=:?#JGB62[M+BS71H91,0)C-&H653
M;SI)#_K8I(FCD5'&VN6'_!3_`.#K6$#)J?C:75KB]DL%\.1_#[Q#)XF5XX8I
MWD;1UL3J"0+%-"QG:W$.)H_GRZ@U[WM%.]I)+;1]=4G=6U]U--)]]$LX\M_=
M6FNF_P!E)K2SO;6333L^FY[OHD]Q<Z-9R7EJEC=20HTULDOFK;N5&Y`X`#!3
MD9P,XS@5:J.VN%N[:.51(JR*'`="C`$9Y5@"#[$`BI*J7Q/2WD3#2*5[^?\`
MPV@4445)05\[_%O]G'X&^+_B-JVI>)O!*ZEKUW*'O+GS9QYS[0,X64#H`.`.
ME?1%?/\`\5?^2A:I_P!=1_Z"*]#+:E2%1NG)Q=NC:_(Y<93ISBE4BI*_57_,
MY/\`X9-_9O\`^B>+_P!_KC_X]1_PR;^S?_T3Q?\`O]<?_'J\CN/&?C;Q7\.?
MBXV@ZE_Q47AG7IX="3[+"PD2"WM;A;0@K@K*3)&7.743$@@JN/(_%W[9?B+5
M/&_@WQYX?\2+'\*-4\4IITMM]C@DBO\`3(M.D-U<^:4,L>R[GRQ#X"Z81P'D
MSZOU[$<JFZ\[<L9/WWI&:33>NEKZ]K/HKG`\'AU=>RCHY1^%:N-TTM.MM+VO
M]Y]<?\,F_LW_`/1/%_[_`%Q_\>H_X9-_9O\`^B>+_P!_KC_X]7C?[)/QL\1^
M-_@1XF\5>+IA>75GK&J7$$$-NL;6MDK>=;VN$'SO'"RQECDLRD\YKD_"W[6?
MB^[N?">A7&DVEY;^(ETZPU/Q''K,4%]I>HZG:R7B"ULOLC0SVT,6U%D:4LS*
M`T<@620OZ[BK1_?5+RY++F=[U%>">MDW9K>R:U>P?4\,G*].%H\^O*MH.TFM
M+M+1][=#Z0_X9-_9O_Z)XO\`W^N/_CU'_#)O[-__`$3Q?^_UQ_\`'JYG]GWQ
M_>?$_P"#/A_6]02--2NK<QWGE#$;SQLT4K)_L,Z,R]1M(Y/6NRJ_K6)Z5Y_^
M!2)^JX;_`)]1_P#`44_^&3?V;_\`HGB_]_KC_P"/4?\`#)O[-_\`T3Q?^_UQ
M_P#'JN44?6L5_P`_I_\`@<O\Q_5,-_SZC_X"O\BG_P`,F_LW_P#1/%_[_7'_
M`,>K6\1?LQ_`'4M(T&&^\"K-:Z?8M!IR>;/_`*/`;F>0IQ+WFDF;G)^?KC`%
M6M37_P#D$Z'_`->3?^E,]1+$XFZO6G_X$^WJ..%P]G^ZC_X"O\CG_P#ADW]F
M_P#Z)XO_`'^N/_CU'_#)O[-__1/%_P"_UQ_\>JY7@_[=?Q`\7>$O#7A^Q\%Z
MMXATO5M0N+F>0:#:6$^H2PP6SN2/M\;VP@1S&\W29HU*P[I"%,UL?B*4'.5:
M=E_??^?3J.G@</.7*J4+_P"%?Y'MG_#)O[-__1/%_P"_UQ_\>H_X9-_9O_Z)
MXO\`W^N/_CU?+/PY_:1\8V_QCN_&?B36[S6OA7KEFL'AZR\*[-;$LL=A;7$T
MYT^VTMM07+_:-N;V1\.BM:K]\=!\7OCOXTT3Q+XVN;'7K33/#]QX$@U;PU!)
MH,T&H6%U+-Y/FW"S*TAF+.H6%X$6,@"16RVVIXS%1:BZU2[3=N9W5HREKKHV
MHNRW_&T0PN%E%S5.%E;[*ZN,=--;.2O^NE_H;_ADW]F__HGB_P#?ZX_^/4?\
M,F_LW_\`1/%_[_7'_P`>KYD^'GQC^(\OACP-%-XDF:2S\>/X=\3P^(-,LW\0
M/$Z&6&UG>QV6$<RJZ,\ELDD;)Y81@2SU]3U5/%8J</:*O.U[?&_Y8ROOM:2]
M=;:6;3PN&4N5THWM?X5_-*/;>\7^'6Z5/_ADW]F__HGB_P#?ZX_^/5K>+OV8
M_@#K%W9OJG@1;F2&QMX(&\V?Y($B58DXE'W4`'KQU-5:U/%G_'U9_P#7C;_^
MBUJ7B<3S+]]/_P`"?^9:PN'M;V4?_`5_D<__`,,F_LW_`/1/%_[_`%Q_\>H_
MX9-_9O\`^B>+_P!_KC_X]5ROG_\`;I\7_$NQB\-Z#\,M2M]$U348;_4KF^DO
M+:T(BM$B;R@UQ8WJ-N\TL46#>XBP)81N<36Q^(I0YY5JEE_>?W[[+KY#IX'#
MSER1I0O_`(5_D>Z?\,F_LW_]$\7_`+_7'_QZC_ADW]F__HGB_P#?ZX_^/5\C
M_"#]JCXA7/Q7_P"$T\57.K2?#'6DOK"RT;2],_M.^@GMD5Q+_9UI9/>Q,R(S
M'_3+K<90H@C7$M>OZ-\1/&GB7]H'6;&QU+2X_#NI>#(-7\.6%[HEQ:W%G<O(
M4,EZ)&68DL0##LA9%4ALN25OZYB^:,/;5+M-VYGI:,I:W>EU%V[^EVLXX7"N
M,I>RA9-+X5_-&.FFMG)7_P"&OZS_`,,F_LW_`/1/%_[_`%Q_\>H_X9-_9O\`
M^B>+_P!_KC_X]7R+J'QF^+FJ>!OA7KB>)H6L=)TZXUCQY-I=UI^G7>JJE[%#
M&L%E/8WTCQL%N`(T>VZJ#=AAD_8U.GC,3.'.J\[7:^*71VOOM?8IX3#)\KI1
MO9/X5UZ;;V_,I_\`#)O[-_\`T3Q?^_UQ_P#'J]N_9T^'_@OX;>!)M/\``NCC
M0]&DO'GDMPSMNF*(&;YF8\JJ#KVKQVO9_P!G[_D1YO\`K[?_`-!2N/,*U>5*
MU2I*2OLY-K[F=&%P]&$[PA&+[I),[FBBBO#/2"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`*X/XO_\`)0?A7_V-$_\`Z9=4KO*X/XO_`/)0?A7_`-C1/_Z9=4H`
M[RBBB@`HHHH`****`"O-_$?[(GPW\6^/3XFU'PGI]SK#2":20O(L4S]=SPAA
M$Y)Y)922>N:](KS_`,5?M'^'_"/QWT#X?W4C#5M>MI+A)-P$<##_`%<;?[4F
MV3`ZY5>/F%<./IX.<(_7(Q:NK<R3]YZ*U^IT8?&U\,W*A-P;T=FU=/IIT/0!
MQ39$65&5E5E88((R"*=5>\U6UTYE%Q<V\!;D"20+G\Z[6TEJ<YBZU\(O"?B3
M=_:/A?P[?[LY^TZ;#+G/7[RGT'Y5R>L_L8_"O768S^!M!CW'/^CPFV[Y_P"6
M96O0/^$GTW_H(6/_`'_7_&J]YX^T+3G"W&M:3`S#($EY&I(_$UP5\#@:NM:G
M"7JHO\T=E',\71_A591])-?DSRL?L!_#O3P/['A\1>']OW3IVN72;>IXW.W<
MY^M'_#'U]I0_XD_Q8^*=EC[J7.K+>1)Q@`*Z=.O&?Y5Z=_PL[PW_`-##H?\`
MX'Q?_%57N_C+X/L)-D_BKPW"Y&0LFIPJ<>O+5P/)<HC\,(Q_POE_]):.S_6+
M,'\=9R_Q6E_Z5<\Z'P-^+6CG_B7_`!GDN(QTAU'PU;39Y[R*P;I_7UI!I7[0
M&B#]SJWPOUQ5^\+NUN[61AUX,9(SV&>*]!_X7EX)_P"AP\+?^#6#_P"+JM=?
MM&_#VQF\N?QYX-ADQG:^M6RM^1>H>7X*.L*\X_\`<63_``E)H7]O5'_$A3E_
MW#@OQBHLX<_$?XXZ'_Q]?#7POKFT<_V=XB%MNX[><OKZ^A]C2_\`#3?C72?^
M0M\&/&4.TX/]GW5OJ'MQM(SSG\.:[+_AIGX;_P#10/!'_@]M?_BZJW/[6/PQ
MM)C&WC[PFS+W34XG7\U8BI=-0^#'R7JZ37_I"?XB_M;"2_B8:G\G-/\`]+:_
M`Y8_MP:#:+C6/!_Q*T%3PW]H^')5`!SUVENP)^E<_J'[0O[./Q!F:+6(_"-Q
M-QOCU?PX593UY\V''8=^P]J]%_X:Z^%__0^^%O\`P81_XUEZW^UU\'M1W6]]
MXO\`#%XJ\;9")DY]#M(].E$<;BJ6L,;2^<?UC47Y&=2ODU56K4)?*HK?=*#_
M`#/.KGX#?LI?$D?+;?#O<W\%IJXL7[?PQRH?3G'K[UJ:7^P1X`N49O"7C3X@
M>'UY*MH/BZ;Y.HR-Q?N3U[DU+K7Q1_9I\1%FOI/AS<.QR7;38]_7/WO+SU]Z
MXC6C^R3?S_O)M%@FC;*O9O?P[6'0@QX''XCI6W^M.94U9UZ,EYU7'\&IGG2R
M7A:H^9P<'W4(-_>I09J?&G]FSQC\-_AWJ$UC\;/&MU9S(;<P:_9VFIVI#!N;
MB25`J0@<L[#H,*&=D0M_X)S>*]/TZPU+17U6'Q9K%U?WTCZY$)#<3(MS*Z^?
M&Y9HHY`QF1Q\A:9U;;*09?'_`-IL?!^3X3W2^`?'^K2ZA%-'(=*N+^\FM[N(
M<%0LB[=RDA@2?X2.I%9/_!,3P]=:]^T];WEM>1V\&CV%Q<741?:UTC+Y00+W
MP\B.>PV#OBO&K^(F/EF-'*O8PE"HUS2C)2>NEU**BO=W::;?EH>WE_`N0/!U
M<VH8Q^TIIJ,6].]G&4I.\MDXM)>>I^D%%%%?;GAE;6-/.KZ1=6@N+FS-U"\(
MGMV"S0[E(WH2"`PSD$@X('%>*:K^Q1<2Z7<K9_%SXR)=M$P@:?Q*9(E?!VEU
M$8++G&0""1W%>Z45P8S+,-B[>WC>VVK7Y-'=@\RQ.$O["5K^2?YIGPC^S9_P
M3U^(6A?$^ZEU[5-7\&Z3;QR1-?Z'JZ17>H`_=6-D+%4+!6/F*"0`,9Y'TGX1
M_9-/A+Q/8:H/B9\6]2^PSK-]EO\`Q")[6XVG.R1#'\RGH1D<=Q7K=%>-E?"&
M78"FJ=).5G>[;O?Y66GIZGL9IQ=F./J.=5J-U:R2M^-WKZ^A\L_M2?L\_$[X
MU?M'7%W'X'^&/B3X97'@'7?!=W;:IX\U+2-1U9=36T=U=+?2Y1`F^T\DO'<,
MX28R`!D$;<GX&_X)T>-/%W@_PYI/C[7=:TO1=+\=GQ*FC:5\6O$VKWVB60T2
MZL/)M?$$HM=3E:2ZF69HV:.-$:1%+#A_M*BOJ*?NQY>FW_DSG_Z4W:^W0^;E
M)MW]?QBHOTNDKVM>Q\@>.OV3?B]\0OBC\8`=/^'VB^%_%7A72M#\,:D_B_4M
M5U,7.DW5U<6<E];O8Q9CG:Y`FVW<CJ(C\TQD)7S#XU_\$W_CA\</C[J7QBO6
M\*Z+XSU[19/#']@^&_BUXF\.6.@P`0&#4!J6G6<$^I3"2.1FM)[:*(JT:^;F
M/<WZ'45/+>2G+5KK>SUNF[JVK3:NK6WC:6I-[7Y=+V]-+65GT3BGY[.Z;10\
M+:9=Z+X8TVSO]0DU:^M+6*&XOI(EB:\D5`&E*+\JEV!;`X&<"K]%%:2DY2<G
MU^1,(J,5%;(****DH*\5^(_@G5-2\;ZC/!9R20R2`JP(YX'O7M5<+XF_Y#MS
M_O?T%=6%J.,FT8UE=:GS_8?L4^%-+^+<_C^U^&7@^W\>70(F\21:+:)J\H*"
M,[KH+YIS&`ARWW0!TXJ\W[*.COX4BT%O`?AYM#@CN(H]..FVWV2-+@.MPHBQ
ML`E620.`,.)&!SN.=[Q)^TYH?ACP)XV\136&MS:=X`U,Z;JWDP1L\858'EN5
M&\9ABCG$CDD,%BD(4D`-B^-?VU_"O@7X\Z'X`NM/\0SWFNZS!X?CU2W@A?3;
M6^EL9[Y897,HD4^3%$"1&1OO;91G>Q3LCB&U%*UFE;TE9JWK=6]3GY4G*757
MOZQW^ZWX&MIOP8N='M[B&ST&WM8;R5YITABCC6>1_O.P'#,W<GDUX-=?\$F-
M&G^,7A;QLEUXHAU;P9IPTS2!Y.E2M9Q1B=;<)/):-=(L"S@+"DRPN88VECE?
M>[^T_!;]LSPG\>?%T>CZ':ZXLDT^N017%S;)'#+_`&3=VUI.ZG>6*2/=1M$V
MW#IECM^4-K>*?VK/`/P_U75X?$_B?0_"=CH^IVVAMJFMZG:Z?8W6I3P^>MC"
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ME'KMY^G=_F=)_P`*[UK_`*!\O_?2_P"-'_"N]:_Z!\O_`'TO^-:7PE^,VD?&
M73]0N-+6\@;39TAFANXQ%,%D@CN(9=H)(22&:-USAAN*LJNK*O654JU2+M)$
M14)+FCL<#_PKO6O^@?+_`-]+_C6CK7@35I]-TA5L9&:&T9'&1\I\^9L=?0@_
MC76U9OO^/6S_`.N)_P#1CU+Q$M"E!'G'_"N]:_Z!\O\`WTO^-<S\5OV4-'^.
M_AV'1_''@/P[XRTFWN%NXK+7=,MM1MXYE#*LJQS!E#A78!@,@,1GDU[)4.HZ
MC;Z1I\]W=30VMK:QM---*X2.)%&69F/```))/``HEBFE>5K+7[M;_(<8:^[>
MYY-I7[+^FZ%\0M0\76/@G0[/Q7JMLEE>ZU!I]O'J%Y`F-D4DX`D>-=JX5F(&
MT8'`JWXB_9^3Q?#?1ZMX5T[5(]4L7TN]6[M89EN[1\[[>0-G?$VXY1LJ<G(Y
MKS-_^"M/PPE3P`UK:^(KI?B+J<VFZ<DAL;&XC":A)8+,;>ZNHIYQ)+#(R0VL
M<]QL0LT*X(KT[X[_`+5FE_`3QAH>D7GA[Q-K?]JI]JO;O2UM/(T&T^T06_VJ
MY\^>*1H_-N(UVVZ32]3Y>!FCV[=HV6[7SLW+[DVY=$KWV8N51;\DF_P4?Q2Y
M>KTMNC.\&_LJ:3\.O"&E^'_#_@3P_H.@Z+.;G3M-T[3;>UL["4LSF2&)`$C<
ML[MN4`Y=CU)KI?\`A7>M?]`^7_OI?\:/A_\`M(>&OB=\:_&W@/1Y+RYU?X?P
MV,FK3^3BS#W7G[88Y,_/(GD-Y@`PI95R6#JO?57UF;5^^OK>VOS5M>U@]FD[
M=5_P_P"IP/\`PKO6O^@?+_WTO^-:/B7P)JUS<VICL9&"VD*'D<$(`1UKK:LZ
MG_K(?^N*?^@BI^L2N'(K'G'_``KO6O\`H'R_]]+_`(USOQ,_9>TWXU>'X])\
M9>"-#\6Z5#<)=QV>LZ?;W]NDR9V2B.4,H=<G#`9&3@U[!4=W<K9VLDS+(RQ(
M7(C0NQ`&>%4$D^P!)HEB6E=VTU^[4(T[NR/(]._9;TO1_B1?>,K/P/H-KXOU
M2U6RO-<ATZWCU*[MUV[89+@#S'C&Q<*S$#:..!6Q_P`*@O1K7]I?V)%_:/D?
M9OM7EIYWE;MWE[_O;=W.W.,\UP.J_P#!0%],^$^O>*E^#?Q9F;PK>&VUK1R^
M@VVHZ5%]DBNX[B03ZG'$5DBFC(B25KA6<*\*'BMS]J_]NKPK^QQ\.M"\0>+M
M/U..37V"Q:;]NTRRN8<*K2;Y;R[@MBR%T38DS.[NJQK(31]:<5K96:7:W-_G
M=W[-M/J"IIZ+6]_GR_Y65NZLUI8=JW[(^A:_=^';B^^'_AJ]N/"-PUWH4D^E
MVTCZ+,Q!:6U+*3"Y(!+1[2<=:ZK_`(5WK7_0/E_[Z7_&LGPY^T[<Z]^T!#X#
MF^''CS2X;S3IM5L_$-Y)I0TV[MXO)!;RDOFOHLO.B`36L9W!AP%)KU2FJTDM
MK7_X9Z=]+.^N@N6+?]>J^6M_F<#_`,*[UK_H'R_]]+_C7JWP3T>YT3PC+#=0
MM#(;IF"G'3:O^%8]==X$_P"0,_\`UU/\A6&(K2E"S-:,4I:&U1117GG4%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!7S]>_\%&_!HMO'3:;H7C#79O!NM67AZS@T^WM9
M'\67UU.]K%%IQ:X56`N8IX7DN&@C0P2.6$2^;7M_C'P\WB[PCJFDQZCJ6COJ
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MW=MKNSZN-WRM[:M6;T6O1;'J-%%%24%%%%`!1110`5\+_&?_`()R_%3XT?%'
M6O$VH:UX)\[5KDRK&;VZ/DQCY8XP?L_14"K^%?=%%>5FN3X?,81IXF]D[V3M
MJ9U*:FK2/!M`_P""<OPG_L*R_M3P;:C4O(C^UBVUC4&A$VT;]A:4$KNS@D`X
MQD"M.S_X)[_!VP#>7X+MVW=?,O[N3\MTIQ^%>S44XY'ET5I0A_X!'_(/8P[+
M[CQ__A@;X0_]"38_^!-Q_P#'*L6G[#'PELD*IX'TEMQS^\:60_FS&O6**T64
M8!;4(?\`@,?\@]G#LCRS_AB3X4?]"-HG_?#?_%59L_V.?A;8Q%4\!^&V!.?W
MEH)#^;9/X5Z515+*\&MJ,?\`P%?Y#]G'LCSK_AD7X7_]"%X6_P#!?'_A5FT_
M9<^&ME%L3X?^#67.?WFC6\A_-D)KO**I9?A5M3C_`.`K_(?)'L<1_P`,S_#?
M_HG_`((_\$5K_P#$5:M?@'X%LH1'#X*\)0QKT5-'MU4?@$KK:*M8/#K:$?N0
M<L>QRW_"C?!/_0G^%O\`P4P?_$5:M_A3X7M(5CB\-Z!'&O14T^%5'X;:WZ*M
M8:BMH+[D'*C#_P"%9>&_^A>T/_P`B_\`B:N0>$=)MHECCTO3XXU&%5;9`!]!
MBM"BJ5&"VBON'9')_$CX%^$_BUX;.D:]H\-UI[2K,8HI9+4LRYQEHF5B.<X)
MQG!QD"N=^&G[&WPW^#_B^WU[PYX=?3=5M5=(YAJ5W*`'4JP*O*RG()Z@X.#U
M`->G45A/+\+.HJTZ<7);-Q5U;:SM?07)%N]@HHHKK*"BBB@`HHHH`****`"B
MBB@`HHHH`****`"N%\3?\AVY_P![^@KNJ\C\>_$5](\7WUL+"UE$,F-[,^6X
M'H<5T8:+E)I&-9V6IY9X4_9W\9:%\4O'!OO%G@S5OACXZO;F^O?#LOA.X75E
M:>TBMVC_`+0_M`PM'F+<0;,$JQ7(/S5P9_X)PWLGP2\/>'YOB'=77BK0=0O-
M:_X2>;20TUWJ#0F*RN'B$P'^C+':`KO_`'JVV"4WDCWC_A:\G_0-L_\`ON3_
M`.*H_P"%KR?]`VS_`.^Y/_BJZOJKY.2VG*H_]NQV5]]/\NQC[1<W.]^9R_[>
M>[MMKU6S///@1^QA:_`?QSI.J6.N-=6>C6FKV<%F;(1G9?2::ZY<.1F,:>!P
MOS^;GY=N&\1_;1_9X^+4-MXI;X<^%5\47.MZQJ+H\D-A>126&JZ6EO<Q/!=:
MA9#?'/;`>>97\N*>,);W(,D<7UC_`,+7D_Z!MG_WW)_\51_PM>3_`*!MG_WW
M)_\`%5-;!RJT_926G+R?]NW4K?-I>?2Y5*M[.7.M^;FU_F=]?7WG]YY9H'[$
M*OX=\+C6-6L[K5M'GO;R[D.GB6.:2XTI]+14W/\`*(;<QINQF01MPF\@<GXU
M_P""?OC3_A#['0_!GQ,\-Z%I;0Z3::UI^K^#IM2LM>M=/L!:I:RI!J-K(L$C
MJLKQK)MD51#)YD+2I)[_`/\`"UY/^@;9_P#?<G_Q5'_"UY/^@;9_]]R?_%5O
M4IU)SE-K63BWK_+?E^Z[]>MS&ERTU%1^RFE_V]:_Y*W:VEC"^"?@#6M$\?>.
M?$6O)##=:_<V=K!'"BQQS06ELL7VCRUDD">;,T[*K.SK%Y(8[@57TBN4_P"%
MKR?]`VS_`.^Y/_BJ/^%KR?\`0-L_^^Y/_BJ7L9]OR^_Y[Z:=DEH4I16B.KJS
M??\`'K9_]<3_`.C'KB_^%KR?]`VS_P"^Y/\`XJK^K_$Q[;3]+?\`L^U;[1:M
M)@N_R_OI5P.?]G/XU+HS[%*2-RN=^+7PKT/XX_#/7/!_B:UN+WP_XDLY+#4+
M>"\GLY)X)!AT$L#I*F1QE&4X/6JW_"UY/^@;9_\`?<G_`,51_P`+7D_Z!MG_
M`-]R?_%42P\FK-!&I9W3/GWP[_P3)?X=Z`^B^&?&S+HNN3WUOXD'B&TOM?U"
M_P!-N-4GU!+>UO)[_P`ZWF3[0\;32&X60_O&AWY)O_&G_@G#_P`)WXH\/WGA
MOQI?:7:Z;=RW<[^)Y-3\6ZEILTDL;FZT:[N]0!TN["+)&L@2:-4DVB$+O63W
M/_A:\G_0-L_^^Y/_`(JC_A:\G_0-L_\`ON3_`.*HCAYQ<9):Q;:^?Z7UL]+Z
MVN3*49<U_M;^?3[[:7WMH<#^S]^PWX4_9G^.'C+QCX7N_$,4'C*R@@GTN]UW
M4M2M[:X6\OKR>>,75S*B>;)>D^7&B*A$A7_6N*]IKE/^%KR?]`VS_P"^Y/\`
MXJC_`(6O)_T#;/\`[[D_^*IJC-)12T6P.:<G)[O?\CJZLZG_`*R'_KBG_H(K
MB_\`A:\G_0-L_P#ON3_XJK^O_$Q[.>W7^S[5M]K#)R[\;D!QUI>QG?8KF5C<
MJ'4;:2]T^>&*XFLY)HV1)X@IDA)&`ZAPRY'4;E(R.01Q7-?\+7D_Z!MG_P!]
MR?\`Q5'_``M>3_H&V?\`WW)_\51+#S:LU^(E-)W/*/AK^Q9K'AK2-3CUOQ9X
M?GNM;\5V'B;4D\.^%SH>GWS6LXN"\EM]JF!O+F95:XN=^)=B#REVU>^+_P"Q
MK<^(/%LWBKP1XKN-!\6WK7,5S-XG?4O%6EI;7,82>.UL9;^)+%B$0JUJT2#:
M0T<@.!Z3_P`+7D_Z!MG_`-]R?_%4?\+7D_Z!MG_WW)_\54SPKG#DE'1_Y15O
M2T8Z;:;:N[C6Y9<\7K^MV[^MY/7?ST1F?"3X#V_PE\37UY;ZE/>6KZ+I6@6%
MM*G-C:V"3!1OW'<SM,[$A5[#!QFN^KE/^%KR?]`VS_[[D_\`BJ/^%KR?]`VS
M_P"^Y/\`XJM9TZLY.4MWK]YG#DC%1CLK+[M%^!U===X$_P"0,_\`UU/\A7DW
M_"UY/^@;9_\`?<G_`,57I7PBU]O$?A>2X:&.WVW#)M0DCA5YY)]:YL13E&%V
M;T9)RT.IHHHKA.D****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K@_B__`,E!^%?_
M`&-$_P#Z9=4KO*X/XO\`_)0?A7_V-$__`*9=4H`[RBBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`KY_P#BK_R4+5/^NH_]!%?0%>2>/?A-K>O>+[Z\
MMK>-H)Y-R$S*N1@#IFNS!3C&;<G;0PQ$6UH?F?X?^*VER?M_^.-+UCQMX9AU
M6S\03V^G:==?'?5['5HQ_9D+110^%57[%,A=B02XSN:3!90#ZC_P34^&WBK0
M?A7IOB3Q79WT5SX@T#3KB&[G^*_B#QB=1\R$222R6NI1QPV,A)4XMS(/G9=P
M51N^R/\`A2'B+_GUA_[_`*?XT?\`"D/$7_/K#_W_`$_QKT,/4ITX*+DFU&*O
MHMDTWZROKKK;6[U.:K&4Y-VT;;^]W2]%LM-.ECX/\0Z=XS\4P>"_B9IWQ"UK
M3]4;7-;LE\,(]Y/!J=R\UQ;PQ"%;I(-MI!;EY(Y()P1;2O%Y4KO*W6?LS?M0
MZ;\==0^&6M^$Y_$;Z%KVGZGHEW;:OJ4%_+*;$0LEX9;:XGMI'#%D>2*5F+7`
M23#Q%8_K+PY^S%J7A(ZA_9^G1VZZE>27\Z?;-R&:3&]E5F(3<1N*H`I=G<C<
M[$C?LQ:D_B]=>;3HVU2.S-A',UYN$4+.)&5$+;%W,J%F4`MY<8)(10%1J0@N
M5R5NGD[._JG=KI9.]M$@J1E+6VOYJ[Z;+H^MFFKZW6'177?\*0\1?\^L/_?]
M/\:/^%(>(O\`GUA_[_I_C6GMJ?\`,OO%[.78Y&BNN_X4AXB_Y]8?^_Z?XT?\
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MTG4FMYHYO+2!?M`+J)SE%X!^NO\`A2'B+_GUA_[_`*?XT?\`"D/$7_/K#_W_
M`$_QIQK4THWDKIWOIJ]-?72VGNVT21'LYZJVC5OEKI][OKK?JSX[_91^)/Q(
M\7?MB?%ZQ\=^'_%/AVQBT_3+C1;"\O=/GTZTM1=ZG!')`+:YE??<1Q)*[2HC
MAE9"`L<6[Z6KKO\`A2'B+_GUA_[_`*?XT?\`"D/$7_/K#_W_`$_QIQK4XQ4>
M9:*U[ZOU\RI0DYN5M^G;1;>1R-:GBS_CZL_^O&W_`/1:UM?\*0\1?\^L/_?]
M/\:O:_\`![7K^>W:.VC81VL,39F4?,J`'OZBDZU/F7O(/9RML<'537[V33M"
MO;B)=TMO`\B`1O)DA21\J!G;Z*I8]@3Q7<_\*0\1?\^L/_?]/\:/^%(>(O\`
MGUA_[_I_C2J5*<H.*DE==PC&2:;1^5M]\3_B9X'_`&!_&T'P_P#$FI_%RXB1
MKK6_'_A/Q)+<_P!DA;"26YCA_MC5IFCECEAB206[QF-;IF2UBD0*WTM^TI<W
M?QL^'+:/JGAWXJ?#_4'U:PTG0]3MO%C:3]LGO&$3W"'1]2\V5+="\C1W(528
MQA6&6'UY_P`*0\1?\^L/_?\`3_&C_A2'B+_GUA_[_I_C3E4I-ZM6O'331*VB
M[:+3>S=]6'+4T:O?WM>[>MW\]]KK30^,_!_C?XC6G_!1ZU\-:MH?C#3?A]:^
M$]1M-#DFU.RN=/U46\FEDZA+BZ:[:X+S20_OH@57:RD^;,5^GJZ[_A2'B+_G
MUA_[_I_C1_PI#Q%_SZP_]_T_QIQK04(Q<KM7UOJ[R;N_O].R2T4^S=]%_P`"
MR2_0Y&O9_P!G[_D1YO\`K[?_`-!2N&_X4AXB_P"?6'_O^G^->D_"+PQ>>$O"
M\EK?1K',UPT@`8-P54=1]#7-C*D)4[19M1C)2U1U-%%%>4=@4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`-F+K"QC56DP=H9MJD]LG!Q]<&OAGPI^W]\6;^^\7>%YKCP!
M=^+&UGP_HN@75YX-UKPRNES:E=7$-P]UI5_<B]OK6W2#=%>1&V@O7+QH8C%*
MR?<EY;+>VDL+-(JS(4+1N8W`(QPRD%3Z$$$5\XR_\$V--US1]4D\0_%3XL>*
M/%]RNF)IGB_4+G2H]8\.IIUT;NU6U6WL(K1L3,[.UQ;S/,'*2M(F$$Q_B)R^
M'2_=J]Y);:M*U[K>ZDK-2I_PVH_%T[)]&^Z6MUKT5G>\>\_9"^+7BCXI>`]>
MMO&W]@S>+/!OB34/#FI7>B6LMIIVHF"0-%<0P32S20AX)(2T;2R;)-X#NH#&
MK\??C)X1\+?%/X=6>J>*O#>FWFE^(I+F]@NM3AADLXFT?4462168%%+21J&;
M`)D4=6&>H_9^^!-A^SUX"DT6TU;7/$-Y?7]SJVJ:SK,D4FH:Q>W$ADEN)C#'
M%$"20JI%''&B(B(BJH4;7B[P2/%?B#PO?&Y,'_",ZH^I!/+W?:-UE=6NS.1M
MQ]IW9Y^YC'.1I+97WLKM;.5ES-=DW=I:671;&<=W;:[MW4;OE3WU2LGJ]>KW
M,'_AJCX8?]%'\!_^%!:?_'*/^&J/AA_T4?P'_P"%!:?_`!RN\HJ2C@_^&J/A
MA_T4?P'_`.%!:?\`QRC_`(:H^&'_`$4?P'_X4%I_\<KO**`.#_X:H^&'_11_
M`?\`X4%I_P#'*/\`AJCX8?\`11_`?_A06G_QRN\HH`X/_AJCX8?]%'\!_P#A
M06G_`,<H_P"&J/AA_P!%'\!_^%!:?_'*[RB@#@_^&J/AA_T4?P'_`.%!:?\`
MQRC_`(:H^&'_`$4?P'_X4%I_\<KO**`.#_X:H^&'_11_`?\`X4%I_P#'*/\`
MAJCX8?\`11_`?_A06G_QRN\HH`X/_AJCX8?]%'\!_P#A06G_`,<H_P"&J/AA
M_P!%'\!_^%!:?_'*[RB@#@_^&J/AA_T4?P'_`.%!:?\`QRC_`(:H^&'_`$4?
MP'_X4%I_\<KO*P?"/@D>%/$'BB^%R9_^$FU1-2*>7M^S[;*UM=F<G=G[-NSQ
M]_&.,D`P?^&J/AA_T4?P'_X4%I_\<H_X:H^&'_11_`?_`(4%I_\`'*[RB@#@
M_P#AJCX8?]%'\!_^%!:?_'*/^&J/AA_T4?P'_P"%!:?_`!RN\HH`X/\`X:H^
M&'_11_`?_A06G_QRC_AJCX8?]%'\!_\`A06G_P`<KO**`.#_`.&J/AA_T4?P
M'_X4%I_\<H_X:H^&'_11_`?_`(4%I_\`'*[RB@#@_P#AJCX8?]%'\!_^%!:?
M_'*/^&J/AA_T4?P'_P"%!:?_`!RN\HH`X/\`X:H^&'_11_`?_A06G_QRC_AJ
MCX8?]%'\!_\`A06G_P`<KO**`.#_`.&J/AA_T4?P'_X4%I_\<H_X:H^&'_11
M_`?_`(4%I_\`'*[RB@#@U_:F^&+L%7XC>`RQ.`!K]IS_`.1*[RL'XH^"1\2_
MAEXB\-M<FS7Q!I=SIIN!'YGD>=$T>_;D;L;LXR,XZBMZ@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@!';:C'T&:_-[X._\%9_BEK_`,(?'/B36AX/OKC3_A3K?CW1
M[>7X>:]X3BM[ZP5&6TCEO[ITUNW(E4R7%@8TC"IDC[1'C](F7<I'KQ7RMH/_
M``2?\-VOP[OO"FN?$SXJ>+M`_P"$0U3P1HMIJDND0KX7L-1B6&Y-J;33X#)-
MY<<:K)=FX*A3C[[[IA=5>9ZJST\^627XM->FZ5[[T94[KVFW-%OO923?WJZ>
MNST3=FOJ+3+EKW3;>9MH::)7('0$@&IZXSX&_"S6/A%X1DTO6?B%XP^)$[3F
M6+4?$=OI4%U;Q[%40*-.LK2(Q@J6!:-GR[9<C:%[.M)VYM#DHJ2II3WMKZA1
M114F@4444`%%%%`!1110`4444`%%%%`'R1%_P4`U'6_V]-4^'W]L:?X5\)^'
M]<C\++%J/PZUZ^_X2;46TY;XK#X@22+2K%OWR1K;RK/+(87QM,L:KX_8?\%>
M/B/>?\$K+GXDMHO@.+XZ1VK7D6CR6]TNBR0?V6==%P(O/\\Q_P!E*QR)L&="
MNX#@?4NH_L':#J/Q_D\<-XL\;QZ;<Z[%XJN?""7%I_8-SK,5HMG'?MFV-X'6
M*.(^4MRMN7B5S$7RQX]/^"1GPL30%L?MGC!G7X4GX0+<'48]XTHQ-%]J\ORO
M)-_Y;L@G,>`I*[-I()A]()5-_=]+I7D^_O27+:_P237*U:.\)4_;7E\-UZVO
M)6[:1<6]$W*+6J:;^F],N6O=-MYFVAIHE<@=`2`:GJ.TMELK2*%=Q6%`@)ZD
L`8J2JE:[L<E%25.*GO97]>H4445)H%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tpg16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg16.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`'S`R`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**\W_;(
M\17_`(0_9#^*FK:7>7&GZII?@_5[NSNK>0QS6TT=E,Z2(PY5E8`@CD$"J?\`
MPQQX1_Z#'Q4_\.=XE_\`D^L95)<W+!>>KMO?R?86IZI17E?_``QQX1_Z#'Q4
M_P##G>)?_D^C_ACCPC_T&/BI_P"'.\2__)]'-6_E7WO_`.1#4]4HKRO_`(8X
M\(_]!CXJ?^'.\2__`"?1_P`,<>$?^@Q\5/\`PYWB7_Y/HYJW\J^]_P#R(:GJ
ME%>5_P##''A'_H,?%3_PYWB7_P"3Z/\`ACCPC_T&/BI_X<[Q+_\`)]'-6_E7
MWO\`^1#4]4HKRO\`X8X\(_\`08^*G_ASO$O_`,GT?\,<>$?^@Q\5/_#G>)?_
M`)/HYJW\J^]__(AJ>J45Y7_PQQX1_P"@Q\5/_#G>)?\`Y/H_X8X\(_\`08^*
MG_ASO$O_`,GT<U;^5?>__D0U/5**\K_X8X\(_P#08^*G_ASO$O\`\GT?\,<>
M$?\`H,?%3_PYWB7_`.3Z.:M_*OO?_P`B&IZI17E?_#''A'_H,?%3_P`.=XE_
M^3Z/^&./"/\`T&/BI_X<[Q+_`/)]'-6_E7WO_P"1#4]4HKRO_ACCPC_T&/BI
M_P"'.\2__)]'_#''A'_H,?%3_P`.=XE_^3Z.:M_*OO?_`,B&IZI17E?_``QQ
MX1_Z#'Q4_P##G>)?_D^C_ACCPC_T&/BI_P"'.\2__)]'-6_E7WO_`.1#4]4H
MKRO_`(8X\(_]!CXJ?^'.\2__`"?1_P`,<>$?^@Q\5/\`PYWB7_Y/HYJW\J^]
M_P#R(:GJE%>5_P##''A'_H,?%3_PYWB7_P"3Z/\`ACCPC_T&/BI_X<[Q+_\`
M)]'-6_E7WO\`^1#4]4HKRO\`X8X\(_\`08^*G_ASO$O_`,GT?\,<>$?^@Q\5
M/_#G>)?_`)/HYJW\J^]__(AJ>J45Y7_PQQX1_P"@Q\5/_#G>)?\`Y/H_X8X\
M(_\`08^*G_ASO$O_`,GT<U;^5?>__D0U/5**\K_X8X\(_P#08^*G_ASO$O\`
M\GT?\,<>$?\`H,?%3_PYWB7_`.3Z.:M_*OO?_P`B&IZI17E?_#''A'_H,?%3
M_P`.=XE_^3Z/^&./"/\`T&/BI_X<[Q+_`/)]'-6_E7WO_P"1#4]4HKRO_ACC
MPC_T&/BI_P"'.\2__)]'_#''A'_H,?%3_P`.=XE_^3Z.:M_*OO?_`,B&IZI1
M7E?_``QQX1_Z#'Q4_P##G>)?_D^C_ACCPC_T&/BI_P"'.\2__)]'-6_E7WO_
M`.1#4]4HKRO_`(8X\(_]!CXJ?^'.\2__`"?1_P`,<>$?^@Q\5/\`PYWB7_Y/
MHYJW\J^]_P#R(:GJE%>5_P##''A'_H,?%3_PYWB7_P"3Z/\`ACCPC_T&/BI_
MX<[Q+_\`)]'-6_E7WO\`^1#4]4HKRO\`X8X\(_\`08^*G_ASO$O_`,GT?\,<
M>$?^@Q\5/_#G>)?_`)/HYJW\J^]__(AJ>J45Y7_PQQX1_P"@Q\5/_#G>)?\`
MY/H_X8X\(_\`08^*G_ASO$O_`,GT<U;^5?>__D0U/5**\K_X8X\(_P#08^*G
M_ASO$O\`\GT?\,<>$?\`H,?%3_PYWB7_`.3Z.:M_*OO?_P`B&IZI17E?_#''
MA'_H,?%3_P`.=XE_^3Z/^&./"/\`T&/BI_X<[Q+_`/)]'-6_E7WO_P"1#4]4
MHKRO_ACCPC_T&/BI_P"'.\2__)]'_#''A'_H,?%3_P`.=XE_^3Z.:M_*OO?_
M`,B&IZI17E?_``QQX1_Z#'Q4_P##G>)?_D^C_ACCPC_T&/BI_P"'.\2__)]'
M-6_E7WO_`.1#4]4HKRO_`(8X\(_]!CXJ?^'.\2__`"?1_P`,<>$?^@Q\5/\`
MPYWB7_Y/HYJW\J^]_P#R(:GJE%>5_P##''A'_H,?%3_PYWB7_P"3Z/\`ACCP
MC_T&/BI_X<[Q+_\`)]'-6_E7WO\`^1#4]4HKYM_:J_9ST;X6_LO_`!(\3:'X
M@^*5GK?AWPMJ>J:?<-\2/$,P@N(+266)RDEZR/AU4[74J<8((R*^DJ*=23DX
MR5K6ZWWOY+L`4445L,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHKYB_;:_X*J^#?V*OB1I/@=?`OQ@^+OC[5-/.LOX8^&OA9M?U/3M.WF(7M
MRF^-(X3*/+!+EBW\..:F4DK)]?\`A_R3;[)-[(I1;3:Z?\-^;2]6ENSZ=HKX
M7_:+_P""N6I>//"?P2T/]EG1_#?Q`^(G[0S7\GAN?Q5+<:?HWAZTT[']H7.H
MQH!<[H'S$8$VR;P^"2@1X_A'^V!^UQ\,O#GQYT[X_?"WX;6^J?#7P7-XO\.>
M-/!3WS>$M9<6\SK8/'=R"Y>9)(',A0KA"`1'NB>559JG"<YZ**D_7EOS6[VL
MUV;3BFY*P4X.<HPCJY-+TYFDK]KMK3=)IM).Y]V45^6__!,C_@J!^TG^VC\1
MOAQ-KWQ._P""?>H>'?%6GKK&J^$_"7B/5)?'EE;M:F9H19//(B7$3%1*KY"!
M9.>`:^;?!G_!R%^TE+^SM8_&#5/$'["^I:+'JJ07?PUT_7-4M_B1>P#4A9O'
M!8M<R*LSKF5&(<",B0HP^0]"HR=547\5TOO=E^-U\F9QDI4W4CLK+YM-I?<K
MZ^7<_=JBH[68W%M'(4:,R*&*L.5R.AJ2LM@C)27,@HHHH*"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@#RO\`;J_Y,B^,G_8CZW_Z03UZI7E?[=7_`"9%
M\9/^Q'UO_P!()Z]4K&/\:7HOSD+J%%%%;#"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\K_`&ZO
M^3(OC)_V(^M_^D$]>J5Y7^W5_P`F1?&3_L1];_\`2">O5*QC_&EZ+\Y"ZA11
M16PPHHHH`***X#7OVI_AWX8^-;_#G4/&&B6OC:#P]<>++C2I)\2V6E021QR7
MDY^[!$'E4`R%=^'*[A&Y5.26_G^";?W)-OLDWT&DWM_5W9?BTO4[^BO&_"_[
M?OPK\6>`_%?B.'7M5T_3_!4<,VJQ:OX<U/2;Y(Y\BVDAM+JWCN+E+A@4@:".
M1;B0%(B[@K7;?!3XZ>&?VA/!K:YX6O+RXLX;J2QN8+_3;K2[_3[B/&^"YM+J
M.*XMY0&5MDT:-M=&QM92:Y7=KMK\GL_F3S*R?=V^:Z>IUU%%%(84444`%%%%
M`!1110`4444`%?ES_P`%I?\`@@WK_P#P4`_:KT'XO>#-+^#OC#4X_#J>&M4\
M/_$N_P!?T_384BFDFAO+:;1IHIS-^]>-HY"8]IW?>QC]1J*SG34G&3WB[K[F
MOR;7XJSLRXU'%.*V:L_O3_-+\GI='YOM_P`$6O&WP8_9X^`.I_`_7OAG\-?C
ME\`CJ5Q96J66J7O@S5UU0[M0TV4WES<WZ6[MC$_F-(,,52(NHBX?]CK_`((-
M_$'X:>._CU\4O&TGP5\+?$KXO>"M?\)#1_`$FNW&AW=QJ;I<-J=W<ZI/-,DA
MG!0PV\*QH@##<3M'ZL45I6_>.;E]I27HIIJ279-/;:_O)<VI%)^SY>7[+B_5
MQ=XM]VGUWMI?ET/E_P#X)[_\$P/AK^Q=\"?AK#_PK'X2:?\`%KPKX5L]'UCQ
M9H7ARUBO;V\6T2&ZF6]\B.X<2L')9\,X8[ADD5\9_"W_`(-U_$7P/_8G^$M]
MX+F^%'A7]KSX-^([OQ!IWC.TMI6TO7TGOYG-EJ4WV9;BXA-G(D89HF>)DVQD
M*S%OULHK2I6E.JZ^TFT[KHXMR5NRNW=;/9JPJ<5"E[!*\>M^ONN.O?1OSV:U
M13\.RZA/X?L9-6M[.UU5[>-KV&TG:XMX9BH\Q8Y&1&=`V0&9$+``E5)P+E%%
M1)W=Q1C9)!1112*"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#RO]NK_D
MR+XR?]B/K?\`Z03UZI7E?[=7_)D7QD_[$?6__2">O5*QC_&EZ+\Y"ZA1116P
MPHHHH`****`"BBB@#SFS_;$^$>H_&UOAG;_%/X<W'Q'CE>%O"D?B6R;6UD2,
MRLALQ)Y^Y8P7(V9"@MTYH^*O[8?PC^!/CK3?"_CCXI?#GP;XFUF..73](USQ
M+9:=?7R22&-&B@FD5Y`TBL@*@@LI`Y!%?ST?&=8OAG_P<6_M"?&AG\O_`(4C
MXU\-:W<.0Y5;*ZU#3--O"0I&?W%X_4'V]"__`(+P0Q?&G_@JC9?%!98[BW\.
M?&#1/A?ILD3%D\NQLK*\N5SN*[A=7K@\9&,=CE8-^VHX:J]/:M<WDFZ<;K_M
MZI%?>_(G$R]G4Q%-?\NT[/O)*<FG_P!NP;^:[G]+5%?F+_P41_X+B>*OA?\`
MM[7G[.WP=UC]G7P;X@\)Z3'K'BCQ;\:_$<VD>'XGE1'CT^V$+QR27!2:&3<&
M88+J5&TL.T_X)L?\%H?$?[<W[(/Q@UM/`?AKQ!\8_@?<2Z;J>B^&?%%JGA_Q
M/.J.8;JRU&>0PPVDS12G>\D@1(]P:3(!B-12I2K+X8IR]8I\K:[J[LNKW5UJ
M:2BXU(TGO)I?-KF2?:ZU[+9M/0_0:BOPQB_X.7_CA\#?C_\`"/1?B+J7['?Q
M&TOXA7UG!JV@?"C6=3U36O#L-TQB!FU`2SZ6)H92-\4<LK/MXVI(LP^G_P!K
MG_@J[^T9X/\`^"R]K^RS\&_`?PI\31ZWX,_MNSO_`!-<7UC_`&7<M%._VFZG
MA=P]K&8US#'`))-P42(3N&THM<MM>9RBK=XQ<FK[:);WY>[T=HYDG)-_"HM^
MDI<J??5]+7[+5'Z7T5^?W_!(G_@J-\6OVIOVIOCQ\!?CUX3\!:'\3/@K>0LU
M_P""Y+G^Q]3M9#L^5+AY)`00DBN64LDX4Q1M&V[I_P#@M%_P5K_X=E>#/`.B
M^';+PK??$KXMZLVC^'I/%6I?V;X>T9$\L3:AJ,^5VV\330[E#H6#,0PV&HG)
M1C":U52W+;KS;6^>_16;>BN5&+E.<-G"_-Y65W^&NGIOH?;5<)\<?VI/AC^S
M'9Z?<?$KXC>!/A[;ZL[QV,OB;7[324O60`NL1N)$#E0RDA<XW#/6O@+_`()R
M?\%P/%_Q;_;MF_9Z^,&H?L]^,M?UG0Y?$'AOQ=\%/$4NL>'[I8D+2V$ZRR22
MI<JL<SY)7A5`C(97;Y'_`."6/[!_PO\`^"U<'QX_:_\`VM9-9\=6L?B'4-+T
MO1GU2^L;/PYIEG&ESE5M'2<^7'($2)'*@"1BKR.&52YKW5E%1<W)Z)14N3[W
M*Z[:-[6N1M;JY<R@DMVY1<E\N57TN]4M]OW(^$/QO\%_M!^#4\1^`?%_A?QQ
MX>DE>!-4T#58-2LWD3AT$T+,A92>1G([UYGXB_X*@?LT^$/$%]I.K?M$?`O2
M]5TNXDM+RSN_'FE07%I-&Q22*2-IPR.K`J58`@@@C-?FG_P0WTK]ACX4_P#!
M3+QC-^R[^T)XRU:7XC:.8--^&;:'J]OI=I'`K3SR2W5];`W!CVYA+NDD0:92
M\WFX7\V_`'QQ_8=^%'[8/[3MO^UA\&_B1\3?$%W\4=:DT&Z\-7LMO%96HO;@
M21R!-3LP6+\C*OQW'2JF[5(16G-!RUWNI1C96T>[=_)K="CK&;WY9*.FVL7*
M[ZK:WW/9G]-UA^WA\#M5^$E]X_M?C-\*;GP'IEZNFWGB2+Q;I[Z1:73!2MO)
M="7RDE(="$9@QWKQR*YW2?\`@J9^S'K^JVMC8_M&?`>]OKV58+>W@\?Z5)+/
M(Q"JB*LY+,Q(``&23BOR%_X*(:!^SVW_``:RZQXM_9G\!^(/AW\-O'WC2SU8
M:5K=Y-<WQNXM06QEDD,MU=;=WV1<*DI7:`<!BPKXU\2_$'_@GO\`M&_LRW'P
M\^!_[*?[0>K?M)ZSX>%MH=UI\MY?K)JT<`>:X6W35;@R1#9+(5%JWR`_*GWE
M)/EG67*W[-I<OVF^12E;IH[I:]O.Q:ZIZKWDW?[*M)QUZ]+OT?D?U>5R_P`8
M/CCX*_9Z\'-XB\?>,/"_@?P^DR6[:GX@U6#3+-97SL0S3,J;FP<#.3CBO'O^
M"2GPF\=_`G_@FK\%_!_Q,:X_X3?P_P"&+:TU**XD$DUF1DQV[L"06AB,<1()
MYCZGK7YF?\'7/Q>\&_#[]I7]FW7+B^\._$OQ+\-[VYUS4O@YJEE/>VVOZ4^V
M26\F"1/#&JK:R*?/X*Y<*ZQR*3&6H8A4>96Y^7F\KO6RNWHKZ7LM7HF+!MUJ
M'M;:\O-;SMM=Z+5VUW>F[1^S/PI^,/A'X[^"+7Q-X'\4^'/&7AN^9TMM5T+4
MH=1L;AD8HX2:%F1BK*5(!X((/(K:UC6;/P[I%UJ&H75M8V%C"]Q<W-Q*(H;>
M)%+.[NQ`554$DD@``DU^2W_!M?KWA/P=X0\;_%75?&'P=^&]C^U9XJ>_\"?"
MG0=;A@CT3[$9(9K>"W<H6NB)(O,B@3"HL+;4#B*/]+/VQ/\`DT?XI_\`8H:M
M_P"D4U9YE*6&H2K):QC=KM)1NXW6CL]&T7@4L165.^CE9/NKV4K/77S.@^&?
MQK\&_&GX?0^+?!OB[PSXL\*W`D,6LZ-JD%_I\GEL5DVSQ,T9V,K!L-P5(.,4
MWX0_&_P7^T'X-3Q'X!\7^%_''AZ25X$U30-5@U*S>1.'030LR%E)Y&<CO7YY
M_P#!M%_RK]>%/^N?B/\`]+KNOBG_`()U_P#!1'QK_P`$O_\`@UVT_P"*7@'2
M_"^K^((/B1<Z6MOX@MI[BS,4\V')6&:%]PVC!WX]0:Z,3R4:]:E)Z0C!I]W.
M:A;\3*DY5*=.<=Y2J1^4(N5_5V/W<^,WQ_\``?[.7A>'7/B%XV\(^`]%N;I;
M*'4/$6L6^EVLL[*S+"LL[HID*HY"@Y(1CC@UUD<BRQJRLK*PR"#D$5^+O_!4
M[]O/]I;X)_\`!-W1?BI\?/@W^R'XOTCQEXLT3_A%/!VJ:#J'B0:+#=6-_<2-
M?_:)8X3>Q*L4:O;C;\T_4,M>V?M1?\%8OVC/"W_!8+3/V7/@WX!^$WB*/7O`
MR:Y9WOB.>^L%TFY:"9_M%S-"\@>UC,:YAC@$C[@HD0G<"5.47R2^+G<++O&"
MFT_17N]EU:LRI2CRPFG[LH\U^ZYU!-?-K3=]$]#].**_-G_@GE_P6A^('BGX
MC_M0_#[]I[PWX%\,^+/V9+636]4U3P1]JDTJ_P!-CC=Y#'%</)*7`19%)92Z
MSJIBC:-MWRW-_P`'0/Q@@^%L?QT^S_LDR?">35?+;X8IX[D_X6M'8><;<3&+
MS?(W[\2X$!;RSG8%S(,E*+<;/22C)/I:3LM?5/[F]D4XR7,FM8MQMUNE=I=]
M&OO2W=C]RJ\Y^.'[87PD_9CU#3[3XE?%+X<_#VZU:-YK*'Q+XELM)DO$0@,T
M:W$B%U4D`E<@$BNH^%GQ(TOXQ_#+P[XNT.5Y]%\4Z9;:O82.NUG@GB66,D=B
M5<9'8U^&O_!V+XF^&?@[_@HO^RCJGQC\/:QXL^%]EIVIR>(](TJ1H[R_M?/B
MS'$RS0$-G:>)4Z=:FMS4Z].A+1RERN_323U]+:CI<M2C.M'5*/,K==4M/6Y^
MS?P4_;6^#7[2OB*ZT?X<_%OX9>/]6LK<W=Q9>&_%%CJMQ!"&53*\<$KLJ;F4
M;B,98#/(KTVOYA_V6+3X%_M9?\%:_P!FS4?V`?@E\7_AS'X'\10ZEX_U+6KV
M6XLX--\U#*TA:ZO1"K6ZW,66FC$IE6,1LS`U^CWA7_@JE^V+^U+_`,%,?C]\
M`?@QX1_9Y@T_X/ZFFSQ!XQ35XXX;/?Y9BE2UF=I[F4L&0HL4:K!*&R77&\8J
M?LXJZE/G=GV@U>7^%WT_PLQE+E<W)KECR:KO.]H^NG3ND?JU17YO?$7_`(*B
M?M%?M1?MU>/O@3^R9X-^$=U-\%88D\<^,OB1/J":0]_+PME:063>>K!DE^=B
MX8Q2#"!%>7R_Q7_P6=^-W[1G_!,#]I?_`(1W1O!_PG_:6_9Q\^P\=6EU//<V
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M<LZB*ZBC=G@?='(NV0*<QN,94XZ^OQW^"/\`P5,UWX?:O_P4O\3>&?A-\"_"
MOB#]G_4Y);#4=&\+R6-UXNE2[U-%EUJ6.</>2?N=VY3&=TLI_BXYWQY_P7=_
M;4^&G_!._P"&_P"U=J_PE_9]C^$NM7%I::UI2:CJ9\07ZR74L;7EN"X@LX)0
MBI&KM=2(S"1E="53GC*+46W:\:;;>R]HO=U\VMM_+1M=52FXUITEO&4TEU]Q
M)O[E):[=+WM?]JJ*R/A_XSM?B-X#T3Q#8K(MEKUA!J-N)!AQ'-&LBY'KAAFM
M>M*E.4).$M&M&84ZD9P4X;-77HPHHHJ2PHHHH`****`"BBB@`HHHH`\K_;J_
MY,B^,G_8CZW_`.D$]>J5Y7^W5_R9%\9/^Q'UO_T@GKU2L8_QI>B_.0NH4445
ML,***^/_`-H?]OW]H#0_'FH:7\$_V.?'7Q8TG0M0N-+U#6]?\8:7X'M;F:+R
M_GL(KTO<75N2SK]H,44;&/,9E4[A/-KR_P!?\#=%<KMS?U_6C/L"OAG]N?\`
M8MN/'O[0&O6WP^\%VVDW'C_X.^/;#4]6TS28K:#4-9O9-#C@^UW`01M<S)`R
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M]X/_`.Q7US_TKT>N\K,H****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHJCJOBG3-"#?;M1L;/RP"WGW"1[0>A.XBFDWL3*22NR]17B/B_\`;$LO
M"7Q#TCPW'_9OB"^U?5&@MDT>=;N2YM3;3R*`JM^ZF61(4;S"$*R>8&`#B+V#
MPU)J4VAV[ZM':0ZA("TT5LS/%"220@9L%MHP"V!N()VJ#@:U</.FE*?78YL/
MCJ->4H4G=QT?D^WXEZBBBL3K"BBB@`HHID%Q'=(6CD210S(2K;@&4E6'U!!!
M'8@T`/HJKK>LVOAS1;S4+V9;>SL('N)Y6Z1QHI9F/T`)KP.T_P""D/A6S^&M
M]X@\1>$?B/X3NK'4M/T[^P[_`$B.ZU.5;\*UI=!;.:>)+>12[&225/*\J02B
M)EVT)W=O3\79?-N]EN[.VS"6B3?6_P""N_DNKV5U?='T-17CVC_M8ZAXF^/.
MM>#-)^$OQ(U/2?#FK)HVI^+XKG0H]$LYS:P71)274DOV54N(@2EHWS$X#`$U
MSU__`,%%O#-U\-/^$F\-^#?B1XP0ZS?Z2NFV&D16>I,EBC/=7ODWTUL1;(H!
M!)$DN^/RXY"Z@SSQY>9O2W-V]W3WGV7O+5Z6=]DRN5WY>M[=];-V7=^Z]%KI
M;<^@J*\W^'W[57A/XI_%^[\%Z$VL7E]9Z#:>(FOFTV:'3I;:YP81%/(JK+(5
M*LRQ[M@90Y5B%KTBKY6E=^?X-I_<TU\C-23V\OQ2:^]-/YGE?[=7_)D7QD_[
M$?6__2">O5*\K_;J_P"3(OC)_P!B/K?_`*03UZI6$?XTO1?G(?4****V&%%%
M%`!1110`4444`?CC\0O^"/\`\:/B7^T__P`%&-:O/!L<?A[XY^$DM/`-TVKV
M).MZA"D<L*A!-N@Q-"@W7`C&2#G&2/+O&'_!&?\`:B\;_P#!.[]GW3]9\%_V
MQ\8H/CE>?$CXB6[ZYI4<MND\S`W1D6<6\F8XHF*0NS#S``O#`?N_11AOW$81
MA]A0BK]J<_:+[Y)<W=))6#$?ON?F^U*<GZSA[-_=';S>MUH?D7^WO_P2E^)7
M@/\`X*P>(OVDO!/[/?PM_:V\%?$K1(-+USP'XLO-,LKK1;V&".);VWFU&)X%
M7%M%\R[G/G3(8PNV01Z+_P`$7?CAX]_X(^_'CP7JUM\)?AO\8/C/<6^IV?AS
MP7X:T?0-.T:QMIUN(=$N;O3K6$W3$&6(RRO,B[E`=E,CO^O%%9>Q7L'A^EN5
M>2YN:RZ/7^9/3W?A;1I[5^V5;JFF_-J/*K]=NS6MI?$DS^?_`.-?_!,_]L;X
MY?LJ?L_^#]'_`&1_AO\`"?3/@3XDTW5]7TC1/&.CG4O'E\D,44NJ*(V2VA^2
MW(E$]P\SO-&07",1]U7W["OQ6N_^#DS3OV@%\)LOPEA^&YT&37#J=GE+TI(/
M)^S^=]HZL/F$93_:K]%J*ZI5FY^T>_-*7SG#V;^7+LEL]O=21RJC%0Y%M:,?
ME&?.OG?=]5OKJ?G7_P`$^/V$_BK\#_\`@MO^UI\7O%'A7^R_AW\38+)/#6K?
MVE9S?VD8_*W_`+F.5IH\;6_UJ)G'%'_!?C_@EUXY_;JM_@[\1?AEHO@WQIXR
M^!^MS:H?!?BI8CI?C&RE\EY;-_.!A+,UM&FV4HA660F12JY_12BN>,.6E1I1
M_P"7*2B]+Z-M-WT>[3TLUI8Z.;][5JO_`)>M\RZ>\N5I=5IMK=/6Y^8__!-/
M]@CXH7?[>%Y\9O''[.?P*_97\"^'-+;3O#O@3PYH/AG5M;N;YXMDNH/K%E9+
M-%$4EE3RXYHR<!63;N:7Q?QC_P`$U_VU/^"3WQZ^)=Y^R!HOP[^-7P2^,5_<
MZA??#_Q?+`JZ)<3C]XSB>XM1)'LS"ICN&\R-L2PDHDE?M!1537-RVTLG'O>+
M?,T[WO=V?E9<MDD3%VO?6[3]&E9-6M:R;];MN[;/Q_\`^"0O_!&?XV>%/^"A
M-O\`M3?&GPC\%?@5<Z?H\^CZ7\-/AOHUO:VD.^*6W>6;[,[P(6!\T,)KF20R
M[6,0C6,>]?\`!"_]A_XH?L<_$/\`:JOOB1X7_P"$<M?B3\4;WQ%X<?\`M&TO
M/[1L))9V2;$$LACR'7Y9`KC/*]:_0:BM?::II;1<$O)R4WYWYEO?J_*V?LUK
M?K)2^:BX+Y<K_!.^]_AO_@XD_8\^(W[=7_!,7Q'\//A7X=_X2GQA?ZSIEU!I
M_P!OM;'S(H;A7D;S+F2.,849P6!/;-<'_P`%7?\`@C?J7[=/_!/;X>R>%[?_
M`(1W]I#X,Z'I]UX2U2VO$MKK[7;0QF33C<JP50\B9CDWA8YE1PZJ9-WZ045S
MQI\L)QBVG*49W6\915DXOI\[W]-#H]H_:0J/7EC*-NC4G=I_\"UO74\2_P""
M=_C7XQ^./V2/"<WQ]\%GP-\6+&#[!KUHNH65[#?RQ847L3VDLD:K,N'*$@HY
M=<;0K-\0?M)_L._M!?LB_P#!8CQ=^U1\&?A5X>_:-T/XK^&$\.ZUX7O?$UIX
M=U+072*WC+1W%V#"T#K:1=`S'?(A10JR-^IE%;5I<];VZ]UZK3:TE:2L[JS7
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MGTK]I?\`X(1_%WX;_P#!NEX?_9K\"6-A\1OBE#XJ@\1:M%8:C!8V;2//+)*(
M9;QX5,<2-&@+;6<J6"C.T?M!12J1]I!QF[M\EY=6H-2BGTM=:V2*C+EFI15D
MN9I=+S34GWO9OK;78_,O_@X'_P""?'Q>_;>_X):_#'X<_"_PC_PD_C+P[XCT
M>_U#3_[5LK+[/#!IUU#*_FW$T<3;9)$7"N2=V0"`2-B+]@SXL+_P<=:+\>CX
M5_XM/:?#,>'I=<_M.S^2^\MQY/V?S?M!Y(^81[?]JOT<HKHE6DZCJO=SG/YS
MA[-_+EU76_5K0Q=-.E"CTA%17HIJ:OYW27ITOJ?EC\%_^"4/Q*\6?\%)_P!O
M+6/'&@S>&_A?^T1X7/AWP_XABU"SN7N/-@6%Y%MXYC,A3);$J(#MQWKY;^$W
M_!'?]J#X=_`/1?V>8/V4?V7(=>TO6_+;]HG4M/\`#>O+)I7F-.P?3;RSDNYY
MOF,"R219VA5V+CSQ^^5%<]&"IPA36JC&,;=U&3DKVL[WDT[-)IV::-JDG.4Y
MO>4I2OV<HJ+M?2S23U3LTFK,P/A5\/K/X3?#'P[X6T];9;'PWIEOID`M[*"Q
MAV0Q+&-L$")#"N%XCB147HJJ``/@K_@I1^PG\5?C]_P6-_8_^*OA'PK_`&MX
M"^%MQ>/XGU3^TK.W_LP2.I3]S+*LTN0#_JD?%?HI16G,WB(8E_%"7,NS=FM?
M+7I8SY%[">'7PRCR^=M.KZZ=;A7YT_\`!,K]A+XK?L]_\%?_`-L3XI>,/"O]
MD>!/BI>VLWA?4_[3L[C^U%261F/DQ2M+%@,/]:B=:_1:BLZ<>2NL0MU&4?*T
MTD_GII^I53WZ3HO9RC+YQ;:^6NI^6-S^QY^TQ_P2Z_X*1_&KXP?`+X3^&_V@
MOAW^T1/'J>K^'&\6VOAC5_#^I1,\AE,]TODO"TEQ<D!`[MY@W!-@:1W[*'_!
M&CXIS?LE?M=^(/BK?>&[7X[?M?:;?-=:5:7;R:5X6\VWN/LME),@.]HY;@K(
M\>]0(U"-(`6;]3**CV,?8NB_Y'33ZJ#M[J?R2N[NR2O;0U]M+VOMNO,IM=)2
MCLW_`)*ROK:^I^'NF?\`!([]IC]L#_@B/H7[-OCCX6Z-\(_'7P)U6RUKP;JF
MJ>*K#6-,\;MYM\9X9HK7SC:;(K@`>9O61RF=JE]OIW['_P#P3V^-'QD_;.^&
M/B[QA^R3^SC^R7X#^&<$5_KL&CZ!X3\0:KXWU53OCDM)X;2273HXY8T;Y94D
M0/\`+)(V&C_72BNM5I*O+$=7+F?;FY>5R^=DVOAND^70YG1C[%4%HDN5>4;W
MY?D[V?Q)-KFLS\8?!G_!)W]H#2=%_P""H$-QX!\N3]HB]FE^'H_MS33_`,)`
MK7>IR`\7'^CY2XA/^D>5]_'4$#JOVJO^"8/QR^)/_!LQ\/\`]GO1?`_VSXO:
M'!I*7N@?VSI\?DF"\:27_27G%LVU"#\LIST&3Q7ZZ45RSI*5)4GLE27_`()O
MR_??WN_2QT2K-UY8CK)S?E^\45+[N56^=[G'_L]>%K_P-\`O`^B:I;_9=4T?
MP_86-Y#O5_)FBMHT==RDJ<,I&02#C@D5V%%%=->LZM2566\FW]^IST:2I4XT
MH[127W:!11161H%%%%`!1110`4444`%%%%`'E?[=7_)D7QD_[$?6_P#T@GKU
M2O*_VZO^3(OC)_V(^M_^D$]>J5C'^-+T7YR%U"BBBMAA7Y,^-?V7M'_91_;*
M^+'QF\??%+P%\$?COJ'C"?5_`'C7Q5\38[/3/B;X=98V.@7^ES2@0V5M'Y%H
MTD<9ECECAN$W>4BR?K-7Y$_\%J$LU_X*9:$T=G^PQ%J#?#.W$]S^TI?I)I]S
M$-4N_+33[<#?#-&3*7D9MLRS``$P,1ES.&(A*&[YHW[*W.[>O(HN]TXN2::9
MM&*E1FI;+E=N_O*%GY>_?3JDU9I-?6W_``0C\-WWA;_@FAX1@U&Z\+WEU<ZW
MXBOFF\.^(;37],=9]<OYE\F]M7:&9=L@Y!#`Y5E1PRC[`KY]_P""6_\`R8[X
M-_Y-]^]>_P#)$O\`D1_^/R?_`(\??_GK_P!-O-KE?&'[2OQ(^%7_``41ATOQ
MYJ_@GPW\%A\/_$7B&VMK)I+J[D_L^ZTA?[0OKF6*/RF$=W,JVL"LJ@%FEF+H
ML/76C&-?V*T7O>EH1<M_2.G^5VN>ES34JF[<F_G*73YO^G9/ZLHKX-TC]M3X
MP>(O#_QJ75)8_".J7'CKPGX8\)6ITV.6Y\'V&MC3HQ+,&5EDO8X[MYRLP>))
M\1D/&IW>_?L7_$?Q-JWB3XL^`?%?B"\\8:A\*O%,6C6WB"]MK6WO=7M+G2['
M48VN4M8H;?SD-X\1,,,:E8D.W<6)RIQ<TVNBU^7)=>JYXWZ:Z-V93Z-:W[=M
M;2]&T[?D=QXA_P"3GO!__8KZY_Z5Z/7>5Y=)XZT3Q3^UIH-AIFL:7J-]HWAK
M6XM0MK6[CFFL7-WI("RJI)C)VM@,`?E/H:]1I`%%%%`!1110!1\2VE_?:'<1
MZ7>1V.H$!H)I(?.C5@00'7(RIQM(!!P3@J<$?+,?_!2K1=*^+_B+PSXFU2/P
M\VAZJ$>."QEU*258H(EEM8&AC96S<+<$RR;2L>T!0S$Q?4WB70_^$ET.XL3=
MWMBMT`CS6DGE3!<C<%?!*[AE=RX8`DJ5;##E=#_9]\/>%O$4FJ:3'<:7>/=Q
M7*-:E(UBC2W@MC;!=N#`\=O'N1L_,-P*LJ%>["5,/%25>-^UM+/3K9_E^9X^
M9X?&U)P>$FHV?O7NTUKT37YJ^E]M/.?^'CW@.]_Y!>D?$#6]R[D^P^&;E_,]
M<;@O3\J#^WFU\"--^#GQPO\`*AHY#X8\B"0<9^=Y!_+G'XU[]12]MAEM3?SE
M_DD5]5Q[^+$+Y02_.4CP$_M=>/\`4MW]F_`3QY-\H=/MMY:V61QG.YC@\].3
M].PWQ]^.VH[OLOP#M[->&22]\:V9W#T*(A(/U/%>_44?6J2VHQ^;E_\`)(/[
M/Q+^+%3^2IK\X/\`,\!?QQ^TCJ6_[/X%^&FF?-E?MFMSSY7GC]VHY''/`]O1
M38?M/:BS"34/@?IJA\J;:#4IV*^AWD#CCH.?:O?:*/KB6U./W-_FV']DM_%7
MJ/\`[>2_])2/`A\*_P!H;4F_?_%?P?IN'_Y=/"XFRI_ZZ/V[?SI$_9H^,5]M
M_M']H75)=K?\N?A*PM,J<9'!//N<X]/7WZBCZ_4Z*/\`X!'_`"#^Q:#^*51_
M]Q*GY*21X"G[%?B2_"_VE\=/BQ-C(;[%>PV>5/\`NQGGWH'_``3YT>["C4OB
M1\9M:&THWVWQ9(V]3GY3M5>.>@Q7OU%']H8CI*WHDOR0?V%@?M0OZN3_`#;/
M`5_X)H?"J["_VG9>)-;^4HWV[Q#>MYB\\';(O`ST&*OZ5_P3>^".C!?)\`::
M^P$#S[FYG_/?(<_C7M]%)YCBGI[27WL(Y%EJ=UAX7_PJ_P!]CP6S_P"">/@'
M3?%%CJUEI>GZ9=6.I&ZC:PM/LS16X@GBCAC=6WJZO*DIF)+EXAC:H14]L\-6
M%YI6AV]OJ%]_:EU""CW1A$+3@$[2RJ=N[;C<5P"V2%4$*+U%95L55JV]I*]N
MYU87+\-AFWAX*-][=?Z_K=A1116!V!7&_'3X/-\<?`_]ACQ7XR\&_P"D)<&_
M\,:B-/OB%S^[\THV$.<D``G:.<9![*L;QW\1O#_PMT!M6\3:]HWAS2UD6(WF
MJ7L=G;AV^ZN^1@N3V&<FJA5=.2J1=F@]BZO[M*]]++J?/UQ_P35D:"01?M`?
MM*)*5.QG\;;E4]B0(1D>V1]17"?LZ_\`!)?7/AOX)N;'7?CA\6--N)+^>>.W
M\(>(9--L?+9OE=T=&+3.`&<C`!.WYMN]O<_&?_!0'X+^#/!^K:P?B?X"U0:3
M9S7ALM.\16-Q>7?EH7\J&,2@O*V-JKGYF('>N%_9S_X*Y_!C]HA=8W:XO@-M
M',/R^,+RQTLWOF>9S!_I#B3;Y?S=-N]/[U=G^LM:*]E[5>]Y+I\C2/!]:<'B
M5AY<L-&[2ZVZ&]X)_8`M?"FHW<FH?%CXW>+M/U"PNM-NM*\1>)Q?Z?<Q7$+Q
M/OB,(R0')4@C!`ZC(-/PE^Q+XB?X5^,-*\8>/M/\0^)/%@TRT.JV'ATZ;:VM
MEIY0V\?V4W,Q:4XE:23S0K-+\L<:JJ5Z9X9_:G^&WCZ_DL?#7C[P;XGU98)+
MA-/T?6K:^O)E12S;(HG9VP!V%?-?P]_;:^.-O^R]K'B#Q;X-T"R^(NEZGI4M
M_H.J:;_8"Z#I%ZR*)F6#4M4^U2Y$RHK26DC,H\V&W`RW++%2Q$Y3D[Z13>EM
MWRK32^K=^BO=V,JF#^K1C"<7'5M)WOJM7KK;1+S=K*Y[;X`_84^'/@_]HGQ5
M\5[SP?X)UCXB>(-9.IV7B6;PY:_VUI$1T^WLOLT=Z0TVW;#(?E91B=EVXR6Y
M[XC_`+%GB+5;"_N?!_CK2_#?B2^UW5M0_M#4/#1U2&*RU*)8[BU6$74)\P>7
M$Z3;]H>)=T3J2IY?PC^U;\0O&_[>/BCP%#K6F:?X7\-Z^NF)8+\&_$FH&\@&
MF6UXY?Q+'=KI-M*S3.H22+(VHNUFD7,%Q^UE\9/%_@R>RTO3/ASX1\=6^O:_
M%+'?PWNN:9%8:7&KB$O'):L;F8RP*9>$CS*5CF"#=R3=/V*E/X?97\O9WI]M
M]>5M*\M&GJVGK:?M+1^+G5N_/:=O33F2>D5=-/JO<?`7[/-G\.?B%H^KZ?J$
MQT_0_"-OX2MK*6/=)Y4,@=)6ER,G:`I&P<\Y[5Z)7SI\&_V@OB/\1/V@O#\=
MQ=?#^?P3XM\-IXB3P_I^GW;:]X8M)88C:W5[?M.8)!<3"YC2`6L)/EN4EE%O
M-7T77;6C4B^6IO>7R;E*4K^?,VWJ[;:6LN:CR-<U/9J/W*,5'_R5)>>^M[OR
MO]NK_DR+XR?]B/K?_I!/7JE>5_MU?\F1?&3_`+$?6_\`T@GKU2N./\:7HOSD
M:=0HHHK89#J5^FE:=<74BS/';QM*RPPO-(P4$D*B`LS<<*H))X`)KYMN/^"F
M^D^'_#>L7/B3X5_%GP?K5G::9>Z3X?UFWTF+4_$\>H7J6-J+0)?O#'(;F2*-
MH;N6WEC,J;T4'CZ-UZ2^BT*];2X;2XU)8'-I%=2M#!)-M.Q9'5694+8!8*Q`
MR0#TKXT\&_LI_&CQG\*O&L7Q;^&O[//C[QKXJ-A<ZC-K7BJ^US2?$7V>?>-.
M%O)HT(TNRA1YOLVQ;PQR2-)*EQ+)--+*UDT]K+];V=GJM]GIHHMR3C6G+?K?
M3SVT>JLFKJ]UK9W24K^H_%O_`(*%6?P+\&:#J7BCX6_%*PU;5;#4=;U'P_#'
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MWC.D:;(40%,*I>1VP,#<['J2:[7_`(97^&'_`$3CP'_X3]I_\;J"CO**X/\`
MX97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG_P`;H`[RBN#_`.&5_AA_
MT3CP'_X3]I_\;H_X97^&'_1./`?_`(3]I_\`&Z`.\HK@_P#AE?X8?]$X\!_^
M$_:?_&Z/^&5_AA_T3CP'_P"$_:?_`!N@#O**X/\`X97^&'_1./`?_A/VG_QN
MC_AE?X8?]$X\!_\`A/VG_P`;H`[RBN#_`.&5_AA_T3CP'_X3]I_\;H_X97^&
M'_1./`?_`(3]I_\`&Z`.\HK@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'
M_P"$_:?_`!N@#O**X/\`X97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG
M_P`;H`[RBN#_`.&5_AA_T3CP'_X3]I_\;H_X97^&'_1./`?_`(3]I_\`&Z`.
M\HK@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'_P"$_:?_`!N@#O**X/\`
MX97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG_P`;H`[RBN#_`.&5_AA_
MT3CP'_X3]I_\;H_X97^&'_1./`?_`(3]I_\`&Z`.\HK@_P#AE?X8?]$X\!_^
M$_:?_&Z/^&5_AA_T3CP'_P"$_:?_`!N@#O**X/\`X97^&'_1./`?_A/VG_QN
MC_AE?X8?]$X\!_\`A/VG_P`;H`[RBN#_`.&5_AA_T3CP'_X3]I_\;H_X97^&
M'_1./`?_`(3]I_\`&Z`.\HK@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'
M_P"$_:?_`!N@#O**X/\`X97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG
M_P`;H`[RBN#_`.&5_AA_T3CP'_X3]I_\;H_X97^&'_1./`?_`(3]I_\`&Z`.
M\HK@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'_P"$_:?_`!N@#O**X/\`
MX97^&'_1./`?_A/VG_QNC_AE?X8?]$X\!_\`A/VG_P`;H`[RBN#_`.&5_AA_
MT3CP'_X3]I_\;H_X97^&'_1./`?_`(3]I_\`&Z`.WL[Z'4(FDMYHIXU=XBT;
MA@'1BCKD=U92I'8@@\BI:^??"/[0W@K]E?X,6JZ\VJ6\>J>,?$>FZ1I6@>';
M_6[^Z:/5M0D*06.GP33LD<4;,Q2/8BK\Q48K?M?V]OACJWB/P?I6E:EXE\17
M7CK3K75M+;0O"&L:O;QVES*T4,]W-:VLD5BAD5U)NVB"^7)NV[&P1]Y\L=[V
M^=KV];)NW97!Z*[[7^5[7]+M+U=CV.BO,_AS^V%\._BQ\9=<\`Z#KTUYXH\/
M_:/M$+Z7>6]K<?9I4@NA:W4D2V]X;>:1(IQ;22&"1U238QVUZ91O%26SU3[K
MNNX/23B]UH_)]F%%%%`'E?[=7_)D7QD_[$?6_P#T@GKU2O*_VZO^3(OC)_V(
M^M_^D$]>J5C'^-+T7YR%U"BBBMAA7XR_M*?L^_&;_@HM^UC\8+_5;[X+Z/X=
M\"^(]1\+ZG=^*_@;H_BS5_A?HVG6XOM/N[.6]_>:BNJQR&1H@LJP_:"4"$\?
MLU7YK_L_^'OVW/!?B7XT>-/!^M6?C+2_^%M^(8[?X<_%6*\L/M.APW!>VET'
M5`I>W6:/9%$D\<MF/OJ8P'#XRC>KZ0DT[-I/F@DVD[O=JRULV]$FS92M2TZR
MBFM$VN6;:3>B7NIW=M4EK>S^C/\`@CAK=QXC_P"";_PUOKCPIX<\'K<6]VUK
M;:#X;7PWI^HVHO9Q;ZE'IRA1:_;81'=F,``-<D@`$"O4?BK^R9X+^-_Q4T[Q
M1XLTV/Q`ECX;U/PK+HNHV\%WI&HV5_/933BX@EC;S"&L(0H)"X9\JQ(*VOV6
M_B+X\^*_P.T77OB9\.?^%3>-+XS_`-H>%O[?M]>_LW;,Z1_Z9;JL4OF1JDGR
MCY?,VGE37H-=F)?-6E-[W?9[IIZK1W3:T26NB1RX>\*:BOU6SOUN]UHVVWNV
MWJ_F70O^"0_P+\#6/Q*A\(>#],\`R?$J2PGFG\+:;8Z1+H4UCY,EI)8&&!?+
M,=S;Q70602(TX+,K*2I]:_9X_9XT_P#9X\/:Q!#K.N^*-;\3:H^M:]K^M&W_
M`+0UN\:**$2RBVA@MTVP001*D,,:!(5^7.YCZ!1646XJR[6^6CM\VE?O97V5
MM'KH^]_G:U_NT\M;;LX/Q#_R<]X/_P"Q7US_`-*]'KO*X/Q#_P`G/>#_`/L5
M]<_]*]'KO*0!1110`4444`<U\8O'EW\+_A;KWB&PT'4?$UYH]F]S#I=AC[1>
MLHX1<_F<`G`.%8X4_FU^QG_P5S^)WB#X]:]'XE\->(?B!HNN%[P:3X;TTW-[
MH00`#[/&/O0@!5978'/S[MQ8/^I5<IX$^!GA#X8^*_$&N>'_``_INDZMXJN!
M=:K<V\>U[N0`#)[+G&2%P"Q9B"S$GV,OQV%HT*E.O1YY2V=]O\N]UZ/0\W&8
M3$5:M.=&IRJ.Z[_Y]M?4\;T[_@JS\'8[R.U\0:GXA\$WTAPMMXAT"[LVSWRP
M1D&/=A7J'@7]JSX9?$T(-`^('@_59)`"(8-7@:89]8]V\?B!7<:EIEMK-E);
M7EO!=6\PP\4T8D1QZ$'@UY=XZ_83^#?Q(+MJWPT\'2RR9+S0:;':S/GUDB"L
M?Q-8\V`EO&<?1J7X-1_,TY<7'9QE\FOQN_R/6`<BBOFEO^"5WP]\/G=X+\0?
M$OX<L.4_X1SQ5<PJA^DIDX/<>E`_9/\`C?X'&?"G[1.JWD"<K9^)_#MKJ7FX
MZ!K@%9!Z$@<]:/JN%E\%:W^*+7_I/,'UC$1^.E_X"T_SY3Z6HKYI/B#]K#P$
M<77A[X/^/K9.$.G7]UI5W(/5_.!B![?+[>]!_;J\>^#!_P`5K^SI\3M-5>9'
M\/26WB)$'KF%DR`>N!P.:/[+JO\`ARC+TE&_W-I_@'U^FOC4H^L7^:37XGTM
M17SCI'_!5KX+RWRV>N:YK'@W4&X^R^(-#N[.0'N"WEE!CC.6[UZKX&_:<^'/
MQ,V#P_X\\(:Q(_2*TU>"24?5`VX'V(K&ME^*I*]2G)+S3M]YK3QE"H[0FG\T
M=S1117&=(4444`%%17%]#9R0K--%$UP_E1*[A3*^"VU<]3M5C@=@3VJ6@`HH
MHH`*P_'_`,,_#?Q8T-=+\4^']#\2Z:LJSK::K817D`D4$!PDBLNX!F`.,C)]
M:W*YOXJ_$@?"OPM_:AT'Q)XB_?+"+/0[`WET=V?FV9'RC'))XR/6LZTX0@Y5
M-EN5&I*F^>+LUU1P'C;_`()^?!?QKX,U?1O^%8^`])_M:RFLOMVF^';&WO;/
MS$9/-@D\D[)4W;E;!VL`<<5PO[.?_!(OX,_L[?VQNT/_`(3PZQY'/C"SL=4^
MP^5YG^H_T=/+W^9\_7=L3^[73ZI^W9:Z'IMQ>7OPL^,UG9VL;33SS^&A''"B
MC+,S&4!5`&23P*YGX1?\%)[7XD:7=%?A[\0-5OK.9O-70-+&H10Q,S>3O/F`
MJQ4<@C!*MCC@>'+-LJ56,927-K;1_P"1W1XBQL*4J$:\N66ZN^GXGKGAS]DS
MX5^#M3^VZ/\`#/X?Z5>>5)!]HL_#MI!+Y<B-'(FY8P=K(S*PS@JQ!X)JGX-_
M9!\`^!?AMJ?A.STW5[O1=8FCFNUU3Q!J.J74GELK11BYNIY)UAC*+LA601QC
M(55!(,?PT_:;_P"%E>+H-'_X5_\`$[P\UPCL+W6M`-K9QE5+8:3><$XP,]3@
M=Q7Q_P#'[XN>%_A3^SKJFC_&+XY^,[/6[[XC:SHOAO4)O'O_``@W]I7GEDQ_
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MK#Z/<RF"*W#_`-EM=&Q5EA@AC0K`"B1(J[0`*]8KXM_9V^*DVH_MWZ#9W7C7
M5M4\5:OX.SXS\+S^)[J2ZT+4?L]I(KR:`ZI;Z=8((W"7T0:2YGOO+)**"WVE
M714@X)1;OI96U5DVM/+33IVNK-YTZBG>25MM]]4GKYZ_YV=TO*_VZO\`DR+X
MR?\`8CZW_P"D$]>J5Y7^W5_R9%\9/^Q'UO\`]()Z]4KEC_&EZ+\Y%]0HHHK8
M84444`%%%%`'!_"#_DH/Q4_[&B#_`-,NEUWE<'\(/^2@_%3_`+&B#_TRZ77>
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!117D_P#PWG\#?^%N?\*__P"%S_"?_A//[0_LG_A&_P#A+M/_
M`+7^V;MGV;[+YOG>=N^7R]N[/&,T`>L4444`%%%%`!1110`4444`%%%%`!11
M10!\I?$OX@?%?P;^S_%8_"?P-XB\5:AKWCCQ+::KJ>BS:/\`;?#-E_;&H,US
M;P:G>6MO/<,VV.,.[1QLYE>.98_(FX#4_P!EC5-&\8>$-0^'OP7^+G@/Q(^A
M:3867B,?$>%+311:W5Q(T/B'3X-6\J^(\Z:0-&FHB9[R4OL;);ZL_9H_Y)UJ
M7_8U^)/_`$^7U>@41]UW7=/[E:W>VM^]^H5/>CR]+6]=;W?=Z)=K=-SX_P#V
M7O@%\1/"?[2.BV>O>#YM&\+_``UN?&5S;^)GU.SFA\5?VWJJ7EJL$4<K7"^7
M"7^T?:8H0)HXQ'YRG>/L"BBA:12[=>_F^GW)+R#JVNKV[>2Z_>V_,****`/*
M_P!NK_DR+XR?]B/K?_I!/7JE>5_MU?\`)D7QD_[$?6__`$@GKU2L8_QI>B_.
M0NH4445L,*_//XG?\%9_VF]$_;/\>_!OP5^Q6GC?4?!L2:I:WDGQ@TO1VUO1
MYII8K;488;FV&8W:)E=4>0POA'()7=^AE?G3_P`%!_VDK?\`8X_:./A?P/JO
M[<WB#Q5XFT]O%FK:%\*_#]CX^L=.2:XEBBGG76X;I[**22*5$MK&2&$"!L1Q
MDAFSE*U2-V[.ZMIJ[7]=$F].EU;6\=(QO3E9:JSOKHKI/[[I>MG?3EE]1?\`
M!-[P%>_#;]D+P[INI?"'_A16HM=ZE>W7@O\`X2I?$_\`94MQ?W$[O]O4E9?.
M:0SX!PGG;`!MP.N\9?M=?#/X>_%F[\"ZWXVT'3?%FG>&KKQC?:?/<;7T[1[9
MXTFOKAON00AI%`,I7?MD*[A&Y7#_`&!_C;XK_:)_93\,^+_&VA^(?#OB;5#=
M"[T_7/!LOA"^@\NYEB3S-,EO;UX-R(K#-S)O5@XV!@B^)?M2?"CP_P#!7]L2
M/X@6?P9O/%?AF3X9>,;[Q38^&/""ZA-XIU&6[T`QV\L<<>VYO+B.V=464EG6
M%N=J$C:O:%;DE:,;3VN[<L)25NMKI+N]EJ[K/#KG3>K;?6RO>5GKWUW^;O:S
M]D\*?\%#?A-XN\'^*-:37=:TBW\&VL%]JEIKWA;5M#U-()RRVTL5C>6T5U<)
M/(K10M!$XFE4QQ[Y/EKO?@I\=/#/[0G@UM<\+7EY<6<-U)8W,%_IMUI=_I]Q
M'C?!<VEU'%<6\H#*VR:-&VNC8VLI/PK)JNM_M+?#'Q/\3]2\/_$O4OB9I^J>
M%=<U#PO_`,*\U_0[/2-"TO7(=1;2]..J65L=3ND5;B622)?-N)DC5(HE\F,?
M27[">E:AKGC7XW?$&31]<T'P_P#$SQG#JF@VFLZ7<Z3?RVMOHVFZ>]S+9W*1
MSVYDGM)L)-&CE%1B,,IJJ<+\W/HTGIOLX):[.ZE+;K"5G)*XI-:.+TO]^FJM
MNFGK=Z<KBFE)V7I7B'_DY[P?_P!BOKG_`*5Z/7>5Y=)::W;_`+6F@OJ>H:7>
M6,OAK6SI\-KI\EO-;)]KTG(ED::02D_+@JD8&#P<C'J-9C"BBB@`HHHH`*^<
M?#?_``4O\`2^./%.FZ]J"Z/8:5>B#2[Q+>>Z74HP-KO^Z1\?.I()QE77N#7N
M'Q.\+7_C?X?:OH^F:K_8=[J=LULE\(#,;8/PS!0R'=M)`.X8)![8KYR^!7_!
M-:_^!7Q5T?Q18_$+[1)ILV9;?^Q/+%U$PVR1EOM!QN4D9P<'!P<5X&;5<T5>
ME'`03C?WF[-6VV<HMVWT:Z:[F-1U+KD.]_X>'_"F?YK36]2OX^ADM]&O&4'T
MYC'/0_B*#_P4"^'\_P#QZ1^*M0Q]_P"SZ%<-Y?IG*CKS^5>W45U^PS![UH_*
MF_\`Y8RN6?=?=_P3Q$?MZ>%K@[;7PY\0KZ3J4M_#TK,H]3G''^-'_#<FFS?+
M;?#WXM7DW:*'PTQ=OIEP.*]NHH^K8[K77RA_]LPY9]_P/$3^VI)+\L/PB^-3
M2MPHD\->6I/NWF<#WH/[7VN'[OP<^*&[MG3XP,_7?7MU%'U/&=:[_P#`8_\`
M!#EEW/!]6_:/\4:]8O:WWP+\77MM)PT4YMY(V^JMD5Y7X[^"N@_$HNVI_LAZ
M<S2<F:VO;*QF?W9H0C9^IK[,HK:C1QU)WIXN<?107_MIG4PT:BM4U]4G^A^?
M:_L7>*/#_P"\\!_#/XK?#N/K"NB?%N*W48Z;HYEDX[;2>G%:WAGX=?MC>%;A
M3IGB*^;3UX%IX@N-*U.7';=,JHQ[]".M?=U%=4JF825JF+G+_%&D_P`73;_$
MYXY91B[PO'T=ORL?,&B_$+]JK1K%?[2\"^`]:=.,6MPMK+(/?==E,_E]*Y3X
MB_MQ_'WX?2!;OX%:FL:%A++:6<^J1Q@=6+6SL`HY.>>*^RJ*YX8-N5ZM6<O1
MQC^4$OP-I8>=K0FU^/\`7WGY=?&G]O+QC\8_%?AO4IH[/19?"-W]KMH+:">#
M%R&&3*DV&RNW;@@8!<?Q&OT@^#OQ.L?C-\,-%\4:=_QZZQ;"79G/E."5DC)]
M4=64^ZU^<'_!1ZU^&_Q<_:GCO8?#3-<>'KH6NNW-O<_9QK[1L`T;@*<%=K)Y
M@^8CV"X_0[]G+Q9H/C?X'^&]2\,:?'I.ARV@CM;&-`J68C)C:(``#"NC+G'.
M,]Z^=R/$9?+'UX87&.M-ZR@X6Y;.RM/F:E;X6U%7T9ZU;AS-L#1CB\=32ISM
MRN]V]+JZ^S=:V?Z';4445]<<8445Q?QY;XB#P)_Q;!?!;>)C<ISXH:Y%@L'.
M\_Z./,+_`'0!P.22>,&HQYG8%J==J6FV^LZ?-:7EO#=6MPACEAF021RJ>"K*
M>"#Z&L_POX`T'P09CHNB:3H_VG'G?8K..W\W&<;M@&<9.,],FOFKQ/%^V?/X
M:U"-8?V<+AGMI%$5E-K<-S(2I^6)RR!)#T5BR@'!W#J,KP5HG[;&BZI?"[O/
M@+J326UJ%N=2EU/RCM1E98XX`H5]P+R,4&YI0%8JJK'T_P!G0;YW.%UMKK^1
MI[%;W1]@$X%<7X/_`&D/AW\0_AYJGB[P_P"/?!>N>$]$DGAU'6M/UNVNM.L'
M@`,RS7".8XVC!!<,P*@\XKR?0/#?[3GC2+5M&\=7'P/L_#^L:3>V377AIM47
M4K6:2W=(9$^T`QD+(5)![9(R1@_.?Q]_88^,G[5_[-'Q`MM)T/3?A)<:CIUC
M9CP9KME::T/%3Z;I4\$.9+'48H+=&N9(&A>25B/L,#30JH,5<U2#A-Q;3MR[
M/NVF_P#MU+;=WW5M24$G%7WO?RLE9?\`;S;UV5M=]/LZ^_;,^#^F?&B/X;W/
MQ6^&MO\`$2:9+=/"TOB:R36GD=!(B"S,GG%F0A@-F2I!'!S6QX^_:+^'WPI\
M.MK'BCQUX-\-Z2FI#16O=5UJVL[=;X\"T,DCJOGG!_=YW^U>4?L\_LR^/O"/
MQZ\=>+M=^(OB[3])U;Q"EY'X6L;71ET'6E_L:PM6NB6M9M1A)GBD(C%ZN#"G
M#*3O\RUC]E;Q%\"/`][;^#_A*OB32$\1^)XK/PMI5UI=I&+;5;<)%?G[3+'$
M$#B191O\XI=2MY<K95L:DI1A=*[Y.:VUY7@N3R=I2UUM:[2LT9T[2:OHG)+O
M96FW+SLXK3K>R;NF?9$WBC3+;Q+;Z+)J-C'K%Y;2WD%BUP@N9X(FC2258\[F
M1&EB5F`PID0$@L,WJ^./V>OV&OBE\&OV[/#GC[7O%WAKQ9X;C\!3^&)G30I;
M>^TA8DTE8+);EKYA-&\UO=W(<6B$,\P<DR1;/L>NBI",4K.^_P"$I)?>DGU6
MNC:LWG3E*2O)6V_)7_&ZZ>B/*_VZO^3(OC)_V(^M_P#I!/7JE>5_MU?\F1?&
M3_L1];_]()Z]4KEC_&EZ+\Y%]0HHHK884444`%%%%`'!_"#_`)*#\5/^QH@_
M],NEUWE<'\(/^2@_%3_L:(/_`$RZ77>4`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7S_\`#G_E*;\9/^R5
M>`__`$[^,Z^@*^?_`(<_\I3?C)_V2KP'_P"G?QG0!]`4444`%%%%`!1110`4
M444`%%%%`!1110!Y_P#LT?\`).M2_P"QK\2?^GR^KT"O/_V:/^2=:E_V-?B3
M_P!/E]7H%`!1110`45\"_P#!QY'JDO[`6D++)XFC^&K>.M%'Q2?0?/\`MB>$
MO-?^T#^Y!?RP/+WX!&W.>,U\<_LK?\.8?^&F_AW_`,*Q_P"2D?\`"2Z=_P`(
MK_R//_(4^TQ_9/\`CX_<?Z[R_P#6_N_[WRYHPO[VIR?WN6RUEM%W4=-'S6CK
MJTUI8*_[N"E_=O=Z+=JU^ZM=Z:)IZW/UL_;J_P"3(OC)_P!B/K?_`*03UZI7
ME?[=7_)D7QD_[$?6_P#T@GKU2L8_QI>B_.0NH4445L,*_$?_`(+@>-_BA:_M
M::/XHU31?B7\)9!IE[X>T>[\/?M<>%_AK!K]A;:C.R7/V:^MVE=I8WMY7`?$
M8>*-AN3)_;BOR)_X+4)9K_P4RT)H[/\`88BU!OAG;B>Y_:4OTDT^YB&J7?EI
MI]N!OAFC)E+R,VV99@`"8&(YZG\>EZR_](D[]]DUO:S=T]#HIO\`<U?2/_I<
M5;[VGM>Z5K:GVI_P1E\0:EXH_P""<G@"^U;5O$&N:A,VH>;>ZW\2;'XBWTV-
M0N`/,UNR5;>[P``-BCRE`B/S1DU]15\^_P#!+?\`Y,=\&_\`)OOWKW_DB7_(
MC_\`'Y/_`,>/O_SU_P"FWFU]!5Z.,=Z\WYLX</\`!\W^;"BBBN8V.#\0_P#)
MSW@__L5]<_\`2O1Z[RN#\0_\G/>#_P#L5]<_]*]'KO*`"BBB@`HHHH`**J:]
MKUGX7T2ZU+4+B.SL;&)IYYI#A8D49)/T%>1?#?\`;\^&OQ,\5S:1;ZM-ILT>
M[RIM2B%M;W(7))5RV!P,X?:3Z9XKAQ69X3#U(TJ]2,92V3:39W8;+<7B*<JM
M"G*48[M)NQ[117F?BC]LGX6^$-WVSQQH,AC^\+2;[8P_"$.<^U8'_#<N@:R/
M^*;\*_$+Q9N^X^FZ#+Y1]RTFW`SQG%<]3/LNA+E=:-^R:;^Y7?X'13R+,9QY
MU1E;NTTOO=E^)[717BA^.?Q8\2_\@7X/R6,3?=N=:UV"#'UA4%_U[4?V+\?O
M%`_TC6OASX5C8\?8;.XOIE'OYI"$_3V]ZS_MN$OX-*I/T@X_C/E7XFG]BSC_
M`!JM.'K-2_"',_P/:Z9<7,=G"TDTB11KRSNVU5^I->,?\,O>,?$)_P"*B^,W
MC:ZW?>_L:&#1_P`O+#8IUM^P-\.IYUFUFUUSQ/<(<B75]8N)V_(,JGOU'>CZ
M[F,_X>&Y?\<TO_2%4%]3R^'\3$\W^"#?_I;@=AXG_:7^'O@[<-2\:>&K>1>L
M0U".24=ON*2WZ5QTO[>_@"^E:/0?^$D\63*<>7H^BW$Q)]`650?7@XKMO"_[
M.G@'P9M.F>#?#=K(O25=/B:7_OL@M^M=C#"MO$L<:K&BC"JHP`/84>SS6>]2
MG#TC*3^]RBO_`"4/:95#:G4GZRC%?<HR?_DQXJ?VF?'7B/\`Y%SX,>+)@WW6
MUJ\@TG'N0Y8].W7M2G4/C]XJ_P!3I_PW\*0MU^TW%Q?W*9]-F(R1[\&O:Z*/
M[*KS_C8F;\ERQ7_DL5+_`,F'_:E"'\'#07F^:3_\FDX_^2GBA^`?Q0\3?\AW
MXQ7UO$W6WT318+/9GKB4DN?8D<4']A3POK/_`",GB#QYXOW??75M>F9&SU&(
M]F`>F!VKVNBC_5_`O^+%S_QRE/\`"3:%_K!CE_"DH?X(QA^,4F?*OQ._X)4^
M%_%7BB.\\.:U<>%=/(436`MC>*2,`F-VD#+G&3NW\G/`XKZ,^&/PYTWX1^`=
M+\-Z/')'I^DP^5%O;<[G)9G8_P!YF+,<`#+'``XK>HJLOX?R_`UIXC"4E"4M
MVK[=DMDO))(G'Y]F&-HPP^+JN<8[)V^]O=OS;;"BBBO8/("BBN5^,?P2\,_'
M_P`'_P!@>+=-;5=)\]+DVXNIK?,B9VDM$ZL<9/!..AQP*J'*Y+GT7EK^%U^9
MG5<U!NFDY=$W9?-V=ON9TUY>PZ=9S7%Q+';V]NADEED8*D:@9+,3P`!R2>E0
MZ?KMCJ\TL=K>6MU)!_K%BE5VC^=TY`/'SQR+SW1AU!KP+4?^"6/P/ET^=;7P
M5%!=-&PADEU749$C?'RLRBY4L`<$@,,],CK6#\./^"1GPG\*V=U#KVG2^*FE
MF:2">:ZNK26!2[D1GR9U1E"&,9VABRNQ.&"IW*E@N5OVDK_X%_\`)_J>/+$Y
MNJBBJ$+=_:/3_P`IW^Y/Y'U*6VC)X`ZFOGOQ'_P4.TJ#X$ZK\1/#'PY^)GCC
MP_H6J7VFZBEC;:=I-W:+:9\RY,.K7EDS0L0!'MW22;E*H596/4?";]A+X5?`
MWQO;>)/"OA=M*UFT1XXK@:I>385U*L"DDK(V03U!QP1R`:)/V6WDT2^T_P#X
M2!EM=2\=Q>-+E5L\>:D=S%<K9G]YT\R&/+G@@$;.:XJD8>VY82?);=I)J7/!
M;7E=*#D_E9:V/4P\Z[I<U>"4K[1DY)QY9/=QC9N7*EI97N]+VH^#?VP=4\>?
M&&_\+:=\&OBD^G:+?PZ9JWB62Y\/QZ7I5P]G!=LDB-J@O&\M+F-6,5LXW9VE
MP-U8]_\`\%%O#-U\-/\`A)O#?@WXD>,$.LW^DKIMAI$5GJ3)8HSW5[Y-]-;$
M6R*`021)+OC\N.0NH.[X`_84^'/@_P#:)\5?%>\\'^"=8^(GB#63J=EXEF\.
M6O\`;6D1'3[>R^S1WI#3;=L,A^5E&)V7;C);GOB/^Q9XBU6PO[GP?XZTOPWX
MDOM=U;4/[0U#PT=4ABLM2B6.XM5A%U"?,'EQ.DV_:'B7=$ZDJ<)RGR7@ES<B
M?E[2\-'_`';<][6=D[-OE9U14>9<STYK.V_+:=VO._+:^EWJDKFE\(/^"@?@
MGXZ_M0Z]\+/#,<^HZCX=TJWU>ZU)=7TCR3#/!;7$6+(7O]IA6CNXOWKV2P[M
MR^9N&#[I7AOPH_9!U#X7_$W2[@>)M*NO`_A=3/H.D0^'Q9ZI#=-9)9-)>7T<
MPBO$$`94!M4E&5W32;0#[E714Y%;DOMUWW>_3[OSN8TW-_'OIMMLMNN]]_3;
M4\K_`&ZO^3(OC)_V(^M_^D$]>J5Y7^W5_P`F1?&3_L1];_\`2">O5*Y8_P`:
M7HOSD7U"BBBMA@3@5YKX1_;,^#_Q`\(^*/$&@_%;X:ZYH/@A2WB/4K#Q-97-
MGH``9B;N5)2EN`$<GS"N`K>AKN?%\]G:^$M4DU"SEU*PCM)6N;2.T:\>ZB"$
MO&L*AFE++D!`"6S@`YQ7YU/KB?M(>"]0^(4?PR^(_A^\\,77A+R?`)^&&NZ0
MVD>%M+URWO6MP;FQACU&_4!YFMK+S5B6!(+99CNGN53]ZIR-I+2[_E3=N9KJ
MEN]5[O,VU9*525H<_P!R[O3W5V;Z-Z7LOM77W1J_[5WPM\/^"_"_B2_^)7@&
MQ\.^.+B*T\.:K<>(;2.RU^:4$Q16DS2!+AW`)58RQ;!P#7?5^7_C[X>ZW8_#
M[5?$%W\*/'VM>'_B9H7Q+T7PWH5OX3NIKW3;G7-4M[BQ6[MEC,M@EZD4LK2W
M2Q1V^X+.T+$*?T>TC1-=TWX7Z=I\.HV4?B"UL(('O;NU:ZA:944.[1K)&6SA
MN`Z\D'G&#<5>FIM6;MH]TVY)Q?\`>C9-[*TXV[N:GNSY5JKR5ULU'EM):O25
MW;SC*S:U,7X0?\E!^*G_`&-$'_IETNN\KPWX6:%\17\<_$H6_BKP5',GB.$7
M+2>%KF19I/[(TTAD`U!=B["B[26.Y6;<`P5>V_X1[XG_`/0X>`__``D+O_Y9
MU('>45P?_"/?$_\`Z'#P'_X2%W_\LZ/^$>^)_P#T.'@/_P`)"[_^6=`'>45P
M?_"/?$__`*'#P'_X2%W_`/+.C_A'OB?_`-#AX#_\)"[_`/EG0!WE%<'_`,(]
M\3_^AP\!_P#A(7?_`,LZ/^$>^)__`$.'@/\`\)"[_P#EG0!WE%<'_P`(]\3_
M`/H</`?_`(2%W_\`+.C_`(1[XG_]#AX#_P#"0N__`)9T`=Y17!_\(]\3_P#H
M</`?_A(7?_RSH_X1[XG_`/0X>`__``D+O_Y9T`=Y17!_\(]\3_\`H</`?_A(
M7?\`\LZ/^$>^)_\`T.'@/_PD+O\`^6=`'>45P?\`PCWQ/_Z'#P'_`.$A=_\`
MRSH_X1[XG_\`0X>`_P#PD+O_`.6=`'>45P?_``CWQ/\`^AP\!_\`A(7?_P`L
MZ/\`A'OB?_T.'@/_`,)"[_\`EG0!WE%<'_PCWQ/_`.AP\!_^$A=__+.C_A'O
MB?\`]#AX#_\`"0N__EG0!WE%<'_PCWQ/_P"AP\!_^$A=_P#RSH_X1[XG_P#0
MX>`__"0N_P#Y9T`=Y17!_P#"/?$__H</`?\`X2%W_P#+.C_A'OB?_P!#AX#_
M`/"0N_\`Y9T`=Y17!_\`"/?$_P#Z'#P'_P"$A=__`"SH_P"$>^)__0X>`_\`
MPD+O_P"6=`'>45P?_"/?$_\`Z'#P'_X2%W_\LZR?'.A_&F'PM='P]XL^%[ZL
M=JPG4/"=\MO$"P#R,$U$LY1"SB,;?,90A>,,9%BI44(.;V6HXJ[L>I5\_P#P
MY_Y2F_&3_LE7@/\`]._C.OD;Q?\`M*?M.>/_`-EKX'ZCX9^)S#Q5XB^&Z>.-
M;?POX$L9KYF^SVN+F_6]D>W_`+/$DLGFI8(+YFVBVMI0)`G!?LP_M@_%3XU?
M\%>_&FNP>/[33_#-UH_ACPF;S3_`D-QX6UA#-XD-BLQGOTU%&EN/M4EO/:O)
M%ND:*X"E(Q6_LW[5T>J;7W2Y+_.?NQZN5TEHQ5OW2O/^M.9^EH^\V]%%IMZH
M_7:BOCW]LVZ_:%^#GBKPIXXTOXK:=;^$;'4[&SUK2K/P-9KH5M:27*I<WFI2
MSWDNHM^[?;"NGE<2B,R@1&25/H;_`(1[XG_]#AX#_P#"0N__`)9UG'6/-YM6
MZZ6=_1WT?DUNF#T=O*YWE%<'_P`(]\3_`/H</`?_`(2%W_\`+.C_`(1[XG_]
M#AX#_P#"0N__`)9T`=Y17!_\(]\3_P#H</`?_A(7?_RSH_X1[XG_`/0X>`__
M``D+O_Y9T`=Y17!_\(]\3_\`H</`?_A(7?\`\LZ^6_\`@K-^S3>?&3X">$9O
M'MK\'_&@T[XD>";.R.I_#]KJ2T6]\6:-:W"(TU])MBFC?RYHU`\Z$O&2`V0`
M?<%%>3_#?X(^*O@WX(T_PSX0OOA/X5\-Z2C1V6E:/X!FL;&S5F+L(X8M15$!
M9F8A0,EB>IK<_P"$>^)__0X>`_\`PD+O_P"6=`'>45P?_"/?$_\`Z'#P'_X2
M%W_\LZ/^$>^)_P#T.'@/_P`)"[_^6=`$?[-'_).M2_[&OQ)_Z?+ZO0*^??"/
MQJU;X*?!BU^R>`_&_P`3M>U;QCXCM18>$K.UC(9=6U"22>26^NH+6VB&P@":
MY#,SJB>8QK.A_P""H?@>_P!1\(+8^&_'M_IOB2TTR[U34XM/MUM?!O\`:5Z]
MA9QZDKSK*))+R*:`BVCN!$8F>0QQ%9&(^]+E6[:7S>W_``^U]-P>BOV5_P`4
MOS:TW9])T5XM\(OVX_#OQC^.FH>![/P]XPTWRFU--)UV_M;=-)\2MIEU'9ZB
MMHR3/,#;W$BQG[1#")/F>'S44N/::-XJ71ZK\OT!Z2<7NG9^IY%^VA\'/BM\
M;_A5::3\'_C+_P`*.\3PZE'=3Z__`,(E9^)OM%JL<BO:_9KIEC7<[1OY@.X>
M5@<,:^>_V*/@[^V9\$_V\=2TGXQ?&:X^-_P3D\%/<VNNGP=H'AF.+76O(PML
M(+25KQMELLC>8P$3&4C[RJ3T_P#P6@_9T_X:<_96TGP__P`,X_\`#4'V?Q);
MWW_"*?\`"P/^$)^R;;>Y3[=]LWIOV;_+\G/S>?NQ\E?"_P#P3-_X)Q_">U_;
M]M?"GC?]@'_AG3Q1X9T*#Q[HNLO\<;SQ5]HEM=2MQ`(X(YO+?9,@=_F<)LC$
MB!9TW/!:UVGW>^MUR-MI2LKQ5Y)1>\;WOS(>*THI^2\K/GLKM7>KM%N2VE:U
MN5GZG?MU?\F1?&3_`+$?6_\`T@GKU2O*_P!NK_DR+XR?]B/K?_I!/7JE81_C
M2]%^<B>H4445L,*_&7]OJ_\`AC\0/VI?%TVI_LN_M[>)=8TG4;K3Y=6B^"VA
M?$+0]3:.XE(DT^X\0P7\T%@S,S1P64EM;[6W+$C,6/[-5^2G_!:_]EJ3]JC_
M`(*+^&=./[*^O_M71Z/\.DN5T:X^)G_""Z7X=+ZE.IN;:;SD^TSRX"3IM^18
M[0[OFP,)W]M32Z\RZ](N72_\MK;:W=K&\&E1J-].5_?)1ZV_FOWTLKW/NG_@
MEKJ7]K_L-^"[C_A7O_"K-YO?^*9/P\_X0#^SL7DXS_8WVN[^R^9CS/\`CX?S
M/,\SY=^U?(_VM_VP_C7^S9^TUXLFO/\`A"8?`>E_"?Q9XI\-Z)9QSW]QJ5[I
MLNE"WN]0G:.)XP3=R)]FMP51=[M-*600^N?\$M_@]_PH3]AWP;X5_P"%-_\`
M"@?[,:]/_""_\)9_PE7]B^9>3R9_M'<WG>;O\[[QV>;L_AQ7:?&']D?PA\>/
MB%%X@\3QZA?K_P`(CK/@FXTT3B.SO=.U5[1KH2;5$N_%G&JLDBX#OP25*]N*
ML\2Y;Q]_2_>$E'5-ZJ35FFTMUJDUA@W&,;3[KIT4KO>VZ]+[7L]?F7QM^T'\
M5/V>/$7C+X4WGQ$U3QEKU]:>"Y]%\7ZIH^G)?Z0VOZU/I%W^YM+:&U9;<6YG
MM_,A?YWVS&50!7NG[%_Q'\3:MXD^+/@'Q7X@O/&&H?"KQ3%HUMX@O;:UM[W5
M[2YTNQU&-KE+6*&W\Y#>/$3##&I6)#MW%B<O1_\`@F[X97X;^+=%\0>-/B)X
MRU[Q=!IEM)XMU>\LX]=TY-+E,^E_9WM;6&!6M+DM<(SPNSRNQF,P.VO2/V>/
MV>-/_9X\/:Q!#K.N^*-;\3:H^M:]K^M&W_M#6[QHHH1+*+:&"W3;!!!$J0PQ
MH$A7Y<[F)&4;SYM;IV>V[ARZ;)Q2FI-;N2WW4V=DO3KU4;2=]+J4M8Q:T\K)
M&=)XZT3Q3^UIH-AIFL:7J-]HWAK6XM0MK6[CFFL7-WI("RJI)C)VM@,`?E/H
M:]1K@_$/_)SW@_\`[%?7/_2O1Z[RL2@HHHH`****`/GW_@J;XP;P'^PEXXU5
M5:06[Z<KJO4H^I6J-CWVL:_+CP#^TCX9@^)/A$QZ7JGBQ9M;L5N-'LK%I[F]
MB-Q'YD$<;8$DCKE%0'YF8#(!S7['_M+?L^:+^U1\$]:\!^(;G5+/1]>\CSYM
M.D2.Y3R9XYUV,Z.H^>)0<J>">G4?-GPN_P""&OPG^$OQ-\.^*M/\1?$6XU#P
MSJEMJUK%=7]DT$DL$JRH'"VJL5+(,@,"1GD5\7Q#PG3S+'4L7-?`DM]'9MV:
MMJM>EC]0X.XKR_+<KJX7$M\\I2:LGLXQ2UZ:IE_PQ^W%X7\$[?['_97_`&@M
M**=#:?#6*$COU64?6M__`(><?]6]_M/_`/A"?_;Z^GZ*^FIX6=./+3DDO**1
M\94S+!5)<U3#MOSJ29\P?\/./^K>_P!I_P#\(3_[?1_P\X_ZM[_:?_\`"$_^
MWU]/T5I[*M_/^"(^O9?_`-`W_D\CY@_X><?]6]_M/_\`A"?_`&^C_AYQ_P!6
M]_M/_P#A"?\`V^OI^BCV5;^?\$'U[+_^@;_R>1\P?\/./^K>_P!I_P#\(3_[
M?1_P\X_ZM[_:?_\`"$_^WU]/T4>RK?S_`((/KV7_`/0-_P"3R/F#_AYQ_P!6
M]_M/_P#A"?\`V^C_`(><?]6]_M/_`/A"?_;Z^GZ*/95OY_P0?7LO_P"@;_R>
M1\P?\/./^K>_VG__``A/_M]'_#SC_JWO]I__`,(3_P"WU]/T4>RK?S_@@^O9
M?_T#?^3R/Q3^-?\`P6$^/UK\9?%L.B^+=4\,Z/#K5Y%8Z1J/AS3H[S2X%G=8
M[>=7@=EE10%<,S$,IY-?IQ_P34^,_B3]H/\`8G\%^+O%VH#5?$.K?;A=W0MX
MX/.\J_N(4.R-5082-!\JC.,]:\F^*/\`P0U^$_Q:^)OB+Q5J'B+XBV^H>)M4
MN=6NHK6_LE@CEGE:5P@:U9@H9S@%B0,<FOI/]FG]GS1?V5_@GHO@/P]<ZI>:
M/H/G^1-J,B27+^=/).V]D1%/SRL!A1P!UZGAP.'Q4*SE6E>-GUOU70^GXHS?
M(\3EU.CEU)0J)Q;:@D[*+37-:[UMZ[G=4445[!^?!7-_%/XN>'?@IX7_`+:\
M3ZDNEZ;YRVXF,,DV9&SA0L:LQZ'MVKI**SK*HX-4FE+HVKI/S2:O]Z]32C*F
MIIU4W'JD[.WDVG;[GZ'B,W_!1CX.Q0LR^+FD95)"+I5[N<^@S$!D^Y`KG_AQ
M_P`%/?ASXHT^ZDU^:Z\*W$,Q6&&:":[^T1]G#0QD*?53T[$]OHJZMH[VVDAF
MC2:&92CHZ[E=2,$$=P1VKF?A5\$O"OP1TV\M/"VCPZ3!?3?:+@+(\C2OC`RS
MLS8'9<X&3@#)KY^IAL]=>#A7I<FM_P!W+Y:>T;?RE&W:73Z"GB<C5":G0J<^
MEOWD?GK[-)?.,K]UUYOX;?MD?#?XO^+8-!\.>)%U#5KI'>&W-C<P>8$4LV&D
MC5>%!.,YXKYM^(7Q._:$\6?!]M)T/QEX>M_'%G\0=8MM4U'3;RP\.K%HME;R
MR>3:I>V&K&1D9K<$_9I7?#$O`&RGW!7&^/OV=?A]\5O#K:/XH\"^#?$FDOJ0
MUIK+5=%MKRW:^'(NS'(C+YXR?WF-_O7KX6GBHIO$3C*5K)QBXI>]!I\KG*^D
M9)^\KIV5KMOQ\54PTI+ZM"44G=J4E)OW9IJZC&UVXOX79J^NB/EW]GCXM_%#
MX\_M<ZS?1ZG\?H_AW8:M:I:B"V\$0^%8+=M$L;S[/>B6,ZYYS2W#!S;@J&D0
M*RHK%6ZQ\8_BUKW@>]T76/BA:^#]>L?$?B=Y_$>A:)8Q6RP:;;B:WL%AOQ<+
MY15RTCG,KI:RE7AW93[*TOP]I^AW%]-8V-G9S:I<?:[QX(5C:[FV)'YLA`!=
M]D<:[FR=J*,X`%<SX^_9U^'WQ6\.MH_BCP+X-\2:2^I#6FLM5T6VO+=KX<B[
M,<B,OGC)_>8W^]==:/,N6#Y?<Y;[M2O!\W2]N66CM>]M+R;XZ>EG/6TDWT32
M4U;K:[DKO6UKZM(^6?V.OVD_C+\7_P!HG1_$?BR\@L_A[XT2^TFQT"VGMIET
M^]M85E\QH!9)<VX*QR'S)=0N`YF11:Q`K*/MBN6TSX'>"M%^+&H^/;/P?X6M
M/'6L6BV%_P"(H=*@CU:]MEV[89;H)YKQKL3",Q4;%XX%=36TY)I<JMIZ]7UZ
M_P!+6UWG3C*-^9WU_I6_J^^E[+RO]NK_`),B^,G_`&(^M_\`I!/7JE>5_MU?
M\F1?&3_L1];_`/2">O5*Y8_QI>B_.1?4_/WX^_MY?M(_$'XY>*O"OP-U+]B_
MPC#X$ULZ%J-I\3/B!/J6OWSRS0V]G.;+221IZSSR&**&XE>>1GC!2)SY9^H_
MV3?&_P`:M>TJ^TGXW>!?!OASQ#H]O:%=<\'Z^^I:#XA>1&\XP17$4-Y:M&Z<
MQ3(Z[9(]L\IWA/SV_P""N>E1?"+]K#P;X6\)Z-^QWX(L[>Z?XLV/BCX\^*-5
MTZ,^(6U",SIHLEO.GV9EDMK:XN8(RL4[7*N\;$R%_P!!OV"?BUXJ^.7[*OAG
MQ1XV\3?!WQAXEU(W0N]6^%NHS:AX5NMES+&GV2:9F=MJ*JR9)Q*L@'`%;X7W
ML(I[N]GYM:-K_MY35M%:S26T:Q7NUW%;=/)/WDG_`-N\NNKNVKNW,_8J***0
M@HHHH`X/X0?\E!^*G_8T0?\`IETNN\K@_A!_R4'XJ?\`8T0?^F72Z[R@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`I'42(5;HPP:^+?^"MMU)<?$#X"Z3+<:A_9.K>(=06_M+>^FM5O%2P=E5VB9
M6X89'/!K=T#]B/X+ZYI,-R7\16S2*"T4GB;40T9]/]?S]:^>S+/(X:JZ$H<V
MG=+?U,Y5+.WZGI?C#_@GE\)O&W@;P=X<NM!UJQTGP'HY\.Z.ND^*-5TF:/3"
MD2-8SSVMS'+=6SK!%OAN'D1S&"RD\UY/\,?V4/A]8_\`!7OXG:U:^'(;&XT3
MX;>!]2M+:TN9[;3TNGOO%=K]H:SC<6TDR06T4<<CQLT(W^64,DA;9_X8,^"_
M_/UKG_A3ZC_\?KQ7P)^Q5\)+C_@HM\5-+DN-9_LZS^''@VZ@(\17X8RRZGXJ
M63+^=N8;88L*20.2`"QSS1XIC+FFZ>N_Q+5M_P";O<4JG-\5G\T?7'B#]AGX
M;^*_%NAZYJ6G^(KW4-#M+2Q'G>*]6:#5HK1F>V_M*'[3Y6IM$[,RO?+.P9BV
M<DFO7*^5?^&#/@O_`,_6N?\`A3ZC_P#'ZP_B-^R'\$_AYX0O-4?_`(22^>WC
M+1VT/B?4=\[8X7/G\#U)Z#U.`8_UKCM[/S^);O?[P]IK=VOZH^QJ*_/W_@A%
MXROO%U[^T&MS<7CV>G^,K:"PM9KR:Y2PA.GPMY4;2LS;=S$\DDDDGDU^@5?3
MX>M[6G&I:UU<TB[JX4445L,*^?\`_@I9_P`FZ^'/^RJ_#C_U-]"JGXU_X*&6
M?@7QU\9-+U#P5XAL]/\`A/X>TW6;>^O'2U;Q1+>W5_:+#;0M\\<8N+'REFFV
MB4R%T4PB.:7YI_;:_;T\5?%#_@G?+\0K+0?@KJ6C^#OBIX+DU#5?#_Q7_M[P
M_-%:^)M$ND:"\MM-:4N+C9#/'+;1-"A:6,7.$CDER23?9)_)NR_'[NI4H-3Y
M'O>WSY5*WW/]-TT?I%17AOC#]JGQ5\-OV)-.^)_B?P#8^'_%=Q865UJ/AR[\
M0$:?X=DN9(U<WVI"V/DVMLLGF7%P+=A$D4K;6"Y/2_LB?M`7G[37P.L/%U]H
MMCHLUY<W,"C3=5_M;2]0CBF>..\L+SRH3=6<Z*LD4QACWHX(7&"='3DI2B]X
MNS_KK\C-23C&:VEM^9Z;1114E'RE\2_"?QD\>_L_Q:+\(_\`A%XXK_QQXE3Q
M.^I>*+OPY?2:=_;&H9@L;VWL+UK>61RJO,(A(D6_RGCE9)HN?\4?L._$C7M;
MTVST?1?A;X-\'>+-)\+Z5XKTFQUF\N?^$7BT+49;I(M+_P!!B6\2X@D%O^]%
MGY!02`39V#Z-_9H_Y)UJ7_8U^)/_`$^7U>@41]W[T_6RM9]UUL^K=MW<D^96
M\K?C>_KTOU6CNK'RY^SK^R!X^^&W[0>GW6OW/@]O`'@.?Q/<^%Y;"[N9-6U-
MM;U%+PB[A>%(K86J>;"#'-/Y^]9"(-OEGZCHHH6D4NW7J_-^8=6^_3HO)>1\
MF_\`!9:\\*Z?^R5:2^*/B%^T!X!;_A(+6+1X?@QJ+6GC#Q3J#QS)#I5JJHYG
M\T,[F+Y1F%6+*$)KY;_X(17OP1\??M(^(_%FD^*/VQ-<^+EUX5-MIL7[0]WY
M^I/X?%XOGSZ6R#RY+8W@1)#YC,LD8&U,DM^B'[2W[+_AO]JGPMH6F^(IM8L9
MO"^OV7B;1]1TB]:SOM-OK5RR21R`'`9&EB=2"&CFD7N"/+/V)/\`@E3\/OV&
M?B!KGBK1O$'Q$\:^(M6BGLK.]\8:[_:7_".:?-<"YDT[3HE2.*VM6G`D**FX
ML!EB``%A;PJRE+9\VV_P)*WFVVI=.1:>\QXCWZ:C'IR[]^9M_)))QZ\[U]U'
MHO[=7_)D7QD_[$?6_P#T@GKU2O*_VZO^3(OC)_V(^M_^D$]>J5E'^-+T7YR)
MZA1116PPK\HO^"KO[`/C?]I?]H;_`(23QM^Q#X%_:P%NLVG>'=?T#XS7O@.Z
MTC1TD\Z"TO[&>01/<"2>X_?P2NL@&2D/RQU^KM?E_P#%+_@L?^T3X`^.VO:E
MH?P;\$_$#X4:E\1=5^#_`(,T'2=0N+?QGJ'B.SBDVW%U+*391Z=)-;S[G`#P
MQ$.V1&Q?&24JJ6[2;2M?K&.FGQ-R45;5N5MFS:+DJ4GTND];='+[DHN3OHN6
M^Z1]/?\`!*7X#>-?V;?V>[?PGK'PQ\!_!3P-I\4<GA?P+HGB:^\5:EH33-+<
M7HO]4N-J32-<3';'"C)&%;$TH90GU%7S)^S&OQ2L_BCX+7XS7WAN;XC7OA.[
MN]8C\'12)ID4CWS.EM<+(6<06\31Q6TK9:21;PEQNVM]%^+?%FE^`O"NI:YK
M>H6>DZ-HUK+?7]]=RK#;V<$2%Y)9';`5%52Q8G``)K:IB.>I4E.WNMIN]UIN
M[O\`._X&^(RWZO&ER/F]I%26EMVU:WROLG=ZI2N:%%>$Z7_P4F^$.K^"M4UN
M/6O$T)TB]M=/FT>Z\&:W:^(9YKI2]L+?2)+1=0N5E19&1X;=U=8)V!(AE*>L
M?"_XGZ#\9_`.F>*/#.H1ZIH>L1>;;7"QO&QPQ5D>-PKQR(ZLCQNJNCHRLJLI
M`KE>OEH_)VO^6OIJ</,M//\`31F#XA_Y.>\'_P#8KZY_Z5Z/7>5P?B'_`).>
M\'_]BOKG_I7H]=Y4C"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BH;'4;?4XFDMIX;B..1X6:)PX5T8HZDC^)6!4CJ""#R*+#4;?5+<S6
ML\-Q$'>(O$X=0Z,4=<CNK*RD=B"#R*`)J***`"BBB@`HHHH`****`"BBB@`H
MHHH`\K_;J_Y,B^,G_8CZW_Z03UZI7E?[=7_)D7QD_P"Q'UO_`-()Z]4K&/\`
M&EZ+\Y"ZGX@_\%M/VJ_AG:?\%"O$6MZ?XD_85\1ZA\./"-AX6\3Z-\;?#6NZ
M_?65T][/<(+""SM)HY2BW"B3[,6DCWR"=5"(5_3?_@E+=-J7[`?P]OOLOP-L
MX=4MI[Z"/X064UEX.\J6YE=#9PS*LD;%6!E5U5A/YP(!!%?)G[(7Q0_9MUW]
ML#XO>'8_B/<>%_B=HOQ1\3'P%:>,K"'2Y]&UC4$%CJCZ1*TI@UE)KSS)$B?=
M+$'1&B0;&?[D_8F_99M?V,?V:?#WP]M]<OO$UQI;75[J.L7<*6\NK7]W=2WE
MW<^5'\D2R7$\K+&O"*54$XR=L'[N#BG]I1DGTO+FE)+>_+*6K;[6OKRO&7EB
MG_=;BUU]U*$6^UTMDGUO)67/ZM1110`4444`<'\(/^2@_%3_`+&B#_TRZ77>
M5P?P@_Y*#\5/^QH@_P#3+I==Y0`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110!\3_\`!6K_`)*[^SM_V,6J?^FV2NNT
M_P#X\X_]T?RKD?\`@K5_R5W]G;_L8M4_]-LE==I__'G'_NC^5?F_%'^^?)'%
MB/B)J\4\"?\`*1CXJ?\`9./!O_IS\55[77BG@3_E(Q\5/^R<>#?_`$Y^*J\*
MC\$_3_VY&2V9[77(_&O_`)$.[_W3_*NNKD?C7_R(=W_NG^594_B1)YS_`,&^
M_P#K_P!HK_L=K3_TV6]?HQ7YS_\`!OO_`*_]HK_L=K3_`--EO7Z,5^OX'_=X
M>B/2CL%%8OQ(\6-X#^'>O:XD*W+:+IUQ?K"6VB4Q1,^TG!QG;C..]?+W[//[
M6?QU_:4^$FB^+]!\-_"M;/6;.&[\B6_OO.MO,0.$<!,9`/4<&HQF8T,+;VSM
M?;1O\@E)(]%^._[#.E_M`^*/B9>:SJ[#3_B-X0TCPNUF+%)/L+Z=>ZA>1W)+
ML4F5I+Y`870*1`02PD(7Q']L+]F;7/"_[/-YJ7CSQ)X=\7:_X^^+?PS37AI7
MAQ](T>XM(?%FB6L4$=I-=7;J2K`R.\\F_`7:J@*/7_\`A.?VD?\`H6?A/_X'
MW_\`\17B'_!07QE\?KCX#Z"NK>'?AE#:CXE>`61K:]O6<SCQAHQ@4[DQL,PC
M#'J%+$<XKCCGV#E))2=[JVDMT[KIIK_D]`J251MS5[Z/3^ZH_P#I*2^5]]3Z
M<_:B_9]\0?M">&?[/T_Q/HN@OI.H:3KV@276@OJ*VFIV-X;G?=I]IC%S;.%A
M40IY$B%'<3%F3RKO[+7P%OO@%X*UBWUC7+/Q#XA\4:[=^(]8N[#3#I6G&[N2
MN\6MH99F@BPBDJTTK-(TDC.S2$UPO_"<_M(_]"S\)_\`P/O_`/XBC_A.?VD?
M^A9^$_\`X'W_`/\`$4H<08*-^5O6]_=?7EOTZ\L;]^5=D3.2FTY)Z6MH^E[?
M=S2_\"?=GT+17QCXH_X*#?$CX1?M7?"OX9>+]!^'\EU\1M9&FRC2+RZDGTR+
M[/-,)6WJ%RWE8"]<')P,9^SJ]+"XNGB(>TI;>EOS*C*^QY_^S1_R3K4O^QK\
M2?\`I\OJ]`KS_P#9H_Y)UJ7_`&-?B3_T^7U>@5TE!1110!Y%^VA^R3_PV9\*
MK3PK_P`+-^+OPI^R:E'J7]K_``Z\1?V%JLVR.1/(>?RY-T#>9N9-O+1H<_+S
M^''P,\2>,_AU^W'H?PEN/VD?VT?$?[0'AG]H&VT4>!=:\5:G/H^J>!X;I+AM
M5NE:,1R1O9JS,?."NK;A#Y3;J_<?]M#X.?%;XW_"JTTGX/\`QE_X4=XGAU*.
MZGU__A$K/Q-]HM5CD5[7[-=,L:[G:-_,!W#RL#AC7SW^Q1\'?VS/@G^WCJ6D
M_&+XS7'QO^"<G@I[FUUT^#M`\,QQ:ZUY&%MA!:2M>-LMED;S&`B8RD?>52:P
M?N8I5-DG?79N/+-:ZVOR.%FM>9I6;3'BO>PSAN[65MU?FCMI>W-SZ/2R>R:/
MHW]NK_DR+XR?]B/K?_I!/7JE>5_MU?\`)D7QD_[$?6__`$@GKU2N>/\`&EZ+
M\Y$]0HHHK885_.G\4OAI\*O$_P"V'O\`%7[7'Q!^%E[J7[3'C.'6M"TSXI6>
MAVW@JUC34WAU>WMY%)LIY952$W+Y5UG9!RXK^BROP'_:I_8^_9S_`&HOBY^T
M58_&KXA_!_X)_$%OCA%<:U:ZNVD^%]:M/"5K!(Z7&E2-;/+=W.H1W*W+R,'6
M9]@;YD!?GYN7$J>FD>KMI[6C=W\MW_=N[W2-WKAI0UU?35_PZJ6GJ]/[UEU/
MT^_8<\,>%O!'BOP+I_@OXM^(OC=X9/A6_-GXVO/%$/BG4?$6-2E+C4[^$!)(
MX)&>*T('RE+N,L"I5O:/VW_#6L^,_P!CGXHZ/X>\-V?C#7-4\+ZA:6.AW4LD
M,.K2O;NJP,\<L+KO)QE)HF!(Q(APP^/O^"&,"Z;^SA\"[>WL?[+TM?`NH0Z4
M]AIJ6$VM:?'J]PMG>ZG`@`C\^V\FX@<KNDEN+YF8,Y#_`*)U4X7JUX:_%):J
MS^:TL^ZTL>QFE3EC@ZB_Y]1>CNOBEL];KLTVNUEHORZ^']CXMTG]IG0_B_<:
M7\>/B1X%\%ZEH9U7Q%XI^']]IWBQR=,\064EO;Z-'96\US9V4FI6D@DM;#S"
M;^[9IKKRF\K[/_X)T^!-9\$?LZW<VM:9>Z'-XJ\7>)/%5IIEY"T-S86>I:S>
M7MK'+$P#12&">-GB8*T;.RL`RL*]VHKKE5;N^_Y:77WI-/?>[=[GSW+HEVM_
MY*I)>FDG=;;64;6/+I+36[?]K307U/4-+O+&7PUK9T^&UT^2WFMD^UZ3D2R-
M-()2?EP52,#!X.1CU&N#\0_\G/>#_P#L5]<_]*]'KO*R*"BBB@`HHHH`Q?B)
MINDZKX(U*+7IUM-(6$S7-RUP;;[(L?S^<)008V0J'#@@J5!!!%?'_B;]HSX[
M)\4=!TV3X,WWC3P_&TLWARYN?%%EX>;Q(\+EHKNYAD4XF$.R1;9A&0RRR^4-
MBK!]I:KI%IKMG]GOK6WO+?>DOE3Q"1-Z.'1L$$95E5@>Q4$<BC4](M-:BCCO
M+6WNXX9H[B-9HA($D1@Z.`1PRL`P(Y!`(YKJP^(C3^**EZWT]+-,TC-+=7/F
MK_AJ?]I'_HU7_P`R9I?_`,;H_P"&I_VD?^C5?_,F:7_\;KZ=HJOK5/\`Y]1^
M^?\`\D'.OY5^/^9\Q?\`#2W[2^I'9#^S+I^FLO)DN_B)83*WL!&F0>^3QQ2_
M\+\_:@_Z-_\`"_\`X7-O_P#$5].44?6J?_/J/_DW_P`D'M%_*OQ_S/F/_A?G
M[4'_`$;_`.%__"YM_P#XBD/QZ_:A<;5^`/A5&/`9O'$!5?<@)FOIVBCZU#_G
MU'_R;_Y(/:+^5?C_`)GS#_PM3]K#_HE/PQ_\*:3_`.)H_P"%J?M8?]$I^&/_
M`(4TG_Q-?3U%'UJ/_/N/X_YA[1=D?,/_``M3]K#_`*)3\,?_``II/_B:4>-O
MVNK_`/>1^"/@K8(>!#<ZS>RR+[ED&WFOIVBCZW'_`)]Q_'_,/:+LCYC_`.$J
M_:^_Z%3X$_\`@SU#_"C_`(2K]K[_`*%3X$_^#/4/\*^G**/K:_Y]Q^Y_YA[3
MR1\5^"9?VB/&GQ2\0W-UHG@?3?#2G[/XH_X1/4[F.?6)8\"2.S>9=HO41?*:
M52@()C,BRQHT'UQ\-;[0]0\":6_AN."'0TA$5I##"85MU3*&(QD`QLC*59&`
M964J0""*W**G$8CVOV4O3]0E/FZ!1117*9A1110`4444`%%%%`!1110`4444
M`>5_MU?\F1?&3_L1];_]()Z]4KRO]NK_`),B^,G_`&(^M_\`I!/7JE8Q_C2]
M%^<A=3YWT[_@EE\&+SX7>//!GBSPK9_$;PW\0O&6J^.KZT\56MO?"PU'4<B9
MK1A$C6^Q698W4^<@8XD)YK4_X)O?`ZR_9O\`V0O#O@O3?A7_`,*7T[0[O4H[
M7PG_`,),WB/[#$U_<.DWVUF=I/M"L+C:6)C\[RS]ROSW^/W_``2(_9+UW]OK
MXH?$'XT?!'XR_P!F^-'-TMA%X6\1ZS8W-^+B9KC6K;4?#EU<QV]O<A@6M;^.
M&9&C$@6)&*']&OV!_AI\&/A#^RGX9\/_`+/MSX?N_A+8FZ.B2Z)KKZY8L7N9
M7GV7;S3-)B=I0<R-M;*\;<#;#_P.;;2*:6J]U62;TUBE975[-II--%8C^+R[
M^\W=Z-\UVVEKNY:VZJZ;C\7L5%!Z5\6ZG\7OVB/$_P`,?VA=+TJ3^V/'WAGX
MA:5H^CV_A"WTZ*;0-(N-/T2\NH[5]4Q;W5Q##=W966["K+*0WEPQE8HS=M+H
MK_\`DT8_G);Z)7;:*C#F_K\?ZUUT3/M*BOS]^(/[2_Q*U'X?VNB^%?B9X\\+
M^(/`?@[Q9XM\077B_2/#EQK5]J6E36@ATJ_^PP-IPM0MV3*;`)*T?D;;A&\P
MM]Q:9XUN=2^&>GZ_#HVH7UU>V,%X--MFB2X)D56*`S21Q@KN.=SCH>^`:4;Q
MYXNZWOW3<DFNZ;A*SZI7V:;R<K-1>^J]&N5M/LTI1TZ7L]4TL/X0?\E!^*G_
M`&-$'_IETNN\KPWX6?%/7+;QS\2G3X:^-;AKCQ'#))''=:0&M6_LC35V/NO@
M"Q"A_D++MD7G=N5>V_X6_P"(/^B5^//_``+T7_Y85)1WE%<'_P`+?\0?]$K\
M>?\`@7HO_P`L*/\`A;_B#_HE?CS_`,"]%_\`EA0!WE%<'_PM_P`0?]$K\>?^
M!>B__+"C_A;_`(@_Z)7X\_\``O1?_EA0!WE%<'_PM_Q!_P!$K\>?^!>B_P#R
MPH_X6_X@_P"B5^//_`O1?_EA0!WE%<'_`,+?\0?]$K\>?^!>B_\`RPH_X6_X
M@_Z)7X\_\"]%_P#EA0!WE%<'_P`+?\0?]$K\>?\`@7HO_P`L*/\`A;_B#_HE
M?CS_`,"]%_\`EA0!WE%<'_PM_P`0?]$K\>?^!>B__+"C_A;_`(@_Z)7X\_\`
M`O1?_EA0!WE%<'_PM_Q!_P!$K\>?^!>B_P#RPH_X6_X@_P"B5^//_`O1?_EA
M0!WE%<'_`,+?\0?]$K\>?^!>B_\`RPH_X6_X@_Z)7X\_\"]%_P#EA0!WE%<'
M_P`+?\0?]$K\>?\`@7HO_P`L*/\`A;_B#_HE?CS_`,"]%_\`EA0!WE%<'_PM
M_P`0?]$K\>?^!>B__+"C_A;_`(@_Z)7X\_\``O1?_EA0!WE%<'_PM_Q!_P!$
MK\>?^!>B_P#RPH_X6_X@_P"B5^//_`O1?_EA0!WE%<'_`,+?\0?]$K\>?^!>
MB_\`RPH_X6_X@_Z)7X\_\"]%_P#EA0!\Q_\`!6K_`)*[^SM_V,6J?^FV2NNT
M_P#X\X_]T?RKR_\`X*:^-M2\4_&?]GV.^\(>(O#:P^(-399=2FL)%F/]G2?*
MOV:YF.1U^8`>]>H:?_QYQ_[H_E7YOQ1_OGR1Q8CXB:O%/`G_`"D8^*G_`&3C
MP;_Z<_%5>UUXIX$_Y2,?%3_LG'@W_P!.?BJO"H_!/T_]N1DMF>UUR/QK_P"1
M#N_]T_RKKJY'XU_\B'=_[I_E65/XD2><_P#!OO\`Z_\`:*_[':T_]-EO7Z,5
M^8?_``0K\;ZGX6U/]H6*Q\'^(_$D<GC.U9IM.FL(TB/]FP#:WVBYA;/?Y01[
MYXK]`/\`A;_B#_HE?CS_`,"]%_\`EA7Z_@?]WAZ(]*.Q;_:(_P"3?_'7_8O7
M_P#Z325\4?\`!-O7KSP_^RKX'FL[B2"1M#LU.T_>'D)U'>OI[X^_%G7KCX$^
M-8W^&/CBW630;Y6EDNM&*Q@V\GS';?DX'7@$^@-?*W_!//\`Y-,\#_\`8$L_
M_1"5\MQ=HJ?S,<1I8^C_`/A:&N?\_P!)_P!\C_"O#_\`@H+\1M9O/@/H*R7C
MLJ_$KP"X&!U7QAHS`_@0#7J%>*?M^?\`)"]!_P"RC^!/_4OT>OC\+)^VAKU7
MYG/&4K[GT7_PM#7/^?Z3_OD?X4V7XHZZ(VQ?R=#_``C_``K!ILW^J;Z&L>9]
MR>>7<^*/B)>3:A_P5@_9XGGDDFFE\9EG=V+,Y-C>9))K]?:_''XLZG-HW_!3
MW]GNZM].O-6FA\7Y2TM&B6:<_8;OA3*Z1Y[_`#.HXZU^J7_"W_$'_1*_'G_@
M7HO_`,L*_3N'?]S1V4?A(_V:/^2=:E_V-?B3_P!/E]7H%?.DW[5GA?\`9$_8
MX\4?$7QI%K%OINCZ[XGNVTVQM?MVJ73IJVHS-;PPQ%A)(J1R,Q#>6B122.Z1
M1O(O6^*OVMETK]H/3_ASH7P_\<>--3DTVQUC5[_1YM)CLO#-G>3S00S7?VN^
M@F8$V\[;;>*9]L384G"GW(J[275V^=K_`"TUU-Y1<8\\MM_N:7YR2]78]>HK
MQ;X1?MQ^'?C'\=-0\#V?A[QAIOE-J::3KM_:VZ:3XE;3+J.SU%;1DF>8&WN)
M%C/VB&$2?,\/FHI<>TT;Q4NCU7Y?H)Z2<7NG9^I\A_\`!;3X6^,?BY^Q='IO
MAOP[XL\<>&[?Q'I]YX]\)^%[XV>M^+/#,;,;_3[1U969Y!L+0HRO-&DD2L&D
M%?//_!$KX&6WP_\`VI_%VL_!GX$_'+]F_P#9WF\,K9ZCX8^)DEU;7&M^)OM*
M.M]:6-U<W$L2I9_NI)Q)LES&H4-"Q/T%_P`%M(Y;;]D'3=2O?CAJOP`\%:+X
MHL+[QGXFT?7+C1]8ET<"59;6PGM[>XE-T\C0LD2QGS?+*$@,:^'O^"<?[*7P
MH_;,_;PT'XH?`W]NO]HGXI:+\,]'FBU>+Q'XUNG\2"Y>\M)HK8VM]IL8ET:9
M(Y!.",/*D(!RIP9?_'DEWE?K9.FE=I;Q_E3VG>2OL&._@Q]%;IJJC=DWM+^9
MK>%H^9^IO[=7_)D7QD_[$?6__2">O5*\K_;J_P"3(OC)_P!B/K?_`*03UZI6
M,?XTO1?G(74****V&%?D3_P<&_&?PW\&?VQ/@_K'Q*TOX<^'_AWI']D7,OB#
MQ#\(K?QE<>+`^LA-1T:.^FMI_P"SA;6`EO1Y:B64L0AW8K]=J*AQ?M(5%]F2
M?76U]-&GU[_@4I+DE!KXE;\4_P`;6[V=TT[-?%O_``3;^,?C+X[V?PR\6>/#
M<'Q#KG@Z^_T^VT8Z1/XCLX=3FBLM0U*R))M4N+18+FV7``>YO`-BXC;[2IBV
M\:3-(L:+)(`&8+\S`9QD^V3^=>??M<?&:Z_9T_99^(WCZQM(;^^\&^&[_6+6
MVE5VCGF@MWDC1@GSE2R@$+\V,XYQ2E:#J5%LVY6T^[HOP2\D>ABL5+&.C3LD
MXQC#R;N]4M6EK9)N326YZ)17Y\^#?VBOBIJGQ&T3X0:A\1_BIX:\6>/->LF-
MWXI\,>&8_$6A:2VG:K>-=V#6*SZ>UO<S:7Y$<=];-<P`7/F[F:$I]1?L)?&#
M7OC)\"+B;Q1=1ZCX@\+^)==\)7NH)"D/]J-IFJ7-BMTR(`B22QP)(ZHJH'=]
MJJNU1O[-Z^7Y:7?R;Y6G9IWTZGE\VBET=OQNU]ZBVNEK/JK]1XA_Y.>\'_\`
M8KZY_P"E>CUWE>+^-_CQX'T']J#P\M]XS\)V;:7H&M6=X)]7MX_LD[76E%8I
M-SC8Y$<A"M@GRVX^4XZS_AJCX8?]%'\!_P#A06G_`,<J"CO**X/_`(:H^&'_
M`$4?P'_X4%I_\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X
M4%I_\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_
MX:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^&'_1
M1_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^&'_11_`?_A06
MG_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^&'_11_`?_A06G_QR@#O*
M*X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H
M^&'_`$4?P'_X4%I_\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?
MP'_X4%I_\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_
M\<H_X:H^&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^
M&'_11_`?_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<H_X:H^&'_11_`?
M_A06G_QR@#O**X/_`(:H^&'_`$4?P'_X4%I_\<K>\$_%+PS\2UN6\-^(M!\0
M+9E1<'3;^*[\C=G;O\MCMSM;&>N#Z4`;U%%%`!1110`4444`>5_MU?\`)D7Q
MD_[$?6__`$@GKU2O*_VZO^3(OC)_V(^M_P#I!/7JE8Q_C2]%^<A=3\K_`/@M
M=JWC*;]M+PU8R-_P4,;X>V_@M)[<?LVV!CMTU1[V<2_;K@<3.88XL1M@Q!5*
MY\YL?9W_``2W_P"3'?!O_)P7WKW_`)+;_P`CQ_Q^3_\`'][?\\O^F/E5^7O_
M``7`_8"^%K_MJ:/IEEX+_9/\(_V]HE[XJO/%'QQ^)'B;0K77;ZZU2>2ZMK!;
M&_AC\R*27SI%8'B\C"!%3!_2+_@C+\,]-^#W_!.3P!X=TFY^#MYI]@VH>5+\
M+=>OM<\*MOU"X<_9+N]FFN),%B)-\C;9?,484`#?`ZX)M[\S_P#2IWUTV=TM
M-4EL7C_]Y2C_`'?N]FK::ZM6;5]V]3ZBKSGQG^R=X#\>Z/XPLM1T>ZV>.M6M
MM=U>>TU6\LKMK^V@M8+>Z@N(94EM9HX[.V"O;O&08MP.YF)]&HI6_KYI_FD_
M5+L)2:V/$?&?_!.CX0_$/P3H7A_6O#>J:E8^'VN#%+-XDU0WU^ESL^U0WUW]
MI^T:A#<>7'YT-W)-'/Y4?F*^Q<>V1QK%&JJJJJC``&`!3J*?,[6%_7ZG!_"#
M_DH/Q4_[&B#_`-,NEUWE<'\(/^2@_%3_`+&B#_TRZ77>4@"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/B?_@K5_R5
MW]G;_L8M4_\`3;)77:?_`,><?^Z/Y5R/_!6K_DKO[.W_`&,6J?\`IMDKKM/_
M`././_='\J_-^*/]\^2.+$?$35XW8?LCW^F?M)ZK\2X/BU\2H[S6X[*SO=&^
MSZ&=,FL;.>[GM[+G3?M"Q(]]=?.LXF82_-*=JE?9**^>A4E&]NIA<*Y'XU_\
MB'=_[I_E775R/QK_`.1#N_\`=/\`*E3^)`><_P#!OO\`Z_\`:*_[':T_]-EO
M7Z,5^<__``;[_P"O_:*_[':T_P#39;U^C%?K^!_W>'HCTH[''?M$?\F_^.O^
MQ>O_`/TFDKX=_P"">?\`R:9X'_[`EG_Z(2ON+]HC_DW_`,=?]B]?_P#I-)7P
M[_P3S_Y-,\#_`/8$L_\`T0E?+<7[4_F88C9'M]>*?M^?\D+T'_LH_@3_`-2_
M1Z]KKYO_`."G?QF\'_"?X(^%X_%7BOPWX9DO_B#X.N;9=5U."S:XBM?%&DW%
MU(@D9=RPPJTLC#(1%+-A037Q^$BW7@EW7YG-'='TA39O]4WT-9/@+X@Z#\5/
M"-EX@\+ZYH_B30=24O::EI=Y'>6=TH8J3'+&61@&5@2">01VK6F_U3?0U@TT
M[,D^(_'/_*5;]G3_`+''_P!L;ROV"K\??'/_`"E6_9T_[''_`-L;ROV"K]/X
M=_W-'=1^$^>O%'PCU+]H#]@GXO\`@31IK&UU?QI_PF^A6,UZ[);13W.HZG#&
MTC(K,$#."Q56(&<`GBN<_:>_8HU?XT_&O1-8L_`/P4NI;>UT^.W^(%\CP>-/
M!LUM,TC26)^QS+<AAM"#[19F/,F3(&`'M'[-'_).M2_[&OQ)_P"GR^KT"O<3
MLT^SO^?SZ]+/S-JGOPY'LN;_`,FY;^OPK>Z/ES]G7]D#Q]\-OV@]/NM?N?![
M>`/`<_B>Y\+RV%W<R:MJ;:WJ*7A%W"\*16PM4\V$&.:?S]ZR$0;?+/U'110M
M(I=NO5^;\PZM]^G1>2\CY#_X++>.OA'\)_@-X`\9?%WXE77PHM?!OQ!TG6_#
MNOPZ#/KBIJD"SN()+6*&4LDMK]K3<0`A97#!E4'X<_X)/?MG?LB_#7]JNUU"
M3]K;4/C-X\U*`^!?`MC_`,*SU+P[:Z!IFHZK',EAD6I-Q(][)&/M%Q-\JGH@
MW,?T3_X*<:]K/AWX`:?/H?[3GA']E&\;6X4;Q?XCTK2]1M;Q/)G)L%CU&6*$
M.Y`D#*V\"!@!@L1\L_\`!,7]ICXC:]_P4AU+X<Z]^VMX-_:S\)M\.YO$4/\`
MPBWA/1+&VTR\748("+BXTYY-CK&P*(96\P32%DC\M&D,#%/$V?>37_@M.=OB
M2;A!Q4FEII:S;E6,THJ7E%/_`,&-1_ENE*2;2;UUW5H_;W[=7_)D7QD_[$?6
M_P#T@GKU2O*_VZO^3(OC)_V(^M_^D$]>J5C'^-+T7YR(ZA1116PPHHHH`*R_
M'/@K2_B3X*UCP[K5JM]HVO64VG7]LS,HG@F0QR)E2",JQ&001G@BM2BIE%23
MB]F.,FG=;GS3+_P3,T?4K;^TM4^)WQ3UCXB6=U83Z1X^N9=)77]"CLEN4M[>
M%8K!+*2()?7ZN+BUF:47LN]G(C,?LWP&^".C?L[?"[3_``IH;7MQ:6<D]U/=
MWLBR7>HW=Q/)<75U,RJJF6:>665]JJ@:0A550%'845IS-WOUU^>U_GU[[N[$
MTFTWT_+HO1:V6R3:5KLP=0\$B_\`B;I'B3[25;2=+OM-%OY>?-^TRV<F_=GC
M;]DQC!SYG48YWJ**D`HHHH`****`"BOC/_@KI\.O^%L>*OV;?#__``@/@'XG
M?;_B/<?\4UXUN/L^AZEM\.:R_P#I#_8[S&S;YB_Z-)ET0?+]]?"?@9X0E^%G
M[7?@/P?-X-\'?#HZ#\=Y9(O"W@S4VOO#.AQS_#Z^E$=F6MK7RWD8O/*@MH5W
MS[@&WEVJE'GDT]/^'BO+^9O2^WGI52/*KK^1S^Y3T_\`)-W;?K;7]0J***DD
M****`"L'XH^"1\2_AEXB\-M<FS7Q!I=SIIN!'YGD>=$T>_;D;L;LXR,XZBMZ
MB@`HHHH`****`"BBO)_V\/$'B#PI^Q+\7-3\)SW%KXET_P`':K<:9/!*8IK>
MX6TE*2(X!*LI`8,`2"`<'I45)\D'+LK_`-;FE&G[2I&'=I?>>L45^-/QX^$*
M?`SX_P#PW\%:+X9^'MOK.D^)-,^*-E>?#[1;G1M'U&6+0/%$]M!+;/<W4<M\
M7TS]Y>QJDEU'-%NC4Q)7U9_P3@\76OQ;_P""AWQ^^(EC<)>:=\1?"GAC6--G
MC<O#<:?'?^(;.RFC)`^26UM8)ACC,Q(SG-=/L7=I]-_)Z:/S;4UVM!M-WL8R
M?+#G?6,9+S4I\OW).,GYR46EN?=5%%%8E!1110`5@Z?X)%A\3=7\2?:2S:MI
M=CIIM_+QY7V:6\DW[L\[OM>,8&/+ZG/&]10`4444`%%%%`!1110!Y7^W5_R9
M%\9/^Q'UO_T@GKU2O*_VZO\`DR+XR?\`8CZW_P"D$]>J5C'^-+T7YR%U/R"_
MX*V^#?B5X\_;T_X3+2OV>_@_KFEZ?X63PRL_QC^%GB#QY:WZ0W]U,+^S?P_;
MZC;V<!67@7;6MR0SF2':(V'WW_P2U;=^PWX+/_&/O)O3_P`62&/`_P#Q^3_\
M>/O_`,]?^FWFUY+\7O\`@MA_PJ+XJ^)/"O\`PR1^VYXH_P"$=U*XTW^U]`^%
MOVW2M4\J1D\^UG^U+YL#[=R/M&Y2#@9KT#_@C_XG\>>-?V$M!UGXD:?\0=)\
M4:MKOB"]:Q\;P7%OKEE:2:U>O9Q3QSDR)LM6A5%R5"!`I*A:Z,+IAG&.JO>_
MJV_Q;;_1*R58R[JJ4M'=*WI%K[DHI?-;ZL^G****D04444`<'\(/^2@_%3_L
M:(/_`$RZ77>5P?P@_P"2@_%3_L:(/_3+I==Y0`45@_$_P6/B)X"U/1'U36M&
MAU*+RIKK2;LV=Z(L@R)'.HWPET#(9(BLJ!RT;QR!77\KOB;'X'A_8!_9I3XF
M_9O^$?7]G^\'@S[8S,W_``F'V'2O[.^Q$]=7\OS_`+(8_P#2,_:/*YWU,97Y
MM'I;;5N\:DM//W.6*ZRDEIUVIT>>VO6WWM*_HKMR?2*;U/UOHK\7?A;^U3XN
MUG_@LE8^`9/@'JNE_%:;Q7I.M:]XVU._TI/$UCH4FFB*YT\PQ74K/HZBUFF\
MU)VC5GMT:V6YFA=_O[]J#3])\?\`[2?[*/CS2?$U]K6DWGC2:+2H[#5!)HL\
M,WAC7I3=HL1V7#R*L0660R!$3]UY?FS&7:-.Z4K[NWX+5=U>\;Z7<6U>-F^>
M,N93=OA@Y?<I.WDVHW\D]5S)Q/J2BBBLR@HHILDJPQL[LJJHRS$X`'J:`'5\
MV_#>3QU!^WY\;-%NO'5SJ<,_@;P]J>@6-W9?\2?PW)-?:_"OEVJ2*\A*V\#3
M.\WF3.IPT48BBB]F_P"%]>!?^AT\)_\`@WM__BZH0?%#X8VOB>ZUN+Q%X$CU
MJ^MH;*YOUO[1;JX@A:5XHGDW;FC1IIF522%,LA`!8YE5(=7T:W[_`-;[E<Z]
MG*/5\MOE*+_%)JWGJ?F7^UEXB_:,@_8J\'V_@_XR>&=2NKOXVZEX+F3QCJ^L
M:'K_`(FN)_&%]I%H%U'1;VTE6UB%Q;/):VL$>R*U9E/EIY!^K?B-\3]4US_@
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M_AKPCJGPX\+>'-)0Q6.E:1<V5C96:%BQ6.&(JB`LS'"@<DGO73Z%\6O"OBC5
M(['3/$WA_4;V;/EV]KJ,,TKX!)PJL2<`$\=A5RJ1=DG?1+U:23>[>KUU;>NK
M;U>4-+^K=NR;;2Z;+31)::)+1=!11106%%%%`!1110`4444`%%%%`'Q/_P`%
M:O\`DKO[.W_8Q:I_Z;9*Z[3_`/CSC_W1_*N1_P""M7_)7?V=O^QBU3_TVR5U
MVG_\><?^Z/Y5^;\4?[Y\D<6(^(FHHHKYLP"N1^-?_(AW?^Z?Y5UU<C\:_P#D
M0[O_`'3_`"JJ?Q(#SG_@WW_U_P"T5_V.UI_Z;+>OT8K\Y_\`@WW_`-?^T5_V
M.UI_Z;+>OT8K]?P/^[P]$>E'8X[]HC_DW_QU_P!B]?\`_I-)7P[_`,$\_P#D
MTSP/_P!@2S_]$)7W%^T1_P`F_P#CK_L7K_\`])I*^'?^">?_`":9X'_[`EG_
M`.B$KY;B_:G\S#$;(]OHHHKX<Y`ILW^J;Z&G4V;_`%3?0T`?$?CG_E*M^SI_
MV./_`+8WE?L%7X^^.?\`E*M^SI_V./\`[8WE?L%7ZAP[_N:.ZC\)Y_\`LT?\
MDZU+_L:_$G_I\OJ]`KS_`/9H_P"2=:E_V-?B3_T^7U>@5[AL%%%%`'RA_P`%
M+_VG?@AX)TFU\"?$KX1^(/VB_$)@3Q)9_#SP]\/#XVU%8%E^RC4&MWC-O;HK
M22*)9Y(BV)5CWL&6N(_X)O?M5?LZ_P#"PCX9\&_LV^+OV4/&7C9Y(+'2_%7P
MD3P1-XO6TB,[^1/;H;>X,2/(WE--YH`D81[06KK/^"T'_)JVD_\`)W7_`",E
MO_R;I_R-7_'O<_Z[_IQ_O_\`33R*\/\`^"!^LZ[J'Q8^.EK<ZE^V'=>'=/@T
M!;&T_:)UA9/$-C<.M\T_DV62T,#KY)$W"RD%0"86)>$U]I?I\NUOP:3O>^NU
MTD8K2,&NMK+?JU\];RTM9;[-O[6_;J_Y,B^,G_8CZW_Z03UZI7E?[=7_`"9%
M\9/^Q'UO_P!()Z]4K"/\:7HOSD+J%%%%;#"BBB@`HHHH`****`"BBB@`HHHH
M`****`..^-7[/'P__:3\-6^B_$;P+X.\?:/:7(O(+#Q'HMMJMM#.%91*L<Z.
MJN%=AN`SAB,X)KFM0_80^!^K?"6Q\`W7P9^%-UX$TN\;4;+PY+X2L'TFTNFW
M;IX[4Q>4DIWOEU4,=[<\FO5J*5EKY_U^B^X?,]/+^OU?WG*_!SX$^!_V=O"'
M_"/_``_\&^%?`N@&=[HZ;X>TFWTNS,S@!I/*@14WL%4%L9.T>E=5115.3>Y*
M26P4444AA1110`4444`%%%%`!01N&#R#U%%%#UT8'GOPZ_9'^%/P@TNVL?"7
MPQ^'OA>RL]2EUFWM](\.6=C%!?2P-;272+%&H6=X&:)I`-S1L4)*DBNA\%?"
M/PI\-I(W\.^&/#V@/'IUKHZ-ING0VI2QM?,^S6H\M1B&'S9?+C^ZGF/M`W'/
M0T4^9_E^&B^[H#=]_P"M;_GKZZA1112`****`"BBB@`HHHH`****`"BBB@#R
MO]NK_DR+XR?]B/K?_I!/7JE>5_MU?\F1?&3_`+$?6_\`T@GKU2L8_P`:7HOS
MD+J?DI_P6O\`V6I/VJ/^"B_AG3C^ROK_`.U='H_PZ2Y71KCXF?\`""Z7X=+Z
ME.IN;:;SD^TSRX"3IM^18[0[OFP/NG_@EO\`![_A0G[#O@WPK_PIO_A0/]F-
M>G_A!?\`A+/^$J_L7S+R>3/]H[F\[S=_G?>.SS=G\.*^)/\`@J[^P#XW_:7_
M`&AO^$D\;?L0^!?VL!;K-IWAW7]`^,U[X#NM(T=)/.@M+^QGD$3W`DGN/W\$
MKK(!DI#\L=?7?_!*7X#>-?V;?V>[?PGK'PQ\!_!3P-I\4<GA?P+HGB:^\5:E
MH33-+<7HO]4N-J32-<3';'"C)&%;$TH90F^#]W".'FWVWE.6VCNN9+:7E)1M
M>L;[V(4EK;E_""B[;K5JZUCINN:Z?U%103@5\R_\/%+K4_`7Q,U+3_AQK5OK
M'@[QOIO@70-)UJ^73IO$5SJ,&F26=S-A)'L8'.I(S*Z23QPQEFA$N;=5'WI<
MJW_SDHKYN4DDMW?U'RNU^GY:-W?9)+5[+J?35%?'_BO_`(*=>)](\"6LVF_"
MBUU7Q?HMIXCU/QEHG_"5>3#HEIH-U';7IL[C[(QO)I7EC:UCDBMEE0DR26Y&
MT_6VA:U;^(]$L]0LY!+:7\"7$#C^-'4,I_$$4TKQYUJN_D[V?H[.SV=G;9DR
MTERO?5?-6NO)JZNM]4^J.-^$'_)0?BI_V-$'_IETNI/CC^TKX#_9KTJPOO'G
MBC2_#%KJDS6]H]XY7[1(J[F50`2<#D^E1_"#_DH/Q4_[&B#_`-,NEU^?7_!S
MG.]M\*/@[)&VUT\1W1!]/]&%<>.Q$J&'E5CND3*5E<^P?^'J'[//_15O"_\`
MWW)_\11_P]0_9Y_Z*MX7_P"^Y/\`XBOP]\._%/PO_9$*ZAX5M)+Q5Q(\7"R'
MUQGC/I5[_A:7@K_H4XOS_P#KU\5_K?B?Y(_C_F<OUB78_43P#_P4F^!5G_P4
MC^+&N2?$SPXFDZA\-?!=C;7)=]DT\&J>+'FC'R]46X@)_P"NBU[A_P`/4/V>
M?^BK>%_^^Y/_`(BOP2T#XC^$4_:5\6S-X8C:WD\,Z(B19^XZW6KEFZ]PR#_@
M-=S_`,+2\%?]"G%^?_UZTJ\68B+LH1V3Z]4GW&\1)'[:?\/4/V>?^BK>%_\`
MON3_`.(KU+X*?'OP?^T;X/D\0>!_$%CXET6.ZDLFO+,EHA-'C>F2!RNX`^AX
MZ@U_.3\;?B_H=OX%NHM!\.6MA?3H5%TWS-`,<E1_>]ST^O3]4_\`@V`=I/\`
M@EW`S$LS>+]8))[_`+U:]G),XK8V4E4BDEVN:TJKD]3]$:X[]HC_`)-_\=?]
MB]?_`/I-)78UQW[1'_)O_CK_`+%Z_P#_`$FDKZ&?PLV/YLOV>=4\,WGAF.'Q
M/97$S*H\JYA?G&/NL._L1_\`7KT;R/A;_P`^^H?G_P#6KP[X8_\`(LP?0?R%
M=+7XS6BN=GEFI^T+#\-QX"T_[';WPF_X2;0-VX_\L_[9LO,[?W-U=QY'PM_Y
M]]0_/_ZU?/7QMDU>_P!+L[#2_#>K:P5U'3[]YK::TCC1;>]AG=#YTR-O*1'&
M%*Y(R1SCM;.=KFTBDDADMWD0,T4A4O$2,E3M)7(Z'!(]">M7*-J,?5]?)%=#
MTZ<?"RW@:3[+J3;03@'DUV'_``0V\6+XD_X+2>'UM8#8Z9#X:UC[-:[]WECR
MDY8]V/<_EQ7@-Y_QZR?[IKV3_@@%_P`IE/#O_8LZO_Z*CKU^&XKZY%FE'XS^
MB2BBBOTX[@HHHH`****`"BBB@`HHHH`^)_\`@K5_R5W]G;_L8M4_]-LE==I_
M_'G'_NC^5<C_`,%:O^2N_L[?]C%JG_IMDKKM/_X\X_\`='\J_-^*/]\^2.+$
M?$34445\V8!7(_&O_D0[O_=/\JZZN1^-?_(AW?\`NG^553^)`><_\&^_^O\`
MVBO^QVM/_39;U^C%?G/_`,&^_P#K_P!HK_L=K3_TV6]?HQ7Z_@?]WAZ(]*.Q
MQW[1'_)O_CK_`+%Z_P#_`$FDKX=_X)Y_\FF>!_\`L"6?_HA*^XOVB/\`DW_Q
MU_V+U_\`^DTE?#O_``3S_P"33/`__8$L_P#T0E?+<7[4_F88C9'M]%%%?#G(
M%-F_U3?0TZFS?ZIOH:`/B/QS_P`I5OV=/^QQ_P#;&\K]@J_'WQS_`,I5OV=/
M^QQ_]L;ROV"K]0X=_P!S1W4?A//_`-FC_DG6I?\`8U^)/_3Y?5Z!7SSJO[4?
MA7]CC]D?Q?X_\8/J3Z3H?B'Q3<?8],M&O-0U!H]7U*4Q6\"\N_EQR.22$CCC
MDDD9(XW==GXN_MV>&_@[\7])\(W?AWQCJBW4>F3:OK.GVMN^F^%TU.[:RT\W
MA>=)CY]PCH/L\4_EA2\OE1D.?=BG)I+J[?/L;RBXQYGM9OY)I/\`%I?,]MHK
MQ;X1?MQ^'?C'\=-0\#V?A[QAIOE-J::3KM_:VZ:3XE;3+J.SU%;1DF>8&WN)
M%C/VB&$2?,\/FHI<>TTMXJ71ZK\OT$]).+W3L_4_-O\`X+D_M0:]J7BSP_\`
M`GP;H?QZD\5:A#I^NVNJ_"_X@VG@J[>^N[JXL;#3;F]N(I%CM;CRKYVD(VK+
M;6J8+3*5L?\`!!GX<ZU\+_'/QHTGXD>&/COH?QIMUT5M<N/B5\2K7X@2S:4Z
M7C:=';:C:Q0Q*JO]M9H3'O0RJ2S!P%R_^#@'P+^R%X]?PW)\>M3^%>F>/_"N
ME3ZWIZ^*K?7FDU'1Q/'#+:J^CW5O.K27,L0C9ENC&/M+I:RA92N%_P`&^?B;
MX!VE]XMF_9Q^#WA;2]#\37$%GXDUSP5\1]4\1VVE/;1SR6XU*U\0PZ=J%N)#
M+(L+V=I<)*QDWL@BS3R_^'43UE[UVMK<R2[)-6Y'J]5;EN^9F8?8MI'W='WM
M=KJW>_/%65KIW:5E]\_MU?\`)D7QD_[$?6__`$@GKU2O*_VZO^3(OC)_V(^M
M_P#I!/7JE81_C2]%^<A=0HHHK884444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`'E?[=7_`"9%\9/^Q'UO_P!()Z]2FD\J)FZ[03BO+?VZO^3(
MOC)_V(^M_P#I!/7J-P0+>3<-PVG(]:XZTG%U))V:BM>WQ!'XC\8/AC_P4,_;
MA\5V/P=\5>%?%7P]^(5W^UZ=?M/"O@_5M`BTC3?A6]C,62[:^AW3W\*6Z2LZ
M2C>2JA=[':WZI?L;_"/QS\#OV=]"\._$KXAW7Q4\=0/<W6L>)IK%+'[?//<2
M3E8X$)2**(2")%7"A(UPJCY1^3G[+_\`P3L_X)Y?M+:!^SO<:Q^S#KGA_P`3
M?M+6^O7NDVEKXZUN_LM,.E%FN!<7#7T+_.N"FR`\D@[0-Q_7+]EO]ECP'^Q9
M\#M%^&_PST'_`(1KP7X?,YT_3OMMQ>?9_.F>>3][<222MNDD=OF<XW8&``!Z
M7(J<'!JSO9=;*+DK<V[L[IR=W*VKM&*17]ZHG';?M>]_>LKI:62BGRK5K5MO
MT&O`/B)^Q!<>+],^*4FG^+ETG7/'7C/2/'.CWKZ3]HCT"_TVUTJ&W62+SE-U
M$TFEJTBJ\+-'.Z*R,!+7O]%8QTES+?\`R:DOFG%.^^A2DTFN^_FNWH^JZGQ_
MXK_X)B^)]7\"6L.F_%>UTKQ?K5IXCTSQEK?_``BOG0ZW::]=1W-Z+.W^UJ;.
M:)XHUM9));E8D!$D=P3N'U1-X!T6\\%1>';K2[&_T.*WCM?L5W`L\#QQ@!%9
M&!4@;5ZCJ!6Q133M'D6B[>2O9>BN[+97=MV3+67,]]7\W:[\V[*[WT2Z(\-^
M%G[-GPZU'QS\2H;CP#X*GAL?$<,%LDFAVS+;QG2--D*("GRJ7D=L#`W.QZDU
M\%_\'(OPA\)_#;X5_">?P[X7\.Z!-=>(+I)I--TV&U:51;Y`8QJ"0#S@U^E7
MP@_Y*#\5/^QH@_\`3+I=?GO_`,'/7_)(OA!_V,5W_P"DPKS,X_W.IZ&=3X6?
MEW;?ZL?2I*CMO]6/I4E?DIYYR>F?!70](\2?VO#)X@_M`[`TDGB"_E6149F1
M'5IBK(I=R$8%1O;CDUUE%%7.I.;O-M^H7;W.9^*'_(O2?[I_E7ZW?\&U7P,\
M$^/O^":$.H:[X.\*ZUJ#>+-70W-_I,%S,5$JX&]T)P.PSQ7Y(_%#_D7I/]T_
MRK]F/^#7W_E%Q;_]C=K'_HU:^QX2^*7H=.'W/M;_`(97^&'_`$3CP'_X3]I_
M\;KD?C[^S%\-;#X$^-9X/A[X'AFAT&^DCDCT&U5HV%O(000F00><BO:JX[]H
MC_DW_P`=?]B]?_\`I-)7VT_A9UG\P_PQ_P"19@^@_D*Z6N:^&/\`R+,'T'\A
M72U^,UOC9Y84445F!'>?\>LG^Z:]0_X(7>"]'\??\%?/#^GZ[I.F:UI[>&]6
MD-M?VJ7,)81)@['!&1V.*\OO/^/63_=->R?\$`O^4RGAW_L6=7_]%1U]!PW_
M`+XC:C\9^]'_``RO\,/^B<>`_P#PG[3_`.-T?\,K_##_`*)QX#_\)^T_^-UW
ME%?IAW'!_P##*_PP_P"B<>`__"?M/_C='_#*_P`,/^B<>`__``G[3_XW7>44
M`<'_`,,K_##_`*)QX#_\)^T_^-T?\,K_``P_Z)QX#_\`"?M/_C==Y10!P?\`
MPRO\,/\`HG'@/_PG[3_XW1_PRO\`##_HG'@/_P`)^T_^-UWE%`'!_P##*_PP
M_P"B<>`__"?M/_C='_#*_P`,/^B<>`__``G[3_XW7>44`?`O_!37X0^$_AM\
M9_V?9_#OA?P[H$UUX@U-)I--TV&U:51ITA`8QJ"0#S@UZAI__'G'_NC^5<C_
M`,%:O^2N_L[?]C%JG_IMDKKM/_X\X_\`='\J_-^*/]\^2.+$?$34445\V8!7
M(_&O_D0[O_=/\JZZN1^-?_(AW?\`NG^553^)`>*_\$*_@]X1^)&I_M"W'B+P
MMX<UZXM_&=K'%+J.FPW3Q+_9L!VJ9%)`SS@5^@'_``RO\,/^B<>`_P#PG[3_
M`.-U\1_\&^_^O_:*_P"QVM/_`$V6]?HQ7Z_@?]WAZ(]*.QXK\??V8OAK8?`G
MQK/!\/?`\,T.@WTD<D>@VJM&PMY"""$R"#SD5\K?\$\_^33/`_\`V!+/_P!$
M)7W%^T1_R;_XZ_[%Z_\`_2:2OAW_`()Y_P#)IG@?_L"6?_HA*^6XOVI_,PQ&
MR/;Z***^'.0*;-_JF^AIU-F_U3?0T`?"_P`6?#NG^+?^"GO[/>FZK8V>IZ?=
M>+]D]K=PK-#,/L-V<,C`JPR`>1VK]4O^&5_AA_T3CP'_`.$_:?\`QNORY\<_
M\I5OV=/^QQ_]L;ROV"K]0X=_W-'=1^$^==8^"=W\:O\`@GU\6/ASX<_LO3;[
MQ7'XU\.Z9]HS#9VLEQJ&IP1;_+5BL2EUSM0D*.%/2N?_`&AOV-_B!\0OC1=3
M>';KP<O@GQY:>&K/Q;+J%W<Q:EIBZ+J,MYFSA2%X[G[5'*8#YDMOY!02#SL^
M6/:OV:/^2=:E_P!C7XD_]/E]7H%>ZG9KUO;H[='Y&\GS147TO;NK\MVO_`5\
MKKJ?+G[.O[('C[X;?M!Z?=:_<^#V\`>`Y_$]SX7EL+NYDU;4VUO44O"+N%X4
MBMA:IYL(,<T_G[UD(@V^6?J.BBDM(I=NO5^;\Q=6^_3HO)>1\&_\%8O^";U]
M\</BCX?^.F@_M':;^SC>>`;2S;5-;UGPSIVLZ;&+&YGFL;GS+R6%;1HGO;M'
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M];_]()Z]4K&/\:7HOSD+J%%%%;#"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`\K_;J_Y,B^,G_8CZW_`.D$]>I2H)(F5N%8$&O+?VZO^3(O
MC)_V(^M_^D$]>INGF(RGHPP:Y9QYISC:_NK3_P`"!;G\\GC'X&_LK_"?PYI7
MB3P+\8/^"EGC;3?A_P".;[X>>#I/`&M6<BPW\EG)=ZA_8BO!"1;A8I8YF@V[
MBF=KQE9&_9W_`()<:MX3\1_L%_#G5O`_Q$^(GQ4\+:U8/J-CXC\=ZL-4\170
MFFDD:*\G"J#)`[-!MQ\@A"Y.W)^&_A%^SW^UC_P3Q\`P_`SP3^R_\,?CQX7\
M'>(=3U;X9?$O4O&-CIJ>$5OYKAXY;NQN4:Z:XMS<S>:]HR&2%_+1B<L?N3_@
MES^QA<?\$^OV#_A[\)K[5+;6M6\,VDTFIWML&%O/>W-Q+=7'E;@&\H2S.J%@
M"5`)`)P.ZC*]"5WI[EKZ/X7SW6Z?-=OIK9.6X8K6O=='/T:YGRN^U^5I6ZWD
MVHV2?O\`11168!1110!P?P@_Y*#\5/\`L:(/_3+I=?GO_P`'/7_)(OA!_P!C
M%=_^DPK]"/A!_P`E!^*G_8T0?^F72Z_/?_@YZ_Y)%\(/^QBN_P#TF%>;G'^Y
MU/0SJ?"S\N[;_5CZ5)4=M_JQ]*DK\E//"BBB@#F?BA_R+TG^Z?Y5^S'_``:^
M_P#*+BW_`.QNUC_T:M?C/\4/^1>D_P!T_P`J_9C_`(-??^47%O\`]C=K'_HU
M:^TX2^*7H=.'W/T2KCOVB/\`DW_QU_V+U_\`^DTE=C7'?M$?\F_^.O\`L7K_
M`/\`2:2OMI_"SK/YA_AC_P`BS!]!_(5TM<U\,?\`D68/H/Y"NEK\9K?&SRPH
MHHK,".\_X]9/]TU[)_P0"_Y3*>'?^Q9U?_T5'7C=Y_QZR?[IKV3_`((!?\IE
M/#O_`&+.K_\`HJ.OH.&_]\1M1^,_HDHHHK],.X****`"BBB@`HHHH`****`/
MB?\`X*U?\E=_9V_[&+5/_3;)77:?_P`><?\`NC^5<C_P5J_Y*[^SM_V,6J?^
MFV2NNT__`(\X_P#='\J_-^*/]\^2.+$?$34445\V8!7(_&O_`)$.[_W3_*NN
MKD?C7_R(=W_NG^553^)`><_\&^_^O_:*_P"QVM/_`$V6]?HQ7YS_`/!OO_K_
M`-HK_L=K3_TV6]?HQ7Z_@?\`=X>B/2CL<=^T1_R;_P".O^Q>O_\`TFDKX=_X
M)Y_\FF>!_P#L"6?_`*(2ON+]HC_DW_QU_P!B]?\`_I-)7P[_`,$\_P#DTSP/
M_P!@2S_]$)7RW%^U/YF&(V1[?1117PYR!39O]4WT-.ILW^J;Z&@#XC\<_P#*
M5;]G3_L<?_;&\K]@J_'WQS_RE6_9T_[''_VQO*_8*OU#AW_<T=U'X3S_`/9H
M_P"2=:E_V-?B3_T^7U>@5Y_^S1_R3K4O^QK\2?\`I\OJ]`KW#8****`/G7_@
MI5^U;XR_99^$7A5?AWIW@V\\>?$;Q99>#-`N/%][-::!IUW<QS2)->-"/-:,
M^08UCCP[RRQ*#DX/S1_P05_:KN?VP_B!\8_&WBS0_AE_PM#Q!IWAC5/$7B'X
M>Z]J-_HEY#+:W*VFG36UU-*MEJ-DL4BSQ1'!,R%LD9/??\%_/VE+K]F?]CGP
MQ?0_$CP[\);/7O'6E:;>^*M6\&_\)=_9$:">\CF@T]HY(Y)DGM(6#.OR*KNG
M[U8Z\^_X-X/VSM%_:N\&>-;?P1HOA/2?`^C:7H%Y>1>&O",?AW3;'Q-/;SQZ
MQ;0QQPQ"5";6UN@[>8X^W;3)M5$C>!]Y8B3U<6EZ*T']UWJW:[:CKH5C/=C3
M6W,D_7WY+YO16BKJ*BYNS/M#]NK_`),B^,G_`&(^M_\`I!/7JE>5_MU?\F1?
M&3_L1];_`/2">O5*PC_&EZ+\Y$=0HHHK884444`%%%%`!1110`4444`%%%%`
M!1110`5X-_P4'_X*">&_^"<_PK\.^*?$GA/X@^-O^$J\1VWA;2]'\&:7%J6K
M7E[<1S21*D$DT6_(@9<*2Q9E`4Y)'O-?"W_!>#]FGQ)^U;\+_@'X5\-K\0;7
M=\:-!N-4UCP8)4U;PU9""]2744GC1_LWDEU/GLNU&*D]JF7,Y0C'[4H+Y.23
M_!O7IN:4^6TY3Z1F_FHMK\4M.NQVO[*?_!9;X5?M*?\`"?6_B#2?'GP%U;X9
MV]K?Z_I?Q<TJ+PK=6=E<G;!>'S)FC$#O\@9G4[BO&&4M[%_PW-\$_P#A7.K^
M,/\`A</PM_X1'P_J`TG5-;_X2NP_LW3;TXQ;3W'F^7'-\R_NW8-\PXYK\_OV
M^O\`@C7IW[-__!+W]I:3P+J7QP^//Q<^)FCZ?83ZMXMU6;Q5XFOK:WO+=HK*
M`11*QB3]X^U8RW)RQ55"YO\`P4&_8#\._LV^)/V6?%>@_LP3_%+X!_#.'5%\
M8_#?P9X7M]0O)=2O;&VM[;4Y-*;:-0E5HMLCR[G&-[MQFJYDW9Z?"KZVN[OU
MV2CVYY;J*N9\LDK[WYG;2]HJ'RWDWWY(Z)RT/N7]IG_@J+\"OV3_`()>&/B%
MXI^(WAF7POXVO8+'P[=Z;J5O=QZXTDJQF6WD63RWABW;Y9MXCC0$LPX![KQK
M^V'\(_AK?^%[7Q'\4OASX?NO'$<<WAR'4O$ME:R>($D*"-[-9)`;A6,B!3'N
M!+KC.17XO_%O_@G_`.)=>_X)R^-O&UK^S#XFT_PSJ'Q^T_Q]X0^%H\,Q7_B3
M0/#+/:QWT<>FKN-J;KRB9+)"%1<!AY:AJ\\_X*4_L3?%#Q9^V[XX\51_#7XO
M)\.?BYX>T)_"-KX?_9OT3XB7'AW3UTR.W;39?MUQ#)H$]L^Y?*@9>3O##RU-
M3&4KVY7?F2MVO3A/E>_O<TI1NDU[DKI,-.^EGKWM4E'F7ERJ,K-W]Z-FU=K]
MW_$?[4_AGP?^T!<_#[5I[/3;NQ\)R^,KK4;K7-*@@M+&.<PNTEL]V+Y44@L;
M@VOV8`$&</\`)4WPR_:_^$OQK\;R>&?!OQ1^'?B[Q)#I\>K2:5HOB2SO[Y+.
M18GCN3#%(SB%EFA82$;2)8R#AES^9NM?L=_$[P'^TZ+&X\/?$+Q5;Z/^Q+>>
M"&U^ZT-RVH:PMR0MC(\$EQ`;YE`)@CN)F/56D&&*_L6_\$XX/V:?CG_P3E\3
M>%O@W?>$=8M_`6MI\2]6M/#<EG<0WLVBVK(FL2K&I68W,DZ(+DAMVY!TP.FG
M3BZG+>\5=7[^]72=NUJ4?_`UONYJ-J"E%:M)VZ*T*4FO6\Y)><;:=/TK\1_M
M3^&?!_[0%S\/M6GL]-N['PG+XRNM1NM<TJ""TL8YS"[26SW8OE12"QN#:_9@
M`09P_P`E3?#+]K_X2_&OQO)X9\&_%'X=^+O$D.GQZM)I6B^)+._ODLY%B>.Y
M,,4C.(66:%A(1M(EC(.&7/PS^W5\"?''B[_@JQ\3/$6D^#?%6J>'[_\`9-US
MPY:ZG::3<36=SJDFI2O'8),J%&NF4AEA!+D$$+BO-/V+?^"<<'[-/QS_`."<
MOB;PM\&[[PCK%OX"UM/B7JUIX;DL[B&]FT6U9$UB58U*S&YDG1!<D-NW(.F!
MEA8^TMSZ*S];\U=+Y6I1_P#`E\],5'D=J>KW\K*%*3^;YY)><;:=/T7F_;1\
M+P?MUP_L]M8:_P#\)I/X(;QZMZ((?[+%B+W[$8S)YOF^?YASM\K9MYWY^6L7
MX;?\%(?A7X[M_B%<:IKUMX#L?AOX\G^'-]>^++VSTNVO]6BCBDVVTC3$2*XF
M`0-MD8JWR#&3\O?MZ:SXX_8J_P""O7@[]I"U^#?Q6^,7P^U7X77'PZOK?X=:
M,NM:QI-]_:1OXY7M-ZL871=OF955/5MQ56^7/'_[&/Q*_:._89NM4\7?!WQI
M:VWQT_:RLO'USX.N])FDU72_#4[QV[/J,$6Y[;$,3&7>5$8?D@$&IH7J<B[^
MZ[Z6D\1&$?\`RDW+S2YMBL1R0<K=+->:5&4Y?^5$H^3=MS]4/!G_``4(^%?Q
M'^)(T3PYXP\(^(-&_P"$5N/%[>)M-\7:)=:4EE!<M;3$JEZ;O;&ZMOG^S_9E
MVE6F$@V5U'PR_:_^$OQK\;R>&?!OQ1^'?B[Q)#I\>K2:5HOB2SO[Y+.18GCN
M3#%(SB%EFA82$;2)8R#AES^?G[3_`.QQJ/@7_@I#X^C^''PKO='^'<?[)>O>
M&=)7PWX9:WT5-3FU2:9=/@$$8A%S)O,@A3YVW%MISFN%_9-_X)KM^SS\5/\`
M@GGKW@KX17W@?Q'_`,*ZU^#XB:Y:>&Y+.XL]0GT.V,7]L2K&"LWVJ2=4%R0^
MX,B],!TVI1YK.UGZM\U>WEM2C_X&M]V5:;C+E35W]R2A2D_._OR]7&VG3]1=
M`_:E^&/BOXR:A\.=+^(W@/4OB%I*-)?>&+77[2;6;)5"EFEM%D,R`!T)+(,!
ME]17>5_-S_P3^_X)H_&[PG^U]\*_!_C+P_\`&CPUXL\!>.H]:U#Q#8?L]:`-
M)G:WO'GDD?QK]O@O;NVGB+[BWF%O,\L0RE50_P!(U5&*]C&I?5W^ZRU]&VU;
M7;?6RQE)JM*G;1?YO3Y63OY^5V4445!04444`%%%%`!1110`4444`%%%%`'E
M?[=7_)D7QD_[$?6__2">O5*\K_;J_P"3(OC)_P!B/K?_`*03UZI6,?XTO1?G
M(74_)?\`X*J_$7]H;X3?\%$M'\2-H'[7'B;X::+J.CW7A33/@K:?;=$O]-`7
M^VXM;@A*S/>F3;]F$S"$ITQ^]K[P_P""96G_`!.TK]AOP#;_`!@DUB3QU%:S
M"X.LSQSZL+3[1+]A6_DC`1[T6?V<3LO64.3DY->\45M1_=T72WN[W_K[_5M]
M158\]55=K)+[OZU]%V"BBL?X@_$7P_\`"7P9J'B3Q5KNC^&?#NDQ>??:IJU[
M'965E'D#?+-(RHBY(&6(&2*4I)*[+2;=D;%%>:K^V;\'W\!>&_%2_%;X:GPO
MXRO_`.RM`U@>)[+[!KEYO9/LUK/YOESS;T=?+C9FRC#&0:]*JG%K1^GS_IBN
MOZ_KR9P?P@_Y*#\5/^QH@_\`3+I=?GO_`,'/7_)(OA!_V,5W_P"DPK]"/A!_
MR4'XJ?\`8T0?^F72Z_/?_@YZ_P"21?"#_L8KO_TF%>9G'^YU/0SJ?"S\N[;_
M`%8^E25';?ZL?2I*_)3SPHHHH`YGXH?\B])_NG^5?LQ_P:^_\HN+?_L;M8_]
M&K7XS_%#_D7I/]T_RK]F/^#7W_E%Q;_]C=K'_HU:^TX2^*7H=.'W/T2KCOVB
M/^3?_'7_`&+U_P#^DTE=C7'?M$?\F_\`CK_L7K__`-)I*^VG\+.L_F'^&/\`
MR+,'T'\A72US7PQ_Y%F#Z#^0KI:_&:WQL\L****S`CO/^/63_=->R?\`!`+_
M`)3*>'?^Q9U?_P!%1UXW>?\`'K)_NFO9/^"`7_*93P[_`-BSJ_\`Z*CKZ#AO
M_?$;4?C/Z)****_3#N"BBB@`HHHH`****`"BBB@#XG_X*U?\E=_9V_[&+5/_
M`$VR5UVG_P#'G'_NC^5<C_P5J_Y*[^SM_P!C%JG_`*;9*Z[3_P#CSC_W1_*O
MS?BC_?/DCBQ'Q$U%%%?-F`5R/QK_`.1#N_\`=/\`*NNKD?C7_P`B'=_[I_E5
M4_B0'G/_``;[_P"O_:*_[':T_P#39;U^C%?G/_P;[_Z_]HK_`+':T_\`39;U
M^C%?K^!_W>'HCTH[''?M$?\`)O\`XZ_[%Z__`/2:2OAW_@GG_P`FF>!_^P)9
M_P#HA*^XOVB/^3?_`!U_V+U__P"DTE?#O_!//_DTSP/_`-@2S_\`1"5\MQ?M
M3^9AB-D>WT445\.<@4V;_5-]#3J;-_JF^AH`^(_'/_*5;]G3_L<?_;&\K]@J
M_'WQS_RE6_9T_P"QQ_\`;&\K]@J_4.'?]S1W4?A//_V:/^2=:E_V-?B3_P!/
ME]7H%?.\?[2=O^SE\)--*^%_$WC;7/%_Q#\1:'HV@Z`]@E_J%Q_:FJW+[3>W
M-M`%2&VF=BTJX"<9)`J]X[_;]T7X:?$#PYX<UKP/\0+6\U*TTFZUZ=(+">V\
M#G5+IK.QBU%X[MMSRW221$V0NDC\LO(R1%9&]R/O.R[V^;5_ZZ=-S:2<5=]K
M_*]K_?HN_0]ZHHHH`^-_^"WCZY_PRGX?CT6^_:@LHY/%UG_:7_"@]*-]XMN+
M007+/&&$L9M[<L$W3?.`PC4HP<X^./\`@D=\+)-`_P""A?\`PG<<O_!3Z-=;
MMK;P])!\:=#C32[E4M-3G\S4KMG<S6L9`6`(D307$ZC?(+E@OU/_`,'!%KX#
MO/V*]#7XB?"?PC\8M#_X2VU,6B>(_BQ;_#6U@G^RW>VX749YHDD=5WJ+<,2P
MD9L'RR1\[_\`!N6OPI^&OQ5^+<_A/PG\%_@G;>/&T73-'\&Z%\<;+XC:IJ%U
M:PZC/-+YT-S*%1HF9DBQYG^CW+'**NVLOTE6?;]5!=;=--+[WWO:L=_!@NZ_
M*;=]+[;W=GI;:U_T<_;J_P"3(OC)_P!B/K?_`*03UZI7E?[=7_)D7QD_[$?6
M_P#T@GKU2N>/\:7HOSD1U"BBBMAA1110`5^6/QD_:?\`B=\'M$\<?&35G\6Z
M'<:GJGCGPOX8OK;QW<W=DUUI\>K_`&&*X\,S6[:=#;0P:89?MD4RW4DT(\Q?
M*FD6OU.KR=_V'_AC<?%'6/%UUX=N-0U#7A<?:["^U>]O-#,EQ#Y%Q/'I4LS6
M$,\T1=))XX%ED6:8,S"63=/+[UVKJS6]M[:>5U=<RU7:2;1K"<4K/NG]R>]]
MU=IV:L[='9KY-^)FN>(OV<O''CKX0^&_&WQ`O/"^L6?P]D;5=4\3WNK:OHKZ
MYXAN=*U(Q:A=327$/GVT">6$D7R)'+PA":^A/V$]6U#0_&OQN^'TFL:YKWA_
MX9^,X=+T&[UG5+G5K^*UN-&TW4'MI;RY>2>X,<]W-AYI'<(R*3A5%=!X1_X)
M]_"7P7\(?$G@6W\-WU]X?\70Q6^J?VOKVHZM?3Q0J%MHTO;J>2ZB6WP#`L<J
MBW;YHO+;YJ[CX*?`OPS^SWX-;0_"UG>6]G-=27US/?ZE=:I?ZA<28WSW-W=2
M2W%Q*0JKOFD=MJ(N=JJ!T1FDYWUNG9^K@TK;)149)6Z2>VM\+.R^77M&SE?=
MN;UDGIZM7([GXO2Z9\0=-T&_\*^(]/AUF]EL+'5)7LGL[F5+>:XX$=PTRAHX
M)""T0Y`!P3795P?Q?_Y*#\*_^QHG_P#3+JE=Y6)04444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`>5_MU?\F1?&3_L1];_]()Z]4KRO]NK_`),B^,G_`&(^M_\`I!/7JE8Q
M_C2]%^<A=0HHHK885XK_`,%`/!ECXZ_9KO+74I_B1:6-IJVEZE)<^!=,CU36
M;1K:_@N(YDM'AG-S'')&CR1)!,[HC`12?=/M5%3)-V:W337JG==NJZ-/S149
M6_'\=#\V?CK%XX\5>!H]8\6>#_B=\5--\1^`?&G@+PQ>7/@N5=<OIM0?3FL'
MU.R@LX/[.-PL$T;336UM!$MNAE,1=2WZ":1X7U/_`(5?IVD3ZS>V.K0V$%O/
MJ5HD+3"5$4.ZB5)(_F(/WD88)[X-=%16D9<L%372R^YRE=]+MSDVTDGHK*R,
MY*[3?2[Z_:Y5I>^B4(I+?=MMNYX;\+/A9KESXY^)2)\2O&MNUOXCACDDCM=(
M+73?V1IK;WW6)`8!@GR!5VQKQNW,WP7_`,'(O@K4O"OPK^$\E]XO\1>)%F\0
M72K%J4-A&L)^S_>7[-;0G)Z?,2/:OTJ^$'_)0?BI_P!C1!_Z9=+K\]_^#GK_
M`))%\(/^QBN__285Y><?[G4]":GPL_+NV_U8^E25';?ZL?2I*_)3SPHHHH`Y
MGXH?\B])_NG^5?K=_P`&U7P^U;Q'_P`$T(;JS\=>*M`A;Q9JZBTL+?37A!$J
MY;,]I*^3W^?'H!7Y(_%#_D7I/]T_RK]F/^#7W_E%Q;_]C=K'_HU:^TX2^*7H
M=.'W/M;_`(5!X@_Z*IX\_P#`31?_`)7UR/Q]^$VO6_P)\:R/\3O'%PL>@WS-
M%):Z,%D`MY/E.VP!P>G!!]"*]JKCOVB/^3?_`!U_V+U__P"DTE?;3^%G6?S#
M_#'_`)%F#Z#^0KI:YKX8_P#(LP?0?R%=+7XS6^-GEA11168$=Y_QZR?[IKU#
M_@A=H-UXC_X*^>'[6SUK4]`F/AO5F%W81V[S`"),KB>*5,'O\F?0BO+[S_CU
MD_W37LG_``0"_P"4RGAW_L6=7_\`14=?0<-_[XC:C\9^]'_"H/$'_15/'G_@
M)HO_`,KZ/^%0>(/^BJ>//_`31?\`Y7UWE%?IAW'!_P#"H/$'_15/'G_@)HO_
M`,KZ/^%0>(/^BJ>//_`31?\`Y7UWE%`'!_\`"H/$'_15/'G_`(":+_\`*^C_
M`(5!X@_Z*IX\_P#`31?_`)7UWE%`'!_\*@\0?]%4\>?^`FB__*^C_A4'B#_H
MJGCS_P`!-%_^5]=Y10!P?_"H/$'_`$53QY_X":+_`/*^C_A4'B#_`**IX\_\
M!-%_^5]=Y10!\"_\%-?!6I>%?C/^S[)?>+_$7B19O$&IJL6I0V$:PG^SI/F7
M[-;0G)Z?,2/:O4-/_P"/./\`W1_*N1_X*U?\E=_9V_[&+5/_`$VR5UVG_P#'
MG'_NC^5?F_%'^^?)'%B/B)J***^;,`KD?C7_`,B'=_[I_E775R/QK_Y$.[_W
M3_*JI_$@/%?^"%?@C4_%.I_M"RV/C#Q'X;CC\9VJM#IT-A(DI_LV`[F^T6TS
M9[?*0/;/-?H!_P`*@\0?]%4\>?\`@)HO_P`KZ^(_^#??_7_M%?\`8[6G_ILM
MZ_1BOU_`_P"[P]$>E'8\5^/OPFUZW^!/C61_B=XXN%CT&^9HI+71@L@%O)\I
MVV`.#TX(/H17RM_P3S_Y-,\#_P#8$L__`$0E?<7[1'_)O_CK_L7K_P#])I*^
M'?\`@GG_`,FF>!_^P)9_^B$KY;B_:G\S#$;(]OHHHKX<Y`ILW^J;Z&G4V;_5
M-]#0!\+_`!9TR;6?^"GO[/=K;ZC>:3--XOPEY:+$TT!^PW?*B5'CSV^9&'/2
MOU2_X5!X@_Z*IX\_\!-%_P#E?7Y<^.?^4JW[.G_8X_\`MC>5^P5?J'#O^YH[
MJ/PGRAXW_9ZO/CC^S?8Z:GP[^#_QD_LCQSXBFN=&^)D?E6=XO]JZE'YT<\=G
M=)!.&96/^B.KKO0"/(9>2D_X)W_$K0Y-+T'2]6\%WGA'Q-IGAO3O%L]Y=W,-
M[HL>C:I/?)#IT*0-'<QR03BS7S)+;R%@24"4MY2_3G[-'_).M2_[&OQ)_P"G
MR^KT"O<C[KOYIVZ.RM9KJO77I>VAM))_=;TU3NNSTZ:6W04444`?"_\`P<$7
M?@.S_8KT-OB)\6/"/P=T/_A+;41:WXC^$]O\2K6>?[+=[;==.GAE2-V7>PN`
MH*B-ER/,(/SO_P`&Y?ACX<_$#XJ_%O4_#'BOX<_&W0_"+:+/H'C31/@%I?PX
MCTZ_EAU&.ZAC,%M#+)<+#(JL3D+%<C:V)G6OM?\`X*H>%?B1X_\`@?X3\-_#
MW5OB%X?L?$OC32](\8:MX$DBB\2:5HEP9(I+BSD<$Q;+AK4RRHK/'!Y[@84U
MX-_P;X0?'.U^%?BZ+XI/\?)/#<<.E+IK_&,[O$3:T(IAK!MB_P#I!TLO]E^S
M^?\`-_K,?Q56!O\`OWZ+UTAWOHM-5RZZ6T;E6,UITUZ)_.4G;2VNCNG>T7>]
MFDOK[]NK_DR+XR?]B/K?_I!/7JE>5_MU?\F1?&3_`+$?6_\`T@GKU2N>/\:7
MHOSD1U"BBBMAA1110`445\8V'_!773[SXL?%#3]GP<F\-_"=]=;6+*T^)HN/
M'CP:2D@GF3P^+``!IH]B[[U1M97SDA#/,N;EZV<ODK7_`#6F[Z(KDDUS+NE\
MW>R^=F?9U%?+?_#PGQ)X+T+QAI/CCX;Z=HOQ-T&#0;C3/#VD^)FU.PUA=<O'
MT_3LWTEG`T1%Y')'<8MY!"B;T,^0M>I?LP?M"ZA\<+7Q=I?B+0+/PMXV^'^M
M_P!@^(=,LM3;5+**9K6WO(9+:Z>"W>:&2WNH&#/!$P8NI7Y=S:<CNTNF_P""
M>NSMS*]MKJ^Y'-HGW_RNODUJGLULV:WQ?_Y*#\*_^QHG_P#3+JE=Y7!_%_\`
MY*#\*_\`L:)__3+JE=Y4C"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#RO]NK_DR+XR?]
MB/K?_I!/7JE>5_MU?\F1?&3_`+$?6_\`T@GKU2L8_P`:7HOSD+J%%%%;#"BB
MB@`HHHH`X/X0?\E!^*G_`&-$'_IETNOSW_X.>O\`DD7P@_[&*[_])A7Z$?"#
M_DH/Q4_[&B#_`-,NEU^>_P#P<]?\DB^$'_8Q7?\`Z3"O-SC_`'.IZ&=3X6?E
MW;?ZL?2I*CMO]6/I4E?DIYX4444`<S\4/^1>D_W3_*OV8_X-??\`E%Q;_P#8
MW:Q_Z-6OQG^*'_(O2?[I_E7[,?\`!K[_`,HN+?\`[&[6/_1JU]IPE\4O0Z</
MN?HE7'?M$?\`)O\`XZ_[%Z__`/2:2NQKCOVB/^3?_'7_`&+U_P#^DTE?;3^%
MG6?S#_#'_D68/H/Y"NEKFOAC_P`BS!]!_(5TM?C-;XV>6%%%%9@1WG_'K)_N
MFO9/^"`7_*93P[_V+.K_`/HJ.O&[S_CUD_W37LG_``0"_P"4RGAW_L6=7_\`
M14=?0<-_[XC:C\9_1)1117Z8=P4444`%%%%`!1110`4444`?$_\`P5J_Y*[^
MSM_V,6J?^FV2NNT__CSC_P!T?RKD?^"M7_)7?V=O^QBU3_TVR5UVG_\`'G'_
M`+H_E7YOQ1_OGR1Q8CXB:BBBOFS`*Y'XU_\`(AW?^Z?Y5UU<C\:_^1#N_P#=
M/\JJG\2`\Y_X-]_]?^T5_P!CM:?^FRWK]&*_.?\`X-]_]?\`M%?]CM:?^FRW
MK]&*_7\#_N\/1'I1V.._:(_Y-_\`'7_8O7__`*325\._\$\_^33/`_\`V!+/
M_P!$)7W%^T1_R;_XZ_[%Z_\`_2:2OAW_`()Y_P#)IG@?_L"6?_HA*^6XOVI_
M,PQ&R/;Z***^'.0*;-_JF^AIU-F_U3?0T`?$?CG_`)2K?LZ?]CC_`.V-Y7[!
M5^/OCG_E*M^SI_V./_MC>5^P5?J'#O\`N:.ZC\)Y_P#LT?\`).M2_P"QK\2?
M^GR^KT"O/_V:/^2=:E_V-?B3_P!/E]7H%>X;!1110!X#^V#_`,$YO!?[8>J+
MKTWB+XE_#7QY!IHT:W\9?#WQ7=>'=<BL?M"W!M7>)C#<1%U)"7$4H0R.4V,Q
M:N9_9/\`^"3G@W]F+QWI_BS6/B)\<OC9XMT&6>30M7^*'CBY\0R>'O/A$,PL
MX<1VT3.FY3+Y1EVNZ[PK%:^I***?N:1_J[N[=KO5VWN^["?O_%_6EM>^FBOL
MDCRO]NK_`),B^,G_`&(^M_\`I!/7JE>5_MU?\F1?&3_L1];_`/2">O5*QC_&
MEZ+\Y"ZA1116PPHHKA]8_:=^&OA[XEW'@O4/B%X'L?&-G#;W$^A7&O6L6IPQ
MW$T5O;NUNSB55EFGAB0E<.\T:C+,H(M6HK=[!YG<5\8_M!?L&>/OVK?!&L?"
M[7]%^$?@?X?_`-JZMK=EXC\*3W']HWMS=P7L<;3:.]HL,4A:^,D\POYC.\+G
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M4V8/*JAVRRJ3DG)4'M7K%<'\7_\`DH/PK_[&B?\`],NJ5WE0,****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHKC?CI\8Q\#
M/`_]N'POXR\89N$MQI_AC2SJ-\2V3O\`+#+A!MY8D`9`ZD5=.G*<E".[)G-1
MBY2V.RHKY@U;_@I]:Z%I=S?7WP*_:/L[.SB:>>>?P6(XH(U!+.[&?"J`"23P
M`*YOX,_\%?;'XN^#5U*S^"_QJU:2.9X+EO#FA+K%E"X.0GGB1,ML*$@H""V.
M1@GT5DN-<7-0T7FNOS.'^U,*I<O-KZ/_`"/L.BO"?!?[:]Q\2O#?BZ:S^%?Q
M;\+WWAW0[G5K?_A*O#ATZWU!XERL$<GF,&D)Q\I(R,G/!QXO_P`+N^+G@_X,
M^-(-+^*-AXPU#P[-X:UE_$>KZ'9R3BTU)5>YL88[)8+<$85H9)$=DBN07\\A
M6;SZM&=.<H5%9QY;_P#;U[;>C;\EU>AV1K0E",XNZES6_P"W4K_FEZOM=GV]
M17R+\/?&7Q4^(/[?7C:R?5/CDO@+PQXG73X/[-A\%+X-AA72;.Y,%R9T.O,[
MS3-EH<@&2,!E4.5P]8^,?Q:U[P/>Z+K'Q0M?!^O6/B/Q.\_B/0M$L8K98--M
MQ-;V"PWXN%\HJY:1SF5TM92KP[LIS2K1C3]K+1<GM/2-X+[_`'T[=D^\;[^S
M;FJ:U;DH+_$U)V_\E:]6O.WVM17S_P#`'XR>/OB!^T%91^(+W1;?POK_`,.]
M-\1V&C6>G/%<6-W*ZBX::=W9I,LQ5$54"*G.]FROT!73*G*/Q=Y+_P`!E*#_
M`!B_E:]GH84ZD9_#VB__``*,9+\)*_G<\K_;J_Y,B^,G_8CZW_Z03UZI7E?[
M=7_)D7QD_P"Q'UO_`-()Z]4KEC_&EZ+\Y%]0HHHK884444`%%%%`'!_"#_DH
M/Q4_[&B#_P!,NEU^>_\`P<]?\DB^$'_8Q7?_`*3"OT(^$'_)0?BI_P!C1!_Z
M9=+K\]_^#GK_`))%\(/^QBN__285YN<?[G4]#.I\+/R[MO\`5CZ5)4=M_JQ]
M*DK\E//"BBB@#F?BA_R+TG^Z?Y5^S'_!K[_RBXM_^QNUC_T:M?C/\4/^1>D_
MW3_*OV8_X-??^47%O_V-VL?^C5K[3A+XI>ATX?<_1*N._:(_Y-_\=?\`8O7_
M`/Z325V-<=^T1_R;_P".O^Q>O_\`TFDK[:?PLZS^8?X8_P#(LP?0?R%=+7-?
M#'_D68/H/Y"NEK\9K?&SRPHHHK,".\_X]9/]TU[)_P`$`O\`E,IX=_[%G5__
M`$5'7C=Y_P`>LG^Z:]D_X(!?\IE/#O\`V+.K_P#HJ.OH.&_]\1M1^,_HDHHH
MK],.X****`"BBB@`HHHH`****`/B?_@K5_R5W]G;_L8M4_\`3;)77:?_`,><
M?^Z/Y5R/_!6K_DKO[.W_`&,6J?\`IMDKKM/_`././_='\J_-^*/]\^2.+$?$
M34445\V8!7(_&O\`Y$.[_P!T_P`JZZN1^-?_`"(=W_NG^553^)`><_\`!OO_
M`*_]HK_L=K3_`--EO7Z,5^<__!OO_K_VBO\`L=K3_P!-EO7Z,5^OX'_=X>B/
M2CL<=^T1_P`F_P#CK_L7K_\`])I*^'?^">?_`":9X'_[`EG_`.B$K[B_:(_Y
M-_\`'7_8O7__`*325\._\$\_^33/`_\`V!+/_P!$)7RW%^U/YF&(V1[?1117
MPYR!39O]4WT-.ILW^J;Z&@#XC\<_\I5OV=/^QQ_]L;ROV"K\??'/_*5;]G3_
M`+''_P!L;ROV"K]0X=_W-'=1^$\__9H_Y)UJ7_8U^)/_`$^7U>@5\\P_M'VO
M[.7P;MYO^$9\4>-=<\3>/?$>DZ-H'AV.U;4-3N/[5U2X<(UU/!;HL<%O-(S2
MS(,1[06=D1O8_A!\5-'^.7PJ\.^,O#\D\VB>*-.@U2Q:>%H9?*F0.H=&^9'`
M.&4\@@@]*]R.J;72R?SU1M+1I/JK_*]OS.CHHHH`****`/*_VZO^3(OC)_V(
M^M_^D$]>J5Y7^W5_R9%\9/\`L1];_P#2">O5*QC_`!I>B_.0NH4445L,*_G#
M_P""@OC?X2?##_@H?\8?!,WQ^_9OTS0?&FIZSIGC;5M3^'_B34_&^F+J=_97
ML]JMQ9VDME=S:=+8PK9LTZ"W9I59%=`5_H?^*'CG_A6'PT\0^)/['UWQ%_PC
M^FW&I?V5HEI]KU/4O)B:3R+:'(\R=]NU$R-S,HR,U^&GQ"_:,_:H^$_Q_P#B
M1#\,M6_;E\%^#_$7C+4]?AT?2OV0=&UBPM6NKAI'$5W-J(>93G)EVJ9&W.5#
M.Q)A/]_IR71-?^!.*L][)I-W2;32Z/7:5_JSL]>96\K*6JTW5TE=I:MZM*W[
MQ:=Y?]GV_E,TD?EKL9NK#'!-35#8.SV,+2;S(T:EBZ[6)QSD=C[=J_(W]NW]
ML'7]=_:@UCQ-#;_&/PKK6D^!/B!H/AC3IO`_B'3+?2HK>UMPNJ)=-9B"2:9X
MY)A<1R/'#$MFI9'=M\U)M3Y5OJ]7V^7>R]&W;2QCA:?-"'2_*MN_W[*_5[6O
MJC]>**_,CXK^#/!_P1\2_$CP'\.K'0?#OP/UC3?AC<>(;#1]EIHP74_$5Q:Z
MA(PC`C/VS3DMTN6/^MA(:1L')^H/^">?AZQ^'?CKX_\`@SPO8V>D?#OP?X^C
ML?#6F6$"V^GZ0LFB:7<7=K:Q(`D42WDT[[$`59)9.^<;1IW<K?9OOO[K@G==
M%[ZL^MGMH3S72:ZV]+2CS*SZRMO'IKJUJ_6_B_\`\E!^%?\`V-$__IEU2N\K
MR?XC:AXEG^-?PWAU#2=#M=$C\3W/V2[M]6EN+J8_V/J>W?`ULBQY7<21*^"`
M.<Y'K%9E!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%<#\=_VI
M/A_^S-H@OO''BK2M`212T,$LF^ZN0/\`GE`@,DG_``%3BO$/^&I/C9^U'^Y^
M$'PY_P"$*\.3C`\7>/%-N9%_OVUBF9'R.5=LH>,A:PJ8B$7R[OLM7_P/F>GA
M<HQ->'MK*-/^:3Y8_)O=^4;OR/"/V^O^"P_Q,_9;_:S\5^`_#FA^!;K2-`^Q
MB&;4K*ZEN9#-9P7#;FCN47AI2!A1P!UKZ2_X)=?MB^)?VV_V?]7\5>*K#0]/
MU+3?$$VDJFE0RQ0/&EM;2ABLDDC;LSL#\V,`<"OGOXL_\$(O$'QP^(&H>*O$
MWQTGU37]8\M[ZZG\)H6ED6)(^-ETBA0$`50HVJ`.<9KZA_X)\_L5_P##"7P9
MU3PC_P`)-_PE1U+6I=8-W_9WV'R]\%O#Y>SS9,X\C.[=SNQCC)\["QQGUERJ
MWY-;:KY;,^PSNMP[_8\*."<7B$H)M1FKM+WG>22U9[K1117L'YX%%%<7\>O!
M'C+X@>!/[/\``WCA?A[K9N4D.K'18=7(B`.Z,0RLJ98E?F.<`'`YR)E)I72N
M:4::G-1E)13ZN]EYNR;^Y-G:$9%9OA+P;I/@'0HM+T/2]/T?386=H[6RMU@A
MC+,68A%``RQ).!R2:^)?VQ/V'_VE/B/^SCXCT4?'(_$S[<+8'PT/!VEZ+_:8
M6YB<C[7YH\O8%\SJ-WE[?XJ\R_X)S_\`!.7]I+X+KXP5?&A^!Z:D;(A?[)TO
MQ+_;)3[1D_ZYO(\K>/3?YO\`L5Q2QU95%25*5GKT\_.WWM/]?J*?#N`G@YXI
MX^FI1=E&T]5IWBI]>E.2TWWM^G)Z<].]>*?`?5OV<[WX.^(+7X8W7P4F^']G
MJ[C6XO"\FF-H\&I,T;/]I6W_`'*W!;RB=_SD["><4?!OX*?&#P%-KDGC/XS)
M\2K>\TV2WL;(^%K303:W)QME^T0>8<8RI!C8#<&P=N#X-X,_8FUCQ!^Q_J_@
M^Y\!^,K33]#OM&N/"GAWQ]XJA\3:E87UDZ":_BNVO;J*.(J%,$:R1"+RF*V\
M#-@]=&3ES.2<;)=KN[UV;3LE>U[MM;)7/FL91A1DH4YJIKO'FMHG_-&+3N[7
MM:U]]#Z0B_:I^"/@WXY7?P[3XD?"O2OB5K%\CW7AE?$%A!KE]=O!'L+VGF"=
MY6A2+!*EBBICY0*S_CY_PS[_`,*\D_X6C_PIO_A$_P#A)4\S_A*?[-_L[^W<
MG;G[1^[^W9SC/[WK6+\&?V;/&?AO]ICXD>,K[X@>-M)\-ZUXI-_9^$H(M%DT
M75H#I%C;?:))#9/J"/YT4GRK=QC,"G9M8A_)]8_96\1?`CP/>V_@_P"$J^)-
M(3Q'XGBL_"VE76EVD8MM5MPD5^?M,L<00.)%E&_SBEU*WERME6ESE&"FE>7L
MU*VWO7IVAY-7=GK;ENTN5HSY8N7+?1RY;[Z-3O*VE]DK=>:R;NF?3FD_&+X9
MZ[^T!J?A&Q\5>!;SXJ:-IJOJ&BP:E:2>(+&Q)CD4RVZL;B.`F:)@64+F5#_$
M,]U7R7^S'X%\<:)^T-I&@^*_A#K&@^&?ASIGV'0?%5G<:)+IFO7KV<,5YJMP
M4O?[0668JT,4)M``JR2S2.TL:6WUI754A&-E%W7?;J^FZOO9ZZW=FVEA3DY:
MR5GIY]%UZVVTTTLFTKORO]NK_DR+XR?]B/K?_I!/7JE>5_MU?\F1?&3_`+$?
M6_\`T@GKU2N6/\:7HOSD7U"BBBMAA1110!\8_P#!4/Q/?)XNCL'\>>*?`.F^
M&_ACXL\=:?<Z)KL^DFXU;3CIXMY)S"Z?:88%N)&-M-OMY?-'F1OM7'U9I'BC
M4_\`A5^G:O/HU[?:M-807$^FVC0K,9712Z*97CC^4D_>=1@'O@5!\4/@;X)^
M-\6D1^-/!_A;Q>GA^_CU72UUO28-0&FWD>=ES`)4;RYER<2)AADX-=313]VG
MR/?_`(,G?UM)1>^D(V[(J>])-=+_`(J*MZ)Q<M;ZSE:RW\-^%GQ3URV\<_$I
MT^&OC6X:X\1PR21QW6D!K5O[(TU=C[KX`L0H?Y"R[9%YW;E7YH_X+)?LH?%C
M_@H3X`\"Z9X'^'VI:;=^%]5GOKDZYJNF01R(\.Q0AAN923GKD`8[U^@=KIMO
M8SW,L%O##)>2":X=(PK3N$5`[D?>;8B+D\X11T`J:L:]&-:FZ<]F*2NK,_!%
M?^"'_P"U>BX'A+PG_P"%!;_XT?\`#D']K#_H4O"?_A06_P#C7[W5Q_QS^.WA
MO]G'X=S>*?%EQJ5OI$-S;67_`!+M(O-6NYI[F=+>"**UM(I9Y7>61%"QQL<M
MZ9->7_8.!7V?+?OHOO9"H1>R/Q!_X<@_M8?]"EX3_P#"@M_\:/\`AR#^UA_T
M*7A/_P`*"W_QK]FOAM^VG\.?BM+I5OI6L:I;ZCK&LR>'X=,U;0-1TC4X+Y+-
M[XP7%G=P17%L3:QM,IGC170HRE@Z;O5*I\/X-;P_IZK\-1>RA_7]>1^`^M_\
M$*?VJM>TZ2VF\(^$]L@QD>(;?*_3FOT0_P""-_[//Q-_X)Y?L:1_#OQI\/-:
MU36H]=O]3,^BZEI<UJ8IW#(-TMW$VX`<C;@=B:^Z**ZL+EM##-RI*URXTU'8
M\SN/VAM3M/%%GHLGPR\>+J5_:SWL$/VC1SYD,#PI*V[[?M&UKB$8)!._@'!Q
M0^*OC;Q1XY^%_B31+3X7>-H[K6-+NK&%YKS1EC5Y8F12Q%^2%!89P"<=C7JL
MFFV\NHQ7C6\+7D$;PQ3F,&2-'*%T#=0K&-"0."47/05-7<]58H_`70_^"$O[
M5/A^PCMX/"?A5E0`9;Q#;Y/ZU<_X<@_M8?\`0I>$_P#PH+?_`!K][J;-,MO"
MTDC+''&"S,QPJ@=237BO(<$E=Q_$S5&/8_!/_AR#^UA_T*7A/_PH+?\`QH_X
M<@_M8?\`0I>$_P#PH+?_`!K]<;7_`(*>_!.?POK&M3>+-2TW2]$;3_/N-2\,
MZK8+<0W]S]EM+NV\^V0W5G+-\HN[<26X'S&0+\U>G>%_CSX3\:_&#Q5X!TO5
MEO/%G@BVLKK6[%;>5181WBR-;YE*B-F=8G;8C,RC:6"AUS2X?P;5U'^E:_W7
M7WH7LH*_EOY7=E^.GKH?B`?^"(/[5Y'_`"*7A/\`\*"W_P`:]:_X)>_\$EOC
M[^Q=^WSI/Q6\7>"[.\T*RT>_T^6UT?6[*:Z\R=%5"JRRQIM!!SEP1V!K]E**
MUP^48:C-5*:LT.-.*=T>9^*OVAM3\$^%]2UK5/AEX\M=-TBUEO;N;[1H[^5#
M&A=VVK?ECA5)P`2<<`UH?\+?\0?]$K\>?^!>B_\`RPKMM2TVWUG3KBSO+>&[
ML[N-H9X)HQ)',C`AD93PRD$@@\$&IJ],T.#_`.%O^(/^B5^//_`O1?\`Y84?
M\+?\0?\`1*_'G_@7HO\`\L*[RB@#@_\`A;_B#_HE?CS_`,"]%_\`EA1_PM_Q
M!_T2OQY_X%Z+_P#+"N\HH`X/_A;_`(@_Z)7X\_\``O1?_EA1_P`+?\0?]$K\
M>?\`@7HO_P`L*[RB@#@_^%O^(/\`HE?CS_P+T7_Y85GZ/^T-J>O:AJMK:?#+
MQY-<:)=+97J_:-'7R9F@BG"Y-^`W[N>)LKD?-C.00/3*AM=-M[&>YE@MX89+
MR037#I&%:=PBH'<C[S;$1<GG"*.@%`'QW^WK\+/B=^TKXJ^%^J>%?AKK4#^!
M=3O;^YCU75-+A$XFM'A0(8[N3.'8$YQQTR>*\[F^$W[4DS[CX!TT=@!K5D`/
M_(U?H=17FXG*<-7J>UJJ[(E3BW=GYW_\*A_:B_Z$/3O_``=V7_QZC_A4/[47
M_0AZ=_X.[+_X]7W!\<_CMX;_`&<?AW-XI\67&I6^D0W-M9?\2[2+S5KN:>YG
M2W@BBM;2*6>5WED10L<;'+>F37-_#;]M/X<_%:72K?2M8U2WU'6-9D\/PZ9J
MV@:CI&IP7R6;WQ@N+.[@BN+8FUC:93/&BNA1E+!TW8QR#!RORQO;?7;;_-?>
MNXG1BM7_`%_5F?(?_"H?VHO^A#T[_P`'=E_\>J#4O@?^TYJ]C);W'P_TV2&9
M2K`ZW9?_`!ZOT7HI?V#@_P"7\0]C$^$O^"6_[.GQ0_8F/Q5;Q9\.]8OV\=>(
M8-7L1I&IZ7-Y,26<4#++YMU'AMR$C;N&,<@\#ZAUC]H;4]!U#2K6[^&7CR&X
MUNZ:RLE^T:.WG3+!+.5R+\A?W<$K9;`^7&<D`^F5#=:;;WT]M+/;PS26<AFM
MW>,,T#E&0NA/W6V.ZY'.'8=":]:G34(J$=D:+30\J^*OC;Q1XY^%_B31+3X7
M>-H[K6-+NK&%YKS1EC5Y8F12Q%^2%!89P"<=C7Q=\)_V9?VE?A-\)O#?A>Q^
M'^G^7HNFV]I+(=<LCYTD<2HS#]\/ER./:OTLHKDQF7T,2TZRO;8F45+<_/'_
M`(5%^U#_`-"#IO\`X.[+_P"/4?\`"HOVH?\`H0=-_P#!W9?_`!ZOT,FF6WA:
M21ECCC!9F8X50.I)KP2U_P""GOP3G\+ZQK4WBS4M-TO1&T_S[C4O#.JV"W$-
M_<_9;2[MO/MD-U9RS?*+NW$EN!\QD"_-7''(<$Y<JCKVOWV^\ETHI<SV/F[_
M`(5%^U#_`-"#IO\`X.[+_P"/4?\`"HOVH?\`H0=-_P#!W9?_`!ZOM_PO\>?"
M?C7XP>*O`.EZLMYXL\$6UE=:W8K;RJ+".\61K?,I41LSK$[;$9F4;2P4.N>O
MI_V!@M^7\0]C%.S_`*TO^33]#\O;+]ASX]:O^U]\)OB-K7@&%+'P'K_]J:A#
M::S8--<0_9IXL1*TX4ONE4X9E&`><\']!O\`A;_B#_HE?CS_`,"]%_\`EA7>
M45Z.&PM.A#V=/8J,4M$?+^O?"+QIXZ^$_P`,?'GPWC\+W_B;0/%&J>-M-TWQ
M'?SZ;8ZC8ZNNH_N);B""X>"9(=1CDRL,JEX#'PK^:OL'[*OP:N/V>OV</!?@
MJ^OH-4U#P[I4-I>WD$1BBN[D+F:1$))5&D+E5))`(':NZTW3;?1M.M[.SMX;
M2SM(UA@@AC$<<**`%15'"J```!P`*FKHCI?S_#R7EU93U:?]/S?GT]/1!111
M0`4444`>5_MU?\F1?&3_`+$?6_\`T@GKU2O*_P!NK_DR+XR?]B/K?_I!/7JE
M8Q_C2]%^<A=0HHHK891\4>*=,\#^&M0UK6M1L='T?2;:2]OK^]N$M[:R@C4O
M)++(Y"HBJ"S,Q``!)(%?SE_M/V?P1U[]LWXP:MX]_9M^#?QPUG6/'6IWEIXM
MU;]LK1O#MY=633D6T;6*WRF%8XU54C9%=(Q'&P)0L?Z'_C#X2N/'WPD\4:%:
M6OAR^NM:TFZL8;;Q!8F_TBX>6%D5+NW#*9K=BP$D88%D+#(SFOYK/B]^U3>?
M"WXI?$+X=_%FT_X)B>$/B)IOBB^LM3U&X^"^K:UJ^F9N-RM;2VFDW%C,BQL!
M&+DO.!A;C$P?!@]<P@NMM/.\XWMUNFHZIII-ZZF]33"-].97WTM&5MNCO+>^
MJ5MC^F_3-O\`9MOM58U\I<*'WA1@<9[_`%[U4U#P?I.K>(M/UBZTO3;K5M)C
MFAL;V6V1[BS2;:)5CD(W(LFQ-P4@-L7.<"KFG,K:?;E&5D,:[2J;01CL.WT[
M5-3J)-NYQX?^%&W9=NWEI]VAPO@;]E[X9_##X9ZMX+\-?#OP+X=\&^(//_M3
M0=,T&UM-,U+ST$<WG6\<8BD\Q`%?<IW*,'(XK<^&GPN\,_!;P18^&?!OAW0?
M"?AO2U9;/2M&L(K"QM`S%V$<,2JB`LS,=H&2Q/4UO447?Y?AM]W0U>N_F_F]
M_OZ]S@_B_P#\E!^%?_8T3_\`IEU2N\K@_B__`,E!^%?_`&-$_P#Z9=4KO*0!
M1110`4444`%%%%`!1110`4444`%%%5=;UVQ\,Z3<:AJ5Y:Z?8VJ&2>YN95BA
MA4=V9B`H]R:!I-NR+5%?,?BO_@IAH_BW7[CP[\&/"NO?&;Q%"WE22Z2GV?1+
M)_\`IO?R#RP.A!7<I_O`UGG]DOXQ?M0?OOC-\2&\->'YCN/@[P(S6D++V2YO
M6S++D8#(/E)R5(XKE^M*6E)<WIM]^WW79[,<EG37/CI*BNTM9OT@O>]'+E3[
MG=?''_@H?\-?@IX@_P"$>CU"\\9>,Y&,4/AOPO;'5-2DD'5"L?RQL.X=E..Q
MKA1;?M+?M7`>=)I?[/O@^X_Y9Q%=5\37,9]6XAM\CTQ(A/>O<O@;^S-X!_9K
MT#^S?`_A72?#T#*%EDMXMUQ<?]=9FS))_P`#8UW5'L:D_P"++3LM/QW^ZQ7]
MH83#:8*E>7\]2TG\H?"OGSOLSQ'X#_\`!/GX9_`76_[=@TJX\4>,)&$D_B7Q
M)<'5-4FD_P">GF2<1M[QJI^M>W445M3IP@N6"LCS,5C*^)G[3$3<GW;O\O)>
M6P4445H<P4444`%<W\5?B]X=^"7A;^VO%&I+I>F^<MN)C#)-F1LD*%C5F.<'
MMVKI**SJ*;BU3:3Z-JZ^ZZO]Z!WMH>(_\/&O@S_T.7_E)OO_`(S571_^"E'P
M?U+3TFG\27.GRL6!MY]+NFD3#$`DQQLO(`(PQX(S@Y`]D\;>#K'X@^$M0T34
MEF?3]4A:WN%BF:)G1NJ[E((R.#@\@D5S_P`%_@#X9^`&EWMEX8M;JSM=0E$T
ML4EU),N\#&0&)"DC`..N!GH*\>5/-_:I1J4^2VKY)7OZ<^O_`($M]F8_O;[K
M[O\`@E'X1?M4>`_COK-UIWA/7AJU]9P?:98?L<]NRQ[@NX>:B@\L!P>XKQ+Q
M%^TU\9=9_9U\2^)+>;X2_#G7_"_BG4-)NUU:TU#Q+;211L(K*R@B@FLY+B]N
M9I8(P488D?RXX9V937U?7COQ<_8-^&?QM_LUM:T_Q/:SZ1KMSXFLKG0_&&L:
M#=6VHW,+037"S6-U#(&:)Y$QNVA9'``#-GTZ$*ZO[:2;M:\5RV?-!II-RVBI
M+6Z;:5K-G1"5DN;5J5WYKEDK;]9..NZ2;6J2?D?PF_:[^*7Q*_;)U;P7J%]I
M/AW2M#U2"QN=$B^$/B3501_9-K>S(WBB.[3289!)/(BB2'.$0;6:1<V;C]K+
MXR>+_!D]EI>F?#GPCXZM]>U^*6._AO=<TR*PTN-7$)>.2U8W,QE@4R\)'F4K
M',$&[Z5\`?"_1?AA'J:Z-;W$+:U=K?7TD]Y-=RW4ZV\-L)'>9W8MY5O"I.>2
MNXY9F)XWXG?L8?#KXO\`ABXT?6]'U(V=UJ\^N3&PUW4--GDNIXVCGS-;3QR^
M5+&S))!N\IU8JR$<5O64FK4]'R6])W@^:SO=64M&VG>UDF[33LK<^OO*_G%*
M:M=6LVW'5)-6O=M(X7X0_M0>-_&O[2GAS3=8A\.V?@?Q]X2'B/0[>+1[Z.ZL
M6,=LZ12ZI(XM+NXDWW;&T@A62&*V$KNRN,_1E><^%/V3_`?@CXMS>-M+TB\L
M]:DC*1P+J]XVE6;,BQM-;Z<9396\[HH1IH84E=2P9B&8'T:MJDH.W(K;Z;]6
M]]WI;5_<E9+.G&:7ON[TU^2OILM;Z+IO=W;\K_;J_P"3(OC)_P!B/K?_`*03
MUZI7E?[=7_)D7QD_[$?6_P#T@GKU2N6/\:7HOSD7U"BBBMAA1110`4444`%%
M%%`!7@?_``4H^$VM_&?]F!M'T'P[XE\57<'B30=3GTOP]K4>BZM<VMKJMK<7
M'V6[>ZM1#,(8G*L+B)@0-K@XKWRBI<;M/LT_G%IKY76I496^YK[U8_/OP'\!
M?B7\&M<T'QQH_P`(_BUJ^CVOQ.E\21^$-7\9:5KGBZQLV\+2Z4\\^H7^K/#,
M'NMI2(ZA,\<6W!4?N8ONGX<^*K[QOX*T_5=3\,ZWX/OKQ"\VC:O+9RWM@0Q&
MV1K2>>W)(`;]W,XPPY!R!MT5HY-JS[)?))+]+_E9:&?*KIK^M6_U?ZW>H444
M5)04444`%<W\9?!-Q\2_A!XJ\-V=X-/N_$&CW>FP71!(MGFA>-9..?E+`\<\
M5TE%9UJ,:M.5*>TDT_1Z&E*I*G-5([II_<?G/X:_8E^*'BKX3KX/F\,_$G1_
M#L=QX3M=9T_Q;XXM]<_M.[LM7MY;[4M+Q>SQV=B+1)"L"):;L1A;.,J%/N7[
M`GP`^(GPU^)_BWQ=\1M/AM]?\8Z%IT>I7,-Y'/'/>6U[J<:J`)'8;;(V!SPI
M+D#D,!]345T*K)<SZR;;?76VGIHK);62V22Y_9KD]GT]VWERM/\`&VO?5OWG
M<****S-`HHHH`****`"BBB@`HHHH`****`"BBB@#P/\`X*4?";6_C/\`LP-H
M^@^'?$OBJ[@\2:#J<^E^'M:CT75KFUM=5M;BX^RW;W5J(9A#$Y5A<1,"!M<'
M%?._@/X"_$OX-:YH/CC1_A'\6M7T>U^)TOB2/PAJ_C+2M<\76-FWA:72GGGU
M"_U9X9@]UM*1'4)GCBVX*C]S%^@E%%.\%)1^T[_^D?A[BWONVM;-.3YK7Z)K
M[[_CJ]OGH8GPY\57WC?P5I^JZGX9UOP??7B%YM&U>6SEO;`AB-LC6D\]N20`
MW[N9QAAR#D#;HHIMW=R8Z*P4444AA1110!S?QE\$W'Q+^$'BKPW9W@T^[\0:
M/=Z;!=$$BV>:%XUDXY^4L#QSQ7P7X:_8E^*'BKX3KX/F\,_$G1_#L=QX3M=9
MT_Q;XXM]<_M.[LM7MY;[4M+Q>SQV=B+1)"L"):;L1A;.,J%/Z,45$::C4]HN
M\6^SY')J_P`Y-^MGO%-.4FXJ/:]O+FY;_P#I*7I=;-I_+/[`GP`^(GPU^)_B
MWQ=\1M/AM]?\8Z%IT>I7,-Y'/'/>6U[J<:J`)'8;;(V!SPI+D#D,!]3445K*
M3E:_33Y=%\MEY$\JYG)=;?@DOT_RLM`HHHJ1A1110`4444`%%%%`'E?[=7_)
MD7QD_P"Q'UO_`-()Z]4KRO\`;J_Y,B^,G_8CZW_Z03UZI6,?XTO1?G(74***
M*V&%?A[^V:GPXUKXY?%#PMX7^)GQP\`Z;X3UGQ+JWBWQCHOPV@U+1[S1=1U?
M2!XATB&\FG$DEQI^HSI=-=V\.;.$R`+*Z*S_`+A5^!OQ;^.W[!?C/]NWXNR?
M&OXL?&/X-ZEX6\?ZUH.H_#S1/$6MZEX3\9PFYA:]O+B"WTP_9TO[B!?M%K%.
M%9K5&)/#487_`'^G_AEMN[N"M;JFVN9+WFM+./.;2NL.W9M<T?3:?W2WY9/1
M:OXN4_>VRV_8H=DC2IL7:[')<8ZD^]?%W[2O_!0CQ[^QY\9=2M_%5_\`";Q5
M8R:'KOB"'P-X?%Q#XDT'3K&UGGM-2O+Z:X*/;W,ENMLV+&%8I[V-$EG$+-)]
MI6CQR6D30[?)9`4P,#;CCCZ5\P?'?_@G]XL_:P>X\-_$[XH6.O?#6WO+^_TN
MST[PFFF^)+62YM+NT5)=2%R]N\<,-[,J>58P2-LAWR/B7SE._-UZW[Z]KZ<W
M57TTM>-[K'#\GLUS6Z/2^MEZWL_6^SLTFGS6O?MM_%+X+/XP\"^,O^%>ZY\3
M+>W\+3^'=3TK2[K3-%D/B#4Y=*B6>UENYY7^QW$$DK[;A#<1[540-DU[+^R/
M\;_$WQ(O?B'X3\;G0KGQC\+O$2Z#J.H:+8RV&GZNDUA::A!<Q6TLT[P9BO$C
M:-IY2'B9MV&"CSC_`(=W>)O&GA;QAJ'CCXG6>M?%#7K70;73/$^D^&/[,L]'
M&AW;W^G.;&2ZG,K&\DDDN,3QK,K[$6``&O6/V8/V>M0^!]KXNU3Q%K]GXI\;
M?$#6_P"WO$.IV6F-I=E+,MK;V<,=M:O/</##';VL"A7GE8L'8M\VU=XN-Y\W
M9VMMO#EMUNES\S>]UN[-3K9?+M>_+[S?3E<M8I*ZTV5T0_$;XG^&O$?QK^&^
MA:?XAT._UO3O$]RUWI]O?Q2W5J%T?4U8O$K%UPS*#D#!8#O7K%<'\7_^2@_"
MO_L:)_\`TRZI7>5B4%%%%`!1110!7U2:XM],N)+.".ZNHXF:&%Y?*65P#M4O
M@[03@9P<9S@]*\Y_X:J\-W\EOI.FR)=^.+F06_\`PBLEQ'%J=G+_`!?:4R?)
MB0`L9N49=IC,I>,/W_BG^U#X8U+^Q?L/]L_99?L'VW=]F^T;#Y?F[/F\O?MW
M;><9QS7X>?'']FKXS:I^U7XFN_'/A76_&?B339X]5UN>WM9[BVNK0ML25#`5
M<0%4*J(RK(L94!2A`]S)<JAC7-3FH\JOKN_^!\SDQ6.IX9Q]JFU)VNE?[S]T
MJ*^'_@+\"/"OQ9T-M0^`/[2GQ&T%H1N?1[W4%U>'3L<8>PN@LB<\98X;'!/6
ML?XV_MJ?&/\`8FUV#1]?\=?![XK:A,ZQ1Z-;V=W9^)+AC]T""U62*/=S]\#)
MZ5PXC"0I-QG446NDKQ?XZ?B>G@\-+&-+">^WV3?Y7/OBN2^,'QX\&_`#PTVL
M>-/$FD^'-/`.Q[R<(\Q'58T^_(W^R@)]J^'/C+^WI^T?XJATV)OA5XN^#/A6
M^C#7^O6N@2^)M1LEQR1&1$D(/3#IN!P00:V_V6;_`/9'G\7)KNI_$"W\<?$)
MG'G:M\1KF1+Z.4=$CCNU2*,JV=H0%AP`QXKCJ87%_P#+JG=?S;K_`,EO?\/4
M]*CE^&IP]IBZC_P05Y?-OW8_^3/^Z>DM^VW\2OVEB;?X#_#6XDTB8[4\9^-%
M?3=)*G_EI!`/W]POH5Q@CE35K0_^";2_$_5K?6OCMXXU[XM:I#()HM*=CI_A
M^R;MY=G$0&(Z;G/S`?,O6OIC1]9L]?TZ.ZT^ZM;VTE&8YK>59(W'LRD@_A5J
MN/ZK=_OGS>73[O\`.XY9U*DN7`05)=UK-^LWJO\`MWE7D9_A3PCI/@30+?2M
M$TS3]'TNS79!:65NEO!"/144!1^`K0HHKJVT1XTI.3YI;A11102%%%%`!111
M0`4444`%<7\>6^(@\"?\6P7P6WB8W*<^*&N18+!SO/\`HX\PO]T`<#DDGC![
M2LOQAXYT7X>:,VI>(-8TO0]/5Q&;K4+N.UA#'HN]R%R>PSS5T[\RLK^0I3C!
M<TMEWV/E?XI2?MG1>`]09#\`1,JH8?[$76VO_-WKY?E!@4SOVY\S]UMW>9^[
MW5#X0G_;1G\8>(?.7X#QS*UN$34%UG[&(O+X^S&/Y""_F;]Q,H;[V(_)KWR_
M_;!^$^G6_FR?$KP*R[E3$6N6TK99@H^57)QDC)Q@#).`":BT_P#;,^$NISS1
MQ_$GP2K6Y(8RZQ!"I^9T^4NP#<H?ND\%6Z,I/IJI7Y;>P7_@+\C#^U\(O=]I
M"_JO\SD?`UG^T?J7ASQ=:^.I/A#`UQH=S'H<_A-]1%S%J!7$1D%SA?+Y)RK`
M@@=B2/BSXF_L]?$#Q=^Q)\5-#_9^^&MQX-\"ZI96YU?PUK-MJG@W4M5NH-)F
M^W&QMA8S32RS77V)96\M$O?(F43-YIF/Z3>"?C3X.^)EY/;^&_%GAOQ#<6L?
MFS1:9J<-Y)$F<;F6-B0,\9/>O#?$?[;GQ`U+]GS7O''A+X3Z5]N\-^(+S1;O
M0/%WBQ](O9%A<10&(V5CJ"O<7$CQJD!VX\U0SALH/+J-^VE=6=HMI+91DDOD
MW-7771[)G3&M"JH5(--)M*S5FY1?XI1=GTU6[1POP'_89U'7_P!N+QM\6/$W
M@WX)V\D/B>&>"YU/X:-?>+`R:'I\8DT_Q!)=1[;=)]ZJ19'_`%<RY5F.SB?B
MM^SMIG@_X2W^C^-O`/CSXC>"(/&WB:>'3[C1-2\5ZE<ZA<6__$NU`C$LQ42&
M=8[DCRX'EB8/"J!E]<\&?\%%-4\6_MHWWP?EM_@/I.I:/J,6GW>F7GQ99/%U
MP3IT%]-+::+_`&7FXB03.JL;A-ZPNYV8*C0O/V^O%6O>!&NO#/PI9O%2ZWK%
MD?#WB/Q)%I4R6.F('GNFE@BNE$KAX1'!@C=.HDDBPY7GJQ@Z5F[1]E:ZZ1YJ
M5YIZV=U&S=[7OJH:.GS*4=+RYT]5N^6I:+6EU9RNM&[6T;1POP`^$OQZT+_@
MHCX3\2?$;3]'U'PVGPYO-#MM3L_$5Y=-8%/[%=TN;8V2VZWDUVMRYD6Y<RQ+
MQ@6V'^UJ^;_@#_P4"/[0?[3VK>#=-\,PV'A&TL(+BPU^]DU2&XU6XELK6]-O
M$K::-.=DCN6W)'J4DZ^2[&`)EA](5VUG.T>96W?WRE+\V_SZG/144K0=]OPB
MDOPMZ;=+'E?[=7_)D7QD_P"Q'UO_`-()Z]4KRO\`;J_Y,B^,G_8CZW_Z03UZ
MI7%'^-+T7YR->H4445L,****`"BBB@`HHHH`****`"BBB@`HHKPO_@IQXU\9
M?#C_`()X?&K7OAZ+[_A-=)\&ZG<Z.]E_Q\P3K;N1+%WWH,NN.<J,<XK'$5E1
MI2JO[*;^Y7-:%)U:L:2^TTOO=CW2O@7XZ_\`!Q3\'O@_XU\::?H/P]^/GQ9\
M/?#>>2T\6>,/`G@S^TO#7ARYB+>?#<WDDT2JT2KO=E#1[6!5VY`_+W_@B%\/
MO$&@?ML?!'6O`WQ<_9MM=>^)/AS4;GQ;I7@WQ'XNUSQ/XJB:Q,DDNO17*W%C
M9WL-P5F&Y[13*T@3S`56O>?V!_V^H?V+O^",LWPCT3QA^SO\,_V@/A+K^L:;
MXW\*_&N_GL8M0C-S=W$[P6\#"XO))HY(501AT8[DY^7.N(3I)SDU>*O;NU+E
M;3ZPCIS-:WDM%9WBC:I917Q-*_9.+DKKI)VT6L;;N[2/O3]I?_@NC\(_V?O`
MWP6\0Z%X;^*7QEL?C]%=S>#8OAYH":G>7XMEB:4&VFF@F#CS<;`A=3'(&52M
M9L__``72\+^&/V9?B;\5_&?P!_:D^&?AKX6P6$]Y%XR\#Q:-=:P+RZ6U1;$2
MW029HW93(&=-JL#R2!7YP?$/XV_%'_@HOHO_``2[\4:+J?A?X!_$+Q7JGC&T
MT>^\-^%%N-)\-PVOE6]NUMIMU*R-&;:!5"-)M&_*X``'TY_P62^!/QG^!/\`
MP03_`&CK3XS?'K_A?.IW[Z--IU__`,(38^%_[+A&JV(:'R[1V67<WS;FP1TZ
M4L5>C2JS>\:DHJ_E**MINTGK=)=M=#3!QC6JX>D]>=1<FO.<XMZ]'RV5KO6^
MVIZ]HO\`P<5?#ZTUCPVWCKX"_M7_``A\)^)K^WTZ'QCXX^'@TSP[:27'$!FN
MEN7VJYP`RJPYR<*"P_096#J".0>01WK\%?VL/`'QH^#_`,2OV;_`_P"V)^T!
MX@^)'[(/Q*GTMCJ&B>%])\,QZ7K,*I-96&IM%"\AL\A"7\X%U61\(T.ZOWHC
MV^6NW;MQQCIBNJK3C&,K;J<X^:4>72712O=Z73BXM-IG#2J2DXWV<(R\FW?6
M/>-K+6S4DTTFAU%%%<YT!1110`4444`%%%%`!1110`4444`%%%%`'B>M_MY>
M$-!_;_T7]G&;3?$C>.-<\'R>-8+Y+>$Z4EDEP]N8VD,HE$V]"0HB*XQ\V>*7
MP;^W?X1\<?MW^,/V>;33?$D?C3P3X;M?%%]>S6\(TN6VN'1$2*02F4R`N,AH
ME7&<,:^+/VU/BQX4_9(_X.._@K\1?B3X@T_P3X*\5?"'4_"UIKVLR+9Z4E_#
M?27!BDNI"(HSLD7[Y4`O&,Y<5X?X]^*7A?\`:F_;F_X*._$7X>>(--\8^"]'
M_9U;PXVN:1,EYI=Q>-I\LI2*YC)CDVB)A\A(RK#/RUS^WM2A5M?2LY?]PU5Y
M?36-->=UW.AT.:LZ47:[HJ+_`,;I*5N]KS^Y]F?K7^T!^T)_PH%_!J_\(/\`
M$/QK_P`)CXCM/#F?"FC?VD-#^T;O]/OOG7R+*+;^\F^;9D?*<UZ'7X`:1^Q%
M\/?V;/V`O^">?C[P[I5S_P`)Q\5_B[\.]0\4:U=W]Q=7&I%(K@V\0$LC)#%#
M')Y2)$J+L1<@D`US'BC]@;X<_M(?`W_@IY\3O%UKK^H>*_A7\2_%&I>$GBUV
M[MK/0[N$/.;E+:.187ED(1'>5'.R-`NTC)ZL5%8?VJEK[)U.;T@J-TEUUJ.U
MVMM;7TQH1]M&E*.GM%"R\YNK9OM;V:3M??2]M?Z)J*_FP_;H\4^-_P!L;XH?
MLT^'OBIXL^#1\&W'[/6A>*[%OC=XKUS0_#6LZM)&OVV]CGTN:&234L'8%E<[
MD+X4LRU^QO\`P07U#Q5J?_!*_P"&$GBSQWI?Q*N$ANHM-\1V$6IQQZAIZ74J
M6W_(2MK:Z;9&HC#R1#<L:$%P0[:^P:]JF_@DX^MIRA\FW%M+JKN^C1A[7^&_
MYDGZ7BI_-)-)O36VEG=>=^,?^#B7P1H7Q4^)'A;0?V>?VLOB%_PJG7KWP[X@
MUCPAX#M]6TJVN;5V67]^EX-JX4N/,"-L()45]??LB_M8^"?VX?V=O#/Q0^'F
MI/JGA7Q5;&>U>6(Q3P.K%)8)4/W)8Y%=&&2,J2"RD,?R+_X)\?LI?M"_M%_M
M/_MO2?!_]J*;X#:#'\;==LM2TR+X>Z?XBDU&9G;_`$A;FXE26`A&"@1D8*[@
M0:N?MG_\$D_AK\&/CU_P3K_9C^T^(-9\!S:EXSCUVXEOY+2^\0>;:6]S=K++
M;LCQI.=\;+&P(B8KD\L>?"<TZ=*,_BJ*G;UE!RDW:ZY=K:\WEO;IQ$4J]50^
M&FZM^ND+V6K3YO=MM;=WT5_VPKR_XY_M?^"OV>?BK\,?!/B*ZOAXE^+VKRZ-
MX<M+:T:43R0PF::21^$CC1`,Y;<2X"JW./R`^,7[._[+_C7_`(*A?&KX3_M;
M:]:>"?A;\%_!&@6'P1\.ZSXMNM"TFQTMK("[N;%O,C^U70FBC4[GE>1E=667
MRAY?@%WX!\+?M/\`P7_X)X>.?VL))K[0_$6O>(?"VI>*?%NM7.E/JOAJW:23
M2WO)_.C$1+/D3;@\B!&:1P<TZ-JDZ=G[LI4[O^[.;BEV4]+2C?W?>LVX-$U(
MN"FI?$HRV_F5/GNMN:*772[Y59*2DOZ3J\\^&_[0G_"Q_CE\0/`__"#_`!#T
M'_A`#8C_`(2#6-&^RZ'XD^U1-)_Q+;G>?M/D[=DORKL=@.<YK^:CXV'QI\7/
MVI/C5\2M?^*WP!^'_P`6_"'Q2FTGPSJ?BWQ/XL;XA>'X([N,:?;Z/INF">WN
M;`QL$5ELY_EFF+%058?1G_!2HWS:#_P5B_M1K=M3^P_"W[6;=66$S9@W[`P#
M!=V<`@'&,UG"I?#_`%AK>/-;U=.VO=*?O+IINFF:PH\U7V%]>:,;^L^1NVFG
M\KZV=^7K_0=17XO_``W_`&/_``C_`,$]?^"U'[$UQ\,+CQ5IEY\</!NO#Q]<
M7_B"\U.7Q7)!I2W"S7)N)'^8S%9"$VH&C0JJXK]H*ZZU'V:3OUDGZPG*#MW3
M<;IZ:/9'%3K<TK6WC&2])Q35^SZ-:KS"BBBL#8****`"BBB@#RO]NK_DR+XR
M?]B/K?\`Z03UZI7E?[=7_)D7QD_[$?6__2">O5*QC_&EZ+\Y"ZA1116PSA_V
MF].\7:Q^S?\`$"T\`RK!XZNO#>H1>'9&E$0CU%K:06QWGA<3%.3TZU^.7B[]
MMCX+_%#_`()Z_"_]G+X3ZC\:?^&OOA[?:=?^'O"\NG:W#XDT/Q:LK?VA<ZC<
MRPBW>%3<W[W.]S'Y,LNU5^7;^XM?G9I__!S3^S7X!^+_`,4/`OQ=\40_#/Q-
M\/?&NH^%;:TCL-7US^U[:U=8UO2]O8>7"9)/,7R=SE?+SO8,#1A_]XY%JWRR
MMUO3EIROUFKI)MV35N5LN:;I<Z6W-&^Z]^.JDNJM!VU2U:=^9(_0^U$BVT?G
M%6EVC>5Z%L<XJ2FV\ZW4"21G='(H93CJ#R*\9F_X*$_"&S^)UYX4N_%4VG7E
MC<7=G)J=]HU_:>'Y+FTC>6ZMHM7E@73Y;B!(IC)#'<-)']GG#*#%(%)22;OI
MN_DM_DC*G&\$XZK37?TU\_Q/:**\=\(_M[?"SQI\+O$GC"WU[4K'1_"*12:I
M%J_A[4M)U*!9@#;,EC=6\=W*+@D+`8XF%P_R1>8WRUVGP4^.GAG]H3P:VN>%
MKR\N+.&ZDL;F"_TVZTN_T^XCQO@N;2ZCBN+>4!E;9-&C;71L;64FN5IN+W6_
ME<?,K)]VU\UNO5=2C\7_`/DH/PK_`.QHG_\`3+JE=Y7!_%__`)*#\*_^QHG_
M`/3+JE=Y4C"BBB@`HHHH`X7]J'QKJ7PU_9G^(GB+1YUM=7T#PQJ6I6,QC601
M3PVLLD;;6!5L,H.""#CD5^,P_P""QW[2$7S?\+&W[>=K:!I>&]CBVS^5?MK\
M4?A[9?%OX9>(O"FI274.F^)M+N=)NI+9@LR13Q-$Y0L&`8*YP2",XX/2OC/_
M`(A]/@T>OBCXGL.X_M&QY_\`).O(S+#XJI)/#R:776Q^@<&YMDF$HU(YK24Y
M-JUX*6EO/8;KO_!.3XA?MA?$^#QY\2K[P[\(KJ)7\FP\#1!M8DWC&;O4.C2#
MI\@92#@;:=\&/V?O'7_!,&[O)],^'>A?%KPK<2,\^NZ%:"#Q?!&S$GS8W+?:
M%&<!(V]2=HK[JHKW<-45-WK+VFEO>U:7]U[Q](V7=,^)QV.KUX>RHOV,=^6F
ME&+_`,2^V_.?,^S/,_V?_P!L'X>_M,VT@\*>(+>?4K;(NM)NE-KJ5FPX820/
MA^#D%@"N1P371?$7X&^"_B];F+Q5X3\-^(U(V_\`$RTV&Z9?H74D8]1R*X_]
MH#]B7X>?M'74>H:UI#Z?XDMB&M/$.D2FQU:T<?=99DY;;V#AE'I7F/\`QD-^
MR(O_`"R^/W@>W'M9>*;)!^:76/QD<_W:[XX>C5?-A9\LOY9.WW2T3^?+\SQ_
MK%>C_&C=?S1_6.Z^5_D:6K_\$G_A/!J$E]X1_P"$P^&NIR'<;SPGXAN;&0'L
M0K,Z#'LH%5C^S!^T'\,3N\&?'R/Q):1_ZO3O&F@QW.?3==PD2G_OFO1?V?\`
M]MKX>?M'74FGZ+J[Z?XDMB5N_#VKQ&QU:T<?>5H'Y;;W*%E'K7K59UL1BZ4O
M9XC?M)7_`#7Y'=2Q2JQYH24E]Y\P']H7]I+X7';XL^".@^-+6/\`UNH>"O$(
M7\4M;H>:V?3-2V7_``5<^&NB7<=IXZTOQ]\+;Z0[!#XI\.7%NK-[/&)%*GLQ
M(!'/%?3517UC!J=I);W,,5Q;S#:\<J!T<>A!X-9>WHR^.G_X"VOSNOP-.:+W
M7W?TSD/AE^T?\/\`XSQJWA/QIX7\0LW_`"RL=2BFF7V:,-O4^Q`-=I7BOQ-_
MX)S_``1^+CM)J_PW\-QW+'<;G383ILY;^\7MS&S'W)-<5_P[BU3X?C=\-/CA
M\5O!>W_565[?)KFF0^FVWG`_'+G.!1[/#2^&;CZK3[U_D'+![,^GZ*^8/L/[
M6GPI'[N^^%/Q8L8^HN(9M#U2;Z;,VZY[Y]J!_P`%!_%GP]^7XD_`'XH>&53_
M`%M[HD<7B*QAQU9Y8"NU??:>U'U&;_AM2]&K_<[/\`]F^FI]/T5\P>#_`/@K
M-\'_`!)XSN;*3Q=IMOI\L)EM))[:XM+J"5$S):S0RH&,AVDQM&&5R?+P'">;
M]">`M5UG7-#:]UK3XM)FNI6DM[$/YDUK!@;%F8$J9CRS!/E4MM!?;O;*MAJM
M+^)%KU)E"4=S;HHHK`D*R?&?@'0OB/I"Z?XBT72=>L%D$PMM1LX[J$.`0&V2
M`C<`2,XSR:UJYOXI^)_$'A+PO]J\,^%V\7:GYRH+$:C%880YW.9)/EXP.,$G
M/UJ*E?V,75=]-=$V_DDFV_17*AA_;R5'3WM-6DOFY627J['*^)/V,OA;XCT.
MXL5\`^#=.^T`*UQ9Z#91SHN02%8Q';D97<,,`25*L`PR_A_^P3\*?A['?QQ^
M#=!U:&^N7N535=,M;PVI9W;9&[Q;P@#*@4L0%C7')9FYWX@?M&_&;PYX)U2^
M7X*_V>UK;M)]J/B:VOA;X'WS#&H>0#J0".GIFN)_9;_:\^,7Q*\'7EPGP_3Q
MY';W&P:DFI6^CJ"1DQX==LA''*`8R,]17BSXYHPKQP;=6\DW_#J=/)QYGZJ+
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MG]F24M).,DK:V25[GGULO6%C]7?+9NUHN,E=PJ/>+<=E)/72]W:Q]W>`OA?I
M_P`.]9\57UC->2S>,-8_MN\$[JRQ3?9;>UVQX4$)LMHSABQW%CG!`'G/Q*_8
M@TGQ]H-Y:V'C'QUX/O;_`%N^UF74]$N+-;PK>Q^5=6@,]M+&()$Q_!YJ%%9)
M$90P\*_9D\!^/_B_^V#XG\9ZOH>N6OA[1]>M8R;KXV^*+:70G_L'3IOL?_".
M1Q?V9=(L\Q#O-,I<R2.REE`;EOBMXWD\#?"6_L?BI\9?&FF>'[+QMXFMV\5'
MQ))X=O)M1BM]^F62RV7DKY>YIO*M1\DK011LDY8A]J_+"/[Q7M33MH[PO27)
M;J]8Z/25DKM.YG3;G;E=KSLGM:3C4?-?I:TM5JKWLFK'UIX'_9.TOP'\4+/7
MX/$OBV^T?18/*T'PQ?3VT^E>'',"V[RVKF#[9EH@4\N6YDB4.VR-#C'JE?G_
M`/L4?$3QWXA_;AMYO&GQ$BU#QAJ=C=VWB'X>1ZE>PWWAFV2&)[;4+G3Y+Q[2
M*&0K&J/;V$$C/<Y:ZE!:*OT`KHJ1DK<SN[>O5]>NGW;=#GHRB[\BLD[=NBZ=
M/UWZGE?[=7_)D7QD_P"Q'UO_`-()Z]4KRO\`;J_Y,B^,G_8CZW_Z03UZI7+'
M^-+T7YR->H4445L,****`"BBB@`HHHH`****`"BBB@`HHHH`\_\`A)^R9\*_
M@!XHU;7/`?PS^'_@G6M?!&IW^@^';/3;K4LN7/G20QJTGSDM\Q/))ZUG_%S]
MB#X+?M`>-H?$WCSX0_"_QMXCMX4MXM5U_P`*V.I7T42,S(BS31,X569B`#@%
MB1U->H44+2UOL[>7IV#>]^N_GZ]SF_%GP9\'^/?%_ASQ#KGA/PWK6O\`@^26
M;0-3O],@N+S0WE4+*UK*ZEX&=54,8RI8*`<@5-\3OA7X7^-G@>^\,>,_#>@^
M+O#6J!!>:3K6GQ7]C=A'61/,AE5D?:ZJPW`X90>H%;U%%E;EZ;C3:::Z'+?$
MCX&^"?C)\.F\'^+_``?X6\5>$9!$K:)K&DP7VG,(BK1`V\J-'\A52OR_*5!&
M,"NATG2;70-*M;&QM;>RL;*)(+>W@C$<4$:@*J(JX"JH```&`!BK%%.[U\]7
MYON39:>6B\D%%%%(84444`%%%%`!1110`4444`%%%%`!1110!RGQC^`_@?\`
M:*\(KX?^(/@SPIXZT%9UNAIOB'2+?5+,3*"%D\J=&3>H9@&QD;CZU0\"?LP?
M#3X7?"O4?`OAGX=^!?#O@C6%G6_\/:7H-K9Z5>B=/+F$MM'&(G$B?*^Y3N7@
MY%=U12LK-=]_/U[CN[I]MO+T.+O?V;OAWJ7A3PKH-QX!\%W&A^!;JWO?#6G2
M:';-:>'KBW&+>:SB*;+>2($A&B"E!]TBH[7]F7X;66@^,-*A^'O@>'2_B%<3
M7?BFS30K5;?Q+-,,32WR!-MR\@.&:4,6'7-=Q13EK>_6]_.]KW];*_HNPEI:
MW3;RM>WW7?WON>;?$+]C3X/_`!<\!^'_``KXL^%/PV\3^&/"<:PZ'I&K>&;*
M]L-&14$:I;021M'"H154",*`J@=!BO0=)TFUT#2K6QL;6WLK&RB2"WMX(Q'%
M!&H"JB*N`JJ```!@`8JQ13N[M]W=^;[OS"RT\M%Y(YOP!\&_"'PHO]>NO"WA
M7PWX:NO%6H/JVM3:5ID-G)J]Z_W[FY:-5,TS=Y'RQ[FG>*/A%X3\;^,_#WB3
M6O"_AW6/$7A%YI-"U2]TV&XO=%:9`DS6TSJ7A,B`*QC*[@`#D5T5%+:UNFWE
MT_(._G>_SW^_J>?_`!Q_9-^%?[3DFFM\2OAG\/\`XA-HOF#3V\3>';/5C8^9
MM\SROM$;^7NV)G;C.U<]!5SXP?LW_#O]H7PE9Z!X^\!>"_'&@Z;.MS::;X@T
M2VU.TM955D62.*9&16"LRA@`0&(Z$UVE%&RMTO?Y]_4?,[W^7R['G>J_LA_"
M;7?B[I_Q`OOA?\.[SQYI*Q+8^))_#=G)J]D(EV1B*Z,9F0(ORKM8;1P,"I/%
M7[)OPK\='Q=_;GPS^'^L?\+`%J/%'V[P[:7'_"2?9<&V^V[XS]I\G`\OS=VS
M`VXKT"BCI;U_'5_>TFQ+35>7X;?=T['*ZE\"_!.M>-/#/B2\\'>%;OQ%X+AE
MM_#VJ3:3!)>Z%%*GERI:3%-\"N@"L(RH91@Y'%=5113<F]_ZOJ_QU"R_KRV"
MBBBD`4444`%%%%`'E?[=7_)D7QD_[$?6_P#T@GKU2O*_VZO^3(OC)_V(^M_^
MD$]>J5C'^-+T7YR%U"BBBMAE'Q1XITSP/X:U#6M:U&QT?1])MI+V^O[VX2WM
MK*"-2\DLLCD*B*H+,S$``$D@5^#_`.T5H7Q6^*OQG^);>#_$7_!2[Q)XB\;^
M*[R_^'>K?#/QO'/\)+K2KNX#V#KJD;-';V_E,=VT[8!A2#L.?WNK\!/VTOVG
MM>TKXS_'3Q;HMO\`\$W_``3K'@KQMJVF0S2WVN^%?B]J2V]UY?G";2[BWU"6
M29#AS#(HN%\P!71@&QC;ZRD_Y7]W-"[];V2[)O1WNMG?ZN[?S+[[2LO2W-==
M7;56L_US_P""4LWQ"G_8+\"_\+/_`.$T_P"$IC%[&G_"8*J^(CIRWLZZ<=2V
M@9O?L0MO.8C<TFXMEB37RG^T;JEU^W;I/Q"^&]G\/_B=\/\`2_#\7B"Q\`^%
M1\,-=TVS\3:W);7L1U6_U5K%=,@M9FN)_(B,VUC/]HFD,CI!#]??\$UOVIM6
M_;,_8R\)^/M>M=`M=;OI+[3;]]!NI+K2+Z>RO9[*2[LI)/WC6L[6YFBWY;RY
M%!9B"Q]VKKQ49?6')]&_D[JTEYK6UT]7>UTFN?"U%&%X]_PUO'2VG1V:NE:]
MF[_G?\3-+\2_M&^*_'7QB\-^`OB-9^&]'L/AZK:)JGAB[TG6M:DT/Q!<ZMJ4
M<5A=11SS&"WG01E$83RH4A9R*^BOV$]*U#7/&OQN^(,FCZYH/A_XF>,X=4T&
MTUG2[G2;^6UM]&TW3WN9;.Y2.>W,D]I-A)HT<HJ,1AE-?0U%*-3EYE'9WT[<
MS@Y>>\(V[*^]TT[?HOE%<L5VO;=I7;MLM#R?XC>$]0TOXU_#?4)_$^N:E:77
MB>Y$>F7$5FMK:9T?4R"C1P),=H!4;Y&X8YR<$>L5P?Q?_P"2@_"O_L:)_P#T
MRZI7>5F,****`"BBB@`HHHH`****`"BBB@#S/]H#]C_X>_M-6T9\5^'[>?4K
M;!M=6M6-KJ5FPY4QSIA^#@A22N1R#7DO_"(?M!?LC_-X?U2/X[>";?DZ;K$J
MVGB6SC':.Y^Y<X&3^\&XG`4"OJ:BNZCF%6$?93M*'\LM5\NJ^31R5<'3E+VD
M?=EW6C^?1_-,\9^`O[>'P_\`CQK;:#'>7GA;QI"0ESX9\0VYT_4X7_NA'XD/
M?Y"QQR0*]FKS_P"/7[+/@']IG1!9>-/#>GZNT:XM[O:8KRT[@Q3IB1.><`X/
M<&O&?^%0?'C]DL^9X!\2+\8O!T)R/#?BFX$.L6L8_@M[_P"ZYP,`2@``8"D\
MUM[#"U_X$N27\LGI\I?_`"27JS/VU>C_`!8\R[QW^<?\K^B/J:BO"_@G_P`%
M!/`OQ6\2KX8UC^TOA]XZ4A9/#GB:`V-VS'@>4S?),#SMVG<0,[17NE<6(PU6
MA+DJQ:?];=UYHZJ->G5CS4W=?U]P4445@:GG/CO]F'PK\7_'$VK^-='T3Q7;
MPP"WTZPO],BE@LE('F2-NW>;,S#ASCRU`5%4F1I.K\!>%[SP;H;:=<ZM<:Q#
M;RL+.6Y!-S%;X&R*60DF9EY`D(#,NW=N<,[VO$?B_2?!UK'-J^J:=I4,K^6D
MEY<I`KMUP"Q`)]JOQ3+/$LD;*\;@,K*<A@>A!JOK#E^[YKVZ=OET_4TE&?*F
MUIT[#J***DS"BBB@`HHHH`****`"BBB@`HHHH`\K_;J_Y,B^,G_8CZW_`.D$
M]>J5Y7^W5_R9%\9/^Q'UO_T@GKU2L8_QI>B_.0NH4445L,****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@#RO]NK_DR+XR?]B/K?\`Z03UZI7E?[=7_)D7QD_[$?6__2">O5*QC_&E
MZ+\Y"ZA1116PPK^?']L3]IOP'J'_``4>^)WB#X@?MC_!WX-_$;P;XVN--TG3
MX/V8M.\<W^E6MFZI8R+KGV:69I_+5"ZF7?!,)$`0(%']!U?`6J?\$OOVJ/"?
MQ0\=:E\,OVVH?AQX/\8>*=1\3P^&XO@QHVHIIK7DYE>,7$TV^0\_,^%+MN<C
M<S$J@K8N%2?PI/T3YH6?7HI:\LNJMJ:2:>'E#JY+YQM*ZVVORZ771WTL?<GP
M\\&Z+\//`VDZ)X=TS2]&T/3;9(;*RTZS2SM+>,#A8X8P$C7T50`*V:;;HT<"
M+(_F2*H#/C;N/<X[9KXC_:W_`&P_C7^S9^TUXLFO/^$)A\!Z7\)_%GBGPWHE
MG'/?W&I7NFRZ4+>[U"=HXGC!-W(GV:W!5%WNTTI9!#4I.53E6K?,_P#P&+D^
MVK2T\^RNUG0IR<$GOHM?-I=WWU=WZMVO]O45\+^-OV@_BI^SQXB\9?"F\^(F
MJ>,M>OK3P7/HOB_5-'TY+_2&U_6I](N_W-I;0VK+;BW,]OYD+_.^V8RJ`*]T
M_8O^(_B;5O$GQ9\`^*_$%YXPU#X5>*8M&MO$%[;6MO>ZO:7.EV.HQM<I:Q0V
M_G(;QXB888U*Q(=NXL34:;E=QV5]>]G%-+T<X_?I>S%?IUT=NJ35XOT:VZ]&
MD[G<?%__`)*#\*_^QHG_`/3+JE=Y7D_Q&^(>GZ]\:_AOH\%OKD=Y8^)[EI)+
MC1;RVM6VZ/J:G9<21+#)RPP$=LC)&0"1ZQ4#"BBB@`HHHH`*B6^A>]>V6:(W
M$:+*T0<;U1B0K$=<$JP![[3Z5D?%#Q!=>$OAIXBU6Q$+7FF:9<W=N)3B,R1Q
M,R[O;(&?:ORG\-?'GQ9X=^*">,+?6[V3Q!),'EN)IF/VD9!\N3GYHS@`J>,>
MF*^/XGXNI9-4I4ZE-RY[WMI9+MW>NVGJ?6<-\*5,WIU:D*BA[/OU;OOV6F^O
MH?KI17SK-\3/VDV'[OX<^#%W?WM35MGU_?C]*Y?7?B9^U803_P`(-X=LTSM#
M61MYSGUPUVQP?4UVU.)*<5=8>L_^X<OUL>4\IY?XE:FO^WN;_P!)4CZRHKXK
MN?B!^T=)+_Q-%\:6,*DB9-)\+Z?<-@]-C&0DX..1VS5'5?B3X@T:)9/&&K?M
M+:>I*EY;71;:T@`X!.]6P.O0`X]S7-_K5S.T<-47^+EC_P"W-_@1+!X*"O4Q
M</E&I^L$OQ/N*FS3+;Q-)(RQHHRS,<`#W-?G^?VAO@5*7CUSX@?&Z^D0!634
M]6=V/<<1GMVSCK^-6+GXR_LAPGSY+;Q'XAN$)8&4:E,V3U'SNJ^_->IA\1FV
M)CS4,,K=W.27X4Y+\3@J9EPY2=JN.U[*,?UJ1?X'VYJGQ3\,:&2+WQ'H-F5.
M")]0BCP>O=JYO5/VM/ACI`_?>//"K8`/[C48Y^O^X37QRO[8'[/NG2B/P[\%
M;S4I%P%;5(+6WB;'3YI97X/&21SWZ5N>'OVLEUP(OASX6?`[P?'(2D<FL>)+
M#@$]62&-2H/!P3_"?44-YC>TZF'I^M2[^Z\7^!E_;W#RTINM4_PPM^*4E^)Z
MM\>/CM^S?\?_``^=#\97&E>*HL.($72[J:XA/<PRQQ[HV..JLN?7%>'Z)\2_
M'/[.FK6Z?!G7O&GQ(\'[U7_A&?%FA7<S6D9Z"UOD3S`/X51TV@#^*O5-&^)'
MQ3\50,L/Q8_9W\+V[/C&AN;YD/OYL@4MC'MP*W;+X&>,O&9;^V?VE]6OMOWU
MT*RL=,V9S@9C+'\3UP:]+#5,PC'V<L?1</Y53E)?*\Y)/S5F<U3,LLJ2YZ.`
MK.7\SJTX_?I%V\FF9E[_`,%2-)\/:Y8>']<\#^)-`\6WD:-_9>I3PV>YFZ"-
MYS&T@/&#L!8\8KIO$O[7OC;0-WVCX9Z;HZ<CS=:\::?8A.`02C?,0<CIZ]:K
MZA_P30\"^-4A;Q9XC^(OCM8SOC_MWQ')<*"1U&P+CC'3LH]\^3^._P#@E/=?
M"?Q=)XF^%J^%_%%J/GE\(^-;%+JUE'I!=*`Z''"A\C)RS$5M3R6G6:C+'SB_
M*%-)OR;C)KY_>7//,5!7AEU)K^]4J-KU47%/Y/Y'AO[7WQIU+XS?%HWVI:CX
M?GCCM8UM;31]9BU.VLDQ\R^9&<;B^YC]1U`%?;O_``3FT3Q)H/[-5K%XCCNH
M?,O9I=,BN`5DCLR$V\'D`R>:PSV8'H17RI\7OVF?ASX2MI-#\=?"/5_`GC"R
MN]/EA\*V6A6WV-+6.YCFNKF&>,K'<ATADC$AVX#!$7F5V^\/@%XHTWQM\+=-
MU?0_$?\`PE/A_45\[2[YLM,+<X`BE<G+R(P92S!7X`<%PS-X%#@%97FD\U]O
M.;FMI)7]ZSNY1=FG9\MHQ6CLW8]^IQ]6S/+H914P\(>SL^:+?2ZMR2]Z+VNW
M*3=]4F['94445[YXP4444`%%%%`!1110`4444`%%%%`'E?[=7_)D7QD_[$?6
M_P#T@GKU2O*_VZO^3(OC)_V(^M_^D$]>J5C'^-+T7YR%U"BBBMAA1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`>5_MU?\F1?&3_L1];_`/2">O5*\K_;J_Y,B^,G_8CZW_Z03UZI
M6,?XTO1?G(74****V&%%%%`!7F/QA_9'\(?'CXA1>(/$\>H7Z_\`"(ZSX)N-
M-$XCL[W3M5>T:Z$FU1+OQ9QJK)(N`[\$E2OIU%)Q3W\_Q3B_O3:^949RB[Q=
MO^`[K\4?.^C_`/!-WPROPW\6Z+X@\:?$3QEKWBZ#3+:3Q;J]Y9QZ[IR:7*9]
M+^SO:VL,"M:7):X1GA=GE=C,9@=M>D?L\?L\:?\`L\>'M8@AUG7?%&M^)M4?
M6M>U_6C;_P!H:W>-%%")91;0P6Z;8(((E2&&-`D*_+G<Q]`HJ^>5W+J]_/;\
M[)ONTF[M(CE5E%;)W_"WX+1=EHK(X/XO_P#)0?A7_P!C1/\`^F75*[RN#^+_
M`/R4'X5_]C1/_P"F75*[RI&%%%%`!1110!#J5A;ZKIUQ:W4<<UK<1M%-&XRK
MHP(8'V()%?"/C&\\0:;^U#>Q^$_".E^*M`O;.QAMM7O[F+3VU!7ENA$9KK!>
M2.6020F0[&N5MH5+R!QYWW=?V$&JV,UK=0PW-K<QM%-#*@>.5&&&5E/!!!((
M/!!JK>>%-+U!;@7&FZ?.+RW6SG$ENC>?`I8K$V1\R`NY"G@;VXY-=6'JTH.]
M6"GVOT?==;]FFCS<QP=?$)*C5=/NUNU_*]TXOJFG_GX>?^&FO%(_YH_X5MW_
M`.OV^NH\_E&<9_-?0T?\,[?&KQ+SK7QWDL8F^];:+X7M;?;])F)?OCIV!ZU]
M`45I]>DO@C%?]NI_FF9?V/3?\6I4E_V_)?A%Q7X'S^?V`K?7/F\1_%+XP>(=
MWWX9?$1@MC](XT&/S[5<T?\`X)L_!C2KG[1+X.75+IOOS:CJ%U=L_7J'D*]_
M3L/2O=**3S'$[*;7II^5AQR++T[NC&3[R7,_OE<XGPU^S5\._!NW^RO`OA&P
M9?XX=(@60_5MN3U[FNSM[>.TA6.*-(XT&%5%VJH]A3Z*Y9U)S=YMOU/1I4*=
M)6IQ45Y)+\C/O_".DZJ&^U:7I]SYC;F\VV1]Q]3D=:Q[_P"!_@O5?,^U>#_"
M]SY@P_FZ5`^_ZY7FNHHKGE0IR^**?R1IRH\_OOV4/AEJ+;I/`/A%?EV_NM+A
MBX_X"HY]^M8MY^PK\);[;O\`!&EKMSCRWEC_`#VN,_C7K5%<TLLP<OBI1?\`
MVZO\A>SB^AXB_P#P3M^$<;[[7PW=6$K'F2WU>\5B/3F4C'X=A2?\,"^#;8_Z
M#JWCC2]O^K-KK\Z^3_N[L]>>N>M>WT5C_8F7]*,5Z12_(GV,.R/S:_;1_8\N
M_#_QF4^#_#/Q%\53&R07^L7=G-J)E<_=C298<LJH%SEF&3C`V\_5_P#P3D\"
MV_PX_9@T[28_">H>$+VWNYSJ%M>6DMO)=SD@FXQ(`S!DV#/0;"HX6O=J*QP&
M3RPF*J5Z=5\LTDX=++X?_`=;>K[F5/"PA4]HM_\`,****]HZ0HHHH`****`"
MBBB@`HHHH`****`/*_VZO^3(OC)_V(^M_P#I!/7JE>5_MU?\F1?&3_L1];_]
M()Z]4K&/\:7HOSD+J%%%%;#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\K_;J_Y,B^,G_8CZW_
M`.D$]>J5Y7^W5_R9%\9/^Q'UO_T@GKU2L8_QI>B_.0NH4445L,****`"BBB@
M#D?CM\:=*_9\^%VH^*M8@U"\M[-X+:"RL(EEO-2N[B>.VM;2%694\V:XEBB3
M>Z(&D!9T4%AF_L\?M#Z?^T/X>UB>'1M=\+ZWX9U1]%U[0-:%O_:&B7BQ13"*
M4VTT]N^Z">"57AFD0I,OS9W*.?\`VY/ACX@^*/P$,?A/3UUCQ'X;U[1O%%CI
MC7@M/[6;3=2MKUK02,0BO-'`\:&0B,2.A=E4$C+_`&+_`(<>)M)\2?%GQ]XK
M\/WG@_4/BKXIBUFV\/WMS:W%[I%I;:78Z=&MR]K+-;^<YLWE(AFD4+*@W;@P
M#HV?/S]+V_\`)+>M[SNNG*GI]ISLE&W];W372UDT^MVK/1KN/B__`,E!^%?_
M`&-$_P#Z9=4KO*\G^*?[.-KXP\?>%=3@F\5-'#KDMYJ9C\5ZC"EM"UA>QAH4
M%P!$?.DA7]R%(5V7[A<'<_X9Q\/_`/01\>?^%QK7_P`ETA'>45P?_#./A_\`
MZ"/CS_PN-:_^2Z/^&<?#_P#T$?'G_A<:U_\`)=`'>45P?_#./A__`*"/CS_P
MN-:_^2Z/^&<?#_\`T$?'G_A<:U_\ET`=Y17!_P##./A__H(^//\`PN-:_P#D
MNC_AG'P__P!!'QY_X7&M?_)=`'>45P?_``SCX?\`^@CX\_\`"XUK_P"2Z/\`
MAG'P_P#]!'QY_P"%QK7_`,ET`=Y17!_\,X^'_P#H(^//_"XUK_Y+H_X9Q\/_
M`/01\>?^%QK7_P`ET`=Y17!_\,X^'_\`H(^//_"XUK_Y+H_X9Q\/_P#01\>?
M^%QK7_R70!WE%>2_#K]F^%?#]Q_PD&I>/&O_`.U-0\K'CC5_^/3[;/\`9/N7
M6/\`CV\GK\W][YLUO?\`#./A_P#Z"/CS_P`+C6O_`)+H`[RBN#_X9Q\/_P#0
M1\>?^%QK7_R71_PSCX?_`.@CX\_\+C6O_DN@#O**X/\`X9Q\/_\`01\>?^%Q
MK7_R71_PSCX?_P"@CX\_\+C6O_DN@#O**X/_`(9Q\/\`_01\>?\`A<:U_P#)
M='_#./A__H(^//\`PN-:_P#DN@#O**X/_AG'P_\`]!'QY_X7&M?_`"71_P`,
MX^'_`/H(^//_``N-:_\`DN@#O**X/_AG'P__`-!'QY_X7&M?_)='_#./A_\`
MZ"/CS_PN-:_^2Z`.\HK@_P#AG'P__P!!'QY_X7&M?_)=0^'/A-<>`_B]IEYI
M-YXDFT"31[Z'4$U'Q%>ZE']I,UD;8A+F:3:VQ;KYD`X)!/*T`>A4444`%%%%
M`!1110!YK^V7H%]XK_8_^*VEZ79W6HZEJ7@[5[6TM+:)I9KJ9[*94C1%!+,S
M$`*`220!57_AL?PC_P!`CXJ?^&Q\2_\`R!7JE%8RISYN:#6UM5?:_FNXM3RO
M_AL?PC_T"/BI_P"&Q\2__(%'_#8_A'_H$?%3_P`-CXE_^0*]4HHY:W\R^Y__
M`"0:GE?_``V/X1_Z!'Q4_P##8^)?_D"C_AL?PC_T"/BI_P"&Q\2__(%>J44<
MM;^9?<__`)(-3RO_`(;'\(_]`CXJ?^&Q\2__`"!1_P`-C^$?^@1\5/\`PV/B
M7_Y`KU2BCEK?S+[G_P#)!J>5_P##8_A'_H$?%3_PV/B7_P"0*/\`AL?PC_T"
M/BI_X;'Q+_\`(%>J44<M;^9?<_\`Y(-3RO\`X;'\(_\`0(^*G_AL?$O_`,@4
M?\-C^$?^@1\5/_#8^)?_`)`KU2BCEK?S+[G_`/)!J>5_\-C^$?\`H$?%3_PV
M/B7_`.0*/^&Q_"/_`$"/BI_X;'Q+_P#(%>J44<M;^9?<_P#Y(-3RO_AL?PC_
M`-`CXJ?^&Q\2_P#R!1_PV/X1_P"@1\5/_#8^)?\`Y`KU2BCEK?S+[G_\D&IY
M7_PV/X1_Z!'Q4_\`#8^)?_D"C_AL?PC_`-`CXJ?^&Q\2_P#R!7JE%'+6_F7W
M/_Y(-3RO_AL?PC_T"/BI_P"&Q\2__(%'_#8_A'_H$?%3_P`-CXE_^0*]4HHY
M:W\R^Y__`"0:GE?_``V/X1_Z!'Q4_P##8^)?_D"C_AL?PC_T"/BI_P"&Q\2_
M_(%>J44<M;^9?<__`)(-3RO_`(;'\(_]`CXJ?^&Q\2__`"!1_P`-C^$?^@1\
M5/\`PV/B7_Y`KU2BCEK?S+[G_P#)!J>5_P##8_A'_H$?%3_PV/B7_P"0*/\`
MAL?PC_T"/BI_X;'Q+_\`(%>J44<M;^9?<_\`Y(-3RO\`X;'\(_\`0(^*G_AL
M?$O_`,@4?\-C^$?^@1\5/_#8^)?_`)`KU2BCEK?S+[G_`/)!J>5_\-C^$?\`
MH$?%3_PV/B7_`.0*/^&Q_"/_`$"/BI_X;'Q+_P#(%>J44<M;^9?<_P#Y(-3R
MO_AL?PC_`-`CXJ?^&Q\2_P#R!1_PV/X1_P"@1\5/_#8^)?\`Y`KU2BCEK?S+
M[G_\D&IY7_PV/X1_Z!'Q4_\`#8^)?_D"C_AL?PC_`-`CXJ?^&Q\2_P#R!7JE
M%'+6_F7W/_Y(-3RO_AL?PC_T"/BI_P"&Q\2__(%'_#8_A'_H$?%3_P`-CXE_
M^0*]4HHY:W\R^Y__`"0:GE?_``V/X1_Z!'Q4_P##8^)?_D"C_AL?PC_T"/BI
M_P"&Q\2__(%>J44<M;^9?<__`)(-3RO_`(;'\(_]`CXJ?^&Q\2__`"!1_P`-
MC^$?^@1\5/\`PV/B7_Y`KU2BCEK?S+[G_P#)!J>5_P##8_A'_H$?%3_PV/B7
M_P"0*/\`AL?PC_T"/BI_X;'Q+_\`(%>J44<M;^9?<_\`Y(-3RO\`X;'\(_\`
M0(^*G_AL?$O_`,@4?\-C^$?^@1\5/_#8^)?_`)`KU2BCEK?S+[G_`/)!J>5_
M\-C^$?\`H$?%3_PV/B7_`.0*/^&Q_"/_`$"/BI_X;'Q+_P#(%>J44<M;^9?<
M_P#Y(-3RO_AL?PC_`-`CXJ?^&Q\2_P#R!1_PV/X1_P"@1\5/_#8^)?\`Y`KU
M2BCEK?S+[G_\D&IY7_PV/X1_Z!'Q4_\`#8^)?_D"C_AL?PC_`-`CXJ?^&Q\2
M_P#R!7JE%'+6_F7W/_Y(-3RO_AL?PC_T"/BI_P"&Q\2__(%'_#8_A'_H$?%3
M_P`-CXE_^0*]4HHY:W\R^Y__`"0:GE?_``V/X1_Z!'Q4_P##8^)?_D"C_AL?
MPC_T"/BI_P"&Q\2__(%>J44<M;^9?<__`)(-3RO_`(;'\(_]`CXJ?^&Q\2__
M`"!1_P`-C^$?^@1\5/\`PV/B7_Y`KU2BCEK?S+[G_P#)!J?-G[5W[1^B_$W]
MEOXE>&]#\/\`Q4O=:\0>%=4TS3[<_#;Q%%Y]Q-:2QQIO>R"+N=E&6(49R2!S
M7TG1113IR4G*3O>W2VU_-]P"BBBMAA1110`4444`%%%%`!1110`4444`%%%%
M`'S3_P`%)/VO-7_9-T_X7#3?&GPO^&]GXY\6/H6I^*/'UF]UH^C0+IE]>*S*
MM]8C>\MK%$I:<#,O1C@5YS^SW_P4C\3?$_QOX+T.#Q%\(_B5I&L?$^Y\#7'C
M+P9%*NDZS;1^&;C6?,M8OMER(9HITCMWS<7",$D(V,VV/W;]KK]F[Q3\=M5^
M&VN>"_%^@>#_`!+\-?$<GB"SGUOPY-KMC=^9IU[8/%)!%>6;CY+UG#+,,,@R
M"":\I\0_\$[?B-K/BG2?'T?Q5\$P_%FS\:)XON=2?P!<-X?G$>B7&BQVJ:<N
MJK<(!!.9#(]](QE!X";8T=%J+DY+^KPU6_3F_EZ[NU]*MFDH_P`DO_`K5+?G
M#75>2U:^O**Y7X.:1XXT3PAY/Q`\1>%?$^O^>["\\/>';C0K/R2!M3[//>WC
M[P=V7\[!R/E7&3U5#T,D[A1112&%%%%`!1110`4444`%1WMY'I]G-<2G;%`A
MD<XS@`9-24V>!+J!XY%62.12K*PR&!X(-14Y^1\F]M+]^A4;7][8_-#7O^"P
MOQ2U/X$77CCPB/AUJUSXEBT*\\->']2\'Z]I5Q9IJ.KV-F8EO)Y5L]<5(KT+
M)=6,D,=O.(E:.19@5^E?!'[=>I?$[_@H5X?^&^@P:#>?#O5_AU<>*7U(*[ZA
M_:22Z:Z0!A)Y8B%GJ=O(04+,9E(8`$-QNK_\$H-6\:3>!;?Q%\2-,O-)^$-S
MIL'@.&R\+/:7&GZ9:ZQIFH/;7\AO72\G>/2;2W6>..V5!YKF&0L`O:_LS_\`
M!.=?V=/C'X?\7?\`":76O2:%8>(],$-QI_EO+;ZE>:;)9Q^9YK;5LK/2[6T'
MRDRA`Y*'*GIH>S]WGVO/?>W(U!/>]VT]W:4=6T^8*UM7'R]-TVUY*S6ROS;6
M1],T445B2%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`9/B
M;Q_H/@O4-'M-8UK2=)NO$-Y_9VE0WMY';R:G=>6\GD0*Q!EE\N.1]B9;:C'&
M`2)+7QCI%]XKO=!@U339M<TVVAO+O3DN4:[M8)FD6&62('>J2-#,%8@!C$X!
M.TX^7/\`@IW\(M'^.OQ0_9E\+ZXLXL=2^(MVR3V[^7<V%Q'X9UN6"Z@?!\N>
M&9(Y8W'*21HPY%?.WC'XW^-A\9/VE/[7DU7PSXJ\'^#/A[H'CC6-/$MDUMI?
M]N:N-3UFQF5<I&=+FFNDDB):W)89$L#`$=4[Z._716TU;Z6;]YNR2::O:5M)
M4[:_W8OYRJ.%K>BNO-6=M+_I]17YIZ#XGD^+OC?P#X,\)_$[XA:[\#M<^,]Q
MH^@>(-*\=ZE-<Z_I2>$+N^N;:/7([IKR\MH]5BF42_:&9&B:)7`A4+N#X;:M
MXW\7^'M:N?B=\9+:X\6?&WQ%X*U&WL_'6I6]F="C.KE;"*!)1'!AK:,K=0JE
MY&/ECN$545*Y7SQBOM)-7T^+D2OO;6HK[VM)J^B<5%R0YWTNW;LO:M_.U*6F
MFKBG;5K]$*S;7QCI%]XKO=!@U339M<TVVAO+O3DN4:[M8)FD6&62('>J2-#,
M%8@!C$X!.TX_,7Q_^T+;^%_@#X?\*>+/''BJ)M-\;>.]$T6_\1?&74/A_I-[
M!IFMR6MI!?\`B*`2ZE<WZ6[!;:V#2"X6.>2<,T*2+Z3_`,$O?BIK/Q?\<:KX
MNUS4KC4?$FM?L^?#Z\U.]D^6:6]+>(//9L*N'\T/G`'(/`K.4DJ-2OTBD_-I
MQE+[_=UW2NM;W2UE1<6X/XD[?-5(TW\M6U>S=MC]`Z*_*JX^)FF_#_\`8`_9
MOF\6?$'X@3>(/BAX37Q7>:IXM^.FJ^!M#U'4FL;#>DVM1&6\CN,2L;73;4"W
MEQ=221EHQ(.>_P"%P^./C5^R[XT^(^J?$KXE0>(OAW^S5X4\<Z;'I?BB^TJS
M7Q"T>M/<75S;VSQ1W+&2R1'BF5H7"D/&V%V]$J+4IQ?V)*+_`/)KV[VY7;O>
M-VKNTTZ<II<N\DK+UG&"_&2;[:V3Z_KM17YO_M?_`!FM=/\`C_XJ7Q%\5O&G
M@[XF:?XM\&6W@3POI7BR]TZ#5_#]Q<:8+JX73(9!#?1RW$VIPSW$D+M"L"IO
MC5%9JOP"^.'Q"U7_`(*?ZMIVK>,M!M]<M_&?B.TUKPN_Q%UO4=3/AJ&";^SF
M7PHE@]C8+Y::=<)J"W"F<RNA=I+GR1C'7[I/_P`!47;M?WDI7MRM-/I?.Z=/
MVJV]WU]Y-[?*R:O=N/=V_2JBOS=_X)Y_'#P[XE\5^/-)\1?%J;QEH3^"I=0\
M4^,-(^,6JZAIMF4GVO=ZE:W20R^#]1D225TL[2X6-%BN5(4VD;+^D%N5,">6
MV^/:-K;MVX=CGO\`6KE"T8R[J_XM===UI=)VW2>@I22G*"Z.WX1>GREKV\[C
MJ***@84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%</\`
M'7]HSPC^SAH-A?\`BN^U")M7NQ8:;8:9I-YK.J:K<;&D,5K8V<4US<,L:22,
M(HFV1QN[81&8>$_\%?/AQXB^)7P`\(V^EV-KJ_AJP\96-[XNTV[\%7?C:UO]
M,6&Y5%GT2TEBN-0A2]:RE:*)\J(O,*NL;(WE'P"\#>*/V7_"'P)^(6M:'XS\
M4>$O"ND>*-`DM=/\!7UKJ?A.UU+4+:XTR6+0([F\OEM(8;5;18%,MU#!-!YB
M1*DXCF#YDV]+2M_Y+=>EW[JOIUO9-%RC;E2UNF].CNU\[6NTM;.*2]ZZ^E=8
M_P""C/PET;X:>'_%3:MXFO+'Q-K<_ANPL=/\&:U?ZTVIP1S2S6<NEP6CWT$T
M<=O,[I+`A54R<`@FKKG_``4G^%_AR/P^MW;_`!774/%$5[<:=I,?PG\52ZO+
M#9O!'<3/8IIQNHH4>Y@7S)(U1C(-I;FOE6/PG\:/VJ/&'PTU'4K75O`L*?&*
MYU"R\<^$/AJ_A/4[K3U\)7UN^HWNEZU_:+VS&ZS8B2^B4R1K"450\+5ZW\:_
MV6/B)XK_`&R_@];Z3\5?BQH\GA_X>^*;6^^(%IHNASW5S<2W^BM#;7?F:8^G
MJ9%1V"16\,C"U.UL"0G3E:E%/KTZ_P`-SZV^TN5IV:VM="Y5>U^E[]+\\H]+
M]$GUZ[)H^E?@5^T'X4_:1\'W&M^$KZ]N;6RO9=.O;;4-+N])U#3;J/&^"YL[
MN.*YMY`K(X2:-&*2(X!5U8Y/[1/[77@/]E:#2V\9:EJT5SK0G>RL='T#4->U
M">*W0/<3BUL()YQ!$K)YDQ01QF2,,REU!\+_`.">?@IO`GA^ZT?XM>%O$NL?
M&BQ\=74VL>+]2\,S7-GXCU0Z>T46N6-S#;+:6=O-ID20`1^6L#;K5V>5]TVI
M_P`%";O7/AO\4OA[XZ\,7'CC3=8M-/U;0)KO1?AQ=^.K.6UN3:3-;2VME*ES
M;7+O:QM;W;!K6,Q2K<`[X@8Q#Y.5T];I/KJW&^FB>LK)72E9KW>;W0HJ\FIZ
M;^6BDUJ]5LMU>+=[-1]X]-^(/[=WPI^&5WX;CU/Q6LT'BJQBU6RO=,TZ[U2P
MM["9E2&^N[JUBD@LK21F`2YNGBA?:^'.Q]OK-U=Q6-K)//)'##"I>21V"JB@
M9))/``'.37Y?7W[.GCC]GC]EG7/A7J7@CQEXA\1?%3]GW1?AUHDFFZ3)JUE8
MZW;QZG!-9WMW;1-#9QHVIP2_:;@Q6[A9RK`H17W;I7P-\4>,H==\-_%#4OAI
M\0/ACJ=BEE;^')O!4JSL%V?\?MQ<7]Q!>*=I.T6D/)4]L':M32<E!WLY)/H[
M-I+36ZLKO9WNK*Q%TG&^MTKZ6>T7?=JS;DK7NG!IMNZ7D'BWXB_LT?%_2_#O
MQZF\4>,/'NBZEKWV'P_;:-K/B;7M)UK4M/FEC#67AVTDEM[QX)+26=98;*0#
M[,;D-A!,/4?$G[?OPP\-_#WP=XF74O$^M:;X^69M$@T#P=K.N:C<^2,SA[*S
MM9;J`PGY)1-$AB?Y'"O\M>/?L[:_J'[+_P"Q1JMCK7AOXK>'EU;Q]XS@2^\*
M>$9-7U3P[!<Z_JLUI?IIXM[B:2)U:$QLEI<1_O8G=/)+./)/#'P.\*^'OAS\
M,]2^)^A_M16>G:#=^+%\/ZCX*LO$5CJ&JP:CJ<=RM[K5MH(&JP7UTB>>5>."
MV5FF$D-O(8K=,G;6%/9.^NRNM5VYGHELWI9.SM<XVFW+HY1TU;47)1DO[NFN
MZ6KNKI/]$O"7B>V\:^%M-UBSCU"&TU2VCNX8[^PGT^Z1'4,HEMYT2:&0`_-'
M*BNIR&4$$5F?%'XM>'_@QX>M=5\3:A_9NGWVJ6.C0R^1)-ON[VZBM+:/$:L1
MOGFC3<1M7=EBJ@D?`?Q8_8TU[X_>"/%FI?%;P'>>,O'&C_`:U31KNZT]KN:U
MU])=6DC>U9!M758MUOB6#]]&TIV,!*=V'^T!^S/<?L^^,_$,W@OX:^)K/PC/
M;?"SQ1K,?ASPQ>ZA)JVJ6?BR>?5+UX[:*2:\U!;5(I+AP)+AU$;2;CM-73Y9
M5(QE[J<DG?I%SDFV]+/EBW>UDVMUJ#@TF][*^G5VIO3YU$O-1EL?H]\1/B5H
MOPI\/QZIK][]AL9KZTTV-Q#),TES=7$=M;QJD:LQ+S2QKP,#=DX`)&[7R[XH
M^,-G^V;\5_A9H_AKP[\2+?P[X?\`$<GB37[GQ)X!USPU`HL[24VD0.I6D`D9
MKR:VD4*&'^C,<AE&?G_]G+_@F+X$OH_@"OBCX+V<\>M^`=67Q]%JNAR/%J]\
MATYK*/6$D7;<20DSFV2Z#&'R_P!R$\L;<)2E",G);7?JN6Z^;:DO2S!6;]U]
M%]]VFODDGZMK2Q^B%KXJM;SQ7>Z,D6I+>6%M#=2R/I]Q':,DK2*HCN&00R.#
M$VZ-'9XP4+JHD0M4^(GQ*T7X4^'X]4U^]^PV,U]::;&XADF:2YNKB.VMXU2-
M68EYI8UX&!NR<`$C\K/"/[-7Q&\??!+0M+\5^!_'UW)JG@OX*Z3J\=WI=ZEQ
M,MGXDO&U*&5MH?=!;.&GR=T<;AGV@Y/OGP0_9PU#P1^TEJ7PYT+P#=^$?A/H
MWQAE\7:;:V6B-8:!:V%IX:TUXDM51%@5)-8N3,JH`K2VURP.^-J['12JRA?2
M,FK]U&5--I=^6;:U>L7TV*T7"Z6K27WN#DE?_$N5NRLG?I9_7W@O]H[P-\1O
MC'XO^'^@^)M-U?QAX!@L[CQ%IMJYDDT<7?FFW69@-BR.L,C>7NWJNQF4*Z%N
M)^)G_!0?X;_!WXB1^&?$<7Q*TZ^FU:UT.&\_X5IXEFTB>\NI$B@B348[!K-]
M\DB(&68KN.,@@XX/X0?"?2?V8?VX/C5KFC^!9O#'@%?A_P"')H!X>\,2_9;R
MZCO_`!#<7BVT%I"3<7.;A)'CA1Y6:="5)D&>Q\;>#M4^+G[>_@UM0T_4!X+^
M&'AN;Q'9236<JV=[KE]))9Q.LA789;6SCO`4W%E&HJQ4?(:QBKSII[/?Y)MV
M?2ZBU&Z>K5PK1Y74Y>EN5_XE&UUUM*:O;9)^IT'@K]MOX:_$/XT2^`=)UK4K
MCQ`LMW;032:#J$&DZC/:';=6]IJ4D"V5W/`0XDAMYY)(S%,&4&*3;ZO7QW\0
M/%.H_'+]N;X9WFE:'\8%U#X?ZY>0ZEX>\1^#I+/PMI%J;.^MI-;MM5$"P7-W
M(LT,<21WUR/*NG!M8Y!+)!Y#^SE_P3%\"7T?P!7Q1\%[.>/6_`.K+X^BU70Y
M'BU>^0Z<UE'K"2+MN)(29S;)=!C#Y?[D)Y8VXRJ6I^TMT?SLF[I=G:R=WKI>
MZ:1*-IN/I\KMJS?=6[*]T[)--_;6H_M(0:3^T;I_P[N/"/C6-=5@=K7Q*;*$
M:)-<I"9VM`_F_:#((07,H@^S@_N_.\W]W7I%?(__``3:_9=\5:)\*/@W\0_%
MWC;XI6?B2Q^&^E^&]1\&:S#9+I]F8X!OW)-9_;H;AI-C2E;A#*T$(D#K%&J_
M7%=-:FJ<G!.]FU?TDTGVU5GZ;ZW9.MW?R_)7_&__``%8****R`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@#PG]KK6[*S^*GP=\/72:]Y?Q(\177A>[;3M7-C&;9=+O=1=)
MDV-YJ.U@J?(T4BB1L2!6D23R7XF^/_A_\$_C+X\\.^//%'Q!TO0?!NB^';N\
MUDZQ=:@^LVNKWU]96NBFU@@:38DMG&!*A:XE-RP:3YI#)[?^UW\#/$?Q47P#
MXD\%R:(WC+X7^)1XDTNRUFXEM=/U;=97=C/:33Q1RO`'@O)2LRPRE'1#Y;C(
MKQOQO^Q'\3/CSJFO>-/%<?@'PWXT\0>(?`\G]DZ3K%YJ>G6.E>'M;_M)O],E
MM('GN9O.NL#[+$BGRD+'#2UA]4HU:BYX[R2;?\K<4WOK9-Z;Z.ZLU?W*/$&.
MPU%4</5<8J*LE;27/)RZ7UA97VO:WO+3%_X7C\(M'L]4O/$WCKXE6MNWB6#P
M?:64<6O7>M:U%)I%OJL.BW&FG3DN8YA!*3Y<:2W+`$/<&6:>!=OQ-\4?@CX9
M^$'AWQS??$CXL:IH?C"6YL+:*SL-9U+5-0L;42>?IT^G6]J]Y##:F%UGEDA2
M>)@ZS3!I7#ZD'["?BZ+]K1?'AU'PY_8Z_%Z3Q_Y/VB;[3]@;P8-"$6WRMOG_
M`&KY]N[9Y7._=\E>:^/O^"77CUO"G@_4-*FT?6O%'A7Q)XXNQ80?$7Q!X(MY
MK#Q!K#ZC%)_:6DQ?:_.A$=JKV[1M#)OF^8%(Y*SJ8&AR1<8J[46_)\J<D_-R
M;5]$M6[JYU?ZSYFII?6';K:RZSLUIHDHPTU?O1M\*1])W/Q)^'/['_P&O?B3
MXC\?:A=>![H6#)X@U*\DU.&&TN)8X+%(VB5B8=UQ&!*0S-YADED;EZSIO^"E
MGP=M_`EAX@;7O$`CU+7G\+PZ6/"&LG7AJBV[71LGTK[)]OCF-NOG*CP*6C9'
M7*NI/G/[9O[-FO\`@G_@EOX;^&?@71;/5M<\*WW@NQL+&UM;Z\L5^QZWI;.Q
M226>Z^RQI$SL9)9'2)&+.=I:I_#/[&?Q(\5_';PA\3O%S>!]'UZ#XBR>+M9T
M?1]5NK^SL;%/#-WHMO#;W,EK`US.SRQRN\D,`"LR#=Y2E^ZG1IQ<XP^&,FEZ
M+D?S;4I>2M=]G\_7Q5;$Q^LXEWJ23;\VH.RM]G5)==[+NO3]7_;]^&.F>/O$
M/A6/5-;NM?\`#D%V\L4/AK5)+6^N+6V%S/8VEVML;>\ODBRS6=M)+<J$DS%F
M-PO#_"+_`(*R_##QM^S_`/"KQMXF;7O!]U\4-"M]<&FR>'M6O%T**1XX6FO)
MULU6ULQ-($2^NE@MYE'F(Y3+#$\._L/?$"'XI:3H=]<>#8?A;X1\>ZY\1-)U
M>+4+BY\0:A<ZHFH$V$]I);"&".*;5KH_:8[J1Y([>%/*0R.R^(WW_!('XC:E
M\-/A]I.H6W@_5KRR^&>G_"OQ)!'\3O%.@Z9'::?-<+#>B'2TMCJJSP74QEL+
MIH51@J)<E6DD94+.W/UY/_29\W^'WN16E>RU3LVU-2,5S*+VO9]_>26E_P"2
M\]]WR?$E?ZT\7?\`!0;X?_"W7?$UGXLU2.SDT?Q<G@VQMM'T_5-9U#4;]M*@
MU,6_V6&RWFX,,K,L=O\`:%953$GF,T,?>_"7]HSPG\<]$T/4O"]UJVI:?XBM
M;J[M;EM$OK:*+[-,L$\-PTL*BUN4E8H;:X\N;,<N$/E2;?`=)_8'\6:5^U+;
M^-$U'P[_`&);_%MO':PFYN&NO[/_`.$+&@B+#1$&?[4-^"Y7ROFWE_DKTS]C
MGX)^+OV<O!4OAG58?#E]I]]XC\4^(9[^TU*8S0'4-<N+ZSA6%K<!\P73>:YD
M7RY(@JK*KETI1CRQUU<8M]->1.2_\"O]W+NTR*FEG'Y^5W/\E&/37FOI:QU7
MQ._:F^'OP?\`'&D^%=>\5:;#XPUX(^F>&[7=?:YJ,;2>69H;"`/<R0H=QDE6
M,QQ(CN[*B,P\R;]M7QEH/Q?\.VOB3X7P>'?ASXR\3W?A+1-9NO$+QZ_+=01W
M4BW,^DR6B+'9S"RN'CD2[EE,30R-"BN_E=OXK_8]\+ZM\39/&V@:AXI\!>++
MJYCNKZ^\,ZM)9V^L.NQ':]L&WV%Y(\*+`9[BWDG2,*(Y(VCC9/'/A+\!OCMJ
M/[56L>,/BMX5^$OBBPO+F]TS1]3M/'FHE_"6A2;@D-EI+Z.L/VJ50GVF=[SS
M)22HD6&.*!>>\[)1^*SWVZ65^[O:[:5N9M:)2<N6TGTTMW6CUMM9;V5V]%=7
M;4O@O_@J+Y?AJ?Q)XZ\"/X7\+ZUX$U+XE^#Y[#5SJ=_K>BV/D/*EU;O!`MI?
M&*[M'6W26X0^:P\X%.?3?V:/VF_$?Q/^(/B3P/X^\&Z7X'\=>'=,T[7FL=+U
MY]<L;G3KYKA()%N7M;5O.66TN(Y8_**H50K)('R/`/#/_!,KQY\0?AS;^"?B
M)JW@VQT3P)\,-8^%GA+4M#EGO;C5(+X6D2ZK>VLL,*6LT4.GVO\`HL<MPC.\
MI\U0%!]J_99^!WQ"T_XR^*?B=\5(_!NG>+=>\/Z3X5ATSPOJ5SJ6GPVMA)>3
MFY,]Q;6S^9/-?2GRO+(B6)`))"S$=5J=_=O:SWWMS3Y7VYG'DYET3T2::4U/
MANOBOTU5_<NM=>6W/9[N25W9KFC\1_\`!4+X)^%?&=YH%YXFUS^T;/4KK0_W
M'A'6;FWN=4MC()=,MYX[1H;C4/W;%+.%WN)5VM'&ZLI.MJG_``4)^%.E_"SP
MWXP_MK7KS2?%EY=6&FVVG^%=6OM6>:U:5;M)-.AMGO8/L[0R+,9H4$++B0H2
M`>:T#]C_`,3:5_PBGF7VAM_87Q<UGQ]<;9I?GL;S^U/*C7]WS./ML6Y3A!M?
M#G`W>'?$7X>^-OV`M8\/^.--TN/QIXDN/%'CLC2K#0/$FKVITK7M734TE:;2
M=*OI+>ZA,%JICEB2*;?,HF&Q7KE4G[).7Q67W\L79+SE)QWTLV[[&LJ:YVHN
MZN__``&]37Y*,7MKSV5CZ%O/^"B/@'&@:U8ZA#?_``_U?P1<^/)_$J";;;6*
MS6T-H$MA$9I9+IIY!%&`'<P,J)(QVB!?^"HOP6;0#??V]XH69=?7PL=*;P1K
MJZT-4:S-\MG_`&:;/[9YQM1YH7R<E<>HKYS\#?L<^.?AE^PC=:_XS2.U\::/
MX9\$G1],LM)O]8DMI]#N(]26UN;2QAN;C$NHR31RBU6Y*1!)%W-&:UOV7/A#
M\3OVH_C7IWQD\2>'K'P3:6?Q4_X2<:;>0:I9S3V$?A"71?W$=_9VMVS?:YOO
M7-K:;DC=E0KY;R]*@O:2IO[+=WY<ZMKW<6U:RLX\SWY3+3DY^Z=O-J%[==Y[
M:O1I6T;/K3X^?M4^"_V:-,TNX\5W>M"76FD%E8Z-X>U'7M2N%B3?+*+.Q@FN
M/)C4KYDIC$<9=`S*74'D;#_@I#\&=7_X2N2Q\77&H6/@G3(]6UC4K/0]1N=-
MMH98+>X@1;N.`V\L\T5W;M%;Q2/-,)!Y:.00$_:3^#_Q`D^.7@SXH?#.Q\&Z
M]XB\-Z-JGANXT;Q/JT^CV<]I?R6<YN$NX+2[D66*6PB'E>3MD65\NA1=WE'C
M#_@GCXZ^)O[/WQX\/^)==\+W'B;XG^+='\9:?/I%SJ&D6<EUIUCH@$4CQL;J
MRCEN]*D7?!+++#%*CJ[2+@8T]5)RTLG]_,DE_>]U\[M;;E6MVM%&-XIO>U_U
M?EU6K?1[:/V8?M]?"]OA!'XV&K:^=,FU=O#Z:</"NK?\)`^I*&9K(:/]F_M'
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M1YG=_P#@*6G7F36KY8_7MY_P4,^$VF_&1_`-QXAU'_A)K?5+70[P0^'=3FT[
M3K^ZBBEM;:YOUMC:6[SK/$(A-*GFLX5<ME1@W'_!3;X9>$]$LI?$FJ7(U35;
M_7[73].\,Z%K7B.YO(M'U%[&[D6&WL!.3$P0R@1%$)<K)+$OG-R/BO\`8*\8
M:[IOQ(AAU+PVK>,/B_X4\?V1>XG`BL-*&@"XBDQ$<3M_95QL5=R'?%N=<MMC
M_9Z_8%\8_";XOZ'X@U+4O#,UGIMG\0[>5+:XG:5F\0>)+?5+(J&A482")EER
M1MD("^8N6&<KJDI+XK-M>E*,DOG4;AN]C.G%.$7-ZWC?TO-2?X1>VGST]7^(
M'[?_`,)?AG%X2FU3Q3-):>-M/AUC3;S3M'OM2LXM/E>)([Z[GMH9(K&T9ID`
MN+MHHOO?/\C[?9*_./Q1_P`$>O&UW\.OAKI`_P"$;\0W%K\)]'^%WBR*3XB^
M)_#.FVZV/FAKE(-)\DZQ!(MW=*UK=M;`B./;+'YDM?HM86:Z=8PV\>[RX(UC
M7+%C@#`Y))/U))K:K&FK\CO[TDO\*DU%^KC9WV=]+6L9^\FEOHKO;6ROU?7F
M5GJK)ZJ29-1116)04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
;`%%%%`!1110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tpg16a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg16a.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.C1!-C0T,S9&0S(P.3$Q131!,S`U.35&-$1%1$8U0S`U
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C1!-C0T,S<P0S(P.3$Q131!
M,S`U.35&-$1%1$8U0S`U(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C1!
M-C0T,S9$0S(P.3$Q131!,S`U.35&-$1%1$8U0S`U(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.C1!-C0T,S9%0S(P.3$Q131!,S`U.35&-$1%1$8U0S`U
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`"V`3@#`1$``A$!`Q$!_\0`Y0`!
M``(#``,!`0$```````````<(!@D*`P0%`0(+`0$``04!`0$`````````````
M!@$"`P0)!0<($```!@(!`0,&!`\%$0P+`0`"`P0%!@<!"``1$A0)(1,6EM87
M,5,5-D%1(M*35-15E=565[<8"G.S-'1V87&1H;$RLB-UM2:V=SA8>!F!8C,D
MI*5&)Y>GUTC!T4)#HV0EA6:&*&@1`0`!`@($"`H'!`D%```````!`@,1!'$T
M!08A,4%1$U,V!Y&QP=$2,G)SDQ5A4K+3%E87@>$B8_"A0M(4=)15"&*"DK,8
M_]H`#`,!``(1`Q$`/P#OXX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'/#XZ_A"
M4/N]7=E;B6';6Q$%L75[4BWCH-':JF\=C<&>SH,RS6T&DZ7-CE#7UV7F'O8O
M,*,I5R/MI,8#CLCQ@S@:H_V='P;*NG&IVL_B=,VRNT4/VEE<,V'9V40)9#)/
M5<-?7E7:M&M4L00*2P=<K>'",M)@'1,G7.9R0US)`(T`B<9*R%U_#/NH'AXZ
M$^+#.92_SZ]9=4/BG;>5W7I\^7E.MJ;&W,[NU8U[4L=<5:)(U%.TRMNQW1O2
MG&(TQ11>51AH"P%%9P$-YGA]:Q/&J&L<1@$[>BI;>,Q=I+=6R\[+%V_3O8VX
M7<^;VY(218,&'#01)',;:T@#V0DLS>D*QC'8X%U^`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X&MN8^)G5$2?-V&8=>VFJ+TJA-72!X<5T96Q9'<,JMJ2V'!HM
M#:D-E:=G)D"0^P('ABQ(?.88!N*H6`J<DI3SL!#BKQ4YX3)55*I-';5=MLX*
M3)Y;>6N;=;M(#45C3D7BT"EP[7:;04RE-`+"1R-'9K.A:6E(>E=#G82HA26C
M)3X5&AM+JNR(M<E8US;T&5*%T)M2"1&QX>L5IAHE2N+S>/M\F8%"I&9D1B12
M<U.90C"A9R(L><ASY<<#/.`X#@.`X#@.`X#@.`X#@5*W[0K7/13=)M;4:MQ<
M7#4[8I"@;T"8Y8N7+5=0S`A*C1I$P#%"I4I/,"`LLL(AC&+&,8SG/3@:W/V:
MF.2&)^"YIPP2IA>XR^H45O\`?660M2]D=T?>+TLI4GRI;7-.E6$84)C@&%Y$
M#&!EC"+'7&<9X$IRA,7NGXFL>@2=.`[6SPQ!M5NV$(!00L=A;Z6G%U6*ICZ@
M0#,)706N%.O"F2JA8[0TL@D[5D>,&)?(&EWPBK!U8LOQCKG=M6=B+.2Q"%0>
M]H'*D%Z6]8]@7CX@UIO%@H9G);Q=X>O2-]<0NFJ(1YRS1122C;W1<3V,Y)[.
M3^@=D_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#6%LOHI-[[EFYCP@F<6C:/
M8+7S5&OJZ4K"'5Q/8;'UGMNZ+=2KIHV$)4H#H4]/$V9DQF$*S*XQ*6LP'S!F
M"!C"IPM'?$(17G;N\K,3IZ#:6\8=-J-E%.N=E7(IH:+5"ZPNFH_#I<PV:EIM
M'/WNQVB1U+EP<V]1'4C:O0N&$1"E(:1E<<&X77RG4E%:[TE0);LHD"&GJ9KB
MH0/IF,H%3TE@$)9X;AU$%*(L2(]Q*:?/="Q!R6(?U.<9QC/`\41@D?$[V"A,
M'(S4K3+42)N*/FLT4=T2G06&.1B<H9T@,,P4)>O.-Z9SGZHP7`SCW>QCXM\]
M;Y?^/>`]WL8^+?/6^7_CW@/=[&/BWSUOE_X]X#W>QCXM\];Y?^/>`]WL8^+?
M/6^7_CW@/=[&/BWSUOE_X]X#W>QCXM\];Y?^/>`]WL8^+?/6^7_CW@/=[&/B
MWSUOE_X]X#W>QCXM\];Y?^/>`]WL8^+?/6^7_CW@,5[&,9QG!;YC.,]<9]+Y
M?\./_OO`_15]&19R(0'W.<_#G,OE^<^3R??WZ7`]5/6$+295"2-S@D$N4F+5
MPDLDDZ82Y::`!9JU:(AX+RK6&EE!"(TSM&""$.,YZ8QT#UTU25\A-P>A81H5
M&`B!A0A>'Y&HP`6.@P8/3.A1N`CQ\..O3/T>!]'W>QCXM\];Y?\`CW@/=[&/
MBWSUOE_X]X#W>QCXM\];Y?\`CW@/=[&/BWSUOE_X]X#W>QCXM\];Y?\`CW@/
M=[&/BWSUOE_X]X#W>QCXM\];Y?\`CW@/=[&/BWSUOE_X]X#W>QCXM\];Y?\`
MCW@/=[&/BWSUOE_X]X#W>QCXM\];Y?\`CW@/=[&/BWSUOE_X]X#W>QCXM\];
MY?\`CW@/=[&/BWSUOE_X]X#W>QCXM\];Y?\`CW@,5[&,9QG!;YY,]?G=+L_T
MLOG3@9MP'`<!P'`<!P,"B'SBM+^6[;^C>`\#/>`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'H.KJV,36Y/;TX(FAF9T"QU=G
M5R5$(6YL;&].8K7N#@M4C+3HT2)*2,PTTP00%EAR(6<8QG/`JHX[]Z3-%*QW
M8YSVKH=!0\NDXH3&+:567%R8*^R\!KB4;&&Q_&X81*GTG+0J$8E"+)Q92<PP
M0<`#D6`M2T.[3(&EK?F%T;GMB>VY$[LKTT+4SDTN[2Y)BEK<Z-;BB-.1KVY>
MC.`:0>4,91I0PB"+(<XSP,3B'SBM+^6[;^C>`\#/>`X#@.`X#@.`X#@>FX=_
M[@N^2NY_*G<U/R;\H>>[AW_S(^Y]^[M_QCN?>.SYWS?U?8Z]GR].!H58=_/$
MG,>]\(B&GM*[.<-,8]5[*_V)"K%L>N*DC]NS,+9.+&:)G(K7-1@<HU0=".!<
MJD86\Y.L$H6HVTK(3C#C2`DO5OQ5[(V6\*VR?$%C.K[J_P`RKVN[J>V&"1.8
M1U7"KLEM*R"<15T%6KIAV<IJVQ1U7PS*O&'=J3K@)E'FTN%XPA,-"3O">WZL
MG?NN;EEL[CE,+6NL+*8H1$;MUME,LE%!W,F>:TAT]>PP<^?M#%-4KU63M*1,
M+Z%2GRE$XI\]W,%V30%!M=X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%(
M?$G;9(]Z%[71^)UT]6N[R:F99%C(-&RUZJ1N+%)TH6"5.<>:VD],ZR%]BT7<
M5CLC:4I@%+NI0@1%9\X>'@:-Z#E#K6EO1S:JQ6W9Z\]9X9LKL:ODFRTIU`L^
M+V=:LMN+4*@X`T3!PU'@5,Q^;1N+0U;5ZF!)GYMA;>W+C3\9,+_MZY>I#=_X
M;<#G5:Z"ZNPB<M*Z+S9FJ!D[W'Y`F4A<HSAT[V[L;$]M1IB56VK6%H<$R92W
M9$4-$,D2;ZC)?D"=(8CL;#Y9>#9#"1J,31O[P87#GTLD8_=Y!<@R22*=&#*#
M@G(<9P(8\Y%C.>N,9P'`9_W2Q/O_``OU0?/;?@.Z6)]_X7ZH/GMOP'=+$^_\
M+]4'SVWX#NEB??\`A?J@^>V_`=TL3[_POU0?/;?@.Z6)]_X7ZH/GMOP'=+$^
M_P#"_5!\]M^`[I8GW_A?J@^>V_`=TL3[_P`+]4'SVWX'Z%)877':?X9D/7':
MP&(O@<YQU\N,"S-A8#G./H],]/I<#6U!O#UNNIM<KAJ.G]QG&L[>MW:*T=L'
M38UCIYL<9`;/++M[-EJ&"3P603EUC<JAP(VG2Q1<F"<@,<&A*$0#$IV<YP%3
M::\,NT)YJ_MCJU(]NE!-7WO+M[XA>Z:*TBR1=;+;GORTD4E]]L).*G+A[K6B
M"(P+&M)"V_SK(X)%QAJTPY9D2@878T;T1M'4%QV`FDLV)CMVV;LA,:_E4Z>T
MU&I*?@C255U4Q:H(@W0ZL(E8CJTL2DR,10@QT6=[--<560BR$L)8`\"_W=+$
M^_\`"_5!\]M^`[I8GW_A?J@^>V_`=TL3[_POU0?/;?@.Z6)]_P"%^J#Y[;\!
MW2Q/O_"_5!\]M^`[I8GW_A?J@^>V_`=TL3[_`,+]4'SVWX#NEB??^%^J#Y[;
M\!W2Q/O_``OU0?/;?@.Z6)]_X7ZH/GMOP'=+$^_\+]4'SVWX#NEB??\`A?J@
M^>V_`=TL3[_POU0?/;?@.Z6)]_X7ZH/GMOP'=+$^_P#"_5!\]M^`[I8GW_A?
MJ@^>V_`=TL3[_P`+]4'SVWX#"2P_HO\`"^GT>D0?,?T_3?/3@:?/]J/N;:W^
M$>H'@X;4W/5(^IC;9%Y6S2>F9LM;U(A99WZ%UY<CJIL)Q8'1.0:;@UQ;VE04
M#).1$=#PYP%[=.]OE6UK-.P2?6W8S5>QZR>6AHF=7;&0=)''?S,A;CG2/R*'
M2F.N\D@M@19U3)C@=[:G$\254080I+(-#@.0N5P'`<!P'`P*(?.*TOY;MOZ-
MX#P,]X#@1[BS:S=54PC[?9L*$]0UO<%$R1MDOC1[U!TJ3!I*URD*'*Q4./@;
M#`"R,Q<2`HH8/J\=,9QP*TZFGNTED%W2(.R4ZO:'1BS%->PP3LYU(\13Y)*K
MVK96>XIG6N*^BYKF])'^0N"?)HEAI02A9*$7VRPB"%MHW+XG,4ZY7$)1'94D
M:W-6R.2J-O;:^)VYY09!A<T+CFQ2J+2.:+)@<&IS,A-+ZX[0<=>!D7`<!P/&
M</)91I@<8SD!8QXQGX,Y"'(L8ST\O3.<<I,X1B-25/[Z7Y=\5S*X/5=?+$Y"
MY6VN2'OTA,6-:U(I/3^94A`M#G(#PD]LHS`<!,#GR>7&<8_(.V?^26\&R-IW
MMGU[+RE46KE5,51<N?Q1$S$3Q<$\\<Z.7=M7[=R:.CIG">>4J_K'[:Y^"EX)
MC^>HDOW=CKSS/_J7;G^TY7XESS,?SZ]U4>&4$4/L!M,@16Z%NJ&#J0&[#7&:
MIR:ID.<E*AR(`SB0>;6AZE@&+.,9S\/-_/?\F=MY2JS$;*RT])E[=R<;ES@F
MN,9CBY&2YMJ_1,1-J.&/IX^6/V)O5;,[6(4JE>OJ*NT2%$G.5K%JM;(DZ5(E
M3%B.4*5*@UQ"42004#(AC%G&`AQG.>:,?\I-NS/HT[(RTU3_`#+GF6?/;_51
MX99'X>NZJG=Z$71,AQQI84=67L_TVVJF<]<:DDR>/PV#2,^1@)<!#4)"5:Z5
MFE$@R+.1$$`,SV<CR''ZBW&V]M'>7=RSMG:MFUE\W=F9FW;F:HICDB:JN.KG
MPX(G@C'#%[N4O5W[$7;D135/)#8#R7MDX#@.`X#@.`X#@.`X#@.`X#@.`X'*
M9XD:S;.V=Y)[IJVNV\T/IRWK)I2YIU8FOY;^P1&+Z$:P:T2>>V7%ZEL>/I3/
M1Z^K<VD>5;,N0>>PN<2BF$G)7=C<",#H-T<46^KTTU757^!Y!=BG7^IC[2#)
M0!+DV)N;"&4;_P"DY8!""7)LKLBRXAZ_4K?.XX%IN`X#@.`X&!1#YQ6E_+=M
M_1O`>!GO`<#_`#[I`YQ*+:^>))4U;RUKW,KFP=:+JNS9ZV8EJBX:Y[&ZX[+K
M?$`CQWNSV(?7(B66Y,J<3'R=YD$AALLRZ.N8)#57FLA;%I0N!L#T6MR%M'AR
M^*_0E(SJ#OE_7_:OBCNFIANK$,?JVI2\7>NM9JQ4NC]I[#4BQ_8Z^C,2<98U
M(1I2G0W!LBPH/3JEPS,G9"U?[.BHCR)MV?BM>,5,22MFN':6NI5]T?3)=&1^
M466ZT#W&S:*E,:2.:]%)K`UY<V0A.[O1F`O)BM\&F><B<DY_0.F/@.`X'@4_
MP91^X&_O8N4J]6=`Y,M5I,_Q>(K5D?=5C4H/=WH@\:0X1>#ROE=<+`#@8SV3
M,`%Y0]<?4Y\N.<OM\HB=X,QCUM?CE!<QK%4+5^]ZRORN=?LV>1;T*6)$E06Q
M8I*:T<%2MT+P;?-MJ#,!.SCM''/I(C3,_3R,7ESSUMKTT^EE>/4,O]F62Y_9
M]B'MW-9D]>:XDC4XRIW4-ZY((E:E[T,!2HCLB%E.?@&0Y,(&(..T#.<A%T\O
MDYK[-II_QMN</[2VGC3I^SM9ZZT;0YQ_II6!_2JRF\<Z/=V78_+::O(F.0U:
M'0+R?MPX#@.`X#@.`X#@.`X#@.`X#@.`X'*7N!>4MTT\23<J=5)XKOA?ZQNF
MPK3K<LL&A-O(].I18$6=JRIYMC4?D71AL>)`:12R/N(#\%%XRE-082F8)"HR
M>>>'2)K1-7:R->:3G[]8E;6X]3.KX5)76T:;2+4%3V"X/+`A7*YA7")R<WIP
M20N0''94MQ9RM2:!*8#`C!YZBR$X<!P*%^)[8%F5?H5LG,Z>6GM5A(H8VM3,
M])UZMF.8$4KET<B<ED8)$B;W=3$LQV+/BU=EZ"D589<)^_9)-"GR6(-$=/UK
M&%5^1[1R^'G+1K<Q[,77(Y.BJ_;+8=PH5[F3=J76%FU4PPRUYG.&VXHP]QMJ
MECR[R**'RE>V*7]+E\3$)BL]U2AOJ\-V=SVP]!M7YW8CJ^3":O=0,JQ:_/QX
MSI#+$Z7O:.//;BZN(RQO#A(6!(D4"<CS!9<1'=Z&:/)V3!!.,,DTG&]V6:.N
M)"2:;-4`C$XWN%#,3B#7L%+"`P14E&2(0P`P/'8$+'9%C&<]>N,!G_I+)OS=
MR#\,PWVCX$;#V*@I8QEF.46+,+&,HPL=I5,$99A8\EF%C"*;X$$98PY"+&?+
MC.,XSSPZ]Y]VK=<V[FT<C373,Q,3?M1,3'!,3$U<$QRPQ=/8C@FNC'3#U0[`
MUN7A3V54+!A7D0EG9LVH`X4B&'(!B4])KCSV1!STSD77KCEOXJW7_P!RR'^H
MM?WU/\1E^LH_\H0!2%[5PWRW90P"R&DA,V"..18#8U3I0E$F4=1Q!HDHAS(H
M`@'FD"[>2LB!D0>F<]K&<8NJWGW:IB)JVCD8BJ,8QOVN&,9C&/XN&,8F,>>)
MCD5Z>Q]>CPPL"3L/71`<EIW"'$@$,9F0$VC4)8<F&"R,P>0@FV,9&8/.<BS\
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MC$X<DQRQ/+'+#&P2OZT::X`_`:9'/7X,C=U3^Y>F\O6RKLO+@<,]S<4.5A)6
M4)[H</`E&`?4CR$/3&.G/0VAM.]M*;<WK>7M]'1%%/16XM_PQP4Q.$\,4QQ8
M_2OKKFO#&(C".2,'[:7S(>OW`7]@/F/9NN4:5M/&L9^SW.[N@UOV?*015T?"
ML[G3XS*I$O8$I01BJZH,")$!U=D"C(R\`#GK@&09P/R9ZXSSH[W9]D,MIJ3#
M(:M#?CZ2R;\W<@_#,-]H^3YNGI+)OS=R#\,PWVCX#TEDWYNY!^&8;[1\!Z2R
M;\W<@_#,-]H^`])9-^;N0?AF&^T?`>DLF_-W(/PS#?:/@/263?F[D'X9AOM'
MP'I+)OS=R#\,PWVCX#TEDWYNY!^&8;[1\!Z2R;\W<@_#,-]H^`])9-^;N0?A
MF&^T?`>DLF_-W(/PS#?:/@/263?F[D'X9AOM'P'I+)OS=R#\,PWVCX#TEDWY
MNY!^&8;[1\!Z2R;\W<@_#,-]H^!^XDDEZXZUW(,>7X?EF&^3^;Y)'UX'-MXP
MEV6I`+HFM,.MI>`K5<'V)KHJ'5Z?O4?;P=GE:"31$J#R*12HB-QQYAB*-()*
ML5$LJQ;D#<)(FP`X>1$J`@#?CI]4BZ@M4-:J.<IVEL]=4%$U36BBQ4"-*WM\
MW'"80R1W$G;T2,T],G;W@#?@\@(3#/[4,/48L]19"QO`<#U5R%$Z(5C8YHTK
MBVN*50A<&]<G*5HER)62-.K1K$IX#"%*5208(!A8PB`,`LXSC.,\"N1^E^GZ
MJG2=>5.K&NQ]")W;+^GI4ZF*[,JHA]$>)4)Z*@`X[F+%NPE`\CRIPEP=D6<Y
M[7EX%AFAH:8^TM;"PMC>R,;(W(FAF9FE&G;FII:6U,4B;FQL;TA9*1"WH$9(
M"B22@!+*+!@(<8QC&.!B<0^<5I?RW;?T;P'@9[P.735>20`)5@-=GQHR0-R:
MQI_AE<4H@!7MG^&#X(:$[`@"RH0&9SU+_P#:)%UQCJ'/U/,+O!RUN-[,[71&
M%568N8X<&,^E/#I0;.44?XFK&)X9Y%O<O&K'Y%._7'^\#GK_`+OF,]>0GH-/
MA:_1T?3X?W(<JIVUCQ)+^RIAKH(H5XG"1!"7CJ6D]T%/8\V+J5GRY5!-S]#I
M@7/8VI8QRV0X]2Y_Y^8^ADN44>C1ACZO/],_0SJ;336>-Q1]>FJNW!S=4*`\
MQL0*!A3I5"_(,X2A6'^:P(M($WH(W(?JL@QG`?+G'/-L9.+UZFU,S$3//^Y9
M%NB9PX?#^Y\/P`Y0]3)CWQD<@5Y6.;AM,V9,%C'83IDY52PL"5`A(QG($K>A
M)Q@LDH/U(`8^GUSGHUW.Y3+Y'<FQELK3%%FFJK@CEF<,9GGF>64PV;331E8I
MIX(Q="?/J;T#@>!3_!E'[@;^]BY2KU9T#D6UTQTA"C^:^/6?^=%O.7^^/:#,
M>]K^U*"YC6*OV^-/_(NQG`CVTOF0]?N`O[`?-[9NNT:5:>-:[]G:QTUHVAQ_
M_M*P/T5TWSHYW9=C\MIJ3#(:M&ET"\G[=.`X#@.`X#@.`X#@.`X#@.`X#@.!
MRL>(S3U^T_N+O%+X/0FD>U,4\2/6:JZE0+]I=E*MIB2:N'P2)OM8.(G6(VA@
M3K8&OS^J78DIR"*C*<CWY,I[0@&@($(.@72*K#J-TXU8IA18:2VCZIU]J*O#
M[-;G3+VV3LZ'P1C8#9.U.^3C\N+0[C09-2&Y&+(TX@9Z\"T7`<!P'`<#`HA\
MXK2_ENV_HW@/`SW@<CM*?UD__P`I<^_QO?.<RN\#M5F_?W/M2A&<UFK3*<>0
MM@116?S@O+_+,=^BJJ.>OM/5LA_DH_\`??7U\5/L^6616)\SGK^+Y_J9YI9+
M6J-*RGUH3G^SM_,7>+_6C;?T30OG13NH[(6O:GR)AL_5XTNC/GTMO'`\"G^#
M*/W`W][%RE7JSH'(MKIGK"%']W'K'_.J[G+_`'Q[09CWM?CE!<QK%7[?&G_D
M78S@1[:?S(>OW`7]@/F]L[7*-*L<:UW[.U_FT;0_ZZ,__1537.CG=EV/RVFI
M,,AJT:9=`O)^W3@.`X#@.`X#@.`X#@.`X#@.`X#@<<LBU9W7V%VDO3<^\?`9
MT^VZ_6(A=(-D2;+?\0&CK1CU9(*KCCQ'\J*E?'*F75G11"Q&Y>C7JDR9&`W+
MF4>H$K/*4%DIPZG=9$J:.T;4L!/JV!:_22%597J"0ZY5W)F&41JBQF1\HA'7
MK(Y1YO96];&H^)`<B;E9*%&F6$),C)+"'&0A"?>`X&!6C9T&I>NYE:UER)OB
MD#@3`ODDG?G(X!*9"VMY61B"7@0L"5+UAN0$)4Q>!'JE1I9)01FF`#D-*U<^
M(+N)M`55];5HPU!K-=-H[,[@PE29:</?;N;:RJW5=GC[DBB,JB\2LNMA.5OS
M`Z;LQ;FH(=RFYEZ+@%$JQ%$"-#:7I[?ZK9;5>E=@G]G;XDZ6)`$$CDK0C5&&
M,K0]I<J6Z1_)BM8/*CY`PZMR@Q()0+SP4@@>=SV\"X&7PVP8$:^V8H*F\0,(
M/FK>,@XN2LHRC@`KR"$B$48%;D!@0FEB#G.,YZ"#G'PXX&?XGT%SGIB:1+.<
M_!C$C9^N?^6<#E(I`P!I$],+$$PLRR9X,LP`L#`8`<M>Q`&`8<Y",`PYQG&<
M>3.,\YE=X':K-^_N?:E",WK-6F4X&^=P4;DC!8C\%F9("<(8"1'8!GS03AE@
M,,`4(SI@60A$+`>N<8SGR<AD88QZ6/HX\.'&P(;K"/VFQ/\`/ULY25J4US*4
M&R]/F&R"6NKDA7BC,0C`&P\A_B;$D-1>8C`C\GA-\Y@9V`8+SC&1\]G:F8V5
M?R^7MY"<S-VS:Z.>DHMTTS'IW*_2B:+E4XXUX888<&./(R5S1,1%/I8Q&'#A
MSS//]+,K$^9SU_%\_P#IYY^2UJC2QQZR6?V>V1QYEA.[Y3R_,S2:;M"W&%%N
M;HA0&&%YJF'!P,`%1Y0A@[0!8QG&.G4.?I9YT5[J.R%GVI\B7[.U>-+H@]/H
M)^6L2]8V?[LY]*;YZ?03\M8EZQL_W9P/"IGT%RG48Q-(EG/F#?@D;/\`%B_^
M<Y2KU9T#E`UQS@4'/$'.!!$^/0@BQGK@01.JW.!8SCR9QG&>N,\Y?[Y=H,Q[
MVKQR@V9UBK^G*L#R+L1P(]M/YD/7\7%^]F<WMFZY1I5IXUD_V>V31MEUNV>2
MO$A8VE2+<V>G!3N3L@0GB)'5E/!`:$I4H*,$6,18L8%C'3.0Y^EGG1SNR['Y
M;34F.0U:/VM^?I]!/RUB7K&S_=G)^W#T^@GY:Q+UC9_NS@/3Z"?EK$O6-G^[
M.`]/H)^6L2]8V?[LX#T^@GY:Q+UC9_NS@/3Z"?EK$O6-G^[.`]/H)^6L2]8V
M?[LX#T^@GY:Q+UC9_NS@/3Z"?EK$O6-G^[.`]/H)^6L2]8V?[LX#T^@GY:Q+
MUC9_NS@/3Z"?EK$O6-G^[.`]/H)^6L2]8V?[LX#T^@GY:Q+UC9_NS@/3Z"?E
MK$O6-G^[.`]/H)^6L2]8V?[LX#$^@N?)B:1+.<^3&,2-G\O_`"S@:=Y1X'&F
M4<=A*:.O#=71I@E+R(I16^I.YMHTE5C](%XSU+>D9ZY4NC]%V$],'*KN;>PI
MVY,$)QV<$"\F0A?/3?275[2J%R-DUFB2EL1V4\(I?.)S(9Y,+6G5DO"5N`V-
M#Q*K*GTAE,IDA38TAPG0%C6"2(T^<@3EEA%G&0N%P'`PJQJVKVWX1(JTM:$1
M2R*\EZ'#9*H/.&%LE$3D;=@\E5A"]L#RF6-CFDPI3EF8+.*&'`P!%TZXQG@:
MRV#PA:/J-D7BU0FTAU"L8N^KBO:)672=>TD0IB9EX,B**S*N00>5UO(Z\?H`
MEBS8C2-9"YM-5-@D"4Q.>#)/9&&PVA:6A^NU+UG1D$[^;$JOAS-#VE4[G%*G
MAV`UI0E+'M[4$$)DRAZ?UXC5JT9111(E*@S("P`S@&`^Q$$J;$AM$.$Q&,!F
M[=TQ@DO&,=:X@6<],=GR=<YX&?83)\9QG!!.,X\N,X*!C.,_S,]G@<D5)>0J
M?XQY,8LR?],8\F,?X7OGP8YS+[P>U6;]_7]J4(S>M5:93ER%,!P,*L3YGO7\
M7S_4SS:R6M4:2/6A.'[.Z46.";PX&6`>/UHVW/U8`B^"IX9T^'&?@[6>G\_/
M.BO=1..Z-KVI\B8;.U>'1?W5-]KD?8B_K>?2F\=U3?:Y'V(OZW@>%2F3=V4?
M\7(_X`[_`-T7]$L7^]Y2KU9T#D<USQT@ZC^[KW_?5=SE_OEV@S'O:O'*"YC6
M*D_\B[&<"/;3^9#S^X"_>S.;VSM<H]I=3QK5?L[I11FM.T63"BQY_73L#'48
M`BSTQ5E.]GX<9^#M9_H\Z.=V78_+?M\B7Y#5H=`7=4WVN1]B+^MY/VZ=U3?:
MY'V(OZW@.ZIOM<C[$7];P'=4WVN1]B+^MX#NJ;[7(^Q%_6\!W5-]KD?8B_K>
M`[JF^UR/L1?UO`=U3?:Y'V(OZW@.ZIOM<C[$7];P'=4WVN1]B+^MX#NJ;[7(
M^Q%_6\!W5-]KD?8B_K>`[JF^UR/L1?UO`=U3?:Y'V(OZW@.ZIOM<C[$7];P'
M=4WVN1]B+^MX#NJ;[7(^Q%_6\#F>OLL#U(:-:MV[SC&YFMFMTXF5C!VTU]30
M1ULNN4LU@DDK*./>U%*U6J$_5<[UVYS,AZCUU5L`!$?<67!KBT,Y)XEO`WLZ
M?5;!J2U7UZJ.L;`S:]<UU4$"B4$LW+DS/6;`B#/'D*6.S$3U'1C87D<B:@%*
MLK$>>ZJLF^=+Z`'C'`L?P'`<!P'`P*(?.*TOY;MOZ-X#P,]X'(Y2G]98'^4N
M>_XW/G.97>!VJS?O[GVI0C.:U5IE.7(6P'`PJQ/F>\_Q?/\`4%S:R6M4:5:>
M-.G[.Y\Q=X?]:)N_1/#.=%.ZCLA:]J?(E^SM7C2Z,N?2V\<#P*?X,H_<#?WL
M7*5>K.@<BVNGS(4?W<>O[ZKN<O\`?'M!F/>U^.4%S&L5)_Y%V,X$>VG\R'K^
M+B_>S.;VS=<HTJT\:UW[.U_FT;0_ZZ=@?HLIOG1SNR['Y;34F&0U:-,N@7D_
M;IP'`<!P'`<!P'`<!P'`<!P'`<!P.1GPK?&5\#.H]8(-8+ZZ:UZ9;"6@GG3_
M`''6T"J6P%JZ'K919LJDQT#33=CJM4O<(*D-4%*FQIRN4(6I.:6F("$L@`0A
MU,4M-ZMLRHZVL6D5K,YT_.H7'I=6;E'6@]@8G&%2%M3NL=7M3*I;VI2UH5C:
MJ+,+(,3$&%A%T$`.>N.!)W`<",+HL=7455SBR6^O9_;#E$6)0YM=:U:Q^D4_
MF[KD925KCD9:Q')4PESFO4%EB/4'$I$9.1J%!I9!1@PAK<(\4.<*%XZC+T>N
M0>XJ.TE,`=-5@VA1'R@EC2*IV>Z5=HH[E'.@5`YQ4J$R-N*[L6Y!=,.ZP",:
M8&,9.P&QFB+HA>Q-.5Q>->"<\PVSXHURQC(>T9;>^-Y+B3U4L[XA)4+$Z1[9
M%P#4:PLD]00%20/!1II?9,$'W(A\XK2_ENV_HX@/`SW@<CM*?UE@?Y2Y]_C<
M^<YE=X':K-^_N?:E",YK-6F4X\A;`<#"K$^9SU_%\XQ_/Z"YM9'6Z-*M/K)R
M_9VL]8+O%_,VD;L?T*FA7_KYT5[J.R%F?^J?(E^SM7AT:<^E-XX'@4_P91^X
M&_O8N4J]6=`Y%M=/F0H_NX]?WU7<Y?[X]H,Q[VOQR@N8UBI/_(NQG`CRT_F0
M]8^F0/'_`,,SF]LW7:-*ZGC6P_9V\=-9]H/]=&?Y_P"ZRF^='.[+LAE]-7D3
M#(:M#H$Y/VX<!P'`<!P'`<!P'`<!P'`<!P'`<"K^H>HM1Z4ZW51JS413\Y5M
M3;$NCT363M8V2"6'('!_=Y(H$\NZ)G94BQ1\HO9_9$6E)#@OLX[/7&<Y"SP`
M`+`$LL`2RP!P$``!P```XQTP$(0XP$(<8^#&.!_7`<")+Y'=P*:LG]6Q+72N
M^1Q-T)J@NVW-]:*U*F9Y7F&E;,UT999"_!8VXTS*@TM*C-,4>:P5U!@>3`!I
M\K?3C?&O4%576@@NMCGM+4-BW/(9`GG6SEGS)BV;#L%6<+ATVLRR[9;-5X6Y
MU]8,6<Z[8TS.SM4/<&(N,-P&PG*/!:<P@-H.GE!+=;-5*2U^?GI/(7JO*[;(
M[)WIH&K2-RZ1J@'N$G-8#<A1N2=F`]N*@"`9F`*@I0EY,SYWM9X&4PRO8V4]
MV6G`9*/-IYH@`7D<]G9IN<#KV"G"\Z>;)!G'B[9N>F1B%G`>@<9[.,8P$@8@
M,>#G`L&R?&<9ZXSZ=3CR9Q_^Q<#E-H\`2D\\*#VNP59,\+!VQC,'V02U[`'M
M&&"$88+H'RB%G(LY\N<YSSF7W@]JLW[^Y]J4(SFLU:93KR%,!P,*L3YGO/\`
M%\_U!<VLEK5&E6GUH2K^SX1QM>X3O`:O&[@$7M$V@#AND,A9B\A#5$.$'(R6
M=T0$FCQDT7U0@Y%TSTZ],8Z=%>ZCLA9]J?(E^S]7AT.>[^._&2?UZG'M%SZ4
MWCW?QWXR3^O4X]HN!X5$`CV$ZC.#9/\`\`=_TZG&?A+%C/PR+Z7*5>K.@<I&
MN.,8@IN,?!A[>@XZYR+/0+JMQCJ(6<B%GI]'.>N><O\`?+M#F(_FU>.4%S&L
M5+`\B[&<"/;2^9#U^X"_>S.;VS==HTJT\:Q_[/C&&IZUOV>4KAO`3`[F3PG&
M&^2R-G)R`NKJ@$'(DS0ZH4PS,9-%U'D&1YQTQG.<8QTZ.=V78_+Z:O(F.0U:
M-,M]_N_COQDG]>IQ[1<G[</=_'?C)/Z]3CVBX#W?QWXR3^O4X]HN`]W\=^,D
M_KU./:+@/=_'?C)/Z]3CVBX#W?QWXR3^O4X]HN`]W\=^,D_KU./:+@/=_'?C
M)/Z]3CVBX#W?QWXR3^O4X]HN`]W\=^,D_KU./:+@/=_'?C)/Z]3CVBX#W?QW
MXR3^O4X]HN`]W\=^,D_KU./:+@/=_'?C)/Z]3CVBX#W?QWXR3^O4X]HN`]W\
M=^,D_KU./:+@,0".X\OG)/Y/ISJ<9_I9D73/`S7@.`X#@.`X#@8%$/G%:7\M
MVW]&\!X&>\#D=I3^LL#_`"ES[_&]\YS*[P>U6;_S%S[4H1F]9JTRG'D+8#@8
M38OS.>L?33"_L1<V\CK=&E6GC3K^SM_,7>'_`%HV[]$\+YT4[J.R%GVI\B7[
M/U>'1ESZ4WC@>!3_``91^X&_O8N4J]6=`Y%=<L=(.?\`W<>_[[+N<O\`?+M#
MF/>U^.4%OZQ5_3E6`Y%V,X$>VGG_``(>OXN//]``^;VS=<HTKJ>-:_\`9V_\
MVC:'^9NE8&/^ZNF^='.[+L?EM-7D3#(:M&ET"<G[<.`X#@<]^^,.L"1>)1K/
M$=;=B=M7':65S*AK8D%=1JRG%CU,U7TEJ.7.J*]9?:-9M)31"K`7[+'+5L>;
M$\E"]O2IY`4-M-0)6W(3`K'XS^PMK)+NO%PJS82RX%&-6_"8D6[=""IVTWN'
MQ:2[*MFTI%;`=)H1%74AEN1A0Q]K3LPHZZA7M6/ED[MI\JCTQI(=1T5<%KM&
M(XZ.182G%R86=P7E!*&0$I:L;TZA46$@P0C"0@/,%C`!9R(/3IG/7@?>X#@.
M`X#@:5-A;@W.B/C(^'E5ZJ9PB*Z8V\W[4-#3`X>H?E-@6G*8!K4"=.LCN4UQ
M3%QUOCD2E*D@F,M[9D:G)I*E6L.S@T@@L*&>+MM#M35N]#>VTYLO:%;UE454
M:B3>8*H&*)I:.UL5V]N"FK.161NK%'Z/.LOO&O[8A)"AJC[1$U&5[.<W*E*P
MA(F,PX\#J>X#@.`X#@.`X#@0G=6R>O>MR&+N>P-VU72C=-Y`"*0]=:4[C4&2
M2:2F$#589&,^1N+<6Y.(4I8C1%%9$(!>.T+ICR\"9TZ@A602J2G$J4RDDM0G
M4)S`'$*"#@!,).).+$(LTDTL6!!$'.<"QG&<9Z<#!XA\XK2_ENV_HW@/`SW@
M<BE/+$R,B?&J3@$@S9D]`'(Q8QD0O2Y\SG`<?#GIC/E^ESF?OW9NWM[,Y3:I
MFJ>GN3P>U*$YN)G,U8<\IB^7VG[<+_H\B7R_.=74P^C5S'R^T_;A?'R_.=7*
MGHU<S$IRZ(5L4>2$R@!IN4HQ8`'RYS@`<Y%T^GTQY>;&5R>9MYBFNNB8IB58
MIJQQ6$_9W/F+O#_K1MWZ)X7SH7W4=D+/M3Y$NV?J\.C+GTIO'`]=5_!5/\7.
M_>Q<I/$.0W7U8E100T:DX!(1OKV$':SC&19PZK<YP''PYZ8SY?I<YB;VV;M_
M>+,Q:IFJ8NUX^&4&OQ,YBK!./R^T_;A?]'D>^7YSJZEGHU<Q\OM/VX7_`$>/
ME^<ZNI3T:N9@UD.:%=#7HA*H`:;W4P?8#Y1=@)8^UG&/H],9YMY+*9FUFJ*[
ME$Q3$KJ::HG&>);W]G:_S:-HL_3W3L#/_=73?.BG=EV/RW_<E^1U:ET"\GS<
M.`X#@4]GOA^Z66C=R?9*P=:ZLE=\I7&&NQ%K.L?";,PN%>Y1BA"D;L6<6:<*
M+B;R<H\#P().2\9QCX>H'3P^M'GQDIR./>J-$/+%KX[N3Y2C4[5Q&W)%6CD\
MOILH=C(J2M0GX;T[G)3LN)Z?'5.:N`6>(&32RQA"X7`<!P'`<!P(6L37BG;7
ML*J;5G\,(D$_I!/9:6K9&-V?V]1$R+@B'H'8P$R5J=4+>NS)(G_Q00E9*@2?
M'U9&2C?J^!4A]\(SP[I.KH]9(=;V=Y-UX@U?UG6I;C.+15)!U_5,F33.MH?8
MR`V<"175'X1+4H7%M33,M^+3+,C-#C`C#,B#9!P'`<!P'`<!P'`T^^()(V"H
M=BJMN^W(+/IG1YFGFX-%X,A--6!?`&^X;4D5`.<08G*&UW$IHZLQD_B,+?6T
MAQ/2%(CLX$C//+"?@(PO%IA#)S76F&J5>SU.>UV5!M9*.ATR1NYACBH;9M&J
MMC#+($KF:%0`U:>B?$1H#LX-QDP01=!^7M<#(8J@MO#[9&02*O`#%,4&3AF0
M>3Y+/,Q7\'#@U,'W@`[!."PA!G&1#_M@19[7E[(0S;N5O_E-6WJ-)_\`Q$X&
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M$\/)A'!A#<L6:;%'H4S,PO3W&W_RFK;U%E'_`(B<]YF8^P+[A>QOX,O=<I/D
M21KV(&1PB4C[X4C3HCP+0];`+\W@[*O(>SCM8QV/(+/7R!]TQNMXPLPL4GK?
M&#`#!G.(+)^N,##D.<X_ZQ/H=>)X1I65>!R)4/M!VUFJ(H(SQE)&V"DHD1'>
M%!JHP)*<N:9#CM&G9SD6<Y$+Z.>?'OT8W?Z2N[.8O3<N5S55,T6YF9F<>/Z.
M*'F_++.,SZ4XS./(];'@7YQ_YO;!SGZ?H@'K_2FF.7?HUN_U]WX=L^66?K2_
M,>!<+'_F^L'U/Q_5]->/T:W?Z^[\.WYCY99^M5X(?O\`L+_)D/ZWE@YQG&<9
MP*(8%UQG'3.,]9IY<9X_1G=_K[OP[9\LM?6GP0O#H]HE(M$8#85>U[;+--FN
MQ;4=;9<5TS@#@4X-[R\1B)QA6VI,L\\3DG-^"8D4>$1F/.8,.&'.<AP'GT78
M&Q+&[^S*-EY>NJY:HF9B:HB)X>3".#@;MFU%FWT=,S,+J=QM_P#*:MO464?^
M(G/:97P8ZMN%^2+E0GRN$>4<@D;)@L<(E(\F@87Q<SEK,9S8!79PM"C\[@/3
M.`X'TP(7PY#[*AMN,X@\HJ6URF,-)-++4EP.2#,3F#`((#P`-L,18Q$BS@6,
M"QD.<XZ9\G*3&,3$3A(K(7K[M^`LL`]X#C1@`$(S<T/%P"-%C&,",$$$LP`.
M1Y\O3&.F/H<A,[K[P3.,;P;0B/<93[EJ]!>ZZOP4^9_?ZO\`MY_IN&?]A,9]
MK>4_"V\/YAVA\#*?<G07NNK\%/F?GZONWG^FZ=_N45&?:S/*_A?>'\PY_P"!
ME/N3H+W75^"GS'ZONW?^FZ?_`-A<9]K./POO#^8<_P#`RGW)T%[KJ_!3YDOU
MQ!-AX8QJVJ67A$[3<#WE8XI9!(*I/8%R%M4$I"TS"!+&YVF1J4Z$T@PP)YF,
MGCR?G`L]D(<<D^S,GF<CE(R^;S-W-WXF9FY<IHIJG&>"/1MTTTQ$<481I9[=
M-5%.%54U3SSAY&?X0V_]&3UMT^CT@LGS_2]XF.O/07L?BZZX9&S%NHWNN$`Q
MKWM$),.$RDS(?DA\<F@!N!BL`G.0JBT.#<8[..SV^F,BQCM9#V)`PW<[L3PU
M-5AP&,N;BV+43?(T%=O2]:Q+%*<PE.[)$3E8!S>K4H#1X-`6>$10Q!Q@6,XZ
MXYBOVZ[MBNU;KJMW*J9B*XB)FF9C"*HBJ)B9CCB)B8YU*HF8F(G">=7G&OVW
MN,8QG=TW.<8Z=?<3&>N?YN?\+>0S\+;P_F':'P,I]RUN@O==7X*?,_?U?]O/
M]-PS_L)C/M;Q^%MX?S#M#X&4^Y.@O==7X*?,_/U?=O/]-T[_`'**C/M9ROX7
MWA_,.?\`@93[DZ"]UU?@I\Q^K[MYY?\`^W3_`(/)UHN,^3/T_G9CC\+[P_F'
M/_`RGW)T%[KJ_!3YDPUS!MA8;'SFB5W=$[2<S'=Q7E220U6>PKD[>K&6)&R!
M11N=I4!J=K`#(0'##DXWM9R//7&.2G9V5S&2R=&6S68N9J_3CC=KBBFJK&<>
M&FW333&'%&$1P1SL]%-5-,4U535//.'D9]A%;_7'635OTZXZ](-)^O3KY>G_
M`%B9Z9Z<WEZ2.`X#@.`X#@.`X$%;-WY'=6]?[:V&EK!))5':BACI,W2,PXMH
M-E+^0VA!V&A@`_NS"R9='`\T!1/>UJ5/@0L9,-`'J+`4FD_B@IJXC5BBN#4#
M9NJ;:AC-64DB5$2)?KP]3>XX_:MV0S7MA<ZXDT(O64U;U:;2GS6B=27E^:3D
M!*U.H&'))Y0Q![0O$^9(LDLP-W:M[&4`_P!*JZ3D%N1VPCJ0=APBA[TDTGA3
M%LJHDE<W%-X6\51#I5#70B3%H7)0_LJ5`>M-;LI`>=R%O-?-CXKLF7:#Y7K"
M_P":\KZT)+54=LY:HC:B'V\[08T#/.Y!69[*_.R]QA\7FY"Z/B7+"$6%;FUJ
MLI@&I@%GF!!,;\2O5V6(]QW]BDCPY0?2,YF0VG/$#0-9&Y,\.T?7/(F2K#"#
MA+I\XI7)")E!W0G)*Y\%A&C,4&8%V0P8GQ)'%RC:E%'-(MOY-?[-:*BL)CJ^
MTM%+BL6`F%UFV6\BFTUGJFY2*!C\#D$'?$66E:?+PF.SH<8VI"CER1820%T]
M>[SA.S%)UG?5<X>BH9:45;Y4RHY(U',<C:@J\#)7,D@:#\C$WOC$YD'(UA81
MF%!4$#\V887V1B"9.!6G:W9-#JQ6#;8A];3ZWG61695M1Q"N*T-A::7RJ;V]
M.&:`Q-O0+;#EL&AJ`C+R]E"4'KG1*442$0NUG.,!R%1'OQ14L?:RV!TT^V<2
M;%"NJMZ4%JR<NUX!9V7&VX!8UF0&:)I?[]<TBK@KW%*H?LY5`E.5!"UN/2F$
M!/+$#@??C?B<P`8VXBVJ2N?7A4U[!I-:+G!;I]3)6_7VQ9;`6.Q*>7V1(XC9
MTKBRZ"74U2=L1LCVPK7A&0[.*9(XY1&&>0+6:];&QC8>ED>P#3'Y%`ZQ?S9.
M[0Q\L`V.MN)?63(X+2&&X4.&I]>"&N`S]D1?+3.8O,2K!LQY"A00G\YV,!6^
M(^)OK[8]`6-L36;7/I]%(E?A^M,`865F;4$LONV%3M%8_#FJI&^2/+&D6-,_
M>I@E"V.+L>U(L(`FN2@PAM+RKX&!2CQ36=GKAOL&,Z?;>6*>PMEV.U^Q&)16
MKP.VLI&O,H]$;3;+2?Y#:S'`7J7HG$LU4TL,5>)"]/[,5AS0)3D)R<\T-F,0
ME;#.XG%YQ%5^'6+S*.LLKC;F$A2F"XL,B;4SNSKPIEA*=6GPL;UA9F`&E@,!
MVN@@X%C.,!'&QMX1W6BA+AV#EK._R&,TQ74LLE]88J4VG25Z;(DSJGA4UL)3
MRY,[2-V7EI<E$84JTQ'G!8\X:`/46`A.$;F)$T$FUF;85!*=`('$%\8;TTNV
MRM769BB\F.D^5A).&N2UW>%AL#68B6$$IQ%.JEO./.5EA3@.Z&=@/KR+>?6R
M&[`L.NTVLV%0B2S.IX!;-=2>83J"1N'6<BLF8S&&QF*5RX.\F2+IE,52F&'*
M\)$*8X)B)2084,S(\A"&7R7<;4:&!GPIAM+KI%`U2XM;/:&9)=E;,>*W=WMX
M=(\RM4\RYR5+Z(.3N_L:U$E(<.[FJ%:0XD`1&%#"$/YFFY.H=;RQG@5A[3ZY
M0.<R)H9)!'X9,KMK6,RI\89*(P$=>V>//4F1.SDT/XR1X1*221DJLASYH0NF
M>!EDVV+U]K1ACDJL:]*=@,8F+,.11&1S2S(7%F&4Q\HIH/,?(Z[OCTA;WMG+
M)?T`\J4QAI.`K2,]KH<7V@]6';-:WV(YJV2`;`4G.'E!7S5;2YIB%J0:2.:*
MJGTL)K+9:M"S/JQ4F@#N4+`DKR,(6X\.>H#A8X&75C;=579%")W35F5_;4(5
M+%S<FF-9S*.SN+*'!L/RF<D)$@B[BZ-)JQ`I#DLXH)N1E#QT%C&>!(/`I/LC
MN&]49;%84C`=8;PV<LFSJ_LNSTS%3SO2$?*C4+JV0UI%G]VD+K=MN50U]5+Y
M:S42F)1G*SA]3!#"`(.N0^O5N\^NEA5!4-NRB>,%$%7/)I)7D5@M^2>'UK/,
MVW!Y@_UW/*D*:G61#0R&=Q&>19Q;#R&=4XD*3$N34IIZ<PHT8?5L;=C62O6F
M\<EW+6<WGNOM7V7;%@TQ!+&@3]<:&.52RN[Q*R<P$,E(>4*],-E-1Y[Z!*04
MLZ%G&%^7.`SJ([*45,I;&:T;K7KI/<4IKQEM-%22R=Q$%PIX.^-R5R2R%779
M#T?)P,Y1*H(3%@$XTF!XST,SCIG@?$*W#U(/#8PR=H]=C@4\G=%EMB*NNMC`
MU<D8UR!K>E5B"!)<XA:=H<W1,G4C<N[!(/4%%CR$9@<9`BVDJA]LVAJYA;RF
ML%)L;5MM6]6UC01WCLHK9SA]0KZG;WA65)VIY4%.6'P=OMXVTU"!4F.+3J,C
M-+R$O!@6-X#@.`X#@.`X#@.!2SQ&*8GFQ.C>SM'5@@,<[`M"JGR(Q5$2]-T<
M4&NKF-,`L:1^=E*1N:%B<L(C"5!I@`E&@"+X<8QP*;[%^%HR.NO]F16&2W83
M8.V;4FFJ\=?9S>^Q$H?K#8:.KK:^H[9L"*5[.U#O%#:Y0(V"/.CSDQE,1/"Q
MQ3I\@4&*$Z`)(1,QZ*;$4`];A471$$52:%;AV+4K0U;D67:[A<%DU+K1(FB5
MHKGK">`O>UI99<['1[<0Y(JY2H@#;CCYZG4+0#&W.JA4%G-;-4-AZK31?7)+
M;UITQKSI].VQ'KJ\UJ71+NQ;):S."9B=8=2=U(Y_$K*LUJDE#%-"J(KGMO-C
MBZ3MIQ#KE:>X'J,I`QF[]*+=MA;XG[6S(&./(MB(QJLIH-S<79O`ROTJH**@
M=,L;ZE:QK7>*,*B9,B-M4*#$F#"TBD:A.6=YO`<A"\O8_$1;$U[W;7.I5C1N
M?[L6[6;!85?0B\M9R[DUNU^IJGF^$K9<Q32464U50]6]:DB)7IF?+:YN!$9;
M5:9R/\XN($@X&WG6Z.H8C0U3QALIE5KR@884S-:6DUSS%Y&XUN6D3X*Q''.1
M0M^E$9D#HGR'(U*]*Y+\+#S!G#/-,&,>0FW@4,\1+7:<[0TO7580-=*F561M
M+JU.Y+)X),4<!G$.@5>79$9=.)?#I2K-+&VR2/1UJ/4I>[A-5F&`P`DL9F0A
MR%5[N\*Z(/#30$3CCC>MMA7;G5W<>R]NV'LE82*]W6O*^HZ]H5%L)K>8)=!Y
MZU-$.?)FVHD#5&5*$825ZLW)9G>%YIH0'!_#JN])3,V\.64UT,_7*X]E+2D6
MRNW[K8Q4ULK8;5W,<C+Y"&*4KI?9,DN<.P\V6'(8`O?AX`D8H_#CG%OPG,5M
MI!(7\UFIO;,PZ`*=@[EL2)?J_>E%,+JZAK/KY[A]N80PY=T%=;`/C65#)?:M
M>/LBB3PWA<V!'(&%.B>V<T!:,:`8!J0K[(M1;_30&^9,SPM*^SR->*<@WKJ2
MO<2V+MQEQ5_$1UKVHLEDBUR^0X9)98Q-;P2U_+!J0@ET)2A7"3)#3#P!!\JK
M/>R-5ZN@R?3:R+!@&WMZW_LSMO"JHOK6^+3F%1J;/#.W0/4KTKG]K0EL7AG4
M0:4V9[(8^J5$$D87-+4H&!84Z)PWVQ).4DBL92D1@F$D)H^S)R8:G"T@(B11
M+<F++C!`&`T]B"2P@#A*'"(8TF`E8\R+)?9SP*O^('4<UOS1[;"DJW:@OL]M
M>@[-@,19ANZ)@"YOTHBSBTMR+Y<<5;>A:,J%"K`<*33R0DYSV^V'IUP%#-K]
M")%7505!&M/H1>%@EL^Q*:Q+)0F;#MMGWTU,*ZF+`K52NIJR/$"F%J0.NB%*
MQ[0I'L2/!;F2S*%BAF`6Z^;.P%`&?P_-S(C4,"JMWTUCEPR&6>$VTZ"N=@OE
MQTJL#KY<!5GW,J.G2UTEZX,JE4#0M$I:'TQSCR,QY4G($00MN%7G`-X3Y-M!
M]EH=3*!-#Z@73"PE7B$[16[8DCJ=]ULC>Q$TJ:T45KQR%3Y@L:_RI37L;42A
MN?&DN0'J0JYJTL9XP-`B5Y.,X"+*-U*W,1RW0FI-I]"GVSM?-,JDUZ8(^NBU
MRZMO[))MB8^D-:I+=]XKYM8D<LV9P37@E2,V&1YN:SPN*\P][4D#7`;D*$,+
MU^U>DNU-A2AYKI17.QVIFH&[FLE"ZIRI&[-;S&%.LE4W,;LI?XLN$D6F,-@C
MJJ32..05&H;L*"CR:^`6C[9X57:"3KB\)&Z)O4IM=576U=U#))%9GBY9<9@P
MN$0BN$%<;1R2>.U%L[HYPXSY?Q%Y^U`8VY8F2$+C&-,(L:E$+N>$^0V/^%OK
M3-:#B=UR>?51:5,2&Y)S%)"MA=Q['1K8Z>#/B<`8X@<].K]7R%)6K"G-&@[@
MWDMABI6L:&Y(I<!DJ!]Q1AM0X&J3=S01PW+V7JM]>7ZT*]@4.U&VMKULMRGK
MIGE13:O;JM"=:WK*X=BB*SGL&DDS0H6>$O;AW!<)6PB4("L*B\&C3YX&J:W?
M"UV6F5>ZJ(%FMKDH;F#4&P]/;-HF@=JF*D8G"YVX6NYR=QO:12V9&6"ZS:F=
MA_,`>Y(%">XV*WJ34AIY+JORIRD#YS5JI>6R40V[JJJ]<FEB-@.Z/B23!NVH
M63BN`NUS/#Y4EY:\-]&C3JG1';2:32Z16`B2.;H_=B/98&D)YJ]2<,"$L)BD
M&D>XQ>X]>6`IK^:12J*XM^'6BX67#9[KPR5FT0XS0U1KM*Y2K@[$41LQ:E_Q
MFQ%P3EPW1W+C:5@:"QQXDQ8:,D\-?5`QR<['@@T#U6H:K7N4:@Z,ZY4Y/+$U
MYL+5JS5]DR>![54U+'&0UVY67AWJ^%6XKC$!?Y#'6FX2$[LA6*G#+JS)#A)3
MU@;D/#ZTWV3IF9:M/EHP)]C396`_%,.E(IA:L'LV5-*3:W8RB[>I9&[R2+&H
M$LK>UT5C[D2ZGM[<F1(G-O.+"`*<:,Y0&]C@.`X#@.`X#@.!\]W=6]A:7-\=
MU($34S-RUU<UA@3!EI&]N3&K%JD8"@&&B`0F)$/.`A$+.,>3&<\#1I8'B);4
M2"M@6A2C%3L400+2QV\2>P6&T(W*).JF^O$FE,W,I>G8FMC4UC(858<@JJNG
M9W>I$J+=TJ!V[FA);#2E!RE*&RC8%\V6E%<UZ\:I2VC:N+D2HB4V):^PT;DT
MW::\JTN(.<B[XSUE%I?7A<JD;F[X0I3Q+96S(6E"-2KR)4,LL@8:ZJJ\9UF2
M5[`07UKKL&NL(F'TZMMZ=T150I51K._7Y*)?!]?5K$8]3!%8F6W9!^BR,V.)
M2FMRPWER1KRO6`1G8<1!,;UXP-&M4,*?$=$;8R6PV5!>CW;6OT:K*(N%V4+&
MM;G5D9K<D]ILYUDI(=\BLRZ4->&X4??'XV0@7@&TEK0E*<D!6C:+QHV'7.R8
M/:<A4QN,:--C?3+?;4HD$5=G*U5=@7GJWL7L]$H'"P-LH3,A$K)C<$@:8*,1
M"\I2IEW8&I3`+P=D+3-.^5ETW5M4/.S]32&Q-@=C2++N2`ZV:>Q]FLF0U;KU
M$$\;>50Y=+Y%83!%+`<:UC<K:0O[ZV*4A#T^.H4+`W+<!($H"<]8MRF38F=*
M(^A;E+<Q3[7.@=OZ,4N*$;:_O-'7JTN2+#?,&PM6Y)&B;0F9QM22N)`H$6),
MY(_-Y,$`X?`O'P*HSW85Z9]C&ZA8/$U,P=8YK[-MC+%;D(4I;XL8R'GT'J:!
MPX]U<V=B#*K+F*-Y$6<M4%(TI#`8`XPKO19H`HO6?BBSAGJ*/2&_=9[0DE[6
M-MQMGKG"-?=6FN-6A)FL>O#S9+N%G>I#)IS"8JZNC17M?G9<G@E6F;%;H#(4
MQ80&D]L,[B7C$ZLR:'SF?N$2V"@T0CU.16^J]=IS4RAH-V$K*83-FK%G=J19
MDCRYOSL\&6K)FJ-?([VE87<UR=D1A*8U"I*6"#"+4\3^3/M5R=+1U+6#5.QL
M<V$04,]UEM%#V5(YQ93'Z&'MG9,E-9JXLF0M$LC[90+:<8E7(7X"$QR6)P@.
M.Z@*/#`=3/%E,V6JN9[DGO\`6##HQK11K.1?-@LS6]2"=6MM2=`H7,[#C-11
MA*_#<8K6E5*'[#.ERX(W!TF;^X`);>RC2`6.(3\S>)HVR:2)DAU&7?3)=?;!
M4-0NP4,OR'QB-S2)BVN;CFRAIK&5$*L*=L#XRK+$<F%M</-J#0DDO!O:R!0A
M/)"&U+@.!5*?["O#+L:QT)"8LHE[JR4)/MB['0(`I0OA\<;G4F$5;!XD-U<F
M=EQ*K,FWRH(@Y6H+2)D\?.`>,KO)1H0HI5_BBSMKJ-MDE^:S6A([QGNXVU&L
M\"U[U>;(Q9LK;S:$5V)("&A\D,EG<,B#FZ-->U^I$Z/)2U*U'N0,A("$LPK(
MPSV'^,5JQ*8A-I^X1/8&!PI@I=BO^`2">5.H9R[^K1^F;)61"^EFI&].C^[O
MR>U90TQK+.\I&-U/<G9$8F3GH5)2P08;9GB>R215G*&RDJ3LBI]D8]L+&J#=
MJTVAA;,D<8NK)I/.U,_E!K-7%DR%JED>:=?&M6H3K43\6B$X'D!P<;T"4<$7
M:<>*RGV,J.4;;I72HH=HIJ_0S4=L3/8^RN;G*[+VH65Y$)]9,3IN(-[WW^)U
MI4ZI^$V@4."-P<IE(%X4S7CNR/*Y<%AFKQ.6N2/W=S**O*F@5I>NO5.;!0R_
MH=%XS,8PW;:E+6&CIW%U$,L*=,CPSBL!4RI'((3C,DIW(X(NPK1G$`#:QP*[
M[4WB;KS24DL1M9PR27*'B$UY6T8-&(E/);6MN;QZKZO8ER@(@92M;C.Y<@`L
M.P+&2DGG!X^J#C&0H.U;L[`"V+8%JT=6J=6%VYSSX>RR,EPJ2)KL/M:.5B^O
MRJ\DTO#/3X@DA[K:[`<Q8C`F<U0F8^RZ?*AJ@>6\H)#WYM_>.B$[U<E(N6M:
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M**FM^1EC&,Q.F=0$&B\Z49C`62X#@.`X#@.`X&)3\J/GP2:D2Q2>BBIT2DA4
MF6)@G#4I(^8SK`/*E.%.G5J!'D-V3!@P`HT>18QV0"STQD.>)MJ>JI=K55J5
MRVO55"VP;POXY$=GW",4M+;")OKPLV==)T]969'Q^80.E.SR901@?%23)Z)W
M?6M.^/28^/''$$*4P7UWHJF9S76=*5G;R!4;0[?9\.E[ZN=M7GVVZ]>M?\M3
M(U1.GK8:F>V8NO'5Y4K-(=Y-(E"QL:CV0&4CL40TA7F'A!$NJ*JTZS8U)?&X
M32]6ROG_`(2)]TO\,USEL3BS++J_V19'O7M''HJ@D\Y29;M@9(!(QF=R=UY$
M8P+*U89@CZD(:\MO65UCMV[:(=)I]8\WN>6P'?=PV)?6.N8"9!:UK"6+Z>03
MZ$35KO"P*S2@5UE)VE&O:)E$AS%T.3NCD0")/`"B\D!<O7*KM/6*":C$2W:)
MCG$BC6Z:J6O:^55#*F"/69;CKX<TR9814JA'.D:<Z&12):>O#.[LKV[#-0N3
M<S$E$9*,7%)B`J?)(Z[01OUN_P!FM:%I7(V2BL=\9)J$9%JI@1,>J_2N2S:E
MDMC50]H-C+*H^/S"G(9:F6A76,Q1K,KVR/8;T[>PR]E[!^0V#>&-'(4US6EC
M!V`W223Q[PG]&H%4R=F:92C2SZCV=`[N\AO168]1QJ*9B)?9;U\D-C,MRA>T
MB=E-4J4)9:PG(0W<<"A*M"S)/$S;WN,O1;M+7?2])&K>AAJ5<D41.#(;BE3[
M1]CMCLJ1%,CLB>I7B;,;DW)E1SF2;EN4B(`EP,T05GJRN=<D%WT(Z,.QBU]D
M[5XB/B13")Q@=52UM+E=PS.,7P1<]/F/"D&$;(FIE"ZNIY;Z?GY/?\M6`),Y
MRI*X&OBWZ\U7B>I='*8-L-8]LNT>\/BIH+1+?7-8O4&L"?,ZS>75%74]]14^
M<)3(PR2=@OE'%DZ>(R`:0ISRKR%:J1H<*59(>UK+!5+_`'MM=-=];^6Q+8*2
MJ-G6-#4CA23:T&P%X=M)M4D4KL-0=4L^N>H<3:+ZWLA"IHC+),I.ZG,+NXB$
M[*5`7-&@#QWG7NDK;K_,WNC-@7J3(85X7FOT(V:A%,5R\LH[QJMT8XP@T@N4
M<C):C8K4>RT4>4&7.*MKWAV<%\96C;W!M`U>8<$H?U5;-<3]/K]7;ISY3%Y?
M)-\O##<;E0O];0R,2N"1NO%D5=-8V/T:H>Q=@:]PXWYL4GCS07EJETF"TMAS
M@XO"II*$G0I@ZC>`X%!G%"R)/$T8'R,O1;K,773$^,V["STK@E41BOTUOO#]
M2UDM+LJ1$L+DD<9B1,&)T;DRL]T"8>W*1)RTI9AH@K75%<ZYH+KI-S8-C%C_
M`"9L\2;Q#YG&8T.JI:V`DUT3"O;]27!3!CNJ#A&T)J?:'9V5ER`[_P"G/N6G
M!27.1J2N!KVMRO-3XEIW2A\/V%L2W5$=\/R*0BD$-?5F^0&>V"S.6\>IJRN;
MTBRB;(E$;8)3%;W115*EBC_E,4ZB6=%BE(@"J5$A]/6"#KW[8S9^;[Z7VX17
M8:0N6P+*TU"X4FU,BF$OKGHWK&WOT^7*:@L"[*;+ET;UM9<K&:.,\RDKJ>RN
M[B(3J<H`Y($(?/NNO-'&S7:3/%([!N\H;X+X45*PS9N&TY7+\Q>_RC7.*L+;
MII;RJ0I&E1&*<V3C+^@&[1!"]A=W17'5BEO6-?R7V%R0/%6;+<;].]D5NZ<_
M61B627<?PM%-SI)-6L,B\O@,&KM_0N^NZ`R,T%8VP5?"=;]OY,S,A&6F6R0;
M4D/7N3P:T)LID)`=3'`HMXB[6T.NM&2U<E1Q>4H+PUA?JA4.C>[N+,_7U'-C
M*P?J,@KX!F0."A"R6):;<U,2I<<$M&W$N(E2DTH@DPP(4X;*THE1L8BL8G9E
M6@II9OE)EC#K<XTT^'X9O$R65$],+\G77*E6F)7*#M3?AQ>0M!*0#.*<9,\W
M(C0^;:<!GNR=*WV];*ZA2%?O55D"D31"S(K7D`L#3![GU?3;8!J;3EUIVM$G
MPB_8?&X5:LO@0E**-L;DL='%I8P/`FD2OM.AP0C6M:QUA1':W99-G%ST)F;O
M&&!"PBJ"9(/3,FQ-@E+OL4<;E0#&&#]7:7Y$T$A4>65!QWE!U*SP-/C)$9BX
M)Z_K/5RZ+(C>FZ#:C0]&_P"P\@IV,2*%2+8F*ZRZWME6S&O&+-AM&T#"]6:D
M3PE>9"TT(4M")_/P,R8H"0K6P(;&)77/A6AJQ_#/-AFP^F''PHM.JYBI:6OI
M*DGK!3K7;MK8U_V&JUY01I;)%MYRFYWI-AFCS0TG2E!,65`/*,2M4F)R%7KK
MC=_HKXG]>!M:=O5;M>T?A4)=]KW=JAKUMJZ<7+#W34]RKN1-;"YVB9>56S>S
MHN&&-3ZP1F)S!C,=<HUIKY&4XW1*2&]'P_T+"GB^RSD0]!7V!)]RK[E%T1TA
J.O"CK6Q7A:P&MU9$.2IN0H)$JA]6`C1+@Y-IBMK6NHE1B8\0,]D`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tpg16b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg16b.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.C="-#0R-C9&0S(P.3$Q130X,C-$1C%&1$%#-$4R0S%"
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C="-#0R-C<P0S(P.3$Q130X
M,C-$1C%&1$%#-$4R0S%"(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C="
M-#0R-C9$0S(P.3$Q130X,C-$1C%&1$%#-$4R0S%"(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.C="-#0R-C9%0S(P.3$Q130X,C-$1C%&1$%#-$4R0S%"
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`#O`6,#`1$``A$!`Q$!_\0`V@`!
M``(#``,!`0$```````````<(!@D*`P0%"P$"`0$``00#`0``````````````
M!@0%"`D!`@<#$```!@(!``0(!@H."`,(`P`"`P0%!@<!"``1$A,)%!465I;6
M&)@AU!=7UPHQ<=$B5'245;8X03(CLS5UE3='EUC(&8FRDR2U=W@Y65(S)E%A
M0I)#TS358B<H$0$``0(#`0</"@4#!0```````0(#$00%!B$QL1)R-0=!47&1
MH=$R$U-S%54V%PC!4I*BLM+3%#1482*3E!;P@U:!0F(C9/_:``P#`0`"$0,1
M`#\`[^.!%-W4G6^Q5826GK:8C9'`I8)D.=FLAU=F-5X;&9$TRZ-N2)V8UK>Y
MH5[')V%&N(&6;C';)PX'@8,B`(/D0G7^OH38;Q<`2GB4VX^PEFK1QLN8N7CB
M6#KR/O3K)&B&)E!*="WH&)+(7Q6N$`A,68H4G=<X9F0%]0)MX#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@8-`:U@]6MCJR5]'D<58WF3R&8JV-K&I+92
M)%+7,][DR]J:AGF(&,#Z^JSUZDA&60G-7*3U&2^V.-&,,YX#@.!@RRM8,XV&
MRVNXQU$X6#&8T\1",R5>-2L51N/R)8WKY&BCR=0>8@9#9$H:4F'!0E**4K2D
MA!9Q@RR2P!#.>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&O77"D(Y:]
M,0VPYO,KJ<I5*?*%<\K4E[6\SI3E!4K?$9?@[6SS)`UH"2TR4``ED$EEAP'X
M,<"</9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+S
MDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>
M`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O
M>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3
M:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\
M/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+S
MDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>
M`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O
M>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3
M:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\
M/7W@/9-K+SDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+S
MDO+WB;P]?>`]DVLO.2\O>)O#U]X#V3:R\Y+R]XF\/7W@/9-K+SDO+WB;P]?>
M!3_Y-4GEKY/>7=T^*?;!^1GL/EPM7M?D]]G[Y4/$_A7E9X3X1Y:?[3X9U_#>
MQ_V?M?!_W/@6TTI_5AJS\3DOZ:23@6FX#@.`X#@.`X#@?S.<8QG.<XQC&,YS
MG.>C&,8^'.<YS\&,8QP-"'=X=_UKYWA^]FQ^D,%KIZA3A3!<[7UQ9CM,6UY9
MKY9*YG!<,DCK&V),QMRAAZ2E1+FE*$K7".;Q&#%DO)6<9#?&<Y-Z;)P5"]$0
M),6`U0$Y405D@HT>`%&'8&,.2BS!BQ@.1=&,YST8X'E.5I$QB<I0J3D&JS.Q
M2EG'%E&*3L!R+)2<`Q!$<9U<=/5#TYZ.!_52I*B3FJEJDA(E)#USE*HXM.G)
M#TX#UC3C1`++#TYQCISG&.G/`_J=0G5DE*4IY*E.>`)A*A.:`XDXL6.D)A1I
M8A`,`+'V,XSG&>!K'WY[RUET3O30*D76H7>R56^%\GT8U2)MEZ&-)ZU5$N4$
M;LR-R;E;$[FR9.+,X"/P8HY&+`4HL=ITC#T!X-\>\T9-&MD.[SUW=*?>+'6;
M_7<Y4LT2IMF""-I:Q5-SU6C-F0.;2K8G8Z4$&BL<!O@Y)Z(6`HQX[3.3`]`;
M.!N3<6`\P:]$`"8X"=2,:H@($Z@P82RR#Q9,Q@HX9@\!P$70+.<XQT?#P/9.
M.*3E&'GFED$$@$:<<<,)9118`Y$,PPP>0@```<=.<YSC&,<#66D[REA6=ZRI
M[KHJIW03R1JP1M`7=0)@@,8E#8H?R&($4+AX6/PS*@0CNUPMPXB+SC&<=E]@
M7`V8!5I!J348%2<:P@L!IZ4)Q8E))1O3V9AI&!9-++,Z/O<YQC&?V.!XQN+>
M6(P!B]&`9)Q"<T(U1`1%'JA=1,08$0\9`<H'\!8<]`AY^#&,\#_:Q8E;TBI>
MM/+3(T2<Y6K4&BP$HA,G+$:<<8+/P!`66#.<Y_\`9C@:3I[WYNO"?NS=B>\]
MI&`S2X:EH2R15L1%G-<@K9^GZI-9\%K!9(VD]:EDJACCHU\VPK2Y7(@*U"=+
MG`B"1&8P$-MM.68@MZK*QLM*BPR#LBM8+9`8T<X$."]B23F--TB3-ZH\DM/X
M2)$%P[')^"BP&B+R((<?8P$BF*TI)Z=,<I3E*57:>"IS#BP'J>Q#@9O@Y0A8
M,.[(.<9%U<9ZN/L\#V.!H"V^[]052;7332C2[1^_>\1O^H&EM?+X;Z96)6*&
M5*0Y$I%A#(\2H;%*LK)3X(K`$Q-E,G)*4&8(P<8H+.(+"W'=A]ZU1G>>5G8D
MEA$7FM,VM1DL\@M@J$M=,2VSNI98(;@6F(<C0X((<69P.:%A)*K)28X*E$H(
M/3D&E"!P-G8UR(L!!ABQ*`M4(`4Q@U!00*!#QT@"0,0\!-$/'PXP'IZ>!_@Q
MR;BLFA-7HBQ$&D$'!,5$`R2<ISU4Q)N!&8R6:H%\``YZ,CS]CIX'E*6)%!&5
M)"I.<F#U\B4%'E&$![/I[3I-`(1>.SZ/A^'X/V>!X\N"#",3AE<CP@``0Q+L
MJ2?`P@"+(1#$IZ_8X`$6.C.>MT8SP/:`,!@`F%B",L80C`,`L"`,`L8$$01!
MSD(@B#GIQG'P9QP*$[X[TL^EZ'7B/-<&.MJZMJMB*\UWI.J$4@+C2E^=Y8Z$
M>5LP<G@QK><-D2K:*]LY.2C*<8<9[`G(B^WP8$(.[X3O:*U[H;7N&77-JZ=K
MBD5BV4AKF$U>PRA)$75Z-RSNC]('X3TL9)"6F:XVW-P,'="0S(SU9!?2'K];
M`2*_]Y/7!7=;N7>CPB(KYS7B768S8]'7Q#^D:7A66C8?&;Q!%,A$VN"-`]L;
MN2H;%1_@AH2U*8?[GGHZ.!B)G>@,1?=(X[UOY'7C,?SKF5L+\BOEDAP\^!&=
M3_TQY;>3_@/A&,#Z?"O%O5Z/_I=/P<"OMP]^_1=):"Z?[DR:H+(DUF;S,48/
MUWU(K50DFEJ325R1$F6&1]*YE-[>G&U,>5R8I6X@0B'D]6G*)2FG'`+R&%ZB
M]_`"UMLX/I#NII#??=X;"7"RGOE%M=Q+$\@B-JED%N2D;0VR0I@BQC:_&D-I
MA9!0DQY!RLL281Q2@1))H;!-']]&C;Z8;<U$^0!545X:9[!2&DK1KM=(4TFR
ML8A]JZ5?:K$Z)V]JR=%;1BH,K$@!D!,3F$FE"$/`0&##8)P'`<#77_2A_F*?
MW/N!-VE/ZL-6?B<E_322<"TW`<!P'`<!P'`<#4GWY&YXM$^['V;N9G<!(;&?
MXB.G:>P1D?AYMH6UVD08%C8$H031K8RA6JWK&`_#U&T7`X,8A>)W=\-_<T;'
M1'1;>'7N7Z+OSW%-Q[FN6BGNOZNN6&;!RXQWG"-#+S<&*'!44&8/Z!E`XA(R
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MKUMNQ,,!HYQN19?+/167E)/4,CKV,V:J'DF3MK2;$TB<Q80`LI8>F$?D.3##
M!B#*/K&KLTPS;[N"K*ECFBCL$AW>#8!*92[G@0L;`6Y/5,JTZIV<C\@2($@4
MC(J-&8:((0%$#'G.`@%G`>MW[CHSRKO7/JYT*8'AK=94@W$D\X71]O6IUKLD
MB(97K^M*D:E`G,,4$LRHB-K\E*1!P4/P0[(<YP6/H#6-6VBU>[QW#]9GD5]6
M'>"Z.ZT;);`S>E:_B-N3.&PN,6RG:+ED".S7*/L3DE02A\9B(4W(4"=Q"H0)
MTF5`<$=8W`P!'*FWK;VTT$^K0ZAWW=]G-U#;E6_:L(V7F:&=.C!)K%CU06>F
MAM9UO(IP)5EQ4$*65QPC*P>89D9X4QV<".3E""$LL]3Q#NS^_6WI8]29'-)6
MAUZ[E6[[0JF%SJ>2"W'"JI4QQEIF;)6"!TESH\R,R,HW=,4])FQ4I,,))=LE
ME_N8B\<"ANJ-<[AJZ,TA[PG7RC]C&O<>>;%M,UGN^5L[_4XFJ;:I@=IO,$DZ
MI1QIR:V:SJLD.*!O$A*:AI"W`7@2S)F!X,*P6&TBB="ZY[P_ZP%WQ,4V`G]U
MAJR@;`UQM*/5I`[,>(?&'NQPL32*-/$H1)<*BW1+&T#<YIR4X`EXZKH<+KXS
M@.>!V1;&5)"[XH*XZ6L-.Z*('9U:R^$RQ,Q/2^./!K`^L:Q`XE-CZU&D.+0L
M$F-S@L\D03"Q?#C@?G):X:TU3`_JJG>5;(QM-(`6C:]I1.JIFI62IX<6`R)U
M7MO3BJ($-T84*1L[.YDY?#LJ51)05"L(@]H+.,!Z`V,/FH,8[OC:_P"K>WQ1
MEJWZ9<>Y,Q@<#VFELSN6<2Y%;K`]U]3PUC0X1MY=5#(SQU$AG*U`A:T1)#>D
M0EI<!)R<G`=P*$35GV([PFV>]ZV#F6ONRMN7Y1&R=G53KQL/$=UH/K966A"2
MLG)W2UFD7P*:V#$Q&-F#VL@YS69`8F5%`.$F,)7B./R'??W>TGO.9:0:M239
MG+8;?KC2\*Q:ZYG?H]*6UYF*-K*0.<B2R&).CU&G@,ERE"X"/0JCDPQ*<]07
M1\&`YW/JX,F8X%N)WY%,6X[MK-M#G>:46#)&V1K"4<KDE:B?I_EH?T6%W8JG
M2.-2IP-4Y.+R,DDEU(,SU0'%B$$P=X1NWI3M3W87?>,VEX6_,XH.-2&*W[.8
M97Y$3:)=/C9"(`I,V64P)2VJS,+S6)>+P\"T]2(`,F&!"6<4(P-;7>!3\P_N
MT_JO`FR7JBW62[%Z2''@32$[QH^MS;!(RW/ZA2(A9E2YI4KBN)*5"'D>"S3P
M!,S@0\8R&14;H56W>(_6!>^*B&PL[N8RIZ$GNNEH,580BRGB)1.0V$%A9L1M
MUEC>F\(+=4#"V-[FG+3!P5C('4[/7QG`<\"INQ&Q-I=UXS]\AW-$*<90?/=J
M[SJQV[NU$%W<CG$=>[K/!$8L*/1E=V@UB,F(QE.6TIQE#!V;F$\?3@?V0GOO
M+:@GE5[+]SEW-2*L[GV7UCA&I3U/)QKM4EZ-E"ONU%R1]%-D,A7R"S9*^Q],
MM0L#G&SGT3?X82IR4XJ0)^H8<4,`;=_J\49VCJ9'O!0UMQ>4PC7FNKS0+=6J
MTL38JM-C[,HMB?P2,N;4A,)1`9C+%S4&(.+2C&F2..$Q@33U(L8&8([.`^;N
MD+RS^LN]T/!I1USXK`-6=J[4AB!2/`D0["<H[.VE<N2E9Z<>,4;5%T1O6^S@
M)(>C@:IN](W(C-T=_E!XM)=6MDMUM9^[2IV4QJ<57K/6#C;*LZ^K]ARY.Z.<
ML;"C2&AN:V9M=&])@PXP)H7)B&`O`LX'U0KOW;U_RE;W)G?A=V1+XC9T*GFJ
MM0WO9U0UI;L;<XM:[50-HLCM(`-,BBSB'"MO<8R])\KU@0A[(.9"7D`A%B"+
M(;-OE/KI5]3I&N(G$6,2D:%@K(X[#XW=!=B)WDN-&0D>/".L&48?,>#X19QX
M1D><=`>C.,\#7/6)R*DMQ_JG%B;`]E%Z4'HFBAT<?9=G#9%&&Y)#'98%J/5K
MW$`&YM<52R;Q(19I@P?"(DS(@A!@>`[`KZW=T0K3=_5'5.U@1^3[=W2DDZBA
M@-U=H;!D<&1E@0K5JARDR%$Y/57M\K3MPU!"D7@Z562TGFFF!`0$60U<Z^*%
M4.^M,;YQ:,%83QNU>[PI&Q+"3I2P@3'3:(OL"BT;<5@2\8#X?EB6GA",7WX@
MG#^ST\#IEX#@.!KK_I0_S%/[GW`F[2G]6&K/Q.2_II).!:;@.!IL[V-BV1C$
M%<]B:+N+:)(X4]%4JR.U5KLZ5I'X5!WM&I?I5)]AMEFJ6GGR:\ZECL>8"$RB
M%M:16L5)R5`$2,]4LR>D"JEE;#W8H.N?O!(7L7:JICH[=BG]=J]UN9W-N1:]
MVG0LNC]&-KJ-U@1[$<\NUBV(JN=5(VU]-5A<6\)*!.2$"<LTLT(L=K_VIUGH
MN`7J@VEMBWIAN[W?MC[`/[39I\:DT3HFZ4[I02F.S^D8JG842&$0"(MM^K41
MK",Q0V*<-:`X_`S@G"."39"1?<$W$CO=<(MRMIWRJ;=DM;62X7P[SYF<-FH4
MQ*:3V4F4PJ)BM\,73J61MG<THIK=$QQ:;PYM;CW!&C&4G,+P4&UKN[)Y/YKK
MLM:++FKE9TIIZ[=@]?\`-GO@4.)#8S%2%QS&NHO+Y.8UHV]M5RMPCC$E`ZJ2
M"2RU;B4<?U0B,$'`6=<+,`W24J+FPB=G+5>'0;8K3MS(-M=2&?P3PU0B4#D!
M9@2@87%Y#VQ9(A=;X,=.,\"F^Y^E^O>_9-)-^RM2W'*F&@[7:;GA<7:9$CCT
M:<9RR!++;%,R:&^3!3RIN2I^U)PE4])?8JCP?8-%P)1VPHVIMUM?K'UDV!IV
MPI34UI-B%ME+4B,9F=RQXJ>6Z0M+@TO"2285M3JUO32G4$'EYZP!EX^SC.<9
M"MFL_=R:MZGWF@V,JFKK_,M=OUP@FJ9#_,IR"7%CIVMTL=01)J4I'23"+5.[
M<WQ1`1E</(CQE)\8SGX19R$*;A=R]H#NW<LAONV:&OZ,V5/&)MB]L.M.66X5
M4AN:.M($I"-HM9GC$Q(;9:3A"A)3#-&66I,3DE`$;GLB\@#(=B.Z"T*V,8-:
MV)RUWN6H3-1H\;#:#D>O$X4TS+X-"%)>0+(>FDT5F)3JJ9UIHC#S1FC$MRI/
M/-PHP8I4"-"8-)>[WU0[O&2W5(M4*,M^O"K\/A:VP8TKEILJC*AR@B!U0,SL
MUH9-,G16A=5(7Q8:M494&&K#U`S#,Y%G'0$J[GZK:[=X#23MK]M1KS+;&KMQ
M7I7I$4+#4T2"+R5`2I3MTIB$D;)2G=8[($)"PXH)Y!F,&$'&$FA,),&6(*$Z
M0=QUW=^@EU(]B:=H*^I9<K(UKF>'3BY9VGL9=`T+FE5-[AB'(EC^@:&I8H;%
MQR7PH2<U44G-,`68#!AG7"VU7Z*:UT^NW?<854-S)5/>%2:52W97*Z2I7`#X
M\3)LE32^&1<)TF_])$'))FO[,"7HP6(P.0_M`XP$&RSNA="9SHY6?=\RG7*V
MW>@Z8>E4GJ1:=*RR[0KJ5+'QY?U,EB]C$2DI\1.ARJ0*RC,"ZZ<U,;V1A0@A
M!U0\&IW<_P"ANEUSI]@*2U_NXJUS:ED=-RB4SF>JK!46'&Y<\IWJ2.MA%2F8
M.!4HE#L<C(3C5FX"$M$06F*+`2#`.!$U?=P?W85:7A&;LCNKUUGDP:P5=K0*
MDWVQW1^UT@UBJE0%Q<KC%.N4U/CB%8WK"@&)B!]JB*R47CL<A++"$+[TIJ!0
M>O\`L]L[M[6]2V\ANK;PV(&W2ZN;\A=F1U%!TAJ*/^)(^JDV4#!@D@X6#.PQ
MCM,YZ<\"Y)DQ5&EC*-KV<F%&`$686-#'1@,`/&0C`,(I'D(@"#GHSC/P9QP-
M(L7[B'NYX96NV=.1JC=DFNKMSC(WFW(.3:RX3"WDQ*RFZV&-+`$IDJ&*(%)9
M>U$"$,L1IQB4&$XAY*^]X%S[4T7UMN1XTD?9O4-RJG#N^GYHD>MPD$E2-Q3&
MYLC/%&-O%)RB)-T2PDM#"T&!`4_MA%BSG]N+&0J5LYW'?=S;97?-+[LK7B_&
M*76JK9%]UL57V@\5O`;O6L*S"U$LM.&1J;I6J0+33PA$>H*PF//,QVHQY.R(
MS(;>8*7'*RA<4KJO:;D<-@D&CS1$X?$X\RQAL8XY&V!"0V,S*TH$\B`0D0-R
M!,`HH`<=`0AQP-5&^'<Q]WYWB5EH+JO;7:Y&"XT[60Q.MGT]+$E:2N7,20D"
M9$US,UKD*AKDH$*,&$Y*A0E$M+38"3@_L@%@`%DJ#T$TSUIU.E&DU4:ENS7K
MM/F20LEDPYV(;7Y;98):TA9)(YSR1NDN/?9`].K:`)7A)A^!)BRRP)NQ`46$
M`4!@?U>/NNZ]^3L]HUYV2<W2I+4B%L5D]RBY9!(W.".,(=U$@98E%LN<V.0L
MT`.?%&%:YM((!AQ4$DC4F&B*!G`;(:5T_H.@-G]G-OZXJ6WD-U[=#B`[I=7)
M]0NK&ZB@Z,:%@\21]5)LH&#!)!@NT[#&.USGISP,4O+075'8K;K7G>&U=?K%
M?-A-84X4U62,AQ;F]I)`E<')X91R-@328*"2&QEZ=U"UM$HQG*12/KA^QC'`
M;U:$:M=XFRP!#L?1ULJ)-4SVJD-5VA7DC+KBUJZ<G`*8+GF*SJ,RU*ZHD;GE
M"G$H3&=JG,-3E&=3!A8!A#(M&]+]:>[MK)ZJ[6&AK&C3?+9*JFE@2V2N2*96
M)9$O68$$V1SJ:/LK4.SZO+*'D!(,Y+3)PB'DHH`C#,C"D_>@4+<<CVB[M+O`
M-?Z5LZ:V'IOL"IBMK0Z.HF4R22G6"_D),(M-6S(B9`9EX<8&`0'`I)][UR%"
MD76Q@'3@+J:DZ8:^Z42_9"?4E5%R8G&U]H*;=NZ7321))F^RF7GJWM<7DE>[
MR7)K:S(U<C7&)T96`DDY4BZ,8QT8P'Q5VA^L+CNK*=^E%(VM\O\`/J;54-8H
MPO+=FO[%K18UIV4]EG%?FR,U@D0QM:!(3DP\&>D")/C.,]GC@:PS_JR?=$*+
M(-GF=8MBB8X?*Q3`RE$UN.2>E<N`E>%G@((F5+`NI3($>.S"D`Y!+"1^Y8Z"
M\8#@-K^W6EFJ6\E!(=:-C=77N75.P@:\PEJ;4;+&'2N%;&VY9F5QKM]890A<
MHBK:VG.4I>$HPD#2YR0:683G(,A5C0?N;=`^[FLAWN2@M>KC>+C=VH^/)[5M
M^6);(F$;CRTL)"]GBBISD2=MCJ=P3`"2H/3)0K#4^,DB.R2(98@PGN[**N(G
M>[O,^\3OFD[3A$DV.LZ-T7K_`!*1M[`D?VK6;7UH1QEFES@W"D`!MN+7?T(7
M(E./(A@3(RC.G.#L9X&ZWRU7>8$[_(X]ZR<!Y:KO,"=_D<>]9.`\M5WF!._R
M./>LG`H#Y1*?E*[7R6E'3_B`^,>P\&:>W[3V3/`O%G5\<]GXPZG^T='6[+P;
M[[K]?]SX%D]*?U8:L_$Y+^FDDX$&;C=Y366H\\C%)-M,;+;/;&3B*AF<6H[6
M2G7ZPWXN,*G5QCK5)YM+C\M%>5W%G"3-IB'PQT=2AECP(S).2@B'@*ID=]:=
M71Q#CN)W;W>&:@UTK4DI_EBE=/M-NUE'"^MDM:Y6(ZT=))T]0)F2G'IBP*U:
M`9!PE&>@00E&""%[K^T/UMVLE;-9=@I;")=5430PV4'5E<-FU6RW)5P%BUY0
MUM<S37DHCK=:M=X/>UPBVUW+4D@*<E18>@M2:$0>NZ]W;JL[;`LNQYT-D:28
MLKU%Y:&&-5B3MJI%VL&#18$'@MG2&C$#^15CY9$+AY)+<UO"AK&K2)TJ?JBZ
MZ<D8`QJMNZ^TSJ_-KIF>NG^11^WJ[D-.NT,L*RK$L*$PNFY<Z*7R45'447EL
MF=6JHZZ?7M3A6>V1\"`G)Y"<0>KA,GP6'PD'=3ZCH*S?:YPENI<Y/MA1>T_E
MH==B;J==CV2<P6.J8;!'B+W^OFI]HQPN%0I<J9FU*E<2T:=K6*2.R$%2?V@7
M-I*EJXUWJR'4S4S"*.0&"MQK>QMQ[DYO;@:-6M5.KN\/;\]JU[W(9%('I>H7
MN+@M//6+ERDT\XP9A@A9#V)%_.A6G\2V'^]1;@29P'`<!P'`<!P'`<!P'`<!
MP'`<"B6U7>2ZA:82ILA%\V#(6F4K(.OM-X9H55]G6JJ@51M3R1'G6WK/#6<1
ME8:UJUN>S\)C7UZRB;\&@'C!F>S,ZH8U+.]9T4AEU,]$/%S&J)6ZO=6Q59*6
M"`6+)Z?B4OO!K3/5-PZP+MCT5<JH@4JL]J7I3V9"[.Z0]84L3BP'`3B\B"<I
M;N9K7!MD&'4J46@SM5]/].R^_BH4<G<1A:*A@ZTI`_S64/Q:,<>BS8!2,S"?
M"]4G-5A3'C)",!)@@A7&ON]\[ONRJZN:UF.\C6B#T/"X_9LZ=)S7-G5\I659
M,UZEH@-HP%GFD/9'BSJ\L5[2#01]VCQ#DD>%_53IA&'&%@&%F]8MMJ,V_A\C
MF5'R9W=283,7*O9_%Y?#)C6EBUU.6I(A<5<3G]<6$QQJ;0][\5.J5842N0DY
M/2*BCB\B`/&>!9/@.`X#@.`X#@.`X#@.`X#@.`X&NO\`I0_S%/[GW`F[2G]6
M&K/Q.2_II).!3?OI=H+(U%TV3V355VU]K*^S&^J%I^4;#SR-,TU!4%?6'."6
M:86!'X$]EG(+`D<49##E13886=@*/"I3@'[AD6`K/W:%S+;"V+6QU?\`6!*>
M[S=..MI2J%K9"Z-U?KYW)[%PCY8K$&^U&\N$J.01H!^4QB81?@AOC'&3,](0
M<#H%"$(`A``(0@"'`0A#C`0A"''0$(0XZ,8#C&/@QP/[P'`<!P(SD7\Z%:?Q
M+8?[U%N!)G`<!P'`<!P'`<!P'`<!P'`<!P-!??&V1;TO?(AI7#->=JSZ'V#@
MCLFW%VNUPULF5XR=II`X]R0J];ZWS$FY2-'.K>P2>B<W54(Q-&61:)04G4*E
M)?8!7O8>0+[PV?H#4)XTLW6K'NXM=U^M5GY5U_J)9TE#M';\.11-VIVOIQ*V
MMN'FMJ/UV,2-:B2'.`C'!V>6OP,8B$J$TPT(FJS47O.ZB[V:LMF+>UQH^[7^
M=UYO._6W<]>VQ8JF.O4<EBNL$E,THN5S&EFB/5PLAD)A[7'(BPGK%;:X@&[N
M:M<2=DW!P1_9M`7MME(^\6M]NTJW>BD$MS2O7Y*_0&V$$&C.P$`VTU\OTBR8
M+3VDYTG$5$YM0%7MJ0;^H0`+'&Y2[)RR4"KMUH\%!L[[F"D=DHQ-.\%V=V+S
M8^%>W-ZUE)(4?;M1H-?;%DC/5E-L%?.TW>:%0ODD.J9L>WPDU$UMBY<>YFMS
M44J4YSE0`0@WK<!P'`<!P'`<!P'`<!P'`<!P'`UU_P!*'^8I_<^X$W:4_JPU
M9^)R7]-))P*C]Y.T[C*(\_/=:2_NOXQK='H3&79^6=XE$IX^1IBLM),UI;K(
M7UT0/[1!FV(8AJQ,G;AG]1:4[C,R(S)(PAX%-.ZVE=E/6S"Q'++T^K]6*UXK
M.4G8C_=EH!IMC@J@.<<P4X*S!3-^Q\G"8`Q!<\=A_P#DF)/OL?8R%B>\HH6/
M6[/D:1-8-\S/9.354.,:<T;4-ISVIV6CK%2O;HH?MOYPZUW(F5+B.1MR<6("
MYRE1*YM)(9P-K:D5KW,28X*:7]"[9I_9>S=[+09:AV3AE+V=KQ3S$Y1/;F\V
M*XH9/DT%J>!-`F[6ZOS4-!FO[G=\['(7>+2(U2Z+6=>7DO&0>#@&$".TGEFM
MVNM;W52-[6VZ6CN3W8ULWGM+)7FYIC/_``&PDL@UY[78N.HY*_O4?JB00)7<
M4G:D@V9,V-Z8@DDC)&3$!8BPF*2U'#83O/%^[5BUC7&+1ZU)S3$UL>+'[%6\
MO=TU@.>NVTLU+J<FWU\[4V<VQ^X76HH]*E[*E>R?#5*88B0@(6F%C#;WW8SZ
M\N>KY\?7RZ06#'ZMO?92F*UG4J>U\HD,GJBI+TG<$KM2ZRUS4*U\M5-,:9"&
MSQF<:<<M"AP8:88;D9@@L/)WV8@MN%$E0$9Z1&V6`6VKO*EE*PZDY!&,"4!2
M&8[=)T!QC/4']]\/`D3RBG'S=&>E;)]S@/**<?-T9Z5LGW.`\HIQ\W1GI6R?
M<X#RBG'S=&>E;)]S@/**<?-T9Z5LGW.`\HIQ\W1GI6R?<X#RBG'S=&>E;)]S
M@/**<?-T9Z5LGW.`\HIQ\W1GI6R?<X#RBG'S=&>E;)]S@/**<?-T9Z5LGW.`
M\HIQ\W1GI6R?<X#RBG'S=&>E;)]S@/**<?-T9Z5LGW.`\HIQ\W1GI6R?<X#R
MBG'S=&>E;)]S@/**<?-T9Z5LGW.!##+MC6$DG`JRCLSJ%^L@"I<A%7[/>E:N
M4U"L;!+`N*4471NISU@]$-N48-#DGI!D@S&>C(!=`3/Y13CYNC/2MD^YP'E%
M./FZ,]*V3[G`>44X^;HSTK9/N<!Y13CYNC/2MD^YP'E%./FZ,]*V3[G`>44X
M^;HSTK9/N<!Y13CYNC/2MD^YP'E%./FZ,]*V3[G`>44X^;HSTK9/N<!Y13CY
MNC/2MD^YP'E%./FZ,]*V3[G`>44X^;HSTK9/N<!Y13CYNC/2MD^YP'E%./FZ
M,]*V3[G`>44X^;HSTK9/N<!Y13CYNC/2MD^YP'E%./FZ,]*V3[G`H%XVDORE
M=?R1'VWM_P#A?8>/VO\`A'V2^P\5]MT=GUO`?]I[7]I_]+]OP+*Z4_JPU9^)
MR7]-))P-:?UAI&WK="(H6JBM:RQQ!N%J2*,IKUE+;&==6V2FVZT)6YTV/*=$
MRPB34;@"@U,_M@2\F&D*0G8R'!&18"*.ZW@MBQS9I:X2G7#N"*J;!5I*T_E/
MW:KIA9L6)4:Z1P136K)Q!8[_`/UVK"6(3GGPCX%)23[S/[`;2=@>[;TAVGL<
M%NW[K]&;&LH$6;(0&8N#U,VIWQ$F9>XNK7'\F1V2LY0FQ$Y.ZD\!>09QVQXA
MYZ19Z>!EF=$=/LWA&]D1:^5V9>$1;61M8;$-:SCGA*&--`8_''120:J&UNDF
M8&,L"1$[JTY[JE3E%EE*`A++P$/)6FBNG=//%Q/U::X5/$G&_P!&X-=PY;XH
M@-13AC=E#HK=XRXM*X*MI21-W6O:L]6TI"$[:J/4&&FD#,%D7`PQK[M/0YFI
M"2:X-FKM6I:8E\L1SR0PP+4K,PX35L+2IVB5XD!RXR4HY`QH4925O5D+BCD"
M('@R<11'27D+6UO6\"I^!Q.KZNB+#`J\@K(AC<0AT8;D[4PQ]D;BL%)$#<A3
M!`646#'2(0L](S3!"&,0AB$+(?)D7\Z%:?Q+8?[U%N!)G`<!P'`<!P'`<!P'
M`<!P'`<!P'`<"L3.#_\`V988^I\'LQTV'(^K^S\JE[YP'K='V>CIST<'\.JL
M[P'`<!P'`<!P'`<!P'`<!P'`<!P'`UU_TH?YBG]S[@3=I3^K#5GXG)?TTDG`
MUH][S<[L39>J&JDJ[N]FWDHF]).Z/$]+G#`AF,2BJZ*#3DDS-!'8VHF=E%J:
MF0.8G%X,+A3FE5-[L24E5E*`F@X%_:`[N#0K5:=CM#6_46A*1L0UB<(R9,ZW
MKI@BTB%'G8Y$I<V83FVI"%.6]<H;B!FE]/5&(D.<X^#'`N(O>F=J.;TSH[-C
M:H=E84#40O7I49SFN'U<`1MY2@TL:U6/(L=!9>!#STX^#@?Z&[M)3F0R&.C<
M6\J4IBY,T#6I@.:A$2/LS5A"`1N%9J4HS[T1@09`$7P9ST\`C=VEQ4."-O=&
MY<K:3PI75*C6IE2AL5#!V@$S@00:,U$>,O[[`#,!%D/P]'1P/3!*8R8SJ)"7
M(F(Q@29."J?`.[>)G3"3&]@HPH<PJ,HB<IS\=0?6'CJ#^#/1G@?9).)4$E*$
MYI9Y!Y8#B#R1A-).)-#@99I1@,B`868`6,A%C.<9QGIQP(WD7\Z%:?Q+8?[U
M%N!)G`<!P'`<!P'`<!P'`<!P'`<#DV^M4;$7CK[7FDZVE;@LVI!RJR[:;Y4H
MK29OL.6/K>WQ>('HB'$YD6HA+@H#5)HR`&Y$``S!9QT=.<\@NWF8S66TZW7E
M+M=JYQIW:9F.MOX;\,J_A/T;0=:VRS>5V@R.5S^2\11_)?MT7(C&:]VGCQ/%
MJW(W8W\,)W'+\T[.[A/3<D=$?>2;$83K"0'`+47/8Y*DG(L8R,A22)\ZQ2@D
M72$8?V,X^#IQT9YXS_D6OQN?F[_TZN^V81T,]$5415&S^E83_P#+9^X^C[16
MYG_<EV"_KLL;_P#><X_R/7_W=_Z=7?<^YCHC]0:3_;6?N,-(O_;P-B.RX/>'
MWP!T-@T=2'ON+DL#"U2WD2*4G)6@Q7AZP>-*A4J#CP%YSD`!J!BQCI%GE95M
M!KOH^FO\U?X\WZXQX]6]%%$Q&_UYE';70_T4SM=?RLZ%I?Y:G2\O7%/Y:SA%
M=68S--56'$PQFFFF)G?PB.LS+VBMS/\`N2[!?UV6-_\`O.4?^1Z_^[O_`$ZN
M^D7N8Z(_4&D_VUG[C#9WMYM_`XVND"KO%]D'8U.#(4+.V738IB]S6"QGLDY/
M6?.H47^R88+[T`,9S\.>C&?M8UW:&_=BU3F[\8SO\>K<[JWZKT4]#VE9"YGK
MNSVE5<2F9BF,M9QJGJ1X&Y_&>I&Z[5OJR-V6W?\`W8R2PKJL>9VC-#=A+J9\
M2:=R-UE+X6S-;@R`;&D+J\J5:X2!O`:/!1>1Y"#K9Z.CIYD+H<54Z7:BNJNN
MOBQC55,S5,S&,S,RT[=*ERS=V[U"O+V,OELOX^J*+5FW3;M6Z::IBFFBBF(B
M(B(B,=^9W9F9ET*\NSSPX#@.`X#@.`X#@.`X#@.`X&NO^E#_`#%/[GW`F[2G
M]6&K/Q.2_II).!$VV'>F=W]HS.F&L]L=G(-2D[D\5(F[#&Y,@EJM<Y114[.K
M&G>B1Q^./*8"4YV8U9&,#,"/KD"^]Z.C.0UCTWWGE#[O=]+KO$-.-K#+DI%D
MT3V4=+2AD,=9NVP,NQ$UHT^&'O4BB[XW,;4Y2-&Q*UH$:O)!QR<@PT`1@P9G
M`@E+O2*WTOM*VC:YL?%;6!MY9]$%0^IR;QL.*QVO=-:]'*'TISVNCICTM9G:
M!384G<R<I%;(>;)Y(X1Y`B1"2)$B]80%(+7;:S;YI><[1R&+RSO/X#WD6NE8
M:RRYS?&Y;L(_5""NJ%01AG84N%93T=3-AU(YRQY?"$1.8\X'*')6?@PXG(R@
M@4PVE(5K5#99IP^,*6W++[J"[)?WAKY5\B/53QU<2Y;00)58=[K6=:;)$URL
MTG?["3)'%R"!^2@PYIR1`(39`4$R2*&:,M6[T:H^O4U"%]U;(;7U^6W3#61W
MC!FI"K917K#M(\0)A?RT:\VMU1\N2Q^&.CFA4BRE=7LEI/6@.5G@R8&[3NH#
MFH6H29%"UQCE33'>6R\<UU7X6&N3:?KS'[ZL!IJ,J,N9QZHUQA3?%DA25C.[
M090F<A-@G.2<%YX%IY.HL3%MPC!#1"A(`-E@X9C3I(_%K5*;J1CK#<4Y<4-3
MHC\`Z/O2S3P]/3]]P)%\)LS\R07TH?\`U0X#PFS/S)!?2A_]4.`\)LS\R07T
MH?\`U0X#PFS/S)!?2A_]4.`\)LS\R07TH?\`U0X#PFS/S)!?2A_]4.`\)LS\
MR07TH?\`U0X#PFS/S)!?2A_]4.`\)LS\R07TH?\`U0X#PFS/S)!?2A_]4.`\
M)LS\R07TH?\`U0X#PFS/S)!?2A_]4.`\)LS\R07TH?\`U0X#PFS/S)!?2A_]
M4.!QT_6]#9095^BGE$A8$8,6G<?@N65U<7(8Q^24,[3!X5S,U!*!@/1T9#D>
M<Y_8QR`=(/-MOE3\C+KX/_;?-^9M\-QQ?DB%@L/1G./M9SCGA,[[:_;\"'EZ
MXO\`Q"_^;/W><.[X9+<XENQCF8\B.`80!()'XN)*#X,4<I/(!A0$\1N!EF*<
M](NC[[&,?!CE;7FK%64C+4V>+5%4U<;CS.[,1$[F&&$Q3O=1%\MH6JV=H*]<
MOZCXVU79IM39_+6Z(\717<N41%R*YJXT579QJP_FB(C"-V7W.N/_`,0O_FS]
MWE$E#%9;G.6T73G.?@']G/3_`/#RNT_]1'9A%=K^:+G(JX'Z%/U4@Z9%]T\V
MA8FV,*D/M(WMGM79[=4"OM?&+#UPY(1L#D3U,9^QGM.G./LXQS)31>;;7)C@
MAI)Z3/;;/];Q]?VZG2EX39GYD@OI0_\`JARZ(&>$V9^9(+Z4/_JAP'A-F?F2
M"^E#_P"J'`>$V9^9(+Z4/_JAP'A-F?F2"^E#_P"J'`>$V9^9(+Z4/_JAP'A-
MF?F2"^E#_P"J'`>$V9^9(+Z4/_JAP'A-F?F2"^E#_P"J'`>$V9^9(+Z4/_JA
MP'A-F?F2"^E#_P"J'`>$V9^9(+Z4/_JAP'A-F?F2"^E#_P"J'`>$V9^9(+Z4
M/_JAP-?_`&TR^4KI\71?PC_$!Z_4\=.W8>./9+ZO@W:>3_:>+O%GW_;=3M/"
M/W/LNI^Z<"RFE/ZL-6?B<E_322<"IO?%7W8>KFGZVZ:I,HV)R4%J4U7LJNJ_
M(X3+(/1%8V#/FV,2^VG&)DJ4;U-@PPET`:%H1#,.-P<,[!1@21AR%*^ZWV@E
M]O;-*8D^=ZYW;FYJ(-:RMUQ3^JE#M-<6B4<B<8Z47+C)"BGLB-%&64*D12M/
MX/D)IBHG/6#U?A#=79VIFJ]V2$$NN;6C7ZW)66WIFDN3V=35<SV0EM2(:@U&
MV`>I5''9R`WI#%9HBB<&]F6(T>0XQD6>D,U#2M.`G,?M`%2UF&RXE&_(Z*V&
M&!Q8,YC,0[(PCR5C\MPU8?V:-]B<,'@*906EZHLXZG1G/`\T5IZHX*[SF00F
MK:YAS]9[AAVLI[BL(C,>=[#=,!4@PY3ER:&Q(LEKA@"T[';+QJ#.@T>.G[X7
M2&,H]:=<FZM'BEV^@*30T[(5JAR?ZF1U5!4M:/CBK5$+E;@\00AA!%G-:J7)
M2CC#3DHS!FEA'G.1!QG`2RR,C-&F=JCL<:&Q@C[$W(FAD8F1`E:F=F:6Y.6D
M;VMJ;$)1")O;D"0D!1)!(`%%%AP$(<8QC'`P:1?SH5I_$MA_O46X$F<!P'`<
M!P'`<!P'`<!P'`<!P.,[ZX=_-;H9_P`5;F_1&%<@'2#S;;Y4_(RZ^#_VWS?F
M;?#<<3Y7[0/VN>$SOMK]OP(>3G#N<!P,6EO\&B^T/_1Y7:?^HCLPBNU_-%SD
M5<#]%#ZIC_TE&[_F5OC_`'BP<R4T7FVUR8X(:2NDSVVS_GZ_MU.F;ET0(X#@
M.`X#@.`X#@.`X#@.`X&NO^E#_,4_N?<";M*?U8:L_$Y+^FDDX&IKOW;=HF35
M]6NI<CV0UNUOODNW->]E:YE&Y4`G[MKFJ(@5C/AK2A>)0BCZNL%+HXOT8,2J
MVM[6=CAK/-&<2`)I"@`9WW9,,VQ<[,^5>>63W-=IT8N@#DG0R?N[JID#-/U#
MR]K&M1'5`IX*5R&/&PM:E;UF5!&/OU)Q9609_<Q\#=E(95&(DG;E<JD;%&DK
MN^LL7:5#^[(&<ATDLD<"6F.QYN-<%"<"U\?G106F1I"LB/4GC"66$0LXQP(<
ME.V6K<'MZ/Z_3/8ZC(G>TK-928O3$DM:#,MIR(Z2&&$QXID@+B^)I2Z&/AI(
MPHPDI1Y4B#G!?6SC@??A>Q%`V0\V1'*\O"HIW(*<6#;[;8X?8\/DKM5ZXO"P
M1B.P6]F>%BN'*2\-RCK`<`)Q!RG-QG&,ECZ`Q)!N+J2Z5(^7\V;0:]N-&1AU
M/89)<B&Y:[5U<P/B90G2'LKS/2)$9%VQV*5+"2\ICE0#NN<7CJ](P](3G&9/
M&YK'6.7PZ0,DLB<F:D+[&Y/&G5"^1Z0,CHG+6-KPRO+8>J;G1K<$AH32%!!A
MA1I8L""+.,XSP,/D7\Z%:?Q+8?[U%N!)G`<!P'`<!P'`<!P'`<!P'`<#C.^N
M'?S6Z&?\5;F_1&%<@'2#S;;Y4_(RZ^#_`-M\WYFWPW'$^5^T#]KGA,[[:_;\
M"'DYP[G`<#%I;_!HOM#_`-'E=I_ZB.S"*[7\T7.15P/T4/JF/_24;O\`F5OC
M_>+!S)31>;;7)C@AI*Z3/;;/^?K^W4Z9N71`C@.`X#@.`X#@.`X#@.`X#@:Z
M_P"E#_,4_N?<";M*?U8:L_$Y+^FDDX%:>]HV+M_6S6.*O]"077^S[=L[8>CZ
M%@M>;*!?ODXET@N"59BC<V94L:E"6@>"%2@"H"A>I3H2DB=1D8\F=D6,.<V0
M6UN%W66WDEM6Q^[N[F>NY7%]8W2_K+>M-U=Y5G/[)UCC5EPRO[;25^G5-+?"
MC9_`7&4-;D:3(F5.6XI.G")4>:6>$D.A/O)JJKZ?$:47<XL[F]RZ`;O:7_)Z
MI/>Y+EFC:>9;"UV4]OY,,(<PQ0R2GLN1)`NJE$<N1HCCR23BBSCL##7MLA,<
M5MNGL2[T+M4N>MT+%NRF&%@T-F&M]>IG"?10^#UA7N)I$+!>8PXW"J@4!@QC
MG*$DV8'UJCK8Y-RU,O3G#*4!&%.57R<6IK9!J]U*B9[C;6OO=3W/6&^\<@L!
M>&N:L[TKEFOXY'2]KMB5G2/+O;<ND<,GK@E9U`SG5:7E>L+",I;VB@)ED=K:
MA/V\<9V[K]171O=BPVTJ#8[CLUIAH2=<DVP3-K-M+'(7,WDLIB3QE(56Y<RA
M\?<7@\G"9C>%+<D4F$*$N`DANE[JA(E*U)*=HTSJX]5$PO39B=T"R*FM2PDH
MJ"FU]3^2U.<SL"Q&@4L47>(NXE.#0E$24$MK5I\@`$O(0X"S\G'8WRMPG!">
M#Y08;+!\3"/5O^%HDW4C'3EQ`6A$G+/ZO1\!8A!^S\/`D3KVA^#0+\MD/Q#@
M.O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#KVA^#0+\MD/Q#@.O:'X-`ORV0_$.`Z
M]H?@T"_+9#\0X#KVA^#0+\MD/Q#@.O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#KV
MA^#0+\MD/Q#@.O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#KVA^#0+\MD/Q#@.O:'
MX-`ORV0_$.!QU_6\Q2K-7Z*>494?+!\J5Q^#>)#W(X>1^24,[3M\+DY`0@ZO
M1T=7IST\@'2#S9;Y4_(RZ^#_`-M\WYFWPW'%^5^T#]KGA,[[:_;\"'DYP[G`
M<#%I;_!HOM#_`-'E=I_ZB.S"*[7\T7.15P/T*?JI(IICNG6WQ`3%QHO:1O;X
M7=0[%*NT\8L'7Z0HTIQ/5Z?L?#]C_P!_,E-%YMM<F."&DKI,]ML_Y^O[=3I0
MZ]H?@T"_+9#\0Y=$".O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#KVA^#0+\MD/Q#
M@.O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#KVA^#0+\MD/Q#@.O:'X-`ORV0_$.`
MZ]H?@T"_+9#\0X#KVA^#0+\MD/Q#@.O:'X-`ORV0_$.`Z]H?@T"_+9#\0X#K
MVA^#0+\MD/Q#@.O:'X-`ORV0_$.!0+K3+Y2O_)BWA'^(%T]'A+OV'C?V3.CJ
M]/@O:^`>*_AZW1VGA/P='9_#P+*:4_JPU9^)R7]-))P(7[T6N72W=1)?6C;I
M$F[P$$OD,7;W*@S+KC&O:\E$F6F.I-BL%K2?&"XS(X(ZMZ92B,1&$.&#Q8$2
M8'JCQD.?S2+4*G9+M1(=*MNNZ9MS723W13#?>*^W+R[R4S;J76=7&O\`<%?N
MS92J!X:S<.RBM@6&X(7&01](XEISL9($Y)SDYZ?(0[#>Q)ZA9?9%]F5V>2B^
MH'J%]ET9*[,'1U0=GD..KT='5Z/@X'\RG(R>%3DDK*D)>2@J,E@R>$K.>MDL
M)O5[3!>1?#T=/1T\``DDH1HRRBBQGBP,X8"P`$</`<!P,T0<8R8+`<8QTYZ<
M]'`_QA(DP0)+A*GPE'U^NFP27@@?:"R,SK$]7LQ=<8LYSTX^'.>G/`\^,8#C
M`0XP$(<8P$.,8QC&,8Z,8QC'P8QC'`C21?SH5I_$MA_O46X$F<!P'`<!P'`<
M!P'`<!P'`<!P.,[ZX=_-;H9_Q5N;]$85R`=(/-MOE3\C+KX/_;?-^9M\-QQ/
ME?M`_:YX3.^VOV_`AY.<.YP'`Q:6_P`&B^T/_1Y7:?\`J([,(KM?S1<Y%7`_
M10^J8_\`24;O^96^/]XL',E-%YMM<F."&DKI,]ML_P"?K^W4Z9N71`C@.`X#
M@.`X#@.`X#@.`X#@:Z_Z4/\`,4_N?<";M*?U8:L_$Y+^FDDX&O+O<]D*!AS5
M':!VR7=X-KG1LL(CEBAW;TW)L%EB$.?F-Y?FYRKNQ[/J)!)YK7Z<AH"%W6!6
M-.6M8W??^$!&F$#@:L]1MJNYLUVNM7<&G5[]XQWN&V[Q!%]30AC5+-@]K9Y!
M(G('QJ>G.-LC[8L0@T#JAAF;PT)U*U>Z+R2Q$-1PP#P$LX!@=54^NRL:E15Z
MHMB91^NU=HSB&U?!FN0N1!3A)[,GJTALC4%8$Q':GO+ZO<#^I@!`!A`6`9P\
M@)`,80BM\W=U4C>Q;-J8^73&&_8%_P`MY+;7YR=\%G+H[LRV1LL97R@II,A;
M/,WZ/-YR]O8UCB0\+T0<'ITQA0@BR'P:S[P73"X7.X6FN]AH$_**$8G>5VHJ
M./=&)FCT.CZYV;'^<()#(FUH8);`V)T8U:5:^,REP:4JDG)1J@!F0AR&)-7>
M>Z(/5+R/8%MV&CQ]812:L]</B\R-3]++$\[D:),Z1F*)*P5Q(BT79ZE#.L`O
M:R4;,>)S;^LK2]JG`,T(6UJRTZ\NZNX?;532YFGE<3YD2R*(RU@494M;TTK,
M"P6>2(8"CTYY)H!DGIS@%J$J@L9)P`&@&`(>E(OYT*T_B6P_WJ+<"3.`X#@.
M`X#@.`X#@.`X#@.`X'&=]<._FMT,_P"*MS?HC"N0#I!YMM\J?D9=?!_[;YOS
M-OAN.)\K]H'[7/"9WVU^WX$/)SAW.`X&+2W^#1?:'_H\KM/_`%$=F$5VOYHN
M<BK@?HH?5,?^DHW?\RM\?[Q8.9*:+S;:Y,<$-)729[;9_P`_7]NITS<NB!'`
M<!P'`<!P'`<!P'`<!P'`UU_TH?YBG]S[@3=I3^K#5GXG)?TTDG`S&TMD:%J&
M>4W4=I63%XQ8FQDG<8/3<"<C354BL5\;6A2\O*1H9D:98H$VMK6G$)6L/"4A
M(R8668:$PXH`P^/4NR>M%HVK>-&U'8L'>[>UY>V2/WA73*'#=*H.X/C20],)
MCPU'HT)ZQJ7H5O00N384(LGX-)P;@XLPL(5F[P^D8].A:LV:@JU),[2KS<C4
M4EEF"**"D4L@\!4;&5V\V`I;7`A&L71N/";F<)[NJ+R25A(GSE0/L@YX&M>]
M8I8SK+=F])VRJ+D,O?8/O(ZNV@J.W4=5S!34+'3#:V4=(5EMKKT;FDV`1Q;6
M3?5;K'!M*QR3OYBS"8E,D.)4A'P(!>X#:VR>N]9TI56N%YQ6Q]+^[2M*C+Z9
MYI4<DKA)+;.4/FNZ=-0%<OTI;V:)W&?.@4@_.A"QB5.3&),I1B,5`/6A+P$P
M2:QE$XWFBO>:1^C-E4NHM73*HZ_G0'#6JW6RSW>1I=?=I8@X6^BH)PB!%OO\
M9J6070QQE6YH&-2=USE1B/"A(C,.X&VSNTHU)F36A9())"Y%6R:V;WV2O&&5
MW+FI5'I5#*ZN*\9S/X&UR2,+<!4Q1[6QI\(<%+68$!S><M$0<`!P#`!"P,G;
M)V*VX.83+X^4B/;+!&TI1PI2<>WI\`C&<DJUF)>4%Q,R'.,=<)2?'P?M?A^`
M)%\4V'YZ1OT%5^NG`>*;#\](WZ"J_73@/%-A^>D;]!5?KIP'BJP_/2-^@JOU
MTX&D6K.]=OW9&XN\#J_52C&&[R-3X74SIK\O\,1P7.U,AGTJG<"DCZWO<HF*
M:+QBGXG,((O`G>2SU)[LWMJH]*48(Q*68$;![W';QF<;*UXE-4:WK=U(MNW2
M&CL*2P636.]ZGRR=7C4ZF[RI&ZV4M;$EB,A-55^S.7E0T@9CW%.X%)BRL9"I
MZ0!\O_&8V<GD%JF/T92U+2#:AQ9=X9#>U83^1RYAK.ND?=[S`JO+I:X=.H^6
M\OLH>+#F:Y$5#_#&]$0%(J[5Q$3D&>D-TFL=SNVU.NM'[*0.4M3?#[UJV$6I
M'FQT@YQCHU-LVCZ%^):'(Q/-,)S'!JRMRG/$7]X(TH60_!T<"<_%-A^>D;]!
M5?KIP'BFP_/2-^@JOUTX#Q38?GI&_057ZZ<!XIL/STC?H*K]=.`\4V'YZ1OT
M%5^NG`>*;#\](WZ"J_73@<=/UO1))$M7Z)Y?GQL=P#M*X\)PM[`<RY)'B)0O
MKB,&:^._;X$'.,8QC`.C[/3GD`Z0>;;?*GY&77P?^V^;\S;X;CB^*_:!^USP
MF=]M?M^!#R<X=S@.!BTM_@T7VA_Z/*[3_P!1'9A%=K^:+G(JX'Z%7U4=#+%'
M=/-IC+(F=K2>TC>V/!ET8/=CNTPXL'7'X47(FL.0BS]C'9_!_P"W/,E-%YMM
M<F."&DKI-]ML_P"?K^W4Z4O%-A^>D;]!5?KIRZ($>*;#\](WZ"J_73@/%-A^
M>D;]!5?KIP'BFP_/2-^@JOUTX#Q38?GI&_057ZZ<!XIL/STC?H*K]=.`\4V'
MYZ1OT%5^NG`>*;#\](WZ"J_73@/%-A^>D;]!5?KIP'BFP_/2-^@JOUTX#Q38
M?GI&_057ZZ<!XIL/STC?H*K]=.`\4V'YZ1OT%5^NG`>*;#\](WZ"J_73@4`\
M!E?RE=7RB:.W_P`0/L>V\F#^S\:>R9VOAW8>4?3X)XN_</!^OUNU_=NUZ/W+
M@63TI_5AJS\3DOZ:23@:I-]G=STW[TK7KO*+1IVT;AU7;]/[!U6D\JJ2O'FV
MY-JY9+Y:3=/6VUG*"1I(XRHN)6''1&QU<Z-B8\],(!91N,EG!`,,6T\E!.^/
M>]/G>(4+25M5/K#7.E3GK6^W):]72&EG+:NTI-:+',&PF/P^6H6662.*TVQL
M*A*-X<$@!`7G^"EXP667D0=%7`<!P'`<",Y%_.A6G\2V'^]1;@29P'`<#`+6
MKQOMRL+$JIW?)5&6FR81*((Z2*#/'D],V-NEC*M8ESI%'[P99EED*%*N$8C5
M8*,RG/"$>`YR'HX&A"O>YCV7U-E^U$UTKW@F;6[6%J)1>K6M)5_GM,Q;ZE(K
M)9(&TY_EZ&&5M&$<@!740>S`0(M,4#"%Q4JC70*\!F`X#W(!W3^TL:UEHZN@
M2#42"7=J%M)7FW-%32%)+YE4=NVW$;),8]=<CVX>)R^"L"3R6Y44U6'*79L5
M"4IE(PX`#P<DI.$/C![E[86MH35,VHJ_Z>3;7X8M[HYL#*;#@4P45#+2.\/F
MY%E6J]P&/QR0$2AI=JDES8A!%REZD\AR0ILA7]D,>,@#=]JMK]&M4-:J'UGA
MS@L>(S0]3P6JF=Z<22D[@]IH5'4#%E[7)R!F$IUCP<C$I-+`(0`#-R'&<XQT
M\"?>`X#@.`X#@<9WUP[^:W0S_BK<WZ(PKD`Z0>;;?*GY&77P?^V^;\S;X;CB
M?*_:!^USPF=]M?M^!#R<X=S@.!BTM_@T7VA_Z/*[3_U$=F$5VOYHN<BK@?HH
M?5,?^DHW?\RM\?[Q8.9*:+S;:Y,<$-)729[;9_S]?VZG3-RZ($<!P'`<!P'`
M<!P'`<!P'`<#77_2A_F*?W/N!-VE/ZL-6?B<E_322<"N.ZNE#YLK8T:F+9WD
MNZ.FI#-#$\<'7FMUMUU7\0D9I+T\.69B\-DO@4I<5<B4`<L(AGEG@)RF1DAP
M#`@B$(*%:?/MVZH=[.3H2;O==&^-*VII5)]D'O.PT@A,_M&A[#A=HQV$M`R9
MM"8]'L)8?8C$]FA*;%B<O&%*/MB\BR+(A!T4\"E;[O)`6K9P_59FJ/9:?3!H
M<X*SS6P*\I&22JDZV<;#:B']A36':"0P#)&1DQ]8G7K.TP+P1(H*,'\`\<"/
M&KO3M15\NL>.N;_8$/C=>1BW)>BM^:5=-([2MJLM`K,MMWF4C8ZMKRSVHKK!
MS").X)VOM3CQA$)$%46$0\!_EB[T36QXJJQ+,7L-]PY[K28P*`/%%3BBI]&M
MCGB8VV!,;3C%$*96-N93*55MEJ>LPB2!&4HP2H[89'@BKL0M-KML/7>SU:);
M0K;RF1-V'V1Q"1Q:=1=V@]@P"=0UV4,4P@5@0M^(3O$6E\8>$HR%:0\/P?>F
M%B,),+,$&3R+^="M/XEL/]ZBW`DS@.`X#@.!7MWVKU^8+.24R\60W(;/<'##
M8@AYK3(\N2Y7UVHHSP,PMF&B5)DICXC">>`T1"<2HK!HP9&'I"PG`<!P'`<!
MP'`<#C.^N'?S6Z&?\5;F_1&%<@'2#S;;Y4_(RZ^#_P!M\WYFWPW'$^5^T#]K
MGA,[[:_;\"'DYP[G`<#%I;_!HOM#_P!'E=I_ZB.S"*[7\T7.15P/T4/JF/\`
MTE&[_F5OC_>+!S)31>;;7)C@AI*Z3/;;/^?K^W4Z9N71`C@.`X#@.`X#@.`X
M#@.`X#@:Z_Z4/\Q3^Y]P)NTI_5AJS\3DOZ:23@:>^^14]R,1<E<$=X-KN\;5
M;=NU<-[73-(U1!+FLR]I77ATJD^&M/'HM6SNRL)+.;,!N99:AR4INLI$(L(Q
M"R`&0@GN'5Z"1WML*]:G]U#4W=TZB1!]E%/6W(IS-722;@S"]X27''-K@;_'
M5JM<K@,7BS3),J'-J4GJ""'`X&"333?".S#J@X&@6Z]>9(X[NR&25+I]LQ!]
ME9+L/3%B1W=QEOMV=]81TNQ!JQKM8R81<ZRV5!'G5YJV'/,5.@PH:Z>'J!)5
M92[(%6#4P5.G^G^W]UT+5VDK5K9/(6^:1,VS$G^6>:/L$;ZFV">G44G0T;"J
M@E:"4N;\X_*TT23"J0G.[6U$1TU/E.KR8,01<"PTYB.SMY6Q(>\`0Z?7E!6Z
MJ[?TN<V76R8FULU;"VK#:!;]@"+AD[)'&^>.L,4.+0?L/G$81+'Q*<^8CYV0
M"(\)2X$&RKN^8C8[?";YM:SJW?J<=]EMG[,OI@JF7B9L3F#P=\9X;"X>CGZ6
M.NKZQ-<W?&:"%N[BB3+584)SCX.,T9I1F>!/TGC;\9;<%4`L&4$$+&NPC4B`
MIMA`DS27@$8SE.B,.B1JTXK.!8QTJC5!G1C'WW3TYR$C^2\A^<B6?R9`O4S@
M/)>0_.1+/Y,@7J9P(WL^=P6DV-))[CV7:ZIC:YR*9D3_`&,^5%"V96[GD*%1
M#6F<Y%'&Y&>X')DAI@20CR8(!8A8QT!ST?&_F,OEJ/&9FNBW;QPQJF*8QZV,
MX+EI>C:OKF9G)Z+E<QF\W%,U319MUW:^+&&-7%HBJ<(QC&<,(Q05[;NF/_<7
MH/\`KJUO^*\I/3&D_NLO_4H[Z0^[GI!]1:Q_9YC\,]MW3'_N+T'_`%U:W_%>
M/3&D_NLO_4H[Y[N>D'U%K']GF/PU?);N=J&9L]1CD1W@M''-22H-C$;@[EW)
MKX)&A5+Y+KN<W-ZI04FP@*.<@-QYI(#L=<SP0>2_@`/G/I;2YIFJ,S8XL=7Q
ME/5WNKU<)[3YST?;>TW:;-6B:M%ZJ)F*?RE_&8IPXTQ'B\9BGC4XS&]QHQWX
M6#]MW3'_`+B]!_UU:W_%><>F-)_=9?\`J4=]]/=ST@^HM8_L\Q^&>V[IC_W%
MZ#_KJUO^*\>F-)_=9?\`J4=\]W/2#ZBUC^SS'X:;:ML:N[Q:W-\I?9]DMIF9
M7`+2\.U;2*GINW-3H-,4L`VN*V-QYR3HEPDAX#<%&""9DL>!='1G&>5=C,Y?
M-4>,RU=%RWCAC3,51CUL8Q1[5=&U?0\S&3UK*YC*9N:8JBB];KM5\6<8BKBU
MQ3.$X3A.&$X)0\EY#\Y$L_DR!>IG/LMIY+R'YR)9_)D"]3.`\EY#\Y$L_DR!
M>IG`>2\A^<B6?R9`O4S@/)>0_.1+/Y,@7J9P..?ZWLU.3;5^B8E\F=Y`$VTK
MD"6!S2QY,%-D,2A>1#*RR,C2,0C,9Z,]ID>.C'P8QGIY`.D'FVWRI^1EU\'_
M`+;YOS-OAN.+PK]H'[7/"9WVU^WX$/)SAW.`X&+2W^#1?:'_`*/*[3_U$=F$
M5VOYHN<BK@?H6?51F1V7]T\W'HI@^LA/M(WJ'P)N118]/@07%AP(SM'>.N:O
MK&?9SCM.KC]C&.9*:+S;:Y,<$-)72;[;9_S]?VZG2IY+R'YR)9_)D"]3.71`
MCR7D/SD2S^3(%ZF<!Y+R'YR)9_)D"]3.`\EY#\Y$L_DR!>IG`>2\A^<B6?R9
M`O4S@/)>0_.1+/Y,@7J9P'DO(?G(EG\F0+U,X%&$>]-*O&PL_P!9(Q/MFYI8
M]6/YT3L5U@^K\TF%60V6$0%+98XM(+BCU(N%9-LC%%%Z8P*(UT"H&I4DI@AR
MH-`7D(L@7>GZJ3VP)[5PK6VBKR<UC1$PV9G#'=.I=C4N<P4A!1"+D,]5&V90
M\9(RUEGE&%)\!%DU8<0:`@)@BQX"%D]5]F83N)%7":U#*]E6V,(TT;<$3O;V
MN$DHU-*&F6MAKPPO<)S;5-1`4T8UC<7@WPQLPI3EA,+ZP\=H#K!:?R7D/SD2
MS^3(%ZF<!Y+R'YR)9_)D"]3.`\EY#\Y$L_DR!>IG`>2\A^<B6?R9`O4S@:_?
M$CM\I?9^6+]U_P#$#\#\(\!BW:^%>R7X5XVZOD[V/AO@_P#LW4ZG@W8_?=EV
MO[IP+):4_JPU9^)R7]-))P(/W9[J_3K?A[C,]NR'2QANR!-25FK?8:G;#EU3
M7?7B!"YN#TA31J:Q)S28,1HG=U4*BDS@F7)`*3<FX*P9@(L!5'NW.[&VP[N&
M]+.;F[=M5LUIK<CE+[1E<3O&#(<;)-M_/Q<=;@3=5;K+@14]2O;(P@*=AK@(
MQF'EE&E)PB[89@;Q.`X#@.`X$9R+^="M/XEL/]ZBW`DS@.!RS?6V!B+[O6GS
M0]'7+VN@X@YSC&<8SY`V3C/3C/P9QG&<XSC]G&>CD-VYIBK1)IJW8X\<$LE/
MA6NW+/2A1=M3--R,M5A/^Y;_`-8.'^++M?US&A-DD7=4#W@D`'`M&J$-":>$
M..LH1YR6(8"3OL]06<Y!GIQTYQT9SCS535%4Q$SAV6XRS=LUVJ:Z[='&F(Q_
MEAD/6UC_`#(^?Z_/_P!KG&%?7GMOKQ\OY.CM,)7*:(S+F@U-`Y.:PHT;TB7+
MO'+*#!QSB<Q#0K"4IBL*WP=&!&HP:')>#,Y$'JA%RXVZ;$9"Y15?B+U=5%44
M\6O_`+8KQC&*>+C/&C#=PZ\H9G;NIU;6Y3-6=*KKTS+V<S:JO1=RT1/CZLK-
M-<6ZKL7.+3%FOC1-,5[W%IG%FW6UC_,KY_K\_P#VN6["OKSVTSX^7^91]%B\
MR=]>V>/.*N/Q9V<'SL!EM:=6J$6B"K&'."SUH@@"/*8C/WP@AS@0^CJXSCIZ
M<?6S:JNW(HFJ8IF=U0:GG[.1R5S,46K=5VFF>+$QN8]3'^$.Q;ZG&H-5ZC[D
M*3Q=<X[:Y((8NC&,?S2PGJA"''P!+!CX`AQ\&,?!S)#92W1:T:W;MQA1#2K\
M0&=S6H=).;SF=KFYF:XB9F>S,1$1U(B-R(C<B-R'85R2/$S@.`X#@<9WUP[^
M:W0S_BK<WZ(PKD`Z0>;;?*GY&77P?^V^;\S;X;CB?*_:!^USPF=]M?M^!#R<
MX=S@.!BTM_@T7VA_Z/*[3_U$=F$5VOYHN<BK@?HH?5,?^DHW?\RM\?[Q8.9*
M:+S;:Y,<$-)729[;9_S]?VZG3-RZ($<!P'`<!P'`Y>H?15V0[O,FE[UCUXWP
MH6;R7O`K6M?=.R;/M>0R[2"\M3I'`%Q!TDB*<AW!4*V6RM[+CA,99$3.&9QP
MY`<6X*<I4P18"7:_UBLZT]<N^:O2^M=+GE]R[G6K>-8LE-MDB;:CN&5Z?4JW
M&5)1]:5G+Y8B5-L6232*)WE[0FFEX2.2M]$9G_S@F<"7.Y_@MRPZ>[6":X1M
MM4NB"AOU[:M5:FW<?IV[W7%)U'X"XH+\.C[?:4@E-BQNJSW++,F0)ERW*$YP
M2+#FPLM$('6#>9P'`<!P-=?]*'^8I_<^X$W:4_JPU9^)R7]-))P+3<!P'`<!
MP*P;1[,I];8]!<M-7SZ\K0MJ=$UO4=,UD;%$<MG<IQ'GZ8NW0]3N11.&1E@C
M4/BSBY.+DYN"9,G(3=7I$:86`091K5L!%MG:=C-P11FDL5)>54B89%")JB2M
MTUKZ=0F1NL-GL!EZ!"M<D">10^7,2Q"HRG4*$QPB<&D&F$F%F"#*Y%_.A6G\
M2V'^]1;@29P'`Y8_K;G_`$\:B_YK(/\`H%9'(?MONZ+A&_QXX)9(?"Y,4])D
M553$4QE:L9G>C_V6W`6BR@\&)[5S1ECZ@>DO)H<Y#][C'0+H^#I^#GB$:/G*
MOYIIF,6TBKI'V;L3XFB_15%,88X[DS&_A_#^+VNEK_.R+_6XX]"YOYLNOO,V
M=\K1VSI:_P`[(O\`6XX]"YOYLGO,V=\K1VSI:_SLB_UN./0N;^;)[S-G?*T=
MM\=]3HU3:H`F<T1IP0Y&`KM0XR;T8ST@#G.<8P//['3\&<\^MG2<W:N17-,S
M$*'4>D#9[/92K+TWJ*:JHG#=ZKN.^IM8SC4#</&<=&<;6),9QG[.,XJ:%=.,
M_P#OQSWG9CFJCLM3'3G,3M_F)C=CBQPR[$.2%X\<!P'`<#C.^N'?S6Z&=.<8
MQ\JES?#G/1C'_I&%?9SGD!V_B:M.MTTQC5-<_(RW^$.Y;L[9YV[=JBFU3EZ)
MF9G"(B)N8S,N*4G+=V0.NZH@BR'&1![4.>KG/_P]/[.<?L\\>C1LY,8S3,2V
M0U=).S=NJ:*+U%5,=7'?_B\O2U_G9%_K<<>A<W\V77WF;.^5H[9TM?YV1?ZW
M''H7-_-D]YFSOE:.V=+7^=D7^MQQZ%S?S9/>9L[Y6CML<E"=(H:5&4CBD4'%
M`$/L`FAZY@>K]]V?_B'C'P]'[/*C+:7FK%V*YIG#%:-;V[T#4\A7EK=ZB+DT
MS$;N_,QO/T0_JF/_`$E&[_F5OC_>+!S(/1>;;7)C@AI\Z3/;;/\`GZ_MU.F;
MET0,X#@.`X'RW!\96D99;H[M;:8<$0R@.#@D1C-`'.`B$6%0:7D80YST9SCI
MQC/.LU4T^%,0^MNQ>NQ,VJ*JHCK1,\#Y_EC$/.J-_P`N-GQKG'C+?SJ>W#Z?
MD\YY*[]&KO/\&S2)EE&&`DD?4#`6,8""7UGP:>((<B"25D]<23@PS..@/7&`
M/3GX<XQ\/'C+?SJ>W!^3SGDKOT:N\KS5>V,?L^=3:!**QLFMUE?";D\F>["=
MJ3*CZ9R>&5ID3.TI%$+N*:N3@L<F-Y*4`&2D&F`$(P&FEFAZF>>/1\ZGMPZQ
ME<U,X1:NXQ_X5=Y8GRQB'G5&_P"7&SXUSCQEOYU/;AV_)YSR5WZ-7>/+&(>=
M4;_EQL^-<>,M_.I[<'Y/.>2N_1J[S[:18D7IRU:%4F6I3>G)2E(>4I3F8"+(
M!9+.)$,L?5&'.,]&<]&<='.T3$QC&[#X5T5VZIHKB::XWXF,)[3V><NIP-=?
M]*'^8I_<^X$W:4_JPU9^)R7]-))P+3<!P'`<!P*$[M5I=CF_ZQ;!Z^U\S7%8
MFKUKRF8'TX[SE!6QUBPNQJDG52RAOC4S>TRJ--$M8\RY*Z),.?8HE):(X@1Q
M0S`"X&7Z*4[9%-4,)'<:5A:;:LVTKEOJQ8S%G;+_`!N$R:\+-DUCGP-GD&4+
M;Y0$PM$_D-IJ\)!9:U4F-.+Q@H8.!*$HJHUXL6,OQ3_81+?A),1.@VZ<O*!&
MV'N`6+P!,A2%+`>")E.4QO062'J8ZF.GH^#@9+\E+?YZ6E_6-)_CO`?)2W^>
MEI?UC2?X[P()V!T+UJVMB#9`-DHI(+HA+-(4LL:HQ-YY,UC4ADJ%$O;D;T22
MB>T(\K4R%T4%`R(0@X"<+X.G/3RGS&5RV;HBWF:*:Z(G'">OUUVT;7M9V>S-
M6<T/,W<KFJJ)HFJB8B9IF8F:9QB=R9B.TJ'_`(!O=)_V.H9Z3V%ZV\I/0VE>
M0H[O?2'WD[>^M<U]3[A_@'=TI_8ZAGI/87K=QZ&TKR%'=[Y[RMO?6N:^I]P_
MP#NZ4_L=0STGL+UNX]#:5Y"CN]\]Y6WOK7-?4^X?X!W=*?V.H9Z3V%ZW<>AM
M*\A1W>^>\K;WUKFOJ?</\`[NE/['4,])["];N/0VE>0H[O?/>5M[ZUS7U/N+
M5:Z]WGJKJ*PR:+ZQ05XH^.S.0`E<J9H'.IHA0/LD+;DK0!Z7%+7Q?G*W#8A)
M(Z09`'("\=.,Y^'E;8R]C+6_%9>F*+?6A&M4U?4];S4Y[5[]>8SDQ$375AC,
M1O1N1&\L1\E+?YZ6E_6-)_CO/LMI\E+?YZ6E_6-)_CO`Q<-6N/EH<4*8VGY)
MXBZ890_E$?>KY0Y=E85`.OA9X;UL-N"L]&<]ET?8^^Z>!E'R4M_GI:7]8TG^
M.\!\E+?YZ6E_6-)_CO`K=L5W<VI>W**)MVSE?.MWH((M=7*'(YW.ILM(CJ]\
M3)4;NK;P(7Y!T'."5$2`S(^OCJEXZ,8S\/*;,Y/*YR(C-6Z:XIG&,>HO>B[2
M:]L[7<N:%FKN5KO4Q37-&'\T1CA$XQ.Y&,]M5[_`.[I3^QU#/2>PO6[E+Z&T
MKR%'=[Z^>\K;WUKFOJ?</\`[NE/['4,])["];N/0VE>0H[O?/>5M[ZUS7U/N
M'^`=W2G]CJ&>D]A>MW'H;2O(4=WOGO*V]]:YKZGW#_`.[I3^QU#/2>PO6[CT
M-I7D*.[WSWE;>^M<U]3[A_@'=TI_8ZAGI/87K=QZ&TKR%'=[Y[RMO?6N:^I]
MQ<>@]&==M6(%FK=<X[):;KK+\[RC,.A<]F21EQ(7\PDUZ=PDK7E<<%4Y&)P9
M,Z!X!TAQT!QROM6K=BW%JS$4VXWH13/ZAG=4S=>>U&Y5=SER<:JYPQF>O.$1
M&/7W-V=U-?R4M_GI:7]8TG^.\^BC/DI;_/2TOZQI/\=X&,--6N(I'+`.4QM0
M+$6-C\FQYL1]P$8!-N<NW5$2LPI%U5_P9[7.?_X_!P,G^2EO\]+2_K&D_P`=
MX#Y*6_STM+^L:3_'>!5C8/NRM-]KWB-R#9"MGFXGJ'MJYGB[C+;&L7MV1K<U
M1*UP1(\-$H:BNR5JTX#!9,",72''1G&/@Y09S3-/U":9SUFB[-.]QL=S'L3"
M5[-[=;8;'T7;>R^HYC(T7YB;D6IICCS3O3/&IJWL9P5]_P`!SNI_[*C5_6+;
M?KYRB_QK0/VEKN]])_?;TM_\@U#MV_PW\SW#?=39QG&=4VG.,XSC.,V+;?1G
M&?@SC/\`Z\^QG'.?\;T&-V,I:Q_Z]]Q/39TM51--6OY^:9C"=VWO3_MOGI.X
M%[I%"<8H1:@QQ(H-Q@)IZ:=VL2<:'`0@Q@TPN<A&9C``XQCISGHQC&/L8Y47
M=&TN_1XN_9IKHQWIFJ8^TLVG])6WFE9B<WIFI7LOFIIF)KMT6:*IB<,8F8M1
M,Q.$=I]'_`<[J?\`LJ-7]8MM^OG*;_&M`_:6N[WUZ]]O2W_R#4.W;_#/\!SN
MI_[*C5_6+;?KYQ_C6@?M+7=[Y[[>EO\`Y!J';M_AKP5%J/3]!5Y':EI@$ZKJ
MM8D6N)C,-8+'FN6AE*<W-8\N!:/+D]."WJJG5P//%@9P^@9N>CHQT8Y>+-FU
ME[5-BQ3%-FF,(B-Z(ZSSK4=1S^KYZ[J>J7:[^H7ZYKN7*YQJKJG?F9Z\I)^2
MEO\`/2TOZQI/\=Y]%$?)2W^>EI?UC2?X[P*$>0Z7Y2/!_*2<]'M\^(^V\L'G
MPKLO90\:>'^$>$=IXWZ_[AX5_P"=X'^X=/4^#@6CTI_5AJS\3DOZ:23@6FX#
M@.`X#@.`X#@.`X%-MSMG9YK/'*<^2VDD]^V1>-XQ^CX9!5]GMM0M079ZAL[F
MQSTZS5TBTP3HT2!K@:@/981#&<8:#&,X_9"I<B[SRS:XK#:,^X-/7""[):SI
M->7K-%M]YQB70VRHMM#9&:LJB0QB\4,-0HFTD<O;75*ZIUS`4H;S&W.0A/).
M*.R&0-N^VT\;M%EI"]M$&ZL[5M>K;FF^MC/$-JX7:K!;DQI"/MLFDM92)[3U
MS$'.KUSLUO"?+>['MKDU#-R,L\P@>"@G!(=`]X_7&TTXHV#T+#WN8K9Y5CU;
M5\&KW$EB.U.;&M<NAR2!VR@&@6G?+$\VNT.4?(C81)E(0,;HX#,"F2E>$AG^
M^>\]=Z$TFZ6Q,XK-['?S$CP.$5?7;$YO$EF*QB0A<WL]0X)&]<TPZ)QEISE<
M[O;H(E`WHP9SG)APR2#0C7:#?>:TO.RZYI;5V6;-RB(T6+9N\D<>L2)U\&LJ
M4$Z.;0V',)LG1+`6):,L5QMYRRQLO+:!:4T'B-7I\B)"8$>7#WG$RB;4ZVI2
M>G5FWUK#7M(U[L/<-^XFT9JU&V5E8<8-L`H5,Q&9-QBF\Y7$*Y3C=WQ`0N9B
M4(C"$051JTP1!8;4F![;I,Q,LC:#A*&F0-+<]M9XR34XSVYU1DKT1PR#P%G$
M",3'A%D`PX$'.>C.,9QP/K<!P'`<"B.V^U]Q4=9FOU,T+K:V['65?2*W7E(U
M/EW--&LD98:?;8:O>ERI_=8+.\.BIP%,R"R4Y:<K..S$+(LX^P%;'OO0++;:
MO#A)IZX&;5MNY,1TFEFM[S><8:(TSV1-Z]Q;4=E#3>Z2&O;)(8(ZUPM0N!"C
MQ*E5]HJ$G.3$FE"P(/9,[R._X8MO.`7)HB]1:^J=HAHVD9JFK38"(7,"TZ$(
MG0H183M$9*V0J,+$=DPL:50I21M<TD8D'5*(1+LFC-PG"T%"[OUYM+;KQ#M>
M$15H5!$ZIA,^F.P[,^$A@K?,;/1(9)`:A84>&\X^2S8ROE87Y]"$]-B.I5C>
M2H")2M[(D/G[?;YUSJ-(:7@KM$YO8MB7;9U801GC,-9',YNB$:L.S(S62JT;
M%E_BU3&X=#F!YDY!1051P5CLX&%)$A0\B--("&]B>\J<:-M:UF!AULF%HT9J
M\"LQ;@7TT3J,,`:7S:B5`]M0(G7#DB4OEO&0N%NZ*02@*56VC:FA84,C"X_(
MDX0_MH]XK8]7V5)%;AIG99^HT#NB"4).=I%\XC$=<RIE/GJ)Q-!+X'1;JVAE
M5BTPTS.>-36KD:5R(,.-$K-0H5I*00S`VE\!P'`<#7+L?N5?U=[.Q;5G7#4M
MGV.FCO0[E?\`(7:2;#LE$LT;BZ&P4M=$MQ&72MY\:^N:MV6`-Z`=@$LK&>GI
MS]D,REN_5(Z[0FK%>]T]I[4"VK*0KU7R3R"WVN<!;,H'4YO-4HI:B88YXXCQ
M)(DXSW4QM0H4YQ^21CZP,YR&-IN\QU?;=I;`U2L:R*^K&<LLBJ".50;)K`9`
MF7FJM^N6F?M1\/;<%$^!IDYKP2V)S#5!I3DL&`"<>3!A*R$C3GO"-(ZSG,YK
M2P-GZ?B$\K%F=9!8D7?9:B0ND*:69"QN*Q5)BS>@MG$<EDJ#P0H\0#EYBLLM
M,`XP6`\#%UO>=:`M]/,-_J=K*F^1R339PK=FGJ=Y4K6@^?-2`YU<8@H+1H5#
M@VR!*UDY4B3*B23/!Q`,QC(#`9$$@5OO1I_;T!EEI5IL15\PKR"UTGMR83!I
MD1`V2/5BJ4S)$GG3FK/"1@B-'+:\?"0JNC)>36I2#IZQ8L<#')/WC&B<*GHJ
MNF6U](1.P2P+QJ8E))TTL;PARVPMLL104Y$.9J8+:H,A3PF<2"E`BS%1!G[B
M$P01A"'V5.^NF:37AOVQ4[)U,3KF[.@F)KMD<J1XB[E(0/"N/F1I`/\`_/62
M<EY;U"<;:60)<`:<WK%8P6/(0L!6MF5]<D#BUHU3,XY85=S=I(?8G,XDZI'J
M//S4IR((%;>XHC#2#<`-+&4:#IP82<`99@0F`$'`9QP-=?\`2A_F*?W/N!-V
ME/ZL-6?B<E_322<"TW`<!P'`<!P'`<!P'`UL]Y!K7(MHD>G4(;$-D"B\=W*A
M<YLV0U/8<@JJ;0F!M-270UJ92VSV'R&,3*/ED2%[;DI@VI4%6,*OJ=&2Q&9P
M$![8=VI7<9T8V3I[7Z`61:T\V%FNNJBSW6Q[>L*V[=LZ.PF\ZP/7H7^T[8G#
MK+S6*%5PB=,HDH',@M`FP=E*`)YF<C")$VF!G=A[>2S8/3;4"0[`55>&O4LB
MZF%L$CQ*;/HV\JY2^/X6SP>:6]+E3I%*0V2*R%OD"5,J-(;I&V)'`TO*<T0"
M@^EK'IMN#I_;LF>D\J528_O(6"6SG;RS:^C,!6XU4WE&T/+XQ6Q!HS)48&R2
MT2MC!X(B!"K2N1I;LPMB]26,+HXB"%L=F->MC5W=M;5T<]6[,=P;NG%760UQ
M*0NT&JJL9&^G/K22F9(:D8:Z:(7"`!2'%F=FH-++.-R=G!IF<!#T!"^RS'LM
M1.P]CV_3NKMA[,(=G=)H!K<A2UX_UTUCJV[JLD5LN$.4VD">RZ)@:JDE+?=!
MPE[XW^-#VLQG&$2(SMRLY"I]D,.Q\$1:\:%V9I]MW=>DVM&OFO[%8COK%%ZD
M?V[<*V8C&&(;A"90[SZZJS>HOKW"G-F(&XM12+PR7+1Y2*C2FQ.<0X!T@LZK
MPUI:UOBU8S>%MR)5XG<"DY#@U>$)BC?%JXA&>J2$K$/7[(T!1IA81@S@(A!Z
M,Y#Z/`<!P'`U:[OZA.>U&UVD2EU^6ACJJN8QM4=.Y_2%RSJC)+%WN5L%4(X0
MVK9I6,NB$Y&W28YI7@RD3G&)3A)NE0'&`@Z0B#:GNRJH44KJ]KA5M02B?U4M
M[P.LKLV0'(;&FLJG4K91QBP4\YM*S+3E4TS9<I=\+3&D@Y9ET/7X)`026'L"
M^H$(1@NL%V]V+:VX$-T>U1';L8VACL'F>M=K.;TF?%]*VLXOB:O)13]^6#.I
M,HG[AKS667D$_CI!(UF4S=AY;"L95#3","1=3='MF-)`6EI/4=K39FH^X&(O
M8"M-PF2!U'))33NQBYWC^=DX+,8!+6A;$US%=#T,<EB@LM2I,T%K'-MZY84;
M<(06HVJHJ]7W4^GJQ'+9-LO:<5V:U+ETPGZR-P*"OLECD&V@K^<RN4N,9B"2
M+0IJ(BT.;#3#2D"<O)A"+K!+,.%G`@I9MG3FTQ$R[PW76K];II9L7[R]362V
M#7^SOT!35722A13L!H&Y`WF4^REIF;&3#HQ7I3^R>*&AZ$_F+?`@=@<4(7`]
MJ>3N^K'W2;8G>^CVZ4IU7UJLV%M^M;/6$3I=VJFSI]&@HD:3:J]I(^7K&),X
MQZ"O"@:B*1HAG$G;\H_'*L"M?X"0A#?GP'`<!P-/6RO=^P+;KO(X?.]A*576
M'0L1T??H@S2<4LDD6:FVW%]\L[QAA[2%2Z-R%4X*(:$Y1U3@&H\%AZ>M@WHQ
MP*:]Y#J5L-(+*D=6TC3&RKO2$@T/2Z\T@7JC.J=K-I=IBUG6,G=:VW4N:QG9
M/>H*4;&ER83V),Q+SBE(SG<L\!IZH>!A`_LQ;<F5_L3KR/1B<NC]N)KEW:U2
MQF]U3E5">'4U**3H*O6"SW&TE*Z;)YJRHJ-DK8J=6,QG0N@W"1)\D)\$CR6I
M$%M]AM9]DD,7WUE%<4Y+ESK:/>/:[W`L=:Y9Z<=[^D^O==U-03%(;`UO,M@:
MR!H+CAKY&%V(\H>0D&H3TRHU($"@1!@@J%!X3OGKU7^V,0B&JN_*V.;I;;P:
M2RNTU,]IRY=O(SK:IUPKQALF9GN:VTHQ#6.]YX_18]@1(T"GQ;!PKQ&I0BRV
MIBAA.^QM.JK'EO=[P:EM?YWK36.U+&HT<O.@+/31.(V##M8Z`E[=L@B=S8]"
MIC/618WYC==2>/9,PYJAF)9V$2C(3#A@$$H6MIE:LIG%Z/8:)$_!G/?3Z1["
M%K5:.**PR*AJAA>O+4]V"=A<OR(^/0I1'GHK!!V,*P9)/[$@6#,9&$!W;I1M
M,6X#N!EAVS36R5EWIVZMW+XIJG)J:CVQ;_5%^P5##X3<]0AML#O7;P8U.V3P
M+&U6)`[GM;JM-(,*,+&`X-O7=DTG(:-UDRSRF*7)"'F>6M:]NJHSL!9L&M*W
MT>;(ERQ^PXSMUK&*Q.NXU)9/DS+LN86<M8D9UJ\TC*Q2;@TS@;".!KK_`*4/
M\Q3^Y]P)NTI_5AJS\3DOZ:23@6FX#@.`X#@.`X#@.!!NR=YL>MU)SNXWUO4/
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M4WN76.:4;B@1FJ,+$Y>6]:,H+!5QWE6C5M?*F=`=B8>\M=-5H"YIY)5*"4L$
M,(J3J+/"++B\VD3`TQ*PX,V*4!R5:YQY:Z)$"XO*50,I3G!60CO/>DZQ6!2&
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M":E4C?H^^,KBE#@T"9<T"$$T99Y7`L5P'`<!P*OONR2%OV&?Z2:V;+HUU=1B
MB\[OE2;#JY+86UOKJYM-91AEC;$UNKE(Y-,RXC(EPDQ>`GE(VH&"BSC%9(<!
M4RGN]8J21UE=MS[$Q65:F5_7&TJ36J'I;99G\R?R=6_P.!S&!.LG@\<9GAXA
M#_8.)C_L+(H`8M3%B3DJNR6FB3`"6ZA[S_1>^+!@M65;>R213VQC9*WQA@5P
M*THP/$HAR9T7RBNI&XRR$,;3"K;9&QE5K#X>]*$$G`A($I\`[#(3!!]JH.\>
MTKONX?D$J.\6R96H;Y=FM<=21.P6Y%)FVLG$MFG4BA<J>HDVP^<1*//AG@!K
MPT+UK68N`8G*/&<6,`0K<B[U2'1Y;'Y)<,=9J\IV14;LC>[;,BGUP>I`Y1^I
M]D8E1E2Q^/10IG)52B87<V2Y*N;FQ"(Y8:X*DZ%,6H$9U\!)A7>'Q"DJCK:P
M]_D31J5,KL>9F[5Y3A6)K;$[C=9,(2W9,\VR17\.>@1)VBL25)5LU7=3,7BJ
MA6!,>Z"Z,&F!+S;N'"'^;ZKCBYK;):,W&A#^ZTK;R$]T1@=ILVQHFQX]&5C(
M[-2`Y*WSVKD[HYM:@8P']NS'$&$8R:2+(7%X#@.`X#@4?4;I-R=#M#,T%;SB
M>5[KS8K72#"15,?>K!LRW;J3)FH$WB,1A+4WEED-\<D\J;6##@I5E(BW-.Y#
M6')$B,1^0@B`][7KDWZQ:V7SM$Z&:_2[8^N9C8S!4K='["N"1ID,`>D37.6]
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M)RE"2.)WP34Z/Q9`C4R3(<"P$+!12]\N6R-IZW2AD2L,CBL&A5O5VX)G$U:7
M8%52A0MBSR[#3&(T_BI\A5BL:I`O3!,/!X(M;5`1XRI&66%B>`X&NO\`I0_S
M%/[GW`F[2G]6&K/Q.2_II).!:;@.`X#@.`X#@.`X&NSO0F1>HU@;I\F3*7!I
MH38/6/8N:MB4HQ0-97%*7M!9S8B@28HD\Q2&/0UK6N_9X#TB$WXZ,XS\/`I3
ML9K-MO*Y%NE1%*U1%9UKUWD<SJJQ%>SWRL1%J;J$:55?5?5]TI917J\XN93M
M0XPBKB%T0''"ER56L=>S7G(BB.U,"TN[DXW]6TPT0_4O6J>$R*1W&]5W84GC
M5N:Z,MGP_76."6E"M6H%5DS=#`B9[:B,A.G8PN@S5<:+5FK%B#*I.20((#JC
M5FSULLU.?V+3YUU<@-$:Y;S5$.O)M;5463+6R5W(92RJ(RYRE4%G$R3REZM9
MR9']8ZNAJU2O$M[8]R&$Q4`1@4HM?1^XZPTYKLZW1U[2\7HWN6F?7FQ)G,Y>
MQFU]$+XAMR:_60FA4Q.C67Q8.O7[-<*4;L]HTBQM(1FF#'D>,X"(,TUV=[HW
MFWHV'E;I2L.K&'I[![N%XN=JC=SUG<.&1BH>,;$7&QM4IG-;.*^%R^3/ED'Q
M7J-K.K<#4+`I0J%N2<G#3DA+DR[L.U45H[C[O4C&8_!=^D6W9MXZNSYTEA1C
M1<]+LM*57#776VRQ(W%6GC5370:SOK:L3G$IE#<\^!/F<9&D)%D*4W+:T\26
M1,]=T%<UB_BNKO=M);OEKJJO&M'2V:/LN2.VL\KFNN4AIMM4*YU);-KE-#O"
MT4D9@K(<="S1+`N@!HQI!AN[K5M4S?O2MEK08A#%#JGU0H?6V1KB\?["XVNX
M6!9=W.+04<'/9J%\.@<R93%./AR1X[`#.<"R(.`V1<!P'`<#7'3Z$=?=Y?N4
MU2(78J=B*4UFMFLE)N?O7AAI]+.*HLAC1&Y+`$1T,?'AF6GD!$,18)(69G`<
M&8Z0K?+--+Z>YI-W0,):U;0\]\=0.W;<(Z41G&#J,KZM*H9'N9"3FN6#"G%J
MDD24X*;!XPXFY("862((@9R&&,VD.P;>^1=<XP]$TM"'ODMJ=O9"YMTLB_AJ
M"@;.K&[8O$[#(+3.(SU;^<LF3>'#:`(W5/U^DPD(2Q=4-<^L%D738DST>I>G
MH)2\JD&LW=T[S0FEK9J2\JZG".[S\,%,UO6=F%M34-(]4?!Y6\(FXY0CFA;2
M\^4`EB;P/(6\:DX-F%T]T;7.P-JZLPJV("&141KYH'9-#QB=MLJPRR>M;U<)
M)2!,$L:%(DKD2[D6!'FF&N;LT/F2#RVIQ*P9@03C`]8*AV?;&V&L$]K.7;.,
M-&VGL7&M.MM]8)0AF5_593B&WJ:B<[K62Q+>M@'-%7BDJ+25$B1I+)AY(L2I
MM<%(3F]L7HBR^!.M/Q9^D^L'U?ZD$J`YLL"/'4?LA)V\E(<C%%JMI+6"4HY<
MX+DAP0*FAL<9':#`QDE'8`,1SJ`K(>D(^J'0=P'`<!P'`UP]W(WF05@VLI!\
MSV,[K#=/9!]?B%`@X<72,WO/G*^JRF1H>H4,]#)818:8L!^,9+RJ0J2,"$-.
M9T!477_1[86$MFBA<P@30E6T5I?O%4<Y%B615P%&['NR7U<O@#6@,2N9V',I
M^98\X8-6),FIDH0=0\8,F!QD*@V_I'<58:=5TJML==4S&**[E2%:[V%,9O+V
M,=>Q._8!<.O5BE0:8*8WE\5_)^_&UPI1.CZD2+&PA&:,P8AXZ`B#,J4<KCWO
MV.WK5*Z/B-=ML[E7=>PJV8_'+HK2U\L%8UT\63;%F%RBQZX<ED#E$L=&`E`@
M"U,ZUP4D,CZA,/[,1AI!(6!O#NMYC:^SV[.X,)2M=6[:)Y/KI-]#-B3WHMT$
MTN=0TDU,$G@<GCZ)P..;*HM.0B<8U,D!Z<HUY9E>#L8-$D1"+#7#N-<=Q-J#
M=:L9!3U5"L?;:9=W+++BA*W8&KW"R-8+D6J*#ABFE3Z]3J5<ONO#_F(I7B`.
MT4"O:QEKU1C@:VF(3BS`WPY;E$Y[V%#)H^(1K)KUHU*H+8R]-D.4P9GL3<U>
M2Z!Q-:9C..LYML3I!Q=!D_?"(3N:8P75PH!UPV0<!P-=?]*'^8I_<^X$W:4_
MJPU9^)R7]-))P+3<!P'`<!P'`<!P'`]=6D2."14@7I4ZU"M3G)%J)626I2*T
MBDL1*A*J3G!&2H3J"1Y`,`\9",.<XSC.,\#PM;6VLC:W,K,WH6AG:$*1K:FI
ML2$(&UL;4"<M(A;V]"E+*3(T*)*4`LHHL(2RRPX"'&,8QC@>]P'`]!T:FQ\;
M'!E>VY`\,SNB5-KJTNB-.X-CFW+B1IEJ!P0*RSDJU$L3F"+-*,`(LP`LA%C.
M,YQP,(JVG:CHZ+`@U*5;7-/PHM>K=`0^KH1&:_BX'-PR`2]Q#'XFV-+2%>M$
M6')QV">T,R''6SGHQP)&X$5'432"FUDU[J*;JI1>")HS'T=R'5Y$3;52,.23
MDV61-88V@4N(:,IU!A?@P%F">H8(/5Z!9QD,^:(^PQ_QGXA9&AE\=NZV0//B
MEM1MWC9^<NS\8O;GX&23X>[K^Q!VRDWKG&]0/6%GHQP/K\!P'`<#Y*M@8E[N
MT/ZYE:5C['RG(AA>E3<C4.S*0]%IB7@EI<321K&XIV*1DA4A)&`)X2@8'@6`
MAZ`^MP'`BJ`T52-4/\TE574Y5=;2BR''#Q8<D@->Q&'/T]=\'JE6'29O$=:&
MYPE#CA2N.,[=<8>;VAPQ=;I&+.0E7@17:-%TE>*:/H[JIVJ[?21-X+D452VC
M7L2GZ:,R`H'9E/L?(EC0[%,SP67]Z%2FP6?C'P8%T<#.PQV/@?`R<#$S@DH&
M;$=!(0MB(+X"/A6>,,,077!&%X6?"_';^"X,[#ML=?J];X>!]G@.`X#@.!\D
MAA8TKRY2-*S-2:0O")M;7=](;DA+PZMS*8O-9T#DYEDA6KD;2:ZJA)BC1B`0
M)2;D&`Y,'TA];@?/=FEJ?FMQ8WQL;WIE>$*IL=FAV1IG%K=&U<0-,M;W%O6%
MG)%J%8F,$6:4:`19@!9"+&<9SC@855U/U)1T5+@M*U=7500DE<L<RH=5T)C4
M`BQ3DX""->X%Q^*-C2T@7+A@#DXW!/:&YQC(LYZ.!(O`BI]HFD)1948N:34W
M54BN"%)!M\-M=]KV(N]E1)`9X5@Q%&9TX-"B4,*0>%Q_26E5%`SVP_@^_%TA
MG[<PL;0L>G!I96EL7R1P*=Y$N;VY&B6/[J0VH6<ES>E*8DLYT<"6AK3)0''B
M,,"F3E%8SU"P!P'UN`X&NO\`I0_S%/[GW`]K4^\(O%-?J^CR^*7(X+&HJ2IE
M"R,T5;\M8CQ^6,A,Z[;(XS"W5A=D_0/&.U3*#2^MC..GIQG&`L3[2,,\R=@?
M=HOSZ.^`]I&&>9.P/NT7Y]'?`>TC#/,G8'W:+\^CO@/:1AGF3L#[M%^?1WP'
MM(PSS)V!]VB_/H[X#VD89YD[`^[1?GT=\![2,,\R=@?=HOSZ.^`]I&&>9.P/
MNT7Y]'?`>TC#/,G8'W:+\^CO@/:1AGF3L#[M%^?1WP'M(PSS)V!]VB_/H[X#
MVD89YD[`^[1?GT=\![2,,\R=@?=HOSZ.^`]I&&>9.P/NT7Y]'?`>TC#/,G8'
MW:+\^CO@/:1AGF3L#[M%^?1WP'M(PSS)V!]VB_/H[X#VD89YD[`^[1?GT=\!
M[2,,\R=@?=HOSZ.^`]I&&>9.P/NT7Y]'?`>TC#/,G8'W:+\^CO@/:1AGF3L#
M[M%^?1WP'M(PSS)V!]VB_/H[X#VD89YD[`^[1?GT=\![2,,\R=@?=HOSZ.^`
M]I&&>9.P/NT7Y]'?`>TC#/,G8'W:+\^CO@/:1AGF3L#[M%^?1WP'M(PSS)V!
M]VB_/H[X#VD89YD[`^[1?GT=\![2,,\R=@?=HOSZ.^`]I&&>9.P/NT7Y]'?`
M>TC#/,G8'W:+\^CO@/:1AGF3L#[M%^?1WP'M(PSS)V!]VB_/H[X#VD89YD[`
M^[1?GT=\![2,,\R=@?=HOSZ.^`]I&&>9.P/NT7Y]'?`>TC#/,G8'W:+\^CO@
M/:1AGF3L#[M%^?1WP'M(PSS)V!]VB_/H[X#VD89YD[`^[1?GT=\![2,,\R=@
M?=HOSZ.^!1?Y8(Y\H7C#R<M;L?;I\K^Q^1NTO#_%_LP>3'B[Q;Y)^'>5/C#]
1W\3=GXU\6_[=X/X)^[<#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tpg17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg17.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$[`F`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHKS#]K3XZ3?LX_!O5O%T,>C3KI,1E:'4]0:RBGQ
MR(D=4<F5^BC&">I%`'I]%?(/Q._X*G6?@+3M,N#X5E"Q>'K?Q/XB@NM26&XT
MBTEE2)50*K+*^YP<$J,>AXKZOTS5[:;1(;_[0JVEQ"MPKR,%"HP!!)/3@T`7
MZ*JZ9K-IK,`EL[FWNH2<"2&02*?Q!(JU0`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,_%7X<R?$_PK-I<>O:
MUX?^T`H]SIC1"5D/#*1+&ZX(X^[D=B*Z:B@#YYOO^"8OPON=-TBQMX=;L;'3
M[8V=W;P7ORZU"THF9+HLI+`R`-\I7'08'%>_#2+;[%]G,,;6X01^4R[DV@8`
MP>,58HH`X?X2Z;;Z9KWBJ&UMX;6&/4!MCA0(@^0=`.*[BN.^&?\`R-'BS_L(
M#_T`5V-`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110!QWPS_Y&CQ9_P!A`?\`H`KL:X[X9_\`(T>+
M/^P@/_0!78T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`5YK^U?\1];^$'P2U_Q1H4WA^&\T*T>\VZP9/L]QL4
MD0C8RG>^-H.>"1P:]*KS[]HC]FCPW^T]X7LM'\32:Y'9Z?>)?P_V;J<UBXF0
MY1B8V&[:>0#D4`>`?$#]N;XC^$+OX5ZYJO@ZQ\'_``V\4Z&FH^*=?U"RGU%-
M`NG=%CMV,,B^6KA@1(X8#(!KZP76K6QTM[R:ZA6S5!+YQ;Y`A&0V?0UY_P"*
M_P!D7PK\0/#^F:3XBNO$WB#2=/QYEEJ&LW$UOJ15@R_:4W8FVD`C<.,"O3(;
M:.WB5(T5$C4(J@8"@=`*`.'^#&OV7B35O%%YI]U#>6DVH#9-"VY&^0=#7>5Q
MOPT7/BCQ9[:@N/\`O@5V5`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M445R?Q:^*,/P>\'76O7UCK>H6-GS+%I6G/>W"+W;RTYVCN>U`'645R7P9^+E
MG\;/!D.O:?IVOZ;97!_=)J^G26,[C^\(WYV^]=;0`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`<=\,_^1H\6?]A`?^@"NQKCOAG_`,C1XL_["`_]`%=C0`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%<=^T'_R1#Q3_`-@Z7_T&NQKCOV@_
M^2(^*?\`L'2_^@T`5OV9O^2#>%_^O)?ZUW5<+^S-_P`D&\+_`/7DO\S7=4`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4%L45Y5^V/X_U;X5_`C7O$.BZYINA:II=NTEH]Y9_:
MUO9\'R[98]R_-(V%&,GG@4`>JE@!UH!W"O@WXV_\%%/B7\-[.S6Z\.Z=I.K>
M'?"5KXH\0:=)827(U!Y9XX?L\+EU,>`Y8\$J1BOMS3_$%O'X8AU.99H8Y;9+
METV,[QAE#8VJ"21GH!F@#$^&?_(T>+/^P@/_`$`5V-<#\%M>M?$FJ>*+RS:5
MK>;4`4,D+PM]P=5<!A^(KOJ`"BBL'XF?$W0O@YX%U+Q-XFU*#1]`T:$W%]>S
MY\NVC'5FP"<?A0!O49KY=C_X+4_LL2H&7XU>$65N0<S?_&ZI^(_^"P?[)_BO
M1[C3[WXS>$Y+6Z0QRJLMS&S*?1E0,/J"*`/J[-%?G/\`LA_\%#OV3?A%K/C#
M4/\`A<&DPW,VNW,5DUYK6I7JBR^7RPBS%P%ZXXS7O'_#Z7]EG_HM7A'\YO\`
MXW0!]045XC\!O^"C_P`#_P!J#QY_PB_P_P#B/H/BKQ!Y+7/V&S,GF>6O+-\R
M@8'UKO/#O[1'@3Q=XXN/#.E^+O#^H>(+4D3:?!>H]Q&1UR@.16D*4YIN*;MO
M9;>I$JD8M*32OMYG945QD'[17@.Y^(+>$X_%WA]_$RG!TP7J?:@?]S.:-7_:
M)\":!X^B\*WWB[P_:^))SB/39;U%N7/LF<U?U6M>W(]K[/;OZ>9'UBE:_,M[
M;K?MZG9T5QOC#]H;P+\/O%MKH.N>+=`TG6KX@6]E=7B1SS9Z;5)R:=X__:#\
M#_"K4K*S\2>+-!T.ZU+'V6*]O$A>XSTVACS1'"UG9*#UU6CU].X/$4E>\EIO
MJM/4["OE+_@KC^W[XD_X)X_LVVGC;PUH.B^(+ZXU**Q-MJ<DJ0A7."V8R#D5
M[_\`$+X^^"?A/:65QXF\5:%H4.I8^RO>WB0K<9Z;23SGVKX+_P"#D(_\+#_8
M3T.WT'_B<7&H:S!<6L=I^]:XC!!+J!U`'>E'#U7:T7[VVCU].XW7IJ]Y+3?5
M:>I\OG_@Z5^+8/\`R3'X<_\`@9>?_%5B_$3_`(.=?BMXK\!ZQIT_PS^'L<-Y
M:O$[)=WA901C(^:OSOLO">J:GK;Z;;Z?>3ZA&?FMDC)E7ZK5?5_!VK7$UUI$
M>FWC:JT15;01GSB?]WK1]7JVORO>VSW[>OD/VU.]N9;7W6W?T\S]$_A=_P`'
M.'Q4\'_#O2--M_AK\/)8;.W$:L]W>!B!Z_-6Z?\`@Z6^+8_YIC\.?_`N\_\`
MBJ_,W3_!NKZ,ECI-YIM[;:H4P+22(K,3_N]:M:OX1U7P_J45G?:=>6=Y-_JX
M9HRKO]!0\/55VXO1V>CT?9^?D"K4W9*2UUW6W?T/Z,O^"/?_``4/\3?\%'/@
M;K_BKQ/X?T+P]>:1J[:='!I<DKQR(%SN/F$G/TKZZK\R?^#9BVD\#_LI^.+'
M68VTN\CUY[QH+H>7(L.S_6$'^'WK]!OA_P#M!^!_BMJ%]:>&O%F@ZY=:;G[5
M%97B3-;XZ[@IXHEAJT;W@_=WT>GKV$J]-VM):[:K7T.PHKC?!O[0W@7XB>*[
MK0M"\6Z!JVL6)(N+*UO$DFAQUW*#D4FC?M$^`_$7CR;PO8^+O#]YXCMR1)IL
M5ZC7*$>J`YIO"UDVG!Z*[T>B[^GF)8BDTFI+5VW6_;U.SHKC)/VBO`</Q!_X
M1-O%WA]?$Q.!IAO4^U9_W,YH\0?M$^!/"?CF#PSJ?B[P_8^(;H@1:=/>HES)
MGIA"<T?5:U[<CVOL]N_IYA]8I6OS+>VZW[>IV=%<;XW_`&A?`OPU\2V>C^(/
M%F@:/JVH$"VM+N\2*:?/3:I.3FG?$']H'P/\)[BQA\3>*]!T*34L?95O;Q(3
M<9Z;=QYS[4HX:M*UH/WMM'KZ=P>(I*]Y+3?5:>IV%%9%QX^T2UN].MY-5L8Y
MM7&;)&F`:Z'^P/XOPK7K.46MT:J2>P4445(PHHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"N+^-O[._@S]HS0[/3?&FAPZY9Z?<K>6T;SRP^
M3,O*R*8V4AAV.>*[2B@#SO5/V3/AWKSZ&^H^%[+5)O#F1837TDMU-$,[MK/(
MS-(N[G;(6&><5Z$L:I]U5';@4ZB@#COAH=WBCQ9GG_B8+U_W!78UQWPS_P"1
MH\6?]A`?^@"NQH`*^>_^"KO_`"CH^+O_`&+\O\UKZ$KY[_X*N_\`*.CXN_\`
M8OR_S6@#^8'3C_H$/^Z*DE>01-Y05I,?*'.%S[XY_*H]._X\(?\`=%34`9/A
M>QU+36N5O/L/ES3-,&@D=B">V&4?G6MN-%%`'WI_P;=0K<?\%'Y5;.#X=N\\
M_P"R*_<;0_V9/"/ASQ=-KMCI-G:ZK.27NHK=$F8GU<#=^M?AW_P;9_\`*2*3
M_L7KO_T$5_0-51G))I/<EQ3U://8OV8O",'C0^(5TFR76"<F[%NGG9_W\;OU
MHU/]F+PCK'C&/7[G2;*;5HSE;M[=&F!_WR-WZUZ%15>VJ=WVWZ=A>SAV1Y[X
MH_9E\(^,O$EOJVI:59WNH6I!CN)X$DE3'3#,"1^=.\:?LT>$_B#?VMUK&EV>
MHSV>/)>Y@29H\=,%@2/PKT"BA5IJUF]-M0]G!WNEJ<!XT_9K\*?$*VM(=8TR
MTU&.QQY"W,"3"+'3:&!Q^%?`W_!R3X0A\$?L(:'-I,]UI\UCK,$$+VTIB:-"
M>54KC`/H*_3BOS>_X.<_^3"-/_[#]M_.A59JUF]-ANG%WNMS\)HKF[M;UKJ'
M4+^&Z8\SQW#+*?JP.:JZO>7D=I=WBZAJ"WRQ$BY%PXF!]=^=U6&ZU7U/34U>
MPDMII)UBDX;RI#&Q'ID<XH]K/:[[_/N'LX]ANCW=[?:=9WEQJ&H3WNS/VF2X
M=I@?]\G/ZU;N[F[U&X6:ZU#4+JXC^[+-<-)(OT8G(JII&DQZ)8K;PO</$GW?
M.D,C#VR:M4>UF]V]0]G'L?M=_P`&R?A=/%_[)_CB[U.ZO+^YDU][4RW$S2.8
M]OW,MD[?;I7Z'>"_V9_"?P^OKJXT?2[/3IKW/G/;0)"TF>N2H&?QKX%_X-;_
M`/DS_P`:?]C-)_Z`*_3JAUIN]V]=]=Q*G%6LEH>>^%OV9/"/@SQ%<:MINE6=
MCJ%UDRW$%ND<CYZY90"?Q-&E?LQ^$=%\8R:_:Z390:M(26NX[=%F8^[@;OUK
MT*BCVU3N^VX>SAV1YZ_[,/A"3QK_`,)"VDV1U@'/VO[.GG9]=^-WZT:W^S'X
M1\1>+HM=O-)LKK582"EU+;H\R_1R-WZUZ%11[:IO=]M^G8/9PVLCS[Q;^S-X
M2\<:[;:EJFE6=_?6F/*GN+=)9(\=,,P)'X4OC;]FGPG\0Y[636-+L]2DL<>0
MUS`DQBQTV[@<?A7H%!Z4*K-6LWIMKL'LX.]TM3XQ_;U\5K\)?&G@N"V^($G@
M3RU(MTAT4:BUP`X'#;3Y6.G&.M?7GA*[EOO#MG+,ZR220HQ<?\M,J#N_'KCW
MKY+_`."BOC@^#/'GA6/_`(3[3?`WVK<?*GTC^T&O\.!G.T[,=/QS7UAX'&/"
M]B<)\T$9RGW7RHY'IGKCWKTL9%K!T&U_-T\^_(K_`/@4_EL<.%E_M-57[=?+
MMS.W_@,?GN:U%%%>2>B%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`444A8`]10`M%-\Y=N=RX'4YIRL&&1S0!QWPS_Y&CQ9_P!A`?\`H`KL
M:X[X9_\`(T>+/^P@/_0!78T`%?/?_!5W_E'1\7?^Q?E_FM?0E?/?_!5W_E'1
M\7?^Q?E_FM`'\P.G?\>$/^Z*FJ'3O^/"'_=%34`%%%%`'WM_P;9_\I(I/^Q>
MN_\`T$5_0-7\_/\`P;9_\I(I/^Q>N_\`T$5_0-0`4444`%%%%`!7YO?\'.?_
M`"81I_\`V'[;^=?I#7YO?\'.?_)A&G_]A^V_G0!^$AZT4'K10`4444`?N%_P
M:W_\F?\`C3_L9I/_`$`5^G5?F+_P:W_\F?\`C3_L9I/_`$`5^G5`!1110`44
M44`%!Z44'I0!\=?\%%/&;^#_`!WX55?&_AGP7]JW'R]4TO[<]_\`.!E#@[,=
M/QKZO\#KCPO8_*@W0(<H?E;*CD>QZXKY1_X*)>*)/"_COPJJ>+/`_A3[1N)3
M7M/%Y)>?.!F(_P`..GU-?5W@==OA>Q^55S`A^4Y5OE'(]CU%>IC(VPE!VWYN
MF^O?E5__``*7RV//PTKXFJK]NOEVYG;_`,!C\S6KD_COJMUH?P6\57EE<36M
MY:Z5<RPS1';)$XC8AE/8@UUE!&X8/(KR*D7*#BM+H]2C-0FIM7LT['YQ_LQ>
M#OCA^T5^R+X6U3PYJGBS1_%VHSM(?&6K?$2\NH(U2X;<SZ80\<@**4$;*!R#
MD5]4?$+QQ\8O".N0Z?HNE-KEK;VL8DOE\-6]P+B7'SL&;6+8C)YQY0QZFO<D
M18EVJJJH[`8IU>EB,=[2HY**2NW;??IY)=DDNMCSL/@W3IQA*3;2M?:_GW?S
M;?GJ[_&_[77QX^/'@[]DCQ!K.G:/>:7K4%[;0RW-MH4=O<65B\BK//'&E]>[
MF5"QW';MZXXKE?C3\2K#PA8_#*[^!?Q4\4>.O&VI:S9P7.E)XKG\11ZI8O\`
MZ][JWDDD2!1P3*%CV$XXZ5]Y57M-*M;"1G@M;>%W^\T<84M]2*5'&1@TW%?$
MI::7227*][Q=MO[TNZM=7#N2LI?9:UUU=_>Z>\NC\EMK?QKXX?M-^9\-/B+H
M_P`.=2TG7/BQX/T22[?0X7\ZXLYO+)3='CGYN@[G`KY4O_B_IDW[!UGXLTKX
MR^-+KXZ26L-PNG0^*)[B^?52R^99G2-_E[`Q=?*,'`&<\9K]%E@1)&=44,W5
M@.34*Z3:I>&X6UMUN#UE$8WG\>M9T:\8)JVK<7=/56O=+1Z2OMKLKWV-)4Y-
MQUNHWT:NG>UN;57:L[;:2>SU/A?2_C7XN\3_`+7=EX?^.GB34OAIX5C\)VM]
MI4%KK4F@V>K:@P/VD274;1L[H,'RO,&TGH:Z[]D7XD^)-8^*_P`8-)T_QMK&
MJ?"/21#_`,(_XLU:Y%\MC,R9F2&[GW"YC5L_,[.%(`R:^O+RP@U&+R[B&&=,
MYVR(&&?H:<MG"MMY(BC$.-OEA1MQZ8Z5I/&1E%I02O%JRVNW?FMO=;)WOYV]
MTSCAY)J\KZQ=WO[J2:72TK-O3J]+ZGP5^Q5^T+#X:_X*$?%/PGK7QRNO'/AU
M=+TZ329M;\0VDD,]U(7\P6R1!(0>@*1+QQ7WR#N&15-?#VGIMVV-FOEG*XA7
MY3ZCBKE9XG$1JJ%E9QBD]M;*U]$MRZ5*49SDW=2=^NFB5M7Y!1117*;A1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1101D4`(S8[9IB7'F_=VL!QPV<&OEO\`X*6?!C4_BAX=T6X7P7K'C[0M+\R7
M4M,3XER>#=,5!SONC&,SJ!GAF"@=:^3?V$OAM\#?B_\`M#VNE^$/!O@OX8ZY
M8?Z6E_\`#SX^-JU].T9R8Y;2!\2QG&&W@CK0!^K0.17@O_!2?Q_XT^$O[(/C
M3Q9X$\3:?X5UKPWITE^MW=::E\7"#.Q4D8(,^I#8]*]XA0QPJI9F*@`ENI^M
M<[\3O@[X3^->@_V5XP\-Z)XGTO=N^R:I9QW4!/NC@@_E0!\B?'#]H#XG^!_#
MOPA^*L_B21?A6?"UC=^,;'1YK./5KO4+CRMLR1RPN9(OWG,<3(W4CI7V;%K,
M<.CF^2*ZFC>)9TC2(F5E(!`"]=WM6'#\`?`]N=%V>#_#:_\`".)Y>E8TZ+_B
M7+Z1?+\@_P!W&*Z[%`'!_!C6%UO5?%%T+:]LQ+J`_=7<)AE7Y!U4UWE<=\,Q
M_P`51XL_["`_]`%=C0`5\]_\%7?^4='Q=_[%^7^:U]"5\]_\%7?^4='Q=_[%
M^7^:T`?S`Z=_QX0_[HJ:H=._X\(?]T5-0`4444`?>W_!MG_RDBD_[%Z[_P#0
M17]`U?S\_P#!MG_RDBD_[%Z[_P#017]`U`!1110`4444`%?F]_P<Y_\`)A&G
M_P#8?MOYU^D-?F]_P<Y_\F$:?_V'[;^=`'X2'K10>M%`!1110!^X7_!K?_R9
M_P"-/^QFD_\`0!7Z=5^8O_!K?_R9_P"-/^QFD_\`0!7Z=4`%%%%`!1110`4'
MI10>E`'QW_P42UR30_'GA58]=^'>@^=NROB>U^T27/SC_4_W0.A]\5]7>!TV
M>%['Y%3,"'Y3E3\HY'L>WM7RC_P41NY;'QWX5\N\^&NG^9NS_P`)9&)))?G'
M^H]!Z^^*^KO`Z[/"]C\FS]PG`.5^Z.GMZ>U>IC(I8.@_\7Y^B_-_(\_#R_VF
MJO3\O5_DC6HHHKRST`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HS10PW
M+0!Y#^WOHC>)_P!C/XD6,=C#JC76B3H+65'DCF.!P5C!9O7:HR<8[U\8_P#!
M(?QE?7WC[1=)N/B1HNN+::28_P"PX/@+<^#9K3:,;3J#G8VW&.`-^,]37UU^
MUS^S58?$BWA\7?\`"T_'GPCU3PS;L4UK0M;6ULHTR"3=6TZO:S(#_P`]$_$5
MY%H/QT^.'P'U;PI'K7Q&^`?QJ\&^*KY;+3]7EU:/PEKEWDC)A16FL[QU7G9%
MY9/I0!]GCI10OW110`4444`<=\,_^1H\6?\`80'_`*`*[&N.^&?_`"-'BS_L
M(#_T`5V-`!7SW_P5=_Y1T?%W_L7Y?YK7T)7SW_P5=_Y1T?%W_L7Y?YK0!_,#
MIW_'A#_NBIJAT[_CPA_W14U`!1110!][?\&V?_*2*3_L7KO_`-!%?T#5_/S_
M`,&V?_*2*3_L7KO_`-!%?T#4`%%%%`!1110`5^;W_!SG_P`F$:?_`-A^V_G7
MZ0U^;W_!SG_R81I__8?MOYT`?A(>M%!ZT4`%%%%`'[A?\&M__)G_`(T_[&:3
M_P!`%?IU7YB_\&M__)G_`(T_[&:3_P!`%?IU0`4444`%%%%`!0>E%!Z4`?'G
M_!1&*;_A.O"IB@^&K9W9/BY\2'YQ_P`>_/3U]\5]6^!UV>%[(;2G[A.,Y4?*
M.GMZ>V*^4/\`@HGILE[X[\*M'H_PYU';NRWBRZ$,B?./^/<9Y'K[XKUSXK?M
M)W7[.WA+0YAX!\6^*+.]^SVHFTF6SV0S285$Q//&V,\`@$8KU,9_NE#_`+>_
M,\_#_P"\U?E^1[316;X6UNXU[1;>YN],N]'N)DW/:7+1M+`?1C&S*3]":TJ\
ML]`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***&.!0!Y?^VGIGAW6OV4
M_'EIXNU*71_#5QI$R:A>QVWVIK>+')$6#YG.!LQ\V<=Z_)O]E/\`9-T_XP_&
MS0_"<>M7_@>[FECUO0](\6?!-=`L=2M(SEKC2=ET\<$I09)PKG.XKS7Z@?MM
MZ[XZ;X?3:/X9^%MQ\4-!UVVDM-9MM-\2V^CZI:1M_'`+@".0X_Z:*P.,9KX;
M^%/[)FNZW\6/#&K>%?@C^UGIEYH,R6O]J^.OB]%IMKIEN&!95C2>XDFCZC:B
M88<$@4`?JAI5@NE:9;VJO)(MO$L0>0[F8*,9)[FIC(JG!/--M$:.TB5OO*@!
MYW<X]>]?.?\`P58\=:M\-/V*?&VO:'\0KCX=:MI&GRW=I?6TEM'/<R(,B)6G
M!`SW"C<>U`'T8]U'']Y@*='*LH^4YK\W/C]^U[\2+72?!UUHOB2_@D_X5[I>
MN:&;._C">+-5DDA29)!M/G?*SDQCOSBOT/T^_O?^$8M[C['&VH/;)(]OO\L>
M:5!*[L''/?%`&)\,_P#D:/%G_80'_H`KL:X/X,W=Y>:KXHDOK..QNFU`;X$N
M!.J?(/XP!G\J[R@`KY[_`."KO_*.CXN_]B_+_-:^A*^>_P#@J[_RCH^+O_8O
MR_S6@#^8'3O^/"'_`'14U0Z=_P`>$/\`NBIJ`"BBB@#[V_X-L_\`E)%)_P!B
M]=_^@BOZ!J_GY_X-L_\`E)%)_P!B]=_^@BOZ!J`"BBB@`HHHH`*_-[_@YS_Y
M,(T__L/VW\Z_2&OS>_X.<_\`DPC3_P#L/VW\Z`/PD/6B@]:*`"BBB@#]PO\`
M@UO_`.3/_&G_`&,TG_H`K].J_,7_`(-;_P#DS_QI_P!C-)_Z`*_3J@`HHHH`
M****`"O./BO^UY\+/@5XCCT?QI\1O!GA35)HA/'::KJ\%I,\?3<$=@=OO7H]
M?S\_\'/T2Q?\%`M$D`7/_",Q9R,Y^<USXJNZ-/G2N?:<`\*T^(<WCEE6HZ::
M;NDF]-=FT?L%X@_;A_9I\47$<M_\7/A/=R1?<,VOV4FSZ;F.*\[_`&N_V\O@
M3KWPVT.UTWXO?#>ZDM_$%A*8XO$-L[*BS`LV`_0#OVK^:'RU"MPOK]VJ>LKN
MMHSB/YI%'W1Q7!_:LGIR_B?N&*^CU@J-)U?K<VU_<CWM_,?UD/\`\%'/V?U<
M_P#%Z/A>&!Y_XJ2T_P#BZAN/^"D?[/\`$=S?&SX8*H'.?$EK@?\`C]?RD$?-
MC:G7'W:BOT7[%-E4.Y"/NTO[6DM>7\?^`=#^CI@U%OZY/_P"/^;/[&_"OBO3
M?&V@VNJ:/J%KJFFWT8EM[JUE$L,Z'HRL."/<5HUX7_P3<B$?[#7PO5?E5="@
MX'3[HKW2O83NKH_EO&4/88B=%?9;7W.P4444'.%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!03Q10>E`'GO[5/CO4OAG^SCXR\0Z+'>/JVCZ7+<V@M;87$HD4<$1D$-C
MJ1@\`U\(_P#!.7]OCXJ?M#_M3>%_#?B;XT?"7XG:3)I$UY=6WPVTF4-92<X7
M5FF)%NP^Z%CVDN""N*^A/^"FWQ$^(GP;TKP7XJ^'^N^#+-M-U$K?Z7XH\7Q>
M&;'58V4@*;B16#,"00N.<5Y/_P`$E/CW\5+W5V\&_$"/X(ZO<7)N+^;7_#'Q
M$L=8U6ZW.S*CVL$*%E4$+OR>!F@#]!!TK/\`$7A/2O%]JMOJVF:?JD"-N6.[
MMTG53Z@,",UH+THH`SX?"FEV\5G''INGQQZ>VZU5;=`+8^J#'RGZ8K0HHH`X
M[X9_\C/XL_["`_\`0!78UQWPS_Y&CQ9_V$!_Z`*[&@`KY[_X*N_\HZ/B[_V+
M\O\`-:^A*^>_^"KO_*.CXN_]B_+_`#6@#^8'3O\`CPA_W14U0Z=_QX0_[HJ:
M@`HHHH`^]O\`@VS_`.4D4G_8O7?_`*"*_H&K^?G_`(-L_P#E)%)_V+UW_P"@
MBOZ!J`"BBB@`HHHH`*_-[_@YS_Y,(T__`+#]M_.OTAK\WO\`@YS_`.3"-/\`
M^P_;?SH`_"0]:*#UHH`****`/W"_X-;_`/DS_P`:?]C-)_Z`*_3JOS%_X-;_
M`/DS_P`:?]C-)_Z`*_3J@`HHHH`****`"OY^_P#@Z"_Y/ZT3_L68?_0VK^@2
MOY^_^#H+_D_K1/\`L68?_0VKAS+^`_E^9^P>!O\`R55/_!/\C\WR<*:JWNFP
MZDBB5YEVG.$D*C]*M'I4=>"C^V,1A:=>'LZJNGT^=QR[44*K,=O=NIJ*_.;*
M3_=-/J.]_P"/*3_=-3+X32>D&EV/ZNO^";__`"8Y\+_^P'!_Z"*]RKPW_@F_
M_P`F.?"__L!P?^@BO<J^LA\*]#_-/-_]^K?XY?FPHHHJCSPHHHH`**"<"@,&
MZ4`%%&<5YU=?M<_#&R\>_P#"+3>.O#4?B3?Y?]FM>H+K=T^YU_&@#T6B@'(H
M)Q0`44`YHH`****`"BBB@`HH+!:*`"BJ^HM<+;2?91&T^P^6)"0A;MN(Y`]<
M5X_^S9\9_B%\4/''BBQ\4:+X-TW3?#MS]D672M0N;B>9^Q*R0HH&!V)H`]HH
MHHSS0`4444`%%%%`!1110`4444`%%%%`!1110`4-THH/(H`^3?\`@JSJ?Q*O
M_AEX;\-?"6Q^%=_XR\1:HD$*>,O)=TB_C>RCG1HGN!_#Y@*^QKS/_@FO^P?J
MG[.WQTOO%OBKX%V>F^,=7MF&I?$34O&MKK.J7#'K#%;06\45M$3P$A50!US7
MNO[='[`EC^W+J7@6/6-:U+2='\)ZF-1N(M-O)["\NL#[L=S`Z21_4&K?[/G_
M``3C\`_LR^/AXD\-WWQ&N-0$;1>7K/CC5=6M=K=?W-S.Z9]\9%`'OR]**!TH
MH`**9YZ[<X;\J5)!(.*`.0^&?_(T>+/^P@/_`$`5V-<=\,_^1H\6?]A`?^@"
MNQH`*^>_^"KO_*.CXN_]B_+_`#6OH2OGO_@J[_RCH^+O_8OR_P`UH`_F!T[_
M`(\(?]T5-4.G?\>$/^Z*FH`****`/O;_`(-L_P#E)%)_V+UW_P"@BOZ!J_GY
M_P"#;/\`Y212?]B]=_\`H(K^@:@`HHHH`****`"OS>_X.<_^3"-/_P"P_;?S
MK](:_-[_`(.<_P#DPC3_`/L/VW\Z`/PD/6B@]:*`"BBB@#]PO^#6_P#Y,_\`
M&G_8S2?^@"OTZK\Q?^#6_P#Y,_\`&G_8S2?^@"OTZH`****`"BBB@`K^?O\`
MX.@O^3^M$_[%F'_T-J_H$K^?O_@Z"_Y/ZT3_`+%F'_T-JX<R_@/Y?F?L'@;_
M`,E53_P3_(_-\]*CJ0]*CKP3^X`J.]_X\I/]TU)4=[_QY2?[IJ9;,BI\#]#^
MKK_@F_\`\F.?"_\`[`<'_H(KW*O#?^";_P#R8Y\+_P#L!P?^@BO<J^LA\*]#
M_-+-_P#?JW^.7YL****H\\****`!AN&*_"/]H+_@X._:*^&G[0/C;PWI<W@/
M^S-!U>>RM?.T-FD\M'*KN;S1DX'7`K]W*_E&_;"_Y/`^*'_8QW?_`*-:@#ZP
M/_!R%^TP1_KOA[_X(&_^/5QT_P#P<0_M&-\:(?$7V7PJ;J/3#I?G#PVWDA3)
MOX_?9Z_Q?A7Q[1WH`^\_^(D+]I<=)OAXOL-!;_X]6W\+O^#B+]I#QA\5?"^C
MWDW@'['JVK6UG<;-"8/Y;R*K;3YO!P>M?GC75?`7_DO_`(#_`.Q@LO\`T<M`
M']9MD=UK&Q^\R@GZXJ6HK'_CRA_W%_E4M`!1110`4444`<+^TUK=[X7_`&>_
M&VIZ;=36.H6.C7,]M<0G$D$BQL593Z@U_-SIO_!6/]IB2S5F^.'Q`8DGDW<?
MJ?\`IG7]'G[7'_)KWQ`_[`%Y_P"BFK^3_2O^/!?JW\S0!]%?\/8OVE(SN;XX
M>/@J\DF[CP!_W[KD_AO_`,%7/C];:UKW]F_&[QG]HO+D2S>5=INE(_BYCYQ7
ME-*6)H`^@?\`AZ_^TM_T6[Q]_P"!<?\`\;K["_X(4?MW_&C]H3]O3_A'?''Q
M.\6>*=!_L26X^P:A.CP^8&P&P%!S7Y=U]V_\&X__`"DE_P"Y>F_]"H`_H/HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"@T44`?$?[6-AK'PX_;Q
M\)^.M%UC4O'5Y-''I/\`PKM'O(?LJLV6U&)HY!#E0,$S1LN#@$&OLZ=[I-/D
M^R+"UUM^19V*H&QT)4$X]P*O44`<'\%WU!M3\3MJ<=C'>G4!YBVCN\0^0="X
M!_2N\KCOAG_R-'BS_L(#_P!`%=C0`5\]_P#!5W_E'1\7?^Q?E_FM?0E?/?\`
MP5=_Y1T?%W_L7Y?YK0!_,#IW_'A#_NBIJAT[_CPA_P!T5-0`4444`?>W_!MG
M_P`I(I/^Q>N__017]`U?S\_\&V?_`"DBD_[%Z[_]!%?T#4`%%%%`!1110`5^
M;W_!SG_R81I__8?MOYU^D-?F]_P<Y_\`)A&G_P#8?MOYT`?A(>M%!ZT4`%%%
M%`'[A?\`!K?_`,F?^-/^QFD_]`%?IU7YB_\`!K?_`,F?^-/^QFD_]`%?IU0`
M4444`%%%%`!7\_?_``=!?\G]:)_V+,/_`*&U?T"5_/W_`,'07_)_6B?]BS#_
M`.AM7#F7\!_+\S]@\#?^2JI_X)_D?F^>E1U(>E1UX)_<`5'>_P#'E)_NFI*C
MO?\`CRD_W34RV9%3X'Z']77_``3?_P"3'/A?_P!@.#_T$5[E7AO_``3?_P"3
M'/A?_P!@.#_T$5[E7UD/A7H?YI9O_OU;_'+\V%%%%4>>%%%%`!7\HW[87_)X
M'Q0_[&.[_P#1K5_5S7\HW[87_)X'Q0_[&.[_`/1K4`>>4444`%=5\!?^2_\`
M@/\`[&"R_P#1RURM=5\!?^2_^`_^Q@LO_1RT`?UFV/\`QY0_[B_RJ6HK'_CR
MA_W%_E4M`!1110`4444`>=_M<?\`)KWQ`_[`%Y_Z*:OY/]*_X\%^K?S-?U@?
MM<?\FO?$#_L`7G_HIJ_D_P!*_P"/!?JW\S0!8HHHH`*^[?\`@W'_`.4DO_<O
M3?\`H5?"5?=G_!N,?^-DO_<O3?\`H5`']"%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`''?#/_D:/%G_80'_H`KL:X[X9_P#(T>+/
M^P@/_0!78T`%?/?_``5=_P"4='Q=_P"Q?E_FM?0E?/?_``5=_P"4='Q=_P"Q
M?E_FM`'\P.G?\>$/^Z*FJ'3O^/"'_=%34`%%%%`'WM_P;9_\I(I/^Q>N_P#T
M$5_0-7\_/_!MG_RDBD_[%Z[_`/017]`U`!1110`4444`%?F]_P`'.?\`R81I
M_P#V'[;^=?I#7YO?\'.?_)A&G_\`8?MOYT`?A(>M%!ZT4`%%%%`'[A?\&M__
M`"9_XT_[&:3_`-`%?IU7YB_\&M__`"9_XT_[&:3_`-`%?IU0`4444`%%%%`!
M7\_?_!T%_P`G]:)_V+,/_H;5_0)7\_?_``=!?\G]:)_V+,/_`*&U<.9?P'\O
MS/V#P-_Y*JG_`()_D?F^>E1U(>E1UX)_<`5'>_\`'E)_NFI*CO?^/*3_`'34
MRV9%3X'Z']77_!-__DQSX7_]@.#_`-!%>Y5X;_P3?_Y,<^%__8#@_P#017N5
M?60^%>A_FEF_^_5O\<OS844451YX4444`%?RC?MA?\G@?%#_`+&.[_\`1K5_
M5S7\HW[87_)X'Q0_[&.[_P#1K4`>>4444`%=5\!?^2_^`_\`L8++_P!'+7*U
MU7P%_P"2_P#@/_L8++_T<M`']9MC_P`>4/\`N+_*I:BL?^/*'_<7^52T`%%%
M%`!1110!YW^UQ_R:]\0/^P!>?^BFK^3_`$K_`(\%^K?S-?U@?M<?\FO?$#_L
M`7G_`**:OY/]*_X\%^K?S-`%BBBB@`K[M_X-Q_\`E)+_`-R]-_Z%7PE7W;_P
M;C_\I)?^Y>F_]"H`_H/HHHH`****`"BBB@`HI`X/<4N>*`"BD5P_0YI:`"BB
MF^8H;&X9H`=12;QZTN<T`%%%%`!1110!&URJMM^8MV`[TY'WC_&OSZ_:M^$?
MQ7\1?M@:I=:39ZQ+J-QJ=A-X0U2*TFEM=+LT1?M2O*I\N/<V[AL9SWK[QUY]
M5M?#MPVEPV]QJBQ?N4G8K$[X_B/84`8GPS_Y&CQ9_P!A`?\`H`KL:\)^%/C[
MQ[:>*?$FGW'@_2[S55N%FNWBUM88`2HP$!C9OSKN?^$V^('_`$(>F_\`A1K_
M`/&*`.]KY[_X*N_\HZ/B[_V+\O\`-:]'_P"$V^('_0AZ;_X4:_\`QBO-OVPO
M`'Q*_::_9A\:>`;'PIH>DWGBK3GL8KNYU_S(;<L0=S*L&2..@YH`_F#T[_CP
MA_W14U?HC;?\&QGQ]M[=$/B;X8G:,9^W77_QBGG_`(-D?CX#_P`C-\,?_`ZZ
M_P#C%`'YUT5^B@_X-D_CX?\`F9OAC_X'W7_QBC_B&2^/G_0S?#'_`,#[K_XQ
M0!@_\&V?_*2*3_L7KO\`]!%?T#5^47_!+;_@C9\:/^"?G[4#?$#6)O`OB:S;
M3)K#[)8:K-#+ND``;=)!MP/2OT@_X3;Q_P#]"'IO_A1K_P#&*`.]HK@O^$V^
M('_0AZ;_`.%&O_QBC_A-OB!_T(>F_P#A1K_\8H`[VBN"_P"$V\?_`/0B:;_X
M4:__`!BL;1OC9XSUCQ9J6CQ^`[/[5IB*\I;Q$FTANF#Y.?S%`'JU?F]_P<Y_
M\F$:?_V'[;^=?<G_``FWC_\`Z$/3?_"C7_XQ7R]_P5=_8W^*W_!1;]G*V\$Z
M+H_A?PO>6^I17QNM0UQIXBJ')7$<&<F@#^>$]:*_10_\&RGQ\/\`S,WPQ_\`
M`^Z_^,4'_@V2^/@_YF;X8_\`@==?_&*`/SKHK]%#_P`&R7Q\'_,S?#'_`,#[
MK_XQ1_Q#)?'S_H9OACS_`-/]U_\`&*`/J[_@UO\`^3/_`!I_V,TG_H`K].J^
M%?\`@DC^Q!\6/^";OP2U[PKK>E^%?%-UJ^K-J*7&G:T\,<:D8VD209S[U]7#
MQMX__P"A$TW_`,*-?_C%`'>45Y3I/QK\::KXOU+18_`EG]KTV-)9=WB)-A#=
M,'R<_G6S_P`)M\0/^A#TW_PHU_\`C%`'>T5P7_";?$#_`*$/3?\`PHU_^,4?
M\)M\0/\`H0]-_P#"C7_XQ0!WM?S]_P#!T%_R?UHG_8LP_P#H;5^X_P#PFWC_
M`/Z$/3?_``HU_P#C%?F]_P`%9?\`@C=\:/\`@HW^TEI_CC1IO`OA>RL]*33F
MM=1U:::5V5B=P,<&,<_6N3'4Y3HN,%=Z?F?I7A/GF"RGB"&,S"IR4U&2O9O5
MJRV39^')Z5'7Z6_\0N'Q\;_F:OA?_P"!]W_\CT@_X-;?CX?^9J^%_P#X'W?_
M`,8KQ_J=?^4_K#_B+?"7_0;'_P`!G_\`(GYIU'>_\>4G^Z:_3#_B%M^/?_0U
M?"__`,#[O_XQ3+C_`(-;/CY);21_\)3\+\L,`G4+KC_R!2E@Z[5N4F7BUPDT
MTL;'_P`!G_\`(G[&_P#!-_\`Y,<^%_\`V`X/_017N5>!_LO^%?B-\`?@#X1\
M%W7A'1=2NO#FG1V4MU!X@"1SLHQN4-!D`^AKO_\`A-OB!_T(>F_^%&O_`,8K
MZ**M%)G\)YC6C5Q=6I#9RDUZ-L[VBN"_X3;X@?\`0AZ;_P"%&O\`\8H_X3;X
M@?\`0AZ;_P"%&O\`\8JCC.]HK@AXV\?Y_P"1$TW_`,*-?_C%8OA#XV^,_&,^
MI1VO@.SW:;<&WD\SQ$@RP],0]/K0!ZO7\HW[87_)X'Q0_P"QCN__`$:U?T^C
MQMX^S_R(>F_^%$O_`,8K\>_C;_P;E_'CXK_&KQ9XJM];^'-E;^(]4FOX[>74
M+EI(5D<L%8B#!(SVH`_,.BOT6_XAC_C]_P!#)\,__`ZZ_P#C%'_$,?\`'[_H
M9/AG_P"!UU_\8H`_.FNJ^`O_`"7_`,!_]C!9?^CEK[L_XAC_`(_?]#)\,_\`
MP.NO_C%:WP[_`.#;3X]>"?B-X>UR3Q!\-;B+1=2@OGB2_N0TJQN&*@F#`)QC
MF@#]R['_`(\H?]Q?Y5+7`Q>,O'T,,:CP+IIVJ!_R,2__`!BE_P"$U\?D_P#(
MBZ:/?_A(U_\`C%`'>T5YCH7Q7\?:Y/>QCX<QVOV.7RLW&O*BS>Z'R.1[UH_\
M)M\0/^A#TW_PHU_^,4`=[17!?\)M\0/^A#TW_P`*-?\`XQ1_PFWQ`_Z$/3?_
M``HU_P#C%`$'[7'_`":]\0/^P!>?^BFK^3_2O^/!?JW\S7]47QEA^(GQ0^$W
MB3PY#X,TFTFUS3I[&.:7Q"&2)I$*AB!!D@9Z"OQVM/\`@V'^/UK`$_X2;X9-
M@DY^W77<Y_YX4`?G=17Z+?\`$,?\?O\`H9/AG_X'77_QBC_B&/\`C]_T,GPS
M_P#`ZZ_^,4`?G37W9_P;C?\`*27_`+EZ;_T*NJ_XAC_C]_T,GPS_`/`ZZ_\`
MC%?0G_!,+_@C%\:OV`OVH_\`A8.L3>!?$EG_`&8]A]BL-5FAF#,<[MTD&,#T
MH`_6*BN#/C;Q_G_D0]-_\*-?_C%)_P`)M\0/^A#TW_PHU_\`C%`'>T5P7_";
M?$#_`*$/3?\`PHU_^,4?\)M\0/\`H0]-_P#"C7_XQ0!WM%>>VOQ-\80^+M+T
M[4O`WV6TU!BKWMKJPNDM<?WU\I?YUZ!%N`^;GGTH`^3?BI_P4]TWX#_MB^-/
M`/B[25LO"/@_PO9Z\^LVJRW5Y/-<7'DK`+=%.>>A&3[5KV'_``5J^$=[X!\0
M:U.WC#3;CP[J-OI$^B7GAZXAUFYNKA=UO'!:E=\AD7++CL.U+\=/^"8/A7X[
M_'3Q'X_U#Q#XCL=4\2:98:7-!:F'R(8[2X$Z,H92=S,,')/'2LOXI?\`!)GP
MI\1]6\8:M%XJ\6Z/XB\3ZOINO66J6CP&70+VQC,<4L*NA1P03E9`PYH`POV1
M?^"JMO\`%N[\92>--)N_#-G:^/G\&^'+=M*GM[]_E4K]LA<DQ29;GH*[O4?^
M"K'PGM]%M;BQD\4:YJ&H>()_#-CH^F:++<:G?WD+%9?+@')C4J<R$A>.M<@?
M^"1&ECX;ZMIT?Q0^(2>+M7\5)XRD\78LFU&/4`%#,L1A^S[&"@;3&0.U5-+_
M`."-V@>$?#GAU_#OQ&\>Z-XS\+Z]-X@L_%)6SN;R2:=BT\<L+PF!XW9F.-@Q
MGC%`';ZW_P`%8?A#X;^),?AF^OM<M+I+JWT_4+J;36CM-%O)SB.TNG)S',3P
M5VD#N17G/C?_`(*YZ;XC_:F^$_@CX<Z7J&L:%XT\4S^']4\0:AHUS#IDRQ1L
M6^PW1Q'+(KJ01@CBNCTS_@D;X1T3]I6;XG6^L->:IK$T=YKT&K^']+U-M5NE
MZSI--`9+5F[B%E`[8JK\./\`@C_X?^''Q1\+ZS;_`!#\>77AKP-XBG\3>&_"
MMPUJVGZ1<S[O-'F"+SY%)=B`\AQGB@"/]HC]NOXJ:)^W:?@K\,?!O@76KRU\
M--XBEN/$.J7-F;O`SY$1AC<*QZ;G!'K6]X'_`."J7A_5/V3]$^*FN>!_'FGV
M=V98M7M--T[^T_[!DA=DE,TB%08P5)#`$D?PBC]I3_@F/_PO;]J&'XK:'\5O
M'WPVU^32#H5^N@16+B^LSPRA[B&1HF(_C3##M7+_`!6_X(D_#GQWX.\(^'](
MUSQ)X=T7PEID^E1V;K;:K#=),S-).R74;J+IF8GSE&[G`P*`.Q^*?_!7CX.?
M"1F>_N/%M_9PZ5:ZW=WNF>'KJ\MM/LK@9BGF=%(13D9!^8$]*UOAQ_P4T\!_
M%O3/%3>'M#^(E_K'@_RGO-!/AN:'5IH9<&.XB@DVEX6!!#Y`KG/$G_!)SPCX
MD^'WB7PXWB?Q5#:>)O#5AX8FD4P&2&"T`"2+E,>8VWG(QZ`50^-?_!(3PK\:
MO$NM:Q<^,/%=A?:M:Z=:[8A;R6H6SV[/,A="LZML&4DRO)P*`-?5O^"O?PCT
M[X8:9XF@7QAJ;:H]TJZ/9:'))JMN+9RD[2PY&U488)W8/;-'BC_@L#\&_"'A
MSP_J=W<>)##KVD1Z_+%'I;&;1=/D8JMU>+N'E1D@CC<>.E?./[1/_!%[Q%H'
MA;P;H'P]^R^+-!T.YO-2N(M0FL+&5+^>7S%=8)+26T^SJ?\`EFL8;`P#WKUR
MZ_X)*+\7-4\#^//'FMZ#'\4])T2#1M?DLO#&G:AHNI0Q,2B16MW"ZVY7/WHM
MG/;&!0!]D>&/$UAXS\-Z?K&EW4=YINK6T=Y:7$?W9X9%#HXSV*D'\:O55T72
MH]$T>TLH518K.%(4"QK&H"J`,*H"KTZ``#M5J@#S7X:?\EQ\;?[T7_H(KTJO
M-?AI_P`EQ\;?[T7_`*"*]*H`****`/B/_@K?\6OC!\!=4^'FI_#GXH#PE8>+
M/$%KX=N]/D\-V>HJ@E<*9UDE&X.`W"GY>*\U^-G_``45^*_[(W[:_B/3/%NO
M:7X@^!WA/2;:PUC4WTJ.VO\`2=0GMS+'?2NGR^3NPI4`#+5]T?'/]FKPA^T;
M;Z'%XPTDZM'X;U&/5M/7[3)#Y%S&04?Y"-V"!P<BL3QY^Q7\.?B?)X\;7O"]
MKJD?Q.L8].\30W$\C1:G!&H1$*[L+@`<K@]\T`?G9\9_^"H/QZ@\0^`[7PYK
MM^T>I>`9_%ETWA_P=;:U]KF7<RM.K,##:[0-SQG('(KT;Q/_`,%$OBCIGQ&^
M'?BKQ1XF?PG\#?%FE6)M?%GA3PO'K^CW>I2E5D@U"23]_9`OO52J[<CEJ^A/
M&7_!'3X!>-]*\&V5WX0U2WM?`>EC0](BT_Q-J5AML1G_`$:4PSH9XCD@K*6!
M'!K>\1?\$P?@UXHU_1;NZ\+7BZ?X?6+['H4.MWL.A;H\>6SZ>DHMI&7`.60\
MC)YH`^@+5UEMT>-E99`&!'1@>XJ2FP)Y42J%50HP%'0#VIU`!1110`5YK\/_
M`/DO_B__`*]X?YFO2J\U^'__`"7_`,7_`/7O#_,T`>E5R_QET#7/$GPXU.U\
M-^)9O".L&(O!JD5C%>M;D`G_`%4OR-GWKJ*CO+<7=K)$R[EE4HPSC(/!H`_*
M3P[^VI^TX_\`P3:A^)&G_$O2/$?Q%\3>)I]#TJWO/"UI;V%J(+AX]NV/EFE"
M8RQP"_'2M7XB?\%AO'WB#X._%#5O"]]I.C^)/AWX6C75M*DL$GET76UP)U*M
M]Y<GY0W!S7W#I'[`?PNT#X4Z3X'M/#)C\,:)JKZW96@OYR8+MI#*TF\ON.7)
M."<>U97C7_@F5\%OB#XF^(VL:EX'M&U+XL6,>G>*IX+N>W_M6&,87(1P$<?W
MTVL?6@#XW^'G[>O[3'C/X1?$30O#?VSQ1\1_#UCINLV%CK/A6WT;Q2^FS"/S
M[F"QW_9KA0681EF7<<`@YK[(_P""=7[15G^TO\!%UB'QEK7C34-/OYK#49=:
M\.KX?U73;B-L-:W-HH"K(AX)7@]B:R_!O_!*#X+^`/`&H>']'T/Q%I_]IQQP
M3ZRGBS5'UTQ1XV1KJ+3FZ2-<#"+(%&.E>K_L^_LW>#OV7/`@\-^"='_LK36G
M>ZG:2XDNKB\G<Y>:::5FDED8\EG8DT`=W1110!YOX$_Y.&\7?]>EO_,UZ17F
M_@3_`).&\7?]>EO_`#->D4`%%%%`!6)X]\.ZGXE\*7UGH^M2>'=4N(RMMJ4=
MK'<M:-_>$<F4;Z'BMN@]*`/RN\%_M@?M'0_L._%KQY)\6-.USQ=X?\4WGA+0
M8[KPG9V]G"\,PC2XD6/YG9^A4G:":T[#_@K5\1-=\&^)-/-UHNC_`!$^'?@F
M[N?%FD/9(PM-7B@,BS*&Y\EOE('0YQ7VQ9_L#_"ZP^&&L^#8_#.WPYX@UB37
M[^U%_/F>]=_,:7?OW#+<[00/:JGBS_@G?\(?''Q0\1>,]4\$V=QXE\6Z!_PB
M^KWJ7,T;7^GXVB)U5PN0.-^-WO0!\.?L]?\`!0G]I3XC_"_Q)H^ER3>)/B1?
M^"+3Q5X8T_Q3X5@\/:IJ!<)]HDL8E?R+NW7<VQI"A)V@]:^O/^":'[33?M(?
M"C5FU+QAXC\1>*_#VHO8ZWI_B/PM'X=U?0+A<;K:>WC^1MIZ.N0P[FG?#'_@
MDI\$/A!X/OM'T'P[KUN;ZR&FC4YO%.IW.K65J,;8+:]DG:>VC&!\D3J/:O4/
MV<OV4O`_[*?AF]TOP7I,UFNJ7+7NH7EY>SZA?ZE.W66>XG=Y9&X'+,:`/0U3
M+;J?0.E%`!1110`5YI^SW_R%/%W_`&%&_K7I=>:?L]_\A3Q=_P!A1OZT`>EU
MXS^V=^W/X1_88\,^'=4\6:;XJU6/Q1JJ:/96^@Z;]ON#*RL^YH]RG8JJQ)&2
M`.AKV:O-?V@/V5O#'[2>M>"-0\12:M'<?#_7(_$&E_8KD0@W**RCS!M.Y,,?
MEX^M+7FCVNK^E]?P-*?)KS]G;UL^7\;7\C#T/]O3X<>+?&/P[T?1-4N-:_X6
M?;WESHU[9P;K55M4#S+.S$-$X#8VLN<@@XIT_P#P4)^"MMKSZ>_Q&\.K)'<_
M8WN?-8V*39QY9NMOD!L\8+]>.O%8)_X)G?#&']K6V^,=G%KVF^((+>ZADTNT
MU`QZ+<R7*[9[A[3;M\]QC,BE2<#.:SQ_P3%\)Q?#:;P)#XT^)4'PYN+AIW\*
M)J=O]@VM+YS1"4VYNA&9,L5\_OCIQ5<R:BTK/JKZ7YGI>VW+RV?*[MNZ5K.9
M6326UE=]>NJ7W*SDK6=F[W7=?$/]N?X1_"KQC>>'==\>:%9Z_I]M%>W.FH[7
M%U#!("4F:.-6;RR`3NQCWKMO!7Q>\*_$?P?I_B#0?$6BZOH>K)OL[ZUO(Y(+
MD9P=K`X.""".H(Q7(_#W]D3P?\+OC'XD\<:-%J%KJWBC2[+1[F'SP;6"WM49
M(EB3&5.&.3DY.*S?A)^P;\+_`(1_"31/!:^%]+\3:/X=FFN+!O$-G!J4]N\L
MK2L5=X_E^9SC`'&*NT+/773]>;OMI;7N*6UUY:?]NIO73:=TM-59Z-6=_P"+
M/[:OPO\`@IKUQH_B#QAI=KK5K;&[EL8R]Q-!'C<&E$:MY08="^T$<BN4^#?_
M``4.\)_%S]GCP#\1O[/U'2]-^(ER;73K>:XM?,1O-:,%BTJJP.W.$+'!Z58O
M/V`?#%E\5O$_B[PSXD\;>![SQI!#;Z[::%>6Z6>I+"ACC)2:"4Q,JD@&%H^M
M+X9_X)X?#[PC\&/`O@.S;Q`-"^'=[]OTHR:AON&E\PR'S9"N7!8GTJ:-N5>T
MWYJ=_*/,_:6[^[;E?6VJCL*M\$E3WUM_X`[7_P"W[7TT75G0^*_VVOA9X,^(
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M?"73?A#;^/9OB!X97PA=7`LX=36\#123DX$(`RWFYXV8W>U<7\3_`/@FMX#^
M*&N:#J4U_KNFW7A[3#I-O%:0Z?)8M"3N)^Q3VLMI'(3_`,M(H8V[`@<5%X`_
MX)F^`_A;\!+CX=Z#J6O6FAWFL2ZY</<V^FZA)-<R$%CLNK26!1D#`2)2O8BJ
MZ2]=/3FZ_P#;NM]-=+,E;QOVU];=/^WM.NFMUL>B:=^UM\.=0^'6H^+F\4V-
MCX;TDA;K4-0CEL88R<8YF5"V<C&W.2<#FJ?P\_;8^$WQ4TG6;[0_'_ANZMO#
ML(N-3:6Z%LUC$1GS)%EVLJ?[1&/>O-Y_^"3_`,,=;^#7B#P/X@O_`!MXJTCQ
M#?Q:F[:QK)G:PN(\;&MH@BP0J-H^18MA[J16E;?\$R?AQ<_#;Q1X5UA;K7-+
M\66@LKQVTS2M,NDC'/R3:?9VSYS@_,6''2B7VK>5ON5^U];Z:*R7O:NQ&UXW
M[Z^E_GTUO=^FFM>__P""HWPQO?C;\.O`_AN^E\4ZA\1+NYMK>:T4PQV:PP^:
M96\T*9$;H#'NY]J]6^,/[37@/X!7%C;^+O$^FZ/>:GG[):,6ENKD#JR0QAI&
M4=V"X'<UY[I'_!/?P_'XZ\`^(-;\9_$3Q9>_#)Y'\/1ZKJ%L(;/?#Y)#)!;Q
M>;A!@&3<WO6Y\7_V+O#_`,5OC7H_Q'M=<\5^#_'&BV$NEPZMH5U"KRVLA#-#
M)'<131,I(!SLW#'6KGRV@H]Y<S\M>6RNO)/735KFLDS=?]NK_P`"N[ZZZ<MK
M:*[5M+MFKXH_;#^&?@GP7I/B#5_%^FZ;INO';IOVA9$N+\CJ(H"OG/COA#@<
MG%5M._;>^$NI_#K7O%D?C_PY'X?\*@'6;J>Y^S_V2"0`;A'`>($D8+J,YXK.
M^('[%6C_`!(U3PEKE[XM\;V_C3P4)DTWQ1:75M#J6V5=LJR)Y'V9U9>"#!],
M'FN;U_\`X)F>`O&_A3QY8^)=6\9>)M3^)$-O;:UKE_?Q#4)(8&5HXH_*B2&)
M!L`PD0R.N3S41WUVN_DKZ6[Z;WY;/:]ES53Y>>//M>-^]K^]Z67P_%?2]KOE
M['P7^W/\(_B'XA;2=&\>:'?:D+1[Z*V5W62[@0;FD@#*//4#DF+=@5S/P8_X
M*=?!GXX?#K7O%6G>*&TO0_#,DB:G<ZQ9RV$=H$D\LNSR*%VENF#GD<"NT\2_
MLI>%O%?Q9^'GC.Z;4QK'PQM[NVT98[@+"$N8EAD\Q=OS':HQ@C!KB8/^"<_@
M^+X8^*O!+>(/&TW@WQ9<&[FT>2]@,-C*TXG9H)/(\X9<9(>1QCC`HEM[O9_?
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MKT*N+^`OP(T/]G+X?)X9\/-?-IL=Q+=`W<WG2;Y&W-\V!QGH,5VE:5.6_N=E
M]]M?Q)I\_+[^^OYZ?@%%,\[/\+?E3U.14&@4444`%%%%`!1110`4444`%%%%
M`!1110!YK\-/^2X^-O\`>B_]!%>E5YK\-/\`DN/C;_>B_P#017I5`!113)9O
M*_A+'T%`#Z*S['Q7IVJ:A-:6U]9W%U:\3P13H\D)_P!I0<K^-+KGBC3?#7V?
M^T+^QL?M4GE0_:)UB\Y\9VKN(W'`S@<T`7Z*H:'XHT[Q19_:-,OK/4K?<4\V
MUG2:,,.HW*2,CTJ_0`4444`%%%%`!7FOP_\`^2_^+_\`KWA_F:]*KS7X?_\`
M)?\`Q?\`]>\/\S0!Z51110`45GZMXITW0KJ"&]O[&SFNCMA2>X2-I3Z*&(+'
MZ4]O$%FD<[&YMPMJ<3$S+B+_`'N?E_&@"[16?;>*M.O+YK6&^LY;N-0SP).C
M2*#T)4'.*T%.10`4444`>;^!/^3AO%W_`%Z6_P#,UZ17F_@3_DX;Q=_UZ6_\
MS7I!.!0`45EIXRTM]2FLAJ%A]LMUWRV_VE/-B7N67.0/<BI7\36,<4,AN[39
M<9\IO/3$N.3M.><>U`%^BJ>C^(++Q!;>=8W5K>0@E?,MYEE4$=1E21FH]=\5
M:;X8M?/U*_LM.M\X\RZG2%,^F6(%`&A14%AJ4.J6L<]O+'/!*-R21N'1QZ@C
M@U/0`457U75[70K%[J\N+>TMX^7EGD6.-![LQ`%5+GQCI=GHZZC)J%A'I[C(
MNFN46`C_`'R=OZT`:=%48_$EC-]GV75J_P!L&Z#;,I\\>J<_-^%!\1V:Q3.U
MQ;A+=_+E;SDVQMZ,<X!]CS0!>HK/OO%%CIEQ;17-Y:6\EX=L"RSHC3'T4$_-
M^&:+SQ5IVG7]O:W5]9VMU=9$,$TZI+-_NJ3EOPH`T*\T_9[_`.0IXN_["C?U
MKTI6W+FO-?V>_P#D*>+O^PHW]:`/2Z**CN;E;6-F<JJJ"S$G:%'J2>*`)**S
M]'\2V?B&T%Q875K?0[BOF6\ZRJ".V5)&:K:W\0]"\-7;V^I:SI.GW$</VAX[
MF\CA9(LX\PAB"%SQGIGB@#9HJ*ROH=2M([BWECG@F4/')&P9'4]""."/<5+0
M`4444`>??!#5;K4M:\6+<7-Q<+!J.R,22%A&N#P,]!]*]!KS?X!_\AWQC_V$
MOZ&O1G?8,T`.HK/N?%FFV>K1V$NH6,=],,QVSW"+,X]D)R?RIQ\2V(M//^U6
MOD^9Y._STV[_`.[G.-WMUH`O45GZ?XFL=7EFCL[RTNY+<[95AG60QGT8`G'X
MU-J6L6NC6+W5Y<06=O'RTL\@C1?J3P*`+5%4]$\06/B2R%SI]Y:WUNQP);>9
M94/_``)215R@`HJ.[NX[*%I)66..,;F=V"JH]23P*HVGB_2[_2GOK?4=/GL8
M\[[B.Y1H4QURX.!^)H`TJ*S;;Q=IMY8174.H6$MK._EQ3)<HT<C'HH8'!/L*
MD;7[59YH_.A\RW&Z9?-7=$OJPSP/KB@"]16?J'BK3]*TY+RZOK*WM)"%2>6X
M1(G)Z`,3@YINJ^+=/T.&&2]O+.SCN&"1//<)$LC'H%+$;L^U`'(?$K5;JS^+
M'@^"&YN(H;B1Q+&DA59/]X=#^->@BO-?B>XD^,'@EA@AI).GX5Z4.E`'Y_\`
M_!1#X2R7/_!0C]GJQM?'?Q/T'3_B-JU];:WIVD^+KRQM+I(+821JL2.%3#<G
M9C(XKF_$G_!4KXN_"?\`9[\2^-I]!\&WN@V_CA_`'AR"S2ZO+^U$;&/[=?-)
M*B2?=Y173)/+@U^B&L^"-&\1:UINI:AI.FWVHZ.[26%U<6J236+,,,T3L"4)
M'!*D9%9U]\&_">I>%-0T&X\,^'YM#U9WDOM.?3H6M+QG.6:2(KM<L>22"30!
M\&^,/^"JWQ-\%_`:UF\0V.A>$/B)?W-^=#LIM"?4?^$GL[:$2_:1!#>A+)3W
M$EPY`Y`/2JG@#_@H'\4OBK^UO\&]0_X2[PCX;\'^-/AMJ'B&[\,36N\7]W;O
MC$,K2AMY/3&X*N<ANM?<5Q^RC\,;OP;9>')OA[X'E\/::_FVFF/H5LUI:OW9
M(RFU2?4"KU]^SMX!U2?19;KP3X3N)/#6[^QWDT>W9M)W##?9R4_=9!((3&<T
M`?GWIW_!4+]HSQ7J7A&VT^S^"]DWQ`\,ZGXCT[[1;:C)_9BV(+&.7$H\TR`8
MRNT+[U7MO^"UOQ9^)7BKPSH_@OX<:?>:I-H\&H7EKY0FBU>4SK#*(9I+F$6\
M0!9@Q68Y`&*_1B'X,>$8)+-T\+^'4DT^"2UM673(0;:&3AXXSM^5&_B48![U
MDZU^RY\-?$8T?^T/A_X*O?\`A'6WZ5YVB6S_`-FG.[,.4_=_-S\N.>:`/BWQ
MK_P5%^+WA;XCW%X=$^'UOX-TGQUIO@R\TV?[3)JTCWA*EUF5Q"IC(_NL&]J]
M"_X)H?'WXB_%;]H']H;0?''CSP_XEM/!OBTV&DZ5;V8M[[2X#&K#=AR?*^;`
MW+DD$[NU?4UW\&O"5^LPN/#'AV<3W27TGF:;"WF7"?<F;*\R+V<\CL:=HOP=
M\*>&O&^I^)]-\-Z%I_B76D6/4=6MK"*&^U!5^Z)IE4/(!V#$XH`Z2B@<"B@`
MHHHH`****`/-?AI_R7'QM_O1?^@BO2J\U^&A_P"+X^-O]Z+_`-!%>E4`%97C
M2.*X\+:E#<2W4-O+:2I)):@^?&I4@LF,G<!R,`G(K5J.6#S6'S%<>E`'XT_L
MO?%2/]CK4OB)I'@?2;KXI^#]/M@Z_$GPOX.GT7Q=I<DUPP-KJ<]U"T5QY?),
MRHS*IR4X%=9\.OBO\1_VC/!?A/\`X3*;7?%4/A?XG0'1]1N;4SRM:M9RMEID
MMK=9E#<;_)4=LFOUJ6';CYVX]3FE$3#^-J`/RX\,_$?XS:IX4T/0?#6O:]\/
M+6[@\1:A=OH7A:UADFEMHM]NNUX#&FYNX7<_K7)_$K]NK]IC5?#?PECGUQO!
M-IKWAIY1K][`VFP7VL)<B-8[H"RN,[H^3"!#NY(85^N@BP3\S<^]-$)!/SMS
M0!SWP<NM>OOA5X?F\3W&G7GB&6PB;4)[")X[668J-S1J^&"D]`0#72TV-/+7
M')^M.H`****`"O-?A_\`\E_\7_\`7O#_`#->E5YK\/S_`,9`>+_^O>'^9H`]
M*HHHH`_)3_@N7HR3?\%`/`%UJD>F0:0_@2^@MKS6?"5]XCL?MOG.8XH8[89B
MNF.`DI/RD@]JQO!O[*'BCQ+\7/V<?#\MCXN\#^%?BYH:7WQ&\-WL4MQ)-+I8
MW0>;.>83,&RRMAC@`]*_8)X]_P#$P^AIJP;%8!OO=:`/R6\`>)_A+\7?^"PE
MIJW@/0U^&U]\,8KK2=/CET/4+&X^(FIF)D"2S^28ULD&`)9"6)'`(K],_P!G
M_7?B'XB\"+<?$SP[X;\+^)//=6LM"U>35+3RL_(WG20PMN(ZC9@>IKMS$2N-
M[4]1M%`!1110!YOX$_Y.&\7?]>EO_,UZ17F_@3_DX;Q?_P!>EO\`S->D,NX8
MH`_"'5/"%Y<?\%!?B9:MX7;Q%XBN_BPDD6AQ>%]07Q!J6FLX\R:/5POD1V2K
MRT;<,.,BOHC]GCX%Z;\%/CK\>M0^*+>(O%WPI_9]1[7P9H;Z5/,T<-TIN90@
M4'[4^YS$",@#@X%?JE]GXQO;;Z4H@VD?,W'O0!^1G_!.R:2^_9Z_:(\;?`5=
M/\+>-O&^-1L/`<6EZE8P^%;5%98BF80'OG!RRQY4,!S74?M`V.O^*/V`O@_J
MW[1?B#PGHOC;1)+F^L=.\0^#M1\46OB&?RF"V]];`(R3'`QR>HQDU^I30;VR
M6;Z4"#:V0S?SS0!^4_B3_@HY\0_A!X6\,Z5>:1>_##6/$WPZO)_#O@_0O#<U
MTG]H1N@@EBMTB>2`.FXB*7`4=>:XOQ-_P42^*WQ7\6^![.U^,EYX&TZ/2M)?
M5-6N+'^S[.SNGN-MS'?"2RE)DD7Y4&Z%5;FOUH;X->&6^*2>-CI-O_PE<=F=
M/74CGSA;D@F/KC;D#MVKC/B'^PE\)?BO\0)?%'B#P3INI:Y<F(W4S2S1QWIC
M.Z,SPHXBFVGD>8K8H`^;_P#@O+X<U+QK_P`$]+6QT*SF\67-UK&FB.%(Y+B'
M4E\Q>91"I)B8<L0,8)KYD_:X_P"">OC3X'?LUZ'I,=OX9U*]^(GQ0TF_A\(Z
M7IUY=>#_``]'N7(>WSYAB;'[P@(I!Z"OV!ALX[6UC@A5;>&%0B)&H544<``=
M`!Z4+:[2?F;GM0!^*FL_"7Q1H?[-VL?#'P7H^O\`A_\`:<A^(4\_AFWT^TGL
M_#?A*?RW)GL68.L=A)#D;78_O&'`Q71?&V^^&NB?\$DO#-CXHT/Q-I_Q$T?Q
M3G58+G3]1N+JYUR*0?;;LK`A$BLW*NR[<?=K]BA;\_?;&,8/2G&/)^\U`'XQ
M_MCZMI7Q:^,7B#6M>T[6/$EOXP\%:/#\)[IM%O)F2]2XC\T6W[O-M,K`EBX0
MXR>E4_AAK_Q:^$?[:EC+XN\.:#XR^+5QKFE:>VA:YX/N=2U1M+*,#?VNKA_)
MMA$/O;5Y/WCFOVF$.,_,W-`@Q'MW/]<T`+;EF@0NNUB`6&<[3Z9KS?\`9[_Y
M"GB[_L*-_6O2D78H'7'>O-?V>S_Q-/%W_84;^M`'I=>#?\%+_`'A_P"*/[%_
MC30?%/BK7/!.AW]JHN-;TJSEO)K':ZL&:&)6:2/(`9<8()&17O--9-QSW%`'
MXY_#;]K3Q7\,?V6)M!T7PU<>"8WU6[M=(\??#O0F\,^'O$WDJOEW%Q#=6=Q)
M'+)V2.,K(VX!AVZB_P#'OC[XJ:7H7CKQ)HMYJ7B^;X6/%=377A_S(KF5=1"@
M/`\6PL5^;:4&>NT5^L?E$MG>WTI@M</GS)/89Z4`?ES\4OC[\?O#FG:QK?A[
MQ;XJT73?!+>'$L/#]AX8MVL[Y;@-]I67,!D*#`XC*[/:KEA^UE^TAXP_X*!W
M'AF;Q#I/@V.WUJW73]$U7S$LM8TAH$:22*!;)VEDW%L2_:D`/!7BOT]:'<V=
MS?G2B/`^\U`"J<TM-C3RUP/UIU`'F_P#_P"0[XQ_["7]#7I!/%>;_`,_\3WQ
MC_V$OZ&O1W7>*`/Q!_X*D:!>-_P4R^*#2Z4+J^U#0M-'A^WG\)ZAJE]J\R21
MLT&FW=N"MG(0""[9&,YKVCX7_LT7\W_!1*'POXAA\3:+\%=-\/P_$>Z\)7<4
MMPMEKLB9E#W2\2;2O^K'/.,5^JABR/O,/I2>1D?>;KGK0!^3W_!/#Q9X'^+_
M`.WC\4OB-\)M+L?AOK5SHL^@^'?!U[H6HZ6NL,DI>34K\B'RU=FR$526*X-=
M+I^E?$KXG?\`!.7Q1;_M0>);'P?:Q^-)GL-0U/0=0UMV1)6\J&YM-B%[1AD*
M00-N,FOT]$7^TQI/L^'#;FW=,^M`'Y3_``>_;[UKX"?#+X4W5]H.E_##P#J?
MB+4]'M)?#'A&YLK+Q?"MKFVNHM.,<ES`&EP`,8)ZG%>;^,/^"EOQK\9?"'PO
MIL?Q#\0>&?$#KJ\FLW4NDMIEUH[)=*MK/>!K&8BV6+.56)2>"7%?L!XK^$/A
MOQSXOT'7]6TFVOM8\+RO-I-W(#YEB[KM=DP<<KP<@UROQI_8X^&O[0^NVVJ>
M,?"]MJ^I6MNUFETMQ/:S/`Q!:%VA=#)&2.4?*GTH`\1_:XN-1\8?\$<O%K6O
MB27X@:I?^"I-NM:3^^.LR-&<R1>4HW9.1A5'3H*^'O$_[`/C/X4_\$NO'WCV
MXT[1_#UQXR\!:-I=OX*\%VEX+>YDW09O+Z%P&>Z_OB-!QN&3UK]B?#'@O2_!
M/AZQTG1;*UTG2]-B$%K:6D2Q0V\8Z*J@8`K2$6#UH`_%_1?A)_PI7X:_&+P7
MXV\(76F^//%5AHO_``A^C^"M(NK/PW+>-D6=_;J=YANED^:X9B``.1S73_"7
MP_IW@S_@FY\<O"_[2-CK]S\9H9$'B[4I(+VYC\077DYLVMWM4S+&J;5(4%=P
M)-?KQY.?XFY]Z3R,*%#,H'3!H`_&_P`7^._!OQ%^&W[/6O\`C;3]1\0_!;1_
MAYJ>A74%YX=OI[:U\1+&JPQR6QAWB<$#8[)CCAJ\QO8/B]\%-;\'WWCK1='U
MC6=*\+6__"$Z!XO\&W7B;^V0]]E;>W9'"6=PL9!WL"ZKUP!7[OM$67[[*?44
MB6^Q<;W/J<]:`/'[G4K[6?$7PON]5TO^Q=3N;99+K3]V[[%(44M%G_9.1^%>
MR#I7FOQ27;\8O!/_`%TD_I7I0Z4`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`',^&/AZWAWQWKFM?:O-_M@H?)V8\K:`.O>NFHHH`****`"BBB@`HHHH
M`****`"BBB@`KF/#GP\.@_$+6-=^U>9_:T:)Y.S'E;??OFNGHH`****`"BBB
M@`HHHH`*",BBB@#F=`^'S:+\0]8UXW7F?VI#'%Y&S'E;<\Y[YKIJ**`"BBB@
M`HHHH`****`"BBB@`HHHH`****``]*YCX=?#P^!+G6)#=?:?[4NC<XV;?+SG
MCWZ]:Z>B@`HHHH`****`"BBB@`IK@GI3J*`.9^'_`,/?^$'OM8F^U&Y_M:Y^
MT;=FWRNO'OUKIJ**`"BBB@`HHHH`****`"BBB@`HHHH`****`.9\6_#T^)_&
;&B:L+KR?['=F\K9GS<^_:NE4$#GUI:*`/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tpg18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg18.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.D5"13!&-4,Q0S(P-S$Q131!.$)!04%#-3%$0C(P13=&
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D5"13!&-4,R0S(P-S$Q131!
M.$)!04%#-3%$0C(P13=&(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.D5"
M13!&-4)&0S(P-S$Q131!.$)!04%#-3%$0C(P13=&(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.D5"13!&-4,P0S(P-S$Q131!.$)!04%#-3%$0C(P13=&
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`%2`3$#`1$``A$!`Q$!_\0`WP`!
M``,!``,!`0$```````````<("08$!0H#`@$!`0`"`P$!`0`````````````%
M!@(#!`$'"!````8"`0("`PP&`P</#0```@,$!08'``$($1(3"105&"$BU!:6
MMA=7=]<X6#$C)-67F$$R-U'1,S14539AD5)RDD-38]-DE"65&3F!L4*RDV4F
M5F;69V@*$0`"`@("`0,"!`,#!@8."P`!`@`#$002!2$Q$P8B%$%1,A5A0B-Q
M,P>!D5)3)!:A8I)C-#7PL=%R0]-$5&24)54V&,'ATJ.S=,0F%S<X_]H`#`,!
M``(1`Q$`/P#1RO>2UF/T@A+?7/([E.X<V)9YIUIUM'(=8,RN$KC)+^/D$NZ1
M)K(@PR+)(3<<GENBE&I%)B=!%SSY<G7)R!I2_$+.V'1_AZ]F_P!1\,N<>_1M
M=`VUW#7?58VNIV%MV*.?]1MA+!J"MZ,U@FSWOH]S&SYJIU-_YBE0]NW4[7[?
MK/;\)5?8=8456\/Z:UMRV,ILXY?0%!8U`V2B/)3D9QTO/SL;D@=:0ZRJKH3D
M-!;)L1/-K*>F&1.<+8N-E;NTPBM1M")B>FYOD[8PHSUQ0W0U*VK%)Q9.MA%L
MPP/)T&_1H?!-?;[7D.K/RWMZ&9!SNS?N:E*N%)"FJ@NK,G+DRLPKP5PW5V.A
M9V'SN[0T"!OM\:ZMU#>*@U>KMV*AQEB][+QY`83`+YR,6*Y)><$P5Y9LTKFJ
M%_'%(LJ6AX#>\V2\D+D4U/()Z&T(ZJFL)JZFV1`Q/9SM,5L0;##E*U;L#>F6
M+D2;H+9AHR^WL6NZE^VLV$]ZGJ.R?2>JD\MB]Z$2S:>E?3C6'6NL/AK[N2*`
M$)/#UK)VFIU;59IV.WT4VJWLP**$L=Z:UO<'/)K%9F*`BJE"[9+HLF9AY]VO
MR3F$:K_AA5$(<'PSBY3O*B</W(F326%QZ-,U^(7);5]8IV^&1^22,^=.29F5
MJ5Z@X@I"WIR-:_6F&A`'NW]#=TM[M451;H]3O_9L1]+[-YJ&QQH+'@BUU,GN
M&TC%E]:@$+81HTMS4V-+KK+^=>]V%=UG#`9:*M>[[:UK",<RVP'2H5^'6JQR
M0"@-7&KE\U\F.4GE4W\2W/%>-RN&>8HV6C`5+R%T#$9O3D<8XE8$?7+&T139
M(R(W)(TM]"6:+T%0GV`X`0>)L.HS6V^OT>R[3Y%38UOQZ_X%5V-+\<,:+>QZ
M^T$J3XM0%JG`/AU=02ODY]GK[M]>G\=L55[S5^:#2M"GZ38NAO<2K>IKM4UW
M)GR%=0P#@@3+&_,JNDVN>._+6:T?7T;X8\F+4K^N(JJ3V`\J[]@C)<<LW!JB
MLV<QPR.%0-:P2=^.0G+6]M<S5S6A=21[V>(A0'4I1IW:_;:7Q_NA[/<=E6/9
M"^5KV'U6W*M2[/U&UJE:DN@-8V1Q\UL'GNU=0W7]GVW5DV]=U)L-I;Z3;3KW
MC7V;Z<9PE;EK45\/92A(PY53Q\Q\S/DPID\/DE74G1HJ(FGF`BX!MKA8MC3I
MNMHB2-#R]QJ066HB,;A3JS&,)TBC:LI$V%K!+M(A%+3Q%D^)H'#T3-V=O3#;
M`KJ[K4V]JKAEFKIU5V+`EF<`6VUZMA)R*Z79*W8L29EVY'74=P])Y/T[:R6%
ML\;'V3IJ"G$$\*VW:O4<K%2QE490'N%7FAS)-4,O*U2S"?RRBW/1GX%ET87,
MUH6%VF<DF"%;'INEE!C$%R!%'"@U@YGW#1:V$I,:1UZ!\3-G4`]POQUJ?H'<
M?<?<Y!_V/]N^X/:9QYL&M]N16V`MAOHSCG/>Q*=9=WM=YY)U>O5=K\?7:7=%
M*]>,'`5[[KUKL0%C5PMQR*8DP^;9,YS!>%<@=J_G,QKF1N5P\:(D=*J^DCI$
M96C8IIR#K6*RA&T21F/2NS2)VC[LI2C-(,+-T4<+M%K?NYJUJEV_F'QSK+2_
MV&YWU%-RABON5-7>61BI!P2JDX/J!-WN/K_'.[WP$^]UNBV[JR0&"6I6"KJ&
M!&5/D9$B>SET_P""O+KA,S0JX;@LBB>7]FROCU8=4W;8LFN1=&)RGK>4V+`;
M4KJ>V$XOL\CNR1PY4V/31MP/:5:=44>6G(4$B,-[.HL;:[78Z#857KLZK;W=
M=\!;*KM,Z_N5%@!SIOJL.!9R:FY>2-QL9)J[#7]OHF[W5)2_5W].JX%F*6Z^
MW:VN,(<A+JKK*G#)PYUAUL#$(1W4@YMWI6?*2B:,MB`T$ECO)^1677U<;@5M
MO<JLBM;%AT&<+`C+=;T<.BZ!N51V4,["N*/6M)O5O5:(!LLP)O?KGZU;>SLV
M.KJ*CO%ZJ_=JQEM<G6:I;Z+7\,K5^^F'"D6FNT*JX68[]E77ZM79W<AH'M-;
M39?'O%=D7E+JQ^GC_0R48@JMJ9)(.86\M6Y.=4TJ3EE)K./J&U%D1Y;\JH/`
M]*['L%&K9W")W*XL88ZN>I9&#4K33T$9@#VV!("8X;0IPE[*`8+?3.DY^%?'
M]P<?O-KJJ+#:YQE6V-I;;]DC):U0JX6O(9%`Y*9YM\T^5]MK("=6C9K'M+Z\
MCU^A:E5&?"K8;&=V?TN=R`RG,M/Q%YBSFX[VY'\9+?C]3H[.H%HJF;IY;1<X
M=9U6<W@%NMCV-G4DGOS.SO4>E3`_Q9Q1KT)^C@"*]'/*,V$W80[M6NK>Z:WM
M*/<5]7L6T[E8#'N>S5LU/4P/UH]-HY`@&NQ70Y\&:MNTZ?:Z_6.58[77?=H1
MG*@;-NL];@_S<J@ZD>"CC(!'FKGFFV5R,G%@5WQ'X?61)Z[M]KI:[.9$R>X.
M]'M#[ZDI1K3-U-5Z\GI1;,W%KFN%V);ER4P/AKF]`J+WO6M;WE???LT]KL/D
M7BSK/CFC5M6U')78NNV4*:S+C%G^Q:^_8:\@\O9;T.9-II:^SJZ73W.:=OON
MP;2JN'AJ*DH=[]E6P>#5W6::AL9P[A3^H3J7/S-9K*:Y\LF1\?ZKAUDOOF*$
M.;<2;*YPNAL?JYZ8ZA73]_7NPT+$_+GA#&']I5H%R(D(%H]$["3W&=-9:>UT
MA5\VO^+]<R_:'J]O?HN8\@:*'U'IY*OD^]K[0(XD<;.(;"\B*OH[SI\2K[SL
ME?\`<*^SUM"ZI1Q/OVG:KN(Y?HX6ZQP&'E#YPV`9HIOEW>-N5[R$8BJSJ>.\
MBN-5[/%$6,4\V.\(J*)&1'V.9,UH-\H/C@98HB:^*2EO,-;3$1+B2KV:5L?:
M#1@HXE=GJ-'N]#Z-';NV*K/=.#5;IW6:]RCCGW!9;6HH8<?IN1G`*.LE+.6M
MVVSU-ZE[Z=?5O0IZ65[=2VJ3R_2:0;/='GE[1X'ZU(SHY.\R9AR)XD75$IFT
MQ.&6UQC\QSAQ2TZ<:<G+E+JZEK:[WQ1,TC4KADD4H&-W"@D,1EA9"]N5E>*D
M6$GDC$8#81;W].FON?)/@_=:YL&IL_+'UK4=<%;M-=JJ]1^%E+92RIR%Y!L%
M05\\W>.^IT/S#IV*/?K_`!6K95UR!QW#KV(ISY6RLAT?'CT(/D@6PG7FAR:!
M5US`1.--LZGDSQSY30+C'7],$2Y:!LMYQOMXBNN.$I3R`UD"M:&R>QB4#6+=
M:2FZ0F-2X`1&!*[]\?5_<=MI=&^L%&]VG:W:%X/+AJVZ=K-NOG`9ZJ=`+N*^
M!R#JG@@R0W%HZ_>[5=LM^V=?U-?85NN"]U-U16BOB2%%S[ROJ%`S8/%LDGB)
M,KWG9-K%YNVAQ031ZF8B.F':/,TFAT\L9XC=_6&Q/$,8)*ONNFX,ICOJ664X
MSNLE*;/2-*Q*CCTJCO\`1Q^$6/KZE*^SU-OLD).I5M;-*J@Y74^P_"M]Q/`K
M7:P324++Q9&Y,>:KR]A[G7-IZMX5=N_3U[BQ.*;'N+^[3K/ZO9K!#[@8*V01
MQ`PYHY6_/R,<<N/%5$U=5-;T@RWKS=YB5,HGU]W+8BWC]7$FKVR[%-6R&Q;.
M>D3_`"-C>+J>8^(MA:=>CM:9<I&G*-`226`?#TSV;O3_`!70US773M?&$VJJ
MG;#<%O\`:71U["";]@M;[@>X\VJ2P`.X1#T[U5>OV?RC>M#V6Z7R'[>UD'ZF
ML12^Y:GI30BIP=:QP6QZL\$9W71'GY.6UI\M;D58=PUDU3IO;Z$=9--ZL8;-
MD;`R2/T=(E6JV)HM2%EM4G0M:L\.MD.2$!*C973>@ZZ[UFCY+]MJ/56$>RG]
MUZ]%#YK=6??UD1F"G]5+L'*$\+"G!OH8S;T1MVJ[;%=`?VW><LF'1T73V'8*
M3Z+<BE0WZD#\E^I09!+SS8Y([O>U>+O&Z@:E=4U`\3*3Y!;E]I6S*69O<$<Y
M:Y<4GK`AN:(D_O8WLP,0`%([G'#2@#X@U6N_8`CE.]W7U[_D_==AFS4Z#NFH
MV.`5;=A7U3N%J5&*Z[/%@XM_3\(`1R)6,Z*G7NJ^-=3K@U/W74K<A)+)K!-A
M=4!V.7M4`J<C^H3DG/XWJHZ^HSRCXE0#D0SQYQ:HS<E,I)[J)NJWPW1K3OT<
M,5.,;6N;;L&MJD!XC4HE2?>M"V#Q"^FMASB^>:=?2=7V55V-G53KWM`RU?NU
M6:WO("0>59>MUY8/)"3@DC,[OB&Q?V?9:?\`Y/N?N'LMX#\+:=DT.0#]+@6(
M2H/AAC(\D3)7C#S>G;-5GE@\>>*7&>!LJ?E=QKMRR8^@L2[YZ\QND$-6+H^M
M$E=I*\L<DGUCMB\4G-+[MF`<-'#*Z?J0C$"5V_N]SO[^H#IG3^,=7V'N,,#V
M[EU:!K\4&2RK;7779_,P]RW^8F(U7U=3HJ.S"/RV_D?8Z/M@Y^JMMNYKN;GP
M&:MK&KQA5/MU_P`HFG?#_DP[\H:4F4IE<.1P"QJSL^WZ&M*,LST;(HVEL6GY
M$NBT@<(@_*$+8M<XH^;(*7-XU"8A4!.H"6<`)H!Y$]FVML_%]?O=`V#0[+JV
MV*U<`65_5=2Z/Q)7DEM-BAE)#*%88S@3.JMNO\BV.HV.+6Z6^E7-<\;%>NC8
MK=0WU`-5>F589#!AZ8F-GEE\N;YHSACP97V%6T2>>/\`<G(R5<;"9ANQ7MWN
MA%*[!N:U$4)L)8Q*&0R.'014^("F\Y#MQ];)"C`G]H@!V#79TQ3:T_C73[.5
MV][XII/25^H"S5ZE-EEO)P<WTTV.KIR".R)822Q$5N,NKL?)>THY/3I?(MPV
MJ?!*7=F-<^U^0H>],AL<U1R@&4!OA,/,ID\8XK<U.1)=3,2MSXI<HYCQZ:8J
M9+%Y2*9MT7L""PLN3N+J%C&>S+5A,O&H$E*)4%@$0$&C-Z%L6N/4O.SI_&]H
MC![WL:=9A_J1;VEW7\U_TR%J%N#QRQ*YP,SNWL:F_P!YIK]2]1UAVU/I[I'6
M)V'`C^4<F]K(R<#EC/B>NNOS`.24;MKFK7=-<?:SE3'PIIFL+TD\LGMHO$;W
M/6>9P:5S5YKJ.,[/$W@]JFI**+&;1+U8Q-.PCT$_8![Z:YG[36TNGW_D?9!Q
MU/6=R^G<M>&N>I*-6]KJ@<+RJ38/*MV'N'@J-^LKMT*?W+MNLZ.A@N]VG6)M
M*S`^W4S[-^NJ/C+,KFH$%?*X?D/T9]Y3_F$VI+K8XA,5FTG%(-7'/>L)E8/'
MS;//%DBLF(+87!&2R/BY<;?ZB31,HV41)U&>F/95RLM$>3Z.?H0A:'E@?K[]
M;MNT^-;7%N_ZW2;;_IG^B]2;->L]7)L,+4>^D\N/MN/<*G"KRA=?M]7<Z?K_
M`)!4'KZW?WDU>+^;%9Z+[EM^GZ36PUK/HSS7G7GSR`Z#VV;F@'+FA>/MVP2C
M$<8Y-N%J1N!'5;;#O,+*K29US$]3M(PVQ'7",M34H12&-HEQ?I[8?X:1>064
M(L0#=&:X>K(W[-G0;_K.GJ[-Y2GU4LE%M5>Q2S'#+94;ZRC8*V\;<!>(G=V5
MOV&I3V##&M9V5.F4;^\S?7L/7:N,J4/VYY*3E18GDD&5TJCS3K]E]:4YR3G/
M'BM8GQTLGE@NXEN>F:T7N06PVNRRWY13,4M9O9S(@WQHZ&K)8THP+&LY6!V(
M).-.!WA``(\NCQV@Z%+\I?\`(^LJV-8+]0JN?3LV_:N)QE'6FU4=/T%JO<'E
M^&7:6KI'OSK@O7\?W;:K2?!NKJV:==FK`SQ=!<'8-]+!'"D94F]W/OERHX84
MJPV@0P,+@&36S7E5*9=.G9QCM2U*EGKD>A-M2Y9*TMKLY1ZM(QZ/H"Q440+H
MH4D`$(H`Q&@XK-@_N.IUJO54=JRP>[<Q6I?:ILO*<O\`6WBLTZZL50VNI=U4
M'/?1K>YI[>X%LL.KK^X*ZQRL?-M=7@>3QK]WWKBH9Q37841FP)7^QN=E^1:<
M\(*9A-14Q9]C\R62Z#TDUBMPK%=*18%6QQJDS;8S?(28V<\2JN)"TK=G[3IB
MO6H-FDE%Z,WL9@>]JS;\AV_C]*O3=K=0-YC<""G'9HU[:65?+,3<BU,N`68,
MX5%:1MFS33T5'=\EOKV.W73K%3##K93=:M@8Y`-8J)M4YR$<(2Y0'FV/S-)F
M`4/@\QJ".-MQ-7F&QS@)=S0SRQW50QF<9)"S[":+2KAX71](Z2%A?(@K;E*9
M&N3HU!)B@TDX6A%:$-UOM=KL=5]OE-3LM?M2W(@O3?U2;'O4GC]+AK*!Q<$?
MTK%..099L[3WNHUNS.R`VUHU=;?7C]-VOV5]--;GU*-7[EBNGG^I2V#P96D+
M^8YS<Y!%T+YL$!H@EBK"9\-H53BQCM;4OE#=)5;9:D*#,'AW8-,+,,QBE<?/
M`!,AULTQ.>`8AFC+_J[C=&W8W]?K^QKX*I^94];8A)P]5=O7,"2/47/MBJ]"
M,"@6%2SE5DC3[-/<7]58O,GXS;O(Q_EL9=]",?G6NK[E3#UN*A@%!,NG".4=
MU1J]>(O&>XX?6BZ5WY3%VV9(IG7<EEJME8PU+]'(6)&V(Y8PH75U421+-A#6
MFJ!$>CFD:T7HS0M[U8+4HV>^[;KJ@:_V[1KV3C'$V6[[ZQK0?A6B<65C]1;*
ME0,&5_6>^CXWU?:6M[AWM\:PS^H(N@=KW7/H;&="K*/IP0P;/B5Z=_-"L[<#
MA;]#>/L=E<OG7F66%Y?S/&#K&/84!*&(ODX9$5I+GM7'3PE;`")A6KFX)(MA
M3[-`0:8;HO0H/IK;>YK^.JG"J[ONGW]PLV2FNVD=LX(`Y6(4U2QX@.2W%0?6
M2/:V5=4W>M8'LKZ;LM/54+@-?]U]H,^3QK8-M<03E1Q#,<9`Y-]\R;E_%6'F
MF<^<9Z7$[^7<K*?>03LCN"2!B=H01;!6^U6\BB2S86.0H)MNOU9@E!<C(3-Y
M+B662$XPL[9I(]GUM?3T_)K_`'5Z3]Q?K[E`!O&S7?33994,A&UT78HM')EL
ML]QJU4-4Q;J72OM[Y_C=+(=X]97O):<BI4LJO=:;!_>&TOKV*60&M5"L22X`
MF3_OC.+/^13S_L0OX1GZ!_\`E^^6_P#G&G_RF_\`LS\^?_SYT/\`YEM?\I/^
M[/[>/*[2./%25<>V^['%DG.^7#_S(J:ZT<'1FNM46>MNPVXF#2*,GR(1#TE:
MBU2ED5"VM2B7H%A^^A6Q]NOS_P!/39TVC\4U]=@VS\7HJI#,#QVJ@VRNQ78@
M(*U[%&U94R<F`(1SRQQGZ!W[*>R[#Y)M;5>=3Y%;=8U8)!H9ZZ/99+!Y+Z]^
MO5>K`*6*E/I!S.Q<?+L"YQ'S*XP?;AP3O,44+5:YQ*A16@52>OI!BIP[:-&*
M3"^-Q81,VW(.C#4&]>+X'7H'Q=\M_6)9\67XO6Q6I>\VNQ%A&3C9V]?9%)7P
M#P&N$]S(Y<N7!<<3OT=^W5^4)\GN`LO'5Z>FR#Z0S:E-U1M!\X]TW%^&#PQQ
MY-G(-O!6T:DM=;<?&2_HM7TEL"DZ?IR[V>S:;56G%IJKHQC%&:\LV(HV>SJX
M=H--4$?7+$:DHY:[-2P@:?9B7Q$_B&V3=[&W=WNS9OHZOLNVM[#@N/=U[[U6
MN_V;&!0K8E=)(MI?%M?,?2[H834TJM3JNMU@`W9]9UZZ26$$5W4HS6*M]:D.
M>%SV-6:[:RJ6VH2<HR=%,.&EKM-_.W)WC[R#9J_MNQ*6AM*7<99M1%V?#K%2
MUVJ=UT'L5NC49G=4F1"Q6!1(W(ON*5*690E5:*,0=2@#R-3G4-_3UV-73]AM
M+L%`<V:]RU"@OKV/R4<Z51;!;7:&>JIQC#*_:^;M?1;:/N]GU]-E26$!5MJM
M<6NEZ(`2!<O.LUO6R![5R0XX\;7?E@5[6+WQ%4,,_?'1@XS1[E`@E2"2LJ%:
M]W;)^5R8!]E3*1O;8K9T<<7K)$H6KMITB$Q/VJM$%:)+*#O>J[4TK6VM5:A7
MT=WQI.EJUU)Q3JUWZ]JD.<EVXZ_%\@<GL:TD'Z3Y;9M6WIV+6?\`MG_>`]M9
M=Q&'N--](0)Z(B+<JU^6*UTHAY$EYQD(\L64L-?47QIF?(<J=<.N-5EQ&R:N
MJ\56E,]K/)=7R<4QJ"O[0MX4X<V23PBO7T"40`MT79G%R);4I:I4,.E'CR"[
M^Q9OZO?=F/NN^T*<4/G@&N76;43;M4\BVR*68@HU=7OL;O:\*BX[%5;:V_UN
MB!1U?:/9]PA^HK7?>-B^BAAQ"4VV`J0ZVNM+-4K@X<8XT]64ZJNR%EP0.&7&
M\\^G;G?/Y&JXM6?QN-E4!9H5/;L<VZ5S4[D.X0%MCR$M)1*\UU039OD8%A:7
M9+>`DX'>F'S_``H#1Z_X]UE?$ZEW7K1V3,?:?32P6W[?UX4FVG8"!E'N#>M`
MR#[V:\OE1][=[S?V%X6U[!LZY:LV+MM7735IEE'+^G:%+.'X?9KR*E&J!;2=
M!Q/',?/@D]]-C/-VJJ*GXU1"PYJF<8XYMU8S/EM,$DCJ:%R^-O*I&2TR>70R
M@"EZ-Q&F,-$B],2:'L(]],Q^)K^WZOR'<;(1]Q-?3!P"AVJ:+>UMJ!^L)<-7
M1J9Q_3=FO498/'R5CO\`['ID!K12]NR02P]K4NM_;ZK/'$,NQM[5R`$,%I0L
M"&7&D?-_C&Y<O./;Y2K+/4E9O2R9U9.&>8.$3,F[<WNM665%;(;TSC&"9)$3
MW-O=%47"E."6XI3`%G;$$776M;U(MU'<]7W>NRC8ZOL:]M58$J[5I8H1L,I`
M/N9)!SXQ^,WAZGZ[?ZR]6-&_U]^JQ4A607+Q+KD,"5]0",&1LT\.;"G]Y5MR
M!Y6W6R6K)Z,03`FC8-5=8J*?JV!R.>,6XS([-7-+_/;8F$ILK<=//;T"I0]E
MMS8D4&[3H@GFF'BR6FFNG=:HVKV6]IV:AN#X:G6M-365ZX4#@]EE2O9:Q=V"
MJB\$!#:K;++ZZ-2T5_M]&W7L\.)S;=2+%K-S%CRKK%A*5J$'/ZW+D)QIE27D
MSBJ>U>*UB.5UP"0"XEV=/)['I$T\<&./WE=B6>,4Z85!7(R]%D^D4GL"4-2>
M6DB*<$I#:D4&)AC4(3!C($E[NIV1U>W7O*B"U>EMZXUU#V=<K950GW`J'(^\
MS4^Y87=PS._#VR]C/AWM=?<I?5]2K=W%?8AG/N6K8ECO[`<\1]N%MLKK0*&1
M5H!9EI`,JR#RPI<Z4ERWXX-7(_3'4G(J[I)R&AFD]:K-S>`SN9V4RVK+XC.)
M`DL=O9K7IZ12!L/1*F738R+%#(O.1G+C-=#,C:*C7U?3=?<*KQT=E(H%B<J;
MM>JZ^X4[=.<79%X7D&1<UJYK8^)(-M5GM][LZQ96O9ZC5[`1^-BVMJ5:0OU;
M<9H854J^"MF+,E653B23PT\O0/%6_+YY!J)A5ZAWOR"57#'6N*3H%AH"J8<.
MK%DO&C<8K'&>52I>>-]1R8'I8G)6M6;4DB%I3X&R4Z>2U=D:G4[74I[EB[79
M+N%W?)1AK)KM6H`"BOZ`RX`(R>9LL9K&AK]5=CL]7LR$2S6Z]M3BBX#H;O?6
MQB23[@9G5CGB4X*JH$P3IY8%'V3RAO[E/R$-4W%,+8;:\A$`;`*I?`$M.5-7
MK,I)+@34NB,W2*I)J3RQU6O+DI4Z)+,4&E!`G!HKN'&Z.O5I];?ILH?:VNPN
MV;[/(%BM753KU&O)7CK4U<%;U=K+6('+`DM[8LW-O6M!XZFII+14GXJYMLNV
M+>?@DW.Z`+C^FE2*"<DR(:-\HN/T#*..NH3<RXJI^+/*CD5R$INKCH5XH8O"
M^04*>(\=2B>2J)>J4B8H._R%:O;W`2<1HTY@4HR=;#L\79U]^QJ['7;>V_W&
MWH=!O=5S("&VK:V*K:'8*,!M:FE*,8/O8YDH?IG#V>O3O5[U.NHHIW>YT.Q*
MC+!;M6AZKQECEON[7:]F)S6Q8`/G(]W;'E:FV(DODQONI&D7W#S7KOF43'Y=
M6>IA5JLV!P2+P,ZF;<@)4XC^[;K22(V`:M20-<U]%@DX^P>DW0WDTJOLM+K-
M0"NW]NV^TNQ8O*NS]S>Q\\,CC=J-8'U[LMQL0/Q!/COV+4VMOL-BSW$7?ZS3
MU/Z;<7K^SXD.'P<K<4"75<0'I:RKE]?(<%$_)Z2QZL.04!%<\7:E/(3E9QYY
M5.H*YH6.UK`(,[T:Z5F[*H#!Z\898-&BB\C.KK19!YZLY>D`KV8I-7GA&:=W
M:%J=<_0^U[EE71?(-GLU]Q^3W?<`YI9@`J!"QXLB<0N%6I0)'=AKCL%[LD)5
M9W/24=<W!<+5[#GC<!G+LR!0X9LM8&LY`,$7E;BXG;MCSR:&M)F9ILWUW5_&
M[Z9+Z/%'G9'5D_N*%R&0P/BX,<B-1@9'ZQ(&SSF3JA)BSC#DB`"48PAZ@WG-
M\37['?\`D/9OG[9:]9-96QXWMNFVC=NJ!^K!ZVJFFRQ/Z89E4GF3C?\`)F.Y
MUW2]8#RO>[8-V/.-'7MU]FBNSP5`;L071218<6-CAZV]N/@Y-K\Y%TI:UG7!
M"'*ON/=VHKSJYF9Z+:V6\FEQ;&1<@0UNHODJ9G@U59SJX"5N")+'4K@ZEE%)
MU2PP`=BW[U7'K^Q';W#GV%>ML4(4)K5EV$LJSL+EO>]JJZT5H#74+&6XUET\
M[.T(W^N?JJ@$T;FUV<,2Y1Z+*KF>@_3[3W64U\W(=UK+UHP#`KR3)P!M&ON.
M3_QYKB]:Q7L$WLODG-K`075QM06Q!I2T\@[$D%AI6DV&_27%SRG:N5SYLE&H
M,<3V]PUH0U2`6_"T3'/UZ;'QKK/BNV>?7Z'3U:)<#%I:IW<;%+9*U6$6$`.M
MP1E1T*D'EU5;?L=_V7R.E<;N_P!NV\%)RBJ]81]:P>#96W%2S`UL0"A!5C._
M>O+_`(Z;Y;*ORY8W9$@;HX+C^71#?:#^UII&_)DP&XI$*1JF(I<S(5`O%"(1
M:$I0G((*V$DL6@`#DG\F8_(MI-@_TEKVM*U1DV'CHW:]J(SL>3NZZX5[6^IF
M9K""?!XNC`Z:JY`%<WT[JGB`B*V[7>K>V@R$KK:\FNH>%153/\T]_".%)4-Y
M&WKR`U8QS@.Z^-5.<=QQ448*3%QP%2$30@,L`[Z>SANAC]\<-[VCVG(TG]']
MPXSO][H[BO\`=>O^3Z&?;_WD[+[LMZ_;_P"QOJ<`/'N?K]SEE/3CC\9CUJ?M
MVU\?V1]?[%UIU`/3WL[2;/N$^?;_`$<./U>O+/C$DKBYQL+XU<2ZHXMES`R8
MEUA5R6M0S8QD`R&O04R)2C]<"80.3F6A$/TCN\#2HW6NG3OS=\M/^].IL:I_
MH>_UZ:N?U\>&JFMSQ].<\.?'QC/'/XS=T+_LG8)O#^IP[&W:X_IS[NT^SPSY
M].?#ECSCE@9Q*I\?/+/3T/)N`\C!<:F3[X.\?[?HHE(9""&G5E`M<V+F"DQY
MP),OW%AL?Q:Z:2`"NTH\;W32^WWW0-G'=[?<X\[7Q[1ZOAG]/V5FJ_OY_$V?
M;8]O`X\\\VX^8_[/_P!DZO5\O^C=[N=ERQ^K[M-E/9QGP*_N,\\GEP_2.7BT
M'%WC$7QLC-WQTN9FS#5R\B[NO\:LQB`R;CP[D?\`3X.*@)`Z.>G(N/;UX6EF
MQ$[4_P!;91?Z,C5UN/Q70^,Y\:/7V:ON8_7SV-F_GQ_EQ]QQX\CGAG/G`E'N
MY]]M=YCSL[%-O#_1]G5UM;CR_'E]OSS@8Y\<'&352%^6,GA_%'BCQ@#<ZE>#
MC!R:AW(PJ:"@I"<V9F1*T)59.HD:Q:E!Q;$6N%)O0]K0JE6R]$^)X(MB[`]7
M7G['>Z'<_7^R=6NGCT][CU;];[A/GAGG[W'#>1PY?S3@V*!?K=[KDX_>MVW8
M)_U/N]A5O<!_IX]KVL_3GESP,<3'UU^53/K-B_*"GH?RN.K/C_R?OAOY)R.(
M):=;I'/F6PQ/4*D4KBR:?K9PA;5E4S)\A@%:E!ZE)>"#%`RR7,)/4L7-UU`T
MJ^FIM/N4='V@VZ%\CFOWC[HINR6+"JVVPTO7[9!%1L%JHR/U[S+MW=CL(.%W
M:]4=+8)^K&-0Z:W4Y\([4BM;%8.K!7*>V[ATLZ[\&276=\[9MNRSR-\V*5@5
M/G-NHJ48&N`P>N)A7VG\A5Z]!N3C<@ROTO:80$.BMD>'X@M#[PQW8]2.P^+]
MK\:]S@.S[*[;]S&?;][6U=?V^.1RX_;<^7)<\\8'')RZRW]M[_J^]QS/6=?5
MJ\/3W/:VK]GGR\\>7O<..&QQY9.<#G$_E\)R7SR\7C=L+PZX%5G.:X*+2Q4I
M*JLP$UI-#3@WL"W3^8*%+&LM%ZQ*"`#CU-WHONUH/B;L7<7_`+O\A[KO6YT_
MO'4[&B51L-3[^UK[/NI9CRR>QP`XC]7+/TX,+UO6?MW0]5T@9;/VSLZ-P,R^
M+?9HV:?;9,^%?[CD3R/A../JR*K\?_)M'3%M<3K,<[HKV0G<1I'8KFQ/C!QN
M8XE<5X(K#BTIC"IPY&72IGTFE-@SAO`_$G^L2"T")4<4<,Y"(TPHQ-[H;*Z6
MPVX*ZTLLZ6SKC52/:UU5UUA[Z5#.+"VN6?FS@EVX&LM8;)'NJ:^W5Z_K"MW*
M]B'L;W;@X>YC0;#Q!I"WNB`*K*%J#%A6%DT1SROT\?XB59Q5U=*I676?+)IY
M1AG&X*02:\F-?(9UOKXE"8-2@PM"4>-S]5^GZ5FB"$'C^!O>_"US=0?VJWXO
M:/K_`-V]2F@?A]Q[6E?I\CZ^WR][W,#GCCQR<\AYNU_>+\D7/'_>'8V+?S]C
MW[Z;\#_6<?:XY^C/+.!C!OQ><*L^>0TMDJJ>0B$/`W'_`*[)LNK2[?@$QBJM
MN<&QYB$IB!<L@CH:@7@7!.":C=TA@34X0&:.(&:2/EV*#?\`TW%;ZK*RNCKR
M!##PP\CZD8#'+FA4L&0DJR=M-RU(Y7FNU]!KL1N+(RNK'\""'4,A]&&0RL"/
M.#,@X`VSQOY$>5!5/'R?O;>LK1]YYV3*[A3TKIWIICDMK-**8.,(>ZX9G5"S
M5_4<B=7I2VLK*D?FY:E((*"E7B/+&8/=UM[K\HLIU@5Z[2^$C2J;8+7-<$[+
M0PMMV:R^QQYWIQ*\?:4<&H1JVX>YIJLZ5=FQ5^\WOE]>VZ:X%:T9T-M>557]
M0+5E5KM+AN;6N_);K%=;PG^5^Y'5:X]]_J#^4+MS*8>=J^]5=<I3H:9=D=+0
M,3='"ZA+E9"@FHTU>-X(\4UZD.W("7]H]8[4>_S9KE>M?J3U8Q7U0W!BWZSL
M?N*[`W6N*>U]=IV&9"@45>W4O%@IY;=I5[(]F>RR5[*C5JQ62HH31-+:8JY<
MR1792++`Y86M9=^D../XG>5R[S6'>8<QW1R2>YW(_,-CT*;)7(&&NVB'(:E6
MPJ$#B+4FK]C,D$BVMB3<>`E2E1.:E0MT``RU"Y2,S9VN:G7^RZ>OK-%B-BCO
MCVM=UF'8W<].U4L50BLBOIJ@XA,TE4/UJ;7Z:-C_`-OIW>XBO7^TCK[*4RBM
M3G:#%&RSH[IM/EB7Q;EQA"M:R?+^&E\2=^XLW*EY"UTQ\F.-+'9,#'-4]#O"
MNJ;"K:SV9H:7MC=:M4W1Z_97Y"HB[4X)'!-)Q%`6I3-#2C3G>"#OMNSW6WW&
MOFL]CHG6V5R&_P#*EVJ[:"1BMZV!518MRLKMR!\8CZ-<)T='2WGW%T=Q-C5?
M])4IKOK,MP'BU;:G8.4-)!"&LH0>47UIY6*F`P2E8@[\C9)8#O4W/^9<\'2;
M2.!LJ1\GCS-%<X7KX,Z)&5Y0-+3HI3-A]KDF)[?#3A#I('NWO7+U==?56=":
M033T?4[^BH)\W+NIMI[K-_*U?W7)@`18R''MAL+GVE;=I7W`L(6WN.PTMMB`
M.-;:C:C%$48REAU<+D\D5QDV%26E.;>7P1,6;S*VC=K*&_\`[Q!B0,AY^H>2
MIW4VD-((J9])3E[D)/QRV8%'ZQ[1B;N@A>#UWK7B9%;'4B_XF?B_/`/=W]A[
MF/\`76Z=OM<<_P`OVF.?+S[F>(XX,I1O>S\E_P!XN.3^TTZ7MY_U2;2>YRQ_
M-]SGCCQP_4>7BE'_`'&B/\RR[^%B7_[YS]9?_,;;_P"Z%_\`63_XF?E__P"7
MM/\`WLW_`*N/_&S??/S+/TC&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(E?5/(^%)>4;5Q,,;))NPW>CW6^TSP!&@W$01%HFS?!%+<<OVY:<POXW9
MR`8`K239&R-"%LW0N@=X:3C?LWZZO!ZY=0V9_F^\.R*^&,YX_;/SSC&5QRR<
M8;CC2^Q]WS]_9LI7C\#JI0]G/TP"-A.&,Y(;.,#-@LSF<8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1,V?-&K
M=VM:@HA%(_;U25L^I;DA$O00B^Y(LBM*\CRH6G>I"X<>[.=FM6E>2HG-4*,:
MDW:4*H0#FXL9B522`PD4;LH?W'5VS73LU:POL;6M;BM@]EJUN#8;%NK997?4
MS(]:V*K,N55DDM1D^PW:;&MI2ZFNO[BL`M26OJ.""5^C8"G6L"NCLES*CAB`
M<R4?*SBU=5`<2JMD'#:-.BV?Q[D<LB-2VKR-!#>*4/9J%G@H#8$@A%KR;3I&
MYJA/>EA1L"]"8AJB8ZH,-2;0)2AA%V]TO[C9;OU>]D?'=;<9]D^UN44;65I0
M5Y9SM@I_7M1@_MBMGL/N(DX-)-C3KLHV`BWU=_9I%=?-NM;LK5[[V\@%3[<H
M/H1U(^X-J(A9'>5TXIKE/)FHO(8C5MR>32B,2&Q><\4?V3Z09`X(YS!JTB=C
ML4/@DU>BUB979D.;V!H1I3BW#1A3HG2EB/!O0A!W*(GWGRG5N[`"^[9_P[3:
MO%B!5LV7?I^=[TCZ19[CO:`0?;N/(?4`97]C9NHZ7?JU3[%5?^(`HK%9_NZ,
M]L5IKL`!%950H*X#5?3^@XG/6%6L1JO@[YF%QQ%PDR.?<,?,!DL4XGR);.I.
MO,XU1-AM2H7=+"*A"I=Q%0R)J5<P<2UC<3^H6)%7HIP1IRRB@1/0;^W9J?">
MUL<OVG8=Y5I;-S?59LZB]UL]<NO<3GW*AJ(*N)'ELVMFTEY)]SC]P^7ZP`73
MU>@.Q54`!73>>CJW#?6@`5+CL$6FU0'RJC/$`2?[%'Q1F7/3S>FGEU92%&EA
M?'CCE85;P^:6(YL#!%%0:,?1O=K5G'S'5O0D6DU.X49"9Q;][=DW<4`G0?&W
MLR&L>^GX1\BVNO+_`+WI?)=VK5="3L4EM#1>A*.)YCWM@'EP']1D1'/$*IEM
M%GV_F?QK6VPK=?L_'M=K48`4W$]AM+<;A^AA741CG_=J[LN,DCB&>Q>5A>JV
MLKODKQS-*_\`YU;!F3;M>VK/CXY6R5-8VN9W-6Q^!ZS.F"A;HD\9&RO&,7[V
M'8>_?3)GYGG4W_FJZ/&@?_ML;!I/TT![.Q&\U13/$4@WE"GZ.`*CP!(SXNNE
MN;?Q"NTM9UC=IWXU_>.#92JZ/V0M+_Z=8I%A;UY$MZSO>&],'&-==7+".7G$
MBB8M-N%%M-]MN]`SZQY%:]BN,JKUM<FZ^K;.LJ6*4B>Q*&F!JUY5/"Y-IQ+5
M*E*4\TLO]6&8^3Z`IL^0]3HV+3I[&NE&NM.!J:[+M*NKLU$$%5LJM.NK(RO<
MERNUA=%88_'=NR^[HMSLZ;+^\JW5>U;R?N=C%3?=:5BX^O-J)85PR4M3BI0C
MD&WOE$OS?`Y9=W$MT@M/FV32D%IM]E_(7C38S[/:9Y$-TH2R)ICT^F"!W4'F
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MYP2/0F9*[H&"$@,,'!QD9!P?S&0#@_B`?PGH7VFZ@E+'&8S)JJK>11N%C2F0
MZ//L&C#NQQ,:`@"9".,M+@UJ$#"-&F+"65M*65LL`=!#TUK6LW-;8^T-YV8[
MH.1822XSC.'_`%><#\?P'Y3"M5JUVU*@%U&]4'A#Z^JCP?4^H_$_G/>I()!T
M`V0Q!#8HB,C2MV7QP:2/-"8;`N?O'V^K601*,`FI6];4F>EF$>&-3X@O$V+N
MWUP7Z6#+X9:O:!'J*_I/MC\DRJ_1^GZ5\>!/&56!5@"I<.0?],`@/_WP!(#>
MH!(!P9_"F`0-8UOK(KA,15,LI<C'F3-"F-LQ[7(G@XQ.<<[/K>:B$D=W(TY&
M2(1Z@!AHA%`WL74(>GBJJ+6J`!:7YU@>`C<S9R3_`$6YDOE<'F2V<G,]8!C8
MS>6M3BY/\Z\>'%O])>'T8.1Q^GT\2I$4X)5DV<FN2O(V<%1>U-\@EM).C9!Y
MM7,;=V^KGBEH<NB"%WCCL[&.YBAR>2ENC]G`3(S$NR]`"(>N@M:^IJ/5:M]5
M9)VK>VNWEM_2]9NU]37:M2/./]D5RX()+8(^D$^;X^^WZ-L_315U5>D:O5'%
M>QL7BQAX&?\`:&0*00`,@_41+G;8&$3X7)Q,C0*2%-@V0J0[;4>WPMF-4@6F
MM!;MLGT\#88L+":)/HS16S0Z%L/=K6\VJ.!<IX-G'ECQRX9X\OSX\FXY].1Q
MZF>L`W#EY]OEQS_+RP&X_ER"J&QZX&?03CHW3=0PURDKS$*JK>*/$S"H!,'6
M-P>,,;E+`*SC5"L,E7-;6E5/H52@\9AFE0C=#&,0M]=[WO,>"?:'K\#[!AYK
MQ_3/@KY3])^EBOIZ$CT)F;.[[8WW).\OI83FP>0?#_J'E5/KZJ#^`GLH+6E<
M5>V*66LX!":[9EJT;DL:8+%6*(MBMQ-++),<%*!@0-Z4]:822``C1@V9L(-:
MWOIK6;398U:U,S&I`0HR<*"<D*/09/DX_&:A76+&M"@6OCD<>6QZ9/J<?AGT
MG;9A,XQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)73EC7$HM:@I_#(0
MY2ALF"Q"C6QHV(RY?!W10\M3BD<4*(V0MJI"J(;%!R?6E)6CBPJ"M;+%OM%O
M6]NKP3L-78L_NZ=JIR#Y4J''+FO\ZA23Q.02!X/I.K4:E79-@#V7J=3^8RIQ
MQ/J#G`R/(S,_YQ7'(^1/%T.3/5]T,R-#-"FQEBJ2URRTEFLRM!,TQ5E-+_\`
M2(`;<L33J0-[CZJ`6TD-["W`)T6I/ULO/$;G2JKA>=[A.7@ZYP178Q\^XA7D
M;/U?78O%,(6C5;4H?_:5-H2BOE_SOU5-;4,XX$*IKK/XX9BPY^)4<*_Y#D7K
M5-7*N7%JL2&5TK*9;(6YDCU6N"9OE,(45RPB*9G=\A"UW.:E1S\L-'Z2(TXT
M>PBV+].LW;ME-N[=;KC%#6L5&,84L2/'X>/P_#TD?KJ4H12""%'@G)'\"?QQ
MZ9_'&9.GLVW+^=6]_DW2_P!W&<LW1[-MR_G5O?Y-TO\`=QB(]FVY?SJWO\FZ
M7^[C$1[-MR_G5O?Y-TO]W&(CV;;E_.K>_P`FZ7^[C$1[-MR_G5O?Y-TO]W&(
MCV;;E_.K>_R;I?[N,1'LVW+^=6]_DW2_W<8B/9MN7\ZM[_)NE_NXQ$>S;<OY
MU;W^3=+_`'<8B/9MN7\ZM[_)NE_NXQ$>S;<OYU;W^3=+_=QB(]FVY?SJWO\`
M)NE_NXQ$>S;<OYU;W^3=+_=QB(]FVY?SJWO\FZ7^[C$1[-MR_G5O?Y-TO]W&
M(CV;;E_.K>_R;I?[N,1'LVW+^=6]_DW2_P!W&(CV;;E_.K>_R;I?[N,1'LVW
M+^=6]_DW2_W<8B/9MN7\ZM[_`";I?[N,1'LVW+^=6]_DW2_W<8B/9MN7\ZM[
M_)NE_NXQ$>S;<OYU;W^3=+_=QB(]FVY?SJWO\FZ7^[C$1[-MR_G5O?Y-TO\`
M=QB(]FVY?SJWO\FZ7^[C$1[-MR_G5O?Y-TO]W&(CV;;E_.K>_P`FZ7^[C$1[
M-MR_G5O?Y-TO]W&(CV;;E_.K>_R;I?[N,1(YN"GKVKNI+1L!GYGW6I=H+74V
MF36F<(M31Z!0XQB-.;VB(7$EUX28<C.4H0A-"$8!"!O>M"UOW<1/>?3Q8O\`
ME[=_V6G_`+^(E[<1&(C$1B(Q$J7+?QKTK]@-W?/"IL1+:8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B09R?_#3R
M'^PRVOF#(,1*4^C*/^!'_N=YA[B?G/>+?D9J3F<\C$1B(Q$8B5+EOXUZ5^P&
M[OGA4V(EM,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1(,Y/^YQIY#[_`/P9;7S!D&(E0/6A'^P,_P!8/]_./[=O
MX3=[HFF6=DTQB(Q$8B,1*ERW\:]*_8#=WSPJ;$2VF(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2F-N<[J'IBX8[3DK7/ZA>LVV
M:GTS8V4]UKVD?C.H]`@N[EE:<6V^#?'IVUM,WZ4[Z]>TP[11(PF;@=[Y'UNA
MO+HW%BQQS<#*5<O">ZWHG,^%S_:<#S*EVGS3I>I[6OJ=DV&P\?<L52U6OS.*
M_?<>*_<;PN?[3@',N668`T`#2A@,+,`$PLPL6A@,`/6A`&`8=["(`@[ZZWKW
M-ZR>!!&1Z2V`@C(])_>)[&(C$2#.3_X:>0_V&6U\P9!B)3;QDO\`D>__`&0O
M[V,K_#_/-7MW?F?\TT\Q-L8B,1&(C$2I<M_&O2OV`W=\\*FQ$MIB(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$S8NGR[FNT;0E[
MQ';.>J_I3D"L:U_,&EVIL2J4=YK(NG3E1]4WR(\>G*"J'Q.E*;Y&)'U]:M9(
M"M:*,[C=U/L/BZ;NV[UW-5U^T0=FH#Q<5_3AO5,XXV8_4HQX/F?/^W^")V79
M67:^R]'4;I!W==0"-@I^DACYK+8"V\?UH,>#YFC+6V-[*V-S,TI"4#6TH4C8
MVH4P>Q.B;T"<M*C2$`_]`E,G*"`.OZ`AUEJ1%K0(@PB@`#\@/02^UUI36M50
M"U*H``]``,`#^P3SLRF<8B,1(,Y/_AIY#_H_L,MK]/Z/]`9!^G_4Q$H/Z5<O
M^8JS_P"WY-^Z\A?J_*O_`#M_W)ES[O\`T-7_`);_`/<FM>34QG@N3FVLR!4Z
MO#@A:6Q"4)0M<G)6G0H$9`>G<<J6*C"DZ<H/7W1#%K6O[N8LZH.3D!<@>?'D
MG`'^4D`?F?$R5'<\4!+8)P!GP!D_Y@,G^$YE@LFNY6NVUQ>?0N2.>B3%.VY@
ME+&\+M)RMAT:?M(W+E"CP2]CUW"[>W7777?NYL".REE!*J,DX\`$X&?R\G'G
M\?$UET4A6(#,<`9]3C/C\_`)\?@,R(>7+=:#EQ\L,%.2F6Q*P4;>D<V1?!6I
MO=Y4NVWN*54I8FA.XI%Q1!KVF+$G&>64,\HH8A%]!]-ZSU`A['5:X_[*NU4;
M%/HU?(!E8^H7!Y,1YP",C,[=,4O8U=V`&J<!C_*W$D,,^"<C`SXR0<3-ZRWK
ME"&27'HEPY*)8X&1G[F`HJVS$1[,Y@<);]"J2F_5K:<8;&79K+CWQF$T>.F[
MS3?6`@"$HZ;*Q5[*^UDW?<-[7+\;_P"I[B69_P#)!X]HOBL_T\$Y;.VO[#Z/
MN^0SJU\^'H*,:_N,IQG[OF=CQ^OB#@>*Y9B%HKO)YD4TNN*10]S"X\9;'.:F
M)@C*IG>XZ[[>Z>%)")$\">'!M?-B7B$$O:4A*`&P[WK6P[UGNZ*!NW#5Q]M[
MK<,>G'D>.,^<8],^9$Z_(T(6Y$\1^H8;^'(?@V,<O^-F:-YRS=&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(,Y/_
M`(:>0_V&6U\P9!B)2;QCO^%,_P!V+^_F'!/R'^:9<V_,S4S,YC*.\]^/M2\@
M:E8&VZZ-6\C*^A4Y:9C(:H(L%PAB%_:TR1>WKSW6/A>F&-6LG;"%WI!48>3]
M(7%267V_M`"<C=M-2O=U^QW*3;72+0#CW/;+IXL]DGC8591Q8`VTL1;4"RD'
MKIMVCIWZ6K8*VN]O/G@7XN#P%P&:PP)#^0EB<J[#Q:8O^7CQ1X+7QR"5S2K_
M`"V*EXU-U&RI[E,6N2D7BSJLLJ(3:$SI$WQ"L[<2$L<`+<AV1"E?K]8P)E;R
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M?TI<XM*C-K'Z'\BIWQB)4N6_C7I7[`;N^>%38B6TQ$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1(?G=F/;'(DD)@<'46%,S&?4E<FS3ZW1EL9(X):8WIUSD].19
MY>ECHM(-*1IBRAB.$28(6RRP"'FFRUE;A6O)\9]<8']O_:EDZGH]7:TV[3MM
MH:?6"WVE;VVM9[.(8JJ*0<*I!=B0!R4`$D"=9`9PV6#'"9`VD*D(P+'!H=V=
MP"4%R87]F5FM[RR.(23#2=*VY<0(&Q`&(LP/:,&]A$'>\Z[!8O(>/S'Y$>HD
M=V_57]/NG3O*N"JNCKGC96X#(ZY`.&4@^0"#D$9!G:9G(R,1&(C$1B(Q$8B,
M1&(E6+'Y:0&N9JJBI[-*9(TQ3U:.W9U&F\MQB5,D/H]$L9LY6!.T>68L&+1A
MY*8L\U`CWI2H"`K>MXB6@2JDJY*F6HE!"Q&L()5)%:4XM0F5)5!83B%"<\H0
MRCB#RAZ$`8=["(.];UOIO$3]\1&(C$2#.4'X:>0_V&6U\P9!B)2+$35#$2B'
MF0\>*8Y#\2[50W32!G(9MJ^)2VX(;594QL&$&2B?02(/SC&FL+Q6DBC<E%ZS
M4;VE\(!Q@1Z.]PH8]!RN_)&32T&[Q*A9OZ2.U9/,K7S`2RQE0@NB(2[K@L54
MA,,09.=`IW.PJZ6VTU:&[?4EI`7..8Q@L/!!/@Y`S^K(GS[?_P`^T2X\P3E7
M/&ZG9!Q+NU\FW%9)8$ALOB>IY%)2J#,63V))UW'>W66W+DM9A'(W14I+6(%0
MRVI^UMC6`/2EE[WU^AUH^OTO9]?3:=C1UMW4"[B!?M]_DNZH:H`'B]0J]XK7
M8RFO<KY^E9-'V+!?V'6[EU:U;&PNP3IL6.SHLB5'G:?IYU/[SZV713[M.4SR
M;C]?&5Z3D8B5+EOXUZ5^P&[OGA4V(EM,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$2%Y]6TJ=9*GG5:S5+!9EME)BSPH=8Z7*F)]CI#B:YHR%C4)P:SB7)H5JE
M`TB@L_7;I08`81!%[FBRIRWN5-Q?&/3((_\`J_"6?J.[Z_7T6ZGO-5MOK?=-
MJ!+/:LKL*A20_%P5<!0ZE?Y5(((G85[!4%>QL#$C5J7-4H<'-]?7M<$H"Y^D
M;ZM-<7IY5ED!"028M6G"V$LO6@%%Z"`/N!ZYG76*UXCR?4G\R?4R-[GMKNYW
M3MVJM=81:ZT7/&NNM0J(,^3Q4>I\DY)]9W&;)%1B(Q$8B,1&(C$1B)5BXK3E
MSS*2J"HHU..T'1$0NFDV.3Z7,-)0Y:+LW(G@O>])UTQ=2>X+(TB%H9QFO2#M
M:3E[V-$I!)>6D/XR.<[K>M*<463QQXW+$B;G9<CR]I?C1'I'8J9.>-V31UU)
M]96X]D$KP.<H'K6BPMYX2D?BF%^`&H]C\H.GMVBFDV=;J$#:LS@U\OT\%]7X
M_J?'HOZ<GQ/G?<?.WZ[LKDU=4W]+UY4;U_+B:2_Z16A\V\`0UF/Y3A<MXEE8
MZ^BXL+F3PUJA\X@6`8@5PR1#](.,H-RD>RE+8RNABC7I?T0R`Q8#U>I-UK;$
M>9H@[>DX@"!;$=;$%B'*,`0?X'R)]`JMKOJ6ZHYJ=0P/Y@C(/^42]Q9A9I8#
M2A@,*,`$PLPL6AEF%CUH0!@&'>PC`,.^NMZ]S>LRFR?WB(Q$@SE!^&GD/]AE
MM?,&08B4BQ$U0Q$JSS?G+37'$#DI+GBYF/CP6WTO8:5LNR0O/J%MK62N\9<6
M>*2K3D%>UGEN#;)5Z42,LA04I/5^&43OQ1@R!^2W64]/8:+S1M$K[9`)=F#!
M_;K0>7L=59509Y$X((S)SXTE3][JML4C8TTN5[4.`IJ4@V<R<JJ!<EV;Z57)
M/@3&+R8.5T[L:T$E,OW,#R[N4S8X<8&FVG!;PUJR2LEMEO3:]0B-))'R?FGT
MBRB-(+'>"I"J$N:53<D<E+B-0<#999!I8K_M45V4]F12J#3W*`AUR!H)]Q]V
M"FN/(88U5*A"!74*^08.G&CI>:VZZP6EK-T7!A>"=LK2B.#=Z,F&O`YV!@[>
MXO+W#EOI#RO2<C$2I<M_&O2OV`W=\\*FQ$MIB(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B9M6I==W\@[(>Z0X=/[%$T5=)-/=E7K("A*F)2\%JUZ!HKZ!$`0.9
M3]L;VUG%O2X)>TY!:<Q.6/Q=BWK398X?VZ@"^,G)P`/P_P`IEEZOJ.L;KCW/
M>W7T]>;C36M**]CV*H9S];*JI6K+GSR8L`!ZF3AQ<Y)*+B;GN#V*SIX1?=;+
MW&.V-#RCMFM;HK8EPVA7-($M,T#;["7=85W%FAUXB0P?@'Z"/6N[*NSW%Y8P
M<D$?D1ZR/[KJFZ??.F7%E+5I;6X&.=5J\JV*_P`I(\,OG#`C)'F6US9(J,1&
M(C$1B(Q$8B5JN:W)$E?$5*TN4@>KME"#2XQ2M`)5'*GB1QFTY]ASG1.^H2@"
M[@-3=O83G17K00ZT4$P>D2)X1PMDM?(G1-&N6%](5,A>ELFD[CI-5ZE?()(Z
M;"-P=G!<XP%>XG['L.@$EF'F!3$!`47T`'6L1,Q.4=7<7D/*2,BMF^>5$RDL
M7%"R;NL^*H*Y-I2JNUU$KI8'*<EL@R>/.XOC,;XC2%Q3JQ-6A@4*=%)1`%E$
M[NSXX>\J?=KL>RKC[SIGV4R?Z/W6/#8;RF?T^K?3B?)OD]WPH_*J+NSIOLOI
MX?<V5Y^VKR?]G^^`^EN+^:^7E/#-].)JZMXP3:2,ZIO<.75X/D??6TY(L1*&
MZG%S2ZM+DF$4<085NM3$RE$L2';U_2$0!>YEZ!!&1Z3ZPI5@&7!4CQCTQ_"<
MQ7RB0\-5<8J>Q96]S:@GD]#'JRMV4#3FO=?ORD7@HZ]LQ>E3I$06%R.$$MB=
M?#*+*%T1G]/U(]^SV7RQ$8B09R@_#3R'^PRVOF#(,1*18B:H8B5IYF)4BGB9
MR1&KK2.W&)MI.RGUOJZ5PPZQ&"</<?B3J],,>7P=,C<%LHTX/*`@!:-.2-4<
M;L(2>AO9O5=^5FY>@V'UJQ;MA0*QP]PAV(0,JC^9>1(.5`]695R1._&$KM^0
M:=%UAJU[-A$=N80!&8!\L?I"E<ABWC&<@CQ,"_(8DDD/LN2L+A,966G.H1G6
M/-7*?)>0^75&HB^-3O%$Q;;]/C8H.*M-;%=.2E`E:C^IBPD9J\._U(\^BW>U
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ML5&2OZ3_`!7U^D^H\^A&?,T3SFFV,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1,S^0
M?+*MY18;GQQ;KD9:QC3.6$-X66!>I3NY20_8BS*QKE8E3'EZECF7K8'1P"+_
M`*G3"V$'54,.@(GF+;?X6MJ*+$59R0C]-*XA'00YL5PD*!20=$0G>D^I')ID
MD<>FM?X2S8CR50RMJR5!IAFC.XP?=ILJYMS5BK^F1CT_+SF6'J>^'7ZK]?NZ
MM&[UK6"P5VEUXV`8YH];HXR/##/%P!R'@3FIS8G#-UB$:)@'(Z*0RTZZ7.4B
MKVTC52]R>R9.[GF+9!\;Q;1%;DT=FRHT87E$;^J.`/N+"`996PYHBUKQ7T_[
M/,CNT[/9[?=;>VN(L(50JC"HB@*B(/P5%``'^?)),M#Q;Y2P[DA&W0M$N9TU
MB0E2%HL",M:XQ:A(6@WLLJ0QA:H)3&O<,?NWQ42L(/>Z%LDWM-`+6\Y'RU&(
MC$1B(Q$8B5UNRY72*+V:K:O;4LKO*=ICS(PQ'B'MGB;(6/2=PL:>'DZV)NB3
M$,?4(-]#G)5H*8C6Q"$(")TU+TVT5`Q.!?K)9*YQ+7#<AL>PWD(-O\WE!Q>@
MG+U>P[$%"U(@?J&YO*WI,@2!"47K^L(2),F(F==S>7C$;6M-^E+;8<H@54W*
MJ;%O+&CXZ0E#%N1:N,%$ABZEY<1C"Y112H`G+1OPV_81/S626E/Z:UL>ZMO_
M`!>C=W&M6UZ]*\@[-2_IOX_IR?5?R?C^M0%,H?;?!=;L^R?9KV+:.LVB#N:Z
M8X;13]!8_J0GTLX_WB@*?SFA#<WH6AO0M36D3H&UL1IF]N0)"@$)42%$0!,D
M2)B2]!+)3IDY80`"'6M!"'6M99U544(@`0#``_`#T$O-=:55K56`M:@``>``
M/``_@!/6RB+QZ:QUYB4K:$+]&Y"WJ&MY9W(@*A$O0J@;+.(.*%_=UOJ$6N@@
M#UH0=Z%K6]93.5-A$ID/&V6L5*VB[KWRJY*L+9Z+MQZ/&H5(58]?L5060YF=
M=>O4Q0>QC=#A!TZ$`\`S?I(->(B70Q$@SE!^&GD/]AEM?,&08B4BQ$U0Q$@W
MDZC<7#C??J!HL9+4#JMIFS4K;:ZUR-9D=:KSX8\E))TK=R-"4-2:*'B"N,4E
MZV80$C8P^^#K(#Y0CV?']I4M6EO:/U,Q12`02C.OU(+!FLLGUJ&RGU`29^.N
ME??:;V4M>@V:R:U4,SCD/I"GPQ/X*?!/@^)@7Y-=%RNCN3[R@-H""<+F&4\1
MV612&J6/F2\<GW+E]*39U'B&[F2SQ]<:H#!XV0E"M0F'K1%/"@;^04H)#H'7
M5\_HU:/:ZE5!T]:K>U%KZ[B">J/'=Y5O8"4'OI[5"I665CU[LQ'%.5+9;;-C
MJ]IG&SL/5L^YV7(@=DH77(1:SAN53M]VUCA2J[?!`0]A3Z9L@I-S@5M4U>Y"
MD@W&N(&O%,E[6ZR\2R(L"H4I<V,10V5QD6SV\>WM<T#(!M,:I\4PC8-;!L.]
M:SU24"!#@5N77'CBY]77\F.3EAY.?6"2Q+-Y+)P/\4_T3^:_\7T_A((EFM:Y
MK4IK6M:UJ@+MUK6O<UK6I?4W36M?T:UGGKY/K/``!@>`);7$]C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(E0;1GLLMJ8./'RD790SC;MEDWA;[=H)A-9-"HL)@H;%E.
M^XA5:\A1C_5A]\%G3#])-_6[*!B)8.#5G!ZXBC-"XC'6YL8&)+I,B3>`6H/,
M$(6S%*Y<K/"8I7N;@H$(Y2H-$(T\X8AC%L6][Q$ZSU4U_P";4'_0T_\`R>(C
MU4U_YM0?]#3_`/)XB0-=%)'S(QBG]:N*.#W77X5!T(E04_:VNB)1L)KE`YLD
M3:`-XA$D\+0#RM]3$AW:I(V$T'OD3W=)W.BMIH=4CBTGPVRH4M`PV973F:`;
MM$G_`$5X@1E#UVZ=(T]%:](:W$O7@+4PM"UO0PC`%$FW$1B(Q$@6[;E.KHIE
MB,*90SBYY\-0AKN!EG[)+.&1K6G"62I67H0F*"1DL?C+U@M:V+H$@GN.,#K$
M3R:4IDJL43P^R)X%-;9G2@EULJPU9&B5+XY%@[4S0SI]]VV6&QXL6R&QO+WH
M!).NX7<:,8MHDXXB,1&(C$1B)R<X@\6LB*/4)FC.E?8T_HQHG)N5AWL(P"Z"
M*/3F@V$Y(N2'!":0>4()I!P`C`((@ZWI$K-6DXE5*3%KH"Z7E6]M;P8-+1-Q
M.PM?_&Z$@`AEUY-EW0!">SF-(#H2:+M"]I0>*#]H":#:)*7*#\-/(?[#+:^8
M,@Q$I%B)JAB)'5OLM<R2J+,CUP`:C*G?(#+VBS`/JL2!E%`7%@7I)=IU7@.3
MC1-_J$T_QC@F`$67U%H6MZUO(WN*M"_J[Z^S)&CP)<@L&7C]092OU!U8!D*?
M6'"E?JQ)#JK=ZCL]>WK`3V*W(:P`#E^0XC!\')\8/@^A\3)3RT:'X45W;LGE
MM+WMS2NRUSZ9:6&#E\W9!=BQWAG'%5(D2],AX^-ERU_7QJJIE[^A;`J%S:%T
M+T-,B`8I#WAT;8Z[=_\`;=D7_P!3<LV*?O+K0/O7L5;C0-L?2Z`M9MV(#76K
M7-L>K(52O65Z+[VLM)XZ-"6G4JK).DG+@EC:Q'*MW6M:J^2V.RT%,?19R?;#
M(Z2,8B5+EOXUZ5^P&[OGA4V(EM,1&(C$1B(Q$8B,1&(C$1B(Q$8B50MFSI;,
M9<HX]T2X!23LQ&G567902`+6FE(LXAWX9^@BUM,XV0^I]"TT-PM_JM?M:CM*
M`'0T2;ZPK*(U##6N#PM`-&TMWC'GJ51QBQV>W9:9M0ZR!_<S]B5.SZ\K1B.4
MJ31;&88+^@.@ATB2!B(WO6OT[Z?HU[O]W>^FM?\`EWB(Q$8B5MNNG7U\=6RW
MZ?6H8W>D-1"2MBM;L1,?L2-:-VI65M/@E:V)0QN0^NT:OIL]J6;T<5OM\0`T
M3M::N!CN*,GNB-"NC<H8%YC!/H$^:"3)8)*T@=>G,;RFUT[@;Z^*D5`UM.M2
MB`<4+81>XB2[B)"ETW(CJIJ:T+6U'3&S)HK,9*UKMN.`6YRI]\/N$<H,WW::
MHPS%BTH<W$W7@HTVM[WO8Q``)$]32%-KH)MZGEA.Y$SNZ?A3GSJ8`*&!"@2D
M;$:VP6%ICNHV:#1KQ=@3$ZZ&*C>Y0?W&C]ZB6!Q$8B,1,Z+F\PZ+55:,BC;3
M7<FGU2THK;4/+2[H^H2_%OCRKDQ)`XVE<6TP.W*6*D)2DI:_EH-"VQM1Q:@W
MNWO98:MO_**-+<>I*GLTM<@;-J_IH+?I!'JQ'@OC]"D$RA]M\ZUNM[*S7JU[
M+^LU"HW=A<<-8O\`I!'JY'AK`N?;0@G\IH6W.*!W;T#LUJT[@V.B-*XMR](:
M`]*M0+2`*4BM,<7O8#DZE.:$8!:WO0@BUO66=&5U#H04(R"/0@^AEYKL2VM;
M:B&K8`@CT((R"/X$3S,RF<8B<+9-;Q&V8:[P6;MFG-A>"R^_0#3$J]N7)C`J
M&UY9G`C8536]-"PL!Z522()A)H-;UO\`3K:)1*R+'F$`IF^./-ZN(G*4GT+<
M8ZBM8XHM,@N:.MU?O^Q(7/P]!3-MJ,"3M]8HM=-+RM>EI^NA&!"B<OTW_<W_
M`*V\1-3\1(!Y4/U9QKCA=KI<C2_/U6ZK66H)VQQ=DDL@D#S&W9G5-3DU-39$
M&]TD(U:\A9LH)J<G?HW?XPQ%E@$,,3W>U5I==9LV>Z'3#H:SQL%B?U*V1_2M
MU=`R6.51&"EF`DMT?W0[;7?294V4L5@S>0.)R21ZL`/Y%!9O1020)0/@U*:[
ML>Y8U,F&Q^9]_O"3C@I0Q^<<C:G.K*&TS#WJ0P)S.KM&L%25*$3RPY^<E1J%
M3QOXP*E"6-=3%981!VHMUFO?J#M*;7K>\;.NEU^.#;3(=L**Z!P%25'W+;`M
M-8Y;-:G]"HE4UK:;-+KEU_<KT"&LKU`>:T?TE"VV6?5[C)6YUJF-SD!K2H(L
ML>:]9#R5C$2I<M_&O2OV`W=\\*FQ$MIB(Q$8B,1&(C$1B(Q$8B,1&(E7KFMF
M4G29)0](:2+[AD*`#@_2%43M9':8A:H>R3)O*0@WH![RJ#W`9&K8M&+U.M#'
MK2<`Q;1)3J6IHM3D3+B\:"K5G*5BEZDTE=SO39),I0XBT:\2F3.0M:-<'=T4
M:[A"WT`6#02RPA+`$.D23L1&(E/[O.@HK+:TE\NPF>H?B5H^+#7NSFQ1-=8/
MK=:!X`^.+:I1AV^HV/T,322>9K0]F*!%!$:'73BO]OW1]P<4\?'X#.?.?XXQ
MB?1_BR=M^QO9\2K]SY']UBWBBO:NOP7@45@?Z9?F+BH\80,0IDJ<?E,B55PF
M,?3',]%I]DA4+5OOI/KY=7Q3PJ!"UCUZ:$"T2X]DT7O0C]:/,)\,1GZP0LW:
MY8U?5G&3C/KC/C/^20'S!-.ONF74""WVJS>*\>VNP4'O!./T\0^?"_2&R!X`
MDV9OE7C$2K]RU-*29,CO>C]HT-PQ]`6WOT?5'>A1ZYX8E%LXR$2H8=>&0\)0
M]PF1U%K9B!3OL'O:<8PZ1)1J2V8O<<3+E$:VK1GI5BEED\9=R?0I)#)2W"T4
M\1:3-HM[,0.[6H]Z+6^H#0;"86(98PBVB4`LV#6G7O+9XL1ZO-P@,0N=)'X9
M6M@#KF&S1JK]R2E!`*IW99*`&CB"26N0=K$2LGL3.*O>R3Q:-"5K:)9WZ&^3
M7YQG?^!=4_!L1'T-\FOSC._\"ZI^#8B/H;Y-?G&=_P"!=4_!L1'T-\FOSC._
M\"ZI^#8B5%LWRNGBVK&,LF5\J)L6L>QQPRR(FPUI7[%7]RCABWUE#16W#6\L
MIHFPXXMZ;+$I#W'$@`2=LPD(0:K^]\;Z[?WEW;>:@X]VM3BN_CY3W5_FX'R/
MS'@Y'B5'M/A73=MVJ=I?[J@X]^I&*U;/#S7[Z#P_`^1_I#"MD#$ML52O)0@H
MH@CF"YD$$E@*)))H>IBBB2BPZ`6446!*$!998-:T$.M:UK6NFLGP`!@>!+:`
M%`50`H]!/T^AODU^<9W_`(%U3\&SV>Q]#?)K\XSO_`NJ?@V(CZ&^37YQG?\`
M@75/P;$3.[S#X5<#S2UB4N?R$77%/'.M9A.BXGJHZVCR>#1N,,;DL76)(I<T
M$!=H<E(+(-2HAIA!6+U!NR2@B!LW842QOIJ;^[O_`'&\1--<1*\<II/=$&I.
M<SRBE$&U,H+'7^8FM4YK^862FDC7&V)R=E$<8X[")Y7ST*1NYR0LE*9I6<#0
MA;UX!F]ZZ1W9;-^G1]U7[9H0'F&R/!P`Q<9X(A/*QN#X0$A<B275:E'8;E>A
M8QKLNM1%<D!4Y,`2P/KX/C#+Y]3*8<..8-OW/>#56LSN'AS=S`Z<<R[<=W'B
M='K!T=6LVW)XRR_$Z?/DCM>P6IN3NB1Z4C:B%*9M>%PFY6,Q*F`F$$RQG5H*
M]BU1:S6U;]9*+P5]J];?N_<QCDI=!32_].UP$N5F.&0M7:]FYM;K[[`E6SM>
MY[NNV?>JX5UNI*_2RJ&9J[&=%XV*M8#,[>WJMD;)",1*ERW\:]*_8#=WSPJ;
M$2VF(C$1B(Q$8B,1&(C$1B(Q$J)R>Y-LM.FQRMF*3P=EM^R"%8HNHGSX@8XG
M#V)*+P7:P96J7J$P#6QFV+M3(@"\=R6=I`-=O>(*)Z2G+)XF4]&3VI%R+JR1
MR9^7&/\`/9X^6+$C9+/)6K#KTY^>E`73H'7N>$E2E]$Z)*`!)0=!#[J)+?M4
M<:/K^I[^(D4_>F(CVJ.-'U_4]_$2*?O3$1[5'&CZ_J>_B)%/WIB)'4\YS<7H
M@)O0%VE"YN\.03U:=AA\HBKRM*;T0B]+'18,YY2MZ)*FV9K0?$.":<9OL*",
M776M5EH0A<%G/G`&3C\Y/]/T5_9U/MM?KZF@C!#;>_MH7(R*UP"68CR0!A1Y
M8@3K6#F)Q9DK,WOK9?\`4WH3D1H\D"R=1U`M)WH0BSDRU"K<"E2-8F.`(LTH
MP(1`&'>MZS-'6Q0Z^AD;V&AM=7N/H[B\=A,>A!!!`*LI'AE92&5AX(((GN/:
MHXT?7]3W\1(I^],RG%'M4<:/K^I[^(D4_>F(CVJ.-'U_4]_$2*?O3$2JMK6M
M2D5F)W("BKPIH^?`1IDMDUUNS8B@9[KBK:'?AI3!C<_1V^Q6)-W;9W'>NIG^
M*'[$2,.P(EN8K)JCY6TLE>VXMOG%7V4R'$*D*\GJ`TK9@DZ]L7D=WB(G5H<"
M!`%L`M&$*"M#+%U"$6(D1U_,I-0DR9J)MUV6/<,?SMM]#W`[&;,-=PE`&,FK
M+!<!:T43.6I*#M;5IFPA>TP/\J`,(T2Y&(C$1B(Q$8B,1&(E?+ON9=!#&.`5
MXT)YG>$_"H)@L/&:,"!O1D""6Y3N;*B.XQE@T;T/O/.%T&J.T%,1W&C]ZB1#
M,Z815-Q4Y/+7-X432RYM35L/MEV*YD@+=)6^_1[(`%E$$AV(+3&F4G?H[8W%
M;T2D3AUK6MC$,8D2$,1-4,1(COYU>&*C+B>H[,8]7C^U5C.7!EGDM6!;HO#7
M5)&G(]OD\A<!D*@(&9D5``I4G[*-T446(?8+IV[XNP#OJFJLMS=ZTPC^V[\[
M%0UUV$-[=MH/MU6<6X6,K<6Q@R/45I;VFO796UM9M4%%7D6&?0+XY?\`>Y&?
M3,S:\NZK>24)G3O\=ZKL&H*B8D5R:2#LVXXK;$@M5QL6=P.15XYI7&+3*9KW
M5!`&&.O80N;\8A7]C^!.F2$DZ-`"?K--/4_;7)[6PE.K0E)7B]3:]FZ;7<`N
MBEJK]6EBMMKVMKDVN154SUT.VSLKLK_5NLL%S;*OFETLUZTLKK7",PLV5^Y1
MC76E-8XU(#LVK7L#D;)&9ANWF"OPWRVV"*U6A6KXA/7^(U^5)'U\C.IJU5R.
M9$VC)S%2F+&MXFQH5U^Y)D8FXY<$2L9!*G9`A#V'S5/OZ-?8."*238X'ZEUR
M,I8`<$N^5POA3]6'/`Y[4TVNWGT*/-JJJ`G(4[#-6!7RP0%46JS,?/$9"D,I
MG61BX6FV>9]/J&B)V$P)DW&FS7HISE\-=H^P/261R"H'!+J*OZTH#=)])B3M
M>,-((P`/<WUZ;UG1M4'5VK-9B"U=C+D>AXDC(_MQ(ZIF>L,XXN1Y&<X/XC/X
M^?0_B/,T0S1-D8B,1&(C$1B(Q$8B,1&(E8>0G'\FS#X_8\.31Q'<]=DJ]1%R
MDK2D=8])6=5O1KK7LT2*2#Q*(O(-@]PT'0]O5=BDG?<$01HG\TNXTS;["X':
MJ>'Q6;1-Q%'K&KUYB,<"_P`(E!`-".;UH0M^@K&U8#]>WKBNJ=<E$$PO?]8(
M429/HLK'ZN('\D(_^[L1'T65C]7$#^2$?_=V(CZ+*Q^KB!_)"/\`[NQ$A">4
M+Z#+R[`JB!4RN=5T=1Q*0QB;QI*A9E2!N=%;HTO3:Y,S.L4HG1L-<U(3"A$C
M+5%&!UL0!%@%G/8EHL]VG!;&"#_;D'(ELZGLNDNZO]C^0C8342]KJ[*`C.'9
M`CHR.5#*X5,-D%2/0@D3KJSX\U["(R-N=H?`WQ^=GI[E,C<BX8QIT1[_`"->
M:XN(6M&:C.&B:DHS-$IR]B$+118=BWL6]YG36:TXDY8DD_VGUD=W_;+W&^-B
MI#7JU4UTU*3EA54H5.3>,L0,L?3)./&)(/T65C]7$#^2$?\`W=FV0D?196/U
M<0/Y(1_]W8B/HLK'ZN('\D(_^[L1*G6DE89[,E/'^B(7!&V2D%)S+<M<B%QM
M6WT['5P.X+:V;&W;3.%IR))L6F])ONTWE"]+4!T'181HELZUK>'5'"6"O8&T
M$LD8CB3T5`C*]\88888-0L7K3^FAJW)R6&C/4'"]\:<8(6_T],1/WL"OXG:$
M1>8/-FHIXCSXGT2K3#$(H\@XL83D;BW*RMA4-[JVJBP'IE)0@FD'`",.];UB
M)7JK9]+ZNEZ#C_>3N:\+UVE`:6MU=H!)%JLB('B;C,E-#H*=%:\>2=-*"O>A
M=R`^E$:V/Q0:1+<8B,1&(C$1B)!5W7075R%G8HVS#F]MSM0<T5I7B,_12E[<
M@`UM2\/*C7=ZDA<>`/1[FXF:T625K0`]QHP!VB?E25,&5R4\RZ:/`)O=$]VG
M66+/C"-E!4"([A((G%DIG<-B@<9"9LI`B!O77ILXWN.,%O$3]^4'X:>0_P!A
MEM?,&08B4BQ$U0Q$A7DB>V)>/5YJ'N*NTZ9B:BL4QUA;"Y+69[EC<&).VUL=
M:7AL,*<6EP>4_<G)5)Q!/3C,T8#>A!UD5W:\^KM3BK$\0.5C5("77#66K]5=
M:'#V.N2J!B`3XDS\=]S]^T_:L%-OW->'*AN!Y##<6^EL>H5O!/@^)DOY;SW.
MH7R0D/'R4LY;0DAM,.PV]B;>9/,3D<EBC#''RM4,(4'PWD,G^*L?C<YCLCV=
M'7I,<)8N3MJHHK0BM'"U;F9MK5["V]R^Y3M4K:S(H87-9NI94[-BRNU?86TU
MKE;*[E9L>VI:GU^W71U=VJBIJ;=/NH@<@A'H6T,$7Z;*U9VIL<X6F]5KQSL4
M+NED-)>5OD'$7CI*5,\6OE8,RU79;PU/\Q4^EO"<]Q=&<\:I.H2F)7$D3,!4
MI--,6%HMIRUXSS1*`F[-'W*OZ*5UUX"57&U1Z@.01DY]1AFPIRHY'`&9M>ZV
MPEF8\FI]HGTRF0<>/Q^E?J_5]*C.%$Y21I4R'F;1B)&02E1H^/5T)4B5.6`E
M.F3)Y94A)!!!)>@EE$DE`T$(0ZUH(=:UK,G=['-EA)=B22?4D^23_$S0B+6@
MK0810`!^0'@"6[S&91B(Q$8B0[>%\UCQUAI$\MA]4L,<5R!GBJ$U"R/4B<'"
M0/YIA+2U(&>/H')U6JUIA0M!"42+?N;ZY8/C7Q?NOEO8'J^BJ6W<6I[2&=*U
M6M!EF9[&50!G\2)$]SWG6]!J#>[1RFN;%085F)=OTJ%4%B3_``$]71/)*H^2
M+7)W:IWYQ>"88_`C,H2/$:D<3=F5[,;TKJ4B7,\H:VES)$<WK"C0"V5VB`/6
M];WF_P"3_#^_^'W4T=[4E;;%7N5E+*[5=`Q4E7K9E.&!!\Y!$U=+\AZKY!79
M;U=C.M+\'#(Z,K8#8*N%/H0?23ME8DW&(C$1B(Q$K/<]1R0]]1W=2@T#1=L8
M;](3T2TS:6.VW$2![4'UY-A%AWK6Q^^$TN6PB.:U8M"UO9(C`;1)#I^W8W<D
M4U(F0E<T.C<M/8IC#GLKT23P:6-_0#M&9&WBZ#3+D1N^H!ZUX2D@0#BA"+&'
M>(DJXB,1&(C$1B(Q$JQ<-IRI[E&Z`HM2GW:CF@3K9G-#4^ES%24/<.X'QD>`
M>Z0LF+H3H6F-I%O0CS/V@[M3E[V-$E^J:KBM.PU##8F0HVG*-4.+N\N1XEK_
M`"F1.`_'>91)7,S]>Z/KRKWLT\X>_P"G0`Z"6$(0HDD8B,1(]M&L(E;\-<H1
M,D1BEM6B(5HUJ,X:-XC[V@,TH9Y)'G,GHI:G]D6A">E4%[T(`P]-]0[$':)"
MM26?*XI+2>/EZKP*+"(1J%5<V&(@*%HNV*-VM=Z\G0=!2H;#9$W;IY;`[ZBW
M^U$:$0/?8B6LQ$8B,1(;N>Y&FHF-N$%M5RN=2U?\7ZXKQG$#;_-I,85LPM&E
M"+NTB:4!?Z]Q<#->CH$H1&&;_JA$B<O2%-.T26O5H6DY(Y9>L]()#*G]*$P3
M-%64LSTANKF!E*->(W1!A$+W1=`G.*K0E)_48@Z`B6,Q$@SE!^&GD/\`89;7
MS!D&(E(L1-4,1(BY`))>NHFYD5?O"J/3I55L]3PU^0NC4QK6:3FQ=T`QN:5[
M?#4[,S*$+ELLP"M6,"=,(.C#!:"'>\BN\-@ZJYJ\?2H)S9[0*!@7#6Y!K4H&
M#."&522OU`26Z+[;]ZU/O$YZOW%?)>)?DO(9'!<ER?P4>6]/QF%O!"UI`W7W
M&TW'JF6QXB:ZDFIBO2$PKS)*"Y.K5D_%+(L7NYW)I7W9*7]*TPAN$XIQN*0D
MA:^;>-%G)2QD)]#MM"TV/OTUJ:OC[;%!UF*$C6`&U[BMQ#%3<GVR*@9U/L,_
M@@EJNWN5:NK;M-[OR7%GOOSQ]R!6I"*C<4)]TVW<RJ&H?0N4L?A]%^0\DHQ$
MJ7+?QKTK]@-W?/"IL1+:8B,1&(C$3+[S65$L1T]12R$63$J@DR7EI2)K594[
M;4SM$8>L],>@D/+^A6*4:50WIAB]^$PTL(NNM=VL^U?X&IHV?(.SJ['3O[#3
M;H=P-KTL5MM&$RB$`D,?PP#_`&3YM_B<VRG4Z3ZFQ5J;`[37XW6`%*SEL,P)
M`('\2)R_E@+)\X2WFXMLFZ*]O^4FWK#@+K.JYF0,4,>_!J&'@));&]L<75"4
M-M3>&G-[%!FMFE"WO?7>=O\`C57U=.A\;JZCKMOJM(=9;QUMEV>Y,[5N2S,J
ML>1RPRH\$3F_PW?=LV^Y??W*-[8.[7FZE0M;8HK]`I(\#`."?(FM.?")]2C$
M1B(Q$8B,1*K7%5DN8Y4"_J)3I]6>VHB$,V@YJ@"!BNZ'HM['\7W8P71,@FC2
M7L0F1V%K8BA_LQV]IS-]B),55VG$KAB".8Q%2>),8>H;G9I<4XT+]&)`WC\!
MXC,D:CNBAJ?6=5K99Y(]?IUH0=B`((MHDCXB<G+YY"X`@(<YO*6&*-ZI2!&E
M5OSFD;25*H?Z"$XE)A?C&:#[X6@]>T.MBWTUK>\P>Q*QFP@#^,D.NZGL^WM-
M'5Z]VQ<J\B*U+$#\S@>!_;ZGP)TJ54F7)DZU$H(6(U9!2E*K2G%J$RE,>`)I
M*A.>4(91Q!Q8M"",.]A$'>MZWTS,$$9'I.*RMZG-5JE;%)!!&""/!!!\@@^H
M,_?$PE9[GN"1(I`VTE3"="]W;+$/IQBE:#:F.5/$##-IU-BSG1>_=**%H0&I
MN[@G.BS6@:UHH)@M(D@T_4$;IN+F,3*<N>7AV7GO\TFCX;I7*)U+%_03G))$
MOW[XY4I'KM**#T)2$!`24$)8-:Q$E?$1B(Q$8B1?;=2Q>XXH*-2/TQ"J1K4[
MW%I0SG;126%REN%LQID\:<@?K4+FWG>[[F_#.+V(HP(BQB#M$H[!G_F2ML.0
MTO/+_K6'6$R@/=HEI516W%MM&`$B"41,HTZZGK60I=$0MZ*>6X)(#4"C?=H.
MR!@'B)[29V!;M=V775.3?G%1,:L^VMN`:[AKG1.R7:3;;"]F*?1@?27LI-XH
M@[+3>.(KTL\.RB/$,UL.N#8[3K]7;JT-BU$W+\\%)\MC_L\9]3X'F1.WWO3Z
M'84=5N;%=?8[6?:K)^I\?E^6?09_4?`R9["WGGE)3<7`_OG)*OG=V=5Q+#"X
M8R<=A*I-.I:OT(+3&8^A#9FQG*EANNIIN]>"D(",XT02P;WG?):3+Q_IF:-!
MY=Q<@7AMF7(:1L*5K<EC8ETFBM<L6^AXH17[:(U0!O2C.Z#<EFAB/<E(>HA[
M*`6'2):G$1B)!G*#\-/(?[#+:^8,@Q$I%B)JAB)7_E@P.DJXO<BHRR1TJ7O,
M@I"TF9IBIR)W<BY&Y.4*>DB)D$W,/5[7^LU)H2=$)/V@W8^P'OMZR%^0)99U
M%HJS[@*$$(+&7C8A]Q:V(1WKQS1;"*F90+3[?*3OQB^K6^1:.Q>XKI3:K+,2
M%``<9)8^@QZGU`R1YF=/E=6R98J@;.3=-K6C\3JLC[1(FB<<08#126)2-/IC
M3&-SW/:];M,JV7D^CGEC:2U9A)H0''E:&`C0]7?L+*MW[SLZ"ENK?N%J[0Y`
M<$NY**<"P$,C,V,U\DR`+!FC]?5=I4:?6;"M3N44JME)`=D(0KQ=O)0!D958
MXYE2I)(:;+9!2;C$2I<M_&O2OV`W=\\*FQ$MIB(Q$8B,1*+VQZ-R]?'GC_'4
M+:X4Q&W4M->EAK6Q$ZI%[D@&$P555V:O3JD@Y.+8M:>'4K6_5!`MDE"]*'^K
MZ]+?W^MO^ZZZ^[7V0"`]3LC8/J.2D'!_$9FC9U=7<J]C<JKMI)SQ=0RY'H<,
M"/$]57K"Q<%GLBNBF1H9N,<V?`!@\N;VM(A'5<M=#`E$0FPUZ4DH:V+/"@6B
MV9Z5B&8F-%I&J,[=DF9GO=GV7:6"[L]B_9N48#6V-8P'Y`L20/X3'5TM+10U
MZ5-5-9.2$54!/YX4`9E_-;UO6MZWK>MZUO6];ZZWK?NZWK>O<WK>LX9TS_<1
M&(C$1B(Q$8B5(M2N);7,R7\AJ+;!.<A4)B`7!4Z8P"9#<+`WEA+*=F@(NB=!
M:L=1!WZO4[[0N)6O1#]]-EB"B2C$>0M+S2-,\I:K(B"5`\IO'+1OC^TL3TWG
MEB$2L:WAF<UB=>UN[8J+&0I3F@",HT`@[_1UVB0;8EGUU&K6260O61ZT8P?`
M@PU$WQ5^ADC>X@]B>U:]>L*8%S\D$:VRQ`H((4JR>\2?T$`3>THS8LY;04N]
MTJ73CCP,D'/Y?Q_/^$O/2V4;_P`?;I*=VC0WQM^\S7.:J[DX!57W`#]53!F5
M#CE[A*Y88G945,8-#X'ZND%BUXTFKI)*7]LBX9W$U)<,8GY\6.;1$BSTKL:D
M'IG2*-!$$D0B2QB$67O980[WLUT9*\-X.2<?D"?`_P`DB_EG8:G9=O[VHWN*
ME-5;6X(]ZRM`KW8/GZR,@GR1@GR3/TM7D*G3^J(!12B.V9<LY">5&6YL=4KM
M'(DV%B"2XV#/U[4>H"UQ1@V9K>@;%H]P4]B<C6Q"$(&Z5J=[2U-M50L"XL;F
MKEDZE:[U_8]B/(2]O\WDYI>@G+E8@:[4;6B!OP&]`5T3H4H0EEZ_K"$B3+B(
MQ$8B,1&(C$2(KDJ!FM^-IF]0O6QJ61U>"0U]/F718)'!)8E`(*)[:31Z[3B!
MZ%X2Q&9U3KDHA%&AWK>MA1,#+UJBQEU@7M&+.<H*TK;X/K;=YO#\B7/]X,'T
M?+$Y$&?>"VQ@\5]:K07)"R6UKV84;!9$8I5F;,!L(MT;MOC&YM[MPUVK.EO%
M/==_-M'M^1[!_(_RC_P;9;S/E??_``?L^P[79^R>@]9V9K.Q;:"VQK>R00-9
MOR8#Z!X]I\OYFS=$T[*!NJ"Y[N\5;9?J,IA@T57..WY-3D*VG))`R$NA@=:>
MY^^$$@-D3UO7B*U.]DE;"G!K0KNBA$"`D@`#).2<?F?Q/YF?4:JQ56M2EB%4
M#+'+'`QDG\2?Q/XF6US*9QB(Q$@SE!^&GD/]AEM?,&08B4BQ$U0Q$@3E2&,B
MXR\A`322/T.B`Z6LX$HED73#6R.-L`X:\A=GQB1EF$C5NK8AV,X@K0P>(8#0
M>X/7NU'=K6+M)J2%8N]:JK*KH[-8H2NQ&9$:JQB$M5W1&K9@[HI+"9^.F]>^
MTVU46S8&Q655CA6(88!.#C^W!QZX/I,_.(=9O-=\GZ]%82*@H+)7/ANY)*WB
M'&NLU<'8IC`6R;UF-]DMJ*S9`Z)@22*JUC00S-:4"EO1@=G(2=Q4]P@ALS-<
M+>ZHN4??C8TFO"D_;UGEV"I[',+8S.XN5VL2HBI*`%8FSVZCJ(K=/U.UKX/5
M,7%5UBC[MV;71UKN*LP"-4#;8J&Q'V*U9GK*4B_7[(J2L8B5+EOXUZ5^P&[O
MGA4V(EM,1&(C$3/+DMR07+Y,.C*Q16<J0A.,0W3:]4P"1SU17J+9)1YD%CQ\
M?1+"$]D2%$=V^,/>PLQ`MFCUL_98`HG60?D94E;Q1DA,,H[DBQQN/H@(6UO3
M<>K(Z`+#O8S3U!PVH1RM:K/$(T\\P0C3SAB&,6Q"WO$3V4BY15A+6)VC$FI#
MD:^1]^0*6MX:'+CI8BE"X-ZPH1*A*I)&T;",LPL6_P"YO6_=UO6]:WB)$=`<
MBBZ\EZ>EI>TW"CJ5Q4)4%,VE;==RR&B9%2TT9+=3LR?9(C(*<EZ4(-`9',8]
M"5D]J<[?CA"(:)I7B(Q$8B,1&(C$1B)GG>_&F'0Z>NG)&)4S#+*(=0E#O2LG
M"(L;TYRQI2!WH4_@FUZ0T:6P6!/U$>E!L);VE#L&]:4A+&)$FV$4MQ'L>*,D
MVA50TR_1F1(2U[4YHX%&-EG$CZA&686)L":F5IC0B+.),"$TDT`@##H0=ZTB
M1==D'XZUSIBAT+XW5#.+GL`:E'7<#!!HR22=M,'7K"62Q86UBVQP2-!'HU<K
M'TV/W"">XX8=:1);XU<:8?QWCCMIN0L2F?SA?I_LF6LS"ACZ9\?!@Z`0L[4A
M*+(98JR%[\!O1%ZT$LH/>/N-&,6T2RN(C$1B(Q$8B,1&(C$3GG.)19Z>6*1/
M$<8W1^BYBHZ-O3@U(ECHPFK2=IUAC0O4$F*6X:DC?8/90@[$'W-XB=#B(Q$8
MB,1(,Y0?AIY#_89;7S!D&(E(L1-4,1.`M:2-T.K"Q):\1I5,FF-0F4/KI$4*
M-*X*Y.W-3*M6KF%.A7?L2PUV2DB(T6=^J'W]!^]WO.3>;7758;:HVHV%?G@5
MA'(5FL+?2*U4EK"?`0,3Z3MZVB[9["G7UV*;#VJ%89R&)'$C'G.<8QYSC$S:
MX-RSB&1=LPCO%[C0E@,;FL%=G:'<AHTJ9'V#V_&*PD<;99<S0Y>G>W9Y9H3%
MY=/R2&L02TS*\&E*S$.AA2"WJ7U*=E>JV*26IUZ+:66JS/N756G9JU]ELY;%
MBZEC5+<?=]IQ8`!8V81[=:W:HW0J/L6AJF*X_HVM75LW4A1@$)RK78LJ'M)>
M*Z7;D:Q-9,XYW2GMC\T*\@3U9$8;XS-9Q):Q<H:T/#7&F]"`ER<96QRB6+DK
M(Z.C@A;UIT/B4/7+G37>'P>P!`>X\>@9FB%Z$VO(U6NLK+'^5:E0V6D>IK5G
M6O(!)<D`8!,[%T;[,+6.5K5\E4>K,75$K!.!S<N"!GPOU$@2.V:ZJOMKF_5J
M&OY<@D3C'N.EJN#^VIB5I*QG3/\`)JC5M0EH5*4DH(E)0]>]`,>P[]S?3,KZ
M7U[WU[<>Y6Y4_P!JG!_X1."JP6UBP`C(]#ZC\P?X@^#_`!F@V:IG&(E4+4L>
M63V7*N/U&.FV^5`(3F6Q:28LM6AIJ-KP[V%*@V+N2KK2?TW738B%UTB+WM6H
MUH`2PC1)UK>N(E5$/:H/"F[U<R-0#1]QIHU3BZ.*LP2ES?'MQ-ZJ75\>%I@S
MU:DW>S#CA[WOW.FM(GJ;=NFK*%B/Q[N":M$#B7K5N8PO;UM3Z,8\.Y@B6QM)
M+1IU2D]6M,!O18``%L6]9-=!\=[OY1O_`+7T&M9M;_!GX)C/!?+,<D``#U),
MC>U[CK.CU/ONVN2C5Y!>39QR;T'@$DG\/$]93/(*F>0K.]/]+V`R6`TQUW]0
M/JIFTM+VTO/HI"[3<N3N"1$J3J=HU)9FM"!KJ`>MZS?\B^*?(OB>Q7J_(M2S
M4ONKYH'Q]29*\E*D@C((]?437U'>]1WU+W]1>E]5;\6*Y^EL`X((!!P09WDT
MAD8L.+/<+F3.D?HU(D)K<[-:T'>2H3F]-Z$$6MZ,(4IS0A,)-!L)A)H`C`+0
M@ZWJO26E9:[F4HH^7L]$7"]*WZ//IPD-%6^["ULV3$$E[&76L]7=`DE6(TI@
M=$:D7:%\2@[M?M(#`B1+@XB,1&(C$1B(Q$8B4QE]=VA1TQ>[%XWQ=#,X]8"I
M0=8-'JWE+&VLJ9K2_#16?#7%7T0LIQZK0-2%%K6@KB/V@K7I(-]Z))E(TPL@
MAKW8%@NY,TO"?EIC9W,0E"+0H$B?>S&^"PI(=U&RP6.;'L"8C7ZQ2;W*#]B-
M'[U$L%B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@SE!^&GD/]AEM?,&08B4BQ$U
M0Q$CRW4D_7U59*&J%R-LL]9!96EKQR<`DC1()J>QKBHRL5`4_LPB$SP(D8O$
M_5]->^][USB[&N^[2>K7:Q;&`&:RHLXY'/VR^46PIR%;."JOQ+`@$20ZI]*K
ML]>SL5Y:"W*;!Y.4!&00/)&/4#R1Z3/?B11W+>J.24N,LVQ[^G]'ZKQ^):':
MXKFKF>,CE('QZ@+G#44>B$6CC3*&*5PIK1OZ%[6*Q`:E7CI]HO2-;$87.5VZ
MWVNY4ZH+1?4M1PS%U2S;YW(QP4JLJ?54UVCW?<KR`HYEX$ILM7UUA9ONO8#;
M('$('-**Z,!DLZ[`9JC6?:]EFYGF*U&I><$[I3*2\"^/3X]61*&EJE,'E=K.
MK2]3"20Z7O2%<H<6\<H"O4MR5Q4.K2T#DK?,W-(Y>CIB_24ZH6O>CUH>LJB*
M=:K208TZK2_#\'Y*%9'_`!-9P#Q!`Y`'\!.H[EY;W`<7\2`X\,"61PXQXYHU
M:E6QXQCR#/U<F5KCG+^@F%E1DM[2S<<+?:FU&3K?8F;VR2U"B0I@B%L1@PIT
MI(0!V+>]]-?IS*ZVS8N>^TYM=BQ/\2<G_AG%6@K0("2``,DY)Q^)/XD_B?Q,
MN1FN9RKEPVK*7.4E4'1QA!]JNZ`I=+)>:1I:P4G#UHO#^-+^'_`*Y2Y%]X61
MIV+1BD[7CFZ"F+%L2)+-455%*=B"6(Q0A0,OTA0Z/CXYGB6R"621Q%HYYE,E
M=#/U[F^/"KJ8<:/?37N`!H)80ATB25B)4KF%3-E7+"*\*J1;`TLXK6Z:]MIK
M3626\CB#N&%JEQQ[0Y[825#F7I86L]X(`=]!!]W+Y_A_\BZ?X]V6VW?+M-UF
MYUU^JQU^'NK[P`#KS(7QCR#*K\MZ?L>XTM<=6U`W=?<JO47<O;;VR25/'SYS
M^$]5Q.IFXJW?>0,\NY36/QONZQF28A:*GU(A1AC;V*#L,/3I=GR9.F<5"Y3Z
MFV<8+M[>H_<S?\Z^1?'^XU>JZOXVN[^W];J/5SVO;]QV>Y[2<5DJ%'/`&?PF
MOXOU';==?O[W<'6^[W=A;.-'/@H6M:P/K`))XY/]LN5GSR6Z<58=>Q*THB[P
MB;-1;LP/!00G%;&,A6C5$#"<A=6I<3L*EL>&M4`)Z542()I!P`B#O6]8B0#5
MMA2JMY>BX^W>ZF.;TI+.^ARUU@`)TEMQ]$#8]L;T:'04R*U8ZD#K2U/UUIS)
M#Z61K?4T(42V>(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M@SE!^&GD/]AEM?,&08B4BQ$U0Q$KCS"''"^)O)DR82*1Q"*`H2VQ2250],);
M*HVQZ@;[ZT?(XC"I1[5O;6C[SDQ7C$Z,.`$.Q@UONU7?EO`_'MD.YKRJ@$#D
M"Q=0BLI*@H[\4L#,JE&8,RC)$[\7%I^1Z(IK6VW[JO",<*WU#P3@XS^>#C\C
MZ3Y]/)<^CG?-BW%R?D/9EVWJY44](;IL/Z.WZ%<;KQ<8U*ZI1QUJH79=ESF#
M$(>(<56H8HY)$)!2C3G(E(_2E)7]3Z(O/]J[<T5`:C=HCV%V)LLVSL]LNUOU
M94$Z>W8OVVM@)QKT`&5BRO*+=@;/2^Z_'CIE*`H`]K6^QT&UNNOPQ"[5=7^V
M[`8NQ>WZ750RGZF<KLG8Q$J7+?QKTK]@-W?/"IL1.@NBW)(@>F^F:83('R[I
M8A]."<O`)1&ZLB9ANTRJQIUHK>M^BIQ]P&UOZA/=5FM`#K183!Z1._J"HX]3
MT8&R-*A<]O;NN.?IM-7L85,GG4L7:UMRD<@6ZUK9JA0/7822'H2D3A`24$(`
M:UB)*N(C$1B(Q$8B,1(\M&KXI;T/7PR7)CQHE)B=:W.;>>)"^QM]0&:4-$EC
M;J5KTAI?F=6'1J=07O0@BUL.^X`A!VB0[4=H2Q@E(*#O-03NRD2%0L@TZ+("
MB8[LB;=T"-Z;0:WX*";LY`@:>VO6^X`]^DD:$G,]XB6EQ$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(,Y0?AIY#_89;7S!D&(E(L1-4,1(COX
M^6IJ+N51`8S'II.2:LGQD/A\N$C#%93)@19UVQQZ1[<32&_;&\N6BTZK1YA9
M.R#!:&((=[%J#^2KL6=#MU:U:VW/2R\"H?(;Z6Q6Q"V,%)*5LRBQ@$+*&R);
MH?M_WO4.U8]6L-FLLZDAE`898$`E2/7D`2/4`XQ/G8\A\_D&;,4L*FG&"P*A
MKFB*JN^#&6!9/#*`</T+RJGEW0R;UG&:CCD31D:<64+$D?3WXQN.6-:DXE`>
M<>:I$`>[P&U-CJ'[%+;3ST^LUD%K%;[&U'[0V/;0P5JT&OLZ;*K*BU7VWUU(
M"MQ-1VQ8O>IKU5J&&WM;%G!0U%:;.MI*PJN!866G<HN165V+ZJ+980&I$^H/
M(.3$8B99<V;Z6T#R0HEW88N]RR;3:H;C@D#;VIH4.R%-)W255480Y/X$XRS/
M5Z%.6,T"<`M'+S@!3E[T,>MZ1.PI>UXE4#*YA-IOEI,)[+7$3]8]BO-$/P'V
M:R0P/8-6H`%6,#:T("OU#>W$[TG0I0A+!KKW"$B3+[7K+]0W*C^!D@^$XB/:
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M66U64]01=1]@Q63-]01APE]C&MDVCZV'G&1=D;621G"6)MO>C!J3$*I,A)`-
M2>6(DHS*U\M-+=)91<+#[C*%XGC]:GW%YV$,*JR4P]K#"`Y]<2P_%&NI^0:N
MW1P]S7M6WZ_((K/,@*"K6,0,+6I#.<*ODS%3R,9LZ2"Q6!@@EL^:S:=)LO#^
M,'G).=400PJEZVDHG>!H8=":E4**)K%PLIR3QE*O`F>D3BI1A;$HMF$;VI),
M!],WS;;^\6[AKMM&_K\+K04VK6<[QN/M9!J&$J>[D'R]BKE2A]SY]0Z<.J34
M#H72]K*JB&HJ1*Z@@-N"MBFRUEK52A`K#`%.03Z>LK$L$8B4@N:$QFR.5-90
M:8MA3Q&Y%QUO!$Y(3=B`+I\<:E,3JT:@O83T+D@4`"<F4E"`<0<`(P"T+6MX
MB='6,ZEM1S!KH"[7H][]:[/)I"WW+80:LAL2!V8&%2Q1T"0GM5A1AZB_J@>4
MP/2"OUVC08B6\Q$8B,1&(C$1B(Q$8B58MNSI5)I7N@*-6E%6&K2)U5AS[1(%
MK52<17Z]ZZ*@"_9UL^?".X+*VBWUZ]51^@D%Z\1$F>L:RBE21!!#(@D.);TI
MAZQ<O7J#%[W('M>9X[M(Y$ZG]5+N_/*L0C5*@W>Q#'OIKH'00Z1)`Q$8B,1&
M(E<IZJD\PM5/5J"=O%9LZ*"%3?UK'`M1<BE;B<^*VD3>A6/2!R2DM,:+1EG+
MBRRMFG"7$!$+1?=H7-9R>WV@Q0<<^/4^<?\`!^/]LNO45Z'6_'SWUVI7O;+;
M9HX6<_;J4('Y,$927MR50DX'!B!G&.NI"8O<U@XG!_,)7KFF2RJ+`D24@M,A
MEZ2,/BQG2RI"G)ZD$DO!270AA*WLGQ@C\/H#MUK.AV>O+>2"1G\\'&?\LC?E
M/6ZO5]K[.F"E5E%5OMDY:DVH'-3$^24)P,^<8SYS)?S=*Y&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(D&<H/PT\A_L,MKY@R#$2D6(FJ&(E.N<>^5R.E4,CX<,*.<
M6S#+*KR8.%5JI=&:]-N"OF1^+.FE9(9],&UVCD.4R1N&'N6J2M:\`DPH(P#-
M"+7#LON5;FI=14+]1;;!=66"`K9KW5UN2?U+3>]5S5J5:Q:RH8>A[->O3NU=
MO7V+&IV'U_Z-H!/"Q;:K#X'H;*DLI5B"J/8KL,*2*.>7IQ?Y]4S?2JU^3MRV
M5/6Z]Z'?IW?D'D]N))[4E7\DW^V2G.#U=QYA?B:'`XA4]0C4,RY2W%%M3V;X
M!W<:<#N#.:ZZO7==L]$EIV]?770]C9L4B_8V?;VOW38+'+I1;8=7V:+"/;XG
M@BCGF'VSL=ANZ_<I6-2Y]G=6S71LTTZ*C77KJN*X2S9&+GMV%`+?U%L'U5F;
M49PSLE?W?E1QX813<+O;420BKA[;HY-0G*E&]L;VZ*AHDB`S0$P]K#`K"AE'
M"3>,!,848$X1>RQZ#DBM8E5B>:[[#6A_!F`)P#_8I()P"`2"0)ZRE'=&&'KK
MYL/R7QY/_*7QZY8#'D3AY,<4JYG4<L3&EJ$BGC[=1R920,)J<\HV65(:4:2<
M#8BS"S"QZ$$6M[UL.];U[F&5D8HX(<'!!]01Z@S!'6Q!8A!1@""/0@^09/-G
M5G$;=AKI!IJWB7,[EX)Q1R8X:-U9G5$9I0UO["YD;"J:7UG6`"<E4E;T848'
M^G6]ZWC,I"-46;*H;+T_'R\U^E4W`D4J*QLHPD"-JNF+-P==XQ]N@ID-E,*7
M8?6[>'?Z\.O2T^ME#%HM$M;B(Q$8B,1&(C$2L]QVQ)OC"EH^E`(W*Y9"W@7N
M;PK)TLCE/1!48).9/)@$.^PY:9T$%G:M[T<Y*=:WO6B`&"Q$DFI*GC-.Q,N,
MQX2QP5JUBAZE$I>3O3)+-)0XBT:[R>2..]:&L='$_P!W^@LDO02B@A+`$.D2
M3\1&(C$1B(Q$X2>5C`+.0I&V?1-GE*-`ITL0@<T_>:C4>]T,:524(I40$X(=
M:,"$>@&AUT'H6O<S7957:,6`$"2W4][W'17-?U&Q9KV.N&XGPP_B#D''X$C(
M/D8G7MS<@:$"-K:D25M;6].4D0H$)!25&C2D`T62G3)B0@*))*`'6@A#K6M:
MUF8`4<5\`2.NNNV+6OV&9[W8EF8DDD^I)/DD_G/,SV:HQ$8B,1&(C$1B(Q$8
MB9V7+YAT0JJTWZ+-M?2B>553:IM1<L+OCIR445XZJI,22*,)GI`/JXR=2F`H
M*6/Q:#0A,34<!4=W==@U5M_Y11I;C4K4]FE00-FY<<:.7Z<CU;\WQ^A2&,H?
M;?.]7K>S?6KU[;^MU"!N["XX:I?]`8>KD>&LXY]M"&/Y30=N<$+NWH79K5IU
M[8YHTK@W+TAH#TJU"M(`I2*TQQ>]@.3J4YH1@%K>]""+6]99U974.A!0C((_
M$'T,O-=B6UK;40U;`$$>001D$'\B)YF93.,1&(D&<H/PT\A_L,MKY@R#$2D6
M(FJ&(C$1B(Q$S4FG#R[)P_6I)W2PZN#(7J8*5%4N943D0$L3K1S;I?'%\$>V
M`MV*;35(6F;K7(;@CV6>X/VPGJ>I.M%!\U@:]5->T_4Y*W\?1ZR`![8/]VU8
M5%0>5"^YD%GR.]-XZ^RU^NJ\$534&&>-JNEK,Y&/<%EB9?/G'$+CB)[N+TA7
M5.\S:;W#8\B0/CIQFLQFE$E++&!UE>HW(*?0(5KQO1@B1JA:)V8+8`A]\+?]
M'3.G;O.UM6[1&#98S8]<<B3C/XXS(RI#76J,06`\D#`)]20,G`)S@9\>DT0S
MGFR1I:]51>X(DHBDF"J3#+4IG:/2)I.]#D<0DK</QF>41IS#K9S<\M:G6A`&
M'WHP]Q9FA%C&':)%=.6M*DDE443>'HB.VV-`:NCDF2DZ1QZZ8<C$$G4SC1>]
M[*2/R/6PA>FG0MF(C]^(7H2<P`M(EG\1&(C$1B)72Z+@>H\Z-%350@126\)L
MD-4,K>L[QL,%CH#-)E]D3PPGWR6/-)@NB=-U"H=%>M)R?]\&!$ZZFZ@9ZACJ
MI"2O626721>.0V%/GGL'(9S*U0`A6/#F:'KHA*5K7@HD9?1.A2@`44'6M;WM
M$EW$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*/V_P%I:Y;>;[5?5<L943
MF8TFW'64;>!-5;<A1Q0W2R!BN".D@\*1CA[EK1I8M;`):2$"=5LY.`)>J]O?
M&^OW]T;EI=5;'NUJ<5W<?*>ZO\W$_P"<>#D>)3^U^$]1VW:+V5YM16X^_4C%
M:MG@<U^\@\-P/G_C#"MD#$NX222F)*3IRBR$Y!99)!!)82B222@Z`4444#00
M%EE@#K00ZUK6M:Z:RP``#`\`2W@!0%4`*!X$_3/9[&(C$2#.4'X:>0_V&6U\
MP9!B)2+$35#$1B(Q$8B,1*ERW\:]*_8#=WSPJ;$2VF(C$2);BJ%BN&,D-*]:
MOCLD8EY4@@<[8A`(DT#EB,(M()`QJ1:WKN#UV6I3#ZD+$PADFAV$7N(E<FCF
M&@KAT!4?(IEE#9=;2C4*>D#@$PE\?L>,HC`$$V+$`QMI=3$[:NT(/IJ,WH:V
MJ^\H74'8(2)^4Z\QOC%63*3(K`<K/B#(H<T3*F<GZDK9;TJEW<A"`@;4YA\1
M#HY<L&#>BRP]1#WKW-9/_&_C'>?+NR_:?CU#;&^*FL*@JN$099BS%5`'\3(G
MN>[ZOX_I_?\`;VBG4YJG(@G+-^E0%!))_@)XL"\RCBO:*5W65Z\69+T[`Y`9
MWP;%2=LKMM#H8E+6EH'$!40V-(J,1FA-"`>M;V6+0M>YO-_R?X?\B^&[-.I\
MCUSKW[%7N5_4CATY%>09&9?U`CUSF:^D^0]/\BILV.GN%U=5G!_#*5;&<$,`
M?0Y])[-\YLQ:0KTU;4M&)O*+PE*,PV'1.85]-X*TID6C=)EDTE#G)&1K`BAL
M=$+Q%1A>Q&GB#H@G6S1ZZ5F34GBEZ;256VNSD[.ZB9V=-E1+S95B.102W*3O
M)96RR4R0G6Q`9XNQE"VG;&XK>B4B?7])@AC$B37B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D&<H/PT\A_L,MKY@R#$2D6(FJ&(C$1B(
MQ$8B5+EOXUZ5^P&[OGA4V(EM,1&(C$2&KFIY!:[,W'(G55#[#B"P;Y6]AM(`
M[>(A(`@T'NV'>PA<X^Z@#HAS;C=[3KDHM@'K0M`&%$RDY[AN'DYQ^CM4-E2(
MY7R-I*_*CGUD4J:$:I@G,*8EKH0=.(R6<\QPZ2UV^^DA'VDK2E*4[8DQNPF@
MZB^T_P"!7R+I?CGRW:N[W<.AJ['5;-"W@X*66!>)4\+`&\'!*$#\1/F_^*/4
M=EW'045=7KC;OJWJ;6J(R&12>61R3(\^0&!G-\`R;7XKQKD4HG-!)Z^M+D1>
M#8NH?C[&RMM"1U)9J[CS$XOVD1TEEZN+PEL6)1J75P5JQ`*#H7;[\PHO<G_C
MM\CZ#O;^DU>C[%NT.EUSUVWL>3EVO=P&85U`D*1C"``8'F<7^%W3=KU=79;'
M::BZ7W.XKI4HPH5:E4D`NY`)!]6/F:VTI3RJORGF7S=Y#-;EGHDZVP)L,H99
M&ME:V-#$(BD.$8)B@D:T/92)(#>O$WH1YW<<8+>O@<^JR=\1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B09R@_#3R'^PRVOF#(,1*18
MB:H8B,1&(C$1B)4N6_C7I7[`;N^>%38B6TQ$8B,1&(E1N71-81B(,MOS*THY
M0\PK]X3E5[;T@4E(VY"\O(O!U#)`6(0-O\3F.BO1UC<+>]F:Z&E=IQ8!9+])
MT'=?)-[]MZ'6NV]\HS>W6I9N*^6;`_`?B?PD?V?:];TVM][VM]>OJ<@O)S@9
M/H,_F?P$YWB`X5C9@)C=;/<,'O\`M-X7AC<WFT'5B51F$IDH"U[=6D,0J1&*
MX]'6Y.>!0,!N_25YYFU!XA"V#0-W??&/D'Q;834^1:=^GLV)S5;5*EER1R'Y
MC((R/Q$U]5W?4]Y4U_4;%6Q2C<6*'(#8S@_D<>9=O(*2D8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@SE!^&GD/\`89;7S!D&(E(L
M1-4,1&(C$1B)ZQT>V9C+2G/;NV,Y2Y>E:D)KHO2MY:QT7#V6A;4HU9I(5"]8
M9K82B0;V89OW`ZW@>7%8\NWH/Q.!DX'XX'G^R,'B7_D49)_`#TR3^`R1Y,J_
M+=;]M:EM]-]/H!N[W>GN?Z85-_3B);/$1B(Q$8B4^YH4[9=PP.NBZF10)VF-
M;W=7-KI6*RE*]'$7])#52XU8T.*IN;G523M46L]YO1`]=P?=UGT#_#KY!TWQ
M_M-MN];:KZ_<ZW8U2^N%-J&X*`ZAF4'&//U"5+YAU'8]MHZXZM:'V]?=JO"W
M$A&%9.5)`)&<_D9Z;A[3EOUP]<A9S<S+6$7D5TV2QRY!%JH<'-SC;&UL,$C\
M/*+,6NC0R''+UIC,(\S>B-!ZC_3O>='^('R'H.WUNIZSX[9NWZG7:;U-;M*J
MV.SWV6GPKN`HYX'U?A-7Q/J.VZ^[?W>W36JV-S86P)0244+4M?JRJ<GCD^/Q
MEVL^;RY1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2
M#.3_`.&GD/\`89;7S!D&(E(L1-4,1&(C$1B)3SEWQWE/()FBC=&EL1)&Q%S(
MD9$S]9>A(%\F80-+-,V;3>VNN]2J%*P;4H-[`2+0S!=B@D7OM[=2Q=?>KV70
M,%*_5_/7QNJL)K\>KJA1OJ7P?Q&1.E+T35>ET%G)U;@W]W8%6P%+/4\27!.`
M?3R#XQYDHX=0J76$"TG*S^0J"9D-[LT(%D>NJ8L+>S-+\<V*GEI8V="J`WMC
M6O5LZ8T1(`;T$16NW>LQL8/8SJ.*EB0/RR<X_P`GI.*E&KI2MCR95`)_,@8S
M_E]9Y/LF,WU[\K/Y@YQ\(S";(]DQF^O?E9_,'./A&(CV3&;Z]^5G\P<X^$8B
M/9,9OKWY6?S!SCX1B(]DQF^O?E9_,'./A&(CV3&;Z]^5G\P<X^$8B/9,9OKW
MY6?S!SCX1B(]DQF^O?E9_,'./A&(CV3&;Z]^5G\P<X^$8B/9,9OKWY6?S!SC
MX1B)P[)P]D1$XG2]\Y(\EUD$<$D1!`F5+?LY`ZLBQ$D=03`UU/V43HXIV6')
M!I]://[`E"]POKTVB=Q[)C-]>_*S^8.<?",1'LF,WU[\K/Y@YQ\(Q$>R8S?7
MORL_F#G'PC$1[)C-]>_*S^8.<?",1'LF,WU[\K/Y@YQ\(Q$>R8S?7ORL_F#G
M'PC$1[)C-]>_*S^8.<?",1'LF,WU[\K/Y@YQ\(Q$>R8S?7ORL_F#G'PC$1[)
MC-]>_*S^8.<?",1.%K;AY)&N&MB&S>27)>130I4^#='ADOR<IVU2E4/[HH8B
MB"1%-VPF(H^:E(-WX(>XXH6^HNO=M$[KV3&;Z]^5G\P<X^$8B/9,9OKWY6?S
M!SCX1B)_F^)K+K8=;OCE7K8M]`ZWR$F^MBWK77H'6U/N[Z:Q$_WV3&;Z]^5G
M\P<X^$8B/9,9OKWY6?S!SCX1B(]DQF^O?E9_,'./A&(CV3&;Z]^5G\P<X^$8
MB/9,9OKWY6?S!SCX1B(]DQF^O?E9_,'./A&(GK'KAE#Y(S.T=D%R\HGAA?VQ
M>ROC0NY`3DQ"ZL[HE-0N38M+"J`(Q(O1'C*,#K>MB`/>NNL1)K^A.MO_`)?#
M_P!,6_\`+XB2MB(Q$8B,1&(C$1B)\V'F:-?**V?,?CE"\9WZY$T_<>`2Z=5<
MKA-[N-4US3MJ(>347:T][65&/CQ'6FPF1BC8U*%0V>J9$I7$GZ(TBV$6S`:/
MC27W=EVVT#BO2[?X^SV6?777J,VX^]0*B'Y-MTU%!BL^4'*RKPT=Y937UNAK
M."WW6MWB"M/HMLO77T%U+!:./`:UUO,YL&`YPEGE92JG;7M%HYP.CW?%ZV%7
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MV%V`NSKO86S97I5"E=-6#<Z7?9R>08S/0M@*''F#YT%)/?F$R@Q*WQZAI)$)
MVZ6Y79SA19,AB$X53]'5L<7GBA,!;H.=I*UJ#@H>](J`2<N,$L$$6ZA8W+_"
M'=O1W;=H[KL/ZP8^]=4NKH/6/='E*[;7>JH5\57++3BP,1/%A3_B;ILU`&OL
M=)JD:Q#>TEJ[/85DBO&7L%5:;%G(,SKQ-G*KB)F=".44LGO"#R^T%E\L[&15
MI[$?/"=2.W&:_I&TS*4\NZK4C^@^-3RT6"4)I%()JU1]T.<VJ,K50]/2@(.]
M&K`4`H,Q\N?:7L>UV.M3AO4?"^GV>N2M<A]ZRS0KVS57Y78N4E*K*V6PJ+[6
M=0Q9AQ?&ZJ%HTM&]O>U+OFW8ZF\UARR=>I[%]?G9D-KU.$YI8K(&%%81N"\6
M^L_B*_65*>*W&^2W*!67;4@HVK'FR0KTX4:_X[N<*95DF$O2`3I`I5PW<XW9
MQ6BB_#,V(/:'ITU9/EE.CK_)]^CK0HT4V[`@7](`8^%\GZ0<A?)&`)7/BUVU
ML?'=*_=9WV6UU)9OU-X\,W@>67!/C.3+$97I/QB(Q$8B,1&(GQ+/;OS7<N/G
MF3\GH#9]^PB!TZY>;+$K+L^0\B7YY:)ZH:)D)KX\1"EX)J?O[U5;Q22Q`K.$
M])6R-!*2B"G),6:'^KBNO%E7POH=K9#>SV74=*H5G/N7[MG?<+=HVKR:NI]/
MEJV`V!G+@^PP3G)ZBH;?^)FQIU%'73[VXL`@%=6D.DK;[5JSQ6VP[;U;*'@0
MG!_Z^;"DZ95=%ZU;5/*"-1^W+5@?,B#7GY>\IX4\/D_("SKR)LBP;`K./*$Q
M9MB61(6A\L^D^4&E3X.5,BHA$UQ,QE4&ZWXY033)_?>^K>H3HZEV.ZH^6=SJ
M6:SJ`FOJKK(U]%ASFRG7T%/9Z>W9]:VV*JI4N<U+JSK['4BSM[&HZR_X?J;)
MV@2UEVRVW:NMM5(!_1V#N>WUUVNJO7:C>XWN(5*Z\>6A?-@6+P>B2Y\>KPE]
MHV8X7X9RWY"OTPJHA+PXY$)GI_2V%#7J%V?8R5XBL=IYR*+)86IH971J(;$B
M<\X/8>8(6/::O6/T^EK=5MO7\:;I->S6[!\"W;]P-[SN<,R;9V/=1_<54H<K
M2N!5Q7LZ^[<3OMR[L]6M^^3NFKOZ].7MTJAJ6BI`"`:+-8U6*U;&RX,]V.5J
MYRB=K[E2KR%^2DN;?,)L9-9-(<HN1;>VV8DOV/K+8LIMC'(25,]?PI]GPG,V
M0(FQ]CJ<MS*2LIB$Q:@1Z`F[4(AAVY5./\/NQ9%KJO3I?N*02$=K-FM+_N"Q
MYV>S59RM6UCGZ'V,J//E=+?=_-^J#/:]?[F:;?YZE74]RIJ`HX5BZY#3644`
M,[+3BS&)ZY&<BK0?>7<Z=H7?<OU8,,N3ROXSPH@4(M1S+A%NU#<"\KVDWQ)!
MF%W41&ZV=Z`:^$/KPK1NNF,AH*V`Y'LOO%[T"V6?+JZ]FMO;L^9;NOM(4/&O
MJ%Z47TDJ?%-)>RS8KO`1FN50MAXA)Q=K:#\0-E+^*_A]>U38/#-VO[K[#*''
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M&%X=J.F^6UKS4\?;U=SK::#P.//ML3R/ZLAQX(S(7:VGV%O6]`6Y:.QO_%K;
MN+#D+]E^R%RAQGB,(GT>>)R#YR!(4!\RGGPUS^+(IM:E3SQF2RCRP':0QYJI
ME'%E$G9?,`:UJ6709N=2Y6N.92*^<T@5#"X=IJM6(>RUO>7K6\N&UJ4ZO>[7
M6UHUM.K\F[/J`,X>Q=7I'[6F_P`#Q<+E%)0?TVJ.2.?F5D[S7=/^XJRTE_C&
MKVX+?4M9?M1H/2WIFMJB;'?PRV#^GA?$[.H?-,OF1*H1+[/OVLF&+VM5W.>;
MWA7<:K>/'S+R[$/&-V==1223+:YZ/=G[TDAKTTK4<I2)-.3NH+&AWX.M@W6G
MV13TEVW86L1/CG7=DNR@7BVWM6:@;K%4_P!-K+CLV4TCG[RMK.7R2>-@NJOL
M[I='6UFKL/R*[K!38QR:$HVBN^[X#!0=>K8=E!H]K85?3BS<-*_-*YT4!QKX
MMW3-Y96%^+.9M:6O5U6$U]!XPH^(_-.;R1I=>(L&G"F!R9\8^B^!/`TLF3[-
M(3)W9O.ULPG0@AR9VNOWF^1+\)U14OR#9U-#V+?J;7.Q5LBOO,,<9HUM>QK:
M&&2_VMA!(8\>+4VM&SJK/E99V^.:6_LML*1B_P"P;69NM;BOE;=C8J5;5\.B
M[M("\D,Z5WYV>8DBNE+62F^:@;B5?,NQ^%"S:*AVU<:UK(-P_(O97::-0JEH
M`K7X,[0*4Z=L,!INVVGZT9W&`T/<3;NTV]??OZ885V=3\I["GEC*+T.[[>K4
M<?J%]/T;#G#*3SKPPF\47TWZ>KMA1L_??&]6\`^&?NZ';893_**'`:D#/(@A
MR5,]12WFQ<[+XM?CC'8O%ZS;/6]-\,[!E\3?'6FZ_C=V)KW<'A-<TFBS_:]L
M16Q0?$IM;-[86^&L\D$8[%#3+]AT:2'+)J:5-WR+9JN5DZFKLZ]=UR6>G7MZ
MFG<&Q6JAKK779V%50R+4]%#CF;>96$W-N[6Z94J86=I]IMVI9@*EMVMV=NFM
M%G+C34K4T%[66SW4LN0JGM@<OJ8R&DM&(C$1B(Q$8B,1&(C$1B)X&VIKVYA>
M]MJ#;R!$)M"[[1I]N86X9VE(F\*_P_2M(A*`Z,V5H?A['KNZ=?=POTA@O@/C
MEC^;CGCG\\9.,^F3CU@@-CEYXYQ_#.,X_+.!G'K@9])Z5;!X4XI5")QA\67(
ME3J>_*DBV/M*E*H?%(!%J7I0G/2#).=5!8]A&I%K9P];WK8MZWF#+6*PK@>T
MJ,H!Q@(V>:_D%;)Y#T.3GUGN6+<\GF2IS^.4QP/]J8'$_P`N!C&)![#R)XAO
M$<06;&;@H5RBS!/@<>VR=,LMA*EH9;)6/Z**%TX@D"-6-.W2E5)3$R#3(6:`
M\:O997A;'VZS=5[E_P!O?3R;]S3-##)^Y1/=?-9_\*J^W<WCD!PL/X-,'K2@
M[-%@"GK`S7J<#[4<49FL'_@OH="Q;C]++GP1.$K^X?+[M6T9?5-:3;BQ.K@[
MYHUS>$1536KS-E9K`[%H[";'YK0EG.;B:SO?:!X(-"8(A1T](#H6:]-%W-+W
M]`>YH"I+,H,I[7,"NSQX]OW"H1OT\R`#RQ-VXUNGN*F\6KW^7%>>0X9JN7$9
M\AFIR<>IKS_++)E5+51#64QD5G7Q+*0\$R$AH*AD<+:R7],#12=\*;P-NDA;
MP07KM`IT#1X0^YH6M9F&8.C@D/63P/XIR.6XG^7)`)QC)'F:>"8<8&+``WC]
M0'@!OS`'@9])(.8S*,1&(C$1B(Q$8B>CU&8WIL<674>8],[N:M/=FG32@]6.
MA[D/9CB<XH/1_15IJ\P6Q'B-`+9HM]1==XP."I_(@'$?@N#R'$?A@^1CT/D>
M9Z&97-JDBUCDG\2<8R3ZDX`']GCTGCF0R'FNR1^-BD;,?&\M,4@>C&)K&[(B
MD19Q*,M(XB2[6)BTA2DP)6@##HL)@M!Z:%OK[DAS8"?<)8D_B2R\6)/KEE^E
MCZE?!\3#BO$)@<%4`#\`%;DH`_`!OJ`]`WD>9Y!<9C9*-X;R8^QE()$<N42!
M"6TH"T;ZH<R=)W(]X3!3Z)<SG!/K0#Q'A&(T&NT6]Z]S,"B-2-=@#0OHN/I&
M26.!Z#+$MX'J2?69JS)<=A"1>2"6'AL@``Y]<@``'/@``>DXX%*4T6W&-!=2
M5D!I.6)W$UK!`HJ%N-<$:<U(D7F(@M6DPUB5*>,HLW8=C`6,00[UK>]9D?JQ
MR\X)(_@6`#$?ER``/Y@#/I/%)4L5\%@`<?B%/(`_F`WD`^`?(\SWJ.O8"W*V
M!P;X/#T*^*(3VN++4<:94JN--BG0]*6Y@4D(@',R%1HT7>2G$66/NWUUOKO,
MN;\VLR?<9`K'/DJOZ5)]2JX\`^!^$P]M.`KXCVPY8#'@,3DL!Z!B?)/J3YG8
M9C,XQ$8B,1&/7P?2)Z8J.1XAI5,!+"S$L2X*X"UE*:T);2L`Z#-,<@*FT!&D
M:@+B8H,$?H8-Z.V,6Q]>N\Q=5LK%5@#5*H4`^0`OZ0`?``QX'H/PGJDJYL4X
ML+$DCU)/J2?4D_B?4STR*NJ^;49#>W02&H&]+K>DR%%&&1*C3Z$A-:Q:(3$(
M0$E:$V'C3[[0ZZD#$7_4WO69N3:<V?42"//GPV.0\_@W%<C\>(SZ"8J`F"G@
M@@C'C!4D@C^(+,0?P+$CU,\_4.B.AZ,U%HYHS6VC>AZ8VS0];C_7U#O0O1>[
M6V3K^Q_Y-_O?;GO)N?N9/,N7S^/,KQ+Y_P!(K]);U*^,XGG%>/#`X<.&/PX`
M\N&/]'E]7'TSYQF>`"N:]+521<7!(:6MF10B)>L!%V0*J5$CV(0R9(H"AT<^
M%#$+>]A5;-UO>]Y@%44_;`#[?D&X_P`O('(;CZ<@?(.,YFSFQL%N3[H7B&_'
MB1@KGUXD#&/3'B0/:W#6CK<5T&-X8U,89N.EWM7(.$1&`A9HG$7:QF-F?&AG
M63!D1,HRGI`W#?C%A918DQFUQ))@C!:!VBRUL:W:Z_<K]6YJZ^S33RR5K&U4
M:;74>,6"MK$0YPHML^DDY&%X38ZO:Z>Q5^TW+-=[<#ZF.M<E]8S^1LK3EXR5
M4`$2Q@HK%QJ/2QQMA&J]9'//I(F=O$H]<*$FV]0Z^-M/LSUD>@WL@9_7Q1$^
M\V+8?<S'BH7B`./%UQ^'&PY=?['/EQZ,?7,R))/(GZLJ<_Q3]!_M3^4^J_AB
M>G55I7*Y5'ERV`0E8MB02P118JBK$H51D!)H3R01Y0<@&<RA*/#H8=)MEZ"/
M6MZ]W,P[+;[ZDB\J%Y?S8`P!GUP`2`/0`XF#*K5FE@#223Q/IECECCTR3Y)_
M$^L[;,9E&(C$1B(Q$8B,1&(C$1B(Q$K7S$D-QQ;B[>COQZ@KC9-X_1U(&RJH
M>UK&]O4N,X?DNV-@5F+G16B1)$#&N<0KU1@C-""F3&=FA#[0[A^]U=SL.N;J
M]$A;MQZ]<V$X6FNYUKMO8^O&FIGL^D%B5`49(DKTENIK]E7N;WG6UPUQ7U-C
M5(UB4C\,W.JU#.`"^20,F?,DF\N[G=1IS=QT9^.4.>*;E%U>61R1-E%&3P^3
M1)CM/C[<L1CG(Z12P5B-M=/R>53R#Q]++7+:5O5ISCTQGAGFG#V7ENT-S5;O
MM:K!HZKJ^^OV-1>/]*K0W.JW-9J*FR7(HVTJ949$XC:=@&!RM;OJV?\`=_?O
M/&SMNV^*[NGLCTN?>2Y-C7M<#^D/>38NUQQ9_P#HU?)@H!-BN&7";E?3?*OC
MQ;EJUS/YA6:#E[YH3FWPA2HKYI2<9M7]8#J_5OR"0K(TJ;G^=Q*V8:C4-BQ`
M\JG<YI.<R%"=.GWX@0\'QIOLNOZ_1W"/N?\`<>C5]YO75OHVJ[K^O91]+#97
MVWKL5&<6:W%[PC<3(?*G^]W-^_2^K3L^2Z5S5*,_<UIUHH7<#-]59U+^:6(&
M"6I83[1:M6/T[YHGD8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$3UCT],T;:'.02)V;&!A94*IT>7MZ7I6MH:6Q"2-0M<7
M-R7&D(D"%&G+$8:<:,!98`[$+>M:WO-=MM5*>Y<RI6"/+$`>3@>3X\D@#\R<
M3955;?8*J59[6]`H))_L`\F<\"R*[,A[?80)["QP%V*;CVJ<`E+&*'N9#PJ)
M0M!S?)=+MLJPIT6J2R4PBSQ:/-,"`'<(6M;Z+*K:KTU;59=FQE54((9F<955
M4^26'E0!DCR,S1797;2^Q4P:BM69F!!553(<L1X`0@AB3A<'.,3M,US,'/D>
MDC^Q+9JNH6M&^6S9E?U>RN"SU<@=[$F<<A36N</"&?Z`C<)*Y-B12L\`L0_"
M`,0^P.]].FMYK:ZE+5I9U%S@E5)')@N.1`]2%R,D>F1GU$S6JUJVM56-2D`D
M`X!.<9/H,X.,^N#B=:RO3-)&AM?XZ[-C\Q/*).Y-#TRKTKHT.K<K*"<D7MKD
MA-/1KD2HD>AEFE#$`8=ZWK>];SHMJMHL-5RLEH]0P((_'R#Y$T56U7H+:65Z
MCZ%2"#_81XGL\US9&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B)1+S00%F>7'SF+-++-*,XJWB6:4:`)A1I
M8Z]?@F%F`%K81EF`WO0M;]S>MY6/F"J_2<'`*-N:0(_,'=UP1_E$LWP]F3Y%
MKNA(<"P@CU!%5F#_`))\W5Q#.X5</%'`"3&J`47=J?B+R4X(.;H:H5(VI.JN
MRD'?D!QE)7K-F:&X5U)W/<F8D_>(8F%W,`'6M).W7TK8SM_XCZ'0VDMW'Q_Y
MCKJA(\W]4VU?7JVY'CW-!P-&X9+^R-6UO!9I\^Z_-'P3=[ZM0.M[GXAM"_'Z
M:>T&@'L&/P7L:@=FL>%%]6TH)9E$W.Y!6_?$:MV8,L1O'D?$X\A.;0MS!"/*
MUN&_HPW`,9T!QH&FVXTSJ668EFGF#,&80,6B#1"(W[XO>LJFN[L'-C,Q%M@&
M4*'`<@``^H`\!_1Q]0\&6&Q*THU_;5%SKH3QL%F3Y\G'Z#^:'R/!_&4C95/)
MJW?,&YORZ-1KCU9[YQQX]\78W!-\KXW-V!2ACL[K-]LR8$1&M&E-H=7.-BS5
M/O;TO7@/4IA("$>R-@3"UO6NR>KZ#Y!WWMUM77WVQ6U:6!W]G2T-.VFA=C!1
M:_\`:+K4\,+++B[_`-T,>WT#=[3X[U*W6![NE]\\J^"B_8WK]=KVH\6&SA2E
M9!(X5IQ7S8V=FN$G(EDY9\3Z(Y%QZ'&5ZU6M`6R1DP@9Z54"+*-#/;G!D2K$
M2=*C7-Z%P0F@3*"BBRSR-`&$.M"Z9/\`;ZU6MN#[>Q[=6ZBF^MG4JYJV*:[Z
M_<4^5<)8H=3Z,")%:%EQKMU]E*Z]S6V;]>T5GE7[NO<]%AK;`Y5ET)0D`E2,
MC.9:;(R=T8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(E&?,X_\`#LYO_P"`_"W=O^,_XO\`V?OG^&_XK_9?
MZF5KY;_U./3_`*;I>O\`^=UY9/B/_P`04>OI;_\`A63#_P`\W_P^O*M_LO\`
MQ:\$_P#2S_37_$&?^R[_`([_`#O_`.Z^[/HG9?\`^BNI]?\`KSLOT_WO\_ZO
M^8_UG_.^Q*'TW_\`2':>O_P[J^O]W^FO_P"]_P!#_F_>GU1E_P"#+_V@?_5U
MD$WZC_;).C^X3_O!_P!J?*QYM_XT[=_$9^`HO\`/]I?^DTS_`!]?_K7_`)E_
MYOZXRM5?W?>_W/\`?:O_`$K_`*F_N'_ZR_\`2?S_`/0)9T_ONA]?[S:_NO\`
MK']=/_0O^8__`%N)]#G#[\*G'7^R#^QBNOP__P!B/^BS;_97_P#0W^;O^;]N
M?0/D_P#\0;G_`$C^_;^^_O?7^;_Z/^+B4+XY_P!2T?H_2?T^OZF_7_SO^N_Y
M[G+'9!2;C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
0C$1B(Q$8B,1&(C$1B)__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tpg56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg56.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.C$T,34S.49&0S(P.#$Q130Y,#!!.$4T1#<W03@X,SE!
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C$T,34S03`P0S(P.#$Q130Y
M,#!!.$4T1#<W03@X,SE!(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C$T
M,34S.49$0S(P.#$Q130Y,#!!.$4T1#<W03@X,SE!(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.C$T,34S.49%0S(P.#$Q130Y,#!!.$4T1#<W03@X,SE!
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`'P`E@#`1$``A$!`Q$!_\0`A0`!
M``("`@,!`0````````````<(!@D%"@(#!`$+`0$`````````````````````
M$```!@,``0,#`0<"!0,!!0D"`P0%!@<``0@)$1(3(105%S$BU!96EPHR(T&S
M)'<847$984)2--A9D:&Q,R6U)G8W$0$`````````````````````_]H`#`,!
M``(1`Q$`/P#O\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`UBWWYG?%OS#:[G1UY=K4U!K585*=#(X>)>]R-;%7%
M2HVFTU2Y9$61_:HF\)QZT-0C<5"52E)$$TX!90@CV%J;,[#Y7IRA">I++Z"J
M6)\[K&MO>&BXULV9%$#D:)X3FJF342?&Y6L32]:_$DB_'I6O[M4O%KVIRS!?
M3`AGDWRC>/ON>1OD-Y1ZJJZX9G'4/Y5TAK.N=&.7Z:-?'\SP@BTN:X\_/+,B
M&:`"E6C3J$R4PP`#1@&,.MAGE%]Z<A]+W#=5`49>46L.Y.=G1<S7/`6I'(D3
MS!7)LD3A$W%.N$],K8A<`H9&UG)#3$)RHHLT(?<+6C"]B#!X5Y/N"K&6=0H8
M-TI"9,HXO:)&_=._C$$L-3U,SQ)3(DDB<7=8..@2.Z9K41-Q"/;6-=[MIA>S
MW:$#8@KI`?/IX=[-FD9KZ']ZTTJE4P=DS%'D;P3-8DWK79;O8$2$Z0RZ)L4<
M;35IWH43]TK)":>,!0=[,&`(@N5>/=7)G-EOTA0=XW3'J\M[I!X3L%(PAU;9
M,K<+`>%3\U1A.@;%;.QN32C-.?GQ*F#M8H3!]YVM^OMT+>@XWK[R!<=<$-4'
M>^O;TC5(-5DN+TTP=;)&R5.1<@<8ZE0+7I,F#%V!^,($@3.:<0MG!*#OY=:#
MO>_76!B_(_DYX'[N?9/%>2NH*VNF5PUM+>I'%&%0\-,I0,9BA,DV_%QN5-+`
M]N#`0M6D)SER8@Y(0H/+*,,`88`(@RQK[^XW>.9Y7V.DZ`@Y7,D(72UKE%ON
M@G=CC36Z0>1J8A)&S9+TUM[PL<DLH2#0$)TZ4TY>JV`M*$X1A?N#C^1_(KQ#
MW@5)A<C=*5K=RR&;*%*F*,N*Q#*V%(>(DM,ZN,/D:!DE2=A5'GZ*)<-H_L3C
M]"*`:(P`PA"%KX\S_BUYEMATHZ\.V*9A%JL*I.WR2(;<'N1JHJYJ5(DNFF6K
MXDR/S/%'A*9KW*4CBH3*4A0@FG@++$$>PL?;'<O(5'5W45O6GT-6,4J>^9C%
M8%4-G&R`EUK^=2:;H%[K%DS3,F(#I'BVQW;6M0>!Q/4$MH"BMB,/!KTWL,]L
M7I&D*FL2CJGL.PFF,V'TH_22,4=&5*5V5*K#?8A']2F2(&E4VMRUN2":V`6E
M(AK#DQ0PBT$`A#WH.!+KT],\<9W60R%U;6)@86U<\OCV\KDS8T,S0V)35KDZ
MNKDM-(1M[<WHR!FGGFC`444`0A"T'6]X&L.M?-SXG;?MQMHNNN[*)D=F/;ZH
MC+"SA?'-K9Y$_D*_L"6F.39Z:&V#2%8ZK-Z+;@HG(_\`*#$'2/Y_<'U#/NKO
M+%X\.'+';*CZNZ@A=,6,\1-OG+;%I"S3AP6JXFZN;NSM[T`^-Q5[0!3JG)A6
M%!"(T)ON(%O8=:WK>PG/D_LWF+N2N7.V^4+=8;GKEFEKC!7.4QY!(6Y$CEC2
MVL[PX,IA$E9V1?M0F;']&=L02=E"">'VBWO6]:"`^JO+=XY>([+3T[U/U5`Z
M?LU3&&R9%P]Z;)H[.@8T\JG%&UN9^XO%WU*E"N/:5'QE&F`/V$&A^SV"`(06
MR-Z%IPKG_P#\I=S=$;0?Z4EW@&Q4K<^+&\VJC8N&:ES`EJ2-9\B/1#BX]+-$
M@1B5[!OV_%[_`-W`P]7V1R\AY=WVJJNR$E<K_P`BI[*U=?WR@<0%#51A2=,Z
M`$6E&YF*3UYP$8$(4^UXEXM)=$?<?[6!5R]/,SXR.9W"O&F]^M836KG:]4PZ
M[Z_0/T<L82N159/P+3(A+R2&^&+3$*1Z"W'^PA5HA67LO>C"@;^F!*O(/DJX
M;[W=)RR\A=#Q2\'2M4#$Z3E)&VF8-HX\@DRAS2L:E4*3QQB+.`X*&=2$.B1&
MB#LK?NT'6P^H9A0?=?)?45H7?2]!W5';)M#FY^,C%WQ!G;I,C7U\_%/S]&#&
MYT4/3&V-RLT#]&%Z;8D9RD'O3"W[O;L.Q!5J[O.%XI^<+6G%'W;V57U?6M6S
MQ^`F\,=8[9"IQC[O]FE</L5*AHA+BW*#/M%I0_4@\T'[WIZ^[6]:"_U%WW3'
M3=7QBZN?[+B-N55,DQJF-SB$NQ#PQN.DQPTJY((XG>C4+HUK2AIUB-0`I6B4
MEC)/++-`(&@B7K+O'CSA6.,4JZWZ$KJC6J4K3&^+$R]T.&_R90G&G`MW'(FS
M)765/J5KVK*VL/2HC2$030"/&6$0=[##:E\F7!5[T-:?35/]0UC8-)T>PODG
MN"81Y>X*5-:L$=0.3JYN<RB)C:3-V%/^,9U*E-\[:`2X@D1B;1H?3>PEF===
M<XUIS)KLF<VHR1[F7<%A]F!MI2A?E#&*"S[;'J'R$+>A:54A$E?=R5#HH&D?
MSZVI#[P!]!>@8+*?(-QI">D*JY$E=]Q)BZ.N^-,\PJJK5R.2`>)G')`5(#F1
MR;G$+&./$:=0Q9?H@I0L)/,&G]F@>\981!]LN[VY!@G5,%XBEEZ11HZJLIF)
M?X33!B60*I(]M*E!(G5.J"K0LRI@;]G-L4<#PEJEA!HBD_NT'T&7[PD^C^CZ
M2Z10V*Y4A8+582&IK9FM%V*H:4KLE!%K9KHY&GFL+7!=VYN&<XL!S@2$TPC1
MJ8?R:^,T>O7T"$H_Y'.)I3`:2M!@Z`BKE`NC;S'S52<D*:Y:4CL"\BWI_CPJ
M\:B5$=)6I77\S%EY&CE92='L2;>]';"(`A!=K`J96O=/)MP=(VSR%6UT1Z5]
M(T8VJ'BV*J1-LF3O<-;4JUA;E*M<O<&-&P*RR5LG0%B^U6*!:$I#]/H+VA1!
MP_R'_"^U+E[:X=ZU@E7-:Q6WKTPXO:XC$ZQ">8F5$;T"OAZ&(H\H0?4.Q:%Z
M>NM[UO6\"WK_`.2GA^,IWA4\W_'R"H_RS&NV7G[:.SIS.0<K2YR1-3!=)R9K
MBRU1N**UC@5\@0@VL2E;V<>042`8PA95UNNI&.FEG0[M8<404<@KD5NJ[3/=
MTVH65608[J6_SO\`FPB$E,CPXWO2T!X=B"81O0@^OKKU#7_;7FU\6E$;K<%P
M=>PNOCK>JF)WA7*611*T4JR3U1.S',N'S5,B!!#5:-KD/X=0-,%4`@\90-&?
M'HL8!"";N0/)-P]WPX3MKY!Z%B=X.%9(X^OG::-M4N;1QU'*3G9.P'J]R>.,
M0#@.1S$K"#X=F[#LG?NT'U#ZAAG5?EI\=7$%EHJ=ZKZDA--66X11LG".)R%F
MG+@N/BCRX.[6UO(3XY%7IO"G6+V%64$(CM&ZV0+>PZUO6]AE-`>3;@GJ&K+6
MN^D.H*TEM04:<03;MDN*MU@T.K[:ENV[$G25\L%KBJ)"C$WAV9L_8MD!]/;L
M>A?NX$;\\^93Q?=66B@I6@NT:>GUIO&SP,$,"L?(RZ2=2G,V68WQ,4R9(\CE
M;ML(1&`1MQJI480`9P"Q%`$/08M=/G&\4G.]JSFD+I[-KV`VK6CX;&YQ#G6/
M62H7Q][)3IU1K>I4M<)7MJ@P!"HO>Q$'F@_>]/=ZZWK03`N\I7`;;R8U=TK>
ME(@3R:]R8<.:KH_#38V/K),7(G&)C:2VPF+F2<*@$A:%*;8A(0EZ$5L7N]GH
M+83A8?7'.54<T[[$L*TV2,\TZA4,L7]6%B)]4,>X589C`5#'_2%`TJW_`&F?
MS)0@T4#2/Y@[4A]X`^@O:%@D"Y(YH4;D@/"I0N"1.N1*0:%H"A(K)`H3G@T/
M01:":29H6O76M^F\"`^H.L.>.+ZK57=T_9[-455HGUEC2J8OJ%]<&\E\D1YB
M9F;Q)XZU/+ELQ<<4+01:(V6'V[V(0=?7`JQS7YC/&/U_:#=2O.?8U4V1:KRC
M6KF*#$"DD:?9$4VD&+%Y$;3S./QTN1.2-`0:I,2(1*%8$I)I^R_B*,&$,0NC
MSC^*/GBU)S2-T=FU[`;4K5].C4XASK'K)4N$??$Y!"@YO4J6J$N#:>862I!O
M8B#S2_KZ>[UUO6@]+KYSO$ZR5/#;S=.T:\1U/8,UF]=0V:&1VRA-[Y-*X;(D
M\S9A3IBX0-S(4L#9.V@XP9Q!9(PKB_C&/>A:"&05%YI/%]?37<#U4/7L"G#7
M054/]XV^L;&"Q""X15,74HDC_,G`+E#4)BQ`V*7$@`RD@5"K>S0^TK>!;6Q>
MN.<JFYI_\P[$M1DB_-7\F0JP_P!6%B)]/8MPRQ36`B%/VD*!I5O^TT@-E"`)
M0-)/E#M2'W@!Z"]H5LZ<\O'C?XSL!JJSISJJ#U'8#W#&.PVJ-/S+.UZQ9#)*
MH<TC&_%G1Z)O"$*5Q4,RD(`B-";K96_<#6MZ]0S^KO)3PG=G.UF=85/TS7,]
MH"F&Q^>+8G\=4NJP-=H(T@4.SN9+XQ^+!,V,XII3"5$DGMP#E:7VFD`-+&`0
M@S>1]P<FQ7E4/;SS><*!RB.-L,M!=S:<XOT1$P29\;8RSK0Z86]R=MF'2)V(
M0FI_MON4JL0BCRRQEF:`&</W3%!QBPH'5,@M:(--A68T21]A<86N/Q+75KB+
M?%'9_4J#OCVB91)&Z<M!Q92\U*:J`O*^`)GKOT"<\!@,!@,!@,!@,!@,!@,!
M@,!@,##+&7R)JKV>.<03G*Y8W0R4+XND3HMN2A5(D;(N4,B<ANT`S:\XYR+*
M"$G01;-%O0?3?K@=;OP(5APO*/#FRV1:,&HZ12:PB;L?.[Y38T1C!\E7V(NG
M\_33MNMQ6_-!#TE"WLQ^TZ9&?[24Z4?L2Z]!;]P4G7HO'-*;Y_Q[H=`T24_Q
M'.N^U7&A&CHE-)%,1DG2Y+B)N@;(_I;H`L?'!"9*7!5_+J9Q`%E.4'%!3;&8
M(`,"Y'F3K[G>LN^O"?-J-8H=".Z7COJJ(<2AK%O0MEB23CQUU)T][FRB+L*3
MX7.O&LM0$L;@X$?]$6I7:3&A#M7[0T<0"U2O'ST5V'Y-V))M(,_RI>:'BBRU
M:!\B4;/DNI+4;)?7-[,H4/+*O<GQ>GMZLE!3:4$T98%:HHD!>QJM@/"0.7^;
MP<HUYYUZ8<&T+7-&SP0\[2VW#=@;AKG&Y[*YJM2P[;=')8UH6Y.Z+3)W)UP`
MJ!`$:,@HO0S#!!V8(+!5IRWY0_(5XMN6.,3/'YQ)2O/=M4)RPV$=LN-IQN;V
MG%JQC+'!I.WV\U5>TL[3(B+1?V%F+$20%?L:96N,*-,"`0SBPU_^0?INA.C.
MAO)Z]S%\N5RM+FRMJ<Y!\:4D@U&VQ83"LGW(EE%69/9L[R^)M@XFD<YU=\/V
MUB.7:.`G2J0F^\U,5[1!M)[JZ2N'OQ)_C6=&\P-=$*K^NZ:WJ^-,=Z';I0Y4
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M:FY(K5C"0F3$^\>!/O@`J3A*Q?$6W/4SAE`3>;RH=SB\@+[.&*%KY%JTU<KF
MJNQ&^['EZ0E+FM.UQ5PT,@*LTM$E:#`FI1:3B^38=>#]'ZVZ%\;?,_+C<[R%
MUXNGW^4!*N?>9G4A<[*$O_B/,66;LD>65](G+2=X?6%.Z/SJ<2K-.&:8MT>`
M9FAA'H(7NAG0EJC\D_A<\>'5KRL=^N?'EUMU%5CO+%L<?&4-[\W+N;2BN<.C
MD*IQ$N0+C9[$6H:-S^-:H.TZMIYAN_>;O`WC?Y(:Z3H_$Q>)+6:K2P1VGE!L
M=]."$(-J6V@76Z82DLU4$T(37!.2-L&62<-$68LT2:/18?J+>@A/S%4?XNT_
M@ZN:1-T0YNC--QN@S93QQ,X&CBT91[MT$6<%E!'5-(HD0D7.KY)I&>6#9*49
MOY),H5_>!$0)2+0:JD;+Y"[-\I'')_.C'RI)^HU_^/)RC(+N3]_1B?.44")9
M:`13=86SP!#I\;K2%.E9`3-'E%$%D"5`&'0]AU@=N7B:)])0V@F%JZW8.9(Y
M?!KY*%LN1<BLDI8*5-1&O*DN+J6=%-"$\C$\CC!*0+B8>'>A*@"T7OX]!P.N
M'T/Q#8UX=U>6GL7G/RF0BG;.JB"5VQV5245YH897N%"J"G#I+7,>NQVO$QS;
M7)HD+2UB5&N<:+)2'$J#@BW_`+6BM!V`?&7T<\=C^/GDWHZ70MJA+]<%)19\
MDL0:D.D<;2.A:8UB=AQ]K,+"%%%'E4V&*VY-OWZ);U!1?O,T'WB#K9,W!KT=
MY;#_``VJ)8G.\8<*=@>81KHO;]+=';:G9X3UTS<T'&?=B4FU6Q=)%*):!I&M
M$WB3["+9>U`A:T$F]O0[LR8?Y%2]JX:CO'$@LU)XCX4KDB'M=AG;]6">"%]2
M2I.H/C**NTZAW(FP7PY$`HPW6DVD(E`=[]VPZP+[O-Y]R>./Q\]S=5=VPS@5
MELVNX8!70#?Q+%;%8F*4R-S;A1J$1VQ"K!;MNCBYN%K/[>4G`C+-)+1&'#&'
MUT+>!UGO%OU?0'(/9'BC?:U7VX.:7[54RY'\C3K9E(VQ74<';E]6H?=5=2U%
M*9HUZC;@O:[TF)S&(U#\!0D!(S=B`F,"``6Y6O'DGKKLKS^7CPQ2?#]\1&G^
MCHM-+,@'1L#LJ=W?(E3#2J)S"UT<U0U4V,3AO4?)4G&HEBLE6K4E@+2^\P?L
M$&][_'KJBK8!XX8C8E57(TW0CZFLNQNI)JY1>*MM?0B`V7:"Y"3.*?A=:-:Q
MQ3UNS5<[1_;0<S_<'?;N*=2(O821E%@"MT&C=.VW_DF]BMO3T8A,HF]3<2\Q
M$<2LEFQQM6D%P60*)$[W7+ZV0R!">UN\C33YW,;SG5-ZN)*82I&6+9!2D)88
MKW=%_'`@BWG>C_*<83HNX%'C*FG_`)2--8M$N3UZH9%->SW4&`XMS&2&JS+7
M-V7K[SX"_P`V)-K7N]=Z6>@1)W]9->.O^)%%3FR=1%Q*EW$/%-<14Q%(FE4&
M2V"SN5)-SM!F'X%8]N\N;%\8<B5#<1\BPDQO4A&6'9!OM"A_EBKAQ>/)%9=U
M1UL-_5?AGPJ<D]P5@O+-9&IZ8)#S;VPSRN8;0.<A;'$MK/6UII\3&%E@`<I$
M(!&_<`0BC`]=/J&_H/R^>/'R0*6T)JWM#R7]YL%62,YQCLAVMYFY@Y,CE,5:
M4Q/[*V)##(VODS;(EA`-G'D'DC(/+]=C$<<&YWP&SF%Q:%>7=LD\LCD<<J]\
MOW=DZGJ!^>F]G60J$O+I'7!HE\K3.*A,;'XPZ(&!<<G7JM%)3BD9XPCV$H>P
MAHIYG]3/&C_CU+0:$)&Z_P"0:6[-BK01:3N+4XW;TFI0.2$W>M`5(%J<>AE'
M`V(LP&_4.]ZP.\7U-?D7Y8YNO7I":&DEQFD*JG%F.@#]G:`L!$H^N=DS8'28
MLU2,]V6IRTI02P#,&8<$(0[%O6L#^=]R!W)4'.-M^-KL\1EM"ZVGG6/1"WR5
MGR>@[8B-?AJSNR=(-'K6J;OS8*'&)J>5M+&-"2W[`%<<<#1?Q%@,T(.T'T76
M-8Z_R&_'*RD5Y`],+MPQV"X.#25$H]II<E87IE$2M6(0-_VBQ0#YA["8,(A:
M]XO3?[V_4/C=*M@-H?Y%O1E+S>,-+U6,]\$<=KB40\Y&G"RN$+D/4KC'W-A^
MQ"7I,2A,:5(B@`"'02P^GMUKTU@:>F^77K,.5H)_C-NQY8NCF;N4SF6R5I:%
MR3J0>,"O-MO1S;?&S"4WN0LDFA`T#`E-TJ*-/*!\`5&U1NPX%M^HJCZQ2^?Y
M36OCI@O$FWJ`^'BGH]_*G8T9G;M4L:J2-]$O[`TMT%:ZX3G.2"3-:HIM3)OD
M#I*!MT>#_5L&!O\`O'I7_<\)C=EF=VQ+A*-31QD+*"`&\-QBPHZQ+(BF:S-N
M`+`%8B5.XJGLA\.'M)I-ZD`3BWZ_O[W@4F_R6H?$EGAD[GEJR+1Q7*FZ"U8F
M;Y,I8VQ1($"?]?JN+^!&\FI1N*4G0%AVO:`P(?0T?T_>WZA7CSEQBLHKQQX[
MH_.X]"85QO-^_.*D/<+@!F8F",_HD4E7K#%4U.0I2U6H^.3(&\M8<`HWV$:]
M#=@)]^\#@?\`)%J?BN#>+ULGT*B505_T'!IU2CAX[72IV6/QN9J;5%.X*%K9
M:90P5`49)6LVO2E"C[`@D]KT2E3'["$9*880D'S/P6+J9UX-'=^@\7_FN7^7
M'DY-/UJR)L9#M(3U\)FNWM%)A:;BS5Y:E43K1Y!^A%[$7K6P_NZUH*C>;SJ#
MEYM\B'!7$5XL,D1\A<^MLI["Z-C%+4Y-YVN<9Q)HY/H#04,5,]7->U#`E4.9
MSJ[GF^T99NC`"/+WZE#P-?+%U$3;W^*QY'^:5RYX7/7"\PA]&QA=)(F]P:1R
M*@'+HJJY5S_,'J*2%.F=F!6[1%8<D"E/]YQ1#<7LP8C!BP.^_7?_`/S^"_\`
M^G1G_P#LB'`T&?Y.J>1*_'-!$L0*CRB6J>WN0D\7(EQ2H^*'2(ZRP%LA4G(1
M:$L.CQCD(K2T!.MFB3;'H'[WI@:YF.%=97+YFN+>7O)\5Q3S-(^=7`WMCE22
M\64Y+XXT]>2V-DGHGVH&BY;/==OB`N&DHA.$BC13<%0ZMR<8S=Z]J%1H./H"
MO/)?-?(AYJ5'"L2\;4DB2/N5J)G1O<,5MR0RY/(A5DV#0%P8VNDJAL(CFVP7
MJI"KWH_[K>ME_N;'@;_!U/;Z7QK7"A[3KKDO70+/2G2;K($_-$+=2*6;3UD6
MEX8^XPQ)83=_,R)X4Q-&W!<SC-!$8L*%[-[*"7Z!J(I>#1\K_$H?7F/0YF+E
MS]XL+?3+G5ECR($C>0#BTS4#3JUR%'IS<0B-*T9L(Q#UL0="WKUUZX'Q>3.R
M*]>_\3:*#9IS$G8,ZX^X4KV%;;)`UK_YNGC-(*)(=X5&M)51NWN5M9\3=`*&
M]-HQ40-N4Z&`.R#?:$7]+Q+N*2>=^1I>%H;QS,;19_#E2CC*(]VLQ3=WABB+
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M0(1H0W!X#`8#`8#`8#`8#`8#`8#`8#`8#`TN79_C[^*Z_+BDUV3;GQQ;)#/7
MU')[+B\`LZQZ[K*S9`F=37A0[3NN8?)6F*O2UW6'"VM'I.5]UO>QC]3!#&(+
MG=!^.SB_J'G./<H7#04'>J+A*%K15Q#F9$9$MU<8Q-AC.Q.5:.\9-:W:$NC.
MWF[+).0'%;$#>P&:,`(0=A`G'?AB\?G#EI*KPI6IGQSN0QH-8&JS[<L6<7%,
MXFQJBSBG!KAKO8+V]CBQ#F6H,"H&C"4<86887[]%F&`$'/O_`(C.(9-4]R4J
M[U_)5,"O?KI1W%8:+^?I2%P5]$JY`QR13*F=W^_VO8&PYQCZ<.VY(,I)\&S"
MM!]A@M;"3IKX[.7+`GG7]DR:)R!7*NYZ08N>>B51$RD*--):PCD6>8:UM3(B
M3K0)XJX%L+ZH+$L0Z*4#&+0]B]VO7`LC4U/0JD*8KNA:V(<V&O:JKB,57!DP
MG56X/#/$H='4<6CQ6WMP&I7+'%`TH"M?<G"&:,P/O%O>][P,!Y/Y/I/BFE&"
M@.?X\X1NNH^[RF0DIWF0/$I>G*13:1.,KE3Z\OSZK6.+@Y/#ZZGG&"$/0`:%
MH!80`"$.@K+77B6XIJIZH5Z@\&E;3_XQWO=O15'M0[#EBUE@MA]"(1HK-+1(
M5KB?][%W+9QIR9L5#/3HCSAB)T'W>F!.\UXGH*=];5)V^Z,+TW=&TS`Y-5\7
MFD>D3BQD.U>RP:L]TB$V9T0P-TR9"5B\Y0C*7`-TB4F"-(V`>]BP*\K?#UP"
M\\?F<+R6EQROGDNPI?;+,QR*6RA?*(K94U?)!(G2;1*<A=")3'7]*YRA=]H:
MF4@^$D\1/H(H0@;#X>/?#=P-P]9)MRTO5TC=;:`UK&1CL>WK+GMR2R&LSH7\
M3RW09QL-]?=1$I[!ZA6&(0$GGEB$6(SXQC`((9O/_'O\6E_VI-+>E5'2:)R.
MRG`3O9;-4UMV75<$L%Y4*U:MT=Y9!(7)6J+N+@^B7&@7#"F+TJ",6QZV,8QB
M"Y4L\<7'TJKOE:I2JE00ZM.+KFK^^^>(37[DYPQAA=D5D%XU%710F95)`I`F
M`:_JSEA*X1^G!0<(Y3LPT0A[#Z+9\>7*]U]=T!W//(&K5])\T-+NQ5=.6M_=
M64"=H>"'M.:WR1J;CR$,K2H`25?M&!<$X*0:PT16@[&+U"U=@U]![7@\KK2R
MXFPSJOYRQ.,8F$/E#:E>(_(V!W3#2.+2[-JPLU,K1JDYFPB"+7T^F]>F]:WH
M--%??XYWB:KBQXW8C9S_`"&1$PR3&R^'5I/[>M&?4S&'S[TYP;SFJK)5*7.)
M?;,BD\7VB<\@X@`=[",(];WK8;+DW(M'H^N5?<">/N970BV@$G,I\B#(';3'
M^D2&<BL1,R%Q/[G\"6O+E`MF_>A)TI^/_;]WL^F!9G`U9]:^&7Q]=MW<BZ#Z
M!J%X?+'VP,L4EBJ*V+/:^9K1C$>4;-9F&UV.$O[&AG[>@2C$C!]^$PS[`7V^
MQ[*`6$`;*HC$HQ`8I&8+"6%KBT-AD?9XK$XRQHR6YECT;CS>G:6-C:$"<("$
M3:U-B0H@@H&M!+*`$.M>FL""D_(]))>NW#N0EA=0]$.E!).:%DEW(G<3*.I4
M,Y'8R=F#%=J?P0'$,J'L[:[1/W.R_P#;V+V?3`IYV=X8>%^]+O;.B>@8S:9]
MKM-<M54I9%7EV655^A0=F?GR2H6A2CA#^T)U.@O$B4FC&/6Q#WL&A>OQA]`C
M:OO`7X[*XCSS$&J-7<^Q"2V#3MF26+S?HNWYHS/\DHB0NTJK@#@1()0M."T-
MK^\F*%"4@PDM=L!83_>`&@X&Q#J_DRD^U*>74;?L?<Y!!5<FATT3!8Y$\Q1]
M9I=`9"AE,2D+*_,*M&O0N#0\MQ9@?WA%&@]Q9@!@$(.P]=(<DTMSU9?1UN5H
MS/#?.>K9ZPV5=+FYR!S=T[_+HY&R8HVN#:VJS1((^3II)UHPE&644,S>Q;#^
MS6@X+DOB>A.(V:U8QSNR/T1B%O6Y++ND$,62=V>XHQ3R<'%GR8V",CB<:DA+
M"XF$%>C8@T4A)^(/Q%`^OJ$8]O\`B_XM\AFX4X=-52-_F=<"/!`[/ALGDE<6
MG%$"P\*AP96J?0IS9I#IB7FAWLQ&:<8G"(PP0`@&8,0@RGCWQV\?<)5=**CY
MMIQDB<8GZM4X68O>U+A-9;:+@M3*$2E78TNEBEV?9=[T:PXH)*LX:8L!QN@%
MA^4W8PI)!?\`'A\3M=V^PW#'><5@U,2F.K`A]9O5F6._T?$I@4H+6(WN/U"\
M259"T9[>O!L\@O:89`#!B_<V'T#H+[RKAGG.:]$6)U)(XJZ.%O6GRZOXYFKH
M.2O(61TH9SDBV5K8SJ,Z5?A4Z\]Y<#1;7@*TJ^,7L]_M^F!&<&\7_(5=H.&6
MV+PV3)DWCIW/-\MZ4SJ3+!Q7=DL!T:EFY",]<+<R^]:CQ!+TX?-H@7[Q?MW@
M01U+X)O&IV!<TDONW*5?4=DSPM$59[E6UGV'6#7;`4!21*G%9;!"I"TLTL.V
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ME+E+7A0$F`RM,VI7XN0M83BVR1/;@%J+$)<H*V=HS8A:WK>_H'/HN2:30=<O
M7<*9B=0]#2"A6WFQSD@I$[C93:G:IN.PT3.7%A*=L9+B"4#V;M:$K2D1?^WL
M7L^F!BZ+A+F%O[3>O((EK9$#J9_J)'2;E8&U)X@&PM$M3JBCRV86]MI,I&B1
MDMQCL$&EYC22!%LS:<.B]!5[LOPM\*=X7FCZ-OZ,VH?;2*NF:JBI%7EW676`
M#(0P/;Y(6UI4H82_M"93HMVD2DT0QZV(S>P>[U]@?0)2X<\8'*OCQ<K&=N<$
MEK)5EJ(8RWRS=D7/8]K$C31(]Z4L^FE/.WYY*930FOZCYAIM%B/UL&A[WH`?
M0+$=6\NT_P!H\_6/S'?C*YR&HK60,[;,V9G?72,N2U*Q25EEK<%*^,QZ5S;Q
M%/<?3&"$48'8P@V#?J$6];#G;;YWI2^Z8?.>KJKF-V?3<E8$49?H+,$FW1J<
MFMM"FTW?(,0RUJ=Q;CD91R980:4K3*"PFE&`,"$6@UC<]?X__C`YKMB%W/"Z
M4D\LF=9G@6UB5;]M63;47KAU(.2FH'J&1"<2-VCK.[M`410$9^DXQ)-%@$5[
M3"RQA#89T-R52?43USY(+@8G5Z<^8;XB/2-0FMDA=F$MFM:#I71''G=R):U*
M<M];DQ#P?H:)5HQ,;L6MB#OTU@>NK>1Z3J"_NB^GHBRO(KKZF.K[5O3!\DCN
M]"<FNJX^=&8#'6-L6*!-4;8(XU*30ED)"2]F#,V,T0Q>F]!7V_/%1QITF_\`
M54CL^$RA2N[5K>I:OZ0)89_*H\@G[!1LA;9%5Z\2-N<"RV61Q@YJ*3`6H?MS
M#D7N)-T/0M[P(-YH\%'`G)EVP#H"GFR_$UAUFJ<UD6%+.EKGFT9*-=H\ZQ=4
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M9S9DTL&1J3;$C3?$Y.4DELL=G-^;TBAF;2PDE%'!`0;L9@-:&,0MA+=!\QTY
MS;SK!.5*SC0P4E74('73!%)0N4RWYX@<!86J:'Q:^B5J'PA:2O.+.TIV/1I8
M]A%K8?I@:S:[_P`>7Q05?<,=N6,<Z+3%T,F.I_!ZY?[-L>2TI"IB4M*<D3[&
MJD?)*MAJ%2V.)6STX!)C"BS!BW[-Z]-:#8XW<E4HU=;2/MU&Q.H.@Y71;1SD
M\R,<A=C&4ZJV.9#GK>TE1<2C;(G<"Y(/9HEH2M*!%_[>Q>WZ8$#R;Q=<@RJ6
M]KR]9$).W*O(372.M.J&5@F\@8XM/6I#'114A^21YO4DH(Y-A,IYY9KNB"2L
M4#5'&&B&,?NT'GTSXNN-.N^4:LXNO2N7"4452R>N4U:MB>4O;3*8P&K8MN%1
M0Q#-4*HN2`4!C`AHU9FC]#6E&#T;L7NW@7];4"9J;T#6B"("-M1)4"0`QB,$
M!,C(`G("(P>]C&()1>M;WO?KO?UW@?;@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@5^ZMZ"C?*?-MV=&2M*-R9Z>KJ230+&0I2)5TI>&U"9J-0UH,6J$R<U^FDD
M-2-3>3[]#4+EA10-"&,(=AU1N+.T+@X5KON(B0,'0YEFS[ABVO(0RJ>P:&N.
MDHFZ=STQ$'R2=0UO"&ZT6^$/-D1AV1O4==0[8#B/B;&=6,Q,W:^,9P6UL_R+
M^6:LH]TF6ZF<%'RKG7A2"^2>0JF^N;U51\^J90W6R`?-[*B46HA<7B=*'>JU
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M$QVD>=.+<RO^TX$@C1@V,("#0LT[>0OR)<FPKJ]DM`7.5HMWC:Y>X?B5F.\C
MW/@61=G571E-0!E52-VL%,Z)(NT5='+<?37EV</P8G-R:O<F*3ISM_>8$6=C
M=<^45MDK9QU([@Y9C_1<`ZJ\5MD-5Y4+%[FCM<RFM>J;ZE=5$U)857K+:/EG
MVS79$!"K>@AD@D<JABS[;[=`>?HTL.<LGRQ=B/73"ZAU,=J63\RV1977G'KS
M/X)3UR1%'&K-INB[OD(U<+ORQYXQ(;1E9#Y5Q^GMJCT&6LD=/T>WFR(U24F/
M6!#O(/D,G/)7-*N[05Y`9=#:3Y]\-;%>:`I3-%%_7XR7YP]!R&APASFZS9W8
MW>T:^F#HE$B96N.[/D++]T69_P!86%9@;<^K[0M>QO!+U9>-B/L$36%97C\O
M6W4:JEEZL^'Q-LG%.R68PQCBTN*?7@R6GQ*/.:-(9(4IY"=X5$#6IB$Q)Q9!
M8:*HX7*>(&#J%TDO*;/R+6]S>&[HB90?E:3=/S'INN>R;GHV*H9_,+-E!L7E
MK0[T^NAM7NVT*DA"K:UKXWOIWQK@GMX`A#8U//*'V3!T5^WO`H_R<BY`X=OG
MFOEZSZ8DNK&-Z+M198\;HPZ6S"OI^1*OY-KPEI/OIL!'6AS9'TUU)9EFSUI(
MQ@]`Y&PO&_Q@^^;6NV%UIP:IDGG&M_=5RYHU9%M)VQ[Z!8.IZ%(9[)4(4T\)
M2E.;>1+G(LM,4`MO^-6(.T^PZ!H(0/R3V1V+S4]IG>0&TE-^3KK\K7E,I9/%
M%*"PU/1*9PA,H[`O<$OW8JZ5@K]F84;G3BAA1QXN/JO:@,*4[<`"%M,2&&TS
MYV.[)92-J7U-Z)8PPZ5\!=+=>T2YE<I=+5?7%8SVG(@.R(;6TPNJT)6DA73T
M3E$.5!3G/T+`SB_*H]A`F"E5%J"PD7MKRQ^2GDZ`)QM[1RQ9%P5_RLW=E75#
MZRH7H6;1AAK>52&8_BV256!(+0K:`4Q'&)ABAB-'(5[R^OLQ<DZS;?%DXB"D
MJD)=E7E`[V;'7J.^(^S\CNG+_)7:-/<W2BE5#59P>F+*B]PL_/._O(I-$<M4
M0U@ED8=+S`<W`41U85)"4:@K9;>(@)B@.#K3S&]=V-W(KA;919CKR@C[]G7"
MKH@C/,71#P\QM)$94ZU*1=[SV.-V2<U:/'9K:4N<(;IL`X(8\I]`+5"TO1)@
M0EUQY5.L["\9=+R2&/-9U?:_67!_D[N&;RF))ILTR*OCN3XN%QC;O42ELGR=
M^B;NYM6EA)3DH-7Z3.@DYX-:T4(H89U%.VNMZLM*>45&F?E91V+>=^^._F@W
MH:1L5QM]5KI!8?#,NZ"D%CSVNUUMR!\DK@QPRN36!B9VAT8!.+HL*-6*M[WO
M`L?U+W1Y)Z-A?-#X6CX]1Q\==6G(.O>@*VA5T]:T_"9;7LJ:6)C/(@M9S*#W
M?6E.R-JTM5/\N$S2]%"5FMI%P3@$Z4J`WJ5;-DEE5G7=BH%T6=$4]@T3F:1R
M@TB'+X4X)I.PH'LE;$)88ULADGC"HM;H:!P$B1B6)1`.V05L?QA#JA\;]E=W
M1;E#BZB>7WKGE(:7XYNJ>QY_/ND(G9UDNXA4KTJHBB6.,*&'6-"#7,V2)Y,!
M(+:Q65I"#?W01G?`%&>%XZ!\E7;/6MD11YJ)FXPK*FJNISQ_6#T?%KTEU@M,
M[L%Z[:I5BNMV1T[/6?9L<KU)7[+(BD#,2\LKZ;)G8@T@9C>#T-T'84P.H5Y@
MK"[%0]#^2Z,Q*WHWJCHAQWXRI=%:I<?U$;E2":S7N!YCD><V=_:YF./1)P>I
MC&%Y<J<R&)6H<XT-N1%E`.0B//"<;Y\MG>?,Q]P\^6!%^?[`Z59>UN:.9X-8
ME+T=?TT@S7&>A.;)!TTO=-<WQ^=RFXK<EL+8X>L942%I?&P3PJ5E*C-(RB#2
MQA?CFCK*[NI_&]U9-;[KMWK*YJM;.H*GD1BFK+%HI',]1"!K'V)61&ZIM5P7
M6?7B&1121M^SVQX/&L0NA"HL!IQ`23S0T9UK:]KU7R/XE>.;]G\HF[;<%\>(
M&_>6K/F[PL52"Z*DM.40IYZ)YVD+KH1!$D=^=']_"F^Q$'>SZ^>6<1WS#(5B
M"%]:3Y@M]9W<=XUIO8K>_<+\.RMB[\K>'[4FJ)3,8!=[Y.F[F3FJ<G'QTI8L
MA_,=S5W+WHHX;JIV\M@V%&K":%(8$(5HEE34O%Y'*?(I9DCFUXU9.^Q6N>UY
MY-.=.I)I#^D*-2R2X(E`:]H"9\K6<VH(&=7\4=7X$`6,K&G<E"N*IU*Y2U$K
M%'IH.(B'*W_DCV=Y'G^5>+TKM=C0^1N90(^_'GN5?11L!BZ6KZ%4K8:W54!W
M2*'1N@Z=[/=`&I_C^_,7#)!O0@>N!=7_`"((=9[[5?!$3H&02F*66P]72F=5
MD7$Y0OC*ETF%#\;],W-!(RZNA"@"I1'7>1URC2KR?D`>H2C&`HTHX0#@!KHE
M70DNZS\F(>NF&739%24@X=[)H2G6':F3QB.F;K[A:H>@;*DXH&\J=K$$J165
MT+]CIR!\92E(VIB=`$H1&'C"Q?A83/\`T?,*N_\`D))G#->5><"\_@X8HYZF
M:113CAQ?8M"PR%33H.!N4<D&E=H7_/G[[I%/7%R*`YP](N;$)`20*M'&!9;Q
MX>/GD.K_`";^1-7!ZE,9C>4+`Y91\]@-L.TWE+6:6S^2&-[GI#2@?INYH7`N
M2.TD6J#M+RU?M,/WLOV>T'M"<+]JB`=J>4B2\I=8KY,[T%6/&%:7)2M")[(F
M=<PJY[$FMMV5'K:L:1L<3D4=<+4=:1;87%DB#V'"1QO<D,,/*V>N3&@#%)#U
M!,X*]\P\:^-6^*]M9SZ"N[KYC:+UZR=)W>,"I2.<L-,<?;(I.$#C;I`IO>1[
M')I>!G9E:R6K?PY"%<F4.*S:`"8@*RQ[RK^1*]$,4CE-MG'$!FL+Y/[;N>_Y
M-,8U:MHPAUFW#74JWFV2&TLCCE@0%P4PZVUS.):W%.JD)[.F6:,&>M$GT2I#
M&['\Q'D"JZLG*SI#$N15'ZV<'T)W5S?%D[7:2-#5;/;G5/-]&!K>\9PLE_MG
MXC8??H'%2^-#3'RVE:C&$*-<2'6S`GBRO)3WOST\7QS/:3/R).^ET%F\'0&C
M;LAZ*SX/SHQ[[YGLZKB/E7/"7R32R8[=J=<ZV7N2@EN?B!2-K<&\P(6W8QX'
M'S;R&^3F-QF_Z6CL&YSM#I7ECKRJJAM^UJ<J^RK'B2^A;9H5;>Z&P*_Y*+N*
M/VY-K2A9)J-J>XFR2YX<_ATH7HB%>BA)@A1/O7N^^;6K:&3NA+"Y[;+CD/%\
M&DCIU!3.[_0Z,&P^5KFR@Y5`(LSNTOK]_KYK?WIV).E4<>6M0_,YQ#@PC<U!
M7N4&A9B0>93N%BZVL.ND%+M%@4[S-T[3?*-Z(JOY,Z4F"N=.;ZV05';MR1_H
MEOF*JBJ#2M+]8!*YBA4H$[+SFI"("EW^=00,03]Y&.DK"Y3[?OB^Z^_'.L@H
MWP4]2W-%8M*1.RR#N4R@_2%5N+,<_LK8ZM!RHD6R?A-&2>0H^`8@`-#K>\#`
M)CY.O(52C]:]#VHT\<2*_P"3*O'*W4',8TT6M#J4K-Y\A%FW!61".WTS],)!
M*K'9Z@5508K^^;#8V:_Z4EE?;(-[V((5%?N^>T.,+Q[M9W\VIK9ZDN[R!<9\
MP)I15=57G;530Y'OA8FS7290_F&'2YYN*2RQRB,'VF-A[<_A$0^KA&F.)B<D
M0C`M$Y>:3J.F>38/TU>M&QK:]!=%]\GV-6LB@]@<R2R56A$XB[V72U^PJ)VZ
M]O4Y@5*N,2;2B9XTO[>:NB2<:YY&X";6HS:D.QE5>I[JMH,*TGR(R6Q38PSJ
M)J^0%H6,4)<I&I1E*',^)M3B^25>ECVE)FPI/F7JC1DA",0][%O6@S[`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$:6I3M9W<PLL7M:(-LVCT?G$(LAI9W
M8Q;I`GFM<21!+H2]FD(U24*T;#)&M.K+(/\`E3&&%!^4L8?W<#"^@^6>?NJX
M\SQ3H2L&&SV!@4R14SM[X:ZIM(#9?")+6\H"2I9G!L6;3OL(F#DW*21&")-)
M4[WL/O`6,`<7)N/^:IE^HVI/4<<>/U;H-IY=L?[DYXU_-=`L7\U_B:R</A<R
MO8Q(?YX=O8,GXE6_O1^IN_0'M"*I7XSN#9Q><.Z3EG,5;OMV0,N#ACDW6IW8
M1H#ZR1C;Z[<WIB+=2XO*WR#HA!*:G!U1+5R$))/PF@^`GXPD0_C;GE,T,R*,
MUO'HVZ0^Z;*Z6@#R42X.8H=T7:R6>D3&WDC>X.8TCD^NY]F/1IZ95\B`S[\P
M.B0A]OM#5!P_X4G+F7L:*]4SF7\W>^J8[;+5`VOFKGQ^I%TL*1W&4G:I5-[H
MU)+2L^.-@2V<@T])&8(BB<53.Z\]26BUH)9>!NYB]/UI"K#M&UXM$6UFL.ZC
M(6=:<I2C6"<)F97D?%%86-S`>J-2`W'X\/:4GX"RO4O?[_N%]<#$'CE[GV1*
M[]62*IH?(3.I&:/1WH,A^0">FZUF.)Q4Z$QUKE34YG*FM0C:HL>-&6`HDK6R
M]^X7J/6A:"L\:\37CIB%(6+SG'^4Z[1U#;3_`!64V)'#U,J<G632*"#0C@KP
MIG#I(EL^2+82-O+VSB3.A/XO>S/M?B^8WWA[4GB@\=B"Q7VVT/*=<(K)D4B%
M+5TQ2#DJ9Y1R52D6M[T\QPXE_`"(+9<A<5!+^)I"BU(2SS`N>E>ABUL))AGC
M_P".*^D,1E,1H2'-+Q!":Y)B8]G/S@W-`J@JS=)U:M`QNCPM8U3M7]6C&SM*
MT],:K0IS3!E&!.-,,$$B).6>?T%"RGEY'63(GY]F;'.HO(*H+4O&HD=%[)4.
MZF8Q=M1[<MG1^-.0WY6$IO;S$J-"2;\20L@H(`!"L-9^(SQQ4^V6>TU]RM"&
MA)<E6OE)6*8X/,ZE#B^5+)R#4TD@"5XEDK?'>.QM_(-]JTAK/1:4_&5LS8ME
M%;`&;2KQG\'3B]HGTO+.8JV?;NA.H5M@G"Y,ZB,TJK="8VU^[/3`!T!%I4_P
MI`,)36XNJ%:O0@))^$X'P$_&$WZC_/CSTON5@%"'#J:`4J*-':*?2C;$C%&6
M=-"78`%L;*<=FHHC,)Q6/N(6')-:/5M!A91O^V:'`B-!2O#,?DE00=`S5*BE
MA%^7GT52\6!+0F/:WH!>5-1=`SN*-(W\U6]R-&3:KU^>3A`>G;].H]&$D_[?
MM#"H5XI/'?7)5RIX1RI7$=1W]#)I75I-Z$4CVV/$"L4Y:?.H<PM9[\<WP"-R
MHU>9]ZCCQ340=H)8=A]I).@!\?6/#OC2G&VJ_P#LFF*)6MM50-KK'=@7$O`S
MPQIKY6Y"98W%)IMW>FZ'R%F1/TE]K0!\*6?8.2S1J/92D>A["LM*>*SA>D^J
M)!:UP-M16!T-;/2TDZ"Y(W(W-Z2SR,12N*DJ&+-T<:VUYF*X5NN]/;B@WDEY
M6)EQ[/MW"<5L@W>SAA9B!\D>-&;==6AT;6U<T7*>MZRG23]87Z)2+3P^P.U7
M6+I0HGB=U^V2`^)QRTW"+?$<6YK&DE[,*%H_1VQ"V9L*S5AS%X'VOIB?TU5C
M'Q8IZH?DETPJ>TLR6BQ/]DA9[*85:>\("?4YTU<53'&W=A7GC<V),VIT*0)I
MAH4Y(]B'@<:Q5EX#Y!N4\"LDGXMDDAG$K@D&D'//Z^-,@M)98//J59'X$SH&
M]78BVRV:PZT1H%"),-`<F=TP`&E"'O6QAV%A[NX:\5CI#^8>1+IJ2@HXP-XY
M5#^4:B4R0VMI&Z[;V(3S/XO6O\NR6,S.7%J6??Y.0(BU"P*XP(5R\!IP0G:#
M-'!?Q!XY)'-[&LV]:5YCB]THZ>@\7BUC6'$ZK@C2T4977\APYA@[5*9`C0Z4
M)8RD^$W2`"=.%$C2E_!H9)AZ@.>C?.G`E0U:@M>.Q:H8?3<`YNL6K45C@EPP
M0".\QSI]*LFR&@<M5R(]D*@SP]MH716N,4;V7\6Q!/`7K>L"J,,J_P`&E[;B
MG3<`5<36RBX#KR$1M!;$6M")3&-4%755,2E56X+"<FV7+HY^+KID:SE3&LDX
M50VGX#%"4TH81&:"\R'DRFMW+`>AH84<RO+-+;<M96:R/3VO03V87G`(5`9`
M_.ABU\7->V51%H4W&%HTR8!/W21,H($1[5`58<%;/#_%'4U@%71:%.0"TK`;
M8ONISIN6Z.H5AT8C$Z2S`N&/AL9?$"%X+BL_9M*B25P#SFU:$T)?Q;,.",.5
MMW@SD"^45PH+?H:%SLF_)#6\NM<UX_+Z72:65`RI8Y64H3N:)T2.49D<+848
M$B)<TFH%0"/<'8Q:,,]P??2%.\CUM7L[X_HF/URSPN!)3(_:501=[_*/##NV
M&$Q[%JR-G.KA+]OD]C3G]V%8[*!KUR,8#`FB!H&]!S#SQ]S)(H;SW`'VEX4[
M1/E!^K>4<XMB]$>I-IY_J-O2-->.D+=#5(GAN4QUK0%)M>J@85)`/C4:.#O>
MMAD4CBE"T_*K1ZSEY,/KZ0G5:P1RV;GDKSIB;TE350ME\K9"9.[.K@2P-$=A
MZN9/"S:D82?CTK,V:9L(0^T*X-7C#\=HKQ,ZI:>4Z:/MQ^D8+)%,4S.8I8'*
M<K!$.!=G%PC[XRN#;`4*BP+0R(#5^7$KW]UI3\XMF;##K1\._C<N>RIW<%D<
MQ,;]8UFR$R5SV2II];<=-DTD.1(FXYY<&^,3]F:-+C43<04(9:<'N"4'U_9@
M7=E=)U7.76H7R6PUM?7:A)8*<U`O6G+]GP:6BA<CKL3ZU[*6%Z/6"A<N<F_?
MW.CP;*5CW[??[1Z"K5+<<>/LZ#0]OHRMJP?(%4#ATY7,1,B$I=I0UPYWN-_6
MQCJ2(`=`25T&%U?I(SJ&Y[2J#1GMZE*,@&DXB]@T$E2+DKDMK:^>Y+(JNA;$
MAX=9TZKGZ6G+W)@649%8I#2XL>B:Y8G=T+D5#"H2V@3.2%P4J&Q:E3@VL*.^
M,(@A)%60BD?S$RZ%J)!%E[ATXAKJ=2NSHJYB>4%KM3#!FR/5I)B',A<L:%[6
M3`BTI2%0BT`D])L!GJ/8O?L,#Z:XKY7[':6!HZ6I.'6J")J5"J*.[L6XM$MB
MXEVT^W-/&YO&%[',F%O>M)"=+TJ1>2F7A)`%06:$`=:#%;2\>/$ES4K`>=K`
MYIJY?2U4N1#Q5\"8&4R"ME<NA!2TD2^#*X&IC3O$U*XER4A6"0*"/O@J#=*/
MET8/U#(X?Q#R=7[?'FJ#T5!HFUQ2@)%RW'FU@2+&M`UT'+GE#(I37"=&D6EI
M]MDBD#<4N6J1A$X*5>A&F'B,,,$(*R=E^+6B>E>;SZ/@L5A-;/;?4E+<Y0Z4
M.K*ZRMKCO-U57I35P+J8,CZAY*(=(O($M/I$&_N-F&ZWL`C!F%Z&6,)6BOC&
MX'A5'VQS?'>7ZV2TK>;T"16Q"%I#P]DS5\3)V]*U.CD]OCLY24A9&R&I-IG$
MG6D_A=D`VA^W$'6\#P;_`!B<$-?/;GRNW\RP!-1CQ-=V2YQ$!DBVYK+$V>$W
M4]-G@WP5B?SH`D/VH'33MI<!!O:,)NDN]D[#UD^+[@(BM_TB!R]7.ZXW3\HH
M8<6."^J$9U6S2R6ZXI1'U"@]Y,<%*]YM5H2R(UW,.$\Z>"`*@JPG:]V!^!\7
MO`8;=@]\;YB@!EKUVTP-GC,M/-DB@SX*N92H]7B^1LY[Z9'YM(X<T)B"D#L]
MI'!T(VF3C"H^1.2,L)NMGD[G6]':6OMM57'YN[3NCI7S7+ESJ<[%FOE&3EZ;
MY%+*Y5Z0.2,L+(]O34G4&C+T!3H96O::'7KK88]9G$')URI[226E1D*G*:Z:
MVKVHK.)?R%ZLN55[4[O(W^M&$\/WX/QQD&?9:X+6Q:C^V<$BM1\H#]&%E"`$
M+MWB9\=#34$WH9!RC7)%5V/*89.IG&MG2@]0\SNO49;?#YY_,JB0FRQOG+,B
M+^/3RE7$.9P3#/F/,^4WWA*4"X$XWK-HA<?AW/<`0L->PZPX)$65S2+Y.TMD
M=MP2?]4OF;I2O>DCN_6&F2@2O+PM`H=W)#[DAZH:88RA!8RNJ^B-3P2)UI`6
MH;%"(*Q-\8BC(-S=WC3.P-)`4C6U$N+ZO<W8](W)"PDDZ./,V62`(`[T$(=:
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M3AD0EA32N=1K`C+2;4MGY#;8I,&>B,]`U9<G4D]3GK?FRC(CW-?42L1'Y!_.
M<BL=SC3Q2[G<E)-261?>($<<0/58N1%=/70#-]O)5CD\-;EI7LXTYJ*2IS?:
M`,0LWR=>05^KGCMM>NJ7RI2GW@)WM6+6\JNWF3E-)=?2#'T#;-7.)T\D]\59
M+X?>8H=$H#&CE\"B!;$^+#'TY3LS>E).@!O^\KKO)+;\&,P>;GCC<@E=H5SQ
MJKMB)(1NI30G>9Q>G/PIW'D@UJ-D>R&W[IT5I@?*0D5`*WKW`+,UO6@UP7!=
M[]X].[N2:?OD#\Y0GANGO)':?,L^=$S@O9[)Y5EU25TS<]4R3)M)`.$FNRMI
M@T?IXH;0EJW5P("QK1&J#W;6!RG"+5V)P+TQ2EN=3\HKJ>9>RX[-J?Z0L(-[
M0.S-6]V+8\\LCI6CEK5$&1&TDT\XR6;S*30!J3.:Q,V'&.K*@-.`H+3ZP,#Y
MILWBB,2/BRMZ`D'/W6,3D/;,+DD3Y"G-0"B?DJX@M2<V(;(Y395@3NOWY2]N
MK'SBY.;XJD[M+V3X7]&8(G<@7)AI]J@Q-SN+B)[\<O?G,JJ6T;+_`""S'O?R
M$,?--,,`XQ*.J"^FW_M6UEO,LJBT-80K;-95+#+C6EW*>=D%H4#40,]09]GH
MP(@D;KUC[?[+O^X>@^<.8Q=$#XE1592_--W-%YPROVF+]0\T3N'WGT\]$5V]
MLAR^Z4TAM>.)8`I"W;^R^-E<$B?U5"4E!"PD%[>X78NN.F.W^RW^M&N$W[R)
MRQ9/$<XMII9E#>Z46QP!Y5WC1%5R.7I4<;+MMEZ&)<C7N$@4E2A0K$G,,3C*
M)+TG##XZ?$GCP1^:&94T4U-_*%B_^?\`/N.XRQID[(@C%"R2GFU2:WI(*(LA
MZK1&YW`"6.B=@=$R):C3KP#TE3)S4Y00H0'H=5#'7JJ]JZZ?X[Z*NHOP=]%L
M<3E?CGK9G::\YJ!3:)BLEL>.M$CG++C;GR83.0&)FZ(J'%X+`F6HG%(!C"4N
M&I`%J;F[OZ!8+LNE[([KF<"ZGJ'J[D>F>4O&@@A\,,BG5'/EALE(;D-@N%<*
MH@IN&TSK%2V#+EPY3&GI`TQX4;!K998`A#H*0!Z)N_D2I4U05/U[:*.(3SRQ
M^2B)]32IXOCG&AY31+A"+3LF0T9#55\6Q4DCJ[GH_J,D]7,%HY6SJS96H3"`
MQC0IC!DB"Y:WNOI%ZJ+A)GZ]\B+IP76LEYOZIL,WL>MVVNK$)Z*NRE;G:X%1
MT17SY;6ZJL+%_F>G%9TI61Z)-J<V<JTXAM*HP@]/[0]EY26_Z]O_`,J78=0]
M:6I!'6G+#\.JTZ&Q""0F(0.]7.TZ\YY@LL>+CB%APN3SYN8':&3)0!-&DR]G
M.:5(M[/---UL(0DJ!]"=PQJQJ@Z!+ZRN6U]VSY/O)_R,S\NOK#7!],:J^A&#
MMU_IR,H6M@@Z"S'J=)IC13.02Y_S``TQN.TA"1[@:.&%")]V-:-J<;VXPMW?
MDS[8<ND/#QW3;W?5)R2.08;7PS=L4JQK=8I'65#`H?%7Z@BQ6')7J%:C,P4N
M:YP*:0'E;T+XS-!;:V.X;UAMQVZJ:^YIE773-)]8<BT/R7XQT$1B!\2Z;YKF
MS+1R9XGR^O7")KKGM0VP&B>RUQ'+(\^(FI@%&@:$`L(0AT'&SSM>['SH5G:W
M3R86=6'2<X\QK1QI)_'_`!UDJYC10/D$R]UE=P:;,4-D5>.]I,:Z:U2G:9<&
M=+'10POISM]DG)]3`%Z#93X_.A^Q+O[#7\T7<]S5G%XV*7D%8=3/PHT%BC?4
MM^69+DB/GVSB'-4B<DSPQ/'-T,W-5B5$8TF-[_*BP!VK3:$60&O_`)Q57M/)
M5R'R[574%N<P06^>XO/\\V\_TJFK\4XDB*H^KWEZB#<T.MB0V=-$;6H7B0FF
M!7%H#C0D#.*T'_=T,L*UO'>]S7)S=7Z/K7R/2_DIG4>)AUMVL'MMBU7,^NV^
MC'*>WY5]BQ>7FRV!/S7:ZR'0^!18*B%Q(II>U)\I-7!$'6P;`$,._>_=%7AY
MVJBL[F.I5LI3Q\>+^1\J5DZWK0U&PB_5<NY^KR1V!J1UU;]7SVU.P"I!,$ZN
M'Z;ZY<6U<S;)"7H@Y:/_`'0WCPKJV_'?R9I.97J\I*@XY(N]\>&6W/Q28\V1
M=.`K&-SIY\:QMPFMJ>.N,9K]Y>7%Z!H)!;^K+3:B9JC:EM5Z,#L18#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`Q(V`P4]6ZKSX7$CESZI;UKVM-CC.8K>%C2/Y&M6ZJ1H]G."EM,_>3F'"
M&,G?U!O6\#DB8U'$VTNT[`R$;0,PHZAV2U(2MHX^/X-C8DNP$!VG9A[2E>J4
M'H1OXP_N_NZ]`^9@AL/B8?9%HI&XT#[<*/VL#$ULP?M`*5*T"7VMR5-K[<"Q
M:<;H'^G1IHQ>GN$+>P\D\0B:1X/D*6+QU,_JE!JM2^)V5M)>%"L](4@/5'N9
M:8*TU0<A(`2,8A[$(H`0;W[=:U@?"MKR`.2-G;W&#P]P;X\H&J8$*V,LJI&Q
MJC#='&*6=,>B,);%!AP=#V,D(!;%KUWOUP,B<6QM>$9K<[MZ%U;S]DB/0N*0
MA<C.$G/+4IQ&I5)9I!FR%)(#`;V'?M&#0M>F]:W@?$\1J.2':;;^P,CYM'\O
MV>WAJ0N>TGS#3F'?;;6D'_!\IB4H0O;Z>[98-[^H=>@?:O;&UT`G+<V]"XEI
M%J1R2EKTA"L"9Q;S@J4"].%068$E:B4`T82:'T,+'K0@[UO7K@<6BB$3;7UQ
ME#=%XZ@DSP5\+M(D3(VI7UT)]21?$XNY"8MP6E>J8O?M-,%KU+#_`/=UZ!Q:
M6M*X0OW\THJ_A*.3[5*5VY&EBC$G?OO5FC=*UGY<E`!P^Z5:/'\AGR>\?O%[
MM[]=X&4-[8VM))B=J;T+8G.5K%YQ#>D3HR35S@I,6+UIA28LL`U:Y6<,TXS>
MMC-,'L0M[%O>\#@'"`01V9D4<=85$G./-JC[IN87"-LZUF;U7^__`-2B:U*,
MQ"E4?]49^^6`(O\`<%]?WM^H?6FB$21MSNSHXO'4C1(%"U6_-29D;2&Y[5.9
M0"7)2[H2DP4SDH<"2P@/&<$8C0AUH6]ZU@<6U5G7#"D=D#'7\)9D+^ETA?4;
M5%&%N2/2+030:1NR=&@))<4N@'CU\9VA@]!BUZ?7>!R1T-B"E\;I.HBL;/DK
M0FTB:9"<QM9KXV(P@/+"D;G8:42]$F"!49K199@0ZT8+7I^]OU#Y5]?P-U)>
M4SI"8BY)Y&N3.<A(7QMF6$OSDB+`4C<'DI0B,`Z+DA180E&GZ&86$.M!WK6M
M8'UN$.B+LW-30ZQ6..;2Q'(E#&UN#&V+6YF4-I7P-Q[4B4I3$S<<WD_N$")"
M`10?H'>M8'T*8S'%GY3:R/LBO;V:WGO6U+4@/_+G-/P_BCG3Y2!??FMGVQ?V
MXC??LGXP^ST]NO0!<:CA6TFRF!D*V@=5KZAV6U(0;1/CE]Y^1>4FPD:^W=5_
MY!1\Z@'H<;\YGN%OWB]0XU/`8(DW(=I(5$DNY;HT,KVGCC.3N3!/$>(_4AV6
MC#MZT<)4;L?W/R>[9@O7_5OU#Z3H;$%+ZWRA1%8V?)6E-I$U2(YC;#7UL1A`
M>`*1O=AI1+T:8(%1NM%EF!#K1@M>G[V_4-;ZSQ3U,^]'1B_IO??55CL4)N$J
M_P"(\^SZTFF14VR6\W."][BTG$L/AQ=Q/C1`)(Y#<8['G.6K8TQJ"TX$C>4G
M2IB"@LKRIR-#N4V^TCVR>6A<5B7;9"VS[7N:['MBDMGS5ZVU-D;C3,X.T=C4
M39T<0K^(LJ1I86M(A3I6Y$3OVAV::<88%E$T9C:,](J1Q]D2*4![NJ0J4S2@
M(/1*7\[[A]4)#BDX3$Y[THU\BL8-Z$I'^\9L6_K@<<I@,%6)V5(KA<35)(V8
M<;'4JF.,YZ=A-4?_`(@QE)-1B+:S#_\`[>R-%[%_Q]<#]402#JU4?7*X;%%*
MV)ED$Q58HCS0<JC1*796TI4?4&(Q&LQ:;9`/C"FV7H'L#Z>GIK`^X,6C(4I*
M$,=8@HDSSN1)T86AOTE(D&W`QVV^DI])_B*>=NIHE/W0=:/^X%LSW>_>]X'.
MX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8'7@X[\O=D2N>^1MU['+K2HH]R?(3/L^7$[9
M)VGKFMR"BFEI@\90QES3B9NCF^]URHO4<?612ATJD2PEO2ICTZ]$82&'5;Y/
MO(/T57/-%:0.NN<Z4Z\Z6ZK[WJ98LMMFGTIJZCX/Q.[R$U?')!#(C,4,EF]D
MO*0A`TGJR7ML0)U8%2K[?>M%I<"$XIYP^U+5K"2]1PFH.<HK2'),7Y1'US6,
MD<["D%F6W+>A+%<*^ENZ`G;<)FC=<Q^"@0Z7-VG]H>U#H(S9!^TF@_*(.UDM
M7(FU*>O<5B5`A2@V:I6+5!25*G+UO6MF'J#QEDE`UO>OJ+>M8'J;71L>4A:]
MH<4#JA-V,)2UM5IUR0P18M@,"6I2F&DCV6/6];UH6_3>O3>!]^`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P-*T+\$?#Z&PN@Y1:\7?;UA]M/#
M$&N*[LF52)>TT5"6Y;#9HXPN#O#:X-4I,1K+7B1+NF/6KU:E`E2(D:<PLHDW
MYPY)F\&W(U?U+'JQHB;]%\X/<%Z&NCI"L[FI>TR66X*WE-^M^HY942C;_(HY
M*&)97SQ!TZ1CTA=&QQ/TB;TYPE`EX!+!A\@O!'Q8B4P5KB,AZ&@54LL:IR,V
MW0\3N%R(J;J<J@Y"HEM7._1S:ZMKM)I<_LLF5FK%:IL=&83N(?QKM*"0A+T&
MYI4D2KDYJ1:F3K$AX/8>E5$EJ$YP-[UO8#23@C+,!ZZ_9O6]8$1TRE2H4UCI
M$29.C2D6W-PDIDI):=.2'9R$>PE$DA`67K8Q;WO6M:]=[WO`F3`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`IIU#WQS5R(]PV&6M)I.ZV=8:)R=H13M45[-[BMZ1Q]F,"2\RA'7E<,
M<BD::*-1X]%'.:DDA#H_?Q!-$;^Y@2/S5U/1/7=>FV;0,[2S6-H'YSB4B3&M
MSO'93"YBR;*"]0V=0V2H&F4PR5M.S@;/0.*1.H"`P!F@B+&`8@L)@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@1%4?^FS/^[LV_YB#`EW`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&$RN
MRJ[@CG#V2;3N(1%YL.0%12!-$DD;0RNDUDYQ0U!4?BB!Q5IU<@>1D%B']LD`
M:;[`[%[?37K@=:?JV5=%\G>5N[+HL.2+.8^0>CHOSRC1]H1V@Y-T].1,-#Q]
M-M_Y3:28:V2E+SZQV/+7IT<SG5Z9%VU@MF"1"`H^,9(;!_'EMSNCK3NON*&U
MU-JKYPZ&;.=8'5::P(B[US);ODU),L^13CH\VOI"C;9&QLDJ1S!JC[4K<TJ9
M<Z((X!0(L)6RO4-P^`P&`P&`P&`P&`P&`P&`P&`P&!JM8O,CQ+(4O2[JV2&R
MUL>YG5I$JN2ME1SQ\9;NTJ5,C'L[FQ4Q,[ENZM$39_3L0BVD(S=KC"S0AVA-
M*5C#P,\PW*GZ6MED)(=U(YOSET(\\N"H-LYCM97TZVW1'X#^J;O&'.@PLFK`
M()0UV<F>#58$IB8I$M3C&,.S-:T'-V!Y=>-JJL6OZOL5VM:(267QRHI+-U#S
M3-@IX[S:5?1Y2*GV;JZ2Z9AL_.\FGCJ=I&D;Y(:C4@4?_P`X)0-A'L-G6!$5
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M9ZB$`IKC"!#_`+(O:H.4BV(8@V'8#`8#`8#`8#`8#`8#`8#`8#`8#`8'55Y9
MX?\`*/S'<ODDE%&PCGF%P.72=K<6CF5R>9FV<K]2S1\5PB3R^P*+:=F;DO*;
MI+*F5N\?<S1.[^S`F"PG6T6D32'>PCS7AOO=KYOKA0_<14/<:&*=?=175%O'
M^^]7V9&E=&4[T77<6@K7#X1UBU+VYOE<RB\LB(I$XC>4#@DTC=QHFLY.-$1L
MP/K1>*;R>1JL9[S._+JGO-H[;KGA1BZ"Z@D]MOB61\WN_)D@2'R)I'$'UE7R
MKHDIQ@K4@:F-V`O;%BI8F$<YA+T/9@@[:#NVZ>&Q8V"6N3<%83LG:YH6&-[F
MF]=Z%\B-:5K9B<[7M]/=K_AO`B.C6X+0UV`V!6N3B%';,X+TM=UIC@Y*/<I2
M&^]6M-UHQ0,/R>W6]_L#K6O^&!-V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/2H4)T:<]6K/)2I4I)JA2I4&
M@(3ITY`!&G'GG&B"62226'8A"%O00AUO>]^F!3FCN\^>>F+CG50<^O,DM]-6
M;6J/G-SP>+.;MSPRR=*Z$-@ZW1W/H)4.E5A@^49YK>S'..DI!)GW!A0]>S80
M2V^,B)V9;A]Y]S6I*.V)8R2]RD%0UG8#2VQOF&C6[2\9L:*A7/;0<JB4CFC.
MWA*+.DTF&^.IYP/E)$E_TX&SXDDE,24G3E%$)R"BR2""2PE$DDE!T`HHHH&@
M@+*+`'6@AUK6M:UZ:P/9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"(JC_
M`--F?]W9M_S$&!+N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&!KLZ)\DM04_8G_`(]5%%IKUUULH"GV7S9SVG;Y
M#(XHG5&Z*+?;IFRU4DKZB8H3Z^\Q9)7!(>87KU3)E(OW<"0>FN*:^[-45XGO
MN4VT=5,91*E,MYJC5@J(M3UJ/*XQO5)-7*GBR9NDEA-49,2C+(:C'0MC5;,$
M-4D4>@/:%J85!X96T58X+7D2C<%A48;R&J.1&(,C;'(TPMB8/L3H&AD:$R-M
M;DA(?])918`Z_P#3`RG`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&"I+0K5>K
MGZ!%8$*5K:H4$)+02IY0RFGURI4L::3IR)R4!;L<5-.CBPI>'2[1&]HS`G:_
MV]Z%@?)^K]2_R;^HWZHUU^GWW/V?\]_SM&OY-^\^[^P^U_F?\G^$^Y^^_P!G
MV?/[OE_<]/=],#FET\@S8]1R-N4SBC?(9B4>?$6%=(FA(]2DE,4%0I.CC6>L
M+7/A2<@6AC$E+-T`&];WZ:^N!E>!$51_Z;,_[NS;_F(,"7<!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"KO4G97._'
M$2;I3>T^3L*R2K?PM?U^Q(%\OMBU9,9KT2Q.K*QC:=QF4\D2LT00:)0)#0$^
M_0SQE%>H]!A-(R^Z^N:@M</0//LXY(A=B%N,7K2-'VII%T4;6SXP;0K9;-S:
M]&632<[5J51@D3>W/3@XM@-!$<>2I#L`0EGG'EKG_DBOD]8\\5=&:RB@3Q+G
M,#*E&<^RIZ-]VU<FG$J<3%DFF\J<3!B&I<W56K6G"%OW&;UZ:T$_X#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z*/*S/7%9V'Y8Z[O7C+H#H[G)*_('>[K
M.=JJ?"^KZQ&_V)`W4RO.LX=&7UI@/7\<AJ=?N=M[JR+Y.ZKHNSKSE",Y.YE)
MA!\M*UA4M>5WSM9?5-,O%K>-!+Y%>]);,YDEY#E$*I6Z6F7<UUU`>9+W?.$X
M-$34E:Q8R;,+U'&326*E-?YE'^9T4F4.VCAA7Z%4E-HW4*^NK]YXZ$6=[696
M_CJUXJ7V45[9DLLBMX?!;I>7R8,-<6R3MY0<Z*:]B)Y2J4H'-W85)#8,L*T)
MQ>M%Z#^A.[Z=]MJS3")M`\;)W^/&[EJC6T)_N#Z;6%HC"50R?;Z_0`@B]?3Z
MX$1T;IVTUV!I]&VF.^K9G'WXV@M44VB-^Y1^W:0M::<J`#X?;ZZ&,6_=Z_7T
M],";L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@<:\/+1'6ES?Y`ZMS&Q,C>L=7EZ>%J9M:6EK;TYBI>Y.;BM-)2(4")*4(
MPXXT82RRP[$+>M:WO`H[4'E$\>U]2YR@M3]<4U*Y0V,SU(]H/YE_!$.L<CA0
ME$@D<7=I(F9V>8Q]D2@V<K7-*A:E3D:V888$O7NP(F@'D%G/6EPQN+\&T\FM
M;G&.S`E'=G:MDN#O"Z(4LC:?\<ABW,Q:9O/D704Y%OU*`ZHBTT/1&A_?<5&]
M^S0752<PT`DOQZZD#5435="/L7:H4IMET1FO$N01)F*,*21Z-K78]:7$&LX)
MN]JBFH"(*X?H-3\HM:WH)XP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M!QB)D9FU:\N3<TMJ!QD2Q,XR!>C0IDRQ\7HVQ$RI%SNI)*`<XJTK.V)DI9AP
MAC`F3EEZWH``ZT')X#`8$15'_ILS_N[-O^8@P)=P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!HC\_-WP6)<EL-++`O5IS>
MS[@IE_=^1JR3.DDNKI>@Z]LR/RZ\H-&HA&R5KSN,KX8S*`NBY444TZ3`&F4&
M[^;10PUV7YT=SKY5>/N=>9VB%\L6?V%871U+2FH.>N<%!MM(N1Z6B5HQ1_EZ
MSHA[W&61OKA/':+;7AEEC>K2M+<X*UX6Q(E5!UOU#MNLS*SQQI;6"/-+:PL3
M*A2MC.RLR!*UM+2VHB0)T3>VMJ$HA&@0I$Y80%$E``66`.@AUK6O3`Y+`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`B*H_\`39G_`'=FW_,0
M8$NX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8&NT[OQNL7J9MY;Y2KI;T6M@LI3(>LKC9WPACI#F5FT28:JC3K.Q(G%%/;U6
M;^/2>&L^CE*0L0C7,]``.M""S\/YIHR!W)9W0T9KAA27?<1#&AL"T%853O,7
M=EC3<F;&.,HWEW4KE+!$V\E*$P+4W;2MXE.Q'B)$<+8]A*S7%HRQK%S@RQUB
M:%[H/8W-<UM#>WK'$>Q>_8URE(G*.5CV/Z^I@A;]?K@<[@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,#I[<K]9]0VK._)+55Q>2(^A+%5&F7"@N%N
M8X1=')C/RG#9+`8S-K>X5LI*6RML"DS)$7@AA7L$B_.'-+Z\H'`].L<]*]"#
MEIO=ODJF_/W)%=U!..D7-EO?JCI62TE*;`O2A.0N]K<XYIRG2'6O4DX>+:K)
MWB9\FL:<NSJ_E;3PC\DGAR-FVX$(SS%1X`B]T\D%^6_6UU=B4)V)<T$K[A*L
M_&T&J:-L1-5;J9T(X=`2)OA]YG]?FI632JQ9B[O)*]I;U\25Q]L)5(_O4`#=
MF_4.YFZN:9F;E;HL"M&E1%;./"WMKB[K1`UO6MZ3-C2E6N*PSUW_`*"2AC]/
M^&!$='N29X;;"<T8%H$RRVIP82!Q;')G7!"!2C*WI2UNZ1"YHC/>7O\`=.)+
M%O7IOT]-ZWL)LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P."D\GC<)CCY+YB_LT5BD9:ESY(Y+(G-&S,+"RMB<Q6XNSP[.!R="
MW-R%*4(PTXX8"RP!WL6]:U@4=K^W*S\H?-UMI*\4=&5E1TU>'"NXG>3`)72\
MDMZ'(36PYYL.AI$8-1,$M=288%+0F?3$+<>X)?G.0;T6,A5@6DHVB*?YIK"+
MTS1-?1RLJSAR3:1ABL81!2(B1&"^58XKCQB-7/#XZJ=B/6N"PT]:M4#$:>:8
M8(0MA+>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P-<;OXE/'M
M)#^EMRCFB!2)OZUG4.L.Z658C-0-;[((,2S',86\+":SK&AJW)6?\\I2DG:)
M5OJD]8;H0QA]H?<?XGO':LHM5S4X<K5\Z4DKL4=M[A#PJE;P6CLDUJ1L1\P:
M7]SD2N4LCNJ9$!:,X2-<0$Y+[RAA$688$89K(/&]P?*+`I&T7SE.F5DZYQ88
M[%Z3>P1%(B!`([#C-GPUF;6E!M*R+6^&*A;/9RUB92%J4"V<D^$W>Q["[.!$
M51_Z;,_[NS;_`)B#`EW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8$.7KT'2W,L!/L^^;&C=8P8EW98\4]R)2:';E(I&X$M<?CC$U
MHB5CQ(I$]+SPE)4"!.I5G[]=@+WH(MZ"L/27#*'L:WX([W_9CW+N2X$SM+XB
MX\0M0&.O[.MI([J7%+-[\=P*QNMH1*/(P(_Q414%)F4M>4-2M+6;V666%^$:
M-(W)$K>WI4R%`A3$(T2)&04F2(TB8H)*9*E3$A`2G3)R0!````Z"`.M:UK6M
M8'TX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$15'_
M`*;,_P"[LV_YB#`EW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`QQXD!:73LU,HVAXFR2.+)`UPX]\2-;@YEE_,G;QG[$!6J;6E>[%
MZ2[7;3F$E#WOZ"V'V[#65SGPQ94UMQD[2\BDAB]M=.,HUJBDZ=BHU;CS?Q@S
MN0=E[;*B:GA.09-+<4HMZ+>9^YIPN:D7J0WEHD8=`,#:Q@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:(*1\T4NZ'CW7DSI/ANX;FCU(6
MPV4W23=6,NA+W,;,GJET8(FY1:ZXN8L`^<QKF>1/`G1<L>DBQM;8L4<K5'%J
MTPT1@9,H\O4_<6"$5Y`^)97.NW)7T+=7-R[F1%>,":*_99ASO74>MJW'U-TZ
MZ,9<0?XFP0B8-19!J=F"L/?U)K6:F3F)%!H`B-O\_P!$I<R-MJUOR%;\KYQ@
M$8Y^>^OK:<IO`8M(.:'?HR8*X+%8PV5<J-7O-VK8H_H1B?SV98E3)46PFI1+
M1[V5H.PKO>M:]=[]-:_;O?TU@1%4?^FS/^[LW_\`W&(-?_QP)=P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!3CL.UNG8.PPN"<B4:5:
MESVX[.D>:9Y-EQ;-0=!MK<B3J7*SKL<TRL$F<VY"6KUIJ8&9.<XOZP`B`F)2
MPF'A#@^/>(8WS$?-+.F<ZDG0/5]REMQM[]-6"6G+E<SVVB,/:X9#V%&(3)5U
M.Q,\\P+)%F@):)&#?R'"4JA#4#"\>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P.MY&?#CU]`;C[_O"H>V$59W7T<SLM3U?=ZRLRG*1O
M-5N)T(D4GF][,40ED/99O?T/)9U44B<I1IV54U(C5KB(LY2N)VC"2(-XE>F*
MMI;E=!4W17.%2=&<6V)<KO2,OA7-LX<Z7D%>]`09)$[5;KJ@=@WS,[+L.V)$
M]_</QLO_`)Q2JE+D/6U1!X1F[&$7LW@(ED"B>J-K;L=R0<VW5%^;6OM2-RNI
M(V^VE:<CYQFZV?)I#2T\;W%F9*;36(Z+A)7-&L9I$!$D`':(99ON'L.QXZ-3
M8^-ZII>6]&ZM:XK9"UN<$Q*Q$K)WO0ME*$QX!DG%[$'6_06MZ]=8$14@UMC(
MW6$TLS>B:FM#;4X*1-S<E)1(4A0E",X1:9*F`6007LTP0O0(=:]1;W@39@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:8YK8O8/D8EDCJ
M/G)-9'%O&;"^O$3M7KV51Y3$>B[R_#K%#2_PWD6"R1*!QKR*JU)!J<^QGU(!
M1L'J)D1C$'2O0;:Z\@S'6,#AU<QDQY.CT&C++%&4^1OSO*9`>V,+>G;49[W)
M9`L<'Q_=CB$^A*%BL\U0H-V(8Q;$+>\#,<!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"(JC_`--F?]W9M_S$&!+N`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P->/0/D<KNF;C6\[5]2_1/5]Z
M1R,-,WL6NN9:_03)14\1?]F_RXZ67)I)(XA#HPXRDI.::U-0W`;NO(*$:4FV
M5L`QA@+GY5JRE%/0R<<V4CT)TC;5B3B9U,P\YQJNG6%6'!+9KT"+<ZA_1KG-
MB6V,<YIH5MR3C<ETB4E@&G.`:@+7Z&#0@D/E.F.S3[!=^C^T[U2"F$AC9\=A
M_)-&GG)>:J18'!8D<3-NCX[-R>87?;7JC+*4R-?]B@3AV:2WH"BA_((-A.`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!3*I?(1Q
MU=\]Z%K>N+VACQ)>7!*#KDVK5F,C&Q,K<W$KG^7-,E>BT##*H1%%!@T+N\MJ
MA4W-;B2-.I.+,]FAAC<M\FO#L)YVJ7J]\O-*;05[R?4,I^=QR`VG,QV%)A%R
MPX+5'(G#H._3=6:,B#.Q@1[;0E"*1"'H6PB!L0?-)_*+P/"K`I>K)ATA$XM/
M[_C,"F%:QN0L<W9U1T?M,0"JU5SE0X19.@J)1/E0])V=++CF-6XJ];3D%#."
M(O07ZP(BJ/\`TV9_W=FW_,08$NX#`8#`8#`8#`8&II7Y@Z.42>PH]`>:O(-=
M+=6EES^HG^>TGQ5<-DUNLG=7R9PALZ:8_,V)L,:WK4>D[4I1'&%;]NCB1:U^
MSUP+;\C=C59V?#9Y+ZQ8;4AZBKK0>Z<L6#W36LBJ:QX98+`PQF3KV.00R4$D
M.J`S;!,&Y46(6O:,I2'>OKZZP+78#`8#`8#`8#`8#`8#`8#`8#`8'B,8"P#,
M,&$LLL(AC&,6@@``.MB$,8A;T$(0AUZ[WOZ:U@0BU=!UG/(U:KO1LIBG0+_4
MGY1LD4+J:;PV0O`9NA9-O:&OE:_\X4PL$I=RAD@++<528!6S@B-$`'KO0=65
M\@/D@@E_]'2CIJK.O*$Y.[8L1/?C[&/&G&FKIGIL<D20Z+UH"@;KO&($D3>I
MXTEC$/2K$JJ(,XDNA.*I*!\(]FQ;#==XQ*8M*-NG6'2MGUC(Z$#UA9]=OU>4
M+-GHN06/!:OIJG8C3,-D=NN9+Q("MW!9J&+[>'XD2Y<J3C,)+5*356CO:&US
M`8#`8#`8#`8#`IYRIW1SYV5(^DXM2$F-?7?E>\'NAK-)/+3%@%)V1"D4B?6`
MU,K5@=(BY+1+$25;^Y\RMK5@]FM%:V(+AX#`8#`8#`8#`8&O+R6]YI_'Y0+=
M:+56K]=MD2R>1V%5W3<3TH-E$S"#:B566ZMR=$G5K!)*\J&./T@4C"5LO06X
M)9@BPF>\(78K:Q(=;M>P>U*\?$<F@=CQ./SB&R%O,T:B>HS*&I*\LKDG&'>_
M]M6WK"Q^F_W@[WZ;UK>MZP,UP&`P&`P&`P&`P&`P&`P&`P&`P.L'XNN([[@_
M5O?].W-13!$N$G23)%SC1<Y>DENU@=>*UTK*QHX\<KR9\&=.3N?)!&V\+D_Q
MR3)TR-M=?QR%*F%]NO+*"-GGQ]]$L7`OC,1S'ESH2R9URI*^K2["J?F+JY'S
M1T7"`7C(+%)A4VK^8Q^4QF+28EK)5(1+T0I:U;3M[AL7Q+PA4(=A%*OA/RJ'
M5I<E!7+2I-]6?Y#ZX\=J:?\`5!%J5_N)\^/_`"S)$(9RBZ(VM;8W+Y?*6>#,
MB$:=TB;*[$R)YV>/?VPAB.$'<+=4:EP;E:)(Z+612H*V62ZMI;><N0CWO6]'
MIBW9"Y-PS-:UZ>AQ!H/3?[/7`B.D$BA`W6$C5NBYZ4I[:G`#75R+;25ZT0E*
M,>C5);.WM38`P(!Z!_LIR@^T.OW?7UWL)LP&`P&`P(2O+I/G[F6+"FW0ESUK
M347]1`(=K%F#)%RG`\.PZ^T:"'160K>5XQ#T$"=(6<>,0M:"#>]ZU@:_M^4Y
MZML>T_#W#76/6:(\T9#=:+M$T?+W/BP0?W=*4]H]"F1)\>6WW_01S-'7;8?I
MOV[UO6\#W%-_FKMO19ZV1\$\:,:D7R:;FAAMGK>RT:<7[4JQR<W&BZY2.!7[
M/E)(<R-_M]OU]-!]?_@OW3(Q[/L+R\]!B,,&6(:.I>?.7ZK;$Q?UT<F1!/K^
M:NFP;`+>@&*%1YH1>@M[%Z:U@=>_E"PHSS$R=`U/97EH[YYHM"*=J=F*5T)U
MQ\[7''WI,OZ&G2V-VBM<D/(TL8GI3:+0:4_+PHW3:`]4O&(DI,#>B@A;7Q<#
M\F+NF[KNWEVZ>?.CJYG7=,Z?2M]9\^6]R]+;T4)J2H9K4VE%'V(H48(*@="F
MT#26VJ(.8B^\:3#PG@"<(``V@;\J#U1)I+;Y#^/KUX[2@/)2*[P8$@.DN3_>
M9K80KUUSU*A5O,#;SQZ]?64QYD`0'>]C-V$`S-!L]K6TJUN:&L]B5'/X;9T"
MD!`5+),H%)&B61ET)$``_<B>F-6M;SQ`"9KW!T9[@;WZ"UK?TP,[P&`P&`P&
M`P*]\W=34;UM#I5/:"G"&>1:%VE8E-R)S0EFE`0SVKI`?&Y6V>PX(1FI@*R0
MGI%`=;)6HCR5)(ADFEC$%A,!@,!@>HX\E.7LU0<405H0`[,.,`47H1@PEEAV
M,>PAT(9@M!UKU^N]ZUKZX%/>HN[^>>1'&+1FTW"PGFPIXWKW*!5;4E16;<5B
M3-,VJB$2L3/'ZZBT@TG"6L4EE:,7'(R1&"T'0_7`PSG;J7IWH"R"ORG!UF<Z
M\\?B'94"S^A[#@D8MIY=B@)_P2)KYYB)LU?&=M<MF#V<>^.[6K3!#Z"1['^[
M@1K<WCP@O2%N2]]ZVZGO>X*L>'';C"^0D]C):7H.-QM$W%F'-LKB]4_RG,+D
M"6,@Y2<?)'58EV6/>AIO:6$6@LU6CIQ/S/4Z)KJ=\YFHZE&5S_"I2X8^UG`:
M]2OVT0E9B(Y6V+6UC-D2A"G$>;\HQ+#@!$:/8OJ+`UP^4CRB2;F^04G3O'*N
MM[HZ(<U:_HRVZR32J,.;XEXRI*-`LVY#FIL^Z4*/YWLJ%F%IXD6#03UNA'*D
M_N+)V/`N$W>5CQV.M'-G1S?UU3*ZG'.1-L+!,6J5)GY.CG;I&=3`B!.:*/!=
MG%!-R([[E)[685I80``O>#6P[P,^%W]R>*XP4"DLMS=;9-@'ZGE1ADK"VWM(
M9"10C5BIW;4L:H(LA83E\/%I4E1B<0K50MZ(*)&HW\6!%O\`\GE%N=,@O*"U
M/V-:,6/L/]-43!7W'U]NEB.#S^#W(`NZ2OW2&,TE%$!HM>S3L,@"+[G_`&-C
MT;O0=A*N^MW91;PZF:>3NMG$@-?;G9=IJ*R9&"I3U9L+#,D,$!*I%,FM27-U
M9A@&@:4Q(`I*\[VG/-+"`9@0BL/8?6+[3Y-@P[QC]"DSXRP!1`=+VC;_`#/7
MTG)C>F/\F&QQR)BM*Q8EN-#<Q!0?;Z4[<M'>XS:?XM:$()/%:_:*JWUL31<B
M0-MIXFOS7I#;[[TPTC>%UA'PHMW10@VL&6MG!<A;$<W$)G5.OY0T`D^OO221
M!]"=A&0))Y77^GT3@AJOA&O+T.L$XI;'I7;5XSNND-5Z9-&)UI;U%JSCKVLG
M^Y'OX1IM%%MVD>OET?\`)_M;"3C&#OM7<#JO_4KE9DH<ROU"1FCB>KK/?;02
MV<?#2R4[TX2=39#+&E<-;Y^,9^T(&XI6I:0!)^<D\0C0A&A=+>2ERJ!LCKSW
M)2+#=!=A'/;O94)X^+W%55=G,I:8$'00"87/)!I'1(^^]4!U&Y&C&1L)(RM[
MULS84U\IEI=9\6578O0C+V7.GELGT>8J&J/G^/\`+,2?X_$K;L!C1Q,^]'J=
MU_$)1=)+'7/PNDU4)`F#3"&D`WEZ'[R0"#0?#%/.7-5E\2QSC_R1]LO/\W.*
M;E'J.<U_R+.:ZGNZC>E#C)J<F6P3+E,$,<D%<74[N'Y5S7?D)()NE:DS2@T!
M)@!AW"#>59THN-_M$_LKJ;4:?*_5PDJF4KS5J.MV-S61`B*[L!C"35W\T)9F
ME5E">"#!N)J0MV,V/9`B/1/H(R_^/MX.IYLJ1R[[\B#BK;9ZMG6[:#><(9;?
M<25C.2T!@[G)8U43*SJH&BV3M60CTVA/"L&(S9XM;T'02<;QLTGVZ_W"9T3U
MQ]_(*_55Z=!2[Y?2*M;4RN(D1$4J8X,G0%-[5.B0D?DBG,L7R%NXQJ0AUO?M
MT$9G>-Z!KJ=:J8=^FN[W=J:+`66&3-SNNK1:[34KU;.4S:CKC/HXM9'=="DA
M17SDM1GJF`K&([TV/?K@249Q/`C;AD=U&6YU,)^DT"75XKBFNE;6+K%O;5\1
M(AQSZQUV4_@C3/,BD*?2LIV()"L)<Q"6`'H\7OP(Q.\95)KZ;:*1>+D[8>(T
MRV`MLA+)3^V>DVVS3WM<SDL8FIQLJ.V$RR]RAZ9(3HPEF.5#;BU(A'Z*^46Q
MX$F&<-5$=<4DO`R:])BELI@2ZNG)EUU+?P*W3L;A$2(4>XLU7EV`"!,4M`U)
MPGE/*-`2YDN.Q+0'!5"V;L(T-\7W-2NG&BC':5=5OL,9+!766B<GSLWJ1RGX
MI&O9R6,Q,LLE1:^YPNC*=$1H1#0<N&VIU&Q'EDA-$(>PDP[A*A3[BDEZ&J;H
M%.Y5`EM;NQ>NB;T!#_Y:<(B1"%(F^!%V`&&M+[^#3!V!S3(BG`I9L2L!P5(M
MF[#KU6#Q@^UYW&NVZ>-/R%]-<H\RMC29R2.+=5Q.4IG>YYBI;WFZ[J?9!=78
M$2LK2%:U,3-&&MF/$)N,;TS@-0E_ZS0=!M#\.:?I&OX9?]!VWRA<?-5&5S<+
M_*>/=6^^4XYO@*2M-T=Y>;4*I%4ME6*D;S:8ERA<B0#&=H@U@6-Y98O>0:`(
M;FL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"(JC_TV9_W=FW_,08$NX#`8&M^Z
M_*5S#6,V74S61TVZYZ.2>XH?/7)<:%<<\:57H+0-3]Z:E2>NZE0@-]-'*)0]
M-("@;V/T$$(O0(F!"O*_UI[E-@6/7OC1J!QWO0:_I8EAZ%ZV<&HP6M")D=R2
MMN_16L7(]/Z[]K`Q2%0F'O7M7>H=^X)XHGQB\>T3+-6@57KC=%ZFA]5_0_2L
MG>;]NY6HWZ_(H136Q5#QN)!,V(7_`$["G:498!;`62`OT!H-@&M:UK6M:UK6
MM>FM:^FM:U^S6M?\-:P(*LWJ'FVEX?(+!MN^Z>K>#Q1U1L,FE<SL:)Q]B8'Q
MQ*//;V5W<G%U(3('=<0F-&2E,$$\P!8A!#O0=[T$7`[[Y566]!:+8+$=)E9%
ME05NLR%(8+7%G32+O4#>XJLFC!)061&H<Y5JD02&/H]FH-'NY1BL1A0"PB&:
M#6PZ\7<O>75?9MJ-$S\?-(]B(V?QC3*+6W9<!>ZNU4\BM^]9,`9S15-APZR9
M-$WS5-H.=`R)>N/+(.7C<9&T")1F;T`PL-Z5+=JV]T8KIB9TSR2\R/F6YZ6C
M5MM?1CI=]7-#:SN$I@QDD30!;7*4UXFI\@995[&!T,"`!2-5HTX/REE;#L/D
M_5#R;R6F']P!QUS##KH%.D#&TP&:]4/\JKUSK18R+CGJ5NTKBM)!7DO"1X"0
MD`TZ0&!4$&C.V>#V:*&%%)UXQNIR.E&VX>/CN;O'J6]Q-H?+,L'GB<VDJ<9U
M:VXEM4]L5C\I.];)N8K5@0K`]""WD_;3*1M8AJ='E*=_!@8Y9G>WE(Y8CA,"
M[+A'(=,R1PED7;H?W2VQJ\)[PD\Q]0UK$SRU6W^`>DEE\\S]SDOVOV*J0)R8
MH),(T'WWR!!O8;4F-7W/([*A\F8YOQH]\U.]:M*UP/8V>U7:?O$\60<9ASW$
M9&DDYD*5UVKG9A1Z3W@&J&R;V'9FU&]&8&#E-/E;U3KB0=-.!MWWNP$1K2XE
MPB_0U0"K],JD+BC7H!2\4K%.!R'9(R32S=(0H]#"((C-A$$).*;^^?UA8SSY
M-R9NA`0!&5)&XJ*6WJUCK0U#3"UZMF7BD^XH3!QV![#22CBA+@L_J6(8E'H;
M@1>&/^5I93K@A46;P>QWT*P$)[5($-67J_U<75X&52%Q;ET?660QR8<W42$1
M(B5(%ND12,(PB*&8+0@A)93!WS^L3(XGV7RMJAP5^C22*+$U79^[-/L_^2S"
M'!Z9Y4.S/Y=3PO=@["I)0G-QBS31K9`E&U&_GT&DSS'=P=W^.WQQR:07!TER
M:@Z,N>VVNH:N65925@M/W==RZ.KFF<JHTU3*[%(VRP(*4M_-DO:A2:U)2TY:
M<U,(Q06<`-3?BR[Q;:&\D]'\ZUA8'.=#\T=A4=7E6GP:#3ZI.BP.O5-/U(3!
M(3-Y"Y5?9[A^F=BW<^*2C7,"TE04[+$B1"-2K5FF+M!O7MGKXJFJV>JIN'SN
M<U1'HHFQ-.1<IK;G6GIG.FR&-S,L;G:MRJ#;I=9;@X/6WTP"P3A]H8K3C(TF
MV0((Q>H65JZ<6U?C.Z=A4CUKTO;=,PNO'^(MO,*/EFL:2>+FL2+5W^-<9A%'
M:\8/`ID4XS25JB7=IVI6H8\2N_Z71FD830:#7^GJ?SN6Y4"NKH9([(H1R<Y\
MDF[?T1T_TW08[=:V`ID4-0J_-KCF/FV;1@A@,4J/OS237`U0-<66$*HLC0@C
M#9')N`.A+,1P&62GR2=DU/:2&`P"+6*ST'+:Y0TF\O,?BQ$>FDBB\+G=2R%X
M;7R;J2Q+C%ZI:HVF7"V>G3D^NBPA!TD\`_'5D-*-->%S]Z7])6V6()DTS^V>
MTKC=)2RO#:(1R7\$CCKK&(6QIRUVPJM:2-!)@5``""/6@!UH+]`X7I'=T(+[
M7O5[/%@-U=$5<0!WZ/O-;#1Q<N';@ZH:FO-ST$'42!V:!;/6N@D&UZIS]%PS
M=J]:.T$8:\3_``:HIU50;_3#E,ZI6S]/9ZJ,3JV[GF.SYHD9#XZF<C'B06$N
M?!)"6A287I%M3]CL0_D$3LS6AZ"84G!_'J.V45ZE<]5R;;S=!$58HI^M:37*
M0$0)NAX:_2QD*AQ4JBA-X(4'\8+W`V8:DWL`Q"T+?J'H:?']PLQU^*J&[CGF
M,NL13!/80J^44=6[A#=SQ(VB9DDR_EQPCBIIU*$K08)*4NT5]R6G&(L(]!%O
M6PU7(N)_))6O;'4?5]95#XM)N?;XH97E1N=HRF^8[,*GYVJ^+*(?#*V;T40H
MQY9FT]Y2+52QZ$D4B+/,4A2!V)(F3@"%M/%-R1TER/1<\I#I9OYF%%$%RS2<
M<_1F@%\ZDK-75=3QT72@ZMW9RL>$P]R7)X+(7=6E8U&BCC@LYA:<T>O@#[@V
ML:UH.M:UK6M:UK6M:UK6M:U^S6M:_9K6!^X#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$-4TK2+2K/,1JTJPLJY9^D-,2
M*"5("E2-6C3+$IHR1C"6I2*2A%FE[]!EF!V$6M;UO6!(<LE\3@4>=)=.9/'H
M;%&-,-:]2:5/+='H^T(R_P#6J<WAV4I&Y"G!Z_49I@0Z_P#7`U;/'E2;[=6K
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M=(>%P.D`&TT2D9?J$1.]C##B>;NWK"K^T(A=O>`HJ[3"7L;E!)9R91\9J&0U
MI"VE:O-<HHD=;/?+R&_+Y.A.3EJ7$\HLU.81L:<)83-EZ#.$/!E1&V74MQ3>
M<]#6I8U-PAEA4<=Y_?UE'1QX,:&MR:%$TF%71=[BU12.>R%,['[<G$U@UM2+
M8?W`A``(0SBK.)^0Z2C3M#ZJYKI:%QI_DB"9/S2U5[&QD/DM:BE1+5)WD:U`
MJ/=7]K)6G`3*SQF'IP&C"6(.A;UL+-D$$)224R8DI.G3E%D)TY!8"22""@Z`
M42247H("BB@!UH(0ZUH.M>FL#JG6#5=44/T!T76',72OG8O:P!V<[W5U:U\6
MOM#RV%5C9=GI$3T<@F$FG%.-"%PGRF*HT.TL8;%SJ[)&A.E*VG+UHL.PV^>(
MNM^:ZVXV84_)EVW;=]+RV?V).&Y?T`Z(%5B0&8OS^;^I59NC`C@]>J(`JC4_
M2.)BY@5-I1S>[*E?I_MF%ZT&S@8P%A$,8@@``.QC&,6@A``.M[$(0M[UH(0Z
MUZ[WOZ:P((?NI^8HKLS4GZ-H>.;*$8`W3[;U?-`BQE&_`:`>E\A3["(L[]P6
MM_70OIOZX'QRKH3F%5S]*;TE-KU$_P#,Y#&Z;EUD'2*.2JJ#V`*X4=>"'1W2
MG.C`XH!.)FT1Y.]FA$:+90@[WOVX'6QDO7?&?&3N[6/XI.WH:9$#5BQ\F'C\
MD<(Z!M'EF;FGC^Z<SJ'DU<UI.)%S#,W,0A&$!9RU\05'"]Q[64`(SPAL^@WF
MRY[D409$LLI#K&&],K2V`]UXK241+YETF2TR!F.>T<]B$18T@2;&J$U(1O>I
M.TF&HR-F%EK0(SQ[("$LQCR'6Y/I7&&"$^,7OT#$^O[4UNLYLR*4K3C!$FE<
ML((721Y;)[=#=+U*)I3&B.,(1-JE49HO80@]=ZP)YZ:G';\<>(LR\CT%1MGH
M79K<3Y/-[LO)_K)IB#L2K3E-K<7%HO6TW?9(F6I!F'#4$GD?%LOV>P6Q:%@8
M#1;1Y0UEG,;]TU-.'8_4B=$ZAD%;4-"[NE,R<UYR`PIF&@M.Q)/%6]L3H'+8
M3E&A1D_:DL.RP_#O?OT%(O*WXQ.E.P_QUMU3U;9ZJ3TM9,!MZDN7OOJ]JVLS
M5T7;%$<GK`BMELK]ZL)AF<]B3PZ%-;VN4+4;0X*P;&F$3K0B@J-SYX^9I8=R
MTDGCW"U[<@0*OKYIOI'HF]NP>F8_T/<UGR;G5W=9;5E2TBAC-JVHF:(PXSUP
M`J>'PX4?+VU)Q)BT`Q'!T6'8]@]!456*QQ<*UI:IJ]7O#DL>7==!ZYA\36.C
MNX*SUZ]U<5+"S(#EKDM6J3#C3S1"-,-,$,0MB%O>PEK`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'4;\4=
MLV[;75/DAH776%FO_05H"=[#B'3\;5F6'S^\5^R2V`P9TDQ'/5B(6Q^YFZ3K
M!E>/P#<Q'DH(PH%O8A(78EF![PQ:M;,>K(XY\(U.=,]@7=6-"7U(NYB.AKO.
MZ%>JAL*P)'2&[-<*28YMTL%R9I2U&K'!&H6;1)G5`%Y-;`%"`8G3_;X%#*][
M,OBQJ)F70=K=SW<S]4\R5[XZRN%X.5:Z:"(;[8;9NQZB$JE\BHEO1-+%UBOM
MV.I`(G%Q7M;Q\A1>C$VTIF]FB#;5_EBEJW/BGE")$K)F%+.>]:OB2IC@KT:P
MODQ6.M4W5J-1`+B%4E3I"7^6EH"!*#O>!%[ON=`$,H.MAU%[RX&[@\<'6G*\
M-IVN7"'VY)>J*F2<RW=.KP&]L=G7@Q@J]AL."+8DA=%,2-AIUQS8EP)T[:+<
M0LA2GYS%1!@O:';`YU\0W?W4#A"+D\K5S2%?=%2SU;(E5?NTKJCI#G:Z4`W0
MM\8$\2I]X@:"L.>4+"E3_B%8@,;\ZK]*!J0*R`A`1H)LWR'Y%I&5>T?E_)=+
MV#`>@!#;'NL[]\EU_2ZHX3!T,IW*66"5_5]=4C%HI!&)N5$$DD?B4I:G:(L"
M90>:3[PB#9]2//EE5=RE&6V,\Q<1U5U!6$4D<<IR'1E9+'JBH6F,D*MR9&@N
MQS*[16HTLCJ`_:QR"B;C!Z7FB$'YO]>PC8:;S@K@>S;GXLXX+0=F?<)4/5LH
MV,S>O3282=69&@@*#O?K\VC-BW[?3X]>OKH+?6XP]B/=)1-KI*R>?Z^Z&T&+
M?SS,9]5\YL:J!"`UC!-/Y3A+38\#DX`J'D03&W[QW%LM,'8#O</?OT%3V"E/
M+\-\9%LQ[RY!_")G=M,?62%\,2]M$Z,)"P@US2(W&2=1R52WNJ]%HPD!_P#N
M%$BV$?Q"V'>A!9OING>H[5/B>^=>Q5/*B1J)=BI86CH*LKI5RPQ:))^-4IU-
MC&[(CIS,`D[0=%$'%GB.]3`[T#6MA$%+<G]DP6S8Q.K?\FMNWS&&0Y<-ZJY;
MSYS36D2EI![<K1H4SDL@<#22)!I`J4`4^]&K),.,)"$6_9L0=AD'0/#\DORR
MSI\3W1W31K(8TM+6"K>?+1KR`0`L;<`P"IS]'*I)1+?R3P+81'F!=0>@@_[>
M@!WO6!J$Y:K:R/#_`-"]8(;"J/R8=@1&[;)E=G4S:U0F//3<*G2"PC(^[NJ"
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M=9V6,)2SSQ*CBTS"VHTS40`Y2,1@M!*UH1F]BW]=^N!SZ)M;FTOXFY`B0%>F
MM?&B2D)2_0.O0.O8066'T#K?T^GTP*T]2\;<^]BQ-MC-W0O;DYQ==^;KJR8N
MZ.$+MZI906'_`*66U59\</02^#2!(;H(_D1J0$G^S0%!9Q7J7L*#:MWN?QS:
M^PZ5:I=WSQVU[V!)U)5L3*4]:4RP%!]0&]%4C&4Y2:Z(XSIP_P#4RV%IRW4)
M)8CUK,,6Q';#:#2-]4QTG7C+;%"6;#K9KJ0%[$V2N$O21Y;1'`T'[AO6Z3C^
MY:7A",7L4H599"Q*9K8#B@#UL.@EO`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$0U]0E.U7.KBLN
MO*]B\2G5_P`G9)E<$F9&E&@=9W)(]&&V(M#F^JDY)9JLY(RM8-:]V]ZV>:<=
MO6S3SAC#XY'S9SK,:O34C+J#I:4TPB6`<4=12.K8.]UBD<"W-2]%KDT"<V-3
M%2%A;PM.5A-`DT/2DX9NM^\8A;#['CGVA9#+JZL!_I&HGR>4^B_&U+-G>MH:
MY2ZKF[XM$:05W(UC,<\0I%H@.@:*;3DQ>@:]/3TP*[]V^.7E/R1P6$UKUK#I
M/.H57TP%/8TQQ^QY[7A!,L_%*V0AX7&020,![HH0MK@H+3?<","1\YFP:#L>
M]["A%/\`@P\?!EHP^Y7Z-WY.I[S'?1TDI%PLOK+I*R&^"NT%>V!]CQC8QS2S
M'IG$G(<FM.,XHPD8%02@A.^0.M:T&]W`8#`8#`8#`8#`8#`8#`8#`8#`UGW3
MXTH*]6$]]"<DV/*^&^HWL>E<ALVEFYH4U[;*PH6C"2>A:$=R_P!-+@3C'K?N
M7'IT4A+T/>R7(O?[0B@CO;J7DD06+R3<Q.8(,WB`GWVQQTS2BWZ!5I`;++T^
MVG42=.YWI0PAAWH:D8D<C9"3-BUIPT#0?<$X6;Y4>.()5=7V[!YT[].L-T62
MBJ2L6'DB/J.AYQ+)XLBLIFXV)%$8">N=$RMOBL+<UJHM0$DU.4E%[@>OTP(W
M:_+Y2PIK5\,G?,OD$I,FW+2@M-1.<WCQG:M9UP"P[*>R(W"&)ZF3ZE`VM!C^
M^*2TQ(C/ILP>O7TUZ[T&U_`8#`8#`8#`\##"R2QFFF`**+`(9AA@@@++`#6Q
M#&,8MZ"$`0ZWO>]_36L"/':X*D8?ET^6E7++\.R]'?EIO&6[X=F^FRM&_>.9
M/Q[,T+7M]?3U]?I@:7&3R&=P]`7'U/'>6"O&2@JSGCH*04(T+NANB+;8[%FQ
MT7A4`E;C.4S574!E$<U%'!1.@I4II2D0OF2&@%]0^NPMUP/UET+>UF]?T9TS
M$*#8;*Y5F-/,ADAYNFDWFU9S!FN*IFRTVE2B<)_'(P_DN+.D<@IE(=IM%"-U
MOV;V'6A"#9?@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,"(JC_TV9_W=FW_,08$NX#`8#`8#`8#`8#`8#`8#`8#`8#`_
M-ZT+6PBUK>MZWK>MZ]=;UOZ;UO6_IO6]8'6=\T7(?',"M7@7J)VJZ14@:#L[
M:*_NC>3XG9$3N1B@J_G2_!ML@=7GG5A7SA0>.Q4[$GVXB0JS_:;I,:/[4XXL
M8:^>D[9>+<<>4Z<XZ\HW3G4;T/O'D&30>JNM.#[.>B8@LBUP,[NFLF8WGJCN
M?W]YBE>'%`7N:%:ZIQN"(D183RC-_+@=A#[_`,V<4]I9T;\:%S)"]ZUM<AE?
M2E*/BG6AAV(>V9;%;992-"*UOTUIQWL(]Z_U:]=X'S#OOS"I-A3F>/'EQW-+
M`'Y7!L[H<$"$\P7J(7VZ1SY\VM*`#6]!_?WO>]ZWO7T],#Q_6;S,.O\`^`X<
MXRBGS?[)>I1V9-7W[,S7T^\5[C5`%Z4)-[^OQE?[OI_]<#W%.7F^D&AZW$?%
M_6A`]:"`U5.>HK/=21!UOW&;1)(-7S6(`Q!U[=?=;W[1;]?38?W@\P4GYB).
M/V2;O#D2M49N_48:DXGE$@>4NM^NA:(=[3Z'?&E5]/38?>T@]-^NM^[6!^;\
M??64N%O=M^7'L=V+'Z_(32\#YCH`.@^NO:6G,8:>DRDD(=:]/<(P9F]?78M[
M^N!YC\1%)/P@F6?TMY#;A'KT^4,V[GOED1JM^GM%I8T57)*W9510P[WZEC3;
M*^O^GUUKT#WA\)OC$.&0<^\O-<T5IQD&Z6V!8]Q3Q4:>G",!:A2.66$[A4'[
M+'L(A"#OW@]`B]=:],"0&CQ(>,AC3"2(N%>9CB#"R2QA=ZKC4@&,!&Q;)]YS
M\C<CAB!L>_KL7K^SZ_36!I>;/%U**+MWK9K9?"5Q5UC5EF]02FX*4G;M?554
MLNA]92"!5W'VVLDL)74E*US&U,#_`!AR6`3E+`(]FN(Q`("+U&,),XF\(5*2
M*V.NKBZ]\>5-\\MMH2ZHS*'I^M;ZD,_#7D;A]7((S.S2IK7(:S`GU,IFE,<A
M)OM0[#\VP;WL(=;V&P\7ALX[;Q:,@K_UQ5`P;V(D%7]P]91-$2+8AB]=,Y5N
MJ60_6MF"]`G)C0ZV+>]:]?K@?AGC`E+'K1M9^2[R6P902'T1HWF](/;$>*WZ
M?3:AJM2J)4N5ZT+Z^FUH?7UWK?KKT]`_/_$_R>1,&_Y%\JZ*8@*W_P!&VWWQ
M534E("4'7[I2UWJ=_IY[7>N_]0Q&:,W_`/>U^S`?9>;2(%:"2_>,^\0$^FS#
MG)DZ5H!T6A!Z^NDR9O<;R:TIYO\`P"8:(`=_M'Z?7`\?_+#R<P<!FK*\6B"?
M)$GT->N:>Q*JE2MQ]-_O";H9<<>IE63^[]0A-<M^O[-[#@?@O*_'(F$'ZX</
M^1FC-`U__4'5^Y4D5EQ)MWK>M"THF-$.UJ,1GIOU^I9@]"UKU#ZZP,HC/F4\
M8TD5IFU3V#64`=U9FB"&2ZB)70KV-3OUUM*%INF.0)<-0'8=_NA`+>_3>]>N
MOK@7J@%T4]:Y&E-76O6MD)]E_-HZ!3F,2\KXO3U^38X^Z.`=`UK?UWO]F!%W
M6?658<:U@VVI:;984@;I!84%JF)Q*J8*\V38<SL.R7HM@AL3B<-80#<GEW>7
M,SXRRP>F][UZ:]=[UK84?>O,S2<-(;G:S>4?)!4,-62:(11PL:UN'[<A->1A
MRG4K9H3&CY5*W5*%`QMZ^3R!&DT<9]/E/`'6M[WK6!M\P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&!6?LFV;7HKER[K>HZJ%]WVM`(*XO\,K%K"<
M>ND;B0:G*4'$-J093C(/Y>;3CW034C&6N=P(MHDHP*#RAA#K1)/,YVM(N:N,
MI77T[KFPSYY6U\6GTEU'3?$5[=012OXI5!T#:$S%:5!US/ZZD=$VG&W^3KPR
MI*I=%S4F;6X#@C,,TK*1A"V_0WE:ZBCTONFV^=S^:K`Y$XQAW",LMTQT;YLI
MG/5[+VH"/.P)72$P:7C4:J%CB\1E*-:V`<D$E$Z*-C`<-,5[1X'8M=W=M86U
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M[O8(*/\`=/2DGMKFR0T?0/E0O3K%UFUF<[I8O1MY^,FT&-]?UK)T554D1J-W
M?&J/I@IJ21HYF"[+S'+WZ4H4!R<L11AP!!#L0G65YEJU/&*1\P<0].M`![T4
M=2O0EDT)*3R-;]-G'L%R5U-HZE5;T+U"0![.+WH/ILX.]^N@\-^3&T8-H8.@
MO&/W]6(4_P!%;[7,!@/4$0+`'8?F6@<J%G\KDH&PD/N$(U2S)3-!#O>R]:WK
M>PRV&>8GQNRUT2QUSZ@B-32Y4>%&&&]#,LQYTE`7#UT$QN+;;MCD$_(*R!;]
M!_:#4%Z_;H6]?7`V#0Z>P:Q&D#]7\TB<Y8S-ZT6]0Z1L\F:3-[UZZT!Q95BU
M&+>]?7Z#P,LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$UZ4I`>C*DG-*
M6>A<5\'L!HTTO1;.\.$?>D@TZQ*ZM+PQOC4>G7M+XPO3>F7(E!8O4I4G+%O0
M@ZV'8:D(?X'.;H[1M<UN"Z^IH?:S`BG":V.CZ9N);65IW^1:T>CL8M*/V:82
MU/,=71"5,D/9TI"=,@3+FDII3#0JTZCYCS@F&?\`A=XRG,TA[\B'<]<UZR0Z
M@H#.^=ZSM9WC//\`?41Y9^S#SRS7A"#DCFY2TFK"&U,0D$E<FTQ:E3ED.`EA
M0-`P-L^!$51_Z;+_`.[LV_YB#`EW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&(3*OH%8K6<QV#"(A.F124,E0SS
M*-,TG:SR1ZWH91S>]HER0TH>M[]0B!O6_7`U[3#PX>-Z4NITC8^9HW34L,T+
M1,OYLD<VYKDJ'8Q_(,3>XT;)8']F(8_KOV`UZ[P,2_\`C=OJN1A4<T>47M>O
M`$>FDL6O)76/6T'3D%:]"6\I+;D*_GD*(0?W3!BD`U>]?4)P!_O8'YL'FKJ8
M/NT?P)V0RI!"$,&R+?Y&LIR)#Z_&02'1U]5UM8/6M?(<,Q$5[OJ$H.OW=!^[
M\CW05<;$7TOXMNT(`2G!K:V54$"M^P(.7OTULPT@RII0ELL2$@/J(9Q\53:"
M'7KZ?M]`S"%^8SQO2YU2QMUZ=BM13!4<%)J%]%,4SYRE`'#>_0QN+;KMCD%`
MX*R!:]!_9F*2]?M]V]?7`V%P^=PBPV@N00"916<,)N]!*>X?(6B3-!F]AT+6
MBW)E6+48][#OU^@]_3`HQ>'E:X1YUMN6T5:EPR)!:D"31M3-8K#Z*Z%M446#
M+V1/)8TG?7FJJIFL?;E[Q'U92PI,8K"H^W,"/8-:%K`DOEOOSD_L]XG\<YUL
MQPF4CJY%%W.>1R05G;-62&/M<U&^%11U-8K:@L&=5K4^'1I>`A2F).($8D,#
ML6A!],"XV`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$51_Z;,_[NS;_F(,"7<!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,##YG7L!L9J/8K"@\/GC&I*$2I9IG&664-2@D?K[RCVY[1+DAI
M0O7ZA$#>MX&O27^&[QPR9U/DD=YN9*1EYNM_#,N9I5.^:)*@%L6Q^]O74;)X
M(4F'[Q>OT+WK_P"GIZZV&B*M5]1\*>2#R)063^924\@!8+:Y$>D,7ZKFU,VX
MYW_`#N9J[=7D+V\7DT%3QQ`U;&;'4;PVN91[<C)++&(X\O0]AM+X=Z+H?J/R
MV=_6=SE<%>WA72?C'@>*'3:L92U3&,$R5KL;LIP<V`;RRJ5:$#L@1/"4TY/[
M_D+`H!L6M>[6!O-P&`P&`P&`P&`P&`P&`P&`P&`P&!KY[]\AD`X*9:?(=Z^G
M%S6I?=B(8!4E-5T:Q(9;-#$SBQ%S-P:G&5N#/'!JHPT/Q!J=MVJTX/"T\A*E
M+W[SCDX0RK\P5))^A6RF@4KTI^GGZOU1S;-.F'"M@,%15ETY=L8:)37=#3EH
M?W9MM9NERY/*&1$O5EQTYG9W5Z1I%JL@TS?M#;9@1%4?^FS/^[LV_P"8@P)=
MP&`P&`P&`P&`P.%>9`V,`F@+D<,K;Z](X^W>PH9ORN:\M0:F)'[-;^(`@)1^
MH]^@=>GU_;@<U@,!@,!@,!@,!@,#A620-D@`YC;#AG!:'ISCZ[8RAE?&YM!W
MVZXD.AZU\@"S=^FAZ_=%_P`,#FL!@,!@,!@,!@,#AWQ];HZB*<'0T9*4YT9&
M<`P%#.%M=(7E`PM9>P%ZV+03G)R*`(7[`:%L6_IK>!S&`P&`P&`P&`P&`P.'
M;7UN=EC\@0FC,4QIU*978`BAEZ(7GLS2_%EEB'K03@;;7M./W!]=>X6P_MUO
M`YC`8#`8#`8#`8#`P&:MM>MS>YR^8QJ/+B6Y,6:O<ET>;W5=I.6(L@K7O-2'
MJ30E['K00ZWOTU^S`R5HCD>8/G_`L+,R?<_']S^(:T+;]Q\7N^+Y_LR"?E^/
MWB]ON]?3UWZ?MP.9P&`P&`P&`P&`P&`P&`P&`P&`P&!IQ\U/#%T]X\XPNN:9
M-K-W71ZTH>]/,)LQG-2%JTZV41MN*LN$6K'/M;)JF>4TD$K=TYS$K2C>$`EB
M`_8MFDZT%9(]XC.P([9S)`G'I^KK+Y3?^N.6.[;ELB>QB7ZZ_E=\<SP>JF%9
M&V\EO/.JU5$+7EE(,+LN>%:H+HVE*5R8*96,1:G0=A=W;0/#:L;#%;D@`L)V
M2)8T+U#8Y)];$$7O1KTH@*$IW[OI[@;UOTWO`BA!1D<:OO?QLLM-%^2<53NO
M^"RI6'[IS7;!M6M-]5XO4X_98?=Z>FOI]-:P/O\`T@;OZYMK^YLJ_CL!^D#=
M_7-M?W-E7\=@/T@;OZYMK^YLJ_CL!^D#=_7-M?W-E7\=@/T@;OZYMK^YLJ_C
ML!^D#=_7-M?W-E7\=@/T@;OZYMK^YLJ_CL!^D#=_7-M?W-E7\=@/T@;OZYMK
M^YLJ_CL#CU]%QQTV@VXRRTUFVMQ3N[?L^RY6+[1S2!-`F6%>B_7H<2$\>M>O
MKK][ZZP.0_2!N_KFVO[FRK^.P'Z0-W]<VU_<V5?QV`_2!N_KFVO[FRK^.P'Z
M0-W]<VU_<V5?QV`_2!N_KFVO[FRK^.P'Z0-W]<VU_<V5?QV`_2!N_KFVO[FR
MK^.P'Z0-W]<VU_<V5?QV`_2!N_KFVO[FRK^.P'Z0-W]<VU_<V5?QV!\#?1D<
M:@K`MLLM-$%P<5CLMT19<K#I2Y.!FC5JPWU7B]3E)FO47IZ:]?V:U@??^D#=
M_7-M?W-E7\=@/T@;OZYMK^YLJ_CL!^D#=_7-M?W-E7\=@/T@;OZYMK^YLJ_C
ML!^D#=_7-M?W-E7\=@/T@;OZYMK^YLJ_CL!^D#=_7-M?W-E7\=@/T@;OZYMK
M^YLJ_CL!^D#=_7-M?W-E7\=@?`XT;'7=.!(YRZU%J8M8W.`"3[+E>P!7-*],
MZMBK6@KP[^5$XHRC@?\`#0R]>OKKZ8'W_I"W?US;7]S)5_'8#](&[^N;:_N;
M*OX[`?I`W?US;7]S95_'8#](&[^N;:_N;*OX[`?I`W?US;7]S95_'8#](&[^
MN;:_N;*OX[`?I`W?US;7]S95_'8#](&[^N;:_N;*OX[`?I`W?US;7]S95_'8
M#](&[^N;:_N;*OX[`^%)1L>0*'-4CEUJ)E+RM+<74XJRY7H:]<4@1-1:H_>U
M^];-`W-I!.O3TU["@_3U^NP^[](&[^N;:_N;*OX[`?I`W?US;7]S95_'8#](
M&[^N;:_N;*OX[`?I`W?US;7]S95_'8#](&[^N;:_N;*OX[`?I`W?US;7]S95
M_'8#](&[^N;:_N;*OX[`?I`W?US;7]S95_'8#](&[^N;:_N;*OX[`^5;2,==
M$PT+M*;-=FX\1.U3:XV-*5*%:62<6?I.K3B7Z">G&,K7O!OZ"#ZZW]-[P)DP
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&!JD\P_0/67,W)+S;W+*VOHJ;$9#!W"R[
M!F:4,C>V2*N5HUS#28M7\'6-:UA=I+.!R\XLUS<S-)&9`C/&!.H5'IA$A!_0
M=[]NU7Y$J3KQBZ+K"5MUW6_#F2M."X'4Q4@5$<A,Z!.'H7JWHFYUC(.=UM)(
M<O5*P1X*%2FBZUP3MK9[%ZE6KVG#6+;GDJ\CUC]1>79_H?HV#5%S9XTZH=+R
MJB"+:)A%A)NB/T57S.$6S`IE*W_3;.(I%76QZ8EC0K4(!)G4A=\*A`I^R+"%
M4$^TOY/>P%?D"HV"W2[3F.L=_='3J@G+DA7S4)FJ6N*I<Z<DML\X])U[V'IB
M'JPG^RF>%"-7,!CNOT:)8X$A1-6VL.S@[1&`P&`P&`P&!HYU??DCE79?D'YR
M9IASC7CI%^3*7MKDQGE;6ZOL!JHF=W1?=;*['N&6MS4EE$UE;K$:P!(1M*?1
M#&WG"2MGJ+1:UR4A6J)=]]9MO#'6$NB-\I>G70SH^HN1N!.Q'>G8=63ET-:E
MP2F"U=-)#':^9V-OI^0PRK;+E#DGB;]\((_(MLYA2H]0`H:E0'!3KO#R/0U]
M[7I65V#441M]/U[XS^6Z4D#!!F^9QOG:/=N(V1L?)<8G<4,=_6*PHXA=`N9^
MW,!#&:^"&!,D*;0`3C#:9XT+JO>R8WU75714_9[@L+D7L"P^:2KF;88SUVXV
MM%6>!5=9\8E4MA$:%_*;#+TK;:06M;II+3-ZD3>%06G)V:(&@V68#`8#`8#`
MUJ^6^Z.IN>^#.AKEY)55_'K"K&K+(L=XL"PDXGQ-`8I7L`DLS6ND7A`T"MNF
MTU>U[(F:6Y.X#):T1B[:]4%44EVB4A2OKGH_NNL+EYG>*\Z0K$2R\%7/<2YN
MX7C%0HYG->FU[YM@<NI+.Z'GRUE.D=+5I4\2<UB]&[1<Q(U-P$A`W(XTU2!"
M((C[C[W[[C3QY`+%YAEU<1WG;DJZN2>>5$DDD:9WQY2S1U?JA<KW;H>R.;"8
MXN\YD2CH%I8U*MW.%'69F9A*&XA2XK1'I@O_`&YT!UG#?*MQW11BVOXUR5=D
M%Z:+3L#<D`_V18TKJ2L*_F@YA)WMP;"BX''X^^R_;8V-+8:8I7"2*5BU1LH]
M*E(#:W@,!@,!@,!@:;9-?W?9GDNM3FV/+J(C\&?/'[=EO<MP*0IWIV:U-K02
MXJGKR(6??4Y:64,K2-$@6398$R.Q\L12!I*`(PU4N-]R<*=5[W]U94_,/DPG
M\@Z)C/:S)RY!8M#*<ZE!3L?J6(S;N>5_F8+*J`KEOA#.5";!J:OK6=HDVI7\
M>SS$[J[K$+DN/+2#4%!*]5W3Y4GB\>V>899:_.S';5<<2\FV)1CQ-8N2=!X!
M(Y[.KTKFPK@N1WAK.V;EDYD3/4YDI,96LI'$FQ:8E:B-?;%*G!2%I/%%?EV7
MY`[U<YY<@^I::A%QFP/G?KQPJ]AIMVZ-9&2--'ZGR1#"(<UL\'<*^B=IG.+'
M')$SD!1OR-",>A'B)$I/#:Y@,!@,!@,"H_=,UZ$KWEBX9?S$7`4UL,,)E+RW
M2JRQKE,6KYH8XR]/SS.11EO2G*)R],J5K]K:RB.1IEB\XG:E0!*`[0@TMWWU
M]WXQ\L\&=,Q#J.MHG(KOY5YD<JBYG8*49[(N;O7MVV8=&9;)H!+T1S!HFKZ$
M;FA0%4X.<+"B7,R18O6JE*4A&C(/#F_(YW+Y`80[^1=5R3):PAT4X0XG@$OL
M=ZEK&U2E)$+UFT7GMXR%2P-#HP:>YI,FBKHI&VUC3FGE1,HN8GN#B%6J;P-P
M@YWR-].=U43*Z/NFI.D$311ALTY4KBSH3$Z)J6>P2J'6U;`K-NE,Q[7F+W)7
MN]8U%;'89Z)+%0UY'T8T!I11BX>P*2C\#L28#`8#`8#`8&HN[N@.U(CY0.<:
M(CZJIF'G2Y*/ZS70.*KBE3M);%LRFH#4$D:YI9<G`RFN$!AC7*[&$TI&EDT>
ML/(1*ERHX[2A&D2A4:A.YNIZ77=_.?0O2E=]@U_QKS!(;4O:UXC3I=9T_1_8
M+.6\217R14$BAS.!PM>#QJ%)PFOBES&Y2AA4?8EK3P'KC4J8.2Y?[3[5JGHI
M@C?DBM&L8?3L>\3[GU]/?MV.,I'EAEL,LNM6B?619LEC#*B:$*X":4NJ)''H
MZ$QL2-R-,(9BYP.&8`)F\1G?-S]Q6;WL;;*^'M<?KVS:3=*.JN.N<+?'NK*<
MMFE&2>1QCG;]$1*?R\\5C4B.?`G*UI;:\;5("C`Z2B)+#=K@,!@,!@,!@,!@
M,!@,!@,!@,!@,"';]H6L.FZEE=(7*PGR:MYJ)@%(F1,\.[">M%&).RS%FV!V
M8EK>ZI?M9!'TIV_B.!\FB]@%Z@$(.PJ@O\77*B[JM\[/+W?3/?$HE\'FDH=H
MUU%T/&H?)W"N2F\B'M$CK5CLA!7[Y#FI.V@+_!JFXUI-+&8$:<6C3-"#!9CX
M8O';/D5?H931Z]P!`!RPL]239EGMCA:+/.;.%<LMB=_.+7+D:WH"&/UFF#=U
M#3,!O*$:HP>_C]I@]""6*Q\:G(U0=$*NGH-"I@BLK\O8\BC[4YV[:\@JFOI'
M;VB`V9(JNI5]F3A5%:/DT*)$6N4LC0B,,).-+UO19@@["^>`P&`P&`P&!3J\
M>#>:NB5UZNEGQ21K7/I&CH9SC;SA';#GL,6R.GX'+9=-6")IE43D3.>Q%[>Y
MTZZ6'H1)U#@C6#2J1FI_0O`CBJ/%]R=3S'!HQ'T%R2B-UK;\(O*"Q^U^B[UN
M%EC5A5M&I'%X*K:VNS)_*$*9CC"63GK$;4$'XTAW(2.`2=+424\H,[M7Q\\F
M785TH59U7`E/_EF?5CA<QZF22A*L7OM),2:/U1*8>O0/"5=7$N@B1&2<WNC`
M8W+B%A0%&C?FU[\"3.9.6:1Y`K/=3T/$U$9C"N3R.<2%>\R&0S2:3>=2]=MQ
MD\YL&?3%S?)E.YD^*-`TH<W5<K6#))**^3XBBP!"PN`P&`P&`P(QNJGH!T)4
M-FT5:K.=(*SN""R>MY\Q)W-R93W>(S%H5L4@;B7=F5(79L,6-BTPO1Z8XH\K
M8O<`81:UO`I387BBY$LF_$G3#N3?3!;Z.+UW"2GVO>I>B:V:QPVK2R00^)J(
MO!K*88VIC:<PH9RI"8E$F7J%"@Y2`TP\X0PF5ZX2YED--V[0SS!5RZN;WN)T
MONUT9TNEFWZ86D[64Q6N=(W&6Z>=2?T1RJ+MA:-,%6%,B:6],VD%EH""DX0E
MZ84-6$\M^F;VD[">OLV@$5FM]6OI;P[HR&!);[,R,$^+4-"1:2TO.W=KCJ0L
M`EA)XDVR]B)V`0A;V$PX#`8#`8#`8%9+9Y!HRZYI)[#G3#(1S67<X6%R>[R2
M-SJ:0YU!2-HOS))9G'6I7%GUI-9'9P>8ZD-*=TFR75+HO825!81"UL*RU+XB
MN+*8@'Z3Q1CN=YJPN4TO+DE:V-TMT!:4`;5]`2O<VK5L:H=8-BR..M<502,)
M1Z]H(3%MKOI,G`M)/`04$`37>7`_,W12B_UEH1.2+EW3U-5]S_<Z^.V+/H8N
MD]3UC*Y?,HK%$RN)R)G/82`O$\=@KC4`DY[FC6#2JAG)_0K09!RGQQ3O&D6?
M873"^W5,=?EC6K,0VO>EOW?MF`S-^VQO;8H?;<SF*B),I*3?IM$VB3)1CUH0
M@;%K6\"U6`P&`P&`P,:F<289_#Y7!)2D&X1B:QI]B4C0%J5*,:UADC6J9G=(
M!8C-(5I1J6]:8#1A0P&`V+W!%H6M;P-;MB>'?B>RGVG),YMM^15]H*@X=S)5
M#E5W5O253J8I3$&)*(9(HF'75GQO:@9X$Y/WZTWWK7,28G:HT[91?M"Q[WPW
MS9)*[ZIJ]^A3B[1?M-0^']&FKY?+54DGI3]`&.L%#=_-QSR.3,3.W0F/)D;<
MC0*DR9LU\@TH"AG&B&$:67XNN(;>O>']'3ZFP/%F1$%<[/\`BE\U;(3/UE.[
M4#J)WN&M6N0(X!<3Y5QBC8F!;)6YS5-FP%Z)&$)16@!L#P&`P&`P&`P(&LWF
MNI+=L6O+8FK,[GV!54,N.`P&2,TKDT96QV.WRS1MALHM'N/NK:#\DZM\20:3
M+1:VK;C2/D2F$F"$+84BJ[PQ\+U!6TYIJ(,5Z'U'8L9;8A**OEG5'1TWKY1'
MF^=QZQ3F]!#I99KQ'F<#]((T04[;2IRA.[8>J0+-G(UBD@T+I2GE:@YQ:RJY
M9G7+'+)@X4,_<RNB62%F/<,>*2DTL:9J^P9Y@#D-3"W9N<7]C3#,$H0F&[)!
MLCW?"(0-AC7/G$7*7*,TN2>\XT97U,/U]+X8XV657<=;HJPNAL!C@8O&$[7&
M68A&P1IO1M^S3C$S>G3$*%ZE0K-`-2H.-&%J<!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?@A!#K8A;
MT$.OV[%O6M:_]][^FL#Q`869Z_&8`?I^WV""+T]?V>OIO?IZ^F!YX#UUZ^GK
M]=_LU_QWZ?M__9ZX'X(00ZV(6]!#K]NQ;UK6O_?>_IK`_-#"+>]!$$6P^FA:
MUO6]A]=>NO76M_3UU@>6!ZPG%#W[0&ECW^WT",(M^G_KZ:WO>!YA$$7K[1!%
MZ;V'?MWK?H+7[=;]/V;U@>(S2R_3WF`!Z_L]XPA]?_;UWKUP/P)I0]ZT`PL6
M]^OIH(PBWOT_;Z:UO?KZ8'LP&`P&`P'KK7[=^GKOTU_[_P#I_P"^!^!$$6O4
M(@BUZ[UZAWK>O77TWKUU]/76!^X#`_`B"+7J$6A:^NO4.];U]-^F_KKZ?3>!
M^X#`8#`8#`8#`8#`8#`8#`\?>#W>SW!]_IZ^SW:]WI_Z^WU]?3`_-&%[]OH8
M#?OWO0/00=^[8?\`5H/IO][8?^/I^S`;-+U[M[,!K0-Z"/>QAU[=[_9H7U_=
MWO\`^N`V:6$.AB,!H`O](MC#H(O^/T%O?IOZ8`!A9GK\9@!^G[?8((O3U_9Z
M^F]^GKZ8#1I8M"$$P&PA_P!0M##O0?\`C^]O6_36`"86/?H`P`]^GN]`B"+?
MIZ^GK]-[^GK],#P^X3_7_?)^F]AW_N@^@M:UO8=_O?3>M"U]/_K@>P(P#UZ@
M$$>O7T]0BT+7K_Z>NM[UZX#0P;%L&AAV(/\`J#H6MB#_`.^M;]=8'E@,!@,!
M@>.A!%^P0=^@MA^F];_>U^T/T_\`M:_],#RP&`P&`P&`P&`P&`P&`P&`P&`P
M&`P(@O:R)E4U9OLY@%)6!T/*FHUM+;JHK%T@#-,9%I<X)T:DUN<K.E\%AJ8I
MK3'"4G[5.1.]E%"T7H9FP@V&OC_Y"NPO_P!&7NC^Z7"?_P":W`K#='??>4LM
M>GJ^C/CG\AM*(7N)V_)WAI@<X\;;A.9L=$U58(6L]"YV-;UE19LCL7_FM1^0
M*V%"M4GKTFR-G`*/"`%+=]]YQ2UKBKZ3>.;R&W6A8XM4$E9VJ>3CQMM\YA)L
MM.LQ&Z'+W.NK?K6*N<>D^XJ1MO*T%<M2GH%?SB)`:0$86>_^0KL+_P#1E[H_
MNEPG_P#FMP*O>:NU)]9G@/[=L.9TS9/-,S75JV%*ZPL9Z@;E.8WI%<\';R%"
MQWJJ93B(FDO*,O2@G:5T.%H@[03=`'[@:#0CRMRKW)Q2Y]'>0*BN.["\9=&T
MWXJ[]D<B9K#[%1=;).C+Y0U;(Y95%@MD07.,O0-0(U(24CP-N=R2T",!(RR]
M;$H-3C#8M775_DYFSEXM:*D/?;5")1Y-N:'[JZ1]$J.8Z,"EI5/7U)1:<I:.
MJ&(NK<DB,C<)>L??OY"YR$QT6`)*-$V)VX@8`$A5OQA=V]B=S>4JI+MNOH]S
M@<1KSQE7E84HKZ-PMD/I&>(J[ZB>*5DLH8(\L1.;NSL-GJ($U2Y0YMBA2^%F
MMXVQ&O\`Q@M$!"B_?_E5[)N3F^\JTE5I2:UN6.TN)[;NFJ9)8-:T33DF1#IV
M_P"+(44ZIB%4R_2*R8E2,J&UJVIM368Y+92N)3F#-"0:E-,6!L=3=<7SS4Q>
M:3HZFYY7E>OO)?4O`<X=(FYP*(F"ZH@JCGV&,<FYSD,G4,;K)$4NL[3H22SO
MZ$I0])'`@HDO>DYINP!NKX!OZZNJ_%)/>J[MM5AG\JZ$AO1=H,$5B3`QL+/S
MM#UJ"3-4<YR+<6=J97:6/=3@9AI7-W=R`.JAS,/`9_ME%"$'2!\>T:5<QQ?Q
M?][.3!552QACZ(J8%N7-1W;DZL;K:WH)/)E):Z45_->1)E/#*_C4-D3JX("I
M&4V-Y*L#`C&82$9IH@"#>?1?:W3<=F,_Y?HN6P'G*0=>_P"0WY`.;7WI)OJ>
M'R3=9PVK8?$9BF2L\3D))$%DERVBO-"@;W)]"NT/[<W_`*)69L.R0@[O)&A\
MAOAH[HZ_ZO0CGO7'C*O&]^1:6Z8KE]FE5PVV(]![SJJ/'V^16D-E)5<KE,O:
MGD2=85H#BWDKTYPDGP!V$DD)Y-X+9^9O)OXE^?>`[-DW(P;.X^ZUM>46`K"Y
M]%OZ.22.(UL*7NL>9;UD<JC9+P^$L20@G2TA8UH`_(:6A$;O0M!`L1\WOEFZ
M<AE2U%1S<<CO!AY=Z6N1\LZ!Q+F)G;;GG-`]%2NE&-=8Q?3\O@]:P&G"F"-%
MN4]_E`U1($JEP*4-X$"$LTO0;$XSW=WY8O5_8AME]:0CDFD>*N$N,>Q;3KV/
M477-_19+,+!H0RR[AB&IJUJ%TODM3!>F]RVH&QNRIW7)RTNF=T2!T88I#5':
M_G,\GM6D3F&M=WN*)!8U,<6=0T?;?0]1\JHK'AM?WC?T9KUT_F:NZ,/>:Z8J
MUL6&2LMU1-S\N/F"!J+3J#%R,U6(!0;$;W\KO>7$<;\L%2O-H,'8TVY.F/"Y
M5/\`1YM85U`$<2;^R5;>BE47E\.A@F>MUBZKR-#/:#71T2:,,7$"<SMD!W[P
M]M+>1/RF0;M;AWFGJ>5@B]>6QVU=-4GNED)..C[OM:I".>&V=0:,W0T\TRBP
M*YJR<Q^Q'`H+;IC.95;TC6I@"`JUK9AH5/2=B=O]I=S<51Y5VA)H?!6KS;^2
M6@(8CKR$50?%U=9\U5G$)/5:IU3!CPF>Q!EQ29.K.G4.H5^BRW'\@6+:XLDX
M`99X]>Q^K9I3OCPXTHJX*]XN!U-.O*)9LSZ(:*8KN5::M<^77+5,?KB"PB;$
MD5L2ZO.C3%S^M5$K5PVWU,+`2;L2K83MUEY,_(=1E@P.>2[HZ,(>0X50?.,O
MDG5?$U`4[UMSI*YO*')+^J,XZF@KK9.NB:?IR7JS"6F)FQ94VC6:5C/3J5)Q
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M<A;-F)9O&8_^=?7AEA\P,2FJ&X2@W99H=#T4+80^T(69P&`P&`P&`P*O6/?-
MJPJ]:UJB,\CW9:,`FP6S<IZ%B$AI5!655B<'-6@/#+F67V?'+-<OQ29.!6HV
MSL;CKX#PZ+^0S0P!"&TO8G12B&W')3?&KU<D?*W?V%I@\&/F_*>W^\6UW>G%
MK72.!K">@38\RML=0HBUZLN0K&A4),I+"04:=HPL`5GF7D`ZB*OVD%S+Q_=$
M=YA8&EG;NQY,[KJ%<4U%3:?!*$K9ITY-=IN\@6*J&:5#2[NYD-32!O4)7I06
M<>$Q%L(0LNE[%Z)40VXI,/QK=6)GJN']A:8-"#)SRB:^WFV/#TX-BV30!P3=
M!'QMG:H\@1%KU0']:TJ1IE182"SC?>6`,I2]3WHHF-"1LS@/I1(R6W'V%WL2
M<*);S=M@YR<WAS7H%T:L]&3=IT@?7..IT9:M6;%D;\D$G4E_`::9H8`!UH?)
M9(;RJG_(%<>MJ45/\@-X9\954]'6;3[4:>8&V^>S.DIC6_1$;;T@-'`W)F:K
M9FLD+7H)>]FN#&2'T,%H!0PAOD2'O;Y_CN4/Y%:HERQIZ"\;UV]C]FTJ\R,]
MS,8YM%&&\;0.M>G[#0I33'17$[6JPD]":2G4)SREY27>E!903=B#`^K>4U"O
MD#QSV]<]WUK,[5\EO3;[VKT[S];]TW-S=1_44KN2GXT]UE5+'T)!$:5/3S7S
M)"ER--%FY_<$^W1<I4B(4*AE_;#"CU\GPJ6<+4US)6J"T2VR!>;^KZODG*?4
MG4\=DM1TR*<T#8JW=)P+MJG95IRDG.3PD3`'^=$M1+F8P)QH"P&C,5*`[1W@
M'Y4@W.Z#I5Y14QS)2T^EJ^O&MP:.:NY;.[-:WJ&L::2JV=QE!ECSR9&01P3O
M;NN*3Z2@3??%^[W^_P"$/H'5KX$<;)AW,:7E-@>WX97FU?F.M&9Q%.YFD"R2
MRK/(_.:8Z.7_`&R=C=UOM?\`E-]0D.);$K3&(F=K.6GZ+$+Y]A7CQ^RKOI&9
M8D*\?##))193QXN[Y:7F1I[+2QZ8U13<1\D5TN4JD-<#DP',N06Y(8Q'01B/
M[!L*I(N<@+`F:&0'>@W;>2'B'QISG_'7C7;O*</FB5=2G/L&>J,FZRT9ZGFC
M9)+5O.ND%S'7&B:']NC\]M0Z1NKHA>5+FC4A3*R/B1Z)2D)0%AO[4\Z1?Q@^
M(SJ-%X]X1(F&7,O/UP7["&-QD]@VN\JKI7T\F,_-(#Y=)7R2'&[4QQ(<2A3J
M0)@'%>I96MC'H0:C/'OS?XLH))_%'U="O(#:3'W;T='X@[V0WHNG)A=\@[*L
MN64R%[LVMKPB#LY3-KB[1'I68=OY34;*2D5I"DVS/R'VAQ08"Q>8'R'?IW0/
M:+G;\(=X9UYUIUOR81PNAIR((Y!S6SU+';7+A-DM]A`&JLF03VO'"OD+Q,"G
M](>RJD#J6`"%L`,LW88M0'D4\L=B1+E1@D7;<8&^=D^-2[NTU4W3\NT^4^4J
M]<W.3ZJ2,->MQ28B+R)PM5O;4Z61*Y`A<$2;0SC6E"@'\>@AD$.\HWD<Z[E4
M63P_LBM^/$2KP<,/D0>D:2D*EGB!XNZ,6#/XY)B6`RT0*%[1$9*CC9"AS(-4
M.&FYO`9I+\)O_5Z#C=>9OR)]$U#?=^P>UZ\X^!Q#XU.8>T7:J);3L8GB3KVQ
M+;CSH_RI*Y.\U51^11*GW)3'@-#05%MI7(IT>D^Q.2C_`&DPPG7K/RJ=[5W<
ME?W5*I)-.6>(=T+QG;*Z3U9050]:0N`2&YV6,RNUF#O^,N$MC'2E,,AKO)T\
M8C"B-EL1JX!GWI6U1Q1Q(`UW\[VAT7;/;G#L,KCHM?14"GOFZ\O:1WCM55Y!
M4L4E"ZE(#$I8TS*4L3ZS'IIF_2F)S%Q81&NY1XT):S[]/HMR"$_0;+**\FGE
M%Z![_<1PV%?C^7(%Y+;$X;M*NY8=RS$*O8J@B@=MR2;-<CE=C,/7,FZ?$)0&
M0$M*%GW&E[+H!:5*I-`>9@=M/`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$+VWSU
M4%YJ(NML^)F/[A"]/8(NZ(9)+(H[LQ,E+;2W]*F=H>^L#D)$\!9DFU!`S1DF
M"3%"V'W`#O0*DYZJ"BU$H65A$S&!PFGX34H=%TCE<K=WDJ-E.)3`E5.\P?7]
MRTB:`.ZK[<@!H22Q*31:#[ABWL)HP(PN>EJKZ(K"7TM=L'8[)JN?-Y#5,H/)
M"#%+'(6],X(W5.E<"232#1EDN+>2<'VC#O0RP[]?I@??+JJKJ>U?(:5F,09I
M#5,KA+A6\C@KB0(U@>(*ZLID=<8NL3!&`0VI8QG"3#!H6M[*WO7K@0':W`O&
M%Y4Q7?/-N\V538--5&U,;)5L%DD:3K4%>-,;:T+(SH(:NV(#S'2$[,V$)!Z2
MJ2MJ$Q6BCOD!^[@>9'!'&"*Q:-MIJYHJ)AL;FF-'0RAI5&HBWQE?5\14:=?D
MC,7+8`MJ-*Q:&_+C`)1E&$EFK3S`AT,XP0@@U]\.7BYDA;T4Z<-<^[_F*02Z
M2OAS=#"F16Z.,[,1G2Q,L7,BAO6&Q]W4(2C1-.S/Q11VMF%)P#&,0@F97X^^
M+5\D52];SE6RJ2K;FK/H=6['M:@U0HNRFXX=$:NL<X(UFR1R*$1Q08D0#V'X
MRBQ[WL&Q;]V!*=<<TT-4,?M2*UG5L4A<<N^=SJSK896-&8F;YS/K,))3SZ4O
M:?9PP&.<J)(!I6(OXPC]/7VZWZX%.:N\,7BOI:P8A:U7<+T!#[#@#TED<-E2
M")B4.,>?T'NV@>6_3BL6)@.3>:+Y4YPBQ#(."$T&PF`"+037)/'?P_,:WLRH
M97S!4<BK>XK?D/0%CQ1YC!#@ADEW2L2<4AM41RD9BYJG3II,$!CBA-3*=%[$
M`(M`&,(@R\_BSD\_FM9QV'G^L47+[@S)V!?2#3&4;+`EK8F=$;X$M6TM&D/W
M*H][;REAZD8]JE*L/S&F#,$(6PS%7SA1B^U*PN]964846S2\+?Z[JN=F)3?S
ML'A$I3)$<AC;&=H_1)#<ZI4)19H1`&+V@]-;UZ[]0K3)O%-XXII7<)J>6\:T
M3(Z]KB4RB9P:-O$-3+T\9?YP]K)),SFQ8H,&YEMLM?5YJIR;Q'B;UQNP[.('
M[`:"%C8[S%SY$[#LNUHY4$%:)_<4,A]=6A(4C(G"9-H'`&A1'X;$'Q`/0VE1
M'H\QJS$:=+H@)6DPOCWK8?36@U)=E?X_/#=^4:PU9SY3=(<LREDL>`RD<_C-
M5%/)[O"8[9C18TOKB0-B.01W<F89::U!3DE.9ZQ(V!T7H@C1982M!L@K+Q]<
M1TY5=H4?6O+=+1:H;K=53U;5=IH.T+HK8CDK)3D;.EC6[$KR7<I(4D+TE)-]
M247LUM.`K>O7`P+?BK\=&Z%(YAWQW1_Z$)9UJSB*\_E,K\<"Q-%_!J;?DOF_
M/BD^D7HE^]VKV?\`9ZTF]WP!T7H/'7BI\<P(7':[3\=4>BA40N1=T%$XZW1,
MIL01BY'-&SH'*>1[\>>F.975P11Y`4>6F&6E-`B(T(K?Q`]H<K*?&+X_9M2S
M'SO+>2J8D-,QB72>>1B"NL6*5((U,)L]*)#,'Z.KQG;>F);*'=48:X?:*20*
MPB^,T(B_0&@^NP/&EP%:<OJJ>3_D6BY+*J18HM%ZL<UD%:B01&,09<0Y0R-)
M&U$6E:ET>BBY.$QN0JR%"5&+W?$`.ABUL,YHKDZ#4/<O5EW1M2$<HZRL"(3N
M:H43(UL30WGPF&IH@TZ`!"$Q<]OJ\/W*EP<UAXS5(CBRP%DE$`"(.,A?`_&]
M=?HI_)'/%=1K_P`<IE9%@T;^,;5!7Z9S2W_N_P!3)%&/<K']JX3+[\W[S8_>
M$?O_`'=!]->@89-_&%X^K)A$IKF><D4M*X;-+AF'0$C:'F*E*A+;FL(3<*=V
M(G<Q':=VJ13$+2F`Y&(U!`%I1(2S0B!KVX$XU?ROSI2<ZE=E5'3<$KF;S>&U
MW7LI?H@R$,AKK!ZE:!L%;18:-%LMN2LL,93-ID)!!)0"B?0/UUK7H$_8#`8#
M`8#`8#`8%0WWA/F*2&S,;I!Y)M/8;O*'Z:M2"V[B9V&1.LU.4*):J7Q]HGR%
MDW_,)JHS:H`$X"S-#WK8?3Z8%JF9G;8\SM+`SIM(FAC;4+.U(PF''!2-K8E*
M1(4P35!AJ@W1"8@(-"&,0Q>GJ+>]^N\#DL"%3^<J+5W,_=#+*NB"RZ934X*+
MD=AK6P"Q]>Z?`^&R7].W/:D1J-7&!OIXU(TXRMZ&,6]"]0[],##8?QCRO7_.
M+[R'":,@,8YFDS/-8^^TJSM8TD%<62QE;FNF[4:U@/\`4"*1JGE4,\L`PA_W
MA:#[=>FM`M'B_E"[*+C/,UN<_P!86+0\*:(PQ0VLI;&$3S'HBVPMK3L<6*C&
ME81KF!0R,J8*,A0D.)4:2[&3L>RS!A$$(.7B=\;SO0\=YA<.-J0/H**3Y=:;
M#5NHO\$90V,Y-JYF6S01*=44J6R$]G<CDFU*@TT>DNPE:WHL``A"1^6O'YQ=
MQ*MF;CR?SC6M$+K$2LB*;JH"U'MQLE21LUS/8D[F(Y6I^4ML.>E0BM:]OIL\
M7[?7`^J#<$\<5I^AG\A\\UU%O_&>36;,:%_%-B@G]+91<WWFK2>HK[E8_M%L
MWTX'??;'\FA_)OTT'Z>@?E!\$<;\N2[<\Y[YXKBIICN#NE:[D,1:SD3CN!O<
M]7VBZQ;Y3%1^OQ2^P710[&`]/7:LT0O7T^F![U/"/'ZRF+=YW5<_5Z=2%]SY
M^M*X:S$VJ-1:?V#*']FE+_*GQ"%7K8W-TD,>1+#-E"+!\R8`M!UZ;]0M0F;T
M2-O3M29*24VI493>G1!!K:<M$02%,4ET6+W!V2`@.@>W?KKVZ],"EM4^-7@.
MC;J=.BZ@Y!H.NKM=Q.)A]B16NV)K?$)SN#1;JIC^B4VD$65.)/N+/-;"4AAI
M1IH!"V`TP(P^U!XY^$FJY)QT(V<G4:W738[3)&69V*A@3,DD+NDF38<S3%2`
MY.06G:WJ7M2DY.ZN*,M.X.11YH5!QFC3/<')QS@7C:(_IO\`RUSS7C/^D%.S
M#GZL_M&]5K^3J8G_`,O\YUXT?(M'[(_(OG']R`?O,%[Q>@]>[?J&N]\\"W'$
MSZ^+N>P:UJ6:\R1WBV`\E5GR<\5T<<RUTJ@=L.]DHIRQ3(4F$K)(4(WQ2W#;
MP)"QF`/-$<H-`/96!?\`MCQT\)7H_5;)[?Y*H:P7REFEECU9+I'74>6?RO&(
MW]MN.Q(I-I(6C=(<P;2`VB:%Q:EM2"]VRB`;&/8@^JW/'SQ+?5N0>^;CYBJ&
MP[?K@$>*A\\D<41JGEL(B3KI[BJ93[/B1O22-.P?G0%+RE):,S>_B"#UWK88
MX^^,S@:3(6IO?N5:D<T['?4HZ@9AJ&,W[QJOZ;*VM?+[0;W$M6!P1R*3+&1$
M8N^,T*=2-&1L9>_B+]H9K_X'\:ZZ1)Z_!S13Y732<L_1=SDPQJ(FFU:I(H;E
M#V:M)*`G42<UM5F)=NQA0G/[4>R?G^+]S`MG@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8#
M8]GP>IF`$EGCWIG;5#@F:&XE.WNCV\O;RM":-&RQZ.L*)S?Y"\J2R#!@2HDQ
MY^RRQC]OM`+>@_*XM"#6RPFR.!O?Y=`D<%#0YIU+<Z,;VQ/*0!)JIED<;?T3
M9((Z\$$J"S!)5J8@_P"(T`_;[!A%L,_P*H]Q];POA'E&Y^M[#C4HF$,I..M\
MC?HU"]-6Y.[)G&1LD:*(:-/C@U-7S@5OA9@OF4%!^,`O3>Q>FMA4>@/,+SCT
MI87!<"J^.3MV#W]0EJWO7LE&7'P,T"3TR4F*GL"L$O3SMQ(F3,^#4-HP(25:
M72I*/>CME"`8(/@H#S(<\=#^0NX_'?%H;8+1-JH/M%H;+<>C(ENI+4F%+'P8
MFTX+7#DWR)8]O$K@O\\`&YIAHR]I`HE&S-A]H?<%:X]_D3<T/EELB)3S=U\P
M\M2KH`[FF)]Y/-6HD?++S9NI2?!TA)\G.?BW]B95DL1J$OW"Y`G,)"2(9A0?
MJ'08W*_\BNM(E-.B4Y_`W?$AHOE"_P"P:`O_`*GA-81>7TC7+M5LJ(CD[E+T
MZ,DP4O1;#'D:LET/*^T^^`@.`+9/O%H&!9SKOS:\L\A]!<LT-(&.:V,3T_&Z
MZGQ-J5\IB2JN*AK"U['CM85]9]KN#Q(6MQ8H1*9#(P?9K"DYP3P$&:!K8]:#
ML)+[W\K-.\*6%45$!J:^>G^G;T;WJ05KSAS1!RYQ9+K$8T:$#_+G$M:XM+2S
M,B,!:@18CC_E4?9J-@![23!!#,>,_)OSSW'S59?1U1HIVS_HDNFD:NJH+`8"
MHK;=6V#`&#4@DL#E4=4+3DJ=V)3[]A!X%`TAYFAAT8$91P"PUZ\U?Y$E17[*
M.7RI7Q-V[SY3_85ALU1T/TC;-=Q?]$YG9DJ$[I8;$F^21.6R!6J4REV8U*,@
MXE.822:6(9XBB`&FEAL<@_DHYH=JYZ%MNUYQ!^>ZXYSZ5L?F*5S&S[;J$R/N
M$RKD]L(5JD[I$9O(TC*I=MN6ME,;H)%(TP2Q;5("?W?4,2NOR\<!T8[<D-LC
MZ%K]\2=J2HU@I241.4,+U"EK*C1GC<9V]3`AQU'VJ)HGH2-GT,1XE1[NX$IB
MB1B"?LD+.L?9')\FNZ5\UQ[HZEWJ_8*SN3_,JA;+$C"R?1EH9=D:>EKS'27$
M:]"6R?<`^]",.AI-;_WM`]-^@55O;R[\35-S+U)TY7ENPGIUCY!3,AEQ0CGR
M>0>:3-D5OTO;H6@0'$_S`E:T9AKHN'L)AZ@LDP"8[0!B&'V["28IY0/'U+J]
MD]G-W8//((E`7>#1FRG4=LPLY#6\NL8T22(Q6:.*5W/;V5X>7,DY(1HPWXS5
M"<T`![V6+T"4JU[<X]N.N+`N"K>G*-G=5U2Y+&>S+#C=EQ1PA\!<D!!"E2DE
MS^4Y_CF$P*=26,.U)A83`CUL&Q>N!5VQ_+OQU&H]RQ,*GGK+TY#NK>P*UXOB
MLJH*6PN9LT-LNS29&>UN<W4?S`E$W,C>&-'_`'!9035PM""(H@P/KO06J8NT
M>1I1>KSS%'.EJ0?.AX\4>:]4PUV5%%MBM^TF@;6)SXN0YC<_OT(3-;/3!!M0
M1KUV8`.@[]`ARP?*KXV*HE$WA-E=S<OPB7UM)"H?/8S([BAC:^124F@7#_E]
MZ;3W0*I&ZE?C%`32=A]Y(RA!,T$6O3`L0+I[G@*FA$8KHKG[KJ5(>OYR3ZE+
M7LV[$*6,)9HI5UN#1^]RI.1$UI+B,:7Y`A2&A,WOVBUO`G7`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`A^]ZD4WC63]6R2V;@I$Y],;3-6-1$H:H;9K*%N<$Z\1+#(7J.2I"@+<=)
M_@4^J(P0TY@PAV#>_=H-?0/%8^@&69KRC^646RS`&:"/IFN1@%[!Z'[#`"H7
M>AEB]/06M_3>M^F!(G>?(-C]"-=&22L+IZ"@$HH=TE:A0EH^VXW3L^L=EF45
M31IR)%.Y)!)M'$[\@/0$*B@*$*9,J"8I*VH3?*$>@KYRMXQ[3@EGG]!63V[Y
M!D[^OE$)>=4Y*NDZ]L1B?V&"(3$R%CNMS9Z896R::>3UBD)R5K&F+2H!%$!6
M'C#\H0N;TQQFY=(RUAE:/L;M?G0IBC^V'<4YGMN)UY$GH>W!2OV_/S<^5I,U
MB^0;THT1\VE)9>DY0`Z+UO0A""E?DUXCN>:>&KJ;C>CY3=/6%R2^#)&Z$NEW
M3R&/%JS9P,M2*RLYM=IJK;ZZB8BVEJ1'@2[/`ET%.0`O8QC]-B#6!'_&)VCR
M3Y8:[ZSHFK7"R.88QR+TG9L;K%LD=>("ZP[`M.E$+3/*F96V0RZ.J1MMU6I#
MVYV(.+/`RIW!U6B-/3>IIYH5FYX\,GEIY.5^/SL\^UX=>-G5/TNMO"Z>18K5
M]?PJTHZS]@O*4KKE(X]/+[%;UEUO#*Q*@",1/:\3;M0AUM&8I`G)`I#R+\='
ME1JOK]U*YJX\3\W3F4=IBLN3]O<X=9DPCA^RZ'<9>F<5@K@\>D[?+,(#*Q0L
MA8484QHTVBG5P%L)9H?4S89T11WEZK6O/+IPE6?C(.F-?^1GM#LN70?K24]0
M4Y%('7E9=3+$4#3S&05DB6OM@.J*.PY&-V]A)A*X0C0E[2"&7LHT(FFG@`\D
MO035UT4FOJ(4##HO35%<2\_5Y9%/5]:LUO.E>)(-#5-2V!'[.;YLYJN:T5DV
M]'!NZ<YE`E=]G&B4N"%.8`)(PNS<-$^7^#V9R9Y2*#YH8;'ZN?/&L7Q!UKS?
M+;#K9FGU>V$G?390S7!6$@>9$]UN_EIK'/\`RJM,N>UWW#2G"F&7\JHP:<)=
M\27/O=S''/+')^X>>'BI^J>O%$1GRD,:60-;1LU4+.>%$$;2*\?F*9R!2GF8
MI<F<1R5`MV2D;#523X#1E&>_8:(.,/$+WG5!/%S77GB2F_+78U07#6LFE?D7
MF_?$5L*M&9B9Y8XKK%<%7*J&43:-$II17#@>Q;2(&]8/WF>\&M;-,'@;)V'Q
MG]S5S,3>C-\V*[7;J1\]/;_;R7EDR>5<B=[UY\O>%QJ(5G;T(6266&5R">5^
MX(#G!H:Y`>UK]?,=O2A`9KU-#X:M\:'=U'2WQ^](K^7U4N(AOE,[D[$GW+E>
MV!4:E\Y=IGKJ'1]@@,"CZZ32^)5P^I8`Y,YKF\$,2@@@A:I$%*0<+U/$$8U1
MX.^P3I1.Z,M1BZ6/E4"?O(7,:([5WUC627F-A<>IXG,6*+3N*T2U15RZ*<[>
MGQLW""5-SH^M2%":B&N+>%.QZ1B":;`X<[5M3Q-7YR"V^+N`TM>M:\"<_P#(
MT4M%NLVD5]B]*S6M;GB,@E*&OEL87(V=#1[DWQA1*Q*I2YLCJ:^.8ROL#1:&
MI$$8>53Q%=AWGTU$WB@^7&Z14JBX8X,I-T;&5ZJ2-Q4,IJ'L%IGEAPXZ*.TG
M9"E"*,5D28H'O202(Y+K:=.(TS?P[">.X/$GU5=-_P#F(<:,IV+QNN^@HKXT
M9=3C4-ZA$/K_`*/>>9'H#_<512!$V.(SH\4^)T84YJQ\:1H%*@!&M@/+WLPH
M(GF?C;[RO;NFO>\$7([ASA7LP\GOC<MEYY</L"FU\AKJK>5:]L.)VGT7.OY"
MF0Z[&\O"UW2)DS>TFNKVH;]EC&+?H(@L,LH3Q=]SQ:Q.-><)'S^AC#?R'Y4K
M2[XGOD9)L*N5@;^J63R*7OJ:%(6!O>]WB*QK4;Y:D9Y.C>-;;DJ%F+$-8Y@^
M,@H-4"=KCYJ?QX<?R"%4U=,?C_GJE<LDG9M>7I1MC/'1%9V7-[&=IDZKH;#9
M2^W_`!$2>(&FAF2Z2E(DC1N.(-Z6+/4`D(;9/`=SG)9KU[9$M?Y:V6ISCXD6
MRZN".'[0BDC89%$)Z&RK<EMB2>5(Y%&&I"CD;G#J/=XM&U81K'$DE6:</8_E
M]OL#N)X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$#(^6
M.86ZPWNW&_G&AD-KR5*[H9'9R.H*^2V&_H7]NTT/J-[FA$>!)'5*]M.OM599
MZDP"E/\`[9FA`_=P,]K:JZPIF*(X'3]<0*J8,W'JE+?#*VA\>@L40J5QVU"Y
M0CCL7;FMG2GK#Q;&:,!(1&#WZBWO?UP,\P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(^MBS8Q3%:S>UYH%\%$Z
M_CCE*9#J-1YXE;YIJ:B!*%8FZ/,"->[.1X"@[WL)10M!#K8Q["`(A!"FTU\D
M](1)/0K@UPJ\Y^W7JVLDD_\`\'JE_<7ZKH5)8Y*9/'YC9D)7Z;)JWMKHUPIV
M4`3-S>Y.6T#8J6Z3"2%?*,)_=.K*19+!LZN765F(G6FZTU:]D/1K6X;B4:C(
M5ZM`J2&R0L@:!?)FW:31JML2[/5I2CR-F@")02$88L'L&#_BU1*B!6TALXM]
M:F!LH-?&F))<TA4R!HD,DCZUF9#95J,B9G>*Q%W<]+%+NF3I2&I84K$G5IS4
MP0F:/6Y#I97S-9<=4*'&-O;BA9R0FZ1M#BA>5$N+@KDS.R5^6M8&YZC<IV<B
M<$9AFE12I*:066:HT`H8>Q-<]/+9$X1!':]:JY8T!(&[1=-.HN?(FP"EZ31M
M,)P92G0;DB"HD2PE`#9A0=#6F@(UZFB"'8<N]6/7D:5)44CGD,8%JZ2MT,1)
M'J4,;4J63!X0$.K1$TJ=<N(-425T;%12E,@!K:H\@P)@`"`+6]A&MN]04-1\
M?LM^L&SX6V'5#"SK!G\8*E,<',V")%Z2:*>5T7/=DSHD1+3'!.6G-/`44<8H
M*"$>]F!]0DAILJN7YZ;XVQS^%/4B=HLCG36P-,J8G%Z<H2XC`4WS%O:T:\Y<
MLBRXPP(27`LL20T0M:"9O>]8&(1F_:JFEH/E10^6M,KET:C)TGD.XVXMCXTL
MA:22J(FM8W9Q:URH#=*6]X3""H;S@@/)!Z;%K7KZ8&?/,UAL<>(U'I#+8RPO
M\S5JV^'L;R_-36\2Q>@3Z5KD4:;%RLA:^JT206C3BTH#1EE[]PM:U]<#AV6U
M:ODLJ<8+';(@+_-FA&<X.T.99A'G65-:!,LTW*%SC'D+B>[HD9#AO1`S320@
M"=OV;WH7TP,7E%]UO$K@K2BG-S7'V/:I<A41UI;&I:XI&Y''(V^2A0ME3JG+
M$WQDAT;XVM`VA5&`-<3DIP4X#`D'B*#`6+K>NG222EC>(Y9$%:6"O91:K'-Y
MS%"V2)V/7T&5IT<UDM?!*=%TH=$\6&O1FJB5C8@5"2KTB@DHTA248(/JB75<
M`F$X@T(21RQFK=CM6E$1E;]%BVZ(NTE*AGZB.,`(<-.9[@9*V>$@,7JC`)!L
MP-DFI0KQK2QIM!Y-?7%)/<*O>Q&I]=5T,YW?7*/3Q^)8'/[)P7-D+C4Y-40D
M0R0;F+.J:98D*2KT>AHU:GWA)-&`/R;#B0=E4XG<'T,B%)X=$VA%-3F^RY,T
MHT]>RYTK!*YJ;2C,0>&YU<W!WD5>"8UY2TD20DM88@5?C3%P$QPP!)E3W2PV
MSN1MQ$=F4#E\1,:Q2:O[%:D#),V9LD1:U1%7Y4@:W9];QLLI2MJ@:,XI48+0
MTQZ<\)*I.H(*#WKKVJ)B1-BV96-!(#MZ=%S.T(YK.H4QJG-<C?W.-@);_?(3
MDJXU<YM)P"2BC1G>X.RQ@`<`PH`97,K#@%=)&U?8,YAT$0O+JG8FA9,I,RQA
M(ZO:P)@TC.VJ'M:A)7.JH)0MEIRMB.'H._:'?IO`BJ)=6<^S!%8CBBM:#M:&
MJ[:>:0G"F0RV,LI#)9+,Y_AQ1U6:K=]%IEKHX:V6A*.V6>K%K>@%[WKTP)>6
MS:&-TI:8,OEL9139_;G!X88<K?FI-*GMI:O3\HYL\>.5@=W-O;O77SG$DC+)
M]?WQ:P.!K:U(9:D+KV<Q9RT%LL^$MMA1%N=?A;I"MB[DB:EP5QC*,\:H&D1;
MVD`J]OO`0:>`(A>HP^H<NIL"!HY&NARR;1%++FR.#F#E%5,D9B)&WQ(HX2<R
M4KF,U:%S21PM0`0!+C"@IM#UL.Q^NO3`XE#:]?/C$ID<1EL9G+0AE37"G!;#
MI3%WI(WR5S>F=CVT+5Y;T4W)G-`H?$XST8CM+=@&$)1)IPRBC`]S):U7264.
M<(CEDP%_FC*C-<7F(,DQCSK*&EO(5Z;SUSFP(7$]U0(R5XM$#--*``)V_9O?
MN^F!';)U/0,@5V/INM.$#CU4M<.=IG/S)7&P5PW$3A?)6IG(U.-.XF#:TESB
MBI.J*&<`2<_998OWAZU@3%J6Q411YX9-'Q$IES,V*3M/+=LI.Y2(#:;'V\\S
M2GV%+GTMY1B1E"WHQ4%43LO0M&@]P><FD".*L#M(G``S43.C,6J2RU+8C&,H
MKT]V@JGEP:FHC?U_U'J22]?\1:P,>36M5RR9_IPCLF`JK#T2N4[@::8QT^9Z
M3M@S"W(_^5RG$3Y\+>84()XO@]I0@[T+>MZW@8B^]#T^QDL*HN;L,A1/EHZI
MPQPBCPT2)OCL]+:'M[7M$M6-S@:GC@V9O8%`EVE(@F)/W?D`'0O702&ZSF%,
M2%P<WR819F;6F/\`\VNK@ZR!I;D+9%?4W7\S."M6K)3HX_ZD#_ZTP04W[@OW
M_IO`BV#=*U%8*&3/;%*6PF*Q5W?61QF3L]1INC!RM@E`X@H4-[@8^B,6,Z]W
MT#2)?HK2%9HT`2C1&^I80RPN[:8.AR"Q2;<K`VOG5U)8FN=%SZ*#ASD^*%HV
MU.S().%VVR+'4]Q+$G`G+/$<(\.P:#L6O3`RY9+HFWQTN7KY/'D,2-3(5I4H
M6/3:FCIB-T&G*;59;V<I`VC3.)BHH)!FC=@.$8#0-[V+7J&.LUNU1(ED7;H]
M9U>O[C.&);*(2WLLTC3HMF,:;A[+<)!%4J)S..D#&A,UL)RM)HU.4+Z"'K>!
MQA=XU*4*&(WNQ8+%G^P$C&IBD4D<XAJ&2O1LB3`5-*%J;B7]4![6K0#]"M-Y
MBLL_>M[)&8'T%L,G<+"@+2S`D;I.(@VQXR-K9D6^N$E94;,9$&P#>8XRH#HH
M6EHAQMO`[)!'KM#^U*TJ*V(>OD!ZAQRZV:K:_P"1_P`G9E?MWZFF)RJV^^F<
M<2?J":L+2&I"H/\`<.1?\V&*BEY`BPH/N-C"<7L/KH8?4(NK'KOFZVXTQ2B(
M7'78T4EETA@C$C<9M$T3NZ2R-2EZB"UC0MOYLT]6Y*79@/VE(*]YR@CV&!!Z
M"],"1M713NXFBGNK8K3<&<GLN--TSU.XM_*:^1FN!C04P(I%^5_#JGLQU)&E
M"E`<(_:@.R]!]^MAP/8\7#4L>DH(6^V?7C/-#2%ZDB'N<UC2"5*"&MI"_.1J
M>/*W,EV.+0,@PK#MA*WHI*+1HO0O>A8'RTK<E=]!U7!;GJF1()3`+$CC9)HX
M[MZQ"M")&YI2U/V:T3<K6IDKLW#'LA8F^00TRDL90_00=ZP/V4W944+068XR
M6R86VE4U%%,XM5+N0MBEVK^)I6A4_#?94RI%"AW9D!S0B-4$".(#]P6#>RM#
MP.-B-[UK*J:C-]*Y&SPNM90PMDD22&:26'MK6A:GHXLAI.<Y"W2-WB9.UYJ@
MH)?QN)NMC-"7O>C?4&@]-5WY75PMR%VB+IH*%W.<D[#MU5LJ)9(#FA\E["Y!
M:&DIW5.YX$RB$+C]#&066<CT$\H1A?R;`&0#MVN$K)*Y4[3.*,,/AKX!@>IB
M]2R*HXJ0O$0TBV$Y\T]FHFW9:]X+1"*7"2*?O`[#HK81%#,#'H%T)45B,4&?
M6>:,;<&RW28L]?L\C=FECD,R6P-^=X])`QAE5+_O7\M$J933O5($[_I!`.W[
M0CU@94Q6O5LHDCK#8U94`D4O8D0W)[BK%,8Z[21F;BE(41C@ZL:!Q4.C>B+6
M#T2(TXH!>C=Z#O?NWZ8$7M?7/.+JKG(2KAKU*P5[_)9;]/7":11'79BV>[D1
M;"UM<V->M,*]V^>+JRCTP3=&E&@T#TV+>]:"Q1!Y*DDE2F.*4)U!19Y!Y!@#
M23R30:,*.)-+V(!A1@!:$$0=[UO6_76![<!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@<<[L[3(&M>R/S6W/;*ZI3D+FT.Z),Y-;BB4`V6>C7H%A1R18E/!
MO81EF`$`6M^F];P-2_9',%P2?I+DJ34##F>*I(R[.<>9[:@*M?!UU!(FBI+C
M2%'6#'VHT4>L^L%J^0-Y;4R&I220+2SVXW84KL8<4%C>@^8IA<TWN`;4X,D?
MCED\?R*C4#RJV8H-;YP\S=PD!:M:SI@%'&M/VJD`C3P&;,V+8M:"+>OJ$<.-
M/=`O=N)>NE58M+?.(O(88!OY\+L)B6.4@C\0K7H"M5SFGLO:9-%$#DYJ[Y&X
MHDB@D`!(6D(#SDZA7LI*$E%\YSU)RM&ZDT:Q+)M^O$(N5])+6F%,K:4I[(9.
MDY>QHG(Y/HQS%&6,U8A3*-DD;<3DH!_&1\WL+"#7/@IXDM>5E!E35#XFN37C
MV'8<[EL=`A+?4!5U*>A7:M9HW*DJ)$K>)<RR:=QQS'L1Q1Z56D^0!VC$X!Z"
M+9OPWTE)$S7-G.3*7"QKBA5D1N^&&"O-8,T=C4VM9]:5O\UI':X:VN%>KA<$
MB+"@CQ?X$*"2%I6U.-*8:7LLE"'+71Q[>CX5?$#KF%HG.(3:MK+,-76'+ZSD
MT?GM@2>JTL=0.T17N4#_`%NK^?2B9H4HWD;P_.49(;M+`)P"&>5LL.72\:7U
M(K<?WISE$SA,<E\TE=VMSPCE-4[;ZR<YG4:ZNF^J4Z2.U^"YWMS@2YQU[=D3
M8F**6],$10`?[:``3/R]1-GPB]3)U+JA@-81^-<PP/GPEXB\G9GMYL>002:/
M3L;+%*%HC[68W156WN&CVP*X\;B$U6I">G3[UH1P?=T;SU9\^L&Q3HJRLL@:
M[QKFN*Y06`YO:1N=^9'"O)#,I`LG4?;%A9KJ]G/ILH2JT9;*>A5`>&=/\XBR
M]@6)P]-6<J2:!NG.3N5&X4S.$"Z.ZWM6R%S*)$G7.3%=JGH-7&%.U:5N3GOS
MJL46(SF+@&BULL8!BV(>R0[V%D+2K602RW^9INRDMWXFKK`G<BF1RA1I.NVU
MOU)V1`VG[$K1(Q.!P'^5)M"!L0/C)$,>M_3TV%*GZKNF.@GZ?EV[1I=?BGBM
MEJT,@U;\1D\7A_,95F-#[8,:CC*P?#(EL]N**,6@/"\84(TQBA,4F.#IJ)&K
M":':I[EE'5$3LI9!89#A0-U=43=>,=G;N^BE-`+TR@2BE'BK'HA(0S3:12@2
M5<X.:8`T1"=L3'$+##]:1EA\[]SK8KU8D_("6Q(JPLCK>FKDD.REQ>U9E=4I
M1-1E,C,%J+3ISB5CK>%3("AEDJ"OB;BMFC^8DPQ,,(C7\HVP]-:6JGR%PU^@
MM3/75,\C;^^R<86:\5O1C;<13+`5\>:-II+7I,=';)A3JYC4&B`8@*-0?-\X
MA)0FCCNE[8A4CMVWKD7S4N6VZUU4P[BU@SJ'V1)XXBJQ#+TI0U$IKR+PJ#"0
MN)TP&!,G0M@#A%)-+5IYJY:H`2$`1?B&?)2++422-0!R>7OFCI>J8<X*5")Q
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M(>(>9[=YQ;X:VV4^MMB*%E!U[%GZ3KCFW;Y6<J@*-L8P5/`RVYK;4VJ7/:O^
MN3:]3UPWTA<L5FF??$`3A&UI<G7-+'2T(FSLL=-32.P[@NMIO)9(DJ9]>$5@
MU7,*^:>?G!F^`Z3)4B,Z0IT9RPQ4-ETP(R_:7LWT0EA9J04`X%<T5'3L)C\4
MC[A!Y9R2\.+0U%(F2/IT-+V]4$PE_P!@%`B*3#,(CL&5!2!T4'YAEE%_NZWK
M80J@^\)6$Z5#`8)&BX3`9:7.NUGV:2YH,"E/TFZ#)O@45<E2MG1)'-]4.2R?
MM?Y4.Q_*6$1HM_*(K01!@\IY1Z)F-A3"[V.K&JB/MY=2[^VU)5LUIARD]C)Z
M_JV[:N<CG=QG572JFD#@R*;(;ES3IQ;5HS&UL+"!0W*]!**"2ZKXRM2O+"HB
M;K0L3\STTUL\:?HRZRA6Z.EA*G]5-'4ZQ#EJ)OC$,"ZT`*?B;8PE&Q)@'("%
MP$9;87^*)("U]XQR7=)<?36/1Z*N,/FEN5.5IOAD_P!E,KO&GB0-Z-;_`"_+
M/@VN);G-J,,V0JT'9H0'`%K6]_MP*S/_`!=.'2/R5(PIXI#9?+^U[;NY?/F0
M9!,D;X-.XC8$48I/MP1$-KHXRID3OS:(*/:HH82T@2PG@T6'>@QN6<GV_9E9
M1Z$E5+5=.N4951.$+W=MDQ#FIFK-$ZDN.`CGJ[;"U(T((Z%TL%*8U(#TWYS1
M)JS:CX=:*)&'%&4!TW-9=&K#D=01N-(:AK"@(PVUNNLZ/OZR[7&FYA.WJ0Q]
MR/0(!1:,L#J5(6]Q9#7`Y8$;HWEA6$(M!`I`&)1;A:W'8-@J)=6%51=BL2RH
M1,CJT2/S5(H\V,*#R$H.FGUF<2BHV@95ZTRN2S#U19:<28YZ,-(`,T&]*1AD
M5Z137.EQ3"Y)1$89,X//Y_8;;`Z>="UB:./G\^4-RS!MR7YRHC)(LV3!J?:A
M?D`&@Q-^4=V=\6F(-J#`GHS@G2/\YRZ3>/?ESG^20V/)I)#X]P__`#]`I#I"
MIC[>CIFP*7F-@1LX@U(I;UX&IHA:TE.0(G19YI19?H#W?NAADXY!M5TZC=)<
MSO\`(RZME=I4S;20QF?*LC\:KQ)34?A32=7XVM;6#Q="D4H<HJK5$@8).TLA
MQ3\O*6$E:$I"Z!@;'PI9*.D+3C#A&:[/LF2<9\B41%7DQ6B4GI9;2,9EZ.5M
M^WX;5]ZWQY(]OP#41H-^TT0QF:``7KZ@FO"%R*"),N89F,">J+'C"CG>-Q@Z
M+I'E?2+=+Y!;LA@0U-EM$]KAB>E4PF"5F0EK60UGVW09G^0HCU3J&\'_`(C7
MK$&>L5L.85SW8KLIENY@]RV:4O*(;&F.6V^JM))!;3@SS3C>R.\/CISZK-V9
M69$86_=C.3DZVG`E4B"/TO`EIR"#WS'G^JZW;'-ZI6V:8KY2YNT:>=/)4QZI
MM*Y"G4"E(V*#F!BDT0ES9I:0=H!_WJ019I8PEE&""3+DXSN97:$VL*N1*$T4
M<+'FXF.LX*ZT^Q$.$;L>A.8*V_FMQ)N*K+1@;67%7^GWQ,J2I6D#N:UO!IJ5
M0/8S4"L,IC7#DHB]?3V.?CXD_P`Q=[]XIEC?/7=66OE$BK_GJ(\E1>7JI#)U
MS:)\5.9A51R/29.>(6U1:@.M_'I4,(0MMQK")A6/+M'UG/H6W0*75Q7<:@3X
MPM#PT/K6:LA[8GCXWY`Y,A9*(U))OQ_WX`B``\L*CV'!T;H>L"E;SQ_<STRR
MZ`?A8RDU'(KU\2DMHZ0)#G#HA3TTP3]+&HG*6HL@3ZQMT/72Q$8[&.YZY.)4
MRH]I`'@]#4H68LJFYNFA_,CG%8@RSU1SX<F5/M+"=6E@99OM96+K7H3&IS>2
MMQ9.YPMT>=.:/2T@!9H"C-%FD';![@I;4W#_`$17%>.[Y'VNLX%<\-%6LNI9
ME9'LQW@#-)H_+NBP2F$.!J1JBRD4'4US=&D!7Q%HP&FZ!L9.BR-DC"4HUQS.
MZ3)2JH5&FNT8Y7%\ME@,E;.K^T-"RW&$_D"K*"<)4_.+R1N-(9^W6.PNLB%^
M0"9]X(TT[2HM2=H0P@&%>/\`Z'94$$8W!69$F62,4389#%ZMF58)8-1@()?%
MHVR'3.YRNG7.RES:]-<Y1@;]PI;%5('%O"%1I,'V+BPF%ZX2L5RJ*M8-&T\&
M@$J1R'LESF\E9C0(_?J^S;86QQ0J4LR!(X/@7Q7+D0'?Z[,+`<</>C]E^P88
MZ]<S7:^2^U+G2<Z(JQD3])ZB50&)U+:5)!E[8&*5=8U9S&2/Q=@U;*:7>_RC
M=)DS>6F6)%"LIE`4H3'IUA7VA8;1:C135C@D,BTZ:(XBD$9@$#:WMQAA21MA
M;C*$T>(2RA-$8\3HM0PQQJ=$FPHRC"RP_;&`"`.M`WK02?@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,"IO;\]F]:\VRZ55TY2QIEVIA2T;0+8&W0]VF^D4
MYO"N(._IH>@L!(MA1LG<(](E2=")S*$D*4F@&/VZ#[M!#T/M2=UKJN@2DGK:
M8N5DV+8;$@B5YD\Z-TWT37U!V'9I:>.M5*1%,S/;/*E<:TE2%G.*5=^5``8C
M0I0#(4!\E=]Q2ZR8XPHX_`JK<;8GT\*@L&B#=;TH%'6=Q+KZ46<]I+@>'6GF
M>8P!WC<8AB\!Q22//"=6OT`A*>=H*D:</+H#O)XH5-'S'NHBOS".&)Y]9D'4
M2UR>9XU,('Y<PO'\AL=9PFQR'TEHTT*5QCK(E$38@MXR##%I8OO`(@S^']%2
M:-<IR*]YTF_G13#[5MUHDQJ<2)BTWUS#^HYE6JZ0[+;VXXM2"NZP:MN)A!*<
MQ6YA;-EA]RD_0]A&MI^1>(PE_=XO'VN'."[5JV-6\2D<MG3NP0:3!I!@KDZZ
M!J'>,P*=/3))8G/)^*,I6X;<<0L7MR@XQ6G(#O>@]$@\BS4DDE1`C]=*'"(6
M&50*A^3NBZ4$6K%D?1+W$F"*/"N!QF!RUAC3#&E\V0`=U4N?HKZ&CV6D`JV8
MFVI"48!UK(E/*,E[`NBMF:MJZ05?NXF&/Q6=*K%EYT(31P]_5[D@#8;$&5I>
MS2R@[3D(U3B4(DW6S323`C*T$.Q3R`3.PW&+0&NJG@4PM*3V7N!_=);4EK;3
M#6WJZILNUT+WNQ':F$<E>G%M15FH;G9L1QTPQ$K5IS"S3TY@3-AC%J=TV_(*
M&MB1TE6["V3FIZT=I':;F\S@O14$=@6)9]5HE5:HG"".#=:)25]I][<A@=M1
MT(FH*;Z;5G"2%!EPNW+*-T]H8!4#++$\-K^_+@F;_8ELBBXT<4I_H"QJG/CK
M`EBM3/PWF0O".%'+&P!Q"-*2G+"G6+!'>BD\,X1=JR*026NW&*U(WN5-SF[H
MYSZKESI/QL\_CTY>(DKE;@\&P`$0<65RAS4>26UZ-*?PKU"X8C-)0I`:4##G
M[)!9=A]9IJD8;ULZGX6S<ZI[%-25BW5*8M>I2YV6OC6U;LX655UCG_;(FEN"
M`DE+]J7[C!B'H>_;[0KN_>2']*`K(%-FZ,22P*^>+=(ESLY.S]$-3N"TU,00
MQ0^P1CCD(G92VUI@>8'9$?.-;FK[HHW7Y%.`P@K06?9NJGE^43B;MM8F'4!7
M:F8,,MFIDD^SLIFD4#B0YA)UZNKG%D1HA0U$4#;:$XI]->ANGIK\9I-ZJ-!6
MZ*>2MPL%`R(J\JV)S283B75"UPI.VV3)T,(0QNZ3)0!A4V%-'>HD(V*;Q,B+
M&JGID:T+T#[0P(T*M8+]W`X&==Y7HI@#&N8*ACD2D\XEJ%JK8+=9*:3&R%=4
M_9E(<W74PR33Y7S6U16-30RQC0QUS+&O<?Q@AJ52)N6`+3X$E6+Y"!5>I3UU
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M=&33]$)-I(%6L0[_`#,%ES'.8PK^X0'IE'HW2:.(U&P>[XS=%?&8$18A!V'R
MRVN(?.':&O<F:QN#E`7-]=XL>%>X(OQR^2P^0P)Y.V!"J3`5?=Q:4KDVM&Z'
MHO9WR`]I@`#"$%).,J82,[X@V?9JU]>W-B=2['<[=L9RMB.G19$^-D:31"S5
MLC.F47;F-KE+LE(3HU917VSLM*'H8%)VA!QTTX7YVG:,EI=V&7MS`9#V>!R.
M-Q2R[`AS%/XU'G%W>&))8Z&,R-KU.E+6]2%P6`4N0CU(U*Y08:8/9QGN"5W>
MIB&:H)=6%5)8JR!D8YNH*(G;8]S6*;66;*WJ53TU[9BI`SNKLD>%TH<S`I@K
MR"@#/"#7H0#X\".V+CBGF&G:OIM#J6MK=4[>H1QN8Q67OL#L(9KT?]]-U"J8
M0A:PN_Q6,Z#&J?4H#`)7`\01F%[&44(`)!Q;0<CDZ"2JF.4MJ=`]5I)A0N-V
M'.8O7#G*J>41<^M).^P!@?VZ,/;Y$@0EH(3G*DYNAIFU.2:$PLO0<"9F2I:]
M8*L;:411E$HK!JAY$!3Q-V$>](#8DG;=-!;,N,=35:IP($WA^,0CQC,'KZ[%
MO?UP,'AW,]5PM?%GI*FE<ADL.E+K,&26SF>3&<2P#NZQ!]@/Q+Y%)WIR=79H
M:X?)%J%`A4F&I$0#QF$EA.$(S88#+^&N=)JR_P`N.L:E"&/J]R$$C9XU8\_B
MJ*<H9)-I#8ZIHGVH](VXZ8LS=.)6XN+>E7#.);S5AP$X2RC!EB"0&WF.EF@,
ME"@B9A`9=#)Y7[_K\Z_F?>Q2RYO*;&F;;KY',?VPG67S1Q5:.*]AQ&C]%E#`
M4```A7$OAG1M]PZ?JI8W-E55I,F*R8-7L5'8[2K.G$:ABB#,CE,$"RR'2L'U
M:E9%YQ2AW!'"'UP)*(`>JWL`S#`L#:/,=?6O.&RQW1_MB(35LB1T&"^U9;UA
MU@H7Q8UX_/@:7<J%O[0E=2TKML1Q(S@#-*V8/01:"+>MA^/O*U+OC3#64+"\
MQY#"FX]A2?R;+I3#U<ABS@KVY/D/G;A'79O7SR*29V$):Z(G8Q64O6F&'G>\
MTXT8PY'_`,:J@_GY58(HZK&J6_<JE,0,?7H=7FR!:S#C:Z9CJT2[<#W-ET9,
M$W'.NT'WAJ,0BQ#W[A;V'$1SE&F8T8U'$-<H=SX],8[-(PHE,^FTI/BJF'D/
M">(1R-&OKZN&S06+E/ZS2)C)V%L)VH$+X=BT'>@XR5\9\\S6+-4-?X8O.8F,
MR:'LY2"8S)F7MJF?V]$+WDZM&[M#\A=2%:JTX(U.A)H3M#2B2Z))V`@9A8@]
MQO(M/&Q=NC@=3Y*Y('MPD)UC(+.GC=;[VY/29M;I#N26NA?D\Z?TDB9V1`A6
MIU2XQ.>B;T9/LT%(FT4$O0>KX+6Q\H/A#`GC^IBYL3L^)D1JG[$Q7&H1%:Y9
M-(D)AQB1K2H(?"VU($E,`HK>D_OV'9@QB$$?MG,=/L]F+;50,CP6_KY$OFYS
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9,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tpg6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg6.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.C(V1C@S-#<Q0S(P-C$Q130X.$)!.#DX-C(R141%.3DP
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C(V1C@S-#<R0S(P-C$Q130X
M.$)!.#DX-C(R141%.3DP(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C(V
M1C@S-#9&0S(P-C$Q130X.$)!.#DX-C(R141%.3DP(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.C(V1C@S-#<P0S(P-C$Q130X.$)!.#DX-C(R141%.3DP
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`&.`I0#`1$``A$!`Q$!_\0!!``!
M``$$`@,!``````````````$&!P@)!`4"`PH+`0$``00#`0$`````````````
M`0(#!`4&!P@)"A````4#`00#!PD0#0D&!`0'`0(#!`4`!@<1(3%!"%$2$V$R
M%!46"1EQ(E)3-A=7&%B!D:'10I+2(Y,T-=66UI<:P3-C)$14)54F1E8W*?#A
M8D,G1SA("K'Q@F1%:(/39BARHG.ELO*CLX9G=Q$``0,"`@4$#`@)"04'!`(#
M`0`"`Q$$$@4A,4$3!O!180>!D=$B,M)3DQ0551=QH9(CTU06"+'!X?%"4C-#
M)V)R-)0U1648"7,D1-0E@J+"8[-T-K+B\F2C)H-UE?_:``P#`0`"$0,1`#\`
M^_BB)1$HB41*(E$2B)1$HB41*(J"M[%>,;2NZ[;_`+6QY9%MWW?YFA[[O."M
M:$B;JO0[`HD8&NNX&#%"6N$S`@B5`7:JW8E'0F@;*(J]HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B+U]J7H/]R5^PK6^M;3FN/,3_1JO`[H[8[J=J7H/]R5^
MPIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@_W)7[
M"GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#_`')7
M["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#_<E?
ML*>M;3FN/,3_`$:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#_<E
M?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7H/]R5
M^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@_P!R
M5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@_W)
M7["GK6TYKCS$_P!&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@_W
M)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#_<
ME?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7H/\`
M<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7H/]
MR5^PIZUM.:X\Q/\`1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7H/
M]R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@_
MW)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#_
M`')7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ#
M_<E?L*>M;3FN/,3_`$:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:EZ
M#_<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7H
M/]R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>@
M_P!R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI>
M@_W)7["GK6TYKCS$_P!&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIVI
M>@_W)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:E
MZ#_<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J7
MH/\`<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=J
M7H/]R5^PIZUM.:X\Q/\`1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J=
MJ7H/]R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNIV
MI>@_W)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG:
MEZ#_`')7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.ZG
M:EZ#_<E?L*>M;3FN/,3_`$:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.Z
MG:EZ#_<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[J
M=J7H/]R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCNI
MVI>@_P!R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMCN
MIVI>@_W)7["GK6TYKCS$_P!&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCMC
MNIVI>@_W)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V.
MZG:EZ#_<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8[
MJ=J7H/\`<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[8
M[J=J7H/]R5^PIZUM.:X\Q/\`1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H[
M8[J=J7H/]R5^PIZUM.:X\Q/]&F!W1VQW4[4O0?[DK]A3UK:<UQYB?Z-,#NCM
MCNIVI>@_W)7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.V
M.ZG:EZ#_`')7["GK6TYKCS$_T:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z.
MV.ZG:EZ#_<E?L*>M;3FN/,3_`$:8'=';'=3M2]!_N2OV%/6MIS7'F)_HTP.Z
M.V.ZG:EZ#_<E?L*>M;3FN/,3_1I@=T=L=U.U+T'^Y*_84]:VG-<>8G^C3`[H
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M-*^7,//<\X8A]YXNX:#Y++Z#T_PWCI\ZO;_^5[@8_P#$7ORF]Q>4SU]\7`GY
MBU(K^J[NJ?3<<X>OWEB_?_99?=NT^_-]/\KW`WUB]^4WL[$]_?%WD+77^J[N
MIZ;CG#XL\7:;1]RR^T--0_AO#_LI_E>X&^L7NO\`6;J[6M1[_.+O(6OR7=WL
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M[!V:Z_OW<.M/\KO`_P!8O?E-U]I/?YQ=Y"U^2[N\J)Z;CG#V_O+%_#3^BR_=
MU_AG<I_E>X&^L7ORF]Q/?YQ=Y"U^2[N]'QIZ;CG#_B>+]_\`99?=L_\`.[]1
MI_E>X&^L7ORF]Q3[_.+O(6NO]5W=0//<<X?%GB_C_59?U0_AO<I_E>X&^L7M
M/YS=7:_(J??YQ=Y"TU?JN[O*JX;WSV/.:X2!-J;&4>J!M17)9OA(B``(=7LW
M#P2``B(#KOV5<C^[!P&PUDFO'BFK&!IV'0/B5,G7UQBX49%:M=SX"?PG4N&W
M\]3SK)KD47D\:N42B`G0-8;=(IRZ#J`J).P4`..H#PJ9_NR<";H[AUWO::/G
M=O:_"HBZ]^,=X-ZVVW=?)G1\:[HWGMN<0IM!98OW@(#Y++Z"4=V@^&;1'_+H
MK%B^['P'.S''<WNNA!<*@C6"**_)U\<81NPN@M.T34=!KRU+Q]-QSA?Q/%^F
MT=?)9?=P_AM7?\KW`WUB]I7]9NKM*CW^<7>0M?DN[J>FXYP_XGB_7:'N67W\
M/X93_*]P-]8O?E-[B>_OB_R%IJ_5=K[>I/3<<X>GWGB_A_59??O_`([N$!I_
ME>X'^L7M?YS=?:3W^<7>0M?DN[O*B#Y[CG#_`(GB_>']5E]VW77]^[]E/\KW
M`WUB]^4WL[$]_G%WD+77^J[N\JIZ;CG#_B>+Q#7^RR^[9I_#.[3_`"O<#;+B
M]I7]9NKM(.OSB[;!:_)=W>GXD#SW'.'LU9XOW#_59??MT'[][E/\KW`WUB]^
M4WN:T]_G%WD+7Y+N[RJGIN.</^)XOW?V67W[/_.;AUI_E=X&^L7M:?K-[B>_
MSB[9!:_)=W4]-QSA;?WGB\-W]5E]G3K^_>.E#]UW@?9<7ORFZ^TGO\XN\A:_
M)=W>54]-QSA_Q/%^_P#LLONW?QS?J-/\KW`VOTB]I_.;W$]_G%U?V%K\EW=3
MTW/.'_$\7\?ZK+[0WA_#>`;Z?Y7N!OK%[3^<W5VE'O\`.+M'S%K\EW=3TW'.
M'N\"Q?N_LLOOW?QRG^5[@;;<7ORF]Q3[_.+J?L+2O\UW=75O?/6<Z:ZO7:O,
M:,$^H0.Q)8Z+DO6*(B<XJ+O!/Z\.&X`J_']V+@%K:/DO'.Y]Y33S4'YU:?U\
M\9.-61VK1HT8">DZSV%[8_SU?.BBHKX6ZQG(`<I0234LDC4"&`0ZVAFSOK&.
M;30`'9K6/=_=FX#8T/B?>!@/?4DQ&GP$:0#I--("NV_7MQ@YY;(VU)/@U80.
MR:Z.C970NP-Y[?G$*.AF6+P$!$#!Y++@(:<-KW8(4;]V#@1P#FW-X6'2.^;I
M':4GKZXO::/M[4.&L87=U1Z;CG#_`(GB_P#)9??MT'[\[E3_`)7N!OK%[\IO
M8V*/?YQ=Y"U^2[7V^54'SW'.'M_>>+]P?U67W[-1^_=VVG^5[@?ZQ>ZOUFZ^
MTGO\XN\A:_)=W>5$]-QSA_Q/%_#^JR_S0^_>X/SOG/\`*]P/]8O?E-[B>_SB
M[R%KK_5=J[?*J!Y[CG#_`(GB_?\`V67W<`^_=^VG^5[@:O\`2+WY3=7:3W^<
M7>0M=?ZKN[T_$@>>XYP]XL\7\=?Z++]W0?OWN4_RO<#?6+WY3=7:_(GO\XN\
MA:ZOU7=U/3<<X?\`$\7[M/<LOOV;?OW=M^?3_*[P/]8O?E-[B>_SB[R%K\EW
M=3TW'.'M_>>+PW::VLOW1'7]^]`4_P`KW`_UB]^4W7VM2>_SB[9!:_)=W4]-
MQSAZZ>!8OW_V67W;M/OS?3_*]P-LN+WY3>SL4^_OB[R%KK_5=W4]-QSA?Q/%
M_$?<LMM#>`_?M/\`*]P-]8O=?ZS=7:UJ/?YQ=Y"U^2[NIZ;CG#W>!XOW?V57
MWZZ?QW_(:?Y7>!MMQ>_*;V#J3W^<7>0M:_S7=U!\]SSA_P`3Q=PV^2R^G2.O
M[]W:#3_*]P-]8O:_SFZ^TGO\XNU[BU^2[ET+IE//2\[1S**)2V-DR"H)@1"P
M6I^R3$=A`.9UUCE+IWP[==]2?NU]7\<HBE-V&NIA=O30G:#HT$Z2.ZJ3UY<:
M.CWD8MB0=(W>D#933I_$NP:^>SYRD$"IN2XQ>J@8XF<&M`6YCE,;4H=DB\!,
MO4*(!J&\*JD^[!P&Y^)DUZUG-C!T?"0HCZ^^,&MH^&U<=.G"1\&H\J+D^FXY
MP_XGB_7;K_19??J.G\-[GT/G4?Y7N!OK%[\IO<5?O\XN\A:_)=W>54]-QSAZ
M?>>+]P?U67V#L_\`.[AUI_E=X'U&XO:T_6;K[2>_SB[R%K\EW=Z?B0?/<<X?
M\3Q?PT_HLOT;0^_>Y3_*]P/LN+WY3>Y^5/?YQ=Y"U^2[N]'QIZ;CG#_B>+]_
M]EE]V[^.[]M/\KW`VRXO=?ZS=7:3W^<75_86NO\`5=W>5$]-QSA_Q/%WY++]
MW3^&]RG^5[@;ZQ>_*;J[7Y$]_G%WD+75^J[NIZ;CG#_B6+]=-/<LOWW3]^;J
M?Y7N!J?TB]^4WN)[_.+O(6E?YKNZGIN.</\`B>+]P:?T67]4?X;NTI_E=X'^
ML7M?YS=?:3W^<7>0M?DN[O83TW'.'KIX'B_?_99?=NT^_>^UI_E>X&V7%[\I
MO9V)[^^+O(6OR7=U/3<<X7\3Q?Q'W++[M-0_AO1]"G^5[@;ZQ>TK^LW5VD]_
MG%WD+7Y+N[V$]-QSA[O`L7ZZ?V67WZ[!^_*?Y7N!MMQ>_*;W$]_G%WD+2M/U
M7:^VGIN.</\`B>+N`>Y9??Q_ANZG^5[@?ZQ>UI^LW7VD]_G%WD+7Y+N[RHGI
MN.</^)XOW_V67]00^_>Y0_=>X&V7%[\IO9V)[_.+J_L+6E?U7=WE52'GN><(
M!*(L<7&`#`82#:[@`,4!`1((@]U#K!LU#@-#]UW@?9<WORF]Q!U^<7;8+6G\
MUW=Z?B7T!\CO/%C_`)RL?ED8XS:WLFV\V;IWY82C@#.8]P8.S"9ANTZJLA;C
M]4H]FJ`"9$P]FIH;03>3>LKJUSCJZS@VEV#)E<A)@G`[U[>8\SP-8[(T+T9P
M1QOEO&F6"ZMB&7S`!+$=;7;2-I83J=V"LY:ZV7-DHB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBQMYQATY3^9$1V:82R4.NFNG]$I
M7@.^N6<!_P#S7*?_`/8V_P#ZK5Q[BW_XOF/_`+*;_P!-R^!H%B:!M$1_\.W8
M/=V#7U;WO2.WM7ST<SOC774\W2I[8G_;['IV:;=U1O=M1V^VHP#E3L*.U)IQ
MW:?4[]/5W5.]V:.VHW>CL=&NBGMB:\>'L>G;KMJ-[734=OLA3@%?S<Z=L3N[
M_P#1W:!W=]3O>D5^':HW8Y4U43MB;-^\?8](Z:;:;W;4=M3NQ7\W84=L33CN
M_P!'?L[NZF\Z1V]BC`*=CH4]JGW>'L>[W=U-[\';Y<ZG`.SV->E.V)W=X>Q_
MT=>.^F]Z1V^7,F['*G0G;)]W>/L=WKN[OJ-[S$5^';R*8!MU=C5I3M2?]OL>
MYIQW5.]Z1VTW?+1T44=L33CN#V._0>[NIO=FCM[%&#1TTZ%/:IZ\=X>QZ0UX
MU&]VU';4[L5T<_1V5';)]W?_`*.[J^KOJ=Z><=O;J48!RIJI^%>TKA(0`A^]
MVB!O6ZD$3;P#7:4>-8D@<V3TBWH)=HKH<.;X>8]@Z%?;1S1%+X&PZ.]T[.@[
M1VEX'.5,>J8?J0$!`2]4P"&PQ1UT$H_]M7HKD2M#FGH(.@CH(V45M\!8:.YM
M>BAZ1T+Q[=/V71Q)IOVCO^=5S>.VD:OS*-WS#3V.=.V3Z?HDZ``>.^F\=SBO
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M4=VVF\.L$:_SJ1'IT_B["]P+I+`!#&`%0+H0PB310>"9MNP1$=X]%89<^U=O
M&:;8DXFC]'I;T<[1\(62&"X;@?HGIH=H[[H/2:Z"?@7J%4A1,4PZ&`=!`>H&
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MHJS'-)"\0R&K#H:[G&GO3TCX_A5;H6R-,D8IHTM&S5I'\G\"]?;I^R__`(.D
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MZ-O1TJ.W3Z>'23?LTX[ME-X=513\2C=_@Z.A7.P_F>_<$9`@,F8RN%U;UU6\
MY(LW<('_`'L^;B.CJ+E6H&!-_%/TM2*HG`2F*/2`"''^)N&\HXNRB3)<[C;+
M:2-_[3#^B]AV.;LHMWD&>9GPSF3,TRIY9<,(J/T7#35KAM:=.A?:%R-<\N/>
M<W'I)*,4:P&3;>;-TK^L)1P4SJ.<F*4GCB(`YNT?6Z_5VIJAJ9$P]FIH8`$W
MS@ZR.K?-^KS-S:W0,F52$F"<#O7MYCS/&T;=8T+V]P5QMEG&>6BYM2&7S`-[
M$3WS#SCG:=A[!TK.BNN%S1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB418V<Y&OQ3>9+377WD<E[M_N2E=W=KEG`FCC7*3_`(A;_P#J
MM7'^*_\`XQF%*_T.;5K\!VI?G["^,&S4=@CO'3338/'3;QZ:^I(G:0"7:=?9
MYUX",0+B1HTG\O;V\ZCPXWS--=-1TT]COUZO<WTWS>?9\94;INO9K['-\'0I
M\./TZ[N.P==W'0=.'`*;YNJO1W0FY&W\?8[7Q)X<?I'?IO'>'$1UWZ;-?V:D
MS,Y]%?B4;H=FOQ\_P]*>''X".T1TVCOXCOV"/&HWS=KN6Q-R-7=[/;^-5SC^
MP[WRC+NH.QX<LJ^81KB8DE',K$0,5$Q+42E<2,Q.W#(Q4)$,"'.!>T<N$BB8
M0`!$1TK7YGGF79-;"\S&;=P%X8.]<YSI'FC6L8QKGN<[F:TDZ5FY?E5UFMV+
M++XS)<ECGT&@!C!5Y)<0UK6C2XN(`&FJK9]R]YTC<DQV(76.ICWP9B)1N"*A
M&SF+?-I*VUV:D@2YF=P,9%Q;;FUR,4CK&D2O!9)IE,8ZH`4=-9!QKPS<91/G
ML5Y&,KMGF.5[FO88I&D-=&]CVMD:\D@",MQ.);0&H6?<<*YU;7]MELELYU[>
M,:^!K"V03,=4-<QT;G-<WO3I#J-H22`%QKCP/FJUKFM*T)&PI5_<%_MP=V.V
MM5U%WPUO!OX09HHO;<O9LA.P\R5JY*)%NP7/X.)1[3JZ#5RQXPX=S&&YGM[I
MC8[0@3B5KX'1`C$-XR9L;F!PTM)&%P\$E4WW#&<9;N#=0$BZ<YL18YLHD>PX
M7-:Z)SP7L)`<T'$TD5"[9;EMSVVS&YY?W6/GK+,#*.6EWMFOIFW&2[&-;08W
M*Y?O9=U,I6^T1;P11<*&4=EZA-0'0P:58AXYX7N.'G\60WC'\/,D+73!CR,0
MDW-`W!C)WA#11I!)!%10J_/P=Q!:YS%P[/:O9G<S&.9$2W$1(S>--<5`7,[X
MU((&L`U5O;[L:Z\;O6+"Z1MKPF2:G>M!MF^K)OIMX.14R)NW?6/<-Q,F2HG`
M?M2RB:I@`#`7J[:V>69_E^;A[K)TWS9H[>030]\14$":.,NZ2VH&HFJP;_([
MS+6L==[G#(2&X)HI?!IB!$3WEH.(>%3%II6AI0OAQO5V:[==P_4Z:[@Z-^VM
MGOF\^SX]O;6MW3>QV=7-^1/#C](CPVB.T>''APZ-*;YNP_FVJ-R.5>QVD\./
MTCOTWCOZ?5X:U._977HK\6SLJ=R.S^/G_*GAQ]FT>(AM'0--^FW3;]&HW[=K
MOS["HW+=0T=OL]OXT\.-IW--=-NFFO>[]W<WTWS?UM/XTW3>QKVZN;X.A<E&
M2*8.P<";LM?6*!J)D#&W&`-=#)Z]\7HVUCR%H=OH2!)32-0<.8_B^/0KH:W!
MNI-+?@.CNCH7I6=*H*"FIOTZP&+US$4*;O5"&W&`0W#PW;ZKCN!(W$TCX#L/
M,?@5+X,!H[M\_2%Z?&!N`F]70^O='N"/'U:K,IYQV^6K853NF\MGY]JGQ@/#
M4/4`^P.(!W/I5.]Z1RV_#^%-TWE^#X%6U@V3>F3YQ2WK(APEY-O'NY9[V\C&
M0D;&Q+$H&=R4M-SSZ,A8F.;`8.LJY<))@)@#740"M=F><V&36OIN92MBML8;
M6CG$N<:-:UC`7.<XZ,+6DGF67897=9I=ML;",RW3@XAH_5:TN<230!K6@DEQ
M``&M7`>\NF>8[(L3BASCF7&^IZ")=,-&MGL._C92UCM57P74RNAC)N+5<6RD
MT1.HI(%>^!I%3-UU"]4VFJAXUX:GRJ?.V7D8RVUD,<SG![#%)4`1/C>ULC7D
MN&%A95Q(P@U"V=QPEGMO>VN726SG7=\S';AA;()FU(QL?&YS'!N%U78J-`)=
M0!<">P/FRW+KM&R7N/YF0N6_V:<A8K.U5H^]FUXLE%U&HO;8F+/?3D--MT5T
M3D5.W<*%1$INTZNE7K/BW(;ZVN;N&Z8V"S-)]Z'PF$T#@)6S-8Y@((+2X`&H
MPDJW?<,9QEQ@%Q`X^DUW1C+9FR.::.#'0E[7/:=#F`XAHJ!5=;=F'LN61E(^
M$KEL:;997(_CHKR&:E;S$T>0EDDEV#)N6%<R#9==TBN4VA%#=77UVF@Z7,KX
MIR+.LG/$&6W44F2`/)F)<Q@$9(D<XO#2T,H:N--`K6BMYOPYFV19@W*LUMWP
MYD]L;FQTQ/(F`W8`875+ZBC?"J:$`Z%Q\C8NR!B@S`E\QT,P/).'C1`D/>=F
MW>*#R.[,7L=)EL^X)T89\U[4H';N^P6#7O=0&F4<393GKG#+)7OPM:^KHIH@
M6.)#7L,C&![7$'2PN'/K"KS3AO,\F8'YE&R.LA93>1O<US6AQ8]C'N<P@$&C
MPWFUU"MEXP-Q$W'@;YG<];PK=[WI'+\71J6EW3=7+D-BCQ@;I'YQ^^Z?5X:T
MWIYQ7EH[B;IO+\/PJ?&!N`C\X^SI$.Z(;1IO#JJ.WRU<ZG=-U<N1VIXP'NZ=
M&A]-/8]/5UIO=.L:^1^%-TWD-G-\"CQ@;I'N[#[N`>H&_P";4[SI'+N\VI-T
MW;IY?BV+G)/P=@"1S]1T`:(JF$Q2+;`T25,(;%"@&A##Z@UBEYM^^90PZR!L
M^`;1M(V:PKXC;,,+C\]HH>?FKT@:CV"N&=ZHF8Q#@<AR#U3%$IRF*8!]=J'`
MWTZR!,'-Q-<"TC0:Z_S;"K!A#30Z"/B_/32H\8#TCW-A]W$.X`\?4J=Z><=O
MX_A_"HW3>7X/@TIXP-TCOV[#[N`>H'#U:;WI%.7X=H4[IO8Y:/@T*]F,<"9F
MS(R"1QU:!9YHM,#;K%1U<EK6ZK-7$#8CP(&W6]SSL,XN2;!LH4X-6!'"^@@'
M5U'2N/YUQ;D7#S@S-I]V_=.E(;'+*6Q-)!D>(F/P1@@@N?1HH=.A;;*^'<RS
MEI=E\;7L$K8BYSXXV[UXJR/%(Y@,A!!:T'$0:THO*QL`9MR,K<*5K6.Z/Y*3
MZ%I3[BX)BW[+91]W.%CH-[4&0O*7@6+FZ5U$S`2/144>&#:">F@U1?\`&7#V
M60V\]U=,+;J$RPB-LDSI(P`3(UD37O,;0162F$5I4%7[?A7.[FZN+-EN]D]H
MX-FWA;$V%[CA:'OD<QC7.(HT%U7:P"#5>RQN7?/V2[\N/&-C8JO"?OJSU'Z5
MV0*##P12V#Q@+"]+//I%5I%Q`E[`P$[=<G;F``3ZPB`#3?\`&W"^5Y+'Q%?W
M]O'DLS0Z.4N)$@.U@%7.(KI#6EPTUI0J8.$<_N<\=PW;V<SL[C=A=$!I8?Y1
MKA:UU1WQ<&FHH=(71V/B3(&1&T@[ME.S@2BY$8IXE<N3\:V,[*]*`"9%O'WM
M=UO/WJ("/5[1%-1+K;.MKLK-S#B/+<M,8NG3'?-Q,W<%Q-5O.3#&\-)_5=0G
M718T'#]]///;-;$R:VD+)!)+%%1PK5HWCVAP!!J6%P!UE=3D_'E_88O%]8&2
MX(;;NZ,:Q[U_#^,XF9%!M*M$WT:J9[`R$I&G\)9JD5*4JPB!#`(@`"%59)Q%
ME?$=CZRR:82V6\?'BPO9W\9PO;AD:UVAV@Z*5!YBHS?(,QR*X9:9K'NYY(62
MM&)KPZ.0'=OQ,<YM"!5NFM*&E"%;[Q@;I-\X^TW3ZH;M:V^]/.*\M'+4M7NF
M\OP_"I\8#TF#U`/LZ1#NB&T:C>GG';Y:MA3=-U<N1VIXP'I$.X`'W='3I3>]
M(Y;?A3=MY`ZN;X%Y$DCD,4Q3"`E'?H?:&[0W`2Z<.[5+G![<#Z%I53&[MP<W
MPARH><!<DSH%DQ<-]0$@:N$``^J9M=.U3#>9(?\`\GJ5:;.Z,B*4@@ZB3K_D
MGIY:U6^%CP96#X1S'GY:M2XGC`W2.NS;H?8/$0'I']FK^]/..7<YU:W3>7X>
MS32GC`>D>YL/NXZ=`#Q]2F\/..W\?P_A3=-Y?@^`UTIXP'NC\P^[@4>YKP[M
M-YTC7R[?,FZ;RKVO@4#(B`")C#H`")A$#<./_A#=ZE2)"304KRT?`5&Z;RY;
M-BOV^Y<<[QUC261G-A.!M6&@XNYIM1M/6R^GH*W)LQ`B;BG;.93;B\8:$D>T
M**3MRP20,4P#UM!`:XN>..&FYDS*77;1>23N@;5DHC=.W2Z$3%FY,C:4P;S%
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M++2C&-+@VE7$8N^<`6LQ$$Z0%4EN\M6?+KM1C>D!C]R^A):#E[GA4#3UL,KD
MN&VX$5BS$];EE/IQK>-Q0\:+=3M'#)@NB'4-ZX0*-8=_QSPSE=Y)8W]VV.>%
M[&2G!*YD+I*;MLLK6&*+'4$"1S=!!U%7\MX1SS-K>*YR^WWD,Y>(N^8UTQCJ
M'MA8YS7S%A!!$8<0137H5@/&!@]D`AL$!!0!ZP#Q`=!`Q1V=S2N4"716H((Y
MZ]CX%H#"`2#7$.@UKS_"$\8&Z1#NZ'W\1]4>/JTWG2.WRU;"HW3>6SG[>U/&
M!N&H?,/L#B`=P?V*;S;4<MOP_A3=-Y?@^!/&`](]W8?33@`]P/V:;SI'+N[0
MIW3>7X/@%-">,#=(Z[=NA]H\!'NA]#2@EZ1RV?`FZ;R_#\(JKI89SKD/`>0X
M#)V,I]W`71;SDJR*R(J&:OVQC%\+BY1J(@D_C)!(O9K)*`)3%'I`!K0<3</9
M3Q9E$N39S&R2UD;_`-IKMCFG6'-V'NK<Y#G.8\.9BS-,KD,<[#IUT<-H<-N(
M"A7VP<BG/5COG3QTG+1*C:`R7;[9NE?UA*N`%W&NA*5,9>)!3JJOK=?K:BDJ
M`"*1A[-30P`)OG?UB=7>:\`9L;:Y!DRN0DPS`=ZX?JGF>!K'9&A>T>"^-,NX
MQRX7%O1E^P`2Q$Z6GG&TL)U'L%9V5UVN:)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$6-?.2(!RF<R8CN#!^31'40#^J,KQ'8%<KX%_^
M:957VA!_ZC5Q_BL5X8S`?_IR_P#T.7YY)GJ?6-M^J'4.L'>];70=GT:^FPE[
MVE1J`U=M>#3'I)IHT]KEM7CX83V71KM#H];PT^G4F;I&OFY:5&Z.T#EJY;4\
M-)KWVW7I+WVNN[3Z%-]SN%.6G\JG='FT_CY;$\,)[(-PZ;2[]-##NT$/^RF^
M(&L5IS;>XHW1V`<M?+8GAJ?2&G1U@[W740_STWVP$4I35RT;:)NCKIH_%RVK
M(+EHY?+]YI,FM<9V"D<A2,'$]>,\9)=RRM6S(WJ'EYYZS9)K/)$S=(-&[1!-
M5=VX,1,A1$U<?XHXKRSA+)Y<\S5Q-O&0&L`!?)([0R-E=&)SM&(D-8*N<0`M
MKD>0YCQ#FL6396T.O9B1I.%K6C2Y[SL8QND[7:@"2%M197;)W5FC*N)F%@W[
MCI)AR+7'R[\J#?*5L25H7G?B5E@V5=R+!&=81JRL[?2(/>Q;(]8W46(W#4^H
M#TA<0M'"S^(;BXMKJ^N.)[;,\SBM7MF9!&]X:UA#'.JV`-8Y[J4Q->\:`NZ\
MNGBL.,LJR`1S19/993?65E<7$9BW]U)!)CF;C:W#OI'B*-H)HW=UPEQ6-=WM
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M:'QM.8/DMWF@=NXW.:TM>YN`MVTJ5ROBV+B:RXWRK.,HMWOS%F46+8W/8<#I
M66#=]&2["'2!N/$S%O*@@#%H6%_-EC^P;)QUR\7(GCN,P?FR]H.[ELL86AEY
M5%C;T7#R[=I8]U+V[<,E,7%9DA=T>=4YX]XX,H!4@4`I0,&O8/".>9A>\29M
MET5\_,^&;=ML8+IX8X[Z1KS<6XEC:R.9L-&D.:-!<6DDC1PSB')[.WX6R[-+
MBR9EW$,UQ<,?"T/8)+>/`8IW12.=)$YSG.8"320-J`,.G!OPPGLO5VEWZ"!>
M&S?78V^TZQKYN6E<#W1VC\^S\VU/#">RX])>^U`>CN;J;[I'+EK3=&NK3^/E
ML3PPG`P;A`-H<0$#<-H?]E-^><:N;;W$W7,.6WEL3PQ/IV;].L7O-=VNG3QH
M9ME1S:NW^0)NN@4_%RVIX83B;U=I>C0H[M`_9IOM.L4KS<O@3=':.6SEM3PT
MFO?;=>DNHFUU#A]"F^Z='+E5-T>85_'RV+N'+DK-@5JZ'KO%!*JW0$X`=@F8
M/7F5'0?ODN@@GP`=1TV5C,EQ3;QA`;32>?FI^"JOF(-CW;Q5VSHY^WS;%TGA
MO=+N]D'>ZB.F[I'?5_>BFL:N05O=-YM'XN6U/#>Z7AKZX-VS3AW/FU.]Z17\
M:;INT?FV<MJOQRX8$R)S/Y0C<68Z;@+UTV<RUQS"H*J,+8M2.T4FKADD&Q%'
M3M!@W-]K;)$46=+"1),IC&`*T7$O$^5\*9--GV<.(LX2*`"KGO=H8Q@VO<:`
M5H&Z7$AH)&SR7([[/LUAR?*V!U_.Z@J<+10$N<]VQC6U+N<:@25MH3N"8N*^
MLMX+@K`R%8K&!Y#;LY>>50F3[6EK/O+*KBUIJ*F;BD(9I/1\:JO+7H7PX[9H
MB)E"MS$0VJ&ZH]$W#&/R4<5W4]K/F%SQ799EF4=M(V9MK;Z8HV/W9=41`1ND
M=2A>USAWK='==DYUAG]EPI`)HLNM<ES&RL[F=CHA/?31E\LS'/:T-#B=U&VH
M[TLJ,3].--U(Y5LC`W)!AFVHO(4)S(1UTYHNA]95IM9YMDZV\87G<,.5I&3$
M/"$"XXIG.-(]\Z59+ID,5F)CJ$!,^H\VLKG)<XX]SW/+A]I/PB,NR^WDED+'
M6K[F$R/`QN^;<Z''$"^I`>6MKB&CA5Q;9AD_`%CE6ZN(.)Y,VNIK6-H<VXCB
M,#8I7-:/G`)W@AI`JYK'$=[KS+OF+=VEYV2ZYB^+2?LV][8IN*"Q.^NAK)6[
M`7;?ZF%4HR-B86Y'(Q[91\K(K"R[1NN*B3E8I`$JABB'7&578O\`J-S#+LLE
M9+>Q7TDDL3"'RMM_6.-SC&*NP&)KG`$89&M-*BM>=YI"+/K:X9S3-FOBRP6%
MC&Z5X(9OFV!:&E[N]$C)W1XZFK'$%U%KBYFL>6U:F`L.7G<V(H?E\S_<E]7_
M`!-R8OB"W!$^-,?PY&/D[>LG:5V3<]/P+M>157:D<'4(E(%3ZY":!J/:O"^>
MW=UQ?=9;EV8OS7AAF7PR;Y^[<(KISG`Q-DC8QA#HPUYB(+HJZ]*X#GF2VT/"
MCLQS>Q9EO$?K0QQ,;C#KBWW9,CWM>]Y.YEHP3#"V8N-*T6`_AHZ[R;^D.^U]
M3Z%=G[T<^BOQ<_PKKG=-YM/X^6Q1X:/27<.GK@Z/7<-NOT*C>\YZ.7PINF[.
M7/RV*?#>Z333=U@[W7=KIKIKQIO=&O9R";IO-H_%RVJ/#>Z7AKZXO1H7AL_9
MJ=[KTBM?C_(FZ;M'+9RVJ?#1UWEUUZ2]]M'7=W=U!*.?;R*;H<VG\?+8N0U,
MN]6*@W`ICB!A$1,4")D*`"HJH80ZI4R%#41'<%4/N61-Q.(IJ[?-TGMJID&-
MV%HT_@YSRU+ERDF@H=!)!0'!FR/8K/C"`"\,41U$"Z`/9I]Z4P^N$-]6H'.:
M'$T`=J;S='PG;30JY61N(#=-!KYQW.8ZUU?AO2)=P:^N`-FSJ\-F[YM7S+TC
M9V^;\/0K6Z;MU?BV?GVJ?#1Z2:Z[=H;]N@Z:<-=W&IWNFM=M4W3=NO\`'L_-
MM6Q;D3P'=DW(FYKIFTKWN7%6`KE8S$;`6%!2UR77DO*,=U)&W+&MZ+AF;]RT
M9F=$15E9%1,B#1IL`PJ&*4.M>L7B^WRNS;PO:2V[.(<UBDBC=,YK8H(7`LDN
M9GO(&%@Q8&5Q2/%`*`E<PX,X4.?WDE_<ME^SV7/;)<F-I?(]PPN9!"QM2Z67
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MP16=H8WA[3=S@1M-6$TW`+I'?JX.^`"X1]DW9UUC393FD;X<O==W%S<.>TMI
M91/?++(`0"6OC;@86^$7@MK2BQ8RCE&>RWD>]<F7*L52<O>Y).X7I0.)DVPO
MG!CM6+<#!J5I',P3;HDW%23*`;JY3P[E-KPWD=ID5H:P6L09B.MQUOD/\I[R
MY[C^LXKC/$N;2<1Y[=9U*T,,\M6L&J-C0&Q1C1JCC:UH'176J#\-'@)>/$H\
M/7</^ZMT)0-O/R[*T>Z;L'+;RV*/#>Z7=NZP=[KKI\_C4;W1KV<@FZ;KV?BY
M;4\-'I+PUVANT`"\-FGT:DS=(V<NPFZ;M'YMG+:I\-'I+KKMVAWVW39IL]2F
M^%=>WD4W0VZ_Q\MB[..6.`^'*+>#-&QM#K`)3&54$`$6J!#!U5E52AM`=A2C
MJ/"K,DH<-V:$FO8Z>WMUJMD8::BHY:1TUYM07!7D"JK*J)IIH$4.8Q$BG`Q4
MR"(CU`$0U$-N_A5QLE&@$U[VG+XE08F5J!0'5\'+:O5X;TB7<&OK@#9LTX;-
MV_C4F6NWF_,FZ;M&C\7+:GAH\1+PU]<`;=N@[MFFN[C4[[36HUU3=-YN6S\V
MU0+[0!$3$#01'74-@AH(CIIJ([-U!+4@`[?P[?A^--TWES\MBVNVCAW,'*UR
MJY$R`YQID>YLG\T^*7%KPK"W[1N&>MG&.!)`[:6N&]K]GX^,>1+6:NEFS(G'
MLCKE,R9]9PKU-2A73&>\1Y)Q;Q=9\-FZM8,ER;,8KFYDDE9&9KN(G<6T#'.#
MG8'NQ3R`4)I&"35=H\,Y!F609--Q8VWN)\SS'+[BSLH8V.DI%<-#)[F8M!#6
M81A@8:.<XXZ8!IR,@V3Q;FQY3N9>.;#\6.T.4^SAN?(R2)#6';+*TL4W+;-[
MV;+R>GBYK<#BY7/@WBU00=NUW)1(F?76N+9G=0V_!_&7"EZX'B>]S>XW$!/S
MUSZ3-`ZT=&-;F!@KC;5L;8R'%M%OLJM+B^S/@O.\L/\`T>QM(1+(!WEHZVED
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M7J.@#KAKN`U>G+>?%!&XC=DL'>_JU`[WX1J/P+H6[MXX[N6.-XE:)7@/`T/H
MX@O`YG:Z;*KC^&]TOUP=[J.S=T\:N;W1K&I8^Z9V/Q<MJ>&[-Y-P:^N#=LTX
M;-WS:;VM=(V=O\G,FZ;M'YMG+:GAH])=^WUP=]MT'=W=U3OM.O;R*;INT?GV
M?FVIX:/27CIM#?LU'=MW;N%-[JTZ-/Q[?PINF[.1V_FV*/#=F\NX?J@[W;KP
M^C4;WI&KEVTW3=G(;>6Q;I?,\<I>?,HYI@\\VM<<[BS%V/Y,`F+R9D[-:]5"
M:>%V/#-W!!:R;9VF/4?J*%.@@F;3:J)0#H7KRXXX<RW(I.'+N*.\S>Y9WL9_
M<\TKB-+:?H`$%QZ*KM[JFX5SJ^SAF>6DDEMED#J.>/WO_E`'0X?K'2!\*^RN
MO#*]9)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6-/.;
M_P`)/,MN_N-R=OUT]R$MOTT&N4\$?_,<K_\`?P?^HU:#BK_XS?\`_LY?_H<O
MSG%'H`=0-=@','U728-VH<!V5])S(ZITC7S=I>&]V=E5X^'!KO\`JM=YND!#
MZK?3>/Y]->;:F[/3K^+MJ/#@V;=FW=UNC3V713>.V$<M:;MW94^'!T\.DV_7
M7V6ZF\=2E12GQ)NSV?QIX<'3T>RZ`#;Z[HH9';2.6I#&ZG3RJO>A,.6AQ4:.
MW310=@J-'3EJH)0,)NJ)T%DSB`&VZ".E0YQ?WK\+A7:*Z>R-:D,>TU:2/@--
M';7L5GY!PJDNXDI%PN@/VA=P_>K+H::"`H+*N#JHCJ`#ZT0VU2W"S0QK!7F:
M!7GK0:5+A*^F\<XTYR33X*E1X]?>$^'>,9#P[00\-\.>^&;C!H#OPCP@"]41
M#OMU!@#-V`P1TU812FW12B$2EV-SG%XVU-1S4-:KV&N*4.=)0\O*G50U%NJ>
M3D#J("?J]<4%3.A.CU^J&HE$!'C44C`(#8P"*'O1I&RNC2-.U2=\:5<\T-14
MG7SZ_CUKBK2BKE4Z[E==RNH(===RNNX6/H`@':++*G4,(`.S41JMKL#<+<(;
MS`4%?@`4.;(\U<7./.22:=DKU^'!KM'CTF[G^EOU"IWC^<5K\:IW9Z:)X<&F
MT>`^RZ!#V7=H)7;"/R;4W907P=/#I-OU`?9;M0IO'<XU<VQ-V>7/VU'AQ=--
M=FF@=]NTTV^NZ*;QVTCEJ3=NV*0?`(@`:B(F#0`ZPB(ZZAH'6VCK3>/Y]->;
M;W4W9Z?R=M5"5PE!)$7<@5285("C5H;4Q8Y,Y0[-V[*)M!<'(/K$3!L[XW`*
MMNE<X4J,.OX>A5-80,7Z7+2J>/(&5.=5151110XJ'.<YA,8YA$3"(B;40$:G
M>;.]4;MU:GET?`O#PP/9&^:(AO`-^W<`;JG>G^3K4;MR>&![(W1M$=VW;OWZ
MTWFSO>7+X4W9Z>7XU[D)5PU/VC1X[:*"7JBHT<KM5>KJ`Z"H@HF?01`!$-=-
ME4N>U[:/#"*:B*\M>M2&/!J"0>A>]:?DG"J2[B5E'"Z`]9NNO(O5EFYM1'][
MK*KF50U'?U1"H;NF@AK(P#KH`*_#0::=I5.WSZ8W.--(J2:?!4[=%=O:7CX\
M?@Y%Z$E(^'#_``WP]WX8.H`40%WV_A'5ZNS3K;J#=AN[#(]W7504[5*(1,7!
MY<XO&TDU^"M:T^!%IM\Y%(7,G).1;B(H&<OW;@R`B.HG0,LN<43ZAKJ30:-W
M;#5C8P3H-`!HZ:#3V=2.$KQ1SG$#54D_"=>M>IQ*N':O;/'CQXN)0)V[MTNZ
M6ZA1U*7M5U%%-`'<&N@5+"Q@PQM8UO,!0?%^'6H<V1YJ]SC31I).CHJ?R+T^
M&![(WS!'@'#;Q#?56].OO>6Q4[MW3RY:4\,#V1M^O?#OZ-_>TWG\WERU:DW;
MM>WEH^#XT\,#V1OGCN$-NH:[=.%-Z:_HZTW;NSRY!/#`]F;H[X==-===_?4W
MFSO=5.7*J;L]/+;\/Q+EL2N)%P1JU`YU#@)C")A*1)-,`$ZRIQ'JIIID#4QA
MV`%09:"IPZN0Y=E2(7.--/+;W5V+V8;-43QD6J)T1$/#GY1,4T@J03>L2U'K
M$CRB/K2[SCM'HJV'$OWCJ8M@YOQ5HKCFD#`SP=O2>Y\:Z/PP/9&^>/'377;N
M#A5W>_S=?(_D5K=NY<M2>&![(W1O'N[1V[PX4$A_D\OS*=V[IIR^-/#`]F;Y
MX\--NNN\:;PT_1U*-V[IIRT_"N8WGI%F42,Y649$$1,*;.1>M4^L.\>HW73*
M(F#>.FHU0_=OTO9&XZ-8![&D?D531*WP'.;7F)&GM_E0D[()K+.$Y233<.`T
M<.$Y!XFNY`=-2N5B+E57+_\`C$:$1%N[+(S&#H&$4^$"E-JGY['O`YV\YZFO
MP5K6G97@WFGK,#E9R,@S*KIVH-'SIL"VFH@*P-UD^T$NHZ:ZU)+'TQM8::JB
MM/@JH#9&U+"X$C82*_#0HI,O%CJJ+2#]91P4J;A55XY54<)D,!B%<'.L8RX%
M$`$`.(@&E0W=@!K61AHY@-!YQT].M21*34N>32E:FM.W\6I<;PP/9&^8(\.C
M;QXU7O3KHWEL5&[=TUY<BGA@>R-OUWCOUW;^]H9#_)Y<O@4[MW+\'P)X8'LC
M:!W1XAMU#7<'"F\-:][K4;MW9Y<@GA@>S-T=\(;-=^_?K3>;#AY<OA3=NZ>7
MXUVD>D5PFH]=JG;1C<0*NXV]=50``2LV8"/VQTJ&FO`@;1X:TNF(&RIY<BI$
M3B-/+EM.I>I_->&'(!"^#M4`ZC1HF8W41)J/?#K]L5/O.<=IAH'4J>]+N6CL
M=I26.)V\N6G:N!X8'LC;.Z.FW34-^X.%5;W^;2O(_'J5.[=R_!\">&![(W1O
M'=MVB.N\-=E!+_-Y?F3=GIIRY!/#`]F;HWCPTT'?O&@D-/T=2;MW3RV_"GA@
M>R-\\1VAKL#;Q#?3>G7HKK3=NY<NVNQ"Y)<$Q1":F00$O4%`):0[`Q!`"]D*
M/A/9BCU0TZNFFFS=5LMA)J61%U:UPBOPZE<!G:*-<\#X2.QKU+C!+NBMC,BO
MWP,C&ZQF0/'(,SFW]<[0%0;F,'`>KK556%XD+6%XVTTCX#K[BI#9`TM:7!IU
MBIH?ATZ>55[T[AE44R(H3,N@BF!B)HHRC]%%,AA$3`FBFY*F0#".T```&J7-
MB>27LB)(H26@_'32JF[YHHQSP`=A([.@ZUZBS3TC<[,DC()LU-149D?.R-#B
M.T1,U*L#<XG^JU*.M2XL<[>.;&7C4:"HIJ`--'85($H!:'.`.NA-/P[=M5Q?
M#`W]8V_7>(;>C?WM5F3^:HW;N7X/@3PP/9&^>(;].[N`-U-[_-UJ-V[LIX8'
MLS=&\=VW;OWTWFKP>7+X5.[=T\OQIX8'LC;0V[1X:<==XZ4WII^CJY?A4;L[
M:T3PP/9&UW[QW[=FNNX>--Z?Y/+E\";MRVS>;.\VK>/.C=R%Z7FC)VOR_6Q(
MI#/W"*:C=W>+Q`Q%5+6M<ZH`"HJ%`"NG9>L1J0>*@@6NINM#K1L^"+$V5G@E
MXBF:=VS6(P:C>2<W\EA\+7H&E=B\!=7]UQ7=BZNL4>1Q.[]VHO(I\VP_A=^C
M\*^VNQ+$M#&5HP%AV'`1]L6E;$<WBX2$BT"H-&3-N0"$*4I?7**G$.LHH<3'
M4.(F,(F$1KPMF&87F:WDF89A(Z6\E<7/<XU))Y:`-`&@:%ZUL[.UR^U9963&
MQVL;0UK0*``<M)UDZ2JMK#62E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB418T<YPZ<I',N.S9@W)X[0U#99\L.T!`=:Y1P1_\QRO_`-_!
M_P"HU:#BK_XU?UU>B2__`$%?FXJOA[53_P#5.'#9]L'N<>-?1@RG34GEJY?&
MO%`C9L_'RTKU^'#W/H;M-V[=3>.KK-:_'^53NV='QZN;X%/AP]S?W--@[`[W
MA4;TTT5Y:Q^5-TS;^/L=K8H\.'?W->&_3ON]WTWIYS2GQ<NVHW3.SV=?/\*G
MPX=>C0>YLVCKPX\:;TTTD\M7YOC4[MFS\?9[:CPX?V-FF[0-F[<--Z=536OQ
M\NTHW3.CX^U\">'#W-_<VZ".@;MP4WIZ>7+6IW3-NKL]CM*?#A_RTU$0TV][
MO"F]/.:4^+EVU&[9M_'KY_A3PX?\M./6U-WN\:;T\YI3XM'=U*=VSG_#RJ5'
MAP_Y:;-VS=QIO376>6KELYTW3.QV>RI\.']C39NT'9WH;`J=Z[83K^/EM4;I
MG1\?:3PX>YOXZ=(;>]X<*C>GG/+6.6M-VSX^7Y%'AP]/#779OT'UW>[Z;T\Y
MU?$FZ;SZ>SKYU/APZ[-^H```'2(;`#3;UAX4WQVD\MOY/C3=LYQ\?+2JG*[1
MMI(B[LJ:L^LF51FQ4`AR1"1R@9-V^3$H@9V;>DD.PNO6-P"CI"-#CRU5_&IW
M(V#1^35VU2RLJ*RBBRRHJK*F%1510P&.HH8PF$3F,741$>-1O3IJ=-.;;W%)
MB)TFM>6C4O7XP+MVAP'AJ)M``?J=X:4WIY]O-M4;HZ]/.I\8$`=Y>^'38''7
M4>][M-Z>?;S=OLJ=T:[=?+8H\/)LVETT$.&PN@?Z/'2@EZ=%.;8@A/3R[">,
M"])=VW=P$=`[W=MJ-Z::3LYNUV$W1Z=7(:D\8%Z2\!X=]ZW3ZGAI4F4\^GX-
MJ;H]*>,"\!#?LW<0$!$/6[]M-Z:Z#M_/V4W1'/RVZE(2!-FTN\0X;`V"(["[
MATW4WO3H^#9RU[$W)U::?B[2CP\FFFI>]T'O=P:@`=[N'6HWNC2=GQ=Q1N3T
MZE/C$HZ[2\!'O=-0$!`.]X4,IVG3HV;5.Y.O3RV:E'C`O2&P=>&_JZ"/>]\`
M5.]//MYE&Z.O353XP)KL$NP1X!N$1,(Z=76@E.P[>;M]E3NCTTKRV+FQQ7$H
MZ39LR%.H<IA,8PD(DBB0NJBRZAB@1)%,@")C#L"@EZ=G-L4;HTIRY%=M(S[%
MDW/#PJH*(&``DY3J@1255(8#%22U(!THY$_>%WJ;S<*@O-:N(J!R_/VE68M@
MK3X_@["IL9`O2'#HWZ%#V.P0TJ=Z>?;S;>6I4[H]-=?+0I\8$Z2]]J&FG'74
M=I>[3>G8=O-V^RHW)Z=?+8H"0)LVETVAPV%V?Z.X=*C>].C3LV<M:;DZM*>,
M":;1+WN@[MP=;0.]TTVTWO.=GYNPFY/3JY#4GC`NW:7@.W3:8!+_`*/#2I,I
MY]/P;>6I-T>E/&!>DN\--V\0$!'O=^VF]-=>W\_94[H]/+;J4A($V;2[QZ-P
MB`B.PO'2F]YCS[-G+6FY^'EV%'AY---2]Z(#WNX`T`.]W#4;T\^BG-L[B;HT
MVZN6Q/&!=NTNW0>&\!U`.]X4WIY]/P;=B;H]/+9J3Q@7I+O`>&O6TT$>]W@%
M3O377M^/\RC='7IJI\8$#B7OATW:;1$1'O==NM-Z>?37F[?94[D].@\MB[F*
M12=IJOWRO@D,S$"NG(`055CB`"5BQ(8NB[M;3AZU,/7&V:!3>Z*UT?B4;HZM
M/+L+TR=Q^,#)IIIIM&#4@ILF"8@*;=/7:)A$NJJZVG644':8U4[PZ23II^;L
M*=T3KKJY#5RTKJ_&!=NTO#HVCH`>QTU#2JMZ>?3\&WEJ4;H]->71L4^,"=)=
M_<XZ]8>]V#MIO370=O-V^RIW1KHKKY%1XP)LVEX\`W;-WK>.E0)>G1^)-R>G
MEV$\8$$-Y>]T'=N#70.][M-[SG9S=KL*-T>G5RV)XP+J(ZEX#P[X!#0.]X`%
M3O3SZ?QJ=T>GEV$\8%V[0'0=0W:ZB`@(][OVTWIKH.WFV[4W1'/RVZE/C`FN
M\N\>C<(ZB/>ZZ#3>G8?B3<TY]?+8H\8$W:ETZHAIZW=IH`=[QIO>G13XE&Y-
M-NKEL3Q@3I+NU'=O`=0#O=U-Z::3IIS;=G83=5Y^6S4GC`O2'`>&O6T`!^IW
MAI3>GGV\VU3NCT\_9[2GQ@0!#UQ>^'38''41'O>[3>G8=O-V^RFZ/3KY;%'C
M`FS:7302\.]T#_1XZ5&]Z='P;.6M0(3T\NZGC`O$2[MNPO`1T#O=VVF].T[/
MS=A3NCTZN0U+;WYL'S9=Y<ZUW(7U?#>1M?EZMF22&>G^R%L]O-ZV.10]LVNH
MHD)5#F`H%=.@`2-B&T#502E#JWK*ZSK7@FS]%M"R7B&9M61ZQ&#JDD'-^HW6
MX\PTKGO`_`5UQ5=BXN,4>2QN[]^UY'Z#-&O8YWZ(Z5]PMAV':&,;0@+"L*`C
MK8M&V(Y"+A(.*;D;,V3-N4"E*4A``3JJ#J910PB=0XB8PB(B->(,PS"]S6]D
MS',9'2WLKBY[W&I)/*@&H#0%ZNL[.UR^U9963&QVL;0&M:*``<M>L[55U8:R
M4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%0>4<?Q6
M5\;WYC*==/F4-D"TI^SY5Y&'23D6L?<,8YBW:[(ZZ:R)'22#DQB"8AB@8`U`
M:V&4YE-D^:6^:VX:Z>VF9(T.K0EC@X`TH:5&FA6'F-E%F5A-E\Q<(9XG,<1K
M`<""1KTZ="T9C_TZO*4(B(Y*S#J;74?#X7>([1V,-^VN[3]X3B<FOH=G_P#R
M>,NK/<UP_2GI%WJYV>*GZNKRE;?]I68-NG\/AN&W^(U'^8/B;ZG9_P#\GC)[
MFN'_`*Q==MGBKD)_].WRC$*`&R!EE40$1$QY"-`PZ\!ZC<A=`#H"H/W@N)R:
M^BV8^7XRJ'4WP\/W]T=/.WQ5Y?J[O*+_`&]ROJ`"&OC"/WCQ_:>FH_S`\3_5
M;2G_`&_&3W.</T_;W6KG;XJ?J[O*)_;W*^[3\(L-=/N.\0I_F!XG^JVG_?[J
M>YSAZE-_=:N=OBI^KN\HG]O<K\/_`%%A\X/M733_`#`<3_5;3_O^,I]SG#WE
M[KMM\53^KN\HG]O<K[]?PC'_`#OVG<&RG^8#B?ZK:?\`?[J>YSA[R]UKKK;X
MJC]7=Y1?[>Y7X_\`J+#>/']IX;:?Y@>)_JMI_P!_QE`ZG.'O+W7;;XJ?J[O*
M)_;W*^[3\(L/G_M._=3_`#`<3_5;3_O^,GN<X>\O=:N=OBI^KN\HG]O<K\/_
M`%%AL`.'[3QVT_S`<3_5;3_O]U/<YP]Y>Z[;?%3]7=Y1?[>Y7WZ_A%A\[]IW
M:Z4_S`<3_5;3_O\`=3W.</5KO[K7SM[7@I^KN\HG]O<K\?\`U&/X_P#P>`?,
MI_F`XG^JVG_?\9/<YP]Y>Z[;?%7B;_IV^48=-+_RR40XED([;KQ'K(&UVU(^
M\#Q,-=I:'Y?C)[G.'J?M[KMM\5=Y:_\`T^')W`7#$S3Z[<K3C2-=INEHAQ,1
MS9"0*EJ)6Z[A-BJJDD<^G6$@`<0#0IBCH8+<_P!X#BN2%S(;>SCE(T.`><)Y
MP"ZAZ`='1L5<74[PVR1KY);I[!K:7-`(YB0VOPTT]*R#5\RAYO==55=;%$JJ
MLLH*JJJEVRYSG.8=3&,<QA,83#OU&M`>NKC\Z?28J_[)G9[>U;CW7<'?5WZ_
M*/[J]?H2_-Y_!));]=/*N5TTTTZN_O:CWT\??6(O--[7P)[K^#JU]'?K\H_N
MIZ$OS>?P22?'^M<KMU'7;MX<!WT]]/'VVXB\TWEHV)[KN#OJ[_./[JCT)7F\
M_@ED]VGNKE=X?5;![[Z%/?3Q]]9B\TWM_"H]UW!WU=^JG[1_=4^A+\WGM_V2
M2>W3^M<KPZ-O'C3WT\??6(O--Y:=JGW7\''_`(=_G']U/0E^;S^"22WZ^ZN5
MTX>MW]Z.G^6RGOIX^^L1>:;VO@3W7<'?5WZZ_M']U/0E^;S^"22X_P!:Y7<.
MNP=O#79QI[Z>/OK$7FF]KX$]UW!OU=_G']W\J>A+\WG\$DGN$/=7*](#KOWA
MI3WT\??6(O--[:>Z[@[ZN_53]H_NIZ$OS>?P226X`]U<KLTV:AMTU'CPI[Z>
M/OK,7FF]OX4]UW!WU=_G']W\B>A+\WG\$DEO`?=7*[---0W[ATVT]]/'WUB+
MS3>6G:GNOX.^KOUU_:/[J>A+\WG\$DD.T=]URNX0TTW[@I[Z>/OK$7FF]KX$
M'5?P</\`AW^<?W?RIZ$OS>?P22?'^M<KMVZAJ.NNH<*>^KC[ZQ%YIO+1L3W7
M<&_5WZO*/[JZA_YC?S?3U4JB>/;HCRE3`G8L;M7*D)@$=53>$,G!Q4-Q]=U=
M`V!5Z/KOX\8W"9;=QYS$*U[!"MOZJ^#W&HBE;HIHD=V]-=*YD5YD;D"BB/4B
MV!=3M%^1--PBZO!V"9B)GZX%$&K5J8Y1-O`PF#N:[:2==W'CVX6RV[#SMB%>
MD:210_`C.JO@]KB3#*:[#([\GQU7+]"7YO/X))+?KIY5RNFG1O[VK/OIX^^L
M1>:9VO@5SW7<&_5WZ_*/[6M/0E^;SV?[))/9K_6N5V@.NP?7:^MUV<:>^GC[
MZQ%YIO+0GNNX.^KO\X_NJ/0E^;S^"23W::^5<KW-N_?LI[Z>/OK,7FF]OX4]
MUW!U*>COU>4?W5/H2_-Y_!))AN_K7*[!#7:&WCKMI[Z>/OK$6KR34]U_!WU=
M_G']U/0E^;S^"22WZ^ZN5[FS?WHZ?Y;*>^GC[ZQ%3_9,[7P<Z>Z_@[ZN_77]
MH_NIZ$OS>?P227'^M<KN'78.W<&NRGOJX^K_`$B+7Y)O:^!/==P=]7?YQ_=3
MT)?F\_@DD]VGNKE=NT!UW[PTWT]]/'WUB+S3>6C8GNNX.^KOU4_:/[JCT)?F
M\]-/>DD]VGNKE-_LM^FH_.I[Z>/OK,7FF]OX4]UW!WU=_G'[.RI]"7YO/X))
M/>`^ZN5V:#N#;N'C3WT\??6(O--Y:=J>Z[@[7Z._77]H_NIZ$OS>?P226\1]
MU<KN$-.KOW4]]/'WUB+S3>U\"#JNX-'_``[_`#C^ZGH2_-Y_!))\?ZURNW4=
M=NW74.`[Z>^GC[ZQ%YIO+1L3W7\'?5W^<?W5'H2O-YZ:>]+)[M/=7*;P#3K;
M^^^A3WU<??6(O--[?PI[KN#OJ[]7E']U=4[\QYR#/`(D>S;T(U1444:LDKP.
M5HS[8XG4*W3-&F$H'$=!$PF,(;QK)'7CQX&AN\MM'_E#N[=NQ6G=57"#G%VZ
MF%36@D-!T!<QGYD+S>K1N1$^+IQZ8IC&%P\NV0,N<##KU3=BF@EU"AL``(&S
MNU9?UV<>O=43PM',(FT^#;H5;>JW@YHH8)#IVR.[H7*]"7YO/9_LDDMFO]:Y
M7;KKL'UW#79QJCWU<??6(M?DF<M&Q5>Z[@[ZN_SC^[^51Z$OS>?P22>[37RK
ME=1W;=_?!I3WT\??68O--[?PI[KN#J4]'?JI^T?W4]"7YO/;_LDD^']:Y78(
M:[0V[QUV\*>^GC[ZQ%YIO;^%#U7<''_AW^<?W?R*?0E^;S^"22W@/NKE>YL[
M[<.E/?3Q]]8B\TWEIVI[K^#OJ[]=?VC^ZGH2_-Y_!));Q_K7*[A`0TW[@X4]
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MZ$OS>>W_`&220;OZURNS37=Z[CKMI[Z>/OK,6KR3>6G:I]U_!WU=_G']W\B>
MA+\WGJ`^]))CH8#:>5DN74-FI>L0Y3@4=.`@(<!#9H]]7'VRXB'_`/B9VM6I
M/==P=]7?K\H_N\MBV;6%85GXPL^`L*PH".M>T;7CF\5"0D6@5NS9,VQ`(0I2
ME#514^G644,)CJ'$3&$1$1KK3,,PO<UO9,PS"1TMY*XN<YQJ23^+F`T`:!H7
M.;.SMLOMF6=FQL=M&VC6@4`'+6=9.DJKZPUDI1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:GO.]9"NC'N%
M>7U2WKFSE;D;=_.;R[6)?3?EQF+SA<OW38-RW&\;7+:-I.,>/8^\UW<XV3*0
M48]=-PH4NA1JK*XX+GBNQM+QL\EFZUS)Y9'CTOARZXEA<\,()CCE:V1U>]`;
M5P("NW../AS,[F`L;=QQ6^![L/>EUY;L=3%H#G,<YHY\5-JQ*Q!>G-S8^>.2
M2TK_`+QSU;F'LJ<Y7,JQQ19V;;D?O,RW#RYPW*_=%P6?"9Z._<O+AEWL?D&-
M<R$:A/+N)ELW(V%T?M2A7(LBABF=+:9GN9LY@X5OYIBP1F,2#.;%EF\;L"(W
M$=C*V.62,4+G2"I)=759R1%:W-YEIE9EKLYRB.,OQAP+[:;TUC,?S@MY)V5:
MUQTTJT!F$+I^8W*V3[LN_F`YLK#O^]K0M:U^;7D_Y(,/K6Y<#R.C)2T[5Y@+
M7)S$SK,C18K9TUOZ\KF<0#I0`,#AA"E)UNJ(@&NX.A9Z7P^^Z:UWVASQ\\C'
M"H=E\%I=0V##4D&.5[)KT#O23<-J.]:5NLX9$^'.[>-HWF0<)WA:\!M6YC<L
MCN)G!P.(26T+;2"CJ&.5DM*8BMC_`"!Y!OJ_9OGD1O:[K@NM&R.>G--CV<G/
M2*\@2V+-AF5JGB+7A"K"(,(.-.Z5%%`FA""H;3?6+:-:_@[);QP!NIH;HR/_
M`$GEM]<,:7':6L:UHYF@#8HSMK8.*KFUA&&V;E^5N#1H:'2V$,DC@.=[R7N.
MUQ).E;#ZQEC)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1%9KF!SUC?EBQ#>><<MR$M&8_L-FS>S[N"MV;NR9ZLA)LH=@VB[
M<MQE(S<N^>R<@BBDBW044,<X:!5&)SKFWLH6227EW<QP1,8TN<^64X6-`'.=
MNH#22KL<3I&2R`M$<,,DKR2`&QQ-+WN)/,T$\YV+%>1\Y_RLP]FW!=$R?,D/
M/6OD/&^+)O#\I@7+++/+.],P.C-,7QP8:7M4M]KM;Z53.,<[39G:KE(804`"
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MH^%[Y=8WOR5-#RK&WFEYQL<TDIJ%B;@?-&\3<*T`F^32?G9*KILW7615,50I
MBAB,+9,KASD%HRZ<R[MY(&)L+S&^0`Z=WC:X,D\!X:2PD"JNR?-9B_*G:;V.
M.)[FC3AW[,<;214;PL(<8_#:'-Q`8@K.XMY^.4S,_P`8MQCG,$)/PG*E(DB\
MXW9X)+,+.M1SXA6N1PHUNF18-86XF+&+;J"NYCEG2":B9B=?K!I5ITT;.'XN
M*'&F33221QOH:O=&6`X6>&<1D8(SA^<Q#!6JR/1;CUX.'&L)S@Q,DW8TT:]S
MFBKAWH<"QP>TFK*=\`NKQSYP#ETR8WOP8AYDF`F,?6A#9#DK1OO$&2K'O>?Q
M[<SU2,M:_+%M&X[:8SM\6C<\HD+9B]C$7*2[@0)J!A`*R[BWN;:SDO)(WDPW
M3;:6-HQ317#P"R"6(5>R1P-6AP%0':>]-,2VDCNYXHH2-S/`^>*4][#-%&,4
MDD4IHQ[8VT+L)J`YII1PK<CE[YJ\0<S`7VSQT\NN-NO%TW'V]DO'61K&NO&>
M2K!E)B.+,0:-UV+>L5#W!$HST0<'3)4Z/9.4/7$,(`.E7HSS8Q9G&626,TDD
M;7L<'`20N#98G4/>R1DMQL=0@.:=1"M[]HNW6,K7QW36-DPO:6ET;_`E94#'
M&X@@/;48FN;K!7$PUS,1N<<G9NL>SL>7LE:&#+T>XPGLN2Z]IL[/N#)\(SAI
M"Z++MJ%+<BU^N%+;:3S85I!Q$MXQ903IH+J'(8`HMX73Y/#G+R(X;ISS`TZ7
M30QRRP/G&&K6L$\$D8:\MD);B#,.E7[HMMLP.7-(DGCBC=*6^#$Z6-LL<;B:
M8GF)['D,Q!H>T.()6356D2B)1$HB41*(E$2B)1$HB41*(E$2B)1%:3+>#L<9
MP1Q^WR/#.9E+&&4;,S'9I6TO*Q`QU_V`]4D+7EES13MH:0;L72IC':K]HV6`
M=%"&#95ZSGDL,PCS2U.&]BBGC:=8#+F%]O,*&H.**1S02*M)Q-H0"J9VBYL)
M\MFTV=RUC9!J)#)&2MTC2*/C:=!%:4.@D+H,S8!M7+LOC^^UC&B\K86/?DUA
M*\E%95TPL>\[ZL"=QZ[N&1MAC+1#"[&[:'GE=&;L_9B;0Q#)J`4Y<.1MRV&\
M;8RF"YO<ODLGO`Q$02RPRO#0=#7XX(RUX[YI;M:7`Y,;X';F"^CWV7QWL%R8
MZX<;[<OP`N&D-H]X(U$'2#0*T]D<C&'(/E>Q-RNW@T=7G:^,9JQKY6E6[R5M
M=Y<F4;,O%MDCRX>>*907A%)3(*1Y%9HHY72.4_8J"J377=7.9`YU:9Q8,$!R
MXQBU9H<(FQ0&WC;2@:ZD1(=WH:7$NP@TI@VK+B*SS"UNI3/+FK;EMV]P[Z87
M;RZ6ITD$@AH<#B#6@`J_.+,(XYPRYR6[Q]#N8E?+N3;CR_?9W$O*2H2E^76F
MQ2FY5N63=NBQC=R2.2`K5L"39/J^L(&HZZZ-[H\OM\K9_0K5KVQC:T22OF?4
MZS61[CI)H#0:``LJYD==WS\QGTW<D4$;CJJRWB;#$*#0,,;6@FE74J:G2KLU
M0J$HB41::>=OGOSA@OF8N7$./[]Y5\;VG8?*%)\SCI7F!@[LD9[)]P1-\2%N
M>]A9DE`Y6L5&%>2D>P#LETXN>=%<K$T:J!H0V-'-(W*\US@L])?EUY:01VD5
M1//Z3#+*YS74D((=&&,I"6ESN^<-8V3+%D]WE5@U^Z]8FY#YG4,<.Y=`UKBV
MK*CYTN?61IPL)&HJ@9KSIF;28TYJ,@-<2V=:;_"^+.0#(-JV9>+6Y5)IC)<V
MCQ@E?=N7Z9O,19G#BT4W9DV`MD6)RJDU7*IW@<MNLD@M,RM;`3;UDW&MQD[G
MLIA-O"RT<V5FNDI,[P22YFAM&ZZZ'*+E^8QPR2LW9DX3O,T(UTGMVWA8P$@5
M@>;=AT@/+7$U:2`-AW+7S$7?F7,G.;CJXX>W8Z'Y<\SVACFSGD*E))R,Q#7!
MARP\ANWER'>OWC9621F+I713%LFW3!L1,!()P,<VD@A;+P];YLXGTB6_S"`C
M]$,M+@11D;<3FZ7Z:5U`#0L^^:+;,+>TCTQS9)87A)UB2Z==![1LP-$#</Z6
MEU2=%*<SES>Q>`<_FMK(-W6'`X<MGE4RES%7XV4M?(\QE-JPQU=EKPSRXH5]
M",7=E*VE',)LY73%0#32[DZ9FY#)%4$,*&XMH[3,[R^)$-F_+XV%@\%][-+"
M!*#I<'N8T1F('`0\RT:6JY-;3N;E[;-M9KJXNV.#OTFVUJ+BD5-(>!B+L?>N
M;A:RKZA6;R-YSC%$MA',]Y80NAO:E_8NM3&E_-T>8_#^;[2MN2QWDN\(FW+:
MR+&0#&W(R]+RL6Y!=+-V,E#D60!Z!.U$J93ULH\MNSF-I:2-`#LZ@L+B.HWT
M4DI)$1:32*:2,.="Z6D9#22:`TQ(+BUGB<]A<[>Y7=7EN\#YN1MM'B>\._39
M"\QB=C/G`'M#1B<U6WO+SJ3I1MSYVS;.-I[%MT<FD]9T$VRIFS%>:'F#KH\?
MQF/)%\^EG-HVLVF8YRX5O0Z<5'-'#MU(,RHR)1\%4-U:,MMO6EIEF8PDLBO<
M[=9.A?WLI8VZ]'I"XT:Z=P'?AS0RW>0)30U5[`Z.[=8O^=D]2B\$D?@!YMYY
MJN!J=PW<@A]:R@N;&,;:'-VX>=/#-EY+M/$]VCD"/G+OF8ZS(>\TL59#/B"0
MR3)QZ[^/QLTRF,`-FA?<N1L<&44=X#IP<2)E`5#`6K#`VZN;BWLP\R0MN'M8
MX4DE9:ASI]RW09G1,8]SQ&#HC>6U#25B&8V]C:WEZ6AL[;?$YE2R(W&!L3I3
MKACD?)&&NDI3>,#J%P6$^.O.F/<X6;#7+:6.9;!SEOSTP?*G-%Y@L99E0A+R
M@G>2YVPE2XZFHBUH9N&2I=.&`_@[L%(Z`<J`E(JZ"4QLO*K/T]N0WDC@+7-\
MLN;IT0+6S,,-A<78W9>0QT#-T'/F<&MD:V6.(;UH"JSB<98[/+8`F?*Y8V,D
M()B)?/;15E#07-<[?D-C:2\$QR'YMQ66$%YQ'E;N/),5C:-NNZ1&Y+LF\?6=
MDAWCJ^&6%+ZR-;9'YYS'=D9B=025@7/>T<:*=IFCVKXZQU6BR9`.=,Q:U]J?
M2[%V81`B+T1]VQK@6R36L;2Z2X@C=1\L3&#&YS`:,H[P=*R;MALYW6\U,4=S
M';RD'$V">5S61PSN&B*1[W-8&O([YS6ZR`N'@KSCO*SS%WI:5CXTN*^57V0X
M^\GV-YVZ<4Y&LJR\C*8Z?J1U_1-BWE=-MQ=O7+.6<X2$9!FV7.N@GH?JB7;6
M5!:3W$)F8*4LX;L-<0U[K6?!N[AK#1SHB9&-+@.]<X-=0E8TUS%`_!(307C[
M1QH2UES'O"8'N&ALA;%(]C3X;6.<VH"SLK&5]*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$6-7.5F:Y.77E0YBL\6='0DO=6(<.W[D*W8RY$WJUOOYBUK>?2S!K,
MI1KV.D%(U9PV*58$7"*@D$>J<H[:Q+R62,0,B='&Z:]M("]XJUC;BYA@<\C$
MWP&R%WA`5&DT6SRBSBO[X6TQ<(]U*[O:5K'$^0#2#K+0#HU%80VES>YLCL<X
M)O6[.9#DGR>[S-G7E\QNY;8OQOD^/96RPRJPD7LU9PJVWFC-JAL@OS(E)$/9
M/Q3$-_!U1=E,!R]3E,N6V\/$,>0ALLK-YF(,K2T"9MI`Z1AAJW=MPN;CFQ2N
M+HG!L8#Z%W&8+R>YX<GSMH9'/'96\V!U2(S-/#&[>4(D+<,A8T-8#O*%QP!P
M%O>7'SAU_JQEB2^>[_QV:UG*'G$;TOY16Q+P+D<]C<J>9)JWK<=V62QHL;#3
MC;7LQJ1.42?E&6DE03.U*HH*PUH(KFS9EEM=WC@#]C<ES*0LK47%\ZWBFDD#
MN]W+WS49'#WS'FI`B!6XO+><9W<9=8CPN,+K+(0\C#NH[2:XCB:1WV^!BQ&2
M4[LQAS:[PL"RTL7SG7)_?D%=]S(WO=5GP%GXFCL['E,F8QR'C=K=6')9XVBV
M&1K`&\+<B5+XMA>:>MV(+1Q5Q!ZX21$O74(`Y-U:7-G%</F8[?6MY%:RQ`8I
MFSSXO1X]T*O)N<#]P0"),#L)[TK%LIHLQNK>ULW!XNH)9HI-4+F6X!N/G31@
M-N'-=.TD&-I!(H5<WEKYT,0\U5PY6M3&T-F""N'"TC;<1D.)RQA;).(7<1)W
M9#%N.!9-TL@V]!#*+/;>70?:-NU`K5RB<P@"A:N>@SC+69L</HDEQ-`.^&/>
MVY#9FEE<0W;G8'$BF($#4CIF-N&6VDODMF3L(!+70R$B.1KO!+9,+L!KWP:[
M]4K+2L-74HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6N7S
MLV-\A9=Y`L]X\Q5;URW1?UQM;&0MV)M"')/W&+EKDBT'R\C&0ZJ+A"06AF;5
M1X*:J9T1(@/:%$FH#>RL.'%F0SB8VT4.>6DCYJ-(AC8^KI7!X<S"T:RX$"JR
M8WL;E^8M>`XR95>,:PDC&]]N]K8Q2AJ\D-%#6IT:5AES>>;]R,PM"Q;PL;)&
M:LP<R^4N<[DHFLFY^5L['<I=-C8YPW?"RD3,1.-H6S8_$\%:6-8^4=O'!5(=
M1NLJNJL[[4QM:V.37&XXBL+6U>+++&R9M<S2UQX[B?)Y[4.D=+BP[X,@MV-;
MA#.]$0:XU6GNF.N.&+Z2Y9O;T9/;VL$-,%(VW\%PZ-H91Q?B=)(]Q)<0T`FC
M5;5Y@7F":<MO.ORA7-A>]\IY]YG.:QQ9\OS1S=G+M[`OZS\FQ4)(0?-5**0;
M9E:]G^\98L21D,5&^"-VUQ1#9NT`!7*%:A]G#GN09!DT<IRMMO+=/N'L<=Y:
MS6UP^YFN[=[ZN=+F,CF.M`XDA\KVN(9"ZF\9<NR?/\TX@N&,S*-UA:[B+O0+
MB-\0M(LOG8V@#;4X_2I,(QV_SQ:'2!;"/-A8ZOW`/+K*<JF4K&G(^?Y;[QN2
MQ$\GO81TE"<R5M2CE:Z(3-S"46*L2?N6\V,O_2-/M%E6\VFNF<=I0K;YSF4&
M>9?:YRZ%MNY]MN9;-HJ+=]M\RYL3`--O,&B:`@#&)'"F(&NFM;*3+,TN;%DK
MKB-\C+B.Z<>^D$X#L,SMD]NX&%X)T1LB=4@U6L>^<>WWS!/?/*8?Q)@#F!QX
MIS*8KQBPP')WMRZ9+PYCB[GV*<6I6_<UO,;JNNTH*U8<\M<"(LFA7"B'C%)8
M5F_:)`)ZUV6W3[7A?+<P+72S97Q2W,WVY+6RR6K;JQE:R-DE,3S'!(-UX3"T
M![6U"WA?$SBR!SWX(9,CFL3,W$YL=Q*Z_.-SFZ0P;Z-YE%6$NH'$T!R<8Y"R
M0ZY@9WGKBN53F:"S.7_D34P\7&+W$ER6[F/*F89>_P".N5:P,=X\EVC*=N>(
MMQ-@1,TXBB,,H9<ZC999),YZF\N/0'9]FUJXSG-[RRBM8Z.J61/N7NNYV`%\
M#:W+6O;(!+@C<0T][74918^G6G#O#EVX6LN5,O)KJ5Q&Y;O+6UB$,;P<,\G^
MZO<P1U8XNC;C#WX1?+S:#%6:]_S,N1K1S!!<R/,%=-N7YFY7(O+_`)?P=:D&
MVCH,UO8_Q3C93*EKVXK=\%C*W$3-%Y!`5%7CQ59RH"954DRY=Q:V=GD4619?
M()LKAN)WR2.(;)<W5SA=<7&ZKCCB<&,CA9J9'&T$[PO5J2[DOL_DS&>.2*4V
MT<<#"VK8+6%SMW$Z4`L=<.<]TT]':7OHT&-C7'6G%\F%X8>C<TW%"<O>7XO$
MEX^=$R)<7,?9F+FE_N\CYAY2%K.;>2BMN6S$R+NZ;[QX.17Z;I^TA"C(OFZ1
M^S[0B1R5@Y4ZPM<@X:RS-F.=E4>39B)80UT@BS+T^Z&723L;5X:RVIA)JQN.
M&21I!+EL;]MS=YUGV8Y<Z(9R^7+]U,^C=Y:>CV[LQBMWDMC;,]X=0Z"<,L3'
M-+FA5%;/*AF'(MZ8`M23QYS(0?);(\].5;MLK%=SS.1[9F;&Y:%.7-E'1EOY
M6C7$LWO.U,;7+F)%^XCK?G52.6X*IE.FEURD"_91GUEE?KPQS7,.19QO'$M>
MQLCKN%V61RO:3')<Q6X)8:N+0&L+BZ-P%F_N8H,KS$<-,?`R?,,C:06D/<]A
MNG9I<6[7=_%!)B@9(X!@<1(YHP2-)^DV)BH^"BHV$B6Q6<7$,&D9&M"&4.1J
MQ8H)M6C<AUCJ*G*B@D4H"8QC"`;1$:LSS2W,S[B<XIGN+G'G)-2=&C25;@AB
MMH6V\`PPL:&M',!H`TKL*M*ZE$2B)1$HB41*(E$2B)1$HB41*(L6^:SFKM;E
M.M?'UPW'8N1<CR&4LKVAA>R;1QA%PDK<LO?-\"^);[44[@G[;C&D>LNQ,59R
MJY*FW`P'4T3`QBT0F6ZS6WR:TC=)?7,=P]@!:UH;;0/N)"][G-:P;MCJ.<0V
MM`2*U54P;;Y;<9M.X-L[4PXSI+J33,@:6M`)<0^1M6MJXBN$$Z%BQ=/G9<#6
M+?3^R+WL^^+6"R+CL*Q,XW#)W-A,8[!N1\C-81S`V-<T0VRPO=]\/VIKD8IR
M#ZSHVY(F/4<`"SHO5/U=A868S2^AM,OD;+%>7C[6UD:'%MS<1O,;XVLP[V(-
MD:Z,27$<4;GM(:\BA-B\?+E^7OO;R-S)X;,7<T-6F2&V-2V1Q#C&XN8#*(HG
MOE$='%@Q-!JJXO.5X[MNWN9F_P!QB/*[S%7*XG/M[SR`QD\/'4G)^VI]G;<G
M;T#CE?*;?+<>N=^Y4.U>S,#%1CU!N=1!R<IDA4QLOC=?V5A>GYIN9W=M!;M=
MI+_2I3"Q[BS&V(,=0R1RN9.UK@=T34"^T"7,9LLMR'S6\4[Y3I:UNX@W[PW$
M&F4%O>MDB#XB_1CI4JUGG'.<5Y:^!.:VPL13=]8_S)B?"6#\RM[\BP8,&S*`
MRSE%:UHQM"R23QX^\=IIVR](\(=J1(J*Y.HH<3&`N?E>7RR\0Y49,+[*/C7+
M\KN(Z_ML;K::1NJAADBG#"26DG$*`:3BLO8'Y=(\`[V[X8S"_@.CYO=0RM83
MIT2-D:'MIB&@&M="\<4><OO5VKSSS&<^6Z]["QYREYE=8SMJ[(64QM,J7L4S
M6ST(*$D63+*LR]877+R%T)N3R#A"-MUG'+)G=.D%$G`$TMO<B;AZUS>1N',;
MS-)[2.$%K0YS+N2W8T/<1'&8L(%P^61D9>:PE[-*RI+:2'B"3)(';VQM\EMK
MV2:A+FA]DV[E+F`;R02#'Z.R*-\A#"V4->YH.R7#>19/*^/8*_)6P)W&B\Z1
M=="U[AN?&EXR"3(BQDVK\MQ8BOC(MAR+202+VB1F<LXT*.AP*;4H;"YM_1G-
M87!SRP.<*.:6$_H.#FMT@4-6U:011Q6):W/I+7O#"V-LA:TU8X/`_3;@<Z@)
MJ*.PO!!JT:*W1K&62L*KBY+K*O/G5:\W=[(V=>:<3@".PU;MCW5C^&N!>VYV
M.R,K?J=_P=RRZST8N0$B@-03;M$E0ZH'[?<0,K*[@979YA#$W_?+V]MIVS-[
MU\;8+>:`Q`@8BV3>XCWP`I0M-:B,P'I[;&-VB"T;<AS3WS9/2'0D$@Z`6;KF
M).(ZM-;)9T\W*ZS-,\Z\J3+:-O!S>->51L@@:S#27D%\6FY/'ZIE%`N1EY1!
M>`?:@``9^`]]]NW5.77/H%MEMN1B]7\2R9M6M,8?%:Q[C;AIZ/7>::XZ8.]J
M;[Y0Z_=>TH#P]=Y9AZ;EMT-]7F9Z1X%.^P>&,6C)W`G+>KA/*G-7DE2[B7&3
MF5RK;&2TH@L*,8:SRV[BVS<;C#G>C)/@FQ=FM,7G;@DVZ@+]GU!ZG7-1#/NL
MDAR>E3#>WL^/G],GWV&FS=^#6O?:Z#4J+QWI5]!>>"(<HL[*FNIM'7#MY79C
MW_@T.'#X1KHL7S<<A+CFAOV]+V2R>G987;R9YEY32QQ[3-.BP6RQ<]K7$2^O
M"@GXOP@D&%MBB,?U""X[;K>$)]70V+;AT$5Y&#7TJ]RBX_F^J[I]R6].^Q8`
M=&[IBH_4LCTD?[CWO]#EOGZ_#],LC:4Z-W7'73B\'O=:HWF"\VZYSE"7E$ER
MZE;A[MY6\1<M_A1[*&5%FKB[*4'DD]W&)Y2,3.2380XM`9=8G8"KVG;'TZ@[
M&*]$7%%WQ&&Z+KB#+\SW=?!%CZ96'%33O?2A\Y08-WX+L7>Z:TL_1K#+K(NQ
M>@9)F67UI3'ZPBM(][2O>[KT6I9IQXZ8FX:GI\P^;@O7)*O/#;D/FJV+?QMS
MK-\8W!,QTCC24F;TL;)&-X>P+7))1EQ-\@1,+*V9+V[8:?7CE8M-XD\7%0KT
M4R]D-O+;H6<=C%<-WC,MS\YE!0X:MEN!<SP2UQ8B9!2*1N#`TT<QYH5M&RAD
ML<[!2;U#ZMEYG!D-S#%,P?H$"XJ]I+@_!H+2250=^>:FNK(/--9_,%<F=X2X
MF-@<QV/<_P!G*738MWS64+<B++5245PA#707*[.P(W%I1%8T<5*U@DFIUA%9
MRY`-!<.W7J3,#F,@WDV',6$M.%TS;^">%KKASL9<^W$S!'N]VPQQ!I9B.(8&
M;P>L<K;E=OABA]#LH2"*M8^S?"XR0M!;A])W3GSB0R.,DA<UP:,*KN,\V[>+
M*-/8R^:K;7QG!\^4)SN6.S2QM)I7JS6/D"3R'>6.KIN$U_JPTTVDI*2%"-D6
ML9'J,D"_;DG1M!"UEDC+2WR:*];O9,GRR]R\%IP-EMKFPNK*,N'?%LT?I3GO
M<'8)`UK6LC-7*O-V2YC-G#X'"-F;OMYG5&(QW$,]K*XM-6@Q/%JUK6.&)I<2
M9'"C5Q;#\VI>MKH8DQ'-9V@IKE5Y?<U3.>,1V`SQBO&Y7/=CJ4NRX+;@<@90
M7O61A9^U+/N&\W;I#P&`C)%V"2*;ERH4I^O:=)-=1,N<S<)<\MLGER^WE;5D
M89+9NR\SS1`G>3"T<8P&.CBQ%TAC+J4N7S([FXNVP-#<NS',8KRX8ZKGXXKJ
M"]W<+]`9&^Y@:]QD;)(&]XU[0KG8.Y`W.'+?Y)8-7**5Q'Y0'>:72KL+1&.\
MO`RXWGD")I)C<#T;;""":`1]<\\([+3[7KLSIKT2YVW-\-`WAV+*\%?)-RYN
M^Q4V^@^!31O/#.'OL&>Q,UF^UQTQ<0NS.M-0<,P&YI79Z=7'_P"7X/?][L@K
M`6P2B)1$HB41*(E$2B)1$HB41*(E$2B)1%8/FGPD?F3Y;LY8`3N(EHJ9DQ=>
M6."70I%^.R0!KLA'<.$L>(\.C?&96(NNT%#PA'M-.KURZZU8F@9.^W,@#HX;
MRUG+2*AXM[F*<QD'1201X"2"!BK0TH<_+;WU?=^E8<7S<K:5I^TB?'6NG5BK
MTTIHUK'2\?-^8\D<?\MECXY;V%B4V"\X8'S1<LE9>,("#)DQYA5D[:>`2;*`
M7A"M7D]X8<Q'BQWAFG6,`$4U&M^_-GNXI'$#&EMHWUAA@#N];Z="^$X=&%N`
M.:31@QA@;WHI316MD(.&9\A><=Q/9P0&8COOF)H9<1&DNQ&(BA=H+RZI.O'!
MOYIMVA;C&!'.2!A9XR\X%CSPKWOS`"AN>*\W]V-Y;LO*T>J&-BO>P,CUA\:=
M7K]=MKU0X\+?_=&6Q-</#.4936FW*[BVGW]/_.]'P[O]WBKC?2AW3KNN<MS;
M#H;Q7-G.&NR:SGM/1Z\[=]CWE-.'#@%:BW_/MR"9(?<LTJYQG+S>1KQLOD0C
M^3QK:5KVJ<;BN!(^1\07/*Y)BB(3AI8[B)B\=+*$AHX!E5S*@#-VFX*F([;-
MLW]*SB\O<$D5MFO$.57DCV&1SK6.QEOGN=2$LFEJ;QNF)T;V[NNEKB!KLBM9
M,JLK..-S9KO++',FQM<8V"X?>6\4+8\4H?#'01'3*U['8L)`T5NWYJBU<EV<
MGGEE>F.KO&+GYJR+D0YC<GV7GG&.5LWW(6`<6Y*1-Y6%S,7=>^7"H8TA(&-8
MQTFN\3CW;1<$VR!>Q.<^;<2LER*%KMW#-'>7&&%F[+7LDW<CKQPC`W<L\KGL
MD9(72.W0DJUCFM&MMVSQYD(SCEMVV,+,;@X;C=N>&6C"XELD;&DRAT36,8Z5
MS#B?B*V]UI5MTHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M6&?G!.8R\>4WE%R]GW'\7:,Q>%B,;=-!LK]"4&S_``N?NZ!MD7=PEA9&(E#Q
ML>E,F<*%1=(&,">G7*&H@MXI+S.LKR>.2.$9AF=O:ND>*MC;,_"Y],3:D#55
MP%=:OQ1L-M=W+PYWHUC<3AK=;C#$Z0-U'PBVFJNG0J2@^:QYA[';NZ.9S)N,
M\MRCJ0DGD2KR9X2S->K>+M.$CHUQ/R5R6K;=T9YN1)K;RCXJSZ3,JT8M6RR7
M:%*.IS7;R6RMXXP1+&6M<Z:5^B!K<;@U[GX0V%G>EI=(\@O!H12BQK&*[OFB
M6(,<'[MK(VZ972O!.[8VN*5Q%"UK&5H"3K%+`7_YRVR\=<X=I6])7G(7+RRW
MWR,M.8ZTSXTQ3>65+@EY-3*:\,]O<@8]MVX[J;V=%62*:STRK8C1F0#++&)H
M;2W91RQWN?6&;4BER^;*PQSB&Q1,NF7QF?++^S$;W108)'N#:'O20Y5S-?=6
M&1YAE(,D%]<9K#+M<^2V;EAMXF1FC]ZTS7>-C6EQI1P!8%D'>/G,.3RS9A."
M/D"Y[Q?FQ);N>U_>NQ+EC*K./PM=2,DO#9.EI''UEW$PBK.6)$K@J\<*)D;F
M*!5>H8Q0&)P;62\9=`Q-R^X;!<.?WK(I7QLEC:]Y[P;R.1KF&I:_3A)PFEF&
M:.X]#$%7R7['.@:T$ND#)70R4:.^K%(TMD:0#'H+@`0NZS'S*J7C9UP8RY1K
MJ@[IYG;\P`PS)A9-:/%]:<;:5Z2;6W+1RG<\E*(M[:+;3-\]%[X`LX*_D&[1
M4K=!4P"%7;O+,R;>W&65-O)89A;6][(0'BW$DCC(`VM)9!#%*0R,N(K&YV%C
MVN5_+,PRIUO9YO<`W&77MO<2V\;7%CK@P1,?@Q4)A#GRQ,QR-:T.+FU+F/`N
M!B3F3L6_KQD<-Q,E>U]WUCQH>W\B9$A\/Y%CL-K7W;3.,0NZ&:94-;(8M)<R
M,B\ZZD*WEE7C;KB04_M9M+[O1\Q9-F^6,,.3/D<Z`2.HY\1E?&TQ8\+IV,<Q
MS'2QAS<3"25@6_I%DR'+<RE9-G$<;&3F,5#9MTV1V\:VHA+PX/#'X2&O8*:0
ML-;HYHN=:YN9;G&QM@F`Y:GEC\HD#B2:&ULBQ&2T<@98<Y!L.8OB1AX[($%>
MK>U+#62+$BU:+N+>E4P44`RI>KJ(:]L@L^%W<7YF#)E[<RO8'11=[(V*R9;N
M=('/Q->\[XN#*,!#,.(%V(;:6U,V=6F06;VQW5U90S"20%[`^6>6'"6-+#A^
M;'?8B075PN`H>?C#SG6.[\<1.39NX+&L[`,[R@8YYD$(9W'9"ELY0\]?N15<
M>HP+QC#P+VRIZ-<W$*<-',XM=Q./IDP$(V%-1,1W-QEOHK\P@:7W4L&8V5O;
M&!CG;YEY9OO(ZQTWIEDB:)6-C:]K(A)O7!S5@V[I[J2SMPQL%V]F8^DME>T-
MB?EL[;>?#)4,$<+Q()7REE:,<P4+J9+W+SQ8,M"U;%N6XVF9XR3R2K<!;-Q@
MKR\9S5SE+,[3`3W--C@UOC];*S&W()OU5G4BXB4F:2*J9Q4ZJA!-JY0V*?<.
M<PEMN)Y'!P<R"%SL`DN)`2RW;C[VLI9WVA7H6NFB,K00W?;IF+O3-+A#]W`U
MU#._!5V&(/.$..II7"NGG^Y6;2MNRKV>WY-2]@WQ#VY<33(5H8ZR->M@VQ;M
MVO\`Q5;D_D>\K5M66M[&4/*RH&;$7GG$>0KA,Z9A*8A@"\ZVF9F;<JD&"Y?(
MR-KG$-B?)(&NBC9,2(G/E:]CHFAY,@>PMKB%:7ES+1]X6OI%OL;`TF9@MJ^D
M%T(&]:(,+A,2P;LM=BIA-*V9\VV%9')%XXSCI.[W[W';.2=7_?+/&N0G&&;)
M6AH!"Z92(NG-R=M#BF#N%A;[M%TK'N)<CPB2R8BGZ\NN-B:,OGS68B++X-Y5
M\GS8?N93!+NL=#-NYFOC?N@["]CP?`=28_GKN++[7YZ^FW6&./YQPW[!)#C#
M*F/>QN:]A?AQ->QPT.%>'A/G'P+S`W*YM#'-P7,-P!;IKU@F-YXXR'CCRZL(
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M-P8)P'EA&Z[IM^-AH0'T-=V3L?7%?5@!)1$$@1<D/(-R`X`SE,"+&$PQE$LF
M3[N*"GH<,TTK&M&[>U]Q(Z68F:/#*X.D>7-#G'!I:RC313G!=FT-2=W?&W9`
M9?#K'$,,58GXHZL82RH:,;<(?7"TJS?,%R7X$E,S/'_-5GB[KJG^<&(OKECQ
MO`0]I8SQ:1@SN]@6[Q9S,SCVV8*=R5)6TE9;)O!/;E6E#1K@X$1`IGJHGT4F
M<VG#EM!E<MPZ+.<QO;<Q3Z`?2+5SKF&1D/[%LF-H#Y`S'*W!"\EE`NT.$.!.
M-./LOSCB7AFQ;<\/<(Y<_,+UE"[=V<Q;82,,IK*8BVY?(80]K0&OG'?1`BX,
MIYKF+O>"Y@&>7N9K-64[DYB,3X>P]<]U2L5C2`/;EL85NV7NVVE+0@+9LZ,@
M(QY).I@Y9`3HJD<&`50*54YC#RVTS1UI+;W$<;#/#Q)!G3B:_.74#(&;LBM&
MP.]':<#:%F(AK@*4ZD]$:&MA:2+:+)[O+8FZ.\M[HOTEQ[Y\D0>0U[B<5!C!
M5Y4.2N8M:X^9^<Q9S`7AC]AS/SD?>4_;3K'N)K^A+5OT(R#@;EN6'2O:TI96
M7;7;;\"FU<1DF9W'H]<ZB*9#CK6D9"691ZE<0ZS;?3W#<36G"+F1\T\)T4<Q
M\K\8<X%[*!K74JMBV2,9JS."T^EC+HK5]'.:'^C1"&UFT&K'PQBF%A#)#I>T
MJZG*9ROVORE8K6QC:]R3MUDD[PNB_)N8FFT+#ME;CNYZ5[*HVS:%K1T/9]AV
ML@HF4K.&AV;6.9EU[),O6-KM+J\-Q;VMH&X;>SMFP1U<Y[RQKG.J^1Y+WNQ/
M=0N)PMPL;1K6@:ZWM=S/<73W8I[F7&ZC6L:"&M8`UC0&M[UHQ&F*1^*1Y+W.
M)R;K"66E$2B)1%T-TW+#67;-PW?<;U*-M^UH25N*;D%S`5%E$PS%>1D'2@CH
M`%0:-SF'U*L75S#96LEY<N#;>)CGN/,UH))[`"VN0Y)F7$N=V?#N31.FS>_N
MHK>"-NDOEF>V.-HZ7/<`NFQKD2TLMV!9^3K#E$INS+[MZ,NBV99'81_#R[8C
MMDX`NHB0QDE`ZQ1VE,`@.T*LY=F%IFMA#F5B\/LYXVO8X;6N%05LN-.#^(.K
M[BW,>!^*X'6O$F57DMM<Q'7'-$XL>WIH1H.HBA&@JMZS5QA*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*U<?FC'DIF2X\"LYY!7)UJV-!9%F
M;>`2"LWM6X95_#,'XB4XF`?#6&ARB`"4JJ9MH'"M9'G&7RYO)D;)`<RB@;*Y
MFT,>XM![8^,<ZYY>=6O&%CU<676O<VCV\#W^:3Y=#<::.NK>*.:1FK]1]003
M4L>-;2KJ5LUP-*(E$2B)1$HBU9><1\X@P\W[>W+;.7NT3?8AR?=$U9M^E1:D
M-+11UF[92'GXMX=1(I#1JI3]JBH/9+IG$HB0W54+V1P1P9:<797F&*4PYE"8
MMRX_LRYV*K9.8.I3$/!-#JJ#PGBKB:XX=OK+#'O;*7>;UH\,-:&G$SG<*UP[
M17;1;';`O^S<I6=;]_X_N&-NFS[HCD)2#G(IP5PS>M%RZE$#%]<DND;4BJ1P
M*HDH42'*!@$`X)F.77N4WLF79C&Z*\B=A<UVL'\8.L$:"*$&BY997MKF%JR\
MLWMDMI!5KAJ/<(U$'2#H*K"L)9241*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB+$WGBY9U><+E?R=RZ)7'&6I[XR%MM5IJ9@1N>*1:0MVP5QO6C^!!]'!)-I1
MI$':G3,J4FBVI@,4!*-=GN(<[RS,[J-LUK89E!<OB<`1*V%V(QG$"T8N<M<!
MS%7F3.CM;N",ELEQ97$#7`T+#-$Z,/Y^\+L5`03301K6)?-?YLMKEN+LNTL`
MRN,,%XI9Q%^1.0\(Q%CW'9.+[QF[TCH>/CLK&CL"7GA^7=Y+LE"),A'^,73V
M)6:NU2.&JABI&)AW\,F8Q75K=.QVTUF88"XN<ZS<72N<^W:7;H[[>TF;)&\'
M`PMH<5;N5W#,L@MG1,'I\%U%+(X`-%TR-H&YF(&\#6N`DC,;V.:XD$D:%0,#
MYMGF-Q'[S\E@?F,Q;$3N..1:'Y)IGWQ,/3US1$XR974\GULCQJ41D*#?Q4NP
M1=:,F2BSAL9<-7(K)^LK99Q)#G=YG7I;7-RW/&Y>R8-($L;+*VN+=YB=3!CF
M%PZA<PM8-32X`C69';1Y+E^3QL&\S')K_,KF-Q)W<@S"6TE$3VU+PV,VK:O#
M\;MA`Q5R`Y6O-Y07+'>\Y)H7H%\V')<IN%.6'R<G($`F7R6+I#(,C<-SS<B1
MZLP>(WHK?BO[P2:ID:@02@8Y1*!;N:7EMF&49ME=Q$19YAF++@`$DQP199:Y
M<R'47/>([8.WF@N+O!KI-FQM);&]RZ_@DI=64%T'&E`Z>[S!^8/D8*T8QLCR
MUK#6@`J[0K(>9ZY5[LP396=+YR$G?`2MXY;N7'6&V62+=<VK=EH\J6&YR8MO
M!EH*P+U%%W',4&3IZY1,<H"Z;+(+#L,%7A>S/X5RJ&\+79W<V[+N_</"?=.8
MV"+>@$TEBLX+=CQ6H>7XJ.)55U;PGBS,I;1F#)K65UO9MH,+8WO-W=NC=^G%
M-?3SOC)U-#6M[T-60./.4/*MM\Y5P\RCZ_,:V/8\BRNYD_QKA6V+]MHV7%I_
MQ<E!3F<$;GR!<MD25SV@FP,LA(P4-$/';EP?PI55,"$+K\FD.7Y5<6-S\X^8
M-#&#1!`X2%YEA:[%(Q[VG`YH>(B'/=@+S49^9F.]EB=;M##'*UQE--^]HC+7
M0O<T-:]CWEKR9&OD:(HFL<T!V*A+LY->:AGS&<UN3\+Y\Q#8=A\W<#C&#N\;
MAQ-=%TY6QT./;'EK(/*X^F4\AQEBNG[YM+&<)!*0[E)!4H:E.&RK,;&W'#CN
M%,TJ<I-_>7!,7>RN;>-@;)$YSL;0*0X0]K0X!Y(HX`B]+=.9FUMGEFQAO[6S
MB@:V2IC)BFEE#R&EKCID\$FA+14T)!Z$/-EIV`Z=)X?EL6S-HQO)GC3E'M3'
M6=['N"]+571L'(9[T7O6\EK8NRU924?R)%3*)`S.R7;2H%=$6#J@0,^_S">_
M9F@<R-CLRS:SNA@QL%O%:6<UHV&$M<'M<&R,$<@<,+&EI#BZHPK5DEM-8W.^
ME==6EOF#9'NPEUQ-F$\<\LD@IAPN<V3>1X2'8Z"C10V)N_S/5X71`81N::S%
M;&0LQ8=0RO;L9'Y&]_<,/QN.<JS$1-EQ];!K&S=:>9THG'SJ#1)#+RMT2CA1
M!10CL5OM8DPWX6W+IVC?OGRR*TN))OVDIAN))V3$1!D6*DIMRUT;FF)C''YW
M$\U1"0V[[::1T=JS,GWD$40;NXW/M66KHOG`]XC=@=<'`YE)Y'`4BHQ=%F_S
M,UZY9L.WL4PF6,:6%B>.Q'9%DQ6+H>W\U!8>%;TM:Z'=U7!=F#X!CFN+:OF6
M1'SS^54+T"YER"@F9!4@]<#9!DA&:17P#G>C7UC-"]V$S-@L_10VR(IN1`&V
MQW3F1-D89'5<X!M*7-(RB3+H@UKKB#,V3BKL$LN8"?\`WM[J[\W#'3DO!EW<
ME#W@J5DI??FZ+\ROFR^+IN?)-A8ZQ)?&,[^Q;>T!A&VK\MF_<T6[>N/%+!:I
MYI=SN0)O'$R]M@RP2+20C8!C*F<-6Z1W(MRF3-B3QQWEAF=K<BCKY\CHV-_8
M0R.N?2(YPQU7":,C3NW1LE=+,Z1KB68<S+YQE?JWT9C'RV+K8F5XI,\0Q".:
M(/9AK%.`&?."1T436")S7`D^_D0\VZ'*%D$EU2\9@J?/:V+@Q-85_P!JQ^>_
M?<&V$WT&=1K<S[)^;<D64R:S;:`;KR#:"BXM!1^D0Z94T2%2#;^M99;6[WM8
M[Z]EB?*(]$+@S>.H<8=*<+WUBK(0T%^+$35:CT!L;[>*-Q?96SI'1[SPVEXP
M@C!AC#L!+'NP5<*:EMCK5+/2B)1%0V3L@P6)L=7SD^Z$Y!6V\>VG/7E/)1+9
M-Y*'B+<C',K(%CVBSAHDY>"U:F[,AE4RF-H`F#?6=EF7SYMF,&66N$7-Q*V-
MN(D-Q/(:*D`D"ITT!^!8E]>19?92WTX<888W/=2E:-%32I`KHT5(^%:*U/\`
MJ9_-C)*'24E<YE43.<ARCBDH]4Z9A(8HB%RB&H&#3?H-=D.ZH<_:XM-YEM0:
M?M)OH%P<=9.4$`BUOM/\B+Z9>'ZS5YL/?XVSGIIK_=0'YR:ZZ<-]1[HL^^N9
M;YR;_EU/O(RCZK?:OU(OIM?0GZS5YL3^=\Y_HH#;PV?TDZ:>Z+/OKF6^<F_Y
M=#UD90/^%OOD1?3)^LU>;$_G?.?J^]0&F[7^TF[2GNBS[ZYEOG)O^73WD91]
M5OM?ZD7TR?K-7FQ/YVSGQ_W4!P]6Y:>Z+/OKF6^<F_Y=/>1E'U6^^1%],GZS
M5YL3^=LY_HH#\Y-]/=%GWUS+?.3?\NH]Y&4?5;[5^I%],GZS5YL3^=LYCW/>
MH#\Y.&E/=%GWUS+?.3?\NI]Y&4_5;[Y$7TR][;_J8O-C.G"38DUFTAUE`3(9
M?%J:"(&-IIUUE+E!-,HB/?&$"AQ&L6]ZK,\L;22\?<V,C(V%Q;&9WO(&L-8+
M>KCS-%2=@*W/#O%V6\1YY:Y#`U]K/=S-C;+=/@@MV.=H!EG?-@B9709'D,;K
M<X#2JS#_`*B+S>0@`@MFXP"&H&+C5H8H@.F@@8+I$!`=>'17GRZZS^K:PN7V
M=]G4$-W&XM>Q]O?M>UPT%KFFT!!7T=RK_3/^^3GN709QDG#%K>91<QMDAG@S
M?*98I8W"K7LD9>EKFD:005\]_G3_`#H3/FOYG,,Y'Y?Y&[87'O+^SB9BP59U
MD6`F5+^5EVTY/7`=BB[?@V.!HYDS2,*AA%-J)@`.N(#Y2ZW^L.#/N,+6YX;N
M=]E>7!KH9&A[`Z4D/>\"1C'BA#6Z6CP=&@K[A?Z?7W*+_J4Z@.(.&NN3+K>/
MC7C%\T6808XK@1V#8GP06[I(G/B=4233.#'D5E#226Z-^EK_`/44<B3BVK?<
M76WS'&W0M"Q:MQQ\=CYL^CV4Z=D@:6:L7@W&B+MFW?&4*DH)"B<@`.@:Z5Z8
MRWKAZM;G+X+B]SFV@O'Q,+XS#>$L>0,3266SFG":BK7$'82OC9Q9_I5_?#RS
MB?,,NX:X:CS#AV&\F9:W(S#+F">W:]PAEP273)&%[,)+7M:X.)!&U)G_`*D;
MS;$`"7C24S4@HL.B:!<:-EG`EV@*AD$KH,H1,!V=80`-:[EX%RJ'K&M'YAPO
M=PR9<W]])%=PQN/,QTMJT/\`^S6FU>).O_JEX[^[+F<.1=;%O9VW$<Q_H=M?
MY?>W4;?UYX;:ZD=`W8#+A).H'2NA_6:O-A_SOG/]%`?/]TF[2N>^Z+/OKF6^
M<F_Y=>=?>1E'U6^^1%]-\:?K-7FQ/YVSG^B@/SEI[HL^^N9;YR;_`)=/>1E'
MU6^^1%],GZS5YL3?XVSGIIKK[U`?]GE)KKW*>Z+/OKF6U_VDW_+J/>1E%/Z+
M??(B^FU]"?K-7FQ/YVSG^B@/SEI[HL^^N9;YR;_ET/61E`_X6^^1%],JMCO^
MHT\W)+-4WL<_S2Z;J:>O2QNS,*9A#K=FL0+I$Z2H`.HE,`"&M=-<9Y[PUU?Y
MF<IXNS"*SNM.$NM[XQO`_2CD;:ECP?Y+CT@+W#U)_<[Z_/O%<*-XSZG<LR_.
M<G-!(V/-<K;<6[R`=W<V[[MLT$@KX,C!76"005@GYRSSX_+QGSE-OO"G+8;)
MB5ZY+5C;>G)*Y[51MMC'649R1Y<)47J$Z\<'>R23<C4I2%T[-13K#IL'S]UN
M]:W"=[P?)E7"F8Q7E_=N$;Q''<,,<6MY)FAB'?4#0&DG3I%%]-ON$?Z<'7CP
M%]X?+NL;KVR.'+>%LABDNK<&[L[DSWM-W;M#+>68@1%QF)D#15C<)Q:J%\U%
MYZ7!?*[RN-,#\RRF0UY*Q+GER8^D+3ME.Y$5+'F#$E4XQ^LO,1YFR\/-.'1$
M2@42^#'3*'>#6!U+=:'#&5<*NR7BS,(K.:UE(AWC+A^.)_?4&YAE`P.J.^+=
M!;2M"N7?ZC?^GIUQ]:_7N.M/J&R6/,K'.;!AS%GI5I;&*]@I%O*7$L.(7$(C
M<2S%\XR0NIB%=E3S_J+O-T1[59Z^>YI:M4"]919;'#),NHAZTA>M=("HH<=A
M2EU,8=P5Z'X4XGX3XXS5N3<*9C'>W[CJ9;WV%H_6>\V@:QHVN<0%\L.MS[D7
MWB^HCA";CKK:RK+LDX;A!^<GS;*P^5VR.")MV99Y7:FQQL<XDZE1WZS5YL3^
M=LY_HH#\Y>[7=WNBS[ZYEOG)O^77@D=9&4$5]%OOD1?3)^LU>;$_G;.?Z*`_
M.7=LI[HL^^N9;YR;_EU/O(RCZK??(B^F3]9J\V)_.^<PU_\`]4!^<FP=M/=%
MGWUS+?.3?\NGO(RGZK??(B^F3]9J\V'O\;9SZ?[J`_.3?]&GNBS[ZYEOG)O^
M74>\C*/JM]J_4B^FUI^LU>;$_G;.?#_=0&W7H_I)3W19]]<RWSDW_+J?>1E'
MU6^^1%],GZS5YL/^=\Y^K[U`:;M?[2;M*>Z+/OKF6^<F_P"73WD93]5OM?ZD
M7TR?K-7FQ/YVSG^B@.G3;_23II[HL^^N9;YR;_ET'61E!_X6^^1%],GZS5YL
M/?XVSGIIK_=0'YR:ZZ<*>Z+/OKF6^<F_Y=/>1E'U6^^1%]-K3]9J\V)_.V<_
MT4!ZG]I>Y3W19]]<RWSDW_+I[R,I^JWWR(OID_6:O-B?SOG/?I_=0'JZ^Z3=
M3W19]]<RWSDW_+I[R,H^JWWR(OIOC3]9J\V'_.^<]XA_=0'#7_ZDW;*>Z+/O
MKF6^<F_Y=/>1E'U6^^1%],GZS5YL3^=LY[M?[J`[G_U)OVT]T6??7,M\Y-_R
MZCWD91]5OOD1?3)^LU>;#_G?.>[7^Z@/SDW[*>Z+/OKF6^<F^@3WD91]5OOD
M1?3)^LU>;$_G?.>_3^Z@..G_`-2;MM/=%GWUS+?.3?\`+J?>1E/U6^^1%],G
MZS5YL/\`G?.?Z*`Z-=?=)NV4]T6??7,M\Y-_RZ>\C*/JM]\B+Z9/UFKS8G\[
M9S_10'J:>Z7?K3W19]]<RWSDW_+I[R,H^JWWR(OID_6:O-A[_&V<]--?[J`_
M.3?IPI[HL^^N9;YR;_ET]Y&4?5;[5^I%]-K3]9J\V)_.V<^C^Z@.G39_23II
M[HL^^N9;YR;_`)=#UD90/^%OOD1?3)^LU>;#_G?.?Z*`Z-?[2;M*>Z+/OKF6
M^<F_Y=/>1E.KT6^U_J1?3+M8C_J4?-HSCD6<?+9K.YZO6(BMC)NV.MH(@)$.
MWN@@+*!IKU2ZCIMW5QGBO@Z[X-RIV=9Q<V[LO9X;H&74Y8*5Q.;%;.<&_P`J
ME!M(7:_4YD>;=>G%S.!N"&6\?$LS:PQ7UY96#9W5INX9+FYCC?+M$8=C(TM!
M53?K$/F\]=.US?\`HT:](A_:CN5T>>MOJL`)]?6M0-6XOJ_!IM-?PKW>S_2Y
M^^ZX@?9",`D:?6>5TT[=%V='P5Z%\YF)?.C2UL>=,G^>"Z%)SWO[YNZ=@KIM
M]HB9Q)(88?(!"P,*A&$>HMG<E;D,P8K)$,IU#.V_7$>L81KR;DG62^+K8=QA
M>28,MN+AT<A.(AML[O&U:T%QW;0UU`TFHK0E?=3K&^X[99O]PBW^[/D$,,G&
M6497#<VLA<QHDSF.L\[]Z\48VZF?/&7$@".0-J&A?1G^L0^;SUT!7-X[=/[M
M&O2.W;=`;-GT:]:MZV.JY[Q&S/;5SR:`""^))V4`M*FNS:OA._\`TOOOM1QF
M6;A&-D36ESB[-,J`:`*DN)O*``:R304.E4G)?]2SYLR*='9.Y?-GA">Q4J&,
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M`IA>\UT'7164\S5YY.\>2.\XW$67I&2NCEUNF0;MW39PN9P\LMVX,F@69AS.
M#`5'L2Z=HEJ5-<@=4PE,!%";+BGA>RXQLA#,6Q9W$VD,QU$;(I3M8?T7ZV'H
MJ%BY!G]UPY=&2,.DRR0UEBYO_,C&H/&MS-3ATZ5^AG8-_6=E&SK?O^P+@CKH
MM"Z8UO*P<Y%KE7:/6;@@&*("&AT5TC:D52.!5$E"F(<I3`(!Y@S'+KW*;V3+
M\PC=%>1.+7-=K!'Q$'6"*@C2"0N][.\M<PM67EF]LEM(VK7#41^(C40=(.@Z
M56%82R4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41<-Z_9QR9%7
MKA)LDHLFW(=4X$*998P$33`1$-3',.RA(&M02`*E<L!`0`0W"`"'J#12IHB4
M1*(E$2B)1$HB418M\[__``<<TN[^X'+'?;O<3,[]VRN3\%?_`"_+-O\`OT/_
M`*C5HN)__CE]J_HLNO\`F%?DBO\`\(/MWWZZWZ#_``DVFNW?T5ZED_:.I^L=
M79U+H%G@CX!R/3S+B</F#T:Z]4=VW3M/V*IY<NA5?A^/_P#)3\[?PZOLMNFW
MY]1RY?B4<M'XO_$HV=S=T!IIU0X:]Y4]WEV4/+X/%4_.X[]/9#IKH.[HJ$VZ
M?C_'_P"%1_F]CKKU2[]!'U].7+H3\/Q__DGSM^S3J@.NIM=-NO6Z:E.7YNGG
M39W-W`"Z::%W;=>ITT'+ES\N9#2G1\5.C^3SJYF.)N>";80K9R9>,5,JHY:.
M1[5)LU2(HLNLU$3@=`X%)ZTI1`HB.T-1KS5]Y;@?JUS#J^S+C#BVS8,ULK<F
M&XB^;G=*XAL4;G@?.-<\@$/KHU$:5]2_]+;K]^]#P]]XWACJ3ZH\ZGDX+SO,
M!Z=EMWBN;&*SC!FO+F*)QK;21PL>YKH',Q$]^UY*R$.HFF9(BBB:9US]F@11
M0A#KJ::]F@4P@9930->J74=*^1>6\.<09S:SWN4V5U<V=JW%,^*)[VQMK2KW
M-!#1IV_#J7[&>).L7@'@W,\OR7BW.LJRS-\UFW5G#=74,$MU*`78(&2/:Z5U
M`=#`>;7145D&6F86#2=PQR-S"[,W?..S!1R@BLE^]SMP.`I)""J9BF.8-2B8
MH!M&O4OW0>#>KGC/BZ\L^,K;TK.K6%L]K%([YAX:[#*7Q_O',)80TFE"200"
MOE'_`*R77;]Y3J-ZELFS[J0S+U3PAF>826&;7<$=;^%TL>.T%O.:BWCF#)F/
MD#0\.#&M>TO"QH45475,LLJ=990PF455.*JJAM2]8QE%#"<XC]4(B(C7U?AA
MAMH6V]LQL=NP4:QH#6M`U!K6@``;```.9?D"OK^_S6^ES/-)YKK,YWE\DTLC
MY99'GPGODD+GO<3X;GN+B=97JX<-P]&FG5'I'O.BKNFO+E58FC7HY?\`A7EQ
M'U0WZ#QV:[=_14;.7+X4V\OC_$HX?,_T===-V_3KTY<NA/P_'7QE/'YH[M.D
M==-N_IILY<O@[J<OS?C781DO)0JX.XQXHT5T`#=D(=DJ30/6+(B)DU41Z#!J
M'#3?6BXCX7X>XORQ^2\36<%[EL@(+)6AU*Z*M/A,>-CF$$<Z[#ZL.MSK*ZE.
M*H>..JK.[_(^)H""V:UE+,;0:X)8],<T)U.CE8]IYJZ5EK'JNE(UBO)%20?'
M9H*OP('8HIKJ%`Z@=4YS`D!.L`&]=U0$!TV:5\1NLC(<ABZS,RX<ZN8KB?*(
M[UT%NP5FD>YIPN#*#$]N\#@S026T7[N_NV<?<?WGW8>&>LC[R%UEUAQK<Y%%
M?9G,0RSMX6RM,K#*'OP0O$!C,PQ!@DQAH`H%[EC+':+*,!;K+G;+'8G,(K-E
M5NR,9OH9`P]L0Y]`#JCH.N_2M9PWD5C8<>6.1=84%U:Y9Z;''=,(,,K&.<`3
MW[:MI4$FG@U(7)^LGCC/^(.H7/>.?NZWV4YKQ4<DN;C*)VN;>6<]Q'&Y\8&Y
M?AEQ%I:UH?0O+0[14+$R:G)B;=&5EW2JRJ9S$*W$0(@U,0RA3(MVY3"FD)!`
M0'8(CQ$:^X7"7!W"O!.4LRCA&S@M,M#0?FQIDT"CWO\`"D)UXG$K\&W7-UW]
M<'7SQA/Q=US9UF&;\3;Q[<-P\B.V()#H;>W%(;8,(+2R-HU:22*KI@^9QW:;
MO6[MNO5Z:Y0NH]G+XNCG3YV[CINT-OU'O.BB<OS_`,GF4]&[?QZO2737;WW1
M4)R_/T\RCA__`"[^J.P-1[^IY<NA.W7X_P#\NE3\[>&[3V0:Z:CIITU"#H^+
M\7_B4;-.'>]`=73JCPU[RG+ETIRZ*>*G'AOX]7V6S7;\ZG+E^--O=_'_`.%.
M'_=KKU0W[=.O4\N70G;K\=?&3C\_=ITFUTT'?TT3E^;I_63@&[<&[JZ::%[H
M^LZ:CERZ4[7+_P`/.GSM_P#H])M-=![WHJ4V<OCZ.93_`);>KKKH7?MUZ_13
MERZ$Y?GZ>91_ELZNNNAMVW7K]-.7+HY<Z<OS=/.GSOG%Z2ZZ:CWO34)R_-T<
MZ;-N[=Q`---#;]H>LZ*GERZ4&KHY?]WF4_3#?ITAIKJ._HHFWE\?3S*/\_1O
MZH[MNG7IRY="=NOQ_P#Y)QX;^'5]EMTV_/J$UGN?B_&FS3ANZ`TTZO1KWE3R
MY=*<NBGBJ0$0$!`=!*;4!`0`2B!A$IM0'8(#WO14$5%"*@\OSJ6N<QP>TD/:
M00:T((T@U&D4/@D:05?[&,U/2R#]&1<>&,(XC=)!RX#K/"N%=I6IEBFU5(")
M#'U.!AUX[:^<_P!\W@;JTX;RVSS[*[1EIQIF%TX4A(9')$T$RRR1`4Q8G-:'
M-`TG35?ID_T1^OS[T/6GG^><!\89Q-G/4EPYED5)+X.GN[>ZF<&VMI!=N.\,
M>[9)(Z.4R4:WO2%=/K$[0R7:)BL4A5#H`H05R)FZP%4.B!NU(F82CH80`HZ#
MH->$)>'.((<G9Q#-973<BD>6-N#$\0N<-;1)3"3V5]_K;K%X!O.,9NKVUSK*
MY..[:!L\N7MNH77D<3B0V1]N'[UK20:$M5FLHS4ZQ=MH]LX%G$O6/7`6VI%W
M*A1!)XDX<:@;J%.`#U"::$.&NNHU](/N=\#=669\'-XQBLVW'&UO<OBG?/23
M<N!Q1F!A&%F)A:0^A=B!`(II_,S_`*U77[]Z/A/KD]R\F=2Y;U%YGE4-W90V
M`=;.O6.!BNF7T[3O)MU.U[3"US8MTZ,N82]62V!T<-^FFGKM^W7J=%>Z*DZ3
MK7P!``%!0`=JG3T<R?.W\=-=1ZFFNWONBBGE^?IYD_R^IUUT/NV]_P!-1RY=
M"#L\N;^5SJ>/#_\`+TAKU=N[IJ4'1R^#HYU'#AN'?IIIU1VZ"(>LZ*:>7+6G
M:IR_[JGB/JAOT'ZH--=N_HJ.7+\?=3E^?\2CA\S_`$==>KZNG7IRY='+4FW;
M7X__`,E]`WF:_/*7CR1WE'8AR](R5T\NMTR2+9RU7<"X=V8\<*%0+,0HKJ]5
M,R8=4%4Q,5-=,H%,(&`ARZ+BCA>RXQLA#,6Q9W$VD,QVC9%,:5+#^@[6PGFJ
M%NL@S^YX<NC)&#)EDAK+$.?;)&/UQ^DW4[X=*_0WL2^K3R99UNW]8LXRN2T+
MLBVTS`3<<IVC208.BZIJD$0*<BA#`)%$S`4Z:A3$,`&*(!Y?S"PO,KO9<NOX
MW17D+RU[3K!'*H.HC2-"[WL[RVS"U9>V;Q);2-Q-<-1!Y4(V'055E8:R4HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$4"(`&HT4$AHJ=2G4-_#IHE12NQ<*0
MD&<6R<R#YPFW:-$3KN%U#`5-)),HF,8YN```?/V;ZFA4ZS0:U@;S$\S"MFH6
MNW=1H-+/OEQ<$`UD'BS=@Y2FV\$O*VXG).W1BH0K:X5FYD$%##URF$HCH&NF
M%>W7HC06BH<TZ>FE1\%=6M<AR+(CG$<Y9(!-$P/PC66D@&G.16NA5EA;F8B[
M_/:I4_"TF]P22MJG;NRJ*D3NEC'*O'R<7*F230EV"*[99#MDNLF<R0B41J;.
MZ]*CQ%I:X:Z_B[*P,YRR;)KMMK-0M>*@ZS2FBH%:'G"S,`0'<.M9=*+6THIH
MB41*(E$2B)1$HBQ<YWO^#CFE_P#^`Y8X"/\`4F9X!MKD_!7_`,NRS5_3H=?^
MT:M%Q/\`_';[_P!K+_\`05^2(_']_O=O\-=!O'BY-L[H#]"O4LA!>[5X1_'R
MHN@&:&#X/A_/7GV+B</F"&\?8CLUW_-JBJKZ.Q^3_P"Y3KW>/2(:Z&]39I]&
MFA1K//R^*GQKQUV:Z\-==OL0V_YJG1RY?&GY_P`OY%Y:]WIXB.FHC\_7Z%1H
M35RY5K\2C7N]`:`(CIZTNS4?^WA30G1V/R?E377CKMTWCMT$VS=LTZ>--'*B
MGERYJ<^U->[W=X\`+MTTV:='&FA1^?\`+^3:JKMBZ3VN226:,D7$B]21;H.G
M!SF1:(%.HJMJV+IX0=58J8@`B``!1UWUUGUE=6.5]:5M991Q#<3MX;MKC?RV
M\1##<O:`(VODUMC95SB&Z7.PZ11>K?NM?>OXG^Z1?Y_QCU<9983]9^:Y<VPL
M\QNP9699;O>9+J6&VT-EN9G,A:PR'!'&V0%KL=%TLE+R4LZ\-D7J[ER70J9S
MJ&`$"@8IBIMR$`I$4P,.H`4``!V[]:YCP_PUP_PKE3,DX<M+>SRJ,4$<3`UI
MT4)=M>XC6YQ+G;25TCUD=:G6-UO\73<>]9N=9AG7%T[\3KFYE<][.^+@R$5#
M88VDU8R%K&1_HM"JIK?LB,0_@IHHS#)XT5;)K+*F!^U.8O614[<P&\+!%=,I
MP[74=0U`=U=9WG4;P;'QS9=8O#+/5/$MK.7R>C@-@NF.[V5DL0HT%[21B8&T
M-"03I7J[(O\`4!ZZ;KJ#SS[M/6U+]L>J[-LOW%L;][GYAE<\1$EK/:7CL3Y&
MP3,8[=W!?5H+&O:#14)KNV\>D0UT$NW=LT^C7<^A>$A7;KY?@YMJ:[`V\!'7
M;[$=NG=Z*G17ER[*GE^7\BG7NCO#B([Q#Y^OT*C111RY<]?B4:[-_P!3IO'H
M[W7?IKQIHKRY<N=.CL?D_P#N4Z]T=X\1#<(]S9I]&FBB<N7-3XUSHMTW9R#)
MX[0,[;M7*3E5L13LQ7['JJ%()C%,!2F4*'6+H.I=0K79Q:76895<V%A/Z->3
MPOC9*!B,1>"W&!H!<VM6U_2`JN6<"9WDO#/&N5<2<1V'K7([#,(;F:SQ[H73
M8'B3</?1V&.1S6MD`!)C+@-)"[^XKUFKB,HFNOX)'B;4D:S$Y&X%`QA)VX]^
M[.`:=^(E`0`0*%=<=6W4OP%U76U>'[429P\?.7DU'W$A.EW?G]FTG3A90<Y*
M]+_>A^_/]X3[V&9.;UA9J^TX'C>#;9+8ET&6V[6Z(\4336YD:V@WEP7D$5:U
MFI>BWKOFK;4+X$X[9IJ/:1SDQU6INL!=>S`?7MU!$=>T3$!UWZZ5G]8O5+P+
MUHV/HG%=FQ]TT4CN8Z,N(NED@TD5_0=B:>:NE:+[M'WROO`?=.SX9IU2YU-%
MDCW@W&5W),^6W0VB2W<:,>1JGA,<H.MS@,*ZR:?H2DH\D6[;P,CU;P@S8#]8
MJ:R@&,N5(2E*!4NUU$O'0=M<LX7RBYX?X>L\CO+IUY-:0-BW[FAKY&L`:USP
M"1CP@!U-!(J%T]UN<:Y3UD=9>=]8&2Y5'DECG5_)>&QCD,D-M+.=Y-'"\@.W
M(E+S%B&(-(:22*KJ]>[M'4=X[=.KMTX:='&M[H776SEV^QS;4UV[^[O'H-MT
MTVZ]'"FA.7Y?R;%.N[;IIW1V:B79NVZ]/"FA!RY;:\^Q1KLW[]F\=OK1V:[_
M`)M-J;:=C\GY5.O=WB'$0UT$.YLT^C30FOERI3XU&NX=>&NNH^Q';IO^930@
MY=VGXDU[O'I$=-3>IMU^A30FH\N1K\2</F`&FH^Q#UNO[-$Z.Q^3\J:[=^OS
M1X";9W-/HTT)RY<U/C37CKT#Q]B&WN#W*:.7+XTY?E_(FO=XZ[Q'>)]NFFW7
MHX4T<NPIY<OAYMB:[=_2&FHCO`NS=MUZ>%-"CE^3\NQ3KW>@-XAN`VS=LTZ>
M--"<OR?EVJ->[QUWB&X2[=VS3HXTT*>7+FIS;4UW[>[O'H-Z[33;ZE-"C97E
M\/Y%.O=TW!O'B(;.[K]"FA.7+GK\2C78&W@(;Q]B(]77]FB='8_)^53KW>/2
M(:Z&^AI]&FA-O/R^*GQJ-=FNO#77;['?IO\`F4T(>?E\-/Q*=>[N$>(CIJ(]
MS;K]"FBB:N7*M?B5;,+X>PT`C"PJ";)8QUU7TD<0<+JJKB`!X*0Y.S;@5`A"
M]8>L("`Z::UTYQ+U*<)\;\=,XUXUQ9BRV@;%:VCZ"VB`)<Y[VC3*][S4AQP4
M#06FB]P=5_W\.MKJ&^[_`"=1744V'ANZS*^GNLVSJ([S,KM\@$<4-N]PP6<,
M,+6M:]@=+B=(YKV8JBEDY.12>^,DG[PDAUQ/X:5RL#DQM3:]983=<P"&P=1$
M#!L'97:4^491<Y8<EN+6W?DYCP;@QL,6"@&'=TPTIJ`&C9L7D?+^-^-,JXK;
MQWEF;YG!QLVXWPOV7,S;S?5Q&0W(?O2XG2YSG''J=4$@U/.7HXN2';L)9HBI
M(LW(+MI1`.Q,9,Z?4<)N&X!U`,H'5'UG5`PE#4-@5UGP+U.<.=6O$U]G7!KY
M+7)\QB`FLB<4+96.K'+"22YE`7M+344=H(I1>JOO`??<ZQ_O1=5&1\"]=UM:
MYIQQPU>NDL,^8T0WC[6:/=W-I>QM&[FQN9#*V5F!V.+OFG$2J*U[N[0=XCIK
MUMH!QUZ.%=N\OP+Q;R_+TUYMB:]WCIO'CU-G=UZ>%-'+LIRY<]>?8@CW>&F\
M>@^S=L]7C31R["#EW/R[4UV[]XZ[Q#702[=VS3HXTT43ERYJ<VU->[TCQ]B/
MKMF\>Y31T<N6M!R[O_VJ>.\=X<1'>(=S;K]"HT)JY<JU^)-NFX=W5`/7:ZB&
MPNNFHZ]-3M[/+E^-.CL?D_\`N7TQ^9,\R;.<U4Y"<R?,G"OX/E]@GZ;VVK:>
MI+,Y#*$BR6`Y$TRJ`11&W$%2:+K@'VSO">NU$O$N,.,+?A*W]'M\,G$<C:L:
M:%L#2-$D@TU>=<<9U:'.T4!Y%PUPU-Q)-OYL3,D8ZCG#09B/T&'8T'0]XU^"
M-I'WVV];T':<'$VS;,2P@K?@F#:+AH:+;),XZ-CF:146K-FU1*5)%%%(H```
M'T:\TW-S/>3ONKI[I+F1Q<YSC4N)TDDG62N\X8(;:%MO;M:R!@`:T"@`&H`!
M=Q5E74HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5L'=R7RNN\;,+/(3Q:_1
M(9RM*M^SD61A-VAF)!2`PJ@GIKKL*.S;4#&:$"HV]"S&PVE&[Q]<0.BFEIIH
MK\.FB]<A/9%%$$8^SFJ:ZSE1-)PI--%D&Z'5`R3APD5(A^JH?4I@#42".N@U
M!QM%0#2G+E\*AL67Z3),2T"M,)TZ=0Z58G)^09):7<0]R1K>%M:T4&\U/F5D
M4>I)NCG,6-;'."14U(Q%0@K*%'01$A==2Z@,1%\TXB:T@D:-5:[%C7DV5Y?;
M>F7DXCM]KB-`UZ^PM6N8KNA\C7+(V-+W98=N.Y>[&LY(P%]2O:)7/&R,.[;V
MY(6.[DB+1S>-&-!5/4`242>B.SK=37'M<VLX;B>QN\,5ZV5N)L@'?#F;74"=
M2R,QX<XAXEM&\0<&0RWN0Q6KV,D@<YCV2X15Y+1I%'4+3^$+(+"4//6==EG0
MEV76T9^09#3#%W<#N&:P"L8V0>LK;+;35@"7:GDG<TLB/;:.CD;=;J:"&M<(
MO9;A]&N+2[O1HHT='12NG6J<WN[:ULK1H=`UFXC,KB7!V^`HYN)^T$:1765M
MHB+IAY$B!4GI3*K%3*!SMW+5%1<P:B1(7**0"8XCJ4-XA64Z.6,X9?".E8K'
M-D:',((.G0:A535*J2B)1$HB41*(E$5%Y'L*`RG8%Z8UNLCM2V;]M>;M"X",
M'/@;T\/<$<XBY$K1UU%/!W!FKDP$/U3=4VW0:S<NO[C*[^',K7#Z3!*V1M14
M8FD$5&T5&I8U[:17]I+93UW,K',=0T-'"AH=AHM+AO\`ISO-CG.90^/\@F.<
MYCF,-_*:F,<>L<1'Q3]6(ZC79!ZX.)R2XPY?4FO[$Z_.+@XZMLB`H);V@_\`
M-'B=M>/ZN7YL3X/<@?E\INTW?@G=4>][B;R&7^9/CJ?=OD7E;RG^U&KF\#4G
MZN7YL3X/<@_E\KMVZAK_`"3PX<:>]_B;R&7ZO(GZ1/=OD7E;WSH['Z&S8GZN
M7YL7X/L@^KY?*;]--?P1OI[W^)O(9?YD^.GNWR+RM[7_`&HU\_@:T_5R_-B_
M!]D$/_\`/E?F_P#I/'C3WO\`$WD,OU^1/CI[M\B\K>^='B;4_5R_-B?![D#\
MOE-W1^"=U/>_Q/Y'+_,GQT]V^1>5O*?[4:N;P-2?JY?FQ?@]R!T#_3Y7:'`!
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MV+\'N0-^ON^5V=/_`*3QI[W^)O(9?K\B?'3W;Y%LEO?.CQ-NU/U<OS8N[WO<
M@:='E\IN]C^">][E/>_Q-Y#+_,GQT]V^1>5O?.C5S>!J3]7+\V+\'N0/R^5^
M9_Z3PI[W^)O(9?J\B?I$]V^1>5O?.CQ-FQ/U<OS8OP?9!_+Y3?NZWX)TUV4]
M[_$WD,O\R?I$]V^1>6O:_P"U&OG\#6GZN7YL7X/L@_E\KOZ?P3QUI[W^)O(9
M?YD^.GNWR+RU[YT=G]#;M3]7+\V)\'N0/R^4V!LV!_).X=*>]_B?R&7^9/CI
M[M\B\K>^=&KF\#4GZN7YL3X/<@?E\KM#;L'^2=P:T][_`!-Y#+_,GZ1/=OD7
ME;WSH[7@:@GZN7YL7X/<@_E\KM'9H(_R3O#2GO?XF\AE_F3](GNWR+RM[YT=
MOP-:?JY?FQ?@^R#W!\OE-0';M_!.\=:>]_B;R&7^9/TB>[?(O+7OG1V_`UI^
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MWGG1JYO`U)^KE^;$^#W('Y?*[=^@#_).HZ:T][W$WD,OU>1/TB>[?(MLMYYT
M>)LV)^KE^;%^#[(/Y?*;PW&_!.^GO?XF\AE_F3XZ>[?(O+7OG1KY_`UI^KE^
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M7+\V)\'N0/R^4W:::?@G=3WO<3>0R_S)^D3W;Y%Y6\I_M1JYO`U)^KE^;$^#
MW(/Y?*[=NH:_R3PI[WN)O(9?J\B?I$]V^1>5O?.CQ-FQ/U<OS8OP?9!]7R^4
MW]/X)WT][_$WD,O\R?I$]V^1>5O:_P"U';\#6GZN9YL7X/L@AQ#^GRNSIT_D
MG7;QI[W^)O(9?YD^.GNWR+RM[YT>)MVI^KE^;%^#W('Y?*[N(?@G<-/>]Q-Y
M#+_,GQT]V^1>5O*?[4:N;P-2?JY?FQ?@]R!^7RNT.`#_`"3M`*>]_B;R&7^9
M/TB>[?(O*WOG1XFQ/U<OS8OP?9!_+Y7:/`?P3O"GO?XF\AE_F3XZ>[?(O+7O
MG1V_`UI^KE^;%^#W(/3[OE=@[=1#^2=@C3WO\3>0R_S)^D3W;Y%Y6]\Z.WX&
MM/U<OS8OP>Y`_+Y3=LU#\$[ATI[W^)O(9?YD_2)[M\B\K>^='B;4_5R_-B?!
M[D#H]WRN[;L_!.X-:>][B;R&7^9/CJ/=MD7E;VG^U':\#4GZN7YL3X/<@_E\
MKMZ!_!.\*>][B;R&7^9/TBGW;Y%Y6]\Z/$V;$_5R_-B_!]D'\OE-_LOP3IK3
MWO\`$WD,O\R?I$]V^1>6O?.C7S^!K6@'S^'FS^4_D+Q+AZ<Y>+2G(67OB]7,
M;./9Z?4G%/`63(ZR:#+K-&H-@65/JIWPFT#33CV/P1Q9F/%=C>OS*.V8^!\6
M$Q1EA[_'6O?&NH4"X3Q9PY9</75HVQDG<V82X@]P<.]#:$=Z*:S54AYDOS)D
MWS53D'S)\R4(^@N7V"?)/+:MIXD=H_R?(,SE.5)(IRE42MI)0OVY<`]?IU">
MNU$M7&/&,'"4'H]OADXCD;5C#I$`.J20;7G6QA_G.T4!IX:X;FXCFWTM69&P
MT<X:#,1KCC/D_P!=W_9;IJ1]]UOV_!VI!Q-M6S$L(*WX)@VBX:&BVR3..C8]
MFD5%LS9M42D21012*```!]&O-%S<W%Y.^ZNGNDN9'%SG.-2XG222=9*[S@@A
MMH6V]NT,@8T!K0*``:``%W%65=2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(HT#H#;M'9OI4HO$>H&@"`;>YZ@=&G&A)'.E*C#L6M[.T-&W+EN19R#I@@
MF@_B'C1K<Z9VMM7`"$<FWD&2<LJJFU(XC^KKU.J<15.4---:V-JP11>DR%@8
M[41ID!&D4V@$Z-&Q<9XBX>;G;8GO.-L;J[LEPC>*T(?0BO0#4+"_+E@8FF4R
MV;)6O$WB\8R+4UE-)2?A58ZSEDGZ2KQT]R*P`D/!6DH9<$UV+DYG1^U`B"?:
M&`Y<#/(;',XFW%XV)TP(J[#A<:$;=96_ZK\SXKX'S*YMN'I;J#*Y1AW`=O8^
M^!KNV@>"*UU5"MA"W7EVQ)Z6MC+%FA$+2=T-XZ%SBX81MP6-V(LI%O;5H.X]
M=<Z$1;A6C1)NQ4,J9<CA93MBB(@(Z>VSEV7WH;F4+FV6(-9(UQT`Z`2.:FBI
MU%<VXWX+RC/^#X<]X3S2!W$$;723P2QASG/))(;&?TBXTT4HW2M@6/9"^6<3
M==V3#5*UXQ*W1CVT"BY2(V6N=),C5L[:QQ$C$:>%/^H1`"*`F;UHE+J-<FOG
M0:&P/QMUAU--#SE=+<'.SZ82SYI"RUA-&[O3I>T`.>-/>BHU#05LK@3.CPL4
M=\!RO#QS([H%->T!<S5(50.`CJ!P4U`>[6O7.O@7;41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:Z.=_P`WU97/5?G+R;*[
ME)?%6';EE[SN*V$Q5(_NV6*BU3@HCM2`";>),J"AG9A'KB0H%(`"/6#GO"7&
MIX3RN^AMHL>97)CW3G4+(RW%5Y;^DX8N]&JNDZ!0\1XCX7;Q'>V;YY"RR@,A
MD:-#GAP;1H/Z(-.^.NF@:ZK/^WK?@[3@XFV;9B6$%;\$P;1<-#1;9)G'QL<S
M2*BU9M&R)2IHHHI$````^C7"+FYN+RX?=73W27,CBYSG&I<3I)).LE<I@@AM
MH6V]NUK(&-`:T"@`&H`!=Q5E74HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HBM_DEB_>6RZ\7-U'RR!@<'C2+"V"0(EH)FYG)3I"B(`'6*(FTZQ0U`
M:N0X=ZT.\$GE51MH-JX]M1ULEM"*1D'#.9;KMS&.\FS-7J[QVN)U7(*G>&6[
M5V!RB4P`(B/4JA^\W[PX4.C1S?`IT^""37EVUKWS7;D=.R=W-K7!_;UMMH=$
MJJK*UH^>>3+)P@NY.PMIBN1>,.^7<'7T573.H0IR]0P`72L2ZMVF/&YP+6FM
M*5.G8.G\"V.0W-K87C,4?SP?WKGN+8P2""74[Y8H8$M><O.Z,AQ,DW-$SR<?
M;$TJC<-QDDH20L>=E94LA=*"3`[Y`MQH+MQ2$X*$%)1(IA,0Y>M5V>[M<S8^
M"U90X&GYP`C"*UPTJ!I!6MMN";SAF2'/[^:.:U-Q<8'6[G`[QSJX)"_]HQK2
M"T]A;+[!MIIDF4A&T0FJ&++"<M3^''[55G>DY$@5./9,'#@3K2$'#*D[55P8
M3E<."E`IA`O6JMH#6-CT5:!55RN,KR]YJ\DD]SF6:`;`WZ]T=X_.T"JE2E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41>)R%4*8ARE.0X"4Q
M3``E,40T$!`=@@(416BD,11TFHJT7E'3>W!"0(G;S)LT0:]E*@0[L!=]0SU-
M8'*8*)J)'3,3:&T!&LIETZ/2P#>:*N-2=&H<R#O:@>"=/97G>.*$+B>,I>#G
M7EJ2[%J++K,FC1W%2#4.L*:,I%."@FKV0G'JJ)'15`-G6$NRL45K4D]U!T\M
MOX5:2V^4&PX^7;3%Q/W4Z5I&'AT;=CVC:V;2\6GDU9<6CF(B>HO*-S2*QEA3
M>+N$^N(B!0JU%#'#7`/R#73X*K+GO[RYCW,\CG0A^*FS%2E>TLK6;)I'-D&3
M!L@S9MDB(MVK9,B+=!),.J1-%%,"IID*&P```"KJQ%RJ(E$2B)1$HB41*(E$
M2B)1$HB41!V;>BJ7.#&EYU`5[2+'*R^;3EZO:SK?OE#*5I6O"75<5QVK;A,@
M3D58<K-3EKWK*8]DF<;$W.]CGSTZEUQ"K5MV1#>$F$G9Z]<NM^*&29MH81C?
M>VEO<Q-;I>Z*Z@%Q#WHJX.=$<1;2HHZO@E8S+J%[KH5(;9W=Q;RN(HULEM*8
M9N^.@M:\4Q`T.@UTA4]DGG6Y=L.7(VMC*]]QV.WDCE:V<,PKR[W\-"1<Y>EU
M6XWNA@2,>/95/KQ36-=$!VZ5*D1NJ8I3!H8AC18Q',;B&SMBWTN=MT6,)`<X
M68!E(&W$2&Q`5,DGS;1C(!NYI(W*+7TV\#A9AMN2\`EK?29'Q1XC30&ECGR$
M]['&#(XX0XBXC#F$Q(JQ6D9Z\H"Q&9LBS6+(=>_I^W;52NJ\(1X9DHPM-60F
M"I3YI!4@BT(@87"Q0$>R#32HCC?)Z,Q@)N;J,OCBI\Z0USFGO/"J"VII6@()
MUJ].WT??/D(]'@;$Y\G[L":-DC"7Z@")&BIH"[0*Z">C@N:[EXN+)^7<.1V7
M+##(F"V,;*9/MUW=4`T>6Q%R$826/)O4EY(JR<=$-5"ED%SE*DP5.4BQB&,`
M#CP317-A-FD3@;"WN702/_1;(UL9(+M0!,@8UQ-'2-D8.^C<!7/#-;7<-A,U
MPN[BW;/&VAJYCW2M;0:RXB%[\(J1&62>`]I-P5,LXZ4QG+9AA[N@KLQO#VU-
MW:K=EER;&[8=]!V\R=OY-U#OX%P^:2PHH,E``J!SB8Y>J'KME4YI.,GM)+R_
M;(R*./&1@<7%I%06MI5V($8:#OJBBG+X3F=W'96;F.FDE$8[X!H>2&T<ZM&T
M)[ZNK:K%81YXN77F'LOE[O\`Q3=DC<%M\SC:YW&+EU;=EXUXHM9L,M.7+&73
M'/VR#VT9>*9-S@HV?$25[0.J`#J&NTN\ON;','9;<`"<9>;VM>\=;B2WB+VO
MU$A]S$TM&D'&"`6.IJ&9K920"X8XEAS'T&E#47&[N)<#AK`,=M*X..@C!^NU
M7NB\TX<FXJXIZ%RSC.7@[0E0@KLF8N_+6?Q5KS@KD:A#7%(M)55G"2HN5"I^
M#N3I+=H8"]74=*P:CT>.\J/1)JX'_H/PZ\#O!=3;0FFU;412FZDL0UQO8FXG
MQT.-C:%V)S/":,()J0!0$ZE4]HWG9^0(!E==AW7;5[6O)=J,=<EHSL7<D!(`
M@J=!<64Q#.GL<Z[%=,Q#]FH;JG*(#M`:NR12Q8=ZUS<30X5!%6NTAPKK!&D$
M:#L5D.:7.8""]CBUPVM<-;7#8X;0=(VJI:MJI*(NCN*Y[;M&,/-79<,';$,F
MX9M%):XI9A"QB;N1=),8]J=_).&S4KA\]7(BB03]954Y2%`3"`4;W\K(6Z9I
M'86-'A.<02&M&MSB`305-`>9#WL;Y7:(HVESCL:T:W..H-&TG0%RD9B(<2;N
M$;RL:O,Q[5H^?Q*+YJK)LF4@9<C!X[8$5,Z;-7IVJH(J'(4B@IF`HCU1TD`E
MI<!5K782=@=2M#S&FFFNFG4I(+0QSM#9`2W^4&D!Q;SAI(!(U$BNL+LJA0NK
MF)N%MYD,E/R\7!QQ5VS8S^8?M(QD5R]<)M&;<73U5!`%W;I8B21.MUE%#`4H
M"(@%&]](R%NF61V%K1K<XU(:T:RX@'0*G05#W-CC=-(0V%C<3G'0&M&LN)T`
M#G.A=*&0+#%O<3L+VM$6EH2H05V.0N2&%O:\V(-1"'N)8'O9PDJ(/4?WNY%)
M;[<3UOKBZU1L?,(G1`N;,\MC(%=XX.+2UE/"<'`M(;4AP(.D*7=X]T3]$C&!
M[@=!:QS<37D:PTM&(..@MT@T701V:\-2]]O\6Q.6\92F38KM_&F.8Z_;5>WW
M&^"E(=SX?:+:55N!GX.10HJ=HW+U`,`CIJ%1`#=1OEMOG(HR<1;WP;0X3B(J
M!1V@UU'1K4S@VKF,N?FWR`%@=WI<'#$TM!IB#FZ12M1I&A7-J%"41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$6$?.%S+Y1P3<'+38&&\:6+D>_P#F2R_)
M8LB"Y(R#<&.;1MDD3CN[\@NYR3EK8Q]DF9=@+>U#-R()1^TRP&$X`708M([F
M_P`V]66P9WN7W5VYSB1WMMNJL:`#5S]YH)(`IIUZ,QT,$.17>=7#W`6\]G$U
MC6@XG7=PVW:22X86L+L1H'$TH`L1('SFF9<I!@FS<-<O>-WF7\EY7YHL/7O%
M9%S9-V_C6U;FY4VBBUY/[1OVT,57R]O6`N9PB8D8X4C([J@(>$`D8IREJ.&5
MD>86AKDS^&FYS5]&2B(W<%IN<%3&'A\V+&91&YC0X.(=HUEQ*<ODDL+^GK5F
M>19;2*KXL<ME<7PE+J-D#6Q087,W6\:]Q:6C#IY<?YWJS(K$W+KS&95Q5+8S
MY=LWQF4K9N'([VX$YDV-LZXXDYB.B,</&$?$>"7!;V5%K8DF]M3K9T5-\^3;
MMQ0(9TF-7KYD5K<NM82]\]SE,%]ES"TMEO-ZT/?:F/28KID<D<C8SB$C!,YI
MI&,63';W9,L<HB$MAF\EC?D/Q16[01&R\9)0"6U,WS<KB&.B+XB6FK\&?&,\
MU9#N#EEB,\9%PA=%IWK)V2]OLV"[2<FO>_46:Q',A;5KI)JL;>(O>TK#"V%P
MR$J:;-ZL=`RI@2%0;F<VCLIG-E$1<7K!&R0,(#!.0T2,;(2&F.*0EAF-&EK3
M)3#16\E?%G<P=&YL&7RS/W4DQPU@#CNYI`*X#(P;P,!<0'-;7$2!A!CCSGES
MW?RKRF;KLY<)+'F7GG-E)<GME8!DL@1<R]>Y/6OYK8]LDNJ]8J'/$PC3J.32
M$N9FA(E8-VRQ43.3@4#'V4DPR"WRN6&:^SVQ=<MJ7,AB$++J6X)?A+WQQ1VD
MA#A&'2.+6M9I!5,MS:V<V<29B9(<MRA[0YV&LLF]%L(&B.H#9)I;J*-K7/HW
M%B>X`&G"G_.C3&-FV1<99<Q/9-K<TUC9JL#"3&R6686Y,*W$\RA8\EDJULC&
MS#=MIVF_M['$59,%(NYE9]!IOVBC`Z*3=<ZJ/7M6\)S.TM;C*RUN^EOHY=^<
M#;?U>&&9[RS>%S)-];MMPP&1[YV-+&T=2\YDEG/<>LF.]#BM;6XC=#1[IVW<
MQMVQ1M>8P)HY6R"4.<V,,C<\/+0MC6`[XO;(V-8B[;^:XG1FY-P^%%SA')3S
M+6-)6+27$C"4MV]W]JV6\DDW*8""I3QZ/9*E,4!,&AAN74#(-V&B42.B:Y[7
MMPEKC70W2<3"W"YKM%0[4%AVTSIS(28C&V0M:6.Q5``KBT#"]KL37-T@4UFN
MB\U8JRDHB41*(E$2B)1$HB41*(E$2B)1%`[0$.X-6Y6ET3FM\(M(^)2-:T(6
MWYN3)SW&-WQ>0<2X\G[W;\JO.?CC';N:D[5G5X')68L_71D7'1X:1=$7)!+.
MX=VR=&D4^S%@X*!3'*<@UFV<K;7([6"/O,TBM>%8RYM01ZKM#'>M#QLCEIAI
M^U&EM0K>1,;#Q?%<YN`_ADY_G-U*P]\UT-]?1R1.='^D9+7>M>P@X0XL<*E>
M:_(WGU@XNB_[APK:66Y^,YN.53.47:,A<F/7DY>UJXYY;,;XIR.+&;O%=&"B
MIMI<\,\.4C]TV!\BU`Y3^O3UW3<SLK;-;.[A;6%M]Q`'$-`,,6:/?Z-<:=)$
M56ROC961I'>-+Q18O$%F[-<F@L;=^%UME.5,PG%227+[^[N9+;F`EAE9&R1W
MS??EKJ-Q*S6<.1;G?FL=Y0L.R,701H_)^8^<J]HQY:\ORW.;QM];,626ET8U
M>7+/9MMF\H^W\?N8)-0\@6T$$;N;2:3?LG"213C7'X8XS:Y39SO.]L;/+VEV
MD1%UM>SS7#9',`N2\QNC=;;MS8R72MG.EH6]S^\%]=WUS8M;Z/=V;(RUU=XU
M[<HMK1FZ:28`T3QRQS&4/.`1O@`TN5\<T<C?,!<I\YPMDX\CX:9RQ9'*K=ZN
M9;6D\*DG9*?P8UMUIDS"DXAD.(N-25D,EC#F50?2D7*6VY$0"0,`:@:;J1GK
M6\NK5A%@SBF7,(V-$8](MYX88FAC'-,;9;:2-T^&8,:XD&-^\+B-?DV*TR:S
MM<P#)K\\)G*WEY>?1[EANGMG+V]^YCVSLA!A<9!@.)N`-*RCY=>6V_+.Y.>8
M?'R]L97M[(>84\N2+>TLRSO+4+YM<=W6B:"8A#)\K4';6&;7MN6>ID5!%LU2
M5364557VFJWG#-]D=KEMH6/=%B=KD+P7W3IW->Z0D$-J=VV.C&1X6-`((3(R
M+3B63-[LR!CYK<FN`L#888X@8V,`(J&=^7]^]X+JT(6&C#S<7,_:.1<+QV-G
MELVIAZX.6:\O?=;EN)NW?XAYL9#E[A\..9ZS&S#4\O;>3!2(M*JLBZHOV"KO
M;X2`5D<2/&:9AQ&RV?7+I8+L98[2UV"]S2SO)K1XIB9$WT5\L3G&C?2'0@!K
M!7%MK?=#AZ^(`O;/,(77S-8>RVLLP@M[EKM`,S3=MA>W6YD<;ZDAR[PG(_E[
M*$*LSF.57'V"K6CK+Y5<2W-BHMX8\GXC,A,2Y_M;(5[Y"D"6>X=0JENQ]IQC
MDD:66.G<#\RITUT$Q$@#M67=A+GKLYG+AE]QG#;MEJYH(LQ%#<ALE!6/?/?+
M#&6PES!';QN+J]ZW,RXR6>4^J+EYFOX,ES6V?=BM+R:^L8[>(`NI,&B:-\CG
M3!M'3N(KWSCFUB3E1R;9-ZY;/:F3+GY<\;ON8MYDNU;&Q%#85?VK?UG2%L6@
MU?P]P1-Y8WO5S9L>_F8AUVI(-2%?&%8ZO;=8Q#%TN6330V%N,R<ZXFAN+T;J
M0DL$,D[I+>CVEL@PM<<,8D#&:L.DJC,Z7.9W$MJ!'%+963!*W0\2Q0NCFHQU
M8SWV$E[HR7D#20%L3JA2E$6N;SHV'[>S[RQQV'KPMA[=]G7[G'!D#=D*Q:/7
M:Y[?<Y#B!?OP\`34<L_%12@Y*Y#J@V.D53K%ZNH88M77?$V1-;(^%[,R>]LK
M#A=#(RPOG13!WZ+HY1&YI-!C#1IK0TW][/E_#&;W-L`^<6<(P$8A(UU_9-EC
M+?TFOB+VO;M875T5(U305S\SUC9)YJK/R,URK::N$F_)Q@?,G,3:$/<32=O;
ME@C+DR[*/,U8VN:'BEGZEU'Q_*Q24^O%$5?0\@+XZ0$.5(X;FUO;/,\M&=9U
MBM+:^SJ3TN)A<P-O;?+VQ@5:=XRPN;G!)'*'`B.1D+G@B0+8W4$%A!%DE@]\
MT]ADV83Y>XM9(3'<WM@Z*)[78F.N+>*.ZA,;],FX;.&C>,`R"L"/RIG>X\9V
M!#YRYLV?*Q)YIST3%F28'(^2[5R3DG#L+@.UY.W#W?E.031R3(P49EUS+DAY
M)^[0DGQ6I"&663V'B[8Z+))\QG&#/K7AZXG$>%K09FYO@LY'PM`8Z4V.[<8B
MTB6)P=-&[$\+3RW%G%F$-IE+I)K*?,+=DSI`X[IXLII+J*!Y-3;F5L8<\UW<
MSI8H7LW;,-<Y1F\KY@\TK@VX<AQESW'E2;E>65]=R+JW)+RG>2$5F:S2/Y67
MA",`?H/?!&/A+Q0R!.J/75-U0U$-UF,5I;=:F0/LPQED,]M)#@INX\=M(]^F
MM&,:]Q&NC=#=%%B\66+;#A3BS);=\MQ%;VM_;PN><<DK(KH,B)(`WCG,:#B`
M[_PMJUV<P^'<EX:MGG(S-C/&=\W5;7-ESMWOA_F"LJ$@9N0?EE6.?+<7P=S"
M1<`1JH=U%Q3)!:#F7J"0I*1#ELX,<Q&8#6)U?2Q6>9\*9'<EK,LFS%EY&X@`
M6UZRZN3.V1WZ$5[;L:274`N(82*;YY/)^,_1Y9LUSR(L]86/#]M"^FNXM)<G
MMF8!A:=Y+9W+R^-I<*1273*%^$#(B=-BRYT.;/"5B6>D\Y['_/9>UYXF<0^-
M)MC?]J:Y+MB3A<GO,B>33-JQL>*@4UUEWAI%9J+013$I^MU*P^$9(S/P[=6V
MBSL[J0WQ!P-;;^F71N8YJX<>]B(9NZ.,Q>P-!T%MCC,-WF81W='QW&06+(&!
MW?RS-RJV9&V%VG#)'.VM0YIC,<E2*D.^D`@&`I0.("<"@!A#<)M`ZPAL#8(U
M@FE3AU56OC#Q&T2FL@:*GG--)[:\JA5I1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HBP!YWN2N/YR+LY22W9'67<.,L(YRE<FY)M"\%9M,;I@G6+KXLR/8P)
M89`05E6D[<C9R)7"[9'L4C^O$VA#3E[+>#/!FEVP20MRV\@:-HEGW.[?L&%N
M[=BUG2*`Z:9S[V1O#E[E%LYS+JZN+%X=HP[NVNFS2M=K-7L!:V@\+66C2K=<
MRGFS,09_O7E(@'./\;,>6OE^8YP97%BUJG,VPNH;)5@)VK;C^RRVJDS1;2D1
M+`9TNX6=(*]8>U`5%=:QS";K,[_,+][S)<9&ZR@>T]_#*;RTG#V@T:&-A@D8
M!1PJYHP8:D:\NDM;.SMLL;&W=9Y%>S-<*LFC9:WL3F.IWSGNFN(GZ2*ACJNK
M0''M_P":[R_F[`^#>3CFGR'8-P<K^#8_(!02QXK/QM\Y-G8.368<K<U=352W
M82(B%\0V^L26?@W<KA)7*T;*&`Z9#G/GWUW=9E?#B:=YAXO@R^#T:2*HB@S,
M##<7S036F!C601D$-%Q<$X<,0%=JRURR.;*K"(/X=N,T?(^.0@O=EU=\RR<Z
MCB2^X=6:4.!W4$31B,DE-G6$X3F,LCEPMBVLJ26/LD\PEH6>Y@5I]E-S\%9>
M09F"*X86S/3\LI:CV9MUW<[!LU7F!;Q;TK5XJOV!%R`0#5Y[>"]F=?Y9!'%<
MS,8]\1<6Q,F<`9FQN#7.W(?C,56!P;A:0*56-DUC#84RZZFD=E<4KF1R!H=,
M;8&D)D87-:9FQX6O^<HYS2[%WU!JKLWS?_.-(X8OVU+_`$N6BTLD0?/0WY]<
M&RMI9'R5?]JNKV'(!KN>XTR"E.X=L.2A($\*=:,"98$DEQ%T*X,BBD!%%I/%
MEEMPY<VS3-FF06D]H6.."*XM[F&\AE=O1C?%)2\):W=O:#$TEQ#R&WKV*+-[
MG/+>_P`4>5YV(G.='WTD$MNZRD@(8<+96"6R8]X+XRYKG,_E+M[Y\VOG#*%X
MS/-/?A.7V<YDW_,5CC-"&$Y62NNX.7=>R<;8GN7#K/%4S?4I8/E1(NYJ%N=:
M35FS6H*;>0333+'G2`QC4V4XR6*V@L6LNFCUEOS*-V3ZS]&),0;O0UUIZ+$(
MR[3,,>+=%PPW+S#FS9XKZL43;:SCML!QX)+.>2X<Z6N[Q,N733,?&#\VTM(<
M_"6G//D:Y9+@Y8\?Y(CKH7L]C.Y;S1>N:I"PL9E?$Q3BM:\T(9`U@8W)(QL(
MZ5MV,-$"N=P+"/!T[<K*@U0`W4"_<7,?JO+\IB<^5MA;/BWL@H^3'/-/JQ/P
MLCWHCC9C=A8P:=-!B"-\F9W69R,CB-P8@(X_!#88F1![S1N*:7#CE>&M#G$:
M"07.S7K7K)2B)1$HB41*(E$2B)1$HB41*(E$2B+#SF0YT+`Y9YF3@+JM*_+H
MDX[`>5N8)-K9K"'?+25NXE<P#.6MN.2D9F,46NN<=7&@G'I"!6ZANL"BR>S7
M!N;Z.V@NYW->X6;+1S@T5<[TR[;:1A@VN$C@YPT=[X.)W>K/CL"Z"WN9)(XX
M+BYGAQ.)`9Z/9S7LCWFE`P10/%14XB*@"I%L&OG+,(RV*[*RU;EM9#GH.^>7
M#(G,A'124;!QEPQ<7C!_;4-=F.KCCIF>8>(\D1T_<I6"S-<Y6[=TV7*LNF!0
M$VSSJ%V37%U;U9<^C-LG,?$X%D[;^X;;VSX7NP@L<Y[7ESL(##76"%@6!],R
MB/.)JV\)NI[>1D@.\A?;6EQ>2[QK<6@1VSPW`7%SG,+06NQ*[&">;$F6+O)C
M6_L-9+Y>\G2%DER7;%FY*=V#.DO/'X.HU@\N.UKLQA>-]6=)'AG\PT2D&/AQ
M'[$7:)E40(J4U94M@^-MR`]KKFRF;'<1Z0Z)SS((SI`#XWF)X$D9<T.&!Q#B
M`L6&Y=-;V]^(W#+;P?,2U:6O(C;(6$`ET<F!V)K)`USVL>YH+6$KHHKG09W?
MDZ[[+QI@_+V1[!QU>LKC'(.=K>0LY'&]KY(A6_7F+93CY2ZV60;G:P#PY&DI
M)Q$,^C8UT)TUEBBDIU=.^X+,DDSUX$=D;6>:W+S3T@08P<.$.=&QYC<(I96M
MCD`JQQJ*[.2V,5^W*ZX[]KH=]&T=]"V=K'QGOL+9'F.1KS%&YTC1X36DA4#@
MGSD&'\EXJC\I9/<6Q@Z)#&=A9(N5S<V1K2?QEMI9(ON\K!M6'>E*ZCKH;JRL
MM9RA6SIU%-&;U5;L6RBJB:I2\@SC+(\I<X.E#V"X@@;WI&.6:QM[[`VF(8VL
MN&MW9(E<`'AF!S2==E\LN83&WA96=K+V0@'P8;*YDMWRFM.\.[+RX58S2USJ
MC3?6#YO\%WC[U$C8-^6E>UH9;4R$6&O2*O&U6,4P)C*'-,74HZ83DO&3KXT6
M0O4=)-&JZK'4%')4DAZ]:B6EK*]EZ1#&S+C>XG>"81+#%B%*D-+IF_.$",'O
M"X/<UIN.?H8V(%\S[]EI@&AV]?%/*!WU`3@@>0QM7N%7,:YK7$=4?GPY.B8[
M6RP;F)QF&.VUSGLQQ=`3H&9(7,D"9U(M5$J(ODSD16(J*@I`CV!RJ]?LS`8;
MQ@F;):Q.:1)>BL(.C&*X32N@4=WKL5,+M!H315@XA.6Z1;TWE-(;75J\*M#3
M#6M'4KA-.XQ-S),,L9WY@<.14$U+%83B<,349?+&?1EF%\L,P6<ZN]HZ9,T&
M*23%K'-VY2)JD<NB.B*`H`D#8-UMG,,M?>W`=%<1YC<6CHW"CFNMVQ$N-:$$
MF0@M([TMUFNB[=MC@&7/A>)8,PR]UTUPU`-N)(`T:\6(,QXM&NE-%5D[6(K:
MH7).3L>X>L^6R!E&\;?L2RX-,JLI<=RR*$;&MNN/522!58P&7=.#^M212`ZR
MIMA"F'95J6>*$L;*X!TC@UHVN<=C0-)-`30`Z`3J!*NQ0RS8MV"0UN)QV-&@
M5).@"I`J2-)`UD*QL=SN<K\RI:IH3*\--QUYV5=V08*=B&<M(02EKV-(Q$5<
M[I])-F"B46\C7TXU(+1P"3HX*@8J8EU&L@1R&YDLR")XX;>4@Z`67<_H\!:=
M3MY-WE`3A/A4`*PG74#8HIL0,<LUQ$VFFC[6`W$X<-;0R%I?4Z'4HVIH%E*1
MR@HV([(H!FRB!7)%0UZID#)@J50-0UT%,==VM6YB+</,_>B.N*NS#K[5%?A(
MG#70]\UX&'IKJ[:Z*T;OMN_+<B[NM"6;SEN32)W$7*M2KD0>(IK*MSJ)D<I(
M+E`JR)B^N(4=0JX^-\9`>*%S&N'2U[0YI[+2#V54X%DDD+M$L4CXW#F>QQ8]
MIZ6N!!V:-"I+,F9+`P)8$ID[)LJYA;.AW]OQC^0:1<E,KI/+GGXVV89,L?$M
MG;Y4KB8ET$S&*F)4RF$YA`I1$*K6&2]S*URFW%;Z]N&P1-U!TC@XM!)T-!#3
MI<0.E43/;!9W%])HMK6!\TAYHXQ5Q`UF@V"I.P*F,X\S_+_RUM+8>YWRO:6,
M&UZ2+N)M4]SO5&QYU^P:"_?H,$4$'"RH,6(=JL?J@FDGZXY@"L9LL3[P6#7#
MTLQE^&NG`',87G8&A\C&EQ(%7-%=*KPN]']*H=P7AH/.YS7/#0-9<6L>X-`)
MHTFFA=1E+F^Y8L*Q-H3F4<X8]L^)OYJ@_LU\_G$7"5PQCE(%D9>/".*].I"G
M3'7PP0*U#<*FM7L#AF)RDZ,Q;2L9T%M308JZ&U/@EQ&*AI6A5,)%S9-S&W[^
MR>:->W2'$"I#:>$0"*AM2*BH%0N5DKFQY:\/(62YR7FS'MI(9'!LI8IW]P-5
MO*=H[*4S>3BBL1=G7AE`.'[]$`:%U#50*-8YV8>JP#ZP%*L_2&(T;BV-Q'0V
MM,5#AK0JC>Q^@>M`X'+Z'OQI!P@%V&FEQ:",0`);45I4*_S5TV?-6SUDX0>,
MWB"+IH[:JIKMG39PF55!PW72,=)9!9(X&(<HB4Q1`0'2CV/B>8Y`6R-)!!%"
M"-!!!U$'6%4US7M#V$%A%01M!VKWU2JDHB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HBP)YQ<VY9M?)/*ORVX2F8BQ[YYI;]O>"?96F8-E=`XVL;&>/IC(-V2UM
MVQ*'"&F[UE$(Y)E&E?IN&"!UC++H+%3[,:LNM'YMFEQ9;UT-I995+?2N8&F1
MX;<6UK%%'C:YC<4UTQTKBTD1,<&T<01<NIH<NR<YD]@EN9;ZWM(6.)#`^82O
M?)(6EKJ1Q0R%C0YN.0L:32M<4YOGPO?D<R7S)XGYK+MNKF1MC#F",5<QMG9(
MM/'MGP.6IRW\D9-E<225ASMFV<VL^P9*5A;J9MEF#EDBQ4<LG)BJ)G52ZQKE
MG-#FENZ"W@<,XCSVRRQK(PYS9?6$)DMI78W$M>)(YF3!O>!H8]K6@N"HO[67
M+C;79EQV-UE>8W1#\(=&[+'PFX:T@-!8^&YA=&'G%C;(W$12F06:O..0/+K8
MUMY#S3R[9OL"WGR!)6\QG)C`[>0Q[;3F<1AF,V[CAS+X7D!RJDX([<1-H%N&
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MEDOF"9,7:^+IZ6O_`!QB7P<+T5B+<M')-P7)9%S,SOFX)0]WM+=D%^W*)4M`
M/U=2^ZBCR&ZS]]=U9>BF:,4<YC+V1\4#@YI,3JOC>U[&2&2,M[]@J*[*WL9;
MGB*QX=C+0_,;B6"&9U6QF:%K7R-<"!*UH8X.;*8]U(T$L>Y6:S#YVA[;G+[S
M$W[C[E?S+$Y=Q?RLL.:_&-AYB8V'!1F1L3SQEV4;?BJ\+E`YHF)M^30-XXAG
MSJ,N4B)/M#-0QT^MM,PR^\R^4P/#77-MGUKEMW&UP+H77,K6L<#4,>)6XFQN
M8YXCF+6SMC#7TLY&;;./1+AF\.6W]G//;R-`I*Z")LCXP3X+FM>R6KPULD)+
MHG.JVMX<8<X-RW)S'69`Y9D97`D#.\F$;G&X\,9"AL4>*;7FY#)Z5J(7<_SA
M;.2[G:$6?MU2(-X4G;-O!U2+*.".>L@&;-86UI)G<8D$K;*_M(6%Q+'0F6.X
M<Z(C"&S/)C[]X(:QS:1%[75&IM[FXN\KR:_#,#KQMR7X`7ME$45L\/;7OHHV
M[TEE>_>#21K"T5MMSJWCS'1^9N3YQR_<Z]QV/C'FBSHRQ$_@[3Q?RZ9%MZ'@
MV^-K[NMU<MGW9=F/;EEW<J_E[613.+IX]9D3.H!$BB`::S)+*:XXBDRB^?)N
MCE-_?-JUK7--L+7=1C0*QN$SG$N!>:MHX!9V974$60G-;1K-['?65L:.+FN]
M(G?'*\Z31[0```0T$:6UJL>FW/9S08,YZ\]8:S1?L7?G*Y!Q.,\'X]R;)6;:
M-M7+8W,S<6%7N1X.7R`YM:&BHAY!YA?1CEHV3[!!DSDR)(IE3(J!!U[+J2^X
M4SN_8QD.=>D9J_+0W$YA9EEO;OFM"'DXY0V?TF,N<7R,CD90T%,A\;(.),LM
M&XI,JBM;!^8XB,6',;VZ@BN680"V.)T#+>;31HE9)3%4FR]M^<,S#>$QR(Q.
M;N>MCRDP6;?-ZL>8.\+LA\5X6D7.0LU.,@6W;JS!J7(>/[UC8&,+!R:ZH,V"
M#<.N`#UM`T'GN:Y-EMKQ=G>6V9<\V-YE4=M:$_M&74-P^8N?^T)=)'&P4>,(
M<::=*T\=W/ZHLKM[1\]?YK'+)^K':2,;```<(HUSJFAQ4TZ5]+4*?M(:)4\9
MFF^TC&)_')TFR)Y;KM4C>,SHLT6[-(S_`%[42I)D3*)]"E`N@!Q2Y&&YD:6;
MHA[A@J3@TGO:DDG#JTDG1I*S+9P?;L>'[P%@./0,51X5``-.O0`%V=6%>2B)
M1$HB41*(E$2B)1$HBUP\X?*!DCF"R26\K.G;.BXTO*SF["/@]PNYAN]\JLE7
M#8<M!R(%CX:11"#:-[7<%<GZ_;E.<G42.`F$N*R![9KJ312=V5%O1Z#FD=[+
M7^=$PMCI6KZ!V%O?++O9V7.0QY6RHG9-?O)/@D7647=A'IUU;-<,<_13=AQ%
M7`-.+^0?-E9D'-N=+TQ;?&/FF)LM\J&2++C,9W"[N!@:U^9K(SJPR77=$6Z8
M0$HUC<;WPUL5N]D03(=TC+G6<$;*"X/ID7!D.7YG:Q4<79E936`=WN[M8<P.
M8SVTKP'&@FQ>C4:\,;*Z,T9&P+$`$N6V%C*<$HMY67KV@'>2C*KC++:X8.]+
MI!%<!D^,MQQV\)!QE]<Q\'84S],9<L/-W,;&8LL65Q)AV=PY8./L1WO<V2XU
MX2[7UFOKGO6Y;VNG'V,'8N%D[):MV48A$]FW*=511PL8Q`)MIKN!UUF69,Q&
M\S-[`6D4;#%'++,6!V([UTDCV.+RV/`(\`:<1<L*S9>09-8\.N#/5]C(V7&"
M2^:5EL;9A+<($3&,EGJT.>7N<QV)H;A-&84Y>N9[ERNO*>-<>I82NGEZRQG'
M*6<!OR[[IO>.RI8WOO33ZZ;LL1+'L9:+VW;P["?>*!'S![DC?!VZP`JQ7%+[
M9I+EDF9<)P\-WQ#9+'*I+&&1FD31MW@MA(#3<N8V0-ED&^#\%6QM+M&XDN&L
MX@FXAMP72W=S!-)&>]$4D<<,<KVNJXRMDW1>V*D.`G#O"%BCA7S7V:+`@8>%
MNNX\2S2#.S>2NW'[5%W<$@Q=..7'F/R9F"]3';R-IHI.&DK;MY-48T#DU4>I
M*`L5%,"J&YK+GUE)>MN<$A#,W9=@T%0UF1666`C3HD;<6SY&D'1&6.#@^K1I
M+2T?!)=&3"63Y+F]F!_YF87L]Q$3H\!K)6B36<0(:UPH57^:/-L9,R]=U].`
MOBSK9MB];_YI[F%U'N)L9R-CLYXDM>Q[=.1DG#(LUI%O/P2BLH0'!"F:J:D4
M54$2AP"P@NK$,F^:EN(+2\8QL@+XG22YU:9G"R1IUP;JW='*!I#W`-:YM7+D
M+[^F>VV:L&*&',,MF(=KW=IE%]E\P;K&,RW3'Q:@6-<7%KJ-/+SWRT\_&<L;
MV_#)%P%B>4%&Z+3O*U\,9IREC>0GH1Y9$1:]H7>YSM!8?"]W#>!D6"ZSFT&\
M2P9/HY=%FM)G\&*J?:9JV+,[F29SI<-U#(7!SB60RR38W!\8H+UCHZ,<970M
MW@WNZK0"QD$L&2Y;!9D.=<6,EKNI!0&2.`2![65KZ&YQ<U['LWSFX7L!PRNI
M>OD-Y.\D<K<U>TA?EP6?.H7%A#E$QFQ/;+R:<N`FL`8=3QY=KUX66B8\"1TI
M+I]JP,4ZBIV^U4J9_6UR'/,YM\TDOI(6O;Z5GEY>M!IHCN6PAC30^&#&[$!W
MND4.L#'NJ3'+L&JSLKF%U:U+ILPN+IA;4FH$<K6N)(.,$:11QV1UQM4K73S^
MV3?,E-<HF6H"PKDRM8G+YS&-LG98QW9T,>Z;M>VSY`WC;T5=]M68@"K^\YBP
M[CEVSU*.9)+R"NHG;)G53`!9;<1Y;Q+%F=R'^BG++^V:]K2\Q3W(@W,I:T%X
M;ACEB<]@)8):D8"XB,QM9,RX=GRVVD:RY]-LKAS7$-%Q!;R/=-;U)#:NQ1S-
M:\ACW0!M<6%81<YL+E_/TXSRQ@O`>?;20>\M.=8&,<O,>SN.[\>W5+Y`PZXC
M'CR``6-X6U-W)&Q+OP=O*(L955NR4,=$J74$V-;6\]KGYEE</1Y3P^31V)K6
M1Y\)[ECBVK#@MRZ>=@+@V-YWG?8@,7.)!>Y5`RV:]T\3,^!):6N#Y,@N(+<@
M.`=IN"R*!]*.DP[HG055DQRXY/A<SCS`VW9V85<K/N?RS85>X#SEZR+%GRP2
M^$K1A;V286RYE%;:88V>S[)3PQ5-H!0DDA4ZY50$:W;#;Q98;2/"!<Y1Q`)O
MUG3.O,PDL&DZPX#</M0""T/&$T?17\OBCO7YA)FE6NL[3*W66G`#/'#E[9B`
M*;QYQ7+)PZH>&%KQ\V*6?Y5<:Y4MKXO_`,:G"?-E?5\16%<.)<O\A`$R,),6
MW_#S=]FR\TR7=+2990./YN;*YB3NW5TK=E)QA`1;BJ8ADANYG<6^_N9LK:P\
M0-97'7!%):>J[5K(!(1N\0NV70DC:#-O9(I,+@W$S*XHC==9Q=/=*QW";\VO
M,#(6UG;,[-)GQW-&T<Z`VI@-O(UPBBCCG8YS=\UK\8WF+N;?(3+F=;M>7C*M
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M_'F%@_=PN<'1B7`Q\G?LD!8Q_>[5N;J016>42Q,?)?6V>,G;0D-C#<NS!ADE
M``?NRY[(@6/C<))&=]L-DK'QTTY`\H3C!SAW-.;<<7+R]X?Q!C&[<:8KF\MS
M:3ZPWF0'5V6%>,79T5(&Q_`W)*7,C(HO'I&EO"*YDU%B"@%;*]O9<XM,VRV6
M(',;V_WT;7T;#);C+K.RBB?.ZC&NB?;RES92T89S)&#60#&@RY^7WMCF[KDF
MUBM'QR80XR0W#KVXNYKB.",%Q;.R>)@W(<\&U:Q_[LFP/*IC'*W(UDUW<F<L
M"Y5R7;^4>6S&6.K!-AS'<EFA;%LK$W[E:Y[DP1<32U4956TK=5;7A'+>-W?@
MUMJJIF36<D[`@CL6W4;[>[R-[W39C+?6D@G<T,CN(XLML[/OI31K/1YX9B&R
M%N*.3>1XBYX5[-"^]SJ'BJ-K;;*Q'>M]%;5S[626]?<"9D;!B?Z3`Z-KS$TO
M:^$,>*82M]T$<%(2'.$,K;H'BH\P6^N1@1:"`S1$0AUB1:[J,(K&`/8F!NJH
M@`DT3,8N@C@7`(N'@O$I#SWXJ0_2>^!<`ZCM>D`Z=(JKL9!C!#2T4U:J=%-B
M[6K*K2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+&/F3Y7K8YC"8UG%+JNK&N
M5,)W@O?^&<LV0K'#<EA72\A)"VY53Q7.,I2W+E@)^WY1=E(Q<BU<,WB"FARZ
M@`A3"ZYM+WUC82F*[-M+;OT-<V2";`9(I&.!#AB8R1AT.CD8Q[2"U72Z">S?
MEU]&)K!\L4N'$YA;+"XNBD8]I#FN821H-',<YC@0XK'&YO-J67D>QLTQF7<Q
MY-R5EC/C#&4'?^<)%G9<+<R-J8CNE"[K.LZS[5@K<9V/:%L(2Y5UG#=JQ`73
MEXLNH853%,786-X,MN,OFL(PQMCG$.9N%2[TBZA#6M,SB<6`,:V-C&%K8V5#
M*%Q)Q;ADM[%-'>OQ[S++FPCH`T0P7)<9,#6T:9"X@ND>'.?@8'5#0%3?.-YJ
MG%W.1?5SWG=N2KOME.^L>P6.KMAD+2QA>Y4V%KOW,E`3&/9G(UGW1-XCGBNG
M0B_<6ZLQ/*E32!SU^R((8F4O]57[[YH$A=F$%ZT.T%L\&Z#0)&TD,+FQ-#H"
M[=XB]X`<]Q.6V4-9`VE=Q:2VU"7%CXI<9)?%7=F9ID?@GP[QK2&@T:VF6.*>
M5FS\3W1S(W1%W%=,HXYF;DM^Y+N:O7+)H2`7M_&L%C%%M;+N*:,GS5-Q$0*;
M@RBJBJQ'1S"0Q2@4H+Q_IN1'()*MMC<W\V)I+7XLPG=/*`1J$;G%L9`J`!4D
MZ5BV;/0;^#,8C6:WLK&V:'`%I;8L+(W.!UN>#60>"=0`"U^67YEG#%H'NSM<
MOW[*&N+EXS1RR,WR5FX?MVY6^.LSFAS/Y"Z;NM^Q8^YLGWU;WB8G@TU<3F0=
MN!.87`JF'6K=T#>Y#>Y'-0>GQ6#)7L`C'_3I9)(7,A8!"QS]X6RD,J^@-:K-
MBNGP<26G$4?AV687%Y'&XEPWERS#*UTCJRF.I+HV8Z1"C&4:*+*>^_-ZXGR.
MSN.-N:Z;V7B[HY+"\D,HS:N8AKUL?%=K//*M!RG&>$(WCVJW?`;P/0H?:=]9
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MI^^I8-HV!$6]`6JXD/).Z+2\1/(="*!JQ@_!KK77ZC(K93MR%'K:"8!Q[2[G
MM<X.=%SI+DY;<V5'DD;NY$`)K6N*,0,$8KA`)!!`%*I[>&;*GY0QK8[=]Y;W
M)+0`=Y;R.E'121SB7FE3KK6I5ILH>;MPKF**YS8*_P"3NJ7B.=1&QCWDW3<1
MS)S8,QCFU4[;M*Y,=R+9@1]%ST0Z;HR2+A<ZYDWJ)>KHGJ0=1/8MER!N1,>^
M/=YG<WT<S:;UDURV!CPVH+<`9!@H15S))&N)#M&QM+I]KQ!Z_`:][LN@LGQ.
M%8WPP/N7C$-9<XW3C6M&N9&Y@#FU7GRV^;]QQRS7+@BYK4OF_;A=8#Y0XSD[
MM]"YEH-9.?LR,N>"NHEW7"JPB63A6[W#Z!(50R)DF@D4.((@;00YAFG$EUFU
M[F][-'&U^<75I/(&U`C=:13Q,;&*^"YL[B[%4U#:$"M='!EL<%I8V@>XML9[
MR5I-*N-X6%X=HU,+!@I0Z\55GO7'5LDHB41*(E$2B)1$HB41*(E$2B)1%C;S
M3YUN'E]QI&7;:%@,LFWA<V1L=8PM.T)6\#V##OKAR1=+"UXQQ,W8C:]Z.8B*
M8+/NU6.C%O51*70J8B.H4#?S7UK86S6F6YF+*N<6AC6Q22N<:-<31L9HV@J3
MK`6;;6T<MI?7LSRR&QL9;EU&XBX1`=X!B:`7$@5)T<QU+&R)Y[[\N1.'QI;7
M+RVDN:A]D#)>.Y;%"V7&#;%UO.,2Q\1*7A>C[-:-DO9-S8`(7'&H-5V]IJ2Q
MW[]-NM'H&*J8EU@9?-CGRD[RU-I)/(Z4&(QB&[]!DC(;O@Z5UP';D-=NY8F.
MEWC0*+#>/13=-OJM?!=6T#-VUSQ+)>6AOH:%PC#&MM@]\I=X#F%C!(XBO$4\
MX//BC"XR:8!=J\WDUF&X<($P*ODB-1L]C<UL6,3)DK>C_,2%L.S)XG"PG#>0
M2DRVZ:44\*21\6`L(D"XR%U\^W=D_P`[:S6ES<R/EI#N([.X;9W#9&@R8I!=
MOCAB$9>V4O:_&UF(MQYKB++]_'FSFLN(I;2)C8JR;]]]&Z:`1%XAKAACEDG+
M@-UN9&C&0W%GCC*X+[N6T(^3R78"&,[T%5TUFK48W:QOF);+M5S(E>0=U,H^
M%/,0L@0H*MU7,?'.^H.BS9$X"6IG9`W`;=[GL=&UQ#FX7,<1WS'`.<VK3HJU
MSFD4(.L"873N:?2&M;('$=ZXN:1L():PZ1K!:"#4:10FOZL*\E$2B)1$HBZ1
MS<UMLI1&$>7!"-)IRDJNWB',JP0E%T$43N%ED8]5P5VJDDW2,<QBD$"D*)AV
M`(U%11SJC"P$N_D@4J3S`5%2=`J.<)J(&UQ`'236@'.30T`TFAYEU8Y!L(+?
M\K!O>T`M;PCP3RE&Y88+?\+!;P<6OCGPWQ=X1X1]KZG:=;K^MTUV566N:YC'
M`A\M,`VOKJPC]*NRE:[$;WV+#IP5Q4_1IKQ<U*BM5W?CN'%(RQ)6.53*X39]
M9)\U.`O5TB+H,BB5707;A)4IB)]^<I@$`T$*L74OHEO)<R-<61LD<0!I(C#B
M^@VEN%P/,00:4*14F=AC()T5IIH'4()IJ!!!!V@@C6L5L$\\?+US`DQHRM2[
M!@KPROCZ=RA:>/;O\!B[Q6LZWKL"S)%^Z:,W\G&I.?'1B]FV(Z4<*H"*I2"0
MB@DV4MA-%OJ%KQ;PVLDN$UP-O(9)X:ZC^SBD,E*B,@8R,;"Z,R<S*<V=DUXX
M-NQ=7=NTZ<,C[*6.&;`X@:,<K`P.PNDJ<+3@?ARD@[CMZYVJC^VIZ&N%BBY6
M9+/(.48RS5)XV-U7#11PP7<(IN6YMATQ$#D'>`5AT.!LE/FWBK3L(U5!U$5V
MA,0QNBJ-XPT<-K3KH1K!IIH5W-0I2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$7B<Q2%,<PZ%*`F,/<`-1H!4T4$AH)<:-"H&>4*LY359J&2<$
MZC9-50@BD*JJ@=3K(F+J;J$`0`>D:L7[WPVV"-V"=[F@'FTK6W;C*\"%QP`:
M::M.KLZ*555QATRI`CUC"IIUC=<HE$3#IUM-=@[>BKP```'-KY^GH63;R,IN
M\0+PNT$0`-=^G1M'YW'94K))HK!9YYH\!\LD$QN/.>2[>Q]&2;P(^-&5566>
MR#L0U,DSC6"3N0<`D&TYBIB4@;Q"L>>[M[5N*=X:WEL%2N2</\)\0\3R/9DM
ML^5D8JYYHUC0=`)>XAHKTE8PV-YUWDBR!E&)Q+!Y4<-KBN)BO(6Q)3]LS=O6
MO<J+4$1=%A9V6:-4%SMP6*)NT*F7;L$=*Q&YQEYJ3(&QU\(Z!4[.CL@+E.8]
M4/'V5L!GLL<Q87".-S9)"T;0UE<7_9)Z:+8>SD64@@@[8N47;1R0IV[ILJFX
M;+D,&I3)+(F.F<HAMU`=!K9-<'M#V=\T[0NLY@ZWE,%PUS)@["6N!!#AK:0=
M(.A<VI1*(E$2B)1$HB41*(E$2B)1$HB418L<W_+'$<VV*HC$MQ22<?;B64<7
MWW<2!QFT33<+8%WQUS/[=0D+;G+=G(=S-(L>P(\;.TU6YC=<.MIH-#8879A:
M7=PTOBMIS)A!+23NI(VT<-6$R!VD$'#0@@K/M;Y]I9W]O%HEO,OFMFNT$,,H
M`QEI!#@*>#HK76%;V].3OR/)B&Y.41S8&&[[P@WON)M=A>=L3MZV!=-NY-2C
M/+2,OM&/N:"O:4D7\K",9(LH26\8'>-"]LHJFHH4;K[J_P#3Y+UKV.9/9MM9
M(W"C!$R5DT;HFQX0R2-S"&BF`MEDQ-)((PF,M_5OJQ^]#&7C+IC@\N=OF130
M`2%^(R,,,\C*$U8,&`MP`*S,AR%Y!6F+8SS;.:[/#G'M',MX9AD[VD[#=/,2
M3S^]\;-\62F+IFQ8ZZ&ET-+"B[(9L46"J<P68349)+'<',<^MR&X&7.BBR?3
M:,L;FTE;,<;I&WEW'?S28F8-W(VZB9)$&C`U@,;FN:XJB]L_6$3Y<XB+;F2:
MSN('1XFMB=90R6T6`/Q8XY(99V3`G2^5SVEKFMIL,Q=%Y,B;/8M\NW9;=Y7Z
MLN\>3,I9]LKVE:K872YE4(BWX=[*SDH2+BTA!))5X\<NU0#K*'$PU,YMC@;;
M->&MC:'%Y!<]X'?/-`&MJ=36B@`&LU*MP[^A=<8,9.@,!#0-0`Q$N)-*DDZR
M:`"@5PZL*ZE$2B)1$HBTX\R')'DK+63^??(UFVO;UOY'R5A#E[L?E\R_(I6Q
M*3[%:TU+X7RE;EN'DS/G-JA.QDBE'.3K)-6[XCT"*'41*?J4G!;\,>CPLK>O
MXADN+B-H:73V8BRT-82_O'-+H)B(7.#7N8!(`UP<MC:3VXX@L[F[8)+&')[B
M%N(D-CNI778BD[WO@Z/>QR"5H+XQ7=G%4'#OXF62(_E]G2Q?+GS)W%DI7,+*
M\L>8HN3#'F[K3PI;=V1&/E[9+-7G@RSLUJ87EL679VQ$I)\F1S<[=\0)!LS*
MY3*J;81S.AO<NFM7,?+'<7#S)<.D<(XIG6X,9(#GVQ9NS-;FTQ&-SI@7!LF$
MZC+8@QMY'F#YF6<]K90R-APXR;>2>7>0N--\^LF"9MT6,FC;"P@M:<.1JN'N
M:>%R@E9\CR[F=VQ='.C@GFPNO,=LWSCR-Q/9-IVYCNQX.^+<:0LS<K7(+J<M
MBY;4<$1:IQ(,SQ1TEDW9U`,W#)CN+/T1UFV1[+>RM.(HFOETON#F+K^>U<S"
M#H>;ML<SI3&8Y&DX7L.,4Y59364U[>1!LU]G-IET6YC;AW$ELRUMI6G00>\M
M6RQ-CQ!YD+*LPBMJL%<CUWXT:<L=QY4Y2WV0)AOR>YRP-?5Q8O<X04RSC.Z;
MGR*2Z[7FX^^+BO:UGC<9"RU7K&,DH63=.&+IV!#E21454+BYG<V<\6:6L#7T
MO,MR<MEB#1B?8VMS#=6[JEI+IG30"C@8)F0ELK\+6`[#B0377&K,]A<R2SM\
M^S9^ZE:[]G>7-M-:W&`B@;`8)<0[V>,S5C;B<];$?-NXYR5BG"<]9-]8I1Q)
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MIOA"FNJMS4,3JZL)5LW#]DP@22[Y<B2;62;.'KIYJ5%!N5<2F,)PZP@B`"&W
M;I6#G+FQ6[;BXT1->TN-!0`'6>@:ZZEBY<YOHY:T5(!U<^P5&S\"M3G?F4MW
M!D)'RJ-LS.0YF8.<T':]K2-OLWS\A&QW`J)+34BT(JD8J0@F")5E3F$``E5&
M]A9;MFA+9&R>"0X4=\!U+9<-Y=E^;9X+#,+V'+HR0,<P=A%=50VI-?SKYH>8
M;S^O,+<!LDXXM7"C7#T6^,^MB-NAP_=O<CVV=P!T"NC,7)F;$DR<FHIF(F!4
M]>L&NE::ZO<Q+]S&QC7._1.D].G4O4G#?5KU99?<0W&:WEQ>SMJ]N#=F"1S=
M([W2XL)V$@G:M15M,<H9)N?KWM/3>:+6?J=LO-9)?S#B>@)1_P!8BP,B2YU'
M`-"B<QC@G]I$_5$IC`-:=D3`]US>$L(T$Z3I[)(T\U.G0O0F3QW-P\9+EMO;
MW&5RMWH:Z(1!I<-N$#0!J!!&U=WS9VC.V7E+EIN"S5(ADKB-HP3?+M7B3..=
MP2\B@"IWCE95,JZSN&[0H=0@G'UH"`B`5P?+K>/+K?,[>YG?,VZFQ1AY+G`$
M'O?@;LHN2<1Y+F=KGN3YOENZ9';$$@.#6X1X3:']8:QI"^@KS=7-#.CF#&MD
MVO=;J:LB_P!\A!RD2[DU'\3%O/`I.2,6(*JHJ1)^F#8I#@D!2]3O@UTK+X2S
M"\MLSBRR21VZ+]1)).OXCS+1_>)X!X5XCX`O>,[2VMX<XR^(S&2-C6E^)S6E
MCG-`#B"XFIJOI;KNA?,M*(E$2B)1%35Y7?;F/[3N2^;ODTX:U;1A)*X[BEE4
M73E.-A8=HJ^D7RC=D@Y>+$;-43'$J29SF`-"E$=E9F7V%WFE]#EM@PR7L\C8
MXVU`Q/>0UHJ2`*D@:2`L:\O+;+[22^O'8+6%A>]VDX6M%2:`$F@Y@2L&O2K<
M@8_\Q$)^261/S0WUV5[D.M3V/<:_UX?I%P7WK]7PUYG#\F7Q%/I5N0/Y1$'^
M2>1/S0J/<CUJ>Q[CY</TB>]?J]]IP_)E\1/2K<@?RB(/\D\B?FA3W(]:FOU/
M<?+A^D3WK]7OM.'Y,OB)Z5;D#^41!_DGD3\T*>Y#K4]CW'RX?I$]Z_5[[3A^
M3+XB>E5Y`_E$0?Y)Y$_-"GN0ZU/8]QK_`%X?I$]Z_5[[3A^3+XB>E6Y`_E$0
M?Y)9$_-"GN0ZU/8]Q\N'Z1/>OU>^TX?DR^(GI5N0/Y1$'^2>1/S0I[D.M3V/
M<?+A^D3WK]7OM.'Y,OB)Z57D#^41"?DED3\T.[5M_4MUG1G#)E4K74K0R0`T
MY],NI7XNLS@F=F\@O=Y&#0ED,[@#S$MB(KT:UP93SL/(+&QDC)!G^(=C'L'C
MT&J5JW\DLZ%HW47!LBHYM1%N19P*?4()SE)UA#40"M3GO5EQUPWDUWG^<6!A
MRJR@?--(Z:"C(V-+G$_.\P^$KEW`N:9=UC<:93P!PH^6YXFSK,(;.UB;;W%7
MS3O#&#3$`!4U))``!*TA>:L\[[:0YWYN4.:"^36E:>8[U=YEQ[)2+2>F&<'(
M^$HP#ZS6S:,0EG;)LK;2<<JW230!$IV:YC"!CAUO(7W>N),]ZP^.\SX8M&&?
M,,P?)=V\9>UO@:)(VF1[1HB#7!HV,>::U]RO]4G[I?#W4?\`=XX$ZQN'(@S+
MN$[&#(\UDCC+B]LQQV]W((HRYY-XZ>)\CJGY^%NH:-YGI5>03?\`&'A.GW)9
M$_-"O:/N9ZR]?JM_G;?Z5?`OWC\'UIZ5)7_V]S]"H]*KR!_*(A.GW)9$W?DA
M5QO4GUHN;B9E$Q:16H?"13GJ)*+'DZT^`87F*;,8V2C6UT<K2/A!C!'93TJW
M('\HB#_)/(GYH55[D.M3V/<?+A^D5'O7ZO?:</R9?$3TJW('\HB#_)+(GYH4
M]R'6I['N/EP_2)[U^KWVG#\F7Q$]*MR!_*(@_P`D\A_FA3W(=:GL>X^7#](G
MO7ZO?:</R9?$3TJW('\HB#_)/(GYH4]R/6IK]3W'RX?I$]Z_5[[3A^3+XB>E
M6Y`_E$0?Y)Y$_-"GN1ZU/8]Q\N'Z1/>OU>^TX?DR^(GI5>03Y0\)^261/G>Y
M#?5KW,=9@):<KD#@:$;V"H/,?G=:RQUD<'%H>VZ>6.%01!<$$<X(BH0=A&A8
M2><4\[ERRP_*%E^,P)E]C=N6+V@%;#M6.80%U,%VGE4`QDU,]O.P46S`L5!K
M.%-BO:`<2B4!'=TEU_93Q7U6=7\V9YY;&UEOG&U@)DB<72/:2ZC6/<>]C#G$
MTT:%]`/]-+JQRC[R_P!Z3*,GM1)<\,\/%N;YB3%-&QL-M(W<,+GQM!,UT8F!
MH))&*HP@KH?-E>=JY<'7)MBBW.8;+K:U,K8ZCU<>3R$K#W?,O)=C;`D;6[/J
M/XF!DVZJDE;YVW:]93K]N0^H5A_=VRSBKK2X`9<Y);F[N<M?Z-.=Y$'`M:#&
MXB1[7$.C(.*E"0X5J"MY_JC=5V3?=P^])F0D8ZUX2XI:<VR_!!(Z+YYQ%W"S
M=,>UNXNL8##0B-\9I1P6?/I5>03Y0\)^261/S0KOGW,]9>KU6^O^UM]NK]ZO
MG'[Q^#@"XW3PT"I/H]S0`:R3NM`'.4]*MR!_*(@_R3R)^:%7?<AUJ>Q[CY</
MTBQ/>OU>^TX?DR^(GI5>0/Y1$'^2>1/S0I[D.M35ZGN/EP_2)[U^KWVG#\F7
MQ$]*MR!_*(@_R3R)^:%/<CUJ>Q[CY</TB>]?J]]IP_)E\1/2K<@?RB(/\D\B
M?FA3W(]:GL>X^7#](GO7ZO?:</R9?$3TJO('\HB#_)/(GYH4]R'6I['N/EP_
M2)[U^KWVG#\F7Q$]*KR!_*(@_P`D\B?FA3W(=:GL>XU_KP_2)[U^KWVG#\F7
MQ$]*MR!_*(@_R3R)^:%/<AUJ'^Y[CY</TB>]?J]]IP_)E\1/2K<@?RB(/\D\
MB?FA3W(]:GL>X^7#](GO7ZO?:</R9?$3TJW('\HB#_)/(GYH4]R/6I['N/EP
M_2)[U^KWVG#\F7Q$]*KR!_*(@_R3R'^:%/<AUJ:O4]Q\N'Z1/>OU>^TX?DR^
M(GI5>0/Y1$'^2>1/S0I[D.M3V/<?+A^D3WK]7OM.'Y,OB)Z57D#^41!_DGD3
M\T*>Y'K4]CW'RX?I$]Z_5[[3A^3+XB>E5Y`_E$0?Y)Y$_-"GN1ZU/8]Q\N'Z
M1/>OU>^TX?DR^(GI5N0/Y1$'^2>1/S0I[D.M3V/<?+A^D3WK]7OM.'Y,OB)Z
M5;D#^41!_DGD3\T*GW(=:GL>XU_KP_2)[U^KWVG#\F7Q$]*MR!_*(@_R3R)^
M:%1[D>M3V/<?+A^D3WK]7OM.'Y,OB)Z57D#^41!_DGD3\T*>Y'K4U^I[BG\^
M'Z1/>OU>^TX?DR^(GI5N0/Y1$'^2>1/S0I[D.M3V/<?+A^D3WK]7OM.'Y,OB
M)Z57D#^41!_DGD3\T*GW(=:GL>XU_KP_2)[U^KWVG#\F7Q$]*MR!_*(@_P`D
M\B?FA4>Y#K4]CW'RX?I$]Z_5[[3A^3+XB>E5Y`_E$0?Y)Y$_-"GN0ZU/8]Q\
MN'Z1/>OU>^TX?DR^(GI5>0/Y1$'^2>1/S0I[D>M3V/<?+A^D3WK]7OM.'Y,O
MB)Z5;D#^41!_DED3\T*>Y#K4]CW'RX?I$]Z_5[[3A^3+XB>E5Y`_E$0?Y)Y$
M_-"GN0ZU/8]Q\N'Z1/>OU>^TX?DR^(GI5>0/Y1$'^2>1/S0I[D>M3V/<?+A^
MD3WK]7OM.'Y,OB)Z5;D#^41!_DED3\T*>Y'K4]CW'RX?I$]Z_5[[3A^3+XB>
ME6Y`_E$0?Y)Y$_-"GN0ZU/8]Q\N'Z1/>OU>^TX?DR^(GI5>0/Y1$'^2>1/S0
MI[D.M3V/<:_UX?I$]Z_5[[3A^3+XB>E5Y`_E$0?Y)Y$_-"GN0ZU/8]Q\N'Z1
M/>OU>^TX?DR^(GI5N0/Y1$'^2>1/S0I[D.M3V/<?+A^D3WK]7OM.'Y,OB)Z5
M;D#^41!_DED3\T*>Y'K4]CW'RX?I$]Z_5[[3A^3+XB>E5Y`_E$0?1[D\B;_R
M0I[D.M3V/<?+A^D3WK]7OM.'Y,OB)Z57D#^41!_DGD/\T*>Y'K4]CW'RX?I$
M]Z_5[[3A^3+XB>E6Y`_E$0?Y)Y#_`#0I[D.M3V/<?+A^D3WK]7OM.'Y,OB)Z
M5;D#^41!_DGD3\T*>Y#K4]CW'RX?I$]Z_5[[3A^3+XB>E5Y`_E$0?Y)Y$_-"
MGN1ZU/8]Q\N'Z1/>OU>^TX?DR^(GI5>0/Y1$'^2>1/S0I[D.M35ZGN/EP_2)
M[U^KWVG#\F7Q$]*MR!_*(@_R3R)^:%/<CUJ>Q[CY</TB>]?J]]IP_)E\1/2K
M<@?RB(/\DLB?FA3W(=:GL>X^7#](GO7ZO?:</R9?$3TJO('\HB#_`"3R)^:%
M/<AUJ>Q[CY</TB>]?J]]IP_)E\197X7SIBKF&LTV0,.7<VO6T"S$A`&F6L?,
M1J02\65N9^S\'FX^,>B9N5VGJ;L^H/6V".@Z<&XAX:SSA7,/5?$%NZVS#`'X
M'%I.%U0#WKG#30Z*UT+EF2Y[E/$5EZPR:83V>,MQ`.`Q"E1WP!VC32BNU6C6
MW2B)1$HB41*(E$2B+AR/W@\UUT\&6U`-XAV9M0#NC2M-*MRT$3B=(H5IZEWF
M1;KR7=[AUD6=BXMC-/XIG;*Z+=:`:1K0^B)&;$>S(*I@U,8YRJ"8^_0-E<&X
MCLX\]#[*\?*(CH(:XBHYC3XPN^N%N%N'H.'[/?6C)=_&)"27-.(G4"#7"=H7
ML#$5^9&P;=D]"R4;<U]6Z^NX,<7/>,<K)*03UF4Y8Q^@UBRH'=),A,<J:2(=
M8=V@UL^&X6VF2BW@;5MN[#'B&*E-5.?N+K_KAR>QL^+([3*H(H))+6(O8W0U
MI<*`DN)H>G1H-=2TCY$LRVK[N"WF<MB^[+YR='0:3"]I5U:MT(2AIMNHY46E
M%+;;QKJ8BXU$Y0[(ZX%4$!`2@4!TK%S3.K_,(FQR1&.^;H>6--*@T%-&OGKM
M7K/J-ZNLMX'X5]8<<YCE)FNG@PL?<,>R('2<+JU#CMH-"N/B_E#YH<[R`L;$
MQ6[M2W@:I)%O^]BN[28,I=FF+,CM1A),D9R;*1N?M`2*D4IS$#[8&FE:^+*L
MRNY#^A#HKBKH/=/.NU^+NO'J\X)M!;LN&W6;8`UC;7#)HU=](#A`YJDGH60/
M,_YEZQ,1<GN2<HV_>]XWCS`8\L\;Q6EYB0!:UG8P;I&2N%I#0*[5<[!`T05=
M-+K*";JE`1T$1K97O"N7FT>]Q<ZY#2<7Y.;XUY>RG[P?%>:<;0[X119'/<M;
MNL#786$C4XZ1SFFM8K>;,G8>Y>9/E[?MNRB1+>[19.#ZI0<)NU;0DRK+%33.
M9(K9TF0J@&`1U$PUUEPZQS>)[:,MU2U)Z*.`Z.XO;_7+?VUQU$Y\ZS8UD;\O
M;WK6TI\Y%WU`-`/X5]DU=]KY`I1$HB41*(L8.=@PEY0.9TP"("7!64!`0W[+
M/EAX`(UR_@`EO'&4.&L9C;_^JU<;XQ%>$\R!^I3?^FY?G]C<H`(@.@@&SOC;
M0#9INWZ5]1?65=(.WXEX'=:N).CEW=OXT\IM^[>'U1MH[P$-G`:CUB>?G4&U
M=S"NA/*4/]'37V1M^[7=NTIZQ-->SF3T5W1KY'EVD\I@V;@W_5&V#MUUV<1H
M<R)&O30(+5VC0-94>4H=`::;NL;=NTW;].-3ZQ.DUVJ/174I0:N79V_C0;F#
M;NX:^N-MXAPX#KK09B1H)VH;5VG0-BGRE#_1W])OG[MV@!09B=&GGV*?175T
M@:^17#D)=K*,U&+OMNP5$1$S9XZ9.$CZ;%47+8R:J9P':&T2Z[P'2NL.L_JQ
MX(ZW,G.5<702;T,^:N8)'P7,!YXY6$&E23@?B8=.BJ]+?=J^]7UV_=2XI'$G
M53?P"REDK=9=>P1W>77@T`B>VE#@UQ``$T)CF;0=^0,*QLOV/EH$$NRNN7DH
MN4%=$K-Z_>F7`$BIBLDX)VIFSE(.N7;L[X`ZH[1KX>_>FZD.(>H'.[7+#Q'-
MFW#^;1RN@8^65MPV.,M#A<1%QC(JX`/:<+R"`T82OV<?Z:7WV."?OV<$YCQ&
MS@2+AGC;AF:WBO9(X()+!]Q.V1[#870:V;$&L+WPO;CA:Z,F1V,*V;5RY9KD
M7:.5F;@FH$<-UE$%4P.`E-U54C%4*`E$0'0=H5Y+M;FYLYVW%I(^&X;J>QQ:
MX5T&CFD$:-=-B^H%]8V.96KK/,88KBS?3%'(QLC'4-15KP6FA`(J->E906I"
M&B00?S=PS$Z]$B*Z3<\K(DC$!4("J9^R\(`[PP`8._T)_HCNK[+_`'</N<Y0
M,HR_C_K.SRYSQ]W!'<06D%S.+(->T/89I,;9)SL<P!C*Z#6B_)+_`*@_^L!Q
M=;<79]U$_=OX2L^#G93?7&7WV;7UC9OS5TL+G12BSM\#X;-M1B9,\S2EI:]H
M;B"N8-SB<=3"`B([Q,;U-=--`+H(Z!N"OI)9RVMA:LLK!D<-G$P-8QC0UK0-
M`#6C0!T+\[N<7^<<0YK/GF?7,UYG-U,Z2:>9YDED>[2Y[WN)+B:[304H``O'
MRF]3<.GKC?.'9O$=U9)S(TT'F/Y%K!:NT:!MY=E/*4.@----.L;=T;M^E3ZR
MTZ]J>BNI2@U<NSM_&I\I@[G#ZHWJ@.[@-!F)Y]-2AM7<PV)Y2AKN+IK[(VG1
MKN[W2GK$TIBV*?175U#7R/P)Y3;M-`WCWQM_'79Q&H]8G778$%J[F&WE^)4Y
M<8M+C0*15_*Q;I(@@@^B9%RU6*`B(@FNB4Y6[I/7V0`8.!MP5Y?Z\/NR\#=<
MD<F96US=Y%QB1WMY9O>QDA.H7,`<V.45UO:&2:3WSE]+ON9_ZF_7=]TN2VX:
MS6SR[C3JAC(#LJS.*)\UO'M]7W[F/FMR!X$,AEMQH`8QH6+-VDEF,HO#R,ZZ
MFR,C)*)++.W2Z0]N@18IBHN%5106`BNA@W@.H5\(.MOACB'@'CK,>`.(,S&9
MW65W!C,K)9)(B[""<(D-6N`=A>TZ6O#FDFE5^VC[L/6=P3U[=2V0=>7!&0RY
M!E7$N7MN8[>XMH;>Y;&7.:,>Y&%\;BW'#(#22)S)`UN*@\;5"7>R;>'C)QS#
M`^4$3*)/';=(QB$$PCV34Y177$A="%WF'9J%6.JWA[B'C;C3+^!.'LR&6W>:
MW38FR/FDBB#CJ+]WI)V-%-+J-J*U6?\`>-ZP>"NIKJ@S[KIXWR.7/<IX:RR6
M[D@M[6&YNG1QT+FQ-ET`:G/=6C6!SR#AHLI+:(TMM,1)(RLN]4(!%7\M(NW)
MM@ZF*W;&5,V;IB;</5,IL#4V^ONQU'?=;X)ZH&1YKFMW=Y_QH&@FYNWR.AB=
MM]'MG/+&Z=3Y,<FJA:5^)_[YW^J3UT_>K?<\+<*6&7<#=3TKBT9?ET4+;NYC
MTT]/S!D;)9`YM,4,&ZA)J'!X*J?RE#3AN'3UQMG<W;Q$`KU><R)J:\Q7RY%H
M0``!2AY<N=/*4-NH!N#ZHVT.C=O#4:>L377H!3T5U#H&KEV4\I@VZZ#M#ZHV
M_AILW`(!09B=&GG0VKM.@:QRY?&GE*&OU.FH_5&T#N[MVE1ZQ-*5V<W+M?&I
M]$=74-?(_!RHGE,'<XZ>N-O^=O$=U#F1IH.E0+5W,-O+LIY2AT!IIIIUC;0W
M:;M^E3ZQ-=>WE^=/174I0:N79Y54>4WJ<-?7&^ALX#OH,QYSIJAM7:=`V<NP
MI\I0X=7?[(VG0`[MVE1ZQ--)V%3Z*ZND#7R/P)Y3!LTTUVCWQM_'@.\1&I]8
MG779S(+5W,-94>4P<`#=[(V[V.[?L"GK(@G3MJH]%=34-7+L]U3Y2AT!N#ZH
MWSMV\-1H,Q-?"VH;5W,-7+ET)Y3!W-=?9&VCT[MP:!3UB>?G3T5W,-8Y<N=`
MN4.YO';UC;^G=N$!&H]8D[=BD6KJZAKY'EVD\I@V;MP_5&V=S=O$=*DYD=-#
MS%/17:-`U%1Y3!Q`---.^-NW:;M^FM/6.G7M4>BN(U#5R[/*JGRFWZZ#N^J-
MM'>`[N`U`S$\_.I-J[3H&Q/*8-?J=-?9&WZ::[N]TH,QT:]-.9/175U#7R/P
M<J)Y3!LW<=YC;!WCPXCNH<R-->F@06KM&@5T\NXH\I0X`&FF[K&W;M-V_3C4
M^L=)T[5'HKJ:AJY=G;^-!N8.YPU]<;;QZ.`ZZT&9':=J&U=IT#9R["GRE#AU
M=^_K&^8.[=H`5`S$Z*NV$*?175U#7R/P)Y3!LW:ZB/?&V#Q'=QU'2GK$\^SF
M3T5U1H&LJ/*4.YN]D;YH;MXZ!0YB=.GF06KN84H>7+G4^4H;==-P!WQMW`-V
M\-1IZQ(.O;R[2&U=S#5R[/<^%/*8.(!KJ'U1M_`=VX!`*GUB?UN=#:NYAK">
M4P<=-_LC?/W;M!J/6)IKV<OS)Z*ZNH:^1^!1Y3!W-PZ>N-ZNF[>([JDYB::"
MH]%=S#;R[B>4H=`::::=8V[=INWZ4]9:=>U/1'4U#5R[.W\:GRFW[`X?5'W[
MP$-G`=]!F)Y^=#:NTZ!71R[OXT\I0U^ITU]D;3HUW;NK4>L32F+9S*?175U#
M7R/P)Y3!LTT#?Q-OXZ[.(T.8GGV(+5W,-O+E\2>4P!N`-V[K&W;M-V_3C4G,
MM)T[5'HCJ:AJY<OC3RF#;L#A]4;;QZ-X"(T]8FNO;RY?$I]%=S#4.7+F3RF#
MN:ZAMZQM_3NW;`J!F)T"O/L0VKM=!K">4P;-VNH_5&V#T[MPZC4^LCS[$]%=
M74-?+ET?"GE,'0&N@_5&^=NWCH%0<Q.G3S'\BCT5W,-1Y<N=1Y2AMU`-P?5&
MVAT;MX`(U/K'3KT`IZ*ZFH:N79[FM3Y2AMUT':'$WS!#9N`=*CUB?UN=#:NT
MZ!K'+E\:>4H?Z.FOLC:!PUW;NK3UB::]G-R[2GT5U=0U\C\"CRF#N<1[XV_>
M/#B-/61IKTT'YE`M7<PV\N7Q+[&O,;.?"^2#MO99BR#TCL\&MS3:.T=@UX#^
M\7)O.L4O_P#TH?PR+V#U)M+>"0#];E_`P+<571"[=2B)1$HB41*(E$2B+CNT
MC+M7")=.LJBHF74=`U,40#4=!T#;533A<#S%42`N80W60L8<J\N;&\TS*VTH
M%MRTQ)LC3TRS6*1RE&E'JR"T8BLBJW3D7"/K0.("`:B.FM:F_P`N-P0;=P8]
MSAB=32!726_RMG,N;<'<8WO#TK77H%Q;V\1,,;M+=[^CCYVA7DM"PHVP[7@K
M4MML5",@VZ39$JZW:++>NZ[ATY6!,HKNG!S&,<VSK&&LZ"WCMHFPP$B)FK:3
MT_#TKB>>YEF?$F;RYYFI:Z^G?B?AJ`-5`!^J`*`<RK!*'C$ECNBQ[$KI7]N<
MD9M2KJCIH/:+`B"A_FC5XBNO4K;I)'-#'.<6#971VESRID(``4I0`-P`4H`&
MW70`````"FRBMT&U=-<ENQ%UP,S;$ZP;R4'<,5(PDU'N2ZH/HN5:*L7[54`W
MD<-5C$'CH-"UCV.8_2UPHJHWOBD;)&:%IK4:P1J(Z05KEP+YJ/EEY=LF0V3[
M%->BLM;,F,G;3&6GB.HZ(4\'<M4T2D*T36=(H-G1B$`YQ$"Z!J.E<>MN&<MM
M;MM[%C$S7$C3HT]"[FSGKXX^SSA5W"%])`<LDAW4C@SYQ[`6D`NYP6C2MFU<
MA73"41*(E$2B+';FZMR>O#E:YA[5M:*=SMRW%AG(T+`PS!,%7TK+R-JR;5@P
M:)B)04<.G*I2$#7:80KDW!EU!8\799>73FLMHKZ%SG.T!K6R-))/,!I*T?$]
MO-=\.WUK;M+YY+25K6C626$`#I)7P?'\W[SUF.8P<L65M#',(:VT_P!VHCJ.
MJ&N[YM>[SUB\(5_M.ST_^:W9V?RKR*.!^)B!_P!/N?D%>/H_.>S?\6/*N[7W
M-/\`9ZOVC>([J>\7A#6,SL^?]JWNI]A^)O9]S\@IZ/SGK^3%E;8`#[FG^X>`
M?:-HZ4]XO"`_O.ST'RK=1[*?8?B7V?<ZJ^`>TGH_.>SY,65M=0+[FG^T1X!]
MIW`._A3WB\(;<SL^;]JWNJ3P/Q,#3U?<UK^H5/H_.>P?^6/*N\0]S3_@&_\`
M:`V:5'O%X0]IV>KRK=G9U)]A^)O9]SK_`%"H]'YSV?)BRMMU'W,O^&\1^T=.
M[C4^\;A#21F=G77^U;K[:C[#\3>S[G;^@4]'YSV;_BQ96W:^YI_KH/#]HWT]
MXO!X_O.SU^5;M[*?8?B:E?5]SJKX![2>C\Y[-O\`]L65=FSW-/\`CP#[1_FH
M.L7@^M#F=GS?M6ZNVAX'XF`/_3[DT_D'NKJY;S;7.S+/6SJ0Y:,L.4&J!&Z#
M!O;4@B4QM!.X5<NA0ZVBBZ@B`%+U@(4I1'H\$\=]367=?G7%=<==:&>VMAP-
M:X;:QLX9V.N9;>&O?/=5S(&S2%TAIB>0X:B%]X>I+_4)R'[B'W1<HZD/NT\.
MR\0]=N8A^89UFUU"^/++7,;L-Q1QLHR>^?:0MBMVUW<0,6ES@5ZGWFV><Z22
M306Y4<G-02*)$%XZU7;99(A0-L-HWZKD@".OVWK''0/7!QYEUB?=F^[)QEP]
M#EG#\]GD6;VL.&&YMY0XNI]:8XG?BNDNJV371U*!=-=0/^KI]_#JFX_N>).L
M*6?CCA#,KHRW>77T;8=T#K.6S0M:;/"!1D1;)`:#$P$EY[1GYO'GJ81S)G\6
MO*;D6B9D"J%M9^D)FY!U0$R78#U%"@?JCJ)A,)===!KL+[N&97O5IP([JYXX
MS/+IVY1<N;97<4[3'<6DG?M&$D/C?$XN86.&@$:2N@_]1CBGJM^\AUW0?>)Z
MCK',K.7BK+8Y<ZRNZMW1W-AFMO2&1Q<VL,\=U$(Y&S1O.-[7XF,T!>WT?G/9
M\F+*VS3^K3_CP_:-_37H+WB\'ZO6=G2M/VK=1[*^?YX'XF']WW/R"GH_.>SY
M,65=_5]S3_?]QW`-1[Q>$#_>=GYUO8&O4I^P_$U:>K[G73P#R[*>C\Y[/DQ9
M5VZ_U:?\-X_M&[2I]XO"!']IV>KRK=8[*C[#\2U_L^Y^04]'YSV?)BRMNU]S
M+_IT]HWB-/>+PAK&9V?/^U;W4^P_$WL^Y^04]'YSV?)BRML#7W-/]P\/VC>(
M4]XO"`_O.ST'RK=1[*?8?B;V?<ZJ^`>TI]'YSV<>6+*NP0#W-/\`;KT?:.`[
M^%!UB\(;<SL^;]JWM:U)X&XF]GW/R"O8CYOOGH%5/M>6/*H)]?U^MM2&@@4!
M,)1$$-2E-H!==-FNM:K/>L_(K+);N[R>[M+O-X[9Y@A$S!O)@T[MA+G`!I?3
M$2=#:[5RW@'JR]><;Y1D_&F^RK@ZXS&!E]>.BD>+>TQ@W,H;&'/<X1!PC#6D
MF0MV5(IM#S:O.R5ZO*/^6+*LM).ESNCJ.+6>E9HJG.90PE;`W`JYNL(!Z\.I
MJ7870:\'=5GW7^K:/.9./>O#.K'.N*[N=UR^T9,/16RR/+W;Y]0ZX.)QJT88
M]'Z07W-^]#_K`=:-SPG!U(_<HR"]X0ZM,LLH["'-KB%OK*2VMXA#'Z';]]%8
MMP,&&1^]GII`834'7FU>=9PY2D&G+!E2(D4%0=$7;6O(^"*J`H"A2K-$DDQ0
MZYA$!%(2@`#WH`%7>MO[KG59F68#C3J6SFQR+BVWF;.RV=-_NCY&'&TQD'';
MNQ`:!BC%=35C_=/_`-8;KDX>R9W5#]\G([WC/JNO[1]G-F<4+1FL-O,S=/%S
M%WL5^S=O=B/S=QSN>:E5(MYOSGI[4XDY9,J&*(@.I+9?E+J<-3%*7L-A2F$0
M#AI7N7AGK/RB\X>L;KB*[L[7/WVT?I,6^8X,FP@2`.!(<TOJ01H((7Q&ZS^K
M*SR3K%SS*^KOTC->`8<SG&778ADCWUDZ1SK<F-X#F/;&0Q[2-#FG2=:]?H_.
M>S=\6+*N_J^YI_H(_<-P5O/>+PA[3L]7E6]K7J7!OL/Q-[/N==/`*CT?G/9L
M_P#MBRKMU_JT_#=Q_:-V^GO%X0]IV>KRK=?;4?8?B;V?<[?T"GH_>>SY,65M
MW6]S3_\`^1O$:'K%X0U^L[/G_:M[NM/L/Q-[/N=7ZA[J>C\Y[`_Y8LK;-/ZM
M/^/#]H';I3WB\(>T[.E?*MU'LI]A^)1I]7W.K]0]I3Z/SGL^3%E777J^YI_O
M'_X.X!^93WB\(:O6=GM'[5O8VJ?L-Q-[/N:UIX!3T?G/9\F+*N\0]S3_`(<=
M>P[W2GO%X0/]YV=:>5;K'93[#\2^S[GY!4>C\Y[/DQ95W"/N9?\`#9J/VGB-
M/>+PAK]9V==?[5O=0<#\3>S[GY!3T?G/7\F+*P:!K[FGX[!W!^T=\(4]XO"`
M_O.ST'RK=O94?8?B6E?5]SJKX![2>C\Y[/DQ95V"`>YI_O'A^T</G4]XO!X_
MO.SIJ_:M[OY$^P_$WL^YKH_0*>C\Y[/DQ95WZ>YI_P`/_@;J>\7A#VG9Z1Y5
MNSLI]A^)O9]SKIX!3T?G/8/_`"QY5VZCKY-/^'$?M'JZ4]XO"&OUG9UU_M6Z
M^VGV'XF/]WW/R"GH_.>SY,65MW6]S3_CW.PWCLI[Q>$-?K.SU^5;MVZ]:?8?
MB;V?<ZJ^`4]'YSV?)BRKLT_JT_X\`^T;Z>\7@_5ZSLZ5I^U;J[:?8?B;V?<_
M(*GT?G/9N^+%E7?U?<T_T$>Y]HW!3WB\(>T[/F_:M[`UJ?L/Q-[/N:UIX![J
MCT?G/9\F+*NW7^K3\-W']HW:5'O%X0]IV>KRK=8[/Y4^P_$OL^YU_J%/1^<]
MF_XL>5=VON:?[/5^T;Q'<%3[Q>$!I]9V?/\`M6]U1]A^)O9]S\@IZ/SGLW_%
MBRMLT'W-/]P\/VC?I3WB\'@_VG9Z#Y5NH]E#P/Q-K]7W.K]0]I/1^<]F[XL6
M5N`>YI_O'@'VC@._A3WB\(;<SL^;]JWNJ3P/Q,#3U?<UK^H5/H_.>L?^6/*N
M\0]S3_;IQU[#8&E/>+PA[3L](\JW9V5'V'XE]GW.O]0J/1^<]GR8\K;=ON9?
M\.(_:.GYM/>-PALS.SY_VK=?;3[#\3>S[GY!3T?G/9\F+*V[7W-/]P\/VCOA
MI[Q>$`?[3LZ`^5;MVZT^P_$U/[/N=5?`*>C\Y[-O_P!L65MF@>YI_P`>'[1Z
MO<I[Q>$-N9V?-^U;W4/`_$VG_I]S\@]U/1^<]GR8LJ[]/<T__P#D;@I[Q>$#
MKS.S\ZW9V=2G[#\3>S[G73P"I]'YSV?)CRKMU_JT_P"&\=.PW=%/>+PA[3L^
M?]JW7VU`X'XE]GW.W]`J/1^<]GR8LJ[NM[FG_P#\C>(T]XO"&S,[/G_:M[J?
M8?B:G]GW.K]0IZ/SGL#_`)8LK;-/ZM/^/`/M`[=*>\3@\?WG9Z#3]JW4>RGV
M'XF]GW.K]0]I3Z/SGLW?%BRJ.WJ^YI^&WN:H;@&GO%X0.O,[/F_:M[`UZD^P
MW$P-/5]SKIX![J>C\YZ_DQ95VZA[FG_`-H_M&[2GO%X0(_M.STCRK=8[*G[#
M\2U_L^Y^05'H_.>SY,65MW6]S3_@.GM&\1W!0]8W"&OUG9UU_M6]U1]A^)O9
M]S\@IZ/SGL^3%E;8&ON:?[AX?M&\0I[Q>#Q_>=G0'RK=1[*?8?B;7ZON=5?`
M/:4^C[Y[/DQ95W@'N:?CJ(\`^T<!W\*#K%X/]IV?-^U;W?R*3P-Q-[/N?D'N
MJ/1^<]GR8\J[]/<T_P!NG_P`V`%/>+P@=>9V>D>5;L[*?8?B;V?<Z_U"GH_.
M>P?^6/*NW4?<T_X<1^T<>%/>+PAK]9V?/^U;K[:C[#\3>S[GY!3T?G/9\F+*
MV[K>YI_KH/J(;QV4/6+P@/[SLZ5\JW;MUZT^P_$WL^YU5\`IZ/SGL#_EBRML
MZ+:?\=P!]HW[^Y0=8O!XT>L[/73]JW5VT^P_$WL^Y^04]'YSV?)BRKOZON:?
M[1^X;@V4]XO"!_O.SYOVK>[J4_8;B:O]GW.NG@'NIZ/SGLV?_;%E7;K_`%:?
MANWB/VC=4>\7A#VG9ZO*M[OY4^P_$WU"Y^04]'YSV?)BRMNZWN:?_P#R-XC4
MGK%X0U^L[/G_`&K>ZH'`_$WL^YU?J%/1^<]8?\L65=FFSR:?\>'[1M'2GO%X
M0&CUG9T!\JW4>RGV'XFU^K[G5^H>UK3T?G/9N^+%E4?J?<T_WCP_:=P#\RGO
M%X0]IV?-^U;VM:D\#<3:O5]S6M/`*^N[S,V)\G8:Y,FMHY9LJ<L*Z5<G7O,D
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MTQ%V[?X-0V@Q$5;6[%;SS/:R)I<][97`#3WL$>]E)_5#(ZNJ:5H0VI!"K2,O
M"WYBXKBM2/=N5IRU$85Q.-E(J7:MFR5P-EW<29M*.V*$3*BNW;G$X-%UQ0$`
M*J!#"`#:8#)$Z=O[-LSHCL.-C6.<*'30![>^`PFI`)+7`8N^C,C8@:O?")6Z
MZ%CG.8#754N8[O2<0`!(H6D\96_K.0OQCC!:X&*=_P`E:DE?+&US"KXR<VE#
MRT9!2<ZF4$Q1\"9R\RU0.(G`W76+H`AJ(3$Q\[)Y(AB9;&$2D?H&??;FO^T]
M'FPT\FZM-"IEN(8)H+>9P;-<B4Q`ZWB#=;VG\S?18OY[55]4J\L<;?YO.6>Z
MX:^[@MO,]DS41C'+B.!\@O(^04<!:&8'$U$VZVL&=0(W\)8SKB9G&B"93$[,
MYG!1*<2CU@KMHWWEM87EJ,=KFA<+1P\&<M<]C@P[2UT;P0:$%IKL5<D<D5S>
M6D@+;G+X#-<-.@Q1-BWQD=_)$57U%=`(U@A9'50J$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB^9_-<_S.9$YUN>VQ\`3/
M.;)YSQ_E;E?9<O<K:>0;WC>4+%L%)XPL&Y,A1^6+=?W4EB%>/FF2\DZ<M'D*
M\D'2BY!;G*J8IBW^#PUT-AF-Q3T9O$=\R]?<=]')81.B:880ZI,C&O<&"$,D
M8]S'8J`K8\81V\44%N&NJ_AF&6%EOWDWIK[K,&1RR.;A&$NCA#C,71NBC>TM
MU*@+ISGF(G.5D^!M#)O-;`9?<^<[L##5@7?=-ZY"'D=8XD+:ED7%?F'9:"FK
MC<XE+<L_;H2_BM@C%H3BTHX;`U<@<PE&_P`#-MKLY6'@NAFFSZ2[;/5S[FUM
M+N];&VSK5XFMVLMPTQ%K6-BF,@<QKP>/<1NN8#G`G>WTBURG)_1#;T:VWOKJ
MTM09+MHPC<2SR2.DWV,%KV8<+RPB^C?,V9R^<[=>;K6YA+[6P0MEHO,HSS#Y
M43WE>G+-K=0OAQYO8;Z(N@`',]$;F!F#A5R-EE,P$H;1+;X.<+ZUEGNF-?)D
M,-S'$#I]9`NCC;=2@MI*,J]),-T=.\N?17OT,D:,_BG_`'+"^T<(SG7HHE'L
M\N,^+=`UW9S)MH/1_`W1?.8AWT)=E]YX$,Z6_P`O]IY/Q%S%W[A&+Q]F'":M
MTVUCADPC9G)Z=S9FL"UBP,]?:JRDQ"V<E&2SKPQA'HI*R1E"%5<`B4R2F)E+
M]UQSP^+@;ZRNLZL[8PNT1ELLCQ*Z0#3+5N%K&$AC2'.<'DC!1FT<LW!V?&U?
MN+JWR',KD2M%9`Z"T?+$(G$TB(D95[P'/+2&L,="73YSU/.]LSW*!DS'?,??
MF,;!CN;[EDL6[L26''1\.CE(E_Y9C(.;3O\`O<5UYY]9_D^X%N$&U2:(+K&,
MHY57*)$B9W"S(W<>9=;WC=_;74>81B-QI$S=Y3?SB0LI\Y*V6%CF.<<,=*M9
MB[Y4\03!O`F:NM1NLP@CCFWX-9"WTJUB$3-0C'SCR]S:N?WK:M:"'8D<T>4L
MOW.GYUK.D9FG+V-+H\WXO:"7+S:EGW[/VK8!5H'&,%DN7?W_`&!&R"5L948Y
M-E)!1@H2?9/DT68=5GV2@=H&)D8P9?E.?X3->7W%CK&6-]71OM8\PM;+T=L;
M@6QN?',]YE8!,)',<'@-`6SGA9?\07'"3R(+"+AV.Z;,SO9!<7-O=S[]TF@D
M6[H(VMB),):UXD8XN*^@&T)9W/6G:\X_;@T?35NPLL]:%ZP%;.Y&-;/'#<H&
M]=HBLL)0UV[*S,TMH[+,[BSA.***>1C3SAKRT'L@56AR>ZEOLIM;V<`3S6T;
MW`:@Y[&N('9*J*L%;%*(E$2B)1$HB41*(E$2B)1$HB41*(M'RW*'=F2\T9PB
M,JXEN28Q%?7G($LINVCMVX86[>.,&?*ECBU$)V72BY=HI-66M><0NQ69N2G1
M<+H"51$Q``1R8([2:TX>@O6L>RUL>(Q*UVD1R7-Y<OM<0U8Y&/:^(Z2TD.!:
MY7N(IYI);F3+G.QR0</L#F&CJ6[YC=!KM!&[!:)*$5:ZFD$K#/+G([GO*>.;
MBQS>&!KOOBR+.Y8\TVG8MGW,*4O%%5LGGDL^\L2VG#,GTT<CRY5,%V\H$%VH
M]J=D!415*)NK6QRO,+""PM\VSUCKF_8>%9IP6[R>22*POHLT(&C%(V69@N=/
M?DCPB%C</M]&SWT5X$63^G<41QCP8F03F/U94#5$2T&"H(C#:T:`K^9%QAE$
ML!S"#CWE2O$<#9(<<H,3:6-+RQ9/7>SLG'MMXQF65S$#ED@LDV`[OL+5N'P5
MG(VZ:7CT$U%`<*&5!'0=#<MNWO=;YH\7%S)Q)F4QF'SW>29;8,M7M)<P-9+/
M')&VX=_1GM=*&X@"L6Q88)G3V;7Q,CX<LH<&+=!TS,US)]TVH#BY[;>6.4QC
M^DL<R(OHZBMSA?E)R_`..5S)=]\N]QK\Q2?)WS#8,LS+:]C(.)S"N6AO9M*8
M/E+V44O"Y'^/+;C[+*X;1SD\E)!'E4!J=<PB!JS;F6:6US2*S?NL_P`PRG*7
MOF+L6\DM[>\BS.)\P$0=<3"6W8!2/?X>]<TLJK<L#)L[RZ]G:V3ANRSS,0(1
M%@#(;BXM);"9EL3)2"$Q3O<*O,6/2WO]&4_FGL)Y/Q7<63WV1&EZVC,/K`QQ
M!WQ9[OE>N3`EAW'D^(<SRET9.97A-YXS,PS%?$VNY.WD9QFE%E>M4VJQR#UB
M%)L99K-V421V%!ECK\NMHC\V;>+=T+([8@OBCD[QS@97M$K'$5<Y[W7I67?I
M\)O2U]^R*833-[\W#G/B+7/G!:'",AY@;NVEK)7M[T-#!BU>G)KS*V&%J9#Q
M%B&:D#YKYUH:+YH\>H!'LWR^/[;YHH_).,>9))%202:N%;-MV.=,9(0$SMW#
M/FXZ?O,I:TW!X=8,X;RBX(BL&64=Q(]W_!9A;P73'!P%26WD;HV2`$AL\4+@
M"99'#)O'F3[4YF`Y^:.?FEO;"NB[LK^%L;6-T>%;SNW\)<YH$3KINO=@7-M_
M`N:S9)$K/"N58?F/C;RYAY?F1YE7S51G8^<L.W39N4HW&5AVC=PSJ@789-[.
M6P6.ATVZ`0"L8J<`2'45++!;2<.7<%M%)!;.X>?;R0.=\Y+F1EMCOZ@UE<<%
MS(+JO>QR"&O?81MLPN,O'$;[AD;Y`[-[>6QD#JLM+5C&F5L@-:1.;BB-K0A\
MKVS4I'577Y:N4S.6";PA+=Y>FK?EZCKNY(\#.L@7?D*S)S,MHR/,E`W&_8WH
MO>%L#E:QYF>R6I:'9MW#\9A,01*GUS+`0I`Y9G-S;2OS:WLI(AES.(C);,#:
MAUH^!XDW!!;NVOE$;WN(=B>"YS"]Q<N/Y9;Q?9S*K^^8X\4/CN([DXJ.:W!:
MR0[QFEI:V1UPV,"A:*L#@QH:MSD$WF6D)$-;CDV,U<#>,8H3<Q&1*L#&RLLD
MV2)(R+"$7E)M:'9O'93J)-3O79D"&`@K*"7KCQZX=`^=[[5CH[8N):USL;FM
MKH!<&L#B!H+L+:ZZ#4K\#9F1-;<.:^8#2X-P@_`W$ZGRBNUJRKJQRYPUU6W*
M5S0.$%UVJR'+UF99)RV74;.6ZB>.KB.1=NY1,19NLD8.L4Y#`8A@`0$!"M!Q
M/"RXR2:VEKNI#&QU"6G"^5C74(((-"=(-5R?@D!W&.5!P#AZQM]!%0?G6:"#
MH(YQM7SMV-DG+?*5?W*IRTH)WMD.8P;RJ\SG,5RPSUQNIRY0R1B*5P!&R<39
M-SOTUCO;DN3#M_JJ10IK'4>.HE5B8AA4,<]=D7%T;R;B5TKV0YM86EG8W,A;
M4"%^<6T4&98"0'$6@?Z10BL]M*]U&S4'"+.U;%9Y1-;Q&:PS7,A/#`V2CO26
M65U)=6(>YSBQLT[FRP.=WC6W!8UH;;BN8"',QG-]%7%9V'^<TF:FUTP7+_/N
M\\(6?AFY_>/R'DW)\5;%U8G8QEF6W`VFNDXM9TNZ81<V1W/0XM^L[<N.N0*T
M+[6*7,;?*V.>VP;Q#;6<<[:%][;2VU]+,X2%KH'NC?;P?.V\;8P)@TM)%3;G
MO[NWL'YA+`UMV[(;NZDB).&UN8KFRBA:65WK01<3L='*\N>8"6ENFE^)S(&2
M9/DA\YI8>0LAS&1YWE^C.8S&4+DZ886W;EX7'!H8/C[WB']QM[%AK7MAO/1(
MW:9IV\>Q9$53;)J"F503".#?-;+PYD^:T:RXN+O`\-Q!KC:YU+9-?1SG$.DC
MMVND`.'>.?A:UI#1O>#KB0]85QD\AQP6MU9.87`5I=6-M=N90``M9),]L=:N
MW8:'N>X%QUDWS)7MAA;,O.A;DW>T[;6-^0/E=QES!V*QFY>19/<)W]R_76_4
MR3"V^9XJW)>6+[W*UECNFZ7ACJ+.\1$P]8#%V'%-PRRO.*[.YT9;F?%E[:AU
M-%M=,M,K]"E:0*LB>Z>6VF`+6`3MF()B:%A<'&6]S[AUL-#>Y9E%C>,;0UN(
M7YIF;;Z!VQ[W0P1S0E^J6V:RH:]P-;03#E'GRY"N;/5Q6(TS3;_(?R>3'+W/
M/[U)$YTCKC=8FNZ1B7^%FZ$RC?#J:D;F(T,/BM!8[EP)4U0.4QBC.;BXL+SB
M!^58F\31<4RQAL0K)1N690&Q2-:"3`7NE#VN&[PNF<[0'.;B9)-:WW$66>MB
MU_",F5,E^>T04?G.<&21I?1N]W+8BTCYP880T5P`_0UR^O;]D<$X;D,I)ND<
MDO<86,ZOQ-^B1L_)=KBVHU6>!^W2`$T'_C(RG;D*`%(KU@```-*R<_9;1YU=
M,M`P6XG>`&&K!ITAATU8#4,-35M-)567.+K1IJ]T6)^`OKC=%C=NG/KIQNBP
M%U=.(FH!JKOUJ%FI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBM796%L<X]
MO[+F3K3@U(V],Y3-L3^3)4\I*O23\I9UKLK-M]PDP>O'#")!E;T<D@)&B2!%
M1+US@8XB89A<;>P;EL6BS;<33AO_`)MP6F5U3I[XL;HK1M.]`J5=NII+RXCN
MK@XIXK1ELTZJ0QR2RL;0:#1\\AQ'OCBH30`"TMS<DO+;>%MY5M2?L)9Y$9FR
M[!YXOOJ7/=+60<99MIS;;R!O.#E6LPC)6K)Q3FTF!T0C56J9#(CZWUY^M5:2
M/L!EXM"6>J[N6YMJ:XY9Y99I75UN#WSRXF/Q-+7EE,&A8TT,=Q+?S3`.=F=F
MRUN:ZI((X&V[&4U-PQ,:`YM'8FA]<>E>@W([RUFM="U36,]%!MGE/F;3GQN^
M[_+;W\4YGQT-_'OCQWY5*2*IQ%HHD9V+92,,+(R8M1%*IM)7V+\O?:T8<LAD
MBMP`*-CF$@F8X:I!-O7F7>8MXXASJN:TBJ[:V^9>QWGSC<P;&V;%I)$.[W&$
MZXS!NH]R683$6U92IKV'-)R>X?YQ+:AK-S2\RHI:D-(MY<MOX]S1E/$\7+2;
M"3BYJ(>W&UQO==LDN->!F89NZ8&>=MX&X)UTNJ)C:XS86LOHLR87"\MWL?$<
M1^;DC)<R5@K1LC2=#P,6H5H%?=*Y]E-ES@TVEQ&^.48162*1ACDB<:5,;V$M
M>PG"0=(5&YLY!\'\PEO8QMC*%R\P\K$XC<6])VB6(YG<\VL\4N6TI1*:MB];
MFD;;OZ+?7??,#*(E6:R\FHZ?I'*`@I62)7MS=N>1?-YA&VC"SO6LK$^%Y8P4
M8TR1221REK09&O<'DU6.QC&Y0[)'C>6$A<7X^_?("YK\#Y'5>]C7L:YC"XM8
MYH+0%%Y>;XY8,@7JA?EW6M=TS,N8RQXN]F*V4<D)6OF)/&R:1+'>9TM%O="-
MMYGEK<,@0Z#NXVTBXZY0$QC:5=MKJ2SO77UL&,>;HW3&!K=U#<NI6X@BINX)
MN];22)K7#"VAJ`KDSGW%BS+YG.=$RV?;XR3O76\A)D@?-^T?"^KJQN<6]\X:
MG%9K%*4A2D(4I"$*!2%*`%*4I0T*4I0T`"@`:`%8Y)<2YQJXJAC6L:&,`#`*
M`#0`!J`',%Y5"J2B)1$HB41*(E$2B)1$HB41*(E$2B*UV1LQV)BJ5QG"WG(/
M&+_+E^LL:V0FUC'TB1_=C^,DI=LS=JLT54XUL9C$KF%=<2)%$H`(ZB%1$X37
MGH#/Z1Z)<W-#H&ZM(Q+,:ZJM8:ANMVH5*M7<\=C9>L+@TMO2;>"HTG>7,F[A
M%!IHY^@G4T:30+'3$_G#^53-N/[>R7C>_7\];%R9^/RR-1&UKA82S#,)99W$
M)6_-PC^/;R<.R>*-/"&[Y=,K-=DLDX34,DH4PY5K:37L%E=6X#K?,,MFOH'5
MH'001/EFK7P9(VQO#HG4>'MPTJ16_?M=EE_F.6WH++W*[EL%PTCP7O?'&TMV
M/8Y\K0'LJWPM-6.`\<-^<!P+FRY[=MF"89:M`M]2$U%8PN?*&)+TQ[9&6)&W
MS2/C5EC:[K@CF\-<[I%")<+$334(==%/K)`>J+."6^@WL(I+Z,VXW3N]FW#F
MM<)=V>^+0U[2ZE2P.#G`-J1.;QNR2^EL+^@=!=&V>]IQ1-G#S'NC(.]Q.>',
M9L<YI:TDZ%7.8><#$>&+[C,8R[3(E[W^[A&]VS-J8EQQ=>39BR+%<O7$:C?U
M^MK5CWWDG9ZC]FLD1VY$O:'2/U"FZIA"Q:$7MR^WAT,BDCCDD=WL4<DHK'&^
M0]Z'N;WV'20SOG4:033<AUK;LN)`2Z4/,48TR2B(M$AC9K<&%[`3JQ.#14U`
MZW$W.5C#+CZ;:1,;=,,WALLY;Q,:8FV+)"$4>X>:LWT_<KR02D%"0MN2;1\F
M9F=X5%<QAZBB:9ME7]R6VD%W,YL;9K)UU1Q`PL9<^BEI=X)?O""`TD%NFNBB
MKS"-V7WOH3OG)";4#`":F[M#>,T4#@&Q-(>::'"@J#576?YXQ>E#,Y^`NB,O
M^,=7[;^-E5\<R,7>I8RZ[BDFT8U8RYH1^Y3C@9+.R'=@H8%&Z0]<Q-*6]O+<
M30PL%!<"4L<=#"(622/[[5H$3VZ*]^,)H5CR2Q113RO<W_=V-<]M1B`>6!G>
MZZNQM+1HJTU%0JA<Y9Q6R->1'F3,?M#XY12<9"*YO*W$#6(@LGVJ*]Y%5DB#
M;"*J7KBF?=@4Q=H#I6-O(S!Z4'#T;>;O'7O=Y4#!BU8ZD##7%4C0KP8\SBU`
M/I)CW@93OBS3WX;KP:#WU*:#IT*W[?F.L21SA9.$(0'%POK^Q#-YGMZ]8)Y#
MREDN[7A+@BK>.DA*-)%55XZ?+RR:J!T$U&YT2B/:`.@#?@AEFGO[9[71S9?#
M:R2!X()%T^=C`T:ZM-NXNQ`:'-I733%N;F*V%@ZH>W,)KJ-A:00TVC('R8CS
M$3M#:5TM<#317("K:R%XF,4A3'.8I"$*)CG,(%*4I0U,8QAT`I2@&HB.ZH<Y
MK&ESB`T"I)U`<Y4@%Q#6BKBK++\P/+\_)#1_OMXQG$+SO8^)XEO&W7`7$TF;
M^7C)*26L,X1CN0;>/SQ,6Z549+=50$D3]8N@57%$ZZH(FXVNMI;@']$PP83-
M*#J+(L32]P-&U"B27T3%+([=NBFBC=IH622NP1-.UKGO!:P:"2*!7&ACV=<K
M2$NFWCVU/L08JI6Y<<,:+E6@1CCJHKIPDNQ%=$&*_@X$.""G9FZ@`.O5V3(V
M1KG;T$.D:,5:U<T]\VM?"::XA6H-:C6H+0WYHBAB>X4_4>VK'"GZ+FT+7#01
M0M/,NHM2%QBDWG&%C1-AI-&MRNO*1E:C&WR-V]XM106>^/&\0D":5RMA.D=7
MP@`=$U*)M-0JEI=N(2PGT9H.ZIX(`<YCMWL%'!S3AU.#@=((4.+732M>0;@A
MHD!\(XFA[<>W2UP>W%K:0X:""N]EB6U#0UQ2,PWB&,$+*1EKI<.VK8C%=DW8
M&&4?3("D*;I(D<V$%3*@;5(F@Z@&E8]S<P6=H^XNG-99P-<]Q/@L:"9'.Z*&
MKR>>IUK(M8)KB[9%:-+KR5[6M#?"<XT8P#:3J:WHH`K?CD?!2>,VF4W=X8SC
M,27;`PRS>^)J5MV#LF<MV3;`A!$6F)A1C%.(UVT<`FV35/U#$/U"ET'2LN^B
MDM)S:Y@,%PZ2I:_02\M#@:'6XM#372:`<RQ,OEBOXA>Y8=Y$&&CX]-&-<0=(
MU-:XNKL!)YUU\X\Y;F,)!9KN1UA!G;D8RC/)G+4XO8;>$CXXP]E#>(K\?F(Q
M:,C&-U6O@[LJ8B.B=4RO?97+G3$PWDKJ'$<#WES=1K1SBYNPU);T*N)C+^W#
M8`)K6,$@-[]C0UVDBE0`UVL['=*KV0R+CZ)L\,ARM]6;&6`9DA)%OF0N>$9V
M>,<YZO@T@%S.7R<*+)QU@ZBO;]F?4-!&J;C_`'1XBNOFY"X-H_O3B.H4-#4[
M!K.Q50_[RTOM_G&`$U;WPH-9J*Z!M.S:JAB)B(N&+83D!*QTY"RK5%]%S$0^
M;247),G!`40>,)!DJLT>-5R"!B*)G,0P#J`C5<D4D+S%,US)!K!!!'P@Z0J&
M2,E;CC<',.T&HT:-8Z="[&J%6E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6H
MRY.9GG?N7.O/'!86'EJ6L#DT>X]*QQU?5B9&&_,MH7%AZ'RG.L`RU$96:6W8
ML@H=XLS8*FM*31(8$Q6*("8P83;YMCPM)Q9F;#+9QWU]"Z.([MS(;,QXI0YP
MD$CPV0OW>%@?@P![<6(;NYRJ*3.LNR"RD,5U>Y9;W&\D&-@EN+F[@:S`W`6Q
MCT=F)V)SAC<X!V$--0P'GA^3Z2LVSKIEGV3(]>;PYC#.5Z,(3$V0KVCL2X]R
MCXP:Q5T9&NBU+<D8"WK8C)F(=-'D@LL1!`Z8&/U2G*-<@O,M-OFUQET3VN@M
M[Z.T,S_FXM[/##/;L+GT:UTT5Q$6"I&,EE:M*XK8WDEW:Q2/C<+V2WGEW+:O
M>6VLTL%R6-`Q.$4D+R=`=@POP@."R@R5SJX+Q/=MKVM=[N^B,+GDK1AC9$A\
M:7S.XDM>5O\`6C6UBL+WR?%PCFSK37NYQ,M$V/ACI,JRCE,NH"<`K!B@EDS$
M96]IBO'3/A8).\$L[,1?!$74#YFX'5C;WU=`J5E/FB;E/KMCA)EHMO27.9W^
M"V&NX>&U+80*DO(`#6N=J%5UT=ST\O[YOER?6D+WA<;84C[@D+TS5<..;RA<
M)KA:DJI!W&PM7)[Z)2M>[Y>'F4%&JS2.6<+^$)'(!1,&E8L$S;G+8\TB#MQ.
M^)L#2");@S.+(3;Q>',)7#"PL!Q%S/U@LM]O,S./46$F_;CWE-+(#&QLCVSR
M>!"YK'AY#R*-#CJ:56N">:;%G,(^NJ"L]*^[9O"RTXI[<=@Y6QW>&*K^80<^
M#@;=ND+1OB)AIEQ:UP^!K`R?II&;KF1.4#=8H@&9Z-+Z,;H4,;)=U(`07138
M&R;F5HTQR;MS7X'4)8X.%0L/TB(SLA!KO8=[$[]":+$6;V)VJ1F,%I<VM#H.
ML+#2_.?C(EK<^EJ83C;-M*1Y4TKHMCE]R9E,[>>&\+=YI,EVM*7[CNWHZ23D
MT[4\CBV_$D82A5&JCQ&7DV:8*$`_4-5P];NS;TDW0P1R^DMR]S2/GI,O8R2^
M8]IJ<6%\FXPX:^C3FK@-%[/:Y5:03087RQLMY[T%P!@MKR=UK;.#=!!,VZ>Y
MQ+@8YFT:*8C97,OG',\6VODZW[8<\ON.G5M^<HL7DLA<A95@KIF++MW'=TXJ
M;WX^O>\8UKDZP/#KD:2:AD$Q3EHYEV)B@9/K^N&SET1O[?)Y'R,B?F#<Y=)4
M5`]6E^Z9&,0HZ4-HZI=WQ[UHU+:9E9Q6$V9LC;)*++(\JO&`$`F6_NHK>4/.
M$C=1-D+VT`.COG4J5FAR2\TU]<P&*LPW3D:!MR3D<,9?R)BQK?F&XZ<>X\SK
M$6%'Q3]/(F)85])7'-*QDRM(*L2LDY"4`)%FJDBZ<!H:JK]T5OPY8\0,CE9)
M=V<DSK<U?(PQS30BE&L<YDPB$L56->6/%6ZB=);&27/;K)1)#)'!-"ULP.!G
MST4<I9)5SFLD@+]W-1[F@BM1I:,'^2?SG[:\L62N5\_3G,/<5^Y?RSE^-Q-R
MYPG*S/I3\'9&*[YNNW'7O16U9U@^^/DJWH"WXUDK=$S*/)0L;,*';==MH"%7
MWQP6^2Y:T?.WTF56U]=RD]]$VZA@D+Y6MI'#9MEE,5I,6UN&#&9)#JK?(9\]
MS&)@]'R^VOI+2!KS1LSXJ]ZV1^F2[+6/EF@:1N6G2QH`)S?<^<GY43K8+96Q
M=-Y9'E^9"$NRX,10&,<87_?D]<,?8$VRMW('AD3;T`\=V\[L27>=C+H2!6RK
M`R*W:E#LCZ6X[:6;,SE45'3MM+>Z+P08A:W3@V"Y,O[/<R%S2U^*E'-.U5RG
M<96_-IZLMX[V2S<UVB47<4;Y'V^Z/SF]#8WT;ATD4&L5SR(;KD*<`,4#E*8"
MG*)#AU@`=#%-H)3!KM`=H#5APPN+=&@[-2AKL30X5`(KI%#V1L/0O*H5241*
M(E$2B)1$HB41*(E$6&O-;B"_LHWIRB3-E1362C\3\RT!D>^57$HPC3Q=HL;0
MNZ)<R#9)ZLBI)KD?2R!0;H`=8P&$P%T*-6K5KHL[-Z_1;^I,VMZ_^==6HB@;
M371SQ0NU-UN("PL\ADO>'_0+<5NO6^63TU#=6USO)G5.BK6:0W6[4*E:L;8\
MW7S.X]FN0>XK#@K8CXZ/R?C:7YW+(7N:%219#AZ7NR;QYEVUG;=T9G<5V-8Z
M6\0R"#<3K.V#A`PZBT*`;O)[V&PS*2&8$Y._(;@1G36#,9<J98R,:WR5V:;Q
MPJULENR30)'$[OBZ>+.),SOK3$[,9L[?NSH#9LNDS1UZTOJ,0DMOVD32X'#-
M/'A+BVE[L"8$YHK@QQRL\O63,"O\,6SRTYMA\N73E6<R3BZZVE^DL2Z;JN*V
M8?&UOX]NRZ+A0+<CN3;E>J3J$0+1D90"E65^UA1E5Y''=VN=W`W<UKDSK40$
M8GNEFL!9.)>VL;8X\3Y*ASG/(:P-`)>+?%<D5]F>=-R\[V#,\W=.R4MHQL!O
M671JUQ;()BUC6QT:6M=5SC2@.0%R6+S%8-YQLUY\QAA4_,+9?,;CO#%IJL8C
M(=BV'/8KNW$X7G'B[N'WP)>%0D<=3<?<J+@QX?QE+-W9%NJQ6*<HAKLH>;>R
MN<BN`6PSYP;ULY-6-;+;6MM+'(P`R8H_11)$6-<U[7EKBP@$X&96\4M[:9Y"
MY[Y[?+76<D``J0VZFNHY8G.<UE7>D/CE:]S*8(W`N%0,+9+D1YF9R:NJ1E\>
MVT*=RY?\XG>#IHE>]O/&GB+F1LJWHBP$TEUW#)TNA./VKE!4#I(K-DB@=PFE
MU@"M=>VN\R1F70]^]O"[K'305G]>V=Z&G210VT+Y"ZI;B&"N(BNYS6\9<Y_9
MYE;GYF',<MF)%:M;;</7^7R.T@$EMU/$P`#2UQ>*L:2JSOOD#R=&7U:;;#6+
M;,L[&47=_FY[L>0]LR=IVW%-YSE_R1-R>6KG\1(N&I7EP0EH^+P(Z$IG,H5$
MB29U3)[.90YA;G/;R\?*YD$F=9U-"^A^;@ON'I+&%S6C2P/O7G%&VF$DRN:`
M2Y=?.RS,!E#+3=A[_LQ86LC,0I)=6^;MNI&O=^E2V&B5Q(/@!U0`J?\`BP\R
MELX8EL:6_P`GUD/LC6U=<JC=O,+X\Y=[IOG.MGS^3)2ZW4WCB`R@K*6S(7FV
MC7C=4"9-1;1S1R@9-)NY)V8UQFXD-RRRE@C-I:LCMH9K=@C<XN@LI8#.":PB
M-\[@][FUNG13S48R5K7.Y;/&]E_>2.F%_=2-N)8;J8.CIO[F&06SV,I)CC@8
M8F@?[MB@MRY[F/D:RX7(+RA\QV%[_P`$W+EFVR1L;9.%N8FS9E9S<6.7<E$2
M.0\]ML@67"FA\;-HBSVX#;`F.LG!L&\0R6***)"$ZFN?8RB".[;<N#IY<ERB
MV#@9'A\UG/F!F[Z4ND+6QS0EKI#5P.$4PEC=7F4=Q?9G;7L;7[EF<9G<$/W;
M7,ANK/+(HN]BI&"9;><%K`:4QNKCQ'=/6&MHL&/.56]DVZN2#/L#B.,GYR[G
M]NPI7,#:@/#71<%D(7?;KG)L!;B<<JC(.)N;QRC*M6R2!R++*J@1,P',4:Q9
M1;C,LLES`%V31YM9ONA2H]';.PO+AMC8<+YAMB:\4(T':94]S'76X=@S$Y;>
MMMG8@VETZTF;:D..AKM^8\#C0-?A-12JUYY%N'E5R!<_)`^Y.+&C$&%H\V]A
MM+[E<?XFG;3BH3Q9A_+2+>%NQ]Y.130UQP;A9,KLK@5'"!CE*J?40`=NR2\%
M[FE_'(#9R\-9Z8WM(W<LIMX,#X!H#FD#"W`T`FC0*ZN+SQPMR6*RFC>W,H\P
MRC&UP)D8P7HQLE.DAV(%S@YU=#GZ0:FP^)'G,O-<O4=E=UEWF6MBZ<)\I?*?
M?=GV-;TC-VO9MPY'N*_[\1OMS>UBL8AFVO=>4A&:+60BW1#MDT3E6,B1<J2Q
M<[-##EM^,Q@#)S)G&66N[?WT3+::VL8Y\+.G?R2;PDF*2,%A:`\.YKGL%I)+
M<6L0:R`R\525C[UY?:W3GV/S@..C<-&-#J3,<X'&"KL263[R93MSMLZY5S;@
M_E_FN<+F=:S.0\7^55F7*%U1L39R^&+0/<=H0RUP$M.2<+OCLD1(JTFGJ";-
MP+A,W8FT&3@>AV$4[G&[9EE\ZV;K,UVSB&\BPNB(+)G"R`+(I&X',^=`)`*X
MF);HYC>2Q,:Z!]]EK;@N`PQVC^'K&5[FR:'0M-^<#YHSC8YSF8FBM+?/^97,
M-Y<Y+BP[7E<UN+/FK8YG\:Y3M+)=Y9">SZUNVE@F[IS&]W2?+ZVQ+`8@Q+$W
M?/1K5S`SS&<5GYU%84GC8!4$I;-_:MNN!^*GW+8W8\AN9HVM.\=%=">./<8C
M0QS-A=*'6D.\BP4?4O%1R[+K>VM<WR:YCE<9X,PRC"[$8VRP7!C$TA8`[?L:
MYX$D\QA=%<-<UH,8:TWQRA:%[3'FT?-R6Y;N,+=R'=C;+/)4)\<Y01EXFS7Y
MV4HR,[:7^LVLV^)"`@V@`)G*ZD*]\'$H"9+B'-LU)DZRHWPM@EC]#OZF1U&@
M'*)QB:X->-X#^S&C$^C0]I-5UIPD76_5Y.V0RQ2;EHHT=\3ZRA.$M+FDM</#
MT^!4X2-"A_@VTN4Z_<&7+S=L+#7Y;#&YJ;UGH6)M>9N7EUPKG#,-Y8_F[%MQ
MK;[V(7(6W8NT$)^,AI%Y%M6X/%U.S;,SKD(&AMKO+8V299<.?)F4>56=M:33
M#OI&QSSOO(F5<\,>\OLS$S&Z0V]NYHD<&N:>5W4%U?P-N[6&*(G,Q+/#`'=[
M'%E[X(IWNHW$"]KW73L+&/N+B)QCT!PLF$%:MH9(P=EK)^/'\9YML.8SFMO6
MWX*XK&G7E@V6O=5EVLUP[D:Z;"%@Y2A,67#,HW,M!`[8@R9+2C8_8(BHF8EK
M+7/RX1P<1O`S1N0W$5L92'&$R9JR2.T<34MNVV!9&RI+PUDL8?771<-9=V^8
M/R$%]M)G67OF$(,8?##EL\=Y+A.'>P^LA#+*Y@+'D-DHYH)6_#!,EBN9QE`2
MV%(-&W\9R1GSVUF;.UGUFQ;ABY>*JC)PL#(,(Q5M#2:AA6;'(@FBJD<#)AU1
M"EQ%=0MBBN\0>V%H#7&KV-IWK'@DEK@-;7=\-%5BVS[:1TTEL!0SOQ.`HU[Z
MT<]IU.!/Z;=#B#0E7@K&64E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6K6[>
M2'F04S1S<79B_F6Q_CK&7.2XLDU^LE<(RUQYBLAO:^+XO%TB&.;[<Y4:6,U?
M2\6P.LDM)6L_\$55U*4QB%-6+%9Q39$[AO-"Z3*C>W=P1'1CWMNS&7P2.<'C
M=D1ACBP,>6N=A<TT(VMSFLOK2QSO+V-9F5E806PWE7L)@N+F=DH:,!Q`W!HU
MSG,)8W$'-+FDU\V3;=MPO,?:%AY!&W+)S9RGX9Y6K6A'-L^-'%AQV((N^HQ&
MZI!_X[:%NIY/>68JK(]DRZBJ1Q[0W:>LS\[GESO*;[+IL+);SB!F98F@X8VQ
MP9?`VW:PG4UMB,+\6@/`PDMJ[1Y7;195?6-W#4ML\JN;,C0#(^YGGG?.2!1I
MQSN)8!0G40"`+)<POFC[JS[D:.N2;Y@HI]:<.ZY?)BTV%X6#==Q75BF2P8XM
M1=_!XE?1^5[>LFW[+R0XM@7DFW?P$G($?NE%$WG4`$ZRF7H9Q*WB3=M%U'GC
M\P#A^TD8^1T@M)WNJ'10XG-A,;(W-![_`!Z5@RY:7\'-X38X;HY"<M<2#NP\
MQ&/TR.-I:1,[O,8D?(PA@#0W254F2/-52N>9;F7)ES*UE6A8O,'CNX[!D;!Y
M=,<71C>WYV2D;FB+CMG)F5HZ[LIY%B+RR)9QH1-%!U&-8%%T1V[%PF<5$^RU
MUBQEEE;+4L9)=17UE=Q-<#Z/#+92OF^:B!$C&W#G!D[1-A,<;`P,>"\\@N;E
MLV=MOVM(L_1[B"2KCZ1-#<P[AT4LPHQS8VDOB(B#VR&I<YH#5D1R2<DS+E2E
M,B7"^M_EJ;77>T?;T&:Z\(8MR/C^?E+?MQ22<,8^]Y#(N;LQ.)LC9Y(J+-TV
M1HUL@HJJ()#UPZNP?>R'*W9>S%&7W+IBT'YG&8VL#L!!>7@##B=(X[L-;K%3
MIF6N"]9,7!]M%;[IA>*S`8\3JO!$>%U&ES6Q-^<!=J(:,:+H\S)A^]L7Y6=W
M1.1+[F_R-E6Y<XQ7-<C;<XA)65E%2]T+KQU/Q%B^6YXM9''T;$QT8FF9R4[E
M!L<W73%70N/ELGJ3U*[)L4,N4OMWO<34W+VS&6]WFJC;ULD\+P*X89`TE^$D
MY]XV'-;C-/6[3/EV8QRQ-BQ'YB%UL(+=D;C4_P"[.:VX8:`"8%S0W12OKA\V
M"TO67N!]?.1K:NV,NSGSL/G7N6V9O%[*5MV71M'%S?'C_&3V(EKA?L'329=(
MB^*^634*@`@D+8XAVE7+.6UM#E\>Z$EO8#-PUKJ$N&9EY::TT.M\8T@5>148
M*Z+]U>75U%>$O+;N\R;*[%SVZ*.RZXBG?+0:Q<;LLW=:,#M+GC0<K>4_E<#E
M1B<L8_M>[TI'#5S93N/(6',<)0!(EK@^#O(B,E<N.8)VE).47]HIW>H\D8U`
MC=H6/(].W*4Q"D$+$DTUSD5KE5X\RWMI#)`)W$E[[<.)MF25J7/MXW;G>%U7
MQ,B!`+*G%D8PYQ<YG`UL<%UNI'Q-`#1<-9@GE;0`-;<862&,-HV7>/!.\-,/
M+'\VODW"#3!MWX(S]:$5FS##+F+M$]P9(Q+*7CCB\,=<PV79K+S^%D;)@\DV
MA/Q=P6A./FH,I!I-D*OX.<%T#I*`D2Y'<21!L,1PVLF099ED^UY&60QQ1W$!
M-6QO>6O)9(V5F%X!!+<13,9<NF=<%Q!S^ZS2$`@!KKMF[DAET$R,W=*.:8W-
M<*B@)"N5@#S<\9@/)G+SD2*R>\N%7#5A<QL)=3>3MEJU>9#OWF8R2QRK?%[)
MN6,DDRM=BA=)7?@\8DV7*1NLF3MM4A,>N*X9;W=P^`'T%V0Y?E4+":NCARZ1
MKHWO?0;Q[V-`?1K1B)<*"C1:O8Y+^.)]PX>G>OKK-)7`'"]]S:R6NY8TDEC(
MFN;A<7.):P!U7$N6S"L57THB41*(E$2B)1$HB41*(E$2B)1%0^3;^A\58XOW
M)UP(/W4%CRSKDO:9:Q22*\FYC+7AWDT^;QR+A=JW5?+-F1BI%.JF03B`&,4-
M1#'NKCT:'>!CI'E[&M:VE7.>]K&@8B`*N<!4D`:R5E6-JZ^NX[1KFL,C@,3J
MT;7630$T`TF@)Y@2L&[8\Y+8,A;3UY?>%LX8KR`XA<57%8F'[DC+$N:^,J1&
M<'DA%8L<6$^QK?=[62^5N.9BG+5PBZE6BL09$RC\K9'[96TNK"YMY_080)LV
M;>R6LD#"`^*6*)T[S(Y^&,0M@8^4SAYB#8WM+@]I:L!DS/1QF-S6#))(72Q7
M+_V<K6.B8YK&MQ2[['/`QL#F"5YFC+&N:ZJJ!;SA./+3M?)+W-6,,N8.R-C(
MMB'D<*77&VE=F0[I+E6<=VOBT,>K8LN^_+,O=2^[H8+1K8C&54.V>(G3=@AU
M3"%EL#[ED'JP&ZN)[WT,1M!8X7.[;,8W&4,:&"%PE,^+<B,.=O.\<!D&-\1=
M)>-=#8MLY+HS.%8]Q$0V9P+,3L<3BT.AP[VKXZ,.\;7)C#&4KERC"2;Z[\*9
M0P5/Q,B5DYM+)Y;+=OG#9=LD[9RD5/8ZNZ^;-EV;A%70Y6\DHNU5`R2Z::@"
M6IDA8R-CVR,>YU0YHK5CAK::@!PYGL+HW?HN-"K`>=\8\+MW0.:[8]IJ`:>$
MQVC3'(UDC10EH!"O)5A7$HB41*(E$2B)1$HBL;;G,CA>Z;XN;&\7>[`EZVID
MMUA]_`R;=]#NWV1&./F65'UMV\,FV:I7(Y96`^+)*G8F7230(IUC`*9P+DPV
MEQ<64>80-+K65EP]I&O!:W)LYGN;K:UER-UB<`'$M+:AS23ZQS7$#P<5JRV=
M*:'"P7@!MJN\&LM0`*UKWI`.A7RK&1*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1%@+*\XF1[PS9ES#_+/R_-LTH\NLK;-OYRO"Y<L1V*8N/NRYK>:W
M:E86-&SBT+P-?=ZQ5M2#5R](_5M^);G=I)"_%3K@G58QRW5HS-IF[O));N:W
M8_PI7NMWMCGD9$<+3#%(71N<96O<^.01QO`J:[]HLY6V#'!^;NM8[@L.B-D<
MID$(DD&(MDE$9>UC8W@1EKGN;B`7$PSS99]SEF_+MD6KRWV)#XBPCF-7#E\9
M&NGF`?M+_&58VI;ET2LA"8LAL*SD#($8A<J+8$CW8B"BB9S`IU>J)J\NC%UE
MD>;73A'9W$M\R'!60N-G<S6@<X.W>!LLD)<-+BQCJD.<"U8-Y=;K,9,HM&%]
M_;PV,DP>0QK1>6\=R6M<W>8S%')34T/>*`M!Q#8+5I9:I*Z)\(=HOJ4B8&3'
M]]+*@1)'4O?=0-5%#%X`&FVJP8V,,TIHQM.;2>;6L:1\DT[;&W8Y]Q)H%.=6
M@BYYJZNQ0J)U7#:"B8YL=)R=1)!P]DBJ/S.#>Q,1J=,@`<.^`:V,\L'H,08Y
MIGN)BYI(K1K-%`=0TU)*PQDV:VES-+)&[!:M#7#%B!>=.@[013M*^4;+`\."
M!FYVZG9"H4!.50IBE$`$`$-!U+U@X5K'#"XMYEF6]TVY;BI1VT<RP2\XFSOM
M]B6WT<>W=+6A/)WHP=`YB99Q#G?M6Y`,X8N';0Y5NP,0PG$FXXET'8-=J]3S
MLGBXFEFSFUCN[(6CQ@>T/[XD`$`CX]%%P/K*S.3+,FB?%(Z(/FPES3A(T:-N
MDE:C,@Y+R$LZCK;9Y!N%"9;-A4D'K*YY]J5\H`%`4DD22:A"*FTUVCZX==.B
MO6O`'"^0S17&?9QEMK<Y//,V..&.W8[T>A-7/D<UI<TZ*Z#AU+QKQ1QKQ#+>
MML,OS&\BTDDB9VD#FH=!IV]BHIE=F6HF2=I3%Z909QC4B!@EU+GF01D2KI]9
M0C`IY);J&;''03'`"F#:`;ZY#Q9EG!5Y:LRKA_)<HESAS]#7L;&R/":MQFC2
M_$-`#"ZA.E:RSSOC9DN.?,<R;:4%2Z5Q!!%-&G9MT*XD'<&3WKH$U+UOY1,6
M9G+8!NN:5(YZQ.NV4T0?E,<ANJ&O5$1UUV:[*U%UE/5]+P]<9CE-CE)FA+F/
M^9PB-[-$C78A6K37":4H!1<DRG->,)KUEO-?WS@XBA$KCMT5%>9;[^5]6<7P
M1CQ>Y`<%FEHIRH^\+<KO'`G-)OA3,HY<J*KJ=9'JB'6,(@&RO!'$WJ[UY<>J
MI636&(8'L`#7=Z*D`:A6J]N<*,N69!;LNW/=<!IJ7$EQ[XZR=/Y%?RM"N1)1
M$HB41*(E$2B)1$HB41*(E$5G^8.P9G*N!\SXQMUQ'M)_(>+;\LJ%=2RJZ$6V
ME;GMB3A6"\@NU;NW*+))T\*94Z:2ARD`1*4PZ`.)>V[KJ)L37.;\]"XEIPN#
M62L>XM(U/PM.`['46?EETRROXKN08F1NJ12M>BAH".<<RP*B/-U+XVP_BQUC
MJZY6\>97%TMA.\#WOG&_[LOY&\'&'F+Q%#%CF[7K1>8MO'2P3LHE'&:1YACC
MNP<"V6,`ICR#-,V>>(/6^61M?:-N[Z0LD."29M];R6<DDLH#R;AD#VX'.#V5
M9APT<2N/QY7%>90,LS620.;%;[LL[Z."6VGBNF;N(EH$+YH6[UH+7O93OJL;
M2D\O<DG,+S-.;ASCD5WBO%6?X28Y<IS#=@VQ=%SY'QK`FY;LHS>6(UA?=[.[
M2Q_-7&7(4[.KMG*S:$:^*VI4A3(X.4XGQ<MNY.'[N#,\MPW%X+^2>9KP8VNA
MEL'Y>ZV809,+VQ2S2-N"W3(]H,>%@6TNII\VRR;(;ZD.4NL;B",M^<>VXGE@
ME==']G5H]%M6>C8J862'>5DT;',,2F?)J%E)'/MG8OL"<5?D3A+4QA>]R9(9
ML8Q%N0BSJ6O2X;.QX,D\?N^LHFBA"M2-DM"&46-J>K<C;=L;=TYSI34NJT-#
M:ZF#OG%Y&FK^\#JBC&TTV*R[XBC1`T``UJ7NJ:OI0!C2*`,J\@@DO((`O+5A
M7$HB41*(E$6M+F7P3=>7^<#%<T6$O61M2P>6_+T[:3U">NR&QC'YZ0NRS%\:
MN[M;0<K&0\S-1_8KKLT'W:%!(JINJ(:UB$W]O9YW>96[#GOJR-EDYQ%&S.-P
MUYB#N\$F%S6N<0:,(K301NG>K+C*,LR_,>^R]V?A]VQNASK5MLX]^6]_N]Y2
M@!`,E-9T+59AO#N;F^*L]H99OO/-@SD_CFVHK+%EV!R4\^,^ZO',OEW'/I.\
M9N<E+XR(SS,RFTD'D5-&QFXC6JT,^,X25;I$2,38Y@<M;E366,39K)N:6LL,
M1;(R+!'#/O8'P.I=,BG<8W22/D$;)H(:DE]'\>MX\QGS$&_D=%G+LNN&RS-D
MB<[`XQ;LQRM'H9FA%=PP1F5T<DS`T878+]R$[GVP,8M7X<M',-`^^KR/&Q+C
MS&&%K5RA>#6R,HV]>T\HR---920>3>)G$_:LPWD4%[F=H.VJ21V*KM5VD5,^
M/?BXN;Z]MR7FZNKK(+D8GL<V*.'&+^'TB.D#S;E[&R".AN&]^R-P:ZF.Q[_5
ML<V$-@@AX@@+F-D:^9]P(O0)A;NK<-WXAD<S$TBV>\-<YF($VHF^4IV\YEX/
M..:^7?+-WVO97/S&W$M,6]:F5+@G@M.Y.1ZP+%BKTCK;L!8TW/VO'YIBFJ$E
M)%:N$F*K1471BMR.`'EMC?6=E)";=^ZOI8.(8XGMIABD?G\]W;%^MD39;0R.
M@<\!C]Y&!WSHR%LQ\V1YC:7C7.D=E?#1:'5!>Z""".^:#4%\D8J)&Z7`AQ:,
M0)6?GF\(.X+9RSS/1IK*RA,6M)S$1<"',7F+&V;L09`R-<4A/7<I(67/VKF0
M[9C=BECLU4A;7):\=&0;MBZ00%(ZZ1U#:&R`9PE;P/+(GQW!#8VD5F!B9CN7
M1FLL$CG`-D9(XB23$^)K&=ZMAF[HY^(W7T/?":)^)F$X;4,=&(X8Y!2*6)P+
MS&`#+&(_G7OQM*VP5A*$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M9<
M1@SFJY=.8/F1OGE\@<096QIS77W;V49AADW(%QXYGL+Y%8V9!6)<4BR;05@W
MLCDVTIYA;C-X6/\`"8-VW<$53!R)%"F)<RZ9\>50</7E!96U[=S1S-[YPBO)
M_29(71=[5[9WSN9*)`,+VM<PX57?MMY[\YY"#Z:^RMK>2'P1(;42,CF;*<6"
ML3HXWQF)U7,QAS:EIXO+7YO>`Q_S#\QG,MER#@Y?*>1>81_E+'5QVC?N36[&
M,MIW8EIVZ5G-V8,S%VAX<E+1CXQ$EF<@((*IB==0P`!&5F+*LC@L+4.;>-FS
M$RDG$US+N]N)HJ8M`<()&-?A:RCP<-3WQU]_#/F>>W%_>EKK$P9:V)H[TMDM
M+2**0G#0EIG87,Q.=B92H:.\&SZK:S58K)R+U],,6#0PCUD5%P2.!SI"JF5(
M$A$@=770RFNP>[6MS'&8PU@J"=7/\/0N2\*-@9?37<A^=9%1M=0).DCF(',K
M0`A+V?=Y%9)*8<1\LV:O).046(E$L.P8B@=3M%0+UTV":(`<JB@")3";74H:
MV9,QO&P6]I<QPM9&PDN`H-)J:FI`IL"W\5E;SY5)=65U'+>/N7,=`ZI>\Z`S
M`T"M2-GP%7^L.Y[<NA%&0MN983;-)11,';!P1RGU3!ZXNI!,.P"\-0[M;&WN
M+:[B;+:2LD8=>%P/X%UI?93?Y1G3[>_MY+=QU->TM^(A80^="N!_;V%[5?1B
MITW*E[MT/6)J&.=-1D<#I%`FA@$P:;>FO2?W9,M@S3CBY@NFL=&,OD(Q4H""
M*$UT4!70'WDKV>QX$CEMB<9O&;-.IVI?/;+7D\MX%;K@32[Z=AI9F[D8U5LV
M=FEHXYC).V0`Z;.O!P()@$%0*42CQ`*]J6>5=9S9/1N*WY-'P9)&YL/HPD;.
MQWZ#WZFD':!6J\=]7S\CS7/G6-X7&ZF8:/DK1CN?1L^'L*Y9N9Q&]KAMZTK;
MM1.6?*.4RW0A+2`Q1(QB<$O"'4<"!EFDOX)UQ*<Y51+UPT$A:ZHS[-\EX.S5
MS^+K2Z%E&#Z-?Q6YF@,FQCS^TC)&FH:5W5)P_%%:.GS"8MB8"&$-)#B.G1HZ
M"LW,<0;12;(E#N`?-=`(@81.HFFEUM3H=4!$"$(4=E>8OO%?>.R3(>K^3,L@
ME9CD:['A;AQ&E#4$!VG4:CX5VGU(\`>O<X;/0O@90[=.G\"WHX;1%MC6UF^H
M#V+1PF&@@(%*5\Z`I0T``T*&RO)75%Q(>+NKW+^(B,)N6RNI\$TC?_"O4W$%
ME'EV;S6430UD9#:#4.]%?C5SJ[)6F2B)1$HB"(``B(Z`&T1'8``'$:(L<7G.
M#RIQSQW'O^8["C-\P<N&3UHYR5:2+EH[:*G0=-G"*DJ4Z*[==,Q#E,`"4P"`
M[0KE4?`O&DT;98LJS!T3V@M(MY2""*@@X=((T@KCK^+N%HWF.3,;)LC2009H
MP01H((Q:""N/\<SE)^4M@W])UG_C:J_L#QO[(S'^KR^*J?MCPG[2L?/Q^,GQ
MS.4GY2V#?TG6?^-J?8'C?V1F7]7E\5/MEPG[2L?/Q^,GQS.4GY2V#?TG6?\`
MC:GV!XW]D9C_`%>7Q4^V/"?M*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>
M7Q4^V7"?M*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&8_U>7Q4^V7"?M*Q\_'X
MR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>7Q4^V/"?M*Q\]'XR?',Y2?E+8-_2=9
M_P"-JJ'`''+M#<GS(G_V\OBJA_&O"#!5^:6`'3/&/_$I#G,Y2A$`#F6P<(CN
M_P!IUG[?_P!VJKW>\=G1ZFS/^K2^(K9XZX+`J<VRZG_N(O&6C3&7G<K0F/._
M9-LV8OZ'9<LT]8Z&%K5N=]--$+/;73CU63N1G>99-1X$81C<LU)2K)-R'5%5
M)PVZXZ)AIY.R3C^[S'KRN.%8VR/M9AZ#%&`23<1.<11HTESY#)&`!4U:#J7V
M_P"L?[C[>&/],O*.M-UNUG6'E]T[B*]<6T>,MS".*)\3R6@AMM;1VMRX$X&X
M)W-\,UWE?',Y2?E+8-_2=9_XVKUA[O>._8V9_P!6F\1?$'[=<%G^]LN_K$7C
M)\<SE)^4M@W])UG_`(VJD\`<<M-#E&9`_P#MY?%5QO&G"#Q5F9V!'1/&?_$G
MQS.4GY2V#?TG6?\`C:H^P/&_LC,?ZO+XJJ^V7"?M*Q\_'XR?',Y2?E+8-_2=
M9_XVI]@>-_9&8_U>7Q4^V/"?M*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&8_U
M>7Q4^V/"?M*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>7Q4^V7"?M*Q\_'
MXR?',Y2?E+8-_2=9_P"-J?8'C?V1F/\`5Y?%3[9<)^TK'S\?C)\<SE)^4M@W
M])UG_C:JAU?<=.%1D^9$?^VE\16W<;\',.%^:Y>#TW$0_P#$J*R1S^<I6/L?
M7M?09_Q!<![0M>:N%*"ALAVP_E9IQ%L%W36)CVC216<+O))RF1%,"$,/6.%:
M+BC(.)^$>'KSB7.\LOK?*[*!TLCY()&,``T5<YH`Q$AHKM(78?5'E=CUS=9N
M1]5G!U]:77$>>9C#:PLBE9(_YQP#Y,#7$EL4>*1]-36DK5#YF_SH]K9:QEF2
MW.9_+=HVE?ENY5G;Q@)&^[FC(`)FS\D2#Z=3C8]>5=-D'/DK-E=-^S2T!%JJ
MW``TVUT5]WK/^(.L:VS#*8H;B]SJVG=/AB8Z1^XF=6I#03A9(2VNH!S0OIG_
M`*KOW:.$_NT\2\*\9<-LAR_J^S3)X,M>YSFQQ-S'+H6QFKG$#'=6S63:27/?
M'.[8MR?QS.4GY2V#?TG6?^-J])^[WCOV-F?]6F\1?(?[=<%^ULN_K$7C)\<W
ME)^4M@W])]G_`(VJG[`\<>R,R_J\OBJZ.,N$CI&9V-/]O'XR?',Y2?E+8-_2
M=9_XVJ/L#QO[(S'^KR^*I^V7"?M*Q\_'XR?',Y2?E+8-_2=9_P"-J?8'C?V1
MF7]7E\5/MCPG[2L?/1^,GQS.4GY2V#?TG6?^-J?8'C?V1F/]7E\5/MEPG[2L
M?/Q^,GQS.4GY2V#?TG6?^-J?8'C?V1F7]7E\5/MEPG[2L?/Q^,GQS.4GY2V#
M?TG6?^-J?8'C?V1F/]7E\5/MCPG[2L?/Q^,GQS.4GY2V#?TG6?\`C:GV!XW]
MD9E_5Y?%3[9<)^TK'S\?C)\<SE)^4M@W])UG_C:GV!XW]D9E_5Y?%3[9<)^T
MK'S\?C)\<SE)^4M@W])UG_C:GV!XW]D9C_5Y?%3[9<)^TK'S\?C)\<SE)^4M
M@W])UG_C:GV!XW]D9E_5Y?%3[8\)^TK'ST?C)\<SE)^4M@W])UG_`(VI]@>-
M_9&9?U>7Q4^V/"?M*Q\]'XR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>7Q4^V7"?
MM*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>7Q4^V/"?M*Q\]'XR?',Y2?E
M+8-_2=9_XVI]@>-_9&8_U>7Q4^V7"?M*Q\_'XR?',Y2?E+8-_2=9_P"-J?8'
MC?V1F7]7E\5/MCPG[2L?/1^,GQS.4GY2V#?TG6?^-J?8'C?V1F/]7E\5/MCP
MG[2L?/Q^,GQS.4GY2V#?TG6?^-J?8'C?V1F7]7E\5/MEPG[2L?/Q^,GQS.4G
MY2V#?TG6?^-J?8'C?V1F7]7E\5/MCPG[2L?/1^,GQS.4GY2V#?TG6?\`C:GV
M!XW]D9E_5Y?%3[9<)^TK'S\?C)\<SE)^4M@W])UG_C:GV!XW]D9C_5Y?%3[9
M<)^TK'S\?C)\<SE)^4M@W])UG_C:GV!XW]D9E_5Y?%3[9<)^TK'S\?C)\<SE
M)^4M@W])UG_C:GV!XW]D9C_5Y?%3[9<)^TK'S\?C)\<SE)^4M@W])UG_`(VI
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MS.4GY2V#?TG6?^-J?8'C?V1F7]7E\5/MEPG[2L?/Q^,GQS>4GY2V#?TGV?\`
MC:GV!XW]D9E_5Y?%3[8\)^TK'ST?C)\<SE)^4M@W])UG_C:GV!XW]D9E_5Y?
M%3[9<)^TK'S\?C)\<SE)^4M@W])UG_C:GV!XW]D9C_5Y?%3[9<)^TK'S\?C)
M\<SE)^4M@W])UG_C:GV!XW]D9E_5Y?%3[8\)^TK'ST?C)\<SE)^4M@W])UG_
M`(VI]@>-_9&9?U>7Q4^V/"?M*Q\]'XR?',Y2?E+8-_2=9_XVI]@>-_9&8_U>
M7Q4^V7"?M*Q\_'XR?',Y2?E+8-_2=9_XVI]@>-_9&9?U>7Q4^V7"?M*Q\_'X
MR?',Y2?E+8-_2=9_XVI]@>-_9&8_U>7Q4^V/"?M*Q\_'XR?',Y2?E+8-_2=9
M_P"-J?8'C?V1F7]7E\5/MCPG[2L?/1^,GQS.4GY2V#?TG6?^-J?8'C?V1F7]
M7E\5/MCPG[2L?/1^,KI8\R[BS+;63?8NR)9>0V<*Y09R[JS+DB;C;QCMRB+A
MNV?*Q3IT1JNN@43D*<0$Q0U#96FS3(\YR1[(LXM;BUDD!+1+&Z,N`-"0'`5`
M.BH6TR_-LKS9CI,LN(;AC#1QC>UX!.D`EI-#17$K5K8)1$HB41*(E$2B)1%;
M*X2(GN5'M4P.842%3$1T$.L0H&*`@("`#L'YE5[J*2,[P<N0U+57EY=VLP%J
M[#BJ3TT`T?!IY46#/.#<<%(Y'Y?<(7'*EAK6O:5N*<N+5T+%.8B[4CT7QH(Z
M@*$[=)Z[<)J'1ZVJJ:)RB`E$P5UQUAMFFM[3+@YS<NDD)D(.$T:`15PI3X-J
M]$?=\<;9G$'$,4;;GBFVM(FV;7!KL,DSG-?*UI!H]C00UU*MJ"-2UD\PW,ID
M6WK0F\EX)DT64[<-^WAAKEQARG-'VI8\#8!#M;JR(]9,/`T9N9?NT0(U!V59
MN0RA?6Z%T'C/5]P_FG%'$\>79#*8MX\L8,6%M&U&)_22*U*[EXSRS(>'.'X,
MIS>T;=9TVTBO<UN7@23/GN!6.V9BJ610M/?!E"XUJKIVQ>M_\RW)YB^R.9._
M3)9%MMRWG;IRNA`E<1\NJ<[CP9,S!!:*;JNV3=0J;A9%0`ZQ->IMKV'U?<2<
M3]07%%Q=9_EIS%S;8QO+7`LW<A&DFFG5I`!Z5XXZV.HS+NNS*HK#@[,;>R=<
M3[R.![:2`L;I#07:C71BIM6-UV^;P0S%?5BV9C;FLLV)8GCG=TW!<YK>N"#?
MM%F*Z*<*S9LGDNW0FUI1<3B8#F%(")B(:FT"N]S]]..>*.)N2M%J:DA\WZ-*
M!K08P``>;9H70O#7W1.)>K/,+F[SC%/*Z/"2+<.`IK)+7O[!T'6KV/?-PVG@
M)P_R)D[F[Q!!19&I^V<*V:E&2#M59(`<@4J%T.7LBNX.`F`B2)U#F-NW5H,X
M^]MES<L='=97&R$=\,4[2VHVT+*&@U?`N06W4!G/%<AR?*O2)I9'5H&.(;IU
MFI#6C3K<0`NBY7;R9Y*STAB'$QI2X(@$3/CWJ]BE89NWA$14(O-RT0N\<.X]
MHY4``9I&/X2ZUU$J8:U\U^N,S_>-SR6PRXOL,D:'!TH8,.*F@!O>U^'15>HN
M&^K>'J+R&*^SB>WGO7C`V%M<3CJ(Q:B6_I&E!L7T46%;KFU+3B(!V]3D5X]-
M<AWB2)VZ:P*NEUR"5%110Y.J14`VF'736N>]6O!AZON";'@\S^DFR8YIDPX,
M1=(YY[VII3%37II5=>Y]F<><9M-F449B9*X'"78J:`->BNJO1J585SI:A*(E
M$2B+T.?O9Q_^@K__`&S54WPA\*+\[#+TTBAEG*")B$ZZ>1;T(/>#M"XY'8(B
M.HAH:OJYPW?X.';%E14640_[C5\\\^M0<]O"&@@W<O\`];OB5N_'[??U";A'
M_5^KM]3A6Z.9:](V%:D6NKO>?EW$\?MO8$W?N>[=KO[ZI.9:=8\)1Z)HIA%,
M/-RTIX_;^P+PW=GZNS;IMXT&9:M(UE2;77WO-R[J>/V_L":ZZ?ZO?NZ>]V5'
MK$TUC53ET)Z)IIA&OFY:$\?M_8$X^U^J.NT-FW90YETC4.7Y$%KJ[T:SL3R@
M;^P)N_<]1X:[^^V5)S+2=(U@H+30.]V<W+2O6M.-UT%FXB=$JI=!5;'31<)#
M]2H@MH?LU`UWZ"'<W5Q'C7A[+^.<D?DE_=7]F2263V5S);7$3B*!S'QD`Z](
M>'-/-M7;74QUL9_U(\91<8Y'EF0YNUH:)K'.,OM\QL;F,&ICEAG8XM)V21.9
M(TZ:G4K&WDYONWD%96+O-Z^B4U4TSD<>!(R+3M3@FD)@(B";H@J:!UT]!`3!
MZW340^0?WE>`/O)=0]F>*+'CG-\TX`EG$+93>RQ7,;I*X8Y82^CZ@$8XB0=)
M+&BI7ZO?].W[P_\`I^??>S(=7>8=3G"O#?7G9V3KN6U;DUK<6$\<):)+BTNV
MP5B#7.:=U<ACFU:ULDK]"L(B^>-WJ<B@Y52?).`=INB&$JQ'('[0%BG#:!^T
MVZ]-?.6VS+,+/,&9M:S2QYI'*)6RM<1(V0.Q!X<#4.#M-:UKI7WROLCR;,\E
MEX<S&UMY\@FMS;R6\D;70O@<S`Z%T;@6.C+.]+",);HI19%6>>])5!K+3]Y/
MD(YR0%T&3$S(SQRD!C``K+BB9-F0XDTZH`930=Q1KZA_=LZJ?O$=<N56_'?%
MO'>=9=P%,\X!#?22W=Q@=A>&@/+(!4$%TE7C]0:"OSA_ZA_WLON%_<_XCONI
M;JTZF.$.(.O2UA89?2LDM;;*[#?1XXGRO,#9;QQ:6N$=N!&01\^:.:+S!/MR
MIII@74J294RF.*9E#`&SKJ*:`918XCJ8>(\`KZP\,998<)Y/%DF72W,T$6N2
MXGDN)I'4`+Y)9"2YSM9I1O,`ORW]9G'F>]:O%UUQEQ#;97:7MR3AM\OLK>PL
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MV=+<#QL)*]K?=*^]U#]V[.&V'&W`G!W'W5K+,#/8YMEMI)=Q!Q[]]CF#H72Q
M/UG!-O82:`M:`L;+XD[ZBNO$2US*2D7)$5[(Z0HD([;I*%U*X0*F59N<-2B)
M!$2[=`,;0=/B7]XBV^\)U89Q)U==9O$=]F65WD(ECI>R307,`>0Q[HG.Q,.)
MO@2-T.!PEP%5^Q[[A7$/W&?O*\'0=?\`]W#@/)LASW+;IUI.3DUM9WMA>&%K
MIH67$4>"4;N04E@D(<QPQAA=@5!P,O-0[XJD$]68O78%9=HB)`%0BRJ8@D;K
ME.7JBJ4H[MX5Y]X.XHXOX6SAMSP5?W679Q<`0;R"8PN<U[F]XYX+>]+@TG$<
M((!.I>Y.M'J]ZL.L7A>3+^MG),LS[A:S)NS!>VC+V-CX8WG>LA>R0F1K"\-P
M-+R'%K0:T.5-KI3L:<CJY[J>R[HG6ZT:AX.G&I''J@`+*]B5=X8@Z[`ZA=O'
M0*^UG43]W3K9M!!Q)UW\:9W=RD![<MMK^?=#$`1Z1<!P,F@]\R*C#JWCA0K\
M@'WU_P#4:^Z]=RWW5Y]S7JBX,L(6/?#)Q#F60V/I%6DL><OL'0G=$$'#-=5D
M%*[AAJ%70W`@(B(D)M$-=B0;>@`#9H.FVO>\-ZR&)D$5!&QN$"I-`-6DDD_"
M22><KX6W8GO;F2\N@'7,LA>\AK6@N<:DAK`UC03L:T-&H``44!/M_8$WC[7Z
MF@[>]VU7ZR)&L>"K'HFGP1KYN6A/*!OOZA=PCM[/U=NW>&FRI.9:](V%!:ZN
M]Y^7<4>/V_L"[OW/7HUW]]3UEIUCPN7YU'HE13"-7-RTJ?'[?V!.&[L]G$-.
MX.FV@S(Z-(VJ3::^]&S9R[*>/V_L";]/]7ZG3WM1ZRT4J-2>B?R1KYN6A/'[
M;?U"<1W)[>.W;PUV4.9:#I&H<OR(+3^2-J>/V_L"[O\`0UTW:[^^V5/K*A.D
M:^7906FB@;LYN6E!GV^W4A.'M?J[-N\==M!F5-HUGEW4-KK[T:ALY=E/'[?V
M!-^G^KW_`#^]V5'K'5I&HCET)Z)3]$:^783R@;[/6$X^U_.';N#793UC4:QI
M'X.6I!:ZN]&L\O@3Q^W]@330?:]?F[=^S94G,CI-1K!Y=/X%'HF@=Z-1V)Y0
M-]OK"[OW/Y__`.+;MIZRTZ2/"Y?G3T31X.SFY:=*>/V_L"</:_H;=PZ;:#,=
M6D;>7P?A4FTKK;S)X_;\"$WZ?ZOU--_>[:CUCHUCP4]$T^"-?-RT)X_;[^S)
MN$?]7ZNWU.%#F5:Z1L*>BZN]Y^7<3Q^W]@3=^YZ]&N_OJGUEIUC6H]$T>"-7
M,GC]O[`G#=V?J[-O'C09CTC:I-KK[WFY=U/'[?V!-^G^KTZ--_>[*CUB><:J
M<NA/1-/@C7S<M">/V^SUA./M?JCKM#9MV4.9'3I&H<NX@M*:FC64\?M_8%W?
MN>O1J.WO@TJ3F6DZ1K'+X5`M-`[W9S<M*#/M_8%W![7]#;O'7;09E2FD:^7+
M4AM-N'9S<M*>/V^[J$W@&SL_G!M[W94#,=6D:B.70I]$U]Z-?+L)X_;^P)O'
M?V?SM_>AK3UC4:QJ_!RU)Z)I\$:^;EHTIX_;\"$W"/\`J_H]T--E2<RUZ1L*
M"TU=[L.SEV$\?M]OK"[@]AKT:AM[[;3UEIUC04]$T>#LYN6E/'[?V!-_[GOW
MAIMTT'C09B=&D;4-I_)&Q/'[?V!-^G^KTZ--_>U`S*HI4:D]$_DC7R[">4#?
M?U"<1_U?JZ#MX<*',MM1L06O\D4T\NXGC]O[`N[]SUZ-=_?5)S+3K&M1Z)HI
MA&KFY:4\H&_$A>&[L^.W9MX\:>L>D:SR[IU*3:ZSAT:.7=3Q^W]@3?I_J_4T
MW][LJ/6/2-1'+H3T33X(U\W+0GE`W]@3C[7PX#MW!KLJ?672-0Y?D06O\D:R
MGC]O[`N[9^UZ^J/^ELV4.9;:C6#RZ4]$U=[L/+XD\?M_8$^9V?S!#N[=M/65
M#K&OE^=/1/Y.P;.7.GC]OM]83?\`N>_H#:.P=-M0,QU:1M'+H0VFNK1K">/V
M_L";_P!S]33?NVT]95&L:N7YD]$T^"-?-RT(%P-^!";A';V?J[=N\--E2<RU
MFHV%!:ZN]Y^7<3Q^W]@7=O\`M?J:[^^VT]9:=8UJ/1*BF'9S<M*>/V^T>H37
M9N[/U=GJ[AH,QU:172I-H-/>C9R[J^HW_I^'1'F)^8Q<@``>^5:9!`---26J
ML'`1Z:\4?>CFW_$.5O\`_P!)X[4B]1]0$>ZRC,6TI_O3/_H7T&UY=7?Z41*(
ME$2B)1$HB416SN8IDIU%R.PA2)@)MH[.H&H`'$>BKS&$@&O/^=:C,,(E:YW2
M/P+'+F2Y<+'YDX")97%VS>:MQUXQMB<9J*-Y*'D1243%PU=(B19$QB*&*;0V
MABF$I@$!$*Q;[+[2]@-MF#!);G6WXZK)R'B+.N%[]N9\/W#[>\`+<3330=8-
M>A:7L@>;US?B!G;S>#.IF2PK2NFX9N*MR8?KHR$"UNUVA)7)XM5;I"1^==4@
MG(5?JAJ)B@.T!#BMKD%]PY>^N.$[J6UO&B@`IV0*C34:%Z!R7[P3;R%]KQYE
MT%^)V8'RL!#W"E`74-`YH_2%%SV6<5;9EWL#>V/;PQM%PS-1P5]<]DHQ,%,&
M<%33-X%+$?R<85HU%/7JN^P.("`@`\.79KUG<=W-KASN*2:5K``YNOO=1--`
M!J:\]5ROARUZI)87VO"4\=G<S2!Q9/I`)UT>:N:!LPD#1J7C(S$I)-7ET<O2
MUBW"\F60.'Y90DA(B:+(7[4C"-6[P6[Q@;K&ZI4B"4%!$=0"N!<6<>2YS;1^
MJ&B*0Q?/PNB8^X8X>&^,O%)6'6`PU!V+L3AS)+RT,K.*7NN#O:V]U#*\VCV$
MG=QS.CJ8GMU%SA3G6/D7RJ<RO,9*.WEJ-<)L)R-7(O,0ZT+*Q4^1L40'L%6*
MHQLJB+@""'7(<R0B.T1KKW(>"\OXAD?F%IFTLL\;L0BEC;5CJUHZ-PIH.H4(
M63QIUHYUP/9,M<UX?I9S"@N(;ISX'MU&CV`5)'.:A9+\O.>Y/DIR5,1.1L;L
M+<-.*)L;F9+@T8R#M&";)(GG;;D#D(`B9$P`5LH82+%(``8J@@`[&/B+B+@S
M-76V=1/NK*XFJ^1C*$DG"'-:T!M1M``'X5Q#-^'^#^MKA6/,<@NF6U_91$,8
M]U,`TN='.'$DM!K24<^E?2)!2[6X(6)G6/;@RF(YG)M/"4%&SCP9ZW3<H=LW
M5*55!44U`U*8`$H[!KNN-^\C#]A%>P=79YUY'EC=#*Z%Q!<QQ!(-02#0T.T<
MR[6JU;2B)1$HB]+@!,@N4`U$45```#741(8`#3CK4M\(?"B_.3SEB[,RV:<M
MK,L79`<M%,D7H=NX0MB8,BJB>X9#J*)#X+H8A@W=SN5]),FS[+VY1:,](A%+
M:(>&W;&WI7B#-\FO79M=NW$U/2)#X#J:7NZ.TK6^]3G#X)\B[]/<O,[^`?>N
M_6MB.(,O^L0_+;L[*U_J2^K3T>>M?U':^TGO4YP^"?(NT=/<O,;P#;_!=-`#
MCNI]H,O/_$0ZOUV[.RH]27U:>CSZ_P!1W<YD]ZG.&_WJ,B]/N7F=W$?O7=K0
M\0Y?K](AY_#;W5/J2^\A/\AW<3WJ<WZ?W49%T`-?<O,;AX_>O$*?:#+@?Z1#
MH/Z[=NW6H]27U*^CSTI7P':NTI]ZG.&W_91D78(![EYG>.X/O776GV@R[ZQ#
MM'AM[JDY)?`_T>>O\QW<4>]3G#X)\B[^K[EYC>'`/WKT4^T&7G_B(=(_7;L[
M*>I+[ZO/KIX#NXGO4YP^"?(NW4?<O,:;-=1U\%W!3[0Y?K](AY_#;W4]1WWU
M>?;^@[N?"NGGL&9MGVS)HKC+(#=DDN9Z\,-J3"CA0Y2F001;)"S#0Y$SF,8Q
MC`004+O$HA7A/[TG`?'/WA^,LKX!R"6"QX!REOI%U?3O`B?<SM(:V%@.*9T,
M(([VC`Z5S2X$47W+_P!,K[QWW>_N`=2W$O7QQ]O\[Z]N*Y38Y9DEBPNNH<ML
MG@O?=S$;NQBN[LAYWM9'QVT+XXG-<'+KE>7+(YVA69<,9)2Z@@/AX6W,&?F,
M(::J@+7P8Y3;=$P(73IV5A7WW$^I";@MF16.97,/%C*GUB96.QOH-#[>N#=5
MU-:0\#3B)6UR;_7C^]M:]<<O&F=9!E%SU32EK/4#(9(WPPAQ^<AS"AF==EI.
M(R-="XAHW;6BJ[:#PEG*$C31QL87^Y21<G49*)6M,IF%)P(F5140\#ZR2R2Q
M>N81,8!!0``=FE<K^Z?PYQQU(OS?JHXT?#/PX9/3,NOH9`ZW?4X)X3IQ0O-(
MY!&\`DN?A+J575_^JCUN_=]^^?8\*?>GZEYIK/K#;%ZFX@R2[B,.8186F>RN
M@T`LNXF?/6SKB%S@UC8`]L9<&KL_>ISAL_V49%'773^C$QPW_P`%TT#YU>SO
MM!E_UB'5^NWNKXWC)+X_N)OD.[B>]3G#?[U&1=W6]R\SNXB/[UV!K4_:'+_K
M$.NOAM[JCU)?'_AY]7ZCNXGO4YPT_NHR+IH&O]%YC8`[OX+O$*C[09=J](AU
MT\-NWLIZDOJ5]'GI2O@.[B>]3G#X)\B[P+IY+S&NHCL#[UWZ_-H.(,O^L0\W
MAM[JGU)?5IZ//6OZCM?:3WJ<X?!/D7B'N8F-H@&W^"Z:`''=3[09>?\`B(=7
MZ[>ZGJ2^U>CS:Z>`[N<R>]3G`?\`=1D7B/N7F.&\?O7=K0\0Y?K](AY_#;W5
M'J2^^KS_`"'=SG0,4YP'_=/D7@.VV)@`T'0`$1%MH&M3]H,M!TW,-`?UVZN?
M7\7:4C([]VAMO,7$:.\<->K2105T:Z=I4Y+<O>9)>6.^E\8Y%6:H)IM63%I;
M,P)Q12$1`ZKA1F(-TW*ICJ]0H&.':;PT$*^8^=?=SXF^\9UO9EUE]9EZ,EX)
M?<F*TM\;'7K[2`[N$!A.&!L@!D)?5U7N.`%?I9X5_P!23J>_T\ONH<.?=O\`
MNZ6#.->N>VRT7&:7S&R-R:#-KX;^[<^=HWEZ^&1^Y:R"C`R)C3,0"%PY'EOR
MD^`IF6(<AQ#H@%(F=&UIM1J<Q.KU163,@=4J@Z:BH0V@".HANUW/6Q]Q3J]S
M;+FWO5)F+,LSR&$#<7,^]@N',%*F73)#(^E2ZCF5-<(7"ONK?Z[O7)PSQ"_)
MOO7Y+]H>#+N[<X7^66HM[VP;(ZN#T84AN[>(&C6XHY@T`8W4TU>7$^=2HMNW
MQ5D`S@6Z97!D;9EQ3.LD'9G5+HT#JIJ]7K!KMT';H.H!Z_ZBN*N(W]6EAE76
M$WT7C+*V^AW`>]I$I@HV.>.0.+9&2Q8'8FDBM6FC@0ODS]^GA#JLB^\EGG%O
M4#>P9KU0<4O&<Y>ZW:]IM?3:R7-E/`YK9+66VNM\S=2M:XLPO%6/!3WJ<X?!
M1D7=UO<O,;MFW[UV5W!]H,O'_$0Z_P!=NWLKR#ZDOJ5W$^JO@.U=KX$]ZG-X
M?[J,B[`#^J\QN'=_!=X]%!Q!EPT>D0ZZ>&WNJ/4E[2NXGU?J.[B>]3G#X)\B
M[^K[EYCOMF@?>NNM0.(,O/\`Q$/RV]U3ZDOJT]'GK6G@.U]I/>ISA\%&11UU
M#W+S'`-O\%TT`..ZGV@R\_\`$0Z1^NWNJ!DE\?W$WR'=SF3WJ<X;_>HR+NZW
MN7F-P#M$?WKL#6GVAR_7Z1#S^&WNIZDOOJ\^K]1W<YT]ZG-^G]T^1=`#7W+S
M&X=W\%XU/V@R\:/2(=!IX;=O93U)>_5YZ4KX#NXGO4YP^"?(NP0`?Z+S.NH[
M@#]ZZB.OS:C[09?]8A^6WNJ3DE\#_1YZZ/T':^TGO4YP^"C(N_3W+S&\.C]Z
M\`I]H,O.NXAU?KMV=E1ZDOOJ\VNG@.[B>]3G`?\`=1D7;J(?T7F.&NH_>NX!
MUI]H<OU^D0\_AM[JGU)?>0GTU_0=L['PI[U.;_@HR+IIKKY+S&[9M^]>-2>(
M,N^LPZ_UV[=NM1ZDO:5W$]*5\!W<^!/>ISA\$^1=FP?Z+S&S773^"[Q^?]&H
M^T&7?6(>;PV]U/4E\/\`AY]'\AVWL?"GO4YPUT]Z?(N_J^Y>8W[-GWKZE/M!
ME]/Z1#J_7;L[*GU)??5Y]=/`=K[7P)[U.</@HR*.NNG]%YC;IO\`X+N#IW4^
MT&7T_I$//X;>ZGJ2^/[B;Y#NY\*>]3G#X*,B[NMKY+S&[I^]>FI^T&7C3Z1#
MKKX;>ZH&27Q_<3ZOU'=Q/>IS>'^ZC(NS3^J\QN'=_!=XAPJ/7^7ZO2(M=/#;
MMVZT]27M*FWGI3]1W<^)/>ISA\$^1=^GN7F=_`/O7?\`1H.(,O\`K$/RV[.R
MI]27U:>CSUK^H[7VD]ZG.'P3Y%VZA[EYC>&_^"Z:`''=3[09>?\`B(=7Z[>Z
MH]27U:>CS:_U'=SF3WJ<X;_>HR+T^Y>8W`.T?O7=K0\09?K](AY_#;W5/J2^
M\A/\AW<YT]ZG-^FOO49%V!K[EYC<.X?O7B%/M!EP/](AT']=NW;K4>I+VE=Q
M/2E?`=J[2GWJ<X?!1D78(`/]%YG>.X/O7?K3[09=J](AYO#;W5/J2^'_``\]
M='Z#M?:4>]3G#=[T^1>CW+S&\.`?O7;LI]H,O/\`Q$.K]=NSLIZDOO(3ZZ>`
M[N)[U.<!_P!T^1=NH^Y>8X:ZC]Z[@H>(<O\`K$//X;>ZGJ.^^KS[?T';.Q\*
M>]3G#X*,B[NM[EYC<.FT?WKLJ?M!EX-?28=!_7;M[*CU)>TKZ//JKX#M7:^!
M/>IS@&_$^1=FFO\`1>8V:[OX+O&@S_+JT](AUT\-O=Z4]27U--O/H_D.[GPI
M[U.<-WO3Y%WZ;+7F=_1]Z[ZC[09>13TB'5^NWM:U/J2^^KS:Z>`[7VO@3WJ<
MX;/]E&1=NNG]%YCAO_@NF@!\RGV@R_ZQ#JKX;>Z@R2^/[B;Y#NY\*>]3G#X*
M,B[NM[EYC<&\1_>NP-:G[09?K](AUU\-O=4#)+X_N)M7ZCNXGO4YO`/[J,B\
M/ZKS&P!W?P7>(<*C[09=6GI,.NGAMV]E/4E[3^CSTI7P'=Q3[U.</@GR+KKU
M=/)>8UU'<'WKOU^;3[09=]8AYO#;W5/J2_U>CSUK^H[7VE'O4YP^"?(N\0]S
M$QM$`V_P730`^93[09>?^(AU?KMV=E/4E]J]'FUT\!W<YD#%.<!_W49%Z?<O
M,<-_\%W:T/$&7Z_2(>?PV]U1ZDOO(3?(=L[">]3F_P""C(NFG6]R\QWH\?O7
MCT4^T&7@_P!)AU_KM[>M/4E[2OH\]*5\!VKM?`GO4YPW>]/D7H'^B\SQW!]Z
M[Q^?4CB#+]7I$--7AM[JDY)?#_AYZ_S'=SX4]ZG.&[WI\B[^K[EYC?LV?>OJ
M5'V@R_ZQ#J_7;LV:^A/4E]]7GUT\!W<^!/>ISA\$^1=NO]5YC39KK_!=P;>Y
M0\0Y?K](AY_#;W5`R2^^KS[?T'=SX4]ZG.'P3Y%W=;W+S&[9M^]?\OG5/V@R
M_P"L0TK^NW;V4]27U*[B?57P'=SX$]ZG-X?[J,B[-/ZKS&X=W\%WCT5`X@RX
M:/28==/#;W4]27M*[B?5^H[N)[U.<-WO3Y%UUT]R\QOZ/O7:-!Q!E]/Z1#\M
MO=4^I+ZM/1YZUIX#M?:3WJ<X?!1D7;L]R\QP#;_!=-`#CNI]H,O/_$0ZOUV[
M.R@R2]/[B?Y#NYS)[U.<-_O49%Z?<O,[@':/WKL#6GVAR_7Z1#S^&WNIZDOO
MJ\VK]1W<YU]6'_3UVS=ULX7YA$+OMJ>MEXZR?;:S5O/1KN-6<MB6J8G;(%=I
M)BJF4^P1+KH.RO*?WB+VWO<XRU]O(R0-MI`<+@ZGSFBM":5UKT'U*V<]GE]^
MV:-\>*>,C$TMKWFRH'0OH4KSJN[$HB41*(E$2B)1$HBZB1AT)$Q3JF$IBAH`
M@0ANCI#4==.FI&CG6)<VHN2TEQ&&OQ[>PN`E;+9(P&!=30-Y>S3`!#;LW;-H
MT-#KJ>RL9N6-:*;QU/@"Y#B`;KZ:JF)M2ZP%32ZIP3ZX"4Q1*("!^OMUV[*<
MNXKGJ]F[,0<0TD'0!L7!G;%M*YV!HVXK>AYEJ=,$SIOXYHN!BZ=7ZM(1#9T#
M2O?8EGQC=D$:P%@]D7S<F)+QD6\M:LQ)8N?MGJ;TBMFLDFR1U"&$QP7:^&HM
M'':`(AJ<ANKO#0=M:C,,ER[,6GTB)F](ICH,0KTZUROASC+B#AF[;<9?<S;D
M$8HR]V[<!L+344/P+VM^06/;E:N2YDO4DZP4$[&XVT7$L9EL4!***8.V2B"R
MI4NKMZYC=?ZK6N`S]6$<DD<]OF%S#/&^H<QK0:?JDUTCX:KNUOWC[C"8)<BR
M^2P>VCX7O>^-VC2<#@6M)_D@4V*_]W\LF,LD1]H(Y-A(?(,Q:2K!PE<-RP,8
MZD'[N/,FHD[<$!,$2+BJF!]0`1`VW?79$%FQEO'#<$3/C'A/`))Y]5`3T+S[
M=9GCO[B\RZ,6D,[G'=QN=A:UQK@!K4@;*K(1!!)L@BW0(5-%!)-%),H`!2)I
M%`A"E`-``"E*`5F+5+VT1*(E$2B)1%Z^R2';V2>H[1'J%W_.J<3N<J*!.Q1]
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MG<Y2@YD[%'VI/ZPOTJ8G<Y2@YD[%+VI/ZPOTJG$[G*!K1H`%$[%'VI/ZPOTJ
MC$[G*4',G8H^U)_6%^E4XG<Y3"T:@$[%'VI/ZPOTJC$[G*4',G8I>U)_6%^E
M3$[G*4',G8H^U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8H^U)_6%^E3$[
MG*4',G8H^U)_6%^E3$[G*4',G8I>U)_6%^E3$[G*4',G8I>U)_6%^E3$[G*4
M',G8H^U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G
M8I>U)_6%^E3$[G*4',G8I>U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8I>
MU)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8H^U)_
M6%^E3$[G*4',G8H^U)_6%^E3$[G*4',G8I>U)_6%^E3$[G*4',G8I>U)_6%^
ME3$[G*4',G8H^U)_6%^E3$[G*4',G8I>U)_6%^E3$[G*4',G8H^U)_6%^E3$
M[G*4',G8I>U)_6%^E3$[G*4',G8H^U)_6%^E3$[G*4',$[%'VI/ZPOTJ8G<Y
M2@YD[%+VI/ZPOTJ8G<Y2@3L4O:D_K"_2IB=SE*#F3L4?:D_K"_2IB=SE*#F3
ML4?:D_K"_2IB=SE*#F3L4?:D_K"_2IB=SE*#F3L4O:D_K"_2IB=SE*#F3L4?
M:D_K"_2IB=SE*#F3L4O:D_K"_2IB=SE*#F3L4?:D_K"_2IB=SE*#F3L4O:D_
MK"_2IB=SE*#F3L4O:D_K"_2IB=SE*#F3L4?:D_K"_2IB=SE*#F3L4O:D_K"_
M2IB=SE*#F7D4I2]Z4I==_5``U^=0DG6I7E4(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%A#S$<^^)N6S)"6+
M;HL;.=\W,CBR2S9<BF),72-^Q5D8KAISR?EKRNYZR>MCL(V.?ZBH1%-PX[(H
MG*F(!5B"Y@FDNMXX0VEDZW;//)WL,1NA,Z$.?IIB;!*XFE&AI+B`KYMIBZUA
MA&\OKYTP@A9IEE-ON!)A;H&AUQ"UM2,3GAK:E6UO'SK'*O9T])M5$LLW)85M
MV-BK)=[YRL_&<O<&%+`L/-+55[CVZ+QO-LL1>+BI9J@=14Y&:W@A"B9<$P`1
M#80VD\E_+E\P$$L68&QQ2D,C==[N&40L?4M)<VX@#7&C"Z1C0ZI6`+J*2"&6
MTK<2SV+KP11`NE%M'+-#)*YF@@1OMY\;15X$3CAT*YMX><'Y:;$+G1*Y;BN!
ME,8`D<;QUTVR6V)%:Y;K-F%-C[UCS%L0GJOD>.OUX^\$CEHWM2K/$5D1ZITC
M@%-O:W5WZ.RWBD=<7&:ORX1T.\9=1D8V2M.F-HC(GQNHWT>LM<(-+F^MP2]\
MC&V8RH9B)B?F76E'5D:\5J6O88G-`Q"4M90E[:W*YFN;+!W)_AB5SOG^Z'-E
MV/%H)B1NG#2D[=DS*+LEWZ%MV[:4&VD)N=N-5LU5-X,V2.*9$E%%!(DF<Y<*
M\GCLIA;NK)*Z3`T1C%7O@TOKJ$;:@ND=1K014BH!SLJL;K-XC-;,+8V1"1Y?
MWF[::4QU\%Q)#`W2YSR&M!)HK3Y[\XYRI<M.!,9<Q>6[WE82QLQQ%J36-8F/
MM6<G[\NIC=S"'E&2K*S8=J\E448R.G6ZTDNL"36/(<.V5*)B`;<3Y3>P<5Q\
M%N;BSZ2_%IA::L;*Z7<`OD\%D9D[T/<0''0VIT+!L9&YAD$W$\%1DT%N9GO<
M*=[A<\-`UND<UKBU@JX@$Z&@D5WS'\X6..5^+3GK\M',-Q6\TMUW>MWW%C?&
M<Y>L%CFQ(XQO&M[7Y*,>Q:P\!$I)*+..R,Y=IH)'4[`2%ZU:>6X@M[AT5X]L
M%NQ[6/FD[V%CWNPL:Y_.XF@(!:/TB%E6%M/FEM%/ES#-+./FHFZ99.]#Z-9S
MT(T$BI(:VIT*Y-X<P>&["PDMS%W3?D/&X93M.(O=*^/WRYCW]NW"@R7MUU%-
MFK=:1E'5P>,VR;%J@BHY=+N$TDTS*'`HY>86]SEE\<KNXWC-/21;B$#%(Z<O
MW8B:T:WE^CF&EQ(:"1C93+%G=JR]RUS7V3X#-CK1K86L,CY'$TPM8P%SB=0!
MVZ%:'#_.UBW+>16N)7=IY@P[D:;@)"[;'M3.N.I#'$EDJTX@Z))FXK`\,=/6
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MO-'DGBR:GKLL^\)Z%\/MA15SX1!C%2*9`U3>D$-*QLJL[=\.?QYH-Y975SE.
M&W?HBN60Q9B)B[!AD+8S)'&]HD:US9BUP<#WM.8W5W%>9#/E?S=[:C-'&X:`
M9+9TARPPX0_%%\X8I'-+HWD.AJ"W;@YS(^;PSBI=G.M&X"B\CPV#[<P5R:6I
MC_EUCO(]+%W-G96%V%P'O3"DQ=4G$/<GQ<DK"H%CDW<;-Q0'<O`!T#DBA]-C
ME^93,>[.\Z9Z6'<9^ER6N%H^8]$RV)MW"UN%I,,D9>R.4OA=Z(&;H:S:CL61
M9C!EV4/]!P\)S6S+UI<71W,E[F4NYD+L51(V4%[F-;*!<EXEJ`T59S'\O_,/
MFCFNQKS^V)RZ7%;D1R),,6V]8'+_`#D-$LKUYH+?N5NA+Y6%5EXQ.S2>X(8W
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MBG.1;M\S39>'(3E.YGYS-\Q@&Q<*,;`0PR"U\6M==@PUBL[D7GTUYDB-NVQ*
MKPBI6;\'(HO@2`2ZAI787%&96D_6A:<06KG292_B2US-SV`G#:PYE'<.;(-!
M$PB!>(=+B=`UU7%^%;.:RX0N,NNRUEQ'E=Q:X''PYY[*>*-T8%0^-KWAKI-`
M9BJ::E>?GLS;EG*F*\88"L[EGYO66)N9&R94O,+DBT\(KW%?.-\7D.>%GL2%
MLI.X6TM!9/R@S*JT*[5*LUAXI91T/:+G03KC-Y965[GS[7-\,F1VSH;AS&C&
MR]>7"6.VWFID,;@TW9(#W`&"/2YSFYF47.8Y-D5M=Y.6Q\1-.X8YXTV@C9A?
M=X#42/!T6K:EA?\`.R=XS"^]'.1@FZLS<B^/;2Y=<<N6,GC*ZN67*UB84OA,
M+-DY*VL$Y!LF]"XME4)1<Z$#<"UMVV9H@F\4%)-^FF"I@#4P;2?,KJQXYL.*
M;\^EFUS.6>X,+@YSFW-M=6TDL6H/?$;K?M8*8C'@;WQ:L?+;"S^R=]PQ9XK2
M*YRJ2T@Q5:&N8YCHVR4J1'*8MV]U#WLA<12JL)FF#S!SMYHPKE&T,"9OPS:7
M+%C+FBDI1[E^WVF/[POG(>5\2.,>VMCFR;<++/I&8C2.%CO'4J"B3`5$D2)G
M,<=0XOF5G(W)N(;^W<7S7O#L]A;1-J)99)98Y3(]N@Q"-L31$'$/,DCJ`!I)
MWV77<?I&5Y7=-#-SQ%8WMR\Z8XH[1LXHR0`MF$KIRUX;H#(PXUQ`+$>Y.4&_
M\:<D')KAZW^43RBE[^QC#O.:"XKHQU=',?=<)FYMCB+CHE;(F(V.8,8A=<NX
MF'#AHG=$A.KI6H#<HI)&*)>KR3CF2.\XHS&UR%P9E<%M,_+GQZ&^D%S<19,3
M2TE>QHE-U@?)/)5CAI-=#P>QV79?;WUZP^GRWF"Z#G4<VU8Z5T58P/\`>H6]
M[&+3$QK&N$@-119,>;FPES.VAE_E@O;/MDWVQE(#S7%GXCR%=EXJHNG3;+4;
ME]G*N;0F78R\H[4N!"!;@N("HN4$2AJL80V[W,[O+Y+KB:2U<P1WM_DLL5-4
MNZL+QMR]M`*EDT@$AH*O?4#FP'6MPQV514!CM;C.P<(HV.*6Z@-J`*FC'Q,^
M:`)HQM-BWHUQ%;I*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(J4N^
M_+&Q\Q8RE^WG:ED1LG+,("-D;ON*'MIC(3LJH*,9"L7<R\9-W<M)+`)4&R9C
M++&V$*(T9\Y.RU9WUS*:,8-+GD:2&MUN--@!4EI;#)<$$6\3<3W?HL;JQ/=J
M:VNTD!56`@(`(#J`[0$-H"`\0IJ4`@BHU)1$HB]:JJ2"2BZZB:***9U5EE3E
M32223*)U%%%#B!")D(`B(B(``!J-4221Q1NEE<&Q-!))-``-)))T``:23J53
M&.D<&,!<]QH`-)).H`;25U\+-PMR13"=MV7BYZ#E6Y'D9,PK]I*14BT4U[-T
MPD6*J[-XW4T]:=,YBCP&K\D4L+S',US)!3000=(J-!TZ001T:5;8]CQB806U
M(T&ND$@CX000>8@A=I5M5)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(K*YKYB\(<N<&QN+->2+>Q_&RCOP&)+*J.G,I+N@ZHJIQ$#$MI"=E?!BF`RQ
MF[90J)1`R@E`0&K+KB%LXMBX>D%I=A&DX0:%Q`K1H)`Q&C:D"M2KT=O-)&96
M-^:;K)(`K0F@)(JZ@)PBKB`2!0%4W+\WG+-`XDC<ZR^:;&98IF5Q90]VGDS'
M1EI,G:]I"1D4BBI/2%P(@@H*D>BU.^3!,XF2`"FTOW8-E,RVN06SRBK`.^+F
MTKB;AK5H!TN'>MVD*S:_[Y`^ZMZFWC`+W'O0T$@-Q8J4Q$C"#I=48:U"MM=?
MG&N2*R(G'TU<W,78L>RRI'S\K8)$BSLG)7#'6H[8,+G=)0L5#OIEBG;SV4;)
M/?"FZ`M5%R%4`HF"JI(WPW#[604FCBCD=M:V.8N$3W/'>!KRQX:2[26.'Z)I
M0Q[9+<7;:[ATCHP2""7L:'N:&D!Q<&N:Z@&EI!%0:K*ZRKXL[)%K0M\6!<\%
M>5GW&S)(05RVW)M)>&E&:@B4%F;]DJL@KU#E$ARZ]9-0IB&`#%$`N7%M/:3&
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M5MIX:N+`N4FS$H';OY&[[09>`/7!DW"K>6:N]O6,8H\BDSW?<+<3\;LAC%^^
MQRB&YAU,@S%M_>QSEH`&""?%'=,+0T;F0-`HUM)M>'2R^X>X09*1EL^<RR6M
MP\^'9RY>:1O<?"DM)6R6S@=!,;7:225E!:?G'>?AUB#).69#E\5E[5M;!=E\
MR;:^)_ELROA.SX^$0N>$D<H87@B7;E*YI#+-P$Q.Z>24!=3$T4S<.$`%>+`A
M@(-=W!EF3WSK?.I70V%GG-K;7$[RV(R6L\CX)K@0G&ZV=8O#)IP]TS70D@%K
MZTU^6W$G$%O;R9+$Y]_F66W<MO"TB6.*XCMXYK)DEU\VR9MZ]Q@`8R,L<W&'
M.;2M;6[YU+)60LFS&/,?16))5#-F:,20W(_/HHW+*M\CX*<SBT5G;(=W)M)Y
ML@^=6>G:5P&8JQRJ+1,2M0<%,)A`].39;/>26]MF$<D=Y%=74E\T4&ZRYD,T
MEK,P.[[')(R&)[SBC<;F-T8(!5-[?PPV\^96T<ARPY?$RV<\M9O<UD=`TVX<
M"0]K([IER8@&3"*VN`2#A<VI?.&1>39/S@?FVAAKFQP-A047S3WU)6/>V(93
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MV`_-@/!&/9;N_FMKF%KV9>_B6#*GQ$?/%DUS/;[\.T-CD8;=SY(',>&AU-X2
MTU\;0YT.?6X\3^;TN1S(\K#6^?.`7"T%%)/&F3SVQA>T76&9;(?:E(.6S2>2
M[B(_CTC@F8\"V%-4S;K@)`=FV^<93ZOXS=P7%)\_#E^87,DQ%076K;9S(F1U
M;WH,KXWR%]7@-D$;"#&=5E]_O>%+KBFZ&(-S&QLX(F][5UQ<SP22RO.*@+8P
M]C&L)C/>ET@=B:P3YPCFWN,>7B[LLQ&`'-EY=YF,V\G4M;F/;;OYA<J=]X=E
M,CP#?,<=/S]YR4?'V[=$QCI43VJ=@\<,6SDABS#A0#$#5W(P6L,S&D39CPC-
MG=NVN,6YAM&W?HTKL+3<;QC@W>-;!NWZ,,@[Y9M^XY?)=PR$/&6\26N6R/IA
MW\=W-'$)6MJ?1W0[P$@OG$M"?F]2JS'//_DW+^)>0@]S1>,6<USFXHYF)K)\
M5#(RR+F$+C'%]V3;%6RH]Y<CYZQ9!-QR+9\9Z#X"]<4P%-02B%GC3*;,Y/Q/
M81O+K>SX+&8,((-9;@V<1#B!0Q%MS*64`)+`<1#7`['+9I[//K)P:01QCZNT
M@_LHI+O3L^='H\>+8,3N]%6TP"QEYQ3(7*9R`<J".(`M>]$,/\O."+BRUCQK
MA/)N173:&R-=004:C?.6[9NZTK)Y=D)6.%9:&>/H^YC2*B*@&;(D(`GYKGE,
MTZR?0[FKLKGS"SL"YIP!DLEG:NT3/#FOFB$K'NMFQT,;F'?-<_"WC611QMR"
MXC8]C,S:W,KMC:XWN9%=7IKZ.T-<8'/A<PW&]&!P>#&0W$;A9XR=S*#`>>R?
MY4R9:&6L'XKF</M+%PM(VUD^T%K=2NS'6);IBF,+?]J9O8RUNPK5&54-)(1S
M9LK*RAC.RKM4CF:CQK);9AROA]M]27,I>,7VPF;WA;N<RBC)<TXP]K01N(G=
MY&*MDWS74')3(;C-,=L-S9R\)"Y=&`'5$MK?DBM!\XYT9$DP`+VAH8V-[`]9
M,Y*\X-S'6I;?,SFVP(C";;"/)GFBU\%7+A:ZXB[WV:LPF.G8S68G;:OIO>T=
M$X^D7I[T3&W(UU;D\::3;@8[E+MP$MW+(O6F993+?.K#G^>S6+`T!AMRV_EL
MQ,YU'-F>#'O9;<,AW49_:&BTP:VVRZ>QM<++O+N'K;,'2.)?$\2Y>R]$);H?
M$QK?F?2#)*72$_-]Z:^^'Y\^;Y6^KFO>3C^7\^`K7\Y$UY%S6,SM2_F^6).V
MKDNR"LV)R,M?+B^UK7B9^W)>XD1<1A81VA(H)G,"[,^A*IX?L#F!R6*_(,N<
M9?F$H,1HV&2RCOIF.[X$R,F;9.8]G>&,O#VR/%6BC/KQUC'F4EDW",LARZ<B
M32967C;3>Q4&'=.C=<XF2?.!V'=NC;X9WC5KEGI1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1%I7YD;BF.7/S@%Y\Q>392/LS'5[<H5N8IY?,^WKCZZ<FXDP=E
MB*R!<$O?=N7U!6E-P$O#KY-C9.*6073?1@2*<89L+HHI@4UK++F.VL\XRTN;
M!G5W?6<\<CP2V>SA@,;[9C@1\Y#,7S&(N&+>B4-?NZ#*S&*&YDR2\=$^?+K2
M._CG9&6A\5Q.Z!\-RZH=\V^)CH-Y@)C+3&2T3U6,-F9HR1<N2^17GEYL;`A(
MC#-@3O/#9%PW[CS%M[6GC6U[BN*;A(K"/,Q*8]N"2OF[;=BLG6-;DBU2EEW3
MDS=>8)JJ1-<1K=6?H&33R27@=9YEF?"=BUK9'APM[HW0GO<OQ-:T1OE:8G-!
M`QB!T;B3H.!>ON,URV2WM"V[L\OXF$I>S0;FS;8RPP7(:YQ=*VWN):%K:X`1
M*T?-*\F4N:GEWMGSB7*'S%OKE6L_!=Q\K'-O;++(\A8=YP]LW9=LQDS`CMD5
MFLE;0*R3BY$XEPNT653#P\K4YDQ/U*90YMC;<1Y7>U9>7-EDQB@([^1L=SFA
M>&LIIH)&.PZZ2--.^"JS1[;W+LHN+5PE9!FUV9)`06M!L(F-)?S-/S9-:-<"
MVNA7H\W[;M]6#C?/]X#;MRXTL#-W-QF7+N$L?7'!&M:4MG%%SOVA(AV-I+D1
M<6JTO&39.9=%DHFDH1-V!S$(*@A6#.)<NX<R3);Y]<UM+%[917$8A)<RRPVS
MG"H+K:%S8R`3@/>5-%%U/;7W$>99K8#_`'"X]$:'ZFS30VL<5S<LT5+9Y6EP
MD<`7TQ=*O[FGFMA,%PH25WW$_>RCM%PM"VI!HI/+CG!;%U4\#:BHFFBV+IU3
M+K'32`P@'6UKI_K%ZU^$>J[+AF'%5ZV-\CBV*)O?22NJ!WK01A:*BLCN];J-
M=2[#X!ZMN*>L:^?:\.VY=;QZ9)G:(F4%<.+])Y_18VKG<VU:H+N\\GFM)NUG
M;5QK;\';[IOX8FUO9]+KSJ#?:)@E4FPPZ,6Y3`H@HD(*@00[XP5Y0SG[Y>>>
MO),LX?RBVD8R0,:3.Z7>5I0@QAK>^&K#5>DLB^[#P[/P\W.\^S.]M_FG22!T
M;(!#@KBQMDQN`;0DU.H5VJ\G+WYXF$R7((0N3XM2Q?"'/@B%Z6Y*EN:SO".O
MV1O&8>#-Y*&1`XZ"<`<I)Z")SE#;79G"GWKLBN<T9DG'ME-DE^_"T/>2Z'$[
M5B#FA[`3MJ6T.DK@.>_=UN;C)3Q#U<YG%G>7!I<6-#6R86^%@>UQ:]P%>]HU
MY.K0ML[2]9I^U;/F,\9ZR>-TG+-VU507;.VRQ>T1<-UDS"FJDJ00$IBCH(5Z
MPAN([F%MQ;O:^![0YKFFK7-=J<TC001IJ"O.$L,]N]T$[',F82UP<""UPU@@
MZ0X'75:?/.J><TYI>4F'B;(Y2L+RN;\QR<(XNRY920MR>F;&QQ9Z0JMVKQ^6
M%78GF;DE7*"@HLRN2`B@D910#:E*.#-?,MK@1SR!I.D5-*_!T'I6SRW*YK^-
M\[&%S6FE!T?@64GF3^<S-O/;R11^=>8-K;C+)0Y2R#94DVMB$>6]')-+75BB
M-"*1+]_(N&ST@O3E4U.&N@>M`=:VL)Q1AV(.!TU6%>0[B;=EI8<(-#TK;A5U
M8J41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5&7_CNQ<JVL_LC)%J0=[6A*+1S
MB1MRXV"$G$/5XF1:R\8JX9N"F25.QDV2*Z0B'K54RF#:%&?-W,%XS1=6T[)H
MGCPHY8SB9(P['L.EI&D%4R-;+;S6DHQ6UQ"^&5I\%\4C2R2-PVM>TEK@=!!H
MJ>E,'8=F\G,\TS&,K)D\LQ]BRV,6>1'UNQKJ[4<=SSU&1FK*"96;G=GMF3?-
MR*K,S&%%0Y=1+5+&MCAN[9@`M[]L8N6_HSB+%NA*-3\&-V&M:5-%<>YS_1\9
M)]%>Y\/_`)3WMPN<S]4N;H)"MYC+DXY7L-.;W=8NPC8ME&R/$NH"^&\-'*)Q
M]QP;T[@[J(?1:SA:-"-7%VH!D$TB)]4XETZNRD[&W.629/<C>99+X<;^^:_O
M2PXL52:M)&DZBJFRR,OX\TC.#,(35CV]Z6$%I!;AH`06M(H-87.LCE'Y8L;.
M,0N[`P/B^SW6`;9N"S,*+V_:,3&JXOM2ZU`6N2`LH[=N08*,FU0ZSA)'JE4,
M(B.T1US'WMW)=S7[Y'F]N+6*VD?7OGP0EIBA<=9CC+6X6ZAA',L,6ML+./+P
MQOH4-V^Z8RG>MN9`\23M&H2O$CPY^LAQ%=*NI-XXL*Y+PLS(,_:,#+WOCM*X
MD;%NE_'H.9NU$;N8MXVYTX-\H45F!)V/:IHN@((`JF0`-J`5C1DPNF=%WKKB
M$124_3B#Q(&.YVAX#J'14561)\[$V"33"R9LK0=0D:US6O'\H->X`\SCSK'J
MW^67DPQ/E%[(6YA_$5G95S;&WFS6.R@(]K-W?%&:IO+\;1[42F2:LG35Z4\B
M5H1`BX*?;.MK6$Z:RM[+[,O<QME=QN9N#JEC8#5A'Z3&!Q[P]ZVN@#0MY:9#
MG^9077&]G;SRV^52PNGNF@X;>2X?AA<]PT-DE?&0U_AN+3IUUN^RP+AB.8XD
MC&&,;-:1^!03###-"$9IM\8@E!*VPF%FIE3ZL)U+>7.R#L>KHW,)-PUM)[NY
MN<S?G-P]S\U?')&Z4FLA9-AWK2[7ADP-Q#;A%=2XZRW@CL/5;&-&7&9DN[`[
MS>Q.<^-]-6)CWN<TZP7$[5P(SEQP/#-+6816);$CV=D9%N'+MH-FMOL44;<R
M==CZ9D[EON((5,`9W-.2%Q/EG+HFBBJCM41'4XU;9-+&^"1CB'VMD;.(^3M3
M&(C;LYHC&T,+!HP@!5W$;+L3"Y`>+FZ9<RUT[R>)P='*[GD8YH+7'2"`50]K
M<D_*59-^N\HVER]8KM_(3Q]=DBK=T;:K!O,I.[[8+QEYG8N"D$(U.Z&+I1-\
MFW!))R!Q$Y1';6/#%'!ELV3PM#<KN+<V\L7Z,D!<UYA>/TH\3&D,/>@M%`%?
MFFEN+YN93N+K]DS)6O)[X2QM<UD@/E&M>X8_"(<:DKHI_P`W_P`E-T)VFA<'
M+'A^4;6-:S.R+49N+0C_``&'M&-<B\C+>29)E3:.(R,=B*C9-8B@-SB(I]41
M&LUMY=,OY,T;(X9C*Z-SI*]\70AHC?7]=@8UK7#OL+6BM``K48$4+;>(!L+=
M[0#1^V)=*/YLCG.<YO@DN)I4E5G=O*)RR7Y=5Y7O>.#\=W'=61+,88\OR9E8
M!LY<7C946X9NHVWKD3-HVF&$>O'("CVY#G2!$A2F`I0"K=O/-:XA;N+`^[CN
MC3ZQ$0Z.8<TC2`0X4-0":E58CAA8#WL$#X(_Y$+P]KXA_(<)'@MU=\[G*\)_
ME`Y7[IRQ$9TN+!6-YC+D'XK&,OM];C-:;15@T3MH1TL<2^#/7T.@?J-'"Z:B
M[8H%!,Y>J71:S2V4TL]HXQS3%Q>1K+GTQN_DN=3OG-HYVTFI5N6-DUK'8R@&
MTB8&-;L#&ZF=+!30PU:.9587EZP<1D_CBXJL@K&4RPWSM(M`@60(/<R-)5G.
M-LEN$^SZJMXH3$>@Y*]'[<"R13:ZA2WGFM/1?1G&/T*.2.#":;IDS962M9^J
MV1D\S7`:Q(\'64N(V7>_])`?Z4V-LU=.\;%@W8?SAFZCPUU8&\RO'5I5I1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(K$YSGX^U+<?W1+*`E&6[$/IJ
M04$=`!I'(.W*VX!$!$I-`[HUI<^OK;*,JNLZO#2SM+:25YJ-#8VE[OB!6RRC
M*KO.\SMLIL6UNKJXCB9_.>X-&CHK5?!OS^><4NJ5RE<4;``_=3[Y\!KKN"+<
M(BI:<.!C>#6E`IJMW2+;Q8Q'LU%@*4O;=8P"&HB/SLX<ZO[WKIX@N.MKK`)D
MLKF2MG9O+W,9`T_,U`U-`%2SP7&I.FB]']9/6?<]7F7'J;ZGKB&TDL8Q%>Y@
MVF,W;]+V0FGA@UWDA&)I(C9J*L7@.\F6:D)QM/2L^E!OBOH&'8O)%JFE+H/"
M>#.EWK5NBF8[HI%P*8#*'T$=0V;:[#XEZMLORO)6YME]I;"<3$LD9&`6%@J'
M`@5&$BNG8%XJN.).M[@F-V8Y?G=[>V4;F^FQ374LL4S75>Z)S7DES7,#@[5K
MUK+S"%IVWB2W%HIQ*./%$(Y<]N]FGB;LS4I%U"^#=L5(I3HI&$2E-H)Q`-3#
MKK7B[K+S+B3CSB9MK>1MES1K1`V.%NAS6G0\DZZZS7571H7U=ZH[CJVX/ZJ8
M>L/)IWP<,YG$V^?)*XFCY&X#"T#15K@8QA%7$::E;^?-M<R5L7Y&3&)HVZ6M
MP-H;M9&U#I.3+^!@FFDK,6XB8VHE3;)+)NTDP'JD(<P!QT]N?=/XGXHRBPN>
MJGCD3,S6R8VXL1*X%S[20X7L;MI$^A`V!QV+S1UZMX9XOCM^M#@H'U?/*;:\
M!C=&YMP!6.21C@,+I&?I'PAAVK*').04XR9R#&JX^N!T]C7K).(T1;]C>Q%(
M=HY>O8,QR:*$CMB1BGTZRA1`!#;7HWB$QOO3).0U[]$=3HT:#5M*TT[%U[PR
MV<9>V6&HC9I=H(.@D'3J.G0LF.1YA"-,+N7<':*%DISU\7'/R,&G%)PKDDK(
MH18NG,G')II=A*+$3("VI0,)BZCKO'EG"1E]4".9S7EDKV@BI%`=&M<<XUW1
MSK%$TL8Z&,T/\W2>RLQ*Y,N))1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B+I;AN."M.'>W!<LJSA(2.3!9_*2"P-V3-+K`7M7*YO6(I`(AJ8V@!QJQ<
M7-O:0FXNGMC@;K<XT`^$K9Y/DV:9_F,>4Y+!)<YG,:1Q1C$]YYFM&DGH&E6$
M#G+Y2S::<R6$AUW:9)M3;_\`NE:,<8<*G5F-E3_;1^,NV#]V[[P`U\%\3_\`
M_.NOHE\HOG#/.D':>=1P_DC%ER-YW%'*H_A[9*^A'A)&%O)E=/@KC+3IBM&O
M1;RK9S$/P8H"(Z`X8];0Q=-?*_6!UH%O6A9YAE<H?E65.:RK3B;('TWY&$T<
M"TX1TM7WQ^Z!]Q5MQ]P[B+@SCRR?:\?<>PS7)9,PQS6;[7$W*FO$C,43FS,W
M\G_ESTT&M/JOC^=?E'DF#&10YD,,$0?M&SU$CC(EKH+E2=(D73*L@K)%416*
M0X`8A@`Q3:@(:A7J:/C+A26-LC<QL\+@"*RL!T\XKH7P5N_NS?>#LKN6SEX,
MXE,L4CF$MR^Y<TEI+3A<(R"*C01H(TA7CL'*>.,IL',KC:][9OJ*:*@@XD[5
MEV<W&IKB)P[$7S!5=J94#)F`2@<1*("`Z#6VL,TRW-(S+EL\4\0-"6.#A7X1
M4+KGBS@3C/@.[98<:97?95?R-Q-BNHGPR%NC3@D#74TBA(H:BBKVL]<32B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBP<\X`H[2Y<LEF
M9E5.<+65%P1$-5#QX.@-(E`.(&9@?_-74?7FVY=U69X+9P:[U=("36F$T#ZT
MV83IZ/@79_4S)'%UH9(Z858+T%H&LR!KBP-K0%Q(%`2--.=?GK\Z/+A>*=^K
M97QXVNA&W[LCWSJ[[9CB)C+0TJX9"@#M9@F=19PQ<IB(+HD./4*H?40$`$?)
M?43UKY':Y6.$^)[B-MS;@16\P(P31UI3$2&XFG0*TT!=E]>G41G$.>/X_P"!
M<LN;C+LP(N+NV+2^:VG+L4KMVUQT//?U:7%KJM`HL.^4Q_G97):S*,8IP[)H
M[.+9:0C?"&\=VBB9'EP(IJ**B!DFS4`*DJ(%55$I!#03"'=?61QKD/#?",H?
M.Q]M*,38VN;5[J&C&D:!C.B0MK1E374NC.'NJN\ZW>*(.#[6UO;>TQ_[],6R
MQLA@:=.\J.^E=4MB:=)<>:JW+W?<V/+/Q\:U[[1N&YE+O:KLT+6M<7!KWN%=
M416<2#-PV.1*)*H].*B[UP=-`@&,&W7JCX)X4RGC3B[C!V?9#N;::VD,K[B:
MGH\+3H+"#X?>]ZV,!SB`/A7N[K>SGJEZH.K.TX+XC!CX=;;MAM[*(X;A[8&U
M8Z,`][20!SY'EK<1-"3H5T_-\Y^LK'UVV]:5A0#2SG%I71<4U)M&DI.W?>*K
MI%AU'SB3<E;N33;40,BBJJ@D5N4`$I"]76N_8.',^X8XVCZS[_,+B[N18OB:
MYL+60M:"W"UK&"K6@UHTU+@=)V+S9U,=9,W6C=3]3]MPY;V'"E\U]Q'<F9[I
M'`:`)WRG!O2#4.:6X2!0+>K)\V-EY*<LKMABSD9)MDTH]$C])="*:W,N(-)%
MR"1'"2RL6#%$R@$6*F<#B&H;!KMK(>NSA_CW/Y;&&SO&W4$8+Y'81"UVBI&G
M%WQU`@:0NP.(.I/B;JWLSEU]<6LEH^8X,+B9-T:O;710G2*D.IIT+:SR5ORR
MF&3R)5SNBO+RN5<KA0"@=4IC,@`YNJ`%U$`X5Z2X%E,V1F3]$W$E/@J%YSX_
M:&9_@!KAMXAV::?C66]<R7"4HB41*(E$5EN8]X[CN7_-;]@Z<,7K/%E].6CQ
MHNJU=-7"-MR*B+ANY1.FL@LB<H&*<I@,40U`0&M[PNQDG$EA'(&NC=>0@AVD
M$%[:@C:.=:K/'/9DMV]A(>+:0@@T(.`T(.BGPU7P6CS`9<+J7WY,J^MU+MR-
M>6P0$2[?Y<[VOJ"SASA&@KEEA7_81<W\W5RHO`ISKB"II?7OGI/&3XP67/AD
MRK^D:\NG7;_+F\0#94CASA#1_P!+L-O[B+Q4]=<0:?\`?[W9^^D\9/C!9<^&
M3*N_X1KR]3^>]_[%/LYPC3^R["M/(1>+KY53UUQ!7^G7NORTGC:T^,%EOX9,
MJ_,R->6WCL_ES>`;ZD\.<(:?^EV&S]Q%XO;09UQ!H_W^]\])XR?&"RY\,F5/
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M+(*%'0Q#`(&#8(5#N&N#G@M?E67EA-"#;Q$4Z1AU="KBS_B6"1L\&8W[+AA#
MFN;/*US7`U#FN#P00=1!J#IJL5\CVA9<A$2T^D0D+)LFQW8N&"92MGJHG*0B
M#IB002$[A54I0.D!#%$>L;4H#7SB^^9]UGJ4RO@',^MK(Q]GL\M`T[J!H-K=
MRR/#&1;BHW<CR:XXB``"YS2`5^BW_2*_U,_O<\7==O#OW6.-*\=<'YEO&B\O
M)"W,LKM;>%\DEPZ\HXW4$0:UF[N&N><3&,D:358J`FH8AU"D.9-/J@H<"F$A
M.N(@3KF`.J7K"&S7?7QG$;W,,C6DL;2IIH%=53LKLYU^M=TT+)&PO>T3/KA:
M2`78==!K-*BM-6U7NQ19]JS+5S,SISOUF;T&Q8<1%)JF`ID61<NC%,51R5;0
MX`0!*0`(/6UU#3Z#_<>^[CU7]=#\PXDX\N9KJ7*+B,>K&?-LD8]I<V::0.WC
MHRX%I8S`*BCG.Q4'PM_UE/\`4$^\3]SNSR'@?J6RRTL(>*K*X/VAF'I#[>6%
MP;):VMLYHA9<"-[91+,9.]),;&N9B.9]NY<O:SXI"!M'(%Z6G!M>N+6%M>ZY
M^WX=N=0W6540C(B29LDC*G]<<P$`QS#J(B-?:#+.!^K[)+&+*\HR7++?+H`&
MLC9;Q!K6C0/T:GI)J2=)JOQW\8=9O6;U@\1W7&''/$&<YMQ3?2&2>ZN;J666
M5YVESGZ`-36M`:T:&@"@7=_&"RY\,F5?TC7E]'^7-PZ[*S_LYPA[+L-9_<1>
M*N-'.N(-/^_WNKRTGC)\8++GPR95W_"->6OS?Y<VCLJ!PYPC3^R[#4?W$7BZ
MT]=<0?7KW7Y:3QD^,%EP?]\F5?TC7ENZ`_ES?MVT^SG"%/[+L-0_<1>*GKKB
M#Z]>Z_+2>,GQ@LN?#)E7](UY=S;^'-P:5)X<X0T_]+L-8_<1>*GKKB"G].O?
M/2>,GQ@LN?#)E3=I_>->6@#M#7\-[MM/LYPA7^R[#PO(1>*H]=<04_I][J\M
M)XR?&"RW\,F5?FY'O(1Z=!_ES>(!LJ!PYPAH_P"EV&W]Q%XJDYUQ!4_[_>T_
MVTGC)\8++GPR95Z/[QKR]33\-[]1I]G.$*?V785IY"+Q=:>NN(/KU[K\M)XV
MOE1/C!9;^&3*O3_>->7J_P`^<`WU)X<X0T_]+L-G[B+Q4&=<0?7[WSTGC)\8
M++GPR95_2->6FNFFOX;[WN4^SG"%?[+L-?D(O%U="CUUQ!3^G7M:>6DU_*3X
MP67-O^V3*O#_`'C7EZNW^7.(#LH.'.$-%<KL-O[B+Q>TI.=<0?7[WSTGC)\8
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ML-7D(O%UIZZX@^O7NORTGC:T^,%ESX9,J_I&O+Z'\N;`#3;0\.<(::978;/W
M$7BH,ZX@T?[_`'NW]])XR?&"RY\,F5-VG]XUY;]VOX<[W;3[.<(5_LNP\+R$
M7BZNA/77$&R_O:T\M)K^4GQ@LN?#)E7](UY=.NW^7-X@&RH'#G".C_I=AM_<
M1>*GKKB#3_O][L_?2>,GQ@LN?#)E7?\`"->7J?SWOU^A3[.<(T_LNPK3R$6O
MY.M/77$'UZ]U^6D\;6GQ@LN?#)E7](UY>KL_ES>`;ZD\.<(>R[#9^XB\5/77
M$&C_`'Z]V_OI/&3XP67/ADRIN^$:\M-=VNGCOO=E/LYPA7^R[#7Y"+Q=70H]
M=<04_I][6GEI-?RD^,%EOX9,J\/]XUY>KM_ES;OV4^SG"&W*[#6?W$7BJ3G7
M$&FE_>^>D\9/C!9<^&3*O1_>->7J:?AS?LJ/LYPA[+L-7D(M?R=:>NN(/KU[
MK\M)XVM/C!9<^&3*O'_>->/S`#^6]X:[:?9SA"G]EV&H?N(O%3UUQ!]>O:5/
M[Z3QD^,%ES9_MDRKLZ,C7EW-OX<W!I4GASA#3_TNPUC]Q%XNI1ZZX@I_3KW5
MY:3QD^,%ESX9,J;OA&O+?TC_`"YNVT'#G"%?[+L-?D(O%^)/77$'UZ]U>6D\
M9/C!9<^&3*OZ1KRU]0?Y<W[-E!PYPAH_Z78:C^XB\53ZZS_9?WNL?OI/&3XP
M67/ADRKT?WC7EZFGX;[[;4?9SA&G]EV&KR$7BZT&=<0?7KW7Y:3QD^,%EOX9
M,J\1_O&O+U=G\N<--M2>'.$--,KL-G[B+Q4]=<0?7[WSTGC)\8++GPR94_2-
M>6FN[7\-][3[.<(5_LNPU^0B\74H]=<04_IU[6GEI-?RD^,%EO?[\F5?TC7E
MTZCK_+G$-U!PYPAH_P"EV&W]Q%XJDYUG_P!?O::/WTGC)\8++GPR95WZ?WC7
MET::?AOOM:C[.<(>R["M/(1>+K3UUQ!]>O=?EI/&UI\8++GPR95Z?[QKR]7^
M?.&NVAX<X0T_]+L-0_<1>*GKKB"NF^O?/2>,GQ@LN?#)E3=\(UY::[M?PYWN
MRI^SG"%?[+L-?D(O%U*/77$'U^]U>6DU_*3XP67/ADRK^D:\OH_RYW=E!PYP
MAH_Z78:S^XB\7M*3G7$'U^]\])XR?&"RY\,F5>&_(UY:^I^'-^RH'#G"/LNP
MU']Q%XNM/77$'UZ]I7RTGC)\8++?PR95X_[QKR^<'\N;!VT^SG"%/[+L-0_<
M1>+VT]=<0?7KW7Y:3QD^,%ESX9,J_,R->7T/Y<W;*D\.<(:?^EV%*C]Q%XJ#
M.N(/KU[YZ3QD^,%ESX9,J;OA&O+37=J/\N=[MI]G.$*_V78:_(1>+\2CUUQ!
M3^GWNKRTGC)\8++GPR95_2->73K_`#YO'2@X<X0T?]+L-O[B+Q5/KKB#Z_>^
M>D\9/C!9<^&3*O1_>->71IH'\M[]1J/LYPALRNPK3R$7BZT]=<0?7KW7Y:3Q
MM:?&"RW\,F5>G^\:\O5V?RYP#?W:D\.<(:?^EV&S]Q%XO;09UG_U^]\])XR^
MM#S+-T7!>')CXZN6X9RYY%3+F0&X2=PS$C-R`MVZ<$5)N#V4<NW(-TA$W4)U
M^J74=`#4:\)?>'M+&RZQ709=#%!:^A0D,C8UC:G'4X6@"I7K?J8N;JZX*;+>
M2R2S^DR@N>XN=^CHJXDZ%MKKHQ=L)1$HB41*(E$2B)1%87.]N1]WVS)6K*D[
M2-N.%?0CX@[A;2+=VV4]70%-?F5I\\L+/.,MN,DOP'65Y;20R?S9&EI/8!J.
ME;#*LTNLFS*VS:R-+JUN(Y6:/TF.#AVZ47Q?\P$3?]A9LO/#%WX]F&,9;#`B
M[>_E#(EAYDPB)DCM]3`H8KYN<AT>S`P`('`VG5#7Y'\8]64/5VR>SOKP#B6.
M\+(K;":/M2263M=J)(PZJZ21K%%]-^">LC/>.L^CN<OR^-O5\;#>/NGDA[+D
M`&2+90,-1A<,5*/!H5B-;3V&E;Q=LXYZ*+B'E4"2AVXM$R.'2R8IM6SU0@G<
MG*`*`)!,!0,;0`$=-*Q\YX6XKRWADYE?V8DL98F]\XNK$TD'$/U2=H%=&BBH
MX>ZZ^JCBKC2SX=R3-)VYL^Y>V.D4C+>Z<UKFN:92S!)APDQXG-J?!J51N4[I
M@XJ#7DGUPK15T73=,A!MGI43]F>-MQXL`,WCDZ1TA;JK("<R1A*GU"B)@V[?
M7?4=PAE>:6$$#H\6706D<P#=%9'@4D<-&+#M)!K36OE7UB09QQQUK\5YUQ3F
M(<[*;^Y#(ISX;(I"&0QU/S8:T`-#6Z7'2*FJOYYJ3`4L\?W?F.[V5Q15IC&K
M6[9L\E#N#Q%S*J/#]JL>60;+O(N)66(4/"D!$QPU`-==0V/%.4,EC<V<S,RJ
M/&#(R-SHWR:@V0Q@F.,FGSE#38O2W5+>V_"L1S$P1R<1W433%"9&L=#;T!<Y
MK74:^0:2&5!K2O,M\^,D#X]CK@;7=#LY$MWG;F4*@@5TG$-6QW#>/;JIR+5!
M^)%T1[<JYB]H8BA3'VCK6HX*R#,.';:YS#/H869EF;FO(CH8V0QU9"T$@.(+
M>^+G=\:BNI=F\49]:\;WUN_*99&V&7L<UN]+MX^1P:92ZAPU!HT-%0--%NBY
M0T(YMAQFE%J(J,@GI<R0H&`R9>N5H;L]0TVD`0`>C=7JO@4L=P^QS*4,C]7P
MKS#Q\)?7Y,PI(86$_&LH*Y@N%)1$HB41*(K&\S@@'+EG81$``,29!$1'<&EK
M2>T>X%;_`(5T<39>?_W(>G]XW8M3GW]B7=:4]&D_^@K\W-Q<P%<."]H&@++%
M^K'854X`'>[=U?2_TX@=CI7A(VQ+ME-*]7E/^Z!P]GM'H[WATT]/_#TJ/1G'
MFU?@3RH#?VO'8/K]_$>\J?3M--M:<N5$]&=KJGE.'MFS4>"FP./U'&H].J.B
MB>C$'LJ/*</;`W:;C[N'U''HIZ=^"J>BG;3F4^4_[H&[;^V#M#<'>;=*>G[>
MSMVIZ*X\VKD$\J`V_;0X#]7M'I[SATT].H>S1#:GHY^7=3RH#VT-^SO^.\>\
MV?YJ>G?C'+H3T8]&OD4\IP]LZ0W*:Z>IU./1W:>GU^"G3R^!/13T<R>5'[H&
M[;WX^H'>;?\`-3T_;V=O*NI!:NZ.6Q/*C]T#@/\`K-H_6<.FI]/IV_PIZ,X\
MVKEVD\J`]MX[!]?\TW>;*@7VP?`GHSN?I_*GE.'MG2&Y3=]9QZ*>G5'PCIV)
MZ,1RY=I/*</;0W#[/Y@=Y3T[1V*[4%J[5HYEUTQ(,YR/(P>.W)&XNTW+INW#
MJ@[*@'VA`ZQB&,F0IS&$P@&H[--U>=.OWJ=ONODY3PSF>8FPZO[.<W-VR*KK
MBZE%&Q1-J,#&-:7.,AQ$.=H:#0KZ'?<3^^7P]]QRTXKZQN'^'_7W7]F]G'E^
M527-&9=EMH29;FXD<UQGFGED$;!"P1-+(QCD(JT^YO,1[-F,>T:LV[`Q2D.T
M(AJ@L``/KG)3IF%R;41'K'$PZB(AI7,.&NI7JAX4X1?P-E60Y>>'YF8)FRQM
MEDG(%,<TKP7N?72'5&$^#1=1=8OWW/O9]9_6O!UT\2\<YY'QY9S;RS?:7#[6
MWL03^SM+6(B".+8YCF/W@_:%RX$4I$0SUZ\C#*,B/D3)N6!`%1H90%.U150,
M<`5:`D<1`2ZF`2>M#3;74W5Y]VK+.IKK7^W?5==N@X5OX9(+_+9RYS0QW?LD
MMIJ%QW4@:6Q2#42`\`4/JSK[_P!2S./O?_=6DZD/O,90RZZU,ENK>]R/B&P8
MR,R3Q?-2PYC:N(:P7-N][9+BV=X0:3`2:CNO*</;`Z-Q]W#ZCCT5ZT]._!T[
M%\HO13T<R>5'[H&[]TWAN#O.'T-*>G[>SMY53T5W1I'X-B>5`>V]`_5[1Z>\
MX=/=J?3J:.G\/(H;5W+E\:>5'[J&_9W_`,T>\V?LZ5`OMG8V\J:D]&=KJ.6U
M/*</;`XAN/N^LXT].K\%.G8GHIZ%'E0'MF\-NP_#<'>;:>G]W;RJ@M7'FYE/
ME1^Z!P]GM'ZSATT-_P#AZ4]%=T:OC3RH#VWCJ`^O^:/>;/V:>G;!STY=">C'
MGZ?RIY3A[8&_H/N'_P`''=I3T^H^$=.Q/1CT:T\J`]M#<(#L/NX!WG'?0W_X
M*[4]%.K1S)Y4?N@?_P!3>`[N\VZ?0IZ?33TUV[4]&=T:N03RHZ%>[_K-_$>\
M^C4^G'5MK1/1G;".?\J>5`>V!OZ#[AWCWG&H%]W.70GHQZ-:CRG#VSI#<?=]
M9QZ.[3TZO:Z4]%/1S<OA3RH#VP-W^GOX!WG^6E#?[>SMY<R>BNIIIJY!3Y3A
M[8'`?J]H_6<.FGIU#V>G:GHQILY^7=3RH#VT-_\`I\=X]YL_9IZ=L['+H^)/
M17:Q37R*>5`>V=S<?=];QZ*>GU'13IV)Z*>7+;S*/*@.*H;M-Q^&X.\[GS*&
M_/X]O*J"U.JHYE/E1^Z!P'ZO:/1WG"AOZ=OI3T9QYM2>5`>V\=0'U_'>/>?1
MH+[\-$]&=77T_E3RH#VS9KT*;`'?]1QW4].KVD]&<#T54>4X>V!NT'8?=P^H
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MZ-3Z=IIMK1/17<XYT\IP]L#?_I[`'?\`4U`O^6E/1B.W^%/*</;.D-Q]W#ZC
MCT4]._!TIZ*[4:<R>5'[H&[_`$]_`.\_[M*&_P!O9V\JIZ*ZFS2.03RH_=0U
MW_5[^GO.'3W:>G:>ST[>10VSM=1RY:T\J`]MX[._^:/>_P#?I07VSL;>5$]&
M.NNWD4\IP]L#B&X^P/K./[-/3NU3IV)Z*>A1Y4![8&[;L/PW!WFVGI_=V\JI
MZ*[5HYOR*?*C]T#@/U>T?K.'30WU.WTIZ,[HU?&GE0&_M0WZ@/K_`)H]YLIZ
M=L&O5RZ$]&=^/\J>4X>V=/!3</\`X..ZGI_QCIV)Z*:]GEW%]L?F%W(/.0:.
M<@.O:Y=R2.NW@I"EX@`AL"O$7W@Y-[Q^).>P@_\`&O5O4TW!P;AYKN7_`,*W
M05T<NUTHB41*(E$2B)1$HBM)D[71CM'<7I]DMNTXUBW&[QC'S?CTILT]'P+4
MISW07*3<4!&1G,!>Q,?W2LR>#:=RPD3.3=SLF@`;MO#(RW8B8<.X(5-=2NDR
M)ZZ]0X#K70775:]4UW86UMUF7,=K>./^ZS-:]]TPUUQ-B8]Y8#K!86].U=W=
M3%UULV5Y/<]75L^\RL`^E0RO8RT<RAQ;UTKXVAP;6E'X^POD"0QORW6MG63<
MX0YBYG*$=X:Z`8Y?'62K5B`?*/T^H9PO>-MQ[D5D'@!V0"?J"<?6B(5U1UAY
M1FK.!9+%F;V[^%,$6.Y-K,'B('O<<8.DEOA%K`[G`7(NJW,.KO[:9;F<66W?
MK@71]$LQ<Q>B&X)?@#)7Q@!K78MR)),.K"XZ%F?C?'?F['\E,7-S0<P/B2):
MW,T)<.-&EAY46@Y.ZR'2,LL>Z65KRL.T*LV$"R!6*P(\51(/6UW/5-D%CE^1
MVTD.?7&82&+YAD=I/!AM]@F<Z/$Z/]3'A;3:NM^M[-.`,UZZ+@S97;Y5Q0R:
MEY6X9<127%!WT@BQ0,E!I4%]2\ZJA?45RWDQ:;'=K'QZK;R5DF3?&ME&W2IG
M@TX'PIN2.3CCHE[(S$(\C8^H>MZQC`/KP.`>H>$660RII8X&2LE0!1NO;4$>
M#TZM2X1QMOO7YQ8]QNF"/7BU:2*::UKH&FJLGG-K::V2[S\82?@;H%8GP;P5
ML]5.9+Q'%B03>#HJ@`".SAZVNG.L1L+N);ASG,#-VS"`!AIA%`""1KJN]>JV
M6Y9PG;M@BQMK+I+J'PCBJ'$.YM:V.\DR:"6#FA6RXN4?*>X.HJ)#D$?7M=@E
M4(F;79T5V;U=-P\-,%<7SK]-*;0NO.L\N/%+B\4<8(]&P:#H%-':67-<Z77B
M41*(E$2B*G[K\F_)BX?+'Q;Y)>))/RF\<=GXJ\0^!K>-?&7;?:O`O`>OVO6V
M=36LFS]*]+B]!Q>F[QN[P^%CJ,.'IK2BLW&XW#_2L/HV$XL7@X:::UV4UK4T
M'H5MFGQ5-=3;_!>MKMZVNOKNOKT[=:[=_C=_BFU=<_PLT?V=MYNSV?C3_!6X
M?%2[T=-/!.]UVZ?LT_C=3^]*43^%G^':NC5M_*G^"MM_X4]Q=?O3=]3\S]FA
M]]VWUJG\*Z?W;2@YM7<4_P""MJ.OQ4M>L&OWIOX:\--/F4_C=_BFOXU)]UE=
M/JW6.;7L3_!7V?\`"GKUAT^]=>MIM_\`%0>^[9ZTV\W94?PL_P`.U]&NGX:*
M/\%;9_PI[C:?>N[ZK3N_1TJ/XVT_O35\2#W6;/5VWF[*#Z%;0?\`A3TZH?Q7
MO>%3_&W_`!38G\*Z?W;2G1JT*1]"MMU^*GO+K]Z:?Z/<T^A3^-W^*:_C0^ZR
MIKZMV<W8['Q)_@K?^U/OA_BG?=W6G\;O\4UI_"RO]W5KT:U`>A6V:?%3^JT^
M]>[UOF_1^A3^-W^*:OB0>ZS13U=73S=->S\:?X*VG_*GIU?_`"G>_P"6^A]]
MVWUIJ3^%?^&ZNC5RUI_@K;?^%/ZG7[TW?4_,I_&[_%-:'W5Z:^K:4'-JV=CX
ME/\`@K:_\J6O6_\`*=]P[FFGS*?QN_Q37T<OQ*3[K*Z?5U:]&O9^10'H5MFG
MQ4]=3?Q7773UWS?HT'OMV>M%'\*]']G:SS:Z:>S1/\%;_P!J?>C_`!3O==O^
M?N4_C=3^]*4^)![J]GJW4>;GT_E0?0K;=?BI[B_Q7=P^9K]&G\;O\44?PKI_
M=U*#FU=Q3_@K;=?BI=\&OWIIK]3W-/H4_C=_BFM5?PLJ?[-UCF['+4G^"O\`
M^U/OA_BO?<=>[3^-VSUI\2@>ZRO]W5KT:^ZH_P`%;9_PI[C:?>N[ZK3N_1I_
M&[_%*4^)![K-GJ[;S=-4_P`%;3_E3TZH?Q7O?^_?\WNT_C=_BFS\BC^%=/[M
MIAZ-6CD?SJ?\%;;_`,*>\NOWI_X?F?0I_&ZO]Z:U)]UFFOJW975TT['Q)_@K
M:_\`*GWW_E.^[M/XW?XIKY<M2?PLKI]75KT:^6I0'H5MFGQ4_JM/O777ZKN]
M;Z-/XW?XIJ0>ZO1_9VWFZ:]GXT_P5M-GQ4].K_Y7O==O^>G\;?\`%-2?PK_P
MW5T:N6M!]"MM_P"%/<77[UW?4_,_9I_&[_%-?0A]U=-/JZE!S:MG84CZ%;7;
M\5/7K!K]Z;^'<T^A3^-W^*:^A2?=973ZNUCFU[/R)_@K;/\`A3UU-I]ZZ];3
M;\W]F@]]VSUIM4#W6;/5VOHUT_#11_@K;/\`A2[T=/O3=KMT_P`M=*C^-M/[
MUI3XD'NLT4]7;>;GT_E0?0K;=?BI]Z'\4[WA\S7?W:G^-VG^U4_A73^[:4Z-
M2D?0K;=?BI;RZ_>F_P"I[FGT*?QN_P`4U]"G^%E3_9NL<W8['Q)_@K_^U/OA
MW^"=]\WC3^-W^**![K*_W=6O1K[J@/0K;/\`A3W#I]Z[MO6^;]&G\;J?WI2G
MQ(/=7HIZNV\W37LZ^E/\%;3_`)4].K_Y7O>YW*?QN_Q3XD_A7_AVKHU:$_P5
MMO\`PI_4Z_>O_A^9]"G\;O\`%-?QH?=7IKZMV<VK33L*?\%;7_E3[_;]Z=]P
MU^9\R@]]U='K3XE/\+*Z?5U<71KY:E`>A6V:?%3^JT^]==>/=U^C3^-W^*ZE
M'\+/\.UGFU[>S\:?X*W#XJ7>CN\$[W7;I^S3^-U-/K2E/B3^%G^':NCL_E3_
M``5MO_"GN+K]Z;OJ?F?LT/ONV^M4_A73^[:4'-J[BG_!6U'7XJ6O6#7[TW\-
M>&FGS*?QNK_>FOHUJ3[K*Z?5NL<VO8G^"OJ'_"GKUAT^]=>MIM_\5/XW?XI\
M2@>ZS_#M?1KI^&BC_!6T#_A3TT-I]Z;OJM.[]&H_C;_BFKXD'NLV>KM1YNRG
M^"MI_P`J>G5#^*][PJ3[[O\`%*J/X5TT>K:8>C5H_(@^A6VZ_%3WEU^]--?J
M>YI]"G\;O\5U_&I/NKJ:^K=8YNFG+4I_P5O_`&I]]Q\$[[YO'HH/?=L]:*?X
M65_NZM>C6G^"ML_X4]QM/O7N];YOT?H4_C=_BFKXE`]UFBGJZNGFZ:]G7TJ/
M\%;3_E3TZO\`Y3O==O\`GH??=_BFI/X5_P"&ZNC5RUI_@K;?^%/ZG7[TW?4_
M,H??=M]::QVT/NKH:^K:4'-JV=CXE/\`@K:_\J7?A_%-.MPUX;MW"G\;O\4U
M]"D^ZRNGU;6O1KV?D0/0K;-/BIZZF_BNNOU7=ZWT:#WW;/6FU1_"S1_9VWFU
MTT]FG94?X*W_`+4N]'^*=[KMT_9[E0??;33ZTI1![K-GJ[4>;GT_'K0?0K<?
MBI]Z'\5[WA\S7Z-2??=M]:[/R)_"NG]VTIT:NXI'T*VW7XJ7?!K]Z::_4]S3
MZ%/XW?XIK4_PLJ?[-UCF['+4G^"OL_X4]>L/\5UZW'7NT'ONV>M-O-V5'\+/
M\.U]&ONJ/\%;9_PI[AT^]=WU7S:?QNI_>FKXD_A7L]7;>;IJG^"MI_RIZ=4/
MXIWO<[G33^-W^*;$_A73^[:4Z-7+7\:#Z%;;K\5/34NOWII_H_,^A3^-U?[T
MK7XT/NKTU]7;.;L=CXE/^"O_`.U/OO\`RO?4_C=_BFOH3^%E?[NKBZ->CD%`
M>A6V:?%3^JT^]=_U7_B^C3^-O^*:NA/X6:/[.V\W37L_&@>A6X?%2[WAX)WN
MNW_/3^-O^*:OB3^%?^&ZNC5RUH/H5MO_``I[BZ_>F[ZGYG[-/XW?XIK0^ZNA
MKZMI0<VK9V%/^"MK_P`J>O6#7[TW\.YII\RG\;O\4U_&I/NLKI]7:^C7L_(M
M@G+3\7/WM"_%;\A_>M\?R_4][WJ>3WE%^]O'.G9^M\.U[+M?F5UUQ/\`:7UG
M_P#VK?\`K7=M_;>'@TX?^SKIV5S'(?4?H'_]?W/J_&?V?@XM&+LZJK("N/+=
#+__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tpg95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg95.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.5:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.C!$-T,R-#$S0S(P1#$Q131!,44P1#9$0S(Y-$(Y.#,S
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C!$-T,R-#$T0S(P1#$Q131!
M,44P1#9$0S(Y-$(Y.#,S(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DI2330\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C!$
M-T,R-#$Q0S(P1#$Q131!,44P1#9$0S(Y-$(Y.#,S(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7`N9&ED.C!$-T,R-#$R0S(P1#$Q131!,44P1#9$0S(Y-$(Y.#,S
M(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A
M/B`\/WAP86-K970@96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$
M```````/'`%:``,;)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B
M-`=8=^O_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`!,`&0#`1$``A$!`Q$!_\0`RP`!
M``("`P$!`0````````````D*!@L"!P@#`04!`0``!@,!```````````````#
M!08'"`D"!`H!$```!@$"`P0%!0L*!P`````!`@,$!08'``@1$PDA$A05,2,6
M%PI!82)3&%$R0C-#TS2V-W<9<;%2TF.3)$0E551D-2:66)@1``$"!`(%`PP+
M$0`````````!`A$#!`42!B$Q41,'03(487$BTB.SE!55%A<(D;'!0L+#TT14
M=#;14F)R@K+B,U-C<Y,U17655O_:``P#`0`"$0,1`#\`O\:`:`:`:`:`:`:`
MQ2^.SL*/<WR9E"*,ZI8G:9DCBFJ4[>(>+%,FH7M34`Q.PP=H#VZDF9GOEY<N
M$R6Y6S&T,]45%@J*DIT%14THJ+I12<9>E-GW^AD/1%:^LDM5%2*068U-*<J;
M4*GB&[B[F01,,]D+B9),>V[R0CVD`>WUWIUH^E9NSRLMJK>[GS4^<S]G\0W$
MS.$.74F.3HEMYR_-9>W\4^OVM[O_`+]D+_S:2_/:B>=V>?+5S\)G_*'#T19=
M^BVWP67VI.9L*W%'R!C7'M0D8N;<2SIK;72UAEIHLDHJ#&9E7)"+"J07:@\D
M03+Q./=`H?)P#6R3U8^(T^YY0M64KDVHJ+G@J7.J9DW&KL,Z8](XHO6#51J1
M=HAL,`/6(X:,R]FFYWVDFR&437T[4DRY6!$QRI;=$%PIIBY8)ICM)'=9:&,`
MT`T`T`T`T`T`T`T!@.5CF3Q=DE0@]TZ=!N)R&[!X&)7I$Q1X#Q#L$-2+-'V:
MN/U&H[T\J#*:([-5L:NI;A3]^84!VUYM/AF_^J'_`!"7Y!K]67^QUHFYO8MY
MJ:#T(3;50;UW<TYR\J[>N??VYM'^Z'_N&OYC7R*[3AXJM_[-/97[I*_L@S?E
M&NMZ4$-:5F0-H^U%1`(^*6`@+.7HJAZ]BKWN\)A]/'AJ7SN-'$SAU/5<FW1]
M$M/V,N$J1,PI,TO3NLM\<2JNN,.2!BWQLR'E.\=-6Y4C9BOF2(]G,2,$;#FN
M35`EOQKN*S+.Y#H\+*W-9W&2UIA8^0:C%0B0.&;I\DDNB*B,<FJ0%$S"'$I@
M,'R#JXG!_P!;#U@,S<5\MY=O>89D^S5UZI)$^6M-2-1\J9-:U[,39#7)B:JI
M%JHJ<BF(N;.%^1+=E>X7"BH&LJY-'->QV\FKA<UJJBP5ZHL%VHJ$L.MX9A@-
M`-`-`-`-`-`-`=<YA4Y.(\I+?1]5CF[J?2["_0K,F;Z0\0X%[.W4ES(W'EVO
M9MHIZ>S*<5!E-89JMBIK\84_?F&M]:Y-6%JV'FP7:W1_S1?JR_\`-:TM/RJQ
M'JD*C6OO?T3T)S:BHWCNP]\O(NTSZMVEM,,EG+M[%(J)N3(E*D\0*42`DF<#
M"!US#QXG'4@N=IG44]LJ3+G.:K8Z6KKBJ<B'8D;Z<Q7*QVOD124_9_/02#>I
M<^<AD>#&R`/.E6"7`1<.^''F."\./R:L?GJAKG3I^&1.7LI>ICUY$ZA83BM1
M5DQ*K=R9KNZ2=3'+R)L0E1Q#::LGE7'!SV>N$(2Z5XYS&GHD"E*610$3&$7?
M```-=W@';[@SC?E%SI$]&IF&ABJRWHB=W9K6!BUGBUW1V3;JUM+4JY:"=!-U
M,^\7\$G"]MZ7RN?[7U?D<WD<[S^)Y7/[G,Y/,\7W.;R_I=WCQX=OHUZ1-U-C
M#"Z/64U\^(;YCW?0JO>0C#<S(PC",,,81T1U1,HUP)4-`-`-`-`-`-`=4YX_
M8=F7]U.1/U0F-2Z[_P!)JOJ\S\QQ463_`+6VO_(TW?F&IM9*H>#:>L2_1D/P
MR?5$^?6NV<C]\_0O.7VST=S&NWCM"\Y?;.P*THAX%7UB/Z2;\(GU:?SZIZYX
MDGIKYONJ5#9VOZ,Z"+S_`'$/6^(3MQ2B?I(CZF2^4GUBWSZHB[/A,?%=G+UB
M%<VS$EOT+K:>J:6+?VOK/:C_`-<COZ'_`!!-5'PJ?'B;E](_W>EY?WK2CKPD
MSQ34Z_U#]NPD_P"ZW]ROH1X>^/[A.''V$_GX:W(Z>E?D_",7NZ^?7OH^).K]
M++A.J&-+`T`T`T`T!&OU5,);M<^[8V-&V7W9]0<P)92J$\YG([(<CC)P>FQT
M?8T9U@-CBP%R=-PZ>M#"V'Z*O<`1^\#5#\0+5F&\6)*3+4UTFX[]KL39BREP
M(UZ*F)%1=:MT1TPY2^_J[YLX;Y-S\^[\4Z1E9EE;?.EI+=3-JDW[G2EENW3]
M"*B-?V6M(PY2NA_#$^(+_P#9NT__`&!<?ZNK)>8/&/RA-\,?VQF_Z?\`U+O(
M%/\`Z:09'3NF1UY4KA45;MN)L$S2DK57%+G#O=V-KE64O423+(UGBGL4X3,W
ME&<E!@NBJV4`4W"9Q3,`@80UV:/(7%EM5+6MK9CZ3&F-JU;U16QTHJ8M**FM
M%T*FB"ZCHW3C[ZGSK74MM-CDRKJM/-20]MHDL<R=@=NGM>FECFS,+D<FEJHC
MDTH6@/L$[(?DVB;;2A\A287QZ0A0^X4A(`I"%#Y`````]&K\>9V4_)M#_(E]
MJ:__`$Q<6?\`I;[X=4_*'W3V)[*D2B5+:;MU3*(]X2DP[02@(\`#CP""`./`
M-<'9*R>]8OM=O5>K(E+\$B,XT<7I:09F>_(G4KJE/C#^LTV8;16`%!CMCP,S
M`@&`@-L4TE#N`<1$X%Y<,7N@81[>'IU!?D'(\SGVBVKUZ:5VA\=QGXNOY^9[
M\O7KJE?C#^FCM+VNMEDG#?;QA=%=$Y545DL:U$BB2A!XD43.6)`Q#E'M`0[0
MU$I<CY,H:F76T5JMTJKE/1['LIY37,<U8HYKD:BHJ+I146*$)_%_BK,8LN9F
M2^*QR05%K:A45-B]T,F^S_@SP7EON?QKY?XSS#P7L77O"^.Y'A?&<CP'*\3X
M;U??X=[N=G'AJL.DU$<6-V+KJ2OTBY^W_2O'5TZ3@P8NE3L6".+#'''#BTPU
M1TG;VH!1I^%,4P`8H@8H^@2B`@/#L[!#L].@/W0#0#0#0''O%`P$$Q0.("8"
M\0[P@7@`B!?2(`(AQ_ET!RT!P*JF<QR$4(8Z8@!R%.4QB"/H`Y0$1*(_/H#G
MH!H!H!H#6B_%"VKJG;2LJXWJ>6>I;D/*6*=S!,KVNKXHQ177.WBG4"I4^Q04
M?$5"P1U&L/<R,H$79T4SO)$3**'0.8Y1YG8!GFT;I1]6WJ+]&?`-PPMU)E*M
MB>)KV5G>+MH*+"W8]8VB0ALG7U.2:7W+E8L/B[;8+#/-G`QXS+%U',"+(I%,
MW3*HJ`$>_0+ZO&[#8SOZQ?MGS)D[(=CV\YARM'X%REBK(U@EK&WQG=[-/DI4
M-=JJA..9!2I3=2N:Z!)1%J*;=\P!=-<AE"(*H@>G_B25>J[L2R9ANJY?ZL&;
M=P%6W!1N1+E#0%`BG^V:NT]K3)^"9(0[ZI8SM?D$]Q1LB0)+F*0Y>0;O%$3`
M.@+%CGJK%Z<?PVNSW<;8;,ZN.Y+*.V6A4/!+*U2:]BG[EF.RP#@26N<5EG:\
ME,Q%%8`K,R2BIE.<#9)L)@.Z3X@5^_A(=RFXC-?5=R$VR]G7+^36,CM;S#9W
M<5><CVZSPRE@<9#Q6JI,%A9>7=1*+\#OU^XH1$HIE5.4G=*80T!@'4?D-[&7
M/BFK!B_:]DK*R.5(O/V"(C&OE%NLA8O']0CL;XVLEM=*,TWPQ\5CN'A1D9&9
M;<L&2[07'-34YIBG`Y=6CK<[U.ISO\2V$[)\N6O"FW*3SK$;;L?-L<V"3J,S
MFFSR5T:41QD7(=N@E&5C7J$G.*'781"*Z3%&)*FHX26<F,<H&,]=GI]VKHIV
MW8U([-,O[L0OMFH5PE<N[C$,AY#;/K5EB#L%<+'G8KU]VV@ZBF=)VX,UB4CJ
M+*-!*#@[HQ3*F`O]='_,>YC/W3:VGY;W?P$I`;@[ACH[F\!.0P5N;GT&-@FH
MJJ728KP-&`0TI=Z>Q82JZ(((E%5V)R)ID.4A0)*-`-`-`:[CXXC]L73U_=IN
M!_6G%^@+%'PV]SJ>..@SM;OU]L414*53:[GBS6JT3[U&-A8"`ALUY.?RDM)O
MG)B(M63)H@=0YS#P``^[H#7C[/,63_4?ZY-5)A2%?N*]E;?78L^NG;6/<D3J
MN&X[,[[*UBLTN5,@^5H1M/1$.\H)0%XJDB'K%"%$"P9\<-^V?I\_NPSY^M>-
M-`8GT?L"Y.ZI./H'==N'K!FFSSI+;';/MYVK8^E4E'M;R!N.B\42TG;<EN&Z
MY$FDBYK;QVWDW)NZH0CI*$;@)P9N`$"#OH-]0*G=-/<_G'<E8(%_=K>.TS(^
M.L)XVC&;]X\R5FVZ7C%Z5"J!_+4E736,<.6"SE\L0!5*S;*%1*=<Z1#`;!KH
MI]+7(F#(#+F_3?,L-IZEN^5&1M.6+')((G>X.IMH12<Q.(:R@0QT(1^R:IM/
M."-Q`C<6;6-2$4&!3K`:S_'LI;NF?U3J7-YAK<FA9=G>\:!E\@0"[90DB^88
MWR8U?3*L>DN!?$!.0#0SE@K^+<)KI*%$2'`1`W*-'W5[6,P84@]P53S?B"R8
M.G81E:F61'5SJZ-29QZS8CTJLS(2KY!K7Y&.*<2N6[T4'+)8ITUB)J$,4`,I
MP)N(PCNCQXWRUM[R56,MXR>SMDK<=>J:[/)5F5EZC,NZ_848B5Y2;:6:Q\PQ
M60\2V%5LL)!,DH<O`P@=SZ`:`:`UW'QQ'[8NGK^[3<#^M.+]`=I](CH"8\ZC
M'2IVSY$R_OJWX5G'5X/D1U)[;:7E:%2P/%J5_+-QA2FK5'GJS-1L6I(J0X/7
M!U$W`F>K**AW1'AH"V3T[>DGL>Z7E9FX?:KBT\3:;:V;,[OEFZ29[?E:XLVB
MH.&\;*6IT@V)'023DH*A&QC=A'"L4%3("J`'T!YFZN?0HP!U@K5A2V9HS#F#
M%[W!]>NE=@&V,"TPS67;7:1@))ZXEPM5=G%>>R5KZ94>29,HE4-W@$>'`#WW
MM^V-X2VQ;+8#8SA]B]K>)X#%,_B\LF0&)K/*JVR)DF5LO,RZ(T39O[C9)68<
MR3I8R()&=+"!2%2*5,H$*FP'X5G8=L-W+TK=`UR%F//ENQJ5Q(T"LY>+0U*=
M7+H/++&7L(VMU2'<2,_7"<P\<"ZID&KHY7($%=%$Y`+.F@(..J1\/[L3ZJ<^
MUR;E&/MV(\_,HMM"^^[$#N)C+#8HE@0B49&W^"FHN6KUS0BD"\ILX511DD$`
M*B1V"!2I@!$?B_X*W9)69UNYR?NMW-Y,J*+HCMQ2H9O1,=LI4R8@)4I.3;15
MF>BD8`X&,V!LMP^]4*/;H"U=M4VHX&V3X-INW';714,=XCHA)$8"MI2LU.+`
M\F9%S,3<I(3-AD)28DY28EGBKEPLLN83**#W0*4"E`#T3H!H!H#5B_$$>(^V
M[</XB'\2+R?VXRQ]F'SOW%^ZWW5^UC?G^Y3\A[*=SR_O]_\`Q_<\/XSUV@)U
MOA4/?ISE/8?[??\`#_\`=1??=;]H7W4?9[]O?>3"^8>[7R#_`+J\_P#,O.N9
?X'_2^9XSQ'K^7H"[)H!H!H!H!H!H!H!H!H!H!H#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>20
<FILENAME>plx-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:plx="http://www.protalix.com/20141231">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20141231.xsd" />
  <xbrli:context id="C578932">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C578933">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C578941">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C578942">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C578943">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579717">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579718">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579719">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579722">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579723">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579724">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579725">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579726">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579727">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579729">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579730">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579732">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579733">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579734">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579735">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579736">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579737">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579738">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C579739">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580250">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580251">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580252">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580253">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580254">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>
      <xbrli:endDate>2013-06-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580255">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580256">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580257">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580258">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580259">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580262">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580264">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:CollaborationOperationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580265">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:CollaborationOperationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580267">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580268">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580269">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580270">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580271">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580272">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580273">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580274">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580305">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580306">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580307">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580308">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580309">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580310">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580323">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580324">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580325">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580326">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580327">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580328">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580329">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580332">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580700">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-12-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OfficersAndDirectorsInPrivateTransactionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580702">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580703">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580722">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580723">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580738">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandTwelveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580739">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandTwelveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580740">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandTwelveSecondMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580741">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandTwelveSecondMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580742">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandFourteenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580744">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580761">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580762">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580763">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580764">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580765">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580766">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580767">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580768">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580769">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580770">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580771">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580772">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580773">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580774">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580842">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580843">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580844">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580845">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580846">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580847">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580848">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C580849">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581047">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581048">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581051">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:RestrictedAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581067">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581068">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581069">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581070">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-27</xbrli:startDate>
      <xbrli:endDate>2014-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581568">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C581588">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582409">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582410">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582411">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointOneTwoZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582412">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointNineSevenTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582413">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582414">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeSevenZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582415">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582416">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582417">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointThreeSevenZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582418">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:FivePointZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582419">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointEightOneZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582420">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582421">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582422">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NinePointSixSixMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582423">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:OneSixPointSevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582428">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582429">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointOneTwoZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582431">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ZeroPointNineSevenTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582432">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582433">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeSevenZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582434">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582435">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointThreeSevenZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582436">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:FivePointZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582437">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointEightOneZeroMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582438">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582439">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582440">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NinePointSixSixMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582441">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:OneSixPointSevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C582480">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ProductsManufacturedOutsideOfIsraelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583389">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandFourteenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583407">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583408">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583409">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583417">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583418">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583419">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583420">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583428">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C583429">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C587133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C587160">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C592809">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">plx:UponFDAApprovalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C592847">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">plx:UponFDAApprovalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C597744">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-23</xbrli:startDate>
      <xbrli:endDate>2014-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C597749">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C597779">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C598561">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-23</xbrli:startDate>
      <xbrli:endDate>2014-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C598562">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-23</xbrli:startDate>
      <xbrli:endDate>2014-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C598566">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-21</xbrli:startDate>
      <xbrli:endDate>2012-02-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C598567">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-17</xbrli:startDate>
      <xbrli:endDate>2013-09-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>plx:item</xbrli:measure>
  </xbrli:unit>
  <us-gaap:DebtInstrumentFaceAmount id="Tag1" contextRef="C580723" unitRef="USD" decimals="-5">69000000</us-gaap:DebtInstrumentFaceAmount>
  <plx:DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption id="Tag2" contextRef="C580723" unitRef="USD" decimals="-5">9000000</plx:DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag3" contextRef="C580723" unitRef="Pure" decimals="INF">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <plx:DebtInstrumentConvertibleConversionShareNumber id="Tag4" contextRef="C580723" unitRef="Shares" decimals="INF">173.6593</plx:DebtInstrumentConvertibleConversionShareNumber>
  <plx:DebtInstrumentConvertibleBaseValueForConversionRate id="Tag5" contextRef="C598567" unitRef="USD" decimals="0">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="Tag6" contextRef="C580723" unitRef="USDPerShare" decimals="2">5.76</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtDisclosureTextBlock id="Tag7" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 8 - CONVERTIBLE NOTES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;On September 18, 2013, the Company completed a private placement of $&lt;font&gt;69.0&lt;/font&gt; million in aggregate principal amount of Notes, including $&lt;font&gt;9.0&lt;/font&gt; million aggregate principal amount of Notes related to the initial purchaser's over-allotment option, which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture (the &amp;#147;Indenture&amp;#148;) with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of &lt;font&gt;4.50&lt;/font&gt;% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal amount of the Notes, were $&lt;font&gt;66.8&lt;/font&gt; million, after deducting the initial purchaser's discount and commission and offering expenses payable by the Company. The debt discount and debt issuance costs are deferred and amortized over the convertible notes period (5 years).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes is &lt;font&gt;173.6593&lt;/font&gt; shares of the Common Stock for each $&lt;font&gt;1,000&lt;/font&gt; principal amount of Notes (equivalent to an initial conversion price of approximately $&lt;font&gt;5.76&lt;/font&gt; per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Prior to September 19, 2016, the Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the redemption date to the maturity date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The following table sets forth total interest expense recognized for the years ended December 31, 2013 and 2014 related to the Notes:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 90%; margin-left: 0.5in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. Dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Contractual interest expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;888&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,105&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Amortization of debt issuance costs and debt discount&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;127&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;444&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,015&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,549&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock id="Tag8" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The following table sets forth total interest expense recognized for the years ended December 31, 2013 and 2014 related to the Notes:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 90%; margin-left: 0.5in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. Dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Contractual interest expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;888&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,105&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Amortization of debt issuance costs and debt discount&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;127&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;444&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,015&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,549&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
  <us-gaap:DebtInstrumentMaturityDate id="Tag9" contextRef="C598567">2018-09-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="Tag10" contextRef="C578942" unitRef="USD" decimals="-3">888000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="Tag11" contextRef="C578943" unitRef="USD" decimals="-3">3105000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <plx:AmortizationOfDebtIssuanceCosts id="Tag12" contextRef="C578942" unitRef="USD" decimals="-3">127000</plx:AmortizationOfDebtIssuanceCosts>
  <plx:AmortizationOfDebtIssuanceCosts id="Tag13" contextRef="C578943" unitRef="USD" decimals="-3">444000</plx:AmortizationOfDebtIssuanceCosts>
  <us-gaap:InterestExpense id="Tag14" contextRef="C578942" unitRef="USD" decimals="-3">1015000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="Tag15" contextRef="C578943" unitRef="USD" decimals="-3">3549000</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag16" contextRef="C598567" unitRef="USD" decimals="-5">66800000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag17" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/font&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Cost of revenues&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;220&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,756&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,655&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;936&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Marketing, General and administrative expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,775&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,434&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;306&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,751&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,089&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,242&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag18" contextRef="C580700" unitRef="Shares" decimals="INF">13841655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag19" contextRef="C581588" unitRef="Shares" decimals="INF">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag20" contextRef="C580701" unitRef="Shares" decimals="INF">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="Tag21" contextRef="C580702" unitRef="Pure" decimals="0">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="Tag22" contextRef="C580702">P24M</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag23" contextRef="C580703" unitRef="Shares" decimals="INF">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="Tag24" contextRef="C580703" unitRef="Pure" decimals="0">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag25" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 7 - SHARE CAPITAL&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Rights of the Company's common stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The Company's common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/font&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock based compensation &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &amp;#147;Plan&amp;#148;). The Plan has since been amended to, among other things, increase the number of shares of common stock available under the plan to &lt;font&gt;13,841,655&lt;/font&gt; shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;As of December 31, 2014, &lt;font&gt;1,923,444&lt;/font&gt; shares of Common Stock remain available for grant under the Plan.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company's management uses the fair value of the Common Stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;From January 1, 2012 through December 31, 2014, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Options and restricted stock granted to employees:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;a)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Below is a table summarizing all of the options and restricted stock grants to employees for each year of the three-year period ended December 31, 2014:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 81%; margin-left: 1.25in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year of&lt;br/&gt; grant&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;No. of options&lt;br/&gt; or restricted&lt;br/&gt; stock granted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Exercise&lt;br/&gt; price range&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Vesting period&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Fair value&lt;br/&gt; at grant&lt;br/&gt; (U.S.&lt;br/&gt; dollars in&lt;br/&gt; thousands)&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Expiration&lt;br/&gt; period&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;400,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;3&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,288&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,100,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;4&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,292&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;2.37&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;4&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,007&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;10&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,400,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2014 (such grants appear in the table above):&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;On July 16, 2012, the Company's Board of Directors approved the grant of &lt;font&gt;1,500,000&lt;/font&gt; shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, &lt;font&gt;1,100,000&lt;/font&gt; of the shares were issued to the Company's named executive officers and vest in &lt;font&gt;16&lt;/font&gt; equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a &lt;font&gt;24&lt;/font&gt;-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Corporate Transaction or a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining &lt;font&gt;400,000&lt;/font&gt; shares of restricted Common Stock were issued to other employees of the Company and vest in &lt;font&gt;12&lt;/font&gt; equal, quarterly increments over a three-year period, commencing upon the date of grant.&lt;/font&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;On September 28, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a &lt;font&gt;10&lt;/font&gt;-year option to purchase &lt;font&gt;900,000&lt;/font&gt; shares of Common Stock to its then newly appointed President and Chief Executive Officer with an exercise price of $&lt;font&gt;2.37&lt;/font&gt; per share. The options vest over a &lt;font&gt;four&lt;/font&gt;-year period in &lt;font&gt;16&lt;/font&gt; equal quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, as amended.&amp;#160;The Company estimated the fair value of the options on the date of grant, using the Black-Scholes option-pricing model, to be approximately $&lt;font&gt;1&lt;/font&gt; million based on the following weighted average assumptions: dividend yield of &lt;font&gt;0&lt;/font&gt;% for all years; expected volatility of &lt;font&gt;62&lt;/font&gt;%; risk-free interest rate of &lt;font&gt;1.86&lt;/font&gt;%; and expected life of six years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;b)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The fair value of restricted stock granted during the year ended December 31, 2012 was $&lt;font&gt;8.6&lt;/font&gt; million based on the Company's share price on the NYSE MKT on the grant date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2014 is approximately $&lt;font&gt;1.4&lt;/font&gt; million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of &lt;font&gt;1.0&lt;/font&gt; years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2012, 2013 and 2014 was approximately $&lt;font&gt;1.2&lt;/font&gt; million, $&lt;font&gt;112,000&lt;/font&gt; and $&lt;font&gt;46,000&lt;/font&gt;, respectively. The Company did not realize any tax benefit in connection with these exercises.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;During 2014, the Company issued &lt;font&gt;133,930&lt;/font&gt; shares of Common Stock in connection with the exercise of &lt;font&gt;139,388&lt;/font&gt; options by certain employees of the Company. The Company received cash proceeds equal to approximately $&lt;font&gt;46,000&lt;/font&gt; in connection with such exercises.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Options granted to consultants, directors, and other service providers:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in;"&gt;On July 24, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase &lt;font&gt;150,000&lt;/font&gt; shares of Common Stock to its then newly elected chairman of the Board of Directors with an exercise price equal to $&lt;font&gt;3.37&lt;/font&gt; per share. The options vest over a three-year period; the first &lt;font&gt;50,000&lt;/font&gt; shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two-year period. Vesting of the options are subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $&lt;font&gt;193,000&lt;/font&gt; based on the following weighted average assumptions: dividend yield of &lt;font&gt;0&lt;/font&gt;% for all years; expected volatility of &lt;font&gt;62&lt;/font&gt;%; risk-free interest rates of &lt;font&gt;1.9&lt;/font&gt;%; and expected life of six years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2013 and 2014. Approximately $&lt;font&gt;39,000&lt;/font&gt; was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;During 2013 and 2014, no shares of Common Stock were issued in connection with the exercise of options by consultants of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of share option plans, and related information, under all of the Company's equity incentive plans for the years ended December 31, 2012, 2013 and 2014 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Options granted to employees:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px; text-align: center;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,141,030&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,253,579&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.923&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,153,898&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.951&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year:&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; text-indent: 10px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 10px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Forfeited and Expired&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;25,858&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.372&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;20,558&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.603&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;44,201&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.833&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercised (*)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;861,593&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.346&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;79,123&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.418&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;139,388&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.446&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,253,579&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.923&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,153,898&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.951&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,870,309&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.770&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,258,441&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.201&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,614,148&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.591&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,905,559&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.933&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-indent: -14.2pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt; (*) &lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 98%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $&lt;font&gt;4.8&lt;/font&gt; million, $&lt;font&gt;306,000&lt;/font&gt; and $&lt;font&gt;447,000&lt;/font&gt;, respectively.&lt;br/&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Restricted stock granted to employees:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of Restricted Shares&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,394,708&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;970,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year:&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,500,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Vested&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;102,084&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;406,666&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;398,375&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;17,834&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;185,709&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,394,708&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;970,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;386,124&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;c.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Options and restricted stocks granted to consultants, directors, and other service providers:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,238,692&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.385&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;296,167&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.678&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercised (*)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;326,267&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.12&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,208,592&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.136&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt; (*) &lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 98%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $&lt;font&gt;2.3&lt;/font&gt; million.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;d.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2014:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="26"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31, 2014&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="text-align: center; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;" colspan="8"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Options and restricted stock &lt;br/&gt;outstanding&lt;/strong&gt;&lt;/font&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="10"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Options exercisable&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Exercise &lt;br/&gt;prices&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of &lt;br/&gt;options and&lt;br/&gt; restricted stock &lt;br/&gt;outstanding &lt;br/&gt;at end of &lt;br/&gt;year&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted &lt;br/&gt;average &lt;br/&gt;remaining &lt;br/&gt;contractual &lt;br/&gt;life&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of&lt;br/&gt; options&lt;br/&gt; exercisable&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted &lt;br/&gt;average &lt;br/&gt;remaining &lt;br/&gt;contractual &lt;br/&gt;life&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom;" colspan="1" align="center"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a (Restricted Stock)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;490,624&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.001&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;719,207&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.54&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;719,207&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.54&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.120&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;308,801&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.00&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;308,801&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.00&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.972&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;995,853&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.44&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;995,853&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.44&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.350&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;40,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.82&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;40,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.82&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.75&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;56,250&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.75&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.650&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;345,082&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.49&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;345,082&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.49&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.020&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;50,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;50,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.56&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.56&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,708,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,708,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.810&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.900&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;991,916&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.32&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;829,249&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.32&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.550&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;160,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;160,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.660&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;68,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.83&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;68,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.83&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;16.700&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;387,542&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.99&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;387,542&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.99&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,465,025&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,817,984&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The aggregate intrinsic value of the total outstanding options and restricted stock and of total vested and exercisable options as of December 31, 2014 is approximately $&lt;font&gt;3.6&lt;/font&gt; million and $&lt;font&gt;2.7&lt;/font&gt; million, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 1in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;e.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Cost of revenues&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;220&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,756&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,655&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;936&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Marketing, General and administrative expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,775&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,434&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;306&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,751&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,089&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,242&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Public and 144A Offerings&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On February 22, 2012, the Company issued and sold &lt;font&gt;5,175,000&lt;/font&gt; shares of Common Stock in an underwritten public offering at a price to the public of $&lt;font&gt;5.25&lt;/font&gt; per share. The net proceeds to the Company were approximately $&lt;font&gt;25.4&lt;/font&gt; million (net of underwriting commissions and issuance costs of $&lt;font&gt;1.8&lt;/font&gt; million).&lt;/font&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On September 18, 2013, the Company completed a private offering of &lt;font&gt;4.50&lt;/font&gt;% convertible notes due 2018. The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $&lt;font&gt;9.0&lt;/font&gt; million in aggregate principal amount of the Notes, were $&lt;font&gt;66.8&lt;/font&gt; million (net of the initial purchaser's discount and commission and offering expenses payable by the Company). See also Note 8.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag26" contextRef="C580738" unitRef="Shares" decimals="INF">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag27" contextRef="C580740" unitRef="Shares" decimals="INF">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag28" contextRef="C580742" unitRef="Shares" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag29" contextRef="C580744" unitRef="Shares" decimals="INF">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag30" contextRef="C580738">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag31" contextRef="C580740">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag32" contextRef="C580742">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag33" contextRef="C580739" unitRef="USD" decimals="-3">2288000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag34" contextRef="C580741" unitRef="USD" decimals="-3">6292000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag35" contextRef="C583389" unitRef="USD" decimals="-3">1007000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="Tag36" contextRef="C580742">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Tag37" contextRef="C581110">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag38" contextRef="C581110" unitRef="Shares" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag39" contextRef="C581110" unitRef="USDPerShare" decimals="2">2.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag40" contextRef="C581110">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="Tag41" contextRef="C581110" unitRef="Item" decimals="0">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="Tag42" contextRef="C578941" unitRef="USD" decimals="-5">8600000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Tag43" contextRef="C578933" unitRef="USD" decimals="-5">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Tag44" contextRef="C578943">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag45" contextRef="C580761" unitRef="USD" decimals="0">39000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag46" contextRef="C580762" unitRef="Shares" decimals="INF">6141030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag47" contextRef="C580762" unitRef="USDPerShare" decimals="3">3.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag48" contextRef="C580763" unitRef="Shares" decimals="INF">5253579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag49" contextRef="C580763" unitRef="USDPerShare" decimals="3">3.923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag50" contextRef="C580764" unitRef="Shares" decimals="INF">5153898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag51" contextRef="C580764" unitRef="USDPerShare" decimals="3">3.951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag52" contextRef="C580766" unitRef="Shares" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag53" contextRef="C580766" unitRef="USDPerShare" decimals="3">2.370</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Tag54" contextRef="C580761" unitRef="Shares" decimals="INF">25858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Tag55" contextRef="C580761" unitRef="USDPerShare" decimals="3">4.372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Tag56" contextRef="C580765" unitRef="Shares" decimals="INF">20558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Tag57" contextRef="C580765" unitRef="USDPerShare" decimals="3">6.603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Tag58" contextRef="C580766" unitRef="Shares" decimals="INF">44201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Tag59" contextRef="C580766" unitRef="USDPerShare" decimals="3">6.833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag60" contextRef="C580761" unitRef="Shares" decimals="INF">861593</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag61" contextRef="C580761" unitRef="USDPerShare" decimals="3">1.346</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag62" contextRef="C580765" unitRef="Shares" decimals="INF">79123</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag63" contextRef="C580765" unitRef="USDPerShare" decimals="3">1.418</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag64" contextRef="C580766" unitRef="Shares" decimals="INF">139388</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag65" contextRef="C580766" unitRef="USDPerShare" decimals="3">0.446</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag66" contextRef="C580767" unitRef="Shares" decimals="INF">5870309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag67" contextRef="C580767" unitRef="USDPerShare" decimals="3">3.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag68" contextRef="C580763" unitRef="Shares" decimals="INF">4258441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag69" contextRef="C580763" unitRef="USDPerShare" decimals="3">3.201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag70" contextRef="C580764" unitRef="Shares" decimals="INF">4614148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag71" contextRef="C580764" unitRef="USDPerShare" decimals="3">3.591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag72" contextRef="C580767" unitRef="Shares" decimals="INF">4905559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag73" contextRef="C580767" unitRef="USDPerShare" decimals="3">3.933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag74" contextRef="C580761" unitRef="USD" decimals="-5">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag75" contextRef="C580765" unitRef="USD" decimals="0">306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag76" contextRef="C580766" unitRef="USD" decimals="0">447000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag77" contextRef="C580771" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag78" contextRef="C580769" unitRef="Shares" decimals="INF">1394708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag79" contextRef="C580768" unitRef="Shares" decimals="INF">970208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Tag80" contextRef="C580772" unitRef="Shares" decimals="INF">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Tag81" contextRef="C580772" unitRef="Shares" decimals="INF">102084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Tag82" contextRef="C580770" unitRef="Shares" decimals="INF">406666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Tag83" contextRef="C580773" unitRef="Shares" decimals="INF">398375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag84" contextRef="C580772" unitRef="Shares" decimals="INF">3208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag85" contextRef="C580770" unitRef="Shares" decimals="INF">17834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag86" contextRef="C580773" unitRef="Shares" decimals="INF">185709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Tag87" contextRef="C580774" unitRef="Shares" decimals="INF">386124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag88" contextRef="C583417" unitRef="Shares" decimals="INF">1238692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag89" contextRef="C583417" unitRef="USDPerShare" decimals="3">5.385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag90" contextRef="C583418" unitRef="Shares" decimals="INF">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag91" contextRef="C583418" unitRef="USDPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag92" contextRef="C583419" unitRef="Shares" decimals="INF">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag93" contextRef="C583419" unitRef="USDPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag94" contextRef="C583407" unitRef="Shares" decimals="INF">296167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag95" contextRef="C583407" unitRef="USDPerShare" decimals="3">2.678</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag96" contextRef="C583409" unitRef="Shares" decimals="INF">326267</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag97" contextRef="C583409" unitRef="USDPerShare" decimals="2">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag98" contextRef="C583420" unitRef="Shares" decimals="INF">1208592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag99" contextRef="C583420" unitRef="USDPerShare" decimals="3">6.136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag100" contextRef="C583418" unitRef="Shares" decimals="INF">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag101" contextRef="C583418" unitRef="USDPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag102" contextRef="C583419" unitRef="Shares" decimals="INF">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag103" contextRef="C583419" unitRef="USDPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Tag104" contextRef="C583420" unitRef="Shares" decimals="INF">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Tag105" contextRef="C583420" unitRef="USDPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="Tag106" contextRef="C583409" unitRef="USD" decimals="-5">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag107" contextRef="C582409" unitRef="Shares" decimals="INF">490624</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag108" contextRef="C582429" unitRef="USDPerShare" decimals="3">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag109" contextRef="C582410" unitRef="Shares" decimals="INF">719207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag110" contextRef="C582429">P6M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag111" contextRef="C582410" unitRef="Shares" decimals="INF">719207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag112" contextRef="C582429">P6M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag113" contextRef="C582430" unitRef="USDPerShare" decimals="3">0.120</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag114" contextRef="C582411" unitRef="Shares" decimals="INF">308801</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag115" contextRef="C582430">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag116" contextRef="C582411" unitRef="Shares" decimals="INF">308801</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag117" contextRef="C582430">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag118" contextRef="C582431" unitRef="USDPerShare" decimals="3">0.972</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag119" contextRef="C582412" unitRef="Shares" decimals="INF">995853</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag120" contextRef="C582431">P1Y5M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag121" contextRef="C582412" unitRef="Shares" decimals="INF">995853</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag122" contextRef="C582431">P1Y5M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag123" contextRef="C582432" unitRef="USDPerShare" decimals="3">2.350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag124" contextRef="C582413" unitRef="Shares" decimals="INF">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag125" contextRef="C582432">P3Y9M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag126" contextRef="C582413" unitRef="Shares" decimals="INF">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag127" contextRef="C582432">P3Y9M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag128" contextRef="C582433" unitRef="USDPerShare" decimals="3">2.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag129" contextRef="C582414" unitRef="Shares" decimals="INF">900000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag130" contextRef="C582433">P9Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag131" contextRef="C582414" unitRef="Shares" decimals="INF">56250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag132" contextRef="C582433">P9Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag133" contextRef="C582428" unitRef="USDPerShare" decimals="3">2.650</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag134" contextRef="C582415" unitRef="Shares" decimals="INF">345082</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag135" contextRef="C582428">P3Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag136" contextRef="C582415" unitRef="Shares" decimals="INF">345082</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag137" contextRef="C582428">P3Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag138" contextRef="C582434" unitRef="USDPerShare" decimals="3">3.020</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag139" contextRef="C582416" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag140" contextRef="C582434">P3Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag141" contextRef="C582416" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag142" contextRef="C582434">P3Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag143" contextRef="C582435" unitRef="USDPerShare" decimals="3">3.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag144" contextRef="C582417" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag145" contextRef="C582435">P9Y6M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag146" contextRef="C582417" unitRef="Shares" xsi:nil="true" />
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag147" contextRef="C582435">P9Y6M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag148" contextRef="C582436" unitRef="USDPerShare" decimals="3">5.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag149" contextRef="C582418" unitRef="Shares" decimals="INF">1708000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag150" contextRef="C582436">P2Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag151" contextRef="C582418" unitRef="Shares" decimals="INF">1708000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag152" contextRef="C582436">P2Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag153" contextRef="C582437" unitRef="USDPerShare" decimals="3">6.810</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag154" contextRef="C582419" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag155" contextRef="C582437">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag156" contextRef="C582419" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag157" contextRef="C582437">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag158" contextRef="C582438" unitRef="USDPerShare" decimals="3">6.900</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag159" contextRef="C582420" unitRef="Shares" decimals="INF">991916</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag160" contextRef="C582438">P4Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag161" contextRef="C582420" unitRef="Shares" decimals="INF">829249</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag162" contextRef="C582438">P4Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag163" contextRef="C582439" unitRef="USDPerShare" decimals="3">7.550</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag164" contextRef="C582421" unitRef="Shares" decimals="INF">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag165" contextRef="C582439">P5Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag166" contextRef="C582421" unitRef="Shares" decimals="INF">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag167" contextRef="C582439">P5Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag168" contextRef="C582440" unitRef="USDPerShare" decimals="3">9.660</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag169" contextRef="C582422" unitRef="Shares" decimals="INF">68000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag170" contextRef="C582440">P5Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag171" contextRef="C582422" unitRef="Shares" decimals="INF">68000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag172" contextRef="C582440">P5Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag173" contextRef="C582441" unitRef="USDPerShare" decimals="3">16.700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag174" contextRef="C582423" unitRef="Shares" decimals="INF">387542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="Tag175" contextRef="C582441">P1Y11M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag176" contextRef="C582423" unitRef="Shares" decimals="INF">387542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="Tag177" contextRef="C582441">P1Y11M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="Tag178" contextRef="C578933" unitRef="Shares" decimals="INF">7465025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="Tag179" contextRef="C578933" unitRef="Shares" decimals="INF">5817984</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Tag180" contextRef="C582409" unitRef="USD" decimals="-5">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 id="Tag181" contextRef="C580842" unitRef="USD" decimals="-5">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag182" contextRef="C580843" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag183" contextRef="C580844" unitRef="USD" decimals="-3">4756000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag184" contextRef="C580845" unitRef="USD" decimals="-3">2655000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag185" contextRef="C580846" unitRef="USD" decimals="-3">936000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag186" contextRef="C580847" unitRef="USD" decimals="-3">2775000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag187" contextRef="C580848" unitRef="USD" decimals="-3">1434000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag188" contextRef="C580849" unitRef="USD" decimals="-3">306000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag189" contextRef="C578941" unitRef="USD" decimals="-3">7751000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag190" contextRef="C578942" unitRef="USD" decimals="-3">4089000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag191" contextRef="C578943" unitRef="USD" decimals="-3">1242000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag192" contextRef="C598566" unitRef="Shares" decimals="INF">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="Tag193" contextRef="C580722" unitRef="USDPerShare" decimals="2">5.25</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag194" contextRef="C598566" unitRef="USD" decimals="-5">25400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Tag195" contextRef="C598566" unitRef="USD" decimals="-5">1800000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="Tag196" contextRef="C598567" unitRef="USD" decimals="-5">66800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock id="Tag197" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Below is a table summarizing all of the options and restricted stock grants to employees for each year of the three-year period ended December 31, 2014:&lt;/font&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 81%; margin-left: 1.25in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year of&lt;br/&gt; grant&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;No. of options&lt;br/&gt; or restricted&lt;br/&gt; stock granted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Exercise&lt;br/&gt; price range&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Vesting period&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Fair value&lt;br/&gt; at grant&lt;br/&gt; (U.S.&lt;br/&gt; dollars in&lt;br/&gt; thousands)&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Expiration&lt;br/&gt; period&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;400,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;3&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,288&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,100,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;4&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,292&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;2.37&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;4&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,007&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font&gt;10&lt;/font&gt; years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,400,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;</plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Tag198" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Options granted to employees:&lt;/font&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px; text-align: center;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,141,030&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,253,579&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.923&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,153,898&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.951&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year:&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; text-indent: 10px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 10px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Forfeited and Expired&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;25,858&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.372&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;20,558&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.603&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;44,201&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.833&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercised (*)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;861,593&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.346&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;79,123&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.418&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;139,388&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.446&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,253,579&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.923&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,153,898&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.951&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,870,309&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.770&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,258,441&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.201&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,614,148&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.591&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,905,559&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.933&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-indent: -14.2pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt; (*) &lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 98%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $&lt;font&gt;4.8&lt;/font&gt; million, $&lt;font&gt;306,000&lt;/font&gt; and $&lt;font&gt;447,000&lt;/font&gt;, respectively.&lt;br/&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="Tag199" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Restricted stock granted to employees:&lt;/font&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of Restricted Shares&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,394,708&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;970,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year:&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,500,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Vested&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;102,084&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;406,666&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;398,375&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;17,834&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;185,709&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt; font-family: 'times new roman';" width="50%"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,394,708&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;970,208&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;386,124&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag200" contextRef="C580761" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock id="Tag201" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Options and restricted stocks granted to consultants, directors, and other service providers:&lt;/font&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;of&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;exercise&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;price&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,238,692&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.385&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Changes during the year-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;296,167&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.678&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercised (*)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;326,267&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.12&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,208,592&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.136&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;912,425&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.259&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt; (*) &lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 98%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $&lt;font&gt;2.3&lt;/font&gt; million.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="Tag202" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2014:&lt;/font&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="26"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31, 2014&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="text-align: center; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;" colspan="8"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Options and restricted stock &lt;br/&gt;outstanding&lt;/strong&gt;&lt;/font&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="10"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Options exercisable&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Exercise &lt;br/&gt;prices&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of &lt;br/&gt;options and&lt;br/&gt; restricted stock &lt;br/&gt;outstanding &lt;br/&gt;at end of &lt;br/&gt;year&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted &lt;br/&gt;average &lt;br/&gt;remaining &lt;br/&gt;contractual &lt;br/&gt;life&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Number of&lt;br/&gt; options&lt;br/&gt; exercisable&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Weighted &lt;br/&gt;average &lt;br/&gt;remaining &lt;br/&gt;contractual &lt;br/&gt;life&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="center" style="padding: 0px 5px; white-space: nowrap;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom;" colspan="1" align="center"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a (Restricted Stock)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;490,624&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;n/a&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.001&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;719,207&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.54&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;719,207&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.54&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.120&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;308,801&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.00&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;308,801&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.00&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;0.972&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;995,853&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.44&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;995,853&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.44&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.350&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;40,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.82&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;40,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.82&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.75&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;56,250&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.75&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.650&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;345,082&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.49&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;345,082&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.49&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.020&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;50,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;50,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;3.370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.56&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.56&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,708,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,708,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.810&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;150,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.10&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6.900&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;991,916&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.32&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;829,249&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4.32&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7.550&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;160,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;160,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.66&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9.660&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;68,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.83&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;68,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5.83&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;16.700&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;387,542&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.99&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;387,542&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1.99&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,465,025&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,817,984&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag203" contextRef="C580765" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag204" contextRef="C580761" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag205" contextRef="C580765" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag206" contextRef="C580765" unitRef="USD" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag207" contextRef="C583408" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag208" contextRef="C583408" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag209" contextRef="C583408" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag210" contextRef="C583409" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag211" contextRef="C583409" unitRef="Shares" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag212" contextRef="C583407" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag213" contextRef="C583407" unitRef="USDPerShare" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag214" contextRef="C583408" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag215" contextRef="C580742" unitRef="USDPerShare" decimals="2">2.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag216" contextRef="C580766" unitRef="Shares" decimals="INF">133930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag217" contextRef="C580766" unitRef="USD" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Tag218" contextRef="C580773" unitRef="Shares" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Tag219" contextRef="C580770" unitRef="Shares" xsi:nil="true" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag220" contextRef="C583428" unitRef="USD" xsi:nil="true" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag221" contextRef="C583429" unitRef="USD" xsi:nil="true" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag222" contextRef="C578933" unitRef="Shares" decimals="INF">1923444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag223" contextRef="C597744" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="Tag224" contextRef="C597744" unitRef="USDPerShare" decimals="2">3.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag225" contextRef="C597744">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag226" contextRef="C597749" unitRef="USD" decimals="0">193000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag227" contextRef="C597744" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag228" contextRef="C597744" unitRef="Pure" decimals="2">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag229" contextRef="C597744" unitRef="Pure" decimals="3">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Tag230" contextRef="C597779" unitRef="USD" decimals="-6">1000000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag231" contextRef="C581110" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag232" contextRef="C581110" unitRef="Pure" decimals="2">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag233" contextRef="C581110" unitRef="Pure" decimals="4">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag234" contextRef="C581110">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag235" contextRef="C597744">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Tag236" contextRef="C598561" unitRef="Shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="Tag237" contextRef="C598562" unitRef="Item" decimals="0">8</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <dei:EntityPublicFloat id="Tag238" contextRef="C581568" unitRef="USD" decimals="-6">179000000</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="Tag239" contextRef="C581125" unitRef="Shares" decimals="INF">93603819</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:OtherAssetsCurrent id="Tag240" contextRef="C578932" unitRef="USD" decimals="-3">1457000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="Tag241" contextRef="C578933" unitRef="USD" decimals="-3">2202000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryNet id="Tag242" contextRef="C578932" unitRef="USD" decimals="-3">7957000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="Tag243" contextRef="C578933" unitRef="USD" decimals="-3">6667000</us-gaap:InventoryNet>
  <us-gaap:AssetsCurrent id="Tag244" contextRef="C578932" unitRef="USD" decimals="-3">97903000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag245" contextRef="C578933" unitRef="USD" decimals="-3">65520000</us-gaap:AssetsCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag246" contextRef="C578932" unitRef="USD" decimals="-3">1578000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag247" contextRef="C578933" unitRef="USD" decimals="-3">1555000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag248" contextRef="C578932" unitRef="USD" decimals="-3">13711000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag249" contextRef="C578933" unitRef="USD" decimals="-3">11282000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredCosts id="Tag250" contextRef="C578932" unitRef="USD" decimals="-3">141000</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts id="Tag251" contextRef="C578933" unitRef="USD" decimals="-3">113000</us-gaap:DeferredCosts>
  <us-gaap:Assets id="Tag252" contextRef="C578932" unitRef="USD" decimals="-3">113333000</us-gaap:Assets>
  <us-gaap:Assets id="Tag253" contextRef="C578933" unitRef="USD" decimals="-3">78470000</us-gaap:Assets>
  <us-gaap:AccountsPayableTradeCurrent id="Tag254" contextRef="C578932" unitRef="USD" decimals="-3">5254000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="Tag255" contextRef="C578933" unitRef="USD" decimals="-3">3951000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag256" contextRef="C578932" unitRef="USD" decimals="-3">12073000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag257" contextRef="C578933" unitRef="USD" decimals="-3">15496000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag258" contextRef="C578932" unitRef="USD" decimals="-3">9369000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag259" contextRef="C578933" unitRef="USD" decimals="-3">6763000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag260" contextRef="C578932" unitRef="USD" decimals="-3">26696000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag261" contextRef="C578933" unitRef="USD" decimals="-3">26210000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag262" contextRef="C578932" unitRef="USD" decimals="-3">67048000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag263" contextRef="C578933" unitRef="USD" decimals="-3">67464000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag264" contextRef="C578932" unitRef="USD" decimals="-3">41796000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag265" contextRef="C578933" unitRef="USD" decimals="-3">37232000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag266" contextRef="C578932" unitRef="USD" decimals="-3">2371000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag267" contextRef="C578933" unitRef="USD" decimals="-3">912000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag268" contextRef="C578932" unitRef="USD" decimals="-3">2368000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag269" contextRef="C578933" unitRef="USD" decimals="-3">2253000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag270" contextRef="C578932" unitRef="USD" decimals="-3">113583000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag271" contextRef="C578933" unitRef="USD" decimals="-3">107861000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities id="Tag272" contextRef="C578932" unitRef="USD" decimals="-3">140279000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Tag273" contextRef="C578933" unitRef="USD" decimals="-3">134071000</us-gaap:Liabilities>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag274" contextRef="C578933" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag275" contextRef="C578933" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag276" contextRef="C578932" unitRef="Shares" decimals="INF">93551098</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag277" contextRef="C578933" unitRef="Shares" decimals="INF">93603819</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue id="Tag278" contextRef="C578932" unitRef="USD" decimals="-3">93000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="Tag279" contextRef="C578933" unitRef="USD" decimals="-3">94000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag280" contextRef="C578932" unitRef="USD" decimals="-3">184346000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag281" contextRef="C578933" unitRef="USD" decimals="-3">185633000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag282" contextRef="C578932" unitRef="USD" decimals="-3">-211385000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag283" contextRef="C578933" unitRef="USD" decimals="-3">-241328000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag284" contextRef="C578932" unitRef="USD" decimals="-3">-26946000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag285" contextRef="C578933" unitRef="USD" decimals="-3">-55601000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag286" contextRef="C578932" unitRef="USD" decimals="-3">113333000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag287" contextRef="C578932" unitRef="USD" decimals="-3">86398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag288" contextRef="C578933" unitRef="USD" decimals="-3">78470000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag289" contextRef="C578933" unitRef="USD" decimals="-3">54767000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="Tag290" contextRef="C578932" unitRef="USD" decimals="-3">2091000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="Tag291" contextRef="C578933" unitRef="USD" decimals="-3">1884000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockSharesOutstanding id="Tag292" contextRef="C578932" unitRef="Shares" decimals="INF">93551098</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommitmentsAndContingencies id="Tag293" contextRef="C578933" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesAuthorized id="Tag294" contextRef="C578932" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommitmentsAndContingencies id="Tag295" contextRef="C578932" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag296" contextRef="C578932" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesOutstanding id="Tag297" contextRef="C578933" unitRef="Shares" decimals="INF">93603819</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:OperatingIncomeLoss id="Tag298" contextRef="C578943" unitRef="USD" decimals="-3">-25204000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="Tag299" contextRef="C578941" unitRef="USD" decimals="-3">34000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="Tag300" contextRef="C578942" unitRef="USD" decimals="-3">1065000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="Tag301" contextRef="C578943" unitRef="USD" decimals="-3">4935000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag302" contextRef="C578941" unitRef="USD" decimals="-3">588000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Tag303" contextRef="C578942" unitRef="USD" decimals="-3">391000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Tag304" contextRef="C578943" unitRef="USD" decimals="-3">196000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NonoperatingIncomeExpense id="Tag305" contextRef="C578941" unitRef="USD" decimals="-3">554000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag306" contextRef="C578942" unitRef="USD" decimals="-3">-674000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag307" contextRef="C578943" unitRef="USD" decimals="-3">-4739000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag308" contextRef="C578941" unitRef="USD" decimals="-3">-11618000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag309" contextRef="C578942" unitRef="USD" decimals="-3">-27790000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag310" contextRef="C578943" unitRef="USD" decimals="-3">-29943000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag311" contextRef="C578941" unitRef="USDPerShare" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag312" contextRef="C578942" unitRef="USDPerShare" decimals="2">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag313" contextRef="C578943" unitRef="USDPerShare" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag314" contextRef="C578941" unitRef="Shares" decimals="0">90845901</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag315" contextRef="C578942" unitRef="Shares" decimals="0">92368138</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag316" contextRef="C578943" unitRef="Shares" decimals="0">92891846</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:Revenues id="Tag317" contextRef="C578941" unitRef="USD" decimals="-3">34870000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag318" contextRef="C578942" unitRef="USD" decimals="-3">10479000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag319" contextRef="C578943" unitRef="USD" decimals="-3">13651000</us-gaap:Revenues>
  <plx:OtherGainsLosses id="Tag320" contextRef="C578941" unitRef="USD" decimals="-3">-446000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="Tag321" contextRef="C578942" unitRef="USD" decimals="-3">1034000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="Tag322" contextRef="C578943" unitRef="USD" decimals="-3">1509000</plx:OtherGainsLosses>
  <us-gaap:CostOfRevenue id="Tag323" contextRef="C578941" unitRef="USD" decimals="-3">8144000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag324" contextRef="C578942" unitRef="USD" decimals="-3">5428000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag325" contextRef="C578943" unitRef="USD" decimals="-3">9053000</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit id="Tag326" contextRef="C578941" unitRef="USD" decimals="-3">26280000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="Tag327" contextRef="C578942" unitRef="USD" decimals="-3">6085000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="Tag328" contextRef="C578943" unitRef="USD" decimals="-3">6107000</us-gaap:GrossProfit>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag329" contextRef="C578941" unitRef="USD" decimals="-3">36665000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag330" contextRef="C578942" unitRef="USD" decimals="-3">33313000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag331" contextRef="C578943" unitRef="USD" decimals="-3">29761000</us-gaap:ResearchAndDevelopmentExpense>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag332" contextRef="C578941" unitRef="USD" decimals="-3">7976000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag333" contextRef="C578942" unitRef="USD" decimals="-3">8497000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag334" contextRef="C578943" unitRef="USD" decimals="-3">8111000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag335" contextRef="C578941" unitRef="USD" decimals="-3">28689000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag336" contextRef="C578942" unitRef="USD" decimals="-3">24816000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag337" contextRef="C578943" unitRef="USD" decimals="-3">21650000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag338" contextRef="C578941" unitRef="USD" decimals="-3">9763000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag339" contextRef="C578942" unitRef="USD" decimals="-3">8385000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag340" contextRef="C578943" unitRef="USD" decimals="-3">9661000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag341" contextRef="C578941" unitRef="USD" decimals="-3">-12172000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag342" contextRef="C578942" unitRef="USD" decimals="-3">-27116000</us-gaap:OperatingIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag343" contextRef="C579717" unitRef="Shares" decimals="INF">85630157</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag344" contextRef="C579717" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag345" contextRef="C579718" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag346" contextRef="C579719" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag347" contextRef="C579720" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag348" contextRef="C579721" unitRef="Shares" decimals="INF">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Tag349" contextRef="C579721" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Tag350" contextRef="C579722" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Tag351" contextRef="C578941" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag352" contextRef="C579722" unitRef="USD" decimals="-3">4612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag353" contextRef="C578941" unitRef="USD" decimals="-3">4612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag354" contextRef="C587133" unitRef="Shares" decimals="INF">3208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag355" contextRef="C579721" unitRef="Shares" decimals="INF">1496792</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag356" contextRef="C579721" unitRef="USD" decimals="-3">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag357" contextRef="C579722" unitRef="USD" decimals="-3">3138000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag358" contextRef="C578941" unitRef="USD" decimals="-3">3139000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag359" contextRef="C579721" unitRef="Shares" decimals="INF">1187860</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag360" contextRef="C579721" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag361" contextRef="C579722" unitRef="USD" decimals="-3">1198000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag362" contextRef="C578941" unitRef="USD" decimals="-3">1199000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag363" contextRef="C579723" unitRef="USD" decimals="-3">-11618000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag364" contextRef="C579724" unitRef="Shares" decimals="INF">93489809</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag365" contextRef="C579724" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag366" contextRef="C579725" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag367" contextRef="C579726" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag368" contextRef="C579727" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag369" contextRef="C579728" unitRef="USD" decimals="-3">1013000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag370" contextRef="C578942" unitRef="USD" decimals="-3">1013000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag371" contextRef="C587160" unitRef="Shares" decimals="INF">17834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag372" contextRef="C579729" unitRef="Shares" decimals="INF">-17834</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag373" contextRef="C579728" unitRef="USD" decimals="-3">3076000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag374" contextRef="C578942" unitRef="USD" decimals="-3">3076000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag375" contextRef="C579729" unitRef="Shares" decimals="INF">79123</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag376" contextRef="C579728" unitRef="USD" decimals="-3">112000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag377" contextRef="C578942" unitRef="USD" decimals="-3">112000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag378" contextRef="C579730" unitRef="USD" decimals="-3">-27790000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag379" contextRef="C579731" unitRef="Shares" decimals="INF">93551098</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag380" contextRef="C579731" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag381" contextRef="C579732" unitRef="USD" decimals="-3">184346000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag382" contextRef="C579733" unitRef="USD" decimals="-3">-211385000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag383" contextRef="C579734" unitRef="USD" decimals="-3">467000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag384" contextRef="C578943" unitRef="USD" decimals="-3">467000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="Tag385" contextRef="C580842" unitRef="Shares" decimals="INF">185709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag386" contextRef="C579735" unitRef="Shares" decimals="INF">-81209</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag387" contextRef="C579734" unitRef="USD" decimals="-3">775000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag388" contextRef="C578943" unitRef="USD" decimals="-3">775000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag389" contextRef="C579735" unitRef="Shares" decimals="INF">133930</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag390" contextRef="C579735" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag391" contextRef="C579734" unitRef="USD" decimals="-3">45000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag392" contextRef="C578943" unitRef="USD" decimals="-3">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag393" contextRef="C579736" unitRef="USD" decimals="-3">-29943000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag394" contextRef="C579737" unitRef="Shares" decimals="INF">93603819</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag395" contextRef="C579737" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag396" contextRef="C579738" unitRef="USD" decimals="-3">185633000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag397" contextRef="C579739" unitRef="USD" decimals="-3">-241328000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="Tag398" contextRef="C578941" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag399" contextRef="C579730" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag400" contextRef="C579722" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag401" contextRef="C579723" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag402" contextRef="C579730" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag403" contextRef="C579721" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag404" contextRef="C579736" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag405" contextRef="C579734" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag406" contextRef="C579729" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag407" contextRef="C579723" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag408" contextRef="C579728" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag409" contextRef="C579736" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag410" contextRef="C579729" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag411" contextRef="C579730" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag412" contextRef="C579736" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag413" contextRef="C579735" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag414" contextRef="C579735" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag415" contextRef="C579729" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag416" contextRef="C579735" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag417" contextRef="C579721" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag418" contextRef="C579729" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag419" contextRef="C579723" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Tag420" contextRef="C579723" unitRef="USD" xsi:nil="true" />
  <us-gaap:ShareBasedCompensation id="Tag421" contextRef="C578941" unitRef="USD" decimals="-3">7751000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag422" contextRef="C578942" unitRef="USD" decimals="-3">4089000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag423" contextRef="C578943" unitRef="USD" decimals="-3">1242000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="Tag424" contextRef="C578941" unitRef="USD" decimals="-3">3692000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Tag425" contextRef="C578942" unitRef="USD" decimals="-3">3539000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Tag426" contextRef="C578943" unitRef="USD" decimals="-3">3140000</us-gaap:Depreciation>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag427" contextRef="C578941" unitRef="USD" decimals="-3">171000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag428" contextRef="C578942" unitRef="USD" decimals="-3">264000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag429" contextRef="C578943" unitRef="USD" decimals="-3">-1446000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag430" contextRef="C578941" unitRef="USD" decimals="-3">276000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag431" contextRef="C578942" unitRef="USD" decimals="-3">200000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag432" contextRef="C578943" unitRef="USD" decimals="-3">140000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag433" contextRef="C578941" unitRef="USD" decimals="-3">36000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag434" contextRef="C578942" unitRef="USD" decimals="-3">58000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag435" contextRef="C578943" unitRef="USD" decimals="-3">22000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag436" contextRef="C578943" unitRef="USD" decimals="-3">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:AmortizationOfFinancingCosts id="Tag437" contextRef="C578942" unitRef="USD" decimals="-3">127000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="Tag438" contextRef="C578943" unitRef="USD" decimals="-3">444000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag439" contextRef="C578941" unitRef="USD" decimals="-3">1281000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag440" contextRef="C578942" unitRef="USD" decimals="-3">-7160000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag441" contextRef="C578943" unitRef="USD" decimals="-3">-7170000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag442" contextRef="C578941" unitRef="USD" decimals="-3">-243000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag443" contextRef="C578942" unitRef="USD" decimals="-3">-1904000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag444" contextRef="C578943" unitRef="USD" decimals="-3">799000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories id="Tag445" contextRef="C578941" unitRef="USD" decimals="-3">3760000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="Tag446" contextRef="C578942" unitRef="USD" decimals="-3">3918000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="Tag447" contextRef="C578943" unitRef="USD" decimals="-3">-1290000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag448" contextRef="C578941" unitRef="USD" decimals="-3">2977000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag449" contextRef="C578942" unitRef="USD" decimals="-3">-1322000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag450" contextRef="C578943" unitRef="USD" decimals="-3">954000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag451" contextRef="C578941" unitRef="USD" decimals="-3">635000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag452" contextRef="C578942" unitRef="USD" decimals="-3">-30653000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag453" contextRef="C578943" unitRef="USD" decimals="-3">-29281000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag454" contextRef="C578941" unitRef="USD" decimals="-3">2068000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag455" contextRef="C578942" unitRef="USD" decimals="-3">1890000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag456" contextRef="C578943" unitRef="USD" decimals="-3">785000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag457" contextRef="C578943" unitRef="USD" decimals="-3">11000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag458" contextRef="C578941" unitRef="USD" decimals="-3">80000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag459" contextRef="C578942" unitRef="USD" decimals="-3">42000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag460" contextRef="C578943" unitRef="USD" decimals="-3">90000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag461" contextRef="C578941" unitRef="USD" decimals="-3">138000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag462" contextRef="C578942" unitRef="USD" decimals="-3">170000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag463" contextRef="C578943" unitRef="USD" decimals="-3">137000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag464" contextRef="C578941" unitRef="USD" decimals="-3">-2286000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag465" contextRef="C578942" unitRef="USD" decimals="-3">-2102000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag466" contextRef="C578943" unitRef="USD" decimals="-3">-1001000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag467" contextRef="C578942" unitRef="USD" decimals="-3">66780000</us-gaap:ProceedsFromConvertibleDebt>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="Tag468" contextRef="C578941" unitRef="USD" decimals="-3">25328000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag469" contextRef="C578941" unitRef="USD" decimals="-3">1230000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag470" contextRef="C578942" unitRef="USD" decimals="-3">112000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag471" contextRef="C578943" unitRef="USD" decimals="-3">46000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag472" contextRef="C578941" unitRef="USD" decimals="-3">26558000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag473" contextRef="C578942" unitRef="USD" decimals="-3">66892000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag474" contextRef="C578943" unitRef="USD" decimals="-3">46000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag475" contextRef="C578941" unitRef="USD" decimals="-3">127000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag476" contextRef="C578942" unitRef="USD" decimals="-3">226000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag477" contextRef="C578943" unitRef="USD" decimals="-3">-1395000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag478" contextRef="C578941" unitRef="USD" decimals="-3">25034000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag479" contextRef="C578942" unitRef="USD" decimals="-3">34363000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag480" contextRef="C578943" unitRef="USD" decimals="-3">-31631000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag481" contextRef="C579720" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag482" contextRef="C579727" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag483" contextRef="C578941" unitRef="USD" decimals="-3">1136000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag484" contextRef="C578942" unitRef="USD" decimals="-3">186000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag485" contextRef="C578943" unitRef="USD" decimals="-3">120000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <us-gaap:InterestPaidNet id="Tag486" contextRef="C578943" unitRef="USD" decimals="-3">3079000</us-gaap:InterestPaidNet>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag487" contextRef="C578941" unitRef="USD" xsi:nil="true" />
  <us-gaap:AmortizationOfFinancingCosts id="Tag488" contextRef="C578941" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromConvertibleDebt id="Tag489" contextRef="C578941" unitRef="USD" xsi:nil="true" />
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="Tag490" contextRef="C578942" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag491" contextRef="C578941" unitRef="USD" xsi:nil="true" />
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag492" contextRef="C578942" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag493" contextRef="C578942" unitRef="USD" xsi:nil="true" />
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="Tag494" contextRef="C578943" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromConvertibleDebt id="Tag495" contextRef="C578943" unitRef="USD" xsi:nil="true" />
  <plx:NumberOfSubsidiaries id="Tag496" contextRef="C578943" unitRef="Item" decimals="INF">2</plx:NumberOfSubsidiaries>
  <us-gaap:ProceedsFromCollaborators id="Tag497" contextRef="C580250" unitRef="USD" decimals="-5">60000000</us-gaap:ProceedsFromCollaborators>
  <plx:CollaborativeArrangementMilestonePaymentAmount id="Tag498" contextRef="C592809" unitRef="USD" decimals="-5">30000000</plx:CollaborativeArrangementMilestonePaymentAmount>
  <plx:CollaborativeArrangementProfitSharePercentage id="Tag499" contextRef="C580251" unitRef="Pure" decimals="2">0.40</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="Tag500" contextRef="C580252" unitRef="Pure" decimals="2">0.60</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:SupplyCommitmentPerYear id="Tag501" contextRef="C580253" unitRef="USD" decimals="-6">40000000</plx:SupplyCommitmentPerYear>
  <plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights id="Tag502" contextRef="C580253" unitRef="USD" decimals="-6">280000000</plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights>
  <plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits id="Tag503" contextRef="C580254" unitRef="USD" decimals="-5">12500000</plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Tag504" contextRef="C580256">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Tag505" contextRef="C580257">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Tag506" contextRef="C580258">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Tag507" contextRef="C580259">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag508" contextRef="C578941" unitRef="Shares" decimals="0">7280469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag509" contextRef="C578942" unitRef="Shares" decimals="0">10675304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag510" contextRef="C578943" unitRef="Shares" decimals="0">18850724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="Tag511" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;h.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Impairment in value of long-lived assets: &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="Tag512" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;i.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred income taxes&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See Note 10.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Uncertainty in income taxes&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Tax benefits recognized in the financial statements are those that the Company's management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company's management deems more likely than not to be sustained.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <plx:NatureOfOperationsPolicyTextBlock id="Tag513" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;General&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&lt;sup&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#147;ProCellEx&amp;#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's &lt;font&gt;two&lt;/font&gt; subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &amp;#147;Israeli MOH&amp;#148;) in September 2012, by the Brazilian Ministry of Health (the &amp;#147;Brazilian MOH&amp;#148;) in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Taliglucerase alfa is being marketed in the United States under the brand name&amp;#160;Elelyso&amp;#153; by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &amp;#147;Pfizer Agreement&amp;#148;). The Company, through Protalix Ltd., markets&amp;#160;Elelyso&amp;#160;in Israel, and in Brazil under the brand name Uplyso&amp;#153;. See Note 2.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $&lt;font&gt;60.0&lt;/font&gt; million in connection with the execution of the Pfizer Agreement and additional $&lt;font&gt;30.0&lt;/font&gt; million milestone payment mainly in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a &lt;font&gt;40&lt;/font&gt;% and &lt;font&gt;60&lt;/font&gt;% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retains exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is Uplyso. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz committed to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa during the first two years of the agreement. With respect to the first required purchase amount, the Company has recorded revenues of approximately $&lt;font&gt;3.5&lt;/font&gt; million for sales of taliglucerase alfa to Fiocruz in 2014.&amp;#160;In subsequent years, Fiocruz is required to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa per year. Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa. The Brazil Agreement became effective during the January&amp;#160;of 2014.&lt;br/&gt;&lt;br/&gt;If Fiocruz fails to comply with certain of its purchase commitments under the agreement, the Company has the right to terminate the agreement and all rights to the technology that were transferred to Fiocruz will be returned to the Company.&lt;br/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $&lt;font&gt;12.5&lt;/font&gt; million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;
&lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Tag514" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basis of presentation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#147;U.S. GAAP&amp;#148;).&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="Tag515" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Tag516" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Inventories at December 31, 2013 and 2014 consisted of the following:&lt;/font&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,342&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,616&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Work in progress&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;92&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,523&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,919&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Total inventory&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,957&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,667&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:RoyaltyExpense id="Tag517" contextRef="C580325" unitRef="USD" decimals="0">104000</us-gaap:RoyaltyExpense>
  <plx:CommitmentAmount id="Tag518" contextRef="C578943" unitRef="USD" decimals="-5">1200000</plx:CommitmentAmount>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="Tag519" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Functional currency&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company's revenues are derived in dollars. Most of the Company's expenses and capital expenditures are incurred in dollars, and the major source of the Company's financing has been provided in dollars.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &amp;#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &amp;#150; historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Tag520" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;e.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cash equivalents&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:InventoryPolicyTextBlock id="Tag521" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;f.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventories&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the &amp;#147;moving average&amp;#148; basis.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the &amp;#147;moving average&amp;#148; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;If actual market prices for finished products prove less favorable than those projected by management, inventory write-downs may be required. Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Tag522" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;g.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; text-align: left; font-family: 'times new roman';"&gt;1.&lt;/td&gt;
&lt;td style="text-align: justify; font-family: 'times new roman';"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; font-family: 'times new roman';"&gt;2.&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2"&gt;Years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 82%; text-align: left; font-family: 'times new roman';"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="width: 1%; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;Furniture&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;10&lt;/font&gt;-&lt;font&gt;15&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;Computer equipment&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <plx:MonthlyRentLeaseExpense id="Tag523" contextRef="C580326" unitRef="USD" decimals="0">85000</plx:MonthlyRentLeaseExpense>
  <us-gaap:SecurityDeposit id="Tag524" contextRef="C580327" unitRef="USD" decimals="0">315000</us-gaap:SecurityDeposit>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Tag525" contextRef="C580327" unitRef="USD" decimals="0">1014000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="Tag526" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;j.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenues from the license and supply agreement with Pfizer&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company's continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenues from selling products&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The Company recognizes revenues from&amp;#160;selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Company's share in the collaboration agreement&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel and Brazil (since 2014), where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company's share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="Tag527" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;k.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Research and development costs &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the &amp;#147;OCS&amp;#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have &lt;font&gt;no&lt;/font&gt; alternative future use are charged to research and development costs at the purchase date.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="Tag528" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;l.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Concentration of credit risks and trade receivable&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company's trade receivables represent amounts to be received from Pfizer and the Company's customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Tag529" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;m.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Share-based compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company accounts for employee's share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag530" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;n.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net loss per share&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Diluted LPS does not include &lt;font&gt;7,280,469&lt;/font&gt;, &lt;font&gt;10,675,304&lt;/font&gt; and &lt;font&gt;18,850,724&lt;/font&gt; shares of Common Stock underlying outstanding options , restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the fiscal years ended December 31, 2012, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <plx:ScheduleOfUsefulLifeTableTextBlock id="Tag531" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/font&gt;
&lt;div align="center"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2"&gt;Years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 82%; text-align: left; font-family: 'times new roman';"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="width: 1%; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;Furniture&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;10&lt;/font&gt;-&lt;font&gt;15&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;Computer equipment&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Tag532" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;General&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&lt;sup&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#147;ProCellEx&amp;#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's &lt;font&gt;two&lt;/font&gt; subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &amp;#147;Israeli MOH&amp;#148;) in September 2012, by the Brazilian Ministry of Health (the &amp;#147;Brazilian MOH&amp;#148;) in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Taliglucerase alfa is being marketed in the United States under the brand name&amp;#160;Elelyso&amp;#153; by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &amp;#147;Pfizer Agreement&amp;#148;). The Company, through Protalix Ltd., markets&amp;#160;Elelyso&amp;#160;in Israel, and in Brazil under the brand name Uplyso&amp;#153;. See Note 2.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $&lt;font&gt;60.0&lt;/font&gt; million in connection with the execution of the Pfizer Agreement and additional $&lt;font&gt;30.0&lt;/font&gt; million milestone payment mainly in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a &lt;font&gt;40&lt;/font&gt;% and &lt;font&gt;60&lt;/font&gt;% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retains exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is Uplyso. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz committed to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa during the first two years of the agreement. With respect to the first required purchase amount, the Company has recorded revenues of approximately $&lt;font&gt;3.5&lt;/font&gt; million for sales of taliglucerase alfa to Fiocruz in 2014.&amp;#160;In subsequent years, Fiocruz is required to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa per year. Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa. The Brazil Agreement became effective during the January&amp;#160;of 2014.&lt;br/&gt;&lt;br/&gt;If Fiocruz fails to comply with certain of its purchase commitments under the agreement, the Company has the right to terminate the agreement and all rights to the technology that were transferred to Fiocruz will be returned to the Company.&lt;br/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $&lt;font&gt;12.5&lt;/font&gt; million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basis of presentation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#147;U.S. GAAP&amp;#148;).&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt;
&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Functional currency&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company's revenues are derived in dollars. Most of the Company's expenses and capital expenditures are incurred in dollars, and the major source of the Company's financing has been provided in dollars.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &amp;#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &amp;#150; historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;e.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cash equivalents&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;f.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventories&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the &amp;#147;moving average&amp;#148; basis.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the &amp;#147;moving average&amp;#148; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;If actual market prices for finished products prove less favorable than those projected by management, inventory write-downs may be required. Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;g.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; text-align: left; font-family: 'times new roman';"&gt;1.&lt;/td&gt;
&lt;td style="text-align: justify; font-family: 'times new roman';"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; font-family: 'times new roman';"&gt;2.&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="width: 48pt; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2"&gt;Years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 82%; text-align: left; font-family: 'times new roman';"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="width: 1%; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15%; text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;Furniture&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;10&lt;/font&gt;-&lt;font&gt;15&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;Computer equipment&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman';"&gt;&lt;font&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;h.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Impairment in value of long-lived assets: &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;
&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;i.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred income taxes&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See Note 10.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Uncertainty in income taxes&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Tax benefits recognized in the financial statements are those that the Company's management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company's management deems more likely than not to be sustained.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;j.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenues from the license and supply agreement with Pfizer&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company's continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenues from selling products&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The Company recognizes revenues from&amp;#160;selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;"&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Company's share in the collaboration agreement&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel and Brazil (since 2014), where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company's share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;k.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Research and development costs &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the &amp;#147;OCS&amp;#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have &lt;font&gt;no&lt;/font&gt; alternative future use are charged to research and development costs at the purchase date.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;l.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Concentration of credit risks and trade receivable&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company's trade receivables represent amounts to be received from Pfizer and the Company's customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.&lt;/p&gt;
&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;m.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Share-based compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company accounts for employee's share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;n.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net loss per share&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Diluted LPS does not include &lt;font&gt;7,280,469&lt;/font&gt;, &lt;font&gt;10,675,304&lt;/font&gt; and &lt;font&gt;18,850,724&lt;/font&gt; shares of Common Stock underlying outstanding options , restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the fiscal years ended December 31, 2012, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"&gt;&lt;b&gt;o.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Convertible notes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"&gt;The convertible notes are accounted for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: -20.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;p. &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Recently issued accounting pronouncements:&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;"&gt;In August 2014, the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued amended guidance related to the disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. The Company believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;"&gt;In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. The Company is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <plx:RevenueRecognizedOverDesignatedPeriod id="Tag533" contextRef="C578943" unitRef="USD" decimals="-5">4600000</plx:RevenueRecognizedOverDesignatedPeriod>
  <plx:RevenueRecognizedPeriod id="Tag534" contextRef="C578943">P14Y</plx:RevenueRecognizedPeriod>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag535" contextRef="C578933" unitRef="USD" decimals="-3">21454000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="Tag536" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/font&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="4"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Laboratory&amp;#160;equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;14,858&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,138&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Furniture&amp;#160;and&amp;#160;computer&amp;#160;equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,074&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,154&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Leasehold&amp;#160;improvements&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,070&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,427&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Equipment&amp;#160;under&amp;#160;construction&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;28&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;17&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;32,030&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;32,736&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Less&amp;#160;&amp;#150;&amp;#160;accumulated&amp;#160;depreciation&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 20px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;and&amp;#160;amortization&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(18,319&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(21,454&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;13,711&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;11,282&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RoyaltyExpense id="Tag537" contextRef="C580323" unitRef="USD" decimals="0">674000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="Tag538" contextRef="C580324" unitRef="USD" decimals="0">80000</us-gaap:RoyaltyExpense>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Tag539" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: -20.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;p. &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Recently issued accounting pronouncements:&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;"&gt;In August 2014, the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued amended guidance related to the disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. The Company believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;"&gt;In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. The Company is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.&lt;/p&gt;
&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock id="Tag540" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"&gt;&lt;b&gt;o.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Convertible notes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"&gt;The convertible notes are accounted for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:Revenues id="Tag541" contextRef="C580255" unitRef="USD" decimals="-5">3500000</us-gaap:Revenues>
  <us-gaap:ProceedsFromCollaborators id="Tag542" contextRef="C580262" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromCollaborators>
  <plx:MilestonePayment id="Tag543" contextRef="C592847" unitRef="USD" decimals="-5">25000000</plx:MilestonePayment>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent id="Tag544" contextRef="C580265" unitRef="USD" decimals="-5">7100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent id="Tag545" contextRef="C580264" unitRef="USD" decimals="-5">8000000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <plx:CollaborativeAndLicenseArrangementDisclosureTextBlock id="Tag546" contextRef="C578942">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;b&gt;NOTE 2 - LICENSE AND SUPPLY AGREEMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;On November 30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. As mentioned in Note 1, in June 2013, Pfizer returned the commercialization rights in Brazil to Protalix Ltd. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $&lt;font&gt;60.0&lt;/font&gt; million in connection with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $&lt;font&gt;5.0&lt;/font&gt; million upon the Company's filing of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $&lt;font&gt;25.0&lt;/font&gt; million milestone payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to &lt;font&gt;40&lt;/font&gt;% of the results (profits or losses) earned on Pfizer's sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to other adjustments, taking into account Protalix Ltd.'s cost of goods sold and Pfizer's commercial expenses, with certain expenses capped or borne solely by one party (&amp;#147;Collaboration Operation&amp;#148;). As of December 31, 2014 and 2013, the Company accrued a liability in respect of its share in the &lt;font style="font: 10pt Times New Roman, Times, Serif;"&gt;accumulated losses of the collaboration operation equal to&lt;/font&gt; approximately&amp;#160;$&lt;font&gt;7.1&lt;/font&gt; million and $&lt;font&gt;8.0&lt;/font&gt; million, respectively.&amp;#160;After deducting the losses, the Company is entitled to receive in cash its share in the profits of the collaboration operation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The Company has determined that the initial, non-refundable upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line basis as revenue over the estimated relationship period (approximately $&lt;font&gt;4.6&lt;/font&gt; million per year). The Company has estimated that the relationship period for its arrangement with Pfizer will be approximately &lt;font&gt;14&lt;/font&gt; years (commencing upon the Company's receipt of the up-front license payment) based on the Company's last material patent relating to taliglucerase alfa to expire. The $25.0 million milestone payment received during 2012 in connection with the FDA's approval of taliglucerase alfa in the United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during the period in which the milestone was achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The Company's deliverables under this collaboration include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase alfa.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;According to the terms and conditions of the Pfizer Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;</plx:CollaborativeAndLicenseArrangementDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag547" contextRef="C580267" unitRef="USD" decimals="-3">14858000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag548" contextRef="C580268" unitRef="USD" decimals="-3">15138000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag549" contextRef="C580269" unitRef="USD" decimals="-3">2074000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag550" contextRef="C580270" unitRef="USD" decimals="-3">2154000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag551" contextRef="C580271" unitRef="USD" decimals="-3">15070000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag552" contextRef="C580272" unitRef="USD" decimals="-3">15427000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag553" contextRef="C580273" unitRef="USD" decimals="-3">28000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag554" contextRef="C580274" unitRef="USD" decimals="-3">17000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag555" contextRef="C578932" unitRef="USD" decimals="-3">32030000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Tag556" contextRef="C578933" unitRef="USD" decimals="-3">32736000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag557" contextRef="C578932" unitRef="USD" decimals="-3">18319000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Tag558" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="4"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Laboratory&amp;#160;equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;14,858&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,138&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Furniture&amp;#160;and&amp;#160;computer&amp;#160;equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,074&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,154&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Leasehold&amp;#160;improvements&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,070&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,427&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Equipment&amp;#160;under&amp;#160;construction&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;28&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;17&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;32,030&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;32,736&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Less&amp;#160;&amp;#150;&amp;#160;accumulated&amp;#160;depreciation&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 20px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;and&amp;#160;amortization&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(18,319&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(21,454&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;13,711&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;11,282&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.3pt; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; font-family: 'times new roman';"&gt;Depreciation and amortization in respect of property and equipment totaled approximately $&lt;font&gt;3.7&lt;/font&gt; million, $&lt;font&gt;3.5&lt;/font&gt; million and $&lt;font&gt;3.1&lt;/font&gt; million for the years ended December 31, 2012, 2013 and 2014, respectively.&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag559" contextRef="C578932" unitRef="USD" decimals="-3">2342000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag560" contextRef="C578933" unitRef="USD" decimals="-3">1616000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag561" contextRef="C578932" unitRef="USD" decimals="-3">92000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag562" contextRef="C578933" unitRef="USD" decimals="-3">132000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag563" contextRef="C578932" unitRef="USD" decimals="-3">5523000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag564" contextRef="C578933" unitRef="USD" decimals="-3">4919000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Tag565" contextRef="C580327" unitRef="USD" decimals="0">1009000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Tag566" contextRef="C580327" unitRef="USD" decimals="0">1009000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesRentExpenseNet id="Tag567" contextRef="C580328" unitRef="USD" decimals="0">971000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:InventoryDisclosureTextBlock id="Tag568" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 4 - INVENTORIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Inventories at December 31, 2013 and 2014 consisted of the following:&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left;"&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(&lt;i&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,342&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,616&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Work in progress&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;92&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;132&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,523&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,919&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Total inventory&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;7,957&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,667&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt; &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"&gt;

&lt;tr style="vertical-align: top; text-align: justify;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in; text-align: left; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; font-family: 'times new roman';"&gt;&lt;font style="font-family: 'times new roman', times; font-size: 10pt;"&gt;During the years ended December 31, 2013 and 2014, the Company recorded approximately $&lt;font&gt;1.6&lt;/font&gt; million and $&lt;font&gt;1.7&lt;/font&gt; million, respectively, for write-down of inventory under cost of revenues.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryWriteDown id="Tag569" contextRef="C578943" unitRef="USD" decimals="-3">1700000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown id="Tag570" contextRef="C578942" unitRef="USD" decimals="-3">1600000</us-gaap:InventoryWriteDown>
  <plx:EmployeeSeveranceObligationPayment id="Tag571" contextRef="C578941" unitRef="USD" decimals="0">177000</plx:EmployeeSeveranceObligationPayment>
  <plx:EmployeeSeveranceObligationPayment id="Tag572" contextRef="C578942" unitRef="USD" decimals="0">194000</plx:EmployeeSeveranceObligationPayment>
  <plx:EmployeeSeveranceObligationPayment id="Tag573" contextRef="C578943" unitRef="USD" decimals="0">195000</plx:EmployeeSeveranceObligationPayment>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="Tag574" contextRef="C578941" unitRef="USD" decimals="0">670000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="Tag575" contextRef="C578942" unitRef="USD" decimals="0">801000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="Tag576" contextRef="C578943" unitRef="USD" decimals="0">779000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="Tag577" contextRef="C578941" unitRef="USD" decimals="0">36000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="Tag578" contextRef="C578942" unitRef="USD" decimals="0">58000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="Tag579" contextRef="C578943" unitRef="USD" decimals="0">22000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <plx:ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod id="Tag580" contextRef="C578943" unitRef="USD" decimals="0">863000</plx:ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod>
  <plx:ExpectedDefintedBenefitContributionDuringPeriod id="Tag581" contextRef="C578943" unitRef="USD" decimals="0">685000</plx:ExpectedDefintedBenefitContributionDuringPeriod>
  <us-gaap:OperatingLeasesRentExpenseNet id="Tag582" contextRef="C580329" unitRef="USD" decimals="0">1133000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="Tag583" contextRef="C580326" unitRef="USD" decimals="0">1044000</us-gaap:OperatingLeasesRentExpenseNet>
  <plx:MonthlyRentLeaseExpense id="Tag584" contextRef="C580330" unitRef="USD" decimals="0">51000</plx:MonthlyRentLeaseExpense>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Tag585" contextRef="C580332" unitRef="USD" decimals="0">504000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Tag586" contextRef="C580332" unitRef="USD" decimals="0">289000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="Tag587" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;b&gt;NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Company's balance sheets under &amp;#147;Liability for employee rights upon retirement.&amp;#148; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company's balance sheets under &amp;#147;Funds in respect of employee rights upon retirement.&amp;#148; These policies are the Company's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2012, 2013 and 2014, the Company deposited approximately&lt;b&gt; &lt;/b&gt;$&lt;font&gt;177,000&lt;/font&gt;, $&lt;font&gt;194,000&lt;/font&gt; and $&lt;font&gt;195,000&lt;/font&gt;, respectively, with insurance companies in connection with its severance payment obligations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company's balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &amp;#147;Contribution Plans&amp;#148;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The amounts of severance pay expenses were approximately $&lt;font&gt;1.0&lt;/font&gt; million for each of the years ended December 31, 2012, 2013 and 2014, of which approximately&lt;b&gt; &lt;/b&gt;$&lt;font&gt;670,000&lt;/font&gt;, $&lt;font&gt;801,000&lt;/font&gt; and $&lt;font&gt;779,000&lt;/font&gt; in the years ended December 31, 2012, 2013 and 2014, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately&lt;b&gt; &lt;/b&gt;$&lt;font&gt;36,000&lt;/font&gt;, $&lt;font&gt;58,000&lt;/font&gt; and $&lt;font&gt;22,000&lt;/font&gt; for the years ended December 31, 2012, 2013 and 2014, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;The Company expects to contribute approximately $&lt;font&gt;863,000&lt;/font&gt; in the year ending December 31, 2015 to insurance companies in connection with its severance liabilities for its operations for that year, approximately&lt;b&gt; &lt;/b&gt;$&lt;font&gt;685,000&lt;/font&gt; of which will be contributed to one or more Contribution Plans.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;&amp;#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"&gt;During the five-year period following December 31, 2014, the Company expects to pay future benefits to three&lt;b&gt; &lt;/b&gt;employees upon each such employee's normal retirement age. The Company anticipates that the benefits payable will be immaterial.&lt;/p&gt; &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PostemploymentBenefitsPeriodExpense id="Tag588" contextRef="C578942" unitRef="USD" decimals="-3">1000000</us-gaap:PostemploymentBenefitsPeriodExpense>
  <us-gaap:PostemploymentBenefitsPeriodExpense id="Tag589" contextRef="C578941" unitRef="USD" decimals="-3">1000000</us-gaap:PostemploymentBenefitsPeriodExpense>
  <us-gaap:PostemploymentBenefitsPeriodExpense id="Tag590" contextRef="C578943" unitRef="USD" decimals="-3">1000000</us-gaap:PostemploymentBenefitsPeriodExpense>
  <plx:RoyaltiesOnSaleOfProducts id="Tag591" contextRef="C580305" unitRef="Pure" decimals="2">0.03</plx:RoyaltiesOnSaleOfProducts>
  <plx:RoyaltiesOnSaleOfProducts id="Tag592" contextRef="C580306" unitRef="Pure" decimals="2">0.06</plx:RoyaltiesOnSaleOfProducts>
  <plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived id="Tag593" contextRef="C580307" unitRef="Pure" decimals="2">1.00</plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived>
  <plx:RoyaltiesOnSaleOfProducts id="Tag594" contextRef="C582480" unitRef="Pure" decimals="2">3.00</plx:RoyaltiesOnSaleOfProducts>
  <us-gaap:RoyaltyExpense id="Tag595" contextRef="C580308" unitRef="USD" decimals="-5">1500000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="Tag596" contextRef="C580309" unitRef="USD" decimals="0">392000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="Tag597" contextRef="C580310" unitRef="USD" decimals="0">951000</us-gaap:RoyaltyExpense>
  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent id="Tag598" contextRef="C580307" unitRef="USD" decimals="-6">30000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Tag599" contextRef="C580332" unitRef="USD" decimals="0">118000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CommitmentsDisclosureTextBlock id="Tag600" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;b&gt;NOTE 6 - COMMITMENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Royalty Commitments&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of the related projects was not assured.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Under the terms of the funding arrangements with the OCS, royalties of &lt;font&gt;3&lt;/font&gt;% to &lt;font&gt;6&lt;/font&gt;% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed, in the aggregate, &lt;font&gt;100&lt;/font&gt;% of the amount of the grant received (dollar linked), plus, commencing upon January 1, 2001, interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to &lt;font&gt;300&lt;/font&gt;% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Royalty expenses to the OCS are included in the statement of operations as a component of the cost of revenues and were approximately $&lt;font&gt;1.5&lt;/font&gt; million, $&lt;font&gt;392,000&lt;/font&gt; and $&lt;font&gt;951,000&lt;/font&gt; during the years ended December 31, 2012, 2013 and 2014, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;At December 31, 2014, the maximum royalty amount payable by the Company under these funding arrangements is approximately $&lt;font&gt;30&lt;/font&gt; million (without interest, assuming 100% of the funds are payable).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately $&lt;font&gt;674,000&lt;/font&gt;, $&lt;font&gt;80,000&lt;/font&gt; and $&lt;font&gt;104,000&lt;/font&gt; during the years ended December 31, 2012, 2013 and 2014, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments payable would be approximately $0.3 million and would be payable, if at all, as the Company's projects progress over the course of a number of years. No milestone payments were made during 2012, 2013 and 2014.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subcontracting Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company has entered into sub-contracting agreements with several clinical providers and consultants&lt;b&gt; &lt;/b&gt;in Israel, the United States and certain other countries in connection with its primary product development process. As of December 31, 2014, total commitments under said agreements were approximately $&lt;font&gt;1.2&lt;/font&gt; million.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Lease Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company is a party to a number of lease agreements for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental payments are approximately $&lt;font&gt;85,000&lt;/font&gt;. As of December 31, 2014, the Company provided bank guarantees of approximately $&lt;font&gt;315,000&lt;/font&gt; , in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of the next &lt;font&gt;three&lt;/font&gt; years under the operating leases for such premises are approximately as follows: 2015 - $&lt;font&gt;1,014,000&lt;/font&gt;, 2016 &amp;#150; $&lt;font&gt;1,009,000&lt;/font&gt;, 2017 $&lt;font&gt;1,009,000&lt;/font&gt;. Lease expenses totaled approximately $&lt;font&gt;971,000&lt;/font&gt;, $&lt;font&gt;1,133,000&lt;/font&gt; and $&lt;font&gt;1,044,000&lt;/font&gt; for the years ended December 31, 2012, 2013 and 2014, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vehicle Lease and Maintenance Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $&lt;font&gt;51,000&lt;/font&gt;. The expected lease payments for the years ending December 31, 2015, 2016 and 2017 are approximately $&lt;font&gt;504,000&lt;/font&gt;, $&lt;font&gt;289,000&lt;/font&gt; and $&lt;font&gt;118,000&lt;/font&gt;, respectively.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag601" contextRef="C578933" unitRef="USD" decimals="-5">52400000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="Tag602" contextRef="C578932" unitRef="USD" decimals="-3">9867000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="Tag603" contextRef="C578933" unitRef="USD" decimals="-3">8658000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Tag604" contextRef="C578932" unitRef="USD" decimals="-3">23167000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Tag605" contextRef="C578933" unitRef="USD" decimals="-3">28130000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Tag606" contextRef="C578932" unitRef="USD" decimals="-3">38426000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Tag607" contextRef="C578933" unitRef="USD" decimals="-3">40111000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="Tag608" contextRef="C578932" unitRef="USD" xsi:nil="true" />
  <us-gaap:DeferredTaxAssetsNet id="Tag609" contextRef="C578933" unitRef="USD" xsi:nil="true" />
  <us-gaap:OpenTaxYear id="Tag610" contextRef="C581067">2011</us-gaap:OpenTaxYear>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag611" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 9 - FAIR VALUE MEASUREMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The fair value of the convertible notes as of December 31, 2014 is approximately $&lt;font&gt;52.4&lt;/font&gt; million based on level 2 measurement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Tag612" contextRef="C581047" unitRef="Pure" decimals="INF">0.39</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <plx:WithholdingTaxRateOnForeignIncome id="Tag613" contextRef="C578933" unitRef="Pure" decimals="2">0.15</plx:WithholdingTaxRateOnForeignIncome>
  <us-gaap:OperatingLossCarryforwards id="Tag614" contextRef="C578933" unitRef="USD" decimals="-5">138800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Tag615" contextRef="C581051" unitRef="USD" decimals="-5">16900000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Tag616" contextRef="C581048" unitRef="USD" decimals="-5">121900000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="Tag617" contextRef="C578932" unitRef="USD" decimals="-3">5257000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="Tag618" contextRef="C578933" unitRef="USD" decimals="-3">3136000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="Tag619" contextRef="C578932" unitRef="USD" decimals="-3">-491000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="Tag620" contextRef="C578933" unitRef="USD" decimals="-3">-372000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="Tag621" contextRef="C578932" unitRef="USD" decimals="-3">417000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="Tag622" contextRef="C578933" unitRef="USD" decimals="-3">374000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments id="Tag623" contextRef="C578932" unitRef="USD" decimals="-3">209000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments id="Tag624" contextRef="C578933" unitRef="USD" decimals="-3">185000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
  <us-gaap:OpenTaxYear id="Tag625" contextRef="C581068">2014</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="Tag626" contextRef="C581069">2010</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="Tag627" contextRef="C581070">2014</us-gaap:OpenTaxYear>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Tag628" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The components of the Company's net deferred tax assets at December 31, 2013 and 2014 were as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;In respect of:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;Research and development expenses&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;5,257&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;3,136&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Property and equipment&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(491&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(372&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Provision for vacation&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;417&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;374&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Severance pay obligation&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;209&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;185&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Deferred revenues&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;9,867&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;8,658&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Net operating loss carry forwards&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;23,167&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;28,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Valuation allowance&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(38,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(40,111&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <plx:ScheduleOfOpenTaxYearsTableTextBlock id="Tag629" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;A summary of open tax years by major jurisdiction is presented below:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-right: 0.1px;" cellpadding="0" cellspacing="0"&gt;

&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-decoration: none; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; padding-left: 0px; font-family: 'times new roman';"&gt;&lt;strong&gt;Jurisdiction:&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: right; font-family: 'times new roman';"&gt;&lt;strong&gt;&lt;b&gt;Years:&lt;/b&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0px; font-family: 'times new roman'; width: 90%;"&gt;Israel&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; width: 10%;" nowrap="nowrap"&gt;&lt;font&gt;2011&lt;/font&gt;-&lt;font&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0; font-family: 'times new roman';"&gt;United States (*)&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;font&gt;2010&lt;/font&gt;-&lt;font&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;b&gt;&lt;b&gt;&amp;#160;&lt;br/&gt;&lt;/b&gt;&lt;/b&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="margin-left: 0.100000001490116px;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;(*)&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 98%; font-size: 10pt;"&gt;
&lt;div&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Tag630" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;b&gt;NOTE 10 - TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;strong&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company&lt;/strong&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company's income is taxed in the United States at the rate of up to &lt;font&gt;39&lt;/font&gt;%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Protalix Ltd. &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Measurement of results for tax purposes &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Since 2008, the Company has measured the results of the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985, the Subsidiary's results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel consumer price index.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Tax rates&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The income of the Israeli Subsidiary, other than income from &amp;#147;Approved Enterprises,&amp;#148; is taxed in Israel at the regular rates which were &lt;font&gt;25&lt;/font&gt;% in 2012 and 2013 and &lt;font&gt;26.5&lt;/font&gt;% for 2014 and thereafter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;Capital gain is subject to capital gain tax according to corporate tax rate in the year of selling the assets.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;The Law for the Encouragement of Capital Investments, 1959 (the &amp;#147;Encouragement of Capital Investments Law&amp;#148;)&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &amp;#147;Approved Enterprise&amp;#148; or &amp;#147;Benefited Enterprise&amp;#148; status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt;"&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Reduced tax rates&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The Israeli Subsidiary has an &amp;#147;Approved Enterprise&amp;#148; plan since 2004 and &amp;#147;Benefited Enterprise&amp;#148; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &amp;#147;Approved Enterprise&amp;#148; or &amp;#147;Benefited Enterprise&amp;#148; during the tax exemption period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would have been applicable had such income not been exempted.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;In addition to the corporate taxes in Israel, the Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits under the Pfizer Agreement. The withholding tax rate is currently &lt;font&gt;15&lt;/font&gt;%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Accelerated depreciation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first &lt;font&gt;five&lt;/font&gt; years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The Israeli Subsidiary's entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect to its &amp;#147;Approved Enterprise&amp;#148; from the Investment Center.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the &amp;#147;Capital Investments Law Amendment&amp;#148;).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;&lt;/b&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"&gt;Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the &amp;#147;year of election&amp;#148; no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"&gt;&lt;b&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/b&gt;Tax losses carried forward to future years&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;As of December 31, 2014, the Company had aggregate net operating loss (NOL) carry-forwards equal to approximately $&lt;font&gt;138.8&lt;/font&gt; million that are available to reduce future taxable income as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;The Company&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;The NOL carry-forward of the Company equal to approximately $&lt;font&gt;16.9&lt;/font&gt; million may be restricted under Section 382 of the Internal Revenue Code (&amp;#147;IRC&amp;#148;). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;b&gt;Protalix Ltd.&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"&gt;At December 31, 2014, the Israeli Subsidiary had approximately $&lt;font&gt;121.9&lt;/font&gt; million of NOL carry-forwards that are available to reduce future taxable income with &lt;font&gt;no&lt;/font&gt; limited period of use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;b&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred income taxes:&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The components of the Company's net deferred tax assets at December 31, 2013 and 2014 were as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;In respect of:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;Research and development expenses&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;5,257&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;3,136&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Property and equipment&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(491&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(372&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Provision for vacation&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;417&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;374&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Severance pay obligation&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;209&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;185&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Deferred revenues&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;9,867&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;8,658&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Net operating loss carry forwards&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;23,167&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;28,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;Valuation allowance&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(38,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;(40,111&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. The Company used tax rates of 39%, 26.5% and 0%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;e.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Reconciliation of the theoretical tax expense to actual tax expense&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"&gt;&lt;b&gt;f.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Tax assessments&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;In accordance with the Income Tax Ordinance, as of December 31, 2014, all of Protalix Ltd.'s tax assessments through tax year 2010&amp;#160;are considered final.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;A summary of open tax years by major jurisdiction is presented below:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;div class="CursorPointer" align="center"&gt;
&lt;table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-right: 0.1px;" cellpadding="0" cellspacing="0"&gt;

&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-decoration: none; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; padding-left: 0px; font-family: 'times new roman';"&gt;&lt;strong&gt;Jurisdiction:&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: right; font-family: 'times new roman';"&gt;&lt;strong&gt;&lt;b&gt;Years:&lt;/b&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0px; font-family: 'times new roman'; width: 90%;"&gt;Israel&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; width: 10%;" nowrap="nowrap"&gt;&lt;font&gt;2011&lt;/font&gt;-&lt;font&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; width: 0%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0; font-family: 'times new roman';"&gt;United States (*)&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman';" nowrap="nowrap"&gt;&lt;font&gt;2010&lt;/font&gt;-&lt;font&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;b&gt;&lt;b&gt;&amp;#160;&lt;br/&gt;&lt;/b&gt;&lt;/b&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table width="100%" cellpadding="0" border="0" cellspacing="0" style="margin-left: 0.100000001490116px;"&gt;

&lt;tr&gt;
&lt;td style="width: 2%;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"&gt;(*)&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 98%; font-size: 10pt;"&gt;
&lt;div&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <plx:EffectiveAdjustedIncomeTaxRateYearOne id="Tag631" contextRef="C581048" unitRef="Pure" decimals="2">0.25</plx:EffectiveAdjustedIncomeTaxRateYearOne>
  <plx:EffectiveAdjustedIncomeTaxRateThereafter id="Tag632" contextRef="C581048" unitRef="Pure" decimals="3">0.265</plx:EffectiveAdjustedIncomeTaxRateThereafter>
  <plx:EffectiveAdjustedIncomeTaxRateYearTwo id="Tag633" contextRef="C581048" unitRef="Pure" decimals="2">0.25</plx:EffectiveAdjustedIncomeTaxRateYearTwo>
  <us-gaap:AdditionalFinancialInformationDisclosureTextBlock id="Tag634" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 11 - &lt;/b&gt; &lt;b&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Balance sheets:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold; text-align: left; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;a. &amp;#160; &amp;#160; &amp;#160; &amp;#160;Other assets:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Institutions&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;356&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;124&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;State of Israel (see Note 6a)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;366&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,229&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Restricted deposit&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;362&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;416&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Prepaid expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;286&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;369&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Sundry&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;87&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;64&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,457&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,202&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; margin: 0 0 0 75pt;"&gt;
&lt;td style="font-family: 'times new roman'; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;b. &amp;#160; &amp;#160; &amp;#160; &amp;#160; Accounts payable and accruals &amp;#150; other:&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,557&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,243&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Interest payable&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;888&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;914&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Provision for vacation&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,572&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,412&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,785&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,097&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Royalties payable&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;419&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;495&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Liability in connection with collaboration operation - current portion&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,666&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,215&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Property and equipment suppliers&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;186&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;120&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;12,073&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,496&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;br/&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Statements of operations:&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap" style="font-weight: bold; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;c. &amp;#160; &amp;#160; &amp;#160;Revenues:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 70%; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Deferred revenues from the license and supply agreement with Pfizer&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Milestone payment (see Note 2)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;25,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Revenues from selling products&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,307&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,916&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9,088&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 28.85pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;34,870&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;10,479&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;13,651&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
  <plx:OtherAssetsInstitutionsCurrent id="Tag635" contextRef="C578932" unitRef="USD" decimals="-3">356000</plx:OtherAssetsInstitutionsCurrent>
  <plx:OtherAssetsInstitutionsCurrent id="Tag636" contextRef="C578933" unitRef="USD" decimals="-3">124000</plx:OtherAssetsInstitutionsCurrent>
  <us-gaap:PrepaidRoyalties id="Tag637" contextRef="C578932" unitRef="USD" decimals="-3">366000</us-gaap:PrepaidRoyalties>
  <us-gaap:PrepaidRoyalties id="Tag638" contextRef="C578933" unitRef="USD" decimals="-3">1229000</us-gaap:PrepaidRoyalties>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="Tag639" contextRef="C578932" unitRef="USD" decimals="-3">362000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="Tag640" contextRef="C578933" unitRef="USD" decimals="-3">416000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent id="Tag641" contextRef="C578932" unitRef="USD" decimals="-3">286000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="Tag642" contextRef="C578933" unitRef="USD" decimals="-3">369000</us-gaap:PrepaidExpenseCurrent>
  <plx:OtherAssetsSundryCurrent id="Tag643" contextRef="C578932" unitRef="USD" decimals="-3">87000</plx:OtherAssetsSundryCurrent>
  <plx:OtherAssetsSundryCurrent id="Tag644" contextRef="C578933" unitRef="USD" decimals="-3">64000</plx:OtherAssetsSundryCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag645" contextRef="C578932" unitRef="USD" decimals="-3">1557000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag646" contextRef="C578933" unitRef="USD" decimals="-3">1243000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:InterestPayableCurrent id="Tag647" contextRef="C578932" unitRef="USD" decimals="-3">888000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent id="Tag648" contextRef="C578933" unitRef="USD" decimals="-3">914000</us-gaap:InterestPayableCurrent>
  <us-gaap:AccruedVacationCurrent id="Tag649" contextRef="C578932" unitRef="USD" decimals="-3">1572000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccruedVacationCurrent id="Tag650" contextRef="C578933" unitRef="USD" decimals="-3">1412000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag651" contextRef="C578932" unitRef="USD" decimals="-3">1785000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag652" contextRef="C578933" unitRef="USD" decimals="-3">5097000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="Tag653" contextRef="C578932" unitRef="USD" decimals="-3">419000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="Tag654" contextRef="C578933" unitRef="USD" decimals="-3">495000</us-gaap:AccruedRoyaltiesCurrent>
  <plx:AccruedLiabilityInConnectionWithCollaborationOperationCurrent id="Tag655" contextRef="C578932" unitRef="USD" decimals="-3">5666000</plx:AccruedLiabilityInConnectionWithCollaborationOperationCurrent>
  <plx:AccruedLiabilityInConnectionWithCollaborationOperationCurrent id="Tag656" contextRef="C578933" unitRef="USD" decimals="-3">6215000</plx:AccruedLiabilityInConnectionWithCollaborationOperationCurrent>
  <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent id="Tag657" contextRef="C578932" unitRef="USD" decimals="-3">186000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
  <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent id="Tag658" contextRef="C578933" unitRef="USD" decimals="-3">120000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
  <plx:SupplementaryBalanceSheetsInformationTableTextBlock id="Tag659" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Balance sheets:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&lt;font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold; text-align: left; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;a. &amp;#160; &amp;#160; &amp;#160; &amp;#160;Other assets:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Institutions&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;356&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;124&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;State of Israel (see Note 6a)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;366&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,229&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Restricted deposit&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;362&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;416&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Prepaid expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;286&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;369&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Sundry&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;87&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;64&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,457&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;2,202&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; margin: 0 0 0 75pt;"&gt;
&lt;td style="font-family: 'times new roman'; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;b. &amp;#160; &amp;#160; &amp;#160; &amp;#160; Accounts payable and accruals &amp;#150; other:&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,557&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,243&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Interest payable&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;888&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;914&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Provision for vacation&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,572&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,412&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;1,785&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,097&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Royalties payable&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;419&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;495&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Liability in connection with collaboration operation - current portion&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,666&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;6,215&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Property and equipment suppliers&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;186&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;120&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;12,073&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;15,496&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&amp;#160;&lt;br/&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
  <plx:SupplementaryIncomeStatementInformationTableTextBlock id="Tag660" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 1.1in;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Statements of operations:&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap" style="font-weight: bold; text-indent: -26.45pt; margin: 0 0 0 75pt;"&gt;c. &amp;#160; &amp;#160; &amp;#160;Revenues:&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 70%; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Deferred revenues from the license and supply agreement with Pfizer&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;4,563&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Milestone payment (see Note 2)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;25,000&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Revenues from selling products&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,307&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;5,916&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;9,088&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 28.85pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;34,870&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;10,479&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;13,651&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
  <us-gaap:LicensesRevenue id="Tag661" contextRef="C578941" unitRef="USD" decimals="-3">4563000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="Tag662" contextRef="C578942" unitRef="USD" decimals="-3">4563000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="Tag663" contextRef="C578943" unitRef="USD" decimals="-3">4563000</us-gaap:LicensesRevenue>
  <plx:MilestonePayment id="Tag664" contextRef="C578941" unitRef="USD" decimals="-3">25000000</plx:MilestonePayment>
  <us-gaap:SalesRevenueGoodsNet id="Tag665" contextRef="C578941" unitRef="USD" decimals="-3">5307000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag666" contextRef="C578942" unitRef="USD" decimals="-3">5916000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag667" contextRef="C578943" unitRef="USD" decimals="-3">9088000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="Tag668" contextRef="C581103" unitRef="USD" decimals="-3">375000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="Tag669" contextRef="C581104" unitRef="USD" decimals="-3">509000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="Tag670" contextRef="C581105" unitRef="USD" decimals="-3">560000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Tag671" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;NOTE 12 - RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;div style="display: block;" align="center"&gt;
&lt;div class="CursorPointer"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 0.100000001490116px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2014 and the Chairman of the Board for part of 2014)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;375&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;560&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock id="Tag672" contextRef="C578943">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div style="display: block;" align="center"&gt;
&lt;div class="CursorPointer"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 0.100000001490116px; margin-right: 0.1px;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;Year ended December 31,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2014 and the Chairman of the Board for part of 2014)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 0%;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;375&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;560&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"&gt;&lt;font style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <dei:AmendmentFlag id="Tag673" contextRef="C578943">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag674" contextRef="C578943">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate id="Tag675" contextRef="C578943">2014-12-31</dei:DocumentPeriodEndDate>
  <dei:TradingSymbol id="Tag676" contextRef="C578943">PLX</dei:TradingSymbol>
  <dei:EntityWellKnownSeasonedIssuer id="Tag677" contextRef="C578943">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="Tag678" contextRef="C578943">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="Tag679" contextRef="C578943">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag680" contextRef="C578943">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="Tag681" contextRef="C578943">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag682" contextRef="C578943">0001006281</dei:EntityCentralIndexKey>
  <dei:DocumentFiscalYearFocus id="Tag683" contextRef="C578943">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag684" contextRef="C578943">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentType id="Tag685" contextRef="C578943">10-K</dei:DocumentType>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag60" />
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag61" />
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag62" />
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag63" />
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag64" />
    <link:loc xlink:type="locator" xlink:label="value29" xlink:href="#Tag65" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag96" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag97" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag208" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag209" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag212" />
    <link:loc xlink:type="locator" xlink:label="value30" xlink:href="#Tag213" />
    <link:loc xlink:type="locator" xlink:label="value97" xlink:href="#Tag626" />
    <link:loc xlink:type="locator" xlink:label="value97" xlink:href="#Tag627" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote29" xlink:role="http://www.xbrl.org/2003/role/footnote">




 (*)
The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $4.8 million, $306,000 and $447,000, respectively.




</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value29" xlink:to="footnote29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="29" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote30" xlink:role="http://www.xbrl.org/2003/role/footnote">




 (*)
The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $2.3 million.




</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value30" xlink:to="footnote30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="30" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote97" xlink:role="http://www.xbrl.org/2003/role/footnote">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value97" xlink:to="footnote97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="97" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>plx-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:plx="http://www.protalix.com/20141231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.protalix.com/20141231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/plx-daei" id="plx-daei">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cbs" id="plx-cbs">
        <link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cbsp" id="plx-cbsp">
        <link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-csoo" id="plx-csoo">
        <link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-csocicd" id="plx-csocicd">
        <link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-csocicdp" id="plx-csocicdp">
        <link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-csocf" id="plx-csocf">
        <link:definition>007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sap" id="plx-sap">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lasa" id="plx-lasa">
        <link:definition>102 - Disclosure - LICENSE AND SUPPLY AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-pae" id="plx-pae">
        <link:definition>103 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-i" id="plx-i">
        <link:definition>104 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lferur" id="plx-lferur">
        <link:definition>105 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-c" id="plx-c">
        <link:definition>106 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sc" id="plx-sc">
        <link:definition>107 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cn1" id="plx-cn1">
        <link:definition>108 - Disclosure - CONVERTIBLE NOTE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvm1" id="plx-fvm1">
        <link:definition>109 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toi" id="plx-toi">
        <link:definition>110 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsi" id="plx-sfsi">
        <link:definition>111 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rpt" id="plx-rpt">
        <link:definition>112 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapp1" id="plx-sapp1">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapt" id="plx-sapt">
        <link:definition>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-paet" id="plx-paet">
        <link:definition>303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-it" id="plx-it">
        <link:definition>304 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sct" id="plx-sct">
        <link:definition>307 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnt1" id="plx-cnt1">
        <link:definition>308 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toit" id="plx-toit">
        <link:definition>310 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsit" id="plx-sfsit">
        <link:definition>311 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rptt" id="plx-rptt">
        <link:definition>312 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapd" id="plx-sapd">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapulopaed" id="plx-sapulopaed">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lasad" id="plx-lasad">
        <link:definition>40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-paed" id="plx-paed">
        <link:definition>40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-id" id="plx-id">
        <link:definition>40401 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-lferurd" id="plx-lferurd">
        <link:definition>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cd" id="plx-cd">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scnd" id="plx-scnd">
        <link:definition>40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsooarsgted" id="plx-scsooarsgted">
        <link:definition>40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scfvaoogd" id="plx-scfvaoogd">
        <link:definition>40703 - Disclosure - SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scogted" id="plx-scogted">
        <link:definition>40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scrsgted" id="plx-scrsgted">
        <link:definition>40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" id="plx-scoarsgtcdaospd">
        <link:definition>40706 - Disclosure - SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsooarsd" id="plx-scsooarsd">
        <link:definition>40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-scsbcead" id="plx-scsbcead">
        <link:definition>40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnnd1" id="plx-cnnd1">
        <link:definition>40801 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-cnsoierd1" id="plx-cnsoierd1">
        <link:definition>40802 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvmd1" id="plx-fvmd1">
        <link:definition>40901 - Disclosure - FAIR VALUE MEASUREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toind" id="plx-toind">
        <link:definition>41001 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toiditd" id="plx-toiditd">
        <link:definition>41002 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-toiotyd" id="plx-toiotyd">
        <link:definition>41003 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsoa" id="plx-sfsoa">
        <link:definition>41101 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsiapaaod" id="plx-sfsiapaaod">
        <link:definition>41102 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sfsird" id="plx-sfsird">
        <link:definition>41103 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-rptd" id="plx-rptd">
        <link:definition>41201 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/XLink" schemaLocation="http://www.xbrl.org/2003/xl-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfUsefulLifeTableTextBlock" id="plx_ScheduleOfUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryEquipmentMember" id="plx_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UponFDAApprovalMember" id="plx_UponFDAApprovalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EligablePaymentReceivableUponAchievement" id="plx_EligablePaymentReceivableUponAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyCommitmentPerYear" id="plx_SupplyCommitmentPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseAmountToBeSatisfiedToReceiveEntitledRights" id="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognizedOverDesignatedPeriod" id="plx_RevenueRecognizedOverDesignatedPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognizedPeriod" id="plx_RevenueRecognizedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosureTextBlock" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CollaborationOperationMember" id="plx_CollaborationOperationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FurnitureAndComputerEquipmentMember" id="plx_FurnitureAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquipmentUnderConstructionMember" id="plx_EquipmentUnderConstructionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CompensationToTheNon-executiveDirectorsMember" id="plx_CompensationToTheNon-executiveDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeSeveranceObligationPayment" id="plx_EmployeeSeveranceObligationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" id="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpectedDefintedBenefitContributionDuringPeriod" id="plx_ExpectedDefintedBenefitContributionDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccrualsAxis" id="plx_AccountsPayableAndAccrualsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccrualsDomain" id="plx_AccountsPayableAndAccrualsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccrualsLineItems" id="plx_AccountsPayableAndAccrualsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccrualsTable" id="plx_AccountsPayableAndAccrualsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementMaintenanceFee" id="plx_AgreementMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AmortizationOfDebtIssuanceCosts" id="plx_AmortizationOfDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AnnualIncreaseToMaintenanceFee" id="plx_AnnualIncreaseToMaintenanceFee" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationOperationCurrentPortionMember" id="plx_CollaborationOperationCurrentPortionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosure" id="plx_CollaborativeAndLicenseArrangementDisclosure" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeAndLicenseArrangementTable" id="plx_CollaborativeAndLicenseArrangementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentAmount" id="plx_CommitmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesAxis" id="plx_CommitmentsAndContingenciesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesDomain" id="plx_CommitmentsAndContingenciesDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="plx_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="plx_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ConsiderationForLicense" id="plx_ConsiderationForLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleBaseValueForConversionRate" id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleConversionShareNumber" id="plx_DebtInstrumentConvertibleConversionShareNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="DeferredCostMember" id="plx_DeferredCostMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" id="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateThereafter" id="plx_EffectiveAdjustedIncomeTaxRateThereafter" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFive" id="plx_EffectiveAdjustedIncomeTaxRateYearFive" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFour" id="plx_EffectiveAdjustedIncomeTaxRateYearFour" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearOne" id="plx_EffectiveAdjustedIncomeTaxRateYearOne" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearThree" id="plx_EffectiveAdjustedIncomeTaxRateYearThree" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearTwo" id="plx_EffectiveAdjustedIncomeTaxRateYearTwo" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="EmployeesMember" id="plx_EmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FivePointZeroMember" id="plx_FivePointZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ForfeitureRate" id="plx_ForfeitureRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="FundingArrangementsMember" id="plx_FundingArrangementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandTwelveMember" id="plx_GrantYearTwoThousandTwelveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandTwelveSecondMember" id="plx_GrantYearTwoThousandTwelveSecondMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="plx_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxDisclosureTable" id="plx_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="InstitutionsMember" id="plx_InstitutionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LiabilitiesAccruedFromLicensingAgreement" id="plx_LiabilitiesAccruedFromLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ManagementAndConsultingFeesToChairmanOfBoardMember" id="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" id="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="MilestonePaymentsMember" id="plx_MilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MonthlyRentLeaseExpense" id="plx_MonthlyRentLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NinePointSixSixMember" id="plx_NinePointSixSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OCSMember" id="plx_OCSMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OfficersAndCertainEmployeesMember" id="plx_OfficersAndCertainEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OfficersAndDirectorsInPrivateTransactionMember" id="plx_OfficersAndDirectorsInPrivateTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OneSixPointSevenMember" id="plx_OneSixPointSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStockGrantedToEmployeesMember" id="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStockMember" id="plx_OptionsAndRestrictedStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" id="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProbableAggregateMilestonePaymentMember" id="plx_ProbableAggregateMilestonePaymentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProductsManufacturedOutsideOfIsraelMember" id="plx_ProductsManufacturedOutsideOfIsraelMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PropertyAndEquipmentSuppliersMember" id="plx_PropertyAndEquipmentSuppliersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndLicenseAgreementsMember" id="plx_ResearchAndLicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedAmountMember" id="plx_RestrictedAmountMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedDepositMember" id="plx_RestrictedDepositMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesOnSaleOfProducts" id="plx_RoyaltiesOnSaleOfProducts" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOpenTaxYearsTableTextBlock" id="plx_ScheduleOfOpenTaxYearsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" id="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SevenPointFiveFiveMember" id="plx_SevenPointFiveFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SixPointEightOneZeroMember" id="plx_SixPointEightOneZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SixPointNineMember" id="plx_SixPointNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StateOfIsraelMember" id="plx_StateOfIsraelMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SundryMember" id="plx_SundryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationAbstract" id="plx_SupplementalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationRevenueAxis" id="plx_SupplementalInformationRevenueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationRevenueDomain" id="plx_SupplementalInformationRevenueDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationRevenueLineItems" id="plx_SupplementalInformationRevenueLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationTable" id="plx_SupplementalInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SupplementaryBalanceSheetsInformationTableTextBlock" id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SupplementaryIncomeStatementInformationTableTextBlock" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="TaxBurdenDistributionLawMember" id="plx_TaxBurdenDistributionLawMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" id="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="TaxYearThereafterMember" id="plx_TaxYearThereafterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TaxYearTwoThousandNineMember" id="plx_TaxYearTwoThousandNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ThreePointZeroTwoZeroMember" id="plx_ThreePointZeroTwoZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointSixFiveMember" id="plx_TwoPointSixFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointThreeFiveZeroMember" id="plx_TwoPointThreeFiveZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UponNearTermClinicalDevelopmentMilestonesMember" id="plx_UponNearTermClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="VehicleLeaseAndMaintenanceAgreementsMember" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="WithholdingTaxRateOnForeignIncome" id="plx_WithholdingTaxRateOnForeignIncome" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="YissumAgreementMember" id="plx_YissumAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointNineSevenTwoMember" id="plx_ZeroPointNineSevenTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointOneTwoZeroMember" id="plx_ZeroPointOneTwoZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointThreeNineNineMember" id="plx_ZeroPointThreeNineNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ZeroPointZeroZeroOneMember" id="plx_ZeroPointZeroZeroOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PresidentAndChiefExecutiveOfficerMember" id="plx_PresidentAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" id="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoPointThreeSevenZeroMember" id="plx_TwoPointThreeSevenZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ThreePointThreeSevenZeroMember" id="plx_ThreePointThreeSevenZeroMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GrantYearTwoThousandFourteenMember" id="plx_GrantYearTwoThousandFourteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilityInConnectionWithCollaborationOperationCurrent" id="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="OtherAssetsInstitutionsCurrent" id="plx_OtherAssetsInstitutionsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OtherAssetsSundryCurrent" id="plx_OtherAssetsSundryCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentAmount" id="plx_CollaborativeArrangementMilestonePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" id="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>plx-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cbs" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocf" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-id" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-id" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnsoierd1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cnsoierd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiditd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toiditd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsiapaaod" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsiapaaod" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csoo" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csoo" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsird" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsird" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsoa" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsoa" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_AssetsCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableTradeCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesNoncurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_RetainedEarningsAccumulatedDeficit" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" xlink:title="Calculation : us-gaap_Assets to us-gaap_DeferredCosts" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_InventoryNet" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableOtherCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_ConvertibleDebtNoncurrent" order="2" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_DeferredRevenueCurrent" order="13" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_LongTermDebtNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_CommonStockValue" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Calculation : us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_OtherAssetsCurrent" order="13" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetIncomeLoss" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromConvertibleDebt" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2" weight="-1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInRestrictedCash" order="3" weight="-1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="6" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="7" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="12" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_Depreciation" order="22" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentGross" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-id">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnsoierd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Calculation : us-gaap_InterestExpense to us-gaap_InterestExpenseDebtExcludingAmortization" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense" xlink:to="plx_AmortizationOfDebtIssuanceCosts" xlink:title="Calculation : us-gaap_InterestExpense to plx_AmortizationOfDebtIssuanceCosts" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiditd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsDeferredIncome" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="6" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Calculation : us-gaap_DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsiapaaod">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="us-gaap_InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to us-gaap_InterestPayableCurrent" order="20" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:title="us-gaap_AccruedVacationCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccruedVacationCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to us-gaap_AccruedVacationCurrent" order="30" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to us-gaap_AccruedLiabilitiesCurrent" order="40" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to us-gaap_AccruedRoyaltiesCurrent" order="50" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:label="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" order="60" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="Calculation : us-gaap_AccountsPayableOtherCurrent to plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" order="70" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_OperatingIncomeLoss" order="14" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_NonoperatingIncomeExpense" order="24" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingExpense" order="10" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncome" order="20" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_GrossProfit" order="23" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="33" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_SellingGeneralAndAdministrativeExpense" order="43" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to us-gaap_ResearchAndDevelopmentExpense" order="12" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to plx_GrantsAndReimbursementsReceivedOrReceivable" order="22" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_Revenues" order="13" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="plx_OtherGainsLosses" xlink:title="Calculation : us-gaap_GrossProfit to plx_OtherGainsLosses" order="23" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_CostOfRevenue" order="33" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsird">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="us-gaap_LicensesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicensesRevenue" xlink:title="Calculation : us-gaap_Revenues to us-gaap_LicensesRevenue" order="10" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="plx_MilestonePayment" xlink:title="Calculation : us-gaap_Revenues to plx_MilestonePayment" order="40" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:title="Calculation : us-gaap_Revenues to us-gaap_SalesRevenueGoodsNet" order="60" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsoa">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" xlink:title="plx_OtherAssetsInstitutionsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent" xlink:title="Calculation : us-gaap_OtherAssetsCurrent to plx_OtherAssetsInstitutionsCurrent" order="10" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties" xlink:title="us-gaap_PrepaidRoyalties" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidRoyalties" xlink:title="Calculation : us-gaap_OtherAssetsCurrent to us-gaap_PrepaidRoyalties" order="20" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_OtherAssetsCurrent to us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="30" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:title="us-gaap_PrepaidExpenseCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:title="Calculation : us-gaap_OtherAssetsCurrent to us-gaap_PrepaidExpenseCurrent" order="40" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" xlink:title="plx_OtherAssetsSundryCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsSundryCurrent" xlink:title="Calculation : us-gaap_OtherAssetsCurrent to plx_OtherAssetsSundryCurrent" order="50" weight="1" use="optional" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>plx-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocicd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocicd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapulopaed" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapulopaed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasad" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-lasad" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scnd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scnd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsgted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsooarsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scogted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scogted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scrsgted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scrsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scoarsgtcdaospd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsooarsd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsbcead" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsbcead" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toind" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toind" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiotyd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toiotyd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-rptd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocicdp" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocicdp" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="4.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="7.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="arc" order="8.94" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" xlink:type="arc" order="9.94286" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" xlink:type="arc" order="9.94287" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="9.94311" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="arc" order="9.94463" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SignificantAccountingPoliciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueAxis" xlink:label="plx_SupplementalInformationRevenueAxis" xlink:title="plx_SupplementalInformationRevenueAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueDomain" xlink:label="plx_SupplementalInformationRevenueDomain" xlink:title="plx_SupplementalInformationRevenueDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="plx_SupplementalInformationRevenueAxis" xlink:to="plx_SupplementalInformationRevenueDomain" xlink:title="Definition : plx_SupplementalInformationRevenueAxis to plx_SupplementalInformationRevenueDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Definition : dei_EntityDomain to us-gaap_SubsidiariesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:title="us-gaap_SalesRevenueGoodsNetMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SupplementalInformationRevenueDomain" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:title="Definition : plx_SupplementalInformationRevenueDomain to us-gaap_SalesRevenueGoodsNetMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueDomain" xlink:label="plx_SupplementalInformationRevenueDomain_1" xlink:title="plx_SupplementalInformationRevenueDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="plx_SupplementalInformationRevenueAxis" xlink:to="plx_SupplementalInformationRevenueDomain_1" xlink:title="Definition : plx_SupplementalInformationRevenueAxis to plx_SupplementalInformationRevenueDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_1" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerIncorporationMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="3.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to dei_LegalEntityAxis" xlink:type="arc" order="3.75" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SupplementalInformationRevenueAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to plx_SupplementalInformationRevenueAxis" xlink:type="arc" order="3.8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_Revenues" xlink:type="arc" order="10.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_EligablePaymentReceivableUponAchievement" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_EligablePaymentReceivableUponAchievement" xlink:type="arc" order="41" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementMilestonePaymentAmount" xlink:type="arc" use="optional" order="51" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapulopaed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasad">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Definition : plx_CollaborativeAndLicenseArrangementTable to us-gaap_StatementScenarioAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_CollaborationOperationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_CollaborationOperationMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : plx_CollaborativeAndLicenseArrangementTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeAndLicenseArrangementTable" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeAndLicenseArrangementTable" xlink:type="arc" order="5" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedPeriod" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedPeriod" xlink:type="arc" order="8" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_FurnitureAndComputerEquipmentMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_EquipmentUnderConstructionMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_EquipmentUnderConstructionMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AssetImpairmentCharges" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_Depreciation" xlink:type="arc" use="optional" order="16" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cd">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesTable" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentsAndContingenciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain" xlink:title="Definition : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_OCSMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_OCSMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : plx_CommitmentsAndContingenciesTable to us-gaap_RangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain_1" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain_1" xlink:title="Definition : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AnnualIncreaseToMaintenanceFee" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_AnnualIncreaseToMaintenanceFee" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesAxis" xlink:title="Definition : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_FundingArrangementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_FundingArrangementsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_RoyaltiesOnSaleOfProducts" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ResearchAndLicenseAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ResearchAndLicenseAgreementsMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AgreementMaintenanceFee" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_AgreementMaintenanceFee" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProbableAggregateMilestonePaymentMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_ProbableAggregateMilestonePaymentMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ConsiderationForLicense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_ConsiderationForLicense" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_MilestonePaymentsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_MilestonePaymentsMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_RoyaltyExpense" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="us-gaap_LeaseAgreementsMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to us-gaap_LeaseAgreementsMember" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentAmount" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_YissumAgreementMember" xlink:title="Definition : plx_CommitmentsAndContingenciesDomain to plx_YissumAgreementMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MonthlyRentLeaseExpense" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to plx_MonthlyRentLeaseExpense" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_SecurityDeposit" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Definition : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="16" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" xlink:type="arc" order="1.25" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="3.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="9.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="11" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" use="optional" order="36" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" use="optional" order="46" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" use="optional" order="56" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc" use="optional" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" use="optional" order="66" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" use="optional" order="76" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" use="optional" order="86" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" use="optional" order="96" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_VestingAxis" xlink:type="arc" use="optional" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_1" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" use="optional" order="106" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:type="arc" use="optional" order="116" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" use="optional" order="126" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_1" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandFourteenMember" xlink:title="Definition : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandFourteenMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scogted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" use="optional" order="15" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scrsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="2.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="5" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scoarsgtcdaospd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="4" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to plx_OptionsAndRestrictedStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointZeroZeroOneMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointZeroZeroOneMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointOneTwoZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointOneTwoZeroMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointThreeNineNineMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointThreeNineNineMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointNineSevenTwoMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointNineSevenTwoMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeFiveZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeFiveZeroMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeSevenZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeSevenZeroMember" xlink:type="arc" order="5.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointSixFiveMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointSixFiveMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointZeroTwoZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointZeroTwoZeroMember" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointThreeSevenZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointThreeSevenZeroMember" xlink:type="arc" order="7.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_FivePointZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_FivePointZeroMember" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointEightOneZeroMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointEightOneZeroMember" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointNineMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointNineMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SevenPointFiveFiveMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SevenPointFiveFiveMember" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_NinePointSixSixMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_NinePointSixSixMember" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_OneSixPointSevenMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_OneSixPointSevenMember" xlink:type="arc" order="13" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsbcead">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_1" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toind">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_IncomeTaxDisclosureTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Definition : dei_EntityDomain to us-gaap_SubsidiariesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearThereafterMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to us-gaap_RangeAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to dei_LegalEntityAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_1" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearTwoThousandNineMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearTwoThousandNineMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : plx_IncomeTaxDisclosureTable to us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="2.75" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxBurdenDistributionLawMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_TaxBurdenDistributionLawMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_RestrictedAmountMember" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to plx_RestrictedAmountMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_WithholdingTaxRateOnForeignIncome" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_WithholdingTaxRateOnForeignIncome" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Definition : plx_IncomeTaxDisclosureLineItems to plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="arc" order="11" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiotyd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" xlink:title="Definition : us-gaap_IncomeTaxContingencyLineItems to us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_IL" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_IL" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MinimumMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : us-gaap_IncomeTaxContingencyTable to us-gaap_RangeAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="Definition : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_US" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:title="Definition : us-gaap_IncomeTaxContingencyLineItems to us-gaap_OpenTaxYear" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_NL" xlink:title="Definition : us-gaap_IncomeTaxAuthorityDomain to country_NL" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Definition : us-gaap_RelatedPartyTransactionLineItems to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Definition : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Definition : us-gaap_RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocicdp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" use="optional" order="30" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="20" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>plx-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentFlag" xml:lang="en-US" id="label_dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag" xlink:title="Label : dei_AmendmentFlag to label_dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate" xlink:title="Label : dei_CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AwardTypeAxis" xml:lang="en-US" id="label_us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="label_us-gaap_AwardTypeAxis" xlink:title="Label : us-gaap_AwardTypeAxis to label_us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentPeriodEndDate" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate" xlink:title="Label : dei_DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityDomain" xml:lang="en-US" id="label_dei_EntityDomain">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="label_dei_EntityDomain" xlink:title="Label : dei_EntityDomain to label_dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Label : us-gaap_ArrangementsAndNonarrangementTransactionsMember to label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_TradingSymbol" xml:lang="en-US" id="label_dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="label_dei_TradingSymbol" xlink:title="Label : dei_TradingSymbol to label_dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_dei_EntityWellKnownSeasonedIssuer">Entity Well Known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="label_dei_EntityWellKnownSeasonedIssuer" xlink:title="Label : dei_EntityWellKnownSeasonedIssuer to label_dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="dei_EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityVoluntaryFilers" xml:lang="en-US" id="label_dei_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="label_dei_EntityVoluntaryFilers" xlink:title="Label : dei_EntityVoluntaryFilers to label_dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCurrentReportingStatus" xml:lang="en-US" id="label_dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="label_dei_EntityCurrentReportingStatus" xlink:title="Label : dei_EntityCurrentReportingStatus to label_dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityFilerCategory" xml:lang="en-US" id="label_dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory" xlink:title="Label : dei_EntityFilerCategory to label_dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="dei_EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityPublicFloat" xml:lang="en-US" id="label_dei_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="label_dei_EntityPublicFloat" xlink:title="Label : dei_EntityPublicFloat to label_dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityRegistrantName" xml:lang="en-US" id="label_dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName" xlink:title="Label : dei_EntityRegistrantName to label_dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCentralIndexKey" xml:lang="en-US" id="label_dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey" xlink:title="Label : dei_EntityCentralIndexKey to label_dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding" xlink:title="Label : dei_EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:label xlink:type="resource" xlink:label="label_country_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_IL" xml:lang="en-US" id="label_country_IL">ISRAEL [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="label_country_IL" xlink:title="Label : country_IL to label_country_IL" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalYearFocus" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus" xlink:title="Label : dei_DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus" xlink:title="Label : dei_DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="label_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_LegalEntityAxis" xml:lang="en-US" id="label_dei_LegalEntityAxis">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="label_dei_LegalEntityAxis" xlink:title="Label : dei_LegalEntityAxis to label_dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentType" xml:lang="en-US" id="label_dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType" xlink:title="Label : dei_DocumentType to label_dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract" xlink:title="Label : us-gaap_AccountingPoliciesAbstract to label_us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xml:lang="en-US" id="label_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="label_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:title="Label : us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis to label_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">Accounts payable and accruals:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent">Accounts Payable, Trade, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableTradeCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent_1">Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent">Accounts receivable- Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_1">Accounts Receivable, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:label xlink:type="resource" xlink:label="label_country_NL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_NL" xml:lang="en-US" id="label_country_NL">NETHERLANDS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="label_country_NL" xlink:title="Label : country_NL to label_country_NL" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:title="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsNotesAndLoansReceivableLineItems" xml:lang="en-US" id="label_us-gaap_AccountsNotesAndLoansReceivableLineItems">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="label_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:title="Label : us-gaap_AccountsNotesAndLoansReceivableLineItems to label_us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent">Accounts payable and accruals, other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableOtherCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent_1">Accounts Payable, Other, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableOtherCurrent_2" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent_2">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent_2" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:label xlink:type="resource" xlink:label="label_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_country_US" xml:lang="en-US" id="label_country_US">UNITED STATES [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="label_country_US" xlink:title="Label : country_US to label_country_US" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrentAndNoncurrent to label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1">Accrued liabilities accrued related to the Collaboration Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrentAndNoncurrent to label_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:title="us-gaap_AccruedVacationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedVacationCurrent" xml:lang="en-US" id="label_us-gaap_AccruedVacationCurrent">Accrued Vacation, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="label_us-gaap_AccruedVacationCurrent" xlink:title="Label : us-gaap_AccruedVacationCurrent to label_us-gaap_AccruedVacationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedVacationCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedVacationCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedVacationCurrent_1">Provision for vacation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="label_us-gaap_AccruedVacationCurrent_1" xlink:title="Label : us-gaap_AccruedVacationCurrent to label_us-gaap_AccruedVacationCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">Accrued Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrentAndNoncurrent to label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1">Accrued royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrentAndNoncurrent to label_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrent">Accrued Royalties, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrent" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrent to label_us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRoyaltiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRoyaltiesCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRoyaltiesCurrent_1">Royalties payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="label_us-gaap_AccruedRoyaltiesCurrent_1" xlink:title="Label : us-gaap_AccruedRoyaltiesCurrent to label_us-gaap_AccruedRoyaltiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_1">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccruedLiabilitiesCurrent_1" xlink:title="Label : us-gaap_AccruedLiabilitiesCurrent to label_us-gaap_AccruedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Label : us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Less - accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock">Additional Paid In Capital Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock_1">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember" xlink:title="Label : us-gaap_AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1">Share-based compensation related to stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1">Common stock issued for cash, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts">Amortization of debt issuance costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts_1">Amortization of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Label : us-gaap_AntidilutiveSecuritiesNameDomain to label_us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges" xlink:title="Label : us-gaap_AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetImpairmentCharges_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetImpairmentCharges_1" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_1">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="label_us-gaap_AssetImpairmentCharges_1" xlink:title="Label : us-gaap_AssetImpairmentCharges to label_us-gaap_AssetImpairmentCharges_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Assets_1" xml:lang="en-US" id="label_us-gaap_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets_1" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_1">CURRENT ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract_1" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract_1" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent_1" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Label : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:title="Label : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_CommitmentsDisclosureTextBlock">COMMITMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsDisclosureTextBlock" xlink:title="Label : us-gaap_CommitmentsDisclosureTextBlock to label_us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_CommitmentsDisclosureTextBlock_1">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsDisclosureTextBlock_1" xlink:title="Label : us-gaap_CommitmentsDisclosureTextBlock to label_us-gaap_CommitmentsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="Label : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies">COMMITMENTS (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies_1" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_1">Common stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockMember" xml:lang="en-US" id="label_us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember" xlink:title="Label : us-gaap_CommonStockMember to label_us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockValue" xml:lang="en-US" id="label_us-gaap_CommonStockValue">Common Stock Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockValue_1" xml:lang="en-US" id="label_us-gaap_CommonStockValue_1">Common Stock, $0.001 par value: Authorized - as of December 31, 2013 and 2014, 150,000,000 shares; issued and outstanding - as of December 31, 2013 and 2014, 93,551,098 shares and 93,603,819shares, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue_1" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued">Common Stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_1" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued_2" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_2">Underwritten public offering, common stock issued and sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_2" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized">Common Stock, Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized_1" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding">Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_1">Common Stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding_1" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComputerEquipmentMember" xml:lang="en-US" id="label_us-gaap_ComputerEquipmentMember">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="label_us-gaap_ComputerEquipmentMember" xlink:title="Label : us-gaap_ComputerEquipmentMember to label_us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk">Concentration of credit risks and trade receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk" xlink:title="Label : us-gaap_ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConcentrationRiskCreditRisk_1" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskCreditRisk_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk_1" xlink:title="Label : us-gaap_ConcentrationRiskCreditRisk to label_us-gaap_ConcentrationRiskCreditRisk_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures">Convertible Debt, Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures_1">Fair value convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent">Convertible Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent_1">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfRevenue" xml:lang="en-US" id="label_us-gaap_CostOfRevenue">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_CostOfRevenue_1" xml:lang="en-US" id="label_us-gaap_CostOfRevenue_1">COST OF REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue_1" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CostOfSalesMember" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember">Cost of Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfSalesMember_1" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember_1">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember_1" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="label_us-gaap_DebtInstrumentFaceAmount" xlink:title="Label : us-gaap_DebtInstrumentFaceAmount to label_us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentFaceAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount_1">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="label_us-gaap_DebtInstrumentFaceAmount_1" xlink:title="Label : us-gaap_DebtInstrumentFaceAmount to label_us-gaap_DebtInstrumentFaceAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract">CONVERTIBLE NOTES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="label_us-gaap_DebtDisclosureAbstract" xlink:title="Label : us-gaap_DebtDisclosureAbstract to label_us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock">CONVERTIBLE NOTES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock" xlink:title="Label : us-gaap_DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock_1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="label_us-gaap_DebtDisclosureTextBlock_1" xlink:title="Label : us-gaap_DebtDisclosureTextBlock to label_us-gaap_DebtDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1">Conversion price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock_1">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock_1" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_1">Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Label : us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment to label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment to label_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredCosts" xml:lang="en-US" id="label_us-gaap_DeferredCosts">DEFERRED CHARGES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredCosts_1" xml:lang="en-US" id="label_us-gaap_DeferredCosts_1">Deferred Costs, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts_1" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueCurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent_1">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent_1" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsDeferredIncome">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="label_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Label : us-gaap_DeferredTaxAssetsDeferredIncome to label_us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsDeferredIncome_1">Deferred Tax Assets, Deferred Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="label_us-gaap_DeferredTaxAssetsDeferredIncome_1" xlink:title="Label : us-gaap_DeferredTaxAssetsDeferredIncome to label_us-gaap_DeferredTaxAssetsDeferredIncome_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent">Deferred Revenue, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent_1">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1">Severance pay obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Label : us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment to label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xlink:title="Label : us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment to label_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="label_us-gaap_DeferredTaxAssetsNet" xlink:title="Label : us-gaap_DeferredTaxAssetsNet to label_us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet_1">Deferred Tax Assets, Net of Valuation Allowance, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="label_us-gaap_DeferredTaxAssetsNet_1" xlink:title="Label : us-gaap_DeferredTaxAssetsNet to label_us-gaap_DeferredTaxAssetsNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1">Provision for vacation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" xlink:title="Label : us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits to label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Label : us-gaap_DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:title="Label : us-gaap_DeferredTaxAssetsOperatingLossCarryforwards to label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Label : us-gaap_DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance_1">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance_1" xlink:title="Label : us-gaap_DeferredTaxAssetsValuationAllowance to label_us-gaap_DeferredTaxAssetsValuationAllowance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="Label : us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax to label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1">Net (gain) or loss for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" xlink:title="Label : us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax to label_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">Contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="Label : us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" xlink:title="Label : us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount to label_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="Label : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to label_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">SHARE CAPITAL [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="Label : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_1">Net loss per share of common stock - basic and diluted:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_1">Net Loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Label : us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1">Statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:title="Label : us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Label : us-gaap_EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1">Payroll and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xlink:title="Label : us-gaap_EmployeeRelatedLiabilitiesCurrent to label_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="label_us-gaap_EmployeeStockOptionMember">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="label_us-gaap_EmployeeStockOptionMember" xlink:title="Label : us-gaap_EmployeeStockOptionMember to label_us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeStockOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US" id="label_us-gaap_EmployeeStockOptionMember_1">Option to purchase shares of common stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="label_us-gaap_EmployeeStockOptionMember_1" xlink:title="Label : us-gaap_EmployeeStockOptionMember to label_us-gaap_EmployeeStockOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1">Unrecognized share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Unrecognized compensation cost, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityComponentDomain" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="label_us-gaap_EquityComponentDomain" xlink:title="Label : us-gaap_EquityComponentDomain to label_us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ExecutiveOfficerMember" xml:lang="en-US" id="label_us-gaap_ExecutiveOfficerMember">Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="label_us-gaap_ExecutiveOfficerMember" xlink:title="Label : us-gaap_ExecutiveOfficerMember to label_us-gaap_ExecutiveOfficerMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="label_us-gaap_FairValueDisclosuresAbstract" xlink:title="Label : us-gaap_FairValueDisclosuresAbstract to label_us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock_1">FAIR VALUE MEASUREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1">Functional currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">Financial expenses (income), net (mainly exchange differences)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember" xlink:title="Label : us-gaap_FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US" id="label_us-gaap_FurnitureAndFixturesMember_1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="label_us-gaap_FurnitureAndFixturesMember_1" xlink:title="Label : us-gaap_FurnitureAndFixturesMember to label_us-gaap_FurnitureAndFixturesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1">Gain on sale of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GrossProfit" xml:lang="en-US" id="label_us-gaap_GrossProfit">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_GrossProfit_1" xml:lang="en-US" id="label_us-gaap_GrossProfit_1">GROSS PROFIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit_1" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">Impairment in value of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="Label : us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xlink:title="Label : us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to label_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="label_us-gaap_IncomeTaxAuthorityDomain" xlink:title="Label : us-gaap_IncomeTaxAuthorityDomain to label_us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract" xlink:title="Label : us-gaap_IncomeStatementAbstract to label_us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis" xlink:title="Label : us-gaap_IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureAbstract">TAXES ON INCOME [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="label_us-gaap_IncomeTaxDisclosureAbstract" xlink:title="Label : us-gaap_IncomeTaxDisclosureAbstract to label_us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US" id="label_us-gaap_IncomeTaxContingencyLineItems">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="label_us-gaap_IncomeTaxContingencyLineItems" xlink:title="Label : us-gaap_IncomeTaxContingencyLineItems to label_us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="label_us-gaap_IncomeTaxAuthorityAxis" xlink:title="Label : us-gaap_IncomeTaxAuthorityAxis to label_us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain" xlink:title="Label : us-gaap_IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US" id="label_us-gaap_IncomeTaxContingencyTable">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="label_us-gaap_IncomeTaxContingencyTable" xlink:title="Label : us-gaap_IncomeTaxContingencyTable to label_us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Label : us-gaap_IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock_1">TAXES ON INCOME</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock_1" xlink:title="Label : us-gaap_IncomeTaxDisclosureTextBlock to label_us-gaap_IncomeTaxDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_1">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable">Decrease (increase) in accounts receivable and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Increase (decrease) in accounts payable and accruals (including long term)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1">Increase (decrease) in deferred revenues (including non-current portion)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories">Decrease (increase) in inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInInventories_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories_1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash">Increase (Decrease) in Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash_1">Investment in restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US" id="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="Label : us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock to label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1">Schedule of Interest Expense Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" xlink:title="Label : us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock to label_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebtExcludingAmortization">Contractual interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="label_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Label : us-gaap_InterestExpenseDebtExcludingAmortization to label_us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebtExcludingAmortization_1">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="label_us-gaap_InterestExpenseDebtExcludingAmortization_1" xlink:title="Label : us-gaap_InterestExpenseDebtExcludingAmortization to label_us-gaap_InterestExpenseDebtExcludingAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="us-gaap_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPayableCurrent" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent">Interest payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent" xlink:title="Label : us-gaap_InterestPayableCurrent to label_us-gaap_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPayableCurrent_1" xml:lang="en-US" id="label_us-gaap_InterestPayableCurrent_1">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="label_us-gaap_InterestPayableCurrent_1" xlink:title="Label : us-gaap_InterestPayableCurrent to label_us-gaap_InterestPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpense" xml:lang="en-US" id="label_us-gaap_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_InterestExpense_1" xml:lang="en-US" id="label_us-gaap_InterestExpense_1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense_1" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:title="us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPaidNet" xml:lang="en-US" id="label_us-gaap_InterestPaidNet">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="label_us-gaap_InterestPaidNet" xlink:title="Label : us-gaap_InterestPaidNet to label_us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaidNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPaidNet_1" xml:lang="en-US" id="label_us-gaap_InterestPaidNet_1">Interest Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="label_us-gaap_InterestPaidNet_1" xlink:title="Label : us-gaap_InterestPaidNet to label_us-gaap_InterestPaidNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryNet" xml:lang="en-US" id="label_us-gaap_InventoryNet">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryNet_1" xml:lang="en-US" id="label_us-gaap_InventoryNet_1">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_1" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_InventoryNet_2" xml:lang="en-US" id="label_us-gaap_InventoryNet_2">Total inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_2" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:title="us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_InventoryPolicyTextBlock">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="label_us-gaap_InventoryPolicyTextBlock" xlink:title="Label : us-gaap_InventoryPolicyTextBlock to label_us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_InventoryPolicyTextBlock_1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="label_us-gaap_InventoryPolicyTextBlock_1" xlink:title="Label : us-gaap_InventoryPolicyTextBlock to label_us-gaap_InventoryPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves_1">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock_1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWriteDown" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryWriteDown_1" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown_1">Inventory write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown_1" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureAbstract">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="label_us-gaap_InventoryDisclosureAbstract" xlink:title="Label : us-gaap_InventoryDisclosureAbstract to label_us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves">Inventory, Work in Process, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves_1">Work in process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseAgreementsMember" xml:lang="en-US" id="label_us-gaap_LeaseAgreementsMember">Lease Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="label_us-gaap_LeaseAgreementsMember" xlink:title="Label : us-gaap_LeaseAgreementsMember to label_us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="label_us-gaap_LeaseholdImprovementsMember" xlink:title="Label : us-gaap_LeaseholdImprovementsMember to label_us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_1" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_1">Total liabilities net of capital deficiency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent_1">Total long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract">CURRENT LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Liabilities_1" xml:lang="en-US" id="label_us-gaap_Liabilities_1">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities_1" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract_1">LONG TERM LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent">Liability in connection with collaboration operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_1">Long-term Debt, Excluding Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_1" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaximumMember" xml:lang="en-US" id="label_us-gaap_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember" xlink:title="Label : us-gaap_MaximumMember to label_us-gaap_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MinimumMember" xml:lang="en-US" id="label_us-gaap_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="label_us-gaap_MinimumMember" xlink:title="Label : us-gaap_MinimumMember to label_us-gaap_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_1">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_1" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NetIncomeLoss_2" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_2">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_2" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLoss_3" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_3">NET LOSS FOR THE YEAR</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_3" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_1" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OpenTaxYear" xml:lang="en-US" id="label_us-gaap_OpenTaxYear">Open Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="label_us-gaap_OpenTaxYear" xlink:title="Label : us-gaap_OpenTaxYear to label_us-gaap_OpenTaxYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OpenTaxYear_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OpenTaxYear_1" xml:lang="en-US" id="label_us-gaap_OpenTaxYear_1">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="label_us-gaap_OpenTaxYear_1" xlink:title="Label : us-gaap_OpenTaxYear to label_us-gaap_OpenTaxYear_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">Future minimum lease payments, 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">Future minimum lease payments, 2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US" id="label_us-gaap_OperatingLeasesRentExpenseNet">Lease/rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="label_us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Label : us-gaap_OperatingLeasesRentExpenseNet to label_us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesRentExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesRentExpenseNet_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesRentExpenseNet_1">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="label_us-gaap_OperatingLeasesRentExpenseNet_1" xlink:title="Label : us-gaap_OperatingLeasesRentExpenseNet to label_us-gaap_OperatingLeasesRentExpenseNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">Future minimum lease payments, 2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_1">OPERATING LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_1" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">Future minimum lease payments, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:title="Label : us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent to label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards" xlink:title="Label : us-gaap_OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards_1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards_1" xlink:title="Label : us-gaap_OperatingLossCarryforwards to label_us-gaap_OperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:title="us-gaap_OtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US" id="label_us-gaap_OtherReceivablesNetCurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="label_us-gaap_OtherReceivablesNetCurrent" xlink:title="Label : us-gaap_OtherReceivablesNetCurrent to label_us-gaap_OtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherReceivablesNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_OtherReceivablesNetCurrent_1" xml:lang="en-US" id="label_us-gaap_OtherReceivablesNetCurrent_1">Other receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="label_us-gaap_OtherReceivablesNetCurrent_1" xlink:title="Label : us-gaap_OtherReceivablesNetCurrent to label_us-gaap_OtherReceivablesNetCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherReceivablesNetCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherReceivablesNetCurrent_2" xml:lang="en-US" id="label_us-gaap_OtherReceivablesNetCurrent_2">Other Receivables, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="label_us-gaap_OtherReceivablesNetCurrent_2" xlink:title="Label : us-gaap_OtherReceivablesNetCurrent to label_us-gaap_OtherReceivablesNetCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_OtherNonoperatingExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense">FINANCIAL EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingExpense_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense_1">Other Nonoperating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense_1" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingIncome" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome">FINANCIAL INCOME</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingIncome_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome_1">Other Nonoperating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome_1" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Label : us-gaap_PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US" id="label_us-gaap_PaymentsOfStockIssuanceCosts_1">Underwritten public offering, commissions and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts_1" xlink:title="Label : us-gaap_PaymentsOfStockIssuanceCosts to label_us-gaap_PaymentsOfStockIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">Liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1">Pension and Other Postretirement Benefit Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameDomain" xml:lang="en-US" id="label_us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="label_us-gaap_PlanNameDomain" xlink:title="Label : us-gaap_PlanNameDomain to label_us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameAxis" xml:lang="en-US" id="label_us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis" xlink:title="Label : us-gaap_PlanNameAxis to label_us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PostemploymentBenefitsPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PostemploymentBenefitsPeriodExpense" xml:lang="en-US" id="label_us-gaap_PostemploymentBenefitsPeriodExpense">Postemployment Benefits, Period Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="label_us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="Label : us-gaap_PostemploymentBenefitsPeriodExpense to label_us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xml:lang="en-US" id="label_us-gaap_PostemploymentBenefitsPeriodExpense_1">Severance expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="label_us-gaap_PostemploymentBenefitsPeriodExpense_1" xlink:title="Label : us-gaap_PostemploymentBenefitsPeriodExpense to label_us-gaap_PostemploymentBenefitsPeriodExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:title="us-gaap_PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent">Prepaid Expense, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="label_us-gaap_PrepaidExpenseCurrent" xlink:title="Label : us-gaap_PrepaidExpenseCurrent to label_us-gaap_PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent_1">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="label_us-gaap_PrepaidExpenseCurrent_1" xlink:title="Label : us-gaap_PrepaidExpenseCurrent to label_us-gaap_PrepaidExpenseCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt">Debt additional principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="label_us-gaap_ProceedsFromIssuanceOfDebt" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfDebt to label_us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfDebt_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt_1">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="label_us-gaap_ProceedsFromIssuanceOfDebt_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfDebt to label_us-gaap_ProceedsFromIssuanceOfDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromCollaborators" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators">Pfizer Agreement, upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromCollaborators_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators_1">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators_1" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt">Net proceeds from issuance of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt_1">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfPrivatePlacement to label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1">Proceeds from private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfPrivatePlacement to label_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1">Underwritten public offering, net proceeds from issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised">Cash proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_1">Exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_2">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentPolicyTextBlock to label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife">Property and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentUsefulLife to label_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="label_us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentGross to label_us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_2" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="label_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentAbstract to label_us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTextBlock to label_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTypeDomain">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentTypeDomain to label_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentByTypeAxis to label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock to label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentLineItems to label_us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeAxis" xml:lang="en-US" id="label_us-gaap_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="label_us-gaap_RangeAxis" xlink:title="Label : us-gaap_RangeAxis to label_us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeMember" xml:lang="en-US" id="label_us-gaap_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="label_us-gaap_RangeMember" xlink:title="Label : us-gaap_RangeMember to label_us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:title="us-gaap_ReceivableTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ReceivableTypeDomain" xml:lang="en-US" id="label_us-gaap_ReceivableTypeDomain">Receivable Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="label_us-gaap_ReceivableTypeDomain" xlink:title="Label : us-gaap_ReceivableTypeDomain to label_us-gaap_ReceivableTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="Label : us-gaap_RelatedPartyTransactionsDisclosureTextBlock to label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:title="Label : us-gaap_RelatedPartyTransactionsDisclosureTextBlock to label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionLineItems">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="label_us-gaap_RelatedPartyTransactionLineItems" xlink:title="Label : us-gaap_RelatedPartyTransactionLineItems to label_us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Label : us-gaap_RelatedPartyTransactionAmountsOfTransaction to label_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Label : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to label_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyDomain" xml:lang="en-US" id="label_us-gaap_RelatedPartyDomain">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="label_us-gaap_RelatedPartyDomain" xlink:title="Label : us-gaap_RelatedPartyDomain to label_us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsAbstract">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="label_us-gaap_RelatedPartyTransactionsAbstract" xlink:title="Label : us-gaap_RelatedPartyTransactionsAbstract to label_us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_1">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy">Research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpensePolicy to label_us-gaap_ResearchAndDevelopmentExpensePolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedStockMember" xml:lang="en-US" id="label_us-gaap_RestrictedStockMember">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="label_us-gaap_RestrictedStockMember" xlink:title="Label : us-gaap_RestrictedStockMember to label_us-gaap_RestrictedStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_1">Retained Earnings Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsMember" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsMember_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember_1" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues" xlink:title="Label : us-gaap_Revenues to label_us-gaap_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_Revenues_1" xml:lang="en-US" id="label_us-gaap_Revenues_1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_1" xlink:title="Label : us-gaap_Revenues to label_us-gaap_Revenues_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Revenues_2" xml:lang="en-US" id="label_us-gaap_Revenues_2">REVENUES (see Note 11(c))</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_2" xlink:title="Label : us-gaap_Revenues to label_us-gaap_Revenues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RoyaltyExpense" xml:lang="en-US" id="label_us-gaap_RoyaltyExpense">Royalty Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="label_us-gaap_RoyaltyExpense" xlink:title="Label : us-gaap_RoyaltyExpense to label_us-gaap_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RoyaltyExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RoyaltyExpense_1" xml:lang="en-US" id="label_us-gaap_RoyaltyExpense_1">Royalty expense included in cost of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="label_us-gaap_RoyaltyExpense_1" xlink:title="Label : us-gaap_RoyaltyExpense to label_us-gaap_RoyaltyExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">Aggregate intrinsic value of total outstanding options and restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Aggregate intrinsic value of the total vested and exercisable options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected life in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1">Weighted average remaining contractual life, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1">Weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" xlink:title="Label : us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 to label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US" id="label_us-gaap_SaleOfStockPricePerShare">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="label_us-gaap_SaleOfStockPricePerShare" xlink:title="Label : us-gaap_SaleOfStockPricePerShare to label_us-gaap_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SaleOfStockPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SaleOfStockPricePerShare_1" xml:lang="en-US" id="label_us-gaap_SaleOfStockPricePerShare_1">Underwritten public offering, common stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="label_us-gaap_SaleOfStockPricePerShare_1" xlink:title="Label : us-gaap_SaleOfStockPricePerShare to label_us-gaap_SaleOfStockPricePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:title="us-gaap_SalesRevenueGoodsNetMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember">Revenues from sale of products [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember_1" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember_1">Revenues from selling products [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember_1" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNetMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SalesRevenueGoodsNetMember_2" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNetMember_2">Sales Revenue, Goods, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="label_us-gaap_SalesRevenueGoodsNetMember_2" xlink:title="Label : us-gaap_SalesRevenueGoodsNetMember to label_us-gaap_SalesRevenueGoodsNetMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_us-gaap_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="label_us-gaap_ScenarioUnspecifiedDomain" xlink:title="Label : us-gaap_ScenarioUnspecifiedDomain to label_us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1">Summary of Stock Option Activity - Options Granted to Employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Award using Black-Scholes Valuation Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Schedule of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">Schedule of Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock to label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock to label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1">Summary of Restricted Stock Activity - Options Granted to Employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to label_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of Stock-Based Compensation Expense in Statement of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Label : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to label_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Label : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:title="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="label_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:title="Label : us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable to label_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Schedule of Information about Share Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">Schedule of Options Granted to Service Providers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="Label : us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock to label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock to label_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SecurityDeposit" xml:lang="en-US" id="label_us-gaap_SecurityDeposit">Cash deposited as bank guarantee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="label_us-gaap_SecurityDeposit" xlink:title="Label : us-gaap_SecurityDeposit to label_us-gaap_SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SecurityDeposit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SecurityDeposit_1" xml:lang="en-US" id="label_us-gaap_SecurityDeposit_1">Security Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="label_us-gaap_SecurityDeposit_1" xlink:title="Label : us-gaap_SecurityDeposit to label_us-gaap_SecurityDeposit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember">Marketing, General and administrative expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpensesMember to label_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense_1">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Number of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1">Weighted average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation">Share based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensation_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_1">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation_1" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Number of options or restricted stock granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1">Restricted stock awards forfeited, share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Common stock available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1">Shares of common stock approved for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Forfeited and Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Forfeited and Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Outstanding at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1">Outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Number of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Number of Options and restricted stock outstanding at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Number of options exercisable at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1">Maximum exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Minimum exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding">Balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_SharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_1">Balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_1" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharesOutstanding_2" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_2" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementScenarioAxis" xml:lang="en-US" id="label_us-gaap_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="label_us-gaap_StatementScenarioAxis" xlink:title="Label : us-gaap_StatementScenarioAxis to label_us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementTable" xml:lang="en-US" id="label_us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="label_us-gaap_StatementTable" xlink:title="Label : us-gaap_StatementTable to label_us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementLineItems" xml:lang="en-US" id="label_us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems" xlink:title="Label : us-gaap_StatementLineItems to label_us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfStockholdersEquityAbstract">CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="Label : us-gaap_StatementOfStockholdersEquityAbstract to label_us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract" xlink:title="Label : us-gaap_StatementOfCashFlowsAbstract to label_us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="label_us-gaap_StatementEquityComponentsAxis" xlink:title="Label : us-gaap_StatementEquityComponentsAxis to label_us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:title="Label : us-gaap_StatementOfFinancialPositionAbstract to label_us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of options granted to employees and non-employees (includes net exercise)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercise of options granted to employees and non-employees (includes net exercise), shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues">Common stock issued for cash (net of issuance costs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract">CAPITAL DEFICIENCY:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract_1">Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract_1" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_StockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_1" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquity_2" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_2">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_2" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_StockholdersEquity_3" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_3">Total capital deficiency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_3" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock">SHARE CAPITAL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsidiariesMember" xml:lang="en-US" id="label_us-gaap_SubsidiariesMember">Protalix Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiariesMember" xlink:to="label_us-gaap_SubsidiariesMember" xlink:title="Label : us-gaap_SubsidiariesMember to label_us-gaap_SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsidiariesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsidiariesMember_1" xml:lang="en-US" id="label_us-gaap_SubsidiariesMember_1">Subsidiaries [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiariesMember" xlink:to="label_us-gaap_SubsidiariesMember_1" xlink:title="Label : us-gaap_SubsidiariesMember to label_us-gaap_SubsidiariesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_1">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS-</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualAxis" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualAxis">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="label_us-gaap_TitleOfIndividualAxis" xlink:title="Label : us-gaap_TitleOfIndividualAxis to label_us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Label : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="label_us-gaap_TypeOfArrangementAxis">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="label_us-gaap_TypeOfArrangementAxis" xlink:title="Label : us-gaap_TypeOfArrangementAxis to label_us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UseOfEstimates" xml:lang="en-US" id="label_us-gaap_UseOfEstimates">Use of estimates in the preparation of financial statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UseOfEstimates_1" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates_1" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted average number of shares of common stock used in computing loss per share of common stock, basic and diluted:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock">Nature Of Operations [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_1" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_1">General</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_2" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_2">Nature Of Operations Policy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherGainsLosses" xml:lang="en-US" id="label_plx_OtherGainsLosses">Other Gains Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherGainsLosses_1" xml:lang="en-US" id="label_plx_OtherGainsLosses_1">The Company's share in collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses_1" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherGainsLosses_2" xml:lang="en-US" id="label_plx_OtherGainsLosses_2">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses_2" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable">Grants And Reimbursements Received Or Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2">Less - grants and reimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet">Research Development And Engineering Expense Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1">Research and development expenses, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock">Schedule Of Useful Life [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock_1">Schedule Of Useful Life Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock_1" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xml:lang="en-US" id="label_plx_ScheduleOfUsefulLifeTableTextBlock_2">Schedule of Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="label_plx_ScheduleOfUsefulLifeTableTextBlock_2" xlink:title="Label : plx_ScheduleOfUsefulLifeTableTextBlock to label_plx_ScheduleOfUsefulLifeTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LaboratoryEquipmentMember" xml:lang="en-US" id="label_plx_LaboratoryEquipmentMember">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="label_plx_LaboratoryEquipmentMember" xlink:title="Label : plx_LaboratoryEquipmentMember to label_plx_LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_LaboratoryEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LaboratoryEquipmentMember_1" xml:lang="en-US" id="label_plx_LaboratoryEquipmentMember_1">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="label_plx_LaboratoryEquipmentMember_1" xlink:title="Label : plx_LaboratoryEquipmentMember to label_plx_LaboratoryEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MilestonePayment" xml:lang="en-US" id="label_plx_MilestonePayment">Milestone Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MilestonePayment_1" xml:lang="en-US" id="label_plx_MilestonePayment_1">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_1" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MilestonePayment_2" xml:lang="en-US" id="label_plx_MilestonePayment_2">Milestone payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_2" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioTwoMember" xml:lang="en-US" id="label_plx_ScenarioTwoMember">Scenario Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioTwoMember_1" xml:lang="en-US" id="label_plx_ScenarioTwoMember_1">Scenario Two [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_1" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioTwoMember_2" xml:lang="en-US" id="label_plx_ScenarioTwoMember_2">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_2" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_UponFDAApprovalMember" xml:lang="en-US" id="label_plx_UponFDAApprovalMember">Upon FDAApproval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponFDAApprovalMember" xlink:to="label_plx_UponFDAApprovalMember" xlink:title="Label : plx_UponFDAApprovalMember to label_plx_UponFDAApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponFDAApprovalMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_UponFDAApprovalMember_1" xml:lang="en-US" id="label_plx_UponFDAApprovalMember_1">Upon FDA approval Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponFDAApprovalMember" xlink:to="label_plx_UponFDAApprovalMember_1" xlink:title="Label : plx_UponFDAApprovalMember to label_plx_UponFDAApprovalMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage_1" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage_1">Collaborative arrangement profit sharing percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage_1" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage_2" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage_2">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage_2" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EligablePaymentReceivableUponAchievement" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement">Eligable Payment Receivable Upon Achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EligablePaymentReceivableUponAchievement_1" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement_1">Eligable Payment Receivable Upon Achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement_1" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EligablePaymentReceivableUponAchievement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EligablePaymentReceivableUponAchievement_2" xml:lang="en-US" id="label_plx_EligablePaymentReceivableUponAchievement_2">Eligable payment receivable upon achievement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EligablePaymentReceivableUponAchievement" xlink:to="label_plx_EligablePaymentReceivableUponAchievement_2" xlink:title="Label : plx_EligablePaymentReceivableUponAchievement to label_plx_EligablePaymentReceivableUponAchievement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_1">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_2">Protalix Bio Therapeutics Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PfizerIncorporationMember" xml:lang="en-US" id="label_plx_PfizerIncorporationMember">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PfizerIncorporationMember_1" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_1">Pfizer Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_1" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PfizerIncorporationMember_2" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_2">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_2" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplyCommitmentPerYear" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear">Supply Commitment Per Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplyCommitmentPerYear_1" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_1">The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_1" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplyCommitmentPerYear_2" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_2">Supply commitment per year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_2" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">Purchase Amount To Be Satisfied To Receive Entitled Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1">The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2">Supply commitment for entitled rights to be received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2">License and supply agreement potential future payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NumberOfSubsidiaries" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries">Number Of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NumberOfSubsidiaries_1" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_1">Number of subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_1" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NumberOfSubsidiaries_2" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_2">Number of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_2" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod">Revenue Recognized Over Designated Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod_1">Revenue recognized over designated period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod_1" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xml:lang="en-US" id="label_plx_RevenueRecognizedOverDesignatedPeriod_2">Revenue recognized over designated period of relationship</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedOverDesignatedPeriod" xlink:to="label_plx_RevenueRecognizedOverDesignatedPeriod_2" xlink:title="Label : plx_RevenueRecognizedOverDesignatedPeriod to label_plx_RevenueRecognizedOverDesignatedPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RevenueRecognizedPeriod" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod">Revenue Recognized Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RevenueRecognizedPeriod_1" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod_1">Revenue Recognized Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod_1" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RevenueRecognizedPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RevenueRecognizedPeriod_2" xml:lang="en-US" id="label_plx_RevenueRecognizedPeriod_2">Revenue recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRecognizedPeriod" xlink:to="label_plx_RevenueRecognizedPeriod_2" xlink:title="Label : plx_RevenueRecognizedPeriod to label_plx_RevenueRecognizedPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock">Collaborative and License Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1">Collaborative And License Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2">LICENSE AND SUPPLY AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosureTextBlock to label_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborationOperationMember" xml:lang="en-US" id="label_plx_CollaborationOperationMember">Collaboration Operation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationMember" xlink:to="label_plx_CollaborationOperationMember" xlink:title="Label : plx_CollaborationOperationMember to label_plx_CollaborationOperationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborationOperationMember_1" xml:lang="en-US" id="label_plx_CollaborationOperationMember_1">Collaboration Operation Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationMember" xlink:to="label_plx_CollaborationOperationMember_1" xlink:title="Label : plx_CollaborationOperationMember to label_plx_CollaborationOperationMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2">Share-based compensation related to restricted stock award, net of forfeitures (shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2">Share-based compensation related to restricted stock award, net of forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="plx_DepreciationAmortizationAndAssetImpairment" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment">Depreciation Amortization And Asset Impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment_1" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment_1">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment_1" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment_2" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment_2">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment_2" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FurnitureAndComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FurnitureAndComputerEquipmentMember" xml:lang="en-US" id="label_plx_FurnitureAndComputerEquipmentMember">Furniture And Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="label_plx_FurnitureAndComputerEquipmentMember" xlink:title="Label : plx_FurnitureAndComputerEquipmentMember to label_plx_FurnitureAndComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FurnitureAndComputerEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FurnitureAndComputerEquipmentMember_1" xml:lang="en-US" id="label_plx_FurnitureAndComputerEquipmentMember_1">Furniture And Computer Equipment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="label_plx_FurnitureAndComputerEquipmentMember_1" xlink:title="Label : plx_FurnitureAndComputerEquipmentMember to label_plx_FurnitureAndComputerEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EquipmentUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EquipmentUnderConstructionMember" xml:lang="en-US" id="label_plx_EquipmentUnderConstructionMember">Equipment Under Construction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquipmentUnderConstructionMember" xlink:to="label_plx_EquipmentUnderConstructionMember" xlink:title="Label : plx_EquipmentUnderConstructionMember to label_plx_EquipmentUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EquipmentUnderConstructionMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EquipmentUnderConstructionMember_1" xml:lang="en-US" id="label_plx_EquipmentUnderConstructionMember_1">Equipment Under Construction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquipmentUnderConstructionMember" xlink:to="label_plx_EquipmentUnderConstructionMember_1" xlink:title="Label : plx_EquipmentUnderConstructionMember to label_plx_EquipmentUnderConstructionMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompensationToTheNon-executiveDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CompensationToTheNon-executiveDirectorsMember" xml:lang="en-US" id="label_plx_CompensationToTheNon-executiveDirectorsMember">Compensation To The Non -executiveDirectors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompensationToTheNon-executiveDirectorsMember" xlink:to="label_plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Label : plx_CompensationToTheNon-executiveDirectorsMember to label_plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xml:lang="en-US" id="label_plx_CompensationToTheNon-executiveDirectorsMember_1">Compensation To The Non-executive Directors Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompensationToTheNon-executiveDirectorsMember" xlink:to="label_plx_CompensationToTheNon-executiveDirectorsMember_1" xlink:title="Label : plx_CompensationToTheNon-executiveDirectorsMember to label_plx_CompensationToTheNon-executiveDirectorsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" xlink:title="plx_EmployeeSeveranceObligationPayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeeSeveranceObligationPayment" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment">Employee Severance Obligation Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeeSeveranceObligationPayment_1" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment_1">Employee severance obligation payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment_1" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeSeveranceObligationPayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EmployeeSeveranceObligationPayment_2" xml:lang="en-US" id="label_plx_EmployeeSeveranceObligationPayment_2">Employee severance obligation payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="label_plx_EmployeeSeveranceObligationPayment_2" xlink:title="Label : plx_EmployeeSeveranceObligationPayment to label_plx_EmployeeSeveranceObligationPayment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:label="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod">Expected Severance Liabilities Payments For Future Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1">Expected severance liabilities payments for future period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xml:lang="en-US" id="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2">Expected severance liabilities payments for fiscal year end 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:to="label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" xlink:title="Label : plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod to label_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:label="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod">Expected Definted Benefit Contribution During Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1">Expected Definted Benefit Contribution During Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xml:lang="en-US" id="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2">Expected contribution to one or more Contribution Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:to="label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" xlink:title="Label : plx_ExpectedDefintedBenefitContributionDuringPeriod to label_plx_ExpectedDefintedBenefitContributionDuringPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:label="plx_AccountsPayableAndAccrualsAxis" xlink:title="plx_AccountsPayableAndAccrualsAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayableAndAccrualsAxis" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsAxis">Accounts Payable And Accruals [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsAxis" xlink:to="label_plx_AccountsPayableAndAccrualsAxis" xlink:title="Label : plx_AccountsPayableAndAccrualsAxis to label_plx_AccountsPayableAndAccrualsAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsAxis_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccountsPayableAndAccrualsAxis_1" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsAxis_1">Accounts Payable And Accruals Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsAxis" xlink:to="label_plx_AccountsPayableAndAccrualsAxis_1" xlink:title="Label : plx_AccountsPayableAndAccrualsAxis to label_plx_AccountsPayableAndAccrualsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:label="plx_AccountsPayableAndAccrualsDomain" xlink:title="plx_AccountsPayableAndAccrualsDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayableAndAccrualsDomain" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsDomain">Accounts Payable And Accruals [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsDomain" xlink:to="label_plx_AccountsPayableAndAccrualsDomain" xlink:title="Label : plx_AccountsPayableAndAccrualsDomain to label_plx_AccountsPayableAndAccrualsDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:label="plx_AccountsPayableAndAccrualsLineItems" xlink:title="plx_AccountsPayableAndAccrualsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayableAndAccrualsLineItems" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsLineItems">Accounts Payable And Accruals [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsLineItems" xlink:to="label_plx_AccountsPayableAndAccrualsLineItems" xlink:title="Label : plx_AccountsPayableAndAccrualsLineItems to label_plx_AccountsPayableAndAccrualsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccountsPayableAndAccrualsLineItems_1" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsLineItems_1">Accounts Payable And Accruals Line Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsLineItems" xlink:to="label_plx_AccountsPayableAndAccrualsLineItems_1" xlink:title="Label : plx_AccountsPayableAndAccrualsLineItems to label_plx_AccountsPayableAndAccrualsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayableAndAccrualsTable" xlink:label="plx_AccountsPayableAndAccrualsTable" xlink:title="plx_AccountsPayableAndAccrualsTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayableAndAccrualsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayableAndAccrualsTable" xml:lang="en-US" id="label_plx_AccountsPayableAndAccrualsTable">Accounts Payable And Accruals [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccrualsTable" xlink:to="label_plx_AccountsPayableAndAccrualsTable" xlink:title="Label : plx_AccountsPayableAndAccrualsTable to label_plx_AccountsPayableAndAccrualsTable" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AgreementMaintenanceFee" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee">Agreement Maintenance Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AgreementMaintenanceFee_1" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee_1">Agreement maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee_1" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AgreementMaintenanceFee_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AgreementMaintenanceFee_2" xml:lang="en-US" id="label_plx_AgreementMaintenanceFee_2">Agreement maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementMaintenanceFee" xlink:to="label_plx_AgreementMaintenanceFee_2" xlink:title="Label : plx_AgreementMaintenanceFee to label_plx_AgreementMaintenanceFee_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts">Amortization Of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts_1" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts_1">Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts_1" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AmortizationOfDebtIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AmortizationOfDebtIssuanceCosts_2" xml:lang="en-US" id="label_plx_AmortizationOfDebtIssuanceCosts_2">Amortization of debt issuance costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmortizationOfDebtIssuanceCosts" xlink:to="label_plx_AmortizationOfDebtIssuanceCosts_2" xlink:title="Label : plx_AmortizationOfDebtIssuanceCosts to label_plx_AmortizationOfDebtIssuanceCosts_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee">Annual Increase To Maintenance Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee_1" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee_1">Annual increase to maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee_1" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AnnualIncreaseToMaintenanceFee_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AnnualIncreaseToMaintenanceFee_2" xml:lang="en-US" id="label_plx_AnnualIncreaseToMaintenanceFee_2">Annual increase to maintenance fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AnnualIncreaseToMaintenanceFee" xlink:to="label_plx_AnnualIncreaseToMaintenanceFee_2" xlink:title="Label : plx_AnnualIncreaseToMaintenanceFee to label_plx_AnnualIncreaseToMaintenanceFee_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CashlessExerciseOfStockOptions" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions">Cashless Exercise Of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CashlessExerciseOfStockOptions_1" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_1">Cashless exercise of stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_1" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CashlessExerciseOfStockOptions_2" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_2">Exercise of options granted to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_2" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborationOperationCurrentPortionMember" xlink:label="plx_CollaborationOperationCurrentPortionMember" xlink:title="plx_CollaborationOperationCurrentPortionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborationOperationCurrentPortionMember" xml:lang="en-US" id="label_plx_CollaborationOperationCurrentPortionMember">Collaboration Operation Current Portion [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationCurrentPortionMember" xlink:to="label_plx_CollaborationOperationCurrentPortionMember" xlink:title="Label : plx_CollaborationOperationCurrentPortionMember to label_plx_CollaborationOperationCurrentPortionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborationOperationCurrentPortionMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborationOperationCurrentPortionMember_1" xml:lang="en-US" id="label_plx_CollaborationOperationCurrentPortionMember_1">Collaboration Operation Current Portion [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborationOperationCurrentPortionMember" xlink:to="label_plx_CollaborationOperationCurrentPortionMember_1" xlink:title="Label : plx_CollaborationOperationCurrentPortionMember to label_plx_CollaborationOperationCurrentPortionMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosure" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosure">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosure to label_plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementDisclosure_1">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="label_plx_CollaborativeAndLicenseArrangementDisclosure_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementDisclosure to label_plx_CollaborativeAndLicenseArrangementDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeAndLicenseArrangementTable" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementTable">Collaborative And License Arrangement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="label_plx_CollaborativeAndLicenseArrangementTable" xlink:title="Label : plx_CollaborativeAndLicenseArrangementTable to label_plx_CollaborativeAndLicenseArrangementTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeAndLicenseArrangementTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeAndLicenseArrangementTable_1" xml:lang="en-US" id="label_plx_CollaborativeAndLicenseArrangementTable_1">Collaborative And License Arrangement Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="label_plx_CollaborativeAndLicenseArrangementTable_1" xlink:title="Label : plx_CollaborativeAndLicenseArrangementTable to label_plx_CollaborativeAndLicenseArrangementTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentAmount" xml:lang="en-US" id="label_plx_CommitmentAmount">Commitment Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentAmount_1" xml:lang="en-US" id="label_plx_CommitmentAmount_1">Commitment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount_1" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CommitmentAmount_2" xml:lang="en-US" id="label_plx_CommitmentAmount_2">Subcontracting commitment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="label_plx_CommitmentAmount_2" xlink:title="Label : plx_CommitmentAmount to label_plx_CommitmentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesAxis">Commitments And Contingencies [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="label_plx_CommitmentsAndContingenciesAxis" xlink:title="Label : plx_CommitmentsAndContingenciesAxis to label_plx_CommitmentsAndContingenciesAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesAxis_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesAxis_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesAxis_1">Commitments And Contingencies Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="label_plx_CommitmentsAndContingenciesAxis_1" xlink:title="Label : plx_CommitmentsAndContingenciesAxis to label_plx_CommitmentsAndContingenciesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesDomain">Commitments And Contingencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="label_plx_CommitmentsAndContingenciesDomain" xlink:title="Label : plx_CommitmentsAndContingenciesDomain to label_plx_CommitmentsAndContingenciesDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesDomain_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesDomain_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesDomain_1">Commitments And Contingencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="label_plx_CommitmentsAndContingenciesDomain_1" xlink:title="Label : plx_CommitmentsAndContingenciesDomain to label_plx_CommitmentsAndContingenciesDomain_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesLineItems" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesLineItems">Commitments And Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="label_plx_CommitmentsAndContingenciesLineItems" xlink:title="Label : plx_CommitmentsAndContingenciesLineItems to label_plx_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesLineItems_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesLineItems_1">Commitments And Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="label_plx_CommitmentsAndContingenciesLineItems_1" xlink:title="Label : plx_CommitmentsAndContingenciesLineItems to label_plx_CommitmentsAndContingenciesLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CommitmentsAndContingenciesTable" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesTable">Commitments And Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="label_plx_CommitmentsAndContingenciesTable" xlink:title="Label : plx_CommitmentsAndContingenciesTable to label_plx_CommitmentsAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_CommitmentsAndContingenciesTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CommitmentsAndContingenciesTable_1" xml:lang="en-US" id="label_plx_CommitmentsAndContingenciesTable_1">Commitments And Contingencies Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="label_plx_CommitmentsAndContingenciesTable_1" xlink:title="Label : plx_CommitmentsAndContingenciesTable to label_plx_CommitmentsAndContingenciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ConsiderationForLicense" xml:lang="en-US" id="label_plx_ConsiderationForLicense">Consideration For License</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ConsiderationForLicense_1" xml:lang="en-US" id="label_plx_ConsiderationForLicense_1">Consideration for license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense_1" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ConsiderationForLicense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ConsiderationForLicense_2" xml:lang="en-US" id="label_plx_ConsiderationForLicense_2">Consideration for license</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConsiderationForLicense" xlink:to="label_plx_ConsiderationForLicense_2" xlink:title="Label : plx_ConsiderationForLicense to label_plx_ConsiderationForLicense_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2">Base value for conversion rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" xlink:title="Label : plx_DebtInstrumentConvertibleBaseValueForConversionRate to label_plx_DebtInstrumentConvertibleBaseValueForConversionRate_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber_1">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber_1" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xml:lang="en-US" id="label_plx_DebtInstrumentConvertibleConversionShareNumber_2">Number of shares for basis conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="label_plx_DebtInstrumentConvertibleConversionShareNumber_2" xlink:title="Label : plx_DebtInstrumentConvertibleConversionShareNumber to label_plx_DebtInstrumentConvertibleConversionShareNumber_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DeferredCostMember" xlink:label="plx_DeferredCostMember" xlink:title="plx_DeferredCostMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_DeferredCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DeferredCostMember" xml:lang="en-US" id="label_plx_DeferredCostMember">Deferred Cost [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredCostMember" xlink:to="label_plx_DeferredCostMember" xlink:title="Label : plx_DeferredCostMember to label_plx_DeferredCostMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_DeferredCostMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DeferredCostMember_1" xml:lang="en-US" id="label_plx_DeferredCostMember_1">Deferred Cost Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredCostMember" xlink:to="label_plx_DeferredCostMember_1" xlink:title="Label : plx_DeferredCostMember to label_plx_DeferredCostMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:label="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:title="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xml:lang="en-US" id="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember">Deferred Revenue From License And Supply Agreement With Pzifer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:to="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:title="Label : plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember to label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember_1" xml:lang="en-US" id="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember_1">Deferred Revenue From License And Supply Agreement With Pzifer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:to="label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember_1" xlink:title="Label : plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember to label_plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_plx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_plx_DocumentAndEntityInformationAbstract">Document And Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="label_plx_DocumentAndEntityInformationAbstract" xlink:title="Label : plx_DocumentAndEntityInformationAbstract to label_plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2">Additional tax rate, 2014 and thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateThereafter to label_plx_EffectiveAdjustedIncomeTaxRateThereafter_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2">Additional gradual decrease in tax rate, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFive to label_plx_EffectiveAdjustedIncomeTaxRateYearFive_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour">Effective Adjusted Income Tax Rate Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1">Additional gradual decrease in tax rate, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2">Additional gradual decrease in tax rate, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearFour to label_plx_EffectiveAdjustedIncomeTaxRateYearFour_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2">Additional tax rate, 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearOne to label_plx_EffectiveAdjustedIncomeTaxRateYearOne_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2">Additional gradual decrease in tax rate, 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearThree to label_plx_EffectiveAdjustedIncomeTaxRateYearThree_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xml:lang="en-US" id="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2">Additional tax rate, 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:to="label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" xlink:title="Label : plx_EffectiveAdjustedIncomeTaxRateYearTwo to label_plx_EffectiveAdjustedIncomeTaxRateYearTwo_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeesMember" xml:lang="en-US" id="label_plx_EmployeesMember">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesMember" xlink:to="label_plx_EmployeesMember" xlink:title="Label : plx_EmployeesMember to label_plx_EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeesMember_1" xml:lang="en-US" id="label_plx_EmployeesMember_1">Employees [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesMember" xlink:to="label_plx_EmployeesMember_1" xlink:title="Label : plx_EmployeesMember to label_plx_EmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FivePointZeroMember" xml:lang="en-US" id="label_plx_FivePointZeroMember">Five Point Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FivePointZeroMember_1" xml:lang="en-US" id="label_plx_FivePointZeroMember_1">Five Point Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember_1" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_FivePointZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_FivePointZeroMember_2" xml:lang="en-US" id="label_plx_FivePointZeroMember_2">5.000 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FivePointZeroMember" xlink:to="label_plx_FivePointZeroMember_2" xlink:title="Label : plx_FivePointZeroMember to label_plx_FivePointZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ForfeitureRate" xlink:label="plx_ForfeitureRate" xlink:title="plx_ForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ForfeitureRate" xml:lang="en-US" id="label_plx_ForfeitureRate">Forfeiture Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ForfeitureRate_1" xml:lang="en-US" id="label_plx_ForfeitureRate_1">Forfeiture rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate_1" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ForfeitureRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ForfeitureRate_2" xml:lang="en-US" id="label_plx_ForfeitureRate_2">Forfeiture rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ForfeitureRate" xlink:to="label_plx_ForfeitureRate_2" xlink:title="Label : plx_ForfeitureRate to label_plx_ForfeitureRate_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FundingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_FundingArrangementsMember" xml:lang="en-US" id="label_plx_FundingArrangementsMember">Funding Arrangements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FundingArrangementsMember" xlink:to="label_plx_FundingArrangementsMember" xlink:title="Label : plx_FundingArrangementsMember to label_plx_FundingArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_FundingArrangementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_FundingArrangementsMember_1" xml:lang="en-US" id="label_plx_FundingArrangementsMember_1">Funding Arrangements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FundingArrangementsMember" xlink:to="label_plx_FundingArrangementsMember_1" xlink:title="Label : plx_FundingArrangementsMember to label_plx_FundingArrangementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandTwelveMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember">Grant Year Two Thousand Twelve [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandTwelveMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember_1">Grant Year Two Thousand Twelve Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember_1" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandTwelveMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveMember_2">2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveMember" xlink:to="label_plx_GrantYearTwoThousandTwelveMember_2" xlink:title="Label : plx_GrantYearTwoThousandTwelveMember to label_plx_GrantYearTwoThousandTwelveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember_1">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember_1" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandTwelveSecondMember_2">2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandTwelveSecondMember" xlink:to="label_plx_GrantYearTwoThousandTwelveSecondMember_2" xlink:title="Label : plx_GrantYearTwoThousandTwelveSecondMember to label_plx_GrantYearTwoThousandTwelveSecondMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncomeTaxDisclosureLineItems" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureLineItems">Income Tax Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="label_plx_IncomeTaxDisclosureLineItems" xlink:title="Label : plx_IncomeTaxDisclosureLineItems to label_plx_IncomeTaxDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureLineItems_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncomeTaxDisclosureLineItems_1" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureLineItems_1">Income Tax Disclosure Line Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="label_plx_IncomeTaxDisclosureLineItems_1" xlink:title="Label : plx_IncomeTaxDisclosureLineItems to label_plx_IncomeTaxDisclosureLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncomeTaxDisclosureTable" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureTable">Income Tax Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="label_plx_IncomeTaxDisclosureTable" xlink:title="Label : plx_IncomeTaxDisclosureTable to label_plx_IncomeTaxDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncomeTaxDisclosureTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncomeTaxDisclosureTable_1" xml:lang="en-US" id="label_plx_IncomeTaxDisclosureTable_1">Income Tax Disclosure Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="label_plx_IncomeTaxDisclosureTable_1" xlink:title="Label : plx_IncomeTaxDisclosureTable to label_plx_IncomeTaxDisclosureTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1">Increase in liabilities for property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_InstitutionsMember" xlink:label="plx_InstitutionsMember" xlink:title="plx_InstitutionsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_InstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_InstitutionsMember" xml:lang="en-US" id="label_plx_InstitutionsMember">Institutions [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InstitutionsMember" xlink:to="label_plx_InstitutionsMember" xlink:title="Label : plx_InstitutionsMember to label_plx_InstitutionsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_InstitutionsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_InstitutionsMember_1" xml:lang="en-US" id="label_plx_InstitutionsMember_1">Institutions Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InstitutionsMember" xlink:to="label_plx_InstitutionsMember_1" xlink:title="Label : plx_InstitutionsMember to label_plx_InstitutionsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement">Liabilities Accrued From Licensing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement_1">Liabilities accrued from licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement_1" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xml:lang="en-US" id="label_plx_LiabilitiesAccruedFromLicensingAgreement_2">Accrued long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:to="label_plx_LiabilitiesAccruedFromLicensingAgreement_2" xlink:title="Label : plx_LiabilitiesAccruedFromLicensingAgreement to label_plx_LiabilitiesAccruedFromLicensingAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xml:lang="en-US" id="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:to="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Label : plx_ManagementAndConsultingFeesToChairmanOfBoardMember to label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xml:lang="en-US" id="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:to="label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" xlink:title="Label : plx_ManagementAndConsultingFeesToChairmanOfBoardMember to label_plx_ManagementAndConsultingFeesToChairmanOfBoardMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived">Maximum Aggregate Payments Of Royalties To Grant Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1">Percetnage aggregate royalties should not exceed grant amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xml:lang="en-US" id="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2">Percentage amount the aggregate amount of royalties that should not exceed grant received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:to="label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" xlink:title="Label : plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived to label_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MilestonePaymentsMember" xml:lang="en-US" id="label_plx_MilestonePaymentsMember">Milestone Payments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentsMember" xlink:to="label_plx_MilestonePaymentsMember" xlink:title="Label : plx_MilestonePaymentsMember to label_plx_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePaymentsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MilestonePaymentsMember_1" xml:lang="en-US" id="label_plx_MilestonePaymentsMember_1">Milestone Payments Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentsMember" xlink:to="label_plx_MilestonePaymentsMember_1" xlink:title="Label : plx_MilestonePaymentsMember to label_plx_MilestonePaymentsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MonthlyRentLeaseExpense" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense">Monthly Rent Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MonthlyRentLeaseExpense_1" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense_1">Monthly rent/lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense_1" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MonthlyRentLeaseExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MonthlyRentLeaseExpense_2" xml:lang="en-US" id="label_plx_MonthlyRentLeaseExpense_2">Monthly rent/lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MonthlyRentLeaseExpense" xlink:to="label_plx_MonthlyRentLeaseExpense_2" xlink:title="Label : plx_MonthlyRentLeaseExpense to label_plx_MonthlyRentLeaseExpense_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NinePointSixSixMember" xml:lang="en-US" id="label_plx_NinePointSixSixMember">Nine Point Six Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NinePointSixSixMember_1" xml:lang="en-US" id="label_plx_NinePointSixSixMember_1">Nine Point Six Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember_1" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NinePointSixSixMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NinePointSixSixMember_2" xml:lang="en-US" id="label_plx_NinePointSixSixMember_2">9.660 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NinePointSixSixMember" xlink:to="label_plx_NinePointSixSixMember_2" xlink:title="Label : plx_NinePointSixSixMember to label_plx_NinePointSixSixMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OCSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OCSMember" xml:lang="en-US" id="label_plx_OCSMember">OCS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OCSMember" xlink:to="label_plx_OCSMember" xlink:title="Label : plx_OCSMember to label_plx_OCSMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OCSMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OCSMember_1" xml:lang="en-US" id="label_plx_OCSMember_1">OCS Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OCSMember" xlink:to="label_plx_OCSMember_1" xlink:title="Label : plx_OCSMember to label_plx_OCSMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndCertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OfficersAndCertainEmployeesMember" xml:lang="en-US" id="label_plx_OfficersAndCertainEmployeesMember">Officers And Certain Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndCertainEmployeesMember" xlink:to="label_plx_OfficersAndCertainEmployeesMember" xlink:title="Label : plx_OfficersAndCertainEmployeesMember to label_plx_OfficersAndCertainEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndCertainEmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OfficersAndCertainEmployeesMember_1" xml:lang="en-US" id="label_plx_OfficersAndCertainEmployeesMember_1">Officers And Certain Employees Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndCertainEmployeesMember" xlink:to="label_plx_OfficersAndCertainEmployeesMember_1" xlink:title="Label : plx_OfficersAndCertainEmployeesMember to label_plx_OfficersAndCertainEmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xml:lang="en-US" id="label_plx_OfficersAndDirectorsInPrivateTransactionMember">Officers And Directors In Private Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:to="label_plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Label : plx_OfficersAndDirectorsInPrivateTransactionMember to label_plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xml:lang="en-US" id="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1">Officers And Directors In Private Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:to="label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" xlink:title="Label : plx_OfficersAndDirectorsInPrivateTransactionMember to label_plx_OfficersAndDirectorsInPrivateTransactionMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OneSixPointSevenMember" xml:lang="en-US" id="label_plx_OneSixPointSevenMember">One Six Point Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OneSixPointSevenMember_1" xml:lang="en-US" id="label_plx_OneSixPointSevenMember_1">One Six Point Seven Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember_1" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OneSixPointSevenMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OneSixPointSevenMember_2" xml:lang="en-US" id="label_plx_OneSixPointSevenMember_2">16.700 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OneSixPointSevenMember" xlink:to="label_plx_OneSixPointSevenMember_2" xlink:title="Label : plx_OneSixPointSevenMember to label_plx_OneSixPointSevenMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember">Options And Restricted Stock Granted To Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:to="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Label : plx_OptionsAndRestrictedStockGrantedToEmployeesMember to label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1">Options And Restricted Stock Granted To Employees Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:to="label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" xlink:title="Label : plx_OptionsAndRestrictedStockGrantedToEmployeesMember to label_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStockMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockMember">Options And Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockMember" xlink:to="label_plx_OptionsAndRestrictedStockMember" xlink:title="Label : plx_OptionsAndRestrictedStockMember to label_plx_OptionsAndRestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStockMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStockMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStockMember_1">Options And Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStockMember" xlink:to="label_plx_OptionsAndRestrictedStockMember_1" xlink:title="Label : plx_OptionsAndRestrictedStockMember to label_plx_OptionsAndRestrictedStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US" id="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">Options Granted To Consultants Directors And Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Label : plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xml:lang="en-US" id="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1">Options Granted To Consultants, Directors And Other Service Providers Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:title="Label : plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProbableAggregateMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProbableAggregateMilestonePaymentMember" xml:lang="en-US" id="label_plx_ProbableAggregateMilestonePaymentMember">Probable Aggregate Milestone Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProbableAggregateMilestonePaymentMember" xlink:to="label_plx_ProbableAggregateMilestonePaymentMember" xlink:title="Label : plx_ProbableAggregateMilestonePaymentMember to label_plx_ProbableAggregateMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProbableAggregateMilestonePaymentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProbableAggregateMilestonePaymentMember_1" xml:lang="en-US" id="label_plx_ProbableAggregateMilestonePaymentMember_1">Probable Aggregate Milestone Payment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProbableAggregateMilestonePaymentMember" xlink:to="label_plx_ProbableAggregateMilestonePaymentMember_1" xlink:title="Label : plx_ProbableAggregateMilestonePaymentMember to label_plx_ProbableAggregateMilestonePaymentMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xml:lang="en-US" id="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2">Issuance of shares, net of issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" xlink:title="Label : plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses to label_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProductsManufacturedOutsideOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProductsManufacturedOutsideOfIsraelMember" xml:lang="en-US" id="label_plx_ProductsManufacturedOutsideOfIsraelMember">Products Manufactured Outside Of Israel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:to="label_plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Label : plx_ProductsManufacturedOutsideOfIsraelMember to label_plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xml:lang="en-US" id="label_plx_ProductsManufacturedOutsideOfIsraelMember_1">Products Manufactured Outside Of Israel Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:to="label_plx_ProductsManufacturedOutsideOfIsraelMember_1" xlink:title="Label : plx_ProductsManufacturedOutsideOfIsraelMember to label_plx_ProductsManufacturedOutsideOfIsraelMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PropertyAndEquipmentSuppliersMember" xlink:label="plx_PropertyAndEquipmentSuppliersMember" xlink:title="plx_PropertyAndEquipmentSuppliersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PropertyAndEquipmentSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PropertyAndEquipmentSuppliersMember" xml:lang="en-US" id="label_plx_PropertyAndEquipmentSuppliersMember">Property And Equipment Suppliers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PropertyAndEquipmentSuppliersMember" xlink:to="label_plx_PropertyAndEquipmentSuppliersMember" xlink:title="Label : plx_PropertyAndEquipmentSuppliersMember to label_plx_PropertyAndEquipmentSuppliersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PropertyAndEquipmentSuppliersMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PropertyAndEquipmentSuppliersMember_1" xml:lang="en-US" id="label_plx_PropertyAndEquipmentSuppliersMember_1">Property and Equipment Suppliers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PropertyAndEquipmentSuppliersMember" xlink:to="label_plx_PropertyAndEquipmentSuppliersMember_1" xlink:title="Label : plx_PropertyAndEquipmentSuppliersMember to label_plx_PropertyAndEquipmentSuppliersMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ResearchAndLicenseAgreementsMember" xml:lang="en-US" id="label_plx_ResearchAndLicenseAgreementsMember">Research And License Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchAndLicenseAgreementsMember" xlink:to="label_plx_ResearchAndLicenseAgreementsMember" xlink:title="Label : plx_ResearchAndLicenseAgreementsMember to label_plx_ResearchAndLicenseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchAndLicenseAgreementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ResearchAndLicenseAgreementsMember_1" xml:lang="en-US" id="label_plx_ResearchAndLicenseAgreementsMember_1">Research And License Agreements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchAndLicenseAgreementsMember" xlink:to="label_plx_ResearchAndLicenseAgreementsMember_1" xlink:title="Label : plx_ResearchAndLicenseAgreementsMember to label_plx_ResearchAndLicenseAgreementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RestrictedAmountMember" xml:lang="en-US" id="label_plx_RestrictedAmountMember">Restricted Amount [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedAmountMember" xlink:to="label_plx_RestrictedAmountMember" xlink:title="Label : plx_RestrictedAmountMember to label_plx_RestrictedAmountMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedAmountMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RestrictedAmountMember_1" xml:lang="en-US" id="label_plx_RestrictedAmountMember_1">Restricted Amount Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedAmountMember" xlink:to="label_plx_RestrictedAmountMember_1" xlink:title="Label : plx_RestrictedAmountMember to label_plx_RestrictedAmountMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RestrictedDepositMember" xlink:label="plx_RestrictedDepositMember" xlink:title="plx_RestrictedDepositMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RestrictedDepositMember" xml:lang="en-US" id="label_plx_RestrictedDepositMember">Restricted Deposit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedDepositMember" xlink:to="label_plx_RestrictedDepositMember" xlink:title="Label : plx_RestrictedDepositMember to label_plx_RestrictedDepositMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_RestrictedDepositMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RestrictedDepositMember_1" xml:lang="en-US" id="label_plx_RestrictedDepositMember_1">Restricted Deposit Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RestrictedDepositMember" xlink:to="label_plx_RestrictedDepositMember_1" xlink:title="Label : plx_RestrictedDepositMember to label_plx_RestrictedDepositMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_RoyaltiesOnSaleOfProducts" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts">Royalties On Sale Of Products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_RoyaltiesOnSaleOfProducts_1" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts_1">Percentage of royalties based on sale of products developed from projects funded.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts_1" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_RoyaltiesOnSaleOfProducts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_RoyaltiesOnSaleOfProducts_2" xml:lang="en-US" id="label_plx_RoyaltiesOnSaleOfProducts_2">Royalties based on sale of products developed from funded projects, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="label_plx_RoyaltiesOnSaleOfProducts_2" xlink:title="Label : plx_RoyaltiesOnSaleOfProducts to label_plx_RoyaltiesOnSaleOfProducts_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioOneMember" xml:lang="en-US" id="label_plx_ScenarioOneMember">Scenario One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioOneMember_1" xml:lang="en-US" id="label_plx_ScenarioOneMember_1">Scenario One [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_1" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioOneMember_2" xml:lang="en-US" id="label_plx_ScenarioOneMember_2">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_2" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock">Schedule Of Open Tax Years [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1">Schedule Of Open Tax Years Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xml:lang="en-US" id="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2">Schedule of Open Tax Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" xlink:title="Label : plx_ScheduleOfOpenTaxYearsTableTextBlock to label_plx_ScheduleOfOpenTaxYearsTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xml:lang="en-US" id="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">Schedule Of Options And Restricted Stocks Granted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="Label : plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock to label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xml:lang="en-US" id="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1">Schedule of Options and Restricted Stocks Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" xlink:title="Label : plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock to label_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SevenPointFiveFiveMember" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember">Seven Point Five Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SevenPointFiveFiveMember_1" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember_1">Seven Point Five Five Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember_1" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SevenPointFiveFiveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SevenPointFiveFiveMember_2" xml:lang="en-US" id="label_plx_SevenPointFiveFiveMember_2">7.550 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFiveFiveMember" xlink:to="label_plx_SevenPointFiveFiveMember_2" xlink:title="Label : plx_SevenPointFiveFiveMember to label_plx_SevenPointFiveFiveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2">Fair value of at grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">Share based compensation arrangement by share based payment award granted contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1">Shares of common stock issued, lock up period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_3" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">Share Based Compensation Arrangement By Share Based Payment Award Number Of Installments For Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1">Share based compensation arrangement by share based payment award number of installments for vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2">Number of installments for vesting of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesLineItems">Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="label_plx_SignificantAccountingPoliciesLineItems" xlink:title="Label : plx_SignificantAccountingPoliciesLineItems to label_plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesTable" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable">Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SignificantAccountingPoliciesTable_1" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable_1">Significant Accounting Policies [Table].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable_1" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SixPointEightOneZeroMember" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember">Six Point Eight One Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SixPointEightOneZeroMember_1" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember_1">Six Point Eight One Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember_1" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointEightOneZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SixPointEightOneZeroMember_2" xml:lang="en-US" id="label_plx_SixPointEightOneZeroMember_2">6.810 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointEightOneZeroMember" xlink:to="label_plx_SixPointEightOneZeroMember_2" xlink:title="Label : plx_SixPointEightOneZeroMember to label_plx_SixPointEightOneZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SixPointNineMember" xml:lang="en-US" id="label_plx_SixPointNineMember">Six Point Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SixPointNineMember_1" xml:lang="en-US" id="label_plx_SixPointNineMember_1">Six Point Nine Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember_1" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SixPointNineMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SixPointNineMember_2" xml:lang="en-US" id="label_plx_SixPointNineMember_2">6.900 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SixPointNineMember" xlink:to="label_plx_SixPointNineMember_2" xlink:title="Label : plx_SixPointNineMember to label_plx_SixPointNineMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_StateOfIsraelMember" xlink:label="plx_StateOfIsraelMember" xlink:title="plx_StateOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StateOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_StateOfIsraelMember" xml:lang="en-US" id="label_plx_StateOfIsraelMember">State Of Israel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StateOfIsraelMember" xlink:to="label_plx_StateOfIsraelMember" xlink:title="Label : plx_StateOfIsraelMember to label_plx_StateOfIsraelMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StateOfIsraelMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_StateOfIsraelMember_1" xml:lang="en-US" id="label_plx_StateOfIsraelMember_1">State Of Israel Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StateOfIsraelMember" xlink:to="label_plx_StateOfIsraelMember_1" xlink:title="Label : plx_StateOfIsraelMember to label_plx_StateOfIsraelMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember">Stock Options And Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_1" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_1">Stock Options And Restricted Shares [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_2" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_2">Options and Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SundryMember" xlink:label="plx_SundryMember" xlink:title="plx_SundryMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SundryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SundryMember" xml:lang="en-US" id="label_plx_SundryMember">Sundry [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SundryMember" xlink:to="label_plx_SundryMember" xlink:title="Label : plx_SundryMember to label_plx_SundryMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_SundryMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SundryMember_1" xml:lang="en-US" id="label_plx_SundryMember_1">Sundry Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SundryMember" xlink:to="label_plx_SundryMember_1" xlink:title="Label : plx_SundryMember to label_plx_SundryMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationAbstract" xml:lang="en-US" id="label_plx_SupplementalInformationAbstract">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="label_plx_SupplementalInformationAbstract" xlink:title="Label : plx_SupplementalInformationAbstract to label_plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueAxis" xlink:label="plx_SupplementalInformationRevenueAxis" xlink:title="plx_SupplementalInformationRevenueAxis" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationRevenueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationRevenueAxis" xml:lang="en-US" id="label_plx_SupplementalInformationRevenueAxis">Supplemental Information Revenue [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationRevenueAxis" xlink:to="label_plx_SupplementalInformationRevenueAxis" xlink:title="Label : plx_SupplementalInformationRevenueAxis to label_plx_SupplementalInformationRevenueAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueDomain" xlink:label="plx_SupplementalInformationRevenueDomain" xlink:title="plx_SupplementalInformationRevenueDomain" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationRevenueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationRevenueDomain" xml:lang="en-US" id="label_plx_SupplementalInformationRevenueDomain">Supplemental Information Revenue [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationRevenueDomain" xlink:to="label_plx_SupplementalInformationRevenueDomain" xlink:title="Label : plx_SupplementalInformationRevenueDomain to label_plx_SupplementalInformationRevenueDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueLineItems" xlink:label="plx_SupplementalInformationRevenueLineItems" xlink:title="plx_SupplementalInformationRevenueLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationRevenueLineItems" xml:lang="en-US" id="label_plx_SupplementalInformationRevenueLineItems">Supplemental Information Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationRevenueLineItems" xlink:to="label_plx_SupplementalInformationRevenueLineItems" xlink:title="Label : plx_SupplementalInformationRevenueLineItems to label_plx_SupplementalInformationRevenueLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationTable" xlink:label="plx_SupplementalInformationTable" xlink:title="plx_SupplementalInformationTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalInformationTable" xml:lang="en-US" id="label_plx_SupplementalInformationTable">Supplemental Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationTable" xlink:to="label_plx_SupplementalInformationTable" xlink:title="Label : plx_SupplementalInformationTable to label_plx_SupplementalInformationTable" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_1">Supplemental offering and stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_2">Issuance cost not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1">Supplementary Balance Sheets Information Table Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xml:lang="en-US" id="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2">Supplemental Information, Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" xlink:title="Label : plx_SupplementaryBalanceSheetsInformationTableTextBlock to label_plx_SupplementaryBalanceSheetsInformationTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xml:lang="en-US" id="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2">Supplemental Information, Income Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" xlink:title="Label : plx_SupplementaryIncomeStatementInformationTableTextBlock to label_plx_SupplementaryIncomeStatementInformationTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxBurdenDistributionLawMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxBurdenDistributionLawMember" xml:lang="en-US" id="label_plx_TaxBurdenDistributionLawMember">Tax Burden Distribution Law [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxBurdenDistributionLawMember" xlink:to="label_plx_TaxBurdenDistributionLawMember" xlink:title="Label : plx_TaxBurdenDistributionLawMember to label_plx_TaxBurdenDistributionLawMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxBurdenDistributionLawMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TaxBurdenDistributionLawMember_1" xml:lang="en-US" id="label_plx_TaxBurdenDistributionLawMember_1">Tax Burden Distribution Law Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxBurdenDistributionLawMember" xlink:to="label_plx_TaxBurdenDistributionLawMember_1" xlink:title="Label : plx_TaxBurdenDistributionLawMember to label_plx_TaxBurdenDistributionLawMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal">Tax Rate Assumption Related To Deferred Tax Difference Reversal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xml:lang="en-US" id="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2">Tax rates expected to be in effect when deferred tax asset differences reverse</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" xlink:title="Label : plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal to label_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxYearThereafterMember" xml:lang="en-US" id="label_plx_TaxYearThereafterMember">Tax Year Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="label_plx_TaxYearThereafterMember" xlink:title="Label : plx_TaxYearThereafterMember to label_plx_TaxYearThereafterMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearThereafterMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxYearThereafterMember_1" xml:lang="en-US" id="label_plx_TaxYearThereafterMember_1">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="label_plx_TaxYearThereafterMember_1" xlink:title="Label : plx_TaxYearThereafterMember to label_plx_TaxYearThereafterMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearTwoThousandNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TaxYearTwoThousandNineMember" xml:lang="en-US" id="label_plx_TaxYearTwoThousandNineMember">Tax Year Two Thousand Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearTwoThousandNineMember" xlink:to="label_plx_TaxYearTwoThousandNineMember" xlink:title="Label : plx_TaxYearTwoThousandNineMember to label_plx_TaxYearTwoThousandNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TaxYearTwoThousandNineMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TaxYearTwoThousandNineMember_1" xml:lang="en-US" id="label_plx_TaxYearTwoThousandNineMember_1">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearTwoThousandNineMember" xlink:to="label_plx_TaxYearTwoThousandNineMember_1" xlink:title="Label : plx_TaxYearTwoThousandNineMember to label_plx_TaxYearTwoThousandNineMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ThreePointZeroTwoZeroMember" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember">Three Point Zero Two Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ThreePointZeroTwoZeroMember_1" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember_1">3.020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember_1" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointZeroTwoZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ThreePointZeroTwoZeroMember_2" xml:lang="en-US" id="label_plx_ThreePointZeroTwoZeroMember_2">Three Point Zero Two Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointZeroTwoZeroMember" xlink:to="label_plx_ThreePointZeroTwoZeroMember_2" xlink:title="Label : plx_ThreePointZeroTwoZeroMember to label_plx_ThreePointZeroTwoZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointSixFiveMember" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember">Two Point Six Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointSixFiveMember_1" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember_1">Two Point Six Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember_1" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointSixFiveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointSixFiveMember_2" xml:lang="en-US" id="label_plx_TwoPointSixFiveMember_2">2.650 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointSixFiveMember" xlink:to="label_plx_TwoPointSixFiveMember_2" xlink:title="Label : plx_TwoPointSixFiveMember to label_plx_TwoPointSixFiveMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointThreeFiveZeroMember" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember">Two Point Three Five Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointThreeFiveZeroMember_1" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember_1">Two Point Three Five Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember_1" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeFiveZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointThreeFiveZeroMember_2" xml:lang="en-US" id="label_plx_TwoPointThreeFiveZeroMember_2">2.350 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeFiveZeroMember" xlink:to="label_plx_TwoPointThreeFiveZeroMember_2" xlink:title="Label : plx_TwoPointThreeFiveZeroMember to label_plx_TwoPointThreeFiveZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xml:lang="en-US" id="label_plx_UponNearTermClinicalDevelopmentMilestonesMember">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:to="label_plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Label : plx_UponNearTermClinicalDevelopmentMilestonesMember to label_plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xml:lang="en-US" id="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1">Upon Near Term Clinical Development Milestones Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:to="label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" xlink:title="Label : plx_UponNearTermClinicalDevelopmentMilestonesMember to label_plx_UponNearTermClinicalDevelopmentMilestonesMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US" id="label_plx_VehicleLeaseAndMaintenanceAgreementsMember">Vehicle Lease And Maintenance Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="label_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Label : plx_VehicleLeaseAndMaintenanceAgreementsMember to label_plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xml:lang="en-US" id="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1">Vehicle Lease and Maintenance Agreements Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" xlink:title="Label : plx_VehicleLeaseAndMaintenanceAgreementsMember to label_plx_VehicleLeaseAndMaintenanceAgreementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome">Withholding Tax Rate On Foreign Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome_1" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome_1">Withholding Tax Rate On Foreign Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome_1" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_WithholdingTaxRateOnForeignIncome_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_WithholdingTaxRateOnForeignIncome_2" xml:lang="en-US" id="label_plx_WithholdingTaxRateOnForeignIncome_2">Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WithholdingTaxRateOnForeignIncome" xlink:to="label_plx_WithholdingTaxRateOnForeignIncome_2" xlink:title="Label : plx_WithholdingTaxRateOnForeignIncome to label_plx_WithholdingTaxRateOnForeignIncome_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_YissumAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_YissumAgreementMember" xml:lang="en-US" id="label_plx_YissumAgreementMember">Yissum Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_YissumAgreementMember" xlink:to="label_plx_YissumAgreementMember" xlink:title="Label : plx_YissumAgreementMember to label_plx_YissumAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointNineSevenTwoMember" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember">Zero Point Nine Seven Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointNineSevenTwoMember_1" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember_1">Zero Point Nine Seven Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember_1" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointNineSevenTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointNineSevenTwoMember_2" xml:lang="en-US" id="label_plx_ZeroPointNineSevenTwoMember_2">0.972 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointNineSevenTwoMember" xlink:to="label_plx_ZeroPointNineSevenTwoMember_2" xlink:title="Label : plx_ZeroPointNineSevenTwoMember to label_plx_ZeroPointNineSevenTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointOneTwoZeroMember" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember">Zero Point One Two Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointOneTwoZeroMember_1" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember_1">Zero Point One Two Zero Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember_1" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointOneTwoZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointOneTwoZeroMember_2" xml:lang="en-US" id="label_plx_ZeroPointOneTwoZeroMember_2">0.120 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointOneTwoZeroMember" xlink:to="label_plx_ZeroPointOneTwoZeroMember_2" xlink:title="Label : plx_ZeroPointOneTwoZeroMember to label_plx_ZeroPointOneTwoZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointThreeNineNineMember" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember">Zero Point Three Nine Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointThreeNineNineMember_1" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember_1">Zero Point Three Nine Nine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember_1" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointThreeNineNineMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointThreeNineNineMember_2" xml:lang="en-US" id="label_plx_ZeroPointThreeNineNineMember_2">0.399 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointThreeNineNineMember" xlink:to="label_plx_ZeroPointThreeNineNineMember_2" xlink:title="Label : plx_ZeroPointThreeNineNineMember to label_plx_ZeroPointThreeNineNineMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ZeroPointZeroZeroOneMember" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember">Zero Point Zero Zero One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ZeroPointZeroZeroOneMember_1" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember_1">Zero Point Zero Zero One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember_1" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ZeroPointZeroZeroOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ZeroPointZeroZeroOneMember_2" xml:lang="en-US" id="label_plx_ZeroPointZeroZeroOneMember_2">0.001 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ZeroPointZeroZeroOneMember" xlink:to="label_plx_ZeroPointZeroZeroOneMember_2" xlink:title="Label : plx_ZeroPointZeroZeroOneMember to label_plx_ZeroPointZeroZeroOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember_1">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember_1" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xml:lang="en-US" id="label_plx_PresidentAndChiefExecutiveOfficerMember_2">First or second ranking officer of the entity that may be appointed by the board of directors and Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="label_plx_PresidentAndChiefExecutiveOfficerMember_2" xlink:title="Label : plx_PresidentAndChiefExecutiveOfficerMember to label_plx_PresidentAndChiefExecutiveOfficerMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">Options and Restricted Stocks Granted to Consultants Directors and Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xml:lang="en-US" id="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" xlink:title="Label : plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember to label_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_TwoPointThreeSevenZeroMember" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember">Two Point Three Seven Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_TwoPointThreeSevenZeroMember_1" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember_1">2.370 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember_1" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_TwoPointThreeSevenZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_TwoPointThreeSevenZeroMember_2" xml:lang="en-US" id="label_plx_TwoPointThreeSevenZeroMember_2">Two Point Three Seven Zero [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TwoPointThreeSevenZeroMember" xlink:to="label_plx_TwoPointThreeSevenZeroMember_2" xlink:title="Label : plx_TwoPointThreeSevenZeroMember to label_plx_TwoPointThreeSevenZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ThreePointThreeSevenZeroMember" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember">Three Point Three Seven Zero [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ThreePointThreeSevenZeroMember_1" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember_1">3.370 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember_1" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ThreePointThreeSevenZeroMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ThreePointThreeSevenZeroMember_2" xml:lang="en-US" id="label_plx_ThreePointThreeSevenZeroMember_2">Three Point Three Seven Zero [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThreePointThreeSevenZeroMember" xlink:to="label_plx_ThreePointThreeSevenZeroMember_2" xlink:title="Label : plx_ThreePointThreeSevenZeroMember to label_plx_ThreePointThreeSevenZeroMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantYearTwoThousandFourteenMember" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember">Grant Year Two Thousand Fourteen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantYearTwoThousandFourteenMember_1" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember_1">2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember_1" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantYearTwoThousandFourteenMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantYearTwoThousandFourteenMember_2" xml:lang="en-US" id="label_plx_GrantYearTwoThousandFourteenMember_2">Represents information pertaining to grant year 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantYearTwoThousandFourteenMember" xlink:to="label_plx_GrantYearTwoThousandFourteenMember_2" xlink:title="Label : plx_GrantYearTwoThousandFourteenMember to label_plx_GrantYearTwoThousandFourteenMember_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment_3" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment_3">Depreciation and write down of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment_3" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment_3" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2">Common stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:label="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent">Accrued Liability, In Connection With Collaboration Operation, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1">Liability in connection with collaboration operation - current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xml:lang="en-US" id="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2">Carrying value as of the balance sheet date of obligations incurred through that date and payable arising in connection with collaboration operation (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:to="label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" xlink:title="Label : plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent to label_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1">Property and equipment suppliers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xml:lang="en-US" id="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" xlink:title="Label : plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent to label_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNet">Sales Revenue, Goods, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="label_us-gaap_SalesRevenueGoodsNet" xlink:title="Label : us-gaap_SalesRevenueGoodsNet to label_us-gaap_SalesRevenueGoodsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:title="Label : us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized to label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="us-gaap_LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LicensesRevenue" xml:lang="en-US" id="label_us-gaap_LicensesRevenue">Licenses Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue" xlink:title="Label : us-gaap_LicensesRevenue to label_us-gaap_LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicensesRevenue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LicensesRevenue_1" xml:lang="en-US" id="label_us-gaap_LicensesRevenue_1">Deferred revenues from the license and supply agreement with Pfizer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="label_us-gaap_LicensesRevenue_1" xlink:title="Label : us-gaap_LicensesRevenue to label_us-gaap_LicensesRevenue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueGoodsNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SalesRevenueGoodsNet_1" xml:lang="en-US" id="label_us-gaap_SalesRevenueGoodsNet_1">Revenue from selling products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="label_us-gaap_SalesRevenueGoodsNet_1" xlink:title="Label : us-gaap_SalesRevenueGoodsNet to label_us-gaap_SalesRevenueGoodsNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1">Revenues from selling products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xlink:title="Label : us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized to label_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xlink:title="us-gaap_SalesRevenueNetAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SalesRevenueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SalesRevenueNetAbstract" xml:lang="en-US" id="label_us-gaap_SalesRevenueNetAbstract">Revenue, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="label_us-gaap_SalesRevenueNetAbstract" xlink:title="Label : us-gaap_SalesRevenueNetAbstract to label_us-gaap_SalesRevenueNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:title="us-gaap_RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenuesAbstract" xml:lang="en-US" id="label_us-gaap_RevenuesAbstract">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="label_us-gaap_RevenuesAbstract" xlink:title="Label : us-gaap_RevenuesAbstract to label_us-gaap_RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenuesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenuesAbstract_1" xml:lang="en-US" id="label_us-gaap_RevenuesAbstract_1">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="label_us-gaap_RevenuesAbstract_1" xlink:title="Label : us-gaap_RevenuesAbstract to label_us-gaap_RevenuesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherAssetsCurrent" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="label_us-gaap_OtherAssetsCurrent" xlink:title="Label : us-gaap_OtherAssetsCurrent to label_us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue to label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:title="us-gaap_OtherRestrictedAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherRestrictedAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherRestrictedAssetsCurrent" xml:lang="en-US" id="label_us-gaap_OtherRestrictedAssetsCurrent">Other Restricted Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="label_us-gaap_OtherRestrictedAssetsCurrent" xlink:title="Label : us-gaap_OtherRestrictedAssetsCurrent to label_us-gaap_OtherRestrictedAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" xlink:title="plx_OtherAssetsInstitutionsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherAssetsInstitutionsCurrent" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent">Other Assets, Institutions, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherAssetsInstitutionsCurrent_1" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent_1">Institutions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent_1" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsInstitutionsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherAssetsInstitutionsCurrent_2" xml:lang="en-US" id="label_plx_OtherAssetsInstitutionsCurrent_2">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="label_plx_OtherAssetsInstitutionsCurrent_2" xlink:title="Label : plx_OtherAssetsInstitutionsCurrent to label_plx_OtherAssetsInstitutionsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties" xlink:title="us-gaap_PrepaidRoyalties" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidRoyalties" xml:lang="en-US" id="label_us-gaap_PrepaidRoyalties">Prepaid Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="label_us-gaap_PrepaidRoyalties" xlink:title="Label : us-gaap_PrepaidRoyalties to label_us-gaap_PrepaidRoyalties" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1">Restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue to label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidRoyalties_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidRoyalties_1" xml:lang="en-US" id="label_us-gaap_PrepaidRoyalties_1">State of Israel (see Note 6a)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="label_us-gaap_PrepaidRoyalties_1" xlink:title="Label : us-gaap_PrepaidRoyalties to label_us-gaap_PrepaidRoyalties_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent_1">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="label_us-gaap_OtherAssetsCurrent_1" xlink:title="Label : us-gaap_OtherAssetsCurrent to label_us-gaap_OtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" xlink:title="plx_OtherAssetsSundryCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherAssetsSundryCurrent" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent">Other Assets, Sundry, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherAssetsSundryCurrent_1" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent_1">Sundry</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent_1" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherAssetsSundryCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherAssetsSundryCurrent_2" xml:lang="en-US" id="label_plx_OtherAssetsSundryCurrent_2">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="label_plx_OtherAssetsSundryCurrent_2" xlink:title="Label : plx_OtherAssetsSundryCurrent to label_plx_OtherAssetsSundryCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1">Other assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2">Accounts payable and accruals - other:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Fair value of restricted stock granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1">Restricted stock granted, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1">Recently issued accounting pronouncements:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount">Collaborative Arrangement, Milestone Payment, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount_1">Pfizer Agreement, milestone payment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount_1" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xml:lang="en-US" id="label_plx_CollaborativeArrangementMilestonePaymentAmount_2">Collaborative Arrangement milestone payment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:to="label_plx_CollaborativeArrangementMilestonePaymentAmount_2" xlink:title="Label : plx_CollaborativeArrangementMilestonePaymentAmount to label_plx_CollaborativeArrangementMilestonePaymentAmount_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_MilestonePayment_3" xml:lang="en-US" id="label_plx_MilestonePayment_3">Milestone payment (see Note 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_3" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US" id="label_us-gaap_BoardOfDirectorsChairmanMember">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Label : us-gaap_BoardOfDirectorsChairmanMember to label_us-gaap_BoardOfDirectorsChairmanMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_VestingAxis" xml:lang="en-US" id="label_us-gaap_VestingAxis">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="label_us-gaap_VestingAxis" xlink:title="Label : us-gaap_VestingAxis to label_us-gaap_VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_VestingDomain" xml:lang="en-US" id="label_us-gaap_VestingDomain">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="label_us-gaap_VestingDomain" xlink:title="Label : us-gaap_VestingDomain to label_us-gaap_VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheOneMember to label_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheTwoMember to label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1">Vest on the first anniversary of the grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheOneMember to label_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1">Vest over the subsequent two-year period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:title="Label : us-gaap_ShareBasedCompensationAwardTrancheTwoMember to label_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1">Shares vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption">Debt Instrument, Principal Amount Related To Initial Purchaser''s Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1">Aggregate principal amount of Notes related to the initial purchaser's over-allotment option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xml:lang="en-US" id="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2">Principal amount, related to the initial purchaser's over-allotment option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:to="label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" xlink:title="Label : plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption to label_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Depreciation" xml:lang="en-US" id="label_us-gaap_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>plx-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocicdp" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocicdp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scnd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scnd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scrsgted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scrsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsooarsd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasa" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-lasa" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lasad" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-lasad" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toind" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toind" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-daei" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-daei" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsird" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsird" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsit" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsit" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsiapaaod" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsiapaaod" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsi" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsi" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sfsoa" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sfsoa" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapp1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapp1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapt" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sap" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sap" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapulopaed" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sapulopaed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cbs" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocf" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-c" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-c" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnsoierd1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cnsoierd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnnd1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cnnd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cn1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cn1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cnt1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cnt1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lferurd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-lferurd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-lferur" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-lferur" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scfvaoogd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scfvaoogd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sct" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sct" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsbcead" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsbcead" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scsooarsgted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scsooarsgted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scogted" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scogted" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-scoarsgtcdaospd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-scoarsgtcdaospd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sc" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-sc" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csocicd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csocicd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvmd1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-fvmd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvm1" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-fvm1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiotyd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toiotyd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-csoo" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-csoo" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toit" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toit" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toiditd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toiditd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-toi" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-toi" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-id" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-id" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-i" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-i" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-it" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-it" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paet" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-paet" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-pae" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-pae" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-paed" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-paed" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptd" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-rptd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rpt" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-rpt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-rptt" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-rptt" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-cbsp" xlink:type="simple" xlink:href="plx-20141231.xsd#plx-cbsp" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocicdp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" use="optional" priority="0" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_AwardTypeAxis" use="optional" priority="0" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" priority="0" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" use="optional" priority="0" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_VestingAxis" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" use="optional" priority="0" order="84" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" use="optional" priority="0" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" priority="0" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_PaymentsOfStockIssuanceCosts" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" priority="0" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_SaleOfStockPricePerShare" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" priority="0" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" priority="0" order="114" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" priority="0" order="124" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" use="optional" priority="0" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="us-gaap_EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="plx_OfficersAndCertainEmployeesMember" xlink:title="plx_OfficersAndCertainEmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndCertainEmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndCertainEmployeesMember" order="1.25" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:label="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="plx_OfficersAndDirectorsInPrivateTransactionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OfficersAndDirectorsInPrivateTransactionMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="plx_PresidentAndChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_PresidentAndChiefExecutiveOfficerMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" xlink:title="us-gaap_ExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ExecutiveOfficerMember" order="1.625" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Presentation : us-gaap_VestingAxis to us-gaap_VestingDomain" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scrsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_AwardTypeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="2.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FivePointZeroMember" xlink:label="plx_FivePointZeroMember" xlink:title="plx_FivePointZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_FivePointZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_FivePointZeroMember" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NinePointSixSixMember" xlink:label="plx_NinePointSixSixMember" xlink:title="plx_NinePointSixSixMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_NinePointSixSixMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_NinePointSixSixMember" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OneSixPointSevenMember" xlink:label="plx_OneSixPointSevenMember" xlink:title="plx_OneSixPointSevenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_OneSixPointSevenMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_OneSixPointSevenMember" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SevenPointFiveFiveMember" xlink:label="plx_SevenPointFiveFiveMember" xlink:title="plx_SevenPointFiveFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SevenPointFiveFiveMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SevenPointFiveFiveMember" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointEightOneZeroMember" xlink:label="plx_SixPointEightOneZeroMember" xlink:title="plx_SixPointEightOneZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointEightOneZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointEightOneZeroMember" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SixPointNineMember" xlink:label="plx_SixPointNineMember" xlink:title="plx_SixPointNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_SixPointNineMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_SixPointNineMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="plx_ThreePointZeroTwoZeroMember" xlink:title="plx_ThreePointZeroTwoZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointZeroTwoZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointZeroTwoZeroMember" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointSixFiveMember" xlink:label="plx_TwoPointSixFiveMember" xlink:title="plx_TwoPointSixFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointSixFiveMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointSixFiveMember" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="plx_TwoPointThreeFiveZeroMember" xlink:title="plx_TwoPointThreeFiveZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeFiveZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeFiveZeroMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:label="plx_ZeroPointNineSevenTwoMember" xlink:title="plx_ZeroPointNineSevenTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointNineSevenTwoMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointNineSevenTwoMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:label="plx_ZeroPointOneTwoZeroMember" xlink:title="plx_ZeroPointOneTwoZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointOneTwoZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointOneTwoZeroMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointThreeNineNineMember" xlink:label="plx_ZeroPointThreeNineNineMember" xlink:title="plx_ZeroPointThreeNineNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointThreeNineNineMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointThreeNineNineMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:label="plx_ZeroPointZeroZeroOneMember" xlink:title="plx_ZeroPointZeroZeroOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ZeroPointZeroZeroOneMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ZeroPointZeroZeroOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="plx_TwoPointThreeSevenZeroMember" xlink:title="plx_TwoPointThreeSevenZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_TwoPointThreeSevenZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_TwoPointThreeSevenZeroMember" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="plx_ThreePointThreeSevenZeroMember" xlink:title="plx_ThreePointThreeSevenZeroMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ThreePointThreeSevenZeroMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to plx_ThreePointThreeSevenZeroMember" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="plx_OptionsAndRestrictedStockMember" xlink:title="plx_OptionsAndRestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to plx_OptionsAndRestrictedStockMember" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:title="us-gaap_RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasa">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementDisclosure to plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lasad">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:title="plx_CollaborativeAndLicenseArrangementDisclosure" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:label="plx_CollaborativeAndLicenseArrangementTable" xlink:title="plx_CollaborativeAndLicenseArrangementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosure" xlink:to="plx_CollaborativeAndLicenseArrangementTable" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementDisclosure to plx_CollaborativeAndLicenseArrangementTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="plx_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to plx_SignificantAccountingPoliciesLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to us-gaap_StatementScenarioAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CollaborativeAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : plx_CollaborativeAndLicenseArrangementTable to us-gaap_TypeOfArrangementAxis" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborationOperationMember" xlink:label="plx_CollaborationOperationMember" xlink:title="plx_CollaborationOperationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_CollaborationOperationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_CollaborationOperationMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:label="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="plx_RevenueRecognizedOverDesignatedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedOverDesignatedPeriod" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedOverDesignatedPeriod" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RevenueRecognizedPeriod" xlink:label="plx_RevenueRecognizedPeriod" xlink:title="plx_RevenueRecognizedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenueRecognizedPeriod" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_RevenueRecognizedPeriod" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:label="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="plx_LiabilitiesAccruedFromLicensingAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LiabilitiesAccruedFromLicensingAgreement" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LiabilitiesAccruedFromLicensingAgreement" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cd">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" xlink:title="plx_CommitmentsAndContingenciesAxis" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" xlink:title="plx_CommitmentsAndContingenciesDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain" xlink:title="Presentation : plx_CommitmentsAndContingenciesAxis to plx_CommitmentsAndContingenciesDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FundingArrangementsMember" xlink:label="plx_FundingArrangementsMember" xlink:title="plx_FundingArrangementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_FundingArrangementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_FundingArrangementsMember" order="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePaymentsMember" xlink:label="plx_MilestonePaymentsMember" xlink:title="plx_MilestonePaymentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_MilestonePaymentsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_MilestonePaymentsMember" order="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OCSMember" xlink:label="plx_OCSMember" xlink:title="plx_OCSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_OCSMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_OCSMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:label="plx_ProbableAggregateMilestonePaymentMember" xlink:title="plx_ProbableAggregateMilestonePaymentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProbableAggregateMilestonePaymentMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ProbableAggregateMilestonePaymentMember" order="5" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="plx_ProductsManufacturedOutsideOfIsraelMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ProductsManufacturedOutsideOfIsraelMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ProductsManufacturedOutsideOfIsraelMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="plx_ResearchAndLicenseAgreementsMember" xlink:title="plx_ResearchAndLicenseAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_ResearchAndLicenseAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_ResearchAndLicenseAgreementsMember" order="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_VehicleLeaseAndMaintenanceAgreementsMember" order="9" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_YissumAgreementMember" xlink:label="plx_YissumAgreementMember" xlink:title="plx_YissumAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_YissumAgreementMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to plx_YissumAgreementMember" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" xlink:title="us-gaap_LeaseAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="us-gaap_LeaseAgreementsMember" xlink:title="Presentation : plx_CommitmentsAndContingenciesDomain to us-gaap_LeaseAgreementsMember" order="8" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" xlink:title="plx_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AgreementMaintenanceFee" xlink:label="plx_AgreementMaintenanceFee" xlink:title="plx_AgreementMaintenanceFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AgreementMaintenanceFee" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_AgreementMaintenanceFee" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:label="plx_AnnualIncreaseToMaintenanceFee" xlink:title="plx_AnnualIncreaseToMaintenanceFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_AnnualIncreaseToMaintenanceFee" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_AnnualIncreaseToMaintenanceFee" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" xlink:title="plx_CommitmentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_CommitmentAmount" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ConsiderationForLicense" xlink:label="plx_ConsiderationForLicense" xlink:title="plx_ConsiderationForLicense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ConsiderationForLicense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_ConsiderationForLicense" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:label="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="plx_MonthlyRentLeaseExpense" xlink:title="plx_MonthlyRentLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_MonthlyRentLeaseExpense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_MonthlyRentLeaseExpense" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" xlink:title="plx_RoyaltiesOnSaleOfProducts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to plx_RoyaltiesOnSaleOfProducts" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesRentExpenseNet" order="7.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_RoyaltyExpense" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:title="us-gaap_SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" xlink:title="Presentation : plx_CommitmentsAndContingenciesLineItems to us-gaap_SecurityDeposit" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="plx_CommitmentsAndContingenciesTable" xlink:title="plx_CommitmentsAndContingenciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesAxis" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesAxis" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="plx_CommitmentsAndContingenciesLineItems" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to plx_CommitmentsAndContingenciesLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : plx_CommitmentsAndContingenciesTable to us-gaap_RangeAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="plx_CommitmentsAndContingenciesTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to plx_CommitmentsAndContingenciesTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Presentation : dei_EntityDomain to us-gaap_SubsidiariesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerIncorporationMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EligablePaymentReceivableUponAchievement" xlink:label="plx_EligablePaymentReceivableUponAchievement" xlink:title="plx_EligablePaymentReceivableUponAchievement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_EligablePaymentReceivableUponAchievement" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_EligablePaymentReceivableUponAchievement" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CollaborativeArrangementMilestonePaymentAmount" xlink:label="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="plx_CollaborativeArrangementMilestonePaymentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementMilestonePaymentAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementMilestonePaymentAmount" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_Revenues" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to plx_SignificantAccountingPoliciesLineItems" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueAxis" xlink:label="plx_SupplementalInformationRevenueAxis" xlink:title="plx_SupplementalInformationRevenueAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SupplementalInformationRevenueAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to plx_SupplementalInformationRevenueAxis" order="3.8" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to dei_LegalEntityAxis" order="3.75" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationRevenueDomain" xlink:label="plx_SupplementalInformationRevenueDomain" xlink:title="plx_SupplementalInformationRevenueDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationRevenueAxis" xlink:to="plx_SupplementalInformationRevenueDomain" xlink:title="Presentation : plx_SupplementalInformationRevenueAxis to plx_SupplementalInformationRevenueDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:title="us-gaap_SalesRevenueGoodsNetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationRevenueDomain" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:title="Presentation : plx_SupplementalInformationRevenueDomain to us-gaap_SalesRevenueGoodsNetMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_SignificantAccountingPoliciesTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponFDAApprovalMember" xlink:label="plx_UponFDAApprovalMember" xlink:title="plx_UponFDAApprovalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponFDAApprovalMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponFDAApprovalMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:label="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="plx_UponNearTermClinicalDevelopmentMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_UponNearTermClinicalDevelopmentMilestonesMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toind">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="us-gaap_SubsidiariesMember" xlink:title="us-gaap_SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="us-gaap_SubsidiariesMember" xlink:title="Presentation : dei_EntityDomain to us-gaap_SubsidiariesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" xlink:title="plx_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:label="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="plx_EffectiveAdjustedIncomeTaxRateThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateThereafter" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFive" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearFour" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearOne" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearThree" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:label="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="plx_EffectiveAdjustedIncomeTaxRateYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_EffectiveAdjustedIncomeTaxRateYearTwo" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:label="plx_WithholdingTaxRateOnForeignIncome" xlink:title="plx_WithholdingTaxRateOnForeignIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_WithholdingTaxRateOnForeignIncome" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to plx_WithholdingTaxRateOnForeignIncome" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="us-gaap_OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Presentation : plx_IncomeTaxDisclosureLineItems to us-gaap_OperatingLossCarryforwards" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" xlink:title="plx_IncomeTaxDisclosureTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureLineItems" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to plx_IncomeTaxDisclosureLineItems" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to dei_LegalEntityAxis" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to us-gaap_IncomeTaxAuthorityAxis" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : plx_IncomeTaxDisclosureTable to us-gaap_RangeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_RestrictedAmountMember" xlink:label="plx_RestrictedAmountMember" xlink:title="plx_RestrictedAmountMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_RestrictedAmountMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_RestrictedAmountMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxBurdenDistributionLawMember" xlink:label="plx_TaxBurdenDistributionLawMember" xlink:title="plx_TaxBurdenDistributionLawMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxBurdenDistributionLawMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxBurdenDistributionLawMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" xlink:title="plx_TaxYearThereafterMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearThereafterMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="plx_TaxYearTwoThousandNineMember" xlink:title="plx_TaxYearTwoThousandNineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearTwoThousandNineMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to plx_TaxYearTwoThousandNineMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_IncomeTaxDisclosureTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to plx_IncomeTaxDisclosureTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-daei">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_TradingSymbol" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="dei_EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityWellKnownSeasonedIssuer" order="14.5625" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="dei_EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityVoluntaryFilers" order="14.03125" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCurrentReportingStatus" order="14.29688" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" order="13.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="dei_EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityPublicFloat" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentType" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsird">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_MilestonePayment" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_MilestonePayment" use="optional" priority="0" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:title="us-gaap_LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_LicensesRevenue" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_LicensesRevenue" use="optional" priority="0" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_Revenues" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_Revenues" order="81" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:title="us-gaap_RevenuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_RevenuesAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_RevenuesAbstract" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:title="us-gaap_SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_SalesRevenueGoodsNet" use="optional" priority="0" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsit">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_SupplementaryBalanceSheetsInformationTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to plx_SupplementaryIncomeStatementInformationTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsiapaaod">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:label="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" use="optional" priority="0" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableOtherCurrent" order="80" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:title="us-gaap_AccruedVacationCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedVacationCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedVacationCurrent" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:title="us-gaap_AccruedRoyaltiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedRoyaltiesCurrent" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrent" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:title="us-gaap_InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_InterestPayableCurrent" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsi">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sfsoa">
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" xlink:title="plx_SupplementalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="Presentation : plx_SupplementalInformationAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" xlink:title="plx_OtherAssetsInstitutionsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="plx_OtherAssetsInstitutionsCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to plx_OtherAssetsInstitutionsCurrent" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" xlink:title="plx_OtherAssetsSundryCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="plx_OtherAssetsSundryCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to plx_OtherAssetsSundryCurrent" use="optional" priority="0" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_OtherAssetsCurrent" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="us-gaap_PrepaidRoyalties" xlink:title="us-gaap_PrepaidRoyalties" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidRoyalties" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidRoyalties" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:title="us-gaap_PrepaidExpenseCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseCurrent" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapp1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_NatureOfOperationsPolicyTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="us-gaap_ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ConcentrationRiskCreditRisk" order="2.99951" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtPolicyTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="2.98438" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxPolicyTextBlock" order="2.99219" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:title="us-gaap_InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_InventoryPolicyTextBlock" order="2.9375" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2.96875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ResearchAndDevelopmentExpensePolicy" order="2.99805" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionPolicyTextBlock" order="2.99609" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="2.99976" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_ScheduleOfUsefulLifeTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sap">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapulopaed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" order="3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_RangeAxis" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableTradeCurrent" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableOtherCurrent" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AccountsReceivableNetCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_InventoryNet" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="us-gaap_OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_OtherAssetsCurrent" use="optional" priority="0" order="4.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DeferredCosts" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DeferredRevenueCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_ConvertibleDebtNoncurrent" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_DeferredRevenueNoncurrent" order="1.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_LongTermDebtNoncurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_CommitmentsAndContingencies" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_Liabilities" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrentAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapitalCommonStock" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquity" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AmortizationOfFinancingCosts" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_Depreciation" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6.5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_CashlessExerciseOfStockOptions" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_CashlessExerciseOfStockOptions" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to plx_SupplementalOfferingAndStockIssuanceCosts" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInDeferredRevenue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInInventories" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="1.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromConvertibleDebt" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromStockOptionsExercised" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_IncreaseDecreaseInRestrictedCash" order="1.875" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetIncomeLoss" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:title="us-gaap_InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_InterestPaidNet" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-c">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnsoierd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="plx_AmortizationOfDebtIssuanceCosts" xlink:title="plx_AmortizationOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_AmortizationOfDebtIssuanceCosts" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_AmortizationOfDebtIssuanceCosts" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestExpenseDebtExcludingAmortization" order="1.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpense" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestExpense" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnnd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentConvertibleBaseValueForConversionRate" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentConvertibleConversionShareNumber" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:label="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" use="optional" priority="0" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentFaceAmount" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentMaturityDate" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ProceedsFromConvertibleDebt" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cn1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="us-gaap_DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cnt1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lferurd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" xlink:title="plx_EmployeeSeveranceObligationPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_EmployeeSeveranceObligationPayment" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_EmployeeSeveranceObligationPayment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:label="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:label="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="plx_ExpectedDefintedBenefitContributionDuringPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to plx_ExpectedDefintedBenefitContributionDuringPeriod" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_PostemploymentBenefitsPeriodExpense" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-lferur">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="Presentation : us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scfvaoogd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ForfeitureRate" xlink:label="plx_ForfeitureRate" xlink:title="plx_ForfeitureRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="plx_ForfeitureRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to plx_ForfeitureRate" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sct">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsbcead">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scsooarsgted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:label="plx_GrantYearTwoThousandTwelveMember" xlink:title="plx_GrantYearTwoThousandTwelveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:label="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="plx_GrantYearTwoThousandTwelveSecondMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandTwelveSecondMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandTwelveSecondMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantYearTwoThousandFourteenMember" xlink:label="plx_GrantYearTwoThousandFourteenMember" xlink:title="plx_GrantYearTwoThousandFourteenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_GrantYearTwoThousandFourteenMember" xlink:title="Presentation : us-gaap_PlanNameDomain to plx_GrantYearTwoThousandFourteenMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_PlanNameAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EmployeesMember" xlink:label="plx_EmployeesMember" xlink:title="plx_EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_EmployeesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scogted">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ProceedsFromStockOptionsExercised" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="3.375" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="4.1875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStockGrantedToEmployeesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-scoarsgtcdaospd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_TitleOfIndividualAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sc">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csocicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" order="9.94463" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" order="9.94352" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9.94311" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" order="10.21463" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="10.97188" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="9.94286" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9.95825" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.97188" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.94289" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9.9429" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="10.45737" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="9.94287" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvmd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_ConvertibleDebtFairValueDisclosures" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvm1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiotyd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IL" xlink:label="country_IL" xlink:title="country_IL" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_IL" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_IL" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_NL" xlink:label="country_NL" xlink:title="country_NL" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_NL" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_NL" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:title="country_US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to country_US" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" xlink:title="us-gaap_IncomeTaxContingencyTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxContingencyTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:title="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:title="us-gaap_OpenTaxYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:title="Presentation : us-gaap_IncomeTaxContingencyLineItems to us-gaap_OpenTaxYear" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="us-gaap_IncomeTaxAuthorityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxContingencyLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_IncomeTaxAuthorityAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_IncomeTaxContingencyTable to us-gaap_RangeAxis" order="1.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="us-gaap_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-csoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_OtherGainsLosses" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_OtherGainsLosses" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_GrantsAndReimbursementsReceivedOrReceivable" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_CostOfRevenue" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasicAndDiluted" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_GrossProfit" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpense" order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingExpense" order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingIncome" order="9.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ResearchAndDevelopmentExpense" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_Revenues" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_SellingGeneralAndAdministrativeExpense" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to plx_ScheduleOfOpenTaxYearsTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toiditd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsDeferredIncome" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:title="us-gaap_DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsNet" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsValuationAllowance" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-toi">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-id">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryNet" order="4.75" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryRawMaterialsNetOfReserves" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWriteDown" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWorkInProcessNetOfReserves" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-i">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-it">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-pae">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-paed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" xlink:title="plx_LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_LaboratoryEquipmentMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" xlink:title="plx_FurnitureAndComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_FurnitureAndComputerEquipmentMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="plx_EquipmentUnderConstructionMember" xlink:title="plx_EquipmentUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_EquipmentUnderConstructionMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to plx_EquipmentUnderConstructionMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:title="us-gaap_LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_LeaseholdImprovementsMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AssetImpairmentCharges" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_Depreciation" use="optional" priority="0" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentNet" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:title="Presentation : us-gaap_RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="plx_CompensationToTheNon-executiveDirectorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_CompensationToTheNon-executiveDirectorsMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to plx_CompensationToTheNon-executiveDirectorsMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20141231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:label="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to plx_ManagementAndConsultingFeesToChairmanOfBoardMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rpt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-rptt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-cbsp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockParOrStatedValuePerShare" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesIssued" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesAuthorized" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesOutstanding" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details) (Restricted Stock [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">185,709</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">17,834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">3,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Employees [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">970,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">1,394,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">398,375</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">406,666</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">102,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">185,709</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">17,834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">3,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">386,124</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">970,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">1,394,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Open Tax Years) (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IL', window );">ISRAEL [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2011<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IL', window );">ISRAEL [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2014<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2010<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2014<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr>
        <td colspan="3"></td>
      </tr>
      <tr>
        <td colspan="3">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_IL">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_IL</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001144204-15-015672-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-015672-xbrl.zip
M4$L#!!0````(`,>%;$:0,\4/$!<!`+7D$@`0`!P`<&QX+3(P,30Q,C,Q+GAM
M;%54"0`#%?L!517[`55U>`L``00E#@``!#D!``#L76U3XSBV_KY5\Q^\V9F=
MZ2H2XKP#36_10,]2MQLH2$_=N=^$K23:=F2O;!.87W_/D>W$S@LD$"=6HMV9
M76++TM$YC\Z;CZ6/_WH:.L8C%3YS^6G)K%1+!N66:S/>/RV%?IGX%F,EPP\(
MMXGC<GI:>J9^Z5^??OK;Q[^7R^>"DH#:QL.ST1U0XP_&`]*GQN_"#;T#X]8=
M41'=O;J[NC?.B7AP>;F,#S\]"(<=X_\:0`+WCYGO-FIF^[0T"`+O^/!P-!I5
M\';%%?W#6K5:/XQ;E.('',9_O-`:;S\0GR;-PT`L;'UT"'>3AGC#9N.VZ7:M
MP^AFNBE[B6*.C+/&-#S-T#RJR];FT='1H;P[;NJS>0VA6_/P?[]]O;<&=$C*
MTP-8;L@#\9PEWJ=6I>\^'L8WH0^S7JZ:Y;J9/&93-O\1N('-&]GF@(L^(=[X
MD1[Q'R1U\8TYCWC.4V8ZGG`#XK"GBN4.97.S!HT!&(;Q$=EP[,L)WM&>(=ER
M'#Q[@#V?#3T'9RNO#03MG9:@ZW+20^7)MTO&8=1/!#'+Y0%]"@QFGY;.F^W.
M4;T6C3-N07G`@N?XVO@JL_%ZCU%A2%IHAOZ$0>=7_U/Z5`6A`#AJ'?/CX?3#
MR5"'<\:*1_*H8*X],[X4;?!)2LNL`2_'G<=WLCVG>DDNQ5-_F1MUU;C1R)$;
M#5,);L",17`!FA?Y4<.55AUW/[DW]1#E]N21#`N3.^MAH1K+*\/"^NHLK.?)
M0C769(:%C=59V,B-A4=M<!,VS\()9VA_2,<Z:7S#!C*>/(=9+/A&AP\PJ,V@
M7>1[Q;;S^#X`)N#3E_\-@>)S=^B!V\4#_^R)^:5/23.X/G3Y?>!:/Z*^/A[.
M'6)"VN$\VMZEB<W<-#$(L+/C`CRS;1;`@\2Y)<R^XN?$8^`2[:8PCW9<F'<T
M((Q3^Y((#J&3OY-2K%65,$N;XL8V7,6]L##%]6Y!ZMOP;O?.+!4:`=MPSO?'
MEA5:](T=%WT1@HI:GC:[N>,"+(3VWI0P6SLNS,($%;E*<1N)FN)R0V<]-NUC
M%"KW"PC8]51),<+*@DF]OHW4RO[8LD*+7N>1\O=@\GN##@+4*:$=$J;.[NR"
M%'<]45.()5GD]__U7<_T%,.-+IK4=4IH;T6O"W[RM]GYE5Z"`'7J:X>$N>M9
MK,*XT;E)L5.M-=4H^$F;I>I1V:RN9I;PD7S,$K)0V>Q.]]FC-[TS(0CORP41
M+0#/>3J^C3_>^,S<[H`*XM$P8)9_Q2U7>*X@J.5V<T$HF^IY29H]]A<5>R`\
MY5([-F7'7VF?.)>2TJP%N@\??&8S(AC=9A*GVBJ;G7SDI5P2IZ#RFG[[T5KY
M[4=&R.NUC\KE:5!EWH>>YT@U2IPKWG/%4*K-._I(>4BGY$X<ZL=W?G==V[^F
MP7+RWQ7(%2E3@)!3-DD$?A?,.7B^=4#)GG$;0Q0/>_O\C/9]8M*_D@>TY*YX
M'C?1\A_+7]E,T5+R3QI_"2$R#4)!H>$7]H1_+:D$5B'I#OW)[,#?&&?#<*@!
M-P:<LIDM10!'GC3@,H!3-ONV$N`P-Q<&5&@;-X.`EK*)BG'^]=ZB'#Q7=^+5
M)%>Z(W=[DBY:@K&E7)2\1$KJW'6<R(6%)VZ`,]O-2N56JH+R4RX`5D]^>685
M6[L=310BFMS44MQM/[UHHLQU5>ZV!XRB3(=;6_:$-[0^V\I^)*&X4/-<J6UE
M7Y"O%*M^I<2G`]>QKX:><!^EO[2#M=<H4&5#3X4%FNL*5>Z]^<IJ=WSC.[>I
M.'>!?2*T=C;F;"N;,U!9HCFNT7I5N2Q"E"88#ED@-:?T=Z![WJ?<8M2?2/+F
M_%Z_MLH\M)D<<KVJW'ORXF%*OYF:PI1RV3*-J4V:,>4R<.N'1RYJH$@;J:&<
ME4O/*2+G(NUM`7(VE<O8*2+G@IEU]?;$7%K.=]2G1%@#:/&56?`X/>L+NHUT
M3Y$5NGH[8ZH.@()I>O5VUE0=`$4S`;N9+<BD^[7<Y\A]-R/Z0LA]0U&W>IN.
MJB/"0CMMNQF%%T_N!?/5U-ML=&E?[0\Z8)9#(]%S^QMA,'>.)V06`@@%L]WJ
M[5RI,!`V8\S;537V;)EP`[\M!RO7R(<;RE:7G8V(L&?+CB`8#02S`FJOL!/8
M*N-V6>#0F]X5M]DCLT/BI%*>O1[$OP)7W043U`I<X5_Q6\$>02-U!>$^V4*%
MQ;2'U5[9PX)'S%8>"K9=54[!J@&_<RIP^ZW+H>>XSW2KFQL4#7'*9>(+C#B-
MKQE\;>7\NW<Y6\"-6KE6R\6]V,I[KW=Q`T+1HYPV;%)X!T\L)[TFPU3]Z._@
MS@1_4B*Z([<[<$.?<+L[HLXCW3L-5*R@5>&M137*MA(1-Y1+=[T%,/<4)F[O
M`VR*K)P:RN8;--:VJ:*4S1,L!YLO;B@"2I?,#*D-F4*K)^7*M+2<WR+GEK)F
MZ*7\GX?)94S_3>6$I,:A=M<M`A**]8Z_K>Y&8"HB(>4NF#FZ"RUED[R*"S6W
MHY]1J+MHFU40:HY?VK<5WMU-0:$6N.BJW5*N/GIGD%`TYURYBFF5D;"A#(ZZ
M>P?J]^Z;]@F4?8&EH;+AF$#='0\U5%1P2M7=?%'C:\,Y)W6W==1042%1K>XN
MDQI?*D3=ZNYYJ?&UV5B^HVXUQCJAL@=*H=-0UNC@<<U#.CXLZ:MKR2-6I@_(
M\H.;GCR`5#L:8YDK:PB6DGEJMYH+^D@=5^Z"?/GDX<8U&@5C%"C[8DYI%!0K
M_]%I*/M23FD4%,T+4/:%W%(HN*>.PWC_=\JI`">>VV?VD'$&+B$T?J0Q'+2'
M,,&#LN_R=@0/1;,2RKZPVQ$\%,I>F%7U[(5-V?%7VB?.I:1T2O[A@\]L1@33
M0DX)63DC4%`A;R1I9U:;RK[*C)1TESR=A<'`%6/1Q7O/QIF[LZ$;[N01@&95
MW8*X1:*S4%;B^?CJZSH3\OK0HB6PI)S:+@Z6]&%%4UA2W.]?C*7O]UHO;19+
MZE;R;1]+6B]EL&2JN\?;'76`"_8M\.\YM6&D__DY?6?B_N(1V-"'3%ITW>Z`
M7KN\3)^H%6)F8KP)I4Y=CJ&A[,O-W8-&H;*8``UEWWCN'C0*9E#4.Z;ME8*G
MI#Y-ECM%GZ9MM#[N5E!?3ACWJATPVKM,T!=O8KM=[!V5:^W5L(>/='+!WE8.
MCGI7*JQ9KM93BW>=J;#F5M(7[TP,5EOE>C47;G243>84L&:W,-MG9_?F3>]4
MO$;PU!KJG3%;Y"K>C;P*J#74]43N!T30S\2G=MK]E%?].'/R%[6_<YN*E%>"
MV^>!'PON@;"83V]!OC25`L%U^W]4N+<NXP'^@?_>\!QVAYW"W(N?].\F\I1]
M?Y@_\@!QW9'$G@;>^H&G[-<F^0/OFG%Z3Q\I!_AIZ*T?>LHFDG.#'@!-(J\[
M$)1^@8!=:[U\H*=LHGHST)-:3V,O'^PIFPG/'7OW[`F5G@;=^D&G[*=&^8$.
M%=TXM-411F[04[:^<@/0T]8V;_0IF\3/#7UH8L=Z3T-N_9!3-O6?&^3`L9.(
MNV3]`>;S-/)R05Y-O[]8A#S,Y6G$K1]Q^KW%#.+0FY.80T.KX]E\<*=?6TSC
M#C5<DD6!?S3HU@\Z_<)B&G3@RR465NH]C;KUHTY'L#I?/)%'80NY`:DZ\-7E
M4^K`M:ZC95USI0Y:=:2M"[54PJN.T'5UETIXU<&]+@E3"K"ZAE&7]*B$5UWW
MJ.N`%(.LKIK4Q4,JX%276.J*(X7@JM]HZ3(E!6"J7V?IVB95P-K0+[-T090:
M2-4OLG05E1I0[2BG5.,-*(<LP$?E;ELP*09HXQ8#E*;V"'3MT`K\;X2'/6(%
MH:#V31C@OH$WO2M?$.JL'X5Z>^77,%>O=Y3U.E'179-A2L7\+@@/_J1$=$=N
M=^"&/N'V%S<4`<U#Q^WIB='U1E79],]+&P8N,D^^1!6UNRZH-C]TD(_^>%M=
M:'\3#,``4_$(AA;4''1,]7:[*;0HFWW9"[04:M_NNL+[6.X%6@IU`$!=X;T>
M=A4M*1?$S-$%47>;A3T0?"U/P6O[4%S!UW,4O+I[#>R!X/.,-M7]'G&I\ZC/
M73^XZ=T31Q]'G)*YLEI>(9D7*O)KF^H6Q!?Q!(/B1FUMLZ6L*2^\I(NTIH]J
M'76S.6,-?F]13F#R$Z?MN^?R+Q=G9YX'?A=9\K652DX7"*ZA;&*EJ((KK$(^
M:K<;RG[:4\`3\9+;GUT@[:8W#MK.!X2)(5F2D+R\_':Y5E_-R\='&OG`3EGK
MH&&WBIG*(&B-9JK=;FL$K3<A5;"C/+,P2I_*N488=9HM94L$MPFC/R#J8;R?
M'7E^S6)$IB`<V);+CD1**,7BVF)8`LINGZ'@$LAEVQB]!-Z[!+;Q]>W[`\E:
MN;9B((F/U/)AX3;2!N]/F1V5S95."(\>6<L)X2%G$?^^WU],\6Y(B1\*^HGY
M;J-FMH^A1=)1<BO=.?:TJ.=;*J16FAI!:HJ9B>*#U^&0"@)Z8EH5+4U6FA7S
M>TP-=T&Y.V3\Y0%C^<C/'Y89<;;3Y&YJWJ]R+_K<8H%H7B/IU=YOPQFA9/OV
MX,\W]7P5T.&"GM'19W![N7X3`W)!'X(K\+I%B!;@"['HV=`->31:E_3-DA'C
M^X[V9*:_VJ[52P;V)*\@P@V;6FQ('/^T5&Z6/K6.JO(_'P]?&R6B!2G/MK@5
MC%O,`VLGF]U1A\C7YE<P*B,.\-<:@"D6-X]4G#F.*[]3B-R!A/#:&P@?T[U6
MBEYB^!50""@+[J`WF>.T85%;<(/T:3*3^FLSD7!+3>7J^@NHV$JUT5PD@9>&
M7223<Y?#W`+VX-#H3S_Y;`F4`'HO,;F-U\B-U]XTP6:[7FDUC^KSN/_:V$O0
MC*[;'\0)Z1=73/I`!B2$-Z<)CTS?0L14@>8%:%EJW)=P,7?"\J,O,R&WM03`
MQQ8B13:$!,U*N[4(&B^,/$OP!?,MQT4UTP4Z/CO@E"?DM:?):W>.&O72IW\Z
MP0EH:FSVZZ7=)^+^[,RLU1MX'Q??KX8?/#O@._3@Z7*/#)GS;!P;OW;!-_:-
M:SHR[EQP<'\]*?VS'YS\]#?LSTL_<VR852\PIMH?1!<.C'LPX+T38TA$G_%C
MHWIB((UEQM$!@=^,1SUCO]A=AAR?_46C_D^,%'U`7B"'XS"<D.0=&/+*I*\'
M_./ZIGMI=(RR<7YS_<?E7??J\]=+`R_>8Y/#AZ3Q(78^_N&M9Z;RO_5FI=%$
M\C<P:S+T3OYAMJJ[,Z4;#B1X012MF9T#`]U&:#&@!D:%A#\#Z"%$I:!1#6)X
M@CVB@O$<L'BXN`RW9_R<$(0=MHXJU0QW#"##D6:,&Z3?%[0O.TBLCT$BZPS]
M7+L!L@1N.*$-X6JVXX7]+M&I(2+K9@2NG!J+;)SA)4;N5]]P03.426+H#%=:
MN@-C-&#6P!@1WZ#QEZHVSJ07.D[%N.*H$CA$JDC(B`4#V7W,,;P&%.`5M]<#
M0?-^EK-4&BWL#^@BR"&4-.@>XS=L%L.MT3ZY2FXDESHG'Z+ANM#N,^$_Y%1!
MQ'^ZXH?QC<(TN-$5H1\D@QT8UY6SRH$!$PGP.J4'1A_GS)'3.)SD5$7V&#&-
M6)8(D5F1:34(_&,(9#0,EA9-H]+,RN87`Z(*XYD2<6!XY)F`ZC5\.F2$<PCX
M0?TA%H2`^\!W;GPC(`;#;`(/[#0<FS@0)7`OZNJ!PB*1]*8>DI!MI.D>$LE#
M-P/MJ%VGLC,K=P>5$8J0TP#6L6M1:OM&#QI-K9^)=IC?,EFER2(U'I[G+WG$
M%@O\>*&C9DANX5(DMLWP.CSQ,VB>Y978>"6!ZH!E,Z4<6Y7.7"4&Z[(78+Z,
MXM?'R8J<IZ9L<%#D6+A6+/RDV?>E%H2?"9>`"9C/`T8GBR]F0JP+HL5B@[N3
M[4Y>@?Y"PBW48CZP!WPMN`[]HJ+"1C!5<*;^@E^H/6)]-_:P#"Z78)14,'YK
MRI7K?]#+KL!3^K?K8%4V$/"<B!+%RD1B!Q`=S_()A+PK$C.*GK(T!@^ASSCU
MI3+'&^/?-G3)AD-J,U@OH/<]02TJ5^\<U2Q1F6#>&KOJD<GIN6*RM@"D&0.4
M1%K9M17E.Y)%B9__HTG`/+OL31J6S/(T#\!=S_:QV*7XC?XW!&?(06<A,=\S
MI'L89N`S!(MYGB!@D6S(C(JQR]2@F'!$XN?17C&P/B@U2-:G&(%"@07K,%R<
MQ.!1)`O]3+B1[NU`#O:SG/E+3AE,%BXG<L_*)A+<M,!`1'[X\!_PC21[[/^`
MTR$]*U"AO@M0PAT]0,$\A$%$-&@.L/!Q2U`O*".<4>2&1,HGY!YA]M@ET6JE
MP%.Z351%:JD?R:7>RD(6]0X*'RP,I<.T!461<]<`9?(#=48OA-^`*R_ZD,3.
M*H6*`<$,8D9:TF4&C0?$7BSB#PQP3;$#CXBL*8>U_F1!?^/Q(B,7#$B0Z9/A
M-0KX1]4@HG!#T+%;P6:C!2+G1'!=H.(8X$8@TD<'DPL:U(8%X;BC#P:+J'&(
MCVSRP`+#/1^4ST3#S.@X&!,>!W*`2H?BDV:]^DO2=$9)2<J!1`I.A!5-=?Q@
MK0I!`Y%Z&S0Z\&,TH/AA#W(+)0>=^7']Q0?##J4/@@RI5].WDC[*:!5B#X%R
M._;GD:C4(`O,!K:R90C"X]`L+8`8&'XBI)@U*.>A=/,B537Y'<]=ZI]8Q<%]
M/QSB8[^Q#X#Z"<M>=/>`U4A?!"EJ@UYU0F`4@SY>4&!I?S;E<J9N]PP9O`7N
M@=24`,2H>83FU$R0*Y-18=C43"+JJ8_J]Q%3=_XXLHKO"CHD3(96^*;+#AV@
M%YQ'N5N.])23(%""?N2&C@T``YE*A`V)31,9SN,&-`6XAC!<$H[C:.A"A@'6
MQ\CYCUWXJ4DE5D>&=2QXEA<WI/FWI>=M]JC";'`Q]5P'5)1<FW&<#X@![8&Y
M$#=(@3F)2D"^EMOG,H1(%*J,$E`9P+4+6.M2<=?-*!TE%PX&^=-I'`FFXYU'
M`OC9Q/=/2^>A\%TAMT.C(I4LCOAN4<?Q4(?P/F;RY6_?(U;R.R;YP17@[)<M
MD!KQ?"`\^2LF7C8[!N4IAL2)KST2P0BR+W-U1'$/X:F+?B!H8`VFKZ98Y,#"
M+P_F/?L:WPX`6U)"(V8',,11]9=$6F6']M"/J3033^:GO\7,$<G,98AJ$:=,
M'-8'^3ZX0>`.TUGWP)Z3JI^;J0?"1X)XIZ7H_\?@.`SL3'=3S>9W/SU="``B
M.<*$O*=\DO<@)Y?W9;0AZ9[\GD7CU)P`,(`K?EIJS;`AH4XZES&;+9GE?(W`
M$R,&9B258^,?T9M+PX0%Z[L.V,R_LR$Z/@#$S3((-^J:HYI699L"4)A22<M.
M[C`0J9F^?;W%JH>!T6#6ZX#)<F;1BEP7IW[[7KFO&!>H+,%2,?1UHHW;_`^[
M(/JW:X':?F@!=$3TDM_SR6T8T>E%ECNZ&Z_Q*"<9I3*ALV+9CL@VBM'"SW^"
MPKKBO"B4W#?A:QD/Q/K1%V[(;8SX7`'ZQ[(H[?7FNV%IL&!$-94F7F;*4UQ,
M8K4.Q&IKYRCNX2QPD^8Y6897,?(63"2S24]F0;^SK%QE).3%DQ'_>V(L$N]H
MP`):QBA?ANP(]KDTKHOA/R_+U?3L!8;ZJ\+F+3,VIZ>\[NEW.IU9!JS(C3=@
MH2F1MV%1OY2>>O]*4F5.>A7OWBJN'YC5IE['ZW8LY,0VY5:LG4UG454328HV
MYY9")2522=%4+C[&^AV+MT>@\]$:-RF+*(<O89U<B_+PS5S\YW=I[R7UUSMX
MM8JRRU7!F;5VH=1;`9"PHI>_,ZC7"D(KB%E&-1H-K2`VE$TIDI/3Q7J,?)V6
M8JSE=ZF]6J6#52*V&V)9Q>K+>4K[F0OUI%*!74[,VKQS=%`UBQ7]%6#M:/=(
MZPFM)Z:R1,W&D=83&2\I^8GUAJG;F6+5^;^RW^;/^<@^^R5^LIM#M$O]&;>3
M"Y?1RYU4!TC+S*?Z'44^U=?5N47EG:[.U=6Y12@3T-6YNCI75^?JZMRW:@%=
MG:NRW'5U;MZECKHZ5_'JU'V?OZ[.+9!NTM6YNCI7U_7IZMS"5/7IZER]BM5:
MQ;HZ-Q?'0E?GZNK<`K^(WZ/B.UV=J\M/M(+0"D)7Y^KJ7%V=JZON=-6=KL[5
M[I'6$UI/K)0ETM6Y[ZG.G=3COK74]J6SOK[%._5>I,XB.YI_%AD>4]F1QU0N
M/-HMW=O\,N&$5'CL,MD?.9,R2H[^J\ZK"ZZ]<(1>O?2IT^ED3OY;=M!WDCIS
M3&%4POPBJ76SVGP'K7CJ6_KJ34\*(DZSG<LL6T+>S&&$2W#2K+7'I\N],L[J
M!,V<*;@$OR#26HV@!7P=$S%S4N`R7`&/YR6A+3?RS%%_R\`%=.CR(]_&1^U\
M`5V5.E+O0J9B8RIF3O![Y<!!>;9FJS-UMN8+(V5)NH^W*K_IC4_1IN*1673!
MT=8.**Y8P'?C*O=;N1&]%/+,=P3F9L[\6]%L3'<R+I&/"K`7UOXSQPE!J9+H
M[`*:[/2?G`U2?D"&R</+$HXE>[K[>*)F<MR;Z^$!N7!WJKC_E8IX0QK=TU)4
MYJ(+Y&71Q72!O(GN17PM]CRCBVNHFE]#K9&NJS\MH1-1C`+$?#FD"^O7FIY4
MNK#>UH7UTVI@?PKK:WK)[\OD]A#=^K.1O9G<'J+[U<]&]@<`&WR;+'/E*[ZU
MB6+"=CZ%^'X0'8/W2/^?O;_M;MM(\L;A]WO.?@=<WLG&O@[%$."S/<DYBA^R
MWBNQ_;>4F7M>0F!3PA@$.'B0K/GT=U4_``V@28(020%@[VP2B0+1U=55OZJN
MKJ[R$Q(=Z=Q))]^?<=JN90W*#'C&XY@F).WJY/MNS;*&MNZ>9DDSGW^>W5W-
M+L[I/%9.ZV'[5_,9+['L[Y$?G$M?243LT+GC%U7NB1>LZ9$:OQ);TRW??*)X
M%`GK4G[9T;WOXZ:)]Z;CR3/XW&V7@"=0O^,<O@FS>^K:GE<Z9$-5V^I-QL^1
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M4EZ42F<A+^0J3%^2D,B<&``?)JP,U%$I/``C*'OQ6VEOG6L2KM*IE\IRL:G_
M\L4:_?'$":I'/IV$EPI\X=2&NR5\U#T!+Y49*[)")>#6R00\Y70,-O(N\,#%
MC=[_*W'C1VP)K6C^G4YL0Q6SQO7M/JGO]>GS]7MC:EP85_]S^?6]\?;RR\?K
MR]^;XX>=A;-Y\$G:?6F:%7_ZBKO*"*]R8U$VU%_;?_PQPI)MJ\`'\D"73L6R
M07]Z'`95:[S>6/JO-ZZ,X4:&YT9@0T59O4__N'IO_/'_KC&MKV=$+C:SN2+K
MF!7;FO0,:V`.>N+I:^(9E_>`@A17C???G3O$[+[QWG;N6`D_%(VW;,@K,22(
MLQM[,&@<P)N(<0\8W#>03`[-:0'`J/1U?"48D"#WDI`X!!,/`9!=4)9%!!MP
MXI-[('F9X*_X+8_<@I%X-&SA$O?H4S2!T<4&/HX'CRV,FT<ZMU\#L#`X_#L7
M7A\'8=0WKB@_7*SQ"3]0X]N3!=^XLV$5@CA[&7Z84M7?*#_M!8VS0,:;&LC(
MQ%51P%+#X?/2_]G/J@>:(T2TP:2W0>4->Q&L$1[QSU]";(?A?C=^=0,`J]!>
MDR1V':#_H^_TZ7LX2,'O"$^`2%\\G":@@KUBA0M?XILX"T?3-_AW\=OLS2N&
M@O@AA1*&OS<$48I_/P[@=0"'MT8`;PJ!,'!U@01X,B0@;)12GSK&>13-X7Z*
M@>"@+^A;B+'&40%,Y8BL.>S-1F;I[@]_+:/VE@9`:!56NAO!=WR,0IMXKD%X
M="N2QJ&S`RL0)3?_Q&*O\#A^',/6#3Z,W77BV3'#X2OX.WVE.;`H3L-_+X6S
M(<9@9<*-:_N[\3E<N#X62.86B%'$*50,";O&;X9S%T3`8`[[',E[!G$I?SD)
ME((@]VLE0GJ4['428N'FPESQ_218YBV(RPR(C75RF7$#2^*NF`SY(K4>Y!V8
M"0/!F]=`?L1>`H*1P![(`%%8N#'[>K8$^`80)I\LW9@*#*NZG7X+9!Z#_PM\
M,++!?CV*IWF91=F-L!W:T8Y*'GPS6O.ZO4((;MG>/$]!7@C`_@*/6=W?[]R<
M"IX^!.$WP'?*4$X$15%P%WPD?FG015H09*7K9PX,6^N%C1X%[`73Q?$#_R(E
MA'&+^R=LW'59*L5:#U^ZKRH)73OQL.UX?DGA32X(BTXJ`'L.R'IS:]@K]K':
MY&2&9&6#6&<HB>K&)"LOPC7\@LH_M7(QVDX_0H;`5-;6DP$,+5F.!<QM-S3N
M;2\A`A$$X"'.8Z7ZT'40]YB=5:(@/JF`HPQ;@2J;1;Z,!.E0#RQ+K(:>YY$6
M^,SX7]M/T%8RW+%@;<(@N;U3(9)LZ(5HR/*3P5%)DM`1(&&,L+1%DM!TLQK[
MA4KXI]F%6:V6DA-.R:QC.,1N]/.^B//Z9%MSQJYFR<7&]@]2\L<^_1X8R?AS
MPYLZ\*8-<;#FR3G\`Y';(]?(-`>B#-/NC@[P0G4JO7B7O-B;ZB+PVD]<8'9D
MV!Q<=.R=I>(WCI@.H#[)V9G/M/'[A9XI)9$XQ>M_)6`Z<!MD\P8M4;("J7'_
M3?>)GE?=Z8GR/@\ZT`2WY(_8PX&_!2PE(1?TDS4[3BPW=Z"64V'+ZOSR+$E1
M"(O6NGB7WQKWY\4U;0HF%C.9<JPH_G)0:.U2*QVSV$K'E,Q@S;8Y-<N%-[8<
M^#\8&$@"Q\"#BEVW2H3OW=:C!7,J@,WQZ]XW5I`_!7TI^"G+,]B]S$#*?\BY
MZUHXSF5R79/\]]])Z+@1D45[#=).#)J^I=?^7"9W;JU,>)8AW[EH43B7R74-
MP#^D!PLRA-MQYHF+SVCC/?F#K`>?_&FA'9^6FS.87->4XOWWM<LZ"N?\&@WU
MSUH-\YE9=O+*[@>?0MHZ<T_BV\G^MM';?HYWIRCR:##H@2DJ3_SXZ]CR^@SG
M--?S7NGGT_9#S-?_R=;+K!5:KW17%%IV!8:Y*=.D@\K5Z,];!LYIKKI]20<\
M=:MGS6;:3]>*KE>Z<;JN_?16E\9^,C^?O\'K`;5`9#=/CC"=$P9FF[4J^9=?
MTY=+*=7-(K93G#^I5=BH/(?F@]DSGRURV^Q6UR?I2=FLB9['<C9#D5OEZK5E
M:;6F=FHYNZ.ILODNE%0X8:RU+>NNU;C:<F*@U.#_U!/V8["AF3'5DWG4DYXU
M;U8A_6;)O%;N3BUG,Y18>]/-"9#J)-733@$O_)\H(M<`]K>-WE-VK6W8=,^H
M\^R\@4'4!DC#?IY`&X\3=7),ZP_,94RP^L/I,RAQVV7_G.9ZWBO='55_OC!L
MVV7@G.:JK7H'4EY-\,VU6=>*KE>Z>;I^:+-NYC?AVJZW."&V`XK1L"FT<Q'R
M+R\=^S6`PO;SN#O>GM73Q0CJ2L$1#^<;,+OS7MNG7^CHS/3/;_&U8G=W;;5B
MG_'B:\7N[MIJQ3[CQ=>*W=VUU8I]=HM_ROY)`V,V[\_&S]@OZ5"=\5+ZY?Y*
MZZ.QK3CJH;AV16)X/(SOC!O:,`S[*/.N7RM[00J]M/.=P%YFC:=#PCI]K^TP
M=DGTRE@DH<L;K5;N#6:\C!+G3@QOK]?X%=ZNFC6?LF^">_+JV/TP5:T/!ZUN
MAWFR&7WVC?]-O$?#G+`6JL5^N+\&=KB@39[=D#AQ$-)U#F%5%U+/;_A[[N"L
M-U:$3=4M5G/-GT%:L>-YL%RZ#@E9CSO1>C6@/>%38>X;GY<&%;]B$[QB]VE5
M50+1!H^3]$!`B]PH2ECWSCP+?'L%'Y/OQ$EB]Y[DJ;N'P5'D<T-.\F.1?R6V
MUS/@WV%,0F`VJ&%(>PS#5.]A4C:L6!+*&M?#CNOP!'9I,Y(U;[".K=61<LIT
MUMX>U5_JFV[G"+'RB4D7P&C`#0]X=)&LMXX$:^RY#E7A>]YL`P<'KG^$AQ<N
M_`SSH`0D,4@5#=?3F;&>\O>$284-?`S708B$7P/5D<WZN@<XZ;=WV*8&O_,6
M"`L#X)$=L37%SL_8"W%!EK3#/'\O:UT/#\&2("3UY,:(N\4KO\(;UQ5>!&_%
M>3,>X\-YIHEG6(-JF%Q/7H2T6?!WA["N5'WC&M[!6ILC+^5%4ITP5)A+060+
MVB$UJJ9F8*.H6GN+:LDZ5)#5S3VRGPZ8Q\D!N%'`_8WZ\*>UP'\%TLD,NC53
MM,G>COY*B4=]X*@=^`N7RGXO;R?R"%5(L6!BQ5JYX7O72>C<V1')?4=U04)2
M&)5!`0I\9`1BUGI-&V4NC"_P!1<Y3`E^>^>2I?$^18//#`V,!Q<@TT9E9LVV
M>(<M&.@O.:@M9GNC<C"JF/*+MJU4"[DJR2]`"Z#@!7?`JE@8I=;V#=$LJ=`^
M]L$%_+H!I'<<XI&0.H,PRC*!CZD2UX#N^"X`!G$A`'C:@=Y2(^YK":N0WA6E
M![^T3'OD%&>@-HI))-S87ST;,/O*N0L\E`SZK0M</7Q@%2P($`WR<4.83'^G
M@P+S<NMJYAD-FN4A$VY`*!>"`M;U'=_*6I_"7VQ88!L89`-`KQB]KPW88*"\
M+8Q'EWB+HM.4%^@?T,FGUHUF'<$2?U\3:@7N`_#<7<^-'XMOF.3!_(<W1NA&
MWRZ6@-<&[0V+HA=R=N4FV9]-BE]%G4C']-PE_5+D?F?T;`;TX\&@;F:NFYEO
M>O2YFIG?[&QF_ER)1]<E[%0W"X??I*T_M3GJW;YE/`!TY\!QUI]4@,?,G:#F
M4!A0]L=/_[AZ;_SQ_Z[%[\Q/0$Q70,SS!<&.%<UYKAC8(:4L#F)P/A(?/,3@
MUH?WH/>W6A/P&*C#X`01]?S$YH1+W]8^]G:LB#:YT59+W1^IA?&E3^CX8%"7
MQ(V3D%`C^(KY9;7I!FI2^\C<".E%W,$K^0/<G2O97U6F\6ELK!;IC2+MV!%&
MEQSB8K1K"<]*&VQT8U%N$V^SD*2;AHAZ<P)@HTT(2_\]I!I!!1X!=ZO$6TJ)
M[Q4>@Q>7]DLX1NZIT:3T4`_GAQ(.\_<>F;H()WWA8G<]<"<)&/-_@Z.+L6;[
M.ZB!#TX_C3/`%M`G;,]`-U$P?=@=I"S1XOTL]+]CQKZTVQ>QI)SD#(>]^;#:
M3EN]X-FVN0AYPWEO6&@>D$+KS6,60]L0T<I+8ZJD5&5!81Q"%A'?%F-8=+,2
M*>1>-1<:E3R9[#9N[].F*5E27*'R3R+D]YF+H/"-,;@%OP/*XQE7#W"/!\)8
M:)B%76&?=(\^+4;&8(<?1J]/%B_LV+G7YNF(@RIK=,)0I3FH%)$TQT^)2!*/
M.9'P7A>VY[Y`.L6,-@0C4YS+(=NP3DBR%-U_PT)<;@C/R&_?,F7V/E_ZHNW[
M`,]A9(>/8G;91B\]8\G.1^07H1%`+WI+D),13\^`DIL(GL.@;OP0R//8&`@M
MGJ")>"@N^`D"HGE#]I38YUZASPJ1S_FPO,+MCGM&Y8W7O$[<\]"0UVJ\/CCQ
MGP+FQN'N)[_[DBQQ<?^5_>DI.[!L[]4W+C>K!OBN)<W(45LQHK;7EBIJP)Y*
MR^K&W50F.CU8Q4W67SZUK[!CDC=$DNP7MD*=\=P[N!D9UMB,7((_LEIQ7XG%
MS#F:K<%AX#L/D<#G^DL\U(EIW">!Z81R3DSF'X-7A*83G":8,!YPTW?5BTLA
M17;$[7_T'-E]SRV"^BQ0GP461<?><6)5[RSPX`*N>M=&6E+5Y,M?'/G%AIA)
M&K93@,/F7VJ?[VEUW*".IH4#'4D?2W4:\$M&Z4;&GFI[F)<^Y2V'$ST:5I2N
M&QSNF\>3?5Y#V0'C;J\C$%;Q4RK7S5>+&@+/:XPH97X77O.+0S^_8/_=*)N%
MQ]2OWW%CZ2C9KK`H@7]+][&4[NSWG28-I`.$R/_YA665^*"ZI(7N)PEW7]-J
M4NGR'(?^H=[0[\NWSLG"?L6_E'I61T[R#-&:")HX.0]%3!OWGK/6=71.9RC+
M0[WNK9A3(4*DA7J;4(^T`+32/SKPQJ?JZ[+-Q'-1V@+Y>\(6;2/N[#4_0R&'
M1Y[SWWF"00?A9._E?*+$G^*D9'>MEIKP50$@GF]^+5J1%NC%`?RLPT:D3CGY
M#N-=_75MGYH=T.]I,/7-H;C3XJ]AK8/K>H!=H=[Z=%IG/B5XQ-1!C>EB</`<
M!93G_.O5;,6<SMK_Z"R6UE_53D^N`R+;7735,MM5F=4P>UZ3ZX#(:IAM3F!"
M!PZU>A8F'RRU9I[+Y#H@KN(.KU[7<YE<!X168^SY3*X#XJHQ]MPFUP&AU1A[
M/I/K@+AJC-5AD6ZNX_'TL['7<7@Q*:W+YS*Y<Q-P6@Q52\"Y3.[<Q%OC]YE-
M[MP$7./W64WNW,1;X_>93>[<!%SC]Q-"1<:-[7R[#8/$7V#MO2"$E74<0I9+
M=10IWR4#;^7OQ3)1(F\D*N0=DGV?DS@"\</1L)/;#;EU?9^W7L!"PSN%HHX0
MB!D=8T)[A,P4BDU+3=9;GN9-)L0;?/O.9I/,/]RY,;G`(I2THB0B@%2\L3#W
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M5BOV&2^^5NSNKJU6[#->?*W8W5W;DV;D'C4+=SX8]`:#Y[A'WG89T/K=W;7M
MCGY;_>%4:_?)HO?'R[X_133_0Q`N"4Q@8=C^PGC_?>V&.K;?J=A^<W!IW)N-
MG^,:7SN!2;L=Y["VW5'O$;@=EM9NK=UZ;3NHW=:@-];&6ZNW7MM.JO>D/QD\
M1U6<MDN`UN[NKFUWM'LTZEF#YRB\T781T.K=W;7MCGI/^K.A-MXG"_@?+EW_
MX#QXSSM@+HR7__=5O2A^NR+BU82V23TH3H%3]>?;'%";3<S>>-ZL2IT-D(;N
MX_/S*'J'6'5&(&'VAZ.)A@@-$1HB-$2H&36=]\R&%?QN@#!HC-`8H3$B<R-&
M9K/JBS=`%C1$G./LVQT)-8?SWG"FTQ2TMNN5[KZV#_JC9]G]MU,"&GS1X>`\
M*;3T)?[BJ,U\&Z;53]KD6/T94&LL@N3&(V=R,%)QSLU!OF8V)&R`3'0?QI]/
MY3>*?X%CYD;>'IQIQ^RGU!6L:%[#PP;HCL:)(XI^=]AU9E#1S%Z+#9`)#1?:
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MQ>`%%VCZ(_X)UT3\B<^4?AVG.OA!G$J)XRV5?/#'K1\.OZ)8(,VH*J><COGL
M"(1<WQ$C#F+;,X#CH>M'KF/<VUY"\/@K6,=NX$<&2>NZ+9(0+S7%\"T\&XOP
MH`P^?D<<LKHAH3$T>X8U,"WZ[R%MZ@(_C'K&@QT9]GH=!M_=E1T3[]'XBPP(
MHWX^@F``[1Z,W<L_-AQ,2KW#Z"#YEXVFI:=Z1DBB-7%B]QX&[Q<E\S`JM>FW
MIRO<:3%E74,UB]JX0049R?@SPF6XLCU.];T=NC;R)??I`V$V-_=A%(<D=NZ*
MGTI\\%R?7-RIOKN+.3TCDEE_$0=K;O#X!\)>,B=@,Z!L.B^'%ZI/Q,6[7#];
M[.V`,.A;8WAZE]4ZN.C<].NYJP5A__&X?H'R71MI236/+W]Q9/K*KP1$SW6P
M7544!\XWXS8$D87?XL`@J[47/!(2O=[ABQS8>N?DM"REIY>.ZL!RS-EL<#M.
M-M"A<9-[ZT[@>?8Z@G41/Z68V'Q(K8&6?%>Q,X7((<C<W:O&7?2?7[#_;@3:
MPF-B2+$3%')B[M:-(R@8O`O6*_!OJ?M#R<]^WPG-(#@@7SYZT25V/(&U>U5B
M.C)/_@&NJ<(SW9=3716"_3+[M.X=0?>LKJH>;OZTGK5P:@6W30MU7JB'>N7/
M<XYG(=TCO?+:1VJ(R3R#_<FGA&Y)@J4A192N[NR01-U5Q&/N49YR^ZBR:O+#
MI_'@AX-SJE`P[H;<NKZ/OQSV#M*NN/+>!Z+[O+#BL71CSI4ORDROL`+[GRFW
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M_?P/0;@D[AZN?C,N%#Q?#;D371-YQB*1RADV".UJ)PDJ1?<\`/!I^MOR*1]7
M]SO$G$[CACGMS8;U`A(:.#1P:.`X6^"8C7O3FDU#SQ@YGNL01;#:ZC_[YJIP
MF[=&+\&:DVH6.ARG9G?#)GFL8MO-@<$G7:O<(,CG`85/U>>63_H$]?N[PZ#.
MX\A3KGEJ%-$HHE%$HTC\9CB;]$SK,.&<LT*1O8J+;RU>C0_(1:^W=$#0S0-T
M\X"BP#KM;1ZP^5U%X@K=!%A4@#=3P78E8:&10"1W$G#@J<1#X(47+-R0.'$0
MPH_XQ2"^(R&^]=YUB+$.@WL7D/Q$/0?JP\)144&7QM];=9Y89G*7@<QU"CN\
MR?,.5(/[^2JZGI1#QZV&WUY9.$")5ZUG%?1L<AYJ=L#*]ZU>]R[.Z0QE^5`%
M[UN][BV84R$`H(5ZFU`?JLY]!P2@0=[/<5Y7(RZ:7[9MK1].-)46B-^Q>R#5
M6KKC3OGO=*O/<^>[!29[K^83!?[YCDUV4EQ!^QM,?7,H;H'4'\"'.FPL2:/9
M,Z]K^]1,PYJ&-0UK&M9:L>-K`9.;TMOUE'-F?<DZJ#%=#/R=HX#:`%;V+=&K
MV8HYG;7_T5DLK;^JG9Y<!T2VN^BJ9;:K,JMA]KPFUP&1U3#;G,"$#AQJ]2Q,
M/EAJS3R7R75`7,EW$CINI,W)V4RN`T*K,?9\)M<!<=48>VZ3ZX#0:HP]G\EU
M0%PUQNJP2#?7\7CZV=BK-@&K=:!U^5PF=VX"O@Y=1YNJLYG<N8FWQN\SF]RY
M";C&[[.:W+F)M\;O,YO<N0FXQN]3-[IS_07!@GF#<B/+'2P3Q>U&HK;=(=E7
MZ+5P0VY=W\=?]NRX4&M&QYC0'B$SA6)7*V#;DLG4*?VP5ZGBK.QB8>Z'YH/9
MLX:SWF1NE=EP]`5FI8BW3;\9*]_%.3UQY4S\%_^GGF0?@PU_.6]='O>'LU,U
MW6VCS'=Q3N>Q<MW4U[EI]4:6UEBML=KRMEN3IWUK7*\?H];CML[I/%:NF_JJ
M+:_66&UYNZ#)VO(>)>I>L=5QC:#NP7GR]L[V;^'/BR3$Z'I\1VAX_:(>TEW3
MH>1,U+;C5M-F4`M[VMC8[H#G(*V>_1.H-SJOG"U?6ZW89[SX6K&[N[9:L<]X
M\;5B=W=MM6*?\>)KQ>[NVFK%/N/%UXK=W;75BGUVBW_<K/E3*_QOH>V+?B<Z
M(-\XI=*8<F:SU\Y"=]=6*_89+[Y6[.ZNK5;L,UY\K=C=75NMV&>\^%JQN[NV
M)TVX/6J2K36?],S)M#QQ+0-:O\]V;3NDW_W)=*:UNP')]<\;1W[/*UTOC)?_
M]U6]<'V[0M_51+9)M:9.@5+UY]L<2!M:DY[U+"[+YIM!#9"&[J/S\RAZAUAU
M1B`QZ)O-JGO5`%'0"'&.L]>!QS.;_3G-];Q76JOY&2_^.<WUO%=:J_D9+_XY
MS?6\5UJK^=DM_@E*Z#<HE[U0-I_XBZ,6S&^E3&^(O5G]&5!K+(+DQB-G<BA1
M<<[-B3DVL?1@`R2B^S#^?`J_4?@+'#,W\O;@3#MFU<*N($7S2ALV0'<T3AQ1
M]+O#KC.#"NU4:+#03H5V*K13H7&B:3C1'7:=&528/6LPZXT;UAJP`3*AX4+#
MA8:+(K,F?7,XT5!QD!.;%K5?X'=&;)12?5ZCSVNZ!FLZM*)](!U:T:$5'5K1
M.-$TG.@.N\X,*K13H<%".Q7:J=!.A<:)IN%$=]AU9E"AG0H-%MJIT$Z%=BKJ
M'-6(7_$@0_KSPKW/?EL+RE9V>.OZ%W&PAGF],?BO0BX&.[ERS.ENF?@ZFTIN
M7O"+X7AV%/W\XFT21D'X)7#]F(3R`10]X*&MS7]^80X&/[PP'.)Y?'5_?C%X
MP;6#_HA_P@46?^(S3)O"B][H@NVY\[)%X7'K"(W4L<"9457H.1WSV1$(N;XC
M1AS$MF<`QT/7CUS'N+>]A.`I6K".W<"/#)+692LT.<?C-OCT'7'(ZH:$QM#L
M&=;`M(P'.S+L]3H,OKLK.R;>H_$7&4RL_C`W>0-(]6"H_@&59=-O!57"P1C?
MC&O*J$^$E[CLL0]ZQA4)W:70,E2OPZL/O.M&`1LW2FR\"7_:H%+5M*BH.!NT
MA4T(?T:8#%>VQ^=T;X>NC5S+??I`F*W-?1C%(8F=N^*G$I<\UR<7=ZKO[F)=
MSXCDA>%HB`A?Q$.*^IMU?]/Y.+Q0?08NWN7ZV?)MU]T!6#QX^N2XO-BA4?6Z
M'AU#_/=X5Y&X5%&9/*2XM@P\+WB@>(5R'QE1L@+1@/<"V"U1U!#>#"?P'1+Z
M^%P@7_[T%P+XJ-8(,,3/0P*"[3HQ0?8%SC<#X`[PLHB#H]<[G)P#NP4UL`S^
M9UKPO,D%E#I8+J`ZOFD@"_@I/*.J:%9$P:(W4>$U!E7RGU\XY"D8R3UR!R3-
M7D?`#O%3BG_-AT\.43,`1H&<;%,YZ)L2FO*M%/NP(H+R'48>1/.,K[I-?D(1
M5%P46#L8TYH<Q73#,@7^+?Y60@`JGMG?2R)_2#*VPGP]KA\Y$:@>T?(FD/WI
M8-O`3%1F2J"IGV5710<.(N/FZ,@R_GF;(908)AG375JPB<4;.;7GKKXMRI"Q
MR-C%LN.IRF&D<'`B*91<M,.P[,`!I39`AG7DM1)UW65T6`-LD*CAYK&1YJ_5
M,)7*W*CH@6^#K"95P,_-_U-"O3W8^\F&+S.0TJ=5;:7\<9;0+GV8YK:?2&^D
M8?);M^;J;:M5I/E3JBX''5?_O].--RBTK+-@S>W;G*T+R<IV_8)N.S!H:#MQ
M8GORQYZ[W.G(//>J-L@J=]+YU_I5-*^R'>7F5?YHCTW`<Z^8MHP'$/,NSZUC
M*JQ-9-M,Y''KO>ZEI'NE+*G2Y%(5PA.-76>U!R%-CH&I#ID.*1S^3[;Q\FNV
MK;S";>5Q&N<]YTIL/HP^3I7F?5Y_AC6P6R,WAR0M)8.2=M1LB-%\T)M8H_)R
M5%B;IE5G>*IT;<]#:4N2<]-XK`"PO&;@.ZHEDG2[P71=KIP4]$Y"Y*ZUV@R/
M!W)T.K5DS9=\#7(:Y)JD,1KDNJ6=S5>+]O/XR?O4DR!D`QAU+*XT>.][G$DT
M!R&;P(V:2WK,ZHW[L`7II?_=/XXC;KW\L&&^AQ*(RI=MCQBS$K<$Z605L=_C
M!XP&_<'`K!4N:H@X'.;F?#;(\UN4)_<);.ID:O@1F\^?FC7-+BE#?00[&6I-
MS7G/&DR?(\S=7KEK&.F=6@<-<QKFCN&<C>L=Y75IG1JE`!JT-&AIT-*^F?;-
MVCD9#7,:YK1O=OBP<>/3=CL4-7ZV2+%I#8XN\3J91A\EZY3G1A[[-C3E>3B8
M]68US[#:KUP:P#2`:0!K-8!9_8'VJS0L:5C2L-0D6-)^E08P#6`:P%H+8-WQ
MJYJ2U:N#L\T-SLZG5C>$7=M@;8.U#>Z(#9[/Q[W9>%@+F=JO7!K`-(!I`&LU
M@)G]T?'3/+1?I6%)PY*&)>U7:;^J*3S6`*8!3/M5.G=6AV</<A0Q''?D+$);
M86V%M17NB!4>#7J#FH>D[=<MC5\:OS1^M1J_AOV9/O76L*1A2<-2DV!)NU4:
MOS1^:?QJ*WYUQZW2F;,Z-+LS-#O5H5EM@[4-UC:X239X/M";"`U@&L`T@+45
MP/K3L?:K-"QI6-*PU"!8&D]Z5LU<G/;KEL8OC5\:OUJ-7]UQJW3BK([.[H[.
M3G3BK+;"V@IK*]PH*SP<C7N#FH>D[5<N#6`:P#2`M1O`^J.Y]JLT+&E8TK#4
M)%C2?I4&,`U@&L!:"V"=\:MTZJP.SNZ2]8'N"*9ML+;!V@8WR@:/=>:LQB^-
M7QJ_6HI?P[ZIW2H-2QJ6-"PU"9:T6Z7Q2^.7QJ^VXE=WW"J=.:N#L[NE7=<U
MT%986V%MA9MEA4V]C=``I@%,`UA;`6S>'T^T7Z5A2<.2AJ4&P=*%]J@T=&GH
MTM#5/NCJCD>E<V9U6';'(6J_;O"C">NO;7`C9J!M<'.EOZ4VV.Q-!S,=F-40
MIB%,0U@[(<SJ3SJRC="PI&%)PU)'8$E[5AK"-(1I"&LQA'7'L]*9LSI$NVOF
MD_ZL*XGBV@IK*ZRM<$>LL,Z<U0"F`4P#6&L!;-R9"W@:EC0L:5CJ""QIOTH#
MF`8P#6"M!;#N^%4Z?U8'9W<%9^<Z?U;;8&V#M0UNE`V>S\W>W*QW2MI^Y=(`
MI@%,`UBK`6S4']9KN].:A=&PI&%)PU++8&EFS7M6S98Z[5<N#6`:P#2`M1K`
MNN-7Z=Q9'9[=-?-I?SS6X5EMA;45UE:X2588UD+G>&@`TP"F`:R=`#;NS!4\
M#4L:EC0L=026M%^E`4P#F`:PU@)8=_PJG3NK@[,[<M1`UG5P5MM@;8.U#6Z2
M#9[H\F@:OS1^:?QJ*7Z-^[.A=JLT+&E8TK#4(%C2;I7&+XU?&K_:BE_=<:MT
MYJP.SNX^2>U/NU[9H%TFK9I1O@G"!0DO&!=!4P?T_PQS#3,(/'=A_!]WM0["
MV/;C9D^WH@6O/]^.F_LG,*91*GFB>9P06H>S:6\\JG<+I_U>>MOHU1"L(;C9
MT*4A>'_OMC^O=X=['_3"A:#_K<\)[=-J0-6`J@&U\8"J?=HVT:LA6$-PLZ%+
M0_`9^K1=3QEOXMF!CN&WQMA:_1E0:RR"Y,8C9V)P*\[Y/(UN5>8T2CU/.)=3
M%AKJC2;CWL`:ZQU0*^AM/\=UME,G')1#`%K'6=0`:=,^G/;AVN/W:!^N7H)G
M;V9.>_/92/MPK:"W_1S7/EPG')1S\N'2&*WXU0:LE_Z\<.^SW];R-)A(&==T
M#NG=EQ[[H&=<D=!=OC%6=GCK`NF#TPKH^M!$WX0_J5[>9/Y<WQ'#OKT-R:T=
M$\/UX]#U(]<Q[FTO(4:P-&)X(`YBVS.")([`LJ/\&,$Z=@,_,N!7(R01?,N)
M"0IPX'RC'^(WZ;?NX:_P%_R,?">AXT8H/-D+(GST'7'(ZH:$QM#L&=;`'!DN
M_&F]#H/O[@H(\QZ-O\@>P+"?+YACP%0]>!\=)O>DU9\JG^PAV6OBQ.X]O+U_
M-.&@_S/[UMCUWQ@4^EU_0?`U%P/VZ7.)/`BEX7AV%/W\XFT21D'X)8#E)Z%\
MDD*7RB&>QW'CYQ>#%_1WA!7Q>XYD_!GA)ES9'J?ZW@Y=&V><^_2!,`C*?0B"
M1&+GKOBIQ`?/]<G%G>J[NYC3,R)Y;2[B8,T1E'\@/%MF9-U%?(>##GX09TN[
MCJC@A>IC*/$N>;$W0#]_E(O&+L?@X*)#%(KP]+N-!Q?P_=Y5)"[5528/*0PN
M`\\+'A#=F-P#4"0@D``_$45!LEP"7B!<17=V2"YN[`B`S0E6:^)'-L*9`?^/
M3P),QF0%6HX/!VL2TK]&KW?L,3:R_63V%['*@N>5@#5H*E@536^.'<5?U*\1
M/I!#G@*!?(OL@"#9ZPC8(7Y*X:WYZ,@1:`:X)X"1[1\&?5,"2^Y`L@\K`B3W
M3)48*>^*V"+LN[/C/N[/+]A_-R)MX;&&;(3A7;"\@7]+G11*=_;[3E#.3OP'
M)3X\A<--R@#+<>@?Q`X-`L"TR/F.^_*M!;)0`,BJD]LOK69S]@R'+!=<>=<Y
ME$H>BE,O_^Q?]8T%@FP8P>8%C&^01+`'B%YU8>GKPX!U'B@`.T5+J_RY3.X,
MI7NH!>!<)G>&TCW2`G":ZBSY;3SNXO8\<6)[PJF(A1V2?6^#B(9)0G)/_(1$
M]0)0%6<@3^`H!XPX_YJY\BH:#\7DRB5MGGPX66?&9G'*AYZ^93U'"3IV"'OJ
MI3[NB6Q;YG0>*_=$;=T]S9)F/O\\N[N:79S3>:R<UL/VK^8Q[R&6^?9$C_S@
M7/I*(F*'SAU-H%B`*^X%:WJ`2;[CZ69=MWSSN?!QTOM:GAMW4N_[J![WJ#<=
MU^MI==X2\`3J=V0]-&%V3UW;3>)=8)"Y41#.9&-]W,UT;S)^EAN/6K6U:FO5
M/J9JSX?:9I]LO[`[8M_H'<,?=OB-Q/#^GO$;\4EH>W3O8"]6KN_2M$GWGCQQ
M^W#RHYQ&%]5JI9H\5T&NQF"JU9M.G\-=VAQM:8`L=-\\:(C0$%&5469O-'R.
M^\<:(AHH]QHB-$24&34</,?.K($`T9ARD0W0A;;1>^J".F<65#IE@99C8MVT
M-QV;&NVT.Z1Q0N/$UC/FP:Q>\6N-$QHG-$Z<"TZ8/>M9FI0T$"=.5\CI%*4C
MX%TWBMG?J)?XH`5]5-5\<L5\CEX*JB(=!V>VTY?87?&G+P`5KD//!\W1Z-+X
MO%S";/S;Z%3K-9VMBT>H%Y;9'\*G)]7%ML[)K+'HV4^??>,#N0D3.WPT+(L6
M^()_8Z&<M\%J;?N/AAM%"2\2%@7>PI!-P;AG3L>]0:$O-:O!0XN'P4M6@6]<
MT=IC+M8`,Q)@2/@0NG%,?&/-I"_@0F?8L6$;Z]!UL+`9)2-](E\[;-POE'8W
MUB1D`_<-K!CDDQA>%#B$+"+Q+C&E!Q*2;27,K'$_'_-/:YB]Q-<"+>DDD&@'
M)@E<2HNN(<=L'Z;@!%$<E4@W^S/ERU]MKG360K'LHJI93U6U*[*.64$4<T9U
M;9C7-2Q8Y1%:DP^UX![K_J6Z`7(DB]&H/\ZKW0_P=9]Z=NC\^0'6QEHD!(>9
M*71B"1.D@XL!>J"@CI?0&H+J)WF10*Q%:"P3SS-N'NGGK@^*8'N@JZ%S9T<P
M/:#51=&GE011_<2?$`'0#\//X1LYQ9CW!VJM0^!(ZR`"7WS'76-.RRI(6!TO
M).(33KC'=#OWVLED@\*EVJR<PX_`/3=RZ!"HU9F6\R**?%E$&@WXEX^T(!5G
M"E_35WU8=9BV%P641&.VO:"A\$+^^E,27=S:]OHU!<\[@%X21N__E;CQ([[G
M'=#F!5$2DFN0_5\]>.:7__P/P_AK^C7$PE^Q#MI;J0S:91C:_BTM@/;K8_;(
M%_L1/[I\L,/%9U;^\3=X,(X^^E]@FL'BMS"((L-=_/SBVKZU)MC(R$>E^TJ6
M/[]X.YX-IL/9"X!%EWU"WQR],!;$`83UHI]??/STX<4O([I-D:9V>!I/QX2I
M@@FCP6XFF&:7N#!3<<':S85YEY@P5S%AM)L)5GL4@O[K;R1"CX>]W133'P[4
M</#+E^$_#C`UQ<@GF).IUNY?OHS:.R=+K:O'GM/:^U[_K52BWX'A_V"[X=]H
MY6,QG:%*[.:2UOUY]4Y6N8LA:)PUFU&-.S!1QYWI2+5PYO:93JRYU;Z9CDLS
M'0YG.]84[.FTR3/%;_EQ:#MQ8GO7)%RELU7Y450AS<$_#C&=TL@*D+G9_?*;
MXLO??U^[K'`N4_1T0F6?R`1W1TSHX..>S,(/RVX.G5A;W!Q&W642WP4A['T7
M?V+\@FXLV'N_>+8?O>?;NR\8?_F*!/VY7I.0_O2[NW+CE!ME?Z?`#=!2H)".
M*K,$1-OJ#Z>[V'$8:H]O4$=EQX>+>X,-ZJ<$`Q"?EQ_]*+8]#S^//@1A;IQT
M@F4OJ+#0'V.RDE<8)F].G@A=52@L+"[*QD<:J'R7A.E#%,6_IBT0Z%,<'"7=
M'I7<HNELOM6ZCE_\,IL4%;L."?E9O%^MO>"1D"L2WH-,J_GW"6,\V+:!OB6Z
MQD8.\M^Q9M>G(/X'`=*=X-9'_4EG6O*88*;H1FV;J5G<HQR-S!-Q@RT,"!3_
M")_+5+KD:J$P#-&"_>,$+%#2EN?+%QZ6^Q`&*PD34SS,5KOL2PVFDRUR#;H[
MG.>6>N=8AS7`G[,N)@P#TJFH'*5)A2C#Q!R9@^$![6^)Q*-QX.^T5#Q(SST)
M[5N2,W<I7U0QJ!Q?-AAB$.AA?SP9'H4QVR@_E<"HPE*3X6Z!&5OCX7@Z[ZS`
MJ")5DV%%@9E;G168L2J&-:D0PAN;8]B@SKHJ,&-5'"S'EZT",S9;+C!;]H1C
M53AM,FG-GE`:(-IKA$IRHPK.Y9BS66YPB[@/>PY'_6%E!]RX)7'C!/>ROA2[
M2$E)F:6*[^4\M4WG!^/9^(#0LY/@$_.GDJ!5\7(W"-H(!,TZ(?N:*'I*SWI<
M0?0&X[,7/:7W/:XD>I/^9'!`9ZJ5HJ?TT2O8S]'(&AS0KVBEZ"G]^&KF==*?
M#1LJ>NH8&A.#K;&.B=)]KV!!9Q-S/!_N#.-M(>'`KI9X[U[B,%%ZZ=6,H-D?
MCB8']+;VFL#!UE_IBU<P8].Y:;5_^97.=C5#9/9'YCYVO)G+KW2@*Y@2<S@?
MSF:M7W^E#US-&@SZH\:H_[&".Q.EDSNM$-R930?#06>C@1.E`SNM&-R9[K5)
M;V)PYWW6]+P@,'7#QR/8D8]&!W1.2R0>C0.5!.9)X>.#>NT5*3^1P$SKAH]'
M>$(U.N!&NED",WU2^'@\[Z[`*!W6"B9I-!^,Q^,#FJ2&"8S2E:UJDN:'W-@^
MI\!D[A--&_CHQ^",1JZ32Y:<[@P;*](Y1K,#GSY4H?@9>:1TC<?;DR`&DW/B
MD-(YGFSET&@T;2N'V`TJ3"T+$[J?^1S?D?#ZSO8Y+6G:3@&P5;[R5!5A^AZY
MKWW7^_D%C``0]=-S$Z[T9>>5]L:PS(=P3?8E_;DYIO1R*UQOFT\'5J<9EC])
M%?R:J9S?:87L+'-\*%NT)^6GXM??Z!J5^*5RBBOQ"\5K=`IVY0E_9G:I7.5I
MA=S[T6`"_W=V[%)YT-,*L8OA?#:<CKO++GY0I>"8RH^NHH_#$Z%]B?+G9YG*
MK:ZBD^9T-CP)@C609RI'NXIBFK/Q]"!!Z.8R;8,G-E,ZW17":L/9Q+1.(F?'
M\<1VG6C,RD[]<&16"!^9%K!F?L"DIV:=:,S*KGN!+YO#1^/^<'8(\]?(_.9Y
MV4<'QE39TX`>6<=A2P/D95YVQ0MLV2POT[YUR#ALP^2E['0#8RI$#3HN+V7G
MNL"6;LO+EG3X>=F+'HX&%4R2-9^8DYUW@MN=#C]7U#7(,V=;.OQD>L@,G=KI
M\+73<^9ESQ=F7P%,AM;$RHE&*]-SYF4OMC#]S=?E!WUS'V>MC=DY<Y4O:U79
M2\+V>]Q=7W:N\F6M"E46:(ZO.3Q$Y*N1V3GFH"G.;+/.SLU!<[S99F5;F(.F
MN+--DYCF^+--DQB5.UO%*G5=8E2>;$6KU"&)J91:80YV.KZ*#!UKV-`,'2;P
M>Y=E$N5\)">"$Y;QJ>PA6Y4V"*/Y8+([SGMPPD]?<LL<E+UDP)EJ2#WH#W:G
MWAZ&WF>6H[++;(VJE&F;FG-K<*RZ9'O)T<V!!BT/5L#(KV1ENS[\N5`BT$JY
M:9;=;"IROWR9_&&.WNVJYW=RPD\@>Y+)*<J>67:^&R1[9<*/*'OEP?:7O;+#
M?@+9JT_X,U@$L^R[6Z-A-4\,PTH[/8PN6`2S[,:#5E:X&#P<S&9',YJMM0AE
MYY^*W"]?K)WE7<_-')1=_P8)7NO,@6J#<%S!:Y<M4.T.AM4*``SZ\]U5<#IA
M"Y2[@RJ]*N;CV7CGS:(SLP66:G<`(H>54L=_S/3V("]\EG)[T!3A:YL]L%3;
M@^,+7ZML@J7<'U0K#FOUA^.SV!]8ROU!E9O^56*TYV82E-L#BS8"FO]AC;5-
M*`B?<H_0$.%KG4E0;A&.+WSML@G*?4*U`AZ5RK)VPB8H]PD5;AU4*^Q[9D9!
MT1V.BMPO7^:@E]HBY$1/T7:NFNB-)];1'+:V6@1%O[OC2UZKS(&BA9XULJHE
MC%G]R7EL$13=]T`G*]26'([&@]FQ(FNM-0>J/8+%FH6._[`F>H]0D#[E'J$I
MTM<ZDZ#:))Q`^MIE%92;A*I%VP;G<;"LZ($(>EFAY.Q8[Q%*:JEHI$@E#M72
M_$/;A(+L*=HR-D?VVF82RNT?3R)[K;((Y<:1R*-J!<:'YQ(V*K>.1*VL4I-!
MFP2%6BK/$L9T\S[YP[*T32A(GW*?H)*^"O4)GQ_DLGDIP_K'EX-VX;/28Z_6
M`&#</Q[X-`N?E1Y[A5NCYG0PTP!=5$Q%QTPJ<YB2-_W#T@E`!?%3=-)LDOBU
MS6U7=-\\B?BURBXHNG`"DZJ5'9GT9^99V`5%]TVKTMUP[;>K]%+IMT]!+\<Z
ME*.P"DJWO2G"USJCH-PL'%WXVF43E'N%:F>^D_[\//8*BOZ:5K7J#W-S;NZL
MO'-F-D'1G9.*W"]?1O\8ZKS0DE%0M/.L)GTS:VZ-=E;8.#.CH.@->A+I:Y55
M4+00!295+00T/H],($6;4=#+"G<ZS8G>*93U4KE3F%-G30>0%%9!M55HC/2U
MSBHHMPK'E[YV60757F%4K<3$O#^9G(=54.X5*MSLG.A3A9):*AJI4HE#M9S_
M8<VU4<@+GZ+!:G.$KVTV0=&4]23"URJ;H.C0"DRJ5FK"G/2GYQ%`4O1F!;VL
MTH5K-AV/]*6!@F*JM@HC=MW?-/6M@;)94.X5FB)^K;,+JKW"*<2OD8:A"OJ5
M]@W3V7Q80?RFH\EXL+MZ\BG@[Y3:6MI!5&37>`;?W=T1]%G4M5R?F#ZRO8YS
MOBBQF7)(T6+6VEE(>3A1W<<^"J&'94B^/^8'VPV+[%!TD)V-K.WLL*8'9L<F
M,O/,N/2\P+'A0;5LOO^./V8ELU7=7F>CX9:IX5U4*S^S:F,^C4Y%F]79:+2=
MSM%T/#DYH8KNIK/1>`=#)^/QR0E5]!2=C;8THD="Y\/3,U31QW,VFNY@Z'1Z
M>H8JNF?.1K/MA)JCX>CDA"I:U,]&V]`=[Y4,3K_R*CM=W/H6Z82%-T]-:+G;
M(Q*ZS3X@.`UF\Y,36C)D2.@.M,<&&T\FE+H_FUJ)?2(/]$^9BU;NASB?C2=5
MKMR9!<6O-G"!6!M<KR7])G7/1'@E(T_5]-NJ4.O-P@L`.8=[PU!Y@KZ$@4/(
M(OH0!BLDV/8=^!8P?07>)GXWHZQD?HJ,4[DJXU'!5]DY8($^YJU$?";B&V^#
M*);6M&1P*I!FSHJ4;1FJ"M.`R_<@N^"#.]3IRL@KV1DD;YN=`?(FDQ)]E49E
ME*Z][Z^OG#NR2%`(N)MWZ2^^@J<'PH`:AG-D+03)XAH]X6N@[U<OM^0EN\.4
M^I?_]N(W"_<>'_SQ_>+6#J\N+TUK.,*_(]$_&E'\Z)&?7RSAVQ=+>^5ZC\9K
MX\=K=P6J"+IA?`U6MO_CFQ?_?1N_P;?A@XHO*;[3,^@G/2,"=5N^,>C3$>R&
M7AOF8!VS5_Y*O.#!<"/#-F*<FQ$EJY4->R904\/V/"-8&O$=,0*^@8,]I!&F
MO`%"D`VWR)S(B`.#K-9>\$B`CF40&L1V[HQ'8H?B+?%=2,@%_63-.H43V)@M
MC'<$U@1[$0W-GF$-S-%KG.I/2#$2^9__(?CH>'8$Z_XV":,@_!*XP/+P1?8(
MFX)#/&]M+W"S^_,+M`OP>[2V'?$[Y]Y-$,*F\,()/,]>1\`5\9-@%3[VVO"#
M$(2-?W8/K(&Y%CY]H"&*PH?`(Q([=\5/,_X;GNN3BSO5=],UC>F:^K"F(5_3
M.+>F#^XBAB%FY@]O#%BV6]>_\,@27F<"Q+G^&\X;SIU03/V>A+'KV-Z%[;FW
M_FOC)HCC8/5&YN0"V0%<\Q$Q@;J'T%[__(+]-V4A"KQXAT-P,=X8G*WLE:^-
M_Z+*.3#,-8AMX+D+X_^XJW40QL#&-P9?IM?&8/U]BXS+7*O$H.Q=L`R!?XN_
M_8,)(GYX$_Z$GS#!I:*6/9:3//I+O,CQ90,OMM-UVJD:'9S3?]NK]9O_,B>#
M-_M.KFN"_"GH(Z!R2);E&3`W`V?Y#Q).LS]HX3B'R75-\D7$5A;M-?KL!HW@
MZ;4_E\G5%.Q=DV^LX&/@&3URYC5K43B7R74-P/'(Q+C',Q,9PNTX\\3%9R__
M[%_UY0\6N#L+(\/UY4_CNR")8%,:O=)R<RZ3ZYI2O/^^=D,:M\WY-1KJ<Y/[
M*0ZEF>X*91@WMO/M-@P2?X$1GB"$!7<<0I;+0I1#(3`80=GM*QR997DF;5MR
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M*E>O+4NK-;53R]D=397-]^C98JUM67>MQM66$P.E!O^GGK`?@PW-C*F>S*.>
M]*RY8F^JE5LK=Q>7LQE*K+WIY@1(=9+J::>`E\U/%)%K`/O;1N_^'&]2DO\I
MM*/^?)MSJ#YO8!"U`=*PGR?0QN-$G1S3^@-S&1.L_G#Z#$K<=MD_I[F>]TIW
M1]6?+PS;=ADXI[EJJ]Z!E%<3?'-MUK6BZY5NGJX?VJR;^4VXMNLM3HCM@&(T
M;`KM7(3\RTO'?@V@L/T\[HZW9_5T,8*Z4G#$P_D&S.Z\U_;I%SHZ,_WS6WRM
MV-U=6ZW89[SX6K&[N[9:L<]X\;5B=W=MM6*?W>*G85;Q*_;YD?Z\<.^SW]8R
M98PHHZ#%:6ND*]9&A[7.`0;1_\WF_=E8-$@ZU737!YR`W/P'7\A+"A?'$6S[
MZT]/ZH)5:-R6OF9#9]ZL"6]TZ<3NO1L_;NJJI>JIW(JN6J+=,6^XDNN,I5M;
M;=648FLK<R#R^6NVL:H8!B]6SMZ$PBTHL+UW]Z>LH/J9M-.@K<#*K>?VY5OG
M9&&_X\R=IY95Y23/$*V)H(F3\U#$M!31.6M=1^=TAK(\U.O>BCD5-F):J+<)
M]4@+0"O]HP-O?*J^;DMWIA-1V@+Y>\(6;2/N[!<&5,CAD>?\=QH.Z&3[V;V7
M\XD2WXSH<TWXJ@`0SS>_%JU("_3B`'[682-2IYQ\A_&N_KJV3\T.Z/<TF/KF
M4-QI\=>PUL%U/<"N4&]].JTSGQ(\8NJ@QG0Q.'B.`FH#6-FW1*]F*^9TUOY'
M9[&T_JIV>G(=$-GNHJN6V:[*K(;9\YI<!T16PVQS`A,Z<*C5LS#Y8*DU\UPF
MUP%Q)=])Z+B1-B=G,[D."*W&V/.97`?$56/LN4VN`T*K,?9\)M<!<=48J\,B
MW5S'X^EG8Z_C!*RP@-;E<YG<N0GX.G0=;:K.9G+G)MX:O\]L<N<FX!J_SVIR
MYR;>&K_/;'+G)N`:OP_;WV=W/W?77Q`LNS<HUY[=P3)1(F]TC([WGY,X`O'#
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MO-%V$=#JW=VU[8YZ3_JSH3;>)POX'RY=_^`\>,\[8"Z,E__W5;TH?KLBXM6$
MMDD]*$Z!4_7GVQQ0FTW,WGC>K$J=#9"&[N/S\RAZAUAU1B!A]H>CB88(#1$:
M(C1$J!DUG??,AA7\;H`P:(S0&*$Q(G,C1F:SZHLW0!8T1)SC[-L="36'\]YP
MIM,4M+;KE>Z^M@_ZHV?9_;=3`AI\T>'@/"FT]"7^XJC-?!NFU4_:Y%C]&5!K
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M'MF(7_$X0_KSPKW/?EO+E#&BC&M*Q2?"RP3VV`<]XXJ$[O*-L;+#6Q>8-:#_
ML\S^$">2:Q-R88[Z%GR:\N`F_"FE=9V-GB,%?C$<SXZBGU^\3<(H"+\$KA^3
M4#XYHB<S#^XBOOOYA3D8_/#"<(CG\07Y^<7@!1=H^B/^"==$_(G/E'X=ISKX
M09Q*B>,ME7SPQZT?#K^B6"#-J"JGG([Y[`B$7-\1(PYBVS.`XZ'K1ZYCW-M>
M0O#X*UC';N!'!DGKNBV2$"\UQ?`M/!N+\*`,/GY''+*Z(:$Q-'N&-3`M^N\A
M;>H"/XQZQH,=&?9Z'0;?W94=$^_1^(L,"*-^/H)@`.T>C-W+/S8<3$J]P^@@
M^9>-IJ6G>D9(HC5Q8O<>!N\7)?,P*J7^[:\_)='%K6VO7U\Y=V21>.3S\NK.
M#LFO-K#T;;!:$S^RD=-7<>!\^\R8?HFDNO'C-0YX#2KVJP=__.4__\,P_KKA
M?3?%]WTE$:RI$Y,%??.EORA\\J?OQAM&,MS%SR^N[5MS/@=]`O;`'[Z2)6CH
M>#J;CX8O?A&:"P_^^'YQ:X=7EY>F-1SAW]&4_*AP6HS7>]4B366X^)T4F2*&
M3$45H*_,)@LOQ2G=AF#(X+<X,,AJ[06/A$2O<^M?@$8&>!=QL`;0$_B7FLS!
M3H.Q"P5/-E!EA"V"Z@8DY<Z#$WB>O8Z`Z^(GL13X&!K$<&5[_+-[.W1MM!&Y
M3Q\(\ZIR'\*ZD=BY*WXJ09SG^N3B3O7=7;B7RLP6:[`CV6%G1H-#D+F[5XU[
M##^_8/]]L<D0%!X30PK'5,B)N1O\C^"<P+M@O0+_EJ(Q)3_[?:>-`\$!^?+1
MJ)?8\036[E48YL@\^0=82H6AW)=3716"_1*-M.X=0?>LKJH>^J):SUHXM<*6
M5PMU7JB'>N7/<XYG(=TCO?+:1VJ(R3R#_<FGA&Y)@J4A14QH1"GJKB(><X_R
ME,L0E563Q\+'@Q\.SJE"_:H;<NOZ/OYRV"L1&^&D[OG,/B^L>$K6F&.NBS+3
MCW+$U>XSXV[/[MQ6L\WZ:O:&\U%O.CA59FR[5[K;LSNWU6RSWLZG@YZEM;8!
ME5R;X`F_O;/]6_AS(>_A=3U<V^/DN[G8U#":*^)+&Q7MW(!%-[[MYFIJ=>WX
M?+6Z=FDUM;IV<K[G%<+^C:5Z:C^]*32W+0Y@]L:#02F-7$.*]@"ZOYK:`^CX
M?+6Z=FDUM;IV<KZGCK/GIVZ.^_-QE32=8WKQ?R.1=N(;1'/KG/B!U1O,1MJ%
MUS[!F:UFF[5V-)CT)I-3M59M]SIKK>W2:K99:X?S66\X'6NM/9Y#OW<$7IEW
MWT`__T,0+HF[AZO?C`L%SU?2ZD371)ZQ9IURA@U"N]I)@DK1/0\`?)K^MGS*
MQ]7]#C&GT[AA3GNS8;V`A`8.#1P:.,X6.&;CWK1F#\,S1H[G.D01K+;ZS[ZY
M*MSFK=':K.:DFH4.QRDAW+!)'JOV;W-@\$G7*C<(\GE`X5/UN>63/D$Y\>XP
MJ/,X\I1KGAI%-(IH%-$H$K\9SB8]TSI,..>L4&2OLNI;BU?C`W+1Z_U*L!^T
M9'JA.+NRQ/ME&.*-\A5L%W]]S![Y8C_B1Y</=KC@!>#I#9;HH_^%A&ZP^"T,
MHDC49+<&@V)-]ME@.C%?&`E01S]AY;M>&-\C][7O>J"784)>&#]M+2!/2?DM
M"!81S/M3X(LBZ5<DO'<=$ET#29'M('E`?+)>>RX)2Q7CK8'Y?!7C-\MM\26%
M$O)LJ\P;'F!+@;!0/3Z2R\?#]*+$0S2"%RS<D#AQ$,*/^,4@OB,AOA5Y9JS#
MX-X%>%,6FM=EV8]>EGV[$#RYQ.$N<,XUS3D\W'H'JO_\?-5$3\JAXU9B;Z\L
M'*"\J-:S"GHV.0\U.V#5]5:O>Q?G=(:R?*ABZZU>]Q;,J;#YU$*]3:@/56.]
M`P+0(._G.*^K$9/++]NVM@,GFDH+Q._8_7=J+=UQI_QWNM7G>=O=`I.]5_.)
M`O]\(?N=%%?0_@93WQR*6R#U!_"A#AM+TFCVS.O:/C73L*9A3<.:AK56[/A:
MP.2F]!4]Y9Q93ZP.:DP7`W_G**`V@)5]2_1JMF).9^U_=!9+ZZ]JIR?7`9'M
M+KIJF>VJS&J8/:_)=4!D-<PV)S"A`X=:/0N3#Y9:,\]E<AT05_*=A(X;:7-R
M-I/K@-!JC#V?R75`7#7&GMOD.B"T&F//9W(=$%>-L3HLTLUU/)Y^-O:J3<!*
M"FA=/I?)G9N`KT/7T:;J;"9W;N*M\?O,)G=N`J[Q^ZPF=V[BK?'[S"9W;@*N
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MOLV!M*$UZ5G/XK)LOAG4`&GH/CH_CZ)WB%5G!!*#OMFLNE<-$`6-$.<X>QUX
M/+/9G]-<SWNEM9J?\>*?TUS/>Z6UFI_QXI_37,][I;6:G]WBGZ"$?H-RV0ME
M\XF_.&K!_%;*](;8F]6?`;7&(DAN/'(FAQ(5Y]R<F&,32P\V0"*Z#^//I_`;
MA;_`,7,C;P_.M&-6+>P*4C2OM&$#=$?CQ!%%OSOL.C.HT$Z%!@OM5&BG0CL5
M&B>:AA/=8=>90879LP:SWKAAK0$;(!,:+C1<:+@H,FO2-X<3#14'.;%I4?L%
M?F?$1BG5YS7ZO*9KL*9#*]H'TJ$5'5K1H16-$TW#B>ZPZ\R@0CL5&BRT4Z&=
M"NU4:)QH&DYTAUUG!A7:J=!@H9T*[51HIZ+.48WX%0\RI#\OW/OLM[6@;&6'
MMZY_$0=KF-<;@_\JY&*PDRO'G.Z6B:^SJ>3F!;\8CF='T<\OWB9A%(1?`M>/
M22@?0-$#'MK:_.<7YF#PPPO#(9['5_?G%X,77#OHC_@G7&#Q)S[#M"F\Z(TN
MV)X[+UL4'K>.T$@="YP9586>TS&?'8&0ZSMBQ$%L>P9P/'3]R'6,>]M+")ZB
M!>O8#?S((&E=MD*3<SQN@T_?$8>L;DAH#,V>80U,RWBP(\->K\/@N[NR8^(]
M&G^1P<3J#W.3-X!4#X;J'U!9U+_]]:<DNKBU[?7K*^>.+!*/?%Y>W=DA^=6&
M^?T6!(OHTE]\"GRR6GO!(R%7)+QW'1)=A[8?V0XRY-?'JV2]]EP27@,<_>H%
MSK=?_O,_#..OVU[]-EBM";P!7T`_C2Z3^"X(8=D6?P(7PZL8WO.9<OR+!V/]
M^BC*X7T)@8"OV&4^'<]P%S^_N+9OK8$%T@[\@C]\)4O0G_%T-A\-7_PB]`H>
M_/']XM8.KRXO36LXPK^CU?A1X9\8KP]4Y[/XDIY!/^D9$0G=929YR\#S@@<J
M4;B4D1$E*P`S>"^(XS((5Y1=.$&'A#X^%\C7\_R%$$V*#D)<\7/@+XBS$Q/4
M(F08""1(=%%21Z]S$K<#C@QJ>7Y^X1`E.A4!:0,*<2ONP-SM=00<%#]Q+M+'
MT#+!]#W^V3TP!2QZX=,'PMR;W(<P;Q([=\5/I;7R7)]<W*F^NPLSQ`(:'))F
M`*3"^C!'=-`WT<;RS[C[Q3XL(.Z.K(1\\D&>\55=ZR<43L1%@;6#,:W)X:TE
MO`N6*?!O\;>23%*1S/Y>PL1#DK'5_M3C^I&3!^H1+3N.[$\'<QTS49FE%-Z$
M/VVW8`?3@8/(N#DZLHQ_W@;-$L,D>-^E!9M8O)%3>^X$VJ(,&8N,72P[GJH<
M1@H')Y)"R6DX#,L.O`EM`V181UXKX?S*Z+!&1SAJN'ELI/EK-4RE,C<J>N#;
M(*M)5;-S\_^44&\/=B.RX<L,I/1I55LI?YPEP4H?IOFP)](;:9A\/*BY>MMJ
M%6G^E*K+0<?5_^]TXPT*+>LL6'/[-F?K0K*R7;^@VQCI"6TG3FQ/_MASESL=
MF>=>U099Y4XZ_UJ_BN95MJ/<O,H?[;$)>.X5TY;Q`&+>Y;EU3(6UB6R;B3QN
MC<B]E'2O-`=5:DVJ0GBBL=$C."1I<@Q,=<AT2.'P?[*-EU^S;24]=CQ.LZWG
M7(G-QYC'J>RZS^O/L&YN:^3FD*2E9%#2CII1-9H/>A-K5%Z."FO3M!O=3Y6N
M@V0P/'MB9--XK`"PO&;@.Q@E1F$%TNR/*YX\T.FFM'6Y<E+0.PF1N]9J,SP>
MR-'IU)(U7_(UR&F0:Y+&:)#KEG8V7RW:S^,G[U-/@I`-8-2QN-+@O>]Q)M$<
MA&P"-VHNZ3$KONW#%J27_G?_.`Y/*<>K.<KY'DH@*E_0.V+,2MPLHI-5Q'Z/
M'S`:]`<#LU:XJ"'B<)C;MMD@SV]1GMQ;K*F3J>%';#Y_:M8TNZ0,]1'L9*@U
M-><]:S!]CC!W>^6N8:1W:ATTS&F8.X9S-JYWE->E=6J4`FC0TJ"E04O[9MHW
M:^=D-,QIF-.^V>'#QHU/V^U0U/C9(L6F-3BZQ.MD&GV4K%.>&WGLV]"4Y^%@
MUIO5/,-JOW)I`-,`I@&LU0!F]0?:K]*PI&%)PU*38$G[51K`-(!I`&LM@'7'
MKVI*5J\.SC8W.#N?6MT0=FV#M0W6-K@C-G@^'_=FXV$M9&J_<FD`TP"F`:S5
M`&;V1\=/\]!^E88E#4L:EK1?I?VJIO!8`Y@&,.U7Z=Q9'9X]R%'$<-R1LPAM
MA;45UE:X(U9X-.@-:AZ2ME^W-'YI_-+XU6K\&O9G^M1;PY*&)0U+38(E[59I
M_-+XI?&KK?C5';=*9\[JT.S.T.Q4AV:U#=8V6-O@)MG@^4!O(C2`:0#3`-96
M`.M/Q]JOTK"D84G#4H-@:3SI635S<=JO6QJ_-'YI_&HU?G7'K=*)LSHZNSLZ
M.]&)L]H*:RNLK7"CK/!P-.X-:AZ2ME^Y-(!I`-,`UFX`ZX_FVJ_2L*1A2<-2
MDV!)^U4:P#2`:0!K+8!UQJ_2J;,Z.+M+U@>Z(YBVP=H&:QO<*!L\UIFS&K\T
M?FG\:BE^#?NF=JLT+&E8TK#4)%C2;I7&+XU?&K_:BE_=<:MTYJP.SNZ6=EW7
M0%MA;86U%6Z6%3;U-D(#F`8P#6!M!;!Y?SS1?I6&)0U+&I8:!$L7VJ/2T*6A
M2T-7^Z"K.QZ5SIG58=D=AZC]NL&/)JR_ML&-F(&VP<V5_I;:8+,W'<QT8%9#
MF(8P#6'MA#"K/^G(-D+#DH8E#4L=@27M66D(TQ"F(:S%$-8=STIGSNH0[:Z9
M3_JSKB2*:RNLK;"VPAVQPCIS5@.8!C`-8*T%L'%G+N!I6-*PI&&I(["D_2H-
M8!K`-("U%L"ZXU?I_%D=G-T5G)WK_%EM@[4-UC:X439X/C=[<[/>*6G[E4L#
MF`8P#6"M!K!1?UBO[4YK%D;#DH8E#4LM@Z69->]9-5OJM%^Y-(!I`-,`UFH`
MZXY?I7-G=7AVU\RG_?%8AV>U%=966%OA)EEA6`N=XZ$!3`.8!K!V`MBX,U?P
M-"QI6-*PU!%8TGZ5!C`-8!K`6@M@W?&K=.ZL#L[NR%$#6=?!66V#M0W6-KA)
M-GBBRZ-I_-+XI?&KI?@U[L^&VJW2L*1A2<-2@V!)NU4:OS1^:?QJ*WYUQZW2
MF;,Z.+O[)+4_[7IE@W:9M&I&^28(%R2\8%P$31W0_S/,-<P@\-R%\7_<U3H(
M8]N/FSW=BA:\_GP[;NZ?P)A&J>2)YG%":!W.IKWQJ-XMG/9[Z6VC5T.PAN!F
M0Y>&X/V]V_Z\WAWN?=`+%X+^MSXGM$^K`54#J@;4Q@.J]FG;1*^&8`W!S88N
M#<%GZ--V/66\B6<'.H;?&F-K]6=`K;$(DAN/G(G!K3CG\S2Z59G3*/4\X5Q.
M66BH-YJ,>P-KK'=`K:"W_1S7V4Z=<%`.`6@=9U$#I$W[<-J':X_?HWVX>@F>
MO9DY[<UG(^W#M8+>]G-<^W"=<%#.R8=+8[3B5QNP7OKSPKW/?EO+TV`B95S3
M.:1W7WKL@YYQ14)W^<98V>&M"Z0/3BN@ZT,3?1/^I'JYX,]??TJBBUO;7K^^
M<N[((O'(Y^75G1V27^V(+-X&JS7Q(SMV`Y]^&ETF\5T0PKP7?_I@>J_BP/GV
M>8U__^+9?O3KX_OO)'3<B'P)78=\M?U;<@W@\JL'S_WRG_]A&']-QU..<AF&
M^)T5\>-?'[-'OMB/^-'E@QTNV'#1;_!@''WTO\#4@\5O81!%AKOX^<6U?6L-
MAAAQ]A'6OI+ESR_>CF>#Z63\PDA\EWW"9O/"^!ZYKWW7`P@,$_+"^&E/&J.]
MB/P[01$GBTO0#_N6Y%B5T3Y2T6Y*M/]Y]0[>1\=MY`3&NYB_QP2^A(%#R"+Z
M`'HD"5LDAEYDPTXJ#-M(?DU+A`]'@UG-!4<>?8RBA"S>)2'`*B.$B?L.!LYV
MT7$BI1&D[<G&^2'9^`QR8`Y4$Y@?:0)/0%?3W$5H14&I+ZNFI2)AVA99-<OV
MJ4!^4Y:Z;(R>!Q/JZ)/*#HVL34Q>$,==V5[T\POKQ2]6?SB57*/34;^'AH`7
M2/\DK9;2!$X4JY5-]N.G#R]^,8?#^7`@3;C2N'4MM5DV>`4R#V&I-RW)^W\E
M;OSXT8_@M73M/L=W)+R^LWWE8F54E\WC8#H='EX5#DYXV3`"X8.]";_TP(FW
M06[5,WC_'7_,U,]2F3-KMM\J[SNFRC)9\Q-)UJ=D=4-"OG^*+N]MU\--Z8<@
MI"N345DR7M/9?*B2I**:SJWA:#3:`YAJDGHZ`V.5+.%\.AV-*O!BC*'>`[!B
M,Y%5N%!I5US>$_^Y7I.0_O2[NW(ET2C9VR([-MNL806;=1AR#R0>]%]_(U&<
M&A@S8T3)>#-&_/)E^(\#++IB:#:IM?>]_ENI#+T#N/I@N^'?;"^1D*EDFG$^
M)63*%G2`ZCZD(GY@F@ZT>NG[+L$96`E;OR8.H/4[]]Y=$'_Q%<;-6%`R^T79
M_I*4A'K0/XB25R7V!+SY6^#!:SPPY7GNE-R+2MR96$?F3I[<(_+GJQM]^Q`2
M\A%X`!@5Y[E3\F%V<6=(9<><'XD]*FJ/BR##DC\%+)AN09"+"4`(.Q'M#(8,
MRPZ>:9H#C2&,.^6H2!7NG`F&#,M!EQW<&3$,F4U.#B*YX6YV#W>SSW)<DW"5
M>5K#<HB'LN67+Y.BIW440DX_X8VN9:LFS/<MZ,22PGXNFVK9ZYR-<V=)&W97
MJLW5@8D\@+44+\28B.UY-"@"6]B<7Y_QHNQ^`B_D<.#'F*P*+OCLB9:S"H6,
M$0OBOG[OQX"17Y(;SW4^>(&=[0N'Y>"3.9Z4@BD%XS^="_.O?'MQ8)C;"K:(
MN!MD2_0YB8%L'T_G,TK*T233M%1'JP61F@\G@^$,';)J(^;5A,:Z0*-('+U-
MPI!(X911R3'"<(JUA3?@&YJC\30GXN4!JA-0<DJ*\1P%`98UL/8BX*-_#Y\%
MX>,G(@VM#"7MF/MT7IB[_.HJ@Y8,:87Y3B:3JH-NX'+)3E68ZAQ48)@;=@N'
M-XQ;,A=59CL>6X.JX[XC2]<GBU^)#S_$&()A#P-0X"_\\^A3X#M%VDKX7D7T
MX:$<:7N/?S#R2Y!<@;7F>#P^)/E?PF!-0@!&>#:^]&F8?8U`G1/Y$OY68?1P
M:IHY4K>-58>J$A97X9]IS:R:5`&K";`0K&`49U[&N!X`F\55S%Y=:=0ZJ&N:
MPZJC,B'*AJN#M#`<_)\"![8/50=?I[/15(4XA9$<)TC`!P$?!>/]UZ&]($7`
M&]<!VC%\+3_ZYI%JD%0'@X?SL7D0DJAE+I%4"WJMP72XC29YJ!HTU</3T7Q2
MCR:A/5\)F/*DO&IU0!/<Q+E21?.#[$=('9R<3"=JK-A&R.^N?8.!#I>4_(A)
M'92T)I/"XI1'J$Y!+3]U8IF#O2AX&_@T_Q=$YQVYB15V?U('2\%]'.7]EHT#
M[4U/+8=V.IJ,ZM!3D",5/740>`3;O<DV@7T"/;7@=VH-K3KT_![XMQ@HV;18
M=8`7=O]Y6Z`>9#]"ZJ#MW+3VIN,+\2,,-_@+"L5?P%<)2>R&-/(`G^('9+7V
M`AIWD/S@2%)5U03JX+,UG.2U\,#4G6CJ=2R"!9[9Z::^?0+36CZW.1S/AIO`
MO"8AM=SPP70V,9]`2#9\+;=\-+"F\TW#5QBTCKTP,<-SXYR+)BN-BWVQP\_A
M58PY4#2J+)(_,F*4QJ)`C"IEA$;E\&S,E$W8SH$W4EK,+<DHW&D^MN;X%&SL
MQO%V$,;2&3.B=IJ1C7',,>PKYK,M-+&A]J1GIS79&5>M2T_^G'E:SVO?M$J*
MX^+-0]=!Y7G1"=LV].5BX6+HWO:^V.[BH__67KNQ[4E?2HF9U4+8V6@X*NRF
M=@Y9G\1:V#L;3XHQB3U)_$IB&T-N[^W0=_W;"#:,R2KQ$"HP&.=("6VS.OA\
M88&EFN6C?+O'K$]C'3B_L$;FT)H]B4;*VKO`6Y`P8MF]&4UUM@`7X-<4I*\\
M1'42ZGC]%^/Q9&#N18)D!<%GVD90K9!+.02W:\`"6MG1'3R&_\$_W]L>'N)=
MQF_M,'R$5<Y#V$P)XSMHG$V&\\+6MLJ@==FH!/B]PXM'Y6(=0S`>30M'3#6X
M*&)?7XE#X`NPE?]$XF(@95XKE#.8J\.1JJ'J$%7/&,S48=O=1%4Z+9[OA/_Z
M7M;&LV)\THWI63NN/@P/CQ#?D5WX>37,WWY3H(KS.]\)Y$=R?G=R0`GO)2&N
MS(&=&Y5Y%?@^W49%*:Y'=,(WIS:L26CC`GWTG6!%?I>O1\Q56#W:Z9J,K4%>
MK15C*-(;8.,=B`>+5VOF*D@>F=LI&1:HV##(?J2`,5>1LLL/&$S&1R%&!;N[
M5F@$\'8(8MAJ9K2HT';7&HUGL^VDL$'VI$0%K[N6:%@PD(>A1(6_N];'+$32
M*U%2_GM)5E20NW-]"@>K&X?9FQH5'N]:HXO)]%CDJ+!W)]2-IL-Y+7I(7(;;
M8;D$0H4%NC#-B9G7H=S;*PVL1->=V[TIR_![PL#EH@.5#,P<GJDZL-@-"[O\
MJQVY#K@E[UPOB3-/:5@N*Z!@_H:[;Q>#OCG,J-DQ9$WZE.A:[3XYT"??KSX.
M?4K,K1`(YO19->DK7&?/9?E*3L]&LI4`O3U'>0`>UV`V&L]EE[`>'8>=BQ+@
MMSO[.!<\5#.'LV;-16D>MOO"="ZSN3D;30X[%WYD+.&6TEKL=$=GA2"&>.^N
MT91V8:?'.2H<,E4=36D,=AXO30KI3OG1,(V=NC&_V:X?(4I+(Y;OZE>Q>R,>
M:U2]NLJ@2KS?R52^IZ@[J!+$=Z9(#>8[!LVV?5'\><E9GXVJA.8=_)V9H^+1
MAO3N2L,JH757)M_(*J;9[#NL$@5W'>,,QL4SI(W#TMOY7\)@F07QA^4+UA58
M;$WH7*51I5=7&%,)0KORF`:%DXW]AJP3$)B8@VFU(;^2B-BA@U'3=\!Y+Z!Y
MP$57O7P;MPKX3B:3XI'.EL'JT%6^(EMEUSD<%I*"#T]7G1B!-9].BH"^DRX$
M*%;)`A[Z2MS531)&K$01B^B2Q><PB^UF%-:)'$R!PA06]QCUB:36"2W,1O/I
M,Y!:)_9`;U\^B50A)Y*08%:_?^OZA(19<$FZ2C`L7XJL`I^SR2PSC'L,^T1:
MZP0NK-',G#P#K76B&I8Y&0_JTYH>O!+/@S__1GQPO#WXSN5BY?IN%&-TY+X4
M@"G?,:P@`O-BEG2U09]&:)U@R:R84'`"0I4W$W<Z0I,"[-<A=,N9PE!Y77%W
MD,LRIX4+BSO/%+814268H@AXF>9D/R(V'O8,%=<8YU-354.R<-B#"30#<UPL
MMK3YA&?S8?Q0<:NQ0(0R7^!`.1Y#Q>5&&'[;O6)V=Q;V)@<CH8SF0,*VNB94
M'.&1Z?1@-)11>CZU!KND<3*H0T+E>HY#Q:U#(*O*]7US.BX3MF=!QPW?H6>L
M"EK+H%R@5;77K$)D?L"GT*BXJ`@T[G(<QL-"SO3QZ:R#T$CG[*ET7B[^F40L
M<>`ZV)`6J"X&\96`O$=N3*Y(>.\ZA(T%[FEPZ].WY#)\AHKKE+N78C0IW)XX
M-KG/Q9PZX:)G9D[M$AD[RYI^",(E`6(6Q<JFP_)-U=G4K)*N,;0&LX+U/@WI
MNXJ>@*\?ARZ6BJ'*2T<!?(X_+_FK$BR-G2OR,E1<CJUF)<S1?#*=6]M*G.Q!
MST&FEDU*Y17L,B?9OOD))!QX'DK/8E=(RAS.&CB5.OM#F,K\<%.IY,YL+3X]
M5-P%KJ@MYFP*CG=%GTI)1'6?8/L<%%>)JRI'[<$/1GO9M]FM$*8YK^[:')?\
M.H%2(']^2/+5J1R*6\S`V5VI''LEKVS>3"NN+,/@%>HXSV&7`XM;K--9:S.M
MN*=<(&+WU:4G["(5-Y-A^%('FF(&]@#VTP<C06EN2J7UBS(P`U@\'`W*7>N.
MD,;%<#C>;R]],F]<<5<8YK,K1C(PBW>L.KE54=Y#WGV(_ZS,>8ZM2OF:-&Q5
M)JHF#$6W8SH;'J+B?S/V*HKKVJ!+JM9!!39<<#XT<*NBN`V^&Q^&`^GLM#$N
MOO(N^<X#](-.Y0`NON*^>34AF\Y-:]@$!U]Q.;V"R2G$?Y[-1U9>9=]I$PY+
MO=I%5MQMGT^'.^/\^Z19;W:1%;?;8?`*.\_R7;CZ+K+B5GN!B*.ZR(H;ZS#\
M_I?JGT*"R@3MONU=OI'>&`=5<7\=9K1CVS,JW)7MJ'^JO$>_\WK6L_+F.=S3
M\EW_V6"V(W&=N:<SV+8=HLE&,_Q318D!4*4*U:TO9F"_YHWT3Q4E"7;#PY0?
M(#?*/556+MBES`>=R0&\4T5M@VHBME>3QJ,Z>(KZ!X4I-#?^K"B34,%85D]4
M."[Q=6XOJ%RG0SO6BG(*P-5=<<>]KA%N=JP5)19@\`J)7.5;^_4=:T4YA0(1
MNVM7/<&K5117@.%W[1C+I:">0H+2SNQ*Y%*443J(8YU).?[;]AV2*Q\^5%=6
MV'60,RU<%WD**8>UC8KZ#*JM[?9R'DKE'BGJ+:B.['9T<CV1QS]2%&10'8/5
M:DV^&Z)'BAH,^Z_#Z9BEC%V6M.!HS%(B]YZ=H#<(K1*/2W:^*>N@#/CMV[BX
M_CHHCPWWU)D-ZZ`\#=RW#?3)UD&)H@<12$6EA?V7^&2,4!1CJ`YC![)I(T7%
MA8.MAM)A+6UAFK(:2IS<D]KZ\*`H:U!==`\F##M#,_6%00E_%:W@P>:G!,I3
M,UF9ZW!`YZF4[#Y2U!ZH,:1R[MD8=1+JI]-"007U(/L14N?:$]C0^<$)J5(L
MIK3]L4;6WH2\(^L0WE(8?F?1%^4-\GFQH43VZBJ#[JS.HAIT/"SVH]EOT)UE
M5)19LZ-!Q4%!BXE[Z[,2G<[C=6C#*CCX'-:H0)C[TP^)[<E%*4?JP@4[-[]Y
M==AGY$/07*<&BU5HT7)JFNM4<KDP1X6077VJMW:HX`TI"K=61^HJ"KMN'TWS
M).\Q\`$HKE-)QBH45STMQ;7*T(R>2#&M*,`EYK-_N:*5?C\D_@(/U<!1P";%
MGY?O:<<20KYBV:;HSS7Z$.*MV03J7%$:2N4BGD3&X:=3JU+.K+'3J5.!Q[(.
M.ATAI=F[KFR/?%[FNDVFK28STFO9RWQUFTHC%K9RJR",W7]3`PNNL>O;O@.>
M:RYF/%(7<]C9\Z^03+!EI#HTU3D3'14J2U6G"79/8&DB\HZP_W[T"UV],L+J
M%`DRK5G>R=@Y7EWRU+49=A4@F-+R`R>AKT[-(*!O>F#ZR@7A,Q+KW(6YL`I'
M?E6&?`J1=<H%79CS0@'M8U-9)TUI6KA5=`@:15=NJ5+\2-D!>Z>MG^[4%&FL
M6F35*0,TG!=N.QV>K%IUC$UK?D!V%3JX8LT8QPD3LE!T,QLI>UOO]/>+U3?J
M$7'8B=0JHFP.+:MI,U%VU-Y9.&A<%;*JSP.;?]C1'7A0]RXX@+\^_AFA&YA6
MW;F$7>@]:P4;8).)!#[C?PQ\:3YUXF^30HW\I]%RG'G5JF(T'$S&I;27QDVM
M3H#PPIH7';A#3HWGB^)ABP-N?$@V=J[/IE$GT&@-BCU.*P_\=(+K!"G-6<%Z
MG)+@.ANV:2&7OC:]8>`0LH@^A,%*L=E3$US'0)MYJ=YCW%V&(3N@03W)J*QC
ME6>[?(C\8'5)JV-G1[N,[$%(4S99WUUZ^`FD"<G]$(2R4-"(''IL41[D,DKK
MF$11%Z3FX`>BO([1*^Y+GX?R6H=>P^GA*-]@#17?VVJ<E0WB=^^\K4+AP*=1
M<YR9U3%_%Y8YL!H_LSIV\@+,3B5_JM;,9/F%I^_!?KFP+\!>]!G9M6J<3XJ)
MLEN&RJ+?\D,B5?;S4NJD1O,6^)&&Q-E:&]BQ2#O>?^0M/LC6/!IEU_G=(='A
M9E962-BO3EZ]6@Z%>[O'HZY6H[7)4XC;H&MI?+RBYBM[U.]N33`>E^KR/(&:
MX\RL3G!U,IG-*Z'UL\ZLWKW1HTWK_7+)SMV^.W=XE?*K'9//OKK!;3:).H';
MXGG5/B,?@N9:Q=VMR;/27"_D.RS47*I/M?H9EG97W,YD5-<SFX-"4\]]QCX$
MU74VG\/1L%"F_L14*\HN5)"0H3D9FD<E>T,#[I&R3L.N@M@('%7(W=J`>T\Z
ME?6$=MRZ&UN#0FAY#SK16Q2<_NA+@7.V']P1>U*4:JA2/E!*G-E[[(.072<]
MQIP]-]5ULF"H._LTJK-`4DQ"V)7A?0"I)\A(462@2HK+M'C:FWO[DY)N%"4"
M5&*YXS9$E705]17^/4>JLF]57+.O/M`3-J.*N_$J5:D^P:IA;<7%]OTYNZ?<
MJ.^CGV*RU38>AU_=:MN"IXNOXCIY]8%P@FF;S>0F<A>NG<M14-P6+[S]8TQ6
MI?ORO%2XZM7;9NAY]DT`NYH@E"@H(<YL8(VW.1AC;)TW*";M;AHH8T3VL7M/
MI$(T?[@>H&?@$U&%AF8Z9@26@&INS0;;;K./61YB9C[V&WDWQ:QA'[US`1Z?
M`Y_8MYDK5+X`CAR5]?]+4NK[.^B/=A"K'/2)M([+-\J15FL7K9.GT7J5K-?>
M(^JX2R_MP3/_(':8456NT0E4;;/+$[R<(R_YAB$DW$E"V-Q%A*WY=?`KN8)9
M1$N7+*X#WM;MO1^[L4<6++<V(Z\$MA7(8_TMLSCGWL-GI/_N.@B&@,=LEI>W
M(6%L#V+XMVM['Q*\3<:EFEX+^NP#CK)ED292`F^<R+82+&/TR\;2/)Y*2PFN
MU/;FSX@L$^]W=RF);KGG!!`/G/XR_D<.EW:]\0DD*(IU6>,ID&`.3D9#R8(@
M#3.DX71\4-J0.=`P?`H)ER`_"VQ"#;IP19PDI&[_^^^.ERS(@EF:U3J)N:-;
M[)6>MR-CQ?WW*NW-IZ"XHXE4F>8@5!UUHCL#,\J)FH/)=#P<C%HT4\5-_BJ=
MT<W9#$36.NY,/Z[6MANB>'\.W[G1.HAL[_/R]\"__1T;AEY&$8FC+X'G.H_7
M0/^O'KBZV<0V'+'\\M]>_&;AWN.#/[Y?W-KAU>6E:0U'^'<$Y1^-*'[TR,\O
MEO#MBZ6]<KU'X[7QX[6[`J_S$WDPO@8KV__QS8O_OHW?_.=_X/O6\G=>&^9@
M'1N%YWOL@YYQ14)W^<98V>&MZ[\V!O1_INN_,9#6"]=?$'S'Q:`_A@_I(#C$
M#?YPU_]O>[5^\U_F9/"FZD\9%PW7-^YIR"E8&AZP\<)#/AHV9>1K`X?YZ48,
M^-/Z@/,;]*?9;#(BCSG,]1TQ4.1L_Q$XB_OVTI2-90`>D\2?I6'[P*6%Z["+
MK\`GZ<_DNPNOZ1L?ET8,+X^2%3Y`ON,M(GCGDEIIP\$<GJ47/$3XUP59NJ!)
MQ/`0[?FP+Q,8(J+YJTB+OS`>W/@N2'"%6"#$`,\FO"71*\,%NDD4P8A`&@[K
M\#B>83--AD&BQ+GC[^[19\2\0U:$X=_`09Q8-A4/]L4]-C(H*OQY$3RPUW,2
MXP!_<T,#3^)7-IT??)G)3]0OKMQ/H%'XFQ32J:&\I42I8$6N[>\;57S#Q<-6
MJ[A;0\4E9:<\,V+[.XF.J,YFWQIOG\[Q='SGV&8-#HJ+1*"`!08>E/13L$>,
MD4Z)SL4`&PM@!.BR<GWX$.RTY_X;8412>L0#3TKA7Q%`I85!*[X8`<,'"0\8
MWL'K#4)/^RC@X3,+%W['Z]WPCAL2/Q#"OKMD<53;,VR6O4]AS*<DTE'H&S80
M@[<V0T8M[)(`H?'.$7[1LQ\`E.7IPKL\FXZ.LW:HWX%SCL1\\1G8<<,#*7H#
MX-T0M)!L+L;#'24ZB/+3"<D]"2/2-RXI%#(S87L`]S@@?C]DUTHY^&<T\6D!
MGJ_Y(3K8FQYG;K+F['T@N%.E;+BW78].DN#3\/:>X<;X_540HCWY1@"UJ%GP
M@QA_B(T(91=L&A"4KH6"A@<7_HY?@AF+N_9]0S:8L*_.R+1AJ>$+JOFBW4IG
M#"S$K;%BQ#[(*C$^P7X6)+ID/`ZH5XBBX4_/@WE6#=SY$Y@8QC:8_4>4G>Z@
MSS5J(;NV'V5N".)K`0DBV!'0:`=35J9Q5)@E1^9'$'K;MUED#`2,K.!I\&*(
M#:Z26AVH.D=)A,PEBYX$8L2Y\P$^/(`W\'TB)OB9,Y6C.D3Y1R\1B(D8;J1_
M1TT$`I*0^I.47(\Z;;%X9M<4JE!>Q=7:X"A)`70;H?KS,LO(V>A3;4@K;K5/
M9=?03-ZB_IA.U"GU\4L8Q`#TWXU?W0#D/;37!%P`![X'TM,W7CJ!YQ',X4)9
MI*B.(AY)IR)L9\%I'4W?<+D6'\S>O&(;"OS>PQV\[O$"]A2@&^E+'GM&2L;O
M\:+?HQI_XP9KV.RL;(=2!'KIT#>CS5\&3B+Y'@LPOE[`3L]P*'APA<F.:,'2
M#1NJ[>H&\87JGY@IFK.8N'Z4=V<R[82_KV&>,=")9+XEGO?^.RY"E*RE59J.
MV"KQ3\5KT9$`.X@U3(SH,0)(,UYFO,K>EW$+]I$^+-H:'KT!Q\8:#.8%_B#P
MK.@&,<");.*JY!FA*R0,_R>"7P(_:!%)[_VU_S?@.]`+2NX36G>'+3=^Y7V"
M\47`H3\(;($!?2+C\A:K],AS>?_'I30+X8S1%ZWQ!`MKT?GYU_WIPU]S#@;P
M&[F(8HU<C!\"RE3Q>T[PJ)2$J5,1&#E9A3DB^SD`9V3*!WK]C.!V:_%G6!K[
MT3![("ZFQ33RS_Y5W_@0!"R0\"Y,;HW+!3CY;A0SK)<7[\.[XN*!DT==-<^]
M]1)P1C#3R_:6-HN-^/]D,M(K*,O2#<',I5]?X*CP\R)QXAZN!2PZ\?_]N,*%
M6WN@VE1GF3J"-+W_>OU*F%46EL&-B1&#,TJ/FJC_NTB\V%C#%*AS0(741K%=
MNE0K8&UO_2!RF<`_KL&U-'ZS$P<U9>%&F.L"(E>>%WS!EI6]ET,,5#E\(7X)
MA#DD-R&,L<!OO_SM[;M7)==$@%*ZOTAU73GZ`S+'BX*,=S>/]'4?H]`FGFO\
MP5;N$8GX'_#-8=8O\Y*=/OGY?^2U=/-H@N+!7_UK:/\;=E&HUSM?+CU;>OT?
M=NC<X:N'5-3XVZ7=6$AN$P^/K!\-.P%/CL6`<3#NY1H,R.C>CRKFA@5B+B**
MV!I/.N#KGG?!<'L'O)?X"A)/=T2P4FSPE?U/^%U!ZN,Q-R8G``<P)Y?)+?B-
MN$2C7CK[RDI.?P-!=FV\(9BJ7A]$VD5=Q9`@:@]]G^WU5"^D\BT&S+\OBZM2
M"W&9($"!J%%A>@N^\<(V;F@,%/Q@OEC_3$(W@J_AMUJ^/&I)OR&(&?"5;R3.
MMD=_8LAX85S%-$:1V?>;$'GEVRN24?S>`S,8!?R#\?`-2OZ7)>RV0N[;27X(
M_3CGLN5QO>Q1K>TP!D^8HGH6N."Q(#S=B<`.PR:&GF'3I8SH*;9ABV-LI(?B
M!8\$Y7T<_`NGM@!%_-/T.#SG.TF^!,XA#)+;NZ)WR;@:;6(5?`#S8&C*75>?
M8Z62Y<:?ZSRCI:B&U7+AS*_)+<P9Y8^O`!ISL=(]XR$(O<4#B$&ZZ``,W`B6
MO'*BPHB,N<4E[E$`"`G;^O)@0,A31\1:X2`]`VRM0SC29>OV,H(5N0%2'EZ5
M`UI4(JD':1L8L7*7@$H8R^+NZTX!!:-AAPL11,2P%V"9FT8HA4/CL!LPZ*-(
M&Q:RA+_S,Z<R4X!:X"*H>_X`!\D.62H+^G=&LEZ&\';0RD?A)_U%=J0G@_X@
M[TG#/MRC-5S5+C_Y3IQ$;)U42T+G;Z?UP//##3<.MQ)Y82FI*UA3[W$3'6"H
M?LQ,"R5&@9<*=.3AFY1<CE%1V5&+\)R9C<@GB7_U"?T.C>C`RN#!&'#<LWE,
MN/*V4T$N1DISVYQ1GED_T+?EEZ_P`/@\;M03$5:ZX^FA,H*C5XJ](JF%F9#<
M7,IT"YG,Z1;7I1Z&P&E$3CY/1,V,).!G&(LJP=24[FIA$^^@=R4T1<'C?$`_
MT_^8CDG#]MQEY%I+(^2>NZ+OX$>5K)XC6^D5[(MN<*UP#X*^1QBL`,AP.2/;
MX]HIWDE$+BQ;SH@=7=S")@J>#KQRT*U=:`[;Q/]-0/7,&=TH#HMQ!4)/F='>
M42R\X@8;>'&-P='`"VX?#5J9=YF#`N5>06F@F7!BI4V;?6H-33YURYJ^"8S/
MT8/M+0+C;9C\.[=!=0,'/BI$E4`@5@*@<CN4WF8XS=MN]6.2Y0!?C-EW]E6V
M^Z"[4CYNG+$F%JR!+T58>M!X)';(I"DGST(JR?>8^"*4C-/)\'0)6G2!7Z>#
M43?+!WG'D#53V;4'GN$F"ABQ&T@#%'1O_?1LBQUL,>]M&20AAMYON0ZX$4T]
MH#0BE(BWP,]\17CNP=IVL$\6]?.^`=8CP-`B-VF87%J@6]@%A#[;^N-<:$-,
M`"NJPP\^!L23I>W$M+"^`3^A)06`L]DCH(E$J"IST.`M+,I`T(2S$#GN/'O&
M':"/\:_$YB_@:LWGC$#%O5(E4O?!I"BP2,S<H2FP'$37/.LT.W^@1NL[/12%
M`?ZR!?!3ZP@^%*B'VFHL&#>R+7#\$'#YXI*8DM@W_JZP`>Q;Z;)D!%.X5/H7
M[)PC9%4TV2'LYDD-^V/UK%``&-:J9R8)$X@@NFY27![,!@;]@&H4%SK?;`5<
M2<Q.L09K$`8DH5\`3J`#CVAD6G(:BL=:'M.K;;"!)]]>.CDQFZC2=*S9_O-A
M*%&$:\`$!Z$QTQ%)]/X75-,.'[/U@1>S%<L?L?(?/R[3Z2QMUXM2SO##A#3^
MLZ2:G2Z@DV:7;_8'<L)*'6]Z1([23K,9;,Y\.^^R>I[8.7"]D%<"/88'ZMWP
M->&K*29!3\CIZ3B`DY^Y@IR4(A>$&6^CLU`XA<#]U-O/GSY>OW_+N/_)YI:*
MW@1@)QRHZ7CJ&*Z#,/6`4]^!WLX1AA6\>O#7,2F?1QP==.ZNZ!$)`K4/H.30
MO1Y%?5CD!4TUY9;H%N42%#*(7"JBRX3URZ1A0%CLA9U&KC9O&';&E3%\'!DF
M%9QA,8K,S`GL9L#2N-&=H%45_.)2DZ&P<Q?`)IF1EQ*!O_FP2HP2,5I*4<JZ
MEGNAL*'E)CW5T.QZ"W<0F;KUTDC#BKD@B!$5@TML/Y=#:7:>#V_*;PB%?Y+"
M,$?H\K8(!V+Q1PE!MCF/-[;S#1_*TW$949\'!@\E*:U,`9\J(Z'HPF>Q#-A?
MI^R#I0"KD:RD=(8MIL2T-EIRW#SA(L@[MY=VQ-)9LP#@MI5Y)5M11M]=>OB1
M44]">N0B#`1EC?"-(]903%()W/KE&/$CAE#O8#DV!1:V^7T2XK=<UTIN2LY=
M`@FQC24!4X\>,GXT_D'('E]A>O/0N*5)#WR/P#G.L[K`I>'0E:Z*'`ZVP3#0
MFET%.<VY1R4/!/P`O*Y*C3ENB]AALQ0YWAB18P:?^L#7_$<G#PMH_PD&G>2D
M/H6[7"**>6?,8V#^A<L"#B$)EBV7$]9V)\8H4FIO:!(&/8:@)HHLN/)L"&AE
M8,6B4\JH7"\-(KV]<ST&$"S"U'(&?LPV[VJKD'=9@3W@EW]#YBIR6$H'H_P(
M/2H=)7>+:>S4>%ND%W$F"RVJ)4R<W'`%SHQV>KS<PYL1F)&R3#R!1%*H.SOV
MDA<%Z+H-[564)C-E)@F)]\%:(=E2F2W\_IK0!#06I@QN<$W373SK>)4[<N:S
MS^-T!&O-MD="#.AU$)\[X-XC9AWC)CFVZ;50R<K'L`PTV+0&(`9MQC%S@F@[
M=RY,$G,?/)PLRY3B^WU[@88AIB<Y:"]A)\EB-.DD>_1N3(R[JEZ*O^+=+(>:
M>DFN[V!@2:*1QF\6HC6CVD8K.)/F$J$D$*`^W3HRWA@.]K1?T//1;-OJAE*H
M7%Y5?"$M+%2^NM(N5?J<BE:F'BG/BN8-%Z?$+VJMX0],2RA$+4`"'3`*DAR7
MTN-8(OXC7614))'0`PX$KA/FH4G+"+N[=5ZXF4[PJTI"_/-G=`[N!C&Z8D<!
MAO60>$Q$8^,$24R3HYGR(E"D)>>VY,A6RG[-WSOZ%:W:Y^5E>D6!/;TQ8W9#
M&8U69\S>U,B8I7S#Y<%$2-0Y9'5G[Q32)#A%$ON=?8_N%,%L2+*V0^X>.QAC
MS:Y,,$?;P_V2@X=Y>+J;78E9`YXY[MHC:N=*/B^AV7^_75Y^D;,C=J>,5Y/Q
MO%[\&8$.O>?7?[(*"(J&RNV7?Z?.78Z(@A/)..3S,UF4@S1,II*:[FE)A4ES
M;P"W_VA8J%ZDXBQL1^[6!)B1E?V-2"RFD=XH2E:L]BV+S-ELL\<\"W1F4+OX
M6?'&^V4]?G,M<KP`[W10YYPF<M"-[X9+:3S%@-I5[E6JK[9PETE%3^:&89A1
MG$Q+L7CV)0H,U(<!-]")<2,/[$F\.**.'[NDQB(W+&\FY5(%/,CK=J'[LG-'
M%@G6LA)=FQ[Y-O(:S]X4%G%#1:8#(X((92F^I/A.*KX1$U_Z=.3^FS!I%QN5
MK`<6+.T[<&UH6'S(,JY9WBO&R%E@+\*5%,L>X*4X6*37N9`:8SA.VO%`AH`9
M21@%X9>`NO82LL4T@Q837=>X5_)OL<X"_3W",U?^.Y_J#1[8A1>8"&^O(YB"
M^$G,"Q][S?<J_+-[.W1M5.[<I^R^8>%#VGO5N2M^FC$+=,`G%W>J[Z8+$-,%
MP#AWR!<@SBW`@[N(88C)X`>!)1<>62+X"!P1YREQ*.9-RXLYMG>!.T;`GIL@
MCH.5;"#BA7B6@CQ_SJ$9#[LH?&-PU@.HK;^_>0$3>PCM]<\OV']3H?LI7N0&
M+#RFEL==@VV4:)GME3B<O0O6,?!O:627W5E)?\_)J&I.(%`@=_[/+R8E-CR%
MP5QPV;J]-OZ+U7,RS#7>7?7<A?%_8',!8`>">EH&R:J^+Z]:L/X%RU]U<C_%
MH3336FI83:4.->N7^#(7?Z*>Q`)A,>2>6)!$>!GJ%9V8VY65K:_9UGEH-MIM
MK=%G/KD32[2L9$>7[I&"1_G?<@S+_?(\G#VI*#5^_IFP#%O.BT:M^RD\'IKX
M<1O"5GZ!F[$@!)AP'$*6R]U[$MSL["DJ8L\T@SW3P=GWU7XP</</NT0OVBD!
M=59<D"]3O^&]3V,43OZ[P?]Y8VQ:O(<[-R87N+VF>V44926-A^+P7ZIR59X]
M3?_95T[JS-@L3OG0T[=ZPY%59L&>_*@A#6,J>R=>[`+^'%B7VC(GK<?=TV.S
M-S$G6H\/[3C0B1W%;3@X3_X>A-\PID)394A4TUO8'-4_BOAL$!W^R$7(8ME4
MQL1G+!X]/HJS^B0H/3J8'!5`YL_A!;1]^9]`O5%5[YHAW.>WMMU1;7.H=?MD
M'L,Q0PT'Y\H'+#V%EZ?H+?NCQ!<:ILG5N%X_RMQ*H7\2Z#V!5XU!R'%O;`T;
MM7MJ@"QT'^PU1&B(J,JH46]NSC5$G%M4Y1KO.!JNR+'4+M(.G;;Z,TQ37@0)
M9D[NK]<%&#0W`F:K`LA'8M;)07#:FX^G&@2UGZ1Q0N/$%AY->I.)QHF\LR1^
MQ2L%TI_YK0]#_B6[`E+UFD?^<LC7X-'VXD?>7#R[`J)H9SJTQIO;XM+NF:-<
M/^S\J^4VS:)F5+&7I;(]Z;:FPK07;Z[+=?[5^;E^8!>Y&5><1UH@T:97F:-+
M?T%_]79T5U'V%6WY7;E%C;MR'Q+?X45>',Y.*I6=N@/'LL]%/7LQ3W%A:!V"
M%(:/!@&!"%:N8Q#_W@T#7W3J!&AQV/5XJ=9`OG)!6J+@JM@N`][)ZJ#VC3^P
M#F*IXD%VZ8SVA0MI@6$8E6?,;_I:OG"JO7;CXA5_?!^M`A#F7IA5#6#U]Z,@
M"1U2'H#?GO-O:;$@?H\V*S,CR.N$B$CXP0JDBZYU`=APEU9\@*5!X?!%31YQ
MH0&YS*]9XV7"F!<_$%\4UPO[QJ_BG;2JOG_!99(+HQ"7F&.7J`DKAF%E2.[<
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M`7B%-4?2]C?Q74@(@F%\QRJ@T\HV[*IV=GM<5$7M\6OLH'*L'DJ$_5-BWF8P
MH",M0OL!RQ"%"%T,`6B7+'N!P@CSI!LTVB(U,+[Y6&U9NG*./:I[O"RT4UC]
M"NI:2<^*S9SYGF*C-G:Q7_ORB<V<T]OHW5+)W#5[$%O:5%RX,6!Q'EAI3%K!
M.RT$!I:*NZ0@^E3B8=?]S;YEM9#XO07V.=>CA51(*\HU/TX;`?]W6DAE!4XF
MUE)B=EM\/GO#BMQUPN$4_%N*5(P-[+$C[BQ%KRF3Z/((5WT;\['$&G@O?EQX
M(=OJH%[2"H+[L_]-F0[/OJ&U],%%A._<`?!M')ZZ2*E'QHH6XI=$QPSD`6UU
MQ*IK=&&I/RZQ/%9"#1$J#RZ!PYWT\O+3=EW<*-GW0<A::V-#6E9)!/[^3^9I
MWSQ*]5AZV6&5\1!B(&P!=B8230]$]2]L"2(>PWJ((=;2QZW,`ZN(FW44#VZP
MY'_D8+-KN3&V5`)&+O8"$I#$H@WY@JRH%<1-!YLR[H%IV;XJ)FV3?<I;L2_8
MT#*,'[]@5SJP@&C]:'VYC5;-ZJ!5NZUAU03G6)$;P;8CFC7E7*P*>GCH6BTL
M\MN"@BR\"$L<K'F,GW\@C@CD*WSF0-RUV%VD!5[(5X)_\,\$-'[YJ#Z5YP,,
M)Z(FSY8(/G]V-$,.[!W.9PFK_8HG!(+H2F]52SOU=7@,PXZI>].C]9>Q*)7C
M)*N$A6"V;N[+]%8,^S=:KRBV2/T4<C1KC3R"1AY6^:HHA;5-U?(OV'Y%8>/Y
MVL;O5RK^E2_N*`J^4=>"ZV/6519;E^+*7N`J&RL"?E+:4OQ&U,%D,=G,O8&=
M.A8B]EQ:AS=SLO<XO=Q+U[7>;-`;T\*!CJ4XI;/QD@&DYFDO_3K,*Y_RED-+
M7NEY2L+/+U@-C1<UI)A/LM.U\09]DY4,V:ZQU:1Y6]FN2GB<M_5JF1/9,ZGN
M5347E=ZNJKY2R&RY\;`Y2YH`O'OP8O&>?V`OLA//\)AYKZ*(B/5#7:?Y=XR]
ML$+?^:W<5B0S?SC@PDOOK%&!9_]QQD\92/);\@UW]I]@]45Z)NFJ`AP?DM"G
MZ0)/=0CK0L11\6=?D3#S#?TN<G^K+"^M$I)ZQ*)SG@"+*X'.^<B/XC;9J46D
MBD]8_;<V!MQ_QTZ!=X&WP.X8&$Y?I;V5>/1FU^91'$BP;BKP-+8");PK,#^#
MCMCQ,WW29KM-Q?9RF1Z2R+14"()7#6]GN9A_X)&V]_@5GJ$<*.:!6D-5'NAD
M:Q[H;)SF8VYX?:$^.7'PJ/WQ'3N)S\8N->;`L:=;QQZ:XUP.:N'=^8%Y/Q'_
MEM(6?:`'$7^X/G;@^\*ZWD?O$L*S:#.Z2@T3=M-E#LQ\<NQ^8Q=R=EGNWU?B
M!+<^/2'9>'QQFDKNISV^^.>3#N4Y\PR)>T<\Q7CF?)F03?+?)$T8!20B''CL
M$/L016FG)C=*N_U)@$6?%U^FC0FQRR4>]H7\9[IYIX%R&UOM]EBK/7P69#Q*
M;-H#E&`*J$_[?HN7R=U$R7<WPER=!<'H6DB3;&FA`4-N6(@II8'#<E-94B!K
M5TT/1W'`I?N=429.CU/:,(@`L"RZ(+&)B#9%>"B)!YV'/\1BD?4M0GW$EE.[
MQC9KZ-%7D7:<)C]5:.Y*FX<>?GXG[86[7:DH-P`CP9@'X!*L.8#CHX1FA\J-
M,I%KO*%JUK12U6,H<=EO(0&`YEV3V7AA!E[L@"GK/;2D>EG2,)[?MDJ\&!L3
M"45#_8AHIUME?U].9MK+)9_KS=JK)#2!]S[P[J4O%GIT8BYI@.D`Y4ZYROZ!
M3+DQFS8DV#$:R>P9R?H"&`U#")GC?,ZEU*<LIVO")_#`6M^R-N'(L'0-)<<M
M).SXCK>TI:P7#5OD]<\\-CJUTM,X)7-$.^=&QDO6YIIFQ--<B&*[&3FE'RA?
MITG[&V<+_Z6P=I/V#<XZKQ?EZA5/PY`'9MDW$28F>N3>IF^,&0BO<97[H`O$
M^!3`HU9^YO8"3U&C#?/F30:SQ.%>?G#X"TR%DKZT'=Y4QW%#)UEAMT$'1WZ/
MG0)+BL2;BV?MF%D2\PW).A7>LR;=H&<H:')?GIRR4-Q'-6-I4N(1J5D/7T/^
M27:)(R,*WL&[,9Z;Q;">;#&P12;KD,92E[IL%=B4,SJ*<V=X(#R>7N:9'<^I
M.0<A'=;)H$]!.+IC%Z!X7W?/8Z%R:F@%J+9;:/],C05*$T?A--5.6)^B(2FU
M18;/W-AC0#P:_)#=BF/-YC%)/A!)\DR@-UAZ9HZ9Z4VOIXD;:#V\[D+69:^"
MO1+6B741IF_AC81?1BX:)>RL\(IJ5:&5;DBPDRD=S?$2NCO)>K'2V]=H`ND[
M.!=NJ"E?23?J0C?Z%G'2'\`YB]@4J!'A#9*5G"M*F&"7N*DC/L]<:&ZQA+."
M^;>8<L2RFHT-"(2O9.,`O;Q#/(R37Q6E'YI:;-:T#E\E7*HHYU)%R0IS@O^=
M-;ECO>PX@R35N9=;O4J^2C9'>F<K[R$(QZLHK1O%$]]!IRU?I0Q$E`6[SZ+G
MH.I#+=^%HBZ-\!3XE9%%WHU9NA%>PT+WSL!KD_#R3QBCH\VG!G3G[)$-+Q43
MI<V-J`8][C60U.6J0CAP9YRH&%:*8"@';X:\RSHO\Y`=^V866"K=#^]`8.E;
M9<LA6$7U5FX^CCF!D=&M@-*.R2+*<-RF/G5Z>9@;%FRS*-\@6-*P$'81]["_
M^PV*40@`$82I+4(DL7'/^G(%2`U?4O0==\"7HO<A8WIW`9`>-A5I+U`I9U/$
M)5R>/A]NFH[4C]KX+;1S^W<>^6?&QLWN:S]F4/IYN72E&]&P05@:5XZ+6L[L
M!OLR6``,\T8Q"W)]]!<)_@S+$=H+YM;1XWGC9?Z"Q>>W5]FMBE?\MEAJ%U+?
M\18)!X.%ESH%_6SWG%[#3L-SJ;-(F+-(]W)TJR6;2PY9TI0?7,]CH<+'K`>\
MY$+8<6QC,0IA"AE-_/[XUJ'%LW0$>@6!\9\9.O8W>C>$78[/F+]Q4;,+[U'1
MQ&3B*T2V$U='OA)W=9.$$2F$H&3CO4EZPOQWF1@=1(KVE9D")=6$I_`EM105
MWTP31+4\;;GL5\)><4%/:L?<2Z^GPN_NK<]6TO4!QV]=OE*8C\O"-GA=GX8\
MC;6-Z0@)U@[8R'-^?8D)%>W/+A^?^T'N_!QV%>`I^LSOY'>+Z!5;O``/+O$M
MHVSC8'P5F?2*B=+`62=6\U/@9R%5PU[<LP">"%BC@2R?NU#&"VVB:T?MJ,\B
M<?1.&F-T!=O*%4Z*Q6;GZ]FE/A:$2U&$D<0+H\#.@U$@!VU36FEE#1:;5"B@
MRDG>Z?46BA0$/F9ZL*#`5]@'OH6)N#'^E+G'&RH9M=H]]IYT[IIC&[T=3-DF
M[:1CZ@!EQJ9;7O0':4,(#E_"](U*^#K`\+M+Z\6`0\RQ+K.=`%?.%N[)3C:,
ML*;O@4=RY0WRH8*TZ`$,@]D>$D44X'DUA9"JUC)'N1LGO"A+YIL+MQA'9)6"
M6`T1O%H<L[O@:ZI)/<-S5WS<7#T#-ALPK@$&+7'&U/7TB7KT_&SP6!@++:!M
MAFT_<&I!O\[?RBN@L,@*6@)V6,:$;A$0]N4;F`#H/\8[W(A1PBP%O@DMF@ON
M/?J?,N<#O\S!3IB)_%V:HF:B"\:K%Z6KR`R[VMODE:.DDT/8\X!G&4H1O(*`
MBF7A1X_B5?3*.)5NE"(A=]GK@(HUANEH^`E$#\2F&#F4II$?DUN-B%L?UTG%
M$B^N9P6\&"E9K2NL@28<658'BHE2E'FL?I`3(2H[1;K2UXI#+Q%JE.F]9)5/
MRA-'LW>+]I/5'Z.Q);H3EH&D'F%N'.76GH5TL9"1&*5*R9'-5K.0#89ARU\Q
M#H94@Q&FW_A,KXR#C?Y(7P,BACEN43$JU<7R?*O*9I>R[H+%$!V)>=TRI+D#
M:0'EM`X!;"Z#1T)$C)US0JB3S>+T]"H2R#L+5B&ZX#5?]K>LL`4--5S0X_*E
M[8:\=`5+]62H(7T,BJH:,%>%+!_&1^/HB[VDG($`Y(!=)L*=Y5"4WC+.4@]@
MPDO"2O:ILQ,B^9$LL)PK)";,)7/#0:W0>Z!O9^[\E@H,;9<<PDO/,8/`UB6G
M-*QZS9(:'"8?O$(4^CQB>:0`!M^<HM=SB^9R86`)*I2GB!=FE<0+Y!8(8.X5
MSQ_.A?Y%FLY%L&96A8Y/4RMLYZX3B_%WC#F!+#K@18EZ("%7/*8A(MDC.SI)
M-WEI%.KF,1<OSBH.8NZ0``1N!=/P(4<-OG7-G[GDM)HE>\LDNE&48"#I,_]=
MD`MO71&;'KBS,[HEK2+&KA+S32SQ%YE-S^U:Q7Z7E@/-G_<5DY,*W\A$2I64
M7L$NUS"W>7O]GJ>1?B$A?=>F5.1A%ZOU^36VQ)\(VY+@$C*[T2W[#,($KC/=
M6[E>0B]"Y&9KO,P.-7[_4CK4<-@E(:K:(!8N/??T!<_X.0R[V8LPP8M"^0D]
M%A66N%AH%UP"+`T-FGF%ZMS#L"-7\[_(L<1!?S`P\^%$B>[\@8S\0GD2>-(,
M:+00R9@$4]HZ5)KJ'5]56+MLFR:J*\K,G/:LV:`WFN1;X?1RSYB#WF0Z[@T'
MHT(0%\0G]]RL-QL/>E.K\%RVVO)RL"0#[U$<_(OE$"C>DVLR;G@%/3=D?T+0
MI^%2FK#%:C-&(G>5'6.DU1J!&?"-E\Q.X.[VBJQC=F9O#<SAJS0%0#K=QV0:
M-&;2Z7X/G[;HOX>4%,QFR=?>[>'QC(VA;6I<EDO<KCT$B8<;4.K-75`%A(<K
MV($=,)[=&,K*S/])[RO][BY)OL!\!OFG*0DIY*1SI41T;05=6T'75BB]7==6
MT+45=&V%\[@;KVLKZ-H*9UM;@=VAW^UPYP,RN/^./B^_L/,YFP=RKK)3GLOT
MLB!U\ET2*5SWMM2]+01D/GV^?F^8QH5Q]?&W3Q\_?'Q[^>G:N'S[]O.?GZX_
M?OK-^/+Y]X]O/[Z_.F+(I6+HJ"`Z2EI.4/FS3)A=(Z;U&_'QK/7(7#W9%9DO
M(;9R=;\;O[H!;`5#>TU@'^W`]S[Z3A_O=-)[5W0;SDX%BC</>D8I6(2;22E.
MU$N;/SW<P>L>+X('3)I+7P+[^Y2,W^-%OT?WGS=NL(;M^<IV*$4VRZFT?9;<
M["3R74\Y_<K?</460\VK&SS'IC%J,5,,L,<$6\CDHN/9EIC=\61];H#,M[#%
M>O\=%R%*UM(J34=LE?BGXK5X]`3P1&,HT6,4DY4<%,S>EW$+:Y#G0BF#>8$_
M!LOX@JFR`X`-7)7NGWCV0QHG_$3P2Q[P*9+>^VO_;_V>*OD<O_(^P6HKMF_\
M01:`HCZLP.4M;<0CS>7]'Y>Y`"?+%F75ZD79!3__NC_]8H++CU$N%A8_%#(>
MHV+WL%"DU]',(4E6\=@?TRZC@GC*_<?Z&<'MUN+/L#3VHY'&TM*+-Q\"?M;R
M+DQNC<O%BN7CLV61%N_#N^+B83&>A>(6&[M]Y/^3R4CQQM?2#:,X^_H"1^67
M0'OB*-C_]R/-M%[#CIR(2^V@CB!-[[]>9V%#+X#=-.U>$X?$CD6BB`T>`KW'
M[69)7#:*+8R-6@%K>^L'(ACUN"9@)'^S$P<U9>%&6(,&1*X\+SR]DI6]ET,,
M5#E:J0.^!,(<DIL0QEC@MU_^]O;=JW(:.`>EM(='JNO*T?':ONU%0<:[PCT,
M^2;%_Q#;@UD7HO3IDY__1U[+8F`6Q(._FETB=%&O=[Y<>K;T^C]H'FP:O^5O
ME]+%0W*+]<(Q4&`G\5V0=1L"%N`-17Z229TUJI@;%HA%DU'$UAY-4`.&\E2$
M'?!>XBM(?)IB10=GS?X4I#X>X>K[*<$!S,EE<IL`TUAD7<R^LI*S<@,`_38>
M)*2JUP>1=E%7\1J#R_NHW=M>3_7"!]%H[9Z?16?O`Q>-&PIJ(2[QDA"\P*;"
M]-;V[85MW"0Q:PO(%^N?2>A&\+6LS'QKET<MZ3>$]:O!R[I9V\#<=4[)OM^$
MR"O?7I&,XO<>F,$HX!^,AV^D*AK,MY/\$%:W1G;9"EF,)8\*;S.`)TQ176Y[
M24]HTMO&6TOFW#SR',+X`9MGYGT<_`NGM@!%Q0NQ.=])\B5P#F&0W-X5O4O&
MU6@3J^"#-%63NZZ^N'"M8KGQYSK/Z%Q5D78+9WY-1`I(FNR:K73/>`A";_&`
M%X_%HF-W3F8$2UXY46'$YMHN/0H`Z6UVUNJ'W5_/7XSO&=F-^)ZT;B\C6!'6
MC+.<4$TEDB5`&WCHB,$#S#T-N/NZ4T"SJD7\0M4:\WEN^!7-U*')B@CEKEDM
ME_3V.7VJQ!2@-J!7<O+IK7>V=-T-UB%9LP(Z4D)M[K1_,NCGPXM8Y,6CE[_5
M+C_Y3IPDEDY^2]?G:2+=@N6$P>8L-]QPXW#E@C>;[[UR0_5C9EK4A164Z,B6
M.0,;CE%1V5%C*0]R$2C\:U9*(*OP(#*3^,6]2MM.!;DT:TIFURC/K!]*.0&3
MX@/TM+5X2+ZA?D1<KE5!<G,ITRUD4E5T8G.=B6AKF0F\7&=[>/\M%IJBX+&Z
M;((HM$>S9KC+R+66)BKPJQ:B^I+(T\>5YAV^\O<>;T-<3E98`_5.O#/?,YI>
MCTNK\T6!=XPB2"?>)OYO`JIGSEBZ13&N0"//A#=6MHTK;K"!%]?$N?,#+[A]
M-&B+VV4."I1[!:6!9L+Y`2_EL4^MH<FG;EG3-X'Q.7JPO45@O`V3?^<VJ&[@
MP$>%J!((Q$H`5&Z'TML,IWG;K7Y,LAS@BS'[SG.AZ>Z#[DKYN''&FEBP!JO?
M8D4*GO,B;H5D:,2EDGR/63Z,2+[-\'0)6G1!"V*PLKIX\0?DG5:##-+JE9LH
M8,1N(`U0,+VV>B/R:9CWM@P2/.*Q;[D.T(H=G$:$$O$6^)FO"+-L-B8=\"92
MT3?`^BCMJ9>:OVR!I-L;[,(7WBAR8AHBQ%9[(-$)UDUCA<EXL0,`.)L]@IWW
MA*KR9NT!CS)@T<T(-A`V*QW%FN4:_TIL_@*NUGS."%3<*U4BM5R31<(B,7/$
M36P0R,87]V>!2"R'S*,@WVD6#`SPERV`GUI'\*$P[UII-:3";5P('P(N7UP2
M4Q+[QM\5-H!]*UV6C&`*ETK_@E6/2XM\!<MMDQKVQ^I9T7SFS7619&$"$437
M38K+@]G`H!]0C>)"YYNM@"N)V2G6`#,DD81^`3C=W`VN14E#68HTU:MML(%'
M55XZN>SJ>97I6+/]Y\-0H@C7--EN120=D43O?T$U[?`Q6Q]X,5LQ+]<6C?_X
M<9E.9VF[7I1RAA\FI/$?=LLM74"F6NR:YB9_(">LU/%&3X-*.ZL=QYEOYUU6
MSQ,[!ZX7\DK0V]_4N^%KPE=33"*KLP#@Y&>N(">ER(5#%Z,[<=@H%S>$_=3;
MSY\^7K]_R[C_R>:6"G-)77;"@9K^T0?86`?9_=W4=W#9U50F;^#5_^FSRTDL
MXNB@<W=%CT@0J'T`)8?PB_$NWC=9T#KCW!+=TEI;!KW;R\H?^+QL+*M"NI"J
M4&W<,.R,*V/X.#),*CC#8A29F1/8S8"E85UJV=9"$?SB4I.AL',7X-4&2EY*
M!/Z&Q^Z,$C%:2E'*NI9[H;"AY28]U=!B,5ZN;KTTTK!B+@AB1,7@$MO/Y5":
M;@CQ3?D-H?!/4AA.<YV+VZ+LSHV$(-N<1\R&H1=><W1<JB[\5*>`3Y614'3A
MLU@&[*]3]L%2?,=R^]S6[S#DIK71DN/F"1=!WKF]9!6':62&*]:VE7DE6U%&
MWUUZ^)%1SVXHIP:"LD;XQNGEJ(S302$\\R.&4.]@.38%%K;Y?1+BMUS72FY*
MSET"";&-)2&8287EQ0)CG%:WY"OLP'I$QBU->N![!,YQ?ET:7!H.7>4K:_3\
M%>LU\/,OB92<>U3R0.0:XK@M8H?-4N1X8T2.&7SJ`U_S'YT\+*#])QAT0O+$
M70*%NUPBBGEGS&-@_H7+`@XA"98MEQ/>?`.C2*F]H4D8]!B"FBC";X5N"FAE
M8,7O`JBB<KTTB/26UH[$)>-%$=K-P(_9YEUM%4I59<$O_T9OZI1S6$H'HUD=
MY<)1<K>8QDZ-MT5Z$6>RT*):PL3)#5?@S&BGQ\M8C-'!C!2\F,*12`IU9\=>
MA=)<MZ'-JPC3PBZI24+BV0T/48:5WX-?D#6A"6@L3!G<X)JFN_@@).ZMGSMR
MYK//XS16TV;;(R$&].:+SQUP[Q%<BJP\/!"167G,Y:3!IK6-5PH)CID31%[>
M'7,?/)RL5$T>/EN@88CI20[:2]A)LAA-.DE6!S_&756O6/R$MX>*6'4T!P-+
M$HTT?K/@=_8WV&@%9])<HO2^H=@Z,MX8#EZ`6]#ST6S;ZH92J%Q>57PAJ^C?
M<E7ZG(I6IAXISXKFC9:`*?*+6FLL)42UA$+4`B30`:,@R7$I/4Y49,=%1D5*
MNU3`:L(Z81Z:M(RPNUOGA9OI!"NRDHI__HS.P=U@+!=\7V-%%5XZ*DAB6KJ1
M*6\D5V#>>!E0Y[]2(FYJY+_^*N[YK:6LZR-FPSY[1:BL]%&$!H;%I&AIQAMT
M08$-:SODSFZQK0W+%?9H]1:,I>3:U_`:9AY1NTKRZ0?-Y?OM\O*+G.N@A7LK
M84X-X?XS(G+MF71AV"*G$2V52'1/!2I,FAMNW*FC#:!"G\IJUDL)AK9Y>`<0
M?V5_(Q*+:5`VBI+56JHN8[-]&7,"T.\@"[F(GKBFC*T$7/LFK85-'6DW<CQ6
M6P_]:)IS0?>HZB^)DB5RHR+E5(5WHZ(G\YA\J;.#%#9G7Z):SZO]7SHQ[KE%
M+P'TT1;N$H,_O#(OIKBD7-JB[%K=*1&+&NK^(?$='E*B58Q]Y[%[:KS`>^^A
MR)X5\\R:F&"U>O#505&"E>L8Q+]WP\`7G=JRKE#2SB:_3THW1%?%Y'RL&46S
M+OK&'U)'$;D/F-`;6G`@I.E,,"JC.=KTM7R:AKUVX^*&0BY-+;TPVZ.P;-\H
M2$)'T9^,`P"H*X8FN9W/@EJ"O$Z(B%RZC:9CVA[M4&8$H7OKTOTE+`T*AR\B
M@'S^K``Q<P,1#V.^U1)?%`C9-WX5[Z0YO/X%ETDNC$)<Z(;:XX-@\B`?A@4]
MI')N=-EYJUKRW;G#PP-:P95M"W&$5>"S*SOX;/J+F%L^<PJO280R77&1)RQ^
M`,X9;/]?4INPX-F$>`'%2],G:&`Y,QD@5_)6F6WZL?H%SJ=`N,V*=R]>&R]=
M?@="ID)DEP[>E+X89V<'[&F#;7\QI837#*)/LE(S+UW^^MR<A.Y1VY/C'V>9
M$=T1$O/'V68MRDJ$I,T967UKFUT-(;'3?R53GJO()T^B;[P5N"3/XY8FE8F&
M00)4[#!TV=Y1+IC+]H!AB@WLNDG6H4^[R]L)(W5ZB=G1';V%#7OV;OK`:0B"
MG]>QFK2TL_D%R\OB]:,]%]A`NX."ST:U/VTLS.M%95_*EZOFM18%9H*[EV3W
M8^*[D!#$K_B.I4@2N:65\%E%VD2/.\\AX>DH:>4GFT;A<*1%:#]@G#)DK0)0
M:>DU.GN!UY?E^D[PA6\^IF/)U:MAQ7L\;\PIK+[6L.V$+9]45/XC+(R/Z$DZ
MIF;2Q*@HTEIUPIL`X']@Y^$T;2^-_H/!X)XAB#.5XK7M?+-O60`4E`P;);'/
MN6XLI.AYE/:7)')=R2S>L@)?#P.HS'QF01?>BZX+;!?\6^+5O[O-[)$J=E$F
MY2J&;F,^GJN`$R':&*4OE/ICX;'A_NQ_4Z:#]M]CGAI\YP[`;./PU%-)'2->
MM2QMQL%X0.\W=:>,X<<EQL03:EQ0>5B_5>8KEY>?WM'CAL:^#VC?;+0K/H])
M\!8U["9E%MGI4=OGTRC_`Q@P`L[T@Q^)3&<1\L=[`.(Q/`0-,8$6=Q0/+`TF
MJQL7W&">;^30JLWLCB<]1)."27+8""0@B44UYP59L3K/"S'E+?6=M9G*$79;
MPTQ]P0O](<__SI?E.6'E$:N"8E4N([BCM%ZN]DL;:@GR^H%QL`8>KK^G'XAR
M=?0S46UL,/A!5*W95?@)7I@O389]T]WEX]:B<\.)*#])UV=KZ;/1##E0KV@1
M;QVZNPZ2(+K26]723IT7'ANP67.MM)B][3C)*F&AC:V;YC*]>Q57:JA>46R1
MLJ)S-&N-/()&'E;YJBB%M4W5*E5A\[(,5/%SY^K<EG^IK>M:;S;HC6GA0,=2
M'&.G`:3F:2_].LPKG_*60TM>Z7E=UEF7==9EG4]04U67=:XQCB[KK,LZ'_+E
MGB[KK,LZZ[+.QXE1/$,$_7>\[WL7>`O,<<?X^"J](96U]-ZZ>10G#.Q.!':*
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M-ZQ<0=$=L]UHZEO$LT`Q2T^LA8(&6@4`OT0S$VA!TD6Y+FA*I@U+#5]0S5?5
M05XQHE02UAP<\ZJIIZP_=!K<L>K<N/+Y3?>8E@#M#OI<HQ82G]`2*5*;8[>(
M!/(5(WHY.Z!]+O-%2G_,7:):$,S"3JN"J=6!JC.OA8=5`S,0PWI,-`E[!3.(
M1:74U"?*41V*ZH3L;FTLSTKN!,U+<'G4]XK%,[NF4(5RO;/93M@_G^0O?64W
M<(RO3$([?9E7=NKYS2-AY<#&\*ZP6;.2*"U2(^W0Z?/BR[2>#K,>!NT=0`LU
MW?"Z)OA&6JZ3EJYU:5_H*+%IZ2IAT<"TB)?)1;#8?JD'6H*;+M:7@56AE>OL
MH(T*'';)B>U>6)5%FMZ'`R[=[XPRX?>DM/%6*>+R/IN(N%V/:76A0O&TU[Q!
M>Z24_`HUR5BM_78;M^U*1;E1JO0M52R7ZSLAUTK%Q567Z1.7_9956Q?CA1EX
ML8RJS+E>4KTL:1B_=;%*O!AOX`M%0_V(:($V95FZM-P[O]><MVY9>7?7OP^\
M>^F+Y6K<ZP"M<<6*X4RY\5I62+#0(2MMFZPO6-%W(7.BHGHACD&RFUU\`@^V
MY*0BPR3_)(U4B@+AO!(;9;VXO"RO?[8?HE,K/8U3,D>\4NU+5IV17JU,77[Y
MZK5\-Q0H7Z>W/S?.%OY+82WK;K&YC\"K_%9N(0H0>C:MC.N1>YN^,68@O,95
MSG5SR,W<7F#:8+1AWKPV3G8#K9<?7-K$8:UC?IG5#9UDA45R'!SY/1:X*9?,
M9S4QLRJ"Z>XM+;!SSVI+@IZAH,EWU'/*XDI.GIWIKW1QG:\A_R2[#9P1A9U?
M6!&A<[,8=?8[>8N!E9U8*1"6?-]EJ\"FG-%1G#O#`^'Q]#+/['A.S3D(Z;#.
MO<X4A%EO#+YGI:E6-Z*R;^K6M%MHLPKO*$VB\X.X++*I^TFIFA]\YL8>`^+1
M(*VB6>P@PK1^<RWT'C?'S/2F=0Y$*8.-/3[8*U7M.HR764><5YM[=]#1-C?O
MN*+OX%RXH:9\)95F"-WH6\1)?P#GC+<7H4:$U_53<JXH88)=XLJW^#QSH=U<
M,(7>(,,<>W8OS]B`0+1I`!T'Z,U*U^971>F'IA:;%7#!5PF7*LJY5%&RPEMM
M:4!9U'5)*_FFJG,O5RA3%3=/RP%+'H)PO(K2NE$\Z?E<H5.K*$:`12>3&#T'
M5?E$^5(]=6F$I\`O,A?"X4LWPE`2[51!6`WN3W@HC57#AP.Z<_;(AI>*B=*2
M052#'O<:Z!VL!!O(U%&B[81]JVP&OI*(T(:.J(1R`4S6#Z=;T:$=DT7(X"!,
M'>2TI`RW$EC;6+[0NJ0Q'JQDZ6&-T1O<$H:@[4&8&A:$!1LWH"\W-[YRP#&B
M`=J87J4%V.8%TVF1*^G&D0@RB"YCX:;I2#41C=]".[<9+S0:O<H:"*>X^'FY
M=*4Z.>#M+XTK!\L$N\P(L"\#G,N=1#_Z"^SE"+[<=6@OF(]&DTN+#8,^O[W*
M+OF^X@4)4I!/'4':?@Z[4P0K(NAG6^'TI":-M:6>'V&>']V8E5I_<?R1IDQ/
MAN0.%0R]4W_`CF/;N<L:/S":>%6AK4.+9[,6$HS_S&JQO]&KRG*C*FY*U(N:
ME4&*BO8B$U\ALIVXR?R5N*N;)(Q((9XD6^)-TA/FO\O$Z"!2M*_,%"BI)CR%
M+ZFEJ/CFL-CX3,M3H?9$"7NSKCOI27POK8""U>Q%YRS7!QR_=?E*\<R?&U;$
MB<8O:8M4%QO>;0%F?IN>"16M*BHG?_J%]N>VQ^L^TXXG-/N`5G'!0WZ:]D0I
MVS@87T4FO6FOG86J.E(;5_-3X&?Q4<->W+-HG(@^HX$L'Z*PEC]<F^C:43OJ
ML[`:+9'`&%W!MG*%DP*K679H5F."1=12%&$D\7)YL(U@%,@1V)166F^-!1KU
MN>@NPKPGG8N^#7S,V,[*GSI8<CJ6=KHQ]6DR^]$MQ_B#M&'#[GQ,A:C0K@,,
MC[NT,"#XN/\4A5K3E%':TF\C]V2_&>L?T_=@VH%<%"N_E4]+9;$D!)DBBMF\
M!A?K4++,4>[&":^^E[G;PM/%$5DN)RL6A\5K8E9M:!V`Y0/'E3<6C=,$B4B:
M#=A+5F>6EU3':+AR]')J$>8YH+F%;3GM<D5KC+&W\E)W+/)!RYD[W/@@[@0D
MXHE+'H;<>4(4I82!/^UH"T8*FQBC2RES/O#+'.P$\N<O=Q<U$[TJ7J8RZPT;
MR-Y3WH',MS'`DSW8QH"S&$H1MH*`BF7A1X/B5;0HT:-H42#D+GL=-N'!,!H-
M#\58*[P4V9.FD1^3&X*(&Q372<4RS5.CPLI(R14R3WU3WG_=8RT@4B?4#W(B
M1&6G2%?Z6JGE-#-:$KV7K%Y>>>)HR:0NH#3VDU9P%C.L1Y@;1[FU9R%7S/,6
MH^@<[%V$K2K;SBL,JUZP0!UN@6`#87<[B2C%8UJN"C9]P2,A(I#-.2%TPF;!
M<'K!G?4Z!.Q'B,#B,>QO64XN#0%<T#/I[,(`3T'FS8>SC_'N@F+`7,W8?*S<
MIC<9^!Y//N8'<B*\9\'=3(XG:>T:*=\Y")>$%5A6IP!$\B-9]#97]E78/.8>
M@T:B"R!?`ME<J*OMDD.\--,Z79><TK`BAZ(7-,H'+PZ*CHM8'BFPP#>-Z+K<
MHLU;&%A]%.4IPGA#XA%)O+`%A<>[N*GRVD4NS$6P9J:!CD_S%VSGKA.+\7>,
M!8$L.N`*B;)Q(5<\IB'EOHSEKG8WC[DX;E8?&A-T!"!P4Y:&]3AJ\"UE_F`C
MI]7TQ#M'HAM%"09X/O/?!;ER^BT]"&-=AEF!&KZY)/XB,\RYW:38A_(NW]LR
M@`K?R$1*==51;TNW$^;7V)9^(FQ;0#MG4MCOEGG%GD(.V]^X'KVIDI^MW`KG
M]R^ELX+T?LL-]M``)47Y]`7/^/$&NU>"6LY+?_H)/3H4AK38U0`L.C8V!L6Z
M0FW$OHA"2W/-4@?]P<#,1^DDNO/G'/(+Y4G@:6QLLS/-M*]9APJ0ON.K"FN7
M;95$76R9F=.>-1OT1I-YCJ&]W#/FH#>9CGO#P:@0&P7QR3TWZ\W&@][4*CR7
MK;:\'.P@WGL4A^-B.00(]^1JVAM>08_CV)\0LVD4DB8UL:K:D=1B4*ZS#<R`
M;[QD,(\[S%S;[>&K])A<.@''A!.T1=()>`^?MNB_AY04UK-;;G30HZW=DXB=
M*(A[7D'BX2:0.F,75`'AX6/#^'C2GZ9U'5/`M`;TT^>&\CV("VJE5Q46_XAH
MKIS*X`3ZOWW@:Z4.T'H*.4=)VAV)]._4#XL(]95C++%O?+B\^M6XS/*^KU"!
MZ0;K;;"@\0+JT;V\O'K[RIB98QZI86\OG.>EMT3Q\)!Z=E1=0,\6"[K-S;29
MN<JKA%YY`HIHPRP1^\_-1/P-VXULW$ZJH8$Z^.(F*"@Q+V%]>XN9\#'+DW$Q
MW9CZDWCS''@0XDC/H<2#G,NCOHNXBXR?>#?5JM2LOZ?_;-7=K)S;!4O>QA)N
M?E8[+E_\+:_IZ[ZQOZI_)1@'Q[`S0_=<^[_`AY\==E;[>B\,V)L_,></_)?Z
MI'48L0]6''H!!_5H_N@;E\DM:B<SAJA?V<F&$BY^#7#;*SF<B"RRLR96<L4L
ML'0MA>V6^"%_O@U=DEYSI<>$M%8Y1F-HSEN^BZJX1L+4_C9`\NAY2LC/$;"$
MCS2JLL<>CP'G$(R%4.4>O(L@N8DY-6RWN!<YZ<E)VNJ5M@;A`)TR9!D$,0*9
MQ!(>/TIG<<>#4]0CH2UZ^960HG\SR8.G%"'F&&XO."931\ME!8\BOKK9O6]Z
MTFZGW0IH@0^'=K?%\#%N[[&:8.$\*;NI6\4KUSI:64?_L!]E!453SK4LE9`@
MNW5)`_HBLXZ?`$I'*NEY?I1@,AY9$):J+!J&J>[!B&%Z?%?"FHNS[+4+])_1
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MAA*M-"MJBF0VYU&^_\5Z)J:5EF"&U,>F6B6;I$T:5J`83Y]3V!8^+"W&Y*YX
MC-]/LC;KP"I`$]JH')<K-.PE'KFG.&^.&<X;+V&7B]=V!)Z[+&JP1AF+`9=?
M%>65_H$=U2>\C:]+A0RO6,=AD+9_#[#Q(*W&3V]B\TZS*!8,#.03%^F&!\</
MH$D<L(HK<B(?0KR+"V')0ZAM7=3E]/[Z4Q)=W-KV^C7MR?UY^47JR'WI+ZZR
MD]+,T_F"B0T@G=>`W+]Z@?/ME__\#\/XZ]K[_II?3?N:BO5GV(>\(WC@BJ1^
M8=%?=_'SBVO[=CP<OJ`B`N_Y2I8_OW@[GL[F(_@P`4REG_QY]>X%H((#ZN1%
M/[^X&+_X9309X/_]]:?*XVTAKTC02$W0+U_,T3\VC"B/(9AYF?5J>">U:H"?
M/<(Y>REU;!#-(+YXR&=_\3[-SDX)&RL(&V[C%!!MF:/QB++JT'3E9[OQL51`
MLGE,-C"8[^CPP1_?+P"=KBXO36LXPK_C<O^HJ-II[.P#<,#:_ZC%`==NVKE>
MV;\#ZYNN"6]KA'9)'-LZ=GJ>NJFN_T$VU*QP?<ZGLL;]>2[FM'$_?=!>`)VN
MLIY>_3MN#74@^R&TUS^_8/]-E[!8OK7PF/KUQ<F^,?@JLA8(FQ5'9FHE_F7O
M@E4*_%L:,Z=T9[_G1%\UI[3&^J3$AB?4QBW6?O\O:DP&6?5WX__`/@X@$,3P
MM`R2MZG[\JH%ZU_85E:=W'XUII5*EI_E)I4ZU*Q?XLM<_(G>2!3]I^G.(4@B
M,!?1*SHQMRLK6U^SK?/0;#Q-TQI]YI,[L4076Y0<5;I'"A[E?\LQ+/?+\W#V
MI*+4^/EGPC)2[A(.VO3AOQR'D.52;:OW;D"0GXEPV&>B8=<A5S7K:9.!0[[/
MQ+;%JX-Q8CKR;`[5N2$W$C(CC<R7>XF)Q:3].BYPKT<W;BB%2AH/Q?&_5.6J
M/'M:;F1?N:DS8[,XY4-/WQSU9N-9F0=[,J2&.(RI\)UXM0LF]\#*U)8Y:47N
MH"*/>^90*_+!78E#]H\ZLDN8-31+F6/[B^P7GG\<'LRUV!P8/XJD;9`RT?DP
M9%%8*H[B,Q9)'1_%`7\2[!X=>(X*-E9O,!T]`]:T70*>0+U15?6:(=_GM[9=
MTFYSK+7[9![&,8,5AP]0B`Z#&7OD]GZ']B.:H<[G(LI=!#/8%PVF`XUFVE?1
M:]M-]1Y94ZW>.AQ2XDF:(I@QA^;"RP$16E_*20O!'#@>W#15K[8J]4^$6ZD2
M3T+%)_"J,1!J-2MJW`!!Z+X=T/B@\:&RB_4<[E4#\>&X@9ZV^17=W^)M6M@"
M7ID;D>U,CKB/"CY#JS<8ZO"-#M]HW>ZB;D^'$ZW;.G:C.&:*(HDO[*>Q7+'&
MSJZ99A\NI`NGVI%IL[`?$.^Z,_WS6WSMQ71W;;5BG]WB-SI7IE#1X"A^32X?
MUY;*8.CC)QU>/L_P\DMSUAN:\S*7CA]CKG^1Y>#B\DJ?36GPT."Q-WA89F_T
M+,G*+0*/8P:.VN:/M(W>@T&@U9]AF2\LI>N1&JK=S<CXD9AU^C/Z86]JFL\!
M@\T[I]>^D@8*#12;@,+L63-+`T7.+Q*_TO;(V9]W5+/=79(T7\+T:_!H>_'C
M>][9,"U7.BV6*YT-AM:6LJN#%[],IOF:J_E75QMVIAIVM'78V:#RJ)_(@U3,
M-]="@I;V?63_5E1OG9^D>JMNZ:%;>NB6'KJEAV[I<=XZJEMZZ)8>NJ6';NFA
M6WIL;^F1>?W[>O;Y?<$[<A-O<OU'@^=U_77S3=U\4S??5*B\0FD+,08&\%&F
MRF8YNF"-Q]N[[@S'@T*`@;^VU`K&(601?0"S\19+W_.2N=+HEF+TB;5]=#;X
M(!??48^3]?KYP_7`:(.-_V(_YGKIC$I=A^;6;#3=3H&5DJ!Z=ZG[3PA>ZN]\
MP<'HOV5&XM)??((]$O<X4WI*38>0(SO68VH6.%)MT*<16FI"A(1N"4LAH;/B
MTNU#*/(Z6UZPR_#,[^"<^1&Y#$-T79'[[U(W2&&WE`V'K.;9K:T=</&'3Y^O
MWQN6<6'\_O'M^T]7[XW+3^^,JS^_?/G]'\;E;U_?O__C_:?K(QHBMOL\MM61
M1OGL&Y^P=A7=YP_0_QO,>P9H/NX`OAN_Q^",(4Q_68*S33&3A-2EYJ$6_ODE
MH"P+@*R3,$IL%@EYN'.=._'(`P#T+8@3`W[<%GE@M^[!?WX(0F_Q@&$+CXD=
MV]+<$R]8,Y<Y6('WBYX:;N.0LELO`0?;CM!K7]H]?!M98ZMZXV,4VL3K&W_B
M%I'M.L!,1?P]_L)EFR;N)Q;)+TX=O%=PXG$O!P_3DQ(6E]E.CTS'963@BV%0
MMA/YA-$8DYJA_TW`>&+?BIZ@`X9+0C&</`JSRY0`NA?]-;3_[7I(2Y[>;-:*
MF;%/5O8"-R*P"X9M!RX81^[2NX!%?Y%/82:#?OX>H@'JZM']`=T:^H3M[.B6
MA?H"WXF3R%M#.Y427(WH#MP2T'<:'F-;D;7M+DK"9^`A"KX&'/4<0>--]*0;
M?.X^P(YJ"3"(^YXE.`G85@RVX0O8MRQ<.X:-*,S@'C>?MXS/:\_V12SQ2_H,
MO(QN?XB8SOL_+OLE>7&(BWM..T^JM9'6E;!RZ4)LX*:]1I\.>("CET7NYI$%
M<-Y=X@MX5,<JTH<[1BD\(9,XRA/X@Y@E['L3#Z3N)0R_Q#T4>&!@""(2O3)@
MGXC2"F0RX0)&1[;']N]E&OO&50)XP%XHWB=>]XI%:VXP_N`Y[%X3`HA'`T.I
M#"#5`=M:TA@7W7;!UMO^QN)&\&?N*^9G3C?549Q%>F`;N)"0C?Y=Z!L-Z``.
MP8O9_IM'#\3'&"+!!G1`.MA,6#IX&3B2N`9L(;%GG13&EJPKS.#SFL<RI,@V
MQ0E%S'5$2608$>?]X9!&PC./%[D$K%WS73"N5'2'>P4>?%$=,%8R'BQO.[MM
MQE=?R(>3FUP@)H?]^FQ$J+S84RG^3J,\GM3B(:<LT[ZIUA7D1>[)V0:MZ@E.
M@"ZB@Y^.<TEA!O8G6/.([YG8=/+\+>@)5VNJFAB^*3$WU8VM/*D2NFZXOR!O
MRO#D(-T%+K(=HHN17=OK8?CY(B3+!/:8N$\3%D=8^27)0`^-#1J8=*WCX);M
M*E,`7+HA*/!?QM)#XML".J2P((H+S#NTJ='&-H5L`XC[1!&.`\>'[UIYX''!
M#D[00[ASUSQN9KS,"6U>`D?]B5I6X;O&(^#CJ_Q&%GF6C9:R3#4L;G51INS,
M"6?,$`X5GW2>.IDX,Y\72ND!(*=`YV,K296EI+*^3B-IR?HBOVJ<YZ^0G8S/
M^>][-JQ2>KBSMF,6^/=XT"Y0&2\\-?N^AMTX8]9?+'F1RQ8RM;*+A,8FT-)M
M,IM@$/%0;;OQY%K\)P@NO/4JIC%H=%A%[)G!`#([.\0#/,A(P\4"UQ?]BDB.
M^,HG'>S(#JP3#2%[CSTZ!#X18L1$$DP^+XHLO'FNS[UI_"P;%E]@.W=X$+?(
MH4L'\.5'1!</V!PB>D3LT(<=+.;Q51Q<R+L*>2NA6'!^YNG_&P0*N`X.G\//
M;P%R[/5C&F>*P36-!4+]9H/_@O;#C;`*<"]U#+"?LQW"ZJ"%XCL7^J7T,(DN
M+CU:6*034>R>Z+`*<N&UP,5D:3LQ$PVU@]5^^W(IU$/XW_OMWF0;GN[=\ISC
MFRBZ`\&FNA1C`1W0):"':>RM?>-CYG6FFR=76D;J%[BK&]CPDMS`N(C9D5F$
M.S;TZIV$G2,644H\*LM-ZFFJ!8(2IT([CI!1!I&;A:VXU\6CQ1O/O169%/"N
M3,!III.+9V978+7I)G9R6'G;&IM1=U/.`K6U8U@5FVS_%H*3F,6[%!EKUF1;
M<'/XXA?P\\>S8GQURVCU*%,DM5F3V0[*QN;P^)25TMJ0LOF.YNJ#0I[?$0@;
MEP[=@+#I8%?7]_'Q"5,=(4S-76LYF):B^`>G3'6\,-UVO$`I&UG3HU-6.G9`
MRK;DDM+%/+KPCU6G#]-M07UDV/&Y53IKF,[FPQWK.+0&P^-+F.I$8;AC'8>P
MTI/:E%UF$8YW4A4=^-DC^`-\_5*ZK[[QU=D<2E:B`G?-V="<%X]R#D)7Q778
M=LXS+EF7AN8G;/,E#I9DGSLS&AH7QI>OG[^\_WK]#WIH]/[_^_/C%\5I42X9
M_Y!.M(DI@/E<#-E[/\;,"UN"W9-$&7$\.P)A?PO><!!^"6BZDGRSDN5\@6?.
M+T]@XCW]'2]-B-]SL\"?T[Q&-A&:/.;'A4\?"+N2D_NPF!AIE%B#P:.+.]5W
M=_&KAQO`;*DNXF#-[\/P#\1U&KD1K3D0_0+%-G[SE55XH?I:JN@\F)>`346&
MQ,-6EONZ^5;+\>2);R@VR-'3JY<=@_#2NS;2DJHOEXGBR/25N(<,>#(<['+7
M'*;I=C5M5FC@[60\@+AYY&F<5*G2!)[(8''.98"9E?Q^P^;;3H>Y'_1$`#.M
M4AZ4->[/Y52R4UR/RH/5*6>W88][:,CD]_AH!&T=`?O$3RD<-A]-.5Y-`"<%
MD+*KJ*8`N]W(R2\@5KC37\:48I/X31"UH9?\7K=RCX*VL$J!?TO/!"C=V>\[
M83?M8C\IL4%U3]*A&2/'K,5Q9`;))[+[\JH%ZU_`PJJ3VZ^BAE+)\K/<I%*'
MFO5+?)F+/_W9O^H;"P0]%HZ-[X(D`O,:L2(B;E=6MKYF6^>AV9A5H37ZS"=W
M8HF6E>SHTCU2\"C_V^9MP/-P]J2BU/CY9\(R4NX2VE-8E#OL,Q'8..2J_BZN
M)4CI9.E.N5X4H>)TY-DTK<2:BL9#<;R9G1JR\%EARH>>OCGJS<;-:AEWS-4^
M;M6IMLQ)*W('%7G<,X=:D0_N2K2HS<J')/1=O,6?,2=7H=P)5NLDEEOF/M&U
MV'Q`H:OD/S?P'!5LK-Y@^AQE>MLN`;H!2G?7MDO:;3Y+$>YV2D"C@Q6'#U#@
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MH_YP2X_F$S%#%S,^;C%C0U89;/#G+A_5;O13*ASOK9>59"Q]Z`9_N*E1S%@U
M^4JDR97A65MM*5!:Z`RXH:9PC+U@L`W5YF9GPWX^KS%KMU=X;*Q\K-R_;[BI
MTY]HO\0ZEA$?^V,5>R-:]-]#T2%Q5&SZ=Q#LJM!+8&=7F8_^/3P6A(]?[8<_
M>&.TZ!.)/R^_$FP01:2^!Z4N*15Z!EC#D95K&;![P-H$3DK=4BHT9C`GYN0P
M!/X]"+]]]&EC\F@3A:6V*158.-_`P,WC/8'`4O>4*BP<'HK"#Z[O1G=D\1NV
M0=U`8:F+2@46CL?64$WBYA&?0&*IHTH%)H[FA=X:>Y/(>[?ZM_12=_0AP=HQ
M?\"75\F*MZF/WB7DHW_]$/R#8E=*L**O^]#:TC-J`(L^&.3IW7OXNM3?A804
MZ"]U9#DJ_2D!6V?P%;[PGK5*@T7+:%7TYQI:6[I@`:WSJ;F-U/Q(&^1V6^^4
MB>Z=(GG8GMP[961<&!\__>W]I^O/7S^^O]KF-AVVZ^!TK.J98NFF*=W?9QQ\
M2W&(#40M>=)-4]X(`';AJW9<VBAD6P36SS?"!I>\A2AKD8(1EQT!GL.$1+0N
M;]!EUB#E:,I<BB:68@TT#+"GSA_FI4]YR^&$C^*)5%RZ^,WCR;#N2+.[6<8!
MBHGKGC6Z9TT%7K5@_0L>M.Y9HWO6Z)XUK5[WFAI]II/3/6O4W&M"SY8CBU+C
MYY\)R[#EO&C4NI_"X^E24Z"O]H.Q$@>+]:)B%<G738#VF'UW>H=8O>&H63EA
M36@=HGL`:3UNEQZ;O8GY'/54FBWSYU0W!1-H,*:R#H/;$&NHU$*XS6=H^B[[
M<X/)40%D_AQ>0-N77]<HZ>[:=D>US:'6[9-Y#*UJZ2/218U;S!<]2GRA89JL
M:PD<&O2Z4$M@W!M;PT;MGAH@"]T'>PT1&B*J,FK4FS]/I:+F0<0Y156N\3:A
MX8J;$=I%TB4$SKB$P+0W'^N6(-I/TCBA<6(;CR:]R43CQ#XW&PSYEP-<?CSI
M?/4E/UU,Y*!W`4]:<T0Y@YT$JV_PO4M"$."=)3_D8A_X[-M@M;;]1R,D#EJ`
MK<5+S'[^G']S51)S8YD3N<!(CQ8I>0@1,Q?!@X\W"M/]CD';IAI.$-&2*R&!
MSQ,2]0^">9LJE&R[A[ZI7`62_PZI3^^IJRJ0C'95IYA2@ZLJ3R$&J$S`5%5A
M9+2C^`2M+U*%@+7W_?7[U=H+'@FY@E4);=\AGV]`_&FI'%Z$("-&54QD9&ZO
M>C"=4E*J#56/+%4)D6T\0K+FHZ.3I:H;LDUV*%GCO<D2B_R.+,$`+=["D*%[
MD]#G/-OGKPE1#<""P:=V^"@_=+D*$IEL52V1'8L\F>;E[6FD'&=:I8HCNX5D
M-C`;/ZU2(9+=0C:=SH\]K5^)#S_$^!KV5/05C-*M#X9N\='_#-8J1&L5DCOB
M1V!`/OI.L"*_![1HSV^VZ^./OQ*P*>3:_I[-ME3*9+=L#B>JR1Z6P)/R0%DZ
M9;L@CV<=X\&^9AEX8%FGX@$%[^_H&I%%"MZ_N_:-Z[FQ2R)1V^=#$+*:/U_`
M^0\6Z>QF2IN_?7:SR3`S'/N/72:<\B=.&23K/7-/BT0K?8/M1$]FXQ+1%<>M
M4PAI5O(3L!#2?+M!-H?Y.EY[5$*J2%7)34"J)CM*28U&^U*%3/X#QKGS'O'/
M]$'^3$9+R?8#+</!=FPQTS7<\/I:9;=@WQ_*WM1,53%L6Q4V)&VPE4L[ACY4
MK;.9JE;8#LJMV4%+G7U!\`*#[2\HHGT):####0E^D6M:M*U>UTQI>`]>K\MX
M<L1J2[DN&@?XA"6VQL:%\?O'RU\__O[Q^A_&A\]?C?=_?/G]\S_>OS>^?OSM
M?ZZOC#^_?/YD?'U__?'K^S_>?[HNQ!'6!Z&5E]W*8BSYV-AQ!KF^(\;'*+2)
MYQI7R4WD+ESPZ@PW@EWYOQ*0B(41!_#U;\2PC4@8$&/-]S;).O"-A1NMW"BR
M/=S,V[Y!^$;%"$+V0$S"E>NS:JOP"/L[VQOYAD/"V,;_NJ&3K*(8WQ_U#20L
M-Y[A<:OUB!1A?$.,$QDO;T`+%FPPC_BW\1V.@R4*7?@RAC#P>>SM&<7&BJ&2
M`03C5"^,P"?LPQ\C\2$&+XCMW-%XBQAH\8KQA4=3<&)9E`6^>P/?16*C.T+B
MB`<Y^"J.IF]^3^FG;Q=,HD'\B-&>*6%??&_VAK(BF[Q,@@VHLC3<V'@@(642
M#8+:,:,]1X^Q@-D;-*"#E(%NHW<#[P#6N3STTG(YSO%HF=`8&5Y=L,/86(;!
MBB[7.@F=.Y`6%I`"=&/R%7BN@P6R8&5N'IET11A@<J,[*JA8&9B!)GUS9#RX
M(&0P@NM@QUCX:1U$`)JL_@1A#S$IMID?:2014R;\$SX39133TERP@J[O>`DG
M>R_9^D!IRE<RWD_"(HD)2$I^>#N*8-B^\3_!`^IDCQ/@V3?`,/LV)/25$56U
M*+GY)Y(`4Q6Z[;DK-Z;Z#TN)(4DZU",LYZ-Q`V/!(D1+$G*TP:&#!Y^$T9V[
M%J7(`,+=>W>1`,JD$Z,AQKL`2+]A-BMC/=,(OBIDT3<^^C5*)LM1U/1=^3!J
M:DF,S"CDXZ73:0\,7RZV62@);<Y'I4<4@=?Y6/&B?-"52F4FU@ZE'9<4`3;P
M?7P2I(`]!NM51O0@#2JU'Q1@S6T'H9+.D$X:5]3AKJ1DAR01IH\)P4U-3%X6
MT!XB#-\F8"TRW<]]5;4**+!($<4#])_"P,.JX@`Y%+%!LD`O*(BG0@ZOHN>W
MJ!D1`=I)SOB!<F[0;PH^@F**B)Z'AP&>"XN^8(B(?]ID9>EL!)[`X)3"*(%_
MI;392S#M:'\80RB^<N\33<T-N;.]I=!@\:U^P:`!0\*$89Z$7@P@,Q,OC+A`
M4X;O/32!_/V9)F3+2:T>8@YPS0]B>&;IT6WE+H2E+RZ/E[Z(X1^5)K:,E$`0
M3ON6"(,A2XP@7Q@1$(0\WT,W^A89=_8]@AD!\0$9O0]0%AY5^"A)BDK07N(S
MF7F0=\T&QC:B#/Q?M5[-92-+W3Z9KX3M.;E!V'H"5@!@N=H^E7V^I/N9$/C2
MPYW+='L/JS&9#G99C=G`K&`UIM-Y^2FWCC$L6!I"_15996VC)&=]`V-BU.W,
MZ]%>KHJZ^\).'@XGNU@XGE7@H&65'SI4!X:6:YU`-T*#=1%U^80(;%6VV62X
M52J1I7CD7>3I&(>HY=_(KC:N'OXU8%$4<'7X@L+."4?O[:NLL[)GEBG^`^`(
M>KD99RB*XZX3!ET%(2GK3?M]+REG80D"?T%7=<UBQ&E9X=+Z%GQN2:X0RY<T
MS"6<_8C90K#TJ@7*/`<*)F7G!4P^R\F1@0:L=]YOLOT8]D1K]"*8?"!Y*0%B
MQRV6V%V)LCK%]5-T3*D9@RM$\N!KF1\KOL9BXJ5H[KXG131W8%#(':@PXA-(
M5![D;#G0.SV)\WU/8YY&(L;1OP:/MH?(]=F_`COX>?DE#!8)*D9*5.FT9388
M#L8245]`AF2JK!>_#/J#(0O4;QQ@+QI4QRF#R4X:)I5I^,/^C@'NRUMP[V&/
M2D2D^_,R_?)U\!O@/0SG$!=W.2EQJE.5P70[<>`2BI.,O4?>BW/E8Q9K-!ML
M)VZ8$K>#<T+DV&./)7E6':0,MK0#N1@#9\8%><Z_O-K`JG.0P?;CMV&A%5&=
M857M3\SM9UKSL5EYV$NVG4T7A9\>`<Y_"GRG<(HU+T%R42R+S)\`$P9%-*DR
MYN&:W<Q+(+W[`,LT\RD'3^YU`P9ZY<;LN<T'59/!!K1N56.9[*1J8EP8;S__
M\<?':SR&*C:#.63_%U/5_&5<HJK@2SXK+79?HJ;B3UR3#4F<3CT1:ZMC?IJ1
MS1JL*X07>>"8;6YH1$N@D8A9?7Y[A9&`-79C(XLH.Y.)P&KQWHO,,"Y@V^;!
M[HQ'*6'?#`"`,11_(?[&W'7<3+,]'77.:5!"1`;QW`<\<0Q6W#P:MVB<I3&!
MF+YQR?QYS+VF/_"'Z&M";LA[N&W`]G'+Q,L-GH8=/3IK(/Z?=+/R8$<T1&A'
M"$F+_E'6\A3R(F+H-,K)C\R6MNOA'HR&>_B4.>_MB+(<8'+I^KCGIN>3"Q(Y
ML+7%7VZ">Y+?W[F,4R71H6%IW*QE,@1;Y9"P32`+#8CUR2]INYG]9QI5QB/S
M-+(MIFR'()^W\CD%GW9/9M32R`7!<E&)'Y##N=!%X<^V=([,#[AW:6<J^#RT
MQ\]/*5DL`I*>"41WH(]TR<EWQ(">B/G8PK'NY:@S"T&5'P1'6#11_$;5-A.(
MEZP7`-Z_^486KP`)O`18[P#$$Q^O`K&0P/_:?H)G_33R,#"1%N`Z9@B`--N^
MCT>-(1Z:L^0"^,;O'W_]_)4>)>(5HYA>>G#S<7Y.1,0B2/?P"IH^X2=+P"I4
M'`47Z4K>@G*$/@46CD)!$D?N@@'354Q/[Y<\5Z-'S_QYT$%.U&#*@^?((;'9
M>3/>-,_8E<G)RW4012X>+R3KHE0,-_&=<5K$<I&O*=>`SPNRYG$[+CK9Q/'#
M^\!+*-`"?T'SP0-<!N$*6;MMIH#YL(*<UEY^=B&WWKA,+5=]X8BDYQ62T52E
M!D3()V&'I$`F0*Y-XZ*!+QFIXE4;:DEWGXBH.Q47&QK/%0'R4A0=ME#EIQ;5
M+C95CJ2W<>$ORRW9>!1TQ8(.J91S+1;PS'%6($]Z(AEM,!ANM+5[]8;3KY>(
M3J"@J9[WJ&.SPM?CC4/91D6R^7B56Y>N.]#6TQUHF[I/CW+>3,[Q]5R'!C*R
M7(6^D3D,V:<E%VN+9PY(?`\VD/I3-,9-+;I+C3DU5^G=/);*),RT]`HACDS^
MT+X+&YWE5``18*28,;2E$4$V6695B/T4[%OFOO@DIDX'_87/>I$:SKY1@LI$
MP87G`LW)M)S+4SJXK9+M,U#D!&F\%#XR2Y<1JUT2>=N+@K+<`Z8!@,$:][A8
M48P$)@5X`I.YJ=STL@S)D.XC2502:Z82Z9<V"B$>+0J1%YX3#HI_DW+EQ"-.
MX#/?$B3]XU)6*(QCP1/HPY*HE)Z33DY%T@X@H;2L".=CIN6*=Z9'7D'B+=#]
M+.C"H#_,W1U.G^-?I!XS.MB>E^;89$DXZ5Y"U)LVT"T6JQ%&?./I)U3<X6>J
M!GWCDW+^5%=7-GB67'$4NM%R;?A$CY%+@'M'$6WI?D?AE[*O,1VJCXG>_TR3
MND+/10Y+#Z'`,HU`-YOF;.;5+7T:,9&F@-FIR2HLC736RXZ"0\!4NA,+'1<,
M@MA<HMX6H5ZE4A@'V#6D\%A8VBCH4IIY7A@X$B-O&?`X\M&RR.I-#>\&A(QF
M/&",#E;_,A7.(TZ'-RT_MO;)P\A.'&H=[0M%/0[,UTQN+F0F%--,67J*9S@>
MR*D#/V#,`';"(;,0V(\Y\;`F3Z1*<0#1%YMD%-D_?9J=3#?0_/M<09@R4W,6
M;DF668>`XF&F#7*PDP9M(T#:2ZHTJAT+C30X61R=:U-DNXO<Q'?N.O-UI84U
MT8H(/S@U%)&>L)V%_N4W4;*;X%$>2%(H4L"6ML.SPGKR':$T>0OV&&[(5`;$
M?))/#KKC_DNPIHJ$YO1[3&3%6[(PMC0PC8R%>#G*<>PHS3T3`450H6*Z5,1J
MJ=A<P^"=YEA^GKM`V5:03C8J^7+\VA.>!2/2""?)WJZ.BM2V;2`@<8=C&=XP
M\K\9MXF-L4/"C>Z60(2I2*93!8KS^?#+Q%L"4(C-'4WORZXR2):]*`IL2?EV
M=\5.H/E#*8_2$*OKYU*!?5CO7.`T34?+2&<^239^($Z^^3K1Q:52L@[)RHV(
M:DELX4A%KUD:Y$4!-'O(_O*^$V56Y(&/!V]*7QJ4DX/IEZ95GNP;#%JDD*4B
M3;<0!IR6PX#%VS`]<ZC(#BWOD'N#D6*/?-#4W/.U-(L:EN9O!#`3_'DF%LC<
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M#!]!%Q[L<"&ML*J(UBX.6D-S%PLW#WT`FE45LG:QUIJ9PU+MKP/1C,),W;E+
M](0H<J:TJLI>[>+O<#:R2L6@=@WY!!I5-3-V\7,T,,U2T;$GTBA5FYD,5'<"
MRHS['KFO?=?[^44<)N2%\=,^(ZA2^LO3WCX"R(P/;\<\T/3%9BFU<V8.)E.0
M0>!9+M-4?#7_3A4^EA-(S0UUC%J50(JO.V@I59J,.H==R(?+CU^-OUW^_N=[
MXX_WEU=_*NNCY$IZ'M(-&X[[H[&HDGK0B5:K2]S<"<A.Z0H<->IO+$'BC7L4
M>99)R>0^_P?^<.;3L60^#)FS(A#\""F]3=<W/F3?=J,L6XI>=PZQ``O+#Q0'
M0>7$O>P0@(W1PRC_&N.&>!+'+S\;=G9GG(8#;'XQ7ER0MEDX\X;$#WB!&AC]
MC<0L"Q1O<-%8!SL4D.;(3D1:NLB=D%)>#P%W"UC\9P&.0%9[A=!CK$R^[ESP
M'4+G[I')%(A7$((4_ANC2C=8[X<5P`$)37SI`]=?)U(%%K[^\HOIAHT%YF["
MP,;=#6P*HIZT!\LR66\(&-K7&WG>=*ZW7FQ^Q[4QS-?&_Y<$+/4:4"8R7B:^
MO<`BW;12D\^RPPD'`IXA3O>;-)W;Y:625(#``JX,[H(PCW8T6JB2R%N:]XFO
MNW-O[S"*S,631J,YS5P4->(\J^A8KXW/&3IP\4GE([5@'#8P7_E?3-*"HE3U
MC)L$#[3#,+@)0IIL<O,H;`^(DJU7^EE7>OC:^%-A"7"9J35XN"-8GBJ./7H;
MWP_DM:,'2O>VZ^%7*VD^V`6UX@^UXC_O!#[Z8,!9W@JZ&MDZY@^MDAB`'MV)
M>[&KAFV5<^>[_TH$1-"T7'B&?B]A*4D*"<,8+YXF%9Y4^26BGB$>'L8BUYVD
M*0`L(4#*1GLT'-AMNS$M&H26#D^[T%Q%D3C_RN:G)>X9G5L)+D2>=+J=<OTH
M#A.>(%M(5'T(PF\T&=!>N_S0MY#AF$0)WFTS7-SNT]P1@"^ZG>/B!`,[&%RC
M-R^T(#1.$)PL6H\>!HEX*;/2J?J.Q/VQU1\I$V8R/\9C3H_LYFX7AO+1Q]9@
M63ZN]GZY9&<J+'A^;7__"F1C&74?<RU8J#+^0!9X.(;92@EV(LD]G$7?RC4E
MS,%H6]F&CY\^8%6)X3RC_0`$9=4<_N[&=W>!AZ=;_&^?_0]!2-Q;OW`T8>X\
MFE#6PS#'K*K#SH$V7>C?&-`WE8<0.XZ9S.%L5CAGJAK`KT)2N?B$.1AOJ_>"
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M.JA,YY5S1Q8)5L0JL1<8*'7!N<;=>/GLUU(6S&O@V:\R)RV]SQ@5MH]8^1`C
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M;,O7Y;6F'E+]I;9VC?5$4BM]/;^.IYISE5&?2/Y^<F?<V,ZWVS!(_`4Z]T$(
MT.DXA"R7:I&468+.\YX<$3[X#'QP5N%K4Q5+<7^N,J,JCBP&KKCL^\\1]RO?
M#?[/&V,3WQ_NW)A<X$Z+;IL0I$HT_N6(LEF+,%/F7GK6UK/&TS(\'X6W8[J2
M%5A70]-..K26L;UD;-@SAY,6R=B309B.?Q0(IN\49Q44=HDXJ#BU3:UE0%0+
MPQ\1H1NZ@N(S%N(9I^[<*0S_7H)?$O:7H[EY&EG?3&B!H^9&WE/JE1$"3N$3
M%LS04G="J1M.K;9+7:-]7P&\]VXD"HK=VPX]N=+`VP@5&)DG\F-/Q$T-O>V0
MN^%TU`&Y:[K/>Y5K@9K50=+@VP@EL`;S#BB!!M^VR9TY&W=`[IKO^8ILH[1R
MN,;=1LC_O#>;:+=7(^_I)6_6FXQG'9"\ICN^6'A(*K`91!&[!&>(RQ<:B1NA
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MG("UK<4I^H27_<X!2@X'Q8MO/!BK^#>1B+PN?8LO%G6BBT`^*,>L2JBEN%#T
MOY+4,Q'??J^)3UN,+6#=W%U^2S5Z0>SK#[TW@!_IZN#A5WE_D[OA)ML-_D#Q
MG:WS33JUMK#]U,&U_15,0-5<Y.BS7I#U#SA.=+GCJ:-4]`7E*Q:;R@YD^3B%
MG?Q%X:]'S%EKZD6+@D!6T[9\"]*7_[=Z1.V49Q['E+LJLC9X)ED[Z`XAA?2;
M\EMOPI]2VF_R/Z6.9@6OL^AF4E7Y^84Y&/Q0=L.87=M6UZ58!X7M#H'A<U#_
MB=B;9KZ;BN=<6ZT?CK9_0*79Z*!O.GKDEF#V0]DI?E'B^D=6:S8REJSB)?B^
M,6T&AWT]`JPD^Q([4KH@1MB#%+/X6<%:>=<2O:+[FG40\5[UBCWDDW>?Q;UH
MU6UDO@I46LA3T;,MW7`.587RFKCAW-;FAVK8)VS-8PZ,"^/Z\O_W_LKX_,GX
M^.GMYS_>%]3Q"-O+4EM)ZYEZ7%:C)W/_[!K-+J4..RIGLN5-+;^$V,O5_6[\
MZ@8P4[!D)`$W`[X*ZM3'F`6H/[:A=&`[BB",5:=I61V$!<]^B'*MDG^D):YI
M=5SQ35[INM"UG/7CP$8*M%CZ&E\K&\AA/G/Z!]VK%7ZXJ2&^Z0+_'B_ZQO%U
M\93"BX+'=D.N<97<1.["Q8"<6FC%@T)N#Q]\4ZZB=0JF[!C9K"$WJ=#](?7,
M`54-291XH@TL>@9)N*:]Q8ZL'J=@(;M3X^)]&FLPF.4[1F`3>%Y8?<'`BW."
M%UU4"&*)1X"%?K!RL9L[MJB@'WSZ"&#Z!1SBQ`8.\Q81[&4&KS0./HWQN_U@
MO+RD;8^RGFT?_:5'8X2O>H8YGXT9Q1D%/T:;U^O.OB?&#>V@ELT*]I&W=SCY
M*6V!`]\&4F_LR,4&.*+,O'-G^[<D$LC.:<4.%LF*A+P7'`KB]Q.A=A-TS*JN
M8T*S<%G1`AZS3_9)50?QF)O_C4K1,P+X`[:0MGWQ,&T0R`D<3=]<8A,$;!SX
MGC9"@<T(#"W^/'N3<RVX\`E_@K7/9ESE+=UH,=/<WCM_.>8'?`WVBA?U3UDA
MU-PW)OWB=U"=:*U4?!8G1.PE$)L3^`-L`C+[+VVU#[1VQ1U&YG"\Y=U(;FV7
M'EM%R<T_L1H7@),C_XD6E)5M+/RXIMVQZ)_H#QPD:%=T$(H(]NST8>P(2$\5
MSP@CAD^QPZA<:`1$__7WH#M):-^FEEFLVD?_GG`C@59A/#=>XO.9?E7Y)@Z5
MJ=RKKB#4G[`LU=F'3.CQGCTHM)?PZ8(^_RGH&Y.!L-95WX4UE=<):WA)T>L2
MP,U#<PN6^^;1N'?#.&L<LQ40)3@$><@>Y=7"-SV+$:`DVN2O@*ICDZ'88^TS
M\<PV2"C8@J/`"]P?LRRTV5?LYH?3OIEVZSFBB.P:NT[L0*'&7\DB<7@Q[J,;
M_Q.AGC0,]UA!R_*M?Q4B;"R2$+7*AB$OJ'U8P[<"+(:[`I7!L*Z1K`/)?H#&
M,)M.NZAE+UJZ81137Y6V=`/6\JYK4B3"(-_):AWW6*!S0;U=T144&[TE*S$\
M2#X;Q8WQN^!`Q^#1\HZ/>ZD[;AFPJ22AV1&+(UBZTR_PACTW3A4<NJJ8M?;@
MX4CLM)@751G$\E^>LP`47SQ8C12J7+F.*%]I^$P2G$*[-;%>CR060@BK)K^>
MBVPFA5*G-ADZ91I@8^03E@+TX,;L:ZH98GU(-V3[*FM@F9T0EX\;-\?@5$;D
M7PEPS7O$\A78`7KAHFJ"+`0)73-W`YH<PS3RI<779W"!B\:6OH=P\.!Z'K8V
MEQQBFS[-4<I>8?-&;+@.D'&3P%BR^X!RXG!YR;X4B:\!.^6P*-^]T&[JV5[=
M7J\]UZ'P=F<O@!#$*<8EE%SZ#".](WCS$>:\6+BL0V?`.^I)NPRF+TR^\@&;
M%1[DEE;K(6NW)J\<#6GS:_Q&!/".-56"D`[+46(M&L*L[(5HOI@.AEXYZGMT
MARUGX1M?EF"+0MZ"`V24HD&2NI_LS\;E;4A8GSZ*,D7BV`XJ,IPD#)FBR-M2
ML[`I/=IZ/]-F:N?@=>+AJ2-VZ3C$(ZR5\X*L0^*X6>V<SOACFT/DLKER/-M=
MT7[I*H[TZ+Y%N$W@!(D7>FQ[Q/N=H@\FB^<2,#LGH#P[EN7+LMQ&_(786"L9
M8P&]@LF^25RJ"S#1%3SD^B0LE/=DS9VY7Z;R,7EX1FEPSTY?G*?HR]O`9S#,
M8LE<?.@B<"P43L\Y:-"/T38.@/I$#G@`>`9U`R)9"*+A$\O$6[I9+,S)N!O%
M[CKQ;&G#0?4L3#S"VDVS*"=[.`LGT"`D-3"]5.KEUL.@3[2[[#UL5$0,"37-
M7;H./"AV+JB"ML\?A==FWG+?8,Y<2*=#C9[M>@G\RLE4X`R-":[68+B$ZQO)
M<^WEN;:R']%>.WB!V$-H$O.0WLB?"1$"0H9>(5DF_$'N@'&++5[<8SO'@/5^
MAY^QN7:/D413D&#NS``KI@`P2*CW:=.>SI[APGSHJO,KSX*I]'4"O?@J5W54
M4\\VVT(:;RGKSPZD%D\RZFF$CHM`O8AI]Q"L<LSB`3?RR$64^(AJBN#E>U#<
M8`5H\26`/<ACCK?,M&."[06>I?3$]H6^(I*,M-"P_^<3-/GH?Z=MKJPY[40W
M*`:L-]&:KK84J>[$IH=FU.R:M,$Z^7D`$KZ-;:\%WAEQ:#O?(F:4L%%\MGW`
M\`?MDBUM1=:B?F]ZE%U56(YWVG6*S)OB<+E!CG#>IESEU/;=AC:]&,8]"96_
M&J7QA\3WW!7]*WK?,%R/?O2-Y.VI]$YJZ6$%L_<2Z7!5:"M_O7@Y*G<Q.LOL
M9#H$['?9=Z2Q6(S#Q4@LAECI6_^5V)Z[?.1B![X1#.[:*,)B`P%.SIL43E8!
M;":8E>8B++Z!VVN1LRKB`>)O;#AT4*3W5D8^X$40"L-M"RWK!)YDQUX`#3Y+
MY04.U-?\?*2EL)N,;1!$>W$/`@%O$J_.GR+=@^M(HUC)WB=R&Q8*WA2['C\:
M6!1=P#2*9Z-S#HY<EIE8&>WD1,=45VC%&ZYC)"Y$)\6I-VRK:0!8\OC\P$`?
MGR="B+NC!C.>BC,*UZ=G%%R/<-L@^>QH9FE4"F.`\FLS9J!=[1N??;;=IF-)
M$<\2FV+55'&]8)YT-AEI*G9E1@H#EH^%:%F/;2/H-=EO<M"5Y6T4-T^9L.1?
MTS<N_92U^#<:)JU*$@BM"V;1";"$,KP\O[STM61!&;KOFPM4'BL%LF59V#=/
MB4#\E"9,8:T_PJK]N<Q$8;T_Y/DRB7$S2CW1+F2W7E)4+K9I'A6S$D%+;F]#
M<HNA8K]<%O'EI\^_OV+%$2]$<42,GV$*8L`VK]_=%7P9!/<ON>CR<-;/E[($
M$/(\JFJH^FB(<YH9TI-ML0R%0]BCI@TT-=]GC[Q;.<M'OFW0@9P;G!((85X&
MBT>OE21RTI^K!3(-"J5']<RMN.*V83BSTHQ$G^Z7/.,K/^QY&X#=?)G9[(]?
MW\K;20-^S[V'GL#1[$*PF6`[P$,6!U+I$2].%[O]`43Y#HW:&<&#3\+HSEWS
M]%DP7A%-L,7T7"2N,$Y/&$59BZA##MQ:HWO,WL-,.=5(SH5@N41/!*RKC04G
M+OAS2!,^01,2OCN$9S'?PBQ"-&B%:=(]``__\W0(EC>TM-T0E_H;C'%O>UF^
MDC06]0;!NL/47.16MON'4;S`O[W`]&?IG)5:_C/*!-PC6[B,$;DK'5U!B<MX
MDZE39ILLM@*%96Y""I#5$A9%=0P:U7-Y4#_(CR@VT5EB2E(X<FI=Q*3L"8F1
MZP1MT^KYG*/T,+]81^)9BN,<:<QK>LZS6@>^.)"1+"#/%%@(IM#<ZHB%^,JJ
M,13)ZB,6[SBF>W7<FD([RNQTO.90>DD="X$HZQ#)4'&<EMN;*AF<J/TXNSBV
MO5Y,VG-Z4J)6526A:N/V^D5%%?.05;3"E)Z+FX?JX<X5#H,AKK.;U7FZ52+W
MDJ9@+5"M0WZW+$@B@+E(65VD"=)H-5<:T48T6`J/-W3!0M6BX<2K)PN4<B5'
MBJGD?\N5D<G]<C(&[%R8)I*9L7YX&I)/)]Z'`OHMG@-^YZ.<L?=:Q8E]ZD!M
M_OI3FTDHM>PXI!ZEXM5AYEQEU">2W^AV%<('GXDZ;%])1.P0$U!]3'J])U[`
M$DLQ?.='>[1TJSAR6@"NVK*?M(A\D<:_'%$V:Q%FRMP38#SN6>,3M1C:7)6Y
M5KG#9QQ:R]A>,C;LF<-3=3<YQ$(WO7_;EQ"/*>-"-O^I;6K#&CTUI7/6R]'\
M1`U/-A-:X*BYD?>4^FWU1W6_MI9(W7!JM5WJ&NW["N!E*7_T+/G>=FS=+[XQ
M*C`R=:M,#;VGE[OA](B%S]O3)_/(/N\59@OAU3:\26X$-_`V#;[-40)K,.^`
M$FCP;9O<F;-Q!^2N^9YOFF[$JWSH%O'-D/]Y;Z8[Q&OD?0;)F_4FXUD')*_I
MCN^G\JT4FG\K+N]H)&Z&/EC#GJFA6$/Q<XC>K&<.!QT0O>;[P7^SO817KL&$
M<0Q(5,;?2OE*QU&)^OEUC=6?)TSIB2<ML][(.M5Q=OU4@9U'>XW1>BW8S1#L
MT:!GFB<ZNSZ\8!_3CS\2CC?=/%C]&=YW6@0)WC7JC"95G=:3M.GB1'JT,=_I
M2&+8,D.@1;C#(OR$=JF'O\A[I))G\CCOI.NM6!<A9#=B$UJR(7)+I8`P"]N)
M14U]J7P=5E_@I<$6+GP4LD(+&-L/HT(M'UHC.'MGL#2&\Q]Z!G9U^H$F(`YT
M>TG\@=2XQ/V5.('ON)YKRZ72X9\@)%1O>9$'FDQ/ZWLX<9+_](@3?Z:>E+3-
M1"@X@Z6Z8K("^8T?"&%%N6@?GC@('[,R[X6"**+T+9-WK.XHBL'G:C;2-*YE
MXGFT%D=A7U_L@"%78*,59W-A6-89DY576B1IL:T$7@3([/KQHZ"1=5I)5YPV
M(<B]_&5$""O>=8QZG.W3K&6=OL.\`$`4T2ICW=(2[.I`&\=1,4W;HDC]+C__
M_]N[UN;$C6;]/57Y#U.<I';S%K9U1^RQMXJUO>=PLK%=P.9]]Z,0@ZU$EH@D
M=LV_/S,2`H3$14*"&=&5JJRYS?3T3=W3,T_3IG+TTQ"R+QL(BT)/TE8+JW@H
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MUX03Z5JIFV0+EYZ1!*[N<`V3?V6$WQNCSO4P,S25FX8H"+^FP[#HN;8-VFP=
M"BS:("4,;Q/SU^+MV67LEL7SN;5*OZZ:4:G1.36:C0'ZIM,W\R>!_FLZ*&ZD
MN-X-&R42ZL9X1"%)F^$N2=3"RW;I5M)[DJ+$V/_A#H@3]C18S5K\W\*\9N)&
M(/?S[N+);=22-F"S7UU?3?V+9\.8?(B269++WEF^:;O^U,,#8AJ?R%K^_OCS
M3PA=3^RW#_?Q_DYG]-?4)UYJ\;,>63R-51X=C*S136-@/&NR2#$]'&IB/3PF
MBJGJHJ#H#30E'BY\YXE,TT`D&K=(EN%3X(^/%'CT^FKOR?:E;;#H>K\D3\I+
MGAR2I^U%WW+"/.P;_'"7],D5LX],%M$6*T%G-)IW6_@<;F<0?>TZ8YH"TG<S
M-&-)J[).:TMO*X1?L6\B7WQW/WHVO'ZG(TJR0C^GCN-=QI,,;7R4'>XJDF67
MQ.2K2?!>^>[:OMG#X^`>B2*Z0$M/C1:?]K\^/7VY_^/^8=#I?4.?NP^=A]MN
MYPOJ#SJ#\&W4??C\V/NC,^@^/JPY_<1SK,P=C99X*2_2@L6FH-@*WZV.4QMW
M.S<MM-R=IA.M^I-AAQN(_@O&02JG`QGO&\'L"<+*S6[9EAV_%0"H)`BK>+G`
MHJXAWFJ9RK@#YW%;BL`ND&LU#-H%"KN-5[63/[/0LV4R:!>,[5E)G&FPW&H8
MM`EX]]SDSL&:MN^Z%U@<`[C!E2EUB1C$1^+L456)^?5G(1WSR0NFY%[,A51^
MTC].O8:N/<HJ428S5TF[5%3*A[4T5XW36>,2+5>Z\\]'VMUQWKSD2(C012_#
M[3E\(?#E(Y%?FF(G57F/0L^^\CL=A?SSN#0M9&,)/`FAVJ,6N7B0@BTODQ]=
MQP^L8!J6RXJ9_I[4\P1]7B:#?SF6L9>'=UWF\F4UXZIQY7XC!XPV0P_1>JP)
MK+A^5BQ*&0>`SMR*60=>*I,GX=FYL$]Q>)PSNN+SX)+W-&/WSO:Y9`R'W\)E
M9O7'!P$J->C03A%T\"[_RN&RF-'N\Y-M?6Q;;$I2!E8S:,`)MC%8"U-ZV`\\
M*X0,&.'P%##$)CQK;QW]EZQE-+H!^4-L<K:RK8]M*R+D';!]DN;)DX<GAC5*
MMI6%J(13S:VCYY)T\%P0E8!LZVC;L@;[)6SLEYPV"ND3,KU9L=B#U6,ZO&)O
M,\,JQD&]RV24GM'=I'(WN`L=]J2*4']_#OX!_,.^C-+8.N/";PQ4;B<"?CPD
M`_0>'7A^DU:L.3MQHUODZJC>*>'LR^21V%14B(8@&@(_`7YBZ[9P4Q).4:YF
MT$_DPHIC#%%KRQ(!,(@%P*`YEXJ!FI2M+H>`F.0L7%9U[S$+'*$:4O?].1N/
M^M*8R4J4Q@[#<V;-FR[;YPU*<][E+Y4S]BH8PC`72@#JF*8[I?TY)L8L?*A0
MH%?#-+VI8?OQ%U7R19?B"60"\X,?XL`LP`\Q[8<R?<[Z=P-WLKO306Z-/<XL
MAQ:QLZC,8]9<\I(-)U&IN$ZW1,YEQ?2-DDJA,IZ,F4>2HC!2\;!MT&LFAYWH
MW',U`)U1<6C!Z*7[ILK8)CT+U^X!/*->JZR3O4J*#/9ZQO<\NG2['/M!O*G!
M>RYYWF>!ZW@67-?U$W@HWN4/]SSJ*]OZV'8[JTL?R)^_78SR=RYHNSR?MO4>
MNQ[Z;IAA_S&(3GC6X#IZ,+&IM@`=`^(3D&T]K5L1P;IAWR3-DPX]]W%P-05\
M%QN:6T_?U=)5\%T0F8!L:VC=:E-HGZ+2RJ<&G-?>2<^=&79@X<5)50A.>%;>
M.KHO102`'PA-0+:UM.TVI!VP99+FR1?+&%JV%<SH!3W3=1QLTIH.^F$%+]']
MQ:'KA64>Y$[P_*\+9$X]#Q,*Z,5C*`%QKN]U]'=J4X/F+1#-@&QK:=U:4Q(A
MGH&-E@V'5$B@0@(:>K\&_S.U)J\T4O&GDXEM8:^:*S:,63<`$Y;M".L`3"B>
M!)R=00P>P.H"!P$.(L-!2`(XB*IW@'B+*WBC%R`)`9)P+U_7%%IL7;-DP'@@
M'@)'`8XBZ2C4IM*&Q.G(X*5)0#HAQL@L==%DK&%Z]4/O:K'V8;:T)YN6O!7Z
M='WP]5_N.4P!!-4MP*01`^G7&`=7C1%YU/(15".KNFE$_S88"7SM553$?F`$
MF.YC^L@=+RNQ?E6`ANL\R>'H3$Q5->\N\"JV5L[)2UX+L*;TX=B(\:KC/BOQ
M.KL280=-,J?*GV;6RN$+N>`"\+ZVO&?CB7!4\9YNR36390G/DK*,A8/,`>7-
M$!:J+`HI/AP25A4OD%7,H6_8\!!V1GB$[K")7X?80[+8S,NWVND"V-EQ["S]
MR*BEF4G"'+7AG&VJIFLZ0UV60>Y<K&DMJ@2EWJ;4"BA`V='/O+92K"5;U2G7
M$5JTL9(U5M1`B+WE\2<0_BB&L@)0#&ZH%@(YY#F_+?J)3TH,77N4N[VBN;L)
M8@]_Q\X4ST\`\"T#,`IF!<(?Q:!"0#&H4!T$PO2]Y?A`8HNV=$\>5KVLY(#[
M'1YCS\.T9V#TY$=C\BV2L6-D6R;%NPUO/(?WG&?(>/9P>&`P0G)Y&I-)O6(*
MLB<CV&L)!@T,*T5X.%I#-*6I:FS=U&%+Y^NX)K!CL&.P8_[7!'8,=GP>=LPP
M:N11\I,_+!O[@>M@"G`=9A[O?8S1@QM@))563N3=H]7ITC3?&'*2VA2$4^"=
M\*X"`!%97]D>;-[U6?[Y"1\,N[ZR!<,^.^&S73XY1DK22U1*?&S;9'XT\=S1
MU`P`"+:$(\E<&L;9XSRJ35DX19\R!A&-`/H,7`2XB"P7T18!]`Q<!+@(<!$;
M&-5N"KH.+N(HM9\X49+T2UW=O0CVDA+>Z`5P6`"'W8-'LM+46P":#W$2.`IP
M%-MX)`I-I76*]LK@*,!1@*/@R%'(34T5P5$DTJKXY3:X^>Q7UU=3_^+9,"8?
M.F2I%#/;L#];CN&8EF%WG3'%(J?OWEF^:;O^U,,#PL5/MFO^_?'GGQ"ZGMAO
M'QZ#%^QU?!\'?M?Q`RN8AN#;M_,FR-;HIC$PGC59I1>_'"J&'A[?-&[5EMZ6
MI0::.E;TSM?^70.-L&F]&K9_T[B0&Q]E52-Z>GVU>Y[\]&A9],C;Z1$E)1<]
M,7N?/#PQK%'/G1EV8!'9+ZAH%>&*%G%ET^C[SJT7XH#4SC%Y#_N!9YD!'MT:
M_DO'"?^Y_V=J?3=L"MC>"6X-SYL1,_O3L*=X25N[$%^D!&DY)R^'<D4HP%5%
MU,JC?"Z1^[<)O?>VKO>*6("SDIZI<<DI<E$A%>"2K&6J7A85:P;:GSHC;Y8B
M0B[`"I+19GB`Q`1Y2%`*\$'+=$(9),2,NG^=V.X,XQZV#:)3<5M[8JTI>HIX
M:5%56PG![)RO,'D%G;9\"'E="F%##/+)F-%';(JF(BY<U_4$2=ESY*.CB#MO
MBTIN.CJFZ4WQZ$_##(.#%!U%7+>HMI*^.WN27(2H13RQJ(B%"=FBN&H1KRNV
M=#6+EET*NP<Y1=RO*K1;!Y"SB!!2Q!1QPXK8SJ)E?9*<E!3QQDH[4TC9E%"?
MO<:V6=>Y=1T'FU2]_FT%+[<4<8YD;*&^/<;=;%*T%O'4JJ8M`^J#Z"A].44\
MNR:):@7+<:<DQ)I[P+AA.HG![N-VZ?VX6WIJ$44>!:*>$$G>R4NBO%@N()1#
M>?A)",A@>+-/ADT24-Q_P6%FM4A"!W3<1?ZYI#SK<4,BNX\TT:6]PL@7W]V/
MG@VOW^F(DJS0SRG=[S+VV=#&X]E1XGQ(U[8(Q4J\E.E^0!+R2FR%[Y:_E6#/
MF[C->8K\D*D1*M8P>_=DPO]JUW90=B^T[)9RT2KHWXSWC=O2^RYN*2>4WU+N
M0*0=#F%VBV.&:^<!KPR])0!=>7]TY=I)_#P!U:%+`!]K6HNG#E_<D15YU;8J
M5^JL+@')5YLKEZ?A[%%5B?GU+Y5%YIP73,G]&'TF\AT=3J1>*T#4B3,".:&I
MC=W0U"M_AL4;9(35FT.0JBL]^9!K^$)XL$<BGY6#7)OEQ]/Q*]9X7)H6LK$$
MGH10[57Z7#Q8W;4JG1^KIWR*F?Z>U*\2#\B!%1@[F\B!LLK6G5(6<`,!_Q.L
MF"\K%B4%K/C8-T`9BIKZ@1%@Y(Y1U_<,;*_@?&H&`'W6\+H*WT"?LG:*H(-W
M^0,88'UE6Q_;%IN2=(I;E7QJ`-.(@*5S97G#!(WPQ/6M`&(3GK6WCOY+UB3P
M7A";@&QK:-O*20#T^)3_.6V?S.]T(AQ=ZBQ8:`'/Q8;FUM%S23IX+HA*0+9U
MM&U9@_T2-O9+3AN%1%@*Q6(/5H_I`'HQH!?ORR@=&B``&!_X!_`/&QBEL77&
MA=\8:-?]!(ZB"M[H!<A1@!S=JXBNJ!`-030$?@+\Q-9MX:8DG*)<S:"?R(5,
M?`C(T'&7"(!!+``&S;E4#-2D;'4Y!,0D9^&RJGN/6>`(U9"Z[\_9>-27QDQ6
MHC1V&)XS:]YTV3YO4)KS+G^IG+%7P1"&N5`"4`RM2'0MQ%9$Q+\@@Z)=&K8?
M?U$E7W0IGD`$))`#/0+\$"-F`7Z(:3^4Z7/6OQNXDRP8D0,U]CBS'%K$SJ(R
MCUESR4LVG$2EXCK=$CF7%=,W2BJ%RG@R9AY)BL)(Q8NZ+!QXHG//U0!T1L6A
M!:.7[ILJ8YOT+%R[!_",>JVR3O8J*3+8ZQG?\X@;#<6;&KSGDN=]%KB.9\%U
M73^!A^)=_G#/H[ZRK8]MM\53'&#D4_Y,[V*4OW/AN=\MWW(=\B,/?9]W_8/H
MA&<-KJ,'$YMJ"]`Q(#X!V=;3NA41K!OV3=(\F7<Y!7R,6FAN/7U72U?!=T%D
M`K*MH76K3:%]BDHKGQIP7GLGBY;W4-2I@_+6T7TI(@#\0&@"LJVE;;<A[8`M
MDS1/OEC&T+*M8$8OZ)FNXV"3UG30#RMXB>XO#ETO+/,@=X+G?UT@<^IYF%!`
M+QY#"8AS?:^COU.;&C1O@6@&9%M+Z]::D@CQ#&RT;#BD0@(5$M#0^S7XGZDU
M>:61BC^=3&P+>]5<L6',N@&8L&Q'6`=@0O$DX.P,8O``5A<X"'`0&0Y"$L!!
M5+T#Q%M<P1N]`$D(D(1[^;JFT&+KFB4#Q@/Q$#@*<!1)1Z$VE38D3D<&+TT"
MT@DQ1F:IBR9C#=.K'WI7B[4/LZ4]22_Y^FIBOWWHTTTF3/>;#&_VR;`-Q\3]
M%XP#O^N,*:8H+98-*-,&9'F?;-?\^^///R%TG?IQUS'=5]P/C"!\9^//D36Z
M:0R,9TVC`*J$2/)!#X]O&K=J2V\K<N,CI9)"LI(OOKL?/1M>O],1)5FAGU.+
M?)?A^]'&_?MJ(%ZW(*=&$J9?8QS]-88,4LN'>(W,_J81_=M@)#*W5V$;%YKJ
M(W>\+!7[52$NKO,DAR<V,575O-O4J^!?.2<O>2W`FM*'8R,(K8[[K"04[$J$
M';C+G"I_FEDKQU?D@@O`^]KRGHTGPE'%>[HEUTR6)3Q+RC(6#C('E#=#6*BR
M**3X<$A85;R"5S&'OF'#0]@9X1&ZPR9^'6(/R6(S+]]JIPM@9\>QL_0CHY9F
M)@ES6(ESMJF:KND,=5D&N7.QIK6H$I1ZFU(KH`!E1S_SVDJQGG%5IUQ'Z"''
M2M9848<C]I;'GT#XHQC*"D`QN*%:".20Y_RVZ"<^*3%T[5'N_H_F[BZ-/?P=
M.U,\/P'`MPS`*)@5"'\4@PH!Q:!"=1`(TQ>KXP.)+=IS/GF:]K*2$_AW>(P]
M#].FAM&3'XW)MTC&CI%MF120-[R2'5[$GB'CV</A@<$(:N9I3";UBBG(GHQ@
MKV<9=%BL%(+B:!W;E*:JL765B"V=K^.:P([!CL&.^5\3V#'8\7G8,<.PED?)
M3_ZP;.P'KH,I`G>8>;SW,48/;H"15%HYD7>/5J=;W7R#W$EJ4Q!.`<C"NPH`
MAF5]97NP>==G^><G?##L^LH6#/OLA,]V^>08*4DO42GQL6V3^='$<T=3,P"D
MVA*.)'-I&&</1*DV9>$4C=08A%P";#9P$>`BLEQ$6P14-G`1X"+`16Q@5+LI
MZ#JXB*/4?N)$2=(O=77W(MA+2GBC%]!K`;UV#Q[)2E-O`:H_Q$G@*,!1;..1
M*#25UBGZ/X.C`$<!CH(C1R$W-54$1Y%(J^*7V_#PMT#%[XOV'H'%3_V+9\.8
M?/@2W:KQYU6D)12\F`4%3]Z<.E;TSM?^70.-L&F]&K9_T[B0&Q\559.)/EY?
M;1A]SZFEK*FEHTPM9P/@ES`UE=?B].#3_/#@8EZE`+<E-3+_2!?6QTXNN&_8
M"WK^QW5'_@->F5TM,+LJ"ZW$JK.FR$.$5D#J:IO85YE$M`K(ORWH>DXB>M@F
M9CIZ,KQ@-O`,QS?"CNF=5W?J!/[C>.6])6WZ.FVZ*`H[:)-;:H*T'!.70'$[
MBV)EATB%]NDH;J4:8%"*U1T4:T*E%/MWEF_:KC_U,EIVM#+]=$4M.[CIQO+P
M.+A'HH0N4._^2V=P?X>>.KW!-S3H=1[ZG=M!]_&A'SY.A]FAQZ2<-9/_1(FN
M(;F]J5ZV8PR,8P4<*PM*Q!-40^93CRQ_8AMDEB%5L/]NH##(NFE$T#^-Y&\V
M-FX)@S5HVS+/RH1+,7I&"Z+2%D11H]'G_!OSS(1\)4[="G9V.?#".X=H=P#W
MO(M#YP/WO.;U`/EPA5.'(!]R('I`\-W!H)JB41<T^;HO[@RUNX[XU*#=H-W/
M`%1]VFL>R;V*]-VOG56\)6Y6Z0R]=5\GV/'#K7WTWG),>TIG1OZ+X6&R=!]3
M:UE^YS<4N"&"EN,Z%_@-F]/`^H[1R/*P&;@D,)R/06:DWPIS>>L5W;X8%DF&
M'=J+D[[_R36\$?F+L/7Y!5'U#*&XZ$?97QV['N&*%]!WZ=<+7H_?D]6KG&8.
MIB/A918J.?<UJQXF^<7YTJ1+G;BCS5^;YR`9Y;_S@P<Y,:<KAR616RI395,6
M0$D`7`B\%G@MEKV6*K!U*HPM"Z_CFL!K@=?BWFMI;!UZ9\'"-YY6"U]EGE5+
MOD*K+W8>FL@Z^[!VGL=\P:.IC1_'FX9('G];GIS(/&96T<D)J+-#G9V_S3JH
MLT.='>KL4&>'6@W4V6%Q9ZS=4&<_F\6=H79#G;U@N`9U=JBSP]XO[/W6<.\7
MZNQ0L0*O!5Z++Z\%=7;P6N"UP&MQYK6@SKXY$2]:9U^!H\A9(8_JZR-L?>B\
M8F=$P40^V\;SLG"^`23EX]BP?7Q]E?KE<L#;J>?1-RV?Z#ZMG=T[HSM"TG+L
M3"`4,O;%A2A=R&(T^J9AEA/=N>:43O]$4FQWE)HE$_"$0JJ0]'EUHLQAEK,0
M'E)UZL]>AZZ]'#T3R82,_O3E/]&PB=\MA[MW`BN8_1O;]N]$$YT^-GS7P:.N
M[T^QMQQ^`T;)QP<W&GWK,.NS_>G:TQ`^Z+-E8UJ\BF=)H8UDSK+V\_71YX+J
M8>I3Z(H#(YBN3)("")E/\@W[J[-D#[,^64C"+1'0L^O-%G/H*4B/^1P=T\3D
M!]0@4/C3U1D38ZU/U,//EA\0^PD>C->E5NF;H#B>>H^#SI?N?]"G[N/@?^][
MG:?[KX/N;;^)N@^WEZO3)D=.<9/PP#/LKC/";[_CE25N.LE"ST,(@B;I8H*;
MR6'21K.TJ\_DG:6X]$V&3\TF:3!K0VR:([*KM5DVN8#/W[+F6!DB/<M@-EF1
MSR:K%X6+WY-#T]]%H]F6\_>'L>L&CAO@+^0%>@O?"L@W;AIDJ+#XWYB_Z[GT
M^?`2!),/5U<_?ORX?!MZ]J7K/5])@B!?T8^OZ!<;X>#Q\,3I)D8EKXW`]>)!
M;6.([9O&=\.>8JD=O_OBT37\%UT8T?"K4@<4RQY0*GM`N>P!E;('5`\84!;2
M`[:UL@=LE3R@).BEC]@N>T3Q$%7,'O$07:1"2%O+(:+.'C$EZ]BE)8;UL.].
M/1.3$5YM,BH]08B=BZ_]M8GB'R\5?Q_'%_^*.K_X/_3^7[^AGW\:O&`4N(%A
MTZJ(9SF^9:)P-;2FX4["(!7A-^R9%JVZC*8>+<30$L@,TR,WZ1-8M!(BA?^7
MP_()?40UT0_#1\9DXKEOUBMYN-LS](MRJ2,2N-MDBB;Z118TVC`U_,DOBM*B
M+YJ(\&6"35K-L6>72^*OKQ*LS.1OQTM*SO#,F&>T7U?*@P1N%GO)KW9P>/Z-
MJS$)Z2\6G$9AIG?3D%)V5(K\E_9P4OEO$G^6N*5+.19W)9)<LF15DLMW#Y6D
MG'K8ER+)I=?()\EN7-$<8T*>83=)CDPS+6H_U$G9Z+WK(=\B+"=R(I+X;CFF
M1=[^BXC0'UE1_OD;"HPW-'%]*WQY69XXENM:%<?RW4/%L7R(KM%,0\6/5+'H
M:-8'^G_R\O\!4$L#!!0````(`,>%;$8.?G@H]`\``!7C```4`!P`<&QX+3(P
M,30Q,C,Q7V-A;"YX;6Q55`D``Q7[`545^P%5=7@+``$$)0X```0Y`0``[5W=
M<]LV$G^_F?L?=.[K*;*=M'?)--=QE(_QC%-[Y"3MVPU,0C:F%*`#*-OJ7U^`
M(B42Q"=)&9!S+_F@=A>[P&\7BR4`_OS+XR(;W4/*$,%OCTY>'!^-($Y(BO#M
MVZ,5&P.6('0T8CG`*<@(AF^/UI`=_?*?O__MYW^,QU,*00[3T<UZ].4.CKXA
MG(-;./I$R6KYS]$5>8!T\^OY[/QZ-`7TAN#Q6#!G"/_Q1OQQ`Q@<<2TP*_[[
M]N@NSY=O)I.'AX<7CS<T>T'H[>3T^/CEI*(^*LG%KVF^9:@3_SC9_%@G10;1
M"`L+DYWHS$#\^P579$<I*_WPLB`]>?WZ]:3X=4O*4A4AEWDR^?WSQ75R!Q=@
M1XSLQ..:W@R]8<7#"Y*`O!A.:T^.M!3B?^.*;"P>C4].QR]/7G`CCOCXC4:;
M$:0D@S,X'XF_O\[.&VTN*<E!AAY?)&0Q$0239?8X3FX8U[9@SM=+CB>&%LL,
M5L_N*)R_/1*$I\<GKTY.-TW^L.6<]&N<D63>M?D-;S\%E@"F'=O?L/9K'G5M
M'/5N.L&,($C3DZ[=O^/OITA.4(KRKAVQY>ZG!)LS!)8`D*YZU`7T]@G2W27(
M$#U!^_0"'6(P".BN@>"M*Y"`+%EE10P6,T5#+GS,(4YW,4#HX!@TBQ:J-C*2
M-.1F(N@3VE2X/C'.`;LIPCN?U&\!6$Z$)1.8Y:QZ4M@V/CXIH_P/Y>/_GC$&
M\VW,SL`-S(K40/%CCG)ACOSC)*SJTQ6E$.=&"R0:I2%;FJ8]M>$^HTW3`$TJ
MB?R?K;%N3KDEQ82M%HM"VACE<%'QSRE9:+N=N)DSW6DZ>C-J<HQR,M+((#2%
ME">'1Z,'B&[O\N*?P<9T"MC=&4[%7Q_^MT+W(.-*LK.<)Y=TS=/6;R!;0<U8
M>_%*&'#DC04;,@)(OUXP0:=LJHX@QR;B0M8%`C<H0SF"EI"A)Y0PHR(,%PR3
MA*SX*%R!-;C)X!<*4F@)C78..5":.,*[AF'@2!>SU5[1;J417$W2HW4([LS7
M.4G^N",9UY`)I\[7=O<PLNF=1<,6K".<37<VUFY>8/\PCQSQ,-GJ),JFZBZC
M:B):3_F5X,1U]FC3ZGVB3AO,SO=P#KD.Z0S>0[R"5ENM])*]!OJHO$-A"/&W
MVNH9.\ZZ.QC$1^L5=E^P>T!D&%"-O(MO6T>]/M8:@7&-\PSF`&&8?@`4\^2>
M\11GM1`FPI1C%25(%Q[<&254N#"&!XO;!.K="6H`F:=0ET;B`E45Y::$::M/
M2AK-E%+2A$>%OG9C,L>U=B/)*,?T-(XQ/<=\QN*RU[]"74A0D4@CVB2)94`-
M"TJ#39YUE::DN`976MA>YG>0>M475!SF^D*3(SP2.M47#&8/4%]H2H\+,5/"
MX4QSQ-5\#V]RZVK"2B^7;/7T46'%O)IPM;KC:L(@W@$M<>?@';U*DX!'ZD5G
M:8J$+2"[`B@]QU.P1#G(IF2Q(+C("G7AUYE1CL(.C.%AXI9]>W="E^S;I9&X
M0"46!7RY\`YB_H_\*@-XDY-\)%3\IWQN+W9UEM/.XGWEA$>@,=/OU2T>JP'?
M=DH<OHP#AU4V,X,)1/<BH>&9KUM6:6+1I)5JEEB`Y)!2.MCLN>(P2XX++%)A
MU`P3,[&Y+AT1--R6'$[&=EEMZ`17M203,@[E#9>^2-W_U59#=ES>=$'P[1=(
M%TY+,S.Q7-/7$$<%#_.BS,G>CBLRG>RXX%%+7HU;KC1DK:6Z3!8>#&[1P6)@
ME^5"6V1<0W]%R1+2?"U2R)R'.&'!<L$QJB_KNK!(D#"SA(>'/KOW,-8UD3>+
M+.'Q*A)X0"R.$W$MB^+C%6$YA3FB4.C+GXH'<+',R%H\J*U-F,\VBCVU(H-P
MZ%;"X]9YCMMO#W><'`=7*B[?*8QRV;:N)Y00K"(,#T+KBM9JG^<Z5B5/O4A9
M,2Z=+#?UNNW)CHG<51?\_WL^]%$<.(MKG_T5I(BDYSBA$##X'F[^UN5^'40X
M[;K7B0CFMA_F<YCDE_,/C\D=P+=P!G)XB=7*:SJKBPBIL_Q$A`\"G?!!!NDR
M=?3P4:@>7/P4B6N?C2CG<0UY@GF/>(QZM_[*(#?VDJ>;O'OP[5F2H_M-^8=@
M_F#%GY4_$JP#\S!")7CW%1JRBSEZR`)>$&;HL39-NP/J-.$=>*!A)F[=H/;9
M?CK4O5AJ^R#<]"/"`"<#NZFG4#<W=1;:H8M5)W/%DCF!,&4?.63/&5N)>Q(N
MY[7:"E=4A.PE7U&T-BAW%U#V1A<!T3JT+R#(`!WHY>V."@IO[Z+8080"L3>0
M#3UC>PIU"P7.0D-6.+<`N>9YV^5<6X#3%SQ]);3KG^X2H@T=O@`B0W2A5^QP
MU%"JQKIKYA`\#G'Q-6CN,.QRK*]J0VW%4J8EGP#"(L&\Q&>+8F?%QY6H#9WC
M&63+S2JR*%]".!-MLZ]+PG^J*IR*-&48@;6TI:_`\-@>;ETR>`?O:Q$SA*)M
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MEG"WH]#[996W`$U1PD5`M&`=H![AW8%/58IP4:P-ZJ#EWX^$<C7P9K=NLOY"
M`7>_1%A8U;F_8CZ39.A/[7JBBP@)V7XBHL5VCT#<HQ/W'9[]5"OQ_5,D^#:>
M9"@/+I1;4'1AVU^"S_$66<)S!'?W+MPWMKTT*Z']KSCRD=U[2,7F"%LNXL<L
MX=F5^3E"N5/'[1O%KDJ5`/YW)+&Y7260+CIPK@QI^*REH1;?<X2L;W?M&ZT.
M^I1`?1U'I&TKW+ZOQ1FJ>E8K6E6LWP=@K9WV])A5J51M0CR.-L!65YOJ]T\X
M\5BAVN#Y/C"J[Z:G!V=#EPJ5)]&B4KI-E6?C_`E=P=1^MWT_8<XAURSL^P!X
MAXX-%Y;-2E8N$<G.M_=P26&"3&\P5"2MZ]/J),\1DX9.V#?2FDU76\E.X[S3
MH/B([?_O+0ISD^;NBP\[Q/!_9S#?%)KJ6XQ\7R$-+;Y]0^=`XL-''R=,D;UW
MK3HNF923[@4=2*GV^:C0IP[4FGZB^M/[;DRN@:)D.CRD>G5#/_S9FC(<(`@Q
M[Z%PL][^/[H2PI@9>/C,@P]%(&/%:>T99)#>&U9CKHPZPPV,X3U5.8*J3]"X
MFJ_VSGHSRN_2&,3'=8A^J_%OA/YQCHNMJ\P/279.'91,G`>$)><.Z`@FD_RX
M#HAM5?Z(,&)W,/U$2.J')CNG#DTFS@-"DW,'=$232;YA6WJ0F_\P(PC2]"1@
MTL"#.&26#2@:JA90):J`;MK01!PU_?"89*M4%%QJJQ4W<ZWLYGXPL,?@M>J1
M);U[0^>]#6%-!W9M9Z@,0WEO0_/\E="BNCE(=<K.@Z-V\X*5(VI@^-OLC`4G
MT9$M^7*"4I2'6_=56Q>^@,?-O;?Z]9^)5/,EE"9I\$^^;-41%^9O/"++R(-`
MAZO->DY;%Z@XPWNJ<5`5WX9Q[PBUVZK:4WTJQMA.9,7`EL[;]S-B4]L44+J>
M$_H`:&K[1+&'!!O<3!(.&';.'3,0_$SMQ;6Z;*E>/=A<5^J*/#67#6TRUP$C
MS-@!`Z%*;B.N`\\M=?D_JF=ENE4_Z':&JT\'LFMXS]V%Q^CJ1)$KZOJW8$-H
MGQ8.&,V#=>Q`R.^C3USG*;N;-KA3#.X#WP?D`R-\"^@?(P6T[^X.?P$VP$:]
M0Z,S0/OMO?`&I'U7Q4^1`G#[6D?4X/G0B&LCWO-Y(2->,'048P.C5<P!0]*O
MBP8"IK51PX'%$+4Z-F<(+`$@X<IUTO;@XM"GVX>N#1R:[UPK.<)]/*FZE!86
MV\GT7S26OYCDRB=_)LG.%][?70:7=.\+S=?3](TV/G=D;TQQWBCL^_G-*X72
M,#.NS,2:EWHR\<$AR,GJ7K#1M5`5VR+!2GDJXQM("CNM,=A`W`Z_2N*#PXJ3
MU;VPHFNA*J?%A17G*<M*KT;,LYBB7&T?`C>&*>E57-"9D37(G(&CHU;#IDU]
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MBA9!QCUQ%FH;?N+9`]<//AX;X+JA1]K]=CKTHF2@>TK%47&>TLZ1]C+2-H5\
MXVB=(CPN3"D(<;%+C0*%V,8MGW5QU9B_?(J%:/5^N?9R6:Q-\"W"$-)='&N?
M?>C(75MX>G%'#XU^_>$%&^^FJJK_RSCGH&N8<9FWGR#FYF;BYI-T(0Z;YL+X
M>TL"[,<L?Q#$D3EZ]/7JC4XQR[6EZK5!I-A3;[`Q0\Z)1T*:A2<<P+K&+=*M
M/YI8\VR\CC]+H^I[`/<TBWZB`.>,:S*#:'&SHJRX9+Z\0!:FEU1[FW!'[OK7
MQGVX#Q)F_?JH-^"\FU=<(1A7Q"NNXM:5&>6?6W&L^CG\G*C*PHG5$O5L5Y/5
MC#*5C"J@/$E:7BP(Q=W_3$R[K;$RD=1"0YLDVC%SL,AIW-1R]K6D&L8AQ?%[
M<9F*Z<,(2AK)-26::,?:Q28O)Y4$^:QV0FV6IN$V2N\G_C^A`1<H$=,S,WN,
MADHRIT45WFM:`T!<C5([326O[C$M.>K]QGN:W3ZC#+*<X.H`HV)VTY'49K<V
M29QCYV".?>#40M1;\F*9U\07BRJ$59>&Z8HX!E*Y9*,DC7/H/<QS]UVU,(_M
M2X'F/`*"37E%1K@Y667>)JHG5+W:D@@'3?ZK<V",-[P2(V'8!^;&("\,#`SA
MO<DP$*2#T9H*9ZN1QA+"('Q?T^505W##)4"[';D:L.O(6M=LRV2QP\/10!]0
MZ$7&_8IVQC,&BI(<INIORY_EQ<T]"-^*VZ0,!>\N4MHE<#\IAX*S?MW3!8;>
M+:K/_<2"TM*KJDLAC%.TD58=NF3:0\&5BZD]@I@L=U^K"5N2<[W"*5T[I3=*
M4G5B(Y'&/N8>AO9(9B2QZA,Z?HN&\@?QQPU@D#_Y"U!+`P04````"`#'A6Q&
MG68.G;0O```_K0,`%``<`'!L>"TR,#$T,3(S,5]D968N>&UL550)``,5^P%5
M%?L!575X"P`!!"4.```$.0$``.U]:V_D-K+H]PN<_S!W]NN=<3S9))M@<PX\
M?@0&9MR&W3-[<K\$LL1VZT0M]E*2'_GUAU2_].!;)$7V"$@&[6Z25456%:N*
M9-4__^MEE;UY`JA(8?[KV]/WW[U]`_(8)FG^^.O;JG@7%7&:OGU3E%&>1!G,
MP:]O7T'Q]K_^\S_^SS__[[MWYPA$)4C>/+R^F2_!FZ]I7D:/X,UO"%;K__?F
M%CX#M/GU^N[Z_LUYA!Y@_NX=Z9RE^9^_D'\>H@*\P5CD1?WGKV^79;G^Y>3D
M^?GY_<L#RMY#]'CRX;OOOC_9M7Z[;4Y^3<I]AV;C'TXV/S:;IIRATYQ0&!^&
MSCB-__L31N30LHOT\_=UT].??_[YI/YUW[1(:`WQF*<G__WYTWV\!*OHT#@5
M-W[7P+M(?RGJ+S_!."KKY13.Y!MF"_+7NUVS=^2K=Z<?WGU_^AX3\1:OWYLW
MFQ6,4(Q@!N[`XLWVXY>[Z_Z28+XX2=+5R;;-291E&.5ZA/)UC9FJ2%?K#.R^
M6R*P8**_6UN"U0\$G[_5HYT,QPI_!CF1A'<)7$5I;A#%_M`F\*V'>K<"JP>`
M3"+;'M<`IDN,%(JK!_!N/Q$&\:6.;I8?P"*JLM(.0^S&;F*\0[>+*QEXC6`9
M9>G+^QBN3FI$U]G+N[B`<1HG8A1)XP_?G?[]],-&G/_6ZCT,B2):ZV*PZ3H8
M?)7!=00&(+$?8!@J651$NEAL^PY#8,`LF*!?GQ.'<T&<:Z]_W74H^`+""!6/
MI3X;MH88B@X<A`DT@\3`^3`V%_6LQDD$"WU-U1W%#+\,9183B#S$0%MK';H/
M0Z.$J;;\;OL.1@"6KP-0V/0>A@1:E[H8;+H:L2;6P\R)=1L-;.FD>4I\$^)!
MM48&+R7(DX."((@H&#TUD!V8#,:ML3/B$$'41KMI^RVBXJ&VU+##^QA%ZQ-"
MSPG(RF+W34WAN^].MQ[0W[9?_W%?8O<7&W(E)@A<XX_%#DH6/8"L=J$%#<NT
M)*3R&IZ,3MX\>CBL.XNT5B,66=M&;9(.C'&&=L1MC7`E7W*!X$IJSJ$D^A=[
MQ-[\\H8][IL2]G]MCU<O%4;Y[1N($H!^?7N*?ZI]@E_B#!8@^?5MB2IP^!+F
M)1:*RZP>"XL>>"0??&"&RW]7:?EZ#E=KF.,_B[.75,CVO#XL5J'W&8W^#CH7
MK1!!AVYNVPZ]C+8&)805UV"("W>MH!J1?`&B06K*$A^"A$@MHJSH:1N'/(-1
M7\'\OH3QGY];49H.OS#;=7B%TLXDG]#B26TFX:\(E*>(RAC4T9L,P1Y5EQD&
M31@GK,60K?:F0-N&)#0E7ZAJ$-0=B3MT`-(T6`/_<>J##F['$FTHX1Z=3M7P
M!^\8YRQ):N*C[#9*D^O\/%JGV)O@JF2I/ATV$O3Q5%6K4*JGMN4@!,!(=Z#$
MI('D,D)YFC\67`[B-^ZP#JNQISPC19L>LPB&[G')]]YQ26V?7!=%!9*+"F$:
M;@%*8?(URBIP`Y[K7]@>DT+?GN<DU=<M2\EZX>ID:SGG*F!ZK/;W4%CM?ADA
M4&CR&J.S'+/U.@?$;7S"S;$;"TZ?W][_$`K'U2)4_S9;DSDJ+E^P:Y06AY"N
M@J+CCJ.@]!CC!,22TM-A6!GR0?88]:=0V'0C>@;X5&(@%849/J?*3XAI1:K*
MJQXJU1M07N<Q7(%/L&#MUM0V'1[KM/&1?7AD:'`&?;C>HO_#X)+33CS_J%GQ
M8X2')JX-R(OZ#N8=*$J4QB5(:B8]>XY0@C?^<K:X@F@!TK)"/>O,T&C;*1T\
MFD\\9'9J%+C-%.`^7[[_V4.GHE:KLZJLKWUC;<O:&EGMNCM?OYU/7"5+CLZ^
MQ1RRQPD_8T[X\(\?_6,&PM9+F&$DBTWLAF<H41O2#*%.0R_Y0420KB%#'Y/!
M$?Z9UF?)_U1%24@LYI`1VJT9_Z&O+#')15J">X">TAALK+@[$,/'S3S6O@<S
M(.\&;"^F;QNLC[SO>+(U),D9AE2Y_/[4Y/&H:8MRL^V8M2O;8YJQ+G=C^B0!
M-J;)G:79`4_EW;__*#@R^>=)9QTPAG]:O<=9/_XP)3<I%N-%&D=Y>1;'L,I+
M$B^`61JGH.@M>5,XE#HV)4"RHS'-P(-'NZJIUDF6,@=7.366!6J2VY)1>;A[
MF96'Y\M5T`+$[Q_ATTD"THWQAS]T;3[\U1^?P&.476*"RE?*54].B^W,4ELX
MPGT#DGI3B/5S`^OVS^YN`_'F%`HQ;W$R92C"LLPA`K@&-L<`9HLSA*+\L18)
MS@5D;MN.I<]H.YZ?=<"D.,N3&VS>'KZ9XT]%%-=!;_X])KU1NEZ0ZBCNK\[Q
MEQJ:FA&J+4>%W?)6-&$&((YG6(TD:5:5Z1/VJ.(*X<D!Q>5+G%78$+S":T2L
MV*JLC=C98G>M!WM=&SOWE3X`1Z@=0.RROTV(GJW<3;0"W*NULMVDYK#9S?F3
M!Q>,!+4GCJII+*+<TE>RJ`:@H/:.]GT,L-I-H<R#)5I;UD.E=MOQZ-RB\24O
MUB#&S@A(N'(L;-^EE]U^O,=*U'6"ZD3R0S1-**UPOG!TJ_)!CPY4Z_7&58RR
MZWP!T6H;/GH">04HO*_6J1D=D.CDABHJGZMVDZ;,.=<KKA#4IKT?!!%"W0=`
M5*"%L&M4#P7>`K%T`[Z#Q6[8U9^4AFXBWTQO'RJ0T0LK-$=L*47V2.ZUX>TV
MWOPQA?,E0-$:8)LF+LB=(;2&J.91ZO+J=6[H$)7.;@]`=)U1.'!6Z`:M&C([
M=:.!Q`A;<>-F(J:M<8)3'],P^4ZI7W/;DNOGF-MD70FH3[R"JW0`O-^YE`"&
ML'5%&2BV&^]O$-:GA/PM3-BANY5Q.KCA+F63`VJ0JV@.4;9",20_'ZXK'FG1
M'K)S/&BULS;V@W8JB``$U%+@C?F\?:S0&R]<[UGL3>[)O/?1-_^>3!N+2C&Y
MVWE<2BJ!@W9@2C%Y@\'0E$GF<1W$Z<W:V&$<&I/8B^/PF<9E),>6!K)PXZ,W
M::[N?%!"?(I7/OCK/?C2AW_;R"B7(=@&E1_7(3@')+9N0\CM3N[N0UC?LVX7
MZ5\`2<8+16V;X4%VV["B@9(T&PW^"6&.8-ML[:U9#MAQ/5:;ILW2;^/X>KS0
M<(1RU-#M5M;H>^N#.:K[-;VI"`*S1?-$@[*LO&:-E:4W<Q@NT[I(+4'<P*O3
M7`BZB^YK>,S=W;6!0387B+J7Z"]KF%]=G)VMUP@^,3(`"MLU9)K1SE.-+4.5
MGM;FCQQ`SK9;!&,`DF+#V!EF!6)80,2Z*"9LW_$8..U]W@%4R1VP%<B#TF4G
M7_<$F4<*`[4Y'T1_0F5SY/@VI>+72)H3R1N8,GT_!3I_6G<!-:=4$19EEJUG
M]2';V@V(T!R@U3ENC$G*+C!N&5P3G#^G&2A*F'.N<FB.T#$QE$;PV/C0GPE]
MLT0'IM7,GU1..^QTV%QNZ&F\&R[2LC:IL6D=@[K`*H7/M/HWN$RQO\\VR]#I
M&.C.ZH'N<9Q_2>H:Q1=N(S1#]1'D)EWDSNMC&,L*/=D%+]@]?69&_2DP8$JK
M`.TQH'^IJ`:&),Y69,Z4[M9HCFWV]>!N[!#8W,8T&A`$LVA937]+/X2J4+R,
MBBTB<_@1W&-4"V+PS.$=B`&FJW9,,I#<I8_+DA:FUA^D>6RE,8C/C&MD8@9:
M#`/@]R\[?N>=VMXZ<ZQ(6O?G7F&,W<\^LY&`&`,JK#<R9>F-9C:F*J)/*39<
M,:?F2>VYOYX](K"Q;F&)_TVC[*HBB:ANHU?R;9W$:H9=L*WU2U-+IH9L**GA
M0_K,:Q8F;:`",X9-GZ?=/)<E]6A6:9U-$._YOX.(>GK/;]F]=TAKZ3M;R9$X
M-%66`$B?":P?"UYFZ2,)2VX9=+/GDB](`.DL7J98^6YR;O6X0K5K@TWDN_K.
M-YJ3,)"1E*'VPWK6U0LK&K0//6Z1ISJG^@-(1/98`_C.:X,FQ%)L3P#[P'=5
M@3_!^JUAE!UB?:>CIMZL,KB.P'A5U+$5L`:H?+W-R"KD"4F,7<?G>SS0/X27
M[-@_C1=V'/'%S!(D509F"R::W'KLBMU[KVEDN[NHX:ZPPG#P%%#/F,08M%_=
M*$+V)1FH!>G]^$IN'7"2+2GTE)7?9D__9H3@QGW\IM!3=D::/=T_AU-98CAD
M'M1D]P"]<_-(&FH`KXSOB'7"$;_>[]W(V^'W<6G@5]GMMZ#1,5Y>TOXT0QGL
MJ0R]'ZL5&:2,X3[7R:?=/;W7O=@P+\4(VS9C>>RV;B^ZJ&@'J$:GFO(ZP-O'
MWX1P`E!7G_$4K*H55]BI;3KBWFGCEDEHL@CE\&<+_.'Q$W\</U.):)O&,O8`
MTU)DW!>30T'***"`#D#*KBJ4UZ5","E7Z4M=-(0K<N(.'?GC=?!:8RM3/$1M
M*P#K<Y6'%4RM^CS,=]@C>CV<M]?VG!ZYU]<NW1[_,@4HN0Q,SG+@-'`X2-9G
MD.,'?:_!O]7=W-,"B.]D2+;N7S:EMPYBVY*CU<2>)8(4`!LQ*?Y2@$65?4H7
MK/"Z0D_9S:K9TQ-6XX;7U:?`0&1=!6@`#/@Y>A%[N[0V76^WW<8O;Y>#OY*W
M2QW'S\P`)KQ=5F#6F$_;!Z`ZF>[/J;.HB,8[HIYJCH&IYEA?RJ>:8U-)GR"2
MIS(O>TPE?0(HZ3,5L>BSRU3$PE41BZU`S)^A,+%=KPTEL5VCC:>9"D34#$ML
MUQ]UA#4]IAKI4P*H;SX!E.-K_'FR>_'4T/*4*[D:/9D7]SD]7:<44B5I:'40
M27A'52)D*IOP399-"#B*,R5+GY*E-S0US&=X*^&[IC+-Z1LBI7E0[J<"Y28=
M3BFP4^[T*7?Z\#7M/HFD+"FK26-%^TU\=I8DB!KX`)4YNI^GH0.]!:W$N!K>
M@F)VW`_V\ZQ,><J/+D_YE/9S2OLI3OMIG>.FE,932F/C*8T-A2WB&%4`;]C1
M0YK5&1K/*X1`?9D)>SCQY@]6M$*I<S=$(=G99_TW:"),Y-A4@ZO+CV;S3)C:
M:F3C^D8W&3%0B:S2UK)+,/('[KECRR_DE&=#!B9\GSB.LNVH=FWE`Y3MZK.`
M#YB$P?G]%*%:329-9:QM>LP[$$-,V5\@F3T!=`$*3"?)>8U-KQ0F%*Y2ZM=@
M*<E^OO.3#OD#F4D-I/M<RSW\Y'E'GEN"Y0\G'"'B`4'=%_>7TZ?T:5/Z--7N
M4_JT*7V:VF/Q*7W:E#YM2I^FZWE.^:F.,#^5_X\YI]1%0>P+4XJ9;R+%#'5K
M:.9@DLLOHMBKL5U(]?)^XU"G?>@6H@(Q@!NZ3,I_0[!0-OA;G63UU[:3)[S&
M=4B5"+>9:Z0-+P`^^P2B`BQAEEROR(V7S851[JUOB1X=#N/V\(2]^*F3Y&DV
MD3Y)!IK5>R'&3NNK5961F/T%6",0I_5E8OPY`_4*Y\G9"J(R_:O^GCE)[/-\
MH\/W3_P-#>\)AW,5J*7)-*!JC6/F_D;5(1-5C@&>P[PH415S'S[(=FD6BQ)V
M\801V5:C(M5#349I<`%<C6*2?0-8"E2FBZRM6'?QA+_T+,4^T3;MQ":T`+CK
MK"A`B:V1*$4$^_-EA!Z9]5KYC;O;+*-Q"+PD1:B)+9`/Q^I=&C/\T]RY&5Q#
M:]+AE7:3$#B$0Y0!OJ".?N`&>BFYTQ_'NP41Z]R!8#R+V!4'+>IX3WU_!.2B
M["0JW5J/(&2ZF7ORP83&SB$AUT6.)@?W#Y07`VH12GG[)89YN$LK"2O\.P93
M)2A*BZD2E+4W;4S!HO"@0@\Y]:;-IZK$4(\<E?K($>3^^HG*FH@UM_C"B00\
M":T=7H6^J>356"6O]!7"[/R>&=;K_=80\,9O[BY]RTL+Y%.@(J[M*%Q_1#_O
M^BB9A*K)VF4&5TS0[I\VFPKO^%EXQYU=TYN542T;RC+;,&SXK.#&M/'OXL%4
MWV2L^B:#THPG55P6GZ.\6D0QN6V5S*JR2!,P6UP7*`+L1#3*?=M)QF7[>FPZ
MZ<Z`OFFE#M$]3YWE>15EUWF,R*V7.?R,\2]!'N4QN`*T6*=<AP;WB#IXP3+,
MB*<2N8/BG9*0?$XD)F^=JT>5M.QU%3!CW&O.$_(\OY$KDG.;6="V=8>9V=8+
M86/=69:C4%\?BR&XOYQT!U^CC"1NF.7WT?;Y2+UI4'A`V+;YHIW=U@L>8"I<
M62('Z5HQD!$X`10``UPVTL;L\G:PU8)\IU:V`W$G+YB$KBB4:=;7&`J@K%XC
MHIMN.U3$-AN_9=-88[7T@A_85IH4@</,,P$(]^N/==8#,73.'C%JCU$)NLEG
M><Z@2L^V*RC7TPM^83J"&M0/<@.5X$DD!3,>;,R)4[K)-GX%T5;744.,W):M
ML"*CI1><P=0D<@0.O-C"!^%^_;L,R;8W!"TYF<%#L"SDJ-/7!*+QW:=EVX8V
M]ZIIA]ALL3>1Y_`W["^5=R`&Z1.@Y=G2'Z3)+QJ#>,%*3%4R>%H&:9D!T-VS
MX5>P3.,,U"_O,&4-$TO"!U+OW&`[E<Y>L!M=<VG/@;XRTP!I-5F@H4/R6CA>
M+U_6%`N(WZA[4-YIY`7W4)65%%G:RD@P>@`\L6%QOB*2:DM[F!V,FE&A4$^K
MR$%0S38Y7J+T_4:KGB9=JBL]2;J@JQ?<Q55#&E,P6#DIP;3*@8+;0&<KDJV5
MZIG3FU!O^NR:^,L,$B09>EW2&;NWN#_;7MS?TZ(@AOHNOLBR<[GM&LO,:.?%
M6M.M5QG*]`U5_NC]BYO?67>Z,:[+[/4.(U-O=71C4Z)ETWUFM?1BV=D^LA2!
MPQQA`0B[#&`H9S+`>U!:OEZ`-2Q2ENW`:-7-@-QMY2^'R!$V>/-G#=_G#/\N
M=6^+A.:/-6\7A,NW#,[./"'5I\,U@C[^\Y`*T8,Y2@Y8G[_\NR?<H>2J(K<8
MMV]]=B'%BPJ<<YT:O4'X'"@<)#B65)L6TSPJ"[W/M/ZE/I,D[3J?/\/?0818
M[ZZUQ]%CW>8X1\.]S,EQQ<`4!/H\[%_.'WGJ,%1@AHM[(VGS<6.D8^)DU@0Y
MY.4^"GUN-GEAP#$W7\$*&6'FWD"ZO-P8Z(A8F34][CBYCT&?D04'S^Y3*!5Q
M/EXAJ3E9HMGB.D_2IS2IHHR3,H;;MB,*C+:C*8L>/O]*R^4=R.H+4\4R7<_A
M)69#[+#SB@IHCB*:&]$H[M/6\)<:FIH1ZHM)*NRF.M"%&<![^K/G""6"&E#4
M-MUSNW:;\8*,I`;Z1ZRTZP3^F/.B#=\>7LM\?#VTV>KR&OD#!7E"<N?=1"M^
MP0^;H+KA3BN@G"<^H#,2=#JE5`W00JP55;6)4`#JX0X4)4KC$B3W)8S_Y"?>
MX+7MWBNBMW7[\M[JXD*UB:'78[*`8.LV$Q>Q`-CS\@7$%2E3/ELLTA@@+G_R
M&W<8E-78+8?J&AY0D6HYLX@/O,E8`J`C)-3:X%%[?P"5&-W+U3J#KP"PK^1*
M]VDFX!+W"8:#=.;`%".IP>[ST_L/_H6/`C=-F<FT0C).>2[H*-:I7(XO3^Q3
M_TYV1XFR,"7!DS@+QP.S%6:18V-W@1;_.%4HJ2Q![87*576]],"J>EUBX/&F
MN\Z(4;LUM]C%`;<`U<BR)E'0O#LUS.:>>;#R:P^5)T//915BU-K>1)BXSW<D
M]AO$7D+8/H$[#T#:WO=/W>]0KWEW5A=0X0<G1.V[\0EV>\]4D*$@FNP$C1)(
M$R,7`,L>JK_K3Q>MN(RU\;N;LKGQ768=M#<]4.3;\B3&%#:M!VI4+`(0C4/>
M@5K"KXNB(F_$SV'1RW&GTJ7#P/PNGJEU+<M285(<6)=2V+C/H=>(>UZD",2X
M5W&=8_OW*2K!')-:1/S"KWH#T*/84@,$9;X.FAU+\6T51'09\@AV,9G[8.YV
M,SXV_65Z'^"1!&LR;BK"D]OI+,ZJ<@E1^E<OL9)U.*9"5FPXQ[#MVIY^%Y$@
M:R2,D?,2D-QY=6:&\V4*%E+7&#1ZMG)>2O8,:B_7FP^3F[@J!E:Y;>1-81/X
M*.I\;,22`2B%R6\(%L:/+L203&T,/$C?]-8@O00^;PX21%A-9.J7%?<4I1DQ
M<J\@JF?$LC''`F?)INN#^Z;E5VTQ?!9B64JL9@2U*<E=T_5+CM%O'#60<XD"
MVQTH3@M0GY/>D3G[LL8^>_WI4[IBYUMQ`%)*HDV!/%ZIMK(HHTFV86JLIN"D
MNG':DU2K)5`_0T6DHEJ4S0%:4=P]2Q`:;J%Q""%+G_TIMRAL-I%WGRMRL#%P
MG1=EE&5U1!=;`E]!09YS;PQ\DY*F`L^$W,G!^V:E4&,Y?)5))5*L)OPT:-L^
MB"?BH3L1ER_K=%-GA"J^UL:G6:UFQ@]9/&U/MRM[U"CJ??$[IL.^^I^6WCE5
M<B:'@3`5#J*".!I)M#/I/H=]>-AKI\,=Q`%XEW:Z[I;N4[I8=..HRZ2Y+5$%
M#E]B7P>\E)=9#>77MP5X)!\\<&%J9^PB*L%5E**O45;1DFI;&-U86*`S>L@Z
MUNY4^^IZ<!`/(=WO+8(Q`$EQA1EC=ZF35$>N+];=9E$,-I).O[>KU+E[@U>R
M<\@B,6BB7-SJ5<,KA%3`=))(4D.8UQ%S)5ZF])-BXU:_X^5@]O2,QKPTE$)(
M_WL!'DH2OD(5H?H:&UP(V^MW6`[O2_Q/@LWV&/\0/;*>#*D/T.%DE0&.@:6U
M)\P!;VO@%D)6X/W;/X">TAC0Y^P&YD^86+#Q6HLY2<O:_)V\.;F!Y>^`%#*%
MCSGG+K5U>*R7IN;A'8/$N5H.!P)JGY2#/%<%_@3K@_XH.[R1^/$8!7D3G;J"
M:/L5:<>*H(Z#A"N19R`QZ8&!"Q>R<N#3)](8?Q]38^R?C8+DHD+[.'0=,>GD
MUMS&53AWX8>,U3TCT1OK&,30Q#2Z"(`/0E,D%#^,*10?(;E8O]@_:3U?1BE:
M1?ST)W*=.FPNZA3,4R:M63"=LU42N(CW2!@BO#LF^T#W&2FSNGD50HK=$2DD
M5^&X!]Y6`9JZA2(!\"CTOZL%\?F>BCPM(FG^<53S2G<V>?1?$,4(\H3$G4S?
M8E&%:^IJBSS<HQ%QA\OC\R4899)$`O_3T0G\5TBLGPS;/*Y%G@[9A=!W(4]B
MK[-$H0H^@RB1Z/_C:$3_+BW^O$(`-,^87`@^#ZY-L:?#G81>?7E"$WDN22*!
M_WE,@=_>W.64G:.TZ`A1J\7193MCT^\NQQD-!Z\C0%N$N>4>J&WHK#5:H0;:
MQ/=Y0[["76,\ROHRRRDP5O@[_RR%FGTQAV,IF.6`&VS6&$%N]Z:/X'8?IJ^H
M>$N5H)['6/UXL@Z<P!EO_@P',EYO!&7&:XP0'..QJ#?->'TX(L;[,";C*>]I
MS`)%3G8U7HTME6U-KJ:0T8UMU&76#O=OLYA]K6]>M+,AF3ZVD@!EZL"*"^IH
M?%N[B^#S(94,%6)[0,^%I3[8:]]/OD5I'J?K*#M;P2HOZS-TD,SA-9G/*+NM
M4+S$)*'9$T!G609+TFE#4T?HK(S=>*QG<.R0Q<KF-%M^J&<>;:'@G'IX;VXC
M_#?@N?Y)\:(<H[/<S;A>YY`%8=!$C7?WC867D)4_[%GYGR>=Y<+P_]S\0OFA
M!0"\E"!/#E?56VO[_/S\?HW(9=;TY7T,5R?UPI)-I(@+""-4/&()?>N98ZK!
M/E-IR:E.ELKX4_*,(TV>T7ME9RUWAJ$7TMO2?)SC)%J3[KOG5I/1B>$&?!@5
M$^D$C1?PH<XZE"2#*DS-$5M/IR6+F/=Y>^P7I-Q"0J)2Y1QV9K3UATX7Q=IE
MYV:<4NT\T;%5JUWK'8&U2NTFQ7$JV!Q*P6;)53^"6QP<L\/=-0XJ$@'LC!J6
M$//LRXTMQ+G2H68*R9U^#36&_$O>-8J1P&0:3\P$#E?9LA+D^,^=G>`?IVI[
M]5.=M`"#Z=:7P.>KQSIUTB0%]@A,O*#+$G\PFJF<ZH'5;/,[B-#\&<Z7L"JB
M/)D_@^R)?DU3I4O#1Q-W<:N'&"88U"*0:_RU?3#ID:U6MO>P'MHG^.RZ'AH#
MI,UZ:#V0Q[O[6EF4T.JAL:BQ*MV*:OX>Q#!/-)0]K:.4RF]W#$/Q<X@UHOZI
MXQ]S/>JI;DF`2GVJ6]*4QE%L\RM8H1(`>L8NM4X"9=WMY+NBYA(Y4$DSQG;/
M$MJ</14N\4?)3H5+1(5+3%;_GNH#RT+XMF5*-.5>RQ4;>:NUMQTY$<P`*S7V
M_2^0/BY)GN,G@*)'T'++=7T,\QBHNB`F,0A9T,=?,A\<&`O$"=]R_#3F4PXX
MO>*87G%,KSBF5QS3*PY/[GY-%^&GB_#317A#\8BMV7:6)YT*$UOO#B,JO"JO
M/48CIJ`Q1E#7[8?.D<D+^?JX?,-7]H.^SW5J]#Y7P/O==*=[NM/MS@F__'>%
M"3XD<2EFY1*@^3+*MRIX7QKM#F;9%42DDVF'?1`2IIQ[322^B7BAS87S(61H
MA[YCUAM;^F=569015JCY(R^02F9G84=W#$;$\$L2'43\7?[I=.F;/%T:+E1'
M>!JE/2G^G%X=[3XTO4GT2X$,,YP"?K^H1?A1OW4,SZLQ95+Z[-D,IS'89WCR
MLX/%<P'2LB+OF_+D\F6=HDVLR*;!ZP(GPSO50)P"439NC6*';!"BF>QD>B85
M!VW%:Z3ANE95P:@C;TQLU:4\,H-;GOQC4">B\,1.D8X:$]1"PG184!&)0+2.
M7Y'!(0L=HM5C9SZ.^2T]:V+FY"K]=5ZB-"_2F/;H<PS0AHT=.="!:!ZKL1Z-
M10H@NJ-$50A:@%>!I9%R9D\XTWO1'J@KH1H#!2)OYOR+H9/MF\.@3T\`,G:+
M8`Q`4EQA+E(1*>E^W?3&XGZ!"`QW@U*='@>[BSQ*5G-Y^&$@2AKNX]Y>&O?*
M4C""Z%6@7F]I0W1.#4_$MZ5T-H5D[:N7-AQ[BF0')Q"5X4TP7;14OMG"ULC]
M!L1_J_?(PZD1;`Y%Z'9"4V+H@2@0KVP.O:4]0IM#=2*L)EOS3NE8M3F8<.PI
MDLGFL+-41V9SL,D-0?RG$O13"7IC)>A_&#-MV<C5YS=9"S`43K(>:IN.7'3:
M^&L8,"\/'"C($ZG*A39!&;N&PP/E/A<0G9.,W(61GE.J@FHA9N8RB@1"`=3P
MG))ZI5-2K[X@3TF]QF'33AXH:J8OJ;8=EF.T]<R*':)KH=K$Z)FQ&@@V&9>/
M6`#L.:5EM9&6U8^\:CPOP%T^-3H6(8B&,1<]W`314W+B8TE.W'\R[WERXL#C
M`LQTB"%%!C@Y$T<)#,@E5/0D-.!?MIHI+^B4%]0VIU)388L378O36(>=I-I=
M"FKI!-/^Z2=[9[-?ZX-96[D!-,$[RP#;!>]9D,BSW*_<Q?+Y]9PN97W-()O3
M_`B")$$GGY=>J*-0XOL+-G8N@.G"=Y_(.[`+8R/I<?YR!:W(6:0=0Z86[4EI
M9Y!TKAWHX)TIAR[X23=H+U;0JH%!60`ON.W-R3;5U8@.(!,#9_J!@L&D(H8L
M6=!:@DV<ZONU40H'1^0.;IQ$L%A/!83'/!^>;JH$?E-E.J/WZ(Q^*B`\W36>
M[AI_BW>->06$]Z5CS_$?>,Z)?W>1(A#C44CJWMJVNP?H*8W!+8*8*("$%84-
M#-HXFS4Q:%#'N<9GT4(18A/('?,US:D4H$%$_%W^J13@5`IP](3?4RG`89,1
M1-EU@\MBL6BU%#![.PJG"'5`2S75;?1=VQ]9?48N@:/58936PM-%L7$OBOFX
M74ZO$:;7"$=R+WVJ+F4)B6#-CZFZE#_^IJ'J4M9?26W1/<N33EH).T<`=N#T
M3P5,PPGQH,#J7%LX.["$[U3(W7B(QN=K:')TA&``3@6\?([E^%6H2SY48[`@
MUZ1(;9ZLAJ5D56D\YE=#4YFLJ4S65"8KA#)91ZUTIC)9GJF,HRJ'Y>QP4*'L
MU?&)\U3V:BI[-96]\KKLU1$]:I[*7GFO,HZJO)4S&T*AC-71BO/A*').7CA?
MYR5*\R*-OT999=F`D`)M1^@%H`/1`U8CE1J+%$!L4HDJ52TP1@*"`I(4!+ZE
M'M@<')Q5Y1*B]"^0?,&TH<8Y`DE<7+3M.+*`/8:64CRF@$FIFN'`O$U;($7:
MQ]<^<4-R&9@!JIC@8"C0\;(>&.-UA4P(1I=(88\82JM*R@1#-(:?1X&:3'^J
MZ3C5=%0T>Z>:CAH(!?O&75M]<K2,14CF+#TVI!!7J$^+AL(S`LFF+3[:LQF;
M'"W4F2:7Q;01QZ).K'C-4#5:0IW^Y6;UJ_+JE]Z/LT*G^B0YK=.I@IY[?OS_
M`,%;B%>5?"#_SW+`9$5QXP87\AK[P(!F-`A4G!G[;G";\R00TV4Z/QY4&W+@
MS6RCDO:GUAOM880:VE&%!$[,U&8F7LAD9#:@HQ;$N_V@71W%LIQ>.CN\V$ZX
MWHY<&H)C\G<\?.<6=MQVJKGK8E)]#MV&(E*:&N7+&MM:V_.V55JZV#89(&WN
MGCV0`7NL&K>%K"S46"?`+B@,0`O(Q!NEVG;D[IN(,:I,C-/HHAQB[A/)[.-.
MLQS,G^O(DSBLR&I+BRKVV_K`<7:"BH)Y&2VFR,0K`'5H='XVM\AGB\;5]6W(
MWX5])(9NTU3B00]8)-U93=++=PP&E`2Q5M]Q\C>K.6X$;O`DD/_%^Q6G.6W+
MHC8/6$0$NY9X=D;;N'BHA?*,^,'0%/4EL?/P\0Z0.<0_G\.\1%%<5E$V!VCU
M@;>W^8,=;>_S`;N`!5^\-_HPP=[LG1Y-AM7WC?R]E:C:>_`$<NPRB+=6=FO:
MSDIK';!\"396X=R,MJ]R,`OV9>U`0[?QUG@$EY`-W85+2(,>L%BZ=PF%RW=,
M+B&'6-6*X,.W+:S`#I["5?H$N!%,B=:-;8O;.F#YH&];\G/C>MN2P6QDSJLW
M4WG68S1G\5ZO^7$S'W]V1N4^%FI]]C-Z&X_+@/?I"Q$*(>=1VU%8KM/N:'F-
M-Q]C,1D=IQYW_>BG36[*@>Y;&#Z%NH9C9S/4-02[@$7=7:C+V/(?0ZC+P&18
M56[TC9/LY/O'-J);#Q*MFYLHKW7`\L782J7GQOF&*H%9C_-^"F1;[:?3>A!G
MT&OGT#I5VBE-`I3:_,P`#%C>-/8S"XODU19EE#ZKLB_8=60C!E(=J'O/MQ(U
M4)FA\78@M<C!3_8C!\3%W.^-3/[CM&HP';75T7&:>"Y<LQ</HQY/_>/H#)NO
MH,!.QBY)Z%64(JMFC0B<8:.&#2Y@R;)JTD@N4*`&C9`ZJQ)/W4/NTY=:_5P2
M=W^6\\_=Q(T;.PJO<<#L3]]8I&?&]?XB@5B/Z7YVQ73<:[_L1A0F.^HKOL*9
M&(NI9*[SGGYGG9N(25[C0XPI[AF:J&F3LYA-CX^_Y&;%.9>)T.KSFO7\783C
M=R=\^#\FHW';-;B,T>[H6$QF/ESS%Q^G/G-9?\2)M^>=9JUYGYVCD-NPF9J0
MT?#H^$MJ1EPSF`"I/H<)GKZ,4O?B(0;1>&4O+E?K#+Z2L!MZPI-,7ZRSK,8`
M?YHM[D`,'W.R9!LGZQP69=%S63MA!4M0.M$$XU`\J'!AAB:YPA868#'K61B%
MY:*,A2T6IM:OL+<25!5MF#9ZO0H;-(5?IN(ZQ_L!N"^CLD;ITY9Z3CIYB1X=
MJ>/V\(UR;H8SJ3YRU(^73U!F`:$>S53IYL!K2JH<G``J.Q`],5O<1QDHN$F!
MF.TZ#$1IY]:\EUL9*$^9"IOT4_.P1P\E6:Z-K4@LL>H9<PWB*2'IX:7--;Z%
M,+-=CK*)<-)6FMQ#Y+)1VMU%_,NGM!4KD-"E[O*%?&3Y5&J=NQ7')#N[W80<
M^#]:L^;:H5%$,@!.OP,%P!@NS_+D`CR!#*Z)Y&X)$:55E.W93[(H[NFYE:5.
M_3"[2P5>`&QW#S(\YN-O(`<HRC!19\D*STY1(DS_$]C2Q3?AM<;HQJ34QO"<
M*8?,R##VU(.LFIW*?8B^A&FN$Y^GGD!M9G,>O5RD!:&O0LQ:T;+-&Z=1_.:F
M3M$H4&CQ99FF?-P=1'>E)QDJ$=22)!&,W6F6<&Q?HIT%B-\_PJ>3!*0;=8\_
M=+4\_NJ/3^`QRBYS/">OE'@FI\5V%JDM'.&^`4GU)%D_-[!N_^PNQ,B;4RC$
MO,6UE*$(HS*'""`PN!>P[;$SE2WE&E/#`_W&'I$J$11A-Q>2.W8TG;E.O2"(
MD$B.%=2%T@]\<$8/0$!$E8Q%]8=]J!I<X\#W6OLM:'38,/CE6)I;)HJ-/95Q
MJ269:&,$P)[WU4.1)FF$4I%;R&S8]?TH#=TX>,Q]%"J0T=NPFR.V?#/V2.Y+
MM&(=^3N(T'P)$(@6)4#LEYW\ELTGG:R68[CKG$T`JA`FN1-UGE,*A@Y`SC]C
MJE?5BBOBU#8=Z>ZT<<L*-!T+Y?!G*_)-\Z9DT\?Q\R!6RLGM;G6B4U/>H+T]
M+X#2KK*3)':?E::)-YS#LV`+[GGO>-.5@TXYOE7TS_DGLX,]=/_.!`RYK8)C
M?'>.J_`$?XC?JG)N;]9S]8]QE+P^)GLX\/LX'"'K]LFMN[[C9_T9SLY$?8;S
M):R**$^X[U1EFE-<`7ISO_T!"1('.07<\0,0\\_1B]@SH+7I>@;M-GYY!AS\
ME3P#ZC@!+/+E8@%B<F2\Y^J[J`3DADX>IUFZN;M37H&$G#.3@^D*(_+::LQ@
M#8,C=Y\>F1C9#1NJ''G:FSCE$U(;J.@*@Q\>H-))E9;/+!BY/WWO?[*?S3MZ
M^5AA</D%N5J2/E3U78_HF6<^2'1H&Q#<#MZ:$/)DZAH1,A#<ESO<JX2SY'^J
M30*@AK03PV>6TVZG*/5K,(AD/__4N2[16M=9U`"YYYI#A>FS%:SRDJE`^`T;
M?,%JZ*?"D")+2U$(1G9?LTW,BE>PHBV]6D<E%;'I&*J.H)!M24FT(/G(.MBI
MUN*<1C\EQJG[A<HW?:(ML4T3D/N:1Q+XD5RW>GS3[*G&.9N>P?(.A7!;W-,"
MY;[R@H1:Q#_J;5B-CFH;5MTQ5.:AD&UKPVI"<I\^G8_@X5J(,O/TNTJS3[-K
MB`S$)-T""U%@N4]:^Z^T7"YA1BHS;]&:Y5<0@?0QWR!+X1[I/@VVD>CC)[^H
M$JO%*/)`K&:8-1/5GZT!>0B6/WZ"17$>(?2Z@(BD;F9=-A9WZ,3@>1W\XR)E
M,K4CYA(01D@JN^7HLZ*H5G7&OSN0D6?5<X@)!0CA3X0RK"L1R&-P!YX`*J*,
MHG@&CM2._.J-Y!][F9L8+=4U%+1RYME1WH7"\G6\S(W[92`5X[!TXWE\[;$"
MZ\(4KP_KSA2]S_AWQ1IX\?(<"MM+T.TPWZ#<4M&.`07T\4.Z-&C4(T$F%%]>
MJ4[O!*=W@M,[P>F=X/1.4(9Q_7LGN'L*$),C1/1*5O;[W1]D4;]O+.KVZS^N
M/W76LO_#=A*:/_AW/LM$6_D\EC)2``IF>@%VG"_`Y*W(0??;A&"&7'(+=R*E
MWM,IS9W,HSIO\X8.MGJG9T;3,Z/IF9$/SXR&VHU?[AEVX^&'CMU(?O#7;NRA
MK6TW-D8*0#YG:Y!OWSJQ3Y6Z+?K'2(<6(RVQ;,R/3<VP*!]MW`"6?WH>%LSS
M,!TM?</R[F]8WOV-U]Y]#VUM+7W#\>Z]2ZB*UN5XIV;;<\C;")6O<Q3E111O
M:>,>G,EVZZ6Y%G7SH,08`\GBXVOK%ZD28AIC,4N$*8WEXDA.F@FH-;WTIX:N
MU@7(T(MPZ2`1_H&>'-6\`PWE`>04`74`+Z:)&Q!A-^20/=[1G\;J005B5<23
M`K.=XI\)RWV>OL]1'CW6,GR6)]AC*/`$8Z?A"H!B#L^748I643Y;?(012IB/
MY_0':=S+TAG$L='.7CAH:"*$;-9^A#<`GM\A[V&;&4.PE92ZH&J7`EHLV9=$
M)X"3O`%["CM^ZFQ7X851#6\JDN%6Z]N*?U$=!LV;M\7%;-'X3LU\XXT@9[_1
M1QAOZY'U2O0G9+`OH@/:?8JR\T9)KSF<+\$-5@?@!<05>;ASD2(0XX'H6:BU
M^S<L'L7^OAD[0\A7M'/T0*ERE/LH65S`.(V3]6B1LD/))T%LC-VP&]JA-!PO
M_K5#AAO8HC9BD>4P%,69<RB)/MV*[8W;BB/1QSL(4U7@3[!^\$$><^PBT/W'
M1)X'C#8O,PD2V%DZ2Y)T0]%ME";7^7FT3DN26PS&?UX71042\F^4QZ"N&LE@
M)1-#=@N%#AK2[9XAQ[`&)TF#O8U`ISZE&X^1R3N_.8;""6Y2VW19K=UF%+^?
MKGR@'"%\=N@YX_2A1(INU*5F%+E%B)S_UDS]\?70YC9ZK6-#A,X#L7ERFT7Y
M3;0"7%_=)JCNYFH%E/-H`9V?H-,II8I`"['67F\3(:\%Z9"^K%;VH@K([+:]
M&`*UK>-]V.:R0K6)H>MD"PAVJBAS$/.:,853PYJ9RW]7:?EZG6/*JWH*9^42
MH/DRRF<U@<451`N0UJE(-O7/=16_>0Q4]P.3&/AH(H^W!#H.XPC(]D,[7LNL
MWU89\PPF)+N,=S=@%,-,[JS'3]/L($VLF.CV>_+/`T8`?_._4$L#!!0````(
M`,>%;$8%KK5,0KL``)<Q#``4`!P`<&QX+3(P,30Q,C,Q7VQA8BYX;6Q55`D`
M`Q7[`545^P%5=7@+``$$)0X```0Y`0``[?UK<^,XMC:(?C\1YS_@U)R(717A
MK*YR3?=^J\^[-:&TY6K%."V/[:S>-1D3';0$VWQ;)M4DY4SWKS\$2$J\X+(`
M+I"0[(B]N](BUD7"\ZRU<"'P/_^/;\]K\D*3-(RC__KNYQ]_^H[0:!FOPNCQ
MO[[;IA^"=!F&WY$T"Z)5L(XC^E_?O=+TN_]C\O_^?_W/_\^'#V<)#3*Z(O>O
MY.Z)DM_#*`L>*?DMB;>;$W(=?Z5)\71^,[\E9T%R'T<?/C#A=1C]\Z_L?^Z#
ME)+<BRCE?_[7=T]9MOGKG_[T]>O7'[_=)^L?X^3Q3Z<__?3+GZK6WY7-V=-0
MT3Z,F-O+??N._J^_\-8___KKKW_B3W=-TU#4,%?[\Y_^^]/E[?*)/@<?:@;2
M\*\I__`R7@89_S&UWX-(6["_/E3-/K"//OQ\^N&7GW_\EJZ^RW\]0HK?+XG7
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MO__GG_:>=[_M-&EV5)`L*Z?R?VJ^2-GB3\LXCQ.;[$/C.STD\;.J3V+MSUC^
M*ARZY*^DTXYD,9&J^-,P>#S;)@FS&:;+8/T'#9)9M#K/62>`IJYI#:7RIKT!
MJ_.B/W85%M0PE@I.RB>D>$38,Y(_).SI^/C6=FQLT@$"U,M$F@0`@\:4"P]!
M>L]_E+QD>@R"34$(NL[2ZI,V,\J/_S']&B2KN]S*]%N8MB"I;%/^")(VO4B@
MM-L/_3+5<MB+)2;\3\+^)E_8)__/N"!7=U4,^F5;L!:VW>,9UO&N@OIYO-RR
M3')-DS!>R2.ZLETMG$O:]8[E2OO]`[E,O3J*BZ4FU<>D^-RC\*WNQ1C\@PL"
MM[!],VK#L.$*Z;,H]_KU/'X.PD@`<-'C&JZ;CWO#662M/XI;6M7@;32>%'^1
M+\7?(P=A:7_$NM]0`,QZLR8>E7TZ8.60)'DO4<:,=!JMKN(HV']RE_\K#99L
M)B+]1)_O:=+"5$\M[>K#5`M.?6+G.U(%8VP<4.,8ZIS4!4B0YXM<Y$--AM2%
M/&%I7^1UBZE>$.Z46V;:!`593RZX2F2Y:3:M>_OZ?!^O!9E,^+R6REK/>^<R
MH;W^R:RM5IW-FJTGY9^D^'O\;";NDUC[,PKR6:-=,Z&I>]9M8?5WNE[_GU'\
M-;JE01I'=#5/TVTG6X';=THO:7ND6DSC#U9Q)C<#J=9DTE7YQIX3WH!4+4C1
M9'P*P+I=4.'!D-(M^21RHAH0"BZW%/H]7F^C+$A>+\(U3=J32-IV'<ITVB%1
M16(?BR)=]1!JM*4J2NP^)\4#7X@@ZT0!`=3]W05^J[T(\#IHN`5Z.7U[0S=Q
MDK&$E0795HYW=?,.[&7-D="O]@:+!%(K$"Y(A"M*5$L,N^>D:.`+-33]+6`(
M""%=HHC%1'P!8LHM;3A7SX*,/L;)JY0MPE8=DK1:(7%#:!N+$FWE$"8T92H"
M\$])];$OL!=WG`#MJA[N@KS16H1M-13<0OIZ>[\.EQ?K.,BD@!:TZ<"YT08)
MS`*[6%!NJH8`N2Y1P;CXC/`/?0&QJ+,$$);W:1?`M;8B^*JZWBUX;^ACF&9)
M$&57P;-HT4S5K`/A=C,D%(NM8P&YHQV"Y990!>?]QX1][@NB)=TG`+6RH[NX
M;C8705L#"<=%>E[O),%Z'JWHM_^3RNL-2;MN6=YNAU6/B^VC%>(=]:`*O"6U
M*[V+SPE_0/(GOJ!<UHNB8EO9X8(JN]E>6%YKL.$8Z?'S<QS=9O'RG[=/00Z[
MQ3;C&Z7S0E\.>X!0EP-*(2Q"`#Q#8X?:%H@J*A4[WO!&A+<Z(44[4FOH#8T@
MJ!!Q"HXF`<$4PD*VF:#0EGK+>)MS^I71[Y?J#T;!7VH4+#_^Q_RR!>GN@_++
MUQ_THDO70C]*-/3)85]K-IG?WDQGE^1+L7PX\F*NX!>/Y;]5"XK[!GNX*7K*
M]5ZV_;;0B_P3T;RBIF4M;DM;HNUHD_B`MZ>M:P"VJZTMM]_75M^;S)^-'WYU
M/2K<VZ;N_GJ@E4B(][?IL#(,_HM==C`&"-I*.=!HB\P"@1_8/&B:,&%"7;+#
MA7*KIY=L$/6N@@]R,,@949-1<4*%'5>LN*2/P;HH?`1;\Q4M:@SHM.B->XG-
M_FCO*E9CO-U^PC\@9=WMPY9\51?%@-]4`-Y6RR9D=9WM.GRS=P`4$;O^6!"D
MB\=H<;EN#2\4EUIAT9<WW@=<]N?X@!3VAC"H"OI+%$?Y&S#"T"GLT0&W)R]Y
M*9^/#:_C=;@,:3J]9Y.2R_:*#5P@:VTZ5@C@["_6>H2TE5AE![!K6"X^N9W_
M=C6_F)]-K^[(].QL\?GJ;G[U&[E>7,[/YK/;/%"737W9%*P'07?_+Q0X%7_T
M@H)=O7"P#<ZQ]"K.:'H9!Q';<'P11D&TS!V]H4L:O@3W:_KQ=?]OW;N&""K%
M/+54B<GD7M\*E>NVGH"C@9V!R?XS#]^MQ("F+'I@`%X27ZQ42R,0#HV&CU'7
MP2OS*/<Y_R39TM5E&-R'ZS#+0VFY30I6(-AHDD0D(TVH@<CB.T#B3T:3E%Z"
M@Y"9%_#88Z)W4@F132'%WV,*F%RP3O_J5^BQ@9XTXMCC6!9H##3*X\M!D.(?
M/[M)RZ8N..%$KGG/BNL:*TI)4A,]V6W+];24'XTS>XAXQAKFF"_IF+WZ14O_
M8&E7)*%.KTT)%Q%#Y).3N-`R9,S^AGR'XR>$/]]1VDL>"_M?QU<%:#2LK$MJ
MV3<LTLQRD%UIUK'7"W(LL?"_CQ-9IA'?&EM>1/#]*.^*9K`0KA*1Q'"Q""JU
M5%XY8);$')Q80@7[8)[L'G\@'I)-B0$IVP#(D9%-)"IGVTAX<S6>D-KJ![?&
M"&'?X(3D33PM'_!P!P[S_9&'$.AM-C9>R38V7K6WTM4?H&QLW%O`V=AX!=O8
MF#>;7,WN_C:[N9Q>G=]ZMKNQ]K-W=C=VNJ1"X[Y!=W>CH+M&6C7*!ZQ\+GF/
M_LLPHO.,/H-6B`#BJM4@I3C^R@_`6P>K/&JKABLZ*F6[E)#G`=;VA/"F?.IH
MMU!02Q?D"Y,E7-BS22,PN-3K.7!X*M=N%&HTZS0F`!]M$FB1/='$:!)()*&>
M!&I*N!B:BWR"L/F%)O>QQ="\9<]X8-Z05Z^"G)"8-?:+HBHHZ$;M"OQHQNQU
M2>V8?5C0.5Z3Z)CJA3C1&L,)X2T\'4!@X<UTEL@:<8+!`S[F3MW/07;L]0/>
MZ7>3Q?%&LWV'N$;7Z2A#4];?PJ'I_D%K:,H>H`Q-]Q9PAJ9<GWYHFG\Z^7PU
MOYN=D]N[Z=W,M\%I[8?O#$X[G=(>G'Z^[0Y.!1TV:&DJ63WE1ZDN=56J@7"W
M8`4)8X5T`T_1Z@F835!\AZB:"#8L>!/V39`BR@#F2!.D`H`285;P#:EFM:_)
MD`MJ'`NT96',8;O>-RW&8OEG"5WS*^_R7LFS,3F+U[F5..&7OI'%AA;_>DLH
MAQ34#G$^]F(L<_'WH+CU3SN)HF@L3D>=QIBDEGB"FFZZ-L!,;8ON>%D]\&^D
MJNI?&;W4>)"0J24D)<^0^'&U(49FRA9(+,1?)_%+R&X])0]Q0E[*!L>$(VA8
MMD22#V'W)GX-UG9C!)"H."1K1#$)!O(2-5SK+((YIU:T"^6[9EY1#X8.&1%-
ML"4AI5*%E**^(--E(M`;QH%H?1R0O#600G.'`YCZF%?,4HE9]G!+RT%R1!_.
M"3*!GU6]M)>A!+-C%)A$;G$T9$3O%\19W-Y]5JVF'Q>2;*,S&$L^Q.#NK(_I
MI+_I/+_K"5-W#!+:ZC$AN@_*]-N&1JEGA8^BJ^%3F+9SE@;3E*X!Y6##B<)0
M#SS5:VG1NZO'AR[[.7$#?(T=IK?/6[X6<DXW"5V&?'8H__>:LG^P-V&?V:TW
M_^:?7R?QAB;9ZW6.(5;PS_ZU#3?/RJB.JKZ;!)#48U$<]=NBQ0,LKT#!`\?8
MI*:)U%6=D)VRXFWZFKH34BG,_\54GO`F.ZW>1"A<4H@"F@O:":(?BAEAL#Q&
M8@-3_:\%M2/ZR"R"ZD<\]X;C.*LG+FF:D@]L67Y']E5-9[%_NJ;LG<&VB#M8
M#H];'ZU6(?,N6%\'X6H>G06;,`O6M4L49)4/6+!=TP`$<8(:V$.D.@1B#Q!]
M]&HF^S:$-2+SB)3-&G>)>!),X$CIA@E3E'7HKU4@(+8_"'4SH0DSBP%5/J3>
M@W63-_L01F19-'P+^-0G*"<(]22IE.]SLLNO'N+DN4B08;I<Q^DVH7?T6_9Q
M#<DQAGJD*0>L!YG?AOYC)R2X>1/20[76(\!.AM2$R%Z*?&%RA`OZ\K*O-0H5
MX<(.T/+8`=2G"B6><\-Q*C3QP@%)6**\_7Q]?3G[-+NZF][\02[F5].KL_GT
MLGB?AWU,YE<7BYM/T[OYXNJ=&P:9=3AV>))W&V5!\1Z8V3BN*0,;PE4R+FOC
MIE].!VX[4]:%<*FA/5QC%7`U7//C)3TS,$"K8"&&@.5O(0NN?"70&Y)Z_VN;
M9FPZ)[V+;RC[K4-^1-,\6L;/]#).\\_/@O2)[^A>T=7'U\\IS;]`^2Y.]#A=
M9N$+7S?3'3#NT%2'Z"Y,(<4'=[\":H'AQ$U(2')@>%+32A+ZKVV8%.^8)94!
M$M&,Y#F1GSC#_KW,39!-:8/<OY+OM[D9$D8_D+BR1(*=*5].4G?),4'\=,[H
M;MC%-RF*UF\J?J#O=''EXSCAHY@,W`>0'"X[S>Q(2%+H)M\S[3^PQ\P`N:X'
MC\]5\-C9(7M#_ATN?_!A!##(.M1`,O)0K?:%)$4MO[[\/LB_QUG\S#8X\D'G
M#4N[:9C16YJ\A$M:W#K*?I/'B&OY/5AOV[%O:+.J.M*)6?R<X/#7<9`=W'AK
MF"=<.-'(&'<Q42Q][NV0NB&RLT1*4]5]QC5CA%OS,&NX)*DZ@[@/#\I<XL"\
M)J^\W<#D:&Y]`*?'CU!\YI[)?RA"S[(>>FK'L*1\*3?>L,]]>5'A:`.-6=EZ
M%*'&_W*6$6">IMN\+L__-\CA>1:GF?0`;P25-F6H5.5PD5SSK08L'^6>(`5>
MF8'V1$&[[-LOH9P4>]U(H>6$5'H(5W1`@5:'9;L@"F.(57B4J+8,??[R;KSJ
M2.606P*RJJ;<2EH4+B%OPX\A8E/Z)_P#SK/E.\\@V/&>:>,6$&NNG*YX"?2Q
M70+-BA=\9:6"D7"[*``*XX0A(T^1$CW4)B"BP%1-=NU(?634F)0IVWH2-\P`
MU(T0-@#L1`*0$@'G[0`\(+=K;\$L'G97O"B+?X!(F\=*$1SV`KS"+!'4Y@!T
M52F8U)^2^(&LZ'W6RNK\]33^^2I,^<';GO`5`H\N2^&@ZG!3(2I@Y+A01%^&
MUMGJAT2^+-S"XOX>*)]&<>BHTU>':+@;M[J+LG`5KK=9^$)OZ7*;\(78V;?E
M>KNBJXO\5V89:YN5GL^"),K]3J]I4N2T5[&"Z;=0FD#<6VSG'Y<6<6*&^]\$
M*>`X=100K1S:G]2?D?U#\H4]]F7?R@#LZ0;*P2C;B;+N+`N"](!Q8NP(?Q4\
MT_/X.0@CHS#=%0/%VKJ8PX#9]<YEU&M8LPU=-26R^'-"6"/RI6CF=1P2P`,8
M3*3`@D6$O3B4U@I(CLU-<,3)J\JM_``L3-VX%56EVX?:J?D]O:B2=BXYKX=*
M2]+*IU)$&/E)314;"5;*V)ZM8C;QA!0*?0Y1M@3`+HJ$_$(N?PH;Z(6.?_1U
MLPZ(YME`/&;3-8MB%Q/K\TW^VS\%*9LPK*T61G%&PJBD=9XNN55VK.;U+;FG
MRV#+)K*?**$/#W29D:_Q=KW*'Y`@]_!#Y>([P<V1>8`4'W=F*DUI-G_>!&'"
M5DW/<K<>J7122=FX7;U(&N/$,Z4G2/6%S`8@T(A%)_QSLG]`RB>>,%W=O5WJ
M0N#08:)02$"MX>'C)K_)3=GBB&6@&H:6QX<A?3SOA:+Q(ZXRPBHC*BH%7$1,
M@PA9142?L*O#*BB^R9"(VWF&\2K.@C4P7AG%)QZ/[IAV$AQ<;\(BC;0_/8@D
MU>U,FD,S5&V%<:;3%A&Y$C\PHU#7!!3.;<DR1NVN0?#O+6MEWTJ`KX:"F`4M
M&1DI!D2.NY)-:,D20GPS\>>;&W:$V?3V=G9WZ\LQ'PC(`490.^QX$%]!@144
M49T0PN79/6T#4/C70B='NT]@AZ+<*##J4.VTY]&WNW6UFW8\W])6%$Y^)DM3
M%`"#'!0''H0US6UMHC:J,M%%DG=8%IKG\DX9Z!.<]3=@*?I3F:\U>=I%MSL<
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MS&#4X;@-"ML$!^GH\ML[$#M)2W#+2&CF2]@,QG3?Y.U`59N-7(+5QUS$3^"<
M1\N$!BD]I\5_S5*24@4L,TE4N.2VTFNG>4IFV9K@8H7*K%4<&U[)D.\KJ1^\
M#@5JI$$C`@2OP+`@5`6.#KZ@WLDZG;$#N/!G:>YJQBZ:/+N936]G.<1GQ;]^
MR#\C9]/;OY'IU7GQC]G_]7G^^_1R=N7+#I?A\6^;&!TPP,,T.<W.@B1YS0>9
MJCM)C&1!B;$CZS`V2/R$A(0-[\?;+$@RV\#0M6X;#]J:)A^GE].KLQE97,AI
M3Z9WY./LM_G5%5N;R%O^,9O>^!P+9*@"!@$U*&'<;^F`DGY$3)LEN@+5LVB%
MA.E>6:ZK"XSK6?[YFT.T93[#P;0@@[E$]>E@\Q(BRUB(/JV-6)8'-$&!C-O3
M,7%[.BAN?QEBN"TRB@797Y2#["`C57.?+N4:!,6_C(GB7T8>/URLXZ]7>4?D
M_YQ'+S3EMS9&J]TQIOL;',_#=+F.TVU"-2^G8*D5C#KZJ44+%QC?#B^.]/0&
M%F!Z&2DB#U-Q0DHE9*>%1Z3]T<.UBV7WFKQ[H0,-X\*8A<@>43#KHUX<YXZ`
ME\Y6S'H[Y9Z@?.OCY^OKR]FG?"`VO?F#S*\N%C>?IG?SQ17)_V]^]?OLEF^%
M9`.WB_E5/ICC?YW=S7^?W\UGM^1JP28P?U]<_LX>\+'=Q>7B[[Z\=.HO84&C
M/[\H.^ZL9_S\'!:W[>P]T^Y0`0FU*PZ-$$[<`GF&&9-T!@'Q1JUB<K;X]&E^
M]\FC-0I8]W>Y;0*;#F^5P@)6C@\W[+=Z`=;ZHJVZ,ZULT2@:_=OAY`2'^@R"
MBD1?HC\;7,=\-R6-ED8#5!L=\MP`T8'-7;C?Z$0&F39B-4!C/:7X-QBTPI.*
MY,:P5#!>KTL9`"S0[44T,.>^.=/=\]IM_2>PUHNX39I^?Q5GE/S%EVU:@(XW
MH:0]`8WHYAYB#FL^H:E>"&M7>WPUH][@.,%F4N'U@MOHM5T<\9MRKX-DD=QF
M[()-ODY2'5ZMB.I`24%TUTJB41#H(QX1]09A=-3IJ:ZMYJU.2-Z.Q`DI6A8+
MBONK)/RA*!0R0JJ:X4U$6(T&,7&]`:N;"7.@7134MJ];/R&;'+<O'*V;'*WI
MVT$K*,&XP*LO"><3?;ZGB3Z]--O)DTG5#IN-3?OHB6*GWHA@I50C"9`OQ:<>
MC='%7:BBB["W%=0HVBN)(`'&**!7;A"7-)-#'G6+K,0Z.N`-=G"WA9IP]VG7
ME*SK5%`'[:UN-5<"W24<7-<>1GN@NV*M:OC_^].//_WT\[ZX^"N9;K.G.`G_
MG1?''TC`SUPXI\LB>/SR\PG)J?L+']LR#I^0G__\T\E//_'_+XJ2]/_'[XS/
MQ5FC>)NE6?X/MGT&HN[77T[^_.>?3W[Z]7^4VOBS_-.__/3+R?_X^=?BPQ.2
M_\^&LF5@NGX]=&2;%#A`;/M2NO`Z*IUS/.B#N:BU/*8W6V-S6>2+&T*W+!FQ
MNB';HG;!0N_((>QD%4<4J%`0I2ZEY,MP,'(QFRDS8XVB;HJX+4/N_`CQ9!)Z
MK1"%]PJ+1+_12RLO-+F/>X0GZ(LJ4NG)YVA%DZ])F&4T(IOM_3I<YB7!`TWX
M"66-*R-K540:KX\->-KW4_H"K_L.RH@5P+ZHA%8!70E=)5"7<$.YKD\N*X*&
M-0O2U>1;$7W_Q%-2"3I?3RPI8K34J@UY]/0:$F;.*X:6J5XHDU4.1P\W\R+"
M$G!^C>H6^Z$]-*@+1'11O2'BAF\"KQS1K6G)@FUU!<TYOI)KM0:>DDV$`3W;
MY,C1DJTF"F#;L'AS/5DH-M@/>-TX'Q\_Z,QCO#7LQH[RFVV.,_9:\(9MP]$M
M/JI:=V.[N#46S52^H$5TB1$0IX2RD^H!V3WQ;X%2V<TB)@%P(:"02$K('A"0
MAJ1-_B-&6<*/I;X)TW^>)7059NQ?4NIH)3KT44@@44CK$VJ:4EF#\$DN/VD\
M9(M.2_Z0)/G38DTI?[:B)*%+&KX$]VMOUD?UL!#0#8JE+N6DDB+:C0A`_*&P
MVE0O_!4E4AV![-,34K0H__#^R&MD*`)**!PPCEQ`12\TR<(\HIS3^^PB"!.^
M(KM_-T7^^@=8LIL9]))8!(7ZB$93@$$06;5Z)K5&A+4Z(:Q=N4>XUM(;?H+Q
M(N*I(=@$;-5I$++6'Z0Z&GS#[*)`EN49#M%B8_"RAM\HSMX*4"&)Q0E4?4HT
M[+P,Y0W&VO;JI%)O[X*@77^<))"&&6,.UJ0%R6+_U$O>"7I<QS8I2#0,V\MI
M>34<KH8(]RUK/0!6#B$.()[WPI5I[+9"ULAQ.LT6#S?TA4:*#>V"-IUXW&B#
MQ!6!7:RXVU0-H4)=8L+^9!,WY0>^0%_440*XR_NS"_!:6Q&H'7<[,"S^6G1\
M1!_9>U*0P-BV88@`'@`7MW?LS.V;V>^SJ\^^7')K`P)`G(/#P(-X=ANL::I9
M&Y*T$\:U1CM$D`OLHV;_K@THS.M2[6"7>K<`).M+">KEW2[&?:V]#/L#(`1_
MCEEDP`(@13%80(1_?$3X`$9&,X2,&B%9\3F/TBS9LK7)BV!)I\_L;E5)H-0U
M;\5+>7,44NB\P6&&PHJ>'E+A"7M"]H_8_.V2DN*I'TS1=G:',$!XM%DC$^N2
M9R1`.1F.*XW9(XO%W^LDC);A)EB3X"CQI(W#_1$U>E0&'\.H;BR(R,X.5E1[
M@A>-+8]*E(CF([>KWV<W=_./ES-V_/;,OY,1-5TLY(WQ68=B(3%CO#J]L.F0
M[@AK36LE7[!/$=;X@IQL;(^IELEVB>,C6P#'`L,@H>:+XAC@43"$/3Y4F;&&
M$*M5>!WL]6G36'@"52U]$#5ZS;(OI&KK&\4_TS".\K)T27]6Q&4C>>584RGO
M8*P`\-?9T$%MVW0DH=(VV7]"-NPCW\YW,P>19LP!QZ%Z"*+0HQN3>`1E%TD%
M;A@1R;O$4Y^`J;6O_N!(YR)O#]^&@VPW"/<HI<VC/#K3-+L),EJ<P'A-$[:O
M-WB4K96;*U`F-;4"!Z$`XK&+2*"Q:QH(E.JZ<:!J3EC[D^KTW;V(CZ$`A"U-
M+##`ISH4J!3I8H%7&!]@WE=K'A/L+.WMT)WDS]XBE`WSFBLPCY[9BG=Y(--E
MDI:"7-5IB498B0_(O.Q:@=&O+>?K=DA5;PHII>YZ$7-:$F**#(83%R,6D0DK
MF%2C$/_?K^N+&U#,M4'.Z%%T'^P_!=DV";/7\SS.@\8#(@%E_=\4<%`+B3QR
M4=^W[)B6.`WQ;OU>/2;GGE8XPH[75#0*L*CKE[J@KEX9%&`#%-<=<WV0QJ)U
M]?<QHLJP+K;%U<@1^X$F"5W=!=^F:4JS]#J)-WF=]GJ=PR*;1JO=,1W2"&ZJ
MH!/1X0J0"&CJ,5;$-[`+X258W:1J2_+&I&B=EUAE^_Q?3(*?J[&3\87/QN`2
M\-L2H%VV0Q6)V.\MR!UE'2/SF&@OMOL5#SFFZ5O&-""'#8%J+W(<VV@N.[]#
MV$:2J<HVJ#QMV'5`Q$H_G&F%Q.1\=C&[N9F=D[._36]^\V='DZB[I#P1]:J,
M"+RM'.O..A]_8J:MW+#OB\F8LG#@G_CWEKP-#L`A$8($+P);^>+9F?(("75C
M2:AK-T:%O=@37/1W;,!)T!+=<Z%\<$+.?*2"I'^EG%#B04:-II"<(P/BQVD=
M*S!E"Z1&6$W*5T:/"4+@^&H'(B\B[J[BK3Z81\OX63[+#9+238RTI=P,%,6^
MN1P;=BQ:#`=;.GQGF`X)^A&?$D+:05Y3&C"R&P-[KBIBE;G>T&N$]_ITV^[#
MHMUQX]%\VJ$G(KW("F6BTI[FIFVOKL;13]W2^N.D)C<\S4TN+:C,?1VGRGM<
M5UR!3W.3RFD+K.%P-42M;GR:FTK>]WH"`U>F=;L5LKR(T[L<DO^C^FSV;4.C
ME++;"?+_\H.II]'J(XWH0YBEM_GW2(*\.ZZ#5S:?K9M&1K2@&Q7TL>"FBNO_
MG1W5>[T<LZ@,>]@3UY#LW[L'I4KV9LY>*5_QJM2>D)UB4FGV*VYA\D1?HZ*1
M45O-VEL"5+['Q/AA5I][^C<H]5FUL:?M)G@E\?TZ?.1R[^3MA[$#IZ]?Q=,\
MND[B)4W3&YK2'#Y/N>OGN<OKV&B_&%"-K@S2JG$3^8#>.RIH]-8M0I=.J;@T
M"=EKP5R,5'*\%JE)>AJ]H`#4AR@S*&NCD$8=(-3X28IA<C[$"7QVL.S=P/^J
MUF&T"/>^UN"#$<$\(3NG@E^I]8J"TV>MJ2Y%\J9N&%_SPE&J*RQ8$)8)BE-6
M_H2=R<LNABG&SM/U.O[*"BY/"5KO:ST)N\C0THS](GHJN<6187:(LV!MD1TJ
M0W:`DB[RR2%U0NZ8J\>"+/,0#L:67Z$8/%I#GQ%&GP`>??;'E^E=QU,Z.).W
MGD8*<_@B3NTXF\?!G+89G6:>S:DZGT(MW_AY"?GA9`\QNU%Q>13SI2XXY'`V
M%)-%?E4!BPUEEQ5'CY=QFIX%2?*:P^QKD*S`:5^O09?G51K<1!R]SXXRN=*P
M12A1Z!/GZIT`81*D(>)I4`$`3!]%P"C5!@VY)D"4\`GJPV13C7U4S+-\R0>J
M.Y"O&<B7K`UYVR@W3XZ.<.Y7^MO-9^RF,Z!I3RZI2W<B23?<E_OH*+T)#5I0
M7*!'G,X.9XI3@1<]K[5@T[*YJP'`XC&1ZN@"4*AE%-"R?+1':/"V$&J><9`P
M.G:&"2-:#?;8<1'%)5/I#5W&CU'X;_9>QR)[H@D;'B;T*1\AAB^T>->#)<N\
M?ODM""/VSX\T3YHT_Z;RG.3.5C>+N;"%%4W<_0YHF=*)BZ`PY<#RI%1;3>KR
MDY9.RCL-V4:92C?;/L.UDX;Z\ETQ\CU3^T.QO,2L[#ZXYZ98KO<F6CKDFBB^
M.J>V(![CVQ1&\+<525R-LQUY.E)(J<;NWS_F3WX@<5*,W=FD=ZZ)W3X3QJOW
M6(`/RB.,!CY4@&=QE"7A_9:5INQKS9XWZ_B5)NPRKX2R3X/DM=Y(<QLSAE)Q
M36>M%#/D]OQF^)'5WB%P`+4U,:E_YL]\)@9`9<$/!_B2&&>I7!K,#IE0#HZF
MZ.N-:SZ5>][X<*;^M!S35%I(0TVSI5]WN?O(1&B]X0D7O:L@6-G#MQ'P6N@Z
M3C/F?4+9%F_VO5*#2\11M0-J"BOMSF)AC^_J+B3:.647&6UL32[GTX_SR_G=
M'^1B<4-FGZXO%W_,9N1F_MO?[F[)Y^O%%;F9W<UO9I]F5W<>WJJ.BWE0<.Q/
M*DB,M+`""Y88K!UUWITO#US$"?NCVGP%.<'(3H]^OERGQ]4,%LQ_9_/<6O-6
M$TX:K;+Y:2[&)Y78!]53/\__M<0A9/[("-*`F2&U/M"LCY_L&&KN%N"%`YJP
MD<_%YZOS6S)GZ?OV>G9V1Q87NO3^SA";V5/G'!EWS+(K!A8/]8W/-W3--F;P
M(\5OV>WQ]T%*5]6Y#[JA"HK2=F;NJ10G$*%\,Z2<W=<70&3J9V)R^[?IS8R<
M3:_G=]-+_T87.##MAB5,^'<B5"_E@G"%2ZOA(M<L2*(P>DRO:<+]^QBDX9*]
M0Q^NM[GCDM`$E&K%'JT42G`!^H83/?3&].%!IV-2-6!7LQ/>Y(3P1L5)+$4S
M/X(!%!@=MILAJDUGC727KUY`T4EY#;'9&Y/5=@6^26&3HS)EC=@K\LOX^3F.
M2)JQBVT_D/L=3%>%Y%^/&Z?:TA@;J:.6O6W?8#>M`Z4TR</-S=I`W]PD#YM+
MV74ZA,G#]UNXH0C1LM/L5G>-M)Z;HV!RD"QB=Q6\7@O/(I>-+'+<$#1.$'U!
M.&Z">'B@RVSQ,/NV?,JA0F_RP=`B.@M2=DP7^P^[2?(E6"N.WK91T4X=1BIP
M.&OA-29]S<P#F&RB<#*[N*CF4O_[[&_3J]]FY&9Z-R/%OV_)XHJ<36__Y@G3
M;0#6I;T]3#L1P$"5(!SX#7;L'5;&MG&QSE)8T9X-?BH)PD1(/@QBK?GHA_^C
M)O=6H:]/?X.!WX/$N-O*?1=\8ZZR7=_1,ER'Q2M]V05=T218WV9!MLT=>6TT
M5N9+%,W"--I3,V+`0?F.F%&HKT/0T-3/SF2GI'H-C;V:P"-64]$)"3)2ZB([
M96TAGR(9#NHE`0Z34N*HU\N"+!@>"5_=C'*1_!J$N/P"B1T+P_(^O9R%R3L+
MC4%T8#P<MU8I-HW3<BWS,@SN<[>SD*;JF\G!<NTZ0R^'$Y6@_B'5"`!S@$"B
MU3*IFGQ(BC:DULBSR\WA$.F&`T-T=:BNDQ<0V1=@NDF&(*L(".7G>@:ON6]K
M/C:N8.K7-0HNH:G/0P[`Z44.N67KPHL-2WF?Z/,]332Y0]I>DC,$[5$I*?4'
M-T>(S,"9UY7>Y03"GY'B(?E2//9EU4_;YU*FZ6`BXU='3LZKP9'E-,B+K?6`
M&`OJ):KRGW"3?^VG(*7%BE[:V1ARO,`#A_8^T/,CE-/D)5S2:E,*V^2XW_=X
M%4<O-,WST)0?>\GOR*@_9QLBK^+L#YKM3[K0I0)7]F2I!-\>;L!P]7L@IS('
M;AK$*73KM51:Z"XVU7S@&WL;US[PUZH*`Z2P4%X6T[P<@EG)6V;DE6:UH\,\
M"XW.R"</K8[Y+@W,V'85@?VMA1BW-8T3;T>,-:RF^APE>R"EM4BSK,>0<NC\
M'C/<`?:(H\9QEI/7_,R\BS@I/V+M?AZZQE0Z,53A*7'"[U2A_.4\+U%EOH^8
M2\0N#57,GI#"/C][H.;!D2<L-?N'RV*0*#188A,Z,V"V.YYH>%C5M/PK^!86
M.W5WH]9>YFI.2+)O[]7IO&\SEHU7IGL9S?POZ-EU%<5=CHN']I?A+\M?AA&=
M9_19^EJ(&RLV);F)E>&RC/EW'["H-G(.*3T8V#0IB_=JV2I7;?Q>5KQ<-?G"
ME!.NW;=%+V0"V64":Z9:!7JX-<M(WB,D#!BH_[4-LU?F=AS1*#N/GX,PDH5;
M5=MVT!2WQ0E]*C^0`IC$!"`,"24GQ<=D]SGY4CSQ)1`HN[9+9P`2.J04R0BH
M!0+.@`3Y1I=;MG%W\?"04SU1[UA2-FY31-(8AR-*3Y!((K,!8(E8=++[G)0/
M?-LEHN[@+E$@@.@P12@DH`H,0,-QY2(($W89'=V?A*4[WPXBTN*-6@2%/1"O
M<#BDL:1GDE+!Y&(ZOR&_3R\_S\BGV?3VLZ>'4X-0T"&7`7;:%%.)=HEFA+AQ
MZ:8[=P<D`R`<]ODF(+_<4<[LO!VUA@E[S*_EI:36@'SQ[H@=&!A`O(,>KZ.4
MA3%O4.@YF5[76^R)07ZJL3#T'R_PM-._F-`;=7+U(DYH^!@5KW0L7^^2($KS
M3!3&43J-5OS/-9]W2&%GL?76U\X7]OIP"-WW^R#EF1YN`/AOK7U2BI)*EM2%
M^=M8=7'O#XKK#]]NH$%B1"<$V>H5A*=#)9F;C-K+&X=LXYEX&_&FP9HL2P7O
MS)'#PF/N>)KVJ]M?V7Z%8*UXC<9&!3BYBU0X#C5RKY4D^;6(+1%]Y&_)]H@N
M0@?ZA!.!PLE%&`71,LS#1_5V-/F^./KCAQ,2L0NCV1SY^C5_7!X]M@H?'BA3
M3=,??`\U"N091!<M?N'AI*O*)()XP0+L`_:,;>-2@"=11=%*F`CYG@GEC-C+
MO57H]\BEV.`?-V-NDRC,V.U\T>HB_,;^E2K7[_0"[6RH$,!AO=8CS"I:90Q`
M:;GX9/?,LP4]0(]WJ0A%28=V4D$!R<9#%GKV4%OJ`ZQB>%5!BTU=5,^/&F?Z
M`(^"M%&#=Y5+%M%ML*:+A^LDWM`D>V4WOV5LE\CF67[LF)EP*ZA#A5%H:.8I
M#B'!-O74!*J:U"HT=B8R:\RV2E;-^5VD&=D)^$%:0Q1U"&R%PC:584JZM/80
MQ<#$8CH\-S".!6B6=SBDV6DV)98?PF]YM1SP&RK?$GZUR<@M@L=-4DGN7^[7
M0RC-1-T6[713;X'#QJY-I,314`P@4ZW]A/]!BK\\X8>@;[HDD'9@!^?[E@(P
MN^QEPS45]DX1(*RV]!MU-P^0-XO;6W)]L[B8>[+OP+3#]:$-V.6C!JGY\R8(
M$Q8K%\EYF&[B/&,M'B[CZ/$R?*&KXDYEV%:!/JI:8<].%0IS^GP+Q.D62S?T
M/+12/-E+D;RP>>'[U_*R9IV+?5@S.:]JFUY(['`>`=?MT&"CLAM##HPEV%-'
MUCZX(0G+:C6:Q`FI)!E3F.P'+DP*:?\O61R?1=H4.QZ/QDW:U='_TVWV%"=A
M]JI\-T_7O)U\I<UQ0H?&&Z3@(+<"H+],>%*[VV;WS+/7];2]W:4F#!\=\DG$
M!`2#(FIH"K'+-"@CON9-)$UK(8$$K1'Y(_4%DSXB(U#V=&4G9XNKV\7E_'QZ
M-SLGMW?Y?]BN\UMV#>3B>G8SO9OG#;Q[_TC7]Q(ZZ<`B9E-'2D8F/;I&X])E
M^6;[]%LH.YP#(*'F5%/"!:]$/CGA5LN0,;\:\E6"VCTEU>.<5WD#/SDE['\=
MKQ2@T7"K+JGEEQ)I(Y1\^S=.0#E+*2$K_$02N+6?W"?D\D]HR*`"%,A/[J;_
M7=Q1/+\Z6WR:>9JQU#TO+P*U<)'6@5U)12D(P-@([#J+HRR,'MG6M4O-`5,@
M&1G#Q#*X'%/YA<PRB2D#G@DUU(=;M08>'I8$`X.<=``,26DGDE40#P2],><R
MM'6CK+%V'@.]6I1YXFH.P[!&[(A*YB^\JPRE/0R8NP#7@VTAR+R%%U5@IS8%
MS/YI9&"C+0?S@!J_G(ZXC&<$91I4HRX/YP9U6(".O`QF"26RX-&7)_.%S?1Y
M%]ROVQ@'MP=4AF5[9U5APQ]W%6%EQJX:+*2EE2!_[!6[5'T.*@!%,($4?UP.
M5OB)D37J;(9V=PE`1#^?@;X.#O#*V8R&X<8/E8(ZO_;//3R6"`0#R.0&>*N&
M0A0TO3$DY)R<GZ`UV`][;-]$:T;M6*&FW\^`!C8_]B<`-PYJFLO"NJ.M31IO
MD,.YU1X^F7`MC!_`_B)=M\NY9;C;3B*F8-2PT'(;MBVWP,G%*Y1EP3?JRXY/
M-"S!8[0UFL:.S0D-4GI.B__.H^ER&6^C++VA2QJ^J,>T8-%NS`:(8I$,["7J
MJV9`PR#JZ15-JJ?\O!?^KQ_8WNR@;,HN("K;\G>?X^R))G[MTC:!DXB_IF`4
M,%FK0LAJGZ",OJL::A,'QV4Z*9%<M>1(KAJ3?>NW`EQ($G($74^3TW7PRKR;
M1JO\DV2;Q^,PN`_78192Q6)A#V7@!*96YC@.0+X);DUIYTB?8*%470L>JWKP
MV*7!32'-<V#`Y(-U<43:>KL*HT?^"A/)O_ZS)X>A]42M0;@Q8`$\_*B4F@0D
M;UDU7+[5>N&*5)"<?%VC5:F!U%2\<TF$&"_9Y%G"/Z</-$GHZH:^T&@+'XI*
MY+1IO"/G*+9(_',51+KF;*)%6XLL+%3M2-G05_K+0`)@NAI?>DJWY"'L'0F:
MKF8C`581,-I,7HV:<%6A-"F:-NK`*(X^%"=P9V03)VS3B;<5(1Z,+7)3?R![
MEG$6&YH$;&?$6;`)LV"M?Z_"4($V!\D5.&*\SF.GQ%<8M^&_5-WDC!]XG3+J
MQU6C<@:4UZWK?1'T5U^IKL46@/-`?.JI+U,$B0'>8-S]`$YI&1/BBH':3H24
M,CZ^I30@UBT2G0NT>Y;ZYE&>D'-K)I.H`AEM@FO(..*[P"_'RWM-BS;$KFN0
M+>B%^S:^$E<$"0!7Y4C2D[,F"^'CP`!TGV/:QGJB3Y%)YF\!?Q;IP1Z!GB6!
M&YKGIG"9!\&S('T"YP&QF#85M,4<D5'LG2LV=JS9T+&E1,;'?3/"VOG*20D\
M`+14`DO/RZ8XA)JC0-+1>=<@L_W16>2+E_RSZDS(9`_+%=W$J2_G^+I#ID7.
MZ(O-D3-'1EDO%]L:I]&J^F!6W#Q6VX7.%IOTN[[[J>MD&EMU2'3O]VVP,I.U
M%Y"88*E\4C4DY<9A-OFV^ZR4;KYVQ->6/=RQWA.R@AB#0H)NY+%3*XI(!TDK
M1VM8/9QQQR^6BV^73W2U+>Z:Z##KAB[CQ\B?2^_\H1$@A8]-)"]2?N4CO<__
M6:Z83I_9*NF_^>OYFA0/%9>D=+TX:JR!>NL@L@!,P^.(5MF$O1'.9J6WP3HO
MX<NH4=XCZU>H`"-(&AH,,2@+!#HU<N)[AF+\*4H#NW@@+@:BS81W0ECS$[(3
M('6)MP9L<(YS!VTO<EBY![*XF5:^N4/56)*?VHU1>2SVQ$'NZ1B"D[0ENB=D
MN?G>+\I)^E9*,"469&1J"LFI,R!V7$5\@15;Z#2B>?GHI+S6VYOY1`P4@8.R
M'8Z\"+AE5H"-#6!#`#<UDM-"R*;:Z98T?F&_W6>ZVL2L`-'6&6Y0X.2>/)$-
M8SCP$W*8O<-&@6DAJL6!%U'N.@A75U1?3S9:20O)LA5R%="P[:1TK"R8)/Y"
MIEXLAIY-4+9[39'<1=TKS^F\M2J9.\2!NS)PK]X8!JW"+UR=D/S3PT:#08T'
MP\/(\:[8O_2J"G;=)IU(5V^"!.^N5=08UU`/079-8.+A[CE!)PF@+.W*+HKW
M3440=MKA^,&LI=NLOZMM,?QOKT*8::<#@A>TVP5A"Z'C3YU4ZRT#AKU_6M;I
MNSW;KP?;_:=XW7_J0]:"GD2I;B[+9JZ."U1[XR++V1U'*1'V./L9G!,(@H24
M'X!3`D<!D;/,:7O<I%2\GE']/],4"U_P!&R-,#_&$Q=A%*9/=/5;'*_2/%\L
M'FYH2I,7Q2MI8$E9O%9)XK).[Z.+**ZT:D!&A9Y)]8P\LH>>T0\`#3D3P;B2
M4E*N0<%.'T#I+"MH3*)@LI4K=@#E+?EHC&V/K%J_#<3"TP@R9OU(+C?!UT]!
M'CW#8&V66[2"LM2B$,0EL=9#9`:K[!G05ZZFSMV\%=DU\YVZ>JS(F0O%F92V
M4@4*UHZ/44?[\T%F,<#*4@W#Z'/U]"U`$IY+4$'I1R8QN:E*+R++'BZO#=)[
MY8*+]M=5*11,YE>_SZ[N%C?SV:UGS#.\+`@,%2G7@%<%C0HP9\.*/E=2*57L
MBQ'?[T/#QAT\RO=&GA^1_>])F-'S^*O\+2990UD4KS7$I5;'`V0ZU?4;4&@O
M5J,-__##*O_4,Z9TNU'.#UF72SFQ$U`PP3T\W);733,V.&D&V*]'A11X_#3"
MBA^Q<A_$M:>D:B7T-3#Z&9%:GYR5)X:'G,KEZZ6OAV<ZZGL=4HR`3RB52H(*
M$2F^QJA"XN2?\^@ZB9<T-9NJU$M*ZQ2%)')FTOJ(7<FH#)JD++F>^GPE:\9.
M02H;^CYC"8",(M-!\29/?%(-JDSH`5@=UU5JNRBH9957!=9-\?QM8-.@+,-%
MYZB%VR4[16SZF%#*SFE+/]'G>YI($HJR;2N%2-JB\%#I!TZ:D)G04TPL.>$?
MD_WGY$OQQ).Z3-VU'3I!D-"FCU"F2Q@8<`8FR%.\7LV?\W#X`J6)6D)$%ID$
M'F74/B$21VH(2!^)_&3WD-2?^D@E3?>+"07"C)!68DD)N8!`&Y!B^VLVU(=O
MR!NV"25HB,,CJ0=(]!'I!["F*S:I?>;9"0F*;NP20]?E'3YT!`0T&`X>3EX:
MEYBQP<GNU7%2W6VU]NV2QGYPT9;U=H`9MVC?NS.-5K=9O/PG"^KY:'+VKVV8
MO>K#IU),'DPE8MC<47J''FAEUHSH)%92#\+\4-OB<^]XI8:#BF40("D8)Q17
M\F],"+H.YG*C_;&X#_2U`$^B8A9R65X!M:(/X3*DT?+H(6J2%I!`ZDO*N,I_
M=VB9W6TK3P[UMMAT[/J!G@8:)HSX5I-L5MW[!][12="Q*@Y)<:"@S5Y&R95A
M8.,Z=+<L6>*G%J3CZ)%D-'GVNAZW1I%)^#7&D2^!MAPJ:#9"Z`6TDQO(VR#T
M'B$N;BF-V8QH:]>[?KZYF5W=D<OY]./\<GXWG]UZ<HTKH,\!0UO@)@BY(&2@
M.QBVL+<`:RSU@18+TZ+I->^VV^#BS&(JQ09IOH1O?;S6!VA\UC@CB2DG&A3P
M#NX@?,/AK,0O?B>[KE;-(Z!P^N`P>]TDC"G[W9=`M:]\X:6F7`8RP'=7%,C]
M<CC@MZTX!1ID$P`^EP8*+,!&<^:%:%<6.+8;$GE.-O/I+?:$("].%U>_D;O9
MS2>_QSYHP+.;3K"$GB]A7SC)#,\`(''#I4!W[`1Y.\S2H&VV4"N3+!7ZG#=@
M"#)>FC'/)DHUY@LU(Z'8=;K1&\>#,T]"^]1#KF9W9'%!SJ;7\[OI)3F?7<S/
MYK.KLS_>&JA[KSOVA_6X^2N.'N]H\LRN`M,O1"H;MW.3I#$.AY6>8/)59@C`
M3;'H+K&\LE<Z<C)$=,EO:_L:9D_YW^M<2YP4%[C%&YIX=`>>IO^[)(3@I4,X
MH9"`7L/C"WU*7&[%%EX\T.=//O"URO:UBM6\^*<@VR8^31FA`$L?RWM!:]0X
M_2GX%CYOGY4O.@C;M*)RJPT*681V<1C25JVG15-B4O[IV3L)XI[JP%S5H6UL
M-]IV(:WN]P%Q'$9Z'(O:M''<;(.#8Y%=)!RW5`-PW)"8E'_ZAF-A3W5QK.C0
M#H[K;04X5O;[<#B^HN7%\)=Q*EN9%+9IX;C5!@7'0KLX.&ZKUN.X*3%AK]D7
M?Y/OV2<_D&F6)>']-F.W8;+^O@[\V:`G[L$.OE4=W<9WHVT7W\[QX&16HVO!
M$!BL;&708/\^W*[7%J`FG8]V"T]3J]$U/"\TN8_-`0"[B:<M<PP`T-W"8P2`
M[CT\&`#XQ<%6AJX%T^[_)>_^V1VY7-S>DHO%#;G[VXS\,9O>'#`6?L'$PB_C
MUCIG0?ITG<0OX8JN/KY^3NEJ'EV$41`MP^AQNLS"EV*>4[W:9:^H6S49*\*B
MDN4WP,VVYDZ`"&FJ=G(VO?T;N;A<_#UG[<WB$[F87TVOSN97OY'IV=W\=Y_6
MN7N`3T3T?D`6Q`)#A<*`<2BDP)Y(M?3`!2>J2I:)D4J.W+^2[YDH":,?R$Z:
M[,6]6U<>ERZ02GH$PHPZ!2QQ=U&L$=7=/8NC_(-M_MFB6D!2S%$@*(6E9[!2
MEU')\)OA%LG]'+(.5U`3/'`M6>#:U`/7M@I<<:6'!#M%7D<K4QA#(Y<=/8`Q
M#*@<',\.B78#%08FWKAF':!@V&FJ%0PG9*^,[+6]TQ$"KH,@I(_%AJ`VZE]L
M&"JUG@L8/NH9?K.A!T/8=0;4A,T`Z1#CG2FP>PR<\,H/H/(^PREOB>CD/3\$
MEUPSLJI!.K7_PXZ)!U+QCTPYQ'F+(4CG8XG!3NA.F]61W;("0!&LE%`J<AFU
M`-_`_;*"V@GKR*12VUE68%>HW-X=TK("!'S0V`,',C#:*!2"(XR/I!AH]D#G
M@0M.`&8)=M('N*PP$%ULT[-CPOB8A@63%'9I&*#(>OE@F(@#^`;NT[#:"<Q)
M2GD:7ES/;J8'E88AX.LQR]@O#2L4]IE+')T4XTWBXZ1AM6*;R?I#2<,#T05Q
M(AZ3,#ZF84'5T'_"W5"I]2AY^'D^PV\V]#`!>\(=:L)FZ'"($^ZFP.XQI,";
M<`<J[S/0\):(0TZXF[CDFI&-"?=R?TW^?Q4+#V2R?62Z(8[FAR#<N.5%'.UV
M;Q6O%<R^;6B4MLD-;M\N"N3M<<*,SA_,$;C"%B`P2*4GY>[XZ2697YTM/LW(
M][/_OIY=W<YN?R`?V)D\GK!=V_==(@/ATF&H3$Y`OK$0ACZ<51KJ`3">5&H/
M=R_:EL]_.#YXZ5,``L!&#=QY_HCN@F]_T$!V7(*@12LX-UJ@D$5@$X<<3<5Z
M,M3;3]@?)/^+L#_]`+NH<SKPEO=@&\ZUEET`.^UF)^^-M_4;]3<+=[S'L[S'
M7P^VQ[4A#-KG8X>I(G+R*VW3BVVV36AY6,=U\,HOMCW?TGETD:..>2N;LK)7
MU`UZQHJP2&/Y#7"99>X$B'ZF:B=%(_)<GF"SYC>O;\K&)R0'U/_PAKFVT!,1
MO!^,!5'`4*$P6!P*);"+;DL/7#"BS%MEC5Z(G9"2)=4Y3]<[?N3";'*(B?.Z
MQI,IH7')`DF:(]#E,%+P76Z5HN3@KB;;)%S7-&S(Z7Z',=)PPPO$J%/3"TC$
M_WE@L46`/_O@(@6S=6S9:^P17'Q@QFC9N.6"$V+8Y6,N?Y`)V1%I\%(R,FU\
M2LHWN7_EK.(5E6VD!,FH$VU;QD7@$/OE+GEV[!E'@Y:&"?_T3_P,:%I\["65
M)0#0D5:)&PTYF[):&@X/-\<926"L)]K$68:U(66C$Y(W.UX`FN:'7A#T*>8K
M<M37&&<8UM)C/0C;Z1FXT&SY/\H`;.\#9I59:04,OO[B)?<-4->CBA0#V+Z"
M+/7UJ1]'YL)X0ZZZ`PZH8#G<^AH?YF`+GR2(`RT\FOB1<+5'\BM:RI(F^G'L
M"A^0J6YX5+](KD;5QK']GM$0<CJSON^E1%*=TSPH4)SLEY;9L4(,#^^[]P39
M>=['`15XU#4$BQ^14QWGSY37`MHIL1NDG*%>\V;G^?##DS.#:P<-50(&)G_V
MC,%F,+,MN,1PM:RUSF17S1T`[$<:B9P9W89HK!0^!F%#$#8W]RW+1R%T_9*W
MB*/LZ;!&(LBLP!J#(/'"DQR:9_.S($E>'^+D:Y"L]/-Z,@%I;NP*(`<$F4=.
M<I[`F`G3.^+\E;IXQ^LU*\&6K`6IFOC&62D`%/S4@$;.Q+:@BG6#`\U=EA%:
MZH.S5O9@*&L\/T:0&03\/C`;-Y!G3S2YH4L:OK#+"%/VNJ=ZX*,5:`=RA0`.
MO[0>809RE3$`P>3B$_Z,!&E*,U_HI._K+IV@^.B022HH(--XF#*+V>#+!#4&
M^R"+AVZ.K63_^!@!IH_7*!!#NZ128<+HQDI`8:"VU`M=IQ6Z:H_YMHX34C8Y
M2JSI;KU$PEKW/LR!:X/Z&\+JXQ-TS45U@;`Y'KD4WBB!]6M!K(@^!AE=`:.W
MV!B06R+AVMD)U9D)'E%)U=-B(NFQ(2210$Q"H>'1A#Z"4]FQA]*^!&B<E3#S
M:@,H&JA@=4`O6(T_9NN>W``-R\W6NJA<M79#HZ8OV.,TH24+%I6RG;-L/"5.
MJX/UO!$B0DN:<F^$GC-#0,AY(*Z9L4:0)`P7#X\+3.8QV!!.HT;@:C7F(DZN
MDWA)Z2J]R']&[JK@9#1)9+;4THK8QEI0:&CI.VK5;>Z#GKFF.B?3YWC+%DP?
MMM&J.-(P__TV=)F1^('0Y\TZ?J64).'C4]YHNXG9\RQ,*+-R0B)?WGZPQ6(G
M'O0#=3M*&&KK1H^#8`=V\K(QCTX-ENQVVPD>XH1\7TD1!KT?2)$)1<?POFU*
M:%/GT*3P(M7>Q=/EO[9YX,P]SBN![/4ZAVLVC5:S_-/-LWS!RER!),%"%*!&
M#[C'N&$#9!<>+P#J]H$BQVK9FE3-3P@7."%!M"([&;]BA`&XI.'!&*"RN*!7
M)`\)'H(<F!UMJT>@`YAXYZDQ_X6>V+;3O$S<E`TYPNE;1C@X][G%N!<9;_%P
MF\7+?\[3=!ODW706IYEN)*D2D60UL0@JQ55>X68NB24X=X4*]MDIYRI_3JH&
MA+?PBZE*$$BY"8".C(LB43G[1@*<D[-<M0;[(8_EB<_1BB9?DS#+:$0VV_MU
MN,QA^$"3O$0_(<OX^3E,4WYT/TL>887+Y3'C$IPE^B-SW$Q`(]:U>6;B0[/K
MW*']Y-%'&M&',$O/PW2YCM-M0N_HM^QC[LX_95FBI[IV!K%6AT/VGM\&,PS8
MNP(($+;*)Y?SZ<?YY?SN#W*QN"&S3]>7BS]F,W(S_^UO=[?D\_7BBMS,[N8W
MLT^S*T^N8>@-T6X<P0%])\)8JA5$G\.D$?J<91\_W+&(#]4*69(+EY.637%2
MR9.]`O*%J2!<AR?W'_K#+7W^'IU=_N;]_%/V0;&T5/L6;!";7H;!?;CFL[97
M.2*4._D=63&I$FRLN(]Z]M]]J)K"RL.>0=+"YJ3ZF+^,IEL-/8`HV8,59L&S
M-_V,(JJY-<-`>RP\'[3HL71O<)K72Z1`5B*Q!TV]5=7$5W?2$U+3?4+VVM^C
M`@Y@CR0N^%N7E:ZKWY&PT&`QZX*[]]W"YX'G5DS>MC#1-SE[RI71E.WJ"I;+
M9$M79'UD)8T$=%9C/=A+'0::[,9SH\%_C#D1LQ=$S#3JTWJ5P[UZDV1HO*-,
M9V`@?MSDF$/O*GBFY_%S$$:R_"=LU$YQK48X-!9:1N)I6S>`B$V1"?N;L`_(
ME^(C7R8-Q1W6I8NJ8SM\:#060%X-@.$Q/?T62K=>")I(\%PT045SW2HNEDO-
M<"1S@3J.V0>>H;C125(,"[I2AF#65(Y?88</B%[1T"J]IDD8KS3#%+AD&^L0
M21P*P'U$8@;(((`P`#T3\5Q)>D**=IX57`9PZ;+.&&L=,NHU"#CJ$U#=;$X"
MVD5!+!LMW-(7FO#=1U[=+.0:G?KRWQ$^QRWW$[H)PLH5]9EARK;M!")NB\-$
ME1](24)B`D`RH>2D_'A_89)7A^JH>[;+)@`0.NP1R0CX,C1NW,1LJ25+`/%9
MG!)"953V95LH`G3TH;<'>$8.K_OW\JH-J8N'<WHOC[$Z@4Z@E0L@L4;G$2IQ
M%,8@W)&*3]C_DF"U"K,PCH(UV21AM`PW^;\"_NZW+W32]K^`4T#,=&DE$Q1Q
M:S2<H<_'JRWU@5D1IVOO1^]?,8D?"&MQC#`#Q&\,H'D3R<_B=>YSG#!;T@E%
M77M%'&^U1Z>7T!]'4;QMRXQ=3>G)]4/X;YJ0Z6-"RY,WMIL<V'DM4-[Z49Z-
M2E?^T4P,`B7+5+A14:PAIV;8H%!S&<B[AGH@K1O&&X^/#UQ&$=P67A[%[^B%
M)EEXOZ;`4EPBH8SA+0D'U!+ZY"R.MZV9\JLISR^\V#0X%M9*I>6^.8GBS)_1
MKAX3&M:I@*1F74-2Q[N!T><VM'=-]0*?*+SOX>9GE8Z!-L,H;X\W;R+]?@!Q
MG80O04:OU\&2/JOFN$V$07,Q76&'XV69IRY'S@*;MF/HCBK%:+IL2W:-_2,M
M`$'`8;8&@;`!=UL)=/`]*H(=3="#36-!N9MT-B6`-V\1P)9S1E@0]C!#G<7/
MSW'$SZXP2DX".5!>:L@Y)+3`/Y?9J&G.EKUU+8H<5#0K3A/RF;TBC`")*X<7
MC+$U>2A91T#F@%FF;14!HOH3AB+I:/OX86N9:OH!UYL$P[U9;-BJ9SK[1I-E
MF-(5(,$HY10)1B*'3F.E?XY(++-I1F&QELE9D#ZU.$K+IRS5Q(6`?W15`T5)
M5PC&5&05RJO).BH\'=TZ"+.+`%*69V9O$9-&*00+E6@W%.HM(5]4"#.(`<C3
M=G5>Y.NR'=DU?`,0U5UEZ`2B8UYLV/`N6/-1ON&A\N8:5)6/3@,^F6$^NZJ&
MM-8-&:[1UV)ZFC?W_MAM"X"IJ6^$4F4(4&O2!`/?H.YR_1%B&A7IW:GBVQ+K
MUX=PF<+`F#>KS1RB?NPAO]BKZW@=+E^UAPH;BG?3(%`<*S`8>8N;`*&F03$!
MIFQR[7>2,\..B.TVZ!,0':1&R'(?\>L@J\'MXL&WS&?US-5,7/F'7()\*?_K
MWZF[@V$<DLX<H]S/1/8YI0_;]67X(#WN`"X)35]U2;?,[_HX1-)J6.U!^)H>
M2:HZR?'+VI!UWLAS3@OP`J>S%&Q@'N\U&%!X#*0.EIY:)E&`"DA*16-R^680
M:Y][>F+6SXSS6Q*GBO>[`$+0/%,*N25NPS/'C*UL]:!JH4+'4=[*<W8V(0$G
MI@A*8$9R80,RBB'H`0NOJ&+Z7BL"92`7<<N_FE=#U':%N1X$9`HFUS>+Z]G-
MW1]D>G5.9O_7Y_DUNV;HA%S-?+EK"`("..>ZT`$SCKW1!.?;,(`;K$2K;/7#
M&Z`HRUL=*_#LRR]CZ&'N+9`;,=I6D,59L.X7[^#;"E0J``@\(7?,VZ,%(F`O
M`1801]Y!('9L>I]F2;`T+CS:<M#J8R_GEI1M_QPGA9JY'JS<:9$4(^1+U<+W
MR>(./."LE"`+3,Q*WH"=4E!Z0%#K]4SKE<S!UH"L5B][D!1IR5*P6"G,G^3+
M7<!>LSZ<)9X^BSN]ERYMEG.&AZJKUV<@9C$PR\^]73[1U;:YS\;3_34.<6H_
M!NF%5#\G@.]RR^J+,."2X#Q3DW3,WHZ/KC--W6`?VN[UZ,9JK*EO=W$88,:`
MP#+`P?F[TV!"8#E:/>#OQU?FG^K:#[@DE+]U2;?\[?KHF+\-@SWX6],#XZ]/
M=Y`8(`;.7BG<P.S=:S!@KP*K'K!7<8DYE,:J>]"!?!:J<$MLA==#E-=B\SWX
M+E(HF<OQG.0J/,'9KD<EF/8"50;\]P/;@ZU1R6SC0KN^AE4FM6EC`F0O0[X<
MSBR(,^C;CSC1P>_G*/0RC.@\H\_&16Q'$)KS:H)NHT''0\<1H&ZO!^OW:G1S
MG:PEX4U]YW<7+'!6RX`&9O).@0%_Y2`=CK,W[&)IQ?BR\[S%P-IS%*)U[.'P
MJ:Y63YM]ZPG_IU?CMVZ/=&`NZ[0VFG?MNJ"5]^O`V/Q$G^]IHD)GLX4(GU4+
M/(0V;2)B=*<8B-*R?853K^8)1;TCQJJP"X5H+5I*\"KIYP$1RR]O8*N#VHEW
M5=,VAH5-<<"L\`()U6(+`'B+!"?[3WV<&5=V:A?Z>@AT."`0$9`!`I@A6;$.
M,KJZ#O(BZ"X)HC18\D-8X--C%AHZ'#+0@$0M8Y\1Y\;,K$/8"-<WN9E=3N]F
MY^1ZRJ;'[FZF5[?3L[OYXNK6%YJ:PTG`7EM,=DD-UB3BNL?`QIX8,S6-BFLV
M+58V)[P]J0OX/2DV-.*U4V)#87[4"3&)G[KI,*@8+,5A3X5!O7/*>+-I,*T2
M.:\]G``#PP-*8.CDETX<3%0O)K[$KDWY5:KIXJ'VF1E-51I@C!5K<$E>E<].
M>2PQ;$UIH3XYNT](*<"V3-8^]YKH2H!!.0]`*9#^(DW@2`""^NA!(?WX6G^B
MFBXW5@`<IXH4.*WFY1Z[+>6%=NWK>(&Z5CCP:F[?'#[@*ET+06B)WE4$K]`!
M,!Z'[9JY6EE#!7N1YVEE'N"ST6B.MB/69I=G\[/2CE3R"#@WVQ90\\+;>5G-
MNZ-0,6!F0WYS%.J=VRQF]-ZH5HEB0M6[5T?!Z``G+N"+HSIQ>)+RX+71&YK2
M_$=_FD:K<_I"US'?,#+[MJ%1*CL]$"33(:52!HF1`+^PZ*@V!>&B2L.D>LQW
M2=4:D+*%+QR$($%`0#B`NNQ3R(JH-S+N@"L3OQ;(B^@CBQ2093>=S9X0Y(L0
ML]O9].;L;WSC^?GL]]GEHCA&8/;?U[.KVYDWJVSX*`2L*^#A<.2U`X5GQ7&W
M-GF@*6F2#2I)]]QL^HBZ*`ZQVI.AI9YFJEC54L4R3C-/#OPS@8H9484X,R)K
M>9"V&66'!BG^`C?,)`I&BP5M=4'C_\'FKC'<+^7T0+&_Z4>])Q<N:9)^</?P
MPGT<@-<F>WX!>K2<)E^*EH=`8.WV86.T&=%7NMW8`JJ#DC=+PF4^8N%WWNGH
M*F_;):BH+18EY7Z@D5!H`D0[@>1D_W%Y:Z-WQ%)TK8A*6B0(R-.5$=(%`)PA
M"9(%8417LR")PN@QG2Z7V^<MGPT\IP_A,I3/?4,%.]31"R+Q".HAZL`*8!1"
M,ZV:2>VS?%3%/_2%;6!H"*AG"*LN#W4*1*3T!I+XPRB010Q$%H.HHA6IFI$Z
M2L_?#DH!8R47.!UYI-1T3U-MJ1IK<@9RO:7RQ&%N,"J[A*(3`;N\*[V4_:RE
M%K#X$@GI"30`CEP'])H56QB)`_<QPL@X*IL!:>3H^T*C+;VAR_@Q"MGR/>RZ
M6+!<)R9KY9!H!?0/-5+K;4+8IM,R*9N06AM?^`9%A8!Z9H#J<E`C+Z*C)UC$
MC_80@PA0+')`!XR'L.CA#JB`=($/51^2B'Q3?_.Q."7@;<AO6D.E%'0S?=FX
M(H<WR]6MCI"!6[^UO6@F!2IV9YI%R!>:W,<&&3LUBX=I+>P=7,]"HY.B;]&N
MCMHI-+LFRJ@:2X%70M6:3VYFO\^N/L]NR?<II>0JSBCY^>?OES_\<'"=K;O&
M"=#98U[/=!._!NOL5;-O5]BHG61:C7#P*[2,E'#:N@$0;HI,RK\]VULK[JTN
MA%6]VH%QH[$`S.Y[W\D%*`(3IC#@N:H$`BU_GS!:KK<KNLK_P7?3L;=WDX+O
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MABD[(G5>I6>G!:;>('*)J3+H17;0_R*(`U&GSKI/$0KSFD+SB9;%YDL1_5E]
M2??:JKKS..(_@&3H&0!,;.P,(#>,GP,..)CX5FQJ/!TSEF`7G#5+)V1GZY@*
M3K\"CO.BTX^0<YB%YZYPGJ;I]KGZCAO*IGGN:/*,7GB"#6(5G@"#X^8*\"_B
M0^$)<=9ALM";GU1_DG7XP(I/\DJ#Y-`K23AK\`*[*5/1PKK6,&)8/_SHX$TE
M"?-TS."`5$GNYR=)S=()V44>9NP]X+B$^E&''`\K2?YI.MUF3W$2_INN/D<K
MFO"7IHNZF%TB6=7&]#H)EY3??%:KELOZ^>\T?'S*O^CTA2;!([VA[+#1,'H\
MBR-^N.$V6+/?X-2H[!S-.U"-.H)W#E/6:+^UR^PVQI>R383#^RK-F2=%EDS)
MWANR9>Z4YTX4AO@%OOMY%TJX4X1[U9B-V4_15*Z1TC>R<X[4O/,^SXX7EX!)
M>>S`"<O?@WL)3?;OD;W7MW&RM].G[W8P(9X-C'8Q-RAC;K*+N<M:S&6S*B?U
MM;KW`'Q(`=AR"/4>@NL_H&>#,\"8,Q]?A@EO7.R7P9[5E^G'FL3OZA]W5D[V
M?7V8HA?XYG#2K6-MLO^$;/A'/F>(/MC&F_G2T`=MFJMM!W%6RW>&>C--+G1L
M0((B38+76'[]SO*>D#Q@GGM8#UG6A(O]>R\>3E;W]\[E9'4?[_R;TNC_6WLX
M6=WK2PT\D]'#5Z>3U36_WB>KT>*2V[D2M,#I=*;$WDO',R7OD?U0)JM[?K>#
M"?&&D]7O,?>08NZP\]-'&'7''8\%:[IXX%^/?Y=\B,A_`-D`2=.\/6*1-L=)
M-!IOD&IZN15`!)8)3]@3]F8=?W925JW7K+AESSV)@;KN[@8E&$`Z,4(B)B#M
M.)!R4TRHC-ECBZ5;'K6^)F&6T8ALMO?K<)F#[8$F>0`ZR3/N\W,^<N*'@I`-
M1]XF1UYZC,C3YZ?>V!L]@J?E(76_Q?$JO:*9\NH`O8`@BLL$T$BG]@CWH""5
M.1CM).*[PS`)0S-)RQ"_2>+5=IGY=B@\``A"EH'`(V*96%#,LY$`YRS.*\SU
M@5S]!-82='2]9J.J-P$Z4'#O#SNT@UX5)K!GHM66>F'NM*A>4U(^/B&\P0G)
MFQPWW+0SC#AP&_.HV=LEC8(DC#]'Z88NPX>0KLYC-G25E1.Z]NUJ0MX>AV(Z
M?Y#XI3`#()=4>E(].B&UA^1+\=@75FG[O$LJ($PZC)+)"0@%1M:0;'JBJRT?
M-K"1PL?.;--^8BF=+K/P)<Q>[]@F1]V],WB*._SLKQB)R%C?$(OQ"/Y`0D-O
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M9K/2)BW.#+4A!UFK[^*DW#+UQ"1NFNENA,=*E.2RI!#V+;[9X5$1R/H`7!ZO
MC+2J`M,!,<9=_6'NAC/"M"L*`67X`?HU!0=0-8S+*H,Z8!Q>>9+9;^@Z'\GF
M%4J2O=XE090&2YMI&#,UTEP.58,<DLR\=Y*]P2Z81"&@TD;P*64(%R)U*=\"
MC"'F%)'%"KWR@`)3IXHD7O/`74XVL(]/@W86EA/A`)+OT-PP2+=#L<.3!"M^
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M@FR?R<?7QA/0Y(&%+N-=DD)=`VT14WR/H7:)B5W`V"@FT@S<*W;"KMEI/O9T
MX&V#4(M]8WK`FV\=$^BTV3\&X<\8<>@ZB?.,FKVRLZ2S:;2:_6L;;IZK*5EM
MZ(&)2Z.-3APYP,"\Q8XI6JLF842CK!$YJK8G_&*2C.]WVK7W-50`$:6(#D:8
ME`<$M1I5##!$]1BTGRZ7\3;*TJLXH^EEG,>IW,^+,`JB91@]YA44#5_XF@PH
M"EAIDP8%0VW(,<+JNV"'#%,G3"*(F>[F@16EZ`GAPB>$B_.XLE-`]AI\#3%V
M<%5$G#[XEP<@(ZVJ>-2/4!Z=4`BY#^/C:_=&#%@4<VG4]&3#GD:'.4H-Y9<9
MZ$3$OKXBG+S6SP7H28K<"NR>NGST*+JJSM>P[92?YB>\8<8%S5Y49.,6Y\+A
MQB-_4DKMTMJTO+6V<ZI*G^QAK-\P41CH'R0G&'_?8<*_B5O](SW<&BBHUR_6
M3I4W:Q]6Y#;GAG&0MJ6?:3P&VS$/O?8,]R?*VJ>/OD>/HQD>K(`?^CQDM%]H
MR-.2,9P>LZ*7O4_Q$"?/1<P/[N-M5D3ZW>MBM8L=#R/"(])OP/H<ZQCUW@X,
M6:<?7-@9XO10!Q[[$'54IXRZFDWP>1_@,0:O_L?+'V3X\F1WS_[K\>NTIM'J
M*HYH<R-36ML>D!?VV\UF'=+$IN+M;0-0W/:PX2RA]/[>CDO6/O[9Y0E[BXV$
M(#B?H-H5?IW$+V'.2N^V7V+2`12OL5@'"<S6MF`Q^*C(/41AV,^Y@;FM*O>X
M4KZ`7U-;D3VM[S;D$X^EZH.JZ7P/!U:5FJ\!8=SZBRZW29B]GM--G(:9K((2
MMVK70.U6.(%.;!NS#NE8`$2;ELSD+$B?R*KX*P\204KN@^B?Y'$;\(*`>D)V
M24=VZ:KL\0[=FJT%A!D"&NA93*#>&!D\DY0?D?*SP\:"/O@:HF'D`,@O7/^-
M1C0)UGG\GJZ>PRA,,_;*U`LMWZE*F[=.=\*CA8Y.\#32@<0?"[^QN&5F&L([
M$XV33T'R3YKE`B>D%.$E7=`0(K24\NU>="O`"8AMC]LNZ0UTB4)"'_C[%BYZ
MQ8E>`6+0R#!&2$",!2PQ\W;-$-!L6[U5>TC$[\MX%*K;<GQ0!`-+QE\+#$?T
MD;V.!AE1@(UC@9G7F;/+R_G5;SF<9U>SF^DEF5Z=D^GYI_G5_/;N9GHW_WU&
M9O]]/;NZG=V^)3P#*E:7B!ZWOM7MD))MD&)O8&6O\RC_,EN^DVJ1/='D[BF(
MRJGNJSAZH6G.AYMXO;Z($R8D2WRC.-%.H`,[@1/&1OGE,"=7AOX"@(`ZK$N3
MJRVO>>,'$F]\.H9C'%)V8_B8P:&3"09U1I!1WH.4SFGT:;[AO?<M1O'B$;"5
M7KF3_H04MDG-..'629:;W]^[O/,@_^<N-);;IKXPKTCIEB^S+6\R4.J+YC<5
M*@^SB"^_4&T7]-]I^/B4?[7I2SYD>:3-?6'YUWUP4\CW=@2KF._AR+BYLO<O
M.'*V[.._PWQI[Q9&QMSEQ)K]$U)Y0$H7VIN$OTSOV13#,COT!-D_*N`E2:P(
MA98FK1U"3)5O+UJZ.9MTG*_A8]AD0XU=?`O*^$:K^+9AK=^#FA?=]![6Q#_+
MX8T"M`,>OFD]G4?%X:^#3^*+S0\V?=\V[_F<F/C7\B%;F;L^YD18RYE)^>;&
M@6<?6[(-.-NDI/MPLTQ--X:<7SKH@',XT^\"O_V)-\-.N1>VV<T`A?7W(#<6
M:=YLF/.[=):>$R3\+JK1@FWUC.^!:0&-Z<$P*0W_-QNRC$;U'B&S(?IS8,6T
M`^Z9IQIG`<`XU^!Y8I%NWG(4&KRV1G;=JR`$K;#5YT.>R(MH[4+=>_0;ET1O
M//[Y77'WWYU3;!X;;\MYT_[PN\TK^YY/'TE^+TB&VW",WV9!DGFQTWSW#;S8
MP%EZ,ZDM8Y$@(_?T,8PB]D?\0%YID!Q(&D(GY!@;*(4Q882=D^7&VC$V31YF
M6#(KO8O`-(L@[P(.^@T\"DRL_FZ%)AJMWH/2^`A_PV%)4!/['IA.#V6]3>2X
M3_'H=-277-X#WGC,><L![]2[20"C$;O1\-II;!]LB:A'V"PC'"DBU[+VQ.?P
M8QHKK&@-Y:!3#`TSP=]K)*":-C\F$%F6PU`8'>GDZ^\\M8RV4UAL?K"IU[9Y
MST<2XE_+]V%$Q^LQQQ`M9P8<0!26W\Z6/0FU!QP^*(/+<&.'IAM##AT..KSY
M]>*>C?/^Q#E6`Q:?O$>=L5#\9N/.85;._'_8%PFCQ^)[_(Q='2M,8%7`0A/C
MI@'%MQZYDA5[YC"*BPQB5*3\/Z14?!SEIHHK>,%=STBT\"TPA1BB#X/W?I5X
M,@>'#0!5J<:8NWEG+@JZ#IZ[AUE""3>X_I;$:8I=2>DM(1\W)K3DQ0DYBM\`
M$F1?:'(?#W$$CMA/]R?<B.QV3_0E<4+R[LJ2<,DF[5)^U^_C0;T#U8,KZ.?5
MZ(F)%IOE%O'/FSFH*.!7L:7Q<Y0XP$JOPWK/T7...S]T:BR6C[_K4.&;+_L+
M-2Z.0W&</8.*5PBYF??P@8OD8PL?_NWA`WR?RS"B\XP^HX_>.HJQ!FLUQ>-&
MZ\XW'#DTU_UQ&(?W9OH'7?*%:2-<W:$?D]P%/%XXE9$)+7;N#""&2CE1#R`N
M:I=#+^+D@89C;K.3>C#83CN!!Y[O1I'^9GY,HUGY/^:.E*X_D]U'!Q[/>_!O
MP(TINB`PW,Z4CB=#;DXY@DCDUU2>I?]>Q2(V]7?3GN\/F*Z4/%2-3TC*S+T'
MJW$Q_\;#U?ASCQ8^^S(G:>FZ7[%JT/>>=^;?SIL+G@;`\=Y^]BP`>CU[JCON
MK3K1;=2SAZV<P#Y^V-`)/\[^M/KE?#J$V/0+#'`$J)E+D^K/0\E#;LB(?R)G
MGZ!@G(M0G7%P*N?Q!R?OSB8V]]ZWV(1^0O'.^ML[I/@@HZ+[HXH/*BX>]+;U
M\IL$]VOJHD3'M8Z\O1ULW8M-<(:_E0]SYL:>N]\M!_5E4FMX7&>`6E(/?2N<
M'?>Q-\<!O<#?,'>4P<>;6_8LW/8F]B#=L=<NKYG98RFKCR2V.7]SP/?H=IBE
M\T40)K\'ZRV=INGVN?K"&\H6U<_#EW"5%PLW089>-)O:Q2J7X7;'S56FOX\/
M);*!SPX3%-B+2?47>0WI^E#FIM$(A9<H++F,EB"@]A%3P[&%$6^*72.'/8@B
M2`4N,T>X/5(SR.K=PB39Q2IF]#U4#<>'-Q2L#K."[5;I;FZET]EQ-Z'KQW5.
MNN_O0P6J\''0*9'J7K@W-/'J[,X1(.\<3C>@WR!R:!3WICI4.C@"PYU.;Q[%
MI44>!(HA9R8'"Q6'6:L5OB\>^--T^A*$:_:5+N*$G[F`7;(!S6%5;EISXT9W
MX*_A0QVG=]5AL-<9G^3ZGO/X7KYR5CUG;YV1,!]A!='!KSU!B8,7O,VHBA;!
M-681`_EA!P=O*D"(G^/%!J1Z<'^X96&'3!M!AIMZCS"N$'ZT,>8P:T;9-M:[
M.`O6\RA+PB@-EWQ^T^V4'\BTFUE`C6F?9@U`OY(/-::9VX--+J@=F>S^)B]\
MM:AV`#(]L+>L,%GG:A;!A/..IA64+CB;:3B6B.--X6KJLQ\!Q]$$9_/U*&Z7
M[",;M_P>Q(8FR)L+8X=9#ZM6\W^/U[F:=9B]#KUG4VQYB%V;;<O^;K@2_T8^
MU,)&7H^TZZKEQV2W->IE]^#`<X8%OX;9&:4D]R`[HYH>#+0WZE`CBS<UKZ'+
M7@26H39T[JT>^Y9.CT+7.-LZ/0A>AUGJMN:SM]E3G(3_INBG<>OL.-H@4+/C
MU>)?Y_O[M>97=V^XI;Z]53<K?#O]!YX)M%QRMJ(GHZVKA;R=/7<K>-Y'"+_.
MM59Z.4*HV-62*6/ZLK%M:+-)XI<<.VQ!__'X%O3'X/U@2_A#,O\P*S=197H3
MIO^\2"B=1WD<H&DVU!2ERJ[+"4JQ7?\F$52_CP]1W<#G@6<0A%Y,V*?D(?^8
MA.7G)#G.$;Z266[']P!2.QW;B^P['MD?<CSQ>DI2ZK`'X<3Q="2/5<PFJ8P>
MZVRD9[%JV)E(3Z+58=:RS5L-MJPZCU:S;YLPX1J<7@LPA$_(6U9[^N3%SC*4
MW]6'VAGI^[C?C-;/P_V]A"2(5H2+'_Q,*BK'T?>6888>["UGO7S#WXOVYB.B
M-]4_VI?Q/"!B;]NM.;,/L(4[QW?/P1N,Q\XW`1]31#[N4<Q8(Y6Q1B.'DE\/
M<53A1Z)\VZ.#$3/.V#EEA+QQ*-'DX"IR7ZKN42KK]U`U'!_>4+`ZZ$)VL<W2
M+&=,&#V.,/%N:!VYJ`5;]R(9&?Y6D(2TX?B]S8(D<U_FPOUWGY^@ODQJ#=G)
ML_?T,8PB]L=1G3]K2D/TQ&(7!["3"]`+_!1SE('(K#8N0M$L6GD3B`8JE>'>
MM(/1T1V#?2AAR'F5ZWL@$E2\?H>B4[^&Z29N^Q.!3G&'[#6S;V3)ZV#BV^E;
MCV^GWHWHBR\PC5;S'*91%K[0ZSPLI-?Q.ER^&HW.09I`(VV-)H<9`O0=G"_Q
MZ+RP#=UJO8T@O*R)^1PD8:`#!CP3!,-"EU(C-`QY2H=AUBCT+CAA@VH=H:HU
M^(+`3IAP:5)V[9?ROW?T6T8^YE']G__/.XV:J/&,2,<RV^[T=C6I'7<SZ%Y=
MO23]_C[/B@]XQUK7ZMN;Z79]@9*.@PX'5:ZN3SH8NA_"W/.@5ZZ)[+ZE^>3!
MR3[D'/%@=/=QWK?TS-\9WIJ#8_#<Y:SM,5VM.&JP&'#"=;A@X=\D*O^T=BC0
MYVA%DUMVD%3Q)?@PLS$3?,.^_648T7E&GU.CT1J6,="0K;\QAW$=ZY=P&=H1
M?+2-[KU-*V;`"MVU8Q')EFDG7'TU/\8-G+26W`@W0KXP,X3;\7IF#(UMP&B/
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MT$+*D`OP(P05O[=!IK+OQ/_G+O=O&JU8<7L5/-L,ZW%,F99^5J:&B?T]?H6!
MXKZ=AP@QW\;PA#\C[.%!C,61^&`>FONSSS@L6YBT",H87!\[(%O.+E17*-42
M3YF*AIAZU5MW.1VKLN[?%*W^MW(^IG?A^<#SN0I?:J/^\B/^,A&[B"$79^\K
M%]?0Q0>YD]8=0]W.ZH)#A-.97KD7CF=_CR5&#3/UX,9M;T*4^@7(O@M1]1MV
MZ],6"_^G0(\ON%G.:!Q/>/-PSJ/G=RR?!/=K.D*)+;<^1(DMLNYO^I+_5KZ7
MV$+/1\I?`E^Z"VN$[EN]G6I:0<9A$HXV&@R2;KI>#)1N#CT<'40U+7';FV@T
M7#5=L_T&JFD/@]LXU;1'X>UXJNG/FPU-RC=0GL-LB!):8M)EW=PQZ5]VDOPJ
MOE;(77<'3D1M!_9O>&Q\/_42F3=NLX":K4X#?\NTXVA_>#'"K&Q]H<E]/':<
M&*-D[;HP^11\"Y^WS]5H^3UF#(33HX\:CD]Y07)RD`-?$'T=.6`HCH'!&-AR
M<^7+2]S@>QQRC?OCCT/'<X!,_'7H`:K$I-/#9-HF_4LBDE_%UP%JU]VASYAI
M.3#Y%$9OH^B4\<?Q\3!*UCH-]2W3KH^*.;A8X?7ZBLC7<4.%ZY44;N[("TXO
M8M"P`]]1H]#X*R+UE[U45:*HG:BT:[;#B[$B^RY.6F[9`8:TAM3D8Y#++/.0
MD?)G'L4)82^*R:WH<"$?Z^TE)!H"&S;G<)L<O-^Q98$0EJF.#B.PJ&V($MR)
MP89F%[-Y'0,VX*CFS9KO;1\!0$#S2*8`&77&)@LR_NK>[9)&01Y)5&<WJMJV
M$ZFX+0X15'X@44%B`D`&H>2D^LNODP>5'=JE`Z#_.X00R0A(`8++"+2X8WM_
M='QH-)(1H6R$RX"&963H5[H-,%^(3'9_DR_\$]_@WNPO.<Y%_2H%.&^L0+:X
M_T>`]*7N8'9I0QFT+[$/1)=Z@`SQ2[.#R+MB=:A?>G?FM[PCY9B7=;H4]Y>*
M<[+U`!D!_XL'/L?Q%*]7-$EG_]J&V>OT/LV28"E=9#*1E;%$+8M+'(B?R%S2
MF#2@EU+3Y&QQ=;NXG)]/[V;GY/8N_\^GV=7=+5E<D+._3:]^F]V2^14YFU[/
M[Z:7Y'QV,3^;SZ[._L@KKU*';_0$@4K.6`-,2DFLTJ'@M1&D1Z'Z69`^7:SC
MKRF<X5(1.;$%(MA\EGJ%3F.1)2/V=A4H23N]_1NYN%S\_=9GALI!H2*F#DH*
M/G9$E334`W`$]A7Q@*TXQ!$['`@RM:"2D?%/+(-+0)5?R`R4F#*@H%##I/B4
M[#_V<RY"B0`YV0#`D;)-)*N@&PAOHV2[BS`*HF48K*_C-&1+>/"LIQ659S^%
M*'86U'J)G@U5%HVRHEQ1,SM^G%Y.K\YFY/9OL]F=USE1#QE5;H0"3I$CI2J4
MN1(.UR$YG)?1\S3=TM7Y-@FCQVN^JO=[L-[2VHK\;C5>>NJ[K9X.NXWU(%'=
MTG_,S8@6/D`B@:G6_7MMM5,>'I,@8B>HY0"GSYMU_$II<;I:%$<?]I]\'T;+
M]7:5_RNBV6[?X0^^A!!;D`KB23^\=X.+H3Y1I#D0ZJ#OS;-RP`%S^"XZOB>N
MD"*%&"GD3@B7/&ELFTMW&^96[QS1;X,8@27C;C,3>ULLY2/D9X`B6()6*G(9
M9@#?P'V*5CMA'6E4:ATD:<_V4]DC%AJ)X.@'!B*%0G`D\I%)KE[[MG/$!9]8
MZCZ,3#P0`6QSL6,*X&UJ-#>-O>O1S@,GZ%>\;VQS9TZE."5A5%:_[YRJ(\@O
M3HV[#U3A[A7]RA_)5V],A$TJV9JP^W#3\72HBK5NN&=<V:N:Y-'C.8\;*1_F
MAL5(^"%.R#)(G\CWK.3,2U;V.=O$3Y9QFJ4_L)JT+#_]GBR28<LL/,BP:100
M=DH,@\`XV!YHUD=D%0O:NOF=ZM6#7*!H<0A#*30H]ZL8>X/9QWD:/JMDF<3$
ML@;+)0/17.SG0,LB*`FLI<DJ?WE-=`F4C"9L>V:LI@ZS:=E1@#SD(@52MNKH
M@BQ&'$BN0H5PKW6&OB`>/T^9;4`'[O"%"."QM_?^<I/<TV=GN51\TMTH_E>/
M&&B\)QP($R'3P+N_1X.6DVP@M]0'6;NX7SXEY?9+__9S8<(,%M)[`\VSX`T.
MVN!@[8Q))OPQ.7=$9,B&/KM3)7QEAPDKC+D`X8`S:+@\=D1LS`8@M8-'C@$B
M%@$3`A+<];FF:A?K;UT+5M@X;>;<_ZB2[C3+DO!^FU6O:%\'"8U\.?RL'WY`
M:UGF^.FN1:'AYQ>C`4*<!6NK`/.++8A^^6YRQZR29;`)V7]7]"%<AC1:OAX%
M8GYQ@YA?O"K)KN*,GH?I<AVGVX3>T6_9Q]S^/\&5FD9>6\!)Y1VQ2N.OT[&X
MW+8-_V3:)K=_F][,JA>[?66B#C<`@L*@IV>M1`^$S)Z@U_UP7V48$;SMR8!=
M8<+:D[T`^<)$")?Q=G[`'<0MBF%\D(\[M["]3\-5&"0A33]1=@F=+&-)&[93
MDZ`A#HNE'F`F&Y$1`#&[8I/KA!5UX3=RF:U^)%^*CWTAF;PWNVS2]7R'-!T!
M`3N&0PEZ4!=;L`$)#].U3X\*)?K@:H63D</E9K/F6V*#=74$QCQZB)/G`/+V
MNYET)[`"I9%X9.0K%K6@1B%L@^F:U!L2UI*PIJ36UK\U%$,@"=AJ@\0N@4%:
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M+3$!8+!0<L(^9C2MOZ;*CCRXBJ,/0>VSN_R?:5YZ\8,2O$K#RL[O$A*`E0[M
M1#("<H&@-1R%/J>Y.[,T"_/B6?KZC+A1BS3M1BAL$5M&'#1V#.A)TA*9?"X.
M"*'5)^R%[.R)701*-T%2S&KDSQ^JH^E(6IU7Y\G[`)+N[=!""8,V'YJ-NT08
M`"[8L]$"[:9H8=,%)5YVGYV0ZW@=+O/RIORO=^N$=@#1S@"80634\?S?:?CX
ME-'5](4FP2.]VK+I\<4#?S^R=MW3QR`-E]-H=1ZNMYGTH*A^REIAUU89"M_Z
M?1/$,&[MB)[`EJHGE1P)"D$2<4E&_>(E?/:O9?T]R"T[;")/'OF'FVW&7B1;
MQVE*-KD0EV@+G)![9I278JO"K"?OM_1$>">PH#"F'7[LE';#U`$R$#LS]O#"
M%0%9IMU1L!0E5SL*EO<MU^1/R,<=FTH=[V020<9+.EE6!YOU-Y[R?SXM$W[^
MP3^N@FR;VWI8Y)&WF/0H"C/93E,CF?+7`\KTBA%&?O4+!%!3<K;#-$R*)F3Q
M0/:-_"N<S1`16W58BX8@V3W;O,$?ZE(PW&)/(++L\AN-\J?KXT6:-.2[P%KO
MMYI@5HQ><%K%RRU?9V:J>@!._<X35(<X]A7MCAB$LI>@G(#0[I@^816QR)YH
M\EL01NEE/HKKS*VJFM1JA&Z3WB216>U?`0@TJV'?$9CP3PC_B!2?C0]M:3?%
MD)]5`-MVTR9*!^ARLZ0+"X-"&V;=S[+JW1/E9Z,&T>M_I.6\!Y\36>=R<3F=
M'CPFE,^@_WBHZ%#F5C-\H&3.CE*C1`DHRX0&#.%QRJY3^G0]O?KC/VY)\<H8
MNPYT<7DY_;BXF=[-%U=D^MO-C._%.UADJ!*>(3(0T]EO[-S[-!]PW]#P^7Z;
M]S=?P;JA2QJ^T-4B*?XEN%+=4KJ6!(VD>U/!PM?^J=/,J)HW)KHF16.2MR;-
MYJ1J3Q8)V4N,3RL;+,4].UA`10,M399ZBV8758&I>31D\Q%Z@6TVHYLTL9U4
MV(Z3\M^\GQC(R&/\0I.H?$DACZ7Y=]H68RVFJ%F(;((DB]@)4`]<44IS##\5
M"S+TA:[C#=\70[^QH][YSH#E-DGHRH.R94@6*8N=(7B$4B*9V,.NGDQMX]$H
MK[DN:9J2#\7--R(VO3$PJ^JS0<",6-7=E"'K?!^M<A]FT6,84<J.UYP5H>N*
MME^TLY2N575&TKW9:^%K_ZK.S*B:M":Z)E5C4FO-:[Q:>U(*D%QB?`K;8"GN
MV<$"`AMH:1+86S2[J.I,S:,AFU5U-[HRZX3=N>9!B34DI)4EUA"@1BFQ3.S!
M2JQ?"UA']#'(Z.I.?>*8C0MXT,XKK9O9[6QZ<_8W,KTZ)^>SWV>7BVLVET5F
M_WT]N[J=W9Z0JYD',UN#(EM5;PV";,1ZZW;Y1%=;]GK-YY0^;->7X0.]8T6=
M:F\)7*A674&$>O,5[EG_6@ID2\U&@(I)U88MLQ:M"&M&OO"&?FTQ,0!&;-=M
M`LKIA9M,\P2(+LH@H-6^H.1G#$A@V4;E,8-26>/@PQ*EH@&8P9XK`IKLC<K3
M&BKC!BJ/&H2J<L0!"!&+C\MBWCI.7MDA>;SF$9Y#!VI;*S44;7OS1^M'_\)"
M94)-$KGD9/^([)YY<N08K'MCHUX0<$$JTZ3`*.!Q40RHC5D"B:7^-P(E97;O
M"R;,UP,^A6N:9G%$RZN9!=%3UJ06-+M->L-=9K5_B!1H5@.Z(S#9?5+=:#T^
M<J6]%$-^50%*VTV;X!R@QUW$-:$-L]YG46S?_YOB0P\F:.T`H`Q49A!`&6)T
ME&(/*(0&#!%P*D#`;A?&P2)!-18P1`+J)".-@B2,[[[&TOI>VJ8QA=AI@S`>
MEMC%F"#LJM8-<ML2D^HCDG_F49$E[ZX8].L*QZJMMNVAZ0"=[V923F3$$`C%
ME)L`"AYD+5LL:*;/S-"`-#G6UHH_%R:R8`J&/'E]WL01N0C7;-]$_$"NZ2H,
MLB1<DGGTPD[^>2SV`U[G>OF!=9^F1Q`]-'-=AHA!S'"L-R[.I]/-)HE?@K4T
MRRG;U3*=I%UO@"OM]\]X,O5J?(NE2H3O/_<(O^INC,&_N`#%PO9-)`\*#A<9
M46[(`BC\!*L2*B2HL%(\.WRD*'.D+58P)Y_.]MO/7VCM&,'K)'X(,WY(QC7-
M49=CXE'T(HZ5?"U2&LKW)HF5O_TCJZE9-9',M$T:S1N';A8"Q>$U9"\R/N_L
M8!7W[FD!2XWT--GK-;A=9`9S!Q"!SC))$^KULV0W!=39"\"LYM[LQ#P8@0V-
M=F56&@KO*",^,XO8HT%SZYAPST>1UP_AO_.285J]OGY"'K;\3(^$OM!H2XNW
M:\I]S`+LOT'HJX:@@T$?<>@Z6X>/;(='.>^[?ZV'E8[3Y5.8(T&RJF@J6BO;
MX**]*6[J9?]BS<"BFL]@19.J9;6867M!FO#14:WU^*0U!D[<IT,%1(6J:'+4
M0]"Z*,*,;.,`F)5>[Q!6=>_@($8IK\#&L"LK(\-(&#ZM8;BYHLP_VC(,!V\0
MPZJ*R3&&$>NDZDK?CV%\]T238$.W6;A,Y]$R3C;E\0O2>7]SX5JM9"+<F['F
MGO:OEXQLJLEJH&I_2?-'MJ9::TT:S3U:=["`4=RO<P64A2MIDM93&+NHH`RM
M8T&:55&FH/9@]FHX5"O+*?>X1BFI#,QA%U6&IM%@?:J!]8]O,D0KZZH!P(Q9
M6_%I2&`II6M;KYSD;?OS4.<'0EVD,*$AEU2RFO+UML31=F]LU`LB;LAD6E08
M`SQ.JA&E,4L@\5I#!24?"@LD+*G+AIYHPBD*I-K1:P"E)5LPG;Z9N*3.VGVQ
MA+EIG]UJ_WH6/S^'&5^(HLD?-!!NW5>WK&_@E[7LOW-7[0/"9GZI`<WF78G<
MI'A`]D_8_AG"GHT/=EV/Q@8_O6BGKEBBM5]W:*PXV?NO,&6%F^I$^H=U'"=D
MDW_/IR"E)'B.MVR2]"G("'NA*7_V'">4++=I%C^S\V#C!WX'+"TN+G_./R=I
M[GOZ\,KO\UL&:QJM\CYX+3N"W?F7PY/??LX$\]3PS+6LPG2YCMG-@+7=,:D'
MV1X#M.I7$GK`%N?U!(EN])<4%';L4'NZBW?+?;QCN'L]FGBG?C>A#W0P!]IE
MP)CR>'$7?Z2W/`B$["BZ\FS76<2_P.J&77LGNB7&7DE]:&ZAI'^9;.TYPF#>
MQK:FGC97.:ED2"%$[F+RD9*='/N[E"25*"EDQZ=I#^#%.#`0U>S&REK%_&$0
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MRNZ+H3^U@!BBYDVP#P@)%T69U(XY/%CQ5`(D?L@#]OZ)!W.#_1"BK%CL,()2
M60@58U<+4B,6$#FM0^288H@RO5HB!/7B2GY@P@U=QH]1^.\\W[[0Y)RFX6/$
M+OJZIDD8KP1YT4BN<5DE2`[A!C0#__JG4J@YW2UG$"V3LAG9MR.L(=FW)$73
M\;EC!I/8N@>%5YH!Y-N7F7D$3C?W34(-(P"UN&.R@&JRARJ[%9RL]E#=\,8>
M5`*NL:JY6M(-6I&NDX18PBXOX%8QP'IJ`%96HR1TS;F6/H6;-X!=]>61CK#K
MLLZ!5S;P6L9=@G!>K]A6*(J:Q-L:Q(@-YG4&".^NH3)(]6!?+W0KA",%CEG2
M-X".F\0^5"JW3][2=,U?O-H<$W2,<JX)=!#S:O/\OVA53?'O-P">%[L"MXGR
M;N9>>J3G*H/U(!_(:>B_JX-HX6Z8G,\)U=H^E#9:D=T2>NV`VKTH^>+5K=#]
M(*DXJM,.W77V6^E3'=SI.5',JAEUZ6OO@`.2=,]NGK[3Q!8;'A'%P2'/4,MN
M#WLV\<(%7]CNC_G9[.IV1J97Y^3V\_7UY1]D^MO-;/9I=G7W3@>#@YX'I(.;
MBC..%GG!KSYW!])<7#\*FF-26NH-:HH360'SLBL\:3PEN\<>G7@!ZG`9SW00
MD9"I(R;ES-"@<GS;A=B>/<!:]5`#8K[<C80+,&CYT@-BF/<F\1/]^<:\L_B9
M7:_`[=S0E%WBE]'5;9:'^^G7(%FE5S1;/%S$R0,-V::^E(N*]MBAZ:P?V=)?
M9_]S#["^%\(Q,`BN:(Y0Z&UA4ES'5&R8KRLA>RV$JR&%'KZE?O%`:JJ**YT\
MV#2$A^G8":1$ASWTU=TZ%N(8&.CD<!T4IQRSD5_<^\Y'YWQ4G]SC&2-Q3@/J
M[07ZN4$H'KDFY&E)R`_WG)#+.B'Y9I3BF(9DS\V4<S-@2D](E',S?F`OI^^X
M^7W*-?_PSDX]U`Z!G9BG*-H[@UO@XY;VXX8O+\IYEY$*I60XZ&B$'H?<Q!^T
MR#,NH3RKSMW6Y:PB+P\_X]M/=]NEZ+^V8?8J*@M66W[O)3NDJ=RXRLZF$5<(
M/KR+Y1/Q7!7F:-0;NQCWJ0QW6X#CE][O5!,CR5>J(5;6YW23Q^Z0&\_#>9*%
M_R[^':VF:4JS^?,F")/Z]76U0MI<N%8WFPCW#BSFGO:OBHULJJ.%@:I)O2VI
M-^9[>7ASLF\_/O4M0!3WZUH!K>%*FBSV%,0N*E%#ZUB`KHX5#1X?$_J8Y[;=
M/>JUFC.,>%6YW"8)+8[$YIN/V9FCP9H'0Q9^68LXY<DORUT+V76B`;-6W,\>
M1NU/\ZXN5*6%KGL:T8<P(PR\9)N[4!Y=6C3_D4S7:9RK6:ZWJ\I>'N4?F?-!
M&.66:9!$>0F<LMR\76>L&N:Z6-.O29A_N57\-6)J2P^JIR$[6SY)7IG$2[#>
M\FO/B\\?\A^J^,R#DGDX,BL+8O=T1BEW#<QA5[>&IM'8?-I,4&\*L:JZ<@#$
M(E:-%]L\CK%:-#?#RM=MCKA9/N[?,$/2O6\&4K4Z$235FXH&OO6O#&'&U)R#
MZ)CL&O':KVI&=NT\VB=G`H[8LN<$O`-(-PGG#1Q=U'A0L[VAR:HZ+3A]V6'G
M$IK*,L8%.#%WW^U4?V:G[Y_%>8F;;)?=[8>U'``5J24`O4AOND&]ZA_Z`9;4
MY-(JF.P)Q)N0>AN/`CX8";%-3PG8I!-M4LD#U+F(\"";_1#(8ON;QJ`RIN.B
M$#.:U^>A[]B]U5=Q](%^H\LM>[?F/,S'&;FB5/%JBX5\XUT7(WF$]Q0L_,5X
M&\;,K.[M!1-MD\8FB#M^!SS))8A`Q".:VB$K[MW9PE<@#/2TWXGP&-]N7LPQ
M=0`1Z\6K.T*T[V7('NV^##:&QKKFA9]AT(XZ*'G>K.-72F_I"TV"_+=>W*_#
M1^Y'>9"W:%@"%JH/3`!"_8M$L&<(@Q.(+4UQJ%<QJ=J072.R;U7=5#$^$PTP
M$=OUF*@\U`JW"D0_,.ADJ`*SVA>/?+A2(3+=(3+>([*\L<&#Y35WD%2/6=!!
MB;)\!C"#O6P&--D;DZ=`3'JP=<LA)E4+9@XPB;A`-ONVH7P75V7M,@SNPW68
MA30MS:47<5+>+R([^[.'EGJ98J.E/SGM?4<H9*R,:UAKH7-2"=5*G9I85>ND
M[(6#W4U=GIP9V`=\,1(21+PWU]8*!(="!R<UE:4;Z-3@55=%CGV&6]?(4:4X
M_I9`=7F6+Z>SC\D.=:TV`C]PJCD+N^CEG:4/^/0X-:1'F"Z#-7FE`;OL>47R
M@N3/;YPDRN)Q#)(X*"_/Z4,8Y?_]6&Q,/8NC+`GOMRP%G/.7K;2EI:$&05D)
MUH`6(0Q]QBLGX89A`0&J;Q\**@E2BI"Z#"F$O*L@33$FI+X=4$6D!VH2$]Y;
MM+NL%DU<0$5^HTI\QSX8`B.C'[4>A-IT50N:V,<%?[T&7-:QGO=-'%&2UWW/
M<3XH:O#@.G?`AUG!,?`/*?D&P3]BJ3==+ME+]JRJ#.[7;&-G_DFR#=;I]%LH
M.MT$)E`KY'0"O9D,\ZA_F::UHZ:G1GQ2/2=E@^)]RK()^<(:>;!7!MC]L7D'
M"4BE%FQR:&28N:B/`!;[0(X?L:$$'6MUC)!35C)XH,/<=B*W=!X_!V%D%*F;
M(J!878DXI%'3*Y?Q>F?)ECZE`EW,+IIY';5;4`"22`@@&(D*42B-)+!S0*/+
M,*+SC#Z;U3P=*1"9:E(.^=3QS26EZL9L6;77H2,6:TEX4Z_)U44'D%\R6,$H
MMI.&LFQ@/`Y;*S7-]L:FOFK:@_.XL6E91=FC<YAZZH[];90$&A*@!%!*."1;
MPR>7@;\R9$NL0EX7\'DKKV-]$P1`+HF0`V,1EX0R2`PW>^X\)I3???0I8--5
M$5N@O*!"SJA;UKDB:]F?(VH?$+@A-:#AA$1NLGM`:D](_L@#_&LZ-#;XY45X
M%TNT<#XT5)S4*PI35K#A=<D..,\UX#P<"W#4!4</Z*`L*,ET8R\<J>S8(>?T
M^)&C6KKIA1S,I9C:^4J+AW-ZG\W3=,L,G<5I)IR7@$G4TZQ.HC\-8#XAI%VM
M(0T;-/*3QN&6BP?"FI"J#>&-/&`'$`*Q11^)N**6;'%F;+`Y2=P`D[V`USSY
M/,J[/TB?=J=2EL<_\C,I62!BIS#O'N:_?IBKHF3%H,H.G8SO,S;;^A"R@,4V
ML`1I&K/SW'(-7\/LB1\-61WJS*5"?@8$WV'(3IS,+43L5,QEL&'^II4#.\?:
M3GBP>=H%)]2U!R(K<&H1C0WTF@1@KQ\I3EOQ.*=&`=<J'B_Y+\TPSS]?A2D?
M#1\I&I7U#"8:,>N;*-H&ZWFT3&B0TKM8/WL`$JA7-QJ!_KP">810V^CL:,BD
M%I\4STG5@)U=X=],`ZSS8_/N$5%&*=ABS+@@<U+3Z"WV`1RO:`K(A17D\I^T
M-=+TH7!`QYRZ;$!#'4[1H#:!7C/HS?4"W2D$=$>).65Q@(<YQ-+@+!])K&F:
MSK[19!FF=/'`[R=9%&,.06D`$ZB?_J81Z'\<%L@CA//=='8TAURIQ2?5<U(U
M8#,?Q1UV99OQ*0/L_-B\>T1G5"D%6X=2C0LR)X>LZ2WV`1P_1JV"'*T@EP_N
MBBNEXJ*5!Z4!/N;4)Z.AH0ZE--"8P"X-`.9Z@8Z_^;+'6HDR\I@$47FY&2V/
M<SG*:*<L$!"1AUD@Q.O<;)P4\Q0;6OSCK+B0YYI-82@.!3<7;AP;"Q=&.%/3
MU%.,`V,-;.I.T`2KFC3:DEUC4K8F97.OCHDUAE'<KW.%1V9"E;3/R_02QF[.
MA36RC@7IXD38=U#KNWH46.,>9;ZS^L+VV5V&2[;T-4WR`N*1[Q(X#]/E.DZW
MB6A>VT9<G)$`XIAD!GOKA,P0ZV`RZY5-+N=GLZO;&9E>G9/;S]?7EW^0Z6\W
ML]FGV=4=^3*]3[,D6&9^<1B.)QF+31$I8;%6C93'OF':+$6!:RV873P\L_3T
MCFA-#X^&Z6&SD^P5!T-)HYR$]<J#H8]#<!;V"@14SZ31D+\'438EM;;^O!)A
M"AI#FNI>D0!J,*7FP'!U/`[2FD:!;FL$I``O;_XVH-LSN=B#%_GNIN<P8ZJ+
MG8G"W"%NTKR!J=4$XQ(:H56,L-_1K+T^IBDPV7]"BH]\0+RDE]HWO*CZLHG@
M9M/.+2VN>]S1S4)=&V:]7]X/5/5_P#_T81W+"@"Z6WP,(("S'M56BKX")3)@
MB(#3[R:WVWM^LEH^JF*;KY=M0!PL'I0K2&9X0%TEJG2G_(;:B/WJ-%J&5'::
M&5!"F,0D$HC@5OJ$F>)DAJ"(%\O7`F!:7L)<:^+-D690#$@8`0&.F!Y"21E;
M1D*;V_0J-]D+><WD*\*>'R>;N4`>,%7WQYZ;\47'E/1X,[`,+'BC'7`&]LMI
M``<><:;7H`OBWIQQ!L<#E$[:4\ZTLF!"#8>^@0-ZS6A/).J#^O%CT3:X6Z%Q
MH`!_J3AXST0,%N8O$8\Z,_'.:;"_!!^^!U*BH]FE3Z?O&4$$RC89N(!TNQ0?
M<>81+`?.`I<&9_`!U;R#5-"9@\%TH-P@7ZB&B<!R`MY:'\PKI[D`NABM4:"C
MES^KST`D0%FE7V]6BX*Y-!3J!@[U\#5EK0H-!KU91':!0-N8;H%!W%@>I>&J
MW(9[$2?EVK0PA"M;-B*WI"4"=90^8,1IF0$=.<1RD\8#?JUO^<@''J@[-#;X
MY868%TJTH3XP5-P$5[DI*]@4H;0.'':GY[IXZ,6:='_D:.*E/7:0UJO%NO&7
MK>5V[*!SJH#.D2!'O9;=`SF(*]O\8*;=R6RYP1>:9&&>O#\&*?T]6&]I;K?X
M.,V=N`DR4<[MH:66CZVT]*90#]_[YW$[XVK&V>B<%&=0[J1(38PP.<(%>6&P
M%R5,=GRR]D%?C`0%`<4MM#7I?S!\<%&LV+J!S@U6Y+RSHR\P/.$'2M%E8Q>[
M(+/U`9\>>2''*?#"*<"JN.6>`LD[!515X"@4&*)ZW)N\?0H2>K65G*!AIP!2
M,TH4N"._TF.'E:+,KB73Q>J4&;"6\K@,*80\YKT:73#*0Q`*XKI0$9#F?J!\
MT/I/[@$FXG55WSOF!;T_*NK=EG9BDX-5=7+SJ*#/:[FR(]A)>>Q!RBNZ^R`-
MTUI=]R9A;E7(X<,<M7Q[H$E"5^Q$=NDA9_)&C3*LVPB!C#++&.640+>.2QV1
M2?49O[7%H].7%)T6PWYB(<C;C=M`'@0$;JH-H1530!150QT2Q>>'#`A->C>%
M!.:F@$K[#7VA43[4S;]M]<YZM+K=;C;KU]WU6G\/LZ?K?X>Y@#;2]5$GB(EV
MZM"(T^?;X,592R]@!+12OB=J*4Z8_/Y4B6A%"A5D?X<=4T(*+1X&^UZX%48!
M!":(HH6-6G%<.4!NN4Q?UOZXXUDC);XS#9-IH,P\+M=0LWU)A=SJ+,J_\>L\
MRL>FSYP9U1%SHJQN(%;/WB"Q_I'$P#N$;`RSIHD&$"63JA6G=]&.U!IZ=2J@
M$41BV^X3D10@WB*C#2RM*3=[>*!+?AK4ZG]MTXRNYM$R?J9WP3>VDG3W1!,:
M/&3"8MI4M$8]N&AO^IEZV9^"!A;5-`0KFNQ:DJHI*=J2O#'?I4#VS<=GHS%R
MXCX]*F`E5$63F1ZBUD6I:60;!\&LA'S'L+)_!T<QRFH+V!CV.HN18200LVOC
M5JN0D2M8DRQ'+=L<<T)8TN77RV9O#[^J)17'^$5<1E';_(,&R47^T+A&:@N"
M*Z2]H&.&MCUT71W5[/4AY4X-)*NPQH2U]IV4';@84%("-3@=*P4F9!P<IL.7
M0PW+&)`%ED)O"K0]JJ`^L!V@`MJ9&K;^:9A%06VS]GE,@A6[/G=%R^MSV0E"
M]7KHSV\"MO;%3R_8#EOXY/"W*WQJ@F:%#Q<<@I@U#P<I?`I[O?G(U,!S2-[Z
M(,A8AXLI&;M0,Z1BKL"8BD/"=*3"I[*,`5E6^!Q?"NF)VKZ5CR5NAZI\F*D1
M*I_*+`IL#2N?__U-P+9GY6,+VT$KGT5D-^-3DS.J>[C<`*RL^3=$U5.8ZTM%
MI@5<\^2-#X&%=:`8DK"+,3,&YO*F!!P0GN-4.Y5A!*B:3/*\";#VK'/LX#I0
ME<,L#5_D5%8QT*I8V#I]`]CL5\Q88G/04N8NE[8K9AJ21N5,*3D``1L^#E'2
M5`;[<J_0`\X4O/DA\+$)&D-&BA!GQDBNP923`\-UG!)G;QH%NB9ESAL";\]B
MQQZ^`Q4\A:WA2YZ]71ST&L[L_/)&T-NO'.J!WF%+HJ^Q74&TES,KAYC<$.3<
M^S=(*<3-]>9CK@6>2;[&!\'$&E!,>=C!F"$'O\;&#!P.GB.5/J5A!*@:E3UO
M`:Q]"QXKN`Y5[.261BAU2JL8:%7,[AQ&2=,/FSW+&3ML8I8RSYMU_$II*CWU
M0-*B7IZT6_0GCM@F0LG14:SA0*O]9/>!1V\=RWHH!ORD(M@V6[8`ZKJOG>1O
M@0FC?N<YN=/S'MQ@8-/UZGQJT/F8+V^SK8?7<1AE_S=-8FDL4K2JQ2-AJ]XX
M5=CN'Y?$RM48%<E,^+9/_BEA'WL4I51]%P-_:`%@!:V;H!T,#2XBE\R,,3)8
M!&MCPY>SI_H@0QG,;+"!4OB+]&*7^3(;YM#(2_@___C33S\=2;!0UN16D$"L
MMR_BY(&&V3:AK*`7I3AA@WIV:S7H#U:A182<UM:K06:S^63_MR<7)4AZ)M;_
MEB(<-AJV(.BVAYWDJ:X%D][FV6G?WVP&P8/BVKS#U=D(W.4X.:BI$CW]=-4;
M]?AII\</LL.5N0;>X9@99ANMPNAQFB1Y7_!#M^1S.]JV];PC;]L?JSH_$+*1
MPH0&N%+)2?F(U)_Y5$5INS<VZ@41QF4R+;B/`1XGB4YIS!)(//V)H.3-"`T)
M2.K\V!-*F--1OP5A=!FGZ2*:/L?;W`2SRF;C;VBZH<ML\5#-A=V$CT]9^GD3
MYX^R,.$."2(MCL):..ZKL#?M<+Y1_\#>VP\U:7NJGS!YPA20141*%:300>81
M*;60Q0.I])!"$6&:R%[5^%$`"<,Q/HH$T:2?XF;(.7"NN<B#"!ZYY!W+J)QY
MWZ]S'3^0G$E!R;V'@GOYLZ3D7OQ`:,6]I.#>EG$OV:GS8##J'_F4R=P?^J$,
MIGNZ`!M\_UH0,**/^9!PI1Y^(SCDE'^G)?]Z$N^==RHT^<T[Q#F-W_):/RMW
MO]P]Q=LTB%9W7^GZA4JG-J`B]9):*](_C@"]0BB+]98T`4"G8,);[#8BDJH1
M*5IY-`\"QD)LTU<B%FI$6SP;'W=.2D2(S7X8Y&6>&H6^3*&XP:"Z!D-%(4X=
MI3."O4P!,M@3A'FMP]YE/OJ`IRX\<,$V2/%P2_/?<6510H@$085$4]`AG40>
MNBPJ6O9L&=50HPOM1>.#H)T0,$#R*<`&(V!=`92&HP!UV"JD8QD#M("*Y`W"
MUK),Z0M<QR5+P]1PA4O'+`IN#ZF(08.E74'3&Y:(Q<WN_:#S,%VNXW2;T,LP
MHO.,/J>"D@;2O%;(J)OWIA;$F_Y%B\:*FCU*X4GMI<S]<_*%M2"\B0<T`G5Y
M;-HM`L*HQ)HT&1%6+DH,K3U[B+%R0@RR/<:.#6+*8@$'9)A;101V[H+[M6AO
MMZZI.O*635W0H^&%DXA;63"F0B$HB[3\J9]!MMFS.O2+<*#!/1?18MXU:@8*
MJ'M;=@B2!U+^^%@09!H[#3"$'#/Y*4CSZ#(,[L-UF(4TO8B3ZR3>T"1[O<Y[
MF%]A^J]MN)'LJ+/6T8RRICHPB&3G-TI<-C:MI9NAQDDEPG:_U81(+D4J,<+E
MBJN!*TDO*&J)N#9W>P&W16DS71VN^X]_1QG&P@ED+I0Y:7<>W+K&AH><#9M2
M\"3O:D8'-H=(*V$/MJ2-Q0==DAN4$2ASC.96L:<;[3S`)L3I=Y/K_(=Z8H2(
M'W8$:"+_#0-?-5\Y./!19S'3_!MM6<B6OZPF;]2HZ+J-$.@ILXQ1DPETZWC5
M$9G4/_-H#E_19S'L%Q8BO=VX#>5!,."F+A%:,<5#45G4$.'++BA[/&B2OBDB
M,$>SM8`Y72Z3+5U=Y%_X,ES2*&5OJCTF5/9:F*EH+=+!17MCW]3+_E'1P**:
M&V!%D_I8M&Q*6%NR:TQVK<<GDC%PXCX=*J`<5$63B!Z"UD48-[*-`V`6\NL0
M#DH(,\CD(\L*PD'5WH/QXS`85B8.MRA&&1N"C6$/"8T,(X&8G29;`G<=YW#-
MW7RNSXN\&="J1GJ.08LXKOL41$'QCGX^<CS+BZ_M.LMM75":WL5G3T&8/`?1
MXN%C'"3R;;CV2FK5DHV2WM2U][Q_!65E6\UB"Y63O0R?S=]+$29&[F)2";)7
MX+FH1\/7'M"+<8`@H+^YLF8@.!`JN*C+++W`I@6KU=Z)T1<67E`#<Q[A4_`M
M?-X^3Q_S5,Q>`;\.7OGQ-HN'F_@U6+/,?1?S+:8W=$G#%[H29DM;)8UL::X$
M(438>HZ1+2ULZ\*"L<I)*4-V0J228D%@)\>B0_&2027J0T2PQEV,@P)A/#!5
MUHX'!\$#-ZG2R@ML3K!4>4WSGRMCD9D$.V(D.S*D3_%VO2)1G!'Z;4GS/GSD
MW"C.G7C+S-#DRJ&Y@3(=8F$6>V+$T@5T:IR6U,BIS*C!X4ZRISI+R@_CAQI?
MLJ<@DY(F>4\H*^7DRPBTP9R0"=<TS>)H9U8^ZZ)N62\692W[<UWM`T+9)S6@
M(:M$;K)[L"_</!JT:;HT-OCM1<P02[3@/S18G-1&"E-6P.$3`EWH^+)JCP$<
M=2W2`SJH(_`XRI[6KS>Y]DNV&6KV;4.C5/0JCZ9E/3S*6O9'O-H'A/`H-:!!
MN41N4CX@[`GACTCYS`.0:WHT-OCI11`72[0@/C16G$1'A2DKW/#H6"(GR9_]
M:<V10XNG'BQD8T!''1][@`=GU"71C3ZT4MBQP\ZI"CM'`AWE>*4/=!!''E=A
M5-RK=!M^R_]/.NY0MJNE54F[WDA7VN^?4F7JU>`62TW8Q^6%;OFG_/_]&6VH
M.S(&_^8"3`O;-Q$]*#Q<9%&Y(0NHL`QZU&!19D];N*!D3K%F[+PIMV*#ECQG
M_OKC7_[BTX6`O0&BRI'6`$',CXNS6VE.[#RKY<':L]Y8[=CIG^_J*M50W+><
MY/_T"'K=7S]6_F@"@.W:-$'EI.]<)*.F<F`_LJ3#>M*762QH/RISB:XG,6>C
M%@\/X3*/_6PO"DVR((PDUWW70P54IAY"]#+]X0GU"R'D`$QI(*S5,*F:%)NW
MBD:[&WQ\FO2'`R*VZB\11W2R+>[X`#\G41-DM"<4>915@]&;`.P(BNJ`C0Q&
M1P'^/$SH,I=*Y]%U$KX$&;U+@B@-E@QAD&AOH$`<^D$*,(EHX#%J4H#9!=,2
MHJ[)T)T$.P*GE"$U(3^SAPG`9/PU!ZF$R@!%4E[["'3'Z0?J`2;H.XGI'?8@
M`(P*?-3L%M';\%LQ:4)?J"*+*1O6LY6D87^R*CU`R#XR_1K"B<4F^>=\_K:<
MS66/?"*/NCMC^`\OHH)0H`7Y86'B)';++=E`AL=B`6B\&1GTAHPZ?EJ#!F4)
M0*(:>PU`8<8*,Z??37[^RX__^9-/RP`(0%$M!/0`"N92P(8?5)-G[!N:9DFX
MS.CJ-HN7_^3;@NGJ+@;,`]KJJ*=;<QW]N6+K-T*2MC"M(9:QQDDIP@OFO1#A
M4J048Z]_>3G5:(VY&`4"(D*;ZFIQ_1`8X*3^L'("F0V\:C'F@S<US4AL4%="
M`_,!=3PI,VZ>!,U3GGMZ#Y;.^B8O4*HZ@*QDQ3K[C&/$IZ'@-FCNZ)\I@'GA
MN,%G%^`MX.<@>._R1'FX1OY7NIN6S/U89$\TN:7)2[BDUTG\$J[R<:\NOB,H
M[::`7DJQ:(OPS=`223]?0(3O8V(7$6I%84U-;?6!A0RNB92JR$Z7?Y$#`]NB
MX(+'&4'TZ:%<&*`.G8L.LVQ?KUSSLIZKQ<P\`5+3LW&=A\2$%`8>41.SO,A5
MW[-+JG;'*K1?%I;6$(:2M4(!+-D[`AGZV#_EPPVJXP=4SZ1J6#OYJO,^O$?)
MV10T<8_>%'`9J*%)6._@ZB(KFIA&@2X_GPH"7E_2UQ#0528BE^!%3BGL7*24
MG9(\3]-MD/^LBX>S^/DYCO@@^8IFBX?R35G17=MV"IH)QD@!!G$M/$9)-V9V
MM=0U43>IVA?7/502[,3%0J:<5<JEV&>5G!=4M@%8F]'V(&W1VD!1A]T^`]U1
MHC+U`!/T9=HJ8,^OB`@KV,</9%G`/N6PCR@_/ZX\,2'UX+B-X7&O2V@#(1]E
M-Y*A2>Q=2A;F48%_^MUD7H-Z^A3DO]A)A?(="Y9QZL'1H2,@7;4]:D"D(VZG
MRBVOMLLL_11$VX=@F6T3NEILLS1<Y0[,TR2@:]7L@)ELLWR#RF*0VLQ/E*(-
M;%++8*"F2=64U-N2LC&KSHKF?DT5&"*HS5XK`+9H"]/18:Q_^'54BQD81\)R
M68&!T.S1W,$@6-:56T[1C#R'P"_/K=^;>[O=;-:A:EG;0*J9;O12&$2%^H:2
M8@#&M(34ZIA4C?@"U/Z"Y%T[O_()&!QM]AFBJL4ZG72';W[`T5'&`)GM#<TR
M2^QO07^[X-0E!71X8B:"&YK2_#=\RLT5-^[1W7U[\CP`%ZJE`8A0;]K!/>N?
M!$"VU$0#J)A4;7@**%OM+_SUB60&L(CM.DU`,+UPDU^>P-!%\`=:[0M)%OIU
MH/1E8.`.DLJHCP]*Y)A?[JF=\EM85'%>T;`9VX4-,8BD\``EAHOU:TDB$IO4
M-GP7#_R*SJK.;,-?W_$MP`L$.B`?$B2.(JS,D@U@RDC:@HQ'L;,G8'0QTA(R
M;F+A.=W$:0@)AL*6PFC8:HF(=*$/F/&P;0"*[Z9<'=[E$R]#HKA+)1!7];\8
MX0T)&<0'`HO;N-@U906<5F2LH.-?:+0'#C`XFD,'-3Q65[\MHMM@31</U6RU
M*$#JVM9#I+QM?]SK_$`(DPH3&KQ+)2?[6W07$6$/V4)+]=@#S&N[-S;J!1'J
M93(MW(\!'B=A4VG,$DB[BVF+VS<;-VS>!VD>3=D.*@:O_-&F^H%7](6NXTW^
ME&^ZRC__7Y1]_K"-5G3EP=XJ+/BIPVY/`*+L@Y)KQ][RI+9DB[_3>B@#(ZX`
MV@YX)V2SP_`1@4^UB:DW^!"W)MWF/WV0A/$BHM(!D;1-+<\+VO3FA]1N_[PN
M4JVF05=B4GU$V,%V_@QVY-T5@WY=`6([;9M(':3S7>1EL1%#(+`\+(2"!\G4
M%@O*Y&F*!I1DV=6*G23%%DS!D"?%SYL\#=)@^40NSJ?%FOF6+?8&[+C+5;AD
MUV!-'VFT?"7!)L^#+X%/VP6M(:-*><:004UQ3W2U90ETL:'17?#M#QHDZ1U[
MF>N.?LL^YIK^*<QZ<+%&(H2((=`![AU&N@19TW$%H&12M6)C8M:.Y`T);TF^
M\+:$-2:\M1=L,4!);-N#0D;IQ=LD\P:9;G(YT&Y_E!897XK3-DR/':6:8L$%
M3I%*"H`A_"H#:!0!IJ<UF,9MF!X]*M7UB!-4.JI:)&>D[8X^,2EEK'1)ZAM#
M7:B$M?H>N)60J0MP1IMI;N4B^;&$^P.0?"^E[%`JC1%]0"\+&T8ZY;'D8#AD
M5K,99D)S3QR1J5':Q7LZ!2HZO7/'N!0<@SV8Z^7\X@5^!<-%^$+9_\NGSS5-
MZ\E5VK0_[S5>(*1&N04-666"D^*.F.*^&/9Y\3\>S97INC8VZ0(1920B+48,
M#QLG(WB5+3L(\7`N!)$O.XQP(*2.N[U`A#/4EBE''UZK#%EB*!]&_^>/?_ZS
M3[<0(:%&.43NAQK,H3`[(>4CVU]P%C^STSEX&)DF>8Y_Y*].?'S=-RE/8YM^
M#9(5KP+.@XQ>!&'R>[#>M@'J2'L]HV-J[T]#_.^*4#>@.J7A.**M"6])>%-2
M5T=J^LC'5U)O5QW&R)46XP?"U!*FEW#%'D07!Y2('>-0%,'PK+2"WK&2VDE5
MA^S>8`3GM2.G;K&W;5FG>%"C^/UK<8A7V6Y34CS@%'_D%%\QBC\PBK\PU3[L
M##D@CJNKVP-@.4X-C>@/>MF-[-MP),^+^XL=+]F,7Y#5./O.4SM8'2I/O1FU
M,*DH2]@Q4<'ZCB;/Z",7J06TT8O`PLA!4/J=?2EW1`ZZC(5=>U@E#Y?>J29Y
M#GD^^*I'3AG$B*KC)5Y,[5C"C*L'0'[\%4T'_@W*_MV0)^T<PLW.)::K$\+7
MX[8;]M9.&/NP\GF`C'8XGAF6TQZ,:[H^&8UM7$Y-BET;EM"G:-.47'J?T)GV
M=_;W`^BAL[\[6AJ?_;^8L/^%)O?QT%G]E\&#P"_?36;?-F%2T/X]<V/`Z]"Y
M^XL',QU76[94O'B81VD6K-?L\_0B3GZG:19&C]<<IYCS'B;V,&9!8/;&"Z$F
MO\>(Q13034<Q%60=H<@J[/`S]VN62&Z*E+;(]:%';B,"XL1Q"\ZCQ'2(7:0(
M?PQAQJN59[##(X8<G-7IJ`@Z[-ZI>M!YR(/.2QETBG+QD.=N/8TZ;F:!/(L[
MX\X0@3ST9BT<[.V88>?TN\F5/FBP>^TR/UY]/K:HX63VR+>H@;D.'SY&X4.X
MS$?!T^62'2[,S,3K<!G2]#*,Z#RCSZ)C+LT$Z^-%H&#_N&CD(<((#FI/$Z!@
M:B:U=F3?D%0MR1?6EO#&/FS)-X-+;-^1(N*#%+08;`=3-T3D;^J9DK`A!"5@
M*>26?`W/'!.OLM6#=(4*/>%X.]^YUD0%G&<B-($Y5KQ/#^?7<"AT,K*&6>V+
M2#[&A6'2A_&I,U"J1XKHL$1]3SK\QM\.FX6/3]DBHO\W36+YF]+:QHT@+V^,
M0"N=)QA!76%#1QVI:$Z8;^7+KOPI/Y&2/??I[45]/\=FO2'DA4RHS8=1<.0F
M+"NMV6*J",,25'GS'C4:IC31MB^J<&;$Y.K1I[/4IJQ!=?K=Y"\__H^?O7JK
M&@]#REF:_AA"G1\IK%R%JB/`I8T$&;G>"`WI7<MX&;BA&P;HFD@M-K)//<2S
MH->$.);VK@B]^\9BU#I&@<O\V;)BBHAFON28\"U+FB,"E!7AF$#-@C6UKK)?
MRX0Q)'BV^_4G'[.=!18@V<T`"YC9+*<X73S,TR2@:WDZD[>JYS-1J_Z@E=M&
MR&A"Y1JT"F0F_$.^&8E_[!-L%7T7`W]H$6R[K5NX'0H-3C*;Q(PQ,GAN:V'#
MF^36`QGJ]&:!#=1)-+:4+CSLD+^KI0AS!G*-P`>20P"_@7\8P1%F3D<*B)8)
M;R8]C;=XQ\ZGH&J"E-BZ$X7D`LBWZ>81/MV$:ZAA!*P6(1V.5A^66AS#59,-
MW``69T@$LH0^2@);Q<!K/I:2'<O\UN*J>B3F"JB8X[5MM$I>Y16,X'&]4&D\
M[D\>@36$LJ.I5<.`>N-)\9=/>!;U1ZS[#478K#5K0=!=GSI)U6W]\/[EB;?H
M86^&4$;]JTZ3H!Y&'29M-YLUWWL:K.?10YP\%WM2[U/^YJ,PO(`D&A%'(X$`
M6)!/&'%)9T@'9;7\Y/;S]?7E[-/LZFYZ\P>YF%]-K\[FTTMR>S>]XQ^3^=7%
MXN;3]&Z^N")?*D$OPAP,%[%%QPFIHI1LL\<,@=ATNF$G/F_I]%LHW#0-%M*3
MJB'DBE<"SYQ1JVG+BEUU%9-Z&U)K1,I6.:?R=O[R280*"*7D:`*PJB8,(I8*
MA8ZX=1X_!V%DS*ZF&)A?E9ACAC6]<\VQG;4^+"N5`'A6M/2>:2V$&'!-B"TX
MVPIQ$[Y)4.F(<9>J]X#,),&\NY2^8H%-O8Z/KME7-]B'@'L]``Y>>O4VD"%H
M#*@H0QR<C3L-)H24PQ6;D])W@0#-]>Q#>_,"X(TSG@'?^5$)RQGESVL^D`Z'
M,$?[:H]"#,01,:A0B+%X>*!)&#U.H^)NNWF:;H/\9SN+TTR7KD"R$LIH9%'Y
M`_(3ETPZDW!FJ34U:5:UY4MLQ:);U9SP]GZ1#H8?*0--X">CHU*'G)O>H-?-
MG+.)<20D%[/5-2S'%9;9(MS^D&".Y263\&&A>"`P:V;"W<(99^$8;`U]\=C(
M,A::3[^;S.MH)5&<D5>:D4T0^G#$VE#`52X@NP8NZD+RSFCR^C%8,R.W3Y1F
M:;M,Z]Q]+"Z>3+6(RRBX%DP&F_J.6EH9&`>3&:QSTA`BI10IQ`2C',)$"9?U
M:\!C##\9_RUQ+(D#4&W2B.`W(1Q7:T9NH).C5<&IZ=%FQ]LF![2^&XP>V#4?
MV*[#ZL_(!WQVG,JGQ$Y:3'GC9`#6C,.1P54=.8^6\3/E;W>P3ZPK25,]LEH2
MK@<W-ICZCUQ/&I@W"`M@K:VD6<B1G>!A597&4)1'"TM42Z,%5)\B7OA.$.?U
MI9$C#LC2K3'?Z6*-$8\(@U]O@BT[K3B-O'#!%V75V>;..SG@M>>0Y$"L/^^"
M;Q^WR8I&YR%[]^9^R\Q=!E^EK\C`!&H5I4Z@-\UA'O6O$;5VU'S5B$_RYZ1H
M0.HM2-[$HS=R@-T?FW>0@&!JP2:31H:9BTH+8+$/Y%CMI`*=+R\)X4-.6?+@
M@0[S9:/<TDV>%Z9INGW>%-ODUOG?J[OXG#[0),G_%7P[#]GR%\U_3;:)+DF#
MM3B`]]'4C.QVFC"XV.<[H.0"2P>TC+72RXG,),E>E)2RY"XFE31A[?;RI%+@
M!<M[P;)-?P2,MZ*"C<9.N#@LPCC*:M:N."$/RX,[?F3!-YH2=G\5N^%JR^BS
M3=FNH^R)LH<DR36FA'[;4'X$0-Z_]Y2$$:&YVF5&OC[EJ31[BE-*5CM+*4FX
M+>K!%B4?>*;+OZ,Q#67:P=8V]L1#'S_<$.VTR%,0"JUJA"1!FM),Q*=W.C61
MXQN=<"<J_J!!<O>4FP@><OBK9BA4+9L%K+@E1@Q0^8!2@$H,:*DKE./$9$_(
M_I%?TP[*/FW3"`"`%DE$$AT2#(L6L^H+EA&D=JQ@PTHG-E7`[N*;YJ7?JJJ4
MRJ,:RPEEAJU%DC]DB^LG_,^C19FNMK'&&?)L`C?Q-;Y[BK=I$*V4Q[%#F@O"
MJK@Y&EM4WN`%6(D5&%V$PK50^S4F50/?#G,'];F0$`"4B#@A$A,38P1<.0O%
M4F/V`+,)RN0#R=W_M8C-KPR;QXI$4'SNAT742)T_H_P`<W8=1VY.>:,5H'4]
M3JM:]Z>3WA?$226E,0V7%+(3_K"\6H%?0,1BME<W$4'Z/#;L&!$UY%(M9HR%
M*OP8K;%E#2L6H7_Y\:=3GZYGP(21.L8B``EGGDZAWV@N3E-(:LS8H^A4%9Z.
M%%G*J2X,9&%.67V-N9';\-M%^*(87JG:U?.UN%U_(JCL(Q!`HEX#?*'4A.&[
M@#N[\H@]\0GIRHZ,P;^Y"-NB]BU4#PD/)RN#4D,64.&[6XX9+.HD:PD7G,0J
MU(R^O"6U8H.6/)>>_OB7/WM5D?4%B#)7V@+$07[DZ9B94(]M]:T%N5+8&@WA
M"E_P\J;8"`SD(ME:6"S*1QX8?2L:`;TMI(`>'B(:"*3$9!@<3RX3K<R<-;::
M2?=MH`N4A_O@"S4GB_2[RLPR6_;PXEGZ%R^S-`J4(!F[%Y00L_?G31Q=L2EP
MFCR?Y8W#9;`^IR]T'6]8!/H4KFF:Q9'BOCA+#;4L;ZRA-X\L?>Y?#9@;5M/,
M5-^$"9`KOFR9BY!*AM2$R%[*(X;:PBQ&Z'<!CPTU-;GM/>!=E"LV+J""GY4U
MAO#W975H#/`K*Z(AX8^Y$/L[?0J7:WI)@Y1.H]6G(,^PE*^=3Q_S/,O,RS.=
MN7`MR9D(]Z:[N:?]4YN1336Q#51-RK:$-^8GY-::DWU[CU*9!8[B?KTK8#!<
M29.\GN+81<8RM(Z%:9:GFJ@.Y*CV)4,-AVEE7G*/:LQL]/<P>WJ*UVQK5[DW
M?Q%=Q`D-'Z-B>Y<@"8%E:KD'(-.;JF"_^F<:B"DU&?4:)K4F9/=:YB(B9;-R
M_]WXQ(/C(;;J+@')M+)-;GF!/A?Y`6:T)Q)9-GCK6%2&?&PTHDS4ZJU@3]?"
M+/8%XVD3C.RUOCCBVY(__WC[(W^ACUVK5/PZ9!,G_!7V^($WV02O1='R'*QX
MK[`/S^+G31"]\GW.8?XL97=&,XGKA_#?-/F/E$3L?/4D?@A].$+3&<15D\;H
M$$><0/Z#7=_PO*N2I(-G9;M:K2)IUYN12OO]:Q*9>C7AQ%*3XN-]F>_1V%7=
MC3'X%Q>@7-B^B6P8.*RQS)98^*(+>PO@EL6RNZ_RK0R`UC5<*UOW1C?`E_X8
M5QM1(UTE.^'KRL5J,W]_BC_GFV#]`3ZDMV/#+A&00"'5I,)H>')12>O,66.+
M5<]O#5W*:AD#7R@5LDH_=FVLLV4/K[P>_NG'7__S]%BAI*I*4:"$6(GNS"PB
MJGO%3MM6E+F[;?%8(/,#,6L+3`"!WY&LQ]3\H8_OJ^A[6$P"#2"$!&C+2.`_
M)'Z<9FFA,4LLM3)T`TV^+&Y@80F6F2W1A)N5.]J=Y62A)5LP\7S\LU>O9**!
M!Y2+;<'C(@_SK8LLYRN/)8$T%V5C87,\`BB\0<S)8BM`](N$Z[&TV+G-QSR>
M'4L"ZG,Q+?0H$?)"(":AQO"X<IJK9?;L,=;*V&\%9;#DW0MGN"E<9,!9%I<9
MZP$SGLM_^?77XT44**/W0Y2+O,[^P?Y_`<GJTL:BG"YHC,<'J2>(^5QD`TB!
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M!2G9KK/PF>WS?@ZBX)$F8;`F^5?9Q%$:WH=KY@';,EMSB!E@T@EE^V[3:H-M
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MIL0;Y*-\NU8,#L1L"W>.6RW>4>(KL_Y4#Z`^EY^2J49)G8\J,<4IF</B"O^B
M&ITQ>X"Q`O?TQU_^TZ=]T;AH@I_?:XTG_!-\VP8<E%M:>SU`=0J*6QX4+\A0
M4Y422%##3.R[:W*@J1TD(+R!SE48!GF$D.!U=J"W/$F2?.V:)Y_3/*S_)9<]
MF:9ZI:#LPJ=1<.;P9CK;E*]3,/G%MZ2/CBW@+75]T85\5]U@Z5]OL1?$3H%1
MS8<B`!]ZRD(`#WJ(Q0"?;&A=>7N1@S:C-)(6!'"A6E$`$>I-*+AG_8L#D"TU
MF0`J)KR-X&+QJIU'P=P`%[%=KPEXI1=N<LL3'*(7#T"3?0')9P[R*/(F8*>L
M)?"!AU)3`,PXJ"N`5GNC+Z\O;BC;5<;/C0RCASAYYIZ1#4VR((SX*90Q>>11
MDU]YS]#J0;GA$*6JLL,!2KOEASE*SUDG+D/>==-G=BSHOXM_1ZMIFM)L_KQA
M6PKS7O['+R9H?:')?:P+E8;&U:`U4C:IMRXV:"9A1LDJ_LHW3SZ$W^B*!$S.
M@[--X5]-#%V;3A9`&*ZF"64S\[T@O4T_/`;!YA^W[+#:CT%*5^P86QJEA<$D
M)]5C<6C\Q]=]F^OB_-OIUR!9E>N!G'[I/+JF21BO_D[#QZ>,KJ8YK(-'.OM&
MDV68TNLD7!H>&*SEQ5C?0$ZN<3R:5!^0#?MD7!*.\!-TF3PJMEOA8`1?]C%E
MI!\")S"QK07S--W2U?DVR8NDPC9W,[VB7_FCU%5,@1L'A`.HLDG>.\]YEDV9
M``FYA"=T!GT%!1,-.U-&(I`:`?[!YBUFJ<K?E_^V#T%ZSW_@TO*?6"G_)[K.
MTNH3/J'UX:>?/Y136I6+T^4RWN8<R\D7W*_9#2[Y)TGN\&48\)=E0IJ>;9.D
M5KJ4M.FAH?R9K32@D-S"YW[38':&]1PWT3>I&I.R-2^KR_:D)G!"2A$_@H`-
MP#J1P!ZE[6!@H*D;$?I`W7KJNF7B=1Z=Q5%$ERS%LAL/SN)U[F6<\.R\V-#B
M'V+6H^FK37CWU-=[B(WR??I/D_=U0SWZ[J=]T@X3KR?L5<B]"L)TD(82LM/B
M24#!PVZ,#A_!:+Z7WN8`_Z`9AKX`T-\;AU1CRP8[21)&9+GGV%?&L66#8W$E
M3CZ09=GUY>5![V23(\ECNJ&L;?3SP,&R1W^'7'*.C8&#)'EE:R(OP7J;E\;I
M[A7]8,VO#DV?*,W(BATLD#^)[]?A8U"\OQ)&G'FKO'D2;Q^?B@,.>$M686^J
M:CL)4V;`@-/?KW)76(M<)HYHL4P3)]5'S+V(K>NL*YE<_?*577\:/I!U'#W2
MY`</5G2\BP.J=2!OX@#BYI76L.,Z87#)7O/AQ^Q?VY#?'7Z[W6S689X\E76_
MK99FM6^N!2,@VOJ.4ME;&-<&/&.=G1F`$U+)\;?I=I)D)^I7Z6X-OW;LZ(GC
M5KPPU=:)$H=!"!>%N)4/Z,PH3N$JF<!R-MTQ(:V:OFT"Z$KGP2F`528;VW53
M'%NY@<\#I$*X7O;F';W14.M'\CDM#I7)2YAU7A\59V4UA[.5&^O]3.D1U<?C
M$5M3"P]/[#&7PVZ#-4UOBKN8?XOC57I%9>M>JJ:M!2YQ4YSE:H47.$M6$@N`
M]6>1X(1_2LJ/3PA_<$+R1WXL-BE[M;N^K,=`9RU9(")8.88@9CA:E)[<T&7\
M&/'##S^%N8-9S$YBSI[B5;/!O^E*0AI[12U*V2A"(9S]-\"AHY5]/5DMU$[*
MCTA-Z(3LQ$@A=T):S?[MR^:2'ECL!(+>N&Z'"7.%W2""P)'A0LQEN*11N@MZ
MDO@A:=4*#IU6*,R7V,:A=5>YGK-MF4GU044Y/W@FZ[,.B=2=VV9(JW47_H.@
M`'5.1&7#&`YL3N.</E`^($N*SU+"NJ8<1O'6?$C&!V+YZ.PQH7Q;9K$H<?V0
MAX21[Q#MBR'IM(4MBGI/.Z@J/"=@DAJRJ^`9K*H?BX,II>LU&U?G@_S5=CGV
MVQAX=;P6.O:5/!J(S#.\$XA9NN&B*JW!,_49G^,6GUILCU-^"G@QSM1/SM'I
M?9HEP1(R^R-HK9@`:K1&3R4"7_"G@9I&S/)(7;9B*I__(5^JST=^4QK:Q<HL
M(L>$*HW4I-291`6BP:>%4@U79,W$4SHI,CMDUE&G8U(C/G2$]BG+-Q)(^TZ6
MA62]+,DPJ1SO`^'!9474-&(.C'HU\]=#!P2TZ#"`Q*@%`S]>F+\?K7E#2MZP
M%0%%#5$P+_<`)PH*]>OA+A";%"=Z%Q]ZLOD(T(\=\&O[O`W^KD`7_@!\#)G\
MJ].XSX+T:1KQ_[!5W9>\3HFR=)I5.PE^9QL)I+6!E99.Z6"H!2F36/F.57B8
M&H>D'S.=D]JI_:QI<7\A^T=-R#,2VP).D-[Z(+>;^XRTB5)C/PH,G#?W[H(S
MJ$9$E$NE(GA95>,58GZ56P)F6IF",N?6R.QO^M6!0)R(8=`1IF2)J"0Y0P%G
M?^7@O@281VGN^)9OO9-OVH<)U"\!U`CTOW`'Y%'_7?=:.YIK;]3BK4*UWL03
MWACT?FS>/Z++8)2"K5M=QD49_JUN>G-]X,8F`NH?'R.RU%>4H6$+Y](PM0D7
MMW_I+?8"V.EWD^GC8T(?V;[N9;4'/'AFVW=/E+O`3]BC:K-V<2(?2>@Z*.\)
M#6O&?JPB8]4N2"BAWS9T63:^I[EHL.8+2G'"WI-,\]]FU=GC_7UY@;-X=_>)
M7]N['5!%>2<7'E7&W(I]G=!-$*YNXM=@S3;[2X8&LF:MX4"W&<H00&8=I^P7
M:->7^AVA2?D)V7WD1STO[;E.#:_IXW;=WF[>K=4=H<%P#.YHY<'<!_29H6+=
M8C><7-%-G(:>#"/'F@`"+'\,.P6$M@NIS28GN!8:,8^&#)FW6?GNVCQ-@OP+
M?Y]22J[B_+._!#_X`5+[V*B%F7ET1`-*=_W""50D9FS6H_C]UGR@[\-1TS@+
M45J$V"U%6:[%ZF:Y;K?1*GD%S6\)FXIGMEI-,<>#0B]09[/:%L#COJ9@:P:K
M>.CGW)6X9V4#)A4.)`.EAHATB#04:ES.3G4-V<&')U+^P;$@!3K_9($5[#FG
MIG*WLTU=6Y:`4<TP"::0U%-.U6%:Q19O;N?-3R[UP3YP0LD&^QY,(LV^L=/G
M:74G?*-NT6Q>M=`@GGJ":<`<D)GXC#IA!30,'KV!].VFN<K6?#.*<#>9=YML
M;3`F&PA:`%4R0H1HD@X>_42[RYD)L'U4V+<'J)[L$AX:T=!9#^>81ILK,3@I
M?F?;S:4DMIZ@WEY0T[P_Q7!WLFH>Z0,F&:Q3\H'$K'<\(8+%5Y03HA<F^E]G
M(">(I6/CO>NGNYA(=B\1FTUGY[CFWX&/HE(>">Z>@@AR8Q%_>)Z/7RZ",%'M
MBO;.O_;[C/[X-\QM=$/_WDCO;'KTM1"NKQO,VPFW\^&>&2)U9TC-&W+_2NKM
M2H\(=^F$%$Z1FE?E8"3+_2*E8R>D<(V="5XX=T(J]TCI7]&$,`\)<Y%P'_W(
M;OYTF31G^N>BY45]0_EI<8W?>[2W^SYNSGOQZML=4-AG0VD>8(N#;^,'DNRW
ML!1W(_++LGTYO\Z;'^X`@J_^,!]?//4X_(Y[/(OX+DWNV'[C$V_%O_QO29S*
M]HSVTM4>"MGI<GE7+>Q[(`TQ+%VPOKY6HWG"/R"%'"D$=Z4UESVIO^A6M"Y+
M=J[!D]C>"Z'0>W"-`-^)F#8ZP7?D^LL?-T6;M2>.B-3:P=LH?TZ*"NF=*5U(
M>,B54;/V%?U:S@TS;Y,XRO^Y+*Y^OX[7X?*U^-\[^BW[F+OQ3TG"ME73RM7F
M:E#"C*WW.!G:PKH^IA@KG>029"]"FC(GI&A/OI3_98*$2WJR1&^-P$Z$Z8GE
M=F@Q5=>-*@?""B=YU\H)?'H4V7:9/U^_DK"H78,]638-#9ZL;(['"&VZ'9X3
MF)O?:[="OM#:,']W>FHUQN<[)P5;XNT4U#;*FRKHO;75SN/^F^J-[:JWOAJJ
MFS3:U]>6ZM=HE#(GI)`:?\>I);SB_ATNV)MJIJBY8]5SF*._!6!A'A/O_))%
M?J<`F58W#9R0YQW0-^4":O!F<:Y\`V$XI*.\K6!HTL$[#!8>H,+]5!'@I;#W
MX(V"$7"O>OM@0-QWMZ29X[ZM^A^_H&[*E)I00U<@,OG4@>#^1>C3D=^#%ODL
M1IK\]Q9@J=VXB1:1JM%FSC[&0;):/)R'"5WF)M*SIR!,GH/H$WV^ITD+?F9"
MK5DQG1#*:!_F&<Z,E]:6?@"O43'AS]D6@5T+4C4A7XI&GDQ<`2'1&90;0:D]
M`%<+=X?;AA`<CH6_YP$AC!ZGWT+96K*@18M?C18H9!+8Q&%.4[&>)O7VD_(/
M\H7]Z0GZ1;W3@;J\"]NXKK7L@EC5SX,C]CQ^#L)(C=EF&S%JJS:8N&W:147N
M3C48NZ7$'KW%!W[AM]53,@0+.U2"X:*M%,62?A_]%0VVK'F7U_'+)[I@]T@I
MBB$+#;#7',0:7&Y-5?GL]%4!B6'K79U"?8KM]L7&G%*"Y"*>55<V&(/ND@0`
MM<UM`TW@?88@M/L4%^Z^QCWC0D>#<5RH:1@H+G1\'BHNU`UCQ(6]/G!<R$4.
M+BYT,681%V1`-8\+.TTV<6%XM.\BT9"O4$CMHZ9#MDS"BC"2XYR=0O,0)OD?
M012%+[GW0?):'8O#=^/QXW`.!?.XN=!V3S]Z-L2[$QK.M)%PW[2/&N[WN'^A
MQ?E+Z?8^I?_:\GG:K_$'?C;3AN]X/!3`XP9Y!,#CA/EQ7P1A?M[K7X>Y;[\.
M4[[TPC!&5U=;]D46#[RI]#T1AZ9$)26Z*;RHY.A70"Q2\3T$AC=LPQAOG^_>
M+R\LG)#"!BL="BL>15!7!!.'6K=T%D9D9).2T/UV@H>[VL>%H^-$$7X\:P&7
M%_[XG?#8X#LZRF-N8CZG]]G^S>/K)(R6X298%QMM;HK;@>[B>11F8;"^SL/(
M4^YHLLA+_^EZ'6=,J/!4L+\977=MZS.B[MY;B="_9_\-TY@NJ7<LX5F:,%6U
M@WA.R$Y;N:>:E/K(74Q*C62G\C_^(R5,[8>=WK*Z&G^'%#X18J?X$^S(0K/1
MW,IUE#0VJWM@FV1QG1N(TJRXV1\EOMFQ>7^6.-O$V+B%CLTGA26U-SMJIWRR
MZ4.P8W;,]7NP"?=0J*W<LNX[N5$VNN-Y@WM\*[YO0['[E)WEW>3TB367WZEL
MCK]#I/*8Q\F>TTU"EV$@&*^HFK2F@)M-4&9?1%9QIEQ;FO63'`V!2?TO/V8F
MA!W4F5%0=&-['J#>M#M^%W5V_8>XS/^5?UA]E/\/&\GGG_S_`5!+`P04````
M"`#'A6Q&*AUVXPI3``"@,@8`%``<`'!L>"TR,#$T,3(S,5]P<F4N>&UL550)
M``,5^P%5%?L!575X"P`!!"4.```$.0$``.U]67/D.)+F^YKM?\C->=T\JZLR
MLVUJUY0ZRF2CE&22LFIZ7]HH!B*$+@81S4,IU:]?@$%&,$@<CH,'*)K-=&<K
MX'"XXW,G#H?[?_[?IW7TZA$E*2;QKZ\_O'W_^A6*0[+`\>K7UWGZ)DA#C%^_
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M3Q_>4B%>T_E[]6H[@PF)T`U:OF+__?WF_(#G)B%9$.&GMR%9OV,-WFVBIS=A
M2D(<+C9TR$4/V?.&@BK%ZTV$JK\])&CYZVO6^N/[#W_[\''+]S\.R=]9#2,-
MXX7A$+:DMNR3=$4MQW@(%;GM,%)"@B0U'\>.WFX@49`&AF/8DMJS-]5!26LW
M@-"4>VB/@6!C//T%J1W[C&!C2RQI[0:P"!`VY+\EM53_,L6)\024Q/9#R"Q&
MD+D80+`)`F*CAZH#^Z%8#,(!>V+J"$M::V^P^6#N#ABM]0",L5B06K,WY^Z`
M>1Z136"^+JAU8/E!ND]-OTB,TI(Y7>0M+1:(2^L!F#*W9ARG!*-D86J"-7K;
M@<06@XA=#,"<O0/FF3GWS)I]M$1);KPHV%&[&(35&.RW)\O'@)"5^?9D1V\[
M$.-O4FC_20K3^Q`9[T_VY&[VBE;;UGH7ML,A5B,AC@91B!,N`I*:;Z.:O=@.
MRG@<+C[<V'PO6U';#6+YN#;^=)6TU@.PX&_-GNZ*2?9LL:?>4ELC@9C#@#C0
M@:G'WI):LU_@S&(*MM36@S`?@"US;"H\MI;;5&I[F4TA9P\XNN4S9;XEM69O
MSMT!<U.PN=@I)QMC0]^26K,WY^Z`N05W:_;A?6I\CU200MG7+\>^;/G':,6N
M/B^">Q2IQ\#K*TJ2@Z[8-=L7=LWVX9=BF(<<[(=ZQU38_7CK;.J#WB0H17%6
MW$U>T#\<C`$]92A>[.V8\=&Y3"SX5)PB$AYT'K$;49)P)2RD6P;I?2%BGKY9
M!<'F'8/+.Q1E:?67`D!OWG\HKT#_H_SS/X]^!,GBCG(Y>L*[`[.("5]<GXO;
M9#AC$@K:O!M*GMN'($%?@Q0MCLEZ@^*TF*ZC)`GB%5K3Z4N_/N_;7`?/[&_%
MX/<2Q(OK*(@O@S4Z(>L`QP*U=,FJH=UN6!U.4AW>1\GAA`7);DM&_]G"]N'5
M>]GBW8:.)\[>A`\XVIG%,B%K%;!(KRJ^KHG]ZN^ON$-[E9%7W0XI3^E0R(9U
M%5"WLTDP27#V_.OK]Z]?D62!DE]??W@_H%G=H#1+<$B]XVU&PC^_H?4]2@1V
M(6W;`+:@[>#([!1X1$]7`H1V,<0ZT`5#&SM2;ZFB"O'O@OO]HJ#INKF-FDZW
MT6AX4/)'36!?:A&,#CJM`Z#1F3<33]=FZ)S^4[2<$3<4`:#6T`,0*.731@*O
M1P`</@X)AZ/%O_(T*_S@'3E:+/!VI-<!7IS'Q\$&T]5XX=C.TS1'"_:?+!#Q
MF*29<!WLH,OFLMFJR_&`L0TUTHG>5-#=C>/`D5GQK_DVJN$E2I)R2RO18*&^
M#"4I.MA'CG$_)%HDG/X[I^9\'M-%0%ZH[BI[0,G=0Q!?%4:?GI%DB3!='IS'
MUXA:_T+D;OL?@>[NR>4(/+')X6;%R(1['6[M\^6CQ5>*O%H63NV!1%2<=*N(
MHWNJB&`?#"!:&D%H1:LE.>UX[`,D(V]=Q=LTJ%`M8\9=:I5,(*ONW3'E.^XY
M9<='F,5K@OGX<CZ^G(\O7^SQY=X3Z7TPHX&_E2<X#2.2Y@FZ6M;U<8,B=A-4
M[``*;=S7M)$J/J)N.FV8D&VGPWFT\`$M\H@.VQQZTJ,\U_TW?9>[_@=W6(Z0
M2;K7OL"MV0EPX`?=#=RI\QMB0>Q\#BU/I%V-1W*876WQ?/M@&>^#E8?BSCIV
M=?@RJD/W+DW$N>K[M"L7@Z\<Z-]\L\8[IN^KY7F\P(]XD0>19!<J;=NP&4';
M:9L!1$%](ELPGA*L/[W]V3>T_H[2#,<K"48Y+1K(/&@Q;3R*E=$G"@]&`3@,
M[-&'\L)2S;\'O]$6V0E=Q9\%./D]B/+FAJ^CWLLY==[[\,;A;EE!NM:^:8B3
M4@1F2LZ';KQ>L;P?ZL#@&%5<;([I!^X.)6OG1B?DX,SP.!QFX].<A9$;(&?X
MI1%^]MH&+W,65,D6F6D61%&Q-#@C2?G1YX95],;/A7W"^,W6:C5#X[5=F#"E
M)7\9@R6?H/ML'RQRG>`XQ!NZ]5N3/,[*4^8[<A[C#`?1=9Z$#U3FY.H1)4=1
M1(H8LVU<"<=JG?==LU"'?4_0&KO2?.>6YW#@@+WC9^T%+65T3X8/>3I4TSE=
M+]")R6ZH=HIPF@7U-"$J,KN*KFRU.VA>SVIT,#$#L]9AIU9D,KK2''[N>W_G
MQAA.UYN(/"-TBY)''"*^&B])_$CE1]NHCK1X\EK_G=VD7I+L'XAZF9"L8OP7
M$L7W=LZO86H=\INH9?8U0[T8<H?"`#Z1/\T^X4!IVS4\7=.7?V+M/O3M**2#
MZ,M["`8QNQ3W<^FWGQ%("+G;\=/Y5&%890@\Y*4=A*1AV'*2B9JAAIYZ,1KY
M>*IOJ)\H3DB(T"(]H]-:R76UI%OR1[I]N(Z"L-"6",]:Q$UD`XFGBG$3W?6#
M=N#(2MQ_\M1]<Z6D^EN3N+!R+<QSZ$!P/Z![44@7:VQ`D!\,J@JF??M).R9J
M%`C?1XS+%7;?5-@N)N"(*F:]?4]Z^K1!+&D*NZ44[82Z9\@+PNV(X42-L;<Y
MZL6*NY0&L'/YXN>GSUAKY=ORWXN]874+6C25QM]WQ,J5,Y"RFMV`Z;R,VP%(
MY8"\3M=^%^6WZ5/GB).BL3HKBLO^71EYN__9LK5F8-SFW!Y\9:=^'LO<!D7`
M/=N(T(UWB*A4A>`BLU,T;UJ1L/E4C0*FGWXP+AS+;L/I\7[31$W%?QQ$STEW
MF(Y9N'K8R64Q57OJ;A[Z^\XX&W^U&WQI=ENNH8M0]K3*,_9;0E+GK['5G%Q9
ML8S3;,R&LS)NFY:)4<7,>1I!:JP3V?G8"7LXC.(%BS)T;>BZ?%V9/9SO[`2<
MS-BX70)<*%#Z<(^/B6W>QVR/TXX>`QRQ]]]G)"E\K&N?`63GRE4HV<T>PF9^
MQNT8E+*4-O_+R[)XF;_\G42TFX@ZQ;X7#'S.?2P9FIQGE^!HUL;M'73$`MTQ
MO>R%0YX]4)V(G^ATQJ>CI4*-S^P0C&9DW.8O%L(TBY'?YLQSAS<X_?,L0:C^
M5+&/-8&,;Y<K`C[?V?R=S-BXW0%<*,A:X..4G$?30WZ/J9#%E>CV,)8E8J<K
M)Y2$.$7%+>D-T_;WS08EQ;\N\!KK'22X90ER&:Y8OBAOT<D\#>@H7,E3O;;P
MTPOLRY"=Y,GN[K3PCHV"G&5V+,DEHDU?K>(^1GU-U2`=:+8?2S,;**2VHZ=?
M6;Y"MK[G$OTH?M(T*`$QS():Q"_+9.2Z&])&6B.#5>+R\O9[]]9]_[655OA6
MMA<E76BW'S_<'57ZANILH&K?DN&9ULH8A<.?"]=W`V?_"M?[6J.L58?@#YP]
M%+G_V#G)`][<D=.8:OQ96NW/L!=580I5+X/;@[RJA*S\A):"!%#G<I<6F5!Q
M[1_%W#RIU><BY3I428M:SM)6B_&!!8@!`A$9"A$YSRHS:(M7_Q6MN,"X6BYQ
M2#_\U$,?HR2C(U9#!4Q3`P^`QG<XZ:K%+<``W"M?]/9CC[5P5*@[P0D**14+
M4-YF8KFC"XLT"(6[&O,.^'@$=3`A<.HKK#.D@H9BFH;*,6:9$EA\;,8L[`&C
MY>D3"O,,/Z)2("%8-2EK*`53^@Y/,Q6YQ25X#%X'/7PE[&7(<F=YQP\!3M:!
M_``)1M38?*B(?,:LD6+<P17*'G(&ZET51Y#?A35NGGM.T+MJ*<(]0A4^],/;
M7_I<C#HMS"@]O^&VX1=G',W9"Z^"8KO`HLYY2JU'3I'$JB?04R/?0"(X-2U.
M1.D:-WQ`5S&2NBZ#'F`!?_P>Q@(_L0LS5X@<GFVOI<6I$_B.8JVH5L/=#V*)
MX58/VABN]3`%#(L4XA[#-4Z0"!('&/[/=ZV)N:!_V/[&_>E@TM!3AN+%/GB^
M-6V;A&5TQT]O0[+>CH%MY=,P25<9)1O*CO;W8.):SMPV#5MHM!F;7W!R::D;
M*V]S/ZH9'F_$:G"7Q`>63G"[O8H%ONM@:%JAZ49#VM_%#5?Y#*=A1-(\V>9D
MWHE6UH8K$N\7@MW7!$N/[M.BF*K`1MQTVJR09MGI<,[)=9'YID=R7L2^X8;<
M]3^X[W&$3-*]]@4>RDZ``Y?F;N`B/S9$^)+SZ2"P)9$H5LG5>.I3UQC'"#XC
M[F)^73U-;'7LZNUAK>-IH]VYZOLT$1>#W]_SCB=V3[)ADT>J*>+P>!NXJ0$:
MHJ`^,2H83STYK7\._?3?.<Z>]Y5RTZOL`25W#T',S?[GVNT;LG?U<=!F/[S%
MC>M]NMW\C?N9NK9L7C^<Z$Y-NZ*9VS0@O;L0`?_>?$B+_^Q$G,Z@YUZD)9QI
M>-BF<$.G\6)V)3WQ_Z?S7/FS,QE\#B?J3K1?$&W=R6T6)-ET'<JVS-5@NQL^
M^]Z<29/][$M<SI_GCJ0IVTLMPJ-4U!E)E@@/Z4:$(^C-DW!&,#L3Q[/HN3_A
MB&?Z,FLD:53F7!,.`WTFDFMB/%=/<]J(.6V$&2#G#!">98`8-C@Z)21(TCDZ
M>HZ.GJ.CY^AH[_)MS2'5@X=4%W]5I8+^^MQ.!FT39^V&J6;PM2W3P?U=_Q'9
M3N=I\#!M6VF<>MD11@PZFNUNH\#M!@D(#=<_8Q_Z*VJAJ+::6@>P71:R:)_V
M=EC"XL*C:'3WIMC+O`UNTUU)V7_&Q\%=`T_?DEU^AYS<.04QI]DC=#!C/KL#
ML8B^;K;WBVCY]>)]\^2!&Y2P*R3V0>80.F3'\PJ=L!O>-73[Z6ZZA.[G3.L"
MT5;.EC_H1#[32E@CN4ZW54RI?^9_S^,LP7&*PTZ]@YJA8_\@8SA["/?SYJV/
MD$E8>HE?_(WB:RG&4/4U+95Z^P/AU0/UKD?4)08K=(/8U0:.5\<D+D[Z\B"Z
M0\GZHY9#&6QT(.\SP.A>O*L:&A$C\VL#J*-T@AZ',KO2XE6>I5D0+ZB:1N@$
M[4?7I1.T&=WL!`=&Q#2<H(TZ3,.OQ^,$7<W3]JW<U;*MS3YNH-3<N[R2DG%_
M:4ZJ]QD=U@GU(>X$DV)8:JF];NW3R8BY]^%D>-QG)]/QC$[+R?#$];JBDE,M
M?=]L4%+.R!J+PE/[8-FE.VFQG'U(%W,W#<?1DM'T\GQZWL+@<8@33EWZAM$\
M#>DRMJ4K?Z#SOJ0#^3KS`2,KIWV&']$UP7'V_U#"+X"C:%5[5,EMY3/XE:@D
M4/7T\?TZ?*3)'5,)NL\]?V^XR+NDG]MB@+?XB?Z?$'O2=C7T"=J]!/Q!5-0_
M`@6CJAQ?W^<P_/+=,:)#VXX2/2))F6YIPWHY;D'#EX!#D)+Z!Z)H6!42^[YV
MX"*Q&%DQ1N:YV?\+L:AJ6D.CN.E+P"-04?TC4CRP"I-];PGYF"RMYI3=XU$K
MDJX1U8WKN)0T?A'(A"IK`&Q*AE:B\\N8P,F6&4I0MAMQP%AO]))`*%3.<."K
M#VFHRK-<U-W1W_;[JKL?1.H3`:UK.)2V?@F`A*NK?V1*QV;ZWJ$3A/X@U:Y+
MNHJ4MJNCDM_N1>`1H*(!D,@?U4#1]%(,%D;#!BGWDNK6'#QR6[\D5*K5-1PV
MN6,;*-29BU`VKMU*H]B.B0K``UO7$"IM_1(0"E=7_PB5CFV@Z`TY0ND>3+7.
M5+;EH;/=]D5A4Z&J`9'9'ME`H8MR7!8^GEF1=`<.:<Y#)[?YBP*H6F$#8I0[
MN('"^.4P9?]@_W\%`:FP,0^BG,8O"J`J90T(3\[0!HJU4N^/BD4(?(,D:"[:
M(;6:OP2(:BALX#U2:W#5)JGWXC:*XTXH5$$$W$//%PQ7':4->?0IA>RG<4"V
M#,4_BA<W@*HH&A3U(`\5Q4A1ZZY"BK[>>JZ3`AJ@>26QH=.70;`-:CM7_)E&
MQ1^[9)S#5.R(@C0P*-;!=?O')*(2D80.\)'I\8)^R^(4U=2_3ZW-^0:8D-<^
M"'KDKCYU.ESOZ!Q]I5W_:2E\JQ]#+=3Z&<RY&$\\<:>WAC/1[;;ZU!D.Q=VF
M>#@/8E+O9W8A8)EYE2T,*+4D';K&1/>.`5`2HCM7T$4%!YM`OE6,ES@,Z&HH
M#$D>9SA>79,(AQBE%X($_/J$!P%_,,*1XZ^5R]I8*4;(V^67UF%K>D4P]'[K
MEBJGD/J6JB%(,)$E?Y>U;3XXY;?U#7DZHMN!3<')UW3D;/=WM:P)+,&7M&VS
M`"J_K:_X@HCN!E\"3OZ>&-4/(J@*+@FUFKWX]%]I$!;'9=*S),->F@4N=7MQ
MM=:X+G<17S&Y>T!)L$%YAL/T/`Y)LBGP0<1O`/6):VL.'>+!3]M,9YE8*DI4
M/U)O.-6:1&<88[H=KGDK$E]MD`*6D.;\W1>GN>_0TU"&6[#)&?=?,8F+K&\X
M0FE&8E2>/G/0)&I20U"[R:#+"<T=#P')R5E$P/A4>&CW/Z;HJ,,%T1[?U&4N
M<5;<4ERC)&0:6*D/?X#TPB,@);V'^++1D#7X-)F/*>SYAD47Y.@&A81*_!=:
M7#VBY`2E5'Y6`'5;:X:#2"VZ&A*!=!XBT$0CUL@#,AW3@[G6D.$8@Z-J2CCJ
M"3D-K(PB:=$%#NYQA#,J`!4IR='BC&IW>YQ`A3M:)0@)%E:ZI#4TP4D]A)>A
M7JSQ!N?K=9VB4K::M,=YPF9QN[<)M_]#=-JC1=P\Y`$2>X99*]U8H5:7L^E[
MRY%4X:.+U1"A1<K,<K^@)8GH6%S9OH%/27M/(0G5@!,42ICYG6F_O$_Z'J<;
M%%*=H(4\.:VJ??/&3]S>V8UZR4+VI%G8IGY/WFXS^/F@6MT$)J"P'+.@_]U-
M=[O?,1T>?]^0^.SDZ&BS2<AC$`GG7]JNA@%!.W]P`!'4%`N"OOL/<I"Z`=G+
M1V$;CAL8U3M'73>@^T@1Z@;:+PQ'\4J;(?,2!0DKL'5,&],O>W1"=]@1V;!-
MS>YTFG_;:]%#PW5H]>`/JNR48^-NM+B:'NQR'=$0\R$-)R+ZBS"1YGE\#J*-
MQ/T[C3@:0,?RD!KB*O1#H'DN]X/-KBY7)_,Q3#1[Z#"4?;W&6:4T5G"1;N=0
MS#9SG,`R#8J#.SP%A;O+2B$C[LY,BP8FT."E/'2FB)BI@!LW)^6XOVY4<MI;
MI;/*%7E1WJ_N'\3U*U1MZU4LQ&W'.ON"JA1`H?7FO5%E0LQCOPGJ*GI%/-^*
MEI)8%D_G&B:PS4P+.>QO1YR]X#^^%;_5;_Y6?Y6__\VOV1,)93-?M3[=^][K
MA-RS@.FCU2I!*[IV;J)#%D.K0WD80`NC]&ONS11B@PPPQ_W]D4/<+/*0^HX@
MSI>L`CA=G+-2O7A!-P'G:1(@\8&E-NTA=J"TWJ''2"F6^('RW)^(N0O621'5
MY4/M$4=U42]>#L")#D)XU$1^@45;#38H@3#;'T^Y@L?OZ`&'$;I`0<K>^7RC
M`Z([\2`.(3#1)Z[!18?8+]@8J\4&/CI,]U5)7,'H'SA-\_6.DQ`QTG8U<`C:
M^84#B+`V4R[HOU;^8["8@"T,Y1X$U+81"R!HZP\N=(0VQ8:"QSX\M(?SQ@M)
M.@(=,MBIXX4H%8&Y;'OSVGO4,\1[XJ%H69-`V'*L.&Y/!]&160_(%\W`4R&3
M,=T?'\5Q'D3G<9@PJ[LC:KB`".JH41#X!QX=#=AB2,&K^FB.XDG/7K"C-8LL
ME/K.PR9</UDU\0XA"BDM,='N?4P%5^C8V0G!]EGL&4G*32$7"]*6!Y`0M/00
M&1"9K0$B8#*J0KC?@B>\9ON`\G2RNF^X6MZ0YR!BX>YWY+<DB+,;%"+\B'@O
MM<P[J=\-&73B'?*L-64)2A/^YDE8.@$LE>\A>KZAHRZV**=/&X%G4[2L0T_4
MTC]\@62V!9&(R9B*XNWP?!7?!A&Z6E8'Z;P3:U7;^D&UN*UW:('*;8D7"9N!
M8OF=/O;;B:?_U`]$RG_HIR#U"HL66K&`IA[7@;(VN$%JF2$G7A7^.CW+V37B
M-QRSM4"U!#C)T3E=I^;)/U`@?/5GWE$#Q28=>8EI:XTY0+C)&"K/[*=K!DM<
MU%AQ@OAV3Z:0K_<T;<P+==8GZ.N#J%U_^8]ZMD`OU^:72+02`='(D=RDF0)F
MI7IPC\XFNUV1IX]];[K[]K\_B!OOV^C'V/?N^ID"BK7UU:O?W0UA'U(R7:@?
M2_>#9IV8@?S8ZSVBE:;Z@_=Q8]_8=SXM1W7/BCWQ,_^,5=ZH6>FLT<A+[$DE
M=8"M9O\#Y3!UE-D%A7F"L^<3M"$I%CD^0:MF%I=F*R_A(Y?5`7Y:#*H#^7%<
MW4C$$9<]@I'`(KS&4>@(*)'Z72FT&H.<(>!9Z6$QANDHL&VM76JQQLWJM::C
M3SM[0BHI>]+ZO?E!W__N#1Q4LAG..Z=;JT>`;B98%NV[JV)V=)]F21"*OLY&
M?32`HMG'X!DZS&16.QM`#3JC(0`\3ZL"W;!>1UX^N=V"YWD&#]X7^Y*FH]%)
MT++KK>57G#PO=C.)91"1=!JY;1H3V6@SCJEL%SJ!B"2;SGWE$D%/5N\V'4WI
M]@!#/J6\-LTI/6PS^BF5B*0YI8<]-:UTF`Q':;`QR7%4AU2*PK<K\OAN@?`6
M3?0?31#1/_WSE'YNZ,:3ER!(]'.IY_;/PQU9Y/<I7N`@P8),?>J&S8,+3L/!
MC$(X$41#LH99-/L\.([@].5WP-=<U&\NZM=/9;6YJ)\=2)?X+Y0`,:EJ6X>@
MN*WWB`.JP3'`Q%S']$#3EZKI<XVZ<=:,L-700#7J1G%M=!KA%3O`*F_7MP^3
MV!]8@N8C.D7H450%2I>TAD<XJ8=0--2+-0KA?"L`CF(U<9MO-M'S_H"56@J+
M7.*Y>WG+NG\7M?003C"IK=$C9%.]S1@%6*[S)'Q@N5.*9^%WY"NZI2*G+(GY
M'2E?518[Y@@M;O#J@?LBS;R3^F+5H!,/T6>M*VM@FHQ@%VD^CMB,*FM<O-A:
MV2YMRC7)Z'_B(-I&NI6>^RN5=G$57Z)R`<'#L*LN#THSVG;I(;X=Z]$:[?;C
MJ;`_BJW=9<ZVFU?+^FDE!\VR9C6$\IMYB#J`O-9(XO,8TSF2:-O43.(K2;5C
MT@%@7RSJP$.H6>FHLYVQB'N>4JYDP_@%$<,H)BSF\M?7[SU_)'Q$];3`4<[T
M4$:24GV=/H51OMB6ZZ5+[TV^5?75\C1(8JK7E*["B^,#K@ETTG?S)L1-WYX9
M3I>:M;(IQP/S^T4FVZR2^#8CX9_707*5%*6O%K\'48XJ026A=T!*3L"=DM)3
MM.MKQ0F606R]+EP^EW^>RS\/$0^*'E&<MS9<HI^;D:"[GSW%D$`^)Y#9]VV<
MRL.Z-+W^7:KH(1"<"'J'.H;'0!I2$2.LF>'IX$4+E*/3ZJ>6=S7%!HYE[%V2
M9%V(75J#H!PCG*AY@Z,@\@U=NGJP0Q:`6_52ZJWV`VIS7)G$OUZ@51!M`R$Y
M&).TJ$7!MEIXA!ZUA,90X7:]P\4G[>L3-\`8[)SEZS._`\E;OAXXNCV3D7/T
MR"SZGP%C,^MEJ*:;E:%M5EH:O?DX0%I&O?$^@-_60X1#I+;&IH")TZ+P/:)*
M6@R^@2IYX?A#5`G:>H@JB-36J!(PV2TQ>EQA&&QIA$79=<C`VYI1E&;7V*:`
M-C;0`NUJOK"M3;M,NU]^BV7Q3DM9?B-DD5XB?M4^.$'SNR@A&#'T)._JH!K0
MAAWGW9V$ERGD9$>!/3]A%&TSB?*I*>?M8J.S:K]YV(FO=MK^]BGR?:@)VLGH
MA03#/XA22P,Y5=5(W"'F"#I-;>7I\`QNW(W?9;#FKU%TR4!'#'6RX0'8PZY?
M><@@5*0(P]T-6GW,4!]L_V;`7WVS6_^K(MZ+/6R\0=2@<9BA12&NN+ZU%EU]
M_0VC&RFX.6@CYOK0@NB>]<[9PEAZG9.@.@GY'J<;%&+VYD#J;97MFRMQ<7M7
M%L8>?YV='!UM-@EY#"*A14G;U2Q(T&YPBU&KGL`%%9B&D$=E$X*^35/-NG:V
MY?"O8GZ6,&F;NA-MM_%G^E4"FDX]I]\QO;%GR+Q$07*'DO4Q;4P7R=$)W<5&
M9',0CRW^Y!KVT'`=6CWX@RH[Y=BX&RVN3L-(AI@/Z3T(T?\0BS3/XW-P"B3N
MW^G*>@`=RV\%ZCLBJU1+`LUSN1]L;72Y.IF/85+,903'<XZY.<?<G&..OZAA
MF8W6Z"YXVB?NO9"D"X(TKRU7Y,V=)6!9+E%8O(Y;_"M/Z?9YQ_:&?H-87C`4
M+#/NBDR7M)Z`!4PZZ(40:,:(E38X5T(RKKMD*V!NH\KV(QTUR_=Q1G_4AEJ3
M$`RT/>%$8";01"<@V_.J"MIY`C&2ZWNS)J$>Q`K"*4&LK8GN(%;P&E/U>?68
MKV(S)U:CTP)803<A?+7UT!F\"E9C.BE3#[FH:6N$KP-*+825E!/"&$\7G:&L
M9%:MQ<:1%@HP[!_$#&=[.CV4,;HI8:REA^X0QE@-E**$BZYR;$=IFJ\WVY"V
MB#VLOR,GY=`*D:E@=#Y"Q$+:DI0E76GAS;*G&@*->_(&DVYT98A28^9#Y0'A
M`O</G#T\D&B!XU4IT%5\1A*$5_%6"1R(@FEJ8`30>`,[7?D-`09@XW5)WIV;
M/W#O-R@D<8@CO)WY[`Q1$8.(71+E="#/!XT%!\X.>VZ<4#OIV0N@=Z=+`W-P
M.ABO@Z3V1;M)FAX'2?*\),F/(%F(7ENI"82UU]L$7B$7++D%(&4\2IQ]&<-G
MGB./*#^)JJG\TF8,N4B4$A#M*RH81`YR0LA[[S_'R)P+`HH-HPP0,CC(\CY\
MZ/-1IIMOT$[4HSQ[*%*&2E[[RALWOCVBQJ.'C):TFNA1]5V=YWJ80&0JI;MU
M(*)1LAN""FZI;K^"X>:GD';>5_I*0M5<Z8%=OY'8OUW9)L85QD#+&]:6H:*&
M@T=W*G5/-"05Q'"*>%3+4%'?(TER1P?^-:=#B:F+H^.\SXN0SN"'$!4P@L-C
M<"F!-RC1DMP0+2H>_6<]$J%F>]%817[)X")K>8@3?DN?``*0U1P9_,Y-WUMU
M=`U77@_>/9`\#>+%)9:\OX(TYR"$W]P[F`"DML0*GX/7YZ^<);DB$P6`0K0&
MXU&,!V82><0';!HI*"2,)&=L762>&(4QBUX&`1?X8%-NO@$2]^_K#JK8,DM?
MK'!:\$X>1N/ZVV<*S0,''?>^ZZUUSN#TF=<`,_\M>,+K?"V=>VZ;QNPWVHQC
M_MO%T"$BR3"P+W`NZ,G7)*C?<*S&`:]-$P>';4:/`XE(FC@X[,GC9Y^+`&&#
M5Y_<[<<)"?/B&6V\V)XUUG+<"5:)NF2U[0B,K*>;PB,ZD@4;S5D4K#CWA-S?
M:[>$C=\'/<W7F@^BEH]SL@]A41U;-[K>^]R>IO8X3YBVSN@2.XC8ONXT7IRT
M@Z\@36L3+F[JW=P#I;:$@9C+/M"D)T14P[Y&"28+,1RD[6I8$+3S#@@0>2U1
M(&"Q/X3K"0)W2<`"4V^?U_>D&<8N_+TVY8W?O9MJF7R64]SH>O\8L*>IW0[P
M#Q1%_Q63'_$M"E(2H\5YFN:MQ3*X?2M]A;"]=U#0D=\2&@I6U3+\;V]__N7C
MSST#YG<2Y52RY/D,1ZA5;5'9K@605CM/@2&7UPD@6BSV0'C_TX?>D5"N5&[0
MAB0L-K8(Q!8#0MZ\A0M1<T_A`9+>"4I$G/9@^?CEE\^?>P9+`=ECNHA9D>19
MB!%NJQ8T&JT\181,5B=`:#"HYK\H#]+KW%_G]Q$.SR(2-(]%I&U:\W[0QM-9
M%\OI9,X/NJ]F_%//\WV#5BRL)(@SEN%8..7\9JU9;S;S=.*ETCJ9^R:'?0:;
M?I<%=-`)J_NQ0$__A<2^7M"NO1!HMO,4`')YW7SZFRSV#T?[A<"^^OPV<?E5
MGJ59$+/]KA@/`*(V.*1$OB(%K@DWL)'RJ[XB_9U,5!+LST#/Z%]X.PM%2\[9
M8ZNE=QB!R>SH_+'%9!]//`@8MN>A,#APV@H!<=#6<TB(Y78*B@,V^X2,/<."
MY3:6(*'^,V?RMS][.]\<Z1Q-\;;G_7W_D%?WZ3+%B4G*9N[EO:`VG>3>'DA1
MN[)74K@*A-YEH[\.GAD[SNA%36K#;3<98\5"4?2I0D".02@85%&G[8[SE'9(
MBBQ`+,//ACI`%BCYZ^OW^P^CTT*%/<9*7>`0Q>FN#*,@6DK0JA$OU6KE"YY@
M8II!2M@W`%4?_8RB+T44/OMM_-R,O=W][!M\!(+9X6;?:;6K]RXNMQ)!\91"
MU$R`CQ$\FK#$B4!0-WC9=PYP-!_\=#2\`L("<,F:-@#&;^H;R``"VP&-SP``
MMD\.P#;<EB2;=R1R89+GKT$4Q"&Z?4`H2VMLB\=;=U3W7VG'?\H%U.V%+S2\
M%U_,VXV:S'='1KS'5.CF0(#MZ[==B3)CK.KV(T(KO!]O\6JH*D>(A7-WET=_
MN&]5L`D"\N*/T-RL-8_"D"582:^#9X:4HWA!_Y+D%!4XN,=14=FYC,%2[',L
M>FJL5(UZ\L5SN%.7W3K7B#]DS]7[B2'7JAO"4`]Y3.(8%84?68[J8Q)1_)*D
MT$^9$)7$I<`<FW?27\TC6/8W^*--&_@2]RH5/`0U&&7U?;4<'<!2?AE%+OV&
MBJX30F7)GMGUVK]S7%0)+KP*IKREYF':RZ%1Z/<R$5.P5%\G!J`_)L@Y2=^P
M[V2A=)4]H(1O#QH4\H7/(87O.-=7BUM,@_A7EQ':&!W)O6>IB=^#4+*>@35N
M8Y/;>$*P5"NC,T1R65?O8[UUF$RJ&_(<1#4%R+$H:LT'8[OUQ-"H4$>G<&SS
MKL+BO,9C6P=R1(K;\S'):S\Q5"I5TBDN>=RK<"4_D7FZWD3D&:&R%AL8H6"Z
M!E(!=%-!K*Z*ND$N8!1#U==SE6"4#@.E6:D?.6SEC1M8%36>"D!!RN@&E2+6
MU161`R@.=T<TWPXY63,M%GA[EG.&XR`.\<$`:_EK!3?*UOTTUUCZ_7AW+V2I
M*LM;(7WN$[A1)L'L+ERX"XJ]38`7IT\;%A-.OT?%X=I1FJ(,>(ELT$/#16CU
MX)MS,%>/G5O0X@NY)';@+>R-M2;$>9Q2116%0R2W7#""FJFJ"`9?Q9H`BA@H
M0[""U6!?74NIV$+0-XJ+UYH@MWF\2)Y!N.,VY2.NT70B6),IH!.4-1@"\.7I
M`6E;*X*/M+AAXUO,:^@K#,'"NP&AC-T88TN<+B!W5P_R56*K&7\I6&OF._@4
M@KN%7IL9Y&VGU\`K521W?]*VTMW(9)P@1`6=@+')T>^+GWV9R^,@?:"Z8/_%
MHJL>@XB*EQYEQT&2/.-X]7L0"5^Q&_;2>G^JV8OO&+93FUMT:X\%X(E=A(T,
M="(7;#8?#$[DG`;Z45U?DPB'6/G`6TW`#_/C$KC:75X&69Z@J^4N,CDM>#W+
MWGZ!:6K[30#-X(X",$'$3`/RBSD.PVI_"6#D=<7)KT&*TZME0Q'/<@R:$3>,
M"TKL"2JM=&($3UV.[NY_!L`I_W,+@ZD6;0.E0%K/0&JB$2N,`AE6$'W[^=//
M?L*4Q"%BV7"9EFYP^N<Q'3[.V+]$X%13-"$IH_`-B&#I[>`G8[,#W9<O7W[V
M\RM^@NXSF"^4M&S`C-O2,WBII;6"%;?[?:I:#X%T&B0Q%3J]1DF1DQD&*B!5
M,[I51>49V/2T8`4\):M]Q38/07A&$H17Y?,:*E82Q&E0O.=-Z1JB^)\19*OL
MK+\&<"WZ\PS2KC1G!7:+0>P^[9XN)\_7FP`G+/+G*CG!Z8:D072UO"#QZ@(_
MHL7VN!)F!#9=-4.]C;KR#/H.]&6%>C/^^[7LY[_]]-E/S!<IDNZ")R"N%<U;
MSQ1$S7W#)TQN.PP*>=3V3!\_?/$49X]4,20!GG6JFK=P)FKN'<Y`<EOB3,1C
MC[.?//V$7Z(?-24D)*;_#(M@WE3GJ-VTFP8L];OQ#*Z6>K*"L3YO2`RLGP<)
M51::ZRC8E@"I4M'`X*Y+WHKF@9)[!F]#O5C!&LYS[ZU_\?4`_X8JBDX>NZPX
M08\H(H6D99C(5F!Q=`^4LAW1HZ;T#*CZVK#"*(A=;='Z^;VO\"SRG=^@D*SB
MX@$@S)^"Z?C%#F1TW@%33Q.6L%0RJX'RE_=^[J2*(^BO08H6QV3-+*Y,M5A@
M(%Z<%W=O^!&Q#T@J]:$6/36+*)CTY!F4[;5E!6XC]O7+UD^_>`GW[RFZ6IZF
M&5X'F?#E`[]1`Z3-1I[A3RJC%;2:/>]0X^"K/5BHK$GECCE2MO9D/WQ`BSRB
MR*#P6.;1!5XB=9D$,%']X3Z`R!-;-=*!<;0LA).[<-G!+'DVY'[%+B-<Z["D
M"XQ;3-?42QRR4XG6J(&ARU9=\@.:#;OTQ)]TH#\7P<^&XYB`+\HCL@F029&5
MV279['EW7SKA\6CQX1-M=#7)F[M;,+EG;L50+W;[6##/9F'R,=VKL-+I)V0=
MX%CW2J5-";U-J5.Z6N5?;&MUD.1YQ^8;6M^CA+.X5[:MK>DE;0>W$9VI(7JB
M"Y^_*CE6:WH)IQ'8`SMZRNGG6`X68.O60PM!:]\`HR>^'624O/;/T(8+,,Z3
M&+-WG52,,_S$_I5*<:,F:(8(2PA\10]8"6X`)&-7.1X7YX%C^HA_?6:Z.'K"
MXH0Z8$KH1[Q..5YH<N2#A$4(US:Z&-WS!X5&U/F.X"LI'"?=B*+S#*VU\=8B
MA,*M1C@^=>Q/+77UT::$*J1..5[[:\\WQ/R$6M$UOQU[D/75V7J=G>$FB%>R
MST'K]V;XQO[W8660KJXX+7ARC&;]U-8Z@0@CP/RNMX/`D7HO(_B`?`N>\#I?
M2Z>1VZ8QD8TVXYC*QH@)3"39=&X)ZA/:Z&D$FZ!O.%9/*:]-<TH/VXQ^2B4B
M:4[I84\B*QU`!=JGJ)!ON7"'(=`:=!"@+WJ=^=05+5I:]Z'G&N_]$W*OU2Q:
M(CG49HU%TZ\/<RT8WJ=#WP>:E%N2E^75*MPD+=<+ZVDL!8SODF"A2'0+H)!K
MY)!B<'OOIH"Q1"WR^T-'!8P/^7N]+YUK;+^$&MMCK`_C"+\:E8YT:AJ!JA<-
M8*<W*$3XD<WP)<I@ABHC$5@JGV1X4X4FFM80762-JOS1<A9>9^B$%"2!U"(9
M6QD2.'ST:XVH\7+89^5U]:\]V39A:(38Y,ZWR9CO2YY\,-(<YL%7(A#(R^OE
M["[_"'7&`OSQFHA2OA1-_$&31#13T!QV657;\A(;+Z385N=EM;HJH/4W7W/[
M;44%;3Y`NXXQ;#>*@4A%D8HP&CM0+_-T0"]>V%ED"Q8NZ$:L-*W*MU`=MCKU
M>BER4H[XF*1"2^*V:67O/FCC`41D4FE#H]%9=9?E:;PHE0;':/$5Q?0?&;N0
MVDI^1A+V/\J_IY<D#J5+%.-^VN#2[<</`%IIQP2DN@Q=)D(84^"E>.,%(8&&
M6HYI8V:4Y4USAZ:5S:V^5?,S;[SV#;/V13+\OG@`7%G=/!G<K@N@9W3Q!&,_
MB95=F1-,?I@@;RQ8ZS4;>X9(D,Q6H!-Q\/K>I2TZV-N!O9QW6%+*:H4C7N_&
M7\XQW,S4!-JO-N$?3S&-&%D\FB'+MCW211&F7R)6TTFYD5*V;Y=L$[4?DV%)
MYI'H"Z\VL3:_1M$V$1_/WW\VOD.0?;N\O7Q!X#?<H,+;PDW"9P<W3Z\:6-68
M.Y2L0;Y-WKCIT`6-_8,92&Q;C(F8>+T`O49QNDV[55SA71,J-\IP4E0^H']E
M?T#K342>BY<<^].NE*LWT3E0-UR:1T>NN?AG"-TJVM:"G(]N*B=>+.M=1L(_
M'TA$!4K9L5[V#%_"@\C%JWD%^9#I@=8X*TJPL"`F4B0#0S%+!29<VBLIVFF"
MQ!1CLG_8'!,37:C-6LJ\D3A(S+2T5C\3AZNT86BEAM;I.38UM>(0H&K.)4KU
MZR^.]BQ(YPQ(Y^QG.B"T6/&8((^SA/$[ALC1--A>69G,Q;3NJ6J"J:U>;>O3
M@58O6+*(EIZ@-2LO%KIVKBV;]G.?J+TSU-X+PG=_GJ$1K`F'4)3QK'9`GEY]
MW%(%%6<U5\LS'`=T6Q=$UR0M:J,I,0DG;:$30CHX3K4D;$57Z^$2PJL=;-WE
M&L<CA1L>G#F:"CAWK^\5CA8+O'WY<QW@Q7E\'&PP7>*P\R$2%U(+'`6<L/D*
M!4`X`LSJ?+ZT=2'$*.3#!>'F^=U]31;I>V5!,\[9\6$SS_"ED-,*3>V^O=Y8
MWZ`L8/'^IT$2XWB5'H5AOLXCZOL7["5`B$4+'SAAJWJOFM`SO&GKP@J!$&Z>
M/\D`7T.`+QY&>=5@N^ESB2K)E8&#,]R!4@ZF)%P.EW1P\:\\W=X9WA%6;9NN
MH8O4.N<Q'26Z("G].TMA<9V01TRE^_K\/45T@7*U04G`+AB/P@P_;I?4BA?9
M';)J+4>[8.6J4--OU#.R(5S%1^OB*<=9SG!S'M^@=(-"NIDY+>(P$+K!JX<L
M_;XA]*<J5*.A77<=UDH^V78XN-/J%&ND`ZV+7J-U($=5GLIV_-H1!5^V3B]&
M*[8,&/KS385.,OS7MO1Z=7P0KV3/QR$D34\D)9F\G1AHKF=+@(VPQ/HG+Q>J
M)X@..L2%:,(X^7:35FA\O<F+0:Y$,P,A]7!$@$0_@Q:,(PG"JWA[T1\^WR5!
MG%)YZ&BKS\_W.$%T5?S7?N'<+"%GT$6SJ)Q6%R\&VQ::'0C[>B/6WAJ.:X6R
M7Z#=!JV\^KOL`P*KT2-NV`N4^,58BI$V![(1Z%@-[L/'91]47]364W2"MO]=
MTU!Y?:(XD=#OH)6X$M[!B[$58ZT.9"\ZXZVN4?S<"$B?`)4O?DZ?-K25L(JC
M?@\Z[\2:/;P8FS'7ZT!&HS7@*C#3UXN>!XJ3K]0S+%AI;BJ2;"<M;]R\\!$T
M?C&X!VEK((B+QN;U53K3QUE$?K!`7?I/EFXZ+53!2H679UY[M9S@-(Q(RDJ)
MRU=2KKKEY)^WZ];5G0T;2832]/0))2%.Z;*ZN(N\*@Y>FN?%<(+:G8N*8'"?
MX&R.B8&&!#[`=DS578AJ+`/%L'.A6*U7S^-:."/+?"G*3\A!IW$?-<`:]#$Y
M#-OJL6-8&PQOH*\;%^FW^683%2O*(+I:TL%L55"8YGF:YE01B'=?9T1;0[8&
M[>00;:JWCI&L,2RO0[?;AQ'MPE?@TRPQJ?(<BT<Z.-8-3I:DYU)*_0A`#1^'
M_)R)QU\;O6,_DX7DJ]5&-*0S,,;EG4T6]1HZ[,D.Y",R#O0<IU]O9,T#FX"`
M3HGV%MWD@"W73,<8;C'W^IBH+5]5F$S'6W-HE#`]H)D<1,4:Z1B>!XRU3S/&
MM<9@A5\YQ[J<_83BU-*\HP:,33IRM4FF3$.$%ND9!6ZU$[I:UEZ`T<%=+<N[
M&-Y.V:R#VG99MX/!K=IBWHD#G0E,77]4U>98=S2^9^6%:VJ;!"^G?RO=9ONP
MWFVGQHZ!WZGGIM*);IV:CZL1NL\DUF]QJ9W_:.2.%\6!J"G:I:7$%!.!.5PK
MG6!8RM[SY`%UV>I7<]6%G2AX'$PG@:N`;H*@A6BH<^@*!F%ZK$_-X)X,#V"!
M?O87(I:;%D!'L+6)M*,1'4C<T%$F.*3[428%^$R"3Z8\EFB2C=7X(3"0GE!(
M]:-G^Y*QR`\KFF/8?;L^:VQ8O#BSX*C(?LNBV:FQ6_!KRZ)I&4YUVXG=V([0
M[RU+4)2I*(-9=FN'(AB9HP'1ZM"LE^9:4;>7B9B(G?8ZL0GM(7E^W5[)>T>.
MPG_G.$'0($#S#@3@AW0P,=QKZZQ3R$-&HWTG.3*TUW>)[;>-$+CK]R`[&%#U
M,!7`&VNM&\3K#,?S<R^!IO2S;YEW!-L?:&3.&H\=Z&:QZ3Z#F9[!0'/;=#)N
MK^-L#X07FTR[3=L:ZFTF`G29Y)T@M,'0Z]@IN";LCWHT.S5VY7X=]>BCW9UN
MNS(/JQ%Z?=132_)?O291+78@).)"%QR20=_KLF*.]+_8HO:1+G=9H#1*,%DT
M#\X%RC#I@O,.%][%X&X!-/W$B8;4A2E:(SA(U*[%N?HLOO?2COFR'E'/EB3/
MU&%)BP+HT(+`VZ*="&KE.ND$KBV6%4ZUMP:;`OBG\>`G39UC]9\?9K0"M-(O
M7K7W&UN\TM$DV0@+,X'GQ6'F#@<39C>:G>_Q],#O=+G<YMY^"A^">(5NJ.*N
M8CZ0!0[(I(N&%]+KPCO06VC($N!ZG$LP?YE*J3C0Y%B_RK&<(A/^[O.#^SM1
M\$C$;B9*RM^X1O`$)\KZ5L)RHB"W"WX>`=>SE52:.8^7)%EO8:(XO=*C;AYD
M0:F]@[&97BRQ"V9:`=;/.M?G,1T&=9NL^B0U5V$X-;=5*WJZT6IXI&DBAT!%
M%H$+QN\P"KK!QYT#'*BNV6`US=C#5[R][F:+ZN)&9(7HVDTGH:5)'YP2I1I]
M#%J8M1SG?EQW=-J_1N)2P3`BL4:X1(,["K-I)X9J$>5,TQE$L^RKC+GW+B5.
M"4;)XL-@KH6]I03[$'GC5GDE?F-7:2(.ZULQ;JH,BD"*6B(()<7@]JV8$F(B
MN<"*^:RJE`U*%I['+5;+F3+I!!/P]"F,\@7;[M5D5RPTH>2"%:B:W`-$6NI$
M&Y[Z_'98_3@)L,(P"8.>SPCK"$@6D:-C*=D<Q_,:Q&`-4GSF8MIKSM:HM105
MK,I"<1=[1I+MGUEQ$78WPEF76/126ZL8]>*!+;O1D-&:QHAMY0OZST6E!]']
MN(NZ()?Y^AXE.NB4=@`!IJ`#WS$)T8M;.`HXCJG&P^'8KQ-,=_^;(-H6ZKY!
M$7N-=T?.8YSA(+K.D_"!FEAR1<4ZBB)2'`%L,Z@H$>J@;R%XK?KV$M?NM.D`
M\E:#`=05-MB;CB09SZ&>SH(0;54D643)FG.64?SF'F!:4V;C38&X?Z]O?@$?
M'6J6(?H`@AJ`7HH]*;VW8(1KQ1$ZI0RKMS6>'M0=2EIMU=G:O+@A7URC)&0J
M7(F.1?0[D$)6WH&WF-70BR/0RCGNMEU30.VW(,O9XN2D?6``)Y"B\I#`6Q1*
MY':$ND,.U:?<3Y#-:7'A.+-.?:L&&B2]K0.@#76D/!\H]RZJ*L9%T5HJ[)BB
M6O0^%\9Q*[!OQ40C4[+9?GN\J=TF"SF*%\U+ZCVX6"4QE8';=B>X^]7OSB,7
MX4AGUK?)^OQ]=S(1'7.>+`;T,TL<HR(@,<'W.1/MFFJ<@31>%"DVKPF=+Y3A
MI(A]9MG8X!&WCGMO>3)'O;NZX3E=;R+RC-`MH@O9HF#/?817!5[*C(Z<JQLX
M4>U.!D(T`O_C=O:)H<*$;LG)\*I[&LBPQE2(F[E6EHY]-]Y:8<Y:RMVSG&[^
MT39["0^]YKW4X6S2RV3Q;:W2G@!O,D[WCVKM+:#0"_WOKRBF_\KJ^CG)65%R
M)?HU>^`@']S#U%%OILI^$0\>8XGVSUX>E9;**X5DJMG>YK+2YF05X[^*][Y,
MB<=D3>5[8)I]1/N<CY<H^RW`,?OG5[0D;/'^)%\H=L.+OVQTS6N*AMGG]'1O
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M'W0KD-=/&SO1S^^$3A,+!'CNVS'P.??A&IJ<9^?@8,;\=`]-D;RNJ>E40S<X
M_?,L0:C^C+$/]R#CVZ5SX/.=78/U;/GE&/@"N4M-,]0)8S:?+7ISMG@;/J!%
MSNJJ;Y/!L"S$-Q2+"2Y".#,2_IG^1M'-MKNR5S9.^JJ=6%KT-2$_ZE*KG9Z#
M6@S2[WW23F[^EZ&0O%+)MO+),^BUFKN.FPL9!QU/R,(ZTW?W2Q$'(_8\,PA/
M!?5%5UT%;/&UA>A^`69LB?9,`%9IP^2%6*BS>1C$6FU&[_?AP:$R6O<RC95#
M>RWQ/<:9U?>T$Y9RFW;,<OH6WN4<]6WOCF49*'VM:^O?/XU-'G&(!(<K43$6
MS&IG[!]B;(->BPF!FWY'_(1V[YS?I(V^V]GIT>*="U*:^R^>F[M@G\+^FA[E
MV0-)F`J^QU38VG*H".?\^GSZA)(0IZA(Q7G#CENMM]#.&.MNL1TPGK0GZ&F^
MAM^B.Y#([XA#CH)^(V3!C@\O28P.'6EZEU!]4!U3U7Q]+NIN8I28N`%K'@"+
MM^#Q0HS;U2P,8L<6@W<7,#C4#5]Z'Z)@?D(PRFN^D6[2V`ZVKPU:G5?7F[,M
MKTE[[.YFQ;]-V58(TSO+:.#UEALET.\(.L_0NEE(MF,N#4MVSF6P62D'B19\
M&>1/_?6(&SJ$$@_NWKJ"%+%4I,"!.1YNW:-!A^FKB]IFTRF*6#"O?E&JZ.@)
MB]P-@**5NU=",3;)3\@ZP.+:R0`:F/05S>"V#IE/8J8"@;E*.!YF(Y9R\M7B
MF*^A.]L@0NDWQ*ETJ6S7P!>GW5@QU0`)@0NKAZ0MGSJ6./U['0AW0]5!I^/A
M*%Z<H$<4D0V3O_P:26&E0=D`&HC2/^CI*\06C"".IA$G0[NW6Q31/E>_H1@E
M041%/%JL<8S97C'#CZB44N[ZC/IHGCSH]>$?;FV49(M@3=ZF\1-<+`\P-]V>
MS9"^MO*"6>]$NCI:G$OEU#=.&4_PO=I0V)".T+P8<C2*:QM"@B1=96B^NGD1
M5S?*UXJIZ+DB[+K&4?^:X3,:_0_N6/N/DC'5_N#!,!H#]_6DA<7S7`9K)#W2
MXS=JYJ%L-'+U'+1XH_</NAF\^T'N'DB>!O'B[@>*'OE[>!V2VN-.-<G@ABN8
M!6(DL\"V#GE43RG5?0\4_:T)F%NZW(H7!K#A$8+`<TCH+80D\CL"TB&'@?*7
M@>%T1O(D0RC6@A*?2`&C)I&'$)+*;0V?9N]>!Y]68DNN%GE-!%]BWN7A@(@1
MW99)5Q<*?#3OPYI].5V6#7H*XFIIS5&\R5&'Y7!X<W9XGN';0MHX#4_K)-)5
M>BG1$:?+CJ=M(,Y5WZ=9N1B\TTN)'HWQCJG[:GD>+UC^RSR()!]4:=N&R0C:
M3ML*(`KJ$]B"\9@G#C%'*S]_E:GA%<O;DR!#N\QLG)U%![W7<URY['UXLW#G
MOTG7VA=9D+4(NWQ8+H<^T//?#NRMK.(2A!GU)"Q]NG.;$W)P9G<<#K/M:<["
MR.V/,_QJIZ1MA(\HN2?#'W:8+PG*I$2%8M+S>'MW_@?"JP>JIR-6XGN%#EXH
MFVZMW(]`=P_F<@03\PG#SV*G/F,0\?*4BD4*NB!B?@63!&?/O[Y^;QY1Y(N[
M$:FQ^(_?49KMJJ5+BP<Y9N'JT(;+XJ5Z!/-Y&(?):XW?ZQL18U5PG=]O"4F=
MG[.J.;FR81FGV90-9V7<%BT3P_2J9-0?Y.*OJ@1$[?1#%^0'2K;_PFLLBLKL
M@R7(V%VQ?%%6W\D\#6C^KN3Q.O5FZS3_#YP]%*&<S.\]X,T=.8WI7#U+(Q0-
M>U%=[ZAZ&=S\Y'<SLDL<+04)C(3+77I5H^+:_^T_]TBY>LC!?X(G:5$[TFVU
M&!]8@!@@$)&A$)'SK`Y+6[R<`&.H1RYD?M\ROV^9W[?,[UM`+G-^WS*&\Z/6
M_F0.RQM+0-(<EN=IWHLY+._%AN79OD_WZ=-Q^N^<;FC.8_I!S@L=7F4/*+E[
M".+R-/>2Q(\HI=_R&Q)%9R1A1*X_,U:#</5),AR$?U,^WS;Y<NYL9Q=>WTP9
MB=[7+9:G9>,L-5*>[K-OZ64NR_;5%1_'SH+#9W85G<_>Y!P%1V#C:-=)^`FJ
MXR7"6<[N"^/%Z=,&)]L3],J9=N0WP'P=^Q$`W]FO]#Z[D_,S``5X?;ENJY^K
M/$NS@.[HXU6GRQ,A'\=NA<-G=B.=S][DW`9'8-,'<9O"S9S&B]E5&/+YI_-0
M^=E9].DL6O/W@MR%]G7JUEW<9D&2#>XP6*#B>9KF:'&2)[L'!]N@QEH4XRZ"
M4;A',>ZH:?`&'<T6;:__\1FL@42FKV1&'4QOY*-D+P29PI?=7%A9#Z2[SS]X
M(..=_ODM]?R6VI6=3?+MM;%:!GNK/>V+,Y6F*F4,ZK.,!N':;6D.8O9<P\_]
M-)V7ID8&2O(\CO5V[8:S"\?EEGMW00*SJW+AJCJ9;3]]E"M5#)3@;AS.27DM
M.H#+<C*FOJ,49O?6@WMSB8Q).CU+!<T1$.J9&_8P=-@3T-F1#3K;DW198%68
M7MM,,>YBO`ZJCQB-V46-QT5U'M/AI9/R.=KC.B$A0HOTC():)[@#3->L8:6F
M\]>D+V2YSW0UUDL",\"@*I!KHUR\3YC,G`X4Y#-XAKON)*PVI6]_^N0PL>T,
M.%=1..,&G864U:W5VP^?72+/HQU'ZYKOCF4].X^S!,<I#GF%BX9@W<VEE8+U
M[$Y<S9L7#@0F5^DROOCI+62QM)?H1_&3,,N%%K%..'>->*HV9Z*[?JP&.#)(
M,1%?DY?/:8OGM,6C2UM<?I6.XL4-W3'1I2M=T!;&6I80H\-6)C8V[J.6^MB@
MC_%!4B\YLJW:W*9/-AB-WPF6@R1=9>$B(.EF3K0\)UJ61JO.B9;G1,L.!.@\
MT;)_!T2M_<R<,UEG&SGG3.XE9_)X]HQS^N,7E?[8/X<^/PYW.)#Q3O_\.'Q^
M'#[&)Y;SXW#;Q^$&:??'<>MDJZOY>?C\/'Q^'CXJ]V7V/'RBZ2WFY^'VW&=7
M->!L^^FC'#\/?YFY*[QX<C0_.)J$<YK?1!H_-])^L#V_B9S?1,XN:GX3V:>3
M<OXFTB<8M^]6YR<\_3WA^335L]'Y_<[\?F=^OS._WW'M8#E/C+M;.HO?,W?-
M;/8!YG/CA=6+))GZG:G6]?)<O'J$!@XS1:^+5$M%[*L8]4MU`9RZNUU?,,[E
MJ$=K_*I9\M;T.8+-%WISF=?9[$&SY*W9B^LPSE=E<]G6V?AA\S1!\_<Y,>=<
MAM4W"QU;N56X`9J75=6.XIW3_,QI?D:<YL=QQIY=6I9C^C_R*&,G4R<X02'M
MA65Q*7*BWJ+D$8?H.B%TM'3;J4KAXZ#3=DX?JT['!TBC)#_N%-M)UA^KX74&
M\78NHFY0WPT?2'*KV3:Z5G]/2;*<6)"#=TM#9=.:$VA-.($6`_@#B1ABMZG7
M+TF&]N+<4=1\I?S_E.T2=>AYFT,8_>`>L8,$5X;:ZSZ!%7Q@OONW,"4A#H?+
M$KA5+YLN$E/9I!M':=N&90G:#N9ICA8+S.8MB*X#O#B/CX,-IM/!7;]IT33D
M5M`,[D7D<TC,A!<X!"ZONITK>)C:MGD>6S=8HQ*O25PX,2F^A.T:F.*T\P='
M*B%-L</IM_^\QV[P<H,R*AQ:G`9)C.,5?U,):]Q`CJBQ/_`!B6N*(5'G?M>8
MI7HH3MBEF66YC5JKX\-&PXMTH4KI*6PH$NUB3"DW^9-"-.03W<8<]'RXU&[W
MZ.MW=R=+P_!3269+$(T(/'P:GW`$D-H<4OS.1U*=@']!V3A[*VXDTTN472UK
M9<NW5XR<0U]G?=8.>!WT.1Y`MMT6Z49S*M!>U%]R.!I`]3#K[9>__>V7OM<.
MKC'N%MUN<3UU1`^(Y0,4__2SG^G.CA;_RM.L.%V\(X(SAOU!Y*&.Z"<KQ1FJ
MKE.*D)(;%))57/0B>X[<%]O6B5/7;$=N;0/I7\LL^QMCW7Y=5C_NT7ZI4SJ/
M0[)&%^)'?]PV#<MHM/$$QC+)C##7Z+!:?[]_^_&#P3IE)*%PVT57+4I0%BG.
M:\>+\SYLYPE>5!(:88;3Z1XW7SY]^/S9[S<*)LB1OQ&8!G;`\?6&Z&&?I8^?
M?YE>A'OQ]740X*[N!Q;?+NO'%W!::L@,NOI,]]#^^?-'3U]JS\\V!L>U_9,+
M$V!#GDM\,?OBCQ_9<\%P1ZC5+0!NCM0:IX,EA:?IL"1?&T-P\FDU%@V3@:94
M$\X7!P)@>HS+@P!,<``N.-+6+WC)9#3'4J/7_1;[;S]_^NF3OUML<_B(-]E3
M`I"C;;880MN/HB&"1K+/+D6_6K;E5#RRT*(5!7?(:<<#/9",O-@/C=K4(&;<
M&)##.M)N0HJ&U+8T8*:F94BLO$K9/%YU)0MX.`FP&>8UQ/)QO?@PV%N(LP`G
MQ5IN_])$]9P+0M)P,'*2`8/6XT>49)B:ZPFZSWBC%.A`@[(5V`Z@'-SV07-,
M;/0A<`0RQH>A\`"&IEYA+`^EJ&N8/<-HA%<]S`31`,0?TP-,73^@HP-+#Z!@
MY;OM9P23['FX1Y+;\(F[X.DHSQY(HDJPHVK>P+VXN:7)IRA\NR*/[T*2QUGR
MS.3]J?H?3-2?:J*6?_[G^45#J/8/Y?#K/PQNFTJ5$XDD`N,3]<D,K]Z759(2
MV_FZ%,W7I6B^+GV;KY8D%O-U>5%_W37`?'V_%<S7_H?&?+$?O)JOEB06\\7Z
MVI\=#+8$V@UU_WU5+/\`%*+/`(]B>,GI)B/#\0K%X;/L8:&RO4CJ=OOQ@%XR
MAT1?=)4YM+G5EWH2+LX^1&[ATCH;!T"F10.`S87H*6>/\E]M4$Q']0\4B-YO
M<UHT9#MH,1XCD,X.@0BH`CZ/0QWZ!SV[V].,8D,A>:(J;ZS<3(SD4:I""IX?
ME6^?P*N*YK&YN'^1`QV)V0F?\^IX4`TC;+WL5?`1+=2\49_,P)SHK<%@!!_L
M&Y:/6>)\6K\W,XSL?_=KTD6"V<QSK<]ZZ:9A)U>>3:;=@C?!H\D;TYZUYI3J
M)(C9]=::1"<):-U,XK?@":_SM70:N6T:$]EH,XZI;(R8P$223>>6H#ZAC9Y&
M<)SP#<?J*>6U:4[I89O13ZE$),TI/>RI::6#I7(D`U]1[$)'0*=3PM;</06G
MM;.DW"R#\6]T"9ZR)ZK<Y!.B)O54V*TF@QN$2L\$))QT2=+J?)=0NM6INURI
M]E.^K7=99+O&Z_N<,B@>Q=^@$.%'M+A*MO_BG#0:4M>`HD7M"X;,56(&+RU^
M)?*TWWUV@;P;*BW5_L,)>D01V12RQ8O3>$4WLH@%]9\^L:0+Z!(UO:<A=0UY
M6M2^(,]<)6;(T^)7(@\>"?UEB[P8K8(BZ3[]T`]]6L@R9U\M;ZBXL3#Y#+=-
M*]SNH(T/^(*(IX\B0:_::3\/L3(T3*HLIM<HJ3)`X9!:Q@F.\DSX8A=(U4SO
MK:+R"5QZ*C"'FY)/M8_Q,^U64;3\.B%++-IV<%HT<'70PB<,B44SQ\M!G\8E
MH<?P!9MJ1B<-@!BD=0)`1)#;2?]6=!0H(3'9H"1@Y^M;J<J5G`@QJO9-](C;
M>X4DH-@6J!)SV#]1]3/3R=6A7!)_)&G9#MAHM_0)46I1S;'$[;MZI>JEFRH.
MUNHF(O=2JN9-,`F;>X4HF-`6L!(RV+V`ACNH<>WC6J)MU0&%UV%K%;JJUEZ#
MBRNR0VQ5_>^@U?=!IJLZ,]N#,[;EW)^=R;T7B*95=49*XQ/4=,0W!YR"2PD[
M7_U9>;XFC#!J_-P"4_6S7[CA"F4#D:I#KP-?;U%$^US]AF+J6B.*]Z/%&L>8
MR9OA1\5^3X^XF=<#2.P3RHP48HY!*+L2H?"$@>/R5W\@O'J@XSAZI&*NT&7.
M@DRNEL61;2VG+>QXW:ZS!H9-._,)TTX49HYQ4_:55W90]V6P-];9\`^L/7I?
MQZ^X$SZ@1<[JO]<>JZ1%H+`H98(N6;V&#HAL)-:O?$=GJ`BSYW1P9@-%33E:
M;^U$/"G'SEXAI"DJ0G<N<'"/(YQA)(>HH]Z:*S+3WGP!M%NUV3T;-1[#!'*'
M+'`V@MPA'GW:W$C>`MIUPD[4LN?K*-B&;/T[Q\5)AT`1^ATT]*+3@6].Q5@Y
M=GY$AZW77\Z6H-4?I*?Q0"H53IM4WH-3J@;'B&SRTCX^'34,F3[*OY4'+L>U
M*G'4`+^B&"UQEMXBMH6-0W0=/!>AV5#(VG-0P=N&@_>FX$R]CLW&9ES&P6FC
M-+'SF'[40I2F_'L9J!T!NU$9B[(;[RU"3U&.8:]D[O5]2TO<]JL62%,51L?T
M7L4<AYH/5/2Q5G^1HE].:0RQ3^9?#>>K#^>+C0D@V%1Y0RTE#-[<C-J[[H(=
M69CC<9`DSTN2%(76H?!7]Z#"NZP'[P$.5H]C1,OX#O2XM2,(LS326T1$$?G!
MEOE0Z(HI59#E47H/5:4Z'$.4Q\_R]>LXCN_GH_LQ2*ZZ&X20J&7W^)9/0P&.
M,L!R&?E^7X>'O*I[I-*0Y%G#WI44+<Q+*`:T]W)4XN,!7A.1;&,Y#E!/#@$)
M*+17(8-#>ZUW7!V5OOVD?R$QAA.`G31G+/3S`2U^(V3!3C98(H44)8_"0&\-
M2A&P9)3>X@VL#D<PE/'S>CN^D_`F^/&-KE\3'$1ZR%02BH`I(?06EU!E.(*E
MA)W71_`[`?](<(9.R`]QV2!10Q'J:@V]19E(6$>HJG7O=1S`7B"2_+F[L])R
M;FI*(<XDE/X"#ZH.5TB4\',7*370IFW>LXU!<O49C9I$+?NXSFC,C-_BC$;/
MZJ=Y1C/D2Z&7:N_["/[=^([SA!F(YML-&+GPL8:*W#>?8*@8._\`9^J[K]@$
M:#AO(0Q.5_@,,%W#2@!T@_D/X=A4G@-."-7&F+P%?*J)A4H$WD+)O.XS($PG
MX"UF9S%F9P'?;)AT`=70.#<C;EV)\1;%C5.9Y,:%NI?AKI=G_\+;S(B_:I(J
MP[KDPLV,BMQ/GV*H'A?^!,[:U)=$`Y_$B^6BG`\KE8(7TBU*\$JZ1NDJAPF=
M!9*PML\[-MQ*9:"VM6PEDK;C-3/.U!`]T76M:L^QRE,BX=2_$7$A<Y8G,<[8
M64>\8*'^.?W@J\&C056#$8C*1T#IJ\,>6B">IK=3CD&V&]=WNO)+CDE,OSYY
MR&07(@Q*4H.7FL1';&DJPAY8:H:F;X:'_OY?H"!%#R1:G*_I)N-Q6_9,6LH3
M0-'XWDLI?,.?OAKLX`?B9QKH-C3ZA#KX^LRT(*GDK4$)77W6*<>+2HY\H*-<
MT:)<%YU[_K#3W!K?R>V1+G",SC.TU@9IBQ"*T1KA8.HX"L-\G4?L2=4)HC,9
MX@(\]-\1*E_$'JU)DN&_BK_KYLERW7U#M>ZZ'Z^/:,.+=*Y?73^R&V/=C;@;
MF^?5#XM'D/1+'^"$R7/\$"0K84RDO'$3_X+&OJ(9(KL;;`HX55\U7U],[\U,
M`"]>D]8;Z'H33Z$DD=,)@`[[SU/:+]FP_Q%$##J8)#A[_O7U^WIL]_C6/$49
M1]WUS@$1=*U3$GF*)BU=.,&7BF/_!U\=0U'\O!-"`H7A.)Y_.@8A^%6H(P@>
M/!9U]U)T@(G0OHV$3(?PT$(P*]!!@.:FSMSI%GTJLR/:K?<Q.37>3OSW,)$J
MR6;`G.4WJ-A07@=4OW=)$*=!6,HF/;R!DK4J?*G(!BQ=QAT:W5'G<99>+6M_
MT].)K`>8>O@]#.Y.P!@@+G0D\">J01P65M-@OG?V8X-D^O6Y_HOD'D"_`Q@@
MN1V,0DW2H!QQ0XG8_)";\9B;;#(%AJ=SU0'G*K*T]@6'JRB!>J;).W+W@"Y)
M_`8]H3!G->I.<()"VA'_PM:8OA8_H$D_*@3Q8P=L-`(`T&'<@":S_0K/%7Z^
M!7&PVI:'8R$Q<9I'+._C&4+I'3E^8&>907RU_$J"9"$$D7DG-229=.(!G*QU
MHXTI$XXC_M(KPL6A9,"O^JB"Q6$?'ECDN$%?PC!RK;Y&9:-2A'!#RLWUIKF:
MD(>7:PU#9,V#GK>8*%*]:S(^>M$8#F#_Q#V%F;SRU9NHGJ>!.Z"F-0QVPC6V
M`ZZ7]VD5#0W^S-.@!Z!ZQOG(T^3C::XC!Y],+>:^/_"D3F7V*H-[%?773#-E
MC5XWVLOTT:6PZ6:%;I+/QNWB?&K);<+[=#.8N[FELA2G&E?+,QP'<8B#Z)JD
MN,"IW.7HD#:M"40ZF.LY)NLUB6\S"B^*OJND&.Z"U<9`URBY?:"F)]")!F5#
M)2#*P7V*UIP3&[V(]CB``=3="8BQUS6&:Q(6XJ3G:9KOG9`8H+S68E`>MIX"
M$"7RNP??(3.O2YVVI#K*LP>2X+_@H&M3J(!7IY@.^(1ZZ`J`=89>I^EO27:5
M9VD6Q`L<KZ`HY)"H8'A`,AT<BC71%1`/.+I+JBY>P9>_L/^X#U)$__+_`5!+
M`P04````"`#'A6Q&B7!?!O03``#;W```$``<`'!L>"TR,#$T,3(S,2YX<V15
M5`D``Q7[`545^P%5=7@+``$$)0X```0Y`0``[3UK<]LXDM^O:O\#SY]FJT9Q
MG-=L4O%LT;*<J$J6M)*<G=R7%$2"$FXH@`N0MC6__AH@*?$-2G82J(Y5>8A@
M-XGN!AK=C4;SXS\?-[YUC[D@C%Z>7;QX>69AZC"7T-7E621Z2#B$G%DB1-1%
M/J/X\FR+Q=D_?__;?WW\[UZOSS$*L6LMM]9BC:TOA(9HA:U/G$7!K]:4/6`>
MWQW.AG.KC_B2T5Y/(C\*]X-PUGB#+.@"%1\>?4+_O#Q;AV'PX?S\X>'AQ</K
M%XROSB_>OW]_KNZ>I:#"K0)\]?+EQ?D?MZ.Y>NP>F.B!>X1*$AV<8I4Z\[CD
M?HKX^ES>7B*Q`Y=WW7"'D`5^>Q[?3$$Y]FH?_.X<[J:`E%$:;:IAW9"?A]L`
MGP-0#Z`P)\X.3X]40,`K*<3:7KT_Y\P'K!@L2S)I8%&1HX]^`_`?HXQX`_\Q
M!QIP%B*?/+YPV`;`+]Y<O'I]D0([+*(AW^99+[#S8L7NSY.;$NEU[^5%;X_F
M8E*-`C?4._+@,!-6"`4[%`^)I>I]<B.'@L*0DV44XAO&-]?80Y$/0R.B_XF`
M"H](%F(?;S`-<P"9VR'B*QR.T0:+`#FX!3=@2EF6FE2(4@`(83ZKMK0U"`CU
M6-($C7($?TB'\0Q[EIIA'^3XN#P39!/X4G*J;:V&+$BEE[[N6\#Q"^!,"B''
M1X-TU?`!%`$DJYZ-]N]-'X&X4WI*20'`0UB`>4BPR$S!\^>BRD'^H50!BA/Y
M)A/E8N]0H@"%4&(P33Y:'DH3H&#_^Y(CG[,``BSYXVXVK)^V\80`BER$874E
M;DR?NMH]-'WL7AJ_PYIE]:QKYD12>V1_PO)L#6A(0EAJ89[SC1J2'\^+3R@^
M/!+8G=#?U>_B#$VP$Y`FS,(L:(^8'VG5>$EKRMVG,]U9BCW/Y44SRU\!G^?`
M%9SPO#\9SR>CX;6]&%Q;5_;('O<'UOSS8+"8=_RNX7>08WB@X?CK]ARW?IDB
M#E!K'!+@RM\["51*0#"6D8"\:I;`FR8)S!?PW^U@#-R?W%B3Z6!F+X8`T/&^
MAO<.<=P<^U5#LP3>MI=`_[,]_C286\.QU;>GPX4]LJX'-\/^<##N?^V$TB"4
MH"05G6IZ]TQBZ?166S%Y>1EY&@']=H"`[/EGZV8T^7>GN2JY+U!F?LB+)LY?
MQ*8I$8[/1,2Q%,/PTW@(`]X>+RR[WY_<C1?#\2=K"N*`2=`QO9+I/A)HSW5U
MU<SV5T6V`W<'X_G`LL<PX.^FT]%7R_XT&ZAQW_&\BN<!PGN6RXMFCK\N<GPZ
MDT;0XJMB^>!?=\-IQ^LZ7F?<W69?]T(9H3D^#\=?@*^36:<\ZI2'AWG$,^HC
MOFYF\]NR`K&OAJ,AC.>;R<P:W$Y'DZ^#@34;?OH,"^?==#*V9H/%<-9IE'K#
M)6.T:-C_KLC^_N3V=KA05DK'W$J[),-=H6/O;R6KY+,]&Z06><?@RM%++S+C
MEUYH6/R/\@@&13U;#*]&`VL\60PZ+E=QV;O?9-BLKIKY_+[(YQM[.+.^V*.[
M@74[L.=WG4:NYW;(,I:'O&CD]<7+(J\7]A_@R\/2-QR#@NZ&=+5F]D2&R^JJ
MF<UEGU$Z+&H8VS.P/X9C>]P?VJ.]YP[\!ZOD5D4<.R%4"8$'X5X&\J)9!"7_
M<388J6#)U)8NS6)FC^=VOPOP-H5)@HM<H"1HUN2O#@Z56+],F4^<;1<FK)-`
MF!-`\YA_?03_%VCI8]'QORY^$N8"*#K^MXR@=&QO#J5DF$YT+&\*IG1\UOB;
M6>WBZ#C=['%VO-:XGF'.]PR;E]+7>N>S&]U:QRC,>4::\:UUC3I^:WVD,.\D
MZ3C^-"^IDX?.7<K[2SII'.`P=:S7V>UNSFYO3HIY\_+P36;KEVL<(N)W(J@5
M0>0S,-GS@DC;=.(HS06M..X$]B+?&I%[+"SF6=,XLW8;9[#^)R*!3-SX>R<W
M?9J`F\\3T$FK(NS0E"K024#K]+HYIU?'_XJP0YW;VW&^T>_-\)WHN/ZFS/6<
MY]NQ6I]0X!8S"G1,?UNE:@Y(*NC$HO&2L^G$.F&\*PLCDV+0L5H7_*%9TTA>
M-;/[MPH;-1\`&B/.@?Q[W%DY6N8+QA`7JS!GGV9;=<(H6ZAY8<RCS0;QK31%
M)X'$4H;H#(N0$T<>;9Z'S/G3^L01E5<ALP:;P&=;#%Y=)SZ=^+Q[Q-@J)[NT
M22>XTAY!07`WB'#K"_(C;-E"1!LE/+&7HTAEUHE)*R96G&"LU=PJ[2D41%00
M1#=Y#I-*6>^UU'FEC,Z"7#KM]DS31BU"CHN8"/+3)W=#)ZY2!FC--*I:F'*3
MJP]0D1_"M?@5GLBQ$S(>XTW"->;6'/-[XF`9=+DG+N:=D-M:(!7FAUZPNIW`
MK.T1A:K&"J&K:CEWDM)+:NE@E!=4W**34VD/L2BG-8+F*P04P!S;!)@*Q15K
M\"A_@P'B^\Q139V8M!N\U,WM\,K+9@']H\J!+6WR=EY5>Q$(1C#/BR%MTHFB
MY$]5B$+65'(C'TO%-H3%"?@:[N;*#(-U2<E?G6'>)D/<S:>(:P7TOCQ7JK/$
M.]YKTR*R@9_XLI'W%R_+O"^E1G1:Z@`!N"3,BT`UZ(10TE`E(5QC#W-9F&Y(
MX9786J#'SM]I(Q`6;O,"40TZ@90B.26!3&!ID%*POF+4.25M4H@8RJ40L>93
MXF\NJC(G#DLBBCU(6P@<=A)JD^2%`H28F\_T2MITLBH'K0^3E>VHRH?"FJ*M
M3$!2+B4T\@CYXM<X&-#)L(4,>4%^NIW/BXKJ``?*;H;O,8VZ]:A-XIZ;2]S3
MR:8B`:8I=>__`?<_GA=K@R8M^1JBJH(HV02,AQ:M+$I:5QTWKO`[2H(C#2CR
MJI?B]613[^)5[_7%BT<9>CMOT8WJFKLM.Y`BR#>_;?_.FOJ]+5^JH.4;W_5>
MONJ]^NW(]U;7`F[3ARSF.$:4W7DO67_Q[LG=.:XKS]6/BL+%;3KB<Y[#>I:.
M9*LA'S8E4KRCID1MG>7V??"/GXM-19AK.E"+EU[T]@\YLC?%^LYM>I+BR!^]
M/7+['C26BV[J027B.?9#D;8T]2>I,JTZ='DV1B$L>A,/G"VN7B7B0Z4+_!A>
M^<SY<[>8?FL!&E?JC6N4?PC3]F&(-W)]`:JBI0A)&$EL50[^\DQ5#/]``.3,
MHL3WI65Z>1;R",`10'/DA)=G'IBHLO:O`H;W$^8NU+O<*.Y+`XG*L/V$8-*,
M&#@J^S*OW\IW8@+BUVP8A<6>;Y^[^TODR\E[>>9P[,I3'T=1I7;XA$W=&2:;
M9<2%NBEFV,'D'E9Y'O^2_=D3?!#2Z?!B!M85XL[Z&JQDGZE<<:!Q0%>$8G@2
M725AYG'F1.JW@Y!^*"]<O#R:%6F4?>+=J9SZ$?&P.FY2,:';P!HYHT=HR0"(
M\>WN;,`MWBSQOLC5MP:0'$DNV\#\?P9ZXNNCR+DE/A8AC"IPS&7SGHKRG=.9
ME','4P08BP=6%$[%+>.$<A<P>G-MVP'XF??(+Y)0<]LX,OI,/I3%VPLV!_V_
M4K>GG'DD5'O84\P=K#[1LB?O0+2$;*`YB%N_IX*(K=^P@>B!3U;RH<FLV2]J
M4FJVLR:@\O,3K3W&R:P$TR0^<@7S#,P<%&#HE2/D[@8/6(Q>'-6'X!@WU*<>
M^0OS9OKJ08PC9QX%@;_ML\V&A&KJ82XW0C):M`[`D#5"/T^G$=A?2&![(QVY
M!;O"<^"*D)^[6;#$*%7?K_"Q.R.K=9BQW8_!/1G&C(@C34^P1V,AVRN.8_W+
M0OB7(/\FDLY8HJY4$M*$@J4:Z^<,FY[^I)-1>.-(SN2)-X<N$9>`@9'U]:KO
M9HDC-,0KT`X_U[9-(OW[A)C)/>;76)`5E9&GJ7I:UHMI!6[(R#^&?BW%532F
M+_K)PLR;4=1-9^/>H-IO/%0X:$>B&^FS96AA=!="*B[0S5#FK='2$%8Z,YL!
MND_355FZ]@/BK@"5.O%N&/<PD?I6*-2,?GJ&1V4G@%!M/UGF3Z#I61AS2GKO
M&@<<.T2!@4W#0_)7_)NZ*KUBN`D0X7FOY1"<DUG&;R).E?B`"BGQ*,2\-LS3
M"M@XM;'KX1UU,9<'-.!A3I4^U$,:1UQVEBZD&SEFM(<?L1/)56QW`*6L^0]"
M,X[L](C4',P3+F?!9"EC"A*K%-9K`WLR\U6&R94>3HD9$;0D/I'?14RH$:"3
M$S>C8,P=A7QRK+F6N1CP_Q6F\"N$:1Q_"Q:PKR.YU5#'EM:()\.2-`DMR4&3
M*U62@68_DLRJKX/+V3JA9(667#?\X!+HBDC\@N^D".I[?JW45!L:4TCCM%Q]
MET>$8MFW5C+,`!\AR)]$X2*_EZH%/&Z(KK<RA!XM\?<<HFD0Z!9)]4+EM+[!
M6=KJ`$Y'SV3,X8EWC9?A4(A(/K?/1#9`I@4\'9)!2R!_2,$-`6]IP6J%JX$S
M;#.GC\3:QT(,'J$W1.")ISR^Y/QSQH#4P)V,'*MC(/V(<Q6VY>WC)M4XQBTJ
MAX2YC@N.F;?,Z'M?6&Y:(YB[[.RWJN)-FYSS5[AS.H&;?=^%"D+0$%B.J0,>
M3-ZDU0*::],V=+UHU+8`-5`!U?:YPJQM!VV>PJGM=4G3Z"!-5C$P%=QD^;MA
M/-&26>)J`$[&/%`FJHH#RD:@YQ[#\@XOES%R5?H*R(J;I5:8H1!G(\9'()^.
M+JXE;T^2VDZ(-X-;L*4&[\?NM.AMY/3LLG19BJ9AU3WC-'#:R61S]X:S36WF
MPK])N)[^10"ACM3CGF(>4Y@3[=*2X>7;(?48W\1;/,D+,L2W@C9M61IX'G:4
M2>O^;R1"[,:G[Q?H4>H>F82&D1?FMD1:8QCFR#9W7*9NW<#-MH3NX4^/3!:U
MEN<>_N3(G-"#A*G`3X[(Q9KC@\A,$$Z/T`=V$)D2W#0BTRJ.I5WFX@WCED*I
MZ::,T/!_,"\=)ZB\:1X)N[R4O$E>;#=LT-Q$JOY@)LY4&CX-(,9)09[VDX?]
M)C2.-`G9>3E_9UC(/=>)ETZ&.&E8YO_/<$AXX<#`4Y]S.CZ5.C.8J+3%FD4"
M47?Q@/U[7!P'>DCSAD-ME^?88=1M3V(>WCA"=PO4/BA>$=IJAC+-=ZCH;2&4
M50]A;@@KW9@;TDPN#"P2Z3>1IC"IE9.7IH;ER#T4]73TD(S/)%TIK4!5]XR;
M@AF9J$P![.X#%'+Y3",3V<,;;3$,$:/>G+A%%,4V0AQ;EJ6I@90;,#X7K+^6
MZ:J(3KPKAGA)^1Z#:]PHN$6/9!-M[!4(3]822;/<)MZ,;9$O9;U@:IE)3^5G
M&7`XKF'F9/%$<VDJUP*8)TE&P[6_G4'+2&K=I%Y`AI0Z@)/9:QC#XJ\\JSEY
MA#]%6=7<-DY2D_Z\V/5,DWG=]3Q0\5SMOL&R#?VI]=Q;@)I,WBZM>TBGG-S+
M^"UH+X$J<^$/Q3./<(IAEL031NY0E`BLN6\>(7%.E:HCDSN&DWQV8L'J!^SA
MJ*=#?FMB32=M)XS,QT-V<P[(4863DN^&[#X;4D/]DYYE'(.@ATN5[IO:8$5[
MI:*D0CL$$TEU,':%]#G2G-B))[-#&%6C6!VW2XP:D:/X(+R3L8:`,#=RP")%
M-/+@'1'X0?(3+3!B)]Y0<(1+96(.0#%1_BIJD`T8J$UT4C'96P$;1V):`RR3
M3YGZU"4*V\":2&"R[L1AZ@JB*N\;3,@U#I@@#904`,PC)?75)W2.9/6U5$ED
MB*D'^:'^_`%EOL!XK2OSE;EEG##V-?#DYP86Z%%];$!?,:\).D>D*?47LEVO
ML4IWIEH+Z@]\A)DLD4Z6<K?D#K+\6QK!M1#F#>3*,@F9/=FK[1XD,3U5U00E
ML6LP3.6W4U4*J*[VPI$/-</.TX<HGT8T5AG3LFL1\A>8;YZ+FQ4/SG+4D(HW
M1].8UF>26SG(]].3WU]`OU0<D/[.K\DQ%CMD@_R?S5>RHL0CCMS`BP^>RN[*
M^LO5AQ3:PINVI]O8[\+N;AM8<_=YTU#?0.:'@(E4E=G4!&/>"I1T5NX*U!&2
MO6<>`2$L6'6>?.5-`TG8'WG-6V?JE$*9J%;@YI$949=O2]3D6@WL=!#$#?+T
M=4,FOQ;0.*5=W>'D&$;^%&0;V..4]H\X"-G<^^)9R';0IS)0DVY7&1MM$4YD
MX!;MC$8H@RV,3+\GGJ<^:B`/0DFE7U,-XP`40U*.#N,#WU[%CYRO,0Y%49I5
M08]CD,T,=V0IB3,CE5$C6PYE1'MT(UFQ0(]7$7<QO29B5U%KA!Z*%H4.SCC5
MG9Q`L6&J;H)8!_M([;ZF9R-5,JR<V1@&LM307"`_1_%Q#_@NJOV),H[/&Z4'
M`BN$6PU@HE0+.>=5/E8SE'E$R8-@NV,[T.LJ![@1R#R2'EB:#E<53:ZY;2P9
MBOFRIY62:0(RCB1Y_&8L)P?FF[Y/*'&0G_GPTRXGH^0A'XQH'.E?\)HX/E89
MJ&#*9:I]U>]U'X)C','R9/^:^?)(6K*:362E#TQ6-#9;]G2V`/VA^ZWZS8FO
M1*[,^_I\!<'5W#9.1E)9[`*":I>MXC-1C4#FDC2AN&8U:P`QEQREX*4$JFR.
M9BASB9(_Y-^*K(4F&.,(FG(L<\GB$S%K@KU!6C$[R98NYVFU1#".5'W.P7-D
MJS[WXXUC8\YN4TI5:]V5H,PC:N<F:,C2P!E'6-5Y8UD.)<3EXP-M8(TC,#G7
MF)YTW`XIS#**U4$.:9TU%C;-%6-^RF,,B67JS;]"T>G&K-LJ)AV.?#*L46I8
M??9$9(\#E[B@@SN5-*4,'?'&9Q.E!8A3H;'N,Z3%,Q3E>K*'X9T*/_)U"J><
M4(<$R(_)V$5JAY3(#_NE7TCD\I-PMN\S5=,SMG/J2A\^Z9$FJHJ/YY*+PEGC
M#8++_P-02P$"'@,4````"`#'A6Q&D#/%#Q`7`0"UY!(`$``8```````!````
MI($`````<&QX+3(P,30Q,C,Q+GAM;%54!0`#%?L!575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`,>%;$8.?G@H]`\``!7C```4`!@```````$```"D@5H7
M`0!P;'@M,C`Q-#$R,S%?8V%L+GAM;%54!0`#%?L!575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`,>%;$:=9@Z=M"\``#^M`P`4`!@```````$```"D@9PG
M`0!P;'@M,C`Q-#$R,S%?9&5F+GAM;%54!0`#%?L!575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`,>%;$8%KK5,0KL``)<Q#``4`!@```````$```"D@9Y7
M`0!P;'@M,C`Q-#$R,S%?;&%B+GAM;%54!0`#%?L!575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`,>%;$8J'7;C"E,``*`R!@`4`!@```````$```"D@2X3
M`@!P;'@M,C`Q-#$R,S%?<')E+GAM;%54!0`#%?L!575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`,>%;$:)<%\&]!,``-O<```0`!@```````$```"D@89F
M`@!P;'@M,C`Q-#$R,S$N>'-D550%``,5^P%5=7@+``$$)0X```0Y`0``4$L%
3!@`````&``8`%`(``,1Z`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>29
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!5!RX0)0(``%,@```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,FD]OVC`8QN^3]ATB7R=B
M_(>VFP@]=-MQJ[3N`WC)"XE([,AV._CV<T*+IHJ"T)#V7(@@]OO\XL/OD(?Y
M[:9KLR?RH7&V8"*?LHQLZ:K&K@KV\^'KY(9E(1I;F=99*MB6`KM=O'\W?]CV
M%+*TVX:"U3'VGS@/94V=";GKR:8[2^<[$]-7O^*]*==F15Q.IU>\=#:2C9,X
MS&"+^6=:FL<V9E\VZ><=B:<VL.QNMW#(*ICI^[8I34RD_,E6KU(FSPEYVCFN
M"773AP\)@_&#"<.=MP.>]WU/1^.;BK)[X^,WTR4,OFGY;^?7OYQ;Y\>''*!T
MRV534N7*QRZ=0!YZ3Z8*-5'LVGR\YIUI[`OWD?QQ<>#C15P89'B^<?"9'!*$
M0X%P:!".&0C'%0C'-0C'#0C'1Q`.,44!03&J0%&J0'&J0)&J0+&J0-&J0/&J
M0!&K0#&K1#&K1#&K1#&K1#&K1#&K1#&K1#&K1#&K1#&K1#&K0C&K0C&K0C&K
M0C&K0C&K0C&K0C&K0C&K0C&K0C&K1C&K1C&K1C&K1C&K1C&K1C&K1C&K1C&K
M1C&K1C'K#,6L,Q2SSOZ766.J3(F/G_]^%N.8$YU=B-N6PH7?L^^&GDJNC:?J
M1_2I7+XXP-^S3W"4IBWOZM2R7O@0]G./Y:?J]]Z[/J02W-/Y`"\M][![TJ=!
MY&-#^Y[[4%^\3TP%^OF!KPIK&BKZBJH#V7S\2\#B#P```/__`P!02P,$%``&
M``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?
MM8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@
M8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*
M86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3
M.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?
MBG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"```
M`"$`0KC8%6`"``"P'P``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M(*($`2B@``$`````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````O)G-;MLP
M$(3O!?H.`N^US%W*28K(.;0HD&N;/@`ATY816S)$]L=O7\)(I!IH)Q=A+@9$
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M^B%LOJ4A8S[FB5]0>#6,U+!?%7Q3;!M#%ULVD"T$LK"!+!#(E@UD"X$L;"`+
M!+*RG:S0RLI>Y0J7N6,#V4$@NUF!/#:A$XS'H9>^U%6(R-6L;7+*_7N8I%PN
MR\LO7$_LDL"*6+9?+/2+99/80A(KF\0*G>/8)':0Q!6;Q!4D,;TXB#1L'T,;
M6W9I+/2-L'TCT#?"3G"!":YL(BLDLK+C2F%>N5D3?.P>IA0?AUX;"GC0Y=@'
M70X>=%6S[JL:?V@^M7[?3=49AQ#[V#7!)6%'>`4CG&U?Z%[+!K&%(+9L$%L(
M8F&33R#YE&X=Z!UEKW*%R]S-2KXQ!";RC4.ON8!/E-@A+C#$'1N"#D*PFK4?
MC>E\R-_;IO/9RS4**'8U8#'8QH6^M6SF6<@\83-/(/.$S3R!S%.V=11ZQ['W
MO&[<])97W]G7?P```/__`P!02P,$%``&``@````A`,LJ<-27!```VP\```\`
M``!X;"]W;W)K8F]O:RYX;6R4EVUSJC@4Q]_OS'X'A_=[54"][;2]DV+4S""P
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M3R`9K%(G^T-/@A`<6E(G#+@[XZY'D8J)?#$[?6FJ6`N"5"#QYZR,OJ8""3TG
M=XQD:BH^&9)%<'XG2&72=B9@<X?-F$6<D!/+<E=.R)PY]Z!L%L.)&>',?&_+
MP-?4"2@GSI0'*\^S'SB9^[3.,@IHA!-SU1;Q?*B%'X(IJ-"_5\RKBH3-<4*&
M@[8]<];PO>LSBL,?X?B'"J,V(_?,9C#KS/4Y77JV^T`I]]E\`7S@R:%SG8LZ
MO,#I<LG"FBIL=(6-%"R#!?$IMXC'0F(CLS&L[?>Y+G&XAD2Q>YMRQPUQF<:-
M!:FP-R/,YVMBKRA?4A*L_':%QCJ>68$N)/]06#4.9X[E+AL3X_4W5#FKH*@G
M(SZDFCG0"QBQ^6D5X=`Q9T,%-)_:=3?Q2`5*Z!,G(%;(H-%@#8S94.&LF_G&
M`L3`0<-M];=N(<CD^TK&$.H*A)?)YZ'X%</^B&0P@[K"(%H`%VPQBGHWBJKU
M!!.I_R^1P04%3*:ND-DBZX(])O.T2>)V6'>=#P'#19U@4G6%U(\)JWQ"Q9A@
M4G6%U&XXP(<S'!.,J_Y%7,&)LY"!BP2#%JY=39I/L0XNE?%96J>R%%&,<35P
MR6#0\@?C>L$8E\E0>.WNV[C>!JX3#%I>0!][:]S\@A>X-G#(:ADW&CAW1)[#
MT?&W_$\(IQ1W$D/IJTV=X)@D(G_EV8Z[!SB*8AW<2`P%WJ9.;9P6?)Z+%$ZI
M>#<S<">!06=</IQK\VA3201EMGG"_N"N8JCLX@WN%`SX4QTJ*TVD8V)T8=#I
M#\[/L6SJ8'1-!=UF?H*]R"6_%P4$9F7)`?N#T345=.%DV]B!@T;ML0ZFV%0H
M5G6"S5YNC[&LBH]U,,2F`O'E??T"SQ/,H:GPW.["3:*Q/PT=A>>VSE3N9)Y#
MFAE<!A.D,\$\FPK/;1T7KH'0AE_X@Q0Y;C4FYAD&;7XZCQ]0ZW,/G32$5*`[
MA:#8[T)X98Q4HCN%H-IGH1%&&@:MT#KV*VAG6`<C/:J1[M>3P-UO(^(-7$JK
MG_I69X[&IU-*_^U>?O<O````__\#`%!+`P04``8`"````"$`MNTI#\4$``"+
M$```&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)Q8WV^C1A!^K]3_`?%N
MP_(;R_;I`*4]J96JJG=]QGAMHP!K`8Z3_[ZSS!J8]5WBZTL2F&]GOYGY9H?-
M^M-K71DOO.U*T6Q,MK1-@S>%V)?-<6-^_>=I$9E&U^?-/J]$PS?F&^_,3]M?
M?UE?1?O<G3CO#?#0=!OSU/?GE65UQ8G7>;<49]Z`Y2#:.N_AL3U:W;GE^7Y8
M5%>68]N!5>=E8Z*'5?N(#W$XE`7/1'&I>=.CDY97>0_\NU-Y[F[>ZN(1=W7>
M/E_.BT+49W"Q*ZNR?QN<FD9=K+X<&]'FNPKB?F5>7MQ\#P]W[NNR:$4G#OT2
MW%E(]#[FV(HM\+1=[TN(0*;=:/EA8WYFJXQ%IK5=#PGZ5O)K-_O;Z$[B^EM;
M[O\H&P[9ACK)"NR$>);0+WOY"A9;=ZN?A@K\U1I[?L@O5?^WN/[.R^.IAW+[
M$)$,;+5_RWA70$;!S=+QI:="5$``?AIU*:4!&<E?A]_7<M^?-J8;+/W0=AG`
MC1WO^J=2NC2-XM+UHOX704RY0B>.<N(!>V5WED[D,S_XV(N%C(8`L[S/M^M6
M7`U0#>S9G7.I0;8"S[?(D,<8ZX]"A1BED\_2R^`+HNB@/B_;(%Q;+Y#20D$2
MA,2F,4(<BDAO")D_Z36;O;"`[L@9,J%S=J&FWZ_&C:)<I%&,*('D'N)21/H=
M!*.0[!X2Q".$A.'^GS#DHHT)E1K3&-JC^R%M"4)0AS*/J?XBF[T@C,#M/+'O
M)U2"0<AS)EHN$H1$@R"8&_B:/25VVPNG1*$`YG;7BV:1$MK00W/:4L,?ZT$N
MTNAK@DP0$B)]W];8I<1LNQXM0X9F?UB]\+Q@-!/N`>7^?LHE6..L*31!"')>
MQ+:OV5-B]SU'ZX&,V"/F35$1VN'/T)9@C?;D%C6+$*0=,%L[/%)BMB-_S"7J
M9&YV`B>:.H*0EN-8.^L^UHE<I)'7MD\0HG+NQ&&@ZYP`7-=E6E4R"@B"8-J"
M1`#'YSR"]]4BP1KS2828=H0@\X@QG3<Q>[%6E6QN#B'LL2J$,X.C>4[ZL?8<
M5FGLM?T3A;DEG@7^5/@AOE1#>!&;2*)T-$041%.;TS#D-/II]3"<8>24U%HN
M41@51AS<R8<"(O=._Q0`E9CT16.0PVD6P_OZ83C*"/<I.2@@A;F5P'=LK;-3
M#1&R^Q+@/LH'<U@X'<24OIQ;C].7:*J@V<&@Z"-&;>W%[M1W2D`$P.Q98RK]
M($`=\[,A0)G+2?8X<YQ[X'D<\I'6F@E##.[+8DW6*3&[L;8Z(V8_FA1)6<L1
M]CAK''B$]51(E>_YS%QXH:OI*95?U5`TE<X@U-24$;OO3V9*7$ZQQXGCS"/$
MIP92Q!&#GS(+)XX]#9$RB@C#6#N,,HJ`/F`_RKN<9S/Z#YZ8.`5)&%-^5!B(
M@4-/?J,O[*6K52AE=XCQ5%>"UP&S84:+((>:%D7PX6<Z7./NNE9KRD1AL&MC
M)XI9-/N\&FBF&L8-(N9.Z5:AS,=N;$>>']M3IV`P>"?$*U/-VR-/>55U1B$N
M\K['((_C6[R+)O(N.MPF1P-<!<_YD?^9M\>RZ8R*'V"IO0Q!ZRU>)O&A%^?A
MAK(3/5P"AS]/<.GG\`UO+P%\$**_/<CKZOAOA.U_````__\#`%!+`P04``8`
M"````"$`3;WIK7X%```_%@``&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6R46%UOJS@0?5]I_P/B_0*&!)(HR57#UUYI5UJM]N.9$B=!#1`!;=I_OS/8
M$'_T)K0/I3D]<_`9C^V)U]_?R[/Q1INVJ*N-22S'-&B5U_NB.F[,?_Y.OBU,
MH^VR:I^=ZXINS`_:FM^WO_ZROM;-2WNBM#-`H6HWYJGK+BO;;O,3+;/6JB^T
M@O\<ZJ;,.OC8'.WVTM!LWP>59]MU'-\NLZ(RF<*JF:)1'PY%3J,Z?RUIU3&1
MAIZS#L;?GHI+.ZB5^12Y,FM>7B_?\KJ\@,1S<2ZZCU[4-,I\]>-8U4WV?`;?
M[V26Y8-V_T&3+XN\J=OZT%D@9[.!ZIZ7]M(&I>UZ7X`#3+O1T,/&?"*KE"Q,
M>[ON$_1O0:^M\+?1GNIKVA3[WXN*0K9AGG`&GNOZ!:D_]@A!L*U%)_T,_-D8
M>WK(7L_=7_7U-UH<3QU,]QP<H;'5_B.B;0X9!1G+G:-27I]A`/#;*`LL#<A(
M]MX_K\6^.VU,S[?F@>,1H!O/M.V2`B5-(W]MN[K\CY$(EV(B+A>!)Q=Q%Y:[
MF).YCRIW(CT>"4\>&5@!<99><#]NQN/@.;PQN/LBD.M]PI,'+._R?<Z')^=[
M9-+(8!C]B^`YQ9'-YJ.?WBCKLNVZJ:\&K!G(>'O)<`62%6CAO-YR,L[TSR8:
M9AA%GE!E8X)5"&^A.M^V_FRQMM^@HG+.V>D<5V:$`P/+!V4C%8A5(%&!5`!L
ML#CZA)I1?6+]LIJ9[!-5T.<PPMT`W(Q[BJF!,81$`R"$$#DF'BA#3#(`MQA_
M*<>D`P5B).-0\JKQ&1C_?.$.\XE!L$2E^51>N&,<MMAQMD(5B%0@5H%$!5(!
MD%S``A1=W!\]DC<F_!:J4:FU'>,(HU>!2`5B%4A4(!4`:?20[^FC1[*<>\]5
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MJ8<.)]W\A!H2:4BL(8F&I"(BN\"68G*-$M:`P#DV+D5]^^8D>"6V2KA1+!WA
M1ZGID--OIJ.O"<2:0"(+S"UO,5L*/\IYDXH"<G*P[9B>'-:D2,G1-GO"2#PY
MKN4'@3"RI5(1(:>+R6$"]W;,6(M*1N0V<>H^FXX<=?\GV+<(:9A\`/2!\B+7
M3P!.NF<HY)P'9\`$I7B24L)9?)8<BZC-P2,9N8RP<Q+R=_\<(*S/DLM(630[
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MDXO*"K[#V[W/<'<5?L:/W!7<(>@ZB;N">P(=?R(!O"#`_]CCJ^'Z[I(=Z1]9
M<RRJUCC3`]AQ++P=:M@%(/O0U9?^&NFY[N#BKO_S!!>U%*X$'`O(A[KNA@_X
M@O'J=_L_````__\#`%!+`P04``8`"````"$`(AL<0EH)``"[.```&0```'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6R<FVUOVS@2Q]\?L-_!\/O:>GX(DA1;
M]'JWP"VP.-SNOE9L)1%J6X:E-NVW/Y(S-L7A2&38%VW2_H<<#N?_(Z7&]Q]_
M'`^K[^UEZ/K3PSK>1.M5>]KU^^[T\K#^\W]?/E3KU3`VIWUSZ$_MP_IG.ZP_
M/O[RC_NW_O)U>&W;<25&.`T/Z]=Q/-]MM\/NM3TVPZ8_MR?Q+\_]Y=B,XMO+
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M-XAB'`H&27`0\2<.DJ2;.(L*]QA;R$<M[W,S-H_WE_YM)9I&S#B<&]F"\9T8
M5ZXKFUV76)",^54&J5"A'L1N?'\L\OA^^UT4<(>:3[8FN2FV8O);!F)6FD$J
M]H>O[#4#&61F0.>W%2D_?VK/[ZZ`#!*56J\F%=#K4U7Z!!K5#<:"1=3[%RR#
M1-,8$^H%P82@*=6&E%F11TG.+UEL\/LSD$$T@^PV/F0`&L@@K^*RKK3"J$%A
M9K"\V5)LSAQ'M-B@L8M=FA/Y];<,<NTN:.P))?*)H=SM+(/,%18YW5W00&VS
M6IA^IK1U2`(RB":@FP<V%S1QI/HKW12WO3=V5OR[50"WGU0434#/``F@"#-(
M-N5,!@S3W%L0`[!,A^D9,`,0V;L>,Q3S6#5`:ADC:NB'-3.G!,RDU99-%`..
MC/4EM,=0A!6.__E!"\Q-#F)8[`,Q%"'%XCJ)]":8.0113![:5J=7MT;";0:1
M^'V"]_HF,M,@*).$\>@VFVE%K@V-:8#(HQ0,Y3QR`(09'5%$MU5B#E?.^90B
MB'TQ`[^"GN8H8DS`X,[#>,`RA_%`9,^9$,0M&T^I"=HLXZ$(C1=M8GV^&=V6
M!+%-19$4K/,%1=!M:515D=X$,P>&=>YN2X!U1K?EU'@H,HQ7S)5"`FV"/S_C
M)3**EH(:#T4>I0CB8,)PT#(>BOQ*(7GU_E+(*%**0@,?_"\?+82(,0'#/;?Q
M$D#:LO%0Q,Q)..<P'L,WVW@@NAFO+N-Z^DMWJ.F!(-0E#.IL'X((FJ^N\VJB
M,'-@T.?A0Z":PX=7]$VH7VB7&&G(*=_??"J*-)]U`*+(78HT"(LJBN1@^1!%
MI@_G2A%$QI0A8T$OWRBR/9$R&'3[4$6Y'G%0Q,Q)L+?LPY3!G>5#%-WN]JDN
M@-EM0:A+&=1-;`6H0Q%T6Q:)7[>[D)D"0SZW[U(@W[+O4&0VFWX,,M,@,/0[
M_U(&BK;O0.2N1!`%4X:"MNU`Y%>)(!"F#`@+_:R!/7$%H7PY.'UKE3'4<]M.
M1;ELAR+;=AFAW++ME)K0S;(=BK3M=`',Y0:1+6/(9MD.10AY:;L9WV4,Z=R^
M4U&D#-:]$T5FM\T<_1F!GY_O5!1-0Q\CT&TH@E+DXK7N7"4DSMY]WY/M:=WW
M]`R8`HC\*A$$PHP!8:$?KC$-$#$>8*CGX3L`VO*U,P,1,R?!G,-W#-YLWX'H
MYKO)>6_Z+@AM&8,VVW<@@F9+LSRJ9AZT<@9U;M^I*-KPVE*PS2@RNJW4+6F4
M(B?T\_.=BJ)I4-^AR*,401C,&0Q:!QZ*_$H11,)<1I%2E/H9'W<$1+8)<@9[
M;N.I*->!AR)F3@FC">>6C9=+-5F?93P4H?'2S>0_$LQN"V);SK#-,AZ*D/+S
MYUW.H,[#=T`QL8V3=Y>6[ZZHFXC*.?L3^GGZCJ&@=<_,0>2N1!`%<X:"MNU`
M9-INIA)%$`A5%&G+DKYF09%M@8*AGMMV*LIE.Q0Q<Q+*+=NN8.AFV0Y%-]NE
M,_?,(HAL*HJ4V+(=BJ#9XGS>=P5#.K?O5!3-@?H.16:WZ=/((%!!X.?G.Q5%
MT]`S`.11-$UCXDTSBR`.%@P'+>NA:)I%4>I4S32"6%@P+"SUBP4LQI6%]!&O
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M35`QX',;3T6YC(<B9D["N67C50S?+..AZ&8\O7ZCV:H@M*DH4F'+=RB"9JOK
MN(YGCIJ*09W;=RJ*YJ`M!0V/(J/9JIDW*Q6AGY_O5!1-@YYX*()25$F=9'/;
M$83!BL&@[3L0^94BB(050\()[W%'0,1X@,&>A^^`:**+)\_Y^L$5YP21/6=-
M,+?L.Z4F6VWY#D7HNW*3S]PUZR"TJ2B2@F4\%"'EB_E'O)I!G=MX*HKF0(V'
M(K/;]+X8#*H)_?R,IZ)H&M1X*/(H11`':[B]&6>_93P4^95"J.BMSV-'9!0I
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M?!4?$FS%9[2BC1`_]_UX_4:^W;Q][/#Q_P```/__`P!02P,$%``&``@````A
M`(;]PY>F`P``Z@L``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULE%;)
M;MLP$+T7Z#\(NM?:+'F![2"VD+9`"Q1%ES,MT381211(.D[^OD-2EDDJK=)+
M$@W?O+Q9.)S5W7-=>4^8<4*;M1]-0M_#34%+TAS7_L\?#Q_FOL<%:DI4T0:O
M_1?,_;O-^W>K"V6/_(2Q\("AX6O_)$2[#`)>G'"-^(2VN(&3`V4U$O#)C@%O
M&4:E<JJK(`[#+*@1:7S-L&1OX:"'`REP3HMSC1NA21BND`#]_$1:?F6KB[?0
MU8@]GML/!:U;H-B3BH@71>I[=;'\?&PH0_L*XGZ.IJBX<JN/`7U-"D8Y/8@)
MT`5:Z##F1;`(@&FS*@E$(-/N,7Q8^_?1,H\2/]BL5()^$7SAQM\>/]'+1T;*
M+Z3!D&VHDZS`GM)'"?U<2A,X!P/O!U6!;\PK\0&=*_&=7CYA<CP)*'<*$<G`
MEN5+CGD!&06:29Q*IH)6(`!^>C61K0$90<_J]X64XK3VDVR2SL(D`KBWQUP\
M$$GI>\69"UK_UJ"HH](D<4<R!?7=>3R)YVF49N,L@5:D`LR10)L5HQ</N@;^
M)V^1[,%H"<S7R+2./M:_A0HQ2I)[R:*X(`H.]7G:9//9*GB"G!8=9JLQ"]_K
M,;&-V%T1,H&2-C<,`>CM14,J7-$)%/7U<EPU2B=;8Q+:`K:O0&S$[A5$9$/R
M(21;]!`KC&08QO2O774-0SJM?2A5G\9L/N_Y5=ZV&J,[429RYQIRPV!)`M[_
MSZQT@I:V)-U"UI(T9JYZ(XJG;NG-XVDX=[QS\W@V2V\IM\1#[DSQ_VX'"79$
M+]Q^T!@CCZXA-PR6E,R6(J_5>&FETUAI-<:0Y!IRPV!)F@TEC5\:Z>1DR2W.
M5F,@$WU'IE.[(7?CD/P*D<,CCF^5L&*0#ZHSK<9CD$Y.#(M;!^GVU!@CK:XA
M-PR6)!AHKJ3Q2DNGL4IKC"')->2&P9(4P2QT-8VG27DY>1K4N@.EZAXODLRI
M<W<\4\=QEJ;V>6Z=3V?IS=\.0`[^_ZYSI)\+:PXMG$&S[4!&6@>6W+38NN1L
M=W2-%SO2+P+,L/Z"#$=V!S)U:;>;)3<QMBXYSAU=;RBX?@2L?`T+KD%Z<"?A
MK6#JWNQ@ZY*=W,WU:>)<?+F5W<YC&-U]0^@`],JE-Y(:LR/>X:KB7D'/<IV*
MH(]ZJU[UMG+54\M:?P";5HN.^"MB1])PK\('<`TG,YA(3.]J^D/05KW_>RI@
MQU)_GF"GQO!`AA,`'R@5UP^Y#?9;^N8/````__\#`%!+`P04``8`"````"$`
MB]#!;Z\#``#-"P``&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R45EV/
MHS84?:_4_X!X'P@0($1)5A-@VI5VI575;I\).(DU@)'M3&;^?:]M8&UG.IO-
M0Q(NQ\?GGNN/N_GTVK7."Z(,DW[K!M["=5!?DP;WIZW[S]]/#RO78;SJFZHE
M/=JZ;XBYGW:__[:Y$OK,S@AQ!QAZMG7/G`]KWV?U&745\\B`>GAS)+2K.#S2
MD\\&BJI&#NI:/UPL$K^K<.\JAC6]AX,<C[A&!:DO'>JY(J&HK3CH9V<\L(FM
MJ^^AZRKZ?!D>:M(-0''`+>9ODM1UNGK]^=036AU:R/LU6%;UQ"T?;N@[7%/"
MR)%[0.<KH;<Y9W[F`]-NTV#(0-CN4'3<NH_!N@P"U]]MI$'?,;HR[;_#SN3Z
M!\7-%]PC<!OJ)"IP(.190#\W(@2#_9O13[("WZC3H&-U:?E?Y/HGPJ<SAW+'
MD)%(;-V\%8C5X"C0>&$LF&K2@@#X=CHLE@8X4KW*WRMN^'GK1HD7IXLH`+AS
M0(P_84'I.O6%<=+]JT`RHYDD'$G@=R0)8F\9QNGJ5UBBD07FG5A"+US%09S\
M7(NO\I(V%16O=AM*K@ZL/5#.ADJLY&`-S),_*IO9L?\S#)P2)(^"9>MFK@->
M,*CRRR[)HHW_`I6I1\Q>8>![QL39TL3DMSRAB2@FA"B5F+K4`C[D-"<&9NN)
MO5_P2;\`"_T3ZUX%3+&Q*26_Q5@I%^\@`I.DO(4DV0PQ$H+ZWY^0`&_=I69V
ME%KJ]@JC5KVP,K<#A1THM8"A#2:Z7YL`PS[2M"7V0M@KS&I<2@OYF6V1A<\5
MY(?\P@Z46L!0"^M<5RO6?`0GR\=+1`RR5`>VHPJ32M79NZ(50A-M!THM8(A.
M3-$?BQ5@6ZRU\O8*DV12[=);9L9G53Y86R]7`S3M=J#4`H;V]%>T"["E/;.V
MWEYAE-$!&&TM#?5:4VH'2BU@*!7WOG8<?NRR`-M*$U/*7F%B:7*01EX2VP=C
M/D&FPZ>P`Z46,-3"@7N_6@&VU::66H4)%E)N[*56-KEZKQEK!THM8$@%3D/K
M?9M.CC)%!Z$M>@2-AT6R>N^P&#&PN7[</M;E4U@\J20R#2H_YC$S%C?3W6L)
MFJ#;\JS,V?<C*%%;-HIB"Y"/`*U`-Q'1;HF9)$8)5MV3:@LZ1$\H1VW+G)I<
M1&<4PFQS=.[:'D-Q65KQ7'1SLA^;7T`S-50G]+6B)]PSIT5'H%QX*52"JG9,
M/7`RR&;D0#BT4?+O&=IF!/?2P@/PD1`^/<#$_MR([_X#``#__P,`4$L#!!0`
M!@`(````(0".#1;7B`,``/X*```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;)16VX[:,!!]K]1_B/*^Y$H""%@M1-NNU$I5U<NS20Q8F\21;9;=O^\X
M`\$.L$MY`#(Y/CYSQI>9WK]6I?-"A62\GKG!P'<=6N>\8/5FYO[^]7@W<AVI
M2%V0DM=TYKY1Z=[//W^:[KEXEEM*E0,,M9RY6Z6:B>?)?$LK(@>\H36\67-1
M$06/8N/)1E!2M(.JT@M]/_$JPFH7&2;B%@Z^7K.<9CS?5;162")H213HEUO6
MR"-;E=]"5Q'QO&ON<EXU0+%B)5-O+:GK5/GD:5-S058EY/T:Q"0_<K</9_05
MRP67?*T&0.>AT/.<Q][8`Z;YM&"0@;;=$70]<Q^"218$KC>?M@;]870OC?^.
MW/+]%\&*;ZRFX#;425=@Q?FSACX5.@2#O;/1CVT%?@BGH&NR*]5/OO]*V6:K
MH-Q#R$@G-BG>,BIS<!1H!N%0,^6\!`'P[51,+PUPA+RVOWM6J.W,C9+!,/6C
M`.#.BDKUR#2EZ^0[J7CU%T%M1AU)>"")0?WA?3@(1\-@F'S,XJ&B-L&,*#*?
M"KYW8-7`G+(A>@T&$V#6F47@#^KH<KV6*N2H21XTR\P=NPX,EU"?EWD2IU/O
M!3S-#YC%.2:T$<LC0ANH:3,CX('>3C1888J^7(:C-@W6VHZL"PP`=R<VZ@FY
M@`AL2'8.2<8=Q!(;V6*UP_'5M7,4K0<!SM"8^#T)"\3@>M-V+?N!S`A8DH#W
M=O\T&!:%(26*^U(0D[:5#T:PLD]>M)5<6H!T%,6=5UAI\WT4^J/NM:4;;+M=
MMP;;NI.@-^T",8:%_4!F!"PIB2WEMJKJ01]5%3&&I'X@,P*6I-26]/ZNT&#;
MG2@\N=X698$8K.HX]<VR8%5-0!"-X]0H'-85$6!BM]>&IQI8ZO5=:1Q$[ZO7
MX)[ZR._6#*I'S)6I4?_'D`PAAY4]]/6GF\?2#X??[?HUN*<_/O&B?L3@S-%X
M%*7#;F)4;P)B/X&/#<A,0*#+=\7Z``[\V[6WZ+[X_H%P`+US(MB("T>"!;A^
M)L"]_S_B\4JQ3K.H=_PO6LJ9>[!^E`3AR3BTWD)<VAJZ'=$E/AC0VQNX<+#=
MP-NXHF)#E[0LI9/SG6XE0CA,NVC7YCR$^A[KQ1>Z_6D;F.X%=!\-V=#O1&Q8
M+9V2KH'2'Z2P'03V+_B@>-/V`"NNH.]H_VZASZ1PG?@#`*\Y5\<'F-CK.M?Y
M/P```/__`P!02P,$%``&``@````A`$*\!<I6!P``ZAX``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&ULK%G;;N,V$'TOT'\0]+ZR*.IB&7$6D75;H`6*
MHI=GQ99C(;9E2,IF]^\[%$F9'":.`G0?K/7)G"'GD)P9F7=??YR.UO>ZZYOV
MO+:)X]I6?=ZVN^;\M+;__BO_LK2M?JC.N^K8GNNU_;/N[:_WO_YR]]IVS_VA
MK@<+/)S[M7T8ALMJL>BWA_I4]4Y[J<_PEWW;G:H!OG9/B_[2U=5N))V."\]U
MP\6I:LXV][#JYOAH]_MF6Z?M]N54GP?NI*N/U0#S[P_-I9?>3MLY[DY5]_QR
M^;)M3Q=P\=@<F^'GZ-2V3MO5MZ=SVU6/1XC[!_&KK?0]?C'<GYIMU_;M?G#`
MW8)/U(PY7L0+\'1_MVL@`B:[U=7[M?U`5J47V(O[NU&@?YKZM5?^;_6']K7H
MFMUOS;D&M6&=V`H\MNTS,_VV8Q"0%P8['U?@C\[:U?OJY3C\V;Z6=?-T&&"Y
M`XB(!;;:_4SK?@N*@AN'3V/;'F$"\&F=&K8U0)'JQ_A\;7;#86W3T`DBEQ(P
MMQ[K?L@;YM*VMB_]T)[^Y4:$36IRX@DG\'S#R0TB%41X"J*W="+BQC2"T6\0
M?4&$IR!&LWC@=0P7GI\;,!1$>'YJP$CPX"EXU'.([X9,WAL!POD<)PK/.>,M
M^+*.NR2MANK^KFM?+3AZL'#]I6('F:S`E]P>?.1IP[RW7V"-F9,'YF5MQ[8%
M6Z&'3?[]/J3+N\5WV)A;89-P&_B<;(+8UVTVIA]/MTBE!=M>;.@,`SD&"@R4
M"K``&28M8'O^#UHP+TP+.<.$`S"H$GBHA[61I*L-U2U2:2'=9A)0*$3GY-)$
M<@H)7#EAK'-*:0(<31PX@JHX;^</N1^8\=J&PS>%'%(T4,)MQM0WKN0&`RD&
M,@SD&"@P4"J`%@[,;7XXS!@2GQJ.[^JZ)=Q&"8<#R_$T^*'K(D**"9E*(`3J
M)&+DF%%H#(\"`U%*A:*%#\EE?OC,&(7OHG.9<)MHC#8@46!,9<,MK@*E&,@P
MD&.@P$"I`%I\D(;5^%A:HU`[;^]:1D)Q^NA()=SF&L4&`RD&,@SD&"@P4"J`
M%A94"36LV^$P8W0(?;QLW$8)!P,I!C(,Y!@H,%`J@!8.:S*5XG,['&:LKP[U
M<(WA-DHX')#;,J#+&%%23,DTBA?0($*9*\>40J6$Q"<NQ>=0H6@*0,F<KP`S
M1@K@@1)NHRC``:Y`S#($FEJ*&9D$KLD[0'4ZER9389'`^YQ2FN#"0N!<SM=@
MM,8BX$,JC!05!,)E\'W/1934H&0:Q7.#`.V<W*`4.B588DJI4K1]0%A/HAR%
ML0^+6$O^0<X:B;H>H8]ZAT08J7KP'HCK06A,ERBZ5'`B6)UK$??11LBDU9CW
MHYAX:.A<&MQT4TBKT<TR)$&,_)32XCT_NIJLB5'4O)U8"&]YU/).*1H_$4:J
MA)PF<LL27HE<E"A2@Y0)1)#(&PDI-TB%3GHK)94J29>"-4#SI>#MDBX%6O.$
M<"-5"HZ(TQ7#60D,*3`I$VX$B:5-'^W!W!BIT$E>L/1QA2Y5DBX%:X;F2\%;
M)_B\;G^CAR5*?\6;6`-)#20SD-Q`"@,I542/BS5!\^/B+9.VQ$8=9;\00*E1
MEY@CD,#8VQUUXH",Q41\&.D4.\B$RZL#,U5@3H$Y03CVN')@U,R4ZJQUA5@_
M-5\AWGUI"AEUEB@MFEAYCH@`/8=&^AM":E"R";GN,:/43C93K9V0]UGE9&-4
M6]:+S9>"=VZZ%&BM$Z*T=T(*C@@I0F=);ZU;:CC(!#(Y"%TO5OX9>0+/H-`=
M^+`81.''*#N5Z@STG<,:-T6N^769=WRJ<F_49:4M%,IQ1`3N.O[XYB@WO&NV
M+=S^HRJM>26.3Z(;:N1DCM-"6(FI$H?J4T6[I/S(J2X[:Q85V3\HX+RU5+5^
MHX`K_:?0FB,B`.I$QH'%E(P@RNTLF`OS:QHM#`<X"Y8J1]/$^U2?/%KK?2&E
MN)(+H^O\-@*9-(GIK8.7&@XR[""(M3J!4G9N."BP`VC5K]O?.`"EZD"7"W74
MM[>0Q_MA=0N%?J`G\$08J7*I;;3O1S!3G9,:G$P@O.^AKOG+4&YP"HWC+T=!
M](%*E:0+\:EFV#.;X=#XK4L8J4)P&E3PJ5O"E2PU6-F$O,_*)YNI_@F$_[)&
MV3LMED).!A<_#]9W?EH9K?4C!'5('RL11JH4;)"US=>74'BW0O-+#4YF(+F!
M%`92JHB^Y)_J=#W>Q$+BD1(G)K0QH=2$,A/*3:@PH5*#]&!86ZC4`OE;WB>O
M*-BK-/KU),2OLXDP8F=IVL>A;_Q8SUV!E10LO1(EE)E0;D*%";'K0#93[IY+
MP:_W^,7-J>Z>ZDU]//;6MGUA5W=LJTTHOU:$2.2](OH+7#@^>&SB"-_`1>08
M$,:]%=P]F/:9MX+[!1,O/!CX#?S!\^$//OO+8AH";AHOU5/]>]4]->?>.M9[
M",=UV.5>Q^\J^9>AO8Q758_M`'>,XW\/<*=<PP60ZX#QOFT'^84-,-U2W_\'
M``#__P,`4$L#!!0`!@`(````(0!O`>C(L0,``%P-```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;)Q776^C.!1]'VG_`_)[`4-"FBADU&[5W4HSTFBU
M,_OL@)-8!8RPT[3_?N^U">4CH73RD`1R?,Z]Q]>7F_77USQS7GBEA"QB0EV?
M.+Q(9"J*?4Q^_OMX<TL<I5F1LDP6/"9O7)&OFS^^K$^R>E8'SK4##(6*R4'K
M<N5Y*CGPG"E7EKR`7W:RRIF&RVKOJ;+B+#6+\LP+?#_R<B8*8AE6U10.N=N)
MA#_(Y)CS0EN2BF=,0_SJ($IU9LN3*70YJYZ/Y4TB\Q(HMB(3^LV0$B=/5D_[
M0E9LFT'>KW3&DC.WN1C0YR*II)([[0*=9P,=YKSTEAXP;=:I@`S0=J?BNYC<
MT=5]0(FW61N#?@E^4JWOCCK(TU^52+^)@H/;L$^X`ULIGQ'ZE.(M6.P-5C^:
M'?A1.2G?L6.F_Y&GO[G8'S1L]QPRPL16Z=L#5PDX"C1N,$>F1&80`+P[N<#2
M`$?8J_D\B50?8A)&[GSAAQ3@SI8K_2B0DCC)46F9_V=!)J.&)*A)X+,FH9$[
M"^:+VPDLGHW()/C`--NL*WERH&I`4Y4,:Y"N@!DS"\$?&T>3Z[54(4<DN4.6
MF"R)`\L5[,_+)@KG:^\%/$UJS+W%P'N#"1J$!]$T(4$8[9`NFWQ61C`JH^D8
MRKV]T98)+\N$71G,?'9U3\]RN`APK20BGS;\-@*+,770R0M6M?,Z6SV>'RZ"
M+6D+TKZS%K,PO@<S'U]-2)T((+UV!./*".XIAU'#:U.UF&&J45=HFK>XZ"-O
M+68HN!@*8AF/9XB+>AD.O+48Z^V8M=CJ6^=H7!C!7>%@.>M9:S%@<'-<0O]*
M)<.YFZZ-X*YV%/0+RF+J@@IN;Z\6%`6/ITL;=$][4%(U:+C%%!M(R^)I1656
M?515->B"9J\733NSU/:@\4-;@ZS)E(Z<6HH-I97X>&T9=-?D87'5H&YUO5=@
MIVG07M_Z0/Y"PQK4EZ&,B<T]"I8PSESI6/B4_43NMA]UC`\7O8-E*&-R8;-_
MJVO1*6VK!EW0_*W&1:=TKAID35Z.U=>G>A<=-J\H>&],]KE0@^;VD>2V]J!;
M6I_J7'38NBY4M@5-JNS@4]W+H+L':]@Y:U!]JGU_<;6R@UX[&S]6!MT7?S^P
M]>B#E%C9[6?&>V^WUMLAU\Z`.:_V_$^>9<I)Y!$'6`H[UMQMANN[P(S'S0\P
MVY9LS[^S:B\*Y61\!TM]=P'*E9V.[866I9DPMU+#5&N^'N!?#(<YS7<!O)-2
MGR]P_F[^%VW^!P``__\#`%!+`P04``8`"````"$`'>7<#O`"```0"```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R4E5UOFS`4AN\G[3]8OB^?`9(H
M2=50=9NT2=.TCVL'#%@%C&RG:?_]CG&@F'9=>M,&SNO7SSG''&^N'YL:/5`A
M&6^WV'<\C&B;\9RUY1;_^GEWM<1(*M+FI.8MW>(G*O'U[N.'S8F+>UE1JA`X
MM'*+*Z6ZM>O*K*(-D0[O:`N1@HN&*'@4I2L[04G>+VIJ-_"\V&T(:[%Q6(M+
M/'A1L(S>\NS8T%89$T%KHH!?5JR3@UN376+7$'%_[*XRWG1@<6`U4T^]*49-
MMOY2MER00PUY/_H+D@W>_<,+^X9E@DM>*`?L7`/Z,N>5NW+!:;?)&62@RXX$
M+;;XQE^G2^SN-GU]?C-ZDI/?2%;\]$FP_"MK*10;VJ0;<.#\7DN_Y/H5+'9?
MK+[K&_!=H)P6Y%BK'_STF;*R4M#M"!+2>:WSIULJ,R@HV#A!I)TR7@,`_$4-
MTR<#"D(>^_\GEJMJB\/8B1(O]$&.#E2J.Z8M,<J.4O'FCQ'Y9RMC$IQ-0J`_
MQP,G6$9^%/_?Q35$?8*W1)'=1O`3@D,#>\J.Z"/HK\%YR,QPC+G^*U7(49O<
M:)?>"[*0T)Z'712'&_<!:IJ=-7NC66$T:@);D0X*W0K`&QDA\SEC"#U\O?H#
MDEYD(X6>O=_^%8FM2%]1^*/$8H3:31G?9M/B+5Y,2Q&N1M^^I'NC,:=)USB=
MO+!V!IO+=]9B.'W3G1>S-NR-9MFWT8_]V`9+I^$@G*RVJ.!<7TZEQ395%"_L
M;?=&$QFJ<,:<3J.KYZ"%%+\'28MMI&`Q1S*:I$=:K/Q9!]-I.(J"Y^_!HDK>
M0Z7%<ZIH5BBC,51Q'"=V.)V&DU7T'+:H],4U&0MO'V<MMJFB>$YE-.=#E7BS
M3Q&&M[88SMPD;*C,9#:#JZ&BI"FM:XDR?M13UX<.C&_-A;"'"Z$?G^X8@('<
MD9)^(Z)DK40U+6"IYR1P=(09Z>9!\:Z?&P>N8!3W/RNX>2E\@YX#XH)S-3SH
M237>Y;N_````__\#`%!+`P04``8`"````"$`^KD_.SL#``"J"0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6R4EMN.VC`0AN\K]1TBWV].D`.(L%J(
MMEVIE:JJAVN3.,3:)(YLL^R^?<<Q!">A>[@!8O_^\\UX[&%U^UQ7UA/A@K(F
M09[M(HLT&<MILT_0[U_W-S&RA,1-CBO6D`2]$(%NUY\_K8Z,/XJ2$&F!0R,2
M5$K9+AU'9"6IL;!92QJ8*1BOL81'OG=$RPG.NT5UY?BN&SHUI@W2#DO^'@]6
M%#0C*<L.-6FD-N&DPA+X14E;<7:KL_?8U9@_'MJ;C-4M6.QH1>5+9XJL.EL^
M[!O&\:Z"N)^].<[.WMW#Q+ZF&6>"%=(&.T>#3F->.`L'G-:KG$($*NT6)T6"
M[KQEND#.>M7EYP\E1V'\MD3)CE\XS;_1AD"R89O4!NP8>U32AUP-P6)GLOJ^
MVX`?W,I)@0^5_,F.7PG=EQ)V.X"`5%S+_"4E(H.$@HWM!\HI8Q4`P*=54U49
MD!#\W'T?:2[+!,U".XC<F0=R:T>$O*?*$EG904A6_]4B[V2E3?R3R1SH3_.^
M[<>!%X1ONSB:J`LPQ1*O5YP=+2@:>*=HL2I!;PG.Y\@T1Q_K_T*%&)7)G7))
MT`)9$(6`[7E:!V&X<IX@I]E)LYEJ_*%B>U:H!"K;U!AP@+>'AE28T->WX<RF
MQ(KM[+K1`^#=P\Y&(%<4WE"23B7AHI<,8&=#6)7A&53@Z]!J48)@0WI&?Q[W
M_EUV-EJCZTVE:SL>2(V!`1+XFOE['Y):!.@&4A!&(R2MB;L*\!:!Z[I#P78H
MF$\$Z4`01:9@$`*<&S.$U[.IQ&/T<3:U)M+H\%KSS5V^MV\JTM<4`_KP(_1*
M/*:_U)JN!:W1]%&TF,*;@MCU)H+4%(0J[Y>M&Z!''T%7XA%Z=/'5Z%JCT7WH
M:Z/YK3D?Q)/YU)R?A>;\@%NUXM%%]_8Q5(O&_*.;8*,UFC\.9R:`KALMN)S3
MU!@8(,+]^7%$M6B,.+I8-UJCCV487SF66F`@&@,:4?=&W3IJPO=D2ZI*6!D[
MJ+[GP['I1_N6?.>K2W<TOH%6W34VIY^`5MGB/?F.^9XVPJI(`9:N'<%QXKK9
MZ@?)VJYA[9B$)MG]+.$_$8&[S[5!7#`FSP_P8J?_E[7^!P``__\#`%!+`P04
M``8`"````"$`2-=>F^8%``!/&0``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6R<F5MOJT@,Q]]7VN^`>#\A0'.KDAPUH.X>:8^T6NWEF9))@AI"!/3V
M[=<>3\`>:$/;AS9Q_F-^8\_8D^GR^VM^=)Y5667%:>7ZH['KJ%-:;+/3?N7^
M\_?]M[GK5'5RVB;'XJ16[INJW._K7W]9OA3E8W50JG;`PZE:N8>Z/M]Z7I4>
M5)Y4H^*L3O#)KBCSI(:WY=ZKSJ5*MGI0?O2"\7CJY4EV<LG#;3G$1[';9:F*
MB_0I5Z>:G)3JF-3`7QVR<W7QEJ=#W.5)^?AT_I86^1E</&3'K'[33ETG3V]_
M[$]%F3P<8=ZO_DV27GSK-QWW>9:6157LZA&X\PBT.^>%M_#`TWJYS6`&&':G
M5+N5>^??QN'$]=9+':!_,_52L==.=2A>?BNS[1_924&T(4^8@8>B>$3ICRV:
M8+#7&7VO,_!GZ6S5+GDZUG\5+[^K;'^H(=T3F!%.[';[%JLJA8B"FU&@,=+B
M"`#PV\DS7!H0D>15_WW)MO5AY8;3T60V#GV0.P^JJN\S=.DZZ5-5%_E_)/(1
MJG$2&"<W0&\^#T;!?.)/IM>]>$2D)Q@G=;)>EL6+`ZL&GEF=$UR#_BUXOLR,
M.)JYOC=5P$,G=^AEY2Y<!V9107Z>UY-9N/2>(::IT6RZFD`JHHL"9XUN8V;P
M@+>!AE!PZ/XT7-A0C&P7KQLR@.\&UD*->A2^9(V[DNFBD0C84,)BA$-8@1]#
MXZ"5"PEI&">SF\:_CLZ&-+3>,%R1;8B902"!W^'Q0S$@"Y2)A4*:N<Z\#\4)
M?J0B(D4+&S.#8(,-,9P-Q3;;5#YY0YKVR9%MB)E!H$PERK#,X:!KF2,-0[(-
M,3,(I-E7D'"0':69%272S'0&%Q._FT`N"!>88^DAY@)_@DN@58@Y8%>T2L[U
M#8&#[#G,)<&&-"RLMB%F!H$$E>OS2#CH6J9)PY!L0\P,`LF'&O%Y)CW*CI.=
M:R.B9/OC&YXI75HBH9B+5)K*C'0KEUQ,9\*%G`;6<);MC\N>3Q5?%INVKE+=
M,R(6U(XEYA;)@X6;\0S;U#Z5>ZA9']1C(^)<-*RUQ%PCN;!6,ZXK<:+*+N(T
M;[>;B1.)*$=SW)%ROT0^"3@>LT@\+-?#\:BX2SRK@VY\$A%>J"N&S4<*SL<L
MD@]K^'`^JOB2SSJ-;/"`URQQV"5BC9MM(B1^&'9B'`LOBYDHK'(&6/*'SX`:
MA)R!=8S9^"2Z['._;P:LT9B=S2P2$`O\<$!J!Q+0/L'XHF>,QXM._"(CX6N`
M!FF+!,3J/AR0>H$$M,\U/HDN$>P%9#W%1)!9)"#6>@8XL/90AY"@]B''9VW$
MK$W;$G.-X`J^U&KTJ&O]SXC:]$4=2\PMDNM3O2/HZ1V=FFA$E-"^8XX1M,`Q
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MY<-.IQ&UZ;3:6&0$#)-;)*;5'`9B]C2)A54C-B&)#*9U;HW,IYR1]-HB&3_5
M(<*>#K&PGKXQ(KIJP?,F_E@USF@XX7L](L3BS#;%P"A221>;8V&?G[5K4>LZ
MEIA;9.2P*%M<N!0^WK0AE?*/-X<1M=&).I:86R27U1,&QJNO-W0V!XG,JK,+
M'5QO8WMNJ?'"N[$0(]U?T_5NKLJ]BM3Q6#EI\81WTP'4T,;:W)O?!7@Q:MDW
M<)^N+Y^]Y@.XSCXG>_4S*??9J7*.:@<NQZ,90)1T(4YOZN*L+Y4?BAHNLO7+
M`_SC0L']Y'@$XEU1U)<W\&"O^5?(^G\```#__P,`4$L#!!0`!@`(````(0"=
M0(B?`0L``.T\```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)R;6V_B
M2A:%WT>:_X!X;\`VD!`E.6KLNDEGI-%H+L\T<1+4(8Z`[G3_^ZERE>U=>_D$
MD_-PTOFR=MFK+JYE@V__^+5_&?TL#\==]7HW3B:S\:A\W58/N]>GN_%__BV_
M7(]'Q]/F]6'S4KV6=^/?Y7'\Q_W?_W;[7AV^'Y_+\C2R+;P>[\;/I]/;S71Z
MW#Z7^\UQ4KV5K_8OC]5AOSG97P]/T^/;H=P\U$7[EVDZFRVG^\WN=>Q;N#D,
M::-Z?-QMRZ+:_MB7KR??R*%\V9SL^1^?=V_'IK7]=DAS^\WA^X^W+]MJ_V:;
M^+9[V9U^UXV.1_OMC7EZK0Z;;R_6]Z]DOMDV;=>_0//[W?90':O'T\0V-_4G
MBIY7T]74MG1_^["S#ERWCP[EX]WX:W)C%E?CZ?UMW4'_W97O1_+OT?&Y>E>'
MW<.?N]?2]K8=)S<"WZKJNY.:!X=L\12J93T"_SR,'LK'S8^7T[^J=UWNGIY/
M=K@7UI$S=O/PNRB/6]NCMIE)NG`M;:L7>P+V_Z/]SDT-VR.;7_7/]]W#Z?EN
MG"TGBZM9EECYZ%MY/,F=:W(\VOXXGJK]_[PH"4WY1M+0B*T(C23I)+U>)(OE
M!:TL0ROV9]-*,IFGBZOK2\[E*K1B?S:M?.)<[/*HN\7^;%KYQ+FL0BOV9]/*
M\'.9^I&J![[8G#;WMX?J?617DQV+X]O&K<WDQK;<C+@?GW8._-44L&/O&OGJ
M6KD;VWH[ND<[;W_>+U;9[?2GG6O;H%GW:>:Q)F\T;FJYAHL&=`VG<8EH%$V)
M;$!7LEBQXZA&TQ1I#HP']<R<VJYJ^\O.3MI?_2NCZ18G=MW2'&;M@6V;]-,B
M-I3W:9:QID`-ZVV!BN4J;D2B9+&ZBC6J3W,=:W2?AAW+H&8YF[7M1#V<Q3WL
M9N3\+Z]!34^[(JLC';N<)6W[]5Q:>XV_;KG)E7-0<"`XD!PH#C0'AH#(ISW9
MX3/)B>W5-/+'5L+::X@_#Z[\>DRN%C/2Y7YY\1+!@>1`<:`Y,`1$ANT@4L-N
M8#.[17V\A%P1-\[F^MIKB'$/DIEW;O>J>"84O$!P(#E0'&@.#`&1;;L#76[;
M%7';["*V]AIBVX/KVG6ZF-OAA@'G-8(#R8'B0'-@"(B<VUWS<N>NB#MGX[?V
M&N+<`S_3D^L^X[Q$<"`Y4!QH#@P!D7&7A\FF^O$,=V)NF%WOUUY##'-0>!!Z
M8)5F\SF;+H*72`X4!YH#XT$X2G8]3Y:+;FRB+K!98'@7.#'O`K83K;V&=`$'
M!0?"`W^VUW:_@>4@>8GB0'-@"(@,VZM-Y'C8Y:VNXM;9!KL.(N(=2!%(&)J^
MM2^@2`)10#000TG<!2XTD7D_L`M\U(KW-I8?UHD7T2[@I&@U7;I:)EW(J'<\
MT8J:3":!*"`:B*$D[@07=4@G?+SX$Q^,(O,)#RY!M%S55_;Y9+Z*_KL67U@4
MR$-%UUT%$`%$`E%`-!!#2=P3+OD,[PFG9BLA8;[6B1?Y6;Y<]EWI\Z"AWGU5
M1P1H)!`%1`,QE,3>70@BW@<N!1^=[.FV]P?+A*>=Q(M\'ZSJJQJ;Y'F0=(8+
M(`*(!**`:""&DK@+7"`B77!F(?CX%%MG6]C:/8NP<Z3SE0,I@`@@$H@"HH$8
M2F*G+@`1IVZPS]^R)#XVV='L!AON68*(.B9I*]PC<R*@2@)10#000TGLV"4?
MYOA\ED]\7HK'N,L/_BXMB*AC$K."8T_\$DC[-SM>)*%A!40#,93$7>"RT.5=
MX!-4W`4\[24\=^5`"B`"B`2B@&@@AI+8L8L^S/&`:>X#TYEI3E)5/<1YPDD!
M1`"10!00#<10$CE.6:;[^!)6J]D.-N-C&T1D>@,I@`@@,I"0]]RM/;_74U"D
M@1A*8NN?RG)I3Y9+>)(/(MH%D.5`(X#(EI`+:,*RLVI%3=[30`PE<2>P+#=L
M%T_[,AT/M$%$.\&7=:0`C0`B6^(>NB9LMJGVKYU[?A1#-;%[>Y7BZ_W\13YU
M56P5I"R@K(.H\YH#*8`((!*(`J*!&$IBQRY:77R%2WT@^_@*%T34L2_K2`$:
M`40"44`T$$-)[)B%M($SO"^L\8W<?5@3AS4@!1`!1`;BKW1]>[V"&@W$4!+W
M0$]X&S#+?>:*]W%8XSR8Y2DG!1`!1+:D7N/LGDBU?^W6.#^*H9K8O8M)E\]X
M'ZXB]RF_:TUY`LN!%$`$$`E$`=%`#"6QXY[<=C[%I#Z2G5GCD-M"&5WC7"-`
M(X$H(!J(H21VW)/;!LQP'\"B,4Y@C?.4EJ><%$`$$!E(2#-);YKA#6MHQE`2
M=8&S>_DTKZOX5L:6WSJ(NB'.@11`!!`)1`'10`PEL>.>_'9^FF<^B'T\S8.(
M.H;\!AH!1`)10#000TGL^%-A+>L+:WR:!Q%US&-4`1H!1`)1@?B)[Q_FQ)]5
M::@QE,0]X*(7N9A_?+N2.36?W?QA4Q!1Y[ZL(P5H!!`)1`5B'R:[72V=9.PV
M04.)H20V[J(4,3XLQ60^@,57.+Z'!U%G-P=2`!%`)!#5DK[DKMN_-KNZH21V
MSS+<F6''[);R[T>L,\AN0`H@`H@$HEK2W;1E,_:<3[>BSCPYH=B\RSIDZ,^8
M]\DH&O*4'7V=\?B4`RF`""`2B&H)-<\N-KH5=>;)"<7F67H[8[XOM;&CKS-(
M;4`*(`*(!*(""7M\O<6SVT(-18:2V#J+<6>L^]05CSN[65YG/)KE0`H@`H@$
MHEK2C?LRA>L=/[QIR^Q,B,V[+#1\TOOD%)MGSTG6&8]7.9`"B``B@:A`PJ=7
M,.3\N(:V$+F>LQ#W\9#7:KZ]\:M[$)&K.Y`"B``B@:A`&M>3)<N-&DH,);%Q
MEN7.&/=A+!KNC'7[>LX36PZD`"*`2"`JD&`\F5POSGQ8J:$-0TG<$ST9[WRJ
MG?=DO(S?K@81G0J0\4`C@$@@"H@&8BB)'=MQI$M]V&=+<U=U[OMP040=^[*.
M%*`10"00!40#,93$CC\5YN9]88YO;D'4^<N!%$`$$`E$`=&!A.VN?D`?)WM#
M:^(>N"C0N?E_-L<'$75.$I7_5`TT`H@$HH#H0$*RSR#9&UH2&[\HS,TQS&&2
M#2)JG*2I8)P3`542B`*B6])M\]F,W5&95L0W]?E%8:Y6\^T-YCN$N5#6=4<!
M1`"10!00'8C_]F&RRN#S*$-KXF&_*,O-AV2Y(.I\YD`*(`*(!**`Z)9TPP[I
MSK0B&/:+LMQ\2)8+(FJ>IZP"-`*(!**`Z$":G,,O<>2XT9`O+LIRM9I/=I[E
M@HBX!E(`$4`D$`5$!]*XAG1G:$EL_*(LMQB2Y8*(&N?IK@"-`"*!*"`ZD#;=
MK>"[9X86Q=9[PMO2SH./X^RB+[RQ,+T.(MH%$-Y`(X!((`J(!F(HB1U_*KPM
MAH2W(**.(;R!1@"10!00#<10$CMFX>W,V/:$MHQMF.N%%U&GG!2@$4`D$`5$
M!^)#6U]FHR6Q<9;97$X?,+E[LEO&GT<M>%++@11`!!`)1`'10`PEL6,6UH;=
MF2Q\UK(C^,&WWH*(#CF/:`5H!!`)1`'10`PEL6.6T(8]9K8O;$(^3V#S@J06
MRKH^*(`((!*(`J);XAX\L^=`[O52=[;U8;UY_[:H?VEP7QZ>RKQ\>3F.MM4/
M]R;HW#Z^;VG[ENK7U+WSQO@ZN<GK%^H8+Y(;T<=E<F/?RW-YJ2VP+YN^;9[*
M?VP.3[O7X^BE?+2G,)M<V15R\*^K^E].U5O]:N.WZF1?,ZW_^6Q?*R[M6U^S
MB14_5M6I^<4=H'U1^?[_````__\#`%!+`P04``8`"````"$`!<M',,`"``#L
M!@``&0```'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R,55UOFS`4?9^T_V#Y
MO8`A)"0*J9I4W29MTC3MX]DQ!JP"1K;3M/]^UW;"(.W:OB28>WQ\[KG7E_7U
M8]N@!ZZTD%V.21!AQ#LF"]%5.?[U\^XJPT@;VA6TD1W/\1/7^'KS\</Z*-6]
MKCDW"!@ZG>/:F'X5AIK5O*4ZD#WO(%)*U5(#2U6%NE><%FY3VX1Q%,W#EHH.
M>X:5>@^'+$O!^*UDAY9WQI,HWE`#^G4M>GUF:]E[Z%JJ[@_]%9-M#Q1[T0CS
MY$@Q:MGJ2]5)1?<-Y/U(9I2=N=WB&7TKF)):EB8`NM`+?9[S,ER&P+19%P(R
ML+8CQ<L<WY#5;H[#S=KY\UOPHQX](UW+XR<EBJ^BXV`VE,D68"_EO85^*>PK
MV!P^VWWG"O!=H8*7]-"8'_+XF8NJ-E#M%!*R>:V*IUNN&1@*-$&<6B8F&Q``
MOZ@5MC/`$/KH_H^B,'6.DWF0+J*$`!SMN39WPE)BQ`[:R/:/!Y$3E2>)3R0)
MJ#_%XR#.4I+.WV8)O2*7X"TU=+-6\HB@:>!,W5/;@F0%S.?,O(XAU_^E"CE:
MDAO+XK@@"PWE>=C,E\MU^`">LA-FZS%+C`9,/$7LS@A;"I`W:(3,+S4F4,.7
MW3]+LINFDI)H>M[V!<@4L7L!00;(1"-X-];XNC8+SO%L9$6R2`9>9^G68WPW
M68]WHQ>3DX'F_2=;,'3?^.3LH@Q;C\E<&1,2I5-ANW$XR[(A.A$%;3T69=OJ
M[9+935-QA%S:XC&I$S>;S8;3G6F[<93$BR$ZT3:?:GN]5!8\U91DEYH\YF18
M.KMH?!A,EL*'243^^>E5^:GC+V7+5<5WO&DT8O)@)PJ!3(>W?MAM8=BYT1`.
M`1@V/:WX-ZHJT6G4\!*V1L$"_%!^7/F%D;V[$WMI8,RXQQJ^*ASZ*PH`7$II
MS@M["X?OU.8O````__\#`%!+`P04``8`"````"$`$6D^C%8"```O!0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R45,MNVS`0O!?H/Q"\1Y1DRR]8
M#N(&:0,T0%'T<::IE41$%`62MI._[Y)T!-<IVO0BB>+LS,[NDNOK)]61`Q@K
M=5_2+$DI@5[H2O9-2;]_N[M:4&(=[RO>Z1Y*^@R67F_>OUL?M7FT+8`CR-#;
MDK;.#2O&K&A!<9OH`7K<J;51W.'2-,P.!G@5@E3'\C2=,<5E3R/#RKR%0]>U
M%'"KQ5Y![R*)@8X[S-^V<K`O;$J\A4YQ\[@?KH16`U+L9"?=<R"E1(G5?=-K
MPW<=^G[*IER\<(?%*WHEA=%6URY!.A83?>UYR98,F3;K2J(#7W9BH"[I3;;:
M3BG;K$-]?D@XVK-O8EM]_&AD]5GV@,7&-OD&[+1^]-#[RO_"8/8J^BXTX(LA
M%=1\W[FO^O@)9-,Z[':!AKRO5?5\"U9@09$FR0O/)'2'">"3*.DG`PO"G\+[
M*"O7EG0R2XIY.LD03G9@W9WTE)2(O75:_8R@[$052?(3";Y/)%F>Y(LB*V;_
M9F$QHV#PECN^61M])#@TJ&D'[D<P6R&S=S;!^OS9&5KR,3<^*(0BVF(W#IMY
MFJ[9`4LH3IAMQ"PI&3&3$<%0?,P`5<\S^+NR!U\J9R-OR&X;,<O0T7.AR?\(
M>7!)I^?I+XH+H8@)#?_-$4:]W9$'8\W/A.9I?B$4,5D:2EWDR73<C[IQ<&-?
M%9@&/D#762+TW@]EAF'CWWA>MGA>\E"@<0/G=>`-/'#3R-Z2#FH,39,Y#JB)
M$Q\73@^A`3OM<%+#9XL7$^!<I`F":ZW=R\*?J?&JV_P"``#__P,`4$L#!!0`
M!@`(````(0!.3)-L%@,``#<*```9````>&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;)1676^;,!1]G[3_@/Q>P"1`$B6I6E7=)FW2-.WCV0$3K`)&MM.T_W[7
M-B5\M$G(0Q*2XW/N.==<L[Y]*0OGF0K)>+5!V/610ZN$IZS:;]"?WX\W"^1(
M1:J4%+RB&_1*);K=?OZT/G+Q)'-*E0,,E=R@7*EZY7DRR6E)I,MK6L$_&1<E
M47`I]IZL!26I65067N#[D5<25B'+L!+7</`L8PE]X,FAI)6R)((61$'],F>U
M?&,KDVOH2B*>#O5-PLL:*':L8.K5D"*G3%;?]A479%>`[Q<\)\D;M[D8T9<L
M$5SR3+E`Y]E"QYZ7WM(#INTZ9>!`Q^X(FFW0'5[=XQ!YV[4)Z"^C1]GY[LB<
M'[\(EGYG%86TH4^Z`SO.GS3T6ZI_@L7>:/6CZ<!/X:0T(X="_>+'KY3M<P7M
M#L&1-K9*7Q^H3"!1H'$#4T;""R@`WIV2Z:T!B9`7\WEDJ<HW:!:Y8>S/,,"=
M'97JD6E*Y"0'J7CYSX*P+JHE"1H2^&Q(<.3.@S!>7,'BV8J,P0>BR'8M^-&!
M70.:LB9Z#^(5,&MG,\CG?6=0C5YSIQ>9I8"6T([G+7A9>\\08=)@[L>8H$5X
M(-Y6`*K="LXK:_!0&;>\IKK[,>946T]Y-D59@S=HCIR.Y_E`V6+,#N@)P:JN
M11UR=#%DO0B:T1,,!X(6$RU-#WP7G_[OZ<,FZ^J?CUB#^[KS63S0M1CL&UT\
M6[@+O_,Z-:17132E"@WN5Q'[T:`*BQG''4\1TN!+?;68L9">[YV;YWRN&MQW
M-,[58D(;:^0NEKU7:[\7ZW)*$1K<+R(,EBVOO7\L9NP6VCW!KD%?"K8!O:,U
MF$OGH\5VV/3OE>&>;4#MS3([^>[EB2<-)(/N)QK[BT&B#:B5#CZX3[$>(%=O
M*(,>2I],V68VH,O2@QEU(?!WAA/VAZX'TRF(PLZ0\/T/QH0^6">$<,VX,I1P
M;#3S*L#N*2;;>WOTVY.Q)GOZ@X@]JZ13T`R&M>_&("/LP6\O%*_-.;3C"@YL
M\S6'!S0*QZ/O`CCC7+U=Z$>+]I%O^Q\``/__`P!02P,$%``&``@````A`.,2
M&T/_"P``R6H```T```!X;"]S='EL97,N>&ULW%UMC^+($?X>*?_!\B913LH,
M8,P`<\.<%G:<K+29G&XG2J1<%'G`S/C6+YPQNS,7Y;^GJOU6#=ANXS:=S:';
MP8:N>NJIZNKN<F/??/?B>]IG)]JZ83#3!Y=]77."9;AR@Z>9_M<'ZV*B:]O8
M#E:V%P;.3']UMOIWM[_^U<TV?O6<C\^.$VL@(MC.].<XWESW>MOEL^/;V\MP
MXP3PR3J,?#N&P^BIM]U$CKW:8B/?ZQG]_E7/M]U`3R1<^TL1(;X=?=IM+I:A
MO[%C]]'UW/B5R=(U?WG]_BD((_O1`Z@O`]->9K+9P8%XWUU&X39<QY<@KA>N
MU^[2.40Y[4U[(.GV)MCYEA]OM66X"^*9;N2GM.23]ZN9?J5KB<F+<`4@?O?S
M+HR__4WRY\T?WKSI_^N;;__Q@[/ZYX^_/_SLQV_T7J:&R`0?5,N\[%>*A8\3
MR;W4@MN;=1@00T9`$[)U_2D(OP06?@;!`.;AUVYOMK]HGVT/S@P0WC+TPDB+
MP<M@'SL3V+Z3?&-A>^YCY.+7UK;O>J_):0-/L,!(O^>[X"8\V4LTG%?/(Z+)
M;)H@#,ZF(9ZA-OE@DHTGJVVR?SIB$Z=K5*^K#7^<+F9%M5W2=!W&Q0&';73E
MOB)ZHJ?'F6Y9D$,&_3[22AW6D;+IH@_ZSJ;L:G0VRX;6T!I+M8R+Q4._H<*A
M)9/*&H76V_&[L]$I7UF9=6D:/E</P`XGET47NFY%_QY;^#I'G)QY0.O&8TPJ
ME_19URMRXX/K.UOMWOFB_1#Z=H#$TD&-?9L;D[G`DR\>II[Q6\]]"I*)PG:W
M@;GH,G(W,4++`T.^XK*XZS0,:LUH-W]JYJMVN@0=1S*_7&99D&XA>EW/RV?D
MPQ'.6>',[0TL#F(G"BPXT-+W#Z\;F+$&L([!V.HEWZOY]E-DOPX,-F\3:[`-
M/7>%*)X6;)Z<SE,65W?6XH[I)<A$490(M:S%N`.A=_/I0C[2Q70J6ZAAP4NR
MT+<C?$D6:L%_"VF<IAW)E`4REZ?%+JYK^Y?CZ70Z&5Q-)I.I.1R8)B/Y,8UH
M-U@Y+PXN=:71=(A@!`BFP\GTR@`@?7/"5)T5P1``C$>CR6@P-4SXGV6R[A'(
MYA26]HJ]2A`H\BI!H,BK;&G5DY#YTYX"52;%7B4(%'F5(%#DU;'D##Q6[E6"
M0)%7"0)%7F4%08E]%:JWBOLJ0:#(JP2!(J]*FWRF&7BJW*L$@2*O$@3G]FJZ
MK,*)M<7*0X<S,VGSXVP)M[B[:ZZ+K1IAG?H81BLH;637C@9X\2@Y=WOC.>L8
M5J21^_2,?^-P`_\^AG$,%Z5N;U:N_10&M@=O>UF+[&]%2[AL!U?H9GK\["X_
M@3*N*I1PDZCH2D.>]4Q<39ACLS\V1\95LF"3I-IW5N[./[0NUWTT+H%&Y+;>
M<,)AD"M)PZ&H3/;0"ZG[!%LP5S-/"S:`F,A"0K"%#!N+*KVHC:2%F(VD@:"-
MI(6HC=!UCG6NC,E5N(,KQOL.MJQ)OY\41$7U5`LDP(]$S'$0I,TAG[5-CC!:
MVZ:IK9!?#OK&W,`7FQT?L;2FQ:&=-0V.6%G30M1&/FXR[W+"\](%IN<C2/;X
MYKY^&@Q0E#3,\.PEP30_X86:Y%*-<+H[;FZM>&(U2#@V7*7C%@R#2\?S/N+`
M]/=U/A9">>GVYF5--CS`+A3<$8#[*?`MU'#3M\FXEQR`KK)&1FDCS=YLO-?[
MG?_H1!;;FL)4L+-8*RZ.YFS`+H[950K?804R/1'S?13&SC)F6V=8:;\,S[`$
MSR`5)(*GC7ZS1#_P),Q'&_U0@#GJ1.!%J7X(+F'],N,!-PFE00TNH$%=A4<F
M`EAF9PC`"2H0X*:FE`,(3Q4(8/F2(8``+1``G(JH:-,/!B2;00P4*D%_5RHA
MQV16<BH[M+(L_8+^"BLM+OVVHIGD6PCT@F8XJ`#02F59BE658HC;H:<5%,!!
M!046C+IRAKQ!6<Y71@A)NH"A8`320!4C\J*2Y%S060"H9F0N<1Y"@@)3D6H(
M`$<)!.((J,.HQZ!H!*;1H&@(IA"X,?B,?8)&`S="*L(`>)3TBF*>,.!&C#/2
M0""HRI`D&@Q5*9)B4)4C"U<8JE(D@:`J0U)/J$J1%(.J'$E<H2I%$@C`B)(,
M23VA*D52#*IR9.&*H:H422"HRI#$$\..4V2/EDV3(BJIGX[QEUIEI4=P4+;\
MW_?5R[JVD#HH6S2!K*QYLGI*5H[@"[:6(DMI!&?C#F^LG6K/8>3^`HM,_#G9
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M=M^(2@=*[W."_OS?):U1DASNES&[&3V/KZMJE'<[>)9`JIY-=`N)C.?-5UWM
MRA@5K0UDJJO%A8RYJ?3LU&C8[;(D)H6=+@&F-;NZ4;8TFG';P5[&X5;'\W2W
M0^U<F69M05!RA_ZL>MDD=@B"FE0HN&*@+!RNC>N\U"D<87Y*\G+U.-4J+U/6
MV&YSOMI11QM-/W5NY(+[5*?6`>K4CR<01/%4#Z^G,M*HKMXI'%%Z2J*\FIZS
M1SFMR9?F<."33^$E,+G8+RU#T,XHG#/0I=(*(6T1B!,E6`GN#%"7H^^I71)<
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MSJDJ69"[DVD\UONH+&"AJ2R0D,K"O9D$%UQ':"H+U">RAF`MD04_$VXL"_;+
MIK)PYVR!RX0<V107-$EE\=R/!+DWC_F1[3$O<*')(KBHK,*/6#(ALL#DIK(*
M/X+CJ"PPN:FLPH^`D,@R04E3684?P0M4%H1;4UFY'TUP')$U$N3^ZJ@?^5C%
M#:$BN*BLPH]\K`X%8Y7**OS(QRJ:W!17X4>02O@RX8.FL@H_\GG"%,P3U,;"
MCSSW(T'N]S,J'_&&8,0G4@K?P3O"$<Z_1#A*I!1>XZ-\*!CEB93"7WQ\FX+Q
MG4@I/`7RB$4F?"!N4>ZC(<^N*<CNW%YE69</&$.0$KC)\7+GP8-"0GS,"-OP
MC(MI8A"N840,6CP[RT_:`NY?D0OB^P,.HR*"[EXVGAW8<1B]:KC).1?'.WTD
M*.Z/89ASQ$LPX%`$T)_@H2SPO!<->$D8XF,8%S--Q.1]@:=G(.BQ#`VT3M#P
M\8>KOB9HH'4BAD^J.'\2$?,^V.QR#_&Y%(=N$1$?W."3L^(CAV<8YYTBDNZ=
M71S9>?SQ7<H0).8>[WJ2R^!31')_\NP6+>G\\QYN<I*1B/5ATG=P`B\"_"^[
MF-"(K8@00S`O/;@QW*0IZ\2<"(0E@N,AA!\>Y"+V,HJ@C+_948"]A>NZ>S%:
M8E'Q,PZ8_:]>BCO@,-YC?&P1NS=.OAX`HE;.VMYY\4/^X4POWO^9W?X,@BG]
MUO?NYS!F(F9Z\?X#WE<.>C$L?R#=?-C"O<K@K[:+W)G^[[OY>/KNSC(N)OWY
MY,(<.J.+Z6C^[F)D+N;OWEG3OM%?_`<HPV<\7<-#@EH\0XD]ZPFJ7@/S>NO!
MDY:BU-@4_,?BW$PG!PE\MK$+8,/VKLR(WC9_!M7M?P$``/__`P!02P,$%``&
M``@````A`/0DO_J;:0``458!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.2=
MRW(;29:F]V,V[Q`F4UE39A23%'7+[$RU012H1#=%<D@JJ]+:9@$"01*5(,#"
M11)SU8MY@][.F,EF%K.;AU"_23W)?/\Y[AX>$0`E957UIJRKJR@@PB_G\I^K
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M\\N=[8?_TORL`WF'1N+]<?^R^6T:[KB<C:9BP;!XU5^T1D[/[8_F@_ZX^+GL
MSXI]F#=?.V)X,@R\\MG]GYMOG\WZ$M#B]/;Z?#IN?GM\\(?F1T%F3LK+D2B&
M)!WVKUO+/SXY.NL<]/Y0O.P=G?W8/>D<=]^>]?9.-XO>X=[6FC'WD,L9>^TA
M&!^*?REOF\_M+6<SR6Y.DW4$#.O<'XW+6;$'A2^GL]:`G<&@Y'N^'3(H?S5G
M#*/\-!TO)XO^[-:?:O'@<+KFQ;CBD_)F.EL8H1?]19N)/Y>M,</4OR_'X^)?
M)M/WD^*T[,]!CF'1F\^7:]>Z-[V^1I%/%]/!+YNNI//B:+DPZ&$%:U9ZO#P?
MCP;%_GC:7S0?V3LZ/#TZZ+WJG'5?%2\[!YW#O6YQ^F.W>W9Z!V"<74V7<V`&
MQ/AR>,CU?[>UCK<G)]W#LZ)S>LK4W[6^[L^O#-<&^J/\TW+TKC\N)XL6:6&[
MD'%>S,I!R4/GX_)A(4UHR?&1`*WHS^=E>Y3>Y!V#3V>C-N_.I@OD>!#$=?7K
M^V\/7YVB#L5)]_2XNW=6'.T7W3?'!T<_=[O%2>_UCQ#W[?&1OC_KG73?L/'F
MAM&RX^[)V<]%Y_!5T?UO;WO'>FJS..RV'GW5W>]"O%?%WH^=D]?=T^90ON+5
M*TWDNNG?BE9&X_Y@,%OVQ_,6%];3L3GGJ_*B1*&'L`%*+C]'QO&H?SX:CQ8K
MZ'UP=/BZ..N>O"D.>IV7O8/>6:^[0CZF<`PMU!8FTT5[OH,PPVTQFF!/)Y-R
ML)!1?#]:7/'O\;A_/@4L]!&6V?]J;JH:`Z-:E-<WX^EM61:ST>45`K>\X=U9
MN1C-2IF(YLO.!=R#RV)1SJZ+.[8<'EU/D[VC-V]Z9Q((E/20[19/6V;]T\=/
M'YMKV.L<]\#N`HGI[?6ZAWL_MUA<AYC[VUO;VSO%#08*?5N6WQ6=Y>(*O?@5
MUCY$>8KI18%>E]?GZ%*P[;LF1#+RF\7.D^W-[6W[_V(NIV+^C\5($#>TAZ85
M=GW1<-_N;CYYLK.Y_>WS,)J-PJ=/MW<WG^]\ZU-LP@8Y*8O1NW+<-@S#(8(V
MG:#%-_W1\*'DH7\S0JN;Y$(YEM?+L9F087DQ&HS6<#6\7_A#>(:M25LL+2;E
M0L3[_*MW(O0Q),7C0NKP)!ZL0^R[AECO'@51F+NU23)0H!Y._2:]ZK)32<K=
MS[DXW/U,)B>M!W,#=GJ&'7.]`'*%H)VS'@^L(PR^;V;*_B+G-[=NCW[;(M>S
MXJ3[4_?P;9=]S`&<0VG\SL[&X$%+ZT&&X\[AS_]PB@WOG'1E@_:.#@XZ+X^<
M$D7G]4EWI<'9.SHU.Q6G:F[A]<G1Z6F!6=KOM2P09J[;.=G[T8S5*]9Z<&3F
MJNC^X;A[>-HV20>**!X6EW(RYZ;#LW)T?;Z<S0T[6U;]LQ.L-(RGW8.#WN'K
MS>)U]Q!).+#E=5Z]Z1WV3L]$CY^Z:U<89`?;<\"^F\38[QWB*/48<MT.JR?P
MBH_>=->/X-\7&W&D!Q!FA97G(UM*L7]T4N!W%S]#\N:HAX#*>`IMDXX:QKC;
M:(K,X.?].=Z@@L3A:+S$/VX9@=^7,FG":(QJ_Q*3NC2`!Z\<85NC+N<\;9;U
M^F9ISO#=R]C\@E744*NNV7@ZAW@Z)MXMF[9.V5_VQ_W)H.4'YC`7;9/LNWF:
M&P&F!5)Z&5=AOIBWU,[BY8<0%BH,IM>$]G/W)6:EFX_%E/P`7CO.A6Q/2\"_
M9`",VF(V&H@O/E;_?7\VW(R6A#5?E*/%DL>:8M']4,X&"MUA8%B`ZQY#L;+H
MR;@F3J:3A]4G&Z/)8+P<EG.;I@P#M0@@P3M`\)HSYR:A^-<WYB>TXO#`F,T@
M7&O&\#T'Y^%S#"I8=QBNM=:_+JV!9/-K6M/\]8F^CD"=RJ,Y#A[-GGLT:TF>
MNS;XZG)MUC[[V_7P"[V3')X:_-TTC:PTKRD;)Y5.G)I^K9.Q[,%,>>9%T)H2
M/3(^-B>X:_.=TQ^+_8.CWZ]U+_:J)_9/CMY$AP2CTMG#^JP.93K#/R[G"X40
M"F*)=!5&H:4$M-/)@$R&::+!*Y\*GPRI;F;3=Z,ACY[?%AL!CA_$6(:@@P38
MZ)U%6"VX-X40(/-VCEY-6KPJ;UC$R)"M^=W^:`*71CC5Y0?!'X`AZ)A>EP\<
MH3:4RAS?*L-XU9]@4X:C"V)$G.6RC:=[]LA<%L6"4186XZ5;L2Q!UA<&7Z^9
MNR`\ZU][<N!BJ02EA@<M%2D(&2/H?>68<Q(1>OUB]($AUX39UTH1_1KBRPL"
MA?-%0[+=(.OS(6E!+;-)XHPH(4056RU_82]'"A%$MUC<FPS(+6,!-H:E__5`
MNR=@J8?IQC3P7NDL&8*8Y[`4UW32`CF\WC`NS+:_;%R8ULS"V!(MB;R&1FN&
M&JU/Q:S95)I\54XCWV`*QEO;DCG[2JUJ<:NA^[W#G[JG9[BC=^G^\7*&=KBA
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MWEC07T"`3.D8896D%(='HL=/1P<_:9V5<+4@M#[1J][I'I'AVY.NYJE>>]BD
M56]"N@^AMF13\\O3WNO#'KFXCC+?>WM';P\-(8[)R).?:]'],X\7ZQ,([+);
M[!#\?6:(Y@+[6\HC^O^]+B=$@XTLV4R51T"(]-GH0_%R-#TCJ]Z_*0D"!U0'
M@.BM8D/YU9B.\XSK".=FOCR?CX:COK+LFP5)K.+/__8_"1AN^I/;/__;_\)O
M$/+IR?=7#'#[D$()%C:]=KM9I(D/%L,MGJ=H>3Z:WJ"AU_V!K0&'1"Y-?\(D
M>`X4V1@"3T#3#<E-CZ<&JS85#UXK4&(KE:F6VW5]+GU<Z*6X-Z')HAQ-YL%O
M"D.&Y?\#$3CPS<ZLLL0R]ZCU=#\X>:&9_G/,?PEV.N/1Y43YU1_NS9=`_GPP
M&]TL[GU#@?97_WAG6_^"BG@^K.&:"O../IGM4V[U1\Y&UVSPL'Q?G$RO^Q-]
M>]&_'N%PV<#V^#<VY>+%I__76L??9B:5OK^;W\"*'^[A.L[+V;ORWHM(.GF*
M?*B:>C&_G2_*ZV(#"4C$D@QL(4'%*25ISS!3$_^VP76Y@]=RO";N7*R1%>I4
M0_*68ONX_][RUOH;](6GY`54RF+F(,9;/R%-^$?-0H%>Z2YEF/M4S<LA<=,$
MLG<NE?.UU7??=+3NHG]S0\W-'3Y$`2?7O-G:`&\G;'V+#&195'*S>$^J(-,,
M$^I9]-/P^&O*Q.(10B7B-3+4.\U>W6(EB=-9Q?^(M?=O"R^V/W+5>[MUND41
M>NIY^5>SY671&5Z/)E8)MK*(>+/_*NT.:P751:_+\7*`7N"U],<7?7//1Y,_
M>GW%!Z]V=S&:`840QU\?:A[^'BX'"]17"0@:*WZ]O::J4MZ,$1RKMK,W]`X"
M4Q%[8!-HMW+?'EHM98'G:1&3_/#^<#D6VE),4@AE!9Z^.,G<$A00YW*">^,R
M0.4?7'S=7]*6,9/K+2\9GK3WQ0O]7*M59:B@05*HV44,N#TKSV?,,115-E[O
MO7H`?_H&()'5$7U8T7(N=QOI<Y!8.?M[$6<\GU:T(\X3%7KS6;\<C^CA,%[=
M:A$_EOTQ9:V-(!/ID:,?3381F%RE=A"!,-C+6?]7ZG`2[O7#90]5`]*_,;A2
M9\>N06D8+VB!JG*S\E*E%"KU1=]K2*KV:;50:V'QF=@,HPA]9!)6D@$F:%,N
M1@@(\$>9?QQ2;SE#-%BP0PEPDMR%Y2'.!9"*O?'VEN*Z_T?^O6*IMZW&!G"I
ML[PD4K=V%I=SC9?F^)QJF!S?@"%]N=U)8+<0A)%P?LI.)7.F*_TQ,[1ETJ3"
M'D",%!=7XXTFH)/ACP%/AY5BO$=]8\]>?](?]HOS)5'HA$`O;/^/R]EHSFO2
M]]:&5ZO$.?!S"=UFOY1*3#*:^`.RZ5^G-$3`XPIZSTGX#XL)726?/G;'%.?F
MTS__C_\MZ3N^H*8X"_Z"K(#]6^+:A!!TKF&E*4TM<$T,0`0LE@8)*R'=,$:_
MW@$7HX'R$K9_[.P-IK%_.2L=85B!5G9>+MZ7Y:2R!/(K[)NPOJA2X9^=.(`6
MBL"R]8!U6O5LNKR\JH^U&4@U3_O_])&5NH8&AV=2N(:MI%OQEH4;U;90XE`+
M>M1B%F`B<?E0V`:LS@(_PJH%LI$LF\7[Z6P\?`_-$H40O>`:V=9S@I>KI+#B
M;Y,L``LB1E$<_69^2L<P(-3+T[8U"=DW$@AET"6^"B2P>M<Y7MK[.GD+HF1G
M'Z,"BK$I;0!(CJ?![GZ6FR@Z&70)L(16J2!2\Z/8B9`,#;:#F%0UZ]QC+"]0
M.`R,U*ZMF@@#5$3\:^)KRP:EZ$QA-/BPO"%N!\1(59BE`P[O/Z7H7N"ZJ25O
MG1-"(GZ`B\T#O*'%-REOG.M7B>'[N_FHC$Y(0L-1FCADYZ#\*I\'8,.EC5!D
M<[;!B'=;NN\Z4>E94$^A>,,<6ECMUCKL18--/&Z_4!0`G2WKF=54]$C.$^EP
M+JXIX=9FD*4#B\?;OS-*/>5_51?#"Y08Q&`E-42:%Q&^<6B&=+-IOBZ`+EM9
M>Q517FIR'^0<+<1<H5SL)P!(T)IYI:H!.B2NKD+F'%/W'\BP1BE>0;$:!"=>
MF&`RIX*F:(+M2QP2]``TN#:J.U=CYM3X=HWW>"[*RV]#D"WW=(G#0U!'-M1U
M(HZ9\L'.',IGDI]+7$V>GHZ'+>S"/:7A$[?LN35\[F:.N:$9;AVTDJTQS3\-
M6`[KS\K!U80HZ?)6+5^3.<E-?/.(\1&[`[2D+\PG,@;O@V3]__B___%_IL71
M_'U_/)P6>[/EK^;8[X^F=$7]ZA8)S27$C+KG`YK7=/3CYGI`@+GGR0"N>4P*
M'Q:(\7>P=R5RG\?\W:#SBVJ[V';?+B_-U7)5W-)5BLI"%0E5XCI"9+PK/RQ*
MRX$+OK2="BHN`*>'>MT:E<RJ3D@QJD0"P1'LFS&VWH9=L0)?[(HOR'<C,7-B
M77C'0`@0*H&F&2LAQY*VD@759E\U3\-@7R-/IPWR=V"%K8#^F3[%*S??\U]`
MS:QJ8M#,[BL&71*US"8>5&@O$[PB9-BR#.K#)'1>7I![Q!%"S?A+76DD&@`K
M2UE,\62#0+NU9CG@`'H`C8G;V`"I`OS=S>**&GKQ)_KH?`!#)KQ%W[,<DN"$
MB)DM,-W"A8KQ:N+=9MJYT&6T$.4T?TP:L\@QX4N(KSZ,:"S'Q2KN/Z[,"<:>
MP&#EE,70-RUQ";)&*.IB%`0NK62K^+WZYAJ`Z&^EFE6U+LL;KS2$TQERQ3C>
M)*B%F9&IUKZ[]2390K'3\67U!C+10(O4@$;VJD=R@9B8!#JXX=NIZ(B0I>7^
M%2FI[@L13KY\[H<Q'5F*VI0U=5+:=^Q*$+%EE2(1((W&218BF5&;-?Q_]/R+
M!,`U-X!/0D?T=("_GLEM)B?_C+K0.OWI(PPQ>GNZ(3M<<)'6>=$?H9M0V;9\
M&SHO8^QW8?H5]V)&?!2*H(`R]*RA6%N6]+591<T@D(24`:22U+I/1,]U\$#U
M)*_E))97\MXL<0#44'R-D/,>@!%RX=(N9P'(-,:>IRU;M@SIJX7:CS?IQSKL
MG77W?`N'YJ'`=`:XII0@CTYB3MYT.J/HEAR8LXCU"IJ3C<`I(]3268P0\P]D
MS4\MF29\FA!,#X02VA<E_JN^?-B!!4CL_E(P1%)#Q1[]J;*HN1=*;`"2^*]Q
M06V(TBJ,?)]+OBS(L<Q)LL@6[393+8ZB.*.`YHBC+V&M*Z:+I-><CC2#JRDQ
MG1O2M`A1;T(:U--`,;&3TD&)="U6G4TCWB?!F2$$EQX@NG_@/@`.B4>KZ(79
M4)F&%%&E,$K[;06:-DX=%<[8D(UD9@EKH@`VQ!42SVC:`P@;:VI9:DWDR<],
ML%LFI9(:/%TZD>!_?1V=N1E$)@]B%\WGEZT@;-67T/393`?=6N%_1/)A;D'Z
MY76HRZ^`_YU'.?ZKQ"E:YS[N!H&@^FZEC$$B[XKT'UAK7`!GYZ*%DI9:DZOH
MBRQG;/XZ^<5&@=@U/">-C=QE:JA8HD9+]/*\O"(=JB6M"JCNLOWB3,";EI#6
M9I%'53-?D);\*UD!K!V8PCA/?A<-2:"95T#)5XO)3K*`^#PMVN*`82?%^K3/
M())&7_H-2`D+).I+02HKM[!E0\!U]<\MM"0YFYXOKX!Y?:0N;;<EN75JO6FH
M0,<];I=H[=Z5VY:&=]):E)M1@[!@+P1V_'M63B]:E`_'?<8X@PE,K-YD"3#+
M0$-.4^\5X,7`RD''S)7'FE%>:]FRS102[EVIV4?*[>FAUI)ZE=LNPK:GK9M)
MI`7W[Q?QSO>)WE0%,-`E1FR.)7!=X1WINT9ZNF7C&\L0QT+2TH2OC422+D\9
M:C&P34QH4"&FQ`+;*HQ+"6)R1DL.><WG%TLO\A&69!F1/3?)J&*^379%-NPZ
MQ!CLKE)MT7"BXYCCV#9%>.!1"QU-0ZF%!<;3<SGY6KF6S5[HEE4C497?#KNO
M:^=<I[VD88FPBF]FN"DLFJS5[5;1,5>5<Z0+-5)YR&TDI+AG@=L-Z@>R:$Z;
M/.R1)JFK$;QD5T0`\%0O):>:LT_`@9PA599NU,ICZTCG7.;4NG"\B1O&I)E%
M:6TLCJUP1V+`VZ3H%*3A3L<U6BS$>8HERB9&KL*Z%901#:PD)DDH6;T6G-&&
MYAL\$:7/X%X*2T9*S<?D3,Y5B(7+S9G+>4M'CA*S*H%+TFG:FL&$"@&!.]4*
MM"U]X7+'^2&61$_>8$%H1:-,D(R@4970^8$F:C203=#H,2=TY>01,JL#AQEA
MJ'[>U,7%I4PBSL&W*%`.@I$S$,G#"9T=Q'_2XE63!&:9AS,3`]KO3'ZNJ+TB
M)+$#L$6E\ZS,_U)I,+W%8'.$WN2SJ?-GE8"@8*%=!38@&)1J>6N.KXE'>:YL
M.@.1HG=CH^:LV=`:.HWZ;HF0?I:GH\<\%?JWI&`WA.&#$=0SX=*N:BAAB1FK
M7+[N=(XM!]]<Z"#;V5N(P+YP-BTT3F/Z^I*KO6HWS6&U_R]X+:@$4DZX'D*>
MM-XBV.ZYL@X8-I>0*?_Z!0N>%BE]1.V7U]XY#F^EJ98Y,3Y#7#1:=`OM66QQ
M=5>@FP.U%Y)'16-%#!16UES@MOHEX8((+V4,LK2:WQ$W5JVGPB(VDQ*"E69#
M"FW"6&Z*#!:2A$&@D$'*N2(1VF8=HYYM]%)"HE)+HH<9WTGK(?IVXLO[&5><
MS](.=0IP)OW6?N.3<<^((@A"_RH4FUY3L"LG[T;D[HUK0,3[JQ&:JC<K7(WO
M1H45B81R>9'>\Z_3B:=2MXHWM)$UWD/#*@+"-AQTHC5SQWS-\W6O)5)KYGC4
MK(;9<F$,UH-^A@$K,^`ET3G9.4(M!$8[K%`NZ`JJ*B\Z:'M5@8O+:ZF/8AKA
MD2RLUG;N9S.4Y!]=*@MBX"I"*XS/MVKTNG%HDM";=&(9XHM1#;:*<*S`U%R]
MK(&_@;&*H[5YL__C,`E@'98<O!XJL#H&3)+=ENGODL2+3<QRHCU4TPP<SO:&
M'VTI_2/NK5Y:4+<%D6JU+EM(3A-WPRBDXJUL&+"J0*E2&.)PH88J)XPXDN$N
M/*HDT%7^`LF>OI=V-18N`BSIB/J.MMC06)%SYL__]N^M-QP-LL4:,EAU)IX6
M,J+\HQ%L8Q3&K6TF"K#5#6J$"[2BR9)+,-`5[=U-H-PXV![:SVUP`"]U55.I
M60RV'M`"\^]D7A/3ZOO=*O;LW#:].OD&+G'G7`Q57PIR02:%+H2A['=E$-`4
M,ZDX+:'+'47AU1N\!@`"86@!49D!T=YG#J^?5;HE8*9_A&XP>670@ZU:LXLG
MEE&/,=>`C*09L8EWKBJ20(A5ZLA.]A+Z-?E%!%2F)_3$)(4A38R+%;LQ*%L3
M0"*\NL<#"<7V(N"*O"5GT0K$1)WD2^8(.9I89C,=48(LD$XV?CCCH!(NZ4RB
MYHSC<1(V'#^36U7UWO+"+W8=0F;*U(;-+%8OL)9LM4+3TR8?HT7LBXS82OVN
M/<6??66+9T#5=X.M0UG(.)IU%!C'8`7Q">#,CFPC-R12^N"5.B#PY?':78XB
M>88X"2&*DMM(V42)22;RF$H4I=?A&L!DB*`^N#$>'K9V%V=''CU5MF9P2.\:
M/__.F&:;B]A]U](1;BI_\@7JJW7;)VY9'/LEB__']LQC';$WLJD(<P7_8?[J
M"34-_^$Q_*(0+.LE&S3L6J&>>_TM0O7P@-Q]<*=??B1.MV4UVL1C/#Q5E_/^
M.W*N:E="K!66JE^![]7-!M?H$JE<-34(NGSAV*$_)0;F/3@2"FPQ,:,B;7P,
MJNI)JEJ8&:I-%OT$1X\4WCGET').EPJ6UD_C6+Q935GS`Z$FO1472\5>B!9/
M(;^R.]:+([WR<^YM+;G,M.3X2T\90.KF6033G&"8T!PUP*>V>)SX[.S\'<#=
M8EX&@C@^T2FU/89AG!-2'O4TZ:CJPS%:55S3S$D#8PC%K)P?I![_(+J*TKU2
M&8,Q/I3&3[K2=%)^5@6U^>&!A-C;V`1$*\]D[%,:L)"X^;+\)@[<LIAUKQZH
M_9!N9W#]VN328RGA:[!VG]M\U!(9*!-:E0219Y`GV0=LJNR)Z9.)>15O9.2Y
M2/Y>OI8FOU;W^%YE(M:C_5JMEX(5ZW->VL#6OBDF(+9VB.F[HDFO3!38@#H'
M6B^9#K&^-`.JKTQ@;'Z3`&1?EQ_P#>;HI#NR1%5Z(-$J:)/9F0NL@,7!EEU&
MOY$82!($<F/)%'Y.2QM`[V3JI)&6U6&Q!2=Y9E2S.1#%NF5%`Z806^!;W!KD
M6\BF)00G1Y?1N,\F65':`9=G>CFA.4Z6)=^*?!5WTPU],"^"%&E%6"(VDW_5
M1)\:7+C)HXT*HXQELIU@,V+3_]`^3KR3/<GA43]!%ERCE2^DA^Q;@XW<%E+-
M'/TJ<F2+%T6S`VU1MQT6@X97*AWXQO`A`VR,TW#9*4.<9^_NT^>53Y>E&S2I
MQM`L-D)$G\9BX'VP17A^:O,VB\&+:BW?XD*40!,?RTZ=PSUT6/8.`,CMOY[Q
M*"))H3L[Z$K,9E]A,-P6Y=M13,B%"4H;RL)[_@)G<?K>TBN\'U-;R!="['S2
M?&%;R*4PQJJ!HPL[DJ^EX0(8)][;+0`2SOX[:K>VR5)/8Y\P?N8DX(%++WY1
MGX&)]P0OT%S">7"4Y;TRA/%BQ1HL?Z^7SLTE1!!*.B[/X%!4``66:9F4-Y8,
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M1F)2VC<R#UECX$!L;=$^Q_E`>>:(H>!=55:O@QU;??4K&63CM_I31?C0-9O7
M$J4T/DO6YX?2"=-K668B90/%JN,WLB'(B$3)S'AF#J0)\;&,6R%^YF:HA5+3
MD6FB->K5<=W(GL^)P7BX?N!R0UGPULE^*@0EJ)B.WV5-!Q'$W9P+"HGB>1!A
M;?3!"V9;Q387%"592!IAN+1,;NV[>0BA\<@B%V,#<@9#%<F-)X'..G*08%5B
MGY0,SQO9M8W%1E@T`"("9D0T(5:K87MEP35O^VGIP<[CT(3&,4(UI7#DZK(R
M4C$AD:T;^#1AX1[38'C6[C:>$">P"]NK3'M3KAYDH,IB;6+-.E;''1LNWZG`
M?4,>@/_!EHO+F;%Y5+=J?;OEP<6@O6\<.U7D;L1L2ROEB,Z<F=NA;D6YA@C$
M:$;,A86!VLS<55FMI4BP!U."_B-QEE]"DMS?2&4]X$J2CYY)T,P/BEJ0*XMA
MB-3,#4)\)$OJ.\=C`:]*D%>+8HQ0NFRC3VZ*3QSW`_JHDBHA@#I6H?XZA/%!
M/GULCN(R%1'8.K+=4OQM078W,W"5\?1N^.`^"+P][#20B@W-S6V_35ZI@KT@
M$RD+$'6A*=;U:`.&(+ZCQ=C%0NWQ08<@=M[M[G;@CFY,#TTB$,BWM4M!\**"
M_2(UJZN&FVZ;#\G.O0'`)#OT`&Q49T0X%;2N8YZ5,W0X]%,5?;TO"85D!<EH
MG"O$)]F)!H=M<@#J%R?=K-3U2L(2J@,6G7B[8.I:J5$.T*GQ+))+BFFG%@(O
MT]ON3(38SI(6?>MKLK1%'2L2PN*DH.L^#^NMVJ`L4:OV^V2=FVRNP,M+;1K*
M85)9D!S@B8FA6A60`6-6@0L$RH01H%"]XIWGCBODK/88?,D<KZ(9:$IK&+ZY
M;F^GMVUG)UMCA0,0T-6`Q"1F=FK%8=ZD>.1WTHRR:[`1<41`"7(2>@1Z1GL!
M^85?QZS>,)1@*)8?8M'\:DLNGP;`L/:K!XT;M>*N:9`U"GSQ1*_P;L(=FDTW
M;'6"Y9<$&R>XZG;X4J*6M[HH'S=OY50^\[BBDJ"LYN='?74+(YN!KF3Y8-H$
M\')UGRJM(Y@0.3*Z;'L:#A_(S"`^F$:*6.L/&0T`=(M2.`M)$AWU#KWWE.DH
M[<1TF:W">N=4OA/1D<[5NZ\D<ZMXC:?-_.85*-^$N1?#'6%&53F6NX6B=WMT
MP:58*0%&*U9Y49P.=*18!$!8_674/C\IR_762W*2](B=Z<IA6ZYE#--9W*.]
M4SMO(CHGO29Y%,,2.ZI'1(6OPPY]Q>ZR@2@>JK-T7C;S&QH_+.6S9).LN!E,
M"AJTV51S5AL"(303Z`BDP:^^AU$A7TRLN<`J0Z?@<OJ:)%Z?F[KT:^5\AG/;
MH1UU<SSS<5@XJK>TW&0B]UHV)L,18L[,\W'Y%B&CD#95Y\5)[5;)2@!RO%O'
M"=JZLALI`TO^*ASY6OHW5O)EC&B\9'.V.-)X2*3X3^--K]TM%LMF6>X--R*T
MM1"EIK-#Y%B)G>VVYY#+<A^6U+XE7>AIYTSP2`?C[H`(-$J%'5<9:U?B)#0G
MY[TI3VZP%U<8U;-WEM`UM5@KKT$H-2@!33R9HV"A)9R'TTD5DM&O3OR`_H9`
MS-&MG0,P]8[,M.T:",KU8^M"Q+#HM2NL@#$D8D-B4&)5U1A2*!><^`0KOB1)
MBD&[;E0("!-]O92OT$.\SJ)XJK7]<;)@NEYFC[OM`%<RH?)QP5=N$P./BLH?
MXSL0M4+$ION[GUE[G>KRRHFM^X:K6@!NZRK!1@6FIWR;<([-K)W?=AKLGMK1
M;!R66"NJUUVV5&I'#)`>^@O2B@QQ=3@,]%7B%Z[55D[ER/IB=%3<;LQ+OO#(
M9O2DO_<=\`C51"M5WTP)Y3$\X=BFQ"]J3D5-T-0[O]BQW7I`U6SE[/7=*/$T
M(4<K,*8I`DJIY$'MWGD4NB;<PY6NQ-O?S".98L?T\CFY+<*XD#BVE3!,6(A4
MFW,L=#12-ZDX'VIY=0JV).F,O5:A4U-.9$5OI`T,'2GB:.&R)`;(ZA^',QUN
MYK(!N3-H@37&H4F<J)-G&+<8DCMQ*/3"B.RMK=';J(9C%;"##2N^@XW]<2L:
MJL0]9&[#/J->69*1QE?ZT0+92$.$6H"AJ.\*-Z5B<[+TYIX$ME@F`GW%.@."
M.3ND@:UUI6%CW@@9D\C5UDLJ3-G_]L8%#-E)3.FFVD]J`564EZ]<F"*%;!'.
M6BNNQ5E:XG.=@.A45[NMN,:W"369P%7"+NR-5TC&:#",%8ED%_:2>B%E-/=3
M6RB6G%M5UCW:K'HKS%MZ:&FFJFP7ZF`N?]G'D-_"PL:$Z$+59V<>8PHXF;FO
M>R`L+L\S=RR')B%JZW[,19*&@*7"?I6R8\/QPN&Z/L1'S(;%1ZI8J]:>%0'%
M9!'MYT8EI=#02;>]25C;!<N<"Z3?S*%$I>"^%TS1J^PF9AEFLX_LVFCM,CW5
MG:1QJ]5DT2>`2')I<8KX^2<Z-8@)]0-.7#&DQCG+"@AHL]^:"4T(M<@RIHH?
M^N7+87Y+[^%HMP3R]PH&P)SJNFBSU"80+`3.L5!+WKFUE.0EHYO"!((</1:#
M+V&Q-^$I%QP%->A<\LP#=(O^#%K;1%W:I.SU)>HB1-7NCD*?<EPN8I<*1\JQ
M&Q)QB-+:S$/#%>%V2L`HW<+\D2<N?B8>=0%.'DK#[P@"F[%G59=(B^B3A`*?
M/A[2>VA)&R9WO6HBP$M6/[!%A3O4&\];9_K!<17K21:M\@M;AJ1,++V@!([-
M$P)2K[B*Q232U?FTZMYU4;ZR=OR5_2007J_51LLB_G)'W$`*0/,7+!)5`@5O
MVA9D&*:\L5.]1:17?F%\P<YH-PB&/20YBF>;'#3>?/ST6W[V8WOSZ;,GF[O;
MCXU&W.3PG!\">?;HL5/3+%.^$+_J9FP]$?EZXF7EUCH;;R<UH&L/(0$/7]F=
MG*K)6RT;+8"<=K0V6"G_)/NU&-I?37IEX6OG=7>KZ\:R])"2I(*$+&MC5U5P
MD5:Z`4O'H>L=O^3P.4JM8$(LC+7]Z9)FGW,P!.Q[:,)$!;!%^&DFG7M9QR2.
M5;L_0\#8WJ*,;EV]*P"[C/6QA!XTH@@"..0/2?8[IR]IR+<3,,*\4\F+)4?W
M<#WDMIG7OM$YW7M0/-]Y`@:KRN7P&%0\B"SQ)9Z.FB"5\X`0GIU0\FLHDN;,
M,B`IKG&_1*"Y#I$8-(C3]9W$[W2(2KN/DX6G/)@2U5>011`?.TWPGZT,R)%#
MLNR7-IL!E9K]Q#9UT\`H(*=](]C-5A&ORE2E6N$$MB4(5EB)2`*-_5RV12BM
M>T9[DQ47BZ4(82477DYAAM]2`J=,J^.TS"&R)@9'L,10BA[UPR!+/'OO>+#N
M>&LPE),@_^P6GR:6CWD90F(-*<7+C\"9T\;XC/?#C88Z@YW-*GD`+[*^!@8)
MOFI-%)!2<#X5H_")A],EMV)[NZ/6_)7+$0)9M)0.7N%GVJT=2J<AJFYO+J;3
MA;0I(TEPN=,N%`:)'';V1E7]6'QLXL#3NA2>>^0C3S8H0W\8/`$#)/8K:AD*
MBY$6WK,6/T+55Y!GO<76_46^`A&5FPNYYP1]6@3F.DD(PX0C6"T40;3><([&
MH4FD-,4.HI*VR?"QF&>!D5BME&ZH>V?QB[9CBR4E"\)R1XS74JS$0[@5APDN
MF8%$G$8:I2R\!(=V/91\=OM0A_N$)TERG)!+I3?<.I!Z]A-ADA*C9Q)07TKE
M_L794T.3><-D.^1JK,BL(-2L(D5ZC.OA8L4VESQSFD4.I`A<L@]#O0R02"<.
M9$N]OZ<UE^\J4D*`(%&4(MG=.W,.`R)H?2YZ8Y,2D=R-9]8:AGK;PM7T?2(W
M+R4JR"&#TVIAU]6&-I5,82J"Q&-!V96W`01,Q\5X_J"2L&D"QSJK'(U$B+-T
M9?`Y6*D.O5BWE'U5+5LE`W6-&72GPRBA]=GV^(Z:D[6K2*RK69S&U7:@.(0U
M(`=_=([<H(I/@!<U3EC^+^V@7A(_8[V)ZG:;9FK'*"<T?"NO42&BJ)C?#\=)
M)-ID8D(2$.&"+(176ZJ`TUIWHN3IJZR7E!U:R&!:E<067%VG80TY@:\5]KAX
M*;4D<.`*!1G%"=>QI+.PD(JC"790&96&^?T+'JV<EITGYJX\+3:HH&"I$B@Q
MC]`'E?9+AL+5>XER_H4%YFJFEH3RPS,2,G4W+;@'3*W'`D@F#6W@^E=P>4R:
M[3*%6C0;;3:S!_Q@33&;`9TE42F1%\>2<O!YO(@C+?$W0R07;^L7JPI=:6XW
M?O,+C.M^,NNN9S]W%_<C[N*^Z_WO&[_2>S2I%R-7W80L$?#$C$#)$L)(AQOZ
M\'DG-@\H-YVN9/#6C/"(&GQB["8AC;5T"J!_Z4V1Z3H]<-*S0OD]5ZSX*[H6
MCFLW*R%V)$M17TF#E?H]J5NU2(%4K=XH.75Q'1V%J?@T`)A!R*%\`:Y(YA&[
MC4Z.?;KXA>GH\0_3#5J-6-YKH%=#YP),J*_WK2R:+;;)F#3'M=+=,*!Y161K
M+'3@M]T96=7I)3EV)`"5DR*7#A5TU2-1-4++*E97Q=U_DEU5F>QLT&1+.EJC
M#BOTJY.M<2V_H]:2*OC92OKK.E]Q32P\3O?B,IBA4*K%<L-V\UXMS$.X4;.X
M_RA?4M5I%%-P\`2TK?WZIP'(C2PCV"E`:<M)B,]UOR\#!!^*CJXZ;83/<I7;
MS3/8)NNAV&"6O(M&IP,`7TD2!'!14.[0+E%<N10:6'0C@`]8A/&$L\HC/'`7
M"*=D$&Z%9&!K6S`YCHP3D3T5Y%UH%H=@S_IV-XA!1@A7ZALT2T4PQL+<I<'@
MRNA$U+'OH\;%U")^@U4\HDD.&4=`GOR7]DV::0H%=!>DNL@A-2IH]3N_47VO
MUOUTA/$Q<5&48]V6K*;I?S^V1;G&BKO1M+"KF1WSJP(^\1-BRF!I7U5_#9^;
M8&3GF$*=0WQAT$%M7>G(;77WCN7WXDUVGS[>?[:UDZZR$]'N/Z^4IYXI(-CO
MF*TF=%MB28/U\_GK6?*&S`5-T*[,\6CM)PG@G9MH10YG&145!B4/5(@;@AHZ
M.%1C(U-<:S9-`!9;375!451':%G'KL7TTK,"J3'![_JJ(4U\.]9!,_<0->(>
M1EP,'0N#S8A2R#3*G?/N\90Y5$97P=60K\8F5?.KT4U,(&[4&,@UBEM/$_^0
M0NM*#:Y1%#"1IAHT46;5Z/+?Q)UUC<)Q;_5%[-S9#%L!K\G!YQM@&SVMU?M4
M*!95W!F:6GT;$D9`N@V2?(IR$^:[V_HY)$Z@'3I&4==')K<KX/DWWS]<R)N)
M$05\9HV@HV[J#'?8X)961D(\^5S;*YI+"&#]Y>BEKH/2%)+`SW?"HI6KNF`U
MP-HVV$SSP-?0GFJ]YNE^<'G,-3"*&=G<?4,7R$@I^;B2>5J",CUK?WLAQANU
MWUJ(U^L1-.F4(2%BN,\12%W=EC6/EZ<9T2PKI/!IG3=D98@5LB;\))>4W=4J
M5&[)9`O'E#X+-WZ[H_%U3J=P/^IZ<CGKZPB^GQ:H#F/U6=H9$^M4%O'=RG,$
ML?*DDL\')T-$:J*:VG/,X,2)Q8E(9V\WT5DL]=5:A;KIWL1'\];`9(2-JVVR
M:7'-<;3W`+PF[^YQK6==\PI`]C;ECD=/JD('QDK;F$UOZ;LADL>]P3J8[_VT
MW^(>OS[,3SJ?$9(1G>GWJ8[U6\_-4&GU4Y\+R'8)R%:_V1R_O2YQQN[0Q/H@
MA]A8[$/KM#079),FL^Y#3\;$.G#ZF09T4*EJY4?:/^&7.SGU)=EO,&WX9]EO
M"XWR7Q"R'P`")9`=&+GJ%X3V$(/SV:CYRT&/](%JGI[F^>$>28_I3!_&GQ.R
MGM=X;0H0IV.P<^0__JPC2_JFNA'6VB'M`/6GCZFOL[Z?Q8O[S0_2D>I/'QGY
MT\>!E]-F=XR1CE)_^IB?7VZ.W`6#;N0!?_IHLJRQPZW0!"7-IP\X*?;I(Y>,
ML([*,_ST,;^;I/F.+3AT5IF3T7Q@@_K8[LZWS8];OTJX\6AG\_&3Q\WGSEMZ
M\NJNFU(:'N\:85WHWF*$M>Y^W-_=>A9]H,V"?SV)_S*/FP\J%S<:#/53_[:"
M66M?^CFWP[.CDQ4_C99]]3E-?XRF9X\WR1FO:["\XJ(56^S&V.*Q$%+MT%`I
MA`3IGIU64>>$"T-B&K]UI\#ON9517($5I&?:/Z*\'^_[L*BKN=XS<8K7PR43
MS:]?+4,=K@S'J$HK".5HTBQ:UJU<=&P4(<=HIKB_DSG#LG5\D$E&B*A(^LE!
MDB14-V18F!57&TR_-6=`Q."AMWL]#GJ=E[V#'M"OGS_OOCD^./JYVRU.>J]_
M/#LMWA[S&WPGW;/>R<J?MO^JES\G/4\L<?<7K.8,.QI;HK*F[(;IMTO@\%,)
M6<BB#Y+I#:>41G/=%NWY"OEM]')/;[&<4-K3,%9C];P*=/7OA7*2L^@1-`Z,
M:6&U^;(H64XC7\=YZ.4GJD+P;3+NXKGT6^6#=V<JHN<)J@B'_#8A8GL6K"O4
M'EJ$;U<,>;)#'TI(["9(/W_A&QH^4)DG.=>85XT:'"'>K5T7%7]HB!MU#B@E
MV,W]/FRD3O#-;-&X;X0J(HE^)LVJQJD*7)L4D\Q9/%PLNQ<<K\6J%,2\MMK:
M"D)!4!49"79U/X2%H`TX,ZLMFM>FU1%-Z"HTH(.Y.H^06HGA)MVDRR`4:OH4
M4$&\D*."WBR0^X&,VSQ]@]>O])I&#B4\9E#-GGE2GZK9;74\\Y#';[%7D@R_
M.:/Z2N0GA(@KCJ67$&_8LK^,0?NV&";-<B]1N#Q_"S=O6'6;3<QOO:YQ\OJ$
MW@Z^5?S(%4ZH#B==+;:P\W-4];G;2G11L(-_'EN!J?R%N,6Z9ST3H&(5-VI:
M6RW836:*V$D5+2J(=*A:'`7WN'2#TJ?2!M!::]'=(Y3S5(A).S($M,N$\K/R
M@2.D6R,?U#_5<R'_.K.9$:$:JVZ\W3!D_N%Y[A_^57]A<O61I7`4*5O!W^97
M)U_<WWGV;'-[FR-;]W>^?:R_C-W\XXE_7#=/EFFJ=$JNI?]<*.+9#((LG];"
MY!#7H&71<M5]7ECJ&0-#\I39BF7R#)TS":UG30.$D4W-62TK(7S4U<,Z]6]1
M2*S3!Y%>M3/)HU:TE"JP1VIV_$*KA2:&:GA]`(L!79)AJ*$4!_$#_<'\^A12
MJZ7$[T'C-?!:Z\@!SG6#A^ZUL79P.A?4?"U56V=[C!`1)YC<5N@MO1'8O5P!
M1CM!M*X4J@(BX2[VH*!QQ0YS$<OL`EK+#K/1.)N_`>+$=QPX-'Z$1RFQKF/`
M3(3Q*^FJ`,<L`\Q3$]:$VFKK`L=U-LT&;L^7!G)XTP.!C2;J69M-6%08W[XU
M\@2K@"#4Z>X'+JK+>T>`W3M^44W7"Z^`OTQ25@E:_,VE/<G8B!^#DR4ZIM`S
MM_Q]W5E-%C'2EK77%Y?R%F:+&[')3I5.K[R)L/VO0U->\CQ=;8:_(P!]^FP[
M`.CS[9T*0)\]^];^@89(AKZ.J)5:6-)45J^N:7T<NX:4<'23LJYJ8U$D7-T:
M;T;M7(-`(-:*8/;OB)V[3P,WGSROF/GHD?TM4_"7,3/XM;G)2YH<84>*&UJF
M#*<$!6!H/:9\_G2W*5YDI*U#K!FN/I$56@4X2`L3U.J[=9L=\5[NH_:N;U/Q
M+C:*XMU+N`'??(5_1Q+S]+FY2C)ICH2Q'%5QSSQ@E6HAHEWMU-+>5<Z024:6
MDZA^;(Z4*>=,X$EL#VORG'9J">H*D5(J.9P72?=96<2*N__WP[2(@B%R:KM)
MN&CA]RVJJ$H_KN*.4*1K=0@G:UA-9(WQ;Y2'$9=%4$.A[KL"!A8O]H[>O.F=
M*4M_ZHRH$L'95Y_+N3PE99`]WARIGS7'GU@EX5920MN(Q7K-Q_-KK<XR@5I5
MH$B%B1CN<7Y?YHA<F/^2CGFO$DMR&]:BPC=>Z@GU%KQJ>P;SM[HBEIW'M8*Q
MN3;1JU02P,ZM<GC@UMNRP*AT2<'>*2T0"U,+Z\/40JQWBQA`!C;66&L_E9(7
M@H)[9)5=5LKB=3B6MW%G)_BIA-,X^NW#NSWW`.@QL$US-FBL@(#AK-&G.E:M
M@;0)O$=O4686/J+;=8`_J'^<4XZO:S:,T-RM:I$%"=;]$LM%PAY.=YKZNZ&(
M.ZX3J2D";RTI(&IY_2^0052WEL[J:K803.E16$^;1C7U1;'[.XG%T]^9-QXU
M`^GX$GE(I`X>34C?V"0.N0SHN0I.M7",4B31G3D*-K!RFB.=4M")F^W?Q0#$
M?:7X+S_;E>BR$:[!IS7BEW+X@%\SXJH<]?;6[]8*O^RG#CA:#:T/#E(IF8=M
M#'VF.HU1G1$[Z+T\.FF4-4F<:9T16L(B"*)D5M5N!?FJ\BE!6UMY+/K+#HL&
M\<ZO?>$X"@N!AYY6A3RA+?U<&A!JS,PD.2$S1[:*!C?/:BEU7I&K8NX&D32_
M!(W4+F^TR-V,O$[0Z)"*?`SIQ(&<!.'!9PF"4.U/HL7E;DO=JQINX<+HX838
M(?KL'IO6ALA6P:BP)+R2?!.^:#]+WD@Q+EZ<!#A,@1-[";)L0MO,W*7#`R)G
MYA:ALO;[5:3DE$0.^M),VUMTN3HT2X4BE8V^==?3Z@;?/O$`(W2!:'&_/:YH
M[1]P7.-&Q)^>B^0+4A"U.*ACE%R`P?LUP;N5*`%FU7Q%=EG]Z.:&A!B)37*B
MJ)Y[EB00N>)J9,8!2,,R'K0VE-^*=I:IEN8WH"5*K]*9-:,3&T"J'%/>?5M]
MV@+C%A!7>@(8T+AOY_:$!L$VR:=.UU!8SU7,*<=C51F.1HH[B85T0;JJ%2D?
MCQX[7O2S&3D`H*?1(IVVPI6Q)(R.5<H<VS_"KLVVF6'>*EI*D;A;)6R<#?])
MZO'TF64I40T.4%;IRFW/7?YM-..M2;1G^V):O,5Y.R/18G]JF-)M$VHJ,IM)
M0MV;2F&HVZV`-99F+&?R`JQ4X38A<=>]S_326EXH6(NR%L%7"")UR3+Y\1$"
M%>X/L92L;OO.Y$HA#"L.1T>:V<6T.>F@[Z-:TF?TR=;"`7"G8[+.68=9&I,_
M++WZ/IW_E$FLZJO;6[NUTGIZ+KR(D6-3F&+[R38_BQ'`"C>?H=R/XP\K*5<'
M_.$&)[6D-=PWM[0[Q_C;('>+QIM5:S5$MW;T((IJU6L<=?W_W)WK3AQ9EN]?
M)3Y42=0(:*ZVZ3ZRE,:X.GLP,&2Z^I1:\P$#MNG"P"%)5UDZ;S$OT,_23S:_
M_UI[[]BQ=P2D+^4>C53J-AD1^[KNUXI04=W&9A%!3W>MKF`B5%ZH5K(7:6MF
M$U06FV*;0W$667EO,1!CF\A>$@@XC(F!8VTGH4#9RFG\]#:X[S9AN%:P@Q>;
MS11-+3%TE$VA_$F>E]!9TI#@5.IL3:+H0U-&-J`//5K6]L[YF_AE35U;RF7N
M)Q>(^B:L3CQOXL9!"LR5O27D'$4,+V(/*CN-!;#FN2-@UDH^4CKJ(!B[?99R
M8K&`&Q"G9#9"/H2<?!HK$+@,SHSZ[XC_^5_K?T(ZCY*H;KI3E=!/)8"DP[+1
M1\KJ]$;OB97>A-9C'*TX&")FV[:3WU2]>C`2'E)D\2$"L&Y#[9F2._+KE,)8
MR##KJQN1"@5PX]ZR8*Z\NY[%6PU"VMW3*4<1Q:FNM)(3(N]6D2TKVNCR>H`Z
MU4N)&R:)NK:$A&L9QAP^Y*G(P!58ZZ.0=0MC.O^-DE#`9[R)V($A(8JT?.^%
M1,EMJCT`R&8OC$D4"".E[0IRI-6>A",'K4F%S]X/1-8YK^U!:@A?Z=\9MP!Q
MK3B41!JR^2(;$J,K[L>M=/==?G;H`3/Q\JD9U-LYV?1@NDM)Q;B;Y`9*#NG3
M-#F\S/V',^\-Y03%*,53S)KJ49YV8BWK+"_6V7Z0$F$#U@?:7TH[3LH;EVJ$
MGAET5E?<7K@<UQ7::8+.`LVSL?S.S%EX0[0'8<HNV'7W"W3$J$L!CT)\OD,K
MH8"#>9$%3]983#^NF0O$N-]C>\M_6&WV=9DIZ\5A0/:-+E_?>6SJCES3R^N;
M;N\V/8B?MUS>$PQIEU]1#<J[(?YT3I,P;%6^7LW]$A\+V&#.Z2%.T<5?;AMJ
MH7@/@P;%*%WZA:QHU7[V1NI4PRR.76#U!U\(C,2ZE@F\@R<;M3MF='(URHU/
M[^HMN]G0)2+ZT"V:B._LF7I@<\])V2CNP#5.!T!W3+`5_S"!7G4)8J.E*AD3
M:'6(`,ECD__*R5R*Y\(WGKCWS*^;F$\#+D3*D"W;4U)B\N?1\5ZS.SH:3T?[
MI1&K\_`A$^IC8+KS03E:QXBJY!G3G@2'K5@I)@)9M+H_Y??3P3>EO1&0I'"C
M8!(Y^'FRU[S\]ZD@!-,D6M9YTY9=>63(1?1&>'M*/^/1AXL/E!U12:2]T'LQ
M5#BWDB\B/2Q3B_.7I#!FJ7B213^0T.EWKOY*$E#X:*B6C$BM6L+G@P3KE9?O
M@7D(<.E\`?";2<`)RR4IX];-]D-HF4)^B,HYZ=*1V,_."?H6Y@3[@E?N8"'/
M85ZGJIJ+$&SG(4JJ?U@1%&<1D7N*FUUA#4R#25*TH".MJI0+^X-Q.L*BG:L'
M]''%V*]F+I27=WQXU:*`JMM@&>2R!"/U/CR=G)WJ\5',(7UV<0V@W)[<G!,*
M<`KK&U^=KMHXX>+X6V=.6HZB!&0G2:0@QA+H@6?_">;TEVD5#D;6@C02C[MK
M!@`HJ!+-*D15P6(FY5S-`FAK:_6"%AAR0,^ZW[1LYD:S0OO("7ZRM;[\:'L[
M@))#F)L(N=98P(A78\QGYJ:)1B7?!#";Z;$Z-ND^_$B;">)[A#]`S00P,=:Z
MOK9A4,7_CP3*^B#.P2FJ_8[:TAPJW46D/>!+$(%\A3U3HC+\0NLJ,G6)F_$Z
MR0'N4+8\RS\L`=/5AK2>[,^%%B+[)>88U-`Y`HA.L=VKKNG\FEY$^BG,*_HA
M<`>O".H#H+!O79Y<T,Y,P*$,=4$L*ISX)CN.&5P^2#05>'E$_[R]`HU`>)#U
MKS&X"!5)XE<@9<KK"M&KR146C/!AE6C=,:+*I*9`UW4S$0CLS,L5M##E`&_V
M".U>MGY#_GBYI-__L@+HZF;#(J0WNDF6.='HKXBVSE(S`P'UNW8-^P6'%*&D
MIQ!<H*8^KP%Y%T3B76^J7^PB0%>2D)&1W9*10DO6EW<V-I>WMK:&:#+BFV)!
MVEY4NF_?6O<,,V]@K,=4KD*G$,%$VXAG)B:OLZ]KW<4[%.ARM:D6F9'.WHO5
MFSTGW()+%J1%C*TK*/7$O)_86DG:G[Z0)[#CJB&'$JWE>O[V74NJ-\V)(X*=
M8U5<=+ZSE@)6>Q36!64I0Y]RCT+)*$IW#QW%\>YI[GKUQS(&_.[V@*>'!M"B
M%@O>7DC@Z&J[)U5&SC.U8Q9]0N<S<U[>/`%Z%5$D/^/J9.TBN'ZDC1CE:;3,
M-!X3IP.BF3KJ`G8(EH#?0T\J;*K23WZ64'[]IGLC=T]MYO+'@^M5+3LLN7P*
MXK0;*!^:8!B+AY0/]W[#2H\"5OZ.=0/Q#UWT;?7H)Q!-*.F[+3]\D9H9ED^P
MB_9N;4FI:N7+;>9:^:1,9&MC%_9D;#`9J?RF?ZE7?S@I7]QT_:[\.>1WES^O
MK_6_/DEE^EX;*$H]"O!D!MLN!^_"V!*\)+"[Y/]W&_T/L6>/Z,7"4$>3<CGG
MP_2H00*ZP"0=.\S7_T,%G8B5?YFCNZV[Y(]I.:-3\-4^X5):M8H]Z4V;43"[
MOKQ-U+<,%[V$+">E.@HS5EB?AVBMC-8@1FV+^<XHH17,0RWHNQ(DMH4#SZ8,
M2!IF-IMYJ*S&5-T-72&@JDL-4=1>)BE?A$JBZ-BP.9C/:[G!\Z5FK9R0":[N
ME+`B!EC2,>?G)*'VY&MJ\7X=D)V4RU^"E$S</&DVME9@-.3Q7*)EK>#V=E#N
M'Y#;Q2AN)"_6Q=4<'-68.((S=4*7$@^Y/9E34@U4.36U*(`#2I/;BQ3S29LI
MBR28*KE"!FO$%L@,CRC)A8./;W9ER[ZFM`3LQ8!,DK'H+IW(K.Q/&-=%*`EU
M')*'9;=$^&&8Z-[7X"TQ$*-JWWZ4.N'NH;%*>T?+E(>#`)?LK!,?C1(>QS9E
M#)=P1/"V%@;C`LY<SVGY2`#*('38A23XVE@$OBKL[X>'#H!5)!8$;]7[C2>F
MWW>ED?NQO/?T7#D2B.%D"*X^IQR)'IR@HCAR.#<3TJ=$JIWJC/OH`W=[)0N4
MH/GFAC*74L..H`/X.`!A3>_-86!O`9N]=0PICVA+O"`\-\8G.SZ<CBOY;F-U
M\['PR^F4WWZ4$>Q^!K`[IPN]9&&U^2GPS'#S<=08KX>.0JULX9NL=Q@N@&1+
MM/H,3/3JAN$>("</("-RN:`\PJ+6Z<57A#^UX!M7'I28#H21UF5.9WWY[!*-
M=66"RFH>?Y/T5G340J3WUU3,`"J\[$?7%-NF*KOI(TS4!J!6Y9@M:,-%R3\F
M@TOS\>*<,DB<]]KW)K>).)CM]D^FFEI=<L)^H(&7*O3.BX\VOO]3HT0+FC"2
MM"F@$F>Q=A!ZOK[ZY!%O"+A:^Z2:3_-L=O&;CUYAV>M*/-5Q=P^V9&#.$8"%
M(L@`PU>?9+EA@8$4+FHKX73.+MPMV&S$-D*\1ZLEJU\X:$=3W6NU%2W<_59S
M>J2DFO6GN7$J!A]%8N<<.<JM=GC5;A$,*V'9Q/<",E:WHMNK65(T">>.MAE*
MV=LUA<(_G[T\>%>Z6H?.;)\!^ROX<X[L$!($PGN.S@I`,:H7ZK"@T7A6,$CI
M+)P/9<DT7GS0.<1$N=R+(F0SN!X"#J/KFW;R6,.W#%8*:WCF4)0+A#`"26L"
M].^V0I("BVH-XIW<L3,<EE<8@K#=J0<OGV&?:GL4BY[!"CJQ_ZP9RU"DP)5M
M].ESSX[7<CM2)T"A:O;8]S:7=XCD:F6'#I/HGS'-9S>UN;.\^>1)@DLD\L3_
MD[K'#>AT`_HX/PA_L-MP@W:?YN\]Q_;<QD-U8=>/L>\L/&4N,*/R*$P]SX/+
M7`/YMNJY401.'83(`@<P:47CN,M;+N3,8G^*&'#0J[,C>IANL<']5K?\+Y`Z
MUJF#WU50.@#%SJ65``Q1ZHB=+4[?H>YB,A),"59ZE*(!@2-!"N4Y%A,[*J'O
M3S:EQ\AT-^#2BA-X?TYP,.;[VYF2^L-:6TIOJ*[EM[)N0*THEGK3>5_SL.*C
M(9"H9[PG,>SNU^M<"1J4@DJE)PI#4CF^@3341>PO$8`^2?X9$']VW/O<8>#_
M8N''C,/KJSN?+OP0N6;T4?D&B6(:S\LH2<GUVD=?PO=:CD<@1I<80_N%[)U%
M+2AI=6'E`=;7&SH$CBS(^]H=J'CC$+/+5<T%&%^4W\7PVBBP2!(BJRL-77D[
MY!$HKEZT1D=<H/1!R5G`5.#,()JNLA:OL>A#9H`-TT'PH1B2PK&D!#^CC66"
MNXC*)PDX(B?`6[_!^RY9G3.V%N6LNKR7F6AKJ;L\G[\:?3P_*W\_L%#.\M?0
M1Z;\N;8$1PFI>M.UG?)GTV3+'P^S1C((VEGU<8\O+=_?-?,.-IQNA:+*//BC
MQ2E5.\:'(X$<<4'BHUEDZV-!*S?=F^X8_U:I1\6".7Q!IR"@7&H8QNQ=;&WX
MS7YG.W-7?7BG`)NK.*A_E&A2/R&U;C,E+^).O)9*/U-X0Z^"5LC@7IVR$,*W
M5I]$]08A?!,??BN$;X7*&1TIO#R.8U@7"K;.OF/R%Z,9AG`'41UQ]OU$+=>*
MJ-2[IROEC+)JU+>;0*!\_;12BP[O\0"U]<Z_2/!LW0,#D%WMZLM@8`@$^O0N
M#$[QRJNCJ;/[M*Y6$C#;O>RNWA=<]@J48=ETD9H@[:@SWF0@QW\S71CN&=)$
M@!:J<M]=Z(&$`A258EX1@OONL(0`Y8>%KE;EHSA,0"ZMKWS%Z%L%E0F`R]>S
MW96/RLV6SQ,U*1^(#/WS'^6O26PN'W`/%NU-DDSYZ!++43U2MOOZ(?ZJ9BG'
M4KFY*_HI,&F#['K(V%VB<=EU)$VX'Q:<"#MEE$X0Z'NVW':`?KCI,>AL9@8K
M,S9L#%6KJ["CWSA58$=#".Q<5:>5`J5=AU87@+7)+3T])6-TVT#&707\YKND
M%Q*M0O%6(7\->R=WU>J0J6,UO1(@N%B`2WD3''8>3"Z+%)$T%>"_/+G]A7)I
M5V^7FQ^)E5&PISX].5/<KFW;VGL,?)T'B1_-"0X^M:_7M[9&.-:HIL7`U91Y
MI,`__X$6_^+\]2U^,+H7>>I)UTL8[35:UDQ5Z;>7UVE`=X^FS0FB3,_AHK>J
M34B,*JX!6]QU6).EUP03)HQ!UYK>:*A'OK%=FO!E*DP&FO!)-..8]%PP8GH5
MU(;&M"39KT\5MD\FJJ+/M3>9I2Q.5]9/`W\*+R9N?G^ZH!UCZX<A`%46D<VN
MW8L);RYIT<;M:NL?@&A`R2]),+6UNHV9&VJ#BI\WT#M#<&&T)ZZV=`XBI:O'
M<?)`J_XWH]R3E'*4")V_)\T0$S\'?$^P`&E)YL8U]B[Y(S[2[6:Q]]_M9-6!
M=/<I.)A=>E-GA0K.W2VIN0[46@_Y26D1WSUZU)YR,@GWK@@5(Q;^LQMK;]#^
MC&=@UE_A6DSU+(+ML"^K$K(%H6HES9.*,NT>4@[U>#I^MK_7'!Q.]THT+Y]/
M[HD1KMXM!],$S1.KP]"==5*^":Y^#I"AAIU:;3Y=Z7>//NFZ=$!<51O/T+GM
M^Z_:OH547II++"!M!6?<JHSR*ZB4UU95(C`A1?=>0$FEX4>@38XU2X8'54J+
MM+!:2&:.;K?F1;#H(B,::AMF#SQ36I"?Y@!DC(4=QU\4$.L>QRFP^TP9'ISC
M`:'S/ZNZ[$M*D2.M36_A4M',O-P<K(Y6T:)A6?K]'"^U)]J+\B04<(SV8\)[
M2(DTUA$<5D@O>!&<1@32(*^F9!?RU4.*XXR\"Z\88!$,!,ECP%?XM3JIB`TI
M2P;:ED'-MA:?XI_4.#/K9!4_<H-NOCQD4AT.`^=CV7LU^NB<^JE/>QDM1/6_
M&:^<$W%7ZO\D.L7-]C01Z0/MKT&P_![.SFG5V!G.?BG8ENPF.(N]CJ9)$A00
MNL.E@P(.EAGLU2PF>+^6MMU(4S.[/X>X?A7K#)]K*'IV!N@%6N4R4L<ZJ#XQ
M)@'=3^FL8GKW:[F52:>+PEGZ^XPA*763(EMN9&,DL/IM'Z29TRJ>LR_$*K`:
MHJ`ZM;@E477],=+I]LYF9G83[NUF<9]FG3)TL`RD-:V^XEF^QR79M[`C0">T
M.R,:UI8EG(@MA,\]$*&01[97'S]J91KA8+D2*@;<@%[MIKH$RZ(,0H\**$-?
M:'V^+V@$M_W0GH@[C[G_6DX[MU$>A[OB1YUK%G#3MCD2HLX40&T12!00GH=2
M(5?X%5_#;\_^+DJH,E1$(`$L3O&0AB!0\RMKB!6I7\60CR),9=1GQZA/R))@
M[S<:5`"J"4D$H1YM"PYNT90%EN(L`BX5A-!>%.Q&P(DO2X=@ETU<FD=*&9HO
M,FF84)LS:[E92`F%)KXLWG8$(XM-LF/0?*S6-!L(?@`)VPA+XT_5RVRKK%"/
M)TAG.FPNIL/^B%AC3PK/4FXC0AP17L:"8O"(Q3%2]MEA[U)]:!@1\L#NK<92
M`MZPD!0=;5D@GO]!YQ^R\>YPWZY]'S>6@8@/82MGB4%7LQN/'VZLJ=BE(3BH
M3[GKV*R8D]/-,=@LQ/ND8$G=+*[B[%$<8T7D(Y"O<R\Q!!)I_=DD`_1%;WGL
M2]X\)D)2``Q7.EE8P&O=\WL3B1T]VK]%.L!]0]2`5DR`;4?'I*#^O!X)[U9D
M1NMQ&'E]+A!UD%)1(JN$LW3!&/<@32ZE9>)YQ*DVC4&Y.\).ZS^HBW!*D^U$
MI]+.RK1:6MB)_GF#[45DT*RJIBOE.:3)DM*HN<797.5O4_8?9Q%7Q*@`O9=?
M:*NB6G!MN,.^TP`6`5>%P_I3GXTI<D-(4HR*346V9.*,G!6#,3*E&8*NW1:K
M0>!9LBTC08()0;7GNE(T3>1$DM:&[,FM9X@O+W,1V?8U8*5XOIB5(EFLVL,.
MR_P_1??+J7+8RQ]?C,;'S4^C_5?D$NZ-)J_ZB__WOW6/*F2:S@Z:3O^7Y2JF
M0%K$QO<0'010KB"%IAOCD$`D$:/S(+SLT;RZB[:%LQ<QMT^S<I6K31OQ+J;0
M<=Q&DI9@%6;6]8,:=B`8"-&E&\\`%G(L1?V)JY$DI/A;A#(8=YR5="(()&];
MY6?$=WLGQ.B^/K_[]1SBCX<.ZY`Q$8+N;LCIPE;A?"+;XS`00RVD=XN8F,E6
M+;`!6>RR5+'GS&`9[7&^HR:(E`;9`YB$;5]CO4%T!,$)![C]X#X:X];9#Q=7
M-QB$U:W6MAK6E0\,OLO&HWB\U[?78.^EJBS(`)"RD\]2T3IC4A7P[^N+9OV/
MS7_,89>0$Y%:>,?\*HH5\#6.DQ!GM1VS8Q/E9A^2B#D'1$^*CO'/_N-SJ407
MQV[)L@Y=#B@=X62^]YS>,IGSAW>D]8H6A$/C"*_)`K<ULRX=4"72^..-/S:'
M[>&&;:5U)S@,AWP%?_Q_?@)0R.YNG::34W=[3=='HR>H3`&"('-U;R5?P>8?
M*:-1WZ>.S>[4<FP)KZ3WIDX&$2H;4\B2TL86.BDE&O8>U.;008VOT&C0BF41
ME>"6(+8K(!/OK]"UF3$E]Z#<G9^^N[H@CB6`@A4F4WB;$);-"5][=@Z$:Z[W
MQ9OSGE,RP%84'$9.;M_+R`%D#"%AQ:NU9%6:T)[@2!314XBJ(%86-M&+V4S4
M2@MJ]U>!C`AB^U@O:R,M<</5B;G!R9[KUZ`*D^@MI3CJ^.@->B'Y,'P<Z2OW
M.,?^J?QJ"[]64H&NV_4WWR;:WBD6!BM)9IQ_P06Z>)B;-`?<4@9--PA>;;&F
M[8W,CIO0X=)0BP(JSA6TXWHMH_^[-VGH7C,^H,!I9<*;=A\_Q+7($EIIBF]*
M?I7G^>NJPMF6KQW=G['-31!YR<6)>*>&>M8)3!&9ER>_!I(4AL=^QEU+\4I?
MABLOJN,XX8LFI5!\<>?[\N#Z_>QY4GO:P/X=I2+*[6GG,0UV0AS9!2DK^!;2
MXCK;BB_&G16$WT(G<W^%3_9-0B?[S^%E"W%"(202ZSYL`E^6(-TVY,A*^DRX
M)YGRUW`/""4C[JGH0(!D6"@/XJ@!1^,A9:=9S<>57UTK(>8RI+;SP\%X0A_E
M(AG<!U-Q@)C&OD\#K:61:>>MQ#2^>H-,BAF5NIOK.Q3#L86U*P#JXBJKM62R
MO)^6=N6)LVS^L2Q`"I!FJ2#TQ0S&=2+A@9]=:0T^N`A&1DFA:HA3IF#)5/M;
M`;5%C.TW!).G4ZY=2!7\;*PDNW(A0\#.P<M$4N329;I"&@POF_Y"MR4+>E,R
MWI[LPNP?3K&LIDH)G;CG<*5!LHDM2VQ-T8:.IM)L;'\O9H`KR:L;R$-EG&KC
MT2J/=(W\M&4_:4'>J;PX:.I.!P;R5BGC+",S!D7>8H^$TAU<AYK=>#J:'AD=
M8@3!N]0D89.Z>HI'Z3<7U(O9[9KS.+9O>M&L2KAB\,Z_]T"A^2V5,2/GCB>C
M-G<S+Y`MY-G>23Z%13[1''(YI*UEX/1*/E4[GD5'RHT"(Q9Z9HM5(O(C[##N
M>EUT++DSS$V+[F!RQ0B`O!1!@SP@:WZXN+W#A1$`O1]Z!;L`&@^?>6F(#FSK
MJ;SV<Y>J>P@?``>S3XW@*4EY04O,/%=!\A1WI(H692B@@4_.I6-X!@_TW^];
M.N_IL5J.L]\(_KT4(Q!F[AGE(A0X%S[T4((8WM?FX@5#&*2=:[8L+4M`2S@&
MOKG.I5\XQT!20HG&D/QAIVFZ7B!&3FODA,/PA5DH6DQ-3=%(L>!OF!ZP\EF0
M<_D6/A&#DH(/9V&`B^5XL(_<P"(*:N"%LWJ`1)]!2X<A4(&IH3@2T.LD[QZ0
M[+Z^XWI.V"S0GI<M8;.QX;V?#$>>'73`C9SS7Z'3?43)#Y>F/F53SC0,'R(X
MVUN+GQ:(D*\!>;MC&-9"^K!-EJNVL-_&>G6\8U<P>DX8HA\2!%`8L.UQWFW6
M'H8X$8$`/14D#U_+_80A"V85!CDXRM'K1P6E:VN39TQ)]2-^BUZG$(>`U0B0
M5*,4C*NL,Y:FP<S,-=R8*RM]A)X8:M9@3<^$:+^3TGR)WR>F;R=#93@)W;09
MT7WI/?`\1C(Z\X3;2)P[7!-%%GCR^^C*D.]55TQNEL[.E;:BDES&5-.&&E,F
M0@@3/AM\"L";W(0<9H#09*\U<VQ@%!'VQ`&EN%H`EKXX>H.N?(M,&'RY;_04
M9T1@5OZX+6#I$%XNSB4"FJ;-\6)?J:W!^G:IG1@%SW61Q"6_`?T>Q9P6Z#*U
MZ+$!DHS/F:4U9)Q:*-R#-P766K$ELT[%Q.%\7'/>)&H+[8P#H@.:]5"([9E!
MJI=I8I09XU-U>=V-6>:#21+@R0C4Z_F%@082^'MJ_>*>14^3Z4(N)VO<[!:@
M0+7[.)#>'B(O!3FQJ\L#UM*Q?8.KVTUY[":^!1'"9*$`VY&`IE4]>)F`^SWC
M`"&=/AR%J"P$"04^H\0+V0ZY]LA`>5TR';!=^2VN%'$V!?JJ+Z&`+Q?)>/'V
MW-#.W9WZ,+<)`0V0)]@WJE>48L6N+MX0.*@VQRZUBL;`'_U58+WE7X3=&$M`
MFP"2128Q1UE[D@`C$4(GK>+/^8JF@LZ61,>:(*CM7IV,Q=,'$*T;Z*DB\:QO
M8H2P;,3P3M<S:OY<;;@;:A8'-GSY58GL$C_9H!RS6*!52"#ZHYPL]6PA6?M5
M7ELJ-EW/+TWL=SMC.E0;+F(8&]<M#[.[Y*1J%89FUPZ[#W7R0J,)2+\!ZK1:
M0V`-GZ<#I247>+6P+*@X,#FWY:N7(I(YUO<`)XP?I\V1MY3-5^@N.!3;]15I
MOM'IH-%N1!7/8G1@O/=_5Y0*\AB\,,7-;WBLP5I2Y'I4/=,-TV%)@RMN,=1Y
M#>IS>^>S[I=HP4#-R27"N0JX0]<##,M#=/H+TKFT-D75M(P2>`ZN]I;I&N/P
M\-9P<8L>=>^Z(R*EL@:!;C[K4>-4P)Q*#4@C\RMK^\LILT1%!RF![/+B%S?!
M]XUI]`@4:\=MR0^,*@A=8?@XN(A9J04Y-J<ID%5\25G*F,MZ*@]NJHPM6O$P
M%V]H3F/2"YV4N(<+=0M'EW%K!:3X3XE\OE=`N-.2<"GQ"SE09C@1U#XVG%4:
MS:>3428;=]'KD1F,_0;R8B@A1E;=VJLD?YEKT3HV<+"?#Q==B;,09>[HEXOP
M^@$?)2:1*$9*]$Y7D!Q%F6CXA9MF)-P^)H)`&>*L:<:H&8#L,0@F7.*B\SH4
M1<$W@K5B54.]3%V@V`YD/IJQ+*\<UBQK!NXR^'2T[NDX["TG14FV:S5I^9V(
M&`E0*-$@X\LB6B:/7Z%)Y,,R?]@^`Z]9\%(*\8Q6`BVR.AC]6&U.;E*@R[;A
MF&&O]1"N1.XD+,#A`YR'$0U>;L\1#>@='*4<'8&;)DL!J06/[C"D_D+>+KTX
MJZ8P^_*B2P),U6?W5-&/,FIT+]2&A3KI0#]UY&*5SN!BIMK#TN[OU*%[ROD2
M$(&=V)QU%VP.ZOBK//\L.!2%-Z;8QY%'IC\DOM=?WE)Z;1OY+94O*PW/U,W2
MP>'^#^XK7`F3(RO'2$.3EEH/W_KFDRP!P##!7/8?0I5G+1N?*9:SN'I`*#=/
M@13WF/M:[U':[S<0FJ8M7J5I"\&',^H>4:1>$1\'#^S1ZD[,.(SR<F9C<\:5
MJLD^H9!P,./(WB?I]1COZ16&VETJ.#5+$*[Q\:[)*PW_(.K6Z\1M\J6P6NQ1
M,0!\)"8;[1&R%9BXJWTHMH@V&\CLT@J:ZU]1)6?O+FZ"0\>Z*.0U<8IYG+$4
MUVH\'0T#ISK&,:]79[330"3H`,23BP!#8I13<[X2WM.:8B2H-_8S&DUC(LNP
M*J8GVH,&'B;*1P$#JB$"8\[V$.Y@'N]XEME<L%X%DKW'#WBATVH%2@Z3S("W
M*QP[D:C@I=M]/+:VAUS\JVK$'$6'M/RY?>`ZZJGMY'<6A>9,.S/J("TS0W%L
MBRW(`HX5[`<)[-,0W\!/#%;7Q[D'DRGC$]M1B4.Y_O0\1L@'RQR7<UXZ"UQ<
M/T5UM<9\1AB-Z;B!,!B[4JR][M=]5C(2EA1TT[1VF#.EFR3V#=*LNZ?CW$93
M^,/OGG)7;!-XZ]AINL!T]W1I:V>]^FWS\4;Y&Z-]N+"X=6';AY-30X+RK8E0
MWU+CL`K&WJ')[A4YWMW3@YH36+Q(9$!5)N)/).4'#5H"E:8HYU[:?+*\M?&H
M^GEK;7E]O=ICNE>[4`O]T@7*S@M,U"*(Z-:I'L)CT%:0#8,:94%/+M"?72A'
MSVF;;*:WP%:G=I9%2>GZ7:P!_#9WOB<VW;RJNJ:UTHIY]_0\JZ1]C'""LX:0
ML]P`"ZA=JY>PXG`T>`C?U$J)^T))R7\MCT?LQTIZ2_"QL25(WA$0'R,+!<GF
M::,Q`G);6'TD;Y$%1>.+GXITT6BDU??@>`8]5N]01+*X49UJ-(F($S%5$D/-
M`M*!$7L>Y!<E/K)=334'-&[O\#@#^1J$G]Q;E<[,:Y?F@R_-"#CTNK@5,7B3
MG?^4CX2Y'H)5`2GXZ&YLPP"C.9I^W`90I#X`9K!E>27V;_$`Y9,G(!S!5]09
M%*F%A.@TLKG9F,=)Z/>H**S]\Q^BBURDQ9,!K6:$JO;4J>D"E4!;#:,0T"H9
M_._@^-_GQ!"<46!"_!LN!R-3)#>#]@=>_B5[OR)&/RN\N?K5>4()DM`^L\!L
ME0^Z44H]M42DTLAV4WW)N]&!VQ(A[@5O#G+(&P+U2:>FP"FL'4``$:DD"]XL
M<0Q1,3<0!D'X.3^9V0]V=H@>H<]AN>C)JZ.C_3TUWQX=_]R\&!^,#G;'H_UF
M,AU-[6>BSEX<'K\<3<>'!U_T\8.!:>L$IGW1<IZ=X`U%NL:KC^6INLZ3U>:?
M_TC_'0+[B(&RD-6OCHD_O+@C$!-0K39MMP`*.'A0T1KL/%#Z[:.Z^/MQZS+&
M(:);*(<[4F]J@JL#6:RG0PR^_5A^];JSEP:'CL*C90GTEI$"$I"=;/A+&6[_
MRR-SJB,Y.OE(R>1+@ZD8NS^TD+&D;K83YRB7Q!K(^QS>B'=4E1`>%ED.L!]"
ME0FQJW."3I4N8.'`PO?6+[02C8?1[U>."J'JD3/P+II&<%N?MZY79JBN`ZJ&
MD=/V"H(>4K^3V'CP48+,L2][Z!=I1V^+01**C>5<'W%G8[F?EQ>X3N[4K(AC
M-+]/"X`;5?F-N#*?-X8E02RLS6TY]O'>/EC_O#D:'4]_;J;'HX/):%>(/UG\
MS0?1?`,T7WPB,?#4:RBK1N\>6X^WDV04WX'>.:.UMAJIWG*J#DG^4J2K8G[F
M,;EXKS+B/943(Q,S<3>*$/VO2NR,EGR]7MW$9/SCP?C%>'=T,&U&N[N'KPZF
MXX,?FZ/#_?'N>&_2++G)O_HN%-,H+^"9`@[%B`/?,_&A?.D5MG5>`5ZLBG(*
M1^0;UIHDCC;NVCB,`7\YU`L$%Y%#^(M;ZT\KFK1[,GMG'E=D)^%/.<28>`0.
MF4="\*2%FF9Y:3%"3HVK[UQ`00:(H8DMDPSPC27`4I:TPO)S2##<G2PK76!>
MR<3*8Y1O[ZI6D9*.3*[@\+(P=YD$D+#)^8MY,[+>E"-,5*VJIYA+^9Z4C'T9
MF2!/'H!0OL&F6`K6R%!H5M+;W)-@P.`K_NW5$&JZ\R"P3;7R605L5,BV-#=!
M#<"#)-SL4QFH7-C1\>$1525^;D8'SYN]_W@U/I(`T2PM,&J''.]%]WPYP9CZ
M$0?3PV-#C`5&E0^*W)R:3W;:V2VTP%CY25>=<>^)JAO-FH$Z<Y.V!J&]V/@H
M\&7\7C*JK(1?T@@B4WLX7Z\_TH:PW'XV7+F$SQXRN]FXQ;`9+642"N5R/=Z9
MMUI2]CTAU:FV%SQY?M<8S*<M'I(E-%!7*P<P.ZD5"!E"0X?,[WF1(%&)2>3&
M@LA#,,7PLCJPJC3)0E>=))HX8:`BU!@HMU\D3"PT?&+^4[27D0F:Y;#Y<;"[
M*^O&9LI(]>:GR.G#RY/4X_[^2Q2_=(W+5`-QV7EBLG,U^^!W07M,]U1^.<SI
MAQ>9@=IQ2"@]PDG^D=(DJ?M'!0(/DKSGYZC=ERA$2Z\FSYOO*MJWV;RD/MJ[
M&>'09S4`K-_[%#UYM7$?P]I.>00R5Y2__65^M=K$ZDKEP\G%VRM%LJCS79#L
M9?$Q`4'R\]_VB7!JQ@P[^\_RVU1_3GW2/66%3\JW7+1LX]AP9M\@F2KS*PB5
MV%NL)GSY9:0=T(R4PH_\I01[I%+:`E[A@`HBEOG*SPBKD5:^?S1!,S\]F2.3
M2/**]JG4VQ[&MF(O(PJ4LT8QMOP=<M5:(9J_O3Q7K_KJ3":"7@N(#.VMS>D-
MP_#HZUOO9,J.L)P-[7N?-$TU$!1;J,3U&[0_1D,V"FZI<(KE<NN%B/?+/%*^
MV;^QYO_#DLSE$10)*W8`9;P)`OW@$:3QGEU<R^:7NFO*_+,Z_)F%0^9P$C9X
M&Y>A\P@:HPDQ`E0V)<$%[WFU+1]/1,-3**3,#5V;51%Y\7PTNF%[B(N#+];0
M3+!"H21Y,%6YG@>)1A*"E!_+07..["Y8K9/X`DV)U*6<8=^55MDFT^O#&PFC
M+UNSSSL#MNRK>]"^LZ[S*%:I!8H)<2KO6*XLE,@I?WXQIU*GE4B*]P+4O0S>
M_/C38A^=X#@A!&#H(THZ"?0KXB19`))QN\"!H3OM'4SV3`XUTQ$BZ8_'>VZX
M2G<R1/%K57H(^Z.:P?-K:',J0H1Y#EJ-P2#WV9@A!<"6W[`\J&(@4S(`J(OK
M2N+`P3)P.KDA)(E$@Z<<S3)9(KA;AEAS-/E`^D22=SLVEC1TN0?'2\S\H+I0
MP@H>D=`&*5'@Y<5;UYV.E)K`R'LO1X.+&U(D(C8-W5P$]UY$H0#E+7I5N>Q]
M[.+(X2A1<UR<=F=YC+(A&U1"-:9L`^7W#\R).K?<3'MK4"2,&D$L/P6Z23H\
M5]0[#=-N(('!+#6$3RVE>&4!4ZBRRJ(VM7WP!CJ:UD/'_E>5B4,J9S$XR*L3
M3EI8HVJ9YRMGN,_+4]P?CYZ-]\?HCEB5@8VC_<.?]_::X_&/?YY.FE='I#D?
M[TW'7J>C):M#@!!5*,+/HFOOFIH0`00#&ZX6VOH!`^LJ5\G1>5J%T+A\*,5]
M29F!/R@"5RX>DR>$0?VH+/7"G'/M(G-LC*NT4=Y0!@16)]1OS@$7;$G;Y0+2
M>'A2TC*%:K(*LB2`6,B</1,N5OL@F?SE>"K-'>O30U</V`;A:484D\#8#!%X
M$Q^22)%#;9TJ\@#%D+!XX>41^WGRX2Y%*`<D.;<A?TP21RYHQEY/030I#RV9
M@;3Z*,V-HL45H7I@RGTA82L!#;]HV@-B)A[6NS^HM)2J*<@N67%>,Y0%=P!4
M&!?Z:]5B?#O')H>1O7K?EO`'C3LTXHNY<6PK]@#']=DC7%EUL0J('OZD\E4_
M_,GC\M1_.J<R"E%XX10Y^I<@#M*R.6H6./Y2\D`8>1A`!)(I%;N2D8,-D),W
M8[SB[<6_;Z__#I;.2`L<%%]?%A+-`XLY2@/%6'[1B#;@S.%?//3V^B-QTEJV
MQ03-WIE6=(4J%8)^+-9W4#F)/#X-4UY#S\*/HLKP\N1J_D:>>&+3&IEN*)NA
M9J;!O36$%X5E[8!Z&K#-#^>9+#Q$M->:^S1M:M0-J\94>%Y-U9W+7=+$B2]#
M@]CRH0T;^TJ6#^W+V/ZI?&C*O7I_D6%9X41N[15KCWZ(9L1Y4+?.S-TXK?/W
MCH*./;)@QONT>5'=I%F[%;A<G?'Z@>K4WH<S#>!5!P#O?G/S_2-=P?6,[ZNQ
MF"%.+-CYZ2OB2S%6$[GB*#`&JE678W4.H(VKE;<E?EA^DEE,W2(1XN27W>50
MOOXJ;QXX&[#=#]'=SL=PMO;ZM9ME(:STA?O$_%[U/UDFP:F*'8"YI^?I%KA4
M*\!]$VLCEQL\*@KT:54N_@:Q']W.;!?1GJ/TQ]Y"QN7(4?@:YHFM->K:*@TR
M<-X;/)B,P@65PV<7Z4;U2(I$=F,W9)-%/**FM:</,G/#0E/DN:P2LY855O$+
MEK`!,6Z#.NQ(/>\J(&UWJ1PU`F3,@V;BG"E$KB<9,'[*'A\^WH5/Z'ELCH>.
MA@W#(2:SI@X>6/!C`"D1.IQVU&>87<[1+6JQJE`;@@^UOHT?E$>R]QMLD_(@
M4!ML;O73V%5]X)9>I*I:8JQ$,#KK/.M!I"1'RSPBO:97X7[4__-S'#OL\<Q;
MN_8LTT7^#ZFI:_G*L0IGU;U=R]<^ZP9Z&O_M1@_WT+G_;A.!KC]A%XB9ZPMT
M`"S/(*"MD*FVS/_^ZT:S-/O(+-4**)L)5@O^\^AXK]D='8VGQ%(M9?Z\L-H3
M`*?"WA]-_+<8SH3['7$J_9KP=;GI=V:@-FZDE\K563C#$!@4<IVOM]]MV5E;
M_SIB*S)JZV%S)IV*R/%[L-LTHZZ4D3X`FZ^=B93[B6L4+Q@\U&GF;QT\F9:2
M#TP5B5-EKOO;>N5V@(G#>N_OV55N15W`,,^CS*NT'9K2@R/D65%&OV0V0)(O
M0S=)&.7>V_!M$@10/(L4EB_N^E5`S^!MP%`2,'?`J/HBPFGEKRNFBD#0AUD=
M\,5RH5)G*D&ZW+2,4=]Y3&#E"^\L<+%Y@+9LGFP:P>C`-`DJAY#Z&TS]]>%Q
M"!S[P.^^#F3%=><DM0TW,(&C!"&Y?!\R;QF'"4$[Z!Q)CE]VQ0V;UYP@^ENS
M_,_-NNHBJ5^)N6N`ID@=)&*=GC?'4@`7]-;F=WL+GV,`>15<@R'$(@942**1
MU`$U%+:7]U41L$AP+<_L_F]'J=U-#]V1Y<*)DG-A.^E`FVWLZW[:?/^@1N7R
MW851;/3R&,J]KJVNK:TGI)%2$'2,7CX0Z4@Y2L6AVJ+?T6RI'(4^#QH-[DT?
M:/#5J`+\%PQ-_P)GC'T196NKZ]2:CQOXW(UN],NQ:ZL[CUM1X7,'7[?!F^UX
M(D]Z#P3\WO[RC6SZ1AH2L?SX:;+5=_S,]OC+9]LI9BLO>8/&'%\^2]Q3.L"-
M1[U[VEQ=^PJ@$&=;]Q-LAN;ZFN>7D&5CHW=GVV#SEY]C`/+F<8*-?DBD51>%
M<+\4I8(#N[G_',ER_0H["^[@AAZ=]T+]X]7MKP"/<6</G>/.ZB/*+WZM<VPQ
M>J<71M8?K3[^"D<9B-5ZN+89&6Z]TY4BAXR#!,H-QBN.R/WSQ,,%)(XH_C91
MW!P60=IQQ?:/VQ@$'`Q$#B!IJL_??7;D,`("Q=`L:H[<ZZM2TK+-&N*.XEV7
M=!"I"WDDA%D_QQM[>>V5M\+`"4C*#U]^4N/(P6%Z0D`_Q2=16DG+5>K:0\RZ
MC,^(!DJ@5/A2GXFV%<-FUKO8;(%XI`C9;[\LIT!AB&.:Z4L&KGY+_4OU,".L
MN!JAZ/:'7S>/,$U6Y7@E+2@M`+`O>EMI/"Q:8W$DT.92!G^KF:,P#*L3_*N,
M?*%J5VW6R>QX?F19V?5RWU5T[J?<O(+1J#FN(-WGWH,#3]B]V/37?V$QPG+K
MF;(S\M:40PBJ$-VY)<GB-=>.E539![RC4+@1J3>^8K:#*NEZZ,7-<I%#+VZ9
MG(]J$4HTE]]5]YI"JMM+(XOA81A,W[6AV'0VQ*,%9?LI9?J*2EKN]D`@3[6<
M;LAVMHYR(^/)\6AO/]$NI.S2KUU]T4(E=$&1$X1:?+P7+&TUNK$^Q;!G!84S
MNUS!JX.Q<L$L$73R*4L?_O"!&3\I^;-9<C.*!]9G9S_D=?;7!Q(^/W'J$)4]
M:W#ENF:-2FY>>/(ME]W`L\"2TC"$:J1A3F+:YLI`TN:]7X4:[.5E?N+^0ICB
M(J@5(QK-)?SY"88Y#N<&&$+JS"!Z`*==04<^)2GWPWEKMHO4;LAF]CECE8<W
MF(1P+SH.?K7<.*4V'UKFA&NG_<-L=O?TOP4```#__P,`4$L#!!0`!@`(````
M(0"XAJUPA@(``+T&```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE)5?
M;]HP%,7?)^T[6'XG3DB3`B)4A8ZMTB9-T_X\&\<A%G$<V0;:;[_K&"@!QB@/
M$.-S3W[GVG'&#R^R0ANNC5!UAJ,@Q(C73.6B7F;XU\]Y;X"1L;3.::5JGN%7
M;O##Y..'\5;IE2DYMP@<:I/ATMIF1(AA)9?4!*KA-<P42DMJ8:B7Q#2:T[PM
MDA7IAV%*)!4U]@XC?8N'*@K!^)-B:\EKZTTTKZ@%?E.*QNS=)+O%3E*]6C<]
MIF0#%@M1"?O:FF(DV>AY62M-%Q7D?HGN*-M[MX,S>RF85D85-@`[XD'/,P_)
MD(#39)P+2.#:CC0O,OP8C68I)I-QVY_?@F_-T34RI=I^UB+_*FH.S89E<@NP
M4&KEI,^Y^PN*R5GUO%V`[QKEO*#KROY0VR]<+$L+JYU`()=KE+\^<<.@H6`3
M]!/GQ%0%`/"-I'`[`QI"7]K?K<AMF>$X#9+[,(Y`CA;<V+EPEABQM;%*_O&B
M:&?E3?H[DQCH=_/]H#](HB3]OPOQ1&W`)VKI9*S5%L&F@7N:AKHM&(W`V26+
MH3^7DT$D5_/HBMI24!M8C<TDC<9D`QUD.\GT7!)W%;,+BC<3`G@'1DC^?D97
ME.$[C-X8^UV"J9?X!7.Y9D=_=`"@,<<`UYOCQ-#$XQN?1)]Z212VK8L^]4[F
M9_^>[V!!N-NQG/@$Z^ZD'UYR[ZF2T'^ZFMEU30</MO;M>$Y\@I=T;SWU$H\W
MC-,P'D3#KF36E21)%`X'!TD'+GT/G!.?P*4'V_:1F'K)5;BNY"*</X'\`]K0
M)?]&]5+4!E6\@&T<!O<04/OSQP^L:MH'<:$LG!OM90FO"0Z[.0Q`7"AE]P-W
MPAU>/)._````__\#`%!+`P04``8`"````"$`ELUKL'@%``"U%0``&````'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;)1876^K.!!]7VG_`^*]`1O,1Y3DZD+5
MW2OME5:K_7BFQ$E00XB`-NV_W[''!=LT;>A#V]C'Q\<SXV/'JV^O]=%YX6U7
M-:>U2Q:^Z_!3V6RKTW[M_O/WPUWB.EU?G+;%L3GQM?O&._?;YM=?5I>F?>H.
MG/<.,)RZM7OH^_/2\[KRP.NB6S1G?H*>7=/610\?V[W7G5M>;.6@^NA1WX^\
MNJA.+C(LVULXFMVN*OE]4S[7_-0C2<N/10_ZNT-U[M[9ZO(6NKIHGY[/=V53
MGX'BL3I6_9LD=9VZ7/[8GYJV>#S"NE])6)3OW/+#A+ZNRK;IFEV_`#H/A4[7
MG'JI!TR;U;:"%8BP.RW?K=WO9)D'Q/4V*QF@?RM^Z;3_G>[07'YKJ^T?U8E#
MM"%/(@./3?,DH#^VH@D&>Y/1#S(#?[;.EN^*YV/_5W/YG5?[0P_I9K`BL;#E
M]NV>=R5$%&@6E`FFLCF"`/CMU)4H#8A(\2K_7JIM?UB[0;1@L1\0@#N/O.L?
M*D'I.N5SUS?U?PB2*QI(J"()0+WJIPN:,,*BKUD\5"07>%_TQ6;5-A<'J@;F
M[,Z%J$&R!&:QL@#B\_'*8$EBS'<Q2`X%=`?I>-G0=.6]0`1+!<D0DKK.``E,
M1/X!@@P0#^0-&F'E\S6*0:;&P!_HY3(RA*0R86)=N=9@"(#`Z`(^#XX`K]U0
M7SFU)D8(5HJ<6&LP)@:6VR<68,B>/K$5\PPAB4P9"^,H-H7E>G\2!6DR]!NR
MH&AOER7`EJQPH,5$("26LDB26-VYWDW]]$J51'-$";`EBEFB$(*B*/6M'.9Z
M-PG9&$DC4O$<40)LB8HL40A!45$TR9_>':?71(EC2=OSGY>S`%NBQK5B^A"B
M1#%&K7V6Z_UIG/IC51JQ`K/09=UF16*0)6\L6I2'$%5=C%EYSLWN>!QMB"-@
MBKJZSX,FT9:LB4,*QK6K=!&:V!6F2!0@B,F5PB>6AW\A#7U7MXG02E@F&=<N
MPPU)QGS)@.9F=WA-EF7;7\A"[S5DC<282((8#$B<A+&E.S<`A`3P,^P?,YO"
M<&_>`D2@34L/K61E"J-YNMYB3C[+U<G4UL-Q52HPB,'`!"FS`I<K#NQGE(T&
M:PJ;Y>OB`F1MO7`D5L)TZR8L3"T_RQ6)JG'JQ^/23&FSW)U,[3VTMGVF,#AS
M%$?CQ*K(=8-/@VC<OJ:P60Y/IA8?6B')%`:%T8B2297K+D^C2`NJ*6V6SQ-T
M::BDX<86VD:O,'J1XRC98DYNN?D7NW]JX^%HQ*J6=*..XC"RBBTG)L#7&`QI
M=):52[1IY9-:4AA,61#3P'*'W`"$)+Z6,FI9^6UGH!QE21S+%:.G,&CI*9D(
MQ%-!%1V<-1_[)K4\_49]4V]G5E%GDOG]-*24V=O1[`^BL3K,W,XR=HK&#K^'
MFK>],U,8C`SQXR0:8X-.82)(P))1O"ENEO'3J?$S*VV9PBAQ0>AKB5/B]*.!
MA#Z-Q\HPQ<TR?_&-TS)_.V69P@!RC*Z]9S_'F`)G'0$4[5NW,_OFERF,9F=Z
MBSFY9?.B\-,OOR?3J=TSV^X51FW,27R00?5>JZM91D_1LHVBMXU>851=)2S2
M+E*JKI#E'1$&VCEF1F[604"G!P$;M[JR,MWG[VA(`FI!<D6#ZNXH7`63\?PW
MY(G'CMMO@A)M.BT;]Q/*4Q@U-V.1;QN&B:!1>BUV\*8U1]ST9A_9-BL9URZ^
M`'QTA38`'UZA\94,'Y%JWNYYSH_'SBF;9_$"1N$[P]"*KW,96694/+)8[3F\
MVLEV;^B`1[-SL><_BW9?G3KGR'=`Z2]B\)`6G]WP0]^<Y=O.8]/#<YG\]P#/
MHQP><?P%@'=-T[]_$`][PX/KYG\```#__P,`4$L#!!0`!@`(````(0#[8J5M
ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O
M;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[
M=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN
M>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%
M2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A
M/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'
M&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&
MP-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=
M3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q
M!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#0
M0(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>
M?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q
M%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);
MY`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?
MW7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>U
MO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+
M33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<
ME9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;
M1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<K
MW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3J
MMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%
MU^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4
MF0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ
M'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(
M9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+
M=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>
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MH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?
MJ5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&
M#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]
M69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5P
MD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L
M:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I
M"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP``
M`/__`P!02P,$%``&``@````A`.DY'LFL`@``MP8``!D```!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&ULG%5=;YLP%'V?M/]@^;T82`E)%%(U0=TF;=(T[>/9
M`0-6,4:VT[3_?M=VPR#IUFHO@.US#^?<>[FL;QY%BQZ8TEQV&8Z"$"/6%;+D
M79WA']_OKA88:4.[DK:R8QE^8AK?;-Z_6Q^ENM<-8P8!0Z<SW!C3KPC11<,$
MU8'L60<GE52"&EBJFNA>,5JZ(-&2.`SG1%#>8<^P4F_AD%7%"Y;+XB!89SR)
M8BTUH%\WO-<G-E&\A4Y0=7_HKPHI>J#8\Y:;)T>*D2A6G^I.*KIOP?=C=$V+
M$[=;7-`+7BBI964"H"->Z*7G)5D28-JL2PX.;-J18E6&;Z-5GF"R6;O\_.3L
MJ$?/2#?R^$'Q\C/O&"0;RF0+L)?RWD(_E78+@LE%])TKP%>%2E;10VN^R>-'
MQNO&0+43,&1]K<JGG.D"$@HT0>QD%+(%`7!%@MO.@(301W<_\M(T&9[-@R0-
M9Q'`T9YI<\<M)4;%01LI?GE09$4-)/$SR36H?SZ/@WB11,G\=1;B%3F#.35T
MLU;RB*!IX)VZI[8%HQ4PGYQY'8/7OUD%>9;DUK(X+G"AH3P/FS1.U^0!<EH\
M8[8>L\1HP,13Q.Z$L*XM;3[:(*!W$`VI.!<]@Z*^7(Z31ALTU3@+IP*V+T"F
MB-T+B&@*R2\A\^4`F=B8_8\-&P3],TIC&B\&?I>WK<?X3K2)W)UOY*.-B21H
M@7%F_YU1"\XP7(>*IO$?JUZ*QXRDG&_DHXV)%/@RQE)L9[Y>9!MTEIV+*GO,
MPK5I,C_K@=WD-#RS`T/&\OO869H,>??*_0#QWY=@JF8[UK8:%?)@AT,$;QQV
M_=S:PMQR7SD9#F!N]+1F7ZBJ>:=1RRH(#8,4WJS\Y/$+(WO7S7MI8&*XQP9^
M$`S*'08`KJ0TIX6=;<,O9_,;``#__P,`4$L#!!0`!@`(````(0"D?*KR[P(`
M`#8(```9````>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)Q56V^;,!1^G[3_
M8/F]7`,D49*J">HV:9.F:9=G!PQ8!8QLIVG__8YQ0C%INW8O"9SSG8_O7'R\
MNGYH:G1/A62\76/?\3"B;<9SUI9K_.OG[=4<(ZE(FY.:MW2-'ZG$UYN/'U9'
M+NYD1:E"P-#*-:Z4ZI:N*[.*-D0ZO*,M>`HN&J+@592N[`0E>1_4U&[@>;';
M$-9BP[`4;^'@1<$RFO+LT-!6&1)!:Z)`OZQ8)\]L3?86NH:(NT-WE?&F`XH]
MJYEZ[$DQ:K+EE[+E@NQKR/O!GY'LS-V_7-`W+!-<\D(Y0.<:H9<Y+]R%"TR;
M5<X@`UUV)&BQQC?^,DVPNUGU]?G-Z%&.GI&L^/&38/E7UE(H-K1)-V#/^9V&
M?LFU"8+=B^C;O@'?!<II00ZU^L&/GRDK*P7=CB`AG=<R?TRIS*"@0.,$D6;*
M>`T"X!<U3$\&%(0\]/]'EJMJC</8B1(O]`&.]E2J6Z8I,<H.4O'FCP'Y)RI#
M$IQ(9J#^Y`^<8![Y4?QO%M<HZA-,B2*;E>!'!$,#WY0=T2/H+X'YG)G1,>3Z
M4JJ0HR:YT2P]%V0AH3WWFR2(5NX]U#0[8;8&L\!HP`0V8G=&Z`)JVG1D<$'O
M(!I*,14=0E.?;\=9HPZR-8:>+6#[#,1&[)Y!^#8DO83$BP%BI1'^3QHZ:(VA
M54,99U$\\/=UVQJ,F41=R-W4D(X,EB3@?7]E=1",]%A2,IM(,IAY/QL@.+3=
MN]?=Z8MN2SR<I;'XU\=!@Z>BIR-K,*,Z3@VI,21]6D'D>4\392F+WZ-,@VUE
M23#ML,&8[RZ\^7Q2SK$[6OB3Z-1RAUXR1%NBD_>(UF!;=!1,5&T-QLR`'\;1
MY.3L++\W2YZ.C5D'8W\XFR?38IO];=9;0T5)=[2N)<KX0>]F'YHT6,VUL85K
MHU^R[N"`M=V1DGXCHF2M1#4M(-1S$FBT,(O?O"C>]<MDSQ4L[/ZQ@ON9PFGS
M'``7G*OSB[Y:AAM_\Q<``/__`P!02P,$%``&``@````A`/8E*)1%`P``Y0D`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#<N>&ULE%;;;J,P$'U?:?\!^3T!
M0P@0A50-57<K[4JKU5Z>'7`2JX"1[33MW^_83@FXETU?VN`Y/G/FP@S+J\>F
M]AZHD(RW.<+3`'FT+7G%VEV.?O^ZG:3(DXJT%:EY2W/T1"6Z6GW^M#QR<2_W
ME"H/&%J9H[U2W<+W9;FG#9%3WM$6+%LN&J+@4>Q\V0E**G.IJ?TP".9^0UB+
M+,-"7,+!MUM6TAM>'AK:*DLB:$T4Z)=[ULEGMJ:\A*XAXO[034K>=$"Q8353
M3X84>4VYN-NU7)!-#7$_XADIG[G-PPOZAI6"2[Y54Z#SK="7,6=^Y@/3:EDQ
MB$"GW1-TFZ-KO"@P1OYJ:1+TA]&C'/SVY)X?OPA6?6,MA6Q#G70%-IS?:^A=
MI8_@LO_B]JVIP`_A571+#K7ZR8]?*=OM%90[AHAT8(OJZ8;*$C(*--,PUDPE
MKT$`_/4:IEL#,D(>S?\CJ]0^1]%\&B=!A`'N;:A4MTQ3(J\\2,6;OQ9D(NI)
MPA-)!.I/]G`:IC&.Y_]G\:TB$^`-462U%/SH0=>`3]D1W8-X`<PZL@CR\WID
M$)*^<ZTOF:N`EE".AU6"\=)_@!26)\S:8C+D]9AHC"A>09Q)?-#7BX30/RY2
M7QJ+C(*Q@K6%9*9B.K!B<#`2`)D9"G@_.QJ<H]DP\FSN>+88VRO&\^!@Y!EH
M+O>LP5"_H>=YXGBVF-14+<*1(ZP8FN,P/M\>J8*NO5R5!H]5S:+0464QL5$U
MB1+'7(S,L^R--IE_1)4&NZIB1Y7%6%51,AM;BZ%UAM_(5/(131KL:G(*M+88
MJPFGCN)B:`V#K%<\JIY>2X-W_OUNUF!'D^-T;2&)*5XZC]/>JYD6Q="<I8.&
M'(F"27&Y*`UV1$7G`ABW:XNQJL(4NR]_,;)'^"U=&*;AY<(,VE7F)&1]`EEI
MDUF`W>%9C!%1.@O/;3#*&FR]D;H+Y[<=O<-!D6#GG5L;ZAS!J]=/\-A]!=['
M6*5VJ]JETU"QHP6M:^F5_*`W9@A=TY_:;;[&"YC,L$6=\P*VO#GW>P,LV8[L
MZ'<B=JR57DVW0!E,$Q`M[)JV#XIW9A5LN(+U:G[NX7.*PLP/I@#><JZ>'_2'
M0/^!MOH'``#__P,`4$L#!!0`!@`(````(0!L+D4HN@,``*0,```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;*Q7;6_:,!#^/FG_(<KWDIC7@H"JI.HV
M:9.F:2^?3>*`U22.;%/:?[^[.$GMA`*3]@7(Y?'=X^?.YV-Y]Y)GWC.3BHMB
MY9-!Z'NLB$7"B]W*__7S\>;6]Y2F14(S4;"5_\J4?[?^^&%Y%/))[1G3'G@H
MU,K?:UTN@D#%>Y93-1`E*^!-*F1.-3S*7:!*R6A2+<JS8!B&TR"GO/"-AX6\
MQH=(4QZS!Q$?<E9HXT2RC&K@K_:\5(VW/+[&74[ETZ&\B45>@HLMS[A^K9SZ
M7AXOONP*(>DV@WV_D#&-&]_50\]]SF,IE$CU`-P%AFA_S_-@'H"G]3+AL`.4
MW9,L7?GW9!&1J1^LEY5`OSD[*NNWI_;B^$GRY"LO&*@-><(,;(5X0NB7!$VP
M..BM?JPR\%UZ"4OI(=,_Q/$SX[N]AG1/8$>XL47R^L!4#(J"F\%P@IYBD0$!
M^/1RCJ4!BM"7ZOO($[U?^:/I8#(+1P3@WI8I_<C1I>_%!Z5%_L>`2.W*.!G6
M3N#[A),S"T?U0OBN%Y+Y@(S#*0;OKPL,^4J+!ZKI>BG%T8,"`WJJI%BN9`&^
M&A&,AU:6]U0!.=#)/7I9^7/?@PTK2.7S>D9&R^`9Y(]KS*:/&;J(J$%@UH!>
MRQ'$^0\<T0MRQ$PBZ4UC>"/=H1PUB"XA$*I+:`3U=[IR&HUP$=2(H]'856!C
M,*;:D&-D&1Q)QBZ#\Y$1O/+AT\K.I!/98*S(EL&)#.5E[_U\9`1W]SSM1#:8
M254UPY`0]W74O.[F8.KRP,*]G`-<U.4S<P-N#,92PC(X2LQ<!N>50/"E'!B,
M%=DR.)'Q"K(.[?G(".[NN9L#@VEST"G+J'G=S0$<>)O'=3G`15T^MYT<&(RE
MA&5PE"!P[&P*YZ6HT)>R4(.LX+;%C7ZJ>\[PNKC0"XAI=6XSZ":E!K59"5V1
MHOK]#"1H#_9T_)8[E^J))GKYO!#3`5V><Y?'I@;9@IEEE<5E@?WLZLHEION=
M;UPUR(YNEIV(CCW-BEY==E>ERS1#5X9>NIJ.B=<?-+*W1%37343,^RO3A6W/
MHGJAKDV3)-;EAI,,'#/+%#DF-RWO---_G0+Z[=6N1W/KPDB'Q(9P`MJJ'4]Z
M8K6HMN>80<X,+SF3.Q:Q+%->+`XXI.$I::WM`'D_Q.N^8]_@8'G*/ES`C=_'
MWY,)+*C*J>=IVLRH0?L*9L22[M@W*G>\4%[&4J`7#F:0$&FF3/.@15F-7UNA
M83JL?N[AWP"#:S\<`#@50C</*$+[_V+]%P``__\#`%!+`P04``8`"````"$`
M[2VW\PH#``"3"```&0```'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R45MMN
MHS`0?5]I_P'Q7BXFD`0EJ9I4W:VT*ZU6>WEVP`2K@)'M-.W?[]B3$*"735^2
MX#ESYLP%3Q;73W7E/#*IN&B6;N@%KL.:3.2\V2W=W[_NKF:NHS1M<EJ)ABW=
M9Z;<Z]7G3XN#D`^J9$P[P-"HI5MJW::^K[*2U51YHF4-6`HA:ZKA4>Y\U4I&
M<^M45SX)@L2O*6]<9$CE)1RB*'C&;D6VKUFCD42RBFK0KTK>JA-;G5U"5U/Y
ML&^O,E&W0+'E%=?/EM1UZBR]WS5"TFT%>3^%$YJ=N.W#"_J:9U(H46@/Z'P4
M^C+GN3_W@6FUR#ED8,KN2%8LW9LPW<Q=?[6P]?G#V4'U?CNJ%(<ODN??>,.@
MV-`FTX"M$`\&>I^;(W#V7WC?V0;\D$[."KJO]$]Q^,KXKM30[1@2,GFE^?,M
M4QD4%&@\$ANF3%0@`#Z=FIO)@(+0)_M]X+DNEVZ4>/$TB$*`.UNF]!TWE*Z3
M[946]5\$A4<J)"%'D@C4'^W$([,XC)/_L_BHR"9X2S5=+:0X.#`T$%.UU(Q@
MF`*SR6SR9F:0DO&Y,4[6%=`*NO&XFI)@X3]"";,C9HV8N>MTF&B(V+R""#N(
M#_HZD9#Z6&0$37R]_">1QFDH,AIK1(@=')O8IG<P$`"5Z0MX/[`!0Q5[F4_)
M.3$;:(T8G!53TDWO8!`9:"Z/;,`P6[W(DV2<,V)FMFLAF70%QP+TK5&<=-:!
M)IB/RS49\%C3N!J(F1XUD7D7%D6A.;;F*'E#5/(1408\%D6&4=>(P:B3\!P5
M-?6M47+V'11J^A%-!CS6-'IEUH@Y56)<I[Z5S,Z*!YK,2NJ]\.^/L@&/-8U&
M9HT8U)2,C)N^<3;M*CQ0!'?$Y8H,>*@HBCM:?+<0@A-.2'#N#7:N;PXG\5@4
M+@&\(VLF=VS#JDHYF=B;"Y[`$':GN'O68;HFYJ8>G6]@)]ESOS/`3FCICGVG
M<L<;Y52L`,K`F\*`2]PJ^*!%:V^NK="P#>S/$I8_@XLB\`!<"*%/#V9O=7\G
M5O\```#__P,`4$L#!!0`!@`(````(0#%45Y>6@,``-@)```9````>&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;)16VV[;,`Q]'[!_,/S>V')\B8,D0^.BVX`-
M&(9=GA5;283:EB$I3?OWH\34%[5HNY?$%@^/#DF)].K30U-[]TPJ+MJU3V:A
M[[&V%!5O#VO_]Z_;JX7O*4W;BM:B96O_D2G_T^;CA]59R#MU9$Q[P-"JM7_4
MNEL&@2J/K*%J)CK6@F4O9$,UO,I#H#K):&6=FCJ(PC`-&LI;'QF6\CT<8K_G
M);L1Y:EAK482R6JJ0;\Z\DX]L37E>^@:*N].W54IF@XH=KSF^M&2^EY3+K\>
M6B'IKH:X'TA,RR=N^_*,ON&E%$KL]0SH`A3Z/.8\R`-@VJPJ#A&8M'N2[=?^
M-5D6A/C!9F43](>SLQH]>^HHSI\EK[[QED&VH4ZF`CLA[@ST:V66P#EXYGUK
M*_!#>A7;TU.M?XKS%\8/1PWE3B`B$]BR>KQAJH2,`LTL2@Q3*6H0`+]>P\W1
M@(S0!_M_YI4^KOUY.DNR<$X`[NV8TK?<4/I>>5):-'\19"/J2:(+R1S47^S1
M+%HD)$G?9@E0D0WPAFJZ64EQ]N#4P)ZJH^8,DB4PF\A2R,_+D4%(QN?:.%E7
M0"LHQ_TFBZ)5<`\I+"^8+6)RW^LQ\RFB>`%!>D@`^GJ1$+HK<OZF2.,T%3D/
M>WH;QQ8AN:V8":P8+4P$0&;&`E[/C@&O_7@4>18YL6\1@V?%[CQ:F.P,-._?
MV8#A;(UVCM/4B1DQ"ULU$L6.L&)B3I*L]YZH@E/[?E4&[*H:>+$2B$FLJIS$
M_:[66HRMB\6BMTXTI?^CR8`=3?.DYT5-B,DP4S%Q#G@Q,2?98)ZHROY'E0$[
MJM(A6E2%&%25A+F3R&)L)MEBB&FBR@RFT:U__3P;L*LJ=W*%&*Q?G`^[8OTF
M5C+X3C1!JQAK,ITHAL*_KLTX.=HR]Y8C!C.61L05-S8GZ>B^3-01Z#=C>:_+
MLFA7U]#<L)(7$":-1([L8FI>#/=XJLMIX&_HPIX[[A!9Y-RV+4Q2D]1+BTCB
M?-@:RSD%1&$V-!'4AH,4YTS#Y($5K*Z55XJ3&9(1W*A^%0?XEBRA&</@=-8+
M&.QV/>@-,%<[>F#?J3SP5GDUVP-E.,O@J$B<S/BB16>[_TYHF*CV\0A?4`S:
M?#@#\%X(_?1B9G__3;;Y!P``__\#`%!+`P04``8`"````"$`>UP?-!D$```#
M#P``&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)27VXZC.!"&[T?:=T#<
M)V!RCI*,)J#>'6E&&LV>K@F8!#5@A-V=[K??*@S&-J-><M-IG-]_/E>YROCP
M^:TLG%?:\)Q51Y?,?=>A5<+2O+H>W;__>IIM78>+N$KC@E7TZ+Y3[GX^_?;I
M<&?-,[]1*AQPJ/C1O0E1[SV/)S=:QGS.:EK!-QEKREC`8W/U>-W0.&TGE847
M^/[:*^.\<J7#OIGBP;(L3VC$DI>25D*:-+2(!?#S6U[SWJU,IMB5<?/\4L\2
M5M9@<<F+7+RWIJY3)ONOUXHU\:6`=;^199STWNW#R+[,DX9QEHDYV'D2=+SF
MG;?SP.ET2'-8`8;=:6AV=+^0?42VKG<ZM`'Z)Z=WKOWO\!N[_][DZ;>\HA!M
MR).(+W_2@B:"II`YU\&,7!A[QJE?8<A',V_D]M1FY$?CI#2+7PKQD]W_H/GU
M)L!D!2O$A>[3]XCR!"(,-O-@A4X)*P`(_CIECEL%(A2_R1_.4W$[NHOU?+7Q
M%P3DSH5R\92CI>LD+URP\E\I(IV5-`DZ$_B\=R9DO@Q6F^TC+HO.!3X[%Q(\
MC++L3.!3F?S?.CP9DS;$42SBTZ%A=P?V,:R:US%6!=F#(<9V`1G[=6PAJ#CG
M"TYJIX*:PP9Y/?D'[Q52F'2*\U@1F(JP5V"^T#32!CR`4X00\<<)<9))2,S?
M/X\5"U,1CA5+4Q&-%2NE,-8`^7Y\#3CIZ$)25)37RKT-V5DJY)['&(;V0*0-
M&$#@J@-]G&X4P[;00#86B%1`-2G4K:D(>X5*MS9@D(')=#(4FV0[\W?/4B')
M+K_:JF&O4&3:@$&V?H0,Q289L6M$2M8MU!+.&&MWA?+[(;N1-F"`;1X!0[$%
M9I>&E*Q:L,`G-E?_M0J8-F!PX8&L]9:/-QF*+2ZK99RE1.92MAUBUVPO46S:
M@,&V>X0-Q1:;%92SE!AL0R]HJS7L)8I-&S#8"#3@Z8%KU1:=W2@ZC8%GU7"H
M-(I/'S$!L5=/SBR1G5WO'\1J#^=.(_<<@?>M8&OMRE!)!CYIW%:(R8>->3J?
M;.,&G]U&B-0@7W::S4@P6P!?AD??C%CB4(D'TGXZC)BDV*"GDZ+:3'5@=Q4B
M-7JJ@U$H>\T`J(V8@-BGIP/*K@YFZB`(["HF?>?7-'89*\T`V,\:11!6^@`@
MJJT(VJ6,[Y:@,2)HU[+2#(#]K!$@MNWI$91-WHC@J)K[@^"C"/::`5`;,5.,
M_5L#G/@.*+N^`6JUE#/13@;9`[N137NV[!9K?[&URR?29YF@V,PUT(\/%+BB
MC%(]:CO:\=`!VB-XU4&?;8M,-D.Q2S9Y;9'OU'5\I=_CYII7W"EH!C7@SS>P
M+QIY:9$/@M7MF^F%";ALM/_>X+))X?W-GX,X8TST#[B7U/7U]!\```#__P,`
M4$L#!!0`!@`(````(0`5[3W2/@0``(L/```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;)Q7VX[B.!!]'VG_(<I[DS@AX2)@-,3JG9%FI=5J+\\A&(@Z
MB5$<FNZ_GZI42-L."\R\`*DZ+DY=?!PO/K^5A?,J:I7+:NFRD>\ZHLKD-J_V
M2_>?OY^?IJZCFK3:IH6LQ-)]%\K]O/KMT^(LZQ=U$*)Q($*EENZA:8YSSU/9
M092I&LFCJ,"SDW69-O!8[SUUK$6Z;1>5A1?X?NR5:5ZY%&%>/Q)#[G9Y)KC,
M3J6H&@I2BR)M@+\ZY$=UB59FCX0KT_KE='S*9'F$$)N\R)OW-JCKE-G\V[Z2
M=;HI(.\W-DZS2^SV81"^S+-:*KEK1A#.(Z+#G&?>S(-(J\4VAPRP[$XM=DOW
M"YMS-G.]U:(MT+^Y."OMMZ,.\OQ[G6^_YY6`:D.?L`,;*5\0^FV+)ECL#58_
MMQWXLW:V8I>>BN8O>?XJ\OVA@79'D!$F-M^^<Z$RJ"B$&0411LID`03@TRES
M'`VH2/K6?I_S;7-8NF$\BB9^R`#N;(1JGG,,Z3K9236R_(]`K`M%08(NR!C8
M=_Y@%$PC%L7WHWC$J$V0ITVZ6M3R[,#4P'^J8XHSR.80^9(9\>AS_;]4(4<,
M\@6CM+$@"P7]>5U%4;SP7J&F68=9$V;F.CTF,!')!8$%Q+!<,WC`MR<-I;!)
MA]#4Z^VX<,1%)L?0-PFLKT!,1'(%P4P('T+B60\QT@A_)0U<M'2A57T9H[%%
M84T8FD0L9&(;N&8P*$%<O;*W*XI@&&6=2C3I4VU;N";,M)V),)B$UE0DIM^W
M6\+)WZ9B$(5]HQ/%N;T_`KC()CRU"!-FTA)^"M@X&IN`Q`"P:<@^NDM32X`A
MY?A7*.,BF[+UAVO"$&7&@JF]KPQ_.&'6N'#R#PE/3,*WAP'!)E'FV[4E#!$-
MV=C:?HGACD(K36ZXX]E'EL9@X)FK"=IMT@@V24<VJS5AM,UD&[AF,*B`UNE4
M'IM17'1O?Q-&HV0;N&8P*#&029W3[?*T:*L^@QW>@;KQBUAH=3TQ`>-I9`%X
M!Q@.(,,#0&OF8Q5L5UFL8VO6UAU(J^'`PG6+6474^)_G12<#*-H-Z68$TGG9
M%JYC3%XHZQJO.]VE0^"V?C,"47<#-E!#T^]/++7DG?]*;U'9'^=*YX#!-;9T
M;,VTPZ*5XF1@X;K%K!W*ML;GP5DCL;_34^U$Z'C9%HZOD[#OK]0)U5GC=:>G
MI.5&G88[UC@0HG%@'=H),P'^Q-H]O`-<88LBK;%]L(HD[0;K^$/?Z4V"$4C?
M&;:%ZQBSNZC1/\^+E/U.=S7Y[[IK6SC3+"8O%&J-UYWNDJP;=1IVET#TRL4&
MK=6]P4")R:OUE>Y$=&4H1;T7B2@*Y63RA/<=!J])O97N8FN\B[6WJ=X!5Z%C
MNA=_I/4^KY13B!TL]4<3&/F:+E/TT,AC^X*^D0U<@MJ?![CT"GB#]4<`WDG9
M7![PNM9?HU<_````__\#`%!+`P04``8`"````"$`K[[H+!0#``#5"0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R<5MMNFT`0?:_4?UCM>[@8L!/+
M.$H:I:W42E75R_,:%K,*L&AW'2=_WQD6$PR.0_J"#3YS9LZ99<:KZZ>R((]<
M:2&KF/J.1PFO$IF*:AO3W[_N+RXIT895*2MDQ6/ZS#6]7G_\L-I+]:!SS@T!
MADK'-#>F7KJN3G)>,NW(FE?P2R95R0S<JJVK:\59V@25A3OSO+E;,E%1R[!4
M4SADEHF$W\ED5_+*6!+%"V:@?IV+6A_8RF0*7<G4PZZ^2&19`\5&%,(\-Z24
ME,GRZ[:2BFT*T/WDARPY<#<W(_I2)$IJF1D'Z%Q;Z%CSE7OE`M-ZE0I0@+83
MQ;.8WOC+6S^D[GK5&/1'\+WN?2<ZE_O/2J3?1,7!;>@3=F`CY0-"OZ;X"(+=
M4?1]TX$?BJ0\8[O"_)3[+UQL<P/MCD`1"ENFSW=<)^`HT#BS")D264`!<"6E
MP*,!CK"GYG,O4I/'-)@[T<(+?("3#=?F7B`E)<E.&UG^M2"_I;(DLY8$/EL2
M?^Z$LVAQ.8'%M14U`N^88>N5DGL"IP9RZIKA&?27P(S*`O#'UM%I?4TJ:$22
M&V2)Z14E$*ZA/X_K*+A:N8_@:=)B;BT&KAUFUB%<J*8K"<KHEW3:Y$-F!&-F
M-!U+N;4/^FF"TVF"]Z1!,#C3*SX*O8[79K:8IO]'>L+C1`>+S^O"H)C"M7,K
M"OU!0HL9)X0S-=U`!`^5O33&*K,8N/:*><75^7'N:6(Q:%A#.!!K,6.QB_])
MB$%ON6LQXX0XU'MOS/DV(GBH;.BNQ?3=#;RH4W]TE.`-Z^>>YBX&#6MXX;<=
MMIBQ6!]FP?LS-E%O^=N"3N3$23'98=_.E>-7<VAQ"^I['(7STQ[[[YH_#7KH
M[J)CMNZVH!-2<6;TI$YKJ&\GS?GAT().Y,2QT<MY_@##6AV?GI&]ATGT,B`"
M;S@@[':URZ?D:LL_\:+0))$[W)P^;(WN:;?5;V;-7NY^@*5:LRW_SM165)H4
M/(-0SUE`8Y5=R_;&R+I9;1MI8)TV7W/X^\1A07@.@#,IS>$&%W_WAVS]#P``
M__\#`%!+`P04``8`"````"$`TH'H3S4#```/"@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6R,5MMNVS`,?1^P?Q#TWCAR;DT0ITA7="NP`<.PR[-B
MR[%0VS(DI6G_?J3EN%;B)GD)8IHZAX>D2"_O7HN<O`AMI"HCR@9#2D09JT26
MVXC^^?UX<TN)L;Q,>*Y*$=$W8>C=ZO.GY5[I9Y,)80D@E":BF;75(@A,G(F"
MFX&J1`EO4J4+;N%1;P-3:<&3^E"1!^%P.`T*+DOJ$!;Z&@R5IC(6#RK>%:*T
M#D2+G%N(WV2R,@>T(KX&KN#Z>5?=Q*JH`&(C<VG?:E!*BGCQM"V5YIL<=+^R
M,8\/V/7#"7PA8ZV,2NT`X`(7Z*GF>3`/`&FU3"0HP+03+=*(KMGBGDUIL%K6
M"?HKQ=YT_A.3J?U7+9/OLA20;:@35F"CU#.Z/B5H@L/!R>G'N@(_-4E$RG>Y
M_:7VWX3<9A;*/0%%*&R1O#T($T-&`6803A`I5CD$`+^DD-@:D!'^&M$0B&5B
MLXB.IH/);#ABX$XVPMA'B9"4Q#MC5?'/.;$Z*(=5A_;`+5\MM=H3J#=XFXIC
M][`%`!]B<@AME!\%"=$AR!I1(CJG!/@-9/9E%8YGR^`%LA$W/O?.!W[??5J/
M`*)I0X(PNB'UI^?`C,[(C.G"4.Z=H4LSZJ<9^32H?`0U/4^'AR(Z[HH8W[;X
M+@+G4U?0TP6GNKJ0,)QBJ2]PXCEP[4HZS:YS8K[3O(W,"P08NX&<5XS.-7N;
MX<;BFKU;N*F/6_?2'.IQG@!/^02-!8KQWBJ38;^6F<]YG@J=?:K&<JH%A^[1
MO0AOV175PH,^1V/QY;!^.7"%NK3GY:"S3]583N4P8.\"NVZ?#F87NZ\^Z;,<
M3+ZBL%\1MF27^;RDVON(#0'`U"/J:%)<V7#,C0BX4&U+'TR^H@\&!SN:'!<4
MN7'@L36F'D4],X*QR>!RE=HA\:ZI,?F:QA]4"2]UI]\O:&I&0#>#C:E'4\]8
MF$-0%RA.QP+LYJ81NG-A<B3(K5^WXPJAM^*+R'-#8K7#U1K"<FJM[=I?A]@*
MQ_;Q8NT^!X+V#:SCBF_%#ZZWLC0D%RE@#NM;I-U"=P]65?5JW2@+B[C^F\&'
MEX`%-<1BIDK9PP,P!^VGW.H_````__\#`%!+`P04``8`"````"$`V(#.75H$
M``"-$0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R46%V/JS80?:_4
M_X!XOR$V(211DJO=KK:]4BM553^>6>(D:`$C3#:[_[XSMI=@8S;PDH3)^!P?
MCWULL_W^7N3>&ZM%QLN=3V9SWV-ER@]9>=KY__S]_&WE>Z))RD.2\Y+M_`\F
M_._[GW_:7GG]*LZ,-1X@E&+GGYNFV@2!2,^L2,2,5ZR$?XZ\+I(&'NM3(*J:
M)0?9J,@#.I\O@R+)2E\A;.HQ&/QXS%+VQ--+P<I&@=0L3QKHOSAGE?A$*](Q
M<$52OUZJ;RDO*H!XR?*L^9"@OE>DFQ^GDM?)2PZZW\DB23^QY4,/OLC2F@M^
M;&8`%ZB.]C6O@W4`2/OM(0,%..Q>S8X[_X%L'L.%'^RW<H#^S=A5='Y[XLRO
MO];9X?>L9##:4">LP`OGKYCZXX`A:!ST6C_+"OQ9>P=V3"YY\Q>__L:RT[F!
M<D>@"(5M#A]/3*0PH@`SHQ$BI3R'#L"G5V0X-6!$DG?Y?<T.S7GGT\4L)O-U
M&`/*"Q/-<X:0OI=>1,.+_U02T5`*A&H0^-8@X7(6Q?.0`.<=D$!U2.I[2IID
MOZWYU8-)`Y2B2G`*D@T`NP6!$LQ]P.2=O_8]Z*N`*KSM:;3<!F\P<JG.>50Y
M\'G+:3,"(&V9@6T\,R8C,PXM=N51!;HTH9LFG$*#R3M_T>U\%+>XBEGER"H;
M>J#5>#V8#).@V__^4*HD8B:MVNX8[#`#QK-CLF1OAU-%2"A70;=*RRFXF&SB
MJ@C@=J9#M'9+B*=08;))I2*$]B2@"7>FN%J[X0Q7WM?3'1N:'"H"'!TYR[E;
M#BR3+NW75)AL4JF(0PX!]^H"HYXUQ+XFD*U,!AVRU!"W&IR%7=8[;)AML:F0
M2Y#E!"@HC.(1!<*NVS3:&,P2T0%1D\P!9['-ID(N498=R%E'5[@]W*M4ZPWM
MZB3:"4Q1`X:'^]*$2JF5#TYT8U,AERC+#:0H$LWN:^H[`]'68&I:#!1JDC>0
MOCGHD$N3PQ[HBHPI5-\?B-,@H@%1DQR"]"U"AQRBJ,,CPOERQ)*2+<V5JT-`
MTW6]V[YO[$.XI8V??3+;8AOT"0H=Z$++V1>O1U1*MK1H$`P./::HVUYOBIKD
M$[3O$SKDV%^IPR?H<HRFODU(+-`$_+?#UW+@P(!&U!W-KPU=9ELCJ&U"'KO-
MX7+9Q`+J>H>C;Q)4FP1H[2@:.#_0228ALRU%^@C1/P51RR3N".D;@P2P2Q,/
MG!SH)&.0V980?7CHER9T&<,J'#'?9$N31H=P=[I5)QXX0(23C$%F6VS:&/K5
M"1W&,&H-R886B_8%8PW%`^>'<)(OR&R+35D%C"#LOL8:@MNLL3REV2WAOG=O
M%<F&%HNR"JM.]O%!77[5Y;!@]8G]PO)<>"F_X,66PG6OC;:7[@=YVK;CB\V#
MNHP'[3]P&:Z2$_LCJ4]9*;R<'0%S+O>C6EVGU4/#*U@E<)OE#5R#Y<\SO/9@
M<.6;H_8CY\WG`PY9^R)E_S\```#__P,`4$L#!!0`!@`(````(0#1NDST`48`
M`-:O`0`9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*S=69/;1I;V\?N)
MF.^@T/V4BF2M#KLG4,2^<5_OU++<5K0E.22YW?WMWP,B$[G\TZ7"Q.N+L>?7
M!TD`YTF01)*L'__WWQ]_>_6O]U^^?OC\Z:?7DZOKUZ_>?WKW^></G_[QT^O=
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M__WJZZ^?_\R^?/BY_O#IO9QOZ537@[]__OS/KK3XN2/9^`VV3B\]6'YY]?/[
M7][^\=NW]><_\_<?_O'K-VGXK1Q3=V@__/R?^/W7=W).99BKZ6TWTKO/O\D.
MR/]]]?%#%PXY)V__??GWGQ]^_O;K3Z^G-Z]?_?W]UV_IAVZHUZ_>_?'UV^>/
MA_Y_G*@A^HVG:F/90FT\N[NZO;^>3>2Q7CJ(5%[VX'X89#J]FMQ<WW5C///@
MDN'+=O)O]>`W5_>3Z\?9_?/;/:KMY-_ZB%_T>!/I37^JNB;UI^-ECS@93K+\
MA]IR(N?NF8/K_N?^P>0_QCW83&]INO*R$]K%IG],^0^]F_=7TX?;R>WWFC&Y
MT]O*?XS;7^E[_Z@F`).;JYOI[?W#)4;/G26=@<G8$$QT"KK_T,<Z>]FC3G40
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M4/;GC41[R+?,H_\?^>Z&Z?*M#_=)@PG\S`NSKM";Q#XD/J0^9#[D/A0^E#Y4
M/M0^-#ZT/BQ\6/JP\F'MP\:'K0\['_8^''PX^G#RX>Q#%$&&9NI617/4H'L1
MVA>A?Q$:&*&#$5H8V3UTPBQ/A4Z8PZ]<]36YJ_[IM3P'6M?D6S>D3WV-/+/K
M0Y]#8D@"22$9)(<4D!)206I(`VDA"\@2LH*L(1O(%K*#["$'R!%R@IPA441B
M5R.V-6)?(S8V8F<CMC9B;R,V-W*ZZP1;0CHBV%VUO/F22[Z5;/_5ABJ2B6P5
MW;GQGP]%.OXQ)(&DD`R20PI(":D@-:2!M)`%9`E90=:0#60+V4'VD`/D"#E!
MSI`H(CV1V-:(?8W8V(B=C=C:B+V-V-S(Z:X3=GEO,2+L7?4E[#JB3TIFYIH-
MB2$))(5DD!Q20$I(!:DA#:2%+"!+R`JRAFP@6\@.LH<<($?("7*&1!&)78WF
MK&)?(S8V8F<CMC9B;R,V-W*ZZ\18WBR.B'%7[<98B3Q]61?H>^\"/13I],>0
M!))",D@.*2`EI(+4D`;20A:0)60%64,VD"UD!]E##I`CY`0Y0Z*(]$2:D]C7
MB(V-V-F(K8W8VXC-C9SN.LF6VS`CDMU5N\E6<F<NT)`8DD!22`;)(06DA%20
M&M)`6L@"LH2L(&O(!K*%["![R`%RA)P@9T@4D9Y(<Q+[&K&Q$3L;L;41>QNQ
MN9'372?&<H]P1(R[:C?&2F2N6A?H!^\"/10-%VA(`DDA&22'%)`24D%J2`-I
M(0O($K*"K"$;R!:R@^PA!\@1<H*<(5%$>B+-23&)C8W8V8BMC=C;B,V-G.XZ
MR9;[S".2W56[R59BO8*&Q)`$DD(R2`XI("6D@M20!M)"%I`E9`590S:0+60'
MV4,.D"/D!#E#HHCT1)J3V->(C8W8V8BMC=C;B,V-G.XZ,>Z624?D^%+N!EF3
M^R+ZT;M&FZKA(DU*2"DI(^6D@E22*E)-:D@M:4%:DE:D-6E#VI)VI#WI0#J2
M3J0S299ANL!(`LR%2Q9B:/.`Q0$+M%P69#A>H.FR*,.Z0-ME8<:N<^/?K=G8
M:X_/W\[N/AK@7<<U6:^T23$I(:6DC)23"E))JD@UJ2&UI`5I25J1UJ0-:4O:
MD?:D`^E(.I'.),FZ:K?IK62=-@]8H..R],AM`SV7Y4?6!;HN2Y"L<_ON9KU;
M4+*SWJVS3V^OY!;/V)7V?FE*[G[KB_E3]PF8;F8XK]0?KOUG@:%*;QB;#34E
MI)24D7)202I)%:DF-:26M"`M22O2FK0A;4D[TIYT(!U))]*9)#,#C92909L'
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M="9)UG$.)>NT><`"'9>L<]M`SR7KK`MT7;+..K?O;M:[):X16>_*O7L[BMQ+
M_=2_U`]5.NMQ]P%S/_Z@E%49*2<5I))4D6I20VI)"]*2M"*M21O2EK0C[4D'
MTI%T(IU)$G^T2.)/FP<LT'&)/[<-]%SBS[I`UR7^K'/[[L:_6QH;$7^UDF9?
MZK&X-I^`8E)"2DD9*2<5I))4D6I20VI)"]*2M"*M21O2EK0C[4D'TI%T(IU)
MDG4T4K)."S1<7M6S+M!R>57/ND#3Y54]ZP)MEU?U=IV;]6YE;$36U4*:G?5A
M;<U::GWP/U#>?7/'O:['I(24DC)23BI():DBU:2&U)(6I"5I15J3-J0M:4?:
MDPZD(^E$.I,D_FBDQ)\V#UB@XW*IY[:!GLNEGG6!KLNEGG5NW]WX=XML(^*O
MUN3L^"NZ&6YISKOOFG59-Q23$E)*RD@YJ2"5I(I4DQI22UJ0EJ05:4W:D+:D
M'6E/.I".I!/I3)*LHY&2=5J@X7*I9UV@Y7*I9UV@Z7*I9UV@[7*IM^N<K'??
M9QR1]4NY^ZI>D[QQ-I^J>?`^O#XW5<.K>E)"2DD9*2<5I))4D6I20VI)"]*2
MM"*M21O2EK0C[4D'TI%T(IU)\ETCM?IIKF/14\`"#8_B0%V@Y?*M(SY&H.GR
MS2/6!=HNWSZRZ]SX=VM>+[_4=]_0\-[4:KHWEWI23$I(*2DCY:2"5)(J4DUJ
M2"UI05J25J0U:4/:DG:D/>E`.I).I#-)LJ[:;7HK6:?-`Q;HN'R_CML&>B[?
ML6-=H.OR/3O6N7UWL]ZM8ME9[U9L[V1J/+\^U7W1W<]\3^9#&W-5).L$UG.`
M]]6\.%ADOL#D[FRWY&#O['=V4JU06*_!Y#,EW7[+5\#U,\Z<%),24DK*2#FI
M()6DBE23&E)+6I"6I!5I3=J0MJ0=:4\ZD(ZD$^E,DHF)WLK$I`4:+D]"K`NT
M7)Z$6!=HNCP)L2[0=GD2LNO<K'=K#B.RKI8H[*SW)"_S3-9!L;SWZ&:$5960
M4E)&RDD%J215I)K4D%K2@K0DK4AKTH:T)>U(>]*!="2=2&>29!U=DZS3Y@$+
M=%R>A+AMH.?R),2Z0-?E28AU;M_=K'=K#B.RKI8H[*SW-).W]-9SC?\UJ^Z'
M3[JK_^77E_J?WM!DGK824JK)'=[[`&IFJO2$RS69X0M2J<D9_M%;`ZE,E1Z^
MUF2&;TBM(>OD/'IOQA:F2@^_)*U(:TWNWGO/\QM3I8??:C)[OR/M-=G#SZZ]
MCWT=3)4>_JCI,KR;M^XF_XB\J34!.V\]>7GSOS72?53-SYLB<\R)KC*4:K*/
M>?KH'7-FJO0QYYK,6`6IU.0.[]V(K4R5'K[69(9O2"UI05J25J2U)G=7S>O#
MRRS>F"J]JUM-9E=WI+TF>_C9M?=!DX.ITL,?-5V&=\/5W4$?$2YUP]T.5T_6
M96K>_6:2GR1%Y@`3764HU60?X/31.\#,5.D#S#69L0I2J<E<42M2K<F,U9!:
MTH*T)*U(:TWN87O/!QM3I0][J\GLZHZTUV0.^T`Z:KJ,Y69$]FM,1KIR[P9;
M3TY&0''W`UI=;,S1)*14DSF:C)1K,F,5I%*3&:LBU9K,6`VI)2U(2]**M-8D
M)\2\0'CT+M@;4V4"@5.XTU5F[_>:S&$?2$=-EPW=0'3W8NV+1O\#95?=+Q=^
M^_7#NW\^?9;=EG?V@7>\,_DALO[GR:;JCJY]+>EI9K\)`,5J0R<GJLH<9*JK
MS%@9*==D-BQ(I28S5D6J-9FQ&E)+6I"6I!5IK4F.WLJ)]TIO8ZI,3G"^=KK*
M[/U>DSGL`^FHZ;*ADY-9=]/2SDD@#_*Z1P?B4NY>.!3)O_2NSPU=?M'N>N*]
M\HQ-@=XF(:6D3-/D\EMY-]?=/^XG>W)=8O:G()6DRI#IU.S:V_7:5.E=;T@M
M:6'('MY[C;0T57KX%6EMR(PUG?K/1KJJ/UG3Z8-W==KJ`G.J=J0]Z6#(/#Y.
MU=%4R;&XJ>MN*8Y(G;H#:5V&9CW)IPOT>9H;^JO489O$;*.'24F9HMGTDKK)
M)!@[#%YPI))4&7KF7-:F2N]H0VI)"T/V\-Y[M:6ITL.O2&M#9JQ`[/HSH<[6
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M*M&UZ"E@\X`%.BZ_4\GQ`CV77ZID7:#K\EN5K'/[[F:]NUL^(NO]S74GZXKD
M3M7P9FIV[=V\F\^&*GW-C$D)*25EI)Q4D$I21:I)#:DE+4A+THJT)FU(6]*.
MM"<=2$?2B70F2?S12(D_+=!P^956U@5:+K_3RKI`T^676ED7:+O\5JM=Y\:_
MNU,_(O[]C7TG_HKL2STH[GZ.OKNY9ZH24DK*2#FI()6DBE23&E)+6I"6I!5I
M3=J0MJ0=:4\ZD(ZD$^E,DJRC:Y)UVCQ@@8[+I9[;!GHNEWK6!;HNEWK6N7UW
ML]ZM)=A9_S__;L.L7Y5PIH$B]UG`>X4_UQN::1"3$E)*RD@YJ2"5I(I4DQI2
M2UJ0EJ05:4W:D+:D'6E/.I".I!/I3)*9,;1;/YW+S*`%&B[/`JP+M%R>!5@7
M:+H\"[`NT'9Y%K#KW)G1W?ZW9\9W[D'TJP5._!5-A[>$\V[9N+OD&XI)"2DE
M9:2<5)!*4D6J20VI)2U(2]**M"9M2%O2CK0G'4A'THET)DG6T4C).BW0<,DZ
MZP(MEZRS+M!TR3KK`FV7K-MU;M:[)8P16>]7/)RL*Y+I9+W@]^YCSV4QRGO%
M$Y,24DK*2#FI()6DBE23&E)+6I"6I!5I3=J0MJ0=:4\ZD(ZD$^E,DOBCD1)_
M6J#A$G_6!5HN\6==H.D2?]8%VB[QM^N<^-^,6UN[E+MK:YK,:Y@Y*28EI)24
MD7)202I)%:DF-:26M"`M22O2FK0A;4D[TIYT(!U))]*9)'^207U=Q/0V>@I8
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ME/C3`@V7^+,NT'*)/^L"39?XLR[0=HF_7>?&OUNA&!%_M:!A+;?>8(UC3HI)
M"2DE9:2<5)!*4D6J20VI)2U(2]**M"9M2%O2CK0G'4A'THET)DG6T5O).BW0
M<,DZZP(MEZRS+M!TR3KK`FV7K-MU;M:[I8<165<K%7;6A\4+ZZ66_^F]^<U0
M92[UH(15*2DCY:2"5)(J4DUJ2"UI05J25J0U:4/:DG:D/>E`.I).I#-)XH^N
M2?QI@89+_%D7:+G$GW6!IDO\61=HN\3?KG/CWZU0C(B_6M"PXX\UCOD-*"8E
MI)24D7)202I)%:DF-:26M"`M22O2FK0A;4D[TIYT(!U))]*9)%E'(R7KM$##
M)>NL"[1<LLZZ0-,EZZP+M%VR;M>Y6>_6%T9D72U'V%E7Y+ZJ]SZ./+\9JLRE
M'I2P*B5EI)Q4D$I21:I)#:DE+4A+THJT)FU(6]*.M"<=2$?2B70F2?S1-8D_
M+=!PB3_K`BV7^+,NT'2)/^L";9?XVW5N_+LEAQ'Q5RL4=OP5F1^8F=^`8E)"
M2DD9*2<5I))4D6I20VI)"]*2M"*M21O2EK0C[4D'TI%T(IU)DG4T4K)."S1<
MLLZZ0,LEZZP+-%VRSKI`VR7K=IV;]6Y]8436U7*$G75%\L;!+*)-O(]?SV^&
M*G.I!R6L2DD9*2<5I))4D6I20VI)"]*2M"*M21O2EK0C[4D'TI%T(IU)$G]T
M3>)/"S1<XL^Z0,LE_JP+-%WBS[I`VR7^=IT3_]MNR>'E\;^4NXMHFJQ+/2DF
M):24E)%R4D$J216I)C6DEK0@+4DKTIJT(6U).]*>="`=22?2F21_$%HM2)G>
M1D\!FP<LT''YH]`<+]!S^;/0K`MT7?XP-.O<OKM9#RVB_9_^VM$MU]4TN<\"
MWA=7YJ9J>!8@):24E)%R4D$J216I)C6DEK0@+4DKTIJT(6U).]*>="`=22?2
MF20S0R7`F1FT0,.C.+!MH.7R]](Y7J#I\A?361=HN_S-=+O.G1G=^M:(9P&U
M'&:]"+I59,['G!23$E)*RD@YJ2"5I(I4DQI22UJ0EJ05:4W:D+:D'6E/.I".
MI!/I3)*LH[?R+$`+-%RRSKI`RR7KK`LT7;+.ND#;)>MVG9OU;C%K1-;5VI>=
M=47NI=[_FLSM4&4N]:"$52DI(^6D@E22*E)-:D@M:4%:DE:D-6E#VI)VI#WI
M0#J23J0S2>*/KDG\:?.`Q0$+M%SBS_$"39?XLR[0=HF_7>?&OUO?&A'_KMQ[
MP:_(OM2#XEM00DI)&2DG%:225)%J4D-J20O2DK0BK4D;TI:T(^U)!]*1="*=
M29)U=$VR3IL'+-!Q><'/;0,]EQ?\K`MT75[PL\[MNYOU;C%K1-;5VI=]J5<D
M#VO=V_&_"W,[5)E+/2AA54K*2#FI()6DBE23&E)+6I"6I!5I3=J0MJ0=:4\Z
MD(ZD$^E,DOBC:Q)_VCQ@<<`"+9=+/<<+-%TN]:P+M%TN]7:=&_]N?6M$_-5R
MF!U_1?:E'A3?@A)22LI(.:D@E:2*5),:4DM:D):D%6E-VI"VI!UI3SJ0CJ03
MZ4R2K*-KDG7:/&"!CLNEGML&>BZ7>M8%NBZ7>M:Y?7>SWBUFC<BZ6ONRLZ[(
MO=3[WX6Y':K,I1Z4L"HE9:2<5)!*4D6J20VI)2U(2]**M"9M2%O2CK0G'4A'
MTHET)DG\T36)/VT>L#A@@9;+I9[C!9HNEWK6!=HNEWJ[SHU_M[XU(OYJ.<R.
MOR+SL>SY+2@F):24E)%R4D$J216I)C6DEK0@+4DKTIJT(6U).]*>="`=22?2
MF2191R,EZ[1`P^4&#NL"+9>LLR[0=,DZZP)MEZS;=6[6N\6L$5E7:U]VUGNR
MO@-SJ\6\S)].O=\FC`-%LXGYHHRSD]V?Y!BQDY=R]VVV(OD#E_J99DZ*'7+W
MH+O;^_+3=*=N#ENG29'UIP;FI)B4D%)21LI)!:DD5:2:U)!:TH*T)*U(:]*&
MM"7M2'O2@70DG4AG4A0%["E@@89'@8Y'@99'@9Y'@:9'@:Y'@;9';M_=K'=W
M>T=D7=T<MK/>DY-U4'P'2D@I*2/EI()4DBI236I(+6E!6I)6I#5I0]J2=J0]
MZ4`ZDDZD,TFRCJY%3P&;!RS0<<DZQPOT7++.ND#7)>NL<_ON9KV[M3LBZ^I.
ML,GZ_$[1\,02*^E^1\_<YIJ:KW=>?JXZ,57Z&2DE9:2<5)!*4D6J20VI)2U(
M2]**M"9M2%O2CK0G'4A'THET5G3Y41(W(=U-TA$)4?=4[80HLA+2BR0D_.N_
MR=U08,(!REB5DPI2J<C\`DL%J<UF:A^]CULWID#O8TM:D):D%6FMR.SC!K(U
MFZE]]#XGN#,%>A_WI`/I2#J1SHH"H>EN(XX(C;KK:$(3W_4D/UJH]SPA98K,
M2<IUD7OQ\;X`6Y@J/7J)H6I=9':A(2VPW5(7/;L+*U.E=V&-H;:ZR.S"CG3`
M=D==].PNG$R5WH6S/91[&>ANH(WHJ+K?9CHZOU,T-#16XCU1>&^4$E.E]S+%
M4!DD-YO9ST+>)"Y,E1Z\Q%`5I#:;V8-[>]Z8*CUXBZ$6D*79S![<V_.5J=*#
MKS'4!K(UF]F#>WN^,U5Z\#V&.D".9C-[<&_/3Z9*#WZVAW)CU]VD&A$[=4_+
MCITB*W:]>+'S+IW)W5"E]S)59*XV&20WF]FGP/OD7F&J].`EAJH@M=G,'MS;
M\\94Z<%;#+6`+,UF]N#>GJ],E1Y\C:$VD*W9S![<V_.=J=*#[S'4`7(TF]F#
M>WM^,E5Z\+,]E!N[[G[1B-BIVTMV[!19L>O%BYWW09_D;JC2>YDJLF/G#YZ;
MS>Q3X"TM%Z9*#UYB\`I2F\WLP;T];TR5'KS%4`O(TFQF#^[M^<I4Z<'7&&H#
MV9K-[,&]/=^9*CWX'D,=($>SF3VXM^<G4Z4'/]M#N;$;=S/RCC<C%75_S<-Z
M[^6O.YDJO4\Q*='4_R[_W>1F<CWSWL6ENL;\-']&R@V9O<+?`2A,5?=J=G9U
M>R=_Z<_\XSU'E:9<'T1%JDF-IOZX;J>WL]M[<^/U\NZTU37FN!:DI:%GCFME
MJOKC>IQZSXAK4Z$/94/:DG::U*%,;F</_I^UVNL:<R@'TM'0,X=R,E7J4&[[
MOZ^BNN2]S#Z;<CDN)^GWX^YH7\K=.]J*Y"\KF!V>3;T^SDV5/K,Q*2&EI(R4
MDPI22:I(-:DAM:0%:4E:D=:D#6E+VI'VI`/I2#J1S@ZYL1FW#''/90A%[@72
MOZS-396)33^6;*@I855*RD@YJ2"5I(I4DQI22UJ0EJ05:4W:D+:DG:;^:A7Z
M&SE[76+.\H%T))T,76Z%X`_BG$T!KD7='=.7O]B[[V^PVK^ZI<B]%LV\J^'<
M5.D$Q:1$D?Z3+K</M]ZS=\J-,E).*@QUY^A&SM'DT?['_>-LI2G7^UN1:E*C
M2!_"]:U_""TW6I"6I)6A[A#NKNZNI_81>*=J;<KU(6Q(6]).D3J$FYNI_V=A
M]]SH0#J23H;Z0WB8/?<RYVS*D5NYNS,FMUVY]QS:DW<Q]%YHS>^'*GT28U*B
MJ9_<#W>3VT?O94ZJ2\SDSD@YJ3#4G;+)U>SFSKPNO/9;4YIRO<,5J28UFOIC
MN'^<^*_46EUA#F%!6I)6AOI#N)G<V\'U7K>L3;D^A`UI2]IIZ@]A,GN<^7])
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M4D)*21DI)Q6DDE21:E)#:DD+TI*T(JU)&]*6M"/M20?2D70BG4E1%+!`OZ-`
MPZ-`QZ-`RZ-`SZ-`TZ-`UZ-`VR.W[^YMB&YMR'[Y\K(?4+_OEY2<ES$]R80V
MMVMGWLK%7&WG%IF;V.ZN=4L#]JX]_Q/2]VHEP:Q</"ERIJ%:E#`S,V950DI)
M&2DG%:225)%J4D-J20O2DK0BK4D;TI:T(^U)!]*1="*=23(-T<@HT&^9AJP+
M=%RF(>L"/9=IR+I`UV4:LL[MNYOU<<LE]UPN461]=GL0,R&G,S/7+JL#<:!H
M9OT%9F<G'\;=Z;Z4N^_2%=F?)B7%I(24DC)23BI():DBU:2&U)(6I"5I15J3
M-J0M:4?:DPZD(^E$.I.B*&!/`9L'+-#Q*-#R*-#S*-#T*-#U*-#VR.V[F_5Q
MM^<?>'M>D9/UOLJBF%4)*25EI)Q4D$I21:I)#:DE+4A+THJT)FU(6]*.M"<=
M2$?2B70F2=;1R.@I8/.`!3HN6>=X@9Y+UED7Z+IDG75NW]VLCULU>."J@2(K
MV'-23$I(*2DCY:2"5)(J4DUJ2"UI05J25J0U:4/:DG:D/>E`.I).I#-)LMZW
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M)16Y'VW`)UM-E3YU,2DAI:2,E),*4DFJ2#6I(;4..:?T<=PMU$NY<Z%]4N1]
MT,E[4IJ;JN&4DA)-*GJWE^5M]Z-SJ:XQT<M(.:D@E:2*5),:4NN0>XZ[FQ\O
MOWH\]O=*[*N'(C>V-SC'ZB:+^66@V&RH3WNB2'W<8])-0.^))>56&2DG%>[8
M-]=W\H_;OI);5:2:U+ACSQX?9O?>8E[K;.6VH'M//J(%_5MXIP4]N3'W/^XQ
M?QRJ]/F.28FF/N8S7`)376!G'"/GK"HTJ0ET_^!_M*74%6;HBE23&DUJZ(?;
M>_]30JTNX97[L7M/..+\]V\AG?.OWE7*"Q-K.==[J36_/,Y/KV6BF/,_;*@I
M455Z"LP>^0R7<J2,E),*=_#0,US)K2I236K<L6?R2="I-W=;9RMW#G3O5>P>
M="OKW9\1?/ZEX&/_%L?I14_F=?)<%<FI-LVY\5Y?Q\$BTT%W9\>]?7K$VZ<G
M1?:M`E),2D@I*2/EI()4DBI236I(+6E!6I)6I#5I0]J2=J0]Z4`ZDDZD,RF*
M`A;H=S0/U`4Z'@5:'@5Z'@6:'@6Z'@7:'KE]=[,^[LWNHWI/:CY7,M=D7?6&
M-[O6C,0/Q:CM['>\I(R4DPI22:I(-:DAM:0%:4E:D=:D#6E+VI'VI`/I2#J1
MSHKX_O-QW+OW2[GS*GVNR4I(_Q;_KV^'J$V<<`S;Z.?2C%4YJ2"5BLQ7KRM(
M;38+WUII3('>H9:T("U)*]):D=G'#61K-@O?IMF9`KV/>]*!="2=2&=%@=",
MNVGQB)L6L2+[AV)(F=YPB%:NBYR7`U/OH]&%J=+GI<10M2XRO]+2D!;8;JF+
MGMV%E:G2N[#&4%M=9'9A1SI@NZ,N>G873J9*[\+9'LI]HAAW_^,1]S_FFH9>
MQ4K<FWC^+VHFIDKO98JA,DAN-K.?A<Q+OLM'O@I3I0<O,50%J<UF]N#>B\[&
M5.G!6PRU@"S-9O;@WIZO3)4>?(VA-I"MV<P>W-OSG:G2@^\QU`%R-)O9@WM[
M?C)5>O"S/903._DTOO?.X?EW#'V]^_PSF$F>)B]ZWAN:Q"K3NYIJ,Q?FC)1K
M\A[`NVM06&7Z`4IMY@$J4JW)>P#O"!JK3#]`J\T\P(*TU.0]@'<$*ZM,/\!:
MFWF`#6FKR7L`[PAV5IE^@+TV\P`'TE&3]P#>$9RL,OT`9VV7!_`".>Z.VN0:
MM]3F@]F![,N\??7N8$D@AS*]KQ)(]0C#:!)(GR20PY;VW/2^_R2!',KT`T@@
M_=$DD#Y)((<M[0?PCD`".93I!Y!`^J-)('V20`Y;V@_@'8$$<BC3#R"!]$>3
M0/HD@1RVM!_`.P()Y%"F'T`"Z8\F@?1)`CEL:3^`=P02R*%,/X`$TAK-"V1W
M=\Z^M_*]*V1_-\^^J2)W8F6,GUZ[=QBQ1&25Z1V+`R8I5<.I^W53N5OTZ#W%
M2&R'Q]2#26YA$MS!S$GCER^MLNZU\.W5[.'&^L*3__,I$NIA6/WPDFJ8Q!HF
M&5;6'Y]\GUB^@.?>:Y9,8SL)-4Q2/=@SAR>I'LJZP[N_FM[V/[2@OH7G/<=*
MXH=Z?7@2>9AD'B8!5_;7AR>!QW:2>)A$?K!G#D\B/Y2]Y/!D.@SU<GC>?)`7
MO:/F0U?OO&)XDE]$NIBWZ.$]-<EU?"C3)UGF`TSF`TSB#Y/XPR3^,+E(PR3/
M,,DS3/(,DSS#)+\PR2],\@N3L,(DD#`))$P""9-`PB2`,`D@3`((D[3!)%&V
M>8GR[UY_[PK+V]:3:W7?VEF$QP_46&56HH9-M4FB8)(HF"0*)HF"2:)@DBB8
M)`HFB8))HF"2*)@D"B:)@DFB8)(HF"0*)HF"2:*4]9>XZ>/=Y,Y[&I:$83M)
M&$P2!I.$#7:Y,W-U=__<[T)(^H9Z7L_&+4=,KKD>H<V]GLV\IV2YGO6;VDM8
M`9/T]75J$6LVO9OZ9T_2B+$DC3!)(TS2.%AW]JZO_(]+23:'"CTG))LPR29,
ML@F3;,(DFS#))DRR"9-LPB2;,,DF3+()DRS")(LPR2),L@B3O-GF7>W&+0E,
MKK$F(,^?:@G`O=IY+U(D;T.9[J(\?\(D;\K^^@6)Y`W;2=Y@DK?!GGE!(A$<
MRE[R@D0".=3K0Y%`PB20,`FDLK\^/`DHMI.`PB2@@SUS>)+9H>PEAR=Y'NKU
MX4F>89)GF.1967]X$_G(P:W_;D`"C@TEX#`).$P"/EAW,'=7D]ESOR,DX1_J
MY6"\\(];[9A<]ZL2[INIWKR++5\\#F7ZE$KX81+^WM3%-O1F0\*/[23\,`G_
M8,^D0\(_E+TD'1+^H5X?BH0?)N&'2?A[>^;P)/S83L(/D_`/]LSA2?B'LI<<
MGH1_J->')^&'2?AA$O[>GCD\R3ZVD^S#)/N#/7-X,AV&LI<<GDR'H9[38=PZ
MSN0:"SGR7-";_6&(@$GV42?9ATG689)UF&0=)L&&27AA$EZ8A!<FX85)6&$2
M5IB$%2;)A$GZ8)(^F*0/)NF#2=I@DC:8I`TFT8))?&!1%,)0$B)Y#<#-0UF(
M0F&(0FF(0G&(0GF(0H&(O$1XSP_^,ECW0::)O)AZ]\?7;Y\_YN\__.,BW_MD
MT^0:"V1R?GJ3F6+F]RV?-X8J?362\P63TP63LP63DP63<P634P63,P63N0.3
MN0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0.3N0/K
MY@[1SH;N>C=W6!G*0C=W6!E*0S=W6!G*0S=W6.DEPIT[DY%+>9=Z[\:<,N?)
MA!9/:$G`TH!E`<L#5@2L#%@5L#I@3<#:@"T"M@S8*F#K@&T"M@W8+F#[@!T"
M=@S8*6#G@,F$8#.CIQ#.0QC*@DR(P)BA-,B$"%2&\B`3(E#I)<*;$-V:CKUR
MTSUU='^L\SOW%R=J+<A\"D].1V_R3&0^!8M?G`I6W9BE"V_WNGOL]NY];[?Z
M>_+.>Z&),K-2*TV"28]@TB*8=`@F#8))?V#2'IAT!R;S%2;S%2;S%2;S%2;S
M%2;S%2;S%2;S%2;S%2;S%2;S%2;S%2;S%2;S%2;S%2;S%=;-5Z($E!B*0A3*
M0C=?N7DH#=U\964H#]U\9:67"&]"=$L$]H1XZ7SMEQ;<B=&;]3GVR423-85O
MO-5G.3NA*G/OVMOC[K:RO<??F\+];6AW3Y69[S5(WV"R8S#I&DR:!I.>P:1E
M,.D83!H&DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,DRD,
MDRD,DRD,DRD,ZZ8P4:8P,12%;@JS,A0&>?\6J`S%0=Z_!2I#@9#W;TZE-R&Z
M^]YC)D1_G]R=$+W=FJ\QR5F`R4F`R3F`R2F`R1F`R0F`R?'#Y/!A,B%@,B%@
M,B%@,B%@,B%@,B%@,B%@,B%@,B'^'VMGU]S&<270O^+*^S(`"(``*YNJ2-0'
M)=(6)4J6_.9U9#N5#Z5L;6WVW^^YTSV#GCX7U"+E/$3)N3V-GCOG-@;3PQDQ
M"D*,@A"C(,0H"#$*0HR"$*,@Q*(@#"D(PTR%*`BWS&2(@G#+3(<H"+?,A(B"
M:%MV!1'7PMN"^'<O:/`.>MU&4=EZ/SSV@+<M+'0UX]!D_%U+LDI7;#8R<B5&
MJL3(E!B)$B-/8J1)C,(1HW#$*!PQ"D>,PA&C<,0H'#$*1XS"$:-PQ"@<,0I'
MC,(1HW#$*!PQ"D<L"L>0PJGP,(5R-:/"9EZ-PBDM6SC)T,+)AA9..K1P\J&%
MDQ`MG(PHL"N<N&K^FQ1.N?P^_XHI;,./NL//N?Y!Z&1L:C86"@D3(U]BI$N,
M;(F1+#%R)4:JQ"@>,8I'C.(1HWC$*!XQBJ>RPYDTQ:-V%,_$FI1NNK]CIYZF
M9F-*J2<QZDF,>A*CGL2H)S'J28QZ$HMZ,J2>*O1?/R^7<7W=GI[%(]\___R7
M'_[ZZ%-<PDXO.L3C:H:_D^!CRV7ZN:6%;?@9U5C:/0P$2Z=F8TJQ5`Q+Q;!4
M#$O%L%0,2\6P5`Q+Q;!4#$O%L%0,2\6PM+*9I94=+N-@J1A*BJ&D&$J*H:08
M2HJAI!A*BJ&D6"AIB)(59DK&A6,K>?HB2JR4]+=N5K;A%\@DY:J_WP`IRZ8T
M:Z2L;#,QI%0[I)S8X2/.-]W=5'@Z-1L_`D_%\%0,3\7P5`Q/)]8,I?]S-]2=
MFHU#05TQU!5#W<IFZE8V4W=BS5#ZK&#SU&P<"C:+8;,8-HMALQ@V3ZP92I\5
M!)^:C4-!<+$0W!#!*QSR,C\W6/4K'?_N2?704;<$4MG\W&#3_87C8VZS&6J#
M9N/.74WL<-KU9&*'=D\;UN1OT]V^]:QI-G[$\X1=)^Q%PEXF[*9AS5#Z]W?=
M-LW&H7R=L&\2]FIBK>#.WNNIW>RD;-5=H'O3-!N'<I^PMPE[E[!O$_:^80]D
MY4/3;!S*=PE#<.\N*RPCS`2/U8;?8@;G?$(S>&6-N=A<VC4,FRN;V:QVV#RQ
M)EG]NCHV3\W&9&&S&#:+8;,8-HMA\\3:H1RNW@XG6]@\-1N'@LUBV"R&S97-
M;%8[;)Y8,Y2MSH</S<:A8/.TZ<BP60R;Q;!9#)LGU@QETV4%FZ=FX\=BLUC8
M;(C-%68VQSK`;V)S75`XS*5\;F&-N=@LALV5S6Q6.VR>6).L=7?2C<U3LS%9
MV"R&S6+8+(;-8M@\L68H_4M!L7EJ-@X%F\6P60R;*YO9K';8+,9$+(:Z8J@K
MAKIBJ"N&NA-[(`6H.S4;4X"Z8J&NX4&A3-U8#?I-U"W+2E3).$(^M["YNF*H
M6]E,7;5#W8FUR3HL/P^S'^I.S<:AH*X8ZHJAKACJBJ'NQ-JA=%6$NE.S<2BH
M*X:Z8JA;V4Q=M4-=,=050UTQU!5#73'4%4/=B3V0`M2=FHTI0%VQ4-?PH%"F
M;JP16=U3+TRLZE+33-S"N#`QCIDY5PQQ*YN)6]FA/\2=MFU3U9WY(>[4;/Q8
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M6`R%Q5"XL"85H7"%:2["WW:CSM]8_CC%W[)<,O>W,,KJ87]KL['0]DR![7^Z
M!^BC\]1OHW-A\TE9#)W%T%G]H7-E91K:[S>[_OHQ.JLO=!9#9S%T%D/GPIII
M")TKJU]19^ON#A0F96V%T>H=H\4P6@RCU1]&5W8\&QBMOC!:#*/%,%H,HPMK
MLA%&5W@L'2%UNUTG=2QYG")U62*92UW8%R?EVJR6WEE_+SL63QTU%A<VGY3%
ML%@,B]4?%E=6SY;C83OSY_P@L;I"8C$D%D-B,20NK)F(D+BRDHSSLYVG96V%
MQ.H=B<606`R)U1\25W8T&3BLKG!8#(?%<%@,APMKDA$.5W@L&^%PN]W<8=PX
MR>&A?;<$5]F7)N:Q62FVU5GS+N'A4M?5<FQQ.(U\,K+93%S;->Q9TN[YR)J:
MOYY8G7N2]UJ\&-LT_;],V$W";A/V]<B:<7PSL9*-/==YYJ7T:FIQR,;=R)J1
MO4[8FX3=CZP9Q=N)E6QLMJO^%J!W8Y/F([]-V/N$?4C8=R-KAH'$XY$_E@TD
M'IL,Z>@DCL6,$R;B\[+X,9N(*_O21#PV&R?B;7?8D+ATWA0I$A?&+HR3\].$
M(;':(;'Z0^+*ZBGA>K/HYT`D5E](+(;$8D@LAL2%-?N%Q)6-<T^_\(+$V@J)
MU3L2BR&Q&!*K/R2N['@VL%A]8;$8%HMAL1@6%]9D(RRN\%@ZPN)VN\[B6.PX
MQ>*R.#*WN#"*Z\%S9)Z_$.O,ZU)NYV?]E28LGCH:C<7BPIJ9`(O%L%@,B]4?
M%E=6)Y_L=,)=(;&Z1V(Q)!9#XOJ1ASD5B2L;D]%=B,1A;83#ZAR'Q7!8#(?5
M'PY7=C07**RN4%@,A<506`R%"^LFX@J/)",,;C?K#(XUCU,,+FLD<X,+^^(\
M7)N-I9:<3$P=-087-I^'Q3!8#(/5'P975F:>Y?"6K/G7./.P^D)A,1060V$Q
M%"ZLF7E0N+*2C?W9IEN,P6%MA</J'8?%<%@,A]4?#E<VNUK;OPT/C]4='HOA
ML1@>B^%Q84U"8BJN\%A&0N1VNT[D6!0Y1>2RB#(7N;`O3L6U62DXGTU,O306
M%S:?A\6P6`R+U1\65U;FGB7O&$Q^V+DS--8'H+$8&HNA<?W0V4Q<6<G%ZJQ_
M91D::RLT5N]H+(;&8FBL_M"XL@?2@<3J#(G%D%@,B<60N+!N,J[P6#Y"XG:[
M3N)8%#E%XK*(,I=X6EAY^'RB-BO5MCW;==^AG$],'34>%S:?C<7P6`R/U1\>
M5_;@;*R^T%@,C<706`R-"VLF'V;CRDHV-F>+]O+C?N^Y67T@M3X+J<606@RI
MU1]25W8\-SBMOG!:#*?%<%H,IPMK<A,3<X7_O^2$X6TOG>&Q8'**X66!96YX
M85^<IFNS4HK;L^[>&`2?^FD$+VP^48LAN!B"JS\$KZS,3/O]<K_L9.)T0WTA
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M'8G%D%@,B=4?$E=V-!DXK*YP6`R'Q7!8#(<+:Y(1#E=X+!OA<+M=YW`LDYSB
M<%E6F3L\+;4\['!M5HIMN3WK;M'!X:FCQN'"YC.Q&`Z+X;#ZP^'*RMQSOKO8
M]&^*Y7Q"?2&Q&!*+(;$8$A?6S#U(7%G-QMF^.[M"8FV%Q.H=B<606`R)U1\2
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M#//$,$\,T<0030S1Q!!-#-'$0C1#1#/,5.`I*4G+3`8>+Y2TS'3@\4))RTP(
M'B\T:]D51*R=G%(09:UE=H:Q+BQ^44XW(Y]ONUM@2,S4;*P;\B)&6L3(BAA)
M$2,G8J1$C(R(42-BU(@8-2)&C8A1(V+4B!@U(D:-B%$C8M2(&#4B1HV(42-B
MU(@8-2)&C8A%C1A2(X:9"E$C;IG)$#7BEID.42-NF0D1-=*V[&HDEF5.J9&R
MC#.OD<H.7]5D08PDB)$#,5(@1@;$2(`8^R_&[HM1$&(4A!@%(49!B%$08A2$
M&`4A1D&(41!B%(08!2%&08A1$&(4A!@%(49!B$5!&%(0AID*41!NF<D0!>&6
MF0Y1$&Z9"1$%T;;L"B*6>-J"B,=GK+DJ_J_E^OL?+O_\OU<??_WAXS^`"]Z#
M>'A&$7]@Y+.IP@Y_WD8R1M1^G717$<A.UNIP\W`WXKADWX[X2R,ME_CG)5S9
MK(3%&)@81TV,@R;&,1/CD(EQQ,0X8&*4L!@E+$8)BU'"8I2P&"4L1@F+4<)B
ME+`8)2Q&"8M1PF*4L-C[A%'":D<)BT4)&U+"AEAKF+G`HY*3EID-/"HY:9GY
MP*.2DY:=$5U!Q.7_4PJB+!?,"Z*PYHE\9$&,)(B1`S%2($8&Q$B`&/LOQNZ+
M41!B%(08!2%&08A1$&(4A!@%(49!B%$08A2$&`4A1D&(41!B%(08!2%&08A%
M01A2$(:9"O&=YI:9#/&=YI:9#O&=YI:9$/&=UK;L"B)6$DXIB++RT!0$>US9
M=&&`_2TH[NPY_#9:=7^D0`:F9N-O(Q(@QOZ+L?MB[+T8.R]&.8A1#F*4@QCE
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MK'[@:MLO[;\86S0?^#)A-PU[X`-OFV:QA_OS3M:OFP8(U1VPN)+7EDS\H@GY
M__7P+QH>O:-?-)5UI=/]D2<'KEX\//P%!@=.C`-767T3\D7_9SD<.&W%@1/C
MP(EQE&:]\Z.OFWLX2MJ*HR3&41+CD$PL#LGYPH=D:N!#$A=DVD/RI4-1+N#,
M9K%X\NV\.,B[&'F?V`.&<2A*LZHT1Z*[J9!#,75TF+/,.!13NP<^D*,S^\#U
M8M<M0W)TIH[&#^3HB'%T)O;`!W+`9A_(HUBZJ[@4T=21CUA<,3CEB-4K#(<G
ML3Q:;BIKGPQDQA%3.PZ/&`=$C-H0XX"(D7TQ\BU&OL7(MQC)%2.=8M\D[%7"
M[A+V.F%O$G:?L+<)>Y>P;Q/V/F$?$O9=POA-X22PBI=`BE?IXC=%`C,9^$V1
MM,QTX#=%TC(3@M\4LY;=MTI<HCJE(,HEK?D45AD[WIP.=_,`B9F:C?,`>1$C
M+6)D18RDB)$3,5(B1D;$J!$Q:D2,&A&C1L2H$3%J1(P:$:-&Q*@1,6I$C!H1
MHT;$J!$Q:D2,&A&C1L2B1@RI$<-,A:@1M\QDB!IQRTR'J!&WS(2(&FE;=C42
ME\U.J9%ZF6WVI5'8IEV1WXB1!#%R($8*Q,B`&`D08__%V'TQ"D*,@A"C(,0H
M"#$*0HR"$*,@Q"@(,0I"C((0HR#$*`@Q"D*,@A"C(,0H"+$H"$,*PI"",,Q<
MX,ILTC*S@2NS2<O,!Z[,)BT[([J"B&M4IQ1$N:8U_]*HU[GXY_"E<=%==2(Q
M4[/F2T.,M(B1%3&2(D9.Q$B)&!D1HT;$J!$Q:D2,&A&C1L2H$3%J1(P:$:-&
MQ*@1,6I$C!H1HT;$J!$Q:D2,&A&+&C&D1@PS%>)+PRTS&>)+PRTS'>)+PRTS
M(>)+HVW9U4A<>CRE1NJERMF71F%\RB@_61`C"6+D0(P4B)$!,1(@QOZ+L?MB
M%(08!2%&08A1$&(4A!@%(49!B%$08A2$&`4A1D&(41!B%(08!2%&08A1$&)1
M$(84A&&F0A2$6V8R1$&X9:9#%(1;9D)$0;0MNX*(B\&G%$2]>#PKB,*B[)HO
MC>X2!XF9FHUU0U[$2(L861$C*6+D1(R4B)$1,6I$C!H1HT;$J!$Q:D2,&A&C
M1L2H$3%J1(P:$:-&Q*@1,6I$C!H1HT;$J!&QJ!%#:L0P4R%JQ"TS&:)&W#+3
M(6K$+3,AHD;:EJ5&?O_KSQ\_?K[Z_O/W?_S#WS_^\M/'QQ__]K=?O_KATW_'
M'2JKX0:5B7_UR\<?__-W[._ZLOQN07('-T-P>`V1@]LA.'RM.'@Q!(>+]0[N
MAN`NOI`47"\CR)V<:7`U!(>+9M[R?`@.=]@X..P*=P^DW0Z[PJ)I%MP,W7+U
M(PLNAEU9Y+NRV,>`%L/;(S6@Y2*"O*D]ZW8Y[">OA4Z#PR'CW;)I<-A/WK.9
M!'?QD;OT$W>1]5V:]%V,99<.91>IV:69V<4@=^D8]S'$?3K"36C#])\,?A.9
MQOHDM(W!;]/!;V/PVW3P%W'0+])C?A&?=9%^UB8^B\O]R3`V\5E<-LY"D:A<
MH:$`N6Z0;16)XF=5%HK!EU.ZWJQU;)6+OHZM<LW7D7E6NI//6D<V6(7-0F$X
MZX-):!.RL6B7A,ZC0_X:+`M%A_R)31):1X?\R4,6BLQS8VL6BLQSBU\6"D7+
ML\#['*YB*]XCD&RUBJUX='L2.H\0CX7(0G%0^'OZ+!0'I?Q!13^,\S@H_.EG
MLM4RMN*=I%EHF'OSK2+SO!`OVVJ8K-+,KR+SO(0IV6H5Y5!^DO>#+Q-<NM4R
MMEJF151FOO10+N.@\-;Y9!C+R/R1&3$RG\^'P_'/NAOJ+@M$TM.<1\K3C$?"
MTWQ'NK-LLR*P),:C(S.1XD:;R^$V%6>!V.YRN/?#L;BQXW*X=\.QN#$C^LR&
M^2>.5'XP&'YZ`*,4TRWBZ&4'[T\<ACB=\<#B/7N7/,LS2T2\;^^29WIFL7CO
MWB4G>+P8SYWRS$]TYN&=F9D$V6&"V:X19.<(9KM'D!TDF.TB07:28#;:>+'A
M)4__S6)W$;O+8[RC<W\YO)[0.\GS51?$TGTDMHQ8MHO$5A'+]I#8><2R'22V
MCEBV#_$.R4L>3YO%XEV2ESRF-HO%.R4OAS=!>O]XBNV"6+I_Q)81R_:/V"IB
MV?X1.X]8MG_$UA'+QLD[9/>7/`4XB\5K.RG)-!:O[Z0D4TF?QO[QU-_,46++
MB&7[1VP5L6S_B)U'+-L_8NN(9?LPS$?#>TI]'![%.!_GXR2VC%@V3F*KB&7C
M)'8>L6R<Q-81.S).IF>J/IN@A[=ZQY251MG%"PYON4%'WV/+7<2R"2I>^DSI
MIC%*]X+236.4+E\8##7K-+X`B/+?6?1JN5ABU"++ZO.(7>>QFXC=YK%7$;O+
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MI_WI"&X8P4T:N25RFT:^)O)-&GE%Y%4:N2-RET9>$WF3YN`U.7B3YN`U.7B3
MYN`U.7B3YN`U.7B3CN`Y(WB>1JZ)7*>1%T1>IJ-^P:A?IJ-^P:A?IJ-^P:A?
MIJ-^P:A?IB-XP@B>I)&G1)ZE8WO*V)ZE8WO*V)ZE8WO*V)ZE8WO*V)ZE(WC$
M"!ZG(WC$"!ZG(WC$"!ZG(WC$"!ZG(WC$"!ZG([AB!%<E\OOIW/37/_[AG]__
M]/'V^U]^^LL_?OWJ;Q]_Y!+_8GAEY2]_^2ENZB[_Y_.G?W+/_.^^^J]/GS]_
M^OOP/W_^^/V?/_X2#;A=Y,=/GSZ/_X?2_?W_?/KEK\,RPA__3P````#__P,`
M4$L#!!0`!@`(````(0!6O)YVZ@8``'0@```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;*R:6V_B.!B&[U?:_X!R/X5P*"TJ70WD?-)JM8?K%$*)!@A*
MTNG,O]_/B9W8?EFFC/9F4AY__F*_?A,[]CS]]NUX&'S-RBHO3DO#O!L9@^RT
M*;;YZ75I_/6G\^G!&%1U>MJFA^*4+8WO667\]OSK+T_O1?FEVF=9/:`,IVII
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M%MOO5E9M2%%*<S>>L4R;XD`-H'\'QYQ9@Q1)OS77]WQ;[Y?&^-$8O&15[>0L
ME3'8O%5U<?RG+31YBK;RF%>F*Z\\N;^;S4<3D^[UT203GH2NH@6S/LF5NT]Y
M1;KRBA^K1TUKNDQ77L_\6,5[7G'>51Q_K"(];,T=Z7I32VDDFGITO:VE)OFH
M'=9>G.MM';:^:&QFI77Z_%06[P-Z=LD!U3EE;P)S85(V8;!V8#K+_9?CR&HL
MRV>69FE01\A4%3TF7Y\G\_'3\"M9>\-C5ABC1:Q%!/,Q2VOIP-:!HP-7!YX.
M?!T$.@AU$.D@UD$B@2%)V^E+S\[_H2]+P_05RJP$D`17Y5Z+"%'%TH&M`T<'
MK@X\'?@Z"'00ZB#20:R#1`**F/0.4<2\_!84GF312X,\+7ERHHJT:F/,7M@U
M$`N(#<0!X@+Q@/A``B`AD`A(#"21B2(AR7&#A"R:I@PRMZ3A5-.0!]&@24$S
M-6C=!75V!&(#<8"X0#P@/I``2`@D`A(#262BR$J3S0VRLNA&5B'&BA/)AT`L
M(#80!X@+Q`/B`PF`A$`B(#&01":*8#39*H*Q>8=-86)!\N&9AR52M>1$G8SN
M-3]V06((+"`V$`>("\0#X@,)@(1`(B`QD$0FBKRTAE'DO?ZF9-&JAIQ(?@1B
M`;&!.$!<(!X0'T@`)`02`8F!)#)1!&,?3/HZZ*?\R!*I6G*B^G&N^;$+ZOP(
MQ`;B`'&!>$!\(`&0$$@$)`:2R$21ESJOR'O=CRQ:U9`3R8]`+"`V$`>("\0#
MX@,)@(1`(B`QD$0FBF!LB:\H]M,OR":3JJ9`='=IRG[0+-E'=9Y$9"-R$+F(
M/$0^H@!1B"A"%"-*%*2JS9;O\N-_W9]FN]JG=9%09B60Y%!$%B(;D8/(1>0A
M\A$%B$)$$:(84:(@53^V8I?U8VZ=D4JW?D:V*W]%6(Y4KS[J7NVBQ(A8)B`;
MD8/(1>0A\A$%B$)$$:(84:(@56NVMI>U_H%7VT\!15*.9*\"LDQ`-B('D8O(
M0^0C"A"%B")$,:)$0:I^;!%_@WY\S2\_ZQPIEGP8Z9;LHGI+`K+9G@N;Z_JQ
M<!"YB#Q$/J(`48@H0A0C2A2D2LJ6^3=(RK\*9$GE#X5F[V?-MCE592Q$-B('
MD8O(0^0C"A"%B")$,:)$0:I^;!U_@WY\V=_KMS8YZB8DBY,)/<7]'#_63&KW
M4<*D#B(7D8?(1Q1P-&;-4GO,%N(W])BOV_L>KTQ"?<<>3/WIXS4D05I"@K#M
MR?'(U/:";):1#$<!O19Z%I<'-3UJ?.KUU7A>;7_$[P-$W@"RA!@4(8H1)7(J
M56*V&+]!8KYVER5NT826HI+2L&G;18GN66:'^HKCL?;)8_=13+B'!VW]Z?3E
M(K&+R.O1E7OY(LIL]Z;-D;8_%8B`]CA&WL&ES4%51[:V89K\8-YEU;1E=XO8
MB'5ZFKH-U\W]:#M^WMG00F3WB(EGZN(Z?7DO7G=[@3R,\GO$$D^GFIN#OIRR
M*(:C<S!5J.L"->&J0!QIAM.>TW4?)?IA]:A7%@TGHEH3F"-3,X$C`AH3-$^W
MB\CKT96;^2**.VXVU9:L@0B0'-<>`[;G,\>L?,W6V>%0#3;%&SOBHR7<\U.'
MV_-'^NY8L'4Y*0$E8RIIWE-0,J&2YBT')5,JF5[,-J.2YH11KT,%%_G]@K:G
M+K1KOJ!=F`O\84';!Q?XXX*^DB]P<T0M:L336D13WX)-1EC',N<+]IK'$GJ+
M4YU+)?1F7K#W+M:AL]_/E_6EAEV(7]&`7(RGX;@T&I^GE/]2!U<T2LT@#;N>
MTYGO.7W-XK1\S4_5X)#MR#"CNSFMH<KVU+C]41?GYLSOI:CIU+?Y<T^G^QD=
MMHW8YNNN*&KQ@WH\[/Z_P/._````__\#`%!+`P04``8`"````"$`[?]B3M(%
M``"Y%P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLF-MNJS@4AN]'
MFG=`W.\0((<&)=EJ0CCEH-%H#M>4.`EJ"!'0IGW[O8PQV%Z=J)'FIC0?R[_M
MW\NP\/3G1W;6WDE1IOEEIIN]OJZ12Y+OT\MQIO_]E_?C2=?**K[LXW-^(3/]
MDY3ZS_GOOTUO>?%:G@BI-%"XE#/]5%57QS#*Y$2RN.SE5W*!.X>\R.(*?A9'
MH[P6)-[7C;*S8?7[(R.+TXO.%)SB.QKYX9`FQ,V3MXQ<*B92D'-<P?C+4WHM
MN5J6?$<NBXO7M^N/),^N(/&2GM/JLQ;5M2QQPN,E+^*7,\S[PQS$"=>N?R#Y
M+$V*O,P/50_D##90/.>),3%`:3[=IS`#:KM6D,-,?S:=G3G2C?FT-NB?E-Q*
MX7^M/.4WOTCWF_1"P&U8)[H"+WG^2D/#/470V$"MO7H%_BBT/3G$;^?JS_P6
MD/1XJF"YAS`C.C%G_^F2,@%'0:9G#:E2DI]A`/!7RU*:&N!(_%%?;^F^.LUT
MR^H-K.'XR81X[864E9=235U+WLHJS_YE46:CQ52L1@6N7&70&YO]B3W^OHC=
MB,"5BSRL,6@TX-IHV*/><-RW'YD-#+GV!*Z-R/!A#=A?M09<^62^[>:D:0O7
M1_LWV/+6V>+&53R?%OE-@RT(ZU=>8[JA3<<$=WB>L$5M,^>_$@<RAJH\4YF9
M#@.#E"@AV]_GEOTT-=XA0Y,F9O%%C!RQY!$T':FLJX*5"CP5^"H(5!"J(%+!
M6@4;%6Q5L!.``=:V_D+F_Q_^4AGJ+W=FP4%GN*V8R2-X$U<%*Q5X*O!5$*@@
M5$&D@K4*-BK8JF`G`,E,>`)(9G[],.,Y2:-G.N2TD),3V:0%BS$[8Y>(N(BL
M$/$0\1$)$`D1B1!9([)!9(O(3B22A6#'`Q;2:'CR0W(+'JK[N@F"1>N"!GW9
MZ&4;U*8C(BM$/$1\1`)$0D0B1-:(;!#9(K(3B60KO!(>L)5&U[9R,Q8->6HW
M^!(1%Y$5(AXB/B(!(B$B$2)K1#:(;!'9B40R;*081M\[-E0Y][<T;24;QXC=
M^<8`+%27C)8E)Z/+&PDQ`[.-D<8Y5L9Y?WPT6AX?(ZS2J]]I2T1<D4B=TV)<
M?#G?[YQ&RYTS(C[=$'$162'B(>(C$B`2(A(ALD9D@\@6D9U(),.@`'G`,!HM
M&;9L2)M-+@,V/$Z%=!JTJ5*OZ*H-XMO90\1')$`D1"1BQ*+CD>9IPDYY8*)U
MN#33!47"E(;RE):\1>=$0\"*NKKKFTJ]L>H"6AN0BH](T#5K=!5WPRZ`ZT9(
M98V#-AAM,=J)4K+%M*+[_N8S60$(KTH^RD6#Z%.M<WJ@/(N6711OZ'9(:&B-
MY25:\2BS*;=598\'U!^*=:;Z&`4=NM-9R*-89^;(',FCB7@`^RH5*V"35G,/
M&,F*/\E(ADQX3@I&*OFWK/N!SYAQNP(N1JL.T72;**OA=;?Y:O@8!1B%':*Z
MIJT(1]U]$)83C=9J#_C#2CO)'X:41%/VT=)LH_C47(Q6'+&%'@XMQ6:/!XA9
MA90#'!5RQ)0'$U.IQ2,>\$4*T;KK`8N:,DW<BPPI*82>>FU49U&+A-S#>Y%%
MV5:]%\>3H;)9/?II#>\:(3E]C((.W>DL;**:SD:CD=)9U,F@7*/UV`-&-N6;
M:"1#=GUTQ0H:>JP$<Q.0B]$*(P\C'Z,`HQ"C"*,U1AN,MACM)"3O55HYBO[1
MLI4>9=VOS*#\4RJ-18.@*YYJRP;9TF/.5AZT;M=0R)%!%\7&R\X%V4E/1HHC
M69+SN=22_(V>^<%.FT];S`XD%T,'JG48C,J?'*BWON`F-&##5UJX$P=*&=S"
M-?L.K1+P'2@"'/J>QW?@Q>[0US:^`P>HSW5AI/2^H`>K7\0O+`?.%;#.PG;@
M:QGSYX'S#%[C&XN!`]^!P(VV9S@XO<9'LHV+8WHIM3,Y@,G]'DV,@AV]LA]5
M?@7SX;POK^#$M/[W!$?D!(ZZ^CT(/N1YQ7_0#MI#]_DO````__\#`%!+`P04
M``8`"````"$`_(T=4=`&``"Q'0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6RLF=N.XC@0AN]7VG=`N1_`"300`:.&G#EHM=K#=3H$B`8(2M+3,V^_
MY3B.#\6VR&IO.LU'N5S^77;*>/[UQ_72^YX699;?%@;I#XU>>DOR0W8[+8P_
M__"^3(U>6<6W0WS);^G"^)F6QM?EK[_,/_+B6WE.TZH''F[EPCA7U=T>#,KD
MG%[CLI_?TQM\<\R+:US!Q^(T*.]%&A_J1M?+P!P.7P;7.+L9S(-=/.,C/QZS
M)'7RY/V:WBKFI$@O<07QE^?L7G)OU^09=]>X^/9^_Y+DUSNX>,LN6?6S=FKT
MKHD=GFYY$;]=8-P_R"A.N._Z`W)_S9(B+_-CU0=W`Q8H'O-L,!N`I^7\D,$(
MJ.R](CTNC%=B[\VA,5C.:X'^RM*/4OJ_5Y[S#[_(#MOLEH+:,$]T!M[R_!LU
M#0\40>,!:NW5,_!;T3NDQ_C]4OV>?P1I=CI7,-UC&!$=F'WXZ:1E`HJ"F[XY
MIIZ2_`(!P-_>-:.I`8K$/^KG1W:HS@O#&O>GX_'H93H!-V]I67D9]6GTDO>R
MRJ]_,RO2^&)>S,8+/+D7Z^G&8%F'`,^FL=D?3X86@8"?#6#4^(`G#^"ELQ/H
MK@X$GHV32=^<CLGXI4,D+XT3>#9.2']"AC.K@YRP..M`X,D5>5J)6=,6GO]]
M$`3RD*4%3<AFQI\=QH"E6)VQ3ES%RWF1?_1@&X`<*N\QW52(36"F>*ZRQ&JS
M]]^2%[*6>GFE;A8&C`_2LH05]WUIDME\\!U62=+8K![8J!9K;D&7!'7KZ,#5
M@:<#7P>!#D(=1#K8Z&"K@YT.]A(8@+2MOK#Z_@]]J1NJ+U=FQ8$0W-+$Y!:\
MB:,#5P>>#GP=!#H(=1#I8*.#K0YV.MA+0!$3=B-%S,<;*L]):KTP(*=%3II#
M5:05LR%"V#4B#B(N(AXB/B(!(B$B$2(;1+:([!#9RT21$.3H("&U7A@F)+?0
M$*WKQ@@F31B91!5ZW1JUZ8B(BXB'B(](@$B(2(3(!I$M(CM$]C)19(774P=9
MJ74M*Q=CU1"K7>!K1!Q$7$0\1'Q$`D1"1")$-HAL$=DALI>)(AB\BA7!Z'MG
M!-:?+VG:2A6.$4DW!F"BI&0TU61T>"/91FR?2IP3+<[/XZ/6:GR,6"]B8A%Q
M$'$1\1#Q$0D0"1&)$-D@LD5DA\A>)HI@]!`C%Q2?"T:M5<$8D05#Q$'$1<1#
MQ$<D0"1$)$)D@\@6D1TB>YDH@D'1U$$P:JT(MFY(FV`.`Q:\`J0E,%*7@-L:
M\2W(0\1')$`D1"1BQ*3Q*..D]6N'@=;FRDA7%$E#&JM#6O,60HF&@!1U13HD
M8I'7]:4K#%H9D!<?D4`T:_QJZH;"@/N-D)<--QJU`6\QVF&T5Y"J,2U#GU]]
MA%6M\'[G8:X:9*E2O^A2LX9@Q1LZCQM.U(8NMR+UC)#1=#Q5+3QN(5S[&`4"
MR1FA]19RJZ:W,;&TWB)NP0[T<N%.:!':04I6LRI2,D1@JY2R5HM@7?<#IZ^)
M)&7;D*OK-E:6V63R1,LX#[OQ,0HP"C7/9*QYCI0V:K;1*K.#1*PH521B2,LV
M[>"X)JT5U\/!R.6(3_9PHA7['K>04PNY#K!5R!%W/3*U3(NXQ8,\HC5C!Y&:
M$E->D@RI>61I@UO3PSN\&90\0L@55O7.I26C)[[F2OL8!1B%`E&_!,DC1Z+F
M$*T0.\C3%)2R/`Q)>]&:_M@&6DC($4A>C%J<+K=B$VV90UUFCUO(.81Z"X35
M)[V%W(KW-K&T?3;B%@_2BM:P'71C):^R]AC2TDH_MY'6BF>$@Y&+D8>1CU&`
M48A1I"`U?6@=VD$&5K8J,C25K/+"L[03PYJJI&<40JZPDJ;=THH.[[&5MNWZ
MPHH+'V`4"B3WJ%5&T6,KT:,J*:U4.TC*"EM%4H:@5Q[ZFB#D""2%KF^L;F/5
MO/B(-2%:AGK"#^_-QR@0Z)/>0JTW8DZU1(B$'^A-U8T6OAUT:^ID>2=KBFGI
ML`B_3-5Y)Y"#D8N1AY&/48!1B%&$T0:C+48[C/8*4O2#&QE5/_J3P`S@YR?(
MNIEZ3F@0;)X\(]8-LF"K%K68OMTZHJ%L)5X2+%YV[\-^1;^FQ2E=IY=+V4OR
M=WJG`V_"Y;S%[,)I-;;AEQ`(1N<3&P[2#_C4AO/B`TYF-E40?^/,;#B*/>!D
M:--3#OX&#C$V/:?@;^!@`KT\^@8NSE[K@YT^#KA0J_-8YR9<M#WH8679\`LE
M[OEU!/X?=;P:V?#;&S08M#W`A=D]/J6[N#AEM[)W28\@_K!/;W0*=N7&/E3Y
M'28%KFKR"F[*ZG_/<#6:PO7"L`_&QSRO^`?:07O9NOP'``#__P,`4$L#!!0`
M!@`(````(0"*:1A;Z`(``%4(```8````>&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULC%;;;N(P$'U?:?_!\GN3..%2$*&B6W6WTJZT6NWEV20.L9K$D6U*^_<[
M8T.:`**\H&0X<\Z<&3-F<?=:5^1%:"-5DU(61)2()E.Y;#8I_?/[\>:6$F-Y
MD_-*-2*E;\+0N^7G3XN=TL^F%,(28&A,2DMKVWD8FJP4-3>!:D4#WQ1*U]S"
MJ]Z$IM6"YRZIKL(XBB9AS65#/<-<7\.ABD)FXD%EVUHTUI-H47$+]9M2MN;`
M5F?7T-5</V_;FTS5+5"L927MFR.EI,[F3YM&:;ZNP/<K&_'LP.U>3NAKF6EE
M5&$#H`M]H:>>9^$L!*;E(I?@`-M.M"A2NF+S>Q;3<+EP#?HKQ<[TGHDIU>ZK
MEOEWV0CH-LP))[!6ZAFA3SF&(#D\R7YT$_BI22X*OJWL+[7[)N2FM##N,3A"
M8_/\[4&8##H*-$$\1J9,55``?)):XM&`CO#7E,8@+'-;IC29!.-IE#"`D[4P
M]E$B)279UEA5__,@YHKR7*ZT!V[Y<J'5CL"\`6U:CJ>'S8'X?"U0!&)7"$[I
MC!*0,=#`EV7,XD7X`J:S/>;>8^#S'=,A0A#ME$'M>F4$HS)V!4NY]X&^3,+.
MZR1#'>QZ`K.[[!234CKJNV!)Q^]+\!@WJ8$QR.H;0\%X@B/]0!/S`-KW=-I>
M#V)#T*BK;%`(*/8+N>P8P4Z]:_$^X@]U?W*3(2\:'$6S`,*7)3!O*+&/P#C>
M3PL;GW<S':I>ED+P4&H?.76#Z[7W"W#G(XFOF!<F#C7VD:&=R7D[\"OJRUZV
M@^"AU#YR:H>!>I\8_3`V#CX\?BYQ*'((#0U-SQO",]D7ONS(H8_4D`!"9SP=
M[0KG:0++[Z,3!^O\N'&'T-#3[9$GO\3]IJR%WH@OHJH,R=06%W0,NZ^+=I?'
MRMT=Q_'1?.4OE;#[!I9ZRS?B!]<;V1A2B0(XHV`*=K2_%OR+5:U;T&ME89V[
MQQ*N;P'[+T+OA5+V\((73_>'8/D?``#__P,`4$L#!!0`!@`(````(0"Z7AF*
MT08``.(>```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%G;CMLV$'TO
MT'\0]+ZV*.JZ6&\0B4@;H`&*HI=GK2ROA5B6(6FSR=^7U-`69VC+=EXV,7DX
M/G/A'-)\^O"]V3G?JJZOV_W*90O/=:I]V:[K_>O*_>?O3P^)Z_1#L5\7NW9?
MK=P?5>]^>/[UEZ?WMOO:;ZMJ<*2%?;]RM\-P>%PN^W);-46_:`_57LYLVJXI
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ME8:,2/%]_/>]7@_;E<NC11A[G$FX\U+UPZ=:F72=\JT?VN8_`#%M"HSXVD@@
MV>MY?^$G(0NCZU:6P&AT4!1#\?S4M>^.K!KYG?VA4#7('J7EHV?`X^3K)5>E
MC\K(1V5EM"6]Z&5^OCTGT=/RFPQIJ2$90%+7.4%\C,B/"!4_9548`TM)]\19
M1H)RYC*GY[-QI*@688I1@@ED-H1C1'X&P3!$V)`H/4&0&QR[,4]?@679&.%+
MXI/9,5P90)(Q_`]^E`8D!3D"<!X2`P+-^Y$73P!$7-;)_?%7BX@#-/X`@0VD
M"B"G`P(&XM%%/^3)9`$1E)OJ?H)J$2$X)0XB#)!P_/H@FJ(SSN8P"^28QTCM
M"',ZB-A4_8AZ9%,/Y,KYXE"+,/74(\4!$*`>QR&>S6$6J',O)H4CT#3C4U@0
M]?AGJ*M%A#K941E`CE$GS,U)9@05.@C,ZI2P]`)Q)=-&#YR/M0(3PE,JH4P`
M`M_ZX*=I0$HAQX`XIMD2",!8Q"X4NFRGMS-78,S<:B$`T<S#,/)(+G($.--C
M!`*@'H-JA<E^?3OS$8VIIR2FF<88W<,:$>8(IJ.DYN828"!,9C-.`UR7F<9`
M*%,>ALQ+IR1"PR"8($D3;RI1J&"$2<*(>\SHV]@))3VW.P%"93IAE0,##&P]
M&O%\=E:@6>,T@"DKR3$HJ^/'=2EG(%0F]91TM$QCS'*`5=.(T!C(4<CBT/.F
MMHEY*N&YGR?(E<G34"SH%8QJ7&Z-B-.(.EA-CF*&2E[N9PBBA!B2"LS405?V
M#?GW='(+2;7G-V#$/`8[HP2'.'-=!1G(E.D,;:R9QLP[`W;F,.)D1Z5D:I+8
M"Z4^]WL!FH6\('J<,5/7'A+FT[:18P2+$TY2)A""!6D4IY..83^4&MWO!V@8
M\F,*E"Y^P$!_(9,Y.TY>KCMQPLRE04G2_?1!R!!]<N#+F"EVC/.43^U#=W@3
M$:?,)ZHEL`F6Q$DTV4!9\.]2S!%-%'-*+T1?8^;J/+\!(^8QV(F[=-:W==:2
M*(W1$D6*/,>S-/B79C'ENU35MU75.AIHS/%H$'D\8:3IY@1S[O@@"(8<'[`3
MLH[-/3!_Q/45FA0/.;MD&C.I:6Z-"',$TR%R>H7.&1FE6]$'#,24)0&W+K\$
MX;%@4M)Q/PB,",*$3>6$Z<LM8T;SME.+^I&&1-4Z#6B,&558-8T(C0%7U25X
M*FO,\HR(7C];^;:()J0X,XTYWLA(+G(]K7-A7X31_.6;L/]3\CFN(K4[=53=
M^$`^@;]]&=8F@/^9VS">9WS:&CC^/R6;_@VRJ3$Z_J2,<S1K7XGUM,X.,RXE
MF#U1S2M;](Q:6G(#F'FYN8X1_BP&.:'*W=RH\TZ,:%PZEMQHC(Z>NH]-NP\D
MGR#L3B0(`G4B3/\NM>2V6AH_>$#E:\S437)K1)@CF,Y=2LAM);2C"1B(YH//
MY%ZBU:S-:`A+>$BO>H)`8I9>^N&2$QF\K7&/JTA=3'M>!Q8DTPPL'1':SH4-
M@$--!/)&HF>$DO9N#I@+)'0)7\>(>3O8&25A=Q_`N5J%HV[=YC1FWAFP,X<1
M\W:P,V=4]?K5E-NJFI+[3J8Q<T3S&S!B'H.=(1)[I3^";,JZ/OT08%P9]3X`
MS'%'G_GMDV/$F1\_,6+FUT_YY(<*ZPI]6UGMA@28XQM*P+A/=GH^?NG*/4+.
M]"SU%*E*5T-(SX($P%,CO,0U5?=:Y=5NUSME^Z:>$9E\83B-PA-G)I\XQ_?`
MY6E"OC`>BM?J2]&]UOO>V54;N=1;Q+*".GBCA`]#>Q@?OE[:0;XMCO_=RK?D
M2KZP>`L)WK3M</R@7D%/K]//_P,``/__`P!02P,$%``&``@````A`,EQ\ZNP
M`@``RP8``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<5<MNVS`0O!?H
M/Q"\1]0C?L)V$%M(&Z`%BJ*/,TU1$A%1%$@Z3OZ^2]%6)#EM@EYL<3D<S>XL
M5ZN;)UFA1ZZ-4/4:1T&($:^9RD1=K/'/'W=7<XR,I75&*U7S-7[F!M]L/GY8
M'95^,"7G%@%#;=:XM+99$F)8R24U@6IX#3NYTI):6.J"F$9SFK6'9$7B,)P2
M246-/<-2OX=#Y;E@/%7L('EM/8GF%;6@WY2B,6<VR=Y#)ZE^.#173,D&*/:B
M$O:Y)<5(LN5]42M-]Q7D_11=4W;F;A<7]%(PK8S*;0!TQ`N]S'E!%@28-JM,
M0`:N[$CS?(UOHV4ZP62S:NOS2_"CZ3TC4ZKC)RVR+Z+F4&RPR1FP5^K!0>\S
M%X+#Y.+T76O`-XTRGM-#9;^KXV<NBM*"VQ-(R.6US)Y3;A@4%&B"N)7!5`4"
MX!=)X3H#"D*?VO^CR&RYQLDTF,S")`(XVG-C[X2CQ(@=C%7RMP=%3E1'$I](
MKD']:3\.XODDFDS?9B%>49M@2BW=K+0Z(F@:>*=IJ&O!:`G,Y\R\CB[7OZ4*
M\AS)K6-IN2`+`_8\;J(P7)%'J"D[8;8>L\"HP\1#Q.Z,<%D[VK07(*"W$PVE
M&(M.P-37[3AK=(>&&J?SH8#M)209(G:O(*(A)+V$3!<=9)!&\C]IN$/0/[TR
M1N%(PM9C?">Z0N[&@=0'9MZJV?S%JX%`:(A^G?]=7P<>"QLYO/68GK!Q(.T%
M!E+@GO2EN#Y]VW)W:"QIY.C68TZ5F,.E?#&K;<+=`#";)]>=F;Y)^_M)'+[T
ME-?OAXJ_<Y+K@N]X51G$U,$-C`@<Z*)^EFUAEK4WGW0;,$L:6O"O5!>B-JCB
M.1P-@QF\6OMIY!=6-6V'[Y6%*=(^EO#1X-`"80#@7"E[7KAYUWV&-G\```#_
M_P,`4$L#!!0`!@`(````(0"4S4G.]@8``,P=```8````>&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULG%G;CJ,X$'U?:?\!\9Z`;2ZAU>G1@#6[*^U*J]5>GFE"
M$C1)B(">GOG[M2D#K@J=I/NE9^(Z+DZ5RW4,?OST_7APOI5-6]6GM<N6ONN4
MIZ+>5*?=VOWG[R^+E>NT77[:Y(?Z5*[='V7K?GKZ^:?'U[KYVN[+LG.4AU.[
M=O===W[PO+;8E\>\7=;G\J0LV[HYYIWZV>R\]MR4^::?=#QXW/<C[YA7)Q<\
M/#3W^*BWVZHH95V\',M3!TZ:\I!WBG^[K\[MX.U8W./NF#=?7\Z+HCZ>E8OG
MZE!U/WJGKG,L'G[;G>HF?SZHN+^S("\&W_V/"_?'JFCJMMYV2^7.`Z*7,2=>
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MDP(F<9T1PS$B&Q`Z@=JMM`8\Q7<DK5)!20NUJ//+,7#4DS!'X6,"Z0P$([(9
M!,,0>0F)DA&"PA`?"4-/6KMJJ<8T,C\<_?=Y2P$#E:@3F=$!:0T@2LJOG=GK
M&=5@5<H6E80L:0J055\2"YXD@<!4,PR(XX2LB40`QB*V&CT@YFHCV<QU(0=O
M;M&A)O0DFLQH]`_)!(R53#H@K0%$*<*4KB=3@W$RF1\3*H")88/Q@"0[L\V!
MOYJJ#G:3;8[C<*I;1#I^#VD-IJ2G]8'\`09("Q:0]<V0.124-#)'5GTATEIH
M21>[W1#T)$J>/#X%C,EX$)#:R,`<FO*.2,N3R,SB-S*N6N+[R>M)A#PCJ4T!
M`^PN$V];U7D"EYI$UGB*&Z6=J:;[?NK]+,I]R@U4C0$-J:6ECLTAJ3F)S>(M
M^EI?K+*YOD$9J)'=[A@CO%(#,K1ILQNM4_,.:<U<Q^#T:ZFQ^.N>=[OL&0@4
MCH,P30T(X@@"0C)#9L9)GY*C>39.'(-6HO?'H&>1QLT(R90!R.K<%R/2'L&\
MM.X07K?UA(%:X=Q2=38@:"J+F,5D[V44$!&`1`#&5]/FP3%H82(QW%$?(&<X
MAFD'F>TY:)X^ZRWBA/3-3)^.U0*9QIG0PZ`T=J@O;IT*<`!:LJP`;FQ0$#A,
MG)1FRFP59)P>-S)D7XC$.FZ`BA)`;"T.YJZ5R^)^WX&$@=[A&$AW2PT(DI?0
M#I(9LZDO)CAI4A(!>!)/.<(1:/DB$=Q1/B!Z.`)2'BD#D*'($[N$^S1G&"'\
M*"0M2AH$9"$2TR[#06@A>W\0(']J-T^G;$YV8<H&C1S>5[*+$6F/(%Z<2.?U
MTN[11#+YM.MA3QH0)&01KZ:,0$J-?:B+%:U]B0'<CZ;"P]R);MZG.WQ&/VEI
MI@8$,3`2839:IV6AU2^O8W`<1#]OK,&,;G)2E"D'D%D#FN$,F^D!7F+S:BHX
M3%OMK?>7-->S:`E1R30@0Y^)J3.8$@(G@YTJEZ3SWRH@(JXW$C\CJIP4=\H!
M-!2W[U_4#@)PYM.NB#UPOIHT#Z?_0ZJJ/]'0$PN?GF!V\*"J8T<QTZ8SC+1'
M,"\BEG?NRAG1I.>YE`-(L1O;(=UWF<'``D11;%5O'YR\[@2'0K3S1GW,:":?
M*L^D%D#70[B-D1PP$"8/A?4@'`(1SQLAS(@FIZ+)`02;[^)5%%DO7DRD,0-O
MQJU/7YCVA^22@Q(BS;>>8%9@D$M]9+RD#]:A?%;6F[XI'QO`H]!ZYT,1Z!/*
M^[MC/XMT1T%:2&I`P''!1$*:4&8`L$*<;F^)S/9;$P[@0^HJ9M15D!:7&I`)
M0+"(AI@AA`A$1`1.(@`/?3%)"(Z":.M]W4C,:*P@%%(#@BA6D4C(7L\0(.2^
M=3:$6D(`'MMB@8/XD-**&:6UT@2[P8`@B#"((RJU"#`3I40`'"4.@HCM?2\B
M`N12_1U;/J-Y3`UH4J?L8D3:(YB7%COK9'Z]0PJ01M1B+D[`!@3[C]$#>X;-
MEKZ;JH!'P)(P]M97(_$AG>UGD2\6UA-,40PZ.^J_F39E6-HC.)]:F>[/)^@8
MRB<][J7J3DT?6N#SO?!CHDB9L=OL8$8_`NS@4@WNG(YELRNS\G!HG:)^T1=F
M3'TZ'4?A,B]5EWG]S9<W&M1=VCG?E7_DS:XZM<ZAW*JI_C)6"];`;1S\Z.IS
M?\/S7'?J%JW_[U[=FI;J"L1?*O"VKKOAATJQ-][#/OT/``#__P,`4$L#!!0`
M!@`(````(0`73/_9?Q4``.U[```8````>&PO=V]R:W-H965T<R]S:&5E=#@N
M>&ULK)U;;QPYDH7?%]C_(.A]I,JZEV%Y8&62NP/,`HO%SNRS6BK;0DLJ026W
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MH]ON;Y%2#',Q7<A(M[L'.(#_GCW>R]Q`2FY^[__\<7_W^NWJ?+:\6*PFLP;F
M9[]L]Z_Q7H8\/[O]OG_=/?[?P:A)0QT&F:9!\&<:9+JY6"\6\^5ZA5'>Z#E+
M/?&G]KQ8-9/-[$B_>>J'/T]W&Z[UL>//-,CF8CY=K-9][&]XO4P=\6?JV"``
M[G!Y2'9?N^[F]>;3QY?=CS,\$4CG_OE&GJ_F`P;1HAU&&,KXLRJB?#+(9QGE
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MN4`%1JZ',HYW/1%,-I/M<@$<C(9L$PE$HB4N&JS'-IJW'T,Q]BXG8K)-I",2
MB$1+G'\-5C/KH(C/>B.[@['Y[D?RWBOR&2^7ZVPUI)Q18!0=\E&))IE)]';:
MFX."8?E3!ZX5F<0SZA@%1M$A[Z;(CG%3DC]=G##7FX-^N0@2\KF?%VN+=LQQ
M=HP"H^B0#THDR01U)/<'`7.>)Y1]:F5#)4]&1AVCP"@ZY-T4S3%N2NX7F`@C
M5YE&ABEF?4(^\XLR\X.53KI.Q\I1!D8X0)A<^)!$IDQ(1S*?1,W.^H2R`ZV<
M'LK,$PIL%1WR;HHT&3?[_>Z\/Y&,SGY2.1M#0C[[RS+[@U7./J'0$(H.^;!$
MT4Q81[*?],]Z;B7Q(*T-H8Y18!0=\FZ*5!DW^^PO%Q?YB/7^$T=2/1O#((16
M8U=E]@>KG'U"H2$4'?)AB<*9L(YD/^FA]3RAP[%8CCXM=N?]W,^H8Q0818><
MF].*W,[6I\AM/Y)?>!3YJ5]LX]ML-22?46`4'?)1C9);.6842Z8BL_`PZA@%
M1M$A[V9%;D]8\J<LMHI\YHLS7YNM<N8'E584V"HZY$,:);93%EM%-O,LMFP5
M&$6'O)NB6>;IE$5GA4^61LLM=@`T=Q)RN5^4YU+MF./L&`5&T2$?E.B@">KM
M)4=VU.6L)R%MU<JZ25:!K:)#WDT1,>/FB1N=:=)"LV0J\IDOCZ_92J=XQR@P
MB@[YD$9)[92E5E%.<\NH8Q0818>\FR)@1>9/VMY/DQ+:W`_B:(1V41YFM6..
MLV,4&$6'?%"CA';*0JLH^]0RZA@%1M$AYZ9\2F=S__;#V5M[,57D)W=Y=LU6
MP^1F%!A%A[SGH\1TQF*JR"284<<H,(H.>3<K8GK2DCYC.57D<U^>7;-5SCW+
M*5M%AWQ0H^1TQG*JR.:>Y92M`J/HD'<3B;&36Y;TTW:1,QFIF/@)^>27QU?M
MF`/M&`5&T2$?U2@]G;&>*C(?]S+J&`5&T2'O9J&G1U86ELU90I@7J%OZ4<VB
M/*%FJSR[AXZ*`EM%A[SGHV1SQK*I:#E\4-8RZA@%1M$A[^:?)9LSEDU%R*3)
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MM+-@U53D9W=YU,Q6.?FLFFP5'?)1C5+-!:NF(C.[&76,`J/HD'=SE&HN6#45
M^=E='B>S54XPJR9;18>\YZ-4<\&JJ<C.[F254<=6@5%TR+LIVE:HYDD?$BYD
MH&)E2<A/[O*DJ1UM4$-'+4=@J^B0#VJ4;BY8-Q5EGUI&':/`*#KDW:SHYHDK
M"^OF(B&?_/*HF:TTTQVCP"@ZY*,:I9L+UDU%-OG)*J..K0*CZ)!S<UGHYND?
M8O4C^9FOR">_/(9FJR'YC`*CZ)"/:I2F+EE3%9EEG5''*#"*#GDW"TU]^S"T
M9-U4Y)?U\K29K7*"TU@YOL!6T2'O^2C=7+)N*LJ?7+:,.D:!473(NUGHILQN
M.3H=233KY_*`\#J-IK#-J'_+V[]<T>56\Q'7*A]3O9NC1'+)(JG(9C-99=2Q
M56`4'?)NBAX9D3R2Q:1>Y@2Y/""\F)&S2*ACJ\`H.N3=+&1/BBY+Q1%W6?Z6
M!Y2?D78@4O+B\-4-C;;B^7CL?2PT[XAOK&O+`\*+4#F5A#IGY1THY$F2)"^+
MC7SQ;LFZE9!]4@Y&F73)1M[0R1\`KXJ$AFRE,48[N(MG5>C8VPGMK;U6)22O
M;!F7RO-?ME*7.D8A(YDGQ2X[YE:,X8,8)5LKEJV$BB#*<U2VRD$<QD)'14&M
MUOVW6.;3Z::H3U2+OI,/9)2PK5C8$BH"*3+99BOUNF,4,I)J%!6-N96J,4KC
M5JQQBLPSRJAC%!A%AWRN*QIWTM%EQ;*G"(NT>2C*HTNVRF5(8^70`UM%AWQ0
MHQ11WIHL#EV*S.+-J&,4&$6'O)NB7N]6Q-5!Z_!JG.;I6A$FCTEP>3S)5MJQ
M8Q0818>\YX5('EDO61Q7">4*MXPZ1H%1=,B[6>CDZ<>3%6NH(C^[R^-)MLK)
M3V/EV`-;18=\5(7X'DD^:^PJ(3N["75L%1A%AYR;ZU&:VEM[357D9W=Y/,E6
M0X(9!4;1(>_Y*"%=LY`JRGK8,NH8!4;1(>_F*)E<LTPJ<IN6=3YE'-Y?SU8Y
MP6FL'%]@J^B0]WR4-JY9&Q7EXTG+J&,4&$6'O)L5;3SI]:@U:Z,BM.2E>YWW
M^RGWJ6..L\L=M1R!473(!S5*&]>LC0G98QBCCE%@%!WR;H[2QC5KHR(_N8M-
M:)NM-)L=H\`H.N0]%VE[MZJODQ`:55>4B]XRZA@%1M$A[^:?IHUKUD9%?G87
MF^<V6^7DI[%R[(&MHD,^JE':N&9M5&2TD5''*#"*#CDW-Z.TL;?VVJC(:>.Z
M/*IEJR'!C`*CZ)#W?)0V;E@;%>7=3\NH8Q0818>\FX4VGK[SV[!N*G([OW5Y
MO,Q6.?EIK!Q[8*OHD(]JE&YN6#<59>%N&76,`J/HD'=35.O=*^`F:9Q9`17Y
MM;L\.&:KG.`T5HXOL%5TR'L^2APW+(Z*\OK5,NH8!4;1(>]F(8[]QV_3U0G?
MQ=FP<"KR:W=YJ,Q6.?EIK!Q[8*OHD(]JE'!N6#@5Y>JWC#I&@5%TR+M9".?;
MQZ\-BZ,B/[O+@V.VR@E.8^7X`EM%A[SGH\1QP^*H*%>X9=0Q"HRB0\[-9E*H
MHTSODSZ3.HSDE7-@?GZ7QTIC-N2_PG"E@3B+?R+G!'<:6%;$-DH_FPD+Z,#R
M-&@KK*LP>)O&RWWAK66%MX6,OCW7FPEKY<#<;-^4ATQC9M*=ALO.(@!B","R
M(H!1BME,6#('E@N,=">[S)!N8O"6&+RUK/!6Y,L(9[^N-_.3OM<]25)H9+51
MYJ;^ICQT&C-3BS1<CAC1$4-TEA71C1+79L+J.C"S.Z\PU"+US7;PEAB\M:SP
MMM#88U.?A;29)(:"YS-^^7,03*;!S*2;&`(@A@`L*P(8):?-A/5T8'F_"F^3
M769(-S%X2PS>6E9X6ZBJ3/W37G]M)BRY`T.Z3"G*`ZDQ,Z5(P^6`$1PQ!&=9
M$=PHX<5E>0=)<8]N8MD+E((82D$,WA*#MY9Y;_LK>8I52-[L'/G#W4:O]K%A
M*/-U*,^M0]<<+>[I2:*:&2[J(8:;>BPK(A.E,Y$=>:;UTA\70!++[$7;J%UF
M\);LX"TQ>&M9X:W(FO%6'HG3WFQK]*8?%TE235^*\A0[='7!#5WU,4%PQ!"<
M945PHH(FN&.E2*+I`D@L>X92$$,IB,%;8O#6LL);437C[;]2BB20+I+$?"G*
M\VZCMP;E@!'<T-64@AB"LZP(3D30!'>L%$DS70!61].U-WIY4-9@>$MV*`4Q
M>&M9X2V2-,9;,2].`'K_#^IMQ*`\X3;93%.+`-)P.2@$0`P!6%8$("(X(MU)
M,UVZK8YJNHG!6V+PEAB\M:SP5E3->"LS?SD[:4>J%_^X2`;1M*4HS\*-=G4S
M?^BJY4%PQ!"<945P(H(FN&,S/VFF"\#JJ):"&$I!#-X2@[>6>6_[NWN,M_]"
M*?0:(!N),LQ<\U30N3B;:=IQVYR5W#X)N&Z.&.Z;LZP(3G30!'>D%'I!D`L@
M26E^-MM&[3*#MV0';XG!6\L*;T781GB;=-!YFYA=A'#5MG\1%`$,9B;=Q!``
M,01@61&`:-V(`)(TN@`2R\\DO"6&=!.#M\3@K66%MR)>QEN9^:?L2/4>(!?&
M((QYVD\G=";6KCE:1#9TU=H@,F*(S+(B,A$Z$]FQ:9]TT0606/8,=2`&;XG!
M6V+PUK+"6U$UXZW4X;0/YO1>(!=(TDR[`$TGY4]L&^V:XT5L0U=3"6*(S;(B
M-M%`$]NQ2B3)=`%8&4U:H#<+.6_)#I4@!F\M*[P543/>2B5./!OH-4$NDD$S
M[4-!QV7MZH(;NII2$$-PEA7!B0::X(Z5(DFF"R"QO.[CH2"&B4,,I2`&;RWS
MWO:W`+W?6[TTR'JK#"O@(+W3"9V*LYFF%C>H)DG-@>(*56*X0]6R(@#1N1$!
M)%ET`226)P*N>R4&;XG!6V+PUK+"6Q$UX^WI:Y!>(>0"29+IUR`Z%&O7'"]B
M&[IJ=1`;,<1F61&;2*")[<C$U\N%7`!61=,:I';.6[*#M\3@K66%MR)KQMM3
M55EO$W)A#))IGP@Z$6M7%]G0U=2!&"*SK(A,)-!$=JP.23%=`(FMA[=U\400
MPZPAACH0@[>6%=Z*J(WP-FF@\S8QK,EF`:(3L5Y+E(-"`$-7DVYB","R(@#1
MN1$!)%ET`5BIU&E/#-X20[J)P5O+"F]%N(RW)T_[)(`NC$$4;1WH..RN*.JC
M161#5U,'8HC,LB(R$3D3V;%IGS31!7!@]N7`)MU49!B\)3O4@1B\M<Q[VU\C
M]'YO]=8AZZTRI,1,>SKR9C--+:[Y3GJ:'P7<\TT,%WU;5@0@(C<B@*2)+H#$
MS%?B&KVW*#-X2W;PEAB\M:SP5F3+>"O3_J2781N]A<@%,HBBJ41#IV'M:M=[
M9HAM&$XKAM@L*V(3D3.Q'9GX>C^1"R#I9,YZVZA=9J@$V<%;8O#6LL);$2[C
MK52BD=L?QOZ`1F\K<G$,JF@+0<=A[>H*,735I",T8@C-LD-HAU^&=?B%2H_;
MEZ_;=OOPL#^[W7V77W0E#]&GCP,__!ZN:TQ6^4U<O?/<-I6VJ8@OM\VDK=\P
M<]M\^.U>U#9;H`TZ7!MSMI2V/AO<;R5M_4L,W+:6MGX1X;:-M/63A]KF$[0A
M+35?IM(/!Y9:VTSZX2Q0;9-\8N==;9-\8N=:;9-\8I]8;9-\8J=5:YM*/WSJ
M4VV3?OC<I-HF=<"G%-4VJ0-.^=4VJ0/.U-4VJ0..I+6V1OKA(_)JF_3#)\S5
M-JG#0?6H?E.I`SX.K?6;2AWPX6.U3>J`S_5J;8WTP\\3JVW2#S^.J[9)'?##
MKVJ;U`$_.ZJV21WPDYIJF]0!/P2IM4VD']Z\J+9)/[S44&V3.N`5@FJ;U`$_
M@:^V21WP\^Y:6R-UP$^,*VT;=,-+:I46O-\E(U9[X6TJ::M782)5P-M*U3&E
M"G@WJ-HF5<";-96V#;KA3=Q:"SKA3==:"PJ`ETMK+4@_7M"LM2#Y>">RUH+4
MXYW#2LL:??`%A%H+^N`E_EH+LH[WYBLM&R0=[Z776I!RO`I>:T'"\3IUI66-
M/OAJ5:T%??#5I5H+<HUO"]5:D&M\Y:;6@ESC6RZU%N0:WR*IM*S0!]\:K;6@
M#[Z566M!KO%%R%H+<HTO$]9:D&M\?Z_2LD:N\?VX2LL2V<'%'K469`=W:=1:
M$`_NA:BU(!Y<Q5!I66$T?&NYUH)<XZN_E98%1L-]1K469`=7"-5:D!U<PU-K
M079P\TVE98GLX$J(6@MF%2YLJ;0LT`>WN-5:T`<_S*BU(->X?*S6@NQ@QU=K
M079PGU:M!57`%5:5ECGZ8%-6:T$?W'A2:T&N<>=BK06YQC6'M1;D&E<%UEJ0
M:]S.5VF9H4]]?S1#G_KN2#9'];V1;!GK.\8Y<EW?+\Z1Z_IN<88^]3W1#'WJ
M.Z(9<EW?#\GVLKZ[E,UE?6\Y0Z[K.\LI^M3W05/TJ>^"ILAU?0\D6\KZCE(V
ME/7]Y`RYKN\F9?-3W_O(UJ>^\YDBU_5]CVPCZ[O(*7)=WT-.D>N?["#1YR?[
M'?3YR6X'N?[)7@>Y_LG.$;G^R;X1N:[O&M&E^O2@0_79Z3<WU37GL%6L/6\-
M\OR3?2+R7-TEXCZ6#W+;"C^]^%W)GZOK%\I<7?&DR)5QKN5QJO#/\P^?T^]B
M+G?8LJ15>ERCB-7U#"6LKF8H8+^670[_`'[7\O/-U^U_W;Q\O7_:GSULO^"(
M.NG?B'DY_+;FPU]>=\\XNN(W+N]>\5N6^__]AE^KO<5OI9K(-W6^[':O^A>D
M[G+X1=V?_E\`````__\#`%!+`P04``8`"````"$`RS(14X($``#_$```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R46%V/JD@0?=]D_P/A_8*-XE?4
MFX%F=F]R-]EL]MY]1FR5#-`&F''FWV\5!=+=S/7#!Y7CJ>)4=745[>KK>YY9
M;Z*L4EFL;>:,;$L4B=REQ6%M__CW^<O<MJHZ+G9Q)@NQMC]$97_=_/[;ZBS+
ME^HH1&V!AZ):V\>Z/BU=MTJ.(H\K1YY$`;_L99G'-5R6![<ZE2+>-49YYGJC
MT=3-X[2PR<.RO,>'W._31'"9O.:BJ,E)*;*X!OW5,3U5G;<\N<=='I<OKZ<O
MB<Q/X&*;9FG]T3BUK3Q9?CL4LHRW&<3]SB9QTOEN+@;N\S0I927WM0/N7!(Z
MC'GA+ESPM%GM4H@`TVZ58K^VG]@R8@O;W:R:!/U,Q;E2OEO549[_*-/=][00
MD&U8)UR!K90O2/VV0PB,W8'U<[,"?Y?63NSCUZS^1Y[_%.GA6,-R^Q`1!K;<
M?7!1)9!1<.-X/GI*9`8"X-W*4RP-R$C\WGR>TUU]7-OCJ>//1F,&=&LKJOHY
M19>VE;Q6M<S_(Q)K79$3KW4"GZT3YCL3SY_-'_$R;KW`?3LOGN/-?>9/;VMQ
M*:XF33RNX\VJE&<+:@^45Z<8*YDMP7.7'XKFDK%?)0PRA4Z>T,O:7M@6Y**"
M57[;^)/YRGV#E4E:3D`<>.\Y;*%SPJ$?3V?PCH%+A;>..K=8!1#3)3!(MAK8
MYPO>Z4<RZN^\!@1H8CVF2PF'G+'.X$/&U(@X&E+&_7VT@&#]U8!PI<:P'ZX'
MAD9K>Z(FW9OH*@/B4/5C2D,3X"80*8"F$6[TN$8T@E@TC5-#(W'F36E-1_32
M*2%1^C"X"40*H*F&NE=57\\HD@VU$V-1`^+T4D(3X`3,FG@\_[-X(L5&4SO5
MU=Y7!VADJ/9'>@(#XBBJ"2"1$\JZ;L)-DT@!--$S7?3U%"/9%-MOBF;;!\11
MQ':`TEY\LWETG&Z;1PJ@R<7Q;W3%VWL-C0S98W.O$4>1;0+<!"(%T#1"MWU<
M(QK=Z@?$432:`#>!2`$TC0P:U.,B&RLSD[Y>>D%+4F2VR'31[*J18^2>#RPB
M%=%UXU11"N!ZO3*:05H'\XU9$+0D52^9]0@?<"(5T17BX%`4WM<&&(T;:(3]
M$![,@Y;4ZPH'"!\@D8KH2G%8/*Z41HR>4V-%`T8D52DAU+-FK&FL>N'P@5'4
M(F0T-YJQ'@N.D,=CH<&CQS*H9V4Z-2TN9";"!TBD(KI2'!^/*Z6A`S>^5A_*
M9&J5F@C'9VQH-/W*1"JB*\69\;A2FC1:3CWSJ8$1B1;VTRD;MI1>*!\@D8KH
MTG%^*-)OM`F:-IKD\4ROSH`I(ZE-KHGP`2=2$5TA3@]%X9UM@F;.C3)0!E.K
MU$0X,Y%(172E.$,4I3=R21-'R^7@,0P.EGH1A@.$MP@]6?[B24RU(LUTWJ2#
M5"[*@PA%EE56(E_Q+.G!`+J@EW/NDX?'"P,/V1*.-'AVN?P`Q\]3?!!_Q>4A
M+2HK$WMP.7)FL*-*.L#212U/S?%M*VLX>#9?C_!'@X`G^)$#Y+V4=7>!-[C\
M=;'Y'P``__\#`%!+`P04``8`"````"$`5=J].VL#``#4"P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6R45EUOVC`4?9^T_Q#YO20.WX@PM:NZ5=JD
M:=K'LTD,6$WBR#:E_?>[UPY9#*&D+T`NQ^?XV/?>W.6GER(/GKG20I8)H8.(
M!+Q,92;*;4)^_WJXF9%`&U9F+)<E3\@KU^33ZN.'Y4&J)[WCW`3`4.J$[(RI
M%F&HTQTOF![(BI?PST:J@AEX5-M05XJSS"XJ\C".HDE8,%$2Q[!0?3CD9B-2
M?B_3?<%+XT@4SYF!_>N=J/21K4C[T!5,/>VKFU06%5"L12[,JR4E09$N'K>E
M5&R=@^\7.F+ID=L^G-$7(E52RXT9`%WH-GKN>1[.0V!:+3,!#O#8`\4W";FE
MB[LX(N%J:0_HC^`'W?H=Z)T\?%$B^R9*#J<-]X0WL);R":&/&89@<7BV^L'>
MP`\59'S#]KGY*0]?N=CN#%SW&!RAL47V>L]U"B<*-(-XC$RIS&$#\!D4`E,#
M3H2]V.^#R,PN(</Q8$JC^7`*+&NNS8-`2A*D>VUD\=>!:$WE2.*:!+Z/))/!
M>!H-*6A>(0G=AJR_>V;8:JGD(8"D`4E=,4Q!N@#B;D/@!+&W"$[(G`2P5PVW
M\+P:SD;+\!E.+JTQ=PX#GPTF;A`AB#;*H-9?&<&HC$>+6[ES@;;,L%MF^!X9
M!"=DU-K\<#9N>)VRP]A;]OS`JOY^$)R0V-O_V5$Z$/5!DV8[GCID0']U!%OU
MYCCKB*N"]BU-?%Z;^'0\`/S;J8+K?(DZ`K779,9P-NUV,_55WY9"L"]51\[=
M8#]N93NZF4ZQ9*^XP76^1!WQW<RZW4#!M%7?=H-@7ZJ.G+NAH-XF[FW'+O1%
MCB'?T+S;$*9D6_AM1Q9]HH8$$.KP=-(6T-.8#K!-7E%Q'0%*JDEJ6H<\3_/H
M@J=W-0KJNH"G5H<Z/)VT!O0T&5VO(=ITB?^6ZI!OB5ZPA%7=2O<K!XCHDVNJ
M0QV6NOI"%/>YI_/.0+M:P_S":X.^JS=8](FIB]V!=K2'7O=TWAXLE4WP5K>;
M7WA%T7<U"(L^L72Q14"%>2G0NYSL0E_E&/)S[__[W[V/W`SE9HR"JRW_S/-<
M!ZG<XWP4P]301)O9[3;&HCV-CQ:W=8-H_H&9JF);_IVIK2AUD/,-<$8VZY2;
MRMR#D94=;=;2P#1E?^Y@>N8P.418=QLIS?$!E,-F'E_]`P``__\#`%!+`P04
M``8`"````"$`'`72ZE,+``"P-P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
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MROWKVY5.]YAF)"8V?_X9E9<=*4II[ORQR+2K#G0`]+-WW(O2($6V/Q[[/@V\
M?[Z^/?:#R=UX.@P\"N]]+B_79"]2]GN[KY=K=?RO#/)4*IEDI)+0;Y6$TGVP
M+XU2'P#]5GV[CT_%7.>@WYW'GZF^]/M_'M^CZ=8'(/[H?`1>H'O3'UV/82#/
M9UT>T?:Z?7HX5]][M.;HC%W>MV(%>W./3HPN#'D:FU+Y5:50B8@LGT2:QSZ)
M0T5PH?+^]C0:CQ\&WZ@D=RIF@3&^&Q'J"%%_(FW$0<Q!PD'*0<9!SD'!P9*#
M%0=K#C86&)"TC;YTIO\?^HHT0E^MS$(#(WC`Q-01NDO$0<Q!PD'*0<9!SD'!
MP9*#%0=K#C86<,2DP@<Q`]H+VW<Q79NBUV.?:MNJS8DKUD+&>$;@$$@$)`:2
M`$F!9$!R(`60)9`5D#60C4T<*4D.1\K;$HIHVORIR"T-^?I6073RK*"I*W38
M!#5E"20&D@!)@61`<B`%D"60%9`UD(U-'%GI\M1!5A%=RZK%6"@2-`L]!!(!
MB8$D0%(@&9`<2`%D"60%9`UD8Q-'L$DGP42T*Y@B5.=6T=VSHFN"M,X1D!A(
M`B0%D@')@11`ED!60-9`-C9Q-)QVTE!$NQHJ8A4=D`A(#"0!D@+)@.1`"B!+
M("L@:R`;FSB"B;L:V_3<WOQ$M"-8J$BS2",)`KL*?7_D5F'<!.DJ3("D0#(@
M.9!"$E\<CS-/\F,=YBFBG7DN;#\73-A^'ZIXHX($I(+P?_[08XXD;MH;`7B*
ME(.LZ:-R,E'SIEWG+'B*)82L@*R!;*PTCJ8>^8T.HM;AKJH*3>@B8NU9,[=:
M0A7E38V^B&)$":(4488H1U0XR)5!&-Z/KR%/^F-R$/H\+102_LW(,!ER&61'
MBM(=H[:.OL^,1FRB1.4$8^;X$M.N$Z>(,H/,0<)8N8D28WE\Y1>FG<9R9116
MMX.,TAD[,DI$=6*.<#3QN(Q-E)YM)&Y":;U;!18;5&LV`<V@2VJZZ,09HERA
MP*^W!L_W6;473A]7(6%A.R@D':^CD$2LT.#>LXG2$XG$'3<I9-5>;)!4B&5)
M3+O.DB+*$.4&B<0CCTE?F'9*[`HDS&@'@91WM5>B1*R$V.X=BJ<#;KU$B&*#
MQ#S\>S:/Q+0;@2!QAE&Y05)YJ"`[BRN0,)\=!%)>U19((E9![%(4BN=I;KE$
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M1PZ_FZ^NPUT9%#*'&0*)%*'#T`41(TJ@7PHDPVXYHL+NYTZWFW^FT\W/ND+L
MHL2NMZ&)TA..##+E@ANQCO*D91O#1JP#C#-/$66(<HU49G_$G$:A`^0K+>=I
MNC"@]IJYO59\Z5<IGY[\0B&Q,5EKA5UD0A.E.T:(8H/J2_D]>^R4F':=)464
M(<H-$HEG'K^8FW9*[):5L*P=!)(.UQ&H,;V60`&_]_>;*#VU"%&LD:ZA*;N^
M)CK`KB'(G&%4KI'*//)8YD('M-20,(H=))*^TI&HL9J61!-V]D._B3(2`8I5
ME/8[TWNF=()I4D09HMS-/![.6)$73A^WBH3C[""1-*B.1(UGM25BGCT4[XZ9
M8T84&R16P\AC61+3KH5.$66(<H/JQ#,F?6':89D)$VH+)*[=(YK-;_8CZ5T=
MH1H[:PDUY4]!_"9*3S%"%"ND:FD\@?MW[),BRA#E;N:)[X%4]@&ZM20\K2W5
M;R22%MB12+EBYT'1E#_A\)LH(Q&@V$2)4^[![:EIUUE21!FBW*`ZL<_.8&':
MH9:Z.6$?G;!"=$W3!QTBB@PRE=9RV9?I]7[D#Z?LZIR8/'JT%%%FT(W1<A6E
M1QN/9LR_%"8/Z,;]\V\*"WVSKU#]X+S^P$&(*$(4(TH0I8@R1#FB`M$2T0K1
M&M'&0<["%,:QP\*LPUW#K9&E'Z((48PH090BRA#EB`I$2T0K1&M$&P>Y^G5S
M\`$Z>(UL*\HM4J2"@E&SN&-$&:(<T0K1VD'N_+IY;5K#[`XE4L@Y=!EEH0RC
M<D0K1&L'N8<N/.3'KSGBO9U[2QUJU(@>*2)^-3<.`=_F8Q.E-\<$48HH0Y0C
M*A`M$:T0K1%M%,*WAG1R.JDG3:UUQ0[K#+176.K)(!I37![IW2#SZ['J0@%&
M.)6X(2GDS4PWE9==K7(3H/,6D&4)9&6ZJ;SL%FQM`G3>C9W%+4=A<SN4HW3%
MEJ"+@)"I.OYH)Q+-PD?;>P2@#*-R1"M$:P>Y,Q.VK\/,I$MT9B;1A&Q',\$1
M]QP1/1&%"0+*,"I'M$*T=I`[06$A[0E^["%=()VG,]'&C-H39645JHYTU=%E
M%1ED.J)OTU'RAG@TGK"%D.@`DSE%E!ET8[!<1_UJL$('F,&6B%8&W1ALK:-^
M-=A&!^"M?M#-6M?AS.)(.^P^+IJRNY]0=;0,>(0H5H@N6_6>,AX.V4U"@IU2
M1!FB'%&!:(EHA6B-:.,@=WUT,^$!FG"%A,^R-@!V&Q":*+,N9"YKJ<0Z2I;*
M.!BR1QZ)#C!UF2+*$.4:J<PS>#^K`TSF):(5HK5&,O-LR)\B;G0`EC=]8<#=
MG&[?`=7A;GDK9!5NB"@RR)PBW(%4E"KO8'3/GV(D)H\^B2FBS*`;H^7N:-YP
M-&6/A0J31X^V1+0RZ,9H:S8:O6=BCQ_$ES?$%4HJ*9>(_#*&_+3]L3R_EF%Y
M.%QZN^JK^*(%K:FGAP8WWP+Y5)LFQA?T[9#Z&3;G_IP^*TW3XSR8TR=_D7\:
MS3_1@6+#8D1?/VGCXSE]=+,E?C*GCR.V\.F</G77PCUJD-JP0R7O,H_)8&`?
M\BMS85"PA3S*7)@2;"&C0-G:CHS,`65K:R%#0-G:6SQJ:1.>;FUHG#;IZ7:&
MQFEKH5L8RM;60O<6U-)VPJ)@1..TG1EROC1.6PMY5\K6UA)YL[EXP8>ZT=N[
MN7A=ARWTQFPN7I%A"[T!FXM77MA"]ZQTU&VZT7TJ'75;R\*?42VW'<$B&%(U
MMXYS/Z</0[:,3]-LRY31)-OX<C:G#P"VY/'N2:^V$>C=+^E5MPR:@J;O2[UO
M7\OU]ORZ/UUZA_*%EOGP;DI._"R_<27_N5;O]?=N/E=7^J94_><;?3.NI"^\
M#.\H^*6JKOH?.JA!\UV[I[\```#__P,`4$L#!!0`!@`(````(0#LW6?M=P<`
M`-\@```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*R:R8ZC2!"&[R/-
M.UC<QS:;%U2N49D=+QJ-9CE3-BZCMHT%5%?WVT\DN9$9[E8AS:7=_HC\3?Q$
M)@%93[]_NUY&7XNZ*:O;RC#'4V-4W`[5L;R]K8R__XI^6QBCILUOQ_Q2W8J5
M\;UHC-^??_WEZ:.JOS3GHFA'H'!K5L:Y;>_>9-(<SL4U;\;5O;C!D5-57_,6
MOM9OD^9>%_FQ&W2]3*SI=#:YYN7-H`I>_1F-ZG0J#T50'=ZOQ:VE(G5QR5LX
M_^9<WANN=CU\1NZ:UU_>[[\=JNL=)%[+2]E^[T2-T?7@I6^WJLY?+Y#W-]/)
M#UR[^X+DK^6AKIKJU(Y!;D)/%.>\G"PGH/3\="PA`V+[J"Y.*^/%]/:6;4R>
MGSJ#_BF+CZ;W_U%SKC[BNCQNRUL!;L-U(E?@M:J^D-#T2!`,GJ#147<%_JA'
MQ^*4OU_:/ZN/I"C?SBU<;A<R(HEYQ^]!T1S`49`96RY1.E07.`'X=W0M26F`
M(_FW[O.C/+;GE6%/QZ8SG4'TZ+5HVJ@DBL;H\-ZTU?5?&F,R):IA,0WXY!K.
M>.&ZSFPQ_[R*S53@DZO,QNY\:IL#3L5A(O#)1."D/ID&G&IG!7RRL<OQW)PN
M[0%)S)@&?#(-<[`&3,WN/.!S<`Y+-A8^V=CYV%JXICOD>II0A;0H2#FR*_[9
M-":TP+IZ#?(V?WZJJX\1+`)00\T])TN*Z9EP?7BETL(2M?NCTH6:)2HO1&9E
M0'Y0E@W,MZ_/KCE]FGR%.7)@,6L<8ZD1/H\@$X+(!CH(=1#I(-9!HH-4!YD.
M-CK8ZF"G@WT/3,!:X2\4^O_A+Y$A_G)GUAQ(PVW-3![!AP0Z"'40Z2#60:*#
M5`>9#C8ZV.I@IX-]#RAFPB*DF/EX.>4U2:)7!M2TJ$E[.5--6M,84QKK(Q(@
M$B(2(1(CDB"2(I(ALD%DB\@.D7V?*!:"'0,L)-$KPX+B%AZZIJEYR()@<15!
MCJU-?E\$B7)$)$0D0B1&)$$D121#9(/(%I$=(OL^46R%N],`6TET9RLW8\W(
M3$QP'Y$`D1"1")$8D021%)$,D0TB6T1VB.S[1#$,JF6`821:,<QG1/@54&!#
MX8LJM"Q'+=50!''C(T1B1!)$4D0R2BQR/DJ>\T%YDF@ESS40D8\]<]5\?!8O
M7:``7""W8&MJ:C>%4!P7!N@2L0X2,89I:J:FXCC7S'2)#0K9(K)#9-^343PE
M3TG]GN7GMP$2K7I*"92F<-:QM47-YS$\IX""WITB1"32!\4Z2-"8%)&L-TA)
M&[JK`6F3:#5M2FSH'D7>]FRN590($HD+(H=9EC8L9$$F;?TL5SL>"1$N&R.2
M"/*3'TJ5'[)-6[NA9T($?DAQC[3/`^SKPE7_&#*A+(6!CHUZ6/([T$W/Y:24
M`WGVH41]+6VV1H^B+%N;?[&,XO()1JE$_5_4M+)'4?U?5"TE3>_G)Z))>V3H
M)OAYKAE2:M*Q]55.1O&!`4:A1&2=<DR]!.5QKA)CE&"42D2$[3GRC.8%28"P
M:A!I9`<81/M>Q2"*M)K3BMXW111/+<`HE(@NY$MUZD?R.%>),4HP2B4BPN9"
MNWZ9/(X,(GWJ`(-H6ZL81)%:0=H)^*8(XID%&(4<T45LN=#7QH@'=!>Z>T"-
M,4HP2CFBRHN9NU"MSWC`@Q(B+><`AUB'VI]C%&DEI,T.GSS[Z\L60B&+LBW:
M7]@F]@@-BK%T@E&J22],_1$B4P:I\XRTF0-,8EUIWR2*U#*RM<ODDU=X8!*=
MZ>P-!4*AC.JOM&BVB8$RJK_2LOH24;QR$RG/42J1U'(<[1$L>Q35_T754M+0
M#K"4];]]2RGJW0A]$Z$`HU`BF8UM(_^05BP'<F<2C%*)?B*?R2C04ITA;>D`
M9U@7JSY#:UW#FLQ.TJY!4K*W<-`Z+Z)X@H$<R%&(4811C%&"48I1AM$&HRU&
M.XSV"E)=)EWP`)=ITZS<&1CJ/5.;"`48A1A%&,48)1BE&&48;3#:8K3#:*\@
MU3_2"`_PC_;-BG\4N5!SO9)$]PT1Q>LO@&<D4LLPD*.0(SC2T]*6UXA'=0.5
M;*QAS7L7KC;O#*D+O*,M*KZ,XJ<>8!0R-.L_23FNMMQ&RD`UFV%],UR4;FWH
MK:T,D>DC_73U9U@9);.A6C"0HY!%N3`W>EK:`A4I6FHVPYI<"S>Y#,VZ#;GN
MON=C%&`48A1A%&.48)1BE&&TP6B+T0ZCO8)4__0>F&S!6#.R,?B#_4+^@AMV
M,%%A4$1:I=[%U)XK?39PUK\G.:Y\KJ'G1W<WZ6[1M:C?"K^X7)K1H7HG.Y=0
M0L]/`O-MU;GW0O=5M2-P@_/(:@]5AXXLX,CBT1'+@EW:[I6:-@:V;U\>\35L
MZW:S1(M?$Z%'OV![\*8<G].+X[U``X`/K!T/W@$_X*X'KSHQ#V8>O"M\P.<>
MO(K#/)E[\#H-\\W<@_=CF`<+#UY#89XL/'BQ!'PBG(#MY7O^5NSR^JV\-:-+
M<8*+.!V37=2:;E#3+VUU[W8%7ZL6=I:[_Y[A#PD*V(Z;CB'X5%4M_T)^0/QI
MPO-_````__\#`%!+`P04``8`"````"$`)W`STN(*``#(,P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6RLF]MNXS@2AN\7V'<P?#^Q)<MV;"09M'66
M#U@L9G:OW8Z2&&U;@>T^O?T4Q9-8O]H3+?:FT_E8+)(_BV114AY^_W$\]+Z5
MY\N^.CWVO;MAOU>>=M7S_O3ZV/_SC^2W^W[O<MV>GK>'ZE0^]G^6E_[O3__\
MQ\/WZOSE\E:6UQYY.%T>^V_7Z_M\,+CLWLKC]G)7O9<G*GFISL?ME7X]OPXN
M[^=R^UQ7.AX&_G`X&1RW^U-?>IB?/^*C>GG9[\JHVGT]EJ>K='(N#]LK]?_R
MMG^_:&_'W4?<';?G+U_??]M5QW=R\7E_V%]_UD[[O>-NGK^>JO/V\X'&_<,+
MMCOMN_X%W!_WNW-UJ5ZN=^1N(#N*8YX-9@/R]/3PO*<1"-E[Y_+EL?_)FV]&
MT_[@Z:$6Z#_[\ONE\?_>Y:WZGI[WSZO]J22U:9[$#'RNJB_"-'\6B"H/H'92
MS\"_SKWG\F7[]7#]=_4]*_>O;U>:[C&-2`QL_OPS*B\[4I3<W/ECX6E7':@#
M]&_ON!>A08IL?SSV?6IX_WQ]>^R/)G?CZ7#DD7GO<WFY)GOALM_;?;U<J^-_
MI9&G7$DG@7)"/Y43<O?!NM1*W0'ZJ>IV;Y^"N?9!/SNW/U-UZ>?_W+Y'PZT[
M(/[3N0?>2->F_W3MPT#.9QT>T?:Z?7HX5]][M.9HQB[O6[&"O;E'$Z,#0TZC
M"95?10J%B/#R2;AY[),X%`07"N]O3V-O]##X1B&Y4S8+M/%=BU!;B/@3;B,.
M8@X2#E(.,@YR#@H.EARL.%ASL&F``4EK]*69_G_H*]P(?;4R"PVLX$SN4%OH
M*A$',0<)!RD'&0<Y!P4'2PY6'*PYV#2`(R8%/H@YHKVP?1?3L2EJ/?8IMDUL
M!N.)&WD+:>-9@4,@$9`82`(D!9(!R8$40)9`5D#60#9-XDA)<CA2WI906-/F
M3T%N-!Q[`=-0&5&3QB@8W[M&H3$R80DD!I(`28%D0'(@!9`ED!60-9!-DSBR
MTO'4059A7<NJQ5@H,C(+/002`8F!)$!2(!F0'$@!9`ED!60-9-,DCF"33H()
M:T>P4!&C5R3!J!F%OL]"-39&6O@$2`HD`Y(#*23Q17^<<4X[C5-8.^-<$#&K
M:C09LU6E[*T*$I`*XBCVA_PLCDVY$8"[2#G(3!WEDXF:FW+ML^`NEF"R`K(&
MLFFX<305EY-F[G)[#Q/6KJ:23&@Q&VF#\8Q)*XV\.C>720F0&$@")`62`<F!
M%$WBC)U2K0YC%];NV"41AZ<=^V3(QFZ,](Q&AMAJOC]UJ\7&2`3*B)^UB2G6
M7E,@F2$WVLF-D6C'XXN\,,74CJ.=1Z/N(%YM[JJG$$6%[5\P\5P=0FNE1QHA
MBBVJY9JPU"2QY=I+BBA#E"LT\NM-P/-]%MJ%4\=52*2S'U]:GLQ^*3_075PH
MQ`(,$GY9D:QTQ<A6U"BV2"K$O"2V7%=)$66(<HN$X\!CTA>VG!R[`HD4M8-`
M,J-U!)*(A1!/XL5-D59N<_M!%%LDQN'?LW$DMMP*!(XSM,HMDLI#!#6]N`*)
MS+.#0#)1=022B$40.W1"<2LF@9P(`A1;*S&.>[9A);;8Z@-.,K3*+1)^)ZQS
MA2V&^!$99`=Y5,+97&`2-2(C%/=W'BP&V8T*-VQ54>\4P1@$,FZL0(`RV_Z-
MQG*W,=\?LN5<6#>@FD@C.ZBFLLZF:A*-)F;#"<5C,!%!%D6(8D0)HA11ABA'
M5"!:(EHA6B/:.,A=E"([[:"?2F:;^DE$DIFT`;-13QOI8(D4:=RO8T0)U$N!
M9%@M1U0TZ[D*B%RRJ8!XWB6VF-NYH]BE*4:<[4FB"8W52!%`8JXJ3N0S5?E,
M2U6T&66LK2Q*-+(54T291K9BCJC0J/;ERB'RRZ8<?R.#3$<=&22RW0P]3B)%
MG-F71@V40+T42(:><D1%LYX[7)$2=ABNS""=X9JDLCGK[+P-:5AP*!ED*[9L
MQ,K*DRG;&#=BXT:OK10;RQ#E&BG/?L`RC4(;R/<(SB/,;NFR+\S=M:*0B,/&
M6F&'3&BM]-@B1+%%]5%^SQXP);9<>TD198ARBX3C&7^\5=AR<NR$%05(E["J
MS9E`)@]N"#3BMWQ5L9GK((HUTC$T9>=KH@ULTITBRA#E&BG/@<<\%]J@)89$
MHOCQE>?+O)+\Z4E<*,1BB,U^:*UTQ0A1K)#.=Z;W3.D$ZZ2(,D2YZWD\G+$@
M+YPZ;A2)C+.#1#)!=20R.6LCBB8L9P]]8V4E`A1;*[$:`H]Y26RY]I(BRA#E
M%M6.9TSZPI:38U<@D7$V!1)G=T"IR.U#RY>)JB.4R5T;0DWYTP]5D2).#S%"
M%"ND8FD\@?L[UDD198ARU_/$]T`J,PR02N2T3:G^1B*9`CL22>3>OJ;\"8=X
M^2MR9[N51(ABB\24>W`]M>5:Z!11ABBWJ';LLQDL;#D()%+4#@+)C-812*)&
M=(0^H,@B&VEX["LKO1_YPRD[G1/KQTH$K676ZD9K.6MM',Q8_E)8/Z";2%X[
MZ"9S74<WA>I'Y/4#U=`'%"&*$26(4D09HAQ1@6B):(5HC6CC('</$WEO!_UD
MFDSZV0D=\WU@X2NKAE'`3_U(&8T"LYO%B#)$.:(5HK6#W"&+E+7#D&6&VPB9
MR%=);[/K@#*TRA&M$*T=Y'1=['X=NEZ;.XE=J)$1/5+$>4$UXCM7;*WT>D\0
MI8@R1#FB`M$2T0K1&M%&(7SE->J6%M?F3#V9%MNM(E)&]L462T%C:V"%XUY2
MW929E<Q6$R<)OC#+K8'V6X"7)9"5K:;\LD>$:VN@_6Z:7MQP[)9$TW'"+V("
MF1L8/+B)5(WF'H$H0Y0C6B%:.\@=F4A`/[Y'B,7#KI@*36@K-`,,^#$:*2MG
M@"KWM9M+AE8YHA6BM8/<`;;EKF+EW$[,J*,P4(E$W<9`65B%JB)9Z;"*++(5
M,1715O*.1Q_*\$Q$&UC/*:+,HAN-Y=KJ5XT5VL`VMD2TLNA&8VMM]:O&-MJ@
M;LR=O6[I]`C3:87<V^N4)?2AM;*S)GTUTLQ86=%JJO>4\7#(\MX$_:2(,D0Y
MH@+1$M$*T1K1QD&NPB*9[;`!R-RWD20LZ/F]NHK8(`BF++,-K955V%34*-96
M,E3&HR&[Q2?:P,9EBBA#E&ND/,_@E:,VL)Z7B%:(UAI)S[,A?S"VT08MX=TM
MJ:?OE&%3DJ@1I:&R:J#((CM%+3N0]*7">Q3<\XMY8OWH&4L191;=:"U75JHU
M;QA,V9..POK1K2T1K2RZT=J:M48G,+M1BX_`A;A2-KE$Y$?=\JO=8WE^+</R
M<+CT=M57\<$V3>O3@\'J:W+_?OZ)/%&'>8DW_U2G4XPOZ/OS^F$;Y_Z<OL9$
M/XL1?:_>PC\%Y+^MX44PIZ_F6AR-Y_1Q6`OWJ(#>9+64^%/J4UL;E+_,8YI)
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M%^K4P/P-SM-?````__\#`%!+`P04``8`"````"$`).2!N_T#``"1#0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RLEUV3HC@4AN^W:O\#Q?W(EVA+
MB5,JXK>UM36[>XT0E6H@%(EM][^?$R!1DME>NVIO!![.>0]Y<PAQ_/T]S[0W
M5)$4%[YN]4Q=0T6,D[0X^_I?/\)O+[I&:%0D488+Y.L?B.C?)[__-K[AZI5<
M$*(:*!3$UR^4EIYAD/B"\HCT<(D*N'/"51Y1N*S.!BDK%"5U4IX9MFD.C#Q*
M"[U1\*IG-/#IE,8HP/$U1P5M1"J4112>GUS2DG"U/'Y&+H^JUVOY+<9Y"1+'
M-$OI1RVJ:WGLK<\%KJ)C!N-^M_I1S+7K"T4^3^,*$WRB/9`SF@=5QSPR1@8H
M3<9)"B-@MFL5.OGZU/(.`]V8C&M__D[1C3R<:^2";\LJ379I@<!LF"8V`4>,
M7UGH.F$(D@TE.ZPGX(]*2]`INF;T3WQ;H?1\H3#;+@R(C<M+/@)$8C`49'JV
MRY1BG,$#P*^6IZPSP)#HW==M*)PF].+KSJ#G#DW'@G#MB`@-4R:I:_&54)S_
MTP19K50CTF]%X-B*@-R3N5"E?@`XMKF@\F0N]'"="\<OUQVUN7#\<ET+AE<7
M9B=?KFPY/!M.GJUM-/-6MT$0T6@RKO!-@U<+9H:4$7M1+<\"ZW@#--,E6N+?
M.@):@:E,F8RO@QDPV02Z^&WB6H.Q\0:M%[<Q,S7&[D;,>03K,R8;R&`A@U`&
M2QFL9+"6P48&6QGL9+"7P>$!&&"M\!=F^/_PE\DP?[DS,P[NACN2F3R"IP0R
M6,@@E,%2!BL9K&6PD<%6!CL9[&5P>``=,Z'A%3,=6/-^O5KQWF19O@Z]+7JS
M/WSIFC5K8JR[P7.%!`I9*"14R%(A*X6L%;)1R%8A.X7L%7)X)!TKP8Z.E9];
MR*)AD8<F%QZZUK#KX;P-$CT:-,"!9Q!9CFUVLQ8BB/=IJ)"E0E8*62MDHY"M
M0G8*V2ODT!";C:MC(7QROF`ABZXMY..<`;G[,G"[OLS;^+N;#0`WV>IJFY:T
M>"[$?5X@E"66,EB)G%936D/6XC[7W,@26QGL1$ZKV>\.;"_N<\W#@T3'X(%D
M,/LVC?[S=6=97:,;PA8*X7?_1>K#N0CBCQ4(<D^S;:GI%R*(C=892K,8BMM<
M=:F0E2"?U%F+(%;'-4==4S?B-J^S5<A.D$_J[$5076<@N01;468N6`EUFKEJ
MMI;-GB)'U1G-4981+<97MFT<0;<*VNQH@[X'+QGDR]SUH(=5OG(]Z$.5[UP/
M>DGEL&.>UB^KI#^#G72][Y2Y[<$'1]69.1XLGRJ?]KUIO2,WA!#LB,OHC/91
M=4X+HF7H!$,W>T-H[*K94S<7%)?UCNN(*>R%Z],+_/5!L-4Q>Q!\PICR"RAL
MB#]3DY\```#__P,`4$L#!!0`!@`(````(0#D['N5R`4``)P8```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;)Q9VV[;.!!]7V#_0=![K9LE.T:<HK+(
MW0)=8+'8R[,BR[90RS(DI6G_?H<:RAX.4U^2!R<^/AS.&0YY9.;QX_=Z[WPK
MVZYJ#DLWF/BN4QZ*9ET=MDOWG[_EA[GK='U^6.?[YE`NW1]EYWY\^O67Q]>F
M_=KMRK)W(,*A6[J[OC\N/*\K=F6==Y/F6![@DTW3UGD/;]NMUQW;,E\/@^J]
M%_I^XM5Y=7`QPJ*])4:SV51%F37%2UT>>@S2EON\A_R[777LQFAU<4NX.F^_
MOAP_%$U]A!#/U;[J?PQ!7:<N%I^WAZ;-G_>@^WLPS8LQ]O#&"E]71=MTS::?
M0#@/$[4U/W@/'D1Z>EQ7H$"5W6G+S=+]%"QDF+C>T^-0H'^K\K4C?SO=KGG]
MK:W67ZI#"=6&=5(K\-PT7Q7U\UI!,-BS1LMA!?YLG76YR5_V_5_-Z^]EM=WU
ML-PQ*%+"%NL?6=D54%$(,PEC%:EH]I``O#IUI5H#*I)_'WZ_5NM^MW2C9!+/
M_"@`NO-<=KVL5$C7*5ZZOJG_0U*@0V&04`>!WSI($$^F83R;WQ,ETE%@WC%*
M.`GG<1`G=^22Z"CP>XQR>RX>5F<H=I;W^=-CV[PZT,&@OSOF:C\$"X@\5AEK
M<JK[S\H.]59!/JDH2_?!=:"B'?3*MZ<XF#]ZWV!]"\U)D0.OA/-@<E9VG-!D
M9"-#+;B:6G!`(@"OYWE"_Q3%`]TG\;"L5/S;K35J5&2E<9PY'0$Z47"::,AN
MA1R:3&0R,CM*Q(((FY*PPDF;$H?GF0S1T(VWBU9D0S0'5@A0A7'(%XT/$AR0
M!#"2G9K)JO:,X"BYO%)JT-*%5](!4[/L*7+PX%!]M.)`Q@'!`4D`(VG8Y[=7
M6)%!E)%LS))%#DEV!-1.X\4>/QO[5'!`$L#(&_8_S?NV8JM!//^$Y8^<^7`P
M)#[^F)054LX2,PX(#D@"&#)FIHS+O:+(9OK)>=\,>SA%RCFU%0*!/^@)Q`<V
M(+ORN>`!)0$,)>I9AAW.4UB\RXK4(%-1',[,:J?((9(0F*&B^3SV9R';,9E!
M\9-9'/F,(BAE%L[]J75.D8D-I6`=5.EEA8K,%7*W00Y1B(!6&"5Q`&UH5B4S
M*/YT]F!1!*5$T_E,];(919*9#8G0+W=H'-A<)#OU4TTB*BTDLQ!A(9(B9L[*
M3%D'7C]_`S7JV@&L231W''9&,HLC+$12Q,Q=>>+]N:.3&N=QQ)8X#9!TSG1E
M(9F%"`N1&L&FA/V"/Z=^,N4HB[Q?#AJK*8<]7Z0!DJ@<CF061UB(U(C>8V$\
MR/F)&N6=1,WE#1^@TYHJF.^EFD15$(,>CO+,X@@+D1I!%=/+:Z*<E*BXS3'5
MMQA^?D7,0U)-HFJ(;6LU'!'6*$D1LY^4?=Z?.YHN%/;"LU5`G!D?@RTDLQ!A
M(9(B9N[*,$GN5[H'[=7HGI#[14`\6.>,"/9!Q)I9+P`?)*PPDB*F".6%1,2-
MS8,.:HB)F`^G`;%9+88CF<41%B(I8N:N3.[^W-$:KS0/\4^=.T>R@"/"0B1%
MC-Q#YL.WU7T8Q?PXXL_IFD0VK4:2A^')RI^PE<JL$<)")$5,)<R=+V^#$.W5
M[!S^I*Y)5('ERA9'6(BDB)GSNUPY1,.]W#F:1'/G/IU9'&$ADB)F[E"[^[L^
M5*.N=@Z2:.Z(G#J'K52FPYY'"`N1%#&5*&<D^_=*YR@V5\"_4H1(.N>SLI#,
M0H2%2(J8.;_+;-4%V]5G44VBN7-KS2R.L!!)$3/W=YDM7*_:=>?&I4DT=QR&
M7[<C_@"#SF6-$A:B;G?5]$-D5(.7M7A_6)?MMER5^WWG%,V+NHA-X(P[H:=+
MXD^1NC%C^"I8P,6=C:?A(GV+GX6+["U<A`NX2[+CR'`!5TJ`>Z>)X6[XF&_+
M/_)V6QTZ9U]N(&5_,H.%;O%V&=_TS7&X%7UN>K@5'O[<P7\!2K@C\B=`WC1-
M/[Y1$YS^K_#T/P```/__`P!02P,$%``&``@````A`'?X`)Y:%0``\(T``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK-U;;]O(DL#Q]P7V.QA^/[%U
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M?_SC;O_P0X;X]?[[_<N?AT'/SQ[N;L+7Q_W3[:_?Y77_,5O>WL6Q#__`\`_W
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M=<,6.9@<;`XN!Y]#R*',H<JASJ')H1W`A:3VE%_97_^._';#=/F-F?D489#P
M+)DQ(G8I<C`YV!Q<#CZ'D$.90Y5#G4.30SL`E4PYAJEDCA^"XYSLHC^<RYP>
MS,FU3M*G8\PL)78+*2`&8B$.XB$!4D(J2`UI(.U05`HE'1-2V$7+^Y5,[D$.
M\_VZ#Y*--@BZTHG>GH).TQ%B(!;B(!X2("6D@M20!M(.1:55WLPFI+6+/J0U
M)N-3+YO3#KZ%%!`#L1`'\9``*2$5I(8TD'8H*F'ROCXA85VT3E@O\F8]F'2;
M;-*=@F*>"XB!6(B#>$B`E)`*4D,:2#L4E4-9XDS(81>M<]C+.DTZ2`$Q$`MQ
M$`\)D!)206I(`VF'HA+6U63#Q<[K[Q]=M$Y8+[)!!I/N.IMTIZ#3I(,8B(4X
MB(<$2`FI(#6D@;1#43F4-=Z$'';1.H>]+-*D@Q00`[$0!_&0`"DA%:2&-)!V
M*"IAW3I_0L8.X3IED>1-_33OEI>7V;Q+4:>)1S(D2W(D3PJDDE21:E)#DJK^
M.'D.4T6GM%MMOWU'[LJE;!9&&AS[2`7)D"S)D3PID$I21:I)#:E5I//7+;`G
MY.^X'I=E8)Q9GV8]#0^%R\M9/B5/4;%CD3I&,B1+<B1/"J225)%J4D-J%>F4
M=BON"2D]+M!52GM:GK*\G8$*DB%9DB-Y4B"5I(I4DQI2JTCGKUM:3\A?OQ(?
M3LF>Y,_@*(E3#*>H./^*[K1'=WA(B3<D2W(D3PJDDE21:E)#:A7IE':+[PDI
M[=?JPY3VE#*S[<Y\ZF05)$.R)$?RI$`J216I)C6D5I'.7[?P'N:O.S<V7[V3
M#$P].]8OX8>I[4G/UD5^`#U%I=D*,C.0)3F2)P522:I(-:DAM8ITMKM5^S#;
MKR_.9_TB?YC2GH:S%53$CBG*D"S)D3PID$I21:I)#:E5I//7K=@GY*]?X`_S
MUY.>DLM\2IZBTI0$F1G(DAS)DP*I)%6DFM206D4ZI=V:?D)*^Q)@F-*>TF3;
MRKE&'$!!AE&6Y$B>%$@EJ2+5I(;4*E+YFT^K?`[ANO*)I*=D=@)RFZ).4Y)D
M2);D2)X42"6I(M6DAM0JTBF=5OET9VZSRJ<GV6HQ65M203(D2W(D3PJDDE21
M:E)#:A7I_$VK?.:L?'I:R'ON8)F975?8IJB8Y8)D2);D2)X42"6I(M6DAM0J
MTBF=5OG,6?E$&APE207)D"S)D3PID$I21:I)#:E5I//7E1]O?Y>1,@6[=$_Z
M*)E?@8D=4Y8+DB%9DB-Y4B"5I(I4DQI2JTBGM"M2)J2TKVD&;]S=ARITF;,E
M%21#LB1'\J1`*DD5J28UI%:1SE]74$S(7U]_#/-W*DF&1\G\^LS\%)6.DB##
M*$MR)$\*I))4D6I20VH5Z91.*V_F+&]Z6L\';]S'J`$5C#(D2W(D3PJDDE21
M:E)#:A7I_'4%Q80IV=<?PREY)$G6<$KF5V_FIZ@T)4&&49;D2)X42"6I(M6D
MAM0JTBGMRHX)*>VKE&%*>[H:3$E0,0<9DB4YDB<%4DFJ2#6I(;6*5/X6T\J;
M0[@N;R+);IS6DK/\PDZ*.DU)DB%9DB-Y4B"5I(I4DQI2JTBG=%IYLV!Y$VDP
M)4D%R9`LR9$\*9!*4D6J20VI5:3SEY<W?_F4Y8*53R0]6_-K/BDJS=9^K+1-
M#*,LR9$\*9!*4D6J20VI5:2S/:WR6;#RB90RLR45)$.R)$?RI$`J216I)C6D
M5I'.7U[Y_/79RJ)HT9.>K?GEH!259NNI8R3#*$MR)$\*I))4D6I20VH5Z6Q/
M*XH6+(HB#6=K'Y6H8)0A69(C>5(@E:2*5),:4JM(YZ^K3-Z^7.I.$&6GWB+I
M*9E?\TE1<?X5)$.R)$?RI$`J216I)C6D5I%.J61B2DJ[\&P%U5.:?]L%J"`9
MDB4YDB<%4DFJ2#6I(;6*=/ZZRF3"E#P6,G)V-,ZL3XN>)&>#%6A^S2=%Q8X%
MR9`LR9$\*9!*4D6J20VI5:13VA4K$U+:US;#E*+<V2Y`!<F0+,F1/"F02E)%
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MU]-BQV%*3QWC+#6,LB1'\J1`*DD5J28UI%:13NFTJFC%JBC2X'O1I()D2);D
M2)X42"6I(M6DAM0JTOF;5@*M6`)%DMUX,"7SZVDI*LZ_@F1(EN1(GA1():DB
MU:2&U"I2*5U/JXH.X7HOCY0^M[XE%21#LB1'\J1`*DD5J28UI%:1SM^T$FC-
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M[,=*B3>,LB1'\J1`*DD5J28UI%:13NFTRF?-RB?2X$PQJ2`9DB4YDB<%4DFJ
M2#6I(;6*=/ZF53YK5CZ1)+.#969^/2U%I2G9CY7J<\,H2W(D3PJDDE21:E)#
M:A6IE%Y-JWP.X;KRB30HQDD%R9`LR9$\*9!*4D6J20VI5:3S-ZWRN6+E$TD5
MXXO\>EJ*.DU)DB%9DB-Y4B"5I(I4DQI2JTBG=%KE<\7*)])P2O91B0I&&9(E
M.9(G!5))JD@UJ2&UBG3^\LKG];7D%<J;;:33)["+7KIOR9R.F_-Y=L;(I*@X
M22W)D3PID,J>#N]]^A5/JSZN6'UT='IABW5^WB'V&"3D.(8DI/L9^?GE+#NA
M:_HN$I!RT3_N21S&]:E;/VZ6XY`"XK@E1JD85),:4CL<2J=X6H'2W3<A.QW1
MDS2<$KU<Y!<23T'QQ16]#*[M&I)%/P?Q[!9(Y;"?SL"T>N**]41/W1=+3RE8
MK/,2+46E'!S'4AWG\ZRCB1UGARFYFJ^R`!L##G<2.=RZP)%\HO0L\6`A1AT?
M;#%;9"<_RAAPO&W)\&8#5],*BT-XMN0XU@?=SXR=$KE<Y%?Y^HX2E1)YZAC)
MI*CA6-G>;,>BYHMLWW0I*@[O22'1\!&SL<JQJ.$CZKDYK;"X8F'1DYIBRP6.
M@\>.$A5?8)$Z1C*)NF/8<H9YB%%<ZA)'\:20Z'#OCBOD;#BP3M"TRN&*E4-/
MV9S+9OTV1<7749!,HN-!/JL_;&J/HSB2)X5$W<"S3;;]RM0N`ZL$;:;5`8=P
MO5/VI&=0]@2V*2B^LH)D(AT/+M>;_!AI8T":AX[D22'2<>3->I6=C2AC``];
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M5B1L6"1$2G7CEE20#,F2',F3`JDD5:2:U)!:13I_TVJ#S7$]/_RN>"0YW*3:
M8)G7!BDJ3<E^K)1XPRA+<B1/"J225)%J4D-J%>F4=HOB"4?)XQI:I;2G=.YL
MNP$5)$.R)$?RI$`J216I)C6D5I'.W[328</2(9(^2F8EYC9%I2G9CY42;QAE
M28[D28%4DBI236I(K2*5TNMIQ<8A7"^E(Z6==4LJ2(9D28[D28%4DBI236I(
MK2*=OVFER/6Q$ACNTI'T43*KI[<IZC0E289D28[D28%4DBI236I(K2*=TFF%
MRS4+ETAI9]V2"I(A69(C>5(@E:2*5),:4JM(YZ];WK_]7>;Z6`VH*=F3/DKF
M)Q!BQY3E@F1(EN1(GA1():DBU:2&U"K2*9U6WERSO(F4DK4E%21#LB1'\J1`
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MKN5G0T9:5I)K^?6+D9:%])$?61QI64H?^:W`L1;)M?P*WEB+Y%I^S&VL17(M
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M/I9T&(G_U&WF,>]VJ!'_97GS2[=0X2-_ZG;.,9?-.+H592..;D/9A*-[BVS`
ML>TGGU:]Z3X_RF=47"UOND]FLD4^>"E]QEKDPY0WW4<EV4<^FRBCC;T2^:RA
MC'9HN3A-H>>/[W_<?MTUMT]?[Q^?S[[OOLCJ[/)=]X'#I_NOW7KR^(^7_8\/
MY[+B^W7_\K)_./SOM]WMY]U3%R#!7_;[E_@/>5(7/_=/OQU6@!__3P````#_
M_P,`4$L#!!0`!@`(````(0!/.^BLI`0``&@1```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;*R8VX^R.!C&[S?9_X%P_PF(C@Y1OPPB!T_9;/9PS6!5
M,D`-,*?__GL+M-*^LV9,]F8<?SQ]2I^^E-;9SX\\T]Y(6:6TF.O6P-0U4B3T
MD!:GN?[W7_Z/J:Y5=5P<XHP69*Y_DDK_N?C]M]D[+5^J,R&U!@Y%-=?/=7UQ
M#*-*SB2/JP&]D`*N'&F9QS5\+4]&=2E)?&@:Y9DQ-,T'(X_30F\=G/(['O1X
M3!/BT>0U)T7=FI0DBVNX_^J<7BKNEB??L<OC\N7U\B.A^04LGM,LK3\;4UW+
M$R<Z%;2,GS,8]X<UBA/NW7Q!]GF:E+2BQWH`=D9[HWC,C\:C`4Z+V2&%$;#8
MM9(<Y_J3Y>PM4S<6LR:@?U+R7O7^UZHS?0_*]+!-"P)IPSRQ&7BF](5)HP-#
MT-A`K?UF!OXHM0,YQJ]9_2=]#TEZ.M<PW6,8$1N8<_CT2)5`HF`S&(Z94T(S
MN`'XJ^4I*PU()/Z8ZT/H.#W4Y[EN/PS&$].V0*X]DZKV4V:I:\EK5=/\WU9D
M=5:MR:@S@<_.!.R^V19Z:6X`/KNVX[O[AV)N/.#S[OX?N[;P>6__1IME,S5>
M7,>+64G?-:AW2*NZQ.SIL1P+0N&3TD8HINF_9@FFA[D\,9NY#C<&$U!!:;TM
MQN9T9KQ!.22=QL6:H:Q8<@6;>V;KJ6"E`E\%@0I"%40J6*M@HX*M"G8JV/>`
M`=&*?*&Z_H]\F0W+ER?C<G`-W%;"Y`K>Q%/!2@6^"@(5A"J(5+!6P48%6Q7L
M5+#O`2E,6PGSZY6#UR13SW6H:5&3]D0)R6TUUC78)2(>(BM$?$0"1$)$(D36
MB&P0V2*R0V3?)U*$$(=4C[<C9&I8<*&X189C\U$N-+<3]1]^>VK*HJ40B7)$
M9(6(CTB`2(A(A,@:D0TB6T1VB.S[1(H57@EWQ,K43:P\#+<CO3I$Q$-DA8B/
M2(!(B$B$R!J1#2);1':([/M$"NSAKL"86@ILV1&Q('HML*'P1:G:0Z4*5T+$
M@_<1"1`)$8D06;=DR.Y'&N?DKG$RM31.%\AU/%-+>:HZ_36%%D`*[!4\-"UE
MO5N)ZR(`U2)002C:=)XC^28B<9U[KE6+#9)L$=DALN_92)FR`T%_SW)[#6-J
M.=.6V+"![46K[D6$B(_*$^3:;#B<R&&LA(B%-9TJ>R!?7.:N`2*A(#?ZB3J1
MU4RT;9EC^3[6P@0ZDL*#95H*CVWX6!2W0V2MY!!;8L$<B1`MM=R60L2'ZR&R
M$H0E9JF!^N(RMP@0"1&)!&&FHY%2LFMQ64T'SC]R/+=C:>1R+AU2JDMY#I=7
M%1^6=T771'%]<54[\99I*1/O<T%S%FMVT0%&X17=Z"SBJJ[*QB/EU;_F@O;@
MU^Q[V^-?>\;(27DB2Y)EE9;05W:TLYB5P.VYTQT[\)Z`'!3N/3BPT'[!)PZL
M8YB'$P?6(LPW$P<6%\SAO/O4+-A*ORX[!W^A=X<.[$RQCVL[L-_"_&GD/$%`
M^(([<F`G`=P0/<,Y]Q*?R"XN3VE1:1DY0ECF8`+OS[(]*;=?:GIISFS/M(83
M;O/O&7[1('!8,@<@/E):\R^L`_$;R>(7````__\#`%!+`P04``8`"````"$`
MW(^U5*4$``".$0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RLF-MN
MJS@4AN]'FG=`W.]P3G90DJTFA$-.&HWF<$V)DZ`"CH`V[=O/,@<'>^VI&FG?
ME/*Q_-OK][+!F?UXSS/EC9152HNY:HQT52%%0H]I<9ZK?__E?_NN*E4=%\<X
MHP69JQ^D4G\L?O]M=J/E2W4AI%9`H:CFZJ6NKZZF5<F%Y'$UHE=2P),3+?.X
MAMORK%77DL3'IE&>:::NC[4\3@NU57#+KVC0TRE-B$>3UYP4=2M2DBRN8?S5
M);U6O5J>?$4NC\N7U^NWA.97D'A.L[3^:$15)4_<Z%S0,G[.(.]WPXZ37KNY
M0?)YFI2THJ=Z!'):.U"<\U2;:J"TF!U3R(#9KI3D-%>?#/=@Z*JVF#4&_9.2
M6S7X7ZDN]!:4Z7&7%@3<AGEB,_!,Z0L+C8X,06,-M?:;&?BC5([D%+]F]9_T
M%I+T?*EANAW(B"7F'C\\4B7@*,B,3(<I)32#`<!?)4]9:8`C\7MSO:7'^C)7
M37-DF\[DNP'QRC.I:C]EFJJ2O%8US?]MHXQ.JU4Q.Q6X]BKV:&+H4VOR=1&[
M$X%K+_+E`4`O31IP[=HZ(V>B6X\D`4NBT8#KP_U/N[9P?;1_K9V19H*]N(X7
MLY+>%%@U8'EUC=D:-%P#3.FGMIT'/MG_-]<PR4SEB<G,51@8S&(%!?JVL*?3
MF?8&195T,4L<8XH1JSZ"51"3]62PEH$O@T`&H0PB&6QDL)7!3@9[&1P&0`-K
MN;]0K+_"7R;#_.V=6?;@;K@EF=E']$T\&:QEX,L@D$$H@T@&&QEL9;"3P5X&
MAP$0S+0D,W^^__0UR:+G*M0TKTG3DFNRC3'NQJX0\1!9(^(C$B`2(A(ALD%D
MB\@.D3TBAR$1+`0[?D4],AG8Q:'JN;F.KHL5N&R#P-Q[D&D;8M"*!_$Z162-
MB(](@$B(2(3(!I$M(CM$]H@<AD3P&]X5@M^?ERR+;FSMS5AUA"]\KP463#!W
MWC1MT=0U#^IU?$0"1$)$(D0V+3'9>(0\QP_ER:*%/)=`!ODX8CZK+O[N0@O`
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M0:&A]=9%66:SX"931UJ0_EVF5PXP"N_HD\XBL;/Q>"QUMKG+\`)K#X_MV2(G
MY9FL2)952D)?V<$0&BQF'+>G5L]QX04#`C(?N[!_8QZ.7=B#,=^.7=A4,8=3
M\5/SHI+TE^RT_)/XI>G"ER?665HN?$]A_F2[3Y`7?K"T7?@@`*[QGN$T?(W/
M9!^7Y[2HE(R<P!1]Q`ZN97N>;F]J>FW.9,^TAF-P\^\%?O<@<!C21Q!\HK3N
M;U@'_)>4Q7\```#__P,`4$L#!!0`!@`(````(0!\M6_Z8`0``#<0```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*R778^B2A"&[S?9_T"X7Q'P8R3J
M1D4$17.RV3WG&K%5,D`;&L>9?W^J^6BA:W>.)N=&Y*'J+?KM@J;'W]^36'DC
M&8MH.E'U3E=52!K20Y2>)NJOG\ZW%U5A>9`>@IBF9*)^$*9^GW[],K[1[)6=
M"<D54$C91#WG^<72-!:>21*P#KV0%*X<:98$.9QF)XU=,A(<BJ0DUHQN=Z`E
M092JI8*5/:)!C\<H)#8-KPE)\U(D(W&0P_VS<W1AM5H2/B*7!-GK]?(MI,D%
M)/91'.4?A:BJ)*'EG5*:!?L8QOVN]X*PUBY.D'P2A1EE])AW0$XK;Q2/>:2-
M-%":C@\1C(#;KF3D.%%GNK5[4;7IN/#G[XC<6.._PL[TMLJB@Q^E!,R&:>(3
ML*?TE8=Z!XX@64/93C$!?V7*@1R#:YS_H#>71*=S#K/=AP'Q<5F'#YNP$`P%
MF8[1YTHAC>$&X%=)(MX98$CP/E$-*!P=\O-$-0>=_K!KZA"N[`G+G8A+JDIX
M93E-_BF#]$JJ%.E5(G"L1$#NP5RH4MP`'*M<4'DP%WJXR(7CTW5'52X<GZZK
MP_"*POS/TY5UL\Z&/X_6ULIY*]K`#O)@.L[H38%'"V:&70+^H.J6#M;5#5!.
MEVB)/W4$M`)7F7&9B0IFP&0SZ.*W:6\X'&MOT'IA%3/',48[8E%'\#[CLK8,
MEC)P9+"2@2L#3P9K&6QDX,M@*X-=`VA@K?`79OC_\)?+<']K9^8UN!MN2F;6
M$76*+8.E#!P9K&3@RL"3P5H&&QGX,MC*8-<`+3.AX9&9)KSS?O^VJGN39TU4
MZ.U&;[ZTS9J7,?K=X`4B-B)+1!Q$5HBXB'B(K!'9(.(CLD5DUR0M*\&.EI6?
M6\BCX24/3=[P4'Z^JR"8O$;0J&WT0@2)MD1DB8B#R`H1%Q$/D34B&T1\1+:(
M[)JD92LL0T_8RJ,+6VLSYB4Q!^)!7R!B([)$Q$%DA8B+B(?(&I$-(CXB6T1V
M3=(R;/"483RZ9=BB(L(ONP0F-+[H0M/HMKMP*8)JXQU$5HBXB'B(K!'9(.(C
MLD5D5Q*#CZOEU_`IOWATRZ\YD+LO@W[;ET45?W>S!.`F7]*-KBZMV$MQ71@I
M2ZQDX(J<2E-:N#QQO=9<RQ(;&?@BI]+LM0>V%==KS5U#HF4PW]C('T2C_UQC
M>%;;Z)+PU4GXW7N1^G`A@NK;L@6YIQF&]*9=BB`^6G,HS:(C+M>J*T1<03ZI
MXXD@7J??E=[E:W&YKK-!Q!?DDSI;$534&4@NP?Z'FPM60IURKLK]3/DAFY#L
M1!8DCID2TBO?J^@ZM*O`Y3YJWK?@)00"$K<'%CQ]O^%#"YH;<W=H08-B[@\M
M:#+,8?\V*YYBJ>X<]G7%+DCFA@6?/UAG;EJPF&,^ZUFS8G\HZ_0L6*4@7A,7
M8-]V"4YD&V2G*&5*3([@5;<SA'=S5N[\RI.<7HI]P9[FL&,K_IYA@T[@@[S;
M@>`CI7E]P@N(+?_T7P```/__`P!02P,$%``&``@````A``?MPBMP%```&W$`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULK)U;;QM)DH7?%]C_(.A]
M+!;O%&P/Q*K,W0%F@<5B+\]JF;:%MD1#4K=[_OV>*.8E(DY:%-GSTFI_&9F,
MB(RJDUFL*K[_ZQ\/WRY^WST]W^\?/UQV[R:7%[O'N_VG^\<O'R[_Y[_C7]:7
M%\\OMX^?;K_M'W<?+O^Q>[[\Z\=__9?W/_9/OSY_W>U>+C#"X_.'RZ\O+]^O
MKZZ>[[[N'FZ?W^V_[Q[1\GG_]'#[@G\^?;EZ_OZTN_TT=GKX=C6=3)97#[?W
MCY>'$:Z?WC+&_O/G^[O=L+_[[6'W^'(8Y&GW[?8%_C]_O?_^G$=[N'O+<`^W
M3[_^]OTO=_N'[QCBE_MO]R__&`>]O'BXN_[;E\?]T^TOWQ#W']W\]BZ//?Z#
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M_>:I'_Z>[S9<&V/'WS3(YMU\NEBMQ]A?\7J9.N)OZM@A`.YP=4CV.'?#[<OM
MQ_=/^Q\7."*0SN?OMW)\==<8)$_:880RC3^;14R?#'(CHWRXW%Q>8(*>47N_
M?YRON_=7OZ-<[I+-EFVFUJ+/%E(;,NS@0?`@*G"%B$I8F/]_0E@RBH25'=IF
M4..<N1BR1>XR>!`\B`J8&#"1/H89CLKV\91G0CI]N$0QEIGH9AOKX_9@T]6X
M>B(#D4`D:F(\Q\=KSU_W6(P_7$XQD\7E^=J5QC89X1.+43=W%=87HY)\(H%(
MU,1$@8/Q[5&(\1A%_NQM(O-2/3V1@4@@$C4Q_N%PU?[)H;O:O(/YB0>OC&-=
M3P294=EV4](7HQSQ0"00B9J8:%8VFM=K1HRMRXFH;!,9B`0B41/CGZQ3W(ER
MO1$E.S7=,I#U/1&;;G]B*48EW40"D:B)"0?G:AW.Z^D68^MR(BK=1`8B@4C4
MQ/C7X4RG'93JGB[.J.YQ(.M\1C;A<WN6[*M5R3BCP"@:9(,2N5)%]'K6NX.X
MX<R8'=AFI/+.:&`4&$6#K)NB2,I-R?T"SIQX7ND.PF;\3\AF?N$S7ZQRX$,>
MJP8>&&%]>RC4T<J&)%JE0CJ2^8.R&<\3J@[TLM*2PZ*B@5%@%`VR;B(QVLUQ
M.38?%\PG9U^&<G6?D,W^TF>_6-7L$PH=H6B0#4LT[.W93XJGZSZAFNI>MA8^
M^X0"6T6#K)LB3LK-,?O+Q;NZ`WC[@CCIG(ZA2)]6U97/?K&JV2<4.D+1(!N6
M:)H*ZTCM)P74GB=TV+7)RKSO"`V,`J-HD'53M$JY*=F?K<]1V"ZIG@ZA"*%.
M_MHGOUC5Y!,*>?A:C-$@&Y4HG(KJ2/*3'FK/M42.VZ(>*W<J?4*!K:)!QLUI
M0V[/..6/P]B33D;VI..V)'VU*IEG%!A%@VQ()XFM[#_<Z3*C.L\]HX%18!0-
MLFZ*9JD"D;)?X<+'R7([3>*G:B<CD_O%Q%5]M:JYUT(Z%EU@JVB0#>HDN9VR
MW&:D<\]RRU:!433(NBDBYG)_3M4G+=293\AFWF]8L73P!S*CP"@:9$,2#50A
MO7Z^D>V+KWH2T3Y;U<D8&`5&T2#KI@B8<E.J_JSE_30IH<Y]$4=UKE_X[6ON
MJ(,J'?.!$-@J&F2#.DEH<2V6<I]0]:G/5A4-C`*C:)!U4R1-Y?Y(B20!U`DN
MFJ@3[#>LTV*5LSDP"HRB0=9S4;FW>YXT47M.,ME/"0V,`J-HD'%3KM)I-\\^
MI8\#63G-R)Y8_-ZU6I7<,PJ,HD$VJ)/D=,9RFE&MY)[1P"@PB@99-QMR>MXJ
M<L9ZFI%-OM^^5JN:?-93MHH&V:A.TM-9T=-Z?,[7[OC<9BL8X^1[N&K?+?QN
ML%K58-+PLW)=(K!5-,@&(ZKWYJ-XEC12'<49+8L#/:.!46`4#;)N.B4]6Z)F
M++(907!4[OU>L%K5W*>Q:NB!K:)!-BB1N+?G/@DB#N;BYGSM3C;;6;*RA>3W
M5M6J!E,Z9A38*AID@SE);V>LMQG5;/:,!D:!433(NNGT5@KIC%7FC(4X(^2Q
MS$^W\'NK:I73/#`*C*)!-J23A'A6A+BZ.5^[T^8V6YDR6OK-2K6JP:3A]?F(
M4#0=33!S)]>OKX=&:ZO)&:DR8C0P"HRB0=9-)\!GEM&<E3DC4T9+OUFI5B7S
MC`*C:)`-R8GUD<RS(,\3TIDG-+!58!0-LFZ*X*F3IF3^O.]^YDDZE9AE9)/O
M=RO5JB8_C55C#VP5#;)1G23#\R+#^AAVJX5MMK+'L%MY]-6J!I.&5\<P6T6#
M;#!.K(]4$BORG(2U9S0P"HRB0=9-43Q72>>M3N<RDCL-)60KR:EUGSO6LAD8
M!4;1(!O523H\+SI<*VE&A92,;"$YR>CS4+5J!D:!433(QN+$^D@AL2;/$ZKY
M[1D-C`*C:)!UTPGPV8O3>='F?"QN,[)UY&:HKU:YX\`H,(H&F:`6)PGQ:&V/
M@(Q4[AD-C`*C:)!ULR'$YQW$L@IT!W%&-OE^9U"M2O(9!4;1(!O525J\8"W.
M2">?M9BM`J-HD'535.^?<@9=)/U46IR13;[?R52KFOPT5HT]L%4TR$9UDA8O
M6EH\<TN&;;:RIU"_.:A6-1C68K:*!ME@3M+B!6MQ1NI*$:.!46`4#;)N8I9]
M)8EROW[&7T@O=]8Y('ROG%/8)RL@N1?2K:2'VEH5L%O5G8YU\R1Q711QS;YL
M,]+93%85#6P5&$6#K)LGZ>:"=3,A?5<BHX%18!0-LFXV=',)V3DRZ2R2BP.J
M*X^^$)ER=S`.I5'/>*T+XZ/XHPOS==]&:UN0">&.@%P$/:/!(.M`0^#DKHD3
M[_]9LKHEI(X4(D,B\EUUO:BQ<@D-U2K'&/50-IZ3I&W)TI:0W+N@7/+;FFJ5
M71H8A8JD3MR*-M96C&&#<,)WI"I8W)8'Y(+PVX-J58,H'3,*V6I]N-=[.MVX
M^8G98GS@P`9RDM8MB];E#]\FY`)QF>RK5>XX,`H5R6RX&8VU%6/8($[2N"5K
M7$;Z&$U6%0UL%1A%@ZR;#8T[ZVO6)<M>1FA1!X7?)E2K.@UIK!IG8*MHD`WJ
M)$5<%D6L;L[7;D&]S58H=16,L^JK50TF#5^%(+!5-,@&<Y)N+EDW,ZK9[!D-
MC`*C:)!ULZ&;Y^UYEJRE&=E*\LON:E63G\:JL0>VB@:9J%8G*>UH/2IMK9'Y
MVKFYS5:VDORRNUJ58!@%1M$@&XQ3[=<%8L7BG-%XRC[<:<9H8!0818.LFR>)
M\8K%.",CQNNZ>DZ>IXXUF*%VS#D/C*)!UG/10;7U/)+@@VKBQJ_\:=M50G79
MW3,:&`5&T2#KIM-7N31TU@UE*Y;>C-!23Y/^2:^^6N70!T:!433(!G62WLH-
MNVZ3EI#>7C`:&`5&T2#KIDC;VTLD":$ND81L<;O%5;\J5C7!A`);18.LYZ)C
M;_<\J9[V/"%=W(2&%:'`*!IDW71R*<5]G@ZM6$HSLM7M%H5]M:K)3V/5V`-;
M18-L5$Y=CYQ9BH+6@W"^=@JS724KHT/^N_N^6M5@2L>,`EM%@TPPZY-$=;2V
MV]>,JJKWC`9&@5$TR+KIY/+\2EJSE&:$@U*=)_T6I5KE3`^,`J-HD(WJ)'5=
ML[IF5'6S9S0P"HRB0=;-DZ1TS5*:$4XG*L%^\U&M:H+36#6^P%;1(.NY4]?7
M#]4U2VA&]5S1,QH8!4;1(.NFTTNI;CS]?\9MY6O6THSL>=)OEJI537X:J\8>
MV"H:9*,2D7NS2*V3)"J1RJC.?L]H8!0818.LFR)R;W<S2:)V,R%;W6ZGT:^+
M54TPH<!6T2#KN9/7(]7-$KHF)>P9#8P"HVB0==/II53W69<UUD5*<PJW&=GB
M=NK:5ZO<<6`4&$6#3%";DW1SM+:ZF9$J;D8#H\`H&F3==+KY>HEL6!LS,L6]
M\?NW:E42S"@PB@99ST_2Q@UK8T;U]-4S&A@%1M$@ZZ;3QO'4W<W/>0IQP\*9
MD2GO3?TFXK![KE8U^VFL&GQ@JVB0#4ND\,TGQ8U8^VLMODBVV0JNU56`OQ3=
M5ZL:3!I>7;5CJVB0#<;)ZY&#@"5TDY!:XS(:&`5&T2#KIM-+*:7S;ES;L)9F
MA!:5?+];JE8U^6FL&GM@JVB0C4I$[NV5E"11R>LFH>I`SVA@%!A%@ZR;3DLE
M^7+[Q8G?HFU89#.RF???Y%2KFODT5@T\L%4TR(;D=/=(V;.X;A*J#O2,!D:!
M433(N-E-G)1*ZL^[2G`8RNIL83;_?G>GS,H$-!C>("'>XB-J4O`*"<U<<"<)
M<#=A!2ZL?B+>=I'L*AL:#-Z2';S5S'GK1/?/3`4K<C=)S$Z%WP<J,S45I6MF
M"(X8@M/,!>>D^O7CH9L4.:YGS+G7WFTQLZKFMU?*+/N/"4N?H'2MP1"3MG,Q
MG:33W:0(=?8"`2162PGE10S>$L,,$(.WFCEOG1!+>2UGYZR5N@FK=&&VO/Q&
M3)GE)"`X4G@$1PS!:>:"P\>^7>BZB9C[4U5B9BJ(P5MB\)88O-7,>>MD^<],
M!6MV-RFB70^>;N/W9<I,347IFAF"(X;@-'/!.3$_=J07T:[.SOW"%`=*,M-'
M.EY;Z9[/5V;9?TQ8Z9H98B*&F#1S,9VDYG@58J.\6,^+72TY>$MV\)88O-7,
M>CN^54FM^J2\SEA.=?GM3&H]6!B*&Z,>'H6<3ORF2)GEG.-52UJH#V]*:#"\
M;$G;N<A$/55D1VHKO[?)!*`%^+"%Z[*=G@=F>#,4]86WFCEO10Z5MS(/9UU[
MZ?+;FDP@16SU3/COOTI7$UOIFF<'L1%#;)JYV$0656S'9B*IJ`D@L>I9W^7W
M/56&NB$[>$L,WFKFO!595-[*3)RYRLVO;C*1%-754^'W=UWN:H(K7=54$$-P
MFKG@1!95<,>F(JDHZK8<P?.-<Q:O3TMF2&HQFT[\SDF99?\Q8:5K9I@P8HA)
M,Q>3B.<),26M-9.B]3<?Z,3@+3%X2PS>:N:\%354WOZ)`SWIJ@FD:*V>"=I#
MY==%F>HJ7=5,$$-LFKG81!55;,>J*XFH"2"QZAD.=&*8"6*8"6+P5C/GK:BB
M\O9LZ4OJ:L(HBJOG@390^<U1-5I$5KJJ>2"&R#2SD8UO;U*1'9F'_+(G<Y2[
MU?BVRU9(J#K(:?]4S;+[>,M@4NEUN6D'KQDDAO<,:N9"$ND\(:2DM'I.\LNB
M:K+[CAF\37VK';PE!F\U<]Z*&"IOSRVM_"HH$T816CT/;KH063%3\T`,D1%#
M9)JYR$0X563'2BOI+%)5BF:^<<J`VDIFMK9H%U+-5$RE:V:(B1ABTLS%)'IY
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MJP6QXFO#5@MJ&-^^-5K6\`!W>[5:X`'NF&JUP`/<I-1J@0>X":C5`@]PWTVK
M!<6)FU<:+2MX@%NB6RWP`+<<MUK@`>[R;;7``]PIRRTWJ\WU37/J<*\K^C1]
M6Z-X<`\HC[9=HWAP'V6K!<6#6Q=;+2@>W!K(+3?+U?4-GC/A%CQ9="V/_[1:
M$"F>N&FU()[F:#<K*%@S.WCN!#EH1KI"I'@>H_$Y*T2*YQU:+8@4CQBT6E")
MN$^_T;+`:'APO]6"T;#<X):;!0XZ/.G%+7A\'7W:GX-ZPV/=K3[(-1Y1;K4@
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MO_'`NRI;#OPRW??;+[O_N'WZ<O_X?/%M]QG;RLEX8\'3X;?M#O]XV7_'=A._
M3[=_P6_2C?_[%3]"N,./)$SD;OO/^_U+_@<R=U5^UO#C_PL```#__P,`4$L#
M!!0`!@`(````(0!"[L>N!RP``([[```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;*R=6Y/;MK*V[[^J[S^X?+_&H^-(JCB[.*)X)G6D3G=>SB1Q)?:D
M[,G*6O]^-P0T&\`+RU;6SD4R>?"B"70W01*@P!_^Y]\??W_UKZ?/7SX\?WK[
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M`/KWJX\?5&Z02][]^^WK`1WXPT\OO])?X[O1P_V@1_)7_WSZ\I)\4"9?OWK_
MYY>7YX\'+>JI1G5&AL8(_=<8Z7]W7<K$2P/HOS?7[9&[+I75']S\JRWM<7_5
M'Z;&@_3W2A][U"5]+/KC]I:2,W5M^J,[;F]X/[[!S;TQ&Z$_N`EWP_[H87*)
MUK76/W!5^J,[?G\RZHTN+;A6E2/4LT)T]]"[GPX>J#/7:D[YH/1'=]#):#0<
M3[Y1M4_Y>/&7^L-4G=S=Z*\^YZ7ZXS9_J:CHX]OQ^BY_]=G5Z@]S5#)R_51Z
MHT_+RUD>OWMY]^,/GY__>D5C)Z7IES_>J9&X-QM0V/G\UF[OSOBOG?!TDBHK
MD3+S]C6%@<[E+S1,_>O'T7WOAS?_HI'EO=$\HJ;O*N:L4.>^,AO[8.&#Q`>I
M#S(?Y#XH?%#ZH/)![8/&!TL?K'RP]L'&!UL?['S0^F#O@X,/CCXX^>#L@Z@+
M+P<FZH+9$0A>!-&+('P1Q"^"`$80P0A"&-DQ?$.IW>4W#:;_%_FMS*C\YNX^
M,I"$'WC)S`JN$OM@X8/$!ZD/,A_D/BA\4/J@\D'M@\8'2Q^L?+#VP<8'6Q_L
M?-#Z8.^#@P^./CCYX.R#*`+2!9-#%<U!`]&+('P1Q"^"`$80P0A"&-DQ=)*9
MKE5.,H=OPGA,5NJWK^G2U(W)_8>1FZ2/6M.3Q)X#B8$L@"1`4B`9D!Q(`:0$
M4@&I@31`ED!60-9`-D"V0'9`6B![(`<@1R`G(&<@480(HQIA6".,:X2!C3"R
M$88VPMA&&-S(B:Z3V)2D3F+_S;L09>;MZSY=O[J4']U[-QF/6D0I+Z+^9.R>
M%_-.Q$-"#&0!)`&2`LF`Y$`*("60"D@-I`&R!+("L@:R`;(%L@/2`MD#.0`Y
M`CD!.0.)(D02:(YAA&&-,*X1!C;"R$88V@AC&V%P(R>ZSEE`=_'.67!]>%?J
M2[)S]QXU&=!C5)?^_<F#E]F=B*O%A@RZFYL%D*2K99N>NJ;33L2F,S"4`RFZ
M6I;IJ7?2EIV(35=@J`;2=,0V/71;O>Q$;'H%9`UD8XCCZZEW==UV(C:]`T,M
MD'U72UH]N+]W6WWH1&SZ:!MRTHJ>ZFY(*Z5VTTH3+ZTF;GOFG8C;$QMBI160
MI*LE7>U/O:ZFG8A-9V`H!U)TM6S3WCUZV8G8=`6&:B`-D"60%9`UD(TA;@YY
M5Z)M)^(F[L!0"V3?U9+>#_P'\D,G8M-'VY"30S35<$,.*;6;0YI0#O&AYD!B
M0ZR$`9)TM:1?_:DWT9!V(CY8!H9R(`74*H%44*L&T@!9`ED!60/9&.)FAS>:
M;SL1=W4'AEH@>ZAU`'*T:SFI0`VZ(164VDT%3>Q4`!(;8J4"D`1JI4`RJ)4#
M*:!6":2"6C60!L@2R`K(&LC&$/J/7,6GWG"[[41=W,%0"V0/M0Y`CG8M)^YT
MP^S$7=^CWZF)UI=?/[S_[?&9VDNWWH&[E@'-".IY0F7$30=-!M83*)#8$"L=
M@"10*P620:T<2`&U2B`5U*J!-$"60%9`UD`VAM!_K'3P[KRVG:A+!S#4`ME#
MK0.0HUW+20>U).+D0R#N-,O-@;_(W<@;-+@L0%W28RY(32'W[WO>?6`L`N[I
M`E&"*&74NTQ.#^_5/^XM3,82:4^.J$!4"I(8#?SGSDI4W/0:48-H*<@V[]W*
MK$3%YM>(-H+$5K_O7U58I9W5[T^\X6?'`G%5BVB/Z"!(C@^N.HJ*^N)FG9J;
MMM<KOI%U>BJ;9@38*8]J88Z&H-Y#A^:"OI9U4&<A==AR@B@U:-"_9%VO%TP[
M,)ZCI0)1*>B*+RM1<4-K1`VBI2#;O/?TM!(5FU\CV@@26X&TTYXPWAKW_:?`
MG9CA@[6(]H@.@N3X@;2S(^&FG9H/OB'M]/2QDW8:.8-=ATS:>;Z-U9(PI:I5
M9X$H090RTN?O-)AU8#OG6G)2%X+$;Q"W4E27CMP-O/&D$@''K4;4(%H*DN,/
M[CT_K43%YM>(-H+$%O1ERRKM.CIAO;[L6"!>:A'M$1T$R?$']]Z4P5%4U!<W
M!]5$[PTYJ.>%G1PT4\7VT`<H[@%:($H0I0:9T[<?OL:"\1PM%8A*1!6B&E&#
M:(EHA6B-:(-HBVB'J$6T1W1`='20FPYJQO.&=-`3I$XZ&&2G`Z"X!VB!*$&4
M(LH0Y8@*1"6B"E&-J$&T1+1"M$:T0;1%M$/4(MHC.B`Z(CHA.B.B!7N(&BW9
M(YL'6"#BM'"/=0,QI\5[U`6B3@OXJ'/C[N:ZFMNT<_UOK@^I%]?TXZ<,P:-[
M[T[ZT:B<%:)!SWODFHN*+SHQH@6B!%&**$.4(RH0E8@J1#6B!M$2T0K1&M$&
MT1;1#E&+:(_H@.B(Z(3HC(A.%9T4UAHXG2K(`@&G-UQ0%P@YO>6"ND#0Z4T7
MU`7"3F^[V#KW5%%3N/:I\HT')#WC:UT6YNHM0'62=,]'L2$#NG9W<Q"#OO?X
MO!`5GQ`)HA11ABA'5"`J$56(:D0-HB6B%:(UH@VB+:(=HA;1'M$!T1'1"='9
MH$L8W0Q1,[LW9(B>"'8RQ"`K0[K9XO`3]((>MR^/,C*%ER!*$66(<D2%09*S
M)9!*JIDV>N-^+0).X`;1$M$*T1K1QB!IXQ;(3JJ%'PE;$7`;]X@.B(Z(3HC.
M!@621DT+WY`T>A;92II8O=VK'F:'7=8L$*4&B9,R%KF#C[?DDXN*_5*`J8I%
MTH0:T1+JK5ATM0EK47$3-F!JQR)I0HOH`/6.++K:A).HN`EGVY0[#*B9W1LB
MJB>"K8C.U0V2=Z'H9HOM"X4WA[LP]>ARPJU,P%0*))-JMG'O),Y%Q<8+,%4"
MJ:2:;=QK>2TJ-MZ`J260E52SC7LM7XN*C6_`U!;(3JK9QKV6MZ)BXWLP=0!R
ME&JV<:_E)U&Q\;-MRDF[_FW+!A>YLVPP9]1E3VR(=W_BS1(M1,6M3,!4"B23
M:K8+O&F;7%1LO`!3)9!*JMG&O9;7HF+C#9A:`EE)-=NXU_*UJ-CX!DQM@>RD
MFFW<:WDK*C:^!U,'($>I9AOW6GX2%1L_VZ;<M%-3N]\_VM$P=QG:9-U@SLA*
M.S-=[8[)WOL;"U//'NW`5`HDDVJV"[S)R%Q4[(("3)5`*JEF&_=:7HN*C3=@
M:@ED)=5LXU[+UZ)BXQLPM06RDVJV<:_EK:C8^!Y,'8`<I9IMW&OY251L_&R;
M<M-.S;+?D'9Z4I[,L>G'?C=/;[?)6X^;BXHKQH@6C/3<]K@W[-T/O*>XA#4R
MO9TBR@1)JV`N/1>5NIL=W(W&]!Z;_.-=HPJ1<R=*1!6BFI'NUZ@_&HP>O.F:
MAC72KR6BE:`K_5J+2O=KVO>NB!M1<%>VB':(6D:F*[W18.*_^[%GC73E@.@H
MZ$I73J(R71GI-4H3)>\V^RQRZI>;Z30*WI+I2NY<UQ_5+_$(J4<0:Y;!B^-<
M5.S9&-$"48(H190ARA$5B$I$%:(:48-HB6B%:(UH@VB+:(>H1;1'=$!T1'1"
M=':0FS9J'OB&`=),&]L#I$:T2&JEC3^LS?N=2M(&T`)5":(4488H1U0@*A%5
MB&I$#:(EHA6B-:(-HBVB':*6D1ZM0NO,>Y;8@Q4X_HBJDZ#+5`@L*I]%`&.1
MFAV](:GT9*ISU37SJ\Y8-/!&P[GZ$:\>L22I`"V,BI=%1Y.1=_5.T$Z**$.4
M"U(^&I*/>E/['_<%IT+DW-X2486H-HB[<#_RN]!@I26B%:*U(-6%\=WXOF_W
MP'/51N3<A2VB':+6(-.%X9#>+7.]L\=*!T1'1"=!N@N3P;7;G+/((6]OF[OO
MP]S]HT'>8.C=:,U%Q4Z,$2T8Z9-[,NZ-IMYM3L(2.;E31!FB7)!R6>]N,!S+
M?>&]'YI"Y-S@$E&%J&:D^_`P[?EW:@TKI`M+1"M$:T&Z"\/>@YVXWGW+1N3<
MA2VB':*6D>Y";S`=^&_C[5DB?3@@.B(Z"5)]N+\;NF'PXW`6/:2NFM^_8<C5
MRP'.D*N1>_LW\#)NKO8\\(=<0`NC,B=[\($@04LIHDR0W%T$'G2Z)B@_#N[@
M@:`0.QS^$E&%J#:(NQ)Z(&BPVA+12M"5KJQ%9;IR]8%@(W+NUQ;1#E%K$/=K
M0CO"W'OGS!ZK'1`=!5WIUTE4NE\/WF/]6020V[>M??1A[>/1(&]8]B;+YJ)B
M7\:(%HST>$";LTR&0^]2EK!&!H0442;HBN-R46G'T87SZE!MEGGDT*58X'Y5
MB&I&IE]J=F+H7?T;UHCQ):*5H"O]6HM*]VLT=?KE73,W(N=.;!'M$+6,3+^F
M=/,T@D0'IQVXFG3U*.A*OTZB,B?PX-H-U5GDD/:W+1#U88'HT2#:5H9]-D<4
M(UH@2A"EB#)$.:("48FH0E0C:A`M$:T0K1%M$&T1[1"UB/:(#HB.B$Z(SHAH
M$PVSU">QC0+QIHTT4!>(.&VF@;I`S&E##=0%HDZ;:J#.C;LS#:%&9N?V1;U@
MIG[9=/WMF4LU=Q;+(*HJDU@#;^5B'A3))+;;-'_EXF^^^S;HEC2D92/_5>I'
MHU++=U;[O6OE7%1\8L>(%H@21"FB#%&.J$!4(JH0U8@:1$M$*T1K1!M$6T0[
M1"VB/:(#HB.B$Z(S(MH[1"<%A9L#&5DIT+%`P&G[$*P;"#EM((*Z0-!I"Q'4
M!<).FXC8.O=4N6VUA>X]_3EH@RQ_S!'%B!:($D0IH@Q1CJA`5"*J$-6(&D1+
M1"M$:T0;1%M$.T0MHCVB`Z(CHA.B,R+*=1UN*[:4Z\@"`:=<1UT@Y)3KJ`L$
MG7(==8&P4Z[;.C?7;UMO4>]&>.LM!EG^F".*$2T0)8A21!FB'%&!J$14(:H1
M-8B6B%:(UH@VB+:(=HA:1'M$!T1'1"=$9T24ZV8MS1G7D04"3KF.ND#(*==1
M%P@ZY3KJ`F&G7+=U;JZK!8/OGURB5PPAUS5R<AU0;"I:J@6B!%&**$.4(RH0
ME8@J1#6B!M$2T0K1&M$&T1;1#E&+:(_H@.B(Z(3HC(AR'0))XSJR>8`%(DY[
MH&'=0,QI%S34!:).^Z"ASHV[F^MJ`>F&7-?K3=9$ZGQ@4'=+%QNB3C"YJ8?W
M]T7%]WT)HA11ABA'5"`J$56(:D2-0?B:LMK!]A;OP0K*_&+!^?6#(>0]-:&"
M>Q(L1"".,X:[&*1@-Y-JQJXWUYV+@.T68*4$4DDU8]>;9ZQ%P'8;VXJ;CFIF
M^X9TU!/A3CH:U+DB'FCBIN/`F^M;B(I;F2!*$66(<D0%HA)1A:A&U!@42,?;
M9H[5%EO^35HW,VB?NIZOYJ8B32NPKV)$"T&6K8$W%YF(BFVEB#)$.:-NH6KX
M<.\UM&"--+1$5"&J&6GCTX?[OF^[8<G%MIO$:B[HAB364T=6$C_2]C0J,N[B
M5-]SW5Q4[+H8T0)1@BA%E"'*$16(2D05HAI1XR#'I4-_PNSZ1-E%[DZ4&:2F
MPN2B!._MB*IS*:(%(Y-ZH\L"A;N\G[!&4B]%E"'*$16(2D05HAI1XR#7QVJB
MX_O3=JCG1>RT-<A-VZ'WRN=<5.)C,\<B/PU?&!4]D:K+2D^=@-Z%)4%#*:(,
M4>[:IH\6T#]N^`JL52*J$-6N[<%T0E\5<&TW3BTW!.KY^X80Z,=U)P0:N6GN
M+]C-AYU*0@!HP2J=YO0+3&]X35A@YSB8R5"5,S(GT,-DX,6V8(68+A%5B&I&
MQO2$OOWAC9L-2W#D'JIGPAO\KQ\A'?^;ITJZY["&&>]6:WXYCK,I4(QH81"?
M`H,I7N$2K)8BRA#EKO'0%:[`6B6B"E'MVA[0NSQ]+[Z-4\L]!]3SBQV#O[D`
M,=3/010<B<3(W__DT:CH&5Q4@R'$"YZI8JG(I]`"48(H190ARA$5B$I$%:(:
M48-HB6B%:(UH@VB+:(>H1;1'=$!T1'1"=$9$VS9#(",K!3B2M'$SZ@(1IZV;
M41>(.6W>C+I`U&G[9M2Y<7=/E=L>WH?X\,Y(;N0-<9^6X.%=5.RS!%&**$.4
M(RH0E8@J1#6B!M$2T0K1&M$&T1;1#E&+:(_H@.B(Z(3H;!`^$0YOFZ"XR)W[
MYCDC*T/T9,/7)RA,%1)(<G1U&*6HRA#EB`J#Y#?;)9!*JH4G.VH1<(,:1$M$
M*T1K1!N#I(U;(#NI%IXX:47`;=PC.B`Z(CHA.AL42!HU86)?@;_QL&5F7.1'
M$O'03+G(S\X7B%*#Q$D9B]R90^]ULUQ4[)<"3%4LDB;4B)90;\6BJTU8BXJ;
ML`%3.Q9)$UI$!ZAW9-'5)IQ$Q4TXVZ;<"\5M$T-#F!B:,^I.Z=@0[T+AO<>V
M$!6W,@%3*9!,JEFW9?[+U+FHV'@!IDH@E52SC7LMKT7%QALPM02RDFJV<>^&
M<BTJ-KX!4UL@.ZEF&_=:WHJ*C>_!U`'(4:K9QKV6GT3%QL^V*3?M;IL(&\)$
MV)R1E79:Y*6=]WBQ,/6<2Y"QWIE*P7@FU6P7>,_ON:C8!068*H%44LTV[K6\
M%A4;;\#4$LA*JMG&O9:O1<7&-V!J"V0GU6SC7LM;4;'Q/9@Z`#E*-=NXU_*3
MJ-CXV3;EI-WHMLG"B]R]Z6'4Y4ILB)=VWJS10E3<R@1,I4`RJ6:[P'L++A<5
M&R_`5`FDDFJV<:_EM:C8>`.FED!64LTV[K5\+2HVO@%36R`[J68;]UK>BHJ-
M[\'4`<A1JMG&O9:?1,7&S[8I-^UNFS\=X?RI0>[D7=^;=9N+BML4(UHP,O-@
M?9J%\?<W3E@CDVPIHDR0>`I_DR(J=3<[NAM,AO;OD[Q.%"+G3I2(*D0U(]TO
M^H45_23!FU]EB71KB6@EZ$JWUJ)2W7J@CP[KGYV:WR1X5\>-R+E;6T0[1"VC
MKW=KSQ+IU@'14="5;IU$]3W=.HN<NN4FO9KO_?YGA9&>'K9G3`WR%@V\B\M<
M5.S8&-$"48(H190ARA$5B$I$%:(:48-HB6B%:(UH@VB+:(>H1;1'=$!T1'1"
M=':0FS9JFOR&M%%RYQ+].-+('2MA/4]4DC9=148+5"6(4D09HAQ1@:A$5"&J
M$36(EHA6B-:(-HBVB':(6D9ZL.I/Q[VQ=^'<L\0>K,#Q1U2=!%UF1>[&#]=^
MYWH6.8Q,:BKUAA33,Z_.R&0F8]VU'.]I:S[J5)Q/,:*%068M9]`?]WV7)5@K
M190AR@4IE]W?^5\Q*43`32P158AJ1`VB):(5HC6B#:(MHAVB%M$>T0'1$=$)
MT=E![KAUVXS["&;<'PWRQBWO/F(N*HY8C&C!Z.LW#0E+Y#Q,$66"KMPTY*+Z
MGIN&0N3<AQ)1A:AF]/5N-2R1;BT1K01=Z=9:5-_3K8W(N5M;1#M$+2/=K1XM
MIX_\._(]:Z1?!T1'1"=!JA/CN][@V@X'9Y%3)]P,OVW%8*0G]IUA4R/WALY?
MX)^;BJ1B-\:(%@:983-TMY]@K111)NA**N2B^IY4*$3.?2@158AJ@ZYTJ\%:
M2T0K05>ZM1;5]W1K(W+NUA;1#E%KT)5N[;'6`=%1T)5NG43U/=TZBQQR_K8%
MCQ$L>#P:9+W*/T<4(UH@2A"EB#)$.:("48FH0E0C:A`M$:T0K1%M$&T1[1"U
MB/:(#HB.B$Z(SHBB*,`"\8X"`8\"$8\"(8\",8\"08\"48\"88_<N+OCN[\4
M]#=?KQG!&M&C0<Z[-"-XD-?UK#,EEGH\WBP0)8A21!FB'%&!J$14(:H1-8B6
MB%:(UH@VB+:(=HA:1'M$!T1'1"=$9T1T6D`@(RL#.))T6J`N$'$Z+5`7B#F=
M%J@+1)U."]2Y<7=/B]N6JD:P5/5HD)78<T0QH@6B!%&**$.4(RH0E8@J1#6B
M!M$2T0K1&M$&T1;1#E&+:(_H@.B(Z(3HC(AR78?;BBWE.K)`P.D2@+I`R.D2
M@+I`T.D2@+I`V.D28.N<7!_[ZV/J$J#@]?<\+M7<23B#Z"G7>MG5FXZ?AT1#
M$;E-\]=0_N;5:=PMKDC+1O?>TM&C43D7K,'0F\J:BXH'M1C1`E&"*$64(<H1
M%8A*1!6B&E&#:(EHA6B-:(-HBVB'J$6T1W1`=$1T0G1&%$4!9J4`!S<*!#P*
M1#P*A#P*Q#P*!#T*1#T*A#URX^Z>*O[*R]\]57!)9JP1+;"K!RO:N]+?MV4N
M"G9;C&B!*$&4(LH0Y8@*1"6B"E&-J$&T1+1"M$:T0;1%M$/4(MHC.B`Z(CHA
M.B.B<Z(+-0<R>F0FDU!T3F@=+7YW.HZXS3CD-N.8VXR#;C..NLTX[#;CN&OF
MGA-JB<&>\_^[YX1>JK!GM<8:J950N=;Y.\;-1<5NBA$M$"6(4D09HAQ1@:A$
M5"&J$36(EHA6C.2-WS4C>2MT(\ARX<C[>=A65.S"':(6T1[1`=$1T0G1&1&=
M*ET&<,/H5#'L<EJXJ>@O/^E4O%.[?+W\^N'];X_/E$>438&;+O73[\L'ZJ,Q
MKDH9I-96K43T?N,T%Q4W-D:T0)0@2A%EB')$!:(2486H1M0@6B):,;(34;N0
M3ESVQ(95@K:(=HA:1'M$!T1'1"=$9T24==!\RCK#`EEGKT^IO1;_[@"("U=C
MC=3:6)=W\,GTN:C8VS&C41>`!2-Y,SH1).8'(V^Q-145F\\0Y8@*1"6B2I#5
MB+[W_GDM*FY$@VB):,7(SD[C54G%#:N<*XWOB:VHN!$[1"VB/:(#HJ.@*YXX
MB8H;<49$.0R=I!PV[.(+=^2T5Z#^FQS&I:FQ1NY%?.3%=RXJ[E7,2&Y_%HPD
M<HD@RVDC;VTW%16;SQ#EB`I$):)*D-4(_]7Y6E3<B`;1$M&*D9W#G5?9UH95
M3@[WO>?OK:BXX@Y1BVB/Z(#H*.B*)TZBXD:<$5$.0R<IAPT+Y+"]HO3?Y#`N
M-8TULJYG<T0Q(SMAH6+"*B=,_I1]*BKV4(8H1U0@*A%5@JPPC;Q9F%I4W(@&
MT1+1BI&=L.")#:L<3XSAWA0J[J0BMZM%M$=T0'04=,43)U'Q$<^(*&&AK92P
MA@425LV6\Y/3?Y.P>M;=>7+2R$E80/'8(#MA096PR@G3T+OY347%'LH0Y8@*
M1"6B2I`=)N\-YUI4W(@&T1+1BI&=L.")#:OD\K-%M$/4(MHC.B`Z"KK2[9.H
MN-MG1)2=T"/*3L,"V:GFLO\OLE//B3O9J9&3G8#BL4%V=H(J8963G2.9ZKX\
MTZ6B8@]EB')$!:(2427(#I-WBM2BXD8TB):(5HSL[`1/;%AE9R>H=JAJ$>T1
M'1`=!5WI]DE4W.TS(LI.:"MEIV&8G0_V>HJ,G3<^ZE^LN,LK!M&C/K=VCBAF
M9.4F(W%_PLB9-AAY=V2IJ/B(&:(<4<%(CE@BJAA)AVI$#:(EHA4C*Q$922,V
MC.2(6T0[1"VB/2,Q?T!T9"1'/"$Z(XJB`'MD%L@Z&F6<,3$PD43??N*9I`<E
M]])+(]J.B(,]-RJU0T[WD#\8>P](,:NDXL(@>JV5;26(4D09VLH9Z1T0A]/[
ML;]]3(&&2D05HAI18Q!MO<%-7S*B9U1QP[TW&;%BE51<H_D-HBVB'=IJ&5UM
MQ!YM'1`=$9T0G0VR$H*2TB3)U59$CRR[I(3S./^@5@[L:_<W\E3)O3S52.U7
MT$4#?H`VOQSG[6OZ#;Q:M.HM_N$]=\<LD$](+`RR7D)-$*6(,K25,YI<CD]?
MQNO?>\\P!1HJ$56(:D2-0>04R5KC)^V!^SO_06Z%==9H>8-HBVB'MEI&7_?`
M'@T=$!T1G1"=#;(\0-GZ#1=0HG;)1'YS$U7-Y=^0J'KJW[Z7?-!([>]V+5&-
M2HW-H9]KQ&*&0[LPR!E>M1D+I:C*T%;.2`^O@_O)Q/_P6H&&2D05HAI18Y`U
MJ"P9:0_`L-IYD;N_1K,;1%M$.SZ27*E:1E_O_AX-'1`=$9T0G0VRND]9ZF2`
MUW]*4=L!;HJJB?\;4E2O$S@IJM&WQE*CXI%DZGWHTWO6C1\ZJQRRA4'.T*I5
M%DI1E:&MG)$>6*93^J:I-[@7:*A$5"&J$34&60/+DI&YN-"7"]W?'*]8(,/Q
M&BUO$&T1[=!6R^CK'MBCH0.B(Z(3HK-!E@<H:9V<Z($+*&_M+'#S5DWVWY"W
M2N[=`VCTK:'5J,S`<N=_"2E6JZ]DV3H;%P99XVB"*$64H:V<D;ES53\2=_.D
M0#LEH@I1C:@QR.K,DI%VP.!NX@TN*Q;(@+A&RQM$6T0[M-4R^JH#]FCG@.B(
MZ(3H;)#E`$I3)P70`Y2F=@ZX::KF\V](4SW][PRO&GUK>#4J/9KTX5O3\4-G
M1L93C:S!,S$J"Z6(,K25,S*C26#[X@(-E8@J1#6BQB!K-%DRTAZ8TE2)>YZL
M6&"/I^"!#1YLBVB'MEI&V@.C<=]_#66/=@Z(CHA.B,X&60Z@/'5R`#U`>6HG
M@9NG:AK_ACS5L_Y.GFKTK>'4J'@X'7M1BA\Z,Y*G&CG#*:#45+14&=K*&9E;
MM>'HWA_/"C14(JH0U8@:@ZSA9,F(QU-_J6'%`GL\A>YN\&!;1#NTU3+ZN@?V
M:.B`Z(CHA.ALD.4!2E03XZ^Y@!+5*`+/_FI&_X9$U0L`3J)J]*T!U:CT<#*X
M\Z=JXH?.C"2J1M;HF1B5A5)$&=K*&9GA)'3=AZ.5:+I"5"-J^&@R-BX9L0.\
M&;L5ETN5-1K>(-HBVJ&MEM%7^[]'.P=$1T0G1&>#W.'4RP#/`92D=@:XHZF:
MV+\A2?4Z@).D&GUK-#4J/I$&WO10_-"9D235R!HG$Z.R4(HH0ULY(SV6]"Y?
M+7"ON@4:*A%5B&I$C4'66+)DI#TPO?.7'U8LL$=3\,`&#[9%M$-;+2.Z`>SF
M9P;^%TGV:.N`Z(CHA.ALD.4$&E"=/$`O4*[:B>#DZL1?:KH^F7J1NP]2!GUC
M0&65'D_\RSZ7RFBR,,@:.A-$*:(,;>6,]&C2H\^ZX',46BH158AJ1(U!UGBR
M9*3[W[_SOP^Q8H&X8(V6-XBVB'9HJV5TQ05[M'1`=$1T0G0VR')!%#'[F@^B
M1U9<G.#FJ5HUX#%5?>WI&WFJ%QGL,75BUAVNSZ6R2H\HX[N)-^['+)`196&0
M-8`FB%)$&=K*&5T94]%0B:A"5"-J#+*&DR4C[8'1W;V]Z]YTZBWPKE@N_ECC
M<3:(MHAV:*ME]'5_[-'0`=$1T0G1V2#+'Y2V)G&^SR&4Q%VBT57736*U5'!#
M$NN5!2>)N\4&N>#@RM7$J/2)-K[SWM6(N5S&FH5!SG"KK5@H156&MG)&>JR9
M3GO3GI<U!1HJ$56(:D2-0=90LV2D'3"\&_BS5BP0#ZS1\@;1%M$.;;6,M`<F
M]%:[_YRW1T,'1$=$)T1G@RP/4-8Z.8`NH#SM<@GR5*T7W)"G>GG!R=-NQ>%J
MGAJ5/K,>[OPWF^))9Z:[@37(&6RURD(IJC*TE3,R@\ME@R/O!A8-E8@J1#6B
MQB!K<%DRXK$%;PO``VNTO$&T1;3C@\E0W3+ZN@?V:.B`Z(CHA.ALD.4!2E0G
M"49P9T2):OO`'5#5`L$-B:K7$YQ$[988KB:J4>GQ9`IMC">=&4E4C:SA,S$J
M"Z6(,K25,]+CR3AT^PI'*]%TA:A&U/#19'!<,M(.&-U-O.6R%0NDSAHM;Q!M
M$>W05LOHJP[8HYT#HB.B$Z*S0>YXZJ0`>H#2U,X!-TW5`L$-::K7$YPT[988
MKJ:I4>G1I#>^\R<$)IT925.-K,$S,2H+I8@RM)4STJ/)8/(P&GH7W@(-E8@J
M1#6BQB!K-%DR,AZXFWJW/BL6R!BX1LL;1%M$.[35,OJZ!_9HZ(#HB.B$Z&R0
MY0$:3]TD`!=0HMI9X":J6B&X(5'U@H*3J/8:P^7UY/G$(&MC/D8R6BP,LL;&
M!%&**$-;.2,]6CP,QZ-[?T_O`BV5B"I$-:+&(&N\6#*23J\82:?7:&N#:(MH
MA[9:1KK3HTGO8>I_X'*/E@Z(CHA.B,X&69VFW(-04[;9&>%FFYKFOR';]*J`
MDVT:T7P`CV?S":`8T0)1@BA%E"'*$16(2D05HAI1@VB):(5HC6B#:(MHAZA%
MM$=T0'1$=$)T1D2Y!(&D7$(6"'@4B'@4"'D4B'D4"'H4B'H4"'ODQMW-=;5:
M8.?ZW_P=]42O.M!)(#<"(_^]T$>C<O<A&GNO&,U%Q6=/C&B!*$&4(LH0Y8@*
M1"6B"E&-J$&T1+1"M$:T0;1%M$/4(MHC.B`Z(CHA.B.B4T4GA;.;6(`%`DZG
M"M8-A)Q.%=0%@DZG"NH"8:=3Q=:YIXI:K+!/E6],]>JU#>NR,)\8U%T58D.\
MK^UX[U(M1,4G1((H190ARA$5B$I$%:(:46/0Y3<ACO>F]H+.MR?*+W)W04<A
M6<WR7]&8<PUQKB'D7/7^<?_>WRY^(8+.KV`E!9))-6/7>^C,1<!V"[!2`JFD
MFK'K#8RU"-AN8UMQ_:UF>[\_6Z=Z<MC*UD>#Z''+=KLW8SH7%;<I%B0583)X
M(:I+;_TOKR92SH931!FB'%&!J$14(:H1-0YR7:XF+F]PN9[G=%RN$3ULB.<&
M_O<3YM-.Q9Z)$2T,,GM4#Q_\->@$ZZ2(,D'2)`AF[AZL/_9G3`LQPVTN$56"
MKARL%I7*G.G`2\E&RNE8;H34C)T=(76WHQ+\^E`^U1-]3J0T\DX.[W7QN:EH
MS5C$B!:,S%=&'OQW!!,6R&_.4D09HIR1V8E_Z&].7[!`+)>(*D2U(!6#@;_C
M9"/E$`,U'67'X!N^U[-7CN\ULA[)YU-`L:`KN;0P*G.6D.N]==5$S'#BIH@R
M05<.EKL'&]Y/O%F@0LSPP4I$E:`K!ZO=@ZG/A[E+"(V8@1"IB9@;0J3G;9P0
M&22_#9U/`<6(%H@21"FB#%&.J$!4(JH0U8@:1$M$*T1K1!M$6T0[1"VB/:(#
MHB.B$Z(SHB@*L,<`"P0\"D0\"H0\"L0\"@0]"D0]"H0]<N.N+PEOOOSZ]/02
MOWMY]^,/'Y\^__(T?_K]]R^OWC__^8DN"CUZ>=[BKSX__?SV-3W0S%3WZ7SI
M:N@2>K*=79X=`D73$14%:T7#X2RB78,#E51)H7^IZQ]J]$!%M%=_H-9(M8+V
M`P\53571-%!$V\7.U*Q&H)(J43NS!HHFJA7A6I>FA^KT5$GO\BMBKU-1CYRD
M+Y->R:,J*7I!I_=5G_K!/@VHY</+;\E]>ZJD&`3[-.BKHLN8!;4&JBAL4/5J
M$.P5;?XUH[?<0A&F1[^9>H!"U\;3^YEZ-,$2>O*8J8<++*%GAYEZ/,"2B+H;
M[)%R0]`+R@G!&A<7A`Y!#@A&E;9@FZG-!+!5M!/;3.TI@"6T(=N,]J4(Q9OV
MN5)%ETE5+SZTHY`J"B4Q;>>BBD(G!>VEH8I"0:#=#:@HV$+:W6ZF-F7`MJ^I
M9!TLH;WN9FJ/.JQ#.XA12:A/M%43E82Z1'OB4$FH1[0?"96$.D0;1,S47@_8
M`MHR<*:VM<`2VCEPIG:WP!+:0'"F-OX+E8RI)-0?VO^*2D+]H8V&J"34']KD
MA4I"_:$M-F9JMPQL`>W#.%-[A6`);<<X6P1+:%?&F=I-$>O07G=4$NH/;2I&
M):'^T.Y-5!+J#^V<0R6A_M"^)3.UWPBV0`TB:KO)4,F82D)MHPVPJ"34-MI\
MB$I";:.-7Z@DU#8:P69J0Y90"VBT4'LK8Y':2IE&DF`9;2=+80V.IN,AE80&
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M7I3T?)!121XLJ:BD#I;$`^K/(.2#>#BBM@5;T._-%OI!T6\!E>3!DHI*ZF#)
MBDK6P9(=E;3!DB.5G((E<9_.^G[HG,NH)`^65%12!TM65+(.ENRHI`V6'*GD
M%"[I45[W0F=6W*/Q0*^P^!ZEDCQ84E%)'2Q94<DZ6+*CDC98<J224[AD-#L&
MQXD>G5>]T'4K[M'9HR=VO-Y45+(.ENRHY!0LB<EKBZ#7,BK)@R45E=3!DA65
MK(,E.RIIPR6CV2[D@99N!T-\3[?%H?-F/YX=0O[:/]!M=&`DWD]FAU"V[*>S
M0^BXU6A6A7A-0TF(-W3[%^(KNC4.\37=&(?X9C3;AOJ[&<^VH?YN'F;;4'\W
MD]DVU-_-=+8-'3<;S;(0S^DV,,0+NA$.M;,8S\I0.XL'NG$.Q*68S,I0.XOI
MK`P==T$WK"&>C&9IJ#W)>):&VI,\S-)0>Y+)+`VU)YG.TM!Q'^E6-'3<1W4C
M&NCO(]V&AH[[2#>AH>,^TBUHZ+@QW=)?^)MN6/CRXP]_O/OEJ7[W^9</G[Z\
M^OWI9YJVN;_L1?CYPR]J8E__S\OS'Y?/#_SS^>7E^>/ESU^?WOWT]%D):$[R
MY^?G%_X?NJ5Y\]?SY]\N4T,__J\`````__\#`%!+`P04``8`"````"$`T^Y5
MU8$#``#/"@``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RL5MN.FS`0
M?:_4?T!^7PCDCD)620AMI5:JJEZ>'3")M8"1[6QV_[YC'+Q@MM&NU)<0#F>.
MY\SXMKI_*@OGD7!!614AWQTAAU0IRVAUC-"OG\G=`CE"XBK#!:M(A)Z)0/?K
MCQ]6%\8?Q(D0Z8!")2)TDK(./4^D)U)BX;*:5/`E9[S$$E[YT1,U)SAK@LK"
M"T:CF5=B6B&M$/*W:+`\IRF)67HN226U""<%EI"_.-%:M&IE^A:Y$O.'<WV7
MLK(&B0,MJ'QN1)%3IN&78\4X/A3@^\F?X+35;EX&\B5-.1,LER[(>3K1H>>E
MM_1`:;W**#A097<XR2.T\<-D@;SUJJG/;THNHO/?$2=V^<1I]I56!(H-;5(-
M.##VH*A?,@5!L#>(3IH&?.=.1G)\+N0/=OE,Z/$DH=M3,*1\A=ES3$0*!049
M-Y@JI905D`#\.B55,P,*@I^:YX5F\A2A\<R=SD=C'^C.@0B94"6)G/0L)"O_
M:))_E=(BP54$GJ^(W`@<7P,G)M!?N,%BZD]G:O@;D?"UR1N>UR']L3L)IO-%
MD_B-R-DU$IYMY.TQ/5VRI@,QEGB]XNSBP*R&HH@:JS7BAZ#6EEZ/;9KQKUY`
M$Y3(1JE$:(D<*+.`^?.XGBRG*^\1FIY>.=LA)^@S=BU#=5C)QC:PMX&D`WC@
MR-B"+OX'6TI%V6H3VK;`B\^QY:%EM"&Q#>QM(.D`/0\PL6P/8UA;KZ^*MA,J
M*$(P%TTG_/&RG^-6<_P77[L!$@^0_0!)ND@O<QC^M<S?.:F42H0":+'Q,EG.
M+"^:!%Y>2/[<[Y-VAF2Z,D#V`R3I(CU[L%YM>VJ[>J<]I=+8:Y/::D3O<&K^
M[VP@UH#EUEI&>T-JA9..3L\(+/BND=LS2Y'[^6K$G_=J;R\(0VJSB0?(WB!J
MY[#VC<1\!(%>]C#NV[-7Y'[V&K&RGU@SQY!,]@-D?T46>M\+@J75D*0;TG.@
M[B^=S?=V_16Y[T`CE@.K?#M#,@X&R-X@JOY6`^'@5^/"**;^^B#7QTA)^)'L
M2%$()V5G=4C/H0X&U?>'>!K"K(1X"X=[Q29X!=_"?:,YG2W^-@AAMQSJ;,<A
M;$9#?#,)-\V]Q=:9A+"ZE1_S`>X3-3Z2;Y@?:26<@N1@9>3.8>EP?2/1+Y+5
MS:%Y8!)N$LW?$UP<"2S7D0ODG#'9OJ@!S%5T_1<``/__`P!02P,$%``&``@`
M```A`)!Z9K_;!0``#A@``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
MK)C;CN(X$(;O5]IW0+D?(`G'"%@UY,Q!J]4>KM,A0#2$H"0]/?/V6XYC)Z[J
M;<%H;SK-1_FW_;ML*E[\]CV[]KXE19GFMZ6F]X=:+[G%^3&]G9?:7W^Z7V9:
MKZRBVS&ZYK=DJ?U(2NVWU:^_+-[SXFMY29*J!PJW<JE=JNIN#09E?$FRJ.SG
M]^0&WYSR(HLJ^%B<!^6]2*)CW2B[#HSA<#+(HO2F<06K>$0C/YW2.+'S^"U+
M;A47*9)K5,'XRTMZ+X5:%C\BET7%U[?[ESC/[B#QFE[3ZD<MJO6RV`K.M[R(
M7J\P[^_Z*(J%=OV!R&=I7.1E?JKZ(#?@`Z5SG@_F`U!:+8XIS(#9WBN2TU)[
MT:V#/M8&JT5MT-]I\EYV_N^5E_S=*]+C+KTEX#:L$UN!USS_RD*#(T/0>$!:
MN_4*_%[TCLDI>KM6?^3O?I*>+Q4L]QAFQ"9F'7_821F#HR#3-^IAQ/D5!@!_
M>UG*4@,<B;[7S_?T6%V6FCGNS\;CT60V!9G7I*S<E&EJO?BMK/+L'QZELU%)
M%:-1@:=0,1]N/&H:P[-I##(/=@Q#K(</SZ;MM&_,QOIX`K-]5&32B,"S$='[
M4WTX-Y]P`/93/1!X/CV)>=,6GC\_"1U2AZ\DRZ%FD1Z=QH!G19UD=E1%JT61
MO_=@Y\*RE_>(G0.ZI<,"B?3BN2`3[K_R#5*$J;PPF:4&\X-,*F&3?%N-YM/%
MX!LD=MS$K&F,H49L1`3+/"9K8^!@X&+@8>!C$&`08K#%8(?!'H-#!PS`6NDO
M9/K_X2^38?X*9]8"M(:;R$P1(9K8&#@8N!AX&/@8!!B$&&PQV&&PQ^#0`8J9
M<.0H9GY\!HJ<9-%+#7):YJ1A#%63UCQ&;XW=$&(3XA#B$N(1XA,2$!(2LB5D
M1\B>D$.7*!:"'8J%/[G?F<Q2,R#KI;FC^0R9RX/`W#;(,'":RB"9IX0XA+B$
M>(3XA`2$A(1L"=D1LB?DT"6*W_`CI?C]><JRZ-I68<::$W,B=_Z&$)L0AQ"7
M$(\0GY"`D)"0+2$[0O:$'+I$,0Q^HY\PC$4KAFT:(OVR.3!A1\A4-8R1FJJ.
M#!+&NX1XA/B$!(2$G!AL/,H\IT_-DT4K\UP#Z<QGK,YGT\2W+G``+K#?9F.H
MHVWHR.^E`5C"P\"7;1I-9&H@OQ>:(9;8-B$C.=`=(7M"#EVBF,I>>KK5S.>[
MC46KIG)B0H'5\7:"O)5!8EJV)-UFJ/QQFB"]7@%]-!NCX]*5*D+7(\27Y).>
M`K6GL6ZBGD*I`CTI_L%1_81_+%KUCQ,=UJ?C'^I](X/$/&U"'$Y,HTG7*4HM
ME[3P"/$)"515?8Q4PVX+Q1=6>S]A3!VN.M,@E%ISE%IME/2&(D>@)I7&PRDJ
M:UP14;]:UJ6T1Y%/42"0D!X9*(U#$<'?6KNEKLYJX,=W7QV.3.)5M)H_)IK<
MIFD(4:U)LJ%`3AM5GTXH"=WV:]'"H\BG*&@1T]6)/=V1J#G$JMHG[.%%,)18
M8H!KG2/((8$V%-DMZFY"-$Y'1/&%-HTAMMD5$6UO'D5^BS[I+1!1HK>IB0[5
M4$1\D%:LEGW"-U[Z*KXUU;!R+)DZWGLR2KAKZP0Y%+D4>13Y%`44A0I2TX>5
MF$_8P"M2Q0:.U"/()._@,JJU@2"'717`V8^T4%'A?AR%3EVOC1(]^A0%+>HD
MFHGJGO#CJ+9'U5)6A#YA*:]9%4LYZAQ%&W8W!\YTD-VBSM#QP>HT4<UOGFY.
M=92A;JLCC/(H\EOT26\!ZDTW9B@1PE8'>N.^\4M*?G^4)<4YV237:]F+\S=V
M`0DGXVHA,;\=78\M*/5!`'%[8D&M_`&?6E"*4NY/+2@G*=].+:@&*8=;V9>Z
MYD;]KMEM[0?Q:\."6P>JLS8M>)>F_&5DO8!!](OUR(*70>`#V3/<QMZC<[*/
MBG-Z*WO7Y`1F#?OL[K'@][G\0Y7?Z_NXU[R":]CZWPO<NR=P$3;L0_`ISROQ
M@74@;_)7_P(``/__`P!02P,$%``&``@````A`-8X<NDS`0``0`(``!$`"`%D
M;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)R1T4K#,!2&[P7?H>2^3=MM,D*;@<JN'`A.%.]B<K8%FS3D
M1+N]O5G7546OO`S_GR_?.:D6>],D'^!1M[8F19:3!*QLE;;;FCRNE^F<)!B$
M5:)I+=3D`$@6_/*BDH[)UL.];QWXH`&32++(I*O)+@3'*$6Y`R,PBPT;PTWK
MC0CQZ+?4"?DFMD#+/+^B!H)0(@AZ!*9N))(!J>2(=.^^Z0%*4FC`@`U(BZR@
M7]T`WN"?%_KD6]/H<'!QID'W.UO)4SBV]ZC'8M=U63?I-:)_09]7=P_]J*FV
MQUU)(/RXGT9@6,55;C2HZP/?O_HF0=Q5]'=6*=G;,>E!!%!)?(^=[,[)T^3F
M=KTDO,R+69I/TJ)<ESF;SMET]E+1<VNXST>@&03^33P#>._]\\_Y)P```/__
M`P!02P,$%``&``@````A`*$'U,&7`P``HPP``!``"`%D;V-0<F]P<R]A<'`N
M>&UL(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````G%==
M;YL\%+Y_I?V'B/N5M.NF5Q5A<HF36"+`@&3KE>6!TZ`20+83M?OU.\#:0N:P
MM'?&YSS'C\^7#];7QUT^.G`AL[*8&)<78V/$BZ1,L^)^8JSBV<?_C9%4K$A9
M7A9\8CQQ:7RU/_QG!:*LN%`9ER,P4<B)L56JNC%-F6SYCLD+$!<@V91BQQ1\
MBGNSW&RRA$_+9+_CA3*OQN,O)G]4O$AY^K%Z,6BT%F\.ZKU&TS*I^<EU_%0!
M8=M"595G"5-P2WN9):*4Y4:-\&/"<\OL"BU@%_%D+S+U9(\ML_MI10G+N0.&
M[0W+);?,UPUKP5GMM(!E0MK60=T<>*)*,9+9+W#;E3'ZR22OZ4R,`Q,9*Q30
MJM7:CV:=5U()^WLI'N26<R4M$Q3:S6;9U>VNLVO[\U6C`:N^9FVA90*"/L<X
M4SF7_B9@0FDH?^YQ;EBTC%M"SU&DD!L4%PK\14G11CLKN\Q?[N#X7N2[9(IB
M/*6WR$6>@VFTP#B.WJI/`_9O2!3#24OLQ1'U9]0/\%LAS@*]`W+Y9@S2WS\B
M<X_,B(.\F"+'\5=>3+PY#<"'#M%?!B38BS!%WI1&JR!P[RB:A[CQ@I96$()?
MPAC4`(&_K4A0.TRK2KPUB/R08#U=EZ!;XA*P-?-#BI>!Z]]A3$,R7T`$M"8=
M?[DD<1,BK3Q:H!!3!P4D1JY6`W)J#?S)K8NIY\=ZK\P0">D:N2M,EQA%J_"T
M/V+T`T.Z>)1X0$YOKG%L8P*%<%GB02(3Y-(VW[0T0^PV61^@VM=QB+P(.3&!
M@M"J#T=>GV##F+8]_.DE+Q6ICSZ-V4_H#%IFG2084NL%;DCQ.'[1D/)1<(94
MAV.D]^#I(-4G:=TQ[/1/[\!<:S%#=4VG6LB)V$ZY8EG^[^`.Z0U7NMZYG5*G
M0[;[F>,Q(>#5/O`_&.U-^Y!HO]LQ\43+#?4K>/#/@#1ZA:1S`<\R3_6]JG]*
MR.&ISI):.U)E\O"&4^H'LX:?`>G>9:_.@VR9X/06AHV4.N6NTI[R=]5U'7TF
M)()!+]WGO/:T%J)ONX/1/Z[P+BW%M*<<0Z9\PX6`VQ.88W=G07P85:'$'^D=
M9T)?&L/]1-]=AS$GFD/]:)]\6_3-8:!O0:5U/=";!H_F/S<K'N2JBLLI4_QY
MP.UO6E&=7"F,?L_RUPUK`;.MR&LCSI85]SQ]UOE;4(_CZ_:?P[Z\OAA_&L.D
MW=FSS->_"_LW````__\#`%!+`P04``8`"````"$`9%'/QY8```"J````$```
M`'AL+V-A;&-#:&%I;BYX;6P\CL$*`B$41?=!_R!OWS@SBXA0!PKZ@OH`<5ZC
MH$_Q2=3?9YLV%PX7SKUJ>:<H7E@Y9-(P#2,())?70)N&Q_UV.('@9FFU,1-J
M^"##8O8[Y6QT5V\#B6X@UN!;*V<IV7E,EH=<D'KSS#79UK%NDDM%N[)';"G*
M>1R/,G4!&.5$U7"99A"AGP`1?RF-DO\5\P4``/__`P!02P$"+0`4``8`"```
M`"$`50<N$"4"``!3(```$P``````````````````````6T-O;G1E;G1?5'EP
M97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````````````
M`````%X$``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0!"N-@58`(``+`?
M```:`````````````````(0'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+`0(M`!0`!@`(````(0#+*G#4EP0``-L/```/`````````````````"0+
M``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`MNTI#\4$``"+$```
M&`````````````````#H#P``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M`BT`%``&``@````A`$V]Z:U^!0``/Q8``!D`````````````````XQ0``'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"+0`4``8`"````"$`(AL<0EH)
M``"[.```&0````````````````"8&@``>&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;%!+`0(M`!0`!@`(````(0"&_<.7I@,``.H+```9````````````````
M`"DD``!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!`BT`%``&``@````A
M`(O0P6^O`P``S0L``!D`````````````````!B@``'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"+0`4``8`"````"$`C@T6UX@#``#^"@``&0``````
M``````````#L*P``>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`
M!@`(````(0!"O`7*5@<``.H>```9`````````````````*LO``!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L!`BT`%``&``@````A`&\!Z,BQ`P``7`T`
M`!D`````````````````.#<``'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"+0`4``8`"````"$`'>7<#O`"```0"```&0`````````````````@.P``
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(M`!0`!@`(````(0#ZN3\[
M.P,``*H)```9`````````````````$<^``!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L!`BT`%``&``@````A`$C77IOF!0``3QD``!D`````````````
M````N4$``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"+0`4``8`"```
M`"$`G4"(GP$+``#M/```&0````````````````#61P``>&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0`%RT<PP`(``.P&```9````
M``````````````Y3``!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!`BT`
M%``&``@````A`!%I/HQ6`@``+P4``!D`````````````````!58``'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"+0`4``8`"````"$`3DR3;!8#```W
M"@``&0````````````````"26```>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+`0(M`!0`!@`(````(0#C$AM#_PL``,EJ```-`````````````````-];
M``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/0DO_J;:0``458!`!0`
M````````````````"6@``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&
M``@````A`+B&K7"&`@``O08``!@`````````````````UM$``'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0"6S6NP>`4``+45```8
M`````````````````)+4``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````!`V@``>&PO
M=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#I.1[)K`(``+<&```9
M``````````````````7A``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!
M`BT`%``&``@````A`*1\JO+O`@``-@@``!D`````````````````Z.,``'AL
M+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"+0`4``8`"````"$`]B4HE$4#
M``#E"0``&0`````````````````.YP``>&PO=V]R:W-H965T<R]S:&5E=#0W
M+GAM;%!+`0(M`!0`!@`(````(0!L+D4HN@,``*0,```9````````````````
M`(KJ``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&``@````A
M`.TMM_,*`P``DP@``!D`````````````````>^X``'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"+0`4``8`"````"$`Q5%>7EH#``#8"0``&0``````
M``````````"\\0``>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+`0(M`!0`
M!@`(````(0![7!\T&00```,/```8`````````````````$WU``!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`%>T]TCX$``"+#P``
M&0````````````````"<^0``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M`0(M`!0`!@`(````(0"OON@L%`,``-4)```9`````````````````!'^``!X
M;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`-*!Z$\U
M`P``#PH``!D`````````````````7`$!`'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"+0`4``8`"````"$`V(#.75H$``"-$0``&0``````````````
M``#(!`$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(````
M(0#1NDST`48``-:O`0`9`````````````````%D)`0!X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L!`BT`%``&``@````A`%:\GG;J!@``="```!D`````
M````````````D4\!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`[?]B3M(%``"Y%P``&0````````````````"R5@$`>&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0#\C1U1T`8``+$=
M```9`````````````````+M<`0!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL
M4$L!`BT`%``&``@````A`(II&%OH`@``50@``!@`````````````````PF,!
M`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0"Z7AF*
MT08``.(>```8`````````````````.!F`0!X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"+0`4``8`"````"$`R7'SJ[`"``#+!@``&```````````````
M``#G;0$`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A
M`)3-2<[V!@``S!T``!@`````````````````S7`!`'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+`0(M`!0`!@`(````(0`73/_9?Q4``.U[```8````````
M`````````/EW`0!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`
M"````"$`RS(14X($``#_$```&0````````````````"NC0$`>&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0!5VKT[:P,``-0+```9
M`````````````````&>2`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M`BT`%``&``@````A`!P%TNI3"P``L#<``!D`````````````````"98!`'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`"````"$`[-UG[7<'
M``#?(```&0````````````````"3H0$`>&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;%!+`0(M`!0`!@`(````(0`G<#/2X@H``,@S```9````````````````
M`$&I`0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A
M`"3D@;O]`P``D0T``!D`````````````````6K0!`'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"+0`4``8`"````"$`Y.Q[E<@%``"<&```&0``````
M``````````".N`$`>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`
M!@`(````(0!W^`">6A4``/"-```9`````````````````(V^`0!X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`$\[Z*RD!```:!$`
M`!D`````````````````'M0!`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"+0`4``8`"````"$`W(^U5*4$``".$0``&0````````````````#YV`$`
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0!\M6_Z
M8`0``#<0```9`````````````````-7=`0!X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L!`BT`%``&``@````A``?MPBMP%```&W$``!D`````````````
M````;.(!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"```
M`"$`0N['K@<L``".^P``&0`````````````````3]P$`>&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0#3[E75@0,``,\*```9````
M`````````````%$C`@!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`BT`
M%``&``@````A`)!Z9K_;!0``#A@``!D`````````````````"2<"`'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"+0`4``8`"````"$`UCARZ3,!``!`
M`@``$0`````````````````;+0(`9&]C4')O<',O8V]R92YX;6Q02P$"+0`4
M``8`"````"$`H0?4P9<#``"C#```$`````````````````"%+P(`9&]C4')O
M<',O87!P+GAM;%!+`0(M`!0`!@`(````(0!D4<_'E@```*H````0````````
M`````````%(T`@!X;"]C86QC0VAA:6XN>&UL4$L%!@`````^`#X`VQ```!8U
$`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Narrative) (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WithholdingTaxRateOnForeignIncome', window );">Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits</a></td>
        <td class="nump"><a title="plx_WithholdingTaxRateOnForeignIncome" onclick="toggleNextSibling(this);">15.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_WithholdingTaxRateOnForeignIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 138.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember', window );">Restricted Amount [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards[us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember]" onclick="toggleNextSibling(this);">16.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= plx_RestrictedAmountMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">39.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearOne', window );">Additional tax rate, 2012</a></td>
        <td class="nump"><a title="plx_EffectiveAdjustedIncomeTaxRateYearOne[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_EffectiveAdjustedIncomeTaxRateYearOne<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearTwo', window );">Additional tax rate, 2013</a></td>
        <td class="nump"><a title="plx_EffectiveAdjustedIncomeTaxRateYearTwo[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_EffectiveAdjustedIncomeTaxRateYearTwo<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateThereafter', window );">Additional tax rate, 2014 and thereafter</a></td>
        <td class="nump"><a title="plx_EffectiveAdjustedIncomeTaxRateThereafter[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">26.50%</a><span style="display:none;white-space:normal;text-align:left;">plx_EffectiveAdjustedIncomeTaxRateThereafter<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">$ 121.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Thereafter</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_EffectiveAdjustedIncomeTaxRateThereafter</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_EffectiveAdjustedIncomeTaxRateYearOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year Two</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_EffectiveAdjustedIncomeTaxRateYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WithholdingTaxRateOnForeignIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Withholding Tax Rate On Foreign Income</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_WithholdingTaxRateOnForeignIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_SubsidiariesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterialsNetOfReserves" onclick="toggleNextSibling(this);">$ 1,616</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterialsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterialsNetOfReserves" onclick="toggleNextSibling(this);">$ 2,342</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterialsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcessNetOfReserves" onclick="toggleNextSibling(this);">132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcessNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcessNetOfReserves" onclick="toggleNextSibling(this);">92</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcessNetOfReserves</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">4,919</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">5,523</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">6,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">7,957</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
        <td class="nump"><a title="us-gaap_InventoryWriteDown" onclick="toggleNextSibling(this);">$ 1,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWriteDown</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryWriteDown" onclick="toggleNextSibling(this);">$ 1,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWriteDown</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The following table sets forth total interest expense recognized for the years ended December 31, 2013 and 2014 related to the Notes:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 90%; margin-left: 0.5in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. Dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Contractual interest expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">888</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,105</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Amortization of debt issuance costs and debt discount</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">127</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">444</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Total</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,015</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,549</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EANAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 1,243</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 1,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">914</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">888</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
        <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">1,412</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">1,572</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,097</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
        <td class="nump"><a title="us-gaap_AccruedRoyaltiesCurrent" onclick="toggleNextSibling(this);">495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRoyaltiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedRoyaltiesCurrent" onclick="toggleNextSibling(this);">419</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRoyaltiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent', window );">Liability in connection with collaboration operation - current portion</a></td>
        <td class="nump"><a title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" onclick="toggleNextSibling(this);">6,215</a><span style="display:none;white-space:normal;text-align:left;">plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent</span><span></span></td>
        <td class="nump"><a title="plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent" onclick="toggleNextSibling(this);">5,666</a><span style="display:none;white-space:normal;text-align:left;">plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
        <td class="nump"><a title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" onclick="toggleNextSibling(this);">120</a><span style="display:none;white-space:normal;text-align:left;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</span><span></span></td>
        <td class="nump"><a title="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" onclick="toggleNextSibling(this);">186</a><span style="display:none;white-space:normal;text-align:left;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and accruals, other</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">$ 15,496</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">$ 12,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising in connection with collaboration operation (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_AccruedLiabilityInConnectionWithCollaborationOperationCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 1,242</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 4,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 7,751</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenues [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember]" onclick="toggleNextSibling(this);">220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_CostOfSalesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">936</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">2,655</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">4,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Marketing, General and administrative expenses [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember]" onclick="toggleNextSibling(this);">$ 306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_SellingGeneralAndAdministrativeExpensesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember]" onclick="toggleNextSibling(this);">$ 1,434</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_SellingGeneralAndAdministrativeExpensesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember]" onclick="toggleNextSibling(this);">$ 2,775</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_SellingGeneralAndAdministrativeExpensesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details) (Employees [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveMember', window );">2012 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandTwelveMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of at grant date</a></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);"> 2,288,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandTwelveMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveSecondMember', window );">2012 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveSecondMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">1,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandTwelveSecondMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of at grant date</a></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveSecondMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">6,292,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandTwelveSecondMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember', window );">2014 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandFourteenMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);"> 2.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandFourteenMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of at grant date</a></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue[us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);"> 1,007,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue<br>/ us-gaap_PlanNameAxis<br>= plx_GrantYearTwoThousandFourteenMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award granted contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFourteenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveSecondMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_GrantYearTwoThousandTwelveSecondMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) (Compensation To The Non -executiveDirectors [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Compensation To The Non -executiveDirectors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember]" onclick="toggleNextSibling(this);">$ 560</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= plx_CompensationToTheNon-executiveDirectorsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember]" onclick="toggleNextSibling(this);">$ 509</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= plx_CompensationToTheNon-executiveDirectorsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember]" onclick="toggleNextSibling(this);">$ 375</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= plx_CompensationToTheNon-executiveDirectorsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transactions with related party during the financial reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6MAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Deferred Income Taxes) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">$ 3,136</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">$ 5,257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(372)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(491)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Provision for vacation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" onclick="toggleNextSibling(this);">374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" onclick="toggleNextSibling(this);">417</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments', window );">Severance pay obligation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" onclick="toggleNextSibling(this);">185</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" onclick="toggleNextSibling(this);">209</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenues</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">8,658</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">9,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">28,130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">23,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(40,111)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(38,426)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance, Total</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AND SUPPLY AGREEMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeAndLicenseArrangementDisclosure', window );"><strong>LICENSE AND SUPPLY AGREEMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock', window );">LICENSE AND SUPPLY AGREEMENT</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><b>NOTE 2 - LICENSE AND SUPPLY AGREEMENT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">On November 30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. As mentioned in Note 1, in June 2013, Pfizer returned the commercialization rights in Brazil to Protalix Ltd. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $<font>60.0</font> million in connection with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $<font>5.0</font> million upon the Company's filing of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $<font>25.0</font> million milestone payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to <font>40</font>% of the results (profits or losses) earned on Pfizer's sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to other adjustments, taking into account Protalix Ltd.'s cost of goods sold and Pfizer's commercial expenses, with certain expenses capped or borne solely by one party (&#147;Collaboration Operation&#148;). As of December 31, 2014 and 2013, the Company accrued a liability in respect of its share in the <font style="font: 10pt Times New Roman, Times, Serif;">accumulated losses of the collaboration operation equal to</font> approximately&#160;$<font>7.1</font> million and $<font>8.0</font> million, respectively.&#160;After deducting the losses, the Company is entitled to receive in cash its share in the profits of the collaboration operation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The Company has determined that the initial, non-refundable upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line basis as revenue over the estimated relationship period (approximately $<font>4.6</font> million per year). The Company has estimated that the relationship period for its arrangement with Pfizer will be approximately <font>14</font> years (commencing upon the Company's receipt of the up-front license payment) based on the Company's last material patent relating to taliglucerase alfa to expire. The $25.0 million milestone payment received during 2012 in connection with the FDA's approval of taliglucerase alfa in the United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during the period in which the milestone was achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The Company's deliverables under this collaboration include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase alfa.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">According to the terms and conditions of the Pfizer Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><br/></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeAndLicenseArrangementDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CollaborativeAndLicenseArrangementDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative and License Arrangement Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CollaborativeAndLicenseArrangementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0TA!/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0TA!,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T-!
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)
M1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DQ)0T5.4T5?04Y$7U-54%!,65]!1U)%14U%
M3E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y04D]0
M15)465]!3D1?15%525!-14Y4/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^24Y614Y43U))15,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y,24%"24Q)5%E?1D]27T5-4$Q/645%7U))1TA4
M4U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-(05)%7T-!4$E404P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#3TY615)424),15].3U1%/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-14%355)%345.5#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E1!6$537T].7TE.
M0T]-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-5
M4%!,14U%3E1!4EE?1DE.04Y#24%,7U-4051%33PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)
M3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4TE'
M3DE&24-!3E1?04-#3U5.5$E.1U]03TQ)0TE%,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?
M4$],24-)13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y04D]015)465]!3D1?15%525!-14Y47U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]224537U1A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!
M4$E404Q?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0T].5D525$E"3$5?3D]415-?5&%B;&5S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^5$%815-?3TY?24Y#3TU%7U1A8FQE
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-54%!,
M14U%3E1!4EE?1DE.04Y#24%,7U-4051%33$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y214Q!5$5$7U!!4E197U1204Y304-424].
M4U]486(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M24=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Y
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4TE'3DE&24-!3E1?04-#3U5.5$E.
M1U]03TQ)0TE%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DQ)0T5.4T5?04Y$7U-54%!,65]!1U)%14U%3E1?1#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23U!%4E197T%.1%]%455)
M4$U%3E1?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DE.5D5.5$]224537T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y,24%"24Q)5%E?1D]27T5-4$Q/645%7U))
M1TA44U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M0T]-34E4345.5%-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?3F%R<F%T:79E7T1E=&%I;#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!
M4$E404Q?4W5M;6%R>5]O9E]/<'1I;SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?3W!T:6]N<U]'<F%N=&5D
M7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%
M7T-!4$E404Q?4F5S=')I8W1E9%]3=&]C:SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?3W!T:6]N<U]A;F1?
M4F5S=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(
M05)%7T-!4$E404Q?4W5M;6%R>5]O9E]/=71S=#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?4VAA<F5?0F%S
M961?0V]M<#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-/3E9%4E1)0DQ%7TY/5$537TYA<G)A=&EV95]$93PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3E9%4E1)0DQ%7TY/5$537U-C
M:&5D=6QE7V]F7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9!25)?5D%,545?345!4U5214U%3E1?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E1!6$537T].7TE.0T]-15].
M87)R871I=F5?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E1!6$537T].7TE.0T]-15]$969E<G)E9%]);F-O;3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E1!6$537T].7TE.0T]-
M15]/<&5N7U1A>%]996%R<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-54%!,14U%3E1!4EE?1DE.04Y#24%,7U-4051%33(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y355!03$5-14Y4
M05)97T9)3D%.0TE!3%]35$%414TS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U504$Q%345.5$%265]&24Y!3D-)04Q?4U1!5$5-
M-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970U,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)%3$%4
M141?4$%25%E?5%)!3E-!0U1)3TY37T1E=#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS
M:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E
M<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E
M=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R
M=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T
M5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF
M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U
M;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R
M+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y
M-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%1E5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@
M16YT:71Y($EN9F]R;6%T:6]N("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X
M8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,#$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U
M;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M2SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE
M;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A
M;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES
M8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D99/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4$Q8/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T
M<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y04D]4
M04Q)6"!"24]42$5205!%551)0U,L($E.0RX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN
M9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,3`P
M-C(X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A
M=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R
M871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!297!O
M<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y9
M97,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!796QL($MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O
M8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3,L-C`S+#@Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E
M.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R
M:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3T=!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-54E)%3E0@05-31513.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4T+#<V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.#8L,SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE+2!4<F%D93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`Y,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#4W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPV-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#DU-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-2PU,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-RPY,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D953D13($E.(%)%
M4U!%0U0@3T8@14U03$]9144@4DE'2%13(%503TX@4D5425)%345.5#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4W.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)/4$52
M5%D@04Y$($5154E0345.5"P@3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,2PR.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPW,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1%1D524D5$($-(05)'15,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@L-#<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$S+#,S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=6%L<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.34Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PT.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#<V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDL,S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L,C$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-CDV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DQ/3D<@5$5232!,24%"24Q)5$E%4SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@;F]T
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#0V-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#`T
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,W+#(S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0Q+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71Y(&EN(&-O;FYE8W1I;VX@
M=VET:"!C;VQL86)O<F%T:6]N(&]P97)A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!F;W(@96UP;&]Y
M964@<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPR-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#,V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QO;F<@=&5R;2!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`W+#@V
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q,RPU.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,T+#`W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PR-SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13("A.
M;W1E(#8I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%0251!3"!$149)0TE%3D-9
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@4W1O8VLL("0P+C`P,2!P87(@=F%L=64Z($%U=&AO<FEZ960@+2!A
M<R!O9B!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q-"P@,34P+#`P,"PP,#`@
M<VAA<F5S.R!I<W-U960@86YD(&]U='-T86YD:6YG("T@87,@;V8@1&5C96UB
M97(@,S$L(#(P,3,@86YD(#(P,30L(#DS+#4U,2PP.3@@<VAA<F5S(&%N9"`Y
M,RPV,#,L.#$Y<VAA<F5S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I
M=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#4L-C,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T
M+#,T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C0Q+#,R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R,3$L,S@U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<&ET86P@
M9&5F:6-I96YC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-34L
M-C`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(V+#DT-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!N970@;V8@8V%P:71A
M;"!D969I8VEE;F-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#<X+#0W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3$S+#,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E
M-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F
M-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T,#,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4V1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/
M3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H4&%R96YT:&5T:6-A;"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0T].4T],241!5$5$($)!3$%.0T4@4TA%1513
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K+"!!=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O
M8VLL(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L
M-C`S+#@Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDS+#4U,2PP.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#8P,RPX,3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPU
M-3$L,#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P1558044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].4T],241!5$5$
M(%-4051%345.5%,@3T8@3U!%4D%424].4R`H55-$("0I/&)R/DEN(%1H;W5S
M86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($]015)!5$E/
M3E,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2159%3E5%4R`H<V5E($YO=&4@,3$H8RDI/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S+#8U,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L-#<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-"PX
M-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-/35!!3EDG4R!32$%212!)3B!#3TQ,04)/4D%424].($%'4D5%345.
M5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`S-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-/4U0@3T8@4D5614Y515,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DL,#4S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4L-#(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@L,30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=23U-3(%!23T9)5#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#`X-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#(X,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4D5314%20T@@04Y$($1%5D5,3U!-14Y4($584$5.4T53/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R.2PW-C$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L,S$S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#8V-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M<W,@+2!G<F%N=',@86YD(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX+#$Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-#DW/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY-S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y215-%05)#2"!!
M3D0@1$5614Q/4$U%3E0@15A014Y315,L($Y%5#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C$L-C4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(T+#@Q-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PV.#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y314Q,24Y'
M+"!'14Y%4D%,($%.1"!!1$U)3DE35%)!5$E612!%6%!%3E-%4SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PV-C$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PS.#4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PW-C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3U!%4D%424Y'($Q/4U,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(U+#(P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R-RPQ,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3(L,3<R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1DE.04Y#24%,($584$5.4T53/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#DS-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`V-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9)3D%.0TE!3"!)3D-/344\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1DE.04Y#24%,($E.0T]-12`H15A014Y315,I("T@
M3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#<S.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-S0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3D54($Q/4U,@1D]2(%1(12!914%2/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(Y+#DT,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(W+#<Y,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q+#8Q."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S('!E<B!S:&%R92!O9B!C;VUM;VX@<W1O8VL@+2!B87-I8R!A;F0@
M9&EL=71E9#H\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K('5S960@:6X@8V]M<'5T:6YG(&QO<W,@
M<&5R('-H87)E(&]F(&-O;6UO;B!S=&]C:RP@8F%S:6,@86YD(&1I;'5T960Z
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,BPX.3$L.#0V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L
M,S8X+#$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDP+#@T-2PY,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U
M930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S
M9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#`U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%0U1"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#2$%.1T53($E.($-!4$E404P@
M1$5&24-)14Y#62`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H
M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(V+#DT-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L,S4W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,C8L,#<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@8V%S:"`H;F5T(&]F
M(&ES<W5A;F-E(&-O<W1S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T
M;R!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L
M871E9"!T;R!R97-T<FEC=&5D('-T;V-K(&%W87)D+"!N970@;V8@9F]R9F5I
M='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#<V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPQ,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE
M97,@86YD(&YO;BUE;7!L;WEE97,@*&EN8VQU9&5S(&YE="!E>&5R8VES92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.2PY-#,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C<L-SDP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Q+#8Q."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4U+#8P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R-BPY-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPS-3<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M,RPU-3$L,#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@U+#8S,"PQ-3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!F;W(@8V%S:"`H;F5T(&]F(&ES<W5A;F-E(&-O<W1S*2`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ-S4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!C87-H("AN970@;V8@:7-S
M=6%N8V4@8V]S=',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!S=&]C:R!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O
M;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L
M(&YE="!O9B!F;W)F96ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@
M8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R
M9"P@;F5T(&]F(&9O<F9E:71U<F5S("AS:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X,2PR,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#,T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#DV+#<Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N
M+65M<&QO>65E<R`H:6YC;'5D97,@;F5T(&5X97)C:7-E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E
M(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@86YD(&YO;BUE;7!L
M;WEE97,@*&EN8VQU9&5S(&YE="!E>&5R8VES92DL('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S+#DS,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#$R,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3@W+#@V
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#8P
M,RPX,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,RPU-3$L,#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!086ED+6EN
M($-A<&ET86P@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@T+#,T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X,"PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#4L.#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O
M<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PS.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O
M;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L
M(&YE="!O9B!F;W)F96ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPP-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N
M=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<R`H:6YC;'5D97,@
M;F5T(&5X97)C:7-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@U+#8S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X-"PS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.#`L,30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!$969I8VET(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q,2PS.#4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@S+#4Y-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-S$L.3<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@8V%S:"`H;F5T(&]F
M(&ES<W5A;F-E(&-O<W1S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L
M871E9"!T;R!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T
M960@<W1O8VL@87=A<F0L(&YE="!O9B!F;W)F96ET=7)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@
M96UP;&]Y965S(&%N9"!N;VXM96UP;&]Y965S("AI;F-L=61E<R!N970@97AE
M<F-I<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.2PY-#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L-SDP*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#8Q
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,C0Q+#,R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#(Q,2PS.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q.#,L-3DU*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V
M.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE
M971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)2D%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($-(04Y'15,@
M24X@0T%0251!3"!$149)0TE%3D-9("A087)E;G1H971I8V%L*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!C87-H+"!I
M<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M(#$L-S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@87=A<F1S
M(&9O<F9E:71E9"P@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X-2PW,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-RPX,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW
M861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E
M-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H
M965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4U14)'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!/4$52051)3D<@04-4259)5$E%4SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,CDL.30S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,C<L-SDP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3$L-C$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!R97%U
M:7)E9"!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@<')O=FED
M960@8GD@*'5S960@:6XI(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#<U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#$T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3,Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV.3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!E
M>'!E;G-E<R`H:6YC;VUE*2P@;F5T("AM86EN;'D@97AC:&%N9V4@9&EF9F5R
M96YC97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#:&%N9V5S(&EN(&%C8W)U960@;&EA8FEL:71Y(&9O<B!E;7!L
M;WEE92!R:6=H=',@=7!O;B!R971I<F5M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@86UO=6YT<R!F=6YD
M960@:6X@<F5S<&5C="!O9B!E;7!L;WEE92!R:6=H=',@=7!O;B!R971I<F5M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=A:6X@;VX@<V%L92!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@9&5B="!I<W-U86YC92!C;W-T<R!A;F0@9&5B="!D
M:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9&5F
M97)R960@<F5V96YU97,@*&EN8VQU9&EN9R!N;VXM8W5R<F5N="!P;W)T:6]N
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPQ-S`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPQ-C`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@:6X@86-C;W5N=',@<F5C96EV
M86)L92!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PY,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@:6X@
M:6YV96YT;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPY,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPW-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN(&%C8V]U
M;G1S('!A>6%B;&4@86YD(&%C8W)U86QS("AI;F-L=61I;F<@;&]N9R!T97)M
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS,C(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@;W!E<F%T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y
M+#(X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S,"PV-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!)3E9%
M4U1)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S@U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#DP
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,#8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F('!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT(&EN(')E<W1R:6-T
M960@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;6]U;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M<&QO>65E
M(')I9VAT<R!U<&]N(')E=&ER96UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I
M;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PP,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPQ,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPR.#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/
M5U,@1E)/32!&24Y!3D-)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R;VT@
M:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#<X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@<VAA<F5S+"!N970@;V8@:7-S=6%N8V4@8V]S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@
M<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L.#DR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-34X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%1D9%0U0@3T8@
M15A#2$%.1T4@4D%412!#2$%.1T53($].($-!4T@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L,SDU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(R-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!)3D-214%312`H
M1$5#4D5!4T4I($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,Q+#8S,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PS-C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y44R!!5"!"14=)
M3DY)3D<@3T8@645!4CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#8L,SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3(L,#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<L,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%($]&($-!4T@@04Y$($-!4T@@
M15%5259!3$5.5%,@050@14Y$($]&(%E%05(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4T+#<V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@V+#,Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#`S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY355!0
M3$5-14Y405)9($E.1D]234%424].($].($E.5D535$E.1R!!3D0@1DE.04Y#
M24Y'($%#5$E6251)15,@3D]4($E.5D],5DE.1R!#05-(($9,3U=3.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S
M92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY355!03$5-14Y4
M05)9($1)4T-,3U-54D4@3TX@0T%32"!&3$]74RT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%I9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#`W.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T
M964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7
M;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M24=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P
M,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R<^/&(^3D]412`Q("T@4TE'3DE&24-!
M3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO8CX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P
M.SPO8CX\+W`^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[
M('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYA+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.T=E;F5R86P\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#%I;CLG/E!R;W1A;&EX($)I;U1H97)A<&5U=&EC<RP@26YC+B`H8V]L
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M=7`^)B,Q-S0[/"]S=7`^('!R;W1E:6X@97AP<F5S<VEO;B!S>7-T96T@*"8C
M,30W.U!R;T-E;&Q%>"8C,30X.RDN($EN(%-E<'1E;6)E<B`R,#`Y+"!0<F]T
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M;VQL96-T:79E;'D@:&5R96EN(&%S('1H92`F(S$T-SM3=6)S:61I87)I97,N
M)B,Q-#@[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/D]N($UA>2`Q
M+"`R,#$R+"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N
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M9&%S92`H1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0
M<F]#96QL17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E
M9"!B>2!T:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`F(S$T
M-SM)<W)A96QI($U/2"8C,30X.RD@:6X@4V5P=&5M8F5R(#(P,3(L(&)Y('1H
M92!"<F%Z:6QI86X@36EN:7-T<GD@;V8@2&5A;'1H("AT:&4@)B,Q-#<[0G)A
M>FEL:6%N($U/2"8C,30X.RD@:6X@36%R8V@@,C`Q,R!A;F0@8GD@=&AE(&%P
M<&QI8V%B;&4@<F5G=6QA=&]R>2!A=71H;W)I=&EE<R!O9B!C97)T86EN(&]T
M:&5R(&-O=6YT<FEE<RX@5&%L:6=L=6-E<F%S92!A;&9A(&ES('1H92!F:7)S
M="!P;&%N="!C96QL+6)A<V5D(')E8V]M8FEN86YT('1H97)A<&5U=&EC('!R
M;W1E:6X@87!P<F]V960@8GD@=&AE($9$02!O<B!A;GD@;W1H97(@;6%J;W(@
M<F5G=6QA=&]R>2!A=71H;W)I='DN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CLG/DEN($%U9W5S="`R,#$T+"!T:&4@1D1!(&%P<')O=F5D('1A;&EG
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M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY486QI9VQU
M8V5R87-E(&%L9F$@:7,@8F5I;F<@;6%R:V5T960@:6X@=&AE(%5N:71E9"!3
M=&%T97,@=6YD97(@=&AE(&)R86YD(&YA;64F(S$V,#M%;&5L>7-O)B,Q-3,[
M(&)Y(%!F:7IE<B!);F,N("@F(S$T-SM09FEZ97(F(S$T.#LI+"!T:&4@0V]M
M<&%N>2=S(&-O;6UE<F-I86QI>F%T:6]N('!A<G1N97(L(&%S('!R;W9I9&5D
M(&EN('1H92!E>&-L=7-I=F4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N
M="!B>2!A;F0@8F5T=V5E;B!0<F]T86QI>"!,=&0N(&%N9"!09FEZ97(@*'1H
M92`F(S$T-SM09FEZ97(@06=R965M96YT)B,Q-#@[*2X@5&AE($-O;7!A;GDL
M('1H<F]U9V@@4')O=&%L:7@@3'1D+BP@;6%R:V5T<R8C,38P.T5L96QY<V\F
M(S$V,#MI;B!)<W)A96PL(&%N9"!I;B!"<F%Z:6P@=6YD97(@=&AE(&)R86YD
M(&YA;64@57!L>7-O)B,Q-3,[+B!3964@3F]T92`R+CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q:6X[)SY0<F]T86QI>"!,=&0N(&=R86YT960@4&9I>F5R
M(&%N(&5X8VQU<VEV92P@=V]R;&1W:61E(&QI8V5N<V4@=&\@9&5V96QO<"!A
M;F0@8V]M;65R8VEA;&EZ92!T86QI9VQU8V5R87-E(&%L9F$@=6YD97(@=&AE
M(%!F:7IE<B!!9W)E96UE;G0L(&)U="!R971A:6YE9"!T:&]S92!R:6=H=',@
M:6X@27-R865L(&%N9"P@<VEN8V4@,C`Q-"P@:6X@0G)A>FEL("AS964@8F5L
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M97)C:6%L:7IA=&EO;B!O9B!T86QI9VQU8V5R87-E(&%L9F$@;VX@82`\9F]N
M=#XT,#PO9F]N=#XE(&%N9"`\9F]N=#XV,#PO9F]N=#XE(&)A<VES+"!R97-P
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M<V]L9"X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^3VX@2G5N92`Q
M."P@,C`Q,RP@4')O=&%L:7@@3'1D+B!E;G1E<F5D(&EN=&\@82!3=7!P;'D@
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M<G5Z(&EN(#(P,30N)B,Q-C`[26X@<W5B<V5Q=65N="!Y96%R<RP@1FEO8W)U
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M96%S="!A<'!R;WAI;6%T96QY("0\9F]N=#XR.#`\+V9O;G0^(&UI;&QI;VX@
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M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^26X@4V5P=&5M8F5R(#(P,30L
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M;'0@<&%T:65N=',@=VET:"!T>7!E<R`Q(&%N9"`S($=A=6-H97(@9&ES96%S
M92P@86YD(&5S=&%B;&ES:&5D('1H870@=&%L:6=L=6-E<F%S92!A;&9A('=I
M;&P@8F4@=&AE(&9I<G-T(&-H;VEC92!F;W(@=')E871M96YT(&9O<B!N97<@
M861U;'0@1V%U8VAE<B!P871I96YT<R!I;B!"<F%Z:6PN/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CLG/E1O(&9A8VEL:71A=&4@=&AE(&%R<F%N9V5M
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M92!A;&9A('1O($9I;V-R=7HN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I
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M97)E;V8N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/D-U<G)E;G1L
M>2P@<&%T:65N=',@87)E(&)E:6YG('1R96%T960@=VET:"!T86QI9VQU8V5R
M87-E(&%L9F$@;VX@82!C;VUM97)C:6%L(&)A<VES(&EN('1H92!5;FET960@
M4W1A=&5S+"!"<F%Z:6PL($-H:6QE(&%N9"!)<W)A96PN/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CLG/DEN(&%D9&ET:6]N('1O('1A;&EG;'5C97)A
M<V4@86QF82P@=&AE($-O;7!A;GD@:7,@=V]R:VEN9R!O;B!T:&4@9&5V96QO
M<&UE;G0@;V8@8V5R=&%I;B!O=&AE<B!P<F]D=6-T<R!U<VEN9R!0<F]#96QL
M17@N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/DEN(&%D9&ET:6]N
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M=&%L('!E<FEO9',N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/D]B
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M:71I97,N/"]P/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I
M;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT
M.B`M,"XU:6X[)SX\8CYB+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.T)A<VES(&]F('!R97-E;G1A=&EO;CPO8CX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,"XW-6EN.R<^5&AE($-O;7!A;GDG<R!F:6YA;F-I86P@<W1A
M=&5M96YT<R!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H
M(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@
M=&AE(%5N:71E9"!3=&%T97,@*"8C,30W.U4N4RX@1T%!4"8C,30X.RDN/"]P
M/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI
M;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[
M)SX\8CYC+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U5S92!O9B!E
M<W1I;6%T97,@:6X@=&AE('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T
M96UE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[
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M<#X-"CPO9&EV/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X
M="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\9&EV/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU
M:6X[)SX\8CYD+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T9U;F-T
M:6]N86P@8W5R<F5N8WD\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#`N-S5I;CLG/E1H92!D;VQL87(@:7,@=&AE(&-U<G)E;F-Y(&]F('1H92!P
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M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY4<F%N<V%C
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M9F]L;&]W:6YG(&5X8VAA;F=E(')A=&5S(&%R92!U<V5D.B`H:2D@9F]R('1R
M86YS86-T:6]N<R`F(S$U,#L@97AC:&%N9V4@<F%T97,@870@=&AE('1R86YS
M86-T:6]N(&1A=&5S(&]R(&%V97)A9V4@<F%T97,[(&%N9"`H:6DI(&9O<B!O
M=&AE<B!I=&5M<R`H9&5R:79E9"!F<F]M(&YO;BUM;VYE=&%R>2!B86QA;F-E
M('-H965T(&ET96US('-U8V@@87,@9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ
M871I;VXL(&5T8RXI("8C,34P.R!H:7-T;W)I8V%L(&5X8VAA;F=E(')A=&5S
M+B!#=7)R96YC>2!T<F%N<V%C=&EO;B!G86EN<R!A;F0@;&]S<V5S(&%R92!C
M87)R:65D('1O(&9I;F%N8VEA;"!I;F-O;64@;W(@97AP96YS97,L(&%S(&%P
M<')O<')I871E+CPO<#X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CXF(S$V,#L\+V(^/"]P
M/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN
M9&5N=#H@+3`N-6EN.R<^/&(^92XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#M#87-H(&5Q=6EV86QE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2!C;VYS:61E<G,@86QL('-H
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M86QE;G1S+CPO<#X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CXF(S$V,#L\+V(^/"]P/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N
M=#H@+3`N-6EN.R<^/&(^9BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#M);G9E;G1O<FEE<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^26YV96YT;W)I97,@87)E('9A;'5E9"!A="!T:&4@
M;&]W97(@;V8@8V]S="!O<B!M87)K970N($-O<W0@;V8@<F%W(&%N9"!P86-K
M86=I;F<@;6%T97)I86QS(&%N9"!P=7)C:&%S960@<')O9'5C=',@:7,@9&5T
M97)M:6YE9"!U<VEN9R!T:&4@)B,Q-#<[;6]V:6YG(&%V97)A9V4F(S$T.#L@
M8F%S:7,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/D-O
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M9'5C=&EO;B!P97)I;V0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
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M9&ET:6]N<RX\+W`^#0H\+V1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^)B,Q-C`[/"]B/CPO<#X-
M"CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E
M;G0Z("TP+C5I;CLG/CQB/F<N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[4')O<&5R='D@86YD(&5Q=6EP;65N=#PO8CX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SXF(S$V
M,#L\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,S9P=#LG/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#0X<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/C$N/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[)SY0<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!S=&%T
M960@870@8V]S="P@;F5T(&]F(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A
M;F0@86UO<G1I>F%T:6]N+CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z
M("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I
M;G1E<CX\8G(O/CPO9&EV/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^
M#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[('=I9'1H.B`Q,#`E.R<^
M#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#,V<'0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`T.'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXR
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M87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ
M(#$R<'0[('=I9'1H.B`Q,#`E.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,V<'0[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=VED=&@Z(#8P)3L@;6%R9VEN+6QE9G0Z(#`N,7!X.R<@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X-"@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG(&-O;'-P
M86X],T0R/EEE87)S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`X,B4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SLG/DQA8F]R871O<GD@97%U:7!M96YT/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
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M+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/D9U<FYI='5R93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/D-O;7!U
M=&5R(&5Q=6EP;65N=#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\
M9F]N=#XS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/"]D
M:78^#0H\+V1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY,
M96%S96AO;&0@:6UP<F]V96UE;G1S(&%R92!A;6]R=&EZ960@8GD@=&AE('-T
M<F%I9VAT+6QI;F4@;65T:&]D(&]V97(@=&AE(&5X<&5C=&5D(&QE87-E('1E
M<FTL('=H:6-H(&ES('-H;W)T97(@=&AA;B!T:&4@97-T:6UA=&5D('5S969U
M;"!L:69E(&]F('1H92!I;7!R;W9E;65N=',N/"]P/@T*/"]D:78^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG
M/CQB/B8C,38P.SPO8CX\+W`^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYH+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.TEM<&%I<FUE;G0@:6X@=F%L=64@;V8@
M;&]N9RUL:79E9"!A<W-E=',Z(#PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^5&AE($-O;7!A;GD@=&5S=',@;&]N9RUL:79E9"!A
M<W-E=',@9F]R(&EM<&%I<FUE;G0@:68@86X@:6YD:6-A=&EO;B!O9B!I;7!A
M:7)M96YT(&5X:7-T<RX@268@=&AE('-U;2!O9B!E>'!E8W1E9"!F=71U<F4@
M8V%S:"!F;&]W<R!O9B!D969I;FET92!L:69E(&%S<V5T<R`H=6YD:7-C;W5N
M=&5D(&%N9"!W:71H;W5T(&EN=&5R97-T(&-H87)G97,I(&ES(&QE<W,@=&AA
M;B!T:&4@8V%R<GEI;F<@86UO=6YT(&]F('-U8V@@87-S971S+"!T:&4@0V]M
M<&%N>2!R96-O9VYI>F5S(&%N(&EM<&%I<FUE;G0@;&]S<RP@86YD('=R:71E
M<R!D;W=N('1H92!A<W-E=',@=&\@=&AE:7(@97-T:6UA=&5D(&9A:7(@=F%L
M=65S+CPO<#X-"CPO9&EV/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I
M;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\
M9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT
M.B`M,"XU:6X[)SX\8CYI+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.TEN8V]M92!T87AE<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N
M=#H@+3`N-6EN.R<^,2XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$
M969E<G)E9"!I;F-O;64@=&%X97,\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
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M="!T;R!I=',@9&5F97)R960@=&%X(&%S<V5T<RX@4V5E($YO=&4@,3`N/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SX\8G(O/CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N
M-6EN.R<^,BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M5;F-E<G1A
M:6YT>2!I;B!I;F-O;64@=&%X97,\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,6EN.R<^5&%X(&)E;F5F:71S(')E8V]G;FEZ960@:6X@=&AE(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&%R92!T:&]S92!T:&%T('1H92!#;VUP86YY)W,@;6%N
M86=E;65N="!D965M<R!A="!L96%S="!M;W)E(&QI:V5L>2!T:&%N(&YO="!T
M;R!B92!S=7-T86EN960L(&)A<V5D(&]N('1E8VAN:6-A;"!M97)I=',N(%1H
M92!A;6]U;G0@;V8@8F5N969I=',@<F5C;W)D960@9F]R('1H97-E('1A>"!B
M96YE9FET<R!I<R!M96%S=7)E9"!A<R!T:&4@;&%R9V5S="!B96YE9FET('1H
M92!#;VUP86YY)W,@;6%N86=E;65N="!D965M<R!M;W)E(&QI:V5L>2!T:&%N
M(&YO="!T;R!B92!S=7-T86EN960N/"]P/@T*/"]D:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C
M,38P.SPO8CX\+W`^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYJ+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.U)E=F5N=64@4F5C;V=N:71I;VX\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/E1H92!#;VUP
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M4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N
M-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SXQ+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.U)E=F5N=65S(&9R;VT@=&AE(&QI8V5N<V4@86YD('-U
M<'!L>2!A9W)E96UE;G0@=VET:"!09FEZ97(\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,6EN.R<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E(&9R
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M;6%T960@=&AE('!E<F9O<FUA;F-E('!E<FEO9"!O9B`Q-"!Y96%R<R`H8V]M
M;65N8VEN9R!U<&]N('1H92!D871E(&]F('1H92!#;VUP86YY)W,@<F5C96EP
M="!O9B!T:&4@=7`M9G)O;G0@;&EC96YS92!P87EM96YT('!A>6%B;&4@8GD@
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M;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD
M96YT.B`M,"XU:6X[)SXR+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.U)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D=6-T<SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q:6X[)SY4:&4@0V]M<&%N>2!R96-O9VYI>F5S(')E=F5N
M=65S(&9R;VTF(S$V,#MS96QL:6YG('!R;V1U8W1S('5P;VX@9&5L:79E<GDL
M('=H96X@=&AE('-A;&5S('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L
M92!A;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD
M96YT.B`M,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/C,N)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0V]M<&%N>2=S('-H87)E(&EN('1H92!C
M;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[)SY5;F1E<B!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@=&AE
M(%!F:7IE<B!!9W)E96UE;G0L('1H92!#;VUP86YY(&ES(&5N=&ET;&5D('1O
M(#0P)2!O9B!T:&4@<')O9FET<R!O<B!L;W-S(&9R;VT@<V%L97,@;V8@=&%L
M:6=L=6-E<F%S92!A;&9A+"!A;F0@<F5L871E9"!E>'!E;G-E<R!I;F-U<G)E
M9"P@97AC97!T('=I=&@@<F5S<&5C="!T;R!S86QE<R!I;B!)<W)A96P@86YD
M($)R87II;"`H<VEN8V4@,C`Q-"DL('=H97)E('1H92!#;VUP86YY(')E=&%I
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU
M:6X[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^:RXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#M297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M8V]S=',@/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[
M)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&5X<&5N<V5D
M(&%S(&EN8W5R<F5D(&%N9"!C;VYS:7-T('!R:6UA<FEL>2!O9B!P97)S;VYN
M96PL('-U8F-O;G1R86-T;W)S(&%N9"!C;VYS=6QT86YT<R`H;6%I;FQY(&EN
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M(%1R861E(&%N9"!,86)O<B`H=&AE("8C,30W.T]#4R8C,30X.RD@87)E(')E
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M92!C;W-T<R!A<F4@:6YC=7)R960N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#`N-S5I;CLG/E)E:6UB=7)S96UE;G1S(')E8V5I=F5D(&9R;VT@4&9I
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M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY);B!C
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M;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`P+C<U:6X[)SY.;VYR969U;F1A8FQE(&%D=F%N8V4@<&%Y;65N
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU
M:6X[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^;"XF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#;VYC96YT<F%T:6]N
M(&]F(&-R961I="!R:7-K<R!A;F0@=')A9&4@<F5C96EV86)L93PO8CX\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^1FEN86YC:6%L(&EN
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M<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2=S('1R861E(')E8V5I
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M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN
M9&5N=#H@+3`N-6EN.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQD:78^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG
M/CQB/FTN)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW
M-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U
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M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2!E;&5C=&5D('1O(')E8V]G;FEZ92!C
M;VUP96YS871I;VX@8V]S="!F;W(@86X@87=A<F0@=VET:"!O;FQY('-E<G9I
M8V4@8V]N9&ET:6]N<R!T:&%T(&AA<R!A(&=R861E9"!V97-T:6YG('-C:&5D
M=6QE('5S:6YG('1H92!A8V-E;&5R871E9"!M971H;V0@8F%S960@;VX@=&AE
M(&UU;'1I<&QE+6]P=&EO;B!A=V%R9"!A<'!R;V%C:"X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^5VAE;B!S=&]C:R!O<'1I;VYS(&%R
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M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C
M,38P.SPO8CX\+W`^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYN+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.TYE="!L;W-S('!E<B!S:&%R93PO8CX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^0F%S:6,@86YD(&1I;'5T
M960@;&]S<R!P97(@<VAA<F4@*"8C,30W.TQ04R8C,30X.RD@87)E(&-O;7!U
M=&5D(&)Y(&1I=FED:6YG(&YE="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R
M86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDG<R!#;VUM;VX@
M4W1O8VLL('!A<B!V86QU92`D/&9O;G0^,"XP,#$\+V9O;G0^('!E<B!S:&%R
M92`H=&AE("8C,30W.T-O;6UO;B!3=&]C:R8C,30X.RD@;W5T<W1A;F1I;F<@
M9F]R(&5A8V@@<&5R:6]D+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C<U:6X[)SY$:6QU=&5D($Q04R!D;V5S(&YO="!I;F-L=61E(#QF;VYT/C<L
M,C@P+#0V.3PO9F]N=#XL(#QF;VYT/C$P+#8W-2PS,#0\+V9O;G0^(&%N9"`\
M9F]N=#XQ."PX-3`L-S(T/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T:6]N<R`L(')E<W1R:6-T960@
M<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!A;F0@<VAA<F5S(&ES<W5A8FQE('5P
M;VX@8V]N=F5R<VEO;B!O9B!T:&4@8V]N=F5R=&EB;&4@;F]T97,@*&ES<W5E
M9"!I;B!397!T96UB97(@,C`Q,RD@9F]R('1H92!F:7-C86P@>65A<G,@96YD
M960@1&5C96UB97(@,S$L(#(P,3(L(#(P,3,@86YD(#(P,30L(')E<W!E8W1I
M=F5L>2P@8F5C875S92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I
M=F4N/"]P/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#4V+C=P
M=#L@=&5X="UI;F1E;G0Z("TR,"XW<'0[)SX\8CXF(S$V,#L\+V(^/"]P/@T*
M/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@-38N-W!T.R!T97AT+6EN
M9&5N=#H@+3(P+C=P=#LG/CQB/F\N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[0V]N=F5R=&EB;&4@;F]T97,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`U-BXW<'0[('1E>'0M:6YD96YT.B`P:6X[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#4V+C=P=#L@=&5X="UI;F1E
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M96YT:7)E;'DN/"]P/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#4V+C=P=#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQB<B\^/"]P/@T*/&1I=CX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#4V+C=P=#L@
M=&5X="UI;F1E;G0Z("TR,"XW<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^<"X@)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[4F5C96YT;'D@:7-S=65D(&%C8V]U;G1I;F<@<')O
M;F]U;F-E;65N=',Z/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#4V+C=P=#L@=&5X="UI;F1E;G0Z
M(#!I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SY);B!!=6=U<W0@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT
M:6YG(%-T86YD87)D<R!";V%R9"`H)B,Q-#<[1D%30B8C,30X.RD@:7-S=65D
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M96-E;6)E<B`S,2P@,C`Q-BX@5&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!T
M:&4@861O<'1I;VX@;V8@=&AI<R!N97<@<W1A;F1A<F0@=VEL;"!N;W0@:&%V
M92!A(&UA=&5R:6%L(&EM<&%C="!O;B!I=',@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#4V+C=P=#L@=&5X="UI;F1E;G0Z
M(#!I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SY);B!-87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D(&=U:61A;F-E
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M<B!$96-E;6)E<B`Q-2P@,C`Q-B`H96%R;'D@861O<'1I;VX@:7,@;F]T('!E
M<FUI='1E9"DN(%1H92!G=6ED86YC92!P97)M:71S('1H92!U<V4@;V8@96ET
M:&5R(&$@<F5T<F]S<&5C=&EV92!O<B!C=6UU;&%T:79E(&5F9F5C="!T<F%N
M<VET:6]N(&UE=&AO9"X@5&AE($-O;7!A;GD@:7,@8W5R<F5N=&QY(&5V86QU
M871I;F<@=&AE('!O=&5N=&EA;"!E9F9E8W0@;V8@=&AE(&%M96YD960@9W5I
M9&%N8V4@;VX@:71S(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<RX\+W`^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW
M861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E
M-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H
M965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY,24-%3E-%($%.1"!355!03%D@04=2145-14Y4/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ)0T5.4T4@04Y$
M(%-54%!,62!!1U)%14U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,24-%3E-%($%.1"!355!03%D@
M04=2145-14Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M(&ED/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI
M;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6EN9&5N=#H@,&EN.R<^/&(^3D]412`R("T@3$E#14Y312!!3D0@
M4U504$Q9($%'4D5%345.5#PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#`N-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C5I;CLG/D]N($YO=F5M8F5R(#,P+"`R,#`Y+"!0<F]T86QI>"!,=&0N
M(&%N9"!09FEZ97(@96YT97)E9"!I;G1O('1H92!09FEZ97(@06=R965M96YT
M('!U<G-U86YT('1O('=H:6-H(%!F:7IE<B!W87,@9W)A;G1E9"!A;B!E>&-L
M=7-I=F4L('=O<FQD=VED92!L:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE
M<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A;&9A+"!E>&-E<'0@:6X@27-R865L
M+B!5;F1E<B!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@=&AE(%!F:7IE
M<B!!9W)E96UE;G0L(%!R;W1A;&EX($QT9"X@<F5T86EN960@=&AE(')I9VAT
M('1O(&-O;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A;&9A(&EN($ES<F%E
M;"X@07,@;65N=&EO;F5D(&EN($YO=&4@,2P@:6X@2G5N92`R,#$S+"!09FEZ
M97(@<F5T=7)N960@=&AE(&-O;6UE<F-I86QI>F%T:6]N(')I9VAT<R!I;B!"
M<F%Z:6P@=&\@4')O=&%L:7@@3'1D+B!5;F1E<B!T:&4@4&9I>F5R($%G<F5E
M;65N="P@4&9I>F5R(&UA9&4@86X@=7!F<F]N="!P87EM96YT('1O(%!R;W1A
M;&EX($QT9"X@;V8@)#QF;VYT/C8P+C`\+V9O;G0^(&UI;&QI;VX@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="!A
M;F0@<VAO<G1L>2!T:&5R96%F=&5R('!A:60@4')O=&%L:7@@3'1D+B!A;B!A
M9&1I=&EO;F%L("0\9F]N=#XU+C`\+V9O;G0^(&UI;&QI;VX@=7!O;B!T:&4@
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M960@=&\@/&9O;G0^-#`\+V9O;G0^)2!O9B!T:&4@<F5S=6QT<R`H<')O9FET
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M(&5Q=6%L('1O/"]F;VYT/B!A<'!R;WAI;6%T96QY)B,Q-C`[)#QF;VYT/C<N
M,3PO9F]N=#X@;6EL;&EO;B!A;F0@)#QF;VYT/C@N,#PO9F]N=#X@;6EL;&EO
M;BP@<F5S<&5C=&EV96QY+B8C,38P.T%F=&5R(&1E9'5C=&EN9R!T:&4@;&]S
M<V5S+"!T:&4@0V]M<&%N>2!I<R!E;G1I=&QE9"!T;R!R96-E:79E(&EN(&-A
M<V@@:71S('-H87)E(&EN('1H92!P<F]F:71S(&]F('1H92!C;VQL86)O<F%T
M:6]N(&]P97)A=&EO;BX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
M-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I
M;CLG/E1H92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870@=&AE(&EN:71I
M86PL(&YO;BUR969U;F1A8FQE('5P9G)O;G0@;&EC96YS92!F964@<&%Y;65N
M="!O9B`D-C`N,"!M:6QL:6]N('1O9V5T:&5R('=I=&@@=&AE(&9I<G-T("0U
M+C`@;6EL;&EO;B!P87EM96YT('=I;&P@8F4@<F5C;V=N:7IE9"!O;B!A('-T
M<F%I9VAT(&QI;F4@8F%S:7,@87,@<F5V96YU92!O=F5R('1H92!E<W1I;6%T
M960@<F5L871I;VYS:&EP('!E<FEO9"`H87!P<F]X:6UA=&5L>2`D/&9O;G0^
M-"XV/"]F;VYT/B!M:6QL:6]N('!E<B!Y96%R*2X@5&AE($-O;7!A;GD@:&%S
M(&5S=&EM871E9"!T:&%T('1H92!R96QA=&EO;G-H:7`@<&5R:6]D(&9O<B!I
M=',@87)R86YG96UE;G0@=VET:"!09FEZ97(@=VEL;"!B92!A<'!R;WAI;6%T
M96QY(#QF;VYT/C$T/"]F;VYT/B!Y96%R<R`H8V]M;65N8VEN9R!U<&]N('1H
M92!#;VUP86YY)W,@<F5C96EP="!O9B!T:&4@=7`M9G)O;G0@;&EC96YS92!P
M87EM96YT*2!B87-E9"!O;B!T:&4@0V]M<&%N>2=S(&QA<W0@;6%T97)I86P@
M<&%T96YT(')E;&%T:6YG('1O('1A;&EG;'5C97)A<V4@86QF82!T;R!E>'!I
M<F4N(%1H92`D,C4N,"!M:6QL:6]N(&UI;&5S=&]N92!P87EM96YT(')E8V5I
M=F5D(&1U<FEN9R`R,#$R(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@1D1!)W,@
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M=F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XU:6X[)SY4:&4@
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M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/D%C8V]R9&EN9R!T
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M+B!3964@3F]T92`V82X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M:6YD96YT.B`P:6X[)SX\8G(O/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y
M7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K
M<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!23U!%4E19
M($%.1"!%455)4$U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y04D]015)462!!3D0@15%525!-14Y4
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G
M87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@,&EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^3D]4
M12`S("T@4%)/4$525%D@04Y$($5154E0345.5#PO8CX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU
M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\8CXF(S$V,#L\+V(^
M/"]F;VYT/CPO<#X-"CQD:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUT;W`Z
M(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W:61T:#H@,3`P)3LG/@T*#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`N,C5I;CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^82X\+V(^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,3)P=#L@=&5X="UI;F1E;G0Z(#(U+CEP=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,3)P=#L@=&5X="UI;F1E;G0Z(#(U+CEP=#LG
M/CQB<B\^/"]P/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=VED=&@Z(#8P)3L@;6%R9VEN+6QE9G0Z(#%I;CLG
M/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY$96-E;6)E<B`S,2P\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
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M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O
M;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CQS=')O;F<^/&9O
M;G0^/"]F;VYT/CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$-#X\8G(O/CPO
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M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H
M.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ-"PX
M-3@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P
M<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
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M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^1G5R;FET=7)E)B,Q-C`[86YD)B,Q-C`[8V]M<'5T
M97(F(S$V,#ME<75I<&UE;G0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,BPP-S0\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
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M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^,34L,#<P/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXQ-2PT,C<\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M,38P.W5N9&5R)B,Q-C`[8V]N<W1R=6-T:6]N/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
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M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C(X/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXQ-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,S(L,#,P/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A
M9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,S(L-S,V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY,
M97-S)B,Q-C`[)B,Q-3`[)B,Q-C`[86-C=6UU;&%T960F(S$V,#MD97!R96-I
M871I;VX\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`R,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M86YD)B,Q-C`[86UO<G1I>F%T:6]N/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=VAI=&4M
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M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B@Q."PS,3D\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXH,C$L-#4T/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P
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M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXQ,RPW,3$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX
M,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO
M=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`T+C-P=#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV(&-L87-S/3-$0W5R
M<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#L@=VED
M=&@Z(#$P,"4[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL93TS1"=W:61T
M:#H@,"XU:6X[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQB/F(N
M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/D1E<')E
M8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&EN(')E<W!E8W0@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N="!T;W1A;&5D(&%P<')O>&EM871E;'D@)#QF;VYT
M/C,N-SPO9F]N=#X@;6EL;&EO;BP@)#QF;VYT/C,N-3PO9F]N=#X@;6EL;&EO
M;B!A;F0@)#QF;VYT/C,N,3PO9F]N=#X@;6EL;&EO;B!F;W(@=&AE('EE87)S
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R,#$T+"!R97-P
M96-T:79E;'DN/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV
M7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DE.5D5.5$]22453/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P
M,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,&EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^3D]412`T("T@24Y614Y43U))
M15,\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW
M-6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P
M<'@[('=I9'1H.B`Q,#`E.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R<^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\8CYA+CPO8CX\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R<^26YV96YT;W)I97,@870@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,30@
M8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z/"]F;VYT/CPO9F]N=#X\+V9O
M;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@8VQA
M<W,],T1#=7)S;W)0;VEN=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@
M,3)P=#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XU:6X[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*
M/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!C;&%S<STS1$-U<G-O
M<E!O:6YT97(^/&)R+SX\+V1I=CX-"CQD:78^#0H\9&EV(&-L87-S/3-$0W5R
M<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@-C`E.R!M
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY$96-E;6)E
M<B`S,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
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M*3PO:3X\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CQS=')O
M;F<^/&9O;G0^/"]F;VYT/CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N=#X\+V9O
M;G0^/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/CQF;VYT/CPO9F]N
M=#X\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=I9'1H.B`X,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY287<@
M;6%T97)I86QS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P
M)3LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P
M>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^,BPS-#(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ,S(\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-2PU,C,\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
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M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C0L.3$Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^5&]T
M86P@:6YV96YT;W)Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T
M(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C<L.34W/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT
M.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXV+#8V-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX@/"]D:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN+71O
M<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[('=I9'1H.B`Q,#`E.R<^#0H-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R<^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\8CYB+CPO8CX\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY$=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N
M9"`R,#$T+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!A<'!R;WAI;6%T96QY("0\
M9F]N=#XQ+C8\+V9O;G0^(&UI;&QI;VX@86YD("0\9F]N=#XQ+C<\+V9O;G0^
M(&UI;&QI;VXL(')E<W!E8W1I=F5L>2P@9F]R('=R:71E+61O=VX@;V8@:6YV
M96YT;W)Y('5N9&5R(&-O<W0@;V8@<F5V96YU97,N/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E
M.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R
M:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3$E!0DE,2519($9/4B!%35!,3UE%12!224=(5%,@55!/
M3B!2151)4D5-14Y4/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DQ)04))3$E462!&3U(@14U03$]9144@4DE'2%13
M(%503TX@4D5425)%345.5"!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQ)04))3$E462!&3U(@14U03$]9
M144@4DE'2%13(%503TX@4D5425)%345.5#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX@/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,&EN.R<^/&(^3D]412`U
M("T@3$E!0DE,2519($9/4B!%35!,3UE%12!224=(5%,@55!/3B!2151)4D5-
M14Y4/"]B/CPO<#X@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/B8C
M,38P.SPO<#X@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/E1H92!)
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M=6YT960@8F%S:7,N/"]P/B`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN
M.R<^)B,Q-C`[/"]P/B`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R<^
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M86QA;F-E('-H965T<R!U;F1E<B`F(S$T-SM&=6YD<R!I;B!R97-P96-T(&]F
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M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R
M,#$T+"!T:&4@0V]M<&%N>2!D97!O<VET960@87!P<F]X:6UA=&5L>3QB/B`\
M+V(^)#QF;VYT/C$W-RPP,#`\+V9O;G0^+"`D/&9O;G0^,3DT+#`P,#PO9F]N
M=#X@86YD("0\9F]N=#XQ.34L,#`P/"]F;VYT/BP@<F5S<&5C=&EV96QY+"!W
M:71H(&EN<W5R86YC92!C;VUP86YI97,@:6X@8V]N;F5C=&EO;B!W:71H(&ET
M<R!S979E<F%N8V4@<&%Y;65N="!O8FQI9V%T:6]N<RX\+W`^(#QP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,"XU:6X[)SXF(S$V,#L\+W`^(#QP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XU:6X[)SY);B!A8V-O<F1A;F-E('=I=&@@=&AE(&-U
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M=7)A;F-E(&-O;7!A;FEE<R`H=&AE("8C,30W.T-O;G1R:6)U=&EO;B!0;&%N
M<R8C,30X.RDN/"]P/B`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R<^
M)B,Q-C`[/"]P/B`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R<^5&AE
M(&%M;W5N=',@;V8@<V5V97)A;F-E('!A>2!E>'!E;G-E<R!W97)E(&%P<')O
M>&EM871E;'D@)#QF;VYT/C$N,#PO9F]N=#X@;6EL;&EO;B!F;W(@96%C:"!O
M9B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3(L(#(P,3,@86YD
M(#(P,30L(&]F('=H:6-H(&%P<')O>&EM871E;'D\8CX@/"]B/B0\9F]N=#XV
M-S`L,#`P/"]F;VYT/BP@)#QF;VYT/C@P,2PP,#`\+V9O;G0^(&%N9"`D/&9O
M;G0^-S<Y+#`P,#PO9F]N=#X@:6X@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M(#,Q+"`R,#$R+"`R,#$S(&%N9"`R,#$T+"!R97-P96-T:79E;'DL('=E<F4@
M:6X@<F5S<&5C="!O9B!A($-O;G1R:6)U=&EO;B!0;&%N+B!'86EN(&]N(&%M
M;W5N=',@9G5N9&5D(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG:'1S('5P
M;VX@<F5T:7)E;65N="!T;W1A;&5D(&%P<')O>&EM871E;'D\8CX@/"]B/B0\
M9F]N=#XS-BPP,#`\+V9O;G0^+"`D/&9O;G0^-3@L,#`P/"]F;VYT/B!A;F0@
M)#QF;VYT/C(R+#`P,#PO9F]N=#X@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+CPO
M<#X@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/B8C,38P.SPO<#X@
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CLG/E1H92!#;VUP86YY(&5X
M<&5C=',@=&\@8V]N=')I8G5T92!A<'!R;WAI;6%T96QY("0\9F]N=#XX-C,L
M,#`P/"]F;VYT/B!I;B!T:&4@>65A<B!E;F1I;F<@1&5C96UB97(@,S$L(#(P
M,34@=&\@:6YS=7)A;F-E(&-O;7!A;FEE<R!I;B!C;VYN96-T:6]N('=I=&@@
M:71S('-E=F5R86YC92!L:6%B:6QI=&EE<R!F;W(@:71S(&]P97)A=&EO;G,@
M9F]R('1H870@>65A<BP@87!P<F]X:6UA=&5L>3QB/B`\+V(^)#QF;VYT/C8X
M-2PP,#`\+V9O;G0^(&]F('=H:6-H('=I;&P@8F4@8V]N=')I8G5T960@=&\@
M;VYE(&]R(&UO<F4@0V]N=')I8G5T:6]N(%!L86YS+CPO<#X@/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,"`P+C5I;CLG/B8C,38P.SPO<#X@/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C5I;CLG/D1U<FEN9R!T:&4@9FEV92UY96%R('!E<FEO
M9"!F;VQL;W=I;F<@1&5C96UB97(@,S$L(#(P,30L('1H92!#;VUP86YY(&5X
M<&5C=',@=&\@<&%Y(&9U='5R92!B96YE9FET<R!T;R!T:')E93QB/B`\+V(^
M96UP;&]Y965S('5P;VX@96%C:"!S=6-H(&5M<&QO>65E)W,@;F]R;6%L(')E
M=&ER96UE;G0@86=E+B!4:&4@0V]M<&%N>2!A;G1I8VEP871E<R!T:&%T('1H
M92!B96YE9FET<R!P87EA8FQE('=I;&P@8F4@:6UM871E<FEA;"X\+W`^(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV
M7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y44SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M3TU-251-14Y44R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P
M,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,&EN.R<^/&(^
M3D]412`V("T@0T]-34E4345.5%,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CXF(S$V,#L\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XU:6X[)SX\8CYA+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.U)O>6%L='D@0V]M;6ET;65N=',\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT
M.B`M,"XR-6EN.R<^,2XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4
M:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@<&%Y(')O>6%L=&EE<R!T;R!T
M:&4@3T-3(&]N('!R;V-E961S(&9R;VT@=&AE('-A;&4@;V8@<')O9'5C=',@
M9&5V96QO<&5D(&9R;VT@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%C=&EV
M:71I97,@=&AA="!W97)E(&9U;F1E9"P@<&%R=&EA;&QY+"!B>2!G<F%N=',@
M9G)O;2!T:&4@3T-3+B!!="!T:&4@=&EM92!T:&4@9W)A;G1S('=E<F4@<F5C
M96EV960L('-U8V-E<W-F=6P@9&5V96QO<&UE;G0@;V8@=&AE(')E;&%T960@
M<')O:F5C=',@=V%S(&YO="!A<W-U<F5D+CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[)SY);B!T:&4@8V%S92!O9B!F86EL=7)E(&]F(&$@<')O:F5C
M="!T:&%T('=A<R!P87)T;'D@9FEN86YC960@87,@9&5S8W)I8F5D(&%B;W9E
M+"!T:&4@0V]M<&%N>2!I<R!N;W0@;V)L:6=A=&5D('1O('!A>2!A;GD@<W5C
M:"!R;WEA;'1I97,@;W(@<F5P87D@9G5N9&EN9R!R96-E:79E9"!F<F]M('1H
M92!/0U,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/E5N9&5R('1H
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M92P@/&9O;G0^,3`P/"]F;VYT/B4@;V8@=&AE(&%M;W5N="!O9B!T:&4@9W)A
M;G0@<F5C96EV960@*&1O;&QA<B!L:6YK960I+"!P;'5S+"!C;VUM96YC:6YG
M('5P;VX@2F%N=6%R>2`Q+"`R,#`Q+"!I;G1E<F5S="!A="!A;FYU86P@<F%T
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M='D@<F%T92X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^4F]Y86QT
M>2!E>'!E;G-E<R!T;R!T:&4@3T-3(&%R92!I;F-L=61E9"!I;B!T:&4@<W1A
M=&5M96YT(&]F(&]P97)A=&EO;G,@87,@82!C;VUP;VYE;G0@;V8@=&AE(&-O
M<W0@;V8@<F5V96YU97,@86YD('=E<F4@87!P<F]X:6UA=&5L>2`D/&9O;G0^
M,2XU/"]F;VYT/B!M:6QL:6]N+"`D/&9O;G0^,SDR+#`P,#PO9F]N=#X@86YD
M("0\9F]N=#XY-3$L,#`P/"]F;VYT/B!D=7)I;F<@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R,#$T+"!R97-P96-T:79E
M;'DN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/D%T($1E8V5M8F5R
M(#,Q+"`R,#$T+"!T:&4@;6%X:6UU;2!R;WEA;'1Y(&%M;W5N="!P87EA8FQE
M(&)Y('1H92!#;VUP86YY('5N9&5R('1H97-E(&9U;F1I;F<@87)R86YG96UE
M;G1S(&ES(&%P<')O>&EM871E;'D@)#QF;VYT/C,P/"]F;VYT/B!M:6QL:6]N
M("AW:71H;W5T(&EN=&5R97-T+"!A<W-U;6EN9R`Q,#`E(&]F('1H92!F=6YD
M<R!A<F4@<&%Y86)L92DN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[
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M=#XV-S0L,#`P/"]F;VYT/BP@)#QF;VYT/C@P+#`P,#PO9F]N=#X@86YD("0\
M9F]N=#XQ,#0L,#`P/"]F;VYT/B!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R,#$T+"!R97-P96-T:79E;'DN
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/E5N9&5R(&5A8V@@86=R
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M('=E<F4@;6%D92!D=7)I;F<@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^3F]N92!O9B!T:&4@86=R965M96YT
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M9&5R('1H92!A9W)E96UE;G0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CXF(S$V,#L\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M
M,"XU:6X[)SX\8CYB+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U-U
M8F-O;G1R86-T:6YG($%G<F5E;65N=',\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#`N-S5I;CLG/E1H92!#;VUP86YY(&AA<R!E;G1E<F5D(&EN
M=&\@<W5B+6-O;G1R86-T:6YG(&%G<F5E;65N=',@=VET:"!S979E<F%L(&-L
M:6YI8V%L('!R;W9I9&5R<R!A;F0@8V]N<W5L=&%N=',\8CX@/"]B/FEN($ES
M<F%E;"P@=&AE(%5N:71E9"!3=&%T97,@86YD(&-E<G1A:6X@;W1H97(@8V]U
M;G1R:65S(&EN(&-O;FYE8W1I;VX@=VET:"!I=',@<')I;6%R>2!P<F]D=6-T
M(&1E=F5L;W!M96YT('!R;V-E<W,N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T
M+"!T;W1A;"!C;VUM:71M96YT<R!U;F1E<B!S86ED(&%G<F5E;65N=',@=V5R
M92!A<'!R;WAI;6%T96QY("0\9F]N=#XQ+C(\+V9O;G0^(&UI;&QI;VXN/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M
M,"XU:6X[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYC+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.TQE87-E($%G<F5E;65N=',\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/E1H92!#;VUP86YY
M(&ES(&$@<&%R='D@=&\@82!N=6UB97(@;V8@;&5A<V4@86=R965M96YT<R!F
M;W(@:71S(&9A8VEL:71I97,L('1H92!L871E<W0@;V8@=VAI8V@@97AP:7)E
M<R!I;B`R,#$V+B!4:&4@0V]M<&%N>2!H87,@=&AE(&]P=&EO;B!T;R!E>'1E
M;F0@8V5R=&%I;B!O9B!S=6-H(&%G<F5E;65N=',@;VX@=&AR964@;V-C87-I
M;VYS(&9O<B!A9&1I=&EO;F%L(&9I=F4M>65A<B!P97)I;V1S+"!F;W(@82!T
M;W1A;"!O9B`Q-2!A9&1I=&EO;F%L('EE87)S+B!5;F1E<B!T:&4@;&5A<V5S
M+"!T:&4@86=G<F5G871E(&UO;G1H;'D@<F5N=&%L('!A>6UE;G1S(&%R92!A
M<'!R;WAI;6%T96QY("0\9F]N=#XX-2PP,#`\+V9O;G0^+B!!<R!O9B!$96-E
M;6)E<B`S,2P@,C`Q-"P@=&AE($-O;7!A;GD@<')O=FED960@8F%N:R!G=6%R
M86YT965S(&]F(&%P<')O>&EM871E;'D@)#QF;VYT/C,Q-2PP,#`\+V9O;G0^
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M<R!A<F4@87!P<F]X:6UA=&5L>2!A<R!F;VQL;W=S.B`R,#$U("T@)#QF;VYT
M/C$L,#$T+#`P,#PO9F]N=#XL(#(P,38@)B,Q-3`[("0\9F]N=#XQ+#`P.2PP
M,#`\+V9O;G0^+"`R,#$W("0\9F]N=#XQ+#`P.2PP,#`\+V9O;G0^+B!,96%S
M92!E>'!E;G-E<R!T;W1A;&5D(&%P<')O>&EM871E;'D@)#QF;VYT/CDW,2PP
M,#`\+V9O;G0^+"`D/&9O;G0^,2PQ,S,L,#`P/"]F;VYT/B!A;F0@)#QF;VYT
M/C$L,#0T+#`P,#PO9F]N=#X@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N
M-6EN.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^9"XF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#M696AI8VQE($QE87-E(&%N9"!-86EN=&5N
M86YC92!!9W)E96UE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@<V5V97)A;"!T
M:')E92UY96%R(&QE87-E(&%N9"!M86EN=&5N86YC92!A9W)E96UE;G1S(&9O
M<B!V96AI8VQE<R!W:&EC:"!A<F4@<F5G=6QA<FQY(&%M96YD960@87,@;F5W
M('9E:&EC;&5S(&%R92!L96%S960N(%1H92!C=7)R96YT(&UO;G1H;'D@;&5A
M<V4@9F5E<R!A9V=R96=A=&4@87!P<F]X:6UA=&5L>2`D/&9O;G0^-3$L,#`P
M/"]F;VYT/BX@5&AE(&5X<&5C=&5D(&QE87-E('!A>6UE;G1S(&9O<B!T:&4@
M>65A<G,@96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$U+"`R,#$V(&%N9"`R,#$W
M(&%R92!A<'!R;WAI;6%T96QY("0\9F]N=#XU,#0L,#`P/"]F;VYT/BP@)#QF
M;VYT/C(X.2PP,#`\+V9O;G0^(&%N9"`D/&9O;G0^,3$X+#`P,#PO9F]N=#XL
M(')E<W!E8W1I=F5L>2X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV
M7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R
M9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T
M<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4TA!4D4@0T%0251!3#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY32$%212!#05!)5$%,(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4TA!4D4@0T%0251!3#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQB/DY/5$4@-R`M(%-(05)%($-!4$E404P\+V(^/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@
M+3`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^)B,Q-C`[
M/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@
M=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQB/F$N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4FEG:'1S
M(&]F('1H92!#;VUP86YY)W,@8V]M;6]N('-T;V-K/"]B/CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/E1H92!#;VUP86YY)W,@8V]M;6]N('-T;V-K(&ES(&QI<W1E9"!O;B!T
M:&4@3EE312!-2U0@86YD+"!S:6YC92!397!T96UB97(@-BP@,C`Q,"P@;VX@
M=&AE(%1E;"!!=FEV(%-T;V-K($5X8VAA;F=E+B!%86-H('-H87)E(&]F($-O
M;6UO;B!3=&]C:R!I<R!E;G1I=&QE9"!T;R!O;F4@=F]T92X@5&AE(&AO;&1E
M<G,@;V8@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!A<F4@86QS;R!E;G1I=&QE
M9"!T;R!R96-E:79E(&1I=FED96YD<R!W:&5N979E<B!F=6YD<R!A<F4@;&5G
M86QL>2!A=F%I;&%B;&4L('=H96X@86YD(&EF(&1E8VQA<F5D(&)Y('1H92!"
M;V%R9"!O9B!$:7)E8W1O<G,N(%-I;F-E(&ET<R!I;F-E<'1I;VXL('1H92!#
M;VUP86YY(&AA<R!N;W0@9&5C;&%R960@86YY(&1I=FED96YD<RX\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E
M;G0Z("TP+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQB/B8C
M,38P.SPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\8CYB+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U-T
M;V-K(&)A<V5D(&-O;7!E;G-A=&EO;B`\+V(^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^3VX@
M1&5C96UB97(@,30L(#(P,#8L('1H92!";V%R9"!O9B!$:7)E8W1O<G,@861O
M<'1E9"!T:&4@4')O=&%L:7@@0FEO5&AE<F%P975T:6-S+"!);F,N(#(P,#8@
M4W1O8VL@26YC96YT:79E(%!L86XL(&%S(&%M96YD960@*'1H92`F(S$T-SM0
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M96-T:6]N<R`Q,#(@86YD(#$P,D$@;V8@=&AE($ES<F%E;&D@26YC;VUE(%1A
M>"!/<F1I;F%N8V4N($5A8V@@;W!T:6]N(&=R86YT(&ES('-U8FIE8W0@=&\@
M=&AE('1R86-K(&-H;W-E;B!B>2!T:&4@0V]M<&%N>2P@96ET:&5R(%-E8W1I
M;VX@,3`R(&]R(%-E8W1I;VX@,3`R02!O9B!T:&4@27-R865L:2!);F-O;64@
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M($]R9&EN86YC92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY!<R!O9B!$96-E;6)E<B`S,2P@
M,C`Q-"P@/&9O;G0^,2PY,C,L-#0T/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N
M(%-T;V-K(')E;6%I;B!A=F%I;&%B;&4@9F]R(&=R86YT('5N9&5R('1H92!0
M;&%N+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#`N-S5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C<U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SY&<F]M($IA;G5A<GD@,2P@,C`Q,B!T:')O=6=H($1E8V5M8F5R(#,Q+"`R
M,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&]P=&EO;G,@86YD('-H87)E<R!O
M9B!R97-T<FEC=&5D('-T;V-K('1O(&-E<G1A:6X@96UP;&]Y965S(&%N9"!N
M;VXM96UP;&]Y965S(&%S(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U
M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.SQB/D]P=&EO;G,@86YD(')E<W1R:6-T960@
M<W1O8VL@9W)A;G1E9"!T;R!E;7!L;WEE97,Z/"]B/CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP
M+C(U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN+71O<#H@,'!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[('=I9'1H.B`Q,#`E.R<^#0H-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#%I;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I
M;CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^82D\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0^/&9O
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M/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,3)P=#L@=&5X="UI;F1E;G0Z(#(U+CEP=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV(&-L87-S/3-$
M0W5R<V]R4&]I;G1E<CX\8G(O/CPO9&EV/@T*/&1I=CX-"CQD:78@8VQA<W,]
M,T1#=7)S;W)0;VEN=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`X
M,24[(&UA<F=I;BUL969T.B`Q+C(U:6X[)SX-"@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
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M+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SY.;RX@;V8@;W!T:6]N<SQB<B\^(&]R
M(')E<W1R:6-T960\8G(O/B!S=&]C:R!G<F%N=&5D/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^5F5S=&EN9R!P97)I;V0\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO
M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY&86ER('9A
M;'5E/&)R+SX@870@9W)A;G0\8G(O/B`H52Y3+CQB<B\^(&1O;&QA<G,@:6X\
M8G(O/B!T:&]U<V%N9',I/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
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M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXT,#`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/FXO83PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF
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M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!W:61T:#H@,38E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,2PQ,#`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R!W:61T:#H@,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R!W:61T:#H@,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
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M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[('=I9'1H.B`P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXY,#`L,#`P/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\9F]N=#XT/"]F;VYT/B!Y
M96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#`P-SPO
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\9F]N=#XQ,#PO9F]N
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C(L-#`P
M+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B
M;&4^#0H\+V1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@.#DN.#5P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/CQB<B\^/"]P/@T*
M/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/E-E="!F;W)T:"!B96QO=R!A<F4@9W)A
M;G1S(&UA9&4@8GD@=&AE($-O;7!A;GD@=&\@96UP;&]Y965S("AI;F-L=61I
M;F<@<F5L871E9"!P87)T:65S*2!D=7)I;F<@=&AE('1H<F5E+7EE87(@<&5R
M:6]D(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T("AS=6-H(&=R86YT<R!A<'!E
M87(@:6X@=&AE('1A8FQE(&%B;W9E*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT.B`P:6X[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY/;B!*=6QY(#$V+"`R,#$R
M+"!T:&4@0V]M<&%N>2=S($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T
M:&4@9W)A;G0@;V8@/&9O;G0^,2PU,#`L,#`P/"]F;VYT/B!S:&%R97,@;V8@
M<F5S=')I8W1E9"!#;VUM;VX@4W1O8VL@=&\@:71S(&]F9FEC97)S(&%N9"!C
M97)T86EN(&]T:&5R(&5M<&QO>65E<RX@3V8@<W5C:"!R97-T<FEC=&5D('-T
M;V-K+"`\9F]N=#XQ+#$P,"PP,#`\+V9O;G0^(&]F('1H92!S:&%R97,@=V5R
M92!I<W-U960@=&\@=&AE($-O;7!A;GDG<R!N86UE9"!E>&5C=71I=F4@;V9F
M:6-E<G,@86YD('9E<W0@:6X@/&9O;G0^,38\+V9O;G0^(&5Q=6%L+"!Q=6%R
M=&5R;'D@:6YC<F5M96YT<R!O=F5R(&$@9F]U<BUY96%R('!E<FEO9"P@8V]M
M;65N8VEN9R!U<&]N('1H92!D871E(&]F(&=R86YT+"!A;F0@87)E('-U8FIE
M8W0@=&\@82`\9F]N=#XR-#PO9F]N=#XM;6]N=&@@;&]C:RUU<"!P97)I;V0L
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M92!R96UA:6YI;F<@/&9O;G0^-#`P+#`P,#PO9F]N=#X@<VAA<F5S(&]F(')E
M<W1R:6-T960@0V]M;6]N(%-T;V-K('=E<F4@:7-S=65D('1O(&]T:&5R(&5M
M<&QO>65E<R!O9B!T:&4@0V]M<&%N>2!A;F0@=F5S="!I;B`\9F]N=#XQ,CPO
M9F]N=#X@97%U86PL('%U87)T97)L>2!I;F-R96UE;G1S(&]V97(@82!T:')E
M92UY96%R('!E<FEO9"P@8V]M;65N8VEN9R!U<&]N('1H92!D871E(&]F(&=R
M86YT+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT
M.B`P:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY/;B!397!T96UB
M97(@,C@L(#(P,30L('1H92!#;VUP86YY)W,@0F]A<F0@;V8@1&ER96-T;W)S
M(&%P<')O=F5D+"!S=6)J96-T('1O(&-E<G1A:6X@=&5R;7,@86YD(&-O;F1I
M=&EO;G,L('1H92!G<F%N="!O9B!A(#QF;VYT/C$P/"]F;VYT/BUY96%R(&]P
M=&EO;B!T;R!P=7)C:&%S92`\9F]N=#XY,#`L,#`P/"]F;VYT/B!S:&%R97,@
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M9"!O9B`\9F]N=#XP/"]F;VYT/B4@9F]R(&%L;"!Y96%R<SL@97AP96-T960@
M=F]L871I;&ET>2!O9B`\9F]N=#XV,CPO9F]N=#XE.R!R:7-K+69R964@:6YT
M97)E<W0@<F%T92!O9B`\9F]N=#XQ+C@V/"]F;VYT/B4[(&%N9"!E>'!E8W1E
M9"!L:69E(&]F('-I>"!Y96%R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQD
M:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O
M='1O;3H@,'!X.R!W:61T:#H@,3`P)3LG/@T*#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q:6X[
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/F(I/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^5&AE(&9A:7(@=F%L=64@;V8@<F5S=')I8W1E9"!S=&]C:R!G<F%N
M=&5D(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!W
M87,@)#QF;VYT/C@N-CPO9F]N=#X@;6EL;&EO;B!B87-E9"!O;B!T:&4@0V]M
M<&%N>2=S('-H87)E('!R:6-E(&]N('1H92!.65-%($U+5"!O;B!T:&4@9W)A
M;G0@9&%T92X\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^5&AE('1O=&%L('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S
M="!O9B!E;7!L;WEE92!S=&]C:R!O<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T
M;V-K(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&ES(&%P<')O>&EM871E;'D@)#QF
M;VYT/C$N-#PO9F]N=#X@;6EL;&EO;B`H;F5T(&]F(&9O<F9E:71U<F4@<F%T
M92DN(%1H92!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0@;V8@96UP
M;&]Y964@<W1O8VL@;W!T:6]N<R!I<R!E>'!E8W1E9"!T;R!B92!R96-O9VYI
M>F5D(&]V97(@82!W96EG:'1E9"!A=F5R86=E('!E<FEO9"!O9B`\9F]N=#XQ
M+C`\+V9O;G0^('EE87)S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#$N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I
M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/E1H92!T;W1A;"!C87-H
M(')E8V5I=F5D(&9R;VT@96UP;&]Y965S(&%S(&$@<F5S=6QT(&]F(&5M<&QO
M>65E('-T;V-K(&]P=&EO;B!E>&5R8VES97,@9F]R('1H92!Y96%R<R!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"!W87,@87!P<F]X
M:6UA=&5L>2`D/&9O;G0^,2XR/"]F;VYT/B!M:6QL:6]N+"`D/&9O;G0^,3$R
M+#`P,#PO9F]N=#X@86YD("0\9F]N=#XT-BPP,#`\+V9O;G0^+"!R97-P96-T
M:79E;'DN(%1H92!#;VUP86YY(&1I9"!N;W0@<F5A;&EZ92!A;GD@=&%X(&)E
M;F5F:70@:6X@8V]N;F5C=&EO;B!W:71H('1H97-E(&5X97)C:7-E<RX\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SY$=7)I;F<@,C`Q-"P@=&AE($-O;7!A;GD@:7-S=65D(#QF
M;VYT/C$S,RPY,S`\+V9O;G0^('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@
M8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B`\9F]N=#XQ,SDL,S@X
M/"]F;VYT/B!O<'1I;VYS(&)Y(&-E<G1A:6X@96UP;&]Y965S(&]F('1H92!#
M;VUP86YY+B!4:&4@0V]M<&%N>2!R96-E:79E9"!C87-H('!R;V-E961S(&5Q
M=6%L('1O(&%P<')O>&EM871E;'D@)#QF;VYT/C0V+#`P,#PO9F]N=#X@:6X@
M8V]N;F5C=&EO;B!W:71H('-U8V@@97AE<F-I<V5S+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U
M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT
M.B`M,"XR-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,BXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\8CY/<'1I;VYS(&=R86YT960@
M=&\@8V]N<W5L=&%N=',L(&1I<F5C=&]R<RP@86YD(&]T:&5R('-E<G9I8V4@
M<')O=FED97)S.CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`P:6X[)SY/;B!*=6QY(#(T+"`R
M,#$T+"!T:&4@0V]M<&%N>2=S($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E
M9"P@<W5B:F5C="!T;R!C97)T86EN('1E<FUS(&%N9"!C;VYD:71I;VYS+"!T
M:&4@9W)A;G0@;V8@82`Q,"UY96%R(&]P=&EO;B!T;R!P=7)C:&%S92`\9F]N
M=#XQ-3`L,#`P/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O(&ET
M<R!T:&5N(&YE=VQY(&5L96-T960@8VAA:7)M86X@;V8@=&AE($)O87)D(&]F
M($1I<F5C=&]R<R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&5Q=6%L('1O("0\
M9F]N=#XS+C,W/"]F;VYT/B!P97(@<VAA<F4N(%1H92!O<'1I;VYS('9E<W0@
M;W9E<B!A('1H<F5E+7EE87(@<&5R:6]D.R!T:&4@9FER<W0@/&9O;G0^-3`L
M,#`P/"]F;VYT/B!S:&%R97,@=F5S="!O;B!T:&4@9FER<W0@86YN:79E<G-A
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M>&EM871E;'D@)#QF;VYT/C$Y,RPP,#`\+V9O;G0^(&)A<V5D(&]N('1H92!F
M;VQL;W=I;F<@=V5I9VAT960@879E<F%G92!A<W-U;7!T:6]N<SH@9&EV:61E
M;F0@>6EE;&0@;V8@/&9O;G0^,#PO9F]N=#XE(&9O<B!A;&P@>65A<G,[(&5X
M<&5C=&5D('9O;&%T:6QI='D@;V8@/&9O;G0^-C(\+V9O;G0^)3L@<FES:RUF
M<F5E(&EN=&5R97-T(')A=&5S(&]F(#QF;VYT/C$N.3PO9F]N=#XE.R!A;F0@
M97AP96-T960@;&EF92!O9B!S:7@@>65A<G,N/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY.;R!C87-H('=A<R!R96-E
M:79E9"!F<F]M(&-O;G-U;'1A;G1S(&%S(&$@<F5S=6QT(&]F(&-O;G-U;'1A
M;G0@<W1O8VL@;W!T:6]N(&5X97)C:7-E<R!F;W(@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$T+B!!<'!R;WAI;6%T96QY("0\
M9F]N=#XS.2PP,#`\+V9O;G0^('=A<R!R96-E:79E9"!D=7)I;F<@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,3(N(%1H92!#;VUP86YY(&1I9"!N
M;W0@<F5A;&EZ92!A;GD@=&%X(&)E;F5F:71S(&EN(&-O;FYE8W1I;VX@=VET
M:"!T:&5S92!E>&5R8VES97,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^1'5R:6YG(#(P,3,@86YD(#(P
M,30L(&YO('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=V5R92!I<W-U960@:6X@
M8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B!O<'1I;VYS(&)Y(&-O
M;G-U;'1A;G1S(&]F('1H92!#;VUP86YY+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XR
M-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,RXF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#M!('-U;6UA<GD@;V8@<VAA<F4@;W!T:6]N
M('!L86YS+"!A;F0@<F5L871E9"!I;F9O<FUA=&EO;BP@=6YD97(@86QL(&]F
M('1H92!#;VUP86YY)W,@97%U:71Y(&EN8V5N=&EV92!P;&%N<R!F;W(@=&AE
M('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R,#$T
M(&%R92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/&1I=B!C
M;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M
M.B`P<'@[('=I9'1H.B`Q,#`E.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#%I;CLG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;CL@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^82X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^3W!T
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`Q
M,G!T.R!W:61T:#H@,3`P)3LG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q:6X[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/@T*/"]T
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX-"@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`]
M,T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,C(@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/EEE87(@96YD960@1&5C96UB97(@
M,S$L/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<@;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/C(P,3(\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M-B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,SPO
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M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,30\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS
M1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
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M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
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M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SY796EG:'1E9#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^5V5I9VAT960\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SYA=F5R86=E/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^3G5M8F5R/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SYA=F5R86=E/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SY.=6UB97(\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/F%V97)A9V4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/F]F/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SYE>&5R8VES93PO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF
M(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^;V8\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/F5X97)C:7-E/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SYO9CPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF
M(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^97AE<F-I<V4\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
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M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/F]P=&EO;G,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/G!R:6-E/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO
M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SYO<'1I;VYS/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SYP<FEC93PO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
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M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^<')I8V4\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P>#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`T,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY/=71S=&%N9&EN9R!A="!B96=I
M;FYI;F<@;V8@>65A<CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T
M:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M-BPQ-#$L,#,P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXS+C4V,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXU+#(U,RPU-SD\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#$P)3LG/CQF;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/C,N.3(S/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
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M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,RXY-3$\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M96%R.CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('1E>'0M:6YD96YT.B`Q,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^1W)A;G1E9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M<SLG/CDP,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C(N,S<P/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('1E>'0M:6YD
M96YT.B`Q,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^1F]R9F5I
M=&5D(&%N9"!%>'!I<F5D/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR
M-2PX-3@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXR,"PU-3@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M<SLG/C8N-C`S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT-"PR,#$\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D5X97)C:7-E9"`H
M*BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R
M=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M.#8Q+#4Y,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^,2XS-#8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED
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M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
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M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2XT,3@\+V9O;G0^
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@
M-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M,"XT-#8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D]U='-T86YD:6YG(&%T(&5N
M9"!O9B!Y96%R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O
M=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^-2PR-3,L-3<Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS+CDR,SPO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
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M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXU+#$U,RPX.3@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T
M(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N.34Q/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A
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M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U
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M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,RXW-S`\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
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M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^-"PR-3@L-#0Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS+C(P,3PO9F]N
M=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXT+#8Q-"PQ-#@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O
M=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N-3DQ/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C0L.3`U+#4U.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
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M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,RXY,S,\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D
M:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#(Q+C-P=#L@=&5X="UI;F1E
M;G0Z("TQ-"XR<'0[)SX\8G(O/CPO<#X-"CQD:78^#0H\9&EV(&-L87-S/3-$
M0W5R<V]R4&]I;G1E<CX-"CQT86)L92!W:61T:#TS1#$P,"4@8V5L;'!A9&1I
M;F<],T0P(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I
M9'1H.B`Q,#`E.R<^#0H-"CQT<CX-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX@*"HI(#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Y."4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SY4:&4@=&]T86P@:6YT<FEN<VEC('9A;'5E(&]F(&]P=&EO
M;G,@97AE<F-I<V5D(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@
M,S$L(#(P,3(L(#(P,3,@86YD(#(P,30L('=A<R!A<'!R;WAI;6%T96QY("0\
M9F]N=#XT+C@\+V9O;G0^(&UI;&QI;VXL("0\9F]N=#XS,#8L,#`P/"]F;VYT
M/B!A;F0@)#QF;VYT/C0T-RPP,#`\+V9O;G0^+"!R97-P96-T:79E;'DN/&)R
M+SX\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO
M9&EV/@T*/"]D:78^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV(&-L
M87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ
M(#!P>#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,6EN.R<^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SYB+CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SY297-T
M<FEC=&5D('-T;V-K(&=R86YT960@=&\@96UP;&]Y965S.CPO9F]N=#X\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/&1I=CX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQB<B\^/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&)R+SX\+W`^#0H\9&EV(&-L
M87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
M:#H@,3`P)3LG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
M('-O;&ED("%I;7!O<G1A;G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/EEE87(@96YD960@1&5C96UB97(@,S$L/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)R!N;W=R
M87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXR,#$R/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^,C`Q,SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)R!N;W=R87`],T1N;W=R
M87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$P(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^3G5M8F5R(&]F(%)E<W1R:6-T960@4VAA<F5S/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^
M(#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)R!W:61T:#TS1#4P)3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SY/=71S=&%N9&EN9R!A="!B96=I;FYI
M;F<@;V8@>65A<CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^+3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,2PS.30L-S`X/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
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M.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY
M-S`L,C`X/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^0VAA;F=E<R!D=7)I;F<@=&AE('EE87(Z/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SLG('=I9'1H/3-$-3`E/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D=R
M86YT960\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,2PU,#`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
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M=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6QE9G0Z(#$U+CDU
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG('=I9'1H/3-$
M-3`E/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/E9E<W1E9#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ,#(L,#@T
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT,#8L-C8V/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M
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M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXS.3@L,S<U/"]F;VYT/CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z
M(#$U+CDU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG('=I
M9'1H/3-$-3`E/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D9O<F9E:71E
M9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@
M(6EM<&]R=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXS+#(P.#PO9F]N=#X\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^,3<L.#,T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
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M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
M<G1A;G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ.#4L
M-S`Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
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M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SY/=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM
M<&]R=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PS.30L-S`X/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY-S`L,C`X/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS.#8L,3(T/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D
M:78^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX\8G(O/CPO9&EV/@T*
M/"]D:78^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@,6EN.R<^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SYC+CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT/CQF;VYT
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M4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3LG/@T*
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO
M=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^665A<B!E;F1E9"!$96-E
M;6)E<B`S,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO
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M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXR,#$R/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SXR,#$T/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A
M<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/E=E:6=H=&5D/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^5V5I9VAT960\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
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M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/E=E:6=H=&5D/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY.=6UB97(\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
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M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/DYU;6)E<CPO<W1R;VYG/CPO
M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
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M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^3G5M8F5R/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
M,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SYA=F5R86=E/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SYO9CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^97AE<F-I<V4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/F]F/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SYE>&5R8VES93PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^;V8\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/F5X97)C:7-E/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SYO<'1I
M;VYS/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
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M=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^<')I8V4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/F]P=&EO;G,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/G!R:6-E/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:61T:#H@-#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^3W5T<W1A;F1I;F<@870@8F5G:6YN:6YG(&]F('EE87(\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
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M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T
M:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-2XS
M.#4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3$R+#0R-3PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T
M:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-RXR
M-3D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3$R+#0R-3PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T
M:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-RXR
M-3D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M1W)A;G1E9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY%>&5R8VES960@
M*"HI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
M<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
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M.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
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M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/C`N,3(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
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M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^.3$R+#0R-3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
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M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-RXR-3D\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M.3$R+#0R-3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O
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M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D
M;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^-RXR-3D\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PR,#@L
M-3DR/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C8N,3,V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY,3(L
M-#(U/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXW+C(U.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P
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M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY,3(L-#(U/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I
M9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXW+C(U.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U
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M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY,3(L-#(U/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXW+C(U.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.R8C,38P.SPO9F]N=#X\+W`^#0H\9&EV/@T*/&1I=B!C;&%S<STS1$-U
M<G-O<E!O:6YT97(^#0H\=&%B;&4@=VED=&@],T0Q,#`E(&-E;&QP861D:6YG
M/3-$,"!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T
M:#H@,3`P)3LG/@T*#0H\='(^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^("@J*2`\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@.3@E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M+SX\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@,6EN.R<^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SYD+CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT/CQF;VYT
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M<B`S,2P@,C`Q-#H\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+W1D/@T*/"]T<CX-
M"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3)P
M="`Q+C(U:6X[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/&1I=B!C;&%S<STS1$-U
M<G-O<E!O:6YT97(^/&)R+SX\+V1I=CX-"CQD:78^#0H\9&EV(&-L87-S/3-$
M0W5R<V]R4&]I;G1E<B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,"XQ<'@[(&UA<F=I;BUR
M:6=H=#H@,"XQ<'@[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG(&-O
M;'-P86X],T0R-CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/D1E8V5M8F5R(#,Q+"`R,#$T/"]S=')O;F<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS
M<&%N/3-$.#X\8G(O/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,30^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SY/<'1I;VYS(&%N9"!R97-T<FEC=&5D
M('-T;V-K(#QB<B\^;W5T<W1A;F1I;F<\+W-T<F]N9SX\+V9O;G0^/&)R+SX\
M+W1D/@T*/'1D(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\+W1D/@T*/'1D(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG(&-O;'-P
M86X],T0Q,#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/D]P
M=&EO;G,@97AE<F-I<V%B;&4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SY%>&5R8VES92`\8G(O/G!R:6-E<SPO<W1R;VYG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SY.=6UB97(@;V8@/&)R+SYO<'1I;VYS(&%N9#QB<B\^
M(')E<W1R:6-T960@<W1O8VL@/&)R+SYO=71S=&%N9&EN9R`\8G(O/F%T(&5N
M9"!O9B`\8G(O/GEE87(\+W-T<F]N9SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/E=E:6=H=&5D(#QB<B\^879E<F%G92`\8G(O/G)E
M;6%I;FEN9R`\8G(O/F-O;G1R86-T=6%L(#QB<B\^;&EF93PO<W1R;VYG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/"]T9#X-"CQT
M9"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S
M;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/DYU;6)E<B!O9CQB<B\^(&]P=&EO;G,\
M8G(O/B!E>&5R8VES86)L93PO<W1R;VYG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0T(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SY796EG:'1E9"`\8G(O/F%V97)A9V4@
M/&)R+SYR96UA:6YI;F<@/&)R+SYC;VYT<F%C='5A;"`\8G(O/FQI9F4\+W-T
M<F]N9SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)R!C;VQS<&%N
M/3-$,2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SYN+V$@*%)E<W1R:6-T960@4W1O8VLI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<Z
M(#!P>#L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^;B]A/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M(')I9VAT.R!P861D:6YG.B`P<'@[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
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M=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[(&9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/FXO83PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U
M<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<@86QI9VX],T1L969T/CQF;VYT('-T
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M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,"XP,#$\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X(#!P>"`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P
M)3LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG(&%L:6=N/3-$;&5F=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,C`E.R<@86QI9VX],T1R:6=H=#X\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXW,3DL,C`W/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>"`P
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M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,"XU-#PO9F]N=#X\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<@86QI
M9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@@
M,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@=VED=&@Z(#`E.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`R,"4[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C<Q.2PR,#<\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H
M.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X(#!P>"`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,C`E.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXP+C4T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)R!A;&EG;CTS1&QE
M9G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<@8V]L<W!A;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,P."PX
M,#$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/C,P."PX,#$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^,BXP,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS
M<&%N/3-$,2!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/C`N.3<R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3DU+#@U,SPO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+C0T/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
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M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX]
M,T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+C0T
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS1#$@86QI
M9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C0P+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXS+C@R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS
M1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-#`L,#`P/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N.#(\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR+C,W,#PO9F]N=#X\+V9O
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CDP,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE
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M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXY+C<U/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<@8V]L<W!A;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI
M9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,T-2PP.#(\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C,T-2PP.#(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
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M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS<&%N/3-$
M,2!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C,N,#(P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^-3`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/C,N,3`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H
M=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU,"PP,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,RXS-S`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXQ-3`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CDN-38\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXM/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CDN-38\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<@8V]L<W!A;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXU+C`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI
M9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$L-S`X+#`P,#PO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H
M=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR+C8V/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,2PW,#@L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/C(N-C8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS
M<&%N/3-$,2!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/C8N.#$P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,34P+#`P,#PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU+C$P/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
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M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,34P
M+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX]
M,T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU+C$P
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-BXY
M,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXY.3$L.3$V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/C0N,S(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$
M;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXX,CDL,C0Y/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C0N,S(\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)R!C;VQS<&%N/3-$,2!A;&EG;CTS1')I9VAT/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C<N-34P/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^,38P+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@
M86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXU+C8V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^,38P+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXU+C8V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^.2XV-C`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H
M=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXV."PP,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C8X+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@
M86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXU+C@S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS
M1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXQ-BXW,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@
M86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,X-RPU-#(\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXQ+CDY/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$N.3D\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X(#!P>"`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
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M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS<&%N/3-$,2!A;&EG
M;CTS1')I9VAT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U
M8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O
M<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI
M9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R
M:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXW+#0V-2PP
M,C4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<@86QI9VX],T1R:6=H=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O
M=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^-2PX,3<L.3@T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
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M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R<^/&)R+SX\+W`^#0H\+V1I=CX-
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M;V8@1&5C96UB97(@,S$L(#(P,30@:7,@87!P<F]X:6UA=&5L>2`D/&9O;G0^
M,RXV/"]F;VYT/B!M:6QL:6]N(&%N9"`D/&9O;G0^,BXW/"]F;VYT/B!M:6QL
M:6]N+"!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV
M(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T
M;VTZ(#!P>#L@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,6EN.R<^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SYE+CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
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M"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3)P
M="`Q+C(U:6X[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/&1I=B!C;&%S<STS1$-U
M<G-O<E!O:6YT97(^/&)R+SX\+V1I=CX-"CQD:78^#0H\9&EV(&-L87-S/3-$
M0W5R<V]R4&]I;G1E<B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,"XQ<'@[(&UA<F=I;BUR
M:6=H=#H@,"XQ<'@[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<@;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$P(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/BA5+E,N(&1O;&QA<G,@
M:6X@=&AO=7-A;F1S*3PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A
M<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^(#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR,#$R/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
M,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR,#$S/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
M,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR,#$T/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'@[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@
M-S`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^0V]S="!O9B!R979E
M;G5E<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H
M.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@=VED=&@Z(#$P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M97AP96YS97,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^-"PW-38\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR
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M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDS-CPO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P
M>#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY-87)K971I;F<L($=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C(L-S<U/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXQ+#0S-#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,S`V/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT+#`X
M.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[
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M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,2PR-#(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\8CXF(S$V,#L\+V(^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^
M/&)R+SX\+W`^#0H\+V1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN
M.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/&(^8RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M0=6)L
M:6,@86YD(#$T-$$@3V9F97)I;F=S/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#<X<'0[('1E>'0M:6YD96YT.B`M,C$N,W!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@-SAP=#L@=&5X="UI;F1E;G0Z("TR
M,2XS<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T]N($9E8G)U87)Y(#(R+"`R
M,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@86YD('-O;&0@/&9O;G0^-2PQ-S4L
M,#`P/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&EN(&%N('5N9&5R
M=W)I='1E;B!P=6)L:6,@;V9F97)I;F<@870@82!P<FEC92!T;R!T:&4@<'5B
M;&EC(&]F("0\9F]N=#XU+C(U/"]F;VYT/B!P97(@<VAA<F4N(%1H92!N970@
M<')O8V5E9',@=&\@=&AE($-O;7!A;GD@=V5R92!A<'!R;WAI;6%T96QY("0\
M9F]N=#XR-2XT/"]F;VYT/B!M:6QL:6]N("AN970@;V8@=6YD97)W<FET:6YG
M(&-O;6UI<W-I;VYS(&%N9"!I<W-U86YC92!C;W-T<R!O9B`D/&9O;G0^,2XX
M/"]F;VYT/B!M:6QL:6]N*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#<X<'0[('1E>'0M:6YD96YT.B`M,C$N,W!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@-SAP=#L@=&5X="UI;F1E;G0Z("TR,2XS<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.T]N(%-E<'1E;6)E<B`Q."P@,C`Q,RP@
M=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@<')I=F%T92!O9F9E<FEN9R!O9B`\
M9F]N=#XT+C4P/"]F;VYT/B4@8V]N=F5R=&EB;&4@;F]T97,@9'5E(#(P,3@N
M(%1H92!N970@<')O8V5E9',@9G)O;2!T:&4@;V9F97)I;F<L(&EN8VQU9&EN
M9R!N970@<')O8V5E9',@9G)O;2!T:&4@97AE<F-I<V4@:6X@9G5L;"!B>2!T
M:&4@:6YI=&EA;"!P=7)C:&%S97(@;V8@:71S(&]P=&EO;B!T;R!P=7)C:&%S
M92!A;B!A9&1I=&EO;F%L("0\9F]N=#XY+C`\+V9O;G0^(&UI;&QI;VX@:6X@
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y
M7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K
M<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#3TY615)424),12!.3U1%/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/
M5$53(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0T].5D525$E"3$4@3D]415,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P
M,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\8CY.3U1%(#@@+2!#3TY615)424),
M12!.3U1%4SPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`S-2XT-7!T.R!T97AT+6EN9&5N=#H@,&EN.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,S4N-#5P=#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/D]N(%-E<'1E;6)E<B`Q."P@,C`Q,RP@=&AE
M($-O;7!A;GD@8V]M<&QE=&5D(&$@<')I=F%T92!P;&%C96UE;G0@;V8@)#QF
M;VYT/C8Y+C`\+V9O;G0^(&UI;&QI;VX@:6X@86=G<F5G871E('!R:6YC:7!A
M;"!A;6]U;G0@;V8@3F]T97,L(&EN8VQU9&EN9R`D/&9O;G0^.2XP/"]F;VYT
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M92`F(S$T-SM);F1E;G1U<F4F(S$T.#LI('=I=&@@5&AE($)A;FL@;V8@3F5W
M(%EO<FL@365L;&]N(%1R=7-T($-O;7!A;GDL($XN02XL(&%S('1R=7-T964L
M(&=O=F5R;FEN9R!T:&4@3F]T97,N(%1H92!.;W1E<R!A8V-R=64@:6YT97)E
M<W0@870@82!R871E(&]F(#QF;VYT/C0N-3`\+V9O;G0^)2!P97(@>65A<BP@
M<&%Y86)L92!S96UI86YN=6%L;'D@:6X@87)R96%R<R!O;B!-87)C:"`Q-2!A
M;F0@4V5P=&5M8F5R(#$U(&]F(&5A8V@@>65A<BP@8F5G:6YN:6YG(&]N($UA
M<F-H(#$U+"`R,#$T+B!4:&4@3F]T97,@;6%T=7)E(&]N(%-E<'1E;6)E<B`Q
M-2P@,C`Q."X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S
M-2XT-7!T.R!T97AT+6EN9&5N=#H@,&EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,S4N-#5P=#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/E1H92!N970@<')O8V5E9',@9G)O;2!T:&4@;V9F
M97)I;F<L(&EN8VQU9&EN9R!N970@<')O8V5E9',@9G)O;2!T:&4@97AE<F-I
M<V4@:6X@9G5L;"!B>2!T:&4@:6YI=&EA;"!P=7)C:&%S97(@;V8@:71S(&]P
M=&EO;B!T;R!P=7)C:&%S92!A;B!A9&1I=&EO;F%L("0Y+C`@;6EL;&EO;B!I
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M=&EB;&4@;F]T97,@<&5R:6]D("@U('EE87)S*2X\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R!T97AT+6EN9&5N=#H@,&EN
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,S4N-#5P=#L@=&5X="UI;F1E
M;G0Z(#!I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/DAO;&1E<G,@
M;6%Y(&-O;G9E<G0@=&AE:7(@3F]T97,@870@86YY('1I;64@<')I;W(@=&\@
M=&AE(&-L;W-E(&]F(&)U<VEN97-S(&]N('1H92!B=7-I;F5S<R!D87D@:6UM
M961I871E;'D@<')E8V5D:6YG(%-E<'1E;6)E<B`Q-2P@,C`Q."X@5&AE(&EN
M:71I86P@8V]N=F5R<VEO;B!R871E(&9O<B!T:&4@3F]T97,@:7,@/&9O;G0^
M,3<S+C8U.3,\+V9O;G0^('-H87)E<R!O9B!T:&4@0V]M;6]N(%-T;V-K(&9O
M<B!E86-H("0\9F]N=#XQ+#`P,#PO9F]N=#X@<')I;F-I<&%L(&%M;W5N="!O
M9B!.;W1E<R`H97%U:79A;&5N="!T;R!A;B!I;FET:6%L(&-O;G9E<G-I;VX@
M<')I8V4@;V8@87!P<F]X:6UA=&5L>2`D/&9O;G0^-2XW-CPO9F]N=#X@<&5R
M('-H87)E(&]F('1H92!#;VUM;VX@4W1O8VLN(%5P;VX@8V]N=F5R<VEO;BP@
M=&AE($-O;7!A;GD@=VEL;"!D96QI=F5R(&$@;G5M8F5R(&]F('-H87)E<R!O
M9B!#;VUM;VX@4W1O8VLL('!E<B`D,2PP,#`@<')I;F-I<&%L(&%M;W5N="!O
M9B!.;W1E<RP@97%U86P@=&\@=&AE(&-O;G9E<G-I;VX@<F%T92X@5&AE(&-O
M;G9E<G-I;VX@<F%T92!I<R!S=6)J96-T('1O(&%D:G5S=&UE;G0@:6X@<V]M
M92!E=F5N=',@8G5T('=I;&P@;F]T(&)E(&%D:G5S=&5D(&9O<B!A;GD@86-C
M<G5E9"!A;F0@=6YP86ED(&EN=&5R97-T+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#,U+C0U<'0[('1E>'0M:6YD96YT.B`P:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R!T97AT+6EN9&5N=#H@
M,&EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^4')I;W(@=&\@4V5P
M=&5M8F5R(#$Y+"`R,#$V+"!T:&4@0V]M<&%N>2!M87D@;F]T(')E9&5E;2!T
M:&4@3F]T97,L(&%N9"!N;R!S:6YK:6YG(&9U;F0@:7,@<')O=FED960@9F]R
M('1H92!.;W1E<RX@3VX@;W(@869T97(@4V5P=&5M8F5R(#$Y+"`R,#$V+"!T
M:&4@0V]M<&%N>2!M87D@<F5D965M(&9O<B!C87-H(&%L;"!O<B!P87)T(&]F
M('1H92!.;W1E<R`H97AC97!T(&9O<B!T:&4@;F]T97,@=&AA="!T:&4@0V]M
M<&%N>2!I<R!T:&5N(')E<75I<F5D('1O(')E<'5R8VAA<V4@:6X@8V]N;F5C
M=&EO;B!W:71H(&$@9G5N9&%M96YT86P@8VAA;F=E+"!A<R!D969I;F5D(&)E
M;&]W*2!I9B!T:&4@;&%S="!R97!O<G1E9"!S86QE('!R:6-E(&]F('1H92!#
M;VUM;VX@4W1O8VL@:&%S(&)E96X@870@;&5A<W0@,3,P)2!O9B!T:&4@8V]N
M=F5R<VEO;B!P<FEC92!T:&5N(&EN(&5F9F5C="!F;W(@870@;&5A<W0@,C`@
M=')A9&EN9R!D87ES("AW:&5T:&5R(&]R(&YO="!C;VYS96-U=&EV92D@9'5R
M:6YG(&%N>2`S,"!C;VYS96-U=&EV92!T<F%D:6YG+61A>2!P97)I;V0@96YD
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M(')E9&5M<'1I;VX@9&%T92P@<&QU<R`H:6EI*2!T:&4@<W5M(&]F('1H92!P
M<F5S96YT('9A;'5E<R!O9B!E86-H(&]F('1H92!R96UA:6YI;F<@<V-H961U
M;&5D('!A>6UE;G1S(&]F(&EN=&5R97-T('1H870@=V]U;&0@:&%V92!B965N
M(&UA9&4@;VX@=&AE($YO=&5S(&)E:6YG(')E9&5E;65D(&AA9"!S=6-H($YO
M=&5S(')E;6%I;F5D(&]U='-T86YD:6YG(&9R;VT@=&AE(')E9&5M<'1I;VX@
M9&%T92!T;R!T:&4@;6%T=7)I='D@9&%T92X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQD:78^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#,U+C0U<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SY4:&4@9F]L;&]W:6YG('1A8FQE('-E=',@9F]R=&@@=&]T86P@:6YT
M97)E<W0@97AP96YS92!R96-O9VYI>F5D(&9O<B!T:&4@>65A<G,@96YD960@
M1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,30@<F5L871E9"!T;R!T:&4@3F]T
M97,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,S4N-#5P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@.3`E.R!M87)G:6XM;&5F=#H@,"XU:6X[)SX-"@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R
M87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^665A<B!E;F1E9"!$96-E;6)E
M<B`S,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXH52Y3+B!$;VQL87)S(&EN('1H;W5S
M86YD<RD\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/CQF;VYT/CPO
M9F]N=#X\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^/&9O;G0^/"]F;VYT/CPO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#,^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=VED=&@Z(#@P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/D-O;G1R86-T=6%L(&EN=&5R97-T(&5X<&5N<V4\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXX.#@\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M,3`U/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
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M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXQ,C<\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[
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M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
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M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/E1O=&%L/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O
M=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$L,#$U/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXS+#4T.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%3E0\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1D%)4B!604Q512!-14%355)%345.5"!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9!25(@5D%,544@
M345!4U5214U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A
M;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M:6YD96YT.B`P:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\8CY.3U1%(#D@+2!&04E2(%9!3%5%($U%05-54D5-14Y4/"]B/CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#,U+C0U<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^5&AE($-O;7!A;GD@;65A<W5R97,@9F%I<B!V86QU
M92!A;F0@9&ES8VQO<V5S(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&9O<B!F
M:6YA;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE<RX@1F%I<B!V86QU92!I
M<R!B87-E9"!O;B!T:&4@<')I8V4@=&AA="!W;W5L9"!B92!R96-E:79E9"!F
M<F]M('1H92!S86QE(&]F(&%N(&%S<V5T+"!O<B!P86ED('1O('1R86YS9F5R
M(&$@;&EA8FEL:71Y+"!I;B!A;B!O<F1E<FQY('1R86YS86-T:6]N(&)E='=E
M96X@;6%R:V5T('!A<G1I8VEP86YT<R!A="!T:&4@;65A<W5R96UE;G0@9&%T
M92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,S4N-#5P=#LG/CQF;VYT('-T
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M+"!W:&EC:"!A<F4@9&5S8W)I8F5D(&)E;&]W.CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,S4N-#5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#,U+C0U<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SY,979E;"`Q.B!1=6]T960@<')I8V5S("AU;F%D:G5S=&5D*2!I;B!A8W1I
M=F4@;6%R:V5T<R!T:&%T(&%R92!A8V-E<W-I8FQE(&%T('1H92!M96%S=7)E
M;65N="!D871E(&9O<B!A<W-E=',@;W(@;&EA8FEL:71I97,N(%1H92!F86ER
M('9A;'5E(&AI97)A<F-H>2!G:79E<R!T:&4@:&EG:&5S="!P<FEO<FET>2!T
M;R!,979E;"`Q(&EN<'5T<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,S4N
M-#5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/DQE=F5L(#(Z($]B
M<V5R=F%B;&4@<')I8V5S('1H870@87)E(&)A<V5D(&]N(&EN<'5T<R!N;W0@
M<75O=&5D(&]N(&%C=&EV92!M87)K971S+"!B=70@8V]R<F]B;W)A=&5D(&)Y
M(&UA<FME="!D871A+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#,U+C0U<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^3&5V96P@,SH@56YO8G-E
M<G9A8FQE(&EN<'5T<R!A<F4@=7-E9"!W:&5N(&QI='1L92!O<B!N;R!M87)K
M970@9&%T82!I<R!A=F%I;&%B;&4N(%1H92!F86ER('9A;'5E(&AI97)A<F-H
M>2!G:79E<R!T:&4@;&]W97-T('!R:6]R:71Y('1O($QE=F5L(#,@:6YP=71S
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#,U+C0U<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^26X@9&5T97)M:6YI;F<@9F%I<B!V86QU92P@
M=&AE($-O;7!A;GD@=71I;&EZ97,@=F%L=6%T:6]N('1E8VAN:7%U97,@=&AA
M="!M87AI;6EZ92!T:&4@=7-E(&]F(&]B<V5R=F%B;&4@:6YP=71S(&%N9"!M
M:6YI;6EZ92!T:&4@=7-E(&]F('5N;V)S97)V86)L92!I;G!U=',@=&\@=&AE
M(&5X=&5N="!P;W-S:6)L92!A;F0@8V]N<VED97)S(&-O=6YT97)P87)T>2!C
M<F5D:70@<FES:R!I;B!I=',@87-S97-S;65N="!O9B!F86ER('9A;'5E+CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#,U+C0U<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^5&AE(&9A:7(@=F%L=64@;V8@=&AE(&9I;F%N8VEA
M;"!I;G-T<G5M96YT<R!I;F-L=61E9"!I;B!T:&4@=V]R:VEN9R!C87!I=&%L
M(&]F('1H92!#;VUP86YY(&ES('5S=6%L;'D@:61E;G1I8V%L(&]R(&-L;W-E
M('1O('1H96ER(&-A<G)Y:6YG('9A;'5E+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#,U+C0U<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^5&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&-O;G9E<G1I8FQE(&YO=&5S(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$T(&ES(&%P<')O>&EM871E;'D@)#QF;VYT/C4R+C0\
M+V9O;G0^(&UI;&QI;VX@8F%S960@;VX@;&5V96P@,B!M96%S=7)E;65N="X\
M+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E1!
M6$53($].($E.0T]-13QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY405A%4R!/3B!)3D-/344@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y405A%
M4R!/3B!)3D-/344\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A
M;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M:6YD96YT.B`P:6X[)SX\8CY.3U1%(#$P("T@5$%815,@3TX@
M24Y#3TU%/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN
M.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CL@=&5X="UI;F1E;G0Z("TP
M+C(U:6X[)SX\<W1R;VYG/F$N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[5&AE($-O;7!A;GD\+W-T<F]N9SX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^4')O=&%L:7@@0FEO5&AE<F%P975T:6-S+"!);F,N
M(&ES('1A>&5D(&%C8V]R9&EN9R!T;R!5+E,N('1A>"!L87=S+B!4:&4@0V]M
M<&%N>2=S(&EN8V]M92!I<R!T87AE9"!I;B!T:&4@56YI=&5D(%-T871E<R!A
M="!T:&4@<F%T92!O9B!U<"!T;R`\9F]N=#XS.3PO9F]N=#XE+CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN
M.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^8BXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#M0<F]T86QI>"!,=&0N(#PO8CX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^5&AE($ES<F%E;&D@4W5B<VED
M:6%R>2!I<R!T87AE9"!A8V-O<F1I;F<@=&\@27-R865L:2!T87@@;&%W<SH\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z
M("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SXQ+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.SQB/DUE87-U<F5M96YT(&]F(')E<W5L=',@9F]R
M('1A>"!P=7)P;W-E<R`\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I
M;CLG/E-I;F-E(#(P,#@L('1H92!#;VUP86YY(&AA<R!M96%S=7)E9"!T:&4@
M<F5S=6QT<R!O9B!T:&4@27-R865L:2!3=6)S:61I87)Y(&9O<B!T87@@<'5R
M<&]S97,@:6X@;F]M:6YA;"!T97)M<R!I;B!.25,N(%!U<G-U86YT('1O('1H
M92!)<W)A96P@26YC;VUE(%1A>"!,87<@*$%D:G5S=&UE;G1S(&9O<B!);F9L
M871I;VXI+"`Q.3@U+"!T:&4@4W5B<VED:6%R>2=S(')E<W5L=',@9F]R('1A
M>"!P=7)P;W-E<R!H879E(&)E96X@;65A<W5R960@=&AR;W5G:"`R,#`W(&]N
M(&$@<F5A;"!B87-I<RP@8F%S960@;VX@8VAA;F=E<R!I;B!T:&4@27-R865L
M(&-O;G-U;65R('!R:6-E(&EN9&5X+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N
M,C5I;CLG/C(N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/&(^5&%X(')A=&5S
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY4:&4@:6YC;VUE
M(&]F('1H92!)<W)A96QI(%-U8G-I9&EA<GDL(&]T:&5R('1H86X@:6YC;VUE
M(&9R;VT@)B,Q-#<[07!P<F]V960@16YT97)P<FES97,L)B,Q-#@[(&ES('1A
M>&5D(&EN($ES<F%E;"!A="!T:&4@<F5G=6QA<B!R871E<R!W:&EC:"!W97)E
M(#QF;VYT/C(U/"]F;VYT/B4@:6X@,C`Q,B!A;F0@,C`Q,R!A;F0@/&9O;G0^
M,C8N-3PO9F]N=#XE(&9O<B`R,#$T(&%N9"!T:&5R96%F=&5R+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R<^/&)R+SX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;CLG/D-A<&ET86P@9V%I;B!I<R!S
M=6)J96-T('1O(&-A<&ET86P@9V%I;B!T87@@86-C;W)D:6YG('1O(&-O<G!O
M<F%T92!T87@@<F%T92!I;B!T:&4@>65A<B!O9B!S96QL:6YG('1H92!A<W-E
M=',N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^,RXF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#L\8CY4:&4@3&%W(&9O<B!T:&4@16YC;W5R
M86=E;65N="!O9B!#87!I=&%L($EN=F5S=&UE;G1S+"`Q.34Y("AT:&4@)B,Q
M-#<[16YC;W5R86=E;65N="!O9B!#87!I=&%L($EN=F5S=&UE;G1S($QA=R8C
M,30X.RD\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/E5N9&5R
M('1H92!%;F-O=7)A9V5M96YT(&]F($-A<&ET86P@26YV97-T;65N=',@3&%W
M+"!I;F-L=61I;F<@06UE;F1M96YT($YO+B`V,"!T;R!T:&4@16YC;W5R86=E
M;65N="!O9B!#87!I=&%L($EN=F5S=&UE;G1S($QA=R!A<R!P=6)L:7-H960@
M:6X@07!R:6P@,C`P-2P@8GD@=FER='5E(&]F('1H92`F(S$T-SM!<'!R;W9E
M9"!%;G1E<G!R:7-E)B,Q-#@[(&]R("8C,30W.T)E;F5F:71E9"!%;G1E<G!R
M:7-E)B,Q-#@[('-T871U<R!T:&4@27-R865L:2!3=6)S:61I87)Y(&ES(&5N
M=&ET;&5D('1O('9A<FEO=7,@=&%X(&)E;F5F:71S(&%S(&9O;&QO=W,Z/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C5I;CL@=&5X="UI;F1E;G0Z
M("TS-RXQ<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#$N-6EN.R!T97AT+6EN9&5N=#H@+3,W+C%P=#LG/F$N)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/&(^4F5D=6-E9"!T87@@<F%T97,\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/DEN8V]M
M92!D97)I=F5D(&9R;VT@=&AE($%P<')O=F5D($5N=&5R<')I<V4@9'5R:6YG
M(&$@,3`M>65A<B!P97)I;V0@8V]M;65N8VEN9R!U<&]N('1H92!Y96%R(&EN
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M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[
M)SY4:&4@27-R865L:2!3=6)S:61I87)Y(&AA<R!A;B`F(S$T-SM!<'!R;W9E
M9"!%;G1E<G!R:7-E)B,Q-#@[('!L86X@<VEN8V4@,C`P-"!A;F0@)B,Q-#<[
M0F5N969I=&5D($5N=&5R<')I<V4F(S$T.#L@<&QA;B!S:6YC92`R,#`Y+B!4
M:&4@<&5R:6]D(&]F(&)E;F5F:71S(&EN(')E<W!E8W0@;V8@=&AE(&UA:6X@
M96YT97)P<FES92!O9B!T:&4@0V]M<&%N>2!H87,@;F]T('EE="!C;VUM96YC
M960N(%1H92!P97)I;V0@9'5R:6YG('=H:6-H('1H92!#;VUP86YY(&ES(&5N
M=&ET;&5D('1O(&)E;F5F:71S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0F5N
M969I=&5D($5N=&5R<')I<V4@97AP:7)E<R!I;B`R,#(Q+CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SY)9B!T:&4@27-R865L:2!3=6)S
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M(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SY);B!A9&1I=&EO;B!T;R!T:&4@8V]R
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M9R!T87@@<F%T92!I<R!C=7)R96YT;'D@/&9O;G0^,34\+V9O;G0^)2X\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z
M("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SYB+B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.SQB/D%C8V5L97)A=&5D(&1E<')E8VEA=&EO
M;CPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^5&AE
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M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD
M96YT.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^8RXF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\8CY#;VYD:71I;VYS(&9O<B!E;G1I
M=&QE;65N="!T;R!T:&4@8F5N969I=',\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`Q+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#$N,C5I;CLG/E1H92!)<W)A96QI(%-U8G-I9&EA<GDG<R!E
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M:&4@26YV97-T;65N="!#96YT97(N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M:6YD96YT
M.B`M,"XR-6EN.R<^9"XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\
M8CY!;65N9&UE;G0@;V8@=&AE($QA=R!F;W(@=&AE($5N8V]U<F%G96UE;G0@
M;V8@0V%P:71A;"!);G9E<W1M96YT<RP@,3DU.3PO8CX\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R<^5&AE($5N8V]U<F%G96UE;G0@;V8@
M0V%P:71A;"!);G9E<W1M96YT<R!,87<@=V%S(&%M96YD960@87,@<&%R="!O
M9B!T:&4@16-O;F]M:6,@4&]L:6-Y($QA=R!F;W(@=&AE('EE87)S(#(P,3$M
M,C`Q,BP@=VAI8V@@=V%S('!A<W-E9"!B>2!T:&4@27-R865L:2!+;F5S<V5T
M(&]N($1E8V5M8F5R(#(Y+"`R,#$P("AT:&4@)B,Q-#<[0V%P:71A;"!);G9E
M<W1M96YT<R!,87<@06UE;F1M96YT)B,Q-#@[*2X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#$N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,2XR-6EN.R<^5&AE($-A<&ET86P@26YV97-T;65N=',@
M3&%W($%M96YD;65N="!S971S(&%L=&5R;F%T:79E(&)E;F5F:70@=')A8VMS
M('1O('1H;W-E(&-U<G)E;G1L>2!I;B!E9F9E8W0@=6YD97(@=&AE('!R;W9I
M<VEO;G,@;V8@=&AE($5N8V]U<F%G96UE;G0@;V8@0V%P:71A;"!);G9E<W1M
M96YT<R!,87<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[)SX\8CXF(S$V
M,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R<^/&(^/"]B/CQB<B\^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[)SY4:&4@8F5N
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M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[
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M<V5T('1H92`F(S$T-SMY96%R(&]F(&5L96-T:6]N)B,Q-#@[(&YO(&QA=&5R
M('1H86X@=&%X('EE87(@,C`Q,BP@<')O=FED960@=&AA="!T:&4@;6EN:6UU
M;2!Q=6%L:69Y:6YG(&EN=F5S=&UE;G0@=V%S(&UA9&4@;F]T(&QA=&5R('1H
M86X@=&AE(&5N9"!O9B`R,#$P+B!/;B!E86-H('EE87(@9'5R:6YG('1H92!B
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M($%M96YD;65N="!A<'!L>2!T;R!T:&4@0V]M<&%N>2X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[
M)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C<U:6X[('1E>'0M:6YD96YT.B`M,"XR-6EN.R<^/&(^8RXF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V(^5&%X(&QO<W-E<R!C87)R:65D(&9O
M<G=A<F0@=&\@9G5T=7)E('EE87)S/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#`N-S5I;CLG/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M
M<&%N>2!H860@86=G<F5G871E(&YE="!O<&5R871I;F<@;&]S<R`H3D],*2!C
M87)R>2UF;W)W87)D<R!E<75A;"!T;R!A<'!R;WAI;6%T96QY("0\9F]N=#XQ
M,S@N.#PO9F]N=#X@;6EL;&EO;B!T:&%T(&%R92!A=F%I;&%B;&4@=&\@<F5D
M=6-E(&9U='5R92!T87AA8FQE(&EN8V]M92!A<R!F;VQL;W=S.CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I
M;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T
M97AT+6EN9&5N=#H@+3`N,C5I;CLG/C$N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[/&(^5&AE($-O;7!A;GD\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
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M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N
M=#H@+3`N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N,C5I;CLG/C(N)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[/&(^4')O=&%L:7@@3'1D+CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^070@1&5C96UB97(@,S$L(#(P,30L
M('1H92!)<W)A96QI(%-U8G-I9&EA<GD@:&%D(&%P<')O>&EM871E;'D@)#QF
M;VYT/C$R,2XY/"]F;VYT/B!M:6QL:6]N(&]F($Y/3"!C87)R>2UF;W)W87)D
M<R!T:&%T(&%R92!A=F%I;&%B;&4@=&\@<F5D=6-E(&9U='5R92!T87AA8FQE
M(&EN8V]M92!W:71H(#QF;VYT/FYO/"]F;VYT/B!L:6UI=&5D('!E<FEO9"!O
M9B!U<V4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[)SX\8CXF(S$V,#L\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SX\8CYD
M+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T1E9F5R<F5D(&EN8V]M
M92!T87AE<SH\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U
M:6X[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SY4:&4@8V]M<&]N96YT<R!O9B!T:&4@0V]M<&%N>2=S(&YE
M="!D969E<G)E9"!T87@@87-S971S(&%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N
M9"`R,#$T('=E<F4@87,@9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQD:78@8VQA<W,],T1#=7)S
M;W)0;VEN=&5R(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('=I9'1H.B`V,"4[(&UA<F=I;BUL969T.B`P+C%P>#L@;6%R9VEN+7)I9VAT
M.B`P+C%P>#LG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
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M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[)SX\<W1R;VYG/D1E8V5M8F5R(#,Q+#PO<W1R;VYG
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^*%4N4RX@9&]L;&%R<R!I;B!T
M:&]U<V%N9',I/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\<W1R;VYG/B`\+W-T<F]N9SX\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/'-T<F]N9SXR,#$S/"]S=')O;F<^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQS=')O;F<^)B,Q-C`[/"]S=')O
M;F<^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[
M('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQS=')O;F<^,C`Q-#PO<W1R
M;VYG/CQS=')O;F<^/&9O;G0^/"]F;VYT/CPO<W1R;VYG/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T<F]N9SX\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@
M8V]L<W!A;CTS1#,^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\<W1R;VYG/B8C
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M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS
M<&%N/3-$,CX\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,CXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
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M861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H
M.B`Q,"4[)SX\9F]N=#XU+#(U-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M=VED=&@Z(#`E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,"4[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#XS+#$S-CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT/B@T.3$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M<&%D9&EN9RUR:6=H=#H@,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/BD\
M+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M/B@S-S(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@
M,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/BD\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SY0<F]V:7-I;VX@9F]R('9A8V%T:6]N/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N=#XT,3<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
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M("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M,S<T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^4V5V97)A;F-E('!A>2!O8FQI9V%T:6]N/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#XR,#D\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
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M:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^,3@U
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SY$969E<G)E9"!R979E;G5E<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
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M97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SY.970@
M;W!E<F%T:6YG(&QO<W,@8V%R<GD@9F]R=V%R9',\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT/C(S+#$V-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#XR."PQ,S`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^*#,X+#0R-CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^*#0P+#$Q,3PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/BT\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"@T*/"]T86)L
M93X-"CPO9&EV/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
M-S5I;CLG/CQB<B\^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U
M:6X[)SY$969E<G)E9"!T87AE<R!A<F4@8V]M<'5T960@=7-I;F<@=&AE('1A
M>"!R871E<R!E>'!E8W1E9"!T;R!B92!I;B!E9F9E8W0@=VAE;B!T:&]S92!D
M:69F97)E;F-E<R!R979E<G-E+B!4:&4@0V]M<&%N>2!U<V5D('1A>"!R871E
M<R!O9B`S.24L(#(V+C4E(&%N9"`P)2X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/B8C,38P.SPO
M8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E
M;G0Z("TP+C5I;CLG/CQB/F4N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[4F5C;VYC:6QI871I;VX@;V8@=&AE('1H96]R971I8V%L('1A>"!E>'!E
M;G-E('1O(&%C='5A;"!T87@@97AP96YS93PO8CX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XW-6EN.R<^5&AE(&UA:6X@<F5C;VYC:6QI;F<@:71E
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M87@@8F5N969I=',@*'-E92!A8F]V92DN/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CXF(S$V,#L\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XU:6X[)SX\8CYF+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.U1A>"!A<W-E<W-M96YT<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^26X@86-C;W)D86YC92!W:71H('1H92!);F-O;64@
M5&%X($]R9&EN86YC92P@87,@;V8@1&5C96UB97(@,S$L(#(P,30L(&%L;"!O
M9B!0<F]T86QI>"!,=&0N)W,@=&%X(&%S<V5S<VUE;G1S('1H<F]U9V@@=&%X
M('EE87(@,C`Q,"8C,38P.V%R92!C;VYS:61E<F5D(&9I;F%L+CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^02!S=6UM87)Y
M(&]F(&]P96X@=&%X('EE87)S(&)Y(&UA:F]R(&IU<FES9&EC=&EO;B!I<R!P
M<F5S96YT960@8F5L;W<Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C<U:6X[)SXF(S$V,#L\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E
M<B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=VED=&@Z(#8P)3L@;6%R9VEN+7)I9VAT.B`P+C%P>#LG(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^#0H-"CQT<B!S='EL93TS1"=V
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'0[(&)O<F1E<BUB;W1T;VTM
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M<R!N97<@<F]M86XG.R!W:61T:#H@.3`E.R<^27-R865L/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[('=I9'1H
M.B`P)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:61T:#H@
M,"4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=I9'1H.B`Q
M,"4[)R!N;W=R87`],T1N;W=R87`^/&9O;G0^,C`Q,3PO9F]N=#XM/&9O;G0^
M,C`Q-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VED=&@Z(#`E
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/E5N:71E9"!3=&%T
M97,@*"HI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N=#XR,#$P/"]F;VYT/BT\9F]N=#XR,#$T/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CPO
M=&%B;&4^#0H\+V1I=CX-"CQB/CQB/B8C,38P.SQB<B\^/"]B/CPO8CX-"CQD
M:78^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!W:61T
M:#TS1#$P,"4@8V5L;'!A9&1I;F<],T0P(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)VUA<F=I;BUL969T.B`P+C$P,#`P,#`P,30Y,#$Q
M-G!X.R<^#0H-"CQT<CX-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[)SX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^*"HI)B,Q-C`[/"]P/@T*
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M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-54%!,14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.5"!)3D9/
M4DU!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY355!03$5-14Y405)9($9)3D%.0TE!3"!35$%414U%3E0@
M24Y&3U)-051)3TX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y355!03$5-14Y405)9($9)3D%.0TE!3"!3
M5$%414U%3E0@24Y&3U)-051)3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS
M1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\8CY.
M3U1%(#$Q("T@/"]B/B`\8CY355!03$5-14Y405)9($9)3D%.0TE!3"!35$%4
M14U%3E0@24Y&3U)-051)3TX\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@-S$N,W!T.R!T97AT+6EN9&5N=#H@+3$W+C-P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQB/B8C,38P.SPO8CX\+V9O;G0^
M/"]P/@T*/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@-S$N,W!T.R!T
M97AT+6EN9&5N=#H@+3$W+C-P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQB/D)A;&%N8V4@<VAE971S.CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`W,2XS<'0[('1E>'0M:6YD96YT.B`M,3<N,W!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^)B,Q-C`[/"]B/CPO
M9F]N=#X\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8V]L;&%P
M<V4Z(&-O;&QA<'-E.R!W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,2XQ:6X[
M)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^1&5C96UB97(@,S$L
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
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M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SXR,#$S/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
M;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CQS=')O;F<^/&9O;G0^/"]F;VYT
M/CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@+3(V+C0U<'0[(&UA<F=I;CH@,"`P(#`@-S5P=#LG
M/F$N("8C,38P.R`F(S$V,#L@)B,Q-C`[("8C,38P.T]T:&5R(&%S<V5T<SH\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:61T:#H@,"4[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
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M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,3(T/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY3=&%T92!O9B!)<W)A
M96P@*'-E92!.;W1E(#9A*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,S8V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ
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M.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY297-T<FEC=&5D(&1E<&]S
M:70\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
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M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-#$V/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SY0<F5P86ED(&5X<&5N<V5S/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR.#8\+V9O;G0^/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.#<\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C8T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C$L-#4W/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R
M=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P
M861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O
M=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXR+#(P,CPO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E
M<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.#`E.R!M87)G:6XM;&5F
M=#H@,2XQ:6X[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^*%4N4RX@9&]L;&%R<R!I;B!T
M:&]U<V%N9',I/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,CX\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&UA<F=I;CH@,"`P(#`@-S5P=#LG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UI;F1E;G0Z
M("TR-BXT-7!T.R!M87)G:6XZ(#`@,"`P(#<U<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/F(N("8C,38P.R`F(S$V,#L@)B,Q-C`[
M("8C,38P.R!!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=6%L<R`F(S$U,#L@
M;W1H97(Z/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,CX\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@
M8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!T;W`[)R!C;VQS<&%N/3-$,CX\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T
M:#H@.#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^4&%Y<F]L;"!A
M;F0@<F5L871E9"!E>'!E;G-E<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:61T:#H@,"4[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#$P)3LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C$L,C0S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SY);G1E<F5S="!P87EA8FQE/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXX.#@\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY0<F]V:7-I;VX@
M9F]R('9A8V%T:6]N/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXQ+#4W,CPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PT
M,3(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU+#`Y-SPO9F]N=#X\+V9O;G0^
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M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SY2;WEA;'1I97,@<&%Y86)L93PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-#$Y/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXT.34\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY0<F]P97)T>2!A;F0@
M97%U:7!M96YT('-U<'!L:65R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ.#8\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
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M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$R,#PO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ,BPP
M-S,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C$U+#0Y-CPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#!I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQB/B8C,38P.SQB<B\^/"]B/CPO9F]N=#X\+W`^
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=VED=&@Z(#@U)3L@;6%R9VEN+6QE9G0Z(#$N,6EN
M.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
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M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M('1O<#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS
M1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^665A<B!E;F1E9"!$96-E;6)E<B`S,2P\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SXR,#$R/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,3,\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C
M,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR,#$T/"]S=')O
M;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
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M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
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M;VQD.R!T97AT+6EN9&5N=#H@+3(V+C0U<'0[(&UA<F=I;CH@,"`P(#`@-S5P
M=#LG/F,N("8C,38P.R`F(S$V,#L@)B,Q-C`[4F5V96YU97,Z/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:61T:#H@-S`E.R!T97AT+6EN9&5N=#H@,"XU<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SY$969E<G)E9"!R979E;G5E<R!F<F]M('1H
M92!L:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT('=I=&@@4&9I>F5R/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P
M>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXT+#4V,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^-"PU-C,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=&5X="UI
M;F1E;G0Z(#`N-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^36EL
M97-T;VYE('!A>6UE;G0@*'-E92!.;W1E(#(I/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR-2PP,#`\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('1E>'0M:6YD96YT.B`P+C5P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/E)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D=6-T<SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXU+#,P-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^-2PY,38\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
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M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDL,#@X/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`R."XX-7!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT
M.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXS-"PX-S`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
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M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^,3,L-C4Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F
M7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E
M-64T-C0O5V]R:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4D5,051%1"!005)462!44D%.4T%#5$E/
M3E,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4D5,051%1"!005)462!44D%.4T%#5$E/3E,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y214Q!
M5$5$(%!!4E19(%1204Y304-424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE
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M04Y304-424].4SPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,3)P=#L@=&5X="UI;F1E;G0Z(#(U+CEP=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV/@T*/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!B;&]C:SLG(&%L:6=N/3-$8V5N=&5R/@T*/&1I
M=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M
M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I
M9'1H.B`X-24[(&UA<F=I;BUL969T.B`P+C$P,#`P,#`P,30Y,#$Q-G!X.R!M
M87)G:6XM<FEG:'0Z(#`N,7!X.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#$P(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L
M:6,[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
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M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXR,#$R/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXR,#$S/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXR,#$T/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@-S`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^0V]M<&5N<V%T:6]N("AI;F-L=61I
M;F<@<VAA<F4@8F%S960@8V]M<&5N<V%T:6]N*2!T;R!T:&4@;F]N+65X96-U
M=&EV92!D:7)E8W1O<G,@*&EN8VQU9&5S('1H92!I;G1E<FEM($-H86ER;6%N
M(&]F('1H92!";V%R9"!T:')O=6=H(#(P,30@86YD('1H92!#:&%I<FUA;B!O
M9B!T:&4@0F]A<F0@9F]R('!A<G0@;V8@,C`Q-"D\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(",P,#`P,#`@(6EM<&]R=&%N=#L@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,BXX<'0@(6EM<&]R=&%N=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U
M8FQE("%I;7!O<G1A;G0[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(",P,#`P,#`@(6EM
M<&]R=&%N=#L@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXX<'0@(6EM<&]R=&%N
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE("%I;7!O<G1A;G0[('=I
M9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS
M-S4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P
M<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@(S`P,#`P,"`A:6UP
M;W)T86YT.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R+CAP="`A:6UP;W)T86YT
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4@(6EM<&]R=&%N=#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@(S`P,#`P,"`A:6UP;W)T86YT.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`R+CAP="`A:6UP;W)T86YT.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!D;W5B;&4@(6EM<&]R=&%N=#L@=VED=&@Z(#$P)3LG/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C4P.3PO9F]N=#X\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B`C,#`P,#`P("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#(N.'!T("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM<W1Y
M;&4Z(&1O=6)L92`A:6UP;W)T86YT.R!W:61T:#H@,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P
M,#`P("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#(N.'!T("%I
M;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L92`A:6UP;W)T
M86YT.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^-38P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/CPO9&EV/@T*/"]D:78^#0H\
M+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15!#044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4TE'3DE&
M24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`H4&]L:6-Y*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY324=.249)
M0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!
M,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE
M=R!2;VUA;B<[)SX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT
M+6EN9&5N=#H@+3`N-6EN.R<^/&(^82XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#M'96YE<F%L/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[)SY0<F]T86QI>"!":6]4:&5R87!E=71I8W,L($EN8RX@*&-O;&QE8W1I
M=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L('1H92`F(S$T-SM#;VUP86YY
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M<F]#96QL17@F(S$T.#LI+B!);B!397!T96UB97(@,C`P.2P@4')O=&%L:7@@
M3'1D+B!F;W)M960@86YO=&AE<B!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!U
M;F1E<B!T:&4@;&%W<R!O9B!T:&4@3F5T:&5R;&%N9',L(%!R;W1A;&EX($(N
M5BXL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@175R;W!E86X@365D:6-I;F5S
M($%G96YC>2`H)B,Q-#<[14U!)B,Q-#@[*2!A<'!L:6-A=&EO;B!P<F]C97-S
M(&EN('1H92!%=7)O<&5A;B!5;FEO;BX@5&AE($-O;7!A;GDG<R`\9F]N=#YT
M=V\\+V9O;G0^('-U8G-I9&EA<FEE<R!A<F4@<F5F97)R960@=&\@8V]L;&5C
M=&EV96QY(&AE<F5I;B!A<R!T:&4@)B,Q-#<[4W5B<VED:6%R:65S+B8C,30X
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY/;B!-87D@,2P@,C`Q
M,BP@=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B,Q
M-#<[1D1!)B,Q-#@[*2!A<'!R;W9E9"!T86QI9VQU8V5R87-E(&%L9F$@9F]R
M(&EN:F5C=&EO;BP@=&AE($-O;7!A;GDG<R!F:7)S="!A<'!R;W9E9"!D<G5G
M('!R;V1U8W0L(&%S(&%N(&5N>GEM92!R97!L86-E;65N="!T:&5R87!Y("A%
M4E0I(&9O<B!T:&4@;&]N9RUT97)M('1R96%T;65N="!O9B!A9'5L="!P871I
M96YT<R!W:71H(&$@8V]N9FER;65D(&1I86=N;W-I<R!O9B!T>7!E(#$@1V%U
M8VAE<B!D:7-E87-E+B!486QI9VQU8V5R87-E(&%L9F$@:7,@82!P<F]P<FEE
M=&%R>2P@<F5C;VUB:6YA;G0@9F]R;2!O9B!G;'5C;V-E<F5B<F]S:61A<V4@
M*$=#1"D@=&AA="!T:&4@0V]M<&%N>2!D979E;&]P960@=7-I;F<@4')O0V5L
M;$5X+B!486QI9VQU8V5R87-E(&%L9F$@=V%S(&%L<V\@87!P<F]V960@8GD@
M=&AE($ES<F%E;&D@36EN:7-T<GD@;V8@2&5A;'1H("AT:&4@)B,Q-#<[27-R
M865L:2!-3T@F(S$T.#LI(&EN(%-E<'1E;6)E<B`R,#$R+"!B>2!T:&4@0G)A
M>FEL:6%N($UI;FES=')Y(&]F($AE86QT:"`H=&AE("8C,30W.T)R87II;&EA
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M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[
M)SY);B!!=6=U<W0@,C`Q-"P@=&AE($9$02!A<'!R;W9E9"!T86QI9VQU8V5R
M87-E(&%L9F$@9F]R(&EN:F5C=&EO;B!F;W(@<&5D:6%T<FEC('!A=&EE;G1S
M+B!0<FEO<B!T;R!T:&ES(&%P<')O=F%L+"!T86QI9VQU8V5R87-E(&%L9F$@
M=V%S(&%P<')O=F5D(&9O<B!P961I871R:6,@:6YD:6-A=&EO;G,@:6X@075S
M=')A;&EA(&%N9"!#86YA9&$@8G5T(&EN(&YO(&]T:&5R(&IU<FES9&EC=&EO
M;BX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^5&%L:6=L=6-E<F%S
M92!A;&9A(&ES(&)E:6YG(&UA<FME=&5D(&EN('1H92!5;FET960@4W1A=&5S
M('5N9&5R('1H92!B<F%N9"!N86UE)B,Q-C`[16QE;'ES;R8C,34S.R!B>2!0
M9FEZ97(@26YC+B`H)B,Q-#<[4&9I>F5R)B,Q-#@[*2P@=&AE($-O;7!A;GDG
M<R!C;VUM97)C:6%L:7IA=&EO;B!P87)T;F5R+"!A<R!P<F]V:61E9"!I;B!T
M:&4@97AC;'5S:79E(&QI8V5N<V4@86YD('-U<'!L>2!A9W)E96UE;G0@8GD@
M86YD(&)E='=E96X@4')O=&%L:7@@3'1D+B!A;F0@4&9I>F5R("AT:&4@)B,Q
M-#<[4&9I>F5R($%G<F5E;65N="8C,30X.RDN(%1H92!#;VUP86YY+"!T:')O
M=6=H(%!R;W1A;&EX($QT9"XL(&UA<FME=',F(S$V,#M%;&5L>7-O)B,Q-C`[
M:6X@27-R865L+"!A;F0@:6X@0G)A>FEL('5N9&5R('1H92!B<F%N9"!N86UE
M(%5P;'ES;R8C,34S.RX@4V5E($YO=&4@,BX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,6EN.R<^4')O=&%L:7@@3'1D+B!G<F%N=&5D(%!F:7IE<B!A;B!E
M>&-L=7-I=F4L('=O<FQD=VED92!L:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O
M;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A;&9A('5N9&5R('1H92!09FEZ
M97(@06=R965M96YT+"!B=70@<F5T86EN960@=&AO<V4@<FEG:'1S(&EN($ES
M<F%E;"!A;F0L('-I;F-E(#(P,30L(&EN($)R87II;"`H<V5E(&)E;&]W*2X@
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M="!O9B`D/&9O;G0^-C`N,#PO9F]N=#X@;6EL;&EO;B!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE(&5X96-U=&EO;B!O9B!T:&4@4&9I>F5R($%G<F5E;65N="!A
M;F0@861D:71I;VYA;"`D/&9O;G0^,S`N,#PO9F]N=#X@;6EL;&EO;B!M:6QE
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M;&EZ871I;VX@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N(&$@/&9O;G0^-#`\
M+V9O;G0^)2!A;F0@/&9O;G0^-C`\+V9O;G0^)2!B87-I<RP@<F5S<&5C=&EV
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M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CLG/D]N($IU;F4@,3@L(#(P
M,3,L(%!R;W1A;&EX($QT9"X@96YT97)E9"!I;G1O(&$@4W5P<&QY(&%N9"!4
M96-H;F]L;V=Y(%1R86YS9F5R($%G<F5E;65N="`H=&AE("8C,30W.T)R87II
M;"!!9W)E96UE;G0F(S$T.#LI('=I=&@@1G5N9&$F(S(S,3LF(S(R-SMO($]S
M=V%L9&\@0W)U>B`H)B,Q-#<[1FEO8W)U>B8C,30X.RDL(&%N(&%R;2!O9B!T
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M;VUM:71T960@=&\@<'5R8VAA<V4@870@;&5A<W0@87!P<F]X:6UA=&5L>2`D
M/&9O;G0^-#`\+V9O;G0^(&UI;&QI;VX@=V]R=&@@;V8@=&%L:6=L=6-E<F%S
M92!A;&9A(&1U<FEN9R!T:&4@9FER<W0@='=O('EE87)S(&]F('1H92!A9W)E
M96UE;G0N(%=I=&@@<F5S<&5C="!T;R!T:&4@9FER<W0@<F5Q=6ER960@<'5R
M8VAA<V4@86UO=6YT+"!T:&4@0V]M<&%N>2!H87,@<F5C;W)D960@<F5V96YU
M97,@;V8@87!P<F]X:6UA=&5L>2`D/&9O;G0^,RXU/"]F;VYT/B!M:6QL:6]N
M(&9O<B!S86QE<R!O9B!T86QI9VQU8V5R87-E(&%L9F$@=&\@1FEO8W)U>B!I
M;B`R,#$T+B8C,38P.TEN('-U8G-E<75E;G0@>65A<G,L($9I;V-R=7H@:7,@
M<F5Q=6ER960@=&\@<'5R8VAA<V4@870@;&5A<W0@87!P<F]X:6UA=&5L>2`D
M/&9O;G0^-#`\+V9O;G0^(&UI;&QI;VX@=V]R=&@@;V8@=&%L:6=L=6-E<F%S
M92!A;&9A('!E<B!Y96%R+B!0<F]T86QI>"!,=&0N(&ES(&YO="!R97%U:7)E
M9"!T;R!C;VUP;&5T92!T:&4@9FEN86P@<W1A9V4@;V8@=&AE('1E8VAN;VQO
M9WD@=')A;G-F97(@=6YT:6P@1FEO8W)U>B!P=7)C:&%S97,@870@;&5A<W0@
M87!P<F]X:6UA=&5L>2`D/&9O;G0^,C@P/"]F;VYT/B!M:6QL:6]N('=O<G1H
M(&]F('1A;&EG;'5C97)A<V4@86QF82X@5&AE($)R87II;"!!9W)E96UE;G0@
M8F5C86UE(&5F9F5C=&EV92!D=7)I;F<@=&AE($IA;G5A<GDF(S$V,#MO9B`R
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M;"!B92!R971U<FYE9"!T;R!T:&4@0V]M<&%N>2X\8G(O/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#%I;CLG/DEN(%-E<'1E;6)E<B`R,#$T+"!#3TY)
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M<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[)SY4;R!F86-I;&ET871E('1H92!A<G)A;F=E;65N="!W
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY0
M<F]T86QI>"!,=&0N(&ES(')E<75I<F5D('1O('!A>2!A(&9E92!E<75A;"!T
M;R`U)2!O9B!T:&4@;F5T('!R;V-E961S(&=E;F5R871E9"!I;B!"<F%Z:6P@
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M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY#=7)R96YT;'DL('!A
M=&EE;G1S(&%R92!B96EN9R!T<F5A=&5D('=I=&@@=&%L:6=L=6-E<F%S92!A
M;&9A(&]N(&$@8V]M;65R8VEA;"!B87-I<R!I;B!T:&4@56YI=&5D(%-T871E
M<RP@0G)A>FEL+"!#:&EL92!A;F0@27-R865L+CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`Q:6X[)SY);B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E(&%L
M9F$L('1H92!#;VUP86YY(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M96YT
M(&]F(&-E<G1A:6X@;W1H97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X+CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY);B!A9&1I=&EO;B!T;R!T
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M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SY/8G1A:6YI
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M+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@<')E<V5N=&%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T
M-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XU:6X[)SX\8CYB+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.T)A<VES(&]F('!R97-E;G1A=&EO;CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XW-6EN.R<^5&AE($-O;7!A;GDG<R!F:6YA;F-I86P@
M<W1A=&5M96YT<R!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D86YC92!W
M:71H(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@
M:6X@=&AE(%5N:71E9"!3=&%T97,@*"8C,30W.U4N4RX@1T%!4"8C,30X.RDN
M/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5<V4@;V8@97-T:6UA=&5S(&EN('1H92!P<F5P87)A
M=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N
M-6EN.R<^/&(^8RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M5<V4@
M;V8@97-T:6UA=&5S(&EN('1H92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@
M<W1A=&5M96YT<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
M-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW
M-6EN.R<^5&AE('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&EN(&-O;F9O<FUI='D@=VET:"!5+E,N($=!05`@<F5Q=6ER97,@;6%N86=E
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M<RX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9U;F-T:6]N86P@8W5R<F5N8WD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U
M-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M
M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E
M;G0Z("TP+C5I;CLG/CQB/F0N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[1G5N8W1I;VYA;"!C=7)R96YC>3PO8CX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,"XW-6EN.R<^5&AE(&1O;&QA<B!I<R!T:&4@8W5R<F5N8WD@
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M(&1O;&QA<G,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG
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M(&%M;W)T:7IA=&EO;BP@971C+BD@)B,Q-3`[(&AI<W1O<FEC86P@97AC:&%N
M9V4@<F%T97,N($-U<G)E;F-Y('1R86YS86-T:6]N(&=A:6YS(&%N9"!L;W-S
M97,@87)E(&-A<G)I960@=&\@9FEN86YC:6%L(&EN8V]M92!O<B!E>'!E;G-E
M<RP@87,@87!P<F]P<FEA=&4N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&5Q=6EV86QE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$
M161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYE+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.T-A<V@@97%U:79A;&5N=',\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/E1H92!#;VUP86YY(&-O;G-I
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R
M4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S
M($YE=R!2;VUA;B<[)SX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T
M97AT+6EN9&5N=#H@+3`N-6EN.R<^/&(^9BXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#M);G9E;G1O<FEE<SPO8CX\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^26YV96YT;W)I97,@87)E('9A;'5E
M9"!A="!T:&4@;&]W97(@;V8@8V]S="!O<B!M87)K970N($-O<W0@;V8@<F%W
M(&%N9"!P86-K86=I;F<@;6%T97)I86QS(&%N9"!P=7)C:&%S960@<')O9'5C
M=',@:7,@9&5T97)M:6YE9"!U<VEN9R!T:&4@)B,Q-#<[;6]V:6YG(&%V97)A
M9V4F(S$T.#L@8F%S:7,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
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M<B!T:&4@<')O9'5C=&EO;B!P97)I;V0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/DEF(&%C='5A;"!M87)K970@<')I8V5S(&9O<B!F
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M87)K970@8V]N9&ET:6]N<RX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL
M>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/F<N)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4')O<&5R='D@86YD(&5Q=6EP;65N=#PO
M8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E
M;G0Z("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\9&EV(&-L87-S/3-$0W5R<V]R
M4&]I;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#L@=VED=&@Z
M(#$P,"4[)SX-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@
M,S9P=#LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#0X<'0[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG
M/C$N/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SY0<F]P97)T>2!A;F0@
M97%U:7!M96YT(&%R92!S=&%T960@870@8V]S="P@;F5T(&]F(&%C8W5M=6QA
M=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N+CPO=&0^#0H\+W1R
M/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CL@=&5X="UI;F1E;G0Z("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\9&EV
M(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX\8G(O/CPO9&EV/@T*/&1I=B!C;&%S
M<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P
M<'@[('=I9'1H.B`Q,#`E.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,V<'0[)SX\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!T.R!F;VYT+69A;6EL>3H@)W1I
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M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XM=&]P.B`P
M<'@[(&UA<F=I;BUB;W1T;VTZ(#$R<'0[('=I9'1H.B`Q,#`E.R<^#0H-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#,V<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI
M9VXZ(&QE9G0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!T.R!V
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#8P)3L@;6%R9VEN
M+6QE9G0Z(#`N,7!X.R<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,#X-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SLG(&-O;'-P86X],T0R/EEE87)S/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`X,B4[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/DQA8F]R
M871O<GD@97%U:7!M96YT/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^
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M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/D9U<FYI='5R
M93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SLG/D-O;7!U=&5R(&5Q=6EP;65N=#PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[)SX\9F]N=#XS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\
M+V1I=CX-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`P+C<U:6X[)SY,96%S96AO;&0@:6UP<F]V96UE;G1S(&%R92!A
M;6]R=&EZ960@8GD@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D(&]V97(@=&AE
M(&5X<&5C=&5D(&QE87-E('1E<FTL('=H:6-H(&ES('-H;W)T97(@=&AA;B!T
M:&4@97-T:6UA=&5D('5S969U;"!L:69E(&]F('1H92!I;7!R;W9E;65N=',N
M/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&EN('9A;'5E(&]F(&QO;F<M;&EV
M960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M(&ED/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI
M;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYH+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.TEM<&%I<FUE;G0@:6X@=F%L=64@;V8@
M;&]N9RUL:79E9"!A<W-E=',Z(#PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R<^5&AE($-O;7!A;GD@=&5S=',@;&]N9RUL:79E9"!A
M<W-E=',@9F]R(&EM<&%I<FUE;G0@:68@86X@:6YD:6-A=&EO;B!O9B!I;7!A
M:7)M96YT(&5X:7-T<RX@268@=&AE('-U;2!O9B!E>'!E8W1E9"!F=71U<F4@
M8V%S:"!F;&]W<R!O9B!D969I;FET92!L:69E(&%S<V5T<R`H=6YD:7-C;W5N
M=&5D(&%N9"!W:71H;W5T(&EN=&5R97-T(&-H87)G97,I(&ES(&QE<W,@=&AA
M;B!T:&4@8V%R<GEI;F<@86UO=6YT(&]F('-U8V@@87-S971S+"!T:&4@0V]M
M<&%N>2!R96-O9VYI>F5S(&%N(&EM<&%I<FUE;G0@;&]S<RP@86YD('=R:71E
M<R!D;W=N('1H92!A<W-E=',@=&\@=&AE:7(@97-T:6UA=&5D(&9A:7(@=F%L
M=65S+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P
M,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`M
M,"XU:6X[)SX\8CYI+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.TEN8V]M92!T87AE<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@
M,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@
M+3`N-6EN.R<^,2XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$969E
M<G)E9"!I;F-O;64@=&%X97,\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN
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M;R!I=',@9&5F97)R960@=&%X(&%S<V5T<RX@4V5E($YO=&4@,3`N/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[)SX\8G(O/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN
M.R<^,BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M5;F-E<G1A:6YT
M>2!I;B!I;F-O;64@=&%X97,\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P
M(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G
M;FET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED
M/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`Q:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SX\8CYJ+B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U)E=F5N=64@4F5C;V=N:71I;VX\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/E1H92!#
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M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@
M+3`N-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q
M+C(U:6X[('1E>'0M:6YD96YT.B`M,"XU:6X[)SXQ+B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.U)E=F5N=65S(&9R;VT@=&AE(&QI8V5N<V4@86YD
M('-U<'!L>2!A9W)E96UE;G0@=VET:"!09FEZ97(\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#%I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E
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M<W1I;6%T960@=&AE('!E<F9O<FUA;F-E('!E<FEO9"!O9B`Q-"!Y96%R<R`H
M8V]M;65N8VEN9R!U<&]N('1H92!D871E(&]F('1H92!#;VUP86YY)W,@<F5C
M96EP="!O9B!T:&4@=7`M9G)O;G0@;&EC96YS92!P87EM96YT('!A>6%B;&4@
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M<F=I;CH@,"`P(#`@,2XR-6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M
M:6YD96YT.B`M,"XU:6X[)SXR+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.U)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D=6-T<SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,"`Q:6X[)SY4:&4@0V]M<&%N>2!R96-O9VYI>F5S(')E
M=F5N=65S(&9R;VTF(S$V,#MS96QL:6YG('!R;V1U8W1S('5P;VX@9&5L:79E
M<GDL('=H96X@=&AE('-A;&5S('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN
M86)L92!A;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q+C(U:6X[('1E>'0M
M:6YD96YT.B`M,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#$N,C5I;CL@=&5X="UI;F1E;G0Z("TP+C5I;CLG/C,N)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0V]M<&%N>2=S('-H87)E(&EN('1H
M92!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@,6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`Q:6X[)SY5;F1E<B!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@
M=&AE(%!F:7IE<B!!9W)E96UE;G0L('1H92!#;VUP86YY(&ES(&5N=&ET;&5D
M('1O(#0P)2!O9B!T:&4@<')O9FET<R!O<B!L;W-S(&9R;VT@<V%L97,@;V8@
M=&%L:6=L=6-E<F%S92!A;&9A+"!A;F0@<F5L871E9"!E>'!E;G-E<R!I;F-U
M<G)E9"P@97AC97!T('=I=&@@<F5S<&5C="!T;R!S86QE<R!I;B!)<W)A96P@
M86YD($)R87II;"`H<VEN8V4@,C`Q-"DL('=H97)E('1H92!#;VUP86YY(')E
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X
M.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT
M.B`M,"XU:6X[)SX\8CYK+B8C,38P.R8C,38P.R8C,38P.R8C,38P.U)E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!C;W-T<R`\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
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M<V5S(&%S('1H92!A<'!L:6-A8FQE(&-O<W1S(&%R92!I;F-U<G)E9"X\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^4F5I;6)U<G-E;65N
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M86)L92!C;W-T<R!A<F4@:6YC=7)R960N/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/DEN(&-O;FYE8W1I;VX@=VET:"!P=7)C:&%S97,@
M;V8@87-S971S+"!A;6]U;G1S(&%S<VEG;F5D('1O(&EN=&%N9VEB;&4@87-S
M971S('1O(&)E('5S960@:6X@82!P87)T:6-U;&%R(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!P<F]J96-T('1H870@:&%V92`\9F]N=#YN;SPO9F]N=#X@
M86QT97)N871I=F4@9G5T=7)E('5S92!A<F4@8VAA<F=E9"!T;R!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@870@=&AE('!U<F-H87-E(&1A=&4N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/DYO;G)E9G5N
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M;W)M960N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N(&]F(&-R961I="!R
M:7-K<R!A;F0@=')A9&4@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#`@,6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN
M.R<^/&(^;"XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#
M;VYC96YT<F%T:6]N(&]F(&-R961I="!R:7-K<R!A;F0@=')A9&4@<F5C96EV
M86)L93PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^
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M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2=S
M('1R861E(')E8V5I=F%B;&5S(')E<')E<V5N="!A;6]U;G1S('1O(&)E(')E
M8V5I=F5D(&9R;VT@4&9I>F5R(&%N9"!T:&4@0V]M<&%N>2=S(&-U<W1O;65R
M<R!I;B!)<W)A96PN(%1H92!#;VUP86YY(&1O97,@;F]T(')E<75I<F4@4&9I
M>F5R(&]R(&%N>2!O9B!I=',@27-R865L:2!C=7-T;VUE<G,@=&\@<&]S="!C
M;VQL871E<F%L('=I=&@@<F5S<&5C="!T;R!R96-E:79A8FQE<RX@5&AE($-O
M;7!A;GD@<&5R9F]R;7,@<&5R:6]D:6,@8W)E9&ET(&5V86QU871I;VYS(&]F
M(%!F:7IE<B=S(&9I;F%N8VEA;"!C;VYD:71I;VX@86YD(&)E;&EE=F5S('1H
M97)E(&ES(&YO('-I9VYI9FEC86YT(')I<VL@=VET:"!R97-P96-T('1O(%!F
M:7IE<B=S('!A>6UE;G0@;V8@=&AE(')E8V5I=F%B;&5S+B!!<R!A;&P@27-R
M865L:2!C=7-T;VUE<G,@87)E(&=O=F5R;FUE;G0@96YT:71I97,L('1H92!#
M;VUP86YY(&)E;&EE=F5S('1H97)E(&ES(&YO('-I9VYI9FEC86YT(')I<VL@
M=VET:"!R97-P96-T('1O(&ET<R!R96-E:79A8FQE<R!F<F]M('-U8V@@96YT
M:71I97,N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A
M<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE
M<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@
M=&5X="UI;F1E;G0Z("TP+C5I;CLG/CQB/FTN)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2!A8V-O=6YT
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M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SY4:&4@0V]M<&%N>2!E
M;&5C=&5D('1O(')E8V]G;FEZ92!C;VUP96YS871I;VX@8V]S="!F;W(@86X@
M87=A<F0@=VET:"!O;FQY('-E<G9I8V4@8V]N9&ET:6]N<R!T:&%T(&AA<R!A
M(&=R861E9"!V97-T:6YG('-C:&5D=6QE('5S:6YG('1H92!A8V-E;&5R871E
M9"!M971H;V0@8F%S960@;VX@=&AE(&UU;'1I<&QE+6]P=&EO;B!A=V%R9"!A
M<'!R;V%C:"X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R<^
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M/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@3&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P
M,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X="UI;F1E;G0Z("TP
M+C5I;CLG/CQB/FXN)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[3F5T
M(&QO<W,@<&5R('-H87)E/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SY"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!S:&%R92`H
M)B,Q-#<[3%!3)B,Q-#@[*2!A<F4@8V]M<'5T960@8GD@9&EV:61I;F<@;F5T
M(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F('-H87)E
M<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C:RP@<&%R('9A;'5E("0\
M9F]N=#XP+C`P,3PO9F]N=#X@<&5R('-H87)E("AT:&4@)B,Q-#<[0V]M;6]N
M(%-T;V-K)B,Q-#@[*2!O=71S=&%N9&EN9R!F;W(@96%C:"!P97)I;V0N/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/D1I;'5T960@3%!3
M(&1O97,@;F]T(&EN8VQU9&4@/&9O;G0^-RPR.#`L-#8Y/"]F;VYT/BP@/&9O
M;G0^,3`L-C<U+#,P-#PO9F]N=#X@86YD(#QF;VYT/C$X+#@U,"PW,C0\+V9O
M;G0^('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=6YD97)L>6EN9R!O=71S=&%N
M9&EN9R!O<'1I;VYS("P@<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T
M;V-K(&%N9"!S:&%R97,@:7-S=6%B;&4@=7!O;B!C;VYV97)S:6]N(&]F('1H
M92!C;VYV97)T:6)L92!N;W1E<R`H:7-S=65D(&EN(%-E<'1E;6)E<B`R,#$S
M*2!F;W(@=&AE(&9I<V-A;"!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,BP@,C`Q,R!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+"!B96-A=7-E('1H92!E
M9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV92X\+W`^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N
M="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`U-BXW<'0[('1E>'0M:6YD96YT.B`M,C`N-W!T.R<^/&(^
M;RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#;VYV97)T:6)L92!N
M;W1E<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#4V+C=P=#L@
M=&5X="UI;F1E;G0Z(#!I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`P(#`@-38N-W!T.R!T97AT+6EN9&5N=#H@,&EN.R<^5&AE(&-O;G9E
M<G1I8FQE(&YO=&5S(&%R92!A8V-O=6YT960@9F]R('5S:6YG('1H92!G=6ED
M86YC92!P<F]V:61E9"!S970@9F]R=&@@:6X@1D%30B!!8V-O=6YT:6YG(%-T
M86YD87)D<R!#;V1I9FEC871I;VX@*$%30RD@.#$U(')E<75I<FEN9R!T:&%T
M('1H92!#;VUP86YY(&1E=&5R;6EN92!W:&5T:&5R('1H92!E;6)E9&1E9"!C
M;VYV97)S:6]N(&]P=&EO;B!M=7-T(&)E('-E<&%R871E9"!A;F0@86-C;W5N
M=&5D(&9O<B!S97!A<F%T96QY+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@
M=&AE(&-O;G9E<G1I8FQE(&YO=&5S(&%S(&$@;&EA8FEL:71Y+"!O;B!A;B!A
M9V=R96=A=&5D(&)A<VES+"!I;B!T:&5I<B!E;G1I<F5L>2X\+W`^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E8V5N=&QY(&ES<W5E9"!A8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S
M.CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D
M9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I
M;65S($YE=R!2;VUA;B<[)SX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M>"`P<'@@,'!X(#4V+C=P=#L@=&5X="UI;F1E;G0Z("TR,"XW<'0[(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^
M<"X@)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4F5C96YT;'D@:7-S
M=65D(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',Z/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#4V
M+C=P=#L@=&5X="UI;F1E;G0Z(#!I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SY);B!!=6=U<W0@,C`Q-"P@=&AE
M($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H)B,Q-#<[
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M9F9E8W1I=F4@9&%T92!O9B!$96-E;6)E<B`S,2P@,C`Q-BX@5&AE($-O;7!A
M;GD@8F5L:65V97,@=&AA="!T:&4@861O<'1I;VX@;V8@=&AI<R!N97<@<W1A
M;F1A<F0@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!I=',@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#4V
M+C=P=#L@=&5X="UI;F1E;G0Z(#!I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SY);B!-87D@,C`Q-"P@=&AE($9!
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M9VEN;FEN9R!O;B!O<B!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-B`H96%R;'D@
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M:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E
M.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R
M:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P
M,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^
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M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`V,"4[(&UA<F=I;BUL969T
M.B`P+C%P>#LG(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^#0H-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
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M<F]M86XG.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
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M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0^-3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SY&=7)N:71U<F4\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0^,3`\+V9O;G0^+3QF
M;VYT/C$U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[)SY#;VUP=71E<B!E<75I<&UE;G0\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R<^/&9O;G0^,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SLG/B8C,38P.SPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^
M#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E
M-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F
M-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T,C(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY04D]0
M15)462!!3D0@15%525!-14Y4("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!23U!%4E19($%.1"!%
M455)4$U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!0<F]P97)T>2!A;F0@17%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED
M/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY#;VUP;W-I=&EO;B!O9B!P<F]P97)T>2!A;F0@97%U:7!M
M96YT(&=R;W5P960@8GD@;6%J;W(@8VQA<W-I9FEC871I;VYS(&ES(&%S(&9O
M;&QO=W,Z/"]F;VYT/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3)P=#L@=&5X
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#8P)3L@
M;6%R9VEN+6QE9G0Z(#%I;CLG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SY$96-E;6)E<B`S,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M:6X@=&AO=7-A;F1S*3PO:3X\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X]
M,T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO
M<W1R;VYG/CQS=')O;F<^/&9O;G0^/"]F;VYT/CPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX\9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C
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M=&@Z(#`E.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXQ-"PX-3@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
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M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^1G5R;FET=7)E)B,Q
M-C`[86YD)B,Q-C`[8V]M<'5T97(F(S$V,#ME<75I<&UE;G0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,BPP-S0\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,34L,#<P/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ-2PT,C<\+V9O;G0^/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M:6UE<SLG/D5Q=6EP;65N="8C,38P.W5N9&5R)B,Q-C`[8V]N<W1R=6-T:6]N
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
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M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/C(X/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S
M;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXQ-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M,S(L,#,P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,S(L-S,V/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SY,97-S)B,Q-C`[)B,Q-3`[)B,Q-C`[86-C=6UU
M;&%T960F(S$V,#MD97!R96-I871I;VX\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`R,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^86YD)B,Q-C`[86UO<G1I>F%T:6]N/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
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M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
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M<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXH,C$L-#4T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ,RPW,3$\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O
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M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?
M,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U
M930V-"]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4R`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($EN=F5N=&]R>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!
M,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#8P
M)3L@;6%R9VEN+6QE9G0Z(#%I;CLG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$-B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^1&5C
M96UB97(@,S$L/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXH/&D^52Y3+B!D;VQL87)S(&EN('1H;W5S
M86YD<RD\+VD^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,CX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,30\+W-T<F]N9SX\
M<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS
M1#,^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N=#X\
M+V9O;G0^/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:61T:#H@.#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M4F%W(&UA=&5R:6%L<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T
M:#H@,"4[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#8Q-CPO9F]N=#X\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^5V]R:R!I;B!P<F]G<F5S
M<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,3,R/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
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M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C4L
M-3(S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXT+#DQ.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXW+#DU-SPO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
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M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^-BPV-C<\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?
M,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U
M930V-"]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$591$%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-(05)%($-!4$E404P@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4TA!4D4@0T%0251!3"!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($]P=&EO;G,@
M86YD(%)E<W1R:6-T960@4W1O8VMS($=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P
M,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#@Q)3L@;6%R9VEN+6QE9G0Z(#$N
M,C5I;CLG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^665A<B!O9CQB<B\^(&=R86YT
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF
M(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/DYO+B!O9B!O<'1I;VYS/&)R+SX@;W(@<F5S=')I8W1E9#QB<B\^('-T
M;V-K(&=R86YT960\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SY%>&5R8VES93QB<B\^('!R:6-E(')A;F=E
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF
M(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/D9A:7(@=F%L=64\8G(O/B!A="!G<F%N=#QB
M<B\^("A5+E,N/&)R+SX@9&]L;&%R<R!I;CQB<B\^('1H;W5S86YD<RD\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^
M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T
M<F]N9SY%>'!I<F%T:6]N/&)R+SX@<&5R:6]D/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M,C`Q,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C0P,"PP,#`\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^;B]A/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,BPR.#@\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^;B]A/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:61T:#H@,38E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^,C`Q,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q-B4[)SX\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#$P,"PP,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T
M:#H@,38E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^;B]A/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,38E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&9O;G0^-#PO9F]N=#X@>65A
M<G,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SL@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,38E.R<^/&9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-BPR.3(\+V9O;G0^/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,38E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^;B]A/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^,C`Q-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I
M;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CDP,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\9F]N=#XR+C,W/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/C$L,#`W/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,BPT,#`L,#`P/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M9F]N=#X\+W1D/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`X.2XX-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,2XR-6EN.R<^/&)R+SX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@
M4W1O8VL@3W!T:6]N($%C=&EV:71Y("T@3W!T:6]N<R!'<F%N=&5D('1O($5M
M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I
M9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M(#H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R<^3W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<SH\+V9O
M;G0^#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,3`P)3LG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^665A<B!E;F1E9"!$96-E;6)E<B`S,2P\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q,CPO<W1R;VYG
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M<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR,#$S/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@;F]W
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/E=E:6=H=&5D/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/E=E:6=H=&5D/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SY796EG:'1E9#PO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^3G5M
M8F5R/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/F%V97)A9V4\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY.=6UB97(\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/F%V97)A9V4\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^
M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/DYU;6)E<CPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
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M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^;V8\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/F5X97)C:7-E/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO
M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SYO9CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^97AE<F-I<V4\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/F]F/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO
M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SYE>&5R8VES93PO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
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M=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^<')I8V4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/F]P=&EO;G,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/G!R:6-E/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SYO<'1I;VYS/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R
M=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SYP<FEC93PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXV+#$T,2PP,S`\+V9O;G0^
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@
M-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT
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M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^,RXY,C,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T
M:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-2PQ-3,L.#DX/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P
M>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXS+CDU,3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I
M9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^0VAA;F=E<R!D=7)I;F<@=&AE('EE87(Z/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=&5X="UI
M;F1E;G0Z(#$P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY'<F%N
M=&5D/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3`P+#`P,#PO9F]N
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M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,BXS-S`\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#$P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SY&;W)F96ET960@86YD($5X<&ER960\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C(U+#@U.#PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^-"XS-S(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C(P+#4U.#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-BXV,#,\+V9O;G0^
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^-BXX,S,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^17AE<F-I<V5D("@J*3PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXX-C$L-3DS/"]F;VYT/CPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+C,T
M-CPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^-SDL,3(S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXQ+C0Q.#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXP+C0T-CPO9F]N=#X\+V9O
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[
M('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU
M+#(U,RPU-SD\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@
M9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N.3(S/"]F;VYT/CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D
M9&EN9RUR:6=H=#H@,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B
M;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^,RXY-3$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX
M,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-2PX-S`L,S`Y
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXS+C<W,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT+#(U
M."PT-#$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A
M9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U
M8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/C,N,C`Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[
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M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,RXU.3$\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T
M(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-"PY,#4L-34Y/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I
M9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXS+CDS,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,C$N,W!T.R!T97AT+6EN9&5N=#H@+3$T+C)P=#LG/CQB
M<B\^/"]P/@T*/&1I=CX-"CQD:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*
M/'1A8FQE('=I9'1H/3-$,3`P)2!C96QL<&%D9&EN9STS1#`@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[)SX-"@T*
M/'1R/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B`H*BD@/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#DX)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/E1H92!T
M;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960@9'5R
M:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BP@,C`Q,R!A
M;F0@,C`Q-"P@=V%S(&%P<')O>&EM871E;'D@)#QF;VYT/C0N.#PO9F]N=#X@
M;6EL;&EO;BP@)#QF;VYT/C,P-BPP,#`\+V9O;G0^(&%N9"`D/&9O;G0^-#0W
M+#`P,#PO9F]N=#XL(')E<W!E8W1I=F5L>2X\8G(O/CPO9F]N=#X\+W1D/@T*
M/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U
M;6UA<GD@;V8@4F5S=')I8W1E9"!3=&]C:R!!8W1I=FET>2`M($]P=&EO;G,@
M1W)A;G1E9"!T;R!%;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS
M1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/E)E<W1R:6-T960@<W1O8VL@9W)A
M;G1E9"!T;R!E;7!L;WEE97,Z/"]F;VYT/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R<^/&)R+SX\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[)SX\8G(O/CPO<#X-"CQD:78@8VQA<W,],T1#=7)S;W)0
M;VEN=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q,#`E.R<^#0H-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#$P(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R
M=&%N=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^665A
M<B!E;F1E9"!$96-E;6)E<B`S,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O
M;&ED("%I;7!O<G1A;G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/C(P,3(\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXR,#$S/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXR,#$T/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY.
M=6UB97(@;V8@4F5S=')I8W1E9"!3:&%R97,\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SLG('=I9'1H/3-$-3`E/CQF;VYT('-T>6QE/3-$)V9O
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M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXM/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#,Y-"PW
M,#@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=F5R
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M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[)R!W:61T:#TS1#4P)3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SY#:&%N9V5S(&1U<FEN9R!T:&4@>65A<CH\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<@=VED=&@],T0U
M,"4^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^1W)A;G1E9#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#4P,"PP
M,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI
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M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^5F5S=&5D/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=F5R=&EC86PM
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M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=F5R=&EC86PM86QI9VXZ(&)O
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M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
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M<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,34N.35P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R<@=VED=&@],T0U,"4^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^1F]R9F5I=&5D/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/C,L,C`X/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
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M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
M<G1A;G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ-RPX
M,S0\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@=F5R=&EC
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M86XG.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SLG('=I9'1H/3-$-3`E/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D]U
M='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P
M<'0@9&]U8FQE("%I;7!O<G1A;G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXQ+#,Y-"PW,#@\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
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M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
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M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@8VQA
M<W,],T1#=7)S;W)0;VEN=&5R/CQB<B\^/"]D:78^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F($]P=&EO;G,@1W)A;G1E9"!T;R!397)V:6-E(%!R;W9I9&5R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R
M4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX-"@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R
M87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,C(@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/EEE87(@96YD960@1&5C96UB97(@,S$L/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^,C`Q,CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
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M96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR
M,#$S/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M-B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^,C`Q-#PO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/E=E:6=H=&5D/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R
M87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^3G5M8F5R/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/F%V97)A9V4\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SY.=6UB97(\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SX\<W1R;VYG/F%V97)A9V4\+W-T<F]N9SX\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N
M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/DYU;6)E<CPO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
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M<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^;V8\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/F5X97)C:7-E/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O
M;F<^97AE<F-I<V4\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/F]F/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
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M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^<')I8V4\+W-T<F]N
M9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO
M<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q
M-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/F]P=&EO;G,\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P
M.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^
M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/G!R:6-E/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V
M,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SYO<'1I;VYS
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF
M(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXQ+#(S."PV.3(\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#$P)3LG/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CDQ,BPT,C4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
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M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY#:&%N9V5S(&1U
M<FEN9R!T:&4@>65A<BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D=R86YT960\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR.38L,38W/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^17AE<F-I<V5D("@J*3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS,C8L,C8W/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXP+C$R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SY/=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C<N,C4Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDQ,BPT,C4\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB
M;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O
M<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/C<N,C4Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B
M;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
M+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$L,C`X+#4Y,CPO9F]N=#X\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXV+C$S-CPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3$R+#0R-3PO9F]N=#X\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@
M,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^-RXR-3D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.3$R+#0R-3PO9F]N=#X\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
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M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M-RXR-3D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B
M;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^.3$R+#0R-3PO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
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M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-RXR-3D\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*#0H\
M+W1A8FQE/@T*/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M
M87)G:6XM8F]T=&]M.B`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^/"]P/@T*/&1I=CX-"CQD:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R
M/@T*/'1A8FQE('=I9'1H/3-$,3`P)2!C96QL<&%D9&EN9STS1#`@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[)SX-
M"@T*/'1R/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B`H*BD@/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#DX)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/E1H
M92!T;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960@
M9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R('=A<R!A
M<'!R;WAI;6%T96QY("0\9F]N=#XR+C,\+V9O;G0^(&UI;&QI;VXN/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@26YF;W)M871I;VX@86)O=70@4VAA<F4@3W!T
M:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O
M;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=VED=&@Z(#@P)3L@;6%R9VEN+6QE9G0Z(#`N,7!X.R!M87)G:6XM<FEG
M:'0Z(#`N,7!X.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)R!C;VQS
M<&%N/3-$,C8^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY$
M96-E;6)E<B`S,2P@,C`Q-#PO<W1R;VYG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A
M;CTS1#@^/&)R+SX\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#$T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/CQS=')O;F<^3W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S
M=&]C:R`\8G(O/F]U='-T86YD:6YG/"]S=')O;F<^/"]F;VYT/CQB<B\^/"]T
M9#X-"CQT9"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=P861D:6YG.B`P<'@@
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M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N
M/3-$,3`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY/<'1I
M;VYS(&5X97)C:7-A8FQE/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I
M;F<Z(#!P>#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^17AE<F-I<V4@/&)R+SYP<FEC97,\+W-T<F]N9SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$-"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
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M+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/CPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O
M;'-P86X],T0T(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SY796EG:'1E9"`\8G(O/F%V97)A9V4@/&)R+SYR96UA
M:6YI;F<@/&)R+SYC;VYT<F%C='5A;"`\8G(O/FQI9F4\+W-T<F]N9SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1C96YT97(@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CPO=&0^#0H\=&0@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0T(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SY.=6UB97(@;V8\8G(O/B!O<'1I;VYS/&)R
M+SX@97AE<F-I<V%B;&4\+W-T<F]N9SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$-"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O
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M)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<@8V]L<W!A;CTS
M1#$@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M;B]A("A297-T<FEC=&5D(%-T;V-K*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@
M86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C0Y,"PV,C0\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG.B`P
M<'@[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
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M9SH@,'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@<&%D9&EN9SH@,'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SYN+V$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N
M/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X
M(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`P)3LG(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`R,"4[)R!C;VQS<&%N/3-$,2!A;&EG;CTS1')I9VAT/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C`N,#`Q/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>"`P<'@@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P
M)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#(P)3LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-S$Y+#(P-SPO9F]N=#X\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@@,'!X
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`R,"4[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/C`N-30\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@@-7!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG(&%L:6=N
M/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X(#!P
M>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`P)3LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!W:61T:#H@,C`E.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXW,3DL,C`W/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>"`P<'@@,'!X.R!V
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,"XU-#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>"`U<'@@,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<@86QI9VX],T1L969T
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^,"XQ,C`\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$
M;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R
M:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS,#@L.#`Q
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@
M86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C(N,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXS,#@L.#`Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN
M9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/C(N,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A
M;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDY-2PX-3,\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
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M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDY-2PX
M-3,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,BXS
M-3`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXT,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^,RXX,CPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C0P+#`P,#PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS+C@R/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,BXS-S`\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z
M(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI
M9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXY
M,#`L,#`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDN
M-S4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXU-BPR-3`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,BXV-3`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N
M/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS-#4L,#@R/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX]
M,T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N-#D\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@
M86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXS-#4L,#@R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C,N-#D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS1#$@
M86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXS+C`R,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D
M9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/C4P+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXS+C$P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-3`L,#`P/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX]
M,T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N,3`\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)R!C;VQS<&%N/3-$,2!A;&EG;CTS1')I9VAT
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,N,S<P/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,34P+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXY+C4V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
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M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXY+C4V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^-2XP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N
M/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#<P."PP,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR
M:6=H=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/C$L-S`X+#`P,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXR+C8V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A
M;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$U,"PP,#`\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
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M<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$U,"PP
M,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!C;VQS<&%N/3-$,2!A;&EG;CTS
M1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C8N.3`P
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
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M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXT+C,R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H=#X\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT+C,R/"]F;VYT/CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS1#$@86QI9VX],T1R:6=H=#X\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXW+C4U,#PO9F]N=#X\+V9O
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R<@86QI9VX],T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/C$V,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D
M:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C$V,"PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
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M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)R!C;VQS<&%N/3-$,2!A;&EG;CTS1')I9VAT/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CDN-C8P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG
M;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-C@L,#`P/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX]
M,T1L969T/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C4N.#,\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG
M:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@
M86QI9VX],T1R:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXV."PP,#`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^,38N-S`P/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L
M:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R:6=H
M=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXS.#<L-30R/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^,2XY.3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@@
M,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P
M="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R<@86QI9VX],T1L969T
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C,X-RPU-#(\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG
M(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@86QI9VX],T1R
M:6=H=#X\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+CDY/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>"`P<'@@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@
M86QI9VX],T1L969T/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$
M;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<@8V]L<W!A;CTS1#$@86QI9VX]
M,T1R:6=H=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@
M9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N
M/3-$;&5F=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@
M9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-RPT-C4L,#(U
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS
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M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B
M;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)R!A
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[)R!A;&EG;CTS1')I9VAT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#LG(&%L:6=N/3-$;&5F=#X\+W1D/@T*
M/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#LG/CQB<B\^/"]P/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M8VAE9'5L92!O9B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92!I
M;B!3=&%T96UE;G0@;V8@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#@P)3L@;6%R9VEN+6QE
M9G0Z(#`N,7!X.R!M87)G:6XM<FEG:'0Z(#`N,7!X.R<^#0H-"CQT<B!S='EL
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M/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^665A<B!E;F1E9"!$96-E;6)E<B`S,2P\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
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M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXH52Y3+B!D;VQL87)S(&EN('1H;W5S86YD<RD\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^,C`Q,CPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^,C`Q,SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A
M;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R
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M(#!P>#L@=VED=&@Z(#`E.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXR,C`\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#$P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^,BPV-34\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXY,S8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^36%R:V5T:6YG+"!'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E
M>'!E;G-E<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S
M;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXR+#<W-3PO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PT,S0\+V9O;G0^/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
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M;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z
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M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T
M;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG
M.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N
M;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXW+#<U
M,3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[
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M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@
M(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^-"PP.#D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T
M(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$L,C0R/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"@T*/"]T86)L
M93X-"CPO9&EV/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@
M,&EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/&(^)B,Q-C`[/"]B
M/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#%I;CL@=&5X
M="UI;F1E;G0Z("TP+C5I;CLG/CQB<B\^/"]P/@T*/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/5$53("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-/3E9%4E1)0DQ%($Y/5$53(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@26YT97)E
M<W0@17AP96YS92!296-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4]
M,T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#`@,"`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H('1O=&%L
M(&EN=&5R97-T(&5X<&5N<V4@<F5C;V=N:7IE9"!F;W(@=&AE('EE87)S(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$T(')E;&%T960@=&\@=&AE
M($YO=&5S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#,U
M+C0U<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=VED=&@Z(#DP)3L@;6%R9VEN+6QE9G0Z(#`N-6EN.R<^
M#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@
M;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/EEE87(@96YD960@1&5C
M96UB97(@,S$L/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^*%4N4RX@1&]L;&%R<R!I;B!T
M:&]U<V%N9',I/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,CX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,30\+W-T<F]N9SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX\9F]N
M=#X\+V9O;G0^/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
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M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('=I9'1H.B`X,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SY#;VYT<F%C='5A;"!I;G1E<F5S="!E>'!E;G-E/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^.#@X/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXS+#$P-3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H
M.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/D%M;W)T:7IA=&EO;B!O9B!D96)T
M(&ES<W5A;F-E(&-O<W1S(&%N9"!D96)T(&1I<V-O=6YT/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,3(W/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A
M:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXT-#0\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SY4;W1A;#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P
M="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#`Q-3PO9F]N
M=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I
M;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H
M=#H@,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R
M=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^,RPU-#D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F
M-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T
M-C0O5V]R:W-H965T<R]3:&5E=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D8^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^5$%815,@3TX@24Y#3TU%("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E1!6$53($].($E.0T]-12!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($1E9F5R<F5D
M(%1A>"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@:60],T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A
M;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-S5I;CLG/E1H92!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY
M)W,@;F5T(&1E9F5R<F5D('1A>"!A<W-E=',@870@1&5C96UB97(@,S$L(#(P
M,3,@86YD(#(P,30@=V5R92!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*/&1I=B!C;&%S<STS
M1$-U<G-O<E!O:6YT97(@86QI9VX],T1C96YT97(^#0H\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=VED=&@Z(#8P)3L@;6%R9VEN+6QE9G0Z(#`N,7!X.R!M87)G:6XM
M<FEG:'0Z(#`N,7!X.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O
M<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQS=')O;F<^1&5C96UB97(@,S$L/"]S
M=')O;F<^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
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M=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P
M<'@[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#LG/CQS=')O;F<^(#PO<W1R;VYG/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/'-T<F]N9SXF(S$V,#L\
M+W-T<F]N9SX\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R
M=&%N=#L@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(^/'-T<F]N9SXR,#$T
M/"]S=')O;F<^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S=')O;F<^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQS=')O;F<^/&9O;G0^/"]F;VYT/CPO<W1R;VYG/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)R!C;VQS<&%N/3-$,SX\<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T<F]N
M9SX\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQS=')O
M;F<^)B,Q-C`[/"]S=')O;F<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/DEN(')E<W!E8W0@;V8Z/"]T
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M97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T
M:#H@.#`E.R<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[('!A9&1I;F<Z(#!P>#L@=VED=&@Z(#`E.R<^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P
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M97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!W:61T:#H@,"4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[('=I9'1H.B`P)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@=VED=&@Z(#$P)3LG/CQF;VYT/C,L,3,V/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0^*#0Y,3PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^
M/&9O;G0^*#,W,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I
M9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^*3PO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#LG/E!R;W9I<VEO;B!F;W(@=F%C871I;VX\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/C0Q-SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\
M9F]N=#XS-S0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SY3979E<F%N8V4@<&%Y(&]B;&EG871I;VX\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#LG/CQF;VYT/C(P.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#XY+#@V-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#XX+#8U
M.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0^,C,L,38W/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG
M/CQF;VYT/C(X+#$S,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#XH,S@L-#(V/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P
M>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[
M('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#XH-#`L,3$Q/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@
M,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W
M<F%P.R<^*3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T
M86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#XM/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D
M;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^+3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*#0H\
M+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($]P96X@5&%X
M(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED
M/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@
M,"`P+C<U:6X[)SY!('-U;6UA<GD@;V8@;W!E;B!T87@@>65A<G,@8GD@;6%J
M;W(@:G5R:7-D:6-T:6]N(&ES('!R97-E;G1E9"!B96QO=SH\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CLG/B8C,38P.SPO<#X-"CQD:78@
M8VQA<W,],T1#=7)S;W)0;VEN=&5R(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@-C`E.R!M87)G:6XM
M<FEG:'0Z(#`N,7!X.R<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,#X-"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UD
M96-O<F%T:6]N.B!N;VYE.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@<&%D9&EN9RUL969T.B`P<'@[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQS=')O;F<^2G5R
M:7-D:6-T:6]N.CPO<W1R;VYG/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R<^/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#%P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SX\<W1R
M;VYG/CQB/EEE87)S.CPO8CX\+W-T<F]N9SX\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SLG/CQS=')O;F<^)B,Q-C`[/"]S
M=')O;F<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!X
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('=I9'1H.B`Y,"4[
M)SY)<W)A96P\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SL@=VED=&@Z(#`E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('=I9'1H.B`P)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<F]M86XG.R<^56YI=&5D(%-T871E<R`H*BD\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT/C(P,3`\+V9O;G0^+3QF
M;VYT/C(P,30\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/&(^/&(^)B,Q
M-C`[/&)R+SX\+V(^/"]B/@T*/&1I=CX-"CQD:78@8VQA<W,],T1#=7)S;W)0
M;VEN=&5R/@T*/'1A8FQE('=I9'1H/3-$,3`P)2!C96QL<&%D9&EN9STS1#`@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z(#`N,3`P,#`P,#`Q-#DP,3$V<'@[)SX-"@T*/'1R/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`R)3LG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U
M:6X[)SXH*BDF(S$V,#L\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Y."4[(&9O;G0M<VEZ93H@,3!P=#LG/@T*/&1I=CY);F-L=61E<R!F961E
M<F%L+"!S=&%T92!A;F0@;&]C86P@*&]R('-I;6EL87(@<')O=FEN8VEA;"!J
M=7)I<V1I8W1I;VYS*2!T87@@<&]S:71I;VYS+CPO9&EV/@T*/"]T9#X-"CPO
M='(^#0H-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-54%!,14U%3E1!4ED@1DE.04Y#24%,(%-4
M051%345.5"!)3D9/4DU!5$E/3B`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY355!03$5-14Y405)9
M($9)3D%.0TE!3"!35$%414U%3E0@24Y&3U)-051)3TX@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=7!P
M;&5M96YT86P@26YF;W)M871I;VXL($)A;&%N8V4@4VAE971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$161G87)304$Q,C,T
M-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`W,2XS<'0[('1E>'0M
M:6YD96YT.B`M,3<N,W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/&(^0F%L86YC92!S:&5E=',Z/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#<Q+C-P=#L@=&5X="UI;F1E;G0Z("TQ-RXS<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\8CXF(S$V,#L\+V(^/"]F;VYT
M/CPO<#X-"CQD:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*/'1A8FQE(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[('=I9'1H.B`X,"4[(&UA<F=I;BUL969T.B`Q+C%I;CLG/@T*
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SY$96-E;6)E<B`S,2P\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\+W-T
M<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@
M,'!X.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXR,#$T/"]S=')O;F<^/'-T<F]N9SX\9F]N=#X\+V9O;G0^/"]S
M=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SX\<W1R;VYG/CQF;VYT/CPO9F]N=#X\+W-T<F]N9SX\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=&5X="UA;&EG
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M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[/"]S=')O;F<^/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`M,C8N-#5P=#L@;6%R9VEN.B`P(#`@,"`W-7!T.R<^82X@
M)B,Q-C`[("8C,38P.R`F(S$V,#L@)B,Q-C`[3W1H97(@87-S971S.CPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:61T:#H@.#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^26YS=&ET=71I;VYS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I
M9'1H.B`P)3LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,S4V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=H:71E+7-P86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ,C0\+V9O;G0^/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/E-T871E(&]F($ES<F%E;"`H
M<V5E($YO=&4@-F$I/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXS-C8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
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M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,S8R
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE
M9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXT,38\+V9O;G0^/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
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M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M+W1D/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I
M;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^,S8Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXX-SPO9F]N=#X\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A
M9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-C0\
M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R
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M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@
M;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PT
M-3<\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P
M>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L92`A:6UP;W)T86YT
M.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE
M("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/C(L,C`R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQD:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`X,"4[(&UA<F=I;BUL969T.B`Q
M+C%I;CLG/@T*#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXH52Y3+B!D;VQL87)S(&EN('1H;W5S
M86YD<RD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$
M,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@;6%R9VEN.B`P(#`@,"`W-7!T.R<^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!T97AT+6EN9&5N=#H@+3(V
M+C0U<'0[(&UA<F=I;CH@,"`P(#`@-S5P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/CQS=')O;F<^8BX@)B,Q-C`[("8C,38P.R`F(S$V,#L@)B,Q
M-C`[($%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U86QS("8C,34P.R!O=&AE
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS
M<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
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M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI
M9VXZ('1O<#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`X
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY087ER;VQL(&%N9"!R
M96QA=&5D(&5X<&5N<V5S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I
M9'1H.B`P)3LG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^,2PU-3<\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED
M=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W
M:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M,2PR-#,\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@
M,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
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M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M/@T*/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U
M<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US
M<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^.3$T/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T
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M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R
M87`[)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXQ+#0Q,CPO
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^06-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,2PW.#4\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXT,3D\+V9O;G0^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D
M:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^3&EA8FEL:71Y(&EN
M(&-O;FYE8W1I;VX@=VET:"!C;VQL86)O<F%T:6]N(&]P97)A=&EO;B`M(&-U
M<G)E;G0@<&]R=&EO;CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^-2PV-C8\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
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M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$X-CPO9F]N=#X\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M
M;&5F=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P
M.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^,3(P/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X
M(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX
M,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/C$R+#`W,SPO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
M9&1I;F<Z(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR
M:6=H=#H@,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^,34L-#DV/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,&EN.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^/&(^)B,Q-C`[/&)R+SX\+V(^/"]F;VYT/CPO<#X-"CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5P<&QE;65N=&%L($EN9F]R;6%T:6]N+"!);F-O;64@4W1A=&5M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV(&ED/3-$
M161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@.B`G
M5&EM97,@3F5W(%)O;6%N)SLG/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT
M97(^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#@U)3L@;6%R9VEN+6QE
M9G0Z(#$N,6EN.R<^#0H-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A
M<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[
M)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I
M;F<Z(#!P>#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC
M86PM86QI9VXZ('1O<#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS
M1&YO=W)A<#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG
M/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
M('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^665A<B!E;F1E9"!$96-E;6)E<B`S
M,2P\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D
M:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG
M/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^(#PO<W1R;VYG/CPO9F]N=#X\
M+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^/'-T<F]N9SXR,#$R/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^/'-T<F]N9SX@/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P
M861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R
M;VYG/C(P,3,\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B`\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\
M<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SXR
M,#$T/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D
M9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N
M9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N
M9',I/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#LG(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M,"`P(#`@-S5P=#LG/F,N("8C,38P.R`F(S$V,#L@)B,Q-C`[4F5V96YU97,Z
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X.R!W:61T:#H@-S`E.R!T97AT+6EN9&5N=#H@,"XU<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SY$969E<G)E9"!R979E;G5E
M<R!F<F]M('1H92!L:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT('=I=&@@
M4&9I>F5R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=I9'1H.B`P)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@,'!X(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P
M861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`Q,"4[)SX\9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXT+#4V,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M
M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,3`E.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-"PU-C,\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#L@=&5X="UI;F1E;G0Z(#`N-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^36EL97-T;VYE('!A>6UE;G0@*'-E92!.;W1E(#(I/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL
M969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[
M)SX\9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXR-2PP,#`\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F
M=#H@-7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M
M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P+C5P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<SLG/E)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D
M=6-T<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9"`A:6UP
M;W)T86YT.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A
M9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI
M9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXU+#,P-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@
M<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@(S`P,#`P
M,"`Q<'0@<V]L:60@(6EM<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^-2PY,38\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P>#L@=VAI
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M;VTZ(",P,#`P,#`@,7!T('-O;&ED("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
M>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#LG/CQF;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CDL,#@X/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@
M,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`R."XX
M-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z
M(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM<&]R=&%N
M=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L
M92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,[)SXS-"PX-S`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX
M,'!T(&1O=6)L92`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A9&1I;F<Z(#!P
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M(#!P>"`U<'@[('=H:71E+7-P86-E.B!N;W=R87`[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE("%I;7!O<G1A;G0[('!A
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M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4@(6EM
M<&]R=&%N=#L@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:&ET92US<&%C93H@;F]W<F%P.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S.R<^,3,L-C4Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO
M=W)A<#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%3$%4140@4$%25%D@5%)!3E-!0U1)
M3TY3("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@:60],T1%9&=A
M<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#@U)3L@;6%R9VEN+6QE9G0Z
M(#`N,3`P,#`P,#`Q-#DP,3$V<'@[(&UA<F=I;BUR:6=H=#H@,"XQ<'@[)SX-
M"@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)R!N
M;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B`\
M+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,3`@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/EEE87(@96YD960@1&5C
M96UB97(@,S$L/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^
M/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)R!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^*%4N4RX@9&]L;&%R<R!I;B!T
M:&]U<V%N9',I/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN
M9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^/'-T<F]N9SX@
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,3(\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/CQS=')O;F<^)B,Q-C`[
M/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#%P="!S;VQI9"`A:6UP;W)T86YT.R!P861D:6YG.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/C(P,30\+W-T<F]N9SX\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SX\<W1R;VYG/B8C,38P.SPO<W1R
M;VYG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG
M.B`P<'@[('=I9'1H.B`W,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[
M)SY#;VUP96YS871I;VX@*&EN8VQU9&EN9R!S:&%R92!B87-E9"!C;VUP96YS
M871I;VXI('1O('1H92!N;VXM97AE8W5T:79E(&1I<F5C=&]R<R`H:6YC;'5D
M97,@=&AE(&EN=&5R:6T@0VAA:7)M86X@;V8@=&AE($)O87)D('1H<F]U9V@@
M,C`Q-"!A;F0@=&AE($-H86ER;6%N(&]F('1H92!";V%R9"!F;W(@<&%R="!O
M9B`R,#$T*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X.R!W:61T:#H@,"4[
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#$P<'@@
M,'!X(#!P>#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@(S`P,#`P,"`A:6UP;W)T
M86YT.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R+CAP="`A:6UP;W)T86YT.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4@(6EM<&]R=&%N=#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@(S`P,#`P,"`A:6UP;W)T86YT.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`R+CAP="`A:6UP;W)T86YT.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!D;W5B;&4@(6EM<&]R=&%N=#L@=VED=&@Z(#$P)3LG/CQF;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<SLG/C,W-3PO9F]N=#X\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P>"`U<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@<&%D9&EN9SH@,'!X(#5P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z(#`E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@,3!P>"`P<'@@,'!X.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B`C,#`P,#`P("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#(N.'!T("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L92`A:6UP;W)T86YT.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@<&%D9&EN9SH@,'!X.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M+6-O;&]R.B`C,#`P,#`P
M("%I;7!O<G1A;G0[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#(N.'!T("%I;7!O
M<G1A;G0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L92`A:6UP;W)T86YT
M.R!W:61T:#H@,3`E.R<^/&9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M.R<^-3`Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M<&%D9&EN9SH@,'!X(#5P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@=VED=&@Z
M(#`E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W:&ET92US<&%C93H@;F]W<F%P
M.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[('!A9&1I;F<Z(#!P
M>"`Q,'!X(#!P>"`P<'@[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E
M+7-P86-E.B!N;W=R87`[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(",P,#`P,#`@
M(6EM<&]R=&%N=#L@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXX<'0@(6EM<&]R
M=&%N=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE("%I;7!O<G1A;G0[
M('=I9'1H.B`P)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<SLG/B0\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=H:71E+7-P86-E.B!N;W=R87`[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(",P,#`P,#`@(6EM<&]R=&%N=#L@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,BXX<'0@(6EM<&]R=&%N=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE("%I;7!O<G1A;G0[('=I9'1H.B`Q,"4[)SX\9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,[)SXU-C`\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!P861D:6YG.B`P<'@@-7!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!W:61T:#H@,"4[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H-"CPO
M=&%B;&4^/"]D:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V
M.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE
M971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T6D)'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M:71E;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`Q."P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@4W5B<VED:6%R:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M96YT+"!U<&9R;VYT
M('!A>6UE;G0@<F5C96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@;F]T
M(&EN8VQU9&5D(&EN(&1I;'5T960@3%!3(&)E8V%U<V4@=&AE(&5F9F5C="!W
M;W5L9"!B92!A;G1I+61I;'5T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ."PX-3`L-S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`L-C<U+#,P-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C@P+#0V.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8U,2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PT-SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S0L.#<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O=&%L:7@@3'1D+B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U<'!L>2!C
M;VUM:71M96YT(&9O<B!E;G1I=&QE9"!R:6=H=',@=&\@8F4@<F5C96EV960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT('!O=&5N=&EA;"!F=71U<F4@
M<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5P<&QY(&-O;6UI=&UE;G0@<&5R('EE87(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W1A;&EX($QT9"X@
M6TUE;6)E<ET@?"!2979E;G5E<R!F<F]M('-A;&4@;V8@<')O9'5C=',@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]T86QI>"!":6\@5&AE<F%P975T:6-S($EN8RX@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@
M06=R965M96YT+"!F=71U<F4@<F5V96YU97,@86YD(&5X<&5N<V4@<VAA<FEN
M9R!P97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!F:7IE<B!);F-O<G!O<F%T:6]N(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G<F5E;65N
M="P@9G5T=7)E(')E=F5N=65S(&%N9"!E>'!E;G-E('-H87)I;F<@<&5R8V5N
M=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M<&]N($9$04%P<')O=F%L(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G<F5E;65N="P@;6EL97-T;VYE
M('!A>6UE;G0@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S
M7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#,P+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%6D)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A5<V5F=6P@3&EV97,@;V8@
M4')O<&5R='D@86YD($5Q=6EP;65N="D@*$1E=&%I;',I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y($5Q=6EP
M;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!U<V5F=6P@;&EF93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5R;FET=7)E
M(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@
M17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!U
M<V5F=6P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9U<FYI='5R92!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@
M86YD(&5Q=6EP;65N="P@=7-E9G5L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E<B!%<75I<&UE;G0@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD(&5Q=6EP;65N="P@=7-E9G5L(&QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV
M7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R
M9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T
M<R]3:&5E=#,Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%25!!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY,24-%3E-%($%.1"!355!03%D@04=2145-14Y4("A$971A:6QS
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G<F5E;65N="P@=7!F
M<F]N="!P87EM96YT(')E8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#8P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT(')E8V5I
M=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2979E;G5E(')E8V]G;FEZ960@;W9E<B!D97-I9VYA=&5D('!E<FEO9"!O
M9B!R96QA=&EO;G-H:7`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5V96YU92!R96-O9VYI=&EO;B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$T('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]T86QI>"!"
M:6\@5&AE<F%P975T:6-S($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M96YT+"!F=71U
M<F4@<F5V96YU97,@86YD(&5X<&5N<V4@<VAA<FEN9R!P97)C96YT86=E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R
M871I;VX@3W!E<F%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<R!A8V-R=65D
M(')E;&%T960@=&\@=&AE($-O;&QA8F]R871I;VX@3W!E<F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E5P;VX@1FEL:6YG(&]F(%!E9&EA=')I8R!);G9E<W1I9V%T:6]N(%!L86X@
M=&\@14U!(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&9I>F5R($%G<F5E;65N="P@=7!F<F]N="!P87EM96YT(')E
M8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5P;VX@1D1!07!P<F]V86P@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N="!R96-E
M:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-2PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R
M9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?
M9#DW861F935E-#8T+U=O<FMS:&5E=',O4VAE970S,BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M141%04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4%)/4$525%D@04Y$($51
M54E0345.5"`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q
M=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,S(L-S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S,BPP,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@+2!A8V-U;75L871E9"!D97!R96-I
M871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C$L-#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$X+#,Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="P@3F5T+"!4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$L,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,L-S$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,30P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8Y,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&%B;W)A
M=&]R>2!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP
M;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L
M($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PQ,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-"PX-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9U<FYI='5R92!!;F0@0V]M<'5T97(@17%U:7!M96YT(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E
M<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPQ-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`W-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD($EM<')O
M=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@1W)O<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#0R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`W,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17%U:7!M96YT(%5N9&5R($-O;G-T<G5C=&EO;B!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0
M;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14A(04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y6
M14Y43U))15,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y614Y43U))15,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y287<@;6%T97)I86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R+#,T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V]R:R!I;B!P<F]C97-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN:7-H960@9V]O9',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3$Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU,C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!I;G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPY-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=F5N=&]R>2!W<FET92UD;W=N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$L-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y
M7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K
M<VAE971S+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-3T%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DQ)04))3$E462!&3U(@14U03$]9144@4DE'2%13(%50
M3TX@4D5425)%345.5"`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3$E!0DE,
M2519($9/4B!%35!,3UE%12!224=(5%,@55!/3B!2151)4D5-14Y4(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16UP;&]Y964@<V5V97)A;F-E(&]B;&EG871I;VX@<&%Y;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DU+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DT+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3<W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5V97)A;F-E(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=')I8G5T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@P,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV-S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@*&=A:6XI(&]R(&QO<W,@9F]R
M('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@<V5V97)A;F-E(&QI86)I;&ET
M:65S('!A>6UE;G1S(&9O<B!F:7-C86P@>65A<B!E;F0@,C`Q-3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8S+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@8V]N
M=')I8G5T:6]N('1O(&]N92!O<B!M;W)E($-O;G1R:6)U=&EO;B!0;&%N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-70D<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0T]-34E4345.5%,@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6)C;VYT<F%C=&EN9R!C;VUM:71M96YT(&%M;W5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]#4R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M;WEA;'1Y(&5X<&5N<V4@:6YC;'5D960@:6X@8V]S="!O9B!R979E;G5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-3$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDR+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S96%R8V@@06YD($QI8V5N<V4@06=R965M96YT<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA
M;'1Y(&5X<&5N<V4@:6YC;'5D960@:6X@8V]S="!O9B!R979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#0L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<T+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5A<V4@06=R965M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT
M:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYT:&QY(')E;G0O;&5A<V4@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&1E<&]S:71E9"!A<R!B86YK(&=U87)A;G1E93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4O<F5N="!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$S,RPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY-S$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<RP@,C`Q
M-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,30L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<RP@,C`Q-CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#DL,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU
M;2!L96%S92!P87EM96YT<RP@,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP,#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y696AI8VQE($QE87-E($%N9"!-86EN=&5N
M86YC92!!9W)E96UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E
M;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUO;G1H;'D@<F5N="]L96%S92!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!M
M:6YI;75M(&QE87-E('!A>6UE;G1S+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU;2!L96%S92!P
M87EM96YT<RP@,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',L(#(P,3<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q."PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM
M=6T@6TUE;6)E<ET@?"!/0U,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN
M9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F]Y86QT:65S(&)A<V5D(&]N('-A;&4@;V8@
M<')O9'5C=',@9&5V96QO<&5D(&9R;VT@9G5N9&5D('!R;VIE8W1S+"!P97)C
M96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%X:6UU;2!;365M8F5R72!\($]#4R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#
M;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,@8F%S960@;VX@<V%L
M92!O9B!P<F]D=6-T<R!D979E;&]P960@9G)O;2!F=6YD960@<')O:F5C=',L
M('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y097)C96YT86=E(&%M;W5N="!T:&4@86=G<F5G871E(&%M;W5N="!O
M9B!R;WEA;'1I97,@=&AA="!S:&]U;&0@;F]T(&5X8V5E9"!G<F%N="!R96-E
M:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!R;WEA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R72!\(%!R;V1U8W1S
M($UA;G5F86-T=7)E9"!/=71S:61E($]F($ES<F%E;"!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE
M;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,@8F%S
M960@;VX@<V%L92!O9B!P<F]D=6-T<R!D979E;&]P960@9G)O;2!F=6YD960@
M<')O:F5C=',L('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S
M7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#,V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%1TA$2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY32$%2
M12!#05!)5$%,("A.87)R871I=F4I("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`Q."P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y&96(N(#(R+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#$V+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`R-"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#$T+"`R,#`V/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT
M($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$W-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N9&5R=W)I='1E
M;B!P=6)L:6,@;V9F97)I;F<L(&-O;6UO;B!S=&]C:R!P<FEC92!P97(@<VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XR-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD
M97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9RP@;F5T('!R;V-E961S(&9R;VT@
M:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L
M-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^56YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9RP@8V]M;6ES
M<VEO;G,@86YD(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!A=F%I;&%B;&4@
M9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DR,RPT-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,RPX-#$L-C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K(&=R86YT960L
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#8P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5N<F5C;V=N:7IE9"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y5;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0L(')E8V]G;FET:6]N
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!P<FEV871E('!L86-E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I
M<&%L(&%M;W5N="P@<F5L871E9"!T;R!T:&4@:6YI=&EA;"!P=7)C:&%S97(G
M<R!O=F5R+6%L;&]T;65N="!O<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y965S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A
M>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&]R(')E
M<W1R:6-T960@<W1O8VL@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%M-96UB97)=
M('P@3V9F:6-E<G,@06YD($-E<G1A:6X@16UP;&]Y965S(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!A=F%I;&%B
M;&4@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D+"!L
M;V-K('5P('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,C0@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@:6YS=&%L;&UE;G1S(&9O<B!V97-T:6YG
M(&]F('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!3=&]C:R!;365M8F5R72!\($5M<&QO>65E<R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N
M<R!O<B!R97-T<FEC=&5D('-T;V-K(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!I;G-T86QL;65N
M=',@9F]R('9E<W1I;F<@;V8@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%M-96UB97)=('P@3V9F
M:6-E<G,@06YD($1I<F5C=&]R<R!);B!0<FEV871E(%1R86YS86-T:6]N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O
M<'1I;VYS(&]R(')E<W1R:6-T960@<W1O8VL@9W)A;G1E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VX@=&\@<'5R
M8VAA<V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!;365M8F5R72!\(%!R97-I
M9&5N="!A;F0@0VAI968@17AE8W5T:79E($]F9FEC97(@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@;W(@
M<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C,W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@:6YS=&%L
M;&UE;G1S(&9O<B!V97-T:6YG(&]F('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5F5S=&EN9R!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!V86QU92!O9B!A="!G<F%N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@:6X@>65A<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED
M96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AP96-T960@=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C(N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XX-B4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!T;R!P
M=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(%M-96UB97)=('P@0F]A
M<F0@;V8@1&ER96-T;W)S($-H86ER;6%N(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&]R(')E<W1R:6-T
M960@<W1O8VL@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,RXS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&EN9R!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M870@9W)A;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q.3,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E(&EN('EE87)S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D
M('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VX@=&\@<'5R8VAA<V4@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!;365M8F5R72!\($)O87)D(&]F($1I<F5C
M=&]R<R!#:&%I<FUA;B!;365M8F5R72!\(%9E<W0@;VX@=&AE(&9I<G-T(&%N
M;FEV97)S87)Y(&]F('1H92!G<F%N="!D871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!V97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N('1O('!U<F-H87-E('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@6TUE;6)E<ET@?"!";V%R9"!O9B!$:7)E8W1O<G,@
M0VAA:7)M86X@6TUE;6)E<ET@?"!697-T(&]V97(@=&AE('-U8G-E<75E;G0@
M='=O+7EE87(@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!I;G-T86QL;65N=',@9F]R('9E<W1I;F<@;V8@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B
M-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H
M965T<R]3:&5E=#,W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%551!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY32$%212!#05!)5$%,("A3=6UM87)Y(&]F($]P=&EO;B!A
M;F0@4F5S=')I8W1E9"!3=&]C:R!'<F%N=&5D('1O($5M<&QO>65E<RD@*$1E
M=&%I;',I("A%;7!L;WEE97,@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@;W(@
M<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3(@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N
M="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@;W(@<F5S=')I
M8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y697-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!A="!G<F%N
M="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,BPR.#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N
M9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!O<'1I;VYS(&]R(')E<W1R:6-T960@<W1O8VL@9W)A;G1E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6
M97-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!O9B!A="!G<F%N="!D871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(Y,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO
M;G,@;W(@<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#(N,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1I;F<@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&]F(&%T(&=R86YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B`Q+#`P-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T
M,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V
M-"]7;W)K<VAE971S+U-H965T,S@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,5T%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-(05)%($-!4$E404P@*$]P=&EO;G,@1W)A
M;G1E9"!T;R!%;7!L;WEE97,I("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#8^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C(L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^5V5I9VAT960@879E<F%G92!E>&5R8VES92!P<FEC93PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E961S
M(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$Q,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L,C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PQ-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K($=R
M86YT960@5&\@16UP;&]Y965S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3G5M8F5R(&]F(&]P=&EO;G,\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A
M;F1I;F<@870@8F5G:6YN:6YG(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,34S+#@Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,C4S+#4W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,30Q+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R9F5I=&5D(&%N9"!%>'!I<F5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PR,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PU-3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-2PX-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,Y+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-SDL,3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-C$L-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%T(&5N9"!O9B!Y
M96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#@W,"PS,#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$U,RPX.3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(U,RPU-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DP-2PU-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Q-"PQ-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#(U."PT-#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960@879E<F%G92!E>&5R
M8VES92!P<FEC93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@;V8@>65A<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+CDU,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RXY,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,N-38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(N,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F9E:71E9"!A;F0@
M17AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C@S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXV,#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,S<R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XT-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XT,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@
M870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RXW-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXY-3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N.3(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92!A="!E;F0@;V8@
M>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+CDS,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXU.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,C`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R
M8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T-RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#8L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E961S(&9R;VT@97AE<F-I<V4@
M;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,RPY,S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT9"!C;VQS<&%N/3-$.#X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V
M86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0W
M('9A;&EG;CTS1'1O<#X-"@T*#0H-"@T*("@J*2`-"E1H92!T;W1A;"!I;G1R
M:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960@9'5R:6YG('1H92!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"P@
M=V%S(&%P<')O>&EM871E;'D@)#0N."!M:6QL:6]N+"`D,S`V+#`P,"!A;F0@
M)#0T-RPP,#`L(')E<W!E8W1I=F5L>2X-"@T*#0H-"@T*/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D
M9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T
M9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E
M=#,Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5TE!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY32$%212!#05!)5$%,("A297-T<FEC=&5D(%-T;V-K($=R86YT960@=&\@
M16UP;&]Y965S*2`H1&5T86EL<RD@*%)E<W1R:6-T960@4W1O8VL@6TUE;6)E
M<ETI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R
M9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#4L-S`Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3<L.#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5M<&QO>65E<R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W
M87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@;V8@>65A
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<P+#(P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,SDT
M+#<P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y697-T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y."PS
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#8L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`R+#`X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#4L-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L.#,T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG
M(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS.#8L,3(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3<P+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,SDT+#<P.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?
M9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D
M.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S
M+U-H965T-#`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5/,4%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-(05)%($-!4$E404P@*$]P=&EO;G,@86YD(%)E<W1R:6-T960@
M4W1O8VMS($=R86YT960@=&\@0V]N<W5L=&%N=',L($1I<F5C=&]R<R!A;F0@
M3W1H97(@4V5R=FEC92!0<F]V:61E<G,I("A$971A:6QS*2`H3W!T:6]N<R!A
M;F0@4F5S=')I8W1E9"!3=&]C:W,@1W)A;G1E9"!4;R!#;VYS=6QT86YT<R!$
M:7)E8W1O<G,@06YD($]T:&5R(%-E<G9I8V4@4')O=FED97)S(%M-96UB97)=
M+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#8^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VYS(&%N9"!297-T<FEC=&5D(%-T;V-K<R!'<F%N=&5D(%1O($-O;G-U
M;'1A;G1S($1I<F5C=&]R<R!!;F0@3W1H97(@4V5R=FEC92!0<F]V:61E<G,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY.=6UB97(@;V8@;W!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@
M;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$R+#0R
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ,BPT,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(S."PV.3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y-BPQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,R-BPR-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@96YD
M(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`X
M+#4Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ,BPT,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3(L-#(U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92!A="!E;F0@;V8@>65A
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$R+#0R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ,BPT,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY,3(L-#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D(&%V97)A9V4@97AE<F-I<V4@
M<')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W5T<W1A;F1I;F<@870@8F5G:6YN:6YG(&]F('EE87(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#<N,C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+C,X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C8W
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,3,V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`W+C(U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-RXR-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<N,C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W+C(U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR
M-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=')I;G-I8R!V
M86QU92!O9B!O<'1I;VYS(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#,P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$
M-SX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R
M1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-
M"B`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1'1O<#X-"@T*#0H-
M"@T*("@J*2`-"E1H92!T;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N
M<R!E>&5R8VES960@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$R('=A<R!A<'!R;WAI;6%T96QY("0R+C,@;6EL;&EO;BX-"@T*#0H-
M"@T*/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F-#-?
M-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T-C0O
M5V]R:W-H965T<R]3:&5E=#0Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,45$23X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY32$%212!#05!)5$%,("A3=6UM87)Y(&]F($]U
M='-T86YD:6YG(&%N9"!297-T<FEC=&5D(%-T;V-K<RD@*$1E=&%I;',I("A5
M4T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS
M+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P
M=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@96YD
M(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#8U
M+#`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@97AE<F-I<V%B;&4@870@96YD(&]F
M('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.#$W+#DX
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L
M86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@
M96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y
M,"PV,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@=&AE('1O=&%L
M('9E<W1E9"!A;F0@97AE<F-I<V%B;&4@;W!T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@
M=F%L=64@;V8@=&]T86P@;W5T<W1A;F1I;F<@;W!T:6]N<R!A;F0@<F5S=')I
M8W1E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/C`N,#`Q(%M-96UB97)=('P@3W!T:6]N<R!!;F0@4F5S=')I8W1E9"!3
M=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U
M=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES92!0
M<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I
M;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N9"!O
M9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,3DL,C`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV(&UO;G1H<R`Q-"!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@
M>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$Y+#(P-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92P@
M97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@
M;6]N=&AS(#$T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C`N,3(P(%M-96UB97)=('P@3W!T:6]N<R!!;F0@
M4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS
M+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I
M;F<@870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P."PX,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R
M86-T=6%L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O
M9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#@L.#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E
M+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^,"XY-S(@6TUE;6)E<ET@?"!/<'1I;VYS($%N9"!297-T<FEC
M=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R
M97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C
M:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+CDW,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@
M96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY
M-2PX-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L
M(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$@>65A<B`U
M(&UO;G1H<R`X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE
M(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.34L.#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C
M='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,2!Y96%R(#4@;6]N=&AS(#@@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,BXS-3`@6TUE;6)E
M<ET@?"!/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3
M=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E
M9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E
M(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XS('EE87)S(#D@;6]N=&AS(#(U(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S(#D@;6]N
M=&AS(#(U(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(N,S<P(%M-96UB97)=('P@3W!T:6]N<R!!;F0@4F5S
M=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%
M>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXS-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@
M870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T
M=6%L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CD@>65A
M<G,@.2!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE(&%T
M(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-BPR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L
M(&QI9F4L(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XY('EE87)S(#D@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR+C8U,"!;365M8F5R72!\($]P=&EO
M;G,@06YD(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP
M96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO
M;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&]U
M='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-#4L,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN
M9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XS('EE87)S(#4@;6]N=&AS(#(V(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I
M;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-#4L,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E
M;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<R`U(&UO;G1H<R`R-B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XS+C`R,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T960@
M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!
M=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@
M4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I
M;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N9"!O
M9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,@,2!M;VYT
M:"`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N
M9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI
M9F4L(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XS('EE87)S(#$@;6]N=&@@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XS+C,W,"!;365M8F5R72!\($]P
M=&EO;G,@06YD(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#
M;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P
M=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K
M(&]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I
M;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XY('EE87)S(#8@;6]N=&AS(#(R(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O
M<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XY('EE87)S(#8@;6]N
M=&AS(#(R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C4N,#`P(%M-96UB97)=('P@3W!T:6]N<R!!;F0@4F5S
M=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%
M>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@
M96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-S`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U
M86P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R
M<R`W(&UO;G1H<R`R."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES
M86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PW,#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C
M;VYT<F%C='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,B!Y96%R<R`W(&UO;G1H<R`R."!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XV+C@Q
M,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T960@4W1O8VL@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D
M('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N
M9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8N.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&%N9"!R
M97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#$@;6]N=&@@-B!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92P@97AE
M<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A
M<G,@,2!M;VYT:"`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/C8N.3`P(%M-96UB97)=('P@3W!T:6]N<R!!
M;F0@4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L
M86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@
M<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N
M9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3DQ+#DQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N
M=')A8W1U86P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-"!Y96%R<R`S(&UO;G1H<R`R-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E
M>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#(Y+#(T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI
M;F<@8V]N=')A8W1U86P@;&EF92P@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,@,R!M;VYT:',@,C4@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M-RXU-3`@6TUE;6)E<ET@?"!/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R
M:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E
M(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W+C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A
M;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`W(&UO;G1H<R`R
M."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@
M;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF
M92P@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C4@>65A<G,@-R!M;VYT:',@,C@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^.2XV-C`@6TUE;6)E<ET@?"!/
M<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/
M<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Y+C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C
M:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I
M;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XU('EE87)S(#D@;6]N=&AS(#(Y(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O
M<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@
M<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#D@;6]N=&AS(#(Y
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/C$V+C<P,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T
M960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E
M<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I
M<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/
M<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N
M9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#<L
M-30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L
M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE87(@,3$@
M;6]N=&AS(#(V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE
M(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS.#<L-30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C
M='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,2!Y96%R(#$Q(&UO;G1H<R`R-B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y3044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4TA!4D4@0T%0251!3"`H4VAA<F4@0F%S960@0V]M
M<&5N<V%T:6]N($5X<&5N<V4@06QL;V-A=&EO;BD@*$1E=&%I;',I("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06QL;V-A=&5D(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C0R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M+#`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-RPW-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W0@;V8@4F5V96YU97,@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!3
M97)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O
M9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A=&5D
M(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP
M;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C
M871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L
M;&]C871E9"!3:&%R92UB87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<U-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R
M:V5T:6YG+"!'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E;G-E<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;&QO8V%T960@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0S
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BPW-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?
M8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#0S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,4M!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY615)424),
M12!.3U1%4R`H3F%R<F%T:79E*2`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#$X
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/5$53(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I
M<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M.2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<FEN8VEP86P@86UO=6YT+"!R96QA=&5D('1O('1H92!I
M;FET:6%L('!U<F-H87-E<B=S(&]V97(M86QL;W1M96YT(&]P=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S
M="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C4P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%S92!V86QU92!F;W(@8V]N=F5R<VEO;B!R871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!F;W(@
M8F%S:7,@8V]N=F5R<VEO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<S+C8U.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@<')I8V4@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N-S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D
M<R!F<F]M(&ES<W5A;F-E(&]F(&-O;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8V+#@P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8V+#<X,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA='5R:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,34L#0H)"3(P,3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F7S-F
M-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E93E?8C8Y-E]D.3=A9&9E-64T
M-C0O5V]R:W-H965T<R]3:&5E=#0T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$1!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY615)424),12!.3U1%4R`H4V-H961U
M;&4@;V8@26YT97)E<W0@17AP96YS92!296-O9VYI>F5D*2`H1&5T86EL<RD@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#3TY615)424),12!.3U1%4R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R86-T=6%L
M(&EN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,RPQ,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#@X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@:7-S=6%N
M8V4@8V]S=',@86YD(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V
M.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE
M971S+U-H965T-#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5313X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y4("A$971A:6QS*2`H55-$
M("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1D%)4B!604Q512!-14%355)%345.5"!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@
M=F%L=64@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3(N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E
M-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F
M-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T-#8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4T14%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E1!
M6$53($].($E.0T]-12`H3F%R<F%T:79E*2`H1&5T86EL<RD@*%531"`D*3QB
M<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O
M;64@5&%X($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=I=&AH;VQD:6YG('1A>"!O
M;B!T:&4@52Y3+B!R979E;G5E('-O=7)C92!P;W)T:6]N(&]F('1H92!P87EM
M96YT<R!M861E('1O('1H92!#;VUP86YY(&9O<B!I=',@<VAA<F4@;V8@4&9I
M>F5R)W,@;F5T('!R;V9I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O<G=A<F1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S."XX/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D($%M;W5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O<G=A<F1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BXY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]T86QI>"!,=&0N
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T=71O
M<GD@:6YC;VUE('1A>"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@=&%X(')A=&4L(#(P,3(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!T
M87@@<F%T92P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9&1I=&EO;F%L('1A>"!R871E+"`R,#$T(&%N9"!T:&5R96%F
M=&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BXU,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!O<&5R871I;F<@;&]S<R!C87)R>2!F;W)W87)D<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C$N.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?
M9#DW861F935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D
M.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S
M+U-H965T-#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4V34%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/E1!6$53($].($E.0T]-12`H1&5F97)R960@26YC;VUE(%1A>&5S
M*2`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1!6$53($].($E.0T]-12!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PR-3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R('9A8V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E=F5R86YC92!P
M87D@;V)L:6=A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PV-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#@V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A
M<G)Y(&9O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M."PQ,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,RPQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0P+#$Q,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."PT,C8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@
M5&%X($%S<V5T<RP@3F5T(&]F(%9A;'5A=&EO;B!!;&QO=V%N8V4L(%1O=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9#@V93<T9E\S9C0S7S1E
M93E?8C8Y-E]D.3=A9&9E-64T-C0O5V]R:W-H965T<R]3:&5E=#0X+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%-4-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY405A%4R!/
M3B!)3D-/344@*$]P96X@5&%X(%EE87)S*2`H1&5T86EL<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE3
M4D%%3"!;365M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5N('1A>"!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)4U)!14P@6TUE;6)E<ET@?"!-87AI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE
M(%1A>"!#;VYT:6YG96YC>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!E;B!T87@@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^54Y)5$5$(%-4051%4R!;365M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($-O;G1I;F=E
M;F-Y(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<&5N('1A>"!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR
M,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5.251%1"!35$%415,@6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!#;VYT:6YG
M96YC>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!E;B!T87@@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#,^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\
M=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1T;W`^26YC;'5D97,@9F5D97)A;"P@<W1A=&4@86YD
M(&QO8V%L("AO<B!S:6UI;&%R('!R;W9I;F-I86P@:G5R:7-D:6-T:6]N<RD@
M=&%X('!O<VET:6]N<RX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,F0X
M-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E.5]B-CDV7V0Y
M-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T-#DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!
M2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E-54%!,14U%3E1!4ED@1DE.
M04Y#24%,(%-4051%345.5"!)3D9/4DU!5$E/3B`H3W1H97(@07-S971S*2`H
M1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&%S<V5T<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YS=&ET=71I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&%T92!O9B!)<W)A96P@*'-E92!.;W1E(#9A*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@9&5P;W-I
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U;F1R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L,C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F
M935E-#8T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F
M7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T
M-3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5!3D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG
M/E-54%!,14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.5"!)3D9/4DU!5$E/
M3B`H06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5A;',L($]T:&5R*2`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C
M8W)U86QS("T@;W1H97(Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!A>7)O;&P@86YD(')E;&%T960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR-#,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-34W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G1E<F5S="!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@=F%C871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-S(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)O>6%L=&EE<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!I;B!C;VYN96-T:6]N('=I=&@@8V]L
M;&%B;W)A=&EO;B!O<&5R871I;VX@+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y
M(&%N9"!E<75I<&UE;G0@<W5P<&QI97)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U
M86QS+"!O=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-2PT.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$R+#`W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?
M-&5E.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T-3$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5+2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-54%!,
M14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.5"!)3D9/4DU!5$E/3B`H4F5V
M96YU97,I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%262!&24Y!
M3D-)04P@4U1!5$5-14Y4($E.1D]234%424].(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@
M<F5V96YU97,@9G)O;2!T:&4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N
M="!W:71H(%!F:7IE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+#4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-"PU-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0L-38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N="`H<V5E
M($YO=&4@,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5V96YU92!F<F]M('-E;&QI;F<@<')O9'5C=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL,#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY,38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L-C4Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PT
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,T+#@W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,F0X-F4W-&9?,V8T,U\T964Y7V(V.39?9#DW861F935E-#8T#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S)D.#9E-S1F7S-F-#-?-&5E
M.5]B-CDV7V0Y-V%D9F4U930V-"]7;W)K<VAE971S+U-H965T-3(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5!2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%3$%4140@
M4$%25%D@5%)!3E-!0U1)3TY3("A$971A:6QS*2`H0V]M<&5N<V%T:6]N(%1O
M(%1H92!.;VX@+65X96-U=&EV941I<F5C=&]R<R!;365M8F5R72P@55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E
M;G-A=&EO;B!4;R!4:&4@3F]N("UE>&5C=71I=F5$:7)E8W1O<G,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2
M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A
M<G1Y(%1R86YS86-T:6]N+"!!;6]U;G1S(&]F(%1R86YS86-T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4V,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F
M7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-`T*0V]N=&5N="U,;V-A=&EO
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M9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#,U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#`N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970T,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T-#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T-#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#0W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#DN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970U,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-3(N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S)D.#9E-S1F
@7S-F-#-?-&5E.5]B-CDV7V0Y-V%D9F4U930V-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES (Narrative) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 18, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount" onclick="toggleNextSibling(this);">$ 69,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption', window );">Principal amount, related to the initial purchaser's over-allotment option</a></td>
        <td class="nump"><a title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" onclick="toggleNextSibling(this);">9,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage" onclick="toggleNextSibling(this);">4.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
        <td class="nump"><a title="plx_DebtInstrumentConvertibleBaseValueForConversionRate" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion</a></td>
        <td class="nump"><a title="plx_DebtInstrumentConvertibleConversionShareNumber" onclick="toggleNextSibling(this);">173.6593</a><span style="display:none;white-space:normal;text-align:left;">plx_DebtInstrumentConvertibleConversionShareNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1" onclick="toggleNextSibling(this);">$ 5.76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt" onclick="toggleNextSibling(this);">$ 66,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt" onclick="toggleNextSibling(this);">$ 66,780,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
        <td class="text">Sep. 15,  2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Convertible Base Value For Conversion Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Convertible Conversion Share Number</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate principal amount of Notes related to the initial purchaser's over-allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4ZBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 18, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_NumberOfSubsidiaries" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">plx_NumberOfSubsidiaries</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromCollaborators" onclick="toggleNextSibling(this);">$ 60,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromCollaborators</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">18,850,724</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">10,675,304</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">7,280,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">13,651,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">10,479,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">34,870,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights', window );">Supply commitment for entitled rights to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">280,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits', window );">License and supply agreement potential future payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">12,500,000</a><span style="display:none;white-space:normal;text-align:left;">plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplyCommitmentPerYear', window );">Supply commitment per year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_SupplyCommitmentPerYear[dei_LegalEntityAxis=us-gaap_SubsidiariesMember]" onclick="toggleNextSibling(this);">40,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_SupplyCommitmentPerYear<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member] | Revenues from sale of products [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Revenues[dei_LegalEntityAxis=us-gaap_SubsidiariesMember;plx_SupplementalInformationRevenueAxis=us-gaap_SalesRevenueGoodsNetMember]" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues<br>/ dei_LegalEntityAxis<br>= us-gaap_SubsidiariesMember<br>/ plx_SupplementalInformationRevenueAxis<br>= us-gaap_SalesRevenueGoodsNetMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember', window );">Protalix Bio Therapeutics Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_CollaborativeArrangementProfitSharePercentage[us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember]" onclick="toggleNextSibling(this);">40.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_CollaborativeArrangementProfitSharePercentage<br>/ us-gaap_TypeOfArrangementAxis<br>= plx_ProtalixBioTherapeuticsIncorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerIncorporationMember', window );">Pfizer Incorporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_CollaborativeArrangementProfitSharePercentage[us-gaap_TypeOfArrangementAxis=plx_PfizerIncorporationMember]" onclick="toggleNextSibling(this);">60.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_CollaborativeArrangementProfitSharePercentage<br>/ us-gaap_TypeOfArrangementAxis<br>= plx_PfizerIncorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember', window );">Upon FDAApproval [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementMilestonePaymentAmount', window );">Pfizer Agreement, milestone payment amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_CollaborativeArrangementMilestonePaymentAmount[us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember]" onclick="toggleNextSibling(this);">$ 30,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_CollaborativeArrangementMilestonePaymentAmount<br>/ us-gaap_StatementScenarioAxis<br>= plx_UponFDAApprovalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementMilestonePaymentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative Arrangement milestone payment amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CollaborativeArrangementMilestonePaymentAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CollaborativeArrangementProfitSharePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License And Supply Agreement Potential Future Payment Based On Net Profits</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_NumberOfSubsidiaries</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplyCommitmentPerYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplyCommitmentPerYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_SubsidiariesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerIncorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerIncorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div style="display: block;" align="center">
<div class="CursorPointer"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 0.100000001490116px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2014 and the Chairman of the Board for part of 2014)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">375</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">560</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
        <td class="nump"><a title="us-gaap_InterestExpenseDebtExcludingAmortization" onclick="toggleNextSibling(this);">$ 3,105</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebtExcludingAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseDebtExcludingAmortization" onclick="toggleNextSibling(this);">$ 888</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebtExcludingAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AmortizationOfDebtIssuanceCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
        <td class="nump"><a title="plx_AmortizationOfDebtIssuanceCosts" onclick="toggleNextSibling(this);">444</a><span style="display:none;white-space:normal;text-align:left;">plx_AmortizationOfDebtIssuanceCosts</span><span></span></td>
        <td class="nump"><a title="plx_AmortizationOfDebtIssuanceCosts" onclick="toggleNextSibling(this);">127</a><span style="display:none;white-space:normal;text-align:left;">plx_AmortizationOfDebtIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">$ 3,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">$ 1,015</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AmortizationOfDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_AmortizationOfDebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">15 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AND SUPPLY AGREEMENT (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromCollaborators" onclick="toggleNextSibling(this);">$ 60,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromCollaborators</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_MilestonePayment" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_MilestonePayment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRecognizedOverDesignatedPeriod', window );">Revenue recognized over designated period of relationship</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_RevenueRecognizedOverDesignatedPeriod" onclick="toggleNextSibling(this);">4,600,000</a><span style="display:none;white-space:normal;text-align:left;">plx_RevenueRecognizedOverDesignatedPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRecognizedPeriod', window );">Revenue recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">14 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember', window );">Protalix Bio Therapeutics Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_CollaborativeArrangementProfitSharePercentage[us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember]" onclick="toggleNextSibling(this);">40.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_CollaborativeArrangementProfitSharePercentage<br>/ us-gaap_TypeOfArrangementAxis<br>= plx_ProtalixBioTherapeuticsIncorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember', window );">Collaboration Operation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities accrued related to the Collaboration Operation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent[us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember]" onclick="toggleNextSibling(this);">7,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= plx_CollaborationOperationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent[us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember]" onclick="toggleNextSibling(this);">8,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= plx_CollaborationOperationMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=plx_ScenarioTwoMember', window );">Upon Filing of Pediatric Investigation Plan to EMA [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromCollaborators[us-gaap_StatementScenarioAxis=plx_ScenarioTwoMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromCollaborators<br>/ us-gaap_StatementScenarioAxis<br>= plx_ScenarioTwoMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember', window );">Upon FDAApproval [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_MilestonePayment[us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember]" onclick="toggleNextSibling(this);">$ 25,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_MilestonePayment<br>/ us-gaap_StatementScenarioAxis<br>= plx_UponFDAApprovalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CollaborativeArrangementProfitSharePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_MilestonePayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRecognizedOverDesignatedPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue recognized over designated period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_RevenueRecognizedOverDesignatedPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRecognizedPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognized Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_RevenueRecognizedPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=plx_ScenarioTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=plx_ScenarioTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>a.&#160;&#160;&#160;&#160;&#160;General</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx<sup>&#174;</sup> protein expression system (&#147;ProCellEx&#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's <font>two</font> subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &#147;Israeli MOH&#148;) in September 2012, by the Brazilian Ministry of Health (the &#147;Brazilian MOH&#148;) in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Taliglucerase alfa is being marketed in the United States under the brand name&#160;Elelyso&#153; by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &#147;Pfizer Agreement&#148;). The Company, through Protalix Ltd., markets&#160;Elelyso&#160;in Israel, and in Brazil under the brand name Uplyso&#153;. See Note 2.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $<font>60.0</font> million in connection with the execution of the Pfizer Agreement and additional $<font>30.0</font> million milestone payment mainly in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a <font>40</font>% and <font>60</font>% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retains exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is Uplyso. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz committed to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa during the first two years of the agreement. With respect to the first required purchase amount, the Company has recorded revenues of approximately $<font>3.5</font> million for sales of taliglucerase alfa to Fiocruz in 2014.&#160;In subsequent years, Fiocruz is required to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa per year. Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa. The Brazil Agreement became effective during the January&#160;of 2014.<br/><br/>If Fiocruz fails to comply with certain of its purchase commitments under the agreement, the Company has the right to terminate the agreement and all rights to the technology that were transferred to Fiocruz will be returned to the Company.<br/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $<font>12.5</font> million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>b.&#160;&#160;&#160;&#160;&#160;Basis of presentation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;).</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>c.&#160;&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>d.&#160;&#160;&#160;&#160;&#160;Functional currency</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company's revenues are derived in dollars. Most of the Company's expenses and capital expenditures are incurred in dollars, and the major source of the Company's financing has been provided in dollars.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &#150; historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>e.&#160;&#160;&#160;&#160;&#160;Cash equivalents</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>f.&#160;&#160;&#160;&#160;&#160;&#160;Inventories</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the &#147;moving average&#148; basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the &#147;moving average&#148; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">If actual market prices for finished products prove less favorable than those projected by management, inventory write-downs may be required. Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>g.&#160;&#160;&#160;&#160;&#160;Property and equipment</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 36pt;"></td>
<td style="width: 48pt; text-align: left; font-family: 'times new roman';">1.</td>
<td style="text-align: justify; font-family: 'times new roman';">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<div class="CursorPointer"><br/></div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 36pt;"></td>
<td style="width: 48pt; font-family: 'times new roman';">2.</td>
<td style="font-family: 'Times New Roman';"><font><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</font></font></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 36pt; vertical-align: top; text-align: left;"></td>
<td style="width: 48pt; vertical-align: top; text-align: left;"></td>
<td style="vertical-align: top; text-align: left;"></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<div>
<div align="center">
<div class="CursorPointer">
<table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2">Years</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 82%; text-align: left; font-family: 'times new roman';">Laboratory equipment</td>
<td style="width: 1%; font-family: 'times new roman';">&#160;</td>
<td style="width: 1%; text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="width: 15%; text-align: center; font-family: 'times new roman';"><font>5</font></td>
<td style="width: 1%; text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'Times New Roman';">Furniture</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>10</font>-<font>15</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman';">Computer equipment</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>3</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>

</table>
</div>
</div>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>h.&#160;&#160;&#160;&#160;&#160;Impairment in value of long-lived assets: </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>i.&#160;&#160;&#160;&#160;&#160;&#160;Income taxes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">1.&#160;&#160;&#160;&#160;&#160;Deferred income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See Note 10.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">2.&#160;&#160;&#160;&#160;&#160;Uncertainty in income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Tax benefits recognized in the financial statements are those that the Company's management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company's management deems more likely than not to be sustained.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>j.&#160;&#160;&#160;&#160;&#160;&#160;Revenue Recognition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">1.&#160;&#160;&#160;&#160;&#160;Revenues from the license and supply agreement with Pfizer</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company's continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">2.&#160;&#160;&#160;&#160;&#160;Revenues from selling products</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The Company recognizes revenues from&#160;selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">3.&#160;&#160;&#160;&#160;&#160;Company's share in the collaboration agreement</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel and Brazil (since 2014), where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company's share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>k.&#160;&#160;&#160;&#160;Research and development costs </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the &#147;OCS&#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have <font>no</font> alternative future use are charged to research and development costs at the purchase date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>l.&#160;&#160;&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company's trade receivables represent amounts to be received from Pfizer and the Company's customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.</p>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>m.&#160;&#160;&#160;&#160;Share-based compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company accounts for employee's share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>n.&#160;&#160;&#160;&#160;&#160;Net loss per share</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Diluted LPS does not include <font>7,280,469</font>, <font>10,675,304</font> and <font>18,850,724</font> shares of Common Stock underlying outstanding options , restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the fiscal years ended December 31, 2012, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"><b>&#160;</b></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"><b>o.&#160;&#160;&#160;&#160;&#160;Convertible notes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;">The convertible notes are accounted for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;"><br/></p>
<div>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: -20.7pt; font-size-adjust: none; font-stretch: normal;"><b>p. &#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements:</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;">In August 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued amended guidance related to the disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. The Company believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;">In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. The Company is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.</p>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 32,736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 32,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(21,454)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(18,319)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net, Total</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">11,282</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">13,711</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,539</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,692</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">15,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_LaboratoryEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">14,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_LaboratoryEquipmentMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember', window );">Furniture And Computer Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember]" onclick="toggleNextSibling(this);">2,154</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_FurnitureAndComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember]" onclick="toggleNextSibling(this);">2,074</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_FurnitureAndComputerEquipmentMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">15,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">15,070</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember', window );">Equipment Under Construction [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember]" onclick="toggleNextSibling(this);">$ 17</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_EquipmentUnderConstructionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember]" onclick="toggleNextSibling(this);">$ 28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= plx_EquipmentUnderConstructionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EO1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details) (Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="6">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">1,238,692</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">296,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">326,267</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">1,208,592</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">912,425</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 5.385</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 2.678</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 0.12</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 6.136</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 7.259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember]" onclick="toggleNextSibling(this);">$ 2,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="7"></td>
      </tr>
      <tr>
        <td colspan="7">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">




 (*)
The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $2.3 million.




</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 54,767</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 86,398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable- Trade</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">1,884</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">2,091</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">2,202</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">1,457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">6,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">7,957</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">65,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">97,903</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" onclick="toggleNextSibling(this);">1,555</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" onclick="toggleNextSibling(this);">1,578</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">11,282</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">13,711</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">DEFERRED CHARGES</a></td>
        <td class="nump"><a title="us-gaap_DeferredCosts" onclick="toggleNextSibling(this);">113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredCosts" onclick="toggleNextSibling(this);">141</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCosts</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">78,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">113,333</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">3,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">5,254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">15,496</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">12,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">6,763</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">9,369</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">26,210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">26,696</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
        <td class="nump"><a title="us-gaap_ConvertibleDebtNoncurrent" onclick="toggleNextSibling(this);">67,464</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertibleDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConvertibleDebtNoncurrent" onclick="toggleNextSibling(this);">67,048</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertibleDebtNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">37,232</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">41,796</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">912</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">2,371</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump"><a title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">2,253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">2,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesNoncurrent" onclick="toggleNextSibling(this);">107,861</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesNoncurrent" onclick="toggleNextSibling(this);">113,583</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">134,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">140,279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS (Note 6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>CAPITAL DEFICIENCY:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2013 and 2014, 150,000,000 shares; issued and outstanding - as of December 31, 2013 and 2014, 93,551,098 shares and 93,603,819shares, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">185,633</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">184,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(241,328)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(211,385)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(55,601)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(26,946)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 78,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 113,333</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value convertible notes</a></td>
        <td class="nump"><a title="us-gaap_ConvertibleDebtFairValueDisclosures" onclick="toggleNextSibling(this);">$ 52.4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertibleDebtFairValueDisclosures</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" onclick="toggleNextSibling(this);"> 1,780</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock awards forfeited, share</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">185,709</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">17,834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">3,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESWBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
        <td class="nump"><a title="plx_CommitmentAmount" onclick="toggleNextSibling(this);">$ 1,200,000</a><span style="display:none;white-space:normal;text-align:left;">plx_CommitmentAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_OCSMember', window );">OCS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_OCSMember]" onclick="toggleNextSibling(this);">951,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_OCSMember]" onclick="toggleNextSibling(this);">392,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_OCSMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember', window );">Research And License Agreements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember]" onclick="toggleNextSibling(this);">104,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_ResearchAndLicenseAgreementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember]" onclick="toggleNextSibling(this);">80,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_ResearchAndLicenseAgreementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense[plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember]" onclick="toggleNextSibling(this);">674,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_ResearchAndLicenseAgreementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
        <td class="nump"><a title="plx_MonthlyRentLeaseExpense[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">85,000</a><span style="display:none;white-space:normal;text-align:left;">plx_MonthlyRentLeaseExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposited as bank guarantee</a></td>
        <td class="nump"><a title="us-gaap_SecurityDeposit[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">315,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SecurityDeposit<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Lease/rent expense</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">1,044,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">1,133,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">971,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">1,014,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">1,009,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears[plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember]" onclick="toggleNextSibling(this);">1,009,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears<br>/ plx_CommitmentsAndContingenciesAxis<br>= us-gaap_LeaseAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember', window );">Vehicle Lease And Maintenance Agreements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
        <td class="nump"><a title="plx_MonthlyRentLeaseExpense[plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember]" onclick="toggleNextSibling(this);">51,000</a><span style="display:none;white-space:normal;text-align:left;">plx_MonthlyRentLeaseExpense<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_VehicleLeaseAndMaintenanceAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent[plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember]" onclick="toggleNextSibling(this);">504,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_VehicleLeaseAndMaintenanceAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears[plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember]" onclick="toggleNextSibling(this);">289,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_VehicleLeaseAndMaintenanceAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears[plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember]" onclick="toggleNextSibling(this);">118,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_VehicleLeaseAndMaintenanceAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | OCS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump"><a title="plx_RoyaltiesOnSaleOfProducts[plx_CommitmentsAndContingenciesAxis=plx_OCSMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_RoyaltiesOnSaleOfProducts<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | OCS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump"><a title="plx_RoyaltiesOnSaleOfProducts[plx_CommitmentsAndContingenciesAxis=plx_OCSMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_RoyaltiesOnSaleOfProducts<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived', window );">Percentage amount the aggregate amount of royalties that should not exceed grant received</a></td>
        <td class="nump"><a title="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived[plx_CommitmentsAndContingenciesAxis=plx_OCSMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
        <td class="nump"><a title="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent[plx_CommitmentsAndContingenciesAxis=plx_OCSMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 30,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_OCSMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Products Manufactured Outside Of Israel [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump"><a title="plx_RoyaltiesOnSaleOfProducts[plx_CommitmentsAndContingenciesAxis=plx_ProductsManufacturedOutsideOfIsraelMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">300.00%</a><span style="display:none;white-space:normal;text-align:left;">plx_RoyaltiesOnSaleOfProducts<br>/ plx_CommitmentsAndContingenciesAxis<br>= plx_ProductsManufacturedOutsideOfIsraelMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Commitment amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percetnage aggregate royalties should not exceed grant amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MonthlyRentLeaseExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Monthly rent/lease expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_MonthlyRentLeaseExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalties based on sale of products developed from projects funded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_RoyaltiesOnSaleOfProducts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8,17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_OCSMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_OCSMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of property and equipment grouped by major classifications is as follows:</font>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(<i>U.S. dollars in thousands)</i></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="4"><br/></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Laboratory&#160;equipment</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">14,858</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,138</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Furniture&#160;and&#160;computer&#160;equipment</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,074</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,154</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Leasehold&#160;improvements</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,070</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,427</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Equipment&#160;under&#160;construction</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">28</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">17</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">32,030</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">32,736</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Less&#160;&#150;&#160;accumulated&#160;depreciation</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 20px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">and&#160;amortization</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">(18,319</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">(21,454</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">13,711</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">11,282</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGHDK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 18, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 28, 2014</div>
        </th>
        <th class="th">
          <div>Jul. 24, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 14, 2006</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">5,175,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Underwritten public offering, common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Underwritten public offering, net proceeds from issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">$ 25,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwritten public offering, commissions and issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">1,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">1,923,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">13,841,655</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock granted, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="toggleNextSibling(this);">8,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage" onclick="toggleNextSibling(this);">4.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" onclick="toggleNextSibling(this);">66,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption', window );">Principal amount, related to the initial purchaser's over-allotment option</a></td>
        <td class="nump"><a title="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption" onclick="toggleNextSibling(this);">9,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=plx_EmployeesMember', window );">Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Officers And Certain Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_OfficersAndCertainEmployeesMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OfficersAndCertainEmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Shares of common stock issued, lock up period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_OfficersAndCertainEmployeesMember]" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OfficersAndCertainEmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_EmployeesMember]" onclick="toggleNextSibling(this);">12</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_EmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Officers And Directors In Private Transaction [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=plx_OfficersAndDirectorsInPrivateTransactionMember]" onclick="toggleNextSibling(this);">1,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OfficersAndDirectorsInPrivateTransactionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member] | President and Chief Executive Officer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">$ 2.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of at grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">62.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">1.86%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_PresidentAndChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member] | Board of Directors Chairman [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options or restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">$ 3.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of at grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">$ 193,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">62.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember]" onclick="toggleNextSibling(this);">1.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member] | Board of Directors Chairman [Member] | Vest on the first anniversary of the grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember;us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember<br>/ us-gaap_VestingAxis<br>= us-gaap_ShareBasedCompensationAwardTrancheOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member] | Board of Directors Chairman [Member] | Vest over the subsequent two-year period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember;us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember]" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_BoardOfDirectorsChairmanMember<br>/ us-gaap_VestingAxis<br>= us-gaap_ShareBasedCompensationAwardTrancheTwoMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate principal amount of Notes related to the initial purchaser's over-allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverAllotmentOption</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award granted contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of installments for vesting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_EmployeesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_EmployeesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock', window );">Schedule of Options and Restricted Stocks Granted</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Below is a table summarizing all of the options and restricted stock grants to employees for each year of the three-year period ended December 31, 2014:</font>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 81%; margin-left: 1.25in;">

<tr style="vertical-align: bottom;">
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year of<br/> grant</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>No. of options<br/> or restricted<br/> stock granted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Exercise<br/> price range</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Vesting period</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Fair value<br/> at grant<br/> (U.S.<br/> dollars in<br/> thousands)</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Expiration<br/> period</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2012</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">400,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>3</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,288</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2012</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,100,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>4</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,292</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2014</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>2.37</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>4</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,007</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>10</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,400,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><br/></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity - Options Granted to Employees</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted to employees:</font>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px; text-align: center;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,141,030</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,253,579</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.923</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,153,898</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.951</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year:</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; text-indent: 10px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.370</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 10px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Forfeited and Expired</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">25,858</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.372</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">20,558</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.603</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">44,201</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.833</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercised (*)</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">861,593</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.346</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">79,123</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.418</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">139,388</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.446</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,253,579</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.923</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,153,898</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.951</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,870,309</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.770</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercisable at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,258,441</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.201</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,614,148</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.591</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,905,559</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.933</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-indent: -14.2pt;"><br/></p>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;">

<tr>
<td style="width: 2%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> (*) </font></td>
<td style="width: 98%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $<font>4.8</font> million, $<font>306,000</font> and $<font>447,000</font>, respectively.<br/></font></td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity - Options Granted to Employees</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted stock granted to employees:</font>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><br/></p>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of Restricted Shares</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman';"></td>
<td style="text-align: left; font-family: 'times new roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,394,708</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">970,208</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year:</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,500,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Vested</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">102,084</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">406,666</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">398,375</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Forfeited</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,208</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">17,834</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">185,709</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-bottom: 2.5pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,394,708</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">970,208</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">386,124</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<div class="CursorPointer"><br/></div>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock', window );">Schedule of Options Granted to Service Providers</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Options and restricted stocks granted to consultants, directors, and other service providers:</font>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,238,692</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.385</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year-</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">296,167</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.678</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercised (*)</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">326,267</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.12</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,208,592</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.136</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercisable at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;&#160;</font></p>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;">

<tr>
<td style="width: 2%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> (*) </font></td>
<td style="width: 98%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $<font>2.3</font> million.</font></td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about Share Options Outstanding</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2014:</font>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td align="center" style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="26"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31, 2014</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="text-align: center; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;" colspan="8"><br/></td>
</tr>
<tr style="vertical-align: bottom;">
<td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Options and restricted stock <br/>outstanding</strong></font><br/></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td align="center" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="10"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Options exercisable</strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Exercise <br/>prices</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of <br/>options and<br/> restricted stock <br/>outstanding <br/>at end of <br/>year</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted <br/>average <br/>remaining <br/>contractual <br/>life</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of<br/> options<br/> exercisable</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted <br/>average <br/>remaining <br/>contractual <br/>life</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom;" colspan="1" align="center"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a (Restricted Stock)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">490,624</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap;" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.001</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">719,207</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.54</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">719,207</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.54</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.120</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">308,801</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.00</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">308,801</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.00</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.972</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">995,853</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.44</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">995,853</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.44</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.350</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">40,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.82</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">40,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.82</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.370</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.75</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">56,250</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.75</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.650</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">345,082</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.49</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">345,082</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.49</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.020</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">50,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">50,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.370</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.56</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.56</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.000</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,708,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,708,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.810</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.900</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">991,916</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.32</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">829,249</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.32</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.550</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">160,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">160,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.660</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">68,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.83</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">68,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.83</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">16.700</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">387,542</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.99</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">387,542</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.99</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,465,025</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,817,984</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table illustrates the effect of share-based compensation on the statement of operations:</font>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Cost of revenues</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">220</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Research and development expenses</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,756</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,655</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">936</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Marketing, General and administrative expenses</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,775</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,434</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">306</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,751</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,089</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,242</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><br/></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5EBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (29,943)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (27,790)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (11,618)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,242</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">4,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">7,751</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,539</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3,692</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
        <td class="nump"><a title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" onclick="toggleNextSibling(this);">1,446</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</span><span></span></td>
        <td class="num"><a title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" onclick="toggleNextSibling(this);">(264)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</span><span></span></td>
        <td class="num"><a title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" onclick="toggleNextSibling(this);">(171)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump"><a title="us-gaap_PensionAndOtherPostretirementBenefitExpense" onclick="toggleNextSibling(this);">140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PensionAndOtherPostretirementBenefitExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_PensionAndOtherPostretirementBenefitExpense" onclick="toggleNextSibling(this);">200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PensionAndOtherPostretirementBenefitExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_PensionAndOtherPostretirementBenefitExpense" onclick="toggleNextSibling(this);">276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PensionAndOtherPostretirementBenefitExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num"><a title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" onclick="toggleNextSibling(this);">(22)</a><span style="display:none;white-space:normal;text-align:left;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</span><span></span></td>
        <td class="num"><a title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</span><span></span></td>
        <td class="num"><a title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" onclick="toggleNextSibling(this);">(36)</a><span style="display:none;white-space:normal;text-align:left;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
        <td class="num"><a title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" onclick="toggleNextSibling(this);">(3)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">127</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues (including non-current portion)</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(7,170)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(7,160)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">1,281</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(799)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">1,904</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">243</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">1,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(3,918)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(3,760)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals (including long term)</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(1,322)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">2,977</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(29,281)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(30,653)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">635</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(785)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(1,890)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2,068)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Investment in restricted deposit</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">(90)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">(42)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">(80)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num"><a title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" onclick="toggleNextSibling(this);">(137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" onclick="toggleNextSibling(this);">(170)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" onclick="toggleNextSibling(this);">(138)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(1,001)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2,102)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2,286)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt" onclick="toggleNextSibling(this);">66,780</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" onclick="toggleNextSibling(this);">25,328</a><span style="display:none;white-space:normal;text-align:left;">plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">112</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">1,230</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">66,892</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">26,558</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="num"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">(1,395)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">226</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">127</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(31,631)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">34,363</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">25,034</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">86,398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">52,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">27,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">54,767</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">86,398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">52,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump"><a title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">120</a><span style="display:none;white-space:normal;text-align:left;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">186</a><span style="display:none;white-space:normal;text-align:left;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">1,136</a><span style="display:none;white-space:normal;text-align:left;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS-</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
        <td class="nump"><a title="us-gaap_InterestPaidNet" onclick="toggleNextSibling(this);">$ 3,079</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaidNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock net of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">150,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">150,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">93,603,819</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">93,551,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">93,603,819</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">93,551,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><b>NOTE 10 - TAXES ON INCOME</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><strong>a.&#160;&#160;&#160;&#160;&#160;The Company</strong></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company's income is taxed in the United States at the rate of up to <font>39</font>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>b.&#160;&#160;&#160;&#160;&#160;Protalix Ltd. </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Israeli Subsidiary is taxed according to Israeli tax laws:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">1.&#160;&#160;&#160;&#160;&#160;<b>Measurement of results for tax purposes </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Since 2008, the Company has measured the results of the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985, the Subsidiary's results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel consumer price index.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">2.&#160;&#160;&#160;&#160;<b>Tax rates</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The income of the Israeli Subsidiary, other than income from &#147;Approved Enterprises,&#148; is taxed in Israel at the regular rates which were <font>25</font>% in 2012 and 2013 and <font>26.5</font>% for 2014 and thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">Capital gain is subject to capital gain tax according to corporate tax rate in the year of selling the assets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">3.&#160;&#160;&#160;&#160;&#160;<b>The Law for the Encouragement of Capital Investments, 1959 (the &#147;Encouragement of Capital Investments Law&#148;)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &#147;Approved Enterprise&#148; or &#147;Benefited Enterprise&#148; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;<b>Reduced tax rates</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The Israeli Subsidiary has an &#147;Approved Enterprise&#148; plan since 2004 and &#147;Benefited Enterprise&#148; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#147;Approved Enterprise&#148; or &#147;Benefited Enterprise&#148; during the tax exemption period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would have been applicable had such income not been exempted.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">In addition to the corporate taxes in Israel, the Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits under the Pfizer Agreement. The withholding tax rate is currently <font>15</font>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">b.&#160;&#160;&#160;&#160;&#160;<b>Accelerated depreciation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first <font>five</font> years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">c.&#160;&#160;&#160;&#160;&#160;<b>Conditions for entitlement to the benefits</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The Israeli Subsidiary's entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#147;Approved Enterprise&#148; from the Investment Center.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;">d.&#160;&#160;&#160;&#160;&#160;<b>Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the &#147;Capital Investments Law Amendment&#148;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b></b><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;">Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the &#147;year of election&#148; no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><b>c.&#160;&#160;&#160;&#160;&#160;</b>Tax losses carried forward to future years</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">As of December 31, 2014, the Company had aggregate net operating loss (NOL) carry-forwards equal to approximately $<font>138.8</font> million that are available to reduce future taxable income as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">1.&#160;&#160;&#160;&#160;<b>The Company</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The NOL carry-forward of the Company equal to approximately $<font>16.9</font> million may be restricted under Section 382 of the Internal Revenue Code (&#147;IRC&#148;). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">2.&#160;&#160;&#160;&#160;&#160;<b>Protalix Ltd.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">At December 31, 2014, the Israeli Subsidiary had approximately $<font>121.9</font> million of NOL carry-forwards that are available to reduce future taxable income with <font>no</font> limited period of use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><b>d.&#160;&#160;&#160;&#160;&#160;Deferred income taxes:</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The components of the Company's net deferred tax assets at December 31, 2013 and 2014 were as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><strong>December 31,</strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap">(U.S. dollars in thousands)</td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><strong>2013</strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong>&#160;</strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><strong>2014</strong><strong><font></font></strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><strong><font></font></strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><strong><font></font></strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong>&#160;</strong></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';">In respect of:</td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2">&#160;</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;">Research and development expenses</td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font>5,257</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font>3,136</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Property and equipment</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(491</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(372</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Provision for vacation</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>417</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>374</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Severance pay obligation</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>209</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>185</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Deferred revenues</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>9,867</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>8,658</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Net operating loss carry forwards</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>23,167</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>28,130</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Valuation allowance</td>
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(38,426</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(40,111</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>-</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>-</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">&#160;</td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. The Company used tax rates of 39%, 26.5% and 0%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>e.&#160;&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>f.&#160;&#160;&#160;&#160;&#160;Tax assessments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">In accordance with the Income Tax Ordinance, as of December 31, 2014, all of Protalix Ltd.'s tax assessments through tax year 2010&#160;are considered final.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">A summary of open tax years by major jurisdiction is presented below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div class="CursorPointer" align="center">
<table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-right: 0.1px;" cellpadding="0" cellspacing="0">

<tr style="vertical-align: bottom; background-color: white;">
<td style="text-decoration: none; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; padding-left: 0px; font-family: 'times new roman';"><strong>Jurisdiction:</strong></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';"><strong>&#160;</strong></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"><strong>&#160;</strong></td>
<td nowrap="nowrap" style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: right; font-family: 'times new roman';"><strong><b>Years:</b></strong></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"><strong>&#160;</strong></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-left: 0px; font-family: 'times new roman'; width: 90%;">Israel</td>
<td style="font-family: 'Times New Roman'; width: 0%;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; width: 0%;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; width: 10%;" nowrap="nowrap"><font>2011</font>-<font>2014</font></td>
<td style="text-align: left; font-family: 'times new roman'; width: 0%;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0; font-family: 'times new roman';">United States (*)</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
<td style="text-align: right; font-family: 'times new roman';" nowrap="nowrap"><font>2010</font>-<font>2014</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>

</table>
</div>
<b><b>&#160;<br/></b></b>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="margin-left: 0.100000001490116px;">

<tr>
<td style="width: 2%;">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">(*)&#160;</p>
</td>
<td style="width: 98%; font-size: 10pt;">
<div>Includes federal, state and local (or similar provincial jurisdictions) tax positions.</div>
</td>
</tr>

</table>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 01, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">93,603,819</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 179</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 11 - </b> <b>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Balance sheets:</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-weight: bold; text-align: left; text-indent: -26.45pt; margin: 0 0 0 75pt;">a. &#160; &#160; &#160; &#160;Other assets:</td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Institutions</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">356</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">124</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">State of Israel (see Note 6a)</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">366</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,229</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Restricted deposit</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">362</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">416</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Prepaid expenses</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">286</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">369</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Sundry</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">87</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">64</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,457</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,202</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; margin: 0 0 0 75pt;">
<td style="font-family: 'times new roman'; text-indent: -26.45pt; margin: 0 0 0 75pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>b. &#160; &#160; &#160; &#160; Accounts payable and accruals &#150; other:</strong></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Payroll and related expenses</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,557</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,243</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Interest payable</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">888</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">914</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Provision for vacation</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,572</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,412</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Accrued expenses</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,785</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,097</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Royalties payable</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">419</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">495</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Liability in connection with collaboration operation - current portion</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,666</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,215</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Property and equipment suppliers</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">186</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">120</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">12,073</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,496</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;<br/></b></font></p>
</div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Statements of operations:</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap" style="font-weight: bold; text-indent: -26.45pt; margin: 0 0 0 75pt;">c. &#160; &#160; &#160;Revenues:</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 70%; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Deferred revenues from the license and supply agreement with Pfizer</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Milestone payment (see Note 2)</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">25,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Revenues from selling products</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,307</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,916</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9,088</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 28.85pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">34,870</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">10,479</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">13,651</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES (see Note 11(c))</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 13,651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 10,479</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 34,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump"><a title="plx_OtherGainsLosses" onclick="toggleNextSibling(this);">1,509</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherGainsLosses</span><span></span></td>
        <td class="nump"><a title="plx_OtherGainsLosses" onclick="toggleNextSibling(this);">1,034</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherGainsLosses</span><span></span></td>
        <td class="num"><a title="plx_OtherGainsLosses" onclick="toggleNextSibling(this);">(446)</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherGainsLosses</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num"><a title="us-gaap_CostOfRevenue" onclick="toggleNextSibling(this);">(9,053)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_CostOfRevenue" onclick="toggleNextSibling(this);">(5,428)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_CostOfRevenue" onclick="toggleNextSibling(this);">(8,144)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfRevenue</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">6,107</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">6,085</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">26,280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">(29,761)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">(33,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">(36,665)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump"><a title="plx_GrantsAndReimbursementsReceivedOrReceivable" onclick="toggleNextSibling(this);">8,111</a><span style="display:none;white-space:normal;text-align:left;">plx_GrantsAndReimbursementsReceivedOrReceivable</span><span></span></td>
        <td class="nump"><a title="plx_GrantsAndReimbursementsReceivedOrReceivable" onclick="toggleNextSibling(this);">8,497</a><span style="display:none;white-space:normal;text-align:left;">plx_GrantsAndReimbursementsReceivedOrReceivable</span><span></span></td>
        <td class="nump"><a title="plx_GrantsAndReimbursementsReceivedOrReceivable" onclick="toggleNextSibling(this);">7,976</a><span style="display:none;white-space:normal;text-align:left;">plx_GrantsAndReimbursementsReceivedOrReceivable</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num"><a title="plx_ResearchDevelopmentAndEngineeringExpenseNet" onclick="toggleNextSibling(this);">(21,650)</a><span style="display:none;white-space:normal;text-align:left;">plx_ResearchDevelopmentAndEngineeringExpenseNet</span><span></span></td>
        <td class="num"><a title="plx_ResearchDevelopmentAndEngineeringExpenseNet" onclick="toggleNextSibling(this);">(24,816)</a><span style="display:none;white-space:normal;text-align:left;">plx_ResearchDevelopmentAndEngineeringExpenseNet</span><span></span></td>
        <td class="num"><a title="plx_ResearchDevelopmentAndEngineeringExpenseNet" onclick="toggleNextSibling(this);">(28,689)</a><span style="display:none;white-space:normal;text-align:left;">plx_ResearchDevelopmentAndEngineeringExpenseNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">(9,661)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">(8,385)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">(9,763)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(25,204)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(27,116)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(12,172)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">(4,935)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">(1,065)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">(34)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">196</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">391</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(4,739)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(674)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">554</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE YEAR</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (29,943)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (27,790)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (11,618)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock - basic and diluted:</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.32)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.30)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.13)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares of common stock used in computing loss per share of common stock, basic and diluted:</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">92,891,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">92,368,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">90,845,901</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_OtherGainsLosses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ResearchDevelopmentAndEngineeringExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><b>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Company's balance sheets under &#147;Liability for employee rights upon retirement.&#148; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company's balance sheets under &#147;Funds in respect of employee rights upon retirement.&#148; These policies are the Company's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2012, 2013 and 2014, the Company deposited approximately<b> </b>$<font>177,000</font>, $<font>194,000</font> and $<font>195,000</font>, respectively, with insurance companies in connection with its severance payment obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company's balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#147;Contribution Plans&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The amounts of severance pay expenses were approximately $<font>1.0</font> million for each of the years ended December 31, 2012, 2013 and 2014, of which approximately<b> </b>$<font>670,000</font>, $<font>801,000</font> and $<font>779,000</font> in the years ended December 31, 2012, 2013 and 2014, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately<b> </b>$<font>36,000</font>, $<font>58,000</font> and $<font>22,000</font> for the years ended December 31, 2012, 2013 and 2014, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">The Company expects to contribute approximately $<font>863,000</font> in the year ending December 31, 2015 to insurance companies in connection with its severance liabilities for its operations for that year, approximately<b> </b>$<font>685,000</font> of which will be contributed to one or more Contribution Plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">During the five-year period following December 31, 2014, the Company expects to pay future benefits to three<b> </b>employees upon each such employee's normal retirement age. The Company anticipates that the benefits payable will be immaterial.</p> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 80<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35742057&amp;loc=SL14450702-114947<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 4 - INVENTORIES</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>a.</b></font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories at December 31, 2013 and 2014 consisted of the following:</font></font></font></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in; vertical-align: top; text-align: left;"></td>
<td style="width: 0.25in; vertical-align: top; text-align: left;"></td>
<td style="vertical-align: top; text-align: left;"></td>
</tr>

</table>
</div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(<i>U.S. dollars in thousands)</i></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Raw materials</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,342</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,616</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Work in progress</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">92</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">132</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Finished goods</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,523</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,919</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Total inventory</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,957</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,667</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div> </div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.</b></font></td>
<td style="text-align: justify; font-family: 'times new roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">During the years ended December 31, 2013 and 2014, the Company recorded approximately $<font>1.6</font> million and $<font>1.7</font> million, respectively, for write-down of inventory under cost of revenues.</font></td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories at December 31, 2013 and 2014 consisted of the following:</font>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(<i>U.S. dollars in thousands)</i></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Raw materials</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,342</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,616</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Work in progress</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">92</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">132</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Finished goods</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,523</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,919</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Total inventory</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,957</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,667</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 12 - RELATED PARTY TRANSACTIONS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div>
<div style="display: block;" align="center">
<div class="CursorPointer"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 0.100000001490116px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2014 and the Chairman of the Board for part of 2014)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">375</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">560</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table></div>
</div>
</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 8 - CONVERTIBLE NOTES</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">On September 18, 2013, the Company completed a private placement of $<font>69.0</font> million in aggregate principal amount of Notes, including $<font>9.0</font> million aggregate principal amount of Notes related to the initial purchaser's over-allotment option, which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture (the &#147;Indenture&#148;) with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of <font>4.50</font>% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal amount of the Notes, were $<font>66.8</font> million, after deducting the initial purchaser's discount and commission and offering expenses payable by the Company. The debt discount and debt issuance costs are deferred and amortized over the convertible notes period (5 years).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes is <font>173.6593</font> shares of the Common Stock for each $<font>1,000</font> principal amount of Notes (equivalent to an initial conversion price of approximately $<font>5.76</font> per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Prior to September 19, 2016, the Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the redemption date to the maturity date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The following table sets forth total interest expense recognized for the years ended December 31, 2013 and 2014 related to the Notes:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 90%; margin-left: 0.5in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. Dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Contractual interest expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">888</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,105</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Amortization of debt issuance costs and debt discount</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">127</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">444</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Total</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,015</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,549</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><b>NOTE 6 - COMMITMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>a.&#160;&#160;&#160;&#160;&#160;Royalty Commitments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">1.&#160;&#160;&#160;&#160;&#160;The Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of the related projects was not assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Under the terms of the funding arrangements with the OCS, royalties of <font>3</font>% to <font>6</font>% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed, in the aggregate, <font>100</font>% of the amount of the grant received (dollar linked), plus, commencing upon January 1, 2001, interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to <font>300</font>% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Royalty expenses to the OCS are included in the statement of operations as a component of the cost of revenues and were approximately $<font>1.5</font> million, $<font>392,000</font> and $<font>951,000</font> during the years ended December 31, 2012, 2013 and 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">At December 31, 2014, the maximum royalty amount payable by the Company under these funding arrangements is approximately $<font>30</font> million (without interest, assuming 100% of the funds are payable).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">2.&#160;&#160;&#160;&#160;&#160;The Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately $<font>674,000</font>, $<font>80,000</font> and $<font>104,000</font> during the years ended December 31, 2012, 2013 and 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments payable would be approximately $0.3 million and would be payable, if at all, as the Company's projects progress over the course of a number of years. No milestone payments were made during 2012, 2013 and 2014.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>b.&#160;&#160;&#160;&#160;&#160;Subcontracting Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company has entered into sub-contracting agreements with several clinical providers and consultants<b> </b>in Israel, the United States and certain other countries in connection with its primary product development process. As of December 31, 2014, total commitments under said agreements were approximately $<font>1.2</font> million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>c.&#160;&#160;&#160;&#160;&#160;Lease Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company is a party to a number of lease agreements for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental payments are approximately $<font>85,000</font>. As of December 31, 2014, the Company provided bank guarantees of approximately $<font>315,000</font> , in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of the next <font>three</font> years under the operating leases for such premises are approximately as follows: 2015 - $<font>1,014,000</font>, 2016 &#150; $<font>1,009,000</font>, 2017 $<font>1,009,000</font>. Lease expenses totaled approximately $<font>971,000</font>, $<font>1,133,000</font> and $<font>1,044,000</font> for the years ended December 31, 2012, 2013 and 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>d.&#160;&#160;&#160;&#160;&#160;Vehicle Lease and Maintenance Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $<font>51,000</font>. The expected lease payments for the years ending December 31, 2015, 2016 and 2017 are approximately $<font>504,000</font>, $<font>289,000</font> and $<font>118,000</font>, respectively.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 7 - SHARE CAPITAL</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>a.&#160;&#160;&#160;&#160;&#160;Rights of the Company's common stock</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The Company's common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.&#160;&#160;&#160;&#160;&#160;Stock based compensation </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &#147;Plan&#148;). The Plan has since been amended to, among other things, increase the number of shares of common stock available under the plan to <font>13,841,655</font> shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">As of December 31, 2014, <font>1,923,444</font> shares of Common Stock remain available for grant under the Plan.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company's management uses the fair value of the Common Stock.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">From January 1, 2012 through December 31, 2014, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">1.&#160;&#160;&#160;&#160;&#160;<b>Options and restricted stock granted to employees:</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">a)</font></td>
<td><font style="font-family: 'Times New Roman';"><font><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Below is a table summarizing all of the options and restricted stock grants to employees for each year of the three-year period ended December 31, 2014:</font></font></font></font></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 81%; margin-left: 1.25in;">

<tr style="vertical-align: bottom;">
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year of<br/> grant</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>No. of options<br/> or restricted<br/> stock granted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Exercise<br/> price range</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Vesting period</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Fair value<br/> at grant<br/> (U.S.<br/> dollars in<br/> thousands)</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Expiration<br/> period</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2012</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">400,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>3</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,288</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2012</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,100,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>4</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,292</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman'; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 16%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2014</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>2.37</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>4</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,007</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><font>10</font> years</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,400,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><br/></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2014 (such grants appear in the table above):</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">On July 16, 2012, the Company's Board of Directors approved the grant of <font>1,500,000</font> shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, <font>1,100,000</font> of the shares were issued to the Company's named executive officers and vest in <font>16</font> equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a <font>24</font>-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Corporate Transaction or a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining <font>400,000</font> shares of restricted Common Stock were issued to other employees of the Company and vest in <font>12</font> equal, quarterly increments over a three-year period, commencing upon the date of grant.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">On September 28, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a <font>10</font>-year option to purchase <font>900,000</font> shares of Common Stock to its then newly appointed President and Chief Executive Officer with an exercise price of $<font>2.37</font> per share. The options vest over a <font>four</font>-year period in <font>16</font> equal quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, as amended.&#160;The Company estimated the fair value of the options on the date of grant, using the Black-Scholes option-pricing model, to be approximately $<font>1</font> million based on the following weighted average assumptions: dividend yield of <font>0</font>% for all years; expected volatility of <font>62</font>%; risk-free interest rate of <font>1.86</font>%; and expected life of six years.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">b)</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of restricted stock granted during the year ended December 31, 2012 was $<font>8.6</font> million based on the Company's share price on the NYSE MKT on the grant date.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2014 is approximately $<font>1.4</font> million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of <font>1.0</font> years.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2012, 2013 and 2014 was approximately $<font>1.2</font> million, $<font>112,000</font> and $<font>46,000</font>, respectively. The Company did not realize any tax benefit in connection with these exercises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">During 2014, the Company issued <font>133,930</font> shares of Common Stock in connection with the exercise of <font>139,388</font> options by certain employees of the Company. The Company received cash proceeds equal to approximately $<font>46,000</font> in connection with such exercises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2.&#160;&#160;&#160;&#160;&#160;<b>Options granted to consultants, directors, and other service providers:</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in;">On July 24, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase <font>150,000</font> shares of Common Stock to its then newly elected chairman of the Board of Directors with an exercise price equal to $<font>3.37</font> per share. The options vest over a three-year period; the first <font>50,000</font> shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two-year period. Vesting of the options are subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<font>193,000</font> based on the following weighted average assumptions: dividend yield of <font>0</font>% for all years; expected volatility of <font>62</font>%; risk-free interest rates of <font>1.9</font>%; and expected life of six years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2013 and 2014. Approximately $<font>39,000</font> was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">During 2013 and 2014, no shares of Common Stock were issued in connection with the exercise of options by consultants of the Company.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">3.&#160;&#160;&#160;&#160;&#160;A summary of share option plans, and related information, under all of the Company's equity incentive plans for the years ended December 31, 2012, 2013 and 2014 are as follows:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">a.</font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted to employees:</font></font></font></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in; vertical-align: top; text-align: left;"></td>
<td style="width: 0.25in; vertical-align: top; text-align: left;"></td>
<td style="vertical-align: top; text-align: left;"></td>
</tr>

</table>
</div>
<div class="CursorPointer"><br/></div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px; text-align: center;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,141,030</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,253,579</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.923</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,153,898</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.951</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year:</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; text-indent: 10px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.370</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 10px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Forfeited and Expired</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">25,858</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.372</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">20,558</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.603</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">44,201</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.833</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercised (*)</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">861,593</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.346</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">79,123</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.418</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">139,388</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.446</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,253,579</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.923</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,153,898</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.951</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,870,309</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.770</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercisable at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,258,441</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.201</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,614,148</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.591</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,905,559</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.933</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-indent: -14.2pt;"><br/></p>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;">

<tr>
<td style="width: 2%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> (*) </font></td>
<td style="width: 98%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $<font>4.8</font> million, $<font>306,000</font> and $<font>447,000</font>, respectively.<br/></font></td>
</tr>

</table>
</div>
</div>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">b.</font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted stock granted to employees:</font></font></font></td>
</tr>

</table>
</div>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><br/></p>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of Restricted Shares</strong></font></td>
<td nowrap="nowrap" style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman';"></td>
<td style="text-align: left; font-family: 'times new roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,394,708</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">970,208</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year:</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,500,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Vested</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">102,084</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">406,666</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">398,375</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Forfeited</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3,208</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">17,834</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">185,709</font></font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center; padding-bottom: 2.5pt; font-family: 'times new roman';" width="50%"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,394,708</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">970,208</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding-bottom: 2.5pt; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">386,124</font></font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-family: 'times new roman'; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<div class="CursorPointer"><br/></div>
</div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">c.</font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Options and restricted stocks granted to consultants, directors, and other service providers:</font></font></font></td>
</tr>

</table>
</div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="22" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>average</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>of</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>exercise</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>options</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>price</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 40%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at beginning of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,238,692</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.385</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Changes during the year-</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">Granted</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">296,167</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.678</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercised (*)</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">326,267</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.12</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Outstanding at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,208,592</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.136</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Exercisable at end of year</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">912,425</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.259</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="margin-top: 0; margin-bottom: 0; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;&#160;</font></p>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="width: 100%;">

<tr>
<td style="width: 2%;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> (*) </font></td>
<td style="width: 98%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The total intrinsic value of options exercised during the year ended December 31, 2012 was approximately $<font>2.3</font> million.</font></td>
</tr>

</table>
</div>
</div>
</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">d.</font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2014:</font></font></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td align="center" style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="26"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31, 2014</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="text-align: center; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;" colspan="8"><br/></td>
</tr>
<tr style="vertical-align: bottom;">
<td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Options and restricted stock <br/>outstanding</strong></font><br/></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td align="center" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="10"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Options exercisable</strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td align="center" style="border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Exercise <br/>prices</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of <br/>options and<br/> restricted stock <br/>outstanding <br/>at end of <br/>year</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted <br/>average <br/>remaining <br/>contractual <br/>life</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Number of<br/> options<br/> exercisable</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td align="center" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="4" align="center" style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Weighted <br/>average <br/>remaining <br/>contractual <br/>life</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font><font style="font-size: 10pt; font-family: 'times new roman', times;"></font></td>
<td align="center" style="padding: 0px 5px; white-space: nowrap;"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom;" colspan="1" align="center"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a (Restricted Stock)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">490,624</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap;" align="right"><font style="font-size: 10pt; font-family: 'times new roman', times;">n/a</font></td>
<td style="font-family: 'times new roman'; padding: 0px; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.001</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">719,207</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.54</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">719,207</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20%;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.54</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.120</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">308,801</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.00</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">308,801</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.00</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">0.972</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">995,853</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.44</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">995,853</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.44</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.350</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">40,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.82</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">40,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.82</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.370</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">900,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.75</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">56,250</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.75</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.650</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">345,082</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.49</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">345,082</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.49</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.020</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">50,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">50,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">3.370</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.56</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.56</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.000</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,708,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,708,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.810</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">150,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.10</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6.900</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">991,916</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.32</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">829,249</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4.32</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7.550</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">160,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">160,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.66</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9.660</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">68,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.83</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">68,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5.83</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">16.700</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">387,542</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.99</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">387,542</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1.99</font></font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px 0px 0px; vertical-align: bottom; white-space: nowrap;" align="left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" colspan="1" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,465,025</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,817,984</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;" align="right"></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; padding-right: 5px;" align="left"></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The aggregate intrinsic value of the total outstanding options and restricted stock and of total vested and exercisable options as of December 31, 2014 is approximately $<font>3.6</font> million and $<font>2.7</font> million, respectively.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 1in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">e.</font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table illustrates the effect of share-based compensation on the statement of operations:</font></font></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 80%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; font-family: 'times new roman'; padding: 0px; width: 70%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Cost of revenues</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">220</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 10%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Research and development expenses</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,756</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,655</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">936</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Marketing, General and administrative expenses</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,775</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,434</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">306</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">7,751</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,089</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,242</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><br/></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>c.&#160;&#160;&#160;&#160;&#160;Public and 144A Offerings</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">1.&#160;&#160;&#160;&#160;&#160;&#160;On February 22, 2012, the Company issued and sold <font>5,175,000</font> shares of Common Stock in an underwritten public offering at a price to the public of $<font>5.25</font> per share. The net proceeds to the Company were approximately $<font>25.4</font> million (net of underwriting commissions and issuance costs of $<font>1.8</font> million).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -21.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">2.&#160;&#160;&#160;&#160;&#160;&#160;On September 18, 2013, the Company completed a private offering of <font>4.50</font>% convertible notes due 2018. The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $<font>9.0</font> million in aggregate principal amount of the Notes, were $<font>66.8</font> million (net of the initial purchaser's discount and commission and offering expenses payable by the Company). See also Note 8.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 9 - FAIR VALUE MEASUREMENT</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the convertible notes as of December 31, 2014 is approximately $<font>52.4</font> million based on level 2 measurement.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
        <td class="nump"><a title="plx_EmployeeSeveranceObligationPayment" onclick="toggleNextSibling(this);">$ 195,000</a><span style="display:none;white-space:normal;text-align:left;">plx_EmployeeSeveranceObligationPayment</span><span></span></td>
        <td class="nump"><a title="plx_EmployeeSeveranceObligationPayment" onclick="toggleNextSibling(this);">$ 194,000</a><span style="display:none;white-space:normal;text-align:left;">plx_EmployeeSeveranceObligationPayment</span><span></span></td>
        <td class="nump"><a title="plx_EmployeeSeveranceObligationPayment" onclick="toggleNextSibling(this);">$ 177,000</a><span style="display:none;white-space:normal;text-align:left;">plx_EmployeeSeveranceObligationPayment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expense</a></td>
        <td class="nump"><a title="us-gaap_PostemploymentBenefitsPeriodExpense" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PostemploymentBenefitsPeriodExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_PostemploymentBenefitsPeriodExpense" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PostemploymentBenefitsPeriodExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_PostemploymentBenefitsPeriodExpense" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PostemploymentBenefitsPeriodExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">779,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">801,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">670,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Net (gain) or loss for the period</a></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" onclick="toggleNextSibling(this);">22,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" onclick="toggleNextSibling(this);">58,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" onclick="toggleNextSibling(this);">36,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod', window );">Expected severance liabilities payments for fiscal year end 2015</a></td>
        <td class="nump"><a title="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" onclick="toggleNextSibling(this);">863,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ExpectedDefintedBenefitContributionDuringPeriod', window );">Expected contribution to one or more Contribution Plans</a></td>
        <td class="nump"><a title="plx_ExpectedDefintedBenefitContributionDuringPeriod" onclick="toggleNextSibling(this);">$ 685,000</a><span style="display:none;white-space:normal;text-align:left;">plx_ExpectedDefintedBenefitContributionDuringPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee severance obligation payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_EmployeeSeveranceObligationPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExpectedDefintedBenefitContributionDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected Definted Benefit Contribution During Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ExpectedDefintedBenefitContributionDuringPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected severance liabilities payments for future period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax, after reclassification adjustments, of actuarial gain (loss) that has not been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period expense related to postemployment benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Deferred revenues from the license and supply agreement with Pfizer</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">$ 4,563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">$ 4,563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">$ 4,563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment (see Note 2)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="plx_MilestonePayment" onclick="toggleNextSibling(this);">25,000</a><span style="display:none;white-space:normal;text-align:left;">plx_MilestonePayment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue from selling products</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">9,088</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">5,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">5,307</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 13,651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 10,479</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 34,870</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_MilestonePayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</font>
<div align="center">
<div class="CursorPointer">
<table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2">Years</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 82%; text-align: left; font-family: 'times new roman';">Laboratory equipment</td>
<td style="width: 1%; font-family: 'times new roman';">&#160;</td>
<td style="width: 1%; text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="width: 15%; text-align: center; font-family: 'times new roman';"><font>5</font></td>
<td style="width: 1%; text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'Times New Roman';">Furniture</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>10</font>-<font>15</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman';">Computer equipment</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>3</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Useful Life Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ScheduleOfUsefulLifeTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The components of the Company's net deferred tax assets at December 31, 2013 and 2014 were as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div class="CursorPointer" align="center">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><strong>December 31,</strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap">(U.S. dollars in thousands)</td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><strong>2013</strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong> </strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong>&#160;</strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><strong>2014</strong><strong><font></font></strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><strong><font></font></strong></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><strong><font></font></strong></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><strong>&#160;</strong></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';">In respect of:</td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2">&#160;</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;">Research and development expenses</td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font>5,257</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;">$</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font>3,136</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Property and equipment</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(491</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(372</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Provision for vacation</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>417</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>374</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Severance pay obligation</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>209</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>185</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Deferred revenues</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>9,867</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>8,658</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Net operating loss carry forwards</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>23,167</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>28,130</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Valuation allowance</td>
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(38,426</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>(40,111</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>-</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font>-</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">&#160;</td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">A summary of open tax years by major jurisdiction is presented below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<div class="CursorPointer" align="center">
<table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-right: 0.1px;" cellpadding="0" cellspacing="0">

<tr style="vertical-align: bottom; background-color: white;">
<td style="text-decoration: none; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; padding-left: 0px; font-family: 'times new roman';"><strong>Jurisdiction:</strong></td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';"><strong>&#160;</strong></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"><strong>&#160;</strong></td>
<td nowrap="nowrap" style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid; text-align: right; font-family: 'times new roman';"><strong><b>Years:</b></strong></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: 'times new roman';"><strong>&#160;</strong></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-left: 0px; font-family: 'times new roman'; width: 90%;">Israel</td>
<td style="font-family: 'Times New Roman'; width: 0%;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman'; width: 0%;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman'; width: 10%;" nowrap="nowrap"><font>2011</font>-<font>2014</font></td>
<td style="text-align: left; font-family: 'times new roman'; width: 0%;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0; font-family: 'times new roman';">United States (*)</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
<td style="text-align: right; font-family: 'times new roman';" nowrap="nowrap"><font>2010</font>-<font>2014</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>

</table>
</div>
<b><b>&#160;<br/></b></b>
<div>
<div class="CursorPointer">
<table width="100%" cellpadding="0" border="0" cellspacing="0" style="margin-left: 0.100000001490116px;">

<tr>
<td style="width: 2%;">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">(*)&#160;</p>
</td>
<td style="width: 98%; font-size: 10pt;">
<div>Includes federal, state and local (or similar provincial jurisdictions) tax positions.</div>
</td>
</tr>

</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Open Tax Years Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ScheduleOfOpenTaxYearsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsInstitutionsCurrent', window );">Institutions</a></td>
        <td class="nump"><a title="plx_OtherAssetsInstitutionsCurrent" onclick="toggleNextSibling(this);">$ 124</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherAssetsInstitutionsCurrent</span><span></span></td>
        <td class="nump"><a title="plx_OtherAssetsInstitutionsCurrent" onclick="toggleNextSibling(this);">$ 356</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherAssetsInstitutionsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">State of Israel (see Note 6a)</a></td>
        <td class="nump"><a title="us-gaap_PrepaidRoyalties" onclick="toggleNextSibling(this);">1,229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidRoyalties</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidRoyalties" onclick="toggleNextSibling(this);">366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidRoyalties</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted deposit</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">369</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">286</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsSundryCurrent', window );">Sundry</a></td>
        <td class="nump"><a title="plx_OtherAssetsSundryCurrent" onclick="toggleNextSibling(this);">64</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherAssetsSundryCurrent</span><span></span></td>
        <td class="nump"><a title="plx_OtherAssetsSundryCurrent" onclick="toggleNextSibling(this);">87</a><span style="display:none;white-space:normal;text-align:left;">plx_OtherAssetsSundryCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 2,202</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 1,457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsInstitutionsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_OtherAssetsInstitutionsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsSundryCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_OtherAssetsSundryCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1EDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" onclick="toggleNextSibling(this);">7,465,025</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" onclick="toggleNextSibling(this);">5,817,984</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">490,624</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the total vested and exercisable options</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 3.6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate intrinsic value of total outstanding options and restricted stock</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 2.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember', window );">0.001 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointZeroZeroOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember]" onclick="toggleNextSibling(this);">719,207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointZeroZeroOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">6 months 14 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember]" onclick="toggleNextSibling(this);">719,207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointZeroZeroOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">6 months 14 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember', window );">0.120 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember]" onclick="toggleNextSibling(this);">$ 0.120</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointOneTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember]" onclick="toggleNextSibling(this);">308,801</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointOneTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">2 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember]" onclick="toggleNextSibling(this);">308,801</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointOneTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">2 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember', window );">0.972 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember]" onclick="toggleNextSibling(this);">$ 0.972</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointNineSevenTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember]" onclick="toggleNextSibling(this);">995,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointNineSevenTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">1 year 5 months 8 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember]" onclick="toggleNextSibling(this);">995,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ZeroPointNineSevenTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">1 year 5 months 8 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember', window );">2.350 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember]" onclick="toggleNextSibling(this);">$ 2.350</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeFiveZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeFiveZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">3 years 9 months 25 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeFiveZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">3 years 9 months 25 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember', window );">2.370 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember]" onclick="toggleNextSibling(this);">$ 2.370</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeSevenZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeSevenZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">9 years 9 months<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember]" onclick="toggleNextSibling(this);">56,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointThreeSevenZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">9 years 9 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember', window );">2.650 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember]" onclick="toggleNextSibling(this);">$ 2.650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointSixFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember]" onclick="toggleNextSibling(this);">345,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointSixFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">3 years 5 months 26 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember]" onclick="toggleNextSibling(this);">345,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_TwoPointSixFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">3 years 5 months 26 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember', window );">3.020 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember]" onclick="toggleNextSibling(this);">$ 3.020</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ThreePointZeroTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ThreePointZeroTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">3 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ThreePointZeroTwoZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">3 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember', window );">3.370 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember]" onclick="toggleNextSibling(this);">$ 3.370</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ThreePointThreeSevenZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_ThreePointThreeSevenZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">9 years 6 months 22 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">9 years 6 months 22 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember', window );">5.000 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember]" onclick="toggleNextSibling(this);">$ 5.000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_FivePointZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember]" onclick="toggleNextSibling(this);">1,708,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_FivePointZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">2 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember]" onclick="toggleNextSibling(this);">1,708,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_FivePointZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">2 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember', window );">6.810 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember]" onclick="toggleNextSibling(this);">$ 6.810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointEightOneZeroMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointEightOneZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointEightOneZeroMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember', window );">6.900 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember]" onclick="toggleNextSibling(this);">$ 6.900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointNineMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember]" onclick="toggleNextSibling(this);">991,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointNineMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">4 years 3 months 25 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember]" onclick="toggleNextSibling(this);">829,249</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SixPointNineMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">4 years 3 months 25 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember', window );">7.550 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember]" onclick="toggleNextSibling(this);">$ 7.550</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SevenPointFiveFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember]" onclick="toggleNextSibling(this);">160,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SevenPointFiveFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember]" onclick="toggleNextSibling(this);">160,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_SevenPointFiveFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember', window );">9.660 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember]" onclick="toggleNextSibling(this);">$ 9.660</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_NinePointSixSixMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember]" onclick="toggleNextSibling(this);">68,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_NinePointSixSixMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember]" onclick="toggleNextSibling(this);">68,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_NinePointSixSixMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember', window );">16.700 [Member] | Options And Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember]" onclick="toggleNextSibling(this);">$ 16.700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_OneSixPointSevenMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember]" onclick="toggleNextSibling(this);">387,542</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_OneSixPointSevenMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">1 year 11 months 26 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember;us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember]" onclick="toggleNextSibling(this);">387,542</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= plx_OptionsAndRestrictedStockMember<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= plx_OneSixPointSevenMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">1 year 11 months 26 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OneSixPointSevenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointEightOneZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointNineSevenTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointOneTwoZeroMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ZeroPointZeroZeroOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECTBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ (26,946)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ (3,357)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ (26,077)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">25,388</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">1,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">4,612</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" onclick="toggleNextSibling(this);">775</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</span><span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" onclick="toggleNextSibling(this);">3,076</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</span><span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" onclick="toggleNextSibling(this);">3,139</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">112</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">1,199</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(29,943)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(27,790)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(11,618)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(55,601)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(26,946)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(3,357)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93,551,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93,489,809</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">85,630,157</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">86</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,175,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures (shares)</a></td>
        <td class="num"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(81,209)</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(17,834)</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,496,792</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise), shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">133,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">79,123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,187,860</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93,603,819</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93,551,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">93,489,809</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">184,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">180,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">145,814</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">25,383</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,612</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">775</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,076</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,138</a><span style="display:none;white-space:normal;text-align:left;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">45</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">112</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,198</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">185,633</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">184,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">180,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(211,385)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(183,595)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(171,977)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(29,943)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(27,790)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(11,618)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (241,328)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (211,385)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (183,595)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 3 - PROPERTY AND EQUIPMENT</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>a.</b></font></td>
<td style="font-family: 'Times New Roman';"><font><font style="font-size: 10pt; font-family: 'times new roman', times;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of property and equipment grouped by major classifications is as follows:</font></font></font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt;"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 1in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(<i>U.S. dollars in thousands)</i></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="4"><br/></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Laboratory&#160;equipment</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">14,858</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,138</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Furniture&#160;and&#160;computer&#160;equipment</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,074</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,154</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Leasehold&#160;improvements</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,070</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,427</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Equipment&#160;under&#160;construction</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">28</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">17</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">32,030</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">32,736</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Less&#160;&#150;&#160;accumulated&#160;depreciation</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 20px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">and&#160;amortization</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">(18,319</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">(21,454</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">13,711</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">11,282</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.3pt; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left; font-family: 'times new roman';"><font style="font-size: 10pt;"><b>b.</b></font></td>
<td style="text-align: justify; font-family: 'times new roman';">Depreciation and amortization in respect of property and equipment totaled approximately $<font>3.7</font> million, $<font>3.5</font> million and $<font>3.1</font> million for the years ended December 31, 2012, 2013 and 2014, respectively.</td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Balance sheets:</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="3"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong><font></font></strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-weight: bold; text-align: left; text-indent: -26.45pt; margin: 0 0 0 75pt;">a. &#160; &#160; &#160; &#160;Other assets:</td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Institutions</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">356</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">124</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">State of Israel (see Note 6a)</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">366</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,229</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Restricted deposit</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">362</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">416</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Prepaid expenses</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">286</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">369</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Sundry</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">87</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">64</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,457</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">2,202</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 80%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; margin: 0 0 0 75pt;">
<td style="font-family: 'times new roman'; text-indent: -26.45pt; margin: 0 0 0 75pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>b. &#160; &#160; &#160; &#160; Accounts payable and accruals &#150; other:</strong></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 80%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Payroll and related expenses</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,557</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,243</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Interest payable</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">888</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">914</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Provision for vacation</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,572</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,412</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Accrued expenses</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">1,785</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,097</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Royalties payable</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">419</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">495</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Liability in connection with collaboration operation - current portion</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,666</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">6,215</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Property and equipment suppliers</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">186</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">120</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">12,073</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">15,496</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;<br/></b></font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Supplemental Information, Income Statement</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; margin-left: 1.1in;">

<tr style="vertical-align: bottom;">
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Statements of operations:</strong></font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="10" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>Year ended December 31,</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2012</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2013</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong> </strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
<td colspan="2" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>2014</strong></font></td>
<td nowrap="nowrap" style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><strong>&#160;</strong></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">(U.S. dollars in thousands)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap" style="font-weight: bold; text-indent: -26.45pt; margin: 0 0 0 75pt;">c. &#160; &#160; &#160;Revenues:</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 70%; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Deferred revenues from the license and supply agreement with Pfizer</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">4,563</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 0%;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Milestone payment (see Note 2)</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">25,000</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; text-indent: 0.5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Revenues from selling products</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,307</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">5,916</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">9,088</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 28.85pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">34,870</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">10,479</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt; font-family: 'times new roman', times;">13,651</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></td>
</tr>

</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplementary Balance Sheets Information Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplementary Income Statement Information [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-daei</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-cbs</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-csoo</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-csocicd</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-csocicdp</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-csocf</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - LICENSE AND SUPPLY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-lasa</Role>
      <ShortName>LICENSE AND SUPPLY AGREEMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-pae</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-i</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>105 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-lferur</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>106 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-c</Role>
      <ShortName>COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>107 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sc</Role>
      <ShortName>SHARE CAPITAL</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>108 - Disclosure - CONVERTIBLE NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-cn1</Role>
      <ShortName>CONVERTIBLE NOTE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>109 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvm1</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>110 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-toi</Role>
      <ShortName>TAXES ON INCOME</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>111 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sfsi</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>112 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-rpt</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapp1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapt</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-paet</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>304 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-it</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>307 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sct</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>308 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/plx-cnt1</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>310 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-toit</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>311 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sfsit</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>312 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-rptt</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapulopaed</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-lasad</Role>
      <ShortName>LICENSE AND SUPPLY AGREEMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-paed</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40401 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-id</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-lferurd</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-cd</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scnd</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scsooarsgted</Role>
      <ShortName>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scogted</Role>
      <ShortName>SHARE CAPITAL (Options Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scrsgted</Role>
      <ShortName>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40706 - Disclosure - SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scoarsgtcdaospd</Role>
      <ShortName>SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scsooarsd</Role>
      <ShortName>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-scsbcead</Role>
      <ShortName>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40801 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/plx-cnnd1</Role>
      <ShortName>CONVERTIBLE NOTES (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40802 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/plx-cnsoierd1</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvmd1</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41001 - Disclosure - TAXES ON INCOME (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-toind</Role>
      <ShortName>TAXES ON INCOME (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41002 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-toiditd</Role>
      <ShortName>TAXES ON INCOME (Deferred Income Taxes) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41003 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-toiotyd</Role>
      <ShortName>TAXES ON INCOME (Open Tax Years) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sfsoa</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41102 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sfsiapaaod</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41103 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sfsird</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41201 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-rptd</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element plx_MilestonePayment had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_Revenues had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RoyaltyExpense had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 3 4.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 28 values. Shorter duration columns must have at least one fourth (7) as many values. Column '9/17/2013 - 9/18/2013' is shorter (1 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">'Monetary' elements on report '40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40601 - Disclosure - COMMITMENTS (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40801 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</Log>
    <Log type="Info">	Process Flow-Through: Removing column '0 Months Ended
Feb. 22, 2012'</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20141231.xml</File>
    <File>plx-20141231.xsd</File>
    <File>plx-20141231_cal.xml</File>
    <File>plx-20141231_def.xml</File>
    <File>plx-20141231_lab.xml</File>
    <File>plx-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Options Granted to Employees) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="6">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 22, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 46,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 112,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 1,230,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">5,175,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember', window );">Options And Restricted Stock Granted To Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">5,153,898</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">5,253,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">6,141,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and Expired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">44,201</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">20,558</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">25,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">139,388</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">79,123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">861,593</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">5,870,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">5,153,898</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">5,253,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">4,905,559</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">4,614,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">4,258,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.923</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 2.370</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and Expired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 6.833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 6.603</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 4.372</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 0.446</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 1.418</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 1.346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.770</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.923</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.933</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.591</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 3.201</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">447,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">306,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">4,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">$ 39,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember]" onclick="toggleNextSibling(this);">133,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_TitleOfIndividualAxis<br>= plx_OptionsAndRestrictedStockGrantedToEmployeesMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="8"></td>
      </tr>
      <tr>
        <td colspan="8">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">




 (*)
The total intrinsic value of options exercised during the years ended December 31, 2012, 2013 and 2014, was approximately $4.8 million, $306,000 and $447,000, respectively.




</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>a.&#160;&#160;&#160;&#160;&#160;General</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx<sup>&#174;</sup> protein expression system (&#147;ProCellEx&#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's <font>two</font> subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &#147;Israeli MOH&#148;) in September 2012, by the Brazilian Ministry of Health (the &#147;Brazilian MOH&#148;) in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Taliglucerase alfa is being marketed in the United States under the brand name&#160;Elelyso&#153; by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &#147;Pfizer Agreement&#148;). The Company, through Protalix Ltd., markets&#160;Elelyso&#160;in Israel, and in Brazil under the brand name Uplyso&#153;. See Note 2.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $<font>60.0</font> million in connection with the execution of the Pfizer Agreement and additional $<font>30.0</font> million milestone payment mainly in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a <font>40</font>% and <font>60</font>% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retains exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is Uplyso. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz committed to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa during the first two years of the agreement. With respect to the first required purchase amount, the Company has recorded revenues of approximately $<font>3.5</font> million for sales of taliglucerase alfa to Fiocruz in 2014.&#160;In subsequent years, Fiocruz is required to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa per year. Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa. The Brazil Agreement became effective during the January&#160;of 2014.<br/><br/>If Fiocruz fails to comply with certain of its purchase commitments under the agreement, the Company has the right to terminate the agreement and all rights to the technology that were transferred to Fiocruz will be returned to the Company.<br/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $<font>12.5</font> million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>b.&#160;&#160;&#160;&#160;&#160;Basis of presentation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;).</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>c.&#160;&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>d.&#160;&#160;&#160;&#160;&#160;Functional currency</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company's revenues are derived in dollars. Most of the Company's expenses and capital expenditures are incurred in dollars, and the major source of the Company's financing has been provided in dollars.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &#150; historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>e.&#160;&#160;&#160;&#160;&#160;Cash equivalents</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>f.&#160;&#160;&#160;&#160;&#160;&#160;Inventories</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the &#147;moving average&#148; basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the &#147;moving average&#148; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">If actual market prices for finished products prove less favorable than those projected by management, inventory write-downs may be required. Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>g.&#160;&#160;&#160;&#160;&#160;Property and equipment</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top; text-align: justify;">
<td style="width: 36pt;"></td>
<td style="width: 48pt; text-align: left; font-family: 'times new roman';">1.</td>
<td style="text-align: justify; font-family: 'times new roman';">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in;">&#160;</p>
<div class="CursorPointer"><br/></div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 36pt;"></td>
<td style="width: 48pt; font-family: 'times new roman';">2.</td>
<td style="font-family: 'Times New Roman';"><font><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</font></font></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 12pt; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 36pt; vertical-align: top; text-align: left;"></td>
<td style="width: 48pt; vertical-align: top; text-align: left;"></td>
<td style="vertical-align: top; text-align: left;"></td>
</tr>

</table>
</div>
<div class="CursorPointer">
<div>
<div align="center">
<div class="CursorPointer">
<table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 60%; margin-left: 0.1px;" cellpadding="0" cellspacing="0">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; border-bottom: black 1pt solid; font-family: 'times new roman';" colspan="2">Years</td>
<td style="padding-bottom: 1pt; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 82%; text-align: left; font-family: 'times new roman';">Laboratory equipment</td>
<td style="width: 1%; font-family: 'times new roman';">&#160;</td>
<td style="width: 1%; text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="width: 15%; text-align: center; font-family: 'times new roman';"><font>5</font></td>
<td style="width: 1%; text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'Times New Roman';">Furniture</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>10</font>-<font>15</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman';">Computer equipment</td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';">&#160;</td>
<td style="text-align: center; font-family: 'times new roman';"><font>3</font></td>
<td style="text-align: left; font-family: 'times new roman';">&#160;</td>
</tr>

</table>
</div>
</div>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>h.&#160;&#160;&#160;&#160;&#160;Impairment in value of long-lived assets: </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>i.&#160;&#160;&#160;&#160;&#160;&#160;Income taxes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">1.&#160;&#160;&#160;&#160;&#160;Deferred income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See Note 10.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">2.&#160;&#160;&#160;&#160;&#160;Uncertainty in income taxes</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Tax benefits recognized in the financial statements are those that the Company's management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company's management deems more likely than not to be sustained.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>j.&#160;&#160;&#160;&#160;&#160;&#160;Revenue Recognition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">1.&#160;&#160;&#160;&#160;&#160;Revenues from the license and supply agreement with Pfizer</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company's continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">2.&#160;&#160;&#160;&#160;&#160;Revenues from selling products</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">The Company recognizes revenues from&#160;selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in;">3.&#160;&#160;&#160;&#160;&#160;Company's share in the collaboration agreement</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in;">Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel and Brazil (since 2014), where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company's share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>k.&#160;&#160;&#160;&#160;Research and development costs </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the &#147;OCS&#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have <font>no</font> alternative future use are charged to research and development costs at the purchase date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>l.&#160;&#160;&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company's trade receivables represent amounts to be received from Pfizer and the Company's customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>m.&#160;&#160;&#160;&#160;Share-based compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company accounts for employee's share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per share</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in;"><b>n.&#160;&#160;&#160;&#160;&#160;Net loss per share</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;">Diluted LPS does not include <font>7,280,469</font>, <font>10,675,304</font> and <font>18,850,724</font> shares of Common Stock underlying outstanding options , restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the fiscal years ended December 31, 2012, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt;"><b>o.&#160;&#160;&#160;&#160;&#160;Convertible notes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0in;">The convertible notes are accounted for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements:</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: -20.7pt; font-size-adjust: none; font-stretch: normal;"><b>p. &#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements:</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;">In August 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued amended guidance related to the disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. The Company believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0px 0px 0px 56.7pt; text-indent: 0in; font-size-adjust: none; font-stretch: normal;">In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. The Company is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Nature Of Operations Policy</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
